<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
     xmlns:dc="http://purl.org/dc/elements/1.1/"
     xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
     xmlns:admin="http://webns.net/mvcb/"
     xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
     xmlns:content="http://purl.org/rss/1.0/modules/content/"
     xmlns:media="http://search.yahoo.com/mrss/">
<channel>
<title>Bersama Kita Sehat &#45; : Berita</title>
<link>https://edusehat.com/en/rss/category/Berita</link>
<description>Bersama Kita Sehat &#45; : Berita</description>
<dc:language>en</dc:language>
<dc:rights>2025&#45;2055 PS Global Media &#45; Hak Cipta</dc:rights>

<item>
<title>Immune Aging Study in Mice Reveals Clues to T Cell Dysfunction and Cancer Development</title>
<link>https://edusehat.com/en/immune-aging-study-in-mice-reveals-clues-to-t-cell-dysfunction-and-cancer-development</link>
<guid>https://edusehat.com/en/immune-aging-study-in-mice-reveals-clues-to-t-cell-dysfunction-and-cancer-development</guid>
<description><![CDATA[ Age-related changes in CD8+ T cells may hold important clues to understanding cancer immunity, with new findings revealing distinct chromatin signatures of dysfunction and the emergence of a unique regulatory population. 
The post Immune Aging Study in Mice Reveals Clues to T Cell Dysfunction and Cancer Development appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/06/GettyImages-1321240646.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 21 Nov 2026 05:20:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Immune, Aging, Study, Mice, Reveals, Clues, Cell, Dysfunction, and, Cancer, Development</media:keywords>
<content:encoded><![CDATA[<p><span>Data from a new study led by scientists at Monash University looking at immune aging in mice helps shed more light on why bodies become less effective at fighting cancer and infections with age. The preclinical study, published this week in <em>Science Immunology</em>, identified unique genetic signatures in aging immune cells that cause them to become less effective over time, making older individuals more susceptible to disease. The paper is titled “</span><a href="https://dx.doi.org/10.1126/sciimmunol.aej5412" target="_blank" rel="noopener"><span>Aging drives distinct chromatin signatures of CD8 T cell dysfunction and the emergence of a unique CD8 Treg cell population</span></a><span>.” </span></p>
<p><span>“Our immune system is constantly surveying our bodies for potentially cancerous cells and eliminating them, often without us ever knowing,” explained Daniel Thiele, PhD, first author on the paper and a researcher in the laboratory of Nicole La Gruta, PhD, at Monash Biomedicine Discovery Institute. “As we age, this natural defense system becomes less effective, making us more vulnerable to cancer and infections and reducing our ability to respond to vaccines. This study provides a blueprint of immune aging, from which we can now identify potential targets to reverse aspects of that decline.”</span></p>
<p><span>As the title of the paper indicates, the scientists focused on CD8+ T cells, which are part of the body’s frontline defense system for identifying and destroying infected and cancerous cells. According to the team, they identified three distinct ways that aging disrupts the genetic instructions that control how immune cells function, which affects their ability to adapt to new threats, regulate immune responses, and remain healthy. They also discovered a previously unidentified group of aging immune cells that both lose their ability to protect the body against disease and actively suppress the responses of other immune cells. This was true even within the same ageing individual, Thiele noted. </span></p>
<p><span>This research supports findings from separate research also from scientists in the La Gruta lab. That study, </span><a href="https://www.cell.com/immunity/fulltext/S1074-7613(26)00440-1?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1074761326004401%3Fshowall%3Dtrue" target="_blank" rel="noopener"><span>also published this month in </span><i><span>Immunity</span></i></a><span>, found a link between the Granzyme K protein and signs of aging in the heart, liver, and kidneys in preclinical models. </span></p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/immune-aging-study-in-mice-reveals-clues-to-t-cell-dysfunction-and-cancer-development/">Immune Aging Study in Mice Reveals Clues to T Cell Dysfunction and Cancer Development</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>PTSD Brain DNA Methylation Patterns Linked to Age of Trauma Exposure, Sex, and Ethnicity</title>
<link>https://edusehat.com/en/ptsd-brain-dna-methylation-patterns-linked-to-age-of-trauma-exposure-sex-and-ethnicity</link>
<guid>https://edusehat.com/en/ptsd-brain-dna-methylation-patterns-linked-to-age-of-trauma-exposure-sex-and-ethnicity</guid>
<description><![CDATA[ Studying postmortem brain tissue, researchers found variations in DNA methylation in different brain areas that may help explain the development of post-traumatic stress disorder.
The post PTSD Brain DNA Methylation Patterns Linked to Age of Trauma Exposure, Sex, and Ethnicity appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/02/Getty_1402264698_DNAMethylTransferase.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 21 Nov 2026 05:20:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>PTSD, Brain, DNA, Methylation, Patterns, Linked, Age, Trauma, Exposure, Sex, and, Ethnicity</media:keywords>
<content:encoded><![CDATA[<p>The results of research headed by a team at the University of Texas at Austin indicate that stress and trauma can leave molecular marks in the brain that may help explain the development of post-traumatic stress disorder (PTSD).</p>
<p>The researchers analyzed specific regions of the postmortem brains of people with PTSD, those with major depressive disorder (MDD), and those without psychiatric disorders. The identified specific molecular features of the PTSD and MDD brain, and showed that the molecular signatures of PTSD also varied significantly between individuals—more so than for individuals with major depressive disorder. The results suggested that within the PTSD group, factors such sex, race of the person, and when in their lifetime trauma exposure occurred, may all impact on the epigenetic signature.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>“The question that our research aims to address is ‘What is really different about the PTSD brain?’” said Frances Champagne, PhD, at the University of Texas at Austin. “The study found greater variation in DNA methylation patterns across brain regions in people with PTSD than in people with major depressive disorder. It also revealed considerable differences among individuals with PTSD.” The variance could open the door to more individualized treatment options for people with PTSD in the future, the researchers suggest.</p>
<p>Champagne is corresponding author of the researchers’ published paper in <em>Cell Reports</em>, titled “<a href="http://dx.doi.org/10.1016/j.celrep.2026.118270" target="_blank" rel="noopener">DNA methylation profiling of human brain in posttraumatic stress and major depressive disorders indicate specific molecular features</a>.” In their paper the authors stated, “Overall, our findings illustrate an approach to characterizing distinct epigenomic features within the postmortem brain and the association between variation in DNA methylation and psychiatric diagnoses.”</p>
<p>Epigenetic mechanisms, which are molecular pathways through which gene expression is regulated, have been increasingly implicated in the pathophysiology of physical and psychiatric disorders, the authors wrote. One of these mechanisms, DNA methylation, acts like a genetic “dimmer switch” for genes, sometimes blocking genetic code entirely. “Beyond the role of these mechanisms in gene regulation, epigenetic marks such as DNA methylation exhibit plasticity in response to the environment, thus serving as a potential mediator of the gene-environment interplay that is considered fundamental to disease risk and resilience,” the investigators explained.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>Interestingly, PTSD studies have uncovered associations with variations in DNA methylation in peripheral blood (blood and saliva), particularly within genes involved in immune functions such as inflammation and innate immunity, the team continued. However, they pointed out, “While analyses of DNA methylation in peripheral tissues have revealed associations between PTSD and variation in the epigenome, the limited availability of brain-based analyses constrains the potential to reveal critical pathways in the pathophysiology of PTSD.”</p>
<p>For their newly reported study the team carried out detailed methylation profiling of postmortem brains from 302 individuals. All brains were obtained from the Lieber Institute for Brain Development and were matched with the donors’ life history and medical records to assign diagnostic criteria. The analysis included brains from 101 people with PTSD and two comparison groups—100 brains from individuals without psychiatric disorders and 101 brains from people with major depressive disorder. For each brain, three different regions were analyzed—the prefrontal cortex (PFC), the amygdala, and the hippocampus.</p>
<p>“These are the brain regions that seem to be uniquely informative of the PTSD brain,” Champagne said. “Many studies of epigenetics use blood and saliva as a proxy to see what’s going on the body, but we think it’s incredibly important to actually look at the brain for these kinds of mental health conditions.”</p>
<p>The study uncovered specific changes in the brain linked to PTSD, including a relative reduction in oligodendrocytes in the amygdala of people with PTSD, particularly in those exposed to trauma in adulthood. The researchers also found that PTSD was associated with more pronounced DNA methylation differences in the prefrontal cortex, while major depressive disorder was associated with methylation differences in the amygdala. These molecular patterns were associated with differences in the composition of different cell types in the brain.</p>
<p>Within the PTSD group, the molecular variations appeared to be driven by a number of factors, including the sex and race of the person and whether the trauma exposure occurred in childhood or adulthood. One future research focus will be on using these variables to refine and enhance diagnosis. The researchers say it could eventually lead to a more personalized approach to treating mental health conditions.</p>
<p>“Overall, these analyses reveal epigenomic features of the PTSD and MDD brain that can guide cellular and molecular mechanistic understanding of the pathophysiology of these disorders,” the authors stated. “This understanding can inform clinical interventions by identifying unique and shared biological processes that characterize the brain epigenome dependent on mental health diagnosis.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>Because the study analyzed postmortem brain tissue the researchers were not able to confirm whether the methylation differences contributed to PTSD, resulted from PTSD, or were influenced by other factors. The authors also noted that they lacked detailed information about symptom type and severity for each individual, which would be important for developing more personalized methods of diagnosis.</p>
<p>“The more we know about all the variables that impact clinically relevant outcomes, the better we can assess patients and tailor their treatments,” Champagne acknowledged.</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/ptsd-brain-dna-methylation-patterns-linked-to-age-of-trauma-exposure-sex-and-ethnicity/">PTSD Brain DNA Methylation Patterns Linked to Age of Trauma Exposure, Sex, and Ethnicity</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Hamilton hospital introduces AI tool to reduce unnecessary cardiac procedures</title>
<link>https://edusehat.com/en/hamilton-hospital-introduces-ai-tool-to-reduce-unnecessary-cardiac-procedures</link>
<guid>https://edusehat.com/en/hamilton-hospital-introduces-ai-tool-to-reduce-unnecessary-cardiac-procedures</guid>
<description><![CDATA[ Canadian-developed technology is now being used in routine care at Hamilton General Hospital to help cardiologists select the most appropriate diagnostic tests for patients. Hamilton Health Sciences (HHS) has introduced a new artificial intelligence tool into routine clinical care that could help reduce unnecessary invasive cardiac procedures while improving how patients with suspected coronary artery […]
The post Hamilton hospital introduces AI tool to reduce unnecessary cardiac procedures appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/11/ai-image-analysis.png" length="49398" type="image/jpeg"/>
<pubDate>Sat, 21 Nov 2026 05:15:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Hamilton, hospital, introduces, tool, reduce, unnecessary, cardiac, procedures</media:keywords>
<content:encoded><![CDATA[<p>Canadian-developed technology is now being used in routine care at Hamilton General Hospital to help cardiologists select the most appropriate diagnostic tests for patients.</p>
<p>Hamilton Health Sciences (HHS) has introduced a new artificial intelligence tool into routine clinical care that could help reduce unnecessary invasive cardiac procedures while improving how patients with suspected coronary artery disease are assessed.</p>
<p>Known as CarDIA-AI, the technology uses machine learning to analyze patient information and help cardiologists determine whether an invasive coronary angiogram or a non-invasive coronary CT scan is the more appropriate diagnostic test.</p>
<p>The tool began routine clinical use at Hamilton General Hospital’s Heart Investigation Unit in early October 2026, making HHS the first hospital in Canada to implement CarDIA-AI in everyday cardiac care.</p>
<h3>Improving cardiac testing decisions</h3>
<p>Coronary artery disease occurs when arteries supplying blood to the heart become narrowed or blocked, potentially causing chest pain, heart attacks and other cardiovascular complications.</p>
<p>Patients suspected of having the condition are frequently referred for coronary angiography, an invasive procedure involving a catheter inserted through an artery to examine blood flow to the heart.</p>
<p>However, many angiograms reveal no significant blockages. For some patients, a non-invasive CT scan could provide sufficient diagnostic information without requiring catheterization.</p>
<p>CarDIA-AI analyzes patient data to estimate the likelihood of significant coronary artery disease, helping clinicians identify which patients are most likely to benefit from angiography.</p>
<p>The technology supports clinical decisions rather than replacing physician judgment.</p>
<h3>Clinical trial demonstrates promising results</h3>
<p>In a randomized controlled trial evaluating the technology, researchers compared conventional cardiac testing with an AI-guided approach.</p>
<p>Among patients who underwent coronary angiography, approximately 61 per cent in the usual-care group had no significant coronary blockages.</p>
<p>In the CarDIA-AI group, that proportion fell to approximately 24 per cent.</p>
<p>The findings suggest the technology can help clinicians better identify patients who require invasive testing while directing others toward less invasive diagnostic options.</p>
<p>Importantly, the percentages refer specifically to patients who underwent angiography in each study group, rather than all patients assessed.</p>
<p>Reducing unnecessary angiograms could also lower healthcare costs and limit patients’ exposure to procedural risks.</p>
<h3>Developed using Canadian patient data</h3>
<p>CarDIA-AI was developed through collaboration between HHS cardiologists, researchers and the hospital’s Centre for Data Science and Digital Health, known as CREATE.</p>
<p>Researchers initially trained the machine-learning model using 12 years of referral data from nearly 30,000 cardiac patients treated at Hamilton General Hospital and Niagara Health’s St. Catharines Hospital.</p>
<p>The model was subsequently evaluated using information from 22 cardiac centres across Ontario to assess its broader applicability.</p>
<p>Early modelling indicated that the proportion of patients referred for angiography who might have been able to avoid the invasive procedure decreased from 44 per cent to 14 per cent when the technology was used to guide assessment.</p>
<p>The hospital also reported comparable model performance for women and men.</p>
<h3>From research to routine patient care</h3>
<p>Dr. JD Schwalm, an interventional cardiologist at Hamilton General Hospital and director of the HHS Knowledge Centre, played a leading role in developing the technology.</p>
<p>The project builds on earlier research examining how expert clinical review could improve decisions about cardiac diagnostic testing.</p>
<p>By using machine learning to support those decisions, CarDIA-AI aims to make the process more efficient and scalable.</p>
<p>Following several years of development, evaluation and implementation planning, the system is now integrated into routine clinical workflows at Hamilton General Hospital.</p>
<p>HHS believes the technology has potential for wider adoption across Ontario and Canada.</p>
<p>The initiative demonstrates how hospital-developed artificial intelligence can move beyond research into practical clinical applications, supporting more personalized care while helping healthcare systems make better use of diagnostic resources.</p>
<p>The post <a href="https://www.hospitalnews.com/hamilton-hospital-introduces-ai-tool-to-reduce-unnecessary-cardiac-procedures/">Hamilton hospital introduces AI tool to reduce unnecessary cardiac procedures</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Genome Writing Inserts Human X&#45;Linked Disease DNA Into Mice</title>
<link>https://edusehat.com/en/genome-writing-inserts-human-x-linked-disease-dna-into-mice</link>
<guid>https://edusehat.com/en/genome-writing-inserts-human-x-linked-disease-dna-into-mice</guid>
<description><![CDATA[ By swapping 78 kilobases of human DNA into mice, researchers recreated key features of X-linked dystonia-parkinsonism and showed that boosting TAF1 expression may counter some cellular effects.
The post Genome Writing Inserts Human X-Linked Disease DNA Into Mice appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/01/thumbnail_GettyImages-1023097228-e1695336230594-1068x712-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 20 Nov 2026 22:05:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Genome, Writing, Inserts, Human, X-Linked, Disease, DNA, Into, Mice</media:keywords>
<content:encoded><![CDATA[<p>By assembling and swapping in long stretches of engineered DNA with genome writing, researchers can reconstruct human disease-linked regions in another species—an approach that has now produced a mouse model of X-linked dystonia-parkinsonism (XDP), a rare neurodegenerative disorder that causes movement problems that worsen with age. The model compresses a disease course that can take decades in people into less than two months in mice, potentially accelerating studies of disease biology and treatments.</p>
<p>For the study, “<a href="https://www.cell.com/cell/abstract/S0092-8674(26)00926-8?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867426009268%3Fshowall%3Dtrue" target="_blank" rel="noopener">Genome writing reveals SVA retrotransposon consequences in X-linked dystonia-parkinsonism</a>,” published in <em>Cell</em>, an NYU Langone Health-led team rewrote part of the mouse <em>Taf1</em> gene with a corresponding 78-kilobase segment of patient-derived human <em>TAF1</em> DNA. That segment included a disease-causing SINE-VNTR-<em>Alu</em> (SVA) retrotransposon insertion. Because SVAs are found in humans but not mice, conventional mouse models cannot readily reproduce their effects.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>In mouse embryonic stem cells, the researchers found that the intronic SVA—not the hybrid human-mouse gene structure itself—reduced <em>TAF1</em> messenger RNA. Chromatin and transcriptome analyses indicated that the insertion is actively transcribed and acts as a barrier that may prematurely halt transcription, lowering TAF1 expression and triggering cell death. In mice, nervous system expression of the humanized <em>TAF1</em> allele produced severe atrophy centered in the striatum, the brain region affected in people with XDP. Male mice died within two months, versus the roughly 30 years it can take for symptoms to emerge in humans.</p>
<p>The team also used CRISPR activation, or CRISPRa, to increase <em>TAF1</em> expression in the engineered stem cells. Restoring expression rescued cell viability, offering proof of concept that boosting <em>TAF1</em> transcription could be explored as a treatment strategy. “Our experiments establish a rationale for the future development of new therapeutic approaches for XDP patients,” said senior author Jef D. Boeke, PhD, director of NYU Langone’s Institute for Systems Genetics.</p>
<p>A companion <em>Cell</em> study, titled “<a href="https://www.cell.com/cell/abstract/S0092-8674(26)01339-5" target="_blank" rel="noopener">Myelin pathology is a key feature of X-linked dystonia-parkinsonism</a>,” using the same model further implicated oligodendrocytes—the cells that produce myelin around neuronal axons—rather than neurons alone in XDP. The researchers also detected myelin loss in banked human XDP brain tissue, a feature reportedly missed in earlier studies.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>The work positions genome writing as a way to build models for diseases driven by large or human-specific DNA elements that are difficult to reproduce through conventional editing. Important questions remain, including what factors drive variable progression rates in XDP, whether raising TAF1 levels can safely produce durable benefits in animals, and how broadly the method can be applied to other rare diseases.</p>
<p>The post <a href="https://www.genengnews.com/topics/genome-editing/genome-writing-inserts-human-x-linked-disease-dna-into-mice/">Genome Writing Inserts Human X-Linked Disease DNA Into Mice</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Alberta hospital introduces high&#45;tech simulation lab to strengthen rural healthcare training</title>
<link>https://edusehat.com/en/alberta-hospital-introduces-high-tech-simulation-lab-to-strengthen-rural-healthcare-training</link>
<guid>https://edusehat.com/en/alberta-hospital-introduces-high-tech-simulation-lab-to-strengthen-rural-healthcare-training</guid>
<description><![CDATA[ New facility at Wainwright Health Centre provides hands-on clinical training for nursing students, physicians and healthcare teams without the need to travel to larger urban centres. Healthcare professionals and nursing students in rural Alberta are gaining access to advanced clinical simulation technology through a new training laboratory at Wainwright Health Centre. The facility, which opened […]
The post Alberta hospital introduces high-tech simulation lab to strengthen rural healthcare training appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/11/img-alexander-and-norah.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 20 Nov 2026 22:00:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Alberta, hospital, introduces, high-tech, simulation, lab, strengthen, rural, healthcare, training</media:keywords>
<content:encoded><![CDATA[<p>New facility at Wainwright Health Centre provides hands-on clinical training for nursing students, physicians and healthcare teams without the need to travel to larger urban centres.</p>
<p>Healthcare professionals and nursing students in rural Alberta are gaining access to advanced clinical simulation technology through a new training laboratory at Wainwright Health Centre.</p>
<p>The facility, which opened in October and was highlighted in a November 19 Alberta Health Services feature, provides a realistic hospital environment where healthcare workers can practise clinical procedures, respond to simulated emergencies and strengthen teamwork without putting patients at risk.</p>
<p>Located in a specially converted trailer adjacent to the health centre, the laboratory incorporates high-tech clinical equipment, patient manikins and audiovisual technology that allows clinical scenarios to be observed and reviewed.</p>
<h3>Preparing for complex medical emergencies</h3>
<p>The simulation laboratory allows healthcare teams to rehearse a range of medical situations, including uncommon but potentially life-threatening emergencies.</p>
<p>Participants can practise responding to changing patient conditions, monitoring vital signs and coordinating clinical decisions in a controlled setting. Exercises can also be reviewed afterward, providing opportunities to identify improvements in communication, teamwork and clinical performance.</p>
<p>Jason Laberge, director of the Human Factors and eSIM Provincial Simulation Program with Alberta Health Services, emphasized the importance of practising less-frequent, high-acuity medical events to help healthcare professionals maintain their skills.</p>
<p>Simulation training is particularly valuable in rural healthcare settings, where clinical teams may encounter certain complex emergencies less frequently than their counterparts at larger urban hospitals.</p>
<h3>Supporting the rural nursing workforce</h3>
<p>The laboratory will also serve students enrolled in the University of Calgary’s Nursing Program Rural Community Route, which provides nursing education opportunities closer to rural communities.</p>
<p>The Wainwright program welcomed its first cohort in 2021, establishing a local pathway for students pursuing nursing careers.</p>
<p>The new simulation space expands that training environment by allowing students to gain practical experience with clinical equipment and realistic patient scenarios.</p>
<p>Dr. Catherine Laing, dean of the University of Calgary’s Faculty of Nursing, has highlighted the importance of providing rural nursing students with learning opportunities comparable to those available in urban centres.</p>
<p>For healthcare facilities facing workforce recruitment and retention challenges, investments in local education and professional development can help support a sustainable rural workforce.</p>
<h3>Community investment makes project possible</h3>
<p>The Wainwright and District Health Foundation contributed approximately $250,000 toward the purchase and conversion of the trailer into a dedicated simulation facility.</p>
<p>The project also benefited from collaboration between Alberta Health Services, the University of Calgary and local supporters.</p>
<p>Its development reflects the role community fundraising can play in introducing new healthcare training infrastructure outside major urban centres.</p>
<p>The laboratory is available to nursing students as well as existing hospital staff and physicians, allowing the facility to support both new professionals and continuing clinical education.</p>
<h3>Improving readiness and patient safety</h3>
<p>Clinical simulation is increasingly being used by hospitals to strengthen staff preparedness, particularly for events that require rapid assessment, coordinated interventions and effective communication among healthcare professionals.</p>
<p>By creating opportunities to practise and learn from simulated emergencies, the Wainwright facility aims to strengthen clinical readiness while reducing the risks associated with learning during actual patient care.</p>
<p>Although patient outcome improvements have not yet been reported for the new facility, the project provides an example of how rural hospitals can use technology and local partnerships to improve access to advanced healthcare education.</p>
<p>For Wainwright and surrounding communities, the new laboratory represents an investment in the people delivering healthcare, as well as the infrastructure supporting them.</p>
<div><a href="https://www.albertahealthservices.ca/news/Page20010.aspx?utm_source">Alberta Health Services</a></div>
<p>The post <a href="https://www.hospitalnews.com/alberta-hospital-introduces-high-tech-simulation-lab-to-strengthen-rural-healthcare-training/">Alberta hospital introduces high-tech simulation lab to strengthen rural healthcare training</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>COMLEX&#45;USA Level 3 Is Becoming a One&#45;Day Exam in January 2027</title>
<link>https://edusehat.com/en/comlex-usa-level-3-is-becoming-a-one-day-exam-in-january-2027</link>
<guid>https://edusehat.com/en/comlex-usa-level-3-is-becoming-a-one-day-exam-in-january-2027</guid>
<description><![CDATA[ What Residents Need to Know  COMLEX-USA Level 3 is the final examination in the COMLEX-USA sequence and a required component of osteopathic physician licensure in the United States. Beginning in January 2027, Level 3 will transition to a single-day examination with approximately half the number of questions and Clinical Decision-Making (CDM) cases. While this change […]
The post COMLEX-USA Level 3 Is Becoming a One-Day Exam in January 2027 appeared first on Elite Medical Prep. ]]></description>
<enclosure url="https://elitemedicalprep.com/wp-content/uploads/2026/11/pexels-cottonbro-7428217-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 20 Nov 2026 18:50:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>COMLEX-USA, Level, Becoming, One-Day, Exam, January, 2027</media:keywords>
<content:encoded><![CDATA[<h2><b>What Residents Need to Know </b></h2>
<p><span>COMLEX-USA Level 3 is the final examination in the COMLEX-USA sequence and a required component of osteopathic physician licensure in the United States. Beginning in January 2027, <a href="https://elitemedicalprep.com/comlex-level-3-the-complete-guide/">Level 3</a> will transition to a single-day examination with approximately half the number of questions and Clinical Decision-Making (CDM) cases. While this change may ease the burden on residents balancing clinical responsibilities, the revised format does not diminish the importance of thorough, comprehensive preparation.</span></p>
<p> </p>
<h2><b>Understanding the January 2027 Format Change </b></h2>
<p><span>Previously, COMLEX-USA Level 3 was administered over two days within a 14-day testing window and consisted of 420 single-best-answer multiple-choice questions and 26 Clinical Decision-Making (CDM) cases. Each testing block included 70 multiple-choice questions or 13 CDM cases, followed by a scheduled break.</span></p>
<p> </p>
<p><span>Beginning January 13, 2027, Level 3 will transition to a single-day examination consisting of 240 multiple-choice questions and 16 CDM cases. Multiple-choice question blocks will be reduced to 40 questions, followed by an optional break. This represents a substantial reduction in examination length, bringing both advantages and potential challenges.</span></p>
<p> </p>
<p><span>One of the primary benefits is greater flexibility for residents balancing clinical responsibilities. Scheduling a two-day examination and arranging time away from clinical duties can be challenging during residency. Additionally, developing the stamina to sustain performance across two full testing days was previously a significant component of exam preparation. <a href="https://elitemedicalprep.com/comlex-level-3-changes-what-to-expect-and-how-to-prepare/">The single-day format</a> may be more familiar and manageable for examinees, particularly given that CDM cases often require less than the allotted time to complete.</span></p>
<p> </p>
<h4><b>The examination blueprint</b></h4>
<p><span>Importantly, </span><b>the examination blueprint itself is not changing.</b><span> Content areas will continue to be assessed according to the previously established blueprint percentages, despite the reduction in total questions and cases. The examination will continue to assess clinical knowledge, diagnosis, evaluation, treatment, and management through single-best-answer multiple-choice questions and interactive CDM cases.</span></p>
<p> </p>
<p><span>In my experience, Level 3 content felt very similar to Level 2, with a slightly greater emphasis on diagnostic workups and clinical management. CDM cases simulate evolving clinical scenarios in which additional information becomes available as the patient is evaluated. Although the clinical reasoning involved may feel familiar, the format itself can be challenging, particularly when learning how to enter responses appropriately. This differs from the NBME-style cases used in many study resources geared toward USMLE Step 3.</span></p>
<p> </p>
<p><span>For additional guidance and examples of CDM question formats, refer to the </span><a href="https://www.nbome.org/assessments/comlex-usa/practice-resources/clinical-decision-making-cases-tutorial/"><span>NBOME Clinical Decision-Making Cases Tutorial</span></a><span>.</span></p>
<table>
<tbody>
<tr>
<td><b>Feature</b></td>
<td><b>Current format (through Dec. 2026)</b></td>
<td><b>New format (starting Jan. 13, 2027)</b></td>
</tr>
<tr>
<td><span>Testing days</span></td>
<td><span>2 days</span></td>
<td><span>1 day</span></td>
</tr>
<tr>
<td><span>Multiple-choice questions</span></td>
<td><span>420</span></td>
<td><span>240</span></td>
</tr>
<tr>
<td><span>CDM cases</span></td>
<td><span>26</span></td>
<td><span>16</span></td>
</tr>
<tr>
<td><span>Testing sessions</span></td>
<td><span>Four 3.5-hour sessions across two days (14 hours total)</span></td>
<td><span>Four 2-hour sessions in one day (8 hours total)</span></td>
</tr>
<tr>
<td><span>Clinical decision-making</span></td>
<td><span>Separate CDM sessions</span></td>
<td><span>Final session, divided into two sections</span></td>
</tr>
</tbody>
</table>
<p> </p>
<h2><b>Preparing for Clinical Decision-Making (CDM) Cases</b></h2>
<h3><b>What CDM cases assess</b></h3>
<p><span>The CDM cases simulate real-world patient management by requiring examinees to navigate several stages of clinical decision-making. This begins with data acquisition, including selecting appropriate history questions, physical examination maneuvers, and diagnostic tests. Next, examinees must demonstrate data interpretation by developing a differential diagnosis and interpreting clinical findings and test results. Finally, they must apply treatment and management principles by selecting appropriate interventions, providing patient counseling, and establishing follow-up plans.</span></p>
<p> </p>
<h3><b>Practice clinical reasoning, not just memorization</b></h3>
<p><span>One aspect of CDM practice cases that I initially overlooked was the clinical setting in which the patient was presented. Recognizing the setting should influence your approach to clinical decision-making. For example, cases beginning in a primary care setting should prompt you to consider preventive care, patient communication, medical ethics, and <a href="https://elitemedicalprep.com/how-to-study-for-omm-osteopathic-manipulative-medicine-questions/">osteopathic manipulative treatment (OMT)</a>. </span></p>
<p> </p>
<p><span>In contrast, cases presented in an emergency department require a shift in priorities toward identifying unstable patients, recognizing life-threatening conditions, and initiating timely interventions. Also, focus on selecting diagnostic tests and imaging studies that will meaningfully influence clinical management rather than ordering every potentially relevant study. Developing this judgment is an important part of both CDM case performance and real-world clinical practice.</span></p>
<p> </p>
<h2><b>Building a Study Plan Around Residency </b></h2>
<h3><b>Start with a realistic timeline</b></h3>
<p><span>Adequate preparation is essential for a successful exam day, but preparing for Level 3 presents unique challenges. Unlike Levels 1 and 2, you are now balancing studying with night shifts, call schedules, and potentially long clinical rotations. Setting realistic expectations for what you can accomplish each day and starting practice questions early are key to developing a sustainable study routine.</span></p>
<p> </p>
<p><span>If a particular study method worked well for you during Levels 1 or 2, there is no reason to completely reinvent your approach. Instead, consider maintaining the same resources and <a href="https://elitemedicalprep.com/how-to-painlessly-prepare-for-usmle-step-3-comlex-level-3/">study strategies</a> while reducing your daily question volume. It can be easy to feel overwhelmed or question whether you are adequately preparing when comparing your Level 3 study schedule to previous exams. However, you no longer have a dedicated study period. You may be coming home exhausted after a 12-hour shift, only to wake up before sunrise to do it all over again. There is only so much time you can realistically dedicate to studying.</span></p>
<p> </p>
<h4><strong>Strategies</strong></h4>
<p><span><strong>Here are a few strategies</strong> that helped me maintain consistent studying, even on particularly busy days. Remember, doing something is better than doing nothing!</span></p>
<ul>
<li aria-level="1"><b>Complete questions before your shift:</b><span> Even 10 timed, untutored questions can be worthwhile. If time is limited, save reviewing the explanations for after your shift.</span></li>
<li aria-level="1"><b>Take advantage of downtime:</b><span> If you are on a rotation with more downtime, try completing sets of 10 questions in tutor mode throughout the day.</span></li>
<li aria-level="1"><b>Utilize your lunch break:</b><span> If your rotation allows for a dedicated lunch break, use some of that time to complete and review a question set.</span></li>
<li aria-level="1"><b>Make the most of your days off:</b><span> It is tempting to use these days exclusively for rest (and sometimes you absolutely should!). However, days off are also an opportunity to complete one or two longer question blocks and build the stamina needed for exam day.</span></li>
</ul>
<p> </p>
<h4><strong>Final considerations</strong></h4>
<p><span>Ultimately, preparation for Levels 1 and 2 can be relatively structured, whereas Level 3 requires considerably more flexibility. When possible, schedule your examination after a lighter clinical rotation, allowing time to complete longer practice blocks and review any remaining content before test day. Build flexibility into your study schedule to accommodate unexpected clinical responsibilities, and avoid sacrificing sleep to meet an arbitrary daily question goal.</span></p>
<p> </p>
<p><span>Consistency and deliberate studying are more sustainable than forcing yourself to complete a full question block every day simply because that is what you were accustomed to during previous examinations. The goal is to develop a study routine that works with a busy residency schedule. </span></p>
<p> </p>
<h2><b>Preparing for the One-Day Testing Experience </b></h2>
<p><span>Although the one-day format reduces the number of separate testing days, it still requires preparation for a full day of sustained cognitive effort. This can be particularly challenging for residents who have limited opportunities to practice completing multiple question blocks in a single sitting. I highly recommend scheduling your examination after a lighter clinical rotation, when you can dedicate several days to longer study sessions and simulate the demands of exam day.</span></p>
<p> </p>
<p><span>Use these practice sessions to work through multiple timed blocks with planned breaks. This is also an opportunity to determine what works best for you in terms of snacks, hydration, and break timing. Having a plan before test day can help minimize distractions and allow you to focus on the examination itself.</span></p>
<p> </p>
<p><span>One positive aspect of my Level 3 experience was how quickly the CDM cases seemed to move. They are more interactive than traditional multiple-choice questions, which helped break up the monotony of the examination. I also found that they moved relatively quickly because multiple questions often stem from the same clinical scenario or stage of patient evaluation. Many examinees find themselves finishing earlier than anticipated, in part because the CDM cases may take less time than the allotted testing time.</span></p>
<p> </p>
<p><span>Finally, do not overlook the logistical aspects of test day. Confirm your scheduled examination date, testing-center requirements, and arrival time well in advance. Account for traffic, parking, and any other potential delays so that you are not adding unnecessary stress to an already demanding day.</span></p>
<p> </p>
<p><span>The best preparation is to complete timed question blocks consistently and, as you get closer to your examination, incorporate practice sessions that approximate the actual four-session testing format.</span></p>
<h2><b>Common Preparation Mistakes to Avoid</b></h2>
<p><span>Level 3 may feel more manageable than Levels 1 and 2, particularly with the transition to a shorter, single-day examination. However, adequate preparation can be challenging when balancing a demanding residency schedule without a dedicated study period. Over the years, I have seen both my students and myself make several common mistakes when preparing for these examinations:</span></p>
<ul>
<li aria-level="1"><b>Neglecting CDM cases: </b><span>Strong multiple-choice performance does not necessarily translate into proficiency with the interactive CDM format. The NBOME also has specific guidelines and expectations that differ from NBME-style cases. Make sure you practice using NBOME-specific resources and familiarize yourself with the examination policies and instructions available online.</span></li>
<li aria-level="1"><b>Using too many <a href="https://elitemedicalprep.com/free-downloads/">study resources</a>:</b><span> This is a common mistake across all board examinations, but it can be especially detrimental when preparing for Level 3. With limited study time, avoid spreading yourself too thin across multiple question banks and resources. Choose one primary question bank that you feel confident using and prioritize thoroughly reviewing the questions you complete. Understanding why an answer is correct or incorrect is often more valuable than simply increasing your question count.</span></li>
<li aria-level="1"><b>Overloading your schedule or studying without a plan:</b><span> Unrealistic study expectations can quickly undermine consistency, sleep, and even your performance during residency. You likely will not be able to study with the same intensity or structure that you did for Level 1, and that is okay. A realistic, flexible schedule that allows you to accomplish something each day is much more sustainable than an overly ambitious plan that you cannot maintain. Even small amounts of consistent, deliberate studying can add up over time.</span></li>
</ul>
<p> </p>
<p><span>To put this into perspective, I spent the most time preparing for Level 1, where I scored a 730, and the least time preparing for Level 3, where I scored a 972. This is not to suggest that Level 3 requires minimal preparation, but rather that effective studying, familiarity with the examination format, and clinical experience can make a significant difference. The goal is not to replicate your Level 1 study schedule; it is to develop an approach that works for you as a resident physician.</span></p>
<p> </p>
<h2><b>Prepare Strategically for the Updated Exam </b></h2>
<p><span>As COMLEX-USA Level 3 transitions to a one-day examination, residents should recognize that a shorter test does not eliminate the need for thoughtful, comprehensive preparation. Success requires a structured but flexible study plan that prioritizes clinical decision-making, familiarity with the CDM format, and consistent practice. Ultimately, the most effective preparation strategy is one that strengthens your clinical knowledge and reasoning skills while remaining realistic and sustainable within the demands of residency.</span></p>
<p> </p>
<p>Preparing for COMLEX Level 3 while balancing residency responsibilities can be challenging. Our <a href="https://elitemedicalprep.com/comlex-level-3-tutoring/">COMLEX Level 3 tutors</a> can help you create a personalized study plan that fits your schedule. Target your knowledge gaps and strengthen your clinical reasoning. Refine your approach to CDM cases and develop effective test-taking strategies for the updated exam format.</p>
<p>The post <a href="https://elitemedicalprep.com/comlex-usa-level-3-is-becoming-a-one-day-exam/">COMLEX-USA Level 3 Is Becoming a One-Day Exam in January 2027</a> appeared first on <a href="https://elitemedicalprep.com/">Elite Medical Prep</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Maryland backs upper payment limits as other states have second thoughts on PDABs</title>
<link>https://edusehat.com/en/maryland-backs-upper-payment-limits-as-other-states-have-second-thoughts-on-pdabs</link>
<guid>https://edusehat.com/en/maryland-backs-upper-payment-limits-as-other-states-have-second-thoughts-on-pdabs</guid>
<description><![CDATA[ The recent decision by Maryland’s Prescription Drug Affordability Board (PDAB) to set upper payment limits (UPLs) on two prescription drugs is not expected to […]
The post Maryland backs upper payment limits as other states have second thoughts on PDABs appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2023/04/pharmacy-benefit-manager-pbm-e1795107738637.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 20 Nov 2026 15:00:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Maryland, backs, upper, payment, limits, other, states, have, second, thoughts, PDABs</media:keywords>
<content:encoded><![CDATA[<p>The recent decision by Maryland’s Prescription Drug Affordability Board (PDAB) to set upper payment limits (UPLs) on two prescription drugs is not expected to impact what patients pay for their medicine.</p>
<p>The limits, approved Nov. 16, only apply to what state and local government purchasers pay for the drugs, not the amount patients are charged at the pharmacy counter, according to the<a href="https://www.baltimoresun.com/2026/11/16/maryland-drug-payment-limits/"> Baltimore Sun</a>.</p>
<p>Set to go into effect Jan. 1, the limits would make Maryland one of the first states to enforce UPLs. The other state being Colorado, which established a UPL in 2025, which is temporarily being blocked by the courts. Maryland stands out for leaning into its PDAB at a time when <a href="https://avalerehealth.com/thought-leadership/state-pricing-controls-at-an-inflection-point-maximum-fair-price-and-the-shifting-prescription-drug-affordability-board-landscape/">other states are finding PDABs unworkable</a> and are closing them or choosing against implementing them.</p>
<p>As their name suggests, Prescription Drug Affordability Boards (PDABs) are supposed to target affordability, but the question has become: Affordability for who?</p>
<p>Patients <a href="https://schaeffer.usc.edu/research/prescription-drug-affordability-boards-reshape-reimbursement-while-leaving-core-problems-unresolved/">are not seeing reductions</a> in out-of-pocket costs due to PDABs. State governments, which often spend millions on these boards, <a href="https://www.multistate.us/insider/2026/6/8/pdab-implementation-challenges-slow-state-drug-cost-efforts">have yet to realize savings</a>. Meanwhile, the price controls attempted by PDABs can limit access to drugs for patients and have a dampening effect on investment and innovation.</p>
<p>“PDABs target the wrong problem,” explains the Biotechnology Innovation Organization (BIO) <a href="https://www.bio.org/sites/default/files/2026-11/pdabs_promised_cost_savings_-_patients_are_still_waiting.pdf">in a new infographic</a>. “PDABs limit what insurers and other institutions pay for a medicine. But a lower payment limit does not necessarily translate to lower out-of-pocket costs for patients.”</p>
<h2>The wrong lever</h2>
<p>Nine states have passed legislation establishing PDABs. While the rules vary, the basic concept is that a PDAB can review the price of individual drugs and set limits on the amount paid for that drug by state institutions or private insurers. The approach has not achieved the desired results.</p>
<p>“The lever that they’re pulling has a single effect: It reduces the amount of money that insurance companies and their PBMs pay for prescription drugs. But they are not legally required to pass those savings on to consumers,” according to Brian Warren, BIO VP for State Government Affairs. “This can allow PBMs and insurers to be more profitable without improving affordability for patients.”</p>
<p>Furthermore, UPL caps established for drugs through a PDAB can reduce access to that drug, research in <a href="https://www.ajmc.com/view/upper-payment-limit-implementation-risks-for-patients-pharmacies-and-providers">The American Journal of Managed Care</a> shows.</p>
<p>“Given existing incentives in coverage decisions, payers may remove UPL drugs from formularies, shift them to higher cost-sharing tiers, or impose stricter utilization management,” and pharmacies may choose to stop stocking drugs if they might lose money by selling them, the research says.</p>
<h2>Maryland moves forward as others wind down</h2>
<p>As states rethink PDABs, many are closing them or choosing not to implement them:</p>
<ul>
<li><a href="http://law360.com/healthcare-authority/articles/2364855/amid-budget-woe-new-hampshire-shutters-drug-price-board">New Hampshire</a> voted to close its PDAB last year for being costly and ineffective.</li>
<li><a href="https://www.lsc.ohio.gov/assets/legislation/136/hb96/ps/files/hb96-otherboards-and-commissions-bill-analysis-as-passed-by-the-senate-136th-general-assembly.pdf">Ohio</a> defunded its PDAB last year after years of inactivity.</li>
<li><a href="https://gmcboard.vermont.gov/sites/gmcb/files/documents/Act%20134%20Final%20Report%20on%20Prescription%20Drug%20Affordability%20in%20Vermont_0.pdf">Vermont</a> decided against a PDAB after a state study found it unworkable.</li>
<li><a href="https://bio.news/latest-news/patient-groups-praise-virginia-pdab-veto/">Virginia’s</a> governor vetoed efforts to pass PDAB legislation.</li>
<li><a href="https://www.reuters.com/legal/litigation/judge-blocks-colorados-first-of-its-kind-price-cap-amgens-enbrel-2026-07-01/">Colorado’s</a> first attempt at setting a UPL was blocked by a federal judge.</li>
<li><a href="https://www.ourquadcities.com/news/local-news/illinois-law-to-lower-prescription-drug-prices-struck-down/">Illinois</a> legislation to lower drug prices was struck down in court, and related PDAB legislation <a href="https://www.ilga.gov/legislation/BillStatus?DocTypeID=SB&DocNum=3496&GAID=18&SessionID=114&LegID=166497">failed in the legislature</a>.</li>
</ul>
<p>“PDABs are difficult to implement” and require significant resources, says BIO’s infographic. “PDABs across six states have cost more than $28 million to establish and operate.”</p>
<p>Nonetheless, Maryland is moving ahead with PDAB price controls.</p>
<p>As <a href="https://mdtechcouncil.com/statement-from-the-maryland-tech-council-on-pdab-upper-payment-limit-action/">the Maryland Tech Council</a> noted when the state’s PDAB recommended the first UPL in April, price controls can harm innovation, something a state that relies on a robust biotech industry should avoid.</p>
<p>“While tech incubators, centers of innovation, universities and elected officials are working hard to increase the state’s competitiveness, Maryland’s unelected PDAB is putting Maryland’s future as a life sciences leader at risk,” says a statement from the Maryland Tech Council, a BIO affiliate.</p>
<p>“Policies that may alter reimbursement structures or limit market viability can have a chilling effect on investment particularly for early-stage and mid-sized firms that drive much of Maryland’s innovation economy,” says the statement, noting that barriers to innovation also deter America’s efforts to compete globally for biotech leadership.</p>
<p><a href="https://www.bio.org/sites/default/files/2026-11/pdabs_promised_cost_savings_-_patients_are_still_waiting.pdf"><strong>Read: BIO’s PDAB infographic.</strong></a></p>
<p>The post <a href="https://bio.news/state-policy/maryland-backs-upper-payment-limits-as-other-states-have-second-thoughts-on-pdabs/">Maryland backs upper payment limits as other states have second thoughts on PDABs</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Type 1 Diabetes Delayed in Mice by Stem Cell&#45;Derived Vesicles That Calm Immune Response</title>
<link>https://edusehat.com/en/type-1-diabetes-delayed-in-mice-by-stem-cell-derived-vesicles-that-calm-immune-response</link>
<guid>https://edusehat.com/en/type-1-diabetes-delayed-in-mice-by-stem-cell-derived-vesicles-that-calm-immune-response</guid>
<description><![CDATA[ Extracellular vesicles produced by certain types of pluripotent stem cells (PSC) were found to help reduce immune attacks on insulin-producing cells in the pancreas and delay the onset of diabetes in a mouse model.
The post Type 1 Diabetes Delayed in Mice by Stem Cell-Derived Vesicles That Calm Immune Response appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Low-Res_extra-cellular-vesicle.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 20 Nov 2026 07:45:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Type, Diabetes, Delayed, Mice, Stem, Cell-Derived, Vesicles, That, Calm, Immune, Response</media:keywords>
<content:encoded><![CDATA[<p>In people with type 1 diabetes, the immune system mistakenly identifies insulin-producing cells in the pancreas as foreign and attacks them, leaving the body unable to properly regulate blood sugar. While insulin therapy helps manage the disease, it does not stop the underlying immune attack.</p>
<p>UCLA researchers have identified a potential new way to protect these cells by harnessing extracellular vesicles—tiny particles naturally released by nearly all types of cells that help them communicate with one another.</p>
<p>Their preclinical study found that vesicles produced by certain types of pluripotent stem cells (PSCs) can help reduce immune attacks on insulin-producing cells in the pancreas and delay the onset of diabetes in a mouse model. The research was inspired in part by a feature of pregnancy, which means that the mother’s immune system generally tolerates a developing embryo, even though it carries genetic material from the father that the maternal immune system could recognize as foreign. The findings suggest a possible strategy for preserving insulin-producing cells before they are destroyed.</p>
<p>Song Li, PhD, associate dean for graduate and professional education and a professor of bioengineering at the UCLA Samueli School of Engineering and a member of the UCLA Broad Stem Cell Research Center, is senior and corresponding author of the team’s published paper in <em>Nature Nanotechnology</em>, titled “<a href="https://doi.org/10.1038/s41565-026-02320-z" target="_blank" rel="noopener">Pluripotent stem cell-derived extracellular vesicles for systemic immune modulation in diabetes therapy</a>.”</p>
<p>Embryonic development is characterized by “remarkable immune tolerance,” the authors noted, “… yet whether this property extends to pluripotent stem cell-derived extracellular vesicles (EVs) has remained unclear.” Li added, “Nature has designed something amazing. If we can better understand how an embryo avoids rejection by the mother’s immune system, it could be very useful for a lot of immune-related diseases.”</p>
<p>For their study the team investigated whether extracellular vesicles released by pluripotent stem cells—which share characteristics with cells found in early embryonic development—might also possess immune-regulating properties. The researchers compared vesicles from embryonic stem cells (ESCs) and induced pluripotent stem cells, or iPSCs, with those from mesenchymal stem cells (MSCs), which have been widely studied for their ability to regulate inflammation. “Extracellular vesicles (EVs) secreted by adult stem cells, particularly mesenchymal stem cells (MSCs), have been extensively investigated for their regenerative potential across a wide range of pathological conditions,” the team pointed out.</p>
<p>In experiments using mouse and human immune cells, vesicles from both types of pluripotent stem cells showed stronger anti-inflammatory effects than those from mesenchymal stem cells. They also promoted the formation of regulatory T cells (Tregs), specialized immune cells that help prevent the immune system from attacking the body’s own tissues. “… we show that EVs from pluripotent stem cells (PSCs), including embryonic stem cells and induced pluripotent stem cells, outperform mesenchymal stem cell-derived EVs in suppressing proinflammatory cytokine secretion, reducing T cell activation and inducing regulatory T cells,” they stated.</p>
<p>Further analysis showed that the vesicles carry distinctive proteins, lipids, and genetic material that may contribute to their immune-regulating properties, providing insight into how these naturally produced nanoparticles influence immune cells. “… PSC EVs display distinct molecular signatures, containing unique proteins and microRNAs absent from mesenchymal stem cell-derived EVs, including the pluripotency-associated proteins ROR1 and CD133 and members of the miR-302 family,” the investigators continued.</p>
<p>To test whether these immune-regulating effects could help prevent diabetes, the researchers introduced immune cells that attack insulin-producing pancreatic cells into mice, then treated the animals with extracellular vesicles derived from iPSCs.</p>
<p>Because extracellular vesicles are rapidly cleared from the injection site, the team developed an injectable hydrogel that gradually releases them over several days. “Soluble EVs are cleared rapidly from subcutaneous tissue, and therefore, we developed an injectable hydrogel composed of hyaluronic acid (HA) and Pluronic F127 that transitions from a solution to a gel state at body temperature,” they explained. “Both polymers are widely used in biomedical formulations, which further supports the translational potential of this platform.”</p>
<p>The treatment was injected beneath the skin near the neck, where the vesicles could interact with immune cells in nearby lymph nodes. These immune cells could then circulate throughout the body, potentially reducing harmful immune activity in the pancreas. The researchers found that two treatments with extracellular vesicles, either alone or delivered through the hydrogel, significantly delayed the onset of diabetes compared with untreated controls.</p>
<p>At the end of the 90-day study, 55% of mice receiving vesicles in the hydrogel remained diabetes-free. Mice receiving vesicles in the hydrogel also had more regulatory T cells in their lymph nodes and retained more insulin-producing pancreatic tissue than control animals. “Delivered via a biomaterial scaffold, two local injections of induced PSC EVs significantly improved diabetes-free survival in an antigen-specific type 1 diabetes model, increasing regulatory T cell populations in draining lymph nodes, as well as inducing systemic immune modulation and preserving β-cell mass,” the scientists stated.</p>
<p>“One thing that surprised us was that a local injection could provide protection throughout the body,” said Li, who is also a member of the UCLA Health Jonsson Comprehensive Cancer Center and the California NanoSystems Institute at UCLA. “That’s the beauty of this approach.”</p>
<p>The researchers also addressed a major obstacle to developing extracellular vesicle-based treatments: producing sufficient quantities of consistent, high-quality particles. Rather than growing stem cells on flat laboratory surfaces, the team grew them in three-dimensional clusters suspended in gently moving liquid. “Suspension culture allows PSCs to grow as floating aggregates and maintain pluripotency without differentiation into embryoid bodies,” they explained. This approach increased vesicle production 3.4-fold per million cells while preserving important characteristics of the particles.  Because iPSCs can multiply extensively in the laboratory, they could provide a more consistent and scalable source of therapeutic vesicles than adult stem cells, whose growth potential is more limited.</p>
<p>The approach remains experimental, and further studies are needed to determine whether it would be safe and effective in people. Li envisions the greatest potential for patients in earlier stages of type 1 diabetes, when some insulin-producing cells remain functional.</p>
<p>“In the early stages, you still have some pancreatic cells left,” Li said. “If you can regulate the immune cells, you may be able to keep the remaining cells functional.” In more advanced disease, immune regulation alone would not replace cells that have already been lost. However, the approach could potentially help prevent immune rejection of transplanted insulin-producing cells.</p>
<p>The team hopes to test the approach in larger animal models and investigate appropriate dosing, long-term effectiveness, and whether the treatment could weaken the body’s defenses against infection.</p>
<p>Beyond diabetes, the findings could inform research into other autoimmune diseases and strategies for protecting transplanted cells from immune rejection. Acknowledging questions that still remain to be addressed, the authors concluded, “These findings establish PSC EVs as a scalable immunomodulatory platform for autoimmune disease and for immune tolerance in cell therapy.”</p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/type-1-diabetes-delayed-in-mice-by-stem-cell-derived-vesicles-that-calm-immune-response/">Type 1 Diabetes Delayed in Mice by Stem Cell-Derived Vesicles That Calm Immune Response</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Former Verily Leaders Build AI Platform to Get More from Proteomics Data</title>
<link>https://edusehat.com/en/former-verily-leaders-build-ai-platform-to-get-more-from-proteomics-data</link>
<guid>https://edusehat.com/en/former-verily-leaders-build-ai-platform-to-get-more-from-proteomics-data</guid>
<description><![CDATA[ Tesorai’s AI platform reanalyzes massive proteomics repositories, letting researchers mine raw mass spectrometry data instead of condensed forms. In an Alzheimer’s project, it found phosphorylated tau 217 in four datasets where the original authors did not report it.
The post Former Verily Leaders Build AI Platform to Get More from Proteomics Data appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2021/08/GettyImages-1064220756-1024x768.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 20 Nov 2026 07:45:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Former, Verily, Leaders, Build, Platform, Get, More, from, Proteomics, Data</media:keywords>
<content:encoded><![CDATA[<p>Before founding Tesorai in 2024, its three co-founders were long-time colleagues at Verily, Alphabet’s life science company. Melissa Miao, Tesorai’s CEO, led business initiatives and strategic partnerships; Peter Cimermancic, PhD, Tesorai’s CTO, led artificial intelligence teams, and Charlie Kim, PhD, Tesorai’s CSO, launched and led Verily’s molecular science program. While at Verily, they recognized opportunities to use advanced AI to maximize signal extraction from massive laboratory datasets, particularly in mass spectrometry-based proteomics. As Miao told <em>GEN</em> in an interview, “That’s what inspired us to leave and build our own team specifically focused on building AI models to maximize the insights that you could extract from those data sets.”</p>
<p>Today, Tesorai’s AI models process raw mass spectrometry data from labs’ new experiments, public repositories, and company archives. This week, the company announced that it had raised $5.3 million in fresh seed funding, bringing its total funding to $8 million. Investors in the current round include Perplexity Fund, IQT, South Central Ventures, New Stack Ventures, NextGen Venture Partners, f7 Ventures, VitalStage Ventures, and ZAKA. The company’s representatives also say that they have signed contracts with both biopharmaceutical and research organizations. Its list of named collaborators includes teams at MD Anderson Cancer Center, New York University, and the Michael J. Fox Foundation.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>The company plans to use the new funds to expand its work with biopharmaceutical and research customers, grow partnerships across the life sciences, and to extend its platform beyond proteomics to other kinds of molecular data. When asked what kinds of partnerships best fit the company’s offerings, Miao said, “We see applications across all drug development or most drug development stages,” and that spans “target discovery to biomarker discovery all the way down to more development stages.” Besides biopharma, she said that the company is currently expanding into the agrolife sciences space as well.</p>
<p>Focusing on proteomics made sense given the growing interest in these types of studies coupled with several technological advances made in recent years,” Kim said. “We can finally see the whole proteome in the way that genomics was able to 20 years ago,” he said in an interview. But mass spectrometry data “is very challenging to analyze, and there are a lot of opportunities for AI to help.”</p>
<p>But Tesorai plans to expand beyond proteins to other types of omics information. “One of the things we’re really excited about is integrative analysis,” he said. Specifically, “being able to combine different layers of biological data to assemble a mechanistic understanding.” With that in mind, the company plans to take on transcriptomics data next and eventually genomics data as well.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>“We are part of an ecosystem of efforts that are really trying to dramatically accelerate the pace of life science research,” Kim said. “If you think of every experiment as a step forward, what we’re trying to do is make every step bigger by getting more information out of every sample, and we’re trying to make those steps faster, both by our engineering and ability to process massive volumes of data quickly,” as well as “through our agentic interface and making it so that you can execute analysis very quickly in natural language.”</p>
<h3><strong>The platform’s architecture and components</strong></h3>
<p>Anchoring the company’s platform is a proprietary AI model built to analyze proteomics datasets. The components include Tesorai Search, a deep-learning engine that is described in a <em><a href="https://www.sciencedirect.com/science/article/abs/pii/S002228362600313X?via%3Dihub">Journal of Molecular Biology </a></em>paper. According to the company, the engine reads full spectra, enabling it to find more peptides, and its model works out most of the 20 to 40 settings adopted by standard analysis tools. In the paper, they report that Tesorai Search “consistently identifies more unique peptides compared to established search engines like MaxQuant, FragPipe (+MSBooster), PEAKS, and Proteome Discoverer” and that it achieves “average increases of 12–68%.” They also claim that it shows “strong performance even on data not encountered during training.”</p>
<p>The platform also includes Tesorai Trove, which catalogs curated public proteomics datasets from human tissue, and structures studies’ metadata into searchable tables that can be used both by humans and AI models. Most tools available today “only query and mine” the condensed and reduced datasets available in the scientific literature, Cimermancic noted during a conversation with <em>GEN</em>. With Trove, “we can really boost the number of insights and discoveries in biology by allowing scientists to mine raw data directly.”</p>
<p>Key to making this type of analysis possible is the way that Tesorai trains its models. Cimermancic explained it this way: Instead of training models on the fly, which can lead to overfitting and inaccuracies, Tesorai pre-trains its model on data from public repositories and other sources to ensure that it generalizes across experimental conditions and instrument types. Because the data is “heterogeneous to begin with,” the model “doesn’t necessarily have any biases,” he said. Trained models are also validated in different ways. For example, if models are only trained on data from one manufacturer’s instruments, their performance is validated using instruments from other manufacturers. Additionally, the company’s academic partners have designed ways to experimentally evaluate its models, for example, using the AI to detect single gene knockouts in cell lines.</p>
<p>A third tool, Tesorai Chat, runs quality checks, statistics, and charts using conversational prompts. Tesorai shared some benchmarking results for Tesorai Chat earlier this year. On a 94-case proteomics benchmark, Tesorai Chat reached over 92% accuracy ahead of tools like Phylo and GPT-5.4, among others.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>Tesorai received the first patent for its platform last year. In addition to data, the company has also invested in the underlying engineering and infrastructure so that it can process data at scale. “More and more data is being generated in large part because instruments are getting more advanced,” and “what we observed was that software wasn’t keeping up,” which is “why we started building out this proprietary AI model,” Miao said. Furthermore, “because it’s so scalable, we’ve been able to now reprocess massive repositories of data,” enabling scientists to dig deeper into both the scientific literature and the raw data.</p>
<p>The company has also shared data that demonstrates the types of results its platform can provide. “We’ve been able to show that we can increase the number of peptide and protein identifications,” as well as how the platform improves accuracy, Miao said.</p>
<p>Tesorai operates a token system where customers pay for what they use. It’s a new model for proteomics software and one that is more accessible than the traditional annual licensing structure, according to Miao. “We’re looking to be more generous with the credits that we offer for free for academic research teams,” she said. Because “biopharma tends to have slightly different needs, oftentimes, we’ll enter into specific service engagements that might include working within their cloud environment or creating mechanisms where it’s easier to share analyses across departments and divisions. But for the most part, we’re token-based pricing.”</p>
<h3><strong>Searching for Alzheimer’s biomarkers</strong></h3>
<p>To help elucidate the value of the platform, Kim pointed to a recent application of Tesorai’s platform in Alzheimer’s disease, where the team used it to test a newly published Alzheimer’s blood panel against data from five existing brain studies. The multiprotein plasma panel, which could be a tool for distinguishing between early- and late-stage Alzheimer’s, is described in more detail in a <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fdoi.org%2F10.1001%2Fjamaneurol.2026.2650&data=05%7C02%7CUduak.Thomas%40sagepub.com%7C42aab5ce855d45ebcd0108df44f9ada6%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639305511318547563%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=K7VEYJF%2B%2BkEU6VaTsK9qMkNMBMf0dgNi%2Fbyd3G9vgxo%3D&reserved=0"><em>JAMA Neurology</em></a> paper published this year.</p>
<p>Details of Tesorai’s work are published in a bioRxiv preprint titled “<a href="https://www.biorxiv.org/content/10.64898/2026.08.31.748393v1">Rapid Mechanistic Bridging of an Alzheimer’s Disease Plasma Protein Staging Panel Across Brain Proteomics Cohorts</a>” that was posted in September. For the study, “we were interested in understanding whether the biology of those proposed proteins was also reflected in the brain and whether or not, in the brain, that also tracked with the severity of Alzheimer’s disease,” Kim explained.</p>
<p>An initial read of the five datasets in question showed that they appeared to be missing p-tau217, a well-established plasma biomarker for assessing amyloid-beta pathology in people at risk of developing Alzheimer’s. “Because phosphorylated tau 217 (p-tau217) and amyloid beta 1-40 (Aβ40) were not reported for any studies, raw spectra were reprocessed to quantify these proteoforms,” the scientists wrote. As it turned out, p-tau217was present in four of the five original datasets but had not been reported in the original protein summaries.</p>
<p>Additionally, there was evidence across the cohorts that the plasma-derived biomarker panel could “distinguish early from late-stage Alzheimer’s disease,” Kim said. This was also true for other proteins analyzed in the study. The analysis “provided a mechanistic explanation for why these proteins were changing in the blood in association with Alzheimer’s disease severity.”</p>
<p>Furthermore, Tesorai completed the analysis in three weeks, without having to perform a new study. It is one example of the value that Tesorai’s platform offers, according to Kim. Much like this case where a reanalysis of raw data was fruitful, there are likely other instances “where the original intent of the study authors wasn’t necessarily to ask this kind of question, but the questions can be answered because the information is in the data.” And by combining “multiple data sets in this way … there can be major accelerations in being able to validate and answer questions like this.”</p>
<p>The post <a href="https://www.genengnews.com/topics/artificial-intelligence/former-verily-leaders-build-ai-platform-to-get-more-from-proteomics-data/">Former Verily Leaders Build AI Platform to Get More from Proteomics Data</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>AMR Awareness Week: C. diff patient finds her voice in advocacy</title>
<link>https://edusehat.com/en/amr-awareness-week-c-diff-patient-finds-her-voice-in-advocacy</link>
<guid>https://edusehat.com/en/amr-awareness-week-c-diff-patient-finds-her-voice-in-advocacy</guid>
<description><![CDATA[ “My whole childhood, I got lots and lots of infections: ear infections, eye infections, skin infections, UTIs, lung infections—anything opportunistic, I was getting it. […]
The post AMR Awareness Week: C. diff patient finds her voice in advocacy appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/11/1000031701.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 20 Nov 2026 00:40:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>AMR, Awareness, Week:, diff, patient, finds, her, voice, advocacy</media:keywords>
<content:encoded><![CDATA[<p><span>“My whole childhood, I got lots and lots of infections: ear infections, eye infections, skin infections, UTIs, lung infections—anything opportunistic, I was getting it. So I was always on antibiotics,” says Minnie Hatch, a patient advocate from Ogden, Utah. </span></p>
<p><span>Eventually, her prolonged antibiotic use led to another, lesser-known infection: </span><i><span>Clostridioides difficile (C. diff).</span></i><span> Her story shows not only the challenges some patients face with </span><i><span>C. diff</span></i><span>, but also the work that still needs to happen when treating these patients.</span></p>
<p><span>November 18–24 is </span><a href="https://www.who.int/campaigns/world-amr-awareness-week"><span>Antimicrobial Awareness Week</span></a><span>, an annual global campaign aimed at increasing understanding of antimicrobial resistance (AMR) and promoting best practices across human, animal, plant, and environmental health. Additionally, November is </span><a href="https://cdiff.org/see-c-diff/"><i><span>C. diff </span></i><span>Awareness Month</span></a><span>, and as such, Bio.News is sitting down with Hatch to discuss her experiences as a patient and an advocate, and understand more about this misunderstood infection.</span></p>
<h3>Understanding C. diff</h3>
<p><span>“I first started getting sick when I was 19 years old,” Hatch says. “I’m 32 now, and my </span><i><span>C. diff</span></i><span> went undetected for a really long time, at least a year, because I was so young, and my symptoms were so broad.”</span></p>
<p><i><span>C. diff </span></i><span>is a germ that causes diarrhea and inflammation of the colon and while it is more common in senior populations, it can affect anyone. It’s estimated to cause more than 400,000 infections in the United States each year and can be life-threatening.</span></p>
<p><span>This year, the Centers for Disease Control and Prevention’s (CDC) recent </span><a href="https://arpsp.cdc.gov/artr/cdiff?ACSTrackingID=USCDC_426-DM160173&ACSTrackingLabel=November%20is%20C.%20diff%20Awareness%20Month&deliveryName=USCDC_426-DM160173"><span>Antimicrobial Resistance Threats Report</span></a><span>, designated </span><i><span>C. diff </span></i><span>at a threat level of “serious,” indicating that the CDC considers it to pose a significant health hazard to the public, requiring aggressive tracking, prevention, and public health action.</span></p>
<p><i><span>C. diff</span></i><span> causes more than 11,000 estimated deaths in hospitalized patients, and more than $6.4 billion in healthcare costs overall every year, </span><a href="https://arpsp.cdc.gov/artr/cdiff?ACSTrackingID=USCDC_426-DM160173&ACSTrackingLabel=November%20is%20C.%20diff%20Awareness%20Month&deliveryName=USCDC_426-DM160173"><span>the CDC reports</span></a><span>. However, rates of </span><i><span>C. diff</span></i><span> have declined 21% overall from 2018–2020 and remained stable from 2020–2023, per CDC reporting. </span></p>
<p><span>“This is due in part to improvements in </span><i><span>C. diff</span></i><span> diagnosis and the success of efforts to prevent infections. U.S. progress against this threat shows that a comprehensive public health response—grounded in targeted infection prevention, antibiotic stewardship, diagnostic excellence, and increased treatment options—works,” the CDC writes.</span></p>
<h3>An ongoing struggle with C. diff</h3>
<p><span>Hatch herself has seen these numbers play out firsthand, but, as Hatch explains, numbers aren’t the whole story; the patient experience is also incredibly important.</span></p>
<p><span>After months of gastrointestinal issues, the lightbulb finally went on in Hatch’s gastroenterologist’s mind. “He said, </span><i><span>Oh, I didn’t see the forest through the trees. I think you have C. diff</span></i><span>” Hatch explains. </span></p>
<p><span>And indeed, when they sent out a stool sample, it tested positive. Hatch’s doctor was confident that after treatment, she wouldn’t have to deal with </span><i><span>C. diff</span></i><span> again. “But that is not what happened for me. It just got worse,” she says.</span></p>
<p><span>Hatch dealt with years of </span><i><span>C. diff </span></i><span>and she tried a number of treatment options. </span></p>
<p><span>“During COVID, I got </span><i><span>C. diff</span></i><span> again, and this time they weren’t able to treat me,” she remembers. “I wasn’t responding to the antibiotics. I dropped down to 94 pounds, and my doctors told me to put my will together. They said, </span><i><span>There’s nothing we can do. We are waiting for you to go septic.</span></i><span> Luckily, I had found the Peggy Lillis Foundation (PLF).”</span></p>
<h3>The Peggy Lillis Foundation</h3>
<p><span>Hatch had started working with PLF in 2017 shortly after the birth of her son. When the nurses saw that she’d had a previous </span><i><span>C. diff</span></i><span> diagnosis, they put Hatch into quarantine. </span></p>
<p><span>“It put the nurses around me into a panic. They thought I was going to get all the babies sick,” says Hatch. “My son needed NICU care, and they refused to put him in the NICU. The nurses wouldn’t touch me. Ultimately, I ended up asking to be discharged as soon as I could, so I could take my son somewhere that would provide care.”</span></p>
<p><span>Hatch knew her experience wasn’t right, so when she got home she started researching, and found PLF.</span></p>
<p><span>PLF was founded by Christian and Liam Lillis after the death of their mother in 2010 from </span><i><span>C. diff.</span></i><span> When Hatch reached out, they immediately offered to help, and just three weeks after the birth of her son, Hatch and her husband were headed to New York City to participate in a training on advocacy.</span></p>
<p><span>During her COVID-era </span><i><span>C. diff</span></i><span>, as doctors were telling her to get her affairs in order, Hatch was able to tap into her advocacy skills and network to save her life and find a treatment that worked.</span></p>
<h3>Finding her voice as a patient advocate</h3>
<p><span>Ultimately, the cause of Hatch’s repeated infections was discovered to be an autoimmune disorder called “specific antibody deficiency,” which causes Hatch’s body to not create antibodies, leaving the door open for opportunistic infections. So by all accounts, Hatch will potentially have to navigate </span><i><span>C. diff</span></i><span> in the future, making her advocacy work all the more important.</span></p>
<p><span>“When I first started getting sick, less than one in five doctors had even heard of </span><i><span>C. diff</span></i><span>, and only two doctors in my state could treat it at the level I had it,” she says. </span></p>
<p><span>Luckily, Hatch’s voice has gotten more powerful, both for herself and others like her.</span></p>
<p><span>“Nobody can make me cry like a doctor can,” she says. “I find that I still have to advocate loudly. There are many times when, if I have a new doctor, I won’t go to the appointment on my own. Sometimes advocating for yourself is enough, and sometimes it’s not.”</span></p>
<p><span>Hatch didn’t want other people to go through what she had been through. </span></p>
<p><span>“I knew that the best way that I could help other people was to share my story so that doctors could hear it,” she says. “Maybe they would think, </span><i><span>Oh, well, that’s wrong. We shouldn’t be treating people that way.”</span></i></p>
<p><span>Hatch says that more important work she is doing today is peer-to-peer support for </span><i><span>C. diff</span></i><span> patients and their caregivers.</span></p>
<p><span>“For the patients at home,” she continues, “I think the key is not to live in fear and to let yourself live your life. People come into contact with </span><i><span>C. diff</span></i><span> every day and are typically OK.”</span></p>
<p><span>The big issue, Hatch asserts, is misinformation. </span></p>
<p><span>“We can’t treat </span><i><span>C. diff </span></i><span>patients like they’re gross or contagious,” she says. “I’ve had providers refuse to touch me, refuse to work with me, didn’t want me to touch anything, and that is a rhetoric based in fear, not fact.”</span></p>
<p><i><span>If you are interested in learning more, or getting involved, visit: </span></i><a href="https://cdiff.org/"><i><span>https://cdiff.org/</span></i></a><i><span> </span></i></p>
<p>The post <a href="https://bio.news/latest-news/amr-awareness-week-c-diff-patient-finds-her-voice-in-advocacy/">AMR Awareness Week: C. diff patient finds her voice in advocacy</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>New ultrasound technology treats kidney cancer without surgical incisions in Asian first</title>
<link>https://edusehat.com/en/new-ultrasound-technology-treats-kidney-cancer-without-surgical-incisions-in-asian-first</link>
<guid>https://edusehat.com/en/new-ultrasound-technology-treats-kidney-cancer-without-surgical-incisions-in-asian-first</guid>
<description><![CDATA[ Researchers at the University of Hong Kong have performed Asia’s first histotripsy treatments for kidney cancer, demonstrating the potential of a non-invasive technology that destroys tumour tissue using focused ultrasound rather than surgical incisions. Announced November 18, the milestone involved two patients treated at Gleneagles Hospital Hong Kong through a collaborative clinical trial led by […]
The post New ultrasound technology treats kidney cancer without surgical incisions in Asian first appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/11/01J5AYK9MEAP9N0S034R4F44DF.webp" length="49398" type="image/jpeg"/>
<pubDate>Fri, 20 Nov 2026 00:30:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>New, ultrasound, technology, treats, kidney, cancer, without, surgical, incisions, Asian, first</media:keywords>
<content:encoded><![CDATA[<p>Researchers at the University of Hong Kong have performed Asia’s first histotripsy treatments for kidney cancer, demonstrating the potential of a non-invasive technology that destroys tumour tissue using focused ultrasound rather than surgical incisions.</p>
<p>Announced November 18, the milestone involved two patients treated at Gleneagles Hospital Hong Kong through a collaborative clinical trial led by the University of Hong Kong’s Faculty of Medicine (HKUMed).</p>
<p>Both patients, aged 70 and 71, had small kidney tumours measuring approximately two centimetres. The procedures were performed on October 13 and took less than an hour each.</p>
<p>Neither patient experienced observable complications, and both were discharged the following day. At a two-week follow-up, kidney function remained stable.</p>
<h2>Destroying tumours with ultrasound</h2>
<p>Histotripsy is an emerging non-invasive treatment that uses precisely focused ultrasound pulses to mechanically break down targeted tissue.</p>
<p>Unlike conventional thermal ablation, which destroys tissue using heat, histotripsy generates microscopic bubbles within the tumour. These bubbles rapidly expand and collapse, disrupting and liquefying the targeted tissue.</p>
<p>The procedure is guided by real-time ultrasound imaging and performed under general anesthesia. It requires no surgical incisions or needles to reach the tumour and does not use ionizing radiation.</p>
<p>Researchers believe the technology could offer an alternative for selected patients who may otherwise require surgery or other forms of tumour ablation.</p>
<h2>Preserving kidney function</h2>
<p>Kidney cancer treatment often involves removing part or all of the affected kidney, depending on tumour characteristics and the patient’s clinical condition.</p>
<p>Histotripsy offers the potential to destroy targeted cancer tissue while preserving surrounding healthy structures.</p>
<p>One of the two patients treated in Hong Kong had undergone major abdominal surgery approximately 10 years earlier, making a treatment without additional surgical incisions particularly attractive.</p>
<p>The research team is now recruiting additional patients to evaluate the technology’s safety and effectiveness.</p>
<h2>Further research needed</h2>
<p>Although the initial results are encouraging, histotripsy remains investigational for kidney cancer.</p>
<p>The two cases demonstrate early procedural feasibility and short-term recovery, but larger studies and longer follow-up are needed to determine cancer control, recurrence rates and long-term outcomes.</p>
<p>The Hong Kong team previously introduced histotripsy for liver cancer in 2024 and has been investigating additional applications involving other solid-organ tumours.</p>
<p>The latest procedures represent another step in evaluating whether focused ultrasound could eventually provide selected cancer patients with less invasive treatment options.</p>
<p>For hospitals and cancer centres, the development highlights the growing potential of image-guided technologies to expand treatment choices while reducing the physical burden of conventional procedures.</p>
<p>The post <a href="https://www.hospitalnews.com/new-ultrasound-technology-treats-kidney-cancer-without-surgical-incisions-in-asian-first/">New ultrasound technology treats kidney cancer without surgical incisions in Asian first</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Manitoba plans to reopen Victoria Hospital emergency department in summer 2027</title>
<link>https://edusehat.com/en/manitoba-plans-to-reopen-victoria-hospital-emergency-department-in-summer-2027</link>
<guid>https://edusehat.com/en/manitoba-plans-to-reopen-victoria-hospital-emergency-department-in-summer-2027</guid>
<description><![CDATA[ Expanded south Winnipeg facility will include 40 treatment spaces, additional higher-acuity observation beds and dedicated mental health assessment capacity. Manitoba is preparing to restore full emergency department services at Victoria Hospital in south Winnipeg by summer 2027, marking a significant step in the province’s efforts to expand hospital capacity and improve access to emergency care. […]
The post Manitoba plans to reopen Victoria Hospital emergency department in summer 2027 appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/11/shutterstock_2476138081.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 20 Nov 2026 00:30:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Manitoba, plans, reopen, Victoria, Hospital, emergency, department, summer, 2027</media:keywords>
<content:encoded><![CDATA[<p>Expanded south Winnipeg facility will include 40 treatment spaces, additional higher-acuity observation beds and dedicated mental health assessment capacity.</p>
<p>Manitoba is preparing to restore full emergency department services at Victoria Hospital in south Winnipeg by summer 2027, marking a significant step in the province’s efforts to expand hospital capacity and improve access to emergency care.</p>
<p>Announced November 18, the reopening will return emergency services to a hospital whose emergency department closed in 2017 and was converted into an urgent care centre.</p>
<p>The Manitoba government says the project is progressing toward completion of major construction work in spring 2027, followed by the planned opening next summer.</p>
<p>Once operational, the redesigned emergency department will provide 40 treatment spaces, compared with 33 in the existing urgent care configuration.</p>
<h3>Expanded emergency care capacity</h3>
<p>The new department will include two resuscitation rooms, 24 treatment beds, two triage beds, six minor-treatment beds and six dedicated mental health assessment beds.</p>
<p>The redevelopment will also add eight higher-acuity observation beds, expanding the hospital’s ability to monitor patients who require more intensive clinical attention.</p>
<p>Other improvements include approximately 150 additional staff parking spaces.</p>
<p>Hospital staff and south Winnipeg residents participated in consultations that helped inform the redevelopment’s design.</p>
<p>The reopening is expected to give residents of south Winnipeg another location for emergency treatment and may help distribute patient volumes across the city’s hospital network. The effect on wait times will depend on staffing, demand and how emergency services are coordinated.</p>
<h3>Workforce recruitment supports expansion</h3>
<p>The province linked the reopening plans to its healthcare workforce recruitment efforts, reporting that Manitoba now has 500 net additional doctors compared with 2023.</p>
<p>At Victoria Hospital specifically, staffing additions include two physicians since June 2026. The province also reports hiring 24 allied health professionals, 10 healthcare aides and 26 nurses since October 2023.</p>
<p>The figures represent an important workforce milestone, although they do not establish how many emergency-specific staff will ultimately be available when the department opens.</p>
<p>Manitoba is also planning to restore emergency services at other hospitals, including Eriksdale, as part of its broader efforts to rebuild acute-care capacity.</p>
<h3>Staffing challenges remain</h3>
<p>Despite the planned expansion, physician and nursing organizations have raised concerns about the availability of appropriately trained staff.</p>
<p>Doctors Manitoba has indicated that emergency physician availability remains substantially below the national average, while the Manitoba Nurses Union has questioned whether sufficient nursing resources will be available to support additional emergency treatment spaces.</p>
<p>Another consideration is critical care capacity. The province has indicated that Victoria Hospital will provide a step-down level of intensive monitoring rather than restoring a conventional intensive care unit.</p>
<p>These issues highlight the importance of aligning infrastructure investments with workforce recruitment, clinical resources and regional patient-transfer arrangements.</p>
<h3>Rebuilding emergency services</h3>
<p>Victoria Hospital serves a growing area of south Winnipeg and provides inpatient, outpatient, surgical, geriatric rehabilitation and mental health services.</p>
<p>Restoring its emergency department represents a major change in the hospital’s role within the Winnipeg healthcare system.</p>
<p>The planned opening will be an important milestone, but the full benefits for patients and neighbouring hospitals will depend on achieving the construction timetable and ensuring adequate staffing and operational readiness.</p>
<p>For Manitoba, the project illustrates the interconnected challenges of rebuilding emergency capacity, retaining healthcare professionals and responding to increasing demand for hospital services.</p>
<p>The post <a href="https://www.hospitalnews.com/manitoba-plans-to-reopen-victoria-hospital-emergency-department-in-summer-2027/">Manitoba plans to reopen Victoria Hospital emergency department in summer 2027</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Loss of measles elimination status signals growing vaccination crisis</title>
<link>https://edusehat.com/en/loss-of-measles-elimination-status-signals-growing-vaccination-crisis</link>
<guid>https://edusehat.com/en/loss-of-measles-elimination-status-signals-growing-vaccination-crisis</guid>
<description><![CDATA[ America’s loss of measles elimination status is a warning sign of a growing and entirely preventable public health threat that extends beyond measles and […]
The post Loss of measles elimination status signals growing vaccination crisis appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/11/cdc-83YXJwzKwmY-unsplash.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 19 Nov 2026 21:05:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Loss, measles, elimination, status, signals, growing, vaccination, crisis</media:keywords>
<content:encoded><![CDATA[<p>America’s loss of measles elimination status is a warning sign of a growing and entirely preventable public health threat that extends beyond measles and is caused by low vaccination rates.</p>
<p>Measles, which had been officially declared eliminated in the U.S. in 2000, is once again endemic in the country, the Pan American Health Organization (PAHO) <a href="https://www.paho.org/en/news/17-11-2026-paho-urges-countries-step-efforts-stop-measles-outbreaks-and-move-towards">officially announced Nov. 17</a>. The decision is based on proof that <a href="https://www.cnn.com/2026/11/13/health/us-measles-elimination-status">one specific strain of measles virus </a>had been in circulation within the U.S. for more than a year.</p>
<p>“The loss of measles elimination status is a completely preventable setback that reflects our failure to protect thousands of Americans, especially children, from a disease for which we have had a safe and highly effective vaccine for decades,” <a href="https://www.bio.org/press-release/bio-statement-loss-measles-elimination-status">said Phyllis Arthur</a>, EVP and Chief of Global Health at the Biotechnology Innovation Organization (BIO).</p>
<p>“Measles is the canary in the coalmine,” Arthur added. “It is the most obvious sign of the broader risk of low vaccination rates.”</p>
<p>The loss of measles elimination status in the U.S. was no surprise, with outbreaks causing 5,412 reported cases so far this year—the most in since 1991—according to the<a href="https://www.cdc.gov/measles/data-research/index.html"> Centers for Disease Control and Prevention (CDC)</a>. The cases led to<a href="https://beaconbio.org/en/report/?reportid=2090bc17-2eeb-42ef-8021-1248721f25e1"> 10 reported</a> deaths, with six thus far<a href="https://www.cdc.gov/measles/data-research/index.html"> confirmed by the CDC</a>.</p>
<p>The measles outbreaks have been caused by a reduction in vaccination that is also causing concerning increases in other vaccine preventable diseases.</p>
<p>“We need to act as one country with a unified goal of protecting public health,” Arthur said. “Rather than debate how we got here, we must move forward together to reestablish the norm of routine vaccination for a host of pediatric infectious diseases that used to cause significant morbidity and mortality and are starting to cause them again.”</p>
<h2>Unknown danger</h2>
<p>We do not yet know the full extent of the threat, according to Arthur.</p>
<p>“The measles cases we’re hearing about are just the tip of the iceberg. There are many unreported illnesses,” she said. “Adults who were never vaccinated but were protected by herd immunity and kids who should have been vaccinated are being surrounded by this highly contagious disease, and it’s spreading.”</p>
<p><a href="https://evidence.nejm.org/doi/full/10.1056/EVIDpha2600416">A preliminary study</a> of measles outbreaks between January 2025 and September 2026 found 112 cases among pregnant women and 13 congenital cases of measles passed on to newborns. The outbreaks were mostly in communities with low vaccination rates, and 98% of the women involved were unvaccinated or had unknown vaccination status,<a href="https://evidence.nejm.org/doi/full/10.1056/EVIDpha2600416"> said the study, released Nov. 16</a>.</p>
<p>Meanwhile, other preventable diseases are raging. Pediatric influenza, which can be controlled with a seasonal vaccine, hit a near-record last year.</p>
<p>“The 2024–25 influenza season had the highest number of pediatric deaths reported (280) since child deaths became nationally notifiable in 2004, except for the 2009–10 influenza A(H1N1)pdm09 pandemic,”<a href="https://www.cdc.gov/mmwr/volumes/74/wr/mm7436a2.htm"> according to CDC</a>, which recommends flu vaccination. Of the children who died of flu last year, 89% were not fully vaccinated, CDC said.</p>
<p>Pertussis, or whooping cough, which is especially dangerous for infants, saw<a href="https://jamanetwork.com/journals/jama/article-abstract/2822941"> an alarming increase in 2024</a> followed by<a href="https://www.cdc.gov/pertussis/php/surveillance/index.html"> another heavy year in 2025</a>, even though the vaccine is<a href="https://my.clevelandclinic.org/health/drugs/21639-pertussis-whooping-cough-vaccine"> highly effective</a>.</p>
<p>Another routine immunization for babies is the Haemophilus influenzae type b (Hib) vaccine.</p>
<p>“Before the vaccine, Hib was the leading cause of bacterial meningitis in children less than five years old,”<a href="https://pauloffit.substack.com/p/the-return-of-hib"> according to pediatric vaccine expert Paul Offit, MD</a>. “Hib also<a href="https://www.cdc.gov/hi-disease/about/index.html#:~:text=The%20most%20common%20serious%20infections%20caused%20by,infection)%20Infectious%20arthritis%20(swelling%20of%20a%20joint)"> caused</a> pneumonia, sepsis, cellulitis, and arthritis.”</p>
<p>The Hib vaccine became available in 1987, leading to a 99% decrease in infections, so there were typically about two deaths a year in the U.S., Offit said. Yet in 2025, a doctor<a href="https://www.usatoday.com/story/life/health-wellness/2026/04/04/new-hib-cases-concern-deadly-disease-vaccine/89466803007/"> reported two cases in Florida alone</a>, impacting unvaccinated children, one fatal and one causing permanent brain damage. This alarming increase indicates a return of Hib due to low vaccination, Offit said.</p>
<p>Vitamin K shots, routinely given to newborns since the 1960s, protect infants from vitamin K deficiency, which can cause bleeding that leads to permanent brain damage or death. Babies without the shot are<a href="https://okckidsurology.com/vitamin-k-for-newborns-why-it-matters-shot-vs-oral-drops/"> 81 times more likely</a> to experience bleeding due to vitamin K deficiency, with<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7041551/"> as many as 1,700 out of 100,000</a> unprotected babies impacted. But parents increasingly<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7041551/"> decline the vitamin K shot</a>.</p>
<p>“The number of babies that did not receive the shot rose from 2.92% in 2017 to 5.18% in 2024,”<a href="https://www.nih.gov/news-events/nih-research-matters/protective-vitamin-shots-newborns-decline"> according to research.</a> “That’s a 77% increase in infants not receiving the shot over the eight-year period.”</p>
<h2>The need to work on messaging</h2>
<p>The declining vaccination rates that<a href="https://bio.news/health/low-vaccination-rates-put-40-million-children-worldwide-at-risk-of-measles/"> began during COVID</a> dropped even further following this year’s<a href="https://bio.news/bios-view/bio-warns-of-risks-from-change-to-cdcs-vaccine-recommendations/"> changes in federal recommendations</a> for vaccination,<a href="https://www.kff.org/medicaid/kindergarten-routine-vaccination-rates-continue-to-decline/"> according to research</a>.</p>
<p>The solution, Arthur said, is unequivocally proclaiming the necessity of immunization.</p>
<p>“We need to have clear, consistent evidence-based messaging on the value of the measles-mumps-rubella vaccine from senior leaders within and outside of government. We need to have a better discussion of the danger of measles and the benefits of vaccination,” she said. “You hear talk of the risks of measles vaccination, but let’s talk about the much greater risks of measles.”</p>
<p>Along with appropriate messaging, federal authorities need to support state authorities in responding to outbreaks and providing education, Arthur said. She noted that communities with a 93% vaccination rate instead of the recommended 95% are concerning, but the real problem is communities where vaccination rates are in the low 80s.</p>
<p>“State leaders are aware of these communities, and they are better placed to make partnerships with leaders in those communities and reach people with the message that vaccination protects them and their children,” Arthur said.</p>
<p>Beyond the measles vaccine, this same community effort is necessary to encourage the use of all vaccines, according to Arthur.</p>
<p>“We know these diseases cause morbidity, and mortality,” she said. “And all of them are preventable with a very simple intervention, which is the vaccine.”</p>
<p><a href="https://www.bio.org/press-release/bio-statement-loss-measles-elimination-status"><strong>Read BIO’s campaign: Invest in America. Vaccinate.</strong></a></p>
<p> </p>
<p>The post <a href="https://bio.news/health/loss-of-measles-elimination-status-signals-growing-vaccination-crisis/">Loss of measles elimination status signals growing vaccination crisis</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>A human liver has been kept alive outside the body for a record seven weeks</title>
<link>https://edusehat.com/en/a-human-liver-has-been-kept-alive-outside-the-body-for-a-record-seven-weeks</link>
<guid>https://edusehat.com/en/a-human-liver-has-been-kept-alive-outside-the-body-for-a-record-seven-weeks</guid>
<description><![CDATA[ Researchers in Australia claim they’ve kept a human liver alive, on life support, outside the body for seven weeks, opening up speculative new possibilities in biomedical engineering. The feat, whose details are pending publication, was carried out in Sydney after a team led by surgeon and inventor Carlo Pulitano connected a donated liver to a… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/11/EOPS-V1.1-.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 19 Nov 2026 21:05:02 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>human, liver, has, been, kept, alive, outside, the, body, for, record, seven, weeks</media:keywords>
<content:encoded><![CDATA[<div data-chronoton-summary="<ul><br><li><strong>Record-breaking liver survival:</strong> A Sydney surgical team kept a human liver alive outside the body for seven weeks using an automated system of pumps and sensors that mimics the functions of a living body.</li><br><li><strong>Automation was the secret:</strong> When the team compared manual versus automated life-support systems across 55 donated livers, automated perfusion tripled average survival time to four weeks, with one organ reaching seven.</li><br><li><strong>Organs that heal:</strong> Organ perfusion has become more common over the past decade. Researchers have found some evidence that extended perfusion may allow damaged organs to repair themselves before transplant.</li><br><li><strong>A new frontier in medicine:</strong> Long-term organ life-support is attracting serious scientific interest. Two new scientific societies were recently founded to explore the concept. </li><br></ul>" data-chronoton-post-id="1148934" data-chronoton-expand-collapse="1" data-chronoton-analytics-enabled="1"></div>


<p class="wp-block-paragraph">Researchers in Australia claim they’ve kept a human liver alive, on life support, outside the body for seven weeks, opening up speculative new possibilities in biomedical engineering.</p>



<p class="wp-block-paragraph">The feat, whose details are pending publication, was carried out in Sydney after a team led by surgeon and inventor Carlo Pulitano connected a donated liver to a system of automated pumps and sensors that fed the organ nutrients, supplied it with blood, and whisked away waste. </p>



<p class="wp-block-paragraph">In an interview, Pulitano, a transplant surgeon at the Royal Prince Alfred Hospital and a professor at the University of Sydney, likened the life support system to “an artificial body.” Its official name is the Extended Organ Perfusion System.</p>



<p class="wp-block-paragraph">“Our group is the only one in the world to have maintained a human liver under fully normothermic, physiological conditions for seven weeks,” he says.   </p>





<p class="wp-block-paragraph">Normothermic means body temperature, or about 37 °C. The previous record for keeping an internal organ alive outside the body was set in Switzerland several years ago. That organ—also a liver—lasted around two weeks. </p>



<p class="wp-block-paragraph">Most organs destined for transplant survive only a few hours in special ice buckets and need to be raced to their destination. Over the last decade, however, surgeons have been switching to perfusion systems, which pump warm or cold fluids into an organ. This can double the time it can be held before it must be transplanted. </p>



<p class="wp-block-paragraph">Pulitano says the key to breaking the record was to automate the systems used to keep the organ thriving. During <a href="https://easl.eu/event/ilts_congress_2026/">a meeting in Switzerland</a> earlier this year, the Sydney team described perfusing 55 human livers, one after the other. Some were connected to a system that needed to be adjusted manually, but for those placed on the automated system—which produced the seven-week survivor—the average survival time tripled, to about four weeks.  </p>



<p class="wp-block-paragraph">Perfusion has already enabled doctors to <a href="https://www.technologyreview.com/2015/09/01/166380/transplant-surgeons-revive-hearts-after-death/">restart hearts</a> from dead people and keep them beating outside the body. Paulo Martins, a transplant doctor at the University of Oklahoma, says about half the kidneys he transplants are now perfused, even though the process can add $100,000 to the cost of a transplant.  </p>



<p class="wp-block-paragraph">While the research awaits formal publication, the eventual goal is what Pulitano and colleagues call “time-unlimited liver preservation.”</p>



<p class="wp-block-paragraph">Scientists have already discovered possible medical benefits to keeping organs on life support longer than usual. One, they say, is that perfused organs apparently <a href="https://www.technologyreview.com/2026/09/14/1144010/donated-livers-can-be-made-biologically-younger/">start to repair</a> themselves and become stronger after a day or so. That’s what led a Swiss team, in 2022, to transplant a damaged liver <a href="https://www.nature.com/articles/s41587-022-01354-7">that had been kept on perfusion for three days</a>—the longest time any internal organ had remained outside the body before a successful transplant, says Waldemar Hoffmann, the CEO and cofounder of Apersys, a startup formed to commercialize the technology.</p>



<p class="wp-block-paragraph">Pulitano says his own startup, Aeternum Life Technologies, will be helping with a planned trial in Sydney to transplant low-quality livers kept on perfusion for four days.</p>



<p class="wp-block-paragraph">What’s less clear, says Hoffmann, is whether any transplant surgeon would ever want, or need, to use an organ kept alive for nearly two months. He says people in the field believe Pulitano’s record is real, but they don’t know how healthy the organ was at the end or even what so much extra time is likely to achieve. “The key question is what the purpose for a seven-week perfusion would be,” he says.  </p>



<p class="wp-block-paragraph">Yet that’s where things could start to get interesting, <a href="http://pubmed.ncbi.nlm.nih.gov/40259786/">says Martins</a>, the Oklahoma surgeon. Long-term life support could enable far-out concepts like artificial wombs, new types of organ manufacturing, and the chance to experiment directly on human organs outside the body for extended periods.</p>



<p class="wp-block-paragraph">For his part, Pulitano says long-term machine perfusion could help grow new organs. In living donations, surgeons commonly take half of a person’s liver to give someone else. After about two months, both parts will have grown back almost to their full volume. Pulitano says he’s tried dividing a liver and then attaching the sections to the machine. If that works, he says, it could be a way to multiply one donor liver into several full-size organs.</p>



<p class="wp-block-paragraph">“It’s important to have people thinking outside the box and pushing the limits and creating possibilities for things that, right now, sometimes we don’t even have a need for but are going to be needed in the future,” says Martins. “That’s how science moves.”  </p>





<p class="wp-block-paragraph">He’s not the only one who thinks so. For instance, a US company, Bexorg, has been reanimating human brains using perfusion pumps. The idea is to study what effects experimental drugs have on them. That company perfuses brains for about a day but has said it wants to extend the time to two weeks.</p>



<p class="wp-block-paragraph">Similar experiments can be done on livers, says Pulitano, who has already tried adding gene therapies to the organs. “It gives us a living human organ model for translational research that no animal system can match, because the biology, the immunology, and the drug responses are human from the outset,” he says.</p>



<p class="wp-block-paragraph">Meanwhile, in Silicon Valley, patents <a href="https://patents.google.com/patent/WO2024155957A1/en">filed</a> by <a href="https://www.technologyreview.com/2021/09/04/1034364/altos-labs-silicon-valleys-jeff-bezos-milner-bet-living-forever/">Altos Labs</a>, a billionaire-backed longevity startup, describe attempts to introduce reprogramming genes into animal livers maintained outside the body. Eventually, Altos scientists <a href="https://www.cell.com/cell-stem-cell/fulltext/S1934-5909(25)00445-X"></a>have speculated, they might temporarily disconnect a failing organ while it’s still in a person’s body, connecting it to a perfusion machine in order to douse it with ultra-powerful genetic treatments without risking the rest of the body.</p>



<p class="wp-block-paragraph">Doctors probing the limits of organ life support have now formed two new scientific societies to explore the concept. One, founded by Martins and called the International Society for Organ Preservation and Perfusion Therapy, will hold its inaugural meeting this year in Italy. The other, based in China, was <a href="https://info.newsgd.com/node_91423f6a55/e6458c1195.shtml">launched in August</a> to advance what doctors at the First Affiliated Hospital of Sun Yat-Sen University have termed “<a href="https://www.ovid.com/jnls/cmj/fulltext/10.1097/cm9.0000000000003524~organ-medicine-new-concept-of-life-sciences">organ medicine”</a>: research at the level of whole organs kept alive by “bionic maintenance.”  </p>



<p class="wp-block-paragraph">“What is exploding is the idea of this technology that clearly goes beyond simply organ preservation,” says Pulitano. “Basically, that’s a concept that’s entirely new.”</p>]]> </content:encoded>
</item>

<item>
<title>Alzheimer’s Disease and Aging Linked to Changes in the Hypothalamus</title>
<link>https://edusehat.com/en/alzheimers-disease-and-aging-linked-to-changes-in-the-hypothalamus</link>
<guid>https://edusehat.com/en/alzheimers-disease-and-aging-linked-to-changes-in-the-hypothalamus</guid>
<description><![CDATA[ Researchers combined measurements from brain images and single cell transcriptome maps to build a resource, HypoAD, as an atlas of the human hypothalamus in aging and AD, which they have made available to the research community.
The post Alzheimer’s Disease and Aging Linked to Changes in the Hypothalamus appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2020/06/Jun25_2020_GettyImages-91560048_brain-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 19 Nov 2026 10:10:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Alzheimer’s, Disease, and, Aging, Linked, Changes, the, Hypothalamus</media:keywords>
<content:encoded><![CDATA[<p>Before their memory is affected, many individuals with Alzheimer’s disease (AD) may experience trouble sleeping, lose their daily rhythms, and show changes in metabolism and stress hormones. These functions are regulated by the hypothalamus, a structure at the base of the brain. A study headed by researchers at the Buck Institute for Research on Aging has now found that the hypothalamus is not a bystander in Alzheimer’s disease, and its circadian and metabolic control centers show specific age-related changes in volume and gene activity early in the disease.</p>
<p>For their study, the team combined measurements from brain images and single-nucleus RNA sequencing maps to build a resource, HypoAD, as an atlas of the human hypothalamus in aging and AD, which they have made available to the research community.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>Ashley Webb, PhD, associate professor at the Buck Institute for Research on Aging, is senior and co-corresponding author of the team’s published report in <em>Nature</em>, titled “<a href="https://doi.org/10.1038/s41586-026-11305-w" target="_blank" rel="noopener">Hypothalamic volume and cell-type changes in aging and Alzheimer’s disease</a>,” in which they concluded, “Our findings provide a multimodal view of how the hypothalamus is altered in aging and early AD, illustrating region-specific and cell-type-specific changes that have not been observed previously.”</p>
<p>AD is an age-associated neurodegenerative disorder with a prevalence of roughly 10–30% among individuals older than 65 years, the authors wrote. And while the main feature is cognitive decline, they stated, “… AD manifests as a systemic condition involving profound disruptions in sleep, circadian rhythms, metabolic homeostasis, stress responses, and neuroendocrine functions.” These key processes are regulated by the hypothalamus, a small, complex part of the brain that orchestrates a wide range of physiological and neuroendocrine processes that are commonly dysregulated in aging and AD.</p>
<p>“Emerging evidence suggests that hypothalamic dysfunction not only correlates with but also actively exacerbates AD pathology and cognitive decline,” the team noted. However, they pointed out, “Despite its central role in homeostasis and brain aging, the hypothalamus remains an understudied region in the context of human aging and AD.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>Webb noted, “Most of what we know about Alzheimer’s comes from the hippocampus and cortex, because that’s where memory is organized and lives. But patients and families often report disrupted sleep, a change in appetite, or different responses to stress alongside memory changes.”</p>
<p>The hypothalamus is made up of many specialized sub-areas called nuclei. Each nucleus runs a different job. The suprachiasmatic nucleus (SCN) is the body’s master clock, while the arcuate nucleus (ARC) handles appetite and energy balance. Very little is known about how the individual nuclei and their cell types change in human aging and Alzheimer’s.</p>
<p>“No single method can answer this question,” said co-senior author Manu Goyal, MD, director of neuroimaging labs at Washington University School of Medicine in St. Louis. “MRI can tell you what’s happening in living people but is limited in its resolution. Single-cell sequencing tells you what’s happening inside each cell type but requires actual tissue. The goal here was to put them side by side to let us see things that neither could show alone.”</p>
<p>Noting that recent studies even suggest that changes such as circadian disruptions may precede the development of other common clinical symptoms, Webb added, “We wanted to look directly at the part of the brain that controls those functions, and to do it with enough resolution to see which cells are changing with age and in the disease.”</p>
<p>To better enable this insight, the team created HypoAD as an atlas of the human hypothalamus in aging and AD, by combining high-resolution magnetic resonance imaging from hundreds of individuals and single-nucleus RNA sequencing of more than 600,000 nuclei from young participants, patients with AD, and age-matched non-dementia control participants.</p>
<div class="wp-caption alignright"><img decoding="async" aria-describedby="caption-attachment-340774" class="size-medium wp-image-340774" src="https://www.genengnews.com/wp-content/uploads/2026/11/Low-Res_Volumes-300x160.jpg" alt="Three-dimensional reconstructions of hypothalamic subregions from MRI scans of two female individuals at 72 years of age, one healthy (left) and one with Alzheimer’s Disease (right). Differences in volume can be observed in regions involved in regions labeled SCN, AN, and Pe, which are important for sleep, circadian rhythms, and metabolic regulation. [Jürgen Germann] " width="300" height="160" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Low-Res_Volumes-300x160.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Low-Res_Volumes.jpg 700w" sizes="(max-width: 300px) 100vw, 300px"><p class="wp-caption-text">Three-dimensional reconstructions of hypothalamic subregions from MRI scans of two female individuals at 72 years of age, one healthy (left) and one with Alzheimer’s disease (right). Differences in volume can be observed in regions involved in regions labeled SCN, AN, and Pe, which are important for sleep, circadian rhythms, and metabolic regulation. [Jürgen Germann]</p></div>
<p>Using MRI scans from 458 living adults and a high-resolution atlas, the researchers measured the volume of 13 separate hypothalamic sub-regions. Participants were grouped by cognitive status and by levels of amyloid-β, the protein that forms plaques in Alzheimer’s disease. The team then sequenced about 614,000 individual cells from post-mortem hypothalamic tissue. This method shows which genes are switched on in each cell, so changes can be traced to specific cell types and cellular functions. Donors included seven people with mostly early-stage Alzheimer’s disease, seven age-matched healthy controls, and three younger people from published data.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>The researchers validated their findings against spinal fluid protein measurements, a prefrontal cortex dataset from about 800 donors, spatial gene-expression maps, and a mouse model of Alzheimer’s.</p>
<p>The scientists found that though overall hypothalamic volume barely changed with age, different areas of the hypothalamus did either change or increase in volume. The lateral hypothalamus shrank with age, while the SCN, arcuate, paraventricular, periventricular, and dorsomedial hypothalamic nuclei (DMH) grew. Webb said this phenomenon held after accounting for Alzheimer’s disease status, suggesting it is a feature of typical aging. “Together, these findings suggest that hypothalamic nuclei undergo differential volumetric changes with aging, even in the absence of AD,” the investigators noted.</p>
<p>Volume differences tied specifically to AD also occurred but weren’t statistically significant, suggesting that a more sensitive method might be needed to determine what happens with the Alzheimer’s hypothalamus. “… in comparison to aging and sex, differences in the volumes of hypothalamic nuclei in the context of amyloid-β deposition and cognitive impairment were more modest or absent,” they noted.</p>
<p>“If you only measure the hypothalamus as a whole, it looks like nothing is happening,” Webb said. “When you zoom in, you see some regions shrinking and others growing. That tells us aging is reshaping this region in a very specific, structured way.”</p>
<p>The researchers applied machine-learning models to distinguish Alzheimer’s disease cells from control cells using gene expression alone. Their findings indicated that the most important genes centered on two themes, inflammation and circadian rhythm. “At the molecular level, machine learning models identified the inflammatory response and regulators of circadian rhythms as key cellular predictors of AD,” they stated.</p>
<p>Microglia, the brain’s resident immune cells, showed the largest number of altered genes. When the researchers ordered cells along a young-to-old-to-Alzheimer’s path, microglia gradually shifted from a resting state toward the “disease-associated” state seen in other Alzheimer’s disease studies. “This finding suggests that the hypothalamus transitions to an inflammatory state early in Alzheimer’s disease, just like the brain regions involved in memory,” said Webb. The authors further noted in their report, “Consistent with other brain regions, microglia, which are widely recognized mediators of brain aging and neurodegeneration, emerged as particularly prone to transcriptional reprogramming in the hypothalamus in early AD, although our unpaired, cross-sectional data cannot establish a causal or directional relationship.”</p>
<p>The hypothalamus is a diverse area of the brain, harboring many distinct cell types critical for its varied physiological roles. The scientists identified 254 neuron subtypes and found that inhibitory (GABAergic) neurons changed the most, mainly in neuropeptide and receptor signaling. One prominent group of neurons in the SCN showed disrupted signaling by vasopressin, a key output of the body’s clock.</p>
<p>“Sleep and circadian problems are some of the earliest signs of Alzheimer’s, and circadian behavioral changes known as sundowning, occur later in the disease,” Webb said. “But we’ve never had a good molecular explanation for why. Seeing vasopressin signaling disrupted in the brain’s master clock, in people at early stages of the disease, gives us a concrete place to start.”</p>
<p>Total cell numbers did not appear to change. Instead, the data point to cells getting larger through increased activity of mTOR, a growth pathway, along with remodeling of material between cells and inflammatory activation of glia. The authors present this as a hypothesis for future work.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>They also noted several limits to their study, including the small autopsy cohort of 14 donors, which is typical for this kind of study. The MRI and sequencing data come from different people, so the two are compared side by side rather than combined statistically. And because the design is cross-sectional, the results show associations, not cause and effect.</p>
<p>“This is a starting point, not the final word,” Webb said. “Our next step is to follow these changes over time and test whether protecting the brain’s clock, and neuropeptide signaling in particular, can slow the disease or help manage symptoms. If circadian disruption is one of the first things to go wrong, it may also be one of the first places we can intervene.”</p>
<p>In their paper, the team commented, “HypoAD provides a framework to investigate hypothalamic dysfunction and establishes a roadmap for targeted interventions aimed at mitigating physiological disruptions to potentially slow disease progression … We highlight notable vulnerabilities in GABAergic and/or inhibitory neurons, SCN and DMH circadian regulators, and inflammatory microglial cascades, underscoring their potential roles in instigating early hypothalamic dysfunction.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/alzheimers-disease-and-aging-linked-to-changes-in-the-hypothalamus/">Alzheimer’s Disease and Aging Linked to Changes in the Hypothalamus</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>London Calling: Flagship Expands in U.K. to Build AI&#45;Native Platform Companies</title>
<link>https://edusehat.com/en/london-calling-flagship-expands-in-uk-to-build-ai-native-platform-companies</link>
<guid>https://edusehat.com/en/london-calling-flagship-expands-in-uk-to-build-ai-native-platform-companies</guid>
<description><![CDATA[ Flagship expects to recruit and train an initial team of approximately 50 U.K.-based scientist-entrepreneurs and operators for the new Origination Lab, U.K., which will build on three years of experience partnering and conducting R&amp;D across the kingdom.
The post London Calling: Flagship Expands in U.K. to Build AI-Native Platform Companies appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/109A8287_2026-10-13-193415_wksy-JPEG.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 19 Nov 2026 06:35:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>London, Calling:, Flagship, Expands, U.K., Build, AI-Native, Platform, Companies</media:keywords>
<content:encoded><![CDATA[<p>Flagship Pioneering, which for more than 25 years has created and nurtured startups—most notably mRNA vaccine giant Moderna—from Cambridge, MA, has launched its first dedicated company creation unit outside of the U.S. with an initial commitment of £100 million ($131.66 million) that the venture capital giant expects to quintuple in coming years.</p>
<p>The new London-based Flagship Origination Lab U.K. has been established to conceive, test, fund, and build artificial intelligence (AI)-native platform companies that advance human and planetary health and other frontiers of science and technology.</p>
<p>Flagship said the U.K. Lab will operate as part of Flagship Labs, the company’s innovation foundry, with the goal of creating a locally rooted company-creation ecosystem in the United Kingdom that connects to Flagship’s broader global ecosystem, including business units and:</p>
<ul>
<li><strong>Pioneering Intelligence</strong>, Flagship’s AI and machine learning innovation effort designed to originate new companies by harnessing advances in computation integrated with a variety of scientific domains. Pioneering Intelligence was launched in 2023.</li>
<li><strong>Pioneering Medicines</strong>, Flagship’s in-house drug development unit founded in 2020. Pioneering Medicines explores and identifies new product concepts, then works jointly with Flagship’s companies to form integrated teams that advance new treatments through discovery and early clinical development. Medicines also partners with external collaborators.</li>
</ul>
<p>“I think this announcement by Flagship is a testament to the quality of British life sciences research and the investment will be welcomed in the U.K.,” Tim Harris, PhD, DSc, a molecular biologist, biochemist, and geneticist who is an operating partner with SV Health Investors specializing in work with therapeutics startups, told <em>GEN</em>.</p>
<figure aria-describedby="caption-attachment-340769" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="size-medium wp-image-340769" src="https://www.genengnews.com/wp-content/uploads/2026/11/tim-harris-219x300.jpg" alt="" width="219" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/tim-harris-219x300.jpg 219w, https://www.genengnews.com/wp-content/uploads/2026/11/tim-harris.jpg 540w" sizes="(max-width: 219px) 100vw, 219px"><figcaption class="wp-caption-text">Tim Harris, PhD, DSc, a molecular biologist, biochemist and geneticist who is an operating partner with SV Health Investors specializing in work with therapeutics startups</figcaption></figure>
<p>“Labs and people turn ideas into companies so I look forward to seeing some new ones come out of this initiative from the Flagship Pioneering team,” Harris added.</p>
<p>Founded in 1999, Flagship Pioneering has founded and nurtured more than 120 companies—between six and eight each year—employing more than 9,000 people. Thirteen Flagship Pioneering-launched companies have gone public through initial public offerings (IPOs) since 2013.</p>
<p>In London, Flagship expects to recruit and train an initial team of approximately 50 U.K.-based scientist-entrepreneurs and operators for the new Origination Lab, U.K., which will build on three years of experience partnering and conducting R&D across the kingdom.</p>
<p>Flagship is not the first U.S. VC firm to establish an outpost in the U.K. for nurturing startups from the kingdom: Harris noted that SV venture capitalists led by Kate Bingham, managing partner and co-leader of SV’s biotech franchise, have been creating and investing in U.K. and U.S. startups for many years.</p>
<p>Flagship’s new Origination Lab adds to the capital available, creating further opportunities for early-stage companies, Harris added.</p>
<h4><strong>‘Natural home’</strong></h4>
<p>“The U.K. is a natural home for AI and life sciences companies, and we want to see more new businesses across these sectors turning cutting-edge research and technology into new jobs and economic growth,” Chris McDonald, a chemical engineer and member of the U.K. Parliament (Labour Party) who is the kingdom’s Minister for Science, Innovation and Investment, said in a statement. “This new commitment from Flagship Pioneering will kickstart companies of the future in the U.K., who will take breakthroughs in AI and life sciences to the rest of the world and deliver innovations that can save lives.”</p>
<p>Flagship’s announcement comes weeks after AbbVie announced plans to expand its R&D facility in Oxford, U.K., as part of a £120 million ($158 million) investment into life sciences activity within the kingdom. AbbVie plans to expand its existing Oxford campus by constructing a new 12,000-square-foot site focused on research in immunology, neuroscience, and oncology.</p>
<p>However, since last year two other biopharma giants, AstraZeneca and Merck & Co., have dropped plans for large facilities within the U.K. AstraZeneca cited government funding reductions in halting plans for a £450 million vaccine manufacturing center in Merseyside.</p>
<p>Merck aborted plans for an R&D site set to employ 800 (including 180 researchers) at Belgrove House near King’s Cross in London, citing what it called high rebate clawback rates for voluntary and statutory medicines by the NHS, and insufficient government investment in life sciences, reflected in a decline from second to eighth since 2017 in SCI’s global foreign direct investment ranking in life sciences.</p>
<p>Flagship began expanding beyond the U.S. in 2023 when it opened offices in London and in Singapore. Since opening the London hub by signing a Memorandum of Understanding with the U.K. Government, Flagship has announced an agreement with Cambridge University Health Partners and the Milner Therapeutics Institute to collaborate to jointly advance breakthrough scientific research and technologies.</p>
<p>Also from the London hub, Flagship has launched its first transatlantic company, Quotient Therapeutics; accelerated first-in-category clinical trials across the U.K. by Flagship-founded companies such as Generate:Biomedicines; and developed numerous strategic partnerships across academia, data, and regulatory innovation.</p>
<p>Generate was founded in 2018 as a Flagship Pioneering company, and emerged from stealth operations during the COVID-19 pandemic two years later, when it announced that it had built a portfolio of therapeutic candidates for neutralizing SARS-CoV‑2, including antibodies and peptides targeting multiple epitopes on the spike protein peptide, in less than 17 days.</p>
<p>The biologics developer was an early comer applying AI-based approaches to rationally design sequence, structure, and function for protein therapeutics. In February, Generate <a href="https://www.genengnews.com/topics/artificial-intelligence/stockwatch-ai-drug-developer-generates-400m-ipo/" target="_blank" rel="noopener">went public on the Nasdaq Global Market</a> through a $400 million IPO that generated $369.3 million in net proceeds.</p>
<h4><strong>‘New chapter’</strong></h4>
<p>“Today marks the beginning of a new chapter in Flagship’s relationship with the U.K.,” declared Noubar Afeyan, PhD, Flagship Pioneering’s founder and CEO. “Over the past three years, we have seen firsthand the extraordinary depth of scientific imagination, talent, and ambition across the country. With our £100 million initial commitment, which we anticipate scaling through partnership to attract an additional £500 million [$658.6 million], we are now making a long-term commitment to build on that foundation.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>Afeyan announced the new U.K. Lab on Monday at a conference of the U.K.’s Drug Information Association (DIA) and Medicines and Healthcare products Regulatory Agency (MHRA). The DIA-MHRA Global Summit is set to conclude Tuesday during London Life Sciences Week.</p>
<p>“Since first opening our London office three years ago, we’ve been impressed by the talent, imagination, and ambition that make the U.K. a leader in our field—and we are excited about the groundbreaking ventures that will come from combining our unique Flagship model with the U.K.’s distinct strengths,” Afeyan said in a <a href="https://www.linkedin.com/posts/noubarafeyan_for-26-years-every-flagship-pioneering-company-share-7528074845851385856-TGOI/?utm_source=share&utm_medium=member_ios&rcm=ACoAAAAijXMBke7yaGhNnsp7P32n1gHV4SXeNno" target="_blank" rel="noopener">LinkedIn post</a>.</p>
<p>Added Avak Kahvejian, PhD, general partner, Flagship Pioneering and president of its internal innovation foundry and company-creation unit Flagship Labs: “We have developed company origination into a discipline, one led by teams of scientist-entrepreneurs who begin with bold questions about what could be possible.”</p>
<p>“As we extend that capability globally, the U.K. was a clear and deliberate choice for our first expansion. Its exceptional science base, clinical-trial infrastructure, genomics and health-data assets, agile regulatory environment, and brilliant scientists and entrepreneurs create a powerful foundation for innovation,” Kahvejian stated.</p>
<p>The post <a href="https://www.genengnews.com/topics/artificial-intelligence/london-calling-flagship-expands-in-u-k-to-build-ai-native-platform-companies/">London Calling: Flagship Expands in U.K. to Build AI-Native Platform Companies</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Targeting Folate Receptor Reverses Colorectal Cancer’s Resistance to Immunotherapy in Mice</title>
<link>https://edusehat.com/en/targeting-folate-receptor-reverses-colorectal-cancers-resistance-to-immunotherapy-in-mice</link>
<guid>https://edusehat.com/en/targeting-folate-receptor-reverses-colorectal-cancers-resistance-to-immunotherapy-in-mice</guid>
<description><![CDATA[ Targeting FOLR1 with an approved antibody-drug conjugate restored anti-tumor immunity and enhanced anti-PD-1 effectiveness in colorectal cancer, overcoming immune evasion in mouse models.
The post Targeting Folate Receptor Reverses Colorectal Cancer’s Resistance to Immunotherapy in Mice appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/03/May_ADC_GettyImages_JL_2147604791_AntibodyDrugConjugate-e1775154897927.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 19 Nov 2026 06:35:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Targeting, Folate, Receptor, Reverses, Colorectal, Cancer’s, Resistance, Immunotherapy, Mice</media:keywords>
<content:encoded><![CDATA[<p>Colorectal cancer (CRC) is the third most common cancer worldwide. Although immune checkpoint blockade is promising, responses to the treatment have been limited: treatments such as anti-PD-1 have resulted in only 15% of patients experiencing substantial benefits.</p>
<p>Now, a new study shows that a receptor for folate sustains colorectal cancer’s ability to evade a form of cancer immunotherapy—and finds that targeting this receptor with an approved compound can restore the treatment’s cancer-killing power in mice. The data add to the understanding of what factors can shape colorectal cancer’s response to immunotherapy and suggest that integrating folate receptor-based treatments into existing regimens could improve outcomes in patients with treatment-resistant tumors.</p>
<p>This work is published in <em>Science Translational Medicine</em> in the paper, “<a href="https://www.science.org/doi/10.1126/scitranslmed.aed2106" target="_blank" rel="noopener">Targeting cancer immune evasion with anti-FOLR1 antibody-drug conjugate potentiates anti-PD-1 efficacy in colorectal cancer</a>.”</p>
<p>Colorectal cancer tumors possess many properties that stall immunotherapy’s ability to enhance anti-tumor immunity, including defects in the expression of MHC-1. Indeed, loss of MHC-I antigen presentation in tumor cells drives immune evasion and resistance to immune checkpoint blockade in colorectal cancer.</p>
<p>Previous research has connected folate receptor α (FOLR1) to more aggressive disease progression and poorer prognoses in various types of solid tumors. In this study, researchers conducted fluorescence-activated cell sorting–based CRISPR activation screens using a druggable genome library and identified folate receptor α (FOLR1) as a top negative regulator. In the study, they found that “high expression of FOLR1 predicted a poor ICB response, enhanced cancer stemness, and unfavorable patient outcomes.”</p>
<p>In addition, the team’s proteomic analyses revealed that “FOLR1 stabilized the lactyltransferase AARS1 (alanyl-tRNA synthetase 1), which lactylated signal transducer and activator of transcription 1 (STAT1) at lysine-193 (K193), facilitating its interaction with TCPTP (T cell protein-tyrosine phosphatase) and inducing STAT1 dephosphorylation at tyrosine-701.”</p>
<p>The group also tested the potential of mirvetuximab soravtansine, an approved antibody-drug conjugate that inhibits FOLR1. <em>In vitro </em>experiments revealed that FOLR1 indirectly impaired the activity of the STAT1 signaling pathway and dampened MHC-1 activity, which supported the cancer cells’ adaptability and prevented CD8+ T cells from engaging tumor cells.</p>
<p>However, mirvetuximab soravtansine restored anti-tumor immunity and resensitized colorectal cancer tumors to anti-PD-1 blockade in mice.</p>
<p>“Our findings support anti-FOLR1 [antibody-drug conjugate] as a clinically actionable approach to overcome immune evasion and unlock immunotherapy efficacy in [colorectal cancer],” the authors<em> </em>write.</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/targeting-folate-receptor-reverses-colorectal-cancers-resistance-to-immunotherapy-in-mice/">Targeting Folate Receptor Reverses Colorectal Cancer’s Resistance to Immunotherapy in Mice</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>CRISPR Screening Reveals How Genetic Variants Drive Neurodegenerative Risk</title>
<link>https://edusehat.com/en/crispr-screening-reveals-how-genetic-variants-drive-neurodegenerative-risk</link>
<guid>https://edusehat.com/en/crispr-screening-reveals-how-genetic-variants-drive-neurodegenerative-risk</guid>
<description><![CDATA[ Researchers studying human induced pluripotent stem cell-derived microglia-like cells showed how genetic variants can impact cell behavior and used CRISPR gene editing to show how one gene’s effect depends on its cellular context.
The post CRISPR Screening Reveals How Genetic Variants Drive Neurodegenerative Risk appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GEN_OCT_2026_GettyImages-2204954826-Copy.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 19 Nov 2026 06:35:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>CRISPR, Screening, Reveals, How, Genetic, Variants, Drive, Neurodegenerative, Risk</media:keywords>
<content:encoded><![CDATA[<p>Research has started to bridge the gap between identifying genetic changes that can increase the risk of brain conditions, such as Alzheimer’s disease (AD), and understanding how they might impact specific cell functions. Researchers at the Wellcome Sanger Institute, Open Targets, and collaborators, differentiated human induced pluripotent stem cells (iPSCs) derived from different donors into microglia-like (iMGL) cells, and showed how genetic variants impact cell behavior, and more specifically, how they can lead to differences in the ability of brain immune cells to move and clear away biological debris.</p>
<p>Through their research the team also used CRISPR gene editing to show how one gene’s effect depends on its cellular context. They found that the impact of a genetic mutation can be completely opposite depending on the precise cell type and its environment, which is highly important for designing future targeted therapies. The study provides an indication of how to connect genetic risk variants with their downstream effects, as a next step in understanding how genes impact health conditions.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>Andrew Bassett, PhD, at the Wellcome Sanger Institute and Open Targets, said, “While genetic studies have identified around a hundred genomic regions linked to Alzheimer’s, pinpointing the exact genes involved and how they alter cell behavior has been more of a challenge. By growing brain immune cells from stem cells across hundreds of donors, we’ve built a framework that directly connects genetic risk to real cell functions, such as how effectively these cells clear debris in the brain. We also discovered that the impact of a genetic variant can change depending on its cellular environment, in some cases having the opposite effect. This suggests that we can’t just look at the impact of these genetic changes in isolation or in one cell. Instead, knowing the exact cell context is essential to understanding how these genetic changes impact health.”</p>
<p>Bassett is co-senior author of the researchers’ published paper in <em>Nature Genetics</em>, titled “<a href="https://doi.org/10.1038/s41588-026-02843-0" target="_blank" rel="noopener">Integrated QTL mapping and CRISPR screening in pooled iPSC-derived microglia reveals genetic drivers of neurodegenerative risk</a>.” In their report the authors concluded, “By contextualizing variant effects within iMGLs in different inflammatory states, we provide a comprehensive framework for interpreting the function of risk loci in neurodegenerative disorders.”</p>
<p>Genome wide association studies (GWAS) scan genomes and highlight which differences, known as genetic variants, are more often found in patients with specific health conditions. However, while they can signpost regions of the genome they do not explain how those regions alter gene and cell function. “Genome-wide association studies (GWAS) have identified thousands of variants linked to complex traits and diseases, but translating these into biological insight remains challenging,” the authors wrote. “Most variants are non-coding and probably influence disease by regulating gene expression in specific cell types, states or environments.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>To bridge the gap, the researchers developed a framework to map GWAS data to changes in gene expression and cell behavior. For this, they used 261 human stem cell lines to derive brain cells known as microglia, which are a type of specialized immune cell that move around the brain and remove cellular debris or misfolded proteins. This process,  phagocytosis, is an important part of maintaining healthy neuronal function. As the team pointed out, “Mounting evidence implicates microglia in neurodegeneration, but linking disease-associated genetic variants to target genes and cellular phenotypes is hindered by the inaccessibility of these cells,” they pointed out.</p>
<p>First, the team identified which genetic variants change the levels of different genes in microglia cells. Next, they asked if genetic regions that have been previously linked to Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and amyotrophic lateral sclerosis (ALS) also modulate gene levels. This analysis identified 79 regions. “Expression quantitative trait locus (eQTL) analysis identified 7,121 eQTL-associated genes and 79 colocalizations across four neurodegenerative disease genome-wide association studies, half of which had limited prior evidence of causality,” they stated.</p>
<p>These links alone do not inform of the impact on cell function, so to further understand how these changes in gene expression alter cell behavior, the researchers conducted laboratory tests on the microglia, measuring the cells’ ability to move and undertake phagocytosis. Through these tests and computational modeling, they were able to map 34 genes to changes in cell behavior. This highlighted disease-relevant variants at <em>TREM2</em> that were linked to changes in phagocytosis.</p>
<p>To understand further how these genes impact behavior of microglia, the team conducted CRISPR screens, knocking out 251 disease-relevant genes. This also allowed them to show that the impact of the gene depends on the cellular context. For example, knocking out <em>TREM2</em> increases phagocytosis in microglia but decreases it in macrophages, a different type of immune cell. “These results demonstrate that modulation of TREM2 leads to different phenotypic outcomes depending on the cell type, and emphasize the importance of cellular context when interpreting its function in neurodegeneration,” the authors stated.</p>
<p>This research gives a scalable blueprint for studying brain immune cells, which are impossible to safely take samples of in living patients. It could also help find new pathways and drug targets from disease genetic data, giving insight into the cellular mechanisms that are linked to diseases. In their paper the investigators stated, “In summary, this multifaceted approach enabled us to connect genetic variants to effector genes and gene programs, down stream cellular phenotypes and potential disease mechanisms.”</p>
<p>Co-senior author Gosia Trynka, PhD, at the Wellcome Sanger Institute and Science Director at Open Targets, said, “Brain conditions such as Alzheimer’s are incredibly complicated, and understanding how different parts of our genome are linked to these conditions could help us find new ways to identify or treat them. Identifying the associated part of the genome is the first step but it leaves a large translational gap, and our new research has found a way to bridge the gap between association and understanding the impact on the cell function. Connecting this allows us to start to build a full biological picture of disease and will help design future research to accelerate drug discovery.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>Co-first author Marta Perez-Alcantara, PhD, previously at the Wellcome Sanger Institute and Open Targets, further commented, “This ambitious study showcases the potential of iPSC-derived cells for genetic analysis, linking genetic variation to expression, cellular survival and function, and disease susceptibility. This approach is particularly valuable for difficult-to-access tissues such as the brain, allowing us to investigate genetic effects across multiple donors and stimulation conditions in microglia, which are challenging to obtain in sufficient numbers and under the right stimuli from primary human tissues. This framework has the potential to be extended to other diseases, tissues or cellular phenotypes, enabling research that would otherwise be extremely difficult to undertake.”</p>
<p>The authors added that in a broader context “… our study demonstrates the feasibility and value of integrating genetic association data, single-cell transcriptomics, and pooled functional genomics to investigate genotype–phenotype relationships at scale. This framework is also applicable to other cell types and diseases.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/crispr-screening-reveals-how-genetic-variants-drive-neurodegenerative-risk/">CRISPR Screening Reveals How Genetic Variants Drive Neurodegenerative Risk</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Growing Apart: Culture&#45;Based Sterility Test Alternatives</title>
<link>https://edusehat.com/en/growing-apart-culture-based-sterility-test-alternatives</link>
<guid>https://edusehat.com/en/growing-apart-culture-based-sterility-test-alternatives</guid>
<description><![CDATA[ Growth-based sterility testing works for traditional biopharma but is too slow for the cell therapy sector. A new parallel testing pathway and rapid, molecular assay-based testing are a better option.
The post Growing Apart: Culture-Based Sterility Test Alternatives appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2023/06/GettyImages-521677434.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 19 Nov 2026 03:05:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Growing, Apart:, Culture-Based, Sterility, Test, Alternatives</media:keywords>
<content:encoded><![CDATA[<p>In the biopharma industry, culture-based microbial sterility testing methods are not fast enough for personalized cell therapy production, say the developers of a new parallel analysis pathway.</p>
<p>Bacterial contamination is always a risk in biopharmaceutical production. The complex, multi-step nature of processes, the nutrient-rich, aqueous environments in which cells are cultured—and even the raw materials themselves—provide potential entry points for microorganisms.</p>
<p>As a result, regulators require that biopharmaceuticals undergo extensive analysis using standardized procedures. Typically, product samples are cultured to allow any bacterial or fungal contaminants to grow, enabling full identification.</p>
<p>For high-volume products made in multiple, sequential batches—protein therapeutics, monoclonal antibodies—these long testing processes can be incorporated into the manufacturing lifecycle without interrupting market supply.</p>
<p>For firms making single-batch, patient-specific therapies, any steps that delay release, including long sterility testing processes, are hard to accommodate, according to Athena Stathoulis, a researcher at the University of Melbourne in Australia.</p>
<p>“The gold-standard sterility test for cell therapies, USP <71>, takes 14 days to give a result. Fresh CAR T products often have to be infused within 24–72 hours, so the product reaches the patient long before its sterility is confirmed,” she tells <em>GEN</em>.</p>
<p>In practice, the need to deliver CAR T cell therapies to patients as soon as possible means they are often released early, under exceptional protocols based on interim culture results at around 48 hours, Stathoulis explains.</p>
<p>“This approach shortens the detection window and risks missing slow-growing organisms, with full sterility confirmation only arriving after the patient has been infused. This matters because vein-to-vein time is linked to outcomes,” she adds.</p>
<p>Stathoulis, who examined cell therapy sector practices in a recent <a href="https://www.sciencedirect.com/science/article/pii/S1045105626000461" target="_blank" rel="noopener">study</a>, also points out that, unlike steps like leukapheresis, transduction, and expansion that can be optimized, the timelines for sterility testing are fixed by regulatory mandate.</p>
<p>“Sterility testing is the one manufacturing bottleneck that process optimization can’t fix, because the incubation period is set by regulation, not biology. That makes it the rate-limiting step for point-of-care and decentralized CAR T manufacturing.”</p>
<h4><strong>Solutions</strong></h4>
<p>Cell therapy firms do have potential alternative testing options, Stathoulis says, with the most promising being assays that do not rely on bacterial growth.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>“The main alternatives are ATP bioluminescence, solid-phase cytometry, and molecular assays targeting conserved bacterial and fungal ribosomal RNA genes (16S/18S rRNA).</p>
<p>“In our view, the molecular assays are the most compelling. They are not growth-dependent, removing the need for incubation altogether and providing results within hours,” Stathoulis explains.</p>
<p>Another potential alternative, which Stathoulis and colleagues propose in the study, would be to run a combination of sterility testing methods in parallel.</p>
<p>“Our review proposes a three-phase pathway that moves toward this: comprising analytical qualification; then parallel testing alongside compendial methods; and then conditional release,” she says.</p>
<p>Measures set out in the proposed pathway include testing against a facility-specific panel of at least 20 organisms, including skin flora such as <em>Cutibacterium acnes</em>, Gram-negative bacteria, fungi, and slow-growing organisms.</p>
<p>The pathway also calls for the use of viability dyes and enrichment steps to reduce the risk of false positives and false negatives, as well as compendial testing after infusion as a safety net, with a predefined plan for when the rapid and compendial results disagree.</p>
<h4><strong>Adoption</strong></h4>
<p>The degree to which cell therapy firms can use alternative methods depends on regulators, according to Stathoulis, who says, “The barriers to adopting rapid sterility methods are regulatory rather than analytical, and regulation can be reformed. The main obstacles are regulatory fragmentation between the FDA, EMA, and TGA, and a lack of real-world validation data in CAR T products.”</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/growing-apart-culture-based-sterility-test-alternatives/">Growing Apart: Culture-Based Sterility Test Alternatives</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>One Record, From Factory Floor to Patient</title>
<link>https://edusehat.com/en/one-record-from-factory-floor-to-patient</link>
<guid>https://edusehat.com/en/one-record-from-factory-floor-to-patient</guid>
<description><![CDATA[ ParkourSC acquired manufacturing-AI company Quartic to track a drug’s quality across its whole lifecycle. CEO Mahesh Veerina explains how linking factory and shipping data could flag at-risk batches before problems reach patients.
The post One Record, From Factory Floor to Patient appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Mike-ParkourSC_GBPN_IMAGE_19NOV26.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 19 Nov 2026 03:05:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>One, Record, From, Factory, Floor, Patient</media:keywords>
<content:encoded><![CDATA[<p>A drug’s life story is usually told in pieces. How a batch was made lives in one set of manufacturing systems. What happens to it afterward—where it shipped, how warm it got, how long it sat—lives in another. When something goes wrong downstream, quality teams must stitch that history back together before they can decide what to do, and the delay can cost product, time, and confidence in supply.</p>
<p>San Jose–based ParkourSC says it acquired Quartic to close that gap. The deal combines ParkourSC’s clinical and commercial supply-chain AI with Quartic’s manufacturing AI on a single platform aimed at regulated life sciences. The company says the result is one continuous record that can predict which batches, lots, and shipments are at risk, then recommend a response.</p>
<p>For Mahesh Veerina, president and CEO of ParkourSC, the move was less about reaching manufacturing data than about making sense of it. The company could have built its own connectors to the systems that hold batch records, he said, “but it’s not about the data itself.” Quartic, he explains, “consumes this data, contextualizes it around batches and campaigns, and creates intelligence about the key quality attributes” that ParkourSC’s downstream decisions depend on.</p>
<p>The timing reflects where the industry is heading. Companies are shifting more of their portfolios to biologics, and production is spreading across more internal and contract sites. “Supply chain systems, both clinical and commercial, need to become more dynamic in their decision intelligence,” Veerina says.</p>
<p>A temperature excursion shows what that could change. Today, a quality team often judges a cold-chain breach by what happened on the last leg of a shipment. Linking manufacturing and distribution data, Veerina says, “turns a temperature excursion from an isolated event into a decision made with the batch’s full story.” Teams can see the cumulative time a batch has spent in and out of refrigeration from the plant onward, while the platform predicts the remaining stability margin “as excursions occur, so teams know early how much margin a batch has left.” Decisions to release, restrict, or reject product, he adds, become “faster and better justified.”</p>
<p>The approach also reaches upstream. Because Quartic uses shared models across research, clinical, and commercial manufacturing, Veerina says, the multivariate models built for clinical batches “act as the starting point, rather than developing models from scratch,” speeding scale-up and process qualification. He attributed the 15 to 20% gain in biologics batch yield the companies report to models that let operators “run the process close to the ideal-yield batch, repeatably.”</p>
<p>In a GxP setting, meaning one bound by good-practice quality regulations, trust is the harder question, and Veerina draws a firm line. “AI recommends, and a qualified person decides. AI never makes the GxP decision,” he said. The platform relies on interpretable statistical methods, “never black-box models or LLMs,” keeps every recommendation within validated ranges, and attaches a confidence interval and the factors behind it. A human approves each decision with an e-signature, and an audit trail links the data, the recommendation, and the call that was made.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/one-record-from-factory-floor-to-patient/">One Record, From Factory Floor to Patient</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Tuning Extracellular Vesicle Production and Analytics for Compliance</title>
<link>https://edusehat.com/en/tuning-extracellular-vesicle-production-and-analytics-for-compliance</link>
<guid>https://edusehat.com/en/tuning-extracellular-vesicle-production-and-analytics-for-compliance</guid>
<description><![CDATA[ The complexity of extracellular vesicle products developed from umbilical cord blood can potentially be reduced through production processes and simplified quality control strategies, helping to boost this new product class.
The post Tuning Extracellular Vesicle Production and Analytics for Compliance appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Vivienne-PR_Exogenus-T.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 19 Nov 2026 03:05:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Tuning, Extracellular, Vesicle, Production, and, Analytics, for, Compliance</media:keywords>
<content:encoded><![CDATA[<p>A company developing extracellular vesicles (EV) derived from umbilical cord blood cells says that producing a non-conventional product shouldn’t be a barrier to streamlined production processes and quality control analytics.</p>
<p>Exogenus Therapeutics, which is currently developing products targeted at inflammatory and degenerative conditions, says that they’ve managed to implement a production and quality-control (QC) workflow that turns their complicated high-screening analytics into a more sustainable assay panel.</p>
<p>“I think our main message to the corporate EV community is it’s possible to develop and produce an extracellular vesicle-based product that falls outside the mainstream,” explains Andreia Silva, PhD, head of research at Exogenus, who spoke at Cell & Gene Therapy International Europe.</p>
<p>According to Silva, complexities of their production process include the raw material of umbilical cord blood, which has a higher level of variability than conventional EV cell sources as it’s derived from different donors, but which needs to be sculpted into a safe and consistent-quality product.</p>
<p>The product is also complex, she explains, as unlike small molecules, extracellular vesicles are made of thousands of molecules of lipids, proteins, metabolites, DNA, and RNA, all of which may be functional once they reach a target organ.</p>
<p>To overcome this complexity issue, as they move toward the clinical stage of development, the company says it’s managed to develop a production strategy including a panel of assays that can be run using standardized techniques, such as ELISA and Western Blot, to provide efficient and sustainable QC of product batches.</p>
<p>“We can’t do omics on every single batch of product we are going to release because it would become too expensive down the line,” explains Silva. “We’ve been looking at the molecular data generated at the omics level and then selecting specific targets to pass that into the simpler QC panel.”</p>
<p>Although their target choices and QC panel are product-specific, Silva hopes the general lessons will inspire other companies in their QC development. Going forward, she says a future challenge for the EV industry will be developing potency assays.</p>
<p>“Potency assay development for GMP production, so you can use your product in later clinical phases, is still something that needs a lot of development because EVs are such a complex modality,” she says.</p>
<p>“As companies work toward getting an EV product to clinic, we can definitely see strategies emerging for what might be the right way to go.”</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/tuning-extracellular-vesicle-production-and-analytics-for-compliance/">Tuning Extracellular Vesicle Production and Analytics for Compliance</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The Advent of Automated, Gene&#45;Engineered TIL Manufacturing</title>
<link>https://edusehat.com/en/the-advent-of-automated-gene-engineered-til-manufacturing</link>
<guid>https://edusehat.com/en/the-advent-of-automated-gene-engineered-til-manufacturing</guid>
<description><![CDATA[ Automating engineered TIL manufacturing in a way that maintains their tumor-fighting capabilities may move this emerging therapeutic class into a commercially reproducible, economically viable therapeutic option.
The post The Advent of Automated, Gene-Engineered TIL Manufacturing appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/GettyImages-2179695031.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 19 Nov 2026 03:05:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, Advent, Automated, Gene-Engineered, TIL, Manufacturing</media:keywords>
<content:encoded><![CDATA[<p>Tumor-infiltrating leukocytes (TILs) tend to be manufactured at small scale in labs using manual, bespoke processes to account for inconsistent starting materials and conditions. As TIL-based therapeutics move to clinical scale, however, automation and the reproducibility and efficiency it provides become invaluable.</p>
<p>A handful of companies are working to automate the TIL production process. The latest, Terumo Blood and Cell Technologies (Terumo BCT), is using its Quantum Flex<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> Cell Expansion System to automate the production of genetically engineered TILs in partnership with TrAMPoline Pharma and the University of Colorado.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>“Automation could help bridge the gap between development in the lab and clinical scale by utilizing the same scalable technology for both phases to ultimately preserve product quality along the development pipeline,” Mindy Miller, PhD, head of cell therapy scientific development at Terumo BCT, tells <em>GEN</em>.</p>
<p>The challenge is that TILs are produced from T cells that have infiltrated tumors. These T cells typically don’t expand as efficiently as T cells found in the bloodstream, so vastly greater quantities of T cells are needed to produce potent doses.</p>
<p>“We recognized that a process dependent on extensive manual handling would inevitably limit clinical translation,” Eduardo Davila, PhD, professor of medicine at the University of Colorado, and co-founder and CSO at TrAMPoline Pharma, adds. His research into T cell infiltration is the basis for TrAMPoline Pharma’s TIL program. This collaboration “aims to make engineered TIL manufacturing more reproducible and efficient while preserving the cells’ tumor-fighting capabilities.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>To that end, Davila says, “We are focusing on standardized culture conditions, automated feeding, and fewer manual manipulations. Our goal is to preserve engineered TIL identity, viability, and antitumor function.”</p>
<p>The automation process is being undertaken in phases. The first step is to validate automated cell expansion against the existing process. Then, additional steps will be validated and integrated into the workflow.</p>
<p>“We anticipate a substantial reduction in hands-on labor and expedited TIL expansion. Whether total manufacturing time also decreases—and by how much—must be established experimentally,” Davila says. But, Miller adds, “it is still being evaluated.”</p>
<p>Today, it takes about three weeks to manufacture TILs. While neither Miller nor Davila will suggest a target timeframe for engineered TIL manufacturing within this partnership, Davila says, “We anticipate more consistent yield, fewer manual interventions, and greater manufacturing capacity, with the potential to reduce cost and turnaround time.”</p>
<p>Additionally, he continues, “We will evaluate these gains alongside gene transfer efficiency, viability, phenotype, and tumor-specific killing. Improved potency is an outcome to test, rather than assume.”</p>
<p>Miller emphasizes, “Our focus is adapting automation to the particular requirements of engineered TILs.”</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/the-advent-of-automated-gene-engineered-til-manufacturing/">The Advent of Automated, Gene-Engineered TIL Manufacturing</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Saskatchewan to expand access to new ovarian cancer treatments</title>
<link>https://edusehat.com/en/saskatchewan-to-expand-access-to-new-ovarian-cancer-treatments</link>
<guid>https://edusehat.com/en/saskatchewan-to-expand-access-to-new-ovarian-cancer-treatments</guid>
<description><![CDATA[ Public funding for Elahere and Keytruda will begin December 1, offering additional treatment options for eligible patients with advanced ovarian cancer. Saskatchewan is expanding access to ovarian cancer treatment, announcing that two newer therapies will become publicly funded for eligible patients beginning December 1, 2026. The province confirmed November 17 that coverage will be introduced […]
The post Saskatchewan to expand access to new ovarian cancer treatments appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/11/shutterstock_2034955502.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 23:15:12 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Saskatchewan, expand, access, new, ovarian, cancer, treatments</media:keywords>
<content:encoded><![CDATA[<p>Public funding for Elahere and Keytruda will begin December 1, offering additional treatment options for eligible patients with advanced ovarian cancer.</p>
<p>Saskatchewan is expanding access to ovarian cancer treatment, announcing that two newer therapies will become publicly funded for eligible patients beginning December 1, 2026.</p>
<p>The province confirmed November 17 that coverage will be introduced for Elahere (mirvetuximab soravtansine) and Keytruda (pembrolizumab), providing additional options for patients whose cancer has stopped responding to standard treatments.</p>
<p>Approximately eight to 10 patients in Saskatchewan are expected to benefit annually from access to the therapies.</p>
<p>Ovarian cancer is the deadliest cancer of the female reproductive system. Because symptoms can be difficult to recognize, the disease is frequently diagnosed at an advanced stage, when treatment can be more challenging</p>
<h2>New options for difficult-to-treat cancer</h2>
<p>Elahere is a targeted antibody-drug conjugate designed for certain patients whose tumours express folate receptor-alpha (FRα). It delivers an anticancer agent to cells expressing the target.</p>
<p>Keytruda is an immunotherapy that works by helping the immune system recognize and attack cancer cells. It is used in specified treatment regimens for eligible patients.</p>
<p>The two medications are distinct treatment options, with eligibility determined by factors including tumour characteristics and previous treatment.</p>
<p>Clinical studies have demonstrated improvements in outcomes for selected patients, including delayed disease progression and longer survival. However, the treatments are not appropriate for every patient, and both require specialist assessment and monitoring.</p>
<h2>A step forward for public access</h2>
<p>The decision follows national reviews of clinical evidence and drug pricing negotiations through the pan-Canadian Pharmaceutical Alliance.</p>
<p>Canada’s Drug Agency previously recommended reimbursement of Elahere for certain patients with platinum-resistant ovarian cancer, subject to specified conditions.</p>
<p>The Saskatchewan announcement moves beyond the national negotiation process by establishing a provincial coverage start date.</p>
<p>The Saskatchewan Cancer Agency says expanded access will help provide specialized, evidence-based treatment options for patients with difficult-to-treat disease.</p>
<p>Ovarian Cancer Canada also welcomed the decision, noting the importance of eliminating financial barriers to newer cancer therapies.</p>
<h2>Implications for cancer care</h2>
<p>For oncology teams, the expanded funding represents another opportunity to personalize treatment for patients whose disease progresses despite conventional chemotherapy.</p>
<p>Access to specialized testing, appropriate treatment selection and ongoing monitoring will remain important considerations.</p>
<p>The Saskatchewan Cancer Agency received $308.6 million in provincial funding for 2026–27, supporting prevention, diagnosis, treatment, research and patient services.</p>
<p>Patients seeking more information about eligibility for the newly funded therapies are encouraged to consult their oncology teams.</p>
<p>The post <a href="https://www.hospitalnews.com/saskatchewan-to-expand-access-to-new-ovarian-cancer-treatments/">Saskatchewan to expand access to new ovarian cancer treatments</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Physician use of AI rises sharply: Which specialties are the power users?</title>
<link>https://edusehat.com/en/physician-use-of-ai-rises-sharply-which-specialties-are-the-power-users</link>
<guid>https://edusehat.com/en/physician-use-of-ai-rises-sharply-which-specialties-are-the-power-users</guid>
<description><![CDATA[ More than half of U.S. physicians say they use AI in clinical practice daily, with most claiming they have received new “clinical knowledge” from using the technology. According to a survey of more than 3,000 physicians by Doximity released in November of 2026, 52% of physicians said they use AI daily and 85% use it weekly. […]
The post Physician use of AI rises sharply: Which specialties are the power users? appeared first on Today&#039;s Hospitalist. ]]></description>
<enclosure url="https://todayshospitalist.com/wp-content/uploads/2026/11/AI-use-by-docs-doximity-survey-shutterstock_2645963221-11-18-26-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 23:10:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Physician, use, rises, sharply:, Which, specialties, are, the, power, users</media:keywords>
<content:encoded><![CDATA[<p>More than half of U.S. physicians say they use AI in clinical practice daily, with most claiming they have received new “clinical knowledge” from using the technology.</p>
<p>According to <a href="https://www.doximity.com/reports/doctor-driven-ai-report/2026">a survey of more than 3,000 physicians by Doximity</a> released in November of 2026, 52% of physicians said they use AI daily and 85% use it weekly. The number of physicians using AI daily jumped from 37% from Doximity’s survey on the topic in 2025. The number using AI weekly jumped from 51% since that survey.</p>
<p>While physicians said they remain cautious about using AI, 81% said they had learned new clinical information by using the tech.</p>
<p>Here are other findings from the survey.</p>
<h4><strong>How physicians are using AI</strong></h4>
<p>A growing number of physicians in the survey said AI has reduced the after-hours time they spend on documentation and other administrative tasks. That number jumped from 36% to 46% from 2025-26.</p>
<p>In addition, 83% of physicians said their use of AI has increased somewhat or substantially in the last year.</p>
<ul>
<li><strong>Medical literature</strong>: 94% of physicians said they trust AI to search medical literature.</li>
<li><strong>Generating differential diagnoses</strong>: 87%.</li>
<li><strong>Recommending treatment/management</strong>: 86%.</li>
</ul>
<h4><strong>Physician trust in AI</strong></h4>
<p>More than half of physicians said they trust AI but remain cautious. More than one-quarter said they’re spending less time correcting or double-checking information produced by AI compared to a year ago.</p>
<ul>
<li>More than half of surveyed physicians said they worried about the <strong>accuracy and reliability of AI</strong>.</li>
<li>Three-quarters said they <strong>AI had gotten something wrong</strong> clinically in the previous year.</li>
<li>Two-thirds of physicians said they <strong>verify clinical information</strong> produced by AI “all or almost all of the time.”</li>
<li>More than three-quarters trust AI to <strong>identify a potentially urgent or diagnosis patient condition.</strong></li>
<li>Just over one-third of physicians (34%) said factors like <strong>“legal and regulatory uncertainty”</strong> limit their use of AI.</li>
<li>82% said <strong>physicians should be making rules</strong> for the use of AI in medicine.</li>
</ul>
<h4><strong>How physicians think using AI will help</strong></h4>
<ul>
<li>Will improve <strong>work-life balance</strong>: 65%</li>
<li>Will lighten <strong>administrative workload</strong>: 59%.</li>
<li>Will create <strong>more time for patients</strong>: 52%.</li>
<li>Will enhance <strong>clinical decision support</strong>: 51%.</li>
</ul>
<h4><strong>Effects on patient relationships</strong></h4>
<ul>
<li>Nearly three-quarters of physicians said patients have become more likely in the past six months to <strong>use a diagnosis or treatment plan suggested by AI</strong>.</li>
<li>One-third of physicians said <strong>patients using AI are better-informed</strong> than those using a search engine like Google.</li>
</ul>
<h4><strong>Physician use of AI by age</strong></h4>
<ul>
<li>For physicians <strong>30 and under</strong>, more than 90% use AI in their work at least weekly.</li>
<li>For physicians <strong>in their 30s</strong>, that number is 89%.</li>
<li>For physicians <strong>in their 40s</strong>, 86% use AI at least weekly.</li>
<li>For doctors <strong>in their 50s and 60s</strong>, that number drops to 80%.</li>
<li>For physicians <strong>in their 70s</strong>, 66% use AI at least weekly.</li>
</ul>
<p><strong>Which physician specialties are using AI the most?</strong></p>
<p>Nephrology: 65%.</p>
<p>Oncology: 65%.</p>
<p>Radiology: 64%.</p>
<p>Internal medicine: 62%.</p>
<p>Gastroenterology: 59%.</p>
<p>Neurology: 56%.</p>
<p>Psychiatry: 53%.</p>
<p>Ob-gyn: 52%.</p>
<p>Pediatrics: 52%.</p>
<p>Cardiology: 51%.</p>
<p>Family medicine: 51%.</p>
<p>Pulmonology: 51%.</p>
<p>Urology: 50%.</p>
<p>Dermatology: 46%.</p>
<p>Emergency medicine: 46%.</p>
<p>General surgery: 44%.</p>
<p>Pathology: 42%.</p>
<p>Ophthalmology: 40%.</p>
<p>Orthopedic surgery: 37%.</p>
<p>Anesthesiology: 31%.</p>
<p>The post <a href="https://todayshospitalist.com/physician-use-of-ai-rises-sharply-which-specialties-are-the-power-users/">Physician use of AI rises sharply: Which specialties are the power users?</a> appeared first on <a href="https://todayshospitalist.com/">Today's Hospitalist</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Alcohol Suppresses Some T Cells, Boosts Others, Blunting Anti&#45;PD&#45;1 Response in Mice</title>
<link>https://edusehat.com/en/alcohol-suppresses-some-t-cells-boosts-others-blunting-anti-pd-1-response-in-mice</link>
<guid>https://edusehat.com/en/alcohol-suppresses-some-t-cells-boosts-others-blunting-anti-pd-1-response-in-mice</guid>
<description><![CDATA[ In mice, alcohol cut the efficacy of anti-PD-1 immunotherapy by roughly 50%, suppressing tumor-infiltrating and memory T cells while boosting TIGIT-carrying ones. Blocking TIGIT restored the response.
The post Alcohol Suppresses Some T Cells, Boosts Others, Blunting Anti-PD-1 Response in Mice appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/07/GettyImages-544546123.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 09:00:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Alcohol, Suppresses, Some, Cells, Boosts, Others, Blunting, Anti-PD-1, Response, Mice</media:keywords>
<content:encoded><![CDATA[<p>Regular alcohol use may undermine a widely used form of cancer immunotherapy by dampening some T cells while boosting others, according to a new study in mouse models and a retrospective patient cohort. The findings point to a molecular route by which drinking weakens anti-tumor immunity, and to ways it might be countered.</p>
<p>The work, from researchers at the University of North Carolina at Chapel Hill, was published in <em>Science Signaling</em> in a paper titled “<a href="https://www.science.org/doi/10.1126/scisignal.aef1375" target="_blank" rel="noopener">Alcohol use reduces the efficacy of anti-PD1 immunotherapy by disrupting antitumor immunity</a>.” Immune checkpoint inhibition has improved outcomes for some patients with advanced cancers, but relatively few have a complete response. Alcohol use is common and impairs adaptive immunity. Recent studies suggest that as many as 76.4% of patients with cancer still drink, and medical societies have called for more research on how alcohol affects treatment outcomes.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>To probe the link, the team gave mouse models of lung and bladder cancer a moderate-to-heavy amount of ethanol while treating them with anti-PD-1 antibodies. In both models, alcohol reduced the efficacy of the immunotherapy by roughly 50% and increased tumor recurrence.</p>
<p>In mice with MB49 bladder tumors, ethanol reduced the number of tumor-infiltrating T cells and shifted tumor-associated CD4<sup>+</sup> T cells toward a T helper 17 profile over a T helper 1 profile. It also reduced tissue-resident memory T cells while increasing the proportion of T cells expressing TIGIT, an alternative immune checkpoint receptor, and induced SREBP-mediated lipid signaling in tumor-associated T cells, according to the paper.</p>
<p>Targeting those changes helped. Blocking TIGIT with antibodies restored the efficacy of anti-PD-1 treatment in the animals, while inhibiting SREBP signaling with betulin improved it to a lesser extent.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>The researchers then retrospectively analyzed a cohort of patients with skin, lung, bladder, or head and neck cancer treated with immune checkpoint inhibitors. Patients who self-reported eight or more drinks a week had poorer survival after starting treatment. In patients with lung cancer, regular alcohol use was associated with a reduced survival benefit from immune checkpoint inhibition. The effects were less definitive in the other cancers because alcohol use reporting was too limited.</p>
<p>“This work is an initial resource toward establishing the risk of regular alcohol use on the efficacy of [immune checkpoint inhibition] and identifying the mechanisms that might be targeted for intervention,” Gilley <em>et al.</em> wrote. As next steps, the authors say that incorporating patients’ alcohol use into cancer databases will help define its effect on outcomes of various therapies, such as chimeric antigen receptor T cell therapy (CAR T cell therapy), chemotherapy, and radiation, across multiple cancers.</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/alcohol-suppresses-some-t-cells-boosts-others-blunting-anti-pd-1-response-in-mice/">Alcohol Suppresses Some T Cells, Boosts Others, Blunting Anti-PD-1 Response in Mice</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Genetic Barcoding Reveals How Pre&#45;Bone Marrow Transplant Conditioning Impacts Immune System Regeneration</title>
<link>https://edusehat.com/en/genetic-barcoding-reveals-how-pre-bone-marrow-transplant-conditioning-impacts-immune-system-regeneration</link>
<guid>https://edusehat.com/en/genetic-barcoding-reveals-how-pre-bone-marrow-transplant-conditioning-impacts-immune-system-regeneration</guid>
<description><![CDATA[ Researchers used genetic barcoding to track human blood-forming stem and progenitor cells transplanted into mice, revealing how the different cell types regenerate the blood and immune system, and how different forms of pretransplant conditioning affected blood and immune cell recovery. 
The post Genetic Barcoding Reveals How Pre-Bone Marrow Transplant Conditioning Impacts Immune System Regeneration appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/02/GettyImages-1489195647-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 05:25:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Genetic, Barcoding, Reveals, How, Pre-Bone, Marrow, Transplant, Conditioning, Impacts, Immune, System, Regeneration</media:keywords>
<content:encoded><![CDATA[<p>Researchers at the University of Southern California have used genetic barcoding to track individual human blood-forming stem and progenitor cells after transplanting them into mice. The results has revealed how different types of human blood-forming cells regenerate the blood and immune system, and how different forms of pretransplant conditioning—treatment used to prepare a recipient before bone marrow (BM) transplantation—affected blood and immune cell recovery.</p>
<p>The study is one of the first to systematically examine how human stem cells (HSCs) and human multipotent progenitors (hMPPs) respond to various forms of pretransplant conditioning, including chemotherapy and radiation, and contribute to the production of blood and immune cells. Down the line, the results could support the development of more effective and personalized approaches to bone marrow transplantation, which is used to treat blood cancers such as leukemia and lymphoma and certain inherited blood disorders.</p>
<p>“We found that human HSCs and MPPs don’t always behave as we would expect based on previous studies in mice,” said research lead Rong Lu, PhD, professor of stem cell biology and regenerative medicine at the Keck School of Medicine of USC. Lu is also a professor of biomedical engineering, medicine and gerontology. “Our findings underscore the importance of studying human cells directly to understand how they function in the context of transplantation.”</p>
<p>Lu is senior and corresponding author of the team’s published paper in <em>npj Regenerative Medicine</em>, titled “<a href="http://dx.doi.org/10.1038/s41536-026-00522-6" target="_blank" rel="noopener">Tracking human HSCs and MPPs in mice reveals distinct clonal dynamics and responses to pre-transplant conditioning</a>.” In their paper the team wrote, “These findings advance our understanding of human hematopoiesis and provide a framework for optimizing experimental models, improving transplantation conditioning strategies, and informing the preclinical evaluation of HSC-based cell and gene therapies.”</p>
<p>Human hematopoietic stem and progenitor cells (hHSPCs) sustain lifelong blood and immune cell production and are central to bone marrow (BM) transplantation therapies, the authors wrote. However, they noted, “While the functional hierarchy of mouse HSPC subsets is well characterized, the distinct roles of human HSPC populations remain less well defined, particularly at clonal resolution and in the context of transplantation conditioning.”</p>
<p>For their newly reported study, first author Mary Vergel Snodgrass, PhD, and colleagues used genetic barcode-based clonal tracking, which allowed them to follow individual cells and their descendants to see how they contribute to blood and immune cell production over time, comparing two cell types, hematopoietic stem cells and multipotent progenitor cells. Both HSCs and MPPs can produce multiple types of blood and immune cells, but HSCs are thought to have unique long-term regenerative capacity, based largely on animal studies.</p>
<p>The team transplanted human HSCs or MPPs into mice, then used clonal tracking to compare how the two cell populations contributed to blood and immune cell production over time. They found that both HSCs and MPPs produced multiple types of blood and immune cells over an extended period after transplantation, suggesting that human MPPs may have greater long-term regenerative capacity than previously observed in mouse studies. However, HSCs generally produced more blood cells and were better at producing multiple types of blood and immune cells than MPPs. “We found that hHSC clones generated more blood cells, initiated lymphoid production earlier, and exhibited more robust multilineage differentiation than hMPP clones,” they wrote.</p>
<figure aria-describedby="caption-attachment-340738" class="wp-caption alignright"><img decoding="async" class="size-medium wp-image-340738" src="https://www.genengnews.com/wp-content/uploads/2026/11/Low-Res_Rong-Lu-and-Mary-Vergel-by-Chris-Shinn-big-crop-300x169.jpg" alt="Study authors Rong Lu, PhD, and Mary Vergel Snodgrass in the lab " width="300" height="169" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Low-Res_Rong-Lu-and-Mary-Vergel-by-Chris-Shinn-big-crop-300x169.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Low-Res_Rong-Lu-and-Mary-Vergel-by-Chris-Shinn-big-crop.jpg 700w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Study authors Rong Lu, PhD, and Mary Vergel Snodgrass in the lab [Chris Shinn]</figcaption></figure>
<p>The researchers also compared several approaches to transplant conditioning, which helps reduce a recipient’s own stem and progenitor cells and makes room for donor cells. Mice received either radiation treatment, chemotherapy with the drug busulfan, or no conditioning treatment. The conditioning approach influenced how many and which types of blood and immune cells were produced, and how quickly blood cell production occurred, without significantly affecting donor cell engraftment in the bone marrow.</p>
<p>“We also found that HSCs were less affected by conditioning, while MPPs were more sensitive, shifting the types of immune cells they produced,” Lu said. “This suggests that human HSCs can maintain more consistent blood and immune cell production under different transplantation conditions.”</p>
<p>These findings could eventually help clinicians tailor pre-transplant treatments to individual patients, supporting more effective blood and immune cell recovery while minimizing treatment-related complications. While further studies are needed to determine how these findings translate to patients, they could help guide the development of safer and more effective transplantation strategies.</p>
<p>In a final experiment, the researchers transplanted HSCs and MPPs from the initial recipients into a second group of mice to test their long-term regenerative capacity. They found that both cell types continued producing blood and immune cells, but at substantially lower levels. “During secondary transplantation, hHSCs and hMPPs contributed comparably to hematopoietic reconstitution but with substantially reduced output and increased clonal diversity,” they wrote. Their collective findings “… suggest that secondary transplantation is characterized by weaker contributions from a larger number of clones, whereas primary transplantation is dominated by stronger expansion of a smaller number of clones.”</p>
<p>An unexpected discovery was that in mice receiving a second transplant, blood cell production occurred not only in the bone marrow but also in other tissues, including the spleen, which became substantially enlarged. “Extramedullary hematopoiesis was observed in all secondary recipients,” the team stated. Lu noted that this phenomenon has also been observed in human diseases and may indicate that the mouse bone marrow environment does not fully support human blood cell production. “In humans, EMH is associated with pathological conditions such as hematologic malignancies, BM failure, and systemic infections, highlighting its relevance as a compensatory hematopoietic response under stress and disease,” the authors stated.</p>
<p>Next, Lu and her team are investigating how blood-forming stem cells communicate with surrounding bone marrow cells to regulate blood and immune cell regeneration. This work could help explain why different conditioning treatments lead to different patterns of blood and immune cell recovery. In their paper, the team wrote in summary, “Through quantitative <em>in vivo</em> clonal tracking and multi-tissue analyses, this study advances understanding of human hematopoiesis and provides a framework for optimizing experimental models, improving transplantation strategies, and informing the development of HSC-based cell and gene therapies.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/genetic-barcoding-reveals-how-pre-bone-marrow-transplant-conditioning-impacts-immune-system-regeneration/">Genetic Barcoding Reveals How Pre-Bone Marrow Transplant Conditioning Impacts Immune System Regeneration</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Beyond Amyloid and Tau: Alzheimer’s Drug Developer Sees Early Clinical Success for Immunotherapy&#45;Based Approach</title>
<link>https://edusehat.com/en/beyond-amyloid-and-tau-alzheimers-drug-developer-sees-early-clinical-success-for-immunotherapy-based-approach</link>
<guid>https://edusehat.com/en/beyond-amyloid-and-tau-alzheimers-drug-developer-sees-early-clinical-success-for-immunotherapy-based-approach</guid>
<description><![CDATA[ ImmunoBrain&#039;s approach contrasts with decades of conventional thinking among researchers, which held that Alzheimer’s was a disease of toxic proteins—an outgrowth of thinking that immune activity in the brain was in itself a sign of pathology. 
The post Beyond Amyloid and Tau: Alzheimer’s Drug Developer Sees Early Clinical Success for Immunotherapy-Based Approach appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/CO_JanFeb18_GettyImages-687788463_CHRISTIANLAGEREK_SCIENCEPHOTOLIBRARY_HumanBrainCircuitBoard-e1559053521129-1024x831-1-e1794949818926.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 05:25:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Beyond, Amyloid, and, Tau:, Alzheimer’s, Drug, Developer, Sees, Early, Clinical, Success, for, Immunotherapy-Based, Approach</media:keywords>
<content:encoded><![CDATA[<p>Twelve years after a widely quoted <a href="https://alzres.biomedcentral.com/articles/10.1186/alzrt269" target="_blank" rel="noopener">Cleveland Clinic study</a> showed a staggering 99.6% failure rate for Alzheimer’s disease clinical candidates, the percentage has hardly budged.</p>
<p>But ImmunoBrain, an 11-year-old company, has generated early-stage clinical data showing success for a first-of-its-kind, immunotherapy-based approach to treating Alzheimer’s that goes beyond aiming at the two most common targets, amyloid plaques and tau neurofibrillary tangles.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>ImmunoBrain develops treatments intended to address Alzheimer’s and other neurodegenerative diseases by restoring the body’s peripheral immune system to facilitate brain protection and repair. The company uses a novel approach that targets the peripheral immune system to break the vicious cycle between neuroinflammation developed in the brain with neurodegenerative diseases and the progressive decline in peripheral immune function that together derives disease progression.</p>
<figure aria-describedby="caption-attachment-340728" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="size-medium wp-image-340728" src="https://www.genengnews.com/wp-content/uploads/2026/11/Prof-Michal-Schwartz-CROP-SQUARE-300x298.jpg" alt="" width="300" height="298" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Prof-Michal-Schwartz-CROP-SQUARE-300x298.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Prof-Michal-Schwartz-CROP-SQUARE-1024x1018.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/Prof-Michal-Schwartz-CROP-SQUARE-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/Prof-Michal-Schwartz-CROP-SQUARE-768x764.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Prof-Michal-Schwartz-CROP-SQUARE.jpg 1204w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Michal Schwartz, PhD, ImmunoBrain’s scientific co-founder and chief scientific officer</figcaption></figure>
<p>That approach contrasts with decades of conventional thinking among researchers, which held that Alzheimer’s was a disease of toxic proteins—an outgrowth of thinking that immune activity in the brain was in itself a sign of pathology.</p>
<p>“It’s not just a disease of only accumulation of toxic protein,” Michal Schwartz, PhD, ImmunoBrain’s scientific co-founder and chief scientific officer, told <em>GEN</em>. “We know now that the disease is dormant or asymptomatic for 10 to 20 years before symptoms are seen. Once symptoms are seen, the disease progression is driven not only by the amyloid plaque, but an additional major factor, local inflammation.”</p>
<p>“It’s not the primary cause, it’s not the trigger, but definitely a catalyzer,” said Schwartz, who is also a professor of neuroimmunology at the Weizmann Institute of Science in Rehovot, Israel.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>Alzheimer’s starts in the brain, with the accumulated of the toxic proteins such as amyloid and tau. At this stage, local immune cells—microglia—within the brain, supported by the peripheral immune system, can help prevent or minimize damage to neurons, the brain’s functional cells. When the immune system ages and declines, its ability to help the brain is reduced, fueling the brain pathology.</p>
<p>That happens, says Schwartz, when the brain’s own immune cells known collectively as microglia become the source of inflammation.</p>
<h4><strong>Antibody approach</strong></h4>
<p>“Our approach is, we developed a new antibody that targets the inhibitory checkpoint, thereby we boost the level very transiently of immune cells that can facilitate a homing of immune repairing cells from the peripheral immune system to the brain. They are facilitating dampening the local inflammation and thereby creating a supportive milieu within the brain that can rescue neurons and synapses that are still healthy but not functioning well.”</p>
<p>Schwartz’s lab was first to show that the brain is not immune isolated, but tightly dependent on the immune system for its daily maintenance, daily function, protection and repair, as it is the gatekeeper of the brain: “The meaning of it is that aging of the brain reflects more the immunological aging than the chronological aging.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>ImmunoBrain’s lead program applies IBC-Ab002, a company-developed anti-PD-L1 monoclonal antibody engineered specifically for use in chronic neurodegenerative disease settings. Specifically, IBC-Ab002 is engineered for transient, intermittent blockade of the PD-1/PD-L1 pathway. The transient checkpoint blockade allows for triggering of the immune system, initiating an immune cascade by facilitating the homing of immune-repairing monocytes and regulatory T cells (immune system regulators) that clear senescent microglia, and resolves inflammation, thereby helping the brain protection and repair.</p>
<p>IBC-Ab002 combines high-affinity PD-L1 binding with Fc effector silencing and reduced FcRn binding modification designed to eliminate antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.</p>
<h4><strong>Positive first-in-human data</strong></h4>
<p>At the 2026 Alzheimer’s Association International Conference (AAIC), held July 12-15 in London, and in a <a href="https://www.nature.com/articles/s41591-026-04547-8" target="_blank" rel="noopener">study published in <em>Nature Medicine</em></a>, ImmunoBrain shared positive data for IBC-Ab002 from a Phase Ib first-in-human study (<a href="https://clinicaltrials.gov/study/NCT05551741" target="_blank" rel="noopener">NCT05551741</a>) in patients with early Alzheimer’s. Forty patients were enrolled across five ascending dose cohorts (1–30 mg kg<sup>−1</sup>), with dosing administered four times at 3-month intervals, and patients followed up for one year. The study’s primary endpoints were safety and tolerability.</p>
<p>The data showed the antibody to have a half-life of approximately four days across all dose cohorts. IBC-Ab002 generated encouraging fluid biomarker data, as well as reductions of biomarkers associated with neuronal and synaptic damage, with no brain hemorrhaging or ARIA (amyloid-related imaging abnormalities) seen.</p>
<p>Exploratory CSF biomarker analyses at 48 weeks showed reductions in neurogranin (−23.1%), tTau (−12.4%) and pTau181 (−11.0%) at the 30 mg kg<sup>−1</sup> dose compared with pooled placebo, with intraindividual consistency across the three markers in participants treated with IBC-Ab002. A pre-synaptic biomarker, VAMP2, showed a similar trend to neurogranin, with strong correlation between individual responses to both markers.</p>
<p><strong>‘Beyond our expectation’</strong></p>
<p>“The biomarkers show an encouraging result, mainly the Neurogranin that is Alzheimer’s characteristic marker and prediction of cognitive performance. Yet, we cannot speak about statistical significance because of the small number of patients and the short duration of the follow-up, but it was beyond our expectation to see from such a small study,” said Schwartz, one of three corresponding authors on the <em>Nature Medicine</em> paper.</p>
<p>“IBC-Ab002 is intended to transiently re-engage the peripheral immune system, whose ability to support the brain declines with aging, thereby restoring its capacity to protect the brain and dampen brain inflammatory processes,” Schwartz and colleagues wrote. “Because this strategy does not rely on directly targeting a specific brain proteinopathy, it has broader applicability across other chronic neurodegenerative conditions in which neuroinflammation contributes to disease progression.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>Schwartz said she and colleagues are planning a Phase IIb trial for which they have submitted paperwork to the FDA, and for which they are raising funds. That study would include a two-year follow-up of participants: “We are aiming to do a big study, very rigorous, with a very ambitious endpoint, so if successful, as it seems based on the Phase Ib, it may speed up approval of this drug and may be considered as a pivotal study.”</p>
<p>In September, Schwartz was corresponding author of another paper, which <a href="https://www.nature.com/articles/s41593-026-02417-7" target="_blank" rel="noopener">was published in <em>Nature Neuroscience</em></a> that showed in both a mouse model and in Alzheimer’s patients the body’s “factory” of the a potentially protective immune response—the production of monocyte-derived macrophages in the bone marrow and their recruitment to the brain—key processes that help protect against disease progression are compromised: “Our results reveal a dysfunction in bone marrow myelopoiesis in AD and reinforce the concept that AD progression is driven by maladaptive systemic immune processes.”</p>
<p>“We wanted to see whether the deficiency in homing of macrophages that we are boosting with the anti-PD-L1 is reflection of some impairment in the factory of these monocytes, which is in the bone room,” Schwartz said. “When we saw that there is really impairment in production of monocytes in the factory of the monocytes in the bone marrow, I was, wow, very excited, because it further supports the notion that disease is not just disease of the brain. Then we found that the cause of this impairment is elevation of type 1 interferon, which all of us produce when we are encountering viral infection.”</p>
<p>Type I interferon signaling is an essential part of the body’s natural protective immune response. However, when this response becomes chronic, Schwartz explained, its protective effects can turn harmful—transforming a friend into a foe.</p>
<p>“If you have an inflammation in the body, the immune system produces type 1 interferon to dampen inflammation. But if this type 1 interferon is chronically produced, it becomes an enemy of the bone marrow. And we found the same situation in mice and in humans,” Schwartz explained.</p>
<h4><strong>Earlier research</strong></h4>
<p>That finding was in sync with <a href="https://pmc.ncbi.nlm.nih.gov/articles/pmid/25147279/" target="_blank" rel="noopener">earlier research published in <em>Science</em></a> by Schwartz and colleagues in 2014, showing that aging of the brain in both humans and mice was also associated with type 1 interferon.</p>
<p>“And in a way, it’s also linking what we know, that viral infection can catalyze Alzheimer’s disease … It is more likely the uncontrolled immune response to the virus, rather than the virus itself, that causes the damage.” Schwartz added. “It’s not just a disease of the brain. The brain affects the immune system, the immune system is impaired, and they enter into a vicious cycle.”</p>
<p>Last month, ImmunoBrain named to its board Francis Collins, MD, PhD, whose tenure as NIH director from 2009 to 2021 is the longest of any presidentially appointed director of the agency.</p>
<p>“One of my jobs as NIH director was to look across the entire field of biomedical research and say, ‘Are there some really serious gaps here that need to be filled?’ Alzheimer’s disease, because it is so common and so devastating for individuals and their families, obviously has been a high priority for research, particularly through the National Institute on Aging,” Collins recalled. “But despite massive efforts, it didn’t feel like we were necessarily making progress of the groundbreaking type that people were hoping for.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="7"></span></aside>
<p>The Cleveland Clinic’s reported 99.6% failure rate showed little improvement in a <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9198803/" target="_blank" rel="noopener">2022 study</a> that found a 98% failure rate among candidates studied in Phase II and III trials. And a study by Michael A.S. Guth, PhD, JD, <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC13532280/" target="_blank" rel="noopener">published in August</a> blamed the high failure rate on “structural and institutional forces that sustained investment in repeatedly ineffective mechanisms of action across 567 Phase II and Phase III Alzheimer’s trials from 2010 to 2026.”</p>
<p>“The 567-trial record constitutes a structural verdict on a model of drug development that was never designed to solve a problem of this complexity,” Guth asserted. “The uniformity of negative results across all mechanism categories—amyloid, tau, neuroinflammation, metabolic, and synaptic—points toward deeper problems of disease definition, intervention timing, and endpoint validity that institutional and financial pressures have prevented the field from confronting.”</p>
<figure aria-describedby="caption-attachment-340729" class="wp-caption alignright"><img decoding="async" class="size-medium wp-image-340729" src="https://www.genengnews.com/wp-content/uploads/2026/11/Dr-Francis-Collins-CROP-SQUARE-300x300.jpg" alt="" width="300" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Dr-Francis-Collins-CROP-SQUARE-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Dr-Francis-Collins-CROP-SQUARE-1024x1024.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/Dr-Francis-Collins-CROP-SQUARE-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/Dr-Francis-Collins-CROP-SQUARE-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Dr-Francis-Collins-CROP-SQUARE-1536x1536.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2026/11/Dr-Francis-Collins-CROP-SQUARE.jpg 1836w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Francis Collins, MD, PhD, NIH Director from 2009 to 2021 and Board Member of ImmunoBrain</figcaption></figure>
<p>Recalled Collins: “Most of the efforts I saw happening as NIH director were in terms of developing and testing monoclonal antibodies against amyloid. While they provided some positive signals, they certainly didn’t provide the breakthrough benefit that people had hoped for.”</p>
<p>There must be something more going on here, Collins concluded. Maybe genetic research could provide clues?  Studies of large numbers of affected and unaffected individuals using the GWAS (genome-wide association study) approach have now pointed to more than 100 such signals. The dominant pathway relates to microglia and innate immunity.</p>
<p>Yet the field of Alzheimer’s research has done relatively little to explore that area therapeutically, and remains focused, he said, primarily on amyloid and tau and lipids such as ApoE: “The field seems to be stuck on the amyloid hypothesis, but so far that’s not curing people or significantly preventing progression like we hoped.”</p>
<h4><strong>Milestones and growing pipeline</strong></h4>
<p>Alzheimer’s drug development has achieved several milestones during this decade.</p>
<p>Biogen and Eisai made history in 2021 when the FDA <a href="https://genengnews.com/news/biogen-alzheimers-drug-wins-historic-approval-but-fda-requires-new-trial/?_gl=1*1a12h21*_up*MQ..*_ga*MTI1OTkyNTY2Mi4xNzk0NzY0ODEy*_ga_F1EYPPYL3X*czE3OTQ3NjQ4MTIkbzEkZzAkdDE3OTQ3NjQ4MTIkajYwJGwwJGgxNTYyMTY0MjMw" target="_blank" rel="noopener">approved</a> their <a href="https://genengnews.com/news/fda-seeks-review-of-staff-biogen-talks-leading-to-alzheimers-drug-approval/" target="_blank" rel="noopener">controversial</a> human immunoglobulin gamma 1 (IgG1) monoclonal antibody Aduhelm<sup>®</sup> (aducanumab-avwa) as the first therapy indicated for reducing clinical decline in people with Alzheimer’s disease, and the first therapy to tie improved clinical outcomes to removing amyloid beta. But Aduhelm sales never matched forecasts and failed to the drug failed to obtain coverage from the Centers for Medicare and Medicaid Services (CMS).</p>
<p>In 2024, Biogen halted development and commercialization of Aduhelm in order to shift resources to other Alzheimer’s treatments—a year after the companies’ Leqembi<sup>®</sup> (lecanumab-irmb) became the first disease-modifying therapy to receive full FDA approval for patients with mild cognitive impairment or mild dementia.</p>
<p>The FDA has since approved a weekly subcutaneous maintenance dose last year and a subcutaneous starter dose in July, the latter marketed as Leqembi Iklik. The new subcutaneous doses have propelled Leqembi sales to finally outpacing sales forecasts after a slow start for the drug. During the third quarter, Eisai reported $202 million in global sales, up 67% from $121 million in Q3 2025. That includes $68 million recorded by Biogen in “Alzheimer’s collaboration” revenue—the sum of Biogen’s 50% share of net revenue and cost of sales, including royalties, from its Leqembi collaboration.</p>
<p>Another milestone occurred when Eli Lilly <a href="https://www.genengnews.com/topics/drug-discovery/fda-approves-lillys-amyloid-targeting-kisunla-for-early-alzheimers/" target="_blank" rel="noopener">won FDA approval in 2024 for Kisunla<sup>®</sup> (donanemab-azbt)</a>, a once-monthly injection treatment indicated for adults with early symptomatic Alzheimer’s, including mild cognitive impairment or mild dementia stage of disease with confirmed amyloid pathology. Kisunla was approved as the first amyloid plaque-targeting therapy with evidence to support stopping therapy when amyloid plaques are removed.</p>
<p>Among current Alzheimer’s candidates in Phase III development, AriBio on Monday trumpeted data from the Phase III POLARIS-AD trial (NCT05531526) at the 19<sup>th</sup> Clinical Trials on Alzheimer’s Disease (CTAD) conference, being held in Boston through Thursday. The data showed that its once-daily oral small molecule phosphodiesterase-5 (PDE5) inhibitor AR1001 showed statistically significant treatment difference of −0.44 points versus placebo on the Clinical Dementia Rating-Sum of Boxes (CDR-SB) at Week 52 (p=0.0266), representing 31% slowing of clinical decline.</p>
<p>But in the trial’s overall 1,535-participant population, the treatment difference vs. placebo was −0.11 points (p=0.4015), which did not reach statistical significance. AriBio said it plans to discuss the results with the FDA before deciding next steps.</p>
<p>AR1001 is among numerous Phase III Alzheimer’s candidates. Two examples:</p>
<ul>
<li>Roche and its Genentech subsidiary anticipate primary completion in February 2028 for the TRONTIER1 (<a href="https://clinicaltrials.gov/study/NCT07169578" target="_blank" rel="noopener">NCT07169578</a>) and TRONTIER2 (<a href="https://clinicaltrials.gov/study/NCT07170150" target="_blank" rel="noopener">NCT07170150</a>) trials for their anti-amyloid monoclonal antibody trontinemab (RO7126209) in 2028. A prevention study, PrevenTRON (<a href="https://clinicaltrials.gov/study/NCT07717411" target="_blank" rel="noopener">NCT07717411</a>), estimates primary data completion in 2032.</li>
<li>Eli Lilly expects releasing data in 2029 from its Phase III TRAILRUNNER-ALZ 3 trial (<a href="https://clinicaltrials.gov/study/NCT06653153" target="_blank" rel="noopener">NCT06653153</a>) assessing its beta-amyloid plaque targeting next-gen antibody remternetug (LY3372993).</li>
</ul>
<h4><strong>‘Pretty excited’</strong></h4>
<p>“The ImmunoBrain approach is, for me, a completely compelling and novel approach. It is built on a sweeping redefinition of what the fundamental problems are with Alzheimer’s disease. It builds on basic science data that implicates the immune system as a major player in progression, and even as a signal for aging itself,” Collins explained. “I am pretty excited about that.”</p>
<p>Collins said his departure from the NIH—a <a href="https://www.genengnews.com/topics/omics/former-nih-director-francis-collins-praises-the-institution-as-he-abruptly-departs-after-three-decades/" target="_blank" rel="noopener">sudden retirement in February 2025</a> after 32 years with the agency—offers him the opportunity to serve on company boards like that of ImmunoBrain.</p>
<p>“The need for progress in Alzheimer’s disease has been compelling to me for years.  In this new life chapter, I wanted to get more engaged to see if I could be helpful in some way. The data that Michal and her lab have generated over 25 years, building this case for a critical role of the immune system, points to a wholly new vision of the pathogenesis of this common and devastating disease.  Now that we see the encouraging result of biomarkers in a Phase Ib trial, published in a highly regarded peer-reviewed journal, it looks like we’re on the right track,” Collins said.</p>
<p>“I am now really excited about seeing this go forward to a Phase IIb trial with a clinical endpoint. The question is: can we show that this intervention changes the course of the illness?” the former NIH director added. “It will take a big push to answer that. It’s going to cost a lot of money. But of all the things I look at right now that are happening in Alzheimer’s, this feels like an exceptionally novel, encouraging, and potentially groundbreaking way to look at the disease in a new way that hasn’t been adequately explored before.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/beyond-amyloid-and-tau-alzheimers-drug-developer-sees-early-clinical-success-for-immunotherapy-based-approach/">Beyond Amyloid and Tau: Alzheimer’s Drug Developer Sees Early Clinical Success for Immunotherapy-Based Approach</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Mapping the Hidden Viral Communities of the Human Gut Microbiome</title>
<link>https://edusehat.com/en/mapping-the-hidden-viral-communities-of-the-human-gut-microbiome</link>
<guid>https://edusehat.com/en/mapping-the-hidden-viral-communities-of-the-human-gut-microbiome</guid>
<description><![CDATA[ Researchers identified over 116,000 gut viral groups, revealing previously unknown relationships between viruses, bacteria, and metabolism, with findings offering new insights into gut health and irritable bowel syndrome (IBS).
The post Mapping the Hidden Viral Communities of the Human Gut Microbiome appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/GettyImages-2289175590.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 01:50:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Mapping, the, Hidden, Viral, Communities, the, Human, Gut, Microbiome</media:keywords>
<content:encoded><![CDATA[<p>When people hear “gut microbiome” their first thought is likely the bacteria living inside our intestines. However, the human gut microbiome is home to a vast and largely unexplored world of viruses, which could determine how the gut ecosystem works.</p>
<p>New research has characterized a largely unexplored community of bacteriophages within the human gut. The findings provide an integrated picture of the gut ecosystem, connecting its viral, bacterial, and metabolic components, which influence health and conditions like IBS.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p> “Our research highlights that to fully understand the gut microbiome and its links to health and disease, we need to look beyond bacteria and consider the viruses that live alongside them,” notes Cristina Menni, PhD, who leads the metabolomics research group at the Department of Twin Research, Ageing and Genomic Epidemiology, King’s College London. “We reveal a fascinating and largely unexplored dimension of the gut microbiome—discovering that viruses are not only closely associated with bacterial communities, but also with the metabolites that connect the microbiome to our health. This opens exciting new avenues for understanding how the gut ecosystem works.”</p>
<p>The study is published in <em>Nature Communications</em> in the paper<em>, “</em><a href="https://www.nature.com/articles/s41467-026-79230-0" target="_blank" rel="noopener">Population-level characterisation of the human gut phageome and its association with microbial metabolites</a>.”</p>
<p>Research into the human gut microbiome has traditionally focused on bacteria, but little is known about its enormous population of viruses, particularly bacteriophages.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>This work identified over 116,000 viral groups in the gut. More than 99% of these had no close match in the largest existing catalogue of gut viruses, highlighting how much of the viral world within the gut remains unexplored. They found that certain viruses were consistently more common alongside particular bacteria, while others tended to be less common.</p>
<p>“Gut viruses are difficult to study, so most of what we found simply isn’t in existing catalogues,” notes Panayiotis Louca, PhD, Research Associate at King’s College London. “What stands out is how closely they track with gut bacteria and with the chemicals those bacteria produce. We can’t yet say whether the viruses are driving that, and testing it is our next step.”</p>
<p>The team used data from over 1,000 TwinsUK participants, the largest UK Twin Registry with data on gut bacteria, health measurements, and diet. By studying twins, the researchers also found that environmental factors play a major role in shaping the gut viral community, while genetics also contributes to certain aspects of viral diversity. Although genetic factors were estimated to explain around 47% of the variation in overall viral diversity, most individual viral populations appeared to be predominantly influenced by environmental factors.</p>
<p>The researchers also identified a small group of viruses carrying genes linked to harmful bacterial behavior. These viruses tended to occur alongside bacteria that can sometimes cause infections and were less commonly found alongside bacteria involved in breaking down dietary fiber.</p>
<p>Differences in the microbiome might influence conditions, such as irritable bowel syndrome (IBS). IBS affects around 10% of the population and can significantly affect quality of life, yet its underlying causes remain poorly understood.</p>
<p>In a second study, published in <em>Gut</em> today, the research team identified 50 gut viral groups associated with IBS, most of which were less abundant in people with the condition. There were also differences in the patterns of relationships between bacteria and viruses, with many viruses infecting bacteria already linked to the condition, suggesting that IBS may involve changes in how the wider gut microbial community is organized, rather than changes in bacteria alone.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>The next challenge will be to understand whether these viruses actively influence bacterial metabolism and how their relationships with bacteria change in different states of health and disease. Future studies will investigate whether these findings can help explain individual differences in microbial function and ultimately contribute to more personalized approaches to gut health.</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/mapping-the-hidden-viral-communities-of-the-human-gut-microbiome/">Mapping the Hidden Viral Communities of the Human Gut Microbiome</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Three Ontario hospitals unite pathology and radiology to improve cancer care</title>
<link>https://edusehat.com/en/three-ontario-hospitals-unite-pathology-and-radiology-to-improve-cancer-care</link>
<guid>https://edusehat.com/en/three-ontario-hospitals-unite-pathology-and-radiology-to-improve-cancer-care</guid>
<description><![CDATA[ Regional initiative will connect digital pathology and radiology services, supporting more coordinated cancer diagnosis and treatment planning. Three Ontario hospitals are expanding their shared medical imaging platform to include digital pathology, creating new opportunities for collaboration between specialists involved in cancer diagnosis and treatment. Lakeridge Health, Peterborough Regional Health Centre and Scarborough Health Network will […]
The post Three Ontario hospitals unite pathology and radiology to improve cancer care appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/11/988cba92c4cb1ca1_800x800ar.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 01:45:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Three, Ontario, hospitals, unite, pathology, and, radiology, improve, cancer, care</media:keywords>
<content:encoded><![CDATA[<p><em>Regional initiative will connect digital pathology and radiology services, supporting more coordinated cancer diagnosis and treatment planning.</em></p>
<p>Three Ontario hospitals are expanding their shared medical imaging platform to include digital pathology, creating new opportunities for collaboration between specialists involved in cancer diagnosis and treatment.</p>
<p>Lakeridge Health, Peterborough Regional Health Centre and Scarborough Health Network will introduce digital pathology through Sectra One Cloud, an enterprise imaging platform already supporting radiology services across the ENHANCE Ontario hospital network.</p>
<p>Announced November 17, the agreement represents Sectra’s largest digital pathology implementation in Canada to date.</p>
<p>Together, the three hospitals handle approximately <strong>120,000 pathology cases annually</strong>.</p>
<h2>Connecting diagnostic services</h2>
<p>Traditionally, radiology and pathology information may be managed through separate systems, requiring specialists to access different platforms when reviewing patient cases.</p>
<p>The expanded service will allow pathologists and radiologists to access diagnostic images within a shared environment, supporting multidisciplinary cancer care.</p>
<p>By bringing these specialties together, healthcare teams will be better positioned to review imaging findings alongside tissue-based diagnostic information when discussing treatment options.</p>
<p>The three participating hospitals are also partners in the Central East Regional Cancer Program, hosted by Lakeridge Health.</p>
<h2>Strengthening regional collaboration</h2>
<p>ENHANCE Ontario provides centralized information technology services to seven member hospitals.</p>
<p>Six hospitals previously agreed to consolidate radiology imaging on Sectra One Cloud in 2025, with the service becoming operational in early 2026.</p>
<p>Adding digital pathology builds on that infrastructure, enabling diagnostic information to be shared more effectively across participating organizations.</p>
<p>Peterborough Regional Health Centre also provides pathology services to Campbellford Memorial Hospital, Haliburton Highlands Health Services, Northumberland Hills Hospital and Ross Memorial Hospital.</p>
<p>The initiative is expected to support more flexible case reviews and collaboration between hospital specialists, including opportunities to involve subspecialty expertise when required.</p>
<h2>Supporting the future of cancer diagnostics</h2>
<p>Digital pathology enables specialists to examine high-resolution images of tissue samples electronically rather than relying exclusively on conventional glass slides and microscopes.</p>
<p>The technology can support remote consultations, multidisciplinary case discussions and access to specialized diagnostic expertise.</p>
<p>It also establishes infrastructure that could support future digital diagnostic tools as they become available.</p>
<p>The four-year agreement represents another step toward integrated diagnostic services in Ontario, with the potential to improve coordination between pathology, radiology and cancer care teams.</p>
<p>As Canadian hospitals continue to modernize diagnostic services, shared imaging platforms are becoming an increasingly important part of efforts to improve collaboration and support timely clinical decisions.</p>
<p>The post <a href="https://www.hospitalnews.com/three-ontario-hospitals-unite-pathology-and-radiology-to-improve-cancer-care/">Three Ontario hospitals unite pathology and radiology to improve cancer care</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Black Friday Savings are Here!</title>
<link>https://edusehat.com/en/black-friday-savings-are-here</link>
<guid>https://edusehat.com/en/black-friday-savings-are-here</guid>
<description><![CDATA[ The post Black Friday Savings are Here! appeared first on BoardVitals Blog. ]]></description>
<enclosure url="https://blog.boardvitals.com/wp-content/uploads/2022/11/boardvitals-black-friday-1024x538.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 01:20:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Black, Friday, Savings, are, Here</media:keywords>
<content:encoded><![CDATA[<p class="wp-block-paragraph">Black Friday is here! For a limited time only, BoardVitals is offering our biggest discounts of the season. </p>



<p class="wp-block-paragraph"><span>Whether you’re preparing for a <a href="https://www.boardvitals.com/medical-board-reviews">board exam</a>, <a href="https://www.boardvitals.com/moc-recertification-exams-prep">MOC exam</a>, or looking to fulfill your </span><a href="https://www.boardvitals.com/cme"><span>continuing medical education requirements</span></a><span> for 2026, BoardVitals has the right product for every specialty.</span></p>



<p class="wp-block-paragraph">From now through December 1, 2026, save 25% sitewide with code CYBER.</p>



<p class="wp-block-paragraph"><span>Don’t miss out – this sale won’t last long. Happy Holidays from the BoardVitals team! </span><span><br></span></p>
<p>The post <a href="https://www.boardvitals.com/blog/black-friday/">Black Friday Savings are Here!</a> appeared first on <a href="https://www.boardvitals.com/blog">BoardVitals Blog</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Canada moves closer to expanded access to multiple myeloma treatment</title>
<link>https://edusehat.com/en/canada-moves-closer-to-expanded-access-to-multiple-myeloma-treatment</link>
<guid>https://edusehat.com/en/canada-moves-closer-to-expanded-access-to-multiple-myeloma-treatment</guid>
<description><![CDATA[ New national agreement could expand public funding for a four-drug treatment shown to delay disease progression in eligible patients. A new agreement between Sanofi and the pan-Canadian Pharmaceutical Alliance (pCPA) could expand publicly funded treatment options for Canadians diagnosed with multiple myeloma, a cancer affecting plasma cells in the bone marrow. Announced November 16, the […]
The post Canada moves closer to expanded access to multiple myeloma treatment appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/11/shutterstock_529109200.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 17 Nov 2026 22:10:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Canada, moves, closer, expanded, access, multiple, myeloma, treatment</media:keywords>
<content:encoded><![CDATA[<p data-pm-slice="1 1 []"><em>New national agreement could expand public funding for a four-drug treatment shown to delay disease progression in eligible patients.</em></p>
<p>A new agreement between Sanofi and the pan-Canadian Pharmaceutical Alliance (pCPA) could expand publicly funded treatment options for Canadians diagnosed with multiple myeloma, a cancer affecting plasma cells in the bone marrow.</p>
<p>Announced November 16, the agreement covers Sarclisa (isatuximab), used in combination with bortezomib, lenalidomide and dexamethasone. The four-drug regimen is intended for adults with newly diagnosed multiple myeloma who are not eligible for stem cell transplantation.</p>
<p>The agreement represents an important step toward expanded access, although provincial and territorial drug plans must still make their funding decisions.</p>
<h2>Clinical evidence supports treatment approach</h2>
<p>The agreement follows results from the international Phase 3 IMROZ clinical trial involving 446 patients.</p>
<p>At approximately five years of follow-up, <strong>63.2 per cent of patients receiving the four-drug combination remained free from disease progression</strong>, compared with 45.2 per cent receiving the standard three-drug treatment.</p>
<p>The addition of isatuximab was associated with a <strong>40 per cent relative reduction in the risk of disease progression or death</strong> during the study period.</p>
<p>Published in <em>The New England Journal of Medicine</em>, the findings also demonstrated higher rates of complete response and deeper disease control. However, a statistically significant overall survival benefit had not been established at the time of the reported analysis. Treatment also requires monitoring for adverse effects, including infections.</p>
<h2>An important milestone for Canadian cancer care</h2>
<p>Multiple myeloma is Canada’s second most common blood cancer, with approximately 4,400 new cases expected in 2026.</p>
<p>The disease affects the bone marrow and can cause anemia, bone damage, kidney complications and increased susceptibility to infections.</p>
<p>For patients who are ineligible for transplantation because of age or other medical considerations, maintaining disease control is a major treatment objective.</p>
<p>Canada’s Drug Agency recommended public reimbursement of the isatuximab combination in June 2025, subject to specified conditions. The new pCPA agreement brings the treatment another step closer to public coverage.</p>
<h2>Next steps toward public coverage</h2>
<p>While the national agreement establishes negotiated terms, it does not automatically provide public reimbursement. Individual provinces and territories must complete their own funding and listing decisions.</p>
<p>For hospital oncology teams and pharmacists, the agreement could eventually provide another first-line treatment option for eligible patients.</p>
<p>The development highlights the importance of translating promising clinical research into accessible cancer treatments while ensuring appropriate funding and patient care across Canada’s healthcare system.</p>
<p>The post <a href="https://www.hospitalnews.com/canada-moves-closer-to-expanded-access-to-multiple-myeloma-treatment/">Canada moves closer to expanded access to multiple myeloma treatment</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Toward Connected Laboratory Ecosystems</title>
<link>https://edusehat.com/en/toward-connected-laboratory-ecosystems</link>
<guid>https://edusehat.com/en/toward-connected-laboratory-ecosystems</guid>
<description><![CDATA[ In this GEN podcast, the third in a series, LabVantage’s Denise Bell discusses how laboratories can reduce operational fragmentation and build connected, scalable operations. 
The post Toward Connected Laboratory Ecosystems appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Getty_2239922126_ArtificialIntelligence.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 17 Nov 2026 11:25:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Toward, Connected, Laboratory, Ecosystems</media:keywords>
<content:encoded><![CDATA[<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"></div>
</div>

<p></p>

<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph">These days, many laboratories are eager to apply AI, but the systems and workflows that they have implemented often stand in the way. When systems run separately, information gets trapped in silos and scientific context is lost between steps. Also, manual handoffs slow the work down and introduce risk at various points in lab processes. Connecting those systems and workflows first gives AI the operational and scientific context it needs to deliver value that can be both trusted and scaled.</p>


<p class="wp-block-paragraph">In this <em>GEN</em> podcast, the third in a series, LabVantage’s Denise Bell discusses how laboratories can reduce operational fragmentation and build connected, scalable operations. The discussion covers workflow orchestration across laboratory functions and ways to reduce manual handoffs and information silos, while offering some practical starting points for AI adoption. It also looks at how bringing LIMS, ELN, LES, and SDMS together in a unified laboratory execution environment enables workflow intelligence and AI assistance in the right scientific and operational context.</p>


<p class="wp-block-paragraph"></p>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-vertically-aligned-top is-layout-flow wp-block-column-is-layout-flow">
<h4 class="wp-block-heading"><strong><strong>Podcast Guests:</strong></strong></h4>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow">
<figure class="wp-block-image aligncenter size-medium is-resized"><img fetchpriority="high" decoding="async" width="300" height="300" src="https://www.genengnews.com/wp-content/uploads/2026/11/Denise-Bell-VP-Product-Management-and-Marketing-e1794865379160-300x300.jpg" alt="Denise Bell" class="wp-image-340716" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Denise-Bell-VP-Product-Management-and-Marketing-e1794865379160-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Denise-Bell-VP-Product-Management-and-Marketing-e1794865379160-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/Denise-Bell-VP-Product-Management-and-Marketing-e1794865379160-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Denise-Bell-VP-Product-Management-and-Marketing-e1794865379160.jpg 800w" sizes="(max-width: 300px) 100vw, 300px"></figure>


<h6 class="wp-block-heading has-text-align-center"><strong><strong><strong>Denise Bell</strong></strong></strong><br>Vice President, Product Management & Marketing<br>LabVantag</h6>
</div>
</div>
</div>
</div>


<hr class="wp-block-separator has-alpha-channel-opacity is-style-wide">


<p class="has-text-align-center wp-block-paragraph"><br><strong>Produced with support from:</strong></p>


<figure class="wp-block-image aligncenter size-medium"><a href="https://www.labvantage.com/" target="_blank" rel=" noopener"><img decoding="async" width="300" height="57" src="https://www.genengnews.com/wp-content/uploads/2019/12/LV_logo-300x57.jpg" alt="LabVantage logo" class="wp-image-131319" srcset="https://www.genengnews.com/wp-content/uploads/2019/12/LV_logo-300x57.jpg 300w, https://www.genengnews.com/wp-content/uploads/2019/12/LV_logo-696x132.jpg 696w, https://www.genengnews.com/wp-content/uploads/2019/12/LV_logo-741x142.jpg 741w, https://www.genengnews.com/wp-content/uploads/2019/12/LV_logo.jpg 750w" sizes="(max-width: 300px) 100vw, 300px"></a></figure>

<p>The post <a href="https://www.genengnews.com/topics/toward-connected-laboratory-ecosystems/">Toward Connected Laboratory Ecosystems</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Enhancer&#45;Targeted CRISPR Turns Up Healthy Gene Copy in Autism Organoid Model</title>
<link>https://edusehat.com/en/enhancer-targeted-crispr-turns-up-healthy-gene-copy-in-autism-organoid-model</link>
<guid>https://edusehat.com/en/enhancer-targeted-crispr-turns-up-healthy-gene-copy-in-autism-organoid-model</guid>
<description><![CDATA[ In lab-grown human neurons and organoids carrying CHD8 or SCN2A mutations, researchers reduced organoid overgrowth and moved neuronal electrical activity closer to wild-type levels.
The post Enhancer-Targeted CRISPR Turns Up Healthy Gene Copy in Autism Organoid Model appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2018/10/Nov1_2011_3769185_BlueBrainDNA_AutismGeneStudies_AI2888221221.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 17 Nov 2026 11:25:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Enhancer-Targeted, CRISPR, Turns, Healthy, Gene, Copy, Autism, Organoid, Model</media:keywords>
<content:encoded><![CDATA[<p>When a mutation hinders one copy of a gene, the remaining copy has to do the work of two. Researchers at UCLA have now shown, in lab-grown human brain cells, that a CRISPR-based tool could help that remaining copy in models of autism.</p>
<p>The proof-of-concept study, published in <em>Nature Neuroscience</em>, is titled “<a href="https://www.nature.com/articles/s41593-026-02504-9?utm_source=rct_congratemailt&utm_medium=email&utm_campaign=oa_20261113&utm_content=10.1038/s41593-026-02504-9">Enhancer-targeted CRISPR-A rescues haploinsufficiency and mutant phenotypes in organoid models of autism</a>.” It was led by Daniel Geschwind, MD, PhD, at the David Geffen School of Medicine at UCLA. George Chen, PhD, now at Children’s Hospital of Los Angeles, is first author. Collaborators at the New York Genome Center and New York University also contributed.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>“Approximately 15% of the genetic susceptibility of autism spectrum disorder (ASD) is imparted by <em>de novo</em> haploinsufficient mutations of major effect,” the authors wrote. The team focused on two high-confidence autism genes: <em>CHD8</em>, which helps regulate other neurodevelopmental genes, and <em>SCN2A</em>, which is essential for neurons to fire electrical signals.</p>
<p>Instead of editing DNA, the researchers used CRISPR activation, pairing a catalytically inactive Cas9 with the activator p300 (dCas9-p300) to turn genes up without cutting them, and aimed it at fetal-brain enhancers. The team’s concern was that promoter targeting risks overexpression, a particular problem for haploinsufficient genes, which are often dosage sensitive.</p>
<p>“We mapped enhancers of two high-confidence autism genes, <em>CHD8</em> and <em>SCN2A</em>, and used CRISPR-based gene activation targeting enhancers (eCRISPR-A) in human pluripotent stem cell (hPSC)-derived excitatory neurons and cerebral forebrain organoids to correct the effects of haploinsufficiency,” the authors wrote. “Here we show that eCRISPR-A induced a sustained increase in <em>CHD8</em> and <em>SCN2A</em> expression specifically in mutant neurons and cortical organoids, with rescue of gene expression levels and mutation-associated phenotypes, including gene expression and physiology.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>In <em>CHD8</em>-mutant organoids, which grow abnormally large because progenitor cells overproliferate, treatment reduced organoid size in most treated lines and shifted gene expression toward wild-type patterns. In <em>CHD8</em>-mutant neurons grown in two-dimensional cultures, it increased markers of neuronal maturation. In <em>SCN2A</em>-mutant neurons, it showed restored excitability: firing approached wild-type levels in patient-derived neurons. Interestingly, “patient-derived iPSC neurons required higher current injections to achieve sustained firing compared to HUES66-derived neurons across conditions, indicating a line-dependent difference in baseline intrinsic excitability rather than incomplete functional rescue,” reported the authors.</p>
<p>“Our results show that, in human cell models, it’s possible to turn up that remaining copy and move cells back toward typical development,” Geschwind said in a press release. “This is a key first step, and it gives us a new way to think about addressing the biology underlying these conditions.”</p>
<p>The authors call the work “an important proof of principle” and note they were able to “moderately increase the expression of each gene.” However, “the effect of eCRISPR-A decreased over time,” and “an open question remains regarding the effect of introducing CRISPR-A after the expected peak in expression.” They say “further optimization of viral infection, constructs, and use of alternative Cas enzymes” would increase the approach’s clinical utility.</p>
<p>“We are still a long way from the clinic, and there is a lot of work ahead on delivery and timing,” added Chen in a press release, “but these findings provide hope and give us a clear direction.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/enhancer-targeted-crispr-turns-up-healthy-gene-copy-in-autism-organoid-model/">Enhancer-Targeted CRISPR Turns Up Healthy Gene Copy in Autism Organoid Model</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Gut Microbome and Bile Acid Modification Linked with Longevity</title>
<link>https://edusehat.com/en/gut-microbome-and-bile-acid-modification-linked-with-longevity</link>
<guid>https://edusehat.com/en/gut-microbome-and-bile-acid-modification-linked-with-longevity</guid>
<description><![CDATA[ Researchers studying how gut microbes modify bile acids have identified changes in the metabolic activity of the gut microbiome associated with exceptional longevity in humans, and found that amplifying the same activity with engineered bacteria improved metabolic health in aged mice.
The post Gut Microbome and Bile Acid Modification Linked with Longevity appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/04/GettyImages-1683059833.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 17 Nov 2026 07:50:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Gut, Microbome, and, Bile, Acid, Modification, Linked, with, Longevity</media:keywords>
<content:encoded><![CDATA[<p>Researchers from the University of California San Diego have identified changes in the metabolic activity of the gut microbiome associated with exceptional longevity in humans, and found that amplifying the same activity with engineered bacteria improved metabolic health in aged mice.</p>
<p>“Many studies of aging focus on what goes wrong as we get older, but our findings suggest that some changes in the gut microbiome may actually represent the body’s attempt to preserve metabolic health,” said Amir Zarrinpar, MD, PhD, Stuart and Barbara L. Brody Endowed Chair in Circadian Biology and Medicine, and professor of medicine at UC San Diego School of Medicine. “If we can identify those beneficial functions and safely strengthen them, we may eventually be able to develop new ways to promote healthier aging.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>Zarrinpar is senior and corresponding author of the researchers’ published paper in <em>Cell Metabolism</em>, titled “<a href="https://www.cell.com/cell-metabolism/fulltext/S1550-4131(26)00453-5" target="_blank" rel="noopener">Microbial bile acid deconjugation counters metabolic decline in aging</a>.”</p>
<p>For their reported study the researchers focused on how gut microbes modify bile acids. Gut bacteria produce enzymes called bile salt hydrolases (BSH) that chemically modify bile acids, allowing them to influence pathways involved in metabolism, inflammation and the body’s internal clock. “Gut microbes modify bile acids through several reactions, including deconjugation by bile salt hydrolase (BSH),” the team wrote. “Deconjugated bile acids can regulate host gene expression and signaling pathways, including those involved in metabolism, inflammation, and circadian rhythms.”</p>
<p>The gut microbiome—the community of bacteria and other microbes living in the digestive tract—changes throughout life and plays an important role in metabolism, inflammation, and other aspects of health. Previous research has linked age-related changes in the microbiome with frailty, chronic inflammation, and disease, while other studies have found distinctive microbiome features among people who age exceptionally well.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>The researchers first studied young and aged mice and found that aging was associated with increased microbial activity related to BSH and greater bile acid modification. To determine whether a similar pattern occurred in humans, they reanalyzed publicly available data from a human aging cohort. The analysis included bile acid measurements from 48 young adults, 107 older adults, and 125 centenarians. The centenarian group showed higher ratios of certain modified bile acids than both younger groups.</p>
<p>Analysis of microbiome data also found greater abundance of a gene associated with BSH activity among centenarians compared with the older adult group. “Individuals with exceptional longevity show a similar bile acid deconjugation signature, suggesting an association with resilient or exceptional aging,” the team pointed out.</p>
<p>They then asked whether enhancing this microbial function could produce health benefits. The researchers engineered a strain of bacteria native to the gut to continuously produce BSH, and introduced the bacteria into 82-week-old mice—considered aged. A single treatment resulted in stable colonization, allowing the bacteria to persist and produce the enzyme over time.</p>
<p>Approximately 20 weeks after treatment, mice receiving the BSH-producing bacteria had significantly improved insulin sensitivity and modestly improved glucose tolerance compared with mice receiving a matched control bacterium. By 32 weeks, the treated mice also showed changes consistent with lower body weight and fat mass and greater lean mass. Other findings pointed to increased use of fat for energy, improved mitochondrial function, and changes in gene activity related to inflammation and the body’s internal clock. “Using engineered native bacteria, we further increased luminal BSH activity in aged mice and improved insulin sensitivity, accompanied by supportive changes in body composition and other metabolic readouts,” the investigators commented.</p>
<p>The results do not show that the microbial changes caused exceptional longevity in humans or that the engineered bacteria can extend lifespan. The authors note that centenarians and aged mice are not directly comparable, and the human findings provide supporting rather than definitive evidence. “We also acknowledge that aged mice and individuals with exceptional longevity are not directly equivalent and therefore consider the centenarian data corroborative rather than definitive evidence,” they stated. “From this perspective, increased BSH activity may serve as a marker of, or potential contributor to, metabolic resilience during aging. More studies in people will be needed to determine whether increased BSH activity is a marker of healthy aging, a contributor to it, or both.”</p>
<p>The study also points toward a broader possibility: rather than attempting to replace the entire gut microbiome, researchers may eventually be able to identify beneficial microbial functions and selectively enhance them. In their paper they noted, “Together, these findings suggest that elevated BSH activity may have a protective role during aging. They challenge the view that age-related changes in bile acid biotransformations are uniformly detrimental, highlighting microbial bile acid modulation as a potential strategy to improve late-life metabolic health.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>Future studies will investigate how different forms of BSH affect bile acid metabolism, inflammation, energy use, and other aspects of aging, as well as whether the approach works similarly in females, given established differences in aging based on sex.</p>
<p>“The goal isn’t simply to live longer—it’s to understand the biology that allows some people to remain resilient as they age,” said Zarrinpar. “The microbiome gives us an intriguing opportunity because, unlike many aspects of aging, it may be something we can modify. This study gives us a starting point for asking whether beneficial microbial functions can be amplified to help preserve metabolic health later in life.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/gut-microbome-and-bile-acid-modification-linked-with-longevity/">Gut Microbome and Bile Acid Modification Linked with Longevity</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>What Your Heart’s Structure Has to Do With Your Diagnosis</title>
<link>https://edusehat.com/en/what-your-hearts-structure-has-to-do-with-your-diagnosis</link>
<guid>https://edusehat.com/en/what-your-hearts-structure-has-to-do-with-your-diagnosis</guid>
<description><![CDATA[ Words like stenosis, blockage, and defect each point to one part of the heart and what is wrong with it. This guide maps the heart’s chambers, valves, and vessels to the diagnoses people hear most, with five questions to ask your doctor and how to request a consultation with Dr. Giovanni Ciuffo in Las Vegas. ]]></description>
<enclosure url="https://heartsurgeryinfo.com/wp-content/uploads/2026/11/Physician-holds-model-of-artificial-heart-in-hands.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 17 Nov 2026 00:35:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>What, Your, Heart’s, Structure, Has, With, Your, Diagnosis</media:keywords>
<content:encoded><![CDATA[<p><span>Stenosis. Blockage. Defect. If you’ve heard one of these words in a doctor’s office, it probably sounded like a foreign language, and the real questions tend to arrive after you’ve already left the room.</span></p>
<p><span>Here’s the reassuring part: nearly every one of those words is describing a part of the heart and what’s going wrong with it. A narrowed valve. A blocked artery. An opening that shouldn’t be there. That’s the connection between heart structure and diagnosis, and you don’t need a medical degree to follow it. You just need a map.</span></p>
<p><span>This guide builds on</span><a href="https://heartsurgeryinfo.com/a-beginners-guide-to-hearts-structure/"> <span>a basic tour of the heart’s structure</span></a><span> and shows how each part connects to the conditions people are most often told they have, so your own diagnosis starts to make sense.</span></p>
<h2><strong>Why Your Diagnosis Is Really a Structure Question</strong></h2>
<p><span>So what is a diagnosis actually telling you? Almost always, it names two things: a part of the heart, and what’s wrong with it. Once you can place the part, the rest gets much easier to follow.</span></p>
<p><span>Here’s the quick version of the map. The heart has four chambers. The two upper chambers, the atria, receive blood, and the two lower chambers, the ventricles, pump it out. The right side sends blood to the lungs to pick up oxygen, and the left side sends that oxygen-rich blood out to the rest of the body. Four valves act like one-way doors between those spaces, keeping blood moving forward instead of back. The wall itself has three layers: a thin outer covering, a thick middle layer of muscle that does the pumping, and a smooth inner lining. And a set of vessels carries blood in and out, including the aorta, the large artery that sends blood to the body, and the coronary arteries, which feed the heart muscle itself.</span></p>
<p><span>That’s really it. When a doctor says a valve is narrowed, an artery is blocked, or a chamber has an opening it shouldn’t, they’re pointing to one spot on this map. Knowing which spot makes appointments less overwhelming, because you can follow the explanation instead of just nodding along. It also helps when a doctor pulls up an image or sketches a diagram, since you’ll know what you’re looking at and can ask better questions about the plan.</span></p>
<p><span>Our</span><a href="https://heartsurgeryinfo.com/a-beginners-guide-to-hearts-structure/"> <span>beginner’s guide to the heart’s structure</span></a><span> goes deeper if you’d like a fuller refresher. For now, this is enough to start understanding your heart condition one piece at a time.</span></p>
<h2><strong>When the Problem Is a Valve</strong></h2>
<p><span>So what does it mean when your diagnosis points to a valve? Of all the places a heart problem can show up, valves are among the most common, which is why heart valve problems come up so often in diagnoses.</span></p>
<p><span>Quick reminder: you have four valves, the tricuspid, mitral, pulmonary, and aortic, and each one is a one-way door that opens to let blood through and closes to keep it from slipping back. Two of them, the aortic and mitral valves, work on the heart’s high-pressure left side, and they’re the ones most often needing surgical attention.</span></p>
<p><span>Valve problems usually come in two forms. A narrowed valve, known as stenosis, doesn’t open fully, so the heart has to work harder to push blood through. A leaking valve, known as regurgitation, doesn’t close fully, so some blood flows backward. Some valves have both problems at once. Either way, the diagnosis names the valve and names the problem, which is exactly the connection between heart structure and diagnosis we’ve been building toward.</span></p>
<p><span>Severity matters just as much as the type of problem. A mildly narrowed or leaky valve is often monitored over time, while a more severe one is more likely to call for treatment, which is why your imaging and follow-up measurements carry so much weight in the plan your doctor recommends.</span></p>
<p><span>From there, the question is usually repair or replace. Some valves, particularly the mitral valve, can often be repaired and kept in place, which many surgeons prefer when the valve allows it. Others need to be replaced, and replacement brings its own choice between mechanical and biological valves, which our page on</span><a href="https://heartsurgeryinfo.com/biological-or-mechanical-heart-valve/"> <span>choosing a biological or mechanical heart valve</span></a><span> walks through.</span></p>
<p><span>Many of these procedures can be done through smaller incisions, depending on the valve and your case. If you want the specifics, we cover</span><a href="https://heartsurgeryinfo.com/minimally-invasive-aortic-valve-surgery/"> <span>minimally invasive aortic valve surgery</span></a><span> and</span><a href="https://heartsurgeryinfo.com/minimally-invasive-mitral-valve-repair/"> <span>minimally invasive mitral valve repair</span></a><span> in more detail.</span></p>
<h2><strong>When the Problem Is the Heart’s Blood Supply</strong></h2>
<p><span>So what happens when the problem is the heart’s blood supply? The heart is a muscle, and like any muscle it needs a steady supply of oxygen-rich blood to keep working, every minute of every day. That supply doesn’t come from the blood flowing through its chambers. It comes from the coronary arteries, a network of vessels that branch off the aorta and wrap around the outside of the heart.</span></p>
<p><span>When those arteries narrow, usually from a gradual buildup of plaque, less blood reaches the muscle they feed. A partial blockage can cause chest pain or shortness of breath, especially during activity, because the muscle isn’t getting all it needs. A complete blockage can cut off the supply to part of the muscle altogether, which is what causes a heart attack. This is why a diagnosis of coronary blockage is really a statement about how well a specific section of heart muscle is being fed.</span></p>
<p><span>Treatment depends on how many arteries are affected, where the blockages sit, and how much muscle depends on them. In some cases, medication or stents are enough to restore good blood flow. In others, the answer is bypass surgery, where a surgeon uses a healthy blood vessel from elsewhere in the body to create a new route around the blocked section, like a detour around a roadblock.</span><a href="https://heartsurgeryinfo.com/coronary-surgery/"> <span>Minimally invasive coronary bypass surgery</span></a><span> explains how that works through smaller incisions.</span></p>
<p><span>If bypass is what you’ve been told you need,</span><a href="https://heartsurgeryinfo.com/told-you-need-bypass-surgery-what-actually-happens-next/"> <span>here’s what actually happens next</span></a><span>. Seeing a blockage as a structure problem, a section of muscle that needs a better supply, is a big step toward understanding your heart condition and the choices in front of you.</span></p>
<h2><strong>When the Problem Is a Chamber, Opening, or Major Vessel</strong></h2>
<p><span>Some diagnoses don’t involve a valve or an artery at all. They involve a chamber, an opening that shouldn’t be there, or the wall of the body’s largest blood vessel. Here’s how three of them connect back to the structure you just read about.</span></p>
<p><span>An</span><a href="https://heartsurgeryinfo.com/minimally-invasive-atrial-septal-defect-asd-repairs/"> <span>atrial septal defect, or ASD</span></a><span>, is an opening in the wall between the heart’s two upper chambers, which lets blood cross to the wrong side and makes the right side of the heart work harder than it should. Some people are born with one, and others learn about it later in adulthood.</span></p>
<p><span>An atrial myxoma is a tumor that grows inside one of those upper chambers, and because pieces can break loose and travel, it is usually removed promptly.</span><a href="https://heartsurgeryinfo.com/atrial-myxoma-surgery/"> <span>Atrial myxoma surgery</span></a><span> explains how the tumor and the section of wall it grows from are taken out.</span></p>
<p><span>An</span><a href="https://heartsurgeryinfo.com/inoperable-aortic-aneurysms/"> <span>aortic aneurysm</span></a><span> is a weakened, bulging section of the aorta, the major vessel that carries blood out of the heart to the rest of the body, and the wider it grows, the greater the risk that the wall can tear or rupture.</span></p>
<p><span>Each one is a different structure with a different problem. Once you know which chamber, opening, or vessel is involved, the diagnosis stops being a string of unfamiliar words, and the connection between heart structure and diagnosis becomes something you can use when you talk with a surgeon.</span></p>
<h2><strong>Questions That Help Your Diagnosis Make Sense</strong></h2>
<p><span>You don’t need a medical degree to follow your own diagnosis. You just need the right questions. Understanding your heart condition is part of your care, and it starts with what you ask. Doctors use shorthand all day, so it’s easy to nod along without following. Bring these to your next appointment, and don’t hesitate to ask for plain language.</span></p>
<ul>
<li aria-level="1"><b>Which structure is involved?</b><span> Ask your doctor to name the exact part: a specific valve, an artery, a chamber, or the aorta. “A heart problem” isn’t a complete answer.</span></li>
<li aria-level="1"><b>What exactly is wrong with it?</b><span> Is it narrowed, leaking, enlarged, blocked, or open where it should be closed? The structure tells you where the problem is, and this tells you what kind of problem it is.</span></li>
<li aria-level="1"><b>How severe is it?</b><span> Ask whether it’s mild, moderate, or severe, and what that means for your symptoms. Severity often decides whether you need treatment now or careful monitoring.</span></li>
<li aria-level="1"><b>What does the imaging show?</b><span> Ask to see your echocardiogram, angiogram, or CT scan, and have your doctor point to the problem area. Seeing it on the screen can make everything click.</span></li>
<li aria-level="1"><b>Should it be repaired or replaced?</b><span> Repair means fixing the structure you have, and replacement means swapping it out. The right choice depends on your case, so ask which one fits and why. Ask what each option means for your recovery and how long the result lasts.</span></li>
</ul>
<p><span>Write the answers down, or bring someone along who can. If something still doesn’t make sense, ask again. A good surgeon will explain it as many times as it takes, and a second opinion is a reasonable step if the answers you’re getting don’t leave you confident in the plan.</span></p>
<h2><strong>Quick Answers</strong></h2>
<p><b>What is a heart diagnosis actually telling you?</b><span><br>
</span><span>A diagnosis usually names two things: a part of the heart and what’s wrong with it. Once you can place that part on the map of chambers, valves, wall layers, and vessels, the rest of the explanation gets much easier to follow.</span></p>
<p><b>Which parts of the heart can a diagnosis point to?</b><span><br>
</span><span>The four chambers, the four valves, the three layers of the heart wall, and the vessels that carry blood in and out, including the aorta and the coronary arteries.</span></p>
<p><b>What’s the difference between a narrowed valve and a leaking valve?</b><span><br>
</span><span>A narrowed valve, called stenosis, doesn’t open fully, so the heart works harder to push blood through. A leaking valve, called regurgitation, doesn’t close fully, so some blood flows backward. Some valves have both problems at once.</span></p>
<p><b>What does a blocked coronary artery mean for the heart?</b><span><br>
</span><span>It means part of the heart muscle isn’t getting all the blood it needs. A partial blockage can cause chest pain or shortness of breath, and a complete blockage can cause a heart attack. Treatment depends on how many arteries are affected and where.</span></p>
<p><b>What should I ask my doctor to understand my diagnosis?</b><span><br>
</span><span>Ask which structure is involved, what exactly is wrong with it, how severe it is, what the imaging shows, and whether it should be repaired or replaced. Writing the answers down helps.</span></p>
<h2><span>•••</span></h2>
<p><span>If your diagnosis still feels like a foreign language, you don’t have to work it out alone. You’ve already done the hardest part by learning how the heart is put together. The next step is a conversation, and it can start with a simple question: which part of my heart is involved, and what does that mean for my options?</span></p>
<p><span>Dr. Giovanni Ciuffo is the Director of Cardiac Surgery at University Medical Center of Southern Nevada, and he runs a national referral practice, so patients travel to Las Vegas from across the country for a second opinion or a clearer plan. If you’d like to talk through your own case, you can</span><a href="https://heartsurgeryinfo.com/contact-us/"> <span>request a heart surgery consultation in Las Vegas</span></a><span>. Bring your imaging and your questions, and we’ll start with the map.</span></p>]]> </content:encoded>
</item>

<item>
<title>How to Build a Study Schedule for Step 1 and Step 2 CK at the Same Time</title>
<link>https://edusehat.com/en/how-to-build-a-study-schedule-for-step-1-and-step-2-ck-at-the-same-time</link>
<guid>https://edusehat.com/en/how-to-build-a-study-schedule-for-step-1-and-step-2-ck-at-the-same-time</guid>
<description><![CDATA[ Preparing for USMLE Step 1 and Step 2 CK at the same time can feel like an overwhelming undertaking. For many medical students, studying for both exams simultaneously is not necessarily a choice. Curriculum requirements, shelf exam schedules, dedicated study periods, and graduation timelines may mean that you need to prepare for Step 1 while […]
The post How to Build a Study Schedule for Step 1 and Step 2 CK at the Same Time appeared first on Elite Medical Prep. ]]></description>
<enclosure url="https://elitemedicalprep.com/wp-content/uploads/2026/11/pexels-mart-production-7605201-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 16 Nov 2026 21:20:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>How, Build, Study, Schedule, for, Step, and, Step, the, Same, Time</media:keywords>
<content:encoded><![CDATA[<p><span>Preparing for USMLE Step 1 and Step 2 CK at the same time can feel like an overwhelming undertaking. For many medical students, studying for both exams simultaneously is not necessarily a choice. Curriculum requirements, shelf exam schedules, dedicated study periods, and graduation timelines may mean that you need to prepare for Step 1 while continuing to study for Step 2 CK.</span></p>
<p> </p>
<p><span>The good news is that preparing for both exams does not have to mean doubling your workload or creating two completely separate study schedules. The key is learning how to prioritize your time, recognize where the material overlaps, and dedicate enough focused practice to each exam without spreading yourself too thin.</span></p>
<p> </p>
<p><span>In this post, we will walk through how to build a realistic study schedule for Step 1 and Step 2 CK, including how to determine your priorities, divide your daily study time, incorporate practice questions, and adjust your schedule as you get closer to each exam.</span></p>
<p> </p>
<h2><b>Start by Establishing Your Priorities</b></h2>
<p><span>Before creating <a href="https://elitemedicalprep.com/the-ultimate-10-week-step-1-study-schedule/">a study schedule</a>, you need to understand which exam requires the most attention right now. </span><span>One of the biggest mistakes students make is assuming that Step 1 and Step 2 CK should receive an equal amount of study time simply because they are preparing for both.</span></p>
<p> </p>
<p><span>In reality, your priorities should depend on three major factors: your exam dates, your baseline performance, and your available study time.</span></p>
<p> </p>
<h3><b>1. Consider Your Exam Dates</b></h3>
<p><span>The first thing to establish is how much time you have before each exam.</span></p>
<p> </p>
<p><span>If Step 1 is scheduled in six weeks and Step 2 CK is four months away, Step 1 should naturally receive a larger portion of your study time. You still want to maintain some exposure to Step 2 material, but your immediate priority should be building the foundational knowledge and test-taking skills necessary to pass Step 1.</span></p>
<p> </p>
<p><span>On the other hand, if Step 2 CK is approaching first, you may need to prioritize clinical reasoning, management questions, and shelf-style practice while maintaining your Step 1 knowledge through targeted review.</span></p>
<p> </p>
<p><span>Your study schedule should evolve as your exam dates approach. It should not remain exactly the same for several months if your priorities have changed.</span></p>
<p> </p>
<h3><b>2. Evaluate Your <a href="https://elitemedicalprep.com/best-ways-to-use-nbme-practice-exams-to-prepare-for-the-real-thing/">Baseline Performance</a></b></h3>
<p><span>You also need an honest assessment of where you currently stand with each exam. Consider completing a baseline assessment. This will help you identify which exam requires more attention and where your biggest knowledge gaps are.</span></p>
<p> </p>
<p><span>For example, you may have a relatively strong foundational science background but struggle with clinical management questions. In that case, Step 2 CK may require more dedicated practice, even if it is further away.</span></p>
<p> </p>
<p><span>Alternatively, you may be performing reasonably well on shelf exams but have significant gaps in microbiology, pharmacology, and pathology that need to be addressed before Step 1.</span></p>
<p> </p>
<p><span>Your schedule should reflect your actual needs rather than simply dividing your time equally between the two exams.</span></p>
<p> </p>
<h3><b>3. Be Realistic About Your Daily Availability</b></h3>
<p><span>Another important consideration is how much time you can realistically dedicate to studying each day.</span></p>
<p> </p>
<p><span>Are you currently completing clinical rotations? Are you studying full-time during dedicated? Do you have other academic responsibilities or personal commitments?</span></p>
<p> </p>
<p><span>A student who has eight hours available each day will need a very different schedule from someone who can only study three or four hours after rotations. Do not create a schedule based on the assumption that you will study for 12 hours every day if that is not sustainable for you. A realistic schedule that you consistently follow is much more valuable than an ambitious schedule that falls apart after a few days.</span></p>
<p> </p>
<h2><b>Look for Opportunities to Overlap Your Studying</b></h2>
<p><span>One of the biggest advantages of preparing for Step 1 and Step 2 CK together is that the two exams are not completely separate.</span></p>
<p> </p>
<p><span>Step 1 focuses heavily on foundational medical sciences, including physiology, pathology, pharmacology, and microbiology. Step 2 CK focuses more on clinical diagnosis, patient management, and application of medical knowledge.</span></p>
<p> </p>
<p><span>However, the <a href="https://elitemedicalprep.com/the-biggest-study-mistakes-students-make-when-transitioning-from-usmle-step-1-to-step-2/">underlying concepts frequently overlap</a>.</span></p>
<p> </p>
<p><span>For example, when reviewing cardiovascular disease, you might spend time understanding the pathophysiology of myocardial infarction for Step 1 while also reviewing the clinical presentation, diagnostic workup, and management of acute coronary syndrome for Step 2 CK. Do this for as much material as possible to maximize your studying from each question.</span></p>
<h4><span><br>
<strong>An organ-system-based approach</strong></span></h4>
<p><span>This is where an organ-system-based approach can be particularly helpful.</span></p>
<p> </p>
<p><span>Rather than reviewing completely unrelated topics for each exam every day, consider organizing some of your content review around shared organ systems.</span></p>
<p> </p>
<p><span>For example, during a cardiovascular week, you might review:</span></p>
<ul>
<li aria-level="1"><b>Step 1:</b><span> Cardiac physiology, pathology, pharmacology, and relevant mechanisms.</span></li>
<li aria-level="1"><b>Step 2 CK:</b><span> Cardiovascular presentations, diagnostic evaluation, and management of common conditions.</span></li>
</ul>
<p> </p>
<p><span>Your brain naturally learns well by grouping similar information together, so minimize your workload by tackling both Step 1 and Step 2CK content for a certain topic, if you can. </span></p>
<p> </p>
<h2><b>How to Divide Your Daily Study Time</b></h2>
<p><span>Once you have established your priorities, the next step is deciding how much time to dedicate to each exam. There is no universally correct ratio, but I generally recommend assigning a primary focus to one exam while maintaining consistent practice for the other.</span></p>
<p> </p>
<p><span>For example, if Step 1 is your immediate priority, you might dedicate approximately 65-70% of your study time to Step 1 and the remaining 30-35% to Step 2 CK.</span></p>
<p> </p>
<p><span>If Step 2 CK is approaching first, you could reverse that allocation. </span><span>These percentages are simply starting points. Your actual distribution should depend on your baseline performance, exam timeline, and progress. The important thing is that both exams remain part of your routine without allowing one to completely interfere with preparation for the other. The content for each exam builds off of each other so you hopefully should not feel like you are doing double work. </span></p>
<p> </p>
<h3><b>Separate Your Question Practice</b></h3>
<p><span>One thing I strongly recommend is keeping your Step 1 and Step 2 CK question practice separate. Even when you are reviewing the same organ system, you should be intentional about <a href="https://elitemedicalprep.com/how-to-use-uworld-for-step-2-ck-a-practical-study-strategy/">which question bank you are using</a> and what you are trying to accomplish.</span></p>
<p> </p>
<ul>
<li><span><strong>For Step 1,</strong> focus on understanding mechanisms, recognizing pathology, and connecting foundational concepts to clinical presentations.</span></li>
<li><strong>For Step 2 CK,</strong> prioritize clinical vignettes, diagnostic reasoning, <a href="https://elitemedicalprep.com/free-120-step-2-ck-how-to-use-the-official-sample-test/">next-best-step questions</a>, and management decisions.</li>
</ul>
<p> </p>
<p><span>You can absolutely review overlapping concepts on the same day, but you should still practice the specific question styles associated with each exam.</span></p>
<p> </p>
<p><span>For example, if you are reviewing endocrinology, you might complete a set of Step 1 questions on thyroid hormone physiology and pharmacology, followed by Step 2 CK questions on evaluating and managing thyroid disorders. </span><span>This reinforces the same organ system from both exam perspectives.</span></p>
<p> </p>
<h2><b>Sample Weekly Study Schedule for Step 1 and Step 2 CK</b></h2>
<p><span>Let’s put everything together with a practical example. </span><span>Imagine you have approximately six to eight weeks before Step 1 and three to four months before Step 2 CK. You have around seven to eight hours available for studying each day, six to seven days per week.</span></p>
<p> </p>
<p><span>In this situation, Step 1 would receive the majority of your study time, while Step 2 CK would remain part of your daily routine. </span><span>Here is an example of how you might structure your week.</span></p>
<p> </p>
<h3><b>Sample Weekly Schedule</b></h3>
<table>
<tbody>
<tr>
<td><b>Day</b></td>
<td><b>Step 1 Focus</b></td>
<td><b>Step 2 CK Focus</b></td>
</tr>
<tr>
<td><strong>Monday</strong></td>
<td><span>Cardiovascular content review + 60-80 questions</span></td>
<td><span>15-20 cardiovascular questions + review</span></td>
</tr>
<tr>
<td><strong>Tuesday</strong></td>
<td><span>Cardiovascular pathology/pharmacology + 60–80 questions</span></td>
<td><span>Review Monday’s questions + 20-30 new questions</span></td>
</tr>
<tr>
<td><strong>Wednesday</strong></td>
<td><span>Pulmonary content review + 60-80 questions</span></td>
<td><span>20-30 pulmonary questions</span></td>
</tr>
<tr>
<td><strong>Thursday</strong></td>
<td><span>Pulmonary pathology/physiology + 60-80 questions</span></td>
<td><span>Review Wednesday’s questions + 20-30 new questions</span></td>
</tr>
<tr>
<td><strong>Friday</strong></td>
<td><span>Mixed Step 1 questions + targeted review</span></td>
<td><span>Mixed Step 2 CK questions</span></td>
</tr>
<tr>
<td><strong>Saturday</strong></td>
<td><span>Step 1/Step 2 CK timed assessment (alternate days)  </span></td>
<td><span>Step 1/Step 2 CK timed assessment (alternate days)  </span></td>
</tr>
<tr>
<td><strong>Sunday</strong></td>
<td><b>Finish reviewing assessment + Step 1 mixed questions</b></td>
<td><b>Finish reviewing assessment + Step 2 CK mixed questions</b></td>
</tr>
</tbody>
</table>
<p><span>The exact number of questions will depend on your current level, question bank, and available study time. The important thing is to maintain consistent exposure to both exams.</span></p>
<p> </p>
<p><span>I personally recommend doing practice questions in tutor mode to review as you go and save time, but there is time built into the study schedule above for further question review the following day. </span></p>
<p> </p>
<h2><b>How Much Time Should You Spend Reviewing Questions?</b></h2>
<p><span>One of the most common mistakes students make when preparing for two exams is trying to complete too many questions without spending enough time reviewing them. Remember, completing a question is not the same as learning from it. If you complete 40 questions but barely review the explanations, you may be missing the most valuable part of the exercise.</span></p>
<p> </p>
<p><span>I generally recommend a maximum of 5-7 minutes to review difficult questions. For every question you miss, take time to understand whether the problem was a content gap or a test taking strategy error. This distinction is particularly important when preparing for both exams because the same underlying knowledge gap and strategy errors may affect your performance on different types of questions. I recommend <a href="https://elitemedicalprep.com/free-downloads/">Anki</a> or some type of spaced repetition mechanism to ensure that you learn missed content well enough to never miss it again.</span></p>
<p> </p>
<h2><b>Incorporating Assessments for Both Exams</b></h2>
<p><span>Practice questions are important, but you also need to periodically evaluate your overall progress. </span><span>This is where NBME assessments become particularly valuable.</span></p>
<p> </p>
<p><span>I recommend scheduling assessments for Step 1 and Step 2 CK separately rather than trying to evaluate both exams during the same week every time. You can either alternate weeks or frontload the Step 1 or Step 2 CK practice exams depending on which one approaches sooner for you. </span></p>
<p> </p>
<p><span>For example, if Step 1 is approaching, you may want to complete an NBME assessment every one to two weeks, depending on your preparation timeline. <a href="https://elitemedicalprep.com/best-predictor-of-step-2-ck-scores/">Step 2 CK assessments</a> can be spaced further apart while you are still maintaining that exam. </span><span>As you get closer to either exam, your assessments should become more frequent and increasingly representative of your readiness.</span></p>
<p> </p>
<p><span>If your Step 1 performance is improving consistently but your Step 2 CK performance is declining, that may be a sign that you need to rebalance your study time.</span></p>
<p> </p>
<h2><b>Common Mistakes to Avoid When Studying for Both Exams</b></h2>
<p><span>One common mistake is trying to complete two full study schedules simultaneously. Remember, you do not need to complete every resource, video, and question bank for both exams at the same time. Be selective and prioritize the resources that address your biggest weaknesses.</span></p>
<p> </p>
<p><span>Another mistake is neglecting one exam completely because the other feels more urgent. While it is reasonable to prioritize the exam that comes first, maintaining some consistent exposure to the second exam will make transitioning your focus much easier later.</span></p>
<p> </p>
<p><span>Finally, avoid spending too much time creating the perfect schedule instead of actually following one. Your schedule should be a tool that guides your preparation, not another project that takes hours to maintain. Start with a realistic plan, track your progress, and make adjustments as needed.</span></p>
<p> </p>
<h2><b>Final Encouragement</b></h2>
<p><span>Preparing for Step 1 and Step 2 CK simultaneously is undoubtedly challenging, but it does not have to mean twice the workload or twice the stress. The most effective approach is to prioritize based on your exam dates and baseline performance, take advantage of overlapping organ-system content, and maintain separate question practice for each exam.</span></p>
<p> </p>
<p><span>Remember that your study schedule should evolve as you progress. Some weeks will require more attention to Step 1, while others may require a greater emphasis on Step 2 CK. Do not get discouraged if your schedule needs to change. That is part of the process.</span></p>
<p> </p>
<p><span>Most importantly, focus on learning from your practice questions rather than simply trying to complete as many as possible. Consistent review, targeted content reinforcement, and regular assessments will help you identify weaknesses and make the most of your available study time.</span></p>
<p> </p>
<p><b>You do not need two completely separate study plans. You need one organized, flexible schedule that allows you to prepare strategically for both exams.</b></p>
<p> </p>
<p><span>With the right structure and consistent effort, you can make meaningful progress toward both milestones without sacrificing the quality of your preparation.</span></p>
<p> </p>
<p>If you’d like help deciding how to divide your study time between Step 1 and Step 2 CK, an Elite Medical Prep tutor can help you build a schedule around your exam dates, practice scores, and clinical rotations. <a href="https://elitemedicalprep.com/meet-the-tutors/">Meet our USMLE tutors</a> to find someone who can help you put your plan into practice.</p>
<p> </p>
<p><span>Good luck, and happy studying!</span></p>
<p>The post <a href="https://elitemedicalprep.com/how-to-build-a-study-schedule-for-step-1-and-step-2-ck-at-the-same-time/">How to Build a Study Schedule for Step 1 and Step 2 CK at the Same Time</a> appeared first on <a href="https://elitemedicalprep.com/">Elite Medical Prep</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Single&#45;Cell Method Reveals On&#45; and Off&#45;Target Effects of Cas9 Edits on Gene Expression</title>
<link>https://edusehat.com/en/single-cell-method-reveals-on-and-off-target-effects-of-cas9-edits-on-gene-expression</link>
<guid>https://edusehat.com/en/single-cell-method-reveals-on-and-off-target-effects-of-cas9-edits-on-gene-expression</guid>
<description><![CDATA[ A new method called Superb-seq pairs Cas9 editing with single-cell RNA sequencing to show which edits, including off-target ones, occur in each cell and how they alter gene expression, offering a clearer view of genome editing’s potential consequences.
The post Single-Cell Method Reveals On- and Off-Target Effects of Cas9 Edits on Gene Expression appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/07/CO_MarApr17_Getty_182516812_Henrik5000_BlueCells-1068x801-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 16 Nov 2026 21:00:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Single-Cell, Method, Reveals, On-, and, Off-Target, Effects, Cas9, Edits, Gene, Expression</media:keywords>
<content:encoded><![CDATA[<p><span>Scientists at the Salk Institute and their collaborators have published a paper in </span><i><span>Nature Methods</span></i><span> describing Superb-seq, a method of reading out both on and off target edits made by CRISPR/Cas9 technology. According to the developers, the tool makes it possible to read changes made by CRISPR at single-cell resolution to identify unwanted edits and assess how those edits change gene activity. Their paper is titled “</span><a href="https://www.nature.com/articles/s41592-026-03319-z" target="_blank" rel="noopener"><span>Joint single-cell capture of Cas9 edits and transcriptomes reveals on- and off-target effects on gene expression</span></a><span>.” </span></p>
<p><span>“What really inspired Superb-seq was a frustration with the existing state of affairs,” said Graham McVicker, PhD, senior author of the study and an associate professor at Salk. “We knew there were problems with CRISPR making unwanted edits, but also there was no good way to see what those edits were and how they affected the cell—what we wanted to see was invisible using current technologies.”</span></p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p><span>According to the developers, Superb-seq is able to show where unwanted edits are located as well as how those edits disrupt key genes that protect against unhealthy cellular states. Specifically, Superb-seq integrates Cas9 editing, T7 transcription, and single-cell RNA sequencing to capture single-cell edits and their impact on gene expression. The team has tested it on 34,000 cells from three different cell lines. “There are some people that have worked on this off-target issue before that have an awareness of how bad it is, but for many people that pick up CRISPR to use in the lab, the extent of this problem will really come as a surprise,” McVicker said. “I knew off-targets were an issue, but they were far more frequent than I was expecting.”</span></p>
<p><span>Using seven guide RNAs to target genes in one group of 10,000 human leukemia cells grown in the lab, Superb-seq detected 43 edit sites, including 36 of which were off-target, and 5,761 edited cells. Additionally, Superb-seq detected gene expression changes caused by genome edits that are invisible to existing edit detection methods. It also improved interpretation of the effect of edits compared to Perturb-seq, which reads out gene expression and guide RNAs but not the resulting edits.</span></p>
<p><span>The Salk scientists anticipate that Superb-seq could support applications in basic research, drug development, and personalized medicine. For existing studies that have used CRISPR to study different aspects of biology, “Superb-seq could reveal the extent to which off-target edits color all those findings,” said Michael Lorenzini, PhD, one of the first authors on the paper and a staff scientist in McVicker’s lab. Beyond basic discovery, “our tool could be immensely helpful in establishing the safety of genome therapy candidates early on in development. Superb-seq could be used to profile candidates and learn what their off-target edits are, as well as their effects,” he added. </span></p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p><span>The team also envisions Superb-seq as a valuable tool for generating training data to improve the accuracy of machine learning models of cellular function. McVicker, Lorenzini, and another co-author, Brad Balderson, PhD, have filed a patent for Superb-seq. </span></p>
<p>The post <a href="https://www.genengnews.com/topics/genome-editing/single-cell-method-reveals-on-and-off-target-effects-of-cas9-edits-on-gene-expression/">Single-Cell Method Reveals On- and Off-Target Effects of Cas9 Edits on Gene Expression</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>University Health Network introduces Canada’s first multi&#45;position CT scanner</title>
<link>https://edusehat.com/en/university-health-network-introduces-canadas-first-multi-position-ct-scanner</link>
<guid>https://edusehat.com/en/university-health-network-introduces-canadas-first-multi-position-ct-scanner</guid>
<description><![CDATA[ New imaging technology allows patients to be scanned standing, sitting or lying down, offering potential improvements in diagnostic imaging and patient care. University Health Network (UHN) in Toronto has become the first healthcare organization outside Japan to install an advanced multi-position computed tomography (CT) system, introducing new possibilities for diagnostic imaging and patient assessment. Developed […]
The post University Health Network introduces Canada’s first multi-position CT scanner appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/11/canon-multi-position-ct-system-in-canada-ca.webp" length="49398" type="image/jpeg"/>
<pubDate>Mon, 16 Nov 2026 20:55:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>University, Health, Network, introduces, Canada’s, first, multi-position, scanner</media:keywords>
<content:encoded><![CDATA[<p>New imaging technology allows patients to be scanned standing, sitting or lying down, offering potential improvements in diagnostic imaging and patient care.</p>
<p>University Health Network (UHN) in Toronto has become the first healthcare organization outside Japan to install an advanced multi-position computed tomography (CT) system, introducing new possibilities for diagnostic imaging and patient assessment.</p>
<p>Developed by Canon Medical Systems, the technology enables patients to undergo CT examinations while standing, sitting or lying down, rather than being restricted to the conventional horizontal position.</p>
<p>Installed in June 2026, the system has already been used to evaluate more than 200 patients as part of clinical research at UHN. The technology’s Canadian debut was formally announced on November 12.</p>
<p>A new perspective on diagnostic imaging</p>
<p>Conventional CT scanners generally require patients to lie on a scanning table. While effective for many diagnostic procedures, this position does not always reflect how the body’s structures behave during everyday activities.</p>
<p>Multi-position CT creates opportunities to examine anatomical changes associated with posture and weight-bearing.</p>
<p>These capabilities could be particularly valuable in musculoskeletal imaging, where certain abnormalities may become more apparent when a patient is standing. Researchers are also investigating potential applications in lung and abdominal imaging.</p>
<p>The system can transition between conventional horizontal imaging and upright scanning in just over a minute, allowing clinicians to assess patients in different positions using a single platform.</p>
<p>Early findings suggest improved efficiency</p>
<p>Research at UHN is being led by Dr. Patrik Rogalla, Site Director of Medical Imaging at Toronto General Hospital and Professor of Radiology at the University of Toronto.</p>
<p>In an early clinical report published in the Canadian Association of Radiologists Journal, researchers described encouraging results comparing conventional and upright CT examinations.</p>
<p>The initial findings indicated comparable image quality between scanning positions, alongside improvements in patient positioning and examination-room efficiency.</p>
<p>According to the research team, upright chest CT examinations reduced the time patients spent in the CT room by approximately three minutes per examination, largely because of faster positioning.</p>
<p>These improvements could have implications for hospital imaging departments managing growing demand for diagnostic services.</p>
<p>However, further research will be needed to determine how consistently these early efficiency gains translate into higher patient throughput and improved clinical outcomes.</p>
<p>Potential benefits for patients</p>
<p>The ability to complete an examination without lying flat may also benefit individuals who experience pain, respiratory difficulties or mobility limitations.</p>
<p>For some patients, conventional positioning can be uncomfortable or difficult to tolerate. Providing alternative scanning positions could help make diagnostic imaging more accessible while preserving diagnostic image quality.</p>
<p>The new system also creates opportunities to investigate conditions that may be influenced by gravity, posture or weight-bearing, potentially providing clinicians with additional information that conventional examinations cannot capture.</p>
<p>Supporting the future of medical imaging</p>
<p>The technology builds on several years of international research and development, including collaboration between Canon Medical Systems and Keio University in Japan.</p>
<p>UHN is now leading clinical investigation of the technology outside Japan, with additional research expected to explore applications in thoracic, abdominal and musculoskeletal imaging.</p>
<p>The early findings are promising, but the system’s broader diagnostic value and patient-care benefits will require further clinical evaluation.</p>
<p>The introduction of multi-position CT illustrates how Canadian academic hospitals are helping assess emerging medical technologies that could influence the future of diagnostic imaging.</p>
<p>As healthcare organizations look for ways to improve access, patient experience and operational efficiency, innovations that provide greater clinical flexibility may become increasingly important to the evolution of hospital imaging services.</p>
<p>The post <a href="https://www.hospitalnews.com/university-health-network-introduces-canadas-first-multi-position-ct-scanner/">University Health Network introduces Canada’s first multi-position CT scanner</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>StockWatch: Amid Nvidia Turmoil, What Happens to Its Life Sciences Collaborations?</title>
<link>https://edusehat.com/en/stockwatch-amid-nvidia-turmoil-what-happens-to-its-life-sciences-collaborations</link>
<guid>https://edusehat.com/en/stockwatch-amid-nvidia-turmoil-what-happens-to-its-life-sciences-collaborations</guid>
<description><![CDATA[ While Nvidia doesn’t develop new therapies, instruments, or reagents, its AI technology powers numerous collaborations with biopharma and lab tools giants stretching back at least five years.
The post StockWatch: Amid Nvidia Turmoil, What Happens to Its Life Sciences Collaborations? appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Jensen-Huang-GTC-2024-031924__8fe9c08a-2e0e-4991-b7f5-8c6dbde0ae73.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 16 Nov 2026 06:40:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>StockWatch:, Amid, Nvidia, Turmoil, What, Happens, Its, Life, Sciences, Collaborations</media:keywords>
<content:encoded><![CDATA[<p>Shakespeare and Greek mythology have met their match with the dramatic personal downfall story that culminated in Jensen Huang’s sudden resignation as CEO of <strong>Nvidia (Nasdaq: NVDA)</strong> amid turmoil caused by up to three reported extramarital affairs. While Nvidia doesn’t develop new therapies, instruments, or reagents, its AI technology powers numerous collaborations with biopharma and lab tools giants <a href="https://www.genengnews.com/gen-edge/from-model-to-molecule-nvidia-doubles-down-on-ai-drug-discovery/">stretching back at least five years</a>.</p>
<p>Nvidia’s board named Colette Kress as interim CEO. Kress has served as executive vice president and CFO since joining the company in 2013.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>“The Board has full confidence in Colette and the leadership team, and we expect the company’s operations, customer commitments, and product roadmap to continue without interruption,” Harvey C. Jones, an Nvidia board member since 1993 who was named chair on Thursday, said in a statement. Jones is an entrepreneur, technology executive, and active venture investor who had served as CEO and executive chairman of silicon design provider Synopsys.</p>
<p>The first reported affair raised national security issues after Huang disclosed in a <a href="https://nvidianews.nvidia.com/news/a-message-to-our-company">letter to Nvidia employees made public November 8</a> that he had conducted an extramarital relationship with Alice Huang (no relation), founder of Megaspeed International, an Nvidia customer and Singapore-based provider of cloud computing and AI infrastructure services. The disclosure touched off an investigation by Nvidia’s board into Jensen Huang’s relationship with Alice Huang, who according to U.S. intelligence officials may have passed along sensitive information to China’s Ministry of State Security; Beijing has denied she carried out any intelligence activity for China.</p>
<p>Three days later on Wednesday, <em>The New York Times</em> cited five unnamed sources in reporting that Huang had an extramarital relationship with an Nvidia executive identified by the newspaper as Kimberly Powell, who as vice president of healthcare and life sciences served as Nvidia’s top executive overseeing its hardware and software platforms for accelerated computing, AI, and visualization in applications ranging from drug discovery to medical imaging and healthcare analytics. The following day, Reuters cited two unnamed sources in reporting an affair between Jensen Huang and a second Nvidia employee whom it did not name.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>“OK, this is very, very, very sad, and may and will have dramatic consequences for the entire industry,” Alex Zhavoronkov, PhD, the founder, CEO, and CBO of <strong>Insilico Medicine</strong> <strong>(Hong Kong Exchange: 3696)</strong>,” <a href="https://x.com/biogerontology/status/2120817926005571686">posted Thursday on X</a>. “Now, half of the massively overvalued AI drug discovery startups with no productivity metrics, no drugs, and no long-term moat will not be able to fundraise from Nvidia for a while.”</p>
<h4><strong>Bedroom bubble burst</strong></h4>
<p>“Who knew that the AI bubble would burst in the employee bedroom…,” added Zhavoronkov, who also leads Insilico’s board as chairman and executive director. He added in a <a href="https://x.com/biogerontology/status/2120875228981010472">separate post</a>: “Let’s hope it all settles without too much drama and Jensen keeps working hard (and probably even harder).”</p>
<p>On Friday, Zhavoronkov recalled how during his company’s struggling early years, Jensen Huang <a href="https://x.com/biogerontology/status/2121323131801333922">recorded a video</a> marking the launch of Insilico’s Pharma.AI drug discovery platform: “When Jensen recorded this video in 2022 2 weeks before the launch of consumer ChatGPT, I honestly could not hold my tears. When I watched it today, I could not hold my tears either.”</p>
<p>“Some of my followers on LinkedIn are even celebrating. There is nothing to celebrate. This is a real tragedy and it will have industry-scale consequences. I truly hope that Jensen comes back in some capacity,” Zhavoronkov added. “To all my friends at NVIDIA—please stay strong and let’s work together to solve aging. Support Jensen and his wonderful family. We respect you and love you even though we [are] not a buyer of chips.”</p>
<p>The reported affairs and resignation of Huang sent Nvidia shares sinking this past week. The declines compounded a month-long Nvidia stock slide stemming from investor worries about whether the spending of tech giants on AI infrastructure will result in <span data-subtree="aimfl,mfl">sustainable cash flow, profits, and revenue quickly enough to justify the expense. </span>Those fears have caused Nvidia stock to <span><strong>nosedive</strong><strong> 32% </strong></span>since hitting a record closing price of $239.24 on October 6.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>Nvidia shares began the week <span><strong>slipping 4%</strong></span> on November 9, from $186.64 to $178.67.  Shares <span><strong>slid another 5.5%</strong></span> Tuesday to $168.89, <span><strong>rebounded nearly 3%</strong></span> Wednesday to $173.73, then <span><strong>fell again 4%</strong> </span>Thursday to $166.19 after starting that day <span><strong>tumbling 14%</strong></span> following Huang’s resignation. Shares finished this past week <span><strong>dipping 2% </strong></span>Friday, closing at $162.85—a <strong><span>five-day decline of 12.75%</span></strong><strong><span>.</span></strong></p>
<p>“The stakes behind Huang’s resignation reveal the murky waters that businesses using AI are swimming in,” Asa Hiken, senior analyst with Emarketer, wrote in a commentary posted on the website of the market research and digital intelligence company. “On the surface, AI is a tool for powering productivity, creative production, or novel customer experiences, but in the depths it’s a swelling geopolitical powder keg. Disentangling these two sides of the technology is impossible.”</p>
<p>Stacy Rasgon, managing director and senior analyst, U.S. semiconductors and semiconductor capital equipment at Bernstein Research, cautioned that Nvidia’s challenges have not ended with the resignation of Jensen Huang.</p>
<h4><strong>“Considerable uncertainty”</strong></h4>
<p>“We see considerable uncertainty around further news flow that is probably going to be coming down the pipe, as well as the ability of any new CEO to truly fill Jensen’s shoes given how tightly he managed the direction of the business and its relationships with customers, suppliers, employees, and the broader industry ecosystem,” Rasgon wrote in a research note, as reported by <em>Bloomberg News</em>.</p>
<p><span data-subtree="aimfl,mfl">Nvidia and its venture arm NVentures </span>participated in 122 startup funding deals in 2026 as of Friday, according to Crunchbase, while PitchBook counted 67 such deals in 2025 and 54 in 2024. Given Nvidia’s investment in AI startups, Rasgon wrote: “We wonder what will happen to the company’s myriad of investments in the space, various backstops and residual guarantees.” Rasgon downgraded Bernstein’s rating on Nvidia stock to “Market Perform” and lowered the firm’s price target to $200.</p>
<p>“Our gut tells us that we probably haven’t yet fully probed the depths of what might be found here,” Rasgon commented, adding: “We’ve had enough, and prefer to watch from the sidelines.”</p>
<p>A recent example of Nvidia’s life sciences footprint came earlier this month when <strong>10x Genomics (Nasdaq: TXG),</strong> a developer of scalable single-cell and spatial biology platforms, launched Sentira Single Cell, a cloud-based agentic analysis application for users of the company’s Chromium single-cell platform, powered by the Claude models of <strong>Anthropic (Nasdaq: ANT; IPO pending)</strong>. The launch came weeks after 10x unveiled Sentira Spatial Analysis for users of 10x’s Atera <em class="zhvwWe" data-sfc-cp="" data-sfc-root="c" data-complete="true">in situ</em> spatial biology and transcriptomics platform.</p>
<p>Both applications apply Nvidia’s accelerated computing capabilities with the aim of speeding up widely used biological analysis methods; Sentira Spatial Analysis, for example, can reduce the analysis iteration cycle from hours on CPU alternatives to minutes. Underpinning that speed is rapids-singlecell, an open-source, GPU-accelerated Python library designed for large-scale single-cell omics analysis such as single-cell RNA sequencing. Rapids-singlecell was co-developed by Nvidia with scverse, an open-source, community-governed ecosystem of packages for single-cell and spatial omics.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p><strong>“Incredibly powerful company”</strong></p>
<p>“Nvidia is an incredibly powerful company, and it’s not just one person who made it so,” Serge Saxonov, PhD, 10x’s co-founder and CEO, told <em>GEN</em> when asked whether recent Nvidia news including Huang’s resignation would cause 10x to review the partnership. “We’ve had an incredible relationship with the people over there. They’ve done incredible work in this collaboration.”</p>
<p>Over the past five years, Nvidia has initiated a variety of partnerships with tools developers, drug developers, and others within the life sciences. During the J.P. Morgan Healthcare Conference in January, Nvidia <a href="https://www.genengnews.com/topics/artificial-intelligence/jpm-nvidia-launches-ai-collaborations-with-eli-lilly-thermo-fisher/">launched a pair of collaborations with life-sci giants</a>: The company joined <strong>Eli Lilly (NYSE: LLY)</strong> in committing $1 billion over five years to create a “Co-Innovation AI Lab” designed to address key challenges in AI drug discovery. Nvidia also announced plans to integrate its AI technology into the lab instruments of <strong>Thermo Fisher Scientific (NYSE: TMO)</strong> through a collaboration intended to develop intelligent and increasingly autonomous laboratories.</p>
<p>Through a spokesperson, Thermo Fisher confirmed receipt of <em>GEN’s</em> query but offered no comment.</p>
<p>Also on the tools side, <strong>Danaher (NYSE: DHR)</strong> <a href="https://www.genengnews.com/topics/artificial-intelligence/danaher-nvidia-combine-lab-instrumentation-and-ai-to-advance-autonomous-science/">agreed to partner with Nvidia last month</a>. Danaher agreed to combine its scientific instrumentation, automation technologies, laboratory workflow software, and domain expertise with Nvidia’s accelerated computing and AI technologies.</p>
<p>Nvidia in recent years has also partnered with the Novo Nordisk Foundation, the nonprofit majority owner of Lilly’s arch-rival in obesity and diabetes drug development <strong>Novo Nordisk (Nasdaq Copenhagen: NOVO-B; NYSE: NVO). </strong> The foundation agreed in June 2025 to house an Nvidia supercomputer at the Danish Centre for AI Innovation, which last month announced it had invested in 32 NVIDIA DGX Rubin NVL8 systems, giving Denmark access to the latest generation of AI infrastructure.</p>
<p>Earlier, Nvidia partnered with British-based pharma giants <strong>AstraZeneca (London, Nasdaq Stockholm, and NYSE: AZN)</strong> and <strong>GlaxoSmithKline (London: GSK)</strong> to <a href="https://www.genengnews.com/topics/nvidia-powers-up-in-drug-discovery/" target="_blank" rel="noopener">build the U.K.’s most powerful supercomputer, Cambridge-1</a>, in 2020 through a partnership that also included the kingdom’s National Health Service (NHS).</p>
<p>Spokespeople for Lilly, AstraZeneca, and GSK at deadline had not responded to <em>GEN</em> queries about whether they would review their partnerships with Nvidia. Novo Nordisk referred <em>GEN</em> to the Danish Centre for AI Innovation, which at deadline had not responded either.</p>
<p>“Nvidia’s strength has always come from its people, and together with our leadership team, I am committed to building on the extraordinary foundation Jensen created over the last 33 years,” Kress said in a <a href="https://nvidianews.nvidia.com/news/nvidia-announces-ceo-transition">statement</a>. “We will continue advancing the work that has made Nvidia a leader in accelerated computing and AI, and execute on the opportunities ahead. Our focus remains on serving our customers, partners, developers and shareholders.”</p>
<h2><strong>PepGen nearly doubles on record-setting data</strong></h2>
<p><strong>PepGen (Nasdaq: PEPG)</strong> <span>nearly doubled </span>its stock price this past week after announcing dazzling mid-stage clinical results for its lead pipeline candidate PGN-EDODM1 that included the highest level of splicing correction ever reported in a multiple dose trial in patients with myotonic dystrophy type 1 (DM1).</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="7"></span></aside>
<p>PepGen shares <span><strong>rocketed 82%</strong></span> from $2.39 on Tuesday, when it announced its record-setting data, to $4.36 at Friday’s closing bell. The stock surge began when PGN-EDODM1, an enhanced delivery oligonucleotide (EDO) designed to address the underlying molecular mechanism of DM1, aced the Phase II FREEDOM2-DM1 trial (<a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fcts.businesswire.com%2Fct%2FCT%3Fid%3Dsmartlink%26url%3Dhttps%253A%252F%252Fclinicaltrials.gov%252Fstudy%252FNCT06667453%26esheet%3D54638669%26newsitemid%3D20261110113813%26lan%3Den-US%26anchor%3DNCT06667453%26index%3D2%26md5%3D5a92794d5b85f74e98acc93436221eb2&data=05%7C02%7Calex.philippidis%40sagepub.com%7Ccb531c62777e4cc9439808df4036ce7c%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639300276903378491%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=R4jhElEbO8HDvsmXhtBQ34iSQ8Wb3z%2BqB4o5dxECqvI%3D&reserved=0">NCT06667453</a>). PGN-EDODM1 attained a record-breaking 46.5% mean splicing correction in muscle, with four of six participants showing more than 50% splicing correction and all but one of the six, more than 20% splicing correction as measured by the 22-gene panel at Week 13.</p>
<p>In contrast, a pooled group of four participants receiving placebo (combined from Cohorts 1 and 2) showed a mean splicing correction of just 6.8% was 6.8% at Week 13.</p>
<p>Participants also showed sustained improvements in the video Hand Opening Time (vHOT), hand grip strength, 10-Meter Walk/Run Test (10MWRT), and Timed Up and Go (TUG) functional assessments—data that PepGen said offered compelling evidence of PGN-EDODM1’s potential to address multiple clinical manifestations of DM1 and supporting continued development.</p>
<p>“Our ambition is to fundamentally change how DM1 is treated through greater targeting of the underlying molecular mechanism of the disease,” James McArthur, PhD, PepGen’s president and CEO, said in a statement. “The 10 mg/kg results mark an important milestone in that pursuit, with robust splicing correction accompanied by encouraging improvements across multiple measures of muscle function.”</p>
<p>McArthur said the data strengthened PepGen’s confidence not only in PGN-EDODM1’s potential, but in the company’s broader development strategy.</p>
<p>“With our 12.5 mg/kg cohort fully enrolled and the ongoing FREEDOM-OLE study exceeding 135 doses administered, we believe we are well positioned to continue building the evidence needed to advance toward pivotal studies,” the CEO added.</p>
<p>PepGen quickly sought to cash in on its clinical triumph by launching a $125 million public offering of its common stock—though some investors could instead opt for pre-funded warrants to purchase shares of the stock. Net proceeds from the offering are intended, PepGen said, to fund ongoing clinical development of PGN-EDODM1, as well as provide working capital and address other general corporate purposes.</p>
<p>PepGen also granted the underwriters of its offering a 30-day option to purchase up to an additional $18.75 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. Leerink Partners, Stifel, and Guggenheim Securities acted as joint bookrunning managers for the proposed offering.</p>
<p><strong>“New bar in DM1”</strong></p>
<p>PepGen’s clinical success quickly won over analysts and investors.</p>
<p>“PEPG’s best-in-disease splicing and vHOT with favorable (renal) safety at 10[mg/kg] sets the new bar in DM1,” declared Kostas Biliouris, PhD, a managing director on the biotechnology research team of Oppenheimer.</p>
<p>Similarly, Debjit Chattopadhyay, PhD, a senior managing director and equity research analyst covering the biotechnology sector at Guggenheim Securities—one of the joint bookrunning managers for the $125 million public offering—hailed PepGen’s results as “potentially the new benchmark for splicing,” according to several published reports. Chattopadhyay contrasted PepGen’s 49% mean correction with the <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.dyne-tx.com%2Fwp-content%2Fuploads%2FLilleker_2025_MDA_ACHIEVE_Poster.pdf&data=05%7C02%7Calex.philippidis%40sagepub.com%7Ccb531c62777e4cc9439808df4036ce7c%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639300276903390053%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=NxeNPbdQGBLGYN4KvuC6p1jaL7W7C60BWHbr7UtmPd8%3D&reserved=0">25% mean correction at three months</a> reported last year by Dyne Therapeutics (Nasdaq:DYN) from its Phase I/II ACHIEVE trial (<a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT05481879&data=05%7C02%7Calex.philippidis%40sagepub.com%7Ccb531c62777e4cc9439808df4036ce7c%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639300276903400969%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=FLMs4PEuSozS%2FHMrQAKPpGb27YGnFuwqTWRvDGgkjzM%3D&reserved=0">NCT05481879</a>) evaluating a 6.8 mg/kg every eight weeks dose of DM1 candidate DYNE-101.</p>
<p>Tazeen Ahmad, a senior research analyst covering large-cap and small-cap biotechnology companies with BofA Securities, upgraded PepGen shares from “Underperform” to “Neutral,” and raised her firm’s 12-month price target on the company’s shares 140%, from $2.50 to $6.</p>
<p>Investors responded with a buying surge that sent PepGen stock nearly doubling on November 10, <span><strong>rocketing nearly 93%</strong></span> from $2.39 to $4.61. Shares <span><strong>soared another 14%</strong></span> Wednesday, reaching $5.26 before <span><strong>dropping 4%</strong></span> to $5.04 Thursday and <span><strong>skidding another 13.5%</strong></span> Friday.</p>
<h2>Leaders and laggards</h2>
<ul>
<li><strong>Capricor Therapeutics (Nasdaq: CAPR)</strong> shares <span><strong>jumped 26.5%</strong></span> from $8.87 to $11.22 Wednesday after JonesTrading upgraded its rating of the company’s stock from “Hold” to “Buy” with a $25 price target. JonesTrading cited the upcoming Prescription Drug User Fee Act (PDUFA) target action date of November 22 on the company’s re-submitted Biologics License Application (BLA) for its lead cell therapy candidate deramiocel in Duchenne muscular dystrophy (DMD). In August, Capricor proposed narrowing its indication to treating upper limb impairment in DMD patients >9 years old, the population studied in its HOPE-3 trial (<a href="https://clinicaltrials.gov/study/NCT05126758">NCT05126758</a>) and the focus of its primary endpoint. The company also submitted two-year open-label extension data and additional robustness analyses from HOPE-3, and an integrated summary of efficacy across HOPE-3 and the earlier Phase II HOPE-2 trial (<a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT03406780&data=05%7C02%7Calex.philippidis%40sagepub.com%7C4571c158c0f349617bec08deee5ea16e%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639210287674957401%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=jfCAmFpi0Jb9AWfISbsBGxnx0L0%2F7atGyRuFk8m9bMw%3D&reserved=0">NCT03406780</a>). The FDA classified the August submission as a major amendment, extending the review by three months from the original August 22 date.</li>
<li><strong>Oragenics (NYSE American: OGEN)</strong> shares <span><strong>plummeted nearly 43%</strong></span> from 35 cents to 20 cents Friday, after the developer of intranasal brain-targeted therapeutics announced third quarter results showing a net quarterly loss of $2.603 million, and a nine-month net loss of $7.333 million. The stock plunge occurred despite positive news: The NYSE Regulation rules enforcement arm had accepted its plan to regain compliance with NYSE American listing standards and granted an extension through February 25, 2028 to do so. “We believe this approval allows us to maintain our NYSE American listing while we continue to pursue our strategic priorities, capital raising initiatives, and investment strategies designed to enhance long-term value for our shareholders,” CEO Janet Huffman stated. Oragenics lost compliance due to a low stockholders’ equity of $3.7 million as of June 30, plus losses from continuing operations and/or net losses in its five most recent fiscal years ended December 31, 2025.</li>
</ul>
<p>The post <a href="https://www.genengnews.com/topics/artificial-intelligence/stockwatch-amid-nvidia-turmoil-what-happens-to-its-life-sciences-collaborations/">StockWatch: Amid Nvidia Turmoil, What Happens to Its Life Sciences Collaborations?</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>DCIS Cell Atlas Reveals Clues to Invasive Breast Cancer Progression</title>
<link>https://edusehat.com/en/dcis-cell-atlas-reveals-clues-to-invasive-breast-cancer-progression</link>
<guid>https://edusehat.com/en/dcis-cell-atlas-reveals-clues-to-invasive-breast-cancer-progression</guid>
<description><![CDATA[ Researchers created a detailed map of the tumor microenvironment surrounding estrogen receptor-positive ductal carcinoma in situ, which may help better predict progression to invasive breast cancer and inform on future therapeutic strategies. 
The post DCIS Cell Atlas Reveals Clues to Invasive Breast Cancer Progression appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Low-Res_NavinDCIS.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 14 Nov 2026 07:50:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>DCIS, Cell, Atlas, Reveals, Clues, Invasive, Breast, Cancer, Progression</media:keywords>
<content:encoded><![CDATA[<p>Researchers at The University of Texas MD Anderson Cancer Center have created what they say is one of the most detailed maps to date of the tumor microenvironment (TME) surrounding estrogen receptor-positive (ER+) ductal carcinoma <em>in situ</em> (DCIS), the most common form of preinvasive—stage 0—breast cancer. The atlas was created by analyzing samples from normal breast tissue, DCIS and invasive breast cancers.</p>
<p>The study findings may help to explain why some lesions progress to invasive breast cancer and others do not and inform strategies for improving patient risk prediction and developing better targeted approaches for those at higher risk of invasive disease.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>“DCIS is considered a snapshot before breast cancer becomes invasive, but not all DCIS cases progress to invasive disease, and the biology surrounding these lesions has been challenging to examine,” said research co-lead Nicholas Navin, PhD, chair of Systems Biology. “This atlas reveals the surrounding cells and structures that may help disease become invasive. In the future, these findings may allow clinicians to better identify and treat patients with DCIS who are at higher risk of invasive progression while also avoiding unnecessary treatments for those at low risk.”</p>
<p>Navin, together with research co-lead Savitri Krishnamurthy, MD, professor of Anatomical Pathology, as well as co-first authors Siyuan He, PhD, and Aatish Thennavan, PhD, postdoctoral fellows of Systems Biology, and colleagues, reported on their findings in <em>Science,</em> in a paper titled “<a href="http://dx.doi.org/10.1126/science.aef4622" target="_blank" rel="noopener">A cellular atlas of the preinvasive breast cancer microenvironment</a>.” In their report the team stated that their data “… greatly improve our fundamental understanding of the DCIS microenvironment and the progression of invasive disease.”</p>
<p>DCIS occurs when abnormal cells grow inside the breast milk ducts but have not yet spread into surrounding tissue, and is considered to be a precursor to the most common type of breast cancer. “Ductal carcinoma <em>in situ</em> (DCIS) is precursor of invasive ductal carcinoma (IDC), in which the preinvasive cells are confined within the basement membrane of breast ductal-lobular structures,” the authors wrote.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>Mammograms and other breast examinations have increased the detection of DCIS cases, but many of these lesions never progress to invasive disease, making it challenging to determine which patients actually need more aggressive treatment. “Over the last three decades, routine breast mammography screening has led to overdiagnosis of DCIS that now represents up to 25% of all diagnosed breast cancer cases,” the team continued. “If left untreated, only 10-30% of women with DCIS will progress to invasive disease.”</p>
<p>While genetic changes in DCIS have been well-studied, little is known about its tumor microenvironment—the community of immune cells, blood vessels and tissue cells that surround and interact with the cancer cells. The researchers set out to generate a comprehensive cell atlas for DCIS. Using advanced single-cell and spatial profiling technologies, they mapped more than 850,000 cells from samples of normal breast tissue, DCIS and invasive breast cancer. They identified extensive changes in cancer cells and the surrounding microenvironment as disease progressed. “We analyzed 854,911 cells from 159 patients by single cell RNA sequencing and 39 samples by spatial transcriptomics, which identified nine cell types and 60 cell states,” they reported.</p>
<p>The resulting detailed atlas suggests that important biological features associated with invasive breast cancer begin to emerge earlier than previously known. The study also uncovered previously unknown “cancer stromal loops,” ring-like structures made of supportive tissue and vascular cells that surround DCIS lesions, which create conditions that support tumor growth. “Our data reports on remodeling of specific immune, stromal cell types and myoepithelial cells in the DCIS TME, along with changes in cancer cell metaprograms that form cellular ecosystems and spatial niches to support the growth and progression of DCIS,” they wrote in summary.</p>
<p>Additional research is needed to validate these findings and evaluate their potential use in future diagnostic tools and prevention or treatment strategies. The findings could one day help doctors predict which patients need aggressive treatment and which patients may safely avoid it.  The team said researchers will continue studying the cellular features identified in the atlas to determine whether they can predict which DCIS lesions are most likely to become invasive, to help better determine the best strategies for individual patients.</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/dcis-cell-atlas-reveals-clues-to-invasive-breast-cancer-progression/">DCIS Cell Atlas Reveals Clues to Invasive Breast Cancer Progression</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>How Vancomycin&#45;Resistant Enterococcus Evolved in a Danish Hospital</title>
<link>https://edusehat.com/en/how-vancomycin-resistant-enterococcus-evolved-in-a-danish-hospital</link>
<guid>https://edusehat.com/en/how-vancomycin-resistant-enterococcus-evolved-in-a-danish-hospital</guid>
<description><![CDATA[ A genomic study reveals how genetic mutations, recombination, and resistance-carrying plasmids shaped the evolution, diversification, and decline of vancomycin-resistant Enterococcus faecium in Danish hospitals between 2012 and 2020.
The post How Vancomycin-Resistant Enterococcus Evolved in a Danish Hospital appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Low-Res_vre-labeled.png.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 14 Nov 2026 04:15:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>How, Vancomycin-Resistant, Enterococcus, Evolved, Danish, Hospital</media:keywords>
<content:encoded><![CDATA[<p>Vancomycin-resistant <em>Enterococcus faecium</em> is listed by the World Health Organization—in its 2024 Bacterial Priority Pathogens List—as one of the highest-priority bacteria.</p>
<p>In a new study published in <em>Genome Medicine</em>, researchers from Instituto de Tecnologia Química e Biológica António Xavier from NOVA University of Lisbon (ITQB NOVA), in Portugal, investigated the genetic mechanisms behind the rise and fall of the dominant vancomycin-resistant <em>Enterococcus faecium</em> clone (VREfm ST80) from 2012 to 2020 in Danish hospitals. The team assembled and performed whole-genome sequencing and phylogenomic analysis of 334 ST80 isolates collected from colonization (83%) and infection (17%) cases across nine hospitals in the region between 2012 and 2020.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>The results identified two major clusters (Clusters 1 and 2) and nine sub-clusters (1.A–G and 2.H–I). Sub-cluster-1.A (169/334) was the dominant lineage, accounting for 72% of isolates from 2012–2015. The isolates from 2016–2020 “were distributed across all sub-clusters, indicating increasing diversification over time.”</p>
<p>Genetic variation, the authors write, was “driven by accumulation of mutations, recombination and gain/loss of accessory genes and plasmids.” Eight recombination hotspots were identified in core genes involved in cell wall synthesis, phosphotransferase systems, amino-acid biosynthesis, and several transporters.</p>
<p>This work is published in <em>Genome Medicine</em> in the paper, “<a href="https://link.springer.com/article/10.1186/s13073-026-01747-2" target="_blank" rel="noopener">Recombination and accessory genome turnover shaped the rise and decline of <em>vanA Enterococcus faecium</em> ST80 in Denmark.</a>”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>The team also found that this bacterial clone carried a mosaic phage-like plasmid element that made it resistant to several antibiotics at once. The element harbored the <em>vanA</em> operon with <em>ermB, aadE</em>, and <em>aph(3’)-IIIa</em> suggesting “a unique mechanism for co-mobilization of antimicrobial resistance via transduction or conjugation.”</p>
<p>“Using any one of those antibiotics can select for bacteria carrying the whole package, including vancomycin resistance,” explains Maria Miragaia, PhD, leader of the Bacterial Evolution and Molecular Epidemiology lab at ITQB NOVA. “This means that simply reducing vancomycin use may not be enough to reduce vancomycin-resistant bacteria if other linked antibiotics are still being used,” she adds.</p>
<p>The study suggests that targeting the strategies that helped the clone persist—forming biofilms, altering its outer surface, and using alternative sugars in the gut—could help to clear these resistant bacteria from the gut and reduce their spread in hospitals.</p>
<p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/how-vancomycin-resistant-enterococcus-evolved-in-a-danish-hospital/">How Vancomycin-Resistant <i>Enterococcus</i> Evolved in a Danish Hospital</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Downstream Processing: Purifying Complex Antibody Therapeutics When Target Molecules Misbehave</title>
<link>https://edusehat.com/en/downstream-processing-purifying-complex-antibody-therapeutics-when-target-molecules-misbehave</link>
<guid>https://edusehat.com/en/downstream-processing-purifying-complex-antibody-therapeutics-when-target-molecules-misbehave</guid>
<description><![CDATA[ In this GEN webinar, downstream process development and scale up manufacturing specialists will discuss practical strategies for building robust purification processes when the target molecule misbehaves.
The post Downstream Processing: Purifying Complex Antibody Therapeutics When Target Molecules Misbehave appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Getty_2300126174_MonoclonalAntibody.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 13 Nov 2026 23:25:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Downstream, Processing:, Purifying, Complex, Antibody, Therapeutics, When, Target, Molecules, Misbehave</media:keywords>
<content:encoded><![CDATA[<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"></div>
</div>


<p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Register Now</button></p>

<h3 class="w-full text-left">
    <strong>
         Panelists    </strong>
</h3>
<div class="flex flex-row m-0-auto items-stretch justify-center flex-wrap mb-4">
    
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/11/Scherr-headshot-e1794584066338.png" class="h-full w-full object-cover" alt="Image of David Scherr, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">David Scherr, PhD</h2>
                <h3 class="mt-0 !text-[15px] !leading-[21px]">Sr. Scientist<br>Bioprocess Technologies & Engineering<br>Biopharmaceutical Development<br>AstraZeneca</h3>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/11/Scherr-headshot-e1794584066338.png" alt="Image of David Scherr, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">David Scherr, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>David Scherr, PhD, is a senior scientist at AstraZeneca focusing on downstream process development for the Integrated Dynamic Bioprocessing (IDB) platform. He joined AstraZeneca in 2023 and has been a part of CMC teams for GMP implementation of continuous antibody purification. David has also led efforts to implement high-throughput process development and AI-first ways of working. David earned his BS in biochemistry and chemistry from the University of Miami followed by a PhD in biological systems engineering at Virginia Tech.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog>
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/11/Kante-headshot-e1794584145723.jpg" class="h-full w-full object-cover" alt="Image of Anupama Kante, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Anupama Kante, PhD</h2>
                <h3 class="mt-0 !text-[15px] !leading-[21px]">Scientist<br>Avid Bioservices</h3>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/11/Kante-headshot-e1794584145723.jpg" alt="Image of Anupama Kante, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Anupama Kante, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Anupama Kante, PhD, is a scientist in downstream process development at Avid Bioservices specializing in biologics purification, formulation development, and analytical characterization. She has extensive experience advancing monoclonal antibodies and complex biologics from early development through process optimization. Anupama is passionate about building scientific capabilities, driving innovation, and translating technical insights into practical solutions.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog>
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/11/Ruesing-headshot-e1794584239214.jpg" class="h-full w-full object-cover" alt="Image of Sam Ruesing, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Sam Ruesing, PhD</h2>
                <h3 class="mt-0 !text-[15px] !leading-[21px]">Sr. Staff Scientist<br>Thermo Fisher Scientific</h3>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/11/Ruesing-headshot-e1794584239214.jpg" alt="Image of Sam Ruesing, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Sam Ruesing, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Sam Ruesing, PhD, is a senior staff scientist in downstream process development at Thermo Fisher Scientific. He holds a bachelor’s degree in chemical engineering from the Missouri University of Science and Technology and PhD in biomedical engineering from Saint Louis University. Sam’s experience spans all aspects of downstream development, including early-phase development for first-in-human production, adapting processes to new facilities, and late-phase optimization and characterization in preparation for commercialization.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog></div>



<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-malblocks-webinars-info"></p><div><strong>Broadcast Date:</strong> <time>Tuesday, December 8, 2026</time><br><ul><li><strong>Time:</strong> <time datetime="2026-12-08T16:00:00.000Z">08:00 PST, 11:00 EST, 16:00 GMT</time></li></ul></div>


<div aria-hidden="true" class="wp-block-spacer"></div>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow">
<p class="wp-block-paragraph">As antibody-based therapeutics move beyond IgG monoclonal antibodies, downstream process development teams have to purify molecules that do not always fit established platform assumptions. Bispecifics, multispecifics, antibody fragments, Fc-fusion proteins, ADCs, and other engineered formats can introduce new challenges in assembly, stability, impurity profiles, and scalability. Separation of the target molecule from mispaired chains, homodimers, aggregates, fragments, free light chains, persistent host cell proteins, and format-specific product variants can fall outside the limits of standard Protein A, AEX, and CEX purification workflows. For many PD teams, the platform process remains the proper starting point, but the molecule does not always behave like the platform expects.</p>


<p class="wp-block-paragraph">In this <em>GEN</em> webinar, downstream process development and scale up manufacturing specialists will discuss practical strategies for building robust purification processes when the target molecule misbehaves. The discussion will explore how teams decide whether to stay with a platform, adapt it, or move to a more molecule-specific toolbox, how alternative affinity approaches can help when Protein A lacks selectivity or is not applicable, and how polishing strategies with IEX, HIC, and mixed-mode chromatography can be used to address difficult product- and process-related impurities. The panel will also discuss how to balance speed, yield, purity, cost of goods, analytical burden, scalability, and regulatory expectations from early development through tech transfer and manufacturing of standard mAbs and beyond.</p>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><em>A live Q&A session will follow the presentation offering you a chance to pose questions to our expert panelists.</em></p>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><strong>Produced with support from:</strong></p>


<figure class="wp-block-image alignleft size-medium"><a href="https://www.thermofisher.com/" target="_blank" rel=" noopener"><img decoding="async" width="300" height="138" src="https://www.genengnews.com/wp-content/uploads/2023/03/ThermoFisher_logo-300x138.png" alt="Thermo Fisher logo" class="wp-image-221790" srcset="https://www.genengnews.com/wp-content/uploads/2023/03/ThermoFisher_logo-300x138.png 300w, https://www.genengnews.com/wp-content/uploads/2023/03/ThermoFisher_logo.png 558w" sizes="(max-width: 300px) 100vw, 300px"></a></figure>
</div>
</div>

<p>The post <a href="https://www.genengnews.com/multimedia/webinars/downstream-processing-purifying-complex-antibody-therapeutics-when-target-molecules-misbehave/">Downstream Processing: Purifying Complex Antibody Therapeutics When Target Molecules Misbehave</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The Link Between Mental Health and Exam Performance</title>
<link>https://edusehat.com/en/the-link-between-mental-health-and-exam-performance</link>
<guid>https://edusehat.com/en/the-link-between-mental-health-and-exam-performance</guid>
<description><![CDATA[ When preparing for a major exam like the USMLE, it can be tempting to think that the only thing standing between you and a higher score is more studying, more effort, and, inevitably, more burnout. More questions. More Anki cards. Another video. Another chapter of First Aid.   But there is another piece of the […]
The post The Link Between Mental Health and Exam Performance appeared first on Elite Medical Prep. ]]></description>
<enclosure url="https://elitemedicalprep.com/wp-content/uploads/2026/11/pexels-mart-production-7699511-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 13 Nov 2026 20:10:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, Link, Between, Mental, Health, and, Exam, Performance</media:keywords>
<content:encoded><![CDATA[<p><span>When preparing for a major exam like the USMLE, it can be tempting to think that the only thing standing between you and a higher score is more studying, more effort, and, inevitably, <a href="https://elitemedicalprep.com/medical-students-mental-health-why-burnout-happens-and-how-to-prevent-it/">more burnout</a>. </span><span>More questions. More Anki cards. Another video. Another chapter of First Aid.</span></p>
<p> </p>
<p><span>But there is another piece of the equation that is easy to overlook: </span><b>how you are actually feeling while you study.</b></p>
<p> </p>
<p><span>Your physical and mental wellbeing can have a significant impact on how effectively you learn, how well you retain information, and ultimately how you perform on exam day. Studying harder or longer does not always translate to studying more effectively. </span><span>Taking care of yourself is not a distraction from your preparation. It is part of your preparation, and should be prioritized as such.</span></p>
<p> </p>
<h2><strong>Your Brain Is Part of Your Study Plan</strong></h2>
<p><span>It is easy to think of studying as simply putting information into your brain. But learning is an active process that depends on your ability to focus, process information, form memories, and retrieve what you have learned later. </span><span>When you are exhausted, overwhelmed, anxious, or constantly stressed, those processes become more difficult.</span></p>
<p> </p>
<p><span>You may spend hours studying but realize that you barely remember what you reviewed. You may reread the same page multiple times without absorbing it. You may complete a block of questions but find that your concentration starts falling apart halfway through. </span><span>This can be incredibly frustrating because it may feel like you are not working hard enough.</span></p>
<p> </p>
<p><span>In reality, you may be working </span><i><span>too hard without giving your brain the conditions it needs to learn effectively. </span></i><span>You can’t demand performance from a machine with no fuel! </span></p>
<p> </p>
<h2><strong>Physical Wellbeing and Learning</strong></h2>
<p><span>Your physical health plays a much bigger role in studying than many students realize. </span><span>Sleep, nutrition, movement, and adequate breaks are not just general wellness recommendations. They can directly affect your ability to concentrate and retain information.</span></p>
<p> </p>
<p><span>Sleep is particularly important. When you consistently sacrifice sleep to gain additional study hours, you may technically be spending more time with your material, but that does not necessarily mean you are learning more.</span></p>
<p> </p>
<p><span>The same is true for movement and nutrition. You do not need an elaborate wellness routine while preparing for an exam. Even simple habits, getting outside for a walk, eating regular meals, staying hydrated, and giving yourself time away from your desk, can help you return to your studies with better energy and concentration.</span></p>
<p> </p>
<p><span>When I was in my dedicated study periods for my Step exams, I always made my meal times my break times away from my study material and made sure that I got to the gym for a workout every evening. It kept my physical health strong and this helped me perform better while studying material.  </span><span>Your goal is not to create a perfect lifestyle while studying for the USMLE. Your goal is to create a routine that allows your brain to consistently perform at its best.</span></p>
<p> </p>
<h2><strong>Stress Can Change the Way You Study</strong></h2>
<p><span>Some stress is completely normal during exam preparation. In fact, a certain amount of pressure can motivate you to stay focused and keep moving forward. </span><span>The problem is when stress becomes constant and emotionally exhausting. </span><span>This can create a cycle where anxiety makes it harder to concentrate, poor concentration leads to worse performance, and worse performance creates even more anxiety.</span></p>
<p> </p>
<p><span>Suddenly, the problem is no longer just the material. </span><span>You are also trying to study while managing the emotional weight of constantly feeling like you are not doing enough and not seeing the progress you want. </span><span><a href="https://elitemedicalprep.com/how-to-manage-usmle-step-1-test-anxiety/">Recognizing this cycle</a> is important because it gives you an opportunity to interrupt it.</span></p>
<p> </p>
<h2><strong>The Positive Feedback Loop: Feeling Better Can Help You Perform Better</strong></h2>
<p><span>One of the most powerful things to recognize during exam preparation is that wellbeing and academic performance reinforce each other.</span></p>
<p> </p>
<p><span>When you sleep well, maintain your nutrition, take appropriate breaks, move your body, and give yourself time to recharge, you will find that you can concentrate more effectively. Better concentration can lead to better question performance. Better question performance builds confidence. Increased confidence makes studying feel less overwhelming, which can make it easier to stay consistent.</span></p>
<p> </p>
<p><span>And consistency leads to more learning. </span><span>That creates a positive feedback loop:</span></p>
<p><b>Feel better → study more effectively → perform better → feel more confident → study more effectively.</b></p>
<p> </p>
<p><span>This does not mean that feeling good guarantees a high score. There will still be difficult days, frustrating questions, and practice exams that do not go the way you hoped. </span><span>But your baseline state matters. </span><span>When you feel physically and mentally well, you are giving yourself a better foundation from which to handle and overcome those challenges.</span></p>
<p> </p>
<h2><strong>Why Retention Suffers When You Are Burned Out</strong></h2>
<p><span>You might spend ten hours at your desk and feel accomplished because you were “studying all day.” But if the last three hours were spent staring at questions without really processing them, that time was not effective studying. </span><span>As <a href="https://elitemedicalprep.com/spotting-early-signs-of-burnout-in-medical-students/">fatigue builds</a>, attention decreases. When attention decreases, the quality of learning decreases with it. </span><span>This is why sometimes the most productive thing you can do is stop studying.</span></p>
<p> </p>
<p><span>Taking an hour to exercise, eat dinner with friends, call your family, or simply watch something and relax does not mean you are losing valuable study time. It may actually help you return to your material with enough mental stamina to learn more efficiently. And you should be able to do this regularly without feeling guilty or worrying about lost study time. </span></p>
<p> </p>
<h2><strong>Your Practice Scores Are Data, Not a Judgment</strong></h2>
<p><span>The USMLE preparation process can become emotionally challenging when students begin attaching their self-worth to their practice scores. </span><span>A <a href="https://elitemedicalprep.com/how-to-recover-after-a-low-nbme-practice-score-a-step-by-step-strategy/">low score</a> can feel like a statement about your intelligence or your future. </span><span>It is not.</span></p>
<p> </p>
<p><span>A practice question is information. A practice exam is information. Even a bad study day is information. </span><span>If you miss a question because you did not know the content, that tells you something about your knowledge base. If you miss it because you misread the vignette, that tells you something about your test-taking strategy. If you miss questions because you cannot concentrate after studying for eight hours straight, that tells you something about your<a href="https://elitemedicalprep.com/the-ultimate-10-week-step-1-study-schedule/"> study schedule.</a></span></p>
<p> </p>
<p><span>The goal is not to judge yourself based on the result. The goal is to use the result to make your preparation more effective. </span><span>This mindset can significantly reduce the emotional roller coaster that often comes with exam preparation.</span></p>
<p> </p>
<h2><strong>Building a Sustainable Study Routine</strong></h2>
<p><span>There is no single perfect study schedule for the USMLE. </span><span>Some students can focus for several hours in the morning and need a longer break in the afternoon. Others work better in <a href="https://elitemedicalprep.com/microlearning-for-usmle-step-1-prep/">shorter blocks throughout the day</a>. Some prefer exercising in the morning, while others use exercise as a way to decompress after studying, like I did.</span></p>
<p> </p>
<p><span>The important thing is to build a routine that you can actually sustain. Be disciplined and motivated but maintain some flexibility to adjust as dictated by your progress.  </span><span>Your study plan should include time for questions and content review, but it should also leave room for sleep, meals, movement, social connection, and activities that make you feel like yourself outside of medicine.</span></p>
<ul>
<li><span>You do not need to earn your rest by completing a certain number of questions.</span></li>
<li>You are allowed to be a person while preparing for an exam.</li>
</ul>
<p> </p>
<h2><strong>You Do Not Have to Choose Between Your Wellbeing and Your Score</strong></h2>
<p><span>Perhaps the most important mindset shift is recognizing that taking care of yourself and performing well are not opposing goals. </span><span>They are connected.</span></p>
<p> </p>
<p><span>You are not sacrificing your USMLE preparation when you prioritize sleep. You are not being lazy when you take a break. You are not falling behind because you spend time with people you care about. </span><span>You are investing in the brain that has to learn, retain, and ultimately retrieve all of this information on exam day.</span></p>
<p> </p>
<p><span>The students who perform well are not necessarily the ones who study every waking hour. They are the ones who learn how to make their study time effective and sustainable. They are disciplined but recognize the importance of prioritizing the things that keep them healthy and fill their cup as part of their preparation. </span></p>
<p> </p>
<h2><strong>Final Encouragement</strong></h2>
<p><span>Preparing for the USMLE is a marathon. </span><span>There will be productive days and unproductive days. There will be questions you know immediately and questions that make you wonder whether you have ever studied medicine before. There will be practice scores that make you proud and others that make you want to close your laptop and walk away.</span></p>
<p> </p>
<p data-pm-slice="1 1 []">Try not to let any single day define your preparation. Instead, focus on building a routine that allows you to show up consistently, learn effectively, and take care of yourself along the way. If you’re unsure how to adjust your routine, <a href="https://elitemedicalprep.com/meet-the-tutors/">Elite Medical Prep’s 1:1 USMLE tutors</a> can help you use your practice results to decide what to focus on and build a schedule you can sustain.</p>
<p> </p>
<p><span>The better you feel, the better you are often able to focus. The better you focus, the more effectively you learn. The more effectively you learn, the more confident you become. </span><b>Your wellbeing is not separate from your USMLE preparation. It is part of what allows you to perform at your best.</b></p>
<p>The post <a href="https://elitemedicalprep.com/the-link-between-mental-health-and-exam-performance/">The Link Between Mental Health and Exam Performance</a> appeared first on <a href="https://elitemedicalprep.com/">Elite Medical Prep</a>.</p>]]> </content:encoded>
</item>

<item>
<title>More autonomy, fewer NDAs: Volunteers have new requests for brain implant trials</title>
<link>https://edusehat.com/en/more-autonomy-fewer-ndas-volunteers-have-new-requests-for-brain-implant-trials</link>
<guid>https://edusehat.com/en/more-autonomy-fewer-ndas-volunteers-have-new-requests-for-brain-implant-trials</guid>
<description><![CDATA[ Scientists have been working on ways to decode brain activity for decades. Teams have developed brain implants that can be used to control robotic limbs and computers, and even to “speak.” The people who volunteer for trials of those devices play a vital role in that research, and they ought to be recognized for their… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/11/Ian_0010.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 13 Nov 2026 19:55:02 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>More, autonomy, fewer, NDAs:, Volunteers, have, new, requests, for, brain, implant, trials</media:keywords>
<content:encoded><![CDATA[<div data-chronoton-summary="<ul><br><li><strong>Brain implant volunteers want more respect:</strong> Ian Burkhart, who had a brain implant for seven-and-a-half years, helped develop new guidelines pushing for trial participants to have the option to be recognized as genuine research collaborators and listed as coauthors on scientific papers.</li><br><li><strong>Your brain data should be yours:</strong> The guidelines argue that participants' neural data is personal information, and that NDAs or embargoes should not block someone from sharing their own brain data with their doctor.</li><br><li><strong>Losing an implant can feel like losing a limb:</strong> When funding dried up or companies collapsed, participants like Burkhart lost devices—and abilities—with little warning. The guidelines call for researchers to fund and plan removals carefully, giving participants real time to prepare</li></ul>" data-chronoton-post-id="1148474" data-chronoton-expand-collapse="1" data-chronoton-analytics-enabled="1"></div>


<p class="wp-block-paragraph">Scientists have been working on ways to decode brain activity for decades. Teams have developed brain implants that can be used to control robotic limbs and computers, and even to “speak.”</p>





<p class="wp-block-paragraph">The people who volunteer for trials of those devices play a vital role in that research, and they ought to be recognized for their contributions, says <a href="https://www.technologyreview.com/innovator/ian-burkhart/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=*%7Cdate:m-d-y%7C*">Ian Burkhart</a>, who had one implanted in his own brain back in 2014. He’s been working on a set of guidelines for researchers developing brain-computer interfaces (BCIs).</p>



<p class="wp-block-paragraph">Ethics guidelines for clinical trials already exist. But BCI trials are different, says Jennifer Chandler, a professor of law and neuroethics at the University of Ottawa who also worked on the guidelines. “These are people who have a device embedded in their brain, are in trials sometimes for years and years … [and contribute] a significant investment of time, of the body, and of intellectual effort.”</p>



<p class="wp-block-paragraph">Burkhart was left paralyzed from the chest down following a diving accident in 2010, when he was 19 years old. Around four years later, he volunteered to become the first person to trial a brain implant designed for hand control.</p>



<p class="wp-block-paragraph">He had an array of 96 electrodes inserted into the part of his brain that controls movement. The electrodes were connected to a computer via a cable that essentially plugged into his head. Algorithms on the computer were designed to interpret those signals and deliver them to another sleeve of electrodes worn on Burkhart’s arm, <a href="https://www.nature.com/articles/nature17435">allowing him to control it</a>.</p>



<p class="wp-block-paragraph">The first movements were small, but Burkhart was ultimately able to use the system to pour beads from bottles, move small and delicate objects, and even play Guitar Hero, if only during lab visits. It was <a href="https://www.technologyreview.com/2016/04/13/161014/video-shows-paralyzed-man-move-hand-with-brain-implant/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=*%7Cdate:m-d-y%7C*">a scientific breakthrough</a>.</p>



<p class="wp-block-paragraph">Burkhart took part in two years-long clinical trials over the seven-and-a-half-year period he had the electrode array implanted in his brain. “It was a fantastic experience,” he says. “But there’s certainly some things that, knowing what I know now, I would want to do a little differently.”</p>





<p class="wp-block-paragraph">In 2022, Burkhart cofounded <a href="https://bcipioneers.org/">BCI Pioneers Coalition</a>—an organization through which people who have taken part in BCI trials can share their experiences, both with each other and with researchers. Over the last year, members of the group have been developing a set of guidelines based on those experiences. The idea is to help academics, clinicians, and companies run ethical trials that respect participants’ autonomy.</p>



<p class="wp-block-paragraph">The guidelines, <a href="https://bcipioneers.org/our-bci-recommendations/">published on Tuesday</a>, lay out a list of recommendations that fall within 13 categories. One, for example, focuses on recognizing and compensating trial participants. During the trials that Burkhart participated in, “I was going into the lab two or three days a week, for four hours at a time,” he recalls. “That’s [easily] a part-time job if you just count the hours you’re putting in.”</p>



<p class="wp-block-paragraph">As the trial progressed, Burkhart says, he learned more and was able to give more constructive feedback on what was working and what wasn’t. He says he was a key member of the research team. Others who find themselves in a similar position might appreciate being listed as a coauthor on scientific publications or publicly named as a research collaborator, he says. Burkhart and his colleagues acknowledge that not everyone will want this, however.  </p>



<p class="wp-block-paragraph">The guidelines also address the thorny question of privacy. That’s important: The public will always be interested in cutting-edge biotechnologies like these—and the guidelines say researchers also have a duty to prepare participants for the possibility of media attention. In some cases, it might be difficult to completely conceal the identity of trial participants.</p>



<p class="wp-block-paragraph">Things get even more complicated when it comes to the privacy of participants’ <a href="https://www.technologyreview.com/2024/10/04/1104972/law-california-protects-brain-data-doesnt-go-far-enough/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=*%7Cdate:m-d-y%7C*">brain data</a>. Research teams will need to access, analyze, and—at least temporarily—store this data. Burkhart wasn’t too bothered about that in his case, where scientists were collecting neural activity related to movement. But people who have brain implants designed for turning thoughts into words might feel differently. </p>





<p class="wp-block-paragraph">The guidelines state that brain data “should be understood as the participant’s personal information.” They are pushing for participants to be able to access their own brain data whenever they want—something that has not always been possible—and want to make sure people aren’t prevented from sharing it with their own doctors because of embargoes or nondisclosure agreements (NDAs) designed to keep findings under wraps from competitors.</p>



<p class="wp-block-paragraph">“It’s not super common for there to be firm NDAs within a lot of the trials,” says Burkhart. “But it’s something where we want to make sure that that does not happen.”</p>



<p class="wp-block-paragraph">The guidelines also address what comes <em>after</em> a trial. Around five years after Burkhart had his device implanted, the research team ran into some issues with funding. When <a href="https://www.technologyreview.com/2023/05/26/1073655/how-it-feels-to-have-a-life-changing-brain-implant-removed/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=*%7Cdate:m-d-y%7C*">we last spoke a few years ago</a>, he recalled how he was told he would have to have the implant removed and could have it put back in once the team had secured funding. (And we’re talking about <em>brain surgery</em> here.)</p>



<p class="wp-block-paragraph">Ultimately, he kept the implant until 2021, when it was removed after an infection started to develop at the point where the cable led into his scalp. But losing the device after all those years was difficult; he’d regained the ability to move his arm—and then lost it again.</p>



<p class="wp-block-paragraph">Rita Leggett, an Australian woman who had a device implanted in her brain to treat her epilepsy, has said she felt she “became one” with her implant. When the company that made it went bust two years later, <a href="https://www.technologyreview.com/2023/05/25/1073634/brain-implant-removed-against-her-will/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=*%7Cdate:m-d-y%7C*">the device was removed against her will</a>—an act ethicists have described as a potential breach of human rights.</p>



<p class="wp-block-paragraph">Researchers should instead commit to maintaining brain devices for a “reasonable period” after a trial ends, according to the guidelines. Participants should be given plenty of time to prepare for the surgery to remove it. And researchers should set aside extra funds to support trial participants who have to do that.</p>



<p class="wp-block-paragraph">Some of the guidelines are vague and may overlap with existing ethics standards. They don’t all spell out explicit solutions. They were also developed with feedback from a small group of individuals—the number of people living with BCIs is still <a href="https://www.technologyreview.com/2025/04/01/1114009/brain-computer-interfaces-10-breakthrough-technologies-2025/">very low</a>. The team hopes to grow and expand on the guidelines over time. Burkhart also plans to discuss them with researchers at an <a href="https://www.sfn.org/">upcoming neuroscience conference</a>.</p>



<p class="wp-block-paragraph">“This is a living document, and this is version one,” says Chandler. “It’s just the starting point.”</p>



<p class="wp-block-paragraph"><em>This article first appeared in The Checkup, </em>MIT Technology Review’s<em> weekly biotech newsletter. To receive it in your inbox every Thursday, and read articles like this first, </em><a href="https://forms.technologyreview.com/newsletters/biotech-the-checkup/?_ga=2.241810882.15113993.1664981064-43237434.1647441349"><em>sign up here</em></a>.</p>]]> </content:encoded>
</item>

<item>
<title>Sault Area Hospital advances diagnostic care with new SPECT/CT technology</title>
<link>https://edusehat.com/en/sault-area-hospital-advances-diagnostic-care-with-new-spectct-technology</link>
<guid>https://edusehat.com/en/sault-area-hospital-advances-diagnostic-care-with-new-spectct-technology</guid>
<description><![CDATA[ Patients in Northern Ontario are benefiting from faster diagnostic imaging and reduced radiation exposure following the installation of an advanced SPECT/CT system at Sault Area Hospital (SAH). The hospital celebrated the new technology on November 11, recognizing a combined $1.35-million contribution from Alamos Gold and Franco-Nevada toward the equipment purchase through the Sault Area Hospital […]
The post Sault Area Hospital advances diagnostic care with new SPECT/CT technology appeared first on Hospital News. ]]></description>
<enclosure url="" length="49398" type="image/jpeg"/>
<pubDate>Fri, 13 Nov 2026 19:45:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Sault, Area, Hospital, advances, diagnostic, care, with, new, SPECTCT, technology</media:keywords>
<content:encoded><![CDATA[<p>Patients in Northern Ontario are benefiting from faster diagnostic imaging and reduced radiation exposure following the installation of an advanced SPECT/CT system at Sault Area Hospital (SAH).</p>
<p>The hospital celebrated the new technology on November 11, recognizing a combined $1.35-million contribution from Alamos Gold and Franco-Nevada toward the equipment purchase through the Sault Area Hospital Foundation.</p>
<p>The scanner, which began operating during the summer of 2026, replaces equipment that had served the hospital since it opened its current facility in 2011. The upgrade represents an important investment in the hospital’s nuclear medicine program and its ability to provide advanced diagnostic services closer to home.</p>
<p><strong>Improving the patient experience</strong></p>
<p>SPECT/CT combines single-photon emission computed tomography with computed tomography, bringing together functional and anatomical imaging in a single examination. The technology enables clinicians to assess how organs and tissues are functioning while identifying the precise anatomical location of abnormalities.</p>
<p>At Sault Area Hospital, the system supports a range of clinical applications, including cardiac assessments, bone imaging and breast cancer care.</p>
<p>The new equipment can produce higher-quality images in approximately half the time required by the previous scanner, while also reducing radiation exposure.</p>
<p>Shorter examinations can help improve the patient experience, particularly for individuals who experience discomfort or difficulty remaining still during imaging procedures. Faster imaging may also support more efficient use of hospital resources as demand for diagnostic services continues to grow.</p>
<p><strong>Strengthening regional access to advanced imaging</strong></p>
<p>For patients living in Northern Ontario, access to specialized diagnostic services within their own community can make a meaningful difference. Long travel distances can create additional challenges for patients and families already navigating complex health conditions.</p>
<p>By modernizing its nuclear medicine equipment, Sault Area Hospital is strengthening its capacity to provide diagnostic services locally and supporting healthcare professionals with improved imaging capabilities.</p>
<p>The hospital’s medical imaging department is the largest in the Algoma District, performing more than 100,000 imaging examinations annually.</p>
<p><strong>Investing in the future of hospital technology</strong></p>
<p>The installation also highlights a broader challenge facing Canadian hospitals: replacing aging medical equipment while maintaining essential patient services.</p>
<p>Many of the technologies installed when Sault Area Hospital opened its current facility 15 years ago are approaching the end of their operational lives. The hospital has identified surgical and operating room equipment among its future investment priorities.</p>
<p>The SPECT/CT upgrade demonstrates how collaboration between healthcare organizations, hospital foundations and community partners can help sustain access to modern medical technology.</p>
<p>As diagnostic imaging continues to evolve, investments in advanced equipment will remain essential to supporting timely diagnoses, informed treatment decisions and high-quality patient care across Canada’s healthcare system.</p>
<p><strong>Sources:</strong> Sault Area Hospital Foundation</p>
<p>The post <a href="https://www.hospitalnews.com/sault-area-hospital-advances-diagnostic-care-with-new-spect-ct-technology/">Sault Area Hospital advances diagnostic care with new SPECT/CT technology</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Reference Genomes of Malaria&#45;Causing Plasmodium Parasites Completed</title>
<link>https://edusehat.com/en/reference-genomes-of-malaria-causing-plasmodium-parasites-completed</link>
<guid>https://edusehat.com/en/reference-genomes-of-malaria-causing-plasmodium-parasites-completed</guid>
<description><![CDATA[ Using DNA sequenced from patient blood samples, researchers assembled complete reference genomes of neglected malaria parasites, uncovering genetic regions potentially involved in immune evasion and providing new tools for disease surveillance.
The post Reference Genomes of Malaria-Causing Plasmodium Parasites Completed appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/08/Getty_476872691_PlasmodiumCausingMalaria.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 13 Nov 2026 09:05:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Reference, Genomes, Malaria-Causing, Plasmodium, Parasites, Completed</media:keywords>
<content:encoded><![CDATA[<p>Researchers have generated the most complete chromosome-level reference genomes to date for two understudied malaria parasites, uncovering previously inaccessible genetic regions that could help explain how the pathogens evade immune defenses and persist in human hosts.</p>
<p>The study, titled “<a href="https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1014754" target="_blank" rel="noopener">High quality chromosomal genome assemblies of three human <em>Plasmodium </em>species directly from natural infection</a>,” and published in <em>PLOS Pathogens, </em>describes a method for assembling chromosome-level genomes directly from patient blood samples without laboratory culturing. The findings could improve parasite identification, genomic surveillance, and efforts to monitor emerging drug resistance.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>Although <em>Plasmodium falciparum </em>is responsible for most malaria-related deaths, other species, including <em>P. ovale </em>and <em>P. malariae</em>, also contribute to the global disease burden. These parasites can cause chronic infections but remain comparatively poorly understood, partly because researchers lack reliable methods for growing them continuously in laboratory cultures.</p>
<p>To address these limitations, scientists at the Wellcome Sanger Institute and the Parasites and Microbes Research and Training Center in Mali collected blood samples from patients with naturally acquired malaria infections in Faladie, Mali.</p>
<p>The team enriched parasite DNA by removing human white blood cells and uninfected red blood cells before applying PacBio Ultra-Low-Input HiFi long-read sequencing. They combined this approach with Hi-C, a technique that captures interactions between DNA regions to reconstruct chromosome organization.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>The researchers ultimately assembled parasite genomes from eight participants, producing high-quality references for <em>P. ovale wallikeri, P. malariae, </em>and <em>P. falciparum.</em></p>
<p>Unlike earlier fragmented references, the new assemblies resolved previously inaccessible regions near chromosome ends, known as subtelomeric regions. These areas contain repetitive DNA and expanded gene families associated with interactions between parasites and their human hosts, enhancing “understanding of parasite persistence, transmission, immune evasion, and comparative evolutionary studies.”</p>
<p>Notably, the researchers identified more than 2,000 genes belonging to the <em>PIR </em>gene family in <em>P. ovale wallkeri, </em>accounting for approximately one-quarter of its genome.</p>
<p>Comparisons among parasites collected from the same geographic region also revealed extensive genetic rearrangements near chromosome ends, highlighting mechanisms that may contribute to antigenic variation and immune invasion.</p>
<p>“Uncovering these full genomes revealed the extent of expansions of gene families sitting at the ends of chromosomes, which regularly shuffle genetic material to adapt and evade the human immune system,” said first author Sunil Dogga, PhD, formerly of the Wellcome Sanger Institute and now at the Swiss Tropical and Public Health Institute.</p>
<p>The findings are particularly relevant as malaria elimination efforts increasingly confront infections caused by non-<em>falciparum </em>species, which can be difficult to diagnose and may persist even where <em>P. falciparum </em>transmission declines.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>Beyond improving understanding of parasite biology, the genomic resources could support development of more accurate molecular diagnostics, identification of potential therapeutic targets, and studies investigating how parasite populations respond to treatment and control measures.</p>
<p>“Establishing gold-standard reference genomes for these neglected parasites fills a critical knowledge gap in global malaria research,” said senior author Mara Lawniczak, PhD, group leader at the Wellcome Sanger Institute.</p>
<p>The researchers emphasized that incorporating these overlooked species into genomic surveillance will be important for developing more comprehensive malaria elimination strategies. The authors wrote, “This work provides a critical foundation for including these neglected species in global malaria elimination efforts.”</p>
<p> </p>
<p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/reference-genomes-of-malaria-causing-plasmodium-parasites-completed/">Reference Genomes of Malaria-Causing <i>Plasmodium</i> Parasites Completed</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Neuroprotective Protein Atlas Positions the Blood&#45;Brain Barrier as a Selective Checkpoint</title>
<link>https://edusehat.com/en/neuroprotective-protein-atlas-positions-the-blood-brain-barrier-as-a-selective-checkpoint</link>
<guid>https://edusehat.com/en/neuroprotective-protein-atlas-positions-the-blood-brain-barrier-as-a-selective-checkpoint</guid>
<description><![CDATA[ The blood-brain barrier keeps most proteins in the bloodstream out of the brain, but not all. The pathways that import them are damaged early in Alzheimer’s disease models, hinting at new ways to treat the disease.
The post Neuroprotective Protein Atlas Positions the Blood-Brain Barrier as a Selective Checkpoint appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/GettyImages-2203499176.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 13 Nov 2026 05:30:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Neuroprotective, Protein, Atlas, Positions, the, Blood-Brain, Barrier, Selective, Checkpoint</media:keywords>
<content:encoded><![CDATA[<p><span>Working in mice, scientists from the Gladstone Institutes, University of California, and elsewhere have created what they claim is the first atlas of neuroprotective proteins that are transported across the blood-brain barrier and into the brain. According to the scientists, the atlas contains 92 proteins so far and their analysis points to potential strategies for treating neurodegenerative conditions. Details are provided in a new </span><i><span>Cell </span></i><span>paper titled “</span><a href="https://www.cell.com/cell/fulltext/S0092-8674(26)01326-7" target="_blank" rel="noopener"><span>The blood-brain barrier imports diverse neuroprotective proteins through pathways impaired early in Alzheimer’s disease models</span></a><span>.”</span></p>
<p><span>The study suggests that the blood-brain barrier is much more than a physical boundary intended solely to protect the brain from toxins. As Andrew Yang, PhD, a Gladstone investigator and one of the authors on the study put it, “we’re finding that it’s an intelligent interface that plucks the right proteins in the blood, often from distant parts of the body and delivers them to the right cell types in the brain.” Importantly, as the paper’s title suggests, the proteins included in the atlas make their way into the brain through pathways that are impaired early on in the development of diseases like Alzheimer’s.</span></p>
<p><span>To generate the atlas, Yang and his colleagues developed a method of tracking the specific blood plasma proteins that crossed into the brains of mice. They used protein-labeling chemistry to track proteins from multiple organs such as the liver and kidney without disrupting their biology. Specifically, they developed “a bioorthogonal proteomics strategy, an <em>in vivo</em> click-enrichment screen of labeled plasma proteins entering the brain” and used it to systematically map the blood-brain barrier “transportome,” according to the paper. The approach was benchmarked against a commonly used biotin labeling approach and was shown to consistently produce “stronger signals in plasma and brain vessels” as well as to enable “robust detection of plasma proteins in neurons, astrocytes, and microglia.” </span></p>
<p><span>The scientists used the method to tag various mouse blood proteins before injecting them back into the bloodstream. They examined brain tissue to see which labeled proteins successfully crossed the barrier. Of the 861 proteins that the scientists tracked in this way, they found that 92 crossed into the brain. Most were proteins produced primarily in the liver but also in adipose tissue and the intestine. Once there, the proteins were directed to specific types of brain cells to perform specialized functions. </span></p>
<p><span>An example is the liver protein apolipoprotein AI or (APOA1) that once in the brain activates a pathway needed to maintain healthy astrocyte connections. Studies link its absence to a greater risk of developing Alzheimer’s disease. “We think of blood proteins as messengers carrying signals from distant body parts, and the cells of the blood-brain barrier import only the ones the brain really needs,” said Haoyue Zhou, PhD, a postdoctoral scholar in Yang’s lab and first author of the paper.</span></p>
<p><span>A key part of the study was exploring what happens to protein delivery in Alzheimer’s. As the disease progresses, the blood-brain barrier breaks down allowing harmful proteins to leak into the brain. Using their protein-labeling method, Yang’s team discovered another problem. They found that even before the barrier breaks down, it stops importing protective proteins like APOA1 into the brain. Loss of the protein erodes neuronal connections, which contributes to behavioral changes and other early signs of the disease. </span></p>
<p><span>Conceivably, increasing the supply of APOA1 to the brain could help counter the emergence of Alzheimer’s symptoms. To discover whether this might be possible, the scientists tracked proteins in mouse models engineered to produce extra APOA1 in the liver. And indeed they found that as more APOA1 entered the brain, the mice showed fewer signs of the disease. These findings suggest that “Alzheimer’s disease may not start entirely inside the brain” but “when the brain’s supply line from the body is severed,” Yang noted. “If that’s right, we may be able to fight this disease from outside the brain, by restoring what the brain has lost.”</span></p>
<p><span>Boosting production of beneficial proteins like APOA1 to ensure the brain has a sufficient supply is one possible treatment strategy. Another option is harnessing the brain’s natural “ZIP code” system to deliver therapies directly to specific types of brain cells. A third option that Yang and his colleagues are currently exploring is harnessing the blood-brain barrier’s transport machinery to help drugs reach the brain more efficiently. </span></p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/neuroprotective-protein-atlas-positions-the-blood-brain-barrier-as-a-selective-checkpoint/">Neuroprotective Protein Atlas Positions the Blood-Brain Barrier as a Selective Checkpoint</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>High Frequency of Drug&#45;Impacting Gene Variants Found in All of Us Cohort</title>
<link>https://edusehat.com/en/high-frequency-of-drug-impacting-gene-variants-found-in-all-of-us-cohort</link>
<guid>https://edusehat.com/en/high-frequency-of-drug-impacting-gene-variants-found-in-all-of-us-cohort</guid>
<description><![CDATA[ A study finds that everyone in a diverse, nearly 100,000-person sample carried at least one genetic variant that affects how their body processes medications, and a quarter of those people had been prescribed a medication that is known to be impacted by the variant they carried.
The post High Frequency of Drug-Impacting Gene Variants Found in All of Us Cohort appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2177211585.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 13 Nov 2026 05:30:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>High, Frequency, Drug-Impacting, Gene, Variants, Found, All, Cohort</media:keywords>
<content:encoded><![CDATA[<p>A study headed by researchers at the University of Pittsburgh has found that everyone in a diverse, nearly 100,000-person sample from the National Institutes of Health’s <em>All of Us</em> Research Program (All of Us) carried at least one genetic variant that affects how their body processes medications. The results also showed that a quarter of those people had been prescribed a drug that is known to be impacted by the variant they carried.</p>
<p>The researchers say the discovery highlights the value of genetic testing for some medications and that electronic health record alerts could be helpful when a clinician prescribes one of these drugs. Such an alert would allow the clinician to consider prescribing an alternate medication or adjusting the dosage, if appropriate.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>“Many people have experience with taking a medication that is not working well for them or that has a side effect,” said Philip E. Empey, PharmD, PhD, associate professor in Pitt’s School of Pharmacy and associate director for pharmacogenomics at the Institute for Precision Medicine at Pitt and UPMC. “While many things impact how a patient responds to medication, our research tells us that genetics could be [a] factor for a large proportion of patients and it points to the value of precision medicine in prescribing.”</p>
<p>Empey is senior author of the researchers’ published paper in <em>Science Translational Medicine</em>, titled “<a href="http://dx.doi.org/10.1126/scitranslmed.adt8040" target="_blank" rel="noopener">Frequency of pharmacogenomic variation and medication exposures among <em>All of Us</em> Participants</a>.”</p>
<p>Pharmacogenomics (PGx) promises improved outcomes through individualized prescribing, the authors wrote in their paper. “PGx can impact drug effectiveness and toxicity. Many commonly prescribed medications have genotype-guided dosing or drug selection recommendations in their Food and Drug Administration (FDA) approved labeling or in guidelines developed by the Clinical Pharmacogenetics Implementation Consortium (CPIC).”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>More than 300 medications have information on their labels about genetic variant interactions, where genetic testing may be of value to guide prescribing, Empey said. One example is a chemotherapy drug used for colon cancer that could have serious toxicity in up to 8% of patients who carry these genetic variants, so those patients are proactively tested before treatment. However, the authors noted, “Despite the strong evidence supporting the use of PGx data in clinical practice, broader implementation is limited in part by the relative paucity of data on the frequency of variants, alleles, and predicted phenotypes across diverse biogeographical groups.”</p>
<p>For their reported study the research team used data from the National Institutes of Health (NIH) <a href="https://www.nih.gov/allofus" target="_blank" rel="noopener"><em>All of Us</em> Research Program</a>, an initiative that aims to gather data from one million people across the U.S. to help better understand how lifestyle, environment, and genes influence health and disease. Pitt is a key partner in the program, launching All of Us Pennsylvania in 2018. “This study represents one of the largest and the most diverse PGx datasets with linked medication exposures events to date,” the team noted. “<em>All of Us</em> has particular value in identifying and understanding the frequency of both previously unknown and rare variants because of the size of the cohort, comprehensiveness in genotyping approach, and the genetic diversity.”</p>
<p>The team evaluated the frequency of 16 genetic variants known to impact the effectiveness or toxicity of various medications among nearly 100,000 <em>All of Us</em> participants. The results showed that everyone in the study was found to carry at least one such variant with a median of nine variants. “We found 100% of participants carried at least one known PGx variant and nearly all (99.49%) had a predicted phenotype for a gene which has a CPIC or FDA recommendation for a change in prescribing,” they stated. “Among nearly 100k participants in <em>All of Us</em> Research Program, pharmacogenomic variants and actionable results are common and the diversity of the cohort provided for identification of novel variants and population frequencies.”</p>
<p>By then matching the genetic data to the participants’ medical records, the research team also found that more than 24% of participants had been prescribed at least one medication known to interact with a variant they carried. “Clinical impact was high with 24.38% of participants having both an actionable phenotype for these pharmacogenes and a prior exposure to an impacted medication with pharmacogenomic prescribing guidance,” they wrote. The most common medications identified in the review were ondansetron (anti-nausea), ibuprofen (anti-inflammatory), omeprazole and pantoprazole (both treat acid reflux and heartburn), and atorvastatin (lowers cholesterol).</p>
<p>The team also identified over 17,000 novel variants and reported the frequency of known medication-linked genetic variants across multiple ancestry groups, including in populations where these frequencies were not previously estimated. “Importantly, we report thousands of novel variants as well as hundreds of alleles and predicted phenotypes that deviate from known frequencies and/or were previously unreported, especially within Americas and African ancestry groups.” they wrote in summary.</p>
<p>“The limited diversity of racial and ethnic groups in early studies is a challenge in genetic research and skews risk estimates,” Empey said. “That’s part of the beauty of the <em>All of Us</em> Research Program—it was intentionally designed to help close these gaps by including people from a wide range of age groups, backgrounds, and life experiences. It also underscores the value of having a large precision medicine dataset where whole genome testing data can be studied along with clinical data.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>Empey said it will be up to policy makers and health insurers to weigh the benefits of widespread genetic screening for variants that interact with medications against the cost, and that this is a very active area of research. He said it makes sense to screen patients with a panel test that can look for common variants that are known to affect many medications and have these results in their medical record, much like a test for kidney function. This approach is also being applied in situations where patients are on many medications at the same time or in patients starting certain medications known to be impacted by genetics, such as clopidogrel, a medication used after cardiac stenting.</p>
<p>People who have already undergone pharmacogenomic testing should be sure to share their results with their pharmacists and prescribers so that it is integrated with their electronic health record, said Empey, who is leading efforts at UPMC to make it easy for clinicians to see if a patient carries variants that may affect a medication that they’re prescribing and recommend changes when needed.</p>
<p>“Just like with any new technology, it comes down to responsible implementation,” Empey said. “Costs are coming down and the data is increasing, so it is important for patients and clinicians to be aware that the use of precision medicine in prescribing is becoming commonplace.”</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/high-frequency-of-drug-impacting-gene-variants-found-in-all-of-us-cohort/">High Frequency of Drug-Impacting Gene Variants Found in <i>All of Us</i> Cohort</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The Physicians Foundation Announces Two Grant Opportunities to Advance Physician Wellbeing and Strengthen the Healthcare Workforce</title>
<link>https://edusehat.com/en/the-physicians-foundation-announces-two-grant-opportunities-to-advance-physician-wellbeing-and-strengthen-the-healthcare-workforce</link>
<guid>https://edusehat.com/en/the-physicians-foundation-announces-two-grant-opportunities-to-advance-physician-wellbeing-and-strengthen-the-healthcare-workforce</guid>
<description><![CDATA[ New requests for proposals seek innovative solutions to create safer care environments and support physicians transitioning to late-career practice and retirement BOSTON, November 12, 2026 — The Physicians Foundation has announced two Requests for Proposals (RFPs) aimed at addressing critical challenges affecting physician wellbeing, professional fulfillment, and healthcare workforce sustainability. The funding opportunities will support […]
The post The Physicians Foundation Announces Two Grant Opportunities to Advance Physician Wellbeing and Strengthen the Healthcare Workforce appeared first on The Physicians Foundation. ]]></description>
<enclosure url="https://physiciansfoundation.org/wp-content/themes/physicians-foundation/assets/build/images/admin/defaults/default-image.webp" length="49398" type="image/jpeg"/>
<pubDate>Fri, 13 Nov 2026 01:30:02 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, Physicians, Foundation, Announces, Two, Grant, Opportunities, Advance, Physician, Wellbeing, and, Strengthen, the, Healthcare, Workforce</media:keywords>
<content:encoded><![CDATA[<p class="wp-block-paragraph"><em><em><em><em><em>New requests for proposals seek innovative solutions to create safer care environments and support physicians transitioning to late-career practice and retirement</em></em></em></em></em></p>



<p class="wp-block-paragraph"><strong>BOSTON, November 12, 2026</strong> — The Physicians Foundation has announced <a href="https://physiciansfoundation.org/grants/">two Requests for Proposals (RFPs)</a> aimed at addressing critical challenges affecting physician wellbeing, professional fulfillment, and healthcare workforce sustainability. The funding opportunities will support innovative research and scalable interventions focused on fostering safe and respectful care environments for physicians and helping physicians navigate the transition to late-career practice and retirement.</p>



<p class="wp-block-paragraph">The new RFPs come as findings from The Physicians Foundation’s <a href="https://physiciansfoundation.org/research/how-practice-conditions-shape-physician-wellbeing/">2026 Wellbeing Survey of America’s Physicians</a> underscore the growing impact of workplace conditions on physician wellbeing and workforce retention. According to the survey, 42% of physicians have considered retiring earlier than planned and/or leaving clinical practice due to concerns about their wellbeing.</p>



<p class="wp-block-paragraph">These findings highlight the need for tailored solutions that support physicians throughout their careers while addressing systemic challenges that can affect their ability to deliver high-quality patient care.</p>



<p class="wp-block-paragraph">“Physician wellbeing is not just an individual concern. It is essential to the strength and sustainability of our healthcare system,” said <a href="https://physiciansfoundation.org/leadership/">Dr. Gary Price</a>, president of The Physicians Foundation. “We are seeking bold, evidence-based approaches that go beyond identifying problems to create meaningful, lasting change. By supporting research and scalable interventions, we aim to improve physician wellbeing, strengthen the healthcare workforce, and ensure physicians can thrive at every stage of their careers.”</p>



<p class="wp-block-paragraph">The Physicians Foundation is seeking proposals in two priority areas: (1) fostering safe and respectful care environments and (2) supporting physicians transitioning into late career status.</p>



<p class="wp-block-paragraph"><strong>Fostering Safe and Respectful Care Environments for Physicians</strong></p>



<p class="wp-block-paragraph">Physicians increasingly face workplace hostility, harassment, discrimination and other forms of mistreatment that threaten their wellbeing, professional fulfillment and ability to provide high-quality patient care. This RFP seeks innovative, system-level solutions to better understand, prevent and address these challenges.</p>



<p class="wp-block-paragraph">Priority will be given to scalable interventions that move beyond traditional compliance-based approaches to address the structural and cultural drivers of workplace mistreatment. Projects may explore new prevention strategies, peer-support resources and organizational practices that foster safer, more respectful care environments.</p>



<p class="wp-block-paragraph"><strong>Supporting Physicians Transitioning to Late Career Status and Retirement</strong></p>



<p class="wp-block-paragraph">As physicians advance in their careers, they face unique challenges related to professional identity, evolving workplace expectations and retirement planning. The Foundation’s 2026 survey found that 29% of older physicians considered reducing or had reduced their clinical hours due to wellbeing concerns, compared with 22% of younger physicians, highlighting the need for tailored support throughout physicians’ careers.</p>



<p class="wp-block-paragraph">This RFP seeks practical, sustainable approaches that help physicians navigate late-career transitions while maintaining professional fulfillment and a sense of purpose. Projects may explore flexible practice models, mentorship opportunities, peer engagement and retirement planning resources that support physician wellbeing and strengthen workforce continuity.</p>



<p class="wp-block-paragraph"><strong>Funding and Application Details</strong></p>



<p class="wp-block-paragraph">For each RFP, The Physicians Foundation anticipates awarding a limited number of grants of up to <strong>$100,000 per project</strong>, supporting initiatives lasting up to two years. Proposals will be evaluated based on their alignment with the Foundation’s priorities, potential impact, feasibility, and ability to produce measurable, sustainable, and replicable solutions.</p>



<p class="wp-block-paragraph"><strong>Applications for both RFPs are due February 11, 2027, at 5 p.m. ET.</strong> Funding decisions are anticipated by the end of April 2027, with projects expected to begin June 1, 2027. Those interested in applying are encouraged to learn more, <a href="https://physiciansfoundation.org/grants/"><em>here.</em></a></p>



<p class="wp-block-paragraph">Applicants should use the following access codes in the online application system:</p>



<p class="wp-block-paragraph">Supporting Physicians Transitioning to Late Career Status and Retirement: wellbeing2</p>



<p class="wp-block-paragraph">Fostering Safe and Respectful Care Environments for Physicians: wellbeing1</p>



<h3 class="wp-block-heading"><strong>About The Physicians Foundation </strong></h3>



<p class="wp-block-paragraph">The Physicians Foundation is a public charity seeking to advance the work of practicing physicians and help them facilitate the delivery of high-quality health care to patients. As the U.S. health care system continues to evolve, The Physicians Foundation is steadfast in strengthening the physician-patient relationship, supporting medical practices’ sustainability and helping physicians navigate the changing health care system. The Physicians Foundation pursues its mission through research, education and innovative grant making that improves physician wellbeing, strengthens physician leadership, addresses drivers of health and lifts physician perspectives. For more information, visit <a href="https://www.physiciansfoundation.org/">www.physiciansfoundation.org</a>.</p>



<p class="wp-block-paragraph"></p>
<p>The post <a href="https://physiciansfoundation.org/the-physicians-foundation-announces-two-grant-opportunities-to-advance-physician-wellbeing-and-strengthen-the-healthcare-workforce/">The Physicians Foundation Announces Two Grant Opportunities to Advance Physician Wellbeing and Strengthen the Healthcare Workforce</a> appeared first on <a href="https://physiciansfoundation.org/">The Physicians Foundation</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Claire AI™ Feature Spotlight: Summarize Key Concepts </title>
<link>https://edusehat.com/en/claire-aifeature-spotlight-summarize-key-concepts-15300</link>
<guid>https://edusehat.com/en/claire-aifeature-spotlight-summarize-key-concepts-15300</guid>
<description><![CDATA[ The post Claire AI™ Feature Spotlight: Summarize Key Concepts  appeared first on BoardVitals Blog. ]]></description>
<enclosure url="https://blog.boardvitals.com/wp-content/uploads/2026/10/346-BLOG-Summarize-1200x900-1-1024x768.png" length="49398" type="image/jpeg"/>
<pubDate>Fri, 13 Nov 2026 01:25:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Claire, AI™ Feature, Spotlight:, Summarize, Key, Concepts </media:keywords>
<content:encoded><![CDATA[<p class="wp-block-paragraph">Preparing for your boards means working through a lot of information in a limited amount of time. Answering practice questions is important, but so is understanding the concepts behind each answer, connecting related ideas, and knowing what deserves another look. When explanations cover several details at once, finding the main takeaway can slow down your review.  </p>



<p class="wp-block-paragraph">That’s where the new Claire AI<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> summarize feature in BoardVitals can help. It turns the material behind each question into a concise, focused overview, making it easier to understand key concepts, revisit challenging topics, and keep your study sessions moving. </p>



<h3 class="wp-block-heading"><strong>Make Every Study Minute Count</strong> </h3>



<p class="wp-block-paragraph">Medical students and residents have a lot to learn and limited time to learn it. You need to understand the reasoning behind each question while reinforcing the high-yield takeaways most likely to matter on exam day. Claire AI helps bridge that gap by condensing complex topics into focused reviews. </p>



<p class="wp-block-paragraph">When you answer a BoardVitals question, Claire AI uses the question’s context to create an easy-to-digest overview of the related content and key concepts. Instead of sorting through every detail again, you can quickly focus on what matters most and get back to studying.  </p>



<p class="wp-block-paragraph">Use a summary when an explanation brings together several ideas, when a topic feels unfamiliar, or when you want to lock in the main point before moving on. With the key details easier to spot, you can spend less time sorting through information and more time practicing where it counts. </p>



<h3 class="wp-block-heading"><strong>Build Claire AI into Your Study Routine</strong> </h3>



<p class="wp-block-paragraph">During a focused review session, use Claire AI to quickly revisit a weak area without rereading every detail. As exam day approaches, turn to these overviews for a quick way to refresh. </p>



<p class="wp-block-paragraph">Claire AI works best alongside your own clinical reasoning. Use each summary to reinforce learning and guide your next step, and refer to the complete question explanation whenever you need more context or detail. </p>



<p class="wp-block-paragraph">As you work through your question bank, Claire AI summaries make it easier to return to missed or challenging material. They do not replace BoardVitals’ complete explanations; they give you another quick way to reinforce the central lesson and keep building momentum.  </p>



<h3 class="wp-block-heading"><strong>Meet Claire AI for BoardVitals</strong> </h3>



<p class="wp-block-paragraph">Meet Claire AI, now available with most BoardVitals question banks. From explaining challenging topics and summarizing key points to <a href="https://www.boardvitals.com/blog/claire-ai-feature-flashcards/" data-type="post" data-id="15822">creating flashcards</a> and <a href="https://www.boardvitals.com/blog/claire-ai-feature-more-questions/" data-type="post" data-id="15818">generating additional practice questions</a>, Claire AI gives you more ways to engage with the material you are already reviewing. And because Claire AI pulls only from BoardVitals’ up-to-date question bank content, you can trust that the study support stays grounded in the same reliable material you already use to prepare. </p>



<p class="wp-block-paragraph">With AI-powered support built directly into the BoardVitals experience, Claire AI makes each study session more focused and responsive. You’ll get the help you need to study effectively when you need it most. However you choose to use it, Claire AI can help you understand, review, and practice material with greater confidence throughout your board prep. </p>
<p>The post <a href="https://www.boardvitals.com/blog/claire-ai-feature-summarize/">Claire AI™ Feature Spotlight: Summarize Key Concepts </a> appeared first on <a href="https://www.boardvitals.com/blog">BoardVitals Blog</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Claire AI™ Feature Spotlight: Generate More Practice Questions</title>
<link>https://edusehat.com/en/claire-ai-feature-spotlight-generate-more-practice-questions-15301</link>
<guid>https://edusehat.com/en/claire-ai-feature-spotlight-generate-more-practice-questions-15301</guid>
<description><![CDATA[ The post Claire AI™ Feature Spotlight: Generate More Practice Questions appeared first on BoardVitals Blog. ]]></description>
<enclosure url="https://blog.boardvitals.com/wp-content/uploads/2026/10/346-BLOG-Gen-Questions-1200x900-1-1024x768.png" length="49398" type="image/jpeg"/>
<pubDate>Fri, 13 Nov 2026 01:25:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Claire, AI™, Feature, Spotlight:, Generate, More, Practice, Questions</media:keywords>
<content:encoded><![CDATA[<p class="wp-block-paragraph">More questions means more ways to prepare for the boards. Practicing the same concept through different wording, details, and clinical presentations can help you move beyond memorization and learn how to apply what you know. </p>



<p class="wp-block-paragraph">Whether you are preparing for a <a href="https://boardvitals.com/medical-students">USMLE® exam</a>, a <a href="https://boardvitals.com/medical-students">shelf exam</a>, or <a href="https://boardvitals.com/medical-board-reviews">specialty boards</a>, Claire AI<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> makes it easy to turn one review question into a focused learning session, allowing you to stay with a challenging concept and practice it from multiple angles before moving on. </p>



<p class="wp-block-paragraph">This kind of targeted practice is especially useful when you miss a question, hesitate between two answer choices, or reach the correct answer for the wrong reason. Instead of saving the topic to revisit later, you can reinforce it right away while the concept – and your reasoning – are still fresh.  </p>



<h3 class="wp-block-heading"><strong>More Questions, More Prep</strong> </h3>



<p class="wp-block-paragraph">Looking for additional ways to study a concept? Ask Claire AI to generate more questions related to the topic you are reviewing. The questions appear directly in your conversation, so you can keep practicing without stopping to create a separate quiz. </p>



<p class="wp-block-paragraph">For example, if a cardiology question reveals uncertainty about murmurs, ask Claire AI for additional questions about murmurs to keep reviewing. Confused two pharmacology mechanisms of action? Practice the concept again in a new context before moving on. </p>



<p class="wp-block-paragraph">These questions are designed for quick, in-the-moment reinforcement and are not saved as a quiz in your BoardVitals account. Use them as a flexible supplement to your broader study plan. Your question bank, performance insights, detailed explanations, and exam-style practice remain essential for tracking progress and preparing across the full exam blueprint. </p>



<h3 class="wp-block-heading"><strong>How More Questions Can Strengthen Your Board Prep</strong> </h3>



<h4 class="wp-block-heading"><strong>Practice Active Recall</strong> </h4>



<p class="wp-block-paragraph">Answering a question asks you to retrieve and use information, not simply recognize it on a page. More questions extend that practice and help you confirm what you know before returning to passive review. </p>



<h4 class="wp-block-heading"><strong>Apply Concepts in New Contexts</strong> </h4>



<p class="wp-block-paragraph">Board-style questions often test familiar material through unfamiliar clinical details. Related questions help you separate the core concept from one specific vignette and build the flexibility to apply your knowledge when the presentation changes. </p>



<h4 class="wp-block-heading"><strong>Find Gaps Before Test Day</strong> </h4>



<p class="wp-block-paragraph">One correct answer does not mean you have mastered a topic, and one missed question does not always mean the entire topic is weak. More practice gives you a clearer picture. If your reasoning holds across several questions, you can move forward with greater confidence. If it doesn’t, you have found a specific area to revisit before exam day. </p>



<h3 class="wp-block-heading">Meet Claire AI for BoardVitals </h3>



<p class="wp-block-paragraph">Meet Claire AI, now available with most BoardVitals question banks. From explaining challenging topics and <a href="https://www.boardvitals.com/blog/claire-ai-feature-summarize/" data-type="post" data-id="15824">summarizing key points</a> to <a href="https://www.boardvitals.com/blog/claire-ai-feature-flashcards/" data-type="post" data-id="15822">creating flashcards</a> and generating additional practice questions, Claire AI gives you more ways to engage with the material you are already reviewing. And because Claire AI pulls only from BoardVitals’ up-to-date question bank content, you can trust that the study support stays grounded in the same reliable material you already use to prepare. </p>



<p class="wp-block-paragraph">With AI-powered support built directly into the BoardVitals experience, Claire AI makes each study session more focused and responsive. You’ll get the help you need to study effectively when you need it most. However you choose to use it, Claire AI can help you understand, review, and practice material with greater confidence throughout your board prep. </p>



<p class="wp-block-paragraph"></p>
<p>The post <a href="https://www.boardvitals.com/blog/claire-ai-feature-more-questions/">Claire AI™ Feature Spotlight: Generate More Practice Questions</a> appeared first on <a href="https://www.boardvitals.com/blog">BoardVitals Blog</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Claire AI™ Feature Spotlight: Flashcards </title>
<link>https://edusehat.com/en/claire-aifeature-spotlight-flashcards-15302</link>
<guid>https://edusehat.com/en/claire-aifeature-spotlight-flashcards-15302</guid>
<description><![CDATA[ The post Claire AI™ Feature Spotlight: Flashcards  appeared first on BoardVitals Blog. ]]></description>
<enclosure url="https://blog.boardvitals.com/wp-content/uploads/2026/10/346-BLOG-Flashcards-1200x900-1-1024x768.png" length="49398" type="image/jpeg"/>
<pubDate>Fri, 13 Nov 2026 01:25:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Claire, AI™ Feature, Spotlight:, Flashcards </media:keywords>
<content:encoded><![CDATA[<p class="wp-block-paragraph">Getting the most out of your board prep means more than reviewing information once. Repetition is an effective way to reinforce key concepts, identify areas that need more attention, and make each study session more productive. We’re making it easier to add that practice to your routine with Claire AI<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> flashcards.  </p>



<p class="wp-block-paragraph">Created from BoardVitals library of up-to-date content, these front-and-back cards give you a quick, focused way to review important information and strengthen your recall as you prepare for exam day. </p>



<h3 class="wp-block-heading"><strong>Why Add Flashcards to Your Study Routine?</strong> </h3>



<p class="wp-block-paragraph">It is easy to recognize a familiar fact on the page and assume you know it. Recalling that same fact without a prompt is harder. Flashcards put your memory to work by asking you to retrieve an answer, check your response, and return to important concepts over time. </p>



<p class="wp-block-paragraph">That repeated retrieval can support long-term retention and help you quickly spot the topics that need more attention. Whether you are a medical student balancing coursework and clinical rotations or a resident fitting study time into a demanding schedule, flashcards can help you make the most of shorter study sessions. </p>



<h3 class="wp-block-heading"><strong>Build Stronger Recall for Board Exam Day</strong> </h3>



<p class="wp-block-paragraph">Board exams require you to remember a wide range of information, retrieve it quickly, and apply it to specific situations. With Claire AI flashcards from BoardVitals, you’ll review these key terms and concepts with just a few clicks.  </p>



<p class="wp-block-paragraph">Claire AI flashcards reinforce the essential details and relationships found in your question content, helping you build a stronger foundation for answering board-style questions. Use them alongside your review questions to revisit what you have learned and keep important concepts fresh. </p>



<p class="wp-block-paragraph">After completing questions, review flashcards to strengthen your knowledge of terminology, mechanisms, diagnostic clues, and other high-yield connections. Over time, combining practice questions with active recall can help you move beyond recognizing the right answer to retrieving and applying what you know. </p>



<h3 class="wp-block-heading"><strong>Make Every Study Session Count</strong> </h3>



<p class="wp-block-paragraph">Add flashcards to the BoardVitals routine that already works for you. Review them after a quiz, return to them during a quick study break, and spend extra time on the concepts that are still difficult to recall. Flashcards should not be used as a replacement for practice questions, but as another way to reinforce the knowledge you need to pass your board exam.   </p>



<h3 class="wp-block-heading"><strong>Meet Claire AI for BoardVitals</strong> </h3>



<p class="wp-block-paragraph">Meet Claire AI, now available with most BoardVitals question banks. From explaining challenging topics and <a href="https://www.boardvitals.com/blog/claire-ai-feature-summarize/" data-type="post" data-id="15824">summarizing key points</a> to creating flashcards and <a href="https://www.boardvitals.com/blog/claire-ai-feature-more-questions/" data-type="post" data-id="15818">generating additional practice questions</a>, Claire AI gives you more ways to engage with the material you are already reviewing. And because Claire AI pulls only from BoardVitals’ up-to-date question bank content, you can trust that the study support stays grounded in the same reliable material you already use to prepare. </p>



<p class="wp-block-paragraph">With AI-powered support built directly into the BoardVitals experience, Claire AI makes each study session more focused and responsive. You’ll get the help you need to study effectively when you need it most. However you choose to use it, Claire AI can help you understand, review, and practice material with greater confidence throughout your board prep. </p>
<p>The post <a href="https://www.boardvitals.com/blog/claire-ai-feature-flashcards/">Claire AI™ Feature Spotlight: Flashcards </a> appeared first on <a href="https://www.boardvitals.com/blog">BoardVitals Blog</a>.</p>]]> </content:encoded>
</item>

<item>
<title>COMLEX Level 3 Changes in 2027: What to Expect and How to Prepare</title>
<link>https://edusehat.com/en/comlex-level-3-changes-in-2027-what-to-expect-and-how-to-prepare</link>
<guid>https://edusehat.com/en/comlex-level-3-changes-in-2027-what-to-expect-and-how-to-prepare</guid>
<description><![CDATA[ For many medical students, COMLEX Level 3 can feel so far away. Much must come before then, including scheduling away rotations, securing letters of recommendation, applying to residency, interviewing, matching, and finding time along the way to celebrate how far they have come. Then residency begins, and another licensing exam suddenly joins your schedule, already […]
The post COMLEX Level 3 Changes in 2027: What to Expect and How to Prepare appeared first on Elite Medical Prep. ]]></description>
<enclosure url="https://elitemedicalprep.com/wp-content/uploads/2026/11/pexels-ann-hannes-45017-32319624-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 12 Nov 2026 22:40:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>COMLEX, Level, Changes, 2027:, What, Expect, and, How, Prepare</media:keywords>
<content:encoded><![CDATA[<p><span>For many medical students, COMLEX Level 3 can feel so far away. Much must come before then, including scheduling away rotations, <a href="https://elitemedicalprep.com/residency-letters-of-recommendation-everything-you-need-to-know/">securing letters of recommendation</a>, <a href="https://elitemedicalprep.com/navigating-the-eras-application-tips-to-dos/">applying to residency</a>, interviewing, matching, and finding time along the way to celebrate how far they have come. Then residency begins, and another licensing exam suddenly joins your schedule, already loaded with patient care, documentation responsibilities, and learning how to function as a new physician. But don’t let it scare you! Recently, the National Board of Osteopathic Medical Examiners (NBOME) has announced some exciting changes to the exam format. </span></p>
<p> </p>
<h2><b>What’s new?</b></h2>
<p><span>Effective January 13th 2027, the NBOME is <a href="https://www.nbome.org/assessments/comlex-usa/level-3/">transitioning COMLEX Level 3 from a two-day exam into a one-day exam</a>. The new exam will have fewer multiple-choice questions and clinical cases, but the overall exam topics blueprint will remain the same. This will likely make it easier for incoming PGY1s, who already have a lot to navigate scheduling-wise. Of note, however, just because the exam is shorter does not mean the required preparation is any less. Level 3 will still require adequate studying to build the necessary clinical judgment- just adapted to a one-day exam now. This is how I would approach preparing for this exciting transition! </span></p>
<p> </p>
<p><span>In 2024, the NBOME made this announcement, but explicitly stated that the Level 3 exam would retain a very similar proportion of content and cases. Originally, the total testing time was 14 hours, which has now become eight. The previous version of the exam had 420 questions, 26 clinical decision-making cases, and four 3.5-hour sessions. The new exam has 240 questions, 16 clinical decision-making cases, and four 2-hour sessions. When planning test day, however, remember to consider tutorials, authorized breaks, and check-in times. So far, this change is being well received by PGY1s who have yet to sit for the exam and by current fourth-year medical students as they consider coverage arrangements, transportation, and time away from work. Personally, I too believe that removing the second testing day is a meaningful logistical change that works in favor of residents. </span></p>
<p> </p>
<h2><b>Let’s break it down…</b></h2>
<p><span>For the new version of the exam, <a href="https://www.nbome.org/assessments/comlex-usa/examination-format/">sessions A, B, and C will each contain two sets of 40 multiple-choice questions</a>. Session D will contain two sections of eight clinical cases, preceded by a clinical case tutorial. As with Level 1 and Level 2, the resident physician has a 60-minute authorized break allowance, which they may divide as they see fit. Timing-wise, roughly 90 seconds are allocated to each multiple-choice question, based on the 120-minute time limit for two 40-question sessions. </span></p>
<p> </p>
<p><span>As for the clinical case section, you have 120 minutes for 16 clinical cases, averaging roughly 7.5 minutes per case. These are not individual time limits, but pacing parameters to consider when you begin practicing for the exam. If you tend to spend too long on the first half of a session, remember that overthinking another answer choice is unlikely to change your answer. Make your most logical guess and move on so you can answer every question. If time permits, you can always return to a flagged question. Also, don’t expect every question to take the same amount of time; that depends on your strengths and weaknesses, the stem length, and your familiarity with the topic being tested! </span></p>
<p> </p>
<h3><b>How should I study? </b></h3>
<p><span>Level 3 assesses readiness for unsupervised, general medical practice, as the target exam demographic is the newest generation of resident physicians. The relevant competencies include patient care, medical knowledge, osteopathic principles, communication, professionalism, ethics, and systems-based practice. A reduction in question count, as seen on the new version of the exam, is not a reason to assume that an entire subject has been removed from the test. Nor should this change imply the exam will be easier or require less preparation. </span></p>
<p> </p>
<p><span>My recommendation is to use the exam blueprint as a checklist to ensure you are still covering all the foundations that the NBOME expects of you at this point in training. Compare the checklist with your everyday experience in residency and take note of experiences that you may not encounter as often on the hospital wards but are still fair test topics. An internal medicine resident may feel comfortable managing hospitalized adults, but will likely need to review pediatric presentations, reproductive care, or surgical techniques. Familiarity with your own service is surely valuable, but it should not be the boundary of your preparation for the purposes of Level 3 or Step 3! </span></p>
<p> </p>
<h4><strong>My thoughts</strong></h4>
<p><span>I believe that a productive way to study is to move beyond just being able to name a diagnosis. After each practice question, even if the stem does not ask it, ask what the physician should be doing next and why that takes immediate priority. For example, ensure you are able to distinguish between an immediate stabilization step and a diagnostic study. Be able to explain why a reasonable test may be unnecessary. To integrate systems more comprehensively, ask whether your proposed management would change if the patient were pregnant, clinically unstable, or unable to return for follow-up! </span></p>
<p> </p>
<p><span>This framework will ensure you know more about the topic, which will ultimately benefit you in your clinical practice as well. To track weak topics, I would make an error-log spreadsheet around decisions you are making on practice questions. Be specific when completing this log; instead of writing “missed a cardiology question,” write “selected definitive treatment before stabilizing the patient.” A short, actionable phrase will not only help the material stick better, but will make your studying more efficient. Ultimately, this approach connects studying to the clinical work you’ll see for the rest of your career. </span></p>
<p> </p>
<h2><b>OMM on Level 3</b></h2>
<p><span>Osteopathic content remains tested on the new version of Level 3. The published NBOME blueprint lists osteopathic principles, practice, and manipulative treatment as comprising 10% of the exam items. I would interpret this percentage as a ballpark estimate, not an absolute. I would recommend doing the </span><a href="https://elitemedicalprep.com/omm-for-comlex-level-1-and-level-2-ce-study-guide-and-free-anki-deck/"><span>EMP OMM Anki deck </span></a><span>as a refresher on topics you may not have encountered since Level 2. Rotate through these topics, including viscerosomatics, sacral and spinal mechanics, autonomics, and OMT indications and contraindications. The goal is to explain how the finding fits the patient. If you memorize a technique but can’t apply it clinically, you’re likely to get the question wrong. Recognizing that you are a full-time resident physician, ensure to keep the workload manageable. Doing 30-50 Anki cards before bed for a few weeks can help refresh the OMM material while ensuring you still have time to accomplish other checklist items. </span></p>
<p> </p>
<h3><b>An Unfamiliar Section: Clinical Cases </b></h3>
<p><span>Unlike Level 1 and Level 2, Level 3 has a specific clinical decision-making section composed of clinical cases to work through. I recommend adding a separate study block into your schedule for this new section. The NBOME tutorial explains that these cases can use extended multiple-choice and short-answer question styles. They also state that each question will have a response limit, and answers that are harmful or unnecessarily costly may reduce the points you receive. Of note, once you move on in this section, you cannot return to fix your answer! I recommend practicing the task as it will be presented. Avoid writing an entire management plan, but ensure you are considering several competing possibilities. I’m sure with more experience throughout your PGY1 year, some of these decisions will become easier to make. </span></p>
<p> </p>
<p><span>The NBOME emphasizes the importance of specificity: imaging requires you to dictate the anatomical site, medications require drug name and route of administration, and OMT questions require techniques and specific locations. One useful exercise is to explain the answer out loud, then tweak it to be as concise as possible while staying thorough. </span></p>
<p> </p>
<h4><strong>The Clinical Decision-making Section</strong></h4>
<p><span>The clinical decision-making section is after the three multiple-choice sessions. That could help some test takers if certain multiple-choice questions clarify the best management steps for a condition or system. When preparing for the exam, I would definitely practice the clinical case questions after timed practice questions to build test-taking endurance and help cognitively switch between question styles. You don’t need to do a full practice exam every weekend; that is unlikely to be feasible with a PGY1 schedule. Start with a workload you can actually review properly, then build towards longer sessions, schedule-permitting. I also recommend treating breaks as part of the testing simulation. Plan food, hydration, and brief resets that work for you. </span></p>
<p> </p>
<h2><b>How to Build a Plan as a Resident Physician</b></h2>
<p><span>Residency, especially intern year, is no secret: it’s extremely challenging and takes a lot of time. When preparing for Level or Step 3, no single calendar will fit every resident’s schedule. Your baseline knowledge, previous exam experience, residency work schedule, and available study time should guide the study plan. I recommend starting with a baseline assessment, including mixed questions and a few clinical cases. Identify whether the main difficulty is content, pacing, or question interpretation. </span></p>
<p> </p>
<p><span>Review your mistakes honestly and then <a href="https://elitemedicalprep.com/comlex-level-3-the-complete-guide/">craft how you want to approach practice questions</a> from there. I would think that you should save your residency service for last. For example, a general surgery resident may want to focus on internal medicine, psychiatry, family medicine, and OBGYN before spending time on general surgery practice questions. Being exposed to these more familiar concepts daily at work is studying in its own right. If a demanding rotation disrupts your schedule, revise the workload. A smaller plan that you can follow is more useful than an ambitious calendar that leaves you permanently behind.</span></p>
<p> </p>
<h2><b>Resources to Use</b></h2>
<p><span>Before buying or renewing any resources or question banks, I would ask your residency program director what is provided to you. Many programs still provide residents with UWorld or TrueLearn access, which could save you some money on an already-tight residency budget. For the new format of the exam- timed and mixed questions, system-specific questions, explanations that address management priorities, and clinical case-based multi-part questions- these would all be helpful to use in your preparation. </span></p>
<p> </p>
<p><span>When crafting practice question banks, follow the new format when adjusting your test settings to accurately reflect test-day experiences. As with Level 1, Step 1, and Level 2, Step 2, I would not recommend using more than one or two resources to study for Level 3/Step 3. Fantastic resources are available, but indecision about which one to use will do a disservice to you and your limited time frame. As with the preceding board licensing exams, I believe practice questions are key and should remain at the forefront of your study plan. You learn by example! </span></p>
<p> </p>
<h2><b>The Transition</b></h2>
<p><span>A one-day exam likely does sound better, but it should not be the sole reason to move your test from November or December 2026 into 2027. Discuss the timing with your program director/ chief residents, and consider your clinical schedule, readiness, and relevant deadlines based on your individual situation, specialty, and program. </span></p>
<p> </p>
<p><span>In order to register for Level 3, you must have successfully completed Level 1, Level 2-CE, and graduated from an accredited osteopathic medical school in the United States. The NBOME generally recommends about six months of residency training before sitting for Level 3. Everyone’s testing year, circumstances, and program may influence their testing experience, so take others’ advice with a grain of salt and ultimately do what is right for you. When using NBOME resources and practice banks, make sure the page says “2027” at the top to ensure you are using the newly updated practice resources based on the new format. The old materials are surely still clinically relevant, but it may be better to use the new resources to better understand the format. </span></p>
<p> </p>
<p data-pm-slice="1 1 []">Before you sit for Level 3, review the NBOME Bulletin of Information and scheduling instructions so you know what to expect on exam day. Build a plan that gives you time to practice clinical decision-making, work on your pacing, and review the topics you see less often on rotation. If you’d like help building that plan around your residency schedule, explore Elite Medical Prep’s <a href="https://elitemedicalprep.com/comlex-level-3-tutoring/">one-on-one COMLEX Level 3 tutoring</a>. You’ve got this, Doctor. Good luck on Level 3!</p>
<p>The post <a href="https://elitemedicalprep.com/comlex-level-3-changes-what-to-expect-and-how-to-prepare/">COMLEX Level 3 Changes in 2027: What to Expect and How to Prepare</a> appeared first on <a href="https://elitemedicalprep.com/">Elite Medical Prep</a>.</p>]]> </content:encoded>
</item>

<item>
<title>$43&#45;million campaign to transform surgical care at Victoria hospitals</title>
<link>https://edusehat.com/en/43-million-campaign-to-transform-surgical-care-at-victoria-hospitals</link>
<guid>https://edusehat.com/en/43-million-campaign-to-transform-surgical-care-at-victoria-hospitals</guid>
<description><![CDATA[ New hybrid operating rooms and expanded interventional radiology services will advance minimally invasive treatment and specialized care on Vancouver Island. A major investment in surgical infrastructure and medical technology is poised to transform the delivery of specialized healthcare on Vancouver Island. The Victoria Hospitals Foundation has launched a $43-million fundraising campaign to expand surgical and […]
The post $43-million campaign to transform surgical care at Victoria hospitals appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/11/RCP-HOSPITAL-SEPT-2026-205web-705x470-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 12 Nov 2026 18:40:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>43-million, campaign, transform, surgical, care, Victoria, hospitals</media:keywords>
<content:encoded><![CDATA[<p><em>New hybrid operating rooms and expanded interventional radiology services will advance minimally invasive treatment and specialized care on Vancouver Island.</em></p>
<p>A major investment in surgical infrastructure and medical technology is poised to transform the delivery of specialized healthcare on Vancouver Island.</p>
<p>The Victoria Hospitals Foundation has launched a $43-million fundraising campaign to expand surgical and interventional radiology capabilities at Royal Jubilee Hospital and Victoria General Hospital in British Columbia.</p>
<p>The initiative, <em>It’s Time for Surgical Transformation</em>, represents the third and final phase of the foundation’s multi-year campaign to modernize hospital facilities, introduce advanced medical technologies and improve access to specialized treatment.</p>
<p>The project comes as Vancouver Island faces growing demand for healthcare services, driven in part by an aging population. The number of residents aged 85 and older is projected to more than double over the next two decades.</p>
<h2>Bringing hybrid operating rooms to Vancouver Island</h2>
<p>A central component of the campaign is a proposed $25.4-million investment in two hybrid operating rooms at Royal Jubilee Hospital.</p>
<p>These will be Vancouver Island’s first hybrid operating rooms and the first additional operating rooms at Victoria’s hospitals in more than 23 years.</p>
<p>Hybrid operating rooms integrate advanced medical imaging with conventional surgical capabilities, allowing physicians to perform complex procedures in a single clinical environment.</p>
<p>The technology enables surgical teams to visualize anatomy in real time, perform image-guided interventions and undertake open surgical procedures without transferring patients between different treatment areas.</p>
<p>For patients with complex cardiovascular and vascular conditions, this integrated approach can provide greater flexibility during treatment, particularly when minimally invasive procedures and traditional surgical techniques are required during the same operation.</p>
<p>The new facilities will support advanced procedures such as aortic aneurysm repair, vascular reconstruction and interventions aimed at reducing stroke risk.</p>
<p>They will also provide an environment where multidisciplinary teams, including surgeons, anesthesiologists, nurses, imaging technologists and perfusionists, can work together during complex procedures.</p>
<h2>Doubling interventional radiology capacity</h2>
<p>The campaign also includes a $17.6-million investment in interventional radiology services at Royal Jubilee and Victoria General hospitals.</p>
<p>Plans include the construction of two new interventional radiology suites, upgrades to two existing suites and the addition of dedicated patient recovery areas.</p>
<p>The expansion is expected to double interventional radiology capacity across the two hospitals.</p>
<p>Interventional radiology uses medical imaging to guide specialized instruments through small openings in the body, offering alternatives to traditional open surgery for a range of conditions.</p>
<p>These techniques can be used to remove blood clots associated with stroke, control internal bleeding, restore blood flow and treat certain cancers.</p>
<p>For appropriately selected patients, minimally invasive procedures can reduce the physical impact of treatment and support shorter recovery times.</p>
<p>Additional interventional radiology capacity may also help relieve pressure on conventional operating rooms, allowing surgical resources to be directed toward patients who require more extensive procedures.</p>
<p>Having two suites at each hospital will provide greater flexibility when multiple patients require urgent image-guided treatment.</p>
<h2>Building on advances in surgical technology</h2>
<p>The initiative builds on earlier investments that have already introduced new surgical capabilities to Vancouver Island.</p>
<p>The first two phases of the foundation’s campaign raised $38 million, supporting robotic-assisted surgery, advanced oncology equipment and other specialized medical technologies.</p>
<p>Royal Jubilee Hospital and Victoria General Hospital have also been advancing image-guided treatment options, including the use of NanoKnife technology for selected patients with early-stage prostate cancer.</p>
<p>The latest phase shifts the focus toward the physical infrastructure needed to support increasingly sophisticated medical technologies.</p>
<p>As surgical robotics, advanced imaging and minimally invasive techniques continue to evolve, hospitals must adapt their facilities to accommodate new equipment, multidisciplinary workflows and changing clinical requirements.</p>
<h2>Community investment supports the next generation of care</h2>
<p>The $43-million campaign was officially launched on November 3, with $8.2 million already committed.</p>
<p>On November 6, the Victoria Hospitals Foundation announced an additional $3-million leadership gift from the Robert and Devi Jawl Foundation, bringing the amount secured to $11.7 million.</p>
<p>The foundation’s goal is to expand local treatment options, strengthen specialized healthcare capacity and provide clinical teams with the facilities needed to deliver increasingly complex care.</p>
<p>For Vancouver Island patients, the proposed investments could mean greater access to advanced surgical and interventional procedures closer to home.</p>
<p>For Canadian hospitals more broadly, the initiative highlights the growing importance of integrating medical technology with purpose-built clinical infrastructure as healthcare systems respond to rising demand for specialized care.</p>
<p>The post <a href="https://www.hospitalnews.com/43-million-campaign-to-transform-surgical-care-at-victoria-hospitals/">$43-million campaign to transform surgical care at Victoria hospitals</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>St. Michael’s Hospital breaks ground on $14&#45;million neonatal intensive care expansion</title>
<link>https://edusehat.com/en/st-michaels-hospital-breaks-ground-on-14-million-neonatal-intensive-care-expansion</link>
<guid>https://edusehat.com/en/st-michaels-hospital-breaks-ground-on-14-million-neonatal-intensive-care-expansion</guid>
<description><![CDATA[ New and expanded neonatal intensive care unit will provide specialized care for critically ill newborns while improving infection prevention, patient privacy and family-centred care. St. Michael’s Hospital in Toronto has officially broken ground on a new and expanded neonatal intensive care unit (NICU), supported by nearly $14 million in funding from the Ontario government. The […]
The post St. Michael’s Hospital breaks ground on $14-million neonatal intensive care expansion appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/11/shutterstock_2601562281.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 12 Nov 2026 18:40:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>St., Michael’s, Hospital, breaks, ground, 14-million, neonatal, intensive, care, expansion</media:keywords>
<content:encoded><![CDATA[<p><em>New and expanded neonatal intensive care unit will provide specialized care for critically ill newborns while improving infection prevention, patient privacy and family-centred care.</em></p>
<p>St. Michael’s Hospital in Toronto has officially broken ground on a new and expanded neonatal intensive care unit (NICU), supported by nearly $14 million in funding from the Ontario government.</p>
<p>The project will renovate more than 12,000 square feet of space within the hospital’s Peter Gilgan Patient Care Tower, creating a modern environment designed to meet the specialized needs of premature and critically ill newborns.</p>
<p>Part of Unity Health Toronto, St. Michael’s Hospital provides neonatal care to some of the province’s most vulnerable patients. The expansion represents an important investment in specialized hospital infrastructure and the delivery of care for newborns and their families.</p>
<p>Construction is expected to be completed in summer 2027.</p>
<h2>Expanding specialized neonatal care</h2>
<p>The new NICU will feature dedicated neonatal resuscitation facilities, airborne isolation rooms and more private patient rooms, supporting both clinical care and infection prevention.</p>
<p>Neonatal intensive care units provide specialized treatment for infants born prematurely or with medical conditions requiring continuous monitoring, respiratory support and other advanced interventions.</p>
<p>The expanded facility is designed to provide healthcare teams with an improved environment for delivering this complex care, while offering families greater privacy during what can be an extremely challenging period.</p>
<p>Dedicated resuscitation facilities will support rapid intervention for newborns requiring immediate medical attention, while airborne isolation rooms will strengthen the hospital’s ability to manage infectious disease risks within the unit.</p>
<h2>Supporting family-centred care</h2>
<p>An important component of the expansion is the creation of more private spaces for newborns and their families.</p>
<p>Family involvement plays a significant role in neonatal care, with parents often participating in feeding, skin-to-skin contact and other developmental care activities under the guidance of clinical teams.</p>
<p>Modern NICU environments increasingly emphasize the importance of balancing advanced medical technology with opportunities for parents to remain close to their infants.</p>
<p>Greater privacy can help support these interactions while providing families with a more comfortable environment during extended hospital stays.</p>
<p>The expanded unit is intended to support this approach while maintaining the specialized monitoring and treatment capabilities required for critically ill newborns.</p>
<h2>Investing in hospital infrastructure</h2>
<p>The project forms part of Ontario’s broader investment in hospital infrastructure and specialized healthcare services.</p>
<p>By modernizing existing space within the Peter Gilgan Patient Care Tower, the redevelopment will support St. Michael’s Hospital’s ability to deliver neonatal care in a facility designed around contemporary clinical requirements.</p>
<p>The construction project is also expected to support approximately 100 jobs.</p>
<p>For Canadian hospitals, investments in neonatal infrastructure highlight the importance of designing healthcare facilities that support patient safety, infection prevention, multidisciplinary clinical teams and family involvement.</p>
<p>As demand for specialized healthcare services continues to evolve, modernizing hospital environments remains an important part of strengthening healthcare capacity.</p>
<p>With construction now underway, the expanded St. Michael’s Hospital NICU is expected to begin serving newborns and their families following completion in summer 2027.</p>
<p><strong>Source:</strong> Government of Ontario, November 11, 2026.</p>
<p>The post <a href="https://www.hospitalnews.com/st-michaels-hospital-breaks-ground-on-14-million-neonatal-intensive-care-expansion/">St. Michael’s Hospital breaks ground on $14-million neonatal intensive care expansion</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>From recommendation to reality: Why newborn screening needs funding now</title>
<link>https://edusehat.com/en/from-recommendation-to-reality-why-newborn-screening-needs-funding-now</link>
<guid>https://edusehat.com/en/from-recommendation-to-reality-why-newborn-screening-needs-funding-now</guid>
<description><![CDATA[ For the Sereno family, time has always been important. And for Lina Sereno, trusting her gut made all of the difference when it came […]
The post From recommendation to reality: Why newborn screening needs funding now appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/11/sereno-family2.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 12 Nov 2026 04:30:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>From, recommendation, reality:, Why, newborn, screening, needs, funding, now</media:keywords>
<content:encoded><![CDATA[<p><span>For the Sereno family, time has always been important.</span></p>
<p><span>And for Lina Sereno, trusting her gut made all of the difference when it came to her two sons: Salvatore and Giovanni.</span></p>
<p><span>“</span><span>My older son, Salvatore, was diagnosed with metachromatic leukodystrophy (MLD) in October of 2009,” explains Sereno, “but it took approximately seven months to find out what was happening to him. I took him to six different doctors, and each one suggested that he had ADHD. I agreed to medication for two months. Instead of improving, he became worse.”</span></p>
<p><span>It was during this time that Sereno recalls the night her son Salvatore became dazed and unresponsive. “I notified his doctor, and that finally prompted the MRI that got us the MLD diagnosis,” she says. “All these years later, I believe he may have experienced a seizure.”</span></p>
<p><span>Shortly thereafter, Sereno got her younger son Giovanni tested as well and found that he too had MLD. His early diagnosis gave him access to early treatments that Salvatore never had the opportunity to get. “I know with all my heart that Giovanni is thriving today because of that early diagnosis and treatment,” says Sereno.</span></p>
<p><span>“The journey felt incredibly long and lonely,” Sereno recalls. “No parent should have to fight so hard to get answers while their child is losing precious time.”</span></p>
<p><span>As such, the Surge to Save Newborns Act (H.R. 10571), a bipartisan bill introduced in September has been introduced with the aim to close critical gaps in state-level infant health screenings so families like the Serenos don’t lose precious time. </span></p>
<p><span>To discuss both the Sereno family’s own personal journey, as well as the importance of passing H.R. 10571, Bio.News sat down with Lina Sereno.</span></p>
<h3>Newborn screening for rare disease is hope for families</h3>
<p><span>“The fact that a disease is rare makes </span><a href="https://bio.news/latest-news/advocate-explains-why-we-need-newborn-screening-advisory-committee/"><span>newborn screening</span></a><span> even more important,” explains Sereno. “Most parents have never heard of MLD until it affects their own family. By the time symptoms appear, it may be too late to prevent irreversible damage.”</span></p>
<p><span>It was 17 years ago when Salvatore and Giovanni were diagnosed, and the Sereno’s story shows just how impactful time (both gained and lost), and healthcare innovation have been to their family</span></p>
<p><span>“At that time, the only treatment option available to us was a bone marrow transplant,” Sereno says. “My husband and I made the best decisions we could for both of our sons based on the medical knowledge and treatment options available.”</span></p>
<p><span>Today, much more is understood about MLD—especially the importance of early intervention. While a new gene therapy has been approved for MLD the risk remains for children diagnosed after symptoms begin as some of the damage may already be irreversible. </span></p>
<p><span>“I wish I had known how drastically our lives would change,” Sereno says. “Raising two boys with MLD has been incredibly difficult, but it has also shown me the extraordinary strength of our family and the power of love. There have been challenges I never could have imagined, but there has also been so much joy and beauty.”</span></p>
<p><span>Following his bone marrow transplant, Giovanni has remained almost symptom-free for 17 years. “He goes to school, plays video games, has friends and experiences most of what other kids his age do,” Sereno says. </span></p>
<p><span>Unfortunately, for Salvatore, the delay in his diagnosis has had distinct effects.</span></p>
<p><span>“Salvatore’s disease progressed rapidly during his bone marrow transplant,” says Sereno. “He walked into the hospital and left fully disabled and dependent on a G-tube for nutrition.”</span></p>
<p><span>Today, Salvatore is dependent on his family for care. </span></p>
<p><span>“His story is why I want other families to have the opportunity that came too late for him,” says Sereno. “Even if newborn screening identifies just one child a year who can benefit from early treatment, it is worth it. That is one child, one family and an entire lifetime that could be changed.”</span></p>
<p><span>Rarity should never determine whether a child gets that chance, she says. Newborn screenings mean hope for families.</span></p>
<p><span>“Instead of constantly worrying about the unknowns of this disease, parents could have information, access to specialists and the opportunity to act early,” she continues. “Every family deserves that chance. No parent should have to learn that their child has a devastating disease only after symptoms appear and precious treatment time has been lost, when the possibility of treatment is either gone or would not be as beneficial.”</span></p>
<h3>From the RUSP decision to real-world screening</h3>
<p><span>MLD and Duchenne muscular dystrophy were added to the Recommended Uniform Screening Panel (RUSP) on December 16, 2025—a major milestone for families and advocates. However, a federal recommendation does not automatically provide states with the resources to implement it.</span></p>
<p><span>“Rather,” Sereno explains, “each state must take the necessary steps to add MLD to its newborn screening panel. That process may require legislative or regulatory action, laboratory validation, specialized equipment, staff training, clinical follow-up systems and additional funding.”</span></p>
<p><span>While the federal recommendation by RUSP is an important first step to resolving this issue, it is not enough if states cannot implement said recommendations in a timely and efficient manner.</span></p>
<p><span>“Scientific advances and new treatments are creating opportunities to identify and treat babies earlier than ever before,” explains Sereno. “But without adequate funding, states may not have the resources to implement these screenings in a timely manner.”</span></p>
<p><span>It doesn’t matter how many healthcare advancements are made if families can’t (or don’t know to) access them.</span></p>
<p><span>“For families who have spent years advocating for newborn screening, this decision to include MLD and Duchenne muscular dystrophy to the RUSP represents hope,” Sereno reminds. “It acknowledged that early detection matters and that babies should have the opportunity to be identified before symptoms appear.”</span></p>
<p><span>Historically, implementation of a newly recommended condition can take five to six years in many states, and in some cases, considerably longer, which ultimately translates to missed opportunities for early diagnosis and treatment.</span></p>
<p><span>“State laboratories may lack the funding, equipment, facilities or trained personnel needed to establish a new screening test,” she continues. “They must also develop testing protocols, validate results, coordinate confirmatory testing and establish pathways for referring affected newborns to specialists.”</span></p>
<p><span>This has translated to the inclusion of MLD and Duchenne muscular dystrophy varying from state-to-state, creating what caregivers refer to as the “birth lottery,” where two babies with the same condition can have very different opportunities simply because they were born in different states.</span></p>
<p><span>“The state-by-state approach is profoundly unfair,” says Sereno. “It is heartbreaking to know that the state in which a baby is born can determine whether a potentially devastating disease is detected early enough for treatment to make a difference.”</span></p>
<p><span>Newborn screening should not depend on a family’s ZIP code, financial resources or ability to advocate for their child. </span></p>
<p><span>“These are essential steps, but states should not have to face these challenges alone. Without dedicated resources and coordinated support, even a strong commitment to newborn screening can be delayed by financial and operational barriers,” Sereno adds. “Every newborn deserves equitable access to screening for conditions on the RUSP, and every state needs the resources to make that possible.”</span></p>
<p><span>“Our work is not finished,” explains Sereno. “We must now ensure that states move forward with implementation so that this recommendation translates into real access to screening for newborns across the country.”</span></p>
<h3>Surge to Save Newborns bill: Turning a federal recommendation into action</h3>
<p><span>The Surge to Save Newborns bill would allow the progress made through the RUSP to go beyond just the recommendation of addition of new diseases by requesting</span><span> $35 million a year for 5 years to ensure every state is screening for the 40 conditions on the RUSP plus 2 additional conditions not yet nominated.</span></p>
<p><span>“We need to have a coordinated national effort that brings together families, patient advocacy organizations, clinicians, laboratories, policymakers and other stakeholders to ensure that states have the support necessary to put recommended screenings into practice,” Sereno argues. “That means investing in laboratory capacity, testing technology, personnel, training and the infrastructure needed to identify affected newborns and connect them to timely follow-up care.”</span></p>
<p><span>Federal funding is a critical part of this solution and could help states move more quickly while promoting a more consistent and equitable approach to implementation nationwide, she says. </span></p>
<p><span>States should not have to choose between competing public health priorities or delay implementation because they cannot afford the necessary resources. </span></p>
<p><span>“Dedicated federal support could help accelerate implementation and reduce the disparities that currently exist across state lines,” Sereno explains. “This is an investment in prevention, early diagnosis and the future of our children. The cost of implementation must be weighed against the potentially devastating human and financial consequences of a missed or delayed diagnosis.”</span></p>
<h3>Congress must act</h3>
<p><span>When asked what she would say to congress regarding H.R. 10571 Sereno says she would implore them to think about the families behind these decisions. </span></p>
<p><span>“Think about the parents who spend months visiting doctor after doctor, desperately searching for answers,” she asserts. “Think about the children who could have received treatment before symptoms began but were not identified in time.”</span></p>
<p><span>Adding a condition to the RUSP is the beginning of the promise, Sereno says, not the fulfillment of it. Without funding, that promise may remain out of reach for the very babies who need it most.</span></p>
<p><span>The Surge to Save Newborns is about turning that promise into action.</span></p>
<p><span>“I urge policymakers to support the Surge to Save Newborns initiative and the legislation needed to provide states with dedicated implementation funding,” Sereno implores. “We have the knowledge. We have the treatments. We have the federal recommendation. Now we need the funding and the national commitment to make newborn screening a reality for every baby, in every state.”</span></p>
<p> </p>
<p><i><span>Please act now and reach out to your congressman to support the Surge to Save Newborns </span></i><a href="https://surgetosave.org/act-now/"><i><span>https://surgetosave.org/act-now/</span></i></a></p>
<p><i><span>To get more involved and join our coalition, you can reach out to: Elisa Seeger  elisa@aldalliance.org</span></i></p>
<p>The post <a href="https://bio.news/latest-news/from-recommendation-to-reality-why-newborn-screening-needs-funding-now/">From recommendation to reality: Why newborn screening needs funding now</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Surgical site infections add estimated $2,056 per cardiac procedure, analysis finds</title>
<link>https://edusehat.com/en/surgical-site-infections-add-estimated-2056-per-cardiac-procedure-analysis-finds</link>
<guid>https://edusehat.com/en/surgical-site-infections-add-estimated-2056-per-cardiac-procedure-analysis-finds</guid>
<description><![CDATA[ Canadian health economics analysis highlights the financial and operational burden of post-operative infections, including additional hospital bed-days and potential reductions in surgical capacity. Surgical site infections following cardiac surgery could add an average of $2,056 in additional costs per procedure, according to a health economics analysis highlighted by Canadian life sciences company Ondine Biomedical. The […]
The post Surgical site infections add estimated $2,056 per cardiac procedure, analysis finds appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/11/shutterstock_2634279831.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 11 Nov 2026 20:35:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Surgical, site, infections, add, estimated, 2, 056, per, cardiac, procedure, analysis, finds</media:keywords>
<content:encoded><![CDATA[<p>Canadian health economics analysis highlights the financial and operational burden of post-operative infections, including additional hospital bed-days and potential reductions in surgical capacity.</p>
<p>Surgical site infections following cardiac surgery could add an average of $2,056 in additional costs per procedure, according to a health economics analysis highlighted by Canadian life sciences company Ondine Biomedical.</p>
<p>The findings, presented at the Canadian Cardiovascular Congress 2026 and published in the Canadian Journal of Cardiology, suggest that post-operative infections create financial pressures that extend beyond the cost of treating affected patients.</p>
<p>The analysis also estimates that infection-related complications could consume hospital capacity equivalent to approximately 10 per cent of cardiac surgical procedures under the modelled assumptions.</p>
<p>Ondine Biomedical announced the findings November 11, emphasizing the potential role of infection prevention strategies in reducing avoidable costs and preserving surgical resources.</p>
<div>
<div></div>
</div>
<h2>Modelling the financial burden of infection</h2>
<p>The analysis uses a baseline surgical site infection rate of 6.7 per cent and an assumed additional hospital cost of $30,689 for each patient who develops an infection.</p>
<p>Based on these assumptions, researchers calculated an average additional cost of approximately $2,056 across all cardiac surgery procedures, including those in which no infection occurs.</p>
<p>The approach distributes the expected cost of infections across the entire surgical population, providing hospital administrators with a per-procedure estimate of infection-related financial risk.</p>
<p>The researchers describe this measure as an infection tax, intended to illustrate the potential economic impact of complications that may be reduced through effective prevention strategies.</p>
<p>Importantly, the $30,689 incremental cost was adapted from a U.S. healthcare cost benchmark, adjusted for currency and differences in healthcare systems. It was not directly measured in Canadian cardiac surgery patients.</p>
<p>As a result, the $2,056 figure should be understood as a modelling estimate rather than a documented average cost across Canadian hospitals.</p>
<h2>Additional bed-days affect surgical capacity</h2>
<p>The analysis also examined the potential operational impact of infections on hospital capacity.</p>
<p>In a modelled group of 1,000 cardiac surgery patients, a 6.7 per cent infection rate would result in approximately 67 surgical site infections.</p>
<p>Those infections were estimated to generate more than $2 million in additional hospital costs and require approximately 650 extra inpatient bed-days.</p>
<p>The bed-day calculation assumes that patients experiencing a surgical site infection remain hospitalized an average of 9.7 additional days.</p>
<p>Researchers estimated that these occupied beds could otherwise support approximately 100 elective cardiac procedures, representing a potential 10 per cent reduction in surgical capacity.</p>
<p>The findings highlight how infection-related complications can affect operating schedules, patient flow and waiting lists, particularly in hospitals already experiencing constraints on inpatient beds and staffing.</p>
<p>However, the estimate of 100 displaced procedures represents a theoretical opportunity cost. It does not demonstrate that preventing infections would automatically enable hospitals to perform 100 additional surgeries.</p>
<div>
<div></div>
</div>
<h2>Infection prevention as a hospital capacity strategy</h2>
<p>Surgical site infections remain an important patient safety concern because they can result in prolonged hospitalization, additional treatment, readmissions and increased demand for clinical resources.</p>
<p>For cardiac surgery patients, infection prevention is particularly important given the complexity of procedures and the potential consequences of post-operative complications.</p>
<p>Hospitals use a range of prevention measures, including appropriate antibiotic prophylaxis, skin antisepsis, infection surveillance, standardized surgical practices and pre-operative decolonization for selected patients.</p>
<p>The new analysis suggests that evaluating infection prevention programs should include not only direct treatment costs but also the effect of complications on staffing, hospital beds and surgical throughput.</p>
<p>By incorporating these broader operational considerations, healthcare organizations may be better positioned to assess the financial value of prevention initiatives.</p>
<h2>Canadian research examines prevention approaches</h2>
<p>The analysis was presented alongside two related research posters from the University of Ottawa Heart Institute.</p>
<p>One examined implementation of a cardiac surgery infection prevention bundle through frontline engagement, nasal photodisinfection and nurse-led advocacy.</p>
<p>The second examined surgical site infections following cardiac surgery using an interrupted time-series analysis of nasal photodisinfection.</p>
<p>Both were identified in the company’s announcement as research presented at the Canadian Cardiovascular Congress 2026.</p>
<p>Ondine Biomedical develops Steriwave, a light-activated antimicrobial technology used for nasal decolonization in certain jurisdictions, including Canada.</p>
<p>The company has a commercial interest in promoting infection prevention approaches involving photodisinfection. The economic analysis does not, by itself, demonstrate the clinical effectiveness or cost savings of any particular product.</p>
<p>The findings should therefore be considered in the context of the model’s assumptions and the broader evidence supporting individual infection prevention interventions.</p>
<div>
<div></div>
</div>
<h2>Implications for Canadian hospitals</h2>
<p>For hospital executives and surgical program leaders, the analysis offers another perspective on the costs associated with preventable complications.</p>
<p>The financial impact of surgical site infections includes not only additional clinical treatment but also longer hospital stays, increased nursing demands and reduced availability of inpatient beds.</p>
<p>With many Canadian hospitals facing sustained pressure to improve surgical access and manage operating costs, infection prevention remains an important component of patient safety and operational planning.</p>
<p>The findings suggest that even relatively modest reductions in surgical site infection rates could potentially reduce resource use, although actual savings and capacity gains would depend on local infection rates, patient populations, staffing, costs and available surgical resources.</p>
<p>Further Canadian hospital-level economic evaluations would help determine how closely the modelled estimates reflect real-world costs and what improvements can be achieved through specific prevention strategies.</p>
<p>Source: <a href="https://www.tradingview.com/news/reuters.com%2C2026-11-11%3Anewsml_RSK6260Ca%3A0-rcs-ondine-biomedical-cardiac-ssi-infection-tax-at-c-2-056-per-surgery/?utm_source=chatgpt.com">Ondine Biomedical </a></p>
<p>The post <a href="https://www.hospitalnews.com/surgical-site-infections-add-estimated-2056-per-cardiac-procedure-analysis-finds/">Surgical site infections add estimated $2,056 per cardiac procedure, analysis finds</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Argenx Expands Immunology Capabilities with Up&#45;to&#45;$1.15B UNP Acquisition</title>
<link>https://edusehat.com/en/argenx-expands-immunology-capabilities-with-up-to-115b-unp-acquisition</link>
<guid>https://edusehat.com/en/argenx-expands-immunology-capabilities-with-up-to-115b-unp-acquisition</guid>
<description><![CDATA[ The deal is designed to marry UNP’s macrocyclic peptide discovery platform with Argenx’s immunology innovation capabilities to broaden the buyer’s ability to develop oral or long-acting treatments for serious immune-mediated diseases.
The post Argenx Expands Immunology Capabilities with Up-to-$1.15B UNP Acquisition appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Argenx-research-lab-shot__Screenshot-2026-11-10-110538-JPEG.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 11 Nov 2026 02:50:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Argenx, Expands, Immunology, Capabilities, with, Up-to-1.15B, UNP, Acquisition</media:keywords>
<content:encoded><![CDATA[<p>More than a year after they began partnering to develop oral macrocyclic peptides against multiple historically “undruggable” targets, Argenx has agreed to acquire Unnatural Products (UNP) for up to $1.15 billion, the companies said.</p>
<p>The deal—Argenx’s second planned acquisition announced in nearly four months—is designed to marry UNP’s macrocyclic peptide discovery platform with Argenx’s immunology innovation capabilities to broaden the buyer’s ability to develop oral or long-acting treatments for serious immune-mediated diseases. The buyout would transform Argenx from a minority stakeholder in privately held UNP to the sole owner of its shares.</p>
<p>Argenx is looking to diversify its pipeline beyond its antibody-based portfolio, which is led by the blockbuster franchise consisting of marketed drugs Vyvgart<sup>®</sup> (efgartigimod alfa-fcab) injection, indicated to treat adults with generalized myasthenia gravis (gMG); and Vyvgart Hytrulo<sup>®</sup> (efgartigimod alfa and hyaluronidase-qvfc), a subcutaneous treatment combination of the neonatal Fc receptor inhibitor (FcRn) and endoglycosidase that is indicated for gMG and chronic inflammatory demyelinating polyneuropathy (CIDP).</p>
<p>The Vygart/Vyvgart Hytrulo franchise generated $4.534 billion in net product sales during the first nine months of 2026—up 58% from $2.866 billion in January-September a year ago. During the third quarter, Argenx racked up $1.721 billion, up 53% from $1.127 billion in Q3 2025.</p>
<p>“Our ambition is to be the leading immunology innovation company, and as Argenx builds its next chapter, we are investing with discipline where it will count the most for patients,” Argenx CEO Karen Massey said in a statement.</p>
<h4><strong>‘Shots on goal’</strong></h4>
<p>Argenx’s acquisition of UNC builds on a <a href="https://www.genengnews.com/topics/drug-discovery/unnatural-products-argenx-partner-on-macrocyclic-peptides-for-immune-disease/" target="_blank" rel="noopener">collaboration launched in July 2025</a> to develop immunology drugs: “What the platform’s about is being able to take smart shots on goal” in order to “find a successful hypothesis to weave your way through that chemical landscape to a development candidate,” Cameron Pye, PhD, UNP’s CEO and co-founder, told <em>GEN</em>.</p>
<p>The partners agreed to apply UNP’s drug discovery platform, which combines AI-guided compound design, massively parallel synthesis, and direct-to-biology screening capabilities. UNP agreed to conduct research and development until IND-enabling studies, with Argenx having the exclusive option to develop and commercialize products against these targets across multiple indications.</p>
<p>The companies have not disclosed details of their progress toward developing new candidates. Argenx is among UNP’s biopharma giant collaboration partners, along with:</p>
<ul>
<li><strong>BridgeBio Pharma</strong>—Undisclosed value, launched in 2024 to develop macrocyclic peptides for rare diseases and oncology.</li>
<li><strong>Novartis</strong>—Up to $1.8 billion of which $100 million was paid upfront, launched in February to develop an undisclosed cardiovascular disease program.</li>
<li><strong>Merck & Co</strong>.—Undisclosed upfront payment up to $220 million in milestone payments, launched in 2024 to develop macrocyclic candidates against an oncology therapeutic target.</li>
</ul>
<p>“After working together for more than two years, we also know there is a strong fit in how we work: science first, entrepreneurial and focused on patients,” Massey added. “We want to preserve what has made UNP successful while bringing the strengths of both teams together.”</p>
<p>Argenx shares traded on Euronext Brussels rose modestly on news of the deal, climbing nearly 5% Monday from €815.80 ($906.11) to €853.80 ($948.23). The company’s American depositary shares (ADSs) traded on the Nasdaq Global Select Market rose nearly 4% from $927.21 to $962.27.</p>
<p>On Tuesday, Argenx’ Euronext Brussels shares inched up another 1% to €863.40 ($958.89) as of 11:01 am ET, while its ADSs barely rose 0.21% to $964.27 in morning trading as of 11:15 am ET.</p>
<h4><strong>Skittishness and support</strong></h4>
<p>The modest stock bounce appeared to reflect lingering skittishness by investors following a pair of setbacks over the past month.</p>
<p>Argenx shares fell more than 10% on October 8 after it announced it was ending the Phase III UNITY trial (<a href="https://clinicaltrials.gov/study/NCT06684847" target="_blank" rel="noopener">NCT06684847</a>)  assessing efgartigimod subcutaneous (SC) in adults with moderate-to-severe Sjögren’s disease. Argenx followed the recommendation of UNITY’s Independent Data Monitoring Committee (IDMC) to stop the trial for futility after concluding that the study would be unable to meet its primary endpoint.</p>
<p>Then on October 23, the FDA jolted Argenx by requesting the company carry out an additional confirmatory registrational trial evaluating efgartigimod SC in dermatomyositis (DM). The agency reasoned that while Argenx showed positive overall results in the Phase II/III ALKIVIA trial (<a href="https://clinicaltrials.gov/study/NCT05523167" target="_blank" rel="noopener">NCT05523167</a>)  assessing the drug in DM, the subgroup of DM patients was too small for the results to achieve statistical significance.</p>
<p>In contrast to the investor reaction, Thomas J. Smith, senior managing director, immunology and metabolism, and a senior research analyst with Leerink Partners, voiced support for the planned acquisition.</p>
<p>“We like this deal for ARGX as it brings engineering and design capabilities to generate macrocyclic peptides (i.e., oral, long-acting, etc.), signaling confidence in oral FcRn potential and expanding on the company’s early-stage pipeline with potential for further modalities beyond specialized antibodies,” Smith wrote Monday in a research note.</p>
<p>“We believe the deal represents potential for longer-term strategic value given both I&I and large pharma’s focus on oral and long-acting therapeutics capable of driving enhanced efficacy with improved convenience vs. conventional biologics,” Smith added.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>Pye and Joshua Schwochert, PhD, co-founded UNP in 2016, launching the company in a garage on the west side of Santa Cruz, CA, during their final year of doctoral research in the <a href="https://lokey.chemistry.ucsc.edu/members/slokey_picture/" target="_blank" rel="noopener">lab of Scott Lokey, PhD, at the University of California, Santa Cruz</a>. Lokey’s research group focuses on understanding the relationship of stereochemistry and N-Methylation patterns pertaining to cell permeability, as well as applying the relationship to create diverse and permeable drug scaffolds with exquisite selectivity that constrained peptides can offer.</p>
<p>UNP raised $32 million in a Series A financing completed in 2023 and led by Merck Global Health Innovation Fund and TechBio-focused ARTIS Ventures.</p>
<h4><strong>Second acquisition</strong></h4>
<p>If the deal is completed as planned, UNC would be Argenx’s second acquisition this year. The first is Forte Biosciences, a developer of targeted immunotherapies for autoimmune and autoimmune-related diseases. Argenx on August 27 completed its <a href="https://www.genengnews.com/topics/translational-medicine/argenx-expands-immunology-portfolio-with-2-2b-buyout-of-forte-biosciences/" target="_blank" rel="noopener">up to $2.2 billion acquisition of Forte</a>, in a deal also intended to expand the buyer’s immunology portfolio with a pipeline led by FB102, a first-in-class anti-CD122 monoclonal antibody that has shown promising early clinical stage data.</p>
<p>Argenx agreed to acquire UNP for $550 million in upfront cash, plus up to $595 million in payments tied to achieving specified development and regulatory milestones.</p>
<p>The boards of both companies have approved the transaction, which is expected to be completed by year’s end subject to customary closing conditions.</p>
<p>Following closing of the deal, UNP’s staff and leadership will continue to operate from its Santa Cruz, CA, site, which will serve as Argenx’s hub for peptide discovery. UNP will continue to lead its discovery work within a strategic framework agreed upon with Argenx, which will bring clinical development and commercialization capabilities to advance peptide treatments to patients.</p>
<p>“Today is a tremendous milestone for UNP and a testament to the exceptional work of our scientists, employees, collaborators and supporters,” CEO Pye stated. “From the earliest days, we believed our platform had the potential to redefine what is possible in the discovery and design of new medicines. I am so proud of what our team has accomplished and believe Argenx provides the ideal environment to accelerate and amplify that vision to bring innovative therapies to patients.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/argenx-expands-immunology-capabilities-with-up-to-1-15b-unp-acquisition/">Argenx Expands Immunology Capabilities with Up-to-$1.15B UNP Acquisition</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Automation a Path to Lower Cell Therapy Costs</title>
<link>https://edusehat.com/en/automation-a-path-to-lower-cell-therapy-costs</link>
<guid>https://edusehat.com/en/automation-a-path-to-lower-cell-therapy-costs</guid>
<description><![CDATA[ Australian developer Currus Bio predicts that automating the production of its candidate cancer cell therapy, CUR-001, using the Cocoon platform will reduce costs and enhance its ability to scale production as the product moves through trials.
The post Automation a Path to Lower Cell Therapy Costs appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2022/08/GettyImages-1320590180small-1024x738.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 11 Nov 2026 02:50:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Automation, Path, Lower, Cell, Therapy, Costs</media:keywords>
<content:encoded><![CDATA[<p>Australian developer Currus Biologics says automating the production process for CUR-001, a candidate cell therapy for solid tumors, has significantly reduced the amount of viral vector required to make the product.</p>
<p>CEO Sam Cobb shared <a href="https://finance.yahoo.com/healthcare/articles/octane-biotech-currus-biologics-automate-210000192.html" target="_blank" rel="noopener">details</a> of the project this week, telling <em>GEN</em> that, in a bid to minimize manual handling requirements, the firm transferred the existing CUR-001 manufacturing process to the Cocoon automated production platform.</p>
<p>“This involved optimizing several key manufacturing parameters, including the amount of lentiviral vector required for transduction, cell densities during seeding and transduction, and the use of different starting materials.</p>
<p>“Importantly,” she continues, “this optimization enabled us to reduce the amount of lentiviral vector required for manufacturing, which has the potential to significantly reduce manufacturing costs.</p>
<p>“The objective was not to change the fundamental biology of CUR-001, but to establish a more consistent, reproducible, and efficient manufacturing process that can support future clinical and commercial development.”</p>
<p>The optimized process has now been transferred to Melbourne-based contract manufacturer, Cell Therapies (CTPL), which will produce CUR-001 for Currus’ planned Phase I clinical trial program.</p>
<p>The process automation project was supported by Swiss CDMO Lonza, which until recently owned a controlling stake in the Cocoon platform, and Octane Biotech, the original developer that re-acquired the technology in March.</p>
<h4><strong>Scale-up benefits</strong></h4>
<p>Automating the CUR-001 production process is also likely to aid Currus and its manufacturing partners as the cell therapy moves through clinical development toward commercial launch, Cobb says.</p>
<p>“One of the advantages of the Cocoon platform is its modular design, which allows manufacturing capacity to be expanded by adding additional units rather than fundamentally changing the manufacturing process.</p>
<p>“A final decision on commercial manufacturing will depend on clinical outcomes, regulatory requirements, anticipated patient demand, manufacturing capacity, and commercial economics,” she says.</p>
<h4><strong>Automation advantages</strong></h4>
<p>Process automation is likely to become more common in CAR T cell therapy manufacturing, but the widespread use of fully autonomous processes is unlikely, according to Cobb.</p>
<p>“One of the major barriers to broader adoption of autologous CAR T cell therapies is the complexity and cost of manufacturing individual patient batches. Automation provides a way to address both challenges while improving process standardization.”</p>
<p>Some core parts of cell therapy production can already be automated, with things like cell selection, activation, genetic modification, expansion, and harvest being the obvious examples.</p>
<p>However, other aspects of production—material collection, sampling quality control, batch review and release, cryopreservation, and distribution—may prove harder to automate, Cobb says.</p>
<p>“Some of these activities may also become increasingly automated, but I do not think fully autonomous manufacturing is a prerequisite for achieving meaningful improvements in efficiency,” she adds.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/automation-a-path-to-lower-cell-therapy-costs/">Automation a Path to Lower Cell Therapy Costs</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Extracellular Vesicle Product Developer Creates Potency Assay</title>
<link>https://edusehat.com/en/extracellular-vesicle-product-developer-creates-potency-assay</link>
<guid>https://edusehat.com/en/extracellular-vesicle-product-developer-creates-potency-assay</guid>
<description><![CDATA[ A company developing extracellular vesicle-based products has developed a potency assay for quality control. They hope to adapt it for future products and scale it to commercial manufacturing.
The post Extracellular Vesicle Product Developer Creates Potency Assay appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Vivienne-Evox-Neurons-and-EVs-image.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 11 Nov 2026 02:50:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Extracellular, Vesicle, Product, Developer, Creates, Potency, Assay</media:keywords>
<content:encoded><![CDATA[<p>Developing potency assays for complex new biologics, such as extracellular vesicle (EV)-based products, can be a challenge, with some manufacturers putting it off until regulators ask hard questions. That’s the view of Evox Therapeutics, who say they’ve succeeded in developing a potency assay that can be hopefully adapted to multiple future products in their pipeline.</p>
<p>According to Rebecca Gavin, PhD, chemistry, manufacturing, and controls (CMC) director at Evox, the assay has already been pre-qualified and transferred into a quality control (QC) laboratory.</p>
<p>The company hopes it can be fully qualified during a planned first-in-human study next year and, in the future, be used for batch QC during commercial production of their products.</p>
<p>“Our product is quite complex, and that’s why people often struggle to develop a potency assay,” Gavin says.</p>
<p>“Sometimes CMC can get kicked down the road a little, with people thinking they’ll worry about it later when they have more funding, so [the fact] that we’ve developed one already is something we’re really proud of.”</p>
<p>Evox’s product encapsulates a ribonucleoprotein (RNP) within an EV that is used as the delivery mechanism. The RNP is coupled to a guide RNA, which targets a specific gene with the aim of reducing protein production, Gavin explains.</p>
<p>Although this could spur lots of complex questions, such as whether the EV is taken up by the cell and whether the editing machinery makes it to the nucleus, she says that this can lead to over-characterization and over-testing.</p>
<p>“You don’t want to have a batch release assay panel that’s 50 assays long, where you’re having to measure and quantify every aspect of a complex product, and need to dedicate 50% of your batch to testing, especially in the gene therapy field where batch yields are already tricky,” she explains.</p>
<p>To get around this, the company developed an assay that simply measures potency, thereby demonstrating that the product is being successfully assembled and delivered to a cell.</p>
<p>The assay doses EV products at different concentrations onto an immortalized adherent cell line, she says. The cells are allowed to grow for a while, and then the cell lysates are tested on a Jess Simple Western system.</p>
<p>“We get a very specific quantitative readout, and that allows us to determine a dose-response curve, which shows how active our product is at reducing our protein of interest,” she explains.</p>
<p>Going forward, the company hopes this simple potency assay can be fully qualified for commercial production and adapted for multiple products in their pipeline.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/extracellular-vesicle-product-developer-creates-potency-assay/">Extracellular Vesicle Product Developer Creates Potency Assay</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Hybrid Model Captures Lactate Run&#45;Away and Back&#45;Metabolism</title>
<link>https://edusehat.com/en/hybrid-model-captures-lactate-run-away-and-back-metabolism</link>
<guid>https://edusehat.com/en/hybrid-model-captures-lactate-run-away-and-back-metabolism</guid>
<description><![CDATA[ A hybrid model provides hard-to-achieve insights into lactate performance during bioprocessing, creating conditions for more accurate predictions to better manage key batch parameters and variability.
The post Hybrid Model Captures Lactate Run-Away and Back-Metabolism appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Dutton-Gemini_Generated_Image_xq337mxq337mxq33.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 11 Nov 2026 02:50:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Hybrid, Model, Captures, Lactate, Run-Away, and, Back-Metabolism</media:keywords>
<content:encoded><![CDATA[<p>A new hybrid mechanistic-data-driven model of lactate consumption and production for mammalian cell cultures captures both lactate back-metabolism and lactate run-away. It also provides accurate real-time predictions of viable cell density, monoclonal antibody, glucose, and lactate concentrations during bioprocessing, according to researchers from University College London and AstraZeneca.</p>
<p>For biopharmaceutical manufacturers, this model, outlined in a recent <a href="https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/full/10.1002/bit.70417" target="_blank" rel="noopener">paper</a>, provides another tool to accurately predict batch-to-batch variability and failing runs early in the process, according to a team led by principal investigator Li Qin, PhD, postdoctoral research fellow, and senior researcher Stephen Goldrick, PhD, associate professor, digital bioprocess engineering, both at University College London.</p>
<p>By fine-tuning the initial model, the team improved upon the original 88% accuracy rate, reducing the root mean squared error by about 50% for glucose and by about 30% for lactate.</p>
<p>“This model addresses a key industrial challenge,” Goldrick tells <em>GEN</em>. “In fed-batch CHO cultures, cells normally switch from lactate production to lactate back-metabolism. If they do not, the culture goes into lactate run-away, which can cause batch failure or a significantly lower titer. This switch is poorly understood and rarely controlled.”</p>
<p>Therefore, a lactate switch detection algorithm is one of the key features of this model. As Goldrick explains, “Our model uses pH as a soft sensor to detect early, at around day 5, whether the cells will undergo lactate back-metabolism. This information could be built into the control strategy, so the process can be adjusted to avoid lactate run-away.”</p>
<h4><strong>Stratifying parameters</strong></h4>
<p>The novelty of this approach is three-fold, they say, encompassing “new kinetic equations to accurately describe Chinese hamster ovary cell growth and death dynamics…new equations for lactate production and consumption…to better capture metabolic transitions under varying process conditions…and adaptive kinetic updating integrated with a lactate-switch detection algorithm to incorporate online and offline measurements into the model dynamically.”</p>
<p>The model was trained with online data such as pH values, glucose flow rates, and other nutrient feeds combined with historical data such as concentrations of glucose, lactate, and mAb concentrations as well as cell densities accumulated from random runs. The team trained the model on five runs that switched from producing lactate to consuming it (called back-metabolism), three to evaluate predictive performance, one that exhibited lactate run-away (in which the cell culture continued producing lactate), and one external lactate run-away scenario.</p>
<p>That combination helped the researchers determine which parameters could be predicted accurately with online data and which highly variable parameters needed to be fine-tuned using a combination of real-time and historic data. “This targeted strategy significantly reduces model update time compared to full recalibration, while maintaining predictive accuracy,” they note.</p>
<p>Ten is a relatively small number of training runs, the scientists admit, but the values predicted by the model in those runs closely matched those of actual measured values, suggesting this model can make a real contribution to the industry. Further work will extend the measured production values to include amino acid consumption, ammonia accumulation, osmolality dynamics, and product quality attributes.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/hybrid-model-captures-lactate-run-away-and-back-metabolism/">Hybrid Model Captures Lactate Run-Away and Back-Metabolism</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>From Farm Waste to Medical Nanoparticles</title>
<link>https://edusehat.com/en/from-farm-waste-to-medical-nanoparticles</link>
<guid>https://edusehat.com/en/from-farm-waste-to-medical-nanoparticles</guid>
<description><![CDATA[ Fruit peels, rice husks, and other crop leftovers can yield biomedical nanoparticles, but variable feedstocks, scale-up hurdles, and thin safety data still stand between lab promise and reliable commercial bioprocessing.
The post From Farm Waste to Medical Nanoparticles appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Mike-Pandey-bionanomaterials_GBPN_IMAGE_12NOV26.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 11 Nov 2026 02:50:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>From, Farm, Waste, Medical, Nanoparticles</media:keywords>
<content:encoded><![CDATA[<p>The world’s farms produce a mountain of leftovers every year—more than six billion tons of crop residues in 2020 alone, by one estimate. Much of it is burned or buried. A new review argues that a good share could instead become raw material for biomedical nanoparticles.</p>
<p>Writing in <a href="https://doi.org/10.3389/fbiom.2026.1831334" target="_blank" rel="noopener"><em>Frontiers in Biomaterials Science</em></a>, a team led by Sadanand Pandey, PhD, professor in the School of Bioengineering and Food Technology at Shoolini University in Solan, India, surveyed research from 2015 to 2026 on turning agricultural waste into metallic, polymeric, and carbon-based nanostructures. The picture is promising but unfinished.</p>
<p>The appeal rests on the chemistry the plants have already done. Peels, husks, seeds, and pomace are packed with polyphenols, flavonoids, and polysaccharides that can reduce metal ions and coat the resulting particles, replacing harsh chemical reagents. Silica-rich rice and wheat husks are favored sources of silica nanoparticles, while sugarcane bagasse supplies abundant cellulose.</p>
<p>The studies the authors compiled point to a range of uses. Silver nanoparticles made with pomegranate peel extract inhibited <em>E. coli</em> at 16 µg/mL. Zinc oxide particles produced with banana peels broke down 90% of a test dye within two hours and fought <em>Staphylococcus aureus</em> biofilms. Carbon dots made from fruit and vegetable scraps glow brightly enough for imaging and appear far less toxic than conventional semiconductor quantum dots.</p>
<p>The process economics look attractive too. One study cited in the review reported that biologically mediated synthesis cut energy use by 30% and costs by 40% while raising output by 50% compared with conventional methods.</p>
<p>But the authors are frank about what stands in the way, and much of it is a familiar bioprocessing problem: raw-material variability. A banana peel’s chemistry depends on the variety, growing conditions, harvest date, and how the waste was handled. Those differences carry through to particle size, shape, surface charge, and stability, making batch-to-batch consistency hard to guarantee.</p>
<p>Scale-up adds more friction. Green reactions tend to run slower than chemical ones, and lignocellulosic feedstocks often need pretreatment, which can erode cost savings. Without standard protocols for synthesis, purification, and characterization, regulators have little to benchmark against. Long-term <em>in vivo</em> safety data are also thin, and risks such as oxidative stress and bioaccumulation need systematic study before any clinical use.</p>
<p>To close those gaps, the team calls for standardized methods, scalable biorefinery models, and tools such as AI-assisted metabolomic analysis to fine-tune the process. If those pieces fall into place, today’s crop waste could become a dependable supply chain for tomorrow’s nanomedicine.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/from-farm-waste-to-medical-nanoparticles/">From Farm Waste to Medical Nanoparticles</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>How Breast Cancer Chemotherapy May Impact Biological Aging and Loss of Healthy Life Years</title>
<link>https://edusehat.com/en/how-breast-cancer-chemotherapy-may-impact-biological-aging-and-loss-of-healthy-life-years</link>
<guid>https://edusehat.com/en/how-breast-cancer-chemotherapy-may-impact-biological-aging-and-loss-of-healthy-life-years</guid>
<description><![CDATA[ Chemotherapy helps many women survive breast cancer, but the results of new research suggest that chemotherapy may also accelerate biological aging beyond chronological age and increase the risk of earlier death from other causes. 
The post How Breast Cancer Chemotherapy May Impact Biological Aging and Loss of Healthy Life Years appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2020/09/Sep29_2020_Getty_1181263174_DoctorAndPatient-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 11 Nov 2026 02:50:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>How, Breast, Cancer, Chemotherapy, May, Impact, Biological, Aging, and, Loss, Healthy, Life, Years</media:keywords>
<content:encoded><![CDATA[<p>Chemotherapy helps many women survive breast cancer, but the results of new research suggest that chemotherapy may also accelerate biological aging beyond chronological age and increase the risk of earlier death from other causes.  The study, by researchers at Georgetown University’s Lombardi Comprehensive Cancer Center and colleagues, is the first to estimate the lifetime balance of the benefits of curing breast cancer versus possible acceleration of biological aging using population-based simulation modeling. The findings point to a need to explore whether interventions to slow or reverse biological aging could improve long-term health for breast cancer survivors.</p>
<p>“Female breast cancer survivors comprise the single largest segment of the 18.6 million cancer survivors in the United States, said Jeanne Mandelblatt, MD, MPH, director of the Georgetown Lombardi’s Institute for Cancer and Aging Research (I-CARE). “However, some forms of chemotherapy that extend survival have triggered a secondary crisis: treatment-induced molecular damage to the body’s cells and organs, causing acceleration of biological age.” Mandelblatt notes that this accelerated biological aging can result in loss of healthy life years due to earlier onset of aging diseases and conditions like frailty and cognitive problems. “Chemotherapy-induced biologic aging can persist for years, and the effects of this acceleration are not visible for many years.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>Senior author Mandelblatt, together with first and corresponding author Swarnavo Sarkar, PhD, a member of I-CARE at Lombardi, and colleagues reported their findings in <em>JAMA Open Network</em>, titled “<a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2856363?resultClick=3" target="_blank" rel="noopener">Chemotherapy-Induced Biological Age Acceleration and Lifetime Outcomes in Breast Cancer Survivors</a>.” In their report the investigators concluded “These findings suggest that integrating knowledge about biological aging into survivorship care may help identify opportunities to deploy pharmaceutical and behavioral interventions that target aging-related processes.”</p>
<p>While breast cancer survival rates have been steadily increasing over time due to advances in screening and therapeutics, growing evidence also suggests that some breast cancer survivors may experience long-term toxic effects of chemotherapy, including accelerated aging (biological age in excess of chronological age), the authors wrote. This may be associated with the development of chronic aging-related diseases such as cardiovascular disease and diabetes.</p>
<p>“One mechanism by which chemotherapy accelerates aging is through increases in the accumulation of senescent cells, defined as cells that have stopped dividing but are resistant to cell death,” the team continued. “These cells promote further aging through changes in tissue modeling and inflammation, contributing to excess non–breast cancer morbidity and mortality.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>To investigate the potential long-term effect of cancer therapy on the biological aging of breast cancer survivors the team carried out a comparative effectiveness study that used an established population-level simulation model, and current data on chemotherapy’s effects on cellular senescence. “This comparative effectiveness study used an established Cancer Intervention and Surveillance Modeling Network breast cancer model integrating biological aging with breast cancer epidemiology,” they wrote.</p>
<p>The investigators used data about the relationships between chemotherapy and blood levels of the <em>p16 </em>protein, a common biomarker of senescence, to estimate the biological age of breast cancer survivors over their remaining lives. “Biological aging was modeled using data on distributions of post-chemotherapy senescence measured by <em>p16<sup>INK4a</sup></em> levels, and the model assumed chemotherapy-induced senescence only affected non–breast cancer mortality,” they explained. The <em>p16</em> protein levels were used for this study because there is good data from published research and there is evidence from the lab that clearing <em>p16</em>-rich cells could increase their lifespan. There are also evolving studies of other biological aging markers that could be used in future studies.</p>
<p>The population simulation model the researchers developed was based on women who were 30 to 79 years of age; the model compared the effects of types of chemotherapy that caused more vs. less cellular damage (i.e., cytotoxic) and biological age acceleration. Breast cancer survivors who received the most cytotoxic anthracycline regimens were estimated to have lost 9.4 remaining life years on average due to earlier onset of aging-related diseases. “Survivors diagnosed at early ages and/or treated with the most cytotoxic regimens were projected to have the greatest biological age acceleration, with increased risk of death from non–breast cancer causes at earlier chronological ages than expected in general populations,” the researchers stated.</p>
<p>Sarkar added. “The key to our methodology is accounting for the fact that while chemotherapy improves breast cancer survival, treatment can also increase damage to normal tissues. This affects many aging systems, including increasing the number of senescent cells, which are damaged cells that have stopped dividing and are also resistant to cell death. Senescent cells secrete biological molecules that cause several aging-related diseases through added tissue damage and inflammation.”</p>
<p>The data analysis was possible because both Mandelblatt and Sarkar are members of CISNET (Cancer Intervention and Surveillance Modeling Network), a 25-year-old consortium of National Cancer Institute-sponsored investigators who use simulation modeling to improve the understanding of cancer prevention, screening, and treatment and their effects on population trends in incidence and mortality.</p>
<p>While treatment choices will always be based on the potential to cure, Mandelblatt hopes that the model results can be used to guide future studies evaluating the benefits of testing biological age after treatment ends. “Since the goal of treatment is to improve breast cancer survival, oncologists should not modify treatment decisions based on potential for accelerated aging, but our results suggest the need for awareness of possible age acceleration,” the researchers pointed out.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>The goal would be to provide personalized survivorship care to mitigate any aging effects of therapy and improve quality of life and health over a survivor’s lifetime. This is particularly salient now, Mandelblatt noted, since physical activity and medications being used for other purposes show promise in slowing accelerated aging in breast and other cancer survivors, which may recoup the loss of life years estimated in this study.</p>
<p>And as the authors also stated, more research is needed to test the impact of biological age assessment and management of biological age acceleration on survivorship outcomes. “Knowledge about the risks of accelerated aging among women exposed to chemotherapy may help motivate lifestyle changes,” they stated. “Further, as evidence on the safety and utility of senolytic and other anti-aging drugs evolves, modeling may help identify populations of survivors at risk for age acceleration who might benefit from pharmacologic intervention.”</p>
<p>Sarkar added, “There are two next steps we are planning, the first being expanding the scope of this methodology for other types of breast cancer treatments, such as radiotherapy, immunotherapies, targeted therapies and hormonal treatments, which also appear to speed up aging, with effects potentially lasting for many years after treatment. We also plan to include information about survivor characteristics to help guide future conversations about individual outcomes.”</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/how-breast-cancer-chemotherapy-may-impact-biological-aging-and-loss-of-healthy-life-years/">How Breast Cancer Chemotherapy May Impact Biological Aging and Loss of Healthy Life Years</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The Physicians Foundation Celebrates Graduation of Inaugural Leadership Institute Cohort at Brandeis University</title>
<link>https://edusehat.com/en/the-physicians-foundation-celebrates-graduation-of-inaugural-leadership-institute-cohort-at-brandeis-university</link>
<guid>https://edusehat.com/en/the-physicians-foundation-celebrates-graduation-of-inaugural-leadership-institute-cohort-at-brandeis-university</guid>
<description><![CDATA[ 25 physicians from across the country complete a transformative leadership program designed to strengthen physician leadership, influence health policy, and drive meaningful change in healthcare for their patients. BOSTON, November 10, 2026 — The Physicians Foundation proudly announces the graduation of the inaugural cohort of The Physicians Foundation Leadership Institute (PFLI) at The Heller School […]
The post The Physicians Foundation Celebrates Graduation of Inaugural Leadership Institute Cohort at Brandeis University appeared first on The Physicians Foundation. ]]></description>
<enclosure url="https://physiciansfoundation.org/wp-content/themes/physicians-foundation/assets/build/images/admin/defaults/default-image.webp" length="49398" type="image/jpeg"/>
<pubDate>Wed, 11 Nov 2026 02:20:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, Physicians, Foundation, Celebrates, Graduation, Inaugural, Leadership, Institute, Cohort, Brandeis, University</media:keywords>
<content:encoded><![CDATA[<p class="wp-block-paragraph"><em><em><em><em>25 physicians from across the country complete a transformative leadership program designed to strengthen physician leadership, influence health policy, and drive meaningful change in healthcare for their patients.</em></em></em></em></p>



<p class="wp-block-paragraph"><strong>BOSTON, November 10, 2026</strong> — The Physicians Foundation proudly announces the graduation of the inaugural cohort of The Physicians Foundation Leadership Institute (PFLI) at <a href="https://heller.brandeis.edu/">The Heller School for Social Policy and Management at Brandeis University.</a> The program brought together 25 physicians from across the country to develop their leadership skills, deepen their understanding of health policy and management, and strengthen their ability to advocate for patients and elevate the physician perspective in healthcare decisions.</p>



<p class="wp-block-paragraph">Launched to empower practicing physicians to become more influential leaders within their organizations, communities, and the broader healthcare system, PFLI offers a unique opportunity to expand physicians’ impact beyond the exam room. Through two in-person residencies, monthly virtual learning sessions, and peer coaching, participants strengthened their understanding of healthcare policy, organizational leadership, and key drivers of health impacting patients. They developed skills to elevate the physician perspective in healthcare decision-making, helping to shape policies and systems to better serve patients.</p>



<p class="wp-block-paragraph">“Physicians bring invaluable firsthand perspectives to the challenges facing our healthcare system, and their voices must be central to shaping its future,” said <a href="https://physiciansfoundation.org/team/dr-gary-price/">Dr. Gary Price,</a> president of The Physicians Foundation, “The inaugural Leadership Institute cohort represents an extraordinary group of physicians who have demonstrated a commitment not only to advancing their own leadership skills, but also to creating meaningful change for their patients, colleagues, and communities. We are incredibly proud of their accomplishments and look forward to the impact they will make across healthcare.”</p>



<p class="wp-block-paragraph">Beyond the program’s formal curriculum, PFLI fostered a national network of physician leaders united by a shared commitment to improving healthcare. Graduates leave the program with new perspectives, meaningful professional connections and a community of colleagues who will continue to collaborate, exchange ideas and support one another as they advance in their leadership journeys.</p>



<p class="wp-block-paragraph">The Physicians Foundation congratulates the following 25 physicians who completed the inaugural Leadership Institute cohort:</p>



<ul class="wp-block-list">
<li>Hans Chin Arora, MD, PhD (North Carolina)</li>



<li>Jeffrey Paul Cashman, DO (South Carolina)</li>



<li>M. Mayes DuBose, MD (South Carolina)</li>



<li>Nefertiti duPont, MD, MPH (Texas)</li>



<li>Kennedy Ganti, MD, FAAFP, FHELA (New Jersey)</li>



<li>Casey Gokey, MD (Alaska)</li>



<li>Kristin Lynch Grimes, DO (Louisiana)</li>



<li>Donaldo M. Hernandez, MD, FACP (California)</li>



<li>Joseph Maxwell Hendrix, MD, MBA, MS (Texas)</li>



<li>Cynthia Jumper, MD (Texas)</li>



<li>Albert Li, MD, FASRS (New Jersey)</li>



<li>Ashley Lucas, MD, FAAP (Louisiana)</li>



<li>John J. Meier IV, MD, MBA (North Carolina)</li>



<li>Sheila Marie Magoon, MD (Texas)</li>



<li>Mirna Mohanraj, MD (New York)</li>



<li>Sergio Bennett Navarrete, DO (Virginia)</li>



<li>Julie Nguyen, MD (Texas)</li>



<li>Jubril Oyeyemi, MD, FHELA (New Jersey)</li>



<li>Bradford Patt, MD, FACS (Texas)</li>



<li>Jillian Ploof, DO (Louisiana)</li>



<li>Kinga Porter, DO (Florida)</li>



<li>Joseph Aryeh Rosenbaum, MD (New Jersey)</li>



<li>Meghan Schott, DO, DFAACAP, FAPA (Utah)</li>



<li>Rajamalliga N. Lee Sharma, MD, MA (Alabama)</li>



<li>Nancy Jane Wright, MD, FAAP (New Mexico)</li>
</ul>



<p class="wp-block-paragraph">The completion of this inaugural cohort marks an important milestone in The Physicians Foundation’s ongoing commitment to advance physician leadership and ensure physician perspectives are represented in decisions shaping healthcare. Through PFLI, the Foundation is helping to prepare physician leaders to drive meaningful change across the healthcare system, strengthen the practice environment, and ultimately improve care for patients. Learn more about The Physicians Foundation Leadership Institute, <a href="https://physiciansfoundation.org/brandeis-leadership-institute/"><em>here.</em></a></p>



<h3 class="wp-block-heading"><strong>About The Physicians Foundation </strong></h3>



<p class="wp-block-paragraph">The Physicians Foundation is a public charity seeking to advance the work of practicing physicians and help them facilitate the delivery of high-quality health care to patients. As the U.S. health care system continues to evolve, The Physicians Foundation is steadfast in strengthening the physician-patient relationship, supporting medical practices’ sustainability and helping physicians navigate the changing health care system. The Physicians Foundation pursues its mission through research, education and innovative grant making that improves physician wellbeing, strengthens physician leadership, addresses drivers of health and lifts physician perspectives. For more information, visit <a href="https://www.physiciansfoundation.org/">www.physiciansfoundation.org</a>.</p>
<p>The post <a href="https://physiciansfoundation.org/the-physicians-foundation-celebrates-graduation-of-inaugural-leadership-institute-cohort-at-brandeis-university/">The Physicians Foundation Celebrates Graduation of Inaugural Leadership Institute Cohort at Brandeis University</a> appeared first on <a href="https://physiciansfoundation.org/">The Physicians Foundation</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Canadian healthcare spending projected to reach $433 billion in 2026</title>
<link>https://edusehat.com/en/canadian-healthcare-spending-projected-to-reach-433-billion-in-2026</link>
<guid>https://edusehat.com/en/canadian-healthcare-spending-projected-to-reach-433-billion-in-2026</guid>
<description><![CDATA[ New CIHI figures show hospital expenditures rising 5.1 per cent as workforce costs, capacity pressures and investments in healthcare delivery continue to shape spending across Canada. Canada’s total healthcare spending is projected to reach $433 billion in 2026, an increase of 4.8 per cent over the previous year, according to new figures released by the […]
The post Canadian healthcare spending projected to reach $433 billion in 2026 appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/11/shutterstock_2765591399.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 10 Nov 2026 23:10:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Canadian, healthcare, spending, projected, reach, 433, billion, 2026</media:keywords>
<content:encoded><![CDATA[<p>New CIHI figures show hospital expenditures rising 5.1 per cent as workforce costs, capacity pressures and investments in healthcare delivery continue to shape spending across Canada.</p>
<p>Canada’s total healthcare spending is projected to reach $433 billion in 2026, an increase of 4.8 per cent over the previous year, according to new figures released by the Canadian Institute for Health Information (CIHI).</p>
<p>The latest National Health Expenditure Trends report, published November 10, estimates that healthcare spending will account for 12.8 per cent of Canada’s gross domestic product (GDP), equivalent to approximately $10,398 per Canadian.</p>
<p>Although overall spending growth has moderated from the increases recorded in recent years, healthcare expenditures continue to rise faster than the broader economy.</p>
<p>For Canadian hospitals, the findings highlight ongoing pressures associated with workforce compensation, service demand and investments in healthcare capacity.</p>
<h2><img fetchpriority="high" decoding="async" class="alignnone size-full wp-image-146842" src="https://www.hospitalnews.com/wp-content/uploads/2026/11/Buenas-practicas-en-la-institucionalizacion-de-las-cuentas-de-salud_-Componentes-de-la-institucionalizacion-de-las-cuentas-de-salud-_-OECD.jpg" alt="" width="1000" height="795" srcset="https://www.hospitalnews.com/wp-content/uploads/2026/11/Buenas-practicas-en-la-institucionalizacion-de-las-cuentas-de-salud_-Componentes-de-la-institucionalizacion-de-las-cuentas-de-salud-_-OECD.jpg 1000w, https://www.hospitalnews.com/wp-content/uploads/2026/11/Buenas-practicas-en-la-institucionalizacion-de-las-cuentas-de-salud_-Componentes-de-la-institucionalizacion-de-las-cuentas-de-salud-_-OECD-400x318.jpg 400w, https://www.hospitalnews.com/wp-content/uploads/2026/11/Buenas-practicas-en-la-institucionalizacion-de-las-cuentas-de-salud_-Componentes-de-la-institucionalizacion-de-las-cuentas-de-salud-_-OECD-768x611.jpg 768w, https://www.hospitalnews.com/wp-content/uploads/2026/11/Buenas-practicas-en-la-institucionalizacion-de-las-cuentas-de-salud_-Componentes-de-la-institucionalizacion-de-las-cuentas-de-salud-_-OECD-528x420.jpg 528w, https://www.hospitalnews.com/wp-content/uploads/2026/11/Buenas-practicas-en-la-institucionalizacion-de-las-cuentas-de-salud_-Componentes-de-la-institucionalizacion-de-las-cuentas-de-salud-_-OECD-150x119.jpg 150w, https://www.hospitalnews.com/wp-content/uploads/2026/11/Buenas-practicas-en-la-institucionalizacion-de-las-cuentas-de-salud_-Componentes-de-la-institucionalizacion-de-las-cuentas-de-salud-_-OECD-300x239.jpg 300w, https://www.hospitalnews.com/wp-content/uploads/2026/11/Buenas-practicas-en-la-institucionalizacion-de-las-cuentas-de-salud_-Componentes-de-la-institucionalizacion-de-las-cuentas-de-salud-_-OECD-696x553.jpg 696w" sizes="(max-width: 1000px) 100vw, 1000px"></h2>
<h2>Hospital spending expected to rise 5.1 per cent</h2>
<p>Hospitals remain the largest category of healthcare expenditure in Canada, accounting for a projected 25.6 per cent of total spending in 2026.</p>
<p>Hospital expenditures are expected to increase by 5.1 per cent this year, compared with growth of 4.3 per cent in 2025 and 7.0 per cent in 2024.</p>
<p>Employee compensation continues to represent the largest expense for hospitals, accounting for approximately two-thirds of total hospital spending.</p>
<p>According to CIHI’s hospital spending data, compensation costs increased by 7.5 per cent to $53.9 billion in 2024–2025. During the same period, the number of full-time equivalent hospital employees increased by 9.2 per cent, representing the largest annual workforce expansion in decades.</p>
<p>It was the first time since 2010–2011 that hospital workforce growth exceeded compensation growth, suggesting that hospitals are expanding staffing capacity while increases in labour costs begin to moderate.</p>
<p>However, hospitals continue to face elevated costs related to private agency staffing, overtime and sick leave. Although growth in these expenses has slowed from post-pandemic peaks, costs remain above pre-pandemic levels.</p>
<div>
<div></div>
</div>
<h2>Spending growth may signal greater investment in capacity</h2>
<p>One of the report’s central findings is a potential shift in the factors driving healthcare expenditure growth.</p>
<p>In recent years, rising inflation and rapid population growth absorbed a substantial portion of additional healthcare spending.</p>
<p>With those pressures beginning to ease, CIHI estimates that public-sector healthcare spending in 2026 will increase by more than $5 billion beyond what would be explained by inflation and demographic changes.</p>
<p>This suggests that a greater share of new spending may be directed toward expanding healthcare services, improving access, strengthening the workforce and investing in technology.</p>
<p>Lacey Langlois, director of Health Spending at CIHI, said the changing drivers of expenditure growth could indicate greater investment in healthcare capacity and new approaches to delivering care.</p>
<p>The report also emphasizes the importance of measuring whether additional spending produces meaningful improvements for patients.</p>
<p>While the figures suggest opportunities to strengthen the healthcare system, they do not establish that increased expenditure has already translated into improved access or clinical outcomes.</p>
<div>
<div></div>
</div>
<h2>Physician and drug spending continue to increase</h2>
<p>Beyond hospitals, physician services and prescription medications remain major components of Canada’s healthcare expenditures.</p>
<p>Physician spending is projected to account for 14.1 per cent of total healthcare spending in 2026, with expenditures increasing by 8.3 per cent.</p>
<p>The increase reflects continuing demand for physician services and persistent challenges in primary care access.</p>
<p>Drug expenditures are expected to account for nearly 13 per cent of national healthcare spending.</p>
<p>CIHI notes that workforce shortages, population aging and the increasing use of healthcare services will continue to influence spending patterns.</p>
<p>Digital health technologies, including artificial intelligence, may also affect future expenditure trends by changing how care is delivered and how clinical and administrative work is organized.</p>
<p>However, these technologies may require substantial initial investment before potential operational efficiencies can be realized.</p>
<div>
<div></div>
</div>
<h2>Rural hospitals face distinct financial pressures</h2>
<p>CIHI’s accompanying Spending Trends in Health Service Delivery report identifies important differences between urban and rural hospitals.</p>
<p>Although staffing has grown faster than Canada’s population overall, workforce expansion has been stronger in urban hospitals.</p>
<p>Rural hospitals continue to experience greater recruitment and retention challenges, often relying more heavily on overtime and agency personnel to maintain services.</p>
<p>The report also finds that inpatient and outpatient costs have increased more rapidly in rural hospitals, reflecting factors such as patient complexity, longer hospital stays and differences in service delivery.</p>
<p>Rural emergency departments frequently serve broader healthcare needs where access to primary care and other community-based services is limited.</p>
<p>These findings underscore the importance of considering regional circumstances when evaluating hospital spending and allocating healthcare resources.</p>
<div>
<div></div>
</div>
<div>
<div>
<div>
<div><img decoding="async" class="alignnone  wp-image-146841" src="https://www.hospitalnews.com/wp-content/uploads/2026/11/cihi-image.png" alt="" width="902" height="708" srcset="https://www.hospitalnews.com/wp-content/uploads/2026/11/cihi-image.png 660w, https://www.hospitalnews.com/wp-content/uploads/2026/11/cihi-image-400x313.png 400w, https://www.hospitalnews.com/wp-content/uploads/2026/11/cihi-image-536x420.png 536w, https://www.hospitalnews.com/wp-content/uploads/2026/11/cihi-image-150x118.png 149w, https://www.hospitalnews.com/wp-content/uploads/2026/11/cihi-image-300x235.png 300w" sizes="(max-width: 902px) 100vw, 902px"></div>
</div>
</div>
</div>
<p>Canada’s healthcare spending has increased substantially over the past several years, rising from $336 billion in 2022 to a projected $433 billion in 2026.</p>
<p>Public-sector funding is expected to account for approximately 71 per cent of total healthcare expenditures this year, with the remainder financed through private sources, including households and insurance.</p>
<p>CIHI projects public-sector healthcare spending growth of 5.2 per cent in 2026, even as inflation and population growth moderate.</p>
<p>For hospital leaders, the findings raise important questions about how additional resources can best support sustainable staffing, improved patient access, modernization of infrastructure and more efficient service delivery.</p>
<p>As governments and healthcare organizations continue to address system pressures, the challenge will be ensuring that higher spending translates into measurable improvements in capacity, quality and patient care.</p>
<div>
<div></div>
</div>
<p>Primary sources: <a href="https://www.cihi.ca/en/news/canadas-health-care-spending-grows-by-over-5b-above-inflation-and-demographic-pressures-in-2026?utm_source=chatgpt.com">CIHI </a></p>
<p>The post <a href="https://www.hospitalnews.com/canadian-healthcare-spending-projected-to-reach-433-billion-in-2026/">Canadian healthcare spending projected to reach $433 billion in 2026</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Jewish General Hospital advances specialized care for critically ill newborns</title>
<link>https://edusehat.com/en/jewish-general-hospital-advances-specialized-care-for-critically-ill-newborns</link>
<guid>https://edusehat.com/en/jewish-general-hospital-advances-specialized-care-for-critically-ill-newborns</guid>
<description><![CDATA[ Montreal hospital combines advanced neonatal monitoring, emergency care technology and family-centred practices to support approximately 550 premature and critically ill infants annually. The Jewish General Hospital in Montreal is highlighting how advanced medical technology, specialized nursing care and family-centred treatment are helping improve the care environment for premature and critically ill newborns. The hospital’s Karen […]
The post Jewish General Hospital advances specialized care for critically ill newborns appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/11/assets_MS2028371_000001_JGHF_NICU_1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 10 Nov 2026 23:10:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Jewish, General, Hospital, advances, specialized, care, for, critically, ill, newborns</media:keywords>
<content:encoded><![CDATA[<p>Montreal hospital combines advanced neonatal monitoring, emergency care technology and family-centred practices to support approximately 550 premature and critically ill infants annually.</p>
<p>The Jewish General Hospital in Montreal is highlighting how advanced medical technology, specialized nursing care and family-centred treatment are helping improve the care environment for premature and critically ill newborns.</p>
<p>The hospital’s Karen and Murray Dalfen Neonatal Intensive Care Unit (NICU), one of six Level 3 neonatal intensive care units in Quebec, provides specialized treatment for approximately 550 vulnerable newborns each year.</p>
<p>In an announcement issued November 10, the Jewish General Hospital Foundation outlined how investments in emergency care equipment, centralized monitoring and developmental care are supporting the hospital’s ability to manage complex, high-risk neonatal cases.</p>
<p>The unit receives patients from Montreal and regional healthcare facilities across Quebec, providing intensive care for infants requiring advanced monitoring and treatment.</p>
<div>
<div></div>
</div>
<h3>Advanced technology supports critical newborn care</h3>
<p>The hospital has introduced integrated emergency care stations designed to provide essential treatment immediately following complicated or high-risk deliveries.</p>
<p>These all-in-one stations combine radiant warming, controlled oxygen delivery and continuous monitoring of vital signs at the bedside.</p>
<p>By keeping equipment ready for immediate use, the technology is intended to reduce setup delays when newborns require urgent intervention.</p>
<p>The hospital has also implemented centralized remote monitoring across private neonatal recovery rooms.</p>
<p>This allows clinical teams to maintain continuous oversight of infants’ physiological conditions while providing families with greater privacy.</p>
<p>The combination of bedside equipment and centralized monitoring is designed to support rapid intervention, ongoing observation and more coordinated nursing care.</p>
<p>Chloé Décarie-Drolet, head nurse of the NICU and Neonatal Follow-Up Clinic, emphasized the importance of having equipment ready during critical deliveries while maintaining round-the-clock monitoring throughout an infant’s hospital stay.</p>
<h3>Supporting infants from across Quebec</h3>
<p>As a Level 3 neonatal intensive care unit, the Dalfen NICU is equipped to manage complex medical conditions and receive specialized transfers from other healthcare facilities.</p>
<p>Dr. Lajos Kovacs, chief of Pediatrics and Neonatology at the Jewish General Hospital, explained that the unit’s responsibility extends beyond stabilizing critically ill newborns.</p>
<p>The clinical team also focuses on supporting long-term development and helping infants reach important milestones before returning home.</p>
<p>Premature infants may require specialized respiratory support, nutritional management, temperature regulation and continuous observation while their organs and neurological systems continue developing.</p>
<p>The hospital’s approach combines these medical interventions with practices intended to protect early brain development and strengthen parent-infant relationships.</p>
<h3>Family-centred care plays an important role</h3>
<p>Alongside medical technology, the NICU incorporates neuroprotective developmental care into everyday clinical practice.</p>
<p>This includes reducing unnecessary noise, adjusting incubator lighting and encouraging extended skin-to-skin contact between parents and infants.</p>
<p>Specialized seating supports kangaroo care, allowing parents to hold their babies safely while maintaining close physical contact.</p>
<p>These practices are intended to create a calmer environment for developing infants and encourage parents to participate actively in their child’s care.</p>
<p>The hospital emphasizes that families are essential members of the neonatal care team, rather than simply visitors.</p>
<p>Private rooms and continuous monitoring are designed to balance clinical safety with opportunities for bonding and family involvement.</p>
<h3>A family’s experience with neonatal intensive care</h3>
<p>The hospital foundation highlighted the experience of Willow, a baby born 10 weeks prematurely after her mother developed severe preeclampsia.</p>
<p>Weighing approximately two pounds at birth, Willow required 54 days of specialized care in the Dalfen NICU.</p>
<p>Her treatment included advanced incubator technology, close nursing observation and daily skin-to-skin contact with her parents.</p>
<p>During her hospitalization, a nurse identified an unusually rapid increase in weight that required medical attention because of potential cardiac concerns.</p>
<p>According to the family, the clinical team’s prompt response and attention to detail played an important role in Willow’s recovery.</p>
<p>Willow is now 19 months old, and her parents credit the NICU’s clinical team and specialized equipment with helping her overcome the challenges associated with premature birth.</p>
<p>Their experience illustrates the importance of combining sophisticated medical technology with continuous clinical assessment and individualized care.</p>
<h3>Philanthropy supports neonatal innovation</h3>
<p>The Jewish General Hospital Foundation has played an important role in supporting investments in specialized equipment and patient care infrastructure.</p>
<p>Donor funding has helped provide the emergency care stations and monitoring technology used in the NICU.</p>
<p>These investments are intended to strengthen the hospital’s capacity to care for vulnerable newborns while supporting clinical teams working in a demanding, highly specialized environment.</p>
<p>The hospital is affiliated with McGill University and serves as a major teaching and specialized care centre within Montreal’s healthcare system.</p>
<p>Its neonatal services form part of a broader program supporting high-risk pregnancies, premature births and complex pediatric conditions.</p>
<h3>Combining innovation with compassionate care</h3>
<p>For hospitals across Canada, neonatal intensive care presents significant clinical and operational challenges.</p>
<p>Premature and critically ill newborns often require highly specialized equipment, multidisciplinary teams and prolonged hospital stays.</p>
<p>Technologies that improve monitoring and reduce delays in emergency treatment can support clinical teams, while family-centred practices help address the developmental and emotional needs of infants and parents.</p>
<p>The Jewish General Hospital’s approach illustrates how investments in technology, nursing expertise and developmental care can be integrated within a specialized neonatal service.</p>
<p>Although the foundation’s announcement does not provide comparative data demonstrating reductions in mortality, complications or hospital length of stay, it highlights an established model of neonatal care designed to support both immediate medical needs and longer-term development.</p>
<p>As hospitals continue to advance specialized newborn care, combining clinical innovation with family involvement remains an important priority.</p>
<p>Source: <a href="https://www.newswire.ca/news-releases/inside-one-of-quebec-s-six-level-3-nicus-how-the-jewish-general-hospital-university-health-centre-is-redefining-specialized-care-for-fragile-newborns-858493470.html?utm_source=chatgpt.com">Jewish General Hospital Foundation</a></p>
<div>
<div></div>
</div>
<p>The post <a href="https://www.hospitalnews.com/jewish-general-hospital-advances-specialized-care-for-critically-ill-newborns/">Jewish General Hospital advances specialized care for critically ill newborns</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>14 Eastern Ontario hospitals join forces to establish standards for responsible AI use</title>
<link>https://edusehat.com/en/14-eastern-ontario-hospitals-join-forces-to-establish-standards-for-responsible-ai-use</link>
<guid>https://edusehat.com/en/14-eastern-ontario-hospitals-join-forces-to-establish-standards-for-responsible-ai-use</guid>
<description><![CDATA[ New regional collaborative will develop shared tools to evaluate artificial intelligence, strengthen patient safety and reduce duplication across healthcare organizations. Fourteen hospital organizations across Eastern Ontario are joining forces to establish a coordinated approach to the safe, ethical and responsible use of artificial intelligence in healthcare. The Regional AI Governance Collaborative, co-led by Queensway Carleton […]
The post 14 Eastern Ontario hospitals join forces to establish standards for responsible AI use appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/11/shutterstock_2747048747.png" length="49398" type="image/jpeg"/>
<pubDate>Tue, 10 Nov 2026 23:10:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Eastern, Ontario, hospitals, join, forces, establish, standards, for, responsible, use</media:keywords>
<content:encoded><![CDATA[<p>New regional collaborative will develop shared tools to evaluate artificial intelligence, strengthen patient safety and reduce duplication across healthcare organizations.</p>
<p>Fourteen hospital organizations across Eastern Ontario are joining forces to establish a coordinated approach to the safe, ethical and responsible use of artificial intelligence in healthcare.</p>
<p>The Regional AI Governance Collaborative, co-led by Queensway Carleton Hospital in Ottawa and Pembroke Regional Hospital, will bring together expertise from participating hospitals to develop common policies, risk assessment frameworks, vendor evaluation tools and ethical guidelines.</p>
<p>Announced November 9, the initiative is intended to help hospitals make informed decisions about adopting AI technologies while maintaining responsibility for their own procurement, implementation and oversight.</p>
<p>The collaborative will focus on sharing expertise and reducing duplicated work, particularly among smaller community hospitals that may have limited resources to independently evaluate increasingly complex AI systems.</p>
<h3>Addressing the challenges of AI adoption</h3>
<p>Artificial intelligence is becoming an increasingly important part of healthcare operations, with applications ranging from clinical documentation and diagnostic support to scheduling and administrative processes.</p>
<p>However, adopting these technologies introduces questions about patient safety, data privacy, cybersecurity, transparency and accountability.</p>
<p>Hospitals must assess whether AI products are clinically appropriate, how patient information will be protected and what safeguards are necessary to prevent unintended consequences.</p>
<p>Currently, many healthcare organizations independently conduct similar assessments of the same technologies.</p>
<p>The Regional AI Governance Collaborative aims to streamline this work by creating shared evaluation resources that participating hospitals can adapt to their individual needs.</p>
<p>Rather than developing separate frameworks from the ground up, hospitals will be able to draw on common expertise and evidence-informed assessment methods.</p>
<p>Importantly, the collaborative will not approve AI products on behalf of its members. Each hospital will continue to determine which technologies to adopt and how they will be monitored.</p>
<h3>Eight principles to guide responsible AI</h3>
<p>The participating organizations have established eight foundational principles to guide their approach to artificial intelligence.</p>
<p>These principles address accountability, patient safety, fairness, transparency, human oversight, technical robustness, patient autonomy and fiscal responsibility.</p>
<p>Together, they are intended to help hospitals balance the potential benefits of AI with the need to protect patients, maintain public trust and use healthcare resources responsibly.</p>
<p>The collaborative recognizes that effective AI governance requires input from multiple disciplines, including physicians, clinical operations, information technology, privacy, cybersecurity, ethics, finance and hospital leadership.</p>
<p>More than 20 healthcare leaders representing these areas, as well as patient perspectives, have already contributed to the initiative.</p>
<h3>Partnerships with research and technology experts</h3>
<p>The initiative is co-led by Lindsay Wyers, vice-president of transformation, innovation and strategic partnerships and chief digital and privacy officer at Queensway Carleton Hospital, and Scott Coombes, vice-president and chief financial officer at Pembroke Regional Hospital.</p>
<p>The collaborative has engaged Info-Tech Research Group to support the development of practical and scalable governance processes.</p>
<p>It is also partnering with the University of Ottawa, where PhD student Amanda Maria Kutenski will contribute to the development of an ethical AI framework and decision-making tool.</p>
<p>These partnerships are intended to provide additional research and technical expertise as participating hospitals establish their shared approach.</p>
<h3>Fourteen hospital organizations participating</h3>
<p>The collaborative brings together a broad range of healthcare organizations serving communities across Eastern Ontario.</p>
<p>Participating partners include Arnprior Regional Health, Bruyère Health, Deep River & District Health, Hawkesbury and District General Hospital, Hôpital Glengarry Memorial Hospital, Hôpital Montfort, Kemptville District Hospital, Mississippi River Health Alliance, Pembroke Regional Hospital, Queensway Carleton Hospital, The Royal, St. Francis Memorial Hospital, Renfrew Victoria Hospital and Winchester District Memorial Hospital.</p>
<p>The diversity of participating organizations is significant, bringing together hospitals with different clinical services, patient populations and operational resources.</p>
<p>By pooling expertise, the group hopes to make responsible AI governance more accessible across the region.</p>
<h3>Next steps for the collaborative</h3>
<p>Initial planning sessions have already produced foundational AI principles, proposed governance structures, early charter concepts and a regional roadmap.</p>
<p>The next phase will focus on formalizing governance arrangements, identifying AI technologies currently being used across participating hospitals and evaluating priority applications through consistent risk assessment methods.</p>
<p>Over time, the collaborative intends to introduce shared processes for assessing new AI technologies and monitoring higher-risk applications.</p>
<p>The approach could also provide a model for other Canadian hospital networks seeking to coordinate AI oversight.</p>
<p>As healthcare organizations increasingly explore artificial intelligence, establishing consistent governance standards may help reduce duplication, support informed technology decisions and strengthen patient safety.</p>
<p>For Canadian hospitals, the Eastern Ontario initiative represents a shift toward regional collaboration in managing the opportunities and risks associated with AI adoption.</p>
<p>The collaborative remains in its development phase, and its impact on costs, clinical outcomes and patient safety has not yet been measured.</p>
<p>Primary source: <a href="https://www.qch.on.ca/newsroom?newsid=3168&utm_source=chatgpt.com">Queensway Carleton Hospital </a></p>
<p>The post <a href="https://www.hospitalnews.com/14-eastern-ontario-hospitals-join-forces-to-establish-standards-for-responsible-ai-use/">14 Eastern Ontario hospitals join forces to establish standards for responsible AI use</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Montreal Heart Institute introduces Canada’s first advanced AI&#45;assisted cardiovascular imaging system</title>
<link>https://edusehat.com/en/montreal-heart-institute-introduces-canadas-first-advanced-ai-assisted-cardiovascular-imaging-system</link>
<guid>https://edusehat.com/en/montreal-heart-institute-introduces-canadas-first-advanced-ai-assisted-cardiovascular-imaging-system</guid>
<description><![CDATA[ New hemodynamics suite uses artificial intelligence and advanced imaging technology to support precision during minimally invasive cardiac procedures. The Montreal Heart Institute has become the first hospital in Canada to install the Trinias Opera cardiovascular imaging platform, introducing advanced artificial intelligence technology designed to support physicians during complex cardiac procedures. The system is now operating […]
The post Montreal Heart Institute introduces Canada’s first advanced AI-assisted cardiovascular imaging system appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/11/shutterstock_2810402307.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 10 Nov 2026 23:10:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Montreal, Heart, Institute, introduces, Canada’s, first, advanced, AI-assisted, cardiovascular, imaging, system</media:keywords>
<content:encoded><![CDATA[<p><em>New hemodynamics suite uses artificial intelligence and advanced imaging technology to support precision during minimally invasive cardiac procedures.</em></p>
<p>The Montreal Heart Institute has become the first hospital in Canada to install the Trinias Opera cardiovascular imaging platform, introducing advanced artificial intelligence technology designed to support physicians during complex cardiac procedures.</p>
<p>The system is now operating in the Institute’s newly opened Hemodynamics Room No. 3, following a collaboration involving the hospital, its foundation, Christie Innomed and Shimadzu Corporation.</p>
<p>Announced November 9, the installation represents a significant investment in cardiovascular imaging technology and the continued development of minimally invasive cardiac care.</p>
<h3>Improving visualization during cardiac procedures</h3>
<p>The Trinias Opera platform provides real-time imaging of the heart and blood vessels, helping interventional cardiologists navigate medical devices during diagnostic and therapeutic procedures.</p>
<p>The technology combines advanced X-ray imaging with intelligent image-processing capabilities designed to improve the visibility of catheters, guidewires and other devices used during cardiovascular interventions.</p>
<p>One of its key features is a deep-learning-based artificial intelligence filter that identifies and enhances linear structures within medical images.</p>
<p>By reducing image noise and improving the visibility of important anatomical and device details, the technology is designed to help clinicians maintain clear images while working with lower X-ray exposure levels.</p>
<p>The system also allows physicians to adjust radiation settings according to patient characteristics and procedural requirements.</p>
<p>These capabilities are intended to support more precise clinical decision-making while helping healthcare teams manage radiation exposure.</p>
<h3>Supporting minimally invasive cardiovascular care</h3>
<p>Advanced imaging plays an important role in interventional cardiology, where physicians use catheters and other specialized instruments to diagnose and treat cardiovascular conditions without conventional open surgery.</p>
<p>Clear visualization is particularly important during complex procedures involving small blood vessels and delicate cardiac structures.</p>
<p>The Trinias Opera platform incorporates advanced image-processing tools designed to improve device visibility and support clinical workflow.</p>
<p>The technology may also help healthcare teams work more efficiently by providing enhanced imaging information throughout procedures.</p>
<p>Although the system is designed to improve procedural precision and support patient safety, clinical outcome improvements specific to the Montreal installation have not yet been reported.</p>
<h3>Collaboration supports Canadian first</h3>
<p>The installation was made possible through a partnership involving the Montreal Heart Institute, the Montreal Heart Institute Foundation, Christie Innomed, Shimadzu Corporation and associated technology teams.</p>
<p>The project included a significant equipment donation from Christie Innomed and Shimadzu.</p>
<p>Nesrine Ragguem, president and chief executive officer of the Montreal Heart Institute, said the new suite strengthens the hospital’s ability to deliver advanced cardiovascular care while providing clinical teams with modern technology.</p>
<p>The Montreal Heart Institute Foundation also highlighted the importance of partnerships and philanthropic support in bringing new medical technologies into clinical practice.</p>
<p>The project reflects the increasing role of collaboration between hospitals, medical technology companies and charitable foundations in supporting healthcare innovation.</p>
<h3>Advancing cardiovascular innovation</h3>
<p>Founded in 1954, the Montreal Heart Institute is internationally recognized for its work in cardiovascular research, specialized patient care, prevention and medical education.</p>
<p>Affiliated with the Université de Montréal, the Institute operates major research and clinical programs focused on improving the diagnosis and treatment of cardiovascular disease.</p>
<p>The introduction of the Trinias Opera system adds to the hospital’s existing capabilities in interventional cardiology.</p>
<p>Beyond the immediate installation, the partnership is expected to support continued collaboration between the Institute’s clinical specialists and Shimadzu’s research and development teams.</p>
<p>As cardiovascular procedures become increasingly sophisticated, imaging technologies that combine artificial intelligence with advanced diagnostic capabilities are expected to play a growing role in supporting clinical decision-making.</p>
<p>For Canadian hospitals, the Montreal installation provides another example of how advanced medical imaging and AI-assisted technology are moving into clinical environments.</p>
<p>The system’s introduction also highlights the importance of evaluating new technologies not only for their technical capabilities, but for their potential contributions to patient safety, procedural efficiency and clinical outcomes.</p>
<p>The post <a href="https://www.hospitalnews.com/montreal-heart-institute-introduces-canadas-first-advanced-ai-assisted-cardiovascular-imaging-system/">Montreal Heart Institute introduces Canada’s first advanced AI-assisted cardiovascular imaging system</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>BioAdvance: BIO releases national action plan to strengthen US biotech leadership</title>
<link>https://edusehat.com/en/bioadvance-bio-releases-national-action-plan-to-strengthen-us-biotech-leadership</link>
<guid>https://edusehat.com/en/bioadvance-bio-releases-national-action-plan-to-strengthen-us-biotech-leadership</guid>
<description><![CDATA[ A new seven-point plan to strengthen America’s biotechnology leadership amid intensifying global competition from China was released by the Biotechnology Innovation Organization (BIO) on […]
The post BioAdvance: BIO releases national action plan to strengthen US biotech leadership appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/11/BioAdvance-cover.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 10 Nov 2026 19:45:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>BioAdvance:, BIO, releases, national, action, plan, strengthen, biotech, leadership</media:keywords>
<content:encoded><![CDATA[<p><span>A new seven-point plan to strengthen America’s biotechnology leadership amid intensifying global competition from China was released by the Biotechnology Innovation Organization (BIO) on Nov. 10.</span></p>
<p><a href="http://bio.org/bioadvance" target="_blank" rel="noopener"><span>BioAdvance: Securing America’s Biotech Century</span></a><span>, calls for a bold, coordinated national strategy and targeted policy reforms to accelerate medical breakthroughs, strengthen America’s innovation ecosystem, and ensure the next generation of lifesaving medicines is developed and manufactured in the U.S.</span></p>
<p><span>America built the  biotechnology industry, notes BIO President & CEO John F. Crowley.</span></p>
<p><span>“For decades, American biotechnology innovators have turned scientific discovery into hope for patients and families, building an industry that saves lives, drives economic growth, and strengthens our nation’s security and competitiveness,” Crowley says.</span></p>
<p><span>By 2025, the U.S. bioscience industry employed more than 2.3 million Americans across more than 156,000 business establishments and generated nearly $3.2 trillion in total economic output,</span><a href="https://bio.news/state-policy/2026-report-on-biotechs-economic-impact-portrays-a-vast-ecosystem/" target="_blank" rel="noopener"><span> according to </span><span>the BIO/CSBA/TEConomy 2026 report</span></a><span>.</span></p>
<p><span>“America’s biotechnology innovators have built one of our nation’s greatest strategic assets,” Crowley says. “But our leadership is not guaranteed. We must invest, innovate, and act with urgency.”</span></p>
<p><span>As <a href="https://www.bio.org/sites/default/files/2026-11/bio-advance_executivesummary_digital_11042026.pdf" target="_blank" rel="noopener">the Executive Summary explains</a>, China is competing to take over as the world leader in  biotech, posing challenges to our health, economy, and national security.</span></p>
<p><span>“China has steadily elevated biotechnology as a strategic priority, directing massive state resources toward the sector in every new five-year plan,” the Executive Summary says. “Between 2016 and 2021, the value of China’s biotechnology industry grew more than 100-fold.”</span></p>
<h2>The action plan</h2>
<p><span>BioAdvance plan outlines how Congress and the administration can respond to the challenge with actions tailored to America’s strengths. The plan addresses seven actionable priorities across three areas:</span></p>
<p><b>Coordinate: Establish a clear national strategy for U.S. biotech leadership</b></p>
<ul>
<li aria-level="1"><span>Establish a White House Office of Biotechnology.</span></li>
</ul>
<p><b>Accelerate: Bring lifesaving discoveries to patients faster</b></p>
<ul>
<li aria-level="1"><span>Speed up the path to first-in-human clinical studies.</span></li>
<li aria-level="1"><span>Modernize and streamline drug development.</span></li>
<li aria-level="1"><span>Improve patient access to clinical trials.</span></li>
</ul>
<p><b>Build: Strengthen the foundations of American biotechnology</b></p>
<ul>
<li aria-level="1"><span>Sustain support for biomedical research.</span></li>
<li aria-level="1"><span>Expand U.S. biomanufacturing capacity and expertise.</span></li>
<li aria-level="1"><span>Strengthen intellectual property protections and access to capital.</span></li>
</ul>
<p><span>“This moment demands the ambition and determination that catalyzed the biotechnology revolution and made America the definitive global leader,” Crowley states. “BIO stands ready to work with the administration, Congress, and the entire biotechnology ecosystem to accelerate the next generation of lifesaving breakthroughs, and ensure the United States leads the biotech century.”</span></p>
<p><a href="http://bio.org/bioadvance" target="_blank" rel="noopener"><b>Learn more and download the full action plan at bio.org/bioadvance.</b></a></p>
<p><strong>Read more: <a href="https://www.statnews.com/2026/11/10/china-biotech-bio-plan-space-race/" target="_blank" rel="noopener">BIO CEO: American biotech needs a coordinated plan to beat China — now</a></strong></p>
<p>The post <a href="https://bio.news/bios-view/bioadvance-bio-releases-national-action-plan-to-strengthen-us-biotech-leadership/">BioAdvance: BIO releases national action plan to strengthen US biotech leadership</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Illumina Offers Early Access to Duplex Sequencing for MRD, Tumor Evolution Research</title>
<link>https://edusehat.com/en/illumina-offers-early-access-to-duplex-sequencing-for-mrd-tumor-evolution-research</link>
<guid>https://edusehat.com/en/illumina-offers-early-access-to-duplex-sequencing-for-mrd-tumor-evolution-research</guid>
<description><![CDATA[ Illumina has announced an early access program to a duplex sequencing workflow that reads both DNA strands to detect trace ctDNA in molecular residual disease and tumor evolution studies. Kits are expected in early 2027.
The post Illumina Offers Early Access to Duplex Sequencing for MRD, Tumor Evolution Research appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/04/GettyImages-1325872227.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 10 Nov 2026 08:55:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Illumina, Offers, Early, Access, Duplex, Sequencing, for, MRD, Tumor, Evolution, Research</media:keywords>
<content:encoded><![CDATA[<p>Spotting a handful of tumor DNA fragments among one million total DNA fragments may be the kind of sensitivity researchers need when studying molecular residual disease (MRD), the small amount of cancer that can remain after treatment. Illumina has opened an early access program for a sequencing workflow to support research in that range.</p>
<p>Announced this week, the research-use-only workflow is designed to detect trace amounts of circulating tumor DNA (ctDNA) in plasma samples and to support longitudinal, whole-genome studies of MRD and tumor evolution. Kits are expected to ship in the first quarter of 2027.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>The workflow relies on duplex chemistry, which confirms each base call using both complementary strands of the original DNA molecule. Seeing the same change on both strands increases confidence that it is biological rather than an error introduced during library preparation or sequencing, according to the Illumina press release.</p>
<p>On the hardware and software side, the workflow combines the NovaSeq X sequencing platform with DRAGEN bioinformatics software. Illumina said that pairing NovaSeq X sequencing with duplex chemistry yields quality scores above Q65. DRAGEN then generates duplex consensus reads, optimizes quality scores, and interrogates thousands of tumor-specific variants across the genome, combining evidence from the few that may be present in plasma. The workflow supports 5–10 ng of cell-free DNA (cfDNA) input.</p>
<p>In representative studies, the workflow reproducibly detected ctDNA at 2.5 parts per million.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>“Researchers need effective ways to find the faintest traces of tumor DNA—signals that can be especially difficult to detect in early-stage, low-shedding, or low-mutation-burden tumors,” said Cande Rogert, vice president, global head of advanced science at Illumina, in a press release. “This early access technology is an important step toward helping researchers explore those challenging settings with greater sensitivity and generate evidence that can advance MRD research.”</p>
<p>The duplex workflow adds to Illumina’s MRD research portfolio and complements Illumina WGS Oncology Prep, which supports tumor fingerprinting and longitudinal ctDNA monitoring in a standardized whole-genome workflow.</p>
<p>NYU Langone Health is among the early access users and is applying the approach to MRD research. “MRD research is moving fast, and new tools are making it possible to bring ultrasensitive, tumor-informed analysis in-house,” said Matija Snuderl, MD, director of molecular pathology at NYU Langone Health. He added that the team looks forward to “generating evidence with a non-bespoke approach that can help advance our understanding of disease recurrence.”</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/illumina-offers-early-access-to-duplex-sequencing-for-mrd-tumor-evolution-research/">Illumina Offers Early Access to Duplex Sequencing for MRD, Tumor Evolution Research</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>How Cancer&#45;Associated Gene Triggers Cell Division Without Unpacking the Genome</title>
<link>https://edusehat.com/en/how-cancer-associated-gene-triggers-cell-division-without-unpacking-the-genome</link>
<guid>https://edusehat.com/en/how-cancer-associated-gene-triggers-cell-division-without-unpacking-the-genome</guid>
<description><![CDATA[ A study showed how E2F1 can trigger cell division without having to unpack the cell’s genetic material. Instead, it takes a shortcut path by binding directly to a small area of the DNA that remains tightly packaged inside the cell.
The post How Cancer-Associated Gene Triggers Cell Division Without Unpacking the Genome appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/04/GettyImages-2152737017.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 10 Nov 2026 05:15:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>How, Cancer-Associated, Gene, Triggers, Cell, Division, Without, Unpacking, the, Genome</media:keywords>
<content:encoded><![CDATA[<p>Living cells are one of the few materials that can replicate themselves, and this is crucial for tissue development and recovering from injury or illness. But making sure cell division only happens at the right time is essential, otherwise unregulated replication can lead to problems like cancer.</p>
<p>The results of a study headed by researchers at the University of California, Santa Cruz, have now shown that a cancer-related gene known as <em>E2F1</em> can cause cells to divide without having to abide by the normal rules of cell division. Their research found that instead of having to unpack the genetic material inside the cell, E2F1 takes a shortcut path by binding directly to a small area of the DNA that remains tightly packaged inside the cell. The discovery helps to further illuminate the processes that drive cell proliferation and may influence cancer growth and could provide insight that will help in the future design of more precise and targeted treatments.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>“Cancers may overcome the typical checks and balances that our cells are using to maintain a dormant state, dysregulating and increasing the level of E2F1 to find a shortcut back to the cell cycle,” said Ali Shariati, PhD, Associate Professor of Biomolecular Engineering at the Baskin School of Engineering. Shariati, and Professor Chemistry & Biochemistry Seth Rubin, PhD, are co-senior and co-corresponding authors of the researchers published paper in <em>The EMBO Journal</em>, titled “<a href="https://doi.org/10.1038/s44318-026-00936-4" target="_blank" rel="noopener">E2F1 induces a G0-G1 reentry transcriptional program without changing chromatin accessibility</a>.” In their paper the researchers concluded, “Our work redefines the relationship between transcription factor and chromatin dynamics during fate transitions and establishes E2F1 as a potent regulator capable of inducing cell-cycle reentry without changing chromatin accessibility.”</p>
<p>Nearly all cells have the ability to divide, but the majority don’t, instead waiting in a state similar to hibernation. And this hibernation doesn’t happen automatically—the body must constantly send signals to prevent cell division. Otherwise, any body part could grow bigger than its proper size, or grow tumors. “Many cells in the human body reside in a reversible nondividing quiescent state termed G0,” the authors explained. “Quiescent cells repress cell-cycle genes via chromatin-based mechanisms to maintain a non-dividing state, yet remain poised to reenter the cell cycle upon stimulation.”</p>
<p>The UCSC researchers are studying how cells know when and how to divide, and the influence on these processes of genes known to be important in cancer. Rubin’s lab focuses on the biochemistry and gene expression of cell division, while Ali Shariati’s lab studies how cells translate input from the body in order to decide whether or not to divide. “Cells can’t just rely on the assumption that they will stop dividing,” Shariati said. “The cells need to actively say, ‘this is the liver, it should be this large, and after we reach this critical size, let’s just stop dividing,’ That’s called homeostatic behavior, and that’s not a trivial task for the body. It’s a state where the cells are ready to be activated, but normally aren’t, unless there is an external requirement. It’s a delicate balance to maintain.” The authors further explained, “Cells enter quiescence when they do not receive the required signaling cues for cell-cycle progression such as growth factors.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>To recover from injuries or illness, the body can send a signal to cells to leave hibernation and divide. To do so, it must instruct cells to physically unpack the DNA that is tightly wrapped around proteins inside its nucleus. To recreate this process in the lab, scientists typically add nutrients and growth signals to dormant cells, which cause them to divide.</p>
<p>The UC Santa Cruz researchers studied an important gene called <em>E2F1</em>, which is central for cell division and malfunctions in many cancers. “E2F1 is known to be a transcriptional activator that binds to and induces expression of cell-cycle genes such as those encoding cyclins, cyclin-dependent kinases, and DNA replication machinery,” the team noted. Other scientists have found that the activation of this gene can cause cells to divide without growth signals, and the UCSC scholars further confirmed this finding.</p>
<figure aria-describedby="caption-attachment-340488" class="wp-caption alignright"><img decoding="async" class="size-medium wp-image-340488" src="https://www.genengnews.com/wp-content/uploads/2026/11/Low-Res_PressRelease-1-300x119.jpg" alt="On the left, dormant cells (turquoise) lie in wait for biological signals. On the right, cells are awakened by E2F1 (magenta) and begin to divide. " width="300" height="119" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Low-Res_PressRelease-1-300x119.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Low-Res_PressRelease-1.jpg 700w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">On the left, dormant cells (turquoise) lie in wait for biological signals. On the right, cells are awakened by E2F1 (magenta) and begin to divide. [Ali Shariati / UC Santa Cruz]</figcaption></figure>
<p>The team further discovered that E2F1 appears to be taking a shortcut method to cause division. Using a very limited amount of physical space in the genome, the E2F1 protein can bind directly to the genome in order to switch on the genes related to cell division. “… quiescent cells can reenter the cell-cycle and complete their division without global changes in chromatin accessibility when induced by expression of a single transcription factor; E2F1,” they wrote. “Our results show that E2F1 is able to rapidly promote quiescence exit by activating an accelerated gene expression program without global changes in chromatin accessibility.”</p>
<p>Shariati further commented, “The surprising part is, unlike the typical process, E2F1 is able to activate the cell cycle genes without physically unpacking the genome much or at all. That means this is a new way of transcription factors being able to activate genes and let the cells completely change their fate and go on to divide.” And while DNA binding is essential to the ability of E2F1 to trigger cell division, “… deletion of the DNA binding domain in E2F1 led to a complete loss of cell cycle reentry,” the investigators noted, “The precise mechanisms underlying the transcriptional activation of cell-cycle genes by E2F1 without significant changes in chromatin accessibility remain unknown and merits further investigation.”</p>
<p>The ability to activate cell division makes E2F1 similar to a special category of genes that scientists call “pioneer factors,” which can unlock tightly packed DNA to fundamentally reprogram cells. This special status indicates that cells must maintain a precise level of E2F1 to maintain proper cell division. Indeed, the UC Santa Cruz researchers found that cells can sense a specific threshold of E2F1: once levels cross that line, dormant cells begin to divide.</p>
<p>E2F1’s shortcut method of division has its own limitations. The scientists found that cells can only divide at most three times without any additional growth signals. To study cell division over time, the researchers used live single-cell imaging techniques developed in the Shariati lab, including their in-house <a href="https://doi.org/10.1016/j.crmeth.2023.100500" target="_blank" rel="noopener">DeepSea software</a>.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>Nonetheless, the shortcut method to cell division that E2F1 uses happens much faster than the typical process with nutrients. Researchers suspect cancer cells may exploit this E2F1 activity, although more research will be needed to better understand how this mechanism works.</p>
<p>Shariati plans to further study how exactly E2F1 activates the genes after it binds to the genome. This could help to find a more precise and targeted approach for interfering with this pathway in the context of cancer. He also wants to study the eight genes in the same family as <em>E2F1</em>, some of which cause cells to become dormant, and their role in cancer.</p>
<p>Rubin is also interested in whether E2F1 can be targeted in cancers. “There has been much effort in the field to target E2F1’s role in cell division by inhibiting upstream proteins that control E2F1 activity,” Rubin said. “We have been wondering whether there are ways to target E2F1 itself to stop cancer cells from proliferating. The first steps are figuring out what specific cancers would benefit from blocking E2F1 activity, and then finding molecules that bind and prevent E2F1 from activating cell cycle gene expression.”</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/how-cancer-associated-gene-triggers-cell-division-without-unpacking-the-genome/">How Cancer-Associated Gene Triggers Cell Division Without Unpacking the Genome</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Cancer drug study puts numbers to the cost of IRA’s pill penalty</title>
<link>https://edusehat.com/en/cancer-drug-study-puts-numbers-to-the-cost-of-iras-pill-penalty</link>
<guid>https://edusehat.com/en/cancer-drug-study-puts-numbers-to-the-cost-of-iras-pill-penalty</guid>
<description><![CDATA[ The price Americans pay for the Inflation Reduction Act (IRA) “pill penalty” and disincentives for follow-on research is a reduction in new cancer treatments, […]
The post Cancer drug study puts numbers to the cost of IRA’s pill penalty appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/11/towfiqu-barbhuiya-uM5mnbNm8eA-unsplash.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 09 Nov 2026 22:10:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Cancer, drug, study, puts, numbers, the, cost, IRA’s, pill, penalty</media:keywords>
<content:encoded><![CDATA[<p><span>The price Americans pay for the Inflation Reduction Act (IRA) “pill penalty” and disincentives for follow-on research is a reduction in new cancer treatments, a study finds.</span></p>
<p><span>The introduction of the IRA is associated with a 37% decline in follow-on small-molecule oncology studies and a 27% decline in lead-indication small molecule approvals, according to</span><a href="https://link.springer.com/article/10.1007/s43441-026-01061-4"> <span>research by Vital Transformation</span></a><span>. It also showed a 14% decline in the share of orphan oncology studies.</span></p>
<p><span>The research, published Oct. 20,</span> <span>analyzed 1,148 secondary clinical trials associated with 364 medicines approved by the Food and Drug Administration (FDA) from 175 companies between 2018 and 2025. Researchers used statistical modeling to compare post-approval drug development and research activity across disease areas before and after the IRA’s introduction.</span></p>
<p><span>“The findings indicate that the effects of the legislation on late-stage pharmaceutical research may warrant greater attention from policymakers, particularly in oncology, where continued clinical development can expand treatment options for patients with serious and difficult-to-treat cancers,”</span><a href="https://vitaltransformation.com/wp-content/uploads/2026/11/IRA_Press_Release_2NOV-final.pdf"> <span>according to Vital Transformation</span></a><span>.</span></p>
<h2>Why small molecules and follow-up matter</h2>
<p><span>The IRA allows the Centers for Medicare & Medicaid Services (CMS) to control the price of medications by making drug makers engage in “negotiations” or face steep penalties. Biologic medicines are exempted from these price controls for as long as 13 years, but small molecule drugs, which are often prepared as pills and comprise</span><a href="https://www.frontiersin.org/journals/drug-discovery/articles/10.3389/fddsv.2023.1314077/full"> <span>about 90% of prescription drugs</span></a><span>, only receive a maximum of nine years of protection.</span></p>
<p><span>This “pill penalty” creates a disincentive to invest in small molecule drugs, which has been</span><a href="https://bio.news/health/capitol-hill-september-2024-pprv-pediatric-rare-disease-voucher-inflation-reduction-act-price-controls/#:~:text=%E2%80%98A%20classic%20issue,the%20Manhattan%20Institute."> <span>noted by policymakers</span></a><span> and others.</span></p>
<p><span>Follow-up studies investigate whether a drug approved for one condition is useful for another indication. This approach can speed access to new drugs for patients, especially oncology drugs, for which approximately 60-75% of marketed medications have more than one indication,</span><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC13297679/"> <span>according to research</span></a><span>.</span></p>
<p><span>The IRA discourages follow-up studies because drugs approved for an additional indication do not get additional protection from CMS price “negotiations.”</span></p>
<p><span>The Vital Transformation research puts actual numbers to the pill penalty in cancer research, identifying the 27% reduction in studies for new small molecule cancer drugs. It also shows that barriers to developing drugs for second indications puts an even greater damper on research—causing a decline of nearly 40% in follow-up studies for oncology drugs.</span></p>
<h2>Policy corrections</h2>
<p><span>There is bipartisan </span><span>legislation to correct the pill penalty, entitled the</span><a href="https://www.congress.gov/bill/119th-congress/house-bill/1492"> <span>Ensuring Pathways to Innovative Cures (EPIC) Act</span></a><span>. It would give small molecule drugs the same protection from price negotiations that biologics receive.</span></p>
<p><span>The Biotechnology Innovation Organization (BIO) praised the EPIC act when it was introduced.</span></p>
<p><span>“For decades small molecule medicines that come in a pill or tablet have been recognized for improving patient adherence, being easier to take, and more broadly accessible to those who need them. As a result, hundreds of such therapies have been developed,” said</span><a href="https://www.bio.org/press-release/bio-applauds-introduction-bipartisan-bill-eliminate-pill-penalty"> <span>BIO President & CEO John F. Crowley</span></a><span>, explaining the importance of the EPIC Act. “Today, instead of building on years of biomedical progress, some innovator companies and investors are now being forced to pull away.”</span></p>
<p><span>The data indicates a need for policy solutions, according to the Vital Transformation study.</span></p>
<p><span>“We hope this study reinvigorates debate” about the IRA’s “unintended consequences and encourages thoughtful policy solutions,” says the study. “The IRA manifestly creates disincentives that negatively impact patients seeking treatments in areas of high unmet medical need, particularly those requiring cures addressing metastatic late-stage cancers.”</span></p>
<p>The post <a href="https://bio.news/federal-policy/cancer-drug-study-puts-numbers-to-the-cost-of-iras-pill-penalty/">Cancer drug study puts numbers to the cost of IRA’s pill penalty</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Formulation Development Roundup</title>
<link>https://edusehat.com/en/formulation-development-roundup</link>
<guid>https://edusehat.com/en/formulation-development-roundup</guid>
<description><![CDATA[ What leaders suggest are the key considerations for developing robust formulations.
The post Formulation Development Roundup appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/GEN_NOV_GettyImages-2224940107.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 09 Nov 2026 22:05:13 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Formulation, Development, Roundup</media:keywords>
<content:encoded><![CDATA[<p>Formulation development is a critical step in the production of a drug to ensure that it is safe, effective, stable, and suitable for administration. Companies that provide formulation development services are experts in applying best practices to achieve optimal results. <em>GEN</em> sought the perspectives of experts from four leading companies to describe the considerations they make when working with customers on developing new formulations.</p>
<p><em>GEN</em> asked two questions: How would you approach formulation development for a customer’s specific molecule, and what key risks would you evaluate first? How do you determine that you have found a robust formulation rather than just the best-performing formulation under your initial test conditions?</p>
<p> </p>
<h4><strong>Abzena</strong></h4>
<p>Initially, we would perform a developability assessment to understand how the molecule behaves under platform manufacturing stresses, including low pH, freeze-thaw, shear, and hold conditions. This establishes the early-risk profile, including aggregation, fragmentation, oxidation, and deamidation risks, and identifies any molecule-specific liabilities before formulation screening begins.</p>
<figure aria-describedby="caption-attachment-340462" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-340462" src="https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-Abzena-Gary-Watts-300x300.jpg" alt="Gary Watt" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-Abzena-Gary-Watts-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-Abzena-Gary-Watts-1024x1024.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-Abzena-Gary-Watts-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-Abzena-Gary-Watts-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-Abzena-Gary-Watts.jpg 1304w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Gary Watt, PhD<br>Head of Formulation</figcaption></figure>
<p>We would then align with the customer on the target product profile (TPP), including intended dose, concentration, route of administration, and presentation requirements, so the formulation strategy is driven by clinical and product needs rather than screening performance alone.</p>
<p>Once the TPP is agreed, we would confirm compatibility with platform analytical methods and run focused formulation screens assessing pH, ionic strength, excipient compatibility, and thermal stability. For subcutaneous products, we would also evaluate high-concentration feasibility, including solubility, viscosity, and aggregation risk.</p>
<p>Lead formulations would then be challenged through thermal and freeze/thaw stability studies using orthogonal analytical methods. Robustness is demonstrated when the selected formulation performs consistently across relevant stresses, analytical readouts, and small variations in formulation or process conditions, rather than simply being the best performer in the initial screen.</p>
<p>For Phase I/first-in-human (FIH) supply, the final formulation should provide an acceptable stability margin, support scale-up and manufacturing, and generate data suitable for Investigational New Drug (IND) filing.</p>
<p>Good Manufacturing Practices (GMP) batches would be placed on International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)-compliant stability studies, typically for up to four years, to confirm long-term performance and further justify the formulation selection.</p>
<p> </p>
<h4><strong>BioAgilytix</strong></h4>
<p>When approaching formulation development, I would start by understanding the molecule itself: what makes it unstable, which quality attributes matter most, and what conditions are most likely to cause problems. That means looking at physical and chemical stability, aggregation or particle formation, potency and purity, as well as sensitivity to things like pH, temperature, oxidation, agitation, and freeze-thaw. I would also look closely at the excipients, because stabilizers and other formulation components can affect both the molecule and its degradation pathways.</p>
<figure aria-describedby="caption-attachment-340463" class="wp-caption alignleft"><img loading="lazy" decoding="async" class="wp-image-340463" src="https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-BioAgilytix-Jessica-Weaver-e1794230452134-300x300.jpg" alt="Jessica Weaver" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-BioAgilytix-Jessica-Weaver-e1794230452134-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-BioAgilytix-Jessica-Weaver-e1794230452134-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-BioAgilytix-Jessica-Weaver-e1794230452134-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-BioAgilytix-Jessica-Weaver-e1794230452134.jpg 900w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Jessica Weaver<br>Scientific Officer</figcaption></figure>
<p>From the analytical side, an important question is whether we have the right assays to detect those changes. A formulation may alter how a drug degrades, and an assay that works well for the drug substance may not tell the whole story once that molecule is in its final formulation. We need stability-indicating methods that can distinguish the intact drug from degradation products and detect meaningful changes in the critical quality attributes without interference from the formulation itself.</p>
<p>The bigger question then becomes more than which formulation performs best in an initial screen. We need to understand why it performs well and whether it continues to perform when challenged.</p>
<p>For me, that is the difference between a formulation that looks good and one that is truly robust. It should tolerate normal variability in formulation parameters, manufacturing, handling, and storage. If performance falls off as soon as you move away from the exact conditions used in the initial study, you probably haven’t found a robust formulation yet. Confidence comes from analytical and stability data showing that the formulation continues to protect the molecule under the conditions it is likely to encounter.</p>
<p> </p>
<p><strong>Curia Global</strong></p>
<figure aria-describedby="caption-attachment-340464" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-340464" src="https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-Curia-TylerJones-e1794230551980-300x300.jpg" alt="Tyler Jones" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-Curia-TylerJones-e1794230551980-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-Curia-TylerJones-e1794230551980-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-Curia-TylerJones-e1794230551980-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-Curia-TylerJones-e1794230551980.jpg 899w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Tyler Jones, PhD<br>Director of Formulation R&D</figcaption></figure>
<p>We take a bespoke approach to formulation development, where we don’t make assumptions on behavior based on the type of molecule, but rather we use a process to efficiently and pragmatically identify critical quality attributes and understand why a molecule behaves the way it does. First, the Curia team would characterize the molecule across a wide formulation space, systematically mapping pH vs. ionic strength, the two parameters that most strongly influence how molecules present themselves to their environment. This broad physicochemical space allows us to force a molecule down the various degradation pathways it could encounter, and doing this across a range of temperatures allows us to understand the temperature-dependency of these pathways. Many biologics do not follow Arrhenius-type kinetics with regard to degradation activation energies, so understanding which degradation pathways are most relevant at the intended storage temperatures is critical in weighting formulation space performance.</p>
<p>Once this baseline understanding of molecule behavior is established, we can then pointedly mitigate remaining issues. For example, if we achieve good physical stability but are still encountering some chemical degradation such as oxidation, we can then screen antioxidants and have the background data to justify why we are adding such excipients.</p>
<p>Eventually, with enough stability data to have confidence in a final formulation space, we would utilize DOE studies to refine each variable in the formulation. The gold standard for us is long-term stability, so to definitively show the formulation is robust, we run long-term stability studies on a small selection of bracketed formulations around our sweet spot.</p>
<p> </p>
<p><strong>Quotient Sciences</strong></p>
<p>Formulation development should start with the target product profile and the molecule itself, including the required dose and exposure, route of administration, dosage form, and the API’s physicochemical, solid-state, and biopharmaceutic properties. The first priority is to identify the risks most likely to compromise clinical performance or create downstream development barriers. Depending on the molecule, these may include solubility and dissolution relative to dose, permeability, solid-form and chemical stability, excipient compatibility, dose feasibility, and manufacturability.</p>
<figure aria-describedby="caption-attachment-340461" class="wp-caption alignleft"><img loading="lazy" decoding="async" class="wp-image-340461" src="https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-Quotient-AsmaPatel-300x300.jpg" alt="Asma Patel" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-Quotient-AsmaPatel-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-Quotient-AsmaPatel-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-Quotient-AsmaPatel-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-Quotient-AsmaPatel.jpg 900w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Asma Patel, PhD<br>Vice President, Global Commercial and Scientific Consulting, Drug Product</figcaption></figure>
<p>The objective is not to select the most sophisticated technology, but rather the simplest formulation capable of delivering the required clinical performance while remaining viable through scale-up, transfer, and later-stage manufacture.</p>
<p>A robust formulation should be understood, not simply selected. Critical material attributes and process parameters should be challenged across justified ranges, including relevant interactions and boundary conditions, to determine where performance is maintained and where it begins to fail. The formulation choice should then be confirmed through reproducibility across batches, stability over time, performance on representative equipment, clinically relevant<em> in vitro</em> testing, and, where appropriate, human data.</p>
<p>A formulation is robust when normal variability is understood, controlled, and does not materially affect product quality or intended clinical performance.</p>
<p> </p>
<p> </p>
<p> </p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/formulation-development-roundup/">Formulation Development Roundup</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Therapeutic Immune Manipulation</title>
<link>https://edusehat.com/en/therapeutic-immune-manipulation</link>
<guid>https://edusehat.com/en/therapeutic-immune-manipulation</guid>
<description><![CDATA[ Next-generation immunotherapy exploits diverse immune populations to address the challenges that CAR T-cell therapy faces.
The post Therapeutic Immune Manipulation appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Labant_Amgen_Lab-Shot_CAR-T-Alternatives.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 09 Nov 2026 22:05:12 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Therapeutic, Immune, Manipulation</media:keywords>
<content:encoded><![CDATA[<p>Chimeric antigen receptor (CAR) T-cell therapy was a major breakthrough in immunotherapy. To date, according to the Alliance for Cancer Gene Therapy, seven therapies have been approved for blood cancers such as Kymriah<sup>®</sup> and Yescarta<sup>®</sup>. As extraordinary as these CAR T-cell therapies are, the approach struggles with solid tumors, as well as adverse side effects such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) resulting from <em>in vivo</em> T cell expansion. Complex manufacturing for autologous therapies and resultant costs limit the number of patients that can be treated.</p>
<p>Alternative approaches to engaging the immune system have been explored for decades, for instance, bispecific T-cell engager (BiTE) technology pioneered by Amgen. Companies like Artiva Biotherapeutics and Dragonfly Therapeutics are exploring the benefits that natural killer (NK) cells can bring, especially in B cell driven autoimmune diseases. Additionally, rare T cell populations such as invariant natural killer T (iNKT) cells are being harnessed to perform beyond their normal capabilities. Scientists also continue to innovate to try and bring solid cancers with edgy antigens under clinical control.</p>
<p>Importantly, autologous CAR T-cell therapy illustrated that the immune system can be exploited to combat disease as well as the challenges that need to be addressed when doing so. The next generation of immunotherapies is beginning to progress through clinical trials, and a new class of drugs could potentially be introduced for autoimmune diseases as well as oncology indications.</p>
<h4><strong>Harnessing the immune system</strong></h4>
<p>“BiTE<sup>®</sup> technology was developed to address an important unmet need in cancer care,” said Jean-Charles Soria, MD, PhD, senior vice president, global oncology development at Amgen. “For 30 years, we have built on this science, first in blood cancers and more recently in solid tumors.”</p>
<p>While the immune system has a natural ability to recognize and kill cancer cells, tumors can develop ways to evade that response. BiTE therapies bring T cells into direct contact with tumor cells by binding both CD3 on the T cell and a specific antigen on the tumor cell, activating T-cell-mediated killing.</p>
<p>BiTE and CAR T-cell therapies are distinct, complementary approaches that harness the immune system to fight cancer, according to Soria. BiTE “off-the-shelf” therapies are designed to redirect a patient’s own T cells to recognize and eliminate tumor cells expressing a selected target. This can enable treatment without the individualized cell collection and manufacturing process required for CAR T therapy.</p>
<p>Both platforms have demonstrated meaningful clinical benefits in appropriate settings. The optimal approach depends on the disease, the target biology, the patient’s condition, practical treatment considerations, and the totality of clinical evidence. “BiTE therapies may be particularly well suited to cancers with targets that are frequently and consistently expressed on tumor cells, with limited expression in healthy tissues,” said Soria.</p>
<p>Amgen continues to explore the impact of existing BiTE therapies, including the potential to address needs earlier in the small cell lung cancer treatment journey, and the potential to combine BiTE therapies with other innovative mechanisms of action. “We are also investigating new assets across additional tumor types. This includes xaluritamig, an investigational STEAP1-targeted BiTE in advanced clinical development for prostate cancer, where immunotherapy has historically had limited success,” Soria elaborated.</p>
<p>As the understanding of cancer biology grows, immunotherapy will become increasingly precise. Amgen’s focus is to translate deep insights in human genetics and disease biology into the right targets and therapeutic approaches to provide meaningful new options. The company brought to market the first globally approved BiTE molecule in hematologic malignancies, and the first FDA-approved BiTE therapy for a common solid tumor, small cell lung cancer.</p>
<h4><strong>Bumping up defenses</strong></h4>
<p>“The role of any cell therapy is to very potently kill the pathogenic B cells. We use non-genetically modified NK cells in combination with monoclonal antibodies (mAbs) such as Rituxan<sup>®</sup> for targeting the antigen on the B cell,” said Fred Aslan, MD, CEO at Artiva Biotherapeutics.</p>
<p>The Fab region of the mAb binds to the antigen on the B cell while the Fc portion binds to CD16 on the NK cell surface. This three-way binding activates the NK cell to kill the B cell. Given alone, Rituxan relies on endogenous NK cells that can be lowered or have low activity in patients with B cell cancers or autoimmune diseases. Dosing billions of NK cells simultaneously with the mAb positions the mAb to do more.</p>
<figure aria-describedby="caption-attachment-340469" class="wp-caption alignright"><img decoding="async" class="wp-image-340469 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/11/Labant_Artiva_MOA_CAR-T-Alternatives-e1794231580399-300x195.jpg" alt="Artiva_ MOA CAR T Alternatives" width="300" height="195" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Labant_Artiva_MOA_CAR-T-Alternatives-e1794231580399-300x195.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Labant_Artiva_MOA_CAR-T-Alternatives-e1794231580399-1024x665.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/Labant_Artiva_MOA_CAR-T-Alternatives-e1794231580399-768x499.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Labant_Artiva_MOA_CAR-T-Alternatives-e1794231580399.jpg 1398w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">AlloNK is Artiva Biotherapeutics’ lead molecule. The high affinity CD16 NK cell is used in combination with Rituxan (rituximab). The Fab region of the mAb binds to the antigen on the B cell while the Fc portion binds to CD16 on the NK cell surface. This 3-way binding activates the NK cell to kill the B cell. This image was generated using artificial intelligence. [Artiva Biotherapeutics]</figcaption></figure>
<p>Importantly, since NK cells do not expand <em>in vivo,</em> serious side effects that result from T-cell expansion, CRS and ICANS, are avoided allowing therapeutic infusions outside of large hospital settings. However, the high dosages necessitate a robust manufacturing process.</p>
<p>A spin-off of Korea-based GC Cell, Artiva Biotherapeutics’ largest differentiation is its scalable process to manufacture NK cells. Umbilical cord units are selected from individuals with high affinity CD16 on the NK cells. Each umbilical cord creates about 50 intermediates that, in turn, each produce about 80 billion cells. “At a dose of eight billion cells, we can treat about 500 patients with a single umbilical unit. The COGS is a magnitude less than autologous CAR T-cell therapy,” said Aslan.</p>
<p>The company tested the NK cells with multiple targeting mAbs in two oncology and five autoimmune indications, close to 150 patients to date, to generate comparison data between the mAb and the combination therapy.</p>
<p>For example, using Rituxan alone, the average patient had an incomplete depletion; one B cell/ mL remained in the blood. In the combination therapy, no B cells were evident across all indications. In studies with aggressive non-Hodgkin lymphoma and Hodgkin lymphoma using a CD40 antibody, the complete response rate and durability were in line with autologous CAR T-cell therapy. Initial results with autoimmune disease also demonstrated results in line with autologous CAR T-cell therapy.</p>
<p>Artiva Biotherapeutics’ lead indication is refractory rheumatoid arthritis. They are initiating a Phase III trial with data expected by 2028.</p>
<h4><strong>Matching depletion to disease</strong></h4>
<p>The platform approach of Dragonfly Therapeutics for autoimmune disease spans CCR6, CD19, BAFFR, FAP, CD52 and BCMA, each aimed at a different pathogenic population and a different set of diseases, from lupus nephritis to fibrosis to amyloidosis.</p>
<p>The novel immune engagers include both first-in-class mAbs and trispecific immune cell engagers (TriNKETs). TriNKETs are antibody-like molecules with three binding arms: one for an antigen, one for NKG2D, and one for CD16. Both NKG2D and CD16 are activating receptors on NK cells.</p>
<figure aria-describedby="caption-attachment-340470" class="wp-caption alignleft"><img loading="lazy" decoding="async" class="size-medium wp-image-340470" src="https://www.genengnews.com/wp-content/uploads/2026/11/Labant_Dragonfly_Lab-shot_CAR-T-Alternatives-300x169.jpg" alt="Dragonfly Lab" width="300" height="169" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Labant_Dragonfly_Lab-shot_CAR-T-Alternatives-300x169.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Labant_Dragonfly_Lab-shot_CAR-T-Alternatives-1024x576.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/Labant_Dragonfly_Lab-shot_CAR-T-Alternatives-768x432.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Labant_Dragonfly_Lab-shot_CAR-T-Alternatives.jpg 1400w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">The novel immune engagers developed by the Dragonfly Therapeutics team include both first-in-class mAbs and TriNKETs (trispecific immune cell engagers), antibody-like molecules with three binding arms: one for an antigen, one for NKG2D, and one for CD16. [Dragonfly Therapeutics]</figcaption></figure>
<p>In autoimmune disease, CAR T cells and Dragonfly Therapeutics’ biologically native immune engagers both aim for deep depletion of pathogenic B cells and an immune reset, but employ different routes. Not only do NK cells not require the same massive clonal expansion as T cells, but, additionally, NKG2D activation is already tuned by the body to respond to stressed cells. These facets can give a wider window between a depleting versus a harmful dose, sidestepping CAR T toxicity emerging in autoimmune disease.</p>
<p>Recruiting the patient’s existing cells means no expansion phase, no lymphodepletion, no gene modification of a living cell, and, therefore, no secondary malignancy risk from the product itself. A half-life measured in days makes the effect dose-controllable and reversible.</p>
<p>The company’s most clinically advanced autoimmune program, DF5112, a CCR6-targeting mAb, offers a multimodal approach. Overall, DF5112 is designed to deplete pathogenic CCR6+ cells and inhibit chemotaxis, minimizing tissue inflammation, providing benefit across several autoimmune diseases, including psoriatic arthritis, rheumatoid arthritis, lupus, hidradenitis suppurativa, and others.</p>
<p>Near completion of Phase I, the DF5112 CCR6 mAb sits on the specific cells that drive tissue inflammation in many autoimmune diseases, Th17 cells and a subset of memory B cells, while sparing the bulk of the immune system. It is the first molecule to deplete both at once. Early data are on track to be shared end of 2026.</p>
<p>According to Dragonfly Therapeutics, the next generation of immunotherapy is about depleting exactly the right cells. As different autoimmune diseases are driven by different cells, the company is building a toolkit that can match the depleted cell to the disease biology.</p>
<h4><strong>Utilizing distinct T cells </strong></h4>
<p>Another approach is utilizing iNKT cells. iNKT cells are a distinct T cell population with an internal targeting and homing device (iTCR) and modulate both arms of immunity, innate and adaptive. They naturally hone to tissues, promote tumor killing, viral clearance, suppress inflammatory cytokines and GvHD.</p>
<p>MiNK Therapeutics believes that due to iNKT cell biology these cells may represent a foundational approach to immune restoration applicable across a broad range of conditions. iNKTs have shown benefit in treating solid tumor cancers in their native form and MiNK Therapeutics has demonstrated that these cells can be engineered or edited for super-targeting. Clinical data show no neurotoxicity or CRS at 1 billion cells/ dose.</p>
<p>The company’s lead program, agenT-797, an allogeneic, off-the-shelf iNKT-cell therapy, is being evaluated in virally induced acute respiratory distress syndrome (ARDS), where a favorable safety profile, increased survival rate, and decreased secondary infection rates have been observed.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="7"></span></aside>
<h4><strong>Reprogramming tumors</strong></h4>
<p>CAR T cells struggle with solid tumors. Almost no antigens are found solely on tumor cells, plus the antigens that exist are patchy, and get lost over time. According to a USC research team one fix is to install an antigen, but only if the installation stays inside the tumor.<sup>1</sup> The concept is turning a signal the tumor controls into one the physician controls in a safe manner.</p>
<p>Tumor hallmarks like hypoxia are a reasonable biological address, but not a safe one to use alone since brain, liver, bone marrow and gut are also low in oxygen. Focused ultrasound (FUS) gives a precise physical address, but heat-shock-driven expression is a brief spike that fades before T cells can do much.</p>
<p>Therefore, the research team combined inputs to develop SHIFTERS (solid-tumor hallmark inducible, focused-ultrasound triggered enhanced reprogramming system), a two-key AND gated circuit that rewires tumor hallmarks into the clinically-validated antigen CD19 under FUS control. Hypoxia turns on one half of a split Gal4-VP64 transcription factor; FUS heating turns on the other half. Both need to be present for the halves to assemble and switch on CD19.</p>
<figure aria-describedby="caption-attachment-340471" class="wp-caption aligncenter"><img loading="lazy" decoding="async" class="wp-image-340471" src="https://www.genengnews.com/wp-content/uploads/2026/11/Labant_USC_Shifters-schematic_CAR-T-Alternatives-1024x439.jpg" alt="USC Shifters schematic CAR T Alternatives" width="696" height="298" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Labant_USC_Shifters-schematic_CAR-T-Alternatives-1024x439.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/Labant_USC_Shifters-schematic_CAR-T-Alternatives-300x129.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Labant_USC_Shifters-schematic_CAR-T-Alternatives-768x329.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Labant_USC_Shifters-schematic_CAR-T-Alternatives.jpg 1400w" sizes="auto, (max-width: 696px) 100vw, 696px"><figcaption class="wp-caption-text">SHIFTERS combines tumor hypoxia and FUS to induce CD19 in genetically engineered tumor cells. CD19 activates synNotch receptors on engineered T cells, inducing EGFR-directed CAR expression. Primed T cells can then attack EGFR-positive tumor cells, including neighboring cells without induced CD19. Not-to-scale conceptual illustration of a preclinical system; generated by AI. [Wang Lab, USC]</figcaption></figure>
<p>To test the hypothesis, the circuit was pre-installed in tumor cell lines then CD19 synNotch/estimated glomerular filtration rate (EGFR) CAR T cells were infused into 3D spheroids and <em>in vivo</em> immunodeficient mice models. The cells get “primed” by the induced CD19, and then kill surrounding tumor cells via EGFR. Killing stays localized; priming wears off quickly once T cells leave the area.</p>
<p>Testing across different oxygen levels showed the switch only fired at tumor-like one percent, ignoring normal low-oxygen tissue. SHIFTERS holds 60-80% expression through 72 hours, then returns to baseline by about day six; durable enough to work, reversible enough to be safe. With only 25% of tumor cells induced, more than half the entire population was killed.</p>
<p>SHIFTERS is modular. Swapping hypoxia for a liver-cancer-specific promoter reproduced the process in liver cancer cells only, with near-zero activity in other cell types. Next steps include adding ultrasound-gated cytokines (IL-2, IL-18, interferon-γ) to counter tumor immunosuppression without systemic toxicity; building a library of other tumor-hallmark promoters for other cancers; and working out the right FUS dosing schedule and behavior in immunocompetent models.</p>
<p> </p>
<p><em>References</em></p>
<p>1. Guo T, Zhu Z, Qu Y et al. Ultrasound priming gated by solid tumor hallmarks to guide CAR-T therapy. <em>Sci Adv</em>. 2026 Jun 12;12(24):eaed0666. doi: 10.1126/sciadv.aed0666.</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/therapeutic-immune-manipulation/">Therapeutic Immune Manipulation</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>New AI Models Are Turbo&#45;Charging Protein Design</title>
<link>https://edusehat.com/en/new-ai-models-are-turbo-charging-protein-design</link>
<guid>https://edusehat.com/en/new-ai-models-are-turbo-charging-protein-design</guid>
<description><![CDATA[ Computer-designed protein therapeutics move from proof-of-concept to wet-lab validation and even clinical trials as the field heats up.
The post New AI Models Are Turbo-Charging Protein Design appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/GEN_NOV_2026_GettyImages-2172899400.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 09 Nov 2026 22:05:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>New, Models, Are, Turbo-Charging, Protein, Design</media:keywords>
<content:encoded><![CDATA[<p>Getting a new biologic to market is laborious, expensive, and time-consuming, and one of the biggest drains on resources is watching promising candidates fail in preclinical or clinical testing. AI models that can design new proteins may be the ticket to optimizing drug development and providing companies better shots on goal. Companies are taking different approaches to the <em>de novo</em> design, but all share a common need: copious amounts of training data to level up their models. Will it eventually lead to fully autonomous <em>de novo</em> drug design?</p>
<h4><strong>Optimizing multispecifics development</strong></h4>
<p>Sanofi is moving AI-based protein design from proof-of-concept toward real-world drug discovery. Norbert Furtmann, PhD, head of biologics AI and design at Sanofi, says his team’s program is three-pronged: foundational models; property prediction and virtual screening; and <em>de novo </em>design.</p>
<p>The foundational models team develops sequence- and structure based models, analogous to large-language models but trained to “speak the language of proteins,” Furtmann says. These models have been built using a combination of public and in-house data. The property prediction and virtual screening team builds models to predict properties essential for function and developability, including stability, solubility, affinity, and so on. They run large <em>in silico</em> screens on hundreds of thousands of sequences, identifying which designs will move on to lab testing.</p>
<p>This is particularly valuable for multispecifics, where the enormous combinatorial design space makes comprehensive lab testing impossible. “If we have optimized monospecific antibody or nanobody building blocks, let’s say against target A, against target B, and against target C, and we want to plug them together, then we are facing enormous design spaces,” says Furtmann. “That could easily go into the hundreds of thousands of molecules, and you could not test all of them in a lab.”</p>
<p>The <em>de novo</em> design team starts with a target antigen structure and then has the AI model help design antibodies or nanobodies against it. Furtmann says the company’s first proof-of-concept studies on therapeutically relevant targets have been so successful that they are now looking to scale up the program. “We had a target where traditional discovery approaches faced challenges,” he says. Using their <em>de novo</em> design platform, the scientists successfully created functional binders, which Furtmann says are now moving forward into multispecifics.</p>
<p>When designing the binders, Furtmann says, it’s important to look beyond basic characteristics. “We try to think end-to-end and to understand what the monovalent building blocks need to look like to become successful, developable molecules in a multispecific format,” Furtmann says. “If you have a monospecific molecule, and then you plug five of them together for a multispecific, and they don’t behave well anymore, you need to start optimization again.”</p>
<p>The “lab-in-the-loop” workflow is key to this strategy, Furtmann says. This means taking the AI-generated designs, synthesizing them in the lab, and then feeding that data back into the model to fine-tune its designs. To achieve this, the company invests heavily in automation to achieve rapid, reproducible measurements and reliable data. “We aim for integration of the AI with the wet lab to get to fast feedback loops,” he says. “Yes, for monospecific optimization, but also specifically for the more complex multispecific molecules.”</p>
<h4><strong>A whole new type of antibody</strong></h4>
<p>Biolojic Design, based in Ness Ziona, Israel and Washington, DC, is using AI to build “multibodies,” standard human antibodies engineered to bind two or more targets. Unlike bispecific antibodies, which are built from fragments of two different antibodies, multibodies retain the familiar structure of a conventional human IgG antibody. This approach benefits from the established manufacturing, regulatory, pharmacokinetic, and safety advantages of ordinary antibodies, while enabling multiple therapeutic effects from a single drug.</p>
<p>Antibody structure typically includes quite a bit of “unused” space. Antibodies recognize their targets through six complementarity-determining regions (CDRs), but only a small fraction of that surface area is needed for antigen binding. “If you look at known antibody-antigen pairs, most of the CDRs are not involved in binding,” says Yanay Ofran, PhD, founder and CEO of Biolojic. “Each antibody has a lot of ‘free real estate.’ Our models allow us to precisely identify the free real estate and ‘develop’ it to accommodate additional binding.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>The AI model redesigns this part of the molecule, allowing it to recognize additional epitopes without compromising specificity. Each arm of a multibody conditionally binds only one target at a time, but the drug binds differently depending on the tumor, tissue, or patient. This adaptability could help address tumor heterogeneity while limiting off-target interactions.</p>
<p>To build their multibodies, Biolojic fine-tunes temporary, highly specialized models for each project, Ofran says. “This is not a general solution intended to solve all the problems,” he says. “It’s a concentrated effort of a couple of months to build a dedicated model that will make one drug that no other technology can make and then will be retired.” First, existing models propose roughly a billion antibodies, each predicted to possess some desired property, such as binding a particular target or having a good developability profile. Researchers synthesize and test the variants and feed measurements of binding affinity, expression, specificity, and stability back into the model to refine it. That model proposes candidates combining all the required characteristics, which are subsequently evaluated in the lab.</p>
<p>One Biolojic product, a conditional agonist/antagonist, has already entered Phase II trials. The antibody binds the cytokine IL-2 in a context-dependent fashion, enabling it to stimulate T cells that attack the tumor while blocking T cells that protect it. This asset is being developed by Biolojic’s spinout company, Aulos Bioscience. So far, safety and efficacy data are encouraging, Ofran says.</p>
<p>Ofran points out that Biolojic’s approach goes beyond simply speeding up drug discovery. “We want to be fast, we want to be inexpensive, but what we want to do most is to come up with molecules that we are unlikely to find in traditional discovery,” he says. “Not to accelerate the time for getting the same type of molecules that you will get otherwise, but to get molecules that do things that traditionally discovered molecules cannot do.”</p>
<h4><strong>Evolving methods need new benchmarks</strong></h4>
<p>It can be difficult to objectively compare models when proof-of-concept results rely on different targets, assays and metrics, and that’s where Seattle-based A-Alpha Bio comes in. “We are particularly interested in answering this question earnestly: what is the kind of data that helps build better models?” says Natasha Murakowska, PhD, director of applied machine learning at A-Alpha. “What will it require to do this sort of <em>de novo</em> design perfectly every time?”</p>
<figure aria-describedby="caption-attachment-340478" class="wp-caption alignleft"><img fetchpriority="high" decoding="async" class="size-medium wp-image-340478" src="https://www.genengnews.com/wp-content/uploads/2026/11/Seydel-DND-figure-300x187.jpg" alt="AI protein design models" width="300" height="187" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Seydel-DND-figure-300x187.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Seydel-DND-figure-1024x638.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/Seydel-DND-figure-768x478.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Seydel-DND-figure.jpg 1400w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">As AI protein design models proliferate, it’s important to be able to compare different systems against one another using an objective standard benchmark, and to generate large amounts of data for training and improving the models. A-Alpha Bio’s large VHH de novo design benchmark tests models against the same panel of 28 antigens spanning three tiers of difficulty. [A-Alpha Bio]</figcaption></figure>
<p>To that end, A-Alpha is running a large VHH <em>de novo</em> design benchmark. They have invited about a dozen groups to each submit 10,000 designed antibody sequences, which A-Alpha will synthesize and test against a panel of 10 targets, yielding some 110,000 VHHs. Their aim is to build the largest apples-to-apples benchmark of <em>de novo</em>-designed antibodies, evaluating not just whether antibodies bind, but how strongly and how specifically, and what sequence or structural features distinguish the winners.</p>
<p>Central to this effort is AlphaSeq, A-Alpha’s library-on-library yeast display assay. One library encodes the antibodies, the other encodes the targets; when combined, AlphaSeq effectively measures all pairwise interactions. This generates, on the scale of one million quantitative protein-protein interaction data points per experiment, Murakowska explains, revealing information about not only target binding affinity but also off-target effects.</p>
<p>The benchmark’s target panel is stratified into three tiers of difficulty. In Tier 1, a known antibody–antigen crystal structure is provided, and the models must design novel variants that improve binding. Tier 2 provides a crystal structure of the antigen alone, challenging models to choose a bindable epitope and design a complementary interface.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>Tier 3 is what Murakowska calls the “holy grail”: targets where no structural information is provided, requiring the model to infer the antigen’s structure, pick a druggable region, and then design an antibody to bind it. “It stacks complexity, and it tasks model makers in multiple ways,” she says. “If you want to earnestly solve this problem, teams need to think about the holistic problem of representing the right protein, representing the right epitope, which is that surface that the antibody binds, and then also designing for that surface.”</p>
<p>Leveling up AI-assisted drug design requires vast amounts of high-quality data that doesn’t currently exist. A-Alpha recently launched the Atlas Consortium, a collaborative model where companies of very different sizes jointly generate new, shared AlphaSeq datasets under a common experimental framework. One of the key selling points of the Atlas Consortium is that every member, large or small, increases the value of participation for the other members by contributing datasets.</p>
<figure aria-describedby="caption-attachment-340477" class="wp-caption aligncenter"><img decoding="async" class="wp-image-340477" src="https://www.genengnews.com/wp-content/uploads/2026/11/Seydel-GroupPhoto_A-AlphaBio_2026July-e1794232462369-1024x470.jpg" alt="consortium members" width="696" height="319" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Seydel-GroupPhoto_A-AlphaBio_2026July-e1794232462369-1024x470.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/Seydel-GroupPhoto_A-AlphaBio_2026July-e1794232462369-300x138.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Seydel-GroupPhoto_A-AlphaBio_2026July-e1794232462369-768x352.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Seydel-GroupPhoto_A-AlphaBio_2026July-e1794232462369.jpg 1400w" sizes="(max-width: 696px) 100vw, 696px"><figcaption class="wp-caption-text">A new collaborative initiative, the Atlas Consortium, seeks to increase the available body of data to address major objectives for AI-driven protein design. Each quarter, A-Alpha Bio generates datasets using the AlphaSeq platform for training and benchmarking models. These datasets are then pooled and shared with consortium members. [A-Alpha Bio]</figcaption></figure>
<h4><strong>Human out of the loop?</strong></h4>
<p>Anthropic has published results showing that its Claude models can design miniprotein binders with essentially no human involvement. The models designed binders against 15 protein targets and sent the designs to Adaptyv Bio and Twist Bioscience for synthesis and evaluation. Testing confirmed that the Claude-designed minibinders were successful for 14 of the 15 targets.</p>
<p>To achieve this, Claude drew on existing open-source software, including backbone generators like RFdiffusion3; sequence-design tools such as ProteinMPNN; and structure predictors used to screen candidates before synthesis. Within that framework, Claude selected which surface of each target to bind, chose and combined design tools, filtered candidates, and delivered 30 ranked designs per target after 24- to 48-hour autonomous runs. Human involvement was limited to selecting targets, granting permissions, and ensuring the infrastructure was running properly.</p>
<p>Among 1,320 designs, 354 bound their targets, giving an overall hit rate of 27%, although results varied widely depending on the target. Claude was not able to come up with a binder for maltose-binding protein, for instance, although it did produce several binders against TNFα, a therapeutically relevant target that has stumped other AI design efforts.</p>
<p>The designs were evaluated solely for binding affinity, not for activity, and none of the designs were solved structurally. Anthropic describes the result as foundational, a step toward the goal of AI systems autonomously handling drug-discovery from end to end.</p>
<p>“Minibinders are not meant to be drugs,” says Emily Leproust, PhD, CEO of Twist Bioscience. Designing therapeutics will require the model to advance to larger, more complex models, which will require more data points to train them. “That’s why we are adding more and more capacity, so that people can build more data points with us at a lower cost and at speed.”</p>
<p>“What we like about AI is you can do co-optimization of binding and developability at the same time,” Leproust adds. Traditional drug screening involves first optimizing for binding and then engineering in developability after the fact, which can be frustrating and inefficient. Using AI to optimize for both in parallel can boost success rates. “That can significantly, I think, increase the probability that an antibody is going to behave well in the clinic, because you don’t engineer developability after the fact,” she says. “It’s a subtle thing, but it really makes a big impact.”</p>
<p> </p>
<p>The post <a href="https://www.genengnews.com/topics/artificial-intelligence/new-ai-models-are-turbo-charging-protein-design/">New AI Models Are Turbo-Charging Protein Design</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Childhood Cancers May Not Always Need Extra Mutations to Spread, Study Suggests</title>
<link>https://edusehat.com/en/childhood-cancers-may-not-always-need-extra-mutations-to-spread-study-suggests</link>
<guid>https://edusehat.com/en/childhood-cancers-may-not-always-need-extra-mutations-to-spread-study-suggests</guid>
<description><![CDATA[ Childhood cancers may not always need extra mutations to spread, a new review study indicates. Instead, developmental plasticity may let tumor cells shape-shift into states that help them grow, resist treatment, and ultimately metastasize.
The post Childhood Cancers May Not Always Need Extra Mutations to Spread, Study Suggests appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/01/GettyImages-2204955763.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 09 Nov 2026 22:05:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Childhood, Cancers, May, Not, Always, Need, Extra, Mutations, Spread, Study, Suggests</media:keywords>
<content:encoded><![CDATA[<p><span>Data from a new study from scientists at the University of East Anglia and Liverpool John Moores University could help explain why some childhood tumors spread aggressively despite having relatively few genetic mutations. The findings, which are published in a new </span><i><span>Trends Open </span></i><span>review paper,</span><span> indicate that childhood cancers may not always need to develop extra mutations to spread. Some cells may be able to switch into different cellular states between behaviors that help them grow, survive treatment, and ultimately spread. </span></p>
<p><span>Furthermore, in the paper, titled “Developmental plasticity as a framework for paediatric cancer metastasis,” the scientists write that the process may be reversible. “Many childhood cancers arise from cells that are still closely linked to developmental programs used during early life,” and these programs “normally allow cells to move around the developing body, adapt to changing environments, and become different tissue types,”  said Darrell Green, PhD, an assistant professor and scientific group leader for RNA research at Norwich Medical School at University of East Anglia and one of the authors on the paper. “We think that cancer cells in children may exploit this natural flexibility of young, developing cells in order to spread.” </span></p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p><span>To reach their conclusions, the scientists reviewed evidence from various childhood cancers, including neuroblastoma, Ewing sarcoma, osteosarcoma, medulloblastoma, and rhabdomyosarcoma. According to the paper, they integrated “genomic, epigenomic, developmental and single-cell evidence to examine how oncogenic lesions and developmental origins define accessible cellular states, while epigenetic, metabolic, and microenvironmental signals regulate transitions between them.”</span></p>
<p><span>Based on their analysis, the scientists propose that genetic changes determine which cellular identities cancer cells can adopt, while reversible changes in gene activity seem to dictate whether those cells become aggressive, resistant to treatment or capable of forming metastatic tumors. </span></p>
<p><span>This suggests that “rather than needing to acquire new mutations before they can spread, childhood cancer cells may already possess the ability to become metastatic,” Green explained. “The new, key question is not just what mutations they carry, but which cellular state they are in at a particular moment.” It is a point that “challenges the long-held assumption that cancers must acquire new mutations before they can metastasize.” </span></p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p><span>The scientists hope that their work could ultimately lead to new types of treatments or at least point to ways to modify existing treatments. This means, for example, that instead of focusing solely on killing tumor cells or targeting mutated genes, future therapies might aim to stop cancer cells entering the states that make them dangerous in the first place. In fact, “it may eventually become possible to predict when cancers are preparing to spread,” Green said. </span></p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/childhood-cancers-may-not-always-need-extra-mutations-to-spread-study-suggests/">Childhood Cancers May Not Always Need Extra Mutations to Spread, Study Suggests</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>StockWatch: Nurix Nosedives as Sanofi Halts Phase I Immunology Candidate</title>
<link>https://edusehat.com/en/stockwatch-nurix-nosedives-as-sanofi-halts-phase-i-immunology-candidate</link>
<guid>https://edusehat.com/en/stockwatch-nurix-nosedives-as-sanofi-halts-phase-i-immunology-candidate</guid>
<description><![CDATA[ Sanofi halted development of an oral STAT6 degrader that had been under study in a Phase I first-in-human trial in Europe. STAT6, a key drug target in type 2 inflammation, is among the five targets identified by the companies in their collaboration, launched in 2020. 
The post StockWatch: Nurix Nosedives as Sanofi Halts Phase I Immunology Candidate appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/nurix-scientist.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 09 Nov 2026 11:15:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>StockWatch:, Nurix, Nosedives, Sanofi, Halts, Phase, Immunology, Candidate</media:keywords>
<content:encoded><![CDATA[<p><strong>Nurix Therapeutics (Nasdaq: NRIX)</strong> suffered its worst one-day loss as a public company Wednesday when <strong>Sanofi (Euronext Paris: SAN and Nasdaq: SNY)</strong> terminated development of the Phase I immunology candidate SAR448272 (NX-3911)—a key program of the companies’ nearly seven-year, up to $ 2.5 billion collaboration to discover, develop, and commercialize protein degradation drugs for “challenging” diseases.</p>
<p>The rest of the collaboration continues despite Sanofi pulling the plug on SAR448272 (NX-3911), an oral signal transducer and activator of transcription 6 (STAT6) degrader that had been under study in a Phase I first-in-human trial in Europe (European Union Clinical Trials Register number <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Feuclinicaltrials.eu%2Fctis-public%2Fview%2F2026-526014-87-00&data=05%7C02%7Calex.philippidis%40sagepub.com%7Cc95c54bf0ac44b176ea408df3b6c9722%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639295012066774767%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=FBy14hQz1TcP2YE%2BGi9ZXifh%2BnNO7%2FFCA%2F2kR9qSDo8%3D&reserved=0">2026-526014-87-00</a>). The trial began recruiting patients in Germany in July and had planned to expand recruitment into the Czech Republic, France, Italy, and Spain, a milestone that triggered a $10 million payment from Sanofi to Nurix in August.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>STAT6, a key drug target in type 2 inflammation, is among the five targets identified by the companies in their collaboration, which took effect in January 2020 when Sanofi paid Nurix $55 million upfront. At the time, Sanofi committed to paying Nurix up to $2.5 billion in total payments, most of that tied to achieving research, preclinical, clinical, regulatory, and sales milestones.</p>
<p>As of August 31, Sanofi had paid Nurix a total $129 million—the $55 million upfront; $22 million in 2021 when Sanofi exercised an option to expand from three to five targets; $22 million for achieving research milestones; and $30 million for license extension fees—according to Nurix’s <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fir.nurixtx.com%2Fstatic-files%2Fc8ca0871-108d-480d-9f6b-080ac39488ff&data=05%7C02%7Calex.philippidis%40sagepub.com%7Cc95c54bf0ac44b176ea408df3b6c9722%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639295012066792878%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=JZEd8DtVNcs5ZdwuUcpKAULtGF3YcMalBSJBOsZRQ%2FQ%3D&reserved=0">Form 10-Q quarterly report for the third quarter</a>, filed October 13.</p>
<p>Nurix insisted that its recent cash runway guidance would not be affected by Sanofi’s halting development of SAR448272. Nurix said it had enough cash to fund operations into the second half of 2029 based on its $1.1 billion of cash, cash equivalents, and marketable securities as of August 31.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<h4><strong>Reassurance and rejection</strong></h4>
<p>“While [Tuesday]’s news is disappointing, Nurix remains in a strong position, with a substantial cash runway, three clinical-stage programs across our wholly owned and partnered portfolio, and an exciting preclinical pipeline,” Arthur T. Sands, MD, PhD, Nurix president and CEO, stated Tuesday after the close of markets.</p>
<p>The following day, investors appeared to reject that reassurance, selling off enough shares for Nurix stock to <span><strong>nosedive 38%</strong></span> from $25.82 to $15.95. Shares <span><strong>fell another 7%</strong> </span>to $14.84 Thursday on a day the Nasdaq market had its worst one-day performance in the past 19 months—but the stock <span><strong>bounced back 3%</strong></span> Friday, finishing the week at $15.30 and a <span><strong>nearly 43% five-day decline</strong></span>.</p>
<p>“While we can understand the market’s knee-jerk disappointment following the news (STAT6 is regarded as a high-value target), we continue to view Nurix as a differentiated name within the emerging oral protein degrader space,” Tessa T. Romero, a senior analyst focused on biotechnology equity research with J.P. Morgan, wrote in a research note.</p>
<p>The reason why, Romero explained, is Nurix’s ongoing up-to-$2.3 billion global collaboration with <strong>Roche (SIX Swiss: RO and ROP)</strong> to develop bexobrutideg (“bexdeg” or “bexo”; NX-5948), a clinical-phase oral brain-penetrant Bruton’s tyrosine kinase (BTK) degrader.</p>
<p>In addition to the dollars, Romero said, that partnership is also attractive for Nurix because bexdeg can potentially be developed for numerous other therapeutic areas with diseases driven by BTK; the collaboration stretches across malignant hematology, immunology, and neurology.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>Another reason why the Roche-Nurix partnership is attractive, the J.P. Morgan analyst added, is because Roche shoulders 60% of global development costs (with Nurix chipping in the other 40%) while the companies have agreed to split 50-50 both the U.S. commercialization responsibility (Roche holds sole ex-U.S. commercialization rights), as well as the resulting profits and losses from U.S. commercialization.</p>
<h4><strong>$48B market opportunity</strong></h4>
<p>“Historical stock moves around NRIX/STAT6 suggest the program carried some value, but was not the primary driver of NRIX’s value, with the much larger strategic inflection tied to the Roche/bexo partnership,” commented Roger Song, MD, equity analyst with Jefferies, in a research note.</p>
<p>In a June 8 <a href="https://ir.nurixtx.com/static-files/7ab7c64e-19dd-4242-bf61-420c9dfba537#page=15">investor presentation</a>, Nurix quantified the size of that potential inflection as a $48 billion addressable market opportunity across five diseases: chronic lymphocytic leukemia (CLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), chronic spontaneous urticaria (CSU), and multiple sclerosis (MS).</p>
<p>CLL and small lymphocytic lymphoma (SLL) are the two diseases where bex-deg development is furthest along; the drug is under study in the Phase III DAYBreak trial (CLL-306, <a href="https://clinicaltrials.gov/study/NCT07516093">NCT07516093</a>), which is recruiting patients toward an estimated enrollment of 620, and carries an estimated primary completion date of October 2029. Last month, the first patient was enrolled in a Phase I/II combination trial (NX-5948-203; <a href="https://clinicaltrials.gov/study/NCT07520006">NCT07520006</a>) evaluating the combination of bex-deg and venetoclax, a standard-of-care BCL2 inhibitor, in patients with relapsed/refractory CLL, with planned expansion to first-line therapy.</p>
<p>“We see opportunity for upside from bex-deg expansion into inflammatory/autoimmune and neurological indications,” Kostas Biliouris, PhD, a managing director on the biotechnology research team of Oppenheimer, wrote in a research note. “We see CSU as [a] particularly attractive indication given derisking of BTK-targeting by [Novartis’ <strong>(SIX Swiss: NOVN and NYSE: NVS)</strong> BTKi (BTK inhibitor)] remibrulnib and higher bex-deg potency on mast cell degranulation assay without bleeding risk.</p>
<h4><strong>Sanofi’s decision</strong></h4>
<p>So why did Sanofi terminate development of SAR448272?</p>
<p>Nurix offered no reason in its press release, and company executives told Song of Jefferies it was not told in advance of the decision.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>“The decision was due to emerging nonclinical findings that precluded Sanofi from bringing it forward in atopic dermatitis,” Sanofi indicated to Nurix during a quick catch up conversation, according to Romero, who cautioned: “Nurix has <em>not </em>reviewed any data and therefore could not confirm the issues Sanofi saw. Nurix is also unclear whether Sanofi’s broader portfolio strategy played a role in the decision.”</p>
<p>Biliouris offered a possible portfolio explanation for Sanofi’s decision: “It may be driven by robust/convincing (HV) data from other SNY [Sanofi] collaboration (STAT6i), STAT6 degrader safety signals, or SNY strategic prioritization following [<strong>Regeneron Pharmaceuticals (Nasdaq: REGN)</strong>]’s partnership around long-acting IL-13/IL-13 x IL-14,” Biliouris wrote.</p>
<p>Sanofi is partnering with privately held <strong>Recludix Pharma</strong> to develop an oral STAT6 inhibitor or “STAT6i” called REX-8756 (also known as SAR448755). REX-8756 is a first-in-class, reversible orthosteric inhibitor of the STAT6 SH2 domain that targets Type 2 inflammatory pathways (IL-4 and IL-13), and which according to the companies is designed to be highly potent, selective, and durable.</p>
<p>The companies have advanced REX-8756 to a Phase I trial designed to assess the drug’s safety, tolerability, pharmacokinetics, and pharmacodynamics, with single ascending dose (SAD) and multiple ascending dose (MAD) cohorts. The blinded, placebo-controlled trial expects to enroll approximately 100 healthy volunteers.</p>
<p>Recludix presented positive preclinical model data for REX-856 at the Revolutionizing Atopic Dermatitis (RAD) Congress, held June 17-19 in Nashville, TN. Sanofi and Recludix launched their collaboration in 2023. It includes $125 million in “near-term” payments; up to $1.2 billion-plus in development, regulatory and sales milestones; as well as up to double-digit royalties on product sales.</p>
<p>More recently last month, Sanofi and Regeneron expanded their 23-year-old partnership—whose most successful product is the multi-indication blockbuster Dupixent<sup>®</sup> (dupilumab)—by adding multiple next-generation, long-acting antibodies to their alliance. Sanofi agreed to pay Regeneron $1 billion upfront, and up to an additional $7 billion tied to achieving development, regulatory, and commercial milestones.</p>
<p>Under the expanded license and collaboration agreement, Sanofi and Regeneron agreed to co-develop and co-commercialize four new long-acting, Regeneron-invented antibodies targeting interleukin-13 (IL-13), IL-4xIL-13 bispecific, interleukin-4 (IL-4), and interleukin-4 receptor alpha (IL-4Rα). The IL-13 antibody, REGN20423, is now being evaluated in the Phase I AURA-AD trial (<a href="https://clinicaltrials.gov/study/NCT07527923">NCT07527923</a>) in atopic dermatitis, while the other three antibodies are expected to enter the clinic in 2027.</p>
<p> </p>
<h2><strong>Leaders and laggards</strong></h2>
<p><strong>Karyopharm Therapeutics (KPTI)</strong> shares <span><strong>skidded 21%</strong></span> Tuesday, from 11 cents to 9 cents, after the Newton, MA-based developer of nuclear export inhibitors designed to treat cancer said it filed for protection from creditors under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Texas. Karyopharm said it entered into a Restructuring Support Agreement with its lenders, noteholders, and other key stakeholders, under which the company, once reorganized, plans to merge with privately held, London-based <strong>Ayrmid</strong>—which has agreed to serve as lead bidder in a court-supervised sale process intended to maximize value for all stakeholders. Karyopharm said it has secured commitments for up to $55 million in debtor-in-possession (DIP) financing from its existing secured lenders. Upon court approval, the DIP financing plus cash from ongoing operations is expected to support Karyopharm operations during the Chapter 11 process and meet the company’s financial obligations.</p>
<p><strong>Rhythm Pharmaceuticals (NASDAQ: RYTM)</strong> shares <span><strong>surged 28%</strong></span> from $86.44 to $110.68 Wednesday after <em>The Wall Street Journal</em> reported that <strong>AstraZeneca (LSE, NYSE, and Nasdaq Stockholm: AZN)</strong> made a roughly $10 billion offer to buy the rare disease drug developer, citing unnamed sources. AstraZeneca offered to pay $124 a share for the biotech last month, the Journal reported—a 35% premium over Rhythm’s closing share price Tuesday. AstraZeneca raised its bid to $134 a share, according to Reuters. Rhythm has declined comment while AstraZeneca has not commented on the reported offers. Shares <span><strong>slid 5%</strong></span> to $105.02 Thursday before <span><strong>rising again 7%</strong></span> to $112.28 Friday, after the merger-and-acquisition blog Betaville posted speculation from traders that a second potential global pharma giant may have made a counteroffer for Rhythm.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/stockwatch-nurix-nosedives-as-sanofi-halts-phase-i-immunology-candidate/">StockWatch: Nurix Nosedives as Sanofi Halts Phase I Immunology Candidate</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Nova Scotia blood management program helping patients prepare for safer surgery</title>
<link>https://edusehat.com/en/nova-scotia-blood-management-program-helping-patients-prepare-for-safer-surgery</link>
<guid>https://edusehat.com/en/nova-scotia-blood-management-program-helping-patients-prepare-for-safer-surgery</guid>
<description><![CDATA[ Established 25 years ago, the program supports hundreds of surgical patients each month by identifying and treating blood-related conditions before and after procedures. Nova Scotia Health is highlighting the role of its Perioperative Blood Management program in improving surgical safety, reducing the need for blood transfusions and supporting patient recovery. The program, which has operated […]
The post Nova Scotia blood management program helping patients prepare for safer surgery appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/11/shutterstock_2739633431.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 09 Nov 2026 04:00:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Nova, Scotia, blood, management, program, helping, patients, prepare, for, safer, surgery</media:keywords>
<content:encoded><![CDATA[<p>Established 25 years ago, the program supports hundreds of surgical patients each month by identifying and treating blood-related conditions before and after procedures.</p>
<p>Nova Scotia Health is highlighting the role of its Perioperative Blood Management program in improving surgical safety, reducing the need for blood transfusions and supporting patient recovery.</p>
<p>The program, which has operated for 25 years, helps patients undergoing surgery in Halifax and Dartmouth optimize their blood health before, during and after procedures.</p>
<p>One of the first programs of its kind in Canada and the largest east of Montreal, the service focuses on identifying and treating conditions such as anemia and iron deficiency that can increase surgical risks.</p>
<p>The team assesses approximately 150 new surgical patients each month and supports more than 300 additional patients during and after hospitalization.</p>
<h3>Identifying risks before surgery</h3>
<p>Anemia and iron deficiency can significantly affect a patient’s ability to tolerate surgery and recover afterward.</p>
<p>When these conditions go undetected, patients may be more likely to require blood transfusions, experience complications or face longer hospital stays.</p>
<p>The Perioperative Blood Management team works to identify these concerns early, allowing clinicians to implement appropriate treatment before surgery whenever possible.</p>
<p>Ideally, patients are assessed four to six weeks before their scheduled procedures, providing time to improve blood health and reduce potential complications.</p>
<p>The approach emphasizes preserving and managing a patient’s own blood rather than relying unnecessarily on transfusions.</p>
<h3>Supporting hundreds of patients monthly</h3>
<p>The program is led by nurse practitioner Heather Mingo, anesthesiologist Dr. Blaine Kent, and registered nurses Erin Sampson and Katlyn Carver.</p>
<p>Together, the team works with patients and surgical care providers to identify blood-related concerns, coordinate treatment and support recovery.</p>
<p>Their work takes place within a busy provincial surgical system.</p>
<p>Nova Scotia Health reported completing more than 73,000 surgeries between April 1, 2025, and March 31, 2026.</p>
<p>With approximately one in four surgical patients experiencing anemia, early identification and treatment of blood-related conditions represent important opportunities to improve perioperative care.</p>
<p>The program’s work extends beyond preoperative assessment, with patients receiving support during hospitalization and following surgery when needed.</p>
<h3>Reducing unnecessary transfusions</h3>
<p>Patient blood management has become an internationally recognized approach to improving surgical care.</p>
<p>The World Health Organization has formally recognized the importance of blood management since 2010.</p>
<p>Advances in surgical techniques, anesthesia and methods of controlling blood loss have also helped reduce the need for transfusions.</p>
<p>Although transfusions remain essential and potentially lifesaving for many patients, avoiding unnecessary exposure to blood products can help reduce certain risks while preserving blood supplies for those who need them.</p>
<p>The Nova Scotia program also has experience supporting patients who cannot accept blood transfusions for religious or other reasons.</p>
<p>This work has contributed to the team’s approach to individualized surgical planning and blood conservation.</p>
<h3>Recognizing excellence in surgical care</h3>
<p>The Perioperative Blood Management team received the 2024 Dalhousie University Department of Anesthesia, Pain Management, and Perioperative Medicine Internal Team Award of Excellence.</p>
<p>The recognition acknowledged the team’s contributions to patient care and the management of blood-related issues throughout the surgical journey.</p>
<p>Nova Scotia Health highlighted the program during Blood Management Awareness Week, held November 2 to 6.</p>
<p>As healthcare systems continue working to improve surgical outcomes and make efficient use of resources, programs that identify and manage risks before surgery can play an important role.</p>
<p>Nova Scotia’s experience demonstrates how multidisciplinary collaboration and early intervention can support safer procedures, more individualized treatment and improved patient recovery.</p>
<p>Source: <a href="https://www.nshealth.ca/news-and-notices/supporting-safer-surgeries-nova-scotia-healths-perioperative-blood-management?utm_source=chatgpt.com">Nova Scotia Health — Supporting safer surgeries with the Perioperative Blood Management program</a></p>
<div>
<div></div>
</div>
<p>The post <a href="https://www.hospitalnews.com/nova-scotia-blood-management-program-helping-patients-prepare-for-safer-surgery/">Nova Scotia blood management program helping patients prepare for safer surgery</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The Aging Proteome: Clocks, Cohorts, and Clinical Trials</title>
<link>https://edusehat.com/en/the-aging-proteome-clocks-cohorts-and-clinical-trials</link>
<guid>https://edusehat.com/en/the-aging-proteome-clocks-cohorts-and-clinical-trials</guid>
<description><![CDATA[ In this GEN webinar, two experts will show how ultra-sensitive, multiplexed proteomics can measure both the pace of aging and the effects of interventions designed to change it. 
The post The Aging Proteome: Clocks, Cohorts, and Clinical Trials appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Getty_460712007_DNA.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 07 Nov 2026 09:05:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, Aging, Proteome:, Clocks, Cohorts, and, Clinical, Trials</media:keywords>
<content:encoded><![CDATA[<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"></div>
</div>


<p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Register Now</button></p>

<h3 class="w-full text-left">
    <strong>
        Panelists:
    </strong>
</h3>
<div class="flex flex-row m-0-auto items-stretch justify-center flex-wrap mb-4">
    
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/11/XiaoJunMa_headshot.jpg" class="h-full w-full object-cover" alt="Image of Xiao-Jun Ma, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Xiao-Jun Ma, PhD</h2>
                <h3 class="mt-0 !text-[15px] !leading-[21px]">Chief Technology Officer<br>Alamar Biosciences</h3>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/11/XiaoJunMa_headshot.jpg" alt="Image of Xiao-Jun Ma, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Xiao-Jun Ma, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Xiao-Jun Ma, PhD, joined Alamar Biosciences in June of 2021 as chief technology officer. Xiao-Jun is a successful R&D leader with more than 20 years of experience in the life sciences and molecular diagnostics industries. Most recently he served as vice president and chief scientific officer in the Genomics Division of Bio-Techne. During his 11-year tenure at ACD, Ma led the development of a portfolio of<em> in situ</em> RNA and DNA detection solutions for research and clinical diagnostics markets. Prior to joining ACD, he was vice president of R&D/biostatistics at bioTheranostics. Before bioTheranostics, Ma held senior bioinformatics positions at Johnson & Johnson and Monsanto/Searle (Pfizer), where he applied his multi-disciplinary knowledge in molecular biology and bioinformatics to discover novel drug targets and biomarkers. He received his doctorate training in biochemistry at Case Western Reserve University and the University of Iowa and post-doctoral training in molecular genetics at the University of California, Los Angeles.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog>
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/11/MichaelCorley_headshot.jpg" class="h-full w-full object-cover" alt="Image of Michael J. Corley, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Michael J. Corley, PhD</h2>
                <h3 class="mt-0 !text-[15px] !leading-[21px]">Tenured Assoc. Professor of Medicine<br>University of California, San Diego</h3>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/11/MichaelCorley_headshot.jpg" alt="Image of Michael J. Corley, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Michael J. Corley, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Michael J. Corley, PhD, is an associate professor in medicine within the Division of Geriatrics, Gerontology, & Palliative Care and The Stein Institute for Research on Aging. He received his undergraduate degree from UCSD, an MA and PhD in behavioral neuroscience from the University of Hawaii, and completed postdoctoral training at the John A. Burns School of Medicine in epigenetics, immunology, and infectious diseases. Corley leads a global epigenetics research program focusing on understanding the interplay between the immune system, viruses, and aging. His laboratory is at the forefront of generating critical data to advance the development, validation, and implementation of novel biomarkers and therapeutics aimed at promoting longevity.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog></div>



<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-malblocks-webinars-info"></p><div><strong>Broadcast Date:</strong> <time>Tuesday, December 1, 2026</time><br><ul><li><strong>Time:</strong> <time datetime="2026-12-01T16:00:00.000Z">08:00 PST, 11:00 EST, 16:00 GMT</time></li></ul></div>


<div aria-hidden="true" class="wp-block-spacer"></div>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow">
<p class="wp-block-paragraph">Geroscience proposes that slowing the biology of aging could delay many chronic diseases at once. Testing that idea requires biomarkers that are precise, reproducible, and responsive to intervention.</p>


<p class="wp-block-paragraph">In this <em>GEN</em> webinar, two experts will show how ultra-sensitive, multiplexed proteomics can measure both the pace of aging and the effects of interventions designed to change it. In his talk, Michael Corley, PhD, will explain why the aging field is limited less by ideas than by evidence, and how completed clinical trials with banked samples can be used to screen candidate interventions quickly. He will share proteomic and epigenetic findings from a randomized trial of semaglutide, including cardiometabolic and inflammatory protein changes during treatment and after the drug is stopped. He will also describe XPRIZE Healthspan, a global competition whose central biorepository will hold samples from 20 intervention trials.</p>


<p class="wp-block-paragraph">Then Xiao-Jun Ma, PhD, will present a data-driven proteomic module identified across three cohorts that tracks biological aging. He will show how a clock built from this module relates to mortality, cognition, and comorbidity burden, how it compares with DNA methylation clocks, and what it reveals about when proteomic aging accelerates. Key takeaways include:</p>


<ul class="wp-block-list">
<li>Why evidence, not ideas, is the bottleneck in geroscience, and how completed trials can help close the gap</li>



<li>How proteomic measurements capture intervention effects that epigenetic clocks may miss</li>



<li>How an intrinsic, unsupervised protein module can serve as a portable measure of biological aging</li>



<li>What large, harmonized trial biorepositories mean for biomarker discovery in aging research</li>
</ul>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><em>A live Q&A session will follow the presentation offering you a chance to pose questions to our expert panelists.</em></p>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><strong>Produced with support from:</strong></p>


<figure class="wp-block-image alignleft size-medium"><a href="https://alamarbio.com/" target="_blank" rel=" noopener"><img decoding="async" width="300" height="80" src="https://www.genengnews.com/wp-content/uploads/2024/10/AlamarDropLogo_4c-300x80.jpg" alt="Alamar Biosciences Logo" class="wp-image-302414" srcset="https://www.genengnews.com/wp-content/uploads/2024/10/AlamarDropLogo_4c-300x80.jpg 300w, https://www.genengnews.com/wp-content/uploads/2024/10/AlamarDropLogo_4c.jpg 379w" sizes="(max-width: 300px) 100vw, 300px"></a></figure>
</div>
</div>

<p>The post <a href="https://www.genengnews.com/multimedia/webinars/the-aging-proteome-clocks-cohorts-and-clinical-trials/">The Aging Proteome: Clocks, Cohorts, and Clinical Trials</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>ER&#45;Negative Breast Cancer Risk Linked with Blood Levels of Two PFAS Forever Chemicals</title>
<link>https://edusehat.com/en/er-negative-breast-cancer-risk-linked-with-blood-levels-of-two-pfas-forever-chemicals</link>
<guid>https://edusehat.com/en/er-negative-breast-cancer-risk-linked-with-blood-levels-of-two-pfas-forever-chemicals</guid>
<description><![CDATA[ The results of a study found that women with higher blood levels of two common PFAS were more likely to develop estrogen receptor-negative breast cancer, saying their results have important public health implications.
The post ER-Negative Breast Cancer Risk Linked with Blood Levels of Two PFAS Forever Chemicals appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2022/09/Nov19_2020_Getty_1201440632_CancerCell-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 07 Nov 2026 01:55:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>ER-Negative, Breast, Cancer, Risk, Linked, with, Blood, Levels, Two, PFAS, Forever, Chemicals</media:keywords>
<content:encoded><![CDATA[<p>Per- and polyfluoroalkyl substances (PFAS) are a large group of chemicals used in common consumer products. Often referred to as “forever chemicals,” PFAS do not break down easily in the environment and can remain in the body for years.</p>
<p>The results of a study carried out by National Institutes of Health researchers has now found that women with higher blood levels of two common PFAS, perfluorooctanoic acid (PFOA) and perfluorooctanesulfonic acid (PFOS), were more likely to develop estrogen receptor-negative (ER-negative) breast cancer. ER-negative tumors lack receptors that allow the hormone estrogen to help cancer cells grow. There was no clear association observed between the two chemicals and breast cancer risk overall.</p>
<p>“Our findings, which we confirmed using a meta-analysis of prior research, indicate that certain legacy PFAS, including PFOA and PFOS, are associated with a higher risk of ER-negative breast cancer, a more aggressive tumor type with few known risk factors,” said NIH Stadtman Investigator Alexandra White, PhD, who led the study. Although PFOA and PFOS compounds have been largely phased out and replaced with new PFAS compounds, most individuals have measurable levels of PFOA and PFOS in their bodies.</p>
<p>White is senior and corresponding author of the researchers’ published paper in <em>Journal of Clinical Oncology</em>, titled “<a href="https://doi.org/10.1200/JCO-26-00318" target="_blank" rel="noopener">Per- and Polyfluoroalkyl Substance Exposure and Breast Cancer Incidence in the Sister Study</a>,” in which they concluded “Given the widespread exposure to PFAS and limited established risk factors for ER-negative tumors, these results have important public health implications.”</p>
<p>Breast cancer is the most common cancer among women, and incidence rates are rising in the U.S. and worldwide, the authors stated. Established breast cancer risk factors, such as reproductive history, exogenous hormone use and lifestyle factors, have been more strongly linked with hormone receptor–positive than with hormone receptor–negative tumors.</p>
<p>Scientists know less about what raises the risk of ER-negative breast cancer. “Evidence suggests that hormone receptor–negative tumors might have distinct etiologies, yet their risk factors remain largely unknown,” the researchers wrote. “This knowledge gap is concerning as hormone receptor–negative tumors are more aggressive with poorer clinical outcomes.”</p>
<p>The newly reported research drew on the <a href="https://www.niehs.nih.gov/research/atniehs/labs/epi/resources/data-sharing/sister" target="_blank" rel="noopener">Sister Study</a>, which is led by NIH’s National Institute of Environmental Health Sciences (NIEHS). This larger study enrolled 50,884 women ages 35–74 in the U.S. and Puerto Rico from 2003 to 2009. None had breast cancer when they joined the Sister Study, but each had a full or half-sister who had been previously diagnosed with breast cancer.</p>
<p>For their PFAS study White and team included 1,609 women who developed breast cancer and a comparison sample of 2,269 women. “We oversampled estrogen receptor (ER)–negative cases (324 ER-negative, 1,120 ER-positive) to improve statistical power,” they explained in their paper. “To our knowledge, this is the largest study to date of PFAS exposure and breast cancer incidence, particularly for ER–tumors.”</p>
<p>The investigators measured 17 PFAS in blood, collected years before women were diagnosed with cancer. “Seventeen PFASs were quantified in prediagnostic plasma using liquid chromatography-high-resolution mass spectrometry,” they noted. The results of their studies showed that women in the group with the highest PFOA levels had a 67% higher rate of ER-negative breast cancer than those in the lowest group. For PFOS, the rate was 93% higher—nearly twice as high. These numbers describe relative differences between groups, not an individual woman’s chance of getting breast cancer.</p>
<p>The team also carried out meta-analyses, including the current and prior prospective studies, which showed consistent positive associations of PFOA and PFOS with ER-negative breast cancer. “Our meta-analyses of studies with prediagnostic blood measurements further support a positive association between PFOA and ER-tumors, with suggestive evidence for PFOS and ER-tumors,” they stated.</p>
<p>“These findings matter for women’s health broadly,” said first author Che-Jung Chang, PhD, a former research fellow at NIH and a current researcher at DLH, a scientific research organization. “Although PFAS are persistent in the environment and in our bodies, exposure to them is still potentially modifiable, meaning people can take steps to reduce their exposure, and these findings could open new avenues for prevention.”</p>
<p>Because the strongest associations involved tumors without hormone receptors, the authors suggest that PFAS may affect cancer risk through other non-hormonal biologic pathways. Possible pathways include changes in gene activity or immune system. The reported study did not test those potential explanations.</p>
<p>The authors say future studies should evaluate people with higher PFAS exposure and in groups more affected by ER-negative breast cancer. “More research is needed, particularly evaluating the risk of breast cancer associated with newer replacement PFAS chemicals,” White added.</p>
<p>In their paper the authors concluded, “Future studies should prioritize investigating these associations in populations with higher PFAS exposure and a greater burden of hormone receptor–negative breast cancer to better inform targeted prevention efforts. Research is also needed to assess the carcinogenic potential of newer PFAS replacement chemicals, which remain poorly characterized.”</p>
<p>Department of Health and Human Services (HHS) Secretary Robert F. Kennedy, Jr., commented, “Women deserve clear answers about how chemicals in their environment may affect their health. This NIH study links two forever chemicals to a higher risk of ER-negative breast cancer and demands further investigation. Under President Trump’s leadership, we will pursue the evidence, confront environmental health risks, and give women the information they need to protect their health.”</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/er-negative-breast-cancer-risk-linked-with-blood-levels-of-two-pfas-forever-chemicals/">ER-Negative Breast Cancer Risk Linked with Blood Levels of Two PFAS Forever Chemicals</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Novartis Confirms Nine Cases of Tumors in Children Treated with Gene Therapy Zolgensma</title>
<link>https://edusehat.com/en/novartis-confirms-nine-cases-of-tumors-in-children-treated-with-gene-therapy-zolgensma</link>
<guid>https://edusehat.com/en/novartis-confirms-nine-cases-of-tumors-in-children-treated-with-gene-therapy-zolgensma</guid>
<description><![CDATA[ &quot;Two cases to date have shown evidence of vector integration into the DNA of the patients. In both cases, the patients underwent treatment and continue to be monitored,” Novartis said in a statement.
The post Novartis Confirms Nine Cases of Tumors in Children Treated with Gene Therapy Zolgensma appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Dec14_2020_Getty_904268264_XYChromosomes1-1024x683-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 07 Nov 2026 01:55:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Novartis, Confirms, Nine, Cases, Tumors, Children, Treated, with, Gene, Therapy, Zolgensma</media:keywords>
<content:encoded><![CDATA[<p>Novartis has confirmed nine reports—seven of them newly disclosed—in which tumors have developed in children treated with its marketed spinal muscular atrophy gene therapy Zolgensma<sup>®</sup> (onasemnogene abeparvovec-xioi).</p>
<p>“Of those, two cases to date have shown evidence of vector integration into the DNA of the patients. In both cases, the patients underwent treatment and continue to be monitored,” Novartis said in a statement furnished to <em>GEN</em> and other news outlets.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>“Patient safety is our priority. In each case, we timely and appropriately notified health authorities and will continue to work with them on next steps,” the pharma giant added.</p>
<p>To date, Novartis stated, Zolgensma has been used to treat more than 6,000 patients worldwide across clinical trials, managed access programs, and commercial treatment.</p>
<p>The statement added: “The potential risk of tumors due to vector integration is currently included in the Zolgensma prescribing information.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>Zolgensma is an adeno-associated virus (AAV) vector-based gene therapy indicated for the treatment of pediatric patients less than two years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (<em>SMN1</em>) gene.</p>
<p>Zolgensma is designed to address the genetic root cause of SMA by replacing the function of the missing or nonworking <em>SMN1</em> with a new working copy of the gene delivered into a patient’s cells. The gene therapy consists of a recombinant, non-replicating AAV serotype 9 (AAV9) vector whose DNA persists largely in episomal form, according to the therapy’s prescribing information label.</p>
<p>Random integration of recombinant AAV vector DNA into human DNA has been reported with Zolgensma and in published studies about other AAV gene therapies, Novartis has acknowledged.</p>
<p>“The clinical relevance of individual integration events is unknown, but it is acknowledged that individual integration events could potentially contribute to a risk of tumorigenicity. Cases of tumor have been reported in patients who received Zolgensma post-approval,” the label added.</p>
<h4><strong>‘Theoretical risk’</strong></h4>
<p>Zolgensma’s <a href="https://www.novartis.com/us-en/sites/novartis_us/files/zolgensma.pdf" target="_blank" rel="noopener">prescribing label </a>includes a section titled “AAV Vector Integration and Risk of Tumorigenicity.” That section, however, states: “There is a theoretical risk of tumorigenicity due to integration of AAV [adeno-associated virus] vector DNA into the genome.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>The label urges prescribers to report cases of tumors in patients who received Zolgensma to Novartis.</p>
<p>Novartis’ statement followed a statement issued Thursday by the Muscular Dystrophy Association (MDA). In the MDA statement, the association acknowledged awareness of reports about tumors developing in Zolgensma patients.</p>
<p>MDA stated that it “understand[s] that this raises questions and concerns for families, particularly those who have made important treatment decisions for themselves or their children. We take these reports seriously and believe families deserve transparent, timely, and science-based information as more is learned.”</p>
<p>“MDA is seeking additional information, reviewing the available scientific and safety data with clinical and research experts, and has reached out to Novartis,” the association added. “We recognize the sense of urgency from families to access additional information about these reports in order to make informed treatment and monitoring decisions. MDA is working to learn more as soon as possible.”</p>
<h4><strong>‘Confidential channels’</strong></h4>
<p>SMA Europe, an umbrella organization for SMA patient groups across the continent, issued its own <a href="https://www.sma-europe.eu/news/information-regarding-recent-zolgensma-safety-concerns?ref=/news" target="_blank" rel="noopener">statement</a> Thursday saying it was informed about the tumor cases “through confidential channels, and have made clear to Novartis that the SMA community now needs timely public communication.”</p>
<p>“We have strongly urged the company to provide clear information on what is currently known, what remains uncertain, what this may mean for people who have already received treatment, and whether any additional monitoring or action is recommended,” SMA Europe added.</p>
<p>SMA Europe and MDA spoke out after a hospice chaplain <a href="https://www.linkedin.com/posts/rev-carolyn-philstrom-a022aa254_im-deeply-disturbed-to-hear-this-news-that-share-7523572705716273152-Yypr/?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAIZI_4BqbJMjmmSJ_keDePIgmaFCPQ_iaY" target="_blank" rel="noopener">shared on LinkedIn </a> the post of a private Facebook group in which the parent of a child with SMA wrote of being informed by his neurologist that Novartis was withholding information about some of the tumor cases and opting instead for a “tiered rollout” of data.</p>
<p>“I am also sending this screenshot to reporters. I strongly encourage you to abandon any belief that Novartis can control this narrative, and to do something radical for your company: tell the truth,” Rev. Carolyn Philstrom urged.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>During the first three quarters of this year, Novartis’ Zolgensma Group—consisting of the namesake IV-formulation gene therapy and an intrathecal formulation approved last year and marketed as Itvisma<sup>®</sup> (onasemnogene abeparvovec-brve)—generated $1.071 billion in net sales, up 16% from $925 million in January–September 2025. Of that total, $404 million was generated during the third quarter, up 34% from $301 million in Q3 2025.</p>
<p>Zolgensma Group finished last year with $1.232 billion in net sales, up 1.5% from $1.214 billion in 2024. Zolgensma is one of Novartis’ top 20 brands.</p>
<p>Novartis shares traded on the SIX Swiss exchange barely budged, dipping 0.1% to CHF 134.12 ($163.25) on Thursday. Novartis’ American Depositary Receipts, traded on the New York Stock Exchange, slid 1.85% to $161.93.</p>
<h4><strong>Past safety issues</strong></h4>
<p>The nine acknowledged tumors are not the first instances of safety issues tied to Zolgensma.</p>
<p>In 2022, Novartis acknowledged that two patients <a href="https://www.genengnews.com/topics/genome-editing/novartis-confirms-deaths-of-two-patients-treated-with-gene-therapy-zolgensma/" target="_blank" rel="noopener">died of acute liver failure following treatment with Zolgensma</a>. Both cases occurred at approximately five to six weeks post Zolgensma infusion, and approximately 1-10 days following the initiation of corticosteroid taper, Novartis stated at the time.</p>
<p>In response, Novartis revised Zolgensma’s label to specify that fatal acute liver failure had been reported. That marked a change from the previous wording of the gene therapy’s “black box” warning, which previously included acute liver failure as a known side effect that has been reported following treatment.</p>
<p>Zolgensma was developed by AveXis, a gene therapy developer that was <a href="https://www.genengnews.com/news/novartis-to-acquire-gene-therapy-developer-avexis-for-8-7b/" target="_blank" rel="noopener">acquired by Novartis for $8.7 billion</a> in a deal completed in 2018.</p>
<p>A year later, the FDA approved Zolgensma for the treatment of SMA in children under age two with SMA with bi-allelic mutations in the <em>SMN1</em> gene. Zolgensma was the second gene therapy authorized by the FDA for an inherited disease.</p>
<p>Later in 2019, the FDA announced AveXis’ acknowledgement that the accuracy of data from product testing performed in animals submitted in its Biologics License Application (BLA) for Zolgensma had been <a href="https://www.genengnews.com/topics/genome-editing/fda-places-partial-clinical-hold-on-some-trials-of-novartis-gene-therapy/" target="_blank" rel="noopener">impacted by an unspecified manipulation of data</a> intended to support the development of its production process for the gene therapy. AveXis replaced its two top scientific executives, one of whom publicly denied wrongdoing.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="7"></span></aside>
<p>A <a href="https://www.jpeds.com/article/S0022-3476(20)30682-X/fulltext" target="_blank" rel="noopener">2020 paper</a> published in <em>The Journal of Pediatrics</em> detailed two cases of transient, drug-induced subacute liver failure following treatment with Zolgensma.</p>
<p>And a <a href="https://www.nature.com/articles/s41434-021-00273-7.pdf?proof=t" target="_blank" rel="noopener">2021 study in <em>Nature</em>-published <em>Gene Therapy</em></a> showed that of nine children treated with the gene therapy in Qatar, none experienced failure—but all patients experienced elevated levels of the liver enzymes aspartate aminotransferase (AST) or alanine transaminase (ALT), two experienced high prothrombin time, and one experienced elevated bilirubin. One patient experienced vomiting after infusion.</p>
<h4><strong>Beyond Zolgensma</strong></h4>
<p>Zolgensma isn’t the only gene therapy linked to tumors this year.</p>
<p>In January, Regenxbio announced that the FDA placed a clinical hold on its AAV9 gene therapy candidate RGX-111 for the treatment of mucopolysaccharidosis type I (MPS I or Hurler syndrome) after a single case where an intraventricular CNS tumor developed in a 5-year-old boy treated in its Phase I/II trial (<a href="https://clinicaltrials.gov/study/NCT03580083" target="_blank" rel="noopener">NCT03580083</a>). The FDA also placed a clinical hold on a similar gene therapy RGX-121 for the treatment of MPS II (Hunter Syndrome), citing the similarities in products, study populations, and shared risk between the clinical studies. The clinical holds remain in effect.</p>
<p>“The tumor was successfully resected, and the patient remains in neurologically stable condition with advanced cognitive function at five years of age—an outcome that is inconsistent with the natural history of severe MPSI,” the study’s corresponding author, Lindsey A. George, MD, of the Perelman Center for Cellular and Molecular Therapeutics at Children’s Hospital of Philadelphia, <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2601608" target="_blank" rel="noopener">reported in May in </a><em><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2601608" target="_blank" rel="noopener">The New England Journal of Medicine (NEJM)</a></em>.</p>
<p>“Data from three decades of experience with more than 6000 patients have shown that AAV gene therapy is associated with a favorable safety profile<sup><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2601608#core-collateral-r1" target="_blank" rel="noopener"><strong>1</strong></a></sup> and clinical benefits among diverse patient populations,” George and colleagues commented. “That said, our findings support the hypothesis that rare AAV integration can contribute to human oncogenesis, which emphasizes the need to optimize gene delivery methods and monitor transduced tissues after treatment.”</p>
<p>And in October, Michigan-based researchers led by Arul M. Chinnaiyan, MD, PhD, of the Michigan Center for Translational Pathology <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2601608" target="_blank" rel="noopener">reported in <em>The New England Journal of Medicine</em></a> a case of paraspinal neoplasm in a 3-year-old boy with infantile-onset Krabbe disease (with biallelic <em>GALC</em> variants p.Arg220Ter and p.Tyr319Cys) following treatment with Forbes biologics’ AAV gene therapy FBX-101.</p>
<p>“At the time of the last follow-up, the patient remained asymptomatic,” Chinnaiyan and colleagues wrote. “These findings emphasize the need for cassette designs without splice donors, as well as attention to vector purity and extended genomic surveillance after AAV gene therapy.”</p>
<p>And in October, Michigan-based researchers led by Arul M. Chinnaiyan, MD, PhD, of the Michigan Center for Translational Pathology <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2601608" target="_blank" rel="noopener">reported in <em>The New England Journal of Medicine</em></a> a case of paraspinal neoplasm in a 3-year-old boy with infantile-onset Krabbe disease (with biallelic <em>GALC</em> variants p.Arg220Ter and p.Tyr319Cys) following treatment with Forbes biologics’ AAV gene therapy FBX-101.</p>
<p>“At the time of the last follow-up, the patient remained asymptomatic,” Chinnaiyan and colleagues wrote. “These findings emphasize the need for cassette designs without splice donors, as well as attention to vector purity and extended genomic surveillance after AAV gene therapy.”</p>
<p>The post <a href="https://www.genengnews.com/topics/genome-editing/novartis-confirms-nine-cases-of-tumors-in-children-treated-with-gene-therapy-zolgensma/">Novartis Confirms Nine Cases of Tumors in Children Treated with Gene Therapy Zolgensma</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Why Glycosylation Control Is No Longer a Secondary Concern in the Development of Complex Biologics</title>
<link>https://edusehat.com/en/why-glycosylation-control-is-no-longer-a-secondary-concern-in-the-development-of-complex-biologics</link>
<guid>https://edusehat.com/en/why-glycosylation-control-is-no-longer-a-secondary-concern-in-the-development-of-complex-biologics</guid>
<description><![CDATA[ A priority shift is redefining expectations for contract development and manufacturing organizations (CDMOs). This article explains how CDMOs can efficiently move their glycosylation processes upstream using quality-by-design (QbD) methodologies.
The post Why Glycosylation Control Is No Longer a Secondary Concern in the Development of Complex Biologics appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/06/GettyImages-200554028-001.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 22:20:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Why, Glycosylation, Control, Longer, Secondary, Concern, the, Development, Complex, Biologics</media:keywords>
<content:encoded><![CDATA[<p>In developing traditional monoclonal antibodies (mAbs), drug manufacturers have often postponed addressing glycosylation issues until downstream processing.</p>
<p>The new generation of antibody therapeutics, however, offers no such leeway.</p>
<figure aria-describedby="caption-attachment-340114" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="size-medium wp-image-340114" src="https://www.genengnews.com/wp-content/uploads/2026/11/Sojeong-Lee-225x300.jpg" alt="" width="225" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Sojeong-Lee-225x300.jpg 225w, https://www.genengnews.com/wp-content/uploads/2026/11/Sojeong-Lee.jpg 756w" sizes="(max-width: 225px) 100vw, 225px"><figcaption class="wp-caption-text">Sojeong Lee, PhD, Director of upstream development at Samsung Biologics</figcaption></figure>
<p>Compared with conventional mAbs, newer antibody therapeutics such as bispecific antibodies (BsAbs), antibody-drug conjugates (ADCs), Fc-fusion proteins, and advanced immunotherapies are far more sensitive to glycan heterogeneity. Even subtle variations in glycosylation can directly influence therapeutic efficacy and batch-to-batch consistency.</p>
<p>For these newer therapeutics, glycosylation must therefore be considered from the earliest stages of cell line and process development.</p>
<p>This priority shift is redefining expectations for contract development and manufacturing organizations (CDMOs). This article explains how CDMOs can efficiently move their glycosylation processes upstream using quality-by-design (QbD) methodologies.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p><strong>Early glycosylation control drivers</strong></p>
<p>The growing emphasis on upstream glycosylation control is primarily a consequence of increasing biologic complexity. Traditional mAbs are significantly more predictable in behavior, typically displaying stable glycosylation profiles in later clinical phases that pose minimal threat to efficacy or safety.</p>
<p>Modern biologics present a markedly different challenge:</p>
<ul>
<li>BsAbs rely upon highly precise structural configurations to facilitate simultaneous engagement of multiple targets. As a result, even relatively minor glycan asymmetry may impair target binding or compromise functional activity.</li>
<li>ADCs introduce further complexity, with glycosylation influencing drug-antibody ratio (DAR) stability, payload retention, and overall molecular integrity.</li>
<li>Fc-fusion proteins and immunotherapies frequently depend upon tightly controlled glycan profiles to achieve appropriate pharmacokinetic behavior and immune system engagement.</li>
</ul>
<p>Historically, downstream processing provided manufacturers with opportunities to compensate for variability introduced upstream. Adjustments during purification or process optimization frequently proved sufficient to address modest glycosylation inconsistencies associated with conventional antibody therapeutics.</p>
<p>However, this approach is increasingly inadequate for modern biologics. In certain cases, even a minor shift in specific glycan variants can critically compromise the drug’s pharmacokinetic profile, therapeutic efficacy, or safety. Many of these glycosylation-related challenges originate at the cellular and metabolic level during biosynthesis. Once heterogeneous glycan populations have been established, downstream interventions are inherently limited in their ability to fully correct structural inconsistencies.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>Consequently, the industry is transitioning away from reactive correction models toward proactive upstream quality engineering.</p>
<h4><strong>Mitigating regulatory and commercial risk</strong></h4>
<p>Integrating quality considerations earlier in development offers significant regulatory and commercial advantages. If glycosylation inconsistencies emerge during scale-up or commercial manufacturing, the consequences may include batch rejection, additional comparability studies, regulatory delays, or disruptions to clinical programs.</p>
<p>Regulatory frameworks, including ICH Q8, Q9, and Q11, require manufacturers to identify critical quality attributes (CQAs), understand sources of process variability, and establish scientifically justified control strategies. For biologics, glycosylation has long been recognized as an important quality attribute linked to safety, efficacy, and immunogenicity. However, the increasing complexity of newer modalities has intensified expectations around early process understanding and glycan control.</p>
<p>Consequently, proactive upstream glycosylation control helps manufacturers meet these expectations by improving process consistency throughout development and scale-up. It also strengthens regulatory submissions by demonstrating that glycan heterogeneity is understood, monitored, and appropriately controlled across the manufacturing process.</p>
<h4><strong>Clone selection is critical to consistency</strong></h4>
<p>When implementing proactive control of glycosylation upstream, manufacturers must recognize that glycan variability is highly clone-dependent.</p>
<p>A substantial proportion of glycosylation variability, around 80%, originates from the intrinsic characteristics of the production clone itself. Even minor differences in genes such as <em>MGAT1</em> and <em>FUT8 </em>in a clone can alter the clone’s Golgi enzyme expression, which in turn can affect the branching/ fucosylation of subsequent antibodies, thereby affecting antibody-dependent cellular cytotoxicity (ADCC). A single glycan variant can therefore destroy a therapeutic’s mechanism of action.</p>
<p>Consider an Fc-fusion immunotherapy targeting the interleukin-6 receptor. If produced from a clone with high mannose levels, the eventual therapeutic’s half-life could drop from an expected 21 days to three days. Failure to eliminate unsuitable clones during early development may therefore result in otherwise promising candidates exhibiting unacceptable clinical characteristics during later stages.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>For this reason, developers must increasingly assess glycan quality attributes in addition to productivity and titer in early screening activities as part of their clone selection strategies.</p>
<p>Glycosylation-related quality attributes should be assessed in the context of the molecule’s intended mechanism of action and functional requirements. Examples include:</p>
<ul>
<li>Fucosylation levels: As an influencing factor in ADCC activity, fucosylation levels are particularly important for oncology therapeutics and immune-engaging molecules.</li>
<li>Galactosylation patterns: These patterns are significant where complement-dependent cytotoxicity (CDC) activity is required, as increased galactosylation may enhance C1q binding.</li>
<li>Sialic acid linkage profiles: Different sialylation patterns may influence inflammatory responses and pharmacokinetic performance in distinct ways, requiring careful evaluation. Also, sialic acids have a direct, strong correlation with the charge variant profiles, especially with the acidic variants, which can affect the binding affinity, immunogenicity, and other critical attributes.</li>
</ul>
<ul>
<li>High mannose content: As high mannose content can influence clearance rates and immunogenicity risk, it is an increasingly important quality consideration.</li>
</ul>
<h4><strong>High-throughput analytics are transforming cell line development</strong></h4>
<p>To evaluate glycosylation-related attributes effectively during early-stage development, drug developers and CDMOs are increasingly utilizing advanced analytical technologies, including HILIC-UPLC, LC-MS glycopeptide mapping, HPLC, and capillary electrophoresis. By integrating these high-throughput methodologies directly into early screening workflows, these organizations can simultaneously assess productivity and glycan quality, thereby reducing the likelihood that unsuitable clones progress through development.</p>
<p>Importantly, the objective is not necessarily to identify clones exhibiting a perfect glycan profile but rather to identify clones that naturally align as closely as possible with the target profile from the outset, thereby minimizing the extent of subsequent optimization required.</p>
<h4><strong>Structured experimental design</strong></h4>
<p>As biologic systems become increasingly complex, intuition-based optimization approaches are becoming insufficient.</p>
<p>Numerous upstream variables, including temperature, pH, substrate composition, oxygen transfer, amino acid availability, and lipid concentrations, may influence glycosylation pathways within the Golgi apparatus. Even relatively minor variations in culture conditions may alter branching patterns, fucosylation levels, or sialylation outcomes.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="7"></span></aside>
<p>Managing this complexity requires structured and statistically robust methodologies.</p>
<p>Design of experiments (DoE) approaches are therefore becoming essential for identifying critical process parameters while minimizing experimental burden. Screening DoEs allow developers to evaluate which parameters most significantly affect glycosylation outcomes, while optimization DoEs facilitate refinement of process conditions to balance productivity with quality objectives.</p>
<p>These methodologies also support broader QbD principles increasingly emphasized by regulators, including the establishment of process design spaces and robust monitoring strategies under frameworks such as ICH Q8 and Q11.</p>
<h4><strong>The role of automation, analytics, and data integration </strong></h4>
<p>Looking ahead, the continued evolution of upstream glycosylation control is likely to be driven by advances in automation and data analytics.</p>
<p>Many organizations have already begun integrating online monitoring technologies and automated feedback systems into bioprocessing workflows. Over time, these systems are expected to become increasingly sophisticated, enabling more dynamic adjustment of bioreactor conditions in response to real-time glycan analytics.</p>
<p>Artificial intelligence (AI) and machine learning are also expected to play increasingly important roles. As larger multi-batch datasets become available, AI-driven models may help predict relationships between process parameters and glycosylation outcomes with greater speed and accuracy than traditional analytical approaches alone.</p>
<p>However, realizing these capabilities will require substantial investment in organizational infrastructure.</p>
<h4><strong>Glycosylation in the years to come</strong></h4>
<p>No longer a downstream consideration, glycosylation control is set to play an increasingly important role in biologics development and manufacturing strategies.</p>
<p>For biopharma companies and CDMOs, this change will require stronger, AI-enabled technical capabilities to integrate volumes of analytical and manufacturing data effectively at speed, so operators can better understand how upstream conditions may influence glycan outcomes throughout scale-up and commercial production.</p>
<p>Timely insights such as these will only become more vital as the range of biologic modalities continues to diversify and as regulatory expectations surrounding consistency continue to evolve.</p>
<p>Going forward, organizations that integrate these considerations from the outset will be better positioned to support consistent therapeutic performance, reduce late-stage risk, and meet the growing demands associated with next-generation biologics.</p>
<p> </p>
<p><em>Sojeong Lee, PhD, is director of upstream development at Samsung Biologics</em></p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/why-glycosylation-control-is-no-longer-a-secondary-concern-in-the-development-of-complex-biologics/">Why Glycosylation Control Is No Longer a Secondary Concern in the Development of Complex Biologics</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Bowmanville Hospital redevelopment moves forward with $861.4&#45;million contract</title>
<link>https://edusehat.com/en/bowmanville-hospital-redevelopment-moves-forward-with-8614-million-contract</link>
<guid>https://edusehat.com/en/bowmanville-hospital-redevelopment-moves-forward-with-8614-million-contract</guid>
<description><![CDATA[ Major expansion will more than double the hospital’s size, adding advanced critical care, dialysis services and modern patient facilities. An $861.4-million contract has been awarded for the redevelopment of Bowmanville Hospital, marking a major milestone in a project designed to expand healthcare capacity in one of Ontario’s growing communities. Lakeridge Health and Infrastructure Ontario have […]
The post Bowmanville Hospital redevelopment moves forward with $861.4-million contract appeared first on Hospital News. ]]></description>
<enclosure url="" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 18:40:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Bowmanville, Hospital, redevelopment, moves, forward, with, 861.4-million, contract</media:keywords>
<content:encoded><![CDATA[<p>Major expansion will more than double the hospital’s size, adding advanced critical care, dialysis services and modern patient facilities.</p>
<p>An $861.4-million contract has been awarded for the redevelopment of Bowmanville Hospital, marking a major milestone in a project designed to expand healthcare capacity in one of Ontario’s growing communities.</p>
<p>Lakeridge Health and Infrastructure Ontario have selected PCL Partnerships to design, build and finance the redevelopment, which will more than double the size of the existing hospital.</p>
<p>The project will introduce expanded critical care services, new outpatient clinics, a haemodialysis centre, private patient rooms and a rooftop helipad.</p>
<p>Site preparation is expected to begin this fall, with major construction scheduled to start in early 2027. The project is targeted for completion in 2030.</p>
<p>Bowmanville Hospital will remain operational throughout construction.</p>
<div>
<div></div>
</div>
<h3>Expanding healthcare capacity in Durham Region</h3>
<p>The redevelopment is intended to address increasing demand for hospital services in Clarington and the broader Durham Region.</p>
<p>The expanded facility will feature modern patient-centred spaces and additional clinical capacity, allowing more residents to access specialized services closer to home.</p>
<p>One of the project’s most significant additions is Level 3 critical care capacity, providing advanced care for patients with life-threatening illnesses or injuries.</p>
<p>The hospital will also introduce a dedicated haemodialysis centre for patients with kidney disease, reducing the need for some residents to travel to other facilities for treatment.</p>
<p>New ambulatory care clinics will support patients who require diagnostic, treatment or follow-up services without an overnight hospital stay.</p>
<p>Additional features include private patient rooms, improved facilities for patients and families, and a rooftop helipad to support emergency medical transportation and patient transfers.</p>
<div>
<div></div>
</div>
<h3>Contract award clears the way for construction</h3>
<p>The $861.4-million fixed-price contract follows a competitive procurement process managed by Infrastructure Ontario and Lakeridge Health.</p>
<p>PCL Partnerships will be responsible for designing, building and financing the redevelopment under a design-build-finance model.</p>
<p>The project team includes PCL Investments Inc., PCL Constructors Canada Inc., Diamond and Schmitt Architects Incorporated and Cumulus Architects Inc., with TD Securities serving as financial advisor.</p>
<p>Under this procurement approach, design, construction and financing responsibilities are integrated into a single project agreement, an arrangement intended to improve coordination and provide greater cost and schedule certainty.</p>
<p>The contract also includes Buy Ontario provisions and is expected to create opportunities for local businesses, construction workers and skilled tradespeople.</p>
<div>
<div></div>
</div>
<h3>Supporting the region’s growing population</h3>
<p>The redevelopment forms part of Lakeridge Health’s broader strategy to strengthen hospital services across Durham Region.</p>
<p>With the region’s population projected to grow substantially over the coming decades, healthcare organizations face increasing pressure to expand infrastructure and deliver services closer to where patients live.</p>
<p>The Bowmanville project is intended to respond to that demand through a combination of additional capacity, modern clinical facilities and expanded specialized services.</p>
<p>Cynthia Davis, president and CEO of Lakeridge Health, described the contract award as a defining milestone for the hospital and the region’s healthcare system.</p>
<p>The hospital organization emphasized that the redevelopment is intended not simply to create a larger building, but to provide the facilities and services needed to support future generations.</p>
<h3>Hospital services to continue during construction</h3>
<p>PCL Partnerships is expected to begin mobilizing at the hospital site later this fall, ahead of major construction activities in 2027.</p>
<p>Lakeridge Health has confirmed that Bowmanville Hospital will continue providing patient care during the redevelopment.</p>
<p>Maintaining operations during construction will be an important consideration as work progresses, particularly for patients accessing emergency, inpatient and outpatient services.</p>
<p>The Bowmanville Hospital Foundation is also continuing its community fundraising campaign to support the local share of redevelopment costs and the purchase of equipment.</p>
<p>With the construction contract now awarded, the project moves from procurement into the next stage of delivery, bringing Durham Region closer to a substantially expanded hospital and a broader range of healthcare services.</p>
<p><a href="https://www.lh.ca/news-and-stories/posts/contract-awarded-for-the-bowmanville-hospital-redevelopment-project/?utm_source=chatgpt.com">Lakeridge Health — Contract Awarded for the Bowmanville Hospital Redevelopment Project (November 5, 2026)</a></p>
<p>The post <a href="https://www.hospitalnews.com/bowmanville-hospital-redevelopment-moves-forward-with-861-4-million-contract/">Bowmanville Hospital redevelopment moves forward with $861.4-million contract</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Where DNA Copying Fails Can Decide How Cancer Cells Respond to PARP Inhibitors</title>
<link>https://edusehat.com/en/where-dna-copying-fails-can-decide-how-cancer-cells-respond-to-parp-inhibitors</link>
<guid>https://edusehat.com/en/where-dna-copying-fails-can-decide-how-cancer-cells-respond-to-parp-inhibitors</guid>
<description><![CDATA[ NYU Grossman School of Medicine researchers found that DNA-copying problems at a small set of chromosome sites can determine how cancer cells respond to PARP inhibitors, pointing to possible biomarkers of drug sensitivity. 
The post Where DNA Copying Fails Can Decide How Cancer Cells Respond to PARP Inhibitors appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2020/08/Aug3_2020_GettyImages_696241690_DNAandCanceCell-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 15:05:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Where, DNA, Copying, Fails, Can, Decide, How, Cancer, Cells, Respond, PARP, Inhibitors</media:keywords>
<content:encoded><![CDATA[<p>Not all DNA damage is equal. Every time a cell divides, it has to copy its DNA, and some stretches of the genome are harder to copy than others. Cancer cells depend on a protective response to get past those failures. A new study pinpoints where on chromosomes the problems arise and shows that blocking that response with PARP inhibitors lets damage build up at those sites, compromising the cancer cells’ survival.</p>
<p>The work, led by researchers at NYU Langone Health’s Perlmutter Cancer Center, was published in <em>Nature Cell Biology</em> under the title “<a href="https://www.nature.com/articles/s41556-026-02126-0" target="_blank" rel="noopener">Positional replication fork instability drives PARP inhibitor cytotoxicity</a>.” Eli Rothenberg, PhD, a professor of biochemistry and molecular pharmacology at NYU Grossman School of Medicine, and Dipika Gupta, PhD, a postdoctoral scholar in his lab, are co-corresponding authors.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>The team began with CRISPR screens in breast and small cell lung cancer models. The screens flagged ESCO2, a protein that helps hold newly copied chromosomes together, as a strong determinant of sensitivity to PARP inhibitors. Even partial loss of ESCO2 increased sensitivity in colorectal, ovarian, and lung cancer cells. The ESCO2-depleted cells kept the tested homologous recombination response. That DNA repair pathway is impaired in the BRCA-mutated cancers for which PARP inhibitors are typically used.</p>
<p>To find out why the cells were sensitive, the researchers turned to quantitative single-molecule imaging, an ultrasensitive microscopy approach developed in Rothenberg’s laboratory. It let them distinguish subtypes of replication-associated damage sites that other methods cannot readily separate, according to Rothenberg. Reducing ESCO2 increased G-quadruplexes, or G4s, which are folded DNA structures that can obstruct copying. The increase was concentrated at a small subset of replication sites, particularly in repetitive pericentromeric regions next to centromeres.</p>
<p>“The imaging enabled us to move beyond measuring damage across an entire cell,” Gupta said. “We could detect subtle replication problems, distinguish the sites involved, and identify the protective response that the cells relied on.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>That response depended on PARP1 activity and involved two other proteins. TIMELESS helps protect DNA replication, and DDX11 is an enzyme that can unwind G4 structures. PARP inhibition disrupted the response in ESCO2-depleted cells. G4s built up further, DNA synthesis declined, and damage increased near centromeres, which helps explain the cells’ sensitivity to the drugs.</p>
<p>“We often think of DNA damage in terms of quantity: More damage means a greater chance of killing a cancer cell,” Rothenberg said. The findings point instead to location as a factor in treatment response.</p>
<p>The authors said the results provide a foundation for developing biomarkers of cancer drug sensitivity. They also raise the possibility that other DNA-damaging treatments work partly because they are more likely to hit these sensitive genomic sites. Whether that holds in other genetic contexts and with other treatments remains to be tested.</p>
<p>Rothenberg is working with clinicians to apply the imaging approaches to patient-derived cancer cells. The goal is to identify patterns of replication stress and DNA damage that could help predict who responds to treatment. The study was conducted in cancer cell models, so further preclinical and clinical research is needed to establish whether these features can guide treatment decisions.</p>
<p>“Our work reveals a genomic Achilles’ heel—a small subset of sites where replication problems can have disproportionately severe consequences. Identifying those sites helps explain what cancer cells depend on to survive and why a particular treatment can be so effective,” added Rothenberg.</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/where-dna-copying-fails-can-decide-how-cancer-cells-respond-to-parp-inhibitors/">Where DNA Copying Fails Can Decide How Cancer Cells Respond to PARP Inhibitors</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Boehringer Ingelheim Inks Up&#45;to&#45;$7.4B+ Cancer Drug Collaboration with Sino Biopharmaceutical</title>
<link>https://edusehat.com/en/boehringer-ingelheim-inks-up-to-74b-cancer-drug-collaboration-with-sino-biopharmaceutical</link>
<guid>https://edusehat.com/en/boehringer-ingelheim-inks-up-to-74b-cancer-drug-collaboration-with-sino-biopharmaceutical</guid>
<description><![CDATA[ The latest collaboration will encompass six biologic preclinical programs. Five programs focus on treatments originating with a wholly owned SBP Group subsidiary, LaNova Medicines. The sixth comes from another SBP Group subsidiary, Beijing Tide Pharmaceutical. 
The post Boehringer Ingelheim Inks Up-to-$7.4B+ Cancer Drug Collaboration with Sino Biopharmaceutical appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/03-0178_Boehringer_Workplace_Laboratory_Research_RGB.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 07:55:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Boehringer, Ingelheim, Inks, Up-to-7.4B, Cancer, Drug, Collaboration, with, Sino, Biopharmaceutical</media:keywords>
<content:encoded><![CDATA[<p>Boehringer Ingelheim has launched an up-to-$7.358 billion-plus second collaboration with Sino Biopharmaceutical (SBP Group) to develop next-generation cancer therapies based on antibody-drug conjugate (ADC) and T-cell engager (TcE) technologies.</p>
<p>The companies have signed a strategic multi-program option and license agreement designed to deepen their existing partnership in oncology, which encompasses three Boehringer-developed cancer treatments and was launched in 2024.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>The latest collaboration will encompass six biologic preclinical programs. Five programs focus on treatments originating with a wholly owned SBP Group subsidiary, LaNova Medicines. The sixth comes from another SBP Group subsidiary, Beijing Tide Pharmaceutical.</p>
<p>The collaboration is intended to marry SBP Group’s platforms and early-development capabilities with Boehringer Ingelheim’s global oncology.</p>
<p>“Our partnership with SBP Group brings together complementary science to broaden our development portfolio of antibody-drug conjugates and T-cell engagers. It puts our China strategy into action by connecting innovation from China with our global research and development capabilities,” Paola Casarosa, Member of the Board of Managing Directors and Head of the Innovation Unit at Boehringer Ingelheim, said in a statement.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>Under the agreement, SBP Group has agreed to oversee early development. After unspecified clinical milestones are reached, Boehringer Ingelheim may exercise options for exclusive development, manufacturing, and commercialization rights. Those rights may be exercised outside China, Hong Kong, and Macau for four of the programs, and worldwide for the remaining two.</p>
<p>Boehringer Ingelheim has agreed to pay SBP Group upfront and near-term payments totaling $358 million, and up to $7 billion tied to achieving option-exercise, development, regulatory, and commercial milestones of US$7 billion. Boehringer Ingelheim also agreed to pay SBP Group tiered royalties on potential future product sales.</p>
<p>Boehringer Ingelheim said the collaboration added to its efforts intended to build a broad and differentiated oncology portfolio spanning cancer cell-directed therapies and immuno-oncology. The companies reason that their latest partnership will offer opportunities to further the ADC and T-cell engager portfolio through multiple programs and technology approaches.</p>
<p>Investors sent SBP Group shares on the Hong Kong Stock Exchange rising 5% on the news, from HKD 4.885 (61 cents) to HKD 5.15 (65 cents). Boehringer Ingelheim is privately held.</p>
<h4><strong>Commitment to China</strong></h4>
<p>For Boehringer Ingelheim, the latest partnership with SBP Group underscores what it said was a strengthened commitment to China’s growing innovation ecosystem. In October, Boehringer Ingelheim <a href="https://english.shanghai.gov.cn/en-Latest-WhatsNew/20261015/f763213f079843ffa3d2e3c6c390596d.html" target="_blank" rel="noopener">opened its China R&D Center in Zhangjiang, Shanghai</a> designed to expand its early clinical development and external innovation capabilities by connecting its global R&D network with innovation in China.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>Boehringer Ingelheim and China-based SBP Group launched their first cancer-focused collaboration in April 2024, when SBP agreed to develop three oncology drugs originating with the Germany-based Boehringer:</p>
<ul>
<li><strong>Brigimadlin (BI 907828)</strong>—A mouse double minute 2 (MDM2)-p53 antagonist whose development was halted by Boehringer Ingelheim in all indications last year after the drug failed the 400-patient Phase II/III Brightline-1 trial (<a href="https://clinicaltrials.gov/study/NCT05218499" target="_blank" rel="noopener">NCT05218499</a>). Brigimadlin missed its primary endpoint of progression-free survival (PFS) in the trial, which compared the drug to doxorubicin in dedifferentiated liposarcoma.</li>
<li><strong>Obrixtamig (BI 764532)</strong>—A delta-like canonical Notch ligand 3/cluster of differentiation 3 (DLL3/CD3) bispecific T-cell engager. Obrixtamig is under study in the Phase II DAREON<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley">-5 trial (<a href="https://clinicaltrials.gov/study/NCT05882058" target="_blank" rel="noopener">NCT05882058</a>), a dose selection and expansion trial designed to assess the drug in relapsed/refractory small cell lung cancer (SCLC), extrapulmonary neuroendocrine carcinoma (epNEC), and large cell neuroendocrine carcinoma of the lung (LCNEC-L). Last month at the European Society for Medical Oncology (ESMO) Congress in Madrid, Boehringer Ingelheim shared positive data from the Phase Ib DAREON<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley">-9 trial (<a href="https://clinicaltrials.gov/study/NCT05990738" target="_blank" rel="noopener">NCT05990738</a>) evaluating obrixtamig plus chemo drug topotecan in adults with extensive stage small cell lung cancer.</li>
</ul>
<ul>
<li><strong>Zongertinib</strong>—A selective human epidermal growth factor receptor 2 (HER2) inhibitor that covalently binds to the tyrosine kinase domain (TKD) of both wild type and mutated HER2 receptors, including those with an exon 20 mutation. Boehringer reasons that improved selectivity of a HER2 tyrosine kinase inhibitor (TKI) may yield improved tolerability and efficacy. Zongertinib is under study in the Phase III Beamion LUNG-3 trial (<a href="https://clinicaltrials.gov/study/NCT07195695" target="_blank" rel="noopener">NCT07195695</a>) comparing the drug to standard adjuvant treatment in adults with completely resected Stage II-IIIB NSCLC whose tumors have activating HER2 tyrosine kinase domain (TKD) mutations.</li>
</ul>
<p>“Our second partnership with Boehringer Ingelheim marks an important milestone in SBP Group’s international innovation strategy and further validates our scientific capabilities in next-generation oncology,” stated Theresa Tse, Chairwoman of SBP Group. “By combining our innovative platforms and early-development capabilities with Boehringer Ingelheim’s global oncology expertise, we aim to maximize the potential of these programs and bring innovative treatment options to patients worldwide.”</p>
<p>“We will continue to expand our global partner network and contribute high-quality innovation from China to global healthcare,” Tse added.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/boehringer-ingelheim-inks-up-to-7-4b-cancer-drug-collaboration-with-sino-biopharmaceutical/">Boehringer Ingelheim Inks Up-to-$7.4B+ Cancer Drug Collaboration with Sino Biopharmaceutical</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Patient Advocacy Coffee Chat: Basic steps to being a good advocate</title>
<link>https://edusehat.com/en/patient-advocacy-coffee-chat-basic-steps-to-being-a-good-advocate</link>
<guid>https://edusehat.com/en/patient-advocacy-coffee-chat-basic-steps-to-being-a-good-advocate</guid>
<description><![CDATA[ “What does good advocacy look like? Why do we advocate? And what are some tips and tricks for effective advocacy?” asked Karin Hoelzer, Senior […]
The post Patient Advocacy Coffee Chat: Basic steps to being a good advocate appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/11/BIO_CoffeeChat_10_2026b.png" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 04:25:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Patient, Advocacy, Coffee, Chat:, Basic, steps, being, good, advocate</media:keywords>
<content:encoded><![CDATA[<p><span>“What does good advocacy look like? Why do we advocate? And what are some tips and tricks for effective advocacy?” asked Karin Hoelzer, Senior Director of Patient Advocacy at the Biotechnology Innovation Organization (BIO). </span></p>
<p><span>Her questions kicked off BIO’s October Coffee Chat, Advocacy in Action, which welcomed patient advocates from across the healthcare community. While BIO’s Coffee Chats are a monthly occurrence, this month’s chat buttressed BIO’s </span><a href="https://pace.bio.org/"><span>Patient Advocacy Changemakers Event (PACE)</span></a><span>, which took place on October 22 and 23 in Washington, DC. </span></p>
<p><span>The event brought together patient advocates from across the country and across therapeutic areas, providing a forum to share insights, exchange information, and make new connections in the pursuit of better access to and affordability of therapies for patients.</span></p>
<h3>What makes an effective patient advocate?</h3>
<p><span>Every advocate’s story is different. Every advocate comes to patient advocacy with a unique drive behind why they do what they do—some coming from the patient perspective, some from the caregiver perspective, some from a community health perspective. Yet, not matter the background or policy issue at hand, advocacy is empowering—one of the many things effective advocates have in common. </span></p>
<p><span>“Advocacy is an opportunity we have in our country we all need to take advantage of and help folks develop those skills not only in our own community but in other communities because it really does matter,” said Jenny Luray, Senior Vice President of Strategy and Public Engagement, Research!America, “So many Americans think that they don’t have as much power as they do.”</span></p>
<p><span>Amanda Krzepicki, MPH, Policy Director at the Autoimmune Association, agreed. She found her start as an AmeriCorps Community Health Corps member at a federally qualified health center just across the river in Alexandria. </span></p>
<p><span>“While I was there, I saw the stark inequities that impact this region, as well as across the country, and how people rely on community health centers and what a robust resource they are for communities,” she recalled. “So that really made me want to jump into the state policy space.” </span></p>
<p><span>And that motivation has remained a driving force for Krzepicki. “Watching that shift in lawmakers when they realize someone is so passionate about an issue has always been, I think, really fulfilling, and even more so watching bills get introduced because of it.”</span></p>
<p><span>Advocacy provides agency and the power to change the </span><i><span>status quo</span></i><span>. </span></p>
<p><span>“I think it’s so important to be able to tie real patient stories to topics that can be quite complex at times. An area that I have worked on for quite some time is patient access, especially the issue of copay accumulators, copay maximizers, and alternative funding programs, and that certainly is a slow and drawn-out process,” said Brian DuVal, MPH, Director of Patient Advocacy at BIO. “But there have been wins, especially at the state level, and I’ve been pleased to have been part of some of those. So, in general, being able to bring patients together to help demystify some of these complex issues has been very fulfilling.”</span></p>
<p><span>But, breaking such complex issues down and demystifying health policy in ways that are compelling to decisionmakers is not always easy. So how are DuVal, Krzepicki, and Luray training the new class of patient advocates? And what have been some of the biggest lessons learned while working on the Hill?</span></p>
<h3>Paying it forward: Training the new class of patient advocates</h3>
<p><span>Having a hands-on approach to bill making, Krzepicki said, has been one of the most effective motivators for new advocates. </span></p>
<p><span>“Watching a patient react to a bill getting introduced, an office agreeing to get a co-sponsorship on, and the feeling of hope that it elicits is very impactful. I think sometimes we can become quite jaded,” Krzepicki said, “but watching the patients experience success and feel so hopeful can remind us all to be hopeful, and then we ultimately get the result.”</span></p>
<p><span>And patient advocates have been able to advance key legislation to improve patient access. But not every win results in a bill passing the House and Senate—or even just getting introduced. And not every step needs to be made at the federal level.</span></p>
<p><span>“The small wins definitely count,” reminded DuVal. “Keeping advocates motivated between these really big legislative pushes, especially when things may feel slow at times, it is very important to celebrate the small wins and also really understand all the different forms that advocacy can take.”</span></p>
<p><span>Many issues at play today—prescription drug affordability boards, vaccine access and more—are happening at the state level, making advocacy more of a two-hander than a straightforward process. </span></p>
<p><span>Luray echoed her position, saying: “I’d like to see more patient advocacy groups in districts because that’s where you’re most likely to get more of the members’ attention. Forming events with a local healthcare provider, the Lions Club or women’s organizations, whatever works in terms of your disease area, creating those opportunities, all of it is really important. When that member meets you on the ground, they don’t forget it.”</span></p>
<h3>United front: Hill days and fly-ins</h3>
<p><span>Another element of patient advocacy that the speakers discussed was Hill days and fly-ins, which can help policymakers see just how big an issue is through the sheer number of advocates that are at their door. </span></p>
<p><span>And in today’s world, that can happen both physically and virtually, increasing both access and affordability in the very functioning of advocacy itself. </span></p>
<p><span>“We have done a virtual fly-in in the past,” Krzepicki said. “If you have advocates spread out across the country, and you’re maybe a smaller organization, the cost to do a virtual fly-in is much more reasonable than bringing people out and accommodating travel.” Though in-person is still best practice, Krzepicki said. </span></p>
<p><span>“When I was in the consulting space, it was incredible to bring patients to the Hill and to tell their stories, to connect with lawmakers, and I think even more importantly, to connect with staffers,” Krzepicki said. “People are often quite focused on the lawmaker, but a lot of the time, if you can relate to the staff and they have a personal tie, they can use their personal connection with the lawmaker to also sway an issue area.”</span></p>
<p><span>This focus on Hill staffers was echoed throughout the panel, especially considering the fact that staffers often long outlast the legislators themselves. So the trick, the panelists explained, was to be a resource to these staffers even outside of your policy focus. </span></p>
<p><span>“When I was on the Hill, the advocates that I relied on were those that always came in with a lot of information,” Luray recalled. “I never felt they were like gaslighting me, and they were willing to answer questions and be a resource on things that might not be on their top list, but they were able to be helpful.”</span></p>
<h3>Information: An advocate’s greatest asset</h3>
<p><span>Advocates and volunteers have to stay informed, both about which legislators have strong ties and interests in which issues, as well as about the policy issue itself, and adjacent policy concerns—which is a never-ending process, in particular in today’s environment where so many patient access issues are interconnected. </span></p>
<p><span>“It’s keeping advocates really informed and giving them information along the way so they’re learning as time goes on, and developing expertise,” Luray said. “I think it’s very satisfying to people as they get more experienced and comfortable with advocacy than they were maybe three years ago. But it’s a constant effort. You constantly have to be in touch with people.”</span></p>
<p><span>That is even more important this year with the midterms on the horizon. The congressional landscape is changing, and advocates need to be ready. </span></p>
<p><span>“As the new Congress comes in, there’s going to be a lot of new staff,” Krzepicki said. “So I do think at the beginning of next year we’ll be doing a little bit of education around our issue areas and things like that.”</span></p>
<p><span>One way that advocates can prepare themselves is to come to BIO’s monthly coffee chats, where they can talk about the healthcare policies that are impacting patients the most and connect with fellow advocates to learn and plan for future work. </span></p>
<p>The post <a href="https://bio.news/latest-news/patient-advocacy-coffee-chat-basic-steps-to-being-a-good-advocate/">Patient Advocacy Coffee Chat: Basic steps to being a good advocate</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>BIO responds to Health Affairs Analysis, highlighting the importance of orphan drug incentives</title>
<link>https://edusehat.com/en/bio-responds-to-health-affairs-analysis-highlighting-the-importance-of-orphan-drug-incentives</link>
<guid>https://edusehat.com/en/bio-responds-to-health-affairs-analysis-highlighting-the-importance-of-orphan-drug-incentives</guid>
<description><![CDATA[ Orphan drug development is one of the more fraught undertakings in biomedical research. Targeting rare diseases often requires cutting-edge science, but science is not […]
The post BIO responds to Health Affairs Analysis, highlighting the importance of orphan drug incentives appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2023/07/sangharsh-lohakare-Iy7QyzOs1bo-unsplash.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 04:25:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>BIO, responds, Health, Affairs, Analysis, highlighting, the, importance, orphan, drug, incentives</media:keywords>
<content:encoded><![CDATA[<p>Orphan drug development is one of the more fraught undertakings in biomedical research. Targeting rare diseases often requires cutting-edge science, but science is not always enough. The economics of treating small populations can make it difficult to secure the financial support needed to make it through clinical trials and onto the market.</p>
<p>To ensure that promising ideas aren’t abandoned in the face of those challenges, Congress has provided a number of incentives for orphan drug development, including provisions that exempt orphan drugs from government price controls under the Inflation Reduction Act.</p>
<p>But those incentives often come under attack. Recently, <a href="https://www.healthaffairs.org/doi/10.1377/hlthaff.2026.00209">a Health Affairs article</a> suggested that the IRA-related protections weren’t needed, given that some orphan medicines are commercially successful.</p>
<p>That analysis, however, is built on the flawed premise that just because a sliver of orphan drugs earn back development costs, orphan medicines, as a class, don’t face unique and daunting obstacles throughout the R&D process.</p>
<p>BIO believes that kind of thinking is wrongheaded, and <a href="https://www.healthaffairs.org/doi/10.1377/hlthaff.2026.01330">Health Affairs this month published a rebuttal</a> from BIO’s Vice President of Healthcare Policy & Research, Crystal Kuntz.</p>
<p>BIO argued that orphan drugs carry unique scientific challenges, uncertainties in development, and commercial obstacles that would discourage innovation without additional supports.</p>
<p>“Incentives to develop orphan drugs have been critical in encouraging research, and eroding such policies risks starving some of the best ideas in medicine of resources at the exact wrong time for patients waiting to benefit from today’s groundbreaking science,” Kuntz wrote.</p>
<p>BIO noted that the existence of these incentives has led to a “golden age” in orphan drug development, but that much work remains to be done. Thousands of rare diseases still lack a treatment, an indication of the need to not roll back the very policies that are making an impact.</p>
<p>The post <a href="https://bio.news/bios-view/bio-responds-to-health-affairs-analysis-highlighting-the-importance-of-orphan-drug-incentives/">BIO responds to Health Affairs Analysis, highlighting the importance of orphan drug incentives</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Modernizing the Western Blot for the 21st Century: More Than Just Automation</title>
<link>https://edusehat.com/en/modernizing-the-western-blot-for-the-21st-century-more-than-just-automation</link>
<guid>https://edusehat.com/en/modernizing-the-western-blot-for-the-21st-century-more-than-just-automation</guid>
<description><![CDATA[ Traditional Western blotting can confirm whether a protein is present, but it is often treated as semi-quantitative. It can be difficult to determine how much protein is present, compare results across experiments, or distinguish a true biological difference from technical errors. The case for automation becomes stronger when paired with performance data.
The post Modernizing the Western Blot for the 21st Century: More Than Just Automation appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/ProteinSimple-RD-Systems-Western-Blotting-with-Antibodies.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 04:20:15 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Modernizing, the, Western, Blot, for, the, 21st, Century:, More, Than, Just, Automation</media:keywords>
<content:encoded><![CDATA[<p>Sponsored content brought to you by</p>
<p><a href="https://www.rndsystems.com/" target="_blank" rel="noopener"><img loading="lazy" decoding="async" class="alignnone wp-image-338704 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/09/RnD-Systems_primary-logo_color-1-002-300x111.jpg" alt="R&D Systems logo" width="300" height="111" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/RnD-Systems_primary-logo_color-1-002-300x111.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/RnD-Systems_primary-logo_color-1-002.jpg 755w" sizes="auto, (max-width: 300px) 100vw, 300px"></a></p>
<p>In the 1980s, Western blotting was revolutionary. For the first time, scientists could identify a protein of interest within a complex sample with a high degree of certainty. Decades later, the technique remains a cornerstone of protein analysis. But like most technologies, both inside and outside the lab, it is not without limitations. What once felt fit for purpose now has to keep up with the demands of 21st-century biopharma: vast sample sets, aggressive competition, and, most importantly, the ticking clock for individuals waiting for life-saving therapies.</p>
<p>Traditional Western blotting can confirm whether a protein is present, but it is often treated as semi-quantitative. It can be difficult to determine how much protein is present, compare results across experiments, or distinguish a true biological difference from technical errors. The predominantly manual process also makes user-to-user variability difficult to avoid. As a result, time that could be spent moving a program forward is often spent repeating experiments, troubleshooting, or adding orthogonal techniques to gain confidence in the result.</p>
<p><figure aria-describedby="caption-attachment-340263" class="wp-caption aligncenter"><img loading="lazy" decoding="async" class="wp-image-340263" src="https://www.genengnews.com/wp-content/uploads/2026/11/ProteinSimple-RD-Systems-Western-Blotting-with-Antibodies-1024x731.jpg" alt="Western Blotting with Antibodies" width="696" height="497" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/ProteinSimple-RD-Systems-Western-Blotting-with-Antibodies-1024x731.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/ProteinSimple-RD-Systems-Western-Blotting-with-Antibodies-300x214.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/ProteinSimple-RD-Systems-Western-Blotting-with-Antibodies-768x549.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/ProteinSimple-RD-Systems-Western-Blotting-with-Antibodies.jpg 1400w" sizes="auto, (max-width: 696px) 100vw, 696px"><figcaption class="wp-caption-text">Credit: Bio-Techne</figcaption></figure></p>
<p>That delay matters. Therapeutic efficacy, time to market, and a manufacturer’s reputation are all influenced by one common factor: data quality. In another era, prolonged timelines may have been expected and even accounted for. Today, laboratories across the globe are investing in instrumentation that accelerates development pipelines while improving the quality of the data used to make decisions. The data should speak for itself: either the sample is good to go or it is not.</p>
<p>Evolution is natural for almost all forms of technology, and the Western blot is no exception. In the early 2010s, Simple Western<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> technology entered the fray, bringing automation to many steps of the Western blot workflow that otherwise introduce variability. Simple Western, as the name suggests, simplifies the Western blot. The underlying principle remains familiar: proteins are separated and then probed using target-specific antibodies. The difference is that protein separation, immunodetection, and analysis occur in an automated, capillary-based system. The workflow reduces manual intervention and condenses a process that can take at least six hours, and sometimes days, into an approximately three-hour run with minimal hands-on time.</p>
<p>The case for automation becomes stronger when paired with performance data. In one internal reproducibility study, four users ran the same ERK1 Simple Western assay on separate days using HeLa lysates. Across all ERK1 data points collected over four days, the coefficient of variation was below 10%, illustrating how an automated workflow can support consistency across users and experiments<sup>1</sup>.</p>
<p><figure aria-describedby="caption-attachment-340262" class="wp-caption aligncenter"><img loading="lazy" decoding="async" class="wp-image-340262 size-large" src="https://www.genengnews.com/wp-content/uploads/2026/11/ProteinSimple-RD-Systems-GEN-Article_SW_Figure_1_hz-updated-1024x426.jpg" alt="" width="1024" height="426" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/ProteinSimple-RD-Systems-GEN-Article_SW_Figure_1_hz-updated-1024x426.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/ProteinSimple-RD-Systems-GEN-Article_SW_Figure_1_hz-updated-300x125.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/ProteinSimple-RD-Systems-GEN-Article_SW_Figure_1_hz-updated-768x320.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/ProteinSimple-RD-Systems-GEN-Article_SW_Figure_1_hz-updated.jpg 1400w" sizes="auto, (max-width: 1024px) 100vw, 1024px"><figcaption class="wp-caption-text">Figure 1: Dystrophin protein expression was assessed using two different methods: traditional Western blot (A) and Simple Western (B). In the traditional Western blot analysis, 20 μg of protein was loaded per sample lane. For the Simple Western analysis, 1.25 μg of protein was loaded per sample lane for DMD samples and 0.25 μg for healthy controls. [Bio-Techne]</figcaption></figure></p>
<p>Sensitivity is another practical advantage, particularly when sample is limited or the target is low abundance. In a comparison using HEK293 lysates, Simple Western detected GSK3α over more than four logs of dynamic range, while traditional chemiluminescent Western blotting covered approximately 2.5 logs. A dystrophin analysis in Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) samples further showed why this matters: traditional Western blotting used 20 μg of protein per lane, whereas Simple Western analysis used 1.25 μg for DMD samples and 0.25 μg for healthy controls while still supporting clearer measurement of dystrophin expression (<em>Figure 1</em>).</p>
<p>These are just a handful of examples that demonstrate the significant shifts that Simple Western brings to protein analysis. None of this means that traditional Western blotting no longer has value. Its principles remain sound, and its familiarity is part of its staying power. But the demands of contemporary research and development have changed. When decisions depend on speed, reproducibility, sensitivity, and quantitative confidence, a manual workflow can become the bottleneck. Simple Western does not abandon what made Western blotting useful. It brings the technique into a format better suited to the pace and expectations of modern biopharma.</p>
<p> </p>
<p><em><img loading="lazy" decoding="async" class="alignleft wp-image-340264 size-thumbnail" src="https://www.genengnews.com/wp-content/uploads/2026/11/ProteinSimple-RD-Systems_QRCode-150x150.jpg" alt="R&D Bio-Techne Sponsored Content QR Code" width="150" height="150" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/ProteinSimple-RD-Systems_QRCode-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/ProteinSimple-RD-Systems_QRCode.jpg 298w" sizes="auto, (max-width: 150px) 100vw, 150px"></em></p>
<p> </p>
<p><em>Learn More r<a href="https://www.rndsystems.com/instruments/simple-western" target="_blank" rel="noopener">ndsystems.com/simplewestern</a>.</em></p>
<p>The post <a href="https://www.genengnews.com/sponsored/modernizing-the-western-blot-for-the-21st-century-more-than-just-automation/">Modernizing the Western Blot for the 21st Century: More Than Just Automation</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>What Biotech Licensing Really Buys</title>
<link>https://edusehat.com/en/what-biotech-licensing-really-buys</link>
<guid>https://edusehat.com/en/what-biotech-licensing-really-buys</guid>
<description><![CDATA[ In this Point of View Sun Chau Siu, PhD, and Kaisong Zhou, PhD, give insights on the hidden challenges of transferring intellectual property.
The post What Biotech Licensing Really Buys appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/POV-Altruist-Hero-Image-2.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 04:20:14 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>What, Biotech, Licensing, Really, Buys</media:keywords>
<content:encoded><![CDATA[<p><figure aria-describedby="caption-attachment-340279" class="wp-caption alignleft"><img loading="lazy" decoding="async" class="wp-image-340279" src="https://www.genengnews.com/wp-content/uploads/2026/11/POV-Altruist-Dr.-Sun-Chau-Siu-e1793893626383-300x300.jpg" alt="Sun Chau Siu" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/POV-Altruist-Dr.-Sun-Chau-Siu-e1793893626383-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/POV-Altruist-Dr.-Sun-Chau-Siu-e1793893626383-1024x1024.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/POV-Altruist-Dr.-Sun-Chau-Siu-e1793893626383-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/POV-Altruist-Dr.-Sun-Chau-Siu-e1793893626383-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/POV-Altruist-Dr.-Sun-Chau-Siu-e1793893626383.jpg 1045w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Sun Chau Siu, PhD <br>Executive Director,<br>Head of Regulatory Affairs<br>and Project Management<br>Altruist Biologics</figcaption></figure></p>
<p>Biotech licensing is often framed as a transaction around intellectual property. The molecule still comes first: if the biology is weak, the target is undifferentiated, or the clinical rationale is unconvincing, no amount of technical discipline will rescue the program.</p>
<p>What it tends to underestimate is a related question: once the rights change hands, how much of an asset’s apparent value will survive not only clinical development but the transfer itself? In biologics, the asset is never just the molecule. It also includes the development system built around it: cell line history, process development logic, analytical methods, comparability strategy, manufacturing experience, documentation discipline, and the technical judgment accumulated over time. A licensing agreement can specify rights to those assets and the obligations surrounding their transfer. It cannot guarantee that the development system behind it will remain reproducible when another organization takes over. Yet licensing diligence does not always treat the transferability of that development system as a distinct attribute of the asset being acquired.</p>
<p>At signing, a biologics asset can appear meaningfully de-risked. The target may be compelling, the early package persuasive, and the market opportunity attractive. Even so, the asset can carry technical liabilities that emerge only when transfer, scale-up, validation, or regulatory review exposes the gap between a promising molecule and a reproducible development system.</p>
<p><figure aria-describedby="caption-attachment-340276" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-340276" src="https://www.genengnews.com/wp-content/uploads/2026/11/POV-Altruist-Portrait-Kaisong-Zhou-e1793893794694-300x300.jpg" alt="Kaisong Zhou" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/POV-Altruist-Portrait-Kaisong-Zhou-e1793893794694-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/POV-Altruist-Portrait-Kaisong-Zhou-e1793893794694-1024x1024.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/POV-Altruist-Portrait-Kaisong-Zhou-e1793893794694-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/POV-Altruist-Portrait-Kaisong-Zhou-e1793893794694-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/POV-Altruist-Portrait-Kaisong-Zhou-e1793893794694.jpg 1225w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Kaisong Zhou, PhD<br>Chairman and CEO<br>Altruist Biologic</figcaption></figure></p>
<p>Those liabilities rarely present themselves as a single obvious flaw. More often, they emerge in forms that are easy to dismiss during the optimism of dealmaking. Consider a potency assay that performs consistently in the originating laboratory. The method transfers on paper, the procedure is followed, and the initial results appear acceptable. Months later, however, differences in reference standards, laboratory conditions, or system suitability behavior begin to create unexplained variability. What looked like an analytical transfer becomes a development problem because the originating team’s tacit understanding of the assay never truly transferred. A comparability strategy may exist on paper, but not at the level required once process changes begin to accumulate. A program can transfer successfully at pilot scale and still require substantial redevelopment before Process Performance Qualification (PPQ) or commercial readiness because the development rationale was never designed to travel.</p>
<p>That is why these issues are dangerous. Scientific risk can reveal itself at multiple stages, including in the clinic. Transfer risk often does not. It can remain buried until another organization has to reproduce the process, defend the analytics, explain the development history, and carry the program forward under different operating conditions.</p>
<p>What makes this dynamic harder to manage is a structural incentive problem. After signing, organizational incentives can make transfer problems surprisingly easy to defer. The seller has closed the deal, while the technical teams on both sides may still be working through how knowledge, responsibilities, and decisions will transfer. Problems that might be correctable early can instead compound quietly, becoming harder and more expensive to address by the time they are visible. In practice, transfer risk begins as soon as the transaction is signed.</p>
<p>This is why the language of licensing can be misleading in biologics. Intellectual property can be assigned precisely, but process knowledge, development judgment, and technical context do not transfer as neatly. A contract can define rights, territories, and economics, but it cannot guarantee that tacit knowledge reflected in assay behavior, deviation history, control strategy logic, and the many small decisions behind them will be understood and reproduced by the receiving organization.</p>
<p>The industry’s response to transfer failures can sometimes focus too heavily on additional documentation. Documentation is not the same as understanding. In many biologics programs, the critical knowledge that determines whether a process is reproducible is held by a small number of people: the scientist who characterized the founding cell line, the process development lead who resolved the early instability, the analyst who knows why the potency assay behaves differently after a weekend shutdown. That knowledge is rarely captured in a batch record. When those individuals are engaged in the transfer, problems can surface earlier. When the transfer relies heavily on documentation alone, they may be hidden until much later, often when they are more difficult and expensive to address. The critical question is therefore not how much documentation exists, but how much of the knowledge required to interpret that documentation can actually travel. Some biologics programs are reproducible in the hands of the originating team without being equally transferable to a new organization. They are reproducible performances, held together in part by the people who run them. Licensing moves the rights. It does not move the cast.</p>
<p>The deeper issue is structural. The industry has sophisticated tools for evaluating scientific risk: target biology, mechanism of action, probability of clinical success, and competitive differentiation. Chemistry, Manufacturing, and Controls (CMC) diligence can assess regulatory compliance, batch history, manufacturing experience, process understanding, and analytical readiness. The gap is that these assessments do not necessarily answer a distinct licensing question: whether the underlying development rationale can be reproduced by a new organization.</p>
<p>That is why transfer-readiness should be treated as a distinct diligence dimension, alongside scientific, commercial, and regulatory assessment. The key question is not only whether an asset is scientifically attractive, but whether another organization can inherit it without materially relearning it. Four questions provide a practical test: Is the process sufficiently understood, rather than merely functional? Are the analytical methods reproducible across laboratories, rather than demonstrated only within a single one? Can the comparability strategy withstand expected process evolution? And does critical institutional knowledge live in the system, or primarily in the people who built it? In practice, these questions should be part of technical diligence before a deal is signed, because what appears to be a manageable transfer issue can become a material driver of cost, timeline, and post-deal execution.</p>
<p>Not every transaction is built on a fully mature development system; some deals are option bets, acceleration strategies, or pipeline-replenishment moves. But those motives do not change the nature of the risk. A buyer is not only acquiring scientific potential, but also inheriting the consequences of how that potential was developed.</p>
<p>This becomes even more consequential for complex modalities such as antibody-drug conjugates (ADCs), where development depends on tightly linked knowledge across the antibody, linker and payload, conjugation process, analytical methods, raw materials, and multiple internal or external suppliers. A transfer may therefore require reconstructing a network of technical relationships and control strategies, not simply reproducing a process.</p>
<p>Transfer-readiness should not be confused with development maturity. An early-stage asset can be intentionally immature yet highly transferable if its critical knowledge, assumptions, and decision logic are well understood and captured. Conversely, a more advanced asset can carry significant transfer risk if too much development knowledge remains tacit or organization-specific.</p>
<p>That distinction has economic consequences. An asset requiring substantial process redevelopment, analytical remediation, or knowledge reconstruction after licensing may still be attractive to acquire, but its timeline, resourcing requirements, and risk profile are different from those of an asset that can be transferred with minimal relearning. Transfer-readiness therefore has implications not only for technical execution, but for how an asset is valued, resourced, and integrated after the deal.</p>
<p>Biotech licensing starts with differentiated molecules. But in biologics, value is not created by discovery alone. The question is whether the knowledge system that made the asset valuable can move with it.</p>
<p> </p>
<p><em>Sun Chau Siu, PhD, is executive director, head of regulatory affairs and project management at Altruist Biologics. Kaisong Zhou, PhD, is chairman and CEO, Altruist Biologics (an Innovent CDMO).</em></p>
<p>The post <a href="https://www.genengnews.com/insights/what-biotech-licensing-really-buys/">What Biotech Licensing Really Buys</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Revealing the Chemistry Around Us Through Mass Spectrometry</title>
<link>https://edusehat.com/en/revealing-the-chemistry-around-us-through-mass-spectrometry</link>
<guid>https://edusehat.com/en/revealing-the-chemistry-around-us-through-mass-spectrometry</guid>
<description><![CDATA[ Mass spectrometry-based exposomics could be a powerful approach to measuring and understanding environmental impact on health.
The post Revealing the Chemistry Around Us Through Mass Spectrometry appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/GEN_NOV_2026_GettyImages-1390096829.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 04:20:13 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Revealing, the, Chemistry, Around, Through, Mass, Spectrometry</media:keywords>
<content:encoded><![CDATA[<p><figure aria-describedby="caption-attachment-340303" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-340303" src="https://www.genengnews.com/wp-content/uploads/2026/11/TL-Bruker-Dr.-Matthew-Lewis-headshot-e1793898683528-300x300.jpg" alt="Matthew Lewis" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/TL-Bruker-Dr.-Matthew-Lewis-headshot-e1793898683528-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/TL-Bruker-Dr.-Matthew-Lewis-headshot-e1793898683528-1024x1024.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/TL-Bruker-Dr.-Matthew-Lewis-headshot-e1793898683528-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/TL-Bruker-Dr.-Matthew-Lewis-headshot-e1793898683528-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/TL-Bruker-Dr.-Matthew-Lewis-headshot-e1793898683528.jpg 1170w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Matthew Lewis, PhD<br>Vice President of Metabolomics and Lipidomics<br>Bruker Daltonics</figcaption></figure></p>
<p>Health is increasingly viewed through the lens of family history and genetics, nutrition and fitness, and, for many, medications and treatments for various conditions. However, public perception is waking up to another factor: the chemistry of our environment.</p>
<p>From air quality and drinking water to clothing and cookware, there is growing skepticism surrounding the multitude of synthetic materials that coat and comprise our environment. This realization that the world around us has an impact on our growth, development, and well-being follows a century of industrial expansion in which the chemistry of the world changed far faster than the means to measure or understand its impacts. A scientific field concerned with this frontier of research has been quietly maturing for twenty years. It is called exposomics.</p>
<p>Exposomics, a modern omics approach to understanding environmental impact, is still an emerging science, but it is already changing how we think about the relationship between the environment and our health. This article explores how researchers can now study the chemistry of the world around us and the body’s response to it with unprecedented breadth, increasingly bringing both into a common analytical framework. The growing attention to the chemistry around us is well founded. It is also now matched by the means to investigate it.</p>
<h4><strong>What is the exposome?</strong></h4>
<p>The exposome as a term was introduced in 2005 as a deliberate complement to the genome. It refers to external factors that have an impact on an organism’s biology (in our case, on human health). Across a person’s lifetime, these will include environmental, lifestyle, occupational, dietary, biological and social influences, each capable of imparting (alone or together via complex interactions) measurable molecular signatures and provoking equally measurable biological responses. Exposomics is the science of measuring it and its impacts.</p>
<p>Today, scientists are gaining a clearer understanding of how much the exposome matters. Working with UK Biobank data, researchers compared what genetic risk scores and environmental exposures each contribute to ageing and early death. Set against age and sex alone, polygenic risk scores across 22 major diseases added less than two percentage points to the explained variation in mortality. The exposome added seventeen.<sup>1 </sup>The two are not rivals, however. Inherited risk still explained more for dementias and for breast, prostate, and colorectal cancers, while environment explained more for diseases of the lung, heart, and liver.<sup>1</sup> The difference is that while genomics is a mature science, exposomics remains emergent, operating across a much broader chemical landscape.</p>
<h4><strong>Technology for exposomics research</strong></h4>
<p>For most of the twentieth century, environmental health science was concerned with identifying potential health concerns, testing them, and regulating them if needed, one at a time. This approach shaped our view on the dangers of lead, asbestos, and tobacco, slowly over decades. However, exposures are not always singular concerns. The chemical world around us is complex, with a stunning diversity of components interacting with biology and each other in ways that isolated testing cannot capture or represent. Even modern environmental monitoring only concentrates on a short list of regulated pollutants, despite inhalation exposure spanning thousands of organic compounds, numerous inorganic substances, and a large biological component.<sup>2</sup> Exposomics takes a different approach. As a modern “omics” science, it measures molecular signals broadly rather than selectively (both the exposures themselves and the body’s biochemical responses) and relies on data-driven statistical analysis to find the patterns that matter.</p>
<p>Here, high-resolution mass spectrometry is a key enabling technology. It separates and detects molecules according to their mass with enough precision and selectivity to distinguish compounds that differ only slightly and, critically, without being told in advance what to look for. And importantly, the same technology is as applicable to studying the chemistry of living systems (e.g. biofluids and tissues) as it is to environmental samples (e.g. air, water, dust, soil, food and consumer products). Using mass spectrometry, a single analysis of blood or urine can measure hundreds or thousands of signals at once, including those from pollutants, drugs, dietary compounds, molecules produced by gut bacteria, and the body’s own metabolic responses to all of it. When applied to air analysis, measurements of diverse and unexpected components can be made continuously and in real time, capturing short-lived compounds and brief exposure events that a filter sample collected over hours would average away.</p>
<h4><strong>Enabling understanding and action</strong></h4>
<p>Measuring the chemistry around us is valuable, but measurement alone does not explain how an exposure influences health. These measurements become most useful when they can be connected. The objective of exposomics is to link the source of an exposure, the amount that enters the body, the biological responses it provokes, and ultimately any impact on health.</p>
<p>Completing that chain remains difficult, and the field is clear-eyed about where the challenges lie. Detecting a signal in a mass spectrometer is not the same as knowing what chemical produced it, and many of the signals detected remain unannotated, collectively constituting what researchers often refer to as the dark matter of the chemical exposome.<sup>3</sup> Their identification depends on reference libraries that are still underdeveloped for environmental chemicals, and workflows vary enough between laboratories that studies can be difficult to compare.<sup>3</sup> However, progress is being made, for example, in artificial intelligence methods that predict chemical behavior to improve confidence in identification,<sup>4</sup> and in the prioritization of harmonized workflows throughout the field.<sup>3</sup> Still, for today, mass spectrometry-based exposomics is a powerful approach that can see more than it can readily interpret. And therein lies its promise as a tool for novel discovery.</p>
<p>The challenges extend beyond identifying individual chemicals. Researchers must also account for the sheer scale of environmental exposure and how sharply it can vary among places and people. The World Health Organization reports that 99% of the world’s population breathes air exceeding its guideline limits.<sup>5</sup> At the same time, we know that the exposome is geospatially linked, with recent mobile monitoring studies showing that pollutant concentrations can vary dramatically over surprisingly short distances.<sup>6</sup> Finally, it has been suggested that exposure profiles can differ markedly even between neighbors in the same building,<sup>2</sup> together making the exposome an individual and community matter as much as a population one. As a result, exposomics research is increasingly being pursued across all three scales through multidisciplinary collaborations that combine environmental science, analytical chemistry, epidemiology and clinical research.</p>
<p> </p>
<p><em>Matthew Lewis, PhD, is vice president of metabolomics and lipidomics at Bruker Daltonics.</em></p>
<p><em> </em></p>
<p><em>References</em></p>
<ol>
<li>Argentieri MA, Amin N, Nevado-Holgado AJ, et al. Integrating the environmental and genetic architectures of aging and mortality. <em>Nature Medicine</em>. 2025;31(3):1016-1025. doi:10.1038/s41591-024-03483-9.</li>
<li>Gao P. The human airborne exposome. <em>Nature Health</em>. 2026;1:26-34. doi:10.1038/s44360-025-00026-5.</li>
<li>Talavera Andújar B, Schymanski EL. High Resolution Mass Spectrometry To Investigate the Human Exposome: Where Are We? <em>Exposome</em>. 2025. doi:10.1093/exposome/osaf017.</li>
<li>Sillé FCM, Prasse C, Luechtefeld T, Hartung T. AI redefines mass spectrometry chemicals identification: retention time prediction in metabolomics and for a Human Exposome Project. <em>Frontiers in Public Health</em>. 2025;13:1687056. doi:10.3389/fpubh.2025.1687056.</li>
<li>World Health Organization. <a href="https://www.who.int/health-topics/air-pollution#tab=tab_1" target="_blank" rel="noopener">Air Pollution</a>. Accessed 7 May 2026.<u></u></li>
<li>Robinson ES, Tehrani MW, Yassine A, et al. Ethylene Oxide in Southeastern Louisiana’s Petrochemical Corridor: High Spatial Resolution Mobile Monitoring during HAP-MAP. <em>Environmental Science & Technology</em>. 2024;58(25):11084–11095. doi:10.1021/acs.est.3c10579.</li>
</ol>
<p>The post <a href="https://www.genengnews.com/topics/omics/revealing-the-chemistry-around-us-through-mass-spectrometry/">Revealing the Chemistry Around Us Through Mass Spectrometry</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Beyond the Payload</title>
<link>https://edusehat.com/en/beyond-the-payload</link>
<guid>https://edusehat.com/en/beyond-the-payload</guid>
<description><![CDATA[ In this Point of View Anthony Blaszczyk, PhD, principal scientist at USP provides insights on how delivery technologies will shape the future of cell and gene therapy.
The post Beyond the Payload appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/POV-USP-GTG_16x9-Virtual-background.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 04:20:12 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Beyond, the, Payload</media:keywords>
<content:encoded><![CDATA[<p>Over the last decade, cell and gene therapies (CGTs) have shown the ability to modify disease-inducing biological pathways, restore missing cellular functions, and achieve long-term therapeutic benefit following a single administration. However, even with significant design and development advancements, efficient on-target delivery remains challenging. The ability to safely, efficiently, and repeatedly deliver the correct genetic cargo to the right cell is one of the most critical determinants of clinical success.</p>
<p><figure aria-describedby="caption-attachment-340314" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-340314" src="https://www.genengnews.com/wp-content/uploads/2026/11/POV-AJB-Headshot-300x300.jpg" alt="Anthony Blaszczyk" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/POV-AJB-Headshot-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/POV-AJB-Headshot-1024x1024.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/POV-AJB-Headshot-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/POV-AJB-Headshot-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/POV-AJB-Headshot.jpg 1244w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Anthony Blaszczyk, PhD<br>Principal Scientist, USP</figcaption></figure></p>
<p>While payload design will remain a primary focus, the next era of innovation in CGT may ultimately be driven by the delivery vehicle itself. In many cases, therapeutic efficacy, safety, and manufacturability are directly influenced by delivery performance. As payload technologies continue to advance, delivery may emerge as the key factor separating scientific possibility from clinical reality.</p>
<p>As a follow-up to last month’s article, “For mRNA, Delivery Is the New Standard,” which explored the future of mRNA delivery, this article examines the landscape of CGT delivery technologies. Specifically, we examine the strengths, challenges, and future directions of several leading platforms that are poised to play key roles in the future of advanced therapeutics.</p>
<p>Adeno-associated viral vectors (AAVs), lentiviral vectors (LVVs), and lipid nanoparticles (LNPs) have emerged as leading delivery platforms, each offering unique advantages and limitations. While AAV has largely dominated <em>in vivo</em> gene therapy, LVV has emerged as a viable <em>in vivo</em> delivery approach, in addition to its predominant use for <em>ex vivo</em> cell engineering applications, such as CAR T therapy. LNPs gained global recognition through their deployment in mRNA vaccines during the COVID-19 pandemic and have become a leading non-viral delivery technology. Because each platform employs a fundamentally different approach for transporting genetic material, complementary roles exist within the CGT landscape. Nevertheless, future advances for each platform will likely depend less on the genetic payload and more on improving delivery efficiency, target specificity, and safety.</p>
<h4><strong>Understanding the various delivery approaches</strong></h4>
<p>AAV is a small, non-enveloped viral vector that is approximately 20–25 nm in diameter. Although the overall structure between serotypes is similar, they vary significantly in receptor and surface proteins, which impact tissue targeting and immune recognition. Encapsulated within the capsid is a single-stranded DNA (ssDNA) genome containing the gene of interest (GOI). AAV does have a relatively limited packing capacity of around 4.7 kb, restricting the size of transgenes that can be delivered. Following cellular uptake and nuclear entry, the AAV genomic DNA is converted to double-stranded DNA and expressed by host-cell machinery to produce therapeutic proteins.</p>
<p>LVV contains a lipid envelope that mediates cell entry and encloses an RNA genome along with the viral enzymes required for genomic integration. Compared with AAVs, LVVs possess a larger packaging capacity and can typically accommodate genetic payloads of approximately 8–10 kb, enabling delivery of larger or more complex transgene constructs. Following cellular entry, the RNA genome is reverse transcribed into DNA and transported to the nucleus, where it integrates into the host genome. This permanent integration supports long-term transgene expression, which is unique to LVV as compared to the other delivery systems.</p>
<p>LNPs are synthetic, non-viral delivery systems that are typically 50–150 nm in diameter. These particles contain a dense core of ionizable lipids, phospholipids, cholesterol, and PEG-lipids that encapsulate a genetic payload, such as mRNA or siRNA. LNPs offer the greatest payload flexibility among the three platforms and can accommodate large mRNA molecules, combinations of nucleic acids, and gene-editing cargoes that may exceed the packaging limitations of viral vectors. Unlike viral vectors, an LNP does not deliver its genomic payload to the nucleus. Following cellular uptake and endosomal escape, the released mRNA is translated directly in the cytoplasm to the therapeutic protein.</p>
<p><figure aria-describedby="caption-attachment-340313" class="wp-caption aligncenter"><img loading="lazy" decoding="async" class="wp-image-340313" src="https://www.genengnews.com/wp-content/uploads/2026/11/POV-USP-Delivery-systems-AAV-LVV-LNP-v05-993x1024.jpg" alt="Delivery systems AAV, LVV, LNP" width="696" height="718" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/POV-USP-Delivery-systems-AAV-LVV-LNP-v05-993x1024.jpg 993w, https://www.genengnews.com/wp-content/uploads/2026/11/POV-USP-Delivery-systems-AAV-LVV-LNP-v05-291x300.jpg 291w, https://www.genengnews.com/wp-content/uploads/2026/11/POV-USP-Delivery-systems-AAV-LVV-LNP-v05-768x792.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/POV-USP-Delivery-systems-AAV-LVV-LNP-v05.jpg 1358w" sizes="auto, (max-width: 696px) 100vw, 696px"><figcaption class="wp-caption-text">Delivery mechanisms for LVV, AAV, and LNP. [USP]</figcaption></figure></p>
<h4><strong>Target specificity</strong></h4>
<p>Target specificity is becoming an increasingly important consideration as CGT payloads grow more powerful and complex. Emerging technologies, such as CRISPR, base editing, and prime editing, introduce new challenges due to their size, complexity, and heightened safety risks. As a result, the future success of many advanced therapies may depend not only on what they deliver, but how precisely they can deliver the cargo.</p>
<p>For <em>in vivo</em> delivery, AAV offers the highest degree of target specificity and can effectively target many different cell types. Different serotypes naturally exhibit different tissue tropisms, and capsid engineering efforts have further enhanced the ability to selectively target specific tissues. AAV vectors are widely regarded as the most mature platform for targeted <em>in vivo</em> gene delivery. As regulatory expectations continue to emphasize safety, the ability to precisely direct therapeutic payloads may become even more valuable.</p>
<p>While LVVs generally contain moderate target specificity <em>in vivo</em>, they have demonstrated extraordinary success in <em>ex vivo</em> applications, in which target cells are isolated, genetically modified, and returned to the patient. The success of <em>in vivo</em> LVV therapy will likely depend on continued improvements in targeting technologies, including custom envelope engineering, which may require a shift away from the frequently used VSV-G glycoprotein.</p>
<p>When compared with AAV and LVV, LNP generally has the lowest intrinsic target specificity and the highest degree of off-target delivery. Following systemic administration, LNPs have displayed a tendency to accumulate in the liver, limiting their ability to selectively target other tissues. However, advances in lipid chemistry and targeting strategies have shown promise for improving tissue specificity.</p>
<h4><strong>Safety</strong></h4>
<p>Improved targeting and delivery efficiency can be directly linked to improved safety. In many advanced therapies, high doses are required to achieve sufficient therapeutic activity. However, these elevated doses increase off-target risks, toxicity, and unintended immune responses. Because of this, improved delivery efficiency can improve safety by lowering dose requirements.</p>
<p>AAV vectors are generally well tolerated and have become the leading platform for <em>in vivo</em> gene therapies. Pre-existing immunity against naturally occurring AAV serotypes, however, can reduce efficacy and complicate (re)dosing strategies. High dosing requirements have been linked with serious adverse events, including hepatotoxicity, thrombotic microangiopathy, cytokine-mediated toxicity, and sensory neuron toxicity.<sup>1</sup> These findings have increased regulatory focus on dose optimization, patient selection, and immune monitoring.</p>
<p>LVV is often preferred because its ability to integrate into the host genome can provide durable gene expression, even as treated cells divide and pass the therapeutic sequence to daughter cells. This long-term persistence can be particularly advantageous in therapies targeting proliferating cell populations. However, permanent integration also introduces safety concerns, including the risk of insertional mutagenesis, that do not apply in the same way to non-integrating CGT platforms. Modern self-inactivating LVVs have substantially reduced this concern, yet long-term monitoring remains important.<sup>2</sup></p>
<p>LNPs avoid the genomic integration risks associated with viral vectors and provide only transient expression of their RNA cargo. Although LNPs contain no viral proteins, both the lipid components and the RNA payload can stimulate innate immune responses that contribute to vaccine efficacy and common side effects. LNPs also have relatively high off-target delivery rates, particularly to the liver, that carry additional safety risks. Although uncommon, other risks associated with LNPs are PEG-associated immunogenicity and lipid-associated toxicity.<sup>3</sup>  Some of these risks are amplified in applications requiring repeat dosing, which is increasingly common for RNA-based therapies.</p>
<h4><strong>Future directions</strong></h4>
<p>The future of CGT is expected to see continued advancements in the coming years. Some of the most transformative developments may come from improvements in delivery technology. These innovations may come in the form of enhanced target specificity and expanded delivery of sophisticated payloads, such as CRISPR, base editing, prime editing, and other emerging technologies. Successful progression will rely on the development of delivery systems capable of precisely transporting these payloads to the appropriate cells while minimizing safety risks.</p>
<p>For AAV, future innovation will likely focus on engineered capsids with improved transduction efficiency, enhanced tissue specificity, and reduced susceptibility to pre-existing immunity. These advancements could support lower dosing strategies, which are generally associated with increased safety and decreased manufacturing demands, while also expanding the range of treatable diseases. AAV is also being pursued as a delivery system for gene editing technologies, such as CRISPR. While the high specificity makes AAV a valuable option, the payload limitations introduce challenges. Researchers are working on new ways to overcome this hurdle, such as engineering variants that yield smaller machinery proteins or using dual-AAV systems that split large transgenes into separate vectors.</p>
<p>For LVVs, the future will likely involve continued dominance in <em>ex vivo</em> applications while further expanding into <em>in vivo</em> gene delivery. Achieving that transition will require new envelope designs and targeting approaches capable of delivering genetic payloads with greater precision. If custom-engineered envelopes can develop LVVs that preferentially target specific cells at a high rate, the large payload capacity of LVVs would make them prime candidates for delivering gene editing tools.</p>
<p>For LNPs, advances in lipid chemistry and surface engineering may unlock applications far beyond the liver. If LNPs can be designed to effectively achieve this extrahepatic delivery, a plethora of new uses would potentially be unlocked. Because of their flexibility, scalability, and compatibility with gene-editing systems, LNPs are particularly well positioned to support future generations of RNA and genome-editing therapies. Lastly, innovations can be made to enhance LNP efficiency by improving the endosomal escape issue that plagues these delivery systems.</p>
<p>AAV, LVV, and LNP delivery platforms are all expected to remain central to the future of CGT. AAV remains the leading platform for targeted <em>in vivo</em> delivery, LVV offers unique advantages through its payload capacity and durable expression, and LNPs provide unmatched flexibility and scalability. Rather than a single dominant technology emerging, future success will depend on selecting the most appropriate platform for specific therapeutic objectives. As delivery systems continue to mature, ensuring consistent product quality and analytical characterization will become increasingly important for their successful development and adoption.</p>
<p>Whether utilizing AAV vectors, LVVs, or LNPs, future innovations will require equally sophisticated analytical tools to evaluate quality attributes. To support emerging technologies and new modalities, USP actively engages with stakeholders from across industry, academia, and regulatory communities to identify key challenges and areas where standards can best support adoption and improve consistency. Reference standards can help laboratories develop methods and monitor performance. USP has already developed a portfolio of AAV reference materials that support a wide range of analytical workflows and has recently expanded into LVV reference materials, with additional LVV- and LNP-related standards under development. As the field continues to advance, these standards can help ensure consistent and accurate characterization needed to support development and improve confidence in product quality.</p>
<h4><strong>Conclusion</strong></h4>
<p>As gene therapies become more sophisticated, including the incorporation of gene- and base-editing technologies, efficient and precise delivery will remain a key determinant of clinical success. Continued advances in targeting, payload delivery, manufacturability, and safety are expected to expand the capabilities of AAV, LVV, and LNP platforms. Rather than competing technologies, these delivery systems are likely to serve complementary roles, each offering distinct advantages for specific therapeutic applications. Ultimately, the next generation of transformative medicines may be defined not only by the genetic payloads they carry, but by the ability to safely, efficiently, and precisely deliver those payloads to the right cells at the right dose.</p>
<p> </p>
<p><em>Anthony Blaszcyk, PhD, is principal scientist in the Global Biologics Department at USP.</em></p>
<p><em> </em></p>
<p><em>References</em></p>
<ol>
<li>Ertl HCJ. Mitigating Serious Adverse Events in Gene Therapy with AAV Vectors: Vector Dose and Immunosuppression. <em>Drugs</em>. 2023;83(4):287-298. doi:10.1007/s40265-023-01836-1.</li>
<li>Schlimgen R, Howard J, Wooley D, et al. Risks Associated with Lentiviral Vector Exposures and Prevention Strategies. <em>J Occup Environ Med</em>. 2016;58(12):1159-1166. doi:10.1097/JOM.0000000000000879.</li>
<li>Kim S, Park C, Lee Y, et al. Inflammatory and immune-mediated toxicity of lipid nanoparticles. <em>Biomed Pharmacother</em>. 2026;199:119385. doi:10.1016/j.biopha.2026.119385.</li>
</ol>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/beyond-the-payload/">Beyond the Payload</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Beyond Conventional CRISPR</title>
<link>https://edusehat.com/en/beyond-conventional-crispr</link>
<guid>https://edusehat.com/en/beyond-conventional-crispr</guid>
<description><![CDATA[ Genome editing is not designed to replace neurons or retinal cells that have already been lost. In this article, experts from four companies—eGenesis, Epicrispr, KOMO Biosciences, and Sumitomo Pharma America—discuss how they are moving beyond conventional CRISPR to develop novel approaches for treating disease.
The post Beyond Conventional CRISPR appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Yesavage_Figure-4_Sumitomo.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 04:20:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Beyond, Conventional, CRISPR</media:keywords>
<content:encoded><![CDATA[<p>In December 2023, the FDA approved the first CRISPR-based treatment in the United States for sickle cell disease.<sup>1</sup> Despite this advance, conventional CRISPR-Cas9 systems may introduce potentially harmful DNA breaks and cannot easily be delivered to muscle and brain cells. Moreover, genome editing is not designed to replace neurons or retinal cells that have already been lost. In this article, experts from four companies discuss how they are moving beyond conventional CRISPR to develop novel approaches for treating disease.</p>
<h4><strong>Pig organs save lives</strong></h4>
<p>Xenotransplantation involves transplanting an organ from one species into another, explains Mike Curtis, CEO of eGenesis.</p>
<p>“There are just not enough human organs to satisfy the human need for kidneys, livers, lungs, and hearts,” he notes. “Xenotransplantation opens up a new supply of animal organs.”</p>
<p>Curtis explains how the first animal organs were transplanted into people more than 60 years ago. However, these organs were rejected within minutes to hours because of immune compatibility challenges.</p>
<p>Curtis emphasizes how advances in gene editing over the past 15 years have enabled xenotransplantation. “CRISPR really opened the door to precise gene editing, which has given us the ability to engineer pig organs that are more compatible with the human body,” he says.</p>
<p>The company has made three classes of CRISPR-based gene edits to modify its pig organs for human use. First, it inactivated genes encoding for human-incompatible carbohydrates on the surface of pig organs. “In our studies, a pig kidney modified in this way has been able to function in a human for several days to weeks without hyperacute rejection,” says Curtis.</p>
<figure aria-describedby="caption-attachment-340338" class="wp-caption aligncenter"><img loading="lazy" decoding="async" class="wp-image-340338" src="https://www.genengnews.com/wp-content/uploads/2026/11/Yesavage_Figure-1_eGenesis-1024x463.jpg" alt="three classes of gene edits" width="696" height="315" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Yesavage_Figure-1_eGenesis-1024x463.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/Yesavage_Figure-1_eGenesis-300x136.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Yesavage_Figure-1_eGenesis-768x347.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Yesavage_Figure-1_eGenesis.jpg 1400w" sizes="auto, (max-width: 696px) 100vw, 696px"><figcaption class="wp-caption-text">The three classes of gene edits performed by eGenesis on the pig genome. [eGenesis]</figcaption></figure>
<p>The second class of edits introduced human genes into the pig genome to improve the human immune response to the animal organ. Finally, the third class of edits inactivated endogenous retroviruses in the pig genome, alleviating concerns that infectious diseases could cross over from pigs to people.</p>
<p>eGenesis’s most advanced program is for the kidney. The company’s recent publication in <em>The Lancet</em> describes the first few transplants of pig kidneys into people.<sup>2</sup></p>
<p>Curtis recalls one patient in the study. “This gentleman was doing poorly and had a very high risk of dying on dialysis. He was on the pig kidney for nine months, which improved his condition. He was then able to receive a human kidney transplant and is doing great eight months later.” The company is embarking on its Phase I/II/III RESTORE kidney trial, expected to initiate in the first quarter of 2027.</p>
<p>eGenesis’s second program involves the liver. The patient’s blood is perfused through a pig liver located outside of the body. This procedure provides life support and allows the person’s liver to recover while a human liver becomes available.</p>
<p>Finally, eGenesis is hoping to tackle end-stage heart failure. For the past couple of years, the company has been studying the long-term effects of pig heart transplants in baboons. Its first pig-to-human heart transplant is expected in 2027.</p>
<p>Is eGenesis finished with its gene edits? “One of our ultimate goals is to produce animal organs that require no immunosuppression,” says Curtis. “The only way to achieve that goal is iterative gene editing based on our first generation of organs. If we have our way, it should only get better from here.”</p>
<p>Although most of eGenesis’s edits have used CRISPR technology, the company is agnostic about the specific gene-editing tool. “Our goal is to improve the compatibility of pig organs for human recipients. The specific tool we use, whether it is Cas9, base editing, or prime editing, matters less to us than the outcome,” Curtis notes.</p>
<h4><strong>Epigenetic editing</strong></h4>
<p>While DNA contains the instructions for gene expression, epigenetic tags—such as DNA methylation and histone acetylation—act like switches that turn genes on and off. Epigenetic modifications help explain why people with the same genetic mutation may experience very different outcomes.</p>
<p>“We are leveraging the power of the epigenome to create new therapeutic possibilities,” explains Amber Salzman, PhD, CEO of Epicrispr. She notes how the first generation of CRISPR technology was designed to cut DNA and remove faulty genes.</p>
<p>“In contrast, we bind to the gene with CRISPR-Cas technology and tell the DNA what to do. Should the gene be expressed more, less, or not at all? All without cutting the DNA strands.”</p>
<p>Instead of the Cas9 nuclease used in first-generation CRISPR technologies, Epicrispr’s platform utilizes a much smaller molecule called CasONYX, which is deactivated and unable to cut DNA.</p>
<p>The platform fuses what it calls a modulator to each deactivated Cas nuclease. “These molecules will methylate DNA or put on histone modifications,” notes Salzman. Studies suggest that these modifications can potentially last indefinitely. And because Epicrispr’s Cas molecules and modulators are so small, they can fit into adeno-associated viruses (AAVs), which can access the muscles, eyes, and brain.</p>
<p>The company’s lead indication is facioscapulohumeral muscular dystrophy (FSHD). “We are the only company going after the root cause in FSHD, which is fundamentally a disease of reduced methylation,” Salzman notes.</p>
<figure aria-describedby="caption-attachment-340339" class="wp-caption aligncenter"><img loading="lazy" decoding="async" class="wp-image-340339" src="https://www.genengnews.com/wp-content/uploads/2026/11/Yesavage_Figure-2_epiCrispr-1024x579.jpg" alt="Epicrispr’s CasMINI" width="696" height="394" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Yesavage_Figure-2_epiCrispr-1024x579.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/Yesavage_Figure-2_epiCrispr-300x170.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Yesavage_Figure-2_epiCrispr-768x434.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Yesavage_Figure-2_epiCrispr.jpg 1400w" sizes="auto, (max-width: 696px) 100vw, 696px"><figcaption class="wp-caption-text">Epicrispr’s CasMINI uses a guide RNA to bind to the DNA sequence of interest. A fused modulator molecule can then methylate the DNA. [Epicrispr]</figcaption></figure>
<p>More specifically, FSHD is associated with fewer repeats in the <em>D4Z4</em> region of the genome and a looser chromatin architecture. This structure allows for the expression of the toxic DUX4 protein, which kills muscle cells.</p>
<p>Epicrispr’s FSDH machinery is delivered to the muscle with an AAV. The region is then remethylated to suppress the genes responsible for DUX4 expression. “In patients with less-advanced disease, we can correct enough cells to stop DUX4 production and see a gain in lean muscle volume,” says Salzman.</p>
<p>The company also has early preclinical data on Duchenne muscular dystrophy. A major challenge in treating this condition is that the faulty dystrophin protein is too large to fit into AAVs. However, a protein called utrophin can compensate for a lack of dystrophin.</p>
<p>“We deliver a construct to the muscle cells with an AAV vector that instructs utrophin to be expressed at high levels and make up for the lack of dystrophin,” she notes.</p>
<p>Epicrispr has generated <em>in vitro</em> data for Alzheimer’s disease showing the activation of the <em>SORL1</em> gene in neuronal cells. This gene has been shown to be neuroprotective in the disease. It also has promising preclinical results for retinitis pigmentosa, an eye disease caused by a faulty protein called rhodopsin.</p>
<p>Finally, Salzman argues that Epicrispr’s strategy may be safer than traditional CRISPR. “When you are cutting, you can have genomic instability. Instead, we just make epigenetic marks,” she adds.</p>
<h4><strong>Inserting large genes</strong></h4>
<p>“I think the next phase of genome engineering will be less about changing one letter at a time and more about installing complete genetic programs,” predicts Jesse B. Owens, PhD, assistant professor at the University of Hawaii at Manoa and chief scientific advisor of KOMO Biosciences.</p>
<p>While conventional CRISPR-Cas9 technology is excellent for small edits, the insertion of large amounts of DNA is far less efficient, he notes. Furthermore, CRISPR generates exposed DNA breaks that can cause unwanted deletions or rearrangements.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="7"></span></aside>
<p>Integrases fill a different niche. They actively install gene-sized DNA at a defined site without leaving an exposed double-strand break. “An integrase is like a molecular paste function,” adds Owens. “It recognizes relatively long DNA addresses in the genome and actively inserts large fragments of DNA.”</p>
<p>“Integrases have been known for some time,” he continues. “The key difference is that our enzymes have been engineered with laboratory-directed evolution to be highly effective.” For instance, Owens’s recent publications demonstrate that evolved integrases can insert DNA into the desired genomic destination 80% of the time.</p>
<p>Owens stresses that the biggest remaining bottleneck for many therapeutic applications involves delivering the genetic editing machinery to the right cells. “A hyperactive integrase changes that equation,” he says. “When delivery is scarce, a much more efficient enzyme gives the DNA that reaches a cell a better chance of becoming a correct insertion.”</p>
<p>The company’s partners are currently interested in CAR T and other engineered immune-cell therapies. Such therapies often require large DNA insertions to fit multiple components for cancer therapy—including multiple receptors, persistence factors, and a safety switch within a single genetic cassette.</p>
<p>Beyond therapeutics, integrase technology has many applications in cell-line development and biomanufacturing. For instance, a highly efficient integrase-based system could create a more predictable starting cell-line population and compress development timelines.</p>
<p>“KOMO’s capacity for full gene replacement allows one product to address many different mutations in the same gene, rather than designing a separate editor for every patient’s mutation,” notes Owens.</p>
<h4><strong>Stem cell approval</strong></h4>
<p>“In advanced degenerative neurologic and eye conditions, critical target cells have already degenerated and died,” explains Alex Solyom, MD, vice president and head of clinical research, rare disease and biopharma at Sumitomo Pharma America. Interventions like CRISPR are not targeted to regenerate tissue structures that no longer exist in the patient.</p>
<p>Induced pluripotent stem cells (iPSCs) provide a supply of healthy cells to potentially replace or functionally restore damaged tissue. Researchers can generate them by reprogramming mature cells (such as skin or blood cells) back into an embryonic-like state. Importantly, iPSCs avoid ethical concerns associated with embryonic stem cells derived from fertilized eggs.</p>
<p>iPSCs provide a convenient basis for developing potential therapies. They can replicate endlessly in culture following reprogramming. They are also pluripotent, meaning that they can mature into virtually any specialized cell type.</p>
<p>“With iPSC-derived regenerative therapies, we aim to reestablish functional cells and tissue regardless of the underlying genetic mutation. This can be particularly important for diseases driven by mutations across multiple genes,” Solyom notes.</p>
<p>He highlights Sumitomo’s DSP-3077, an investigational iPSC therapy being developed as an off-the-shelf cell therapy for patients with retinitis pigmentosa, a progressive genetic eye disorder in which retinal photoreceptors degenerate.</p>
<p>Currently in Phase I/IIa trials, DSP-3077 consists of an iPSC-derived retinal sheet produced from a three-dimensional retinal organoid. This organoid is formed during a proprietary self-organizing process in which required cell types are differentiated from the iPSCs.</p>
<p>A single subretinal injection inserts the sheets into the patient’s eye. The injected sheets are designed to physically engraft into the patient’s retinal tissue. “We believe this will support natural retinal tissue architecture and replace degenerated photoreceptors, potentially helping to restore visual function,” Solyom says. In March of 2026, the investigational therapy received an FDA Orphan Drug Designation.</p>
<p>Meanwhile, Sumitomo’s raguneprocel, a dopaminergic neural cell product, is the world’s first approved iPSC-derived medicine. In March 2026, it received conditional, time-limited approval as AMCHEPRY<sup>®</sup> in Japan to improve motor symptoms in Parkinson’s disease.</p>
<p>“Being able to deliver to patients functional tissue made up of a complex structure and multiple cell types—and derived from the same stem cell line—is a worthwhile challenge and a great accomplishment drawing on decades of research,” concludes Solyom.</p>
<p> </p>
<p><em>References</em></p>
<p>1. Singh A, Irfan H, Fatima E, et al. Revolutionary breakthrough: FDA approves CASGEVY, the first CRISPR/Cas9 gene therapy for sickle cell disease. <em>Ann Med Surg</em> (Lond). 2024;86(8):4555-4559. doi: 10.1097/MS9.0000000000002146.</p>
<p>2. Riella LV, Borges TJ, Rosales IA, et al. Porcine kidney xenotransplantation as a bridge to allotransplantation: a first-in-human study. <em>Lancet</em>. 2026;408(10559):1029-1040. doi: 10.1016/S0140-6736(26)01295-X.</p>
<p>The post <a href="https://www.genengnews.com/insights/beyond-conventional-crispr/">Beyond Conventional CRISPR</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Oral Sleep Apnea Therapy Poised to Expand Treatment Options</title>
<link>https://edusehat.com/en/oral-sleep-apnea-therapy-poised-to-expand-treatment-options</link>
<guid>https://edusehat.com/en/oral-sleep-apnea-therapy-poised-to-expand-treatment-options</guid>
<description><![CDATA[ An oral obstructive sleep apnea therapy targeting multiple pathways is poised to improve patient compliance and, possibly, outcomes.
The post Oral Sleep Apnea Therapy Poised to Expand Treatment Options appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Getty_1361394553_SleepApnea.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 04:20:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Oral, Sleep, Apnea, Therapy, Poised, Expand, Treatment, Options</media:keywords>
<content:encoded><![CDATA[<p class="wp-block-paragraph">Right now, there is no pharmaceutical treatment for obstructive sleep apnea, a condition that is estimated to affect more than one billion people globally and approximately 30 million Americans. Multiple studies (notably in 2010<sup>1</sup> and 2017<sup>2</sup>) report that as many of half those prescribed continuous positive airway pressure (CPAP)—the gold standard apnea therapy—reject it outright, and between 12% and 25% of those who begin those treatments abandon CPAP within three years.</p>


<p class="wp-block-paragraph">The reason for such high non-compliance is that CPAP is uncomfortable and socially awkward, Joel Latham, president and CEO, Incannex Healthcare, says. His company aims to be the first to potentially market an oral pharmaceutical therapy for obstructive sleep apnea.</p>


<p class="wp-block-paragraph">Latham says Incannex Healthcare’s mission is “targeting indications that have limited or no treatment options available.” So, while a therapy for obstructive sleep apnea, known as IHL-42X, is its lead therapeutic, the company’s pipeline also includes therapeutics based on distinctly different therapeutic platform to treat generalized anxiety disorder and rheumatoid arthritis.</p>


<h4 class="wp-block-heading"><strong>Oral apnea therapy</strong></h4>


<p class="wp-block-paragraph">Regarding obstructive sleep apnea, “We are targeting multiple pathways, and [the condition’s] underlying, fundamental causes,” he tells <em>GEN</em>. Just as importantly, the therapeutic (code-named IHL-42X) is oral, which should significantly improve compliance and potentially make more people amenable to therapy. It has received Fast Track designation from the U.S. Food and Drug Administration (FDA).</p>


<p class="wp-block-paragraph">The Phase II RePOSA trial showed that IHL-42X significantly reduced the frequency of breathing disruptions during sleep compared with placebo, with individual reductions of up to 83%. Reductions exceeding 30% were achieved by 33.3% of patients receiving the low dose and 41.2% receiving the high dose. A subsequent dose-optimization study, DReAMzz, began patient dosing in August 2026, supported by 14 clinical sites across the U.S. “We expect to have the data from that trial in the first half of 2027,” Latham says.</p>


<figure class="wp-block-image alignright size-medium is-resized"><img loading="lazy" decoding="async" width="300" height="300" src="https://www.genengnews.com/wp-content/uploads/2026/11/OYR-Joel-Latham-Headshot-e1793902112442-300x300.jpg" alt="Joel Latham" class="wp-image-340328" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/OYR-Joel-Latham-Headshot-e1793902112442-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/OYR-Joel-Latham-Headshot-e1793902112442-1024x1024.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/OYR-Joel-Latham-Headshot-e1793902112442-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/OYR-Joel-Latham-Headshot-e1793902112442-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/OYR-Joel-Latham-Headshot-e1793902112442.jpg 1260w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-element-caption">Joel Latham<br>President and CEO<br>Incannex Healthcare</figcaption></figure>


<p class="wp-block-paragraph">“IHL-42X is an oral, fixed-dose combination of acetazolamide and dronabinol,” he continues. “Acetazolamide [a carbonic anhydrase inhibitor used for altitude sickness and glaucoma] induces metabolic acidosis, which signals…there is excess CO<sub>2</sub> in the blood, and thereby causes people to take a breath. Dronabinol [a synthetic tetrahydrocannabinol used to control nausea and stimulate appetites] simultaneously dilates the airways. So, by inducing the taking of a breath and dilating the airways simultaneously, we’re able to reduce the number of apnea episodes that patients experience during the evening.”</p>


<p class="wp-block-paragraph">Because this approach pairs two already-approved drugs, risks are reduced, the development pathway is streamlined, and costs are lowered.</p>


<h4 class="wp-block-heading"><strong>Anxiety and arthritis</strong></h4>


<p class="wp-block-paragraph">To treat generalized anxiety disorder, Incannex Healthcare is developing PSX-001, a psilocybin-based therapy designed to be used with cognitive behavioral therapy. The Phase II trials that completed in 2025 showed a 50% reduction in anxiety in 44% of patients.</p>


<p class="wp-block-paragraph">Generalized anxiety disorder affects approximately three percent of the U.S. population. First-line treatments are selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors, both administered with cognitive behavioral therapy.</p>


<p class="wp-block-paragraph">“The current standard of care has an extremely high non-compliance rate,” Latham says. Medical literature cites non-compliance rates between 40% to 60% within six months. Given PSX-001’s apparent efficacy in Phase II studies, “This is a market where we firmly believe we can make significant impacts for patients suffering from debilitating anxiety disorders.”</p>


<p class="wp-block-paragraph">Its third pipeline therapeutic—for rheumatoid arthritis—is on the back burner for now. “It’s been de-risked, but we truly have our hands full with the two lead assets,” Latham admits. IHL-675A, as this therapeutic is known, has completed “a plethora of preclinical and Phase I and II clinical studies, and the data’s been pleasing…but we’re focusing our resources on those [other] two assets.”</p>


<h4 class="wp-block-heading"><strong>From Aus to the UAE</strong></h4>


<p class="wp-block-paragraph">Incannex Healthcare has changed substantially since being founded in Australia in 2014. When it went public in 2016 on both the Australian Stock Exchange (ASX) and the NASDAQ, Latham—an early investor—joined the company as general manager. “After two years, I was elevated to CEO,” he says.</p>


<p class="wp-block-paragraph">“Then, in 2023, we decided to delist from the ASX and purely focus on the NASDAQ because we firmly believe that’s where our true peers were. Shifting its ASX shares to the NASDAQ made it easier for U.S. brokers to trade Incannex Healthcare stock and for Incannex Healthcare to leverage U.S. investors’ knowledge around the cannabinoid and psychedelic sectors, as well as access more potential investors.</p>


<p class="wp-block-paragraph">Recently, Incannex Healthcare moved its executive headquarters from Melbourne to Dubai, while retaining offices in Melbourne—“where the vast majority of our research team is located”—and New York. “Being in the UAE allows me to efficiently manage the two vastly different time zones that we deal with,” he says.</p>


<p class="wp-block-paragraph">“Abu Dhabi,” he continues, “is quite a biotech hub. That’s one of the leading reasons for me moving here and setting up offices.” The United Arab Emirates is considered an emerging, fast-growing regional biopharma center with very fast regulatory approvals and a strong desire to enlarge its biopharma manufacturing base.</p>


<p class="wp-block-paragraph">“We’re developing relationships, and we’re working with sovereign funds and with the government in relation to potential grants,” Latham says. That funding—an influx of nearly $60 million in the past year, which brought its cash balance to more than $74 million—provides “ample runway to see assets through to potential completion of Phase III,” he adds.</p>


<h4 class="wp-block-heading"><strong>Maturity brings changes</strong></h4>


<p class="wp-block-paragraph">Being president and CEO, he says “has been quite a unique experience,” given the multiple capital markets Incannex Healthcare has competed in, the multiple clinical assets it has developed, and clinical trials it has completed.</p>


<p class="wp-block-paragraph">“Very early on,” Latham recalls, “we were entrenched in preclinical studies. We were able to move quickly, generating data, creating new assays and studies, filing provisional patents, and derisking assets.” Now the operational scale is much larger and, he points out, “We’re at a later stage of development, so things move slower.” Examples of current challenges include onboarding trial sites, ensuring adequate patient recruitment levels, maintaining productive FDA interactions, and managing the permits and licensing necessary to import trial products into the U.S. For Incannex Healthcare’s pipeline, that includes working with the Drug Enforcement Agency.</p>


<p class="wp-block-paragraph">One thing has remained constant, however. From the very beginning, Latham says, “Everything’s been developed completely in-house in collaboration with our chief scientific officer, chief medical officer, and the expert leading advisory boards we’ve established for each of our assets.”</p>


<h4 class="wp-block-heading"><strong>Next milestones</strong></h4>


<p class="wp-block-paragraph">Completing the IHL-42X obstructive sleep apnea study, which dosed its first patient in August, is the company’s next milestone, Latham says. “We’re hyper-focused on getting those results out in 2027.”</p>


<p class="wp-block-paragraph">Meanwhile, Incannex Healthcare continues developing PSX-001 to treat generalized anxiety. “Various potential collaboration discussions are underway as well, so we expect to be able to deliver a few key milestones and updates to the market in the coming months,” he says.</p>


<p class="wp-block-paragraph"><em> </em></p>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column sidebar is-layout-flow wp-block-column-is-layout-flow">
<h3 class="wp-block-heading"><strong><strong>Incannex Healthcare</strong></strong></h3>


<p class="wp-block-paragraph"><strong>Location:</strong> Level 23, Rialto South Tower, 525 Collins Street, Melbourne VIC 3000, Australia</p>


<p class="wp-block-paragraph"><strong>Phone:</strong> 61 (409) 840-786</p>


<p class="wp-block-paragraph"><strong>Website:</strong> <a href="https://incannex.com/" target="_blank" rel="noreferrer noopener">incannex.com</a></p>


<p class="wp-block-paragraph"><strong>Principal:</strong> Joel Latham, president and CEO</p>


<p class="wp-block-paragraph"><strong>Number of Employees:</strong> 30</p>


<p class="wp-block-paragraph"><strong>Focus:</strong> Incannex Healthcare is a clinical-stage company developing therapeutics for unmet needs. Its lead programs are an oral therapy for obstructive sleep apnea and a combination psilocybin/psychotherapy approach to treating generalized anxiety disorder.</p>
</div>
</div>


<p class="wp-block-paragraph"></p>


<p class="wp-block-paragraph"><em>References</em></p>


<ol class="wp-block-list">
<li>Catcheside, Peter G, Predictors of continuous positive airway pressure adherence. <em>F1000 Medicine Reports</em>. September 2010; 2:70 (<a href="https://s3-eu-west-1.amazonaws.com/science-now.reports/f1000reports/files/9008/2/70/article.pdf">doi:10.3410/M2-70</a>)</li>



<li>Jacobsen AR, Eriksen F, Hansen RW, et al. <a href="https://doi.org/10.1371/journal.pone.0189614" target="_blank" rel="noopener">Determinants for adherence to continuous positive airway pressure therapy in obstructive sleep apnea</a>. <em>PLOS ONE</em>. 2017; 12(12): e0189614.</li>
</ol>


<p class="wp-block-paragraph"></p>

<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/oral-sleep-apnea-therapy-poised-to-expand-treatment-options/">Oral Sleep Apnea Therapy Poised to Expand Treatment Options</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Tissue Engineering Takes Shape</title>
<link>https://edusehat.com/en/tissue-engineering-takes-shape</link>
<guid>https://edusehat.com/en/tissue-engineering-takes-shape</guid>
<description><![CDATA[ Personalized grafts, bioinks, and off-the-shelf tissues are advancing regenerative medicine toward broader clinical use.
The post Tissue Engineering Takes Shape appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Fig-2-Humacyte.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 04:20:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Tissue, Engineering, Takes, Shape</media:keywords>
<content:encoded><![CDATA[<p>Tissue engineering is on the move from an ambitious idea toward everyday clinical reality. At the interface of biology, materials science, and engineering, the field seeks to repair or replace damaged human tissues and organs. Some approaches embrace personalized medicine, creating tissues and treatments from a patient’s own cells and materials. Others are developing off-the-shelf engineered products for broad availability. We spoke to experts in the field about the latest developments pushing both strategies forward. Technologies range from heart patches and spinal cord repair to bone, cartilage and vascular grafts, and beyond.</p>
<h4><strong>Living cardiac band-aid </strong></h4>
<figure aria-describedby="caption-attachment-340294" class="wp-caption alignright"><img decoding="async" class="wp-image-340294" src="https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Jordan-Lancaster-e1793897464951-300x300.jpg" alt="Jordan Lancaster" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Jordan-Lancaster-e1793897464951-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Jordan-Lancaster-e1793897464951-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Jordan-Lancaster-e1793897464951-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Jordan-Lancaster-e1793897464951.jpg 933w" sizes="(max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Jordan Lancaster, PhD<br>CEO, Avery Therapeutics</figcaption></figure>
<p>“The concept of making functional tissue to replace damaged tissues and organs has captured the imagination of many for a long time,” says Jordan Lancaster, PhD, CEO of Avery Therapeutics. Case in point: heart failure. Lancaster elaborates, “Today, we manage cardiac diseases like heart failure by administering drugs that help reduce symptoms of the disease. And while the current armament of drugs for heart failure does slow progression of disease, the prognosis remains grim, and the disease continues to advance. There are no therapies today that get to the root cause of heart failure, which is loss of functioning cardiomyocytes (heart muscle cells) and fibrosis. We want to change this. We want to develop novel therapies that address the root cause of disease, and reverse disease in ways that are currently unobtainable.”</p>
<p>According to Lancaster, the company is pursuing an immunomodulatory approach coupled with tissue engineering to essentially create a “living band-aid, of sorts.” Their preclinical collaborative studies employed an allogeneic cardiac patch composed of a proprietary mix of human induced pluripotent stem cell (iPSC)-derived cardiomyocytes and fibroblasts embedded in a bioresorbable matrix. Lancaster explains, “This biologic product is placed on damaged tissue and creates a localized immunomodulatory response that drives disease repair. Our immunomodulatory platform is built utilizing cellular material, a proprietary combination of cells produced via a multi-day manufacturing process. The biologic engages the immune system and recruits immune precursor cells, which drive repair.”</p>
<p>Developing the approach also required overcoming key hurdles such as manufacturing at scale, handleability, and shelf stability (cryopreservation). Additionally, Lancaster says the company has learned a lot about the immune system and its ability to serve as a conserved therapeutic target for diseases of inflammation and fibrosis. “We are exploring and have established deep mechanistic insight into how to redirect the immune system into pro-reparative pathways, which we have validated in highly translatable preclinical models of heart failure. We are keen to advance these insights into novel therapies.”</p>
<p>As a late-stage preclinical company, Avery will initially focus on heart failure of ischemic etiology with plans to advance the technology toward clinical testing.</p>
<h4><strong>Bioinks for 3D bioprinting </strong></h4>
<figure aria-describedby="caption-attachment-340290" class="wp-caption alignright"><img decoding="async" class="wp-image-340290" src="https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Yehiel-Tal--300x300.jpg" alt="Yehiel Tal" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Yehiel-Tal--300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Yehiel-Tal--1024x1024.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Yehiel-Tal--150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Yehiel-Tal--768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Yehiel-Tal-.jpg 1400w" sizes="(max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Yehiel Tal<br>CEO, CollPlant Biotechnologies</figcaption></figure>
<p>While tissue engineering has made remarkable progress, fundamental barriers remain, according to Yehiel Tal, CEO of CollPlant Biotechnologies, including “access to safe and reproducible biomaterials, recreation of the complex biological and mechanical environment of human tissue, vascularization, and scalable manufacturing.” Bioinks, specialized cell-laden gel-based biomaterials, are a critical aspect. He elaborates, “Bioinks must support cell viability while providing the printability, structural stability, degradation profile, and mechanical properties required for functional tissue formation.”</p>
<p>The company is addressing these challenges through its proprietary plant-derived recombinant human type 1 collagen (rhCollagen) platform. Tal reports, “Because our collagen is bioidentical to human collagen and produced without animal or human tissue, it offers a consistent, scalable, animal-free building block for regenerative medicine. Our bioink portfolio combines rhCollagen with complementary biomaterials and photoactive components to tailor mechanical strength, degradation kinetics, and printing performance for different tissues and printing technologies.”</p>
<figure aria-describedby="caption-attachment-340291" class="wp-caption alignleft"><img loading="lazy" decoding="async" class="wp-image-340291 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-CollPlant-Regenerative-breast-Implant-300x252.jpg" alt="3D-bioprinted regenerative breast implants" width="300" height="252" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-CollPlant-Regenerative-breast-Implant-300x252.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-CollPlant-Regenerative-breast-Implant-1024x860.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-CollPlant-Regenerative-breast-Implant-768x645.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-CollPlant-Regenerative-breast-Implant.jpg 1400w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">3D-bioprinted regenerative breast implants, composed of rhCollagen and biodegradable biopolymers, are designed to provide structural support, promote vascularization and tissue ingrowth, and gradually degrade as the patient’s own tissue replaces the implant. CollPlant Biotechnologies’ regenerative implants are currently in preclinical development. [CollPlant Biotechnologies]</figcaption></figure>
<p>One example from this portfolio is BioFlex<sup><img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"></sup>, a ready-to-print kit for high-resolution digital light processing (DLP) bioprinting. DLP bioprinting projects a digital image of each layer of a desired 3D structure onto light-sensitive bioink, selectively solidifying the material to build the structure layer by layer. Tal explains, “BioFlex combines Collink.3D<sup><img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"></sup> 50 with a biodegradable polymer and proprietary photoactive agents, simplifying formulation while retaining the flexibility to create complex, biologically relevant structures. It is intended for advanced tissue models, drug discovery, engineered tissues, and ultimately transplantable organs.”</p>
<p>The company is also applying tissue engineering to medical aesthetics. Tal says, “We have advanced commercial-size, 3D-bioprinted regenerative breast implants through large-animal preclinical studies. These implants are designed to gradually degrade while supporting vascularization and regeneration of the patient’s own tissue.”</p>
<p>Tal believes progress in the field will depend on integrating biomaterials, cells, vascular networks, bioreactors, automation, and computational design into scalable manufacturing platforms. “We see major opportunities in human tissue models, regenerative soft-tissue products, and organ manufacturing, enabled by biomaterials that are both biologically relevant and industrially reproducible.”</p>
<h4><strong>Personalized spinal cord repair </strong></h4>
<p>More than 18,000 people sustain traumatic spinal cord injuries in the U.S. annually, with approximately 310,000 patients living with the condition. The injured spinal cord has little regenerative capacity and develops a cellular and extracellular environment that inhibits neural regrowth.</p>
<figure aria-describedby="caption-attachment-340293" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-340293" src="https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Gil-Hakim-e1793897765662-246x300.jpg" alt="Gil Hakim" width="200" height="244" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Gil-Hakim-e1793897765662-246x300.jpg 246w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Gil-Hakim-e1793897765662-768x937.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Gil-Hakim-e1793897765662.jpg 782w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Gil Hakim<br>CEO, Matricelf</figcaption></figure>
<p>Gil Hakim, CEO of Matricelf<strong>,</strong> reports, “Chronic spinal cord injury is characterized by tissue cavities and scarring that interrupt neural pathways. Regeneration requires addressing inflammation, restoring extracellular-matrix cues, and enabling transplanted cells to survive, organize, extend axons, form functional synapses, and integrate with spinal cord circuitry.”</p>
<p>Matricelf is developing NewRal, a 3D neural-tissue transplant composed of patient blood-derived iPSCs as well as an extracellular-matrix hydrogel derived from the patient’s omental tissue. Before transplantation, the cells differentiate and assemble into 3D neural tissue spheroid constructs containing electrically active neural cells, designed to replace damaged neural tissue and support new neural connections.</p>
<p>“The dual-autologous design may reduce immune mismatch and the need for immunosuppression,” says Hakim. “Compared with transplants using donor cells or synthetic, animal-derived, or standardized scaffolds, NewRal combines patient-specific cells, biological matrix, and preassembled neural tissue.”</p>
<p>Matricelf is addressing manufacturing complexity and patient variability through standardized Good Manufacturing Practices (GMP) processes and optimization via closed-system automation. Hakim indicates that pilot efficacy studies in chronic spinal cord injury animal models have shown improvement in functional recovery and tissue regeneration in 80% of treated animals. The company completed Good Laboratory Practice (GLP) safety studies, advanced GMP manufacturing and clinical site preparations, initiated patient identification activities, and received FDA feedback on elements of the proposed first-in-human clinical program planned for 2027.</p>
<figure aria-describedby="caption-attachment-340296" class="wp-caption aligncenter"><img loading="lazy" decoding="async" class="wp-image-340296 size-large" src="https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Matricelf_NewRal_high_resolution-1024x403.jpg" alt="Matricelf’s NewRal technology illustration" width="1024" height="403" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Matricelf_NewRal_high_resolution-1024x403.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Matricelf_NewRal_high_resolution-300x118.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Matricelf_NewRal_high_resolution-768x302.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Matricelf_NewRal_high_resolution.jpg 1400w" sizes="auto, (max-width: 1024px) 100vw, 1024px"><figcaption class="wp-caption-text">To treat spinal cord injuries, patient-derived cells and an autologous hydrogel are combined to create personalized 3D neural tissue for transplantation at the site of spinal cord injury. Illustrated is Matricelf’s NewRal technology. [Matricelf]</figcaption></figure>
<h4><strong>Living bone and cartilage grafts </strong></h4>
<figure aria-describedby="caption-attachment-340297" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-340297" src="https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Nina-Tandony-e1793898011794-300x300.jpg" alt="Nina Tandon" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Nina-Tandony-e1793898011794-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Nina-Tandony-e1793898011794-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Nina-Tandony-e1793898011794-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Nina-Tandony-e1793898011794.jpg 770w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Nina Tandon, PhD<br>CEO, EpiBone</figcaption></figure>
<p>Tissue engineering is also making strides in the repair of bone and cartilage. According to Nina Tandon, PhD, CEO of EpiBone, “The gold standard treatments for skeletal defects are unfortunately riddled with compromises to meet the standard of ‘replacing like with like.’ Craniofacial bone loss after trauma or tumor surgery, and damaged joint cartilage, are the big ones. What happens today? A surgeon can harvest bone from your hip or leg, so now you have two wounds and real donor-site pain. They can use cadaver tissue, which the body often resorbs. Or they can bolt in metal or plastic that never becomes bone and, sooner or later, needs revising.”</p>
<p>EpiBone aims to shift from replacing tissue to regrowing it using stem cells to create personalized bone and cartilage products. Tandon explains, “Depending on the case, we can shape a graft to a patient’s exact anatomy before it reaches the operating room, or supply it off the shelf, ready when the surgeon needs it. Either way, it is living tissue on a natural bone matrix, so it is designed to integrate and remodel the way native tissue does rather than be tolerated as a foreign object.”</p>
<p>The process begins with adult stem cells seeded onto a natural bone matrix and matured in a bioreactor. Tandon elaborates, “I describe the bioreactor as diet and exercise: it feeds the tissue and puts it through the mechanical loading it will see in the body (going jogging a couple miles a day, roughly). Out comes living, 3D bone or cartilage. Honestly, the biology is the fun part. The moat is manufacturing. Making living tissue reproducibly, at the right size and shape and at clinical grade, is the hard problem, and it is the one we have spent more than a decade on.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>The company has advanced its bone and cartilage programs into human trials. Tandon reports, “In our first-in-human bone trial, we treated six patients with zero product-related adverse events. Those six jaws are the thing I am proudest of.” EpiBone has also tested an injectable cartilage therapy for osteoarthritis in dogs and horses, reporting improvements over standard-of-care treatment.</p>
<p>Looking ahead, Tandon sees the next decade focusing on scale and broader availability of custom and off-the-shelf living grafts.</p>
<h4><strong>Off-the-shelf vascular grafts </strong></h4>
<p>When a patient suffers a severe injury or chronic vascular disease, surgeons may need to replace or repair an artery. Current options include using a patient’s own vein, synthetic grafts, or an animal-derived allograft.</p>
<figure aria-describedby="caption-attachment-340295" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-340295" src="https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Laura-Niklason-e1793897920400-266x300.jpg" alt="Laura Niklason" width="200" height="225" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Laura-Niklason-e1793897920400-266x300.jpg 266w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Laura-Niklason-e1793897920400-909x1024.jpg 909w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Laura-Niklason-e1793897920400-768x865.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Laura-Niklason-e1793897920400.jpg 1183w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Laura Niklason, MD, PhD<br>President and CEO, Humacyte</figcaption></figure>
<p>“Harvesting a vein can be especially dangerous in urgent cases, taking more time in the OR, adding increased risk for infection, and resulting in a second surgical wound with the potential for post-operative pain,” says Laura Niklason, MD, PhD, president and CEO of Humacyte. She also notes some synthetic grafts are prone to infection while animal-derived allografts carry other issues. What is needed is a readily available conduit that behaves like living tissue but resists infection, maintains patency, and integrates seamlessly with the body.</p>
<p>Humacyte has developed acellular tissue-engineered vessels (ATEVs) as off-the-shelf, universally implantable vascular grafts. Niklason explains, “We begin with human vascular smooth muscle cells seeded onto a biodegradable scaffold, which gradually dissolves as the tissue forms.” Pulsatile, artery-like conditioning then prompts the cells to build a strong matrix of human collagen and other extracellular matrix proteins. After the vessel matures, the cells used to grow it are removed while the extracellular matrix and structural proteins remain. The resulting bioengineered vessel can be stored until needed. After implantation, the patient’s own cells gradually repopulate and remodel the vessel, transforming it into living tissue.</p>
<p>The company’s lead product, Symvess<sup>®</sup>, was approved by the FDA in December 2024 as a vascular conduit for adults with extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss and an autologous vein graft is not feasible. In September 2026, the FDA approved extending its shelf life from 18–36 months. Humacyte is also planning submission of a supplemental Biologics License Application in the second half of 2026 for hemodialysis applications.</p>
<p>Niklason believes tissue engineering is at an important inflection point. “What’s changing now is the shift toward manufactured, off-the-shelf regenerative products that have the potential to reach a large scale of patients. The opportunity ahead is to make engineered human tissue a routine part of surgical and medical care for the benefit of the patients who need it.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/tissue-engineering-takes-shape/">Tissue Engineering Takes Shape</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Orphan Therapeutics Accelerator In&#45;Licenses Its First Gene Therapy, Eyes Pipeline Expansion</title>
<link>https://edusehat.com/en/orphan-therapeutics-accelerator-in-licenses-its-first-gene-therapy-eyes-pipeline-expansion</link>
<guid>https://edusehat.com/en/orphan-therapeutics-accelerator-in-licenses-its-first-gene-therapy-eyes-pipeline-expansion</guid>
<description><![CDATA[ The nonprofit biotech evaluates potential therapies based on unmet medical need, clinical evidence of safety and efficacy, and the compatibility of institutional partners. Its funding model combines initial seed investment with commercial revenue and non-traditional funding sources.
The post Orphan Therapeutics Accelerator In-Licenses Its First Gene Therapy, Eyes Pipeline Expansion appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/10/Getty_2235763333_GeneTherapy.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 04:20:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Orphan, Therapeutics, Accelerator, In-Licenses, Its, First, Gene, Therapy, Eyes, Pipeline, Expansion</media:keywords>
<content:encoded><![CDATA[<p><span>Recently, the Orphan Therapeutics Accelerator (OTXL) announced an agreement with UCL Ventures, </span><span>the commercialization company of University College London (UCL), </span><span>and Children’s Medical Research Institute (CMRI) to in-license an investigational therapy program for ornithine transcarbamylase deficiency (OTCD), a rare, X-linked metabolic disorder. The drug candidate in question, now dubbed OTXL-101, was formally known as AAVLK03hOTC. It was developed through a collaboration between Paul Gissen, MBCHB, PhD, and the OTCD project team at University College London, and Ian Alexander, MBBS, PhD, and his team at CMRI. </span></p>
<p><span>This marks the first therapy in-licensed by OTXL, a nonprofit biotech set up specifically to utilize tax and other incentives to “liberate and reininitiate development of shelved therapies for rare and ultra rare conditions” that have been shelved in recent years for various reasons, according to Craig Martin, OTXL’s CEO and co-founder. </span></p>
<p><span>The nonprofit biotech is one part of a four-pronged approach targeting shelved cell and gene therapies. The other parts include the Orphan ClinDevNet, a network of affiliated contract development and manufacturing organizations, contract research organizations, and other partners who have agreed to work under reduced-cost, success-based agreements. </span></p>
<p><span>Approved products can be commercialized through Orphan Therapies, OTXL’s commercial subsidiary, which was established a year ago, or outlicensed to biotech or biopharma partners. Recently, Orphan Therapies established commercial availability for an <em>ex vivo</em> cell therapy for patients with Wiskott-Aldrich syndrome. </span></p>
<p><span>Finally, support for </span><span>OTXL and </span><span>other programs in need of financing or partners can be accelerated and facilitated through CGTxchange, an artificial intelligence-enabled marketplace, diligence, and deal-making platform established through a </span><a href="https://www.genengnews.com/topics/genome-editing/asgct-president-terry-flotte-touts-rare-disease-initiatives-as-his-term-ends/" target="_blank" rel="noopener"><span>joint venture between OTXL and the American Society of Gene & Cell Therapy (ASGCT)</span></a><span>. It serves as a marketplace for shelved therapies with potential that could be picked up by both traditional and non-traditional kinds of investors or funders.</span></p>
<p><span>In fact, OTXL-101 was initially identified with the help of the platform that now underlies CGTxchange, according to Martin. He told</span><i><span> GEN</span></i><span> that prior to in-licensing OTXL-101, the OTXL team looked at more than 80 different therapeutic programs. “We first started looking at it almost two years ago,” he said. At the time, OTXL-101 was outlicensed to Bloomsbury Genetic Therapies, which had initiated a Phase I/II study dubbed the Halting Ornithine transcarbamylase deficiency with Recombinant AAV in Children or HORACE trial. </span></p>
<p><span>The first patient, a 10-year-old male with late-onset OTCD, was treated at Great Ormond Street Hospital in December 2023. The plan was to run a 12-patient trial, however when the Bloomsbury Genetic Therapies shut down in 2025, the program was returned to UCL and CMRI. Preliminary results from the first patient were presented at the 2025 ASGCT annual meeting.</span></p>
<p><span>OTXL had moved on to other candidates at the time, Martin said, but when the initial plans for the treatment fell through, and the therapy was returned to UCL and CMRI, they reconsidered. “We started negotiating with them and found everybody was really feeling like this was a therapy that needed to get to patients. And we were able to structure the deal in such a way that it really fit our model and provided a more viable path forward for the therapy,” he said. </span></p>
<h4><b>A rare disease therapy gets a new life</b></h4>
<p><span>Ornithine transcarbamylase deficiency or OTCD is caused by mutations in the OTC gene that reduce or eliminate ornithine transcarbamylase activity. This enzyme is essential to the liver’s urea cycle, which converts toxic ammonia from protein metabolism into urea for elimination. When ammonia builds up in the blood, it can cause hyperammonemic decompensations, brain injury, and coma. </span></p>
<p><span>The condition is currently managed medically by protein restriction, nitrogen-scavenging medicines, and amino acid supplements. But patients remain at risk for elevated blood ammonia and serious complications. Another option is liver transplantation which can restore metabolic control but carries surgical risks and requires lifelong immunosuppression. Estimates from Orphanet indicate that its birth frequency ranges from approximately one in 56,500 to one in 113,000 live births. </span></p>
<p><span>If it passes further testing and is approved, OTXL-101 could be an important treatment tool. To treat OTCD, OTXL-101 uses a liver-targeted adeno-associated virus vector to deliver a functional OTC gene and restore urea cycle activity. The gene therapy is intended to treat children and adolescents with OTCD and has received U.S. and EU orphan drug designations as well as a U.S. rare pediatric disease designation. </span></p>
<p><span>This initial clinical evidence of the efficacy of OTXL-101, which now spans more than two and a half years, “gives us a sense of its potential to benefit patients,” Martin said. In his conversation with </span><i><span>GEN</span></i><span>, he explained: The data showed that following treatment with the gene therapy, the patient had successfully been taken off Ravicti, a prescription nitrogen-binding medicine for long-term management of high ammonia levels, as well as off of a restricted diet. And they have continued to do well. </span></p>
<p><span>The type of evidence that OTXL will consider for future in-licensed candidates and therapies that are included in the CGTxchange will vary, Martin said. For one thing, not all rare disease therapies will have years of post-treatment data on patients as that will depend on factors such as when the trials were stopped or suspended and their specific endpoints. In general, “the criteria that are most important to us are ‘is this an area of high unmet medical need? Is it a therapeutic approach that we have a good understanding of and based on evidence from clinical trials, wherever they are in that process?’” he said. Other pertinent questions focus on who the partners involved are and whether they can work with OTXL. </span></p>
<p><span>In terms of OTXL-101, “we are going through the process of doing stability and potency testing on the material that had been manufactured for the trial,” Martin said. Also, “we’ve done some other things related to extending patents in a number of countries so that we know we’ve got the ability to provide access in a variety of places.” Finally, the therapy will be listed on the CGTxchange. “We have some of the funds required to continue to move it forward, but we’d like to be able to have a set of funding that would allow us to extend ideally past the next inflection point,” Martin explained. </span></p>
<p><span>Meanwhile, OTXL is exploring other candidates for potential in-licensing deals. “We’re actually in some conversations now and not just around the clinical stage, but also other commercial-stage or commercial products that we might be able to help move forward,” Martin said. It is important to note here that OTXL is modality agnostic and is willing to consider other kinds of treatment approaches beyond cell and gene therapies. Martin pointed to the team’s recent work on the <em>ex vivo</em> cell therapy for patients with Wiskott-Aldrich syndrome. “If there are other therapies like that out there where the traditional commercial model just doesn’t work for big biotechs or biopharma companies, those would be good candidates for us to … put into our existing infrastructure and move forward.”</span></p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/orphan-therapeutics-accelerator-in-licenses-its-first-gene-therapy-eyes-pipeline-expansion/">Orphan Therapeutics Accelerator In-Licenses Its First Gene Therapy, Eyes Pipeline Expansion</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Bird Flu Vaccine Developed Using AI Outperforms Current Stockpiled Vaccines in Preclinical Tests</title>
<link>https://edusehat.com/en/bird-flu-vaccine-developed-using-ai-outperforms-current-stockpiled-vaccines-in-preclinical-tests</link>
<guid>https://edusehat.com/en/bird-flu-vaccine-developed-using-ai-outperforms-current-stockpiled-vaccines-in-preclinical-tests</guid>
<description><![CDATA[ Researchers used an AI-guided engineering approach to create a broadly protective bird flu vaccine that is designed to remain effective across a wide range of existing and future H5Nx variants. 
The post Bird Flu Vaccine Developed Using AI Outperforms Current Stockpiled Vaccines in Preclinical Tests appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Low-Res_4X4A7027-2-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 04:20:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Bird, Flu, Vaccine, Developed, Using, Outperforms, Current, Stockpiled, Vaccines, Preclinical, Tests</media:keywords>
<content:encoded><![CDATA[<p>Researchers at the University of Cambridge and at the University of Cambridge spin-out DIOSynVax reported on the development of a broad-spectrum bird flu vaccine that in animal trials provided complete protection against globally circulating, diverse H5Nx variants of the disease. Current pandemic preparedness relies on stockpiling vaccines against individual virus variants that have already emerged. The Cambridge team’s approach uses AI-guided engineering to create broadly protective vaccines intended to remain effective across a wide range of existing and future variants.</p>
<p>The team’s study, described in <em>Cell Reports Medicine,</em> found the new digitally engineered multi-antigen mRNA vaccine to be superior to bird flu vaccines currently stockpiled by many governments for use in the event of a human outbreak. Their preclinical trial results showed that the existing vaccines tested protected only around 50% of animals exposed to multiple H5N1 bird flu variants, compared with complete protection achieved by the team’s new vaccine, DVX-panH5Nx.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>The results demonstrate the potential of AI-guided vaccine design in developing broad protective population immunity ahead of evolving biological threats. The researchers say the vaccine represents the third success with their AI-guided technique for designing vaccines against highly infectious viruses that threaten animal and human health. The new study in addition demonstrates that the team’s ‘plug and play’ approach can be used to create safe, highly effective vaccines for a plethora of infectious diseases threatening animal and human health globally.</p>
<p>“Rather than providing immunity to a single variant of bird flu, our new broad-spectrum vaccine is protective against a huge range of variants,” said Professor Jonathan Heeney, PhD, in the Lab of Viral Zoonotics, University of Cambridge’s Department of Veterinary Medicine. “It’s designed to anticipate viral evolution, rather than reacting to it … These new-generation vaccines are a game changer for national biosecurity and more resilient public health. They mean we can be prepared to respond immediately to virus epidemics and pandemics, rather than the current scenario of always being on the back foot and responding with a strain which will have changed.”</p>
<p>In their paper, titled “<a href="http://dx.doi.org/10.1016/j.xcrm.2026.103131" target="_blank" rel="noopener">Broad vaccine protection against globally diverse influenza A H5Nx viruses</a>,” senior and corresponding author Heeney and colleagues stated, “Compared to WHO candidate vaccine viruses (CVVs), DVX-panH5Nx confers superior protection against antigenically distinct H5N1 challenges spanning two decades of viral evolution, demonstrating that computationally designed multivalent antigen vaccines can overcome natural influenza diversification and provide a scalable strategy for pre-pandemic preparedness.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>Bird flu is an RNA vaccine (as are the coronaviruses that cause COVID-19) that is spreading in animals around the world and is currently considered a significant threat to global public health, the authors noted. “Influenza A H5Nx viruses continue to diversify and undergo gene reassortment as they infect avian and mammalian hosts worldwide,” they wrote. RNA viruses represent a particular threat to human health because they can mutate rapidly into new strains that can jump from animals to humans and evade our immune systems—and our existing vaccines.</p>
<figure aria-describedby="caption-attachment-340287" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="size-medium wp-image-340287" src="https://www.genengnews.com/wp-content/uploads/2026/11/4X4A7000-211x300.jpg" alt="Professor Jonathan Heeney." width="211" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/4X4A7000-211x300.jpg 211w, https://www.genengnews.com/wp-content/uploads/2026/11/4X4A7000-720x1024.jpg 720w, https://www.genengnews.com/wp-content/uploads/2026/11/4X4A7000-768x1092.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/4X4A7000-1080x1536.jpg 1080w, https://www.genengnews.com/wp-content/uploads/2026/11/4X4A7000.jpg 1242w" sizes="(max-width: 211px) 100vw, 211px"><figcaption class="wp-caption-text">Professor Jonathan Heeney [J.Garget/University of Cambridge]</figcaption></figure>
<p>“It’s when bird flu adapts to live in the airways of mammals that we start to get really nervous,” said Heeney, “not only because of the impact on animal health but because of the threat to humans. If we can make better animal vaccines, then we can better protect human health as well.”</p>
<p>The decades-old approach to vaccine design has been largely reactive, responding to pathogens after they have emerged. The team’s goal is to create broadly protective vaccines for both animals and humans, helping reduce opportunities for pathogens to emerge, adapt, and spread. Their new class of universal vaccines is future proofed. The vaccines not only protect against many variants simultaneously, but potentially against related viruses that haven’t yet emerged and spilt over to humans.</p>
<p>To design the new bird flu vaccine, Heeney and team collected the genetic sequence data of all the bird flu viruses logged by surveillance programs around the world, which take virus samples from wildlife, livestock, and humans infected with bird flu. They built an AI tool to integrate the huge amount of genetic data and use it to design a range of “super-antigens” which contain the antigen features common to this whole group of viruses. These were screened in cells to select the best one for the vaccine, which was then tested in animal trials.</p>
<p>“… we engineered a broadly protective, multi-antigen panH5Nx vaccine using computational and structure-guided HA, NA, and M2 antigens, capturing global H5Nx diversity,” the team noted. Heeney added, “Using AI vastly speeds up the process of vaccine design, and then we can test the vaccine candidates in the lab to make sure they’re robust and safe.”</p>
<p><em>In vivo</em> tests showed that the new DVX-panH5Nx vaccine completely protected mice and ferrets against a range of genetically distinct H1N1 variants—all of which have caused human infections and represent potential pandemic threats. “By integrating HA, NA, and M2 antigens representing global H5Nx diversity, we demonstrated that broad, cross-clade protection could be achieved using a single vaccine formulation,” the researchers commented. “… the broad immunogenicity of DVX-panH5Nx translated into complete protection against lethal heterologous challenges in mice and superior survival in ferrets.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>In comparison, only half the animals survived these same viruses when immunized with the World Health Organization’s existing bird flu vaccine. The bird flu vaccine stockpiled by governments is based on representative virus isolates identified through the World Health Organization’s pandemic influenza preparedness program. It was designed to protect against one specific strain of the disease, but the study found it provides minimal protection against other strains in circulation.</p>
<p>“Here, we present a mechanistically informed, digitally engineered mRNA vaccine, DVX-panH5Nx, designed to anticipate viral evolution rather than reacting to it with single isolate-based vaccines,” the investigators reported. They suggest that their collective data “… support a shift in pandemic influenza preparedness toward broadly protective, digitally designed, multi-antigen vaccines that reflect global viral diversity.”</p>
<p>The next step is to test the new bird flu vaccine in human clinical trials, so that it can be ready to be given to humans immediately, when needed. The team is also working on a seasonal flu vaccine that would provide broad-spectrum protection over several flu seasons. Preliminary results show that the vaccine antigen they designed in 2018 is still effective after seven years.</p>
<p>Earlier this year the team announced that their <a href="https://doi.org/10.1016/j.jinf.2026.106759" target="_blank" rel="noopener">broad-spectrum coronavirus vaccine</a> had proved safe in human trials, and published results showing their <a href="https://pubmed.ncbi.nlm.nih.gov/42836655/" target="_blank" rel="noopener">broad-spectrum influenza vaccine</a> protects against both human and swine flu viruses.</p>
<p>In their newly released paper the team concluded, “Leveraging genomic surveillance data from animal reservoirs and human spillover events, with structural insights and immune correlates, offers a powerful framework not only for next-generation pre-pandemic H5Nx vaccines but also for improving seasonal influenza vaccines and developing more effective broadly protective vaccines against other rapidly evolving RNA viruses.”</p>
<p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/bird-flu-vaccine-developed-using-ai-outperforms-current-stockpiled-vaccines-in-preclinical-tests/">Bird Flu Vaccine Developed Using AI Outperforms Current Stockpiled Vaccines in Preclinical Tests</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Building a Strong Foundation: Essential Anatomy Resources</title>
<link>https://edusehat.com/en/building-a-strong-foundation-essential-anatomy-resources</link>
<guid>https://edusehat.com/en/building-a-strong-foundation-essential-anatomy-resources</guid>
<description><![CDATA[ Anatomy is one of the most fundamental subjects in medical school – it can be considered, both literally and figuratively, the foundation for almost all other subjects you will study in medicine . A solid grasp of human anatomy is crucial for understanding pathology, performing both thorough and targeted physical examinations, and eventually serving your […]
The post Building a Strong Foundation: Essential Anatomy Resources appeared first on Elite Medical Prep. ]]></description>
<enclosure url="https://elitemedicalprep.com/wp-content/uploads/2026/11/pexels-tara-winstead-7722913-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 21:30:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Building, Strong, Foundation:, Essential, Anatomy, Resources</media:keywords>
<content:encoded><![CDATA[<p><span>Anatomy is one of the most fundamental subjects in medical school – it can be considered, both literally and figuratively, the foundation for almost all other subjects you will study in medicine . A solid grasp of human anatomy is crucial for understanding pathology, performing both thorough and targeted physical examinations, and eventually serving your patient’s needs. However, the vast amount of information is overwhelming for early medical students. To help you navigate this challenging subject, we’ve compiled a list of what we believe are essential <a href="https://elitemedicalprep.com/medical-school-anatomy/">resources, study tips, and supplementary materials</a> to set you up for success.</span></p>
<p> </p>
<p><span>Anatomy is one of the oldest and most revered subjects of medical education. Even from the time of ancient civilizations, physicians have sought to understand the human body to improve medical treatment. The practice of dissection dates back as early as 335–280 BCE to the Greek physician Herophilos, often considered the father of anatomy. He was among the first to dissect human cadavers, ultimately laying the foundation for modern anatomical observations and studies (We will not comment on the controversy that he reportedly vivisected live prisoners!).</span></p>
<p> </p>
<p><span>One of the most famous historical figures in anatomy is Andreas Vesalius, a 16th-century Flemish anatomist whose legendary book, </span><i><span>De Humani Corporis Fabrica</span></i><span>, revolutionized the field of human anatomy by correcting centuries-old misconceptions about human anatomy. His meticulous approach and detailed anatomical illustrations set new standards for medical education.</span></p>
<p> </p>
<p><span>Today, you will continue this tradition, using cadaveric dissection coupled with modern resources to deepen your understanding of the human body.</span></p>
<p> </p>
<h2><b>The Importance of Cadaver Lab</b></h2>
<p><span>If your medical school offers cadaver dissection, it is one of the most valuable experiences you can have as a medical student. It is a tradition dating back thousands of years and should be held with the utmost respect. Many consider their cadaver as the first patient that medical professionals ever have. Cadaver lab provides a hands-on and intimate approach to understanding human anatomy in a way that no textbook or digital resource can replicate.</span></p>
<p> </p>
<h3><b>Why Cadaver Lab is Essential:</b></h3>
<ol>
<li>
<ol>
<li aria-level="1"><b>Three-Dimensional Understanding</b><span> – Seeing and feeling anatomical structures in a real human body helps solidify your spatial understanding. Having the ability to physically manipulate structures with your hands on a real individual is a privilege, often cementing core anatomical concepts with ease.</span></li>
<li aria-level="1"><b>Tactile Learning</b><span> – Dissecting a cadaver allows you to appreciate the texture, depth, and relationships between structures.</span></li>
</ol>
</li>
</ol>
<ul>
<li aria-level="1"><b>Team based learning</b><span> – Cadaver lab is almost always carried out in teams, and you should learn from and teach your fellow classmates.</span></li>
</ul>
<ol>
<li aria-level="1"><b>Real-World Application</b><span> – Textbooks and digital models are helpful, but the variability in human bodies becomes apparent in cadaver labs, which is critical for future clinical practice. Make sure to look at other team’s cadavers to see natural anatomic variations.</span></li>
<li aria-level="1"><b>Memorable Learning</b><span> – The hands-on nature of dissection creates lasting mental impressions that enhance long-term retention.</span></li>
</ol>
<p> </p>
<p><span>If full-body dissection is not available, take advantage of prosections (pre-dissected specimens), which still allow for detailed observation and learning. There are also virtual cadaver labs which many medical schools are utilizing – while we do not believe these provide the same learning experience, it is still very possible to learn the same material necessary to be an exceptional physician.</span></p>
<p> </p>
<h2><b>Top Anatomy Textbooks</b></h2>
<p><span>A good textbook is the backbone of any successful anatomy study plan. Here are some of the most highly recommended books for medical students:</span></p>
<p> </p>
<h3><b>1. </b><a href="https://www.amazon.com/Netter-Atlas-Human-Anatomy-paperback/dp/0323680429"><b>Netter’s Atlas of Human Anatomy</b></a></h3>
<ul>
<li aria-level="1"><b>Why it’s great:</b><span> Features world-renowned anatomical illustrations by Frank H. Netter, making it an excellent resource for visual learners. This is one of, if not the most, commonly used textbooks by students.</span></li>
<li aria-level="1"><b>Best for:</b><span> Students who benefit from high-quality artwork to visualize anatomical structures.</span></li>
<li aria-level="1"><b>Bonus:</b><span> You can pair the Atlas with </span><a href="https://www.amazon.com/Netters-Anatomy-Flash-Netter-Science/dp/0323834175/ref=pd_lpo_d_sccl_1/139-2610230-9587924?pd_rd_w=S79aU&content-id=amzn1.sym.4c8c52db-06f8-4e42-8e56-912796f2ea6c&pf_rd_p=4c8c52db-06f8-4e42-8e56-912796f2ea6c&pf_rd_r=XAB71N7HZZ8CGNJ5VNWD&pd_rd_wg=WuSEv&pd_rd_r=fd9f6ef2-7f24-4bf9-a75a-155f4ade4bf7&pd_rd_i=0323834175&psc=1"><span>Netter’s Flashcards</span></a><span> for on-the-go review – there are also numerous pre-made Anki decks exist to reinforce learning. Additionally, there is a </span><a href="https://www.amazon.com/Netters-Anatomy-Coloring-Netter-Science/dp/0323826733/ref=sr_1_1?crid=2Y5WYQSU29EQX&dib=eyJ2IjoiMSJ9.TIYwRo6EJsD33aaTYfzFHmlZ-C27yC-NMWaIUuS4my34zFxoKyOFq0oahRwXGYO5fAGXhb1Nx7dH9kLuh8sTDN2NVAHzQ2-BjT2KUz2NGB1jai5G2qirLtDLPFF3w9op9VWIsam3iqInHeXbRYo3EKzSBLlEXoJwNHP1YAOSwHkeb24wOUp6BE7qvUTD55AOITTSEtj56rPAKEVbdsh1wVzUh47HSnweRaazebjv0ZU.0UNqQtUEesS413tdm87VGCGZhDrqS1sqNUQxOUi1CrI&dib_tag=se&keywords=netter+coloring&qid=1743020014&sprefix=netter+coloring%2Caps%2C122&sr=8-1"><span>coloring book</span></a><span> to accompany the Atlas for those who like an interactive and artistic experience.</span></li>
</ul>
<h3><b>2. </b><a href="https://www.amazon.com/Grays-Anatomy-Anatomical-Clinical-Practice/dp/0702052302"><b>Gray’s Anatomy</b></a></h3>
<ul>
<li aria-level="1"><b>Why it’s great:</b><span> This textbook traces its roots back to 1858 when it was first published by Henry Gray and has been revised for over 150 years. It provides a comprehensive but digestible overview of anatomy with clear illustrations and concise explanations.</span></li>
<li aria-level="1"><b>Best for:</b><span> Visual learners who appreciate detailed diagrams and clinical correlations.</span></li>
</ul>
<h3><b>3. </b><a href="https://www.amazon.com/Clinically-Oriented-Anatomy-Lippincott-Connect/dp/1975209540/ref=sr_1_1?crid=3KDT206D1RKEC&dib=eyJ2IjoiMSJ9.6W4C981YT-JcoRRLNGMxQC2UVEHROka2efcGYWnns385GiLd6JrNTV0Ywd8VAxd8NDw_jh4U_MCj1NXRnYtzjol5dQS4hpeAQrWhUmHNKrvSGSIPDZyCuB-_8sOriYYcnwTjOQmBUIl501s4fXhYqp2grSvuj0hU55ro29WCiGkzm2L9KNJGgGQrOmvrYSfZzPBMpiLZkGDsRRc-Hjje7B8fCdCB0pBb0Z8c3hiTOj0.69_vq9HF0v7_Ml8GvpTv9x5Mpn2_-vU4lzIJDF_zmc4&dib_tag=se&keywords=Moore%E2%80%99s+anatomy&qid=1743020238&s=books&sprefix=moore+s+anatomy%2Cstripbooks%2C99&sr=1-1"><b>Moore’s Clinically Oriented Anatomy</b></a></h3>
<ul>
<li aria-level="1"><b>Why it’s great:</b><span> Unlike Netter and Gray’s, Moore’s focuses a bit more on the clinical applications of anatomy. It does provides in-depth explanations suitable for students who want a deeper understanding (looking at you surgical bound medical students)</span></li>
<li aria-level="1"><b>Best for:</b><span> Those who enjoy case-based learning and integration with clinical practice.</span></li>
</ul>
<h3><b>4. </b><a href="https://www.amazon.com/Anatomy-Photographic-Atlas-Color-Study/dp/1451193181"><b>Rohen’s Anatomy: A Photographic Atlas</b></a></h3>
<ul>
<li aria-level="1"><b>Why it’s great:</b><span> Uses real cadaveric photographs instead of illustrations, making it useful for students who want to familiarize themselves with real human structures. One of the biggest complaints from Netter’s is that it is primarily illustrations (however, some students prefer this as it improves clarity of the images and learning).</span></li>
<li aria-level="1"><b>Best for:</b><span> Preparing for dissections and practical exams.</span></li>
<li aria-level="1"><b>Bonus:</b><span> Provides labeled and unlabeled images for self-testing.</span></li>
</ul>
<p> </p>
<h3><b>5. Surgical Anatomy Textbooks</b></h3>
<ul>
<li aria-level="1"><span>If you are interested in pursuing a surgical subspeciality, there are textbooks made for these purposes as well. Often, these are made for residents and fellows; however, if you are interested in starting earlier, some students like to learn anatomy through future surgical procedures!</span></li>
</ul>
<p> </p>
<h2><b>High-Yield Apps and Online Platforms</b></h2>
<p><span>In the digital age, there are numerous online tools to supplement your learning. Here are the highest-yield resources:</span></p>
<p> </p>
<h3><b>1. </b><a href="https://3d4medical.com/"><b>Complete Anatomy (3D4Medical)</b></a></h3>
<ul>
<li aria-level="1"><span>Provides an interactive 3D model of the human body and is best for visualizing anatomical structures in high detail.</span></li>
<li aria-level="1"><span>Also provides animations to see the body move in real time (i.e. heart pumping, muscle movements, etc.)</span></li>
<li aria-level="1"><span>Also Includes quizzes and guided learning paths.</span></li>
<li aria-level="1"><span>Available on both desktops and mobile devices.</span></li>
</ul>
<h3><b>2. </b><a href="https://apps.ankiweb.net/"><b>Anki Flashcards</b></a></h3>
<ul>
<li aria-level="1"><span>A staple for many medical students – uses <a href="https://elitemedicalprep.com/guide-to-creating-high-yield-flashcard-decks-on-uworld/">spaced repetition</a> to help retain information.</span></li>
<li aria-level="1"><span>This is an ideal resource for reinforcing anatomy given the amount of memorization needed</span></li>
<li aria-level="1"><span>There are numerous pre-made Anki decks, specifically for Netter’s Atlas which are available online</span></li>
</ul>
<h3><b>3. </b><a href="https://www.kenhub.com/"><b>Kenhub</b></a></h3>
<ul>
<li aria-level="1"><span>An online platform offering detailed video tutorials, quizzes, and labeled diagrams.</span></li>
<li aria-level="1"><span>It offers customizable learning plans tailored to different anatomical (and histological) topics.</span></li>
<li aria-level="1"><span>Also available on both desktops and mobile devices.</span></li>
</ul>
<p> </p>
<h2><b>Effective Study Tips for Anatomy</b></h2>
<p><span>Mastering anatomy requires a strategic approach. Here are some tried-and-true study techniques:</span></p>
<h3><b>1. Active Learning Over Passive Reading</b></h3>
<ul>
<li aria-level="1"><span>Instead of just reading the textbook, <a href="https://elitemedicalprep.com/5-study-tips-for-usmle-step-1/">actively engage with the material</a>. Label diagrams, teach concepts to peers, or use mnemonic devices to retain information.</span></li>
</ul>
<h3><b>2. Utilize Dissection and Prosections</b></h3>
<ul>
<li aria-level="1"><span>As mentioned above, if your medical school offers cadaveric dissection, take full advantage of it. Seeing and touching real structures enhances spatial understanding in a one-in-a-lifetime experience.</span></li>
</ul>
<h3><b>3. Use Mnemonics and Memory Aids</b></h3>
<ul>
<li aria-level="1"><span>Whether you like it or not, A LOT of anatomy is strict memorization. Therefore, tips and tricks to help you memorize anatomic structures are a must!</span></li>
<li aria-level="1"><span>Examples: “So Long To Pinky, Here Comes The Thumb” for the carpal bones or “C3, 4, 5 keep the diaphragm alive” for the phrenic nerve.</span></li>
</ul>
<h3><b>4. Focus on Structure-Function Relationships</b></h3>
<ul>
<li aria-level="1"><span>One of the most effective ways to make anatomy meaningful is to understand how structure dictates function.</span></li>
<li aria-level="1"><span>For example, understanding where a muscle/tendon originates from and inserts will directly tell you about its function when the muscle contracts. Similarly, the thickness of the left ventricular wall correlates with its role in pumping blood to the systemic circulation (as compared to the right ventricle which only pumps blood throughout the relatively lower resistance pulmonary vasculature).</span></li>
<li aria-level="1"><span>Recognizing these relationships will help you apply the anatomy you learn to clinical contexts when diagnosing injuries or diseases.</span></li>
</ul>
<h3><b>5. Test Yourself Regularly and Integrate Clinical Context Early</b></h3>
<ul>
<li aria-level="1"><span>Use practice questions and flashcards to reinforce knowledge. Spaced repetition (reviewing material at increasing intervals) is key to long-term retention.</span></li>
<li aria-level="1"><span>Question banks like <a href="https://elitemedicalprep.com/amboss-vs-uworld-which-is-a-better-usmle-resource/">UWorld and AMBOSS</a> allow you to make practice tests just focused on anatomy.</span></li>
</ul>
<ul>
<li aria-level="1"><span>Understanding the relevance of anatomy in real-life scenarios enhances retention. Try linking anatomical structures to pathology and clinical cases through question banks as well.</span></li>
</ul>
<p> </p>
<h2><b>Conclusion: Build Your Anatomy Mastery Step by Step</b></h2>
<p><span>Anatomy is a challenging but rewarding subject that lays the foundation for your career as a physician. By using a variety of different resources including cadaver lab, textbooks, and digital resources, you can develop a solid understanding of human anatomy from the very beginning of medical school! If your school offers cadaver lab, take full advantage of it, it’s one of the most rewarding and impactful learning experiences in your entire career.</span></p>
<p> </p>
<p><span>Remember, anatomy is best learned through repeated exposure and active engagement.<a href="https://elitemedicalprep.com/how-to-make-a-study-schedule/"> Find a study method</a> (or methods) that works for you, and don’t hesitate to seek help from your peers or a <a href="https://elitemedicalprep.com/meet-the-tutors/"><strong>tutor</strong></a>!</span></p>
<p>The post <a href="https://elitemedicalprep.com/building-a-strong-foundation-essential-anatomy-resources/">Building a Strong Foundation: Essential Anatomy Resources</a> appeared first on <a href="https://elitemedicalprep.com/">Elite Medical Prep</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Canadian researchers launch national AI platform to advance personalized pediatric care</title>
<link>https://edusehat.com/en/canadian-researchers-launch-national-ai-platform-to-advance-personalized-pediatric-care</link>
<guid>https://edusehat.com/en/canadian-researchers-launch-national-ai-platform-to-advance-personalized-pediatric-care</guid>
<description><![CDATA[ A new national research initiative led by Holland Bloorview Kids Rehabilitation Hospital aims to improve understanding of childhood disabilities and neurodevelopmental conditions by bringing together health data and artificial intelligence. The initiative, known as Whole-Child Open Neuroscience Data for Empowering Research (WONDER), will enable researchers across Canada to securely analyze existing genetic, brain imaging and […]
The post Canadian researchers launch national AI platform to advance personalized pediatric care appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/11/shutterstock_2579142623-e1793883038891.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 21:05:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Canadian, researchers, launch, national, platform, advance, personalized, pediatric, care</media:keywords>
<content:encoded><![CDATA[<p>A new national research initiative led by Holland Bloorview Kids Rehabilitation Hospital aims to improve understanding of childhood disabilities and neurodevelopmental conditions by bringing together health data and artificial intelligence.</p>
<p>The initiative, known as Whole-Child Open Neuroscience Data for Empowering Research (WONDER), will enable researchers across Canada to securely analyze existing genetic, brain imaging and behavioural information to better understand the factors influencing children’s development, health and well-being.</p>
<p>Announced November 4, the project is being developed in collaboration with the University of Calgary and CHU Sainte-Justine in Montreal, with funding support from Brain Canada’s Platform Support Grants program.</p>
<p>The goal is to help researchers identify patterns that could eventually support more personalized and effective approaches to care for children with autism, attention-deficit/hyperactivity disorder (ADHD), cerebral palsy, mental health conditions and genetic disorders.</p>
<h3>Connecting research across Canada</h3>
<p>Canadian researchers have developed extensive datasets involving childhood development and disability. However, these resources are often maintained independently by different institutions, limiting opportunities for large-scale analysis.</p>
<p>WONDER is designed to address this challenge by creating a national research infrastructure that allows participating organizations to collaborate while maintaining control of their own information.</p>
<p>Rather than transferring sensitive patient data into a centralized database, the platform will use a federated approach.</p>
<p>Under this model, data remain at their original institutions while researchers use coordinated analytical methods to generate insights across participating datasets.</p>
<p>The approach is intended to support collaboration while protecting privacy and respecting institutional data-governance requirements.</p>
<h3>Using artificial intelligence to identify patterns</h3>
<p>Artificial intelligence will play an important role in analyzing the complex relationships between genetic, neurological and behavioural information.</p>
<p>By examining patterns across multiple datasets, researchers hope to better understand why children with similar diagnoses may experience different developmental trajectories, strengths and support needs.</p>
<p>These insights could eventually help healthcare professionals develop more individualized approaches to assessment, treatment and rehabilitation.</p>
<p>The platform will also make advanced analytical methods more accessible to researchers from different disciplines, supporting collaboration among clinicians, scientists and families.</p>
<h3>National research leadership</h3>
<p>The project is led by Dr. Azadeh Kushki, senior scientist and associate chief of data science at Holland Bloorview’s Bloorview Research Institute.</p>
<p>Kushki is also a professor at the University of Toronto’s Institute of Biomedical Engineering and Canada Research Chair in Neurodiversity and Personalized Health.</p>
<p>The initiative is co-led by Dr. Paul Arnold of the University of Calgary and Dr. Clara Moreau of CHU Sainte-Justine.</p>
<p>Together, the research team will work to establish a collaborative infrastructure capable of supporting studies across institutions and research disciplines.</p>
<p>The initiative is also intended to encourage broader participation in childhood disability research and help researchers examine differences in children’s experiences and outcomes.</p>
<h3>Part of a broader investment in brain research</h3>
<p>WONDER is supported through Brain Canada’s Platform Support Grants program, which invests in shared scientific infrastructure and resources.</p>
<p>The initiative is one of four newly supported research platforms in Ontario representing a combined investment of $10.57 million.</p>
<p>These investments are intended to provide researchers with access to specialized technologies, analytical tools and collaborative infrastructure that would be difficult for individual institutions to develop independently.</p>
<p>Since its establishment, Brain Canada’s Platform Support Grants program has invested more than $125 million in 46 research platforms, supporting collaboration across numerous institutions and scientific disciplines.</p>
<h3>Potential implications for pediatric care</h3>
<p>For hospitals and pediatric healthcare providers, the initiative represents an effort to improve how research findings are translated into more individualized approaches to care.</p>
<p>Children with neurodevelopmental conditions and disabilities often have complex needs that cannot be fully understood through diagnosis alone.</p>
<p>Combining information from different research disciplines may help investigators identify biological, behavioural and environmental factors associated with varying health outcomes.</p>
<p>Over time, these findings could inform new approaches to clinical assessment, rehabilitation and treatment planning.</p>
<p>The platform remains under development, and its anticipated benefits for patient care have not yet been demonstrated.</p>
<p>Nevertheless, the project represents a significant step toward building a more connected national research environment, with the potential to advance precision health for children and families across Canada.</p>
<p>Source: <a href="https://hollandbloorview.ca/stories-news-events/news/national-platform-will-advance-personalized-care-children-brain-based?utm_source=chatgpt.com">Holland Bloorview Kids Rehabilitation Hospital — November 4, 2026</a></p>
<p>The post <a href="https://www.hospitalnews.com/canadian-researchers-launch-national-ai-platform-to-advance-personalized-pediatric-care/">Canadian researchers launch national AI platform to advance personalized pediatric care</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>AI can beat physician diagnoses, but productivity boosts are limited</title>
<link>https://edusehat.com/en/ai-can-beat-physician-diagnoses-but-productivity-boosts-are-limited</link>
<guid>https://edusehat.com/en/ai-can-beat-physician-diagnoses-but-productivity-boosts-are-limited</guid>
<description><![CDATA[ Two new studies show that while AI can beat physicians when it comes to patient diagnoses, the technology doesn’t appear to offer improvements in productivity. Here’s what researchers found in reviewing how physicians use AI for diagnosing clinical cases and taking patient notes. AI and diagnoses: Science A study in Science found that an AI […]
The post AI can beat physician diagnoses, but productivity boosts are limited appeared first on Today&#039;s Hospitalist. ]]></description>
<enclosure url="https://todayshospitalist.com/wp-content/uploads/2026/11/diagnostic-test-of-AI-shutterstock_2745796723-11-5-26.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 21:00:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>can, beat, physician, diagnoses, but, productivity, boosts, are, limited</media:keywords>
<content:encoded><![CDATA[<p>Two new studies show that while AI can beat physicians when it comes to patient diagnoses, the technology doesn’t appear to offer improvements in productivity. Here’s what researchers found in reviewing how physicians use AI for diagnosing clinical cases and taking patient notes.</p>
<h4><strong>AI and diagnoses: Science</strong></h4>
<p><a href="https://www.science.org/doi/10.1126/science.aeh7930">A study in Science</a> found that an AI system built by Microsoft named Diagnostic Orchestrator to diagnose complex medical cases reached a correct diagnosis in about 83.2% of cases. Physicians, by comparison, got the right diagnosis in 36% to 47% of cases.</p>
<p>Researchers used 304 clinical cases from The New England Journal of Medicine and 325 emergency department encounters to test the diagnostic skills of humans and AI. Unlike other studies that present one scenario, the Science research started by providing only a brief clinical presentation. The study forced physicians and the AI tool to work through the cases step by step, giving additional information only when follow-up questions were asked.</p>
<p>In nonemergency cases, a group of physicians that included internists and emergency medicine physicians achieved accurate diagnoses in 22.3% of cases without using reference tools. When physicians used reference tools, their diagnostic accuracy jumped to 36.1%. The AI system, by comparison, was accurate in 83.2% of cases.</p>
<p><a href="https://www.medicaleconomics.com/view/ai-system-outperforms-physicians-on-diagnostic-accuracy-in-microsoft-study">A Medical Economics analysis of the study</a> found that the results were similar for emergency cases. AI was accurate in 80.3% of emergency cases compared to 46.8% for physicians.</p>
<p>Researchers noted that AI greatly outperformed even the highest-scoring individual physicians in both emergency and nonemergency cases. The peak performance by physicians on nonemergency cases was 51.8%. For emergency cases, the best physicians were accurate 62.5% of the time.</p>
<p>The study uncovered differences in how physicians and AI approach patient cases. Physicians, for example, asked an average of 5.6 questions before ordering a test. The AI system, by comparison, asked 25.5 questions before ordering a test.</p>
<p>In addition to reviewing diagnostic accuracy, researchers tried to compare the costs of tests ordered by physicians and AI. The AI system spent $5,431 on tests in nonemergency cases compared to $4,725 spent by physicians. In emergency cases, AI spent $4,979 on testing compared to $3,400 for physicians.</p>
<h4><strong>Ambient AI and physician productivity: Annals of Internal Medicine</strong></h4>
<p><a href="https://www.acpjournals.org/doi/10.7326/ANNALS-25-05294">A second study published in Annals of Internal Medicine</a> found that physicians using ambient AI scribes cut the time they spent taking notes but didn’t see other gains in productivity.</p>
<p>Outpatient physicians using an AI system known as Heidi slashed the time they spent on patient notes from 21 to 18.6 minutes. At the same time, median note length jumped from 4,854 to 5,187 characters.</p>
<p>The study found that reducing the time physicians sped on patient notes didn’t lead to other productivity gains. Researchers, for example, found that physicians didn’t close out patient notes any faster either on the day they saw patients or later.</p>
<p><a href="https://www.medpagetoday.com/practicemanagement/informationtechnology/123591">A MedPage Today analysis of the study</a> noted that some physicians have reported spending an average of three hours working on patient notes on their days off. Some experts hope that tools like ambient AI can help reduce time spent on administrative tasks to not only improve physician productivity, but reduce burnout.</p>
<p><a href="https://www.acpjournals.org/doi/10.7326/ANNALS-26-03797">An accompanying editorial</a> suggested that one reason physicians didn’t end up saving more time was that they may have to spend more time on the back end reviewing and editing notes produced by AI.</p>
<p>The editorial hypothesized that the combination of physicians spending less time taking notes and AI producing notes that are longer may produce “downstream consequences” for patient care. And because the technology can produce issues including fabrications, omissions and misinterpretations, the editorial said, regulations may be needed to protect patient care.</p>
<p>The post <a href="https://todayshospitalist.com/ai-can-beat-physician-diagnoses-but-productivity-boosts-are-limited/">AI can beat physician diagnoses, but productivity boosts are limited</a> appeared first on <a href="https://todayshospitalist.com/">Today's Hospitalist</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Rethinking the Clone&#45;First Paradigm for First&#45;in&#45;Human Biologics</title>
<link>https://edusehat.com/en/rethinking-the-clone-first-paradigm-for-first-in-human-biologics</link>
<guid>https://edusehat.com/en/rethinking-the-clone-first-paradigm-for-first-in-human-biologics</guid>
<description><![CDATA[ A stable-pool strategy can move cell line development off the critical path to Phase I while preserving a path to a conventional clonal cell line as a program matures.
The post Rethinking the Clone-First Paradigm for First-in-Human Biologics appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/06/GettyImages-200554028-001.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 06:50:12 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Rethinking, the, Clone-First, Paradigm, for, First-in-Human, Biologics</media:keywords>
<content:encoded><![CDATA[<p>For decades, biologics development has followed a familiar sequence: create an expression construct, transfect host cells, isolate single cells, screen hundreds or thousands of clones, select a lead clone, establish a cell bank, develop the process, and then manufacture clinical material.</p>
<p>It is a proven model. But there is an increasingly important question for early-stage drug development: Does every molecule need to complete that entire sequence before investigators can answer the first clinical question?</p>
<p>For many first-in-human programs, the immediate objective is not commercial manufacturing. It is to produce a relatively small quantity of well-characterized material, establish appropriate controls and determine whether a therapeutic candidate demonstrates sufficient clinical promise to justify further investment.</p>
<p>That changes how developers can think about cell line development.</p>
<figure aria-describedby="caption-attachment-340043" class="wp-caption alignright"><img loading="lazy" decoding="async" class="size-medium wp-image-340043" src="https://www.genengnews.com/wp-content/uploads/2026/10/Jesse-McCool-281x300.jpg" alt="" width="281" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Jesse-McCool-281x300.jpg 281w, https://www.genengnews.com/wp-content/uploads/2026/10/Jesse-McCool-768x819.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/Jesse-McCool.jpg 847w" sizes="auto, (max-width: 281px) 100vw, 281px"><figcaption class="wp-caption-text">Jesse McCool, PhD [GBI Biomanufacturing]</figcaption></figure>
<h4><strong>Moving cloning off the critical path</strong></h4>
<p>One approach is to manufacture initial clinical material from a characterized stable cell pool, while single-cell cloning is deferred or proceeds in parallel.</p>
<p>This is fundamentally different from using a transient expression system. A stable pool consists of cells in which the expression construct has been integrated into the host-cell genome. The challenge is controlling the heterogeneity within that population.</p>
<p>With conventional random integration, cells can differ substantially in transgene copy number, insert integrity and integration location. Those differences can translate into variability in growth, productivity, stability and product quality. Single-cell cloning solves this problem by searching a heterogeneous population for an individual clone with the desired characteristics. An alternative is to reduce heterogeneity earlier.</p>
<p>Transposase-based cell line development systems, such as the Leap-In Transposase platform used in our work, employ a cut-and-paste mechanism for genomic integration. By creating a more controlled integration process, these systems can generate stable pools with a narrower distribution of cellular characteristics than conventional random integration.</p>
<p>The distinction is important. The pool does not become clonal. It becomes more predictable.</p>
<p>That predictability creates the possibility of using the stable pool itself as the manufacturing substrate for an early clinical program.</p>
<h4><strong>What does the data need to show?</strong></h4>
<p>Deferred cloning should not be interpreted as deferred characterization.</p>
<p>A stable pool intended for GMP manufacturing still requires an appropriate control strategy, including assessment of identity, purity and adventitious agents, along with limits on population doublings and evidence that the cell population remains suitable throughout the intended manufacturing window.</p>
<p>The resulting protein also needs to be characterized. The relevant question is whether material produced by the pool has appropriate identity, purity, potency and product-quality attributes for the intended clinical study.</p>
<p>Published experience with transposon-generated stable pools provides an important proof-of-concept. Stable pools have been used for GMP manufacturing at substantial scale, with later clone-derived processes demonstrating comparable process performance and product-quality profiles.</p>
<p>In these studies, viable cell concentration, viability, antibody titer and cell-specific productivity tracked similarly between pool- and clone-derived manufacturing. Product-quality measurements, including purity, charge variants and glycosylation, also fell within comparable ranges.</p>
<p>That does not mean a pool and its derivative clone will be identical across every analytical measurement. Nor does historical experience eliminate the need for molecule-specific assessment.</p>
<p>It demonstrates something more useful: The relationship between pool-derived and later clone-derived material can be characterized and managed.</p>
<h4><strong>Right-sizing the manufacturing process</strong></h4>
<p>Changing the cell line development strategy also creates an opportunity to reconsider scale.</p>
<p>Early clinical studies may require only modest quantities of a biologic, particularly for potent antibodies and other protein therapeutics. Yet sponsors frequently manufacture those first batches using infrastructure designed for much larger material requirements.</p>
<p>A small-scale, closed upstream process can better match manufacturing capacity to the clinical question.</p>
<p>In the SmartScale GMP platform developed at GBI Biomanufacturing, for example, stable-pool development is connected to a shake-flask-based upstream process using OptimumGrowth flasks, progressing from seed culture through a 7-liter production scale. The upstream process is then integrated with downstream purification, drug substance manufacturing and fill-finish.</p>
<p>The principle is more important than the particular vessel: Use the smallest robust GMP process capable of producing the amount of material the clinical program actually requires.</p>
<p>Importantly, starting small should not strand a successful molecule at small scale. A development strategy should anticipate movement into larger single-use bioreactors, fed-batch or perfusion processes if clinical demand increases.</p>
<h4><strong>Sequence the risk rather than eliminate the work</strong></h4>
<p>This approach reflects a broader change occurring in early biologics development.</p>
<p>Historically, developers have often tried to resolve risks associated with later-stage development before administering the first clinical dose. That can make sense when the probability of technical or clinical success is high. For novel therapeutics, however, it can commit substantial time and capital before the most fundamental uncertainty has been resolved: Does the drug work in patients?</p>
<p>A phase-appropriate CMC strategy does not eliminate necessary development activities. It sequences them.</p>
<p>For a suitable molecule, a sponsor can generate a controlled stable pool, characterize that population, manufacture a small GMP batch and establish the CMC package necessary to support the initial clinical investigation. Meanwhile, single-cell cloning can continue in parallel or begin after the program has generated evidence supporting further investment.</p>
<p>If the clinical signal is positive, a derivative clone can be selected, banked and advanced toward the more extensive process characterization expected later in development. Comparability between pool- and clone-derived material then becomes a defined development activity rather than an assumed outcome.</p>
<p>Not every biologic will be a good candidate. Molecules with difficult product-quality profiles, unstable expression, unusual safety considerations or large initial material requirements may favor a conventional clone-first strategy.</p>
<p>But single-cell cloning should no longer be treated automatically as the starting line for every first-in-human biologic.</p>
<p>For appropriate molecules, stable-pool manufacturing provides another option: characterize what matters, manufacture at the scale the study requires and move the first clinical question forward while conventional cell line development continues in parallel.</p>
<p>For drug developers facing increasingly constrained capital and intense pressure to reach meaningful clinical milestones, the question may no longer be, “How quickly can we select the final clone.” It may now be: “Can stable pools move biologics to first-in-human studies faster?”</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/rethinking-the-clone-first-paradigm-for-first-in-human-biologics/">Rethinking the Clone-First Paradigm for First-in-Human Biologics</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>As Therapeutic Modalities Expand, Genomic Profiling Must Keep Pace</title>
<link>https://edusehat.com/en/as-therapeutic-modalities-expand-genomic-profiling-must-keep-pace</link>
<guid>https://edusehat.com/en/as-therapeutic-modalities-expand-genomic-profiling-must-keep-pace</guid>
<description><![CDATA[ The boundaries of what’s considered “druggable” are shifting as advances in cell and gene therapies expand the possibilities for cancer treatment. Expanded insights can open new avenues for biomarker research and therapeutic discovery.
The post As Therapeutic Modalities Expand, Genomic Profiling Must Keep Pace appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Sampled_AdobeStock_NongEngEng_2030363578.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 06:50:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Therapeutic, Modalities, Expand, Genomic, Profiling, Must, Keep, Pace</media:keywords>
<content:encoded><![CDATA[<p>Sponsored content brought to you by</p>
<p><a href="http://sampled.com/gen" target="_blank" rel="noopener"><img loading="lazy" decoding="async" class="alignnone wp-image-309223 size-medium" src="https://www.genengnews.com/wp-content/uploads/2025/02/Sampled_logo-300x76.jpg" alt="Sampled logo" width="300" height="76" srcset="https://www.genengnews.com/wp-content/uploads/2025/02/Sampled_logo-300x76.jpg 300w, https://www.genengnews.com/wp-content/uploads/2025/02/Sampled_logo.jpg 600w" sizes="auto, (max-width: 300px) 100vw, 300px"></a></p>
<p>The boundaries of what’s considered “druggable” are shifting as advances in cell and gene therapies expand the possibilities for cancer treatment. For drug developers, this evolving therapeutic landscape creates new reasons to revisit challenging targets and explore genomic alterations that may have been overlooked when fewer treatment approaches were available.</p>
<h4><strong>A broader therapeutic toolbox opens new possibilities</strong></h4>
<p>For many decades, much of drug discovery was focused on finding a small molecule capable of binding a specific target. While this approach remains important, an expanded therapeutic toolkit now allows developers to target a wider range of biological mechanisms. The maturation of cell and gene therapies, RNA therapeutics, targeted protein degradation approaches, antibody-drug conjugates, and other modalities expand the range of biological targets that may be therapeutically tractable. In this way, disease mechanisms and targets that may once have been considered “undruggable” now warrant closer attention, as they can provide an opportunity for development teams to tackle more ambitious projects.</p>
<h4><strong>Improved genomic profiling means greater opportunity</strong></h4>
<p>Drug developers have often prioritized indications with a substantial unmet need and well-characterized driver genes supported by a strong biological rationale for therapeutic targeting. However, the landscape of cancer-associated variants is diverse and remains incompletely understood, even in well-studied forms of the disease. This creates a growing opportunity for researchers to identify and investigate a broader range of potentially relevant genomic alterations, both in indications already served by targeted therapies and in historically underexplored cancer types with substantial unmet need. One promising approach is to focus on a specific cohort with substantial unmet need while casting a wider net for variant discovery. Gaining broader genomic insights early in development can create more opportunities for discovery, biomarker development, and the identification of potentially transformative therapies.</p>
<h4><strong>Why genomic testing will remain essential</strong></h4>
<p>Many precision therapies rely on genomic information for patient selection, while drug discovery teams use genomic evidence to identify and prioritize targets for therapy development. Diseases such as cancer can be driven by both well-characterized and less common genetic alterations, making a comprehensive, reliable, and rapidly available view of an individual patient’s genomic landscape essential across the personalized medicine continuum, from target discovery through patient selection. While multiomics approaches provide important context for understanding disease biology, researchers must continue to examine genomic variation more broadly and in greater depth for personalized medicine to reach its full potential.</p>
<h4><strong>Closing the gap from sample to hypothesis </strong></h4>
<p>Realizing the potential of broader genomic insights to support therapy development across multiple emerging modalities presents several challenges. Translating samples into usable data at scale requires infrastructure that supports efficient, consistent processing across large cohorts and extended study timelines.</p>
<p>One component of closing this gap is comprehensive genomic profiling (CGP), which brings a wider range of cancer-associated genomic alterations into focus. By assessing single nucleotide variants, insertions and deletions, copy number variants, and select gene fusions, CGP allows researchers to look beyond familiar markers and investigate a broader genomic landscape. These expanded insights can open new avenues for biomarker research and therapeutic discovery.</p>
<h4><strong>Integrating sample stewardship, CGP, and analysis</strong></h4>
<p>Sampled is an integrated analytical laboratory and biorepository offering custom sample collection kitting, secure sample storage, end-to-end sample processing, genomic profiling, and data analysis to support oncology research. Visit sampled.com to explore our comprehensive genomic profiling capabilities and learn how we can support your next research project.</p>
<p> </p>
<p><img loading="lazy" decoding="async" class="alignleft wp-image-340228 size-thumbnail" src="https://www.genengnews.com/wp-content/uploads/2026/11/sam270_qr-gen_v1_CMYK-150x150.jpg" alt="Sampled QR Code November 2026" width="150" height="150" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/sam270_qr-gen_v1_CMYK-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/sam270_qr-gen_v1_CMYK-298x300.jpg 298w, https://www.genengnews.com/wp-content/uploads/2026/11/sam270_qr-gen_v1_CMYK-1016x1024.jpg 1016w, https://www.genengnews.com/wp-content/uploads/2026/11/sam270_qr-gen_v1_CMYK-768x774.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/sam270_qr-gen_v1_CMYK.jpg 1389w" sizes="auto, (max-width: 150px) 100vw, 150px"></p>
<p> </p>
<p>Visit <a href="http://sampled.com/gen" target="_blank" rel="noopener">sampled.com/gen</a>.</p>
<p>The post <a href="https://www.genengnews.com/sponsored/as-therapeutic-modalities-expand-genomic-profiling-must-keep-pace/">As Therapeutic Modalities Expand, Genomic Profiling Must Keep Pace</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Gene That Preserves Bone Stem Cell Supply Throughout Life Identified</title>
<link>https://edusehat.com/en/gene-that-preserves-bone-stem-cell-supply-throughout-life-identified</link>
<guid>https://edusehat.com/en/gene-that-preserves-bone-stem-cell-supply-throughout-life-identified</guid>
<description><![CDATA[ Researchers found that the HOXA10 gene preserves bone stem cell supply throughout life, and say the discovery advances understanding of stem cell biology and could indicate potential therapeutic approaches to improve bone healing and regeneration in aging and disease. 
The post Gene That Preserves Bone Stem Cell Supply Throughout Life Identified appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/03/GettyImages-1459917555.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 06:50:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Gene, That, Preserves, Bone, Stem, Cell, Supply, Throughout, Life, Identified</media:keywords>
<content:encoded><![CDATA[<p>Researchers headed by a team at NYU Langone Health have found that the action of a key gene is required to maintain a lifelong supply of stem cells that make bone healing possible. Working with genetically engineered mice, the team identified the gene <em>HOXA10</em> as a lifelong protector of the stem cell supplies, keeping them from maturing into bone-building cells called osteoblasts until needed for healing.</p>
<p>“Our study shows that<em> HOXA10</em> protects healing capacity normally by acting as a brake on premature maturation,” said Philipp Leucht, MD, PhD, the Jyoti Menon Associate Professor of Orthopedic Surgery in the Department of Orthopedic Surgery at NYU Grossman School of Medicine. “To our knowledge, this study is the first to assign a definitive role for HOX genes in the active maintenance of adult skeletal stem cells.” The findings suggest that HOX genes may represent potential therapeutic targets for boosting bone regeneration.</p>
<p>Leucht, who is also the vice chair for research in the Department of Orthopedic Surgery, is senior and co-corresponding author of the researchers’ published paper in <em>Science Advances</em>, titled “<a href="http://dx.doi.org/10.1126/sciadv.aeg2088" target="_blank" rel="noopener"><em>Hoxa10</em> governs lifelong skeletal stem cell maintenance and bone repair</a>,” in which they reported, “Together, these findings define a conserved Hox-dependent program that preserves skeletal stem cell identity and regenerative competence, revealing how developmental transcription factors are repurposed to sustain the adult skeleton across the life span.”</p>
<p>Skeletal stem and progenitor cells (SSPCs) sustain bone homeostasis and regeneration throughout life, the authors explained, but the transcriptional programs that preserve their identity aren’t well understood. Accumulating evidence suggests Hox genes may play critical roles in maintaining tissue-resident stem cells throughout the lifespan, “… serving as molecular determinants that preserve stem cell identity and function in adult tissues across different species,” the team continued. However, there are “critical gaps” in understanding of how Hox genes may regulate bona fide skeletal stem cells (SSCs) and their progeny. “This has profound implications for understanding skeletal aging, fracture healing, and potential therapeutic interventions.”</p>
<p>For their newly reported study the authors examined the state of bone stem cells in mice for 15 months after they deleted<em> HOXA10</em> in 6-day-old pups. They found that by the end of that period, 90% of the stem cells and descendants that should have been present were gone due to a loss of self-renewal. “Most bone research asks how stem cells become bone,” said Leucht. “We asked how they remain as stem cell replacements in the first place. Without the study gene, bone burns through its reserves too early, which is what we see in aging bone.”</p>
<p>The researchers in addition found that mice engineered to lack <em>HOXA10</em> action could not heal properly after breaking a bone. The proportion of stem cell progenitors in the callus—the temporary tissue bridge spanning a break as it begins to heal—was only 48% for the engineered mice, compared with 76% for control mice with the functional gene.</p>
<p>Other experiments confirmed that deleting <em>HOXA10</em> causes collagen proteins that lay the early framework for rebuilding bone to become disorderly. This is a problem because the rope-like scaffold at a break site must be arranged in neat lines, rather than as a tangled mesh, for new bone to harden with calcium. “Our <em>in vivo</em> genetic studies demonstrate that HoxA genes are not merely correlated with skeletal stemness but are functionally necessary for maintaining this state,” the team noted. “Loss of Hox activity results in depletion of SSC pools, defective matrix organization, impaired repair after serial injuries, and compromised skeletal morphology with age.”</p>
<p>The researchers also obtained bone biopsies from human patients and silenced three related HOX genes at once. The human cells responded like mouse cells, only with more dramatic reductions in stem cell numbers. The human cells also began to die, with apoptosis (programmed self-destruction) up by 50%. This suggests that human stem cells may depend even more on HOX genes for long-term self-renewal, Leucht said. Commenting on their studies in human SSPCs, the authors noted, “Together, these findings demonstrate that distal Hox genes are essential for preserving the core properties of human SSPCs—including proliferation, survival, self-renewal, and inhibition of premature differentiation—thereby supporting their role in maintaining SSC pools in adult human bone.”</p>
<p>To carry out the study the research team genetically engineered mice to have their<em> HOXA10</em>-expressing stem cells tagged with a fluorescent green marker, as well as to have built-in mechanisms that the team could use to switch the genes off on command. This let them accurately track the status of the cells at all stages of life in the study mice.</p>
<p>The investigators learned that <em>HOXA10</em>-positive cells outperform other stem cells in the periosteum, the membrane that covers the surface of most bones, at colony-forming. This test, in which a single cell is prompted to generate a colony of cells by dividing and multiplying continually, is considered a standard readout of self-renewal capacity.</p>
<p>HOX genes have been shown by past studies to control periosteal stem and progenitor cells, or PSPCs, which play a key role in bone healing. HOX genes are known to encode proteins that act like the body’s “zip code,” specifying the position of limbs in the womb. The new study builds on another led by Leucht and <a href="https://doi.org/10.1242/dev.201391" target="_blank" rel="noopener">published in 2023</a>, which showed that increasing the activity of the <em>HOXA10</em> gene could improve fracture healing in older mice.</p>
<p>“Our study identifies <em>HOXA10</em> as a preserver of skeletal stem cell pools over time by promoting self-renewal, suppressing premature maturation, and lining up the protein fibers in a break so that the two ends of broken bone can knit,” said Leucht. “The findings establish HOX genes as potential therapeutic targets for enhancing bone regeneration.”</p>
<p>In their paper the authors concluded, “By illuminating how a single transcriptional regulator coordinates the complex behaviors necessary to maintain SSC across the life span, this work advances our understanding of stem cell biology and provides a foundation for therapeutic  approaches to improve bone healing in aging and disease.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/gene-that-preserves-bone-stem-cell-supply-throughout-life-identified/">Gene That Preserves Bone Stem Cell Supply Throughout Life Identified</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Multiomic Human Glioblastoma Cell Atlas Could Act as Compass to Guide Future Treatment Approaches</title>
<link>https://edusehat.com/en/multiomic-human-glioblastoma-cell-atlas-could-act-as-compass-to-guide-future-treatment-approaches</link>
<guid>https://edusehat.com/en/multiomic-human-glioblastoma-cell-atlas-could-act-as-compass-to-guide-future-treatment-approaches</guid>
<description><![CDATA[ Researchers mapped more than a million cells across glioblastoma tumors, categorizing cancer cells at different stages of their journey within the different environments in glioblastoma tumors, and showing that the cancer cells organize themselves according to a consistent, predictable structural pattern across different patients. 
The post Multiomic Human Glioblastoma Cell Atlas Could Act as Compass to Guide Future Treatment Approaches appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2020/07/Jul15_2020_Getty_1128676746_BrainCancer-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 06:50:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Multiomic, Human, Glioblastoma, Cell, Atlas, Could, Act, Compass, Guide, Future, Treatment, Approaches</media:keywords>
<content:encoded><![CDATA[<p>Aggressive glioblastoma (GB) brain tumors follow predictable rules, not chaotic randomness, according to new research reported by scientists at the Wellcome Sanger Institute, the European Molecular Biology Laboratory (EMBL), the German Cancer Research Center (DKFZ), the Cancer Research UK Cambridge Institute, and their collaborators.</p>
<p>For their study, reported in <em>Nature</em> (“<a href="https://www.nature.com/articles/s41586-026-11234-8" target="_blank" rel="noopener">A spatiotemporal cancer cell trajectory underlies glioblastoma heterogeneity</a>,”) co-senior author Omer Bayraktar, PhD, at the Wellcome Sanger Institute and Professor at the UCL Cancer Institute, and colleagues mapped over one million cells across glioblastoma tumors, categorizing cancer cells at different stages of their journey within the different environments in glioblastoma tumors. They looked at different time stages and used lab-grown mini tumors to mimic this development. The study findings showed that the cancer cells organize themselves according to a consistent, predictable structural pattern across different patients.</p>
<p>Along with challenging previously held beliefs about brain tumors, the newly discovered roadmap opens new paths for developing targeted treatments. As the cancer cells move along in a predictable way during tumor progression, future drugs could specifically target the early developmental-like cells before they transform into harder-to-reach, resistant states.</p>
<p>The reported work has built a new foundational resource for studies to explore the mechanisms and biology of cancerous brain cells. The researchers have made the resulting <a href="https://www.gbmspace.org/" target="_blank" rel="noopener">GBM-Space atlas</a> is freely accessible.</p>
<p>Using the same single-cell multiomic data, investigators also decoded the gene regulators that drive and restrict glioblastoma cell state transitions, highlighting potential targets that could help avoid treatment resistance. The team stated, “In a companion study, we leveraged the joint transcriptomic and epigenetic data generated here to define and perturb gene regulatory networks controlling GB plasticity. Beyond identifying master regulators of GB states, this orthogonal approach suggested hierarchical transitions across GB cancer states and recapitulated the GB trajectory identified here.” These results are published by co-senior author Bayraktar, and colleagues in their companion paper in <em>Nature, titled “</em><a href="https://doi.org/10.1038/s41586-026-11177-0" target="_blank" rel="noopener">Decoding the regulatory programs governing glioblastoma plasticity</a>.” Together the two papers unify understanding of the architecture of glioblastomas with insights about cancer cell plasticity, giving a holistic view of this cancer type.</p>
<p>Bayraktar said, “Glioblastoma has evaded understanding for years, despite being one of the most studied types of cancer tumor. By building the largest, multi-modal atlas of these tumors to date, we have shown that these tumors are not as chaotic as previously accepted. Instead, they follow a set of rules that can be used to rewrite our understanding of glioblastoma and act as a compass to guide much needed new treatments in the future.”</p>
<p>Glioblastoma is an aggressive form of brain cancer, and the most common type of brain cancer in adults, with an average survival time of 12 to 18 months. The most common glioblastoma treatment, when possible, is surgery followed by a combination of chemotherapy and radiotherapy. But as the authors pointed out, “The extensive tumor heterogeneity of glioblastoma (GB), an incurable adult brain cancer, presents a major obstacle to treatment.”</p>
<p>These tumors are difficult to treat due to their location, and as many tumors invade multiple parts of the brain, which can make surgery difficult or impossible in some cases. The tumors are also made up of multiple, highly dynamic cancer cell states that had previously not seemed to follow any consistent rules or pattern. This means that treatment might not destroy every cell, leading to drug resistance and cancer re-emergence.</p>
<p>“Nearly two decades of molecular profiling has found that malignant cells exist across a spectrum of cellular states within each tumor, resembling developmental neural progenitors as well as mesenchymal-like and injury response states,” the authors noted. “… we still do not understand how cancer cells diversify into distinct states and give rise to GB heterogeneity. In particular, whether malignant cells follow stereotyped or variable cellular trajectories across GB tumors is unknown.”</p>
<p>For their newly reported study the Sanger Institute researchers and their collaborators used state of the art multiomic technologies and tailored machine learning computational tools to map multiple sections of brain tumor samples from 12 glioblastoma patients<sup>. </sup>combining single-cell and spatial atlasing, imaging, and whole-genome sequencing data. “Here we applied a holistic multimodal mapping approach to jointly characterize the genetic, cellular and tissue architecture of GB tumors,” they wrote.</p>
<p>The range of information generated offers up a complete understanding of each cancer cell’s molecular state, where it is in the tumor, how it is likely to change over time, how it interacts with the environment around it, and its genetic information. Additionally, the team used samples from multiple regions of the brain tumors, to give a full picture of the cells in each tumor section and how they related to each other.</p>
<p>This allowed the team to see that glioblastoma cells move through the same structural pattern across each patient, following the same rules as the tumor grows. “We identify that glioblastoma heterogeneity is driven by spatially patterned transitions of cancer cells from developmental-like states towards those defined by a glial injury response and hypoxia,” they wrote. The results found that cancer cells in early stages resemble brain stem cells. These developmental-like cells are found at the outer, leading edge of the tumor, where the glioblastoma cells start to invade the surrounding healthy brain tissue. These cells act as a pool giving rise to other cancer cell states.</p>
<p>Then, as the tumor expands, these cells transform into injury response cell states, mimicking cell pathways that are involved in brain tissue repair and wound healing. These injury response cells create an inner structural layer in the tumors. And in the later stages of brain tumor development the core of the tumor is cut off from oxygen, meaning that all cell types transition from injury response into severely hypoxic (oxygen deprived) states.</p>
<p>As well as mapping brain tumor samples, the team developed brain organoids to validate the tumor roadmap. This research also showed that each cancer cell progression stage requires specific immune microenvironments in the tumors.</p>
<p>“This cellular trajectory regionalizes tumors into distinct tissue microenvironments and manifests in a molecularly conserved manner across tumors as well as genetically distinct tumor subclones,” they stated in their paper. “Our findings define a stereotyped trajectory of cancer cells in glioblastoma and unify glioblastoma tumor heterogeneity into a tractable cellular and tissue framework.”</p>
<p>The team suggests that finding ways to interrupt or disrupt these environments could lead to new ways to treat aggressive brain tumors. In the future, new therapeutics could also focus on the gene regulation networks, potentially stopping cell progression, or target the early developmental cells that cannot be easily removed by surgery and often lead to cancer recurrence.</p>
<p>Richard Mair, MBBS, PhD, FRCS (SN), co-author at the Cancer Research UK Cambridge Institute and Cambridge University Hospitals NHS Foundation Trust, said: “For too long, we have approached glioblastoma treatment knowing that each patient’s tumor contains a complex mixture of cancer cells, but without a clear understanding of how best to target them all. This research gives us an opportunity to think differently. If we can anticipate the different biological states a tumor is likely to adopt, we can begin to develop treatments that target multiple aspects of the disease from the very beginning. This could fundamentally change how we design new therapies for glioblastoma, moving towards treatments that are informed not just by what a tumor looks like today, but by what it is likely to become.”</p>
<p>Oliver Stegle, PhD, co-senior author of both studies at the European Molecular Biology Laboratory (EMBL) and the German Cancer Research Center (DKFZ), added, “Combining unbiased single-cell and multiomics techniques with tailored computational tools allowed us to go back to the drawing board and challenge long-held assumptions about glioblastoma. We demonstrate that complex but predictable molecular networks govern cancer cell development. This work shows how computational biology can turn massive datasets into meaningful discoveries for patient care.”</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/multiomic-human-glioblastoma-cell-atlas-could-act-as-compass-to-guide-future-treatment-approaches/">Multiomic Human Glioblastoma Cell Atlas Could Act as Compass to Guide Future Treatment Approaches</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Lonza Expanding U.S. CDMO Footprint with Purchase of Five Merck KGaA Sites</title>
<link>https://edusehat.com/en/lonza-expanding-us-cdmo-footprint-with-purchase-of-five-merck-kgaa-sites</link>
<guid>https://edusehat.com/en/lonza-expanding-us-cdmo-footprint-with-purchase-of-five-merck-kgaa-sites</guid>
<description><![CDATA[ The deal would expand Lonza’s U.S. CDMO network from four to nine sites and grow the company’s U.S. workforce nearly 25% by adding approximately 1,100 employees, resulting in a combined headcount of more than 6,000 employees. 
The post Lonza Expanding U.S. CDMO Footprint with Purchase of Five Merck KGaA Sites appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/b94fd657006030de0f418450a7f34f41-JPEG.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 06:50:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Lonza, Expanding, U.S., CDMO, Footprint, with, Purchase, Five, Merck, KGaA, Sites</media:keywords>
<content:encoded><![CDATA[<p>Lonza plans to more than double its U.S. footprint of contract development and manufacturing organization (CDMO) sites by agreeing to acquire five such sites in the U.S. from Merck KGaA, Darmstadt, Germany, in a deal the companies would only say was valued “in the low- to mid-triple-digit millions Swiss francs.”</p>
<p>At between CHF 100 million and CHF 500 million, the transaction would amount to between $121.6 million to $608.2 million.</p>
<p>The deal would expand Lonza’s U.S. CDMO network from four to nine sites and grow the company’s U.S. workforce nearly 25% by adding approximately 1,100 employees, resulting in a combined headcount of more than 6,000 employees.</p>
<p>The expansion would also add end-to-end development and manufacturing capabilities in the U.S., with the aim of supporting customers from clinical through commercial phases in growth areas that include antibody-drug conjugates (ADCs) and other bioconjugates, viral vectors for cell and gene therapies, as well as advanced drug-delivery technologies.</p>
<p>The deal with German Merck marks a continuing expansion by Lonza of its U.S. CDMO operations. In 2024, Lonza <a href="https://www.genengnews.com/topics/bioprocessing/lonza-completes-acquisition-of-vacaville-ca-site-from-roche/" target="_blank" rel="noopener">acquired for $1.2 billion the large-scale biologics manufacturing site in Vacaville, CA</a> built by the seller’s Genentech subsidiary. More recently in September, Lonza announced plans to construct a large-scale commercial spray-drying facility in Bend, OR, a project intended to establish Lonza as the leading CDMO provider of commercial-scale spray-drying PSD-4 capacity in the U.S.</p>
<p>Lonza topped <em>GEN</em>’s most recent annual A-List of <a href="https://www.genengnews.com/topics/bioprocessing/top-10-contract-development-and-manufacturing-organizations-2026/" target="_blank" rel="noopener">Top 10 Contract Development and Manufacturing Organizations</a>, published in September, based on its 2025 revenues of CHF 6.531 billion ($8.053 billion at the time; $7.944 billion now).</p>
<h4><strong>‘Strong fit’</strong></h4>
<p>“This acquisition is a strong fit with our One Lonza strategy and reflects our disciplined approach to capital allocation, investing in opportunities that will drive long-term, profitable growth and deliver attractive returns,” Lonza CEO Wolfgang Wienand said in a statement.</p>
<p>“<a href="https://www.lonza.com/about-us/strategy" target="_blank" rel="noopener">One Lonza</a>” is Lonza’s approach to growth. Using the metaphor of an engine, Lonza has articulated a set of five core competencies designed to work together to generate long-term value. The five consist of high-performance teams; a leading scientific, technological, digital ecosystem; unparalleled customer partnerships; end-to-end execution excellence; and plug-and-play investment and integration capabilities.</p>
<p>“It will significantly expand our U.S. presence, bringing us even closer to our customers, while increasing the resilience of our global manufacturing network. With high demand for bioconjugates and viral vectors, the acquired sites will strengthen our ability to support customers from innovation to launch and commercial supply,” Wienand added.</p>
<p>Kai Beckmann, Chairman of the Executive Board and Group CEO of Merck KGaA, stated that the transaction with Lonza represented “another important step in advancing our mid- to long-term strategic agenda.”</p>
<p>In May Merck KGaA articulated a four-prong strategy for “<a href="https://www.emdgroup.com/investors/reports-and-financials/earnings-materials/2026-q1/us/Strategic%20Update%20May%2013,%202026%20NA.pdf" target="_blank" rel="noopener">creating sustainable value and growth</a>,” based on combining biology, chemistry, physics, with data and artificial intelligence (AI), and enabled by “enhanced company integration for speed and scale”—a challenge given the company’s heritage of businesses with their own distinct brands, such as EMD Serono, MilliporeSigma, and Sigma-Aldrich.</p>
<p><strong>‘Strong foundation’</strong></p>
<p>“A more concentrated Life Science portfolio will allow us to focus our investments on building our scientific leadership and make us an even stronger partner for our customers,” Beckmann said. “Our CDMO teams have built a strong foundation through their expertise and commitment. We believe Lonza is well positioned to build on that foundation and support the business’s next phase of growth.”</p>
<p>Merck KGaA reasons that the divestment to Lonza will sharpen the focus of its Life Science business sector while providing the CDMO business with a strong platform for its next phase of development.</p>
<p>The Life Science sector consists of a broad portfolio of consumables, technologies, and services that the company said will continue to serve pharmaceutical, biotechnology and CDMO customers from discovery through manufacturing.  During the first half of 2026, the Life Science sector reported net sales of €4.677 billion ($5.236 billion), up 4.3% from €4.485 billion ($5.022 billion) in January-June 2025. During the second quarter, Life Science racked up €2.412 billion ($2.701 billion), up 6.4% from €2.267 billion ($2.538 billion) in Q2 2025.</p>
<p>Merck KGaA is set to report third-quarter results on November 12—while Lonza last month said Q3 results were in line with its expectations, without quantifying its results. Lonza also reiterated its full-year 2026 outlook, which it upgraded over the summer, of 11–12% constant exchange rate sales growth and a CORE EBITDA margin of 33–34%. The company also reiterated its expectation of a negative foreign exchange impact of approximately 2% to 3% on 2026 sales growth.</p>
<p>Lonza said the U.S. CDMO facilities it has agreed to acquire from Merck KGaA include sites in:</p>
<ul>
<li><strong>St. Louis, MO: </strong>Bioconjugates</li>
<li><strong>Madison and Verona, WI:</strong> High-potency payload-linkers</li>
<li><strong>Carlsbad, CA:</strong> End-to-end viral vector solutions, including aseptic fill-finish capabilities</li>
<li><strong>Indianapolis:</strong> Lipid nanoparticle, liposome, and PEGylated protein solutions, including aseptic fill-finish capabilities</li>
</ul>
<p>The four sites are expected, Lonza said, to generate a combined approximately CHF 250 million ($304 million) in sales at a margin of core earnings before interest, taxes, depreciation, and amortization (EBITDA) that is below Lonza’s, with an “insignificant” impact on the group.</p>
<p>Once integrated into Lonza, the buyer said, the four sites are expected to deliver “significant, profitable” growth over time, using existing available capacities and additional expansion space. Lonza expects the sites will benefit from Lonza’s sole or “pure-play” focus on CDMO activity, with further investments in the sites to align with evolving market demand.</p>
<h4><strong>Peak sales forecast</strong></h4>
<p>“Lonza anticipates the business to reach peak sales at Lonza’s future group margin level by mid-2030s,” the company predicted.</p>
<p>Last month Lonza ramped up its growth projections following completion of its transformation into a pure-play CDMO. The company upgraded its Organic Growth Model, consisting of organic sales growth at constant exchange rates (CER) from the low-teens (10%-13%), and core earnings before interest, taxes, depreciation, and amortization (EBITDA) growth that surpasses sales growth—and articulated an upgraded ambition to:</p>
<ul>
<li>Reach core EBITDA margin “in the high thirties in the mid-term”</li>
<li>Drive return on invested capital (ROIC) up to two to three times weighted average cost of capital as of 2026, and</li>
<li>Improve free cash flow conversion on average over time</li>
</ul>
<p>Lonza said it will fund its acquisition of the Merck KGaA U.S. CDMO sites and with cash at hand and its existing credit facilities, maintaining the company’s BBB+ rating.</p>
<p>The deal is expected to close in mid-2027 subject to customary closing conditions. Lonza said the transaction will not affect its previously announced share buyback following its planned divestment of its Capsules & Health Ingredients (CHI) business. Lonza in March announced plans to sell CHI to Lone Star Funds for CHF 2.3 billion ($2.797 billion), in a deal set to close by year’s end.</p>
<p>“I am particularly excited to welcome the highly experienced teams at these sites to One Lonza,” Wienand said. “It takes great people with deep scientific expertise and excellence in development and manufacturing to reliably translate breakthrough innovation into viable therapies for patients. Together, we will build an even stronger offering for our customers.”</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/lonza-expanding-u-s-cdmo-footprint-with-purchase-of-five-merck-kgaa-sites/">Lonza Expanding U.S. CDMO Footprint with Purchase of Five Merck KGaA Sites</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Beyond Outsourcing: Building Better CDMO Partnerships</title>
<link>https://edusehat.com/en/beyond-outsourcing-building-better-cdmo-partnerships</link>
<guid>https://edusehat.com/en/beyond-outsourcing-building-better-cdmo-partnerships</guid>
<description><![CDATA[ Rose BioSolutions CEO David Enloe argues that advanced therapies demand deeper scientific collaboration, earlier problem-solving, and shared accountability
The post Beyond Outsourcing: Building Better CDMO Partnerships appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Rose-BioSolutions_CDMO-Facility.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 06:50:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Beyond, Outsourcing:, Building, Better, CDMO, Partnerships</media:keywords>
<content:encoded><![CDATA[<p>Sponsored content brought to you by</p>
<p><a href="http://www.rosebiosolutions.com/" target="_blank" rel="noopener"><img decoding="async" class="alignnone wp-image-340233 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/11/Rose-BioSolutions-300x108.jpeg" alt="Rose Biosolutions logo" width="300" height="108" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Rose-BioSolutions-300x108.jpeg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Rose-BioSolutions-1024x369.jpeg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/Rose-BioSolutions-768x276.jpeg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Rose-BioSolutions.jpeg 1200w" sizes="(max-width: 300px) 100vw, 300px"></a></p>
<p>For decades, biopharma outsourcing often followed a relatively simple script: a sponsor developed a process, handed it to a contract manufacturer, and expected the work to be carried out to specification. David Enloe, CEO of Rose BioSolutions, believes that model is becoming obsolete—especially for complex cell and gene therapies.</p>
<figure aria-describedby="caption-attachment-340232" class="wp-caption alignright"><img decoding="async" class="wp-image-340232" src="https://www.genengnews.com/wp-content/uploads/2026/11/Rose-BioSolutions-David-Enloe-1-300x300.jpg" alt="David Enloe" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Rose-BioSolutions-David-Enloe-1-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Rose-BioSolutions-David-Enloe-1-1024x1024.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/Rose-BioSolutions-David-Enloe-1-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/Rose-BioSolutions-David-Enloe-1-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Rose-BioSolutions-David-Enloe-1.jpg 1400w" sizes="(max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">David Enloe<br>CEO, Rose BioSolutions</figcaption></figure>
<p>As Enloe takes the helm at Rose, he is pushing for a relationship in which the contract development and manufacturing organization (CDMO) functions less like a vendor and more like an extension of the sponsor’s team. “We’re in the promise-making business,” he said, describing commitments that extend beyond clients to patients and their families.</p>
<p>That mindset changes what a CDMO must bring to the table. Manufacturing capacity still matters, but scientific leadership, regulatory expertise, quality knowledge, and program management increasingly help determine whether a program can move efficiently toward the clinic. Enloe sees this as part of a broader evolution in outsourcing, with development and manufacturing becoming more tightly intertwined.</p>
<p>That is particularly true in advanced therapies, where one program can differ dramatically from the next. Enloe contrasts the emerging model with an earlier era in which manufacturers were often expected primarily to execute a sponsor’s established process. For technically demanding programs, simply following a transferred procedure is no longer enough. Sponsors and CDMOs need to examine risks together, challenge assumptions, and make decisions with the full development path in view.</p>
<p>The value of that collaboration can be greatest early, before a seemingly small decision becomes an expensive obstacle. Rose is investing in scientific, regulatory, quality, and project-management expertise at the front end of client programs. Because a CDMO works across multiple projects, it can bring lessons from prior successes—and failures—to a sponsor that may be advancing only one critical asset.</p>
<figure aria-describedby="caption-attachment-340237" class="wp-caption alignleft"><img fetchpriority="high" decoding="async" class="size-medium wp-image-340237" src="https://www.genengnews.com/wp-content/uploads/2026/11/Rose-BioSolutions_CDMO-Facility-300x201.jpg" alt="Rose BioSolutions Lab" width="300" height="201" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Rose-BioSolutions_CDMO-Facility-300x201.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Rose-BioSolutions_CDMO-Facility-1024x686.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/Rose-BioSolutions_CDMO-Facility-768x515.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Rose-BioSolutions_CDMO-Facility.jpg 1400w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Credit: Rose BioSolutions</figcaption></figure>
<p>“It’s always painful to see an innovator make a process change that ultimately requires substantial rework,” Enloe says. Investing more time—and, in some cases, more money—upfront to identify manufacturing and regulatory risks can help avoid costly delays and rework later.</p>
<p>This early involvement also reflects a shift in how drug developers think about manufacturability. Scientists creating a new therapy are rightly focused on whether it can improve patients’ lives, Enloe says. But development teams increasingly need confidence that the therapy can also be made robustly, reproducibly, and at scale. Manufacturing challenges can no longer be kicked down the road.</p>
<p>For Rose, that means giving clients direct access to technical leaders and encouraging unusually open communication. Enloe describes the desired relationship with a simple image: “We’re just 872 miles down the hallway.” Distance should not determine how closely teams work together.</p>
<p>Trust is central to making that model function. Enloe says sponsors today are more willing to share their concerns, constraints, and objectives than they were earlier in his career. That transparency lets both sides hold each other accountable for decisions and timelines—and improves the chances of solving problems before they threaten a program.</p>
<p>Enloe brings personal perspective to that argument. He spent about 15 years on the sponsor side before moving into CDMO leadership. “I’ve been you as long as I’ve been me,” he tells clients. That experience, he adds, makes his “empathy gene overexpress” when he considers the pressures developers face.</p>
<p>Ultimately, the partnership model is meant to serve a larger purpose. A CDMO might work on rare diseases, cancer, migraine, or mental-health treatments in the same span of time. For Enloe, that breadth is a reminder that manufacturing is not simply an operational service. It is part of the path between an idea and a patient—and the strongest partnerships are built around getting that path right together.</p>
<p> </p>
<p><img loading="lazy" decoding="async" class="alignleft wp-image-340236 size-full" src="https://www.genengnews.com/wp-content/uploads/2026/11/RoseBioSolutions_QRCode.jpg" alt="Rose BioSolutions QR Code " width="138" height="144"></p>
<p> </p>
<p>To learn more, visit <a href="https://www.rosebiosolutions.com/" target="_blank" rel="noopener">www.rosebiosolutions.com</a>.</p>
<p>The post <a href="https://www.genengnews.com/sponsored/beyond-outsourcing-building-better-cdmo-partnerships/">Beyond Outsourcing: Building Better CDMO Partnerships</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Roundtables: Inside the Quest for Cognitive Immortality</title>
<link>https://edusehat.com/en/roundtables-inside-the-quest-for-cognitive-immortality</link>
<guid>https://edusehat.com/en/roundtables-inside-the-quest-for-cognitive-immortality</guid>
<description><![CDATA[ Tuesday, November 17, 2026 In an effort to reach an elusive continuity of the self, some far-thinking technologists are working on ways to keep your brain going—even beyond death. Join science editor Mary Beth Griggs and senior editor for biomedicine Antonio Regalado for a conversation exploring possible paths to keep your mind going, including gradual… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/11/MITTR-Roundtables-Nov26-With-border.png" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 03:20:02 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Roundtables:, Inside, the, Quest, for, Cognitive, Immortality</media:keywords>
<content:encoded><![CDATA[<p class="wp-block-paragraph"><strong>Tuesday, November 17, 2026</strong></p>



<p class="wp-block-paragraph">In an effort to reach an elusive continuity of the self, some far-thinking technologists are working on ways to keep your brain going—even beyond death. Join science editor Mary Beth Griggs and senior editor for biomedicine Antonio Regalado for a conversation exploring possible paths to keep your mind going, including gradual brain replacement and uploading our memories to the cloud.</p>



<p class="wp-block-paragraph"><strong>Going live at 17:00 GMT / 12pm EST / 9am PST</strong></p>



<div class="wp-block-buttons is-content-justification-left is-layout-flex wp-container-core-buttons-is-layout-b192c3d7 wp-block-buttons-is-layout-flex">
<div class="wp-block-button is-style-fill is-style-fill--1"><a class="wp-block-button__link has-black-color has-text-color has-background has-custom-font-size wp-element-button" href="https://events.zoom.us/ev/AqvDmLgUpSLmnGlDBRTVInfuLpbEbkP7nLjovCVsGoSC1i2jsj-x~Aq6BnlbSSzgL8vA66X1w-QGbSPL3EetZLv_MxsmrmoxewbW5YdRLHn0YhlobWLoVAAXaP5HsL41fSqS6q7rEvOEDSg">Register Now</a></div>
</div>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><strong>Related Story</strong>:</p>



<ul class="wp-block-list">
<li><a href="https://www.technologyreview.com/2026/10/15/1145819/six-wild-ideas-perpetuating-your-mind-cognitive-immortality/"><strong>Six wild ideas for perpetuating your mind</strong></a></li>
</ul>



<p class="wp-block-paragraph"><strong>Speakers:</strong></p>



<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-vertically-aligned-center is-layout-flow wp-block-column-is-layout-flow">
<figure class="wp-block-image aligncenter size-full is-resized is-style-default wp-duotone-333-ffffff-2"><img fetchpriority="high" decoding="async" width="300" height="300" src="https://wp.technologyreview.com/wp-content/uploads/2024/01/Antonio-Regalado.png" alt="" class="wp-image-1114149" srcset="https://wp.technologyreview.com/wp-content/uploads/2024/01/Antonio-Regalado.png 300w, https://wp.technologyreview.com/wp-content/uploads/2024/01/Antonio-Regalado.png?resize=150,150 150w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-element-caption"><strong><a href="https://www.technologyreview.com/author/antonio-regalado/" target="_blank" rel="noreferrer noopener">Antonio Regalado</a></strong><br>Senior Editor, Biomedicine</figcaption></figure>
</div>



<div class="wp-block-column is-vertically-aligned-center is-layout-flow wp-block-column-is-layout-flow">
<figure class="wp-block-image aligncenter size-full is-resized is-style-default wp-duotone-333-ffffff-3"><img decoding="async" width="1080" height="1080" src="https://wp.technologyreview.com/wp-content/uploads/2024/01/Mary-Beth-Griggs.png" alt="" class="wp-image-1125906" srcset="https://wp.technologyreview.com/wp-content/uploads/2024/01/Mary-Beth-Griggs.png 1080w, https://wp.technologyreview.com/wp-content/uploads/2024/01/Mary-Beth-Griggs.png?resize=150,150 150w, https://wp.technologyreview.com/wp-content/uploads/2024/01/Mary-Beth-Griggs.png?resize=300,300 300w, https://wp.technologyreview.com/wp-content/uploads/2024/01/Mary-Beth-Griggs.png?resize=768,768 768w" sizes="(max-width: 1080px) 100vw, 1080px"><figcaption class="wp-element-caption"><strong>Mary Beth Griggs</strong><br>Science Editor</figcaption></figure>
</div>



<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"></div>
</div>]]> </content:encoded>
</item>

<item>
<title>Greener Biomanufacturing Starts Beyond the Bioreactor</title>
<link>https://edusehat.com/en/greener-biomanufacturing-starts-beyond-the-bioreactor</link>
<guid>https://edusehat.com/en/greener-biomanufacturing-starts-beyond-the-bioreactor</guid>
<description><![CDATA[ A new modeling study finds that buildings, not bioreactors, dominate energy consumption in antibody manufacturing. Continuous processing and smarter facility design could reduce emissions, but water and disposable materials complicate sustainability decisions for manufacturers worldwide.
The post Greener Biomanufacturing Starts Beyond the Bioreactor appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Mike-mAb-bioprocess-modeling_GBPN_IMAGE_04NOV26.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 03:15:16 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Greener, Biomanufacturing, Starts, Beyond, the, Bioreactor</media:keywords>
<content:encoded><![CDATA[<p>When it comes to making monoclonal antibodies greener, the biggest energy drain might not be the bioreactor. It might be the building around it.</p>
<p>A new modeling study found that approximately 85% of energy demand in antibody manufacturing came from facility infrastructure, including heating, ventilation, and air conditioning (HVAC), lighting, and utilities. Electricity for HVAC alone accounted for 46% of energy use, while lighting added another 21%. Published in <a href="https://doi.org/10.1016/j.nbt.2026.10.002" target="_blank" rel="noopener"><em>New Biotechnology</em></a>, the findings suggest that improving a plant’s layout and operations could be as important as upgrading its production technology.</p>
<p>Benjamin Smith, PhD, a principal data scientist at Amgen, and his colleagues from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) Process Intensification Sustainability Workgroup modeled three manufacturing scenarios: stainless-steel fed-batch, single-use fed-batch, and end-to-end single-use continuous processing. Using BioSolve Process software, the researchers compared water and materials consumption, energy demand, and greenhouse-gas emissions for facilities producing roughly 120 kg of antibody annually.</p>
<p>The fed-batch scenarios relied on 2,000-L bioreactors, while continuous processing used a 500-L bioreactor over a longer production run. Despite its smaller vessel, the continuous system delivered comparable annual output with less infrastructure. Its modeled facility occupied 12,387 cubic meters, versus 14,089 for single-use fed-batch and 14,937 for stainless-steel fed-batch.</p>
<p>That smaller footprint translated into lower energy intensity: 13,239 kilowatt-hours per kilogram of antibody for continuous manufacturing, compared with 17,017 and 19,120 kilowatt-hours for the two fed-batch approaches, respectively. The researchers concluded that, at equivalent output, “facility footprint—not process type—is the main determinant of energy intensity.”</p>
<p>Yet continuous processing was not automatically greener on every measure. Stainless-steel systems consumed considerably more cleaning water but required substantially fewer disposable consumables. Single-use fed-batch had the highest consumables intensity. Continuous processing required more culture medium and certain buffers, demonstrating why sustainability decisions involve competing demands.</p>
<h4><strong>Making the facility work smarter</strong></h4>
<p>The researchers also modeled a more efficient continuous process incorporating a 50% increase in antibody titer, two flow-through polishing steps, fivefold concentrated medium, and reuse of media and buffer bags. Compared with baseline continuous processing, this combination cut water use per kilogram of product by 26% and consumables intensity by 58%. Modeled carbon dioxide-equivalent emissions fell by 66% to 78% relative to the baseline continuous and stainless-steel fed-batch scenarios, respectively.</p>
<p>Building improvements offered another opportunity. Reducing cleanroom classifications where appropriate, optimizing airflow and lighting, increasing equipment density, and improving utilities could together lower modeled facility energy consumption and emissions by up to approximately 35%. Climate also mattered: temperate locations generally required less heating or dehumidification than colder or humid sites.</p>
<p>The findings come with qualifications. The models considered hypothetical single-bioreactor plants, not larger commercial facilities with multiple production trains. The assessment also excluded some lifecycle impacts, including raw-material production and transportation. The workgroup plans to extend the analysis through lifecycle assessment and test-bed data.</p>
<p>For bioprocess developers, the implication is that boosting productivity and shrinking the space needed to achieve it might deliver sustainability gains beyond those available from individual equipment upgrades. Greener antibody manufacturing could begin with rethinking the factory itself.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/greener-biomanufacturing-starts-beyond-the-bioreactor/">Greener Biomanufacturing Starts Beyond the Bioreactor</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Suspended Vials Help Optimize Continuous Freeze&#45;Drying</title>
<link>https://edusehat.com/en/suspended-vials-help-optimize-continuous-freeze-drying</link>
<guid>https://edusehat.com/en/suspended-vials-help-optimize-continuous-freeze-drying</guid>
<description><![CDATA[ Researchers have developed a process with suspended vials accompanied by a digital twin for optimized continuous and autonomous freeze-drying. It offers more uniform and better-quality products, and higher yields.
The post Suspended Vials Help Optimize Continuous Freeze-Drying appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/08/GettyImages-1289557906.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 03:15:14 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Suspended, Vials, Help, Optimize, Continuous, Freeze-Drying</media:keywords>
<content:encoded><![CDATA[<p>U.S. researchers have suspended vials to enable autonomous continuous freeze-drying and have developed a digital twin to help optimize the new process.</p>
<p>The team, from the Massachusetts Institute of Technology (MIT), has found that suspending vials on a wire during freeze-drying, a process called lyophilization, gives a more uniform drying process to produce a more consistent product.</p>
<p>The new process also provides all the existing benefits of continuous processing, such as higher production capacity and improved quality control.</p>
<p>“Because this is a continuous lyophilization technology, you get all the benefits of continuous versus batch manufacturing,” explains Prakitr Srisuma, PhD, formerly a researcher at MIT’s Argonne National Laboratory.</p>
<p>“But we have the unique benefit with the suspended wire technology of [more] uniformity of the [final] product.”</p>
<p>Traditionally, vials are dried in a cupboard where they may be occasionally moved around, disturbing their contents, Srisuma explains. By contrast, suspending the vials on wires moved by magnets means they receive the same exposure to different conditions during drying, and their passage through the drying process is very smooth, he says.</p>
<p>“If a vial has been sitting on a shelf and you try to move it, there’s going to be friction, which will generate small particles but, with suspended vials, we avoid those issues,” he explains.</p>
<p>The team had previously spoken to <em>GEN</em> about <a href="https://www.genengnews.com/topics/bioprocessing/continuous-manufacturing-making-freeze-drying-a-hot-topic/" target="_blank" rel="noopener">modeling lyophilization processes</a>. Since then, they have developed a digital twin of the continuous lyophilizer, which they can use to help optimize the process.</p>
<p>Going forward, the team aims to use the digital twin to develop advanced predictive control and optimization strategies. In addition, Srisuma says, the researchers may explore using microwave lyophilization.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/suspended-vials-help-optimize-continuous-freeze-drying/">Suspended Vials Help Optimize Continuous Freeze-Drying</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Small Bioprocess Monitoring Hits the Goldilocks Zone</title>
<link>https://edusehat.com/en/small-bioprocess-monitoring-hits-the-goldilocks-zone</link>
<guid>https://edusehat.com/en/small-bioprocess-monitoring-hits-the-goldilocks-zone</guid>
<description><![CDATA[ A viable-cell-density-on-a-chip monitor offers hope for more fully functional, PAT-compliant in-line monitoring for small bioprocesses, filling a current instrumentation gap. The catch? It’s still in early development.
The post Small Bioprocess Monitoring Hits the Goldilocks Zone appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/12/Oct1_2024_GettyImages_1397353290_MotherboardMainMicrochip_RESIZE4014-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 03:15:12 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Small, Bioprocess, Monitoring, Hits, the, Goldilocks, Zone</media:keywords>
<content:encoded><![CDATA[<p>Process analytical technology (PAT) bioprocess monitoring instruments generally are designed for large-scale processes, which leaves small-scale bioprocessing at a decided disadvantage. In the days of blockbuster therapeutics, that wouldn’t have mattered much. Today, however, process intensification and increasingly personalized therapies are decreasing batch sizes, so the lack of real-time PAT monitoring options for small-scale manufacturing is a growing concern.</p>
<p>That limitation is felt particularly in the paucity of in-line instrumentation to measure viable cell density, where biocapacitance probes are too large. Alternative, offline viable cell counting methods such as the trypan blue exclusion method limit real-time monitoring in small vessels and, according to a team of Swiss scientists, are impractical for small-scale bioprocessing.</p>
<p>The team led by Yves Mermoud, PhD, research scientist, Eastern Switzerland University of Applied Sciences (OST), and colleagues from OST and Zurich University of Applied Sciences is showing progress in remedying that situation with a viable cell density that appears to be neither too big nor too cumbersome but, as Goldilocks said, just right.</p>
<p>They recently <a href="https://www.researchgate.net/profile/Samuel-Huber-3/publication/415249643_625_-_Bioimpedance_Microsensor_for_Cell-Density_Monitoring_in_Small-Scale_Bioprocessing/links/6ac4f5865770bb0daeda65c0/625-Bioimpedance-Microsensor-for-Cell-Density-Monitoring-in-Small-Scale-Bioprocessing.pdf" target="_blank" rel="noopener">reported</a> on a proof-of-concept, miniature, viable cell density sensor that they tested against concentrations of Chinese hamster ovary (CHO) cells. This work is admittedly in its early stages, but it promises a PAT-compliant sensor for small volumes that currently lack good measurement options.</p>
<p>The miniature bioimpedance sensor they are developing has a 1 x 10 mm footprint at a 25 µL working volume. “Performance [is] close to conventional probes,” Mermoud and colleagues report.</p>
<figure aria-describedby="caption-attachment-340171" class="wp-caption alignnone"><img fetchpriority="high" decoding="async" class=" wp-image-340171" src="https://www.genengnews.com/wp-content/uploads/2026/11/Dutton-Picture1-300x114.jpg" alt="" width="374" height="142" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Dutton-Picture1-300x114.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Dutton-Picture1-1024x388.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/Dutton-Picture1-768x291.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Dutton-Picture1-1536x582.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2026/11/Dutton-Picture1.jpg 1637w" sizes="(max-width: 374px) 100vw, 374px"><figcaption class="wp-caption-text">The miniature, proof-of-concept, bioimpedance sensor has a 1 x 10 mm footprint at a 25 µL working volume. [Yves Mermoud, PhD, research scientist, Eastern Switzerland University of Applied Sciences]</figcaption></figure>
<h4><strong>A good starting point</strong></h4>
<p>The team measured electrical impedance from 10 kHz to 5 MHz, with an amplitude of 200 mV. The detection limit was approximately 0.5 × 10<sup>6</sup> cells mL⁻¹. Deviations at the upper and lower limits were comparable to those of commercial probes, according to data the team presented at the recent Eurosensors 2026 meeting.</p>
<p>There, they reported a linear correlation when measuring the viable density of CHO cells and closely—but not perfectly—tracked reference cell counts. More specifically, Mermoud tells <em>GEN</em>, “Their measurements showed strong correlation with the reference cell counts (R² = 0.92), indicating that a linear relationship explained 92% of the observed variation.”</p>
<p>To create these miniaturized sensors, the researchers fabricated evaporated platinum thin-film electrodes onto a 100 mm fused silica wafer by photolithography. The wafer was cut into 15 x15 mm microchips that were connected to an impedance analyzer. Each chip features two microfluidic channels.</p>
<p>“The PAT microchip cell density sensor has already demonstrated continuous at-line monitoring in representative 14-day CHO fed-batch cultivations,” Mermoud says. “In these studies, cell suspension was circulated through an external demonstrator module housing the PAT microchip. Our focus now is on improving signal analysis to account for process-related changes in the culture medium over time.</p>
<p>“Going forward, we will package the PAT microchip as a standard insertion probe for direct inline deployment in the bioreactor and expand the data analytics with multivariate models that leverage the microchip’s multiple sensing modalities,” Mermoud elaborates.</p>
<p>“We are currently seeking industrial partners to support and accelerate this final translation into a commercial process sensor.”</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/small-bioprocess-monitoring-hits-the-goldilocks-zone/">Small Bioprocess Monitoring Hits the Goldilocks Zone</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Standardized Apheresis Processes Would Help Cell Therapy Sector</title>
<link>https://edusehat.com/en/standardized-apheresis-processes-would-help-cell-therapy-sector</link>
<guid>https://edusehat.com/en/standardized-apheresis-processes-would-help-cell-therapy-sector</guid>
<description><![CDATA[ Variation in collection practices, or apheresis, and handling procedures is a source of cell therapy starting material variability and a major headache for manufacturers, suggesting a degree of standardization would help the industry.
The post Standardized Apheresis Processes Would Help Cell Therapy Sector appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2018/12/Nov1_2018_GettyImages_998855520_InsertingSyringePatientArm.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 03:15:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Standardized, Apheresis, Processes, Would, Help, Cell, Therapy, Sector</media:keywords>
<content:encoded><![CDATA[<p>Variability in collection practices at sampling sites has an impact on the quality of cell therapy starting materials, say the authors of new <a href="https://www.sciencedirect.com/science/article/abs/pii/S1465324926009667" target="_blank" rel="noopener">analysis</a>, who suggest that a degree of standardization would aid industry.</p>
<p>Biological factors, such as age, disease status, treatment regimen, and donation history, impact the quality of cells harvested at collection sites, which is a challenge for cell therapy developers trying to turn these variable materials into consistent products.</p>
<p>But biology is not the only source of variability, according to Christina Celluzzi, PhD, from the Association for the Advancement of Blood & Biotherapies, who says firms should not underestimate the role cell collection practices play in determining quality.</p>
<p>“Variability at the apheresis stage complicates comparability assessments when manufacturers change processes, transfer technology, or add capacity. It also limits how efficiently sponsors can use comparability protocols and post-approval change strategies,” she tells <em>GEN</em>.</p>
<h4><strong>Standardization</strong></h4>
<p>Celluzzi and colleagues looked at the impact of variation in apheresis and handling protocols in a recent <a href="https://www.sciencedirect.com/science/article/abs/pii/S1465324926009667" target="_blank" rel="noopener">study</a>, concluding that standardizing parts of these processes would aid cell and gene therapy developers.</p>
<p>“Not every area needs the same degree of standardization,” she says, adding, “for example, there will always need to be flexibility with regard to device selection and vascular access techniques.”</p>
<p>“In contrast, the elements of apheresis that support comparability and traceability would benefit most from tight standardization. These include minimum donor eligibility data elements, definitions of quality attributes, and product identification and labeling,” Celluzzi says.</p>
<p>She cites existing standards—such as <a href="https://www.isbtweb.org/resource/in-015-an-introduction-to-isbt-128---english-v6-pdf.html" target="_blank" rel="noopener">ISBT 128</a>, which covers terminology, labeling, and chain of identity—as an ideal starting point for industry efforts to standardize cell collection practices.</p>
<p>“Adoption of such standards should be paired with implementation support, so that standardization doesn’t widen capability gaps between collection sites.</p>
<p>“We believe the technical content of best practices is best developed by stakeholders, for example through consensus efforts led by organizations such as PDA and ASTCT. Regulators would then recognize or incorporate those standards rather than author them from scratch,” she continues.</p>
<p>That said, the clarification of existing regulations covering cell therapy starting materials would also help industry, according to Celluzzi.</p>
<p>“We’re also asking FDA to clarify several points: how it distinguishes investigational from commercial starting materials, its expectations for collections made outside the United States, and how consensus standards can support regulatory submissions.”</p>
<p>Harmonizing material receipt procedures at cell therapy production facilities would help too, Celluzzi says, citing strictly defined temperature limits and cryopreservation media specifications as examples.</p>
<p>“Common templates for leukapheresis manuals, SOPs, and chain-of-custody and chain-of-identity records would be beneficial,” Celluzzi says, adding, “Risk-based site qualification would let manufacturers focus audits on product-specific risks instead of repeatedly reassessing established quality systems.”</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/standardized-apheresis-processes-would-help-cell-therapy-sector/">Standardized Apheresis Processes Would Help Cell Therapy Sector</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Building Custom DNA without Bacterial Constraints</title>
<link>https://edusehat.com/en/building-custom-dna-without-bacterial-constraints</link>
<guid>https://edusehat.com/en/building-custom-dna-without-bacterial-constraints</guid>
<description><![CDATA[ Moving high-fidelity DNA assembly from the production queue to the lab bench and the science can start sooner.
The post Building Custom DNA without Bacterial Constraints appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/RibbonBio_DNA.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 03:15:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Building, Custom, DNA, without, Bacterial, Constraints</media:keywords>
<content:encoded><![CDATA[<p>Sponsored content brought to you by</p>
<p><a href="https://ribbonbio.com/" target="_blank" rel="noopener"><img decoding="async" class="alignnone wp-image-336834 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/08/RibbonBio_logo_primary_RGB-300x97.jpg" alt="Ribbon Bio logo" width="300" height="97" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/RibbonBio_logo_primary_RGB-300x97.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/RibbonBio_logo_primary_RGB-1024x330.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/08/RibbonBio_logo_primary_RGB-768x247.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/08/RibbonBio_logo_primary_RGB-1536x495.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2026/08/RibbonBio_logo_primary_RGB-1303x420.jpg 1303w, https://www.genengnews.com/wp-content/uploads/2026/08/RibbonBio_logo_primary_RGB-696x224.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/08/RibbonBio_logo_primary_RGB-1392x449.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2026/08/RibbonBio_logo_primary_RGB-1068x344.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/08/RibbonBio_logo_primary_RGB.jpg 1921w" sizes="(max-width: 300px) 100vw, 300px"></a></p>
<p>The standard way to build custom DNA still runs through a living cell: assemble the sequence, push it into bacteria, grow overnight, extract, clean up. Molecular biologists have leaned on this for half a century, and for most constructs it works. But it is slow to schedule, demands culturing and biosafety infrastructure, and quietly fails on the sequences researchers care about most.</p>
<p>Those failures were the starting point for Ribbon Bio. “Sometimes the sequence we want to study is precisely the sequence that bacteria do not want to maintain,” said Divya Vijay Pratheek, the company’s vice president of product, in a recent GEN webinar. Toxic elements and secondary structures can collapse a clone, costing days or weeks of troubleshooting. Outsourcing relieves the bottleneck but puts proprietary sequences in someone else’s hands.</p>
<h4><strong>Taking out the host</strong></h4>
<p>Ribbon Bio’s cell-free assembly technology removes bacteria from the equation entirely thus eliminating several practical burdens. Without a host, Pratheek explained, there is no endotoxin or residual genomic DNA to carry into downstream assays, contamination that matters most for therapeutic and patient-facing work. Since sequences no longer have to survive inside a living host, toxic or unstable designs become workable, and the failure points of transformation, colony selection, and plasmid prep fall away.</p>
<p>The workflow opens with software. Ribbon Bio’s proprietary algorithm reads target sequences for trouble spots such as GC content, repeats, homopolymers, and secondary structure, then lays out oligo pools with boundaries chosen to sidestep them. Ribbon’s proprietary enzymes stitch the oligos into fragments, checked before assembly into the finished molecule. The design is tuned most to catch most complexities, before they lead to failed reactions.</p>
<h4><strong>From service to bench</strong></h4>
<p>The company first sold this as a synthesis service, MiroSynth<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley">, which it still runs for extremely complex molecules. These days, the MiroMine<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> kit puts the method directly in customers’ hands enabling them to build complex DNA in house. The early-access version builds molecules up to roughly 7 kilobases, needs only standard lab hardware, and runs manually or using automation, with platform scripts in progress.</p>
<p>The figures came from Ribbon Bio’s own runs. Molecules near 3.4 and 6.8 kb returned 100% sequence-perfect reads, and a roughly 4 kb construct came in at 88%, shown openly against the company’s 90% accuracy floor. Fragments ranging from 30%–70% global and 20%–82% local GC content, plus repeats and homopolymers, cleared the same four-hour workflow. Endotoxin levels sat at or below 0.1 units per microgram, with no detectable bacterial genomic DNA.</p>
<h4><strong>A library builder’s test</strong></h4>
<p>Flock Bio, a company that assembles pooled custom DNA libraries, is an early user of Ribbon Bio’s kit.  In one internal study, the company’s scientists ran 12 fragments through MiroMine and got all 12, roughly half of them high-complexity, cleanly assembled.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>The payoff was speed. With MiroMine, Flock ran fragment assembly, cleanup, checks, and pooled ligation inside one working day; with cloning adding three to four days, a full library can land in a week. “If we get that oligo pool on Monday, we’re shipping by Friday,” said Matthew D. Youngblut, PhD, Flock Bio’s co-founder and chief scientific officer, who pointed to value of fast-turn work for things like antibody discovery, binder design, and more.</p>
<h4><strong>The takeaway</strong></h4>
<p>For over fifty years, traditional DNA assembly has relied on bacterial propagation, a process that introduces labor intensive processes, sequence constraints, contamination risks, and extended production cycles. In this webinar, Ribbon Bio and Flock Bio lay out a case for retiring that requirement: purer starting material, access to sequences bacteria reject, and a turnaround counted in days instead of weeks. For scientists working in therapeutic development, endotoxin-free production addresses regulatory and safety concerns that currently require additional purification steps. The technology also enables iteration cycles that match the pace of modern screening technologies, particularly in competitive areas like antibody discovery.  While the program is young and not every use case is proven, the direction is clear: pull the build onto the bench, and the science can start sooner.</p>
<p> </p>
<p><em><img decoding="async" class="alignleft wp-image-340203 size-full" src="https://www.genengnews.com/wp-content/uploads/2026/11/RibbonBio_QRCode.jpg" alt="Ribbon Bio QR Code" width="146" height="151"></em></p>
<p> </p>
<p><em>Try MiroMine<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> in your lab today at <a href="https://ribbonbio.com/miromine/" target="_blank" rel="noopener">www.ribbonbio.com/miromine</a>.</em></p>
<p>The post <a href="https://www.genengnews.com/sponsored/building-custom-dna-without-bacterial-constraints/">Building Custom DNA without Bacterial Constraints</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>HIV&#45;Blocking Antibody Shows Promise, but Resistant Strains Break Through</title>
<link>https://edusehat.com/en/hiv-blocking-antibody-shows-promise-but-resistant-strains-break-through</link>
<guid>https://edusehat.com/en/hiv-blocking-antibody-shows-promise-but-resistant-strains-break-through</guid>
<description><![CDATA[ A new study finds that the VRC01 antibody initially protects against HIV infection, but resistant strains can cause breakthrough infections as antibody levels decline, highlighting the need for multiple antibodies.
The post HIV-Blocking Antibody Shows Promise, but Resistant Strains Break Through appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/08/GettyImages-2204954260.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 03:15:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>HIV-Blocking, Antibody, Shows, Promise, but, Resistant, Strains, Break, Through</media:keywords>
<content:encoded><![CDATA[<p>One of the mechanisms being developed to help combat HIV is to prevent HIV-negative individuals, who are at risk of acquiring HIV-1, from becoming infected. One form of this preventative strategy is using broadly neutralizing antibodies (bnAbs)—administered intravenously—that could protect individuals from acquiring HIV-1. This could be most relevant for people with partners living with HIV, people at increased risk of HIV exposure (including individuals with ongoing sexual exposure risk), people who cannot or prefer not to use conventional PrEP, and among populations with high HIV incidence—for example, communities in regions of sub-Saharan Africa with substantial HIV transmission.</p>
<p>The antibody-mediated prevention (AMP) clinical trials were landmark trials in this area—the first to investigate whether intravenous infusion of a bnAb could prevent HIV-1 acquisition. The trials focused on the bnAb VRC01, which targets the CD4-binding site on the HIV-1 envelope (Env) glycoprotein. By binding to this region, VRC01 can neutralize susceptible HIV-1 strains and potentially prevent the virus from infecting host cells.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>The broadly neutralizing antibody VRC01 has been thoroughly vetted as a potential prophylactic that could prevent people from becoming infected with HIV. Now, a new analysis of data from two clinical trials in the Americas and sub-Saharan Africa shows that the antibody initially provides strong protection, but that some strains of the virus can still cause breakthrough infections after treatment has stopped. The findings point to the importance of combining multiple types of antibodies to suppress HIV completely and to prevent breakthrough infections in vulnerable people.</p>
<p>This work is published in <em>Science Translational Medicine</em> in the paper, “Extended <em>in vivo</em> activity of VRC01 HIV-1 prophylaxis entails initial protective efficacy and subsequent breakthrough infections.”</p>
<p>Antibodies such as VRC01 are designed to halt the virus’ ability to infect its host initially through common sites of exposure. VRC01 has recently progressed to large-scale clinical trials, but scientists must test whether it can provide meaningful, real-world protection against the ever-evolving myriad strains of HIV.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>In this new report, researchers parsed data from HVTN 704 and HPTN 085, two clinical trials where participants received infusions of VRC01 for 80 weeks. The two parallel antibody-mediated prevention (AMP) prevention efficacy trials evaluated whether intravenous infusion of the anti-CD4 binding site broadly neutralizing antibody VRC01 prevents HIV-1 acquisition.</p>
<p>The researchers focused their attention on the period after the treatment ended, from weeks 80 to 104. More specifically, they analyzed HIV-1 acquisition in AMP through the week 104 final study visit.</p>
<p>The researchers showed that VRC01 initially protected against HIV strains that were considered highly sensitive to the antibody, achieving a prevention efficacy of 66.3%. They write that against viruses considered highly sensitive to VRC01, “VRC01 prophylaxis maintained cumulative prevention efficacy of 66.3%, suggesting that the antibody successfully blocked or cleared these infections.”</p>
<p>As VRC01 concentration waned, suppressed viruses—often evolving greater resistance because of selective pressure—emerged as detectable infections. After week 80, some of the participants were still diagnosed with HIV that was considered more resistant to the antibody, and diagnoses were higher compared with the placebo group. They write, “In the post–week 80 period (after the final dose at week 72), HIV diagnosis and resistance to VRC01 were more frequent and greater in the VRC01 groups versus placebo.”</p>
<p>The findings, the authors explain, suggest that, “whereas single antibodies can block sensitive strains, multiple antibodies are likely required to prevent both viral escape and breakthrough infections.” The authors write that their results carry implications for the design and analysis of future trials of HIV-1 broadly neutralizing antibodies, such as the importance of testing for the virus far after infusions have ended.</p>
<p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/hiv-blocking-antibody-shows-promise-but-resistant-strains-break-through/">HIV-Blocking Antibody Shows Promise, but Resistant Strains Break Through</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>How Epigenomics Is Transforming Drug Discovery and Development</title>
<link>https://edusehat.com/en/how-epigenomics-is-transforming-drug-discovery-and-development</link>
<guid>https://edusehat.com/en/how-epigenomics-is-transforming-drug-discovery-and-development</guid>
<description><![CDATA[ In this GEN eBook readers will discover how epigenomic insights are improving every stage of the drug discovery pipeline, from target identification and validation to mechanism-of-action studies and therapeutic optimization.
The post How Epigenomics Is Transforming Drug Discovery and Development appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Epicypher_CoverImage_Nov2026.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 04 Nov 2026 23:40:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>How, Epigenomics, Transforming, Drug, Discovery, and, Development</media:keywords>
<content:encoded><![CDATA[<div aria-hidden="true" class="wp-block-spacer"></div>


<p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Read Now</button></p>


<p class="wp-block-paragraph">Understanding gene regulation has become essential to modern drug discovery. While DNA sequence and RNA expression provide valuable information, they reveal only part of the story. Epigenomic technologies, particularly chromatin mapping assays like CUT&RUN, are enabling researchers to investigate the regulatory mechanisms that control gene expression, offering a level of insight that transcriptional profiling alone cannot provide.</p>


<figure class="wp-block-image alignright size-medium"><img decoding="async" width="232" height="300" src="https://www.genengnews.com/wp-content/uploads/2026/11/Epicypher_eBookCover_Nov2026-232x300.jpg" alt="Epicypher eBook Cover, How Epigenomics Is Transforming Drug Discovery and Development" class="wp-image-340189" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Epicypher_eBookCover_Nov2026-232x300.jpg 232w, https://www.genengnews.com/wp-content/uploads/2026/11/Epicypher_eBookCover_Nov2026-791x1024.jpg 791w, https://www.genengnews.com/wp-content/uploads/2026/11/Epicypher_eBookCover_Nov2026-768x994.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Epicypher_eBookCover_Nov2026-1187x1536.jpg 1187w, https://www.genengnews.com/wp-content/uploads/2026/11/Epicypher_eBookCover_Nov2026.jpg 1200w" sizes="(max-width: 232px) 100vw, 232px"></figure>


<h4 class="wp-block-heading"><strong>Introduction</strong></h4>


<p class="wp-block-paragraph">In this <em>GEN</em> eBook, <em>How Epigenomics is Transforming Drug Discovery and Development</em>, readers will discover how epigenomic insights are improving every stage of the drug discovery pipeline, from target identification and validation to mechanism-of-action studies and therapeutic optimization.</p>


<h4 class="wp-block-heading"><strong>Read this eBook to learn:</strong></h4>


<ul class="wp-block-list">
<li>Why understanding gene regulation matters in drug discovery and development</li>



<li>How epigenomic profiling is being used to identify novel therapeutic targets, elucidate drug mechanisms of action, investigate treatment resistance, and support development of emerging modalities such as targeted protein degraders (e.g. PROTACs, molecular glues)</li>



<li>How next-generation technologies, including CUT&RUN, are providing unprecedented insights into gene regulation</li>
</ul>


<p class="wp-block-paragraph">Through expert perspectives and real-world case studies, this eBook demonstrates how researchers are applying epigenomic approaches to answer critical biological questions, characterize therapeutic responses, and make more informed decisions throughout drug development.</p>


<p class="wp-block-paragraph">Whether you’re working in target discovery, translational research, or therapeutic development, this eBook provides a practical overview of the technologies and strategies that are reshaping modern drug discovery.</p>


<p class="wp-block-paragraph">Read this eBook to learn how CUT&RUN and related epigenomic tools are helping pharmaceutical and biotechnology researchers uncover disease mechanisms, identify high-confidence drug targets, and accelerate the development of more effective therapies.</p>

<p>The post <a href="https://www.genengnews.com/resources/ebooks/how-epigenomics-is-transforming-drug-discovery-and-development/">How Epigenomics Is Transforming Drug Discovery and Development</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Kamau Therapeutics Releases Encouraging Sickle Cell Clinical Data Ahead of ASH Meeting</title>
<link>https://edusehat.com/en/kamau-therapeutics-releases-encouraging-sickle-cell-clinical-data-ahead-of-ash-meeting</link>
<guid>https://edusehat.com/en/kamau-therapeutics-releases-encouraging-sickle-cell-clinical-data-ahead-of-ash-meeting</guid>
<description><![CDATA[ The findings, part of a trove of abstracts that will be presented at next month’s American Society of Hematology (ASH) conference, show precise correction of the SCD mutation in the β-globin gene in three SCD patients as well as restored expression of adult hemoglobin (HbA).
The post Kamau Therapeutics Releases Encouraging Sickle Cell Clinical Data Ahead of ASH Meeting appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2021/06/June04_2021_Stocktrek-Images-Getty-Images_Sickle-Cell-Disease-e1622842099798.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 04 Nov 2026 23:40:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Kamau, Therapeutics, Releases, Encouraging, Sickle, Cell, Clinical, Data, Ahead, ASH, Meeting</media:keywords>
<content:encoded><![CDATA[<p>Kamau Therapeutics, a California biotech company co-founded by Stanford University physician-scientist Matthew Porteus, MD, PhD, has emerged from stealth with the release of preliminary clinical data on its first cohort of gene-edited patients with sickle cell disease (SCD).</p>
<p>The findings, part of a trove of abstracts that will be presented at next month’s American Society of Hematology (ASH) conference, show precise correction of the SCD mutation in the β-globin gene in three SCD patients as well as restored expression of adult hemoglobin (HbA). In contrast to FDA-approved Casgevy, which overcomes the SCD mutation by switching up expression of fetal hemoglobin (HbF), Kamau is employing a direct replacement of the SCD mutation using homology-directed repair (HDR) of the β-globin gene.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>All three patients are currently transfusion-independent and have not experienced any pain crises since receiving their gene-edited hematopoietic stem cells (HSCs). In addition to the predominant HbA profile being restored, Kamau reports that the sickle hemoglobin (HbS) level fell below 20% of total hemoglobin in the two patients who have reached the 6-month post-infusion mark.</p>
<figure aria-describedby="caption-attachment-297262" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="wp-image-297262 size-medium" src="https://www.genengnews.com/wp-content/uploads/2024/06/MatthewPorteus_Headshot-243x300.jpg" alt="Matthew Porteus" width="243" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2024/06/MatthewPorteus_Headshot-243x300.jpg 243w, https://www.genengnews.com/wp-content/uploads/2024/06/MatthewPorteus_Headshot-828x1024.jpg 828w, https://www.genengnews.com/wp-content/uploads/2024/06/MatthewPorteus_Headshot-768x950.jpg 768w, https://www.genengnews.com/wp-content/uploads/2024/06/MatthewPorteus_Headshot-1242x1536.jpg 1242w, https://www.genengnews.com/wp-content/uploads/2024/06/MatthewPorteus_Headshot-1657x2048.jpg 1657w, https://www.genengnews.com/wp-content/uploads/2024/06/MatthewPorteus_Headshot-340x420.jpg 340w, https://www.genengnews.com/wp-content/uploads/2024/06/MatthewPorteus_Headshot-679x840.jpg 679w, https://www.genengnews.com/wp-content/uploads/2024/06/MatthewPorteus_Headshot-324x400.jpg 324w, https://www.genengnews.com/wp-content/uploads/2024/06/MatthewPorteus_Headshot-648x800.jpg 648w, https://www.genengnews.com/wp-content/uploads/2024/06/MatthewPorteus_Headshot-696x860.jpg 696w, https://www.genengnews.com/wp-content/uploads/2024/06/MatthewPorteus_Headshot-1392x1721.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2024/06/MatthewPorteus_Headshot-1068x1320.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2024/06/MatthewPorteus_Headshot-1920x2374.jpg 1920w" sizes="(max-width: 243px) 100vw, 243px"><figcaption class="wp-caption-text">Matthew Porteus, MD, PhD,<br>Co-Founder, Kamau Therapeutics<br>Associate Professor of Pediatrics, Stanford University</figcaption></figure>
<p>Porteus told <em>GEN </em>he was “very encouraged” by this early readout of Kamau’s RESTORE trial. “These were the target results that we were expecting once we got HDR to work in engraftable HSCs,” Porteus said. “We are now full speed ahead on enrolling more patients and moving to talk to the FDA about the registration trial design.” The Phase I/II RESTORE trial is enrolling some 15 participants.</p>
<p>Between the abstract submission and next month’s presentation at ASH, Porteus said Kamau has “further data that gives us confidence in the safety, efficacy and sustainability of the approach.” Porteus says that the updated data will be included in the ASH talk, which will be given by John DiPersio, MD, Director of the Center for Gene and Cellular Immunotherapy at Washington University School of Medicine, on December 14 in New Orleans.</p>
<p>“Achieving hemoglobin levels above 10 g/dL, with sickle hemoglobin below 20% and adult hemoglobin predominant, in patients who also remain free of vaso-occlusive events, is an encouraging early signal,” DiPersio said in a press release. “Seeing that profile alongside stable engraftment of corrected cells is what we would hope to see from a durable correction of the underlying mutation.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>Vali Barsan, MD, co-founder and CEO of Kamau Therapeutics, said his team applies “process engineering to HDR, nature’s own high-fidelity repair pathway.” The HDR pathway “can implement corrections we design directly into a patient’s own stem cells,” Barsan continued. “That has been the promise of gene editing from the beginning, and these data are early clinical evidence that it can be realized.”</p>
<h4><strong>Direct deposit</strong></h4>
<p>Porteus, who is head of R&D of Kamau, has been <a href="https://www.genengnews.com/topics/genome-editing/a-story-of-perseverance-an-interview-with-matthew-porteus/" target="_blank" rel="noopener">steadfast in his determination</a> to translate some of the basic insights he helped define regarding DNA repair and recombination into the clinic, especially for the benefit of patients with SCD. He said his new company adopts a twin-stranded approach: reduce production of pathogenic HbS and restore the body’s own production of normal HbA. Kamau’s gene replacement strategy is a 1:1 exchange of the faulty HbS allele with a healthy HbA copy, rather than a gene addition strategy.</p>
<p>“We developed nula-cel to work in a patient’s own stem cells, enabling those cells to produce adult hemoglobin under the body’s normal regulation,” Porteus said. The nula-cel therapy directly corrects the SCD mutation in the β-globin gene. That is in contrast to the HbF switching approach taken in Casgevy, the gene editing therapy sponsored by Vertex Pharmaceuticals and CRISPR Therapeutics, approved in late 2023.</p>
<p>A major question is whether Kamau’s HDR strategy will offer any long-term clinical advantages compared to Casgevy. Porteus believes it might. “Since we see a greater reduction in HbS than the HbF [switching] approaches, we think that it will prove better at preventing the myriad of multi-organ damage that the disease causes,” Porteus told <em>GEN</em>. For example, “it has been shown that exchange transfusion, in which the target is to keep HbS below 30%, is better at preventing stroke or recurrent stroke than upregulation of HbF.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>In addition, Porteus said, “evolution has selected a tunable HbA as the solution to oxygen delivery to tissues under various conditions, whereas HbF is not tunable in its oxygen unloading. This may result in better long-term organ health.”</p>
<p>Of course, Kamau still faces some very stiff headwinds en route to commercial viability. In December 2024, Editas Medicine suspended its own gene editing asset for SCD after it was unable to find a pharma partner to move the therapy to approval despite strong clinical data.</p>
<p>Porteus notes that in his reading of Editas’ published data, “it did not appear the clinical results were improved over Casgevy.” Moreover, there are encouraging signs that the gene therapy approaches approved in 2023 are beginning to reach patients. “That Lyfgenia is, and Casgevy will soon be, profitable as patient infusions logarithmically increase quarter-over-quarter, while only addressing a tiny portion of the [SCD] patient population, gives us conviction on the commercial upside,” Porteus told <em>GEN</em>.</p>
<p>“The demand is there and we will be part of the solution to meet that demand,” Porteus insists. And as the CAR T commercial market demonstrates, “being first to market helps but the ultimate winner is best in indication.”</p>
<h4><strong>ASH anticipation</strong></h4>
<p>DiPersio’s presentation at ASH next month will be entitled: “First Clinical Results of Precise HBB Gene Correction by Homology Directed Repair in Patients with Severe Sickle Cell Disease: Safety and Efficacy from Phase 1A of the RESTORE Study” (NCT04819841). He will present results on three SCD patients treated with Kamau’s revised manufacturing process (V2.0) for nula-cel, along with continued follow-up of the first patient ever treated with nula-cel four years ago, under the auspices of Graphite Bio, Porteus’ previous company. <a href="https://www.genengnews.com/topics/genome-editing/a-sickle-sequel-matthew-porteus-launches-kamau-with-positive-nula-cell-patient-zero-results/" target="_blank" rel="noopener">Graphite Bio halted its SCD clinical trial in late 2022</a> and subsequently disbanded.</p>
<p>The ASH data “provide early clinical evidence that precise HDR-mediated correction of the native HBB gene is feasible,” Porteus said. “We look forward to learning more as the RESTORE trial progresses.”</p>
<p>All three V2.0 treated patients achieved transfusion independence before they were released from hospital, achieving neutrophil engraftment at a median of 21 days. In the two patients with more than six months of follow-up, total hemoglobin exceeded 10 g/dL, with relatively low levels of HbS (17.6% at 12 months and 19.1% at 8 months) and high HbA (77% at 12 months and 67% at 8 months).</p>
<p>Bone marrow HDR allele frequencies stabilized at approximately 20%, consistent with durable engraftment of gene-corrected HSCs. Single-cell analyses showed more than 90% of circulating red blood cells contained protective levels of HbA. There were no serious adverse events related to nula-cel or the multistep gene-editing process V2.0-treated patients, but some consistent with the busulfan conditioning and stem-cell transplantation.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>Off-target gene editing remained low and unchanged, Kamau said. HDR allele frequencies exceeded the 20% target in all three patients (32–38%). HSC mobilization required a median of just 1.3 apheresis cycles to reach target cell dose.</p>
<p>Nula-cel, which has received Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration (FDA), is an <em>ex vivo</em> approach. Kamau engineers a patient’s own stem cells outside the body, verifying each cell product’s quality, potency, and safety, before reinfusing the HSCs into the patient. Kamau claims this offers a measure of control that would not be possible using an <em>in vivo </em>gene editing approach.</p>
<p>Kamau is funded by a group of investors including Khosla Ventures, Cormorant Asset Management, NEVA SGR, Draper VC, Modi Ventures, and Regeneron Ventures. The company’s leadership team also includes chief technology officer Ramji Krishnan, PhD, who brings experience in CMC leadership at BMS/Celgene, and autologous HSC gene therapy experience at Rocket; chief medical officer Jacob Garcia, MD, previously at Juno/BMS; and chief business officer Reza Afkhami, formerly with Global Blood Therapeutics, where he helped manage <a href="https://www.genengnews.com/topics/drug-discovery/pfizer-to-acquire-gbt-for-5-4b-adding-sickle-cell-disease-drug-and-pipeline/" target="_blank" rel="noopener">the company’s 2022 acquisition by Pfizer</a>.</p>
<p>The post <a href="https://www.genengnews.com/topics/genome-editing/kamau-therapeutics-releases-encouraging-sickle-cell-clinical-data-ahead-of-ash-meeting/">Kamau Therapeutics Releases Encouraging Sickle Cell Clinical Data Ahead of ASH Meeting</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>14 Canadian hospitals join forces to accelerate medical research</title>
<link>https://edusehat.com/en/14-canadian-hospitals-join-forces-to-accelerate-medical-research</link>
<guid>https://edusehat.com/en/14-canadian-hospitals-join-forces-to-accelerate-medical-research</guid>
<description><![CDATA[ New agreement aims to reduce research delays, strengthen collaboration and bring medical discoveries to patients faster Fourteen University of Toronto-affiliated hospitals have signed a landmark agreement designed to simplify collaborative medical research, reduce administrative delays and accelerate the development of new treatments. The Master Collaboration Agreement, established through the Toronto Academic Health Science Network (TAHSN), […]
The post 14 Canadian hospitals join forces to accelerate medical research appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/11/shutterstock_1607312089.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 04 Nov 2026 23:35:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Canadian, hospitals, join, forces, accelerate, medical, research</media:keywords>
<content:encoded><![CDATA[<p><strong>New agreement aims to reduce research delays, strengthen collaboration and bring medical discoveries to patients faster</strong></p>
<p>Fourteen University of Toronto-affiliated hospitals have signed a landmark agreement designed to simplify collaborative medical research, reduce administrative delays and accelerate the development of new treatments.</p>
<p>The Master Collaboration Agreement, established through the <a href="https://tahsn.ca/?utm_source=chatgpt.com">Toronto Academic Health Science Network (TAHSN)</a>, introduces a shared legal and operational framework that will make it easier for participating hospitals to conduct research across multiple institutions.</p>
<p>The initiative addresses a longstanding challenge in Canadian healthcare research: the complexity of coordinating studies involving several hospitals, each with its own administrative and approval processes.</p>
<p>Under the agreement, participating institutions can use a common framework for eligible research activities, reducing the need to negotiate separate legal arrangements for each collaboration.</p>
<p><strong>Early results demonstrate significant improvements</strong></p>
<p>The initiative builds on a pilot launched in December 2024 involving the Centre for Addiction and Mental Health (CAMH) and University Health Network.</p>
<p>Sunnybrook Health Sciences Centre and Unity Health Toronto subsequently joined the initiative, creating a four-hospital pilot.</p>
<p>According to the November 3 announcement, average research study activation timelines in the pilot decreased by more than 75 per cent, from 448 days to 109 days.</p>
<p>The framework is supporting 43 collaborative research studies at various stages of implementation, including projects involving cancer, cardiovascular disease and Alzheimer’s disease.</p>
<p>These early results demonstrate the potential for streamlined administrative processes to reduce the time required to initiate collaborative medical research.</p>
<p><strong>Strengthening Canada’s research competitiveness</strong></p>
<p>The agreement comes as Canada faces growing international competition for clinical trials, research investment and scientific talent.</p>
<p>According to the participating institutions, Canada’s clinical trial activity declined 11 per cent in 2024, while its international ranking for industry-sponsored Phase 3 trials fell from fifth to eighth.</p>
<p>The 14 hospitals participating in the agreement collectively represent a significant component of Canada’s healthcare research infrastructure.</p>
<p>Their combined research funding exceeded $1.7 billion in fiscal 2025.</p>
<p>Participating institutions include SickKids, CAMH, Sunnybrook Health Sciences Centre, University Health Network, Sinai Health, Women’s College Hospital, Trillium Health Partners and several other leading academic hospitals.</p>
<p><strong>Implementation will take place in phases</strong></p>
<p>Although all 14 hospitals have signed the agreement, implementation will occur gradually as institutions adapt their internal research processes.</p>
<p>The framework is intended to simplify collaboration while maintaining institutional requirements for research ethics, privacy, security and oversight.</p>
<p>For researchers, the initiative could reduce administrative duplication and make it easier to launch studies involving multiple healthcare organizations.</p>
<p>For patients, the longer-term objective is to support faster development and evaluation of new treatments and healthcare innovations.</p>
<p>The agreement also provides a potential model for other Canadian academic health networks seeking to improve research collaboration.</p>
<p><strong>Source:</strong> <a href="https://trilliumhealthpartners.ca/newsroom/Pages/2026/14-leading-Toronto-hospitals-sign-landmark-agreement.aspx?utm_source=chatgpt.com">Trillium Health Partners — November 3, 2026 announcement</a> and <a href="https://tahsn.ca/master-collaboration-agreement?utm_source=chatgpt.com">TAHSN Master Collaboration Agreement</a>.</p>
<p>The post <a href="https://www.hospitalnews.com/14-canadian-hospitals-join-forces-to-accelerate-medical-research/">14 Canadian hospitals join forces to accelerate medical research</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>PACE panel notes challenges IRA poses for patients</title>
<link>https://edusehat.com/en/pace-panel-notes-challenges-ira-poses-for-patients</link>
<guid>https://edusehat.com/en/pace-panel-notes-challenges-ira-poses-for-patients</guid>
<description><![CDATA[ Changes brought on by the Inflation Reduction Act (IRA) often increase patient costs and reduce access, while also harming the innovation that brings new […]
The post PACE panel notes challenges IRA poses for patients appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/11/JDR_4635-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 04 Nov 2026 20:05:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>PACE, panel, notes, challenges, IRA, poses, for, patients</media:keywords>
<content:encoded><![CDATA[<p><span>Changes brought on by the Inflation Reduction Act (IRA) often increase patient costs and reduce access, while also harming the innovation that brings new treatments, according to patient advocates.</span></p>
<p><span>Correcting the situation requires raising the patient voice and telling patient stories, said panelists at BIO’s Patient Advocacy Changemakers Event (PACE), in Washington DC, Oct. 22-23. PACE has been held annually for 15 years and provides a unique opportunity for patient advocates, the biotech industry, and other stakeholders to promote the development of new treatments.</span></p>
<p><span>“The Inflation Reduction Act was signed into law about four years ago now. Are patients better off?” asked</span><a href="https://pace.bio.org/2026-program/cui-bono-benefits-price-controls-1"> <span>panel</span></a><span> moderator</span><a href="https://pace.bio.org/speakers/karin-hoelzer"> <span>Karin Hoelzer, BIO Senior Director of Patient Advocacy</span></a><span>.</span></p>
<p><span>On balance, panelists maintained, patients are not better off. IRA price controls clearly create a barrier to access by discouraging investment in innovative new drugs, but there are many other more direct, negative impacts on patients, the panelists said.</span></p>
<h2>The out-of-pocket cap and Medicare Part D</h2>
<p><span>If there is good news out of IRA it is the out-of-pocket cap on annual payments by patients whose prescriptions are covered by Medicare Part D, said the panelists,</span><a href="https://pace.bio.org/speakers/jennifer-snow"> <span>Jennifer Snow, Founder and Managing Director – Apteka</span></a><span>, and</span><a href="https://pace.bio.org/speakers/patrick-wildman"> <span>Patrick Wildman, SVP of Advocacy & Government Relations – Lupus Foundation of America</span></a><span>.</span></p>
<p><span>Both cautioned that the Part D redesign that brought about the cap also brings in some challenges.</span></p>
<p><span>“For people who have high costs to address their medical needs, the cap would be really important for them,” said Wildman. “But for people who don’t hit the cap, their costs may actually have gone up as a result of the IRA. And that’s simply because there’s been a shift from co-pays to cost share.”</span></p>
<p><span>Both he and Snow also expressed concern about what the IRA would mean for future changes in Part D.</span></p>
<p><span>“I worry about the long-term kind of return on investment of the Inflation Reduction Act when we’re looking ahead to the Part D redesign,” said Snow. “From a beneficiary perspective, I think we’re in for a huge, huge shift in terms of Part D. The benefit is just not stable right now, and I think longer term, we’re going to be looking for solutions on how to ensure that Part D can stay at least as great as it is now.”</span></p>
<p><span>One immediate challenge brought about by the cap has been an escalation of insurance companies’ utilization management practices, which create barriers to accessing drugs, according to Wildman.</span></p>
<p><span>Snow agreed: “We’re up to like 50% of branded drugs requiring prior authorization in Part D,” she said. “It’s just under 10% for step therapy.”</span></p>
<h2>Part B and other price controls</h2>
<p><span>Another area where future changes could cause problems is in Medicare Part B, which covers drugs that are administered by a professional provider. Under IRA, these drugs will be subject to price controls in 2028, and the result will likely be new challenges to access, the panelists said.</span></p>
<p><span>“We don’t know what reimbursement mechanism they’re going to use for providers, and the providers may be underwater,” Snow said. “If providers can no longer afford to provide those negotiated drugs, what happens to access?”</span></p>
<p><span>“There are real impacts on patients. And I think our role is to show what those impacts are,” Wildman said. “In the case of a low reimbursement for administering a price-negotiated drug, the downstream impacts are the patient doesn’t get that drug or they have to change providers.”</span></p>
<p><span>Along with the IRA, the panel also looked at other mechanisms to control prices, including Prescription Drug Affordability Boards (PDABs), which are being used by several states to control or cap the reimbursement insurers, state Medicaid programs, and public entities pay for prescription drugs.</span></p>
<p><span>“Much like the Inflation Reduction Act, PDABs look at drug pricing and affordability,” but from a state perspective, Snow said. “Is it affordable to the state who’s trying to set it up or affordable for the patient? Those two cannot be reconciled. And I think we see that on the federal level, too. Drug pricing is not about affordability. From a patient advocacy perspective, the more we push back on that notion, I think, the stronger the affordability story becomes.”</span></p>
<h2>Patient stories</h2>
<p><span>Wildman agreed that the approach states take with PDABs tends to ignore the patient’s perspective, and said that federal efforts at drug price control are similarly challenged. He said patient advocates are trying to make the Centers for Medicare & Medicaid Services (CMS) take patients into account when deciding on their actions.</span></p>
<p><span>“I think that is part of the solution, making sure that CMS is fully engaged with the patient community and is looking at us not only as a partner in ensuring the stability of the program but also the future of the program,” he said.</span></p>
<p><span>Snow reached out to the audience of patients and patient advocates at PACE, asking for their help by sharing their stories.</span></p>
<p><span>“Those who are patient advocates, your experiences, the experiences of the people you represent, are critical to helping inform our white papers, or issue briefs, or comment letters. Or you can go to CMS yourself and share your experience,” Snow said.</span></p>
<p><span>She added that CMS used to listen to taxpayers who fund them and patients who used their services, but that has changed.</span></p>
<p><span>“Over time, it has felt more like there are other stakeholders who are getting the voice. And I think it’s time to wrench that back and make sure that the patient voice is heard. For that, we’ll need your stories,” Snow said.</span></p>
<p>The post <a href="https://bio.news/federal-policy/pace-panel-notes-challenges-ira-poses-for-patients/">PACE panel notes challenges IRA poses for patients</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Alamar, Nightingale Health Team up on UK Biobank Neurodegeneration Protein Study</title>
<link>https://edusehat.com/en/alamar-nightingale-health-team-up-on-uk-biobank-neurodegeneration-protein-study</link>
<guid>https://edusehat.com/en/alamar-nightingale-health-team-up-on-uk-biobank-neurodegeneration-protein-study</guid>
<description><![CDATA[ Nightingale Health will run the measurements in its labs using Alamar’s NULISA platform to quantify hundreds of blood proteins in 80,000 UK Biobank samples, seeking early molecular signs of neurodegeneration.
The post Alamar, Nightingale Health Team up on UK Biobank Neurodegeneration Protein Study appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-1869420709.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 04 Nov 2026 09:15:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Alamar, Nightingale, Health, Team, Biobank, Neurodegeneration, Protein, Study</media:keywords>
<content:encoded><![CDATA[<p>Many of the blood proteins that could flag <a href="https://www.genengnews.com/?s=neurodegeneration&filter=&page=null" target="_blank" rel="noopener">neurodegeneration</a> are so scarce that standard assays barely register them. A new UK Biobank study will test whether an ultrasensitive platform can pick them up across 80,000 blood samples, potentially years before symptoms appear.</p>
<p>Alamar Biosciences and Nightingale Health announced the UK Biobank Proteomics for Risk Identification and Signatures of brain health in Midlife (UKB-PRISM) study on November 2, 2026. Nightingale will run the measurements in its own laboratories using Alamar’s NULISA platform, quantifying hundreds of circulating proteins in samples from UK Biobank participants. The Michael J. Fox Foundation for Parkinson’s Research, Alzheimer’s Research UK, and LifeArc are funding the work, which is expected to be completed by the end of 2027.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>NULISA, short for NUcleic acid Linked Immuno-Sandwich Assay, pairs antibodies tagged with DNA oligonucleotides to capture a target protein. A capture-and-release process washes away background signal, and the DNA reporters are then read out by next-generation sequencing.</p>
<p>The timing reflects a growing view that the biology behind Alzheimer’s and Parkinson’s disease begins years before diagnosis. The companies noted that Alzheimer’s and other dementias affect more than 55 million people worldwide and Parkinson’s affects more than 12 million, with both projected to rise sharply by 2050.</p>
<p>“Working with Nightingale and UK Biobank, we can now measure those signals across tens of thousands of people, years before symptoms appear, and give researchers everywhere a new way to ask when and why these diseases begin,” said Yuling Luo, PhD, Alamar’s founder, CEO, and chair.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>UK Biobank’s deputy chief scientist, Adam Lewandowski, PhD, said proteins help repair tissue, regulate inflammation, and support countless bodily functions, “yet we still know relatively little about how they work together to influence brain health.”</p>
<p>Samantha Hutten, PhD, principal biomarker scientist, translational research at the Michael J. Fox Foundation, said the data could help “evaluate potential biomarkers and inform future therapeutic research.” LifeArc CEO Sam Barrell said the resource could also help lay “the groundwork for more accurate diagnosis” of rare dementias, which can be difficult to diagnose because their symptoms overlap with other conditions.</p>
<p>After the study is completed, the full dataset will be made available to approved researchers worldwide through the UK Biobank Research Analysis Platform.</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/alamar-nightingale-health-team-up-on-uk-biobank-neurodegeneration-protein-study/">Alamar, Nightingale Health Team up on UK Biobank Neurodegeneration Protein Study</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Recursion Eyes H2 2027 Pivotal Trial for Lead Candidate After Positive Phase II FAP Data</title>
<link>https://edusehat.com/en/recursion-eyes-h2-2027-pivotal-trial-for-lead-candidate-after-positive-phase-ii-fap-data</link>
<guid>https://edusehat.com/en/recursion-eyes-h2-2027-pivotal-trial-for-lead-candidate-after-positive-phase-ii-fap-data</guid>
<description><![CDATA[ Following 12 weeks of treatment, Recursion said, 87% of patients (13 of 15) had a reduction in total polyp burden, with a 47% median reduction. Approximately one in three patients achieved reductions of ≥65%. 
The post Recursion Eyes H2 2027 Pivotal Trial for Lead Candidate After Positive Phase II FAP Data appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/recursion-pharma-1024x576-1.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 04 Nov 2026 05:40:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Recursion, Eyes, 2027, Pivotal, Trial, for, Lead, Candidate, After, Positive, Phase, FAP, Data</media:keywords>
<content:encoded><![CDATA[<p>Recursion said it expects to launch its first registrational trial in the second half of this year for its lead candidate REC-4881 based on talks with the FDA, after the oral familial adenomatous polyposis (FAP) therapy generated positive mid-stage clinical data.</p>
<p>Most patients treated with REC-4881 showed reductions in both the number of larger, higher-risk polyps and in lower GI polyp burden, according to updated data from the Phase Ib/II TUPELO trial (<a href="https://clinicaltrials.gov/study/NCT05552755" target="_blank" rel="noopener">NCT05552755</a>). That data was presented by Lisa Boardman, MD, a gastroenterologist and Professor of Medicine at Mayo Clinic, at the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer (CGA-IGC) Annual Meeting, being held through Wednesday in Denver.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>“REC-4881 is reducing the larger polyps that often drive much of the surgery for these [FAP] patients, across the GI tract from a single oral therapy,” Najat Khan, PhD, Recursion’s president and CEO, said in a statement. “This is a lifelong disease with no approved pharmacologic therapies, and REC-4881 is the clearest proof point yet of what we built Recursion to do.”</p>
<p>Recursion said its anticipated second half 2027 timing for a registrational trial will depend on its talks with the FDA, with additional details set to be provided later this year.</p>
<p>Recursion announced the REC-4881 data after the close of markets on Monday. The news appeared to make little impression on investors, as Recursion shares stayed all but flat Tuesday as of 12:55 pm ET, inching up 0.1% to $3.84, a penny above yesterday’s closing price.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<h4><strong>Licensed from Takeda</strong></h4>
<p>REC-4881 is a first-in-class, oral allosteric inhibitor of MEK1 and MEK2 that Recursion is developing through a global licensing agreement with Takeda Pharmaceutical signed in 2020 and covering FAP and related areas of oncology. Recursion agreed to pay Takeda $1.5 million upfront, up to $39.5 million in payments tied to achieving development and regulatory milestones, plus low-to-mid single-digit royalties on net sales of products containing the drug by Recursion, its affiliates, or sublicensees.</p>
<p>Takeda initially developed the drug as TAK-733 and used Recursion’s artificial intelligence (AI) platform to uncover targeted areas of oncology where the drug could be effective.</p>
<p>For FAP, a rare genetic disorder, the standard of care has long consisted of lifelong active endoscopic surveillance and eventual prophylactic surgical removal of the colon.</p>
<p>“People have been doing research in the chemoprevention space in FAP for decades, and at least in the United States, we still don’t have an agent that is FDA approved,” stated Bryson Katona, MD, PhD, TUPELO study investigator and director of the GI Cancer Genetics Program, University of Pennsylvania Perelman School of Medicine. “We’re still having to send FAP patients for major surgeries and we’re still doing frequent scopes on these patients. The need for effective chemoprevention in FAP is very large, and it’s only going to increase over time as the number of FAP patients continues to increase.”</p>
<p>Estimates of prevalence FAP vary widely. While Recursion has counted >50,000 FAP patients in the United States and EU5 (France, Germany, Italy, Spain, and the United Kingdom), other institutions have shared figures showing FAP to affect <a href="https://www.jax.org/education-and-learning/clinical-and-continuing-education/clinical-topics/cancer-resources/fap-and-afap" target="_blank" rel="noopener">approximately one in 6,800 to 31,000 individuals worldwide</a>, including <a href="https://rarediseases.org/rare-diseases/familial-adenomatous-polyposis/" target="_blank" rel="noopener">about one in 5,000 to 10,000 Americans</a>.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>Recursion is among biopharmas working to develop treatments for FAP.</p>
<p>One FAP treatment is already in Phase III study—eRapa<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley">, which since 2024 has been developed by Biodexa Pharmaceuticals under an exclusive global license from Emtora Biosciences, which licensed eRapa from the University of Texas (UT) Health San Antonio in 2012, when Emtora was known as Rapamycin Holdings.</p>
<p>eRapa is an oral tablet formulation of the mTOR inhibitor rapamycin (sirolimus), sold in generic versions; Pfizer ceased selling the branded version, Rapamune<sup>®</sup>, in 2023. Last month, Biodexa said it had enrolled 100 patients in its registrational Phase III Seranta trial (<a href="https://clinicaltrials.gov/study/NCT06950385" target="_blank" rel="noopener">NCT06950385</a>) of eRapa, which has an estimated primary completion date of July 2030.</p>
<p>Also in clinical trials for FAP is Tempest Therapeutics’ TPST-1495, a first-in-class oral small molecule selective dual EP2 and EP4 prostaglandin receptor antagonist targeting prostaglandin E2 (PGE2) signaling in the tumor microenvironment. In March, Tempest launched a Phase II open label trial (<a href="https://clinicaltrials.gov/study/NCT06557733" target="_blank" rel="noopener">NCT06557733</a>) designed to assess how well TPST-1495 reduces the number of polyps in the small bowel and colon in patients with FAP. The study’s estimated enrollment is 38 patients with primary completion expected June 30, 2027.</p>
<p>Recursion’s TUPELO trial was designed to study polyp burden reduction after 12 weeks on REC-4881 (4mg once daily) and again after 12 weeks off-treatment. Following 12 weeks of treatment, Recursion said, 87% of patients (13 of 15) had a reduction in total polyp burden after 12 weeks of treatment, with a 47% median reduction. Approximately one in three patients achieved reductions of ≥65%.</p>
<p>Since the initial November 2025 data cut, all four patients added to the study showed a reduction in total polyp burden, including two patients with 89% and 98% reduction, respectively. At Week 25, after 12 weeks off treatment, 85% of patients (11 of 13) remained below baseline.</p>
<p>Recursion reasons that the persistence of polyp burden reduction below baseline in most patients studied may allow for dosing flexibility.</p>
<h4><strong>‘Certainly encouraging’</strong></h4>
<p>“Seeing durability over a twelve-week course is certainly encouraging. In longer trials we’ll see exactly how long that durability lasts, but I think it is a very encouraging first sign for this drug,” Katona said.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>Within the upper GI tract, 92% of patients (12 of 13) had reductions in polyp burden after 12 weeks of treatment, with a 55% median reduction. Nearly half (six of 13) achieved reductions of ≥65%, more than one in three achieved ≥75%, and two patients achieved reductions of ≥98%. Half (six of 12) improved by at least one Spigelman stage at Week 13, while 92% (11 of 12) remained below baseline at Week 25, after 12 weeks off-treatment, and six of 11 had equal or greater reductions during the off-treatment period than during treatment.</p>
<p>Within the lower GI tract, nine of 11 patients (82%) with measurable polyp burden at baseline had reductions after 12 weeks of treatment, with a 50% median reduction, and four of 11 achieved reductions of 65% or more. At Week 25, after 12 weeks off-treatment, seven of 10 patients remained below baseline.</p>
<p>Six of eight patients that showed polyps greater than 5 mm at baseline had reductions in the number of these polyps after 12 weeks of treatment. Four achieved reductions of ≥80%, including two whose larger-polyp counts fell from more than 90 polyps to one. In both of those patients, all of the larger polyps were in the upper GI tract.</p>
<h4><strong>One patient, 98% reduction</strong></h4>
<p>The highest responder was a patient who went from 1,344 mm of total polyp burden to 32 mm, a 98% reduction, and from 96 upper GI polyps >5 mm to one. Recursion cautioned that the patient was not representative of the overall population.</p>
<p>The company also cautioned that the study collected its polyp counts using >5 mm as the largest size category; separate counts for polyps >10 mm were not collected.</p>
<p>Six of the eight patients assessed at Week 25 were below their baseline count after 12 weeks off treatment. Most of the larger polyps at baseline were in the upper GI, Recursion said.</p>
<p>No new safety signals were observed as of the data cutoff in the expanded patient population, which includes patients 18 and older. Most treatment-related adverse events (TRAE), according to recursion, were Grade 1 or 2 (21 of 26 patients, 80.8%). The highest-grade TRAE was Grade 3 in four patients (15.4%), and there were no Grade 4 or 5 TRAEs.</p>
<p>The most common TRAEs were consistent with MEK1/2 inhibition, including dermatitis acneiform, rash, CPK increase, diarrhea, and asymptomatic LVEF decrease. Adverse events were manageable, and most resolved within 12 weeks off treatment. Four patients were discontinued for Grade 1 or 2 TRAEs, with no discontinuations for a Grade 3 event.</p>
<p>Recursion announced the clinical data along with third quarter earnings that showed a reduced quarterly net loss year over year. Recursion ended the third quarter with a net loss of $119.036 million, compared to a net loss of $162.253 million for Q3 2025, on revenue that tripled to $18.552 million from $5.175 million. For Q1-Q3 2026, Recursion cut its net loss to $367.545 million from $536.637 million a year ago.</p>
<p>The post <a href="https://www.genengnews.com/topics/artificial-intelligence/recursion-eyes-h2-2027-pivotal-trial-for-lead-candidate-after-positive-phase-ii-fap-data/">Recursion Eyes H2 2027 Pivotal Trial for Lead Candidate After Positive Phase II FAP Data</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Precision Automation Meets Biology</title>
<link>https://edusehat.com/en/precision-automation-meets-biology</link>
<guid>https://edusehat.com/en/precision-automation-meets-biology</guid>
<description><![CDATA[ In this GEN podcast, a cellular workflow automation specialist from Molecular Devices explores what precision automation means for working biologists and how purpose-built instruments, software, and expertise can support it. The conversation covers where variability creeps into cell-based work, how automation can take over routine tasks, and how instruments, software, and scientific expertise can work together. It also considers how a lab’s needs shift as their work matures, and what that means for choosing the right tools at each step.
The post Precision Automation Meets Biology appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Getty_1435758706_LabEquipment.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 04 Nov 2026 05:40:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Precision, Automation, Meets, Biology</media:keywords>
<content:encoded><![CDATA[<p></p>

<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow">
<p class="wp-block-paragraph">For laboratories running cell-based research, automation can mean high-throughput work, but its real value is in reducing repetitive work, controlling variability between experiments, and boosting consistency while still supporting flexible processes. Small manual inconsistencies can have an outsized impact, and the tools that are meant to help can sometimes get in the way. Precision automation ensures that the technology serves the question being asked.</p>


<p class="wp-block-paragraph">In this <em>GEN</em> podcast, a cellular workflow automation specialist from Molecular Devices explores what precision automation means for working biologists and how purpose-built instruments, software, and expertise can support it. The conversation covers where variability creeps into cell-based work, how automation can take over routine tasks, and how instruments, software, and scientific expertise can work together. It also considers how a lab’s needs shift as their work matures, and what that means for choosing the right tools at each step.</p>


<p class="wp-block-paragraph"></p>
</div>


<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow">
<h4 class="wp-block-heading has-text-align-center"><strong>Podcast Guest: </strong></h4>


<figure class="wp-block-image aligncenter size-full is-resized webinar-pic-caption td-caption-align-center"><img fetchpriority="high" decoding="async" width="1400" height="1400" src="https://www.genengnews.com/wp-content/uploads/2026/11/MattStoltz-_Headshot.jpg" alt="Matt Stoltz" class="wp-image-340164" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/MattStoltz-_Headshot.jpg 1400w, https://www.genengnews.com/wp-content/uploads/2026/11/MattStoltz-_Headshot-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/MattStoltz-_Headshot-1024x1024.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/MattStoltz-_Headshot-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/MattStoltz-_Headshot-768x768.jpg 768w" sizes="(max-width: 1400px) 100vw, 1400px"><figcaption class="wp-element-caption"><strong>Matt Stoltz</strong><br>Sr. Cellular Workflow Automation Specialist<br>Molecular Devices</figcaption></figure>
</div>
</div>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column sponsor-box is-layout-flow wp-block-column-is-layout-flow">
<p class="wp-block-paragraph"><strong>Sponsored by</strong></p>


<figure class="wp-block-image size-medium is-resized"><a href="https://www.moleculardevices.com/" target="_blank" rel="noreferrer noopener"><img decoding="async" width="300" height="68" src="https://www.genengnews.com/wp-content/uploads/2023/03/Molecular-Devices_Logo_Color-300x68.png" alt="Molecular Devices logo" class="wp-image-221725" srcset="https://www.genengnews.com/wp-content/uploads/2023/03/Molecular-Devices_Logo_Color-300x68.png 300w, https://www.genengnews.com/wp-content/uploads/2023/03/Molecular-Devices_Logo_Color-1024x232.png 1024w, https://www.genengnews.com/wp-content/uploads/2023/03/Molecular-Devices_Logo_Color-768x174.png 768w, https://www.genengnews.com/wp-content/uploads/2023/03/Molecular-Devices_Logo_Color-1536x348.png 1536w, https://www.genengnews.com/wp-content/uploads/2023/03/Molecular-Devices_Logo_Color-2048x464.png 2048w, https://www.genengnews.com/wp-content/uploads/2023/03/Molecular-Devices_Logo_Color-696x158.png 696w, https://www.genengnews.com/wp-content/uploads/2023/03/Molecular-Devices_Logo_Color-1392x315.png 1392w, https://www.genengnews.com/wp-content/uploads/2023/03/Molecular-Devices_Logo_Color-1068x242.png 1068w, https://www.genengnews.com/wp-content/uploads/2023/03/Molecular-Devices_Logo_Color-1920x435.png 1920w, https://www.genengnews.com/wp-content/uploads/2023/03/Molecular-Devices_Logo_Color-1853x420.png 1853w" sizes="(max-width: 300px) 100vw, 300px"></a></figure>
</div>
</div>

<p>The post <a href="https://www.genengnews.com/topics/omics/precision-automation-meets-biology/">Precision Automation Meets Biology</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Lost and Found: Neural Pathway for Forgetting Found in C. elegans</title>
<link>https://edusehat.com/en/lost-and-found-neural-pathway-for-forgetting-found-in-c-elegans</link>
<guid>https://edusehat.com/en/lost-and-found-neural-pathway-for-forgetting-found-in-c-elegans</guid>
<description><![CDATA[ Researchers identified the key molecular and neural pathways that cause the nematode Caenorhabditis elegans to actively forget a specific odor it previously remembered, providing a framework for understanding how specific memories are differentially eliminated.
The post Lost and Found: Neural Pathway for Forgetting Found in C. elegans appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2023/05/GettyImages-1128676754-e1765821893874.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 04 Nov 2026 02:05:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Lost, and, Found:, Neural, Pathway, for, Forgetting, Found, elegans</media:keywords>
<content:encoded><![CDATA[<p>For as long as human inquiry has existed, people have tried to understand how and why we remember and forget. As we have begun to understand how the brain works, researchers have slowly uncovered the biological mechanisms underlying memory. Researchers from Kyushu University have now found the key molecular and neural pathways that cause the nematode worm <em>Caenorhabditis elegans</em> to actively forget a specific odor it previously remembered.</p>
<p>Through extensive studies of the <em>C. elegans</em> nervous system, the team discovered that a peptide called NLP-47 triggers this process of active forgetting. NLP-47 is received by a different neuron further along the circuit, which in turn sends a signal to the neuron storing the memory of the odor, leading to its erasure. Most strikingly, when <em>C. elegans</em> memorized two different odors simultaneously, this circuit erased the memory of only one odor while leaving the other intact.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>“There are many diseases that involve memory loss,” said research lead Professor Takeshi Ishihara, PhD, at Kyushu University Faculty of Science. “But before we can understand what goes wrong, we need to understand how forgetting works in the brain, and I hope this research will lead to a better understanding of such brain functions.”</p>
<p>Ishihara is senior and corresponding author of the researchers’ published paper in <em>Current Biology</em>, titled “<a href="http://dx.doi.org/10.1016/j.cub.2026.10.015" target="_blank" rel="noopener">Neuropeptidergic-glutamatergic circuit regulates selective forgetting of olfactory learning</a>.” In their paper the authors concluded that their findings may “… offer insights into disorders associated with dysregulated forgetting, including dementia and PTSD.”</p>
<p>Forgetting specific memories is “… as essential as forming them,” the authors wrote. “…  animals must selectively discard irrelevant experiences while preserving others to adapt to constantly changing environments.” But as they further noted, “Despite proposals of selective forgetting in psychological frameworks, the molecular and neuronal mechanisms underlying this selectivity remain largely unexplored.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>Ishihara commented, “Research on memory has focused on how it is formed and maintained. How memories are lost has received less attention. We usually think of forgetting as a failure of memory. But forgetting is just as essential for adaptation and survival. This raises a question: How does the brain decide which memories to erase?”</p>
<p>To uncover the mechanism of active forgetting, the team has been studying the model organism <em>C. elegans, </em>a nematode with only 302 neurons. Because each neuron has been identified, it is possible to trace a memory and its erasure to specific neurons. <em>C. elegans</em> are blind but have an exceptional sense of smell. <a href="https://doi.org/10.1016/j.celrep.2013.02.019" target="_blank" rel="noopener">In 2013,</a> Ishihara’s team used <em>C. elegans</em> to identify the neurons that cause the active forgetting of a specific odor memory housed in another neuron.</p>
<p>However, at that time, the team could not identify the molecules that activate this pathway. For their newly reported study first author and PhD candidate Yuuki Onishi, and colleagues set out to identify the responsible molecules. The researchers trained <em>C. elegans</em> to learn a specific smell, diacetyl. “<em>C. elegans</em> exhibits chemoattraction to various odorants, including diacetyl …” they explained. After about four hours—the time it usually takes for the organism to forget a smell—diacetyl was administered again. If the <em>C. elegans</em> moved toward the diacetyl smell, it meant that it had forgotten the memory, if not, the memory had been retained.</p>
<p>The <em>C. elegans</em> olfactory system comprises two pairs of sensory neurons, AWA and AWC, which receive volatile attractive odorants. In a previous study, Ishihara’s team identified that AWA neurons store the memory of the odor, and that memory was erased by signals from AWC neurons. Experiments aiming to identify the “forgetting” signal released by AWC identified the neuropeptide NLP-47 and its receptor GNRR-1. When the team then investigated which neural circuits these two factors affected, they discovered that AIZ neurons, which are located between AWC and AWA, were involved. “Neuropeptide NLP-47, secreted from AWC neurons, regulates forgetting of the olfactory memory through its receptor GNRR-1, an orthologue of the human GnRH receptor, in AIZ interneurons,” the scientists wrote.</p>
<figure aria-describedby="caption-attachment-340135" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="size-medium wp-image-340135" src="https://www.genengnews.com/wp-content/uploads/2026/11/Low-Res_Ishihara-release-figure-1-300x169.jpg" alt="When C. elegans learns two odors at the same time, the two memories do not share the same fate. Four hours later, the memory of diacetyl has faded while the memory of isoamyl alcohol remains. The researchers identified the neuropeptide and the neural circuit that direct this selective forgetting. [Takeshi Ishihara/Kyushu University] " width="300" height="169" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Low-Res_Ishihara-release-figure-1-300x169.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Low-Res_Ishihara-release-figure-1.jpg 700w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">When <em>C. elegans</em> learns two odors at the same time, the two memories do not share the same fate. Four hours later, the memory of diacetyl has faded while the memory of isoamyl alcohol remains. The researchers identified the neuropeptide and the neural circuit that direct this selective forgetting. [Takeshi Ishihara/Kyushu University]</figcaption></figure>
<p>Ishihara further explained, “First, AWC releases NLP-47 and activates the GNRR-1 receptor on the AIZ neurons. The AIZ neurons would then release glutamate, another neurotransmitter. The glutamate then acts on the GLR-4 receptor on the AWA neurons that house the memory of the scent, leading to active forgetting. When we used optogenetics to suppress the activity of the AWC and AIZ neurons, we found that the nematodes were more resilient to forgetting.”</p>
<p>Follow-up experiments revealed that this active forgetting was highly specific. When nematodes were trained to remember two odors—diacetyl and isoamyl alcohol—simultaneously, the NLP-47/GNRR-1 pathway only forgot the diacetyl smell. “Simultaneous conditioning with two odorants revealed that neuropeptidergic-glutamatergic signaling selectively promotes forgetting of diacetyl memory without affecting isoamyl alcohol memory … indicating that forgetting can be regulated in a memory-specific manner,” the investigators stated.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p><em>C. elegans</em> in which NLP-47/GNRR-1 or glutamate did not function were more resistant to forgetting the smells. “Discovering that this forgetting system is not indiscriminate and can target a specific memory is fascinating,” Onishi said. “At first, I was not expecting to find such a concrete mechanism of active forgetting with a remarkable specificity. I hope this research will lead to a deeper understanding of forgetting and eventually to more insights on conditions and pathologies involving memory.”</p>
<p>Commented Ishihara, “Interestingly, receptors like GNRR-1 are found in other organisms, including humans. In rodents, these receptors are found in the hippocampus, the brain’s center for memory, although their role there is not yet known. Our findings may also lead to an understanding of the mechanisms by which mammals forget specific memories.”</p>
<p>In their paper the authors concluded, “Our findings provide a framework for understanding how specific memories are differentially eliminated and suggest that such mechanisms extend to other species.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/lost-and-found-neural-pathway-for-forgetting-found-in-c-elegans/">Lost and Found: Neural Pathway for Forgetting Found in <i>C. elegans</i></a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>2026–2027 Residency Match Timeline Explained (IMG + U.S. Students)</title>
<link>https://edusehat.com/en/20262027-residency-match-timeline-explained-img-us-students</link>
<guid>https://edusehat.com/en/20262027-residency-match-timeline-explained-img-us-students</guid>
<description><![CDATA[ If you’re planning to apply for the 2026–2027 residency match, it can feel like there are a hundred tasks to remember, and they all matter. Between ERAS, personal statements, letters of recommendation, interviews, and ranking, it’s easy to feel overwhelmed before you even begin.   The good news is that the Match follows a fairly […]
The post 2026–2027 Residency Match Timeline Explained (IMG + U.S. Students) appeared first on Elite Medical Prep. ]]></description>
<enclosure url="https://elitemedicalprep.com/wp-content/uploads/2026/11/pexels-towfiqu-barbhuiya-3440682-9810172-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 03 Nov 2026 22:45:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>2026–2027, Residency, Match, Timeline, Explained, IMG, U.S., Students</media:keywords>
<content:encoded><![CDATA[<p><span>If you’re planning to apply for the 2026–2027 residency match, it can feel like there are a hundred tasks to remember, and they all matter. Between ERAS, personal statements, letters of recommendation, interviews, and ranking, it’s easy to feel overwhelmed before you even begin.</span></p>
<p> </p>
<p><span>The good news is that the Match follows a fairly predictable timeline every year. Once you understand the sequence of events and what you should be focusing on at each stage, the process becomes much more manageable.</span></p>
<p> </p>
<p><span>This guide will walk you through the key milestones step by step so you can stay organized, reduce stress, and put together the strongest application possible.</span></p>
<p> </p>
<h2><b>Spring–Early Summer 2026: Laying the Groundwork</b></h2>
<p><span>Before the application cycle officially opens, this is your preparation phase, and it’s one of the most important parts of the entire process.</span></p>
<p> </p>
<p><span>For U.S. students, this is the time to finalize your Step 2 CK (if you haven’t already), complete core rotations, and make a decision about your specialty choice. For IMGs, this period is especially critical for ensuring your ECFMG certification is on track, completing exams, and securing U.S. clinical experience if possible.</span></p>
<p> </p>
<p><span>Across the board, this is when you should begin working on your application materials. Start <a href="https://elitemedicalprep.com/tackling-the-residency-personal-statement/">drafting your personal statement</a> early, even if it’s just a rough version. <a href="https://elitemedicalprep.com/residency-letters-of-recommendation-everything-you-need-to-know/">Reach out to potential letter writers</a> and give them plenty of time, strong letters rarely come from last-minute requests.</span></p>
<p> </p>
<p><span>It’s also a good time to start building your program list. Think broadly at first, then refine based on competitiveness, geography, and overall fit.</span></p>
<p> </p>
<h2><b>June–August 2026: ERAS Opens and Application Assembly</b></h2>
<p><span>ERAS typically opens in early summer, and this is when things start to feel real.</span></p>
<p> </p>
<p><span>You’ll begin entering your experiences, uploading your personal statement, and assigning letters of recommendation. This stage can take longer than expected, especially when it comes to <a href="https://elitemedicalprep.com/navigating-the-eras-application-tips-to-dos/">describing your activities clearly and thoughtfully</a>.</span></p>
<p> </p>
<p><span>A common mistake here is rushing through the application just to “get it done.” Programs do read these sections carefully, and small details, like how you describe your clinical experiences, can make a difference.</span></p>
<p> </p>
<p><span>For IMGs, make sure all required documents are uploaded and verified as early as possible. Delays in documentation can impact when your application is considered complete.</span></p>
<p> </p>
<p><span>Your goal during this period is simple: have everything ready well before submission opens.</span></p>
<p> </p>
<h2><b>September 2026: Application Submission</b></h2>
<p><span>This is one of the most important milestones in the entire process.</span></p>
<p> </p>
<p><span>Applications are typically submitted in mid-to-late September, and timing matters. Submitting your application on time, or ideally on the first day it opens, ensures that programs review your application as early as possible.</span></p>
<p> </p>
<p><span>At this point, your focus should shift from building your application to double-checking everything. Make sure your personal statement is polished, your letters are assigned correctly, and your experiences are accurate.</span></p>
<p> </p>
<p><span>Once you hit submit, there’s a natural urge to keep tweaking things, but in reality, most programs will review your application as it is at submission. This is why preparation beforehand is so critical.</span></p>
<p> </p>
<h2><b>October–January: Interview Season</b></h2>
<p><span>After submission, the waiting game begins, but not for long. Interview invitations typically start going out in October and can continue through December or even January. Some specialties have coordinated interview release dates while others have rolling invitations that come out throughout these months. </span></p>
<p> </p>
<p><span>This period can feel unpredictable. Some students receive multiple invitations early, while others may wait longer. Both experiences are normal.</span></p>
<p> </p>
<p><span>Once interviews begin, your role shifts again, from applicant to storyteller. Programs already know your scores and experiences; now they want to understand who you are, how you think, and how you’ll fit into their team.</span></p>
<p> </p>
<p><span>Preparation is key. Practice common interview questions, reflect on your experiences, and be ready to discuss your journey clearly and authentically. Prepare for polished answers but don’t sound too rehearsed or scripted. </span></p>
<p> </p>
<p><span>It’s also important to stay organized. Keep track of interview dates, program details, and your impressions after each interview. These notes will become incredibly valuable when it’s time to rank programs. I recommend creating a spreadsheet with each program name and program features that matter most to you so you can refer back to it when you create your rank list. </span></p>
<p> </p>
<h2><b>January–February: Creating Your Rank List</b></h2>
<p><span>Once interviews wrap up, you’ll move into the ranking phase.</span></p>
<p> </p>
<p><span>This is where you <a href="https://elitemedicalprep.com/nrmp-rank-list-timeline-explained-deadlines-strategy-match-process/">submit your list of programs in order of preference.</a> The Match algorithm is designed to favor the applicant, meaning your best strategy is to rank programs based on where you genuinely want to train, not where you think you’re most likely to match.</span></p>
<p> </p>
<p><span>This can be a surprisingly difficult decision. Factors like location, program culture, clinical exposure, and long-term goals all come into play.</span></p>
<p> </p>
<p><span>Take your time during this phase. Revisit your notes, talk to mentors, and reflect on where you felt most comfortable and supported during interviews.</span></p>
<p> </p>
<p><span>For IMGs, it’s especially important to balance ambition with realism, ensuring your list includes a range of programs. I recommend that unless you’d rather go unmatched than rank a certain program, you include all programs on your rank list. </span></p>
<p> </p>
<h2><b>March 2027: Match Week and Match Day</b></h2>
<p><span>March is when everything comes together.</span></p>
<p> </p>
<p><span>Match Week typically begins on a Monday, when you’ll find out whether you matched. If you did, you’ll wait a few more days until Friday to learn where. If not, you’ll enter the <a href="https://elitemedicalprep.com/understanding-the-supplemental-offer-and-acceptance-program-soap/">Supplemental Offer and Acceptance Program (SOAP)</a>, which is a fast-paced process to secure an unfilled position.</span></p>
<p> </p>
<p><span>Match Day is when you <a href="https://elitemedicalprep.com/how-to-prepare-for-residency-match-day/">officially learn where you’ll be training</a>. It’s one of the most memorable days in your medical journey, and a moment that reflects years of hard work.</span></p>
<p> </p>
<h2><b>Key Differences for IMG Applicants</b></h2>
<p><span>While the overall timeline is the same, <a href="https://elitemedicalprep.com/residency-application-timeline-for-imgs/">IMGs often have additional steps to manage</a>.</span></p>
<p> </p>
<p><span>ECFMG certification, visa considerations, and obtaining U.S. clinical experience can all impact your timeline. Because of this, starting early is even more important.</span></p>
<p> </p>
<p><span>Programs may also review IMG applications differently, placing more emphasis on U.S. experience, Step exam scores, and letters from U.S. physicians. Being proactive and strategic in these areas can make a significant difference. </span></p>
<p> </p>
<p> </p>
<h2><b>Staying Organized (and Sane) Throughout the Process</b></h2>
<p><span>The Match is a long process, and it’s easy to feel overwhelmed at different stages. One of the best things you can do is break it down into manageable phases, focus on what matters now, rather than worrying about everything at once.</span></p>
<p> </p>
<p><span>It’s also important to remember that there’s no single “perfect” path. Some applicants receive early interviews, others later. Some feel confident throughout, others second-guess themselves. These variations are normal.</span></p>
<p> </p>
<p><span>What matters most is consistency, putting together a strong application, preparing thoughtfully for interviews, and making decisions that align with your goals.</span></p>
<p> </p>
<h2><b>Final Thoughts</b></h2>
<p><span>The 2026–2027 Match cycle may feel daunting, but it follows a clear structure. Once you understand the timeline and what’s expected at each stage, you can approach the process with much more confidence.</span></p>
<p> </p>
<p><span>Start early, stay organized, and focus on steady progress. You don’t need to have everything figured out right away, you just need to take the next step, one phase at a time.</span></p>
<p> </p>
<p data-pm-slice="1 1 []">If you’d like guidance along the way, <a href="https://elitemedicalprep.com/residency-advising/">Elite Medical Prep’s residency advising</a> can help you strengthen your application, prepare for interviews, and build your rank list with confidence. Schedule a complimentary consultation to discuss your goals and get personalized support.</p>
<p> </p>
<p><span>And before you know it, you’ll be opening that Match Day envelope and stepping into the next chapter of your medical career. Remember…it just takes 1 interview to get your match! </span></p>
<p>The post <a href="https://elitemedicalprep.com/residency-match-timeline-explained-img-and-us-students/">2026–2027 Residency Match Timeline Explained (IMG + U.S. Students)</a> appeared first on <a href="https://elitemedicalprep.com/">Elite Medical Prep</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Israeli surgeons perform pioneering robotic&#45;assisted lung transplant without traditional chest opening</title>
<link>https://edusehat.com/en/israeli-surgeons-perform-pioneering-robotic-assisted-lung-transplant-without-traditional-chest-opening</link>
<guid>https://edusehat.com/en/israeli-surgeons-perform-pioneering-robotic-assisted-lung-transplant-without-traditional-chest-opening</guid>
<description><![CDATA[ Surgeons at Beilinson Hospital in Israel have performed the country’s first robotic-assisted lung transplant using small incisions instead of the extensive chest opening traditionally associated with the procedure. The operation, carried out in October at Beilinson Hospital in Petah Tikva, used the da Vinci robotic surgical system to connect a transplanted lung to the recipient’s […]
The post Israeli surgeons perform pioneering robotic-assisted lung transplant without traditional chest opening appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/11/lungsurgery.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 03 Nov 2026 22:25:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Israeli, surgeons, perform, pioneering, robotic-assisted, lung, transplant, without, traditional, chest, opening</media:keywords>
<content:encoded><![CDATA[<p>Surgeons at Beilinson Hospital in Israel have performed the country’s first robotic-assisted lung transplant using small incisions instead of the extensive chest opening traditionally associated with the procedure.</p>
<p>The operation, carried out in October at Beilinson Hospital in Petah Tikva, used the da Vinci robotic surgical system to connect a transplanted lung to the recipient’s blood vessels and airway.</p>
<p>The procedure places the hospital among a small number of medical centres worldwide to have performed robotic-assisted lung transplantation. According to the hospital, approximately 20 such procedures have been performed globally.</p>
<h3>A less invasive approach to complex surgery</h3>
<p>Traditional lung transplantation often requires surgeons to open the chest extensively to access the lungs, sometimes involving division of the breastbone or separation of the ribs.</p>
<p>Although the procedure can be lifesaving, the surgical approach can cause substantial postoperative pain and make breathing, coughing and clearing lung secretions difficult during recovery.</p>
<p>The robotic-assisted technique is designed to reduce trauma to the chest wall by allowing surgeons to operate through smaller incisions.</p>
<p>Using robotic instruments, the surgical team completed the delicate connections between the donor lung and the recipient’s blood vessels and airway.</p>
<p>The operation was led by Dr. Yuri Peysakhovich, head of thoracic surgery at Beilinson Hospital.</p>
<p>Hospital officials described the achievement as an important step toward making less invasive lung transplantation available to selected patients.</p>
<h3>Encouraging early recovery</h3>
<p>According to the hospital, the patient experienced a favourable early recovery following the procedure.</p>
<p>Dr. Dan Gorfil, director of the hospital’s cardiothoracic surgical intensive care unit, reported that the patient required very little pain medication beyond paracetamol.</p>
<p>The hospital also reported a shorter intensive care stay and overall hospitalization than the team had anticipated.</p>
<p>These observations are encouraging, although the experience of one patient cannot establish whether robotic-assisted lung transplantation consistently produces better outcomes than conventional surgery.</p>
<p>Further procedures, comparative studies and longer-term follow-up will be needed to assess the technique’s safety, effectiveness and suitability for different transplant recipients.</p>
<h3>Extensive preparation and teamwork</h3>
<p>The operation required months of preparation and coordination among numerous hospital departments.</p>
<p>The multidisciplinary team included thoracic surgeons, anesthesiologists, operating room nurses, pulmonologists, cardiopulmonary bypass specialists, intensive care professionals and laboratory personnel.</p>
<p>One of the major challenges involved maintaining patient safety while robotic instruments occupied the surgical field, potentially limiting immediate physical access to the patient.</p>
<p>To prepare, the team conducted a dedicated simulation exercise and developed detailed plans for ventilation, circulation monitoring and emergency intervention.</p>
<p>As an additional precaution, the patient was connected to cardiopulmonary bypass equipment before the procedure, allowing the team to provide immediate support if required.</p>
<h3>Building on earlier experience</h3>
<p>The robotic transplant followed another minimally invasive lung transplant performed at Beilinson approximately one month earlier.</p>
<p>That operation used two small incisions rather than the extensive opening associated with conventional transplantation.</p>
<p>The earlier procedure helped the surgical team develop experience with less invasive access to the chest before undertaking the more technically demanding robotic operation.</p>
<p>Beilinson Hospital has extensive experience in lung transplantation, having performed more than 1,000 lung transplants.</p>
<p>Hospital officials say that experience, combined with specialized robotic training and multidisciplinary planning, was essential to introducing the new technique.</p>
<p>Potential implications for transplant surgery</p>
<p>Robotic-assisted surgery has become increasingly established in several surgical specialties, but lung transplantation remains a particularly demanding application because of the complexity of connecting major blood vessels and airways.</p>
<p>The Beilinson procedure illustrates how robotic technology may expand the possibilities for minimally invasive surgery in highly specialized hospital programs.</p>
<p>For eligible patients, reducing surgical trauma could potentially improve comfort, breathing and mobility during the early recovery period.</p>
<p>However, robotic lung transplantation remains uncommon, and its broader clinical role has not yet been established.</p>
<p>As more hospitals gain experience with the technique, research will be needed to determine which patients may benefit most and whether improvements in recovery can be demonstrated consistently.</p>
<p>The Israeli procedure represents an important technical milestone in the continuing development of transplant surgery.</p>
<p>The post <a href="https://www.hospitalnews.com/israeli-surgeons-perform-pioneering-robotic-assisted-lung-transplant-without-traditional-chest-opening/">Israeli surgeons perform pioneering robotic-assisted lung transplant without traditional chest opening</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Saint John Regional Hospital advances surgical care with $10.9&#45;million fundraising campaign</title>
<link>https://edusehat.com/en/saint-john-regional-hospital-advances-surgical-care-with-109-million-fundraising-campaign</link>
<guid>https://edusehat.com/en/saint-john-regional-hospital-advances-surgical-care-with-109-million-fundraising-campaign</guid>
<description><![CDATA[ Saint John Regional Hospital in New Brunswick is moving forward with two major surgical technology initiatives following the successful completion of a $10.9-million fundraising campaign. The Saint John Regional Hospital Foundation announced November 2 that its Working Wonders Campaign for Surgical Excellence had exceeded its $10.5-million target. The funding will support the development of Atlantic […]
The post Saint John Regional Hospital advances surgical care with $10.9-million fundraising campaign appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/11/New-Brunswick-Hospital-Advances-with-Robotic-Surgery-Technology-Startup-Ecosystem-Canada.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 03 Nov 2026 22:25:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Saint, John, Regional, Hospital, advances, surgical, care, with, 10.9-million, fundraising, campaign</media:keywords>
<content:encoded><![CDATA[<p>Saint John Regional Hospital in New Brunswick is moving forward with two major surgical technology initiatives following the successful completion of a $10.9-million fundraising campaign.</p>
<p>The Saint John Regional Hospital Foundation announced November 2 that its Working Wonders Campaign for Surgical Excellence had exceeded its $10.5-million target.</p>
<p>The funding will support the development of Atlantic Canada’s first cardiac-enabled hybrid operating room and one of Canada’s first spinal robotic surgery programs.</p>
<p>The investments are intended to expand access to specialized surgical services and help more patients receive advanced care closer to home.</p>
<h3>Advancing spinal surgery</h3>
<p>One of the campaign’s major priorities is establishing a robotic spinal surgery program at Saint John Regional Hospital.</p>
<p>The technology is designed to support surgeons during complex spinal procedures by assisting with surgical planning and instrument positioning.</p>
<p>According to the foundation, the investment is already supporting the hospital’s spinal surgery services.</p>
<p>The program also creates opportunities for surgical education and recruitment, helping strengthen the hospital’s capacity to deliver specialized care.</p>
<h3>New hybrid operating room planned</h3>
<p>The second major investment involves construction of a cardiac-enabled hybrid operating room.</p>
<p>A hybrid operating room combines the capabilities of a conventional surgical suite with advanced medical imaging technology, allowing teams to perform procedures that may require both surgical and image-guided techniques.</p>
<p>Construction is underway, with the facility expected to open in 2028.</p>
<p>The planned operating room will support the continued development of specialized cardiac services at the hospital.</p>
<h3>Community support driving healthcare innovation</h3>
<p>The fundraising campaign brought together donors, volunteers and community partners to support the hospital’s surgical modernization efforts.</p>
<p>The $10.9 million raised exceeded the foundation’s original target by approximately $400,000.</p>
<p>Horizon Health Network President and CEO Margaret Melanson welcomed the investments, noting that spinal robotics is already contributing to surgical care while construction progresses on the hybrid operating room.</p>
<p>The initiatives reflect the importance of collaboration between hospital leadership, healthcare professionals and community foundations in supporting major equipment and infrastructure investments.</p>
<p>For New Brunswick patients, the projects represent a significant commitment to expanding specialized surgical capabilities within the province.</p>
<p>The investments also illustrate how Canadian hospitals are incorporating advanced surgical technologies while planning for future clinical needs.</p>
<p>Although the new hybrid operating room remains under construction, the completed fundraising campaign establishes an important milestone in the hospital’s long-term surgical development.</p>
<p>Source: <a href="https://sjrhfoundation.ca/2026/10/29/working-wonders-campaign-raises-10-9-million/?utm_source=chatgpt.com">Saint John Regional Hospital Foundation — Working Wonders Campaign announcement</a>.</p>
<p>The post <a href="https://www.hospitalnews.com/saint-john-regional-hospital-advances-surgical-care-with-10-9-million-fundraising-campaign/">Saint John Regional Hospital advances surgical care with $10.9-million fundraising campaign</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>PACE panel lays out patient input possibilities in PDUFA VIII</title>
<link>https://edusehat.com/en/pace-panel-lays-out-patient-input-possibilities-in-pdufa-viii</link>
<guid>https://edusehat.com/en/pace-panel-lays-out-patient-input-possibilities-in-pdufa-viii</guid>
<description><![CDATA[ The law guiding U.S. drug approval was created to meet the demands of patient advocates, and the patient community still shapes the process. Stakeholders […]
The post PACE panel lays out patient input possibilities in PDUFA VIII appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/11/960px-US_Food_and_Drug_Administration_lapel_pin.png" length="49398" type="image/jpeg"/>
<pubDate>Tue, 03 Nov 2026 04:30:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>PACE, panel, lays, out, patient, input, possibilities, PDUFA, VIII</media:keywords>
<content:encoded><![CDATA[<p><span>The law guiding U.S. drug approval was created to meet the demands of patient advocates, and the patient community still shapes the process.</span></p>
<p><span>Stakeholders discussed their latest opportunity to impact the Prescription Drug User Fee Act (PDUFA), which regulates America’s gold-standard drug approval process, at BIO’s Patient Advocacy Changemakers Event (PACE) in Washington, DC, on Oct. 22-23.</span></p>
<p><span>PDUFA has roots in the 1980s, when ACT UP activists fought for AIDS patients, according to Steve Berman, VP for Science and Regulatory Affairs Strategy at the Biotechnology Innovation Organization (BIO), who led the PDUFA discussion at PACE.</span></p>
<p><span>“At that time, drug development in the U.S. was very different than it is today. Seventy percent of all new medicines were available outside the U.S. before they were available here,” and drug review often took three years, Berman said. “At the height of the AIDS crisis, patients couldn’t get drugs to save their lives. Patient advocates said this was unacceptable.”</span></p>
<p><span>Congress responded with PDUFA. First passed in 1992 and reauthorized every five years, PDUFA requires drug makers to pay fees to help fund the Food and Drug Administration (FDA). In return, FDA is required to provide a professional, efficient approval process. Before the act, FDA drug review averaged close to 29 months, and today the average is down to 10 months,</span><a href="https://www.pharmacytimes.com/view/understanding-the-fda-approval-process-and-pdufa-dates"> <span>according to a report</span></a><span>.</span></p>
<p><span>“It is absolutely critical to have a functional FDA, to have a well-funded FDA, to have an FDA that has processes and the infrastructure allowing for more regulatory certainty,” said panelist Adora Ndu, Chief Regulatory Officer and EVP of Portfolio Strategy at BridgeBio Pharma. Along with Berman, Ndu represented the biotech industry during recent negotiations with FDA to create</span><a href="https://bio.news/federal-policy/pdufa-letter-stresses-stability-transparency-maturity-says-bio-negotiator/"> <span>a proposal for the contents of PDUFA VIII</span></a><span>.</span></p>
<h2>Why PDUFA reauthorization matters to patients</h2>
<p><span>The reauthorization process, which provides an excellent opportunity for patient input into FDA operations, is currently underway.</span></p>
<p><span>The process began with a public meeting, including many speakers from the patient advocacy community. This transitioned to the biopharma industry, represented by BIO and others, negotiating with FDA officials about the fees industry will pay and the services and initiatives the agency will provide in return. The six-month-long negotiations ended in August with the</span><a href="https://bio.news/federal-policy/pdufa-letter-stresses-stability-transparency-maturity-says-bio-negotiator/"> <span>PDUFA VIII commitment letter</span></a><span>.</span></p>
<p><span>Throughout negotiations, FDA had monthly check-ins with stakeholder groups consisting of 50-60 patient advocates. That input was crucial, according to Ndu.</span></p>
<p><span>“[FDA] would pull from the stakeholder meetings to say, ‘This is what we’re hearing, how does it inform the direction that we should take?’ ” she said.</span></p>
<p><span>Patient input continues as Congress uses the commitment letter’s proposals to create PDUFA legislation, which must be reauthorized by September 2027.</span></p>
<p><span>“Patient advocacy groups play an important role in helping educate Congress members about the importance of user fees overall and the details of this particular agreement, and also in shaping any policies that may come along as riders,” said Berman.</span></p>
<p><span>As panelist Jeff Allen, President and CEO of Friends of Cancer Research, told the session at PACE, PDUFA updates are essential.</span></p>
<p><span>“Science and technology are evolving rapidly,” Allen said. “This five-year process gives us all the opportunity to check in and make sure policies are in place to keep pace with the science.”</span></p>
<p><span>Along with adding necessary updates, Congress members often use the “must-pass” nature of the act to add riders that are not central to PDUFA’s mission. As Congress increasingly delays “must-pass” legislation, that strategy is risky, Allen said.</span></p>
<p><span>“I’m sure we will see some good ideas from various policy proposals that could appropriately ride along this PDUFA package,” Allen said. “But I think we have to keep this relatively narrow, in order to make sure that we don’t inadvertently derail an important process.”</span></p>
<h2>Increasing patient voice in drug development<b> </b></h2>
<p><span>The proposal in the commitment letter aimed at achieving the basic, but challenging, goal of ensuring FDA operates efficiently, according to Ndu. This resulted in a PDUFA VIII commitment letter that contains improvements to increase patient participation, she said.</span></p>
<p><span>Ndu highlighted some provisions benefiting the rare disease community, including continuing the successful</span><a href="https://www.fda.gov/industry/fda-rare-disease-innovation-hub/rare-disease-innovation-science-and-exploration-rise-workshop-series"> <span>Rare Disease Innovation, Science, and Exploration (RISE) workshop series</span></a><span>. The PDUFA VIII commitment letter envisions 10 RISE workshops.</span></p>
<p><span>RISE workshops “enable a discussion around the barriers in drug development, bringing all the stakeholders together to ensure conversation can happen and can actually translate into enabling more treatments,” Ndu said.</span></p>
<p><span>The entire patient community can benefit from “continuation of patient-focused drug development activities from prior PDUFAs,” proposed in PDUFA VIII, according to Berman.</span></p>
<p><span>“FDA would be required to hold multiple public meetings talking about how they consider patient-focused drug development and patient preferences in their regulatory decision making,” he said.</span></p>
<p><span>Ideally, FDA should include data from patient experiences in their drug labelling, and this is a step in that direction, Ndu said, noting that “FDA will share some of the case studies of how they have considered patient experience data.”</span></p>
<p><span>Berman maintained that PDUFA VIII’s improved patient engagement opportunities will result in better drug development.</span></p>
<p><span>“One of the reasons why drug development is so slow and expensive is that science is challenging,” he explained. “And the best way to address scientific challenges is as a community.”</span></p>
<p>The post <a href="https://bio.news/federal-policy/pace-panel-lays-out-patient-input-possibilities-in-pdufa-viii/">PACE panel lays out patient input possibilities in PDUFA VIII</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Inflammatory Process Identified as Link Between Pulmonary Hypertension and Cognitive Decline</title>
<link>https://edusehat.com/en/inflammatory-process-identified-as-link-between-pulmonary-hypertension-and-cognitive-decline</link>
<guid>https://edusehat.com/en/inflammatory-process-identified-as-link-between-pulmonary-hypertension-and-cognitive-decline</guid>
<description><![CDATA[ A study investigating the observed connection between pulmonary hypertension and cognitive decline symptoms has linked brain abnormalities in pulmonary hypertension to the same inflammatory processes that drive disease in the lungs and heart. 
The post Inflammatory Process Identified as Link Between Pulmonary Hypertension and Cognitive Decline appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/low-res-1-e1793639966551.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 03 Nov 2026 04:25:18 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Inflammatory, Process, Identified, Link, Between, Pulmonary, Hypertension, and, Cognitive, Decline</media:keywords>
<content:encoded><![CDATA[<p>A study by University of Pittsburgh and UPMC researcher-clinicians has uncovered why many pulmonary hypertension (PH) patients report symptoms of cognitive decline.</p>
<p>The team carried out a multimodal investigation involving brain MRI studies, blood-based molecular profiling, and functional studies in mouse models, and linked specific brain abnormalities in pulmonary hypertension to the same inflammatory processes that drive the disease in the lungs and heart. The findings suggest that cognitive decline may be present in other vascular and inflammatory conditions beyond pulmonary hypertension. The results also point to neural targets that may be relevant for future diagnostic, prognostic, and therapeutic approaches.</p>
<p>“Patients often assume memory issues or trouble concentrating are unrelated to their pulmonary hypertension,” said research lead Stephen Chan, MD, PhD, Vitalant Chair in Vascular Medicine and director of the Vascular Medicine Institute and Center for Pulmonary Vascular Biology and Medicine at the Pitt School of Medicine and UPMC. “Our findings suggest those symptoms are a central part of the disease process and deserve attention.”</p>
<p>Chan is senior author of the researchers’ published paper in <em>Journal of Clinical Investigation</em>, titled “<a href="https://doi.org/10.1172/JCI195110" target="_blank" rel="noopener">Cerebellar and frontal lobe alterations in pulmonary hypertension implicate an inflammatory lung vascular/brain axis</a>.”</p>
<p>Millions of people are affected by pulmonary hypertension, which causes high blood pressure in the blood vessels of the lungs. Common symptoms include shortness of breath, chest pain, and feeling lightheaded. More recently scientists have linked pulmonary hypertension with cognitive issues such as impaired executive function and memory problems. “Cognitive impairment is increasingly recognized in pulmonary hypertension (PH), a disease traditionally viewed as limited to the heart and lungs,” the authors wrote. “Given that inflammation is shared by PH and neurodegenerative diseases, we investigated its role in driving brain and cognitive deficits in PH.”</p>
<p>Recent research by Chan identified a genetic variant in a gene called NCOA7, which produces a protein of the same name. In a quarter of pulmonary hypertension patients, this variant drives inflammatory responses and worsens the odds of survival. Chan hypothesized that the same variant might be connected to brain inflammation that leads to cognitive impairment in people with pulmonary hypertension.</p>
<p>To test that theory, Chan and colleagues used brain MRI scans and blood tests to look for brain changes that were unique to pulmonary hypertension. They first compared the brain scans of people with pulmonary hypertension against those without, using data from a large public health database and a smaller group of UPMC patients to test and confirm their hypothesis.</p>
<p>Patients with pulmonary hypertension in both test groups had a consistent and substantial loss of brain tissue and weakened communication between two brain regions involved in memory, attention and planning—the cerebellum, at the base of the brain, and the frontal lobe, just behind the forehead. Notably, the same brain changes were absent in people with other heart, lung, and psychiatric conditions. “Using structural and functional MRI data from UK Biobank (N = 248 PH) and a prospective validation cohort, we identified reduced cerebellar white matter volume, thinner frontal gyri, and weakened cerebellar-frontal connectivity in patients with PH but not in other heart or lung diseases,” the team reported. These changes were accompanied by worsened executive function and processing speed.”</p>
<p>The brain differences could not be explained by low blood oxygen, poor heart function, or the medications used to treat the disease—evidence that the changes are specific to pulmonary hypertension, rather than a side effect of the disease’s effects on the heart and lungs.</p>
<p>By analyzing genetic data from both groups of patients and conducting additional laboratory studies, the team found that the NCOA7 variant already linked to blood vessel inflammation in pulmonary hypertension is also connected to inflammation in the cerebellum of these patients.</p>
<p>Examining cerebellum tissue from patients and mice with pulmonary hypertension, they saw signs that brain immune cells—microglia—had become overactive, and evidence that neurons were changing in response. Mice that both developed the disease and lacked the NCOA7 gene had more severe cerebellar damage than mice with pulmonary hypertension alone, establishing that the gene plays a causal role in regulating brain inflammation in this disease. “Postmortem analysis and PH mouse models showed cerebellar microglial activation and structural deficits worsened by NCOA7 deficiency,” the investigators wrote in summary. “Collectively, these findings support PH-associated cerebellar–frontal brain deficiencies linked to chronic neuroinflammation and NCOA7 dysfunction.”</p>
<p>Chan suspects that this mechanism is active in other diseases beyond pulmonary hypertension. “I believe that NCOA7 deficiency may underlie a spectrum of inflammatory conditions—including those that may contribute to dementia and aging,” Chan said. “If so, these findings could introduce new diagnostic and therapeutic avenues for preserving brain function in a much broader group of people.” The authors added: “From a translational perspective, the association of inflammatory plasma biomarkers with structural and functional brain alterations may inform new diagnostic and prognostic strategies … Our findings also open avenues for testing whether PH-associated neuroinflammatory changes are therapeutically reversible.”</p>
<p>Current guidelines for managing pulmonary hypertension do not include cognitive screening, and no biological marker exists to predict or track how much the disease affects the brain. This study points to a potential marker and identifies inflammation as a potential therapeutic target for preserving brain function and quality of life.</p>
<p>“This changes the way we look at a disease like pulmonary hypertension,” said Chan. “In medicine, we typically treat the symptoms of one organ system; but the reality is that our bodies are very complex, and disease processes may be affecting multiple parts of the body in a variety of ways.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/inflammatory-process-identified-as-link-between-pulmonary-hypertension-and-cognitive-decline/">Inflammatory Process Identified as Link Between Pulmonary Hypertension and Cognitive Decline</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>FDA Sets May 1 PDUFA Action Date for uniQure’s Huntington’s Disease Gene Therapy</title>
<link>https://edusehat.com/en/fda-sets-may-1-pdufa-action-date-for-uniqures-huntingtons-disease-gene-therapy</link>
<guid>https://edusehat.com/en/fda-sets-may-1-pdufa-action-date-for-uniqures-huntingtons-disease-gene-therapy</guid>
<description><![CDATA[ uniQure has aligned with the FDA on what the company calls key elements of the confirmatory study design: The study is being designed as a randomized, standard-of-care trial enrolling approximately 200 patients in a 2:1 ratio of ifezuntirgene inilparvovec to standard of care, with Total Functional Capacity (TFC) at 36 months serving as the primary endpoint. 
The post FDA Sets May 1 PDUFA Action Date for uniQure’s Huntington’s Disease Gene Therapy appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/uniQURE-EXTERIOR_1583081674129-EDITED-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 03 Nov 2026 04:25:16 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>FDA, Sets, May, PDUFA, Action, Date, for, uniQure’s, Huntington’s, Disease, Gene, Therapy</media:keywords>
<content:encoded><![CDATA[<p>The FDA has set a May 1 target action date under the Prescription Drug User Fee Act (PDUFA) for uniQure’s Huntington’s disease gene therapy candidate ifezuntirgene inilparvovec—which, if approved, would be the first treatment shown to modify the fatal, inherited neurodegenerative disorder—after accepting the company’s Biologics License Application (BLA) under Priority Review.</p>
<p>The action by the FDA, announced Monday, marks a complete reversal of agency opposition that surfaced last year and hardened earlier this year.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>The FDA did caution uniQure, however, that it was tentatively planning to discuss the BLA at a future advisory committee meeting, most likely the Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC). No date for such a meeting had been set at deadline, though uniQure said it was told it would be notified by the agency when that happens.</p>
<p>uniQure submitted its BLA to the FDA in September, as well as a Marketing Authorization Application (MAA) to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA).</p>
<p>“The FDA’s acceptance of our BLA for review marks an important milestone for the Huntington’s disease community, which has waited generations for a treatment that changes the course of this devastating disease,” uniQure CEO Matt Kapusta said in a statement.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>One analyst offered another reason for the significance of the FDA action: “We see the acceptance of the BLA as an important milestone for ifezuntirgene inilparvovec as it further removes regulatory risk,” Lachlan Hanbury-Brown, research analyst, healthcare with William Blair, wrote in a research note.</p>
<h4><strong>Investor caution</strong></h4>
<p>However, investors appeared more cautious, as uniQure shares dipped 3% to $24.03 as of 10:56 am. ET from $24.83 at Friday’s close despite the positive news. Chatter on investor websites suggested several possible reasons why investors were reluctant to buy uniQure stock:</p>
<ul>
<li>The PDUFA target action date was later than expected.</li>
<li>Four-year data for the gene therapy showed lower slowing of disease progression than earlier three-year data.</li>
<li>Continuing concerns about risk in the ongoing trials.</li>
</ul>
<p>Ifezuntirgene inilparvovec uses the company’s gene-silencing miQURE<sup>®</sup> platform and incorporates a microRNA designed to silence the huntingtin gene and the potentially highly toxic exon 1 protein fragment. Patients receive a single administration through targeted, MRI-guided, convection-enhanced stereotactic neurosurgical delivery directly into the striatum (caudate and putamen).</p>
<p>uniQure has aligned with the FDA on what the company calls key elements of the confirmatory study design: The study is being designed as a randomized, standard-of-care trial enrolling approximately 200 patients in a 2:1 ratio of ifezuntirgene inilparvovec to standard of care, with Total Functional Capacity (TFC) at 36 months serving as the primary endpoint.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>uniQure said it plans to begin patient screening in the United States by the end of 2026.</p>
<p>In addition to Priority Review, uniQure’s BLA for ifezuntirgene inilparvovec has been granted the FDA’s Breakthrough Therapy, Regenerative Medicine Advanced Therapy (RMAT), and Fast Track designations.</p>
<p>The FDA reversal follows a change in leadership at the Center for Biologics Evaluation and Research (CBER) as Vinayak (Vinay) Prasad, MD, who opposed uniQure’s BLA, resigned for the second time in March, effective April 30. Prasad relinquished his roles as CBER director and FDA chief medical and scientific officer under Martin A. Makary, MD, who resigned effective May 12.</p>
<h4><strong>FDA stunner</strong></h4>
<p>Under Prasad, the FDA <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.genengnews.com%2Ftopics%2Fgenome-editing%2Funiqure-staggers-as-fda-questions-data-for-huntingtons-gene-therapy-candidate%2F&data=05%7C02%7Calex.philippidis%40sagepub.com%7C7d6a4029d2a441dd46ed08de7c76c9f6%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639085047353474402%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=zbb16UnyYtcIzvKJGmCgGhleaCrz7ncpqJsnuw8swco%3D&reserved=0">stunned uniQure in November 2025</a> when it told the company that what it had called “game-changing” data in September, showing <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.genengnews.com%2Ftopics%2Fgenome-editing%2Fgene-therapy-significantly-slows-huntington-disease-progression%2F&data=05%7C02%7Calex.philippidis%40sagepub.com%7C7d6a4029d2a441dd46ed08de7c76c9f6%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639085047353487080%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=F%2FolhGKO8AE54WlV%2Fc6TJjlvmFLZggg9Q1UPJRElcU4%3D&reserved=0">significant slowing of HD progression</a> in patients treated with the gene therapy candidate, may not be enough to secure FDA approval. The data prompted one analyst to predict ifezuntirgene inilparvovec (then known as AMT-130) would <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.genengnews.com%2Ftopics%2Ftranslational-medicine%2Fstockwatch-uniqure-shares-reach-five-year-high-on-game-changing-huntingtons-data%2F&data=05%7C02%7Calex.philippidis%40sagepub.com%7C7d6a4029d2a441dd46ed08de7c76c9f6%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639085047353516935%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=7dQJW8yAGUGNEDXNL%2FkI%2FRDGud7CWET2H02EuVJtU7E%3D&reserved=0">generate $4 billion peak worldwide annual sales by 2032</a>, though a consensus of other analysts forecasted just $1.7 billion in peak sales.</p>
<p>Key among uniQure’s Phase I/II results was the statistically significant 75% slowing of disease progression as measured by the composite Unified Huntington’s Disease Rating Scale (cUHDRS) at 36 months in patients treated with the high dose of 6×10<sup>13</sup> gc/subject of ifezuntirgene inilparvovec, compared to a propensity score-matched external control derived from the Enroll-HD natural history database. That more than met the primary endpoint of the Phase I/II study, which consisted of trials in the United States (<a href="https://clinicaltrials.gov/study/NCT04120493">NCT04120493</a>) and Europe (<a href="https://clinicaltrials.gov/study/NCT05243017">NCT05243017</a>).</p>
<p>The FDA stepped up its public criticism against uniQure on March 2, when it issued what the company termed a “strong” recommendation to conduct a prospective, randomized, double-blind, sham surgery-controlled study to support a future marketing application for AMT-130. The FDA concluded that data from uniQure’s earlier Phase I/II study, which compared ifezuntirgene inilparvovec to an external control, were not sufficient to provide the primary evidence of effectiveness needed for the agency to approve the gene therapy candidate.</p>
<p>UniQure stock responded to the FDA jawboning by plummeting 42% on March 2 and 3, then flattening in the middle of that week, before rebounding 58% by March 6. The <a href="https://www.genengnews.com/topics/genome-editing/stockwatch-under-fire-from-fda-uniqure-stock-roller-coasters/">stock gyrations followed Prasad announcing his resignation plans</a>.</p>
<p>In June, with Karim Mikhail then serving as acting CBER director, the FDA reversed itself and <a href="https://www.genengnews.com/topics/translational-medicine/stockwatch-positive-phase-iii-data-sells-investors-on-intellia/">accepted the three-year analysis</a> from the two Phase I/II trials as the primary basis of a Biologics License Application (BLA) for accelerated approval of ifezuntirgene inilparvovec. Mikhail has since been appointed permanent CBER director.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<h4><strong>Four-year data</strong></h4>
<p>Last month, uniQure reported positive four-year data for ifezuntirgene inilparvovec showing a continued slowing of disease progression based on the two ongoing Phase I/II studies. At 48 months TFC, the primary measure of uniQure’s confirmatory study, showed consistent slowing of functional decline, with absolute treatment benefit maintained in Month 48. Differences seen between the high and low doses on both composite cUHDRS and TFC were consistent with a dose-dependent treatment effect, uniQure said.</p>
<p>The primary endpoint of cUHDRS showed a 44% slowing of disease progression (non-significant p=0.144) while TFC showed a 61% slowing of disease progression (nominal p=0.008), according to uniQure.</p>
<p>“While efficacy in the high-dose group as measured by the cUHDRS softened from year 3 to year 4 and thus could point to a weakening of treatment effect, we see concerns from this endpoint as overdone given several caveats in the analysis, and the fact that it is not the primary endpoint of the confirmatory study or the basis for the current BLA,” Hanbury-Brown commented.</p>
<p>“We believe the additional 48-month results from the ongoing Phase I/II study of AMT-130 in HD continue to show a positive clinical benefit, especially around the more important regulatory endpoint of TFC, which increased separation from the external control group from 3 to 4 years following treatment,” Hanbury-Brown added.</p>
<p>In its announcement Monday, uniQure said the two trials have dosed 51 patients with ifezuntirgene inilparvovec. The U.S. randomized study enrolled 26 patients, of which six received a low dose of ifezuntirgene inilparvovec, 10 a high dose, and 10 a sham procedure. Four control patients subsequently crossed over to treatment after approximately 12 months.</p>
<p>The European open-label study enrolled 13 patients—six receiving low-dose ifezuntirgene inilparvovec and seven, the high dose. A third cohort of 12 patients explored both doses in combination with immunosuppression, while and a fourth cohort of six U.S. patients is evaluating the high dose in patients with lower striatal volumes compared to those enrolled in previous cohorts.</p>
<p>The post <a href="https://www.genengnews.com/topics/genome-editing/fda-sets-may-1-pdufa-action-date-for-uniqures-huntingtons-disease-gene-therapy/">FDA Sets May 1 PDUFA Action Date for uniQure’s Huntington’s Disease Gene Therapy</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>FDA Delays PDUFA Action on Agios’ Mitapivat sNDA for SCD</title>
<link>https://edusehat.com/en/fda-delays-pdufa-action-on-agios-mitapivat-snda-for-scd</link>
<guid>https://edusehat.com/en/fda-delays-pdufa-action-on-agios-mitapivat-snda-for-scd</guid>
<description><![CDATA[ The FDA has delayed a decision on Agios Pharmaceuticals’ supplemental New Drug Application (sNDA) seeking additional approval for mitapivat in sickle cell disease (SCD) until next year. 
The post FDA Delays PDUFA Action on Agios’ Mitapivat sNDA for SCD appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Aug16_2016_Getty_481945753_SickleCellRedCells.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 03 Nov 2026 00:50:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>FDA, Delays, PDUFA, Action, Agios’, Mitapivat, sNDA, for, SCD</media:keywords>
<content:encoded><![CDATA[<p>The FDA has delayed a decision on Agios Pharmaceuticals’ supplemental New Drug Application (sNDA) seeking additional approval for mitapivat in sickle cell disease (SCD) until next year. The FDA has extended its target action date under the Prescription Drug User Fee Act (PDUFA) by three months, from the originally scheduled November 1, 2026, to February 1, 2027, Agios acknowledged in a statement.</p>
<p>Investors punished Agios with a stock selloff that sent the company’s share price slumping nearly 18% from $37.23 to $30.55 on Friday.</p>
<p>The three-month extension was triggered by what the FDA deemed a major amendment to the sNDA—namely the submission, at the agency’s request, of additional information to assess whether a Risk Evaluation and Mitigation Strategy (REMS) would be necessary for mitapivat in SCD.</p>
<p>Agios responded to the FDA on October 19 by submitting approximately nine months of updated safety data through October 9 from the ongoing open-label extension periods of the Phase II/III RISE UP trial (<a href="https://clinicaltrials.gov/study/NCT05031780">NCT05031780</a>).</p>
<p>According to <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01480-7/fulltext">data published October 24 in <em>The Lancet</em></a>, 56 (41%) of 138 patients in the mitapivat group showed a hemoglobin response, compared with two (3%) of 69 patients on placebo (95% CI; two-sided p<0·0001). The annualized rate (95% CI) of sickle cell pain crises was 2.6 for mitapivat compared with 3.1 for placebo (two-sided p=0.1213). Serious adverse events were reported in 28 (20%) patients on mitapivat vs. 20 (29%) patients on placebo; one mitapivat patient’s event was deemed treatment related.</p>
<p>Mitapivat, an oral pyruvate kinase activator, “has the potential to be an effective and convenient disease-modifying treatment for people with sickle cell disease, researchers concluded in the study.</p>
<p>The new data, Agios said, continued to show no cases of hepatocellular injury (HCI) among patients with SCD treated with mitapivat who showed a pattern and severity similar to those observed trials for mitapivat in adults with thalassemia, Agios stated, adding that the risk-benefit profile of mitapivat in SCD remained unchanged.</p>
<h4><strong>“More cautious stance”</strong></h4>
<p>“Based on our recent conversations/inbounds, investors were focused on the potential for a REMS in SCD and how the FDA might be considering safety in this patient population, and we see the news being perceived by the market as signaling a more cautious stance from the FDA overall,” Tessa T. Romero, a senior analyst focused on biotechnology equity research with J.P. Morgan, wrote in a research note.</p>
<p>Romero added that the delay “also seems to be surprising the market,” as Agios investors are concerned the agency’s action narrows mitapivat’s potential first-to-market advantage relative to Novo Nordisk’s SCD candidate etavopivat, which Novo has told investors it would advance to a first regulatory filing in the fourth quarter of this year.</p>
<p>Agios has, since January, marketed mitapivat as a treatment for thalassemia, under the name Aqvesme®. Mitapivat is also marketed for hemolytic anemia under the name Pyrukynd®. Both mitapivat drugs combined have generated $65.491 million in net product revenue during the first half of this year, more than triple (209% above) the $21.181 million racked up during January–June 2025.</p>
<p>The company plans to report third quarter results on Thursday.</p>
<p>“Even if a REMS is necessary, management expects no additional delays and is launch ready. While the extension could delay the commercial launch by ~3 months, management does not believe it changes the commercial opportunity,” Andrew Berens, MD, senior managing director, targeted oncology and a senior research analyst with Leerink Partners, wrote in a research note.</p>
<p>Berens projected in April that mitapivat in SCD had a 60% chance of reaching the market, with peak sales of about $550 million in the United States.</p>
<h4><strong>“Interesting period”</strong></h4>
<p>“We believe Agios is navigating an interesting period, with the Aqvesme launch in thalassemia underway,” Romero commented. “That said, we struggle to see meaningful near-term upside for the stock and think it may take some time for investors to gain conviction in the launch trajectory of mitapivat in SCD, if/when approved.”</p>
<p>Agios said it will continue its labeling discussions with the FDA, including elements of a potential REMS, and will keep working closely with the agency to bring mitapivat to the market as soon as possible.</p>
<p>“We have strong conviction in mitapivat’s potential to transform care for people living with sickle cell disease, grounded in the comprehensive data from the RISE UP clinical program and further supported by the additional data we submitted in response to the FDA’s recent request,” Agios CEO Brian Goff said in a statement.</p>
<p>Agios’ sNDA was submitted under the FDA’s accelerated approval pathway, and has been granted Priority Review. The accelerated approval requires a confirmatory clinical trial—a condition Agios is satisfying through the Phase III REIGNITE trial (<a href="https://clinicaltrials.gov/study/NCT07656415">NCT07656415</a>), which dosed its first patient in July. The trial is designed to demonstrate the clinical benefit of mitapivat on reducing transfusion burden in patients aged 12 years and older with sickle cell disease.</p>
<p>“We are launch-ready, building on our commercial infrastructure and the strong relationships we have established over several years with hematologists, sickle cell centers, and patients,” Goff added. “We will continue to work expeditiously with the goal of bringing mitapivat to patients with sickle cell disease as soon as possible.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/fda-delays-pdufa-action-on-agios-mitapivat-snda-for-scd/">FDA Delays PDUFA Action on Agios’ Mitapivat sNDA for SCD</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Sentira Brings Claude’s AI to 10x Genomics’ Chromium Platform</title>
<link>https://edusehat.com/en/sentira-brings-claudes-ai-to-10x-genomics-chromium-platform</link>
<guid>https://edusehat.com/en/sentira-brings-claudes-ai-to-10x-genomics-chromium-platform</guid>
<description><![CDATA[ 10x Genomics launches Sentira, an Anthropic Claude-powered AI platform designed to accelerate single-cell data analysis, broaden research access, and streamline workflows while raising questions about expertise and AI reliability.
The post Sentira Brings Claude’s AI to 10x Genomics’ Chromium Platform appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/GettyImages-2253444748.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 03 Nov 2026 00:50:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Sentira, Brings, Claude’s, 10x, Genomics’, Chromium, Platform</media:keywords>
<content:encoded><![CDATA[<p>Ask any single cell researcher for their biggest experimental bottlenecks, and they will say data analysis. Going back to the beginning of the field, there has always been a “last mile problem,” notes Michael Schnall-Levin, PhD, CTO of 10x Genomics. Why? Because researchers have unique experimental methods and questions, each of which involves some level of writing their own analysis code. It has been “not scalable to write software that can do everything for everyone.”</p>
<p>But now, with advances in LLMs, researchers can use tools to answer questions without needing to be bioinformaticians. Today, 10x is launching Sentira Single Cell, a cloud-based agentic analysis powered by Anthropic’s Claude models as an application for Chromium users.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>Schnall-Levin thinks that this will be “massively accelerating” for users. How much faster? “What might have taken someone weeks before could take hours,” he says. And that speed will not only help individual researchers but ultimately, he notes, be beneficial to the pace of scientific research and progress. It is not just about speed, however. Schnall-Levin says that there will like be other benefits. For example, it may reveal results in data that people are not currently seeing.  In addition, the company hopes that Sentira will broaden the group of people who can ask questions of single-cell data directly.</p>
<p>Sentira is, for the company, an umbrella of software capabilities. Sentira spatial was launched a few weeks ago; today’s announcement is specific to single-cell analysis. Sentira is not locked to any model: it can use different LLMs but the Anthropic models are working well, Schnall-Levin reports. And the project follows with Anthropic’s general push into the life science industry.</p>
<p><strong>From virtual lab to AI-powered single-cell analysis</strong></p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>The idea for the Sentira project started at the beginning of 2026, with some work 10x Genomics was doing together with James Zou, PhD, associate professor, Department of Biomedical Data Science at Stanford University. Zou’s name has become infamous with the concept of the “Virtual Lab” which he explains as a laboratory made of algorithms. The idea was first introduced in the 2025 <em>Nature </em>paper, “<a href="https://www.nature.com/articles/s41586-025-09442-9" target="_blank" rel="noopener">The Virtual Lab of AI agents designs new SARS-CoV-2 nanobodies.</a>”</p>
<p>Built on 10x Cloud, Sentira Single Cell provides the computing power needed to analyze Chromium data and run multiple analyses in parallel without requiring researchers to configure or manage their own infrastructure. The customer will interact with a chat interface which will help them go through and dynamically ask questions in the data that involves (on the back end) scripting and writing different analysis code.</p>
<p>10x is not training its own LLM model. Rather, it relies on models from Claude. The company will use researchers’ data to understand how the application is performing and to make improvements. But there is no flow back into the models themselves, the company asserts.</p>
<p><strong>The extra cost of going agentic</strong></p>
<p>The company reports that the cost will be an added “modest” cost. More specifically, the company notes that Sentira pricing is credit-based, through 10x Cloud Credit packs. The rough estimate is that each agentic session costs ~12 credits, with complete analysis through to experimental conclusions requiring around 60 credits. At launch, all users will receive 100 promotional credits for the first Chromium dataset uploaded to Sentira Single Cell, enough for users to become familiar with the platform and get to experimental conclusions. Credit packs are available in a range of sizes, with volume discounts that lower the price per credit as pack size increases. (See below for more specific pricing information.)</p>
<p><strong>The promise and peril of AI-driven analysis</strong></p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>When asked about potential concerns about using AI in this way, Schnall-Levin notes (chuckling) that generally speaking he is “far more nervous about AI risks outside of this.”</p>
<p>One point that they discuss within the company, however, is how—as these tools get more powerful—people may have a tendency to rely on them without thinking. And although 10x does believe that the Sentira tools are accurate, he asserts that they are not perfect. “We don’t want someone to just start putting stuff out in a publication with no additional review. We think that this is a really good way to generate initial analysis and exploration, but people are still on the hook and responsible for it.” People need to understand the power and also the limitations, he notes.</p>
<p>Social media is ripe with discussion on the role of AI in single-cell analysis. Luciano Martelotto, PhD, director of global market development for single cell at Waters Biosciences, has expressed opinions—not about Sentira, specifically—but about using AI to analyze single cell data, in general. He notes one worry which is that “nothing in an AI-generated analysis looks broken. The code runs, the plots are pretty, the story makes sense. The mistakes that matter are the silent ones.”</p>
<p>None of the mistakes are “AI being dumb,” he continues. “It does what it’s asked. What it doesn’t do is get that uneasy feeling when a result looks too good. That feeling comes from having watched data go wrong, and I don’t think it can be prompted or coded into existence… not yet, at least.”</p>
<p>And when data analysis becomes increasingly automated and outsourced, will researchers lose the ability to analyze single cell data on their own?  Schnall-Levin sees this as an age old question about technological progress. He points to how few people today can navigate our location by the stars, because modern technology means that we do not need to. But it is a double-edge sword: expertise may be inevitably be lost as people are empowered to accomplish tasks without having to learn the details. Still, the benefits of these new technologies are very likely to outweigh the downside. Either way, this is the direction the world is moving in, and now the single cell field has another tool to move with it.</p>
<p> </p>
<p><strong>Pricing Information:</strong></p>
<table>
<tbody>
<tr>
<td><strong>Credit Packs</strong></td>
<td><strong>Pack Price</strong></td>
<td><strong>Price per Credit</strong></td>
</tr>
<tr>
<td>10x Cloud Credits – 100 Pack</td>
<td>$120</td>
<td>$1.20</td>
</tr>
<tr>
<td>10x Cloud Credits – 1,000 Pack</td>
<td>$1,150</td>
<td>$1.15</td>
</tr>
<tr>
<td>10x Cloud Credits – 2,000 Pack</td>
<td>$2,200</td>
<td>$1.10</td>
</tr>
<tr>
<td>10x Cloud Credits – 10,000 Pack</td>
<td>$10,500</td>
<td>$1.05</td>
</tr>
<tr>
<td>10x Cloud Credits – 25,000 Pack</td>
<td>$25,000</td>
<td>$1.00</td>
</tr>
</tbody>
</table>
<p>The post <a href="https://www.genengnews.com/topics/omics/sentira-brings-claudes-ai-to-10x-genomics-chromium-platform/">Sentira Brings Claude’s AI to 10x Genomics’ Chromium Platform</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Ottawa researchers identify protein involved in breast cancer development</title>
<link>https://edusehat.com/en/ottawa-researchers-identify-protein-involved-in-breast-cancer-development</link>
<guid>https://edusehat.com/en/ottawa-researchers-identify-protein-involved-in-breast-cancer-development</guid>
<description><![CDATA[ Laboratory findings point to a possible treatment target, but further research is needed. Researchers at The Ottawa Hospital and the University of Ottawa have identified a protein that could offer a target for future breast cancer treatments. The team, led by Dr. Luc Sabourin, studied Sox10 in a mouse model of HER2-positive breast cancer. Removing […]
The post Ottawa researchers identify protein involved in breast cancer development appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/11/Mouse-mammary-gland_1280.jpg.webp" length="49398" type="image/jpeg"/>
<pubDate>Tue, 03 Nov 2026 00:45:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Ottawa, researchers, identify, protein, involved, breast, cancer, development</media:keywords>
<content:encoded><![CDATA[<p>Laboratory findings point to a possible treatment target, but further research is needed.</p>
<p>Researchers at The Ottawa Hospital and the University of Ottawa have identified a protein that could offer a target for future breast cancer treatments.</p>
<p>The team, led by Dr. Luc Sabourin, studied Sox10 in a mouse model of HER2-positive breast cancer. Removing the protein from cells lining the milk ducts prevented tumours from developing.</p>
<p>In separate experiments, deleting Sox10 from tumour cells reduced their capacity to renew themselves. Those cells also failed to grow and spread to other organs when transplanted into mice.</p>
<p>The findings, published in Proceedings of the National Academy of Sciences, come from laboratory and animal research. They do not establish a treatment for patients.</p>
<p>“Our next step is to find and test possible drugs that target this protein,” Sabourin said in the hospital’s announcement.</p>
<p>Sabourin is a senior scientist at The Ottawa Hospital and an associate professor at the University of Ottawa.</p>
<p>Source: <a href="https://ohri.ca/en/newsroom/researchers-uncover-key-ingredient-breast-cancer-initiation">https://ohri.ca/en/newsroom/researchers-uncover-key-ingredient-breast-cancer-initiation</a></p>
<p>The post <a href="https://www.hospitalnews.com/ottawa-researchers-identify-protein-involved-in-breast-cancer-development/">Ottawa researchers identify protein involved in breast cancer development</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The project your team keeps pushing to the future</title>
<link>https://edusehat.com/en/the-project-your-team-keeps-pushing-to-the-future</link>
<guid>https://edusehat.com/en/the-project-your-team-keeps-pushing-to-the-future</guid>
<description><![CDATA[ Behind every appointment is a support and administrative team, and many are stretched thin. An extra pair of hands can help them finally tackle the work that keeps slipping. Patients remember the nurse who comforted them or the physician who explained their care. They often miss the hospital ecosystem of support and administrative staff that […]
The post The project your team keeps pushing to the future appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/11/Health-Studies-Population-Health-Joyce-Jang-3.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 03 Nov 2026 00:45:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, project, your, team, keeps, pushing, the, future</media:keywords>
<content:encoded><![CDATA[<h4><strong>Behind every appointment is a support and administrative team, and many are stretched thin. An extra pair of hands can help them finally tackle the work that keeps slipping.</strong></h4>
<p>Patients remember the nurse who comforted them or the physician who explained their care. They often miss the hospital ecosystem of support and administrative staff that makes every visit possible.</p>
<p>According to a 2026 labour market report by Financial Accountability Office of Ontario, the province’s health care and social assistance sector added 14,700 jobs in 2025 yet still recorded 36,500 vacancies, the most of any major industry in the province. In IT, finance, operations, research administration and communications, every open role means work piles up.</p>
<p>Most teams also carry a list of ideas they never get to: a records clean-up, a better referral tracker, clearer patient instructions. The problem is rarely a lack of will. It is lack of time.</p>
<h3><strong>An extra pair of hands,<span class="Apple-converted-space"> </span>with a plan</strong></h3>
<p>A growing number of health care and research teams are filling that gap with university students on co-op work terms. These are full-time, paid work terms of four, eight or 12 months in support and administrative roles.</p>
<p>This differs from placements, where medical students complete mandatory real-world training in hospitals. Here, the focus is on the support functions that often do not need students with core medical skills but help medical teams do their work.</p>
<p>In practice, a co-op student might keep health records accurate, organize research study files, check data for missing entries or track orders and invoices. A mathematics and statistics student can analyze appointment data to find the busiest times. A computer science student can support IT teams with troubleshooting. A health policy student can organize documentation to help teams keep pace with regulations.</p>
<p>Not every project justifies a new permanent position. A records clean-up or a data review has a start and an end. A co-op student can take on that kind of work for four, eight or 12 months, without the long-term commitment of a full-time hire. The hospital team sees the results first, then decides what comes next.</p>
<p>The Arts and Science Co-op team at U of T Scarborough helps students from more than 57 undergraduate programs across the sciences, social sciences and humanities connect with co-op opportunities.</p>
<p>Students benefit too. They gain exposure to the health care system while using skills and learning from their own academic programs. After the work term, they return to school with real-world experience that informs their future career decisions.</p>
<h3><strong>Built on relationships</strong></h3>
<p>“I often ask hospital teams, “which administrative task takes up most of your time and attention?” The answer is usually something important but repetitive that keeps them occupied and away from strategic projects that require their specialized knowledge and experience. That’s when we share that our students are already supporting such administrative tasks in the healthcare space and share the detailed benefits of participating in our program.“<span class="Apple-converted-space"> </span></p>
<p>Antonella Poon, Team Lead – Arts and Science Co-op at University of Toronto Scarborough.</p>
<h3><strong>What about privacy and<span class="Apple-converted-space"> </span>patient data security?</strong></h3>
<p>Hospital teams are right to ask. Good placements have clear tasks and oversight. Students look only at the information they need, use approved systems and their own logins, avoid downloading anything that could identify a patient, and raise privacy questions with a supervisor right away. Qualified staff review the work and make the final call on test results, billing, patient advice, public statements and staffing.</p>
<h3><strong>What changes for your team</strong></h3>
<p>• Clinic staff get time back. Nurses, physicians and managers can focus on their specialties.</p>
<p>• Shelved projects start to move. A student with a clear scope can advance an idea while staff review the work.</p>
<p>• A fresh set of eyes. Students ask why things are done a certain way, sometimes exposing outdated steps.</p>
<p>Arts and Science Co-op is a proud founding member of the U of T co-op community, with more than 50 years of experience in co-op education. <b>Get in touch with their co-op representatives</b> to explore projects a co-op student could take on in your team. Get support on scoping the work, shaping the role and navigating the next steps.<span class="Apple-converted-space"> </span></p>
<p>The post <a href="https://www.hospitalnews.com/the-project-your-team-keeps-pushing-to-the-future/">The project your team keeps pushing to the future</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Canadian study finds cancer signals in blood up to eight years before diagnosis</title>
<link>https://edusehat.com/en/canadian-study-finds-cancer-signals-in-blood-up-to-eight-years-before-diagnosis</link>
<guid>https://edusehat.com/en/canadian-study-finds-cancer-signals-in-blood-up-to-eight-years-before-diagnosis</guid>
<description><![CDATA[ Researchers studying stored blood samples from Ontario Health Study participants have identified signals associated with breast and prostate cancers up to eight years before diagnosis, according to the Ontario Institute for Cancer Research. The findings, published in Cell Genomics, could help inform future approaches to earlier detection and monitoring people at higher risk. The team […]
The post Canadian study finds cancer signals in blood up to eight years before diagnosis appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/11/shutterstock_2783991317.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 02 Nov 2026 10:25:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Canadian, study, finds, cancer, signals, blood, eight, years, before, diagnosis</media:keywords>
<content:encoded><![CDATA[<p>Researchers studying stored blood samples from Ontario Health Study participants have identified signals associated with breast and prostate cancers up to eight years before diagnosis, according to the Ontario Institute for Cancer Research.</p>
<p>The findings, published in <em>Cell Genomics</em>, could help inform future approaches to earlier detection and monitoring people at higher risk.</p>
<p>The team examined blood collected from people who appeared healthy when they donated samples but subsequently developed cancer. Researchers identified patterns of DNA methylation—chemical changes to DNA that can provide clues about cancer development.</p>
<p>The work was co-led by Dr. Philip Awadalla, a former OICR Senior Investigator, and Dr. Nicholas Cheng, a former member of his laboratory.</p>
<p>For healthcare teams, the potential lies in more personalized screening and follow-up. However, the findings require further validation before the approach could be used in routine care. Researchers are planning a prospective clinical trial and exploring ways to make testing faster, more accurate and more affordable.</p>
<p data-pm-slice="1 1 []"><strong><a href="https://oicr.on.ca/early-signs-of-cancer-detected-in-blood-up-to-eight-years-before-diagnosis/">Read the original OICR report</a>.</strong></p>
<p>The post <a href="https://www.hospitalnews.com/canadian-study-finds-cancer-signals-in-blood-up-to-eight-years-before-diagnosis/">Canadian study finds cancer signals in blood up to eight years before diagnosis</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>StockWatch: Gene Editing Shares Jump on ESGCT Data, FDA Draft Guidance</title>
<link>https://edusehat.com/en/stockwatch-gene-editing-shares-jump-on-esgct-data-fda-draft-guidance</link>
<guid>https://edusehat.com/en/stockwatch-gene-editing-shares-jump-on-esgct-data-fda-draft-guidance</guid>
<description><![CDATA[ Shares of gene editing therapy companies mostly surged this past week on two growth catalysts: Data readouts at the European Society of Gene and Cell Therapy’s 33rd ESGCT Annual Congress, and the FDA&#039;s new draft guidance for personalized gene therapies.
The post StockWatch: Gene Editing Shares Jump on ESGCT Data, FDA Draft Guidance appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GettyImages-1407334381-1068x748-1-1024x717-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 02 Nov 2026 03:20:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>StockWatch:, Gene, Editing, Shares, Jump, ESGCT, Data, FDA, Draft, Guidance</media:keywords>
<content:encoded><![CDATA[<p>Shares of gene editing therapy companies mostly surged by double digits this past week on two growth catalysts. One catalyst was expected: The European Society of Gene and Cell Therapy’s <a href="https://www.genengnews.com/topics/genome-editing/hamburg-hosts-2026-european-gene-therapy-conference/">33rd ESGCT Annual Congress</a>, which finished Friday in Hamburg, Germany, brought forth the usual flurry of data presentations, including many positive readouts by developers of new editing-based therapies.</p>
<figure aria-describedby="caption-attachment-340047" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="size-medium wp-image-340047" src="https://www.genengnews.com/wp-content/uploads/2026/10/Diamantas_Kyle_900-x-900_Flag-253x300.jpg" alt="" width="253" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Diamantas_Kyle_900-x-900_Flag-253x300.jpg 253w, https://www.genengnews.com/wp-content/uploads/2026/10/Diamantas_Kyle_900-x-900_Flag.jpg 370w" sizes="(max-width: 253px) 100vw, 253px"><figcaption class="wp-caption-text">Kyle Diamantas, FDA acting commissioner</figcaption></figure>
<p>The other catalyst happened October 27 when the FDA issued draft guidance (<a href="https://www.regulations.gov/docket/FDA-2026-D-11783">FDA-2026-D-11783</a>) intended to help sponsors develop and pursue approvals for personalized gene therapies designed to treat patients with rare genetic diseases. The guidance, <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/individualized-human-genome-editing-products-considerations-bla-submission-and-postapproval"><em>Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management</em></a>, offers a regulatory framework for submitting and managing Biologics License Applications (BLAs) for individualized genome editing products.</p>
<p>“For patients with rare genetic diseases, a one-size-fits-all approach to treatment simply does not work and neither should a one size fits all approach to regulation,” FDA acting commissioner Kyle Diamantas, said in a statement.</p>
<p>Maury Raycroft, PhD, equity analyst at Jefferies, viewed the draft guidance positively in a Friday note: “Gene editing cos have underperformed the past yr, but we anticipate a range of de-risking data & reg catalysts ahead; recent constructiveness from FDA/gov should keep momentum going.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>The draft guidance introduces to the FDA the concept of the Individualized Feature Space (IFS), a set of pre-defined limits describing allowable limits of variation for genome edited (GE) components of an individualized GE product, so such therapies can vary from patient to patient without needing to perform additional clinical trials, while remaining within the scope of a single BLA.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>“For a GE product whose only variable feature is a gRNA spacer sequence, the IFS should describe which types of spacer sequences are allowable in the BLA—such as any spacer sequence that targets a defined class of pathogenic gene variants in a specified gene and results in the same editing outcome (e.g., correcting the gene so that it encodes the wild-type protein),” the draft guidance explains.</p>
<p>The FDA is soliciting public comment through November 27, both <a href="https://www.regulations.gov/docket/FDA-2026-D-11783">online</a> and via <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/individualized-human-genome-editing-products-considerations-bla-submission-and-postapproval">mail</a>.</p>
<h4><strong>Mostly positive impact</strong></h4>
<p>Since the draft guidance was issued after the close of markets, investors had to wait until Wednesday to see the impact of the proposed rules plus ESGCT data on gene editing stocks. That impact turned out to be mostly positive, with shares of four gene editing therapy developers <span><strong>rising between 4% and 29%</strong></span>. Even higher gains earlier in the week were dampened by a <span><strong>nearly 3% drop</strong></span> in the Nasdaq Composite on Friday, sparked by disappointing third-quarter earnings reported by tech and artificial intelligence (AI) companies.</p>
<p>The biggest gainer this past week was <strong>Prime Medicine (Nasdaq: PRME)</strong>, whose shares enjoyed a <span><strong>five-day leap of 29%</strong></span> from $3.67 to $4.72—a <span><strong>20% falloff</strong> </span>from the 52-week high Prime reached on Thursday, when its share peaked at $5.91 at 9:57 a.m. ET.</p>
<p>The draft guidance continued a month-long <span><strong>53% surge</strong></span> sparked by a pair of positive clinical developments: Last month Prime received FDA clearance allowing the launch of a planned Phase I/II trial for its <em>in vivo</em> Prime Editor PM647 in alpha-1 antitrypsin deficiency (AATD).</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>And on October 5, Prime dosed the first patient in a Phase I/II open-label trial (<a href="https://clinicaltrials.gov/study/NCT07748403">NCT07748403</a>) assessing its <em>in vivo</em> Prime Editor PM577a in adults and teens as a treatment for H1069Q-mutated Wilson disease, the first reported instance of prime editing being used to edit DNA directly in a person. Prime says initial data from the trial is expected in 2027.</p>
<p>“Overall, we see promise over the long-term for the pipeline and could consider becoming more constructive on the stock as we move closer to value-creating milestones (initial clinical data) in 2027,” Tessa T. Romero, a senior analyst focused on biotechnology equity research with J.P. Morgan, commented in a June 18 research note that followed clinical trial clearance for PM577a in New Zealand.</p>
<p>Second highest among editing stocks this week with a <span><strong>13% jump</strong></span> is <strong>Beam Therapeutics (Nasdaq: BEAM)</strong>. The developer of CRISPR base editing therapies saw its shares climb from $24.05 on October 23 to $27.23 Friday, driven in part by positive initial data from its Phase I/II trial (<a href="https://clinicaltrials.gov/study/NCT06735755">NCT06735755</a>) showing clinical proof of concept for BEAM-301 for the treatment of glycogen storage disease type Ia (GSDIa).</p>
<p>BEAM-301 is a liver-targeting lipid-nanoparticle (LNP) formulation of base editing reagents designed to correct the R83C mutation, which is associated with the most severe form of GSDIa.</p>
<h4><strong>Maximum outcomes</strong></h4>
<p>As of data cutoff August 17, two of three patients in the trial’s 40 mg cohort achieved the trial protocol’s maximum 15-hour controlled fasting duration—a result consistent with restored endogenous glucose production, Beam said. The two also saw 100% reduction in daily starch requirements, no longer requiring starch supplementation, and improved glucose control with more time spent in the euglycemic range and less in the hyperglycemic range.</p>
<p>“BEAM-301 appears impressive at first clinical data look,” Myles R. Minter, PhD, a partner and biotechnology analyst with William Blair, wrote in a research note. Minter has estimated that BEAM-301 will generate peak annual sales of $475 million.</p>
<p>That would be 31% above the $362 million in peak sales modeled by Minter’s colleague at William Blair, Sami Corwin, PhD, a biotechnology-focused healthcare analyst, for Genglycos® (pariglasgene brecaparvovec-opnr), which won FDA approval in August as the first-ever drug authorized to treat GSDIa in adults and children ages 8 and older. Genglycos is marketed by <strong>Ultragenyx Pharmaceutical (Nasdaq: RARE)</strong>.</p>
<p>The third 40 mg patient showed no time to fasting hypoglycemia (TTH) increase, potentially due to high body mass index (BMI) and heterozygosity for the R83C mutation, according to Beam.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>“This could be solved with moving to the higher 60 mg dose or could warrant a BMI restriction in future cohort or even evaluation of potential weight-based dosing,” Minter added.</p>
<p>Based on the data, Beam is advancing BEAM-301 to a 60 mg cohort, where it has begun enrollment, and plans to engage with the FDA about a potential approval path.</p>
<p>Beam and Prime are likely to benefit from the FDA’s framework for genome editing drugs, Jefferies analyst Raycroft said: “We believe the framework could support/accelerate [Beam’s] PKU program entering the clin YE26/early’27 by leveraging data across 3 mut[ation]-specific PAH base editors.”</p>
<p>As for Prime, Raycroft noted that the company has FDA alignment to develop additional mutations under the same IND using most of the H1069Q package: “Follow-on editors may need only mut[ation]-specific off-target work and limited clin data for pot’l licensure.”</p>
<h4><strong>Data presented and awaited</strong></h4>
<p><strong>Editas Medicine (Nasdaq: EDIT) </strong>saw its shares <span><strong>rise 11%</strong></span> this past week, from $2.40 October 23 to $2.67 Friday. The company presented two posters at ESGCT: One detailed a <a href="https://www.editasmedicine.com/wp-content/uploads/2026/10/ESGCT-2026-Poster-P0781_tLNP-Platform-Process_FINAL.pdf">configurable, GMP-ready manufacturing platform for targeted LNP therapeutics</a> shown to enable rapid evaluation of novel binders and cargos while maintaining consistent T-cell targeted LNP (tLNP) quality across scales, binders, and batches.</p>
<p>The other showed robust <em>in vivo</em> delivery of mRNA to targeted T cells using its <a href="https://www.editasmedicine.com/wp-content/uploads/2026/10/ESGCT-2026_poster-P0361_RTO_FINAL.pdf">scalable tLNP platform</a>, which allowed for transient expression of CAR in targeted T cells, resulting in deep B-cell depletion in the blood within 24 hours post-dose. Researchers also reported seeing therapeutically relevant B-cell depletion in lymphoid tissues, “creating the potential for clinically meaningful immune reset for autoimmune therapy.”</p>
<p><strong>Intellia Therapeutics (Nasdaq: NTLA)</strong> shares also <span><strong>grew 11%</strong></span> week-over-week, from $11.21 to $12.47. Intellia investors are also waiting for clinical data on lonvoguran ziclumeran (Lonvo-z), a one-time CRISPR/Cas9 gene-editing therapy being developed to treat hereditary angioedema (HAE). Those results are to be presented in two oral presentations and five poster presentations at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting, set for November 12–16 in Phoenix. The presentations include four-year follow-up data from patients who received a one-time 50 mg dose of lonvo-z.</p>
<p>On November 12, Intellia executives and HAE key opinion leaders plan to discuss the company’s preparations for the commercial launch of lonvo-z during a conference call with analysts.</p>
<p><strong>CRISPR Therapeutics (Nasdaq: CRSP)</strong> shares <span><strong>rose 4%</strong></span> this past week from $49.39 to $51.42 Friday as investors await third-quarter results set to be released this month, and clinical data updates such as a planned readout from the Phase Ib trial (<a href="https://clinicaltrials.gov/study/NCT07491172">NCT07491172</a>) of CTX310<sup>®</sup>, a CRISPR/Cas9 <em>in vivo</em> gene editing therapy candidate targeting angiopoietin-related protein 3 (ANGPTL3), in patients with severe hypertriglyceridemia. That data will be presented at the American Heart Association (AHA) Scientific Sessions 2026, set for November 6–9.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="7"></span></aside>
<p>Not all editing therapy stocks reaped the fruits of the FDA guidance and ESGCT data announcements. Shares of <strong>Caribou Biosciences (Nasdaq: CRBU)</strong>, a CRISPR therapeutics developer whose co-founders include Jennifer Doudna, PhD, <span><strong>dropped nearly 21%</strong></span> from 53 cents on October 23 to 42 cents Friday. Caribou thus continued a slide triggered by its <a href="https://www.genengnews.com/topics/genome-editing/stockwatch-caribou-plunges-as-it-pursues-strategic-alternatives/">review of strategic alternatives</a> and plans to reduce a “substantial” portion of its workforce—a decline that has caused the company’s stock to <span><strong>plunge 66%</strong></span> over the past month from $1.27 on September 30.</p>
<h4><strong>Anthropic details acquisition, partnerships</strong></h4>
<p>Anthropic used a <a href="https://www.anthropic.com/research/early-progress-drug-development">press release</a> rather than the <a href="https://www.sec.gov/Archives/edgar/data/2130357/000162828026067168/anthropicpbc-sx1.htm">Form S-1 Registration Statement</a> disclosing its initial public offering (IPO) plans to flesh out its progress and plans in the drug development space it has targeted as one key area of future growth.</p>
<p>The AI giant—which <a href="https://www.genengnews.com/topics/artificial-intelligence/anthropic-ipo-discloses-plans-for-life-sciences-growth/">filed for its long-awaited IPO </a> on October 26—acknowledged pursuing its own drug discovery efforts and disclosed that in August, it acquired Mithril Medicine, a developer of treatments for two rare forms of muscular dystrophy staffed by a single person, founder Cody Tranbarger, a biotech entrepreneur and investor. Tranberger used Claude to organize contracts, logistics, and experiments with 11 external labs, as well as to delegate “many other aspects of Mithril’s operations.” Mithril has advanced within 18 months a therapy for one form of muscular dystrophy from an idea to positive results in mice.</p>
<p>“If his drug candidates continue to hold up, we expect a drug to be ready to start clinical trials in humans as soon as late 2028,” Anthropic predicted.</p>
<h4><strong>“Deep research partnerships”</strong></h4>
<p>Anthropic also listed a series of six “deep research partnerships” with drug developers. Two of the six are public companies, <strong>Bristol Myers Squibb (BMS; NYSE: BMY)</strong> and <strong>Generate: Biomedicines (Nasdaq: GENB)</strong>, which in February <a href="https://www.genengnews.com/topics/artificial-intelligence/stockwatch-ai-drug-developer-generates-400m-ipo/">carried out its own $400 million IPO</a> (of which $369.3 million was net proceeds). The other four partners are private companies: <strong>BigHat Biosciences</strong>, <strong>Divergence Labs</strong>, <strong>Enveda</strong>, and <strong>The Column Group (TCG)</strong>.</p>
<p>Anthopic’s release also offered some details of its work with collaboration partners:</p>
<ul>
<li><strong>BMS:</strong> The pharma giant used Anthropic’s Claude family of large-language models to estimate the likelihood of success for planned clinical trials of an unidentified early-stage drug. “Together, we plan to expand this work in 2027 to understand its potential for increasing the probability of success in early development,” Anthropic said.</li>
<li><strong>Generate:</strong> Six Generate scientists used Claude Code to propose new designs for part of a chimeric antigen receptor T cell (CAR T) therapy’s genetic instructions, creating room for additional instructions addressing other types of cancer. One design “about 70%” shorter showed greater effectiveness than the standard version in lab tests: “Compact ICDs [intracellular domains] may lower the dose needed to generate CAR T cells <em>in vivo</em> and enable more complex CAR therapies, such as CAR cocktails,” <a href="https://generatebiomedicines.com/wp-content/uploads/2026/10/refactored-intracellular-domains-enhance-car-expression-and-function.pdf">Generate concluded</a>.</li>
<li><strong>BigHat:</strong> Researchers from the protein and antibody drug developer joined Anthropic in applying Claude to <a href="https://cdn.prod.website-files.com/64ff35ef45fc1e4545e5ffa1/6ae0ea8e28d4a390cbe66b52_bighat_pilot_retro_final_v2.pdf#navpanes=0">improve binding, stability, and anti-clumping properties</a> of two antibody fragments that could become parts of future drugs: one designed to target cancer cells, and one designed to keep a drug in the body longer.</li>
<li><strong>Enveda:</strong> The developer of molecules based on living organisms “reduced human review time by 89%, from over 25 hours to less than three, by linking its manufacturing documents to Claude. After reviewing 1,061 pages of documentation, Anthropic Claude caught all 11 issues that human reviewers had spotted and flagged seven they missed: “A promising development for future use cases in decreasing the time, cost, and error rates in drug development,” <a href="https://enveda.com/CMC-Document-Processor/">Enveda concluded</a>.</li>
<li><strong>TCG:</strong> A spinout of the venture capital firm, called Pleiades, will use Claude to reduce scientific, operational, and administrative overhead as it runs more, and more complex, drug development programs “than is usual for a small team,” Anthropic said, adding: “The savings will enable previously untenable risks on a larger array of challenging and innovative projects.”</li>
<li><strong>Divergence:</strong> Using Claude, the food allergy drug developer generated “roughly 35,000” antibody designs in about a month for testing. Divergence found three design arms designed to bind tightly to IgE, and 20 that could help dislodge IgE from the immune cell (three of which dislodged more IgE than standard medication). Divergence plans to build a drug that combines the two types of arms, <a href="https://divergencelabs.com/publications/ige-preprint.pdf">stating in a study</a>: “We expect biparatopic construction … to provide a significant boost to potency and disruptive efficacy.”</li>
</ul>
<p>In a <a href="https://www.linkedin.com/feed/update/urn:li:activity:7521638389297618945/">LinkedIn post</a>, however, Geoff Harris, PhD, CSO and co-founder of Excellergy—an indirect, wholly owned subsidiary of <strong>Novartis (SIX Swiss: NOVN and NYSE: NVS) </strong>acquired for up to $2 billion in June—said Divergence Labs’ study “doesn’t describe a drug, but the components of what might be a drug someday, maybe, which is years behind the competition.”</p>
<p>“A monoclonal antibody drug that is exceptional at disarming the IgE axis already exists and is in the clinic today,” Harris added, namely Excellergy’s lead candidate EXL-111, a trifunctional allergic effector cell response inhibitor designed to treat allergic diseases by targeting the IgE axis. EXL-111 is in a Phase I trial (<a href="https://clinicaltrials.gov/study/NCT07356713">NCT07356713</a>) with an estimated primary completion date of December 7.</p>
<p>Anthropic says it envisions Divergence and its other partners applying Claude to ultimately bring their candidates into the clinic as well: “We plan to continue extending Claude’s role into clinical trials as these drug programs advance, and as we partner with more organizations whose drug development programs are already at the clinical stage.”</p>
<h4><strong>Leaders and laggards</strong></h4>
<p><strong>Acumen Pharmaceuticals (Nasdaq: ABOS)</strong> shares <span><strong>cratered 91%</strong> </span>from $2.29 to just 21 cents Friday after the developer of Alzheimer’s disease (AD) drugs targeting amyloid beta oligomers announced that it was ceasing development of its lead pipeline candidate sabirnetug (ACU193) and evaluate its strategic options after the humanized monoclonal antibody failed the Phase II ALTITUDE-AD trial (<a href="https://clinicaltrials.gov/study/NCT06335173">NCT06335173</a>) in participants with early AD. Sabirnetug missed its primary endpoint of change from baseline in cognitive and functional decline as measured by the Integrated Alzheimer’s Disease Rating Scale (iADRS) at 18 months vs. placebo at either the 35 mg/kg or the 50 mg/kg dose. Sabirnetug also failed to achieve statistical significance on key secondary efficacy endpoints, including the Clinical Dementia Rating–Sum of Boxes (CDR-SB), and did not show any meaningful difference between the sabirnetug and placebo treatment arms. Acumen said it plans to take steps to carry out cash conservation measures and explore strategic options.</p>
<p><strong>Aspen Neuroscience (ASPE) </strong>shares <span><strong>dipped 0.7%</strong></span> from its initial public offering (IPO) price of $15 a share to $14.89 Friday as the developer of autologous induced-pluripotent stem cell (iPSC)-derived therapies for neurodegenerative diseases began its first full day of trading. Shares began the day at $14.70, below the IPO price—the low end of its $15-$17 price range when it priced 9.375 million shares, raising $140.625 million in gross proceeds. Proceeds are intended to fund clinical trials for its lead candidate, the Parkinson’s disease therapy sasineprocel, now in the Phase I/IIa ASPIRO open-label dose escalation study (<a href="https://clinicaltrials.gov/study/NCT06344026">NCT06344026</a>), as well as development of the company’s microglia programs, including initiating IND-enabling studies.</p>
<p><strong>Genmab (Nasdaq: GMAB) </strong>shares <span><strong>jumped 28% </strong></span>from $44.67 to $57.29 Wednesday after the antibody drug developer announced data from the global Phase III LiGeR-HN1 trial (<a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06525220&data=05%7C02%7Calex.philippidis%40sagepub.com%7C131a0ad3a85b4a2196a708df362706b1%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639289213847837766%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=F7Z5EC0YjX9EddbZXCq2F5TVWspvkNjDkg%2FKyTmFnZ0%3D&reserved=0">NCT06525220</a>) assessing petosemtamab in combination with pembrolizumab, the cancer immunotherapy blockbuster marketed by <strong>Merck & Co. (NYSE: MRK)</strong> as Keytruda®, vs. pembrolizumab alone in patients with first-line (1L) PD-L1 positive recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). Based on the first interim analysis assessed by an independent data monitoring committee, treatment with the petosemtamab combination showed a “statistically significant and clinically meaningful” improvement in overall survival (OS), reducing the risk of death by 50%, and objective response rate (ORR) vs. pembrolizumab [OS hazard ratio 0.50, p<0.0001; ORR odds ratio 3.17 p<0.0001), meeting the trial’s dual primary endpoints regardless of HPV status.</p>
<p><strong>Iovance Biotherapeutics (Nasdaq: IOVA)</strong> shares <span><strong>tumbled 35%</strong></span> from $14.81 to $9.56 Thursday after the tumor infiltrating lymphocyte (TIL) cell therapy developer announced data from Cohorts 1 and 2 of its Phase II IOV-LUN-202 trial (<a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04614103&data=05%7C02%7Calex.philippidis%40sagepub.com%7C131a0ad3a85b4a2196a708df362706b1%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639289213847909389%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=c5nxp6oOYcCUls%2Fe3WaUlxpyB%2F75klzTvl85Ch11Smo%3D&reserved=0">NCT04614103</a>) evaluating lifileucel in previously treated metastatic non-small cell lung cancer. As of the October 14 data cutoff 17 of 69 patients responded, an ORR of 24.6%, consistent with the 25.6% ORR previously reported in 39 patients but less than what investors expected. Iovance said a retrospective analysis found a biomarker-enriched subgroup defined by Kirsten rat sarcoma viral oncogene homolog (<em>KRAS</em>) wild-type status, human epidermal growth factor receptor 2 (<em>HER2</em>) wild-type status, and current or former smoking.</p>
<p>The post <a href="https://www.genengnews.com/topics/genome-editing/stockwatch-gene-editing-shares-jump-on-esgct-data-fda-draft-guidance/">StockWatch: Gene Editing Shares Jump on ESGCT Data, FDA Draft Guidance</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Medical Students Mental Health: Why Burnout Happens and How to Prevent It</title>
<link>https://edusehat.com/en/medical-students-mental-health-why-burnout-happens-and-how-to-prevent-it</link>
<guid>https://edusehat.com/en/medical-students-mental-health-why-burnout-happens-and-how-to-prevent-it</guid>
<description><![CDATA[ If you’ve ever felt emotionally exhausted after weeks of studying, questioned whether you’re “good enough” despite working incredibly hard, or found yourself losing motivation for something you once loved, you’re certainly not alone. Burnout has become increasingly common among medical students, and for good reason.   Medical school asks students to absorb enormous amounts of […]
The post Medical Students Mental Health: Why Burnout Happens and How to Prevent It appeared first on Elite Medical Prep. ]]></description>
<enclosure url="https://elitemedicalprep.com/wp-content/uploads/2026/10/pexels-mikhail-nilov-9159061-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 31 Oct 2026 19:25:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Medical, Students, Mental, Health:, Why, Burnout, Happens, and, How, Prevent</media:keywords>
<content:encoded><![CDATA[<p><span>If you’ve ever felt emotionally exhausted after weeks of studying, questioned whether you’re “good enough” despite working incredibly hard, or found yourself losing motivation for something you once loved, you’re certainly not alone. Burnout has become increasingly common among medical students, and for good reason.</span></p>
<p> </p>
<p><span>Medical school asks students to absorb enormous amounts of information, perform well on high-stakes exams, navigate emotionally challenging clinical experiences, and often put their personal lives on hold, all while maintaining the expectation of excellence. It is no surprise that many students eventually find themselves running on empty.</span></p>
<p> </p>
<p><span>The encouraging news is that burnout is not inevitable. Understanding why it happens is the first step toward preventing it before it swallows you.</span></p>
<p> </p>
<h2><strong>Burnout Doesn’t Happen Overnight</strong></h2>
<p><span>One of the biggest misconceptions about burnout is that it appears suddenly. </span><span>In reality, burnout usually develops gradually. It often starts with small changes that students dismiss: feeling a little more tired than usual, struggling to focus during lectures, losing interest in hobbies, feeling irritable, and not taking care of yourself like you normally would. </span></p>
<p> </p>
<p><span>Over time, those small warning signs can accumulate into emotional exhaustion, decreased motivation, cynicism, and the feeling that no matter how hard you work, you’re never doing enough.</span></p>
<p> </p>
<p><span>Many students don’t recognize burnout until they’re already deeply affected by it. </span><span>Learning to identify those early signs allows you to make adjustments before your physical and emotional energy become completely depleted. For practical ways to respond to these early warning signs, explore our guide on <a href="https://elitemedicalprep.com/how-to-manage-stress-during-medical-school/">how to manage stress during medical school</a>. </span></p>
<p> </p>
<h2><strong>Perfectionism Can Become Your Biggest Obstacle</strong></h2>
<p><span>Medicine attracts highly motivated, high-achieving individuals, and those qualities often contribute to success. However, they can also become major contributors to burnout.</span></p>
<p> </p>
<p><span>Many students hold themselves to impossibly high standards. <a href="https://elitemedicalprep.com/how-to-recover-after-a-low-nbme-practice-score-a-step-by-step-strategy/">A practice score that isn’t perfect feels like failure</a>. Missing one study day creates guilt. Asking for help feels like weakness.</span></p>
<p> </p>
<p><span>Over time, this constant pressure becomes exhausting. </span><span>One lesson many experienced physicians eventually learn is that perfection is not required to become an excellent doctor. Growth, consistency, and resilience matter far more than flawless performance.</span></p>
<p> </p>
<p><span>Learning to celebrate progress instead of demanding perfection can significantly reduce unnecessary stress throughout medical school.</span></p>
<p> </p>
<h2><strong>Your Identity Should Be Bigger Than Medicine</strong></h2>
<p><span>Medical school is incredibly demanding, but it should not become your entire identity. </span><span>One common pattern among burned-out students is that every aspect of their self-worth becomes tied to academic performance. A difficult shelf exam, a disappointing evaluation, or a lower-than-expected practice score suddenly feels like a reflection of who they are as a person.</span></p>
<p> </p>
<p><span>This mindset makes setbacks much more painful and personal than they need to be. </span><span><a href="https://elitemedicalprep.com/balancing-medical-school-and-life-strategies-for-maintaining-a-social-life/">Maintaining interests outside of medicine</a>, whether that’s spending time with family, exercising, reading, cooking, volunteering, or simply enjoying time with friends, helps create perspective during difficult periods.</span></p>
<p> </p>
<p><span>Contrary to what you might think, taking breaks often improves productivity rather than reducing it.</span></p>
<p> </p>
<h2><strong>Rest Is a Crucial Part of Training</strong></h2>
<p><span>Medical students frequently view rest as something that must be earned.</span></p>
<p> </p>
<ul>
<li><span>“I’ll take a day off after this exam.”</span></li>
<li>“I’ll exercise once dedicated is over.”</li>
<li>“I’ll catch up on sleep after rotations.”</li>
</ul>
<p> </p>
<p><span>Unfortunately, those milestones rarely stop coming. </span><span>The reality is that recovery is not separate from learning, it supports it. Sleep improves memory consolidation. Exercise reduces stress hormones. Time away from studying improves concentration and decision-making.</span></p>
<p> </p>
<p><span>Students who <a href="https://elitemedicalprep.com/crafting-a-personalized-study-routine-in-medical-school/">schedule recovery intentionally</a> often maintain higher productivity over longer periods than those who try to push through constant exhaustion.</span></p>
<p> </p>
<h2><strong>Comparison Is an Endless Trap</strong></h2>
<p><span>All medical students are extremely high achievers, so put them in one big group together and it’s a recipe for endless comparison!</span></p>
<p> </p>
<p><span>Someone always seems to finish studying earlier. Someone scores higher on practice exams. Someone already knows which specialty they want. Someone else somehow appears to balance research, volunteering, and a social life effortlessly.</span></p>
<p> </p>
<p><span>What students rarely see are the challenges behind those successes.</span></p>
<p> </p>
<p><span>Comparing your progress to someone else’s highlight reel almost always increases stress without improving performance. </span><span>Your medical school journey is unique. The pace that allows someone else to thrive may not be sustainable for you, and that’s perfectly okay.</span></p>
<p> </p>
<h2><strong>Learn to Ask for Help Early</strong></h2>
<p><span>One of the strongest predictors of long-term success in medicine is not independence, it’s knowing when to seek support. </span><span>Students sometimes wait until they are completely overwhelmed before speaking with advisors, mentors, counselors, or academic support services. Others worry that asking for help means they are somehow less capable than their classmates.</span></p>
<p> </p>
<p><span>In reality, reaching out early often prevents small struggles from becoming much larger ones. </span><span>Support may come from faculty mentors, classmates, <a href="https://elitemedicalprep.com/meet-the-tutors/">tutors</a>, family members, or mental health professionals. Every physician needs support at different points in training. </span><span>There is strength in recognizing when you don’t have to navigate everything alone.</span></p>
<p> </p>
<h2><strong>Burnout Prevention Looks Different for Everyone</strong></h2>
<p><span>There is no universal formula for maintaining well-being during medical school. </span><span>Some students recharge through exercise. Others need quiet evenings at home, creative hobbies, faith communities, or spending time outdoors. Some benefit from <a href="https://elitemedicalprep.com/time-management-in-med-school-balancing-class-boards-and-life/">structured routines</a>, while others need flexibility.</span></p>
<p> </p>
<p><span>The important part is identifying what consistently helps you feel physically and emotionally restored, and protecting that time as intentionally as you protect study time. </span><span>Prevention is almost always easier than recovery.</span></p>
<p> </p>
<h2><strong>The Bottom Line</strong></h2>
<p><span>Burnout is common in medical school, but it is not something students simply have to accept as part of becoming a physician. It develops gradually through chronic stress, perfectionism, unrealistic expectations, and neglecting personal well-being. </span></p>
<p> </p>
<p><span>The students who sustain themselves throughout training are rarely those who work the longest hours. They are often the ones who recognize their limits, ask for help when needed, maintain interests outside of medicine, and understand that taking care of themselves ultimately allows them to take better care of their future patients. And you should surround yourself with people who support you in doing all these things. </span></p>
<p> </p>
<p><span>Medicine is a marathon, not a sprint. Protecting your mental health isn’t stepping away from your goal, it’s one of the most important ways to reach it. If you could use support with the academic demands along the way, <a href="https://elitemedicalprep.com/contact/">EMP’s 1:1 tutoring</a> can help you build a study plan around your needs, goals, and schedule. <a href="https://elitemedicalprep.com/contact/">Get started</a> with personalized support for your preparation.</span></p>
<p>The post <a href="https://elitemedicalprep.com/medical-students-mental-health-why-burnout-happens-and-how-to-prevent-it/">Medical Students Mental Health: Why Burnout Happens and How to Prevent It</a> appeared first on <a href="https://elitemedicalprep.com/">Elite Medical Prep</a>.</p>]]> </content:encoded>
</item>

<item>
<title>100 Million&#45;Cell AI&#45;Ready Dataset with Single&#45;Cell and Proteomic Data Created by Parse and Nomic</title>
<link>https://edusehat.com/en/100-million-cell-ai-ready-dataset-with-single-cell-and-proteomic-data-created-by-parse-and-nomic</link>
<guid>https://edusehat.com/en/100-million-cell-ai-ready-dataset-with-single-cell-and-proteomic-data-created-by-parse-and-nomic</guid>
<description><![CDATA[ Parse Biosciences and Nomic Bio are partnering to create Cascade, a 100-million-cell multimodal dataset combining single-cell and proteomic data to advance AI-driven immune modeling, drug discovery, and therapeutic target identification.
The post 100 Million-Cell AI-Ready Dataset with Single-Cell and Proteomic Data Created by Parse and Nomic appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GettyImages-2242943155.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 31 Oct 2026 04:45:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>100, Million-Cell, AI-Ready, Dataset, with, Single-Cell, and, Proteomic, Data, Created, Parse, and, Nomic</media:keywords>
<content:encoded><![CDATA[<p>Parse Biosciences, a QIAGEN company and a provider of scalable and accessible single-cell sequencing, and Nomic Bio, focused on high-throughput proteomic profiling, today announced their partnership to generate Cascade, a 100 Million cell foundational dataset to understand the human immune response. The dataset’s scale and depth will offer pharma partners cellular- and protein-level insight into immune biology, with the goal to accelerate their ability to identify and validate new drug targets.</p>
<p>Cascade is a multimodal, perturbation dataset that captures how immune cells respond to treatment across multiple timepoints. The dataset will combine 100 million single-cell RNA-seq profiles with more than 11,000 proteomic secretome profiles, capturing how different immune cell types respond to over 150,000 individual and combinatorial cytokine and drug perturbation conditions. By pairing transcriptomic and proteomic readouts of the same immune responses over time, Cascade will provide researchers a view into the mechanisms driving human immune signaling, filling a critical data gap for building predictive, virtual cell models.</p>
<p>Cascade has already drawn foundational partner commitments from leading pharmaceutical and biotechnology companies, including GSK, Pfizer, Sanofi, Graph Therapeutics, and Turbine, underscoring the demand for large-scale, multimodal immune data in drug discovery.</p>
<p>The single-cell RNA-seq data generation will be performed in Parse’s GigaLab, a high throughput service lab capable of profiling billions of cells a year. These data will be paired with proteomic secretome data that will be generated through Nomic’s Omini 1000 platform, which will measure more than 1,000 secreted proteins across all samples.</p>
<p>“Biological AI modeling has hit a data bottleneck. Despite their central role in drug discovery, there is a surprisingly small amount of available data measuring the human’s immune response to key perturbations like cytokines and other drugs,” notes Charlie Roco, PhD, co-founder and chief technology officer at Parse Biosciences. “Cascade is a critical step to revealing these interactions, and we expect to dramatically improve the predictive power of our partner’s AI models as a result.”</p>
<p>
</p><p>The post <a href="https://www.genengnews.com/topics/omics/100-million-cell-ai-ready-dataset-with-single-cell-and-proteomic-data-created-by-parse-and-nomic/">100 Million-Cell AI-Ready Dataset with Single-Cell and Proteomic Data Created by Parse and Nomic</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Opentrons Raises $40M in Series E to Expand Its Robotics, Software, Data Infrastructure</title>
<link>https://edusehat.com/en/opentrons-raises-40m-in-series-e-to-expand-its-robotics-software-data-infrastructure</link>
<guid>https://edusehat.com/en/opentrons-raises-40m-in-series-e-to-expand-its-robotics-software-data-infrastructure</guid>
<description><![CDATA[ According to the company, the funds will support the next phase of its growth in enabling autonomous science in labs and biopharmaceutical companies using its AI and robotics systems.
The post Opentrons Raises $40M in Series E to Expand Its Robotics, Software, Data Infrastructure appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/01/Trends-Automation-GettyImages-2210278635.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 31 Oct 2026 04:45:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Opentrons, Raises, 40M, Series, Expand, Its, Robotics, Software, Data, Infrastructure</media:keywords>
<content:encoded><![CDATA[<p><span>Opentrons Labworks has raised $40 million from a Series E financing round led by healthcare investor Avego, with additional investment from BroadOak Capital Partners. The company has said that it plans to use the capital to scale its robotics, software, and data infrastructure tools.</span></p>
<p><span>Specifically, the funds will support the company’s efforts to design artificial intelligence and robotics systems that work together to design, execute, and learn from scientific experiments. This includes investing in AI-driven experimental execution, extending its automation capabilities, and expanding into new markets and geographies. </span></p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p><span>Additionally, the funds will allow Opentrons to enable faster protocol development through its software and AI, expand capabilities across its robots and instruments, and provide deeper integration of its tools into the broader lab automation ecosystem. </span></p>
<p><span>“Drug developers and AI companies alike are moving experimental work forward toward automated workflows that generate usable data,” said James Flexner, managing partner at Avego. “We see a significant opportunity for autonomous science to converge around Opentrons’ platform.” James Atwood, PhD, Opentrons’ CEO, added “we made lab automation accessible for any lab, and our systems are built for AI to run experiments directly. That is why autonomous science is standardizing on Opentrons.”</span></p>
<p><span>Opentrons reports that to date, it has deployed over 11,000 robots to laboratories in over 80 countries. Its customer base includes academic groups, diagnostic labs, and global pharmaceutical companies, Earlier this year, the company announced that it is using <a href="https://www.genengnews.com/topics/drug-discovery/opentrons-uses-nvidia-tech-to-build-training-data-that-powers-physical-ai-in-the-lab/" target="_blank" rel="noopener">Nvidia’s Isaac and Cosmos AI platforms</a> to generate training data needed to develop and deploy physical AI-enabled laboratory robotics.</span></p>
<p>The post <a href="https://www.genengnews.com/topics/artificial-intelligence/opentrons-raises-40m-in-series-e-to-expand-its-robotics-software-data-infrastructure/">Opentrons Raises $40M in Series E to Expand Its Robotics, Software, Data Infrastructure</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>No Nonsense: David Liu Lauds Progress in Disease&#45;Agnostic Gene Editing at ESGCT</title>
<link>https://edusehat.com/en/no-nonsense-david-liu-lauds-progress-in-disease-agnostic-gene-editing-at-esgct</link>
<guid>https://edusehat.com/en/no-nonsense-david-liu-lauds-progress-in-disease-agnostic-gene-editing-at-esgct</guid>
<description><![CDATA[ Liu ensured that his return visit to ESGCT (having spoken at the congress in Barcelona in 2019) would be one of the highlights of the conference. The “meta lesson” of the past few years in therapeutic genome editing is that different scientific approaches and applications can synergize with regulatory, manufacturing, and economic advances “to achieve the mission we’re on.”
The post No Nonsense: David Liu Lauds Progress in Disease-Agnostic Gene Editing at ESGCT appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/KevinDavies_DavidLIu_ESGCTPodium_edited.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 31 Oct 2026 01:10:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Nonsense:, David, Liu, Lauds, Progress, Disease-Agnostic, Gene, Editing, ESGCT</media:keywords>
<content:encoded><![CDATA[<p><strong>HAMBURG</strong>—The distinguished researcher who had the dubious honor of speaking before David Liu, PhD, in a plenary session at the European Society of Gene & Cell Therapy (ESGCT)—2018 Kavli Award winner Virginijus Siksnys, PhD—opened his talk with a bashful admission: “I’m just the warm up for David,” the Lithuanian chuckled.</p>
<figure aria-describedby="caption-attachment-340012" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="wp-image-340012 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/10/KevinDavies_DavidLIu_ESGCTPodium_edited-300x189.jpg" alt="" width="300" height="189" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/KevinDavies_DavidLIu_ESGCTPodium_edited-300x189.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/KevinDavies_DavidLIu_ESGCTPodium_edited-1024x645.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/KevinDavies_DavidLIu_ESGCTPodium_edited-768x484.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/KevinDavies_DavidLIu_ESGCTPodium_edited.jpg 1400w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">David Liu, PhD, speaking at ESGCT 2026, Germany. [K. Davies]</figcaption></figure>
<p>Liu ensured that his return visit to ESGCT (having spoken at the congress in <a href="https://www.genengnews.com/topics/genome-editing/promising-results-reported-in-tay-sachs-gene-therapy-trial/" target="_blank" rel="noopener">Barcelona in 2019</a>) would be one of the highlights of the conference. The “meta lesson” of the past few years in therapeutic genome editing, Liu began, is that different scientific approaches and applications can synergize with regulatory, manufacturing, and economic advances “to achieve the mission we’re on.”</p>
<p>That mission is already confronting the immense challenge of expanding the early clinical promise of genome editing beyond the vanishingly long tail of genetic diseases. There are more than 200,000 known mutations responsible for some 8,000 known genetic diseases, affecting roughly 400 million families.</p>
<p>Liu’s journey into precision genome editing kicked off ten years ago with the publication of the first landmark base editing report. Prime editing (PE) was described three years later. The two technologies, both building off the CRISPR-Cas chassis, provide a vast repertoire of potential gene edits encompassing single-base substitutions and are being commercially driven by two biotech companies co-founded by Liu—Beam Therapeutics and Prime Medicine.</p>
<h4><strong>AI and PE </strong></h4>
<p>Liu gave two examples of how his lab is integrating artificial intelligence (AI) into the development of enhanced prime editing technology.</p>
<p>In the first example, <a href="https://www.nature.com/articles/s41586-026-10820-0" target="_blank" rel="noopener">published a few months ago in <em>Nature Biotechnology</em></a>, Liu’s lab used an AI tool called ProteinMPNN to improve the overall attributes of prime editors. In 2023, Liu’s lab used phage-assisted continuous evolution (PACE) to evolve prime editors in the lab. Although these evolved PE6 prime editors had higher activity, they tended to exhibit lower stability and expression levels.</p>
<p>ProteinMPNN, Liu said, excels at the inverse protein folding problem: generating sequences that can fold stably into a given structure. By allowing ProteinMPNN to redesign as many as 25 percent of the reverse transcriptase amino acids, the researchers were able to remedy stability deficits. The new PE8 variants show stronger expression and editing efficiencies in various cell types.</p>
<p>Another recent paper describes <a href="https://www.nature.com/articles/s41587-026-03261-7" target="_blank" rel="noopener">the development of a free machine learning tool called OptiPrime</a> to predict prime editing outcomes. “We can’t call it Optimus Prime or Hasbro would sue us,” Liu joked.</p>
<p>Each pegRNA contains multiple regions that are subject to variability that can significantly impact PE efficiency. OptiPrime helps simplify the search through potentially hundreds of potential pegRNA variants that can all in principle engineer the same edit. Researchers can use the <a href="https://optipri.me/" target="_blank" rel="noopener">OptiPri.me website</a> to generate a rank-ordered list of the top pegRNA candidates. The relevant information can be copied and pasted into the online order forms for a researcher’s favorite gene synthesis service.</p>
<figure aria-describedby="caption-attachment-340008" class="wp-caption aligncenter"><img decoding="async" class="wp-image-340008" src="https://www.genengnews.com/wp-content/uploads/2026/10/KevinDavies_DavidLIu_ESGCT_stage-1024x758.jpg" alt="David Liu, PhD, speaking in a plenary session at ESGCT 2026" width="500" height="370" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/KevinDavies_DavidLIu_ESGCT_stage-1024x758.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/KevinDavies_DavidLIu_ESGCT_stage-300x222.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/KevinDavies_DavidLIu_ESGCT_stage-768x569.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/KevinDavies_DavidLIu_ESGCT_stage.jpg 1400w" sizes="(max-width: 500px) 100vw, 500px"><figcaption class="wp-caption-text">David Liu, PhD, speaking in a plenary session at ESGCT 2026 in Hamburg, Germany. [K. Davies]</figcaption></figure>
<h4><strong>Ten years after </strong></h4>
<p>By any measure, the pace of uptake and clinical potential of base and prime editing has been remarkable. Liu counted nine examples—representing he estimated one person-century of work—of precision genome editing rescuing disease phenotypes in animal models, including progeria, sickle cell disease, cystic fibrosis, phenylketonuria, and spinal muscular atrophy.</p>
<p>Several programs have progressed to IND-enabled studies and encouraging clinical results. In March 2025, Beam Therapeutics reported the first clinical correction of a human pathogenic mutation, a subject with alpha-1 antitrypsin deficiency (BEAM-302). Around the same time, <a href="https://www.genengnews.com/topics/genome-editing/asgct-2025-worlds-first-patient-treated-with-personalized-crispr-therapy/?_gl=1*z8smdu*_up*MQ..*_ga*NDA0NjcwOTU3LjE3OTMyOTE3NDY.*_ga_F1EYPPYL3X*czE3OTMyOTE3NDYkbzEkZzAkdDE3OTMyOTE3NDYkajYwJGwwJGg5NzcwODI2OTA." target="_blank" rel="noopener">the Baby KJ story</a>, which revolved around bespoke base editing, captured the world’s attention, revealing that even babies aren’t prisoners to the mutations in their DNA.</p>
<p>Liu also pointed to clinical progress in prime editing. In April 2025, the first <em>ex vivo</em> prime editing patient—57-year-old Tracy Atteberry—was dosed (<a href="https://www.nejm.org/doi/abs/10.1056/NEJMoa2509807" target="_blank" rel="noopener">reported at the end of 2025</a> by Jennifer Gori, PhD, and colleagues). The 57-year-old Atteberry, from Nebraska, received prime-edited stem cells engineered to repair the two-base gene deletion. And in October, the first patient was dosed in an <em>in vivo </em>prime editing trial for Wilson disease (PM577a).</p>
<p>Liu said he was feeling optimistic because regulators in the U.S., U.K. and elsewhere in general “are not standing in the way.” There seems to be “a liberalization of policies around initiation and BLAs for drug approval.” Indeed, the day before Liu’s lecture, the U.S. Food and Drug Administration issued a well-received draft guidance, “<a href="https://www.fda.gov/media/195887/download" target="_blank" rel="noopener">Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management</a>.”</p>
<h4><strong>Disease agnostic approach</strong></h4>
<p>Liu closed by focusing on his group’s work in developing a multi-disease therapeutic approach using only a single treatment, which would benefit more patients than just those with a very rare mutation. Around 30 percent of genetic diseases feature at least one premature stop codon. As was <a href="https://www.genengnews.com/topics/genome-editing/single-prime-editing-platform-shows-potential-vs-multiple-diseases/" target="_blank" rel="noopener">reported last year</a>, Liu’s team has pursued the idea of using suppressor tRNAs, which can read through the stop (or nonsense) codon, thereby restoring production of a full-length protein.</p>
<p>“A tRNA approach enables far fewer drugs to target a larger number of mutations/diseases,” Liu said.</p>
<p>There are 418 tRNA genes in the human genome, signaling considerable redundancy in translation as there are only 61 coding triplets. “You don’t need 418 tRNA genes,” he said. Many humans are lacking at least one of these tRNA genes, showing that humans can tolerate tRNA mutations. Liu’s idea was to “convert a dispensable tRNA into a permanent tRNA suppressor,” a method called prime editing-mediated readthrough of premature termination codons (PERT), which could be used as a one-time treatment for multiple genetic diseases that shared the same premature stop codon.</p>
<p>Led by postdoc Sarah Pierce, PhD, Liu’s lab used prime editing to convert each of the 418 human tRNAs into a suppressor tRNA, engineering each anticodon to the three triplets (CUA, UCA, and UUA) that recognize the three stop codons. As described in the 2025 paper, Liu’s team chose to focus on a leu tRNA, which exhibited the highest suppression activity. This was converted into an optimized suppressor.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>“We’re not over-expressing this optimized suppressor tRNA,” Liu said. By only making about 40% of the tRNA that was replaced, Liu said he was “optimistic we can achieve suppression without over expression.” The most promising data so far comes from the use of PERT to treat a mouse model of Hurler syndrome. PERT treatment led to the expression of about seven percent of the wild-type enzyme activity, which Liu suggested “can rescue the disease.”</p>
<p>Although it is early days, Liu closed by saying he was “very hopeful that various therapeutic approaches… will help increase the applicability of gene editing to more and more patients.” However, “until regulatory streamlining and clinical derisking continues to drive the risk and cost lower and lower, the vast majority of genetic disease remain too rare to be pursued by industry.”</p>
<p>In one new effort to tackle rare diseases, researchers at the Broad Institute, Boston Children’s Hospital, and The Jackson Laboratory have partnered to establish a non-profit collaboration called the <a href="https://www.jax.org/news-and-insights/2026/july/jax-launches-the-center-for-therapeutic-genetics" target="_blank" rel="noopener">Center for Therapeutic Genetics</a> (CTG) that, Liu said, “we hope is mimicked everywhere… to connect patients with rare diseases.”</p>
<p>The project has received initial commercial support from several companies, including Apertura and Viralgen, as well as Liu’s gene editing companies, Beam Therapeutics and Prime Medicine.</p>
<p>The post <a href="https://www.genengnews.com/topics/genome-editing/no-nonsense-david-liu-lauds-progress-in-disease-agnostic-gene-editing-at-esgct/">No Nonsense: David Liu Lauds Progress in Disease-Agnostic Gene Editing at ESGCT</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Blocking Protein Slows Pancreatic Tumor Growth and Reduces Immune Suppression in Mice</title>
<link>https://edusehat.com/en/blocking-protein-slows-pancreatic-tumor-growth-and-reduces-immune-suppression-in-mice</link>
<guid>https://edusehat.com/en/blocking-protein-slows-pancreatic-tumor-growth-and-reduces-immune-suppression-in-mice</guid>
<description><![CDATA[ Scientists identified a potential therapeutic target for pancreatic ductal cell adenocarcinoma, discovering that the protein ANO6 is involved in a process helping pancreatic cancer cells obtain nutrients from surrounding cells, while suppressing the immune system’s ability to fight tumors. 
The post Blocking Protein Slows Pancreatic Tumor Growth and Reduces Immune Suppression in Mice appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_nature-cancer-cover-art.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 31 Oct 2026 01:10:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Blocking, Protein, Slows, Pancreatic, Tumor, Growth, and, Reduces, Immune, Suppression, Mice</media:keywords>
<content:encoded><![CDATA[<p>Researchers headed by a team at Fox Chase Cancer Center have identified a protein called anoctamin 6 (ANO6) as potential therapeutic target for pancreatic ductal cell adenocarcinoma (PDAC), the most common form of pancreatic cancer. The team’s research discovered that ANO6 helps pancreatic cancer cells obtain nutrients from surrounding cells while suppressing the immune system’s ability to fight tumors. In particular, ANO6 enables cancer-associated fibroblasts (CAFs)—cells that make up much of the dense tissue surrounding pancreatic tumors—to transfer cholesterol and other lipids to cancer cells.</p>
<p>In preclinical tests the scientists demonstrated that blocking ANO6 slowed tumor growth and reduced immune suppression. “These findings help explain how pancreatic cancer cells obtain essential nutrients despite the unusual structure of the pancreatic tumor microenvironment,” said Igor Astsaturov, MD, PhD, a professor at Fox Chase. “Cancer-associated fibroblasts are not passive bystanders. They actively support tumor growth by transferring lipids to cancer cells.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>Astsaturov is co-senior author of the researchers’ published paper in <em>Nature Cancer</em>, titled “<a href="https://doi.org/10.1038/s43018-026-01265-5" target="_blank" rel="noopener">ANO6-mediated trogocytosis of cancer-associated fibroblasts promotes pancreatic cancer cell growth and immune suppression</a>,” in which they reported “Blockade of ANO6 antagonizes tumor growth, partly by disrupting cholesterol delivery to cancer cells, and attenuates immune suppression, identifying ANO6 as a candidate therapeutic target in PDAC.”</p>
<p>Pancreatic ductal adenocarcinoma is surrounded by dense connective tissue and has relatively few functional blood vessels as these collapse due to the expansion of CAFs and their self-generated collagenous fibers acting as a functional unit. How cancer cells obtain nutrients such as cholesterol in this environment isn’t well understood. “How PDAC cells obtain membranous lipids such as cholesterol has, therefore, remained unclear and resolving this could reveal a therapeutic strategy,” the authors wrote.</p>
<p>“We found that CAFs can act as a source of these nutrients,” said co-senior author Edna Cukierman, PhD, professor and co-leader of the Cancer Signaling and Microenvironment Program at Fox Chase. “Using laboratory and animal models, we discovered that CAF units acquire cholesterol from the bloodstream and transfer it to nearby pancreatic cancer cells through a process called trogocytosis.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>The study showed that during trogocytosis, cancer cells take small pieces of the CAF cell membranes, allowing them to acquire cholesterol and other lipids needed for survival and growth. In their paper the authors further explained, “… we show that CAFs transfer exogenous cholesterol and other nutrients through contact-dependent transfer of plasma membrane (PM) fragments, a process known as trogocytosis (trogo, ‘to gnaw’), whereby PDAC cells nibble CAF membranes.”</p>
<p>The process depends on ANO6, which helps prepare the CAF membrane for transfer. When researchers reduced or eliminated ANO6 in CAFs, the cells were less able to support pancreatic cancer cell survival as effectively. In mouse models, tumors supported by ANO6-positive CAFs grew substantially faster than those without functional ANO6.</p>
<p>The study also showed that the same process can interfere with the immune response. CAFs form direct contacts with cytotoxic T lymphocytes (CTLs), immune cells that can recognize and kill cancer cells. During these interactions, the T cells can acquire CAF membrane material, including cholesterol. Excess cholesterol in the tumor environment can contribute to T-cell exhaustion, making the immune cells less effective.</p>
<p>“CAFs also inhibit T cell activity in pancreatic tumors, a major barrier to immunotherapy in this cancer type,” the investigators noted. “We link this immunosuppression to trogocytosis of the CAF membrane by cytotoxic T lymphocytes (CTLs), which causes CTL exhaustion, and show that ANO6 inhibition in CAFs attenuates it.”</p>
<p>Astsaturov further commented, “With Serge Fuchs, professor at the University of Pennsylvania and co-author on the paper, we were surprised to find that the same cellular mechanism can benefit the tumor in two ways—by supplying cancer cells with lipids while also weakening cancer-fighting T cells. Targeting ANO6 could potentially disrupt both of these tumor-supporting functions at the same time.”</p>
<p>The team’s studies in mouse models showed that blocking ANO6 reduced cholesterol accumulation in tumor-infiltrating T cells and improved markers of T-cell activity. Laboratory experiments also showed that T cells exposed to CAFs with reduced ANO6 had greater cancer-killing activity. Cukierman commented “Excitingly, reducing ANO6 expression also disrupted the stromal synapse-mimicry circuit we previously identified, which coordinates tumor nutritional support, CAF-unit metabolism, and immune suppression. These findings position ANO6 as the missing mechanistic link that unifies nearly a decade of discoveries by our team.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>The researchers tested whether disrupting ANO6 could slow pancreatic cancer growth. In mouse models, treatment with the niclosamide or clofazimine—drugs that inhibited ANO6-dependent activity in the study—significantly reduced tumor weight. Niclosamide also reduced the delivery of cholesterol to pancreatic cancer cells.</p>
<p>The researchers noted that trogocytosis is one of several ways pancreatic cancer cells may obtain lipids, and that further research is needed to determine whether selectively targeting ANO6 could be an effective treatment strategy. The ANO6-targeting drugs used in the study may also be deployed to treat other recalcitrant cancers beyond pancreatic adenocarcinoma. And as the team further noted, “Both agents may inhibit targets unrelated to ANO6 and there remains a possibility that their antitumor activity is not exerted solely through trogocytosis.”  Still, they stated, “With that caveat, these well-tolerated and inexpensive compounds provide a tractable pharmacological entry point for testing ANO6 blockade and support the development of selective ANO6 inhibitors for CAF-rich desmoplastic tumors such as pancreatic cancer.”</p>
<p>Astsaturov added, “We believe our findings identify ANO6 as a potential therapeutic target that could simultaneously disrupt the nutrient supply supporting pancreatic cancer cells and reduce the immune-suppressive effects of the tumor microenvironment.”</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/blocking-protein-slows-pancreatic-tumor-growth-and-reduces-immune-suppression-in-mice/">Blocking Protein Slows Pancreatic Tumor Growth and Reduces Immune Suppression in Mice</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Eating disorders are on the rise. GLP&#45;1s could make things worse.</title>
<link>https://edusehat.com/en/eating-disorders-are-on-the-rise-glp-1s-could-make-things-worse</link>
<guid>https://edusehat.com/en/eating-disorders-are-on-the-rise-glp-1s-could-make-things-worse</guid>
<description><![CDATA[ GLP-1 weight-loss drugs are one of the biggest biotech breakthroughs of the last decade. But to some clinical psychologists, they can represent something more sinister—a potential trigger for eating disorders. A new report suggests that the global incidence of anorexia nervosa and bulimia nervosa shot up between 1990 and 2023—by a whopping 71%. By 2023,… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/10/261028_GLP1EatingDisorder.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 18:05:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Eating, disorders, are, the, rise., GLP-1s, could, make, things, worse.</media:keywords>
<content:encoded><![CDATA[<div data-chronoton-summary="<ul><br><li><strong>Eating disorders are surging globally:</strong> A new study in JAMA Psychiatry found anorexia and bulimia rose 71% between 1990 and 2023, affecting an estimated 18.1 million people—and experts say the true number affected by eating disorders is likely three times higher.</li><br><li><strong>Social media is fueling the crisis:</strong> TikTok's algorithm served users with eating disorders 4,343% more harmful content than those without—and clinicians say "thinspiration" trends can trigger new cases.</li><br><li><strong>GLP-1 drugs are making things worse:</strong> Experts are already seeing patients—some as young as 11—misusing weight-loss drugs</li></ul>" data-chronoton-post-id="1147838" data-chronoton-expand-collapse="1" data-chronoton-analytics-enabled="1"></div>


<p class="wp-block-paragraph">GLP-1 weight-loss drugs are one of the biggest biotech breakthroughs of the last decade. But to some clinical psychologists, they can represent something more sinister—a potential trigger for eating disorders.</p>



<p class="wp-block-paragraph">A new report suggests that the global incidence of anorexia nervosa and bulimia nervosa shot up between 1990 and 2023—by a whopping 71%. By 2023, there were an estimated 18.1 million people living with one of these two disorders.</p>





<p class="wp-block-paragraph">What’s worse is that the number is likely to be much higher than that once we factor in other eating disorders. And, disturbingly, those in the field are already starting to see GLP-1 weight-loss drugs exacerbating the issue.</p>



<p class="wp-block-paragraph">Cheri Levinson is a clinical psychologist at the University of Louisville in Kentucky who has specialized in eating disorders for almost 20 years. She says she’s now seeing more patients with more severe symptoms than at any other time in her career, and that many of them are misusing GLP-1s. “This is the worst I’ve seen things,” she says.</p>



<p class="wp-block-paragraph">Eating disorders are mental health conditions in which people’s eating behaviors impact their health. They include anorexia nervosa (defined by a fear of weight gain), bulimia nervosa (in which people binge and purge), binge eating disorder, and others.</p>



<p class="wp-block-paragraph">It’s thought that some people have a genetic predisposition to certain eating disorders, but that some external factor is what triggers their onset. That might be stress, or social pressure to be skinny. Often, simply restricting food intake can trigger an eating disorder, says Levinson.</p>



<p class="wp-block-paragraph">Eating disorders—along with the pressure to look thin—were already prevalent in the 1990s (the <a href="https://www.cosmopolitan.com/lifestyle/a73344972/fashion-week-smoking-skinny-heroin-chic/">heroin chic</a> era springs to mind). To find out how things might have changed since then, Ruhai Bai at the Children’s Hospital of Nanjing Medical University in China and his colleagues pulled together data from studies and surveys conducted on populations around the world. The team used statistical models to fill in any data gaps.</p>



<p class="wp-block-paragraph">That research allowed the researchers to estimate the annual incidence of two eating disorders—anorexia nervosa and bulimia nervosa—for each of 204 countries and territories between 1990 and 2023. They also estimated the impact those disorders had on global health by calculating their disability-adjusted life years (one <a href="https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates/global-health-estimates-leading-causes-of-dalys/">DALY</a> represents a year of healthy life lost).</p>



<p class="wp-block-paragraph">The findings, <a href="https://media.jamanetwork.com/media-releases/10.1001/jamapsychiatry.2026.3457">published in <em>JAMA Psychiatry</em></a> on Wednesday, are unsettling. Between 1990 and 2023, there was a 71% increase in the incidence of those two eating disorders, the team found. Those conditions had a huge impact on global health, too. In 2023, they “cost the world the equivalent of about 3.83 million years of healthy life,” says Bai.</p>





<p class="wp-block-paragraph">Bai and his colleagues expect these figures to continue to rise. In 2023, an estimated 18.1 million people had either anorexia nervosa or bulimia nervosa; by 2050, the team predict, the two conditions could affect 21.8 million people.</p>



<p class="wp-block-paragraph">It gets worse. Those two conditions represent less than half of all eating disorders, says Levinson, who was not involved in Bai’s study. The true impact of these disorders is “probably three times the rate that they’re reporting,” she says.</p>



<p class="wp-block-paragraph">Bai and his colleagues didn’t explore the reasons for this rise (although Bai points out that it can’t be entirely explained by population growth). So how did we get here?</p>



<p class="wp-block-paragraph"><strong>Social media may have played a role.</strong> “Social media comparisons, influencers, challenges, diet trends can all be precipitating … events for an eating disorder,” says Cynthia Bulik, a clinical psychologist at the University of North Carolina, who was not involved in the new study. Bulik has been studying and treating eating disorders since the early 1980s. “Between 1990 and 2023 there has clearly been an upsurge of those types of environmental exposures,” she says.</p>



<p class="wp-block-paragraph">Many social media users are exposed to filtered and modified images of skinny influencers who may have undergone cosmetic surgery or extreme dieting and who are promoting “thinspiration” or “fitspiration” content. But users with eating disorders appear to be more likely to engage with this content—and to be fed more of it as a result.</p>



<p class="wp-block-paragraph">When researchers at the University of Melbourne <a href="https://www.sciencedirect.com/science/article/pii/S1740144524001293">investigated this phenomenon</a> a couple of years ago, they found that the algorithms of TikTok users with eating disorders delivered 4343% more “toxic eating disorder videos” than those of users who didn’t have the disorders. They also got more content focused on dieting or exercising. Many were fed over 1000 problematic videos per month. Bulik describes social media as “quicksand” for people with, or at risk of, eating disorders.</p>



<p class="wp-block-paragraph">The covid-19 pandemic—and the social isolation that accompanied lockdowns—also appears to have contributed to the rise in eating disorders. Research conducted in 2021 found that the number of people hospitalized with eating disorders in the US <a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2786185"><em>doubled</em> between 2018 and 2020</a>.</p>





<p class="wp-block-paragraph">Researchers don’t yet have good data on how trends in eating disorders might have progressed since 2023. But anecdotally, things seem to be getting even worse. “There are more eating disorders, more severe eating disorders… and we’re seeing earlier ages of onset,” says Levinson. “We’re seeing eight- and nine-year-olds with eating disorders.”</p>



<p class="wp-block-paragraph"><strong>“From what I’m hearing and seeing, I am not going to be surprised if that number isn’t at least doubling again,” she adds.</strong></p>



<p class="wp-block-paragraph">Levinson particularly worries about the impact of GLP-1 weight-loss drugs, which have exploded in popularity in recent years. A <a href="https://news.gallup.com/poll/712157/glp-usage-reaches-new-high.aspx">Gallup survey</a> conducted earlier this year suggested that 15% of Americans had used one of these drugs for weight loss. And they’re becoming more accessible—drug companies are working on new formulations that are both easier to take and more effective, and many people can buy versions of these drugs from compound pharmacies or dubious online sources.</p>



<p class="wp-block-paragraph">In <a href="https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2850584">a small study</a> published earlier this year, Levinson and her colleagues found that 30% of people with eating disorders had used GLP-1 drugs. The drugs might benefit some of those people. But 10% appeared to have misused the drugs. And Levinson thinks that figure is also an underestimate.</p>



<p class="wp-block-paragraph">Levinson says she and her colleagues have seen children develop eating disorders after being prescribed GLP-1s for medical reasons. They’ve seen others—even children as young as 11—buy versions of these drugs over TikTok.</p>



<p class="wp-block-paragraph"><strong>“We’re very concerned that GLPs will lead to even faster and more extreme weight loss</strong> in people with anorexia nervosa, and that patients will come to us in even more advanced stages of illness that become difficult to reverse,” says Bulik.</p>



<p class="wp-block-paragraph">Both Bulik and Levinson are continuing to study the impacts of these drugs in eating disorders. In the meantime, both urge medical professionals to consider the risks GLP-1s might pose to people with those disorders. Bulik contributed to a set of <a href="https://onlinelibrary.wiley.com/doi/10.1002/wps.70096">research and clinical guidelines</a>, published earlier this month, that recommends doctors screen for eating disorders before prescribing the drugs, for example. The guidelines also recommend more patient education and more robust monitoring of people who take GLP-1s.</p>



<p class="wp-block-paragraph"><em>If you think you or someone you know might have an eating disorder, you can find information and support at</em> <a href="https://www.nationaleatingdisorders.org/"><em>the National Eating Disorders Association</em></a><em>.</em></p>



<p class="wp-block-paragraph"><em>This article first appeared in The Checkup, </em>MIT Technology Review’s<em> weekly biotech newsletter. To receive it in your inbox every Thursday, and read articles like this first, </em><a href="https://forms.technologyreview.com/newsletters/biotech-the-checkup/?_ga=2.241810882.15113993.1664981064-43237434.1647441349"><em>sign up here</em></a>.</p>



<p class="wp-block-paragraph"><br></p>]]> </content:encoded>
</item>

<item>
<title>Healthcare economics: How hospitals can stay viable without pushing costs onto patients</title>
<link>https://edusehat.com/en/healthcare-economics-how-hospitals-can-stay-viable-without-pushing-costs-onto-patients</link>
<guid>https://edusehat.com/en/healthcare-economics-how-hospitals-can-stay-viable-without-pushing-costs-onto-patients</guid>
<description><![CDATA[ 
When it comes to private healthcare, the narrative is that the charges are high. From the courts to patients, the demand is for private hospital charges to be regulated. This impression that private hospitals overcharge patients cannot be further from the truth. Private healthcare is India faces the challenge of delivering modern quality healthcare at […]
The post Healthcare economics: How hospitals can stay viable without pushing costs onto patients appeared first on Express Healthcare. ]]></description>
<enclosure url="https://cdn.expresshealthcare.in/wp-content/uploads/2026/10/30161422/Dr-S.-Chandrakumar-Founder-and-Executive-Chairman-Kauvery-Group-of-Hospitals.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 17:50:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Healthcare, economics:, How, hospitals, can, stay, viable, without, pushing, costs, onto, patients</media:keywords>
<content:encoded><![CDATA[<div><img width="750" height="400" src="https://cdn.expresshealthcare.in/wp-content/uploads/2026/10/30161422/Dr-S.-Chandrakumar-Founder-and-Executive-Chairman-Kauvery-Group-of-Hospitals.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://cdn.expresshealthcare.in/wp-content/uploads/2026/10/30161422/Dr-S.-Chandrakumar-Founder-and-Executive-Chairman-Kauvery-Group-of-Hospitals.jpg 750w, https://cdn.expresshealthcare.in/wp-content/uploads/2026/10/30161422/Dr-S.-Chandrakumar-Founder-and-Executive-Chairman-Kauvery-Group-of-Hospitals-300x160.jpg 300w" sizes="(max-width: 750px) 100vw, 750px"></div><p align="LEFT"><span><span><span><span lang="en-US">When it comes to private healthcare, the narrative is that the charges are high. From the courts to patients, the demand is for private hospital charges to be regulated. This impression that private hospitals overcharge patients cannot be further from the truth. Private healthcare is India faces the challenge of delivering modern quality healthcare at an affordable price while continuing to invest in the latest medical technologies for the patients’ benefit and at the same time battling inflation with rise in salaries of doctors and paramedical staff, consumables and more. </span></span></span></span></p>
<p align="LEFT"><span><span><span><span lang="en-US">This angst is understandable. While Out-of-Pocket Expenditure (OOPE) as a share of Total Health Expenditure </span></span></span><span><span><span lang="en-US">declined over a decade from 64.2 per cent to 43.4 per cent,</span></span></span><span><span><span lang="en-US"> it is still a significantly large percentage with households financing </span></span></span><span><span><span lang="en-US">56.44 per cent of current health expenditure</span></span></span><span><span><span lang="en-US"> and </span></span></span><span><span><span lang="en-US">nearly 31 per cent of the population</span></span></span><span><span><span lang="en-US"> face financial hardship from out-of-pocket payments.</span></span></span></span></p>
<p align="LEFT"><span><span><span><span lang="en-US">This may lead one to think that all increases in costs are just shifted on to the patient. But this is not true. An increase in tariff is usually the last option on the table. The scrutiny is on how we work and what can be done to reduce costs without compromising quality. The fact is that every inefficiency inside a hospital eventually lands on a patient’s invoice and it is this that we must tackle first!</span></span></span></span></p>
<p align="LEFT"><span><span><span><span lang="en-US"><b>Waste – The first place to look</b></span></span></span></span></p>
<p align="LEFT"><span><span><span><span lang="en-US">An OECD’s review on </span></span></span><span><span><span lang="en-US">Tackling Wasteful Spending on Health</span></span></span><span><span><span lang="en-US"> estimated that around one-fifth of health spending makes little or no contribution to better outcomes. A </span></span></span><span><span><span lang="en-US">study of US healthcare put the cost of waste </span></span></span><span><span><span lang="en-US">at $760 billion to $935 billion a year, about 25 per cent of total healthcare spends. Of this administrative complexity alone accounted for $265.6 billion. Savings from interventions that address waste were $191 billion to $286 billion. </span></span></span></span></p>
<p align="LEFT"><span><span><span><span lang="en-US">Hospitals in India run on far thinner budgets, yet the same categories also contribute to waste – avoidable complications, repeat tests, idle operation theatres, and too much paperwork that delays discharge.</span></span></span></span></p>
<p align="LEFT"><span><span><span><span lang="en-US"><b>Infection control to control cost</b></span></span></span></span></p>
<p align="LEFT"><span><span><span><span lang="en-US">The top-of-mind factor when one says infection control is hospital-acquired infections (HAIs). A </span></span></span><span><span><span lang="en-US">study of the impact of HAIs on costs and clinical outcomes</span></span></span><span><span><span lang="en-US"> found that an infection acquired in the ICU roughly doubled the median treatment cost, from Rs 92,893 to Rs 1,80,469, and stretched ICU stay from 6.7 to 13.4 days. Another </span></span></span><span><span><span lang="en-US">recent study</span></span></span><span><span><span lang="en-US"> in a tertiary hospital reached a similar conclusion with length of ICU stay being the main reason for the added cost.</span></span></span></span></p>
<p align="LEFT"><span><span><span><span lang="en-US">It is here that hospitals must realise that while hand-hygiene audits, ventilator and catheter bundles, and antibiotic stewardship are clinical programmes, they also belong on a finance committee’s agenda. A patient who avoids a bloodstream infection goes home sooner with better clinical outcomes, pays less, and frees a bed for the next admission.</span></span></span></span></p>
<p align="LEFT"><span><span><span><span lang="en-US"><b>Fix the process</b></span></span></span></span></p>
<p align="LEFT"><span><span><span><span lang="en-US">Process redesign is not glamorous, but it works. </span></span></span><span><span><span lang="en-US">Methods utilising lean tools such as value-stream mapping</span></span></span><span><span><span lang="en-US"> and root cause analysis help to reduce waste and improve productivity. A </span></span></span><span><span><span lang="en-US">survey of private hospitals</span></span></span><span><span><span lang="en-US"> in India found that management commitment to lean practices had a statistically significant effect on both operational and financial performance. High volumes, standardised protocols and strategic use of data can produce outcomes on par with US centres at a fraction of the cost. Theatre scheduling, discharge planning and bed turnover may not be glamorous but lead to gains that can be passed on to the patient. </span></span></span></span></p>
<p align="LEFT"><span><span><span><span lang="en-US"><b>Buy better</b></span></span></span></span></p>
<p align="LEFT"><span><span><span><span lang="en-US">Pharmacies alone accounted for Rs </span></span></span><span><span><span lang="en-US">1.63 lakh crore, or 21.2 per cent of current health expenditure</span></span></span><span><span><span lang="en-US"> in 2022-23, up from Rs </span></span></span><span><span><span lang="en-US">1.53 lakh crore in the previous year. </span></span></span><span><span><span lang="en-US">During the same period, private hospitals increased their </span></span></span><span><span><span lang="en-US">current health expenditure (CHE) share from 26.96 per cent in 2021-22 to 30.83 per cent</span></span></span><span><span><span lang="en-US">. It is here that pooled procurement can help to lower prices, especially for large buyers. Autonomous agencies such as those affiliated to state governments can </span></span></span><span><span><span lang="en-US">negotiate and secure lower prices</span></span></span><span><span><span lang="en-US">. Medicines and consumables deserve the same scrutiny. Hospital groups can apply the same logic and manage inventory more scientifically through central purchasing, a disciplined formulary and quality-assured generics.</span></span></span></span></p>
<p align="LEFT"><span><span><span><span lang="en-US"><b>Transparency about price</b></span></span></span></span></p>
<p align="LEFT"><span><span><span><span lang="en-US">Efficiency helps patients only if the savings reach them. Fixed package prices for common procedures, published in advance, protect families from open-ended bills and push hospitals to manage and prevent any variation in cost. </span></span></span></span></p>
<p align="LEFT"><span><span><span><span lang="en-US">Of course, why these points can help hospitals stay financially viable without pushing costs onto patients, none of this removes the need for higher public spending. government health expenditure is still only </span></span></span><span><span><span lang="en-US">1.43 per cent of GDP</span></span></span><span><span><span lang="en-US">. Private hospitals cannot wait for policy to support cost structures, though. Staying viable without burdening patients must be decided in reducing waste, choices about infection, patient flow and optimal purchasing. These steps may not make headlines but will have impact and help viability in the long run!</span></span></span></span></p>
<p>The post <a href="https://www.expresshealthcare.in/news/healthcare-economics-how-hospitals-can-stay-viable-without-pushing-costs-onto-patients/455714/">Healthcare economics: How hospitals can stay viable without pushing costs onto patients</a> appeared first on <a href="https://www.expresshealthcare.in/">Express Healthcare</a>.</p>]]> </content:encoded>
</item>

<item>
<title>IP: American as apple pie and essential for biotech</title>
<link>https://edusehat.com/en/ip-american-as-apple-pie-and-essential-for-biotech</link>
<guid>https://edusehat.com/en/ip-american-as-apple-pie-and-essential-for-biotech</guid>
<description><![CDATA[ The United States leads the world in biotech innovation, and a major driver is its strong intellectual property (IP) system. In fact, IP rights […]
The post IP: American as apple pie and essential for biotech appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/10/smithsonian-8OIVMGwvS7E-unsplash.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 03:45:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>IP:, American, apple, pie, and, essential, for, biotech</media:keywords>
<content:encoded><![CDATA[<p><span>The United States leads the world in biotech innovation, and a major driver is its strong intellectual property (IP) system.</span></p>
<p><span>In fact, IP rights are as American as apple pie. President George Washington not only talked about the importance of intellectual property protection in his first State of the Union address, but American IP rights were codified in the Patent Act in April of 1790—only 14 years into the country’s founding.</span></p>
<p><span>“That’s because the Founders, in creating our country and looking at the model of what was working and not working in England, saw that economic protection for scientific discoveries and innovations was critical to grow, support and nurture the economic success of a new country,” said Coke Morgan Stewart, the President and CEO of the Council for Innovation Promotion (C4IP), and former Deputy Undersecretary of Commerce for Intellectual Property and Deputy Director of the U.S. Patent and Trademark Office (USPTO) during</span><a href="https://ipprotectionmatters.org/episodes/30d15670-12ac-4c15-8f37-3e9b03f3ff26:ip-protections-for-scientific-discoveries-and-innovations-critical-for-americas-economic-success/"> <span>a conversation she had with the Center For Individual Freedom</span></a><span>.</span></p>
<p><span>For</span><a href="https://www.usipalliance.org/october-ip-month"> <span>IP Awareness Month this October</span></a><span>, Bio.News looks at how IP has helped facilitate decades of innovation in biotech, helping patients lead better, healthier, and long lives. </span></p>
<h3>The circle of biotech innovation</h3>
<p><span>It all starts with the spark of an idea. </span></p>
<p><span>A scientist in a lab makes a discovery and recognizes its potential to fill an unmet medical need: a treatment, therapy, or even a cure. So the scientist’s institution or company files a patent on their discovery. But why?</span></p>
<p><span>The biotech industry is one of the most research-intensive industries operating today, requiring often over a decade of work and billions of dollars to get a drug, treatment, or cure to market. </span></p>
<p><span>And IP protections, in many ways, act as the armor around an idea or invention, allow for:</span></p>
<ul>
<li aria-level="1"><span>The incentivization of innovation, allowing inventors to recover their research and development costs and profit from their hard work;</span></li>
<li aria-level="1"><span>Prevention of counterfeiting, which doesn’t just prevent theft of an idea, but also the ability to profit from its introduction to the market, allowing inventors to keep developing new ideas; and</span></li>
<li aria-level="1"><span>Attraction of investment, building economic value for both individual companies, as well as the economy as a whole.</span></li>
</ul>
<p><span>Any biotech, big, small, or in between, needs IP protections to keep the circle of innovation turning, but when it comes to small biotechs, the stakes are much higher, making these protections even more imperative—and protecting them is good for patients too.</span></p>
<p><a href="https://bio.news/bio-convention/ahead-of-bio-ip-conference-research-highlights-why-biotech-needs-strong-patents/"><span>As Bio.News reported</span></a><span>: “By most estimates, small and medium-sized biotech firms are behind the majority of new drugs. One study shows 55% of drugs gaining Food and Drug Administration (FDA) approval between 2011-2022 were developed by companies with less than $500 million in revenue.”</span></p>
<p><span>“There’s a lot of people who believe that patents stifle competition,” said panelist Dede Willis, CEO of Orbit Geonomics</span><a href="https://bio.news/bio-convention/bio-2026-biotech-threatened-by-pressures-on-patent-protection/"> <span>during the 2026 International BIO Convention</span></a><span>. “I would actually argue the opposite, for life sciences in particular, especially biotech, where the timelines to get to market and the cost to develop a product are extremely high. The patents are actually increasing competition because they’re enabling new technologies to be funded and commercialized.”</span></p>
<h3>Completing the cycle</h3>
<p><span>Let’s look at the end of a development cycle: the R&D was successful, the clinical trials are complete, and the FDA is on board. The drug is going to market and the investors are making a return on their investment. What do they do? Say </span><i><span>Thanks, that was fun, but I am moving on</span></i><span>. Well, as it would turn out, not really.</span></p>
<p><a href="https://www.bio.org/toolkit/intellectual-property/circle-biotech-innovation"><span>As BIO has found</span></a><span>, “Revenue from product sales helps fund future research. U.S. biopharma firms reinvest about 34% of their revenue into R&D, more than almost every other industry.”</span></p>
<p><span>And the numbers behind that 34% are huge. As the study, “</span><a href="https://www.nature.com/articles/d41573-024-00131-2"><span>Comprehensive measurement of biopharmaceutical R&D investment</span></a><span>” found, “global biopharmaceutical R&D investment totaled $276 billion across 4,191 global companies in 2021.”</span></p>
<p><span>And these numbers have been holding steady and even gaining momentum.</span></p>
<p><a href="https://bio.news/bio-convention/big-summit-experts-see-signs-of-ma-momentum-in-2026/"><span>As Bio.News reported in February</span></a><span>: “both licensing and M&A in biopharma, saw over 4,000 deals and more than $600 billion in headline value—and 2026 seems to be keeping up this momentum.”</span></p>
<p><span>Continuing, “there were a total of 4,341 deals in 2025, compared to 3,883 in 2024, and the $606 billion in total deal value was higher than the $421 billion in 2024. The $291 billion in upfront cash and equity of 2025 was an improvement over the $191 billion in 2024. Notably, large cap biopharmas signed fewer, higher-value deals, with 255 in 2025, compared to 294 in 2024.”</span></p>
<p><span>And thus the cycle continues, and even powers itself.</span></p>
<p><span>As a last example, a</span><a href="https://www.uschamber.com/assets/documents/GIPC_IPIndex2026_Annex_v3.pdf"> <span>2026 study</span></a><span> published by the U.S. Chamber of Commerce Global Innovation Policy Center found that the U.S.’s strong IP safeguards not only make it more competitive today, but also ensure competitiveness for the future.</span></p>
<p><span>“Economies with robust IP environments are 97% more likely to be prepared for the future of growth,” the study observed. Continuing, “economies with strong IP systems are 59% more likely to be able to transform their economies using sophisticated, state-of-the-art technologies compared with economies whose IP systems require improvement.”</span></p>
<p><span>And so, IP proves itself time and time again to be a key element of innovation, progress, and competitiveness.</span></p>
<p>The post <a href="https://bio.news/federal-policy/ip-american-as-apple-pie-and-essential-for-biotech/">IP: American as apple pie and essential for biotech</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>BIO supports FDA’s new Fit&#45;for&#45;Purpose Rare Disease Framework Initiative</title>
<link>https://edusehat.com/en/bio-supports-fdas-new-fit-for-purpose-rare-disease-framework-initiative</link>
<guid>https://edusehat.com/en/bio-supports-fdas-new-fit-for-purpose-rare-disease-framework-initiative</guid>
<description><![CDATA[ BIO praised a Food and Drug Administration (FDA) initiative targeting more tailored, patient-centered, and predictable development of rare disease drugs, while recommending ways to […]
The post BIO supports FDA’s new Fit-for-Purpose Rare Disease Framework Initiative appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/10/wikimedia-david-richfield.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 03:45:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>BIO, supports, FDA’s, new, Fit-for-Purpose, Rare, Disease, Framework, Initiative</media:keywords>
<content:encoded><![CDATA[<p>BIO praised a Food and Drug Administration (FDA) initiative targeting more tailored, patient-centered, and predictable development of rare disease drugs, while recommending ways to make it happen, at an Oct. 28 public meeting.</p>
<p>The<a href="https://www.fda.gov/news-events/press-announcements/fda-launches-rare-disease-framework-initiative-develop-holistic-fit-purpose-framework-rare-disease"> FDA’s Fit-for-Purpose Rare Disease Framework Initiative</a> seeks to accommodate the unique challenges of developing and reviewing drugs for rare diseases.</p>
<p>Compared to other conditions, rare diseases have small patient populations, limited natural history data, and disease heterogeneity, and they pose challenges in generating conventional clinical evidence. Attracting investment for rare disease drug development can be difficult due to the constraints of small patient populations and certain regulatory challenges.</p>
<p>For all these reasons, <a href="https://pubmed.ncbi.nlm.nih.gov/37353796/">95% of rare disease patients still lack an approved treatment,</a> though rare disease impacts over <a href="https://www.fda.gov/patients/rare-diseases-fda">30 million Americans</a>, making efforts to ease drug development both welcome and urgently needed.</p>
<p>“We strongly support FDA’s effort today,” E’Lissa Flores, Senior Director, Science and Regulatory Affairs at the Biotechnology Innovation Organization (BIO), told the public meeting. “BIO sees this Framework as an opportunity to translate fit-for-purpose principles into consistent practice, with greater predictability, early alignment, patient input, and appropriate consideration of uncertainty, while maintaining scientific rigor and FDA standards.”</p>
<p>Led by FDA’s Rare Disease Innovation Hub—in partnership with the Center for Drug Evaluation and Research (CDER), the Center for Biologics Evaluation and Research (CBER), and the Office of the Commissioner—the <a href="https://www.fda.gov/news-events/press-announcements/fda-launches-rare-disease-framework-initiative-develop-holistic-fit-purpose-framework-rare-disease">initiative was announced</a> Oct. 14, and<a href="https://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/fda-rare-disease-framework-initiative-public-meeting-10282026"> the public meeting</a> was called as the first major step in its development.</p>
<p>“BIO’s members appreciate that FDA is seeking input before moving forward and welcome the opportunity to provide feedback through this public meeting and through written comments until Dec. 11,” Flores said.</p>
<h2>FDA’s basic principles for the initiative</h2>
<p><a href="https://www.fda.gov/news-events/press-announcements/fda-launches-rare-disease-framework-initiative-develop-holistic-fit-purpose-framework-rare-disease">FDA said the following principles</a> would be instrumental in developing the Fit-for-Purpose Rare Disease Framework Initiative:</p>
<ul>
<li>“Providing greater clarity, consistency, and predictability in regulatory decision-making through tailored guidance and transparent communication.”</li>
<li>“Embedding the patient’s voice both early, and at clearly defined milestones, in the drug development and review process.”</li>
<li>“Further leveraging external expertise to support customization of regulatory review.”</li>
<li>“Building shared resources, robust training, and institutional knowledge on rare disease drug development and review.”</li>
<li>“Applying risk-based approaches, particularly to chemistry, manufacturing, and controls review and pre-approval inspections.”</li>
<li>“Championing the use of cutting-edge science, novel methods and innovative statistical approaches in rare disease drug development.”</li>
</ul>
<h2>BIO’s initial recommendations</h2>
<p>In her comments at the public meeting, Flores highlighted some emerging themes for consideration when implementing the initiative:</p>
<ul>
<li>“BIO encourages FDA to apply fit-for-purpose evidentiary approaches that maintain scientific rigor while reflecting the realities of rare disease,” Flores said. To do this, FDA should consider all available evidence—such as natural history, biomarker, and real-world evidence—and apply it consistently across all FDA centers and review teams.</li>
<li>The fit-for-purpose principles should extend to the Chemistry, Manufacturing and Controls (CMC) portion of an investigational new drug (IND) application, as this component is also different for rare diseases. “BIO supports risk-based approaches to the timing and generation of CMC evidence that recognize the realities of rare disease development while maintaining appropriate product-quality standards,” Flores said.</li>
<li>The Framework presents an opportunity to move innovation into regulatory practice. FDA should seek to advance methods from pilots and workshops into routine regulatory use and for updating guidance.</li>
<li>Early and ongoing FDA-sponsor alignment is essential, through early conversations about expectations that take place before an IND. “That includes early dialogue around endpoints, evidence-generation strategies, trial design, preclinical and CMC expectations, and acceptable uncertainty,” according to Flores.</li>
<li>“Patient input should be embedded throughout the development lifecycle,” Flores emphasized. This means FDA should clarify when patient input should be provided, how it will be considered, “and how patient engagement, patient experience data, and patient preference information can appropriately inform regulatory decision-making.”</li>
<li>Consistent implementation across review divisions and FDA centers is essential. “The Rare Disease Innovation Hub can help by integrating expertise across the Agency, sharing successful approaches and best practices, and facilitating external expertise to support reviewer education and ensure decisions reflect the latest science,” Flores said.</li>
</ul>
<p>“BIO looks forward to continuing its engagement with the FDA to advance fit-for-purpose regulatory approaches that maintain scientific rigor while supporting the timely development of safe and effective treatments for patients with rare diseases,” Flores concluded. BIO plans to work closely with its members to submit detailed comments and key recommendations to docket in support of FDA’s development and implementation of the Framework.</p>
<p>FDA has issued a Request For Information on the initiative and is accepting written<a href="https://www.federalregister.gov/documents/2026/10/16/2026-21142/fit-for-purpose-rare-disease-framework-initiative-public-meeting-request-for-information-and"> comments through the Federal Register until Dec. 11</a>.</p>
<hr>
<p><em>(Photo by David Richfield, Wikimedia Commons.)</em></p>
<p>The post <a href="https://bio.news/federal-policy/bio-supports-fdas-new-fit-for-purpose-rare-disease-framework-initiative/">BIO supports FDA’s new Fit-for-Purpose Rare Disease Framework Initiative</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>CDC report details impact of AMR pathogens</title>
<link>https://edusehat.com/en/cdc-report-details-impact-of-amr-pathogens</link>
<guid>https://edusehat.com/en/cdc-report-details-impact-of-amr-pathogens</guid>
<description><![CDATA[ The most dangerous antimicrobial-resistant (AMR) pathogens in America are causing an estimated 9.7 million infections and 50,800 deaths in the U.S. each year, says […]
The post CDC report details impact of AMR pathogens appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/10/cdc-iwkcspbMWx8-unsplash-e1793305581228.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 03:45:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>CDC, report, details, impact, AMR, pathogens</media:keywords>
<content:encoded><![CDATA[<p><span>The most dangerous antimicrobial-resistant (AMR) pathogens in America are causing an estimated 9.7 million infections and 50,800 deaths in the U.S. each year, says the Centers for Disease Control and Prevention (CDC).</span></p>
<p><span>Released Oct. 27, CDC’s</span><a href="https://arpsp.cdc.gov/artr/antimicrobial-resistance-threats"> <span>latest report</span></a><span> on AMR pathogens identifies 19 bacteria and fungi that pose urgent, serious, or concerning threats to human health.</span></p>
<p><span>“The most comprehensive estimate to date of the impact of drug-resistant pathogens on human health in the United States …</span><a href="https://arpsp.cdc.gov/artr/antimicrobial-resistance-threats"> <span>the AR Threats Report</span></a><span> provides critical data that can help guide policy, investments, and interventions to protect Americans from drug resistance,” according to CDC.</span></p>
<p><span>These dangerous pathogens have mutated to the point where existing antimicrobial drugs are no longer able to contain them. Germs that were once mostly considered threats to hospitalized patients are also causing infections in people who receive care outside of hospitals.</span></p>
<p><span>Combatting these new superbugs requires new antimicrobials, but there are few such drugs in development because the market for antimicrobial innovation is fundamentally broken.</span></p>
<p><span>“This latest report shows more detail on the enormous threat of AMR, which we know has the potential to cause</span><a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01867-1/fulltext"> <span>nearly 170 million deaths worldwide by 2050</span></a><span>,” says Emily Wheeler, Vice President of Infectious Disease Policy at the Biotechnology Innovation Organization (BIO). “We need new antimicrobials for the most critical infections, and the only way to get that is with policy solutions that encourage development and innovation, such as the PASTEUR Act.”</span></p>
<h2>A policy solution for market dysfunction</h2>
<p><span>Unfortunately, the market for developing new antimicrobials is broken.</span></p>
<p><span>The need to use antimicrobials judiciously makes it</span><a href="https://workingtofightamr.org/wp-content/uploads/2026/07/The-Toll-of-the-Broken-Antimicrobial-Market-2026.pdf"> <span>nearly impossible for biotechs</span></a><span> developing these innovative drugs to recoup their investment. In recent years, the FDA has approved a few new antimicrobials from small companies, but today, nearly every company behind those innovations “have either gone into bankruptcy or the economic equivalent. Their R&D investors are completely wiped out,”</span><a href="https://bio.news/biosecurity/pasteur-act-amr-antimicrobial-resistance-barda-carb-x-2023-bio-international-convention/#:~:text=Furthermore%2C%C2%A0when%20we%20develop%20new%20antibiotics%2C%20%E2%80%9Cas%20soon%20as%20we%20start%20using%20them%2C%20the%20bacteria%20respond%2C%E2%80%9D%20said%20Kevin%20Outterson%2C%20Executive%20Director%20of%20CARB-X%2C%20in%20an%20interview%20during%20the%202023%20Biotechnology%20Innovation%20Organization%20(BIO)%20International%20Convention."> <span>Kevin Outterson</span></a><span>, whose organization CARB-X leads a public-private partnership to fund new antimicrobials,</span><a href="https://bio.news/federal-policy/senators-seek-solutions-for-amr-maintaining-us-biotech-leadership/"> <span>told an Aug. 7 Senate hearing</span></a><span>.</span></p>
<p><span>One policy proposal to address the problem is</span><a href="https://www.bennet.senate.gov/2026/06/24/bennet-young-colleagues-reintroduce-bipartisan-pasteur-act-to-fight-antimicrobial-resistance/"> <span>the PASTEUR Act</span></a><span>, which would encourage development of new, innovative antimicrobials for the most critical infections.</span></p>
<p><span>Instead of a model based on volume, PASTEUR would implement a new contracting model that provides predictable support for qualifying new antimicrobials, ensuring health care providers have the tools they need to treat superbugs.</span></p>
<p><span>Government incentives for new AMR treatments would save lives, and money, Outterson said. “This would be a remarkably great value for the U.S. taxpayers,” he maintained. “A Center for Global Development study found a 28-to-1 return.”</span></p>
<p><span>The price of inaction is steep, and not only in lives.</span></p>
<p><span>“Seven bacterial threats included in the report that are commonly associated with health care caused more than 42,000 deaths in 2023 and resulted in nearly $12 billion dollars in healthcare costs,” </span><a href="https://www.cdc.gov/antimicrobial-resistance/programs/AR-investments.html"><span>CDC said</span></a><span>. </span></p>
<p><span>Given AMR’s costs in lives, health, and money, BIO supports the PASTEUR Act. The “legislation would help to repair the broken marketplace for antimicrobials by enabling a business model centered around the appropriate use of new and novel treatments,” said</span><a href="https://buddycarter.house.gov/news/documentsingle.aspx?DocumentID=16321#:~:text=%22The%20introduction%20of,need%20them%20most.%22"><span> BIO President & CEO John F. Crowley, when the bill was reintroduced</span></a><span> in Congress earlier this year.</span></p>
<p><span>BIO has called attention to patient challenges with AMR, including by sharing the story of patient advocate</span><a href="https://fightofourlives.com/stories/katy/"> <span>Katy Grainger in “The Fight of Our Lives.”</span></a><span> BIO also has more</span><a href="https://www.bio.org/policy/human-health/antimicrobial-resistance"> <span>resources on AMR here.</span></a></p>
<h2>CDC’s list of the 19 most-dangerous pathogens</h2>
<p><b>Urgent Threats</b></p>
<p><span>These pathogens are public health threats that require urgent and aggressive action.</span></p>
<ul>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/cauris"><i><span>Candida auris</span></i><span> (</span><i><span>C. auris</span></i><span>)</span></a></li>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/acinetobacter"><span>Carbapenem-resistant </span><i><span>Acinetobacter</span></i></a></li>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/CRE"><span>Carbapenem-resistant Enterobacterales (CRE)</span></a></li>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/gonorrhea"><span>Drug-resistant </span><i><span>Neisseria gonorrhoeae</span></i></a></li>
</ul>
<p><b>Serious Threats</b></p>
<p><span>These pathogens are public health threats that require prompt and sustained action.</span></p>
<ul>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/cdiff"><i><span>Clostridioides difficile</span></i><span> (</span><i><span>C. diff</span></i><span>)</span></a></li>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/campylobacter"><span>Drug-resistant </span><i><span>Campylobacter</span></i></a></li>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/candida"><span>Drug-resistant </span><i><span>Candida</span></i></a></li>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/TB"><span>Drug-resistant </span><i><span>Mycobacterium tuberculosis</span></i></a></li>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/nmeningitidis"><span>Drug-resistant </span><i><span>Neisseria meningitidis</span></i></a></li>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/salmonella"><span>Drug-resistant nontyphoidal </span><i><span>Salmonella</span></i></a></li>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/typhi"><span>Drug-resistant </span><i><span>Salmonella</span></i><span> Typhi</span></a></li>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/shigella"><span>Drug-resistant </span><i><span>Shigella</span></i></a></li>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/spneumoniae"><span>Drug-resistant </span><i><span>Streptococcus pneumoniae</span></i></a></li>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/ESCRE"><span>Extended-spectrum cephalosporin-resistant Enterobacterales (ESC-RE)</span></a></li>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/MRSA"><span>Methicillin-resistant </span><i><span>Staphylococcus aureus</span></i><span> (MRSA)</span></a></li>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/paeruginosa"><span>Multidrug-resistant </span><i><span>Pseudomonas aeruginosa</span></i></a></li>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/VRE"><span>Vancomycin-resistant </span><i><span>Enterococcus</span></i><span> (VRE)</span></a></li>
</ul>
<p><b>Concerning Threats</b></p>
<p><span>These pathogens are public health threats that require careful monitoring and prevention action.</span></p>
<ul>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/GBS"><span>Clindamycin-resistant group B </span><i><span>Streptococcus</span></i><span> (GBS)</span></a></li>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/GAS"><span>Drug-resistant group A </span><i><span>Streptococcus</span></i><span> (GAS)</span></a></li>
</ul>
<p>The post <a href="https://bio.news/health/cdc-report-details-impact-of-amr-pathogens/">CDC report details impact of AMR pathogens</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Building the Future of AAV Gene Therapy</title>
<link>https://edusehat.com/en/building-the-future-of-aav-gene-therapy</link>
<guid>https://edusehat.com/en/building-the-future-of-aav-gene-therapy</guid>
<description><![CDATA[ This eBook brings together perspectives from across the AAV development and manufacturing continuum. It explores how early commercial planning can help avoid costly delays, how standardized platform approaches and off-the-shelf plasmids can streamline development, and how next-generation innovations are helping overcome long-standing manufacturing bottlenecks.
The post Building the Future of AAV Gene Therapy appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Catalent_AAVGeneTherapyEbook.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 03:40:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Building, the, Future, AAV, Gene, Therapy</media:keywords>
<content:encoded><![CDATA[<div aria-hidden="true" class="wp-block-spacer"></div>


<p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Read Now</button></p>


<p class="wp-block-paragraph">Adeno-associated virus (AAV) gene therapies have transformed the treatment landscape for rare and genetic diseases, delivering potentially life-changing outcomes for patients and validating the promise of genetic medicine. As the field continues to mature, however, the challenges facing developers are evolving. The question is no longer simply whether an AAV therapy can demonstrate clinical efficacy. Increasingly, success depends on whether organizations can reliably develop, manufacture, scale, and deliver these therapies in a commercially sustainable way.</p>


<figure class="wp-block-image alignright size-medium"><img fetchpriority="high" decoding="async" width="232" height="300" src="https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Catalent_Cover-232x300.jpg" alt="Building the Future of AAV Gene Therapy: Strategies for Scalable Development, Manufacturing, and Commercialization Catalent eBook" class="wp-image-339984" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Catalent_Cover-232x300.jpg 232w, https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Catalent_Cover-791x1024.jpg 791w, https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Catalent_Cover-768x994.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Catalent_Cover-1187x1536.jpg 1187w, https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Catalent_Cover-1583x2048.jpg 1583w, https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Catalent_Cover-scaled.jpg 1978w" sizes="(max-width: 232px) 100vw, 232px"></figure>


<p class="wp-block-paragraph">Today, gene therapy developers must navigate a complex environment characterized by rising demand, manufacturing capacity constraints, global supply chain considerations, and increasing expectations for commercial readiness. Traditional approaches that worked during early clinical development may not be sufficient as programs advance toward registration, launch, and long-term commercial supply. As a result, the industry is placing greater emphasis on platform technologies, integrated development strategies, resilient supply chains, and manufacturing innovations that can accelerate timelines while improving scalability and consistency.</p>


<p class="wp-block-paragraph">This eBook brings together perspectives from across the AAV development and manufacturing continuum. It explores how early commercial planning can help avoid costly delays, how standardized platform approaches and off-the-shelf plasmids can streamline development, and how next-generation innovations are helping overcome long-standing manufacturing bottlenecks. It also examines the growing importance of supply chain orchestration and case management in ensuring therapies reach patients safely, efficiently, and on time.</p>


<p class="wp-block-paragraph">As the number of AAV-based therapies advances through clinical development and toward commercialization, organizations that successfully integrate manufacturing strategy, supply chain planning, and technological innovation will be best positioned to deliver therapies at scale. The lessons and insights presented in these articles highlight practical approaches for addressing today’s challenges while preparing for the future of gene therapy. Together, they provide a roadmap for developers seeking to accelerate development, optimize manufacturing performance, strengthen supply resilience, and ultimately improve patient access to transformative AAV-based medicines.</p>

<p>The post <a href="https://www.genengnews.com/resources/ebooks/building-the-future-of-aav-gene-therapy/">Building the Future of AAV Gene Therapy</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>First Whole&#45;Body Single&#45;Cell Atlas of Adult Vertebrate Generated in Danionella cerebrum</title>
<link>https://edusehat.com/en/first-whole-body-single-cell-atlas-of-adult-vertebrate-generated-in-danionella-cerebrum</link>
<guid>https://edusehat.com/en/first-whole-body-single-cell-atlas-of-adult-vertebrate-generated-in-danionella-cerebrum</guid>
<description><![CDATA[ Researchers created the first comprehensive whole-body single-cell atlas of an adult vertebrate, the tiny, transparent fish Danionella cerebrum, offering a new resource for studying brain regeneration, cellular diversity, and investigating how different tissues function together.
The post First Whole-Body Single-Cell Atlas of Adult Vertebrate Generated in Danionella cerebrum appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/low-res-1.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 03:40:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>First, Whole-Body, Single-Cell, Atlas, Adult, Vertebrate, Generated, Danionella, cerebrum</media:keywords>
<content:encoded><![CDATA[<p>Whitehead Institute researchers have created the first comprehensive whole-body single-cell atlas of an adult vertebrate, the tiny, transparent teleost fish <em>Danionella cerebrum</em>.</p>
<p>The team profiled more than 600,000 cells from across the fish to build the whole-body single-cell transcriptome atlas of which genes are active in which cell. A cell’s transcriptome is the full set of RNA molecules it has made from its DNA at a given time, providing a snapshot of which genes the cell is using.</p>
<p>Together, the data provide a molecular reference for the cell types found throughout <em>Danionella</em>, the patterns of gene activity that distinguish them, and where many of them are located. Offering a new resource for studying brain regeneration, cellular diversity, and investigating how different tissues function together, the atlas gives researchers a baseline for exploring how injury, aging, drugs, or other changes affect cells across the whole animal.</p>
<p>The team has made the atlas publicly available through <a href="https://digifish.wi.mit.edu/" target="_blank" rel="noopener">DigiFish</a>, an interactive resource for exploring cell types and gene activity throughout the animal. Paired with <em>Danionella</em>’s transparency and growing experimental toolkit, the atlas can help researchers identify specific cells and genes to study or manipulate and then follow their activity in the animal.</p>
<p>“Once you have a spatially resolved atlas, you know what cell types exist, but you also know the neighbors of those cell types in this context,” said Kutay Deniz Atabay, PhD, who led the work as a postdoctoral researcher in the lab of Whitehead Institute Member Peter Reddien, PhD. “This gives you access at multiple different levels of complexity, from molecular to cellular to systems.”</p>
<p>Atabay is first author, and Reddien senior and corresponding author of the researchers’ published paper in <em>Science</em>, titled “<a href="https://www.science.org/doi/10.1126/science.aeg1125" target="_blank" rel="noopener">Whole-body single-cell atlas of an adult vertebrate, <em>Danionella cerebrum</em>,</a>” in which they stated, “This whole-vertebrate transcriptome atlas yields a comprehensive resource for myriad questions in biology and neuroscience.”</p>
<p><em>Danionella cerebrum</em> is one of the world’s smallest vertebrates (∼12 mm in length), and has the smallest vertebrate brain on record, containing ∼650,000 neurons within 0.6 mm<sup>3</sup>, the authors wrote. This is approximately four times the size of the Drosophila brain, but with all the major vertebrate brain regions. Viewed from above, <em>Danionella cerebrum</em> offers a rare sight in a vertebrate, in that its brain is visible through the top of its head. “Thanks to its optical transparency, <em>D. cerebrum</em> is arguably unparalleled for noninvasive live whole-brain and whole-body imaging at single-cell resolution in an adult vertebrate …” the team noted.</p>
<p>Since the species was adopted for neuroscience research in 2018 and formally described in 2021, the tiny, transparent fish has drawn rapidly growing interest for its unique biology.</p>
<p>Whitehead Institute researchers recognized that the tiny fish brought whole-animal single-cell profiling within reach, allowing the team to create the first comprehensive map of cell types and gene activity across an adult vertebrate. That perspective could help reveal how cells in different tissues coordinate their responses—and how changes in one part of the body influence others.</p>
<p>Cell atlases have become increasingly detailed, but extending them across a whole adult vertebrate has been difficult for the basic reason of size. Profiling the cellular diversity of larger animals comprehensively is technically demanding and expensive. “The molecular mapping of cell transcriptomes across the entire animal anatomy of an adult vertebrate has not been achieved, largely because most vertebrates are too large for comprehensive molecular access to their cellular and molecular complexity, the investigators pointed out. <em>Danionella</em>—at barely one centimeter long—makes the experiment possible, while its close relationship to zebrafish allows researchers to draw on genetic tools developed for one of biology’s most widely used model organisms. “We reasoned that the extreme miniaturization of <em>Danionella</em> could enable organism-wide cell type profiling and facilitate high-throughput molecular studies,” they continued. “<em>D. cerebrum</em> is also closely related to zebrafish, which allows for the transfer and use of an expansive molecular toolkit, and its genome, similar to many other teleosts, is approximately half the size of the zebrafish genome.“</p>
<p>Atabay first became interested in <em>Danionella</em> in early 2019, while searching for a small, transparent animal in which he could watch the nervous system regenerate. Its miniature size and accessible brain made it especially promising for that work, and the researchers found that the fish has broad regenerative capacity, including in the brain and fins. Reddien’s lab, meanwhile, had already seen the value of a comprehensive whole-animal cell atlas through work on planarians, regenerative flatworms whose small size had made such an atlas possible. Together, those interests led to a larger question.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>“Deniz and I had the thought: Would it be possible to get a cell-type transcriptome atlas for a complete vertebrate?” said Reddien, who is also a professor of biology at Massachusetts Institute of Technology and an Investigator with the Howard Hughes Medical Institute. “Here’s an animal where we’d have a chance.”</p>
<p>To build the atlas, the researchers used single-cell RNA sequencing to measure gene activity in individual cells collected from across the brain, spinal cord, eyes, internal organs, fins, head, and trunk. They paired those data with spatial methods that mapped cell types and patterns of gene activity back to their locations in tissues. In their paper the team explained, “We combined regionally stratified single-cell RNA sequencing (scRNA-seq) with whole-animal spatial transcriptomics [multiplexed high-throughput fluorescent <em>in situ</em> hybridization (MERFISH) and hybridization chain reaction fluorescent in situ hybridization (HCR-FISH)] to build, validate, and explore a body-wide single-cell transcriptome atlas.”</p>
<p>The resulting atlas was extensive enough to capture even exceptionally rare cell populations. Looking across the animal revealed patterns that can be difficult to see when tissues are studied separately. In the nervous system, neurons from the same region often had more similar patterns of gene activity, even when they used different neurotransmitters—the chemicals neurons use to communicate—than when compared with neurons using the same neurotransmitter in different regions. Similar patterns have been observed in other vertebrates, including mammals, suggesting that regional and developmental identity may be an important organizing feature of vertebrate nervous systems.</p>
<p>The atlas also revealed signs that adult cells retain a molecular memory of where they belong in the body. The researchers found that fibroblasts, a type of connective tissue cell, maintained region-specific activity of genes best known for establishing different parts of the body during development. Cells in the pectoral and pelvic fins, for example, retained gene programs associated with forelimb and hindlimb development in other vertebrates. What these persistent signals do in adult <em>Danionella</em> remains unknown, but they may help tissues maintain or rebuild the appropriate structures. In planarians, positional information provides molecular guidance that helps regenerating tissues rebuild the correct structures.</p>
<p>The team also used the atlas as a reference for studying <em>Danionella</em>’s remarkable regenerative abilities. After injuring the telencephalon, a region of the forebrain, the missing neurons regenerated and the researchers were able to trace a progression from an early wound and immune response to neural stem-cell activity and the production and maturation of new neurons. “… profiling telencephalon regeneration revealed a temporally ordered molecular cascade, involving signatures of wound response and immune cell recruitment, radial glia proliferation, neurogenesis, and neuronal maturation …” they stated.</p>
<p>For Reddien, the advance presents numerous, diverse opportunities for new science. “There’s been this era of genome sequencing, where you get the complete list of all the genes that it takes to make an organism,” he says. “The transcriptomes of cells tell you how that genome is being utilized in the different cell types. To have the transcriptome of every cell type seems like a big turning point in how one would investigate the biology of an organism.”</p>
<p>In their paper the authors concluded “These findings and resources position <em>D. cerebrum</em> as a powerful model for systems neuroscience, stem cell biology and regeneration, biomechanics and collective behavior, and evolutionary biology.”</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/first-whole-body-single-cell-atlas-of-adult-vertebrate-generated-in-danionella-cerebrum/">First Whole-Body Single-Cell Atlas of Adult Vertebrate Generated in <i>Danionella cerebrum</i></a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Brain Quality Control Selectively Eliminates Neurons with Abnormal Variants in Development</title>
<link>https://edusehat.com/en/brain-quality-control-selectively-eliminates-neurons-with-abnormal-variants-in-development</link>
<guid>https://edusehat.com/en/brain-quality-control-selectively-eliminates-neurons-with-abnormal-variants-in-development</guid>
<description><![CDATA[ In developing fetuses, the human brain generates an excess of neurons, most of which are eliminated around when the baby is born. New research suggests that this is an important quality-control mechanism.
The post Brain Quality Control Selectively Eliminates Neurons with Abnormal Variants in Development appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2022/10/Getty_183878409_FetusWithDNAUmbilicalCord-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 03:40:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Brain, Quality, Control, Selectively, Eliminates, Neurons, with, Abnormal, Variants, Development</media:keywords>
<content:encoded><![CDATA[<p><span>By analyzing genomic data from neurons, scientists from Harvard Medical School (HMS), Boston Children’s Hospital, and their collaborators have gained insights into a critical quality-control mechanism that takes place in the developing fetal brain. </span></p>
<p><span>During development, the human brain generates an excess of neurons, most of which are eliminated around when the baby is born. According to a study published this week in </span><i><span>Nature</span></i><span>, scientists report that neurons with multiple copy number variants, including DNA  duplications or deletions, are widespread in the developing brain. However they are selectively eliminated shortly before or after birth likely because the genomic alterations disrupt their ability to form synapses. </span></p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p><span>Full details are provided in a paper titled “</span><a href="https://www.nature.com/articles/s41586-026-11190-3#author-information" target="_blank" rel="noopener"><span>Perinatal elimination of genetically aberrant human cortical neuron</span></a><span>.” The findings reported there are significant because copy number variants can impact brain function and may contribute to neuropsychiatric conditions, including autism, schizophrenia, epilepsy, and intellectual disability. A better understanding of the pruning process in the developing brain could improve how autism and other disorders in which neural development goes awry are treated. </span></p>
<p><span>As Diane Shao, MD, PhD, HMS instructor of neurology at Boston Children’s and a co-first author on the study noted, “If that quality control system can be disrupted, that could be part of what goes wrong in neurodevelopmental disorders like autism. Understanding the mechanism could eventually point us toward what to look for, and maybe what to protect.”</span></p>
<p><span>One of the first steps in the study was exploring the prevalence of copy number variants in developing human brains. To do that, the scientists designed single-cell whole genome sequencing approaches that allowed them to lightly sequence the genomes of single neurons. They used this method to sequence over 1,500 neurons from 16 individuals. They then validated the results with deeper sequencing of over 800 neurons from 12 individuals. They then used various computational methods to identify copy number variants in each sequenced genome. With their approach, it was possible to see the genomic changes “one neuron at a time, map where in the genome they occur, and compare how common they are from before birth to old age,” explained Peter Park, PhD, co-senior author on the paper and professor of biomedical informatics at HMS.</span></p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p><span>The data showed that an average of nearly 26 percent of neurons in the prenatal cortex had widespread copy number variants, but this rapidly decreased to an average of 6.2 percent after birth. </span><span>Specifically, “neurons with widespread CNVs were mainly eliminated perinatally, timed roughly parallel to periods of programmed cell death, whereas neurons with smaller CNV burdens declined slowly in frequency with postnatal age,” the scientists wrote. </span></p>
<p><span> “We were totally unprepared for how common these were in early development,” said Christopher Walsh, MD, PhD, a co-senior author on the paper and professor of pediatrics and neurology at Boston Children’s Hospital. “But it makes sense in the context of what we know about the formation of excess neurons and in the context of the IVF literature.” </span></p>
<p><span>Next, the team explored the pathways through which the abnormal neurons are eliminated. By sequencing and analyzing DNA and RNA from over 44,000 individual cells, they found that neurons with widespread copy number variants also had abnormal expression of the genes involved in the creation and maintenance of neural synapses. It suggests that unlike healthy brain cells, these abnormal neurons fail to make critical connections during fetal development which causes them to die off. </span></p>
<p><span>“This competition for synapses has been described for years, but without the benefit of a genomic understanding,” Walsh noted. We didn’t realize that this struggle for survival—this Darwinian competition—was nature’s quality control mechanism in the brain.”</span></p>
<p><span>As part of the study, the team also confirmed some earlier findings that flawed neurons continue to be eliminated throughout adulthood, albeit at a much slower rate. Currently, they are looking into whether this neural elimination process is different in developing brains of people with autism and other neurodevelopmental disorders. They are also exploring whether this process plays a role in development of adult-onset neurodegenerative disorders like Alzheimer’s disease. </span></p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/brain-quality-control-selectively-eliminates-neurons-with-abnormal-variants-in-development/">Brain Quality Control Selectively Eliminates Neurons with Abnormal Variants in Development</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Discovery could help predict which early breast cancers will spread</title>
<link>https://edusehat.com/en/discovery-could-help-predict-which-early-breast-cancers-will-spread</link>
<guid>https://edusehat.com/en/discovery-could-help-predict-which-early-breast-cancers-will-spread</guid>
<description><![CDATA[ Immune cells that normally protect the body from infection can also drive the progression of some early breast cancers, McGill University researchers have found. The discovery points to a potential way of distinguishing relatively harmless cases of ductal carcinoma in situ (DCIS) from those most likely to become invasive, one of the biggest challenges in […]
The post Discovery could help predict which early breast cancers will spread appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/Focused-Laboratory-Researcher.png" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 03:35:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Discovery, could, help, predict, which, early, breast, cancers, will, spread</media:keywords>
<content:encoded><![CDATA[<p>Immune cells that normally protect the body from infection can also drive the progression of some early breast cancers, McGill University researchers have found.</p>
<p>The discovery points to a potential way of distinguishing relatively harmless cases of ductal carcinoma in situ (DCIS) from those most likely to become invasive, one of the biggest challenges in breast cancer care.</p>
<p>DCIS is an early form of breast cancer that accounts for roughly one-fifth to one-third of cancers detected through screening.<span class="Apple-converted-space"> </span></p>
<p>“Many patients diagnosed with DCIS face difficult treatment decisions because we can’t reliably predict which lesions will progress,” said lead author Tarek Taifour, an MD PhD student in McGill’s Department of Medicine. “We’ve identified a mechanism that brings us a step closer to identifying those at highest risk.”</p>
<p>DCIS is normally held in check by a thin layer of cells that acts like a protective barrier, preventing cancer cells from spreading into nearby tissue.</p>
<p>Researchers studied the disease in mice, human breast tissue samples and 3D tumour models grown in the lab to understand how some cancers break through the barrier.</p>
<p>Results published in Cell Reports Medicine point to an unexpected role of the immune system.</p>
<p>Neutrophils – immune cells best known for fighting infection – release an enzyme called neutrophil elastase that weakens this barrier, the study found. When researchers blocked either the cells or the enzyme, the protective barrier remained intact.</p>
<p>“Cancer can sometimes hijack normal immune processes and turn them into processes that help disease progress. This appears to be an example of that,” said senior author William Muller, Professor in McGill’s Department of Biochemistry.</p>
<p>Many patients diagnosed with DCIS undergo surgery, radiation or other treatments without knowing whether their lesions would have ever become dangerous.</p>
<p>The findings suggest neutrophil elastase could one day serve as a biomarker, helping doctors tailor treatment to a patient’s risk and avoid unnecessary treatment for those whose cancer is unlikely to progress.</p>
<p>Physicians have disabilities too: New research calls for a more accessible medical workforce</p>
<p>New research indicates that five per cent of practising physicians report a disability “always or often,” and another 12 per cent report disability “sometimes.” The authors call for action on improving accessibility to ensure equity and sustainability in the physician workforce. The study is published in CMAJ (Canadian Medical Association Journal).</p>
<p>“Physicians with disabilities frequently face discrimination, inaccessible workplaces, and inadequate support,” writes Dr. Michael Quon, a general internal medicine specialist and clinician investigator at The Ottawa Hospital, and an assistant professor, University of Ottawa, Ottawa, Ontario, with coauthors. “Not retaining physicians with disabilities in the workforce means losing skilled providers with valuable perspectives, negatively affecting human health resources. Improving accessibility in medicine is important.”<span class="Apple-converted-space"> </span></p>
<p>The study, based on data from the 2021 Canadian long-form Census, helps fill an important gap in evidence about the prevalence of disability in practising physicians and their demographics. Unlike other studies, which were voluntary, the Census is mandatory, with a 97% completion rate by a randomly selected 25% of the population living in Canada, making this study nationally representative.<span class="Apple-converted-space"> </span></p>
<p>The most commonly reported disability was mental health (40%) followed by visual (37%), hearing (15%), mobility or physical (13%), and cognitive or learning (6%). Disabilities were more common in female (6.0%) than male physicians (4.5%).</p>
<p>The authors note that younger age does not preclude disability.<span class="Apple-converted-space"> </span></p>
<p>“While disability rates generally increased with age, the prevalence in physicians younger than 35 years remained notable (5.2%),” says Dr. Quon. “The prevalence of hearing, mobility, and physical disabilities increased with age, while mental health disabilities were more common in younger age groups.”</p>
<p>Physicians report fewer disabilities compared with other professions, such as law, academia, engineering, and nursing, as well as the general workforce. <span class="Apple-converted-space"> </span></p>
<p>The authors emphasize that supporting physicians with disabilities is important for Canada’s health systems.<span class="Apple-converted-space"> </span></p>
<p>“Disabilities are an important yet often overlooked contributor to workforce diversity,” write the authors. “Ensuring accessible work environments and equitable policies can promote the well-being and retention of physicians with disabilities and support those seeking to return to practice. Beyond benefits to the physicians themselves, advancing accessibility might enhance patient care by fostering a workforce that better reflects the populations it serves.”<span class="Apple-converted-space"> </span></p>
<p>“Prevalence and characteristics of disabilities in physicians in Canada; an analysis of Canadian Census data” is published October 13, 2026.<span class="Apple-converted-space"> </span></p>
<p>The post <a href="https://www.hospitalnews.com/discovery-could-help-predict-which-early-breast-cancers-will-spread/">Discovery could help predict which early breast cancers will spread</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Hamburg Hosts 2026 European Gene Therapy Conference</title>
<link>https://edusehat.com/en/hamburg-hosts-2026-european-gene-therapy-conference</link>
<guid>https://edusehat.com/en/hamburg-hosts-2026-european-gene-therapy-conference</guid>
<description><![CDATA[ GEN&#039;s Kevin Davies, PhD, reports from ESGCT where patient safety, expanding access to gene therapy, and progress towards an HIV vaccine were prominent themes among the early talks at ESGCT 2026.
The post Hamburg Hosts 2026 European Gene Therapy Conference appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/ESGTIllustration-scaled-e1793274396802.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 00:00:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Hamburg, Hosts, 2026, European, Gene, Therapy, Conference</media:keywords>
<content:encoded><![CDATA[<p><strong>HAMBURG</strong>—The historic German port city of Hamburg is playing host to the European Society of Gene & Cell Therapy (ESGCT) conference this week.</p>
<p>As noted in the opening session, the Port of Hamburg was established more than 800 years ago. It is also a proud center of editing—newspapers rather than genes—as the site of the headquarters of <em>Der Speigel</em> and <em>Die Zeit</em>. And of course, Hamburg famously helped forge the sound and legend of the “Fab Four”—the Beatles played numerous gigs between 1960-62 in the central St. Pauli district. It was also where Ringo Starr met his future bandmates in 1960.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>Patient safety, expanding access to gene therapy, and progress towards an HIV vaccine were prominent themes among the early talks at ESGCT 2026. In the opening plenary session, Dimitrios Mougiakakos, MHBA, discussed his group’s research on CAR T therapy for lupus, noting progress but some patient deaths. “Lower risk does not mean no risk,” he said, pointing to the rapid production of CAR T cells as a potential risk factor. A “Volkswagen approach” might be better than a “Ferrari approach,” he concluded.</p>
<p>Italian professor Giuliana Ferrari, PhD, discussed her team’s research on beta-thalassemia, one of the “less rare of the rare diseases,” characterized by more than 400 different globin gene mutations. Ferrari noted that some of the patients in the <em>ex vivo </em>TIGET-BTHAL Phase I/II trial, which began in 2015, had restarted blood transfusions, while others remained transfusion-independent after nine years, producing respectable levels of hemoglobin.</p>
<p>Ferarri’s team has spent several years optimizing manufacturing protocols to launch a new trial, Bthal FT007-01. The first two patients have been enrolled in this Phase IIb trial, an academic initiative between Italian groups designed to provide affordable access to gene therapy. Refinements include the implementation of a shorter 40-hour cell culture and gene transduction protocol (down from 60 hours) and a change in conditioning regimen.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<h4><strong>HIV hope</strong></h4>
<p>In addition to his academic position at Scripps Research Institute, Bill Schief, PhD, is also the vice president of protein design at Moderna. Although he acknowledged he was a slightly unusual choice for a plenary speaker, as his work was not technically gene therapy, he relished the chance to present his team’s promising work on the quest to engineer a specific immune response and to develop a functional HIV vaccine.</p>
<p>The statistics remain sobering: More than 40 million people live with HIV, but more than 20 percent do not receive antiretroviral therapy. There are 1.2 million new HIV infections and 570,000 deaths per year. All told, 44 million people have died of AIDS, and global funding for AIDS research is going down. “We need a vaccine,” Schief emphasized.</p>
<p>Schief and colleagues are designing vaccines to guide the immune system toward antibodies that target conserved, vulnerable regions of the HIV envelope protein. Hope resides in the development of broadly effective Abs (bnAbs). A successful HIV vaccine will need to induce multiple classes of bnAbs, Schief said.</p>
<p>Schief reviewed research to deliver a sequence of immunogens, using priming, “shepherding,” and “polishing,” with the goal of producing bnAbs and long-lived plasma cells to sustain production. The strategy is “very complicated but not crazy,” Schief said, citing the need for serum bnAbs to have breadth, potency, and durability.</p>
<p>Over the past two years, researchers have reported clinical results and animal studies that represent significant advances towards their goal. In 2025, <a href="https://www.science.org/doi/10.1126/science.adr8382" target="_blank" rel="noopener">Schief’s team reported promising Phase I results in <em>Science</em></a>. IAVI G002, conducted in the U.S., tested an mRNA vaccine designed to activate the desired antibody precursors, followed by a different mRNA vaccine intended to advance their development. IAVI G003 was conducted in Rwanda and South Africa, testing the initial vaccine approach in African populations.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>“Let’s make sure the strategy works there [in Africa],” Schief said. The findings provided proof of concept but stopped short of a full vaccine. Earlier this year, Schief and colleagues published in <a href="https://www.nature.com/articles/s41586-026-10837-5" target="_blank" rel="noopener"><em>Nature</em></a> results showing that <a href="https://www.genengnews.com/topics/infectious-diseases/germline-targeting-hiv-vaccine-generates-broadly-neutralizing-antibodies-in-primates/" target="_blank" rel="noopener">germline-targeting vaccines can induce pre-specific bnAbs</a> in memory B cells and serum in non-human primates.</p>
<h4><strong>CAR T promise</strong></h4>
<p>Michel Sadelain, MD, PhD, presented a compelling overview of the promise of CAR T therapy in oncology and other therapeutic areas. Of the seven CAR T therapies approved in the U.S. to date, five target CD19. In oncology, survival duration has quadrupled from about six months to more than 25 months. Sadelain said there was promising data in other fields, including rheumatology (lupus, arthritis, and scleroderma), as well as preliminary results in neurology (myasthenia gravis). This progress has all been achieved with the original two molecular designs that yielded Yescarta and Kymriah: CD28z CAR and 4-1BBz CAR.</p>
<p>But progress in tackling solid tumors with CAR therapy has not kept pace with hematological malignancies, Sadelain said. He listed five primary challenges in this regard:</p>
<ul>
<li>The need to increase functional persistence of T cells</li>
<li>Potency</li>
<li>Sensitivity</li>
<li>The need to understand and prevent toxicity</li>
<li>New targets</li>
</ul>
<p>In one line of research, Sadelain’s team revisited signaling strength, with a view to tempering it. In 2025, the group showed that by switching from three ITAMs to a single ITAM, they could create a strong effector function with much greater persistence. This “1XX” signaling module was <a href="https://ascopubs.org/doi/abs/10.1200/JCO-24-02424" target="_blank" rel="noopener">taken to the clinic in B-cell lymphoma</a>, with excellent responses seen administering as few as 25 million cells—a tenth of the regular dose (100-400 million cells).</p>
<p>In another approach, Sadelain’s team has used CRISPR to develop a new CAR—<a href="https://www.nature.com/articles/s41591-021-01621-1" target="_blank" rel="noopener">the HLA-independent T cell (HIT) receptor</a>—that is at least 10-fold more sensitive. The characterization of this CAR in solid tumors such as renal cell carcinomas in immunodeficient mice continues.</p>
<p> </p>
<p><em>*ESGCT 2026; Hamburg, Germany; October 27-30, 2026.</em> <strong></strong></p>
<p></p>
<p>The post <a href="https://www.genengnews.com/topics/genome-editing/hamburg-hosts-2026-european-gene-therapy-conference/">Hamburg Hosts 2026 European Gene Therapy Conference</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Doing more with dialysis: A renewed patient experience</title>
<link>https://edusehat.com/en/doing-more-with-dialysis-a-renewed-patient-experience</link>
<guid>https://edusehat.com/en/doing-more-with-dialysis-a-renewed-patient-experience</guid>
<description><![CDATA[ HN Summary • SHN’s largest dialysis redevelopment added 23 treatment stations across Centenary and General hospitals, expanding capacity and improving comfort, privacy and safety.•  • Patients helped evaluate new dialysis equipment, with patient Scott Spence-Lee reporting less fatigue and more energy after treatment. • Upgraded units feature stronger infection prevention measures, dedicated isolation spaces and […]
The post Doing more with dialysis: A renewed patient experience appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/Dialysis-scaled.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 23:55:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Doing, more, with, dialysis:, renewed, patient, experience</media:keywords>
<content:encoded><![CDATA[<p><strong>HN Summary</strong></p>
<p>• SHN’s largest dialysis redevelopment added 23 treatment stations across Centenary and General hospitals, expanding capacity and improving comfort, privacy and safety.•<span class="Apple-converted-space"> </span></p>
<p>• Patients helped evaluate new dialysis equipment, with patient Scott Spence-Lee reporting less fatigue and more energy after treatment.</p>
<p>• Upgraded units feature stronger infection prevention measures, dedicated isolation spaces and sustainable water-recycling technology.</p>
<hr>
<p>For the thousands of patients who receive dialysis through Scarborough Health Network’s (SHN) Regional Nephrology Program each year, it is more than a simple treatment, it is a way of life. By medical definition, dialysis means the process of artificially filtering toxins and waste from the blood when the kidneys no longer can. For patients who require or prefer dialysis in a hospital setting, it means spending several hours, multiple times each week away from home receiving treatment, without which they risk losing their energy, mental clarity, and longevity of life. The dialysis unit becomes a constant setting in their lives, and that setting should reflect the compassion, patience, and exceptional quality care patients deserve during treatment.</p>
<p>For 70-year-old Scott Spence-Lee, who has lived with kidney failure since 2018, the impact of these experiences is something he lives every week. SHN sought to improve the care experience for patients like Scott through a major redevelopment.</p>
<p>As part of our journey to Build It Forward to better meet the needs of our community now and into the future, we completed the largest dialysis redevelopment in SHN’s history. The multi-year projects included the creation of a brand-new, modern dialysis unit at Centenary Hospital and the expansion and renovation of the existing dialysis unit at General Hospital. Together, these projects have added 23 new treatment stations, increased capacity to meet growing community needs, and created modern care environments designed around comfort, privacy, dignity, and safety.</p>
<h3><strong>A new chapter in dialysis care</strong></h3>
<p>Scott’s journey with kidney disease began when he spent three weeks in hospital and learned he was experiencing kidney failure.</p>
<p>“It was a shock,” Scott recalled. “I was diagnosed at SHN, and eventually my care team determined that dialysis was the next step.”</p>
<p>After receiving training on dialysis equipment and beginning regular treatment, Scott became familiar with the routine that accompanies life-sustaining dialysis care. Earlier this year, he was one of the first patients to transition into SHN’s new dialysis unit at Centenary Hospital, located on the first floor of the Margaret Birch Wing.</p>
<p>The patient-centred unit features 21 dialysis stations, enhanced infection prevention and control measures, environmentally sustainable water-recycling systems, and a flexible design that can evolve alongside future advances in dialysis care.</p>
<p>“The new space is more private, more modern, and much more conducive to receiving treatment. It is a comforting space,” Scott said. “I love my nurses and care team. They work as a real team and make you feel part of it. They’re always available, they make me feel welcome, and they encourage you to ask questions.”</p>
<p>But for Scott, the effects of the new and improved dialysis unit extended beyond the space itself. One of the most significant improvements has been the introduction of the modern, innovatively designed B. Braun Dialog IQ hemodialysis machines. Patients, including Scott, played an active role in evaluating and testing equipment before it was selected, helping ensure the technology reflected real-world needs and preferences. Scott felt the difference right away.</p>
<p>“With this newer technology, you finish your treatment and immediately get your mojo back,” Scott shared. “Before, when I finished dialysis I was so tired and had trouble focusing. Now, when I get home after dialysis, I can still do things.”</p>
<p>The difference has been noticeable to his family as well.</p>
<p>“My eldest daughter said I’m better because I can spend more time with my family now and don’t sleep as much as I used to. I move around more. I can play with my grandson more.”</p>
<p>The upgraded technology also helps deliver more consistent treatment, even when common challenges, like blockages in the blood-filtering tubes, arise during dialysis sessions. Combined with the purposefully designed treatment environment, these improvements are helping patients feel better supported both during and after their care.</p>
<h3><strong>Designed around the<span class="Apple-converted-space"> </span>patient experience</strong></h3>
<p>At SHN, patient experience was a central consideration throughout the dialysis redevelopment process.</p>
<p>“Clinical care is shaped not only by the treatment itself, but also by the setting in which it is provided,” said Dr. Paul Tam, Medical Director and Chief of Nephrology at SHN. “Our patients often spend many hours each week receiving dialysis, making it essential that the environment supports their comfort, privacy, and well-being. These upgraded facilities will allow us to combine leading-edge technology with a patient-centred approach.”</p>
<p>The redevelopment has transformed care across both hospitals. At General Hospital, the renovated TD Hemodialysis Isolation Unit includes newly modernized treatment areas and dedicated segregation treatment rooms designed to better support medically vulnerable patients while enhancing infection prevention and control.</p>
<p>At Centenary Hospital, the entirely new Ted Rogers Hemodialysis unit provides a welcoming and accessible environment designed to improve both patient and staff experiences while expanding SHN’s ability to meet the growing demand for kidney care services in Scarborough.</p>
<p>“These redevelopment initiatives are creating modern care environments designed with accessibility, safety, and patient experience in mind,” shared Ethel Macatangay, Director, Nephrology and Chronic Disease Management at SHN. “By investing in advanced technology and purpose-built spaces, we are strengthening our capacity to deliver exceptional, compassionate care and meet the evolving needs of our community for years to come.”</p>
<h3><strong>Looking ahead</strong></h3>
<p>While dialysis remains an essential part of his routine, Scott feels reassured knowing he is receiving care in a unit designed with patients at its centre, in a hospital that is dedicated to investing in its patients’ future.</p>
<p>“When you come to SHN, you feel the compassion and the genuine care,” he shared. “The staff, the equipment, the environment—it all makes a difference. I’m grateful to be receiving my treatment here.”</p>
<p>As SHN continues to Build It Forward, stories like Scott’s demonstrate how investments in modern facilities, innovative technology, and patient-centred care can help patients not only receive treatment, but live more fully beyond it.</p>
<p>The post <a href="https://www.hospitalnews.com/doing-more-with-dialysis-a-renewed-patient-experience/">Doing more with dialysis: A renewed patient experience</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>How Canada can further develop its biotech talent</title>
<link>https://edusehat.com/en/how-canada-can-further-develop-its-biotech-talent</link>
<guid>https://edusehat.com/en/how-canada-can-further-develop-its-biotech-talent</guid>
<description><![CDATA[ HN Summary • Canada produces strong scientific talent but needs more workers with practical experience in biotech manufacturing, clinical trials, regulation and commercialization. • Hands-on training, active research facilities and opportunities within growing Canadian companies help turn academic expertise into industry skills. • Keeping companies and development work in Canada allows experienced talent to support […]
The post How Canada can further develop its biotech talent appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/shutterstock_2847245267.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 23:55:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>How, Canada, can, further, develop, its, biotech, talent</media:keywords>
<content:encoded><![CDATA[<p>HN Summary</p>
<p>• Canada produces strong scientific talent but needs more workers with practical experience in biotech manufacturing, clinical trials, regulation and commercialization.</p>
<p>• Hands-on training, active research facilities and opportunities within growing Canadian companies help turn academic expertise into industry skills.</p>
<p>• Keeping companies and development work in Canada allows experienced talent to support future ventures, strengthening a sustainable biotech ecosystem.</p>
<hr>
<p>Canada’s biotech sector continues to produce promising therapies, medical technologies and transformative research. The past 12 months alone have seen breakthroughs from Toronto’s AmacaThera, which licensed its drug delivery solution to global pharma firm Pacira; Calgary’s Providence Therapeutics, which launched a major clinical trial for its personalized pediatric cancer vaccine in Australia; and Vancouver’s AbCellera, which published Phase 2 trial results for its potentially game-changing treatment for menopause-related hot flashes. In recent years, federal and provincial governments have also invested billions of dollars in new research facilities and biomanufacturing infrastructure to strengthen the country’s life sciences ecosystem. Yet, as more companies look to scale, many encounter the same challenge: finding people who have done it before.</p>
<p>“We need people who have been there and done that, and have had success with entrepreneurship,” says Scott Bratman, co-founder of Adela, which is developing novel cancer detection tools, and an associate professor of medical biophysics at the University of Toronto. “Success breeds further success.” <span class="Apple-converted-space"> </span></p>
<p>That gap extends well beyond the C suite. Companies need scientists who understand how to translate discoveries into products, specialists who can operate in regulated environments, teams that have taken therapies through clinical trials and manufacturing experts who know how to scale production. They also need executives who have raised capital, navigated regulatory approvals and brought technologies to market. Those skills are built through experience. Canada has many of the ingredients needed to develop that workforce, including exceptional scientific talent, new infrastructure and a growing base of biotech companies. The challenge is creating enough opportunities for people to put those assets to work, learn by doing and carry that experience from one company to the next. <span class="Apple-converted-space"> </span></p>
<p>When a company scales, it does more than just commercialize a new technology — it invests resources into developing talent whose knowledge and skills strengthen the next generation of companies. For Canada, the biggest question is how to ensure the ecosystem has all the necessary components to facilitate this process.<span class="Apple-converted-space"> </span></p>
<h3><strong>Turning scientific excellence into industry experience</strong></h3>
<p>Canada’s biotech talent challenge has often been framed as a brain drain problem. The country recently came fifth globally for higher education; the University of Toronto was ranked the 7th best institution in the world for human biological sciences and the 11th for medical technology programs. The prevailing assumption has been that our universities produce exceptional scientists — but we inevitably lose them to better opportunities elsewhere. While that may have been a worrisome trend in the past, it’s no longer a given. Indeed, according to a StatsCan report from 2025, 89 percent of the 2015–2020 cohort of graduates from Canadian STEM programs were filing taxes in Canada three years later.</p>
<p>It has also been generally assumed that Canada’s strength in producing exceptional scientists should naturally translate into strength in biotechnology. “There is really strong access to talent, especially on the early research and development side,” says Bharat Srinivasa, co-founder and partner at Amplitude, a venture capital firm with a focus on funding precision medicine. But graduating talented scientists is not the same as building biotech talent. “The average student that comes out of a STEM program is not ready to walk into a biomanufacturing and GMP facility and actually work from day one,” says Maura Campbell, president and CEO of the not-for-profit organization OBIO, which supports the growth of early-stage life sciences ventures. “We aren’t training people sufficiently.”</p>
<p>Life sciences graduates recognize that scientific expertise requires continued training and specialization. The same thinking must extend beyond academia and into industry. Knowing the science is one thing; learning how to scale a process, manufacture under regulated conditions or prepare a therapy for clinical use requires a different set of skills, many of which can only be developed through hands-on experience. As OBIO’s Campbell points out, although students would greatly benefit from working on state-of-the-art equipment, universities typically lack the infrastructure, expertise and facilities to provide that option.</p>
<p>That is the gap organizations such as the Canadian Alliance for Skills and Training in Life Sciences (CASTL) are working to address. Through partnerships with academic institutions, industry stakeholders and government agencies, CASTL offers specialized training modules, hands-on laboratory experiences and certification programs designed to align with current industry standards. These programs aim to bridge the gap between academic education and industry requirements, ensuring that graduates are job-ready and that existing professionals can upskill to meet evolving demands.<span class="Apple-converted-space"> </span></p>
<p>“Hands-on training is a key component of success,” says Sidney Reid, CEO of CASTL. “It gives people a safe place to take risks and make mistakes, because doing is such an important part of competency development.”</p>
<p>CASTL has achieved significant milestones in strengthening Canada’s biomanufacturing workforce through hands-on training, strategic partnerships and national expansion. Through one recent national reskilling program, CASTL trained more than 425 people across Canada, helping people without industry experience develop the skills needed to enter the sector.</p>
<p>But that kind of training requires both infrastructure and sustained investment. Workers cannot develop manufacturing expertise without access to manufacturing facilities and equipment. Scientists cannot build preclinical experience without laboratories and projects to work on. Clinical expertise develops through running clinical trials. Contract Research Organizations (CROs) give specialized teams the opportunity to perform similar work repeatedly across different companies and technologies.</p>
<p>That means Canada’s infrastructure gaps are also talent gaps. When preclinical work is outsourced to CROs abroad, for example, along with missing out on economic activity, the country loses the workforce training and technical expertise that come as a result of doing that work. In this context, infrastructure isn’t just about buildings and equipment — it also encompasses the places and pathways where people learn.<span class="Apple-converted-space"> </span></p>
<h3><strong>Successful companies are<span class="Apple-converted-space"> </span>Canada’s best talent program</strong></h3>
<p>Universities provide a solid scientific foundation, but biotech companies are the real-world classrooms where scientists, operators and entrepreneurs learn how to move a discovery through development, navigate regulatory requirements, raise capital, scale manufacturing and ultimately bring a therapy to patients.</p>
<p>For Molly Shoichet, a professor in U of T’s department of biomedical engineering<span class="Apple-converted-space">  </span>and founder of AmacaThera, the value of real-world experience has become increasingly clear over time. “My second company benefits so much from the first,” she says. Shoichet’s team had already navigated many of the scientific, regulatory and commercial decisions every young biotech company faces, allowing them to move “10 times faster” the second time around as a result, she says.<span class="Apple-converted-space"> </span></p>
<p>Former InBC Investment Corp. CEO Jill Earthy has witnessed a similar phenomenon in the British Columbia life sciences ecosystem. Established companies such as STEMCELL Technologies (founded in 1993), Zymeworks (founded in 2003) and AbCellera (founded in 2012) have become training grounds for people who can carry their experience into the next generation of ventures. STEMCELL, for instance, provides opportunities for a steady stream of UBC co-op students and grads; Zymeworks co-founder Ali Tehrani is now a venture partner at Amplitude, where he shares his previous learnings to help guide other founders. Over time, that movement creates a deeper pool of people who know how to build and scale biotech companies.</p>
<p>Amplitude’s Bharat Srinivasa describes the cycle this way: “Those companies generated capital and made money that allowed talent and capital to recycle. Experienced entrepreneurs, managers and teams could then go and build bigger, stronger companies.”</p>
<p>This is why it’s critical to keep scaling companies in Canada. “When companies are acquired or scale elsewhere, we don’t just lose the company,” says Jason Field, president and CEO of Life Sciences Ontario. “We lose the talent, the expertise and the experience that would have helped build the next generation.”</p>
<h3><strong>Talent is the outcome of a healthy ecosystem</strong></h3>
<p>Leaders across biotech often talk about creating an environment where experienced CEOs can take a risk on a startup knowing there will be another opportunity if it fails. The same principle needs to apply across the biotech workforce.</p>
<p>A scientist needs to see a pipeline of companies where they can build a career. A CRO needs a steady flow of ventures conducting research here so it can employ and develop specialized staff. Manufacturing talent needs facilities that are not simply built, but consistently used, allowing workers to accumulate experience in process development, quality and GMP manufacturing. The same is true for clinical trials, regulatory expertise and every other part of the development pathway.</p>
<p>That does not mean every company needs to become a global success or remain independent forever. “Even if a company stays for only 10 years, it makes a real difference for those 10 years,” says Molly Shoichet.</p>
<p>The key is cultivating enough activity across the system that the closure of a single company does not signal the end of someone’s career in Canadian biotech. The feedback loop must extend from the lab bench to the C-suite, with a critical mass of ventures progressing through different stages to ensure that people keep working, infrastructure is maintained and expertise accumulates.</p>
<p>Ultimately, Canada’s greatest competitive advantage won’t be found in the number of startups it creates, but rather in its ability to create a thriving, self-sustaining ecosystem where knowledge, talent and infrastructure are continuously shared and reinforced.</p>
<p><b>By Sana Maqbool</b><b></b></p>
<p><i>Hospital News has partnered with MaRS Discovery District to highlight Canadian innovations in health and life sciences.</i><span class="Apple-converted-space"> </span></p>
<p>The post <a href="https://www.hospitalnews.com/how-canada-can-further-develop-its-biotech-talent/">How Canada can further develop its biotech talent</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Why PAD monitoring needs a real&#45;time view of blood flow between visits</title>
<link>https://edusehat.com/en/why-pad-monitoring-needs-a-real-time-view-of-blood-flow-between-visits</link>
<guid>https://edusehat.com/en/why-pad-monitoring-needs-a-real-time-view-of-blood-flow-between-visits</guid>
<description><![CDATA[ HN Summary • PAD can cause serious complications, and recurrent artery narrowing after treatment makes ongoing monitoring important to protect patients’ limbs. •Current surveillance provides snapshots during scheduled visits, leaving gaps when blood flow may decline unnoticed. •Emerging portable technologies could enable more frequent tissue blood-flow monitoring, but research is needed to establish their effectiveness […]
The post Why PAD monitoring needs a real-time view of blood flow between visits appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/shutterstock_2365447841-e1793289812218.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 23:55:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Why, PAD, monitoring, needs, real-time, view, blood, flow, between, visits</media:keywords>
<content:encoded><![CDATA[<p><strong>HN Summary</strong></p>
<p>• PAD can cause serious complications, and recurrent artery narrowing after treatment makes ongoing monitoring important to protect patients’ limbs.</p>
<p>•Current surveillance provides snapshots during scheduled visits, leaving gaps when blood flow may decline unnoticed.</p>
<p>•Emerging portable technologies could enable more frequent tissue blood-flow monitoring, but research is needed to establish their effectiveness and impact on PAD outcomes.</p>
<hr>
<p>An estimated 800,000 Canadians are living with peripheral artery disease (PAD), though some experts say the true number is likely higher. PAD causes reduced blood flow to the legs, resulting from atherosclerosis narrowing the arteries and limiting the oxygen that reaches muscles and tissue. As the disease progresses, poor circulation can lead to pain at rest, wounds that won’t heal and, in the most severe cases, amputation. Each year in Canada, roughly 7,720 lower-limb amputations are performed in adults with diabetes, of whom 86% also have a documented PAD diagnosis. Because the plaque behind PAD is usually present elsewhere in the body as well, people with the condition also face a higher risk of heart attack and stroke.</p>
<p>Treatment for PAD begins with managing the disease and its risk factors, typically through smoking cessation, structured exercise, and medications that lower cholesterol, control blood pressure and blood sugar, and reduce the risk of blood clots. When those fail to control symptoms, or when a limb is at risk, revascularization becomes the next step, and endovascular approaches are now first-line for many patients.<span class="Apple-converted-space"> </span></p>
<p>Because the underlying atherosclerosis remains after the procedure, restenosis is the main threat to long-term durability, with one-year rates as high as 30% to 60% reported in patients with chronic limb-threatening ischemia. Post-procedure monitoring after revascularization gives clinicians the chance to catch recurrent narrowing and reintervene before the vessel occludes. However, the tools used to monitor blood flow after treatment have not kept pace with treatment options. Emerging technologies that measure tissue perfusion directly could give clinicians more information between scheduled visits, and research now underway will help determine how that information should guide care.</p>
<h3><strong>Current tools for<span class="Apple-converted-space"> </span>post-procedure monitoring</strong></h3>
<p>Surveillance after revascularization typically relies on some combination of clinical assessment, the ankle-brachial index (ABI), and arterial duplex ultrasound. The ABI is inexpensive and easy to perform in an office, while duplex offers detailed imaging of the treated segment and is the most accurate noninvasive option. Practice varies widely, in part because clinical guidelines consider the effectiveness of routine surveillance in asymptomatic patients uncertain. Canadian data on PAD care are limited, but U.S. figures point to a significant shortfall. In an analysis using historical data of more than 1.4 million Medicare patients who underwent lower extremity bypass or peripheral vascular intervention, just over half received any follow-up imaging within a year of their procedure.<span class="Apple-converted-space"> </span></p>
<p>Even when patients do return for follow-up, the tools differ considerably in what they catch. A 2024 systematic review of surveillance after femoropopliteal endovascular treatment found that the ABI detected restenosis with a sensitivity of 55% to 67% and clinical follow-up with a sensitivity of 52% to 64%, meaning either approach on its own can miss a third to nearly half of recurrent lesions. Duplex, which shows blood flow through the treated segment in real time, performed far better, reaching 91% sensitivity and 100% specificity in the one study the review identified, but it requires a vascular lab, a trained sonographer, and a scheduled visit. Those requirements limit how often it can be repeated and tie surveillance to patients keeping their appointments, leaving long stretches between visits when restenosis can develop unobserved.</p>
<h3><strong>How advanced monitoring benefits pad patients</strong></h3>
<p>Nearly every tool used after revascularization captures perfusion at a single point in time during a scheduled visit. Continuous or more frequent monitoring could track perfusion between appointments and flag a decline that might otherwise go unnoticed until symptoms return, much as remote monitoring of heart rhythm and blood glucose lets clinicians act on trends in other chronic conditions. Because perfusion measurements assess circulation in the tissue, they could help support a combined diagnostic alongside imaging of the treated artery. While research in PAD is still early, investigators are testing the feasibility of optical techniques such as laser speckle contrast imaging to measure perfusion around revascularization.</p>
<p>Portable blood flow technology is also being studied in stroke, a condition closely linked to PAD because the same atherosclerosis often affects other arteries. In a 2024 study of 135 patients evaluated for suspected stroke, an algorithm based on scans from a portable optical blood flow monitor detected large vessel occlusion with 79% sensitivity after a 70-second scan, compared with 60% and 50% for two stroke scales commonly used by emergency medical services. The study shows how a compact device could potentially measure blood flow directly without a vascular lab or imaging suite, making more frequent monitoring accessible to more patients.</p>
<h3><strong>Building the evidence for better pad monitoring</strong></h3>
<p>While blood flow restoration techniques have advanced to support more patients with PAD, the monitoring they receive after a procedure has remained relatively unchanged. Restenosis remains common, surveillance practices vary widely, and the tools in routine use capture only occasional snapshots of a process that unfolds gradually between visits.<span class="Apple-converted-space"> </span></p>
<p>Other areas of chronic disease care suggest a better path. In conditions such as heart failure and diabetes, direct monitoring gives clinicians a steadier stream of data and has allowed them to recognize problems earlier and adjust treatment before patients deteriorate. There is good reason to believe PAD patients could benefit in a similar way, particularly those with diabetes, kidney disease, or limb-threatening disease, for whom a missed restenosis carries the greatest consequences. Research on post-procedure monitoring in PAD, including studies that compare monitoring approaches and measure their effect on limb outcomes, would give vascular specialists a clearer picture of how to protect the results of revascularization long after patients leave the procedure room.</p>
<p>The post <a href="https://www.hospitalnews.com/why-pad-monitoring-needs-a-real-time-view-of-blood-flow-between-visits/">Why PAD monitoring needs a real-time view of blood flow between visits</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Tiny snake&#45;like robot could transform sinus surgery</title>
<link>https://edusehat.com/en/tiny-snake-like-robot-could-transform-sinus-surgery</link>
<guid>https://edusehat.com/en/tiny-snake-like-robot-could-transform-sinus-surgery</guid>
<description><![CDATA[ When developing a miniature robot for sinus surgery, a team of Hamilton doctors and innovators looked to nature for inspiration. The result is a micro-sized, snake-like robot they’re developing that’s remotely maneuvered up a patient’s nose and through intricate pathways to reach the sinuses, much like a snake weaves through underground tunnels. Team member Dr. […]
The post Tiny snake-like robot could transform sinus surgery appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/Snake-robot.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 23:55:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Tiny, snake-like, robot, could, transform, sinus, surgery</media:keywords>
<content:encoded><![CDATA[<p>When developing a miniature robot for sinus surgery, a team of Hamilton doctors and innovators looked to nature for inspiration. The result is a micro-sized, snake-like robot they’re developing that’s remotely maneuvered up a patient’s nose and through intricate pathways to reach the sinuses, much like a snake weaves through underground tunnels.</p>
<p>Team member Dr. Sarah Khalife – a Hamilton Health Sciences (HHS) otolaryngologist — received an HHS DRIVE SPARK grant to support the development of the SMART-ENT surgical robot, aimed at making sinus surgery less invasive and more precise.</p>
<p>Otolaryngologists treat problems involving the ears, nose, throat, head and neck. Khalife subspecializes in rhinology and skull base surgery, focused on surgery treating conditions of the nose, sinuses and skull base using cameras through the nose.</p>
<p>HHS DRIVE SPARK awards celebrate early-stage, high-potential ideas that are igniting change across the hospital system with grants up to $50,000 to support bringing promising innovations to life.</p>
<h3><strong>A nose for innovation</strong></h3>
<p>The SMART-ENT prototype device is just three millimetres in diameter, about the same thickness as a cell phone charging cord. Khalife is developing this innovation in partnership with Dr. Onaizah Onaizah, a mechanical engineer who leads a McMaster University lab specializing in making tiny, millimetre-scale robotic tools for health care; Dr. Benjamin van der Woerd, an otolaryngologist subspecializing in laryngology at St. Joseph’s Healthcare Hamilton; and Dr. Crystal Fong, a neuroradiologist at HHS’ Hamilton General Hospital specializing in using medical imaging like MRI and CT scans to find and diagnose problems affecting the head, neck and spine. Fong is also an associate professor at McMaster University, and Khalife, Onaizah and van der Woerd are assistant professors. Another key team member at the forefront of research and development is Griffin Smith, a biomedical engineering master’s graduate.</p>
<p>“McMaster is our academic partner, and this innovation is a great example of what’s possible when our researchers and innovators collaborate on projects,” says Dr. Marc Jeschke, HHS’ vice president of research and innovation, and chief scientific officer. “By combining our expertise, we’re turning great ideas into innovations that have the potential to make a real difference in health care.”</p>
<figure aria-describedby="caption-attachment-146737" class="wp-caption alignnone"><img decoding="async" class=" wp-image-146737" src="https://www.hospitalnews.com/wp-content/uploads/2026/10/Snake-robot-2-1024x683.jpg" alt="" width="815" height="543" srcset="https://www.hospitalnews.com/wp-content/uploads/2026/10/Snake-robot-2-1024x683.jpg 1024w, https://www.hospitalnews.com/wp-content/uploads/2026/10/Snake-robot-2-400x267.jpg 400w, https://www.hospitalnews.com/wp-content/uploads/2026/10/Snake-robot-2-768x512.jpg 768w, https://www.hospitalnews.com/wp-content/uploads/2026/10/Snake-robot-2-1536x1024.jpg 1536w, https://www.hospitalnews.com/wp-content/uploads/2026/10/Snake-robot-2-630x420.jpg 630w, https://www.hospitalnews.com/wp-content/uploads/2026/10/Snake-robot-2-150x100.jpg 150w, https://www.hospitalnews.com/wp-content/uploads/2026/10/Snake-robot-2-300x200.jpg 300w, https://www.hospitalnews.com/wp-content/uploads/2026/10/Snake-robot-2-696x464.jpg 696w, https://www.hospitalnews.com/wp-content/uploads/2026/10/Snake-robot-2-1068x712.jpg 1068w, https://www.hospitalnews.com/wp-content/uploads/2026/10/Snake-robot-2.jpg 1800w" sizes="(max-width: 815px) 100vw, 815px"><figcaption class="wp-caption-text">Left to right: Griffin Smith, Dr. Onaizah Onaizah, Dr. Benjamin van der Woerd, and Dr. Sarah Khalife.</figcaption></figure>
<h3><strong>A maze of narrow passages</strong></h3>
<p>The sinuses are a network of air-filled bony spaces tucked inside the skull, connected to the nasal cavity by narrow, intricate passageways. These small openings allow mucus to drain and air to circulate. People have eight sinuses, four on each side of the face, and each is unique in size and shape.</p>
<p>For endoscopic sinus surgeries, doctors use a high-definition monitor and sinus CT scan for a precise map to guide them, as they clear out blocked pathways so sinuses can drain and the patient can breathe normally again.</p>
<p>This is done using a tiny camera and specialized instruments that are long and thin with different angles, so they can access the sinus area through the nose. But these tools are also straight and rigid, with several used at once to perform procedures.</p>
<p>“While considered minimally invasive, it can be challenging to navigate the different angles and narrow network of passageways to reach hard-to-access areas with these tools,” says Khalife, adding these instruments are standard in Canada and worldwide.</p>
<p>“Our surgical robot will be much smaller, less invasive and easier to maneuver.”</p>
<h3><strong>Inspired by nature</strong></h3>
<p>When imagining a better way, the team turned to nature, drawing on how snakes slither through underground tunnel systems, elephants deftly move their trunks and octopus tentacles bend, twist and reach into tight spaces.</p>
<p>“Nature has spent millions of years finding ingenious ways to navigate challenging environments and reach places that seem almost impossible to get to,” says Onaizah. “We wanted to learn from those remarkable designs and bring that ingenuity into the operating room.”</p>
<h3><strong>A better way</strong></h3>
<p>The SMART-ENT surgical robot features a single, thin piece of flexible tubing that houses multiple built-in channels so several tasks can be performed at the same time. The tube can accommodate specialized ports for suctioning fluids, delivering medication and cleaning the area. It also includes an LED light and a tiny camera, about the size of a grain of table salt, at the very tip to help the doctor see clearly, alongside a treatment laser to precisely target tissue.</p>
<p>“Our goal is to automate the tool by using a patient’s CT scan as a digital map to guide it safely through the nose and sinus area remotely,” says Khalife.</p>
<p>By applying a controlled magnetic field, a computer can precisely steer the tiny tube around tight corners and into hard-to-reach locations automatically.</p>
<p>“This tool also has the potential to be used in other types of surgeries, where doctors are operating on small, intricate, hard-to-reach areas,” adds Khalife.</p>
<h3><strong>Investing in HHS innovators</strong></h3>
<p>DRIVE SPARK funding will be used to help further develop this tool, with the goal of getting all the approvals in place for a clinical trial to test it in surgeries, down the road.</p>
<p>“This funding allows us to take an idea from the clinical setting and develop it into something that could have a meaningful impact,” says Khalife.</p>
<p>The post <a href="https://www.hospitalnews.com/tiny-snake-like-robot-could-transform-sinus-surgery/">Tiny snake-like robot could transform sinus surgery</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Drones could cut travel delays and reduce spoilage of donated blood</title>
<link>https://edusehat.com/en/drones-could-cut-travel-delays-and-reduce-spoilage-of-donated-blood</link>
<guid>https://edusehat.com/en/drones-could-cut-travel-delays-and-reduce-spoilage-of-donated-blood</guid>
<description><![CDATA[ Delivering blood from collection sites to labs is a fast-paced, labour-intensive process. Donated blood can deteriorate within a few hours at room temperature, leaving little room to manoeuvre in case of unexpected traffic congestion or other delays between collection sites and blood centres. But if you can’t get through traffic, you can go over it, […]
The post Drones could cut travel delays and reduce spoilage of donated blood appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/Drones.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 23:55:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Drones, could, cut, travel, delays, and, reduce, spoilage, donated, blood</media:keywords>
<content:encoded><![CDATA[<p>Delivering blood from collection sites to labs is a fast-paced, labour-intensive process. Donated blood can deteriorate within a few hours at room temperature, leaving little room to manoeuvre in case of unexpected traffic congestion or other delays between collection sites and blood centres.</p>
<p>But if you can’t get through traffic, you can go over it, thanks to drone technology.</p>
<p>In a study published in the journal Computers & Operations Research, Concordia PhD candidate Amirhossein Abbaszadeh and Hossein Hashemi Doulabi, an associate professor in the Department of Mechanical, Industrial and Aerospace Engineering, present a new optimization model that uses drones to support mobile blood donation vehicles (“bloodmobiles”). The model offers a faster, more efficient and more reliable way to transport donated blood in cities.</p>
<h3><strong>Powered by smart logistics</strong></h3>
<p>The researchers’ Drone-Aided Mobile Blood Collection Problem is the first integrated framework that coordinates the movements of both bloodmobiles and drones to preserve blood freshness and improve overall system performance.</p>
<p>At its heart is a smart logistics system where bloodmobiles travel to multiple collection sites while drones shuttle between them and a central blood centre. This method eliminates delays caused by traffic and ensures that freshly donated blood reaches the blood centre quickly for processing into its components — such as platelets, which must be separated within six hours.</p>
<p>The researchers achieved this by developing a mixed-integer linear programming model that synchronizes the routes, schedules and collection activities of both bloodmobiles and drones. Because such a large-scale optimization problem is computationally demanding, the team also designed a rolling-horizon-based matheuristic algorithm. This type of algorithm breaks the problem into smaller, more manageable parts, solving sequentially while simultaneously exploring nearby alternatives to find better ones.</p>
<p>“Vehicle routing problems are not new to operations research, but the perishability of blood brings a time-sensitive challenge that changes how routes must be planned,” says Abbaszadeh. “That’s when I thought of using drones.”</p>
<h3><strong>Cross-town coordination</strong></h3>
<p>Unlike previous studies that treated bloodmobiles and drones as separate systems, this work fully integrates their operations. Drones can take off from, land on or travel aboard bloodmobiles, allowing flexible coordination across multiple collection points without fixed infrastructure.</p>
<p>The model also considers the age of the blood — the time elapsed since donation — as a key optimization factor, rewarding fresher blood deliveries to ensure quality.</p>
<h3><strong>Putting the model to the test</strong></h3>
<p>The researchers used Quebec City as a real-world case study to test their model. They identified 13 potential collection sites, estimated the number of potential donors at each site and calculated the distance to the nearest blood centre.</p>
<p>“We used Google Maps to calculate the road distance and the most direct flight path since drones don’t need to use roads,” explains Abbaszadeh.</p>
<p>“We performed several analyses using different parameters: What if we used drones that had more load capacity, higher battery capacity or moved at higher speeds? We then compared the drone-aided system to the bloodmobile-only system.”</p>
<p>They found that adding drones to the blood collection fleet significantly reduced transport times. It also increased hourly delivery rates and maintained better consistency in blood freshness.</p>
<p>The authors write that their findings demonstrate the real potential of drone-assisted logistics in healthcare supply chains, particularly in time-critical operations like blood collection. They add that their framework could be adapted to other humanitarian or medical delivery contexts where speed, coordination and freshness are essential.</p>
<p>Read the cited paper: “Drone-Aided Mobile Blood Collection Problem”</p>
<p>The post <a href="https://www.hospitalnews.com/drones-could-cut-travel-delays-and-reduce-spoilage-of-donated-blood/">Drones could cut travel delays and reduce spoilage of donated blood</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Behind the diagnosis: Supporting patients living with dementia</title>
<link>https://edusehat.com/en/behind-the-diagnosis-supporting-patients-living-with-dementia</link>
<guid>https://edusehat.com/en/behind-the-diagnosis-supporting-patients-living-with-dementia</guid>
<description><![CDATA[ HN Summary • Unity Health Toronto takes a person-centred approach to dementia care, recognizing each patient’s history, relationships, routines and preferences.  • Hospital teams use reorientation, personalized music and “My Story” profiles to support engagement, comfort and independence. • Community and long-term care programs offer tailored activities and family support, helping maintain connection as care […]
The post Behind the diagnosis: Supporting patients living with dementia appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/Dementia.png" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 23:55:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Behind, the, diagnosis:, Supporting, patients, living, with, dementia</media:keywords>
<content:encoded><![CDATA[<p><strong>HN Summary</strong></p>
<p>• Unity Health Toronto takes a person-centred approach to dementia care, recognizing each patient’s history, relationships, routines and preferences.<span class="Apple-converted-space"> </span></p>
<p>• Hospital teams use reorientation, personalized music and “My Story” profiles to support engagement, comfort and independence.</p>
<p>• Community and long-term care programs offer tailored activities and family support, helping maintain connection as care needs change.</p>
<hr>
<p>For people living with dementia or other memory-related conditions, care can look different depending on where they are in their journey. Whether in a hospital setting or long-term care, care teams from across Unity Health Toronto stress the importance of seeing the person behind the diagnosis. They recognize that each patient or resident has life experiences and relationships built outside of their care setting, as well as routines that help them feel safe and comfortable.</p>
<p>Specialized memory care services are available in hospital, in the community and in long-term care. At Providence Healthcare, for example, the Adult Day Program (ADP) supports people living in the community with moderate to severe dementia through social programming designed around their individual needs. The program also provides support for families and caregivers.</p>
<p>As needs change over time, patients can move between care settings. Someone who first received care at St. Michael’s Hospital may later access rehabilitation, community programs or long-term care at Providence Healthcare. This connected approach helps ensure patients and families can access the right care at the time they need it.</p>
<figure aria-describedby="caption-attachment-146757" class="wp-caption alignnone"><img fetchpriority="high" decoding="async" class="size-full wp-image-146757" src="https://www.hospitalnews.com/wp-content/uploads/2026/10/Dementia-2.png" alt="" width="936" height="702" srcset="https://www.hospitalnews.com/wp-content/uploads/2026/10/Dementia-2.png 936w, https://www.hospitalnews.com/wp-content/uploads/2026/10/Dementia-2-400x300.png 400w, https://www.hospitalnews.com/wp-content/uploads/2026/10/Dementia-2-768x576.png 768w, https://www.hospitalnews.com/wp-content/uploads/2026/10/Dementia-2-560x420.png 560w, https://www.hospitalnews.com/wp-content/uploads/2026/10/Dementia-2-80x60.png 80w, https://www.hospitalnews.com/wp-content/uploads/2026/10/Dementia-2-150x113.png 150w, https://www.hospitalnews.com/wp-content/uploads/2026/10/Dementia-2-300x225.png 300w, https://www.hospitalnews.com/wp-content/uploads/2026/10/Dementia-2-696x522.png 696w" sizes="(max-width: 936px) 100vw, 936px"><figcaption class="wp-caption-text">ACE volunteers cart stocked with “Music Connections” equipment, activities and reminiscence materials to help engage patients and encourage conversation.</figcaption></figure>
<h3><strong>Supporting memory care in acute care</strong></h3>
<p>At St. Michael’s Hospital, occupational therapists Lisa Vandewater and Paula Isenberg work as part of the geriatrics team on the Acute Care of the Elderly (ACE) Unit. The team works with patients over 65 years old who often have complex geriatric syndromes, a term used to describe common age-related health challenges such as falls, dementia, delirium and difficulties managing daily life independently.</p>
<p>Vandewater and Isenberg assess patients’ cognitive function and safety, helping determine whether they can safely return home or if they require additional care. During a patient’s stay, they work to help them with confusion and dementia by doing simple things like reminding them where they are and regularly working to talk through the date and mark the passing of days on the calendar. This helps patients to stay oriented as long stays in hospital can affect a person’s sense of routine.</p>
<p>Vandewater says hospitalization can be especially difficult for someone living with dementia. Loved ones may not always be present, and an unfamiliar environment can increase confusion and anxiety. Programs such as the ACE volunteer program help to support reorientation and cognitive stimulation. In hospital, patients often have many daily tasks done for them, but for people living with dementia, opportunities to stay engaged and mentally active are important to maintaining function and independence.</p>
<p>The ACE volunteers also help patients complete “My Story,” a person-centred information sheet posted above a patient’s bed, that captures details about their life. A patient’s profile might include information about what they like to be called, who matters to them, what they enjoy and what helps them feel calm. “My Story” allows staff and volunteers to have a basic overview of who the patient is outside of the hospital and encourages patients to reminisce and stay mentally active.</p>
<p>The unit is also piloting “Music Connections”, a program which gives patients access to personalized playlists of familiar music.</p>
<p>“What’s interesting for individuals with dementia, particularly Alzheimer’s disease, is that the part of their brain that houses musical memories is fairly well preserved,” Vandewater says. “I was recently working with someone who loved the Bee Gees, and when one of their songs came on, they lit up and said, ‘Oh, look, I can still groove,’ and she started dancing away.”</p>
<p>For Isenberg, moments like these reflect the importance of looking beyond a patient’s immediate medical needs. Person-centred care recognizes that a person is more than a blood test or an X-ray. There’s a whole life and story behind who they are.</p>
<h3><strong>Creating connection in long-term care</strong></h3>
<p>At the Houses of Providence, Unity Health’s long-term care home at Providence Healthcare in Toronto’s east end, memory care takes place in a different setting: one where residents live, build relationships and settle into daily routines.</p>
<p>On the secured unit, staff support residents, often with memory-related conditions, who may become disoriented or wander. The unit gives residents the freedom to move about safely while reducing the risk of getting hurt or lost.</p>
<p>On the floor of the unit, Activation Assistants Sheri-Lynn Barton and Trexie Yntig shape days around movement, music, spiritual care, cultural celebrations and activities that reflect residents’ interests. Programs may include balloon tennis, mini bowling, karaoke, outdoor concerts and creative seasonal games.</p>
<p>Barton says flexibility is key. Some days residents are eager to join activities, while on others they need something quieter. The goal is to meet people where they are and create opportunities for joy and connection.</p>
<p>“This is what I am here to do. I work to bring the joy and fun into their daily lives,” Barton says. “Most of our residents can’t express it anymore, but you can see it in their faces, they’ll smile at you and clap along.”</p>
<p>Registered nurse Priyatharisini Gnanasekaran says building trust with residents and families is central to the work. Families often share important details about routines and cultural preferences that help residents feel at home.</p>
<p>“We care for the person, not just the diagnosis,” Gnanasekaran says. People living with dementia continue to experience emotion and connection even as memory and communication change.”</p>
<p>“The smallest moments of connection can make the biggest difference for people with dementia,” she adds.</p>
<p>For many residents, long-term care represents one stage in a broader care journey. Some may have previously accessed community-based supports, received care elsewhere or within Unity Health before arriving at the Houses of Providence. Across Unity Health Toronto, our commitment to person-centred care continues wherever the care journey leads.</p>
<p>The post <a href="https://www.hospitalnews.com/behind-the-diagnosis-supporting-patients-living-with-dementia/">Behind the diagnosis: Supporting patients living with dementia</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>New Alzheimer’s treatments bring leading care closer to home for patients across southeastern Ontario</title>
<link>https://edusehat.com/en/new-alzheimers-treatments-bring-leading-care-closer-to-home-for-patients-across-southeastern-ontario</link>
<guid>https://edusehat.com/en/new-alzheimers-treatments-bring-leading-care-closer-to-home-for-patients-across-southeastern-ontario</guid>
<description><![CDATA[ Kingston Health Sciences Centre (KHSC) is expanding access to new treatments for Alzheimer’s disease, bringing emerging care closer to home for patients across southeastern Ontario who traditionally needed to travel to larger centres such as Toronto or Ottawa. These new disease-modifying treatments are designed to slow the progression of Alzheimer’s disease in eligible patients, with […]
The post New Alzheimer’s treatments bring leading care closer to home for patients across southeastern Ontario appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/Kingston.png" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 23:55:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>New, Alzheimer’s, treatments, bring, leading, care, closer, home, for, patients, across, southeastern, Ontario</media:keywords>
<content:encoded><![CDATA[<p>Kingston Health Sciences Centre (KHSC) is expanding access to new treatments for Alzheimer’s disease, bringing emerging care closer to home for patients across southeastern Ontario who traditionally needed to travel to larger centres such as Toronto or Ottawa.</p>
<p>These new disease-modifying treatments are designed to slow the progression of Alzheimer’s disease in eligible patients, with the greatest benefit expected when treatment begins in the earlier stages of the disease.</p>
<p>Bram Fisher, who was diagnosed with Alzheimer’s several years ago, is one of the first patients in Canada to access these drugs. For him, the treatment means more time to remain independent and continue doing the things he enjoys — including playing music with the band, Old Gravel Road.</p>
<p>“I would say the progression has been fairly slow, and we’ve been pretty lucky,” says Bram. “I’m still able to do the things I enjoy — I play in the band; I go for walks and go for lunch with friends.”</p>
<p>Bram is now receiving one of the new Alzheimer’s drugs through KHSC’s cognitive neurology program under the care of memory disorders specialist Dr. Durjoy Lahiri who arrived at KHSC in June 2024.</p>
<p>“The idea is to slow down the disease, so patients remain independent for longer periods of time,” says Dr. Lahiri.</p>
<p>KHSC is among the first health sciences centres in Canada to begin offering access to these emerging treatments recently approved by Health Canada. Dr. Lahiri’s goal is to build a larger Alzheimer’s therapeutics program in Kingston that can serve patients from across the region.</p>
<p>“The goal is to build a modern treatment program right here in Kingston,” says Dr. Lahiri. “Kingston can function as the referral centre for the whole region outside of Toronto and Ottawa. We want to create a robust and scalable program.”</p>
<p>The program is expected to grow significantly as awareness of these treatments increases. Dr. Lahiri estimates that as many as 25 to 30 patients could be receiving infusions through KHSC within the next six-to-nine months, with the potential for that number to continue growing.</p>
<p>Early diagnosis will be critical to ensuring patients can benefit from these treatments. To support earlier diagnosis, KHSC has also developed a new blood test to diagnose Alzheimer’s disease early, with funding support from the University Hospitals Kingston Foundation (UHKF) and YGK Healthcare Champions.</p>
<p>“This is a very new development in the field. It’s cutting-edge clinical care,” says Dr. Lahiri. “The blood test will help quickly identify patients who may benefit from further assessment and consideration for disease-modifying treatment.”</p>
<p>For Bram’s partner, Bryn, the new treatment options are welcome as the couple navigates the realities of an Alzheimer’s diagnosis.</p>
<p>“Neither of us thought this is what we would be doing in our retirement years,” says Bryn. “It has been a bit of a challenge.”</p>
<p>For Bram, the ability to continue living his life as independently as possible is what matters most.</p>
<p>“It’s not a cure,” he says. “But I’m still able to do the things I enjoy, and I am happy about that.”</p>
<p>For patients like Bram these new treatments offer something deeply meaningful: more time to enjoy the moments that matter most, whether that’s making music, spending time with friends and loved ones, or maintaining independence for as long as possible.</p>
<p>The post <a href="https://www.hospitalnews.com/new-alzheimers-treatments-bring-leading-care-closer-to-home-for-patients-across-southeastern-ontario/">New Alzheimer’s treatments bring leading care closer to home for patients across southeastern Ontario</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Drug shortages: What, why, and how (Part 2 of 2)</title>
<link>https://edusehat.com/en/drug-shortages-what-why-and-how-part-2-of-2</link>
<guid>https://edusehat.com/en/drug-shortages-what-why-and-how-part-2-of-2</guid>
<description><![CDATA[ HN Summary • Drug shortages can compromise patient safety and access to treatment. Prolonged shortages can exhaust reserve supplies and alternatives, while switching medications may introduce dosing errors, adverse effects and higher costs, particularly when substitutes lack insurance coverage.  • Multiple supply pressures leave Canada vulnerable. Manufacturing problems, recalls, increased demand and shipping disruptions can […]
The post Drug shortages: What, why, and how (Part 2 of 2) appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/shutterstock_2670749007.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 23:55:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Drug, shortages:, What, why, and, how, Part</media:keywords>
<content:encoded><![CDATA[<p><strong>HN Summary</strong></p>
<p>• Drug shortages can compromise patient safety and access to treatment. Prolonged shortages can exhaust reserve supplies and alternatives, while switching medications may introduce dosing errors, adverse effects and higher costs, particularly when substitutes lack insurance coverage.<span class="Apple-converted-space"> </span></p>
<p>• Multiple supply pressures leave Canada vulnerable. Manufacturing problems, recalls, increased demand and shipping disruptions can trigger shortages. Canada’s small share of the global pharmaceutical market and reliance on imported drugs add to these challenges.</p>
<p>• Proactive coordination can help protect continuity of care. Governments, manufacturers, distributors and healthcare teams all have roles in managing shortages. Designated monitoring staff, standardized substitution protocols, shared supply information and clear patient education can reduce disruption and support safer care.</p>
<hr>
<h3><strong>What is a drug shortage?</strong></h3>
<p>A drug shortage occurs when there is not enough supply to meet its demand. In recent years, drug shortages have become a growing global public health concern, affecting patient care, healthcare providers, and the health care system. The impact of each drug shortage will vary based on factors, such as duration of the shortage, available alternatives or substitutions, and associated cost implications, etc.</p>
<p>In Canada, drug shortages last an average of several months. Extended duration of drug shortages could heighten the potential for patient harm as reserve stocks deplete, along with available therapeutic alternatives. Patients faced without a suitable alternative are disproportionately impacted compared to those with other therapeutic options. Despite the availability of alternatives, medication safety risks may still exist. Switching products, particularly when patients are not familiar with the alternative, and returning to the original product after the shortage is resolved, may pose risks or potential drug therapy problems, such as ineffective or duplicate therapies, dosing errors, or adverse drug events. Alternative options may also impose additional costs to patients and the healthcare system. Patients or institutions could face higher out-of-pocket costs if the available therapeutic alternative is not covered by the patients’ insurance plans or not listed in the hospital formulary, respectively. Consequently, drug shortages may exacerbate socioeconomic barriers for patients to access their medication(s).</p>
<h3><strong>Why do drug shortages occur?</strong></h3>
<p>Drug shortages can be caused by many reasons, for example, manufacturing or quality issues, unexpected increases in demand, reductions in supply, or fluctuations in both supply and demand, safety issues resulting in drug recalls, shipping delays or distribution problems, or drug discontinuation, etc.</p>
<p>Canada takes up about 2% of the global drug sales, a relatively small market of which most of the drugs are imported and likely sourced from a single supplier. This has led to Canada being prone to drug shortages. Readers can learn more about health product shortages in Canada by viewing a Government of Canada resource: “Building resilience: Health Canada’s plan to address health product shortages, 2024 to 2028”<span class="Apple-converted-space"> </span></p>
<h3><strong>How to address and/or<span class="Apple-converted-space"> </span>prevent drug shortages?</strong></h3>
<p>While Health Canada plays a key role in responding to drug shortages (e.g., by leveraging regulatory tools to allow more supplies, such as, importing foreign-authorized drugs), many other interested parties or stakeholders also help address and/or prevent drug shortages. They include:</p>
<p>• Provinces and territories – communicate and collaborate with hospitals, pharmacists, retailers, and distributors to manage supply of drugs;</p>
<p>• Manufacturers – mandatory reporting of anticipated and actual drug shortages and discontinuations of drugs to Health Canada. Increase production of drugs or expedite resupplies;</p>
<p>• Importers and distributors – manage and monitor inventory of drugs and expedite delivery of resupplies;</p>
<p>• Healthcare providers and patients – Readers can refer to the October 2026 issue – “Drug Shortages: How Pharmacists Can Help” where we shared what pharmacists and patients could do during drug shortages to support safe, equitable, and continuous care.</p>
<h3><strong>Steps Forward</strong></h3>
<p>Drug shortages can interrupt or disrupt workflow for pharmacists and other healthcare workers significantly and unexpectedly. Assigning designated individuals or personnels to monitor for drug shortages, developing standardized substitution protocols, triaging usage, sharing knowledge and supply information among institutions, providing education and actionable steps when drug shortage does occur can alleviate workplace stress and promote seamless continuity of safe and effective patient care.</p>
<p>By working proactively, establishing reporting and response protocol, and improving communication and transparency throughout the drug supply chain, the negative impacts of drug shortages could be mitigated. The Health Canada Infographic: Helping Canadians deal with drug shortages highlights valuable tips that everyone can help with drug shortages.</p>
<p>Olivia Mendicino and Taylor Monrad are PharmD students at the Leslie Dan Faculty of Pharmacy, University of Toronto; and Certina Ho is an Assistant Professor, Teaching Stream, at the Leslie Dan Faculty of Pharmacy and Department of Psychiatry, University of Toronto.</p>
<p>The post <a href="https://www.hospitalnews.com/drug-shortages-what-why-and-how-part-2-of-2/">Drug shortages: What, why, and how (Part 2 of 2)</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Scarborough Health Network a leader in preventing harm</title>
<link>https://edusehat.com/en/scarborough-health-network-a-leader-in-preventing-harm</link>
<guid>https://edusehat.com/en/scarborough-health-network-a-leader-in-preventing-harm</guid>
<description><![CDATA[ HN Summary • SHN recorded the lowest hospital harm rate among Ontario’s large community and teaching hospitals for the second consecutive year.•  • Its 2025–2026 rate was 1.9 affected patients per 100 hospitalizations, compared with the national hospital rate of 5.8. • Safety initiatives include tiered team huddles, delirium prevention and barcode medication scanning, supporting […]
The post Scarborough Health Network a leader in preventing harm appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/SHN.png" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 23:55:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Scarborough, Health, Network, leader, preventing, harm</media:keywords>
<content:encoded><![CDATA[<p><strong>HN Summary</strong></p>
<p>• SHN recorded the lowest hospital harm rate among Ontario’s large community and teaching hospitals for the second consecutive year.•<span class="Apple-converted-space"> </span></p>
<p>• Its 2025–2026 rate was 1.9 affected patients per 100 hospitalizations, compared with the national hospital rate of 5.8.</p>
<p>• Safety initiatives include tiered team huddles, delirium prevention and barcode medication scanning, supporting SHN’s goal of zero preventable harm.</p>
<hr>
<p>Scarborough Health Network (SHN) has achieved the lowest hospital harm rate among Ontario’s large community hospitals and teaching hospitals, leading both peer groups for the past two years. The result is based on the latest data from the Hospital Harm Project, a collaboration between the Canadian Institute for Health Information and Healthcare Excellence Canada, which measures unintended harm to inpatients that could potentially have been prevented through evidence-informed practices.</p>
<p>“Becoming Ontario’s safest hospital network for the second consecutive year is not by chance. It reflects what is possible when purpose, accountability, and continuous improvement are embedded across an organization. That’s what it means to be one of Canada’s top performing hospitals,” said David Graham, President and CEO.</p>
<p>The Hospital Harm Project tracks preventable harm in four areas: healthcare and medications, hospital-acquired infections, patient accidents, and procedures. The harm rate is the number of affected patients per 100 hospitalizations; a lower rate means safer care. For 2025-2026, SHN had a harm rate of 1.9, compared to the national large community hospital and teaching hospital rates of 5.2 and 6.7, respectively; and national hospital rate of 5.8. This means that patients experience harm at SHN between two to three times less than at comparative hospitals in Ontario and around the country.</p>
<p>SHN has achieved these leading harm rate results while responding to Scarborough’s rising healthcare demands, which are growing at a pace unmatched elsewhere in the province. Scarborough not only has one of Ontario’s most complex communities with a higher burden of chronic illness, it has also seen the fastest growth in emergency department visits among a population with more than 100,000 residents who do not have a family doctor.</p>
<p>“Despite the growing demands on our health network to meet our community’s needs, SHN has never compromised on our commitment to delivering exceptional quality care and patient safety. The plans we have put into action and practice are sustaining and making the difference,” said Graham.</p>
<p>“Today, we deliver more care at higher quality than any other hospital system in the province.”</p>
<p>Quality and Patient Safety is one of the key pillars of SHN’s Strategic Plan 2024–2029. This is further reinforced through clear targets in closely aligned corporate scorecard and Quality Improvement Plan, and performance is continually tracked from the frontline to the Board of Directors.</p>
<p>“Every patient deserves safe, high-quality care every time they come to SHN. Achieving the lowest harm rate in Ontario among large community and teaching hospitals for the last two years reflects the commitment of our teams to delivering evidence-informed care, continuously improving how we work, and placing patient safety at the centre of every decision,” said Glyn Boatswain, Executive Vice-President, Clinical Programs, and Chief Nursing and Allied Health Professionals Executive.</p>
<p>“This achievement belongs to our clinicians, professional staff, and support teams who work every day to prevent harm and improve patient experience. By listening to patients and families, learning from data and outcomes, and strengthening care practices across our organization, we are creating safer care for the diverse communities we serve in Scarborough and advancing our goal of zero preventable harm.”</p>
<p>Key priorities for ensuring safe patient care include establishing coordinated clinical practice, timely information, and reliable processes to prevent the occurrence of harm, such as pressure injuries, falls, and infections. One example is tiered huddles—brief, focused check-ins that occur at different levels of the organization—which create a structured, supportive way for healthcare teams to communicate. This helps to quickly escalate concerns about safety issues, and operational challenges, and drive quality improvements in real-time.</p>
<p>SHN’s delirium strategy also demonstrates how teams are addressing potential harm through prevention, early identification, and consistent care. Delirium prevention bundles, standardized assessments, and reduced use of benzodiazepines and sedatives help protect older adults from avoidable harm. Updated order sets, provider education, and patient resources also promote safer sleep and anxiety management during hospital stays. Additionally, SHN is part of a hospital-led research project on delirium that is exploring an AI-powered tool and electronic medical record data to identify high-risk patients who may benefit from targeted prevention strategies.</p>
<p>Another example of how SHN is leveraging technology is barcode medication administration scanning. Staff scan patient and medication barcodes with handheld devices to confirm the right patient, medication, dose, route, and timing, while automatically documenting each step in the patient’s electronic medical record through the Epic clinical information system. Together, this technology and standardized practice help reduce medication errors and support safer, more reliable care.</p>
<p>That commitment to leveraging technology to improve care and safety was recognized in August when the Healthcare Information and Management Systems Society awarded our organization Stage 7 of the Electronic Medical Record Adoption Model. The designation places SHN among the first large, multi-site hospital systems in Ontario to achieve the highest international benchmark for digital health excellence.</p>
<p>SHN’s focus on quality and safety has also been recognized through several national designations. In the summer of 2025, SHN achieved Quality Improvement Status as a Choosing Wisely Canada Hospital for reducing unnecessary tests and treatments and became the third organization in Canada recognized as an Age-Friendly Health System by the Institute for Healthcare Improvement for its system-wide commitment to compassionate, inclusive care for older adults. While achieving the lowest harm rate for the second year in a row marks an important milestone in delivering the safest care, SHN remains focused on the work ahead. This includes continuing to analyze performance data, share learnings across teams, and invest in practices and technologies that help prevent harm. The Love, Scarborough campaign helps accelerate this work by funding investments that enhance the exceptional quality care for our community. The goal is not simply to lead the province in safety, but to keep advancing toward zero preventable harm for every patient, every day.</p>
<p>The post <a href="https://www.hospitalnews.com/scarborough-health-network-a-leader-in-preventing-harm/">Scarborough Health Network a leader in preventing harm</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Glenrose patient and family advisor shares her journey to help others</title>
<link>https://edusehat.com/en/glenrose-patient-and-family-advisor-shares-her-journey-to-help-others</link>
<guid>https://edusehat.com/en/glenrose-patient-and-family-advisor-shares-her-journey-to-help-others</guid>
<description><![CDATA[ HN Summary • Former Glenrose rehabilitation patient Brittney Neunzig draws on her spinal cord injury experience to help improve care as a volunteer patient and family advisor. • She advises on hospital policies, programs and patient resources, helping embed patient and family perspectives in service design. • As a peer mentor, she supports newly injured […]
The post Glenrose patient and family advisor shares her journey to help others appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/AHS.png" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 23:55:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Glenrose, patient, and, family, advisor, shares, her, journey, help, others</media:keywords>
<content:encoded><![CDATA[<p><strong>HN Summary</strong></p>
<p>• Former Glenrose rehabilitation patient Brittney Neunzig draws on her spinal cord injury experience to help improve care as a volunteer patient and family advisor.</p>
<p>• She advises on hospital policies, programs and patient resources, helping embed patient and family perspectives in service design.</p>
<p>• As a peer mentor, she supports newly injured patients with community reintegration, sexual health and parenting from a wheelchair.</p>
<hr>
<p>Brittney Neunzig is no stranger to Glenrose Rehabilitation Hospital. At the age of 13, she underwent rehabilitation here after a snowmobile accident left her paralyzed. Twenty-six years later, as a volunteer, she’s starting her third year as a patient and family advisor at the hospital.</p>
<p>“I haven’t been a patient for a long time, but I’ve stayed closely connected to the Glenrose as a peer mentor for patients with spinal cord injuries,” she says. “I see a lot of great things happening there for patients, but I also see some gaps that need to be addressed.”</p>
<p>As a patient and family advisor, Neunzig helps improve the quality, safety and experience of healthcare programs and services by sharing her own experience and perspective with the goal of improving service delivery for other Glenrose patients and their families.</p>
<p>“I have a lot of knowledge to share around what does and doesn’t work for patients, from my own experience and through my peer mentor work, and I wanted to be able to lend my voice in ways that help improve things for others,” she says.</p>
<p>At Alberta Health Services (AHS), these volunteer roles play an important part in patient engagement —something that staff across the Glenrose take seriously.</p>
<p>“Patient and family advisors bring diverse patient, family or caregiver perspectives to current and future healthcare programs and services at our hospital,” says Amanda Proctor, staff liaison for the Glenrose Patient and Family Advisory Council (PFAC).</p>
<p>“Advisors share their experiences and provide their insight and ideas on policies, procedures, redesigns, projects and research that impact healthcare delivery.”</p>
<p>As part of her involvement with the Glenrose PFAC, Neunzig has been asked to consult on different projects and initiatives, such as new patient webpages, apps and resources, as well as programs and policies. She brings her experience as a pediatric patient to the table, as well as what she hears and sees as a peer mentor.</p>
<p>“At one point we did a consultation about what information and resources are important to send home with spinal cord injury patients and how to best structure it,” she says. “Anytime I can influence something related to spinal cord injuries, I’m proud of it. I’ve also consulted on how user-friendly news apps, websites or surveys are.”</p>
<p>Neunzig adds that, as an advisor, she’s here to offer her advice and experience to decision-makers within the hospital, and sometimes more broadly within AHS.</p>
<p>Proctor adds: “Getting these voices to the table is essential in ensuring that patients and families are represented in the design of services they receive. Advisors are engaged in projects early and often to ensure that projects can progress with patient and family voices embedded in every step of the process. Without these volunteers, we wouldn’t have the depth of wisdom to draw from on the projects we undertake.”</p>
<p>Neunzig says: “Healthcare is a team sport, and I think that patients and families need to feel empowered and like their voices are being heard in all of the systems they have to be in.”</p>
<p>In addition to being an advisor, Neunzig also supports other spinal cord injury patients as a peer mentor, something she’s been doing for many years. She also teaches classes related to sexual health and returning to the community to newly injured patients on unit 3B, which is home to the Adult Spinal Cord Injury and General Neurology Inpatient program.</p>
<p>“I’m a parent, so I get asked if I can come in and chat with others that might relate to my own experience,” she says. “There might be a mom on the unit, and I’ll come in and talk to them about things like strategies for parenting from a wheelchair. I like doing that, too.”</p>
<p>While many view volunteering as a way of “giving back” to the community, Neunzig feels she gets even more back.</p>
<p>“Honestly, the best part of volunteering is what other people are giving back to me,” she says.</p>
<p>“Learning about other peoples’ lived experiences has really allowed me to have more compassion and empathy for people who have other disabilities and better understand their own experiences. I feel like I’m growing as a person because I get to do this.”</p>
<p><i>By Katie McLaughlin</i></p>
<p>The post <a href="https://www.hospitalnews.com/glenrose-patient-and-family-advisor-shares-her-journey-to-help-others/">Glenrose patient and family advisor shares her journey to help others</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Told Your Heart Condition Is Inoperable? Here’s What a Second Opinion Can Change</title>
<link>https://edusehat.com/en/told-your-heart-condition-is-inoperable-heres-what-a-second-opinion-can-change</link>
<guid>https://edusehat.com/en/told-your-heart-condition-is-inoperable-heres-what-a-second-opinion-can-change</guid>
<description><![CDATA[ Being told your heart condition is inoperable often reflects one hospital&#039;s own capabilities, not a universal fact. This guide covers why that label gets applied, what it typically leaves out, questions to ask, what a second opinion can actually change, and when a consultation with Dr. Giovanni Ciuffo in Las Vegas is worth pursuing. ]]></description>
<enclosure url="https://heartsurgeryinfo.com/wp-content/uploads/2026/10/Heart-Condition-Is-Inoperable.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 16:30:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Told, Your, Heart, Condition, Inoperable, Here’s, What, Second, Opinion, Can, Change</media:keywords>
<content:encoded><![CDATA[<h4>Post Summary</h4>
<p><strong>Why are some patients told their heart condition is inoperable?</strong></p>
<p>Patients are told their heart condition is inoperable for a range of reasons, and those reasons are real even though the word itself sounds more absolute than it usually is. Age is one of the most common factors and is often treated as disqualifying on its own, even though age alone rarely tells the whole story. Frailty and other health conditions, including lung disease, diabetes, or kidney issues, get weighed heavily because traditional open-chest surgery places real strain on the body. Prior surgeries matter too, since scar tissue from an earlier procedure can make a second traditional operation riskier than the first. Beyond a patient’s individual health picture, a significant part of what goes into an inoperable label is what one hospital or surgical team is equipped to handle safely. Every program has its own risk tolerance and its own set of specialized capabilities, and those limits vary widely from one hospital to the next. A patient turned away as too high risk at one center may be a reasonable candidate at another, simply because that second team has more experience with complex, high-risk cases or offers techniques the first program does not. This does not mean every inoperable diagnosis is wrong, only that it reflects one specific evaluation rather than a universal medical ceiling.</p>
<p><strong>What does the inoperable label often fail to account for?</strong></p>
<p>An inoperable label often leaves out the existence of minimally invasive and specialized high-risk surgical techniques that many general cardiac programs simply do not offer. Traditional open-chest surgery is not the only surgical option for high-risk patients, even though it is often presented that way in the initial conversation. Minimally invasive approaches use smaller incisions and place considerably less strain on the body, and for some patients an off-pump technique avoids stopping the heart altogether, which can open the door for patients whose age, frailty, or other health conditions ruled out the traditional route. Some programs specialize in high-risk and complex cases specifically, meaning they have built real, ongoing experience evaluating exactly the kind of patient a general program routinely turns away. Being told a case is inoperable often means one surgeon, using the tools available at one hospital, has concluded traditional surgery is not safe, not that every surgical option everywhere has been ruled out. A program built specifically around minimally invasive and high-risk heart surgery may look at the same imaging, test results, and history and still see a real path forward, simply because evaluating difficult cases is what that program does routinely.</p>
<p><strong>What questions should you ask after being told you’re inoperable?</strong></p>
<p>Patients who receive an inoperable diagnosis have specific questions worth asking before accepting it as final. First, ask what specifically makes the case inoperable: whether it is age alone, a particular health condition, or something about what that specific hospital or surgical team is equipped to handle, since only one of those describes an absolute limit rather than a local one. Second, ask whether a program built around high-risk or complex cases has actually evaluated the imaging and history, since a general cardiac team and a specialized high-risk program do not always assess the same case the same way. Third, ask whether the diagnosis would look different at a program that specifically treats patients other surgeons have turned away, a fair and reasonable question rather than a confrontational one. Fourth, ask what would actually need to be true for the case to become operable elsewhere, since an answer involving a specific technique, a specific kind of experience, or specific equipment is useful information rather than a dead end. A confident surgeon should welcome all of these questions, and asking them before accepting an inoperable diagnosis as final is easier than wondering afterward whether enough was asked.</p>
<p><strong>What can a second opinion actually change for an inoperable diagnosis?</strong></p>
<p>A second opinion on an inoperable diagnosis can change more than patients expect, though not every case is reclassified. The most direct change is risk reclassification: a team with more experience evaluating high-risk and complex cases does not always agree with a general program’s assessment, not because the first evaluation was careless, but because risk tolerance and specialized expertise genuinely differ from one program to the next. The second change is access to a pathway that was never on the table, such as a minimally invasive or off-pump approach that was not offered or even mentioned at the first hospital, which may become a real option once a program built around exactly these cases takes a look. The third change is harder to quantify but just as real: clarity. A second opinion does not guarantee a different answer, but hearing the same conclusion from a specialist who evaluates high-risk cases every day carries a different kind of certainty than hearing it once from a general program, and moving forward with real confidence matters even when the outcome does not change. Patients have gone through exactly this process before, and real accounts of that experience exist for anyone who wants to see how it plays out in practice.</p>
<p><strong>When is the right time to seek a second opinion on an inoperable diagnosis?</strong></p>
<p>Seeking a second opinion on an inoperable diagnosis makes sense in nearly every case, and doing so soon after the diagnosis matters more than most patients realize. The earlier a second opinion happens, the more options remain genuinely open, before a general treatment plan is set and before a patient has mentally settled into the diagnosis as final. Waiting does not close every door, but it can close some of them, and there is little upside to waiting once a patient already wants a second set of eyes. Timing matters even more when the inoperable label came from a general cardiologist or general cardiac surgery program rather than a specialist in high-risk cases. That is not a criticism of the first team, since general programs handle the overwhelming majority of heart conditions well, and an inoperable conclusion from such a program is an honest reflection of what it is set up to do. It is precisely this situation, a general assessment rather than a specialized one, where a second, more specialized look tends to matter most. Some practices focus specifically on evaluating patients who have already been told no elsewhere, and that focus is worth knowing about before settling into a decision a different set of eyes could have changed.</p>
<p><strong>Who is Dr. Giovanni Ciuffo, and why do patients travel to see him for inoperable cases?</strong></p>
<p>Dr. Giovanni Ciuffo is a cardiothoracic surgeon who serves as Director of Cardiac Surgery at University Medical Center of Southern Nevada, based in Las Vegas. His practice focuses specifically on evaluating patients who have already been told their heart condition is inoperable by other surgeons or hospitals, including cases where a minimally invasive or high-risk surgical pathway was never raised as an option. Because specialized high-risk programs are not available everywhere and require experience most general cardiac programs do not maintain, patients are not always told these programs exist, which is exactly the kind of gap a second opinion is meant to close. Patients travel to Las Vegas from across the country for a second opinion with Dr. Ciuffo specifically because of this focus, rather than treating it as a purely local option, reflecting the practice’s national reach for exactly this population. Consultations are available whether a patient lives nearby or is traveling from elsewhere, and reaching out does not require a patient to have already decided anything. For anyone who has only heard the word inoperable and no further explanation, requesting a consultation is a way to find out whether that word is genuinely the final one for their specific case.</p>
<p>•••••</p>
<p><span>Being told you’re inoperable doesn’t sound like a diagnosis. It sounds like a verdict. Where other news at least comes with a next step, “inoperable” can feel like the conversation is over before it started, and that weight is real. It deserves to be taken seriously, not brushed past with reassurance you haven’t earned yet.</span></p>
<p><span>Here’s what’s worth knowing before you accept that word as final: being called inoperable often reflects what one surgeon, at one hospital, is equipped to offer, not a universal medical fact about your heart. That distinction is the whole reason a second opinion for an inoperable heart condition exists.</span></p>
<p><span>This guide walks through why that label gets applied, what it doesn’t account for, the questions worth asking, and what a second opinion can actually change.</span></p>
<h2><strong>Why Some Patients Are Told They’re “Inoperable”</strong></h2>
<p><span>So why do some patients get told their heart condition is inoperable in the first place? The reasons are real, but they’re rarely as absolute as the word makes them sound.</span></p>
<p><span>Age is one of the most common factors, and it’s often treated as disqualifying on its own, even though age alone rarely tells the whole story. Frailty and other health conditions, like lung disease, diabetes, or kidney issues, get weighed too, sometimes heavily, because traditional open-chest surgery puts real strain on the body. Prior surgeries matter as well; scar tissue from an earlier procedure can make a second traditional operation riskier than the first.</span></p>
<p><span>Here’s what’s easy to miss in the moment: much of what goes into an inoperable label is about what one hospital or one surgical team is equipped to handle safely. Every program has its own risk tolerance and its own set of specialized capabilities, and those limits vary widely from one hospital to the next. A patient deemed too high-risk at one center may be a reasonable candidate at another, simply because the second team has more experience with complex, high-risk cases or offers techniques the first program doesn’t.</span></p>
<p><span>None of this means every inoperable diagnosis is wrong. It means the label reflects a specific evaluation, made by specific people, at a specific place, and that evaluation is worth understanding in more detail before treating it as the final word.</span></p>
<h2><strong> What “Inoperable” Doesn’t Always Account For</strong></h2>
<p><span>What does the inoperable label typically leave out? Usually, minimally invasive and specialized high-risk surgical techniques are not offered by many general cardiac programs.</span></p>
<p><span>Traditional open-chest surgery isn’t the only surgical option for high-risk patients, even though it’s often treated that way in the initial conversation. Minimally invasive approaches use smaller incisions and place considerably less strain on the body, which can open the door for patients whose age, frailty, or other health conditions would otherwise rule out the traditional route. Some programs also specialize specifically in high-risk and complex cases, meaning they’ve built real, ongoing experience evaluating exactly the kind of patient a general program routinely turns away.</span></p>
<p><span>This is the distinction most inoperable conversations skip. Being told you’re inoperable often means one surgeon, using the tools and techniques available at one hospital, has concluded traditional surgery isn’t safe for you. It doesn’t necessarily mean every surgical option, everywhere, has been ruled out. A program built specifically around minimally invasive and high-risk heart surgery may look at the same imaging and see a real path forward.</span></p>
<p><span>We’ve written more about </span><a href="https://heartsurgeryinfo.com/second-opinion-for-inoperable-heart-surgery/" target="_blank" rel="noopener"><span>what an inoperable second opinion actually looks for</span></a><span> if you want the fuller breakdown of how that evaluation works. The short version: this gap between “not offered here” and “not possible anywhere” is common enough to matter, and specific enough in any one case that it’s worth building a program around exactly this kind of evaluation to take a direct look before accepting the label as final.</span></p>
<h2><strong>Questions Worth Asking After an Inoperable Diagnosis</strong></h2>
<p><span>Being told you’re inoperable can feel like the end of the conversation, but there are specific questions to ask about an inoperable heart diagnosis before you accept it as the final answer.</span></p>
<p><span>What specifically makes my case inoperable? Ask whether it’s your age alone, a particular health condition, or something about what this specific hospital or surgical team is equipped to handle. Those are three very different answers, and only one of them describes an absolute limit rather than a local one.</span></p>
<p><span>Has a program built around high-risk or complex cases actually evaluated my imaging and history? A general cardiac team and a specialized high-risk program don’t always see the same case the same way, and it’s fair to ask whether your case has been reviewed by the second kind, not just the first.</span></p>
<p><span>Would this diagnosis look different at a program that specifically treats patients other surgeons have turned away? This isn’t a question meant to second-guess your surgeon. It’s a reasonable one, and a confident surgeon should have no issue with you asking it.</span></p>
<p><span>What would actually need to be true for my case to become operable somewhere else? If the answer involves a specific technique, a specific kind of experience, or a specific piece of equipment, that’s useful information, not a dead end, and it tells you exactly what to look for elsewhere.</span></p>
<p><span>None of these questions is confrontational, and asking them before you accept an inoperable diagnosis as final is a lot easier than wondering later whether you asked enough.</span></p>
<h2><strong>What a Second Opinion Can Actually Change</strong></h2>
<p><span>So what can a second opinion on an inoperable diagnosis actually change? Sometimes, more than you’d expect. Sometimes, less. Both outcomes are worth knowing for certain rather than guessing, especially for a decision this significant.</span></p>
<p><span>The most direct change is risk reclassification. A team with more experience evaluating high-risk and complex cases doesn’t always agree with a general program’s assessment, not because the first evaluation was careless, but because risk tolerance and specialized expertise genuinely differ from one program to the next. What reads as too dangerous in one setting can read as manageable in another with the right technique and team.</span></p>
<p><span>The second change is access to a pathway that was never actually on the table. A minimally invasive or off-pump approach that wasn’t offered, or even mentioned, at the first hospital may be a real option once a program built around exactly these cases reviews the same imaging and history.</span></p>
<p><span>The third change is harder to quantify but just as real: clarity. Not every case gets reclassified, and a second opinion doesn’t guarantee a different answer. But hearing the same conclusion from a specialist who evaluates high-risk cases every day carries a different kind of certainty than hearing it once from a general program, and moving forward with real confidence matters even when the outcome doesn’t shift.</span></p>
<p><span>Patients have gone through exactly this process before. </span><a href="https://heartsurgeryinfo.com/inoperable-heart-surgery-patients/" target="_blank" rel="noopener"><span>One patient’s own account</span></a><span> of being told her case was inoperable, and what happened after that, is worth reading if you want to see what a second opinion on heart surgery actually looks like in practice, start to finish.</span></p>
<h2><strong>When to Seek a Second Opinion, and Why Sooner Helps</strong></h2>
<p><span>So when does it actually make sense to seek a second opinion on an inoperable diagnosis? Close to always, and especially soon after you first hear the word.</span></p>
<p><span>Timing matters here in a way it doesn’t always get the credit it deserves. The earlier a second opinion happens, the more options are still genuinely open, before a general treatment plan gets set, before you have mentally settled into thinking this is just how it is. Waiting does not close every door, but it can close some, and there is no real upside to waiting once you already know you want a second set of eyes.</span></p>
<p><span>This matters even more if the inoperable label came from a general cardiologist or a general cardiac surgery program rather than a specialist in high-risk cases. That is not a criticism of the first team. General programs handle the overwhelming majority of heart conditions well, and an inoperable conclusion from such a program is an honest reflection of what it is set up to do. It is also exactly the situation where a more specialized second look tends to matter most.</span></p>
<p><span>Some practices focus specifically on evaluating patients who have already been told no elsewhere. That focus is worth knowing about and worth acting on before you settle on a decision that a different set of eyes could have changed.</span></p>
<h2><strong>Quick Answers</strong></h2>
<p><b>What does it mean to be told your heart condition is inoperable?</b><span><br>
</span><span>It means one surgeon at one hospital has concluded that traditional surgery is not safe for you, given your age, health conditions, or the program’s own capabilities. It does not necessarily mean every surgical option, everywhere, has been ruled out.</span></p>
<p><b>Can an inoperable diagnosis change with a second opinion?</b><span><br>
</span><span>Sometimes. A specialized high-risk program may reclassify the risk, offer a minimally invasive or off-pump pathway not previously mentioned, or confirm the original assessment with greater certainty. Not every case gets reclassified, but it is worth finding out for certain.</span></p>
<p><b>What makes someone a minimally invasive candidate despite being called inoperable?</b><span><br>
</span><span>Candidacy depends on the specific reason for the inoperable label. Age or frailty alone often leaves more room for a minimally invasive approach than a program without that specialization initially suggested, though every case still needs its own direct evaluation.</span></p>
<p><b>How is a high-risk second opinion different from a routine one?</b><span><br>
</span><span>A high-risk second opinion specifically involves a program built around evaluating complex and previously declined cases, rather than a general cardiac team. That specialized experience is often the deciding factor in whether a different outcome is possible.</span></p>
<p><b>What should I bring to a second opinion consultation for an inoperable diagnosis?</b><span><br>
</span><span>Bring your full imaging results, the specific reasons given for the inoperable label, a current medication list, and a written list of questions, including what would need to be true for your case to become operable elsewhere.</span></p>
<h2><span>•••••</span></h2>
<p><span>If you have been told your heart condition is inoperable and want another set of eyes on your case, <a href="https://heartsurgeryinfo.com/contact-us/">Dr. Giovanni Ciuffo is worth talking to.</a> He serves as Director of Cardiac Surgery at University Medical Center of Southern Nevada, and his practice focuses specifically on evaluating patients whom other surgeons and hospitals have already turned away.</span></p>
<p><span>Patients travel to Las Vegas from across the country for a second opinion on heart surgery with Dr. Ciuffo when they have been told their condition is inoperable elsewhere, not just locally. Consultations are available whether you live nearby or across the country. If the word inoperable is the only answer you have gotten so far, reach out and find out whether that is genuinely the final word for your case.</span></p>]]> </content:encoded>
</item>

<item>
<title>Three&#45;Photon Microscopy Reveals Neural Activity Deep in the Mouse Brain</title>
<link>https://edusehat.com/en/three-photon-microscopy-reveals-neural-activity-deep-in-the-mouse-brain</link>
<guid>https://edusehat.com/en/three-photon-microscopy-reveals-neural-activity-deep-in-the-mouse-brain</guid>
<description><![CDATA[ By optimizing laser, optical, and acquisition parameters, The Rockefeller University researchers developed a three-photon microscopy platform that captures deep-brain neural activity in living mice at single-cell resolution without surgically removing the overlying cortex.
The post Three-Photon Microscopy Reveals Neural Activity Deep in the Mouse Brain appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/07/GettyImages-827580658.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 09:05:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Three-Photon, Microscopy, Reveals, Neural, Activity, Deep, the, Mouse, Brain</media:keywords>
<content:encoded><![CDATA[<p>Watching neurons deep inside the brain usually means contending with scattered light—or removing tissue to get a clearer view. Now, researchers at The Rockefeller University have redesigned a three-photon microscopy platform to record neuronal activity in deep brain regions of living mice without surgically removing the overlying cortex.</p>
<p>Led by Alipasha Vaziri, PhD, head of Rockefeller’s Laboratory of Neurotechnology and Biophysics, the team developed Three-photon Ultra-Deep Imaging (TrUDI). Their study, “<a href="https://www.nature.com/articles/s41592-026-03251-2">Cellular-resolution three-photon ultra-deep imaging (TrUDI) of neuronal population activity at 2-mm depth in the mammalian brain,</a>” was published in <em>Nature Methods</em>.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>TrUDI generated approximately 250 times more detected fluorescence photons at the same laser power as previous approaches, enabling single-cell-resolution recordings of neuronal population activity at depths of approximately 2 mm.</p>
<p>“Often in technology, people stick with a certain laser or parameter for historical reasons, and everyone just accepts those limitations,” Vaziri said. “We wanted to take a clean slate approach.”</p>
<p>As light penetrates brain tissue, scattering makes it increasingly difficult to distinguish fluorescent signals from background. Three-photon microscopy produces less background fluorescence than two-photon microscopy, potentially allowing deeper imaging. However, generating sufficient signal requires energetic laser pulses, and increasing average laser power risks heating and damaging tissue.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>Previous three-photon functional recordings had reached approximately 1.2 mm, short of the technique’s theoretical depth limit of more than 2 mm.</p>
<p>The researchers used computer models to guide coordinated changes to the laser and optics. The authors wrote, “TrUDI matches the parameters of the excitation laser, the optical system, and the acquisition to linear and nonlinear limits for safe laser exposure while satisfying the spatiotemporal requirements of single-cell resolution calcium (Ca<sup>2+</sup>) imaging.”</p>
<figure aria-describedby="caption-attachment-339959" class="wp-caption alignleft"><img fetchpriority="high" decoding="async" class="size-medium wp-image-339959" src="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_Vaziri_101926_HERO-300x200.jpg" alt="TrUDI" width="300" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_Vaziri_101926_HERO-300x200.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_Vaziri_101926_HERO.jpg 700w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">A volumetric rendering of stacked images taken with the Vaziri lab’s new platform TrUDI. [Laboratory of Neurotechnology and Biophysics at The Rockefeller University]</figcaption></figure>
<p>The team also developed a neuron-targeted excitation scheme that switches on the laser only as it scans identified cells. “The way we did this was through a series of very systematic, principled, and ground-up optimizations,” Vaziri said.</p>
<p>Together, these changes increased the fluorescence signal available for recording transient activity in individual neurons. The platform was tested in mice, and the paper reports recordings over fields of view approximately 230 by 230 µm<sup>2</sup> at 8.6 Hz, reaching approximately 2 mm into the mouse cortex and hippocampus.</p>
<p>The advance expands access to circuits that previously required removal of overlying tissue for optical imaging, potentially helping researchers investigate how neuronal populations across deep brain regions coordinate their activity. It does not, however, make every deep structure accessible.</p>
<p>“There are regions of the striatum that are inaccessible, and there are still a number of deep brain nuclei which are much deeper that still require invasive approaches,” Vaziri added.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>For now, the work demonstrates how coordinated optimization can bring three-photon imaging closer to its fundamental depth limit while preserving the tissue above the regions being studied.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/three-photon-microscopy-reveals-neural-activity-deep-in-the-mouse-brain/">Three-Photon Microscopy Reveals Neural Activity Deep in the Mouse Brain</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>How the Heart Stays Strong with MCT1&#45;Dependent Mitochondrial Lactate Import</title>
<link>https://edusehat.com/en/how-the-heart-stays-strong-with-mct1-dependent-mitochondrial-lactate-import</link>
<guid>https://edusehat.com/en/how-the-heart-stays-strong-with-mct1-dependent-mitochondrial-lactate-import</guid>
<description><![CDATA[ Preclinical study results suggest how the heart can keep itself well-fueled even under times of stress, by burning glucose in the cell cytosol while burning lactate in the mitochondria.
The post How the Heart Stays Strong with MCT1-Dependent Mitochondrial Lactate Import appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/07/GeneTherapy_GettyImages_2101175464_HolographicHumanHeart.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 05:30:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>How, the, Heart, Stays, Strong, with, MCT1-Dependent, Mitochondrial, Lactate, Import</media:keywords>
<content:encoded><![CDATA[<p>Maintaining energy flow to the heart is a complex process which can break down during common but severe cardiovascular disease conditions such as heart failure. Researchers previously knew that heart muscle seems to do an unusual metabolic trick to always get enough energy, which is using two carbohydrate energy sources—glucose and lactate—at the same time.</p>
<p>In most human tissues, using more glucose makes it harder to use lactate, and vice versa, but the heart is different. Working with experimental mice, scientists headed by a team at the University of Utah have now found a unique cell-level difference that helps keep heart muscle fueled up, which is the ability to burn glucose in the cell cytosol while burning lactate in the mitochondria. This spatial separation allows both energy-generating reactions to happen simultaneously, helping keep the heart fueled up no matter the energy source.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>While mostly dispensable to daily life, this process is crucial to preventing heart failure when the heart is stressed. “This appears to be a critical backup system for heart function,” says Gregory Ducker, PhD, assistant professor of biochemistry at University of Utah Health. “In an emergency, we would really, really rely on this.”</p>
<p>The findings could point to new potential therapeutic strategies for some serious heart disorders. Ducker is senior author of the researchers’ published paper in <em>Nature</em>, titled “<a href="http://dx.doi.org/10.1038/s41586-026-11182-3" target="_blank" rel="noopener">MCT1-dependent mitochondrial lactate import sustains cardiac metabolism</a>,” in which they stated, “Thus, the existence of a parallel lactate-based pathway for carbohydrate oxidation can sustain cardiac energetics and maintain myocardial structure and function under diverse stress conditions.”</p>
<p>The heart is the hardest-working muscle in the body, beating constantly no matter what the body’s energy reserves look like. The heart’s energy demands can be met through the use of both glucose and lactate as fuel. “The heart possesses a dynamic capacity to oxidize a variety of fuels, including glucose and lactate, to meet its energetic demands under diverse dietary, exertion, and injury stressors,” the authors wrote.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>Laboratory work and experiments in mice reported by Ducker and colleagues now suggest how the heart can use both fuel sources at the same time. Their research found that the separation between glucose and lactate metabolism depends on a molecule called MCT1, which moves lactate to the inside of the mitochondria. “We further observe that MCT1, traditionally localized to the plasma membrane, also resides in the inner mitochondrial membrane of mouse and human cardiomyocytes,” they wrote. Genetic mutations in MCT1 prevent lactate from entering the mitochondria and disrupt the heart’s energy balance, leading to heart failure when stressed. “Genetic ablation of MCT1 abolishes mitochondrial lactate oxidation, disrupts adaptation to neurohormonal, hemodynamic or ischemic stress and accelerates the development of heart failure with enhanced mortality,” the investigators further stated.</p>
<p>These results uncover a new requirement for lactate to fuel the injured heart and suggest new therapeutic targets to re-energize the heart during heart failure. “Our findings help point to new areas in which we could target the heart muscle to benefit and repair itself by allowing it to use lactate better,” Ducker said. “That’s the long-term goal: to help the heart muscle heal.”</p>
<p>The discovery of a new pathway through which the heart muscle can use lactate to generate energy opens promising opportunities for developing new treatments for serious heart conditions, including heart failure and heart attacks.</p>
<p>“Rather than simply releasing lactate into the bloodstream as a waste product, we may be able to enhance the heart’s ability to use it as a valuable source of energy,” says Stavros Drakos, MD, PhD, Professor of Medicine at University of Utah Health and co-senior author of the study. “By optimizing this process, we could potentially improve heart muscle function in patients suffering from heart failure or heart attacks.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/how-the-heart-stays-strong-with-mct1-dependent-mitochondrial-lactate-import/">How the Heart Stays Strong with MCT1-Dependent Mitochondrial Lactate Import</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>2026 report on biotech’s economic impact portrays a vast ecosystem</title>
<link>https://edusehat.com/en/2026-report-on-biotechs-economic-impact-portrays-a-vast-ecosystem</link>
<guid>https://edusehat.com/en/2026-report-on-biotechs-economic-impact-portrays-a-vast-ecosystem</guid>
<description><![CDATA[ The latest portrait of America’s biotech industry describes a growing economic force responsible for $3.19 trillion in total U.S. economic output and employment of […]
The post 2026 report on biotech’s economic impact portrays a vast ecosystem appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/10/BIOR_GSD_TEConomy-Report_3Stat_102226.png" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 02:00:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>2026, report, biotech’s, economic, impact, portrays, vast, ecosystem</media:keywords>
<content:encoded><![CDATA[<p><span>The latest portrait of America’s biotech industry describes a growing economic force responsible for $3.19 trillion in total U.S. economic output and employment of 2.31 million workers.</span></p>
<p><span>But the BIO/CSBA/TEConomy 2026 report, released Oct. 28, also details important, perhaps less-noticed trends. For example: Biomanufacturing employment grew at nearly 16% nationwide in 2021-25, with 26 states adding jobs and 16 of them growing by more than 20%. The report also includes eye-opening data on the broad geographic expansion of the clinical trial subsector, vital for innovators and patients.</span></p>
<p><span>This is the 12</span><span>th</span><span> edition of this overview of the biotech industry on the national, state and local levels. Produced every two years since 2004 by TEConomy Partners for the Biotechnology Innovation Organization (BIO), the BIO/CSBA/TEConomy report includes individual reports for 50 states, Puerto Rico and the District of Columbia.</span></p>
<p><span>The new report indicates biotech remains strong in the U.S., says Peter Pellerito, a Senior policy Advisor for BIO who has worked on the reports since the beginning.</span></p>
<p><span>“U.S. industry continues to be the leader in global biotechnology competitiveness and biosecurity because of a strategic history of sustained cutting-edge, biology-based research and workforce development partnerships at all levels of industry activity,” he says.</span></p>
<p><span>“Just as drug and pharmaceutical basic and applied research efforts have identified new therapies for patients, so too has the economic impact footprint of our industry grown,” says Pellerito. “While innovation and capacity in biomanufacturing remain substantial in national hubs like California and Massachusetts, the industry continues to expand across all 50 states, Puerto Rico, and the District of Columbia, helping diversify local economies through the creation of quality jobs.”</span></p>
<h2>Employment: Booming growth plateaus</h2>
<p><span>The report shows rapid expansion in biotech from 2021 through 2025: employment in the industry grew 7% and the number of biotech business establishments reached 156,000 by</span> <span>2025. But the strong growth occurred in the post-pandemic years of 2022 and 2023 and has eventually slowed and leveled off in the last two years.</span></p>
<p><span>“The overall employment gain masks two distinct periods. Industry employment rose 5.7 percent in 2022 and increased another 1.2 percent in 2023 before declining 0.3 percent in 2024 and growing just 0.4 percent in 2025. Employment in 2025 was essentially unchanged from its 2023 level,” according to the report.</span></p>
<p><span>“The hiring slowdown warrants attention,” because biotech job growth has generally outpaced private job growth for the past 25 years, the report notes. Still, the healthy growth in 2021-25 touched much of the country.</span></p>
<p><span>“Forty-one states, the District of Columbia, and Puerto Rico experienced net bioscience employment growth over the period,” the report says. “The leading states by absolute job gains were Texas, Florida, Massachusetts, Illinois, North Carolina, Pennsylvania, New York, Ohio, and New Jersey.”</span></p>
<h2>A massive clinical trial ecosystem</h2>
<p><span>The report features a special focus on clinical trials, noting the efforts states make to attract this patient-centered business activity.</span></p>
<p><span>“The special analysis conducted for this report identified 63,468 distinct clinical studies active in the United States or Puerto Rico during 2021–25,” the report says. “Universities, hospitals, research institutes, and other research organizations sponsored 66 percent of these studies, while industry sponsored an additional 29 percent.”</span></p>
<p><span>Ryan Helwig, TEConomy Principal and Senior Director, who’s worked on 11 reports, explains the importance of the report’s analysis of clinical trials.</span></p>
<p><span>“BIO really understood that we need to help industry stakeholders and ordinary Americans get their arms around  the vast footprint of these trials,” he says. “This robust clinical research complex is essential to our national competitiveness and a key piece of advancing real innovations into the clinic and ultimately to commercialization for the benefit of patients.”</span></p>
<p><span>States with larger populations have an advantage in attracting clinical trials, which is why larger states were in the top five hosting clinical trials in 2021-25: California (16,738), Texas (13,742), New York (12,695), Florida (11,686), and Pennsylvania (9,395), according to the report.</span></p>
<p><span>Still, “the subsector is spread across the country,” with trials hosted in every state, the District of Columbia and Puerto Rico, Helwig says.</span></p>
<p><span>The wide availability of clinical trials is good news for patients who are eager to participate and gain early access to cutting-edge medicines. Yet, as the report notes, clinical trial opportunities still could be more widely distributed.</span></p>
<p><span>“A strong national clinical research enterprise is most effective when the right studies are accessible to the patients and communities that need them, underscoring the importance of continued investment in clinical research capacity, diverse participant recruitment, and regional site networks,” the report says.</span></p>
<h2>Biomanufacturing booms</h2>
<p><span>The report also has an expanded section on biomanufacturing, focused specifically on the production of biologic medicines and therapies .</span></p>
<p><span>“Biological product manufacturing has been an important growth segment within the U.S. bioscience industry and the pharmaceuticals subsector. In 2025, the industry employed 46,936 workers, an increase of 15.8 percent from 2021,” the report notes.</span></p>
<p><span>The trend toward reshoring is helping drive the growth in biomanufacturing, and states are competing to benefit from the extensive investment in infrastructure and workforce development that’s involved in establishing new biomanufacturing facilities.</span></p>
<p><span>“There are three main pillars of support that states use to attract this segment of our industry,” according to Pellerito: Enabling infrastructure development; encouraging workforce development; and creating a business-friendly environment through measures such as targeted tax incentives.</span></p>
<p><span>States who succeed in attracting biomanufacturing can hope for big rewards. As the report notes, the last couple of years have seen U.S. and international companies commit to projects totaling hundreds of billions of dollars in value with a projected tens of thousands of  generated jobs.</span></p>
<p><span>“Many of these are just at the investment and early building phases,” Helwig says. “Just imagine what that does for the bioscience industry and ecosystem when those facilities start to fully come on line.”</span></p>
<p><a href="http://www.bio.org/jobs"><b>Read the report here.</b></a></p>
<p>The post <a href="https://bio.news/state-policy/2026-report-on-biotechs-economic-impact-portrays-a-vast-ecosystem/">2026 report on biotech’s economic impact portrays a vast ecosystem</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Collaboration and Roadmaps Key to Capsid Accessibility</title>
<link>https://edusehat.com/en/collaboration-and-roadmaps-key-to-capsid-accessibility</link>
<guid>https://edusehat.com/en/collaboration-and-roadmaps-key-to-capsid-accessibility</guid>
<description><![CDATA[ Apertura says widening access to its TfR1 CapX capsid is a core philosophy, and that includes inviting a wide range of collaborations and supporting collaborators through advice and preclinical roadmaps. 
The post Collaboration and Roadmaps Key to Capsid Accessibility appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/AGTX001-Img-1_2x-2.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 01:55:12 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Collaboration, and, Roadmaps, Key, Capsid, Accessibility</media:keywords>
<content:encoded><![CDATA[<p>Providing manufacturing and preclinical development advice, as well as forging a broad range of collaborations, is important to increasing access to capsids and their associated plasmids. That’s according to a gene therapy company focused on engineering adeno-associated virus (AAV) capsids and payloads.</p>
<p>For Jorge Santiago-Ortiz, PhD, vice president, CMC & regulatory affairs at Apertura Gene Therapy, the development and manufacturing story of the company’s own lead capsid, TfR1 CapX, is reassuringly uneventful. This is why he focused his talk at the Bioprocessing Summit in Boston on sharing knowledge about engineered capsids and their manufacturability.</p>
<p>“Giving access to capsids is in everyone’s best interests to advance the field,” Santiago-Ortiz says. “And we have already formed a number of partnerships with different types of institutions, for example, foundations, academic institutions, and for-profit organizations too.”</p>
<p>According to Santiago-Ortiz, Apertura Gene Therapy believes its TfR1 CapX is a best-in-class novel AAV capsid for highly efficient delivery to the central nervous system, even at low doses. Manufacturing the capsid itself involves standard unit operations and commercially available reagents, and has taken place internally and at contract manufacturer and other partner facilities in clinical batches of up to 500 L.</p>
<p>Santiago-Ortiz says the company’s success is down to having considered manufacturability early alongside any modifications groups might need to make to standard analytics techniques for the analysis of bespoke capsids.</p>
<p>However, he says, what resonated most with the Bioprocessing Summit audience was the company’s focus on widening access to its capsid technology. This includes, for example, he says, Material Transfer Agreements (MTAs) for academic researchers and even for-profit companies to evaluate their transfer.</p>
<p>In addition to providing access to the capsid and its associated plasmid, he says, they also provide advice on manufacturing, nonclinical development, and regulatory strategies, alongside analytical development guidance.</p>
<p>“As soon as a partnership is announced, we’re as proactive as possible in providing advice and guidance,” he says. “We want to be open and reachable and answer the questions partners might have.”</p>
<p>In addition, Apertura Gene Therapy helps link up partners who might want to manufacture with the aid of a contract manufacturer.</p>
<p>“We connect different parties who have developed different experience and, hopefully, this list of partners will grow as more people adopt this technology and establish their capability to manufacture this virus,” he adds.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/collaboration-and-roadmaps-key-to-capsid-accessibility/">Collaboration and Roadmaps Key to Capsid Accessibility</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Microbial Dark Matter Could Revive Antibiotics</title>
<link>https://edusehat.com/en/microbial-dark-matter-could-revive-antibiotics</link>
<guid>https://edusehat.com/en/microbial-dark-matter-could-revive-antibiotics</guid>
<description><![CDATA[ Most microbes remain out of reach, and many antibiotic-producing genes stay silent. A new review argues that combining genomics, innovative cultivation, and scalable manufacturing could turn this hidden chemistry into desperately needed new antibiotic treatments.
The post Microbial Dark Matter Could Revive Antibiotics appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Mike-Dark-Matter_GBPN_IMAGE_22OCT26.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 01:55:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Microbial, Dark, Matter, Could, Revive, Antibiotics</media:keywords>
<content:encoded><![CDATA[<p>The world’s microbes have not run out of ways to fight bacteria. Antibiotic hunters may simply have been searching the same familiar territory—and overlooking what happens after a promising molecule is found. That is the central message of a <a href="https://www.sciencedirect.com/science/article/pii/S0734975026002600" target="_blank" rel="noopener">review</a> by Ahmed Hamed, PhD, and Zeinab Khalil, PhD, both at the University of Queensland. The researchers describe “microbial dark matter” as organisms that resist conventional cultivation, along with silent biosynthetic pathways in familiar microbes that could encode undiscovered natural products.</p>
<p>The stakes are considerable. Antimicrobial resistance directly caused an estimated 1.27 million deaths worldwide in 2019, according to figures cited in the review. Yet traditional screening has repeatedly mined the same microorganisms, particularly <em>Streptomyces</em>, often rediscovering known compounds rather than uncovering new antibiotic structures.</p>
<p>Genome-mining tools now identify biosynthetic gene clusters (BGCs)—groups of genes responsible for producing specialized molecules—even when those products never appear in laboratory cultures. Metagenomics extends the search to microbes that scientists cannot grow, while devices that recreate natural environments can bring some previously inaccessible organisms into cultivation.</p>
<p>Consider teixobactin, an antibiotic discovered from <em>Eleftheria terrae</em>, a soil bacterium recovered using an iChip device that cultivates microbes in their native environment. Although teixobactin shows activity against several Gram-positive pathogens, its producer remains difficult to grow conventionally. The review highlights the ongoing reliance on chemical synthesis to supply the compound.</p>
<p>“Detection, however, is not production,” the researchers write. An analysis of 50 studies cited by the authors found that large-scale attempts to express natural-product pathways in alternative microbial hosts produced detectable compounds only 11–32% of the time. Missing genes, inadequate precursor supply, product toxicity, and poor fermentation performance can all stall development.</p>
<p>The review makes bioprocess engineering central to the solution. In one cited study, adding talc microparticles to an engineered <em>Streptomyces</em> culture increased production of pamamycin nearly threefold, from 18 to 50 mg/L. Reworking pathway regulation, engineering microbial production hosts, and optimizing culture conditions offer other routes to better yields.</p>
<p>Artificial intelligence could help researchers choose which clusters deserve attention by connecting genomic and molecular features to predicted biological activity. But predictions still require experimental confirmation, and abundant material is needed to study a promising compound’s mechanism and development potential.</p>
<p>Rather than bet on any single platform, Hamed and Khalil envision an iterative workflow linking ecological sampling, genome and metabolome analysis, activity testing, target identification, and scalable production. The next antibiotic breakthrough, their review suggests, will depend as much on making a molecule as on finding it.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/microbial-dark-matter-could-revive-antibiotics/">Microbial Dark Matter Could Revive Antibiotics</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Decentralization, AI, and Gene Editing Are Opportunities for CGT Contractors</title>
<link>https://edusehat.com/en/decentralization-ai-and-gene-editing-are-opportunities-for-cgt-contractors</link>
<guid>https://edusehat.com/en/decentralization-ai-and-gene-editing-are-opportunities-for-cgt-contractors</guid>
<description><![CDATA[ CDMOs already play a critical role in the cell and gene therapy development and manufacturing space, says Rose Biosolutions. Emerging bioprocessing technologies, production methods, and strategies are creating even more opportunities for contractors.
The post Decentralization, AI, and Gene Editing Are Opportunities for CGT Contractors appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/06/GettyImages-2199680273.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 01:55:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Decentralization, AI, and, Gene, Editing, Are, Opportunities, for, CGT, Contractors</media:keywords>
<content:encoded><![CDATA[<p>Decentralization, artificial intelligence (AI) process modeling, and advances in gene editing are expanding the cell and gene therapy (CGT) production toolkit and creating opportunities for third-party contractors.</p>
<p>The CGT industry makes extensive use of CDMOs, with—depending on who you ask—anywhere between <a href="https://www.grandviewresearch.com/industry-analysis/cell-gene-therapy-manufacturing-market" target="_blank" rel="noopener">66%</a> and <a href="https://www.deloitte.com/content/dam/assets-zone3/us/en/docs/industries/life-sciences-health-care/2024/us-lshc-advanced-therapy-2024.pdf" target="_blank" rel="noopener">90%</a> of CGT production being outsourced to an external manufacturer.</p>
<p>Contractors play a pivotal role, in part, because they have the real-world production expertise that therapy developers lack, says Alan Smith, PhD, global head of innovation at <a href="https://www.prnewswire.com/news-releases/gi-partners-completes-acquisition-of-the-cdmo-and-cell-solutions-businesses-from-charles-river-laboratories-and-forms-rose-biosolutions-302765625.html" target="_blank" rel="noopener">recently founded</a> CDMO, Rose Biosolutions.</p>
<p>“Highly experienced CDMOs offer broad experience and capability, along with mastery of the activities required for a successful manufacturing, quality, and regulatory strategy needed to realize the partner developer’s vision.</p>
<p>“Good CDMOs build relationships; great CDMOs build relationships on trust, defined by competency and intimacy with their partners. The relationship has evolved with the needs of partner developers and grown to include expertise, experience, and trust,” he tells <em>GEN</em>.</p>
<p>Quality control expertise is a major outsourcing driver, according to Smith, who adds, “Strong quality systems employed by CDMO partners limit risk to product quality attributes that are of key concern in the logistics chain.</p>
<p>“A thorough understanding of key product quality attributes and appropriate product characterization lead to development of control strategies that ensure product consistency and meet the requirements of logistics chain,” he says.</p>
<h4><strong>Decentralization</strong></h4>
<p>In recent years, decentralized CGT manufacturing models, where patient-specific therapies are produced local to the intended recipients, have emerged as a way of minimizing transportation requirements.</p>
<p>And this is creating opportunities, says Jeff Mocny, PhD, vice president of scientific leadership at Rose, who tells <em>GEN</em>, “CDMOs can be uniquely positioned to accommodate the manufacturing needs of decentralized paradigms. Drawing on the expertise in product manufacture, required quality elements and expedited release strategies, they can enable high-quality, safe and effective delivery preparations to enable bedside production.”</p>
<h4><strong>Early adoption</strong></h4>
<p>According to <a href="https://www.simon-kucher.com/en/insights/cdmo-growth-report-2026" target="_blank" rel="noopener">analysis</a>, the CDMO space is competitive with most contractors seeking to differentiate themselves based on price and capabilities.</p>
<p>As a result, contractors tend to be well informed about potential market-reshaping advances in technology, Mocny says, citing systems that have recently emerged in the CGT space by way of example.</p>
<p>“There are many new gene editing strategies and gene delivery strategies which are likely to have a significant impact on the CGT space. Additionally, <em>in vivo</em> gene editing and gene delivery are showing promise in early studies and will likely have an impact on the direction that the industry is going.”</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/decentralization-ai-and-gene-editing-are-opportunities-for-cgt-contractors/">Decentralization, AI, and Gene Editing Are Opportunities for CGT Contractors</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Crossing the Digital Validation Chasm</title>
<link>https://edusehat.com/en/crossing-the-digital-validation-chasm</link>
<guid>https://edusehat.com/en/crossing-the-digital-validation-chasm</guid>
<description><![CDATA[ An iterative, risk-based, model-driven digital validation strategy enables rapid responses to process changes and innovative technological implementations that would be slow to validate using traditional processes.
The post Crossing the Digital Validation Chasm appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/06/GettyImages-1357100011-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 01:55:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Crossing, the, Digital, Validation, Chasm</media:keywords>
<content:encoded><![CDATA[<p>A digital validation chasm exists between good manufacturing practices and the adoption of advanced control strategies, according to researchers at the Pharmaceutical Manufacturing Technology Center, University of Limerick. They <a href="https://link.springer.com/article/10.1007/s12247-026-11080-1" target="_blank" rel="noopener">propose</a> bridging that gap with a unified, risk-based digital validation workflow that combines process understanding and model-based design with accepted quality risk management and lifecycle-oriented validation principles.</p>
<p>The chasm between traditional validation processes and digital technologies isn’t a regulatory issue, one of the researchers, Dermot McMorrow, PDEng, assistant professor, digital manufacturing, tells <em>GEN</em>. “Increasingly…it’s more about translating risk-based, lifecycle validation principles into day-to-day engineering practice,” he adds.</p>
<p>“Guidance supports the use of automation, iterative development, digital tools, and critical thinking…but validation is still often implemented through sequential, document-centric qualification activities that are fragmented from engineering development,” McMorrow elaborates. “The challenge, therefore, is organizational and methodological—how to integrate process understanding, risk assessment, engineering development, verification, and evidence generation into a coherent lifecycle.”</p>
<p>The model predictive controller the team developed for pH regulation used a data-driven Hammerstein-Wiener model to help tune the controller and “a process and control focused analysis…to identify and prioritize relevant failure modes and to inform requirements and verification scope,” according to the researchers, who were led by Damian McCarthy, PhD, staff robotics test engineer, and senior author Eoin Hinchy, PhD, associate professor, automated manufacturing.</p>
<p>“The main benefit,” McMorrow says, “is that the workflow connects process understanding, quality risk management, controller development, requirements, verification, and deployment within the same engineering lifecycle. Rather than treating validation-related verification as something performed after engineering is complete, evidence can be generated as the system is developed.</p>
<p>“The approach also creates explicit traceability from identified risks through functional requirements and acceptance criteria to verification activities and resulting evidence,” he adds.</p>
<p>Consequently, verification efforts can focus on the most relevant risks, thus supporting both automated repeatable testing and physical challenge testing. Because process changes can be validated relatively easily, one practical barrier to continuous system enhancements may be overcome.</p>
<p>The team also demonstrated in a real-world setting “that the controller developed and verified within the model-based environment can be deployed within an industry programmable logic controller environment,” McMorrow says. “Using the standard IEC 61131-3 structured text format also provides an industrially recognized representation of the controller implementation and supports traceability within the wider model-based workflow.”</p>
<h4><strong>Iterative imperative</strong></h4>
<p>Implementing such a workflow change, particularly in a highly regulated environment, should be done iteratively, with ample testing and user feedback.</p>
<p>Key implementation points, the researchers note, include assessing the maturity of the innovation to be implemented and the organization’s level of readiness for that advancement. The team’s prior work provides structured tools, such as an innovation maturity rubric, to guide those assessments.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>They found that model-based design-driven digital validation processes mitigated digital validation challenges. Specifically, they “streamlined compliance tasks, reduced resource burdens, and enhanced traceability, demonstrating the framework’s practicality in real-world settings,” according to McMorrow, in his earlier doctoral <a href="https://researchrepository.ul.ie/entities/publication/15208a65-ee25-4c78-8e73-dd34a5dacd7d" target="_blank" rel="noopener">research</a>.</p>
<p>The team’s proposed workflow “has the potential to reduce reliance on repeated manual testing and documentation,” McMorrow says, and thus support the real-time reconfigurations needed in modern production environments.</p>
<p>But, McMorrow cautions, “Any industrial implementation would still need to be incorporated into the organization’s own quality system, validation strategy, and regulatory context. The study…is a practical proof-of-concept…rather than a pre-validation solution ready for direct deployment.” Related work by this team has also applied model-based validation approaches to new and existing equipment, including legacy programmable logic controller systems.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/crossing-the-digital-validation-chasm/">Crossing the Digital Validation Chasm</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Human Dengue Study Reveals How Preexisting Immunity Shapes Secondary Infections</title>
<link>https://edusehat.com/en/human-dengue-study-reveals-how-preexisting-immunity-shapes-secondary-infections</link>
<guid>https://edusehat.com/en/human-dengue-study-reveals-how-preexisting-immunity-shapes-secondary-infections</guid>
<description><![CDATA[ A controlled human trial reveals how preexisting antibodies influence dengue virus replication and immune responses, offering insights to develop safer, more broadly protective vaccines against all four dengue strains.
The post Human Dengue Study Reveals How Preexisting Immunity Shapes Secondary Infections appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/07/GettyImages-1572391417-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 01:55:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Human, Dengue, Study, Reveals, How, Preexisting, Immunity, Shapes, Secondary, Infections</media:keywords>
<content:encoded><![CDATA[<p>Roughly half of the world’s population is now at risk of dengue, with an estimated 100–400 million infections occurring each year. The viral infection (also known as break-bone fever) is more common in tropical and subtropical areas of the world. Currently, prevention relies on control of the mosquito vector that transmits the virus.</p>
<p>Dengue virus has a particularly unique challenges, and is especially pernicious compared with many other viruses, as secondary infections can be worse than the first. Now, a new Phase I trial involving controlled infections in human volunteers provides new details about how preexisting immunity and anti-dengue antibodies affect the nature of secondary infections with dengue.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>The work is published in <em>Science Translational Medicine</em> in the paper, “Dengue virus controlled human challenge reveals that preexisting immunity shapes viral replication and broadly protective responses.”</p>
<p>The findings are among the first to glean insights using a large controlled human challenge, and could inform future therapeutics and the design of more broadly protective vaccines.</p>
<p>Secondary infections with dengue are often the most severe ones because preexisting antibodies can boost viral counts and raise the risk of severe symptoms. This has frustrated the development of badly needed vaccines for dengue. Furthermore, it’s been challenging to understand how pre-infection affects dengue outcomes, as animal models have many limitations and patients usually don’t present until after viral counts have peaked.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>In this study, researchers recruited 45 healthy adults who had either zero, one, or more than one prior infection with any of the four strains of dengue virus (DENV1-DENV4). The volunteers received injections of a live, weakened strain of DENV3 in a challenge study, allowing the researchers to fully interrogate dengue immunity dynamics in humans in a safe and controlled setting.</p>
<p>The findings led to various conclusions: for example, people whose antibodies boosted the replication of the virus had the highest viral counts and waning of CD8-bearing T cells and antibodies. Additionally, people who had higher amounts of antibodies against the viral nonstructural protein 1 displayed more balanced immune responses and lower viral counts.</p>
<p>More specifically, the authors write, “Viremia was associated with more, but still mild, clinical signs and symptoms, and secondary infection resulted in greater viremia, neutralizing antibodies, and protective T cell responses. However, those whose baseline antibodies most efficiently increased dengue virus replication in an <em>in vitro</em> assay experienced delayed inflammatory and adaptive immune activation, the highest viremia, strong acute immune responses, and waning of potent CD8+ T cells and antibodies. In contrast, higher baseline antibodies against the nonstructural protein 1 of multiple serotypes predicted early interferon and balanced immune activation, viremia control, and development of enduring, potent B and T cells, revealing how vaccines can induce broad, long-­lasting protection.”</p>
<p>“Collectively, this work confirms multiple hypotheses generated by natural history studies and reveals the optimal conditions for inducing potent and persistent immunity against DENV1 to DENV4,” they note.</p>
<p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/human-dengue-study-reveals-how-preexisting-immunity-shapes-secondary-infections/">Human Dengue Study Reveals How Preexisting Immunity Shapes Secondary Infections</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>How to Keep the Skin Looking Young: Anti&#45;Aging From the Inside Out </title>
<link>https://edusehat.com/en/how-to-keep-the-skin-looking-young-anti-aging-from-the-inside-out</link>
<guid>https://edusehat.com/en/how-to-keep-the-skin-looking-young-anti-aging-from-the-inside-out</guid>
<description><![CDATA[ Exploring What “Younger-Looking Skin” Means Today, and How to Separate Trend From Truth  To understand how to keep the skin…
The post How to Keep the Skin Looking Young: Anti-Aging From the Inside Out  appeared first on Optima Dermatology. ]]></description>
<enclosure url="https://optimadermatology.com/wp-content/uploads/2026/10/Blog_Oct_Anti-aging_Banner.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 28 Oct 2026 22:15:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>How, Keep, the, Skin, Looking, Young:, Anti-Aging, From, the, Inside, Out </media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"><img fetchpriority="high" decoding="async" width="1024" height="341" src="https://optimadermatology.com/wp-content/uploads/2026/10/Blog_Oct_Anti-aging_Banner-1024x341.jpg" alt='"Anti-aging from the Inside Out" blog with a woman holding a serum. ' class="wp-image-205878" srcset="https://optimadermatology.com/wp-content/uploads/2026/10/Blog_Oct_Anti-aging_Banner-1024x341.jpg 1024w, https://optimadermatology.com/wp-content/uploads/2026/10/Blog_Oct_Anti-aging_Banner-300x100.jpg 300w, https://optimadermatology.com/wp-content/uploads/2026/10/Blog_Oct_Anti-aging_Banner-768x256.jpg 768w, https://optimadermatology.com/wp-content/uploads/2026/10/Blog_Oct_Anti-aging_Banner.jpg 1200w" sizes="(max-width: 1024px) 100vw, 1024px"></figure>



<h2 class="wp-block-heading"><strong>Exploring What “Younger-Looking Skin” Means Today, and How to Separate Trend From Truth</strong> </h2>



<p class="wp-block-paragraph">To understand how to keep the skin looking young, you have to go beyond marketing claims and social media influencers to evaluate the efficacy of specific products, treatments, procedures, and skin care regimens, and what will work best for your unique skin type. When it comes to anti-aging skin care, the science and evidence behind a certain approach often carries more weight than a trend.  </p>



<h2 class="wp-block-heading"><strong>Anti-Aging Has Long Influenced the Skin Care Industry</strong> </h2>



<p class="wp-block-paragraph">The long-sought “secret” for how to keep the skin looking young has fueled product marketing campaigns since the earliest days of advertising, where cosmetic brands took out full-page spreads in magazines like Harper’s Bazaar and Vogue to tout the ability for their products to achieve youthful beauty. In one ad (shown below), Dorothy Gray Salon went so far as to say their collagen cream could “help you side-step the tragedy of the middle years.” </p>



<figure class="wp-block-image size-full is-resized"><img decoding="async" width="165" height="239" src="https://optimadermatology.com/wp-content/uploads/2026/10/image.png" alt='"Who wants to look young" newspaper article.' class="wp-image-205879"></figure>



<p class="wp-block-paragraph"><em>Tokalon Biocel Skinfood, 1939.</em> <a href="https://www.whitfords.co.uk/surface-tensions-the-underlying-truths-of-skincare-advertising/" target="_blank" rel="noopener"><em>Whitfords.co.uk</em></a><em></em> </p>



<figure class="wp-block-image size-full is-resized"><img decoding="async" width="154" height="234" src="https://optimadermatology.com/wp-content/uploads/2026/10/image-1.png" alt='"Does Your Husband Look Younger than You do?" news article. ' class="wp-image-205880"></figure>



<p class="wp-block-paragraph"><em>Dorothy Gray Salon, 1951.</em> <a href="https://repository.duke.edu/dc/adaccess/BH1920" target="_blank" rel="noopener"><em>Duke University Libraries Repository</em></a> </p>



<p class="wp-block-paragraph">Today, the anti-aging narrative has morphed into a massive social media influencer culture of creams, procedures, peptides, personalized routines, tips, trends, and before-and-after glow-up videos complete with the amped-up background music that can instill confidence in even the most critical of consumers. </p>



<p class="wp-block-paragraph">While we know advertising younger skin is nothing new, today’s greater access to information and advice can quickly muddy the waters, leading to confusion and, in some cases, the use of incorrect or untested products that carry risks.  </p>



<p class="wp-block-paragraph">To sort the trends from the truth, this article examines science-backed anti-aging methods shown to promote younger-looking skin, and other approaches that stand out in the crowded influencer landscape. </p>



<h2 class="wp-block-heading"><strong>Copper Peptides Offer Antioxidants, Tissue Rebuilding, and Anti-Inflammatory Properties</strong> </h2>



<p class="wp-block-paragraph">Peptides are short chains of amino acids that signal different processes throughout the body. Their potential to support the skin’s natural repair and renewal processes has elevated peptides as a key ingredient across skin care product lines.  </p>



<p class="wp-block-paragraph">Copper peptide GHK-Cu is a naturally occurring compound made up of exactly what you would expect by the name: the peptide GHK bound to copper. Early clinical research <a href="https://pubmed.ncbi.nlm.nih.gov/35083444/" target="_blank" rel="noopener">found that</a> GHK-Cu “has been shown to promote skin remodeling, wound healing and regeneration, and has prominent antioxidant and anti-inflammatory effects.” </p>



<p class="wp-block-paragraph">Ever the voice for top beauty trends, Vogue <a href="https://www.vogue.com/article/copper-peptides" target="_blank" rel="noopener">published</a> a lengthy article in late 2025 about the anti-aging benefits of copper peptides when applied topically, particularly for stimulating “collagen synthesis, and helping maintain the skin’s firmness and resilience while slowing visible aging.” </p>



<p class="wp-block-paragraph">Copper peptides were discovered in 1973, but they continue to be studied as clinical evidence for their anti-aging properties is limited compared with other, more well-established treatments. </p>



<p class="wp-block-paragraph"><strong>Should you use copper peptides?</strong> Copper peptides are a reasonable anti-aging skin care treatment, but shouldn’t replace proven strategies like sun protection, topical retinoids, or dermatologist-directed treatments. </p>



<p class="wp-block-paragraph"><strong>The Controversial Use of Tanning Peptides for Anti-Aging</strong> </p>



<p class="wp-block-paragraph">“Tanning peptides” – Melanotan II, is a synthetic, injectable peptide that stimulates melanin, the natural pigment the skin produces to protect cellular DNA from sun damage. </p>



<p class="wp-block-paragraph">The anti-aging argument for using Melanotan II requires a bit of circuitous logic: creating a tan with an injectable peptide removes the need to tan under the sun, therefore avoiding one of the biggest contributors to premature skin aging (UV rays).  </p>



<p class="wp-block-paragraph">However, this rather simplistic justification fails to consider the risks of treating any product as a safe substitute for proven sun protection. The FDA has not approved Melanotan II and warns about the marketing and distribution of unapproved injectable tanning treatments. Further, the Skin Cancer Foundation has sounded alarm bells about numerous health concerns associated with Melanotan II use: </p>



<ul class="wp-block-list">
<li>Development of melanoma </li>
</ul>



<ul class="wp-block-list">
<li>Changes in moles and pigmented lesions that can make skin cancer harder to detect </li>
</ul>



<ul class="wp-block-list">
<li>Serious health effects, including systemic toxicity and muscle damage </li>
</ul>



<p class="wp-block-paragraph">Plus, the origin, purity, contents, and dosage are unknown, as patients typically acquire Melanotan II through unregulated online sources. </p>



<p class="wp-block-paragraph"><strong>Should you use tanning peptides?</strong> No. Using a tanning peptide to look tan without UV exposure doesn’t mean you don’t need sun protection, and it doesn’t make a tanning peptide an anti-aging treatment. A tan is the skin’s response to UV radiation, and UV exposure contributes to premature skin aging, including wrinkles, loss of elasticity, uneven pigmentation, and leathery skin. It also increases the risk of skin cancer. Coupled with the other suspected health risks, it’s best to avoid tanning peptides. If you are seeking a bronzed appearance, use a topical sunless tanning product instead. But remember, a self-tanner should never be considered a substitute for sun protection. </p>



<h2 class="wp-block-heading"><strong>Achieving Younger-Looking Skin Using the Bryan Johnson Blueprint</strong> </h2>



<p class="wp-block-paragraph">Bryan Johnson is a tech entrepreneur who, while known for making millions selling Venmo to PayPal in 2013, has more recently caught the public eye for a very different reason. Johnson is dedicated to an extreme anti-aging and longevity regimen called “Project Blueprint”. Johnson’s “don’t die” philosophy involves essentially fighting death and aging by scientifically reversing his biological age – including the aging of his skin.  </p>



<p class="wp-block-paragraph">His approaches to youthful skin include a variety of dermatological treatments to improve skin quality. He has spoken publicly about using treatments like: </p>



<ul class="wp-block-list">
<li>Microneedling </li>
</ul>



<ul class="wp-block-list">
<li>Platelet-rich fibrin and platelet-rich plasma (PRP), in which the patient’s own blood is treated and injected into the skin to release growth factors and rejuvenate the skin </li>
</ul>



<ul class="wp-block-list">
<li>Sofwave, a non-invasive ultrasound device, and Tixel, a fractional skin rejuvenation system, to support collagen and elastin </li>
</ul>



<p class="wp-block-paragraph">On his website, he <a href="https://www.bryanjohnson.com/" target="_blank" rel="noopener">claims</a>: “When I started Blueprint, my skin was in the 98th percentile for damage, with a skin age of 64. Now, my skin age has improved to age 36.” </p>



<p class="wp-block-paragraph">Any dermatologist will caution against taking these claims at face value. Everyone’s skin is different, and one individual’s customized longevity protocol likely isn’t a blueprint for everyone else.  </p>



<p class="wp-block-paragraph">That being said, let’s explore two of Bryan Johnson’s protocols for achieving younger-looking skin; microneedling and PRP.  </p>



<h2 class="wp-block-heading"><strong>Can Microneedling Make My Skin Look Younger?</strong> </h2>



<p class="wp-block-paragraph">Microneedling is a minimally invasive dermatologic procedure that uses ultra-fine needles to make microscopic holes in the top layer of the skin. Doing so stimulates a healing response in the skin, encouraging the production of collagen and elastin, which help keep your skin firm and smooth. </p>



<p class="wp-block-paragraph"><strong>Dive Deeper:</strong> <a href="https://optimadermatology.com/2023/09/05/what-is-microneedling" target="_blank" rel="noopener">What is Microneedling? FAQs About the Different Types of Treatment Options</a> </p>



<p class="wp-block-paragraph">When you see a credentialed aesthetic professional (rather than use an at-home microneedling kit, which can carry significant risks), microneedling can help diminish: </p>



<ul class="wp-block-list">
<li>Acne scars </li>
</ul>



<ul class="wp-block-list">
<li>Dark spots </li>
</ul>



<ul class="wp-block-list">
<li>Large pores </li>
</ul>



<ul class="wp-block-list">
<li>Melasma </li>
</ul>



<ul class="wp-block-list">
<li>Skin Laxity  </li>
</ul>



<ul class="wp-block-list">
<li>Scars due to surgery or an injury </li>
</ul>



<ul class="wp-block-list">
<li>Uneven skin texture and tone </li>
</ul>



<ul class="wp-block-list">
<li>Wrinkles and fine lines </li>
</ul>



<h2 class="wp-block-heading"><strong>Microneedling with Platelet-Rich Plasma</strong> </h2>



<p class="wp-block-paragraph">Microneedling can also be combined with PRP. Microneedling creates controlled openings in the skin while PRP is applied to the treated area. This combination has been used primarily for minimizing acne scars and skin rejuvenation.  </p>



<p class="wp-block-paragraph">While these treatments have generated favorable results, the right treatment depends on your unique skin type and situation. Your provider will help set realistic expectations for what the procedure can accomplish and what results to expect.  </p>



<h2 class="wp-block-heading"><strong>Best-Practice Skin Care Techniques to Reduce the Signs of Aging</strong> </h2>



<p class="wp-block-paragraph">Keeping the skin looking youthful can be simpler than product marketers and social media influencers may lead us to believe.  </p>



<ul class="wp-block-list">
<li><strong>Protect your skin from the sun.</strong> UV radiation damages collagen and elastin, and can cause wrinkles and changes in pigmentation and skin texture. Apply a daily sunscreen with an SPF of 30 or higher, and practice consistent sun protection during any exposure. </li>
</ul>



<ul class="wp-block-list">
<li><strong>Use proven topical ingredients.</strong> Speak to your provider about the best topical ingredients for your skin type and specific concerns. Products containing retinoids, vitamin C, niacinamide, or tretinoin, among others, have evidence supporting their ability to reduce signs of aging.  </li>
</ul>



<ul class="wp-block-list">
<li><strong>Consider cosmetic treatments.</strong> For more significant improvements with faster results, a credential aesthetic professional may recommend in-office procedures like microneedling, laser treatments, chemical peels, injectables, and other collagen-stimulating or skin-resurfacing treatments.  </li>
</ul>



<p class="wp-block-paragraph"><strong>Dive Deeper:</strong> <a href="https://optimadermatology.com/2022/11/30/laser-and-light-treatments-for-skin-rejuvenation" target="_blank" rel="noopener">Laser and Light Treatments for Skin Rejuvenation</a> </p>



<p class="wp-block-paragraph">The reality is that we cannot stop the aging process, but the goal should be to help your skin age in a healthy way while addressing the issues that matter most to you.  </p>



<p class="wp-block-paragraph">This prevailing skin care movement focused on anti-aging from the inside out reflects a shift in how people think about their skin. Rather than simply trying to cover up wrinkles, people are considering their skin’s overall health, structure, and function; this approach can be a positive, as long as evidence-based dermatology is considered above marketing or influencer hype. </p>



<p class="wp-block-paragraph">If you have concerns about minimizing the signs of aging, or want to learn more about how to keep your skin healthy as you age, <a href="https://optimadermatology.com/request-appointment" target="_blank" rel="noopener">schedule an appointment</a> with our team. </p>



<hr class="wp-block-separator has-alpha-channel-opacity">



<h2 class="wp-block-heading"><strong>Frequently Asked Questions About Anti-Aging Skin Care</strong> </h2>



<h3 class="wp-block-heading"><strong>Do copper peptides really help reduce wrinkles?</strong> </h3>



<p class="wp-block-paragraph">Copper peptides such as GHK-Cu have properties that may support collagen production, tissue remodeling, and skin repair. However, clinical evidence for their ability to significantly reduce wrinkles is still limited compared with established anti-aging treatments such as topical retinoids. A dermatologist can help determine whether a copper peptide product is appropriate for your skincare routine. </p>



<h3 class="wp-block-heading"><strong>Are tanning peptides like Melanotan II safe?</strong> </h3>



<p class="wp-block-paragraph">Melanotan II is not FDA-approved as a tanning treatment, and the FDA has identified safety concerns associated with products containing the peptide. Tanning peptides should not be considered a safe alternative to sunscreen or a proven anti-aging treatment. </p>



<h3 class="wp-block-heading"><strong>Does microneedling make your skin look younger?</strong> </h3>



<p class="wp-block-paragraph">Microneedling can improve the appearance of fine lines, wrinkles, uneven texture, acne scars, and skin laxity by stimulating the body’s collagen-production process. Results develop gradually and may require multiple treatments depending on the individual’s skin concerns. </p>



<h3 class="wp-block-heading"><strong>Does PRP work for facial rejuvenation?</strong> </h3>



<p class="wp-block-paragraph">PRP may help improve certain signs of skin aging and can be used with procedures such as microneedling. However, research on PRP for facial rejuvenation is still developing, and results can vary between patients. A dermatologist can help determine whether PRP is an appropriate option based on your goals and medical history. </p>



<h3 class="wp-block-heading"><strong>What is the best dermatologist-recommended anti-aging treatment for skin?</strong> </h3>



<p class="wp-block-paragraph">There is no single best anti-aging treatment for everyone. Effective skin-aging strategies typically include daily sun protection, an appropriate skincare routine, and dermatologist-recommended treatments based on individual concerns such as wrinkles, pigmentation, loss of firmness, or uneven texture. A credentialed aesthetic professional can create a personalized plan that may include topical medications, microneedling, laser treatments, or other procedures. </p>
<p>The post <a href="https://optimadermatology.com/2026/10/28/how-to-keep-the-skin-looking-young-anti-aging-from-the-inside-out">How to Keep the Skin Looking Young: Anti-Aging From the Inside Out </a> appeared first on <a href="https://optimadermatology.com/">Optima Dermatology</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Nova Scotia prepares for provincewide expansion of electronic patient records</title>
<link>https://edusehat.com/en/nova-scotia-prepares-for-provincewide-expansion-of-electronic-patient-records</link>
<guid>https://edusehat.com/en/nova-scotia-prepares-for-provincewide-expansion-of-electronic-patient-records</guid>
<description><![CDATA[ Nova Scotia is preparing for a significant expansion of its electronic patient-record system, with hospitals and healthcare facilities across three additional health zones scheduled to begin using the technology on November 14. The One Person One Record (OPOR) initiative is designed to bring patient information together in a shared clinical system, allowing authorized healthcare professionals […]
The post Nova Scotia prepares for provincewide expansion of electronic patient records appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/Nurses-Reviewing-Patient-Records-Together.png" length="49398" type="image/jpeg"/>
<pubDate>Wed, 28 Oct 2026 22:10:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Nova, Scotia, prepares, for, provincewide, expansion, electronic, patient, records</media:keywords>
<content:encoded><![CDATA[<p>Nova Scotia is preparing for a significant expansion of its electronic patient-record system, with hospitals and healthcare facilities across three additional health zones scheduled to begin using the technology on November 14.</p>
<p>The One Person One Record (OPOR) initiative is designed to bring patient information together in a shared clinical system, allowing authorized healthcare professionals to access medical records, test results, medications and treatment information more efficiently.</p>
<p>The upcoming implementation will extend the system to Nova Scotia Health’s Northern, Eastern and Western zones, completing a major stage of the province’s digital healthcare transformation.</p>
<h3>Connecting healthcare across the province</h3>
<p>The system was introduced at IWK Health in December 2025 and expanded to Nova Scotia Health’s Central Zone in May 2026.</p>
<p>Once fully implemented, One Person One Record is expected to replace or integrate more than 50 existing systems used by healthcare professionals to document and access patient information.</p>
<p>The province estimates that more than 26,000 healthcare professionals will eventually have access to real-time patient information, according to their roles and responsibilities.</p>
<p>For patients, the system is intended to reduce the need to repeatedly provide medical histories when receiving care at different facilities. It is also expected to improve communication among healthcare teams and reduce unnecessary duplication of diagnostic testing.</p>
<h3>Improving medication and patient safety</h3>
<p>A central component of the initiative is Computerized Provider Order Entry (CPOE), which allows physicians and other authorized healthcare professionals to enter and manage clinical orders electronically.</p>
<p>The technology is designed to provide immediate visibility into medication orders, laboratory requests and other clinical instructions.</p>
<p>Built-in clinical decision support can also alert healthcare professionals to potential medication allergies, dosing concerns and other safety issues before treatment is administered.</p>
<p>The system supports electronic medication verification, including barcode scanning to help confirm that patients receive the correct medications and doses.</p>
<p>Nova Scotia Health says these features are intended to strengthen patient safety while improving coordination between healthcare professionals.</p>
<h3>Preparing healthcare teams for implementation</h3>
<p>The November expansion represents a substantial operational change for hospitals and healthcare workers.</p>
<p>Training and practice sessions have been organized to help physicians, nurses and other clinical staff become familiar with the system and its workflows.</p>
<p>During previous implementation stages, Nova Scotia Health advised patients that some appointments and administrative processes could take longer while healthcare teams adjusted to the technology.</p>
<p>The province’s broader initiative is supported by a 10-year, $365-million agreement signed in 2023 to develop, implement and maintain the clinical information system.</p>
<p>The upcoming expansion represents another step toward a more connected healthcare system, with the potential to improve continuity of care as patients move between hospitals, specialists and other healthcare services.</p>
<p>The full impact on patient outcomes, workflow efficiency and healthcare costs will depend on successful implementation and ongoing evaluation.</p>
<p><strong>Sources:</strong> <a href="https://news.novascotia.ca/en/2026/05/07/one-person-one-record-launch-across-central-health-zone?utm_source=chatgpt.com">Nova Scotia Health and Government of Nova Scotia</a>.</p>
<p>The post <a href="https://www.hospitalnews.com/nova-scotia-prepares-for-provincewide-expansion-of-electronic-patient-records/">Nova Scotia prepares for provincewide expansion of electronic patient records</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>PACE panels tackle challenges to access and barriers to coverage</title>
<link>https://edusehat.com/en/pace-panels-tackle-challenges-to-access-and-barriers-to-coverage</link>
<guid>https://edusehat.com/en/pace-panels-tackle-challenges-to-access-and-barriers-to-coverage</guid>
<description><![CDATA[ Breakthrough therapies can change the lives of patients who previously had few or no treatments for their conditions, but only if the patients can […]
The post PACE panels tackle challenges to access and barriers to coverage appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/10/Death-by-1000-cuts.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 28 Oct 2026 18:45:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>PACE, panels, tackle, challenges, access, and, barriers, coverage</media:keywords>
<content:encoded><![CDATA[<p><span>Breakthrough therapies can change the lives of patients who previously had few or no treatments for their conditions, but only if the patients can break through the barriers to accessing those drugs.</span></p>
<p><span>Challenges to access were a primary focus of BIO’s 15</span><span>th</span><span> annual Patient Advocacy Changemakers Event, the premier gathering of patients, advocates, drugmakers, and policymakers, held Oct. 22-23 in Washington, DC. There were several expert panels specifically exploring the challenges of overcoming barriers to coverage for drugs patients need.</span></p>
<p><span>Below are some of the lessons offered.</span></p>
<h2>Death by a thousand cuts: Utilization management</h2>
<p><span>During </span><a href="https://pace.bio.org/2026-program/death-thousand-cuts-1"><span>a session on interconnected challenges </span></a><span>restricting patient access, one utilization management approach panelists discussed was step therapy, which asks patients to fail first on a cheaper drug before getting the drug their doctor prescribed. Panelists said patients feel trapped and frightened when told they can’t get the medicine their doctor recommends.</span></p>
<p><span>The social workers at CancerCare can receive a thousand calls a week from such patients, said Kim Czubaruk, VP of Policy at CancerCare.</span></p>
<p><span>“But behind each call is a patient or a caregiver that really is probably in the toughest moment of their life,” she added.</span></p>
<p><span>The number of people who need help is more than any patient group can handle, said panelist Brian Connell, VP of Federal Affairs at Blood Cancer United. “There are folks who fall through the cracks and don’t get the right treatment. I think that points to the need for broader systemic reform.”</span></p>
<h2>Enabling coverage of new drugs</h2>
<p><a href="https://pace.bio.org/2026-program/getting-runaround-games-payers-play--1"><span>Another session </span></a><span>explored best practices for patient groups seeking to engage payers to ensure coverage for new breakthrough therapies.</span></p>
<p><span>Mike Graglia, CEO of Cure SYNGAP1, said the rare neurodevelopmental disease SYNGAP1 has many symptoms—like seizures and disturbed sleep—that can be treated with other drugs, and other symptoms unaddressed by existing treatments—including a tendency to violence. There are genetic treatments for SYNGAP1 in the pipeline, and Graglia’s group wants to make sure they will be covered by insurance.</span></p>
<p><span>“We’re going to survey our own community and try to measure the impact—the lost earnings, the divorces, the mental health burden, the burden on siblings, all the things that are really easy to talk about, but really actually hard to measure,” he explained.</span></p>
<p><span>When an insurer does not agree to put a new drug in its formulary, patients and their advocates can appeal the decision, sometimes with good effect, panelists said.</span></p>
<p><span>“My message for everyone here is, number one: Always appeal, and tell your whole community, always appeal, especially in the age of AI, where we know 80% of these denials are overturned on appeal,” said Melanie Lendnal, SVP of Policy & Advocacy at ALS Association.</span></p>
<p><span>“In urgent situations, you can ask for an expedited appeal, and get an answer within 72 hours,” added Monica Bryant, Co-Founder of Triage Cancer. She said few in the patient community are aware of this possibility, and even healthcare professionals are surprised to hear it.</span></p>
<h2>From clinical guidelines to access in the clinic</h2>
<p><span>One tool patients and health care professionals can use as evidence in promoting coverage for a new drug is </span><a href="https://pace.bio.org/2026-program/clinical-guidelines-access"><span>through clinical guidelines, according to a session</span></a><span> moderated by Lenja Wiehe, Director, Global Patient Advocacy Lead at Alexion.</span></p>
<p><span>“We all share a responsibility to make sure that scientific progress translates into better care for patients,” Wiehe said. “And clinical guidelines can help us to get there. They turn evolving evidence into recommendations for care; they support patient-clinician conversations; and they provide an important reference point for decisions about care.”</span></p>
<p><span>Unfortunately, many rare disease drugs lack clinical guidelines, which generally need to be developed by government agencies and expert panels, said Jamie Sullivan, SVP of Policy and Advocacy at RARE Foundation.</span></p>
<p><span>According to one study, “Over 60% of the orphan drugs lacked a clinical guideline to begin with,” Sullivan said. “And so it’s just a lack of another input that payers can use” to improve coverage. </span></p>
<h2>By the numbers</h2>
<p><span>Meaningful data can be used to reduce barriers and advance policy that increases access, according to a session on </span><a href="https://pace.bio.org/2026-program/-stories-statistics-shape-smart-policy"><span>telling stories with statistics</span></a><span>.</span></p>
<p><span>Patient surveys can provide the data that helps make meaningful arguments, said Lynn Albizo, Chief Public Policy Officer of the Immune Deficiency Foundation.</span></p>
<p><span>“We use those surveys to get our statistics, particularly for our rare disease community. We can get down to specifically how many people with primary immunodeficiency on IG therapy are on Medicare,” she said. “I have tables of those statistics that I use to be able to share data with legislators.”</span></p>
<p><span>A compendium of annually updated data from peer-reviewed literature can make a high-impact handout said Robert Egge, Chief Public Policy Officer of the Alzheimer’s Association.</span></p>
<p><span>But there are times when numbers can work against you, warned Jennifer Dexter, SVP of Policy and External Affairs at the National Health Council. For example, when seeking Medicare Part D coverage for a rare disease drug, her group sometimes hears that only a small group of people will be served.</span></p>
<p><span>“We have to be there saying ‘It’s our people, it’s the people we’re representing who make up that small number.’ And we really have to put a face to it to overcome the small numbers,” she said.</span></p>
<p>The post <a href="https://bio.news/federal-policy/pace-panels-tackle-challenges-to-access-and-barriers-to-coverage/">PACE panels tackle challenges to access and barriers to coverage</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Compensation for medical residents: How much do trainees earn?</title>
<link>https://edusehat.com/en/compensation-for-medical-residents-how-much-do-trainees-earn</link>
<guid>https://edusehat.com/en/compensation-for-medical-residents-how-much-do-trainees-earn</guid>
<description><![CDATA[ What kind of compensation do the medical residents working in your hospital earn? According to survey data from Medscape, average pay for first- and second-year medical residents comes to $74,000 in 2026. That number is up from $65,000 in 2024—a 6.5% increase—and up from $68,000 in 2025. Here’s a look at compensation for medical residents, […]
The post Compensation for medical residents: How much do trainees earn? appeared first on Today&#039;s Hospitalist. ]]></description>
<enclosure url="https://todayshospitalist.com/wp-content/uploads/2026/10/resident-comp-shutterstock_2841055595-10-28-26.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 28 Oct 2026 18:30:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Compensation, for, medical, residents:, How, much, trainees, earn</media:keywords>
<content:encoded><![CDATA[<p>What kind of compensation do the medical residents working in your hospital earn?</p>
<p><a href="https://www.medscape.com/p11/medscape-resident-salary-debt-report-2026-does-pay-match-2026a10011lh">According to survey data from Medscape,</a>  average pay for first- and second-year medical residents comes to $74,000 in 2026. That number is up from $65,000 in 2024—a 6.5% increase—and up from $68,000 in 2025.</p>
<p>Here’s a look at compensation for medical residents, including data on housing costs, benefits and residents’ attitudes toward pay.</p>
<h4><strong>Geography and resident pay</strong></h4>
<p>Medscape’s survey found that resident compensation can differ by up to $15,000 between parts of the Northeast and the South. That mirrors the trend in which physician pay is typically lower in the Northeast, in part because of the desirability of cities like Boston and New York, and higher in parts of the South.</p>
<p>That trend is significant because housing costs are high in those areas, with the Medscape survey finding that rent eats up more than 30% of resident pay. That’s why 57% of residents said their pay doesn’t cover their basic living expenses. (Twelve percent of residents said they received a housing allowance.)</p>
<h4><strong>Resident compensation by specialty</strong></h4>
<p>While there are huge differences in physician pay based on specialty, those gaps aren’t apparent during training. Hospitals, which Medscape’s survey said was the site of residency training for 65% of physicians, tend to pay all residents the same regardless of their specialty plans.</p>
<p><a href="https://www.ama-assn.org/medical-residents/residency-life/resident-physician-pay-still-rising-growth-trails-inflation">AMA data released earlier in 2026</a>  show that nearly all hospitals pay their residents the same amount regardless of specialty plans. Those data also said that 71% of training programs pay chief residents about $5,000 more a year.</p>
<h4><strong>Benefits during residency training</strong></h4>
<p>Medscape’s survey found that medical residents often get benefits offered to other employees.</p>
<p>Health insurance, for example, is offered to 92% of residents. Dental insurance is offered to 82%, and vision benefits are offered to 73%.</p>
<p>Here’s a full list of benefits offered to residents from the Medscape survey:</p>
<p><strong>What benefits do residents get?</strong></p>
<p>Health insurance: 92%.</p>
<p>Paid time off: 90%.</p>
<p>Dental (paid in part or in full): 82%.</p>
<p>Vision (paid in part or in full): 73%.</p>
<p>Retirement: 72%.</p>
<p>Meal allowance: 66%.</p>
<p>Travel allowance: 65%.</p>
<p>Liability coverage: 57%.</p>
<p>Exam/licensing fees: 47%.</p>
<p>Book allowance: 45%.</p>
<p>Life insurance: 43%.</p>
<p>Commuter assistance (parking, public transit): 27%.</p>
<p>Housing allowance: 12%.</p>
<p>Childcare: 5%.</p>
<h4><strong>What do residents think about their compensation?</strong></h4>
<p>When asked if they feel their pay is fair in the Medscape survey, 63% of residents answered “no.” The top reasons given for that dissatisfaction, however, focused more on residents’ not feeling valued than on their financial situation.</p>
<p>Medscape’s analysis noted that the number of residents who feel unfairly paid has dropped over time, from 73% in 2025. When the survey asked what would make residents feel their pay was fair, a raise of at least 26% was identified by two-thirds of respondents.</p>
<p><strong>Why residents feel their pay is unfair</strong></p>
<p>Doesn’t reflect hours worked: 83%.</p>
<p>Doesn’t compare to other medical staff: 83%.</p>
<p>Doesn’t reflect required skills: 76%.</p>
<p>Doesn’t meet cost of living: 61%.</p>
<p>Inadequate benefits: 29%.</p>
<h4><strong>Medical school debt</strong></h4>
<p>One factor in the financial stress medical residents feel is medical school debt. In the Medscape survey, 54% of residents reported carrying loan debt exceeding $150,000, with 30% having loans of more than $250,000.</p>
<p>The post <a href="https://todayshospitalist.com/compensation-for-medical-residents-how-much-do-trainees-earn/">Compensation for medical residents: How much do trainees earn?</a> appeared first on <a href="https://todayshospitalist.com/">Today's Hospitalist</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Bonjour Genomics: A Video from ASHG</title>
<link>https://edusehat.com/en/bonjour-genomics-a-video-from-ashg</link>
<guid>https://edusehat.com/en/bonjour-genomics-a-video-from-ashg</guid>
<description><![CDATA[ GEN editors Uduak Thomas and Julianna LeMieux, PhD, recap ASHG, highlighting key sessions, Ultima Genomics’ user group meeting, Illumina news, and insights from PacBio’s new CEO Mark Van Oene.
The post Bonjour Genomics: A Video from ASHG appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GettyImages-1177333932.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 28 Oct 2026 04:20:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Bonjour, Genomics:, Video, from, ASHG</media:keywords>
<content:encoded><![CDATA[<p>Uduak Thomas, Senior Editor at <em>GEN</em>, took a minute away from the talks, posters, and expo hall to join Julianna LeMieux, PhD, <em>GEN’</em>s Deputy Editor in Chief, to talk about the meeting, the sessions they attended, and the trends that they are noticing.</p>
<p>Although they had only been at the meeting for a day, there was plenty to discuss: Ultima Genomics’ user group meeting, the opening Presidential address given by ASHG President Susan Slaugenhaupt, PhD, Illumina’s news, and an interview with PacBio’s new CEO Mark Van Oene. PhD.</p>
<p> </p>
<div>
<div><br>
</div>
</div>
<p>The post <a href="https://www.genengnews.com/topics/omics/bonjour-genomics-a-video-from-ashg/">Bonjour Genomics: A Video from ASHG</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Vitamin Derivative Pantethine Alleviates Psoriasis Symptoms in Small Human Trial</title>
<link>https://edusehat.com/en/vitamin-derivative-pantethine-alleviates-psoriasis-symptoms-in-small-human-trial</link>
<guid>https://edusehat.com/en/vitamin-derivative-pantethine-alleviates-psoriasis-symptoms-in-small-human-trial</guid>
<description><![CDATA[ Researchers found that the vitamin B5 derivative pantethine prevented the development of psoriasis in mice, and in a small-scale trial in human psoriasis patients administering pantethine in combination with topical calcipotriol/betamethasone dipropionate helped to alleviate symptoms. 
The post Vitamin Derivative Pantethine Alleviates Psoriasis Symptoms in Small Human Trial appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2021/11/Getty_872062320_Psoriasis.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 28 Oct 2026 04:20:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Vitamin, Derivative, Pantethine, Alleviates, Psoriasis, Symptoms, Small, Human, Trial</media:keywords>
<content:encoded><![CDATA[<p>Researchers headed by a team at State Key Laboratory of Biomedical Analysis (SKLBA) (formerly known as National Center of Biomedical Analysis) in Beijing have discovered that the vitamin B5 derivative pantethine limits the activity of dendritic cells (DCs), which are immune cells that are key contributors to autoimmune diseases such as psoriasis. The newly reported study showed that pantethine prevented the development of psoriasis in mice, and in a small-scale trial in human psoriasis patients administering pantethine in combination with topical calcipotriol/betamethasone dipropionate helped to alleviate symptoms.</p>
<p>In their published study in <em>Journal of Experimental Medicine</em> (<em>JEM</em>) (“<a href="http://dx.doi.org/10.1084/jem.20252558" target="_blank" rel="noopener">Vanin-pantethine metabolic axis shapes dendritic cell function and affects inflammatory disorder progression</a>,”) senior author Wei-Na Zhang, PhD, a researcher at the State Key Laboratory of Biomedical Analysis, and colleagues, suggested that their findings point to “… a potentially viable metabolic strategy for DC-centered intervention in AIDs [autoimmune diseases].” Zhang co-led the new <em>JEM</em> study with Qing Xia PhD, Ai-Ling Li, PhD, and Tao Zhou, PhD, also from the State Key Laboratory of Biomedical Analysis, and Cheng-Xin Li, PhD, from The First Medical Center of Chinese PLA General Hospital in Beijing.</p>
<p>Dendritic cells are specialized immune cells that help to coordinate the different parts of the immune system. They can engulf and present foreign antigens to activate highly specific T cells, as well as secrete a variety of immune signaling molecules to recruit other types of immune cells and promote inflammation. Because of this central role in directing immune responses, abnormal activation of dendritic cells is thought to underlie a variety of autoimmune diseases, including psoriasis. “Aberrant activation of dendritic cells (DCs) is intricately associated with inflammatory diseases, rendering DCs an appealing therapeutic target,” the authors wrote. “Metabolites are emerging as crucial regulators of DCs, yet therapeutic strategies targeting DC metabolism for inflammatory diseases remain underexplored.”</p>
<p>Zhang further added, “Emerging evidence highlights that metabolic pathways and their associated metabolites play vital roles in regulating immune cell function and autoimmune progression. But therapeutic strategies targeting metabolism in inflammatory diseases remain underexplored.”</p>
<p>Through their study the team found that levels of metabolic enzymes known as Vanins are elevated in the dendritic cells of patients with psoriasis and several other autoimmune diseases. Vanin enzymes convert the metabolite pantethine into vitamin B5, an essential nutrient required for cellular energy production. Pantethine itself is a widely available nutritional supplement often used to lower blood cholesterol levels due to its ability to inhibit cholesterol synthesis. Intriguingly, cholesterol can promote the activation of dendritic cells, and high blood cholesterol is a major risk factor for the development of psoriasis.</p>
<p>Through their study the team showed that depleting these enzymes inhibited dendritic cell activation and limited their ability to activate T cells. Moreover, treating mice with a drug that inhibits Vanins prevented the animals from developing psoriasis.</p>
<p>Zhang and colleagues determined that increased Vanin activity in dendritic cells reduces panthetine levels, leading to increased cholesterol synthesis and dendritic cell hyperactivation. Replenishing pantethine levels reversed this process, lowering the accumulation of cholesterol and suppressing dendritic cell activation. “Pantethine supplementation or pharmacologically induced Vanin inhibition reduces cholesterol overload, impedes DC activation, and mitigates psoriasiform inflammation,” they wrote.</p>
<figure aria-describedby="caption-attachment-339879" class="wp-caption alignright"><img decoding="async" class="size-medium wp-image-339879" src="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_Cao_et_al-300x165.jpg" alt="Psoriasis patients prescribed pantethine capsules in addition to topical ointments show a marked improvement in symptoms after 3 months of treatment (bottom). [© 2026 Cao et al. Originally published in Journal of Experimental Medicine. https://doi.org/10.1084/jem.20252558]" width="300" height="165" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_Cao_et_al-300x165.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_Cao_et_al.jpg 700w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Psoriasis patients prescribed pantethine capsules in addition to topical ointments show a marked improvement in symptoms after three months of treatment (bottom). [© 2026 Cao et al. Originally published in <a href="https://doi.org/10.1084/jem.20252558" target="_blank" rel="noopener"><em>Journal of Experimental Medicine</em></a>]</figcaption></figure>
<p>“We found that pantethine administration effectively alleviated psoriasis in mice, suggesting that insufficient pantethine levels may be the crucial contributor to hyperactivation of dendritic cells and autoimmune inflammation following the upregulation of Vanins,” Zhang noted.</p>
<p>To investigate further the researchers initiated a small-scale trial of pantethine supplementation in 24 human psoriasis patients. Every patient was treated with topical calcipotriene/betamethasone ointment, but half of the patients also received oral pantethine. Over the course of 12 weeks, patients given the additional pantethine treatment showed improved symptoms, particularly if they had elevated blood cholesterol levels at the start of the trial. “Importantly, our clinical trial revealed that pantethine combination therapy significantly decelerates the progression of psoriasis in patients,” they reported.</p>
<p>Zhang commented, “Our investigator-initiated clinical trial demonstrated encouraging therapeutic efficacy of pantethine as an adjunctive therapy in psoriasis, but these findings should be interpreted as proof-of-concept for clinical feasibility rather than direct mechanistic validation. Overall, our study uncovers the Vanin-pantethine-cholesterol axis as a key metabolic pathway governing dendritic cell activation and provides a foundation for therapeutic strategies targeting several dendritic cell–mediated autoimmune diseases.”</p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/vitamin-derivative-pantethine-alleviates-psoriasis-symptoms-in-small-human-trial/">Vitamin Derivative Pantethine Alleviates Psoriasis Symptoms in Small Human Trial</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Artiva Axes 94% of Workforce, Weighs Strategic Alternatives After Two Patients in Phase IIa Trial Die</title>
<link>https://edusehat.com/en/artiva-axes-94-of-workforce-weighs-strategic-alternatives-after-two-patients-in-phase-iia-trial-die</link>
<guid>https://edusehat.com/en/artiva-axes-94-of-workforce-weighs-strategic-alternatives-after-two-patients-in-phase-iia-trial-die</guid>
<description><![CDATA[ In announcing the layoffs and strategic alternatives review, Artiva disclosed that two patients in the trial who underwent the study treatment died in Grade 5 safety events. One patient succumbed to leukoencephalopathy while the second experienced sudden death.
The post Artiva Axes 94% of Workforce, Weighs Strategic Alternatives After Two Patients in Phase IIa Trial Die appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Artiva_Facilties_Exterior_Updated-RESIZE1220.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 28 Oct 2026 04:20:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Artiva, Axes, 94, Workforce, Weighs, Strategic, Alternatives, After, Two, Patients, Phase, IIa, Trial, Die</media:keywords>
<content:encoded><![CDATA[<p>Artiva Biotherapeutics said it will eviscerate its workforce 94% and evaluate strategic options after two patients treated with its lead candidate in a Phase IIa trial died—though one death was unrelated to the treatment.</p>
<p>Artiva has ended development of the lead candidate, a non-genetically modified, allogeneic, cryopreserved NK cell therapy called AlloNK<sup>®</sup> and also called AB-101. AlloNK had been evaluated in a Phase IIa “basket” trial (<a href="https://clinicaltrials.gov/study/NCT06991114" target="_blank" rel="noopener">NCT06991114</a>) assessing the candidate in rheumatoid arthritis (RA), Sjögren’s Disease, idiopathic inflammatory myopathies, and systemic sclerosis in combination with rituximab—the monoclonal antibody treatment for arthritis and several forms of cancer marketed by Roche’s Genentech subsidiary and Biogen as Rituxan<sup>®</sup>.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>In announcing the layoffs and strategic alternatives review, Artiva disclosed that two patients in the trial who underwent the study treatment died in Grade 5 safety events. One patient succumbed to leukoencephalopathy, a fatal neurological event, following treatment, which included protocol-specified lymphodepletion with cyclophosphamide and fludarabine.</p>
<p>“The investigator and an independent safety review assessed the event as likely related to fludarabine-associated neurotoxicity,” Artiva said in a statement. “Given the widespread use of fludarabine-containing lymphodepletion regimens in cell therapy development, Artiva intends to share additional details of this case in a scientific publication.”</p>
<p>After reporting the event to the FDA and the trial’s data safety monitoring board (DSMB), the agency requested that Artiva pause enrollment and dosing in the Phase IIa study, Artiva said. The company also paused its plans to begin enrollment and dosing in a Phase III trial of AlloNK.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>The second patient experienced sudden death approximately two months after beginning study treatment. “The investigator assessed this event as unrelated to AlloNK or any other component of the study treatment regimen, and the cause of death has not been determined,” Artiva stated, adding that the second death was also reported to the FDA and DSMB.</p>
<h4><strong>‘Deeply saddened’</strong></h4>
<p>“Throughout the development of AlloNK, the safety and well-being of patients have remained our highest priority. We are deeply saddened by the deaths of two patients who participated in our clinical studies and extend our sincere condolences to their families,” Artiva CEO Fred Aslan, MD, stated. “We plan to provide findings from the first case, which was assessed as likely related to fludarabine toxicity, given its widespread use in cell therapy conditioning regimens.”</p>
<p>In halting development of AlloNK, Artiva also cited uneven clinical data as well as an assessment of the therapy’s risks and benefits, the likelihood of future enrollment delays, and the overall development and potential commercial outlook.</p>
<p>According to the company, the data “continued to demonstrate deep B cell depletion and clinical activity consistent with the Company’s previously reported findings.”</p>
<p>“However, longer-term follow-up did not reflect the level of durability of clinical response the Company believes is needed to support continued development,” Artiva added. “The Company will work closely with the FDA, investigators, and institutional review boards to ensure an appropriate and orderly close-out of its clinical development program, including continued safety monitoring and reporting as required.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>As a result, Artiva has canceled a presentation of AlloNK clinical data at the upcoming ACR Convergence 2026 conference, to be held November 6-11 in Orlando, FL. The company is also canceling an investor webcast it had scheduled for November 9.</p>
<p>“Updated clinical data may be presented at future scientific meetings depending on the outcome of the strategic alternatives process,” Artiva added.</p>
<p>Investors responded to Artiva’s announcement with a stock selloff that sent shares tumbling 30.5% on Tuesday, from $6.16 to $4.27 as of 2:04 p.m. ET.</p>
<h4><strong>Analyst downgrades</strong></h4>
<p>Several investment firms downgraded their ratings of Artiva stock, including Cantor Fitzgerald, TD Cowen, Needham & Co., H.C. Wainwright, and Wedbush—where David Nierengarten, PhD, managing director and a senior analyst covering small-mid cap biotech stocks, cut his firm’s rating from “Outperform” to “Neutral” and slashed its 12-month price target 90% from $40 to $4.</p>
<p>Artiva also retained Leerink Partners to assist in the company’s strategic review, which will entail evaluating internal options and potential strategic alternatives intended to maximize stockholder value.</p>
<p>Among options under review, Artiva said, include a merger, business combination, sale or licensing of assets, dissolution, and liquidation. Artiva does not plan to offer updates on the review “unless and until the Board of Directors has approved a specific course of action, the process has concluded, or the Company determines that further disclosure is appropriate or required by law.”</p>
<p>Artiva will also carry out a reduction of its workforce by approximately 94%. That would amount to roughly 98 of the 104 full-time employees that Artiva employed as of June 30, according to the company’s <a href="https://d18rn0p25nwr6d.cloudfront.net/CIK-0001817241/0c3c7f0b-10f5-4c7b-b009-26e549fa823a.pdf" target="_blank" rel="noopener">Form 10-Q quarterly report for the second quarter</a>, filed August 6 with the U.S. Securities and Exchange Commission.</p>
<p>As of September 30, 2026, Artiva said in its statement, it had approximately $319.1 million in cash, cash equivalents and investments—a preliminary and unaudited figure, the company cautioned. The announcement did not quantify how much Artiva expects to spend on its planned workforce reduction.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>Complete quarterly results will be included in Artiva’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/artiva-axes-94-of-workforce-weighs-strategic-alternatives-after-two-patients-in-phase-iia-trial-die/">Artiva Axes 94% of Workforce, Weighs Strategic Alternatives After Two Patients in Phase IIa Trial Die</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>ASHG: Nabsys Links Cytogenetics and Genomics to Map Hematologic Cancers</title>
<link>https://edusehat.com/en/ashg-nabsys-links-cytogenetics-and-genomics-to-map-hematologic-cancers</link>
<guid>https://edusehat.com/en/ashg-nabsys-links-cytogenetics-and-genomics-to-map-hematologic-cancers</guid>
<description><![CDATA[ Blood cancers carry complex genomic rearrangements that no single assay fully captures. At ASHG 2026 in Montréal, Nabsys presented early data comparing its Electronic Genome Mapping technology with established cytogenetic methods and previewed new analysis software for hematologic malignancies.
The post ASHG: Nabsys Links Cytogenetics and Genomics to Map Hematologic Cancers appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/07/Getty_1441707827_leukemiaWhiteBloodCells.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 27 Oct 2026 21:10:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>ASHG:, Nabsys, Links, Cytogenetics, and, Genomics, Map, Hematologic, Cancers</media:keywords>
<content:encoded><![CDATA[<p>Blood cancers are often driven by large-scale genomic rearrangements, including translocations, deletions, duplications, and other structural and copy number changes, that no single assay captures well. In practice, characterizing a hematologic malignancy can mean piecing together results from karyotyping, fluorescence <em>in situ</em> hybridization (FISH), chromosomal microarray, and sequencing, each with its own resolution limits and blind spots.</p>
<p>Nabsys is positioning its Electronic Genome Mapping (EGM) technology as one way to close some of those gaps. At the American Society of Human Genetics (ASHG) 2026 Annual Meeting, held October 20–24 in Montréal, the Providence, RI-based company shared preliminary data on EGM in hematologic malignancies and previewed analysis software built for that application.</p>
<h4><strong>Bridging two disciplines</strong></h4>
<p>In a Nabsys-sponsored CoLab session on October 22, Alka Chaubey, PhD, FACMG, the company’s chief medical and genomics officer, presented “Electronic Genome Mapping in Hematologic Malignancies: Bridging Cytogenetics and Molecular Genomics” on behalf of Brynn Levy, MSc(Med), PhD, FACMG, of Columbia University. The talk covered early findings on how well EGM detects structural and copy number variants, including how its results compared with established cytogenetic methods.</p>
<p>The work builds on OhmX Platform installations at Columbia University Medical Center, awarded through the RAMP UP Program from Hitachi High-Tech America and Nabsys. Running on OhmX, EGM is designed to give a high-resolution, genome-wide view of structural and copy number variation. Nabsys frames the technology as a complement to existing tools rather than a replacement.</p>
<p>“Researchers need a more complete view of the complex genomic changes in hematologic cancers,” said Barrett Bready, MD, Nabsys’s founder and CEO. “These preliminary findings highlight EGM’s potential to complement established methods.”</p>
<h4><strong>Software shaped by users</strong></h4>
<p>Alongside the data, Nabsys demonstrated Nabsys Navigator<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley">, its cloud-based platform for EGM analysis and visualization. Navigator includes two pipelines: SV-Discover<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley">, for genome-wide structural variant analysis, and SV-Verify<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley">, for confirming structural variants flagged by other technologies. Booth visitors could also preview the company’s forthcoming hematologic malignancy analysis software, the same tool used to analyze samples in Chaubey’s presentation, and weigh in on its development. Bready said the company is “pairing that work with software development shaped directly by the researchers who will use it.” The OhmX Platform is for research use only and is not intended for diagnostic procedures.</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/ashg-nabsys-links-cytogenetics-and-genomics-to-map-hematologic-cancers/">ASHG: Nabsys Links Cytogenetics and Genomics to Map Hematologic Cancers</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Single&#45;Cell Multiomics: Phenotypic Plasticity in Colorectal Cancer Metastasis</title>
<link>https://edusehat.com/en/single-cell-multiomics-phenotypic-plasticity-in-colorectal-cancer-metastasis</link>
<guid>https://edusehat.com/en/single-cell-multiomics-phenotypic-plasticity-in-colorectal-cancer-metastasis</guid>
<description><![CDATA[ In this GEN webinar, Mirjana Efremova, PhD (Queen Mary University of London) will show how these technologies can be used to analyze primary and liver-metastatic CRC patient samples to reveal cancer cell states. 
The post Single-Cell Multiomics: Phenotypic Plasticity in Colorectal Cancer Metastasis appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Getty_2135397939_ColonCancer.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 27 Oct 2026 21:10:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Single-Cell, Multiomics:, Phenotypic, Plasticity, Colorectal, Cancer, Metastasis</media:keywords>
<content:encoded><![CDATA[<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"></div>
</div>


<p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Register Now</button></p>

<h3 class="w-full text-left">
    <strong>
        Panelists:
    </strong>
</h3>
<div class="flex flex-row m-0-auto items-stretch justify-center flex-wrap mb-4">
    
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/10/MirjanaEfremova_headshot.jpg" class="h-full w-full object-cover" alt="Image of Mirjana Efremova, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Mirjana Efremova, PhD</h2>
                <h5 class="mt-0 !text-[15px] !leading-[21px]">Senior Lecturer<br>Queen Mary University of London</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/10/MirjanaEfremova_headshot.jpg" alt="Image of Mirjana Efremova, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Mirjana Efremova, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Mirjana Efremova earned a PhD in computational biology at the Medical University of Innsbruck, Austria, where she investigated the process of clonal evolution of cancer under immunosurveillance and how the immune system shapes tumor progression. She did her post-doctoral work at the Teichmann Lab, Wellcome Sanger Institute, where she co-led the development of the first human atlas of the maternal-fetal interface in early pregnancy using single cell transcriptomics. She also developed a cell-cell communication statistical framework CellPhoneDB (www.cellphonedb.org) for predicting enriched receptor-ligand pairs between the different cell types and inference of cellular communication networks.  In May 2020, she started a lab at Barts Cancer Institute, Queen Mary University of London (U.K.) within the Centre for Cancer Evolution. Her lab is focused on investigating the non-genetic mechanisms driving cancer initiation, metastasis, and therapy resistance.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog></div>



<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-malblocks-webinars-info"></p><div><strong>Broadcast Date:</strong> <time>Thursday, November 19, 2026</time><br><ul><li><strong>Time:</strong> <time datetime="2026-11-19T16:00:00.000Z">08:00 PST, 11:00 EST, 16:00 GMT</time></li></ul></div>


<div aria-hidden="true" class="wp-block-spacer"></div>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow">
<p class="wp-block-paragraph">Phenotypic plasticity—the ability of tumor cells to switch states in response to their environment—drives colorectal cancer (CRC) progression, metastasis, and therapy resistance, but what controls it has been unclear. The application of single-cell multiomics and spatial transcriptomics in primary and metastatic tumor samples can reveal regenerative and inflammatory cancer cell states.</p>


<p class="wp-block-paragraph">In this <em>GEN</em> webinar, Mirjana Efremova, PhD (Queen Mary University of London) will show how these technologies can be used to analyze primary and liver-metastatic CRC patient samples to reveal cancer cell states. These regenerative and inflammatory cancer cell states resemble metastasis-initiating cells in mouse models, are regulated by the transcription factors AP-1 and NF-κB, and sit at the invasive edge in an immunosuppressive niche. Improved understanding of these microenvironment-driven states and their regulators offers researchers new ways to target metastasis.</p>


<p class="wp-block-paragraph">Webinar attendees will learn more about:</p>


<ul class="wp-block-list">
<li>The regenerative and inflammatory cancer cell states found in primary and metastatic CRC, including a hybrid regenerative/stem state, and how liver metastases re-establish the primary tumor’s heterogeneity;</li>



<li>Transcriptional regulation of these states as well as signals from fibroblasts, macrophages, and T cells, and where the states sit in the tumor; and</li>



<li>How to apply single-cell multiomics and spatial transcriptomics to link cell state, regulation, and tissue location, and identify candidate targets to limit plasticity and metastasis.</li>
</ul>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><em>A live Q&A session will follow the presentation offering you a chance to pose questions to our expert panelists.</em></p>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><strong>Produced with support from:</strong></p>


<figure class="wp-block-image alignleft size-medium"><a href="https://www.10xgenomics.com/" target="_blank" rel=" noopener"><img decoding="async" width="300" height="77" src="https://www.genengnews.com/wp-content/uploads/2019/10/10x_Logo-300x77.jpg" alt="10x Genomics logo" class="wp-image-129310" srcset="https://www.genengnews.com/wp-content/uploads/2019/10/10x_Logo-300x77.jpg 300w, https://www.genengnews.com/wp-content/uploads/2019/10/10x_Logo-768x197.jpg 768w, https://www.genengnews.com/wp-content/uploads/2019/10/10x_Logo-1024x263.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2019/10/10x_Logo-696x178.jpg 696w, https://www.genengnews.com/wp-content/uploads/2019/10/10x_Logo-1392x359.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2019/10/10x_Logo-1068x274.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2019/10/10x_Logo.jpg 1400w" sizes="(max-width: 300px) 100vw, 300px"></a></figure>
</div>
</div>

<p>The post <a href="https://www.genengnews.com/multimedia/webinars/single-cell-multiomics-phenotypic-plasticity-in-colorectal-cancer-metastasis/">Single-Cell Multiomics: Phenotypic Plasticity in Colorectal Cancer Metastasis</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Toronto hospital performs Canada’s first robotic&#45;assisted hybrid procedure for atrial fibrillation</title>
<link>https://edusehat.com/en/toronto-hospital-performs-canadas-first-robotic-assisted-hybrid-procedure-for-atrial-fibrillation</link>
<guid>https://edusehat.com/en/toronto-hospital-performs-canadas-first-robotic-assisted-hybrid-procedure-for-atrial-fibrillation</guid>
<description><![CDATA[ St. Michael’s Hospital in Toronto has achieved a Canadian first by performing the robotic surgical component of a hybrid ablation procedure designed to treat patients with persistent atrial fibrillation. The procedure represents an important development in minimally invasive cardiac care, combining robotic surgical technology with catheter-based treatment to address abnormal electrical activity responsible for irregular […]
The post Toronto hospital performs Canada’s first robotic-assisted hybrid procedure for atrial fibrillation appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/Gianluigi-Bisleri_SMH_20260916_-7-400x268-1.png" length="49398" type="image/jpeg"/>
<pubDate>Tue, 27 Oct 2026 21:00:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Toronto, hospital, performs, Canada’s, first, robotic-assisted, hybrid, procedure, for, atrial, fibrillation</media:keywords>
<content:encoded><![CDATA[<p>St. Michael’s Hospital in Toronto has achieved a Canadian first by performing the robotic surgical component of a hybrid ablation procedure designed to treat patients with persistent atrial fibrillation.</p>
<p>The procedure represents an important development in minimally invasive cardiac care, combining robotic surgical technology with catheter-based treatment to address abnormal electrical activity responsible for irregular heart rhythms.</p>
<p>Atrial fibrillation, commonly known as AFib, is the most common heart rhythm disorder. It occurs when the heart’s upper chambers beat irregularly and can cause fatigue, shortness of breath and heart palpitations. The condition is also associated with an increased risk of stroke and heart failure.</p>
<h3>Combining two approaches to treatment</h3>
<p>Many patients with atrial fibrillation respond to medication or conventional catheter ablation. However, treatment can be more challenging for individuals with persistent forms of the condition.</p>
<p>The hybrid approach combines two procedures performed at different times.</p>
<p>During the surgical stage, cardiac surgeons treat abnormal electrical pathways from outside the heart. Electrophysiologists subsequently use catheter-based techniques to identify and treat problematic electrical signals from inside the heart.</p>
<p>At St. Michael’s Hospital, the surgical component was performed using a robotic platform that allows surgeons to operate through small incisions with enhanced visualization and instrument control.</p>
<p>The approach is intended to provide more comprehensive treatment for selected patients whose atrial fibrillation has been difficult to manage.</p>
<h3>Multidisciplinary cardiac care</h3>
<p>The program brings together cardiac surgeons and electrophysiologists, including Dr. Gianluigi Bisleri, Director of Minimally Invasive Cardiac Surgery, and Dr. Paul Angaran, Director of the hospital’s Cardiac Arrhythmia Program.</p>
<p>Their collaboration reflects a growing emphasis on combining specialized expertise and advanced technology to improve treatment options for complex cardiovascular conditions.</p>
<p>The hospital says clinical evidence suggests hybrid approaches can improve long-term heart rhythm outcomes for selected patients with persistent atrial fibrillation compared with catheter ablation alone.</p>
<h3>First patient travels from Alberta</h3>
<p>The first Canadian patient to undergo the robotic surgical component travelled from Alberta to Toronto for treatment.</p>
<p>Jon Davies had been living with atrial fibrillation for nearly three decades before receiving the procedure.</p>
<p>According to the hospital, Davies recovered from the robotic surgery and returned home within days. He is awaiting the second stage of his treatment, which will involve catheter ablation.</p>
<p>Although his full treatment and longer-term outcomes remain to be assessed, the procedure demonstrates how robotic technology may expand minimally invasive treatment options for patients with complex heart rhythm disorders.</p>
<p>The milestone also highlights the growing role of multidisciplinary teams in developing advanced cardiac programs within Canadian hospitals.</p>
<p><strong>Source:</strong> <a href="https://unityhealth.to/2026/10/st-michaels-hospital-completes-canadas-first-robotic-hybrid-procedure-for-atrial-fibrillation/?utm_source=chatgpt.com">Unity Health Toronto</a>, October 26, 2026.</p>
<p>The post <a href="https://www.hospitalnews.com/toronto-hospital-performs-canadas-first-robotic-assisted-hybrid-procedure-for-atrial-fibrillation/">Toronto hospital performs Canada’s first robotic-assisted hybrid procedure for atrial fibrillation</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Medical AI, brain&#45;computer interfaces and surgical robotics take centre stage at 94th CMEF</title>
<link>https://edusehat.com/en/medical-ai-brain-computer-interfaces-and-surgical-robotics-take-centre-stage-at-94th-cmef</link>
<guid>https://edusehat.com/en/medical-ai-brain-computer-interfaces-and-surgical-robotics-take-centre-stage-at-94th-cmef</guid>
<description><![CDATA[ Het bericht Medical AI, brain-computer interfaces and surgical robotics take centre stage at 94th CMEF verscheen eerst op International Hospital. ]]></description>
<enclosure url="https://interhospi.com/wp-content/uploads/sites/3/2026/10/cmef_3a.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 27 Oct 2026 17:25:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Medical, AI, brain-computer, interfaces, and, surgical, robotics, take, centre, stage, 94th, CMEF</media:keywords>
<content:encoded><![CDATA[<div class="avia-section av-5pjryc-19691d8fe024ecd22f4cf1b0746f9172 main_color avia-section-default avia-no-border-styling  avia-builder-el-0  avia-builder-el-no-sibling  avia-bg-style-scroll container_wrap fullsize"><div class="container av-section-cont-open"><main role="main" itemprop="mainContentOfPage" class="template-page content  av-content-full alpha units"><div class="post-entry post-entry-type-page post-entry-20421"><div class="entry-content-wrapper clearfix">


<div class="flex_column av-4vqtes-8a6e6b2dd0d572ce1d6026a3282c73a3 av_one_fifth  avia-builder-el-1  el_before_av_three_fifth  avia-builder-el-first  first flex_column_div av-hide-on-mobile av-zero-column-padding  "><section class="av_textblock_section av-key24etv-8cf8563f9a5147bae87b81cc26a3527e " itemscope="itemscope" itemtype="https://schema.org/BlogPosting" itemprop="blogPost"><div class="avia_textblock" itemprop="text"><p></p>
</div></section></div>

<div class="flex_column av-4j6544-3dd207ac880e0091524d5c381bfaef43 av_three_fifth  avia-builder-el-3  el_after_av_one_fifth  el_before_av_one_fifth  flex_column_div av-zero-column-padding  "><section class="av_textblock_section av-key254dz-6dca32f8382240f7ccc291ef75096d96 " itemscope="itemscope" itemtype="https://schema.org/BlogPosting" itemprop="blogPost"><div class="avia_textblock" itemprop="text"><p></p>
</div></section><br>
<section class="av_textblock_section av-ke9srown-cfbd4a744a50962f9a592b08939de968 " itemscope="itemscope" itemtype="https://schema.org/BlogPosting" itemprop="blogPost"><div class="avia_textblock" itemprop="text"><header class="entry-content-header"><h1 class="post-title entry-title" itemprop="headline">Medical AI, brain-computer interfaces and surgical robotics take centre stage at 94th CMEF</h1><span class="post-meta-infos">/ <span class="blog-categories minor-meta">in <a href="https://interhospi.com/category/e-news/" rel="tag">E-News</a>, <a href="https://interhospi.com/category/events/" rel="tag">Events</a>  </span></span></header>
</div></section><br>
<section class="av_textblock_section av-23o2c4-8f397adbcbd64996a2025c8abf40a726 " itemscope="itemscope" itemtype="https://schema.org/BlogPosting" itemprop="blogPost"><div class="avia_textblock" itemprop="text"><p><strong>The 94th China International Medical Equipment Fair (CMEF) Autumn Edition brought together clinicians, manufacturers and buyers at the Capital International Exhibition & Convention Center in Beijing from 21–24 October 2026. The programme centred on artificial intelligence (AI), precision diagnostics and surgical robotics.</strong></p>
<p><span></span></p>
<p>The fair drew more than 120,000 healthcare professionals and about 3,000 exhibitors from 21 countries and regions, with visitors from more than 150 countries and regions. Across around 170,000 square metres, it covered digital health, intelligent medical devices, rehabilitation technologies and connected healthcare solutions alongside diagnostics and robotics. Exhibitors unveiled more than 1,000 innovative products.</p>
<p><img fetchpriority="high" decoding="async" class="alignnone wp-image-20422" src="https://interhospi.com/wp-content/uploads/sites/3/2026/10/cmef_3a.jpg" alt="CMEF" width="532" height="354" srcset="https://interhospi.com/wp-content/uploads/sites/3/2026/10/cmef_3a.jpg 800w, https://interhospi.com/wp-content/uploads/sites/3/2026/10/cmef_3a-300x200.jpg 300w, https://interhospi.com/wp-content/uploads/sites/3/2026/10/cmef_3a-768x512.jpg 768w, https://interhospi.com/wp-content/uploads/sites/3/2026/10/cmef_3a-705x470.jpg 705w" sizes="(max-width: 532px) 100vw, 532px"></p>
<h3><strong>Regional collaboration in focus</strong></h3>
<p>A central feature was the Beijing-Tianjin-Hebei Coordinated Innovation Pavilion in Hall A4. It showed how combining research, engineering and clinical expertise across the region is moving healthcare innovation forward. Exhibits drew on Beijing’s districts, science and innovation industrial parks, pilot testing platforms and specialist technology companies. They spanned AI-assisted diagnosis and treatment, brain-computer interfaces (BCIs), smart medical devices, rehabilitation technologies and elderly care.</p>
<p>The pavilion programme also included healthcare reform discussions, hospital innovation project presentations and demonstrations of AI-powered mobile medical vehicles. “Youcu Plan” projects were released, and award-winning scientific and technological innovations were shown.</p>
<h3><strong>Medical AI beyond imaging</strong></h3>
<p>The Medical AI Frontier Zone highlighted Chinese work in medical robots, BCIs, embodied AI, healthcare AI models, high-quality datasets, innovative drugs, medical devices and 5G-enabled technologies. According to the organisers, AI applications are moving beyond medical imaging and diagnostic support into real-world clinical and operational settings. The zone served as a platform for technologies heading towards broader commercialisation.</p>
<p>A separate International Zone presented devices and healthcare solutions from overseas companies. It emphasised exchange between foreign firms, buyers and industry stakeholders.</p>
<h3><strong>Support for overseas buyers</strong></h3>
<p>The WeSeries programmes were built to help international buyers find suitable products and suppliers. The WeTalk stage hosted presentations from companies in medical robotics, surgery, surgical instruments, emergency and critical care monitoring equipment, and paediatric healthcare. The WeMatch Hub arranged one-to-one meetings between buyers and exhibitors. WeTour provided English-language guidance, customised tours, product demonstrations, hands-on experiences and consultations with participating companies. The aim was to help buyers turn first contacts into concrete collaborations.</p>
<h3><strong>Policy and clinical themes in the conference programme</strong></h3>
<p>More than 100 conferences, thematic forums and seminars ran alongside the exhibition. Topics included the Outline of the 15th Five-Year Plan, Three-Medical Linkage initiatives, the Medical and Health Foundation Strengthening Project, medical innovation, AI-assisted diagnosis, medical-engineering translation, medical insurance reform and the future of patient care.</p>
<p>Co-located events were the International Component Manufacturing & Design Show (ICMD), the China International Rehabilitation and Personal Health Show (CRS), the China International Elderly Care and Nursing Show (CECN) and the China International Home Care Exhibition (Lifecare).</p>
<p>CMEF is organised under RX Global, which runs more than 350 exhibitions and conferences annually across 22 countries and 43 industry sectors.</p>
<ul>
<li>For more information, visit: <a href="https://www.cmef.com.cn/en" target="_blank" rel="noopener">https://www.cmef.com.cn/en</a></li>
</ul>
</div></section><br>


<div class="hr av-klqcq5xv-fb118132a60cd57f133869cf62f2257a hr-invisible  avia-builder-el-7  el_after_av_textblock  el_before_av_social_share "><span class="hr-inner "><span class="hr-inner-style"></span></span></div><br>
<div class="av-social-sharing-box av-ke9sz9xv-3e02cbd0889cb70a2a9058e399d76f75 av-social-sharing-box-minimal  avia-builder-el-8  el_after_av_hr  avia-builder-el-last  av-social-sharing-box-fullwidth"><div class="av-share-box"><h5 class="av-share-link-description av-no-toc ">Share this</h5><ul class="av-share-box-list noLightbox"><li class="av-share-link av-social-link-facebook avia_social_iconfont"><a target="_blank" aria-label="Share on Facebook" href="https://www.facebook.com/sharer.php?u=https://interhospi.com/medical-ai-brain-computer-interfaces-and-surgical-robotics-take-centre-stage-at-94th-cmef/&t=Medical%20AI%2C%20brain-computer%20interfaces%20and%20surgical%20robotics%20take%20centre%20stage%20at%2094th%20CMEF" data-av_icon="" data-av_iconfont="entypo-fontello" title="" data-avia-related-tooltip="Share on Facebook"><span class="avia_hidden_link_text">Share on Facebook</span></a></li><li class="av-share-link av-social-link-twitter avia_social_iconfont"><a target="_blank" aria-label="Share on X" href="https://twitter.com/share?text=Medical%20AI%2C%20brain-computer%20interfaces%20and%20surgical%20robotics%20take%20centre%20stage%20at%2094th%20CMEF&url=https://interhospi.com/?p=20421" data-av_icon="" data-av_iconfont="entypo-fontello" title="" data-avia-related-tooltip="Share on X"><span class="avia_hidden_link_text">Share on X</span></a></li><li class="av-share-link av-social-link-whatsapp avia_social_iconfont"><a target="_blank" aria-label="Share on WhatsApp" href="https://api.whatsapp.com/send?text=https://interhospi.com/medical-ai-brain-computer-interfaces-and-surgical-robotics-take-centre-stage-at-94th-cmef/" data-av_icon="" data-av_iconfont="entypo-fontello" title="" data-avia-related-tooltip="Share on WhatsApp"><span class="avia_hidden_link_text">Share on WhatsApp</span></a></li><li class="av-share-link av-social-link-linkedin avia_social_iconfont"><a target="_blank" aria-label="Share on LinkedIn" href="https://linkedin.com/shareArticle?mini=true&title=Medical%20AI%2C%20brain-computer%20interfaces%20and%20surgical%20robotics%20take%20centre%20stage%20at%2094th%20CMEF&url=https://interhospi.com/medical-ai-brain-computer-interfaces-and-surgical-robotics-take-centre-stage-at-94th-cmef/" data-av_icon="" data-av_iconfont="entypo-fontello" title="" data-avia-related-tooltip="Share on LinkedIn"><span class="avia_hidden_link_text">Share on LinkedIn</span></a></li><li class="av-share-link av-social-link-mail avia_social_iconfont"><a aria-label="Share by Mail" href="mailto:?subject=Medical%20AI%2C%20brain-computer%20interfaces%20and%20surgical%20robotics%20take%20centre%20stage%20at%2094th%20CMEF&body=https://interhospi.com/medical-ai-brain-computer-interfaces-and-surgical-robotics-take-centre-stage-at-94th-cmef/" data-av_icon="" data-av_iconfont="entypo-fontello" title="" data-avia-related-tooltip="Share by Mail"><span class="avia_hidden_link_text">Share by Mail</span></a></li></ul></div></div></div>

<div class="flex_column av-1ziaaf0-b945285943f655b3c584bc38c6af1f49 av_one_fifth  avia-builder-el-9  el_after_av_three_fifth  avia-builder-el-last  flex_column_div av-hide-on-mobile av-zero-column-padding  "><section class="av_textblock_section av-key26scb-767e6508335704b90077f977070d6be8 " itemscope="itemscope" itemtype="https://schema.org/BlogPosting" itemprop="blogPost"><div class="avia_textblock" itemprop="text"><p></p>
</div></section></div>
<p>Het bericht <a href="https://interhospi.com/medical-ai-brain-computer-interfaces-and-surgical-robotics-take-centre-stage-at-94th-cmef/">Medical AI, brain-computer interfaces and surgical robotics take centre stage at 94th CMEF</a> verscheen eerst op <a href="https://interhospi.com/">International Hospital</a>.</p></div></div></main></div></div>]]> </content:encoded>
</item>

<item>
<title>Spatial Proteomics for Precision Oncology</title>
<link>https://edusehat.com/en/spatial-proteomics-for-precision-oncology</link>
<guid>https://edusehat.com/en/spatial-proteomics-for-precision-oncology</guid>
<description><![CDATA[ In this GEN webinar, Bernd Bodenmiller, PhD (University of Zürich), illustrates this integrated approach through two recent examples. 
The post Spatial Proteomics for Precision Oncology appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Getty_1786420513_StomachCancer.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 27 Oct 2026 06:45:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Spatial, Proteomics, for, Precision, Oncology</media:keywords>
<content:encoded><![CDATA[<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"></div>
</div>


<p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Register Now</button></p>

<h3 class="w-full text-left">
    <strong>
        Panelists:
    </strong>
</h3>
<div class="flex flex-row m-0-auto items-stretch justify-center flex-wrap mb-4">
    
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/10/BerndBodenmiller_headshot.jpg" class="h-full w-full object-cover" alt="Image of Bernd Bodenmiller, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Bernd Bodenmiller, PhD</h2>
                <h5 class="mt-0 !text-[15px] !leading-[21px]">Associate Professor<br>Dept. of Quantitative Biomedicine<br>University of Zürich<br>ETH Zürich, Switzerland</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/10/BerndBodenmiller_headshot.jpg" alt="Image of Bernd Bodenmiller, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Bernd Bodenmiller, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Bernd Bodenmiller, PhD, is a quantitative biologist who develops novel experimental and computational approaches for the quantitative analysis of tumor ecosystems to improve our understanding of the mechanisms of tumor development. He is the founding director of the Department of Quantitative Biomedicine (DQBM) at the University of Zürich, which fosters research and education at the interface of biomedical research, biotechnology, and computational biology to guide development of next-generation precision medicine. His group has pioneered the development of imaging mass cytometry, which enables the simultaneous imaging of dozens of proteins and transcripts in tumor tissues and the histoCAT software toolbox. His group applies these methods to unravel how cells in the tumor ecosystem drive cancer development to identify mechanisms that might be exploited for therapeutic targeting.</p>
<p>Bodenmiller obtained his PhD in the group of Ruedi Aebersold, PhD, at ETH Zürich. For his postdoctoral training, he joined the laboratory of Garry Nolan, PhD, at Stanford University. In 2012, he became a group leader and in 2013 an SNF/ERC assistant professor at the University of Zürich. In 2019, he was tenured and became the founding director of the DQBM. In October 2020, Bodenmiller was appointed as Dual Professor for Quantitative Biomedicine at UZH and ETH Zürich.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog></div>



<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-malblocks-webinars-info"></p><div><strong>Broadcast Date:</strong> <time>Monday, November 16, 2026</time><br><ul><li><strong>Time:</strong> <time datetime="2026-11-16T16:00:00.000Z">08:00 PST, 11:00 EST, 16:00 GMT</time></li></ul></div>


<div aria-hidden="true" class="wp-block-spacer"></div>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow">
<p class="wp-block-paragraph">Tumors are complex cellular ecosystems in which cancer cell phenotypes, their spatial organization, and their interactions with immune and stromal compartments determine disease progression and therapy response. To resolve this complexity, the use of highly multiplexed Imaging Mass Cytometry<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> (IMC<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley">) together with multiomic profiling and artificial intelligence (AI) can identify clinically relevant features of the tumor microenvironment, providing a rich framework for patient stratification and targeted therapy in precision oncology.</p>


<p class="wp-block-paragraph">In this <em>GEN</em> webinar, Bernd Bodenmiller, PhD (University of Zürich), illustrates this integrated approach through two recent examples. In a study of 323 epithelial ovarian cancers, tumors with more diverse cell phenotypes and spatial organization recurred faster. His lab also identified a therapy-resistant tumor cell phenotype (TUBB3+/pRB+) associated with recurrence and poor response to standard therapy. Spatial transcriptomics and <em>ex vivo</em> drug screening of 3D sphere models and patient samples showed that these cells resist standard-of-care agents but are sensitive to specific inhibitors. In 498 clear cell renal cell carcinomas, the use of AI revealed three survival ecotypes that predict survival better than basic clinical data and molecular stratification models. Each ecotype has its own genomic and metabolic features and is predictive of treatment outcome. Deep learning predicted the ecotypes directly from routine H&E slides, and the findings were validated across five cohorts comprising more than 2,500 patients.</p>


<p class="wp-block-paragraph">Webinar attendees will learn how integrating spatial single-cell proteomics by IMC with multiomics and AI identifies therapy-resistant cell populations and prognostic tumor ecosystems. This approach provides a detailed framework for patient stratification and targeted therapy in precision oncology.</p>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><em>A live Q&A session will follow the presentation offering you a chance to pose questions to our expert panelists.</em></p>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><strong>Produced with support from:</strong></p>


<figure class="wp-block-image alignleft size-medium"><a href="https://standardbio.com/" target="_blank" rel=" noopener"><img decoding="async" width="300" height="214" src="https://www.genengnews.com/wp-content/uploads/2023/02/standardbio_logo-300x214.png" alt="Standard Biotools logo" class="wp-image-221017" srcset="https://www.genengnews.com/wp-content/uploads/2023/02/standardbio_logo-300x214.png 300w, https://www.genengnews.com/wp-content/uploads/2023/02/standardbio_logo-768x549.png 768w, https://www.genengnews.com/wp-content/uploads/2023/02/standardbio_logo-696x497.png 696w, https://www.genengnews.com/wp-content/uploads/2023/02/standardbio_logo-588x420.png 588w, https://www.genengnews.com/wp-content/uploads/2023/02/standardbio_logo-100x70.png 100w, https://www.genengnews.com/wp-content/uploads/2023/02/standardbio_logo.png 785w" sizes="(max-width: 300px) 100vw, 300px"></a></figure>
</div>
</div>

<p>The post <a href="https://www.genengnews.com/multimedia/webinars/spatial-proteomics-for-precision-oncology/">Spatial Proteomics for Precision Oncology</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Anthropic IPO Discloses Plans for Life Sciences Growth</title>
<link>https://edusehat.com/en/anthropic-ipo-discloses-plans-for-life-sciences-growth</link>
<guid>https://edusehat.com/en/anthropic-ipo-discloses-plans-for-life-sciences-growth</guid>
<description><![CDATA[ Anthropic’s Form S-1 Registration Statement did not reveal what research areas it is pursuing through the molecular biology lab it disclosed last month, and what if any new therapies it is seeking to discover and develop. But the IPO filing said that Anthropic is creating AI agents based on its Claude family of large language models that focus beyond accelerating drug discovery and development, toward handling many of the physical tasks associated with creating new therapies. 
The post Anthropic IPO Discloses Plans for Life Sciences Growth appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/ANTHROPIC-LAB-IMAGE-ORIGINAL-CROP11111-JPEG.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 27 Oct 2026 06:45:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Anthropic, IPO, Discloses, Plans, for, Life, Sciences, Growth</media:keywords>
<content:encoded><![CDATA[<p>Anthropic plans to expand its growing presence in life sciences by investing further in knowledge, talent, partnerships, and additional acquisitions, the artificial intelligence (AI) giant disclosed in its long-awaited initial public offering (IPO) filing.</p>
<p>Anthropic’s <a href="https://www.sec.gov/Archives/edgar/data/2130357/000162828026067168/anthropicpbc-sx1.htm" target="_blank" rel="noopener">Form S-1 Registration Statement</a>, filed Monday with the U.S. Securities and Exchange Commission, did not reveal key details such as what research areas it is pursuing through the molecular biology lab it disclosed last month, and what if any new therapies it is seeking to discover and develop. Nor did it quantify Anthropic’s total spending on life science activity.</p>
<p>The IPO filing also did not say how much money Anthropic seeks to raise on Wall Street—how many shares at what price—though news reports have had the company pursuing an eye-popping valuation of $2 trillion, 13% above the $1.77 trillion valuation of Elon Musk’s SpaceX when it went public in June. Anthropic plans to begin trading public shares on the Nasdaq Global Select Market under the ticker symbol ANT.</p>
<p>However, the filing said that Anthropic is creating AI agents based on its Claude family of large language models that focus beyond accelerating drug discovery and development, toward handling many of the physical tasks associated with creating new therapies.</p>
<p>“Claude is used in drug discovery and development by our customers, our biotechnology partners, and our own researchers. We are building AI agents that support scientists at each stage of that process,” Anthropic stated.</p>
<p>“Beyond knowledge work, we believe frontier AI has the power to transform physical work. Advances in Claude’s general capabilities, together with our Model Hardware Standard, now allow it to operate lab and manufacturing equipment such as microscopes, liquid handlers, and off-the-shelf robotic arms.”</p>
<p>In August, Anthropic publicly <a href="https://www.anthropic.com/news/model-hardware-standard-research-preview" target="_blank" rel="noopener">previewed</a> its Model Hardware Standard (MHS), which began as a collaboration between Anthropic and Howard Hughes Medical Institute (HHMI) Janelia Research Campus. Anthropic described HMS as “a shared specification for AI agents to safely operate physical devices, to a first group of scientific research labs and advanced manufacturers.”</p>
<p>“Currently in research preview, our Model Hardware Standard enables AI agents to find, understand, and safely operate lab and manufacturing equipment such as microscopes, liquid handlers, and off-the-shelf robotic arms,” Anthropic explained in its IPO filing. “Our Model Hardware Standard is model-agnostic and lets any agent harness reach devices with a programmable interface through standard protocols such as MCP.”</p>
<h4><strong>AI workbench</strong></h4>
<p>And in June, Anthropic <a href="https://www.genengnews.com/topics/artificial-intelligence/claude-science-is-here-antibiotics-designed-by-text-prompt-among-applications/" target="_blank" rel="noopener">released Claude Science</a>, an AI workbench for scientists that consolidates fragmented research tools, including more than 60 scientific databases and connectors pre-configured for genomics, proteomics, structural biology, and more, into a single reasoning layer. One Anthropic partner, Basecamp Research, has made available through Claude Science its antibiotic design and vaccine target prediction <a href="https://www.biorxiv.org/content/10.64898/2026.01.12.699009v1" target="_blank" rel="noopener">EDEN models</a> for global public health research.</p>
<p>In the IPO filing, Anthropic also summarized many—though not all—of its recent life-sci activities: “To build the best tools for the industry, we have invested in deep life sciences expertise of our own, hiring industry experts, building a molecular biology lab, acquiring Coefficient Bio, and partnering with industry leaders.”</p>
<p>Those efforts have paid off, the company said: As of September 30, 2026, Anthropic included among its customers “nine of the 10 largest” pharmaceutical companies, without disclosing their names. Those 10 are among the over 50% of the Fortune 500 that Anthropic counts among its customers with $100,000 or more of revenue on a TTM [trailing 12 months] basis. Anthropic added that every company in the Fortune 10, and more than 30% of the Forbes Global 2000 were also among its customers with $100,000+ revenue TTM.</p>
<p>Anthropic is carrying out life sciences research through a molecular biology lab and a research group <a href="https://www.genengnews.com/topics/translational-medicine/stockwatch-nektar-shares-flat-as-90m-jury-verdict-less-than-sought-in-lilly-suit/" target="_blank" rel="noopener">formed earlier this year</a> “to see whether general AI models can systematize and accelerate discoveries capable of revolutionizing biology and medicine,” the company stated last month. “Our focus is on fundamental biology research using Claude: exploring datasets of DNA to identify uncharacterized protein families, generating hypotheses at scale, and testing them through experiments in the lab.”</p>
<p>The IPO filing offered no details about how many researchers are based at the lab, and how much R&D spend the lab accounts for of Anthropic’s total research and development expense. That expense jumped more than quintupled during the first six months of this year, to $9.741 billion from $1.85 billion in January-June 2025. For all of last year, Anthropic spent a total $6.338 billion on R&D, according to the Form S-1.</p>
<p>The research lab generated worldwide headlines last month when Anthropic <a href="https://www.anthropic.com/research/claude-discovers-novel-enzyme-system" target="_blank" rel="noopener">announced</a> that its Claude large-language model “discovered a novel enzyme system with properties reminiscent of CRISPR, with only high-level direction from our scientists.”</p>
<p><a href="https://x.com/DarioAmodei/status/2102831170299834652?s=43" target="_blank" rel="noopener">Elaborating further in a post on X</a>, Anthropic CEO Dario Amodei described the novel enzyme system as “a molecular machine that we suspect could represent a new gene editing mechanism. Its precise function, biotechnological utility (if any), or level of significance is not yet clear, but at minimum it is work I would have been proud to do as a PhD student.”</p>
<h4><strong>‘Something interesting’</strong></h4>
<p>“The work was done mostly, though not entirely, by Claude: our life sciences team suggested a broad area of research, Claude read through the literature and a bunch of genome data and discovered something interesting, then Claude proposed experiments to verify the discovery and our team carried them out,” Amodei added.</p>
<p>In April, tech news outlets <em>The Information</em> and the Substack-based <em>Newcomber</em> newsletter founded by Eric Newcomber first reported that Anthropic acquired the stealth AI biotech startup Coefficient Bio for about $400 million in stock. Anthropic confirmed the acquisition though not the price in its IPO, saying it bought the company “to accelerate our research in the life sciences.”</p>
<p>Founded last year, Coefficient has developed an AI platform for purposes that include planning drug research and development, managing clinical regulatory strategy, and identifying new drug opportunities, <em>OncoDaily</em> reported. Coefficient was established by co-founders that include Nathan Frey, PhD, and Samuel Stanton, PhD, both previously with Genentech’s Prescient Design computational drug discovery unit. Another co-founder, Aris Theologis, serves as CEO and was previously chief business officer at Evozyne and a vice president at Paragon Biosciences.</p>
<p>According to the IPO filing, Anthropic finished January-June 2026 with a staggering net loss of $80.748 billion, up more than six-fold from the $12.969 billion net loss the company reported for the first six months of 2025. However, revenue leaped 14-fold to $16.286 billion in the first half of this year, from $1.163 billion in January-June 2025.</p>
<p>And Anthropic’s operating loss, defined as operating expenses exceeding revenue from core business operations, actually shrunk during the first half of 2026 to $693 million from $2.135 billion a year earlier.</p>
<p>For all of 2025, Anthropic reported a net loss of $41.965 billion, up five-fold from the $8.309 billion net loss of 2024, itself more than five times the $1.531 billion net loss of 2023.</p>
<p>Goldman Sachs and Morgan Stanley are co-leading the IPO, with participation by 20 other banks and other investment institutions.</p>
<p>The post <a href="https://www.genengnews.com/topics/artificial-intelligence/anthropic-ipo-discloses-plans-for-life-sciences-growth/">Anthropic IPO Discloses Plans for Life Sciences Growth</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>World HUPO 2026: Asia&#45;Pacific Ambition and the Road to Predictive Biology</title>
<link>https://edusehat.com/en/world-hupo-2026-asia-pacific-ambition-and-the-road-to-predictive-biology</link>
<guid>https://edusehat.com/en/world-hupo-2026-asia-pacific-ambition-and-the-road-to-predictive-biology</guid>
<description><![CDATA[ Conversations at HUPO 2026 revolved around questions that reach beyond the proteomics community: who will develop disease, why treatment fails, and whether a computational model can help us decide which experiment to run next.
The post World HUPO 2026: Asia-Pacific Ambition and the Road to Predictive Biology appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/HUPO-image-2-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 27 Oct 2026 06:45:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>World, HUPO, 2026:, Asia-Pacific, Ambition, and, the, Road, Predictive, Biology</media:keywords>
<content:encoded><![CDATA[<p>By the time the Singapore Human Proteome Organization (HUPO) congress began, streets were being closed ahead of the Formula One Grand Prix. The humidity was a considerable change from the snow outside last year’s meeting in Toronto.</p>
<p>HUPO assembled 1,428 delegates from 45 countries under the theme “Proteomics Plus: Transforming Lives.” Across the September 27–October 1 program, conversations kept returning to questions that reach beyond the proteomics community: who will develop disease, why treatment fails, and whether a computational model can help us decide which experiment to run next.</p>
<figure aria-describedby="caption-attachment-339629" class="wp-caption aligncenter"><img fetchpriority="high" decoding="async" class=" wp-image-339629" src="https://www.genengnews.com/wp-content/uploads/2026/10/HUPO-image-3-1-300x225.jpg" alt="" width="448" height="336" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/HUPO-image-3-1-300x225.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/HUPO-image-3-1-1024x768.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/HUPO-image-3-1-768x576.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/HUPO-image-3-1.jpg 1400w" sizes="(max-width: 448px) 100vw, 448px"><figcaption class="wp-caption-text">Credit: Gustav Ceder</figcaption></figure>
<p>The program itself reflected a field broadening its reach. Alongside the main scientific sessions were pre-congress workshops and training courses, short flash talks linked to poster sessions, and mentoring and networking for early-career researchers. The Early Career Researcher (ECR) program also featured manuscript, poster and three-minute thesis competitions. HUPO continued its interactive Bioinformatics Hub format, with 11 sessions spanning AI, multiomics and reproducibility. One, led by the Human Protein Atlas, explored integrating multiomics data and AI tools into its resources.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>The exhibition hall and industry-supported seminars added another dimension. Thermo Fisher Scientific and Olink shared a booth for the first time, while Illumina showcased proteomics approaches for population-scale studies. Both hosted scientific seminars. Their presence underscored how technology development, data analysis and clinical research are increasingly part of the same conversation.</p>
<h4>An invitation from China</h4>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>Fuchu He, PhD, chairman of the National Center for Protein Sciences in Beijing, set out an ambitious direction in the opening keynote. He leads the China-initiated Proteomic Navigator of the Human Body, or π-HuB, whose published roadmap envisages investment running into billions of renminbi over three decades.</p>
<p>Jing Yang, PhD, π-HuB’s secretary-general and a researcher at Guangzhou National Laboratory, described an effort to profile organs, tissues, cell types, and individuals, building a reference for how human biology changes over a lifetime.</p>
<p>The ambition is to “predict the proteomic states of each person across their lifetime,” he explained, accounting for influences including the microbiome, immune system, environment, and lifestyle. Reliable individual predictions remain a research goal.</p>
<p>“We really want to collaborate with HUPO,” Yang told <em>GEN</em>, describing discussions about extending cooperation beyond conferences and communication into science and funding.</p>
<h4>Building a cell, together</h4>
<p>Tiannan Guo, PhD, a professor at Westlake University, connected spatial proteomics and temporal perturbation proteomics with the development of AI-based virtual cell modeling. His presentation described proteomic work spanning 58 major tissue types, 251 more finely defined tissue types, and 25 carcinoma types, as well as a perturbation proteomics-based virtual cell model for triple-negative breast cancer with potential clinical benefits.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>Guo’s virtual-cell framework brings together existing biological knowledge, cellular architecture, and dynamic measurements of responses to perturbations. Models would guide experiments, and the resulting measurements would test and refine their predictions.</p>
<p>The Westlake AI Virtual Cell–Yeast, or WAY, project divides that challenge into interconnected cellular functions, including metabolism, membrane systems, and stress responses. Task-specific AI agents would work together.</p>
<p>Contributors to the published framework include researchers affiliated with ETH Zurich, Stanford University, and the University of Toronto, among others.<strong><sup> </sup></strong></p>
<h4>Cells have to cope with lunch</h4>
<p>Florian Rosenberger, PhD, a SciLifeLab fellow and assistant professor at Karolinska Institutet, gave an example of what a real cell must handle.</p>
<p>“Life is all about being able to deal with the little fluctuations,” he told <em>GEN</em>, including “being able to deal with lunch without dying instantly.”</p>
<p>His single-cell deep visual proteomics work investigates mitochondrial disease while preserving tissue context. Access to oxygen and nutrients varies between neighboring cells, as can the accumulation of mutations. Rosenberger compared the patchwork of cellular states to a Portuguese tile floor.</p>
<p>By isolating cells in different functional states and arranging them in an inferred sequence, or pseudotime, his group can investigate proteomic changes associated with deterioration. This reconstructs a possible progression rather than following the same cell through time. The aim is to distinguish responses associated with failure from those that might support resilience. Rosenberger stressed that this is early work, but understanding those responses could eventually inform research in other diseases involving mitochondrial dysfunction.</p>
<p>“What is the normal working range that a cell can have, and when does it tip over into disease?” he asked.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>Fabian Coscia, PhD, head of the spatial proteomics group at the Max Delbrück Center in Berlin, described how cancer cells can differ in their response to treatment. Rare cell populations may carry protein states associated with resistance before treatment begins; others adapt during treatment. Comparing pretreatment and post-treatment samples helps investigate both possibilities.</p>
<p>In Alzheimer’s brain tissue, his group found that neurons with visible tau pathology and neighboring cells without it did not separate neatly into affected and unaffected categories. Proteomic measurements revealed intermediate states.</p>
<p>“You have an entire trajectory of states,” Coscia said. These are precisely the distinctions a predictive model will need to capture.</p>
<h4>From tissue to accessible samples</h4>
<p>Birgit Schilling, PhD, a professor at the Buck Institute for Research on Aging, spoke with<em> GEN</em> in Toronto the previous year. This year in Singapore, she described how her laboratory was now using spatial mass spectrometry to investigate human osteoarthritis, finding localized changes in bone that bulk analysis could obscure.</p>
<p>“What I’m particularly excited about is that we took that to then bring that back to a biomarker fluid,” she said. The team is following tissue-level discoveries with biomarker work in synovial fluid, the fluid within the joint.</p>
<p>Mitchell Lai, PhD, a senior lecturer in pharmacology at the National University of Singapore, examines Alzheimer’s biomarkers in an Asian cohort with substantial cerebrovascular disease, testing their usefulness beyond the Western populations that dominated earlier studies.</p>
<p>“Now we are more interested in prognostic biomarkers,” Lai said. He wants measurements that help anticipate future dementia and cognitive impairment.</p>
<p>His work with the NULISA technology, explores brain-derived phosphorylated tau. The assays recognize both a phosphorylation site and a brain-associated splice variant, distinguishing a more specific signal within circulating tau.</p>
<p>Lai emphasized that longitudinal research requires comparable assays even when samples are collected years apart.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="7"></span></aside>
<p>Jochen Schwenk, PhD, who chaired HUPO’s Plasma Proteome Project over the past decade, noted a substantial increase in abstracts describing studies of human biofluids in large cohorts. He welcomed the trend but cautioned against drawing conclusions too early without considering findings from similar studies. He also highlighted growing interest in microsampling, which could make sample collection easier and broaden the role of proteomics in precision medicine.</p>
<p>Gabriel Mazzucchelli, PhD, head of the omics group in the University of Liège’s mass spectrometry laboratory, is exploring a different sample: sweat. His team has developed a spectral library containing around 4,000 proteins and conducted pilot work on treatment monitoring. An overnight collection patch under development could make repeated sampling possible without hospital visits.</p>
<h4>Mapping protein forms and functions</h4>
<p>The separate, closed Day of the Research Initiatives brought π-HuB, the Human Proteome Project, and the Human Proteoform Project together to discuss the field’s future.</p>
<figure aria-describedby="caption-attachment-339630" class="wp-caption alignright"><img decoding="async" class="size-medium wp-image-339630" src="https://www.genengnews.com/wp-content/uploads/2026/10/HUPO-image-1-1-300x225.jpg" alt="" width="300" height="225" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/HUPO-image-1-1-300x225.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/HUPO-image-1-1-1024x768.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/HUPO-image-1-1-768x576.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/HUPO-image-1-1.jpg 1400w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Credit: Gustav Ceder</figcaption></figure>
<p>Neil Kelleher, PhD, director of Northwestern University’s Chemistry of Life Processes Institute, described the Human Proteoform Project’s ambition as having “the genome project moment for proteins.” Representing the Consortium for Top-Down Proteomics, he proposed a reference set of intact molecular forms of proteins across human cell types and body fluids, estimating 50–100 million distinct proteoforms.</p>
<p>His presentation argued that distinguishing those forms could improve biomarker selection, patient stratification, and drug-target decisions. “It is a structural project more than a functional one.”</p>
<p>The proposed reference would require roughly 10 years and $300 million–$500 million annually, he estimated.</p>
<p>Cecilia Lindskog, PhD, an associate professor at Uppsala University and chair of HUPO’s Human Proteome Project, described the complementary challenge.</p>
<p>“We want to determine the function of every human protein,” she said, noting that fewer than a third have well-characterized, experimentally validated functions. She wants shared standards, complementary methods, and potentially shared samples and joint pilot studies to help close that gap.</p>
<p>The Human Protein Atlasintroduced a helpdesk at the congress alongside a Bioinformatics Hub session on integrating multi-omics data and AI tools.</p>
<p>Coscia described workshops bringing imaging researchers, the Human Protein Atlas, and the mass spectrometry community together around data formats and integration. He called for better protocols, interlaboratory comparisons, and metadata that make experiments reproducible. He also cautioned that exploratory spatial proteomics remains largely a discovery technology; some findings may reach clinical practice through established methods such as immunohistochemistry.</p>
<h4>Beyond the congress</h4>
<p>At the gala dinner in the Flower Dome at Gardens by the Bay, there was plenty to discuss. Singapore’s population studies, China’s international initiatives, and the clinical questions running through the conversations gave “Proteomics Plus” substance: more ways to measure biology, more people contributing, and more demanding questions about what the results mean.</p>
<p>By the next HUPO, it would be great to hear how those models performed on new data and whether candidate biomarkers held up in larger, more diverse patient cohorts. The next step is to show not just what proteomics can measure, but which experiments and clinical decisions those measurements can improve.</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/world-hupo-2026-asia-pacific-ambition-and-the-road-to-predictive-biology/">World HUPO 2026: Asia-Pacific Ambition and the Road to Predictive Biology</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Predicting Leukemia Survival May Be Aided by Six Gene Scoring System</title>
<link>https://edusehat.com/en/predicting-leukemia-survival-may-be-aided-by-six-gene-scoring-system</link>
<guid>https://edusehat.com/en/predicting-leukemia-survival-may-be-aided-by-six-gene-scoring-system</guid>
<description><![CDATA[ Researchers studying mice and human data identified a six gene signature, and developed a scorings system, that could help forecast acute myeloid leukemia patient survival, and potentially point to new therapeutic targets. 
The post Predicting Leukemia Survival May Be Aided by Six Gene Scoring System appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/05/GettyImages-1632999309.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 27 Oct 2026 03:10:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Predicting, Leukemia, Survival, May, Aided, Six, Gene, Scoring, System</media:keywords>
<content:encoded><![CDATA[<p>A study by researchers at the Centre for Genomic Regulation (CRG) has identified six different genes that can help forecast survival of patients with acute myeloid leukemia (AML), a type of cancer that has very variable outcomes between patients.</p>
<p>Headed by ICREA Research Professor Luciano Di Croce, PhD, a researcher at the CRG, the team created a scoring system by moving repeatedly between laboratory experiments with mice and patient records, crossing the two to look for genes that behaved consistently in both.</p>
<p>The investigators had initially focused on a gene called <em>PHF19</em>, which the Di Croce lab has studied for more than a decade and is thought to suppress blood cancer formation. PHF19 belongs to a family of genes that keep other genes switched off, a system that cells use as they progress along the differentiation process from immature to mature cells.</p>
<p>Through their research the team found six genes that reliably predict AML patient survival. Some genes—<em>CARMIL1, HOPX,</em> and <em>ALDH1A1</em>—were more active in patients with poor outcomes while others—<em>CALR, STAR,</em> and <em>PHF19</em>—were less active. The collective activity of all six genes, which the researchers called the PHFScore, divided patients into groups with sharply different survival prospects.</p>
<p>Findings from the study could point to new ways of helping to predict outcomes in patients with this type of blood cancer, contributing to the development of future prognostic tests, and may suggest new therapeutic targets. Patients suspected of having AML already give a bone marrow sample for laboratory analysis, and measuring six genes is simpler and cheaper than reading a broader genetic profile.</p>
<p>“<em>PHF19</em> on its own already tells us something about how patients will fare, but combining it with five other genes is a dramatic improvement which gives us more accurate information for AML prognosis,” said Di Croce.</p>
<p>Gianni Gamarra Figueroa, PhD, added, “Some of the genes have never been linked to blood cancer before and could also be potential new therapeutic targets. These genes haven’t been described in leukemia or even in how blood forms. We don’t yet know what they are doing there, which is exactly what makes them worth exploring.”</p>
<p>Di Croce is senior author and Gamarra Figueroa is first author of the team’s published paper in <em>Science Advances</em>, titled “<a href="http://dx.doi.org/10.1126/sciadv.aed6757" target="_blank" rel="noopener">Polycomb factor PHF19 affects AML initiation, patient prognosis, and survival</a>.” In their paper the authors concluded “By integrating our <em>in vitro</em> multiomic data with the molecular and clinical data from various AML datasets, we successfully identified a molecular signature—the PHFScore—to identify patient prognosis.”</p>
<p>Acute myeloid leukemia is “… a heterogeneous malignancy characterized by diverse genetic and epigenetic alterations,” the authors wrote.  Earlier work in the Di Croce’s lab showed that mice lacking the <em>PHF19</em> gene manifest a condition resembling myelodysplastic syndrome (MDS), where blood cells fail to mature properly and build up in the body without yet becoming cancerous. “We previously showed that the Polycomb-associated factor Phf19 is required for hematopoietic stem cell (HSC) maintenance and state control in mice and that its loss (Phf19<sup>KO</sup>) impairs HSC function,” the team continued.</p>
<p>“Leukemia develops in stages, as a cell gradually accumulates defects,” explained Gianni Gamarra, PhD, “Losing <em>PHF19</em> doesn’t cause leukemia on its own, but it is already a push down that road.”</p>
<p>The new study asked what happens when leukemia originates in cells that have similar starting conditions—not cancerous, but not quite healthy either. The researchers introduced a leukemia-causing gene into mouse blood cells with and without <em>PHF19</em>. Cells lacking the gene formed more colonies in the lab and, when transplanted into mice, took hold more easily. They also stayed locked in an immature, stem-cell-like state.</p>
<p>“Blood cells form a hierarchy,” added Gamarra Figueroa. “At the top are stem cells, which are still plastic and could become almost anything. As they move down, they mature and take on a fixed identity. The more a cancer holds on to that plasticity, the more malignant it tends to be.”</p>
<figure aria-describedby="caption-attachment-339826" class="wp-caption alignleft"><img fetchpriority="high" decoding="async" class="size-medium wp-image-339826" src="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_Ph19-normal-left-vs-KO-right-300x238.jpg" alt="Spleen tissue from a mouse without PHF19 (left) and a mouse with normal PHF19 function (right). Dense clusters of immune cells sit within blood-rich regions in pink. Without PHF19, cells are altered in their differentiation process " width="300" height="238" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_Ph19-normal-left-vs-KO-right-300x238.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_Ph19-normal-left-vs-KO-right.jpg 700w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Spleen tissue from a mouse without PHF19 (left) and a mouse with normal PHF19 function (right). Dense clusters of immune cells sit within blood-rich regions in pink. Without PHF19, cells are altered in their differentiation process [Gianni Gamarra/Centro de Regulación Genómica]</figcaption></figure>
<p>The plasticity made the cells harder to treat. Cells without <em>PHF19</em> largely ignored the effects of chemotherapeutic drugs which are commonly used to push leukemia cells into a mature state, one of the strategies doctors use against a disease in which cells become stuck partway through development and multiply unchecked. “<em>Phf19</em> deletion promoted acquisition of stemlike features and reduced responsiveness to differentiation-inducing AML therapies,” the team stated.</p>
<p>To check whether their mouse model reflected human disease, the researchers compared which genes were switched on and off in both the mouse cells and from data generated in human studies. The same pattern appeared in patient datasets. “Molecular and functional consequences of Phf19 loss paralleled those observed in the datasets of patients with AML,” they further noted. “Patient data from different AML datasets allowed us to determine that patients with low levels of PHF19 expression had a stemlike transcriptomic profile, which, according to the literature, is linked to more chemoresistant leukemias.”</p>
<p>Among younger adults treated for AML, those with the lowest levels of <em>PHF19</em> survived for less time than those with the highest. they were also less likely to go into remission after standard chemotherapy. Fewer than half did so, compared with up to 85% of patients with the highest levels.</p>
<p>“The patients have advanced leukemia, so we are comparing mice and humans at very different stages of the disease, yet the molecular data point in the same direction, which gives our model a great deal of strength,” said Gamarra Figueroa.</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/predicting-leukemia-survival-may-be-aided-by-six-gene-scoring-system/">Predicting Leukemia Survival May Be Aided by Six Gene Scoring System</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Overcoming Bottlenecks: Biopharma’s Big Challenge Is Execution</title>
<link>https://edusehat.com/en/overcoming-bottlenecks-biopharmas-big-challenge-is-execution</link>
<guid>https://edusehat.com/en/overcoming-bottlenecks-biopharmas-big-challenge-is-execution</guid>
<description><![CDATA[ The biggest challenge facing the biopharma industry isn’t scientific innovation. It’s manufacturing execution. Closing this gap is one of the greatest opportunities biopharma has today to enhance resilience and unlock the full value of its science.
The post Overcoming Bottlenecks: Biopharma’s Big Challenge Is Execution appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2023/07/GettyImages-1460261281.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 27 Oct 2026 03:10:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Overcoming, Bottlenecks:, Biopharma’s, Big, Challenge, Execution</media:keywords>
<content:encoded><![CDATA[<p>The biggest challenge facing the biopharma industry isn’t scientific innovation. It’s manufacturing execution.</p>
<p>That’s the opinion of Nicolas Pivet, vice president and general manager of manufacturing and digital solutions at Cytiva. Major scientific advances have enabled the development of truly amazing therapeutics such as RNA technologies and cell and gene interventions, yet manufacturing innovation hasn’t kept pace. “Our ability to manufacture these therapies reliably, repeatedly, and at scale remains a major constraint,” Pivet tells <em>GEN</em>.</p>
<figure aria-describedby="caption-attachment-339781" class="wp-caption alignright"><img decoding="async" class="size-full wp-image-339781" src="https://www.genengnews.com/wp-content/uploads/2026/10/Nicolas-Pivet-Headshot.jpg" alt="" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Nicolas-Pivet-Headshot.jpg 200w, https://www.genengnews.com/wp-content/uploads/2026/10/Nicolas-Pivet-Headshot-150x150.jpg 150w" sizes="(max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Nicolas Pivet, vice president and general manager of manufacturing and digital solutions at Cytiva. [Cytiva]</figcaption></figure>
<p>“The industry often focuses on symptoms [of biomanufacturing bottlenecks] such as paper batch records, disconnected laboratory information management systems, fragmented automation architectures, isolated enterprise resource planning deployments, or data silos. Those challenges are real, but they are not the root cause,” Pivet stresses.</p>
<p>“The deeper issue,” he says, “is that many manufacturing environments evolved over decades and were never designed as connected systems. Digital capabilities were often layered on to solve local problems rather than integrated around end-to-end manufacturing performance. The result is an environment that is increasingly data-rich but…insight-poor.”</p>
<p>In that environment, organizations can’t extract actionable insights early enough to affect outcomes. They have a visibility problem.</p>
<h4><strong>Focus on observability</strong></h4>
<p>The first step in resolving the bottlenecks is to solve specific problems.</p>
<p>“You cannot control what you cannot see,” Pivet says. He advises industry to focus first on improving observability. Gaining insights into process deviations early enables earlier intervention, which creates better decisions and improves confidence in those decisions, he explains. This is the foundation of advanced manufacturing.</p>
<p>“Then connect the data, workflows, and decisions required to improve the outcome,” Pivet advises. “Biopharma does not lack information. It lacks accessible, contextualized, and trusted information,” he says. “Connecting process, equipment, analytical, and workflow data establishes the foundation required for predictive analytics, advanced automation, digital twins, and AI.”</p>
<p>“Only after that [has occurred] should advanced control or AI-enabled decision-making become part of the discussion.”</p>
<p>Therefore, rather than starting with AI use cases—as many try—organizations should first focus on observability, and then address interconnectivity, data integrity, and maintaining operational context for those data flows. When those are resolved, AI can be added to the mix. “AI does not fix weak foundations,” he says. “It exposes them.”</p>
<h4><strong>Face organizational barriers</strong></h4>
<p>The barriers to digital transformation are more often organizational than technical. That’s because biomanufacturers consider change riskier than maintaining current practices. In 2025, “more than a third of biopharma companies were still in early exploration or had not started their digital transformation journey,” he says, underscoring his point.</p>
<p>Trust is typically the rate-limiting step, and that is established only by reliable performance. Therefore, “the organizations moving fastest are those demonstrating value on real manufacturing problems, validating outcomes, and gradually scaling successful approaches rather than attempting sweeping transformations,” Pivet observes.</p>
<p>Manufacturing equipment in the future will not just be smarter; it will be designed from the outset as elements of connected, interoperable systems that provide early visibility and easy integration into automated and connected workflows.</p>
<h4><strong>Prepare the workforce</strong></h4>
<p>“The conversation around AI often focuses on technology. The more important conversation is about people,” Pivet emphasizes.</p>
<p>Automation, agentic and generative AI, and other smart manufacturing technologies are changing roles throughout the workforce at, seemingly, warp speed. Everyone, from equipment operators, process engineers, data scientists, and quality professionals up through the executive suite, is coming to grips with new ways of working that require new skills and new ways of thinking.</p>
<p>“Data literacy, systems thinking, automation fluency, model interpretation, and cross-functional collaboration are becoming increasingly important,” Pivet points out. Consequently, people are spending less time collecting information and reacting to events, and more time interpreting data and optimizing processes.</p>
<p>The workforce, however, is still in transition. “The Global Biopharma Index reported that 29% of organizations experience severe shortages in digital and AI-related skills,” he says.</p>
<p>“Workforce readiness is one of the defining challenges of this decade,” Pivet continues. “The most successful manufacturers I encounter are not necessarily the ones deploying the most advanced technologies. They are the organizations creating confidence around new ways of working.”</p>
<p>Within five years, he predicts a plethora of hybrid roles that blend both process and digital expertise. Future titles may include digital process engineer, manufacturing data scientist, process intelligence specialist, and manufacturing systems architect, he adds.</p>
<p>Filling those new roles means preparing the workforce today. He advocates upskilling individuals enterprise-wide, ensuring the various functional teams learn together, rather than treating digital transformation as the purview of any particular group.</p>
<p>Even today, across industries, traditional learning programs are being complemented by immersive learning experiences. Biopharma will be no different, especially given its growing complexity and limited opportunities for hands-on learning in the face of good manufacturing requirements, production schedules, and equipment availability.</p>
<p>Immersive learning experiences involving mixed reality and augmented reality “allow operators, technicians, and engineers to interact with equipment and workflows, and troubleshooting scenarios in highly realistic digital environments,” he says. By accelerating learning, enhancing retention, and building confidence, workers are better prepared when they enter live manufacturing environments.</p>
<p>Eventually, Pivet says, “Immersive learning may become as important to workforce development as flight simulators became to aviation training.”</p>
<h4><strong>Ease tech transfer</strong></h4>
<p>The tech transfer process also has a major bottleneck, but it has nothing to do with technology or human factors.</p>
<p>“The most common reason transfers fail is not because process instructions are missing,” he says. “It is because process understanding fails to transfer with them. Receiving organizations often inherit process descriptions, specifications, and operating procedures, but not the context explaining why those parameters matter or how the process behaves under changing conditions.”</p>
<p>Those gaps are becoming ever more important as therapies become increasingly complex. Successful tech transfer, therefore, includes transferring process understanding. Digital twins help minimize the gap between process instructions and process understanding by enabling teams “to test assumptions virtually before testing them physically,” Pivet says, thus enhancing success. In this way, “…uncertainty is removed rather than relocated.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="7"></span></aside>
<h4><strong>Lead with digital change</strong></h4>
<p>If you can prioritize only one area for improvement, Pivet advises choosing digital infrastructure because, he explains, “people and processes increasingly depend on information. Digital infrastructure creates the conditions for successful technology transfer, effective workforce development, predictive analytics, process understanding, and operational improvement. Without trusted information flows, organizations struggle to scale knowledge, replicate success, or improve decision quality.”</p>
<p>High-quality information flows, he predicts, will be a major determinant of manufacturing competitiveness in the coming decade. “The companies best positioned to lead the next era of biomanufacturing will be those that combine AI initiatives with strong connected-data and observability foundations,” he suggests. By doing so, they will be better able to translate scientific innovation into predictable, scalable, operational performance.</p>
<p>“Biopharma does not have an imagination problem,” Pivet reiterates. “It has an execution problem. Closing that execution gap is one of the greatest opportunities our industry has to accelerate patient access, improve resilience, and unlock the full value of the science being developed today.”</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/overcoming-bottlenecks-biopharmas-big-challenge-is-execution/">Overcoming Bottlenecks: Biopharma’s Big Challenge Is Execution</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>South African Labs Strive for Africa’s Biopharma Sovereignty</title>
<link>https://edusehat.com/en/south-african-labs-strive-for-africas-biopharma-sovereignty</link>
<guid>https://edusehat.com/en/south-african-labs-strive-for-africas-biopharma-sovereignty</guid>
<description><![CDATA[ Africa still imports 99% of its routine vaccines and 70–90% of its biopharmaceuticals. The Africa CDC warns this vulnerability could cost the continent up to $1.1 trillion in skills and jobs through 2050. 
The post South African Labs Strive for Africa’s Biopharma Sovereignty appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/a-petri-dish-for-growing-micro-o.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 27 Oct 2026 03:10:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>South, African, Labs, Strive, for, Africa’s, Biopharma, Sovereignty</media:keywords>
<content:encoded><![CDATA[<p>Africa still imports 99% of its <a href="https://jogh-ep.org/article/154008-strategic-pathways-to-pharmaceutical-self-reliance-in-africa-lessons-enablers-and-opportunities" target="_blank" rel="noopener">routine vaccines</a> and 70–90% of its biopharmaceuticals. The <a href="https://africacdc.org/investment-in-health-research-and-development/#prId=372147" target="_blank" rel="noopener">Africa CDC </a> warns this vulnerability could cost the continent up to $1.1 trillion in skills and jobs through 2050.</p>
<p>This is motivating a biotech revolution building up in South Africa—the continent’s most industrialized nation where startups are confronting <a href="https://espace.enap.ca/id/eprint/423/" target="_blank" rel="noopener">“pharmaceuticals apartheid”</a>—tinkering with low-cost, decentralized biotech R&D and manufacturing prototypes.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>So much is at stake and urgent, said Nick Enslin, co-founder and COO of Immobazyme, one of the flagship South African startups that specializes in advanced biomanufacturing and precision fermentation with the goal of making affordable, high-value recombinant proteins, enzymes, and growth factors to help slash Africa’s biopharma import bill.</p>
<p>“One of the biggest things we realized as a country, but also as Africa, is that we’re importing 99% of our biologics and drugs. For the COVID-19 vaccine, we were the last group of people to get this vaccine,” he lamented. A cursory look at the South African Clinical Research Association, the equivalent of the FDA, shows they still follow the 2014 FDA guidelines, he said. “And that’s quite old,” he told <em>GEN</em>.</p>
<p>As a result, they would need to update their regulations to understand the science better, what biosimilars are, what mRNA vaccines are, and why the science is moving so fast that regulators are struggling to keep up.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>Africa has “many opportunities” to domesticate its medical biologics supply chains, but reality is daunting, said Enslin, citing a recent <a href="https://www.bloomberg.com/news/articles/2026-06-19/aspen-disruption-triggers-south-africa-contraceptive-shortage" target="_blank" rel="noopener">“disruption</a>” at Aspen—Africa’s largest generic drugs maker—which threatens an oral contraceptives shortage in South Africa.</p>
<p>Part of the reason is that GMP manufacturers of biosimilars, specifically, are far and few between on the African continent.</p>
<p>“In South Africa, we’ve only got a handful, and most of them are looking at small molecules, chemicals, and stuff like that, necessarily creating bio-biologics,” said Enslin.</p>
<h4><strong>The mission</strong></h4>
<p>The mission is clear for Immobazyme, which recently captured the limelight after raising $1.45 million in venture funding (bringing the total the company has raised to $2.9 million), which is modest by Silicon Valley standards but significant in South Africa’s limited venture finance ecosystem.</p>
<p>“Having our own GMP facility, manufacturing biosimilars for the African continent, that’s where we want to be by the end of the 2030s,” said Enslin, who is talking about “lower hanging fruit” for Africa’s biotech innovators to grab and accelerate through development and into the market.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>He added that he is referring to “nutraceuticals, cosmetics, food and beverages, and agribiotech, which are subject to lower regulation and certification than drugs and other medicines. But it’s still the same premise that the African continent is struggling with these kinds of novel products.”</p>
<p>His first patent came about when he was a student at South Africa’s Stellenbosch University, the premier South African and African research corridor in the Western Cape Province, where billionaires live adjacent to bubbling ideas in biotech, banking, and software.</p>
<p>“We realize that these enzymes, whether it’s in an industrial application or mRNA manufacturing, are relatively expensive. And you use them once, and then you can’t recover them. You can’t reuse them again even though they’re perfectly fine to reuse,” he said.</p>
<p>So, they developed a method to immobilize enzymes on a solid metal matrix, allowing substrates to pass through and undergo enzymatic reactions while the enzymes remain in place for repeated use, he explains, giving an example of lactose-free myelin oligodendrocyte glycoprotein (MOG).</p>
<p>“What they do is they immobilize lactase, which is an enzyme that breaks it down into simpler sugars. And they passed the milk over and got lactose-free milk. But the current enzyme immobilization technologies that were out there at the time were either quite expensive or they weren’t optimized for multiple different kinds of applications. So, this is where PepTrap came in,” Enslin said, referring to the proprietary, synthetic cellulose-based enzyme immobilization technology developed by Immobazyme that traps and stabilizes enzymes, allowing them to be reused cost-effectively across multiple industries.</p>
<p>Getting the science right was the easier part for Enslin and his two co-founders. Scaling the science into any kind of business “is just really tough, but scaling a biotechnology company in South Africa is even tougher. It’s capex heavy. It’s infrastructure heavy. And then every time you 10x your manufacturing capability, you have to basically buy a completely new production pipeline to meet that scale,” he said.</p>
<h4><strong>The hub</strong></h4>
<p>For decades, South African universities have been excellent at generating world-class research papers, but much of that IP stays stuck in academic journals. LaunchLab CERIBIO is a 300 m<sup>2</sup> biotechnology laboratory and business incubator at Stellenbosch University and looks to actively disrupt this “<a href="https://council.science/blog/publish-or-perish-mentality/" target="_blank" rel="noopener">publish or perish</a>” culture in South Africa. Enslin’s Immobazyme startup is one of the most successful spinouts from this incubator.</p>
<p>“It is very challenging to do commercial work in a university laboratory,” said Anita Nel, chief director of innovation and commercialization at Stellenbosch University. Hence, they have created this space to ensure that the university’s biotech spinout companies have a dedicated, shared space. They actively encourage their researchers to publish their results once CERIBIO has the opportunity to protect their inventions, as publications also bring credibility to their research. “It is more a case of patent before you publish than preventing publication at all,” she added.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>When a university researcher comes to LaunchLab CERIBIO with a breakthrough, there is a filtering method to ensure the presentation can translate into commercial success. “We perform due diligence on every new invention that is disclosed to us to make very sure that there is commercial potential, that it is novel, and to determine what the best route to market is—either a license to a company with an existing market or a new spinout company with the support of the university,” she told <em>GEN</em>.</p>
<p>The spinouts from LaunchLab CERIBIO are also supported to de-risk the ventures further and are connected to both local and global investors who can provide funding to help them progress faster. “These investors understand the deep-tech and biotech space and feel comfortable investing in this sector, without expecting the fast progress that you typically see in fintech,” she added.</p>
<h4><strong>Nod of approval</strong></h4>
<p>Immobazyne’s recent venture financing success is a riposte to critics who for a long time have argued that Africa’s biotech can’t attract this kind of liquidity. It’s a massive nod of approval, Enslin explained. “I think that’s a testament to the kinds of companies that are coming out of the African continent and that resilience and the determination. There have been some amazing success stories coming out of South Africa,” he said, pointing to South Africa’s Kapa Biosystems, which was acquired for a record $445M by Roche in 2015.</p>
<p>“It’s an affirmation that we can actually build something incredible here. I think it’s heating the ecosystem here on the ground in the Western Cape specifically. I mean, they’re calling us the Silicon Valley or the Cape Silicon Valley,” he said with humor.</p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/south-african-labs-strive-for-africas-biopharma-sovereignty/">South African Labs Strive for Africa’s Biopharma Sovereignty</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Dr. Ryan Jay, DO, Joins Optima Dermatology’s Scarborough, ME Practice</title>
<link>https://edusehat.com/en/dr-ryan-jay-do-joins-optima-dermatologys-scarborough-me-practice</link>
<guid>https://edusehat.com/en/dr-ryan-jay-do-joins-optima-dermatologys-scarborough-me-practice</guid>
<description><![CDATA[ Dr. Ryan Offers Medical, Surgical, and Cosmetic Dermatology Services for Patients of All Ages  Board-certified dermatologist Dr. Ryan Jay, DO,…
The post Dr. Ryan Jay, DO, Joins Optima Dermatology’s Scarborough, ME Practice appeared first on Optima Dermatology. ]]></description>
<enclosure url="https://optimadermatology.com/wp-content/uploads/2026/10/Blog_Meet-Ryan-Jay_4x5.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 26 Oct 2026 23:30:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Dr., Ryan, Jay, DO, Joins, Optima, Dermatology’s, Scarborough, Practice</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"><img decoding="async" width="1024" height="341" src="https://optimadermatology.com/wp-content/uploads/2026/10/Blog_Meet-Ryan-Jay_Banner-1024x341.jpg" alt="" class="wp-image-205807" srcset="https://optimadermatology.com/wp-content/uploads/2026/10/Blog_Meet-Ryan-Jay_Banner-1024x341.jpg 1024w, https://optimadermatology.com/wp-content/uploads/2026/10/Blog_Meet-Ryan-Jay_Banner-300x100.jpg 300w, https://optimadermatology.com/wp-content/uploads/2026/10/Blog_Meet-Ryan-Jay_Banner-768x256.jpg 768w, https://optimadermatology.com/wp-content/uploads/2026/10/Blog_Meet-Ryan-Jay_Banner.jpg 1200w" sizes="(max-width: 1024px) 100vw, 1024px"></figure>



<h2 class="wp-block-heading"><strong>Dr. Ryan Offers Medical, Surgical, and Cosmetic Dermatology Services for Patients of All Ages</strong> </h2>



<p class="wp-block-paragraph">Board-certified dermatologist <a href="https://optimadermatology.com/provider/ryan-jay-do" target="_blank" rel="noopener">Dr. Ryan Jay, DO</a>, is joining Optima Dermatology’s Scarborough, ME practice, where he will deliver expert skin care treatment to patients of all ages.  </p>



<p class="wp-block-paragraph">Dr. Jay treats a variety of skin conditions, including acne, eczema, psoriasis, hidradenitis suppurativa, and skin cancer, and has been providing clinical care to patients since 2016. </p>



<p class="wp-block-paragraph">After growing up in New York City, and completing his education in Columbus, Ohio, Dr. Jay settled in Portland, Maine with his partner where he is excited to join Optima Dermatology and continue serving patients with expert dermatology care.  </p>



<p class="wp-block-paragraph">In Ohio, Dr. Jay earned his Bachelor of Science in biology and Bachelor of Arts in French from Denison University in Granville, graduating magna cum laude and being inducted into Phi Beta Kappa, the oldest and most prestigious academic honor society in America. He then completed his residency in dermatology at OhioHealth Riverside Methodist Hospital, where he served as Chief Dermatology Resident and scored amongst the top of dermatology residents on board exams.  </p>



<p class="wp-block-paragraph">He went on to earn his Doctor of Osteopathic Medicine from Ohio University Heritage College of Osteopathic Medicine, where he led the top 10 percent of his class.  </p>



<p class="wp-block-paragraph">Throughout his career, Dr. Jay has contributed to numerous medical publications and has served in a variety of educational and teaching roles. He is a member of the American Academy of Dermatology, the Gay and Lesbian Dermatology Society, and the International Dermoscopy Society. </p>



<p class="wp-block-paragraph">Dr. Jay has an ongoing commitment to advancing medical education and patient care. He is passionate about giving back to the community and has served in numerous community volunteer roles.  </p>



<p class="wp-block-paragraph">We recently had the opportunity to learn more about Dr. Jay, his approach, and the path that led him to become a board-certified dermatologist. </p>



<hr class="wp-block-separator has-alpha-channel-opacity">



<h3 class="wp-block-heading"><strong>What made you decide to pursue a career in dermatology? What did the path to get there look like for you?</strong></h3>



<p class="wp-block-paragraph">My interest in dermatology started as a medical student when I first experienced a “Kodachrome Session”, in which dermatologists in training intricately described skin conditions with their unique language and listed several potential diagnoses just from looking at a photo. I had never experienced such a special skill in medicine! After further experience in the field with mentors, I loved the diversity of conditions, procedures you perform, and ages of patients you treat on a daily basis. A day in the dermatology office is never boring! The longitudinal relationships with patients and restoration of their confidence and quality of life has proven incredibly rewarding too. </p>



<p class="wp-block-paragraph">The path to becoming a dermatologist required tremendous dedication to studying, research, and procedural practice. Though I discovered my love for dermatology in the latter half of medical school, I quickly got involved with various research projects in the field and found mentors who taught me every aspect of dermatology. I then spent four amazing years in residency, where I learned dermatology from many different settings. This experience included numerous outpatient clinics, a busy resident clinic, hospital consults, and clinics and consults at one of the largest children’s hospitals in the country. Dermatology training also required learning how to diagnose everything under the microscope: dermatopathology. This field represents another unique factor I love about dermatology and sets us apart from other specialties. Now I couldn’t imagine myself doing any other career. I was fortunate to have incredible mentors in dermatology who paved the way for me, and I hope to do the same for aspiring dermatologists in the future. </p>



<h3 class="wp-block-heading"><strong>What is your favorite aspect of being a board-certified dermatologist?</strong> </h3>



<p class="wp-block-paragraph">I enjoy being able to use visual acumen and investigative skills to help diagnose and manage my patients’ skin conditions. It is such an intellectually stimulating field that always seeks to improve diagnostics and treatments with research! In addition, seeing patients develop confidence, agency, and a better quality of life as you help manage skin concerns is the most rewarding aspect of dermatology. </p>



<h3 class="wp-block-heading"><strong>What is your approach to treating your patients?</strong> </h3>



<p class="wp-block-paragraph">My approach centers around patients feeling as welcomed and comfortable as possible. Skin can be such a vulnerable topic for people, and I want to ensure that everyone feels safe expressing their concerns so they get the personalized care they need. </p>



<h3 class="wp-block-heading"><strong>What is your number one tip when it comes to taking care of your skin?</strong> </h3>



<p class="wp-block-paragraph">Daily sunscreen, a topical retinoid, and protective gloves when washing dishes (we don’t realize how much damage is done to our skin barrier from frequent hand washing!). Consistency is key too. </p>



<h3 class="wp-block-heading"><strong>What is one thing you want your patients to know about you?</strong> </h3>



<p class="wp-block-paragraph">I am a very warm and friendly person with a genuine interest in the personalized care of my patients. You will feel heard and welcomed in a way that makes you feel like you’re getting help from not only a doctor with attention to detail, but also a friend. </p>



<h3 class="wp-block-heading"><strong>What do you like to do when you are not in the office treating patients?</strong> </h3>



<p class="wp-block-paragraph">When I am not in the office, you will find me living and breathing anything related to food. My partner and I love to explore the diverse food scene of Portland and cook using local products when possible. We also love to travel around the country and world to explore other cultures, cuisines, and geographic landscapes. I try to stay active and enjoy running, playing tennis, hiking, doing peloton workouts, and exploring the water and winter activities of Maine. In terms of sports watching, we are an Arsenal F.C. household! Finally, I have rekindled my love for French (I was a French major in college and studied abroad in Aix-en-Provence) and hope to regain these language skills. </p>



<hr class="wp-block-separator has-alpha-channel-opacity">



<h2 class="wp-block-heading"><strong>What to Expect From Dr. Jay and His Team</strong> </h2>



<p class="wp-block-paragraph">Patients visiting Dr. Jay and his team at Optima Dermatology’s Scarborough practice will receive quality care backed by advanced training and experience. </p>



<p class="wp-block-paragraph">Dr. Jay is currently accepting new patients at our Scarborough, ME practice. To schedule an appointment, call 207-770-5621, or schedule an appointment <a href="https://s.odoro.com/optimaderm/" target="_blank" rel="noopener">online</a>.  </p>
<p>The post <a href="https://optimadermatology.com/2026/10/16/dr-ryan-jay-do-joins-optima-dermatologys-scarborough-me-practice">Dr. Ryan Jay, DO, Joins Optima Dermatology’s Scarborough, ME Practice</a> appeared first on <a href="https://optimadermatology.com/">Optima Dermatology</a>.</p>]]> </content:encoded>
</item>

<item>
<title>New Weyburn General Hospital prepares to welcome patients November 1</title>
<link>https://edusehat.com/en/new-weyburn-general-hospital-prepares-to-welcome-patients-november-1</link>
<guid>https://edusehat.com/en/new-weyburn-general-hospital-prepares-to-welcome-patients-november-1</guid>
<description><![CDATA[ The $134-million-plus Saskatchewan hospital project brings acute care, mental health services and emergency treatment together under one roof. The new Weyburn General Hospital in southeastern Saskatchewan is preparing to welcome its first patients on November 1, following an official grand opening ceremony held October 23. The modern healthcare facility will provide expanded services for residents […]
The post New Weyburn General Hospital prepares to welcome patients November 1 appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/Bright-Modern-Hospital-Room.png" length="49398" type="image/jpeg"/>
<pubDate>Mon, 26 Oct 2026 23:25:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>New, Weyburn, General, Hospital, prepares, welcome, patients, November</media:keywords>
<content:encoded><![CDATA[<p><em>The $134-million-plus Saskatchewan hospital project brings acute care, mental health services and emergency treatment together under one roof.</em></p>
<p>The new Weyburn General Hospital in southeastern Saskatchewan is preparing to welcome its first patients on November 1, following an official grand opening ceremony held October 23.</p>
<p>The modern healthcare facility will provide expanded services for residents of Weyburn and surrounding communities, with 25 private acute care rooms and 10 inpatient mental health beds. Each acute care room includes a ceiling lift and an accessible washroom designed to improve patient comfort and safety.</p>
<h3>Expanded emergency and surgical services</h3>
<p>The hospital features a larger emergency department with dedicated trauma care spaces, an advanced operating theatre, upgraded laboratory and medical imaging facilities, and expanded ambulatory and allied health services.</p>
<p>An onsite Emergency Medical Services base and heliport will also support emergency response and transfers of critically ill or injured patients requiring specialized treatment.</p>
<p>By bringing services together in one location, the Saskatchewan Health Authority aims to improve coordination among healthcare professionals while reducing the need for patients to travel between facilities.</p>
<h3>Major investment in regional healthcare</h3>
<p>The Government of Saskatchewan committed more than $134 million toward the hospital project, with additional funding for equipment, furnishings and capital costs provided through community donations and the Weyburn and District Hospital Foundation.</p>
<p>The new facility was designed to support the region’s healthcare needs while providing modern working environments for physicians, nurses and other healthcare professionals.</p>
<p>The hospital’s opening represents an important investment in rural and regional healthcare infrastructure, where access to specialized services and emergency treatment remains a priority.</p>
<p>With the official ceremony complete, healthcare teams are preparing for the transition to the new building ahead of its November 1 opening to patients.</p>
<p><strong>Source:</strong> <a href="https://www.saskatchewan.ca/government/news-and-media/2026/october/23/new-weyburn-general-hospital-celebrates-grand-opening">Government of Saskatchewan</a>, October 23, 2026.</p>
<p>The post <a href="https://www.hospitalnews.com/new-weyburn-general-hospital-prepares-to-welcome-patients-november-1/">New Weyburn General Hospital prepares to welcome patients November 1</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>StockWatch: Investment Banker Talks U.S.&#45;Chinese Deals, IPOs, and a Tough Climate for Startups Seeking Capital</title>
<link>https://edusehat.com/en/stockwatch-investment-banker-talks-us-chinese-deals-ipos-and-a-tough-climate-for-startups-seeking-capital</link>
<guid>https://edusehat.com/en/stockwatch-investment-banker-talks-us-chinese-deals-ipos-and-a-tough-climate-for-startups-seeking-capital</guid>
<description><![CDATA[ Geoff Meyerson addressed the growth of U.S.-Chinese licensing/collaboration deals, the recent growth of IPOs, and the still-chilly climate for startups seeking financing in a recent interview with GEN Edge.
The post StockWatch: Investment Banker Talks U.S.-Chinese Deals, IPOs, and a Tough Climate for Startups Seeking Capital appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/A-List_GettyImages2-1401171512-1024x682-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 26 Oct 2026 08:30:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>StockWatch:, Investment, Banker, Talks, U.S.-Chinese, Deals, IPOs, and, Tough, Climate, for, Startups, Seeking, Capital</media:keywords>
<content:encoded><![CDATA[<p>Barring something cataclysmic over the next two months, it’s fair to say 2026 has been the year biotech stocks have shaken off the post-COVID doldrums. The largest electronic transfer fund by total assets, the $11 billion <strong>iShares Biotechnology ETF (Nasdaq: IBB)</strong> <span><strong>soared 34%</strong></span> over the 12 months ending Friday, from $154.58 to $207.74, while the second-largest ETF, the $10.6 billion <strong>State Street SPDR S&P Biotech ETF (NYSE Arca: XBI), <span>leaped 39%</span></strong> from $107.56 to $149.54.</p>
<p>That bounceback helps explain the surge in initial public offerings (IPOs) this year vs. 2025–27 offerings totaling $7.776 billion, up a sizzling 573% from $1.155 billion in 11 offerings in all of 2025. During the third quarter, nine IPOs totaling $2.4 billion reached Wall Street, the largest number in five years, according to investment bank Locust Walk.</p>
<figure aria-describedby="caption-attachment-339794" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="size-medium wp-image-339794" src="https://www.genengnews.com/wp-content/uploads/2026/10/Geoff-Meyerson-Locust-Walk-And-Banyan-BioInnovations-CROP11111-RESIZE3663-300x277.jpg" alt="" width="300" height="277" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Geoff-Meyerson-Locust-Walk-And-Banyan-BioInnovations-CROP11111-RESIZE3663-300x277.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Geoff-Meyerson-Locust-Walk-And-Banyan-BioInnovations-CROP11111-RESIZE3663-1024x945.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/Geoff-Meyerson-Locust-Walk-And-Banyan-BioInnovations-CROP11111-RESIZE3663-768x708.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/Geoff-Meyerson-Locust-Walk-And-Banyan-BioInnovations-CROP11111-RESIZE3663-1536x1417.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2026/10/Geoff-Meyerson-Locust-Walk-And-Banyan-BioInnovations-CROP11111-RESIZE3663-2048x1889.jpg 2048w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Geoff Meyerson is CEO and co-founder of the investment bank Locust Walk. He is also co-founder and CEO of investment firm Banyan BioInnovations.</figcaption></figure>
<p>“Yes, we’ve absolutely had a comeback year,” declared Geoff Meyerson, CEO and co-founder of the investment bank Locust Walk. He is also co-founder and CEO of Banyan BioInnovations, an investment firm launched in May to nurture startups by identifying best-in-class or first-in-class clinical-stage assets, forming new companies, or “NewCos,” around them, then providing experienced, centralized support to help them accelerate drug development.</p>
<p>In its recently released 2026 Q3 Market Conditions Report, Locust Walk tracked measures showing growing strength yet continuing challenges for biotech companies during the third quarter:</p>
<ul>
<li><strong>Global licensing deals</strong> fell to a two-year low of about $48 billion in 41 transactions, from $71.5 billion in 43 transactions during Q2, with the average deal declining to $1.171 billion from $1.662 billion as deals focused more on clinical-stage assets than milestone-heavy discovery/preclinical assets.</li>
<li><strong>China leads in licensing, </strong>accounting for 58% of 2026 value through Q3, up from 48% a year ago, while the United States placed second at 26%. Europe and the United Kingdom slipped to 8%.</li>
<li><strong>Mergers and acquisitions (M&A) </strong>totaled $42.1 billion in 30 transactions, down from a three-year high of $80.7 billion in 35 transactions during Q2. However, total M&A value of $173 billion during Q1–Q3 2026 is already larger than all of 2025.</li>
<li><strong>PIPE (private investment in public equity)</strong> activity grew to $3.808 billion across 14 deals, well over the $603 million of Q2 and $1.151 billion of Q3 2025.</li>
</ul>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>Meyerson addressed the growth of U.S.-Chinese licensing/collaboration deals, the recent growth of IPOs, and the still-chilly climate for startups seeking financing in a recent interview with <em>GEN Edge </em>(edited for length and clarity).</p>
<p><strong><span><em>GEN</em> <em>Edge</em>:</span> Public stock markets and private VC markets have shown strength this year, yet we’re seeing plenty of companies avoid them through licensing and collaboration deals, many reaching multiple billions of dollars. Why have licensing-collaboration deals continued to grow despite improving markets?</strong></p>
<p><strong>Geoff Meyerson:</strong> It’s a good question. It’s a complicated answer. In the United States, most licensing deals are early-stage discovery and preclinical. It’s rare to do a clinical stage license in the United States, because typically, if you want to get access to U.S. rights as a pharma company, you have to buy the company. In the United States, companies won’t do a license unless it’s a non-core asset. That’s why the M&A statistics show that 91% of total deal value was for U.S.-headquartered companies. The difference, though, is where global licensing deals are derived from: 58% of the total value is coming from China, compared to 26% from the United States.</p>
<p><strong><span><em>GEN Edge:</em></span> Why?</strong></p>
<p><strong>Meyerson:</strong> Because for Chinese companies, the Hong Kong markets have effectively shut down. That was a very popular route last year to raise capital. Now, because of red chip and other policies, it’s becoming significantly harder to raise capital in Hong Kong, and a lot of Chinese companies are in line, and the government makes the decision as to whether or not a company can go public.</p>
<p>If you also look at the M&A statistics out of China, approximately 1% of the total deal value is from M&A. If you can’t get liquidity as an investor via going public, and you can’t get an exit via M&A, how else can you either support your company or potentially return capital to the shareholders? The only other option that I’m aware of is licensing. The licensing deals have become the lifeblood and the source of revenue or capital for Chinese companies. That’s why that trend is so material.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>In many cases, you can even return the capital to your investors from a license, which in the United States would be double taxed, highly inefficient; that’s why you don’t see a lot of that happening in the United States. The difference also is that the upfronts in China are typically lower as a percentage of the total deal value compared to the United States, because in China, optics matter more. In the United States, the share of the expected net present value matters more. The Chinese companies don’t value the royalties as much. They value very large milestones that in many cases will never be achieved, so that inflates the total deal value number, and that’s one of the reasons why the number is so skewed in China’s favor.</p>
<p><strong><span><em>GEN Edge:</em></span> How concerned are you about Washington, both the Trump administration and Congress, tightening the rules for U.S.-Chinese collaborations?</strong></p>
<p><strong>Meyerson:</strong> It’s an interesting question and interesting timing for it, because [on October 16], the Chinese government made a major proclamation about <a href="https://www.jdsupra.com/legalnews/china-proposes-new-restrictions-on-5034995/">not being able to transfer certain technology platforms outside of China</a>. There’s just as much, if not more, risk in the actions of the Chinese government compared to the U.S. government. In China, one-party rule can make a decision, and it happens. In the United States, you need Congress, you need legislation. Yes, there could be executive orders, but it’s not the same force and permanence. So, there’s definitely geopolitical risk.</p>
<p>My instinct is that it’s not going to be something that is going to be shut down, ever. There will always be a way around it. I’m not going to cover that here, but all kinds of strategies can be deployed to minimize some of the regulatory barriers. Undoubtedly, it’s going to get harder before it gets easier, and it’s going to be driven by both governments, not just the United States.</p>
<p><strong><em><span>GEN Edge:</span> </em>What effect has the growth in U.S.-Chinese licensing collaborations had on the market and public company stocks?</strong></p>
<p><strong>Meyerson:</strong> I think the U.S. companies that don’t know their competitive set out of China run the risk of having their technology being surpassed from a data perspective. And what’s changed is a lot of U.S. companies have decided not to publish their early-stage pipeline, they’re not publishing patents early. They’re waiting till the last minute, because as soon as that patent is filed, 18 months later it publishes. And the second it publishes, tons of AI bots are circling, figuring that out, and within a week or two, you can design chemical matter or biology around it.</p>
<p>I’m not so sure that market capitalization of the companies is being impacted, but I do think that whenever there’s positive data in the United States, that spurs lots of Chinese companies to push harder. If there’s positive data in China, and that can be read through to the United States, it’s just like any competitor announcing data can impact the stock price of your drug if it’s in the same class, if you haven’t fully differentiated from everyone else. Is it a class effect? Or is it something that is unique to a specific drug? I don’t know if there are direct impacts of all this competition, other than data emerging that, just like any other data coming out in a class and having an impact.</p>
<p><strong><span><em>GEN Edge:</em></span> This year has seen one pause in biotech IPO activity just after the Iran war started, after Generate Biomedicines went public. The markets heated up again in the spring through summer, but have held back in recent weeks. How much of that is investors and others waiting to see what Anthropic does with their IPO, or are there other reasons for the pause lately?</strong></p>
<p><strong>Meyerson:</strong> My guess is that the recent swoon with the specialists has really caused an issue. That’s number one. And number two, with the inflation print and the increase in rates on long-dated treasuries, that has a real negative impact on biotech. My instinct is, the markets will recover for the specialists. Who knows how long the rates will be higher on the long-dated bonds, but I think it will be coming back. I don’t think the cycle is over.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p><strong><span><em>GEN Edge:</em></span> What effect is Anthropic’s IPO having on AI-focused biotech IPOs?</strong></p>
<p><strong>Meyerson:</strong> I’m not so sure AI biotech IPOs are actually meaningful, because at the end of the day most drugs—probably more than half of the drugs now were discovered using AI. And 99.5% of all drug spend happens after you have a lead candidate. AI has an impact, but not nearly as much of an impact at that point compared to the early discovery. You’ve still got to put a drug in a human and test it, and that’s not something AI can accelerate. I think AI’s impact on biotech will be certainly felt, but not nearly as much as, obviously, an AI company that’s been transformational.</p>
<p>As it relates to Anthropic, I don’t think that people are in biotech are really focused on that, to be honest. If anything, once Anthropic and OpenAI get public, that will be a lot of capital unlocked at LPs [limited partnerships] that could potentially recycle that into other funds. If anything, I think it’s going to be a huge boon to tech and biotech to have huge values  of money, or quantums of capital, being recycled in the ecosystem.</p>
<p><strong><span><em>GEN Edge:</em></span> Is that because Anthropic has made moves in recent months to position itself as a life-sci research and development company? </strong></p>
<p><strong>Meyerson:</strong> Yes, they’re going to dabble. But at the end of the day, it’s just like Google, when they started playing life sciences. They’ve got to either be selling tools to those that are developing, or they’ve got to be developing [drugs] themselves. There’s no way around it. You’re doing one or the other. If they’re just selling technology to other people, that’s fine, that’s a SaaS [software-as-a-service] model. If they’re actually developing drugs and putting molecules in patients, they’re not going to have an advantage from an AI perspective. Maybe they can recruit patients a little faster, maybe they can streamline some of the results.</p>
<p>But the reality is, you still need to wait for disease course to play out, and you have to have patients and doctors, and all these things that they have zero experience with. So, they’re going to have to build a pharma company if that’s what they really want to do. I’m not convinced Anthropic or any of these AI companies are going to build pharmas. And if they do, they’ll probably spin it off into a separate company, because it’s not going to grow nearly as fast, it’ll be a drag on their growth. My guess is they’re going to be a drug discovery engine, and they’ll license stuff out, which is fine, but that’s still relatively low value.</p>
<p><strong><span><em>GEN Edge:</em></span> What has been driving PIPE activity, and what companies are more likely to go that route for going public?</strong></p>
<p><strong>Meyerson:</strong> The rationale for a PIPE is manyfold. One, there’s been many more reverse mergers that have taken place as a viable normalized way of getting public. If, let’s say, there were 20 IPOs at one point this year, there were 20 reverses, which means, really, 40 companies got public, not 20, but those 20 that got public via reverse all needed a PIPE to complete that. A lot of the PIPEs are from reverse mergers. With quality investors, the aftermarket performance of PIPEs has actually also outperformed that of the IPOs. So, there’s a feeling that you can get a better deal in a PIPE than an IPO or a secondary [offering], and as a result that’s driving people to want to participate.</p>
<p>Then the question is, which companies would want to do a PIPE if you can get a better deal as a secondary? The answer is nobody. Why would you want to do a pipe at a lower price if you can get a better deal as a secondary offering? I think the difference is, for companies where it’s not clear how their data is going to be reacted to by the market, you can lock in the money and not take the price action risk, versus someone who is confident the market’s gonna love the data, you can probably roll the dice, release your data, and then, then do the secondary on the heels of that data release.</p>
<p>We’ve seen times where people came out with data that they thought would be great, and the market hated it, and the stock went down, and then they couldn’t raise capital. So, there is some certainty and some value in doing a PIPE to have the certainty of raising the money, even if it’s potentially at a lower price than you’d have been able to get if you released the data first.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="7"></span></aside>
<p><strong><span><em>GEN Edge:</em></span> The report also tracked 46 venture financing deals in North America during the third quarter, down from 55 in Q2 but above the 38 of Q3 2025. The average deal size has grown to $96 million from $83 million in Q2 and $75 million in Q3 2025, with most deals concentrated in Series B, rounds. Doesn’t this confirm what startups have long been complaining about, that they find it hard to raise capital for Series A in earlier rounds?</strong></p>
<p><strong>Meyerson:</strong> Yes. I tend to differentiate between Series A, Series B, versus stage of development, because Banyan Bio is starting companies that are Phase II companies through a Series A round. I would think about it’s probably more driven by stage of development than round of financing. Raising money for discovery slash preclinical drugs, drug companies, is really hard. And most of it is going to clinical stage and beyond, which is really saying the market has changed, fundamentally, from 2020, 2021, where if you had a clinical stage drug, you were probably not gonna raise money, because everyone was focused on high-science white space platforms, really sexy iPSCs, and all the different, technologies.</p>
<p>I think what people are saying is that a startup needs to be incubated longer in academia and only spin it out when you have a full development candidate, or later, if not already an IND on file. One of the reasons you’re seeing a lot of NewCos out of China with clinical or late preclinical assets is, you’re able to in-license it for cheaper than what you would have done to develop it yourself on your own. I think that’s the arbitrage out of China that a lot of these investors are seeing. So, yes, it’s a tale of two cities. If you’re doing early discovery high science it’s a very tough spot in the market.</p>
<p><strong><span><em>GEN Edge:</em></span> Will that, in turn, compel some of these companies to try going public instead?</strong></p>
<p><strong>Meyerson:</strong> Yes, but the public market wants clinical data also. It doesn’t value preclinical companies very highly, so you can do it, but you’d better be a really great team, with great investors, and a highly promising story in a very interesting area. Ordinarily, that’s going to be very hard to do.</p>
<p><strong><span><em>GEN Edge:</em> </span>Where are startups looking as alternatives to traditional VC, as a result?</strong></p>
<p><strong>Meyerson:</strong> Family offices have been a big ask, but they’re not stupid either. The more a family office looks like an institutional investor, the more the answer’s going to look like it. So, disease foundations or families that have family members with a particular disease is generally an interesting way of attracting capital. The challenge is, without having them raise their hands, that they have a kid, or a family member, or a parent with that disease, it’s very hard to find them.</p>
<p>That’s where the disease foundations often do a very nice job, and if you partner with them, that can be an interesting approach. Some of the universities are actually investing in their own spinoffs to get to a point where they can create more value. But candidly, we used to play in that space, and we don’t anymore because of the challenge of getting funding.</p>
<p><strong><span><em>GEN Edge:</em></span> On the VC side, biologics’ share of financing value has continued to grow. What biologics are investors drawing toward, and what indications? Is it still cancer, maybe immunology, or has recent success brought neuro on the map?</strong></p>
<p><strong>Meyerson:</strong> Cancer and immunology are always going to be the two biggest, as a general rule, but, CNS is definitely doing okay. They’re the big three. I’m kind of surprised that rare disease has not had the same receptivity that it used to have. I think people are focused on larger markets, larger opportunities, because that’s where pharma is focused. I would say probably the most value to be found is in rare disease or smaller opportunities that could still be meaningful, just not mega-blockbuster.</p>
<p><strong><span><em>GEN Edge:</em></span> Looking ahead, what does the fourth quarter hold? Can you offer a preliminary look at what 2027 will hold for the markets?</strong></p>
<p><strong>Meyerson:</strong> Obviously, people are on hold until the midterm elections. I think once there’s clarity around what the balance of power is going to be, I think that will help. The hope is that there’ll be some bipartisan legislation aimed at improving the efficiency of the American drug development system. That’s something that I’m certainly supportive of and a champion of.</p>
<p>I’m not someone who’s going to tear down China to build up the United States. I think the United States should compete with China; I think that’s the right approach. I think that there will be, hopefully, some optimism to get some stuff done in ‘27. If that happens, I think the markets will continue apace.</p>
<p>It’s hard to tell: Does the interest rate continue to go up? If it goes up, I think we’re going to see a more challenging biotech ecosystem. Pharma has not gotten out from their patent cliffs. In fact, that’s a feature, not a bug. Every pharma, by definition, has a patent cliff they have to go through. The question is when and how much. So, there’s a built-in buying mechanism.</p>
<p>China’s not going away. There’s risk there with regulation on both sides, but fundamentally, I’m an optimist. I’m bullish on the industry, mid- to long-term. It’s very hard to predict one quarter to the next, for sure. But I don’t think the cycle has already played out. We only really started in earnest doing well a year ago. So, after four years of painful time, I don’t believe that we’re only going to have one year of a window, and then it shuts down again. I think the industry’s too large and too robust for that to happen.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/stockwatch-investment-banker-talks-u-s-chinese-deals-ipos-and-a-tough-climate-for-startups-seeking-capital/">StockWatch: Investment Banker Talks U.S.-Chinese Deals, IPOs, and a Tough Climate for Startups Seeking Capital</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Multiomic Study of MSS CRC Identifies Vulnerabilities Pointing to Therapeutic Possibilities</title>
<link>https://edusehat.com/en/multiomic-study-of-mss-crc-identifies-vulnerabilities-pointing-to-therapeutic-possibilities</link>
<guid>https://edusehat.com/en/multiomic-study-of-mss-crc-identifies-vulnerabilities-pointing-to-therapeutic-possibilities</guid>
<description><![CDATA[ Researchers analyzed mulitomic and clinical data from 2000 colorectal cancer samples and used an AI tool, iPhenMap, to help identify cancer cell vulnerabilities and drug combinations that could be used to treat MSS CRC.
The post Multiomic Study of MSS CRC Identifies Vulnerabilities Pointing to Therapeutic Possibilities appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/09/GettyImages-683401718.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 24 Oct 2026 02:20:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Multiomic, Study, MSS, CRC, Identifies, Vulnerabilities, Pointing, Therapeutic, Possibilities</media:keywords>
<content:encoded><![CDATA[<p>An international study headed by scientists at RCSI University of Medicine and Health Sciences, and The Institute of Cancer Research, London, has identified potential new ways to treat microsatellite stable (MSS) colorectal cancer (CRC). The team integrated multiomic, single-cell, and clinical data from around 2,000 CRC tumors and developed an AI tool, iPhenMap, to create biological tumor maps.</p>
<p>The study uncovered vulnerabilities in these tumors and identified the drug combinations—including drugs already approved to treat other tumor types—that <em>in vivo</em> experiments in models indicated could be used to target CRC, potentially enabling more effective treatments. The researchers suggest that their results provide a clear roadmap for repurposing existing drugs and for new drug development to create more effective, personalized treatments for patients who currently have limited options.</p>
<p>Research co-lead Professor Annette Byrne, PhD, head of the RCSI Precision Cancer Medicine Group, Department of Physiology and Medical Physics, said “Patients with MSS RAS-mutant metastatic colorectal cancer urgently need better treatment options, particularly when their disease no longer responds to standard therapy. While these findings remain preclinical, they highlight promising therapeutic opportunities and provide a strong foundation for further development. The next step will be to identify the biological features that predict response and determine how these approaches can be advanced safely towards clinical evaluation.”</p>
<p>Professor Byrne is co-senior and co-corresponding author of the team’s published paper in <em>Cancer Cell</em>, titled “<a href="http://dx.doi.org/10.1016/j.ccell.2026.09.014" target="_blank" rel="noopener">Multiomic characterization of microsatellite-stable colorectal cancer reveals distinct biology and targetable vulnerabilities</a>.” In their report the researchers concluded, “Collectively, the results present a rich resource for the CRC research community and provide evidence for combinatorial treatment approaches with translational potential.”</p>
<p>Microsatellite stable colorectal cancer accounts for 80-85% of the 2,500 new bowel cancer cases diagnosed annually in Ireland, but remains challenging to treat, with limited response to many newer therapies. “Between 40% and 50% of these cases harbor mutations in the retrovirus-associated sequences (RAS) gene superfamily, 8–10 with RAS-mutant (RAS-mt) patients consistently displaying inferior outcomes compared with their RAS-wild-type (RAS-wt) counterparts,” the authors wrote.</p>
<p>Trials combining chemotherapy with newer targeted drugs or immunotherapies have delivered only modest improvements over current standard treatments. As the authors further pointed out, “As MSS CRC patient survival in particular has not significantly improved in recent decades, a concerted effort to unravel disease complexity is warranted.” And integrated analyses of multiomics datasets could provide key insights, they suggested.</p>
<p>Using 2,000 patient tumor samples—including more than 300 MSS CRCs that had not previously been profiled—the researchers analyzed genetic, metabolic protein, and clinical data with the help of artificial intelligence (AI) tools, revealing previously unrecognized ways in which the cancer cells divide, grow, adapt and interact with their environment. “To our knowledge, no study to date has presented a global integration of bulk genomics, epigenomics, proteomics, and metabolomics with single-nucleus/single-cell RNA sequencing (sn/scRNA-seq) and clinical parameters (phenome) in the MSS CRC setting,” they stated in their paper.</p>
<p>To do this the team developed a machine-learning AI tool called iPhenMap, which can create a biological map of the tumor. Using this map, they were able to spot connections between the different elements of the tumor—such as the genetic and metabolic features—that have been missed in previous studies that looked at the data in isolation.</p>
<p>Importantly, they found previously unidentified vulnerabilities in the tumors. They then tested these vulnerabilities in laboratory models and showed that certain drug combinations could work well to target them and treat the cancer. For example, the targeted drug trametinib—approved to treat various cancers including melanoma, lung cancer, and thyroid cancer, with a specific mutation—was shown to significantly reduce tumor growth and extend survival in the laboratory models when combined with other drugs.</p>
<p>The researchers hope this work will accelerate the path to clinical testing of new treatment strategies for colorectal cancer using drugs which have already been developed and approved. In addition, the team believe their AI approach could be used to identify more effective drugs for other tumor types.</p>
<p>In their paper the investigators wrote, “In conclusion, the in-depth molecular characterization of MSS CRC has revealed biological insights and promising therapeutic opportunities. By seamlessly integrating genomic, epigenomic, proteomic, metabolomic, and snRNA-seq/scRNA-seq expression analyses, we have substantially advanced understanding of the disease’s complex and heterogeneous biology and in parallel have identified promising new contexts of vulnerabilities with further translational potential.” Given what the team describes as “… the dearth of available effective treatments for MSS CRC patients …” the newly identified vulnerabilities may represent “the foundation for precision oncology treatment frameworks aimed at improving outcomes in this intractable disease setting.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>Research co-lead and co-senior author Professor Anguraj Sadanandam, PhD, group leader, Systems and Precision Cancer Medicine Group, The Institute of Cancer Research, London, said, “A major strength of this research is the scale and diversity of the dataset, which was only possible through collaboration with European partners. By bringing together data from patients across multiple countries and integrating DNA, RNA, epigenetic, protein, metabolic, single-cell and clinical data at this scale, we were able to expose connections between tumor biology and therapeutic dependency that would otherwise be missed. AI and machine learning will increasingly help cancer researchers to bring these complex data together, not just to classify tumors, but to understand how they behave, identify their vulnerabilities and guide the development and repurposing of treatments, so that patients can live longer and healthier lives.”</p>
<p>Rodrigo Dienstmann, PhD, Vall d’Hebron Institute of Oncology, Barcelona and University of Vic–Central University of Catalonia was co-senior author of the study.</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/multiomic-study-of-mss-crc-identifies-vulnerabilities-pointing-to-therapeutic-possibilities/">Multiomic Study of MSS CRC Identifies Vulnerabilities Pointing to Therapeutic Possibilities</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Wirelessly Powered Electronic Implant, ECHO, Enables Drug&#45;Free Management of ‘Diabesity’</title>
<link>https://edusehat.com/en/wirelessly-powered-electronic-implant-echo-enables-drug-free-management-of-diabesity</link>
<guid>https://edusehat.com/en/wirelessly-powered-electronic-implant-echo-enables-drug-free-management-of-diabesity</guid>
<description><![CDATA[ Researchers developed an implantable, wirelessly powered electronic device, ECHO, that uses electrocatalysis to remove excess glucose from the bloodstream on demand, and could offer a drug-free approach to managing obesity and type 2 diabetes (T2D). 
The post Wirelessly Powered Electronic Implant, ECHO, Enables Drug-Free Management of ‘Diabesity’ appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/07/GettyImages-2174865889.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 24 Oct 2026 02:20:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Wirelessly, Powered, Electronic, Implant, ECHO, Enables, Drug-Free, Management, ‘Diabesity’</media:keywords>
<content:encoded><![CDATA[<p>Researchers at ETH Zürich, the University of Lyon, and the University of Basel have developed an implantable, wirelessly powered electronic device, known as ECHO, (electrocatalytic closed-loop health optimization)  that could offer a drug-free approach to managing obesity and type 2 diabetes (T2D). These two interlinked metabolic disorders often coexist—as “diabesity”—affecting billions of people worldwide.</p>
<p>The team’s implantable device uses electrocatalysis to remove excess glucose from the bloodstream on demand. Tested in a diabesity mouse model, the device was coupled to a continuous glucose monitor (CGM) via a smartphone, enabling autonomous closed-loop metabolic control, such that the electrocatalyst was only activated when glucose levels exceeded a predefined threshold. The results showed that the device rapidly restored elevated blood glucose level to the normal range, with repeated treatments maintaining glucose control for weeks, without any drug use. Lowering glucose also shifted whole-body metabolism toward the use of stored fat, so treated mice also demonstrated reduced body weight.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>Research lead Martin Fussenegger, PhD, a professor at the Department of Biosystems Science and Engineering, ETH Zürich, is senior and corresponding author of the team’s published paper in <em>Science Advances</em>, titled “<a href="https://doi.org/10.1126/science.ady8560" target="_blank" rel="noopener">Wireless electrocatalytic closed-loop system for drug-free management of diabesity</a>.” In their report the team wrote in summary, “We believe that closed-loop electrocatalytic devices could establish a platform concept for regulating disease-relevant metabolites, offering a potential route toward drug-sparing, dynamically controlled metabolic interventions.”</p>
<p>Obesity and diabetes are closely interconnected metabolic disorders that reinforce one another through complex hormonal, inflammatory, and energy-regulation processes, together contributing to the global rise of diabesity. “The physiological relationship between obesity and diabetes is bidirectional and self-reinforcing, involving a complex interplay of metabolic, hormonal, and inflammatory changes,” the authors explained. Existing treatments rely heavily on long-term medication and lifestyle changes, while current glucose-monitoring and insulin-delivery systems face limitations in accuracy, reliability, personalization, and cost. “Current treatments rely largely on drugs that lower blood glucose or body weight, but these therapies can produce side effects, require lifelong administration, and may lose effectiveness over time,” the authors continued.</p>
<p>Emerging approaches, including engineered therapeutic cells and drugs that target both weight and blood glucose, offer promise but remain constrained by concerns of side effects, safety, and affordability. Another emerging strategy involves electrocatalysis, which uses electrode surfaces to drive chemical reactions that convert glucose into other compounds. “A subcutaneous implant containing a solid electrocatalyst that directly removes excess glucose from the bloodstream at an electrically adjustable rate could provide a dose-controllable, drug-free therapeutic alternative.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>Using electrocatalysis, Debasis Maity and colleagues developed the implantable ECHO device. The wirelessly powered device uses a platinum (Pt)-decorated gold (Au) nanoclusters embedded in a porous, conductive graphite felt (GF) matrix. The electrocatalyst converts circulating glucose into gluconate, which can be excreted through the kidneys.</p>
<p>Connected via smartphone to a continuous glucose monitor, ECHO automatically activates when blood sugar exceeds a predetermined threshold, enabling targeted glucose removal without the need for external insulin or medication.</p>
<p>In a proof-of-concept study in obese mice with type 2 diabetes, the authors showed that wireless activation of the device at low power (0.75 volts and 10 milliamperes) restored normal blood glucose levels within an hour, and shifted the body’s energy use from glucose toward fat. Over six weeks of treatment the mice experienced reductions in body weight and triglyceride levels, alongside increases in circulating free fatty acids and ketone bodies. These changes occurred without detectable episodes of low blood sugar or adverse effects on physiological function, inflammation, or behavior.</p>
<p>“The CGM system tracked glucose concentrations and transmitted the data to a smartphone, which processed the data and sent instructions back to the ECHO device, which in turn rapidly adjusted glucose concentrations to maintain homeostasis in response—achieving this without hypoglycemic episodes or the need for small-molecule drugs or biopharmaceuticals,” the authors wrote.</p>
<p>In a related <a href="https://doi.org/10.1126/science.aem0762" target="_blank" rel="noopener">perspective</a>, William Bentley, PhD, and Gregory Payne, PhD, at the Fischell Department of Bioengineering, University of Maryland, wrote, “Existing bioelectronics devices provide notable access to the nervous and neuromuscular systems … future electronic intervention devices might help to manage diseases other than diabetes, modulate human-microbiome interactions, or maintain redox homeostasis in stress conditions, among many other applications.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/wirelessly-powered-electronic-implant-echo-enables-drug-free-management-of-diabesity/">Wirelessly Powered Electronic Implant, ECHO, Enables Drug-Free Management of ‘Diabesity’</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>PACE: Patient featured in ‘Fight of Our Lives’ shares her story</title>
<link>https://edusehat.com/en/pace-patient-featured-in-fight-of-our-lives-shares-her-story</link>
<guid>https://edusehat.com/en/pace-patient-featured-in-fight-of-our-lives-shares-her-story</guid>
<description><![CDATA[ Seven fingertips and both lower legs. For Katy Grainger, that was the toll sepsis took—and the beginning of a second career spent making sure […]
The post PACE: Patient featured in ‘Fight of Our Lives’ shares her story appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/10/fight-of-our-lives.png" length="49398" type="image/jpeg"/>
<pubDate>Fri, 23 Oct 2026 22:50:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>PACE:, Patient, featured, ‘Fight, Our, Lives’, shares, her, story</media:keywords>
<content:encoded><![CDATA[<p><span>Seven fingertips and both lower legs. For Katy Grainger, that was the toll sepsis took—and the beginning of a second career spent making sure others recognize it sooner.</span></p>
<p><span>Grainger, a member of the board of directors at the Sepsis Alliance and author who now speaks nationally on sepsis awareness, opened the second day of the Biotechnology Innovation Organization’s (BIO) Oct. 22-23 Patient Advocacy Changemakers Event (PACE) in Washington, D.C. For a room full of patient advocates, her session was less a personal account than a demonstration of what a well-told story can do—the skill at the center of nearly everything else on this year’s program.</span></p>
<p><span>“I think most of the people in this room have seen a TV show where they have heard the term </span><i><span>sepsis</span></i><span>, and usually it happens in a really excited situation: you’ve got a patient in a bed; they’re getting sicker and sicker; they don’t know what’s going on, and someone says, </span><i><span>Oh my gosh, we have to do something,</span></i><span>” began Grainger. “But the reality with sepsis is that 80–90% of it actually happens out in the community. Meaning that you start getting sepsis when you’re at home, and it’s up to you to get yourself to that hospital to save your own life.”</span></p>
<p><span>Today, Grainger commits her time to raising awareness about the risk of sepsis, and the importance of the patient voice. She is featured in “</span><a href="https://fightofourlives.com/stories/katy/"><span>Fight of Our Lives</span></a><span>” BIO’s storytelling campaign.</span></p>
<h3>It could happen to anyone</h3>
<p><span>“I had a small infection on my thumb that was no bigger than a mosquito bite, but there was something about it that told me that something was wrong,” Grainger recalled.</span></p>
<p><span>It was a sunny afternoon in Hawaii, just days after Grainger had taken a vacation with her children that a perfect storm of events led her to the hospital with severe sepsis. </span></p>
<p><span>“I noticed that I had a bump on my thumb. It was pretty small, but it was a weird color, kind of purplish and it had this white haze,” said Grainger. “It just looked unusual, and my gut really told me that something wasn’t right.”</span></p>
<p><span>As so, Grainger did the right thing; she took herself to the hospital. There, doctors gave her antibiotics, took a sample to test and sent her home. But there were a few other issues at play.</span></p>
<p><span>First, her local town was dealing with a higher risk of infections due to past flooding. And second, Grainger was home alone, as her husband was out on a fishing trip for the weekend. Unfortunately for Grainger, while home by herself, her symptoms started coming on fast. </span></p>
<p><span>“I don’t really remember what happened that weekend,” she said. “I can only guess based on text messages.”</span></p>
<p><span>She continues, “I sent my husband a text and I said, ‘</span><i><span>Hey, I threw up, but don’t worry, I’m fine. It was just because of the antibiotic that I took on an empty stomach,’</span></i><span> which also tells me I wasn’t eating. I had these little clues that I just was not generally well all weekend, but I was dismissing it—and that’s really common.”</span></p>
<p><span>Her next text to her husband said goodnight, and that she was going to bed early. </span></p>
<p><span>“That could have been my last text ever to my husband,” Grainger said. “But luckily, I woke up the next morning.”</span></p>
<p><span>Even in her confused state, Grainger was able to call a friend, saying something was wrong and she needed to go to the hospital immediately. Upon arrival, Grainger’s blood pressure was 50/30.</span></p>
<p><span>“I have since been told that that can be called 50/dead,” Grainger said.</span></p>
<h3>Road to recovery</h3>
<p><span>What followed was an emergency sepsis protocol by the hospital, a week in an induced coma, the loss of her lower legs and parts of her fingers—she praised the doctors for saving her thumbs—and a long road to recovery. </span></p>
<p><span>“They extubated me in the hospital, and when they did that, I also was awakened,” Grainger remembered. “The first thing I saw was my missing fingertips, and I immediately went into a very deep depression. We spent three weeks trying to save my hands and feet, and amazingly, we were able to save my hands.”</span></p>
<p><span>But even throughout her hardship, Grainger found hope. And with her new lease on life, albeit a very different life, Grainger has committed herself to helping patients and spreading awareness. </span></p>
<p><span>“Because of the incredible medical care I got, I’m here today, and I can speak to you about the power of the patient voice,” she concluded. “If there’s one thing I’ve learned through all of this, it’s that there is nothing that can replace the story that a person tells about what they have been through. That speaks to people like yourselves in this room; it speaks to government officials; it speaks to people doing the testing and designing the products for patients; and it makes such a difference.”</span></p>
<p>The post <a href="https://bio.news/latest-news/pace-patient-featured-in-fight-of-our-lives-shares-her-story/">PACE: Patient featured in ‘Fight of Our Lives’ shares her story</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>OMM for COMLEX Level 1 and Level 2&#45;CE: Study Guide and Free Anki Deck</title>
<link>https://edusehat.com/en/omm-for-comlex-level-1-and-level-2-ce-study-guide-and-free-anki-deck</link>
<guid>https://edusehat.com/en/omm-for-comlex-level-1-and-level-2-ce-study-guide-and-free-anki-deck</guid>
<description><![CDATA[ In my experience, studying the OMM portion for COMLEX Levels 1 and 2 works best when combined with your typical medical practice questions. It’s important to learn the reasoning behind the findings, start early, and use tools like spaced repetition to master the material.    As an osteopathic medical student, I understand how overwhelming board […]
The post OMM for COMLEX Level 1 and Level 2-CE: Study Guide and Free Anki Deck appeared first on Elite Medical Prep. ]]></description>
<enclosure url="https://elitemedicalprep.com/wp-content/uploads/2026/10/pexels-liza-summer-6347889-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 23 Oct 2026 19:30:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>OMM, for, COMLEX, Level, and, Level, 2-CE:, Study, Guide, and, Free, Anki, Deck</media:keywords>
<content:encoded><![CDATA[<p><span>In my experience, studying the OMM portion for COMLEX Levels 1 and 2 works best when combined with your typical medical practice questions. It’s important to learn the reasoning behind the findings, start early, and use tools like spaced repetition to master the material. </span></p>
<p> </p>
<p><span>As an osteopathic medical student, I understand how overwhelming board prep can feel because you have another whole subject to cover within the same amount of time. Not only must you master the clinical material, but you must also be able to view its implications within the framework of osteopathic manipulative medicine in case you get an exam question testing these very principles. Then comes the other question every osteopathic medical student likely asks themselves: <a href="https://elitemedicalprep.com/comlex-vs-usmle-which-exam-should-you-prioritize/">should you take USMLE in addition to COMLEX?</a></span></p>
<p> </p>
<p><span>Depending on your specialty interest and program scope, it may be beneficial to take both exams. Suddenly, you have two practice assessments to fit into your schedule, extra costs, and another exam date booked. Even before dedicated, this can feel overwhelming. OMM is likely the subject you keep promising to review in the future. But I am convinced that OMM does not have to be the portion of COMLEX that worries you! It can accompany your medical education as another tool for understanding musculoskeletal mechanics, anatomy, and physical exam findings that you will see in almost every board question- whether USMLE or COMLEX. </span></p>
<p> </p>
<p><span>This guide shares my study approach, explains how to review OMM for both Level 1 and Level 2, and shares a free Anki deck. This deck includes 561 cards across 17 osteopathic disciplines, organized to make reviewing this subject more manageable! </span></p>
<p> </p>
<h2><b>Finding Room for OMM in your Study Plan</b></h2>
<p><span>Personally, the hardest part of studying OMM for boards was deciding where to fit it into my study plan. After reviewing cardiology, renal physiology, surgery, or infectious disease, it may feel daunting to squeeze sacral biomechanics into an already 15-hour study day. My advice is to integrate OMM into your study schedule before it becomes an urgent matter you have put off for too long. Not every student needs the same plan. Someone with a very strong understanding of anatomy may only require a few retrieval lessons. On the other hand, someone who feels overwhelmed by diagnoses may need to reframe the subject in a whole new light. It is important to recognize your strengths and weaknesses, and craft your schedule in a way that capitalizes on them. For a broader framework, see our guide to <a href="https://elitemedicalprep.com/how-to-prepare-for-the-usmle-and-comlex-exams-simultaneously/">preparing for USMLE and COMLEX simultaneously</a></span></p>
<p> </p>
<h2><b>How I used UWorld, NBMEs, NBOMEs, and OMM Anki/ Study Guides</b></h2>
<p><span>UWorld and NBME practice exams remained at the center of my study schedule for the clinical material. This would have been the plan even if I had not taken the USMLE. I believe there is no question bank with explanations and graphics as complete and attractive as UWorld. I supplemented that work with OMM Anki Cards and my study guides from preclinical OMM courses. If I had a question on scoliosis, vertebral anatomy, referred pain, or any other clinical subject that aligns with OMM, I would review the corresponding OMM deck that same evening to build those mental associations. </span></p>
<p> </p>
<p><span>Each resource had a specific purpose! Practice questions helped me apply my medical knowledge, assessments helped me identify my weaknesses, and the OMM Anki deck gave me a dedicated way to review material that needed separate attention but shared a similar underlying clinical basis. That distinction is important to make: NBME resources will not assess your OMM comprehension. Integrate multiple resources spanning multiple subjects so you don’t fall behind!</span></p>
<p> </p>
<p>If you’re deciding which tools to combine, explore our <a href="https://elitemedicalprep.com/top-resources-for-comlex-level-1-and-2-what-to-use-and-when/">top resources for COMLEX Level 1 and Level 2</a>.</p>
<p> </p>
<h2><b>Why does the same OMM Anki deck help for both Level 1 and Level 2?</b></h2>
<p><span>Luckily for you, the same foundational OMM knowledge remains useful across both board exams. What changes is really just in the context in which you apply it. </span></p>
<p> </p>
<p><span>For Level 1, the focus remains more on foundational biomedical sciences and osteopathic principles. These same principles translate over to Level 2, but this exam emphasizes clinical sciences and competence for residency. Level 1 focuses more on anatomy, terminology, and diagnostic patterns. These same fundamentals appear on Level 2 but integrate clinical interpretation, treatment selection, and the safety of osteopathic techniques based on your patient population. These are not exclusive categories, but rather overarching focus points! </span></p>
<p> </p>
<p><span>Both exams require you to connect the same OMM knowledge you learned during M1 and M2 preclinical years to patient presentations. The deck preserves this foundation, while your practice questions help you make the concepts more clinically relevant. The deck combines factual recall and diagnostic reasoning. Some sections reinforce terminology, foundations, and anatomy while others ask you to interpret findings or choose a treatment setup. Below is how I recommend approaching each subdeck. </span></p>
<p> </p>
<h2><b>Foundations of OMM</b></h2>
<p><span>You will want to start here if OMM terminology still feels confusing at times. This subdeck covers somatic dysfunctions, TART changes, motion barriers, planes/axes, spinal mechanics, and the osteopathic foundational models. Knowing this vocabulary will be helpful for the rest of the Anki deck and ultimately to successfully answer board questions. I recommend paying attention to how to identify restrictive barriers versus positions of ease, as this distinction defines the nomenclature behind osteopathic diagnoses. Always remember to recognize the motion deficits when coming up with a diagnosis- you’ll thank yourself when you go on to learn treatment options! </span></p>
<p> </p>
<h2><b>OMT Principles & Techniques</b></h2>
<p><span>This subdeck focuses on the different technique categories within this field. Examples include muscle energy, soft tissue, HVLA, counterstrain, myofascial release, and facilitated positional release. This deck also touches on the high-yield contraindications to these modalities, which is relevant to know when you get a board question on a patient with multiple comorbidities! I also recommend mentally organizing whether the treatment modality is direct or indirect. Then consider whether the technique in question fits the clinical profile of the patient being presented to you. This is more useful than memorizing a treatment without understanding its clinical relevance. </span></p>
<p> </p>
<h2><b>Cervical Spine</b></h2>
<p><span>The cervical cards cover anatomy, OA/AA mechanics, typical cervical motion, exam findings, and the relevant clinical tests. Do not blindly apply one coupling rule to every cervical segment. Translate the exam language into the cervical segment’s motion preference. Feel free to use your hands to help visualize it! These hand movements help build muscle memory, since you practice them in your OMT labs. </span></p>
<p> </p>
<h2><b>Thoracic Spine/ Scoliosis</b></h2>
<p><span>This section highlights thoracic landmarks, facet joint orientations, the rule of threes, spinal diagnoses, and key concepts in scoliosis. Work on connecting the static findings with motion testing. I found it really helpful to visualize a static exam on a patient first, then follow the motion as the question progresses. When it comes to scoliosis, there are certain numbers I felt like were really important to know, including the Cobb angle degrees that would implicate the cardiopulmonary system. The goal is to be able to interpret whatever findings are given to you on the exam! </span></p>
<p> </p>
<h2><b>Ribs & Respiration</b></h2>
<p><span>The rib subdeck addresses anatomy, respiratory motion, inhalation/exhalation dysfunctions, key ribs, and the key muscles used in the treatments. The key to recognizing rib mechanics is really understanding how to utilize the respiratory cycle to assess thoracic cavity motion. You must identify the respiratory phase that is restricted, then name the dysfunction and figure out which rib matters for the proposed treatment modality. Visualizing the rib movement really makes the complicated stem easier to follow! </span></p>
<p> </p>
<h2><b>Lumbar Spine</b></h2>
<p><span>This subdeck includes anatomy, nerve root findings from the lumbosacral plexus, disc pathology, spondylosis, and spondylolisthesis. These are not only relevant to the OMM section of COMLEX, but also to the neurology questions on USMLE </span><span>and</span><span> COMLEX! It’s important to distinguish between a mechanical finding and a clinical diagnosis. I think this section is especially relevant, since so many neurology questions involve the lumbar spine. Connect motor, sensory, and reflex information rather than memorizing each feature separately. </span></p>
<p> </p>
<h2><b>Innominate/Pelvis/Psoas/Piriformis</b></h2>
<p><span>This is a very high-yield subdeck! These cards cover hip maneuvers, pelvic landmarks, flexion testing, anatomy, muscle patterns, innominate rotations/flares/shears, pubic dysfunctions, and the associated symptom distributions. Anatomy is pivotal to explaining these patients’ presentations. Consider how a muscle’s attachments and actions relate to posture, movement, and discomfort. I also found it really helpful to visualize muscle attachments and origins when learning the treatment positions for these dysfunctions. I also found it helpful to sketch the pelvis when first doing this Anki deck! </span></p>
<p> </p>
<h2><b>Sacrum</b></h2>
<p><span>Oh, sacrum. The sacral cards cover axes, torsions, unilateral/bilateral dysfunctions, spring tests, seated flexion tests, and relationships with L5- which is very high yield! I believe sacral diagnoses can become more manageable if you interpret the findings in an organized sequence. Combine the sacral sulcus depth, ILA findings, and motion tests into one diagnosis, and practice explaining why this diagnosis makes sense considering sacral mechanics. You cannot just memorize buzzwords! COMLEX will present you with any combination of findings. You must recognize how the different puzzle pieces fit together. </span></p>
<p> </p>
<h2><b>Short Leg Syndrome/Gait</b></h2>
<p><span>This section discusses the gait phases and the classically tested OMM patterns associated with short leg syndrome/ compensation. Although lower-yield, I still believe it’s helpful to know the contents of this deck to better understand overall mechanics! </span></p>
<p> </p>
<h2><b>Cranial/TMJ</b></h2>
<p><span>This subdeck covers traditional cranial principles, strain patterns, vault-hold findings, and related concepts. This section is quite large, but cranial is one of those fields that requires great visualization and attention to detail. For every cranial question, I used my hands to work through the spatial relationships. I recommend doing that when doing this deck as well, to strengthen that muscle memory for test day! </span></p>
<p> </p>
<h2><b>Upper and Lower Extremities </b></h2>
<p><span>The upper extremity subdeck reviews shoulder anatomy/exam, thoracic outlet, clavicle and radial head mechanics, and common elbow, wrist, and hand conditions. The lower extremity subdeck reviews the knee and various high-yield tests, fibular head mechanics, ankle and foot anatomy, and injury-related patterns. This ties in well to the trauma and MSK clinical questions you may get on COMLEX or USMLE. Connect the physical exam findings with the structure being examined, the motion involved, and the likely functional problem! I personally felt like this deck was floridly high-yield during my OMM review because these topics overlap with many MSK/ sports medicine questions. </span></p>
<p> </p>
<h2><b>Viscerosomatics</b></h2>
<p><span>This section reviews sympathetic and parasympathetic anatomy, the organ-related spinal levels (extremely high yield for both Level 1 and Level 2), GI subdivisions (foregut, midgut, hindgut), and traditional OMM associations. Understanding the major anatomical organizations before learning the individual organizations is helpful for this section. I found it helpful to test myself in both directions. That is, test the viscerosomatic levels and see if you can name the organs, and vice versa! You must know all these levels extremely well. </span></p>
<p> </p>
<h2><b>Chapman’s Points and Tender Points</b></h2>
<p><span>These cards distinguish Chapman reflex points from counterstrain tender points and review their selected locations and associations. I did this subdeck multiple times because the points are easy to mix up. A location associated with an organ in a traditional teaching model is not interchangeable with a counterstrain treatment point!</span></p>
<p> </p>
<h2><b>Lymphatics</b></h2>
<p><span>This smaller subdeck focused on general lymphatic treatment sequence, central outflow, diaphragm restrictions, and lymphatic-related concepts. Lower yield, but still helpful in case you get a question on it!</span></p>
<p> </p>
<h2><b>Integrated Practice</b></h2>
<p><span>This section combines high-yield findings into short diagnostic and treatment problems in an open-ended fashion (I found that being able to answer questions open-ended made sure I really knew it).  It includes spinal, pelvic, sacral, rib, and extremity applications while integrating OMM safety principles. </span></p>
<p> </p>
<h2><b>How to Use the Deck</b></h2>
<p><span>I recommend beginning approximately eight weeks before your exam and doing a manageable amount most evenings. This creates room for repeated review alongside practice questions! Students with larger knowledge gaps may need to begin earlier. Students closer to their exam should prioritize weaknesses while protecting time for question practice. </span></p>
<p> </p>
<p><span>With 561 cards, doing roughly 15-20 new cards on study days can make an initial pass feasible within several weeks. However, cards to review definitly accumulate, so stay consistent! Reduce new cards when the workload stops being sustainable. During the first two weeks, establish your routine and review the foundations. Add regional sections as you become comfortable with the terminology. During weeks three through five, continue introducing cards while increasing application. Pair each topic with OMM questions. After a missed question, return to the relevant section and identify what failed: recall, interpretation, or treatment reasoning. During weeks 3-5, continue introducing cards while increasing application. Pair each topic with OMM questions/ subjects that you did earlier that day to form mental associations. After a missed question, return to the relevant section and identify what failed. Was it recall, interpretation, or treatment reasoning? During weeks six and seven, emphasize mixed questions and difficult cards because familiarity with a section heading can otherwise become a clue. In the final week, focus on recurring errors and manageable review. Avoid creating an enormous backlog of new material. Keep the facts you already understand accessible while addressing specific remaining gaps.</span></p>
<p> </p>
<h4><strong>Fill out the form below to receive your free COMLEX Level 1 and Level 2-CE Anki Deck via email!</strong></h4>
<p><span data-mce-type="bookmark" class="mce_SELRES_start">﻿</span><span data-mce-type="bookmark" class="mce_SELRES_start">﻿</span><span data-mce-type="bookmark" class="mce_SELRES_start"></span></p>
<p> </p>
<h3><strong>More steps</strong></h3>
<p><span>Before revealing a card, commit to an answer. For diagnostic cards, give a brief explanation. Recognizing the answer after turning the card over is different from retrieving it independently. If you repeatedly miss a concept, pause the cards and repair the underlying understanding (i.e., watch a YouTube video, refer to your preclinical OMM notes, etc). A drawing, short explanation, or comparison table may help more than another immediate repetition! At that point, memorizing a card helps less than understanding the underlying concept. Keep a short error log with specific entries. This will give you a concrete list to refer to. <strong>Make it SPECIFIC! </strong></span></p>
<p> </p>
<h2><strong>Final thoughts</strong></h2>
<p><span>Use practice questions to check transfer. You should be able to apply the concept when the wording changes, when findings appear in a different order, or when the vignette includes distracting information. That is what you will see on boards! I recommend completing relevant True Learn or ComQuest OMM-specific practice questions for your review of the topics being taught with these cards. For additional strategies for applying these concepts, read our guide on <a href="https://elitemedicalprep.com/how-to-study-for-omm-osteopathic-manipulative-medicine-questions/">how to study for OMM questions</a>.</span></p>
<p> </p>
<p><span>Finally, keep OMM within the larger purpose of medical education. It offers another perspective on structure, function, and examination. Appropriate use still depends on the patient’s condition, the evidence, your training, and treatment safety.</span></p>
<p> </p>
<p><span>You got this! OMM is a fun extra subject to study. Do not let it scare you! If you’d benefit from more guidance along the way, EMP’s tutors can help you work through challenging OMM concepts and fit your review into a manageable study plan. Explore our <a href="https://elitemedicalprep.com/comlex-level-1-tutoring">COMLEX Level 1 tutoring</a> or <a href="https://elitemedicalprep.com/comlex-level-2ce-tutoring/">COMLEX Level 2-CE tutoring</a> for personalized support throughout your preparation.</span></p>
<p>The post <a href="https://elitemedicalprep.com/omm-for-comlex-level-1-and-level-2-ce-study-guide-and-free-anki-deck/">OMM for COMLEX Level 1 and Level 2-CE: Study Guide and Free Anki Deck</a> appeared first on <a href="https://elitemedicalprep.com/">Elite Medical Prep</a>.</p>]]> </content:encoded>
</item>

<item>
<title>In the biotech world, you can’t see everything</title>
<link>https://edusehat.com/en/in-the-biotech-world-you-cant-see-everything</link>
<guid>https://edusehat.com/en/in-the-biotech-world-you-cant-see-everything</guid>
<description><![CDATA[ Earlier this week, I attended a screening of You Can See Everything, the buzzy new documentary about the disgraced former biotech CEO Elizabeth Holmes.  I went in not really knowing what to expect. I’d avoided spoilers (and won’t be giving anything away here, either!). I was wondering what new information this film could reveal, given… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/10/YCSE_NP_1_1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 23 Oct 2026 19:15:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>the, biotech, world, you, can’t, see, everything</media:keywords>
<content:encoded><![CDATA[<div data-chronoton-summary="<ul><br><li><strong>Holmes's charm is still unsettling on screen:</strong> Even knowing the full Theranos story, the documentary captures how effectively Holmes plants seeds of doubt—journalists who interviewed her in her prime later admitted she had fooled them completely.</li><br><li><strong>Peer review isn't a perfect safety net:</strong> Science's built-in fact-checking system has real cracks—10,000 papers were retracted in 2023 alone, and preprint servers, press releases, and social media now routinely bypass it.</li><br><li><strong>Reporters face the same vulnerability as investors:</strong> Even seasoned science journalists rely on trust and expert opinion to vet claims, raising an uncomfortable question: how confident can anyone really be that they wouldn't have fallen for it too</li></ul>" data-chronoton-post-id="1147610" data-chronoton-expand-collapse="1" data-chronoton-analytics-enabled="1"></div>


<p class="wp-block-paragraph">Earlier this week, I attended a screening of <em>You Can See Everything</em>, the buzzy new documentary about the disgraced former biotech CEO Elizabeth Holmes. </p>



<p class="wp-block-paragraph">I went in not really knowing what to expect. I’d avoided spoilers (and won’t be giving anything away here, either!). I was wondering what new information this film could reveal, given how familiar many of us are with the Theranos story thanks to years of media coverage, the best-selling book <em>Bad Blood</em>, and the Hulu series <em>The Dropout</em>, starring Amanda Seyfried.</p>



<p class="wp-block-paragraph">Like many others who have seen the film, I came away feeling unsettled. But not just about Holmes’s fraud and the somewhat disturbing interactions between the subjects. The film reignited a concern I’ve had about covering science for most of my career: Despite our best efforts, we never can actually <em>see everything</em>.</p>





<p class="wp-block-paragraph">In case you’re rusty on the details, Elizabeth Holmes dropped out of Stanford University in 2003 to run Theranos, a diagnostics company she founded, when she was just 19. She went on to claim that her company had invented a way to run over 100 diagnostic tests on just a few drops of blood.</p>



<p class="wp-block-paragraph">Holmes raised hundreds of millions of dollars for Theranos, which was valued at $9 billion in 2014. <em>Forbes</em> named her the youngest self-made female billionaire—she was <a href="https://www.forbes.com/profile/elizabeth-holmes/">worth $4.5 billion</a> when she was just 30 years old.</p>



<p class="wp-block-paragraph">Things started to unravel in 2015, when <a href="https://www.wsj.com/articles/theranos-has-struggled-with-blood-tests-1444881901">an investigation by the <em>Wall Street Journal</em></a> raised concerns by former Theranos employees that the tests didn’t work. Some also said that the company’s device had not been tested properly, and that blood samples had been analyzed on machines from other companies instead. <em>MIT Technology Review</em> named it one of the <a href="https://www.technologyreview.com/2015/12/31/164066/the-6-biggest-technology-failures-of-2015/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=*%7Cdate:m-d-y%7C*">biggest technology failures of 2015</a>.</p>



<p class="wp-block-paragraph"><em>Forbes</em> had revised Holmes’s worth to $0 by 2016. That year, a damning government report said that <a href="https://www.technologyreview.com/2016/04/01/161208/theranos-promised-a-revolution-but-delivered-dangerous-errors/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=*%7Cdate:m-d-y%7C*">the company’s lab was struggling with basic procedures</a> and gave patients results even when they knew they could be wrong.</p>



<p class="wp-block-paragraph">In 2018, Theranos, Holmes, and former company president Ramesh Balwani were <a href="https://www.technologyreview.com/2018/03/14/241044/sec-charges-theranos-founder-elizabeth-holmes-with-massive-fraud/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=*%7Cdate:m-d-y%7C*">charged with “massive fraud.”</a> In 2022, she was sentenced to a little over 11 years in prison for defrauding investors. She began serving her sentence in May 2023.</p>



<p class="wp-block-paragraph">It was around a month before this that filmmakers Nathan Fielder, Lance Oppenheim, and their colleagues began documenting Holmes and her partner, Billy Evans, at home with their two young children. I’m not giving anything away when I say it’s an extremely intimate portrayal—at least of how the two adults interact with Fielder, who is also a central character in the film.</p>



<p class="wp-block-paragraph">As you might know if you’ve seen <a href="https://www.youtube.com/watch?v=HvW_N5p1q44">the trailer</a>, there are plenty of super close-ups. I felt as if I spent most of the film staring straight into the faces of those people. And almost the whole way through, they all seemed to be trying to figure each other out. Holmes is known for her dishonesty, but she invited cameras into her home in an apparent bid to reframe the narrative and position herself as an honest person with an unusual mind. Will anyone believe her?</p>





<p class="wp-block-paragraph">I couldn’t help feeling some empathy for Holmes, a mother we see preparing to leave her two kids for a lengthy prison sentence. And even though I have long known the facts, Holmes is clearly an effective manipulator. You can see her plant the seeds of doubt in Fielder’s mind. At times, I felt she was convincing me, sitting in my cinema seat. Maybe she really didn’t <em>mean</em> to lie?</p>



<p class="wp-block-paragraph">But then I remembered how other journalists felt after being taken in by her claims. “I blew it,” <em>Fortune</em>’s Roger Parloff <a href="https://fortune.com/2015/12/17/how-theranos-misled-me-elizabeth-holmes/">reflected</a> in 2015, a year after profiling Holmes and her company. “I’m pretty sure she lied to me,” <em>STAT</em>’s Matthew Herper <a href="https://www.statnews.com/2026/10/20/elizabeth-holmes-superpower-authenticity-vs-truth-matt-herper-take/">wrote</a> recently, having interviewed Holmes in 2015. Even the former employee turned whistleblower Tyler Shultz, who <em>knew</em> the product didn’t work, said that he could “have a five-minute conversation with her and walk away feeling like my work was changing the world,” he <a href="https://www.statnews.com/2022/06/01/theranos-whistleblower-tyler-shultz-lessons-learned/">said in 2022</a>.</p>



<p class="wp-block-paragraph">I didn’t cover Theranos in the 2010s. If I’d interviewed Holmes, would I have fallen for it all?</p>



<p class="wp-block-paragraph">One of the early red flags in the Theranos case was the lack of published, peer-reviewed data. Much of the company’s work was classified as a “trade secret.” Scientists tend to publish their work in journals—a slow process that involves having the work evaluated by often anonymous experts in the field, who provide feedback, highlight questionable conclusions, and often ask for clarification. Peer review is meant to add rigor to the publication process. You should be able to trust published scientific papers.</p>



<p class="wp-block-paragraph">Except that sometimes you can’t.</p>



<p class="wp-block-paragraph">Scientists aren’t perfect. Some will exaggerate their results or inflate their importance. Some manipulate data to serve a hypothesis. Sometimes these infractions are caught during peer review, but not always. There are plenty of examples of scientific findings that could never be replicated by other labs and ended up collapsing under the weight of real evidence. Many papers ultimately end up with corrections. Some are withdrawn—<a href="https://www.nature.com/articles/d41586-023-03974-8">10,000 research papers were retracted in 2023</a>.</p>



<p class="wp-block-paragraph">At any rate, there’s been a shift to sharing research in other ways. Today, many scientists opt to publish their work at preprint servers like arXiv, medRxiv, and bioRxiv before they submit them to established journals. Those outlets bypass peer review. So do company press releases, social media posts, and many conference presentations. And I get a lot of my stories from conversations and interviews.</p>



<p class="wp-block-paragraph">I’ll admit I’ve looked at a scientific finding and thought: A scientist has just said they’ve done that. <em>How can I be sure they really have?</em></p>



<p class="wp-block-paragraph">I like to think that I hold myself to high journalistic standards here, as does everyone at <em>MIT Technology Review</em>. I would never publish a story about some new scientific development without doing my own form of peer review, and asking scientists—ideally people I know and trust—what they think of a new claim. </p>



<p class="wp-block-paragraph">But the film is a stark reminder of how easy it can be to fall for an appealing narrative. While most scientists are, I hope, pretty honest, and Holmes is certainly an outlier, we should all continue to interrogate the claims being fed to us. If you’ve seen the film, let me know what you think!</p>



<p class="wp-block-paragraph"><em>This article first appeared in The Checkup, </em>MIT Technology Review’s<em> weekly biotech newsletter. To receive it in your inbox every Thursday, and read articles like this first, </em><a href="https://forms.technologyreview.com/newsletters/biotech-the-checkup/?_ga=2.241810882.15113993.1664981064-43237434.1647441349"><em>sign up here</em></a>.</p>]]> </content:encoded>
</item>

<item>
<title>Ottawa Heart Institute reports significant reduction in surgical infections following new prevention protocol</title>
<link>https://edusehat.com/en/ottawa-heart-institute-reports-significant-reduction-in-surgical-infections-following-new-prevention-protocol</link>
<guid>https://edusehat.com/en/ottawa-heart-institute-reports-significant-reduction-in-surgical-infections-following-new-prevention-protocol</guid>
<description><![CDATA[ Canadian cardiac centre reports a 51.5% relative reduction in certain surgical-site infections in an observational evaluation involving more than 2,100 procedures. A new evaluation at the University of Ottawa Heart Institute suggests that a light-activated infection-prevention treatment may help reduce surgical-site infections among patients undergoing coronary artery bypass surgery. The findings, presented at the 2026 […]
The post Ottawa Heart Institute reports significant reduction in surgical infections following new prevention protocol appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/Sterile-Surgical-Instruments-in-the-Operating-Room.png" length="49398" type="image/jpeg"/>
<pubDate>Fri, 23 Oct 2026 19:05:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Ottawa, Heart, Institute, reports, significant, reduction, surgical, infections, following, new, prevention, protocol</media:keywords>
<content:encoded><![CDATA[<p><em>Canadian cardiac centre reports a 51.5% relative reduction in certain surgical-site infections in an observational evaluation involving more than 2,100 procedures.</em></p>
<p>A new evaluation at the University of Ottawa Heart Institute suggests that a light-activated infection-prevention treatment may help reduce surgical-site infections among patients undergoing coronary artery bypass surgery.</p>
<p>The findings, presented at the 2026 Canadian Cardiovascular Congress in Ottawa, examined 2,172 cardiac bypass procedures performed between June 2023 and January 2026.</p>
<p>Researchers reported that infections at sites where blood vessels were removed for bypass surgery declined from 3.3 per cent to 1.6 per cent following the introduction of a nasal photodisinfection protocol.</p>
<p>That represents a relative reduction of approximately 51.5 per cent.</p>
<p>The findings were announced October 23 by Canadian medical technology company Ondine Biomedical, whose Steriwave system was used in the hospital’s infection-prevention program. <a href="https://www.investegate.co.uk/announcement/rns/ondine-biomedical-inc-npv-cdi---obi/ottawa-heart-institute-reduces-cabg-ssis-by-51-5-/9837640?utm_source=chatgpt.com">Investegate</a></p>
<h3>A different approach to preventing infections</h3>
<p>Surgical-site infections remain an important concern for hospitals because they can complicate recovery, extend hospital stays and increase healthcare costs.</p>
<p>The Ottawa evaluation focused specifically on infections occurring where veins or arteries are harvested from a patient’s leg or arm during coronary artery bypass grafting.</p>
<p>Traditionally, some hospitals have used mupirocin, a topical antibiotic applied inside the nose before surgery, to reduce bacteria that could contribute to infections.</p>
<p>The newer approach uses a photosensitive compound activated by red light to reduce potentially harmful microorganisms in the nasal passages.</p>
<p>Unlike conventional antibiotic treatments that may require patients to follow a multi-day application schedule, photodisinfection is administered by healthcare professionals at the point of care.</p>
<h3>More than 2,100 procedures examined</h3>
<p>Researchers compared outcomes from two consecutive periods.</p>
<p>The first involved 1,678 coronary bypass procedures during a 24-month period when mupirocin was used.</p>
<p>The second included 494 procedures during the first eight months of the hospital’s photodisinfection program.</p>
<p>The evaluation found that the proportion of patients experiencing infections at blood-vessel harvest sites decreased from 3.3 per cent to 1.6 per cent.</p>
<p>Patient adherence to the infection-prevention protocol also improved.</p>
<p>Researchers reported 93.3 per cent compliance with the nurse-administered photodisinfection approach, compared with 35.4 per cent during the earlier mupirocin period.</p>
<p>The findings suggest that simplifying how preventive treatments are delivered could help hospitals improve consistency in infection-control practices.</p>
<h3>Important limitations</h3>
<p>The evaluation was conducted at a single hospital and compared outcomes across different periods rather than randomly assigning patients to treatments.</p>
<p>Consequently, the findings demonstrate an association between the new protocol and lower infection rates but do not establish that photodisinfection alone caused the improvement.</p>
<p>Other changes in clinical practices or patient characteristics may have influenced the results.</p>
<p>The findings have been reported in conference abstracts, and further peer-reviewed research will help determine how effectively the approach performs across different hospitals and surgical populations.</p>
<h3>Implications for Canadian hospitals</h3>
<p>The results highlight growing interest in infection-prevention technologies that can be incorporated directly into existing surgical workflows.</p>
<p>For hospitals, improving adherence to preventive measures can be as important as introducing new technologies.</p>
<p>A treatment administered by healthcare professionals immediately before surgery may help reduce the challenges associated with asking patients to complete preventive treatments independently.</p>
<p>The findings also underscore the role of nursing teams in implementing infection-prevention programs and monitoring compliance.</p>
<p>As Canadian healthcare organizations recognize National Infection Control Week, October 19–23, the Ottawa experience offers an example of how clinical innovation and changes in care delivery may contribute to safer surgical procedures.</p>
<p>Further evaluation will be needed to establish whether similar improvements can be achieved consistently across other healthcare settings.</p>
<p>Source: <a href="https://www.investegate.co.uk/announcement/rns/ondine-biomedical-inc-npv-cdi---obi/ottawa-heart-institute-reduces-cabg-ssis-by-51-5-/9837640?utm_source=chatgpt.com">Ottawa Heart Institute infection-prevention findings — regulatory news announcement</a></p>
<p>The post <a href="https://www.hospitalnews.com/ottawa-heart-institute-reports-significant-reduction-in-surgical-infections-following-new-prevention-protocol/">Ottawa Heart Institute reports significant reduction in surgical infections following new prevention protocol</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Cryo&#45;EM and AI&#45;Designed Scaffold Reveal How Andes Hantavirus Binds Cells</title>
<link>https://edusehat.com/en/cryo-em-and-ai-designed-scaffold-reveal-how-andes-hantavirus-binds-cells</link>
<guid>https://edusehat.com/en/cryo-em-and-ai-designed-scaffold-reveal-how-andes-hantavirus-binds-cells</guid>
<description><![CDATA[ Using cryo-EM and an AI-designed scaffold, researchers mapped how Andes hantavirus engages a receptor on human cells. The findings explain how antibodies block attachment and may highlight a potential target for antiviral development.
The post Cryo-EM and AI-Designed Scaffold Reveal How Andes Hantavirus Binds Cells appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/02/GettyImages-2186951140.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 23 Oct 2026 12:00:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Cryo-EM, and, AI-Designed, Scaffold, Reveal, How, Andes, Hantavirus, Binds, Cells</media:keywords>
<content:encoded><![CDATA[<p>Hantaviruses can turn exposure to infected rodents into a life-threatening illness, including a pulmonary syndrome that can progress rapidly to respiratory failure. Andes virus adds another concern: unlike other hantaviruses known to cause human disease, it can also spread between people. Understanding how it first attaches to human cells could help researchers identify ways to interrupt infection.</p>
<p>Researchers at Albert Einstein College of Medicine in New York, Institut Pasteur in Paris, and LSU Health Shreveport have now resolved that interaction in near-atomic detail. Combining cryo-electron microscopy (cryo-EM) and functional experiments, they showed how the Andes virus spike captures a human receptor—and how antibodies interfere.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>The study, published in <em>Nature</em>, is titled “<a href="https://www.nature.com/articles/s41586-026-11184-1" target="_blank" rel="noopener">Structural basis for protocadherin-1 recognition by New World hantaviruses</a>.”</p>
<p>Previous research established that Andes virus and other New World hantaviruses use the cell-surface protein protocadherin-1 (PCDH1) to enter host cells. What remained unclear was how the viral spike recognized this receptor. An isolated spike subunit could not bind PCDH1; the interaction required the assembled, four-part structure.</p>
<p>To examine that assembly, the team engineered a soluble Andes virus spike using methods that included an artificial intelligence–designed scaffold. The scaffold helped stabilize the square-shaped complex outside the virus, allowing the researchers to combine it with PCDH1 and analyze the resulting structure using cryo-EM.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<figure aria-describedby="caption-attachment-339755" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="size-medium wp-image-339755" src="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_ANDVgreen_PCDH1pink-1-1-300x300.jpg" alt="PCDH1" width="300" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_ANDVgreen_PCDH1pink-1-1-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_ANDVgreen_PCDH1pink-1-1-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_ANDVgreen_PCDH1pink-1-1.jpg 700w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">rVSV-ANDV infected cells (green) and PCDH1 bound to them (pink) [Albert Einstein College of Medicine]</figcaption></figure>
<p>The images revealed that PCDH1 binds asymmetrically within a deep central pocket formed by four copies of the viral Gn glycoprotein. Rather than presenting a receptor-binding site on an individual subunit, the spike builds one through the arrangement of its components.</p>
<p>Mutagenesis experiments identified three Gn loops that help shape the binding site. Changes involving these loops also enabled the researchers to transfer PCDH1-binding ability from New World to Old World hantavirus glycoproteins, according to the paper.</p>
<p>The team also investigated four neutralizing antibodies. Structural and functional analyses showed that the antibodies prevented receptor binding through two mechanisms: obstructing access to the PCDH1-binding site or creating a physical barrier that prevented receptor engagement.</p>
<p>“The depth of this pocket also helps explain how the virus limits antibody access. What’s striking is how the same pocket can accommodate the receptor while restricting antibody access. PCDH1’s long, slender shape lets it reach deep inside, but most antibodies are too bulky to follow,” said Rohit Jangra, PhD, assistant professor of microbiology and immunology at LSU Health Shreveport.</p>
<p>That distinction suggests a direction for therapeutic development. According to the researchers, engineered molecules with a narrow, elongated shape might reach farther into the pocket and block attachment. The team intends to explore this vulnerability as a basis for antiviral strategies against Andes virus and potentially related pathogens, including Sin Nombre virus.</p>
<p>The authors wrote, “Together, these findings define the structural determinants of hantavirus–receptor recognition, reveal how a virus can mask its receptor-binding site by recessing it in a surface depression and how antibodies can counter this strategy, and provide a framework for the design of antiviral therapeutics targeting the hantavirus spike.”</p>
<p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/cryo-em-and-ai-designed-scaffold-reveal-how-andes-hantavirus-binds-cells/">Cryo-EM and AI-Designed Scaffold Reveal How Andes Hantavirus Binds Cells</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>PerturbAI and OpenAI Launch AI Reasoning Agents for Biomedical Discovery</title>
<link>https://edusehat.com/en/perturbai-and-openai-launch-ai-reasoning-agents-for-biomedical-discovery</link>
<guid>https://edusehat.com/en/perturbai-and-openai-launch-ai-reasoning-agents-for-biomedical-discovery</guid>
<description><![CDATA[ A year-long collaboration involving scientists at PerturbAI, OpenAI, and their other institutions yielded an AI reasoning framework that turns datasets into testable hypotheses, with thousands of agents analyzing whole-brain genomic data in minutes instead of months.
The post PerturbAI and OpenAI Launch AI Reasoning Agents for Biomedical Discovery appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/06/GettyImages-2224152938.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 23 Oct 2026 04:45:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>PerturbAI, and, OpenAI, Launch, Reasoning, Agents, for, Biomedical, Discovery</media:keywords>
<content:encoded><![CDATA[<p><span>This week, PerturbAI, OpenAI, and their collaborators shared results from a year-long effort aimed at developing an artificial intelligence (AI) reasoning framework that helps scientists interpret large experimental datasets, connect results with existing research, and generate testable hypotheses. Details are provided in a new bioAxriv preprint titled “</span><a href="https://www.biorxiv.org/content/10.64898/2026.10.15.759436v1" target="_blank" rel="noopener"><span>Distributed AI agents enable comprehensive discovery of biological insights at scale</span></a><span>.” </span></p>
<p><span>Besides the scientists at PerturbAI and OpenAI, other authors listed on the paper are scientists affiliated with Scripps Research Institute, University of California, San Diego, and Howard Hughes Medical Institute. In the paper, they explained the results of applying the AI framework to data from </span><a href="https://www.biorxiv.org/content/10.64898/2026.03.16.711480v1" target="_blank" rel="noopener"><span>PerturbAI’s whole-brain atlas</span></a><span>, published earlier this year. Specifically, the team developed thousands of agents to analyze cellular responses, search the scientific literature, and connect experimental results with existing biological knowledge. The system then synthesized the findings into a reasoning atlas that linked genes, cell responses, details from existing literature, and possible biological mechanisms. </span></p>
<p><span>When applied to the whole-brain atlas, “thousands of parallel agents thoroughly examined the dataset in minutes” and without access to the source manuscript “recovered its conclusions, predicted held-out perturbation effects, and identified perturbation relationships with shared or opposing outcomes across effect strengths,” the scientists wrote. In fact, the system completed the analysis in 32 minutes. Furthermore, “distributed agents scaled literature coverage with workload, retrieving 100s times more references than [a] single-agent mode.” </span><span> </span></p>
<p><span>To evaluate the quality of the agents’ interpretations, biologists reviewed their reports for novelty, evidential support, follow-up priority, and confidence level. According to numbers reported in the preprint, in blinded comparisons against reports generated by single AI agents, human experts preferred the reasoning-agents’ interpretations 75% of the time or 45 of 60 judgements. Single agent interpretations were preferred in 10 or 16.7%, and five were ties (8.3%).  </span></p>
<p><span>The work builds on a year-long collaboration that is now expanding into joint drug-target discovery that will leverage PerturbAI’s proprietary causal biological data. Using PerturbAI’s causal<em> in vivo</em> data, PerturbAI and OpenAI will now apply their AI reasoning frameworks to discover new drug targets. “Biomedical experiments are generating data faster than scientists can interpret it, meaning promising new discoveries are likely to remain hidden,” said Grace Zheng, PhD, CEO and co-founder of PerturbAI. “By combining large-scale causal data generated directly in living systems with frontier AI, our partnership with OpenAI is making it possible to investigate more biological data, faster and with greater depth, and to make target discovery more systematic.”</span></p>
<p><span>“By combining PerturbAI’s experimental data with OpenAI’s reasoning capabilities, we can help scientists uncover new biological insights and identify promising leads for drug discovery,” added Joy Jiao, head of life sciences at OpenAI. “The scale, quality, and speed of PerturbAI’s discovery engine make them an ideal partner, and this is just the beginning of what we can achieve together. Running nearly 2,000 agents in parallel shows how we can scale biological interpretation alongside high-throughput experimentation, helping researchers turn those findings into better medicines.”</span></p>
<p>The post <a href="https://www.genengnews.com/topics/artificial-intelligence/perturbai-and-openai-launch-ai-reasoning-agents-for-biomedical-discovery/">PerturbAI and OpenAI Launch AI Reasoning Agents for Biomedical Discovery</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Nvidia, UW Institute for Protein Design Unveil Open&#45;Source Protein Design AI Model</title>
<link>https://edusehat.com/en/nvidia-uw-institute-for-protein-design-unveil-open-source-protein-design-ai-model</link>
<guid>https://edusehat.com/en/nvidia-uw-institute-for-protein-design-unveil-open-source-protein-design-ai-model</guid>
<description><![CDATA[ RFD4-Proteina is an open model based on Nvidia’s NVIDIA BioNeMo™ artificial intelligence (AI) platform for chemistry and biology that combines programmable protein design with search capabilities. RFD4-Proteina generates targeted protein designs, enabling scientists and agents to search and refine those designs using molecular inputs, constraints, and scoring objectives. 
The post Nvidia, UW Institute for Protein Design Unveil Open-Source Protein Design AI Model appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GettyImages_1402266486_proteins-1024x538-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 23 Oct 2026 04:45:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Nvidia, Institute, for, Protein, Design, Unveil, Open-Source, Protein, Design, Model</media:keywords>
<content:encoded><![CDATA[<figure aria-describedby="caption-attachment-339716" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="wp-image-339716 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/10/David-Baker-493455cCPMichel1212026-web-200x300.jpeg" alt="" width="200" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/David-Baker-493455cCPMichel1212026-web-200x300.jpeg 200w, https://www.genengnews.com/wp-content/uploads/2026/10/David-Baker-493455cCPMichel1212026-web-683x1024.jpeg 683w, https://www.genengnews.com/wp-content/uploads/2026/10/David-Baker-493455cCPMichel1212026-web-768x1151.jpeg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/David-Baker-493455cCPMichel1212026-web-1025x1536.jpeg 1025w, https://www.genengnews.com/wp-content/uploads/2026/10/David-Baker-493455cCPMichel1212026-web.jpeg 1281w" sizes="(max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Nobel laureate David Baker, PhD, IPD’s director and a professor of biochemistry at UW Medicine [UW Medicine Institute for Protein Design]</figcaption></figure>
<p>The University of Washington (UW) School of Medicine <a href="https://www.ipd.uw.edu/" target="_blank" rel="noopener">Institute for Protein Design</a> (IPD) has partnered with Nvidia to develop an open, generative model that uses biomolecular reasoning designed to improve how well researchers can design new proteins with specific functions.</p>
<p>RFD4-Proteina is an open model based on Nvidia’s <a href="https://github.com/NVIDIA-BioNeMo" target="_blank" rel="noopener">NVIDIA BioNeMo<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> artificial intelligence (AI) platform</a> for chemistry and biology that combines programmable protein design with search capabilities. According to its developers, RFD4-Proteina generates targeted protein designs, enabling scientists and agents to search and refine those designs using molecular inputs, constraints, and scoring objectives. Potential applications include designing proteins to interrupt disease processes or detect signs of disease in diagnostic tests.</p>
<p>RFD4-Proteina concurrently refines a protein’s sequence and structure alongside the structures of interacting molecules, so that a change in one effortlessly leads to changes in the others. RFD4-Proteina has achieved five-fold to 10-fold higher design success rates while generating protein candidates five to 10 times faster than previous models, the developers said.</p>
<p>Lab bench tests showed that RFD4-Proteina achieved higher computational design success rates and generation throughput than the evaluated baselines across four benchmark suites: protein binding, small-molecule binding, enzyme scaffolding, and DNA binding, Nvidia said.</p>
<p>The model helps researchers explore and prioritize candidates for laboratory testing. And by remaining open, UW and Nvidia added, RFD4-Proteina will enable investigators to build on its capabilities by exploring more potential protein designs and advancing promising drug candidates into lab testing faster.</p>
<p>“We are moving from an era of discovering the proteins nature has made to one in which we can design entirely new ones,” Nobel laureate David Baker, PhD, IPD’s director and a professor of biochemistry at UW Medicine, said in a statement. “RFD4-Proteina expands what scientists can create, from proteins that could advance drug discovery to enzymes that break down pesticides.”</p>
<h4><strong>‘New solutions’</strong></h4>
<p>“RFD4-Proteina will open the door to new solutions in medicine, sustainability, materials and biotechnology,” Baker added. “I think with these improved generative AI methods, we’ll see better medicines … and applications more broadly outside of medicine and sustainability, new ways of breaking down polymers, new ways of making bioplastics.”</p>
<figure aria-describedby="caption-attachment-339714" class="wp-caption alignright"><img decoding="async" class="size-medium wp-image-339714" src="https://www.genengnews.com/wp-content/uploads/2026/10/UW-IPD-dry-lab-RFD4-PROTEINA-300x202.jpg" alt="" width="300" height="202" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/UW-IPD-dry-lab-RFD4-PROTEINA-300x202.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/UW-IPD-dry-lab-RFD4-PROTEINA.jpg 640w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Members of the RDF4 modeling team run tests at the Institute for Protein Design. [Sierra Adler / UW Medicine Institute for Protein Design]</figcaption></figure>
<p>RFD4-Proteina derives its name from the IPD’s <a href="https://www.bakerlab.org/2023/07/11/diffusion-model-for-protein-design/" target="_blank" rel="noopener">RosettaFold Diffusion</a>, a guided diffusion model for generating new proteins, and Nvidia’s <a href="https://research.nvidia.com/labs/genair/proteina/" target="_blank" rel="noopener">Proteina-Complexa</a>, a generative model for protein binder design for protein and small molecule targets. Proteina-Complexa combines inference-time optimization with a pretrained flow-based generative model built on Nvidia’s La-Proteina AI model developed for atomistic protein design.</p>
<p>RFD4-Proteina is available through partners that include Amazon Bio Discovery, Anthropic’s Claude Science, Benchling, Databricks, Google Cloud, Hugging Face, Nebius, OpenAI, and Tamarind Bio. The partners enable researchers and developers to integrate the open protein design model into agent, cloud, and scientific computing workflows.</p>
<p>At IPD, researchers who have applied the model to their novel protein design challenges reported that RFD4-Proteina represented an improvement over past methods’ efficacy and speed.</p>
<p>“We were able to precisely control what types of glycans (sugars important for immune-system recognition) are attached to proteins in ways past models haven’t been able to achieve, and to do so in under just a week rather than months,” said Meg Lunn-Halbert, a UW PhD candidate in biochemistry and in biological physics, structure and design.</p>
<h4><strong>From months to days</strong></h4>
<p>Added Seth Woodbury, a UW bioengineering predoctoral candidate and National Science Foundation fellow: “In just a few days we designed a pesticide-degrading enzyme that performs many fold better than my previous best, which took months to design.”</p>
<p>RFD4-Proteina arose from a collaboration between IPD and Nvidia researchers and is immediately available for use as an open-source resource hosted through Berkeley Software Distribution (BSD-3).</p>
<p>IPD leaders of the project were three UW PhD students—Nathaniel Corley, Maxwell Kazman, and Rafi Brent—as well as Kieran Didi, a visiting student from the University of Oxford.</p>
<p>The development of RFD4-Proteina was funded by the Howard Hughes Medical Institute, Gates Foundation (INV-092109), Grantham Foundation, Fund for Science and Technology, Schmidt Sciences, OpenFold consortium (part of OMSF), Rosetta Commons, and additional supporters of the IPD. According to its website, the Gates Foundation <a href="https://www.gatesfoundation.org/about/committed-grants/2025/12/inv-092109" target="_blank" rel="noopener">committed $25,748,619</a> through a grant dated November 2025.</p>
<p>The Jen-Hsun and Lori Huang Foundation provided a computational grant that was critical to RFD4-Proteina’s development, UW stated in announcing the introduction of RFD4-Proteina.</p>
<p>Baker is a Howard Hughes Medical Institute Investigator and one of three winners of the 2024 Nobel Prize in Chemistry “for computational protein design,” along with Sir Demis Hassabis, PhD, and John Jumper, PhD.</p>
<p>Hassabis is a co-founder of Google DeepMind who is now chief scientist of Google parent Alphabet and the founder/CEO of Google-co-owned Isomorphic Labs. Jumper announced plans in June to leave Google DeepMind for Anthropic, the AI giant that has filed for an initial public offering (IPO) that would value the company at an eye-popping $2 trillion.</p>
<p>The post <a href="https://www.genengnews.com/topics/artificial-intelligence/nvidia-uw-institute-for-protein-design-unveil-open-source-protein-design-ai-model/">Nvidia, UW Institute for Protein Design Unveil Open-Source Protein Design AI Model</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>EQT to Acquire Qiagen for $12.1B, Plans to Take Tools, Diagnostics Provider Private</title>
<link>https://edusehat.com/en/eqt-to-acquire-qiagen-for-121b-plans-to-take-tools-diagnostics-provider-private</link>
<guid>https://edusehat.com/en/eqt-to-acquire-qiagen-for-121b-plans-to-take-tools-diagnostics-provider-private</guid>
<description><![CDATA[ EQT has €354 billion in assets under management and a three-decade track record of acquiring, developing, and sometimes selling companies that include life sciences tools/tech concerns. 
The post EQT to Acquire Qiagen for $12.1B, Plans to Take Tools, Diagnostics Provider Private appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/S_1191_0_CC_GEN_QIAGEN_Employee_0267-16x9-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 23 Oct 2026 04:45:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>EQT, Acquire, Qiagen, for, 12.1B, Plans, Take, Tools, Diagnostics, Provider, Private</media:keywords>
<content:encoded><![CDATA[<p>An entity of Swedish private equity firm EQT has agreed to acquire Qiagen for €10.8 billion (about $12.1 billion) cash, both said today, in a deal that would take private the global life-sciences tools, diagnostics, and workflow solutions provider following on-and-off takeover attempts over nearly seven years.</p>
<p>The buyer is EQT Private Equity, a holding company indirectly controlled by the firm’s EQT XI fund and managed and controlled by affiliates of EQT. Within EQT Private Equity, “indirect participations” or stakes are held by co-investors Luxinva, a wholly owned subsidiary of the Abu Dhabi Investment Authority; and CPP Investment Board Europe, a wholly-owned subsidiary of Canada Pension Plan Investment Board or CPP Investments.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>EQT’s takeover offer followed what Qiagen called a comprehensive review by its Supervisory Board and Managing Board evaluating the company’s strategic prospects through discussions with strategic and financial parties.</p>
<p>Qiagen said that its boards concluded that a buyout by EQT would offer the best prospects for the company’s next growth phase by giving it greater flexibility to invest longer term under a private owner while providing shareholders with attractive and certain cash value.</p>
<p>“After considering Qiagen’s stand-alone strategic prospects and the alternatives available through discussions with strategic and financial parties, we unanimously concluded that this is the best path forward for Qiagen, its shareholders, and other stakeholders,” Stephen H. Rusckowski, chairman of Qiagen’s Supervisory Board, said in a statement.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<h4><strong>‘Compelling value’</strong></h4>
<p>“This transaction offers shareholders compelling value while positioning Qiagen for its next phase of development under private ownership,” Rusckowski added.</p>
<p>News of Qiagen’s strategic review emerged in January through a <em>Bloomberg News</em> report that said the company was weighing a potential sale, attributed to unnamed sources, amid fresh interest from would-be buyers in acquiring the company.</p>
<p>Investors reacted to news of the strategic review with a <a href="https://www.genengnews.com/topics/bioprocessing/stockwatch-qiagen-shares-rebound-on-report-it-is-assessing-strategic-options/" target="_blank" rel="noopener">buying surge</a> that sent Qiagen shares to their highest levels since February 2023, a 17% one-week gain that saw its New York Stock Exchange shares rise from $47.57 on January 16 to $55.62 on January 23. Qiagen’s European shares, traded on the Frankfurt Stock Exchange’s XETRA market, rose 12.5% from €40.99 ($45.55) to €46.13 ($51.46).</p>
<p>Qiagen shares slipped since then as investors questioned whether the company would reach agreement with a buyer, and as the company lowered its full-year guidance to investors. In April, Qiagen cut its net sales growth forecast from 5% down to 1–2%, while lowering its adjusted diluted EPS forecast from $2.50 to $2.43. The reductions followed weaker than anticipated sales—a year-over-year 5% drop at constant exchange rates—of Qiagen’s QuantiFERON blood test kit due to reduced demand for immigration-related tuberculosis testing in the U.S. and Middle East.</p>
<p>Qiagen shares reached a 52-week low of €27.56 ($30.62) May 12 on XETRA and $32.13 the following day on NYSE before climbing back to the low €40s on XETRA and mid-$40s on NYSE.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<h4><strong>Cautious investor reaction</strong></h4>
<p>On Thursday, investors appeared to react cautiously to the deal. Shares on XETRA rose 5% from €42.82 ($47.77) to € 44.94 ($50.13). On NYSE, shares barely rose 0.4%, from an even $50 to $50.22. Qiagen has suspended its full-year guidance for this year due to the planned acquisition.</p>
<p>At €46.50 ($51.88) per share, EQT Equity Partners’ offer for Qiagen represents an 8.6% premium above Qiagen’s closing stock price Wednesday—but a premium of 40.3% to the XETRA closing price of €33.15 ($36.84) on July 8, the last trading day before news reports about private equity firms being interested in acquiring Qiagen. The premium climbs to 46.9% when compared to the three-month volume-weighted average price (VWAP) on XETRA of €31.66 ($35.18) per Qiagen share up to and including July 8.</p>
<p>The €10.8 billion ($12.1 billion) enterprise value of the deal includes approximately $1.1 billion of net debt, Qiagen said.</p>
<p>“Qiagen’s management team and employees have built an exceptional company with a portfolio of highly attractive products and respected brands, strong market positions and considerable technical expertise,” stated Matteo Thun-Hohenstein, Partner at EQT. “EQT brings deep sector experience, a global network and operational capabilities, and we are proud to partner with Qiagen’s highly talented and capable employees to further invest in Qiagen’s continued product innovation and growth.”</p>
<h4><strong>Track record</strong></h4>
<p>EQT has €354 billion in assets under management and a three-decade track record of acquiring, developing, and sometimes selling companies that include life sciences tools/tech concerns.</p>
<p>In 2019, EQT <a href="https://www.genengnews.com/topics/bioprocessing/eqt-agrees-to-acquire-majority-interest-in-cdmo-aldevron/" target="_blank" rel="noopener">acquired a majority interest in Aldevron</a>, which it sold two years later to Danaher for approximately $9.6 billion. Also in 2021, EQT joined the private equity business of Goldman Sachs to <a href="https://www.genengnews.com/topics/drug-discovery/goldman-sachs-eqt-to-buy-parexel-for-8-5b-continuing-cro-consolidation/" target="_blank" rel="noopener">acquire contract research organization Parexel for $8.5 billion</a>. In 2023, EQT co-led a €129 million ($138 million at the time; $144 million today) <a href="https://www.genengnews.com/topics/translational-medicine/going-dutch-vectorys-138m-series-a-to-advance-vectorized-antibody-programs-for-neurodegenerative-diseases/">Series A financing of Amsterdam biotech VectorY</a>, with proceeds intended toward advancing its vectorized antibodies for neurodegenerative disease treatment. Other current and former portfolio companies of EQT include SPT Labtech, Galderma, Dako and HemoCue.</p>
<p>EQT says its healthcare and life sciences experience includes around 100 investment professionals across 15 countries, with over €30 billion (about $33.6 billion) invested across more than 210 companies in healthcare globally.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>EQT Private Equity said it had obtained enough committed equity and debt financing to fund the offer and related transaction costs. Morgan Stanley, Jefferies, Deutsche Bank, SMBC, Crédit Agricole, and UniCredit are acting as bookrunners and mandated lead arrangers for the committed debt financing.</p>
<p>Both EQT and Qiagen stressed the prospective buyer’s plan for long-term ownership of the tools/diagnostics giant. Under the Business Combination Agreement signed by both, EQT Private Equity agreed to support Qiagen’s long-term development through “commitments relating to Qiagen’s strategy, business, key brands, operational footprint, R&D activities, employee arrangements, prudent financing, and culture of excellence.”</p>
<h4><strong>Mid-2027 close expected</strong></h4>
<p>Upon completion of the transaction, which is expected to close in mid-2027, Qiagen said it will continue to operate under its own name and brand. If closing has not occurred within 10 months of October 21 (August 21, 2027) because required regulatory approvals remain pending, Qiagen may opt to pay shareholders an interim dividend of up to $0.47 per share. Any interim dividend would not be deducted from the offer price.</p>
<p>Qiagen said its boards will recommend that the company’s shareholders tender their shares into the takeover offer and vote in favor of the deal in a position statement to be published after EQT publishes the offer document detailing the transaction. The Takeover Offer will be subject to a minimum acceptance threshold of 50% of Qiagen’s outstanding share capital plus one share, approval of post-closing measures and a decision to adopt them by Qiagen’s boards, merger control and foreign investment clearances, and additional conditions.</p>
<p>Qiagen shareholders who do not accept the Takeover Offer will receive a cash distribution in an amount per share equal to the Offer Price less applicable withholding taxes—which Qiagen said may result in a lower net amount being received than if the shareholders had accepted the Takeover Offer.</p>
<p>If the deal goes through, EQT’s planned purchase would end nearly seven years or on-and-off merger-and-acquisition activity surrounding Qiagen. In March 2020, Thermo Fisher Scientific <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.genengnews.com%2Ftopics%2Fcoronavirus%2Fthermo-fisher-to-expand-coronavirus-infectious-disease-dx-with-planned-11-5b-qiagen-acquisition%2F&data=05%7C02%7Calex.philippidis%40sagepub.com%7C28b88f85661e4c341de808de59e20c86%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639047025085584898%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=Rmudj4AreTISalol8OzJBF%2BKvc%2FBEflHXO3VafkxDxc%3D&reserved=0" target="_blank" rel="noopener">offered to acquire Qiagen for approximately $11.5 billion</a> in a deal driven by the COVID-19 pandemic. Thermo Fisher explained at the time that it sought to purchase Qiagen in order to expand its molecular diagnostics portfolio with a SARS-CoV-2 coronavirus test and other infectious disease tests.</p>
<p>However, Thermo Fisher <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.genengnews.com%2Ftopics%2Fcoronavirus%2Fthermo-fisher-qiagen-part-ways-as-covid-19-fuels-collapse-of-12-5b-deal%2F&data=05%7C02%7Calex.philippidis%40sagepub.com%7C28b88f85661e4c341de808de59e20c86%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639047025085609061%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=74Y6gYE7f9KBZz2HGpCBxudVZy9NZtgjMN%2FXaRY93b4%3D&reserved=0" target="_blank" rel="noopener">terminated its buyout offer five months later</a> when it failed to win support from two-thirds (66.67%) of investors, with only 47% of holders of outstanding Qiagen shares agreeing to tender their shares. Key to the deal falling through was vocal opposition from the hedge fund Davidson Kempner, an activist investor that raised its stake in Qiagen from 3.6% to 8%. The deal collapsed despite Thermo Fisher sweetening its offer to $12.5 billion by raising its per-share offering price from €39 ($43.34) to €43 ($47.98).</p>
<p>Two years later, in 2022, <em>The Wall Street Journal</em> reported that Bio-Rad Laboratories was in talks with Qiagen on a merger deal valued at more than $10 billion, a deal that neither company confirmed at the time.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/eqt-to-acquire-qiagen-for-12-1b-plans-to-take-tools-diagnostics-provider-private/">EQT to Acquire Qiagen for $12.1B, Plans to Take Tools, Diagnostics Provider Private</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Proteins Circulating in Blood Linked to Future Risk of Prostate Cancer</title>
<link>https://edusehat.com/en/proteins-circulating-in-blood-linked-to-future-risk-of-prostate-cancer</link>
<guid>https://edusehat.com/en/proteins-circulating-in-blood-linked-to-future-risk-of-prostate-cancer</guid>
<description><![CDATA[ The results of a large prospective proteomic study have associated proteins linked with the immune system, cell adhesion, blood vessel formation, and known prostate cancer genes, to future risk of developing prostate cancer, including aggressive disease. 
The post Proteins Circulating in Blood Linked to Future Risk of Prostate Cancer appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2020/07/Jul14_2020_Getty_1178748795_ProstateCancerCells-scaled-e1627958312296.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 23 Oct 2026 04:45:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Proteins, Circulating, Blood, Linked, Future, Risk, Prostate, Cancer</media:keywords>
<content:encoded><![CDATA[<p>The results of a large prospective proteomic study, headed by Oxford Population Health, have linked proteins associated with the immune system, cell adhesion, blood vessel formation, and known prostate cancer genes, with the future risk of developing prostate cancer (PCa), including aggressive disease.</p>
<p>Findings from the study, involving more than 2,500 men, revealed biological differences between those who later developed prostate cancer, and those who did not. The results may may help guide future studies aimed at identifying men at greater risk of the disease.</p>
<p>Professor Karl Smith-Byrne, MPhil, DPhil, at Oxford Population Health, said, “Finding proteins linked to known prostate cancer driver genes in blood collected years before diagnosis gives us new insights into the earliest stages of the disease. Together with existing and future genetic evidence, these findings may help us identify biological pathways that could be targeted to prevent aggressive prostate cancer.”</p>
<p>The study, “<a href="http://dx.doi.org/10.1016/j.eururo.2026.08.014" target="_blank" rel="noopener">Circulating Immune and Cancer Driver Gene Biomarkers Precede Prostate Cancer Diagnosis by over 10yr</a>,” is published in <em>European Urology</em>, and was presented at the American Society of Human Genetics (ASHG) Annual Meeting. In their paper co-senior author Smith-Byrne and colleagues, concluded, “These findings identify candidate protein risk factors for overall and clinically significant PCa, and warrant further validation and mechanistic evaluation.”</p>
<p>Prostate cancer is the most commonly diagnosed cancer in men worldwide, but relatively little is known about why some men develop the disease or why some cancers become aggressive. Most established risk factors, such as age and genetics, cannot be changed. “Identifying individuals at future risk of clinically significant prostate cancer remains challenging because of the limited number of established predictors,” the researchers noted. Their previous research had identified potential protein risk factors for prostate cancer, “… suggesting that broader proteomic investigation may provide further insights into the mechanisms underlying PCa development.” This is particularly important, they noted, given the lack of preventive strategies.</p>
<p>High-throughput proteomic technologies allow large-scale evaluation of potential protein-disease associations. For their newly reported study, which was part funded by Cancer Research UK, the investigators analyzed blood samples from 982 men who subsequently developed prostate cancer and a randomly selected sample of 1,573 men from the European Prospective Investigation into Cancer and Nutrition (EPIC). They measured more than 6,000 proteins in the blood and looked for differences linked to the later development of prostate cancer, particularly aggressive disease. Participants were followed for around 16 years. “This study is the largest population-based investigation of proteomic risk factors for PCa to date, with comprehensive protein profiling and a case-cohort design enabling robust risk estimation,” the investigators stated.</p>
<p>Their analyses identified circulating proteins associated with future PCa risk, including proteins related to immune, adhesion, angiogenesis, and PCa driver-gene pathways. “Notably, these protein differences were detectable in the blood long before a man’s diagnosis with PCa, and many were associated with clinically significant disease,” they commented.</p>
<p>Twelve proteins were linked to prostate cancer diagnosed more than 15 years after the blood sample was collected. These included GZMK, a protein produced by immune cells involved in recognizing and destroying abnormal cells, suggesting that immune processes may help keep prostate cancer in check long before it is diagnosed.</p>
<p>The researchers also identified seven proteins linked to aggressive prostate cancer. “The long follow-up and detailed characterization of clinically relevant subtypes allowed the identification of proteins associated with aggressive disease,” they stated. One protein, ANKRD1, was consistently linked to several serious forms of the disease, including cancers that had spread or were ultimately fatal. Other findings pointed to processes involved in how cancer cells interact with surrounding tissue and how new blood vessels form.</p>
<p>First author Zhe Huang, PhD, a postdoctoral epidemiologist at Oxford Population Health, said, “Prostate cancer is not one disease. Many prostate cancers grow slowly and may never cause harm, while others are aggressive and can be life-threatening. By measuring thousands of proteins in blood collected years before diagnosis, we can begin to investigate how men who later develop aggressive prostate cancer may differ from men who do not. Ultimately, we hope this will help us understand the biology of aggressive prostate cancer and identify markers that could improve how we assess risk in the future.”</p>
<p>The study also found links with blood levels of proteins produced by genes already known to be important in prostate cancer, including <em>ERBB3, KRAS,</em> and <em>NRAS</em>. These proteins were particularly linked to aggressive prostate cancer diagnosed around a decade later. This does not mean cancer was already present when the blood was collected, but the findings may provide clues to biological changes associated with the future development of the disease.</p>
<p>The researchers compared their results with other large population studies and genetic evidence to test the robustness of their findings. Several findings were supported by these additional analyses, although not all could be confirmed. The proteins identified are not yet suitable for use as clinical tests; most associations were modest and further studies are needed to establish whether they could improve prediction of clinically significant prostate cancer. “Studies integrating tumor genomics and circulating proteomics will be required to clarify the relationship among circulating protein levels, genomic alterations, and disease development, and dedicated prediction studies are warranted to support their potential utility for biologically informed risk stratification,” the researchers concluded.</p>
<p>Future research through the Prostate Cancer Aetiology and Prevention Programme (PCAP), funded by Cancer Research UK, will investigate whether these findings could ultimately contribute to better ways of predicting or preventing prostate cancer.</p>
<p>Professor Ruth Travis, DPhil, at Oxford Population Health, and one of the PCAP programme leads, said,” For the first time, technologies that allow us to measure thousands of proteins simultaneously are giving us unprecedented insight into the earliest stages of prostate cancer development. Combined with large, long-term population studies, they allow us to look back many years before diagnosis and investigate the biological changes associated with future cancer risk. Understanding these processes is a critical step towards developing new strategies to prevent prostate cancer.”</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/proteins-circulating-in-blood-linked-to-future-risk-of-prostate-cancer/">Proteins Circulating in Blood Linked to Future Risk of Prostate Cancer</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>ABP Board Pearls: 6 High&#45;Yield Topics for Your Pediatrics Exam</title>
<link>https://edusehat.com/en/abp-board-pearls-6-high-yield-topics-for-your-pediatrics-exam</link>
<guid>https://edusehat.com/en/abp-board-pearls-6-high-yield-topics-for-your-pediatrics-exam</guid>
<description><![CDATA[ Welcome to high yield topics for the ABP exam! Today we’ll discuss six topics commonly tested on boards: well-appearing patients that may not actually be well; fractures that may have negative imaging findings; headache red flags; the diagnostic evaluation of fever in small children; foreign body aspiration; and systemic rash syndromes! We’ll use clinical vignettes […]
The post ABP Board Pearls: 6 High-Yield Topics for Your Pediatrics Exam appeared first on Elite Medical Prep. ]]></description>
<enclosure url="https://elitemedicalprep.com/wp-content/uploads/2026/10/pexels-silverkblack-39219726-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 23 Oct 2026 01:30:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>ABP, Board, Pearls:, High-Yield, Topics, for, Your, Pediatrics, Exam</media:keywords>
<content:encoded><![CDATA[<p><span>Welcome to high yield topics for the ABP exam! Today we’ll discuss six topics commonly tested on boards: well-appearing patients that may not actually be well; fractures that may have negative imaging findings; headache red flags; the diagnostic evaluation of fever in small children; foreign body aspiration; and systemic rash syndromes! We’ll use clinical vignettes and lists of risk factors to help you break down these topics and nail every board question on them!</span></p>
<p> </p>
<p data-pm-slice="1 1 []">For help fitting these topics into your study schedule, read our guide on <a href="https://elitemedicalprep.com/how-to-approach-abp-board-prep/">how to approach ABP board prep</a>.</p>
<p> </p>
<h2><b>1. “Well-Appearing” May Not Be Well</b></h2>
<p><span>There are lots of reasons a patient you think is well-appearing may not be. There are dangerous diseases which present with only minimal symptoms. There are patients like infants and those developmentally disabled who can’t exhibit severe symptoms. </span></p>
<p> </p>
<h3><b>Case Examples:</b></h3>
<ul>
<li><strong>Infants with fever<br>
</strong>Infants, especially less than 3 months old, may have few symptoms or signs of illness. For example, a well appearing 1 month old with fever still requires blood and urine testing to rule out sepsis.</li>
<li><strong>Appendicitis with minimal early findings<br>
</strong>Even if patient has no fever or minimal pain, if any peritoneal signs are present → evaluate for appendicitis.</li>
<li><strong>MIS-C initially thought viral<br>
</strong>Many dangerous diseases present initially as non-specific viral syndromes, including MIS-C. Pay attention to fevers greater than 4 days and worsening systemic symptoms to trigger a work up. MIS-C has prominent GI symptoms, meningismus and rash.</li>
<li><strong>Orbital abscess without fever initially<br>
</strong>Even significant infections like orbital cellulitis may have only edema and mild pain, without fever initially.</li>
<li><strong>DKA discovered during weight-loss workup<br>
</strong>Patients with mild DKA may appear overall well with only mild symptoms of nausea, abdominal pain and weight loss. Maintain a high index of suspicion whenever weight loss is present.<br>
<b><br>
</b></li>
</ul>
<ul>
<li>
</ul>
<h3><b>Board Pearls – Red Flag Combinations:</b></h3>
<p><b>Remember the following patient presentations:</b></p>
<ul>
<li aria-level="1"><b>Pain severe enough to wake from sleep</b><span> – malignancy, fracture</span></li>
<li aria-level="1"><b>Abdominal pain with jumping</b><span> – appendicitis, peritonitis</span><b><br>
</b><b></b></li>
<li aria-level="1"><b>Persistent fever >5 days </b><span>– malignancy, sepsis, rheumatologic disease</span></li>
<li aria-level="1"><b>Weight loss + subtle symptoms </b><span>– DKA, adrenal insufficiency, malignancy</span> </li>
</ul>
<p> </p>
<h2><b>2. Refusal to Bear Weight = Fracture Until Proven Otherwise</b></h2>
<p><span>The classic patient is a happy toddler who fell down an hour ago, has a normal X-ray, but still refuses to walk. Maybe it’s just a sprain? Maybe not! Remember this list:</span></p>
<p> </p>
<h3><b>Fractures with Possible Normal X-Rays:</b></h3>
<ul>
<li><strong>Toddler’s fracture/Spiral fracture of distal tibia<br>
</strong>Watch for a twisting injury to the leg. On exam the leg may look normal with only mild tenderness!</li>
<li><strong>Any Salter-Harris type 1 (Example: Distal fibula after ankle injury)<br>
</strong>These may present like a simple ankle sprain, but aren’t! Focus on tenderness along the epiphyseal plate.</li>
<li><strong>Stress fractures<br>
</strong>These are true fractures that need splinting. Most commonly in the medial distal tibia, the same location as medial tibial stress syndrome, but symptoms will be more severe.</li>
<li><strong>Slipped capital femoral epiphysis (early on)<br>
</strong>Typically seen in obese children, SCFE may initially only have hip discomfort with a normal X-ray. Consider MRI.</li>
<li><strong>Scaphoid fracture<br>
</strong>Usually after a fall on an outstretched hand (FOOSH), any patient with snuffbox tenderness of the wrist requires a thumb spica splint.</li>
</ul>
<p> </p>
<h3><b>Board Pearls – Empiric Splinting Indicated if X-ray is Normal but…</b></h3>
<p><b>Each of the following on this list indicates a possible underlying fracture, so splint empirically and follow up!</b></p>
<ul>
<li><b></b><span>Refusal to walk</span></li>
<li><span>Fussy with manipulation</span></li>
<li><span>Localized severe tenderness</span></li>
</ul>
<p> </p>
<h2><b>3. Severe Headache Red Flags</b></h2>
<p><span>The boards loves asking about headaches, and for good reason – they are common, often benign, but potentially deadly! Focal neurologic deficits on exam are always a red flag – even if the patient is otherwise well, get brain imaging!</span></p>
<p> </p>
<h3><b>High Risk Headache Features → Consider Imaging</b></h3>
<p><b>This list describes headache features that may suggest increased intracranial pressure. Lying supine overnight increases ICP naturally, so any further elevation from a mass will cause night or morning symptoms.</b></p>
<ul>
<li><span>Headache waking from sleep</span></li>
<li><span>Morning headache</span></li>
<li><span>Worsened by Valsalva (coughing, exerting, etc)</span></li>
<li><span>Changing over time: Frequency, intensity</span></li>
<li><span>Associated with altered mental status, vomiting, ataxia</span></li>
<li><span>Occipital location</span></li>
</ul>
<p> </p>
<h3><b>High Risk Exam Findings → Obtain Imaging</b></h3>
<p><b>These are the most commonly seen early onset signs of increased ICP. If the patient presents with these findings, strongly consider imaging.</b></p>
<ul>
<li><span>Abnormal eye movements</span></li>
<li><span>Gait abnormality or ataxia</span></li>
<li><span>Weakness</span></li>
<li><span>Papilledema</span> </li>
</ul>
<p> </p>
<h3><b>Board Pearls – Classic Brain Tumor Presentation:</b></h3>
<ul>
<li aria-level="1"><span>Remember the classic presentation: </span><b>progressive course of morning vomiting and headache, with papilledema and focal neuro deficits on exam. </b><span>Get brain imaging right away!</span><span><br>
</span></li>
</ul>
<p> </p>
<h2><b>4. Fever Without Source in <2 Years</b></h2>
<p><span>ABP loves testing you on fevers! Remember, the priority is to get blood cultures and urine testing on patients at risk for invasive bacterial infections. The following lists are crucial:</span></p>
<p> </p>
<p><b>Fever: Risk Factors for Invasive Bacterial Infection → Consider Urine Testing and/or Blood</b></p>
<p>This list describes features that make a fever higher risk for being caused by a bacterial source. If the patient has a fever like this, consider blood and/or urine testing to rule out IBIs like UTI and bacteremia.</p>
<ul>
<li><span>Greater than 102.2F (39 C)</span></li>
<li><span>Greater than 48 hours duration</span></li>
<li><span>Fever that recurs after initial resolution</span></li>
</ul>
<p> </p>
<p><b>Patient: Risk Factors for Sepsis → Consider Blood Work</b></p>
<p>This list shows patient factors that increase the likelihood they may have sepsis, particularly in the setting of fever. Infants less than 3 months are one of the highest risk groups – always consider blood work and even lumbar puncture if indicated.</p>
<ul>
<li><span>Age less than 3 months</span></li>
<li><span>Ill-appearing</span></li>
<li><span>Unimmunized</span></li>
<li><span>Immunodeficiency</span></li>
</ul>
<p> </p>
<p><b>Patient: Risk Factors for UTI → Consider Urine Testing</b></p>
<p>This list contains patient factors that increase their risk for having a UTI in the setting of fever. Younger patients, especially females, are at highest risk. Remember, if there’s no identifiable fever source on exam, consider urine testing!</p>
<ul>
<li><span>No signs or symptoms of another fever source</span></li>
<li><span>Female: less than 2 years old</span></li>
<li><span>Uncircumcised male: less than 1 year old</span></li>
<li><span>Circumcised male: less than 6 months old</span></li>
<li><span>History of UTI or urogenital abnormality</span></li>
</ul>
<p> </p>
<h3><b>Board Pearls:</b></h3>
<ul>
<li aria-level="1"><span>Memorize fever and patient risk factors for bacterial infections!</span></li>
<li aria-level="1"><span><2 yrs with fever without source → </span><b>always consider UA</b></li>
<li aria-level="1"><span>Urine dip with leukocyte esterase alone → </span><b>may NOT be UTI</b></li>
</ul>
<p> </p>
<h2><b>5. Foreign Body Aspiration</b></h2>
<p><span>It’s easy to catch the kid who just inhaled a grape and is actively choking. It’s harder to catch the actual most common presentation of foreign body aspiration: a subacute cough syndrome with few other findings. </span></p>
<p> </p>
<h3><b>Historical Features of Choking or Coughing Episode:</b></h3>
<ul>
<li aria-level="1"><span>May be days or weeks before presentation</span></li>
<li aria-level="1"><span>Usually self-limited</span></li>
<li aria-level="1"><span>Followed by symptom-free or cough-only period</span></li>
<li aria-level="1"><span>May be forgotten by caregiver</span></li>
</ul>
<p> </p>
<h3><b>Clinical Presentation:</b></h3>
<p><b>Most foreign body aspirations will have at least one of the below findings, whether acute, subacute or chronic.</b><b></b></p>
<ul>
<li><span>Subacute cough</span></li>
<li><span>Stridor</span></li>
<li><span>Unilateral wheeze on exam</span></li>
<li><span>XR normal for small, radiolucent objects (eg., peanut)</span></li>
<li><span>XR with unilateral hyperinflation or atelectasis if obstruction</span></li>
<li><span>Fever if post-obstructive pneumonia</span></li>
</ul>
<p> </p>
<h3><b>Board Pearl:</b></h3>
<p>Obtain bronchoscopy if any of the above findings suspicious for aspiration are present, even if the child is overall well-appearing and without systemic symptoms!</p>
<p> </p>
<h2><b>6. Rash + Systemic Symptoms = Think Bigger</b></h2>
<p><span>Children get rashes all the time – so which ones are dangerous? Whenever systemic symptoms or signs are involved, think about bacterial and immunologic conditions. For boards, remember these syndromes!</span></p>
<p> </p>
<p><b>Board Pearls – Rash Syndromes:</b></p>
<ul>
<li><strong>Palpable purpura on legs + joint pain only → think HSP<br>
</strong>We’re used to remembering HSP involves GI and renal findings like abdominal pain or hematuria. But these findings are delayed in onset, and often missing early on!</li>
<li><strong>Rash with neurologic findings </strong>→ think meningococcemia, Rocky Mountain spotted fever, viral encephalitis, or MIS-C</li>
<li><b>Meningococcemia </b>= petechial or purpuric rash + fever. With these findings, rule out meningococcal disease first and foremost.</li>
<li><b>RMSF </b>= Papular rash of wrists, ankles with meningismus. The fever and headache are prominent in RMSF, but the rash is delayed in onset until days 3-5. Thrombocytopenia is classic. Urticaria is not typical and suggests another diagnosis.<b><br>
</b><b></b></li>
<li><b>HSV encephalitis</b> = Vesicular rash + confusion, AMS. For any vesicular rash in an encephalitic patient, start empiric acyclovir as soon as possible!</li>
<li><b>MIS-C = </b>Rash + GI-prominent sepsis syndrome. These patients are systemically ill with meningismus as well. Look for a recent COVID diagnosis.</li>
<li><strong>5 days of fever with late-onset rash → think roseola<br>
</strong>If well-appearing patient, no need for sepsis work up even despite prolonged fever. Remember, roseola may cause sterile pyuria (ddx: UTI) and erythematous tympanic membranes (ddx: AOM), so don’t overtreat for something that isn’t there!</li>
<li><strong>Kawasaki and scarlet fever both have fever, rash, pharyngeal erythema and strawberry tongues<br>
</strong>But Kawasaki has prolonged symptoms >5 days, while scarlet fever remits by days 3-5 and the rash fades around day 6. Kawasaki’s lymphadenopathy is usually painless, while scarlet fever’s is painful. Both may have epidermal desquamation.</li>
</ul>
<p> </p>
<ul>
<li>
</ul>
<h2><span><strong>Final thoughts</strong></span></h2>
<p><span>That wraps up our high yield ABP topic discussion! Remember not to be fooled by certain well-appearing patients, especially febrile infants and patients early on in their course of illness – they still need a work up! For fractures, remember the list of those with initially negative imaging. Regarding headaches, memorize the red flag symptoms and signs, and always get imaging for focal neuro signs! With fever in children under 2 years old, remember the risk factor lists we reviewed, because boards loves testing on those. </span></p>
<p> </p>
<p><span>Remember the classic presentation of foreign body aspiration, and its subacute counterpart. And finally, now you can distinguish different rash syndromes by their associated characteristics. </span>As you review these topics, practice identifying the key clues in each vignette and explaining why the other answer choices are incorrect. For more ways to strengthen your preparation, explore <a href="https://elitemedicalprep.com/common-pitfalls-in-abp-prep-and-how-to-avoid-them/">common pitfalls in ABP prep and how to avoid them</a>. <span>Good luck on your exam!</span></p>
<p>The post <a href="https://elitemedicalprep.com/abp-board-pearls-6-high-yield-pediatric-topics-for-your-pediatrics-exam/">ABP Board Pearls: 6 High-Yield Topics for Your Pediatrics Exam</a> appeared first on <a href="https://elitemedicalprep.com/">Elite Medical Prep</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Patient advocates launch PACE by reviewing their big hits in 2026</title>
<link>https://edusehat.com/en/patient-advocates-launch-pace-by-reviewing-their-big-hits-in-2026</link>
<guid>https://edusehat.com/en/patient-advocates-launch-pace-by-reviewing-their-big-hits-in-2026</guid>
<description><![CDATA[ Patient advocacy is often a long game, so it is important to remember (and celebrate) the home runs as the hits come—and keep on […]
The post Patient advocates launch PACE by reviewing their big hits in 2026 appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/10/Patient-Advocates-B-roll-Scratch.00_08_00_13-Still002.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 23 Oct 2026 01:15:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Patient, advocates, launch, PACE, reviewing, their, big, hits, 2026</media:keywords>
<content:encoded><![CDATA[<p><span>Patient advocacy is often a long game, so it is important to remember (and celebrate) the home runs as the hits come—and keep on coming. </span></p>
<p><span>The Biotechnology Innovation Organization (BIO) launched their 15th annual Patient Advocacy Changemakers Event (PACE) in Washington DC on Oct. 22 with a celebration of some of advocacy’s biggest recent wins during their </span><a href="https://pace.bio.org/2026-program/patient-advocates-leading-way-1?&filters.date=22-Oct-2026%2C23-Oct-2026%2C&sortby=customfield_6234%20asc&searchgroup=libraryentry-2026-program"><span>Home Run! Patient Advocates Leading the Way</span></a><span> panel. </span></p>
<p><span>Michele Oshman, BIO Chief Patient Advocate and SVP, Patient Advocacy Center of Excellence, asked a panel of patient advocates about 2026’s banner achievements.</span></p>
<h3>Hitting it out of the park in 2026</h3>
<p><span>One big area that advocates got a few good hits in was the vaccine space. This is especially important in the wake of the COVID pandemic, which saw some states restricting vaccine access in ways that surprised many public health professionals. </span></p>
<p><span>Sue Peschin, MHS, President and CEO at the Alliance for Aging Research explained how, even though her organization works primarily with older populations, when it came to vaccine legislation, partnering with pediatric and chronic disease advocates got policies to home base faster.</span></p>
<p><span>“We started something called the Our Best Shot Network to really bring the different coalition leaders together,” Peschin said, “so that folks could coordinate and amplify each other’s opportunities.”</span></p>
<p><span>As a result, advocates have been able to co-lead a number of sign-on letters to the Food and Drug Administration (FDA) to highlight issues that would not have otherwise gotten as much attention, particularly when it comes to the Advisory Committee on Immunization Practices (ACIP). The network has also brought in center-right politicians to help sway their colleagues when problematic vaccine policy arises.</span></p>
<p><span>“There was an initiative to require prescriptions in order to get a COVID vaccine that was almost up for a vote at ACIP,” said Peschin, “and because of connections that we had made with conservative friends, they contacted ACIP and pulled back on that vote and made sure that that didn’t come up. No matter what you think about COVID vaccines, that would have set a horrible precedent for vaccines overall. So that was a big deal.”</span></p>
<p><span>There were wins in the Alzheimer’s community as well. </span></p>
<p><span>“We have new blood tests, blood-based biomarker tests,” recalled Erika Sward, Chief Advocacy Officer for the UsAgainstAlzheimer’s. “There are two pieces of legislation that are advancing through the House and the Senate called the </span><a href="https://www.congress.gov/bill/119th-congress/house-bill/6130/text"><span>ASAP Act</span></a><span> and the </span><a href="https://www.congress.gov/bill/118th-congress/senate-bill/2379/text"><span>CHANGE Act</span></a><span>, both of which are basic common sense laws that will make sure that people have access to cognitive testing tests and also these blood-based biomarkers for screening once they have been approved by FDA.”</span></p>
<p><span>Another example Sward gave started in 2025.</span></p>
<p><span>“For fiscal year 2026, the president’s budget proposed a 40% cut to the National Institutes of Health (NIH),” Sward explained. “By the time they finally finished the budget in March of this year, we had a $415 million increase to the NIH, and that is because we all worked together.”</span></p>
<p><span>There have also been some groundbreaking wins that were a long time coming, as Annie Kennedy, Chief Mission Officer at the RARE Foundation explained.</span></p>
<p><span>“We, as an organization, worked for a number of years with our patient advocacy coalitions and our industry coalitions and crafted what was called the Speeding Therapy Access Today (STAT), which would have established a rare disease center of excellence at the FDA,” Kennedy recalled. “And while that momentum and those hundreds of advocates that were repeatedly going to the Hill for a number of years didn’t yield a center of excellence, it did yield the Rare Disease Innovation Hub at FDA.”</span></p>
<p><span>Kennedy continued: “We’ve had wonderful acceptance and championship from both Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) when that hub was first established. That has remained. Despite all of the changes and shifts in the different individuals who’ve been leading the agency, there has been unwavering and unflagging support for the hub.”</span></p>
<h3>Moving forward together</h3>
<p><span>So how do advocates reach these wins and then keep on going? Panelists emphasized collaboration.</span></p>
<p><span>“The secret sauce for all of us has been in the collaborations that we form,” said Kennedy. “The strength has been in the coming together and understanding where the opportunities are to lean in and where the opportunities are to pivot from what we thought we would be working on this year.”</span></p>
<p><span>“While you are at PACE, make a point to meet people that you’ve never met before and get their contact information so that you can follow up with them,” said Sward. “Figure out how you can create new networks that may help you move forward. Find other organizations with whom to lock arms—and ask questions.”</span></p>
<p><span>“Don’t be afraid to stop a speaker and say, </span><i><span>What the heck does that mean?</span></i><span> That’s important,” said Peschin. “That is a great way to both learn more and make deeper connections.”</span></p>
<p>The post <a href="https://bio.news/federal-policy/patient-advocates-launch-pace-by-reviewing-their-big-hits-in-2026/">Patient advocates launch PACE by reviewing their big hits in 2026</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>PACE: Pushing past the pain to achieve access for the 21st Century</title>
<link>https://edusehat.com/en/pace-pushing-past-the-pain-to-achieve-access-for-the-21st-century</link>
<guid>https://edusehat.com/en/pace-pushing-past-the-pain-to-achieve-access-for-the-21st-century</guid>
<description><![CDATA[ Patient advocates are no strangers to the sometimes painful challenges of promoting access to medicines and treatments. The key, they say, is staying two […]
The post PACE: Pushing past the pain to achieve access for the 21st Century appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/10/21st-century-pain-points.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 23 Oct 2026 01:15:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>PACE:, Pushing, past, the, pain, achieve, access, for, the, 21st, Century</media:keywords>
<content:encoded><![CDATA[<p><span>Patient advocates are no strangers to the sometimes painful challenges of promoting access to medicines and treatments. The key, they say, is staying two steps ahead.</span></p>
<p><span>“We’ve all experienced decades of incredible innovation as it relates to the biopharmaceutical community,” Kate Mevis, Associate VP of U.S. Federal Policy at Merck told an Oct. 22 session of the BIO Patient Advocacy Changemakers Event (PACE) in Washington, DC. “But we really need to make sure that access, coverage, cost, and the policies that govern those, keep pace with this innovation.”</span></p>
<p><span>Mevis moderated the PACE panel called </span><a href="https://pace.bio.org/2026-program/21st-century-access-pain-points-patients--1?&filters.date=22-Oct-2026%2C23-Oct-2026%2C&sortby=customfield_6234%20asc&searchgroup=libraryentry-2026-program"><span>21st Century Access: Pain Points for Patients</span></a><span>, which investigated barriers to patient access.</span></p>
<div class="ast-oembed-container "></div>
<p><span><br>
So what have been patient’s biggest pain points in recent years? And what are advocates doing to relieve the pressure?</span></p>
<h3>Utilization management remains a major pain point</h3>
<p><span>“Eighty percent of people living with psoriasis or psoriatic arthritis report that they have been subjected to some sort of utilization management,” said Leah Howard, President and CEO of the National Psoriasis Foundation. “That statistic is even higher in Medicare. About 90% of patients accessing therapies through Medicare experience utilization management.”</span></p>
<p><span>Howard said she’ll often ask a gathering how many audience members have experienced step therapy, prior authorization challenges or other forms of utilization management. “Literally, every single hand in the room goes up,” she said.</span></p>
<p><span>These utilization management challenges are compounded by insurers using copay accumulators and maximizers, said Carl Schmid, Executive Director at the HIV+Hepatitis Policy Institute. </span></p>
<p><span>“Patients rely on copay assistance for over $20 billion to help us pay for our drugs. That’s a lot of money,” Shmid said. “But unfortunately, pharmacy benefit managers (PBMs) and insurers are stealing around $7 billion of that through copay accumulators and maximizers.”</span></p>
<p><span>And these two pain points together are often even more magnified by the fact that patients are rarely dealing with just one disease.</span></p>
<p><span>“Most people have multiple diseases,” said Pam Traxel, SVP, Alliance Development and Philanthropy at the American Cancer Society Cancer Action Network. “So one of the things that’s so important about resolving utilization management is it is not just that a patient is studying one time to get access to one medicine. If you have a chronic disease, you are doing this throughout your entire life in many different areas.”</span></p>
<h3>Pain points in the real world</h3>
<p><span>And these issues are not just hypothetical, they are happening in real ways. </span></p>
<p><span>“Earlier this year, one health insurance company came out with their policy for 2026 that took a treatment that was approved nine years ago for psoriasis and psoriatic arthritis, and said that for a patient on their formulary to access that treatment, they would have to go through 14 other therapies, over 42 months to get to that one that their clinician wanted them to use,” explained Howard. “And this wasn’t because this was some brand new therapy that had just been approved.”</span></p>
<p><span>Luckily, the National Psoriasis Foundation and their partner groups in Pennsylvania, where this plan was located, succeeded in getting the insurer to reduce the list to five alternative therapies and 15 months, a noted improvement on the original plan.</span></p>
<p><span>But as Shmid pointed out, there is still work to be done on many advocacy fronts. </span></p>
<p><span>Shmid’s organization, the HIV+Hepatitis Policy Institute, filed a discrimination lawsuit three years ago after finding that some insurers were not covering the HIV drugs people needed, or were placing all HIV drugs on the highest formulary tier—a clear violation of the Affordable Care Act, </span><a href="https://bio.news/health/how-to-break-down-barriers-in-hiv-care/"><span>as Bio.News reported.</span></a></p>
<p><span>The HIV+Hepatitis Policy Institute won their suit, but the problem now is that the ruling is not being enforced. </span></p>
<p><span>“I get a lot of calls from people who are faced with these thousands and thousands of dollars in charges, and they say, ‘</span><i><span>Wait, I’m looking at the literature. You won. Why am I being charged this?’</span></i><span> And they’re angry,” Shmid said. </span></p>
<p><span>“It’s hard enough to pay their premiums, and now they’re being stuck with thousands of dollars of bills that they didn’t expect,” he continued. “We cannot give up on this issue. We have to hold the federal government accountable. We have to hold the insurers and PBMs accountable for what they’re getting away with right now.”</span></p>
<h3>Pushing back against the pain</h3>
<p><span>But advocates see reasons for hope.</span></p>
<p><span>“I think the American people have reached the boiling point on this issue,” said Shmid. “It’s not just the patients. It’s not just the caregivers, our families. It’s not just the providers. It’s members of Congress. Everyone is experiencing this prioritization or step therapy.”</span></p>
<p><span>The challenge of advocacy, however, is the ability to maintain momentum on established issues, while also anticipating new ones.</span></p>
<p><span>“There needs to be an urgency around our desire to remove these barriers because as we are fighting the original issue, the insurers are onto something totally different,” said Traxel.</span></p>
<p><span>At its core, the driver of patient advocacy is to ensure that biotech innovation can actually serve the common good it is intended for. </span></p>
<p><span>“When people talk about the promise of drug discovery and the great developments that happen, the fact that those treatments are sitting on the shelf and the patient can’t access them makes it feels like this whole process is for naught,” said Howard. “We can’t let that happen.”</span></p>
<p>The post <a href="https://bio.news/latest-news/pace-pushing-past-the-pain-to-achieve-access-for-the-21st-century/">PACE: Pushing past the pain to achieve access for the 21st Century</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>ASHG President Susan Slaugenhaupt Calls for Hope, Leadership, and Communication in Science</title>
<link>https://edusehat.com/en/ashg-president-susan-slaugenhaupt-calls-for-hope-leadership-and-communication-in-science</link>
<guid>https://edusehat.com/en/ashg-president-susan-slaugenhaupt-calls-for-hope-leadership-and-communication-in-science</guid>
<description><![CDATA[ ASHG President Susan Slaugenhaupt, PhD, opened the society’s Montreal meeting with a heartfelt address emphasizing hope, leadership, and the importance of communication amid the challenges facing science today. 
The post ASHG President Susan Slaugenhaupt Calls for Hope, Leadership, and Communication in Science appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/ASHG_Susan-Slaugenhaupt_rectangle.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 23 Oct 2026 01:10:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>ASHG, President, Susan, Slaugenhaupt, Calls, for, Hope, Leadership, and, Communication, Science</media:keywords>
<content:encoded><![CDATA[<p>The American Society of Human Genetics (ASHG) meeting, being held in Montreal this week, kicked off with the Presidential address given by Susan Slaugenhaupt, PhD, Professor of Neurology at Harvard Medical School and ASHG President.</p>
<p>Slaugenhaupt opened the speech noting that “it’s really hard to know what to say in a presidential address” and that one of her friends told her that, “right now, people just need a message of hope.” And another said, “You always speak from the heart, so just do that.” Slaugenhaupt proceeded to deliver her heartfelt address—emphasizing hope, leadership, and the importance of communication amid the challenges facing science today. Some of the highlights are here.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>“Persistence is not simply how we survive difficult periods in science. It is how we protect our passion, strengthen our teams, and turn discovery into a better future,” she asserted. “I know I’m not alone in feeling anger and frustration about what has happened to science in the United States, how it is reviewed, funded, and perceived by the public. The very idea of education is under attack. Scientific priorities are increasingly shaped by political forces rather than rigorous peer review. We see people rejecting vaccines, distrusting physicians, and dismissing decades of evidence-based progress. As scientists, our instinct is to respond with data. We want to explain the evidence. We want to demonstrate what the science shows, that the data alone are not bridging the divide. Whatever our individual political beliefs are, politics should not determine the value of scientific discovery. So what do we do? We act, we persist, we communicate. The most successful people I know are not people who never encounter barriers. They are people who meet those barriers with persistence and determination and keep going.”</p>
<p>Slaugenhaupt told the story of the quote below being taped to her office door by a team member after a particularly hard day in the lab. The piece of paper has remained tacked above her desk for nearly 30 years.</p>
<figure aria-describedby="caption-attachment-339692" class="wp-caption aligncenter"><img fetchpriority="high" decoding="async" class="wp-image-339692" src="https://www.genengnews.com/wp-content/uploads/2026/10/Unknown-1-1024x768.jpeg" alt="Susan Slaugenhaupt quote" width="696" height="522" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Unknown-1-1024x768.jpeg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/Unknown-1-300x225.jpeg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Unknown-1-768x576.jpeg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/Unknown-1.jpeg 1440w" sizes="(max-width: 696px) 100vw, 696px"><figcaption class="wp-caption-text">The quote referred to by Susan Slaugenhaupt, PhD, in her ASHG presidential address [Julianna LeMieux]</figcaption></figure>
<p>The message that stayed with Slaugenhaupt from that quote is that persistence and determination are what carry us through when everything else has been exhausted. “That lesson helped shape me as a scientist and later as a leader,” she noted.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>“Recounting this story brings me to an important lesson beyond persistence and determination, and that is the importance of building a cohesive team that has your back. Always pay attention to your team and treat them well. It doesn’t matter if this is your lab team or your leadership team. Those people make you better every single day. Give credit generously. Ask people what they need to succeed. Notice the quiet members of your team. Make it safe to admit mistakes and create opportunities for people to grow in their roles. At some point in your career, success becomes less about advancing yourself and more about helping others advance. When that shift happens, embrace it.”</p>
<p>“This career is not easy, but your work is absolutely essential. Never forget that. If there is one quality that defines scientists, it’s passion. We don’t do this job because it pays particularly well or because there isn’t anything else we’re interested in. We do it because we can’t imagine doing anything else. Most of us caught the bug early. Curiosity became fascination, fascination became purpose, and eventually science became part of who we are. No matter how challenging the current environment is, I still see this passion in people every day and all of you. Most importantly, I see it in young people.”</p>
<p>“For the past 15 years, I’ve run an undergraduate summer student program. Every summer, those students arrive at the lab and they bring something remarkable with them. They bring optimism, energy, possibility. They are completely convinced that they will make discoveries that will change lives. And honestly, some of them probably will. Whenever I begin to think about the future, I think about those students, and that is why I remain hopeful. Hundreds of millions of people worldwide live with a genetic disease. They often face diagnostic odysseys only to learn that their disease has no treatment. Those of you who work with families know that there is nothing more powerful than a parent’s determination to help their child. They do not stop. They do not quit. They do not lose hope. They embody persistence.”</p>
<p>She also emphasized the importance of communicating science and designed the Presidential Symposium to focus on exploring the barriers that limit meaningful public engagement and discuss what scientists can do to help bridge these gaps. Because, she said, “speaking out is not optional anymore. It is part of our responsibility. Protesting might not be for everyone, but communicating must be. We must all be more vocal about the critical role in science and more specifically human genetics and genetics plays in improving the health of people around the world.”</p>
<p>“Over the past 18 months, we have witnessed an unprecedented challenge to science in the U.S. Actions that undermine scientific integrity, public trust, and research funding have affected all of us. Sadly, I suspect we’re not simply waiting for a return to the way things used to be. We are being asked to help shape what comes next. So when the path forward feels uncertain, remember this, your work matters. Build teams that support one another and celebrate one another’s success. Tell people outside this room what you do and why it matters. Protect the passion that brought you to science in the first place and above all, persist. Persist for the students who are just beginning their journeys. Persist for the patients and families who are waiting for answers. Persist for one another and persist because the future of human health depends on what we discover together. I am absolutely convinced that human genetics and genomics will continue to transform medicine and improve lives around the world.”</p>
<p>“Every person in this room is part of that future. The world needs your science. The world needs your voice and now more than ever, the world needs you to persist. Thank you.”</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/ashg-president-susan-slaugenhaupt-calls-for-hope-leadership-and-communication-in-science/">ASHG President Susan Slaugenhaupt Calls for Hope, Leadership, and Communication in Science</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Southlake Health launches new initiative to connect patients with care before hospitalization</title>
<link>https://edusehat.com/en/southlake-health-launches-new-initiative-to-connect-patients-with-care-before-hospitalization</link>
<guid>https://edusehat.com/en/southlake-health-launches-new-initiative-to-connect-patients-with-care-before-hospitalization</guid>
<description><![CDATA[ New population health program will use data, research and community partnerships to improve access to care. Southlake Health has launched a new initiative aimed at improving how healthcare is delivered across northern York Region and southern Simcoe County, with a focus on helping patients access services before their conditions become more serious. The Population Health […]
The post Southlake Health launches new initiative to connect patients with care before hospitalization appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/shutterstock_2730576377.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 21:30:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Southlake, Health, launches, new, initiative, connect, patients, with, care, before, hospitalization</media:keywords>
<content:encoded><![CDATA[<p>New population health program will use data, research and community partnerships to improve access to care.</p>
<p>Southlake Health has launched a new initiative aimed at improving how healthcare is delivered across northern York Region and southern Simcoe County, with a focus on helping patients access services before their conditions become more serious.</p>
<p>The Population Health Management Advance, known as PHM Advance, will bring together clinical expertise, health data, research and community partnerships to identify gaps in care and develop more proactive approaches to supporting patients.</p>
<p>Rather than relying primarily on hospital-based treatment after health problems escalate, the initiative will explore opportunities to identify people who may benefit from earlier intervention and connect them with appropriate services.</p>
<p>The approach is intended to improve health outcomes, strengthen coordination between providers and potentially reduce avoidable hospital admissions.</p>
<h3>Using data to improve patient care</h3>
<p>Population health management involves examining the healthcare needs of communities and using that information to guide how services are planned and delivered.</p>
<p>Through PHM Advance, Southlake will identify opportunities for improvement, test new approaches, evaluate their effectiveness and expand those that demonstrate positive results.</p>
<p>A dedicated team at the hospital will collaborate with local healthcare providers to develop practical solutions that help patients navigate the health system and receive care in appropriate settings.</p>
<p>The initiative comes as Southlake serves communities experiencing continued population growth and increasing demand for healthcare services.</p>
<h3>International expertise supporting local innovation</h3>
<p>Southlake has also established a Global Advisory Board featuring healthcare leaders from Canada, the United States, the Netherlands and Singapore.</p>
<p>The board will contribute expertise and perspectives on population health management, helping the hospital evaluate approaches that could improve care delivery.</p>
<p>PHM Advance forms part of Southlake’s broader strategy to develop a Distributed Health Network, which aims to provide care across multiple locations and community settings rather than relying on a single hospital campus.</p>
<p>The model emphasizes bringing services closer to patients, improving connections between healthcare providers and supporting people in maintaining their health for longer.</p>
<h3>A shift toward prevention</h3>
<p>The initiative reflects a broader effort to move healthcare delivery toward earlier intervention and stronger coordination between hospitals and community-based services.</p>
<p>For patients, that could mean receiving additional support before a manageable health issue becomes an emergency.</p>
<p>For healthcare providers, it offers an opportunity to improve communication, identify unmet needs and direct resources toward patients who could benefit most.</p>
<p>Although the initiative is newly launched and its outcomes have yet to be demonstrated, Southlake intends to use ongoing evaluation to determine which approaches should be expanded.</p>
<p>Source: <a href="https://southlake.ca/news/southlake-launches-new-population-health-management-advance/?utm_source=chatgpt.com">Southlake Health — Population Health Management Advance</a>.</p>
<p>The post <a href="https://www.hospitalnews.com/southlake-health-launches-new-initiative-to-connect-patients-with-care-before-hospitalization/">Southlake Health launches new initiative to connect patients with care before hospitalization</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The Organoid Odyssey: A Glimpse Into the Past, Present, and Future of hPSC&#45;Derived 3D Models</title>
<link>https://edusehat.com/en/the-organoid-odyssey-a-glimpse-into-the-past-present-and-future-of-hpsc-derived-3d-models</link>
<guid>https://edusehat.com/en/the-organoid-odyssey-a-glimpse-into-the-past-present-and-future-of-hpsc-derived-3d-models</guid>
<description><![CDATA[ In this GEN webinar, our expert speaker, Arati Naveen, PhD, will trace the foundational discoveries that shaped organoid technology as a new approach methodology (NAM), while highlighting pioneering contributions and contemporary advances.
The post The Organoid Odyssey: A Glimpse Into the Past, Present, and Future of hPSC-Derived 3D Models appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Getty_1435534172_StemCell.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 03:55:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, Organoid, Odyssey:, Glimpse, Into, the, Past, Present, and, Future, hPSC-Derived, Models</media:keywords>
<content:encoded><![CDATA[<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"></div>
</div>


<p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Register Now</button></p>

<h3 class="w-full text-left">
    <strong>
        Panelists:
    </strong>
</h3>
<div class="flex flex-row m-0-auto items-stretch justify-center flex-wrap mb-4">
    
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/10/AratiNaveen_3-e1792592201588.jpeg" class="h-full w-full object-cover" alt="Image of Arati Naveen, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Arati Naveen, PhD</h2>
                <h5 class="mt-0 !text-[15px] !leading-[21px]">CIRM Postdoctoral Scholar<br>Cedars-Sinai Medical Center</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/10/AratiNaveen_3-e1792592201588.jpeg" alt="Image of Arati Naveen, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Arati Naveen, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Arati Naveen, PhD, graduated with her bachelor’s in biomedical engineering from the University of Buffalo. She then moved to L.A. to pursue her master’s in stem cell biology and regenerative medicine at the University of Southern California (USC). She received her PhD in biomedical and translational sciences at Cedars-Sinai in the Jefferies Lab, where her dissertation project explored the interplay between heart disease and immunometabolism. In the Sharma Lab, her work focuses on using cardiac organoids to study autoimmune mediated heart disease and for predictive modeling of drug cardiotoxicity.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog></div>



<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-malblocks-webinars-info"></p><div><strong>Broadcast Date:</strong> <time>Thursday, December 3, 2026</time><br><ul><li><strong>Time:</strong> <time datetime="2026-12-03T16:00:00.000Z">08:00 PST, 11:00 EST, 16:00 GMT</time></li></ul></div>


<div aria-hidden="true" class="wp-block-spacer"></div>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow">
<p class="wp-block-paragraph">Human induced pluripotent stem cell (iPSC)-derived organoids combine the ability to generate diverse cell types with the retention of parental genetic backgrounds, providing opportunities to investigate human development, disease mechanisms, and individual differences in therapeutic responses. These models capture aspects of complex tissue architecture and multicellular interactions within a more physiologically relevant spatial environment. Over the past two decades, advances in stem cell reprogramming, directed differentiation, and three-dimensional culturing techniques have enabled the development of organoid models for the brain, retina, heart, lung, intestine, liver, pancreas, kidney, and many more.</p>


<p class="wp-block-paragraph">In this <em>GEN</em> webinar, our expert speaker, Arati Naveen, PhD, will trace the foundational discoveries that shaped organoid technology as a new approach methodology (NAM), while highlighting pioneering contributions and contemporary advances. This webinar will examine the ways in which the challenges of tissue maturation, vascularization, reproducibility, and scalability, are being addressed. One example explored is harnessing microgravity to strengthen organoid performance and support the broader adoption as NAMs.</p>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><em>A live Q&A session will follow the presentation offering you the chance to pose questions to our expert panelist.</em></p>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><strong>Produced with support from:</strong></p>


<figure class="wp-block-image alignleft size-full is-resized"><a href="https://www.corning.com/" target="_blank" rel=" noopener"><img fetchpriority="high" decoding="async" width="300" height="300" src="https://www.genengnews.com/wp-content/uploads/2023/11/Corning_Logo.jpg" alt="Corning Logo" class="wp-image-277211" srcset="https://www.genengnews.com/wp-content/uploads/2023/11/Corning_Logo.jpg 300w, https://www.genengnews.com/wp-content/uploads/2023/11/Corning_Logo-150x150.jpg 150w" sizes="(max-width: 300px) 100vw, 300px"></a></figure>
</div>
</div>

<p>The post <a href="https://www.genengnews.com/multimedia/webinars/the-organoid-odyssey-a-glimpse-into-the-past-present-and-future-of-hpsc-derived-3d-models/">The Organoid Odyssey: A Glimpse Into the Past, Present, and Future of hPSC-Derived 3D Models</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Raman+NIR Spectra Improves Glucose Soft Sensing</title>
<link>https://edusehat.com/en/ramannir-spectra-improves-glucose-soft-sensing</link>
<guid>https://edusehat.com/en/ramannir-spectra-improves-glucose-soft-sensing</guid>
<description><![CDATA[ Combining Raman and NIR spectroscopy into a single framework creates a multi-modal soft-sensing option that is effective for fed-batch, online, and in-line glucose sensing, preparing the way for hybrid/continuous processing.  
The post Raman+NIR Spectra Improves Glucose Soft Sensing appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2020/08/Aug7_2020_Getty_626533919_FemaleScientistUsingFTIRSpectrophotometer-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 03:55:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>RamanNIR, Spectra, Improves, Glucose, Soft, Sensing</media:keywords>
<content:encoded><![CDATA[<p>Accurate glucose monitoring has been a bottleneck in fed-batch fermentation for years, and is especially critical as biopharmaceutical manufacturers transition toward hybrid and continuous bioprocessing for advanced therapeutics.</p>
<p>Fusing Raman and near-infrared (NIR) spectroscopy into a multimodal soft-sensing framework appears, however, to remove that bottleneck. This new framework provides high-frequency, low-latency measurements that aren’t typically available with existing commercial, off-line sensors. Its developers say it provides “accurate, online-compatible glucose soft sensing,” and that it is also amenable for in-line applications.</p>
<p>More specifically, Raman spectroscopy offers crisp, highly specific chemical fingerprints, while NIR offers broad, information-laden spectral coverage. Realizing this, a team including senior authors Xiwei Tian, DEng, of East China University of Science and Technology in Shanghai and Yinlan Ruan, PhD, of Guilin University of Electronic Technology, encoded each modality separately and then merged them using dual-stream, cross-attention transformer architecture (DS-CAT).</p>
<p>The team tested their system using 142 preprocessed, synchronized Raman-NIR records.</p>
<p>Writing in <em>Bioprocess and Biosystems Engineering</em>, they <a href="https://link.springer.com/article/10.1007/s00449-026-03437-0" target="_blank" rel="noopener">report</a> that their model explained 99% of the variation in true glucose concentration. Anything above 95% is considered good. Likewise, the root mean square error of 1.09 g/L was well within the level needed to ensure effective feed control. Furthermore, the mean absolute error of 0.89 g/L achieved by this model suggests it is consistently accurate. Such consistency is particularly important for real-time processing controls, where outliers could negatively affect feeding strategies. Results remained similar throughout five-fold validation, the scientists report.</p>
<p>Additionally, “Prediction-based perturbation…revealed strong dependence on Raman information, while Raman-block sensitivity analysis identified 1122−1335 cm<sup>-1 </sup>[which is associated with carbohydrate vibrational modes] as the interval showing the strongest prediction sensitivity,” Tien, Ruan, and colleagues point out. Those findings are comparable to other literature reports, while demonstrating the enhanced sensitivity, reduced noise, and reduced drift of this new framework.</p>
<p>Notably, the researchers note that the DS-CAT framework “outperform[ed] partial least squares regression, gradient boosting regression trees, convolutional neural networks, and temporal convolutional networks under the same evaluation protocol.” By performing better than these four industry-standard modeling approaches, DS-CAT has the potential to substantially improve soft-sensor capabilities for real-time glucose monitoring.</p>
<p>These findings suggest the DS-CAT approach to glucose sensing may enable reliable insights that lead to better control of a critical parameter in closed-loop mammalian and microbial fermentation. If so, the high-frequency and low-latency data measurements this method delivers may become a key element in a rational transition from fed-batch fermentation toward continuous manufacturing.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/ramannir-spectra-improves-glucose-soft-sensing/">Raman+NIR Spectra Improves Glucose Soft Sensing</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Patients Should Be Considered When Choosing a Vector Production Method</title>
<link>https://edusehat.com/en/patients-should-be-considered-when-choosing-a-vector-production-method</link>
<guid>https://edusehat.com/en/patients-should-be-considered-when-choosing-a-vector-production-method</guid>
<description><![CDATA[ Vector production costs have a disproportionate influence on gene therapy prices, according to researchers who say that, given this, choosing the vector manufacturing method that best suits the intended use of the product is vital.
The post Patients Should Be Considered When Choosing a Vector Production Method appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/05/Getty_1211253347_AsepticVirusLab-scaled-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 03:55:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Patients, Should, Considered, When, Choosing, Vector, Production, Method</media:keywords>
<content:encoded><![CDATA[<p>Viral vector production costs have a disproportionate influence on gene therapy prices, so choosing the virus manufacturing method that fits the product and its intended patient population is critical.</p>
<p>That is the view of researchers at Thermo Fisher Scientific, who examined the economics of gene therapy production in a <a href="https://www.nature.com/articles/s41434-026-00631-3#Sec21" target="_blank" rel="noopener">study</a> and concluded that choosing the right vector manufacturing platform is challenging.</p>
<p>“Optimal platform choice depends on indication prevalence, dose requirements, desired serotype flexibility, development timelines, and willingness to invest in process intensification,” study author Seyed Pouria Motevalian, PhD, writes.</p>
<p>Motevalian and co-authors compared three recombinant adeno-associated virus (rAAV) manufacturing methods—transient transfection, producer cell line approaches (PCLs), and baculovirus-based production—and found that the cost drivers for each differ markedly.</p>
<p>“On a per-batch basis, baculovirus infection is the most cost-efficient platform, followed by transient transfection and PCLs. However, when costs are normalized to vector titer, the ranking shifts, with transient transfection becoming the lowest-cost platform.</p>
<p>“Each platform has a distinct economic fingerprint: transient transfection is dominated by plasmids, transfection reagent, media, and endonuclease; PCL perfusion processes are driven by media and perfusion-related single-use hardware; and the baculovirus platform shifts a greater share of cost into downstream operations, particularly affinity capture,” Motevalian says.</p>
<h4><strong>Patient focus</strong></h4>
<p>With all this in mind, Motevalian and co-authors argue that, rather than focusing on material and reagent costs, developers must also factor in the needs of the target patient population when choosing how to produce viral vectors.</p>
<p>“Our analyses suggest there is no universally ‘best’ rAAV platform. Optimal platform choice depends on indication prevalence, dose requirements, desired serotype flexibility, development timelines, and willingness to invest in process intensification,” they say.</p>
<p>For example, for products intended for smaller populations, transient transfection, in which vector genes are introduced into producer cell lines, may be the best approach, despite the high cost of the DNA plasmids required.</p>
<p>In contrast, for mass market gene therapies, baculovirus infection or PCL-based vector manufacturing methods are a more cost-effective option, particularly in combination with optimized upstream and downstream processes.</p>
<p>Understanding these dynamics is critical for developers, according to the authors, who say gene therapy firms must factor them into process development as early as possible.</p>
<p>“Integrating quantitative cost modeling into platform selection and process development decisions early in program design will be essential for making rAAV therapies economically sustainable and expanding global patient access,” they say.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/patients-should-be-considered-when-choosing-a-vector-production-method/">Patients Should Be Considered When Choosing a Vector Production Method</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>iPSC Manufacturing Starts with the Source</title>
<link>https://edusehat.com/en/ipsc-manufacturing-starts-with-the-source</link>
<guid>https://edusehat.com/en/ipsc-manufacturing-starts-with-the-source</guid>
<description><![CDATA[ For iPSC developers, scalable manufacturing begins long before the bioreactor. Pluristyx leaders explain why starting material, process discipline, automation, and shared data will help therapies reach patients reliably and affordably.
The post iPSC Manufacturing Starts with the Source appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Mike-iPSCs_GBPN_IMAGE_15OCT26.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 03:55:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>iPSC, Manufacturing, Starts, with, the, Source</media:keywords>
<content:encoded><![CDATA[<p>For developers of induced pluripotent stem cells (iPSCs), the path to commercial-scale manufacturing can be derailed long before cells reach a production bioreactor. According to two leaders at Pluristyx, one of the field’s most persistent problems is surprisingly basic: many programs begin with cell lines that were never intended for clinical manufacturing.</p>
<p>“It is difficult to find the right cell line,” said Benjamin Fryer, PhD, CEO and cofounder of Pluristyx. Researchers often build promising processes around readily available lines, only to discover later that the material lacks the provenance, consent, or good manufacturing practice (GMP) pedigree needed for human use. By then, Fryer said, teams may have invested years in process development, animal studies, and publications—only to restart with a new line.</p>
<p>Clinical readiness also depends on whether donor consents support the intended use, said Priya Baraniak, PhD, chief commercial and development officer at Pluristyx. Beyond that, developers face the familiar manufacturing demands of robustness, reproducibility, and scale at a cost that is “clinically and commercially feasible,” she noted.</p>
<p>That makes the choice of starting material a bioprocessing decision, not merely a research decision. As developers move from milliliter-scale work toward liters or tens to hundreds of liters, Fryer said, “the manufacturing process has to be somewhat similar.” Passage number and population doublings should be controlled so cells at small and large scale are effectively the same biological age. Production format matters, too. “You need to make sure that the cells are available in the process format you’re going to use,” Fryer said. A therapy intended for suspension culture, for example, should move toward suspension early rather than undergo a disruptive conversion late in development.</p>
<p>Baraniak put the principle simply: “Standardizing your input is really important.” Even high-quality cells can introduce variability if their passage history, characterization, or biological state changes from run to run.</p>
<p>That issue is especially important for iPSCs because their expansion potential can create a false sense of security. “We often fall into a false narrative that these cells can be expanded forever and they’re an evergreen source,” Baraniak said. “They accumulate genetic mutations and aberrations as you expand them,” potentially leaving developers with a process built around cells that no longer behave as intended.</p>
<p>The challenge extends beyond raw material into process design. Baraniak said cell manufacturing still relies too heavily on “golden hands”—highly skilled operators whose tacit knowledge can be difficult to reproduce across people, sites, and scales. “You can’t rely on just golden hands,” she said. Processes must instead be engineered to minimize operator-dependent decisions and tolerate normal manufacturing variation.</p>
<p>That transition also changes the role of automation. Fryer cautioned that simply replacing a human hand with a robotic one does not solve a poorly understood process. Manufacturers first need to understand why cells respond to particular media, handling steps, environmental conditions, and culture parameters. That mechanistic knowledge can guide smarter automation, closed systems, and process analytics rather than locking fragile procedures into hardware.</p>
<p>The same manufacturing discipline could expand the usefulness of iPSCs in new approach methodologies (NAMs), including drug screening, toxicology, disease modeling, and engineered tissues. Unlike limited primary tissues, well-controlled iPSC banks can provide renewable human material representing different donors, disease states, and genetically engineered variants. But those models only become useful at industrial scale if they can be manufactured, distributed, and reproduced consistently.</p>
<p>For Baraniak, that need for reproducibility reflects how far the field has come. “We’ve moved past the point of proving that these therapies have viability, that iPSCs work,” she said. “So now it’s how do we make them work over and over and over.”</p>
<p>That shift—from demonstrating biological possibility to engineering repeatable manufacturing—might define the next phase of iPSC commercialization. Better starting materials, deeper process understanding, automation, and more open sharing of manufacturing experience will not eliminate biological complexity. But they could keep that complexity from becoming the bottleneck that prevents promising iPSC technologies from reaching patients.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/ipsc-manufacturing-starts-with-the-source/">iPSC Manufacturing Starts with the Source</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Researchers Validate Buoyant Mass for Cell Health Testing</title>
<link>https://edusehat.com/en/researchers-validate-buoyant-mass-for-cell-health-testing</link>
<guid>https://edusehat.com/en/researchers-validate-buoyant-mass-for-cell-health-testing</guid>
<description><![CDATA[ Scientists have used measurement of buoyant mass by suspended microchannel resonator (SMR) technology to assess the immune fitness of T cells and predict patient response to immune checkpoint blockade (ICB).
The post Researchers Validate Buoyant Mass for Cell Health Testing appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GettyImages-2279568676-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 03:55:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Researchers, Validate, Buoyant, Mass, for, Cell, Health, Testing</media:keywords>
<content:encoded><![CDATA[<p>U.S. scientists have shown that measuring the buoyant mass of T cells can help predict patient response to immune checkpoint blockade (ICB) immunotherapy.</p>
<p>The team from the Massachusetts Institute of Technology (MIT) showed that measuring the buoyant mass of T cells predicted patient response more accurately than a traditional tumor mutational burden (TMB) approach.</p>
<p>According to the researchers, the new technique could be used not only to predict cancer cell sensitivity to treatment, but also to address the productivity of cell cultures used in gene therapy manufacturing.</p>
<p>“We’ve wanted to show people this is a new physical marker that predicts the fate of the T cells,” explains Jiaquan Yu, PhD, a research scientist working in microfluidic engineering and cancer immunology at MIT.</p>
<p>“By fate, we mean we measure the naïve state of the T cells and get an indication of how they will behave after activation.”</p>
<p>The team used suspended microchannel resonator (SMR) technology, a specialized instrument that uses a vibrating sensor containing a microfluidic channel to measure buoyant mass, Yu says.</p>
<p>The buoyant mass of the T cells is measured relative to water and from the buoyant mass, they were able to calculate the immune fitness of the cells, Yu continues. And, thus, whether they were likely to activate to fight cancer as part of treatment with ICB immunotherapy.</p>
<p>“For T cells, being in the heavier group suggests you’re better equipped to produce proteins,” Yu says. “And that capacity gives us an indication of the fitness of the cells and their ability to respond after activation.”</p>
<p>The team was able to test the performance of the technique in a clinical study of 28 patients with melanoma receiving ICB, Yu explains. And, in that study, they were able to prove that measuring buoyant mass was more effective than TMB at predicting treatment response.</p>
<p>“People are underestimating simple non-molecular signatures, such as mass, volume, and density, as we’re all focused on biomarkers focused on genes and RNA,” Yu says.</p>
<p>“What we’re showing here is that mass gives a result that integrates a lot of information.”</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/researchers-validate-buoyant-mass-for-cell-health-testing/">Researchers Validate Buoyant Mass for Cell Health Testing</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Using AI Agents and Bio&#45;Foundation Models to Automate Vector Design for Cell Line Development</title>
<link>https://edusehat.com/en/using-ai-agents-and-bio-foundation-models-to-automate-vector-design-for-cell-line-development</link>
<guid>https://edusehat.com/en/using-ai-agents-and-bio-foundation-models-to-automate-vector-design-for-cell-line-development</guid>
<description><![CDATA[ In this GEN webinar, Asimov’s VP of Business Development and Commercial Strategy Jamie Freeman, PhD, will show how Asimov combines bio-foundation models, AI agents, and synthetic biology to tailor expression vector design for each molecule. 
The post Using AI Agents and Bio-Foundation Models to Automate Vector Design for Cell Line Development appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2022/09/GettyImages-1150965935-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 03:55:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Using, Agents, and, Bio-Foundation, Models, Automate, Vector, Design, for, Cell, Line, Development</media:keywords>
<content:encoded><![CDATA[<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"></div>
</div>


<p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Register Now</button></p>

<h3 class="w-full text-left">
    <strong>
        Panelists:
    </strong>
</h3>
<div class="flex flex-row m-0-auto items-stretch justify-center flex-wrap mb-4">
    
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/10/JamieFreeman_headshot.jpg" class="h-full w-full object-cover" alt="Image of Jamie Freeman, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Jamie Freeman, PhD</h2>
                <h5 class="mt-0 !text-[15px] !leading-[21px]">VP of Business Development and Commercial Strategy<br>Asimov</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/10/JamieFreeman_headshot.jpg" alt="Image of Jamie Freeman, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Jamie Freeman, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Jamie Freeman, PhD, is VP of Business Development and Commercial Strategy at Asimov, where he works with partners to improve the design and manufacturing of novel biological therapeutics. Prior to joining Asimov, Jamie was responsible for the development and initial commercialization of Horizon Discovery’s CHO Source platform. Jamie earned a PhD in cell and molecular biology from Cardiff University, followed by a postdoc at the MRC Laboratory of Molecular Cell Biology.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog></div>



<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-malblocks-webinars-info"></p><div><strong>Broadcast Date:</strong> <time>Thursday, November 12, 2026</time><br><ul><li><strong>Time:</strong> <time datetime="2026-11-12T19:00:00.000Z">11:00 PST, 14:00 EST, 19:00 GMT</time></li></ul></div>


<div aria-hidden="true" class="wp-block-spacer"></div>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow">
<p class="wp-block-paragraph">Protein foundation models have transformed binder design, but turning those binders into drugs remains an empirical, trial-and-error process. Lead optimization, cell line development, and process development each still rely on screening large numbers of candidates, clones, or conditions, with little ability to predict which will succeed.  As pipelines shift toward bispecifics and other complex formats, that approach is getting harder to sustain.</p>


<p class="wp-block-paragraph">In this <em>GEN</em> webinar, Asimov’s VP of Business Development and Commercial Strategy Jamie Freeman, PhD, will show how Asimov combines bio-foundation models, AI agents, and synthetic biology to tailor expression vector design for each molecule. He will highlight how scientists use Kernel, Asimov’s computer-aided genetic design software, to automate the design of optimized expression vectors, and how AI agents can take on custom genetic designs for uncommon requirements. </p>


<p class="wp-block-paragraph">Through a series of case studies, he will also share how AI-designed vectors outperformed Asimov’s own previous best designs, how rapid stable pool data changed which multispecific lead a partner advanced, and how a model predicted chain ratios to improve correct pairing without reducing titer. Key takeaways from the webinar include:</p>


<ul class="wp-block-list">
<li>How exploring genetic design space, rather than relying on off-the-shelf vectors, can improve titer and product quality for both standard and complex formats</li>



<li>How AI models trained on measurements from inside the cell can learn the mechanisms of expression and apply them to design better expression vectors</li>



<li>How model-guided workflows and stable pools bring better-informed decisions to vector design and lead selection</li>
</ul>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><em>A live Q&A session will follow the presentation offering you a chance to pose questions to our expert panelist.</em></p>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><strong>Produced with support from:</strong></p>


<figure class="wp-block-image alignleft size-medium"><a href="https://www.asimov.com/" target="_blank" rel=" noopener"><img decoding="async" width="300" height="53" src="https://www.genengnews.com/wp-content/uploads/2023/01/asimov_logo-300x53.jpg" alt="asimov logo" class="wp-image-216608" srcset="https://www.genengnews.com/wp-content/uploads/2023/01/asimov_logo-300x53.jpg 300w, https://www.genengnews.com/wp-content/uploads/2023/01/asimov_logo-1024x181.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2023/01/asimov_logo-768x136.jpg 768w, https://www.genengnews.com/wp-content/uploads/2023/01/asimov_logo-696x123.jpg 696w, https://www.genengnews.com/wp-content/uploads/2023/01/asimov_logo-1392x248.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2023/01/asimov_logo-1068x189.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2023/01/asimov_logo.jpg 1400w" sizes="(max-width: 300px) 100vw, 300px"></a></figure>
</div>
</div>

<p>The post <a href="https://www.genengnews.com/multimedia/webinars/using-ai-agents-and-bio-foundation-models-to-automate-vector-design-for-cell-line-development/">Using AI Agents and Bio-Foundation Models to Automate Vector Design for Cell Line Development</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Bridging the Translational Gap in Pancreatic Cancer Through Biology&#45;First Modeling</title>
<link>https://edusehat.com/en/bridging-the-translational-gap-in-pancreatic-cancer-through-biology-first-modeling</link>
<guid>https://edusehat.com/en/bridging-the-translational-gap-in-pancreatic-cancer-through-biology-first-modeling</guid>
<description><![CDATA[ In this GEN webinar, our expert speaker Josh Wheeler, MD, PhD, will discuss a biology-first, interpretable AI approach to understand patient tumor states and next-generation preclinical models that reproduce their biological complexity.
The post Bridging the Translational Gap in Pancreatic Cancer Through Biology-First Modeling appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Getty_2190808113_PancreaticCancerCells.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 03:55:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Bridging, the, Translational, Gap, Pancreatic, Cancer, Through, Biology-First, Modeling</media:keywords>
<content:encoded><![CDATA[<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"></div>
</div>


<p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Register Now</button></p>

<h3 class="w-full text-left">
    <strong>
        Panelists:
    </strong>
</h3>
<div class="flex flex-row m-0-auto items-stretch justify-center flex-wrap mb-4">
    
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/10/Josh_Wheeler_headshot_2000px-e1792604937405.jpg" class="h-full w-full object-cover" alt="Image of Josh Wheeler, MD, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Josh Wheeler, MD, PhD</h2>
                <h5 class="mt-0 !text-[15px] !leading-[21px]">Vice President, Research and Development<br>Genialis</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/10/Josh_Wheeler_headshot_2000px-e1792604937405.jpg" alt="Image of Josh Wheeler, MD, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Josh Wheeler, MD, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Josh Wheeler, MD, PhD, is the vice president of Research and Development at Genialis with more than 15 years of experience spanning academic research, computational biology, and biotechnology. His work sits at the intersection of clinical development, translational medicine, AI and machine learning, diagnostics, and precision oncology. At Genialis, he leads clinical and research innovation strategy, biomarker and diagnostic development, clinical trial assay and regulatory strategy, and biopharma partnerships. Josh previously trained and practiced at Stanford across anatomic pathology, neuropathology, molecular diagnostics, and computational biology. He earned his MD from the University of Colorado Anschutz Medical Campus through the NIH-funded Medical Scientist Training Program and his PhD in biochemistry from the University of Colorado Boulder.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog>
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/10/Matthieu-Spriet.jpg" class="h-full w-full object-cover" alt="Image of Matthieu Spriet, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Matthieu Spriet, PhD</h2>
                <h5 class="mt-0 !text-[15px] !leading-[21px]">Technical Specialist<br>Inventia Life Science</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/10/Matthieu-Spriet.jpg" alt="Image of Matthieu Spriet, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Matthieu Spriet, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Matthieu Spriet, PhD, is a technical sales specialist at Inventia Life Science with expertise in 3D biology, biochemistry, cell signaling, oncology, and assay development. He earned his PhD in biochemistry and molecular biology from the University of Nebraska Medical Center. His thesis focused on profiling and understanding RNA expression in cholangiocarcinoma.</p>
<p>After graduating, Matthieu spent many years working in early-stage drug discovery, developing cell-based assays across multiple disease models, including oncology, immunology, cardiology, hepatology, and regenerative medicine. Matthieu is passionate about scientific communication and collaboration, with a focus on advancing biomedical research through advanced 3D cell models and drug discovery innovation.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog></div>



<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-malblocks-webinars-info"></p><div><strong>Broadcast Date:</strong> <time>Wednesday, November 18, 2026</time><br><ul><li><strong>Time:</strong> <time datetime="2026-11-18T16:00:00.000Z">08:00 PST, 11:00 EST, 16:00 GMT</time></li></ul></div>


<div aria-hidden="true" class="wp-block-spacer"></div>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow">
<p class="wp-block-paragraph">Pancreatic cancer is experiencing a renaissance in therapeutic options and improvements in patient outcomes. Accelerating therapeutic advances demands a more robust translational pipeline linking patient biology to preclinical model systems. The tumor microenvironment shapes both prognosis and therapeutic vulnerabilities, making its representation in preclinical models critical for translation.</p>


<p class="wp-block-paragraph">In this <em>GEN</em> webinar, our expert speaker Josh Wheeler, MD, PhD, will discuss a biology-first, interpretable AI approach to understand patient tumor states and next-generation preclinical models that reproduce their biological complexity. During the webinar, he will present Genialis Supermodel, an interpretable AI foundation model that translates tumor RNA-seq into biological states that can be compared across patients, experimental models, and Inventia’s RASTRUM platform, which enables bioprinted PDAC models with increasing microenvironmental complexity through the addition of cancer-associated fibroblasts (CAFs) and T cells.</p>


<p class="wp-block-paragraph">Using pancreatic cancer as a case study, he will demonstrate how increasing microenvironmental complexity moved the bioprinted models toward distinct biological states observed in patients. You will learn how CAFs drove EMT and TGF-beta/SMAD activity with loss of classical epithelial identity, while adding immune cells produced inflammatory and interferon programs. These changes also exposed therapeutic biology not apparent in monoculture, including altered RAS/MAPK, EGFR, beta-catenin, and YAP/TEAD signaling. Key takeaways include:</p>


<ul class="wp-block-list">
<li>How technologies from Genialis and Inventia provide a framework to connect patient tumor biology with experimentally tractable model systems</li>



<li>How patient-centered models generate therapeutic hypotheses that monoculture may miss</li>
</ul>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><em>A live Q&A session will follow the presentation offering you a chance to pose questions to our expert panelists.</em></p>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><strong>Produced with support from:</strong></p>


<figure class="wp-block-image alignleft size-medium"><a href="https://inventialifescience.com/" target="_blank" rel=" noopener"><img decoding="async" width="300" height="82" src="https://www.genengnews.com/wp-content/uploads/2026/10/Inventia-Life-Science_Logo_HighRes_Pink-300x82.png" alt="Inventia Life Science Logo" class="wp-image-339662" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Inventia-Life-Science_Logo_HighRes_Pink-300x82.png 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Inventia-Life-Science_Logo_HighRes_Pink-1024x279.png 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/Inventia-Life-Science_Logo_HighRes_Pink-768x210.png 768w, https://www.genengnews.com/wp-content/uploads/2026/10/Inventia-Life-Science_Logo_HighRes_Pink-1536x419.png 1536w, https://www.genengnews.com/wp-content/uploads/2026/10/Inventia-Life-Science_Logo_HighRes_Pink-2048x559.png 2048w" sizes="(max-width: 300px) 100vw, 300px"></a></figure>
</div>
</div>

<p>The post <a href="https://www.genengnews.com/multimedia/webinars/bridging-the-translational-gap-in-pancreatic-cancer-through-biology-first-modeling/">Bridging the Translational Gap in Pancreatic Cancer Through Biology-First Modeling</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>ASHG: Signals Based on Clinical Obesity Show Stronger Links to Cardiovascular Health than Those Linked to BMI</title>
<link>https://edusehat.com/en/ashg-signals-based-on-clinical-obesity-show-stronger-links-to-cardiovascular-health-than-those-linked-to-bmi</link>
<guid>https://edusehat.com/en/ashg-signals-based-on-clinical-obesity-show-stronger-links-to-cardiovascular-health-than-those-linked-to-bmi</guid>
<description><![CDATA[ Researchers also developed a clinical obesity polygenic score that combined information from numerous genetic variants, a score that was shown to be significantly associated with BMI, body fat percentage, and waist circumference. 
The post ASHG: Signals Based on Clinical Obesity Show Stronger Links to Cardiovascular Health than Those Linked to BMI appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GettyImages-2158974218.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 03:55:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>ASHG:, Signals, Based, Clinical, Obesity, Show, Stronger, Links, Cardiovascular, Health, than, Those, Linked, BMI</media:keywords>
<content:encoded><![CDATA[<p>Conducting the first genome-wide association study and analysis based on a new definition of clinical obesity, a research team has identified genetic signals that differed substantially from those associated with body mass index (BMI)—yet showed stronger connections to cardiovascular health.</p>
<p>The researchers—nine from Johns Hopkins University, one from The Ohio State University—analyzed 151,642 people with clinical obesity and 128,874 controls without obesity spanning five ancestry groups, using data from the UK Biobank and <em>All of Us</em> Research Program. The biobank says it possesses the world’s most comprehensive dataset of biological health and lifestyle data gathered from a half million participants, while <em>All of Us</em> is the NIH initiative designed to advance precision medicine by collecting and study data from 1 million or more people living in the United States.</p>
<p>Researchers identified 127 independent genetic loci associated with clinical obesity. Of these, 63 had no significant association with BMI. The most discordant variant, researchers reported, was rs15285, a single-nucleotide polymorphism (SNP) located within the 3′-untranslated region (3′UTR) of the <em>LPL</em> gene that encodes lipoprotein lipase. That variant was colocalized to expression quantitative trait loci (eQTLs) for lipoprotein lipase, and associated with elevated triglyceride levels.</p>
<p>The team also developed a clinical obesity polygenic score that combined information from numerous genetic variants, a score that was shown to be significantly associated with BMI, body fat percentage, and waist circumference. Compared to a BMI polygenic score, the clinical obesity polygenic score developed by the researchers showed improved association with cardiovascular risk factors and proteomic markers of inflammation—such as interleukin-6, fibroblast growth factor 21, and hepatic growth factor—as well as markers of insulin resistance, including adiponectin, resistin, leptin, and leptin receptor.</p>
<p>The clinical obesity polygenic score improved risk discrimination over a BMI polygenic score for myocardial infarction (heart attack), heart failure, and stroke, the research team added.</p>
<p>Researchers then validated the improvement across four additional long-running U.S. public health studies:</p>
<ul>
<li><strong>Atherosclerosis Risk in Communities (ARIC)</strong>, a study of the NIH’s National Heart, Lung, and Blood Institute whose focus has widened from identifying risk factors for subclinical atherosclerosis to risk factors for heart diseases including heart attack, coronary heart disease, stroke, and heart failure. About 16,000 U.S. adults have been enrolled.</li>
<li><strong>Multi-Ethnic Study of Atherosclerosis (MESA)</strong>, an NHLBI-sponsored study of the characteristics of subclinical cardiovascular disease and the risk factors that predict progression to clinically overt cardiovascular disease or progression of the subclinical disease. MESA enrolled 6,814 adults during its baseline period between 2000-2002.</li>
<li><strong>Framingham Heart Study</strong>, under NHLBI direction, was launched in 1948 to identify common factors or characteristics that contribute to cardiovascular disease. Since 1971, the Boston University School of Medicine has served as NHLBI’s contractor and academic partner for the study. More than 15,400 across multiple cohorts have been enrolled.</li>
<li><strong>Women’s Health Initiative</strong>, which first won funding in 1992 and is also NHLBI-sponsored, focuses on strategies for preventing heart disease, breast and colorectal cancer, and osteoporosis in postmenopausal women. 161,808 women have been enrolled.</li>
</ul>
<h4><strong>‘Biologically and clinically relevant’</strong></h4>
<p>“These findings demonstrate that clinical obesity captures genetic loci distinct from BMI that are biologically and clinically relevant to cardiovascular health,” the researchers concluded.</p>
<p>Findings were reported in “<a href="https://content-cdn.sessionboard.com/content/ir9aMTzTJWbLVh1FTe9F_SohailZahid_ASHG2026_poster.pdf" target="_blank" rel="noopener">Genome-wide analysis and polygenic prediction of clinical obesity</a>,” a poster study presented during the American Society of Human Genetics (ASHG) 2026 Annual Meeting, held October 20-24 in Montreal. Co-corresponding authors were Sohail Zahid, MD, PhD, an investigator at the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease; and Alexis Battle, PhD, director of the Malone Center for Engineering in Healthcare and director of the Research, Strategy, and Partnerships, Data Science and Artificial Intelligence Institute at Johns Hopkins.</p>
<p>The research team posted a <a href="https://www.medrxiv.org/content/10.64898/2026.05.20.26353665v1" target="_blank" rel="noopener">preprint version of their study on medRxiv</a> on May 22.</p>
<p>“Stratifying individuals into low, intermediate, and high inherited obesity risk groups, we found that clinical obesity polygenic risk reclassified 35% of individuals compared to BMI polygenic risk,” researchers reported in the preprint. “Unlike rare variant panel testing which already guides targeted therapy in monogenic obesity, further work is needed to determine the incremental benefit of clinical obesity polygenic scores for diagnosis, risk stratification, or management beyond BMI-based assessment.”</p>
<p>The new clinical obesity definition used by researchers was <a href="https://www.thelancet.com/commissions-do/clinical-obesity" target="_blank" rel="noopener">introduced last year by <em>The Lancet</em> Diabetes & Endocrinology Commission</a>.  The 58-member Commission set out to establish objective criteria for disease diagnosis, aid clinical decision making, and prioritize therapeutic interventions and public health strategies, by characterizing excess body fat and dysfunctional adiposity beyond BMI.</p>
<p>“We recommend that BMI should be used only as a surrogate measure of health risk at a population level, for epidemiological studies, or for screening purposes, rather than as an individual measure of health,” the Commission stated last year. “Excess adiposity should be confirmed by either direct measurement of body fat, where available, or at least one anthropometric criterion (e.g., waist circumference, waist-to-hip ratio, or waist-to-height ratio) in addition to BMI, using validated methods and cutoff points appropriate to age, gender, and ethnicity.”</p>
<p>In people with very high BMI (i.e., >40 kg/m<sup>2</sup>), the Commission continued, excess adiposity can pragmatically be assumed without further confirmation: “We also recommend that people with confirmed obesity status (i.e., excess adiposity with or without abnormal organ or tissue function) should be assessed for clinical obesity.”</p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/ashg-signals-based-on-clinical-obesity-show-stronger-links-to-cardiovascular-health-than-those-linked-to-bmi/">ASHG: Signals Based on Clinical Obesity Show Stronger Links to Cardiovascular Health than Those Linked to BMI</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>BCG Vaccine&#45;Induced Trained Immunity May Help Protect Against Dementia</title>
<link>https://edusehat.com/en/bcg-vaccine-induced-trained-immunity-may-help-protect-against-dementia</link>
<guid>https://edusehat.com/en/bcg-vaccine-induced-trained-immunity-may-help-protect-against-dementia</guid>
<description><![CDATA[ The results of a preclinical study suggest that the BCG vaccine, which is widely used to prevent tuberculosis and treat bladder cancer, may also have properties that reduce the risk for dementia by inducing trained immunity.
The post BCG Vaccine-Induced Trained Immunity May Help Protect Against Dementia appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/02/GettyImages-1440168032-e1707342315623.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 03:55:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>BCG, Vaccine-Induced, Trained, Immunity, May, Help, Protect, Against, Dementia</media:keywords>
<content:encoded><![CDATA[<p>The results of a preclinical study headed by researchers at Johns Hopkins University School of Medicine suggest that the Bacillus Calmette-Guerin (BCG) vaccine, which is widely used to prevent tuberculosis and treat bladder cancer, may also have properties that reduce the risk for dementia. BCG is a live, weakened vaccine made from an altered strain of the bacterium <em>Mycobacterium bovis</em>.</p>
<p>The team found that in mice genetically engineered to develop biological symptoms of dementia (PS19 mice), those animals that received the BCG vaccine were less likely to show hallmark signs of the disease, such as neurofibrillary (tau) tangles (NFTs) in the brain, sustained immune cell activation, and memory loss compared to mice that received no vaccine. BCG-treated mice performed better in a novel object recognition test, and showed improved maintenance of body-weight and survival.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>Research lead William Bishai, MD, PhD, co-director of the Johns Hopkins Center for Tuberculosis Research, believes that myeloid cells in the central nervous system and brain are using information from BCG to recognize and help the body respond to the formation of plaques and tangles characteristic of Alzheimer’s disease and related dementias. Bishai said, “We’re hard at work trying to understand the detailed mechanism for how it works, but this research points to early clues that aspects of trained immunity are likely driving this response.”</p>
<p>Trained immunity refers to the ability, in mammals, of innate immune system cells to take on an expanded role. Following an initial stimulus, innate immune cells, including monocytes and macrophages, may learn how to identify and respond to future threats that are different from the first. Typically, other immune system cells, such as T cells, take on this type of adaptive and learned response.</p>
<p>Bishai is senior and corresponding author of the team’s published paper in <em>Science Advances</em>, titled “<a href="https://doi.org/10.1126/sciadv.aej4603" target="_blank" rel="noopener">BCG vaccination mitigates tau pathology and restores cognitive functions in PS19 mice</a>,” in which the authors concluded “Our study strongly suggests that dementia protection by BCG is a credible observation that merits future basic research and large-scale prospective clinical trials to provide definitive answers.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>Observational studies in humans—those not designed to show cause and effect—have linked off-target effects of vaccines to a reduced incidence of dementia. “There is a growing appreciation that vaccines may have beneficial off-target effects such as reducing the risk of dementia,” the authors wrote. The shingles vaccine has been <a href="https://www.nature.com/articles/s41586-025-08800-x" target="_blank" rel="noopener">linked</a> to a 20% reduced incidence of dementia, while several previous studies cited by the researchers found that BCG used as an immunotherapy for non-muscle invasive bladder cancer was linked to a 12% to 78% reduced risk of dementia throughout a three- to 15-year period.</p>
<p>“While less publicized, there is also considerable evidence that Bacille Calmette-Guérin or BCG, the live attenuated vaccine to prevent tuberculosis (TB) and treat bladder cancer, may also have dementia-preventive properties,” the team continued.</p>
<p>It’s been postulated that trained immunity is a mechanism by which BCG could protect against dementia, they noted. “Upon exposure to a first antigen such as BCG, innate immune cells, typically myeloid cells, have been shown to undergo epigenetic and metabolomic reprogramming such that upon exposure to a second, unrelated antigen, their immune response is greater than it was to the first,” they explained.</p>
<p>To test directly whether BCG could represent a preventive therapy for Alzheimer’s disease, the team turned to the PS19 (P301S) mouse model, which develops symptoms of dementia, specifically marked by tau pathology or a clumping of tau proteins in the brain representing late stages of the disease. ‘The overexpression of P301S tau is associated with AD-relevant pathological and functional features, including neuronal loss, microgliosis, neurofibrillary tangles (NFT) deposition, and cognitive impairment,” they wrote.</p>
<p>The team divided mice into cohorts that received the BCG vaccine and those that received a saline injection. An additional comparison group included age-matched mice that did not have dementia and that also received the saline injection. Mice in the BCG treatment group received the vaccine at three months of age. Multiple assessments, based on brain imaging, memory recall (through an object recognition test) and indicators of disease, including neuroinflammation and the expression of genes linked to Alzheimer’s disease, were conducted eight to nine months later.</p>
<p>The researchers found that those mice that received BCG were about five times more likely to have signs of reduced tau deposits in their brain. They were also four times less likely to have markers of sustained inflammation, signaling that their immune cells had already likely responded to tau by clearing out some of the tangles, and had created a stable or protective immune response.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>The untreated mice showed activation of 716 genes connected to Alzheimer’s disease, cell death, and neuroinflammation. BCG administration normalized all but nine of these. Compared to untreated mice, the mice who received BCG were less likely to have signs of brain atrophy and also more likely to live longer and perform better on tasks related to remembering and identifying objects.</p>
<p>“BCG seems to be reducing the degree of hyperinflammation in the brain—which is a good thing—and it may be doing it through a trained immune cell mechanism,” said Bishai. “There are a number of other characteristics of trained immunity that we are studying in the lab now.”</p>
<p>In their paper the team wrote in summary, “We found that early BCG administration starting at three months of age reduced brain atrophy, p-tau levels, and neuronal loss measured at the later time point of eight to nine months. Simultaneously, BCG therapy restored glutamate levels <em>in vivo</em> and improved recognition-memory performance, body weight, and survival of PS19 mice, suggesting key disease modifying effects.”</p>
<p>This research, Bishai says, is believed to be the first to study BCG and dementia in mouse models with tau pathology (specifically showing how immune cells may play a role in clearing neurofibrillary tangles). “Mechanistically, our study identified BCG-induced trained immunity properties as playing key roles in the clearance of tau NFTs,” they stated. Others have found similar findings with BCG and improved cognition in amyloid mouse models—which represent earlier stages of the disease marked by plaque formation.</p>
<p>“This is a great example of translational science working in reverse—starting with an intriguing observation in people and then going back to the laboratory to understand why it might be happening,” commented co-author Barbara Slusher, PhD, professor of neurology at the Johns Hopkins University School of Medicine and director of the Johns Hopkins Drug Discovery program.</p>
<p>Slusher cautions that researchers still need to understand more of the underlying biology before they can say who might benefit, when treatment would need to be given and whether the effect can be safely reproduced in people at risk for dementia. “If we can identify the specific immune changes that are protective, we may be able to develop even more targeted approaches for the prevention of Alzheimer’s disease.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/bcg-vaccine-induced-trained-immunity-may-help-protect-against-dementia/">BCG Vaccine-Induced Trained Immunity May Help Protect Against Dementia</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Canada’s nursing workforce grows, but shortages and wage pressures persist</title>
<link>https://edusehat.com/en/canadas-nursing-workforce-grows-but-shortages-and-wage-pressures-persist</link>
<guid>https://edusehat.com/en/canadas-nursing-workforce-grows-but-shortages-and-wage-pressures-persist</guid>
<description><![CDATA[ New Statistics Canada figures show registered nursing employment has increased by more than 100,000 since 2019, while vacancies remain elevated and inflation-adjusted wages have barely improved. Canada’s nursing workforce has grown significantly since the COVID-19 pandemic, but persistent staffing shortages and limited wage growth continue to challenge the healthcare system, according to a new Statistics […]
The post Canada’s nursing workforce grows, but shortages and wage pressures persist appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/Nurse-Caring-for-Patient-in-ICU.png" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 03:45:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Canada’s, nursing, workforce, grows, but, shortages, and, wage, pressures, persist</media:keywords>
<content:encoded><![CDATA[<p>New Statistics Canada figures show registered nursing employment has increased by more than 100,000 since 2019, while vacancies remain elevated and inflation-adjusted wages have barely improved.</p>
<p>Canada’s nursing workforce has grown significantly since the COVID-19 pandemic, but persistent staffing shortages and limited wage growth continue to challenge the healthcare system, according to a new Statistics Canada report released October 19.</p>
<p>The report, Canada’s Health Workforce: An integrated summary based on Statistics Canada data, 2025, found that employment in registered nursing occupations increased by 33.3%, or 102,800 positions, between 2019 and 2025.</p>
<p>Registered nursing occupations, which include registered nurses, registered psychiatric nurses and nurse practitioners, experienced the largest employment increase among the health occupations examined over that period.</p>
<p>In 2025 alone, registered nursing employment grew by 25,300 positions, an increase of 6.5% from the previous year.</p>
<p>Despite these gains, the findings reveal an uneven recovery across nursing professions, with ongoing recruitment pressures and wages that have struggled to keep pace with inflation.</p>
<h2>Practical nursing shortages remain a concern</h2>
<p>One of the report’s most significant findings involves licensed practical nurses (LPNs).</p>
<p>While registered nursing employment expanded considerably, the number of employed licensed practical nurses showed no net growth between 2019 and 2025.</p>
<p>At the same time, the vacancy rate for licensed practical nurses remained at 12.3% in 2025, nearly five times the 2.5% rate recorded in 2016.</p>
<p>Although the rate has declined from its 2023 peak of 18.7%, it remains substantially higher than the national average across all occupations.</p>
<p>Registered nursing occupations recorded a vacancy rate of 5.0% in 2025, while nurse aides, orderlies and patient service associates had a vacancy rate of 4.7%.</p>
<p>These figures suggest that workforce pressures remain concentrated in certain nursing roles, even as overall employment continues to increase.</p>
<h2>Wages struggle to keep pace with inflation</h2>
<p>The report also raises concerns about the purchasing power of nursing wages.</p>
<p>Among registered nurses aged 25 to 54, average hourly wages adjusted for inflation were 1.4% lower in 2025 than in 2019.</p>
<p>Licensed practical nurses in the same age group experienced a 0.6% decline in real average hourly wages over the six-year period.</p>
<p>While nominal wages have increased, inflation has largely offset those gains.</p>
<p>Across all health occupations, inflation-adjusted average hourly wages for workers aged 25 to 54 increased by 3.2% between 2019 and 2025.</p>
<p>The comparatively weaker wage performance among nurses may add to ongoing discussions about recruitment, retention and compensation across Canada’s healthcare system.</p>
<h2>Healthcare employment reaches 1.7 million</h2>
<p>Canada’s broader healthcare workforce has also expanded.</p>
<p>In 2025, more than 1.7 million Canadians were employed in health occupations, representing 8.2% of total national employment.</p>
<p>That was an increase of 81,200 workers from 2024 and 279,400 from 2019.</p>
<p>However, workforce demand continues to exceed available staffing in many areas.</p>
<p>Statistics Canada recorded 67,900 job vacancies across health occupations in 2025. Although this was below the 2023 peak of 90,700, it was nearly three times the number recorded in 2016.</p>
<p>The overall vacancy rate for health occupations was 4.5%, compared with 2.7% across all occupations.</p>
<h2>Implications for Canadian hospitals</h2>
<p>The findings highlight the importance of looking beyond total employment growth when assessing healthcare staffing.</p>
<p>While more nurses are entering or remaining in registered nursing occupations, persistent vacancies among practical nurses and other healthcare workers can create challenges for hospitals, long-term care facilities and community healthcare providers.</p>
<p>Population aging, increasing demand for health services and workforce retention remain important pressures.</p>
<p>The report suggests that workforce planning will require continued attention to recruitment, retention, compensation and the distribution of healthcare professionals across occupations.</p>
<p>For Canadian hospitals, the central challenge is not simply increasing the number of healthcare workers, but ensuring that sufficient professionals are available in the roles and locations where patients need them most.</p>
<p><em>Source: Statistics Canada, Labour market characteristics of Canada’s health workforce, 2025, released October 19, 2026. <a href="https://www150.statcan.gc.ca/n1/daily-quotidien/261019/dq261019b-eng.htm?utm_source=chatgpt.com">Read the official Statistics Canada release</a>.</em></p>
<div>
<div></div>
<div>
<div></div>
</div>
</div>
<p>The post <a href="https://www.hospitalnews.com/canadas-nursing-workforce-grows-but-shortages-and-wage-pressures-persist/">Canada’s nursing workforce grows, but shortages and wage pressures persist</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>SickKids and Microsoft announce five&#45;year partnership to advance AI&#45;powered pediatric care</title>
<link>https://edusehat.com/en/sickkids-and-microsoft-announce-five-year-partnership-to-advance-ai-powered-pediatric-care</link>
<guid>https://edusehat.com/en/sickkids-and-microsoft-announce-five-year-partnership-to-advance-ai-powered-pediatric-care</guid>
<description><![CDATA[ Strategic agreement will strengthen cloud infrastructure, connect clinical information and support more personalized approaches to diagnosis, treatment and prevention. The Hospital for Sick Children (SickKids) in Toronto has announced a five-year strategic partnership with Microsoft Canada aimed at accelerating digital transformation and expanding the use of artificial intelligence to support pediatric healthcare. Announced October 20, […]
The post SickKids and Microsoft announce five-year partnership to advance AI-powered pediatric care appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/sickkids-microsoft-canada-partnership-azure-announcement.jpg.webp" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 00:10:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>SickKids, and, Microsoft, announce, five-year, partnership, advance, AI-powered, pediatric, care</media:keywords>
<content:encoded><![CDATA[<p>Strategic agreement will strengthen cloud infrastructure, connect clinical information and support more personalized approaches to diagnosis, treatment and prevention.</p>
<p>The Hospital for Sick Children (SickKids) in Toronto has announced a five-year strategic partnership with Microsoft Canada aimed at accelerating digital transformation and expanding the use of artificial intelligence to support pediatric healthcare.</p>
<p>Announced October 20, the agreement will strengthen the hospital’s digital infrastructure and support its Precision Child Health initiative, which seeks to provide more individualized care by combining clinical information, research and advanced technologies.</p>
<p>Under the partnership, SickKids will expand its use of Microsoft Azure as its primary cloud platform, creating a more connected and scalable environment for clinical systems and healthcare data.</p>
<p>The collaboration will explore how cloud computing, artificial intelligence and advanced analytics can help clinicians and researchers access information more effectively, identify emerging health risks and develop more personalized approaches to patient care.</p>
<h3>Building a stronger digital foundation</h3>
<p>A major component of the agreement involves improving the technology infrastructure supporting key clinical systems, including the hospital’s electronic health record.</p>
<p>By strengthening connections between clinical, research and operational information, SickKids hopes to provide healthcare teams with more timely access to relevant data.</p>
<p>The initiative is also intended to support the responsible development of AI applications that could eventually assist with earlier diagnosis, more targeted treatment and improved prediction of patient outcomes.</p>
<p>These capabilities remain areas for development and exploration under the partnership, rather than newly announced clinical tools already in routine use.</p>
<h3>Supporting healthcare professionals</h3>
<p>The agreement extends beyond technology infrastructure.</p>
<p>Microsoft Canada will provide Azure credits to support exploration of new cloud and AI solutions, along with technology partner assistance and investments in digital skills development.</p>
<p>These resources are intended to help SickKids clinicians, researchers and administrative teams build the knowledge required to evaluate and use emerging technologies effectively.</p>
<p>Workforce education will be an important component as healthcare organizations increasingly examine how artificial intelligence can support clinical decisions, research and hospital operations.</p>
<h3>Advancing precision child health</h3>
<p>The partnership supports SickKids’ broader strategy of moving toward more individualized pediatric care.</p>
<p>Precision Child Health aims to bring together information about each child’s medical condition, genetics and other relevant health factors to help clinicians better understand individual needs.</p>
<p>Artificial intelligence and advanced analytics could eventually help researchers identify patterns in complex health information, supporting new opportunities for diagnosis, prevention and treatment.</p>
<p>SickKids has already established an enterprise AI program focused on responsible development and implementation of artificial intelligence across clinical care, research and hospital operations.</p>
<p>The new agreement builds on that work while expanding the digital infrastructure needed to support future innovation.</p>
<h3>Security and responsible implementation</h3>
<p>As healthcare organizations increase their reliance on connected digital systems, protecting patient information and maintaining the reliability of clinical technology remain essential priorities.</p>
<p>SickKids says Microsoft’s cloud security capabilities will support the protection and resilience of critical systems and data.</p>
<p>The organizations also intend to advance responsible AI practices as they evaluate potential applications in healthcare.</p>
<p>The announcement does not specify a total financial value for the agreement or provide a timeline for deploying individual AI applications in clinical practice.</p>
<p>Leaders from Microsoft Canada visited SickKids on October 15 to mark the partnership and learn more about the hospital’s work.</p>
<p>For Canadian hospitals, the agreement represents another example of how healthcare institutions are investing in digital infrastructure as a foundation for future advances in clinical care, research and operational efficiency.</p>
<p>Source: SickKids — <a href="https://www.sickkids.ca/en/news/archive/2026/sickkids-and-microsoft-canada-join-together-to-help-teams-diagnose-faster-treat-smarter-and-predict-better/?utm_source=chatgpt.com">Official partnership announcement, October 20, 2026</a></p>
<p>The post <a href="https://www.hospitalnews.com/sickkids-and-microsoft-announce-five-year-partnership-to-advance-ai-powered-pediatric-care/">SickKids and Microsoft announce five-year partnership to advance AI-powered pediatric care</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>New compression&#45;free 3D breast imaging technology receives Health Canada licence</title>
<link>https://edusehat.com/en/new-compression-free-3d-breast-imaging-technology-receives-health-canada-licence</link>
<guid>https://edusehat.com/en/new-compression-free-3d-breast-imaging-technology-receives-health-canada-licence</guid>
<description><![CDATA[ Regulatory milestone could expand diagnostic imaging options for Canadian healthcare providers, although clinical availability will depend on adoption by hospitals and imaging centres. A new approach to breast imaging could soon become available to Canadian patients following the announcement that Health Canada has licensed a dedicated three-dimensional breast CT system designed to capture detailed images […]
The post New compression-free 3D breast imaging technology receives Health Canada licence appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/KONING-CORPORATION-KBCT.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 21 Oct 2026 20:30:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>New, compression-free, breast, imaging, technology, receives, Health, Canada, licence</media:keywords>
<content:encoded><![CDATA[<p>Regulatory milestone could expand diagnostic imaging options for Canadian healthcare providers, although clinical availability will depend on adoption by hospitals and imaging centres.</p>
<p>A new approach to breast imaging could soon become available to Canadian patients following the announcement that Health Canada has licensed a dedicated three-dimensional breast CT system designed to capture detailed images without breast compression.</p>
<p>Koning Health announced October 20 that its Vera Breast CT system has received a Canadian medical device licence, allowing the company to begin introducing the technology to healthcare providers across the country.</p>
<p>The system uses cone-beam computed tomography to create three-dimensional images of breast tissue. Unlike conventional mammography, which requires the breast to be compressed between imaging plates, the technology captures images without compression.</p>
<p>The resulting volumetric images allow radiologists to examine breast tissue from multiple angles, potentially providing additional anatomical information during diagnostic evaluations.</p>
<h3>A different approach to breast imaging</h3>
<p>Traditional mammography remains an important tool for breast cancer screening in Canada. However, researchers and medical technology companies continue developing imaging methods that may improve diagnostic assessment and the patient experience.</p>
<p>The Koning system is designed to address both image visualization and examination comfort.</p>
<p>By eliminating compression, the technology offers a different examination experience for patients who find conventional breast imaging uncomfortable.</p>
<p>Its three-dimensional imaging capabilities may also provide clinicians with additional views of breast structures during diagnostic assessment.</p>
<p>The technology is intended for diagnostic breast imaging and should not be considered a replacement for established mammography screening programs. Its specific authorized uses in Canada will be governed by the conditions of its medical device licence.</p>
<h3>Canadian adoption will determine patient access</h3>
<p>Although the regulatory milestone permits the company to move forward with commercial introduction, it does not mean the technology is already available at Canadian hospitals.</p>
<p>Individual hospitals and diagnostic imaging centres will determine whether and when to introduce the system, taking into account equipment procurement, clinical requirements, staff training and operational considerations.</p>
<p>Koning has not announced specific Canadian hospital installations or patient appointment dates as part of the licensing announcement.</p>
<p>For healthcare providers, the development represents another potential option in the evolving field of breast diagnostic imaging.</p>
<p>As imaging technology advances, clinical evaluation will remain important in determining how new systems complement existing diagnostic pathways, improve patient experiences and contribute to effective care.</p>
<p>The Canadian authorization follows the company’s recent regulatory registration of its breast CT technology in Australia.</p>
<p>With October marking Breast Cancer Awareness Month, the announcement highlights continuing efforts to develop imaging technologies that support the assessment of breast health.</p>
<p>Source: <a href="https://www.prnewswire.com/news-releases/koning-vera-breast-ct-receives-licensure-from-health-canada-for-breast-imaging-in-canada-302914525.html?utm_source=chatgpt.com">Koning Health — October 20, 2026</a></p>
<p>The post <a href="https://www.hospitalnews.com/new-compression-free-3d-breast-imaging-technology-receives-health-canada-licence/">New compression-free 3D breast imaging technology receives Health Canada licence</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Average cardiologist pay: $700K&#45;$1 million</title>
<link>https://edusehat.com/en/average-cardiologist-pay-700k-1-million</link>
<guid>https://edusehat.com/en/average-cardiologist-pay-700k-1-million</guid>
<description><![CDATA[ Average cardiologist pay is now topping $700,000, with surgeons now averaging $1 million, as the specialty sees big gains in productivity. According to data from MedAxiom, average pay for cardiologists was $727,712, reflecting a 5% bump from 2024 data. In addition, every cardiology subspecialty reported the highest compensation in the survey’s history. Leading the pack […]
The post Average cardiologist pay: $700K-$1 million appeared first on Today&#039;s Hospitalist. ]]></description>
<enclosure url="https://todayshospitalist.com/wp-content/uploads/2026/10/cardiology-pay-shutterstock_2674533403-10-21-26.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 21 Oct 2026 20:25:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Average, cardiologist, pay:, 700K-1, million</media:keywords>
<content:encoded><![CDATA[<p>Average cardiologist pay is now topping $700,000, with surgeons now averaging $1 million, as the specialty sees big gains in productivity.</p>
<p><a href="https://www.beckerscardiology.com/cardiology/cardiologist-compensation-hits-record-highs-10-numbers-to-know/">According to data from MedAxiom</a>, average pay for cardiologists was $727,712, reflecting a 5% bump from 2024 data. In addition, every cardiology subspecialty reported the highest compensation in the survey’s history.</p>
<p>Leading the pack were cardiac surgeons, whose average pay exceeded $1 million for the first time in the survey’s history. Pay for that group was up from $942,700 in 2024.</p>
<p>Electrophysiologists reported an average pay of $803,000. General/noninvasive cardiologists reported average comp of $654,848, and advanced heart failure cardiologists reported average pay of $662,297.</p>
<p>Here are other data highlights from the survey:</p>
<p><strong>Productivity gains.</strong> All cardiology subspecialties reported gains in productivity. The biggest was among cardiologists specializing in advanced heart failure, with a year-over-year productivity gain of 11%.</p>
<p>Average work RVUs for electrophysiologists also jumped 10%.</p>
<p><strong>Volumes/panel size.</strong> New patient volumes and new patient visits reached record highs in 2025, with both growing by 18% over the last five years.</p>
<p>Cardiologists reported carrying average panels of more than 2,000 patients, and median new patient volume reached a record of 727 in 2025. That latter number was also up 18% from 2024.</p>
<p><strong>APP support.</strong> The use of advanced practice providers (APPs) by cardiologists has boomed. APP productivity in the specialty exceeded 2,000 work RVUs for the first time in the survey, exceeding 2,000 for the first time. That’s an increase of 30% since 2021.</p>
<p><strong>Advanced imaging.</strong> These studies grew, with median volumes for advanced imaging jumping 36% from 2024-25 to 38 studies for every 1,000 active patients. The ratio of imaging studies to cardiac cath procedures exceeded 50%.</p>
<p><strong>Ablations.</strong> Electrophysiology volumes have also jumped, with median ablations per electrophysiologist rising 140% over the last five years.</p>
<p><strong>Gender differences.</strong> Female cardiologists earned about 85% of their male colleagues: $632,368 vs. $745,998. Female cardiologists reported 78% of work RVUs of their male colleagues.</p>
<p><a href="https://www.beckerscardiology.com/cardiology/cardiologist-compensation-hits-record-highs-10-numbers-to-know/">Becker’s Cardiology reported</a> that more than 60% of female cardiologists practice general/noninvasive cardiology, which pays less than interventional cardiology.</p>
<p><a href="https://www.businesswire.com/news/home/20261013235222/en/MedAxiom-Releases-2026-Cardiovascular-Provider-Compensation-Production-Survey-Report-Revealing-Record-Compensation-Rising-Productivity-and-Growing-Workforce-Demands">More information is available from a MedAxiom press release, which offers a link to the full report.</a></p>
<p>The post <a href="https://todayshospitalist.com/average-cardiologist-pay-700k-1-million/">Average cardiologist pay: $700K-$1 million</a> appeared first on <a href="https://todayshospitalist.com/">Today's Hospitalist</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Exercise in a pill</title>
<link>https://edusehat.com/en/exercise-in-a-pill</link>
<guid>https://edusehat.com/en/exercise-in-a-pill</guid>
<description><![CDATA[ We all know exercise is good for us. It builds muscle, strengthens bones, lowers blood pressure, and boosts mood. By deciphering how movement benefits the body, researchers hope to develop medicines that can offer some of the same perks—without the workout. The idea isn’t to replace exercise but to bring its upsides to people who… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/10/Excercise-Final-v.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 21 Oct 2026 17:05:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Exercise, pill</media:keywords>
<content:encoded><![CDATA[<p class="wp-block-paragraph">We all know exercise is good for us. It builds muscle, strengthens bones, lowers blood pressure, and boosts mood. By deciphering how movement benefits the body, researchers hope to develop medicines that can offer some of the same perks—without the workout. The idea isn’t to replace exercise but to bring its upsides to people who struggle with frailty, disability, or chronic illness. </p>



<h3 class="wp-block-heading">The sticking points</h3>



<p class="wp-block-paragraph">It will take a lot of experimentation to untangle the myriad pathways by which exercise promotes health. But IDing the cascade of hormones, enzymes, and other molecules related to physical activity is just the first step. Scientists need to figure out how to turn that knowledge into safe and effective drugs. That’s a tall order: <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9293739/">More than 90%</a> of treatments that enter human studies fail.</p>



<p class="wp-block-paragraph">There are regulatory hurdles too. The FDA approves medications to treat diseases, not to enhance wellness, says Thomas Burris, a pharmacologist at the University of Florida whose work focuses on diseases that respond to exercise, like obesity, type 2 diabetes, and dementia.</p>



<h3 class="wp-block-heading">The progress</h3>



<p class="wp-block-paragraph">There may never be a pill that delivers all the benefits of exercise, but research could lead to new medicines that mimic some aspects of working out. Scientists have already identified many important exercise-related signals and have even developed compounds to regulate them. (Some preliminary results have been so promising that doping authorities have proactively banned the compounds.) </p>



<p class="wp-block-paragraph">Burris and his colleagues are focused on a receptor that’s always switched on, even without exercise. Working out appears to boost that receptor in muscle cells, which in turn helps bolster endurance over time. Burris’s lab has spent years <a href="https://news.ufl.edu/2023/09/exercise-mimicking-drug/">designing a drug</a> that cranks up the receptor’s activity directly, and mice treated with the drug ran longer and farther than mice that weren’t. They “become marathon mice without having to do any type of exercise,” Burris says. There are even indications—also in mice—that the compound mimics some of the cognitive benefits of exercise and could help treat heart failure. Burris founded a company called Pelagos to carry the work forward into a clinical trial.</p>



<p class="wp-block-paragraph">Other workout-mimicking drugs have already entered human studies. In June, the biotech firm Cambrian Bio <a href="https://www.cambrianbio.com/news-and-publications/cambrian-bio-presents-positive-human-translational-data-for-atx-304-the-first-ampk-network-activator-at-the-american-diabetes-associations-86th-scientific-sessions">reported</a> that its experimental drug ATX-304 boosted metabolism and reduced liver and belly fat in people with obesity and prediabetes<em>. </em>It activates a metabolic switch that helps cells sense when energy supplies dip and coordinates the production of more fuel—the same switch that helps us sustain long sessions jumping rope or swimming laps. Cambrian hopes it will help people lose weight without losing muscle, a common concern with GLP-1 medicines.  </p>



<hr class="wp-block-separator has-alpha-channel-opacity">



<h3 class="wp-block-heading">Progress meter ………… 5</h3>



<figure class="wp-block-image size-full is-resized"><img decoding="async" width="387" height="48" src="https://wp.technologyreview.com/wp-content/uploads/2026/10/purple-20.svg" alt="" class="wp-image-1147277"></figure>



<p class="wp-block-paragraph"><strong>Our understanding of how exercise benefits the body is still coming into focus, and drug development is prone to failure.</strong></p>]]> </content:encoded>
</item>

<item>
<title>WHX Dubai 2027</title>
<link>https://edusehat.com/en/whx-dubai-2027</link>
<guid>https://edusehat.com/en/whx-dubai-2027</guid>
<description><![CDATA[ Het bericht WHX Dubai 2027 verscheen eerst op International Hospital. ]]></description>
<enclosure url="https://interhospi.com/wp-content/uploads/sites/3/2026/10/WHX-labs.png" length="49398" type="image/jpeg"/>
<pubDate>Wed, 21 Oct 2026 16:55:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>WHX, Dubai, 2027</media:keywords>
<content:encoded><![CDATA[<div class="avia-section av-5pjryc-19691d8fe024ecd22f4cf1b0746f9172 main_color avia-section-default avia-no-border-styling  avia-builder-el-0  avia-builder-el-no-sibling  avia-bg-style-scroll container_wrap fullsize"><div class="container av-section-cont-open"><main role="main" itemprop="mainContentOfPage" class="template-page content  av-content-full alpha units"><div class="post-entry post-entry-type-page post-entry-20414"><div class="entry-content-wrapper clearfix">


<div class="flex_column av-4vqtes-8a6e6b2dd0d572ce1d6026a3282c73a3 av_one_fifth  avia-builder-el-1  el_before_av_three_fifth  avia-builder-el-first  first flex_column_div av-hide-on-mobile av-zero-column-padding  "><section class="av_textblock_section av-key24etv-8cf8563f9a5147bae87b81cc26a3527e " itemscope="itemscope" itemtype="https://schema.org/BlogPosting" itemprop="blogPost"><div class="avia_textblock" itemprop="text"><p></p>
</div></section></div>

<div class="flex_column av-4j6544-3dd207ac880e0091524d5c381bfaef43 av_three_fifth  avia-builder-el-3  el_after_av_one_fifth  el_before_av_one_fifth  flex_column_div av-zero-column-padding  "><section class="av_textblock_section av-key254dz-6dca32f8382240f7ccc291ef75096d96 " itemscope="itemscope" itemtype="https://schema.org/BlogPosting" itemprop="blogPost"><div class="avia_textblock" itemprop="text"><p></p>
</div></section><br>
<section class="av_textblock_section av-ke9srown-cfbd4a744a50962f9a592b08939de968 " itemscope="itemscope" itemtype="https://schema.org/BlogPosting" itemprop="blogPost"><div class="avia_textblock" itemprop="text"><header class="entry-content-header"><h1 class="post-title entry-title" itemprop="headline">WHX Dubai 2027</h1><span class="post-meta-infos">/ <span class="blog-categories minor-meta">in <a href="https://interhospi.com/category/events/" rel="tag">Events</a>  </span></span></header>
</div></section><br>
<section class="av_textblock_section av-23o2c4-8f397adbcbd64996a2025c8abf40a726 " itemscope="itemscope" itemtype="https://schema.org/BlogPosting" itemprop="blogPost"><div class="avia_textblock" itemprop="text"><h3>Date: 25-28 January 2027</h3>
<p><span></span></p>
<h4>Venue: Dubai Exhibition Centre & Dubai World Trade Centre, Dubai, UAE</h4>
<p><a href="https://www.worldhealthexpo.com/events/healthcare/dubai" target="_blank" rel="noopener">https://www.worldhealthexpo.com/events/healthcare/dubai</a></p>
</div></section><br>


<div class="hr av-klqcq5xv-fb118132a60cd57f133869cf62f2257a hr-invisible  avia-builder-el-7  el_after_av_textblock  el_before_av_image "><span class="hr-inner "><span class="hr-inner-style"></span></span></div><br>


<div class="avia-image-container av-1slha5w-ec52f72a365891ef6a11b6d8be2a536c av-styling- av-img-linked avia-align-center  avia-builder-el-8  el_after_av_hr  el_before_av_hr " itemprop="image" itemscope="itemscope" itemtype="https://schema.org/ImageObject"><div class="avia-image-container-inner"><div class="avia-image-overlay-wrap"><a href="https://www.worldhealthexpo.com/events/healthcare/dubai" class="avia_image " target="_blank" rel="noopener noreferrer" aria-label="WHX labs"><img decoding="async" fetchpriority="high" class="wp-image-20415 avia-img-lazy-loading-not-20415 avia_image " src="https://interhospi.com/wp-content/uploads/sites/3/2026/10/WHX-labs.png" alt="" title="WHX labs" height="945" width="946" itemprop="thumbnailUrl" srcset="https://interhospi.com/wp-content/uploads/sites/3/2026/10/WHX-labs.png 946w, https://interhospi.com/wp-content/uploads/sites/3/2026/10/WHX-labs-300x300.png 300w, https://interhospi.com/wp-content/uploads/sites/3/2026/10/WHX-labs-80x80.png 80w, https://interhospi.com/wp-content/uploads/sites/3/2026/10/WHX-labs-768x767.png 768w, https://interhospi.com/wp-content/uploads/sites/3/2026/10/WHX-labs-36x36.png 36w, https://interhospi.com/wp-content/uploads/sites/3/2026/10/WHX-labs-180x180.png 180w, https://interhospi.com/wp-content/uploads/sites/3/2026/10/WHX-labs-705x705.png 705w" sizes="(max-width: 946px) 100vw, 946px"></a></div></div></div><br>
<div class="hr av-1csd104-f216505c48d840050a0e988af6192511 hr-default  avia-builder-el-9  el_after_av_image  el_before_av_social_share "><span class="hr-inner "><span class="hr-inner-style"></span></span></div><br>
<div class="av-social-sharing-box av-ke9sz9xv-3e02cbd0889cb70a2a9058e399d76f75 av-social-sharing-box-minimal  avia-builder-el-10  el_after_av_hr  avia-builder-el-last  av-social-sharing-box-fullwidth"><div class="av-share-box"><h5 class="av-share-link-description av-no-toc ">Share this</h5><ul class="av-share-box-list noLightbox"><li class="av-share-link av-social-link-facebook avia_social_iconfont"><a target="_blank" aria-label="Share on Facebook" href="https://www.facebook.com/sharer.php?u=https://interhospi.com/whx-dubai-2027/&t=WHX%20Dubai%202027" data-av_icon="" data-av_iconfont="entypo-fontello" title="" data-avia-related-tooltip="Share on Facebook"><span class="avia_hidden_link_text">Share on Facebook</span></a></li><li class="av-share-link av-social-link-twitter avia_social_iconfont"><a target="_blank" aria-label="Share on X" href="https://twitter.com/share?text=WHX%20Dubai%202027&url=https://interhospi.com/?p=20414" data-av_icon="" data-av_iconfont="entypo-fontello" title="" data-avia-related-tooltip="Share on X"><span class="avia_hidden_link_text">Share on X</span></a></li><li class="av-share-link av-social-link-whatsapp avia_social_iconfont"><a target="_blank" aria-label="Share on WhatsApp" href="https://api.whatsapp.com/send?text=https://interhospi.com/whx-dubai-2027/" data-av_icon="" data-av_iconfont="entypo-fontello" title="" data-avia-related-tooltip="Share on WhatsApp"><span class="avia_hidden_link_text">Share on WhatsApp</span></a></li><li class="av-share-link av-social-link-linkedin avia_social_iconfont"><a target="_blank" aria-label="Share on LinkedIn" href="https://linkedin.com/shareArticle?mini=true&title=WHX%20Dubai%202027&url=https://interhospi.com/whx-dubai-2027/" data-av_icon="" data-av_iconfont="entypo-fontello" title="" data-avia-related-tooltip="Share on LinkedIn"><span class="avia_hidden_link_text">Share on LinkedIn</span></a></li><li class="av-share-link av-social-link-mail avia_social_iconfont"><a aria-label="Share by Mail" href="mailto:?subject=WHX%20Dubai%202027&body=https://interhospi.com/whx-dubai-2027/" data-av_icon="" data-av_iconfont="entypo-fontello" title="" data-avia-related-tooltip="Share by Mail"><span class="avia_hidden_link_text">Share by Mail</span></a></li></ul></div></div></div>

<div class="flex_column av-1ziaaf0-b945285943f655b3c584bc38c6af1f49 av_one_fifth  avia-builder-el-11  el_after_av_three_fifth  avia-builder-el-last  flex_column_div av-hide-on-mobile av-zero-column-padding  "><section class="av_textblock_section av-key26scb-767e6508335704b90077f977070d6be8 " itemscope="itemscope" itemtype="https://schema.org/BlogPosting" itemprop="blogPost"><div class="avia_textblock" itemprop="text"><p></p>
</div></section></div>
<p>Het bericht <a href="https://interhospi.com/whx-dubai-2027/">WHX Dubai 2027</a> verscheen eerst op <a href="https://interhospi.com/">International Hospital</a>.</p></div></div></main></div></div>]]> </content:encoded>
</item>

<item>
<title>Takara Bio USA, SPT Labtech Team Up to Automate NGS Library Prep Workflows</title>
<link>https://edusehat.com/en/takara-bio-usa-spt-labtech-team-up-to-automate-ngs-library-prep-workflows</link>
<guid>https://edusehat.com/en/takara-bio-usa-spt-labtech-team-up-to-automate-ngs-library-prep-workflows</guid>
<description><![CDATA[ The partners are targeting NGS core labs with a combined offering that automates next-generation sequencing library prep workflows using kits from Takara Bio and SPT Labtech’s firefly instrument. They are starting with RNA-seq with plans to expand. 
The post Takara Bio USA, SPT Labtech Team Up to Automate NGS Library Prep Workflows appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/12/GettyImages-1481209562.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 21 Oct 2026 06:15:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Takara, Bio, USA, SPT, Labtech, Team, Automate, NGS, Library, Prep, Workflows</media:keywords>
<content:encoded><![CDATA[<p>Takara Bio USA and SPT Labtech have inked an agreement that will allow them to provide automated library preparation workflows that pair Takara Bio’s next-generation sequencing library prep chemistries with SPT Labtech’s firefly liquid handling platform. Under the terms of the partnership agreement, the companies will first optimize select SMART-seq<sup>®</sup> RNA-seq library prep workflows, a new offering from Takara Bio, on SPT Labtech’s firefly with plans to ultimately expand to a growing menu of new RNA-seq, DNA-seq, and immune profiling kits.</p>
<p>The target customer base for the combined offering is NGS core labs and customers who prepare NGS libraries from a high volume of samples and need to expand their current capabilities. With the new offering, the company claims that these customers will have access to automation scripts to easily deploy workflows that can generate high-quality, reproducible sequencing data and that are easy to integrate into labs’ existing processes. The partners also note that SPT Labtech’s firefly does not require a large footprint, making it suitable for labs constrained by staffing, space, and cost.</p>
<p>Both partners will discuss the collaboration during this year’s annual meeting of the American Society of Human Genetics.</p>
<p>For Takara Bio, the partnership fits into a bigger picture. The company is incorporating automation as an integral part of an NGS technology launch package. The company plans to start shipping its SMART-Seq mRNA long read extended kit in January 2027. This will be the first product launched with an optimized workflow for the firefly instrument. Takara Bio claims that the combined products will help labs standardize long-read transcriptomics at scale while benefitting from greater input flexibility, better recovery of full-length transcripts, and greater quantification confidence among other benefits. Automation scripts are already available for download on the SPT cloud portal for two existing kits, SMART-Seq mRNA LP and SMART-Seq Total RNA Library Prep with ZapR<sup>®</sup> Depletion with unique molecular identifiers.</p>
<p>Commenting on the partnership, Andrew Farmer, DPhil, president and CEO of Takara Bio USA, noted that the company is committed to making its NGS chemistries easier to implement at scale. “Through our collaboration with SPT Labtech, automation is becoming a foundational element of how we bring NGS products to market. As we introduce new library preparation technologies, customers can expect automated workflows to be built into the product experience from the start,” he said.</p>
<p>Paul Lomax, head of genomics at SPT Labtech, noted that by combining their products, both companies aim to help “more laboratories access the benefits of automated library preparation without the infrastructure requirements often associated with larger automation platforms.”</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/takara-bio-usa-spt-labtech-team-up-to-automate-ngs-library-prep-workflows/">Takara Bio USA, SPT Labtech Team Up to Automate NGS Library Prep Workflows</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Roche, Hansoh Launch Up&#45;to&#45;$15B+ Cancer ADC Collaboration</title>
<link>https://edusehat.com/en/roche-hansoh-launch-up-to-15b-cancer-adc-collaboration</link>
<guid>https://edusehat.com/en/roche-hansoh-launch-up-to-15b-cancer-adc-collaboration</guid>
<description><![CDATA[ The companies&#039; strategic collaboration will consist of two preclinical Hansoh ADC programs and “multiple” ADC programs based on Roche-identified targets, to be developed through Hansoh’s ADC technology platform.
The post Roche, Hansoh Launch Up-to-$15B+ Cancer ADC Collaboration appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Getty_2179548801_AntibodyDrugConjugate.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 21 Oct 2026 06:15:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Roche, Hansoh, Launch, Up-to-15B, Cancer, ADC, Collaboration</media:keywords>
<content:encoded><![CDATA[<p>Roche and Hansoh Pharmaceutical Group have launched their second collaboration focused on developing cancer-fighting antibody-drug conjugates (ADCs), a partnership that could generate more than $15 billion for the Shanghai-based drug developer.</p>
<p>Roche and Hansoh have agreed to develop an unspecified number of ADCs “across multiple cancer types,” without disclosing the cancer types and targets they plan to focus on. The companies did say, however, that their strategic collaboration will consist of two preclinical Hansoh ADC programs and “multiple” ADC programs based on Roche-identified targets, to be developed through Hansoh’s ADC technology platform.</p>
<p>“Expanding our strategic collaboration with Hansoh marks an important step in advancing our ADC vision,” Boris L. Zaïtra, head of Corporate Business Development at Roche, said in a statement. “Exploring next generation ADCs is one of the most compelling frontiers in oncology today, offering the opportunity to address critical unmet needs and accelerate potential therapies for patients worldwide.”</p>
<p>Roche’s latest Hansoh partnership was announced October 19, a year and two days after the pharma giant was granted an exclusive global license (excluding China, Hong Kong, Macau and Taiwan) by Hansoh to develop its HS-20110, an ADC being developed to treat colorectal cancer and other solid tumors. HS-20110 consists of a humanized anti-CDH17 monoclonal antibody covalently conjugated to topoisomerase inhibitor (TOPOi) payload.</p>
<p>At the time, Roche agreed to pay Hansoh $80 million upfront and up to $1.45 billion in potential development, regulatory approval, and commercialization milestone payments, plus royalties, toward developing HS-20110. The drug is under study in advanced colorectal cancer in a global Phase I/II trial (<a title="Original URL: https://clinicaltrials.gov/study/NCT07283367. Click or tap if you trust this link." href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT07283367&data=05%7C02%7CSavannah.Wiegel%40sagepub.com%7C457be5dcfb8f4fe223d708df2ec75245%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639281105751915276%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=YPNLp%2B1eB6Uvla0qKAAhjIbrqPgWLHKJmdmRyyva3Xc%3D&reserved=0" target="_blank" rel="noopener" data-auth="NotApplicable" data-linkindex="0">NCT07283367</a>) in China whose primary completion date is December 31, 2029; as well as in advanced solid tumors in a global Phase I trial (<a title="Original URL: https://clinicaltrials.gov/study/NCT06892379. Click or tap if you trust this link." href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06892379&data=05%7C02%7CSavannah.Wiegel%40sagepub.com%7C457be5dcfb8f4fe223d708df2ec75245%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639281105751944126%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=iosS%2FLGC1HyYtPliI45Dz9PnvZXIAZtYaBhi8VfQNxc%3D&reserved=0" target="_blank" rel="noopener" data-auth="NotApplicable" data-linkindex="1">NCT06892379</a>) in the U.S. and China whose primary completion date is December 31.</p>
<p>“Building on the ADC partnership we announced last year, we are delighted to further strengthen our collaboration with Roche,” stated Eliza Sun, executive director of Hansoh’s board. “This new agreement reflects our shared commitment to advancing ADC innovation and underscores our strategy of leveraging our deep expertise to accelerate the development of transformative therapies for cancer patients globally.”</p>
<p class="x_MsoNormal" data-olk-copy-source="MessageBody">Investors sent Hansoh shares on the Hong Kong Stock Exchange rising nearly 10% over two days, from HKD 31.38 ($3.94) at the start of Monday trading to HKD 34.38 ($4.31) at Tuesday’s close. Roche’s two classes of stock traded on the SIX Swiss Exchange each climbed roughly 3% during the period: RO bearer shares rose from CHF 384.60 ($463.21) to CHF 395.60 ($476.46), while ROP participation certificates went from CHF 379.20 ($456.67) to CHF 389.90 ($469.56).</p>
<h4><strong>Four ADCs disclosed in pipeline</strong></h4>
<p>HS-20110—identified with the placeholder name “CHU”—is one of four cancer-fighting ADCs disclosed online in <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.roche.com%2Fsolutions%2Fpipeline&data=05%7C02%7Calex.philippidis%40sagepub.com%7C5aa2b45fbc2a4779ff2508df2e1f490f%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639280384782719394%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=dMePOleHd17aiLs3XzYg04uQ8qh4N1ZUoHO9ufJGzgw%3D&reserved=0" target="_blank" rel="noopener">Roche’s pipeline</a>, last updated July 23. The other three are:</p>
<ul>
<li><strong>RG6648</strong>, a c-Mesenchymal-epithelial transition factor (cMET)-targeting ADC whose active antitumor payload is the antibody YL0010014. When released, YL0010014 is designed to arrest the cell cycle of tumor cells, leading to tumor cell apoptosis. MediLink licensed the ADC, which it called YL211, in 2024 for up to nearly $1 billion, including $50 million in upfront and near-term milestone payments.</li>
<li><strong>RG6810</strong>, a DLL3-targeted ADC with a topoisomerase I (Topo1) isomerase payload, being developed to treat small cell lung cancer (SCLC). Roche licensed the ADC, which it called IBI3009, from San Francisco and Suzhou-based Innovent Biologics last year for $80 million upfront and up to $1 billion in development and commercial milestone payments, plus tiered royalties on net sales.</li>
<li><strong>Tam-Peli (tambotatug pelitecan or RG6919)</strong>, a B7H3-targeting ADC for solid tumors licensed worldwide except China, Hong Kong, and Macau in January from Suzhou, China-based MediLink, which called the candidate YL201. The ADC was developed using MediLink’s Tumor Microenvironment-Activatable LINker-payload (TMALIN<sup>®</sup>) platform.</li>
</ul>
<p>Last month, MediLink released positive interim data from the Phase III TAISHAN-302 trial (<a href="https://clinicaltrials.gov/study/NCT06612151" target="_blank" rel="noopener">NCT06612151</a>) assessing Tam-Peli vs. standard-of-care topotecan in Chinese patients with relapsed SCLC who progressed after prior platinum-based chemotherapy with or without a PD-L1 inhibitor. TAISHAN-302 met its primary endpoint of overall survival (OS) with Tam-Peli demonstrating a statistically significant and clinically meaningful OS benefit, reducing the risk of death by 54% (median OS 13.3 vs. 9.4 months; stratified HR=0.46; p<0.0001).</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>Tam-Peli also showed robust efficacy across secondary endpoints, significantly extending progression-free survival (PFS) (median PFS 7.4 vs. 2.8 months) and response rates (59.1% vs. 9.7%) vs. topotecan. The Tam-Peli data was presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC) in Seoul with simultaneous <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.nejm.org%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2610229%3Faf%3DR%26rss%3DcurrentIssue%26referrer%3Dhttps%253A%252F%252Fwww.google.com%252F&data=05%7C02%7Calex.philippidis%40sagepub.com%7C5aa2b45fbc2a4779ff2508df2e1f490f%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639280384782749883%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=OeWCYKS3VJxKecK82rPuRQMiW8s%2FHDlAg4cSveQXuEA%3D&reserved=0" target="_blank" rel="noopener">publication in <em>The New England Journal of Medicine</em></a>.</p>
<h4><strong>Ongoing ADC collaborations</strong></h4>
<p>Roche has several other ongoing discovery and development collaborations with Chinese partners focused on ADCs.</p>
<p>In August, Roche’s Genentech subsidiary agreed to license ADCs it plans to develop with Shanghai-based DualityBio based on its DualityBio Unique Payload Antibody Conjugate (DUPAC) platform. The ADCs would be developed against Genentech-defined oncology targets using payloads from DUPAC. Roche agreed to pay DualityBio $45 million upfront and more than $1 billion in development, regulatory, and commercial milestone payments, plus tiered royalties.</p>
<p>Through its latest partnership with Hansoh, Roche aims to multiply the number of ADCs in its development pipeline and product portfolio. Roche now markets two ADCs. One is Kadcyla<sup>®</sup> (ado-trastuzumab emtansine / RG3502), a HER2-targeted antibody and microtubule inhibitor conjugate approved to treat HER2-positive breast cancer. Kadcyla is under study in combination with Roche’s Tecentriq<sup>®</sup> (atezolizumab) in the Phase III ASTEFANIA trial (<a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04873362&data=05%7C02%7Calex.philippidis%40sagepub.com%7C5aa2b45fbc2a4779ff2508df2e1f490f%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639280384782767152%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=tqWwZVSif8QrDwiGxFVZ5N9wyXSgA8O3rt1iX17UE%2B4%3D&reserved=0" target="_blank" rel="noopener">NCT04873362</a>) for high-risk early breast cancer.</p>
<p>The other marketed Roche ADC is Polivy<sup>®</sup> (polatuzumab vedotin), which is approved for specific types of lymphoma.  While a consensus of analysts expects Kadcyla and Polivy to rack up a combined CHF 3.5 billion ($4.3 billion) this year, according to LSEG data cited by Reuters.</p>
<p>Hansoh has agreed to lead early development of the programs through the completion of global Phase Ia clinical trials. After that, Roche agreed to oversee further development of the programs worldwide except China, Hong Kong, Macau, and Taiwan—where Hansoh will retain all rights to develop, register and commercialize the programs.</p>
<p>Also outside China, Hong Kong, Macau, and Taiwan, Hansoh has the option to select up to two programs and contribute to their development. In return, Roche will pay Hansoh unspecified “incremental upside” payments stemming from their commercialization in the United States.</p>
<p>Roche has agreed to pay Hansoh $400 million upfront, an additional $110 million to be paid next year on the first anniversary of the collaboration, and more than $15 billion in payments tied to achieving development, regulatory, and commercialization milestones associated with the programs. Hansoh could also gain from Roche tiered royalties on potential future product sales.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<h4><strong>Patent cliff pressure</strong></h4>
<p>The partnership is one of several collaborations through which Swiss-based Roche hopes to recoup sales it expects to lose as its aging blockbusters lose patent exclusivity. The best-selling of these drugs is its Genentech-marketed multiple sclerosis drug Ocrevus<sup>®</sup> (ocrelizumab), which <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.genengnews.com%2Ftopics%2Fdrug-discovery%2Ftop-20-drugs-heading-for-the-patent-cliff-2026-2029%2F&data=05%7C02%7Calex.philippidis%40sagepub.com%7C5aa2b45fbc2a4779ff2508df2e1f490f%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639280384782782029%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=RHVVkDomkTBk8KTqPamt%2B9hVynu2PkIAs3QfinxBAFI%3D&reserved=0" target="_blank" rel="noopener">heads for the proverbial “patent cliff” in 2027</a>. Ocrevus generated CHF 3.47 billion ($4.192 billion) in sales during January-June and CHF 7.01 billion ($8.467 billion) in 2025.</p>
<p>That sales pressure has prompted Roche to launch numerous collaborations: In addition to the Hansoh and DualityBio collaborations, Roche has partnered since August alone with:</p>
<ul>
<li><strong>Rona Therapeutics</strong>, another Chinese biotech, on an agreement to license its RNA interference (RNAi) obesity and metabolic disease candidate targeting activin receptor-like kinase 7 (ALK7), announced October 13 and valued at up-to-$1.16 billion ($100 million upfront and near-term).</li>
<li><strong>Defand Therapeutics, </strong>a Chinese startup, on a drug discovery partnership of undisclosed value (though <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fendpoints.news%2Froche-does-fourth-china-deal-since-august-teaming-with-defand-on-degraders%2F&data=05%7C02%7Calex.philippidis%40sagepub.com%7C5aa2b45fbc2a4779ff2508df2e1f490f%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639280384782794666%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=3wwi8ubmEbjcOqrkDg3pFV6Y8090aBKnNQ9IfT9pvTM%3D&reserved=0" target="_blank" rel="noopener">reportedly</a> up to about $1 billion, up to $10 million of that upfront) to discover and develop molecular glue therapies for multiple cancer and immunology targets, announced October 7.</li>
<li><strong>Ataviastik Bio, </strong>a Cambridge, MA hematology drug developer, on a partnership to discover and develop small molecule therapeutics against multiple targets for cardiovascular, renal, and metabolic (CVRM) diseases, valued at up to $1.9 billion ($70 million upfront), announced September 24.</li>
<li><strong>Earendil Labs</strong>, a Wilmington, DE, biologics developer, on a research collaboration with Genentech to discover and develop multiple therapeutic bispecific antibody programs in oncology, valued at up to $1.15 billion ($55 million upfront), announced September 24.</li>
</ul>
<p>At up-to-$15.5 billion, the latest Roche-Hansoh collaboration is among the largest but not the largest partnership between a Western pharma and a Chinese biotech. That distinction belongs to AstraZeneca’s up-to-$18.5 billion collaboration ($1.2 billion upfront) with CSPC Pharmaceutical Group to develop “multiple” injectable next-generation therapies for obesity and type 2 diabetes across eight programs announced in January. That does not include a separate up-to-$1.77 billion ($30 million upfront) partnership by the companies to develop small interfering RNA (siRNA) therapies for kidney diseases, launched in July.</p>
<p>In May, Bristol Myers Squibb (BMS) <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.genengnews.com%2Ftopics%2Fdrug-discovery%2Fbms-hengrui-pharma-partner-on-13-programs-in-up-to-15-2b-collaboration%2F&data=05%7C02%7Calex.philippidis%40sagepub.com%7C5aa2b45fbc2a4779ff2508df2e1f490f%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639280384782815248%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=6dXHP%2BUSMzcHBa3SrGlzm5IsfPgBo1fJp%2Bo%2FvYo96As%3D&reserved=0" target="_blank" rel="noopener">launched an up-to-$15.2 billion partnership</a> with Hengrui Pharma to co-develop 13 early-stage programs in oncology, hematology, and immunology. The 13 consist of four oncology/hematology assets from Hengrui, four immunology assets from BMS, and five “innovative” assets to be jointly discovered and developed by both companies. Also in May, Pfizer <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.genengnews.com%2Ftopics%2Fdrug-discovery%2Fpfizer-innovent-ink-up-to-10-5b-cancer-treatment-collaboration%2F&data=05%7C02%7Calex.philippidis%40sagepub.com%7C5aa2b45fbc2a4779ff2508df2e1f490f%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639280384782826682%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=gps5ijxT%2BVzbPbuATAcMdIKK01rJbBMjQ4N%2FKrpK3lU%3D&reserved=0" target="_blank" rel="noopener">inked an up to $10.5 billion oncology alliance</a> with Innovent Biologics to develop 12 early-stage and <em>de novo</em> antibodies and antibody-drug conjugates (ADCs) designed to treat various cancers.</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/roche-hansoh-launch-up-to-15b-cancer-adc-collaboration/">Roche, Hansoh Launch Up-to-$15B+ Cancer ADC Collaboration</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>New Catalytic Reactive&#45;Hydrogen Membranes Capture and Break Down PFAS</title>
<link>https://edusehat.com/en/new-catalytic-reactive-hydrogen-membranes-capture-and-break-down-pfas</link>
<guid>https://edusehat.com/en/new-catalytic-reactive-hydrogen-membranes-capture-and-break-down-pfas</guid>
<description><![CDATA[ Newly developed palladium-coated membranes capture PFAS and use reactive hydrogen to break their carbon–fluorine bonds. During 58 days of continuous operation, the system achieved up to 96% removal and 83% defluorination.
The post New Catalytic Reactive-Hydrogen Membranes Capture and Break Down PFAS appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/03/GettyImages-2149301660.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 21 Oct 2026 06:15:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>New, Catalytic, Reactive-Hydrogen, Membranes, Capture, and, Break, Down, PFAS</media:keywords>
<content:encoded><![CDATA[<p>Researchers at Arizona State University (ASU) and collaborating institutions have developed catalytic reactive-hydrogen membranes that capture and chemically break down six per- and polyfluoroalkyl substances (PFAS) in water. The approach couples contaminant removal with carbon–fluorine bond cleavage, addressing a limitation of conventional treatments that separate “forever chemicals” from water but leave contaminated waste requiring further handling.</p>
<p>The study, led by Bruce Rittmann, PhD, director of ASU’s Biodesign Swette Center for Environmental Biotechnology, involved collaborators at Rice University, Tongji University, the National University of Singapore, and Nanjing University. Published in <em>Proceedings of the National Academy of Sciences</em>, the paper is titled “<a href="https://www.pnas.org/doi/10.1073/pnas.2613985123" target="_blank" rel="noopener">Catalytic Reactive-Hydrogen Membranes for Rapid Capture and Hydrodefluorination of Six PFAS of Regulatory Concern</a>.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>“PFAS are hard to break down, and normal processes that we use don’t work,” Rittmann said.</p>
<p>That persistence stems from the compounds’ strong carbon–fluorine bonds. Activated carbon, ion exchange, and membrane filtration can remove PFAS from water, but do not themselves resolve the challenge of destroying the captured contaminants. The new system instead brings PFAS and reactive hydrogen together on palladium-coated membrane fibers under ambient conditions.</p>
<figure aria-describedby="caption-attachment-339638" class="wp-caption alignleft"><img fetchpriority="high" decoding="async" class="size-medium wp-image-339638" src="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_rittmann-defluorination-300x169.jpg" alt="" width="300" height="169" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_rittmann-defluorination-300x169.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_rittmann-defluorination.jpg 700w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">A palladium-coated membrane uses hydrogen to help break down PFAS “forever chemicals.” [Jason Drees]</figcaption></figure>
<p>Hydrogen gas travels through the fibers to the palladium catalyst, where it generates two forms of active hydrogen with complementary functions. Surface hydrogen supports PFAS capture, while subsurface hydrogen stored as beta-phase palladium hydride supplies the driving force for hydrodefluorination.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>“The palladium attracts the PFAS molecule, and the palladium attracts the hydrogen and puts them together,” Rittmann added.</p>
<p>Solid-state analyses identified formation of the palladium hydride and associated lattice expansion. In the paper, the researchers described their findings as “a mechanistic framework for how active hydrogen is generated, stored, and deployed in catalytic membranes.”</p>
<p>The team tested PFOA, PFOS, PFNA, PFHxS, PFBS, and GenX. During 58 days of continuous operation, the system achieved up to 96% removal and 83% defluorination.</p>
<p>Performance also varied by compound. Long-chain PFAS were removed and defluorinated faster than short-chain analogs. GenX was more resistant, which the authors attributed to its ether linkage, weaker adsorption, and higher average carbon–fluorine bond dissociation energy. Nevertheless, the membrane enabled GenX removal and defluorination, producing 2-propoxypropanoic acid.</p>
<p>Practical deployment will require further engineering, including reducing palladium use. “Palladium is expensive,” Rittmann said. One potential application is treating concentrated waste streams generated by existing PFAS-removal systems, rather than replacing those systems outright. The researchers are also developing related hybrid membranes combining palladium with pollutant-degrading bacteria, although the current study’s catalytic system uses palladium rather than microbes.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/new-catalytic-reactive-hydrogen-membranes-capture-and-break-down-pfas/">New Catalytic Reactive-Hydrogen Membranes Capture and Break Down PFAS</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Immune Pathway Contributing to Radiation Therapy&#45;Related Lung Damage Identified in Mice</title>
<link>https://edusehat.com/en/immune-pathway-contributing-to-radiation-therapy-related-lung-damage-identified-in-mice</link>
<guid>https://edusehat.com/en/immune-pathway-contributing-to-radiation-therapy-related-lung-damage-identified-in-mice</guid>
<description><![CDATA[ Working with a mouse model of radiation-induced lung injury, researchers uncovered an immune pathway that may contribute to radiation-related lung damage and, suggest their results may point to a potential preventive strategy.
The post Immune Pathway Contributing to Radiation Therapy-Related Lung Damage Identified in Mice appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_High-Quality-WomenCenter_031221_-175.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 21 Oct 2026 02:40:13 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Immune, Pathway, Contributing, Radiation, Therapy-Related, Lung, Damage, Identified, Mice</media:keywords>
<content:encoded><![CDATA[<p>More than 70% of people diagnosed with lung cancer will undergo radiation therapy (RT) at some point in their treatment, but while such therapy is often lifesaving, it can permanently damage healthy lung tissue and limit future cancer treatment options.</p>
<p>Working with a mouse model of radiation-induced lung injury (RILI) researchers headed by a team at City of Hope have uncovered an immune pathway that may contribute to radiation-related lung damage, which may point to a potential preventive strategy. The researchers suggest that insights from their preclinical study could lead to new treatments that prevent radiation therapy from harming healthy lung tissue and so improve patients’ quality of life.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>Research lead Heather McGee, MD, PhD, an assistant professor in the departments of radiation oncology and immuno-oncology at City of Hope, said, “Many researchers in our field study how radiation activates well-known immune cells such as T cells to fight cancer. We are the first group to show that radiation also reprograms rare immune cells called innate lymphoid cells, and that these cells play a key role in driving damage to healthy lung tissue.” McGee is corresponding author of the team’s published paper in <em>Nature Communications</em>, titled “<a href="https://doi.org/10.1038/s41467-026-77637-3" target="_blank" rel="noopener">Type I IFN promotes ILC2-to-ILC1 plasticity in pre-clinical radiation-induced lung injury</a>.”</p>
<p>Lung cancer is one of the leading causes of cancer-related mortality worldwide, accounting for about 18% of all cancer-related deaths, the authors wrote, and radiation therapy (RT) plays a critical role in the treatment of patients with lung cancer. However, they noted, “Although RT can cure patients with lung cancer, it can also lead to severe complications, such as radiation-induced lung injury (RILI), pneumonitis, and radiation-induced lung fibrosis (RILF).”</p>
<p>When healthy lung tissue is damaged, the effects can be severe and long-lasting. Up to 20% of patients struggle with debilitating breathing difficulties and reduced quality of life, leaving some patients tethered to heavy oxygen tanks. “RILI can significantly impair lung function, often leading to supplemental oxygen dependence,” the team added. McGee leads a team of scientists investigating the role that innate lymphoid cells play in the response to radiation.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>To better understand how radiation damages healthy lung tissue the researchers developed a mouse model of radiation-induced lung injury and focused their studies on the potential role of innate lymphoid cells (ILCs). “While ILCs have been implicated in the pathogenesis of various lung diseases, their contribution to RILI has not been investigated,” they noted in their report. “In this study, we evaluate how high-dose, restricted field radiation therapy affects lung ILC function and plasticity in the context of RILI.”</p>
<p>The team used a number of techniques to track radiation’s impact on the immune system. “Using a mouse model of localized lung irradiation, we combine flow cytometric characterization of ILC subsets and cytokine production with single-cell transcriptomic and pseudotime analyses to define radiation associated changes in ILC phenotype and function, they explained. “We further use adoptive transfer experiments to determine whether ILC2s acquire ILC1-like features after irradiation<em> in vivo</em>.”</p>
<p>Their results showed that radiation provoked a dramatic transformation of ILCs causing them to adopt different identities and altering their functions. One type of ILC, called ILC2s, helps protect the lungs from damage. Radiation transformed these cells into another type, ILC1s, which promote inflammation that damages healthy lung tissue.</p>
<p>The researchers also discovered what drives this transformation, showing that radiation increased levels of the signaling protein interferon-beta (IFN-β), which acted as the switch that pushed protective ILC2 cells to become inflammatory ILC1 cells. Tests on human ILCs showed similar biological changes. “These findings identify radiation-induced type I interferon-mediated ILC plasticity as a mechanism underlying the pathogenesis of RILI,” the investigators noted.</p>
<p>McGee said, “Much like a player switching teams, radiation-induced IFN-β can shift these immune cells from a protective role to one that promotes inflammation. Our findings shed light on a previously unknown mechanism that leads to radiation-induced lung damage.”</p>
<p>The investigators in addition tested whether blocking the IFN-β signaling pathway during radiation could stop the harmful immune cell transformation. The found that in mice, disrupting this pathway reduced inflammation, limited lung injury, and decreased the fibrosis that can permanently scar healthy lung tissue.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>“Our findings suggest that high levels of IFN-beta contribute to the development of lung damage during radiation and that blocking this signaling pathway could offer a potential treatment to reduce this debilitating side effect,” said first author Jaeho Kim, MD, PhD, a radiation oncology postdoctoral fellow at City of Hope.</p>
<p>If the team’s approach proves effective in people it could protect patients from long-term lung damage, expand radiation options for individuals with chronic lung conditions such as chronic obstructive pulmonary disease (COPD), and enable more aggressive radiation treatment when needed. In their paper the team stated, “In conclusion, our study identifies an immune regulatory mechanism whereby type I IFN-induced ILC2-to-ILC1 plasticity contributes to the pathogenesis of RILI,” they concluded. “We also demonstrate that inhibiting this plasticity by blocking IFNAR1 signaling can alleviate lung damage in mouse models, offering a potential therapeutic strategy to minimize the side effects of radiation therapy in patients.”</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/immune-pathway-contributing-to-radiation-therapy-related-lung-damage-identified-in-mice/">Immune Pathway Contributing to Radiation Therapy-Related Lung Damage Identified in Mice</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Canada’s Arctic Research Could Help Discover Next&#45;Gen Therapeutics</title>
<link>https://edusehat.com/en/canadas-arctic-research-could-help-discover-next-gen-therapeutics</link>
<guid>https://edusehat.com/en/canadas-arctic-research-could-help-discover-next-gen-therapeutics</guid>
<description><![CDATA[ Unlocking the Arctic’s subterranean DNA must ensure a delicate balance between scientific rigor and ethical stewardship. Synthetic biology and chemistry could help discovery of new life-saving therapeutics. 
The post Canada’s Arctic Research Could Help Discover Next-Gen Therapeutics appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Bhatnagar-and-team-out-in-the-field-credit-Athabasca-University-free-to-use-cc.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 20 Oct 2026 23:05:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Canada’s, Arctic, Research, Could, Help, Discover, Next-Gen, Therapeutics</media:keywords>
<content:encoded><![CDATA[<p>Buried under the permanently frozen soils of Canada’s Arctic is a biological trove not tapped by modern medicine.</p>
<p>Canadian scientists, fascinated by the extreme Arctic tundra, are tinkering with sophisticated genomic toolkits, digging subterranean material. There is hope that their bioprospecting could also be latched on by biotech innovators aid discovery of next-generation drug therapeutics.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>Labs work to biosynthesize complex bioproducts in scalable fermenters hoping to never need to grow the Arctics sensitive native organisms.</p>
<p>Canada’s Arctic permafrost and ancient boric soils contain huge amounts rich DNA that has degraded over thousands of years, says Srijak Bhatnagar, PhD, who leads the Enviromics Group, a computational biology and environmental microbiology research lab at Canada’s Athabasca University. He and his team have spent years gathering environmental DNA from Canada’s Arctic waters.</p>
<figure aria-describedby="caption-attachment-339556" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="size-medium wp-image-339556" src="https://www.genengnews.com/wp-content/uploads/2026/10/Bhatnagar-at-work-credit-Athabasca-Univeristy-free-to-use-creative-commons-300x169.jpg" alt="Srijak Bhatnagar, PhD, at work in his laboratory at Athabasca University" width="300" height="169" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Bhatnagar-at-work-credit-Athabasca-Univeristy-free-to-use-creative-commons-300x169.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Bhatnagar-at-work-credit-Athabasca-Univeristy-free-to-use-creative-commons-1024x576.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/Bhatnagar-at-work-credit-Athabasca-Univeristy-free-to-use-creative-commons-768x432.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/Bhatnagar-at-work-credit-Athabasca-Univeristy-free-to-use-creative-commons-1536x864.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2026/10/Bhatnagar-at-work-credit-Athabasca-Univeristy-free-to-use-creative-commons.jpg 1920w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Srijak Bhatnagar, PhD, at work in his laboratory at Athabasca University. [Athabasca University]</figcaption></figure>
<p>“Permafrost is revealing frozen organisms that are a historical record from tens of thousands of years ago. They could be cold-adapted, ancient, or new in the sense that humanity has not seen them in a while,” he tells <em>GEN</em>.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>The motivation for various biotech innovators bioprospecting the Arctic for biosynthetic gene clusters is not only academic but commercial, he says.</p>
<p>There is a hope that aids for making novel antibiotics could someday emerge from such bioprospecting, and “antibiotics are a billion-dollar industry globally” he says.</p>
<h4><strong>Cultivating new microbes</strong></h4>
<p>In the past, nearly 99% of environmental microbes could not be cultivated under conventional laboratory settings—and this left big biochemical pathways hidden, says Justin Nodwell, PhD, a biochemistry professor at the University of Toronto. His lab specializes in taking streptomycete biosynthetic gene clusters (BGCs)—genes identified in unculturable environmental microbes that remain silent in standard conditions—and using synthetic biology to express them in <em>Streptomyces</em> to produce new antibiotics and natural products.</p>
<figure aria-describedby="caption-attachment-339557" class="wp-caption alignleft"><img decoding="async" class="size-medium wp-image-339557" src="https://www.genengnews.com/wp-content/uploads/2026/10/Dr-Nodwell-in-his-lab-credit-Nodwell-Lab-cc-free-to-use-300x213.jpg" alt="Justin Nodwell, PhD, in his lab with a colleague at University of Toronto." width="300" height="213" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Dr-Nodwell-in-his-lab-credit-Nodwell-Lab-cc-free-to-use-300x213.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Dr-Nodwell-in-his-lab-credit-Nodwell-Lab-cc-free-to-use-1024x726.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/Dr-Nodwell-in-his-lab-credit-Nodwell-Lab-cc-free-to-use-768x545.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/Dr-Nodwell-in-his-lab-credit-Nodwell-Lab-cc-free-to-use-1536x1090.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2026/10/Dr-Nodwell-in-his-lab-credit-Nodwell-Lab-cc-free-to-use.jpg 1800w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Justin Nodwell, PhD, in his lab with a colleague at University of Toronto. [Justin Nodwell, PhD, Nodwell Lab]</figcaption></figure>
<p>So it seems, local labs in Canada are overcoming this hurdle through <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4324309/" target="_blank" rel="noopener">high-throughput metagenomics</a> and single-cell DNA sequencing.</p>
<p>“When we obtain total genomic material directly from permafrost cores, bioinformaticians can build complete genomes of unculturable organisms, and this shows cryptic BGCs,” Nodwell says.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>It is true that specialized metabolism from more conventional environments has been mined extensively not just for antibiotics, he says, but also, chemotherapeutic drugs. Nodwell shared the example of doxorubicin, a frontline chemotherapeutic, rapamycin and others, pointing out a phenomenon known as the <a href="https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/dereplication" target="_blank" rel="noopener">dereplication</a> problem. Dereplication involves the process of identifying interfering substances in samples.</p>
<p>“You tend to rediscover things that are known. And that certainly is something we’ve encountered in this lab. In terms of whether going to Arctic environments is going to lead to new metabolites, I think scientifically that very interesting though the jury isn’t entirely in,” he says.</p>
<p>On the importance of prospecting extremophile microorganisms, he brings the example of Hazel Barton, PhD, a microbiologist and ecologist at the University of Alabama. She studies cave microbiomes, often cave exploring ancient caves, including a cave in New Mexico called the Lechuguilla Cave, which has not been accessed from the surface of the earth for around 4 million years.</p>
<p>Microbiologists like Nodwell are curious to know if “there is new stuff down there, stuff that hadn’t been sampled before. At the very least, there should be stuff that hasn’t been exposed to antibiotics used in medicine”.</p>
<h4><strong>Expensive synthetic biology </strong></h4>
<p>In Canada, researchers studying the Arctic permafrost, including Nodwell, are energized to find new microbes stuff there—though he cautions against wild expectations.</p>
<p>“I guess we’ll also find some things that we’ve seen before—but whether if that can be turned that into distributable medicinal products—it’s still it’s impossible to say,” he says.</p>
<p>From the perspective of the synthetic biology that he studies, the main obstacle occurs when taking a streptococcal BGC, identified from a non-culturable cord adapted environment, and trying to refactor it for expression in a standard warm-adapted host platform, such as <em>Streptomyces.</em></p>
<p>Some of the biosynthetic gene clusters are enormous, up to 100,000 base pairs, which is a lot of synthetic DNA to make, he says of the technical challenges Canadian researchers face.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>“[If] you’re going to do it synthetically, and it’s very expensive. If you’re going to do it by PCR, that’s a lot of reactions. It’s a major undertaking to build something like that. But it is doable,” he says.</p>
<p>“But whereas there’s good algorithms for finding the biosynthetic genes for compounds, the boundaries are often somewhat mysterious. Like you’ll find a string of, let’s say, 15 genes that are clearly involved in making a molecule. And then there’ll be a few on either end that it’s like maybe they’re involved, maybe they’re not. And so, if you don’t know the biochemical pathway that makes the molecule, it’s very hard to say what genes you need and where to do that cutoff. There are ways around that now, but there still is often a sort of a judgment call you have to make”.</p>
<h4><strong>Blind curve</strong></h4>
<p>In the endeavor to bioprospect Canada’s Arctic—Bhatnagar warns of a “blind curve”. Canadian researchers and biotech innovators can sequence the data and make it publicly available in places like GenBank or SRA.</p>
<p>But because of the financial hefty and mismatches, “a company elsewhere, most likely [in the] US, is going to mine it, create a product that could, for all we know, be a billion-dollar product,” Bhatnagar says.</p>
<p>Crucially, Canada is not a signatory of the UN <a href="https://treaties.un.org/pages/ViewDetails.aspx?src=TREATY&mtdsg_no=XXVII-8-b&chapter=27&clang=_en" target="_blank" rel="noopener">Nagoya Protocol on Access to Genetic Resources</a>. For indigenous populations who live in the Canadian Arctic, discussion on biopiracy and ownership of genetic materials is critically important.</p>
<p>“Canada is not a signatory of Nagoya Protocol, so we do not protect biocultural property. [For indigenous populations] that genetic knowledge is coming from what was their biocultural property, and they would as: What’s our benefit?”</p>
<p>This is a very important question to consider since what has traditionally happened is outsiders go to indigenous peoples, gather existing knowledge, listen to traditional knowledge, learn about traditional medicine, to see that knowledge used for developing patents without consideration of the indigenous people providing the original knowledge.</p>
<p>“I come from India (originally), and I distinctly remember in my childhood reading articles about how some of the traditional plants and medicines that we had been using; a western company basically isolated the chemical and patented it, and I’m like how can you patent it when we have been using it for like thousands of years?”</p>
<p>Overall, unlocking the Arctic’s subterranean DNA must ensure a delicate balance between scientific rigor and ethical stewardship. Yes—synthetic biology and chemistry could help discovery of new life-saving therapeutics, but Canadian researchers must establish build solid frameworks to protect Indigenous biocultural rights thus making local bioprospecting a mutually beneficial public good.</p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/canadas-arctic-research-could-help-discover-next-gen-therapeutics/">Canada’s Arctic Research Could Help Discover Next-Gen Therapeutics</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>P.E.I. reinstates hospital masking measures as respiratory illness activity increases</title>
<link>https://edusehat.com/en/pei-reinstates-hospital-masking-measures-as-respiratory-illness-activity-increases</link>
<guid>https://edusehat.com/en/pei-reinstates-hospital-masking-measures-as-respiratory-illness-activity-increases</guid>
<description><![CDATA[ New precautions coincide with National Infection Control Week and aim to protect patients, healthcare workers and visitors. Prince Edward Island has reinstated masking measures across Health PEI facilities in response to increasing respiratory illness activity, reinforcing the importance of infection prevention as healthcare organizations across Canada prepare for the fall and winter respiratory virus season. […]
The post P.E.I. reinstates hospital masking measures as respiratory illness activity increases appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/shutterstock_1916702450.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 20 Oct 2026 23:00:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>P.E.I., reinstates, hospital, masking, measures, respiratory, illness, activity, increases</media:keywords>
<content:encoded><![CDATA[<p>New precautions coincide with National Infection Control Week and aim to protect patients, healthcare workers and visitors.</p>
<p>Prince Edward Island has reinstated masking measures across Health PEI facilities in response to increasing respiratory illness activity, reinforcing the importance of infection prevention as healthcare organizations across Canada prepare for the fall and winter respiratory virus season.</p>
<p>The measures, which took effect October 16, 2026, apply across Health PEI facilities and are intended to reduce the risk of respiratory infections among patients, healthcare workers and visitors.</p>
<p>Under the updated policy, members of the public are asked to wear masks when within two metres of a patient. Masking is also encouraged in hallways of acute care facilities, while healthcare workers must follow established infection prevention procedures and masking guidelines.</p>
<h3>Masks are available at facility entrances to help patients and visitors comply with the precautions.</h3>
<p>Health PEI says the decision follows increased respiratory illness activity across the province. The organization will continue reviewing the measures and adjust them when conditions permit.</p>
<p>The precautions extend beyond masking. Healthcare personnel are expected to maintain established infection control practices, including hand hygiene, appropriate cleaning procedures, staying home when ill and reporting respiratory symptoms through workplace channels.</p>
<p>Staff are also strongly encouraged to remain up to date with influenza and COVID-19 immunizations.</p>
<p>The announcement comes as Canada marks National Infection Control Week from October 19 to 23. Organized by Infection Prevention and Control Canada (IPAC Canada), this year’s theme, IPAC: Powered by You, emphasizes the role of healthcare professionals and others in preventing infections across care settings.</p>
<p>Infection prevention remains an important part of hospital operations, particularly during periods of increased respiratory virus circulation. Patients receiving hospital care may be especially vulnerable because of age, underlying medical conditions or weakened immune systems.</p>
<h3>Measures such as appropriate masking, hand hygiene, respiratory precautions and environmental cleaning are designed to reduce opportunities for infection transmission.</h3>
<p>For healthcare organizations, seasonal respiratory illness also presents operational challenges. Infections can contribute to staff absences, additional isolation requirements and pressure on available patient-care resources.</p>
<p>P.E.I.’s decision illustrates how healthcare systems can adjust protective measures in response to changing conditions rather than maintaining identical requirements throughout the year.</p>
<p>As hospitals across Canada prepare for the respiratory illness season, infection prevention teams will continue to play an important role in assessing risks, supporting frontline staff and maintaining safe environments for patients and visitors.</p>
<p>The post <a href="https://www.hospitalnews.com/p-e-i-reinstates-hospital-masking-measures-as-respiratory-illness-activity-increases/">P.E.I. reinstates hospital masking measures as respiratory illness activity increases</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Canada’s health ministers advance workforce reforms and national health&#45;data sharing</title>
<link>https://edusehat.com/en/canadas-health-ministers-advance-workforce-reforms-and-national-health-data-sharing</link>
<guid>https://edusehat.com/en/canadas-health-ministers-advance-workforce-reforms-and-national-health-data-sharing</guid>
<description><![CDATA[ Federal, provincial and territorial discussions also address long-term healthcare funding, rare disease treatments and access to care in rural and northern communities. Canada’s federal, provincial and territorial health ministers have outlined priorities for strengthening the country’s healthcare system, including improving workforce mobility, advancing public health information sharing and developing a sustainable approach to healthcare funding. […]
The post Canada’s health ministers advance workforce reforms and national health-data sharing appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/hospital-news-health-ministers-workforce-550px.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 20 Oct 2026 23:00:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Canada’s, health, ministers, advance, workforce, reforms, and, national, health-data, sharing</media:keywords>
<content:encoded><![CDATA[<p>Federal, provincial and territorial discussions also address long-term healthcare funding, rare disease treatments and access to care in rural and northern communities.</p>
<p>Canada’s federal, provincial and territorial health ministers have outlined priorities for strengthening the country’s healthcare system, including improving workforce mobility, advancing public health information sharing and developing a sustainable approach to healthcare funding.</p>
<p>Meeting in Winnipeg on October 16, ministers examined growing pressures on healthcare services and the need for closer collaboration to improve access to care and strengthen the long-term sustainability of publicly funded healthcare.</p>
<p>A central focus was the healthcare workforce, particularly the challenges facing internationally educated health professionals seeking to practise in Canada.</p>
<p>Ministers agreed on the need to improve pathways into the Canadian healthcare system and called on national medical certification bodies to better align their work with federal, provincial and territorial workforce priorities.</p>
<p>The discussion comes as hospitals and other healthcare organizations continue working to recruit and retain qualified professionals while responding to growing demands for care.</p>
<h3>Progress toward national health-data sharing</h3>
<p>Another important development was support for a proposed Canadian Public Health Information Sharing Agreement.</p>
<p>Ministers from participating jurisdictions affirmed their support for the agreement, which would establish a framework for securely sharing public health information between governments.</p>
<p>Once finalized, the agreement is intended to provide a more complete picture of health risks and emerging trends across Canada, supporting faster decisions and more coordinated responses to public health threats.</p>
<p>The agreement has not yet been signed.</p>
<h3>Rare disease funding confirmed</h3>
<p>Health ministers also welcomed confirmation that federal funding of $500 million annually will continue for the National Strategy for Drugs for Rare Diseases.</p>
<p>The strategy is intended to support access to treatments for people living with rare diseases, an area where specialized medications can present significant financial and access challenges.</p>
<p>The funding confirmation provides continuity for the strategy, although it does not represent a newly announced additional $500 million investment.</p>
<h3>Long-term funding and healthcare sustainability</h3>
<p>Ministers discussed the renewal of federal-provincial bilateral healthcare agreements, including investments supporting home and community care and mental health and substance use services.</p>
<p>They also considered an approach to long-term federal funding sustainability, with attention to accountability and health system productivity.</p>
<p>Further discussions on this work are expected before the end of 2026.</p>
<p>Improving healthcare access in rural, remote and northern communities was another priority. Ministers examined the potential for virtual care to support continuity of care and expand access to services in areas facing geographic and workforce challenges.</p>
<p>Other discussions addressed immunization programs, the response to HIV, Indigenous health equity and the continuing toxic drug crisis.</p>
<p>The ministers also agreed to continue work on the Canada Health Act Services Policy, with further engagement planned by spring 2027.</p>
<p>The Winnipeg meeting did not produce a comprehensive new healthcare funding agreement. However, it identified several areas where governments intend to continue coordinating reforms affecting healthcare delivery across Canada.</p>
<p>British Columbia and Quebec were not parties to the meeting communiqué because their governments were in caretaker periods during provincial elections.</p>
<p>For hospitals and healthcare organizations, the next steps will be important in determining how national discussions translate into changes in workforce recruitment, public health preparedness and access to patient care.</p>
<p>Source: <a href="https://www.canada.ca/en/health-canada/news/2026/10/federal-provincial-and-territorial-fpt-health-ministers-meeting.html?utm_source=chatgpt.com">Health Canada — Federal, Provincial and Territorial Health Ministers’ Meeting, October 16, 2026</a>.</p>
<p>The post <a href="https://www.hospitalnews.com/canadas-health-ministers-advance-workforce-reforms-and-national-health-data-sharing/">Canada’s health ministers advance workforce reforms and national health-data sharing</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>ASHG 2026: Landmark UK Biobank, IMU Immune Profiling Initiative Taps Ultima and Waters</title>
<link>https://edusehat.com/en/ashg-2026-landmark-uk-biobank-imu-immune-profiling-initiative-taps-ultima-and-waters</link>
<guid>https://edusehat.com/en/ashg-2026-landmark-uk-biobank-imu-immune-profiling-initiative-taps-ultima-and-waters</guid>
<description><![CDATA[ IMU Biosciences and UK Biobank will profile 80,000 blood samples using technologies from Waters and Ultima Genomics, creating a high-resolution immune dataset to advance AI-driven biomedical research and disease prediction.
The post ASHG 2026: Landmark UK Biobank, IMU Immune Profiling Initiative Taps Ultima and Waters appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GettyImages-2242943155.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 20 Oct 2026 12:15:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>ASHG, 2026:, Landmark, Biobank, IMU, Immune, Profiling, Initiative, Taps, Ultima, and, Waters</media:keywords>
<content:encoded><![CDATA[<p>London-based IMU Biosciences, together with the UK Biobank, has announced a collaboration to generate the world’s most detailed, large-scale picture of the human immune system. By integrating high-dimensional immune-cell profiling, transcriptomic analysis, and AI-based computational methods, the study aims to reveal the human immune system in unprecedented detail and scale.</p>
<p>The project will add a high-resolution immune data layer and a foundational dataset to UK Biobank by generating more than 100 million immune data points from each of tens of thousands of samples to create the largest, most detailed immune dataset assembled to date. In order to do so, the project has selected the technology of both Waters and Ultima Genomics.</p>
<p>The project will use IMU’s HD Immunology platform in conjunction with Waters Corporation’s flow cytometry and multiomic instrumentation (BD FACSDiscover Cell Analyzer platform and BD Rhapsody single-cell multiomics platform) as part of their strategic partnership announced in June. Ultima’s recently launched UG200 Sequencing Platform will produce the project’s readouts and support large scale data generation. Taken together, the project will profile blood samples from an initial cohort of 80,000 blood samples from UK Biobank participants with the hope to expand across the full UK Biobank cohort of 500,000 participants.</p>
<p>“We are proud to be selected alongside the BD platforms from Waters to power foundational dataset generation and enable a new layer of single-cell immune-profiling data,” said Gilad Almogy, PhD, CEO of Ultima Genomics. “Building on our ongoing work with the 600,000-sample UK Biobank Pharma Proteomics Project, this demonstrates the platform’s suitability for large-scale omics data generation from large, deeply characterized biobank cohorts.”</p>
<p>The project will begin this year and will add a new immune profiling data layer on top of UK Biobank’s existing de-identified genomic, imaging, clinical and lifestyle data. Over time, the resulting data will be returned to UK Biobank and made available to approved researchers studying how immune variation relates to disease risk, progression, treatment response, and long-term health outcomes.</p>
<p>As part of the selection process, Ultima’s UG200 Sequencing Platform was validated on its performance with the BD Rhapsody platform and to work together to enable the large-scale project. The UG200 Sequencing Platform was launched in February 2026 and is now shipping.</p>
<p>Uniting UK Biobank’s population-scale samples with single-cell immune profiling, the collaboration is designed to generate immune data at the scale, reproducibility, and resolution needed for both broad biomedical research and future immune-prediction studies.</p>
<p class="framer-text framer-styles-preset-1v5ef23" dir="ltr">“This new dataset,” notes Naomi Allen, DPhil, chief scientist at UK Biobank, “will provide our global research community with a valuable insight into how the immune system changes with aging. Scientists will be able to study which specific immune cell changes contribute to the future risk of conditions like cancer, diabetes, and dementia, paving the way for earlier disease detection and more accurate diagnosis.”</p>
<p class="framer-text framer-styles-preset-1v5ef23" dir="ltr">“Blood samples from UK Biobank’s generous participants,” Allen continues, “have already been turned into genetic, proteomic, and metabolomic data. When complete, this detailed map of the immune system will in turn fuel the detection of new drug targets and help clinicians to understand who might respond best to a particular treatment.”</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/landmark-uk-biobank-imu-immune-profiling-initiative-taps-ultima-and-waters/">ASHG 2026: Landmark UK Biobank, IMU Immune Profiling Initiative Taps Ultima and Waters</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>ASHG: Long&#45;Read Genomics Meets Clinical Data in PacBio, Verily Health AI Deal</title>
<link>https://edusehat.com/en/ashg-long-read-genomics-meets-clinical-data-in-pacbio-verily-health-ai-deal</link>
<guid>https://edusehat.com/en/ashg-long-read-genomics-meets-clinical-data-in-pacbio-verily-health-ai-deal</guid>
<description><![CDATA[ A multi-year collaboration will connect PacBio&#039;s HiFi sequencing with Verily Pre, combining long-read genomic and clinical data for biomedical research and AI model development.
The post ASHG: Long-Read Genomics Meets Clinical Data in PacBio, Verily Health AI Deal appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2023/12/Aug2023_GettyImages_1444892930_DNAMolecularStructure-resize-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 20 Oct 2026 08:40:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>ASHG:, Long-Read, Genomics, Meets, Clinical, Data, PacBio, Verily, Health, Deal</media:keywords>
<content:encoded><![CDATA[<p>PacBio and Verily Health have entered a multi-year collaboration to combine PacBio’s HiFi long-read sequencing with Verily’s clinical data and cloud-based analysis. The companies said the arrangement is intended to produce clinico-genomic datasets that can be used in biomedical research and in the training and deployment of artificial intelligence models.</p>
<p>Under the agreement, PacBio sequencing workflows will be connected with Verily Pre, a platform for governing, analyzing, and using health data. Verily will configure the platform’s Workbench research environment to aggregate, analyze, and curate HiFi genomic datasets alongside real-world clinical information. The companies also plan to use Verily Pre’s trusted agentic environment for AI model training and inference.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>Long-read sequencing can capture structural variants, methylation patterns, and full-length RNA transcripts that may be difficult to resolve with short-read methods. Integrating those data with clinical records, however, can require separate tools and customized workflows. The collaboration will focus on connecting these steps and supporting larger long-read studies across research organizations, biopharma companies, clinical institutions, and population genomics programs.</p>
<p>PacBio develops sequencing systems for life science and clinical research. Its HiFi technology generates long reads and is used in areas including human genetics, oncology, infectious disease, and agricultural research. The company said its whole-genome sequencing workflows already operate within the Verily Pre environment, providing a technical starting point for the expanded work.</p>
<p>Verily Health is a healthcare data intelligence company whose technology is designed to help organizations manage and analyze protected health information. Verily Pre, its primary data platform, includes governance, modeling, and secure research tools.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>“Working with PacBio, we hope to deliver a meaningful impact to researchers and innovators working to find new answers for neurology, oncology, rare disease, and other areas of critical unmet need,” said Stephen Gillett, chairman and CEO of Verily Health.</p>
<p>PacBio president and CEO Mark Van Oene said the companies aim to create a path for turning complex biological information into data that can be used at scale in AI workflows. The announcement did not disclose financial terms, specific customers, or a timetable for broader deployment. Over the course of the collaboration, the companies plan to extend the integration to larger and more complex long-read programs.</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/ashg-long-read-genomics-meets-clinical-data-in-pacbio-verily-health-ai-deal/">ASHG: Long-Read Genomics Meets Clinical Data in PacBio, Verily Health AI Deal</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Psychological Stress Triggers Arthritis Flares in Mice via IL&#45;6&#45;Dependent Pathway</title>
<link>https://edusehat.com/en/psychological-stress-triggers-arthritis-flares-in-mice-via-il-6-dependent-pathway</link>
<guid>https://edusehat.com/en/psychological-stress-triggers-arthritis-flares-in-mice-via-il-6-dependent-pathway</guid>
<description><![CDATA[ A study in mice offers up a biological explanation for how psychological stress can contribute to arthritis flares, and identifies a stress-responsive pathway that could be explored as a potential therapeutic target. 
The post Psychological Stress Triggers Arthritis Flares in Mice via IL-6-Dependent Pathway appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/08/GettyImages-2182156911.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 20 Oct 2026 05:05:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Psychological, Stress, Triggers, Arthritis, Flares, Mice, via, IL-6-Dependent, Pathway</media:keywords>
<content:encoded><![CDATA[<p>Psychological stress has long been associated with worsening symptoms in rheumatoid arthritis (RA). However, the underlying mechanism connecting psychological stress to the occurrence of joint inflammation has remained poorly understood. Headed by a team at Chiba University, a study in mice suggests that arthritis may retain a form of tissue inflammatory memory that can be reactivated by stress. The study results offer up a biological explanation for how psychological stress can contribute to arthritis flares, and identify a stress-responsive pathway that could be explored as a potential therapeutic target.</p>
<p>Better understanding of this pathway in the future could help guide the development of strategies to improve disease management and the quality of life of people living with RA.</p>
<p>“Our findings suggest that targeting the stress-responsive pathways may offer a future therapeutic strategy that acts without broadly suppressing the immune system,” noted research co-lead professor Hiroshi Nakajima, MD, PhD, at the Graduate school of Medicine.</p>
<p>Nakajima is senior and co-corresponding author of the researchers’ published paper in <em>Science Advances</em>, titled “<a href="http://dx.doi.org/10.1126/sciadv.aec9257" target="_blank" rel="noopener">Fibroblast-like synoviocytes exacerbate autoimmune arthritis upon psychological stress in an IL-6–dependent manner</a>.”</p>
<p>Psychological stress affects a variety of biological processes, including the immune system, the authors wrote. “It is well documented that acute psychological stress exacerbates inflammatory diseases.” However, while psychological stress can exacerbate autoimmune diseases such as rheumatoid arthritis (RA), the underlying biological mechanisms aren’t aren’t well understood. “The relationship between psychological stress and the exacerbation of RA has been recognized over the past few decades, but the underlying molecular mechanisms have remained unclear,” the team continued. In particular, how psychological stress can trigger inflammation in joints that were previously affected, even after the disease has gone into remission, remains an important unanswered question. “… the mechanisms underlying tissue inflammation during remission remain unclear,” they noted.</p>
<p>To answer this, the Chiba University team, in collaboration with researchers at Asahi General Hospital, and International University of Health and Welfare Narita Hospital, investigated how psychological stress can reactivate arthritis, examining stress-induced flares in a mouse model.</p>
<p>For their study the researchers used an antigen-induced arthritis (AIA) mouse model in which arthritis was allowed to enter a remission-like state before the animals were exposed to restraint stress. Their experiments indicated that exposure psychological stress reactivated inflammation in the joints. Using tissue analysis, immune-cell profiling and molecular measurements, the researchers traced the inflammatory signals activated by stress, finding that stress activated the sympathetic nervous system and brown adipose tissues (BAT), a type of body fat involved in producing heat. Stress activation caused BAT to release interleukin-6 (IL-6), an inflammatory signaling protein.</p>
<p>“Our findings suggest that the effects of psychological stress on arthritis extend beyond the immune cells traditionally associated with autoimmune disease. Instead, stress can activate processes within other tissues that contribute to the return of joint inflammation,” said study co-lead assistant professor Shigeru Tanaka, at Chiba University Graduate School of Medicine.</p>
<p>The researchers further identified which cells within the joint respond to this circulating IL-6. Their findings pointed to fibroblast-like synoviocytes (FLS), specialized cells found in the synovial tissue surrounding the joints. IL-6 stimulates these cells to produce CXCL1, a chemokine (immune-signaling protein) that attracts neutrophils, a type of white blood cell involved in inflammation. The resulting recruitment of neutrophils contributes to the reactivation of joint inflammation. Blocking the CXCR2 receptor, which responds to CXCL1, significantly reduced stress-triggered arthritis in the mouse model.</p>
<p>“In the RA joint, various cells, including macrophages and FLS, produce IL-6, creating an inflammatory network through their interactions,” the investigators explained. “Our study demonstrated a phenomenon in which IL-6 originates from outside the joint and stimulates FLS, leading to the recurrence of arthritis.”</p>
<p>The researchers further tested the pathway by blocking key receptors and monitoring changes in inflammatory markers, joint swelling, and immune-cell accumulation. When the mice were treated with a β3-adrenergic receptor antagonist, the researchers observed a reduction in plasma IL-6 levels, joint swelling, CXCL1 expression, and the accumulation of neutrophils in the joints.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>“Our current research revealed that β3-adrenergic receptor blockade successfully suppresses stress-induced arthritis flares,” they wrote. “This finding suggests a possible therapeutic strategy targeting the sympathetic nervous system.”</p>
<p>Nakajima added, “Our findings suggest that targeting the stress-responsive pathways may offer a future therapeutic strategy that acts without broadly suppressing the immune system.”</p>
<p>The researchers in addition examined whether this stress-related pathway was reflected in people with RA. They found that patients with Trp64Arg, a specific variant of the <em>ADRB3</em> gene, which makes cells less responsive to stress-related hormones, showed a weaker link between perceived stress and arthritis activity when compared to patients without the variant. However, because this analysis was observational, the findings do not prove that stress directly caused changes in disease activity.</p>
<p>Overall, the findings suggest that arthritis may retain a form of tissue inflammatory memory that can be reactivated by stress independently of lymphocytes. “These findings identify a BAT–IL-6–fibroblast axis that reactivates inflammatory memory in arthritis and suggest that targeting stress-responsive pathways may provide a complementary therapeutic strategy alongside current RA treatments without broadly suppressing systemic immunity,” the team concluded.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/psychological-stress-triggers-arthritis-flares-in-mice-via-il-6-dependent-pathway/">Psychological Stress Triggers Arthritis Flares in Mice via IL-6-Dependent Pathway</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Landmark UK Biobank, IMU Immune Profiling Initiative Taps Ultima and Waters</title>
<link>https://edusehat.com/en/landmark-uk-biobank-imu-immune-profiling-initiative-taps-ultima-and-waters</link>
<guid>https://edusehat.com/en/landmark-uk-biobank-imu-immune-profiling-initiative-taps-ultima-and-waters</guid>
<description><![CDATA[ IMU Biosciences and UK Biobank will profile 80,000 blood samples using technologies from Waters and Ultima Genomics, creating a high-resolution immune dataset to advance AI-driven biomedical research and disease prediction.
The post Landmark UK Biobank, IMU Immune Profiling Initiative Taps Ultima and Waters appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GettyImages-2242943155.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 20 Oct 2026 05:05:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Landmark, Biobank, IMU, Immune, Profiling, Initiative, Taps, Ultima, and, Waters</media:keywords>
<content:encoded><![CDATA[<p>London-based IMU Biosciences, together with the UK Biobank, has announced a collaboration to generate the world’s most detailed, large-scale picture of the human immune system. By integrating high-dimensional immune-cell profiling, transcriptomic analysis, and AI-based computational methods, the study aims to reveal the human immune system in unprecedented detail and scale.</p>
<p>The project will add a high-resolution immune data layer and a foundational dataset to UK Biobank by generating more than 100 million immune data points from each of tens of thousands of samples to create the largest, most detailed immune dataset assembled to date. In order to do so, the project has selected the technology of both Waters and Ultima Genomics.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>The project will use IMU’s HD Immunology platform in conjunction with Waters Corporation’s flow cytometry and multiomic instrumentation (BD FACSDiscover Cell Analyzer platform and BD Rhapsody single-cell multiomics platform) as part of their strategic partnership announced in June. Ultima’s recently launched UG200 Sequencing Platform will produce the project’s readouts and support large scale data generation. Taken together, the project will profile blood samples from an initial cohort of 80,000 blood samples from UK Biobank participants with the hope to expand across the full UK Biobank cohort of 500,000 participants.</p>
<p>“We are proud to be selected alongside the BD platforms from Waters to power foundational dataset generation and enable a new layer of single-cell immune-profiling data,” said Gilad Almogy, PhD, CEO of Ultima Genomics. “Building on our ongoing work with the 600,000-sample UK Biobank Pharma Proteomics Project, this demonstrates the platform’s suitability for large-scale omics data generation from large, deeply characterized biobank cohorts.”</p>
<p>The project will begin this year and will add a new immune profiling data layer on top of UK Biobank’s existing de-identified genomic, imaging, clinical and lifestyle data. Over time, the resulting data will be returned to UK Biobank and made available to approved researchers studying how immune variation relates to disease risk, progression, treatment response, and long-term health outcomes.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>As part of the selection process, Ultima’s UG200 Sequencing Platform was validated on its performance with the BD Rhapsody platform and to work together to enable the large-scale project. The UG200 Sequencing Platform was launched in February 2026 and is now shipping.</p>
<p>Uniting UK Biobank’s population-scale samples with single-cell immune profiling, the collaboration is designed to generate immune data at the scale, reproducibility, and resolution needed for both broad biomedical research and future immune-prediction studies.</p>
<p class="framer-text framer-styles-preset-1v5ef23" dir="ltr">“This new dataset,” notes Naomi Allen, DPhil, chief scientist at UK Biobank, “will provide our global research community with a valuable insight into how the immune system changes with aging. Scientists will be able to study which specific immune cell changes contribute to the future risk of conditions like cancer, diabetes, and dementia, paving the way for earlier disease detection and more accurate diagnosis.”</p>
<p class="framer-text framer-styles-preset-1v5ef23" dir="ltr">“Blood samples from UK Biobank’s generous participants,” Allen continues, “have already been turned into genetic, proteomic, and metabolomic data. When complete, this detailed map of the immune system will in turn fuel the detection of new drug targets and help clinicians to understand who might respond best to a particular treatment.”</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/landmark-uk-biobank-imu-immune-profiling-initiative-taps-ultima-and-waters/">Landmark UK Biobank, IMU Immune Profiling Initiative Taps Ultima and Waters</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>ADC Development from Concept to Clinic</title>
<link>https://edusehat.com/en/adc-development-from-concept-to-clinic</link>
<guid>https://edusehat.com/en/adc-development-from-concept-to-clinic</guid>
<description><![CDATA[ This eBook brings insight on integrated end-to-end solutions for precision engineered therapeutics.
The post ADC Development from Concept to Clinic appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Cover-Image_ADCs-8-x-11-scaled-e1792182648204.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 20 Oct 2026 01:30:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>ADC, Development, from, Concept, Clinic</media:keywords>
<content:encoded><![CDATA[<div aria-hidden="true" class="wp-block-spacer"></div>


<p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Read Now</button></p>


<figure class="wp-block-image alignright size-medium"><img decoding="async" width="232" height="300" src="https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Eurofins_eBookCover-232x300.jpg" alt="Eurofins eBook Cover" class="wp-image-339513" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Eurofins_eBookCover-232x300.jpg 232w, https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Eurofins_eBookCover-791x1024.jpg 791w, https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Eurofins_eBookCover-768x994.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Eurofins_eBookCover-1187x1536.jpg 1187w, https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Eurofins_eBookCover.jpg 1200w" sizes="(max-width: 232px) 100vw, 232px"></figure>


<p class="wp-block-paragraph">Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the therapeutic activity of small molecule payloads, enabling targeted delivery while minimizing off-target effects. Their potential in areas such as targeted cancer cell killing and targeted protein degradation has fueled significant growth, resulting in numerous FDA approvals and more than 100 ADCs currently in clinical development. However, ADC development remains complex and highly empirical, requiring careful optimization of linker chemistry, payload selection, bioconjugation strategies, drug-to-antibody ratio (DAR), stability, and overall antibody integrity.</p>


<p class="wp-block-paragraph">The ADC journey begins with linker-payload synthesis and bioconjugation. Eurofins Discovery offers extensive expertise in the design and synthesis of linker technologies, including protease-sensitive, glycosidase-sensitive, pH-sensitive, PEGylated, branched, and shielding linkers. Payloads are manufactured in specialized high-containment facilities to ensure the safe handling of highly potent compounds. Multiple conjugation options are available, providing flexibility to explore different designs and generate ADCs with customized pharmacokinetic profiles, improved stability, and controlled DAR distributions.</p>


<p class="wp-block-paragraph">Once conjugation is complete, ADCs undergo purification using a range of chromatography techniques. These methods remove unconjugated antibodies, excess linker-payload materials, and aggregates to produce highly pure ADC preparations. This is essential for more reliable downstream analyses and ensures more accurate assessment of ADC performance.</p>


<p class="wp-block-paragraph">DAR analysis is then conducted using high-resolution liquid chromatography-mass spectrometry (LC-MS). This approach confirms linker-payload incorporation, identifies individual DAR species, and provides detailed insights into ADC homogeneity. Such information is critical for optimizing product consistency, efficacy, safety, and manufacturability.</p>


<p class="wp-block-paragraph">Finally, a comprehensive suite of biochemical, functional, and cytotoxicity assays is essential to characterize ADC candidates. Data-driven assessment of binding, biological function, and therapeutic potential, through both <em>in vitro</em> and <em>in vivo</em> studies, helps identify the most promising candidates for further advancement and development.</p>


<p class="wp-block-paragraph">Eurofins Discovery provides a fully integrated ADC development platform spanning every stage of the workflow, from linker-payload design through analytical characterization and functional assessment. By leveraging deep expertise in chemistry, biochemistry, and antibody optimization and characterization, Eurofins Discovery scientists help mitigate development risks and shorten timelines while optimizing ADC safety, efficacy, and manufacturability.</p>

<p>The post <a href="https://www.genengnews.com/resources/ebooks/adc-developmentfrom-concept-to-clinic/">ADC Development from Concept to Clinic</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Alberta hospitals resume normal operations following major emergency response</title>
<link>https://edusehat.com/en/alberta-hospitals-resume-normal-operations-following-major-emergency-response</link>
<guid>https://edusehat.com/en/alberta-hospitals-resume-normal-operations-following-major-emergency-response</guid>
<description><![CDATA[ Code Orange activations have ended following a coordinated emergency response to the tragic incident at CFB Wainwright, which involved hospitals and emergency medical services across Alberta and Saskatchewan. Alberta’s acute care system has returned to regular operations following a large-scale emergency response to the deadly incident at Canadian Forces Base Wainwright on October 17. Acute […]
The post Alberta hospitals resume normal operations following major emergency response appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/shutterstock_1826972669.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 19 Oct 2026 21:50:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Alberta, hospitals, resume, normal, operations, following, major, emergency, response</media:keywords>
<content:encoded><![CDATA[<p><strong>Code Orange activations have ended following a coordinated emergency response to the tragic incident at CFB Wainwright, which involved hospitals and emergency medical services across Alberta and Saskatchewan.</strong></p>
<p>Alberta’s acute care system has returned to regular operations following a large-scale emergency response to the deadly incident at Canadian Forces Base Wainwright on October 17.</p>
<p>Acute Care Alberta confirmed on October 18 that all Code Orange activations across the province had been stood down following an emergency response involving hospitals, ambulance services and healthcare professionals from Alberta and Saskatchewan.</p>
<p>The incident, involving a rapidly spreading fire during military training, resulted in four deaths and dozens of injuries. The scale of the emergency required extensive coordination between provincial health services, emergency responders and receiving hospitals.</p>
<h3>Extensive emergency medical response</h3>
<p>Emergency Health Services–Alberta deployed 30 emergency response units directly to Wainwright, including 22 ground ambulances, six fixed-wing aircraft and two helicopters.</p>
<p>The response involved provincial emergency medical services and contracted partners from both Alberta and Saskatchewan.</p>
<p>Emergency operations continued for more than 10 hours as medical teams stabilized patients and coordinated transfers to hospitals throughout the province.</p>
<p><strong>Patients were initially treated at Wainwright Healthcare Centre before being transferred to four major facilities:</strong></p>
<ul>
<li>University of Alberta Hospital in Edmonton</li>
<li>Royal Alexandra Hospital in Edmonton</li>
<li>Foothills Medical Centre in Calgary</li>
<li>Red Deer Regional Hospital Centre</li>
</ul>
<p>The coordinated response helped distribute patients requiring specialized treatment across multiple healthcare facilities.</p>
<h3>Hospitals return to regular operations</h3>
<p>During the emergency, several Alberta hospitals activated Code Orange protocols, which are used when a major incident produces multiple seriously injured patients requiring a coordinated healthcare response.</p>
<p>The emergency placed significant pressure on hospital resources, particularly in Edmonton, where officials temporarily advised residents to consider alternative emergency departments when possible.</p>
<p>Although Code Orange activations have ended, Acute Care Alberta cautioned that hospitals continue to face high patient volumes and localized staffing pressures, particularly in the Wainwright and Flagstaff County areas.</p>
<p>Patients injured in the incident continue to receive treatment, and officials anticipate that their ongoing care will require substantial hospital resources.</p>
<p>The agency emphasized that returning to regular operations does not mean the impact on the healthcare system has ended.</p>
<h3>Coordinated response highlights emergency preparedness</h3>
<p>The incident demonstrated the importance of coordinated emergency planning, particularly when a mass-casualty event occurs in a smaller community with limited local hospital capacity.</p>
<p>The ability to mobilize ground and air ambulances, coordinate patient transfers and activate emergency protocols across multiple hospitals was central to the healthcare response.</p>
<p>Acute Care Alberta acknowledged the efforts of physicians, nurses, paramedics, emergency responders and other healthcare professionals who worked under exceptionally difficult circumstances.</p>
<p>The agency said its focus remains on supporting affected patients, their families and healthcare providers as recovery continues.</p>
<p>While the immediate emergency response has concluded, the incident highlights the importance of maintaining coordinated emergency medical systems capable of responding to large-scale incidents across provincial and regional boundaries.</p>
<p><em>Source: Acute Care Alberta, October 18, 2026.</em></p>
<p><a href="https://acutecarealberta.ca/Page84.aspx?utm_source=chatgpt.com">Read the official announcement</a></p>
<p>The post <a href="https://www.hospitalnews.com/146429-2/">Alberta hospitals resume normal operations following major emergency response</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>PACE: BIO’s 15th annual patient advocacy event focuses on access</title>
<link>https://edusehat.com/en/pace-bios-15th-annual-patient-advocacy-event-focuses-on-access</link>
<guid>https://edusehat.com/en/pace-bios-15th-annual-patient-advocacy-event-focuses-on-access</guid>
<description><![CDATA[ America’s biotech industry has facilitated 50 years of innovative breakthroughs that have changed the landscape of healthcare as we know it—offering the promise of […]
The post PACE: BIO’s 15th annual patient advocacy event focuses on access appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/10/michelde-and-John-at-PACE-2025.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 19 Oct 2026 18:20:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>PACE:, BIO’s, 15th, annual, patient, advocacy, event, focuses, access</media:keywords>
<content:encoded><![CDATA[<p><span>America’s biotech industry has facilitated 50 years of innovative breakthroughs that have changed the landscape of healthcare as we know it—offering the promise of giving people more time with the people they love.</span></p>
<p><span>But none of these breakthroughs mean anything if they can’t get into the hands of patients. That is why the patient voice is so important to biotech and the policy around it.</span></p>
<p><span>To amplify the voice of patients and their advocates, the</span><a href="https://pace.bio.org/"> <span>Biotechnology Innovation Organization’s (BIO) 15th annual Patient Advocacy Changemakers Event (PACE)</span></a><span> will convene October 22–23 in Washington DC. PACE is an opportunity for patient advocates to build community, connect with fellow patient groups and BIO members, and discuss policy issues that impact patient access, affordability, and the promise of future innovation.</span></p>
<p><span>“PACE is a unique event among all the gatherings of patients and caregivers and advocates in our community,” says John F. Crowley, president and CEO of BIO. “It’s the one chance we have to bring together people living with disease, people who care for those living with disease, researchers, government policymakers, and industry leaders to come together in a forum to discuss all the different ways in which we can partner, share ideas, and advance therapies for everybody in need.”</span></p>
<p><span>“Getting 21st Century medicines to patients requires a 21st century approach to affordability and access, and PACE brings patients, advocates, and BIO members together to shape access today and deliver hope for tomorrow,” says Michele Oshman Chief Patient Advocate and Senior Vice President, Patient Advocacy Center of Excellence.</span></p>
<p><span>So what can participants expect from the event, and what is BIO working to facilitate?</span></p>
<h3>Some changes for 2026</h3>
<p><span>This year’s PACE makes some additions, focusing on specialized breakout sessions, new keynote speakers, and timely policy issues (like access and affordability) that are affecting patients immediately.</span></p>
<p><span>“We have multiple specialized breakout sessions for folks who are truly DC experts and who work on policy every day, as well as breakouts for organizations that may be building that capability,” explains Oshman. </span></p>
<p><span>“This year’s PACE program goes a little bit deeper into policy than perhaps in past years. And there are a couple of reasons for that,” Oshman says. “One is that we’re gearing up for PDUFA VIII (the Prescription Drug User Fee Act reauthorization), and we want to make sure that patient advocates share their voice as part of that process. We’re also at a unique time in terms of patient access to therapies. We recognize the affordability and access challenges patients are facing, and now is the time to prepare for the next congressional session and bring your voice to the Hill.”</span></p>
<p><span>Additionally, BIO is welcoming baseball’s all-time Iron Man,</span><a href="https://pace.bio.org/speakers/cal-ripken-jr?&azletter=R&searchgroup=libraryentry-speakers"> <span>Cal Ripken Jr.</span></a><span> as the keynote speaker to the event. He will talk about his career and philanthropic work, and how his own patient journey shaped his work, in a conversation with Crowley.</span></p>
<p><span>“I used to say that I have two hats,” recalls Crowley, “on one hand, I was the entrepreneur, the CEO, the drug developer. On the other hand, I was the father of two children with a very rare disease. I came to realize that it really is just one hat with one aligned mission.”</span></p>
<p><span>It was that spirit of storytelling that helped Crowley, and patient advocates like him, understand that advocacy is a holistic endeavor, not a mission of parts.</span></p>
<p><span>“I think early on there was a view that people living with diseases or their loved ones weren’t sophisticated enough or weren’t objective enough,” he explains. “The opposite is actually true. We are the ones oftentimes who care the most, who know the best, and who have the unique ability to convene everybody who may bring any value toward advancing therapies that might alleviate suffering, and extend and enhance life. So that patient perspective I’ve come to learn is not only </span><i><span>one</span></i><span> important part, it is </span><i><span>the most</span></i><span> important part of everything we do in biomedical research.”</span></p>
<p><span>Patient advocates are the keystone when it comes to driving innovative medicines into the hands of patients, and events like PACE provide the ideal space for these conversations.</span></p>
<p><span>“If we simply innovate and we don’t ensure access for everybody in need, we will have failed,” says Crowley. “And that’s why this conference is so important: to not only talk about what it takes to advance what we call the virtuous circle of innovation, but how we actually then make sure that everybody has access to that medicine.”</span></p>
<p><span>These conversations and more will permeate the week’s event, not only helping keep advocates more informed, but connecting them to colleagues that can collaboratively help them reach their goals.</span></p>
<p><span>“My hope for PACE this year is that it’s the beginning of a conversation, not the culmination of one,” says Oshman.</span></p>
<p><a href="https://pace.bio.org/"><b>Find out more and register for PACE.</b></a></p>
<p>The post <a href="https://bio.news/health/pace-bios-15th-annual-patient-advocacy-event-focuses-on-access/">PACE: BIO’s 15th annual patient advocacy event focuses on access</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Diasome’s HDV&#45;Insulin for T1D Finalizing Phase III Plans After Promising Data</title>
<link>https://edusehat.com/en/diasomes-hdv-insulin-for-t1d-finalizing-phase-iii-plans-after-promising-data</link>
<guid>https://edusehat.com/en/diasomes-hdv-insulin-for-t1d-finalizing-phase-iii-plans-after-promising-data</guid>
<description><![CDATA[ HDV is intended to address the difficulty of insulin, GLP-1, or other molecules traveling to the liver when injected subcutaneously, due to the large number of receptors in peripheral tissue such as fat cells and muscle cells.
The post Diasome’s HDV-Insulin for T1D Finalizing Phase III Plans After Promising Data appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/HDV-Diasome-3-rendering-JPEG.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 19 Oct 2026 03:55:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Diasome’s, HDV-Insulin, for, T1D, Finalizing, Phase, III, Plans, After, Promising, Data</media:keywords>
<content:encoded><![CDATA[<p>Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists have revolutionized the treatment of type 2 diabetes (T2D). None of these blockbuster drugs, which have generated billions for their developers, are indicated for type 1 diabetes (T1D)—though six professional groups earlier this year published a <a href="https://journals.sagepub.com/doi/10.1177/15209156261449879">consensus statement</a> designed to facilitate their safe use in managing T1D.</p>
<p>New Orleans-based Diasome says T1D treatment represents an unmet need that it is looking to address through its next-generation formulation of insulin targeting hepatocytes—which regulate how the body stores nutrients and controls whole-body blood glucose and fat metabolism—by using and clearing insulin, GLP-1, and serotonin as they enter the liver through the portal vein.</p>
<p>Diasome’s formulation comes from its own hepatocyte-directed vesicle (HDV<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley">) lipid nanoparticle platform, designed to deliver peptides, proteins, and hormones—including insulin—to the portal-hepatic region with precision.</p>
<p>HDV is a phospholipid bilayer bicelle that is designed to bind standard insulin lispro and preferentially direct it to hepatocyte receptors, enhancing cellular uptake and bioavailability by mimicking natural cell membranes. Its net negative surface charge enables electrostatic binding with positively charged proteins and peptides.</p>
<p>Biotin-PE is embedded in HDV’s surface membrane, enabling what Diasome says is efficient targeting to hepatocytes, where the sodium-dependent multivitamin transporter is most highly expressed, facilitating selective hepatic uptake.</p>
<p>In binding up to 100 proteins and peptides onto each disc, concentrating and directing biologics and drug therapies through the portal-hepatic highway, HDV is intended to address the difficulty of insulin, GLP-1, or other molecules traveling to the liver when injected subcutaneously, due to the large number of receptors in peripheral tissue such as fat cells and muscle cells.</p>
<figure aria-describedby="caption-attachment-339531" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="size-medium wp-image-339531" src="https://www.genengnews.com/wp-content/uploads/2026/10/Diasome-Bobs-Headshot-in-Color-NEAR-SQUARE-JPEG-291x300.jpg" alt="" width="291" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Diasome-Bobs-Headshot-in-Color-NEAR-SQUARE-JPEG-291x300.jpg 291w, https://www.genengnews.com/wp-content/uploads/2026/10/Diasome-Bobs-Headshot-in-Color-NEAR-SQUARE-JPEG-994x1024.jpg 994w, https://www.genengnews.com/wp-content/uploads/2026/10/Diasome-Bobs-Headshot-in-Color-NEAR-SQUARE-JPEG-768x791.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/Diasome-Bobs-Headshot-in-Color-NEAR-SQUARE-JPEG.jpg 1024w" sizes="(max-width: 291px) 100vw, 291px"><figcaption class="wp-caption-text">Robert Geho, Diasome’s co-founder and CEO</figcaption></figure>
<p>“Either subcutaneously or via oral administration, we’re able to preferentially deliver enough of those payloads into the liver and the portal vein that feeds the liver to basically mimic the endogenous release of those materials,” Robert Geho, Diasome’s co-founder and CEO, told <em>GEN</em>.</p>
<p>“Diasome is taking these commonly used APIs [active pharmaceutical ingredients] and adding very elegant chemistry to them in kind of an API-agnostic fashion and changing the biodistribution in an important way to enable the liver, especially, to just basically turn back on in response to those targeted molecules.”</p>
<h4><strong>Pivotal studies</strong></h4>
<p>Diasome is preparing to advance its HDV-insulin formulation into pivotal studies after generating positive Phase IIb data earlier this year and presenting it at two conferences earlier this fall.</p>
<p>“We’re working hard right now to finalize our Phase III planning. It’s a combination of finalizing the protocol, doing the power calculations, figuring out how many studies need to be run, choosing the insulin that we’re going to use, and then at some point fairly soon, get in front of the FDA and have a discussion about our pivotal program. We are very much dialed in on all of that Phase III preparation,” said Geho, himself a T1D patient.</p>
<p>Diasome is far from alone in developing treatments for T1D, an historically tough-to-drug indication; the primary treatment remains insulin, along with daily management (checking blood sugar and counting carbohydrates), and adjunctive therapies.</p>
<p>By year’s end, Lexicon Pharmaceuticals hopes to resubmit a new drug application (NDA) for sotagliflozin in T1D, depending on positive data from the Phase III STENO1 trial (<a href="https://clinicaltrials.gov/study/NCT06082063">NCT06082063</a>) sponsored by the Steno Diabetes Center Copenhagen.</p>
<p>Sotagliflozin is an oral inhibitor of sodium-glucose co-transporters 1 and 2 (SGLT1 and SGLT2) marketed for heart failure as Inpefa®. Lexicon’s effort to expand the label to T1D (under the name Zynquista) was stymied in 2024 when the FDA rejected the company’s NDA for the drug as an add-on therapy to insulin for adults with T1D and chronic kidney disease (CKD). Lexicon responded by launching STENO1 and two other investigator-initiated trials, SUGARNSALT (Joslin Diabetes Center; <a href="https://clinicaltrials.gov/study/NCT06217302">NCT06217302</a>) and SOPHIST (University of Dundee, <a href="https://clinicaltrials.gov/study/NCT06435156">NCT06435156</a>).</p>
<p>Another SGLT2 inhibitor, dapagliflozin, was rejected by the FDA in 2019 as an adjunct treatment to insulin in adults with T1D. Since then, researchers have studied it in combinations for T1D, such as with pioglitazone, marketed by Takeda Pharmaceutical as Actos<sup>®</sup> (<a href="https://clinicaltrials.gov/study/NCT03878459">NCT03878459</a>) and in combination with insulin and Novo Nordisk’s semaglutide marketed for obesity as Wegovy<sup>®</sup> and for T2D as Ozempic<sup>®</sup> (<a href="https://clinicaltrials.gov/study/NCT03899402">NCT03899402</a>). Dapagliflozin is marketed by AstraZeneca as Farxiga<sup>®</sup> for T2D and specific forms of heart and kidney disease.</p>
<h4><strong>Expanding landscape</strong></h4>
<p>This year has seen better news for T1D drugs: The T1D landscape expanded in June when the FDA approved a broader label for Sanofi’s Tzield<sup>®</sup> (teplizumab) widening use of the CD3-directed monoclonal antibody to children aged 1 year and older with Stage 2 T1D. Tzield was initially approved in 2022 for children ages 8 and older, as the first disease-modifying therapy in autoimmune T1D. A year later, Sanofi inherited Tzield by acquiring its original developer Provention Bio for $2.9 billion.</p>
<p>Another T1D candidate fared worse in July when Roche ended development of acmopatide (CT-868), a once-daily dual GLP-1/GIP receptor agonist for T1D with obesity—despite generating positive Phase II data a month earlier showing the drug improved blood glucose management and reduced body weight. Roche instead opted to focus its T1D development effort on enicepatide (CT-388), a once-weekly subcutaneous injectable which CEO Thomas Schinecker told analysts held greater potential for development in multiple indications.</p>
<p>Roche inherited both drugs when it <a href="https://www.genengnews.com/topics/drug-discovery/roche-to-acquire-carmot-therapeutics-for-up-to-3-1b/">acquired Carmot Therapeutics for up-to-$3.1 billion</a> in a deal completed in 2024.</p>
<p>The T1D treatment landscape may be shaken as early as November, when Eli Lilly—whose GIP/GLP-1 receptor agonist tirzepatide is marketed for diabetes as Mounjaro®—is expected to read out data from two Phase III trials comparing the drug to placebo in adults with T1D and obesity or overweight—the 49-week, 905-patient SURPASS-T1D-1 trial (<a href="https://clinicaltrials.gov/study/NCT06914895">NCT06914895</a>), and the 20-month, 465-patient SURPASS-T1D-2 trial (<a href="https://clinicaltrials.gov/study/NCT06962280">NCT06962280</a>).</p>
<p>A T1D indication would likely add billions in new sales to Mounjaro, which racked up $18.605 billion in revenue during the first half of 2026—up more than double (106%) from $9.041 billion a year earlier. Lilly is set to report Q3 results on October 29.</p>
<h4><strong>Positive case</strong></h4>
<p>Researchers from Diasome and partners have made a positive case for HDV-insulin in recent weeks, presenting data from the Phase IIb OPTI-2 trial (<a href="https://clinicaltrials.gov/study/NCT06238778">NCT06238778</a>) at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD), held September 28–October 2, 2026, in Milan.</p>
<p>During OPTI-2, a 25-week double-blind trial, 226 adults with T1D treated with multiple daily injections were randomized 1:1 to bolus insulin with insulin lispro (sold under several generic versions and marketed by Eli Lilly as Humalog®) or Diasome’s hepatic-directed insulin lispro (HDV-L) with continuous glucose monitoring (CGM) for 12 weeks of optimization followed by13 weeks of maintenance therapy.</p>
<p>The data, initially published in June, showed that HDV-L was non-inferior to insulin lispro in reducing A1C. HDV-L was also associated with reductions in clinically meaningful hypoglycemia, including severe hypoglycemia, while preserving glycemic control in people with T1D using multiple daily injections.</p>
<p>“These data support advancement into Phase [III] studies,” the researchers concluded.</p>
<p>Five insulin lispro-treated subjects had severe hypoglycemic events compared to zero with HDV-L (p = 0.0598). And while treatment emergent adverse events (TEAE) were similar between groups, but only one person randomized to HDV-L had serious TEAEs, compared with eight insulin lispro patients. There were no deaths or cases of diabetic ketoacidosis.</p>
<p>A week later at the inaugural Breakthrough T1D Clinical & Research Congress held October 9-11 in Philadelphia, researchers presented both previously published findings from OPTI-2 as well as new data from the trial showing that compared to insulin lispro, HDV-L was associated with a lower exposure-adjusted incidence rate (EAIR) per person-year for level 1 or 2 hypoglycemia, level 2 hypoglycemia, and level 1 hypoglycemia.</p>
<h4><strong>“Breakthrough in insulin therapy”</strong></h4>
<p>“We reduced hypoglycemia risk substantially in a six-month double-blinded trial versus insulin lispro. We think it’s a breakthrough in insulin therapy,” Geho said. “Hypoglycemia risk is the single biggest rate-limiting challenge to achieving glycemic control in people with insulin-deficient diabetes. If you can fix that, you can actually enable people to take more insulin safely, which will have a big impact on their A1C control.”</p>
<p>Even with advanced pump technologies and CGM technologies, he added, the unmet clinical need on hypoglycemia is substantial.</p>
<p>“If we look at GLP-1, we’re really focused on the data that’s coming out that some 50% of new GLP-1 users discontinue within one year, 85% discontinue within two years. And why is that? The two big issues are cost and side effects,” Geho said.</p>
<p>Both percentages were reported among overweight or obese patients taking GLP-1s. The roughly 50% one-year discontinuation percentage appears in a <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11786232/">2025 study</a> by researchers at the University of Pennsylvania’s Perelman School of Medicine and health data and analytics company Truveta: 46.5% of T2D patients and 64.8% without T2D stopped within a year—though 47.3% of T2D patients and 36.3% of patients without T2D resumed use of GLP-1s within that year.</p>
<p>The 85% percentage comes from an analysis of real-world integrated pharmacy and medical claims data from 16 million commercially insured members that was posted in July 2024 by Prime Therapeutics, a pharmacy benefit manager.</p>
<p>Three months later, Prime spelled out its <a href="https://www.primetherapeutics.com/documents/d/primetherapeutics/glp-1-year-2-cost-effectiveness-study-abstract-10-24-24">methodology</a>: 3,046 GLP-1 using members were matched to three control members for a total of 8,343 unique control members identified (306 control members matched to more than one GLP-1 user). The mean age of individuals identified was 46 years, 81% were women and 14% had a prediabetes diagnosis.</p>
<h4><strong>“Competitive advantage”</strong></h4>
<p>“So, we think that offering a technology that is more physiologic—in other words, we’re changing where these molecules work enough that the body essentially reaches a better balance, settles down from a GI tolerability point of view—that would be a big competitive advantage,” Geho added.</p>
<p>Geho established Diasome in 2005 with his father W. Blair Geho, MD, PhD. The elder Geho pursued his PhD in pharmacology under the tutelage of Earl W. Sutherland, Jr., a Case Western Reserve University researcher who won the 1971 Nobel Prize in Physiology or Medicine “for his discoveries concerning the mechanisms of the action of hormones.”</p>
<p>Specifically, Sutherland demonstrated how signals from one cell to another are conveyed by a messenger, the hormone, while signals within cells are conveyed by other messengers. Around 1960 he showed how cyclic adenosine monophosphate (cAMP) serves as the secondary messenger within the cell.</p>
<p>To date, Diasome has raised approximately $85 million, attracting capital from investors that have included Eli Lilly and the JDRF T1D Fund (since renamed T1D Fund, A Breakthrough T1D Venture<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley">, following the rebranding in 2024 of JDRF, which was founded in 1970 as the Juvenile Diabetes Research Foundation). The company’s last announced financing was the first closing of its Series C round in December 2023; its amount has not been announced but has been <a href="https://www.crainscleveland.com/health-care/diasome-pharmaceuticals-announces-95-million-first-close-series-c-financing-round/">reported to be $9.5 million</a>.</p>
<p>“We’re anticipating a Series D financing, so that work is underway,” Robert Geho said. “That’s an active part of our work right now.”</p>
<p>Since its founding, Diasome has grown its workforce to between 20-25, counting both full-time employees and significant consultants.</p>
<p>“In terms of full-time headcount, I am anticipating increasing that by probably 25 or 30% over the next several months,” Geho estimated.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/diasomes-hdv-insulin-for-t1d-finalizing-phase-iii-plans-after-promising-data/">Diasome’s HDV-Insulin for T1D Finalizing Phase III Plans After Promising Data</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>StockWatch: Liquidia Rebounds After Settling Legal Wrangle with United Therapeutics</title>
<link>https://edusehat.com/en/stockwatch-liquidia-rebounds-after-settling-legal-wrangle-with-united-therapeutics</link>
<guid>https://edusehat.com/en/stockwatch-liquidia-rebounds-after-settling-legal-wrangle-with-united-therapeutics</guid>
<description><![CDATA[ Two weeks after its stock lost more than half its value following a setback in a seven-year legal wrangle, Liquidia shares finally began bouncing back thanks to a settlement with United Therapeutics that drew mixed conclusions from four analysts about which company won out long-term.
The post StockWatch: Liquidia Rebounds After Settling Legal Wrangle with United Therapeutics appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Oct26_2020_Getty_545863899_Lung-1068x894-1-1003x840-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 19 Oct 2026 03:55:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>StockWatch:, Liquidia, Rebounds, After, Settling, Legal, Wrangle, with, United, Therapeutics</media:keywords>
<content:encoded><![CDATA[<p>Two weeks after its stock lost more than half its value following a setback in a seven-year legal wrangle, <strong>Liquidia (Nasdaq: LQDA)</strong> shares finally began bouncing back this past week thanks to a settlement with <strong>United Therapeutics (Nasdaq: UTHR)</strong> that drew mixed conclusions from four analysts about which company won out long-term.</p>
<p>The settlement ended six lawsuits that encompassed patent infringement, trade secret, and antitrust claims between the companies. Short-term, Liquidia agreed to pay $380.7 million to United Therapeutics and parties to settle antitrust litigation launched in 2019. Back then, <strong>Sandoz Group (SIX Swiss: SDZ)</strong> and its marketing partner RareGen (since merged into Liquidia) accused United Therapeutics of carrying out anticompetitive actions by blocking the launch of a generic version of United’s injectable treprostinil, which first won FDA approval in 2002 and is marketed as Remodulin<sup>®</sup>.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>Liquidia also agreed to remove pulmonary hypertension associated with interstitial lung disease (PH-ILD) as an indication from the label of its sole commercial product Yutrepia<sup>®</sup> (treprostinil) inhaled powder and no longer promote the prostacyclin mimetic for PH-ILD to new patients. In doing so, Liquidia opted not to challenge a U.S. District Court for the District of Delaware decision finding the company to have infringed claims 1 and 14 of U.S. Patent No. 11,826,327, which is owned by United. That decision sent Liquidia shares <span><strong>plummeting 57%</strong></span> from $70.69 to $30.26 on September 30.</p>
<p>The settlement allows Liquidia to continue selling Yutrepia for pulmonary arterial hypertension (PAH) while continuing other ongoing development programs for the drug outside of PH-ILD. That includes Raynaud’s phenomenon associated with systemic sclerosis (SSc-RP). The FDA last month granted its Fast Track designation to Yutrepia in SSc-RP, a disease for which no therapy is currently approved by the agency.</p>
<p>Also, the settlement allows Liquidia to continue developing L606 (liposomal treprostinil inhalation suspension), an extended-release formulation of treprostinil administered twice daily with a next-generation nebulizer. Liquidia is partnering with Pharmosa Biopharm to develop L606 in PH-ILD as well as PAH.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p><strong>“Very favorable outcome” for Liquidia</strong></p>
<p>“We view this as a very favorable outcome for LQDA and broadly in line w/ the base case we previously outlined,” Manoj Eradath, PhD, a senior biotechnology equity researcher with Jefferies, wrote in a research note.</p>
<p>Eradath wrote that investors were concerned about a potential interruption in Yutrepia sales following the decision by District Court Judge Richard G. Andrews, who was appointed in 2011 by President Barack Obama: “The settlement removes that overhang.” Eradath added that the decision also created uncertainty around the PH-ILD development pathway for L606 that is resolved by the settlement.</p>
<p>“Overall, w/ the legal overhang removed, we now view LQDA primarily as a Yutrepia growth story in PAH w/ upside from label expansion + significant pipeline opportunities from L606,” Eradath commented. He raised Jefferies’ 12-month price target on Liquidia stock 22%, from $45 to $55.</p>
<p>Also agreeing that Liquidia won out through the settlement was Serge Belanger, a senior analyst covering the biotechnology sector for Needham & Co.: “The agreement removes legal overhangs around Yutrepia and allows LQDA to build the [drug’s] blockbuster presence in PAH,” Belanger wrote in a research note, as reported by <em>Investor’s Business Daily</em>.</p>
<h4><strong>25% stock surge</strong></h4>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>Investors appeared to side with Belanger and Eradath, as news of the settlement sparked a <span><strong>25% five-day surge</strong></span> in Liquidia’s share price. On Wednesday, the first trading day after the settlement was announced, Liquidia shares <span><strong>soared nearly 27%</strong></span> from $26.81 to $33.94. Shares <span><strong>climbed another 2.5%</strong></span> Thursday, reaching $34.78 before <span><strong>dipping 1% </strong></span>Friday to $34.35.</p>
<p>United Therapeutics shares, in contrast, <span><strong>slipped 0.6%</strong> </span>Wednesday from $543.40 to $540.03, but <span><strong>inched up 0.3%</strong></span> Thursday to $541.51. United’s shares <span><strong>dipped nearly 2%</strong></span> Friday, finishing the week at $533.12 and a <span><strong>3% decline</strong></span> for the week.</p>
<p>Yutrepia finished the first six months of this year with $300.263 million in net product sales, multiples above the $6.517 million reported for January–June 2025. That is because Yutrepia reached the U.S. market on June 2, 2025, following final FDA approval on May 23 of last year.</p>
<p>During a conference call with analysts, Liquidia CEO Roger Jeffs, PhD, and Michael Kaseta, COO and CFO, disclosed that Yutrepia racked up unaudited Q3 net product sales of $222.7 million—a 31% or roughly $52 million leap above second quarter net product sales of $170.382 million, a jump the company attributed primarily to PAH prescriptions. Those sales, according to Liquidia, contributed to the company’s total cash and cash equivalents of $396.1 million as of September 30.</p>
<p>The Liquidia executives said Yutrepia’s sales were split 60/40 between PAH and PH-ILD, with PAH sales trending toward 70%. That trend, Eradath observed, “suggest[s] the commercial impact from removal of PH-ILD may be lower than initially expected.”</p>
<p>By 2028, Liquidia expects Yutrepia to reach blockbuster status with more than $1 billion in annual sales.</p>
<p>Close to blockbuster status is United Therapeutics’ two inhalable forms of treprostinil called Tyvaso<sup>®, </sup>which generated generated a combined $910.1 million in January–June 2026, with Tyvaso DPI the top-seller at $656.9 million<sup>. </sup>The company has marketed an oral inhalation solution of Tyvaso for PAH since initial FDA approval in 2009. The agency approved a nebulizer for the drug in 2017,  an additional indication of PH-ILD in 2021, followed a year later by approval of <span class="iNqyIf" data-sfc-cp="" data-sfc-root="ep" data-epip="">Tyvaso DPI<sup>®</sup><!--TgQPHd|||[]--></span> inhalation powder for PAH and PH-ILD.</p>
<p><strong>“Clearcut win” for United Therapeutics</strong></p>
<p>Two other analysts, however, pegged United Therapeutics as the winner in the litigation with Liquidia. Jessica Fye, a managing director and senior equity research analyst with J.P. Morgan, observed that United stands to gain significant sales as people with PH-ILD shift to its Tyvaso from Liquidia’s Yutrepia.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>“We see a framework in place that should allow for a substantial proportion of current PH-ILD patients on Yutrepia to transition to Tyvaso, and we think much of this process could occur over the next two quarters (i.e., 4Q and 1Q),” Fye wrote in a research note.</p>
<p>Fye added that the increased sales offer a timely lift to Tyvaso’s sales as United Therapeutics awaits FDA review on a new indication for Tyvason, idiopathic pulmonary fibrosis (IPF). The company has said it expects the FDA to complete its review on the IPF indication in late April.</p>
<p>“We continue to see Tyvaso’s IPF launch making UTHR a stock to own as we see a very large market opportunity in that setting,” Fye concluded, without quantifying that opportunity.</p>
<p>And unlike his colleague Eradath, Jefferies equity analyst Roger Song, MD, declared the settlement a “clearcut win for near-/mid-term” and a “decisive win” for United Therapeutics, since United preserved its exclusivity in treating PH-ILD through treprostinil, and “extracted meaningful economics from LQDA.”</p>
<p>“We view the outcome as a clear win for UTHR: Protecting the PH-ILD franchise and avoiding the delays and uncertainty associated with a multi-year appellate process,” Song wrote in a research note. “Importantly, the settlement should improve visibility into future Tyvaso growth in PH-ILD while allowing investors to refocus on continued PH-ILD/ DPI ramp, emerging IPF/ ralinepag opportunity, and broader pipeline development.”</p>
<p>Ralinepag is a once-daily oral prostacyclin (IP) receptor agonist being developed by United Therapeutics for PAH and under FDA review with a Prescription Drug User Fee Act (PDUFA) target action date of June 24, 2027.</p>
<h4><strong>$175M due by October 30</strong></h4>
<p>United Therapeutics will see the bulk of the settlement money, starting with $175 million that Liquidia agreed to pay the biotech giant by October 30, though that date can be extended up to six 30-day periods according to a <a href="https://www.liquidia.com/static-files/12a07a5c-31f6-4fef-92f1-82b3d7f61416">regulatory filing</a>. The payment is intended to resolve United’s antitrust litigation against Liquidia tied to treprostinil injection.</p>
<p>Liquidia also agreed to pay United Therapeutics $145.4 million in two equal installments of $72.7 million due on or before January 31, 2027, and April 30, 2027. In addition, Liquidia agreed to shell out another $60.3 million this month to parties with interests in the treprostinil injection antitrust lawsuit, including United and ICU Medical, which acquired cartridge manufacturer Smiths Medical ASD in 2022.</p>
<p>At the same time, Liquidia terminated its promotional agreement tied to treprostinil Injection and will no longer commercially support the product.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="7"></span></aside>
<p>Despite the millions it stands to receive from Liquidia through the settlement, United Therapeutics shied away from declaring outright victory in its statement about the end of litigation—though it sought to offer an explanation for why it challenged Liquidia in court, stating that Liquidia used United’s clinical trial data for Tyvaso in PH-ILD to build its development case for Yutrepia.</p>
<p>“We are grateful that our significant investments in research and development brought nebulized Tyvaso® and Tyvaso DPI® to people living with PH-ILD after previous therapies failed to effectively treat this challenging disease. The U.S. Patent and Trademark Office awarded us a patent for our innovative PH-ILD treatment in November 2023,” United Therapeutics stated. “Liquidia disregarded our patent and the pending patent litigation and began marketing Yutrepia for PH-ILD in 2025, knowing that a ruling like the federal court’s recent decision could require it to remove the PH-ILD indication from its approved product label.”</p>
<p>United Therapeutics also stated that before the September federal district court ruling, it offered Liquidia a settlement that would have kept Yutrepia available for PAH and PH-ILD patients: “Liquidia chose not to accept our proposal and instead let the court proceedings play out.”</p>
<p>The company also cited its history; it was founded in 1996 as LungRx by chairperson and CEO Martine Rothblatt, PhD, with the aim of discovering a cure for her daughter’s PAH: “Our deep connection to patients and families desperate for life-saving treatment drives our longstanding commitment to ensuring that they receive them.”</p>
<h2>Leaders and laggards</h2>
<ul>
<li><strong>Generate: Biomedicines (Nasdaq: GENB) </strong>shares <span><strong>tumbled 11%</strong></span> from $13.84 to $12.26 Wednesday after the artificial intelligence (AI)-based drug developer launched an up-to-$1.265 billion collaboration with <strong>Zealand Pharma (Nasdaq: ZEAL)</strong>. The companies agreed to design and develop multi-specific protein therapeutics for obesity and other metabolic diseases using Generate’s platform, which integrates generative AI with high-throughput experimental validation. The collaboration aims to combine Zealand’s expertise in metabolic health with Generate’s ability to engineer proteins with AI and refine those designs using experimental data toward desired biological functions. Generate agreed to lead research through lead-candidate selection, after which Zealand agreed to oversee subsequent clinical development, regulatory submissions, and worldwide commercialization. Zealand agreed to pay Generate $30 million upfront and up to $35 million in early preclinical milestones for two initial programs (a third may also be developed), plus up to nearly $1.2 billion tied to achieving development, regulatory, and commercial milestones, plus tiered royalties on worldwide net sales of any commercialized products resulting from the collaboration.</li>
</ul>
<ul>
<li><strong>Recursion (Nasdaq: RXRX)</strong> shares<span> <strong>jumped 11%</strong></span> from $3.74 to $4.16 Thursday on two announcements: <strong>Sanofi (Euronext Paris: SAN) </strong>optioned the first development candidate from the companies’ multi-program research collaboration, a dual-targeting inflammatory disease candidate expected to enter Phase I trials in 2027. The decision triggered a $10 million milestone payment to Recursion, bringing to $144 million the total upfront and milestone payments Sanofi has paid the AI-based drug developer since the companies launched their partnership in 2022. Recursion is eligible for $300 million-plus in additional milestones plus double-digit royalties on net sales of approved products. Recursion also priced a $200 million stock offering: 61.54 million shares of its Class A common stock at $3.25 per share. The offering was expected to close on or about Friday. Investors participating in the financing included Janus Henderson Investors, Invus, Longaeva Partners, ARK Invest, Driehaus Capital Management, and “other prominent healthcare specialists and mutual funds.”</li>
</ul>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/stockwatch-liquidia-rebounds-after-settling-legal-wrangle-with-united-therapeutics/">StockWatch: Liquidia Rebounds After Settling Legal Wrangle with United Therapeutics</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Alberta launches physician&#45;led triage program to strengthen emergency departments</title>
<link>https://edusehat.com/en/alberta-launches-physician-led-triage-program-to-strengthen-emergency-departments</link>
<guid>https://edusehat.com/en/alberta-launches-physician-led-triage-program-to-strengthen-emergency-departments</guid>
<description><![CDATA[ New initiative aims to improve patient assessment, reduce treatment delays and ease pressure on hospital emergency departments. Alberta is moving forward with a Triage Liaison Physician program designed to improve patient flow and strengthen care in hospital emergency departments. The initiative introduces physicians who work alongside triage nurses to assess patients earlier in their emergency […]
The post Alberta launches physician-led triage program to strengthen emergency departments appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/Modern-Emergency-Department-Entrance.png" length="49398" type="image/jpeg"/>
<pubDate>Mon, 19 Oct 2026 03:50:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Alberta, launches, physician-led, triage, program, strengthen, emergency, departments</media:keywords>
<content:encoded><![CDATA[<p><strong>New initiative aims to improve patient assessment, reduce treatment delays and ease pressure on hospital emergency departments.</strong></p>
<p>Alberta is moving forward with a Triage Liaison Physician program designed to improve patient flow and strengthen care in hospital emergency departments.</p>
<p>The initiative introduces physicians who work alongside triage nurses to assess patients earlier in their emergency department visits, particularly those waiting to receive treatment.</p>
<p>The approach is intended to identify patients whose conditions may be deteriorating, initiate diagnostic testing sooner and help reduce delays in medical assessment.</p>
<p>The provincial government confirmed the program’s launch in an October 16 statement from Minister of Hospital and Surgical Health Services Adriana LaGrange.</p>
<p>The initiative follows growing concerns about emergency department overcrowding, lengthy wait times and pressure on frontline healthcare professionals.</p>
<p>Under the model, triage liaison physicians can begin medical assessments while patients remain in waiting areas. This may include ordering blood tests, electrocardiograms and diagnostic imaging before patients are transferred to treatment spaces.</p>
<p>By beginning these processes earlier, hospitals hope to improve patient flow and reduce the time required to reach clinical decisions.</p>
<p>The program was originally announced in January 2026 as part of Alberta’s response to mounting pressures in emergency departments.</p>
<p>However, implementation encountered delays as the provincial government and Alberta Medical Association worked through questions involving physician compensation, working conditions and operational responsibilities.</p>
<p>The October announcement marks a further step in implementing the approach.</p>
<p>While physician-led triage has the potential to improve emergency department efficiency, healthcare professionals have emphasized that adequate staffing, treatment spaces and inpatient capacity remain essential to addressing overcrowding.</p>
<p>The initiative will provide an opportunity to assess whether earlier physician involvement can improve patient safety, reduce delays and support emergency department operations.</p>
<p><em>Source: Government of Alberta; Alberta Medical Association reporting.</em></p>
<p>The post <a href="https://www.hospitalnews.com/alberta-launches-physician-led-triage-program-to-strengthen-emergency-departments/">Alberta launches physician-led triage program to strengthen emergency departments</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Eight&#45;day treatment could expand access to life&#45;saving organ transplants</title>
<link>https://edusehat.com/en/eight-day-treatment-could-expand-access-to-life-saving-organ-transplants</link>
<guid>https://edusehat.com/en/eight-day-treatment-could-expand-access-to-life-saving-organ-transplants</guid>
<description><![CDATA[ Canadian researchers have demonstrated that a short antiviral treatment can allow patients to safely receive organs from donors with hepatitis C, potentially expanding the pool of available organs. Researchers at Toronto’s University Health Network (UHN) have reported promising results from an eight-day treatment protocol designed to prevent hepatitis C virus (HCV) infection in organ transplant […]
The post Eight-day treatment could expand access to life-saving organ transplants appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/TG_Feld_oct2026.jpg.png" length="49398" type="image/jpeg"/>
<pubDate>Mon, 19 Oct 2026 03:50:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Eight-day, treatment, could, expand, access, life-saving, organ, transplants</media:keywords>
<content:encoded><![CDATA[<p><strong>Canadian researchers have demonstrated that a short antiviral treatment can allow patients to safely receive organs from donors with hepatitis C, potentially expanding the pool of available organs.</strong></p>
<p>Researchers at Toronto’s University Health Network (UHN) have reported promising results from an eight-day treatment protocol designed to prevent hepatitis C virus (HCV) infection in organ transplant recipients.</p>
<p>Published in <em>The Lancet Gastroenterology & Hepatology</em>, the study examined 116 kidney, lung, heart, pancreas and kidney-pancreas transplant procedures involving organs from donors with active hepatitis C infections.</p>
<p>All recipients received the Toronto HCV Protocol, consisting of one dose of antiviral medication before transplantation, followed by seven days of treatment after surgery.</p>
<p><strong>None of the 116 recipients developed chronic hepatitis C</strong>, required additional antiviral treatment or experienced HCV-related complications. All had no detectable HCV infection at their 12-week assessment or last follow-up.</p>
<p>The findings could help address a significant challenge in organ transplantation. Historically, organs from donors with hepatitis C were rarely used for recipients who did not already have the virus.</p>
<p>Although modern antiviral medications have made these transplants possible, conventional treatment typically requires eight to 12 weeks, creating additional costs and potential delays in accessing medication.</p>
<p>The Toronto protocol allows most patients to complete treatment before leaving the hospital.</p>
<p>Researchers also compared outcomes with transplant recipients who received organs from donors without hepatitis C. Survival and organ function were similar between the groups, with two-year overall survival reaching 87.1 per cent among patients treated using the Toronto protocol.</p>
<p>“Our original study showed that this approach could work in 30 patients,” said Dr. Jordan Feld, senior scientist at UHN and senior author of the study. “Now we have shown it can be implemented in routine clinical practice across multiple organ types with excellent long-term outcomes.”</p>
<p>The research could have important implications for Canada’s organ donation system, particularly as the opioid crisis has increased the number of otherwise healthy donor organs testing positive for hepatitis C.</p>
<p>By safely using more donated organs, hospitals may be able to reduce transplant waiting times and improve access to life-saving procedures.</p>
<p>The study was supported by the Canadian Institutes of Health Research and UHN Foundation.</p>
<p><em>Source: University Health Network (UHN Research).</em></p>
<p>The post <a href="https://www.hospitalnews.com/eight-day-treatment-could-expand-access-to-life-saving-organ-transplants/">Eight-day treatment could expand access to life-saving organ transplants</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Choosing a Medical Specialty: Expert Insights from Tutors Across Fields</title>
<link>https://edusehat.com/en/choosing-a-medical-specialty-expert-insights-from-tutors-across-fields</link>
<guid>https://edusehat.com/en/choosing-a-medical-specialty-expert-insights-from-tutors-across-fields</guid>
<description><![CDATA[ For many medical students, choosing a specialty feels like one of the biggest decisions they will ever make. It is the question that follows students throughout preclinical lectures, clinical rotations, residency applications, and countless conversations with mentors. Some students know exactly what they want from the moment they enter medical school. Others change their minds […]
The post Choosing a Medical Specialty: Expert Insights from Tutors Across Fields appeared first on Elite Medical Prep. ]]></description>
<enclosure url="https://elitemedicalprep.com/wp-content/uploads/2026/10/pexels-michael-burrows-7129697-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 17 Oct 2026 05:25:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Choosing, Medical, Specialty:, Expert, Insights, from, Tutors, Across, Fields</media:keywords>
<content:encoded><![CDATA[<p><span>For many medical students, choosing a specialty feels like one of the biggest decisions they will ever make. It is the question that follows students throughout preclinical lectures, clinical rotations, residency applications, and countless conversations with mentors. Some students know exactly what they want from the moment they enter medical school. Others change their minds multiple times before submitting their residency applications.</span></p>
<p> </p>
<p><span>As tutors who work with students pursuing everything from family medicine to dermatology, orthopedic surgery, psychiatry, emergency medicine, and internal medicine, we’ve noticed that students sometimes focus on the wrong factors early in the decision-making process. They worry about prestige, salary, competitiveness, or what others expect of them, while overlooking the factors that ultimately determine long-term career satisfaction.</span></p>
<p> </p>
<p><span>The truth is that <a href="https://elitemedicalprep.com/types-of-medical-specialties/">choosing a specialty</a> is rarely about finding the “best” field. It’s about finding the best </span><span>fit</span><span> for you. While every physician’s journey is unique, certain themes emerge repeatedly when experienced tutors, residents, and attending physicians discuss how students should approach this important decision.</span></p>
<p> </p>
<h2><strong>The Biggest Mistake: Falling in Love with a Specialty on Paper</strong></h2>
<p><span>One of the most common mistakes students make is choosing a specialty based on what it looks like rather than what it actually feels like.</span></p>
<p> </p>
<p><span>Every specialty sounds appealing when described in broad terms. Dermatology offers excellent lifestyle flexibility. Emergency medicine provides variety and excitement. Orthopedic surgery allows physicians to fix problems with their hands. Psychiatry offers meaningful patient relationships. Internal medicine provides intellectual complexity.</span></p>
<p> </p>
<p><span>The challenge is that the day-to-day reality of a specialty often differs dramatically from students’ initial perceptions.</span></p>
<p> </p>
<p><span>Many students become interested in a specialty because of one particularly inspiring physician, a fascinating lecture, or a positive shadowing experience. While those experiences are valuable, they provide only a small glimpse into what practicing that specialty actually involves.</span></p>
<p> </p>
<p><span>Tutors frequently advise students to ask themselves a simple question: Could you see yourself enjoying the ordinary days of this specialty, not just the</span><span> exciting ones? Afterall, the ordinary things happen the majority of the time!</span></p>
<p> </p>
<p><span>Every field has routine visits, paperwork, difficult patients, administrative responsibilities, and long days. The goal is not finding a specialty without challenges. It is finding one where the challenges feel worthwhile.</span></p>
<p> </p>
<h2><b>Lifestyle Matters More Than Students Think</b></h2>
<p><span>Medical students often hesitate to discuss lifestyle because they worry it sounds selfish. However, experienced physicians consistently emphasize that lifestyle considerations are both reasonable and important. </span><span>The reality is that your specialty choice will influence your schedule, call responsibilities, family life, weekends, holidays, and overall work-life integration for decades.</span></p>
<p> </p>
<p><span>One of the most common observations tutors make is that students frequently underestimate how much their priorities may change over time. During medical school, it can be easy to imagine working 80 hours per week forever because training already demands so much. But priorities often shift as physicians advance through residency and establish their personal lives.</span></p>
<p> </p>
<p><span>This does not mean students should automatically choose specialties perceived as “lifestyle friendly.” Rather, they should honestly evaluate what kind of life they envision for themselves.</span></p>
<p> </p>
<p><span>Some physicians genuinely enjoy being in the hospital, taking call, and managing critically ill patients. Others thrive when they have <a href="https://elitemedicalprep.com/top-residency-programs-for-work-life-balance-a-guide-for-medical-students/">more predictable schedules</a> and outpatient-focused practices. Neither preference is better than the other. What matters is understanding yourself so that you make the right choice for you.</span></p>
<p> </p>
<p><span>Students who ignore lifestyle considerations entirely often find themselves questioning their specialty choice later. Those who thoughtfully incorporate lifestyle into their decision-making tend to make more sustainable choices.</span></p>
<p> </p>
<h2><strong>Competitiveness Should Not Be the First Factor</strong></h2>
<p><span>Every year, tutors meet students who begin the specialty selection process by asking one question: “What can I realistically match into?” </span><span>While competitiveness is certainly important to understand, it should not be the starting point.</span></p>
<p> </p>
<p><span>Choosing a specialty solely because it appears easier to match into can lead to long-term dissatisfaction. Likewise, choosing a <a href="https://elitemedicalprep.com/the-most-difficult-residency-specialties-to-match-into-why-theyre-so-competitive/">highly competitive specialty</a> simply because it is prestigious can create unnecessary stress if genuine interest is lacking.</span></p>
<p> </p>
<p><span>Instead, tutors often recommend separating specialty exploration from application strategy initially. First determine what specialties genuinely interest you. Then evaluate competitiveness, application requirements, and your likelihood of matching within those fields. Reviewing <a href="https://elitemedicalprep.com/us-doctor-specialties-by-usmle-step-2-ck-score/">USMLE Step 2 CK scores by specialty</a> can help you understand one part of your application’s competitiveness.</span></p>
<p> </p>
<p><span>Many students discover that they become stronger applicants when they pursue specialties they genuinely enjoy. Authentic interest often leads to stronger mentorship relationships, better rotation performance, more meaningful research involvement, and more compelling residency applications. </span><span>Competitiveness matters, but fit should come first.</span></p>
<p> </p>
<h2><strong>Pay Attention to What Energizes You</strong></h2>
<p><span>One of the most useful exercises tutors recommend is <a href="https://elitemedicalprep.com/choosing-your-specialty-gaining-insights-from-clinical-clerkships/">reflecting on your clinical rotations</a> honestly. S</span><span>tudents often focus on which rotations they performed best in academically. However, a more important question may be: Which rotations left you with a full cup at the end of the day?</span></p>
<p> </p>
<p><span>Think back to your clerkships. Were you excited to arrive each morning? Did the day pass quickly? Did you find yourself reading about patients after going home because you were genuinely interested?</span></p>
<p> </p>
<p><span>These experiences often reveal important clues about specialty fit.</span></p>
<p> </p>
<p><span>Some students realize they love procedures. Others discover they enjoy longitudinal patient relationships. Some thrive in acute care environments where quick decisions are required. Others prefer slower-paced settings that allow for extensive patient conversations. </span><span>The activities that naturally hold your attention are often more predictive of future satisfaction than grades or shelf scores alone.</span></p>
<p> </p>
<h2><strong>Don’t Ignore Your Personality</strong></h2>
<p><span>Personality is not destiny, but it often influences specialty satisfaction more than students realize.</span></p>
<p> </p>
<p><span>Certain specialties tend to attract physicians with particular communication styles, interests, and work preferences. This does not mean there is one “correct” personality for each specialty. However, students frequently feel more comfortable in environments that align with their natural tendencies.</span></p>
<p> </p>
<p><span>For example, students who enjoy building long-term relationships may gravitate toward family medicine, pediatrics, psychiatry, or outpatient internal medicine. Those who enjoy immediate problem-solving may find emergency medicine appealing. Students who love anatomy, procedures, and operating room environments may feel drawn toward surgical fields.</span></p>
<p> </p>
<p><span>Tutors often encourage students to pay attention not only to the specialty itself but also to the people practicing it. During rotations, ask yourself whether you can imagine working alongside these physicians for years. </span><span>Culture matters. Finding your professional community can be just as important as finding the right patient population.</span></p>
<p> </p>
<h2><strong>Beware of Specialty Stereotypes</strong></h2>
<p><span>One challenge students face is the abundance of stereotypes surrounding different specialties. </span><span>You have probably heard them all: surgeons are intense, psychiatrists are laid back, dermatologists only care about lifestyle, internists love complexity, emergency physicians thrive on adrenaline.</span></p>
<p> </p>
<p><span>While these stereotypes sometimes contain a grain of truth, they rarely tell the whole story.</span></p>
<p> </p>
<p><span>Every specialty contains tremendous diversity. There are highly academic dermatologists and procedure-heavy internists. There are surgeons with excellent work-life balance and psychiatrists with demanding schedules.</span></p>
<p> </p>
<p><span>Students who rely too heavily on stereotypes may prematurely eliminate specialties that could actually fit them very well.</span></p>
<p> </p>
<p><span>The best way to understand a specialty is through direct exposure rather than assumptions. If you’re interested in a specialty, <a href="https://elitemedicalprep.com/everything-you-need-to-know-about-audition-rotations/">seek rotation opportunities</a> so you can get this exposure and see what it’s all about first-hand. </span></p>
<p> </p>
<h2><strong>The Importance of Mentorship</strong></h2>
<p><span>One recurring theme across every specialty is the value of mentorship. </span><span>Many students make specialty decisions based on limited experiences or incomplete information. Mentors can provide insights that are difficult to obtain elsewhere.</span></p>
<p> </p>
<p><span>Physicians who are several years ahead in training often have a much clearer perspective on what life in their specialty actually looks like. They can discuss lifestyle realities, job market considerations, fellowship opportunities, burnout risks, and career satisfaction.</span></p>
<p> </p>
<p><span>I frequently encourage students to speak with multiple mentors within each specialty of interest rather than relying on a single opinion. Every physician’s career path is unique, and gathering diverse perspectives often leads to better-informed decisions. </span><span>The most valuable mentors are often those willing to discuss both the rewards and challenges of their field honestly.</span></p>
<p> </p>
<h2><strong>Remember That No Specialty Is Perfect</strong></h2>
<p><span>Perhaps the most reassuring lesson tutors share is that there is no perfect specialty.</span></p>
<p> </p>
<p><span>Many students become paralyzed trying to identify the single “right” choice. They compare specialties endlessly, searching for certainty before making a decision.</span></p>
<p> </p>
<p><span>In reality, every field involves tradeoffs. </span><span>A specialty with excellent lifestyle flexibility may involve less procedural work. A highly procedural field may require longer and more intense training. A specialty with strong patient continuity may involve significant administrative responsibilities. Acute-care specialties may offer excitement but also shift work and overnight schedules.</span></p>
<p> </p>
<p><span>Think about your personal priorities and try to choose a specialty with tradeoffs that are aligned.</span></p>
<p> </p>
<h2><strong>The Bottom Line</strong></h2>
<p><span>The goal is finding a field that fits your interests, personality, lifestyle goals, and vision for your future.</span></p>
<p> </p>
<p><span>As tutors who work with students across nearly every specialty, we’ve found that the most successful career decisions usually happen when students focus less on prestige and more on authenticity and overall fit. Pay attention to what excites you during rotations. Seek mentorship. Consider lifestyle honestly. Understand competitiveness without letting it dominate your thinking. Most importantly, trust your experiences.</span></p>
<p> </p>
<p><span>The specialty that fits you best may not be the one you expected when you started medical school, and that’s perfectly okay. Some of the most satisfied physicians we meet are those who remained open-minded, explored broadly, and ultimately chose the field where they could see themselves thriving for years to come.</span></p>
<p> </p>
<p>Need support as you prepare for your next steps in medical school? EMP’s expert tutors can help you strengthen your clinical knowledge, prepare for shelf exams and Step 2 CK, and build a study plan around your goals. <a href="https://elitemedicalprep.com/get-started/">Schedule a complimentary consultation</a> to explore how our 1:1 tutoring can support you.</p>
<p>The post <a href="https://elitemedicalprep.com/choosing-a-medical-specialty-expert-insights-from-tutors-across-fields/">Choosing a Medical Specialty: Expert Insights from Tutors Across Fields</a> appeared first on <a href="https://elitemedicalprep.com/">Elite Medical Prep</a>.</p>]]> </content:encoded>
</item>

<item>
<title>ADC Developmentfrom Concept to Clinic</title>
<link>https://edusehat.com/en/adc-developmentfrom-concept-to-clinic</link>
<guid>https://edusehat.com/en/adc-developmentfrom-concept-to-clinic</guid>
<description><![CDATA[ This eBook brings insight on integrated end-to-end solutions for precision engineered therapeutics.
The post ADC Developmentfrom Concept to Clinic appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Cover-Image_ADCs-8-x-11-scaled-e1792182648204.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 17 Oct 2026 05:05:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>ADC, Developmentfrom, Concept, Clinic</media:keywords>
<content:encoded><![CDATA[<div aria-hidden="true" class="wp-block-spacer"></div>


<p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Read Now</button></p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>


<figure class="wp-block-image alignright size-medium"><img fetchpriority="high" decoding="async" width="232" height="300" src="https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Eurofins_eBookCover-232x300.jpg" alt="Eurofins eBook Cover" class="wp-image-339513" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Eurofins_eBookCover-232x300.jpg 232w, https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Eurofins_eBookCover-791x1024.jpg 791w, https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Eurofins_eBookCover-768x994.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Eurofins_eBookCover-1187x1536.jpg 1187w, https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Eurofins_eBookCover.jpg 1200w" sizes="(max-width: 232px) 100vw, 232px"></figure>


<p class="wp-block-paragraph">Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the therapeutic activity of small molecule payloads, enabling targeted delivery while minimizing off-target effects. Their potential in areas such as targeted cancer cell killing and targeted protein degradation has fueled significant growth, resulting in numerous FDA approvals and more than 100 ADCs currently in clinical development. However, ADC development remains complex and highly empirical, requiring careful optimization of linker chemistry, payload selection, bioconjugation strategies, drug-to-antibody ratio (DAR), stability, and overall antibody integrity.</p>


<p class="wp-block-paragraph">The ADC journey begins with linker-payload synthesis and bioconjugation. Eurofins Discovery offers extensive expertise in the design and synthesis of linker technologies, including protease-sensitive, glycosidase-sensitive, pH-sensitive, PEGylated, branched, and shielding linkers. Payloads are manufactured in specialized high-containment facilities to ensure the safe handling of highly potent compounds. Multiple conjugation options are available, providing flexibility to explore different designs and generate ADCs with customized pharmacokinetic profiles, improved stability, and controlled DAR distributions.</p>


<p class="wp-block-paragraph">Once conjugation is complete, ADCs undergo purification using a range of chromatography techniques. These methods remove unconjugated antibodies, excess linker-payload materials, and aggregates to produce highly pure ADC preparations. This is essential for more reliable downstream analyses and ensures more accurate assessment of ADC performance.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>


<p class="wp-block-paragraph">DAR analysis is then conducted using high-resolution liquid chromatography-mass spectrometry (LC-MS). This approach confirms linker-payload incorporation, identifies individual DAR species, and provides detailed insights into ADC homogeneity. Such information is critical for optimizing product consistency, efficacy, safety, and manufacturability.</p>


<p class="wp-block-paragraph">Finally, a comprehensive suite of biochemical, functional, and cytotoxicity assays is essential to characterize ADC candidates. Data-driven assessment of binding, biological function, and therapeutic potential, through both <em>in vitro</em> and <em>in vivo</em> studies, helps identify the most promising candidates for further advancement and development.</p>


<p class="wp-block-paragraph">Eurofins Discovery provides a fully integrated ADC development platform spanning every stage of the workflow, from linker-payload design through analytical characterization and functional assessment. By leveraging deep expertise in chemistry, biochemistry, and antibody optimization and characterization, Eurofins Discovery scientists help mitigate development risks and shorten timelines while optimizing ADC safety, efficacy, and manufacturability.</p>

<p>The post <a href="https://www.genengnews.com/resources/ebooks/adc-developmentfrom-concept-to-clinic/">ADC Developmentfrom Concept to Clinic</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Danaher, Nvidia Combine Lab Instrumentation and AI to Advance Autonomous Science</title>
<link>https://edusehat.com/en/danaher-nvidia-combine-lab-instrumentation-and-ai-to-advance-autonomous-science</link>
<guid>https://edusehat.com/en/danaher-nvidia-combine-lab-instrumentation-and-ai-to-advance-autonomous-science</guid>
<description><![CDATA[ Danaher and Nvidia are collaborating to advance autonomous science, combining lab instrumentation, automation, and software with accelerated computing and AI so that experiments inform models and models help design better experiments.
The post Danaher, Nvidia Combine Lab Instrumentation and AI to Advance Autonomous Science appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/07/Sampled_AdobeStock_1313726087_Charoen.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 17 Oct 2026 05:05:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Danaher, Nvidia, Combine, Lab, Instrumentation, and, Advance, Autonomous, Science</media:keywords>
<content:encoded><![CDATA[<p><span>Recently, Danaher announced a collaboration with Nvidia that the company says is aimed at advancing autonomous science to support new discoveries. The company described the partnership as part of broader efforts to help shape the future artificial intelligence-enabled science. </span></p>
<p><span>Under the terms of the agreement, the companies are working to combine Danaher’s scientific instrumentation, automation technologies, laboratory workflow software, and domain expertise with Nvidia’s accelerated computing and AI technologies. According to the company, the combined tools will help scientists move faster from prediction to experimental evidence by creating a learning cycle where experiments inform models and models help design better experiments.</span></p>
<p><span>Currently, Danaher and Nvidia are working to integrate AI into scientific instruments through edge computing like NVIDIA DGX Spark, accelerated analytics and data processing with RAPIDS, as well as real-time inference, scientific reasoning and foundation model technologies, including BioNeMo Open Models. Initial efforts are focused on a select group of priority instruments, with the potential to expand across a broader portfolio over time. </span></p>
<p><span>“We are collaborating around a shared vision for more connected, adaptive and accessible innovation, helping researchers solve consequential challenges and translate discovery into human impact,” said Julie Sawyer Montgomery, Danaher’s president and CEO. </span></p>
<p><span>In her comments, Kimberly Powell, vice president of healthcare at Nvidia noted that the partnership is “bringing accelerated computing and physical AI into the lab— connecting models with instruments and real experimental data, where experiments improve models and models design better experiments, helping researchers compress years of discovery into months.” </span></p>
<p><span>Earlier this month, Danaher announced plans to launch its first AI-powered autonomous lab, which is designed to help scientists develop custom antibodies and other molecular tools faster and more efficiently. The company said at the time that the planned lab will combine AI, robotics, and technologies from several Danaher operating companies in one connected workflow. Danaher also said at the time that the lab is part of a broader internal program to build a fleet of smart instruments that among other things are easy to integrate and control programmatically and include agentic systems designed to simplify operations, improve data quality, and generate deeper insights. </span></p>
<p>The post <a href="https://www.genengnews.com/topics/artificial-intelligence/danaher-nvidia-combine-lab-instrumentation-and-ai-to-advance-autonomous-science/">Danaher, Nvidia Combine Lab Instrumentation and AI to Advance Autonomous Science</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>ASHG 2026 Awards Honor Achievements in Research, Education, and More</title>
<link>https://edusehat.com/en/ashg-2026-awards-honor-achievements-in-research-education-and-more</link>
<guid>https://edusehat.com/en/ashg-2026-awards-honor-achievements-in-research-education-and-more</guid>
<description><![CDATA[ ASHG will honor seven recipients with its 2026 Professional Awards, recognizing outstanding contributions to human genetics and genomics research, education, mentorship, and public service at ceremonies this week.
The post ASHG 2026 Awards Honor Achievements in Research, Education, and More appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GettyImages-2235551856.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 17 Oct 2026 01:30:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>ASHG, 2026, Awards, Honor, Achievements, Research, Education, and, More</media:keywords>
<content:encoded><![CDATA[<p>One of the highlights of the annual American Society of Human Genetics (ASHG) meeting are the awards. Indeed, last year, Julianna LeMieux, PhD, <em>GEN</em>‘s Deputy Editor in Chief, covered the <a href="https://www.genengnews.com/topics/omics/eric-green-receives-ashg-leadership-award-to-standing-ovation/" target="_blank" rel="noopener">award ceremony and acceptance speech</a> by Eric Green, MD, PhD, for the Leadership Award, that brought the house down.</p>
<p>This year, ASHG is pleased to recognize seven recipients of its 2026 Professional Awards for their outstanding achievements in human genetics and genomics research, education, mentorship, and public service. Award winners will be recognized during ceremonies at the meeting later this week.</p>
<p>“ASHG is honored to recognize this exceptional group of awardees, whose work demonstrates the many ways human genetics and genomics can advance science and serve society,” said Susan A. Slaugenhaupt, PhD, ASHG President. “Each honoree has helped shape a stronger, more collaborative, and more impactful field. Their achievements inspire our community and reflect the promise of genetics to improve lives around the world.”</p>
<p><strong>ASHG Lifetime Achievement Award</strong></p>
<p>Yusuke Nakamura, MD, PhD: The ASHG Lifetime Achievement Award recognizes substantial and far-reaching scientific contributions to human genetics. Nakamura is the President of the National Institutes of Biomedical Innovation, Health and Nutrition in Japan. His career reflects the extraordinary power of sustained scientific inquiry to transform a field. From pioneering highly polymorphic Variable Number Tandem Repeat (VNTR) markers that helped launch the positional cloning era, to identifying disease genes and illuminating the genetic foundations of cancer, Nakamura has repeatedly expanded what is possible in human genetics, immunogenomics, and genomics research. His landmark contributions to <em>APC</em> and colorectal cancer genetics helped shape modern molecular oncology, while his work on inherited disorders and complex traits broadened understanding of how genetic variation influences human health. Through leadership in the International HapMap Project, early genome-wide association studies, and the creation of BioBank Japan, he helped build the global infrastructure for precision medicine. As a scientist, mentor, and visionary leader, Nakamura’s legacy continues to inspire discovery and improve human health worldwide.</p>
<p><strong>ASHG Leadership Award</strong></p>
<p>Aravinda Chakravarti, PhD: The ASHG Leadership Award recognizes leadership and vision in advancing the ASHG mission through promotion of genetics and genomics knowledge into the broader scientific community. Chakravarti is the Director of the Center for Human Genetics and Genomics, Professor of Medicine, and the Muriel G. & George W. Singer Professor of Neuroscience at the New York University Grossman School of Medicine in New York. Chakravarti has profoundly shaped modern human genetics through foundational contributions to population genetics, statistical genetics, linkage disequilibrium mapping, and the study of complex disease. His work helped identify the genetic mutation involved in cystic fibrosis, advanced understanding of Hirschsprung disease as a model for complex disease, and demonstrated the importance of non-coding genetic variation in human disorders. As a former ASHG president, founding editor of leading genomics publications, and leader in major international initiatives including the Human Genome Project, HapMap, and 1000 Genomes Project, Chakravarti has helped build the knowledge, methods, and collaborations that continue to move genetics and genomics forward.</p>
<p><strong>ASHG Scientific Achievement Award</strong></p>
<p>Wendy Chung, MD, PhD: The ASHG Scientific Achievement Award recognizes remarkable contributions to human genetics and genomics research over the last decade. Chung is Chief of Pediatrics at Boston Children’s Hospital and the Mary Ellen Avery Professor of Pediatrics at Harvard Medical School in Boston. An internationally recognized leader in genomic medicine, she has made discoveries that span congenital anomalies, autism and other neurodevelopmental disorders, cardiopulmonary conditions, metabolic disease, obesity, diabetes, and rare Mendelian disorders. She has helped identify more than 60 new genes for human disease and has led major collaborative efforts that bring together clinicians, researchers, patients, and families to answer urgent scientific and clinical questions. Her work has moved gene discovery from the laboratory into clinical care, shaping genetic diagnosis, population-based screening, newborn sequencing, and emerging therapeutic approaches. Through scientific breadth, translational vision, and patient-centered leadership, Chung has profoundly advanced the field of human genetics.</p>
<p><strong>ASHG Early Career Award</strong></p>
<p>Rebecca Ahrens-Nicklas, MD, PhD: The ASHG Early Career Award recognizes early career independent investigators whose work has had a significant impact on the field of human genetics. Ahrens-Nicklas is an Associate Professor of Pediatrics in the Division of Human Genetics and Metabolism at Children’s Hospital of Philadelphia (CHOP) and the University of Pennsylvania and directs the Gene Therapy for Inherited Metabolic Diseases Program at CHOP in Philadelphia. She is leading a new era of precision medicine, advancing a future where a rare disease diagnosis could lead to a treatment path. Her work to develop and deliver the world’s first personalized <em>in vivo</em> CRISPR therapy for an infant with a severe, ultra-rare disease demonstrated the power of collaboration and the extraordinary potential of individualized genetic medicines. Today, she continues to develop custom therapies for patients with rare diseases, redefining what precision genomic medicine can achieve.</p>
<p><strong>ASHG Advocacy Award</strong></p>
<p>Roxanne Khamsi: The ASHG Advocacy Award honors excellence and achievement in promoting the science of human genetics and its application to the common good. Roxanne Khamsi is a contributing writer at <em>The Atlantic.</em> She has spent more than two decades illuminating the intersection of genetics, medicine, and human experience as a reporter, editor, and science journalist whose work has appeared in <em>WIRED</em> magazine, <em>Scientific American</em>, and <em>The New York Times</em>. She brings clarity, curiosity, and compassion to some of the most complex stories in science, including the diagnosis and treatment odyssey for patients with rare diseases, breaking stories on the genetic mechanisms of COVID, and challenging outdated classifications and models in medical genetics. Her new book, <em>Beyond Inheritance</em>, challenges reductive views of genetic mutations as purely harmful. With the rigor of a journalist and the humanity of a storyteller, she makes science accessible without flattening its nuance.</p>
<p><strong>ASHG Education Award</strong></p>
<p>Robbee Wedow, PhD: The ASHG Education Award recognizes outstanding contributions to human genetics education. Wedow is an Assistant Professor of Sociology and Data Science at Purdue University in West Lafayette, Ind. He is recognized for helping students see genetics—and one another—with greater clarity, curiosity, and care. As co-investigator and instructor of the <a href="https://www.wedowlab.com/humane-genetics-curriculum-hgc" target="_blank" rel="noopener">Humane Genetics Curriculum</a> (HGC), he has shaped a powerful learning experience that helps students understand human genetic variation, the complex roots of human traits, and the difference between what genetic evidence can—and cannot—support. Together with Brian Donovan, PhD, the developer of HGC, they have reached thousands of students in hundreds of classrooms nationwide, from middle school through undergraduate education. HGC gives educators a practical, scientifically precise framework for discussing race, ancestry, and genetics in today’s world. Grounded in discussion, critical inquiry, and mutual respect, Wedow’s teaching has prepared future leaders in his classrooms in medicine, law, public policy, and beyond to use genetics knowledge with both scientific rigor and social responsibility.</p>
<p><strong>ASHG Mentorship Award</strong></p>
<p>Nancy B. Spinner, PhD: The ASHG Mentorship Award recognizes ASHG members who have shown a sustained pattern of exemplary mentorship at the graduate student, postdoctoral, residency, or fellowship level. Spinner recently joined Northwell Health in New York as Associate Chair of Genomic Strategy and Faculty Development in the Department of Pathology. Her move to Northwell follows a 35-year career at the Children’s Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania in Philadelphia where she is now Emeritus Professor of Pathology. She has built a career defined not only by scientific excellence, but by the people she has helped succeed. Spinner was often ahead of the trends in her approach to mentorship, educating her trainees in translational science, and pairing rigorous training with thoughtful, individualized career development. She has trained more than 23 laboratory directors and scientists, all still active in the field, along with fellows, graduate students, undergraduates, and high school students, many of whom have advanced to faculty roles. Through association mentorship programs, service on committees, lectures, and career panels, Spinner creates the kind of collegial, generous environment where people stay, grow, and lead. Her gift is seeing each mentee clearly—and guiding them toward work aligned with their talents, accomplishments, and long-term best interests.</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/ashg-2026-awards-honor-achievements-in-research-education-and-more/">ASHG 2026 Awards Honor Achievements in Research, Education, and More</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Exposure to Common Endocrine&#45;Disrupting Chemicals May Alter Normal Breast Development</title>
<link>https://edusehat.com/en/exposure-to-common-endocrine-disrupting-chemicals-may-alter-normal-breast-development</link>
<guid>https://edusehat.com/en/exposure-to-common-endocrine-disrupting-chemicals-may-alter-normal-breast-development</guid>
<description><![CDATA[ A study in human breast organoids has found that exposure to some common endocrine-disrupting chemicals may lead to molecular changes in breast tissue that could influence susceptibility to breast cancer later in life. 
The post Exposure to Common Endocrine-Disrupting Chemicals May Alter Normal Breast Development appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_261012_organoid.jpg.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 17 Oct 2026 01:30:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Exposure, Common, Endocrine-Disrupting, Chemicals, May, Alter, Normal, Breast, Development</media:keywords>
<content:encoded><![CDATA[<p>The results of a preclinical study by researchers at Tufts University School of Medicine and at Boston University suggest that exposure to some common chemicals—particularly multiple bisphenols at once—may alter how normal human breast tissue develops. Findings from the study using human breast organoids suggest that such exposures may lead to molecular changes in breast tissue that could influence susceptibility to breast disease later in life.</p>
<p>The results lay the groundwork for scientists to investigate whether these molecular changes persist in human tissues, contribute to disease later in life, and could yield biomarkers to help assess breast cancer risk. “If these results are validated by additional studies, they could change how we think about cancer prevention,” said Charlotte Kuperwasser, PhD, a professor of developmental, molecular, and chemical biology at Tufts University School of Medicine. Kuperwasser is senior corresponding author of the team’s published paper in <em>PNAS</em>, titled “<a href="http://dx.doi.org/10.1073/pnas.2613054123" target="_blank" rel="noopener">Environmental chemical mixtures reprogram mammary epithelial development to epigenetic states associated with breast cancer</a>.” The study’s co-first authors are Meadow Parrish and Meloryn Seraj, both PhD students in genetics, molecular, and cellular biology at Tufts Graduate School of Biomedical Sciences.</p>
<p>A growing body of research has raised questions about whether exposure to endocrine-disrupting chemicals—substances that can interfere with the body’s hormones—may contribute to breast cancer risk. “Endocrine-disrupting chemicals (EDCs) are pervasive contaminants in air, water, food, and consumer products, and human exposure to these agents begins in utero and continues throughout life,” the authors wrote. “A growing body of epidemiologic and experimental evidence suggests that developmental exposure to EDCs may contribute to the rising incidence of hormone-sensitive cancers, including breast cancer, in young women.” However, much of what scientists know about how chemicals affect breast tissue comes from animal models or laboratory-grown cells that cannot fully reproduce the complexity of human tissue.</p>
<p>“The breast also is unusual in that it undergoes major developmental changes well after birth, including during puberty and pregnancy,” said Kuperwasser. “And the concern is that breast tissue cells may be highly sensitive to environmental cues, such as chemical exposure, during critical windows of mammary gland development.”</p>
<p>To better capture this complexity, the researchers used three-dimensional breast organoids, grown from breast tissue donated by 13 healthy young women. The organoids contain multiple types of breast cells and can reproduce some aspects of how human breast tissue actually develops.</p>
<p>As the organoids developed over about three weeks, the researchers exposed them to a panel of individual chemicals and mixtures, including endocrine-disrupting chemicals, chemicals that affect metabolism, and known or suspected carcinogens. They then analyzed molecular changes, including changes in gene activity and DNA modifications. “… we developed an AI-assisted 3D human breast organoid high-content screening (3D-HCS) platform capable of quantitatively measuring developmental disruption and morphogenetic alterations across organoids exposed to chemicals,” they explained.</p>
<p>The results indicated that different chemicals affected tissue development in different ways, but the most striking finding involved three common bisphenols: BPA, BPS, and BPF. Individually, the chemicals produced relatively few changes in the organoids. But when combined at very low concentrations—comparable to levels detected in human blood and urine—the mixture of BPA, PBS and BPF disrupted normal breast development in organoids from most of the donors.</p>
<p>“Focusing on bisphenols, we show that a low-dose mixture (BPA, BPS, and BPF; 3BPX) disrupts organoid development and induces transcriptional programs characterized by extracellular matrix remodeling, epithelial plasticity, and partial epithelial–mesenchymal transition, accompanied by widespread DNA methylation remodeling.”</p>
<p>Kuperwasser added, “We intentionally used concentrations of chemicals that were relevant to real-world exposure rather than the very high doses sometimes used in toxicology studies. We also tested a mixture of these because people are typically exposed to multiple chemicals at the same time.”</p>
<p>The team then compared the molecular changes associated with the bisphenol mixture with molecular data from human breast cancers. The exposure-associated pattern was most strongly represented in data from patients with invasive lobular carcinoma—a type of breast cancer that may not cause a detectable lump and can be difficult to detect with a mammogram. “We identify conserved, exposure-induced transcriptional signatures as well as DNA methylation fingerprints that mirror patterns detectable in human breast cancers, suggesting that developmental exposures may leave durable molecular fingerprints that create cancer-relevant tissue states,” they concluded.</p>
<p>The finding does not establish that the chemicals cause cancer or show how the observed molecular changes might contribute to breast disease. Instead, the researchers say the work demonstrates a new way to study how environmental exposures may affect normal human tissue before cancer develops.</p>
<p>“Historically, we have thought about cancer risk largely in terms of inherited mutations, lifestyle factors, and exposures that directly damage DNA,” said Kuperwasser. “These findings raise another possibility: Environmental exposures may subtly alter how normal tissues develop, leaving behind molecular changes that do not cause cancer by themselves but may make the tissue more permissive to cancer many years later.”</p>
<p>She noted that such persistent molecular changes could eventually serve as a kind of biological record—like a “scar” of past exposure. If validated in people, such a marker could potentially help identify individuals at higher risk and inform earlier or more targeted screening.</p>
<p>Future studies involving larger and more diverse groups of donors, as well as a broader range of chemicals and mixtures, are needed to determine how widely the findings apply and if molecular changes observed in organoids are associated with breast disease in people.</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/exposure-to-common-endocrine-disrupting-chemicals-may-alter-normal-breast-development/">Exposure to Common Endocrine-Disrupting Chemicals May Alter Normal Breast Development</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Designing the Ecosystem for CGT Success</title>
<link>https://edusehat.com/en/designing-the-ecosystem-for-cgt-success</link>
<guid>https://edusehat.com/en/designing-the-ecosystem-for-cgt-success</guid>
<description><![CDATA[ This proceedings eBook, developed in partnership with GEN and Cincinnati Children’s Hospital Applied Gene and Cell Therapy Center, captures perspectives and lessons from The Cell Summit ’26 and extends the conversation beyond the meeting itself.
The post Designing the Ecosystem for CGT Success appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/BioLife-Cover-Art.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 17 Oct 2026 01:30:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Designing, the, Ecosystem, for, CGT, Success</media:keywords>
<content:encoded><![CDATA[<div aria-hidden="true" class="wp-block-spacer"></div>


<p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Read Now</button></p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>


<h3 class="wp-block-heading"><strong>Preserving the Promise: Insights from The Cell Summit ’26</strong></h3>


<p class="wp-block-paragraph">In July 2026, BioLife Solutions welcomed leaders from across the cell and gene therapy (CGT) space to Cincinnati, Ohio for the second annual Cell Summit. Once again, our goal was simple: bring together people with different perspectives, from across the CGT ecosystem, to create an environment where we could speak openly about the challenges standing between scientific innovation and successful patient treatment. </p>


<p class="wp-block-paragraph">Cell and gene therapy has already demonstrated what is scientifically possible. CAR T therapies, gene therapies, and other advanced medicines have delivered outcomes that would have been unimaginable only a generation ago. </p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>


<h4 class="wp-block-heading"><strong>The next challenge is scale.</strong> </h4>


<figure class="wp-block-image alignright size-medium"><img fetchpriority="high" decoding="async" width="232" height="300" src="https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Biolife_Cover-232x300.jpg" alt="BioLife October 2026 eBook Cover" class="wp-image-339381" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Biolife_Cover-232x300.jpg 232w, https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Biolife_Cover-791x1024.jpg 791w, https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Biolife_Cover-768x994.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Biolife_Cover-1187x1536.jpg 1187w, https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Biolife_Cover.jpg 1200w" sizes="(max-width: 232px) 100vw, 232px"></figure>


<p class="wp-block-paragraph">Mature healthcare industries demonstrate what coordinated scale can look like. Vaccines can be manufactured and distributed globally at enormous volumes. Insulin is produced continuously and reliably for millions of patients. These industries did not reach that scale through manufacturing capacity alone. They developed interconnected systems of production, supply, distribution, clinical delivery, reimbursement, infrastructure, standards, and oversight that work together repeatedly and predictably. </p>


<h4 class="wp-block-heading"><strong>CGT is still building that system.</strong></h4>


<p class="wp-block-paragraph">As Steven Thompson challenged attendees with his welcome address at The Cell Summit, the question is no longer simply whether these therapies can work. The question is whether the industry can build a system that reliably converts scientific proof into patient access, delivered doses, durable outcomes, and ultimately a sustainable commercial model. </p>


<p class="wp-block-paragraph">That question became the foundation for the conversations that followed. </p>


<p class="wp-block-paragraph">Scientists, therapy developers, clinicians, treatment centers, technology providers, manufacturing experts, and other industry leaders examined the CGT pathway from multiple angles. On the second day of the meeting, eight roundtable groups explored real-world challenges spanning scale-up, scale-out, logistics, manufacturing readiness, CDMO partnerships, commercialization strategy, rare disease reimbursement, and public perception. </p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>


<p class="wp-block-paragraph">Although each group approached their problems from different perspectives, the discussion repeatedly arrived at the same conclusion: scale is an operating system, not a single workstream. </p>


<p class="wp-block-paragraph">Manufacturing, reimbursement, care delivery, logistics, partnerships, data, governance, evidence, and trust are interdependent. An eligible patient must be identified and referred. A product must be collected or manufactured. A dose must reach the treatment center at the right time and in the right condition. The patient must be able to receive treatment. The therapy must deliver the intended outcome. And the economics must support doing it again for the next patient. </p>


<h4 class="wp-block-heading"><strong>If one link breaks, patients wait and the commercial model weakens.</strong> </h4>


<p class="wp-block-paragraph">A manufacturer may successfully release a product, but if the treatment center is not ready, the patient still waits. A treatment center may be prepared, but if reimbursement is unresolved, treatment may not proceed. A therapy may demonstrate remarkable clinical benefit, but if manufacturing, logistics, infrastructure, or economics cannot support repeatable delivery, that scientific success will struggle to reach its full potential. </p>


<p class="wp-block-paragraph">The opposite is equally true. </p>


<h4 class="wp-block-heading"><strong>When the links connect, more appropriate patients can receive treatment, delivery becomes more predictable, resources are used more efficiently, and the commercial model becomes sustainable.</strong> </h4>


<p class="wp-block-paragraph">This is the opportunity in front of CGT: not simply to optimize each individual function, but to design the interfaces between them. </p>


<p class="wp-block-paragraph">This proceedings eBook, developed in partnership with GEN (Genetic Engineering & Biotechnology News) and Cincinnati Children’s Hospital Applied Gene and Cell Therapy Center, captures perspectives and lessons from The Cell Summit ’26 and extends the conversation beyond the meeting itself. It brings together scientific, clinical, manufacturing, and operational viewpoints around a common question: What must be true for CGT to move from scientific possibility to repeatable, sustainable delivery? </p>


<p class="wp-block-paragraph">The first Cell Summit (in 2025) asked how we could work together to improve the development and delivery of cell therapies. This year reinforced that collaboration is not simply beneficial to CGT advancement; it is fundamental to it. </p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>


<h4 class="wp-block-heading"><em><strong>A therapy is not successful when it leaves the manufacturing site. It is successful when it reaches and helps the patient, as intended.</strong> </em></h4>


<p class="wp-block-paragraph">We hope these proceedings encourage continued discussion, challenge conventional thinking, and help our community design the CGT ecosystem as deliberately as we design the therapies themselves. </p>


<p class="wp-block-paragraph">Thank you to our speakers, roundtable leads, attendees, and partners who shared their expertise, challenged assumptions, and made The Cell Summit ’26 possible. </p>

<p>The post <a href="https://www.genengnews.com/resources/ebooks/designing-the-ecosystem-for-cgt-success/">Designing the Ecosystem for CGT Success</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Floridians and health advocates rally to oppose school, daycare vaccine changes</title>
<link>https://edusehat.com/en/floridians-and-health-advocates-rally-to-oppose-school-daycare-vaccine-changes</link>
<guid>https://edusehat.com/en/floridians-and-health-advocates-rally-to-oppose-school-daycare-vaccine-changes</guid>
<description><![CDATA[ BIO voices concerns in statement for hearing about potential rule change. Reducing the number of vaccines required for school children risks the spread of […]
The post Floridians and health advocates rally to oppose school, daycare vaccine changes appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/10/mother-at-fla-hearing-sharpen.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 16 Oct 2026 21:45:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Floridians, and, health, advocates, rally, oppose, school, daycare, vaccine, changes</media:keywords>
<content:encoded><![CDATA[<h4>BIO voices concerns in statement for hearing about potential rule change.</h4>
<p><span>Reducing the number of vaccines required for school children risks the spread of dangerous, preventable diseases, concerned Floridians and public health advocates told a Florida Department of Health (FDOH) panel hearing on Oct. 8.</span></p>
<p><span>The </span><a href="https://www.floridahealth.gov/2026/10/08/florida-department-of-health-holds-public-hearing-on-proposed-revisions-to-school-immunization-rule/"><span>hearing</span></a><span> allowed public input into FDOH’s proposed rule change to eliminate requirements for four of the current 11 vaccines students need to enter public schools and daycare.</span></p>
<p><span>The new rule would mean the hepatitis B, varicella (chickenpox), haemophilus influenzae type b (Hib), and pneumococcal conjugate vaccines would no longer be required for students entering public school or child care programs,</span><a href="https://www.floridahealth.gov/2026/10/08/florida-department-of-health-holds-public-hearing-on-proposed-revisions-to-school-immunization-rule/"> <span>FDOH explains.</span></a><span> Immunization for polio, diphtheria, measles, rubella, pertussis, mumps, and tetanus would still be required.</span></p>
<p><span>The Biotechnology Innovation Organization (BIO) provided written comments to the hearing urging FDOH to maintain its current vaccine requirements.</span></p>
<p><span>“We are deeply concerned that the proposed changes, if enacted, will decrease immunization coverage in Florida and leave many vulnerable to preventable infectious diseases,” BIO wrote. “Vaccination requirements have been instrumental in reducing, and in some cases eliminating deadly diseases. Removing these requirements would reverse decades of scientific and public health progress without evidence-based justification.”</span></p>
<p><span>While the hearing featured many speakers against the proposal and many in favor of it, the overall majority of Floridians oppose the proposed rule and want to keep vaccine requirements as they are,</span><a href="https://www.flfamiliesforvaccines.org/polling"> <span>according to a poll commissioned by Florida Families for Vaccines</span></a><span>. Of the 1,000 likely voters polled by McLaughlin & Associates, 79%—including 71% of registered Republicans—support Florida’s long-standing school entry vaccine requirements.</span></p>
<h2>What they said at the hearing</h2>
<p><span>Speakers who urged against changing the vaccine schedule represented a wide range of viewpoints.</span></p>
<p><span>Evelyn, a 7-year-old cancer survivor, described the importance of her classmates being vaccinated.</span></p>
<p><span>“The chemo broke my immune system. I had to stay away from sick people because their germs could hurt me really bad. I was so happy to go back to school. I missed my friends,” Evelyn said. “Mommy and Daddy knew I would be safe because everybody got their vaccine shots when I couldn’t.”</span></p>
<p><span>Evelyn’s father, Kyle Huneycutt, said his daughter’s diagnosis changed how his family saw the world. “The health of the community around your child matters in a way you may have never considered before,” he explained.</span></p>
<p><span>The patient’s family view was also represented by Donielle Deitz, a caregiver and a volunteer for the American Cancer Society’s Cancer Action Network (ACS CAN), who urged maintaining “evidence-based school immunization requirements.”</span></p>
<p><span>“Childhood vaccines protect people with cancer,” she said, noting that the hepatitis B vaccine FDOH would remove from the requirements “is a powerful cancer prevention tool” against liver cancer.</span></p>
<p><span>Medical professionals also spoke of the risks of changing the vaccination schedule, which may give the impression that some vaccines are less important.</span></p>
<p><span>Angela Moore, a registered nurse, said she had witnessed what can happen when families decide against protecting their children.</span></p>
<p><span>“We have seen children whose parents have denied them safe and effective vaccines be afflicted by diseases that my generation and the generation before me had the luxury of protection from, due to herd immunity,” she said.</span></p>
<p><span>Donald Neel, MD, a pediatrician, recalled the times before the four vaccines were available. “I spent many hours of my life and parents’ lives, holding their hands and praying for their child, who was critically ill with either pneumococcal pneumonia or the various types of meningitis,” he said.</span></p>
<p><span>Many speakers represented the parents’ perspective in opposing the proposed rule.</span></p>
<p><span>“We want to send our children to schools and daycare and not have to worry about preventable diseases,” said Cass Miller of</span><a href="https://www.flfamiliesforvaccines.org/"> <span>Florida Families for Vaccines</span></a><span>. “For families, an outbreak is not just a statistic; it means missing childcare, a parent missing work, or staying away from grandparents because someone has been exposed.”</span></p>
<p><span>Shelly Pedraza, President Elect of</span><a href="https://www.floridapta.org/"> <span>the Florida PTA</span></a><span>, which includes about 200,000 parents, said “Florida PTA opposes the removal of these vaccine requirements,” because parents are concerned about the health risks.</span></p>
<p><span>Those representing teachers said they and their families would be put at risk if vaccination rates drop at their workplace.</span></p>
<p><span>Giving the business perspective, Karen van Caulil, president and CEO of the</span><a href="https://flhealthvalue.org/"> <span>Florida Alliance for Healthcare Value</span></a><span>, noted that employers pay for many health insurance plans, and also suffer when parents are absent for child care.</span></p>
<p><span>“When preventable illness leads to additional doctor visits, emergency care or hospitalization, those costs are felt by families and employers alike,” she said. “That is why employers have a direct and practical interest in policies that help keep children and communities healthy.”</span></p>
<h2>The ‘parents rights’ argument</h2>
<p><span>Those speaking in favor of the rule mostly spoke of the right for parents to make their own decisions, vaccine-related injuries (which occur rarely but are eligible to submit federal remuneration through the Vaccine Injury Compensation Program (VICP)), and unscientific theories on vaccine safety.</span></p>
<p><span>Florida Surgeon General Joseph Ladapo, MD, who has championed the rule change and led the hearing, stressed that there were no questions about the safety and effectiveness of the four vaccines that his new rule would eliminate. Ladapo repeatedly explained that the only reason for the rule change was to increase parents’ right to choose for their children.</span></p>
<p><span>BIO and others noted that Florida already allows for religious and medical exemptions to school vaccine requirements.</span></p>
<p><span>“Current standards ensure that individual choice is protected while maintaining the greatest access to vaccines for those who wish to take them,” said BIO’s letter. “Further loosening the requirements does not impact an individual’s right to choose vaccination or not, it jeopardizes broader immunity levels and increases the likelihood of outbreaks.”</span></p>
<p><span>Ladapo also said other states do not require school children to have some of the vaccines that Florida would cancel. But no state excludes all four vaccines.</span></p>
<p><a href="https://www.immunize.org/official-guidance/state-policies/vaccine-requirements/hepb-child-school-2026/"><span>Every state except for Alabama</span></a><span> requires hepatitis B vaccines, and</span><a href="https://www.immunize.org/official-guidance/state-policies/vaccine-requirements/hib-childcare-2026/"> <span>West Virginia is the only state</span></a><span> that doesn’t mandate a Hib vaccine, according to</span><a href="https://www.immunize.org/"> <span>immunize.org</span></a><span>. Seven states do not require a</span><a href="https://www.immunize.org/wp-content/uploads/laws/pcv-cc-rqt-map-2026.pdf"> <span>pneumococcal vaccine</span></a><span>.</span></p>
<p><span>As of now, all states require children entering public school and daycare to have the chickenpox vaccine, which also helps protect against meningitis, and</span><a href="https://www.epicresearch.org/articles/first-birth-cohort-eligible-for-chickenpox-vaccine-had-a-sharp-drop-in-shingles-cases/"> <span>according to a new study</span></a><span>, prevents later episodes of shingles.</span></p>
<p><i><span>FDOH is accepting comments on the rule proposal by email at </span></i><a href="mailto:vaccinerule@flhealth.gov"><i><span>vaccinerule@flhealth.gov</span></i></a><i><span> until 5 pm on Oct. 19.</span></i></p>
<p>The post <a href="https://bio.news/state-policy/floridians-health-care-advocates-turn-out-to-oppose-changing-school-and-daycare-vaccine-requirements/">Floridians and health advocates rally to oppose school, daycare vaccine changes</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Board&#45;Certified Physician Assistant Brittany Joseph Joins Optima’s Stow, OH Practice</title>
<link>https://edusehat.com/en/board-certified-physician-assistant-brittany-joseph-joins-optimas-stow-oh-practice</link>
<guid>https://edusehat.com/en/board-certified-physician-assistant-brittany-joseph-joins-optimas-stow-oh-practice</guid>
<description><![CDATA[ Brittany Will Deliver Expert Medical Dermatology Care to Patients of All Ages  Board-Certified Physician Assistant Brittany Joseph, PA-C, RDMS, RVT,…
The post Board-Certified Physician Assistant Brittany Joseph Joins Optima’s Stow, OH Practice appeared first on Optima Dermatology. ]]></description>
<enclosure url="https://optimadermatology.com/wp-content/uploads/2026/10/Blog_Meet-Brittany-Joseph_Square.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 16 Oct 2026 21:40:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Board-Certified, Physician, Assistant, Brittany, Joseph, Joins, Optima’s, Stow, Practice</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"><img fetchpriority="high" decoding="async" width="1024" height="341" src="https://optimadermatology.com/wp-content/uploads/2026/10/Blog_Meet-Brittany-Joseph_Banner-1024x341.jpg" alt="" class="wp-image-205812" srcset="https://optimadermatology.com/wp-content/uploads/2026/10/Blog_Meet-Brittany-Joseph_Banner-1024x341.jpg 1024w, https://optimadermatology.com/wp-content/uploads/2026/10/Blog_Meet-Brittany-Joseph_Banner-300x100.jpg 300w, https://optimadermatology.com/wp-content/uploads/2026/10/Blog_Meet-Brittany-Joseph_Banner-768x256.jpg 768w, https://optimadermatology.com/wp-content/uploads/2026/10/Blog_Meet-Brittany-Joseph_Banner.jpg 1200w" sizes="(max-width: 1024px) 100vw, 1024px"></figure>



<h2 class="wp-block-heading"><strong>Brittany Will Deliver Expert Medical Dermatology Care to Patients of All Ages</strong> </h2>



<p class="wp-block-paragraph">Board-Certified Physician Assistant <a href="https://optimadermatology.com/provider/brittany-joseph-pa-c-rdms-rvt" target="_blank" rel="noopener">Brittany Joseph</a>, PA-C, RDMS, RVT, is joining Optima Dermatology’s Stow, OH practice, where she will deliver expert skin care treatment to patients of all ages.  </p>



<p class="wp-block-paragraph">Brittany treats a variety of skin conditions, including acne, eczema, psoriasis, and skin cancer, and has been providing dermatology services to patients in the Cleveland region since 2017. </p>



<p class="wp-block-paragraph">Inspired by her own challenges with acne and eczema in high school and college, Brittany pursued a career in medical care, receiving her Bachelor of Radiologic and Imaging Sciences in Diagnostic Medical Sonography from Kent State University, and her Master of Physician Assistant Studies from Baldwin Wallace University, both in Ohio.  </p>



<p class="wp-block-paragraph"> <br>She has gone on to become a member of the Ohio Academy of Physician Assistants, the American Academy of Physician Assistants, the Society of Dermatology Physician Assistants, the Society of Diagnostic Medical Sonography, and the American Registry for Diagnostic Medical Sonography.  </p>



<h2 class="wp-block-heading"><strong>Continuing a Commitment to Care in Ohio</strong> </h2>



<p class="wp-block-paragraph">With this move to Optima Dermatology’s Stow practice, Brittany is excited for the opportunity to continue serving patients in Ohio. She delivers uncompromising care rooted in the same philosophy practiced by all Optima providers: treating our patients the way we would treat our family and friends.  </p>



<p class="wp-block-paragraph">We recently had the opportunity to learn more about Brittany, her approach, and the path that led her to become a board-certified physician assistant. </p>



<hr class="wp-block-separator has-alpha-channel-opacity">



<h3 class="wp-block-heading"><strong>What made you decide to pursue a career in dermatology? What did the path to get there look like for you?  </strong> </h3>



<p class="wp-block-paragraph">I first encountered the dermatology field when I was struggling with acne and eczema throughout high school and college. I had such a great experience and always felt like the providers truly cared and helped with my skin issues. I started my career in health care as an ultrasound technologist, but after about 4 years, I decided to further my education and applied for PA school. I did some shadowing in dermatology and a dermatology rotation that really sparked my interest. I loved the variety of skin conditions, the procedures, and the autonomy the providers had. After becoming a board-certified physician assistant, I found it difficult to find a dermatology position that didn’t require prior experience in the field, so I decided to pursue a career in emergency medicine. I practiced emergency medicine for 5 years before joining a dermatology practice in 2022. I have since built a diverse medical and procedural foundation through my experiences in emergency medicine, and I love building lasting relationships with patients while helping them navigate their skin health. </p>



<h3 class="wp-block-heading"><strong>What is your favorite aspect of being a board-certified physician assistant?</strong> </h3>



<p class="wp-block-paragraph">I appreciate the solid, diverse medical foundation we receive in school and the ability to treat patients of all ages and medical specialties. I also love the autonomy and confidence I’ve achieved over the years working in several different fields. </p>



<h3 class="wp-block-heading"><strong>What is your approach to treating your patients?</strong> </h3>



<p class="wp-block-paragraph">I always take a shared decision-making approach when treating my patients; I want them to feel heard and have a say in their treatment. I also want my patients to understand their diagnosis and feel comfortable with the treatment plan.  </p>



<h3 class="wp-block-heading"><strong>What is your number one tip for taking care of your skin?</strong> </h3>



<p class="wp-block-paragraph">My number one skin care tip is to use products for sensitive skin: a gentle wash, moisturizer, and sunscreen. More is not always better, especially considering the cost of skin care products.  </p>



<h3 class="wp-block-heading"><strong>What is one thing you want your patients to know about you? </strong> </h3>



<p class="wp-block-paragraph">I want patients to know that I truly understand how frustrating and embarrassing it can be to deal with certain skin conditions because I have been on the other side of it. My passion is helping patients feel more comfortable in their skin and regain confidence. </p>



<h3 class="wp-block-heading"><strong>What do you like to do when you are not in the office treating patients?</strong> </h3>



<p class="wp-block-paragraph">Outside of the office, I spend most of my time with my two young children and husband. We love being active and enjoy the outdoors, whether playing in the backyard with our dog, cat, and chickens, camping, fishing, boating, swimming, or skiing. I also love to cook and try out new recipes for the family. </p>



<hr class="wp-block-separator has-alpha-channel-opacity">



<h2 class="wp-block-heading"><strong>What to Expect From Brittany and Her Team</strong> </h2>



<p class="wp-block-paragraph">Patients visiting Brittany and her team at Optima Dermatology’s Stow practice will receive quality care backed by advanced training and experience. </p>



<p class="wp-block-paragraph">Brittany is currently accepting new patients at our Stow, OH practice. To schedule an appointment, call 440-283-3968, or schedule an appointment <a href="https://optimadermatology.com/request-appointment" target="_blank" rel="noopener">online</a>.  </p>
<p>The post <a href="https://optimadermatology.com/2026/10/16/board-certified-physician-assistant-brittany-joseph-joins-optimas-stow-oh-practice">Board-Certified Physician Assistant Brittany Joseph Joins Optima’s Stow, OH Practice</a> appeared first on <a href="https://optimadermatology.com/">Optima Dermatology</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Robotic surgery expands into complex shoulder replacements</title>
<link>https://edusehat.com/en/robotic-surgery-expands-into-complex-shoulder-replacements</link>
<guid>https://edusehat.com/en/robotic-surgery-expands-into-complex-shoulder-replacements</guid>
<description><![CDATA[ Robotic-assisted surgery is moving beyond traditional hip and knee replacements into increasingly complex orthopaedic procedures, with a recent surgical milestone in Australia demonstrating how the technology is expanding into shoulder replacement surgery. Orthopaedic surgeon Dr. Joe Coory recently performed Australia’s first shoulder replacement using Stryker’s fourth-generation Mako robotic-arm system at Maroochy Private Hospital in Queensland. […]
The post Robotic surgery expands into complex shoulder replacements appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/shutterstock_1529764310.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 16 Oct 2026 21:35:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Robotic, surgery, expands, into, complex, shoulder, replacements</media:keywords>
<content:encoded><![CDATA[<p>Robotic-assisted surgery is moving beyond traditional hip and knee replacements into increasingly complex orthopaedic procedures, with a recent surgical milestone in Australia demonstrating how the technology is expanding into shoulder replacement surgery.</p>
<p>Orthopaedic surgeon Dr. Joe Coory recently performed Australia’s first shoulder replacement using Stryker’s fourth-generation Mako robotic-arm system at Maroochy Private Hospital in Queensland.</p>
<p>The procedure involved a reverse total shoulder replacement, a technically demanding operation commonly performed in patients with severe arthritis, significant rotator cuff damage or certain complex fractures.</p>
<p>The achievement highlights how advances in robotics, three-dimensional imaging and surgical planning are expanding the range of procedures that can benefit from computer-assisted precision.</p>
<h3>Moving beyond hips and knees</h3>
<p>Robotic-assisted surgery is increasingly used in hip and knee replacements, helping surgeons plan procedures and position implants according to individual patient anatomy.</p>
<p>Shoulder replacement presents additional challenges.</p>
<p>The shoulder is one of the body’s most mobile joints, with relatively small bone surfaces and considerable anatomical variation. Successful replacement requires precise implant positioning while preserving surrounding bone and soft tissues.</p>
<p>In reverse shoulder replacement, the normal ball-and-socket arrangement is reversed, allowing the deltoid muscle to compensate for a damaged rotator cuff.</p>
<p>Stryker’s Mako technology uses three-dimensional CT imaging to develop a patient-specific surgical plan. During surgery, the robotic arm assists the surgeon with preparing bone and positioning implants according to that plan.</p>
<p>The robot does not operate independently. The surgeon remains in control throughout the procedure.</p>
<p>According to the Australian report, Dr. Coory has performed more than 100 robotic-assisted shoulder replacements using earlier technology since August 2025.</p>
<p>The latest Mako system introduces improvements designed to enhance surgical precision and operating-room workflow.</p>
<h3>Robotic surgery gaining momentum in Canada</h3>
<p>Canadian hospitals are also increasing their use of robotic-assisted orthopaedic surgery.</p>
<p>According to the Canadian Institute for Health Information (CIHI), robotic assistance was used in 3.1 per cent of hip and knee replacements performed in Canada during 2024–2025, compared with just 0.8 per cent in 2022–2023.</p>
<p>While conventional procedures still account for most joint replacements, the figures demonstrate growing adoption of robotic technology.</p>
<p>Canada has also contributed to advances in surgical guidance for complex shoulder procedures.</p>
<p>At St. Joseph’s Health Care London, orthopaedic surgeon Dr. George Athwal has pioneered mixed-reality technology that allows surgeons to visualize three-dimensional shoulder anatomy during surgery.</p>
<p>Using a specialized headset, the technology overlays digital images of the patient’s anatomy and planned implant onto the surgical field, helping guide instrument positioning.</p>
<p>Although mixed-reality guidance differs from robotic-arm surgery, both technologies demonstrate how digital innovation is transforming complex orthopaedic procedures.</p>
<h3>The future of robotic-assisted surgery</h3>
<p>As robotic systems become more sophisticated, their applications are expanding beyond established procedures into surgeries involving increasingly complex anatomy.</p>
<p>For hospitals, these technologies offer the potential for improved surgical planning, greater precision and more personalized procedures.</p>
<p>However, higher accuracy does not automatically translate into better long-term patient outcomes. Further clinical research is needed to determine whether robotic-assisted shoulder replacement improves recovery, reduces complications or extends implant longevity.</p>
<p>Cost, surgeon training and operating-room integration also remain important considerations.</p>
<p>The Australian milestone represents another step in the evolution of surgical robotics and raises the possibility that robotic-assisted shoulder replacements could eventually become more widely available in Canadian hospitals.</p>
<p>The post <a href="https://www.hospitalnews.com/robotic-surgery-expands-into-complex-shoulder-replacements/">Robotic surgery expands into complex shoulder replacements</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Major milestone reached in construction of Nova Scotia’s new QEII hospital tower</title>
<link>https://edusehat.com/en/major-milestone-reached-in-construction-of-nova-scotias-new-qeii-hospital-tower</link>
<guid>https://edusehat.com/en/major-milestone-reached-in-construction-of-nova-scotias-new-qeii-hospital-tower</guid>
<description><![CDATA[ Construction of the 14-storey Halifax Infirmary acute care tower reaches its eighth level, bringing expanded emergency, surgical and specialized hospital services closer to completion. The project is one of Atlantic Canada’s major healthcare infrastructure developments and will expand the capacity of the Halifax Infirmary to deliver emergency, surgical and specialized medical services. According to an […]
The post Major milestone reached in construction of Nova Scotia’s new QEII hospital tower appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/FL_260817_103-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 16 Oct 2026 21:35:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Major, milestone, reached, construction, Nova, Scotia’s, new, QEII, hospital, tower</media:keywords>
<content:encoded><![CDATA[<p>Construction of the 14-storey Halifax Infirmary acute care tower reaches its eighth level, bringing expanded emergency, surgical and specialized hospital services closer to completion.</p>
<p>The project is one of Atlantic Canada’s major healthcare infrastructure developments and will expand the capacity of the Halifax Infirmary to deliver emergency, surgical and specialized medical services.</p>
<p>According to an October 14 announcement from the Government of Nova Scotia, the podium forms the structural foundation of the planned 14-storey tower and will accommodate several essential hospital services.</p>
<h3>Expanding emergency and surgical capacity</h3>
<p>The new facility will include a larger emergency department, modern surgical suites, ambulatory treatment spaces, laboratories, medical device reprocessing facilities and hyperbaric medicine services.</p>
<p>These additions are intended to modernize clinical environments and support the delivery of increasingly complex care at one of the province’s major referral hospitals.</p>
<p>The expansion is also designed to integrate new infrastructure with the existing hospital campus, allowing healthcare services to continue while construction progresses.</p>
<h3>Construction advances toward 2030 completion</h3>
<p>The scale of the project is reflected in the construction activity completed to date.</p>
<p>Crews have excavated approximately 543,000 tonnes of material, poured 54,000 cubic metres of concrete and installed 5,800 tonnes of structural steel and reinforcing bar.</p>
<p>More than one million working hours have been recorded without a lost-time incident, according to Build Nova Scotia.</p>
<p>Another milestone involved installing 22 large concrete girders that will support green space above the tower’s future loading area.</p>
<p>Work to enclose the building began during summer 2026, while installation of electrical infrastructure and other technical systems continues.</p>
<h3>New hospital services planned for 2031</h3>
<p>The project remains scheduled for substantial completion and transfer to Nova Scotia Health in fall 2030.</p>
<p>Following construction, healthcare teams will undertake equipment testing, staff training and operational preparations before the tower opens to patients in fall 2031.</p>
<p>Work planned for 2027 includes installation of mechanical and electrical systems, elevators and permanent electrical power, alongside continued development of the building’s interior spaces.</p>
<h3>Project receives infrastructure award</h3>
<p>The Halifax Infirmary Expansion Project has also received recognition at the 2026 P3 Awards, where it was named Best Social Infrastructure Project.</p>
<p>The award recognizes collaboration among Build Nova Scotia, Nova Scotia Health, the provincial Department of Health and Wellness, and the project’s construction and development partners.</p>
<p>The redevelopment represents a long-term investment in Nova Scotia’s hospital infrastructure, with the objective of increasing capacity, improving clinical environments and supporting the delivery of specialized care for patients throughout the province.</p>
<p>The post <a href="https://www.hospitalnews.com/major-milestone-reached-in-construction-of-nova-scotias-new-qeii-hospital-tower/">Major milestone reached in construction of Nova Scotia’s new QEII hospital tower</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Tigerlily Foundation joining conversation at PACE</title>
<link>https://edusehat.com/en/tigerlily-foundation-joining-conversation-at-pace</link>
<guid>https://edusehat.com/en/tigerlily-foundation-joining-conversation-at-pace</guid>
<description><![CDATA[ The Tigerlily Foundation was born from a promise made in a moment of profound vulnerability.  In 2006, Maimah Karmo was a 32-year-old mother to […]
The post Tigerlily Foundation joining conversation at PACE appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/10/angiola-harry-SJCalEw-1LM-unsplash.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 16 Oct 2026 18:10:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Tigerlily, Foundation, joining, conversation, PACE</media:keywords>
<content:encoded><![CDATA[<p><span>The </span><a href="https://tigerlilyfoundation.org/"><span>Tigerlily Foundation</span></a><span> was born from a promise made in a moment of profound vulnerability. </span></p>
<p><span>In 2006, Maimah Karmo was a 32-year-old mother to an infant daughter, Noelle, when she was diagnosed with an aggressive form of breast cancer. While undergoing chemotherapy, she made a promise: if she survived, she would create a world where no young woman would face that journey alone. </span></p>
<p><span>This year marks Tigerlily’s 20th anniversary. </span></p>
<p><span>While their legacy and heart remain in breast cancer, their scope now addresses broader health disparities. Tigerlily now focuses on women’s health and oncology. The impact of this evolution is tangible. </span></p>
<p><span>Over the past 19 years, their network of ANGEL Advocates has expanded to all 50 states and across three continents, training hundreds of women in advocacy, clinical trial literacy, and policy. In the past two years alone, they’ve reached more than 7 million Black and Brown patients nationwide, ensuring their voices and lived experiences are not afterthoughts but central to how we define and achieve equitable care. </span></p>
<p><span>In the lead up to the Biotechnology Innovation Organization’s (BIO) </span><a href="https://pace.bio.org/"><span>Patient Advocacy Changemakers Event (PACE)</span></a><span>, taking place on October 22–23, Bio.News sat down with Maimah Karmo to talk about Tigerlily’s work. Karmo will participate in PACE’s panel, </span><a href="https://pace.bio.org/program"><span>In the Wrong Ballpark: Why PDABs Don’t Work</span></a><span> on Oct. 22.</span></p>
<h3>Bio.News: Patient access to treatments is deeply personal to the organization. How does this translate into your work?</h3>
<p><span>For Tigerlily, access isn’t an abstract policy concept; it’s the difference between life and death, and it is deeply personal. When I was diagnosed, I was dismissed multiple times because of my age. I had to fight to get a mammogram, fight to get a biopsy, and fight to be taken seriously. That experience shaped everything we do. Our work, from the exam room to Capitol Hill, is informed by patients and designed for patients.</span></p>
<p><span>We believe that true access is about more than just a price tag. As I often say, what is the point of a drug that I can afford financially if I can’t even get it in the first place? Our policy work, therefore, is dedicated to redefining “affordability” to include timely access. Through our HEAL Policy Center of Excellence, we equip patients with the tools to speak directly to power. Whether it’s fighting for coverage of biomarker testing or ensuring insurance doesn’t delay care through prior authorization or step therapy, our goal is to remove the barriers that stand between a patient and their prescribed treatment.</span></p>
<h3>Bio.News: Tigerlily has been a champion for patient access in state legislatures. <a href="https://bio.news/latest-news/patient-groups-praise-virginia-pdab-veto/">Your work in Virginia</a> was highlighted in Bio.News earlier this year. Can you tell us more about the impact you have had across the country this year?</h3>
<p><span>Our work on Prescription Drug Affordability Boards (PDABs) is a perfect example of how we translate patient concern into policy advocacy. We’ve been deeply engaged in states across the country on this issue because PDABs are often sold as a silver bullet for high drug costs, but the reality for patients is far different.</span></p>
<p><span>First, almost no one outside of the policy world knows these boards exist, especially the communities most impacted. Second, the discussions around them are often misleading. They are framed as a lever to make drugs more affordable for patients, but in reality, they are designed to save money for the state, and there is zero evidence of patient cost savings. Recent studies confirmed that upper payment limits set by PDABs have not delivered a single dollar in savings to patients.</span></p>
<p><span>For Tigerlily, this is unacceptable. We are not saying we don’t want more affordable drugs; we absolutely do! But we want them without creating new access barriers. Our efforts have been focused on educating our community to serve as a catalyst, amplifying their voices to ensure they can engage in these conversations and share their personal stories. We were proud that our work in Virginia resulted in a veto of harmful PDAB legislation, and we will continue to fight to ensure that patient concerns are heard and that affordability policies actually prioritize patient access.</span></p>
<h3>Bio.News: What other policies are a priority for Tigerlily?</h3>
<p><span>Our policy priorities are patient-centered and cover a broad range of issues at both the federal and state levels.</span></p>
<p><span>On drug pricing, beyond PDABs, we are advocating for 340B program reform to ensure that discounts go to supporting vulnerable patients as intended, and we are engaging on Medicare Drug Price Negotiation Program (MDPNP) implementation to ensure that efforts to lower prices don’t inadvertently slow innovation or create new barriers to access for patients.</span></p>
<p><span>We are also prioritizing utilization management reform, including prior authorization and step therapy. These “fail first” protocols delay patients from accessing the treatments their providers prescribe, and we support the Safe Step Act as a crucial interim fix. We are also engaging in policies to ensure access to diverse clinical trials for all, including the Clinical Trial Modernization Act to allow trial sponsors to cover costs like travel and childcare, which are major barriers for underrepresented groups. And with access to clinical trials for innovative therapies as well as already-existing therapies, biomarker testing is a high priority to ensure every patient has access to the current gold standards to receive the best treatment for them and their specific disease markers.</span></p>
<p><span>While our mission has expanded, we remain steadfast in our legacy breast cancer priorities. We continue to support and engage in reauthorization for the SCREENS for Cancer Act to protect funding for safety-net screening programs, the Access to Breast Cancer Diagnosis Act to ensure coverage for diagnostic tests, and the EARLY Act to educate young women and their doctors about breast cancer risks.</span></p>
<h3>Bio.News: Your fourth annual BEACON Symposium takes place this October. What themes will be explored? What does this milestone mean to the organization?</h3>
<p><a href="https://tigerlilyfoundation.org/event/tigerlilys-4th-annual-beacon-symposium/"><span>The BEACON Symposium</span></a><span> has become a cornerstone of our work because it’s where we shift from dialogue to action. This year’s theme is “From Access to Action: Scaling Patient-Led Solutions for an Equitable Future”. It perfectly captures the moment we are in as an organization and as a community.</span></p>
<p><span>The panels will tackle some of the most critical issues facing patients today. One panel, “Bridging the Trial Gap: From Equitable Access to Community-Centered Trials,” will explore how we move beyond simply enrolling more diverse patients to designing trials that are truly centered on community needs. </span></p>
<p><span>The second panel, “The Cost Conundrum: When Drug Pricing Policies Create More Problems Than Solutions,” will dig into drug pricing policy issues and how well-intentioned policies can sometimes backfire and create new hurdles for the very people they aim to help. And most importantly, how advocates can engage and amplify the patient voice to ensure good policies are made that actually lower prices for patients.</span></p>
<p><span>For us, the Fourth Annual BEACON Symposium is a milestone that reflects how much this movement has grown. It’s no longer just Tigerlily’s event; it’s a gathering place for the entire patient advocacy community to co-create solutions. It’s where we, together, become the beacon of hope and light that drives us forward to health equity.</span></p>
<h3>Bio.News: Maimah will be speaking on behalf of Tigerlily Foundation later this month at PACE. What are you most excited to share with the patient advocacy community?</h3>
<p><span>I am most excited to share that Tigerlily’s patient advocacy is not standing still but rather is expanding in new and powerful ways. I’ll be sharing how we are building a bigger table and bringing more voices into the conversation.</span></p>
<p><span>I’ll be highlighting our new programs, which embody this growth. EmPOWER Her is our peer navigation program that connects newly diagnosed patients with trained survivor navigators, providing the compassionate, one-on-one support that I wish I had when I was diagnosed. SheLEADS is a community-led initiative piloting in North Carolina designed to transform the systems of care for Black women by combining peer navigation with provider engagement and policy change. Our BLISS Brunch series is creating joyful, culturally responsive spaces for education and connection, bringing clinical trial literacy directly into trusted community settings. And our newly created IGNITE Center of Excellence is turning community engagement from simple outreach into an evidence-based discipline, ensuring that the trust we build translates into measurable health outcomes.</span></p>
<p><span>What I’m most excited to share is that after 20 years, our commitment to our work is the same: to lead with love, legacy, and unstoppable faith. But our reach and our impact are greater than ever. We are proving that when you center patients and give them the power to lead, you don’t just create change, you build a movement.</span></p>
<p><i><span>You can still register for PACE! Visit </span></i><a href="https://pace.bio.org/registration"><i><span>https://pace.bio.org/registration</span></i></a><i><span> </span></i></p>
<p>The post <a href="https://bio.news/health/tigerlily-foundation-joining-conversation-at-pace/">Tigerlily Foundation joining conversation at PACE</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Genentech documentary celebrates 50th anniversary of biotech</title>
<link>https://edusehat.com/en/genentech-documentary-celebrates-50th-anniversary-of-biotech</link>
<guid>https://edusehat.com/en/genentech-documentary-celebrates-50th-anniversary-of-biotech</guid>
<description><![CDATA[ A scientist and a financier walk into a bar…  It sounds like the setup to a joke, but in the case of molecular biologist […]
The post Genentech documentary celebrates 50th anniversary of biotech appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/10/genentech-documentary-JPG.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 16 Oct 2026 18:10:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Genentech, documentary, celebrates, 50th, anniversary, biotech</media:keywords>
<content:encoded><![CDATA[<p><span>A scientist and a financier walk into a bar… </span></p>
<p><span>It sounds like the setup to a joke, but in the case of molecular biologist Herbert Boyer, Ph.D., and venture capitalist Robert Swanson, it was the setup for an entirely new industry: biotechnology. </span></p>
<p><span>The two founded Genentech, considered the “original biotech” company, which is celebrating its 50th year. And the biotech industry as a whole is looking back on its last half-century and reflecting on the breakthroughs that have saved and improved the lives of patients worldwide. To mark the moment, the documentary </span><a href="https://www.nytimes.com/paidpost/genentech/the-impossible-bet.html"><span>“The Impossible Bet”</span></a><span> was produced in collaboration with The New York Times’ </span><a href="https://advertising.nytimes.com/custom-content/"><span>T Brand Studio</span></a><span> to explore Genentech’s growth and impact and reflect on the role patients have played in the industry’s development. </span></p>
<h3>From the first human insulin to a breast cancer breakthrough</h3>
<p><span>Boyer and Swanson’s first conversation ultimately led to the creation and commercialization of recombinant DNA (rDNA) technology to engineer bacteria to produce vital human proteins. That was a game-changer for diabetes patients.</span></p>
<p><span>“At the time, there was a really urgent patient need. Insulin was derived from animal pancreases, and there wasn’t enough that could be produced to serve all the diabetic patients around the world,” Ashley Magargee, CEO of Genentech, explained in the documentary. </span></p>
<p><span>But thanks to Boyer’s groundbreaking work researching recombinant DNA, and Swanson’s ability to fund and commercialize it, Genentech was able to use recombinant DNA technology to clone and synthesize human insulin and the E. coli gene.</span></p>
<p><span>“For the first time, we had human insulin,” Magargee continued. “Diabetic patients were able to get a sustainable supply of the medicine that they would need. It was such a watershed moment because it proved that Genentech could exist, and that started, really, this wonderful industry of biotech.”</span></p>
<p><span>The insulin breakthrough was followed by the development of a drug to treat breast cancer: Herceptin. </span></p>
<p><span>HER2-positive breast cancers—accounting for 20% of breast cancers—were once a death sentence: “more aggressive, more likely to spread, more likely to recur,” explained Levi Garraway, Executive Vice President, Head of Global Product Development and Chief Medical Officer at Genentech.. </span></p>
<p><span>Heceptin changed that, and is still used today. </span></p>
<p><span>This paved the path toward targeted therapy, which has been one of the most important innovations in rare disease.</span></p>
<p><span>“The most important implication of targeted cancer treatments was that if we can understand the biology of a disease at a detailed molecular level, that understanding can unlock an entirely new era of transformative medicines,” said Garraway.</span></p>
<h3>Compassionate Use and the importance of the patient voice</h3>
<p><span>During the clinical trial stage of Heceptin’s development, the scientists at Genentech looked out their window and saw protestors. They were all breast cancer patients. </span></p>
<p><span>“Really, they were saying, </span><i><span>We need to live.</span></i><span> They were pleading to live. </span><i><span>Why can’t you just give me the drug? I will take all the risk</span></i><span>,” explained Magargee.</span></p>
<p><span>Genentech invited them in.</span></p>
<p><span>“We brought them in and started talking to them about how we could develop a lottery system for compassionate use,” Margaree recalled. </span><i><span>Compassionate Use</span></i><span> allows patients who have life-threatening diseases, and no other options, to receive an investigational medicine before it comes on the market.</span></p>
<p><span>“The outcome of that was a recognition on the part of Genentech that these patient voices are, in fact, incredibly important,” said Margaree. “We’ve come a long way in bringing patients into our research early on to make sure that as we’re working in the drug discovery, drug development phases, we actually are bringing the voice of the patient into everything we do.”</span></p>
<p><span>This patient-informed mindset has shaped decades of work since—whether designing and conducting clinical trials, speaking to the Centers for Disease Control and Prevention, or organizing Hill Day in Washington</span><span>,</span><span> DC, where patients can speak directly to policymakers about their needs. </span></p>
<h3>AI as biotech’s next frontier</h3>
<p><span>As the documentary explains, the road to biotech innovation has never been easy.</span></p>
<p><span>“You have to follow the science wherever it may lead you, in order to make the next leap and get to the next right answer,” said Aviv Regev, Head of Research and Early Development at Genentech. </span></p>
<p><span>While the biotech industry has completely changed the landscape of healthcare on the planet and continues to move at lightspeed, innovation is nonetheless an uphill battle.</span></p>
<p><span>“We still have 90% of all molecules that enter clinical studies fail, and that’s an incredible failure rate,” said Magargee on the </span><a href="https://bio.news/health/ai-drug-discovery-biotech-nvidia-genentech-anniversary-bio-international-convention-2026/"><span>BIO Mainstage at the 2026 International Convention</span></a><span>. “And it’s because drug discovery is very, very difficult – every aspect of it is very difficult.”</span></p>
<p><span>As the biotech industry reflects on the past 50 years, it is also looking ahead to what comes next, particularly to artificial intelligence (AI)—not to replace scientists, but to assist them.</span></p>
<p><span>“We need more scientists than we ever have before, because when they’re equipped and empowered with these tools, they’re asking bigger and more important questions than have ever been able to ask before,” said Magargee.</span></p>
<p><span>“It’s going to be not just faster computers or better algorithms or more interesting science,” concluded Magargee to applause, “it’s going to be so many more birthdays for people, it’s going to be so many more memories, and so much more time with your loved ones, and that’s going to be the impact that we’re going to have together.”</span></p>
<p>The post <a href="https://bio.news/health/genentech-documentary-celebrates-50th-anniversary-of-biotech/">Genentech documentary celebrates 50th anniversary of biotech</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Floridians turn out to oppose changing school and daycare vaccine requirements</title>
<link>https://edusehat.com/en/floridians-turn-out-to-oppose-changing-school-and-daycare-vaccine-requirements</link>
<guid>https://edusehat.com/en/floridians-turn-out-to-oppose-changing-school-and-daycare-vaccine-requirements</guid>
<description><![CDATA[ BIO voices concerns in statement for hearing about potential rule change. Reducing the number of vaccines required for school children risks the spread of […]
The post Floridians turn out to oppose changing school and daycare vaccine requirements appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/10/mother-at-fla-hearing.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 16 Oct 2026 18:10:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Floridians, turn, out, oppose, changing, school, and, daycare, vaccine, requirements</media:keywords>
<content:encoded><![CDATA[<h4>BIO voices concerns in statement for hearing about potential rule change.</h4>
<p><span>Reducing the number of vaccines required for school children risks the spread of dangerous, preventable diseases, concerned Floridians and public health advocates told a Florida Department of Health (FDOH) panel hearing on Oct. 8.</span></p>
<p><span>The </span><a href="https://www.floridahealth.gov/2026/10/08/florida-department-of-health-holds-public-hearing-on-proposed-revisions-to-school-immunization-rule/"><span>hearing</span></a><span> allowed public input into FDOH’s proposed rule change to eliminate requirements for four of the current 11 vaccines students need to enter public schools and daycare.</span></p>
<p><span>The new rule would mean the hepatitis B, varicella (chickenpox), haemophilus influenzae type b (Hib), and pneumococcal conjugate vaccines would no longer be required for students entering public school or child care programs,</span><a href="https://www.floridahealth.gov/2026/10/08/florida-department-of-health-holds-public-hearing-on-proposed-revisions-to-school-immunization-rule/"> <span>FDOH explains.</span></a><span> Immunization for polio, diphtheria, measles, rubella, pertussis, mumps, and tetanus would still be required.</span></p>
<p><span>The Biotechnology Innovation Organization (BIO) provided written comments to the hearing urging FDOH to maintain its current vaccine requirements.</span></p>
<p><span>“We are deeply concerned that the proposed changes, if enacted, will decrease immunization coverage in Florida and leave many vulnerable to preventable infectious diseases,” BIO wrote. “Vaccination requirements have been instrumental in reducing, and in some cases eliminating deadly diseases. Removing these requirements would reverse decades of scientific and public health progress without evidence-based justification.”</span></p>
<p><span>While the hearing featured many speakers against the proposal and many in favor of it, the overall majority of Floridians oppose the proposed rule and want to keep vaccine requirements as they are,</span><a href="https://www.flfamiliesforvaccines.org/polling"> <span>according to a poll commissioned by Florida Families for Vaccines</span></a><span>. Of the 1,000 likely voters polled by McLaughlin & Associates, 79%—including 71% of registered Republicans—support Florida’s long-standing school entry vaccine requirements.</span></p>
<h2>What they said at the hearing</h2>
<p><span>Speakers who urged against changing the vaccine schedule represented a wide range of viewpoints.</span></p>
<p><span>Evelyn, a 7-year-old cancer survivor, described the importance of her classmates being vaccinated.</span></p>
<p><span>“The chemo broke my immune system. I had to stay away from sick people because their germs could hurt me really bad. I was so happy to go back to school. I missed my friends,” Evelyn said. “Mommy and Daddy knew I would be safe because everybody got their vaccine shots when I couldn’t.”</span></p>
<p><span>Evelyn’s father, Kyle Huneycutt, said his daughter’s diagnosis changed how his family saw the world. “The health of the community around your child matters in a way you may have never considered before,” he explained.</span></p>
<p><span>The patient’s family view was also represented by Donielle Deitz, a caregiver and a volunteer for the American Cancer Society’s Cancer Action Network (ACS CAN), who urged maintaining “evidence-based school immunization requirements.”</span></p>
<p><span>“Childhood vaccines protect people with cancer,” she said, noting that the hepatitis B vaccine FDOH would remove from the requirements “is a powerful cancer prevention tool” against liver cancer.</span></p>
<p><span>Medical professionals also spoke of the risks of changing the vaccination schedule, which may give the impression that some vaccines are less important.</span></p>
<p><span>Angela Moore, a registered nurse, said she had witnessed what can happen when families decide against protecting their children.</span></p>
<p><span>“We have seen children whose parents have denied them safe and effective vaccines be afflicted by diseases that my generation and the generation before me had the luxury of protection from, due to herd immunity,” she said.</span></p>
<p><span>Donald Neel, MD, a pediatrician, recalled the times before the four vaccines were available. “I spent many hours of my life and parents’ lives, holding their hands and praying for their child, who was critically ill with either pneumococcal pneumonia or the various types of meningitis,” he said.</span></p>
<p><span>Many speakers represented the parents’ perspective in opposing the proposed rule.</span></p>
<p><span>“We want to send our children to schools and daycare and not have to worry about preventable diseases,” said Cass Miller of</span><a href="https://www.flfamiliesforvaccines.org/"> <span>Florida Families for Vaccines</span></a><span>. “For families, an outbreak is not just a statistic; it means missing childcare, a parent missing work, or staying away from grandparents because someone has been exposed.”</span></p>
<p><span>Shelly Pedraza, President Elect of</span><a href="https://www.floridapta.org/"> <span>the Florida PTA</span></a><span>, which includes about 200,000 parents, said “Florida PTA opposes the removal of these vaccine requirements,” because parents are concerned about the health risks.</span></p>
<p><span>Those representing teachers said they and their families would be put at risk if vaccination rates drop at their workplace.</span></p>
<p><span>Giving the business perspective, Karen van Caulil, president and CEO of the</span><a href="https://flhealthvalue.org/"> <span>Florida Alliance for Healthcare Value</span></a><span>, noted that employers pay for many health insurance plans, and also suffer when parents are absent for child care.</span></p>
<p><span>“When preventable illness leads to additional doctor visits, emergency care or hospitalization, those costs are felt by families and employers alike,” she said. “That is why employers have a direct and practical interest in policies that help keep children and communities healthy.”</span></p>
<h2>The ‘parents rights’ argument</h2>
<p><span>Those speaking in favor of the rule mostly spoke of the right for parents to make their own decisions, vaccine-related injuries (which occur rarely but are eligible to submit federal remuneration through the Vaccine Injury Compensation Program (VICP)), and unscientific theories on vaccine safety.</span></p>
<p><span>Florida Surgeon General Joseph Ladapo, MD, who has championed the rule change and led the hearing, stressed that there were no questions about the safety and effectiveness of the four vaccines that his new rule would eliminate. Ladapo repeatedly explained that the only reason for the rule change was to increase parents’ right to choose for their children.</span></p>
<p><span>BIO and others noted that Florida already allows for religious and medical exemptions to school vaccine requirements.</span></p>
<p><span>“Current standards ensure that individual choice is protected while maintaining the greatest access to vaccines for those who wish to take them,” said BIO’s letter. “Further loosening the requirements does not impact an individual’s right to choose vaccination or not, it jeopardizes broader immunity levels and increases the likelihood of outbreaks.”</span></p>
<p><span>Ladapo also said other states do not require school children to have some of the vaccines that Florida would cancel. But no state excludes all four vaccines.</span></p>
<p><a href="https://www.immunize.org/official-guidance/state-policies/vaccine-requirements/hepb-child-school-2026/"><span>Every state except for Alabama</span></a><span> requires hepatitis B vaccines, and</span><a href="https://www.immunize.org/official-guidance/state-policies/vaccine-requirements/hib-childcare-2026/"> <span>West Virginia is the only state</span></a><span> that doesn’t mandate a Hib vaccine, according to</span><a href="https://www.immunize.org/"> <span>immunize.org</span></a><span>. Seven states do not require a</span><a href="https://www.immunize.org/wp-content/uploads/laws/pcv-cc-rqt-map-2026.pdf"> <span>pneumococcal vaccine</span></a><span>.</span></p>
<p><span>As of now, all states require children entering public school and daycare to have the chickenpox vaccine, which also helps protect against meningitis, and</span><a href="https://www.epicresearch.org/articles/first-birth-cohort-eligible-for-chickenpox-vaccine-had-a-sharp-drop-in-shingles-cases/"> <span>according to a new study</span></a><span>, prevents later episodes of shingles.</span></p>
<p><i><span>FDOH is accepting comments on the rule proposal by email at </span></i><a href="mailto:vaccinerule@flhealth.gov"><i><span>vaccinerule@flhealth.gov</span></i></a><i><span> until 5 pm on Oct. 19.</span></i></p>
<p>The post <a href="https://bio.news/state-policy/floridians-turn-out-to-oppose-changing-school-and-daycare-vaccine-requirements/">Floridians turn out to oppose changing school and daycare vaccine requirements</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Can’t bear to say goodbye to your pet? Biotech’s got you covered.</title>
<link>https://edusehat.com/en/cant-bear-to-say-goodbye-to-your-pet-biotechs-got-you-covered</link>
<guid>https://edusehat.com/en/cant-bear-to-say-goodbye-to-your-pet-biotechs-got-you-covered</guid>
<description><![CDATA[ I don’t remember much about Peppy, my first and only pet cat. I can conjure the sensation of stroking her while she purred, recall how she used to get stuck in trees (just like in cartoons!), and chuckle about the time she pooed in my baby sister’s cot. That’s about it. What I do vividly… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/10/AdobeStock_551902166.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 16 Oct 2026 18:10:02 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Can’t, bear, say, goodbye, your, pet, Biotech’s, got, you, covered.</media:keywords>
<content:encoded><![CDATA[<div data-chronoton-summary="<ul><br><li><strong>Pet longevity is a growing area of research:</strong> Companies like Loyal are trialing drugs in over 1,300 dogs to combat aging, metabolic disease, and conditions like arthritis — and there's even a longevity medicine company focused entirely on cats.</li><br><li><strong>Cloning offers grieving owners "a way to hold on":</strong> For $50,000, US company Viagen Pets will create a genetic twin of your dog or cat — not an exact replica, but close enough that some experts see it as a legitimate response to pet loss.</li><br><li><strong>Cryonics promises revival, but delivers almost nothing:</strong> A handful of companies will freeze your dead pet indefinitely, banking on future technology to bring them back — even those in the field admit reanimation is currently impossible.</li></ul>" data-chronoton-post-id="1146766" data-chronoton-expand-collapse="1" data-chronoton-analytics-enabled="1"></div>


<p class="wp-block-paragraph">I don’t remember much about Peppy, my first and only pet cat. I can conjure the sensation of stroking her while she purred, recall how she used to get stuck in trees (just like in cartoons!), and chuckle about the time she pooed in my baby sister’s cot. That’s about it.</p>



<p class="wp-block-paragraph">What I do vividly remember, though, is the day she went missing. I was 10 years old, and I searched everywhere for her, scouting nearby fields and woods until sunset. I made posters. We never found her. I was devastated.</p>



<p class="wp-block-paragraph">There was no way to get more time with Peppy, but almost 30 years later, pet owners are being offered an ever-expanding set of options to potentially prolong their years with their furry companions. The possibilities include drugs, cloning, and even cryonics. But is that a good thing?</p>





<p class="wp-block-paragraph">There’s certainly a market for pet preservation. And a growing number of biotech companies have their sights set on pet longevity. Loyal, a company that is currently working on three potential longevity drugs for dogs, is <a href="https://loyal.com/clinical-trials">trialing</a> one designed to improve metabolic health in around 1,300 pet dogs across the US. Others are <a href="http://google.com/url?q=https://animalbioscience.com/for-vets/&sa=D&source=docs&ust=1789052975323016&usg=AOvVaw17YrZEtPUxIc3YvqYS9m2e">testing dog drugs</a> that aim to combat both age-related diseases, including conditions like <a href="https://rejuvenatebio.com/pipeline">obesity and osteoarthritis</a>, and aging itself. There’s even a company focused on <a href="https://thecathealth.com/">longevity medicines for</a> domesticated cats.</p>



<p class="wp-block-paragraph">I don’t know how or when Peppy died. But if there had been a drug that might have protected her from diabetes or arthritis, there’s no doubt I would have tried to get my hands on it.</p>



<p class="wp-block-paragraph">That’s about where my enthusiasm for pet life extension ends, though.</p>



<p class="wp-block-paragraph">I’m far less interested in cloning, a relatively new option for people mourning a pet and seeking a replacement. In most cases, this technology involves taking the DNA of a pet, putting it into an egg cell from another animal of the same species, and growing the resulting embryo in a surrogate animal. It worked for Dolly the sheep, who was born the year before Peppy went missing. It has since worked for other mammals, including cattle, horses, and ferrets—and cats and dogs. In the US, a company called Viagen Pets offers to clone cats and dogs for $50,000 a go. This doesn’t result in an exact replica of the animal but a genetic twin.</p>



<p class="wp-block-paragraph">Still, there are lots of reasons why a person might want to clone a pet. On its website, Viagen explicitly offers customers “a way to hold on.” Lori Kogan, a professor of clinical sciences at Colorado State University who has studied human-animal relationships for decades, doesn’t have a problem with the practice. She points out that while we have well-established rituals for coping with the loss of a person—such as funeral services, time off work, and memorial gifts—we don’t really have the same for pets. As a result, pet owners can experience what is sometimes called “disenfranchised grief,” she says. Having their feelings go unrecognized can feel isolating. If cloning a pet brings a person peace, she says, “who are we to judge?”</p>





<p class="wp-block-paragraph">Fair enough. But I can’t help thinking that pet loss in childhood might be different. It’s often the first time a child confronts death. Losing Peppy was a formative experience, and distressing though it was, I like to think it helped prepare me for losses I experienced in adulthood. I wouldn’t want my own children to think that death is not final, and that individuals can be replicated or replaced.</p>



<p class="wp-block-paragraph">Or, for that matter, revived, which is the promise behind pet cryonics. For a fee, a handful of companies offer to cool dead pets to extremely low temperatures and store them for long periods of time—even indefinitely. The idea is that at some point in the future, we’ll have invented incredible technologies that will not only bring your pet back to life but also cure whatever it died of. <a href="https://www.alcor.org/about/">Alcor</a>, a cryonics facility in Arizona, is currently storing the remains of hundreds of pets as well as people. It even recently announced it had cooled a small marsupial—its first pet sugar glider.</p>



<p class="wp-block-paragraph">With cryonics, the chances of being reunited with your pet are bordering on zero. Even those who work in the field acknowledge that the stored people and animals are unlikely to be reanimated. As things stand, there is no way to really and truly bring any animal “back.”</p>



<p class="wp-block-paragraph">I miss Peppy. But given the chance, would I stick her in a vat of liquid nitrogen? Or get another cat to give birth to a genetically identical animal? No, I would not.</p>



<p class="wp-block-paragraph">RIP to the one and only Peppy.</p>]]> </content:encoded>
</item>

<item>
<title>This implant can restore sight for patients with macular degeneration</title>
<link>https://edusehat.com/en/this-implant-can-restore-sight-for-patients-with-macular-degeneration</link>
<guid>https://edusehat.com/en/this-implant-can-restore-sight-for-patients-with-macular-degeneration</guid>
<description><![CDATA[ Age-related macular degeneration (AMD) affects more than 5 million people around the world. And until now, no treatment could restore their vision. The Prima system, which was approved in Europe in July and is awaiting FDA clearance in the US, changes that. It combines a retinal implant with camera-­equipped eyeglasses to improve sight in patients… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/10/prima-implant-2026.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 16 Oct 2026 18:10:02 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>This, implant, can, restore, sight, for, patients, with, macular, degeneration</media:keywords>
<content:encoded><![CDATA[<p class="wp-block-paragraph">Age-related macular degeneration (AMD) affects more than 5 million people around the world. And until now, no treatment could restore their vision. The Prima system, which was approved in Europe in July and is awaiting FDA clearance in the US, changes that. It combines a retinal implant with camera-­equipped eyeglasses to improve sight in patients who develop a blind spot in the middle of their vision due to advanced AMD. After training sessions, more than 80% of recipients were able to read, do crosswords, and use their phones.</p>


<div class="wp-block-image">
<figure class="wp-block-image alignright size-large is-resized"><img fetchpriority="high" decoding="async" width="1045" height="1292" src="https://wp.technologyreview.com/wp-content/uploads/2026/10/ND26-dl_mapped.png?w=840" alt='""' class="wp-image-1146408" srcset="https://wp.technologyreview.com/wp-content/uploads/2026/10/ND26-dl_mapped.png 1045w, https://wp.technologyreview.com/wp-content/uploads/2026/10/ND26-dl_mapped.png?resize=243,300 243w, https://wp.technologyreview.com/wp-content/uploads/2026/10/ND26-dl_mapped.png?resize=768,950 768w" sizes="(max-width: 1045px) 100vw, 1045px"><figcaption class="wp-element-caption"><strong>The retina processes light in three layers of cells: Photoreceptors</strong> convert light into electricity, <strong>bipolar cells</strong> process that signal, and <strong>ganglion cells</strong> transmit the signal to the optic nerve and the brain. Prima replaces the photoreceptors.</figcaption><div class="image-credit">BROWN BIRD DESIGN</div>
</figure>
</div>


<p class="wp-block-paragraph">Developed by the California-based Science Corporation, the system takes advantage of the fact that AMD doesn’t damage all retinal circuitry; only photoreceptors—the cells that convert light into an electrical signal—die off. Prima’s implant mimics those cells and transmits visual information directly to healthy eye circuitry and on to the brain. “We’re leveraging all of the body’s own natural functions to process and transmit the information,” says Frank Brodie, an ophthalmologist at the University of California, San Francisco, and medical director for Prima. </p>


<div class="wp-block-image">
<figure class="wp-block-image alignwide size-full"><img decoding="async" width="3115" height="2905" src="https://wp.technologyreview.com/wp-content/uploads/2026/10/ND26-dl_mapped1.png" alt="" class="wp-image-1146409" srcset="https://wp.technologyreview.com/wp-content/uploads/2026/10/ND26-dl_mapped1.png 3115w, https://wp.technologyreview.com/wp-content/uploads/2026/10/ND26-dl_mapped1.png?resize=300,280 300w, https://wp.technologyreview.com/wp-content/uploads/2026/10/ND26-dl_mapped1.png?resize=768,716 768w, https://wp.technologyreview.com/wp-content/uploads/2026/10/ND26-dl_mapped1.png?resize=1536,1432 1536w, https://wp.technologyreview.com/wp-content/uploads/2026/10/ND26-dl_mapped1.png?resize=2048,1910 2048w" sizes="(max-width: 3115px) 100vw, 3115px"><div class="image-credit">BROWN BIRD DESIGN</div>
</figure>
</div>



<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow">
<h4 class="wp-block-heading">CAPTURE</h4>



<p class="wp-block-paragraph">Glasses outfitted with a miniature front-facing <strong>camera </strong>capture what someone is seeing in real time. The video feed is roughly five megapixels running at 30 frames per second, which is similar to TV. The raw video is transmitted to a connected processor via a <strong>fiber-optic cable</strong>.</p>
</div>



<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow">
<h4 class="wp-block-heading">CONVERT</h4>



<p class="wp-block-paragraph">A small, handheld processor, which can be set on a table or tucked in a pocket, converts the video feed into infrared light signals that route back to the glasses. The device also includes physical buttons that let the wearer adjust contrast, brightness, and zoom.</p>
</div>
</div>



<p class="imageSet__caption wp-block-paragraph"></p>



<div class="wp-block-image">
<figure class="wp-block-image alignwide size-full"><img decoding="async" width="3115" height="1185" src="https://wp.technologyreview.com/wp-content/uploads/2026/10/ND26-dl_mapped2.png" alt="" class="wp-image-1146410" srcset="https://wp.technologyreview.com/wp-content/uploads/2026/10/ND26-dl_mapped2.png 3115w, https://wp.technologyreview.com/wp-content/uploads/2026/10/ND26-dl_mapped2.png?resize=300,114 300w, https://wp.technologyreview.com/wp-content/uploads/2026/10/ND26-dl_mapped2.png?resize=768,292 768w, https://wp.technologyreview.com/wp-content/uploads/2026/10/ND26-dl_mapped2.png?resize=1536,584 1536w, https://wp.technologyreview.com/wp-content/uploads/2026/10/ND26-dl_mapped2.png?resize=2048,779 2048w" sizes="(max-width: 3115px) 100vw, 3115px"><div class="image-credit">BROWN BIRD DESIGN</div>
</figure>
</div>



<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow">
<h4 class="wp-block-heading">DISPLAY</h4>



<p class="wp-block-paragraph">A laser <strong>projector </strong>on the glasses faces the wearer and shines pulses of <strong>near-infrared light</strong> directly at the eye at 880 nanometers—an invisible wavelength. This signal passes through the <strong>pupil </strong>and on to the <strong>retinal implant</strong> in the back of the eye.</p>
</div>



<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow">
<h4 class="wp-block-heading">SEE</h4>



<p class="wp-block-paragraph">The implant is made up of 378 pixels, each with an <strong>electrode </strong>and two <strong>photovoltaic cells</strong>, which do double duty. They convert the light into a current that healthy bipolar and ganglion cells pass on to the brain. They also act as solar cells to power the chip, eliminating the need for a battery.</p>
</div>
</div>



<p class="imageSet__caption wp-block-paragraph"></p>




<p class="wp-block-paragraph"><em>Linda Marsa is a former </em>Los Angeles Times<em> reporter and an author who covers medicine, health, science, and the environment. </em></p>]]> </content:encoded>
</item>

<item>
<title>Proteomics Reveals Ovarian Remodeling Decades After Menopause</title>
<link>https://edusehat.com/en/proteomics-reveals-ovarian-remodeling-decades-after-menopause</link>
<guid>https://edusehat.com/en/proteomics-reveals-ovarian-remodeling-decades-after-menopause</guid>
<description><![CDATA[ 5,812 protein groups were quantified in postmenopausal ovaries, uncovering molecular shifts associated with inflammation, immunity, and extracellular matrix remodeling.
The post Proteomics Reveals Ovarian Remodeling Decades After Menopause appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GettyImages-2282334711.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 16 Oct 2026 07:20:13 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Proteomics, Reveals, Ovarian, Remodeling, Decades, After, Menopause</media:keywords>
<content:encoded><![CDATA[<p>For decades, the postmenopausal ovary has been cast as a retired organ—a fibrotic remnant that stops releasing eggs and then largely sits idle. But a deep look at its proteins tells a different story. Using high-resolution proteomics, researchers found that the ovary continues to reorganize its structure, metabolism, and immune activity for decades after reproduction ends.</p>
<p>Scientists at Northwestern University and the Buck Institute for Research on Aging conducted the study, which analyzed healthy ovarian tissue from 28 postmenopausal women ages 50 to 75. The paper, “<a href="https://onlinelibrary.wiley.com/doi/10.1111/acel.70714" target="_blank" rel="noopener">The Human Ovary Exhibits Dynamic Molecular Remodeling in the Decades Post-Menopause</a>,” was published in <em>Aging Cell</em>. “I would venture to say most people assume those ovaries are just sitting there doing nothing, similar to the appendix,” said co-corresponding author Francesca Duncan, PhD, an associate professor of reproductive science in medicine at Northwestern University Feinberg School of Medicine. “But that’s what makes this study very different.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>Rather than focusing only on hormones, the team measured the tissue’s proteome. They analyzed the samples using data-independent acquisition mass spectrometry coupled with parallel accumulation–serial fragmentation, or diaPASEF. The approach systematically captured peptide signals across samples, allowing the team to quantify 5,812 protein groups. Differential-abundance testing, multivariate modeling, continuous-age regression, and pathway analyses were then used to identify changes shared across age groups and those that progressed with age.</p>
<p>The analyses converged on a shift from cellular maintenance toward active remodeling. Ovaries from women in their 50s contained more proteins linked to RNA processing, gene regulation, proteostasis, and tissue structure. Ovaries from women 70 and older showed stronger signatures of lipid metabolism and innate immunity. The researchers integrated recurring signals into Buck Postmenopausal Ovary Molecular Signature (BuckPOMS), “a 26-protein consensus molecular signature marked by loss of structural and epithelial-associated programs and gain of extracellular matrix remodeling, inflammatory signaling, and complement activation,” the authors wrote. They also validated two extracellular proteins, WNT4 and fibromodulin, by immunohistochemistry. “What became clear across all these methodologies is that the ovary was not stagnant,” said co-corresponding author Birgit Schilling, PhD, professor and director of the Buck Institute’s Mass Spectrometry Center.</p>
<p>“The ovary is not just a reproductive organ,” added Schilling. “It really influences how somebody ages because it speaks to all these other organs, such as the brain, and also to the bone, and women after menopause experience often a lot of bone problems. So, we think there is a connection between all these organs.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>The study advances a field that has largely concentrated on fertility loss, the menopausal transition, or comparisons spanning the entire lifespan. By narrowing the analysis to the decades after menopause, the researchers produced a reference map of continued ovarian aging. Histologically normal ovaries also showed overlap with senescence-associated programs and proteins previously linked to ovarian cancer, particularly among women in their 60s. The authors stress that this is not evidence of malignancy; instead, healthy aging and cancer may share inflammatory and matrix-remodeling biology. That distinction matters as women routinely live decades after menopause and researchers consider how the ovary may influence bone, brain, cardiovascular, and broader systemic aging.</p>
<p>“This ongoing molecular remodeling that occurs in the postmenopausal ovary challenges the notion that the ovary is an innocent bystander in the post-reproductive period and instead suggests a potentially more active role in systemic aging and chronic disease risk in women,” the authors wrote.</p>
<p>Future prospective studies will need documented age at menopause, hormone-therapy history, larger and more diverse cohorts, and longitudinal health outcomes to distinguish chronological aging from time since menopause and treatment effects. “We do not yet know if there’s ever a point in a woman’s life when this organ is no longer beneficial and it’s actually harmful,” said Duncan. “These results really point to the need to ask this question.”</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/proteomics-reveals-ovarian-remodeling-decades-after-menopause/">Proteomics Reveals Ovarian Remodeling Decades After Menopause</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Illumina Combines Multiomics Informatics Applications in New BioInsight Platform</title>
<link>https://edusehat.com/en/illumina-combines-multiomics-informatics-applications-in-new-bioinsight-platform</link>
<guid>https://edusehat.com/en/illumina-combines-multiomics-informatics-applications-in-new-bioinsight-platform</guid>
<description><![CDATA[ Illumina is bringing its software, AI, and data offerings together in the new BioInsight platform, designed to help scientists analyze genomic and multiomic datasets. It will be showcased at ASHG in Montreal.
The post Illumina Combines Multiomics Informatics Applications in New BioInsight Platform appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/03/TL_GettyImages-1284442152-lo.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 16 Oct 2026 03:45:12 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Illumina, Combines, Multiomics, Informatics, Applications, New, BioInsight, Platform</media:keywords>
<content:encoded><![CDATA[<p><span>Ahead of the 2026 meeting of the American Society of Human Genetics (ASHG), Illumina announced the launch of the BioInsight platform, a new unified software environment that provides tools to help scientists extract insights from multiomics datasets. According to the company, the platform provides scientists with seamless access to Illumina’s analysis applications, artificial intelligence tools, and curated data resources in a single environment. </span></p>
<p><span>The company plans to showcase the BioInsight Platform during the annual ASHG meeting being held in Montreal, Canada this year.  </span></p>
<p><span>Illumina’s BioInsight business unit was created a year ago to address what the company perceived to be a gap in analysis capabilities for handling the scale and complexity of multiomics datasets. “With the BioInsight Platform, we are bringing customers one simple place to access the full breadth of our offerings across software, AI, and data,” said Rami Mehio, senior vice president and general manager of the BioInsight business. Moving forward, “customers that use the BioInsight platform will also have access to new capabilities in the future, empowering them to drive the next wave of biological insights for our industry.”  </span></p>
<p><span>The list of tools available on the platform includes SpliceA12, a new genomic AI model that Illumina unveiled last week that is designed to identify disease-relevant splice variants. Being able to predict splice effects is key to resolving variants of uncertain significance in rare disease research, hereditary cancer testing research, and drug discovery. To date, its predecessor, SpliceA1, has been cited in over 3,400 publications and is incorporated into guidelines from ClinGen. </span></p>
<p><span>Details of SpliceA12’s framework, its training, and how it stacks up against other tools are provided in a </span><a href="https://assets.illumina.com/content/dam/illumina-marketing/images/genomics-research/articles/spliceai2/SpliceAI2.pdf" target="_blank" rel="noopener"><span>pre-print</span></a><span> published by scientists from Illumina, University of Oxford, University of California, San Francisco, and the New York Genome Center. According to the article, the tool “reconstructs complete transcripts directly from genomic sequence and considerably improves identification of splice-altering variants and quantification of their effects in diverse benchmarks spanning cryptic splicing, splicing quantitative trait loci, and massively parallel reporter assays.”</span></p>
<p><span>The data shared in the paper includes results from comparing SpliceA12’s to alternative splice prediction models on matched DNA and disease phenotype data from Genomics England cohorts. The findings show that SpliceA12 identified 17% more disease-relevant splice variants than other models. Furthermore, analysis of matched whole genome and RNA sequencing data from the National Institutes of Health’s Genotype-Tissue Expression portal showed that SpliceA12 improved quantification of splice site usage by 34% compared to the next best model. </span></p>
<p><span>Other findings indicate that SpliceA12’s results align more closely with downstream protein effects seen in the UK Biobank proteomic datasets. It also better captured the effects of splice variants across multiple population genomics datasets, according to data shared in the preprint. </span></p>
<p><span>Other applications included in the BioInsight platform include a new version of Illumina’s DRAGEN software solution. Version 4.6 expands where and how scientists can use the secondary analysis software and offers new deployment options including the DRAGEN software mode, which lets scientists run the tool across supported cloud and standard CPU environments. </span></p>
<p><span>Also available are Illumina’s BaseSpace and Connected Multiomics among other applications. Customers will also have access to the BioInsight AI lab, the research arm of BioInsight, which applies multiomic data and AI for tasks like variant prediction and training foundation models.  The platform also features curated datasets for research spanning oncology, rare disease, population health, and multiomics.</span></p>
<p><span>Access is available via a credits-based system in lieu of a more traditional annual subscription. This gives scientists the flexibility to use the capabilities they need while freeing them to explore and adopt new technologies as needed. </span></p>
<p>The post <a href="https://www.genengnews.com/topics/omics/illumina-combines-multiomics-informatics-applications-in-new-bioinsight-platform/">Illumina Combines Multiomics Informatics Applications in New BioInsight Platform</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>How Alzheimer’s Risk Gene APOE4 Disrupts Myelination</title>
<link>https://edusehat.com/en/how-alzheimers-risk-gene-apoe4-disrupts-myelination</link>
<guid>https://edusehat.com/en/how-alzheimers-risk-gene-apoe4-disrupts-myelination</guid>
<description><![CDATA[ Study linked the APOE4 gene with suppression of Wnt signaling in the oligodendrocyte cells that provide neurons with their fatty myelin insulation, and also demonstrated a potential approach to preventing disruption of myelination. 
The post How Alzheimer’s Risk Gene APOE4 Disrupts Myelination appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/12/Dec12_2023_Ralwel-GettyImages-610655320-e1670883749182-1068x467-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 16 Oct 2026 03:45:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>How, Alzheimer’s, Risk, Gene, APOE4, Disrupts, Myelination</media:keywords>
<content:encoded><![CDATA[<p>One of the main ways that the <em>APOE4</em> gene variant—the biggest genetic risk factor for late onset Alzheimer’s disease—undermines brain circuit function is by disrupting myelination, the process of insulating neurons with a fatty sheath that optimizes their electrical transmission. Studies headed by neuroscientists at The Picower Institute for Learning and Memory at MIT have now provided several lines of evidence to implicate a specific molecular pathway in that disruption.</p>
<p>Headed by Picower Professor Li-Huei Tsai, PhD, and Leyla Akay, PhD, a former graduate student in Tsai’s lab, the researchers showed that APOE4 leads to a suppression of Wnt signaling in the oligodendrocyte cells that provide neurons with fatty myelin insulation. The results indicated that when Wnt signaling is deficient the cells accumulate droplets of lipids rather than deploying fats to properly myelinate the neurons’ axon branches.</p>
<p>The team discovered a key role for Wnt using multiple methods, including a screen in which they used CRISPR gene editing to systematically knock out each protein-coding gene in the genome, one by one, in cultures of human APOE4-carrying oligodendrocytes. The screen showed that when genes promoting Wnt activity in oligodendrocytes were lacking, lipid droplets accumulated, and that when genes suppressing Wnt were lacking, lipid droplets were, too.</p>
<p>Experiments in both human cell cultures and in mice modeling Alzheimer’s disease showed that when Wnt signaling in APOE4-carrying oligodendrocytes was restored, myelination rebounded. “This proof of principle of doing CRISPR screens for genetic modifiers of APOE4-associated lipid accumulation in a central nervous system cell type is very exciting,” said Tsai, who also directs MIT’s Aging Brain Initiative. “I think this type of screen not only provides new insights into cellular pathways contributing to lipid metabolism defects, but really also has the potential to provide new targets for drug development.”</p>
<p>Tsai is co-senior author, and Akay is first author of the researchers’ published paper in <em>Cell Stem Cell</em>, titled “<a href="https://doi.org/10.1016/j.stem.2026.09.012" target="_blank" rel="noopener">Genome-wide CRISPR screen reveals Wnt signaling as a potential therapeutic target for lipid accumulation and impaired myelination in APOE4 oligodendrocytes</a>.”</p>
<p>In 2022, Tsai’s Lab led by Akay, together with co-author Joel Blanchard, PhD, and colleagues, <a href="https://doi.org/10.1038/s41586-022-05439-w" target="_blank" rel="noopener">showed</a> that APOE4 caused lipid droplet accumulation in oligodendrocytes and upset myelination. But, Akay said, that droplet accumulation could happen for many reasons. In their newly reported study, which sought to dig deeper into the underlying molecular mechanisms, the team noted, “We previously found that APOE4 expression causes lipid droplet accumulation in oligodendrocytes, reducing myelination, but the underlying mechanisms were unknown.”</p>
<p>For the study now reported in <em>Cell Stem Cell</em>, the team performed a genome-wide CRISPR knockout screen in induced pluripotent stem cell (iPSC)-derived oligodendrocytes. “We used a well-characterized human iPSC line, homozygous for the APOE4 allele, to generate oligodendrocytes, as previously described,” they explained. “This CRISPR screen allowed us an unbiased way to test every single possibility,” Akay said. “What kind of lipid enzymes are involved in this process? And what are upstream pathways that could be targeted?”</p>
<p>In parallel with the CRISPR screen, the team also analyzed the chromatin accessibility of the DNA in human oligodendrocyte cell cultures and in postmortem human brain samples, in each case comparing APOE4-carrying samples to ones carrying the neutral APOE3 variant. “To further understand how APOE4 perturbs the epigenome of oligodendrocytes and to identify putative master regulators of APOE4’s effects on lipid accumulation, we next used assay for transposase-accessible chromatin using sequencing (ATAC-seq) to compare  transposase-accessible regions of the genome between iPSC-derived oligodendrocytes, isogenic except for APOE genotype,” they continued.</p>
<p>This analysis of ATAC-seq data allowed the investigators to assess which genes were most accessible for expression, versus which ones were locked down from transcription. The chromatin analysis showed that genes promoting Wnt signaling were less accessible in APOE4 carriers. “There was a striking overlap between ATAC-seq and CRISPR screen results,” Tsai said. “Both pointed to a dysregulation of the Wnt signaling pathway.”</p>
<figure aria-describedby="caption-attachment-339392" class="wp-caption alignleft"><img fetchpriority="high" decoding="async" class="size-medium wp-image-339392" src="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_Figure3B-wnt-akay-upscale-300x186.jpg" alt="An enlarged figure from the paper shows that untreated APOE4 oligodendrocytes (left) accumulate lipid droplets (yellow), but are rescued by Gsk3b inhibition (right). [Tsai Lab/MIT PIcower Institute] " width="300" height="186" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_Figure3B-wnt-akay-upscale-300x186.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_Figure3B-wnt-akay-upscale.jpg 700w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">An enlarged figure from the paper shows that untreated APOE4 oligodendrocytes (left) accumulate lipid droplets (yellow), but are rescued by Gsk3b inhibition (right). [Tsai Lab/MIT Picower Institute]</figcaption></figure>
<p>Further analysis, including direct observations in cells at the lab bench, revealed how Wnt signaling became depressed in cultured APOE4 oligodendrocytes. Two proteins, beta-catenin and GSK3b, each compete to regulate Wnt. Beta-catenin promotes Wnt and GSK3b suppresses it. The team found that in APOE4 oligodendrocytes compared to APOE3 oligodendrocytes, there was reduced beta-catenin expression and excessive GSK3b expression.</p>
<p>The team then tested interventions that manipulate GSK3b activity. In human APOE3 oligodendrocyte cultures they showed that increasing GSK3b with a chemical called Dif3 increased lipid droplets. In APOE4 oligodendrocytes, they showed that inhibiting GSK3b with a chemical called CHIR99021 reduced droplets. In more complex “organoid” cultures combining APOE4 oligodendrocytes with neurons, they found that inhibiting GSK3b increased myelination and promoted the growth of neural axons.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>The tests suggested that GSK3b inhibition could be a proof-of-concept therapeutic strategy for restoring Wnt signaling and myelination. As a final test, they treated mice carrying APOE4 and genetically modeling Alzheimer’s tau pathology with doses of CHIR99021. The treated mice exhibited a reduction in lipid droplets in the hippocampus of the brain and showed increased myelination, when compared to untreated controls.</p>
<p>“Our results suggest that inhibition of GSK3B could reduce lipid droplet burden in APOE4 oligodendrocytes through increasing mitochondrial us age of stored lipids, or potentially by upregulating lipophagic mechanisms,” the team wrote in summary.</p>
<p>In addition to highlighting suppression of Wnt signaling, the CRISPR screen and chromatin analysis provided key clues about the molecular mechanisms by which loss of Wnt alters how oligodendrocytes metabolize lipids. Akay and Tsai said they are eager to follow up on those clues. They are also interested in investigating GSK3b’s linkage to tau phosphorylation, a major feature of Alzheimer’s pathology. “Given GSK3B’s established role as a major tau phosphorylating kinase, our work draws an interesting potential parallel between oligodendrocyte lipid accumulation and neuronal tau pathology,” the authors noted in their report.</p>
<p>Raw data from the study is available on the <a href="https://osf.io/m4ekt/overview?view_only=6385445b378c42a981aa3e1a50918605" target="_blank" rel="noopener">Open Science Framework</a>. Akay and Tsai have applied for a patent on the CRISPR screen results.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/how-alzheimers-risk-gene-apoe4-disrupts-myelination/">How Alzheimer’s Risk Gene <i>APOE4</i> Disrupts Myelination</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Newly Identified Microexons Offer Clues to Autism Spectrum Disorder’s Genetic Roots</title>
<link>https://edusehat.com/en/newly-identified-microexons-offer-clues-to-autism-spectrum-disorders-genetic-roots</link>
<guid>https://edusehat.com/en/newly-identified-microexons-offer-clues-to-autism-spectrum-disorders-genetic-roots</guid>
<description><![CDATA[ Hundreds of newly identified microexons seem to matter for autism and other neurological conditions, according to a Nature study. A machine learning model of their regulatory code also pinpoints variants predicted to disrupt their splicing in autistic individuals.
The post Newly Identified Microexons Offer Clues to Autism Spectrum Disorder’s Genetic Roots appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2023/08/Fotolia_30836005_JigsawPuzzleBrain.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 16 Oct 2026 03:45:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Newly, Identified, Microexons, Offer, Clues, Autism, Spectrum, Disorder’s, Genetic, Roots</media:keywords>
<content:encoded><![CDATA[<p><span>Scientists from the University of Toronto, the Sloan Kettering Institute, King’s College London, and the Francis Crick Institute have published data that points to a role for several new microexons in the development of autism spectrum disorder (ASD). According to the findings, published today in </span><i><span>Nature</span></i><span>, the scientists identified hundreds of new microexons that appear to be involved in ASD and other neurological conditions, and developed a machine learning approach to predict the impact of ASD-associated genetic variants on how these segments are regulated. </span></p>
<p><span>Full details are available in a paper titled “</span><a href="https://www.nature.com/articles/s41586-026-11119-w" target="_blank" rel="noopener"><span>A microexon regulatory code reveals autism-linked genetic variation</span></a><span>.” In it, the scientists described how they used a computational tool dubbed MicroExonator to analyze over 100 terabytes of publicly available RNA sequencing data. The tool was developed by Guillermo Parada, PhD, the study’s co-lead author and a postdoctoral fellow in the laboratory of Benjamin Blencowe, PhD,  at King’s and the Crick. Using the tool, he identified more than 1,500 new microexons, of which nearly 300 appeared to be specifically spliced in the brain. Furthermore, many are concentrated in genes associated with critical brain-specific processes, supporting a potential link to neurological health. </span></p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p><span>The scientists also explored whether DNA variants found in people with autism might preferentially impact the expanded repertoire of microexons. Specifically they built and applied a machine learning model designed to identify the key regulatory features governing whether a microexon is spliced in or out of messenger RNAs. “What surprised me was that the sequences the model identified as important closely matched those conserved throughout vertebrate evolution,” says Parada.</span></p>
<p><span>Next, the scientists applied the model to whole-genome sequence data from thousands of people with autism and neurotypical sibling pairs. Specifically, they analyzed the predicted impact of ASD-associated genetic variants on the microexon regulatory code. “We were able to show that rare genetic variants generally have the largest predicted effects on the splicing of neuronal microexons,” says Blencowe, one of the study’s senior authors and a professor of molecular genetics at University of Toronto. The model further pinpointed a subset of rare variants predicted to alter microexon splicing that are associated with autism.</span></p>
<p><span>Additionally, the team found that the variants predicted to affect microexons are predominantly detected among the 85% of autistic individuals that previously lacked a genetic link to autism. This is an important point because “hundreds of genomic variants have been associated with autism, and these deliver a genetic diagnosis in 15 percent of autistic individuals,” says Blencowe, who is also a part-time professor at King’s and the Crick. That means that for 85 percent of people with an ASD diagnosis, the genetic explanation for their condition remains unknown. The findings from this study could provide some answers. </span></p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p><span>“In terms of future work, it will be important to understand how disrupted microexons affect interactions between proteins that are important for nervous system development and function,” Blencowe adds. One of the research programs in his lab is also exploring new therapeutic approaches to target microexon dysregulation.</span></p>
<p><span>Furthermore, the scientists believe that the machine learning model they developed can be used to characterize other newly discovered genetic variants and their effects in neurological conditions like schizophrenia and epilepsy where microexons are believed to play a role.</span></p>
<p> </p>
<p>The post <a href="https://www.genengnews.com/topics/omics/newly-identified-microexons-offer-clues-to-autism-spectrum-disorders-genetic-roots/">Newly Identified Microexons Offer Clues to Autism Spectrum Disorder’s Genetic Roots</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Preventing Hospital Infections Could Free Thousands of Canadian Beds</title>
<link>https://edusehat.com/en/preventing-hospital-infections-could-free-thousands-of-canadian-beds</link>
<guid>https://edusehat.com/en/preventing-hospital-infections-could-free-thousands-of-canadian-beds</guid>
<description><![CDATA[ Canadian infection prevention could relieve overcrowding while protecting patients and healthcare workers Across Canada, patients who have been admitted to hospital are spending excessive periods in emergency departments waiting for inpatient beds. Preventing hospital infections could release thousands of the beds they need. Recent data from the Canadian Institute for Health Information show that some […]
The post Preventing Hospital Infections Could Free Thousands of Canadian Beds appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/exec-2725a9d8-4202-48fb-bc71-ed37e6b1cfee.png" length="49398" type="image/jpeg"/>
<pubDate>Fri, 16 Oct 2026 03:40:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Preventing, Hospital, Infections, Could, Free, Thousands, Canadian, Beds</media:keywords>
<content:encoded><![CDATA[<p><i><span>Canadian infection prevention could relieve overcrowding while protecting patients and healthcare workers</span></i></p>
<p><b>Across Canada, patients who have been admitted to hospital are spending excessive periods in emergency departments waiting for inpatient beds. Preventing hospital infections could release thousands of the beds they need.</b></p>
<p><span>Recent data from the Canadian Institute for Health Information show that some admitted patients remain in emergency departments for almost two days or longer before they can be moved elsewhere in the hospital. Limited inpatient-bed availability is one important contributor to these delays. Patients remain under the care of emergency staff while they wait, reducing the capacity to assess and treat new arrivals.</span></p>
<p><span>Governments are responding to hospital crowding with plans for new facilities, additional beds and more staff. These investments may be necessary, but there is another source of hospital capacity that deserves urgent attention: preventing the infections that keep patients in hospital longer.</span></p>
<p><span>Healthcare-associated infections are among the most common adverse events in acute care. They cause suffering and death, increase healthcare costs and consume beds and staff time that are urgently needed for other patients. The growing threat of antibiotic-resistant bacteria makes prevention still more important.</span></p>
<h1><b>Hospitals Face an Inherent Infection Risk</b></h1>
<p><span>Hospitals occupy a difficult position in the fight against infection. They exist to make sick people well, yet they bring large numbers of vulnerable people together. Some patients arrive carrying infections. Others have weakened immune systems, open wounds or invasive devices that make them unusually susceptible. Healthcare workers move frequently between patients, while shared equipment and frequently touched surfaces provide additional routes for microorganisms to travel.</span></p>
<p><span>This does not mean that hospital infections are inevitable. It means that hospitals are inherently high-risk environments in which preventing transmission requires constant vigilance. A 2024 Canadian survey found that approximately 8.1% of hospital patients had at least one healthcare-associated infection. These infections remain among the most common adverse events in acute care.</span></p>
<p><span>Doctors, nurses and other caregivers may clean their hands dozens of times during a shift. Even excellent professionals can miss an opportunity when care is urgent, complicated or interrupted. Infection prevention must therefore involve more than asking people to be careful. Healthcare workers need systems that help them perform the right action at the right moment.</span></p>
<h1><b>Infections Consume Hospital Capacity</b></h1>
<p><span>Healthcare-associated infections cause suffering and death, but their effect on hospital capacity receives less attention. Infected patients often require additional treatment and remain in hospital longer. Surgical and device-related infections, for example, can add approximately seven to 11 days to a hospital stay.</span></p>
<p><span>Using Canadian estimates of the number of healthcare-associated infections and the additional hospital days they cause, approximately 1.7 million bed-days may be consumed each year treating these infections. That is equivalent to having nearly 5,000 hospital beds occupied every day of the year. The calculation is an estimate rather than a national administrative count, but it illustrates the scale of capacity that infection consumes.</span></p>
<p><span>If an effective national effort prevented 70% of this burden, Canada could recover about 1.2 million bed-days annually. That is the equivalent capacity of approximately 3,300 staffed hospital beds. In physical capacity, this would be comparable to adding several large hospitals, without waiting years for new buildings to be planned and constructed.</span></p>
<p><span>The benefit would extend beyond the beds. Every hospitalized patient requires time from physicians, nurses, pharmacists, therapists, diagnostic personnel, cleaners, food-service workers and many others. Preventing infections would allow these overstretched teams to spend less time treating avoidable complications and more time providing surgery, emergency care, rehabilitation and other services Canadians are waiting for.</span></p>
<h1><b>Canadian Technology Can Help</b></h1>
<p><span>Hand hygiene remains one of the most important defences against infection transmission in healthcare. Hygienic Echo Inc. has developed an advanced Canadian system designed to improve it. The wearable Buddy Badge recognizes when a caregiver may have missed an important hand-hygiene opportunity and provides an immediate, discreet reminder.</span></p>
<p><span>The system supports healthcare workers rather than blaming them. It intervenes when microorganisms might otherwise be carried from one patient, surface or care environment to another. Technology cannot eliminate healthcare-associated infections by itself, but it can make safe practices more consistent and measurable when combined with education, environmental cleaning, antimicrobial stewardship and strong clinical leadership.</span></p>
<p><span>Canada has the engineering and clinical expertise to lead in infection prevention. Yet promising Canadian technologies often struggle to obtain their first major customers here. Governments and healthcare organizations should establish practical routes for independent evaluation and adoption, measuring results in infections prevented, hospital days avoided, staff time released and patient outcomes improved.</span></p>
<h1><b>Prevention Is Healthcare Capacity</b></h1>
<p><span>New hospitals and additional healthcare workers may still be needed, but construction is expensive, recruitment is difficult and both take years. Preventing healthcare-associated infections offers a faster route to additional capacity by making better use of the hospitals and workforce Canada already has.</span></p>
<p><span>A national infection-prevention strategy should prepare Canada for future pandemics while also addressing the infections occurring in healthcare facilities today. Governments, hospitals, universities and Canadian companies should work together to identify effective interventions and bring them into use.</span></p>
<p><span>By preventing avoidable infections, supporting healthcare workers and adopting effective Canadian innovations, Canada could save lives, recover thousands of hospital beds and provide care to more people using resources that already exist. That would make Canada both stronger and safer.</span></p>
<p><span>By Dr. Geoff Fernie</span><br><br></p>
<p>The post <a href="https://www.hospitalnews.com/preventing-hospital-infections-could-free-thousands-of-canadian-beds/">Preventing Hospital Infections Could Free Thousands of Canadian Beds</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>6 Free ABFM Practice Questions for Family Medicine Residents</title>
<link>https://edusehat.com/en/6-free-abfm-practice-questions-for-family-medicine-residents</link>
<guid>https://edusehat.com/en/6-free-abfm-practice-questions-for-family-medicine-residents</guid>
<description><![CDATA[ The post 6 Free ABFM Practice Questions for Family Medicine Residents appeared first on BoardVitals Blog. ]]></description>
<enclosure url="https://blog.boardvitals.com/wp-content/uploads/2022/01/family-medicine-boards-prep-1024x768.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 16 Oct 2026 03:15:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Free, ABFM, Practice, Questions, for, Family, Medicine, Residents</media:keywords>
<content:encoded><![CDATA[<p class="wp-block-paragraph">If you’re a PGY-3, the ABFM Family Medicine Certification Examination is likely the next big milestone after residency. It covers the full breadth of family medicine in a single day, and since 2025, it’s organized around how family physicians actually practice rather than by organ system.</p>



<p class="wp-block-paragraph">The six questions below come from the BoardVitals <a target="_blank" rel="noopener" href="https://www.boardvitals.com/family-medicine-board-review">ABFM board review question bank</a> and are written in the same single-best-answer vignette style you’ll see on exam day. Take the quiz, then use the exam overview, blueprint breakdown, and study timeline below to plan your prep for the spring or fall sitting.</p>



<h2 class="wp-block-heading">Take the Quiz</h2>



<div class="riddle_target" data-rid-id="421907" data-fg="#00baff" data-bg="#54d3d1" data-auto-scroll="true" data-auto-scroll-offset="5">

<link href="https://www.riddle.com/embed/files/css/embed.css" rel="stylesheet">
<section><h2>Family Medicine</h2><p></p><p>Here are 6 highly rated ABFM Family Medicine sample questions taken directly from the BoardVitals Family Medicine Board Review. We’re giving you just a taste of what you might expect on your actual board exam. Good luck!<br></p></section><section><h2>A 50-year-old male presents to urgent care with left ear pain for a week. What is the appropriate treatment for this patient?</h2><p></p><p>He is a type 2 diabetic and is not always compliant with his medications. He says the ear bothered him a little bit at first, and he scratched the inside with a q-tip for relief. Over the last 2 days, the ear pain has worsened, is swollen, and he has a bad headache and low grade fever. His vitals are BP 130/90, HR 100, RR 18, Sat 99% on RA, and Temp 100.1°F. His ear has the following appearance.</p></section><section><h3>A 14-year-old male is admitted to the primary care clinic for a rash that occurred during the last few days. What is the most likely diagnosis?</h3><p></p><p>He states that he is a wrestler for his high school and that the rash started a few days after one of his wrestling competitions. There’s no PMH. He notes that the rash is found locally on his left arm and left leg, and he denies any fever, nausea, vomiting, and runny nose. The patient’s temperature = 98.5°F, HR = 90, RR = 20, and BP = 110/80. Physical exam shows the rash pictured below:</p></section><section><h3>A 23-year-old black female presents to urgent care with approximately 3 weeks of body and joint aches. What workup is required for this patient?</h3><p></p><p>Past medical history is significant for a kidney stone. She also reports fatigue, hoarse voice, and waxing and waning cough. She does not smoke and denies fever or sputum. She has a family history of hypertension and diabetes. Her vitals upon arrival are BP 130/80, HR 90, RR 20, Temp 99.1, and O2 Sat 99% on RA.</p></section><section><h3>A 45-year-old male comes to urgent care for an extremely painful thumb. What treatment should be offered to this patient?</h3><p></p><p>He thinks he could have pinched it when he was dressing a few days back, although he never had sudden pain. For the past 2 days, the thumb around the nail is swollen, painful, red, and draining liquid. He is vitals are BP 150/80, HR 95, RR 18, and Temp 98.9.</p></section><section><h3>An 81 year old male presents by ambulance to the emergency room for evaluation of new onset confusion. Which of the following is appropriate?</h3><p></p><p>He has a history of hypertension, type 2 diabetes mellitus, hyperlipidemia, and congestive heart failure. He takes metformin, lisinopril, and pravastatin. He lives in a nursing home. He appears acutely ill and confused about the date and place. His blood pressure is 90/60 mmHg. His heart rate is 92 beats per minute, and his respiratory rate is 22/minute. His temperature is 35 degrees C. SaO2 is 92%. He has crackles in his lung bases. Auscultation of the heart reveals a regular rhythm without murmur, rub, or gallop.</p></section><section><h3>A 25-year-old female presents with 2 weeks of a “cold sore” on her upper lip that will not heal. What is the next step in treatment?</h3><p></p><p>She has tried OTC cold sore cream, bacitracin ointment, and warm compresses to no avail. She denies fever, headache, rash, or other symptoms. She is sexually active with a new partner but denies any symptoms besides the sore. She takes no medications. The sore does not hurt, but she occasionally feels the urge to scratch it. Her vitals upon arrival are BP 100/70, HR 65, RR 16, Temp 98.8, and Sat 99% on RA. On exam, the sore pictured below is evident.</p></section><section><h2>There’s Room For Improvement</h2><p></p><p>Don’t beat yourself up, we’re here to help. Study anywhere, any time with BoardVitals. 100% pass guarantee. Go to <a href="http://www.boardvitals.com/" class="accent-link" target="_blank" rel="noopener"><span data-href="http://www.boardvitals.com" data-auto-link="true">www.boardvitals.com</span></a> today! <br></p></section><section><h3>You’re Almost Ready</h3><p></p><p>But there’s always room for improvement.  Study anywhere, any time with BoardVitals. 100% pass guarantee. Share your result with friends and go to www.boardvitals.com today! </p></section><section><h3>You’re Ready</h3><p></p><p class="">But there’s always room for improvement. Study anywhere, any time with BoardVitals. 100% pass guarantee. Share your result with friends and go to <a class="accent-link" href="http://www.boardvitals.com/" target="_blank" rel="noopener"><span data-auto-link="true" data-href="http://www.boardvitals.com">www.boardvitals.com</span></a> today! </p></section><section><h3></h3></section>
</div>



<h3 class="wp-block-heading">How did you do?</h3>



<p class="wp-block-paragraph">Note which domains gave you trouble. One missed question won’t predict your exam result, but a pattern of misses in one domain is a useful signal about where to focus. For full explanations and more than 2,850 questions across all five domains, <a target="_blank" rel="noopener" href="https://www.boardvitals.com/family-medicine-board-review">start a free trial of the BoardVitals Family Medicine question bank</a>.</p>



<p class="wp-block-paragraph">Dates and deadlines change each year, so confirm everything on ABFM’s <a href="https://www.theabfm.org/become-certified/one-day-exam/" target="_blank" rel="noopener">one-day exam page</a> and <a href="https://www.theabfm.org/?page_id=32" target="_blank" rel="noopener">dates and deadlines page</a> before you register.</p>



<h2 class="wp-block-heading">The ABFM Exam at a Glance</h2>



<p class="wp-block-paragraph">To earn initial ABFM certification, residents must pass the one-day Family Medicine Certification Examination, which consists of 300 single-best-answer questions taken in one day at a Prometric test center. The exam is broken down into four 95-minute sections of 75 questions each, with 100 minutes of pooled break time</p>



<p class="wp-block-paragraph"><a href="https://www.theabfm.org/wp-content/uploads/2026/05/2026-FMCE-Examination-Information-Booklet-v.1.0.pdf">Dates and deadlines</a> change each year, so confirm details with the <a href="https://www.theabfm.org/become-certified/one-day-exam/">ABFM</a> before you register.</p>



<h2 class="wp-block-heading">The ABFM Blueprint, Explained</h2>



<p class="wp-block-paragraph">Since January 2025, the <a target="_blank" rel="noopener" href="https://www.theabfm.org/family-medicine-exam-blueprint/">ABFM exam blueprint</a> has been organized around five domains of care based on what family physicians do in practice, not by organ system. Acute and chronic care together make up 60% of the exam.</p>



<ul class="wp-block-list">
<li><strong>Acute Care and Diagnosis (35%):</strong> Office-based scenarios where you choose the next diagnostic step, make the diagnosis, or start initial treatment.</li>



<li><strong>Chronic Care Management (25%):</strong> Ongoing management of chronic disease in the clinic or in long-term care settings.</li>



<li><strong>Emergent and Urgent Care (20%):</strong> Decisions needed within hours, whether in the ED, hospital, urgent care, or office.</li>



<li><strong>Preventive Care (15%):</strong> Screening, immunizations, and other preventive services in the ambulatory setting.</li>



<li><strong>Foundations of Care (5%):</strong> Biostatistics, health policy, legal and ethical issues, health equity, and related topics.</li>
</ul>



<h3 class="wp-block-heading">Why this matters for how you study</h3>



<p class="wp-block-paragraph">Most residents learn by rotation and organ system, but the exam asks what you would <em>do</em>. A single topic like diabetes can show up as a diagnosis question, a chronic management question, a DKA question in Emergent and Urgent Care, or a screening question in Preventive Care. When you review a topic, practice it across every domain where it could appear.</p>



<p class="wp-block-paragraph">Don’t skip Foundations of Care because it’s only 5%. Biostatistics and ethics questions are often fast points for prepared test-takers and costly misses for everyone else.</p>



<h2 class="wp-block-heading">Spring or Fall? Choosing Your Sitting as a PGY-3</h2>



<p class="wp-block-paragraph">Residents in good standing can take the exam during the final months of residency, so most PGY-3s choose between the April window before graduation and the November window after it.</p>



<p class="wp-block-paragraph">For the 2026 cycle, ABFM required residency to be completed by June 30 for the spring exam and by December 31 for the fall exam. After graduation, you have a seven-year board eligibility period to pass.</p>



<p class="wp-block-paragraph"><strong>The case for spring:</strong> You test before graduation, while the content is fresh and study time can fit around residency didactics. Results also arrive before most first jobs begin. The downside is studying during demanding final rotations.</p>



<p class="wp-block-paragraph"><strong>The case for fall:</strong> You get more total study time and avoid exam pressure at the end of residency. The downside is less structured time once you’re working, and prep can easily slip during a job transition.</p>



<p class="wp-block-paragraph">Ask your program director which sitting most of your co-residents choose and whether your program builds in protected study time. Confirm each year’s eligibility deadlines on ABFM’s <a target="_blank" rel="noopener" href="https://www.theabfm.org/?page_id=32">dates and deadlines page</a>.</p>



<h2 class="wp-block-heading">Ready for More ABFM Practice?</h2>



<p class="wp-block-paragraph">These six questions are a starting point. The <a href="https://www.boardvitals.com/family-medicine-board-review" target="_blank" rel="noopener">BoardVitals Family Medicine board review</a> gives you more than 2,850 ABFM-style questions mapped to the current blueprint, adaptive quizzes, risk assessment reporting, and a 100% Pass Guarantee.</p>



<p class="wp-block-paragraph"><a target="_blank" rel="noopener" href="https://www.boardvitals.com/family-medicine-board-review"><strong>Start your free Family Medicine trial</strong></a><strong>.</strong> No credit card required.</p>



<p class="wp-block-paragraph"></p>
<p>The post <a href="https://www.boardvitals.com/blog/family-medicine-sample-questions/">6 Free ABFM Practice Questions for Family Medicine Residents</a> appeared first on <a href="https://www.boardvitals.com/blog">BoardVitals Blog</a>.</p>]]> </content:encoded>
</item>

<item>
<title>6 Free NPLEX Part I Practice Questions + Explanations</title>
<link>https://edusehat.com/en/6-free-nplex-part-i-practice-questions-explanations</link>
<guid>https://edusehat.com/en/6-free-nplex-part-i-practice-questions-explanations</guid>
<description><![CDATA[ The post 6 Free NPLEX Part I Practice Questions + Explanations appeared first on BoardVitals Blog. ]]></description>
<enclosure url="https://blog.boardvitals.com/wp-content/uploads/2026/09/nplex-part-1-1024x768.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 16 Oct 2026 03:15:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Free, NPLEX, Part, Practice, Questions, Explanations</media:keywords>
<content:encoded><![CDATA[<p class="wp-block-paragraph">The <a href="https://nabne.org/exam-overview/">NPLEX Part I – Biomedical Science Examination (BSE)</a> is the first licensing milestone on your path to becoming a naturopathic doctor. It tests whether you can apply anatomy, physiology, biochemistry, microbiology, and pathology to a real patient, not just recall facts.</p>



<p class="wp-block-paragraph">Below are six free practice questions from the <a href="https://www.boardvitals.com/nplex-part-1-naturopathic-exam">BoardVitals NPLEX Part I question bank</a>, built around one case cluster, the same format you’ll see on exam day. Each question includes a full explanation of the correct answer and why the other choices are wrong. Work through them, then use the exam overview, study tips, and FAQ to plan the rest of your prep.</p>



<p class="wp-block-paragraph"><strong>Taking the exam in February or August?</strong> Sign up for a <a href="https://www.boardvitals.com/nplex-part-1-naturopathic-exam" target="_blank" rel="noopener">free NPLEX Part I trial</a> today. No credit card required.</p>



<h2 class="wp-block-heading">NPLEX 1 Sample Questions</h2>



<div class="riddle_target" data-rid-id="421897" data-fg="#1486cd" data-bg="#54d3d1" data-auto-scroll="true" data-auto-scroll-offset="5">

<link href="https://www.riddle.com/embed/files/css/embed.css" rel="stylesheet">
<section><h2>NPLEX 1</h2><p></p><p>Because the Naturopathic Physicians Licensing Examination is case-based, we’re hooking you up with a set of NPLEX 1 sample questions from a highly interesting case (featuring a zookeeper and an armadillo, no less), and in doing so, we’re giving you an authentic taste of what you’d expect on the real NPLEX 1 exam.</p></section><section><h2>A 40-year-old male presents complaining of neuropathy in his feet and hands.</h2><p></p><p>It started two weeks ago as a mild discomfort that was intermittent but is now constant. He also complains of muscle weakness that began in his legs and now effects his arms and facial muscles. PE reveals absent deep tendon reflexes. CBC, metabolic panel and lipids are unremarkable. He has no previous diagnoses. What is your most likely diagnosis based on this patient’s presentation?</p></section><section><h3>After further questioning, the patient explains his occupational role as a zookeeper.</h3><p></p><p>It includes care taking of the armadillo suite which has consistently welcomed rescued armadillos from the Southern United States over the years. After learning this information, what condition should be added to your differential diagnosis list? </p></section><section><h3>Hansen’s disease is caused by __________?</h3></section><section><h3>What are the common symptoms associated with Hansen’s disease?</h3></section><section><h3>Which of the following best describes the histopathological findings in Hansen’s disease?</h3></section><section><h3>Diagnosis of the bacteria can be made by?</h3></section><section><h2>There’s Room For Improvement</h2><p></p><p>Don’t beat yourself up, we’re here to help. Study anywhere, any time with BoardVitals. 100% pass guarantee. Go to www.boardvitals.com today!</p></section><section><h3>You’re On Your Way</h3><p></p><p>Not bad, not bad. But there’s always room for improvement. Study anywhere, any time with BoardVitals. 100% pass guarantee. Share your result with friends and go to www.boardvitals.com today!</p></section><section><h3>You’re Almost Ready</h3><p></p><p>But there’s always room for improvement. Study anywhere, any time with BoardVitals. 100% pass guarantee. Share your result with friends and go to www.boardvitals.com today!</p></section><section><h3>You’re Ready</h3><p></p><p>But there’s always room for improvement. Study anywhere, any time with BoardVitals. 100% pass guarantee. Share your result with friends and go to www.boardvitals.com today!</p></section><section><h3></h3></section>
</div>



<p class="wp-block-paragraph"><span>How’d you do? Not exactly the answers you expected, right? No matter if you scored well or didn’t perform up to your standards, know that there’s always room for improvement</span>.</p>



<h2 class="wp-block-heading">NPLEX Part I at a Glance</h2>



<p class="wp-block-paragraph">The Part I BSE is a 200-question, case-based exam given in two 100-question sections on one day, twice a year.</p>



<p class="wp-block-paragraph">There is no fixed passing percentage and no curve. The NABNE uses the <a href="https://nabne.org/exam-results/">Angoff method</a>, in which licensed NDs estimate how a minimally competent candidate would perform on each question. The cut score varies slightly from one exam to the next, and you must pass both general exam areas in the same sitting:</p>



<ul class="wp-block-list">
<li><strong>Structure/Function:</strong> anatomy, biochemistry & genetics, and physiology</li>



<li><strong>Disease/Dysfunction:</strong> microbiology & immunology and pathology</li>
</ul>



<p class="wp-block-paragraph">If you fail either area, you retake the entire exam. That’s why balanced preparation matters more than overstudying your favorite subject.</p>



<h2 class="wp-block-heading">How NPLEX Part I Case Clusters Work</h2>



<p class="wp-block-paragraph">Every NPLEX question is tied to a single patient. You read a short clinical summary, then answer several questions about that same case. On Part I, the summary is brief, and the questions ask about the biomedical basis of the patient’s condition, not diagnosis or treatment. That comes later, on Part II.</p>



<p class="wp-block-paragraph">In practice, one case can test several subjects at once. A single patient might prompt a microbiology question about the causative organism, an immunology question about the host response, and a pathology question about the tissue findings. The six questions above follow this pattern. </p>



<p class="wp-block-paragraph">Confused about case clusters? Here are some tips: </p>



<ul class="wp-block-list">
<li><strong>Read the case once, carefully, before the first question.</strong> Details you skim past often answer question four or five.</li>



<li><strong>Treat each question independently.</strong> Getting one item wrong doesn’t mean the rest of the cluster is lost, so don’t second-guess later answers based on an earlier one.</li>
</ul>



<h2 class="wp-block-heading">Ready for More NPLEX Part I Practice?</h2>



<p class="wp-block-paragraph">These six questions are a starting point. The <a href="https://www.boardvitals.com/nplex-part-1-naturopathic-exam" target="_blank" rel="noopener">BoardVitals NPLEX Part I question bank</a> gives you 500+ case-based questions written and reviewed by licensed naturopathic doctors, detailed explanations for every answer, performance tracking by subject, and a 100% Pass Guarantee. And if you’re looking for help with the Naturopathic Physicians Licensing Examination Part 2, then look no further than our <a href="https://www.boardvitals.com/nplex-part-2-naturopathic-exam">NPLEX Part 2 question bank</a>.</p>



<p class="wp-block-paragraph"><a href="https://www.boardvitals.com/nplex-part-1-naturopathic-exam" target="_blank" rel="noopener"><strong>Start your free NPLEX Part I trial</strong></a><strong> today.</strong> No credit card required. </p>
<p>The post <a href="https://www.boardvitals.com/blog/nplex-1-sample-questions/">6 Free NPLEX Part I Practice Questions + Explanations</a> appeared first on <a href="https://www.boardvitals.com/blog">BoardVitals Blog</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Thirty Million Compartments: Testing Single&#45;Molecule PCR’s Potential</title>
<link>https://edusehat.com/en/thirty-million-compartments-testing-single-molecule-pcrs-potential</link>
<guid>https://edusehat.com/en/thirty-million-compartments-testing-single-molecule-pcrs-potential</guid>
<description><![CDATA[ Countable Labs has named Fred Hutchinson its first certified service provider, currently serving researchers across the Seattle region. And the company is continuing to build its list of service providers.
The post Thirty Million Compartments: Testing Single-Molecule PCR’s Potential appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/05/Getty_2273179177_Cancer.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 16 Oct 2026 00:10:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Thirty, Million, Compartments:, Testing, Single-Molecule, PCR’s, Potential</media:keywords>
<content:encoded><![CDATA[<p>Sponsored content brought to you by</p>
<p><a href="https://countablelabs.com/" target="_blank" rel="noopener"><img decoding="async" class="wp-image-331996 size-medium alignnone" src="https://www.genengnews.com/wp-content/uploads/2026/05/CountableLabs_logo-300x67.jpg" alt="Countable Labs logo" width="300" height="67" srcset="https://www.genengnews.com/wp-content/uploads/2026/05/CountableLabs_logo-300x67.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/05/CountableLabs_logo.jpg 475w" sizes="(max-width: 300px) 100vw, 300px"></a></p>
<figure aria-describedby="caption-attachment-332024" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="size-medium wp-image-332024" src="https://www.genengnews.com/wp-content/uploads/2026/05/Getty_2273179177_Cancer-300x170.jpg" alt="Cancer cells" width="300" height="170" srcset="https://www.genengnews.com/wp-content/uploads/2026/05/Getty_2273179177_Cancer-300x170.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/05/Getty_2273179177_Cancer-1024x580.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/05/Getty_2273179177_Cancer-768x435.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/05/Getty_2273179177_Cancer-741x420.jpg 741w, https://www.genengnews.com/wp-content/uploads/2026/05/Getty_2273179177_Cancer-696x394.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/05/Getty_2273179177_Cancer-1392x788.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2026/05/Getty_2273179177_Cancer-1068x605.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/05/Getty_2273179177_Cancer.jpg 1400w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Credit: anusorn nakdee / iStock / Getty Images Plus</figcaption></figure>
<p>Digital PCR (dPCR) earned its reputation by solving a real problem: it let researchers count nucleic acid molecules directly, without leaning on a standard curve. But the method works by assuming something it cannot verify—that each of a limiting number of droplets holds no more than one target molecule. At low concentrations, that assumption mostly holds. Push the input higher, or add a few more targets to the same reaction, and multiple target molecules start sharing individual partitions. At that point, the instrument is no longer counting and is instead estimating using Poisson statistics.</p>
<p>The gap between what dPCR promises and what it can reliably deliver as target input and multiplexing needs surpass dPCR thresholds, is directly addressed by Countable Labs, whose single molecule counting PCR platform was the subject of a recent <em>GEN </em><a href="https://www.genengnews.com/multimedia/webinars/digital-pcr-playbook-applications-and-challenges-across-research-and-clinical-labs/" target="_blank" rel="noopener">webinar</a>. Rather than relying on statistical inference, the company’s technology partitions a sample into a gel-like matrix having approximately 30 million discrete compartments, physically separating individual molecules for direct counting, across the widest-available dynamic range.</p>
<p>Testing this claim under real lab conditions fell to Alex Zevin, PhD, director of the Genomics Shared Resource at Fred Hutchinson Cancer Center. His core facility, which supports more than 100 investigators and processes more than 10,000 samples a year, has spent the past decade layering on quantification technologies: The Nanostring nCounter<sup>®</sup> technology in 2014, ABI QuantStudio<sup>TM</sup> 5 instruments in 2017, the BioRad QX200<sup>TM</sup> digital droplet PCR system in 2024, and, since mid-2025, a Countable Labs demo unit that has successfully processed hundreds of samples across nine labs.</p>
<h4><strong>Counting instead of correcting</strong></h4>
<p>The mechanics matter here. Standard qPCR analyzes a sample in bulk and needs a standard curve to translate a threshold cycle into a quantity. Droplet dPCR and dPCR systems distribute samples across a relatively low number of partitions, subjecting these techniques to sensitivity issues outside of a limited dynamic range. Countable PCR partitions samples at a level that is orders of magnitude greater than that of dPCR by isolating single molecules in a proprietary matrix and performing readouts for direct counting of positive partitions, using 3D light-sheet imaging. It also uses a proprietary universal multiplexing chemistry that sidesteps design constraints of multiplexed assays available on other platforms.</p>
<h4><strong>Putting it to work</strong></h4>
<p>Zevin highlights early results that instilled confidence in the Countable Labs platform. One example he shared involved an Illumina library quantification assay, built simply by tagging existing P5 and P7 primers with the platform’s adapter sequence. It produced a linear response against commercial standards and tracked closely with results from the KAPA Library Quantification Kit, the method his lab already trusted. “What this told me is that we could easily switch our quantification from qPCR to a Countable PCR-based readout,” Zevin said.</p>
<figure aria-describedby="caption-attachment-339368" class="wp-caption alignright"><img decoding="async" class="size-medium wp-image-339368" src="https://www.genengnews.com/wp-content/uploads/2026/10/WebinarArticle_Figure-1_Countable-Labs-300x254.jpg" alt="Figure 1. Results from GAPDH transcript quantification" width="300" height="254" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/WebinarArticle_Figure-1_Countable-Labs-300x254.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/WebinarArticle_Figure-1_Countable-Labs-1024x866.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/WebinarArticle_Figure-1_Countable-Labs-768x649.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/WebinarArticle_Figure-1_Countable-Labs.jpg 1100w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Figure 1. Results from GAPDH transcript quantification using cDNA from two cell lines. Both samples demonstrated highly linear response (r2>0.999) over three orders of magnitude suggesting improved sensitivity compared to standard qPCR.</figcaption></figure>
<p>Similar patterns turned up elsewhere. Working with primers and cDNA from the lab of Steve Henikoff, PhD, at Fred Hutchinson Center, Zevin’s team saw improved sensitivity quantifying GAPDH transcripts in comparison to their existing qPCR approach (Figure 1). A 16S ribosomal RNA assay, built with primers from the lab of David Fredericks, MD, also at Fred Hutchinson, held a linear response across six orders of magnitude down to roughly 10 input copies (Figure 2). It also successfully processed microbiome samples from the lab of Neelendu Dey, MD, another Fred Hutchinson collaborator.</p>
<p>The most clinically weighted example involved <em>BCR-ABL/ABL1</em> fusion detection, which is central to acute myeloid leukemia. Using an off-the-shelf Countable Labs assay, the lab accurately detected positive signals from as little as 55 picograms of input RNA. That work has since grown into another collaboration at Fred Hutchinson, this time with the lab of Jerald Radich, MD,  to compare the assay against validated clinical assays and evaluate its precision across multiple sites.</p>
<p>In her portion of the presentation, Rachel Kane, Countable Lab’s director of business development, discussed a JAK2 V617F example that detected 31 mutant alleles against roughly 773,000 wild-type copies, a sensitivity she put at ten times that of digital PCR. She also described a design in which isolating molecules before amplification means a four-target multiplexed reaction returns the same counts as four separate single-target reactions, avoiding probe competition factors that erode precision on other platforms, as multiplexing increases.</p>
<figure aria-describedby="caption-attachment-339367" class="wp-caption aligncenter"><img loading="lazy" decoding="async" class="wp-image-339367" src="https://www.genengnews.com/wp-content/uploads/2026/10/WebinarArticle_Figure-2_Countable-Labs-1024x391.jpg" alt="Figure 2. Results from 16s quantification" width="600" height="229" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/WebinarArticle_Figure-2_Countable-Labs-1024x391.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/WebinarArticle_Figure-2_Countable-Labs-300x115.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/WebinarArticle_Figure-2_Countable-Labs-768x293.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/WebinarArticle_Figure-2_Countable-Labs.jpg 1400w" sizes="auto, (max-width: 600px) 100vw, 600px"><figcaption class="wp-caption-text">Figure 2. Results from 16s quantification using 338F and 806R primer sequences and control. Serial dilution of control showed highly linear response (r2 > 0.99) over six orders of magnitude. Countable Labs PCR system shows superior sensitivity compared to standard qPCR.</figcaption></figure>
<h4><strong>What comes next</strong></h4>
<p>Where Countable Labs sees the platform heading matters as much as where it has already been. For Zevin, the more immediate future applications are close to home: HIV reservoir detection, where a shrinking reservoir under treatment demands ever more sensitive assays, alongside pharmacogenomic SNP panels and mycoplasma contamination screening. Countable Labs, for its part, has named Fred Hutchinson its first certified service provider, currently serving researchers across the Seattle region. And the company is continuing to build its list of service providers.</p>
<p>Absolute counting quietly becomes statistical correction once concentration or multiplexing climbs. That’s the exact problem a design built around physical isolation is meant to resolve. Whether it holds up at scale and across sites is still being tested. But as Kane put it, “Digital PCR changed what was quantifiable. Single molecule counting changes what’s measurable.”</p>
<p>The post <a href="https://www.genengnews.com/sponsored/thirty-million-compartments-testing-single-molecule-pcrs-potential/">Thirty Million Compartments: Testing Single-Molecule PCR’s Potential</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>New technology improves precision of breast cancer surgery at Alberta hospital</title>
<link>https://edusehat.com/en/new-technology-improves-precision-of-breast-cancer-surgery-at-alberta-hospital</link>
<guid>https://edusehat.com/en/new-technology-improves-precision-of-breast-cancer-surgery-at-alberta-hospital</guid>
<description><![CDATA[ Medicine Hat Regional Hospital introduces magnetic localization technology to support more precise breast cancer procedures and improve surgical scheduling. Patients undergoing breast cancer surgery in southeastern Alberta now have access to advanced technology designed to improve surgical precision, streamline procedures and provide greater flexibility in scheduling treatment. Medicine Hat Regional Hospital has introduced the Sentimag […]
The post New technology improves precision of breast cancer surgery at Alberta hospital appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/Focused-Surgical-Team-in-Action.png" length="49398" type="image/jpeg"/>
<pubDate>Fri, 16 Oct 2026 00:05:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>New, technology, improves, precision, breast, cancer, surgery, Alberta, hospital</media:keywords>
<content:encoded><![CDATA[<p><strong>Medicine Hat Regional Hospital introduces magnetic localization technology to support more precise breast cancer procedures and improve surgical scheduling.</strong></p>
<p>Patients undergoing breast cancer surgery in southeastern Alberta now have access to advanced technology designed to improve surgical precision, streamline procedures and provide greater flexibility in scheduling treatment.</p>
<p>Medicine Hat Regional Hospital has introduced the Sentimag Magnetic Localization System and Magseed technology, giving surgeons new tools to locate and remove breast lesions that may be difficult to identify through physical examination.</p>
<p>The hospital successfully completed its first procedures using the technology on August 28, 2026, according to an announcement from the Medicine Hat Health Foundation on October 14.</p>
<h3>Improving precision during breast cancer surgery</h3>
<p>The Sentimag system uses magnetic detection technology to help surgeons locate targeted breast tissue during an operation.</p>
<p>A small magnetic marker, known as a Magseed, can be placed in or near a suspicious breast lesion before surgery. Surgeons then use the Sentimag detection system to identify the marker’s location, allowing them to target the tissue requiring removal.</p>
<p>The technology is particularly useful for non-palpable breast lesions — abnormalities that cannot be felt during a physical examination but may be identified through mammography or other diagnostic imaging.</p>
<p>The hospital has also introduced a Trident HD Imaging Unit in its Diagnostic Imaging department.</p>
<p>This equipment allows surgical teams to examine removed tissue during an operation, helping confirm that the targeted lesion and magnetic marker have been successfully removed.</p>
<p>The combination of magnetic localization and intraoperative imaging provides additional tools to support surgical decision-making.</p>
<h3>Greater flexibility for patients and surgical teams</h3>
<p>One of the technology’s significant advantages is its potential to simplify surgical scheduling.</p>
<p>Traditional wire localization procedures generally require patients to have a guide wire inserted on the same day as their surgery.</p>
<p>Magseed markers, however, can be placed days or even weeks before the procedure.</p>
<p>This allows hospitals to separate the localization appointment from the operation, potentially reducing scheduling conflicts between diagnostic imaging departments and operating rooms.</p>
<p>Dr. Alisha Tessier, the surgeon who led the implementation of Magseed technology at Medicine Hat Regional Hospital, identified improved scheduling flexibility as an important benefit for patients and healthcare teams.</p>
<p>The approach may help hospitals make more efficient use of operating room capacity while reducing the number of procedures patients must complete on their surgery date.</p>
<h3>Supporting regional cancer care</h3>
<p>The new equipment also supports sentinel lymph node procedures through the use of Magtrace, a magnetic tracer that helps surgeons identify lymph nodes for assessment.</p>
<p>The first procedure performed at Medicine Hat Regional Hospital using the new technology combined breast lesion localization with sentinel lymph node biopsy.</p>
<p>The introduction of the equipment is part of a broader initiative to strengthen breast health services in southeastern Alberta.</p>
<p>Earlier this year, the Medicine Hat Health Foundation announced the development of a comprehensive pilot Breast Health Program at the hospital, supported by the Yuill Family Foundation.</p>
<p>The program aims to improve access to breast health services and expand the diagnostic and treatment options available to patients in the region.</p>
<h3>Expanding access to specialized care</h3>
<p>For patients living outside major urban centres, access to specialized cancer services can involve additional travel, scheduling challenges and time away from work or family.</p>
<p>Introducing advanced surgical technology at regional hospitals can help reduce some of these barriers by allowing more procedures to be performed closer to home.</p>
<p>The Medicine Hat Health Foundation emphasized that established breast lesion localization methods remain safe and effective. The new magnetic system provides an additional clinical option rather than replacing existing techniques.</p>
<p>The investment reflects continuing efforts to strengthen regional healthcare capacity and provide patients with access to modern cancer treatment technologies within their communities.</p>
<p>The post <a href="https://www.hospitalnews.com/new-technology-improves-precision-of-breast-cancer-surgery-at-alberta-hospital/">New technology improves precision of breast cancer surgery at Alberta hospital</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Canada is burning through its young nurses at an alarming rate, MEI warns</title>
<link>https://edusehat.com/en/canada-is-burning-through-its-young-nurses-at-an-alarming-rate-mei-warns</link>
<guid>https://edusehat.com/en/canada-is-burning-through-its-young-nurses-at-an-alarming-rate-mei-warns</guid>
<description><![CDATA[ Ontario: 31 nurses below the age of 35 left the workforce for every 100 new nurses who started in 2024, finds new MEI report Canada is burning through its young nurses at an alarming rate as healthcare systems across the country struggle to retain them, reveals a new publication released this morning by the MEI. […]
The post Canada is burning through its young nurses at an alarming rate, MEI warns appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/economic-note-222026.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 16 Oct 2026 00:05:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Canada, burning, through, its, young, nurses, alarming, rate, MEI, warns</media:keywords>
<content:encoded><![CDATA[<p>Ontario: 31 nurses below the age of 35 left the workforce for every 100 new nurses who started in 2024, finds new MEI report</p>
<p>Canada is burning through its young nurses at an alarming rate as healthcare systems across the country struggle to retain them, reveals a new publication released this morning by the MEI.</p>
<p>“For every 100 nurses under 35 who registered to practise in the country, 34 other young nurses did not renew their registration in 2024,” says Gerard Lucyshyn, vice president of Research at the MEI and author of the report. “While this is an improvement over the year before, the ratio remains high and puts undue pressure on our strained system.”</p>
<p>Across Canada, there were 27,139 nursing positions open in 2025. This is a drop from 2023, but remains roughly three times higher than in 2016.</p>
<p>Ontario saw 31 nurses under 35 leaving for every 100 who entered the profession in 2024.</p>
<p>While this is down from the year before, this ratio remains 40 per cent higher than it was in 2014. This represents the largest deterioration over the 10-year period.</p>
<p>“Despite an improvement over the previous year, Ontario’s young nurses are still leaving in worryingly high numbers,” notes Mr. Lucyshyn. “Ontario needs to give them the working conditions and flexibility they need to remain in the profession.”</p>
<p>British Columbia remains, this year again, the best performer in the country, having cut the turnover of young nurses by 53 per cent since 2014. Yet, with 26 young nurses not renewing their license to practice for every 100 that enter the profession, more needs to be done to keep nurses motivated and in the profession.</p>
<p>Since 2022, the BC College of Nurses and Midwives has streamlined the accreditation process for internationally educated nurses by introducing a “triple-track” application that covers registered nurse, licensed practical nurse, and healthcare assistant designations.</p>
<p>“Flexibility is key,” notes Mr. Lucyshyn. “Nurses are the backbone of our healthcare system, and we need to ensure that the system works for them, not against them.”</p>
<h3>According to the Canadian Federation of Nurses Unions 2026 survey:</h3>
<ul>
<li>Over four in ten nurses reported having worked involuntary overtime in the past six months;</li>
<li>More than nine in ten experienced some form of violence or abuse at work in the past year;</li>
<li>Half are showing signs of burnout.</li>
</ul>
<p>The MEI researcher urges provinces to look to British Columbia’s shift-swapping pools, which allow nurses to trade shifts without administrative approval, as a model to emulate.</p>
<p>Other promising solutions include allowing nurses greater freedom to work for private clinics, travel nurse agencies, or telehealth companies, enabling them to better manage their schedules and maintain a healthier work-life balance.</p>
<p>“Burning through young nurses today means having fewer nurses for tomorrow,” says Mr. Lucyshyn. “Protecting our healthcare system requires loosening the grip of the government monopoly in order to offer nurses the working conditions they deserve.”</p>
<p>You can read the Economic Note here: <a title="https://email.iedm.org/c/eJwsy81yrCAQxfGngR0WNF-6YDEbX2Oqh27vUFfFCIl5_JSpLM__V4eS1hExSk4mTqB9iMbId7IhLmh1iIufYgDMYDy5HKcxeiZjZEkBSU8URxPRwtOY5UZjQTjdCvH_8qE2LCufTXlHo1sojE5BDuv3cINc07v3own7EDALmK_rGgrTNtTz3z0Pleveee8C5s9jrUhNwAwagoDZaAEz57rXrWS1184K4LbhoEVuTAXVyStjY1Uo_YbnXxD2YaMOepRnKvtShdPv2o7Scd35akOum2z9ZN7u6xQwaJyiysY75fIrKHz5rKwNhvyUETXKrwQ_AQAA___GoWQ7" href="https://email.iedm.org/c/eJwsy81yrCAQxfGngR0WNF-6YDEbX2Oqh27vUFfFCIl5_JSpLM__V4eS1hExSk4mTqB9iMbId7IhLmh1iIufYgDMYDy5HKcxeiZjZEkBSU8URxPRwtOY5UZjQTjdCvH_8qE2LCufTXlHo1sojE5BDuv3cINc07v3own7EDALmK_rGgrTNtTz3z0Pleveee8C5s9jrUhNwAwagoDZaAEz57rXrWS1184K4LbhoEVuTAXVyStjY1Uo_YbnXxD2YaMOepRnKvtShdPv2o7Scd35akOum2z9ZN7u6xQwaJyiysY75fIrKHz5rKwNhvyUETXKrwQ_AQAA___GoWQ7">https://www.iedm.org/wp-content/uploads/2026/10/economic-note-222026.pdf</a></p>
<p>The post <a href="https://www.hospitalnews.com/canada-is-burning-through-its-young-nurses-at-an-alarming-rate-mei-warns/">Canada is burning through its young nurses at an alarming rate, MEI warns</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>New Alzheimer’s treatments bring leading care closer to home for patients</title>
<link>https://edusehat.com/en/new-alzheimers-treatments-bring-leading-care-closer-to-home-for-patients</link>
<guid>https://edusehat.com/en/new-alzheimers-treatments-bring-leading-care-closer-to-home-for-patients</guid>
<description><![CDATA[ Kingston Health Sciences Centre (KHSC) is expanding access to new treatments for Alzheimer’s disease, bringing emerging care closer to home for patients across southeastern Ontario who traditionally needed to travel to larger centres such as Toronto or Ottawa. These new disease-modifying treatments are designed to slow the progression of Alzheimer’s disease in eligible patients, with […]
The post New Alzheimer’s treatments bring leading care closer to home for patients appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/MM4_8189-copy.png" length="49398" type="image/jpeg"/>
<pubDate>Fri, 16 Oct 2026 00:05:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>New, Alzheimer’s, treatments, bring, leading, care, closer, home, for, patients</media:keywords>
<content:encoded><![CDATA[<div class="elementToProof">Kingston Health Sciences Centre (KHSC) is expanding access to new treatments for Alzheimer’s disease, bringing emerging care closer to home for patients across southeastern Ontario who traditionally needed to travel to larger centres such as Toronto or Ottawa.</div>
<div class="elementToProof">These new disease-modifying treatments are designed to slow the progression of Alzheimer’s disease in eligible patients, with the greatest benefit expected when treatment begins in the earlier stages of the disease.</div>
<div></div>
<div class="elementToProof">Bram Fisher, who was diagnosed with Alzheimer’s several years ago, is one of the first patients in Canada to access these drugs. For him, the treatment means more time to remain independent and continue doing the things he enjoys — including playing music with the band, Old Gravel Road.</div>
<div></div>
<div class="elementToProof">“I would say the progression has been fairly slow, and we’ve been pretty lucky,” says Bram. “I’m still able to do the things I enjoy — I play in the band; I go for walks and go for lunch with friends.”</div>
<div></div>
<div>
<figure aria-describedby="caption-attachment-146404" class="wp-caption alignnone"><img fetchpriority="high" decoding="async" class="size-full wp-image-146404" src="https://www.hospitalnews.com/wp-content/uploads/2026/10/MM4_8151-copy.png" alt="" width="550" height="367" srcset="https://www.hospitalnews.com/wp-content/uploads/2026/10/MM4_8151-copy.png 550w, https://www.hospitalnews.com/wp-content/uploads/2026/10/MM4_8151-copy-400x267.png 400w, https://www.hospitalnews.com/wp-content/uploads/2026/10/MM4_8151-copy-150x100.png 150w, https://www.hospitalnews.com/wp-content/uploads/2026/10/MM4_8151-copy-300x200.png 300w" sizes="(max-width: 550px) 100vw, 550px"><figcaption class="wp-caption-text">Bram Fisher, who was diagnosed with Alzheimer’s several years ago, is one of the first patients in Canada to access these drugs.</figcaption></figure>
</div>
<div class="elementToProof">Bram is now receiving one of the new Alzheimer’s drugs through KHSC’s cognitive neurology program under the care of memory disorders specialist Dr. Durjoy Lahiri who arrived at KHSC in June 2024.</div>
<div></div>
<div class="elementToProof">“The idea is to slow down the disease, so patients remain independent for longer periods of time,” says Dr. Lahiri.</div>
<div class="elementToProof">KHSC is among the first health sciences centres in Canada to begin offering access to these emerging treatments recently approved by Health Canada. Dr. Lahiri’s goal is to build a larger Alzheimer’s therapeutics program in Kingston that can serve patients from across the region.</div>
<div></div>
<div class="elementToProof">“The goal is to build a modern treatment program right here in Kingston,” says Dr. Lahiri. “Kingston can function as the referral centre for the whole region outside of Toronto and Ottawa. We want to create a robust and scalable program.”</div>
<div class="elementToProof">The program is expected to grow significantly as awareness of these treatments increases. Dr. Lahiri estimates that as many as 25 to 30 patients could be receiving infusions through KHSC within the next six-to-nine months, with the potential for that number to continue growing.</div>
<div></div>
<div class="elementToProof">Early diagnosis will be critical to ensuring patients can benefit from these treatments. To support earlier diagnosis, KHSC has also developed a new blood test to diagnose Alzheimer’s disease early, with funding support from the University Hospitals Kingston Foundation (UHKF) and YGK Healthcare Champions.</div>
<div></div>
<div class="elementToProof">“This is a very new development in the field. It’s cutting-edge clinical care,” says Dr. Lahiri. “The blood test will help quickly identify patients who may benefit from further assessment and consideration for disease-modifying treatment.”</div>
<div class="elementToProof">For Bram’s partner, Bryn, the new treatment options are welcome as the couple navigates the realities of an Alzheimer’s diagnosis.</div>
<div class="elementToProof">“Neither of us thought this is what we would be doing in our retirement years,” says Bryn. “It has been a bit of a challenge.”</div>
<div class="elementToProof">For Bram, the ability to continue living his life as independently as possible is what matters most.</div>
<div class="elementToProof">“It’s not a cure,” he says. “But I’m still able to do the things I enjoy, and I am happy about that.”</div>
<div></div>
<div class="elementToProof">For patients like Bram these new treatments offer something deeply meaningful: more time to enjoy the moments that matter most, whether that’s making music, spending time with friends and loved ones, or maintaining independence for as long as possible.</div>
<p>The post <a href="https://www.hospitalnews.com/new-alzheimers-treatments-bring-leading-care-closer-to-home-for-patients/">New Alzheimer’s treatments bring leading care closer to home for patients</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Six wild ideas for perpetuating your mind</title>
<link>https://edusehat.com/en/six-wild-ideas-for-perpetuating-your-mind</link>
<guid>https://edusehat.com/en/six-wild-ideas-for-perpetuating-your-mind</guid>
<description><![CDATA[ Have you ever thought about what makes you you? Science assures us it has everything to do with the three-pound organ between our ears, with its billions of neurons and trillions of delicate connections. But it’s a lot trickier to explain why we have a sense of self-awareness or to pin down precisely where that… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/10/eye-brains.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 15 Oct 2026 19:40:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Six, wild, ideas, for, perpetuating, your, mind</media:keywords>
<content:encoded><![CDATA[<p class="wp-block-paragraph">Have you ever thought about what makes you <em>you</em>? Science assures us it has everything to do with the three-pound organ between our ears, with its billions of neurons and trillions of delicate connections. But it’s a lot trickier to explain why we have a sense of self-awareness or to pin down precisely where that first memory of Mommy actually resides. As we age, we forget most of what we’ve experienced, yet there’s still undeniable continuity: At 30, or 50, or 70, you will still be you.</p>



<p class="wp-block-paragraph">To preserve that elusive continuity of self, some far-thinking technologists are working on ways to keep your brain going—even beyond death. Let’s call them the “mind savers.” They’re exploring everything from freezing brains in liquid nitrogen to augmenting living ones to uploading our memories to the cloud. Here, we look at six possible paths for keeping your mind going, how feasible they’d be, and what benefits the ­present-day research might bring—even if cognitive immortality doesn’t pan out.</p>



<div aria-hidden="true" class="wp-block-spacer"></div>


<div class="wp-block-image">
<figure class="wp-block-image alignwide size-large"><img fetchpriority="high" decoding="async" width="2383" height="1342" src="https://wp.technologyreview.com/wp-content/uploads/2026/10/Unknown-1.jpg?w=840" alt='""' class="wp-image-1146281" srcset="https://wp.technologyreview.com/wp-content/uploads/2026/10/Unknown-1.jpg 2383w, https://wp.technologyreview.com/wp-content/uploads/2026/10/Unknown-1.jpg?resize=300,169 300w, https://wp.technologyreview.com/wp-content/uploads/2026/10/Unknown-1.jpg?resize=768,433 768w, https://wp.technologyreview.com/wp-content/uploads/2026/10/Unknown-1.jpg?resize=1536,865 1536w, https://wp.technologyreview.com/wp-content/uploads/2026/10/Unknown-1.jpg?resize=2048,1153 2048w" sizes="(max-width: 2383px) 100vw, 2383px"><div class="image-credit">EDDIE GUY</div>
</figure>
</div>


<h3 class="wp-block-heading">Head transplant</h3>







<p class="wp-block-paragraph">White’s experiments have been a source of grim fascination ever since. But to a few neuroscientists they’re inspiration, suggesting that one day a human head transplant—or, as some call it, a body transplant—could succeed. </p>



<p class="wp-block-paragraph">The idea’s main proponent is Sergio Canavero, a controversial Italian surgeon who, 10 years ago, even claimed he’d found a volunteer in Valery Spiridinov, a computer programmer suffering from a degenerative muscle disease. Spiridinov initially agreed to have his head transferred to the body of a brain-dead donor in China, but he later bowed out of the plan and <a href="https://nypost.com/2018/12/18/disabled-man-changes-mind-about-head-transplant/">instead</a> got married. And that might be just as well. Critics say the procedure would be more like murder than medicine. Or, best-case scenario: Volunteers would be left paralyzed and in need of a ventilator for life. </p>





<p class="wp-block-paragraph">Canavero says that’s not necessarily true. He claims people’s views on the operation will change once they accept that reconnecting severed spinal cords is already possible. He pointed <em>MIT Technology Review</em> to a research article from this past summer that he coauthored with surgeons at Moscow’s Sklifosovsky Research and Clinical Institute for Emergency Medicine. The team cut through the spinal cords of three pigs at a point midway along their backs and then tested whether the severed nerve bodies could be fused back together using a surgical sealant. According to that paper, which appeared <a href="https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0349579">in the journal <em>PLOS One</em></a>, all the pigs regained the ability to stand and even walk unsteadily.</p>



<p class="wp-block-paragraph">Does that mean a head could be attached to a new body and then actually control it? Mainstream researchers aren’t convinced. Grégoire Courtine, a spinal rehabilitation specialist at the École Polytechnique Fédérale de Lausanne in Switzerland, says he’s been following Canavero’s claims “with little respect” and thinks that we should “pay zero attention.”</p>



<p class="wp-block-paragraph">“There is no technology … capable of such a crazy idea,” Courtine wrote in an email.</p>



<div aria-hidden="true" class="wp-block-spacer"></div>



<figure class="wp-block-image alignright size-full is-resized"><img decoding="async" width="1000" height="1000" src="https://wp.technologyreview.com/wp-content/uploads/2026/10/BRAIN-laptop.png" alt="" class="wp-image-1146279" srcset="https://wp.technologyreview.com/wp-content/uploads/2026/10/BRAIN-laptop.png 1000w, https://wp.technologyreview.com/wp-content/uploads/2026/10/BRAIN-laptop.png?resize=150,150 150w, https://wp.technologyreview.com/wp-content/uploads/2026/10/BRAIN-laptop.png?resize=300,300 300w, https://wp.technologyreview.com/wp-content/uploads/2026/10/BRAIN-laptop.png?resize=768,768 768w" sizes="(max-width: 1000px) 100vw, 1000px"></figure>



<h3 class="wp-block-heading">Mindclones</h3>







<p class="wp-block-paragraph">Just 12 years after the book came out, artificial-intelligence technology has already brought some of her predictions to “life,” so to speak. Services such as StoryFile, Afterlife AI, and Synthesia allow users to upload their personal information and likeness in order to produce either conversational bots that share their memories or video talking heads that sound (and look) exactly like them. Influencers now let their “AI clones” do their work on TikTok, and some people are even building <a href="https://www.technologyreview.com/2022/10/18/1061320/digital-clones-of-dead-people/">avatars of their aging parents</a> in order to preserve their personalities.</p>





<p class="wp-block-paragraph">While this mimicry can produce comical results, unhealthy attachments, or uncanny vibes, the increasing realism of generative AI invites people to emotionally accept the avatars as real beings. That was the case when Rothblatt appeared as a digital avatar during a 2025 event held by the UCLA Department of Communication called “The Bridge to Humanizing AI.”</p>



<p class="wp-block-paragraph">Her copy, named Marvatar, was projected on a screen, led the discussions, and talked with the meatspace Rothblatt as an equal, at one point saying, “The dance isn’t about who leads, but how we move together.” According to the university, attendees were “visibly moved” and wept “with wonder” at Rothblatt’s vision of digital equality.</p>



<p class="wp-block-paragraph">What’s still missing from Rothblatt’s mindclone prediction is evidence that these avatars have—or ever will have—any kind of true self-awareness. (We asked ChatGPT if it’s conscious, and <a href="https://chatgpt.com/share/6a8363b3-2560-83ea-92ed-c298b6ef4ef4">it answered</a>, “Probably not.”) But all that remains a gray zone. Neuroscientists don’t have a clear definition of consciousness, much less <a href="https://www.nature.com/articles/s41599-024-03553-w">a diagnostic test</a> they could apply to an avatar. </p>



<p class="wp-block-paragraph">Instead, what if the final determination is in the eye of the beholder? Your digital clone might not<em> be</em> you. But at some point it might be good enough for me. </p>



<div aria-hidden="true" class="wp-block-spacer"></div>



<figure class="wp-block-image alignright size-large is-resized"><img decoding="async" width="1000" height="1000" src="https://wp.technologyreview.com/wp-content/uploads/2026/10/BRAIN-jar.png?w=840" alt="" class="wp-image-1146278" srcset="https://wp.technologyreview.com/wp-content/uploads/2026/10/BRAIN-jar.png 1000w, https://wp.technologyreview.com/wp-content/uploads/2026/10/BRAIN-jar.png?resize=150,150 150w, https://wp.technologyreview.com/wp-content/uploads/2026/10/BRAIN-jar.png?resize=300,300 300w, https://wp.technologyreview.com/wp-content/uploads/2026/10/BRAIN-jar.png?resize=768,768 768w" sizes="(max-width: 1000px) 100vw, 1000px"></figure>



<h3 class="wp-block-heading">Brain in a jar</h3>







<p class="wp-block-paragraph">So, campy sci-fi film lovers that we are, it got our attention last year when a company called Bexorg started showing journalists <em>actual</em> human brains in vats, which it has been acquiring from organ donors soon after death and then “rebooting” by infusing them with oxygen-rich artificial blood.</p>



<p class="wp-block-paragraph">The company claims these “physiologically intact human brains” will be more useful than animals for drug testing and safer than trying experiments on living volunteers. Add an Alzheimer’s compound to one of these disembodied brains and researchers can then measure exactly what the drug does inside the organ.</p>



<p class="wp-block-paragraph">Bexorg’s CEO, Zvonimir Vrselja, is “sure” that some people would like to restore consciousness to out-of-body brains, but he’s tried to douse such speculation. While they are metabolically active, the company says, the brains have lost all coordinated electrical activity. That means they aren’t conscious—although, just to make sure, the neuroscientists running the experiments add the strong anesthetic propofol to the tissues. </p>



<p class="wp-block-paragraph">What’s more, right now a brain can be kept “alive” outside the body for only about 24 hours. That wouldn’t be much of a second life. Still, efforts are underway to improve the life-support systems. Bexorg says it hopes to eventually keep its brains going for two weeks.</p>



<div aria-hidden="true" class="wp-block-spacer"></div>


<div class="wp-block-image">
<figure class="wp-block-image alignwide size-full"><img loading="lazy" decoding="async" width="2378" height="1343" src="https://wp.technologyreview.com/wp-content/uploads/2026/10/Unknown-2.jpg" alt="" class="wp-image-1146282" srcset="https://wp.technologyreview.com/wp-content/uploads/2026/10/Unknown-2.jpg 2378w, https://wp.technologyreview.com/wp-content/uploads/2026/10/Unknown-2.jpg?resize=300,169 300w, https://wp.technologyreview.com/wp-content/uploads/2026/10/Unknown-2.jpg?resize=768,434 768w, https://wp.technologyreview.com/wp-content/uploads/2026/10/Unknown-2.jpg?resize=1536,867 1536w, https://wp.technologyreview.com/wp-content/uploads/2026/10/Unknown-2.jpg?resize=2048,1157 2048w" sizes="auto, (max-width: 2378px) 100vw, 2378px"><div class="image-credit">EDDIE GUY</div>
</figure>
</div>


<h3 class="wp-block-heading">Gradual brain replacement</h3>







<p class="wp-block-paragraph">On paper, the goal is to manufacture tissue to graft into the brains of stroke victims, reversing damage and restoring function. Less officially, the project’s existence is a surprise coup for an extreme plan to defeat aging advanced by Jean Hébert, the neuroscientist leading the program, who argued in his 2020 book,<em> Replacing Aging</em>, that we can live longer by replacing our aging brain cells with young ones.</p>





<p class="wp-block-paragraph">We don’t want to lose our identities. That’s why—according to Hébert—it would have to happen gradually, in small chunks, so our brains would have time to adapt to the new tissue.</p>



<p class="wp-block-paragraph">Scientists who applied for the program say Hébert insisted on a very specific technological approach. While most researchers engineer individual cell types, ARPA-H asked for complex chunks of young, functional cortex—more or less like what you’d find in a developing fetus. “He wanted to create essentially an embryonic form of cortex that he thought you could somehow graft into an adult brain,” says Marius Wernig, a Stanford University stem-cell researcher who applied.</p>



<p class="wp-block-paragraph">Skeptics say it’s unknown whether replacement brain chunks will ever properly function as part of your brain—say, by taking over memories. What’s more, it’s still unclear how to manufacture youthful cortex, or what ARPA-H calls “neocortical precursor tissue,” in the lab. One idea is to employ the latest advances in brain organoids. Imagine, if you will, a human cortex grown in a lab dish without a body. </p>



<p class="wp-block-paragraph">We know that the agency has an aggressive timeline: Over the course of five years, it wants researchers to lay the foundation for the first human tests of replacement cortex. The aim, it says, is to “take the ‘permanent’ out of brain damage.” And maybe out of old age, too. </p>



<figure class="wp-block-image alignright size-large is-resized"><img loading="lazy" decoding="async" width="1000" height="1000" src="https://wp.technologyreview.com/wp-content/uploads/2026/10/BRAIN-alsobrain.png?w=840" alt="" class="wp-image-1146277" srcset="https://wp.technologyreview.com/wp-content/uploads/2026/10/BRAIN-alsobrain.png 1000w, https://wp.technologyreview.com/wp-content/uploads/2026/10/BRAIN-alsobrain.png?resize=150,150 150w, https://wp.technologyreview.com/wp-content/uploads/2026/10/BRAIN-alsobrain.png?resize=300,300 300w, https://wp.technologyreview.com/wp-content/uploads/2026/10/BRAIN-alsobrain.png?resize=768,768 768w" sizes="auto, (max-width: 1000px) 100vw, 1000px"></figure>



<div aria-hidden="true" class="wp-block-spacer"></div>



<h3 class="wp-block-heading">Brain upload</h3>







<p class="wp-block-paragraph">Scientists are already mapping this wiring in simpler animals. Two years ago, Seung took part in analyzing a fly brain that had been cut into paper-thin sheets and imaged with an electron microscope. Then he and his colleagues used image-analysis software to trace 139,255 neurons and about 55 million synapses. The fly map could lead to energy-efficient software that computes the way real brains do, Seung says. </p>



<p class="wp-block-paragraph"> Others believe the ultimate outcome of “connectomics” research  will be what’s called “whole-brain emulation,” or sometimes just “uploading.” It’s the idea, popular in some quarters of Silicon Valley, that a simulation created from a sliced-up brain could become so detailed that it would reproduce not only a generic intelligence but a particular one, like yours—complete with memories and opinions, and able to live again in a data server somewhere. </p>



<p class="wp-block-paragraph">Setting aside the question of whether a simulation would really be you, everyone agrees that this technology isn’t coming in time for those of us alive today. A <a href="https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0326920">survey</a> of 312 neuroscientists, published in 2025 in <em>PLOS One</em>, estimated that human whole-brain emulation wouldn’t happen before 2125.</p>



<p class="wp-block-paragraph">That long and unpredictable tech horizon helps explain why two US companies, Nectome and Sparks Brain Preservation, are offering to preserve human brains (or bodies) today by infusing them with the same potent chemicals used to “fix” the brains of fruit flies for connectome mapping. The idea: If the fine details of a brain’s structure can be preserved, one day in the far future it might be reanimated. </p>



<p class="wp-block-paragraph">But there’s a startling twist. Because brain tissue needs to be preserved quickly after a person’s death, both companies say they want to work with people taking advantage of medical aid in dying, now legal in 13 states and Washington, DC. In that procedure, doctors supply a lethal dose of drugs, but it’s the patient—someone with a terminal prognosis—who pushes the plunger. For a fee, the companies say, they can have a preservation team at the ready. So far, the service is not popular. The companies each say they are still awaiting their first aid-in-dying customer. </p>



<div aria-hidden="true" class="wp-block-spacer"></div>


<div class="wp-block-image">
<figure class="wp-block-image alignwide size-full"><img loading="lazy" decoding="async" width="2410" height="1353" src="https://wp.technologyreview.com/wp-content/uploads/2026/10/Unknown-3.jpg" alt="" class="wp-image-1146283" srcset="https://wp.technologyreview.com/wp-content/uploads/2026/10/Unknown-3.jpg 2410w, https://wp.technologyreview.com/wp-content/uploads/2026/10/Unknown-3.jpg?resize=300,168 300w, https://wp.technologyreview.com/wp-content/uploads/2026/10/Unknown-3.jpg?resize=768,431 768w, https://wp.technologyreview.com/wp-content/uploads/2026/10/Unknown-3.jpg?resize=1536,862 1536w, https://wp.technologyreview.com/wp-content/uploads/2026/10/Unknown-3.jpg?resize=2048,1150 2048w" sizes="auto, (max-width: 2410px) 100vw, 2410px"><div class="image-credit">EDDIE GUY</div>
</figure>
</div>


<h3 class="wp-block-heading">Synthetic neocortex</h3>







<p class="wp-block-paragraph">That’s right: an extra brain.</p>



<p class="wp-block-paragraph">Recently, we’ve seen inklings of how this might come to pass. In 2024, Science Corporation, in California, unveiled a “biohybrid” brain-computer interface featuring nerve cells grown on a digital chip. Placed on an animal’s brain, these cells sent out long, thin axons that integrated with the animal’s own neurons. The result: two-way communication from computer to brain, in the brain’s language.</p>





<p class="wp-block-paragraph">The technology could permit new types of medicine, like an implant that directs brain cells to produce dopamine and thereby treat Parkinson’s. But Max Hodak, the company’s CEO, says it also might count as a new brain part, which he likens to a “big, externalized cranial nerve.” </p>



<p class="wp-block-paragraph">Such a device could serve as the connector to Kurzweil’s computerized neocortex in the cloud, giving a living person unlimited extra processing power. Still other entrepreneurs believe if you kept adding biohybrid components to a brain, eventually you could morph it into an immortal machine. </p>



<p class="wp-block-paragraph">Daniel Burger, founder of the venture-­funded stealth startup Eightsix Science (its name refers to the 86 billion neurons in a human brain), says this dream could require mixing several of the brain-saving techniques on this list. He thinks we might need brains in vats, affording neuro-­engineers easy access, so they can gradually replace brain parts with biohybrid neural grafts. </p>



<p class="wp-block-paragraph">The ultimate goal is to migrate your mind into your extra, engineered brain, without ever breaking the continuity of self. “It’s not the typical ‘scan, store, simulate,’” says Burger. “I don’t think simulations will be conscious.” He adds, “We’re saying it’s going to be way more complicated, and it’s probably going to look like gradual brain replacement into a hardware brain.”</p>



<p class="wp-block-paragraph">Once your mind is hardware, you won’t need a biological body. Instead, you could take up residence in a data center somewhere and perhaps even have backups distributed around the globe. “From that point on,” Burger acknowledges, “stuff becomes really crazy.”</p>]]> </content:encoded>
</item>

<item>
<title>Pig kidneys that were “frozen” for a year have been brought back to life</title>
<link>https://edusehat.com/en/pig-kidneys-that-were-frozen-for-a-year-have-been-brought-back-to-life</link>
<guid>https://edusehat.com/en/pig-kidneys-that-were-frozen-for-a-year-have-been-brought-back-to-life</guid>
<description><![CDATA[ Pig kidneys that were cooled to -150 °C and stored in a freezer for months have been successfully rewarmed and shown to work again for the first time, say scientists. They hope to replicate the findings with human organs. The kidneys—which are similar in size to human ones—were left in a glass-like state, in one… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/10/pig-freeze.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 15 Oct 2026 19:40:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Pig, kidneys, that, were, “frozen”, for, year, have, been, brought, back, life</media:keywords>
<content:encoded><![CDATA[<div data-chronoton-summary="<ul><br><li><strong>Frozen kidneys brought back to life:</strong> Scientists have successfully vitrified pig kidneys—cooling them to -150°C—and rewarmed them after up to a year in storage. The kidneys regained color and produced urine, key signs they were working.</li><br><li><strong>Nanoparticles are the secret ingredient:</strong> Iron oxide nanoparticles infused into the organs allow for rapid, even rewarming when activated by an electromagnetic field—solving one of cryobiology's longest-standing technical headaches.</li><br><li><strong>A revolution for transplantation:</strong> Long-term organ banking could mean organs wait for patients, not the other way around—giving doctors time to better match donors and recipients and potentially reduce the need for lifelong immune-suppressing drugs.</li><br><li><strong>Still not ready for prime time:</strong> The rewarmed kidneys showed signs of injury, likely from toxic cryoprotectant chemicals, and produced less urine than expected.</li></ul>" data-chronoton-post-id="1146091" data-chronoton-expand-collapse="1" data-chronoton-analytics-enabled="1"></div>


<p class="wp-block-paragraph">Pig kidneys that were cooled to -150 °C and stored in a freezer for months have been successfully rewarmed and shown to work again for the first time, say scientists. They hope to replicate the findings with human organs.</p>



<p class="wp-block-paragraph">The kidneys—which are similar in size to human ones—were left in a glass-like state, in one case for over a year. Once they had been rewarmed, tested in machines, and transplanted into pigs, the kidneys regained their color and made urine—key signs they were working.</p>





<p class="wp-block-paragraph">“Ten years ago … I wouldn’t say I had high hopes it was actually going to work,” says Erik Finger, a transplant surgeon at the University of Minnesota who co-led the work. “After we did the last transplant, I walked out of the room and said, ‘This is a big deal.’” The research was shared at the preprint server <a href="https://www.biorxiv.org/content/10.64898/2026.10.07.756990v1">bioRxiv</a> and has not yet been peer-reviewed.</p>



<p class="wp-block-paragraph">The kidneys aren’t perfect, and the researchers have yet to demonstrate that they can sustain life over the long term. But the results represent a milestone achievement, say others in the field.</p>



<p class="wp-block-paragraph">“Thank God that someone’s actually managed to do it in one organ and prove that it works,” says Peter Kilbride, a cryobiologist and cofounder of Kyros Kairos, a company focused on improving funding for cryopreservation research, who was not involved in the research. “For years, people have been trying and failing to get to this step. Finally, we’ve got this breakthrough.”</p>



<p class="wp-block-paragraph">“Their work is amazing and will enable us to truly, indefinitely bank organs,” says Korkut Uygun, a biomedical engineer and professor of surgery at Harvard Medical School, who was also not involved in the research. “It is a revolutionary time for transplantation.”</p>



<h3 class="wp-block-heading">Buying time</h3>



<p class="wp-block-paragraph">Every year, tens of thousands of organ transplants take place in the US alone. These procedures are thought to have <a href="https://jamanetwork.com/journals/jamasurgery/fullarticle/2100153">saved 2 million years of life in the last 25 years</a>. But there’s plenty of room for improvement.</p>



<p class="wp-block-paragraph">One major challenge is the lack of available organs. Even when an organ becomes available, it can be difficult to get it to the right recipient within 24 to 36 hours, which is the current limit for preserving human organs.</p>



<p class="wp-block-paragraph">People who receive organ transplants must also take drugs that suppress their immune systems for the rest of their lives. These drugs are meant to stop their bodies from rejecting the new organs. But they come with side effects and increase the risk of infections and cancer.</p>



<p class="wp-block-paragraph">The ability to bank organs for long periods of time holds the promise to address all these challenges. Doctors would have more time to match organs to recipients. They’d be able to limit the risk of organ rejection, too—potentially by preparing recipients, and their immune systems, beforehand.</p>



<p class="wp-block-paragraph">“With real organ banking … instead of the patients waiting for the organ, it’s the organs that are waiting for the patients,” says Finger.</p>





<p class="wp-block-paragraph">Scientists have been able to cool cells to ultra-low temperatures through a process called vitrification, which essentially turns them to something like glass. This procedure is already used to store eggs, sperm, and embryos. Vitrifying whole organs is much harder.</p>



<p class="wp-block-paragraph">Some problems can be avoided with cryoprotectants—chemicals that work like antifreeze and prevent damaging ice crystals from forming. But these chemicals tend to be incredibly toxic. It’s also difficult to rapidly and uniformly cool large tissues, and just as hard to evenly rewarm an organ all the way through.</p>



<p class="wp-block-paragraph">Working with John Bischof, a bioengineer at the University of Minnesota, Finger and colleagues have come up with a solution. Once an organ has been loaded with a cryoprotectant, they infuse it with iron oxide nanoparticles. These nanoparticles don’t do anything to the cells. But when it’s time to rewarm the organ, they can be activated with an electromagnetic field. </p>



<p class="wp-block-paragraph">When the radiofrequency of that field switches between two states, the particles also flip, realigning themselves with the field. That causes them to release heat throughout the organ. Adjusting the power of the field allows the team to control the rate of heating so that it gets faster once the organ reaches -120°C. </p>



<p class="wp-block-paragraph">The researchers successfully vitrified rat kidneys using this approach in <a href="https://www.nature.com/articles/s41467-023-38824-8">work published in 2023</a>. Back then, they were able to rewarm kidneys that had been kept in a freezer for up to 100 days before transplanting them into rats.</p>



<p class="wp-block-paragraph">Since then, the team has been trying to achieve the same success with bigger organs. Pig kidneys are thought to be a good model for human ones—they’re about the same size and look similar. Rat kidneys weigh around one gram; pig kidneys are around 100.</p>



<p class="wp-block-paragraph">It hasn’t been easy. The cryoprotectant used for vitrifying rat kidneys didn’t work as well in the pig organs. “We had to rediscover and modify the cocktail,” says Bischof. “That’s why it’s taken us three years.”</p>



<h3 class="wp-block-heading">Deep-freezing kidneys</h3>



<p class="wp-block-paragraph">The first step in the procedure is to remove a kidney from a donor pig. Once it’s out, the kidney is flushed with a commonly used organ preservation solution to remove the blood, bagged, and temporarily laid on a bed of ice in a cooler so it can be taken over to the engineering lab.</p>





<p class="wp-block-paragraph">There, team members unpack the kidney and hook it up to a device they’ve designed to control the organ’s temperature and pressure. Then they start to load it up with the cocktail of cryoprotectants, slowly enough to ensure an even spread through the organ but quickly enough to minimize any toxic effects. It takes around two hours.</p>



<p class="wp-block-paragraph">The next step is to infuse the organ with the iron oxide nanoparticles, which are pumped through the organ for around seven to eight minutes, says Finger. Then it’s time to cool the organ by pumping cold nitrogen vapor into a chamber housing it.</p>



<p class="wp-block-paragraph">It’s a delicate process, and the team must ensure that the organ is cooling all the way through. At the same time, they must lower the kidney’s temperature as quickly as possible to prevent ice from forming. “Oftentimes there are multiple people doing different things to make sure that things don’t go awry,” says Bischof.</p>



<p class="wp-block-paragraph">Once the organ reaches the vitrified state at around -120 °C, it “behaves like a glass,” says Finger. “At that point, you can stay stable for long periods of time—we think indefinitely.” The team then pauses the cooling process to ensure that the organ is glassy throughout. Otherwise, it could crack.</p>



<p class="wp-block-paragraph">After the pause, if everything goes well, the kidney is ultimately cooled to -150 °C. Once it’s in the freezer, it can stay there for days, weeks, or even months. The team has kept a small number of kidneys banked for over a year.</p>



<h3 class="wp-block-heading">Pink right up</h3>



<p class="wp-block-paragraph">The real test of these kidneys comes when they’re taken out of the freezer, rewarmed, and flushed of their chemicals and nanoparticles. Can they support life? So far, the team has tested some of them in a couple of different ways.</p>



<p class="wp-block-paragraph">In one set of experiments, the researchers put rewarmed kidneys on <a href="https://www.technologyreview.com/2026/07/24/1140790/the-quest-to-keep-organs-alive-outside-the-body/">perfusion devices</a>—systems that are already used in transplant surgeries both to provide organs with nutrients and to help doctors assess them while they’re out of the body.</p>



<p class="wp-block-paragraph">In another set of experiments, Finger and his colleagues transplanted rewarmed kidneys into pigs and monitored them for two hours. In both experiments, the rewarmed kidneys seemed to recover, says Finger. “They pink right up,” he says. </p>



<figure class="wp-block-video"><video height="1080" width="1920" controls src="https://wp.technologyreview.com/wp-content/uploads/2026/10/Suppl-video-2-acute-transplant.m4v" preload="none"></video><figcaption class="wp-element-caption">The team see blood flow into the rewarmed, transplanted kidney, allowing it to “pink up.”</figcaption><div class="video-credit">COURTESY OF THE RESEARCHERS</div>
</figure>



<p class="wp-block-paragraph">There are lots of ways to measure the function of a kidney, but one key test is whether or not the organ can make urine. By this measure, the rewarmed kidneys did well, although they produced around two-thirds of the amount that would normally be expected. “They produce urine … within a minute or so,” says Finger. “We know that they work.” </p>



<p class="wp-block-paragraph">Most of the rewarmed kidneys had been banked for days or weeks. But one had been in the freezer for just over a year. When Finger and his colleagues rewarmed it and put it on a perfusion machine, they found that it produced urine “immediately.” “It actually looked better than many of the [other] kidneys,” says Finger. “We’re comfortable now saying we can store them for a year and rewarm them with excellent function.”</p>



<p class="wp-block-paragraph">“It’s a very big deal to go a year,” says Kevin Myer, president and CEO of <a href="https://www.lifegift.org/">LifeGift</a>, an organ procurement organization based in Texas. Being able to store organs for that length of time would transform organ transplantation. He envisions banks of organs that could be used on demand in emergency cases where people can’t wait, such as for some drug overdoses or gunshot wounds.</p>



<h3 class="wp-block-heading"><strong>Final hurdles</strong></h3>



<p class="wp-block-paragraph">But the procedure isn’t ready for prime time just yet. As well as producing less urine than expected, the rewarmed kidneys also showed signs of injury. The damage seems to be caused by the cryoprotectant chemicals, say the researchers.</p>





<p class="wp-block-paragraph">“This is one big breakthrough that solves half the problem,” as Kilbride puts it.</p>



<p class="wp-block-paragraph">The team has shown that the rewarmed kidneys can regain blood flow, which is “very important,” says Greg Fahy, a cryobiologist who is considered a pioneer in the field. But he’s worried about the extent of the damage to the organs. “We can’t tell from these experiments whether these kidneys might have supported life or not.”</p>



<p class="wp-block-paragraph">But Fahy, who is chief scientific officer at the biotech companies Intervene Immune and 21st Century Medicine (where he is also executive director), acknowledges that it’s not clear how these kidneys might fare once they’re inside a living animal for the long term. </p>



<p class="wp-block-paragraph">Finger also hopes to find ways to repair the damage seen in the kidneys. Other research has shown that the health of transplant organs <a href="https://www.technologyreview.com/2026/09/14/1144010/donated-livers-can-be-made-biologically-younger/">can improve while they’re on perfusion machines</a>. And damaged kidneys might undergo some level of self-repair once they’re in a body. At any rate, human kidneys may cope better with the process than pig kidneys, says Finger.</p>



<p class="wp-block-paragraph">The next step will be to test the kidneys in pigs over longer periods of time. The team, along with many other researchers in the field, will continue the search for less toxic cryoprotectants, too. Finger, Bischof, and their colleagues are also planning experiments with human kidneys.</p>



<p class="wp-block-paragraph">Finger is optimistic. “We’re going to see that there’s injury, and it’s not perfect … but now we’ve got to the point where it works,” he says. “These are big, historic milestones in our field, and we’re excited about it.”</p>]]> </content:encoded>
</item>

<item>
<title>Told You Need Bypass Surgery? What Actually Happens Next</title>
<link>https://edusehat.com/en/told-you-need-bypass-surgery-what-actually-happens-next</link>
<guid>https://edusehat.com/en/told-you-need-bypass-surgery-what-actually-happens-next</guid>
<description><![CDATA[ A bypass diagnosis does not automatically mean traditional open chest surgery. This guide covers the real next steps, how minimally invasive bypass techniques differ from the traditional approach, questions to ask before choosing a surgeon, actual recovery timelines, and when a second opinion with Dr. Giovanni Ciuffo in Las Vegas makes sense. ]]></description>
<enclosure url="https://heartsurgeryinfo.com/wp-content/uploads/2026/10/Bypass-Surgery.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 15 Oct 2026 16:00:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Told, You, Need, Bypass, Surgery, What, Actually, Happens, Next</media:keywords>
<content:encoded><![CDATA[<h4>Post Summary</h4>
<p><strong>What are the immediate next steps after a bypass surgery diagnosis?</strong></p>
<p>After a bypass surgery diagnosis, the first step is confirming the full diagnostic picture rather than accepting the headline recommendation alone. Bypass recommendations are typically based on imaging, most often a coronary angiogram, that shows exactly which arteries are blocked, how many, and how severely. Patients are entitled to see these specifics directly from their cardiologist rather than only the summary conclusion, because the details shape which surgical approaches are even available. The second step is understanding urgency. Some bypass diagnoses are genuinely emergent, meaning a blockage puts the patient at immediate risk and surgery needs to happen quickly, while others are more stable and allow real time to research options, ask questions, and seek a second opinion before scheduling anything. Patients should not assume they are in the emergency category until a doctor has said so directly, since that distinction changes how the following weeks should be approached. Finally, patients should bring the right people into the conversation early, including their primary care physician and cardiologist, who should coordinate with whichever surgeon is chosen, along with the people in their life who will be part of their recovery, since a major diagnosis like this rarely affects only one person.</p>
<p><strong>Is bypass surgery always open heart surgery, or are there other options?</strong></p>
<p>Bypass surgery is not always open heart surgery in the traditional sense. Open heart surgery specifically refers to procedures performed through a full sternotomy, cutting through the breastbone to access the heart directly, and traditional bypass surgery has long been performed this way. However, minimally invasive bypass techniques also exist, sometimes called MIDCAB or off-pump bypass depending on the specific method. These approaches use smaller incisions between the ribs instead of a full sternotomy, and some can be performed without stopping the heart or using a heart-lung machine at all. For eligible patients, this can mean less trauma to the chest, a shorter hospital stay, and a faster return to normal activity than the traditional approach typically allows. Not every patient is a candidate for a minimally invasive approach, and not every surgeon offers it, since it requires specialized training that most cardiac surgeons do not pursue and is not available at every hospital. That means a surgical plan may reflect what a particular surgeon is equipped to offer rather than every option that exists for a specific case, which is why it is worth asking directly whether a minimally invasive approach applies before deciding anything.</p>
<p><strong>What questions should you ask before choosing a bypass surgeon?</strong></p>
<p>Choosing a bypass surgeon deserves more than a single conversation, and there are specific questions worth asking before committing to anything. First, ask which approach is being recommended and why, specifically whether traditional open-chest bypass or a minimally invasive technique is on the table, and what makes one more appropriate than the other given the patient’s own imaging results. Second, ask how many times the surgeon has personally performed that specific technique, since experience matters more with minimally invasive approaches, which demand more specialized training than the traditional method most surgeons default to. Third, ask what recovery actually looks like for someone in that particular situation, requesting a real timeline tied to age, overall health, and the specific approach being recommended rather than a generic average. Fourth, ask whether another surgeon would see the case differently. This is not a confrontational question, it is a fair and reasonable one, and a surgeon confident in their recommendation should have no issue with a patient seeking a second opinion before scheduling surgery. A good surgeon expects and welcomes these questions, and asking them before a surgery date is set is far easier than wishing they had been asked afterward.</p>
<p><strong>What does recovery from bypass surgery actually involve?</strong></p>
<p>Recovery from bypass surgery depends heavily on which approach was used, though some general patterns hold. Traditional bypass surgery, performed through a full sternotomy, typically involves a hospital stay of about a week, followed by several weeks of restricted activity while the breastbone heals, with driving, lifting, and certain movements usually off limits early on. A full return to normal activity, including work and regular exercise, often takes about two months. Minimally invasive bypass approaches tend to shorten this timeline, since the chest is not opened the same way, hospital stays are often shorter, and many patients find early restrictions lighter and their return to daily activity, work, hobbies, and time with family faster, though the exact timeline still depends on the patient’s overall health and age rather than the technique alone. Recovery from bypass surgery is not only physical. The weeks afterward bring their own emotional adjustment, which deserves as much attention as the physical healing itself. Whatever the specific timeline turns out to be, recovery is best understood as an ongoing process rather than a single milestone, and it is normal for some parts of it to take longer than expected and other parts to move faster.</p>
<p><strong>When does a second opinion on a bypass diagnosis make sense?</strong></p>
<p>A second opinion on bypass surgery makes sense more often than most patients act on it. Bypass surgery is a major decision, and seeking confirmation or a different perspective does not mean distrusting the original surgeon, it means treating the decision with the seriousness it deserves. Second opinions are a normal, expected part of major medical decisions rather than a last resort reserved for when something feels wrong. This matters even more for patients who were only ever presented with the traditional open-chest approach. If minimally invasive options were never raised, that is not necessarily a red flag on its own, but it can be a sign the conversation did not cover everything available. A surgeon who has not walked a patient through both the traditional and minimally invasive paths, and explained why one fits their specific case better than the other, has not provided the full picture, even if their original recommendation turns out to be correct. Some surgeons focus specifically on re-evaluating cases like these, for patients who were told one thing by one surgeon and want to understand whether that is genuinely the only option. For anyone in that position, exploring a second opinion is worth doing before committing to a surgical date.</p>
<p><strong>Who is Dr. Giovanni Ciuffo, and why do patients travel to see him for a second opinion?</strong></p>
<p>Dr. Giovanni Ciuffo is a cardiothoracic surgeon who serves as Director of Cardiac Surgery at University Medical Center of Southern Nevada, based in Las Vegas. His practice is built around re-evaluating cases for patients who were told they need bypass surgery and want another perspective before committing to a surgical plan, including cases where a minimally invasive approach was never raised as an option. Because minimally invasive bypass techniques require specialized training that not every surgeon pursues, patients are not always told these approaches exist, which is precisely the kind of gap a second opinion is meant to close. Patients travel to Las Vegas from across the country for a second opinion with Dr. Ciuffo rather than treating this as a purely local option, reflecting the practice’s national reach for this type of consultation. Consultations are available regardless of whether a patient lives nearby or is traveling from elsewhere, and reaching out does not require a patient to have already decided anything. For anyone who has only heard the traditional approach described as their only option, requesting a consultation is a way to find out whether that is genuinely the full picture for their specific case.</p>
<p>•••••</p>
<p><span>You just found out you need bypass surgery, and it’s a lot to take in all at once. The diagnosis often comes fast, and so does the picture people jump to: a long hospital stay, a slow recovery, months away from the life you’re used to living. That fear is normal, and it’s worth pausing on before anything else.</span></p>
<p><span>Here’s the reassuring part: bypass surgery doesn’t automatically mean the traditional open chest procedure most people picture. Depending on your case, minimally invasive approaches are available and can change what recovery actually looks like.</span></p>
<p><span>This guide covers what happens after a bypass surgery diagnosis: the immediate next steps to take, how surgical approaches differ, the questions worth asking before you choose a surgeon, and what recovery really involves.</span></p>
<h2><strong>The Immediate Next Steps After a Bypass Diagnosis</strong></h2>
<p><span>So what are the actual next steps after a bypass diagnosis? Before anything else gets decided, it helps to slow down and get the full picture, not just the headline.</span></p>
<p><span>Start with the diagnostic details. A bypass recommendation is usually based on imaging, most often a coronary angiogram, that shows exactly which arteries are blocked, how many, and how severely. Ask your cardiologist for these specifics rather than just the summary. Knowing whether you’re dealing with one blocked artery or several changes affects which approaches are even available, and it’s information you’re entitled to see for yourself.</span></p>
<p><span>Next, find out how urgent your situation actually is. Some bypass diagnoses are genuinely emergent, meaning a blockage puts you at immediate risk and surgery needs to happen quickly. Others are more stable, giving you real time to research your options, ask questions, and even seek a second opinion before scheduling anything. Don’t assume you’re in the emergency category until a doctor has told you so directly. That distinction alone can change everything about how you approach the weeks ahead.</span></p>
<p><span>Finally, think about who else belongs in this conversation. That includes your primary care physician and cardiologist, who should be coordinating with whichever surgeon you choose, but it also includes the people in your life who will be part of your recovery. A major diagnosis like this rarely affects just one person, and having support lined up early makes the rest of this process easier to navigate.</span></p>
<p><span>These are the next steps for bypass surgery worth taking before you commit to anything: get the details, understand the urgency, and bring the right people into the conversation.</span></p>
<h2><strong>Traditional vs. Minimally Invasive Bypass: Understanding Your Actual Options</strong></h2>
<p><span>So is bypass surgery always open-heart surgery? Not necessarily, and this is one of the most important things to understand before you commit to a surgical plan. We’ve written a longer explainer on this exact question if you want the full breakdown, but here’s the short version: “open heart surgery” specifically refers to procedures done through a full sternotomy, cutting through the breastbone to access the heart directly. Traditional bypass surgery has long been performed this way, but it’s not the only way it’s done anymore.</span></p>
<p><span>Minimally invasive bypass techniques exist, and depending on your specific case, they may be an option worth exploring. These approaches, sometimes called MIDCAB or off-pump bypass depending on the technique, use smaller incisions between the ribs instead of a full sternotomy, and some can be performed without stopping the heart or using a heart-lung machine. For eligible patients, the result can be less chest trauma, a shorter hospital stay, and a faster return to normal activity than the traditional approach typically allows. Minimally invasive heart surgery explains how these techniques work in more depth, including which conditions are good candidates.</span></p>
<p><span>Not every patient is a candidate, and not every surgeon offers these approaches. That second part matters more than most people realize. Minimally invasive bypass surgery takes specialized training that most cardiac surgeons don’t pursue, and it isn’t available at every hospital. That means the surgical plan you were handed may reflect what your surgeon is equipped to offer, not necessarily every option that exists for your specific case. That’s not a knock on the surgeon who gave you the diagnosis; it’s simply a reality of how specialized this particular skill set is. It’s worth asking directly whether a minimally invasive approach applies to you before you decide anything.</span></p>
<h2><strong>Questions Worth Asking Before You Commit to a Surgeon</strong></h2>
<p><span>Choosing a bypass surgeon is one of the biggest decisions in this whole process, and it deserves more than a single conversation before you sign off on anything. Here are the questions to ask before bypass surgery that actually change the picture, not just ones that make you feel informed in the moment.</span></p>
<p><span>Which approach are you recommending for me, and why? Ask specifically whether traditional open-chest bypass or a minimally invasive technique is on the table for your case, and what makes one more appropriate than the other given what was found on your imaging.</span></p>
<p><span>How many times have you personally performed this specific technique? Experience matters more with minimally invasive approaches, since they demand more specialized training than the traditional method most surgeons default to, and volume is a fair thing to ask about directly.</span></p>
<p><span>What does recovery actually look like for someone in my situation? Ask for a real timeline, not a general one, tied to your age, overall health, and the specific approach being recommended, not just the average patient’s experience.</span></p>
<p><span>Would my case look different to another surgeon? This isn’t a question meant to create doubt. It’s a fair, reasonable thing to ask, and a surgeon confident in the recommendation should have no issue with you seeking a second opinion before scheduling anything.</span></p>
<p><span>None of these questions are confrontational, and a good surgeon will expect at least some of them, and welcome all of them. Choosing a bypass surgeon should not feel rushed, and asking direct questions now is a lot easier than wishing you had later, once a surgery date is already on the calendar.</span></p>
<h2><strong>What Recovery Actually Looks Like</strong></h2>
<p><span>So what does recovery after bypass surgery actually involve? The honest answer is that it depends heavily on which approach you have, but there are some general patterns worth knowing before you go in.</span></p>
<p><span>Traditional bypass surgery, done through a full sternotomy, typically means a hospital stay of about a week, followed by several weeks of restricted activity while the breastbone heals. Driving, lifting, and certain movements are usually off limits early on, and a full return to normal activity, including work and regular exercise, often takes a couple of months.</span></p>
<p><span>Minimally invasive bypass approaches tend to shorten this timeline. Because the chest is not opened the same way, hospital stays are often shorter, and many patients find the early restrictions lighter and the return to daily activity, work, hobbies, time with family, faster. That said, faster does not mean instant, and your own timeline will depend on your overall health, your age, and how your body responds, not just which technique was used.</span></p>
<p><span>Bypass surgery recovery time is not only physical, either. The weeks after surgery bring their own emotional adjustment, and that part deserves just as much attention as the physical healing. We have covered what that looks like in more depth on our page about </span><a href="https://heartsurgeryinfo.com/psychological-aspects-of-recovery/" target="_blank" rel="noopener"><span>the psychological aspects of recovery</span></a><span>, and it is worth reading before you go into surgery, not just after.</span></p>
<p><span>Whatever your timeline turns out to be, recovery is a process, not a single milestone, and it is normal for it to take longer in some ways than you expected and faster in others.</span></p>
<h2><strong>When a Second Opinion Makes Sense</strong></h2>
<p><span>So when does a second opinion on bypass surgery actually make sense? More often than people assume, and more often than most patients ever act on.</span></p>
<p><span>A bypass recommendation is a major decision, and getting confirmation, or a different perspective, does not mean you distrust your surgeon. It means you are taking the decision as seriously as it deserves. Second opinions are a normal, expected part of major medical decisions, not a last resort for when something feels wrong or unclear.</span></p>
<p><span>This matters even more if you were only ever presented with the traditional approach. If minimally invasive options were never raised, that is not necessarily a red flag on its own, but it is a sign the conversation may not have covered everything available to you. A surgeon who has not walked you through both the traditional and minimally invasive paths, and explained why one fits your case better than the other, has not given you the full picture, even if their recommendation turns out to be the right one.</span></p>
<p><span>Some surgeons focus specifically on re-evaluating cases like these: patients who were told one thing by one surgeon and want to understand whether that is the only thing. If that sounds like where you are right now, it is worth exploring what a second opinion on bypass surgery could actually change for you and for the decision ahead.</span></p>
<h2><strong>Quick Answers</strong></h2>
<p><b>Is bypass surgery always open heart surgery?</b><span><br>
</span><span>No. Traditional bypass surgery uses a full sternotomy, but minimally invasive bypass techniques exist and use smaller incisions between the ribs instead. Not every patient is a candidate, and not every surgeon offers these approaches, so it’s worth asking directly whether one applies to your case.</span></p>
<p><b>How soon after a bypass diagnosis do I need surgery?</b><span><br>
</span><span>It depends on urgency. Some diagnoses are emergent and require quick action, while others are stable enough to allow time for research and even a second opinion. Ask your cardiologist directly which category your case falls into before assuming you’re short on time.</span></p>
<p><b>How does recovery differ between traditional and minimally invasive bypass?</b><span><br>
</span><span>Traditional bypass typically means a hospital stay of about a week and a couple of months before a full return to normal activity. Minimally invasive approaches tend to shorten both, though your own timeline depends on your overall health, not just the technique used.</span></p>
<p><b>Can I still get a second opinion if I’ve already been scheduled for surgery?</b><span><br>
</span><span>Yes, in almost every non-emergency case. Scheduling a date does not close the door on getting another perspective, and a confident surgeon will not discourage you from seeking one before you go through with anything.</span></p>
<p><b>What should I bring to a consultation?</b><span><br>
</span><span>Bring your imaging results, any test reports from your cardiologist, a current medication list, and a written list of questions, including the ones about approach, experience, and recovery.</span></p>
<ul>
<li><span>••••</span></li>
</ul>
<p><span>If you have been told you need bypass surgery and want another set of eyes on your case, Dr. Giovanni Ciuffo is worth talking to. He serves as Director of Cardiac Surgery at University Medical Center of Southern Nevada and has built his practice around exactly this kind of re-evaluation, including minimally invasive approaches many surgeons do not offer.</span></p>
<p><span>Patients travel to Las Vegas from across the country for a second opinion on heart surgery with Dr. Ciuffo, not just locally, and consultations are available whether you live nearby or across the country. If a traditional approach is the only one you have heard so far, reach out and find out whether that is actually the full picture for your case.</span></p>]]> </content:encoded>
</item>

<item>
<title>Alzheimer’s Small&#45;Molecule Therapy Shows Promise in Mice and Early Human Trial</title>
<link>https://edusehat.com/en/alzheimers-small-molecule-therapy-shows-promise-in-mice-and-early-human-trial</link>
<guid>https://edusehat.com/en/alzheimers-small-molecule-therapy-shows-promise-in-mice-and-early-human-trial</guid>
<description><![CDATA[ A small-molecule therapy, VG-3927, targeting microglial TREM2 signaling showed neuroprotective effects in preclinical studies for Alzheimer&#039;s disease and was well tolerated in a Phase I trial.
The post Alzheimer’s Small-Molecule Therapy Shows Promise in Mice and Early Human Trial appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GettyImages-1490968075.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 15 Oct 2026 05:15:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Alzheimer’s, Small-Molecule, Therapy, Shows, Promise, Mice, and, Early, Human, Trial</media:keywords>
<content:encoded><![CDATA[<p>One of the hallmarks of Alzheimer’s disease is the extracellular deposition of amyloid-β (Aβ) plaques. Current treatments for Alzheimer’s disease include anti-Aβ therapeutics that have demonstrated proof-of-concept disease modification; however they have yielded only modest clinical benefits. Because of this, researchers aim to identify other targets and have recently focused on microglia—the brain’s resident innate immune cells whose duties include maintaining neural networks and clearing cellular debris.</p>
<p>Now, a small molecule therapy for Alzheimer’s disease that targets the brain’s microglia cells protected neurons in a mouse model and was found to be safe in humans, according to new research that includes results from a Phase I trial involving 115 participants and patients. More specifically the new work reports on “VG-3927, an oral, CNS-penetrant small-molecule TREM2 agonist that engages the transmembrane domains of TREM2 and its adaptor DAP12 to promote higher-order receptor complex formation and downstream signaling.”</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>This work is published in <em>Science Translational Medicine</em> in the paper, “Preclinical and first-in-human evaluation of VG-3927/SAR448851, an oral small-molecule TREM2 agonist for Alzheimer’s disease.” The therapy stands at the leading edge of a new class of experimental drugs that target microglia through small molecules rather than antibodies, the latter of which have faced various obstacles to translation.</p>
<p>Microglia contain the transmembrane receptor TREM2, which supports the cells’ ability to respond to signs of disease and to break down amyloid-beta. Genetic studies have identified multiple rare coding variants of TREM2—such as p.R47H (Arg47→His)—which impair TREM2 signaling and correlate with a higher risk of late-onset Alzheimer’s disease.</p>
<p>Here, a large collaboration across multiple research teams engineered two small molecules that activate human TREM2: VG-3927 and VG-3909. The compounds reduced markers of neuronal damage and inflammatory signaling when given to cultured neurons and microglia and boosted microglia’s ability to break down amyloid-beta in a mouse model.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>More specifically, the authors note, “In human iPSC-derived neuron-microglia-astrocyte cultures, VG-3927 reduced inflammatory cytokines and markers of neuronal damage. In 5xFAD amyloidosis mice expressing the common variant of hTREM2 (5xFAD;hTREM2CV), VG-3909 induced neuroprotective transcriptional reprogramming of microglia, particularly in the plaque niche; enhanced Aβ phagocytosis; and boosted brain glucose metabolism.”</p>
<p>The team then tested ascending doses of the small molecules in a Phase I trial. In the first-in-human, randomized, double-blind, placebo-Phase I trial (NCT06343636), VG—3927 was well tolerated across single and multiple ascending doses of up to 140 milligrams and penetrated the central nervous system. It also reduced levels of a marker of TREM2 in the cerebrospinal fluid in patients with Alzheimer’s disease—a promising finding in the nascent field of TREM2-targeted therapies.</p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/alzheimers-small-molecule-therapy-shows-promise-in-mice-and-early-human-trial/">Alzheimer’s Small-Molecule Therapy Shows Promise in Mice and Early Human Trial</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Contracting Expansion: A Path to Better CAR T&#45;Cell Therapy Production</title>
<link>https://edusehat.com/en/contracting-expansion-a-path-to-better-car-t-cell-therapy-production</link>
<guid>https://edusehat.com/en/contracting-expansion-a-path-to-better-car-t-cell-therapy-production</guid>
<description><![CDATA[ Shorter cell expansion steps could significantly accelerate CAR T-cell therapy production processes, according to researchers, who cite microfluidic culture systems, real-time PAT tools, and AI-enabled predictive models as key enablers of this new rapid manufacturing paradigm.
The post Contracting Expansion: A Path to Better CAR T-Cell Therapy Production appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GettyImages-2189264798-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 15 Oct 2026 01:40:13 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Contracting, Expansion:, Path, Better, CAR, T-Cell, Therapy, Production</media:keywords>
<content:encoded><![CDATA[<p>Shortening the time allotted to cell expansion in CAR T-cell therapy production could yield more effective, lower-dose products that get to patients sooner than those made using current methods.</p>
<p>The steps involved in making a CAR T-cell therapy—separation, enrichment, activation, modification, expansion, harvest, and cryopreservation—do not actually take a long time—usually between 10 and 21 days.</p>
<p>Yet, for the seriously ill patients who need them, the wait can still be too long. Analysis in <a href="https://www.tandfonline.com/doi/full/10.1080/14796694.2024.2393566" target="_blank" rel="noopener">2024</a> suggested that some 30% of therapies made each year go unused, because the intended recipient’s health deteriorates while the product is being made.</p>
<p>As a result, reducing “vein-to-vein time”—the time required to turn patient-derived material into a therapy and administer it—has become a goal for the CAR T industry, with most efforts focusing on process efficiency or decentralized production.</p>
<h4><strong>Contracting expansion</strong></h4>
<p>Another way of reducing vein-to-vein times would be to shorten <em>ex vivo</em> expansion, <a href="https://link.springer.com/article/10.1186/s13036-026-00666-5#Sec22" target="_blank" rel="noopener">according</a> to Marta Costa, PhD, and colleagues at Portugal’s iBET, who say a “rapid manufacturing” approach would yield more effective, more consistent therapies.</p>
<p>“Rapid manufacturing changes the manufacturing goal as, instead of maximizing the number of cells produced outside the body, it aims to make fewer but fitter cells, by limiting expansion to three days or less.</p>
<p>“This preserves naïve and stem cell-like memory T cells, which proliferate and persist much better once infused, and this can, ultimately, result in lower CAR T cell doses,” she tells <em>GEN</em>.</p>
<h4><strong>Fitter cells</strong></h4>
<p>Under the current manufacturing paradigm, expansion processes run for as long as it takes the culture to achieve a desired density—often in the order of 10⁸ cells. The problem is that, after this period, the cells are often fully differentiated and exhausted.</p>
<p>Limiting expansion would increase the proportion of “fitter” naïve T cells harvested and, according to Costa and colleagues, produce therapies as effective as those made from fully differentiated cells, but at a much lower dose.</p>
<p>Achieving such precise control over shortened production processes will require innovative digital technologies, Costa says.</p>
<p>“Automation is what makes speed safe and allows for reproducibility. It also makes decentralized and point-of-care manufacturing realistic, allowing CAR T cell manufacturing to run at many hospitals supported by a closed, standardized and sensor-equipped system that is essential to ensure product quality.”</p>
<p>Costa cites the CliniMACS Prodigy and Lonza’s Cocoon as technologies that could facilitate the approach, adding, “They are being explored for rapid CAR T cell production as they integrate the steps from leukapheresis to final product in one closed system.</p>
<p>“Besides,” she continues, “to truly allow CAR T-cell therapies to rely on rapid manufacturing processes, faster analytics for product release are needed as several assays still take a week or more to assess product safety and potency.”</p>
<p>AI modeling also has a potential role to play, according to Costa.</p>
<p>“At the moment, most CAR T cell manufacturing processes follow a fixed recipe that is applied regardless of how patients’ cells respond. AI and data-driven approaches have the potential to shift this paradigm by predicting how cells will grow and differentiate, while enabling continuous, online monitoring of cell state.</p>
<p>“These insights can then be used to dynamically adjust process parameters and steer cells toward a desired quality phenotype. Ultimately, this could enable more adaptive manufacturing strategies, including selecting the optimal harvest timepoint based on the evolving state of the cells rather than a predefined culture duration,” she says.</p>
<p>“The evidence increasingly shows that cell quality matters more than cell quantity. Shorter processes produce fitter cells, cost less, increase capacity, and help patients who cannot wait weeks. That combination is hard to argue against, and it is also one of the reasons <em>in vivo</em> CAR T cell strategies, which remove <em>ex vivo</em> manufacturing altogether, are rapidly gaining momentum. We will see what the future holds.”</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/contracting-expansion-a-path-to-better-car-t-cell-therapy-production/">Contracting Expansion: A Path to Better CAR T-Cell Therapy Production</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Turning Process Understanding Into Control of Lipid Nanoparticles</title>
<link>https://edusehat.com/en/turning-process-understanding-into-control-of-lipid-nanoparticles</link>
<guid>https://edusehat.com/en/turning-process-understanding-into-control-of-lipid-nanoparticles</guid>
<description><![CDATA[ Splitting lipid nanoparticle manufacturing into multiple mixing steps can help better control the size, shape, and stability of particles, with the aim of improving product quality during commercial-scale production.
The post Turning Process Understanding Into Control of Lipid Nanoparticles appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GettyImages-1441708537-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 15 Oct 2026 01:40:12 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Turning, Process, Understanding, Into, Control, Lipid, Nanoparticles</media:keywords>
<content:encoded><![CDATA[<p>A new academic spin-off company aims to help manufacturers of lipid nanoparticles (LNP) produce products that are of consistent quality when produced at scale.</p>
<p>Bizon Labs, a spin-out of the Massachusetts Institute of Technology (MIT), is named after bison who run toward storms, as an indicator of how the company tackles head-on the challenges of improving LNP formulations.</p>
<p>According to Cedric Devos, PhD, a postdoctoral associate in the Department of Chemical Engineering at MIT, their work aims to physically optimize LNP delivery through adapting processes, rather than focusing on optimizing via chemistry alone.</p>
<p>“Our goal is specifically to reach a level of control over particle attributes that will enable novel biological applications,” he explains.</p>
<p>“One key example, often given in the field, is that you need extremely specific particle features to target specific organs, and these can’t be achieved yet with what’s out there in process work.”</p>
<p>The process innovations that the team behind Bizon have pioneered, Devos says, are in achieving control over LNP size and morphology that’s extremely difficult with conventional techniques.</p>
<p>This allows, he says, processes to be better understood and, thus, replicated at a variety of production scales.</p>
<p>To achieve this, the team split traditional mixing processes that produce LNPs in a single step into multiple steps to give better control over their attributes. For example, this allows them to tweak LNP shape to enable better product stability for long-term storage, he says.</p>
<p>In addition, he adds, breaking up the mixing process into multiple smaller steps allows companies to develop more complex models and simulations, which should, in turn, help them to understand their processes better.</p>
<p>But among the critical pillars they’re looking at for the future are optimizing the therapeutic cargo, better mechanistic understanding of the LNP process, and improving downstream processing, including purification.</p>
<p>“We’re still doing research,” he says. “There’s much more to control.”</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/turning-process-understanding-into-control-of-lipid-nanoparticles/">Turning Process Understanding Into Control of Lipid Nanoparticles</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>For Biocatalysis, Solvents Are a Key Bioprocessing Parameter</title>
<link>https://edusehat.com/en/for-biocatalysis-solvents-are-a-key-bioprocessing-parameter</link>
<guid>https://edusehat.com/en/for-biocatalysis-solvents-are-a-key-bioprocessing-parameter</guid>
<description><![CDATA[ Deep eutectic solvents can modulate multiple biocatalysis process parameters, thus minimizing or eliminating the need for bioengineering in certain enzymes while enhancing productivity and product quality.
The post For Biocatalysis, Solvents Are a Key Bioprocessing Parameter appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/Getty_1939530453_PharmaceuticalLab.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 15 Oct 2026 01:40:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>For, Biocatalysis, Solvents, Are, Key, Bioprocessing, Parameter</media:keywords>
<content:encoded><![CDATA[<p>As biomanufacturers slowly transition from aqueous to non-aqueous solvents for biocatalysis, deep eutectic solvents (DES) are getting more attention as sustainable, tunable options. Their primary uses in biocatalysis are to enhance substrate solubility and enzyme activity, modulate enzyme stability, and tune stereo- and regioselectivity.</p>
<p>Furthermore, research shows DES can increase titer and productivity compared to traditional catalysts, and enzymes catalyzed in DES are thermally stable without the need for protein engineering.</p>
<p>But the choice of solvent isn’t a straightforward decision. Scientists are learning that the solvent itself is a key process parameter with spillover effects that can even affect stereochemistry.</p>
<p>The choice of solvent can have profound effects on product quality, according to a recent <a href="https://www.sciencedirect.com/science/article/pii/S2693125726000397#sec5" target="_blank" rel="noopener">literature review</a> by Xiamen University scientists Yuxuan Hou, a student, and professors Jinyu Meng, PhD; Binghui Chen, PhD; Jifeng Yuan, PhD; and Shizhen Wang, PhD.</p>
<p>“DES composition and water content shape the enzyme-specific microenvironment and thereby affect catalytic performance,” they note. Changing it affects the DES hydrogen- bond network, viscosity, diffusivity, polarity, and solvent distribution around the protein surface.</p>
<p>They cited studies in which the residual activity of cellulase and pectinase rose and then fell as water quantities increased, and a hydrogenase/TiO<sub>2</sub> photocatalytic system in which increasing the solvent quantity reduced dioxygen transport, and increasing the water content increased activity.</p>
<p>Additionally, they write, “Accumulating evidence indicates that DES can enhance enzyme thermostability while preserving catalytic activity.” The choice of hydrogen bond donors and acceptors was a key determinant.</p>
<p>For example, in the case of <em>Candida rugosa</em> lipase, the hydrogen bond donor enabled the enzyme’s half-life to increase from one hour to more than nine hours using DES. For <em>Humicola insolens</em> cutinase, the hydrogen bond acceptor was the key determinant, increasing half-life from 22 minutes to 62. The benefit is that modulating thermostability through the solvent rather than through bioengineering is faster and more cost-effective.</p>
<p>“In addition, the aqueous fraction can affect the interactions between DES components and proteins, and alter hydration, thereby further modulating enzyme thermostability,” the scientists point out.</p>
<p>Changing the solvent can also affect the stereoselectivity and regioselectivity of an enzyme<em>. </em>Hou and colleagues cite <a href="https://doi.org/10.1002/adsc.201601064" target="_blank" rel="noopener">one study</a> in which baker’s yeast was used to convert arylpropanones [high value intermediates used to manufacture some active pharmaceutical ingredients]. With water as a solvent, the arylpropanones were largely converted to the “S” version, but when DES was used, the conversion was predominantly to the “R” version.</p>
<p>This solvent-modulated selectivity significantly enhances flexibility, but it also means quality must be finely controlled to ensure the choice of solvent doesn’t negatively affect the product.</p>
<p>Clearly, the choice of solvent has serious consequences for product quality that biomanufacturers may not fully appreciate. The challenge is a lack of data regarding enzyme behavior in various solvents.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/for-biocatalysis-solvents-are-a-key-bioprocessing-parameter/">For Biocatalysis, Solvents Are a Key Bioprocessing Parameter</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Cell Therapy Manufacturing Takes Shape Across Asia&#45;Pacific</title>
<link>https://edusehat.com/en/cell-therapy-manufacturing-takes-shape-across-asia-pacific</link>
<guid>https://edusehat.com/en/cell-therapy-manufacturing-takes-shape-across-asia-pacific</guid>
<description><![CDATA[ Cell and gene therapy is accelerating across Asia-Pacific, but manufacturing remains fragmented. Strategic automation, adaptable bioprocessing platforms, stronger supply chains, and workforce development could help therapies scale across diverse markets.
The post Cell Therapy Manufacturing Takes Shape Across Asia-Pacific appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Mike-APAC-CGT_GBPN_IMAGE_08OCT26.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 15 Oct 2026 01:40:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Cell, Therapy, Manufacturing, Takes, Shape, Across, Asia-Pacific</media:keywords>
<content:encoded><![CDATA[<p>Cell and gene therapy (CGT) is gathering momentum across the Asia-Pacific region (APAC), but translating that growth into scalable manufacturing will require more than simply moving established processes into new markets. The challenge is that the region cannot be treated as a single manufacturing environment.</p>
<p>“APAC is better viewed as a collection of complementary ecosystems rather than one uniform market,” says Jerry Huang, APAC marketing manager, cell therapy technologies for Terumo Blood and Cell Technologies. China has a fast-growing CGT innovation and commercialization ecosystem, while Japan brings particular strength in induced pluripotent stem cells and regenerative medicine. Korea combines strong biologics and contract development and manufacturing organization capabilities, and Australia offers an established clinical-trial infrastructure.</p>
<p>Those strengths are accompanied by significant manufacturing differences. “Each country can have different regulatory requirements, import rules, manufacturing capabilities, and reimbursement environments,” Huang says. As a result, he adds, developers “cannot assume that a single, centralized manufacturing site will efficiently serve every Asian market.”</p>
<p>For bioprocessing teams, those differences quickly become practical concerns. CGT manufacturing can involve many individual operations and transfers between systems, creating more opportunities for manual intervention and variability. Media and reagents may also differ in availability and regulatory acceptability from one country to another, complicating technology transfer and localization.</p>
<p>Supply chains can compound the problem. According to feedback from customers in Thailand, Huang says, “some imported materials can take up to three months to arrive,” which makes inventory planning and supplier agreements part of good manufacturing practice (GMP) operations. Fresh-cell logistics can be equally demanding. He points to an example of shipping from Taiwan to U.S. clinical sites, where “flight schedules and even typhoon risk need to be factored into manufacturing planning.”</p>
<p>Workforce constraints add another layer of complexity. In some organizations, CGT manufacturing personnel can require six to nine months of training for required proficiency, while turnover among skilled operators and senior GMP managers can introduce additional operational risk.</p>
<p>Automation could reduce some of those vulnerabilities, but Huang argues that it should follow process understanding, not substitute for it. Here, Huang points out that the most crucial issue is “simplifying and integrating fragmented workflows, while using automation where it adds value and balancing a standardized core workflow with modularity and adaptability for different pipelines, process needs, and local requirements.”</p>
<p>In China, for example, Terumo Blood and Cell Technologies is working with local partners to build a more simplified, integrated, and fit-for-purpose chimeric antigen receptor (CAR) T-cell manufacturing workflow. “The idea is not to replace local technologies,” Huang says, “but to bring together each partner’s strengths with our global manufacturing experience and quality standards.” The goal, he adds, is to “simplify the workflow, reduce manual steps and operational complexity, and improve batch economics” while maintaining the consistency and scalability required for clinical and commercial manufacturing.</p>
<p>Ultimately, Huang sees regional scale depending on manufacturing approaches “designed for the region’s diversity rather than attempting a single model and trying to make it work everywhere.” Standardized manufacturing cores, more integrated workflows, digital traceability, resilient supply chains, qualified material alternatives, and a larger GMP-trained workforce could all help turn Asia-Pacific’s diverse CGT ecosystems into a more connected manufacturing landscape.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/cell-therapy-manufacturing-takes-shape-across-asia-pacific/">Cell Therapy Manufacturing Takes Shape Across Asia-Pacific</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Preterm Birth for Some Women Linked to Specific Autoantibodies</title>
<link>https://edusehat.com/en/preterm-birth-for-some-women-linked-to-specific-autoantibodies</link>
<guid>https://edusehat.com/en/preterm-birth-for-some-women-linked-to-specific-autoantibodies</guid>
<description><![CDATA[ By analyzing maternal sera from term and preterm pregnancies, in combination with studies in live mice and in human placental tissues, researchers identified antibodies that play a role in triggering early labor.
The post Preterm Birth for Some Women Linked to Specific Autoantibodies appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/02/Getty_2147604693_bioprocessing.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 15 Oct 2026 01:40:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Preterm, Birth, for, Some, Women, Linked, Specific, Autoantibodies</media:keywords>
<content:encoded><![CDATA[<p>A typical pregnancy lasts 40 weeks, but for about one in 10 pregnant women labor begins too soon, and premature or preterm birth is the leading cause of newborn deaths worldwide. Doctors have struggled to understand why preterm birth occurs—or how to predict which pregnancies are at highest risk.</p>
<p>By analyzing maternal sera from term and preterm pregnancies, in combination with studies in live mice and in human placental tissues, researchers at University of California, San Francisco (UCSF) identified antibodies that play a role in triggering early labor. The antibodies were present in higher levels and appeared earlier during pregnancy in women who went on to give birth to their babies before 37 weeks’ gestation, compared to women who delivered their babies at term.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>For their study the researchers used a new immune profiling tool built at UCSF, which they suggest could lead to new ways of screening for preterm birth risk and to new preventive interventions. “We built our tool to find exactly these kinds of hidden immune signals,” said Joe DeRisi, PhD, the Gordon M. Tomkins Professor of Biochemistry and Biophysics. “The fact that it’s pointing us toward why some pregnancies go wrong is an exciting result.”</p>
<p>The results also hint that an existing drug used to treat certain inflammatory conditions might feasibly represent a potential candidate for preventing preterm birth. DeRisi is senior author of the scientists’ published paper in <em>Nature Immunology</em>, titled “<a href="https://www.nature.com/articles/s41590-026-02689-y" target="_blank" rel="noopener">Evidence for maternal autoantibodies in the pathogenesis of preterm birth</a>.”</p>
<p>Every pregnancy presents a puzzle for the human immune system. A fetus is not genetically identical to a mother, yet her body must not reject it. “The maternal immune system is reprogrammed during pregnancy to tolerate a semi-allogeneic fetus, yet the mechanisms by which immune tolerance is established and maintained in normal human pregnancy remain incompletely understood,” the authors noted.  In most cases the immune system knows not to attack. However, as the authors pointed out, “Failure to establish or maintain maternal–fetal immune tolerance is associated with preterm birth, and complications of prematurity remain the leading cause of death in children under five worldwide.”</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>To investigate whether the immune system could be triggering some cases of preterm births research lead and first author Elze Rackaityte, PhD, formerly a postdoctoral researcher in the DeRisi lab and now an assistant professor at UCSF, recruited volunteers who were being seen at UCSF’s fertility clinic. The team collected initial blood samples and then tracked a handful of women after they became pregnant from frozen embryo transfers.</p>
<p>“We wanted to capture the immune system before pregnancy, and then measure what changed,” Rackaityte said. “This patient population was particularly well suited to answering that question, because the timing of pregnancy following a frozen embryo transfer could be closely tracked.”</p>
<p>The researchers used a technology called phage immunoprecipitation (IP) sequencing (PhIP-seq), which the DeRisi lab has substantially refined and advanced. PhIP-Seq allows researchers to take a broad look at the antibodies in a person’s blood and determine which proteins they recognize—including, in this case, whether any are reacting to the body’s own proteins.</p>
<p>For their reported study the team used the approach to identify a set of antibodies that appeared consistently once pregnancy began. With that baseline established, the team then turned to a much larger dataset: blood samples from more than 2,000 pregnant women across eight cohorts, including samples collected by California’s statewide prenatal screening program at 15 weeks of gestation. This could show whether any antibodies were specifically associated with preterm birth, not just with pregnancy itself.</p>
<p>The data showed that women who went on to deliver prematurely experienced broader antibody changes earlier than those who delivered at term. Within the broader antibody signature seen in women with preterm deliveries, one antibody that reacted against a protein called IL1RA—which is known to control inflammation in the body— stood out.</p>
<p>IL1RA works by blocking a molecule called IL1β, which drives a kind of inflammation known to trigger uterine contractions. IL1RA is the body’s natural brake to keep IL-1β in check. An antibody that neutralizes IL1RA removes that brake, allowing IL1β and the inflammation it causes to rise unchecked. This could explain why some women with the antibody go into labor too early.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>To confirm the significance, Rackaityte injected the IL1RA antibodies into pregnant mice. IL1β levels rose in the mothers’ blood, and their placentas showed signs of damage—something also seen in human preterm deliveries. “Consistent with our hypothesis, anti-IL1RA injected dams also exhibited profound reproductive defects,” the team wrote.</p>
<p>Wondering how the immune molecule was linked to placental health, Rackaityte next examined human placental tissue to find where IL-1RA was normally located. She found it accumulated in the junctions between cells lining placental blood vessels where nutrients and oxygen cross from mother to fetus. “The placenta is basically stocking up on this inhibitor to protect the pregnancy, and it’s deposited in these strings that go along with the flow of blood,” Rackaityte said. “The first time I looked under the microscope, I thought something went wrong because I had never seen a protein organized like this before.”</p>
<p>The researchers caution that the anti-IL1RA antibodies were seen in only a fraction of preterm births, so there are likely many other causes. They also don’t yet know whether the antibodies were already present before pregnancy—triggered by previous infection or immune disease—or appeared after conception, since the women who carried the antibody signature were only followed after they conceived.</p>
<p>Anakinra, a synthetic form of the IL1RA molecule, has already been used for nearly two decades to treat inflammatory diseases including rheumatoid arthritis. The new results suggest that the already-approved drug could be worth investigating as a potential way to prevent preterm births, by putting the brakes back on IL-1, preventing inflammation and preterm uterine contractions. “Just the fact that this drug has been around for a while, and that we have decades of safety data on it, is very compelling for use in pregnancy,” Rackaityte said.</p>
<p>In her new lab, Rackaityte plans to continue studying anti-IL1RA antibodies as well as follow up on other antibodies that were found in the preterm-birth-associated immune signature. In their paper the authors concluded, “Beyond an individual protein, these collective proteome-wide data, representing thousands of individuals, reveals that pregnancy itself elicits a broad and shared program of humoral autoreactivity, and that preterm birth is distinguished by a markedly expanded signature targeting proteins essential for placental function, vascular remodeling and immune regulation.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/preterm-birth-for-some-women-linked-to-specific-autoantibodies/">Preterm Birth for Some Women Linked to Specific Autoantibodies</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Hôpital Montfort Introduces Digital Pre&#45;Triage Technology to Improve Emergency Care</title>
<link>https://edusehat.com/en/hopital-montfort-introduces-digital-pre-triage-technology-to-improve-emergency-care</link>
<guid>https://edusehat.com/en/hopital-montfort-introduces-digital-pre-triage-technology-to-improve-emergency-care</guid>
<description><![CDATA[ New Canadian platform allows patients to share medical information before meeting a triage nurse, helping streamline emergency department workflows. Hôpital Montfort in Ottawa has introduced a digital pre-triage platform designed to improve how patients are assessed and processed in the emergency department. The technology, called EmergConnect, allows patients to provide information about their symptoms and […]
The post Hôpital Montfort Introduces Digital Pre-Triage Technology to Improve Emergency Care appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/shutterstock_2712061503.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 15 Oct 2026 01:35:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Hôpital, Montfort, Introduces, Digital, Pre-Triage, Technology, Improve, Emergency, Care</media:keywords>
<content:encoded><![CDATA[<p><strong>New Canadian platform allows patients to share medical information before meeting a triage nurse, helping streamline emergency department workflows.</strong></p>
<p>Hôpital Montfort in Ottawa has introduced a digital pre-triage platform designed to improve how patients are assessed and processed in the emergency department.</p>
<p>The technology, called <strong>EmergConnect</strong>, allows patients to provide information about their symptoms and medical history before their initial assessment by a triage nurse.</p>
<p>Patients can access the platform using their smartphones, tablets available in the emergency department or remotely before arriving at the hospital.</p>
<p>By collecting relevant patient information earlier in the care process, the system aims to reduce administrative tasks for healthcare professionals and support more efficient emergency department operations.</p>
<h3>Improving the emergency department experience</h3>
<p>Emergency departments across Canada continue to face significant challenges related to patient volumes, staffing pressures and lengthy wait times.</p>
<p>Digital pre-triage technology offers an opportunity to simplify the collection of patient information while helping clinical teams prepare for incoming patients.</p>
<p>At Hôpital Montfort, EmergConnect is intended to complement existing clinical triage procedures rather than replace assessments conducted by healthcare professionals.</p>
<p>The platform also supports the transfer of patient information from paramedics before ambulance arrivals, potentially improving communication between emergency medical services and hospital teams.</p>
<h3>Supporting healthcare professionals</h3>
<p>Following several months of evaluation, Hôpital Montfort adopted the platform as part of its efforts to modernize emergency department operations.</p>
<p>By allowing patients to enter information directly, the technology could reduce repetitive documentation and give nurses access to relevant details earlier in the assessment process.</p>
<p>The initiative reflects growing interest among Canadian hospitals in digital solutions that improve clinical workflows and support healthcare professionals.</p>
<h3>A Canadian healthcare innovation</h3>
<p>EmergConnect represents an example of how digital health technology can be integrated into existing hospital operations without replacing the essential role of clinical staff.</p>
<p>Although the hospital has not yet established whether the technology reduces overall emergency department wait times, its implementation provides an opportunity to evaluate how digital pre-triage can improve patient experiences and operational efficiency.</p>
<p>As Canadian hospitals explore new approaches to managing emergency department demand, initiatives such as EmergConnect may offer valuable insights into the role of digital technology in supporting patient care.</p>
<p>The post <a href="https://www.hospitalnews.com/hopital-montfort-introduces-digital-pre-triage-technology-to-improve-emergency-care/">Hôpital Montfort Introduces Digital Pre-Triage Technology to Improve Emergency Care</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Exploring Safer Hospital Discharges</title>
<link>https://edusehat.com/en/exploring-safer-hospital-discharges</link>
<guid>https://edusehat.com/en/exploring-safer-hospital-discharges</guid>
<description><![CDATA[ New study shows how community warming centres have the potential to reduce hospital burden. People experiencing homelessness often visit emergency departments (EDs) as a source of shelter, particularly during the colder months. Researchers at UHN found that hospital-affiliated warming centres, operated in collaboration with community partners, have the potential to reduce ED length of stay […]
The post Exploring Safer Hospital Discharges appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/TG_haymanimage.jpg.png" length="49398" type="image/jpeg"/>
<pubDate>Thu, 15 Oct 2026 01:35:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Exploring, Safer, Hospital, Discharges</media:keywords>
<content:encoded><![CDATA[<div class="heading-2">
<div class="article-headings">
<p class="heading-subtitle">New study shows how community warming centres have the potential to reduce hospital burden.</p>
</div>
<div class="article-image ">
<p>People experiencing homelessness often visit emergency departments (EDs) as a source of shelter, particularly during the colder months. Researchers at UHN found that hospital-affiliated warming centres, operated in collaboration with community partners, have the potential to reduce ED length of stay for people experiencing homelessness.</p>
<p>In Toronto, rates of non-urgent ED visits by people experiencing homelessness during winter months have been increasing. This is often due to limited sheltering options, as people experiencing homelessness may seek care in the ED for a range of concerns, including access to shelter.</p>
<p>Following an ED visit, people experiencing unsheltered homelessness may face barriers to accessing shelter beds and other safe discharge locations. Due to the medical risks associated with discharge to an unsafe environment, this can result in patients remaining in the ED even after their medical needs have been addressed. This delay contributes to ED overcrowding, which causes reduced service quality, increased risk of mortality, and greater staff distress.</p>
<p>As the number of people experiencing homelessness continues to rise, identifying safe discharge options is becoming increasingly important to help reduce ED overcrowding while ensuring patients receive appropriate support after leaving the hospital. To address this need, UHN’s Social Medicine program worked with community partners to establish a hospital-affiliated warming centre in Toronto in 2023 to provide a safe location for discharges during the winter months.</p>
<p>To examine the impact of this warming centre, the researchers looked at the relationship between ED visits by people experiencing homelessness and the operation of the Toronto-based hospital-affiliated warming centre. This warming centre were operated in collaboration with a community partner with expertise in supporting people experiencing homelessness. The team analyzed administrative data on ED and hospital-affiliated warming centre utilization from the winter seasons between November 2022 and April 2025.</p>
<p>The research team found that the hospital-affiliated warming centre supported 1,196 visits during its first year and 638 visits during the second year. In the second year, when a referral pathway from the ED to the warming centre was open, it was associated with decreased ED lengths of stay. This suggests that the referral pathway may have helped facilitate faster discharges.</p>
<p>The study also found that in the second year, municipal shelter system volumes correlated with ED length of stay, suggesting that shelter capacity may influence patient flow in the ED.</p>
<p>Overall, the researchers say that hospital-affiliated warming centres have the potential to reduce ED burden. More research and monitoring of these interventions are needed to ensure optimal outcomes.  The researchers note that improved access to emergency shelter beds and affordable and supportive housing is necessary to improve the health of people experiencing homelessness.</p>
<p><em>Dr. Nick Kerman, Research Associate with the Gattuso Centre for Social Medicine at UHN, and Clinical Psychologist at UHN, is the first author of the study.</em></p>
<p><em>Dr. <a class="ext" href="https://www.uhnresearch.ca/researcher/kaitlin-hayman" target="_blank" rel="noopener">Kate Hayman</a>, Clinician Investigator and emergency physician at UHN, is the corresponding author of the study. She is an Assistant Professor in the Department of Medicine at the University of Toronto.</em></p>
<p><em>This work was supported by UHN’s STAR-EM (Summer Training and Research in Emergency Medicine) program and UHN Foundation. The warming centre was developed and delivered through collaboration among UHN Emergency Medicine, the Gattuso Centre for Social Medicine at UHN, and a community partner with expertise supporting people experiencing homelessness.</em></p>
<p><em>Kerman N, Yanikomeroglu S, Ragusila A, Vitkin N, Coyle S, Steer L, Boozary A, Hayman K. <a class="ext" href="https://pubmed.ncbi.nlm.nih.gov/42573946/" target="_blank" rel="noopener">Development of a hospital-affiliated warming centre to reduce emergency department pressures among patients experiencing homelessness</a>. CJEM. 2026 Aug 10. doi: 10.1007/s43678-026-01250-y. Epub ahead of print. </em></p>
</div>
</div>
<p>The post <a href="https://www.hospitalnews.com/exploring-safer-hospital-discharges/">Exploring Safer Hospital Discharges</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>How to Build a Study Plan After Failing USMLE Step 1</title>
<link>https://edusehat.com/en/how-to-build-a-study-plan-after-failing-usmle-step-1</link>
<guid>https://edusehat.com/en/how-to-build-a-study-plan-after-failing-usmle-step-1</guid>
<description><![CDATA[ Failing the USMLE Step 1 can be one of the most discouraging moments in medical school. It’s natural to feel disappointed, frustrated, or even question whether you’re capable of becoming a physician. But while failing Step 1 is undoubtedly a setback, it does not define your future career.   Every year, students who do not […]
The post How to Build a Study Plan After Failing USMLE Step 1 appeared first on Elite Medical Prep. ]]></description>
<enclosure url="https://elitemedicalprep.com/wp-content/uploads/2026/10/pexels-thirdman-7236846-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 14 Oct 2026 21:00:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>How, Build, Study, Plan, After, Failing, USMLE, Step</media:keywords>
<content:encoded><![CDATA[<p><span>Failing the USMLE Step 1 can be one of the most discouraging moments in medical school. It’s natural to feel disappointed, frustrated, or even question whether you’re capable of becoming a physician. But while failing Step 1 is undoubtedly a setback, it does not define your future career.</span></p>
<p> </p>
<p><span>Every year, students who do not pass on their first attempt regroup, adjust their approach, and go on to pass the exam, graduate medical school, match into residency, and become excellent physicians. I have worked with many of these students as a tutor at Elite Medical Prep. The difference is rarely that they suddenly became “smarter.” More often, they learned how to study more effectively, addressed the factors that contributed to their first attempt, and built a plan that was realistic instead of overwhelming.</span></p>
<p> </p>
<p><span>The most important thing you can do after a failed attempt is truly delve into understanding what went wrong. A stronger study plan starts with reflection, not just more hours.</span></p>
<p> </p>
<h2><strong>Start by Identifying What Actually Happened</strong></h2>
<p><span>One of the biggest mistakes students make after failing Step 1 is assuming they simply “didn’t study enough.” </span><span>Sometimes that is true, but often it isn’t.</span></p>
<p> </p>
<p><span>The real question is </span><i><span>why</span></i><span> the exam didn’t go as planned. Were there significant content gaps? Did timing become an issue? Did anxiety affect your performance? Were you consistently passing practice exams before test day, or were your scores suggesting you weren’t quite ready? Did life circumstances interfere with your preparation?</span></p>
<p> </p>
<p><span>Being honest with yourself can be difficult, but it is one of the most valuable parts of <a href="https://elitemedicalprep.com/how-to-recover-after-a-low-nbme-practice-score-a-step-by-step-strategy/">rebuilding your study plan. </a></span><span>For some students, the problem is a lack of foundational knowledge. Others understand the content but struggle to interpret USMLE-style questions. Some rely too heavily on memorization without developing clinical reasoning. Others were not prepared for the marathon test day that they had to focus through. </span></p>
<p> </p>
<p><span>The goal isn’t to assign blame. It’s to identify the factors you can improve moving forward.</span></p>
<p> </p>
<h2><strong>Avoid Repeating the Same Study Plan</strong></h2>
<p><span>Each student requires an individualized approach, but one constant is that it’s probably not wise to repeat the same plan that resulted in a failure in the first place.</span></p>
<p> </p>
<p><span>Instead, think of your previous study plan as valuable information. It showed you what worked and, more importantly, what didn’t.</span></p>
<p> </p>
<p><span>If you spent months passively reading review books but completed very few practice questions, your new plan should look different. If you rushed through thousands of questions without reviewing mistakes carefully, that’s another opportunity to adjust. If you used six different resources simultaneously and felt overwhelmed, simplifying may be the better approach. </span><span>A new outcome usually requires a new approach.</span></p>
<p> </p>
<h2><a href="https://elitemedicalprep.com/how-to-make-a-study-schedule/"><strong>Build a Timeline That Fits Your Reality</strong></a></h2>
<p><span>Another common mistake is creating an unrealistic study schedule based on someone else’s experience. </span><span>One student may have six uninterrupted weeks to prepare. Another may be balancing classes, clinical responsibilities, research, family obligations, or part-time work. Some students need to rebuild significant foundational knowledge, while others simply need to strengthen question interpretation and test-taking strategy.</span></p>
<p> </p>
<p><span>Your timeline should reflect your own circumstances, not someone else’s study calendar you found online. And it should be </span><i><span>realistic</span></i><span> for </span><span>you</span><span>.  </span><span>Rather than asking, “How quickly can I retake the exam?” consider asking, “When will I truly be ready?”</span></p>
<p> </p>
<h2><strong>Focus on Weaknesses Without Ignoring Strengths</strong></h2>
<p><span>After reviewing your previous performance, you’ll likely notice certain subjects or systems that consistently gave you trouble.</span></p>
<p> </p>
<p><span>It can be tempting to spend all your time fixing those weaknesses, but balance is important. While weaker areas deserve extra attention, completely neglecting subjects you already know well can lead to forgetting important concepts over time. This can be especially detrimental when you’re taking an exam that demands integration of all these various topics. </span></p>
<p> </p>
<p><span>Many students benefit from structuring their weeks around both reinforcement and remediation. Continue reviewing stronger topics periodically while dedicating additional time to the areas that need the most improvement. </span><span>This approach helps maintain your current knowledge base while steadily closing knowledge gaps.</span></p>
<p> </p>
<h2><strong>Let Practice Questions Guide Your Studying</strong></h2>
<p><span>One of the biggest shifts many successful repeat test-takers make is relying more heavily on active learning. </span><span><a href="https://elitemedicalprep.com/how-to-use-usmle-step-1-practice-questions-effectively/">Practice questions</a> are not simply a way to measure progress, they are one of the best learning tools available.</span></p>
<p> </p>
<p><span>As you work through questions, pay attention not only to whether you answered correctly but also to why. Did you misunderstand the concept? Misread the question? Eliminate the correct answer too quickly? Fall for a common distractor?</span></p>
<p> </p>
<h2><strong>The review process is often where the deepest learning happens.</strong></h2>
<p><span>Some students even keep an error log to identify recurring patterns. Over time, you may notice that many incorrect answers stem from the same underlying issue, whether it’s pharmacology, physiology, statistics, or question interpretation.</span></p>
<p> </p>
<p><span>Understanding your mistakes is far more valuable than simply counting how many questions you completed.</span></p>
<p> </p>
<h2><strong>Don’t Ignore Test-Taking Skills</strong></h2>
<p><span>Not every incorrect answer reflects a content problem. </span><span>Many students know significantly more medicine than their practice scores suggest because they struggle with timing, second-guess themselves, or misinterpret what questions are actually asking.</span></p>
<p> </p>
<p><span>If your content knowledge is reasonably strong but your scores remain lower than expected, it may be worth focusing specifically on <a href="https://elitemedicalprep.com/usmle-step-1-practice-question-mistakes-to-avoid/">test-taking strategy</a>.</span></p>
<p> </p>
<p><span>Learning how to identify the key clue in a vignette, eliminate distractors efficiently, and avoid overthinking can meaningfully improve performance without memorizing hundreds of additional facts. </span><span>Sometimes the biggest improvement comes from changing how you approach questions rather than how much you study.</span></p>
<p> </p>
<h2><strong>Use Practice Exams Strategically</strong></h2>
<p><span>Practice exams can feel intimidating after an unsuccessful attempt, but they are one of your most valuable tools. </span><span>Rather than viewing practice tests as judgments of your ability, think of them as progress reports. They help determine whether your current study plan is working and identify areas that still need attention before test day.</span></p>
<p> </p>
<p><span>Many students delay <a href="https://elitemedicalprep.com/when-to-take-the-nbme-practice-exams/">taking self-assessments</a> because they fear disappointing scores or want to prioritize massive content review first. Unfortunately, waiting too long often leaves little time to adjust.</span></p>
<p> </p>
<p><span>The truth is the practice exams are the only way to truly measure your progress. They are your assessment tool. It’s my recommendation that you take every single NBME practice test form available if you can. You’ll know your study plan is working if you see consistent upward progress. </span></p>
<p> </p>
<h2><strong>Reach Out for Support </strong></h2>
<p><span>One mistake many students make after failing Step 1 is trying to manage everything alone. </span><span>It’s understandable to feel embarrassed or discouraged, but isolation rarely makes the process easier.</span></p>
<p> </p>
<p><span>Consider reaching out to faculty advisors, academic support offices, mentors, trusted classmates, or tutors. Sometimes an outside perspective can identify study habits or reasoning patterns that are difficult to recognize on your own. You may feel alone in this experience but you’re not! As I stated earlier, many students struggle with Step 1 but are ultimately successful and go on to become excellent physicians. </span></p>
<p> </p>
<p><span>Working with a tutor is not a sign that you’ve failed, it is simply another resource. A good tutor can help pinpoint weaknesses, improve question interpretation, develop accountability, and create a study plan tailored to your individual needs. <strong>Consider reaching out to us here at Elite Medical Prep to<a href="https://elitemedicalprep.com/usmle-step-1-tutoring/"> meet with an expert tutor</a> </strong>who can help support you and tailor a study plan to your specific needs and goals. </span></p>
<p> </p>
<p><span>Support looks different for everyone, but very few students succeed entirely on their own.</span></p>
<p> </p>
<h2><strong>Take Care of Yourself Along the Way</strong></h2>
<p><span>Preparing for a retake can be emotionally exhausting. </span><span>Many students carry anxiety into their second attempt, worrying that every practice score predicts another disappointing outcome. Others become so focused on studying that they neglect sleep, exercise, nutrition, or time with family and friends.</span></p>
<p> </p>
<p><span>Ironically, these habits often make studying less effective. </span><span>Your brain performs best when it has opportunities to recover. Building regular breaks, movement, and healthy routines into your schedule is not wasted time, it is part of preparing well.</span></p>
<p> </p>
<p><span>Remember that consistency almost always outperforms burnout.</span></p>
<p> </p>
<h2><strong>Know When You’re Ready</strong></h2>
<p><span>One of the hardest decisions after failing Step 1 is choosing when to schedule the retake.</span></p>
<p> </p>
<p><span>The pressure to move forward quickly is understandable, especially if academic timelines or graduation requirements are involved. However, taking the exam before you’re consistently ready can place unnecessary stress on an already challenging situation. Afterall, it doesn’t make the timeline any faster to rush a re-take and fail again. </span></p>
<p> </p>
<p><span>While no one ever feels completely prepared, your decision should be based on objective evidence rather than hope alone. Consistently strong performance on practice exams, improved confidence with question interpretation, and steady progress across weaker areas are much better indicators than simply wanting to be finished. </span><span>Giving yourself enough time to prepare properly is often one of the best investments you can make.</span></p>
<p> </p>
<h2><strong>The Bottom Line</strong></h2>
<p><span>Failing Step 1 is not the outcome anyone hopes for, but it is also not the end of your journey. Many physicians who have experienced this setback have gone on to build successful careers because they approached their second attempt differently.</span></p>
<p> </p>
<p><span>Instead of asking, “How can I study harder?” ask, “How can I study smarter?” Take the time to identify what went wrong, create a realistic timeline that fits your life, strengthen your weak areas without neglecting your strengths, and use practice questions to guide your learning. Most importantly, don’t be afraid to ask for help.</span></p>
<p> </p>
<p><span>A failed exam does not define your ability to become a physician. What matters most is how you respond to it. With honest reflection, a thoughtful study plan, and <a href="https://elitemedicalprep.com/get-started/">the right support system</a>, your next attempt can become the turning point that moves you confidently toward the rest of your medical career.</span></p>
<p>The post <a href="https://elitemedicalprep.com/how-to-build-a-study-plan-after-failing-usmle-step-1/">How to Build a Study Plan After Failing USMLE Step 1</a> appeared first on <a href="https://elitemedicalprep.com/">Elite Medical Prep</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Physician work&#45;life balance: Which specialties rank the highest?</title>
<link>https://edusehat.com/en/physician-work-life-balance-which-specialties-rank-the-highest</link>
<guid>https://edusehat.com/en/physician-work-life-balance-which-specialties-rank-the-highest</guid>
<description><![CDATA[ Which specialty offers the best work-life balance for physicians? A new survey has tried to quantify what the word “lifestyle” means for physicians by ranking factors that contribute to work-life balance. Marit Health compared survey responses from more than 24,000 physicians, rating factors like hours worked per week, schedule quality and call “burden.” Analysts then calculated […]
The post Physician work-life balance: Which specialties rank the highest? appeared first on Today&#039;s Hospitalist. ]]></description>
<enclosure url="https://todayshospitalist.com/wp-content/uploads/2026/10/work-life-balance-shutterstock_2751209543-10-14-26-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 14 Oct 2026 20:30:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Physician, work-life, balance:, Which, specialties, rank, the, highest</media:keywords>
<content:encoded><![CDATA[<p>Which specialty offers the best work-life balance for physicians? A new survey has tried to quantify what the word “lifestyle” means for physicians by ranking factors that contribute to work-life balance.</p>
<p><a href="https://www.marithealth.com/posts/2026-physician-lifestyle-balance-index">Marit Health compared survey responses from more than 24,000 physicians,</a> rating factors like hours worked per week, schedule quality and call “burden.” Analysts then calculated lifestyle rankings for 36 specialties, with a score of 1 considered average.</p>
<p>The specialty that came out on top was preventive medicine, which received a score of 1.5 on Marit’s lifestyle index. Rounding out the top five were dermatology, with a score of 1.44, and allergy/immunology (1.39), rheumatology (1.34) and psychiatry (1.33).</p>
<p>Hospital medicine came in at No. 27 on Marit’s list with a lifestyle score of 0.81. Emergency medicine physicians gave their specialty a score of 0.95, coming in at No. 19 on the list.</p>
<p>Here’s a look at the factors like work hours, call schedule and paid time off that went into Marit’s lifestyle rankings.</p>
<h4><strong>Hours worked per week</strong></h4>
<p>When it came to physician work hours, Marit found an average work week of 45.6 hours across the 36 specialties on its ranking of work-life balance.</p>
<p>Preventive medicine physicians reported working an average of 40.5 hours per week, which was on the low end on the report, and a factor in its top spot on the lifestyle ranking. No. 2 on the list, dermatology, logged an average work week of 38.8 hours, the second shortest work week on the list.</p>
<p>At the bottom of the lifestyle ranking list, neurosurgery averaged 56.6 hours per week. That was the longest work week of the specialties surveyed.</p>
<p>Hospital medicine averaged 45.2 work hours per week in Marit’s data. Emergency medicine averaged 35.5 hours per week.</p>
<h4><strong>Call schedule</strong></h4>
<p>“Call burden,” as Marit described it, was another key factor in work-life balance for physicians. The lowest-ranking specialties tended to be those that respond to emergencies, take around-the-clock call or cover nights. They included neurosurgery (#36), general surgery (#35), critical care (#34), ob-gyn (#33) and anesthesiology (#32).</p>
<p>Call burden had a powerful impact on the lifestyle scores of specialties. While emergency medicine had the lowest average workweeks of any specialty on the survey—35.5 hours—the specialty’s low score on schedule—0.61—helped drive it down to No. 19 on Marit’s overall lifestyle ranking. (An average score for call burden in Marit’s data was 1.0.)</p>
<p>As Marit said in its analysis: “Thirty-five hours of nights, weekends and rotating shifts produces a very different experience than 35 hours of predictable daytime work.”</p>
<p>When it came to call burden, hospital medicine received a ranking of 0.97. Emergency medicine saw a score of 0.86.</p>
<h4><strong>Paid time off</strong></h4>
<p>Marit found that among the 36 specialties on its list, physicians received an average of five weeks of paid time off. For hospital medicine, the number was 3.9 weeks.</p>
<p>ED physicians reported the lowest amount of paid time off—3.7 weeks, tied for last with oral/maxillofacial surgery.</p>
<p><strong>Top five specialties for lifestyle</strong></p>
<p>Preventive medicine: 1.50</p>
<p>Dermatology: 1.44</p>
<p>Allergy and immunology: 1.39</p>
<p>Rheumatology: 1.34</p>
<p>Psychiatry: 1.33</p>
<p><strong>Bottom five specialties for lifestyle</strong></p>
<p>Anesthesiology: 0.64</p>
<p>OB-GYN: 0.64</p>
<p>Critical care: 0.64</p>
<p>Surgery: 0.61</p>
<p>Neurosurgery: 0.50</p>
<p>The post <a href="https://todayshospitalist.com/physician-work-life-balance-which-specialties-rank-the-highest/">Physician work-life balance: Which specialties rank the highest?</a> appeared first on <a href="https://todayshospitalist.com/">Today's Hospitalist</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The US military’s race to make fake blood</title>
<link>https://edusehat.com/en/the-us-militarys-race-to-make-fake-blood</link>
<guid>https://edusehat.com/en/the-us-militarys-race-to-make-fake-blood</guid>
<description><![CDATA[ Its call sign was Morphine 1-2.   In February 2007, the hulking dual-­rotor casualty evacuation helicopter had just flown three wounded soldiers to a field hospital in Balad, north of Baghdad, when another call came: an emergency mission to fly through an insurgent-controlled area in broad daylight. Typically, helicopters would be in a spot like… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/10/260917-KaloCyte-044-thumb.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 14 Oct 2026 17:05:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, military’s, race, make, fake, blood</media:keywords>
<content:encoded><![CDATA[<p>Its call sign was Morphine 1-2.  </p>



<p>In February 2007, the hulking dual-­rotor casualty evacuation helicopter had just flown three wounded soldiers to a field hospital in Balad, north of Baghdad, when another call came: an emergency mission to fly through an insurgent-controlled area in broad daylight. Typically, helicopters would be in a spot like this only at night, and with all lights turned off. </p>



<p>As it passed near the city of Karmah, in the eastern side of Al-Anbar province, an insurgent fired a portable missile launcher. The tail gunner, who likely saw the shot roaring in, yelled for the pilot to make an evasive move. But the missile had already locked on, and the ensuing blast started a fire on board. After the pilot battled the failing machine for 58 agonizing seconds, Morphine 1-2 plunged to the ground. All seven crew members were killed.  </p>





<p>Why was the helo there in daylight? “It was getting blood and bringing it back. It was [on] what we call a ‘blood run,’ and [it’s] the highest of priorities besides casualty evacuation,” explains Lieutenant Commander Robert Murray, a Navy officer and program manager at DARPA, the Defense Advanced Research Projects Agency, who studied this incident as an intelligence officer.</p>



<p>Today, a <a href="https://www.who.int/news/item/12-06-2026-safe-blood-supply-improves-as-voluntary-donations-exceed-85---but-many-people-still-lack-access">chronic shortage of blood</a> in both the <a href="https://www.army.mil/article/270961/the_army_is_planning_for_a_conflict_with_china_including_shoring_up_blood_supply">military</a> and <a href="https://www.theguardian.com/us-news/2026/jul/30/american-red-cross-blood-supply-crisis">civilian worlds</a> is fueling a race to develop synthetic alternatives. About <a href="https://jts.health.mil/assets/docs/cpgs/Frozen_Deglycerolized_Red-Blood_Cells_05_Aug_2024_ID26_v1.2.pdf">90% of preventable battlefield deaths</a> are due to hemorrhage—bleeding that happens when a blood vessel ruptures—and it’s <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12584296/">the leading cause</a> of maternal deaths worldwide. A <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12035996/">study published in <em>Transfusion</em> in 2025 found that of 1.2 million trauma patients</a> in the United States who potentially needed blood before reaching a hospital, just 1% received it. The shortage results in about <a href="https://www.facs.org/media-center/press-releases/2024/surgeons-address-the-urgent-need-to-eliminate-blood-deserts/">10,000 preventable deaths each year</a> in the US, according to the American College of Surgeons. Globally, that figure <a href="https://www.facs.org/for-medical-professionals/news-publications/news-and-articles/bulletin/2024/february-2024-volume-109-issue-2/viewpoint-blood-deserts-face-the-burden-of-global-blood-deficits/">is likely in the millions</a>. </p>



<p>One reason for the shortfall is that blood has a storage problem. Whole blood lasts only 35 days when refrigerated, so banks separate out components to stretch the timeline. But that’s an imperfect solution. The platelets that help wounds clot are typically stored at room temperature and last for a week or less. Hospitals and the military freeze the red blood cells that carry oxygen, as well as the protein-rich plasma that restores volume and aids coagulation. Once thawed, though, both will spoil within days. “What happens if I don’t know when I’m going to be attacked? Well, thaw it and you let it expire, right?” Murray says. </p>



<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">
<p><strong>A <em>JAMA</em> study of combat injuries in Afghanistan suggests a magic number for someone who needs a transfusion: You have 36 minutes to get started.</strong></p>
</blockquote>



<p>That’s why Murray—who, in addition to his military experience, has a PhD in physiology—is leading a DARPA effort to address blood’s battlefield problems. He’s in charge of a new $73 million dollar program called RAPIID (for “resuscitation and prevention of ischemia-induced dysfunction”). Its goal is to create shelf-stable versions of the three major transfusion constituents: plasma, platelets, and red blood cells. As it gets underway late this year, RAPIID picks up on decades of work to synthesize blood or help it last longer. Most recently, that includes a prior $47.5 million DARPA project called FSHARP (for “fieldable solutions for hemorrhage with bio-artificial resuscitation products”), in which researchers have demonstrated promising results in animals. </p>


<div class="wp-block-image">
<figure class="wp-block-image alignwide size-full"><img fetchpriority="high" decoding="async" width="3000" height="1791" src="https://wp.technologyreview.com/wp-content/uploads/2026/10/240611-KaloCyte-synthetic-blood-181.jpg" alt="a machine on a workbench with tubes and jars" class="wp-image-1146257" srcset="https://wp.technologyreview.com/wp-content/uploads/2026/10/240611-KaloCyte-synthetic-blood-181.jpg 3000w, https://wp.technologyreview.com/wp-content/uploads/2026/10/240611-KaloCyte-synthetic-blood-181.jpg?resize=300,179 300w, https://wp.technologyreview.com/wp-content/uploads/2026/10/240611-KaloCyte-synthetic-blood-181.jpg?resize=768,458 768w, https://wp.technologyreview.com/wp-content/uploads/2026/10/240611-KaloCyte-synthetic-blood-181.jpg?resize=1536,917 1536w, https://wp.technologyreview.com/wp-content/uploads/2026/10/240611-KaloCyte-synthetic-blood-181.jpg?resize=2048,1223 2048w" sizes="(max-width: 3000px) 100vw, 3000px"><figcaption class="wp-element-caption">KaloCyte techs use a device called a tangential flow filtration machine<br>to process unencapsulated hemoglobin.</figcaption><div class="image-credit">MATT ROTH</div>
</figure>
</div>

<div class="wp-block-image">
<figure class="wp-block-image alignwide size-full"><img decoding="async" width="933" height="933" src="https://wp.technologyreview.com/wp-content/uploads/2026/10/20240705_nf_blood_powder1_1400px.jpg" alt="gloved hand pouring clumps of red powder from a vial onto a petri dish" class="wp-image-1146256" srcset="https://wp.technologyreview.com/wp-content/uploads/2026/10/20240705_nf_blood_powder1_1400px.jpg 933w, https://wp.technologyreview.com/wp-content/uploads/2026/10/20240705_nf_blood_powder1_1400px.jpg?resize=150,150 150w, https://wp.technologyreview.com/wp-content/uploads/2026/10/20240705_nf_blood_powder1_1400px.jpg?resize=300,300 300w, https://wp.technologyreview.com/wp-content/uploads/2026/10/20240705_nf_blood_powder1_1400px.jpg?resize=768,768 768w" sizes="(max-width: 933px) 100vw, 933px"><figcaption class="wp-element-caption">After processing, the hemoglobin is concentrated and then freeze-dried to make it shelf-stable.</figcaption><div class="image-credit">MATT ROTH</div>
</figure>
</div>


<p>With RAPIID trials for the different components occurring in parallel, the goal is to have bags of dried blood products deployed in the field by 2029. That puts Murray in the position of a conductor coordinating an orchestra of clinical trials with the FDA, while also sourcing the paraphernalia that goes along with transfusions—everything from combat-durable storage bags to tests that could check how much artificial blood a patient already has. </p>



<p>Getting it all done will be tough, but the military is feeling the pressure to address its shortage. Blood drives may not deliver in time after a mass-casualty event, and a <a href="https://jamanetwork.com/journals/jama/fullarticle/2658323"><em>JAMA</em> study of combat injuries in Afghanistan</a> suggests that if the injured person needs a transfusion, the magic number is 36 minutes. “If something is survivable—and generally we classify most all hemorrhage as survivable—[you’re] almost guaranteed to survive if you get the blood before that 36-minute mark,” Murray says. After that, the chance of survival “starts to drop precipitously.”  </p>



<hr class="wp-block-separator has-alpha-channel-opacity">



<p>In the mission to make portable,<strong> </strong>shelf-stable blood components, plasma is the low-hanging fruit. Researchers have known how to isolate and freeze-dry plasma, the yellowish liquid that makes up 55% of whole human blood, since the late 1930s. On the battlefields of World War II, its mix of water, salts, and thousands of types of proteins helped restore blood volume in wounded soldiers—and to some degree controlled bleeding. In the 1960s, the US abandoned freeze-dried plasma because it carried a risk of transmitting hepatitis to recipients from infected donors. But screening, testing, and drying techniques improved, and starting in 2010, the US military launched a yearslong effort to rebuild its capacity for producing these products. Over the past two years, the FDA has allowed two types of freeze-dried plasma to be used in emergencies by the US military—and one can even be used by civilians. </p>



<p>As for platelets, efforts at <a href="https://www.tandfonline.com/doi/10.1080/10731190600974962?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed#d1e104">extending their life</a> date back to the 1950s, but they haven’t seen a ton of success. Bioengineers have, for example, attempted to attach the membranes of <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC13197205/">platelets</a> to synthetic particles. The most successful project comes from a company called Cellphire, which freeze-dries <em>actual</em> human platelets. The product has <a href="https://www.cellphire.com/news/announces-cryptics-phase-2-3-clinical-study-final-topline-results">shown safety and efficacy</a> in humans in clinical trials, but its dependence on donors means it’s unclear whether this approach can scale.</p>



<p>Red blood cells have been similarly tough to preserve or mimic. Their most critical component is hemoglobin, which carries oxygen and comes encased in a cell membrane. For more than a century, researchers have been looking for ways to deliver hemoglobin without the immunological challenges created by this exterior, including the fact that donors’ and recipients’ blood types need to be compatible. Evolutionary pressure developed that wrapper for very good reason, though: “Naked” hemoglobin tends to break down quickly in the bloodstream, and that can <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8526348/">cause organ damage</a>. It also scavenges nitric oxide, our body’s natural mechanism for opening up blood vessels, and causes those channels to constrict.</p>





<p>This problem became all too clear in the 1980s and 1990s, when fears that transfusions could transmit HIV sparked interest in a class of membrane-free delivery mechanisms called hemoglobin-based oxygen carriers (HBOCs). One, named HemAssist, consisted of hemoglobin subunits linked together to avoid the rapid-breakdown problem. It had the added benefit of lasting roughly a year in cold storage (red blood cells last about 40 days)—but it didn’t solve the nitric oxide problem, so it constricted blood vessels. In a clinical trial, 24 of the 52 people who <a href="https://www.wsj.com/articles/SB891369100869844000">received HemAssist</a> died, compared with eight out of 46 in the control group. The parent company terminated trials in 1998. A <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC2364833/pdf/bmj-336-7651-news-00977.pdf">review of clinical studies</a> published in <em>JAMA</em> in 2008 further solidified HBOCs’ fate, finding that they generally triple patients’ chances of heart attack and increase the risk of death by 30%.</p>



<p>More recently, researchers have tried to grow red blood cells in a lab using a technology called “blood pharming,” which involves making them from progenitors known as induced pluripotent stem cells. The stumbling blocks? Cost and yield. DARPA launched a <a href="https://www.darpa.mil/news/2013/on-demand-blood-transfusions">pharming initiative</a> in 2008, using stem cells from discarded umbilical-cord blood, but was unable to get the cost below tens of thousands of dollars per unit of red blood cells. They pulled the plug and offloaded the research to the <a href="https://www.usuhs.edu/4D-Bio3/research#odbprog">Uniformed Services University</a>. Even if the cost were lower, though, pharmed blood can’t be stored in a backpack. “These are still cells—they still require a refrigerator, they still require special handling,” Murray says. </p>



<p>It won’t be easy to solve all these challenges at once. “Each one of those projects individually is a massive undertaking,” says John Holcomb, a surgery professor at the <a href="https://www.uab.edu/medicine/surgery/trauma/faculty/holcomb#:~:text=Holcomb%20has%20served%20in%20multiple,and%20film%20Black%20Hawk%20Down.">University of Alabama at Birmingham</a>, who was a combat surgeon in Mogadishu, Somalia, during the battle that inspired <em>Black Hawk Down</em>. “I think that they will probably be successful individually. How we use those individual products, or combine those products together, I think remains to be seen.”</p>



<hr class="wp-block-separator has-alpha-channel-opacity">



<p>Several years after DARPA gave<strong> </strong>up on lab-grown blood, Murray was stationed at a base on Okinawa, an island 400 miles southwest of the Japanese mainland, where he witnessed the vulnerability of the blood supply firsthand. The site houses a blood bank that serves the roughly 27,000 Marines commanded from the island—plus thousands more military personnel on the base and deployed within a 100-million-square-mile stretch of the Pacific called <a href="https://www.militarytimes.com/news/pentagon-congress/2026/06/17/fair-winds-indopacom-pentagon-returns-command-name-to-us-pacific-command/">USPACOM</a>, which ranges from western India to Hawaii and from Antarctica to the Arctic. “The blood center is right next to the hospital, which is about 200 meters from all of the satellite communications on that island,” Murray told me. A missile strike could take out all three.</p>



<p>Murray wondered: Is there a way to produce synthetic blood that could last longer? As he completed his PhD in physiology in 2018, the military was also awakening to the vulnerability of the Okinawa facility. The <a href="https://media.defense.gov/2020/May/18/2002302061/-1/-1/1/2018-NATIONAL-DEFENSE-STRATEGY-SUMMARY.PDF">2018 National Defense Strategy</a>, which shifted military focus from terrorism to a potential ground war with China or Russia, showed war planners the risks of relying on a single site for blood runs covering all of USPACOM. DARPA then got serious once again about making fake blood and kicked off the FSHARP program in 2023. <a href="https://www.darpa.mil/about/people/robert-murray">Murray came aboard</a> as a deputy program manager in DARPA’s Biological Technologies Office in 2024 and was named a program manager in 2026, just a few months before RAPIID <a href="https://www.darpa.mil/news/2026/rapiidly-transitioning-shelf-stable-blood-substitutes-battlefield">put out its call for proposals</a> this past May. </p>


<div class="wp-block-image">
<figure class="wp-block-image alignwide size-full"><img decoding="async" width="1916" height="1916" src="https://wp.technologyreview.com/wp-content/uploads/2026/10/SynthoPlate-cryoTEM.jpg" alt="TEM image of platelets" class="wp-image-1146264" srcset="https://wp.technologyreview.com/wp-content/uploads/2026/10/SynthoPlate-cryoTEM.jpg 1916w, https://wp.technologyreview.com/wp-content/uploads/2026/10/SynthoPlate-cryoTEM.jpg?resize=150,150 150w, https://wp.technologyreview.com/wp-content/uploads/2026/10/SynthoPlate-cryoTEM.jpg?resize=300,300 300w, https://wp.technologyreview.com/wp-content/uploads/2026/10/SynthoPlate-cryoTEM.jpg?resize=768,768 768w, https://wp.technologyreview.com/wp-content/uploads/2026/10/SynthoPlate-cryoTEM.jpg?resize=1536,1536 1536w" sizes="(max-width: 1916px) 100vw, 1916px"><figcaption class="wp-element-caption">SynthoPlate, seen here under a microscope, is a synthetic platelet carrying peptides that help it mimic the work of natural platelets, including sticking to broken blood vessels and to one another.</figcaption><div class="image-credit">COURTESY OF SEN GUPTA</div>
</figure>
</div>


<p>Before he took the helm, related work had been underway for years. Aided by FSHARP funding, researchers at a company called KaloCyte continued testing a technique—originally developed by doctors who are now at the University of Maryland, Penn State, and the University of Pittsburgh—that “upcycles” hemoglobin from expiring donor blood. “We take that hemoglobin and then we package it in a lipid nanoparticle that functions like an artificial cell membrane,” explains CEO Elaine Haynes. </p>



<p>The product, called ErythroMer, is essentially a new kind of HBOC. The membrane prevents breakdown, limits dangerous scavenging of nitric oxide, and also helps the hemoglobin take up and release oxygen. Each ErythroMer cell includes a lipid called KC-1003, which acts like a sentry: In response to high pH in the lungs, it signals another small molecule within ErythroMer to move away, allowing oxygen in. Then, in tired tissue, where pH is lower, KC-1003 brings the small molecule back, releasing the oxygen.  </p>



<p>Using a well-understood process called lyophilization, similar to one that World War II–era scientists used with plasma, the team freeze-dries its product to store at room temperature, where it can remain stable for two years. In a 2016 study of mice and rats with up to <a href="https://www.sciencedirect.com/science/article/pii/S0006497119310286">70% of their blood removed</a>, ErythroMer stabilized blood pressure and oxygen delivery—without the devastating constriction of blood vessels that sank HemAssist. FSHARP furthered that work, helping fund studies on how the HBOC interacted with plasma and platelets.</p>



<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">
<p><strong>Much like the handle of a Swiss Army knife, the synthetic platelet has specialized attachments—peptides that serve as the biological equivalents of a corkscrew or a nail file.</strong></p>
</blockquote>



<p>KaloCyte, though, still has plenty to figure out. Haynes says the company can source only about 1,000 to 2,000 units of expiring hemoglobin a month. So it has licensed a yeast strain that it aims to use to create its own hemoglobin in the lab.</p>



<div class="wp-block-group is-layout-constrained wp-block-group-is-layout-constrained">
<p>Over a video call from her desk, Haynes showed me a sample of ready-to-use ErythroMer. It was encased in a heavy-duty storage bag with two chambers. One was full of scarlet powder—the hemoglobin product—and the other of sterile water to rapidly rehydrate it in the field. Eventually, she explained, under Murray’s master plan, “you’ll have another container with the synthetic platelet, and then a third container with the plasma.” </p>



<p>But achieving that vision depends on finding a synthetic platelet that works.</p>
</div>



<p>To do that, DARPA has turned to Anirban Sen Gupta, a bioengineering professor at Case Western Reserve University. “Traditionally platelets were thought of [as] blood cement, but it’s not that simple,” he explains. “They are, in my opinion, like drones, surveilling the blood vessel wall continuously, looking for signs of injury.” Sen Gupta’s team, which also includes collaborators at the University of Pittsburgh, used FSHARP funding to continue work on a product called SynthoPlate. Fabricated from a lipid nanoparticle that he likens to the handle of a Swiss Army knife, it has specialized peptide attachments—the biological equivalents of a corkscrew or a nail file. The first version has three: One binds to a chemical called von Willebrand factor, which helps platelets stick to the walls of injured blood vessels; another attaches to collagen, which acts as a scaffold for regrowing cells; and the third mimics a blood protein called fibrinogen, which acts like a Lego connector that allows the synthetic platelets to stick to real ones near a wound. Like ErythroMer, the product is freeze-dried and can be reconstituted with sterile water. It keeps for over a year at room temperature and at least three months at a desertlike 122 °F.</p>



<p>In a 2026 paper in <em><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC13335430/">Advanced Science</a></em>, the researchers showed that SynthoPlate cut bleeding time and blood loss by more than half in mice with low platelet counts. In a <a href="https://www.sciencedirect.com/science/article/pii/S1538783625008311">separate study</a>, they also safely injected the faux platelets into rats’ bone marrow—a more useful delivery site, given that a bleeding patient might not have an available vein. Sen Gupta and a colleague have spun this work out into a company called Haima Therapeutics. </p>



<p>The good news, as he sees it, is that the pharmaceutical industry excels at mass-­producing millions of billions of lipid nanoparticles—witness Operation Warp Speed, in which these blobs of fat held delicate snippets of mRNA in covid shots. “The magic of the artificial platelet is in all those peptides that are decorating the surface of the particle, but the scalability of the platform is very well established,” he says.</p>



<hr class="wp-block-separator has-alpha-channel-opacity">



<p>Around the world, prospective<strong> </strong>blood alternatives abound. Researchers at Cambridge University in the UK are trying to <a href="https://www.nhsbt.nhs.uk/news/the-nhsbt-led-restore-trial-into-growing-blood-featured-in-the-new-yorker/">pharm red blood cells</a> for people with rare blood types or blood disorders like sickle cell anemia, and other researchers have also <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7804213/">cultured platelets</a> and <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10959681/">red blood cells</a>. Japanese scientists are already <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12829376/">testing their own version</a> of encapsulated human hemoglobin in human subjects.</p>





<p>Over the course of the next three years, RAPIID will move DARPA’s efforts closer to real life. In addition to ErythroMer and SynthoPlate, the agency in early October announced funding of blood components for five other companies. Among them is a firm called Abioremedi that eschews hemoglobin for synthetic versions of other oxygen-carrying proteins such as cytoglobin, neuroglobin, and myoglobin encased in albumin—the most-abundant protein in human plasma. Octapharma USA won the sole contract to supply plasma to RAPIID, and will also be competing in platelets with an FDA-approved pair of clotting proteins it affixes to a disc-shaped nanoparticle.</p>



<p>With those players in place, the agency will focus the next year on getting technologies through large FDA-regulated animal studies. Murray has set up a bit of a Hunger Games scenario: Each contractee working on blood components only has one year of guaranteed funding. He says he’s taking advantage of advancements in the field since FSHARP launched, but is also hedging against any manufacturing or regulatory setbacks ahead of his 2029 deadline. Getting cut doesn’t mean the product is bad, just that the time frame was too demanding. </p>



<p>The second and third years will focus on human trials, overseen by the University of Colorado Anschutz Medical Campus. That will include using the products in situations where the risk of side effects is outweighed by the danger of doing nothing, such as with severely injured people in ambulances.</p>



<p>The possibility of fatal outcomes has invited second-guessing about DARPA’s choices. For Shibani Pati, who directs the Center for Research in Transfusion Medicine and Cell Therapies at the University of California, San Francisco, Murray could be making things too “DARPA hard” on himself by backing products like SynthoPlate and ErythroMer, which are previously untested in humans. “They need to make a very concerted effort to take what they’ve already developed and push it through to approval through the FDA,” she says. “Not start with moonshot projects that will take forever to get through.” For platelets, Pati thinks the RAPIID program would have done better to tap Cellphire, since its products have already received millions from the Pentagon and shown safety and efficacy in humans. (Murray notes that he can only select companies that apply, and Cellphire did not.)</p>



<p>She has similar qualms about ErythroMer. A different HBOC that sources hemoglobin from cattle, called Hemopure, has been approved for use since 2001 in South Africa, she notes. And though it hasn’t been approved by the FDA—it was part of the fateful 2008 <em>JAMA </em>study—US doctors are cleared to use it for patients who have bad immune responses or religious objections to conventional transfusions. </p>



<p>Holcomb, the surgery professor, worries the effort will run into issues with interactions between the products. He notes that individual blood components have more than one role: Red blood cells also help with clotting, platelets also are anti-inflammatory, and plasma helps tune coagulation. There’s no guarantee that the versions RAPIID helps develop will work in the same ways.  </p>



<p>Murray says that FSHARP’s animal studies tested all the products together, using whole blood as a baseline, precisely because of such possible interactions. The cocktail met its program metrics in all but one area: The clotting was not quite as good, perhaps because negative charges in some molecules repel one another. </p>



<p>“I do not think they will replicate all the functions that whole blood does in our body,” Holcomb says. But, he admits, “you may not need to, right? When you get seriously injured and you lose 50% of your intravascular volume, you’re dead, right? So if you lose 30% and maybe you’re hanging on to life just barely, maybe you show up with all these different products, and you have enough whole blood left in you to do these other functions.” </p>



<p>Murray is determined to complete trials so that shelf-stable blood can be delivered in 2029. In addition to the storage bags, he’s already sourcing finger sticks for in-field blood testing and a battery-powered device to heat up the blood components.</p>



<p>The danger of blood runs—and, by extension, the vulnerability of millions in combat zones, maternity wards, and ambulances—drives his scientific daring. Knowing the stakes, he told his boss in 2024 that even if FSHARP failed, “we should invest 50 million more dollars in it and do it again.”</p>



<p><em>Andrew Rosenblum is a technology journalist and the author of the techno-thriller </em>Stretch Goals.</p>]]> </content:encoded>
</item>

<item>
<title>The Top 10 Questions Shaping the Future of Optogenetic Biomanufacturing</title>
<link>https://edusehat.com/en/the-top-10-questions-shaping-the-future-of-optogenetic-biomanufacturing</link>
<guid>https://edusehat.com/en/the-top-10-questions-shaping-the-future-of-optogenetic-biomanufacturing</guid>
<description><![CDATA[ This article explores the ten most important questions facing optogenetic biomanufacturing as it moves from proof‑of‑concept demonstrations toward mainstream adoption in modern bioprocessing.
The post The Top 10 Questions Shaping the Future of Optogenetic Biomanufacturing appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/240516_Prolific0454-2.png" length="49398" type="image/jpeg"/>
<pubDate>Wed, 14 Oct 2026 06:15:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, Top, Questions, Shaping, the, Future, Optogenetic, Biomanufacturing</media:keywords>
<content:encoded><![CDATA[<figure aria-describedby="caption-attachment-339161" class="wp-caption alignright"><img decoding="async" class="wp-image-339161" src="https://www.genengnews.com/wp-content/uploads/2026/10/240516_Max_Horner_0524-1-scaled-e1791910673532-300x300.jpg" alt="Maximilian Hoerner" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/240516_Max_Horner_0524-1-scaled-e1791910673532-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/240516_Max_Horner_0524-1-scaled-e1791910673532-1024x1024.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/240516_Max_Horner_0524-1-scaled-e1791910673532-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/10/240516_Max_Horner_0524-1-scaled-e1791910673532-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/240516_Max_Horner_0524-1-scaled-e1791910673532-1536x1536.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2026/10/240516_Max_Horner_0524-1-scaled-e1791910673532.jpg 1617w" sizes="(max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Maximilian Hoerner, PhD</figcaption></figure>
<p>The emergence of increasingly complex biologics such as multi‑specific antibodies, cytokines, fusion proteins, and other structurally demanding modalities has exposed the limits of conventional bioprocessing. Many of these molecules are difficult to express at commercially viable yields, and their quality attributes can be highly sensitive to the cellular environment. As a result, productivity, consistency, and cost remain major constraints across the industry.</p>
<p>Traditional cell line development (CLD) relies on constitutive promoters that drive static expression throughout development and production. Because production is always on, cells must divide and manufacture protein simultaneously, even when the product is burdensome or toxic. While this model worked relatively well for easy-to-express monoclonal antibodies, it does not work well for next-generation biologics, where the inherent trade-off between higher specific productivity and rapid cell growth, both competing for the same cellular resources, is increased. Light‑controlled gene expression using optogenetics is emerging as a credible alternative.</p>
<p>This article explores the ten most important questions facing optogenetic biomanufacturing as it moves from proof‑of‑concept demonstrations toward mainstream adoption in modern bioprocessing.</p>
<p><strong>1. What is optogenetics, and why is it relevant to biologics manufacturing?</strong></p>
<p>Optogenetics uses light‑responsive proteins to control specific cellular functions. In biomanufacturing, the key application is regulating gene expression with light instead of relying on constitutive promoters or chemical inducers. When light‑controlled gene expression systems are engineered into production cell lines, illumination at defined wavelengths can switch expression on, off, or to intermediate levels.</p>
<p>This is important because it introduces a fundamentally different control modality. Conventional systems provide static expression, whereas optogenetics enables dynamic, reversible, and tunable control. As biologics become more complex and more sensitive to expression conditions, having a way to precisely modulate transcription directly, rather than perturbing the entire cell by modulating process parameters such as temperature, will become increasingly valuable.</p>
<p><strong>2. What core limitation in biologics manufacturing does light</strong><strong>‑</strong><strong>based control address?</strong></p>
<p>The main limitation is the inherent competition between cell growth and protein production. In constitutive systems, cells must divide and manufacture protein at the same time, drawing on the same finite pool of metabolic resources. This creates a structural trade‑off: clones that produce strongly have a slow doubling time and/or do not grow to viable densities, while clones that grow well often produce only modest titers. This trade‑off becomes much more pronounced for challenging molecules such as multi‑specific antibodies, cytokines, and fusion proteins that are aggregation‑prone or place a significant burden on the host cell.</p>
<p>Optogenetics addresses this by separating the growth and production phases. Cells can grow in an uninduced, low-burden state and then transition into a productive state upon illumination. As light acts directly on transcriptional regulators in a dose-dependent manner, expression can be tuned precisely rather than modulated indirectly through temperature shifts or coarsely and irreversibly by chemical induction. Chemical inducers can also negatively affect cell performance through off-target effects and are difficult to remove during downstream processing, which has limited their adoption in mammalian biomanufacturing. The direct, tunable control by light also enables more deliberate modulation of pathways that influence critical quality attributes such as post-translational modifications (PTMs), which is increasingly important for complex biologics and biosimilars.</p>
<p><strong>3. How does optogenetic light exposure work, and is it safe for cells and media?</strong></p>
<p>Optogenetics uses light as an informational cue rather than an energy source. Because photoreceptors respond to brief, low-intensity pulses and stay “on” for a tunable period of time before reverting to the off state, optogenetic systems can maintain precise control without continuous or high-power illumination.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>The wavelengths used in bioprocessing are in the visible range and non-ionizing, operating well under established phototoxicity thresholds. At these levels, light does not harm cells or DNA, nor does it disrupt cellular physiology. Although certain media components are known to be light-sensitive, the illumination used for optogenetic induction has not shown detrimental effects on cellular performance.</p>
<p><strong>4. What is the impact of optogenetics on lab operations?</strong></p>
<p>Optogenetic workflows use standard lab equipment with the addition of illumination devices compatible with existing infrastructure, such as plates, shake flasks, or bioreactors. The main operational difference occurs during pool generation and single-cell cloning, where cells must remain uninduced. This is achieved by working under “safe light” conditions, visible wavelengths that do not activate the specific optogenetic system but allow the operator to handle the cell culture. Only small areas of the lab need to be adapted for this purpose. For all other operations, including biomanufacturing, local interventions to shield cells from room light are typically sufficient.</p>
<p><strong>5. How many cellular functions can be controlled with light in a single cell line?</strong></p>
<p>Current systems can independently regulate cellular functions using two or three different wavelengths. For example, one color may control production while another modulates a critical quality‑related pathway. Functions that require coordinated timing can be linked to the same wavelength. As genetic circuit design advances, the number of independently controllable functions is expected to increase.</p>
<p><strong>6. When might optogenetically manufactured biologics reach clinical and commercial stages?</strong></p>
<p>Optogenetic cell line development is already being explored for multiple programs. Regulatory agencies have established pathways for evaluating emerging bioprocess technologies, and optogenetic systems are beginning to move through these mechanisms. If early development proceeds as expected, optogenetically controlled processes could support clinical filings in the next two years, with commercial adoption following thereafter.</p>
<p><strong>7. Can optogenetics be integrated into existing facilities?</strong></p>
<p>Yes. Optogenetic manufacturing does not require new bioreactor designs; illumination hardware can be added to standard single‑use or stainless‑steel systems. For single‑use bags, light is delivered externally through the bag without breaching the sterility barrier; for stainless‑steel tanks, cultures can be circulated through illuminated loops. No cleanroom redesign is required.</p>
<div class="my-8"><span data-render-ad="6"></span></div>
<p><strong>8. How does optogenetic manufacturing scale to larger bioreactors?</strong></p>
<p>Scaling optogenetic systems depends on three factors: the sensitivity of the photoreceptors, the lifetime of their activated state in the dark, and the mixing and light-scattering characteristics of the bioreactor. Modern optogenetic systems for biomanufacturing are designed to respond to very low light intensities, and once activated, they gradually return to the off state in the dark at a characteristic rate, typically over tens of minutes.</p>
<p>Since stirred-tank bioreactors mix continuously and scatter light throughout the vessel, cells receive sufficient illumination over the photoreceptor’s characteristic activation lifetime even at large volumes. Simulation studies and early pilot-scale experiments up to the 200 L scale suggest that optogenetic activation can be achieved at commercially relevant scales, including stainless steel and single-use systems.</p>
<p><strong>9. What has convinced established players to evaluate this technology?</strong></p>
<p>Biologics development and manufacturing are intentionally conservative, with new technologies adopted only when they demonstrate clear, reproducible benefits and maintain patient safety. For any emerging bioprocess platform, the threshold for evaluation is data showing that it can deliver meaningful improvements without introducing new risks or operational complexity.</p>
<p>In comparative studies, optogenetic induction has produced more than two‑fold increases in titer for standard monoclonal antibodies as well as for more difficult‑to‑express therapeutic proteins. These gains have been achieved while maintaining or improving critical quality attributes, including those influenced by folding, assembly, and post‑translational modification.</p>
<p>As the next generation of therapeutics become increasingly complex, leading biopharma and CDMO players see the need for novel biomanufacturing platforms capable of meeting that complexity without compromising titers, and for that reason several key players are actively evaluating optogenetic technology for potential integration.</p>
<p><strong>10. Where is optogenetic biomanufacturing headed in the next decade?</strong></p>
<p>If current trends continue, optogenetic control may become a standard tool for managing expression, quality, and other cellular functions in biologics manufacturing. The ability to modulate gene expression dynamically opens possibilities for more efficient production of complex therapeutics, more predictable quality profiles, and more flexible facility design. As the technology matures, it is likely to be adopted across CDMOs, biotech, and biopharma companies seeking greater control over their manufacturing processes.</p>
<p><em>Maximilian Hoerner, PhD, is the head of optogenetics at Prolific Machines</em></p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/the-top-10-questions-shaping-the-future-of-optogenetic-biomanufacturing/">The Top 10 Questions Shaping the Future of Optogenetic Biomanufacturing</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Enodia Therapeutics Inks Pfizer Deal to Develop Sec61&#45;Targeting Small Molecules</title>
<link>https://edusehat.com/en/enodia-therapeutics-inks-pfizer-deal-to-develop-sec61-targeting-small-molecules</link>
<guid>https://edusehat.com/en/enodia-therapeutics-inks-pfizer-deal-to-develop-sec61-targeting-small-molecules</guid>
<description><![CDATA[ Backed by multiple Sec61 inhibitor families, proteomics and cryo-EM datasets, and machine learning-driven design, Enodia Therapeutics’ platform is the foundation of a new research collaboration and license agreement with Pfizer. 
The post Enodia Therapeutics Inks Pfizer Deal to Develop Sec61-Targeting Small Molecules appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/11/GettyImages-1405788998-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 14 Oct 2026 06:15:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Enodia, Therapeutics, Inks, Pfizer, Deal, Develop, Sec61-Targeting, Small, Molecules</media:keywords>
<content:encoded><![CDATA[<p><span>Biotechnology firm Enodia Therapeutics has announced a research collaboration and licensing agreement with pharma giant Pfizer to discover and develop small molecule inhibitors of Sec61, using Enodia’s proprietary platform. </span></p>
<p><span>Under the terms of the agreement, Enodia will perform discovery activities to screen, optimize, and develop Sec61 inhibitor candidates against multiple collaboration targets. Following the collaboration term, Pfizer will be responsible for all clinical, manufacturing, regulatory, and commercial activities. Furthermore, Enodia will receive an upfront payment and is eligible for future research, development, and sales milestone payments, as well as tiered royalties on net sales, bringing the total potential value to more than $500 million.</span></p>
<p><span>Enodia develops novel small-molecule therapies for targeted protein degradation using its platform, which is designed to identify small molecules that enable selective Sec61 translocon modulation, a novel approach to inhibit disease-driving proteins when they are synthesized and before pathological effects occur. To date, the company has built a broad chemical space that spans multiple Sec61 inhibitor families and is supported by biological datasets including proteomics and cryo-EM data as well as tailored cell-line libraries. </span></p>
<p><span>“Enodia has built a broad platform that enables selective Sec61 translocon modulation, a novel approach to inhibit disease-driving proteins while preserving essential physiological functions,” said Yves Ribeill, PhD, Enodia’s CEO. “We look forward to collaborating with Pfizer, combining their deep expertise and clinical resources with our approach for precisely targeting pathological proteins to bring forth potential new medicines.”</span></p>
<p><span>Earlier this year, Enodia announced that it had </span><a href="https://www.genengnews.com/topics/genome-editing/targeted-protein-degradation-drives-deal-between-enodia-therapeutics-and-kezar-life-sciences/"><span>purchased assets from Kezar Life Sciences’</span></a><span> Sec61-based discovery and development program. At the time, Enodia said that the acquisition helped advance its understanding of Sec61 selectivity mechanisms. The company also said that insights from Kezar’s programs would further strengthen Enodia’s core focus on Sec61-driven selectivity for targeted protein degradation. Under the terms of the purchase agreement, Kezar received an initial upfront payment totaling $1 million, and was expected to receive future payments upon achievement of certain development, regulatory and commercialization milestones. </span></p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/enodia-therapeutics-inks-pfizer-deal-to-develop-sec61-targeting-small-molecules/">Enodia Therapeutics Inks Pfizer Deal to Develop Sec61-Targeting Small Molecules</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>X&#45;Chromosome Gene Linked to Increased Autism Diagnosis in Males</title>
<link>https://edusehat.com/en/x-chromosome-gene-linked-to-increased-autism-diagnosis-in-males</link>
<guid>https://edusehat.com/en/x-chromosome-gene-linked-to-increased-autism-diagnosis-in-males</guid>
<description><![CDATA[ New research suggests that variants in the MECP2 gene on the X chromosome might help partly explain why autism is diagnosed about four times more often in males than it is in females. 
The post X-Chromosome Gene Linked to Increased Autism Diagnosis in Males appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2022/05/Getty_1015900158_AutismBrain-1024x683.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 14 Oct 2026 06:15:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>X-Chromosome, Gene, Linked, Increased, Autism, Diagnosis, Males</media:keywords>
<content:encoded><![CDATA[<p>Researchers at Baylor College of Medicine, the Duncan Neurological Research Institute (Duncan NRI) at Texas Children’s Hospital, and collaborating institutions have identified new genetic candidates that help explain why autism is diagnosed about four times more often in boys than it is in girls. The study, involving tests in induced pluripotent stem cell (iPSC)-derived neurons (iNeurons), revealed that small changes in the gene <em>MECP2</em> on the X chromosome might help explain part of this difference.</p>
<p>Huda Zoghbi, MD, Distinguished Service Professor at Baylor, director of Duncan NRI, and a Howard Hughes Medical Institute investigator, is senior and corresponding author of the team’s published paper in <em>The American Journal of Human Genetics</em>, titled “<a href="https://doi.org/10.1016/j.ajhg.2026.09.011" target="_blank" rel="noopener">A massively parallel reporter assay of <em>MECP2</em> cis-regulatory elements reveals genetic candidates for male-biased autism</a>.” In their paper, the team concluded, “These findings suggest noncoding <em>MECP2</em> variants can cause idiopathic, male-biased autism and provide a framework for uncovering regulatory variants in other X chromosome neurodevelopmental genes that may contribute to autism’s missing heritability.”</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>“Autism is a common, heritable neurodevelopmental trait that affects how a person communicates, interacts with others, and experiences the world, and is characterized by altered social interactions and restricted, repetitive behaviors or interests,” Zoghbi explained. “It is diagnosed about four times more in male individuals than in female individuals, suggesting sex-specific factors may increase male vulnerability,” the researchers added in their paper.</p>
<p>In the current study, the researchers drew from their long experience with gene <em>MECP2</em>, which is on the X chromosome and has been associated with neurodevelopmental conditions, including autism. “We tested the idea that the predominance of autism in males could be explained in part by mild mutations in an X chromosome gene’s regulatory regions,” commented Rebecca Meyer-Schuman, PhD, a postdoctoral associate in the Zoghbi lab. “Females might be protected from such a mild mutation because of their second X chromosome, but males, who have only one copy, would be more vulnerable. The regulatory regions are like dials that control whether a gene will be expressed and by how much. And what better place to start looking at these regulatory regions than the gene <em>MECP2</em>, where brain health depends on how much of the gene is expressed, and where mutations can cause neurodevelopmental disorders that include autism.”</p>
<p>Previous murine studies by Zoghbi lab and others have taught researchers that <em>MECP2 </em>produces a Goldilocks protein, meaning that it must maintain a “just right” concentration or activity level for a healthy brain. Having too little—about 50% or less of the normal levels—leads to Rett syndrome, and having twice the normal levels causes a different neurodevelopmental condition called <em>MECP2</em> duplication syndrome. “Both loss-of-function and gain-of-function variants lead to severe neurodevelopmental conditions—Rett syndrome (MIM: 312750) and <em>MECP2 </em>duplication syndrome (MDS; MIM: 300260[intellectual developmental disorder, X-linked, syndromic, Lubs type (MRXSL)]), respectively,” the authors commented. “Because <em>MECP2</em> is on the X chromosome, hemizygous male individuals have a more severe phenotype than heterozygous female carriers with the same variant.”</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>Meyer-Schuman also noted, “Previous studies in mice also showed us that milder changes in <em>MECP2</em> levels, for instance reducing the expression by 30% or increasing it by 50%, do not cause the more severe features of Rett syndrome or <em>MECP2</em> duplication syndrome like seizures or motor problems, but lead to autism-like behaviors.”</p>
<p>For their current study the team used a massively parallel reporter assay (MPRA) to screen the regulatory regions of the <em>MECP2 </em>gene in induced pluripotent stem-cell (iPC)-derived neurons. “This allowed us to identify and manipulate the regulatory regions and determine what kinds of changes would alter their function,” Meyer-Schuman said. The researchers also screened <em>MECP2 </em>regulatory regions in autistic individuals and tested the genetic variants they identified using the MPRA assays.</p>
<p>“We identified two regulatory regions where male autistic individuals inherited a variant from their unaffected mother that altered regulatory activity,” Meyer-Schuman said. “One of these variants reduced <em>MECP2 </em>expression by approximately 30% in human neurons, a magnitude that produces social deficits, hyperactivity and anxiety-like characteristics in mice. As predicted by the mouse model, this individual was diagnosed with autism and ADHD but had none of the defining characteristics of Rett syndrome.”</p>
<p>In their paper, the authors commented that their work supports a broader hypothesis that altered dosage or expression of sex chromosome genes are a major source of the male bias observed in autism. Zoghbi added, “These findings, a result of integrating human and animal studies, suggest that <em>MECP2 </em>regulatory variants can contribute to male-biased autism and reveal just the tip of the iceberg, providing a framework for uncovering regulatory variants in other X chromosome neurodevelopmental genes that may contribute to autism’s missing heritability.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/x-chromosome-gene-linked-to-increased-autism-diagnosis-in-males/">X-Chromosome Gene Linked to Increased Autism Diagnosis in Males</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Spatial Biology Moves Toward Translation</title>
<link>https://edusehat.com/en/spatial-biology-moves-toward-translation</link>
<guid>https://edusehat.com/en/spatial-biology-moves-toward-translation</guid>
<description><![CDATA[ Spatial technologies preserve tissue context to guide therapeutic development and translate molecular insights into clinically actionable information.
The post Spatial Biology Moves Toward Translation appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_10x-Genomics-Figure-1_Atera_stage-III-B-cervical-cancer-tissue-section-Copy.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 13 Oct 2026 23:05:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Spatial, Biology, Moves, Toward, Translation</media:keywords>
<content:encoded><![CDATA[<p>If “Spatial Biology” conjures images of a science conducted in zero gravity aboard the International Space Station, think again. As one of the most rapidly advancing areas in biomedical research and precision medicine, spatial biology probes the inner landscape of intact cells and tissues down to single-molecule resolution. By preserving location and organization, instead of dissociating tissue into component parts, this discipline maps fine architecture, cellular neighborhoods, and individual molecules.</p>
<p>Maintaining that context is driving new ways of characterizing disease progression, identifying biomarkers, advancing therapeutics, and monitoring treatment responses. Fueling these advances is an expanding toolbox that encompasses high-plex imaging, spatial transcriptomics and proteomics, multiomic profiling, and increasingly sophisticated computational analyses. We consulted industry leaders about how the field is progressing, barriers that remain, and their vision for what is needed to propel spatial biology into its next phase.</p>
<h4><strong>Scaling spatial discovery </strong></h4>
<p>While genomics and single-cell sequencing profile molecular features and cellular states, spatial biology answers questions that neither can address, such as where those features and cells are located and how they are organized.</p>
<figure aria-describedby="caption-attachment-339238" class="wp-caption alignleft"><img loading="lazy" decoding="async" class="wp-image-339238" src="https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Kamila-Belhocine-PhD-Copy-e1791901844534-300x300.jpg" alt="Kamila Belhocine" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Kamila-Belhocine-PhD-Copy-e1791901844534-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Kamila-Belhocine-PhD-Copy-e1791901844534-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Kamila-Belhocine-PhD-Copy-e1791901844534.jpg 368w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Kamila Belhocine, PhD<br>Senior Director<br>10x Genomics</figcaption></figure>
<p>“When you dissociate a tissue into individual cells, you lose something fundamental: where those cells were and how they were organized relative to one another,” observes Kamila Belhocine, PhD, senior director of spatial biology at 10x Genomics. She continues: “Spatial biology puts that context back. In cancer, for example, knowing that a particular immune cell population is present within a tumor sample is useful. But knowing whether those cells have infiltrated the tumor core, are sitting at its margin, or are excluded from it altogether can tell you something very different about the biology, and potentially, about response to treatment. The same principle applies to understanding tissue architecture in cases like development and cell differentiation, and disease progression.”</p>
<p>Several barriers have prevented spatial biology from going mainstream in the biopharma/biotech industry. Belhocine says, “I think about four things: speed, reliability, cost, and interpretability. Spatial needs to be fast enough to fit into routine research workflows, robust enough to generate consistent results at scale, affordable enough to use across large studies and, ultimately, straightforward enough to turn the resulting data into biological insight. The first three are fundamentally technology and engineering challenges. Interpretability is harder because it also requires accumulating evidence and validating which spatial signatures are truly meaningful and actionable.”</p>
<p>However, according to Belhocine, single-cell technologies had to address similar issues. “A decade ago, single-cell analysis was largely a specialized technique. Continued innovation made it easier, more scalable, more robust, and dramatically more cost-effective, opening it to a much broader community and enabling much larger studies. We think spatial is following a similar trajectory.”</p>
<figure aria-describedby="caption-attachment-339235" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-339235" src="https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Gary-J-Latham-PhD-Copy-e1791901959881-300x300.jpg" alt="Gary Latham" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Gary-J-Latham-PhD-Copy-e1791901959881-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Gary-J-Latham-PhD-Copy-e1791901959881-1024x1024.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Gary-J-Latham-PhD-Copy-e1791901959881-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Gary-J-Latham-PhD-Copy-e1791901959881-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Gary-J-Latham-PhD-Copy-e1791901959881.jpg 1200w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Gary Latham, PhD<br>Chief Technology Officer<br>Bio-Techne</figcaption></figure>
<p>Belhocine says the company’s newest spatial instrument, Atera, which will be shipping in the second half of the year, is an important step in that progression. “This technology combines whole-transcriptome spatial profiling with single-cell sensitivity and subcellular resolution at a massive scale designed for much larger studies.”</p>
<p>Looking ahead, Belhocine predicts, “As spatial technologies become more scalable, robust and cost-effective, researchers can apply them across much larger patient cohorts to identify biomarkers and signatures of treatment response. Additionally, AI will undoubtedly accelerate that trajectory even further.”</p>
<h4><strong>Spatial multiomics </strong></h4>
<p>Gary Latham, PhD, CTO, Bio-Techne, provides another perspective on the role of integrating protein analysis and gene expression in spatial biology. “A fuller understanding of tissue biology requires seeing where proteins and genes are expressed, how they relate, and how they interact within the tissue architecture.”</p>
<figure aria-describedby="caption-attachment-339240" class="wp-caption alignleft"><img loading="lazy" decoding="async" class="size-medium wp-image-339240" src="https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Bio-Techne-Fig-1-Copy-297x300.jpg" alt="Human breast cancer" width="297" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Bio-Techne-Fig-1-Copy-297x300.jpg 297w, https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Bio-Techne-Fig-1-Copy.jpg 342w" sizes="auto, (max-width: 297px) 100vw, 297px"><figcaption class="wp-caption-text">Automated spatial biology systems enable high-throughput, hyperplexed analysis of tissue samples. Human breast cancer sample stained with 105-plex multiomics panel on COMET. The image shows a HER2+ tumor with HER+ cells and immune infiltrates. Markers shown: HER2 (white), collagen I (teal), CD45 (red), and CD38 (yellow). [Bio-Techne]</figcaption></figure>
<p>This molecular multiplexing can provide a more complete view of tissue biology. “Spatial biology is unique from other technologies because it takes us from seeing what is there to understanding <em>what is where</em>,” says Latham. He continues, “This is critical because biology can’t be understood as a parts list. Instead, it is a dynamic system of interactions and networks where location defines meaning. While single-cell sequencing can tell you which cell types exist and their molecular states, spatial biology tells you how those cells are organized, how they may be interacting, and how these relationships may influence disease biology and clinical outcomes.”</p>
<p>Latham indicates that the field is working to overcome several challenges. “There is a need for reproducible, standardized automation for today’s biomarkers and tomorrow’s multiomic precision medicine. Many spatial biology workflows remain exploratory and manual during early discovery phases. As programs move toward translational research, the focus shifts to robustness, reproducibility, and standardized, validated workflows. Ultimately, clinical adoption requires validated panels, automation, and throughput suited to routine testing.”</p>
<figure aria-describedby="caption-attachment-339239" class="wp-caption alignright"><img loading="lazy" decoding="async" class="size-medium wp-image-339239" src="https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Bio-Techne-Fig-2-Copy-300x280.jpg" alt="Human prostate cancer" width="300" height="280" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Bio-Techne-Fig-2-Copy-300x280.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Bio-Techne-Fig-2-Copy.jpg 368w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Automated spatial biology systems enable high-throughput, hyperplexed analysis of tissue samples. Human prostate cancer sample stained with a 105-plex multiomics panel on COMET. The image shows tissue fibrosis associated with cancer-associated fibroblasts (CAFs). Markers shown: COL1A1 RNA (yellow), E-Cadherin (white), alpha-SMA (blue), and FAP (magenta). [Bio-Techne]</figcaption></figure>
<p>According to Latham, Bio-Techne is helping address these barriers in several ways. Its COMET Suite provides an end-to-end automated platform for hyperplex immunofluorescence and multiomics staining, imaging, and analysis of tissue samples. Additionally, its RNAscope portfolio enables same-section multiomics, with 80,000 RNA probes spanning 450 species and compatibility with multiple automated staining instruments.</p>
<p>Latham believes the spatial multiomics approach can connect gene and protein expression with tissue architecture within the same cells and microenvironment, revealing biological relationships and linking state to function that no single modality can uncover.</p>
<p>He says several areas are seeing the fastest adoption of spatial biology. “Oncology and immuno-oncology continue to dominate spatial biology applications, while immunology and neuroscience represent the next-most prominent areas of focus. Biodistribution of gene therapies is an especially high-impact application: spatial multiomics can localize an AAV vector, transgene mRNA, or oligonucleotide therapeutics such as ASOs and siRNAs to specific cells, then measure changes in the target or downstream gene expression and the associated protein phenotype.”</p>
<h4><strong>Integrated discovery & translation</strong></h4>
<p>Spatial biology is increasingly moving beyond simply identifying where cells are located to understanding how cellular neighborhoods, cell–cell interactions, and biological pathways shape disease biology. As Thomas Campbell, PhD, senior director of product management for Bruker Spatial Biology, explains, “Biology is inherently multi-dimensional, and no single spatial technology can or will capture every aspect of that complexity. The field needs multiple fit-for-purpose approaches that allow researchers to ask different questions and connect insights across DNA, RNA, proteins, and cellular function.” This ability to examine biology from complementary perspectives is becoming increasingly important as spatial research moves from discovery toward translation.</p>
<p>According to Campbell, understanding these context-dependent differences is driving the field. “The next phase of spatial biology will be about using high-plex discovery to develop focused, quantitative assays that can be deployed across large cohorts. One of the biggest challenges in translational biopharma is the discovery-to-translation gap. A study may identify dozens or hundreds of potentially relevant biomarkers, but a translational or clinically deployable assay demands a much smaller, highly reproducible panel.”</p>
<p>Thus, defining a clinically relevant spatial signature requires insights across the genome, transcriptome, and proteome. Campbell says Bruker Spatial Biology’s portfolio comprises platforms spanning multiple omic layers—including DNA, RNA, proteins, post-translational modifications, miRNA and live cell function—“because we recognize that no single modality can fully resolve the biological complexity that drives disease.”</p>
<figure aria-describedby="caption-attachment-339237" class="wp-caption alignleft"><img loading="lazy" decoding="async" class="wp-image-339237" src="https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Thomas-Campbell-PhDr-Copy-300x300.jpg" alt="Thomas Campbell" width="200" height="199" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Thomas-Campbell-PhDr-Copy-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Thomas-Campbell-PhDr-Copy-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Thomas-Campbell-PhDr-Copy.jpg 368w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Thomas Campbell, PhD<br>Senior Director<br>Bruker Spatial</figcaption></figure>
<p>That integrated approach is reflected in several of the company’s platforms. CosMx<sup>®</sup> Spatial Molecular Imager (SMI) provides a view of the whole transcriptome at subcellular resolution, while enabling the simultaneous measurement of RNA and protein within the same tissue section. The CellScape<sup><img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"></sup> XR platform provides quantitative spatial proteomics using flexible assay chemistry. Meanwhile, the GeoMx<sup>®</sup> Digital Spatial Profiler (DSP) profiles the whole transcriptome and more than 1,200 proteins from distinct tissue compartments. Campbell says that, together, these three platforms “provide complementary views of biology and, when used together, enable a more complete understanding of cellular function across multiple omic layers.”</p>
<p>Campbell sees this transition from discovery to translation as one of the most important opportunities for spatial biology. “Whether it’s in oncology, immunology, or neuroscience applications, the future of spatial biology is not simply just about generating more data; it’s translating increasingly sophisticated spatial discoveries into assays that can answer focused biological and clinical questions across large numbers of samples,” he says. “That requires a portfolio of complementary technologies. High-plex discovery platforms can reveal the complexity and heterogeneity of disease, while more focused and quantitative approaches can translate those findings into reproducible biomarkers and clinically relevant assays. Ultimately, the value of spatial biology will be measured by how effectively we can connect discovery to clinically actionable insights.”</p>
<h4><strong>From plex to precision </strong></h4>
<p>“Historically, spatial biology involved a fundamental tradeoff between plex, sensitivity, and resolution—researchers had to sacrifice one to gain another,” suggests Mike Miller, PhD, CTO and CPO at Quanterix. He says that is now shifting. “With today’s tools, those tradeoffs have narrowed considerably. The current challenge becomes building a platform that delivers reproducibility, rigor, and clinical-grade integrity at scale.”</p>
<p>The company is addressing those needs in several ways. Miller reports: “Our Akoya PhenoCycler-Fusion platform enables researchers to visualize and quantify 100+ proteins in a single tissue section at single-cell resolution.” The platform uses molecular barcoding chemistry. Miller elaborates: “Molecular barcoding is a way of identifying and measuring multiple proteins in a tissue while avoiding many of the limitations of traditional immunohistochemistry and conventional multiplexing approaches.”</p>
<figure aria-describedby="caption-attachment-339236" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-339236" src="https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Mike-Miller-PhD-Copy-e1791902140174-300x300.jpg" alt="Mike Miller, PhD" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Mike-Miller-PhD-Copy-e1791902140174-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Mike-Miller-PhD-Copy-e1791902140174-1024x1024.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Mike-Miller-PhD-Copy-e1791902140174-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Mike-Miller-PhD-Copy-e1791902140174-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Mike-Miller-PhD-Copy-e1791902140174-1536x1536.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Mike-Miller-PhD-Copy-e1791902140174.jpg 1800w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Mike Miller, PhD<br>Chief Technology Officer<br>Quanterix</figcaption></figure>
<p>This approach combines three main components: an antibody that recognizes the target of interest; a unique molecular barcode, consisting of a short oligonucleotide sequence attached to the antibody; and a complementary oligonucleotide carrying a fluorescent reporter that binds to the barcode, enabling target visualization and quantification. “The key advantage is that the fluorescent reporter can be reversibly hybridized and removed without removing the antibody or repeatedly staining and stripping the tissue. This enables a cyclical imaging workflow.”</p>
<p>The company also recently introduced its PhenoCode2.0 chemistry as part of its new molecular barcoding kit, “which lets researchers reliably barcode virtually any antibody of their choice.” Miller continues: “This means researchers can easily expand and customize their biomarker panels to address new hypotheses, incorporate emerging biomarkers, and scale between unbiased discovery and targeted validation, accelerating the path to new insights.”</p>
<p>Beyond expanding what can be measured, Miller believes the next phase of spatial biology will focus on translating high-plex discoveries into larger, clinically relevant studies. “That’s ultimately what will separate platforms going forward, bridging the gap between generating a striking image in discovery and generating a measurement that holds up in a clinical trial or diagnostic setting.”</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/spatial-biology-moves-toward-translation/">Spatial Biology Moves Toward Translation</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>How COVID, Characterization, and Commerce Are Driving an RNA Revolution</title>
<link>https://edusehat.com/en/how-covid-characterization-and-commerce-are-driving-an-rna-revolution</link>
<guid>https://edusehat.com/en/how-covid-characterization-and-commerce-are-driving-an-rna-revolution</guid>
<description><![CDATA[ COVID-19 accelerated efforts to develop faster, more efficient ways of manufacturing high-quality RNA sequences.
The post How COVID, Characterization, and Commerce Are Driving an RNA Revolution appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GEN_OCT_2026_GettyImages-1215274453-Copy-Copy.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 13 Oct 2026 23:05:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>How, COVID, Characterization, and, Commerce, Are, Driving, RNA, Revolution</media:keywords>
<content:encoded><![CDATA[<p>The technology underpinning RNA <u><a href="https://publichealth.jhu.edu/2021/the-long-history-of-mrna-vaccines" target="_blank" rel="noopener">vaccines</a></u><sup>1</sup> and therapeutics<sup>2</sup> has been around for decades. However, until recently, only a handful of products were on the market.</p>
<p>Everything changed in 2020 when mRNA vaccines proved<sup>3</sup> to be effective against SARS-CoV-2, the virus that causes COVID-19. In the years since, many more RNA products entered the clinic as developers recognized both their therapeutic and commercial potential.</p>
<p>The pandemic also kick-started efforts to optimize RNA manufacturing that will likely shape the sector for decades to come, according to David Sokolowski, global workflow manager for nucleic acid therapeutics at Cytiva.</p>
<p>“The COVID vaccines heralded the rapid industrialization of RNA and LNP [lipid nanoparticle] technologies, and due to the nature of a pandemic, large amounts of vaccine safety data were generated. However, it remains a nascent industry with limited applications commercially available, and this space is where developers are rushing to build.</p>
<p>“Manufacturing good quality RNA and LNP became easier with the proliferation of high-quality reports from successful studies, trials, and campaigns occurring all over the world.</p>
<p>“Now, we’re supporting the development of therapeutics with even grander aspirations and increasingly exotic biology—whether they are encoding and producing mAb via RNA, or enabling next-generation <em>in vivo</em> cell therapy, LNP-mediated therapeutics have no shortage of potential advances ahead,” he continued.</p>
<h4><strong>Manufacturability</strong></h4>
<p>The key to developing any RNA-based product—be it a vaccine or a therapeutic—is to ensure it can be produced in bulk in a cost-effective and efficient manner, says Luis Avila, PhD, a scientist at services firm Novoprotein Scientific.</p>
<p>“RNA design fundamentally determines both manufacturability and biological performance, but optimizing for one often comes at the expense of the other.” The best approach is to design for manufacturability from the start,” he says, adding “the right template architecture can contribute with optimized promoter design, transcription initiation sequences, encoded polyA tails, transcript boundaries, and sequence composition to improve IVT [<em>in vitro </em>transcription] performance while minimizing problematic secondary structures.”</p>
<p>“Combined with other factors, such as engineered RNA polymerases, optimized reaction chemistries and advanced capping technologies, these design strategies will improve RNA yield, integrity, and translational performance all while reducing the generation of dsRNA,” he tells <em>GEN</em>.</p>
<p>The type of RNA being made should be the key consideration in any assessment of manufacturability, according to Avila, who cites the differences between messenger RNA and self-amplifying RNA to illustrate the point.</p>
<p>“For mRNA, coding-sequence composition, transcript length, GC content, and secondary structure strongly influence IVT efficiency. Whereas optimized UTRs [untranslated regions], cap structures, and poly(A) tails primarily govern RNA stability and translational efficiency.</p>
<p>“For saRNA, the incorporation of the large alphavirus replicase cassette substantially increases transcript length and structural complexity, thus making IVT more challenging while enabling intracellular RNA amplification that dramatically lowers the therapeutic dose required,” he says.</p>
<p>Producing circular RNA—a covalently closed-loop structure that is stable and resistant to exonuclease degradation—can be even harder, according to Avila.</p>
<p>“circRNA presents an even greater manufacturing challenge because linear IVT is followed by an additional circularization step whose efficiency remains a major bottleneck. Following circularization, translation relies on efficient cap-independent initiation through optimized IRES [internal ribosome entry site] elements and RNA architecture.”</p>
<h4><strong>Characterization</strong></h4>
<p>So, designing an RNA therapeutic or vaccine with manufacturing in mind is critical. However, the ability to realize that optimized blueprint on the factory floor is entirely dependent on being able to characterize the product in real-time, as it is being made.</p>
<p>And, unfortunately for the industry, RNA characterization is a complex challenge, says Matthew Ranaghan, PhD, applications scientist at analysis technology firm Refeyn.</p>
<figure aria-describedby="caption-attachment-339229" class="wp-caption alignleft"><img loading="lazy" decoding="async" class="size-medium wp-image-339229" src="https://www.genengnews.com/wp-content/uploads/2026/10/Gareth_TwoMP-with-model-Copy-300x169.jpg" alt="TwoMP with model" width="300" height="169" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Gareth_TwoMP-with-model-Copy-300x169.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Gareth_TwoMP-with-model-Copy.jpg 420w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Analyzing multiple RNA molecules in a single pass reduces the experimentation burden on RNA developers. Being able to visualize characteristics within minutes—as shown here—would benefit any developer, says Refeyn. [Refeyn]</figcaption></figure>
<p>“Thorough Characterization of RNA is critical to ensuring the safety, stability, and efficacy of next-generation RNA therapeutics, yet it remains a significant analytical bottleneck.”</p>
<p>“Current methods are limited to various types of chromatography, which struggle with poor resolution for large RNAs, or mass spectrometry, which requires digesting samples into smaller oligos with RNases. While both have advantages, they demand extensive and time-consuming method development.”</p>
<p>Traditional RNA analysis usually consists of separate assays looking at specific characteristics. For example, size exclusion chromatography is used to assess aggregation while enzyme-linked immunosorbent assays are used to check for trace amounts of double-stranded RNA.</p>
<p>One promising alternative is mass photometry (MP), a technique that can analyze RNA molecules within minutes based on only nanograms of material within minutes in a single experiment. There are multiple potential advantages according to Ranaghan.</p>
<p>“A single readout replaces the need for multiple instruments, drastically reducing hands-on time, reagent costs, and the need for extensive method development across different platforms. A single readout also enables at-line process monitoring, allowing for immediate go/no-go decisions during bioprocessing and purification.”</p>
<p>“We envision the faster speed and higher resolution of MP to enable its use as a multi-attribute tool for at-line assessment of the various critical quality attributes (CQAs) of RNA therapeutics,” he says.</p>
<p>“We have already demonstrated how MP can rapidly assess integrity, fragments, multimer, and purity in a single measurement. We are also actively building out more applications,” Ranaghan adds.</p>
<h4><strong>Commercial concerns</strong></h4>
<p>Manufacturers of RNA products also need to develop commercialization plans as early as possible—in parallel with process development—to ensure they reach the patients who need them and garner the revenues needed to fund future research.</p>
<figure aria-describedby="caption-attachment-339227" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-339227" src="https://www.genengnews.com/wp-content/uploads/2026/10/Gareth_Rajiv_Gangurd-Copy-300x300.jpeg" alt="Rajiv Gangurde" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Gareth_Rajiv_Gangurd-Copy-300x300.jpeg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Gareth_Rajiv_Gangurd-Copy-1024x1024.jpeg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/Gareth_Rajiv_Gangurd-Copy-150x150.jpeg 150w, https://www.genengnews.com/wp-content/uploads/2026/10/Gareth_Rajiv_Gangurd-Copy-768x768.jpeg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/Gareth_Rajiv_Gangurd-Copy.jpeg 1200w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Rajiv Gangurde, PhD<br>Vice President<br>Parexel International</figcaption></figure>
<p>And, for some firms, developing such plans can be a steep learning curve, says Rajiv Gangurde, PhD, vice president of chemistry, manufacturing, and controls (CMC) for cell and gene therapies at contract research organization Parexel International.</p>
<p>“Like many newer modalities, RNA-based therapies typically emerge out of academia or start-up biotech, and transitioning from academia to industry can be challenging due to differences in objectives, differences in expertise, fundraising, etc.”</p>
<p>“In addition, newer modalities require heavier than usual investment in CMC activities to establish proof-of-concept as well as manufacturability. There is heavy reliance on external partners, creating capability and capacity constraints.</p>
<p>“Most importantly,” Gangurde continued, “a phase-appropriate CMC strategy aimed at global approvals can significantly derisk development and help minimize costs and timelines.”</p>
<p>Yet preparing a CMC strategy that will win approval in multiple markets is no small undertaking, particularly, as Gangurde points out, because regulatory guidelines for RNA-based therapies are still evolving.</p>
<p>Another challenge is the lack of consistency. For instance, the U.S. Food and Drug Administration (FDA) and EU EMA use different definitions and guidelines for CMC.</p>
<p>Gangurde told us, “Harmonization of guidelines and expectations across the two agencies will be hugely beneficial to developers of RNA therapies. For example, while both agencies recognize potency/efficacy assessment as a critical quality attribute (CQA), there are some differences in method validation requirements, timing, and regulatory expectations across clinical phases.”</p>
<p>“While the FDA accepts real-world experience and surrogate endpoints, particularly for rare or life-threatening diseases, EMA requires more comprehensive clinical data and demonstration of long-term efficacy for approval. The EMA also mandates an appropriate degree of method validation at each stage of development, whereas the FDA does not expect validation of the potency assays during Phase I,” he added.</p>
<p>The product component designations used by regulatory agencies can also differ. For example, the lipid nanoparticle for the COVID-19 vaccine, Spikevax, consists of four lipids: SM-102, PEG2000-DMG, DSPC, and cholesterol.</p>
<p>The FDA designates each of these components as a “drug substance,” whereas the EMA designates them as “novel excipients”—each designation has differing data submission requirements.</p>
<h4><strong>Continuous process</strong></h4>
<p>In the future, RNA manufacturing methods are likely to keep improving, according to Novoprotein’s Avila, who says continuous production processes are likely to have a major impact.</p>
<p>“One of the most exciting developments is the emergence of continuous or flow-based IVT manufacturing. This has the potential to improve productivity, reduce costs, and enable more consistent large-scale RNA production through continuous enzyme utilization and process integration.”</p>
<p>“As equally transformative are advances in engineered low-dsRNA T7 RNA polymerases, improved co-transcriptional capping chemistries, and integrated continuous purification. All of which will enable improvements in RNA quality, simplify downstream processing, and accelerate GMP manufacturing,” he added.</p>
<figure aria-describedby="caption-attachment-339230" class="wp-caption alignleft"><img loading="lazy" decoding="async" class="wp-image-339230 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/10/Gareth_TwoMP-Auto-with-model-Copy-300x214.jpg" alt="TwoMP- Auto with model" width="300" height="214" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Gareth_TwoMP-Auto-with-model-Copy-300x214.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Gareth_TwoMP-Auto-with-model-Copy.jpg 724w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">RNA characterization is a challenge using current technologies. Refeyn claims its mass photometry system—seen here at lab in Waltham, Massachusetts—reduces the number of assays required. [Refeyn]</figcaption></figure>
<p>This view is shared by Ranaghan from Refeyn, who cites the shift toward continuous flow manufacturing as one of the most exciting advances in the field.</p>
<p>“Moving away from traditional batch processing to a continuous flow model is highly logical because it minimizes the time that the fragile mRNA product spends exposed to active reaction components that drive fragmentation and aggregation. This shift not only improves overall yield and intactness, especially for massive transcripts like saRNA, but it also creates a mandate for faster, real-time analytics.”</p>
<p>For Parexel’s Gangurde, efforts to make production more efficient and sustainable will drive innovation, with the WHO’s recently launched <u><a href="https://www.who.int/news/item/13-06-2025-mrna-technology-transfer-programme-s-phase-2.0-discussed-with-partners-on-the-sidelines-of-g20-summit" target="_blank" rel="noopener">mRNA Technology Transfer Programme Phase 2.0</a></u><sup>4</sup> being a case in point.</p>
<p>“This is a major global initiative aimed at scaling up commercially viable mRNA-based vaccine and therapeutic production in low- and middle-income countries—where the need for these therapies is most critical.”</p>
<p>Launched in 2021 in collaboration with the Medicines Patent Pool (MPP), the initiative has enabled 15 partners across Latin America, Africa, Eastern Europe, and Asia to receive foundational mRNA technology.</p>
<p>Phase 2.0 focuses on building local manufacturing capacity so countries can make mRNA vaccines and therapeutics for future outbreaks and diseases like influenza, TB, HIV, malaria, dengue, and leishmaniasis, as well as oncology drugs and mAbs.</p>
<p>Gangurde says, “By decentralizing production, the program reduces reliance on a few high-income countries for mRNA supply, supporting global access for mRNA-based therapies.”</p>
<p><em> </em></p>
<p><em>References</em></p>
<ol>
<li>Beyrer C. <a href="https://publichealth.jhu.edu/2021/the-long-history-of-mrna-vaccines" target="_blank" rel="noopener"><em>The Long History of mRNA Vaccines</em></a>. Johns Hopkins Bloomberg School of Public Health; 2021. Accessed August 12, 2026.</li>
<li>Chatterjee S, Bhattacharya M, Lee SS, Chakraborty C. An insight of different classes of RNA-based therapeutic, nanodelivery and clinical status: Current landscape. <em>Current Research in Biotechnology </em>2023;6:100150-100150. doi:10.1016/j.crbiot.2023.100150</li>
<li>Parvin N, Mandal TK, Joo SW. The Impact of COVID-19 on RNA Therapeutics: A Surge in Lipid Nanoparticles and Alternative Delivery Systems, Systems. <em>Pharmaceutics</em> 2024; 16(11): 1366. Doi: 10.3390/pharmaceutics16111366</li>
<li>World Health Organization: <a href="https://www.who.int/news/item/13-06-2025-mrna-technology-transfer-programme-s-phase-2.0-discussed-with-partners-on-the-sidelines-of-g20-summit">WHO. mRNA Technology Transfer Programme’s Phase 2.0 discussed with partners on the sidelines of G20 Summit</a>. Who. June 13, 2025. Accessed August 12, 2026.</li>
</ol>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/how-covid-characterization-and-commerce-are-driving-an-rna-revolution/">How COVID, Characterization, and Commerce Are Driving an RNA Revolution</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>UCB Dedicates Future U.S. Biologics Manufacturing Campus in Georgia</title>
<link>https://edusehat.com/en/ucb-dedicates-future-us-biologics-manufacturing-campus-in-georgia</link>
<guid>https://edusehat.com/en/ucb-dedicates-future-us-biologics-manufacturing-campus-in-georgia</guid>
<description><![CDATA[ Some 330 permanent jobs are expected to be based at the approximately 460,000-square-foot campus, which will occupy 79 acres within the Rowen innovation district in Georgia’s Gwinnett County. 
The post UCB Dedicates Future U.S. Biologics Manufacturing Campus in Georgia appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/be461031910_ucb_stillcam01_fr001_nopeople2_2_1_1_0.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 13 Oct 2026 23:05:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>UCB, Dedicates, Future, U.S., Biologics, Manufacturing, Campus, Georgia</media:keywords>
<content:encoded><![CDATA[<p>UCB has dedicated the Rowen, GA, site where it plans to build a $2 billion biologics manufacturing campus that is set to open as the Belgian-based drug developer’s first U.S. manufacturing site.</p>
<p>When completed in 2032 or 2033, the campus is expected to support commercial production of recently approved and future biologic medicines, applying artificial intelligence, automation, and advanced manufacturing technologies. The campus is intended to further integrate UCB’s U.S. patient value chain from research and development through manufacturing and delivery.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>Some 330 permanent jobs are expected to be based at the approximately 460,000-square-foot campus, which will occupy 79 acres within the Rowen innovation district in Georgia’s Gwinnett County. UCB bought the 79 acres from the Rowen Foundation, which is developing a 1,900-acre campus on Highway 316, launched in 2020 as a “knowledge” community for biopharma and other innovation-based fields.</p>
<p>In its announcement of the campus site dedication, UCB said it chose to build its first U.S. manufacturing campus in Georgia because of what it called the Peach State’s strong life sciences ecosystem, highly skilled workforce, robust infrastructure, and access to leading academic and research institutions.</p>
<p>Another factor in the decision: Gwinnett County has committed $174 million in incentives and infrastructure investments to support UCB’s project.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>UCB’s project is the brightest recent success of Georgia life sciences leaders, who worked through industry group Georgia Life Sciences to lay out a 10-year “Roadmap” last year with the aim of “positioning Georgia as the scale-up manufacturing hub of the Southeast.” The UCB project, announced in March, helped place Georgia among the “Next 5 States” within <em>GEN</em>’s <a href="https://www.genengnews.com/topics/drug-discovery/next-10-u-s-biopharma-clusters/">Next 10 U.S. Biopharma Clusters</a> A-List.</p>
<p><strong>“Long-term commitment”</strong></p>
<p>“Our manufacturing investment in the United States reflects our long-term commitment to patients, strengthening our ability to serve them while contributing to scientific innovation, highly skilled jobs, and economic growth in Georgia,” UCB CEO Jean-Christophe Tellier said in a statement.</p>
<figure aria-describedby="caption-attachment-339205" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="size-medium wp-image-339205" src="https://www.genengnews.com/wp-content/uploads/2026/10/assets_MS2006199_000001_UCB-Dedication-3-RESIZE-1500-300x200.jpg" alt="" width="300" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/assets_MS2006199_000001_UCB-Dedication-3-RESIZE-1500-300x200.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/assets_MS2006199_000001_UCB-Dedication-3-RESIZE-1500-1024x683.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/assets_MS2006199_000001_UCB-Dedication-3-RESIZE-1500-768x512.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/assets_MS2006199_000001_UCB-Dedication-3-RESIZE-1500.jpg 1500w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">UCB executives and dignitaries cut a ceremonial ribbon to mark the dedication of UCB’s future biologics manufacturing campus in Rowen, GA. Jeffrey Kessler, U.S. Department of Commerce Under Secretary for Industry and Security, stands at left. At the center are Georgia Gov. Brian Kemp (R); UCB CEO Jean-Christophe Tellier; Katherine Raeymaekers, Consul General of Belgium in Atlanta; and Nicole Love Hendrickson (D), Chairwoman of the Gwinnett County Board of Commissioners. [UCB]</figcaption></figure>
<p>Tellier and other UCB leaders were joined at a dedication ceremony by dignitaries that included Georgia Gov. Brian Kemp (R); Jeffrey Kessler, U.S. Department of Commerce Under Secretary for Industry and Security; Nicole Love Hendrickson (D), Chairwoman of the Gwinnett County Board of Commissioners; and Katherine Raeymaekers, Consul General of Belgium in Atlanta.</p>
<p>During the ceremony, the dignitaries joined top UCB executives in unveiling the Emmanuel Janssen Circle, a commemorative stonework installation just completed within the roundabout to the entrance of the future campus. Janssen (1879-1955) was a Belgian businessman who founded Union Chimique Belge (UCB) on January 18, 1928. The company initially focused on industrial chemicals before evolving into a developer of biologics for indications in neurology and immunology.</p>
<p>“UCB’s new biomanufacturing campus builds on the entrepreneurial legacy of Baron Emmanuel Janssen, founder of UCB, while strengthening the transatlantic collaboration that drives economic growth, scientific innovation, and improving people’s lives,” Raeymaekers stated. “Today’s site dedication reflects the strength of the partnership between Belgium, the United States, and the State of Georgia—and our shared commitment to enduring progress, innovation, and opportunity.”</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>UCB worked with numerous public and private partners to locate its biologics manufacturing campus in Rowen—including the Metro Atlanta Chamber; Georgia Quick Start, which provides customized workforce training through the Technical College System of Georgia; Gwinnett County Government; Georgia Power Company; the public-private economic development initiative Partnership Gwinnett; and the Georgia Department of Economic Development.</p>
<p>Headquartered in Brussels, UCB employs more than 10,000 people in nearly 40 countries—including the United States, where the company employs more than 2,000 people in research, development, manufacturing, commercial operations, and corporate functions.</p>
<p>UCB has maintained a U.S. presence for nearly a century. The company now employs more than 400 people in Georgia, where it established its Stateside headquarters in Atlanta in 1993.</p>
<p>More than 1,000 construction jobs are expected to be created in connection with the campus during the six- to seven-year projected timeframe for design and construction.</p>
<p>“At UCB, our purpose is to create value for people living with severe diseases, and that purpose guides the science we pursue, where we invest, and the choices we make for the long term,” Tellier added.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/ucb-dedicates-future-u-s-biologics-manufacturing-campus-in-georgia/">UCB Dedicates Future U.S. Biologics Manufacturing Campus in Georgia</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Derm Deep Dive: Navigating Eczema Treatment With Topical Corticosteroids</title>
<link>https://edusehat.com/en/derm-deep-dive-navigating-eczema-treatment-with-topical-corticosteroids</link>
<guid>https://edusehat.com/en/derm-deep-dive-navigating-eczema-treatment-with-topical-corticosteroids</guid>
<description><![CDATA[ Understanding the Risks, Benefits, and Alternative Options  It can take just a single eczema flare-up to leave someone desperate for…
The post Derm Deep Dive: Navigating Eczema Treatment With Topical Corticosteroids appeared first on Optima Dermatology. ]]></description>
<enclosure url="https://optimadermatology.com/wp-content/uploads/2026/10/Blog_Oct-Eczema-DDD_Square.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 13 Oct 2026 23:05:02 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Derm, Deep, Dive:, Navigating, Eczema, Treatment, With, Topical, Corticosteroids</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"><img fetchpriority="high" decoding="async" width="1024" height="341" src="https://optimadermatology.com/wp-content/uploads/2026/10/Blog_Oct-Eczema-DDD_Banner-1024x341.jpg" alt="Navigating Eczema Treatment with Dr. Sisto" class="wp-image-205778" srcset="https://optimadermatology.com/wp-content/uploads/2026/10/Blog_Oct-Eczema-DDD_Banner-1024x341.jpg 1024w, https://optimadermatology.com/wp-content/uploads/2026/10/Blog_Oct-Eczema-DDD_Banner-300x100.jpg 300w, https://optimadermatology.com/wp-content/uploads/2026/10/Blog_Oct-Eczema-DDD_Banner-768x256.jpg 768w, https://optimadermatology.com/wp-content/uploads/2026/10/Blog_Oct-Eczema-DDD_Banner.jpg 1200w" sizes="(max-width: 1024px) 100vw, 1024px"></figure>



<h2 class="wp-block-heading"><strong>Understanding the Risks, Benefits, and Alternative Options</strong> </h2>



<p class="wp-block-paragraph">It can take just a single eczema flare-up to leave someone desperate for relief and treatment. Topical corticosteroids are commonly used to provide that relief; however, like any medication, it’s important to know what topical corticosteroids are, what they do, and the potential risks or side effects. </p>



<p class="wp-block-paragraph">For National Eczema Awareness Month, this Derm Deep Dive has all the details about topical corticosteroids for eczema so you can feel informed and confident about your eczema treatment plan.  </p>



<h2 class="wp-block-heading"><strong>Topical Corticosteroids Have Long Been Used to Treat Eczema</strong> </h2>



<p class="wp-block-paragraph">Corticosteroids include pills, inhalers, injections, and topicals, and help reduce inflammation in the body. Corticosteroids first came on the scene in the 1950s – a revolutionary treatment for eczema at the time. Today they are one of the most commonly prescribed treatments for eczema flare-ups. </p>



<p class="wp-block-paragraph">The popularity of corticosteroids is easy to understand for anyone who has experienced eczema. The <a href="https://nationaleczema.org/blog/nationwide-survey-underscores-concerns-with-topical-steroids/" target="_blank" rel="noopener">National Eczema Association</a> reports that 68% of adults and 74% of children with eczema experience at least one flare-up each month, and for some, daily. And flare-ups can cause far more symptoms than dry or irritated skin. Patients often experience intense itching, redness, inflammation, or discomfort that can interfere with everyday life.  </p>



<h2 class="wp-block-heading"><strong>Dive Deeper:</strong>  </h2>



<p class="wp-block-paragraph">Topical corticosteroids are applied directly to the skin and help suppress the body’s inflammatory response to reduce eczema symptoms. They’re offered in a variety of strengths, from low-potency formulations to highly potent medications, but stronger doesn’t always mean better; your treatment depends on the severity of your eczema and where it’s located.  </p>



<p class="wp-block-paragraph">And while corticosteroids can provide significant relief from eczema symptoms, potential side effects and safety concerns can make patients hesitant to use them. It’s just as important to understand what you’re using as it is how you’re using it. </p>



<h2 class="wp-block-heading"><strong>The Possible Side Effects of Topical Corticosteroids</strong> </h2>



<p class="wp-block-paragraph">The American Academy of Dermatology states that side effects from topical corticosteroids are rare when a dermatologist manages treatment and the medication is used as directed; however, side effects can occur and depend on the potency, amount, frequency, location of use, and duration of treatment.  </p>



<p class="wp-block-paragraph">Side effects can include: </p>



<ul class="wp-block-list">
<li>Easy bruising </li>
</ul>



<ul class="wp-block-list">
<li>Stretch marks </li>
</ul>



<ul class="wp-block-list">
<li>Changes in skin pigmentation </li>
</ul>



<ul class="wp-block-list">
<li>Breakouts similar to acne or rosacea </li>
</ul>



<ul class="wp-block-list">
<li>Skin thinning </li>
</ul>



<ul class="wp-block-list">
<li>Visible blood vessels </li>
</ul>



<p class="wp-block-paragraph">Skin thinning is the most common side effect, especially in adults, and is often preceded by wrinkled or weakened skin.  </p>



<p class="wp-block-paragraph">Encouragingly, a PubMed <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8264889/" target="_blank" rel="noopener">study</a> in 2023 identifies “no evidence of harm” when topical corticosteroids are used as recommended to treat flare-ups, and supports the belief that intermittent use yields fewer side effects.  </p>



<h2 class="wp-block-heading"><strong>Is Topical Steroid Withdrawal a Concern?</strong> </h2>



<p class="wp-block-paragraph">Withdrawal symptoms, also called Topical Steroid Withdrawal Syndrome, typically occur only if the high potency medication is used for an inappropriate and prolonged time. The National Eczema Association <a href="https://nationaleczema.org/blog/warnings-for-topical-steroids-eczema/" target="_blank" rel="noopener">lists primary symptoms</a> as burning, stinging, and bright red skin, which can appear days or weeks after ending the use of topical corticosteroids. </p>



<p class="wp-block-paragraph">Because eczema is a chronic inflammatory condition, symptoms can return when treatment is stopped. While it’s more likely your symptoms are an indication the underlying eczema has returned, they could signify eczema withdrawal. If you experience any concerning symptoms after discontinuing corticosteroid use, contact your dermatologist right away.  </p>



<p class="wp-block-paragraph">The National Eczema Association <a href="https://nationaleczema.org/blog/topical-steroid-guidelines-atopic-dermatitis/" target="_blank" rel="noopener">acknowledges</a> that instructions for topical corticosteroid use can be confusing for patients, which increases the chances of the medication being used incorrectly. Studies about topical corticosteroids draw a line between incorrect use and the increased likelihood of side effects and withdrawal, underlining the importance of working closely with your dermatologist and following a treatment plan.  </p>



<h2 class="wp-block-heading"><strong>Can You Minimize The Risk of Side Effects From Topical Corticosteroids?</strong> </h2>



<p class="wp-block-paragraph">Following your dermatologist’s treatment plan is the most effective way to minimize the risk of any potential side effects. Recommendations for responsible topical corticosteroid use can include: </p>



<ul class="wp-block-list">
<li><strong>Using the Lowest Necessary Potency:</strong> Stronger or potent formulations are primarily used on thicker skin like the limbs, palms, or soles of the feet, while mild potency options are more ideal for the face or skin folds. Make sure you are using the correct potency for the affected area. </li>



<li><strong>Following a Twice-Daily Application:</strong> Most dermatologists will recommend applying a topical steroid twice a day, then taper to once-daily. </li>



<li><strong>Trying a “Short Bursts” Approach:</strong> Use the medication for a short duration – typically one to two weeks or until your active rash and intense itchiness subside.  </li>



<li><strong>Applying Carefully to Sensitive Areas:</strong> The face, neck, groin, and skin folds are more sensitive and typically don’t require high-potency medication or high-frequency applications. </li>



<li><strong>Moisturizing Regularly:</strong> Eczema treatment isn’t all about medication. Moisturizers help support the skin barrier and can be an important part of an eczema treatment.  </li>
</ul>



<p class="wp-block-paragraph">The right treatment plan will increase the likelihood you’ll be able to manage your eczema and experience some relief from your symptoms.  </p>



<h2 class="wp-block-heading"><strong>Alternatives to Topical Corticosteroids for Eczema Treatment</strong> </h2>



<p class="wp-block-paragraph">We know consistent moisturizing is a foundation of successful eczema treatment. But if moisturizers aren’t cutting it and you are looking for alternatives to topical corticosteroid use, there are a number of options to consider.  </p>



<h3 class="wp-block-heading">1. <strong>Topical Calcineurin Inhibitors (TCIs)</strong> </h3>



<ol start="1" class="wp-block-list"></ol>



<p class="wp-block-paragraph">TCIs are prescription medications designed to treat eczema in individuals who either haven’t seen results from topical corticosteroids or cannot use them. TCIs can be applied directly to the skin and work by stopping the activity of certain cells in the immune system.  </p>



<h3 class="wp-block-heading">2. <strong>Janus Kinase (JAK) Inhibitors</strong> </h3>



<ol start="2" class="wp-block-list"></ol>



<p class="wp-block-paragraph">These oral or topical medications are not steroids. They prevent the protein cytokines in the skin from attaching to certain receptors in the body that cause immune system overactivity. JAKs are ideal for individuals who haven’t had success with other treatments. Some side effects can be serious, so it’s important to speak with your dermatologist about JAKs and potential risk factors. </p>



<h3 class="wp-block-heading">3. <strong>Injectable Medications</strong> </h3>



<ol start="3" class="wp-block-list"></ol>



<p class="wp-block-paragraph">Non-steroid injections can be effective at treating eczema flare-ups. They contain biologics that target specific pathways involved in the immune response.  </p>



<h3 class="wp-block-heading">4. <strong>Phototherapy</strong> </h3>



<ol start="4" class="wp-block-list"></ol>



<p class="wp-block-paragraph">Using controlled doses of ultraviolet light, dermatologists can help reduce inflammation in patients who aren’t responding to topical treatments. A Cochrane Library <a href="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013870.pub2/full" target="_blank" rel="noopener">study</a> found that phototherapy effectively reduced itching and visible symptoms in patients with eczema.  </p>



<h3 class="wp-block-heading">5. <strong>Other Non-Steroidal Topical Treatments</strong> </h3>



<ol start="5" class="wp-block-list"></ol>



<p class="wp-block-paragraph">There are numerous prescription medications like criaborole, roflumilast, ruxolitinib, and tapinarof, which are prescribed depending on the specific diagnosis, severity, and patient’s age. These topical treatments can be highly effective at treating mild-to-moderate eczema symptoms.  </p>



<h2 class="wp-block-heading"><strong>When Should I see a Dermatologist About My Eczema?</strong> </h2>



<p class="wp-block-paragraph">You should see a dermatologist as soon as you have concerns about your skin health, especially if at-home moisturizing or other treatments aren’t reducing your symptoms.  </p>



<p class="wp-block-paragraph">Working with a dermatologist is an important first step in eczema management. They can help you understand whether eczema is causing your symptoms or whether you have another skin condition – and which treatment will work best.  </p>



<p class="wp-block-paragraph"><strong>Dive Deeper:</strong> <a href="https://optimadermatology.com/2023/09/29/psoriasis-vs-eczema" target="_blank" rel="noopener">Psoriasis Vs. Eczema – Identifying, Treating, & Managing Each Condition</a> </p>



<p class="wp-block-paragraph">If you are prescribed a topical corticosteroid, your dermatologist will also help you navigate what can be a complex treatment plan. You should get the following information from your dermatologist before beginning any eczema treatment plan: </p>



<ul class="wp-block-list">
<li>Which potency is appropriate </li>
</ul>



<ul class="wp-block-list">
<li>Where and how often the medication should be applied </li>
</ul>



<ul class="wp-block-list">
<li>How long your treatment should last </li>
</ul>



<ul class="wp-block-list">
<li>When you may need to transition from a corticosteroid to another treatment </li>
</ul>



<ul class="wp-block-list">
<li>Whether an alternative treatment could work better for you </li>
</ul>



<p class="wp-block-paragraph">Eczema remains a primary skin issue for Americans, and seeking treatment is often the only way to find effective relief. At Optima Dermatology, our board-certified providers are experts in skin issues and will help you navigate your treatment whether it is topical corticosteroids or an alternative option – so you can take control of your eczema and get back to your life.  </p>



<p class="wp-block-paragraph"><a href="https://optimadermatology.com/request-appointment" target="_blank" rel="noopener">Schedule an appointment today</a> with one of our expert providers, and get the eczema treatment help you need, and deserve.  </p>



<hr class="wp-block-separator has-alpha-channel-opacity">



<h2 class="wp-block-heading"><strong>Frequently Asked Questions About Topical Corticosteroids</strong> </h2>



<h3 class="wp-block-heading"><strong>Are topical corticosteroids safe for treating eczema?</strong> </h3>



<p class="wp-block-paragraph">Yes. Topical corticosteroids are considered an effective first-line treatment for many eczema flares and can be safe when used as directed. The risk of side effects depends on factors such as the steroid’s potency, how often it is applied, how long it is used, and where it is applied. Your dermatologist can help determine the appropriate medication and treatment duration for your skin. </p>



<h3 class="wp-block-heading"><strong>Can topical corticosteroids make eczema worse?</strong> </h3>



<p class="wp-block-paragraph">Topical corticosteroids are generally used to reduce eczema-related inflammation and itching rather than make eczema worse. However, symptoms can return after treatment is stopped because eczema is a chronic condition. If your eczema repeatedly worsens after stopping a topical corticosteroid, talk with your dermatologist to determine whether you are experiencing a typical flare, a medication-related reaction, or another skin condition. </p>



<h3 class="wp-block-heading"><strong>What are the side effects of using topical corticosteroids for eczema?</strong> </h3>



<p class="wp-block-paragraph">Potential side effects include skin thinning, easy bruising, visible blood vessels, stretch marks, pigmentation changes, and acne-like or rosacea-like breakouts. The risk is generally higher with potent steroids, prolonged use, and application to thin or sensitive areas of skin. Following your dermatologist’s instructions can help minimize these risks. </p>



<h3 class="wp-block-heading"><strong>What is topical corticosteroid withdrawal, and how do I know if I have it?</strong> </h3>



<p class="wp-block-paragraph">Topical corticosteroid withdrawal (TSW) is a reported reaction that can occur after reducing or stopping prolonged use of topical corticosteroids, particularly potent steroids used inappropriately. Symptoms may include intense redness, burning, itching, or swelling. However, these symptoms can overlap with an eczema flare, so it is important to see a dermatologist for an accurate evaluation rather than assuming that symptoms are caused by TSW. </p>



<h3 class="wp-block-heading"><strong>What can I use for eczema instead of topical corticosteroids?</strong> </h3>



<p class="wp-block-paragraph">Several non-steroidal options may be available, including topical calcineurin inhibitors such as tacrolimus and pimecrolimus, topical PDE-4 inhibitors such as crisaborole and roflumilast, topical JAK inhibitors such as ruxolitinib, and other prescription treatments. Moisturizers, trigger management, phototherapy, biologic medications, and oral treatments may also be appropriate depending on the severity of your eczema. A dermatologist can help determine which options are best for you. </p>
<p>The post <a href="https://optimadermatology.com/2026/10/13/derm-deep-dive-navigating-eczema-treatment-with-topical-corticosteroids">Derm Deep Dive: Navigating Eczema Treatment With Topical Corticosteroids</a> appeared first on <a href="https://optimadermatology.com/">Optima Dermatology</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Federal government invests more than $31 million to support internationally educated health professionals</title>
<link>https://edusehat.com/en/federal-government-invests-more-than-31-million-to-support-internationally-educated-health-professionals</link>
<guid>https://edusehat.com/en/federal-government-invests-more-than-31-million-to-support-internationally-educated-health-professionals</guid>
<description><![CDATA[ Six projects will help internationally educated healthcare professionals navigate licensing requirements, including expanded opportunities for family physicians in Ontario. The federal government has announced more than $31 million for six projects designed to help internationally educated health professionals enter Canada’s healthcare workforce. Announced October 7, the funding includes $20 million to support 50 additional positions […]
The post Federal government invests more than $31 million to support internationally educated health professionals appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/shutterstock_2486141279.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 13 Oct 2026 23:00:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Federal, government, invests, more, than, 31, million, support, internationally, educated, health, professionals</media:keywords>
<content:encoded><![CDATA[<p data-pm-slice="1 1 []">Six projects will help internationally educated healthcare professionals navigate licensing requirements, including expanded opportunities for family physicians in Ontario.</p>
<p>The federal government has announced more than $31 million for six projects designed to help internationally educated health professionals enter Canada’s healthcare workforce.</p>
<p>Announced October 7, the funding includes $20 million to support 50 additional positions annually over four years through Practice Ready Ontario. The investment is expected to help prepare up to 200 internationally educated family physicians to practise in the province by 2028–29.</p>
<p>The Ontario initiative will focus on improving access to primary care in underserved northern and rural communities, as well as Francophone communities. It includes a dedicated stream for French-speaking internationally educated family physicians.</p>
<p>Five other projects across Canada will provide resources and practical tools to help physicians, nurses, occupational therapists and physiotherapists navigate provincial and territorial licensing requirements and prepare for Canadian practice.</p>
<p>According to Health Canada, internationally educated professionals can face lengthy, costly and complicated credential recognition processes. The projects aim to address those barriers and expand the workforce available to deliver care.</p>
<p>The post <a href="https://www.hospitalnews.com/federal-government-invests-more-than-31-million-to-support-internationally-educated-health-professionals/">Federal government invests more than $31 million to support internationally educated health professionals</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>BIO supports retaining current vaccine recommendation categories</title>
<link>https://edusehat.com/en/bio-supports-retaining-current-vaccine-recommendation-categories</link>
<guid>https://edusehat.com/en/bio-supports-retaining-current-vaccine-recommendation-categories</guid>
<description><![CDATA[ BIO’s comments advise strengthening communication and clarity of recommendations, and maintaining access. The Advisory Committee on Immunization Practices (ACIP) should remain the body responsible […]
The post BIO supports retaining current vaccine recommendation categories appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2023/04/vaccine-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 13 Oct 2026 19:30:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>BIO, supports, retaining, current, vaccine, recommendation, categories</media:keywords>
<content:encoded><![CDATA[<h4>BIO’s comments advise strengthening communication and clarity of recommendations, and maintaining access.</h4>
<p><span>The Advisory Committee on Immunization Practices (ACIP) should remain the body responsible for making vaccine recommendations, and ACIP’s recommendation categories do not need to be changed, BIO tells the Department of Health and Human Services (HHS).</span></p>
<p><span>The Biotechnology Innovation Organization (BIO) made these comments in its Sept. 20 response to a HHS</span><a href="https://www.federalregister.gov/documents/2026/08/24/2026-17250/request-for-information-categories-used-in-federal-vaccine-recommendations-and-the-role-of-shared"> <span>request for information (RFI)</span></a><span> that asks “whether the categories currently used in Federal vaccine recommendations are adequate.” The RFI contained a proposal on restructuring ACIP’s established vaccine categories, which currently include: routine (universal) recommendations, risk-based recommendations, and recommendations based on shared clinical decision-making.</span></p>
<p><span>“The current vaccine recommendation categories were developed to translate ACIP’s scientific assessment into clear clinical guidance about which populations could be considered for a vaccine and under what circumstances, while supporting consistent implementation, coverage, and access,” say BIO’s comments, prepared by Phyllis Arthur, BIO EVP and Chief of Global Health. “The categories were not intended to signal different standards of evidence or different levels of confidence in vaccine safety and effectiveness.”</span></p>
<p><span>Some of BIO’s specific recommendations include:</span></p>
<h3>Maintain ACIP’s authority</h3>
<p><span>“All policymaking should reflect that ACIP is tasked with making vaccine recommendations, while other entities are tasked with different and specific areas of vaccine policy,” BIO comments say. “Grounded in its statutory role, decades of experience rigorously evaluating vaccine evidence through a transparent and deliberative process, and its critical ties to vaccine coverage, access, and the broader public health system, ACIP remains the appropriate federal entity for developing vaccine recommendations, consistent with the distinct responsibilities established by Congress.”</span></p>
<p><span>The comments also note that the well-established complementary roles of ACIP—through the Centers for Disease Control and Prevention—the Food and Drug Administration (FDA), and other agencies have historically delivered an effective federal vaccine system.</span></p>
<h3>Existing categories work and should be explained</h3>
<p><span>“Changes to the recommendation categories are not needed; if any change is made, it should be led by ACIP and include opportunity for meaningful public comment,” according to BIO’s input. “BIO believes the current recommendation categories provide an appropriate framework to support vaccination decisions.”</span></p>
<p><span>BIO underlines the importance of making it clear that the Shared Clinical Decision-Making (SCDM) category does not mean a vaccine is less important than others. An SCDM recommendation simply indicates a healthcare provider and patient should discuss whether to administer the vaccine because the expected benefit may depend on an individual’s specific circumstances.</span></p>
<p><span>“Importantly, the use of SCDM should not diminish vaccine confidence or create the perception that these vaccines are less valuable or less appropriate for patients who may benefit from them,” the comments say.</span></p>
<h3>Avoid threats to patient access</h3>
<p><span>Because federal and state vaccine schedules are defined by ACIP, changes to the meaning or status of an ACIP category could have consequences beyond clinical guidance.</span></p>
<p><span>BIO therefore wants HHS to make it clear that routine, risk-based, and SCDM vaccines all remain ACIP-recommended vaccines, so that patients maintain their insurance coverage. This extends to other access programs as well, including: the Vaccines for Children program, state pharmacist scope-of-practice laws, and hospital/facility vaccination requirements, among others.</span></p>
<p><span>“Americans who want to receive vaccines should be able to do so without cost-sharing, regardless of how a vaccine recommendation is categorized,” writes BIO.</span></p>
<p><a href="https://www.bio.org/letters-testimony-comments/bios-response-hhs-request-information-categories-used-federal-vaccine"><b>Read BIO’s full comments.</b></a></p>
<p>The post <a href="https://bio.news/federal-policy/bio-supports-retaining-current-vaccine-recommendation-categories/">BIO supports retaining current vaccine recommendation categories</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>StockWatch: Caribou Plunges as It Pursues Strategic Alternatives</title>
<link>https://edusehat.com/en/stockwatch-caribou-plunges-as-it-pursues-strategic-alternatives</link>
<guid>https://edusehat.com/en/stockwatch-caribou-plunges-as-it-pursues-strategic-alternatives</guid>
<description><![CDATA[ Caribou has halted trials of vispacabtagene regedleucel (vispa-cel, formerly CB-010) a treatment for relapsed or refractory B cell non-Hodgkin lymphoma; and of CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of patients with r/r multiple myeloma.
The post StockWatch: Caribou Plunges as It Pursues Strategic Alternatives appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Caribou-lab-shot-1024x546-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 13 Oct 2026 05:05:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>StockWatch:, Caribou, Plunges, Pursues, Strategic, Alternatives</media:keywords>
<content:encoded><![CDATA[<p><strong>Caribou Biosciences (Nasdaq: CRBU)</strong>, whose co-founders include Jennifer Doudna, PhD, capped a <span><strong>one-year 83% freefall</strong> </span>of its stock after announcing plans to evaluate strategic alternatives, as investors responded with a selloff that sent shares of the CRISPR genome-editing cell therapy developer<span><strong> plunging 62%</strong> <strong>this past week</strong></span>.</p>
<p>Caribou announced plans to carry out an unspecified “substantial” reduction of its workforce—which numbered 97 people as of February 27, according to its most recent Form 10-K Annual report, filed March 5—as well as a halt to trials of its two clinical-phase pipeline candidates, both allogeneic chimeric antigen receptor (CAR) T-cell therapy programs, and other cost reduction measures also yet to be specified.</p>
<figure aria-describedby="caption-attachment-339164" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="size-full wp-image-339164" src="https://www.genengnews.com/wp-content/uploads/2026/10/Rachel-Haurwitz-PhD__696x464-SQUARE-696-CROP.jpeg" alt="" width="296" height="296" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Rachel-Haurwitz-PhD__696x464-SQUARE-696-CROP.jpeg 296w, https://www.genengnews.com/wp-content/uploads/2026/10/Rachel-Haurwitz-PhD__696x464-SQUARE-696-CROP-150x150.jpeg 150w" sizes="(max-width: 296px) 100vw, 296px"><figcaption class="wp-caption-text">Rachel Haurwitz, PhD, Caribou Biosciences co-founder, president, and CEO</figcaption></figure>
<p>“Caribou’s story has taken a heartbreaking turn,” co-founder, president, and CEO Rachel Haurwitz, PhD, <a href="https://www.linkedin.com/feed/update/urn:li:activity:7513328985603264513/">posted on LinkedIn</a>, announcing the company’s strategic review. “This decision is not a loss of belief in our science, our clinical data, or what these programs could mean for patients. It reflects the difficult reality that the current financing environment for allogeneic CAR T-cell therapies has made it impossible to secure the capital required to responsibly advance them.”</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>Haurwitz co-established Caribou in 2011 along with Doudna and two other co-founders: Martin Jínek, PhD, a former postdoctoral fellow in Doudna’s lab, now at the University of Zurich, who led the seminal 2012 study leading to the Nobel Prize; and James Berger, PhD, professor in the department of biophysics and biophysical chemistry at Johns Hopkins University School of Medicine.</p>
<p>Caribou became operational in 2012, which would make it the oldest CRISPR therapeutics company as far as Haurwitz could recall in a 2021 interview. That year, Caribou went public through an upsized initial public offering (IPO) that raised $321 million in aggregate net proceeds after deducting underwriting discounts and commissions and other offering expenses. Caribou sold 21.85 million shares at an IPO price of $16 a share, up from <a href="https://www.genengnews.com/topics/genome-editing/ipo-raises-304m-for-caribou-developer-of-gene-edited-cell-therapies/">earlier plans to sell 13.5 million shares</a>.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>Two years later, Haurwitz <a href="https://www.genengnews.com/gen-edge/force-of-nature-caribou-biosciences-hits-clinical-runway-with-crispr-based-cancer-therapeutics/">shared with <em>GEN</em></a> her journey from graduate student in Doudna’s lab to launching a biotech start-up: “This is the only job I’ve ever had!”</p>
<h4><strong>Trials halted</strong></h4>
<p>As a result of the strategic review, Caribou has halted trials of vispacabtagene regedleucel (vispa-cel, formerly CB-010) a treatment for relapsed or refractory (r/r) B cell non-Hodgkin lymphoma. Caribou has said vispa-cel is the first allogeneic CAR T-cell therapy “to our knowledge” that has reached the clinic with a PD-1 knockout, a genome-editing strategy designed to improve antitumor activity by limiting premature CAR T-cell exhaustion.</p>
<p>To manufacture vispa-cel, Caribou applies Cas9 hybrid RNA-DNA guide or “chardonnay” (chRDNA) to make three edits: A knockout of the <em>TRAC</em> gene to remove the T cell receptor; a site-specific insertion of an anti-CD19 CAR into the <em>TRAC</em> gene; and a knockout of PD-1.</p>
<p>Also halted were clinical studies of CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of patients with r/r multiple myeloma (RRMM). To manufacture CB-011, Caribou uses Cas12a chRDNAs designed to direct precise genome editing, in order to make four edits:</p>
<ul>
<div class="my-8"><span data-render-ad="5"></span></div>
<li>A knockout of the <em>TRAC</em> gene to remove the T-cell receptor</li>
<li>A site-specific insertion of a humanized anti-BCMA CAR into the <em>TRAC</em> gene</li>
<li>A site-specific insertion of a gene encoding a B2M–HLA-E-peptide fusion into the <em>B2M</em> gene</li>
<li>The resulting knockout of the endogenous <em>B2M</em></li>
</ul>
<p>“This method simultaneously eliminates endogenous HLA class I presentation on the surface of the CAR T cells and expresses HLA-E, a minor HLA class I antigen, to blunt both T and NK cell-mediated rejection of the CAR T-cell therapy by the patient’s immune system,” Caribou explained on its website.</p>
<h4><strong>Strategic pivot</strong></h4>
<p>The development of CB-011 and vispa-cel followed a strategic pivot by Caribou from a platform company for biopharma partners applying genome editing in research or product development, to a developer of genome-edited therapies based on its own next-generation CRISPR technology.</p>
<p>While that pivot has generated positive data readouts, it has not shielded Caribou from the financial challenges faced by numerous gene-edited therapy developers. In April 2025, Caribou chopped its workforce by 32% and pruned its pipeline by ending all preclinical research, the Phase I GALLOP trial (<a href="https://clinicaltrials.gov/study/NCT06752876">NCT06752876</a>) of vispa-cel in lupus (before the first patient could be dosed), and development of CB-012, including the Phase I AMpLify trial (<a href="https://clinicaltrials.gov/study/NCT06128044">NCT06128044</a>) assessing the candidate in relapsed or refractory acute myeloid leukemia (AML).</p>
<div class="my-8"><span data-render-ad="6"></span></div>
<p>“It was really about right sizing the organization relative to our focused priorities,” Haurwitz explained last year in an interview. Asked how hopeful she was about an improving economic environment over the next 12 months, she replied: “I remain a believer and I remain an optimist. I’d probably be in the wrong job in the wrong line of work if I weren’t.”</p>
<p>“I certainly think for the work that we are doing, I continue to fully believe that doing right by patients is the North Star, because business success falls out from that in terms of nearer term clinical catalysts and opportunities that come from doing right by patients. And longer-term commercial opportunity also comes from doing right by patients,” Haurwitz added.</p>
<p>Caribou has retained Wedbush Securities as its exclusive financial advisor to assist in evaluating strategic options.</p>
<p>Caribou announced its pursuit of strategic alternatives after the closure of financial markets on October 6. The following day, Caribou shares began three days of stock declines, <span><strong>nosediving 46%</strong></span> from $1.14 to 62 cents. Those shares <span><strong>tumbled another 22%</strong></span> Thursday to 48 cents, but closed Friday with another <strong><span>4% decline</span></strong>, finishing the week at 46 cents.</p>
<p><strong>Cash crunch</strong></p>
<p>Daina M. Graybosch, PhD, senior managing director, immuno-oncology and a senior research analyst with Leerink Partners, reported in a research note that Caribou was facing an increasingly pressing cash crunch at a time when the company needed significant capital to fund its planned Phase III ANTLER-3 trial, designed to assess vispa-cel in second-line auto-CAR T ineligible diffuse large B-cell lymphoma (DLBCL).</p>
<p>Caribou never enrolled patients in the pivotal study, though it reached agreement with the FDA in May on a design for the trial, which was expected to be a randomized, controlled clinical study enrolling approximately 250 CD19-naïve second line (2L) large B cell lymphoma patients ineligible for transplant and not candidates or not eligible for autologous CAR T-cell therapy.</p>
<p>“We are sympathetic to management’s stated rationale for exploring strategic alternatives,” Graybosch commented. “Evidently, investors were unwilling to fund the trial on what would have been highly dilutive terms, especially in the context of lingering clinical risk and uncertainty around the strength of vispa-cel’s Ph[ase I/II] outcomes and partial HLA-matching strategy, as well as substantial in- and out-of-class competition.”</p>
<p>That competition, she wrote, included epcoritamab, a bispecific T-cell engager (BiTE) therapy already marketed as Epkinly® by <strong>Genmab (Nasdaq Copenhagen and Nasdaq: GMAB)</strong> and <strong>AbbVie (NYSE: ABBV)</strong>.</p>
<p>On October 5—the day before Caribou’s strategic alternatives announcement—Genmab and AbbVie reported positive topline data from the Phase III EPCORE DLBCL-2 trial (<a href="https://clinicaltrials.gov/study/NCT05578976">NCT05578976</a>) showing that the combination of epcoritamab, rituximab, the corticosteroid prednisone, and three chemotherapy drugs showed statistically significant and clinically meaningful improvement in progression-free survival (PFS) in frontline diagnosed DLBCL patients.</p>
<div class="my-8"><span data-render-ad="7"></span></div>
<p>The combination therapy, nicknamed R-CHOP, consists of rituximab—the CD20-directed cytolytic antibody marketed by <strong>Genentech</strong>, a member of the <strong>Roche Group (SIX Swiss: RO and ROP)</strong> and <strong>Biogen (Nasdaq: BIIB)</strong> as Rituxan®—plus cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone. In DLBCL patients with an International Prognostic Index (IPI) score of 2 to 5, R-CHOP reduced the risk of disease progression or death by 51% (HR 0.49 [95% CI 0.36, 0.67]; p-value < 0.0001).</p>
<h4><strong>“Interesting” timing</strong></h4>
<p>“The timing of [Caribou’s] initiative is interesting,” Graybosch observed. “We believe there is enhanced strategic value and clinical rationale for allogeneic cell therapies in a world where TCEs [T-cell engagers] become entrenched in the 1L [first-line] setting.”</p>
<p>As for CB-011, it began development much earlier than vispa-cel, “with an appreciably more challenging competitive setup in RRMM, where we saw elevated clinical risk for its post-BCMA therapy development path due to potential efficacy-compromising loss-of-antigen,” the Leerink Partners analyst added.</p>
<p>Single target allogeneic BCMA CAR-T treatments have posed a <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10657357/">potential risk of RRMM relapse through antigen loss</a> as myeloma cells mutate or downregulate BCMA to evade the CAR T cells. To minimize that risk, Caribou designed its Phase I CaMMouflage trial (<a href="https://clinicaltrials.gov/study/NCT05722418">NCT05722418</a>) to limit the therapy dosing to BCMA-naïve patients—an approach that proved successful when the company last year announced positive data from a 12-patient, BCMA-naïve cohort showing a 92% overall response rate (11/12 patients), a 75% or greater complete response rate (9/12), and 91% minimal residual disease (MRD) negativity (10/11 evaluable patients).</p>
<p>To avoid the risk of antigen loss, several developers of allogeneic BCMA CAR-Ts have designed dual targeting CAR Ts. For example, <strong>Allogene Therapeutics (Nasdaq: ALLO) </strong>is developing ALLO-329, which targets CD19 on B cells and CD70 on activated T cells. ALLO-329 generated positive preclinical data in April, with a data update from the Phase I RESOLUTION trial (<a href="https://clinicaltrials.gov/study/NCT07085104">NCT07085104</a>) expected later in Q4.</p>
<p>Another challenge to CB-011 and other allogenic therapies for RRMM: The multiple myeloma space has been reshaped by autologous BCMA CAR-T therapies that have won approval by demonstrating safety and effectiveness—including Carvykti<sup>®</sup> (ciltacabtagene autoleucel), co-marketed by <strong>Legend Biotech (Nasdaq: LEGN) </strong>and <strong>Johnson & Johnson (NYSE: JNJ)</strong>; and Abecma<sup>®</sup> (idecabtagene vicleucel), marketed by <strong>Bristol Myers Squibb (NYSE: BMY)</strong>.</p>
<h4><strong>Souring on the stock</strong></h4>
<p>Graybosch downgraded Caribou’s rating from “Outperform” to “Market Perform” and chopped the firm’s 12-month price target 75%, from $4 to $1. Graybosch was among several Wall Street analysts who responded to Caribou’s news by souring on the company’s stock, downgrading their ratings:</p>
<ul>
<li><strong>Brookline Capital Markets (Leah Ruch Cann)</strong>—From “Buy” to “Hold,” no price target.</li>
<li><strong>H.C. Wainwright (Robert Burns)</strong>—From “Buy” to “Neutral,” no price target.</li>
<li><strong>RBC Capital Markets (Luca Issi, PhD)</strong>—From “Outperform” to “Sector Perform,” price target slashed 90% from $10 to $1.</li>
</ul>
<p>Caribou reported $113.8 million in cash, cash equivalents, and marketable securities as of the end of the second quarter on June 30—a <span><strong>4% dip</strong></span> from the $118.6 million reported at the end of Q1, but a <span><strong>20% drop</strong></span> from the $142.8 million Caribou had as of December 31, 2025, and a <span><strong>38% slide </strong></span>from the $183.9 million reported June 30, 2025.</p>
<p>“We expect that our existing cash, cash equivalents, and marketable securities will be sufficient to fund our operations for at least the next 12 months from the date this Form 10-Q is filed with the SEC [U.S. Securities and Exchange Commission],” Caribou stated in its most recent Form 10-Q quarterly report detailing second-quarter results, filed August 13.</p>
<h2><strong>Leaders and laggards</strong></h2>
<ul>
<li><strong>Arrivent BioPharma (Nasdaq: AVBP)</strong> shares <span><strong>plummeted 47%</strong></span> October 6 from $28.46 to $15.09 after the cancer drug developer announced that its lead pipeline candidate firmonertinib failed the Phase III FURVENT trial (<a href="https://clinicaltrials.gov/study/NCT05607550">NCT05607550)</a> designed to assess the oral, mutation-selective epidermal growth factor receptor (EGFR) inhibitor in previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations. Firmonertinib did not meet its primary endpoint of meaningful progression free survival (PFS) compared to chemotherapy as evaluated by blinded independent central review (BICR). Arrivent said that clinical benefit was seen in secondary endpoints such as PFS by investigator’s assessment and confirmed objective response rate by BICR. A trend toward improved overall survival was also seen, the company added.</li>
<li><strong>Pacira BioSciences (Nasdaq: PCRX)</strong> shares <span><strong>soared 44%</strong> </span>Thursday from $25.20 to $36.39 after <strong>Viatris (Nasdaq: VTRS)</strong> agreed to acquire the non-opioid pain drug developer for $1.65 billion. The deal adds to Pacira’s portfolio with two marketed drugs—the postsurgical pain relief therapy Exparel® (bupivacaine liposome injectable suspension), and the osteoarthritis knee pain treatment Zilretta® (triamcinolone acetonide extended-release injectable suspension). Viatris said it plans to apply its intellectual property expertise and ability to extend product lifecycles and sustain meaningful sales post-competition “to maximize the long-term value of the Pacira portfolio” and expects to expand its reach across select markets. Pacira generated approximately $746 million in revenue and approximately $177 million in adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) during the 12 months ending June 30. Viatris plans to commence a tender offer for all outstanding Pacira common stock shares for $36.50 per share cash. The deal is set to close by year’s end.</li>
</ul>
<p>The post <a href="https://www.genengnews.com/topics/genome-editing/stockwatch-caribou-plunges-as-it-pursues-strategic-alternatives/">StockWatch: Caribou Plunges as It Pursues Strategic Alternatives</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Why IMGs Struggle with USMLE Question Interpretation (And How to Fix It Fast)</title>
<link>https://edusehat.com/en/why-imgs-struggle-with-usmle-question-interpretation-and-how-to-fix-it-fast</link>
<guid>https://edusehat.com/en/why-imgs-struggle-with-usmle-question-interpretation-and-how-to-fix-it-fast</guid>
<description><![CDATA[ Knowing the Medicine vs. Understanding the Test One of the most frustrating parts of preparing for the USMLE as an international medical graduate (IMG) is realizing that sometimes you actually do know the medicine, but still miss the question.   Many IMGs walk away from practice blocks thinking: “I knew that diagnosis. How did I […]
The post Why IMGs Struggle with USMLE Question Interpretation (And How to Fix It Fast) appeared first on Elite Medical Prep. ]]></description>
<enclosure url="https://elitemedicalprep.com/wp-content/uploads/2026/10/pexels-artempodrez-8519259-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 10 Oct 2026 22:25:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Why, IMGs, Struggle, with, USMLE, Question, Interpretation, And, How, Fix, Fast</media:keywords>
<content:encoded><![CDATA[<h2><strong>Knowing the Medicine vs. Understanding the Test</strong></h2>
<p><span>One of the most frustrating parts of preparing for the USMLE as an international medical graduate (IMG) is realizing that sometimes you actually </span><i><span>do</span></i><span> know the medicine, but still miss the question.</span></p>
<p> </p>
<p><span>Many IMGs walk away from practice blocks thinking:</span><span><br>
</span><span>“I knew that diagnosis. How did I not see it?”</span></p>
<p> </p>
<p><span>If this happens often, it usually does not mean you have major knowledge gaps. More commonly, it means you are still learning how the NBME wants you to <a href="https://elitemedicalprep.com/usmle-for-imgs-navigating-language-and-clinical-vignette-challenges/">interpret clinical vignettes</a>.</span></p>
<p> </p>
<p><span>This is an incredibly common challenge because many international medical education systems emphasize precision, memorization, and attention to detail. Those are valuable skills clinically, but on the USMLE they can sometimes work against students when they become too focused on isolated clues instead of the overall clinical picture.</span></p>
<p> </p>
<p><span>The NBME is usually not testing whether you can identify the most obscure detail in the vignette. More often, it is testing whether you can recognize the dominant pattern of disease and make good clinical decisions from it.</span></p>
<p> </p>
<h2><strong>In other words, they want you to zoom out.</strong></h2>
<p><span>The “Zoomed-In” Thinking Pattern You Must Develop</span></p>
<p> </p>
<p><span>One of the biggest differences between struggling and high-scoring students is the ability to identify the </span><i><span>bulk</span></i><span> of the question quickly. Many IMGs naturally approach vignettes by carefully analyzing every sentence equally, and in great detail. Early on, this creates a huge amount of cognitive overload because suddenly every detail feels important. And the question stems can get LONG. </span></p>
<p> </p>
<p><span>For example, a question may clearly describe septic shock, but the student becomes distracted by one unusual lab value or one symptom that feels slightly atypical. Instead of trusting the overall presentation, they begin searching for a rare diagnosis that perfectly explains every single detail.</span></p>
<p> </p>
<h2><strong>This is where <i>overthinking</i> becomes dangerous.</strong></h2>
<p><span>The reality is that NBME questions are usually far more representative than students think. Most of the time, the exam writers are not trying to trick you into picking a zebra diagnosis. They are testing whether you can recognize the most likely and clinically important explanation for the patient’s presentation.</span></p>
<p> </p>
<p><span>Strong USMLE test-takers identify the central story of the vignette first and then use the smaller details to support that interpretation rather than replace it.</span></p>
<p> </p>
<h2><strong>Why the NBME Wants You to Focus on the “Bulk” of the Question</strong></h2>
<p><span>Many IMGs assume every detail in the vignette carries equal weight. In reality, the NBME prioritizes patterns. </span><span>A patient may not present with every classic symptom. A lab value may be slightly atypical. Real patients are messy, and NBME questions are designed to reflect that reality. If 90% of the vignette points toward one diagnosis, that overall pattern usually matters far more than one small inconsistency.</span></p>
<p> </p>
<p><span>This is why students often hurt themselves by trying too hard to explain every detail perfectly and getting hung up on questions when they can’t make all the pieces fit.</span></p>
<p> </p>
<p><span>You may correctly recognize myocardial infarction initially, then suddenly abandon that reasoning because of one extra sentence that makes you wonder about a rarer diagnosis. Or you may identify nephrotic syndrome immediately, only to second-guess yourself because one lab value does not fit your mental textbook definition exactly.</span></p>
<p> </p>
<p><span>The USMLE absolutely rewards careful reading, but it rewards prioritization far more than perfectionism. In fact, the questions are designed for you not to be able to reach perfection in most answer explanations.</span></p>
<p> </p>
<h2><strong>The Fear of “Missing the Trick”</strong></h2>
<p><span>Another major issue for IMGs is becoming overly worried that the exam is trying to fool them. </span><span>Because the USMLE style feels unfamiliar at first, many students start assuming every unusual phrase must completely change the diagnosis. Ironically, this often leads students to change correct answers into incorrect ones.</span></p>
<p> </p>
<p><span>The NBME does include <a href="https://elitemedicalprep.com/common-nbme-question-traps-and-how-to-avoid-them/">distractors and subtle wording differences</a>, but the majority of questions are still testing common disease patterns and core clinical reasoning. The exam is difficult because it requires integration and prioritization, not because every question hides a rare diagnosis behind one strange clue. Overwhelmingly, the NBME is </span><span>NOT</span><span> trying to trick you. </span></p>
<p> </p>
<p><span>Learning to trust the overall clinical picture is one of the biggest turning points in preparation.</span></p>
<p> </p>
<h2><strong>How to Retrain Your Brain During Questions</strong></h2>
<p><span>If you notice that you’re making some of these strategy errors, that’s an excellent first step because once you know the mistakes you’re making you can work toward fixing them. One of the most helpful habits is learning to <a href="https://elitemedicalprep.com/usmle-step-1-sample-questions-examples-answers-and-explanations/">summarize the vignette before looking at the answer choices</a>.</span></p>
<p> </p>
<p><span>Instead of trying to decode every individual sentence, pause and ask yourself:</span><span><br>
</span><span>“What is the overall clinical picture here?”</span></p>
<p> </p>
<p><span>Even a quick mental summary like:</span><span><br>
</span><span>“This sounds like heart failure,”</span><span><br>
</span><span>“This sounds like adrenal insufficiency,”</span></p>
<p><span><br>
</span><span>or</span></p>
<p><span><br>
</span><span>“This sounds like nephritic syndrome”</span><span><br>
</span><span>can anchor your reasoning and prevent spiraling into overanalysis.</span></p>
<p> </p>
<p><span>Over time, this becomes more automatic and you’ll do it instinctively while you’re reading through the question. It takes practice…so be patient. </span></p>
<p> </p>
<p><span>With enough repetition, your brain stops processing every line independently and starts recognizing entire clinical patterns. This is why experienced test-takers can often answer questions quickly without feeling rushed. They are not necessarily smarter or reading faster — they simply recognize the overall presentation earlier.</span></p>
<p> </p>
<h3><strong>Why Practice Questions Matter So Much</strong></h3>
<p><span>This skill cannot be developed through passive studying alone.</span></p>
<p> </p>
<p><span>Question interpretation improves through <a href="https://elitemedicalprep.com/why-nbme-questions-feel-harder-than-uworld-and-what-to-do-about-it/">repeated exposure to NBME-style reasoning</a>. Every practice question teaches you something about how the exam prioritizes information, frames distractors, and signals important diagnoses.</span></p>
<p> </p>
<p><span>Eventually, you begin to recognize which findings are usually high-yield and which details mainly exist to create realism. Questions feel less chaotic because you develop a better filter for what actually matters most.</span></p>
<p> </p>
<p><span>This is also why delaying question practice can hurt IMG students significantly. Many students wait until they “finish content review” before doing enough questions, but interpretation skills only improve through active engagement with vignettes themselves. <a href="https://elitemedicalprep.com/how-to-use-usmle-step-1-practice-questions-effectively/">The content review and practice must happen </a></span><i><span>simultaneously</span></i><span>. </span></p>
<p> </p>
<h2><strong>Final Encouragement</strong></h2>
<p><span>If you constantly feel like you “knew the material but interpreted the question wrong,” try not to view that as failure. Interpretation is a skill, and like any skill, it improves with intentional practice and repetition.</span></p>
<p> </p>
<p><span>Eventually, the NBME style begins to feel familiar. You stop fighting the vignette and start understanding what the exam writers actually want you to see. </span><span>That is often the moment everything finally starts to click.</span></p>
<p> </p>
<p>If you know the material but struggle to apply it to exam questions, <a href="https://elitemedicalprep.com/get-started/">EMP’s personalized USMLE tutoring</a> can help you identify recurring mistakes, refine your question approach, and build confidence in your clinical reasoning.</p>
<p>The post <a href="https://elitemedicalprep.com/why-imgs-struggle-with-usmle-question-interpretation-and-how-to-fix-it-fast/">Why IMGs Struggle with USMLE Question Interpretation (And How to Fix It Fast)</a> appeared first on <a href="https://elitemedicalprep.com/">Elite Medical Prep</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Sickle Cell Trait Linked to Distinct Malaria Parasite Variants</title>
<link>https://edusehat.com/en/sickle-cell-trait-linked-to-distinct-malaria-parasite-variants</link>
<guid>https://edusehat.com/en/sickle-cell-trait-linked-to-distinct-malaria-parasite-variants</guid>
<description><![CDATA[ A study in Cameroon found that sickle cell trait is associated with distinct malaria parasite genotypes, potentially explaining reduced disease risk despite similar infection rates.
The post Sickle Cell Trait Linked to Distinct Malaria Parasite Variants appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_IMG_1436_084226.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 10 Oct 2026 04:05:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Sickle, Cell, Trait, Linked, Distinct, Malaria, Parasite, Variants</media:keywords>
<content:encoded><![CDATA[<p>Malaria is one of the deadliest infectious diseases on the planet, afflicting people for the entirety of recorded history. In places where malaria is most common, it’s shaped human evolution by driving higher rates of a protective genetic change. Two copies of the genetic change cause sickle cell disease, but one copy helps protect people from malaria. More specifically, sickle cell hemoglobin (HbS) confers protection against symptomatic malaria caused by <em>Plasmodium falciparum.</em></p>
<p>Now, a new study has found that people with the sickle cell variant are almost exclusively infected by a distinct variety of malaria parasites, which might contribute to their lower rates of disease.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>“Sickle cell trait may protect against malaria, not only by changing how the human host responds to infection, but also by shaping which parasites are able to survive and establish infection,” says Sandrine Nsango, PhD, associate professor of molecular biology at the University of Douala and researcher at the Centre Pasteur du Cameroun, Head of the Department of Biomedical Sciences, Faculty of Science, University of Bertoua.</p>
<p>This work is published in <em>Nature Microbiology</em> in the paper, “<a href="https://www.nature.com/articles/s41564-026-02502-4" target="_blank" rel="noopener">Sickle cell haemoglobin status shapes malaria parasite genotype in asymptomatic infections.</a>”</p>
<p>Previous work had discovered the unusual strain of malaria by investigating the rare cases where people with the sickle cell variant develop disease symptoms. The new research extends these findings to asymptomatic infections, in which people are infected by the parasite but don’t get sick. While less visible than the disease itself, asymptomatic infections were extremely common, affecting three-quarters of the healthy study population.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>HbS carriers with symptomatic malaria harbor parasites enriched for <em>P. falciparum</em> sickle-associated alleles (Pfsa+). While these may partially overcome HbS-mediated protection, their role in asymptomatic infections is unclear. Researchers analyzed the genetics of over 2,246 healthy schoolchildren in a region of high malaria transmission in Mfou, Cameroon, as well as the malaria parasites infecting them. The team found that people with and without the sickle cell variant tend to be infected by genetically different varieties of malaria parasites.</p>
<p>In addition, specific varieties of the parasite infect people with and without the sickle cell variant at similar overall rates<em>.</em> They write, “analyzing the parasite Pfsa and the human HbS genotypes for 1,701 asymptomatic <em>P. falciparum</em> infections confirmed that heterozygous HbS (HbAS) and homozygous non-HbS (HbAA) genotypes have similar rates of asymptomatic infection.” However, despite being infected at similar rates, people carrying the sickle cell variant are much less likely to develop symptomatic malaria.</p>
<p>The researchers found that which parasites are present in an asymptomatic infection differs based on if the infected person has the sickle cell variant. They write, “the HbS genotype is strongly associated with parasites carrying the Pfsa+ alleles at the Pfsa1 and Pfsa3 loci, indicating a selective advantage for these alleles in HbS carriers.” These findings suggest that the sickle cell variant influences which parasites can infect a person, whether or not they develop disease symptoms.</p>
<p>People with the sickle cell variant are just as likely to become infected—albeit with a different variety of the parasite—but they’re a tenth as likely to develop harmful disease. These observations suggest that the biological characteristics of this parasite variety may contribute, at least in part, to the protection against disease conferred by the sickle cell trait.</p>
<p>To understand why people with sickle cell don’t get disease as often—and use that knowledge to develop better therapies—researchers should not only look at the biology of the sickle cell variant but also investigate the differences in the malaria parasite.</p>
<p>Nsango says that their findings emphasize that malaria is an example of a continued evolutionary interaction between humans and the parasite. “The sickle cell mutation is one of the clearest examples of how infectious diseases can shape human evolution, but our findings suggest that humans also shape the evolution of the parasite in return,” Nsango says. “Understanding these interactions may help us anticipate how malaria parasites adapt in the future and design more effective strategies for malaria control.”</p>
<p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/sickle-cell-trait-linked-to-distinct-malaria-parasite-variants/">Sickle Cell Trait Linked to Distinct Malaria Parasite Variants</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Multiomics in 2026 and Beyond</title>
<link>https://edusehat.com/en/multiomics-in-2026-and-beyond</link>
<guid>https://edusehat.com/en/multiomics-in-2026-and-beyond</guid>
<description><![CDATA[ Multiomics analysis combines data from two or more omics layers—such as genomics, transcriptomics, proteomics, and epigenomics. However, published criticisms of multiomics approaches have highlighted concerns about data integration and a tendency toward […]
The post Multiomics in 2026 and Beyond appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GEN_OCT_2026_GettyImages-2204954826-Copy.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 10 Oct 2026 00:25:13 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Multiomics, 2026, and, Beyond</media:keywords>
<content:encoded><![CDATA[<p>Multiomics analysis combines data from two or more omics layers—such as genomics, transcriptomics, proteomics, and epigenomics. However, published criticisms of multiomics approaches have highlighted concerns about data integration and a tendency toward false-positive findings.<sup>1–3</sup></p>
<p>What additional roadblocks might accompany ambitious multiomics projects in 2026? Could any bottlenecks emerge in cost, sample preparation, data integration, or AI implementation? We recently interviewed experts from five companies to gain their perspectives. Here is what they had to say.</p>
<h4><strong>Sample preparation</strong></h4>
<p>“I sound like a broken record because I can’t stop talking about the importance of sample prep in multiomics work,” says Michael Easterling, PhD, vice president of MALDI/Imaging at Bruker Daltonics.</p>
<p>Easterling stresses challenges such as section-to-section variability, internal standards, FFPE samples, and long sample runs that complicate downstream algorithms. “For multiomics imaging, these issues are not as well defined as some of the bulk methods that have been around much longer,” he notes.</p>
<p>Scott Jelinsky, PhD, senior director of R&D at Thermo Fisher Scientific, agrees. “Different molecular classes have different requirements for sample collection, storage, and preparation,” he says. “Therefore, careful experimental design and standardization are essential.”</p>
<p>Easterling mentions the consequences of inadequate freezing during biopsies, which can disrupt cell structures and lead to ice crystal artifacts. “It is important to really make sure that you have a solid workflow to correctly harvest tissue and provide a good chain of custody from the point that it’s harvested all the way to the analyzer.”</p>
<p>What are some tips for multiomics researchers hoping to prepare their samples in an optimal way? “Community networking is key here,” argues Easterling. “I would say get involved with the overall spatial imaging community and network and find out exactly how to do these things.”</p>
<p>Another practical consideration, according to Jelinsky, is planning the workflow from the beginning so that sample collection, aliquoting, storage, and analytical requirements are compatible across different assays. “Decisions made early in the study can have a significant impact on what can be measured and how confidently the different datasets can be interpreted together,” he notes.</p>
<h4><strong>Data integration and analysis</strong></h4>
<p>Multiomics technologies generate vast amounts of high-resolution data across modalities that often behave differently from a statistical perspective, notes Najiba Mammadova, PhD, associate director of product management at 10x Genomics. “Multiomics assays have advanced incredibly quickly, and now the analysis and interpretation tools need to keep pace,” she notes.</p>
<p>Mammadova specifically highlights the challenges of computationally aligning multiple omics from different cells or tissues. After all, how can researchers be certain that they are measuring the same cells and biological features?</p>
<figure aria-describedby="caption-attachment-339145" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="wp-image-339145 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_10x-Genomics_Figure-2-Copy-300x300.jpg" alt="10x Genomics MultiPro Human Discovery Panel" width="300" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_10x-Genomics_Figure-2-Copy-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_10x-Genomics_Figure-2-Copy-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_10x-Genomics_Figure-2-Copy-768x767.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_10x-Genomics_Figure-2-Copy.jpg 788w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">The 10x Genomics MultiPro Human Discovery Panel, which integrates into existing Flex scRNA-seq workflows, is the largest antibody-based, single-cell protein panel, enabling integrated analysis of 326 protein targets. [10x Genomics]</figcaption></figure>
<p>“That’s why I think measuring multiple modalities from the same cell or tissue is so important,” she adds. “It reduces the need to reconstruct the biology after the fact and gives researchers a more direct view of what’s happening in the sample.”</p>
<p>Vanee Pho-Conners, PhD, vice president of global marketing at Mission Bio, agrees that data integration is often a major hurdle with multiomics work. “Each omics layer has its own data structure, distributions, and variabilities, so combining them isn’t plug-and-play,” she explains. Multiomics analysis also often requires cross-disciplinary expertise in biostatistics, machine learning, and biology—capabilities many labs lack in-house.</p>
<p>“It’s important to ask how you can combine these data sets in a clean way where you preserve all the information, reduce the noise, and start to make biological inferences,” adds Easterling. “It’s not something that’s routine today, but the situation is changing rapidly, and new ways to integrate these datasets of varying dimensionality are starting to appear.”</p>
<p>Timing is yet another important consideration, notes Jelinsky. Proteins, RNA, and metabolites may exhibit different kinetics and respond on different timescales, so measurements collected at the same time may not always align. “Understanding those temporal relationships is essential when integrating and interpreting the results,” he says.</p>
<figure aria-describedby="caption-attachment-339148" class="wp-caption aligncenter"><img decoding="async" class="wp-image-339148" src="https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_Thermo-Fisher_Figure-1-1024x626.jpg" alt="Thermo Fisher’s multiomics solutions illustration" width="500" height="306" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_Thermo-Fisher_Figure-1-1024x626.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_Thermo-Fisher_Figure-1-300x183.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_Thermo-Fisher_Figure-1-768x470.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_Thermo-Fisher_Figure-1-1536x939.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_Thermo-Fisher_Figure-1.jpg 1814w" sizes="(max-width: 500px) 100vw, 500px"><figcaption class="wp-caption-text">Thermo Fisher’s multiomics solutions include services as well as products for sample preparation, separation, acquisition, and analysis. [Thermo Fisher]</figcaption></figure>
<h4><strong>AI and multiomics</strong></h4>
<p>“I think the rate-limiting multiomics questions are shifting from ‘Can we measure this?’ to ‘Can we <em>interpret it</em>?’ And that’s where AI has enormous potential,” notes Mammadova. “We’re generating increasingly rich, high-dimensional datasets, and AI can help researchers identify patterns, interpret those data more quickly, and ultimately build models that can predict things like disease progression or treatment response.”</p>
<p>However, Easterling warns that even the most advanced AI technologies often cannot overcome challenges associated with inadequate sample preparation. “Unfortunately, if a model’s trained on an inconsistently prepared section, it’ll give you a confident biological story that’s completely wrong. And the reader of this data may have no way to tell.”</p>
<figure aria-describedby="caption-attachment-339149" class="wp-caption aligncenter"><img decoding="async" class="wp-image-339149" src="https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_Mission-Bio_Figure-3-1024x379.jpg" alt="DNA, RNA, and protein workflow " width="500" height="185" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_Mission-Bio_Figure-3-1024x379.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_Mission-Bio_Figure-3-300x111.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_Mission-Bio_Figure-3-768x284.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_Mission-Bio_Figure-3-1536x568.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_Mission-Bio_Figure-3-2048x757.jpg 2048w" sizes="(max-width: 500px) 100vw, 500px"><figcaption class="wp-caption-text">The DNA, RNA, and protein workflow on Tapestri’s single-cell platform. Each cell is encapsulated in its own droplet, and a unique molecular barcode (specific to each cell) gets attached to each DNA, RNA, and protein molecule. [Mission Bio]</figcaption></figure>
<p>As an example of recent AI advances, Easterling highlights multiomic workflows pioneered at the Medical University of South Carolina for single-cell analysis. The group has developed an AI algorithm that assists lasers in targeting individual cells rather than clusters of cells.<sup>4</sup> Pho-Conners also emphasizes how Mission Bio is using machine learning to jointly cluster DNA, RNA, and protein—referred to as triomics—from the same cell. “We are using a combination of triomics and AI-driven integration to establish disease resistance. This really goes beyond correlations using a single omics layer,” she says.</p>
<div class="my-8"><span data-render-ad="6"></span></div>
<p>Although Jelinsky is generally optimistic about AI advances in multiomics, he foresees fundamental limitations. “I see AI as a tool that can help researchers navigate complexity and generate better hypotheses rather than as a replacement for scientific judgment. AI does not remove the need for rigorous experimental design or biological validation,” he stresses.</p>
<h4><strong>Challenges with extracellular vesicles</strong></h4>
<p>Distinct multiomics challenges also exist in analyzing extracellular vesicles (EVs), small membrane spheres released by cells that contain multiple omics (DNA, RNA, protein, metabolites, and lipids).</p>
<p>“EVs are how cells talk to each other, and a living cell sends up to ten thousand a day. This makes them good biomarkers,” says Pierre Arsène, founder and CEO of Mursla Bio.</p>
<p>However, with traditional EV analysis, each potential omics layer is measured from EVs derived from an unknown blend of cells. There is usually no way to know whether a protein signal and an RNA signal came from the same tissue, for instance.</p>
<figure aria-describedby="caption-attachment-339151" class="wp-caption aligncenter"><img loading="lazy" decoding="async" class="wp-image-339151" src="https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_Mursla-Bio_Figure-4-1024x338.jpg" alt="Mursla’s biomarker discovery workflow" width="500" height="165" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_Mursla-Bio_Figure-4-1024x338.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_Mursla-Bio_Figure-4-300x99.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_Mursla-Bio_Figure-4-768x254.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_Mursla-Bio_Figure-4-1536x507.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_Mursla-Bio_Figure-4-2048x676.jpg 2048w" sizes="auto, (max-width: 500px) 100vw, 500px"><figcaption class="wp-caption-text">Mursla’s biomarker discovery workflow for tissue-specific extracellular vesicles. Antibody-coated magnetic beads capture hepatocyte-derived vesicles from under two milliliters of plasma, leaving behind extracellular vesicles from other tissues. [Mursla Bio]</figcaption></figure>
<p>“Tissue-specific extracellular vesicles (TS-EVs) are how we recover that record,” explains Arsène. Mursla’s technology begins with a blood draw. Liver-specific EVs are then captured using antibodies against proprietary surface markers (more specifically, hepatocyte-EV markers). Finally, proteomics and RNA sequencing are performed on two milliliters of plasma for biomarker discovery.</p>
<p>“The great thing about TS-EVs is that they arrive addressed, carrying surface proteins specific to the sending cell and sealed behind a membrane that shields proteins and RNA from the enzymes that would destroy them in blood.”</p>
<p>EvoLiver, Mursla’s blood test for liver cancer surveillance in cirrhotic patients, holds an FDA Breakthrough Device Designation. It analyzes three proteins and five microRNAs derived from hepatocytes. Proteins provide information about tumor surface phenotype and metabolic reprogramming, while microRNAs reveal the regulatory programs driving that phenotype.</p>
<p>As with so many other multiomics platforms, Arsène stresses the importance of TS-EV sample preparation. “Blood handling standards for EVs lag well behind standard liquid biopsy, so our clinical work relied mostly on prospective collection under a common protocol rather than using legacy biobanks.”</p>
<h4><strong>The future of multiomics</strong></h4>
<div class="my-8"><span data-render-ad="7"></span></div>
<p>Mammadova highlights the potential for cost-related challenges in multiomics, particularly as the field moves toward larger studies. “Making these technologies more scalable and cost-effective will be critical to expanding their use across research,” she adds.</p>
<p>“However, I see more overall challenges than roadblocks in multiomics work,” she concludes. “They’re the kind of problems the field works through as technologies mature.”</p>
<figure aria-describedby="caption-attachment-339031" class="wp-caption alignright"><img loading="lazy" decoding="async" class="size-medium wp-image-339031" src="https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_Bruker-_Figure-5-Copy-300x159.jpg" alt=">19,000 genes and the 64-plex CosMx Human Immuno-Oncology Protein panel" width="300" height="159" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_Bruker-_Figure-5-Copy-300x159.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_Bruker-_Figure-5-Copy.jpg 656w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Detection of the whole transcriptome along with over 64 proteins in a human breast cancer FFPE tissue section using Bruker’s CosMx spatial molecular imager. [Bruker Spatial Biology]</figcaption></figure>
<p>Spatial multiomic layers will also become increasingly critical for decoding the complexity of disease biology, predicts Prajan Divakar, PhD, Bruker Spatial Biology vice president of product management. “Investigators continue to demonstrate the need for more complete spatial datasets, and we are seeing clear applications and momentum for clinical translation,” he says. Divakar highlights Bruker’s CosMx<sup>®</sup> spatial molecular imager, which measures the whole transcriptome and over 64 proteins.</p>
<p>Finally, Arsène argues that simply adding more layers of analysis without biological resolution is unlikely to advance multiomics research in the future. For instance, in the largest study of a blood-based cancer test ever run (involving around 50,000 participants), incorporating an additional protein layer in advanced adenoma increased the sensitivity only modestly—from about 15% to 16%.<sup>5</sup> “More and more layers allow you to gain dimensions, but you end up losing coherence. And no cohort in the world is large enough to train that coherence back computationally.”</p>
<p>Jelinsky agrees that the value of multiomics will lie not in generating more data, but in selecting complementary measurements that address a specific biological question. “I think the future of multiomics will be less about generating the largest possible number of measurements and more about determining which combination of measurements provides the most meaningful biological insight,” he says.</p>
<p> </p>
<p><em>References </em></p>
<ol>
<li>Behrens LMP, Fernandes GDS, Gonçalves GF, et al. Limitations and opportunities in multi-omics integration for neurodevelopmental, neurodegenerative and psychiatric disorders: A systematic review. <em>Neuroscience</em>. 2026;599:76-93. doi: 10.1016/j.neuroscience.2026.01.019.</li>
<li>Hayes CN, Nakahara H, Ono A, Tsuge M, Oka S. <em>Genes (Basel)</em>. From Omics to Multi-Omics: A Review of Advantages and Tradeoffs. 2024;15(12):1551. doi: 10.3390/genes15121551.</li>
<li>Baião AR, Cai Z, Poulos RC, et al. A technical review of multi-omics data integration methods: from classical statistical to deep generative approaches. <em>Brief Bioinform</em>. 2025;26(4):bbaf355. doi: 10.1093/bib/bbaf355.</li>
<li>Dressman JW, Bayram MF, Angel PM, Drake RR, Mehta AS. Single-Cell Multiomic MALDI-MSI Analysis of Lipids and N-Glycans through Affinity Array Capture. <em>Anal Chem</em>. 2025;97(24):12493-12502. doi: 10.1021/acs.analchem.4c06233.</li>
<li>Shaukat A, Burke CA, Chan AT, et al. Clinical Validation of a Circulating Tumor DNA-Based Blood Test to Screen for Colorectal Cancer. <em>JAMA</em>. 2025;334(1):56-63. doi: 10.1001/jama.2025.7515.</li>
</ol>
<p>The post <a href="https://www.genengnews.com/topics/omics/multiomics-in-2026-and-beyond/">Multiomics in 2026 and Beyond</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>‘Molecular Movie’ of Penicillin Synthesis Could Inform Future Antibiotic Development</title>
<link>https://edusehat.com/en/molecular-movie-of-penicillin-synthesis-could-inform-future-antibiotic-development</link>
<guid>https://edusehat.com/en/molecular-movie-of-penicillin-synthesis-could-inform-future-antibiotic-development</guid>
<description><![CDATA[ An international research team have revealed previously unseen rapid chemical stages in the formation of β-lactam antibiotics such as penicillin, offering insights that could help to support future antibiotic development. 
The post ‘Molecular Movie’ of Penicillin Synthesis Could Inform Future Antibiotic Development appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_Penicillin-biosynthesis-image.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 10 Oct 2026 00:25:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>‘Molecular, Movie’, Penicillin, Synthesis, Could, Inform, Future, Antibiotic, Development</media:keywords>
<content:encoded><![CDATA[<p>Researchers from the University of Oxford and international collaborators have revealed previously unseen rapid chemical stages in the formation of β-lactam antibiotics such as penicillin, offering insights that could help to support future antibiotic development.</p>
<p>Rather than relying on static X-ray crystallographic structures of the enzyme, the Oxford University team, collaborating with partners from Diamond Light Source, Lawrence Berkeley National Laboratory, PAL-XFEL, and SLAC National Accelerator Laboratory, followed the reaction in real time. To do this they used X-ray free-electron lasers (XFEL) to observe the enzyme isopenicillin N synthase, (IPNS) as it converts its linear peptide substrate into the β-lactam ring system of penicillin.</p>
<p>The study brought together expertise in structural biology, spectroscopy, chemistry, computation and enzyme engineering. The approach, they say, provides a powerful way to study fleeting chemical intermediates that have previously been inaccessible, both in antibiotic biosynthesis and in other biologically important enzyme reactions.</p>
<p>The team captured several rapid stages in the reaction. These included a thioaldehyde intermediate formed just before the β-lactam ring is created, and a monocyclic β-lactam intermediate, representing the first ring-shaped structure on the way to forming the complete penicillin scaffold. These steps provide the clearest picture yet of how the IPNS enzyme assembles the penicillin scaffold. Subtle movements throughout the enzyme help guide these chemical steps, showing that both the enzyme’s shape and its chemistry work together to control penicillin formation.</p>
<p>The results show, in unprecedented detail, how the enzyme IPNS achieves an exceptionally complex transformation in a single step. Christopher Schofield, PhD, Professor of Chemistry, University of Oxford, said, “Penicillin has shaped modern medicine, but there is still much to learn about how nature builds this important antibiotic structure. By capturing these fleeting steps, we can better understand how enzymes control complex chemistry with remarkable precision … As rates of antimicrobial resistance continue to rise, understanding this process will ultimately help us make existing antibiotics more efficient and design new antibiotic structures.”</p>
<p>Allen M Orville, PhD, group leader of the XFEL Hub, further commented, “The XFEL Hub at Diamond brought specialist expertise in time-resolved X-ray methods and XFEL-based structural biology to this study. Working closely with our colleagues in Oxford and at partner facilities, we helped bring together the experimental approaches needed to capture these fleeting stages of enzyme catalysis. The results show the power of combining complementary expertise and X-ray techniques to move beyond static structures and reveal how enzymes work in real time. It is a great example of how time-resolved structural biology can uncover new principles of enzyme function and, ultimately, inform the design of new catalysts and therapeutics.”</p>
<p>Schofield is co-senior author of the researchers’ published paper in <em>Nature Catalysis</em>, titled “<a href="https://doi.org/10.1038/s41929-026-01618-4" target="_blank" rel="noopener">Unanticipated intermediates during isopenicillin N synthase catalysis identified by time-resolved X-ray free-electron laser studies</a>.”</p>
<p>Ever since penicillin was developed into a working drug at the University of Oxford in the early 1940s, β-lactam antibiotics have been among the most important medicines for treating bacterial infections. Their activity depends on a special ring—the β-lactam ring—a highly strained chemical ring system that interferes with bacterial cell wall synthesis, ultimately causing the cell wall to fail and the bacteria to die. “Isopenicillin N synthase (IPNS) catalyses the biosynthesis of isopenicillin N (IPN), forming the fused four-membered β-lactam and five-membered thiazolidine ring system that is characteristic of the penicillins,” the authors explained.</p>
<p>Rising rates of antimicrobial resistance are undermining the effectiveness of existing antibiotics. Today, <a href="https://www.who.int/news/item/13-10-2025-who-warns-of-widespread-resistance-to-common-antibiotics-worldwide" target="_blank" rel="noopener">one in six bacterial infections</a> is resistant to antibiotics, the authors noted, citing WHO figures. With too few new antibiotics in development, understanding how nature builds these molecules is an important step towards replenishing the antibiotic pipeline.</p>
<p>Scientists have been studying how nature constructs this β-lactam ring for decades, but the key fleeting reaction intermediates have been too difficult to observe directly.</p>
<p>To capture the reaction in real time, the researchers used a system in which thousands of tiny droplets containing anaerobic enzyme microcrystals were deposited onto a moving 2 mm wide tape. As the tape entered an oxygen filled chamber, oxygen rapidly diffused into the crystals and initiated the reaction simultaneously across the sample. By precisely controlling the speed of the tape, the researchers could determine how long each crystal reacted before reaching the X-ray interaction point, where an ultrafast XFEL pulse recorded an atomic resolution snapshot.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>Combining thousands of these snapshots allowed the team to build a frame-by-frame “molecular movie” of penicillin biosynthesis. This method allows individual reaction intermediates that exist only for tiny fractions of a second to be observed at atomic resolution, and under physiological temperature and pressure, before they disappear.</p>
<p>The newly reported findings help to resolve a long-standing mechanistic question that has remained unanswered for more than four decades. The work also showed that water molecules inside the enzyme play a key role in guiding the reaction. The combined results of their studies, they noted, “… reveal unexpected insight into the IPNS reaction mechanism including the vital roles of active-site water molecules.”</p>
<p>The study ultimately builds on the work of Nobel prize-winning Oxford chemist Dorothy Hodgkin, PhD, who first solved the structure of penicillin in 1945 using X-ray crystallography.</p>
<p>Beyond penicillin, IPNS belongs to a large family of iron-dependent oxygenase enzymes involved in human biology, including those that enable us to sense and respond to changes in oxygen availability. The mechanistic insights from this work could therefore have implications beyond antibiotics, offering new principles for enzyme engineering and catalyst design.</p>
<p>“These findings provide structural insight into IPNS catalysis, inform on the wider Fe(II) oxygenase superfamily and highlight the power of X-ray free-electron laser methods for resolving transient enzymatic intermediates,” the team stated in their paper. First author Patrick Rabe, PhD, Wellcome Career Development Award Investigator, University of Oxford, said, “These insights matter because they can inform how we think about antibiotic biosynthesis and future strategies for developing antibacterial medicines. The ability to capture structural snapshots over milliseconds to seconds of reaction time allows us to connect enzyme motion, iron chemistry and water-mediated proton transfer. This gives us a much richer view of how IPNS controls a difficult chemical transformation. By understanding this process in atomic detail, we can begin to think about engineering these enzymes to produce new or improved antibiotic scaffolds.”</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/molecular-movie-of-penicillin-synthesis-could-inform-future-antibiotic-development/">‘Molecular Movie’ of Penicillin Synthesis Could Inform Future Antibiotic Development</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Immune Cell Atlas Charts How People’s Aging Paths Diverge</title>
<link>https://edusehat.com/en/immune-cell-atlas-charts-how-peoples-aging-paths-diverge</link>
<guid>https://edusehat.com/en/immune-cell-atlas-charts-how-peoples-aging-paths-diverge</guid>
<description><![CDATA[ Two people born on the same day can have immune systems that age differently. An immune cell atlas shows that a ratio between two cell types can reveal who is on a healthy or unhealthy path.
The post Immune Cell Atlas Charts How People’s Aging Paths Diverge appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2019/08/Aug26_2019_Getty_1148114678_WhiteAndRedBloodCells_1400.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 10 Oct 2026 00:25:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Immune, Cell, Atlas, Charts, How, People’s, Aging, Paths, Diverge</media:keywords>
<content:encoded><![CDATA[<p><span>Studies of the immune system show that two people born on the same day can have immune systems that age differently, leaving some older adults with resilient defense systems and others with dysfunctional ones that put them at increased risk for age-related diseases. Now a new study led by scientists at Washington University School of Medicine in St Louis, Nationwide Children’s Hospital in Ohio, and King’s College London provides a map of human immune aging that could help explain these different trajectories. Details are published in a new </span><i><span>Immunity </span></i><span>paper titled “</span><a href="https://dx.doi.org/10.1016/j.immuni.2026.09.012" target="_blank" rel="noopener"><span>Single-cell analyses of global cohorts outline determinants of immune aging and link the ratio of GZMK⁺ to GZMB⁺ Tem cells to health trajectories</span></a><span>.”</span></p>
<p><span>According to the paper, a ratio between two immune cell types can reveal whether someone stays healthy or may face risk of future disease. To get to this insight, the scientists first analyzed approximately 12.4 million individual immune cells from the blood of over 2,600 mainly healthy adults ages 20 to 90-plus across eight cohorts in North America, the United Kingdom, Asia, and Australia. </span></p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p><span>Their analysis showed that while the blood of younger people was uniformly enriched with naive immune cells that had not been exposed to specific pathogens and remained adaptable to new infections or vaccines, older immune systems were more diverse. Specifically, some older participants had a greater abundance of immune cells that reflect inflammation.</span></p>
<p><span>To map this shift, the researchers placed each participant on a spectrum based on the ratio between two types of white blood cells: specifically, granzyme B-producing cells and granzyme K-producing cells. Some white blood cells, known as effector memory CD8 T cells, use granzymes to destroy target cells or coordinate immune responses. While granzyme B-producing cells serve as direct destroyers of diseased cells, granzyme K-producing cells have been less studied and may play a role in boosting immune responses. </span></p>
<p><span>Next, the researchers evaluated whether participants’ positions on the spectrum, which corresponds to a specific type of CD8 T cell, could dictate their risk of getting sick. In other words, they looked at whether having more of one type of CD8 T cell has an impact on the person’s health as they age. To answer that question, the scientists turned to the UK Biobank. </span></p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p><span>While that dataset includes protein information from the participants, it lacks counts of CD8 T cells. To get around this hurdle, the scientists used a smaller dataset of seemingly healthy adults that included data on CD8 T cell counts and blood proteins to create a computer model to map out the protein tracks left behind when either granzyme B-producing or granzyme K-producing cells dominated. They then applied this model to the baseline blood protein samples of 50,000 participants from the UK Biobank, calculating their position on the immune cell spectrum.</span></p>
<p><span>Using this approach, the scientists were able to draw out some useful insights for their work. Specifically, they found that healthy adults whose immune system leaned heavily toward granzyme B cells at baseline tipped the scale toward a higher risk of death a decade later compared to those with more granzyme K cells. The granzyme B-dominant group also was more likely to develop chronic conditions, including Type 2 diabetes, hypertension, liver disease, and renal failure, among others, over the following decade.</span></p>
<p><span>“A higher level of granzyme B cells in a healthy state means the immune system might be already reacting to something,” said Marina Terekhova, MD, a professor in pathology & immunology at WashU Medicine and one of the co-authors on the paper. “It isn’t a formal disease diagnosis, but it may indicate the body is off track.”</span></p>
<p><span>A healthy immune system gradually shifts toward granzyme K cells over time, while an immune system that leans toward granzyme B cells signals unhealthy aging. Because individuals can reach this granzyme B state much earlier in life, their immune systems age on different trajectories, explaining why two people born in the exact same year can face different risks for chronic disease and death decades later.</span></p>
<p><span>These findings point to “clues in the blood that can tell us whether someone is on a healthy or unhealthy aging trajectory,” said Maxim Artyomov, PhD, the alumni endowed professor of pathology and immunology at WashU Medicine and one of the corresponding authors on the paper. Artyomov and his lab are now adapting their research into a simple blood test that can be processed using standard equipment. “Identifying specific biological red flags in the immune system could pave the way for early-warning tests that spot disease risks years before a clinical diagnosis.”</span></p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/immune-cell-atlas-charts-how-peoples-aging-paths-diverge/">Immune Cell Atlas Charts How People’s Aging Paths Diverge</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The Biggest Study Mistakes Students Make When Transitioning from USMLE Step 1 to Step 2</title>
<link>https://edusehat.com/en/the-biggest-study-mistakes-students-make-when-transitioning-from-usmle-step-1-to-step-2</link>
<guid>https://edusehat.com/en/the-biggest-study-mistakes-students-make-when-transitioning-from-usmle-step-1-to-step-2</guid>
<description><![CDATA[ For many medical students, the transition from Step 1 to Step 2 feels surprisingly difficult, and not always for the reasons they expect.   After spending months or even years learning basic science concepts, memorizing pathways, and mastering Step 1-style thinking, students often assume Step 2 will feel easier because it is “more clinical.” In […]
The post The Biggest Study Mistakes Students Make When Transitioning from USMLE Step 1 to Step 2 appeared first on Elite Medical Prep. ]]></description>
<enclosure url="https://elitemedicalprep.com/wp-content/uploads/2026/10/pexels-armin-rimoldi-5553058-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 09 Oct 2026 21:10:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, Biggest, Study, Mistakes, Students, Make, When, Transitioning, from, USMLE, Step, Step</media:keywords>
<content:encoded><![CDATA[<p><span>For many medical students, the <a href="https://elitemedicalprep.com/navigating-the-transition-from-step-1-to-step-2-ck/">transition from Step 1 to Step 2</a> feels surprisingly difficult, and not always for the reasons they expect.</span></p>
<p> </p>
<p><span>After spending months or even years learning basic science concepts, memorizing pathways, and mastering Step 1-style thinking, students often assume Step 2 will feel easier because it is “more clinical.” In some ways, that’s true. You’ve also likely had your clerkship exams for practice. But Step 2 also requires a major mindset shift that catches many students off guard.</span></p>
<p> </p>
<p><span>One of the biggest mistakes students make is approaching Step 2 with the exact same study strategies they used for Step 1. While there is certainly overlap between the exams, the way you think through questions changes significantly.</span></p>
<p> </p>
<h2><strong>Step 1 Rewards Memorization More Than Step 2</strong></h2>
<p><span>Step 1 often emphasizes foundational science knowledge and mechanistic thinking. Students spend enormous amounts of time memorizing details, pathways, pharmacology, and physiology. Even though critical reasoning matters on Step 1, there is still a strong emphasis on recalling specific facts quickly. I notice this difference a lot when I tutor my Step 1 vs. Step 2 students. On Step 1, test taking strategies are definitely helpful, but there are a lot of details that you either know…or don’t. </span></p>
<p> </p>
<h3><strong>Step 2 is different.</strong></h3>
<p><span>Clinical questions are often less about identifying a disease and more about determining what to do next. Two answer choices may both technically describe the same diagnosis, but the real challenge becomes choosing the best management step, interpreting risk factors, prioritizing interventions, or understanding hospital workflow. There is a tremendous amount of logic and test taking strategy that can be used to your advantage. </span></p>
<p> </p>
<p><span>Many students transitioning to Step 2 continue studying as if brute-force memorization alone will carry them through. They spend too much time rereading notes or trying to memorize every guideline detail instead of practicing logical clinical reasoning.</span></p>
<p> </p>
<p><span>The students who improve the fastest on Step 2 are usually the ones who learn how to think like clinicians rather than just test takers.</span></p>
<p> </p>
<h2><strong>Overvaluing Content Review and Undervaluing Questions</strong></h2>
<p><span>Another major mistake is spending too much time on passive review early in Step 2 prep.</span></p>
<p> </p>
<p><span>After Step 1, students are often used to long content review phases involving textbooks, sketch resources, flashcards, and detailed memorization. But <a href="https://elitemedicalprep.com/how-to-use-uworld-for-step-2-ck-a-practical-study-strategy/">Step 2 learning tends to happen much more effectively through questions.</a></span></p>
<p> </p>
<p><span>This is partly because clinical reasoning is difficult to learn passively. You need repeated exposure to patient presentations, management algorithms, diagnostic patterns, and decision-making frameworks. Questions teach you how diseases actually appear in real clinical scenarios rather than in perfectly organized textbook chapters.</span></p>
<p> </p>
<p><span>Students often delay question-heavy studying because they feel “not ready yet.” But unlike Step 1, where content gaps can feel very obvious, Step 2 improvement often comes from learning how questions are framed and how clinicians prioritize information. My </span><i><span>biggest</span></i><span> piece of advice is to keep up with practice questions and anki cards for </span><b><i>all</i></b><span> specialties throughout your clerkship year. Don’t be done studying for one specialty after that clerkship is over because it’s difficult to retain that information by the time Step 2 rolls around. </span></p>
<p> </p>
<p><span>Many students are surprised by how much their scores improve once they stop obsessing over memorizing and start focusing more heavily on application, especially when they have kept up their knowledge for each specialty throughout clerkship year.</span></p>
<p> </p>
<h2><strong>Forgetting That Third Year Is Already Step 2 Preparation</strong></h2>
<p><span>As I alluded to previously, one of the most important mindset shifts students miss is realizing that clerkships themselves are Step 2 studying.</span></p>
<p> </p>
<p><span>Students sometimes separate “rotation studying” from “Step 2 studying” when, realistically, they are one in the same. Shelf exams, patient encounters, oral presentations, and daily clinical exposure all build the foundation for Step 2 success. In fact, the clerkship questions literally are Step 2 questions about that specialty that could come up on the exam.</span></p>
<p> </p>
<p><span>The students who tend to struggle most are often those who treat third year as something to simply survive before worrying about Step 2 later.</span></p>
<p> </p>
<p><span>In reality, <a href="https://elitemedicalprep.com/us-residency-matching-for-imgs-2/">consistent shelf preparation throughout the year</a> makes Step 2 dedicated far less stressful. Students who build strong clinical reasoning gradually during rotations often require much less cramming later.</span></p>
<p> </p>
<h2><strong>Comparing Your Dedicated Period to Everyone Else’s</strong></h2>
<p><span>One issue students rarely anticipate is <a href="https://elitemedicalprep.com/how-long-should-you-study-for-step-2/">how variable Step 2 dedicated time can be</a>.</span></p>
<p> </p>
<p><span>Unlike Step 1, where many schools historically built in 4-6 week long dedicated periods, Step 2 timing often depends heavily on fourth-year scheduling, away rotations, residency application timelines, and specialty-specific demands.</span></p>
<p> </p>
<p><span>Some students may get six weeks of dedicated study time. Others may only have two or three. Students pursuing competitive specialties may need to schedule away rotations early, limiting flexibility even further. Some students are balancing sub-internships, research, residency applications, or travel during the same period they are trying to prepare for Step 2.</span></p>
<p> </p>
<h3><strong>This creates a major problem: comparison.</strong></h3>
<p><span>Students often panic when they hear classmates discussing eight-week study plans while they only have a short dedicated window. But Step 2 preparation is much more cumulative than many students realize. Your third-year foundation matters enormously.</span></p>
<p> </p>
<p><span>A shorter dedicated period does not automatically mean lower performance if you built strong habits throughout clinical rotations. Whatever your study timeline looks like, prepare accordingly so that your schedule demands are realistic for what you need to accomplish. </span></p>
<p> </p>
<h2><strong>Waiting Too Long to Take NBMEs Seriously</strong></h2>
<p><span>Another common mistake is delaying self-assessment exams because students feel anxious about scores. </span><span>Many students avoid NBMEs early because they worry about underperforming. Others save practice exams until very late in dedicated, leaving little time to <a href="https://elitemedicalprep.com/guide-to-interpreting-nbme-practice-exams-for-usmle/">identify weaknesses properly</a>.</span></p>
<p> </p>
<p><span>But practice exams are one of the most valuable tools for understanding how you are thinking clinically. They often reveal timing problems, management gaps, and reasoning issues that question banks alone may not fully expose.</span></p>
<p> </p>
<p><span>My recommendation is to take one of the NBME self assessments about 4-6 weeks out from your Step 2 test date to establish a baseline and then take 1 self assessment weekly to evaluate your progress. </span></p>
<p> </p>
<h2><strong>The Step 1 Flavor to Step 2 Questions</strong></h2>
<p><span>One subtle but important mistake is underestimating the value of a solid pre-clinical foundation. </span><span>Step 2 rewards prioritization and efficiency much more heavily than Step 1, but you may notice that many Step 2 questions have a Step 1 flavor to them. For example, you may see a gram stain pop up that you never thought you’d see again after Step 1 was over! </span></p>
<p> </p>
<p><span>Students who have a solid pre-clinical foundation and performed well on Step 1 often do very well on Step 2. So, it is important to carry those strong study habits and spaced repetition forward into your clinical year. </span></p>
<p> </p>
<h3><strong>Ignoring Fatigue and Burnout</strong></h3>
<p><span>By the time students begin Step 2 prep, many are already exhausted.</span></p>
<p> </p>
<p><span>Third year can be emotionally and physically draining. Students are <a href="https://elitemedicalprep.com/time-saving-tips-for-studying-for-your-shelf-exam-during-clinical-rotations/">balancing shelf exams, long clinical hours</a>, evaluations, residency planning, and constant transitions between rotations. You’re basically working a full-time job and studying full-time as well. Unlike Step 1 studying, which often occurs during preclinical years, Step 2 preparation happens while many students are already running low on energy.</span></p>
<p> </p>
<p><span>One mistake students make is underestimating burnout. Some assume they should be able to study with the same intensity they used during Step 1 dedicated. But the reality is that Step 2 preparation often requires more balance and sustainability.</span></p>
<p> </p>
<p><span>Students who maintain realistic expectations and flexible schedules often perform better than those trying to force extreme study hours while mentally depleted.</span></p>
<p> </p>
<h2><strong>Resource Overload Happens Again</strong></h2>
<p><span>Just like Step 1, students frequently fall into the trap of using too many resources. </span><span>One classmate recommends one question bank. Another swears by a specific podcast. Someone else says a certain Anki deck is essential. Suddenly students are juggling UWorld, AMBOSS, CMS forms, podcasts, flashcards, videos, and review books simultaneously.</span></p>
<p> </p>
<p><span>Most students eventually realize that <a href="https://elitemedicalprep.com/best-resources-for-step-2-exam/">mastering a few core resources</a> is much more effective than spreading themselves thin across everything available.</span></p>
<p> </p>
<p><span>For many students, high-quality questions and careful review of targeted content gaps become the true backbone of Step 2 preparation. And don’t be afraid to switch up your routine if you find that it’s not yielding the results you are aiming for. </span></p>
<p> </p>
<h2><strong>The Bottom Line</strong></h2>
<p><span>The transition from Step 1 to Step 2 is not just about learning new material, it is about learning a new way to think.</span></p>
<p> </p>
<p><span>Students who continue relying entirely on memorization-based strategies often feel frustrated when their scores plateau despite long study hours. Meanwhile, students who embrace clinical reasoning, question-based learning, and gradual skill-building often improve much more efficiently.</span></p>
<p> </p>
<p><span>It is also important to remember that Step 2 preparation looks different for everyone. Some students have longer dedicated periods, while others are balancing away rotations, research months/years, and residency applications simultaneously. Comparing timelines rarely helps.</span></p>
<p> </p>
<p><span>At the end of the day, Step 2 is less about becoming a perfect encyclopedia of medical facts and more about becoming a thoughtful clinical decision-maker. The earlier students recognize that mindset shift, the smoother the transition tends to be.</span></p>
<p><span></span></p>
<p>If you need support adapting your study approach, <a href="https://elitemedicalprep.com/usmle-step-2ck-tutoring/">EMP’s 1:1 Step 2 CK tutoring</a> can help you strengthen your clinical reasoning, address knowledge gaps, and build a study plan that fits your schedule.</p>
<p>The post <a href="https://elitemedicalprep.com/the-biggest-study-mistakes-students-make-when-transitioning-from-usmle-step-1-to-step-2/">The Biggest Study Mistakes Students Make When Transitioning from USMLE Step 1 to Step 2</a> appeared first on <a href="https://elitemedicalprep.com/">Elite Medical Prep</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Implanted sensor could detect worsening heart failure before symptoms appear</title>
<link>https://edusehat.com/en/implanted-sensor-could-detect-worsening-heart-failure-before-symptoms-appear</link>
<guid>https://edusehat.com/en/implanted-sensor-could-detect-worsening-heart-failure-before-symptoms-appear</guid>
<description><![CDATA[ A tiny implanted sensor being evaluated in an international clinical trial could give physicians an earlier warning that a patient’s heart failure is worsening — potentially before the patient realizes anything is wrong. BayCare’s Morton Plant Hospital in Florida recently became the first site to implant an investigational heart-failure monitoring system as part of the […]
The post Implanted sensor could detect worsening heart failure before symptoms appear appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/NORM-HF-Trial-Newsroom_10062026.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 09 Oct 2026 20:45:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Implanted, sensor, could, detect, worsening, heart, failure, before, symptoms, appear</media:keywords>
<content:encoded><![CDATA[<p>A tiny implanted sensor being evaluated in an international clinical trial could give physicians an earlier warning that a patient’s heart failure is worsening — potentially before the patient realizes anything is wrong.</p>
<p>BayCare’s Morton Plant Hospital in Florida recently became the first site to implant an investigational heart-failure monitoring system as part of the international <strong>FUTURE-HF2 clinical trial</strong>.</p>
<p>The technology is designed to continuously monitor changes associated with fluid buildup, one of the major problems experienced by people living with heart failure.</p>
<p>The miniature sensor is implanted in the inferior vena cava, the large vein responsible for returning blood from the lower body to the heart.</p>
<p>Once implanted, the device measures pressure inside the vein.</p>
<p>Patients can take readings from home, allowing information to be transmitted to their healthcare team without requiring a hospital or clinic visit.</p>
<h3>That could provide clinicians with an important early-warning system.</h3>
<p>When the heart cannot pump effectively, fluid can begin accumulating in the body. Patients may eventually experience shortness of breath, swelling, fatigue and rapid weight gain.</p>
<p>But physiological changes can begin before those symptoms become obvious.</p>
<p>By identifying increasing venous pressure earlier, physicians may be able to adjust medications or other treatment before a patient’s condition deteriorates enough to require hospitalization.</p>
<p>Reducing hospital admissions is particularly important in heart failure, where patients frequently experience repeated episodes of worsening disease.</p>
<h3>Implantable monitoring technologies are therefore becoming an increasingly important area of cardiovascular medicine.</h3>
<p>Rather than relying primarily on symptoms, weight changes and periodic clinical examinations, these systems can provide physicians with physiological information while patients go about their normal lives.</p>
<p>The investigational system being studied in FUTURE-HF2 could potentially extend that approach by using the inferior vena cava as a location for monitoring changes in cardiovascular pressure.</p>
<p>Researchers will evaluate the safety and effectiveness of the technology and whether information generated by the implant can help clinicians improve heart-failure management.</p>
<p>The device remains investigational, and its participation in a clinical trial does not mean it has received authorization for widespread clinical use.</p>
<p>If successful, however, technologies like this could contribute to a larger shift in chronic disease management — from responding to deterioration after symptoms appear to detecting physiological changes early enough to intervene.</p>
<p>The post <a href="https://www.hospitalnews.com/implanted-sensor-could-detect-worsening-heart-failure-before-symptoms-appear/">Implanted sensor could detect worsening heart failure before symptoms appear</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Canadian children’s hospitals expand AI&#45;powered rare disease detection as gene therapy research advances</title>
<link>https://edusehat.com/en/canadian-childrens-hospitals-expand-ai-powered-rare-disease-detection-as-gene-therapy-research-advances</link>
<guid>https://edusehat.com/en/canadian-childrens-hospitals-expand-ai-powered-rare-disease-detection-as-gene-therapy-research-advances</guid>
<description><![CDATA[ New funding will help Canadian children’s hospitals identify rare genetic disorders earlier while supporting an experimental gene therapy trial. Canadian researchers are advancing two initiatives aimed at improving the diagnosis and treatment of rare childhood diseases, supported by approximately $1.77 million in new funding from Canadian non-profit organization Conscience. The projects include expanding an artificial […]
The post Canadian children’s hospitals expand AI-powered rare disease detection as gene therapy research advances appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/ChatGPT-Image-Oct-8-2026-08_00_04-AM.png" length="49398" type="image/jpeg"/>
<pubDate>Fri, 09 Oct 2026 20:45:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Canadian, children’s, hospitals, expand, AI-powered, rare, disease, detection, gene, therapy, research, advances</media:keywords>
<content:encoded><![CDATA[<p>New funding will help Canadian children’s hospitals identify rare genetic disorders earlier while supporting an experimental gene therapy trial.</p>
<p>Canadian researchers are advancing two initiatives aimed at improving the diagnosis and treatment of rare childhood diseases, supported by approximately $1.77 million in new funding from Canadian non-profit organization Conscience.</p>
<p>The projects include expanding an artificial intelligence system developed at the CHEO Research Institute in Ottawa and advancing plans for a Canadian clinical trial of an experimental gene therapy for CLN7 Batten disease.</p>
<h3>AI helping diagnose rare diseases</h3>
<p>The ThinkRare system uses artificial intelligence to analyze electronic medical records and identify patterns that may indicate an undiagnosed genetic condition.</p>
<p>Rare diseases can be difficult to recognize because symptoms often resemble those of more common illnesses. As a result, children may undergo years of medical appointments and testing before receiving an accurate diagnosis.</p>
<p>According to Conscience, ThinkRare has already contributed to 23 rare-disease diagnoses at CHEO, with a reported diagnostic yield of approximately 70 per cent among patients referred for further assessment and testing.</p>
<p>In one case, the technology helped identify a rare condition in a patient who had attended 153 outpatient appointments over 17 years without receiving a diagnosis.</p>
<p>Conscience is providing $1 million to support the system’s expansion to additional pediatric institutions, including McMaster Children’s Hospital in Hamilton, Alberta Children’s Hospital in Calgary and Stollery Children’s Hospital in Edmonton.</p>
<p>The technology is designed to support physicians and genetic specialists by identifying patients who may benefit from further investigation.</p>
<h3>Advancing experimental gene therapy</h3>
<p>A second initiative will receive $768,823 to support efforts to bring a clinical trial for CLN7 Batten disease to Canada.</p>
<p>The rare inherited neurological disorder can cause progressive vision loss, seizures and deterioration of motor and cognitive abilities.</p>
<p>The project involves CureSPG50, The Hospital for Sick Children (SickKids) and Elpida Therapeutics.</p>
<p>Researchers are developing an experimental gene therapy designed to introduce a functional copy of the MFSD8 gene, which is affected in children with the disease.</p>
<p>An earlier Phase 1 study involving four patients provided preliminary safety information and early indications of possible benefit. The proposed Phase 1/2 trial would involve nine additional children.</p>
<p>The treatment remains experimental, and further research is required to establish its safety and effectiveness.</p>
<h3>Improving care for children with rare diseases</h3>
<p>Together, the initiatives highlight the growing role of artificial intelligence and genetic medicine in pediatric healthcare.</p>
<p>Earlier diagnosis could help reduce unnecessary testing, improve care coordination and provide families with answers sooner. Meanwhile, advances in gene therapy offer opportunities to investigate treatments for conditions with few existing options.</p>
<p>The projects also demonstrate the importance of collaboration among Canadian hospitals, researchers and non-profit organizations in addressing complex healthcare challenges.</p>
<p>The post <a href="https://www.hospitalnews.com/canadian-childrens-hospitals-expand-ai-powered-rare-disease-detection-as-gene-therapy-research-advances/">Canadian children’s hospitals expand AI-powered rare disease detection as gene therapy research advances</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Alberta hospital expansion to add more than 3,000 surgeries annually</title>
<link>https://edusehat.com/en/alberta-hospital-expansion-to-add-more-than-3000-surgeries-annually</link>
<guid>https://edusehat.com/en/alberta-hospital-expansion-to-add-more-than-3000-surgeries-annually</guid>
<description><![CDATA[ Alberta is investing $12.5 million to expand surgical services at Fort Saskatchewan Community Hospital, with renovations expected to increase the facility’s surgical capacity by nearly 50 per cent. The expansion, announced October 8, is projected to support more than 3,000 additional procedures annually once the upgraded facilities are fully operational. Construction is expected to begin […]
The post Alberta hospital expansion to add more than 3,000 surgeries annually appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/shutterstock_1543438424.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 09 Oct 2026 20:45:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Alberta, hospital, expansion, add, more, than, 3, 000, surgeries, annually</media:keywords>
<content:encoded><![CDATA[<p>Alberta is investing $12.5 million to expand surgical services at Fort Saskatchewan Community Hospital, with renovations expected to increase the facility’s surgical capacity by nearly 50 per cent.</p>
<p>The expansion, announced October 8, is projected to support more than 3,000 additional procedures annually once the upgraded facilities are fully operational.</p>
<p>Construction is expected to begin in the coming weeks, with completion anticipated by 2029. The hospital will continue providing surgical and other healthcare services throughout the renovation period, with construction scheduled in phases to minimize disruptions.</p>
<h3>Expanding surgical capacity</h3>
<p>The project will modernize several areas of the hospital to accommodate growing demand for surgical services in Fort Saskatchewan and surrounding communities northeast of Edmonton.</p>
<p>Planned improvements include expanded day surgery facilities, relocation of outpatient and intravenous therapy services, and upgrades to the hospital’s Medical Device Reprocessing Area.</p>
<p>Medical device reprocessing is an essential component of surgical operations, ensuring reusable instruments and equipment are properly cleaned, disinfected and sterilized before use.</p>
<p>The hospital currently provides ophthalmology, gynecology, general surgery and endoscopy procedures.</p>
<p>The expansion is intended to increase the number of patients who can receive surgical care closer to home while reducing pressure on other healthcare facilities in the region.</p>
<h3>Part of a broader surgical investment</h3>
<p>The Fort Saskatchewan project is being funded through the Alberta Surgical Initiative, a three-year, $284-million program focused on upgrading operating rooms, modernizing surgical infrastructure and purchasing equipment at hospitals across the province.</p>
<p>The initiative is intended to improve surgical access and make better use of existing hospital resources.</p>
<p>According to the provincial government, Alberta completed 332,847 surgeries during the previous fiscal year, exceeding its annual target and establishing a new provincial record.</p>
<p>The province has also committed $525 million toward delivering 50,000 additional publicly funded surgeries over three years.</p>
<h3>Meeting growing healthcare demand</h3>
<p>Fort Saskatchewan and neighbouring communities have experienced population growth, increasing demand for healthcare services.</p>
<p>By expanding surgical facilities within the existing hospital, the province aims to accommodate more procedures locally while supporting the healthcare needs of the growing region.</p>
<p>The project also illustrates the importance of investing in supporting hospital infrastructure, including instrument reprocessing and outpatient services, alongside operating room capacity.</p>
<p>Once complete, the upgrades are expected to provide additional surgical capacity and improve access to treatment for patients throughout the region. <a href="https://www.alberta.ca/announcements.cfm?xID=9792019212581-92CF-2198-DEC1ACC35BDE6B9A">Alberta.ca</a></p>
<p>The post <a href="https://www.hospitalnews.com/alberta-hospital-expansion-to-add-more-than-3000-surgeries-annually/">Alberta hospital expansion to add more than 3,000 surgeries annually</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Canada proposes major changes to medical assistance in dying legislation</title>
<link>https://edusehat.com/en/canada-proposes-major-changes-to-medical-assistance-in-dying-legislation</link>
<guid>https://edusehat.com/en/canada-proposes-major-changes-to-medical-assistance-in-dying-legislation</guid>
<description><![CDATA[ Federal government plans to permanently exclude mental illness as a sole qualifying condition while introducing a framework for advance requests. The federal government has announced plans to introduce significant changes to Canada’s medical assistance in dying (MAID) legislation, addressing two of the most debated aspects of the country’s assisted-dying framework: eligibility for people with mental […]
The post Canada proposes major changes to medical assistance in dying legislation appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/ChatGPT-Image-Oct-8-2026-10_39_09-AM.png" length="49398" type="image/jpeg"/>
<pubDate>Fri, 09 Oct 2026 20:45:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Canada, proposes, major, changes, medical, assistance, dying, legislation</media:keywords>
<content:encoded><![CDATA[<p>Federal government plans to permanently exclude mental illness as a sole qualifying condition while introducing a framework for advance requests.</p>
<p>The federal government has announced plans to introduce significant changes to Canada’s medical assistance in dying (MAID) legislation, addressing two of the most debated aspects of the country’s assisted-dying framework: eligibility for people with mental illness and advance requests for individuals who may lose the capacity to provide consent.</p>
<p>The proposed changes, announced October 7, 2026, would indefinitely maintain the exclusion of people whose sole underlying medical condition is a mental illness. The government also intends to introduce legislation addressing advance requests for MAID.</p>
<h3>Mental illness exclusion</h3>
<p>Under current federal legislation, individuals whose only underlying medical condition is a mental illness are temporarily excluded from eligibility for MAID until March 17, 2027.</p>
<p>The federal government now proposes making that exclusion indefinite, rather than allowing eligibility to expand when the existing deadline expires.</p>
<p>The issue has generated considerable discussion among healthcare professionals, mental health advocates, policymakers and disability rights organizations.</p>
<p>Supporters of maintaining the exclusion have raised concerns about assessing whether psychiatric conditions are irremediable, protecting vulnerable patients and ensuring adequate access to mental healthcare.</p>
<p>Others argue that excluding mental illness as a sole qualifying condition raises questions about equitable access to MAID for people experiencing severe and persistent psychiatric disorders.</p>
<h3>Advance requests for MAID</h3>
<p>The government is also proposing a legislative framework that would address advance requests for medical assistance in dying.</p>
<p>Advance requests would allow eligible individuals diagnosed with certain serious, incurable conditions to document their wishes while they retain decision-making capacity, in anticipation of potentially losing that capacity as their illness progresses.</p>
<p>The issue is particularly relevant for people diagnosed with neurodegenerative conditions, including Alzheimer’s disease and other forms of dementia.</p>
<p>Under the proposed approach, provinces and territories would have a role in determining whether advance requests are available within their healthcare systems.</p>
<p>Quebec has already established a framework permitting certain advance requests for MAID.</p>
<h3>Implications for Canadian healthcare providers</h3>
<p>The proposed changes could have important implications for hospitals, physicians, nurse practitioners and healthcare organizations responsible for assessing and delivering MAID services.</p>
<p>Healthcare providers would need to understand any new eligibility requirements, consent procedures and documentation obligations arising from future legislation.</p>
<p>Advance requests could also introduce additional clinical and ethical considerations involving patient autonomy, capacity assessments and the interpretation of previously expressed wishes.</p>
<p>The federal government is expected to introduce legislation later this fall.</p>
<p>The proposed changes have not yet become law. Existing federal MAID eligibility requirements and safeguards remain in effect.</p>
<p>The post <a href="https://www.hospitalnews.com/canada-proposes-major-changes-to-medical-assistance-in-dying-legislation/">Canada proposes major changes to medical assistance in dying legislation</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>We’re still figuring out the side effects of GLP&#45;1 weight&#45;loss drugs</title>
<link>https://edusehat.com/en/were-still-figuring-out-the-side-effects-of-glp-1-weight-loss-drugs</link>
<guid>https://edusehat.com/en/were-still-figuring-out-the-side-effects-of-glp-1-weight-loss-drugs</guid>
<description><![CDATA[ This week my colleague Antonio Regalado had an interesting update on GLP-1 weight-loss drugs. According to research presented at an aging meeting in Boston, these drugs seem to affect at least some measures of biological age. Overweight and diabetic people who take GLP-1s have a biological age around two to three years younger than similar… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/10/GettyImages-2292410673.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 09 Oct 2026 17:20:02 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>We’re, still, figuring, out, the, side, effects, GLP-1, weight-loss, drugs</media:keywords>
<content:encoded><![CDATA[<div data-chronoton-summary="<ul><br><li><strong>GLP-1 drugs may slow biological aging:</strong> New research from Eli Lilly and Novo Nordisk suggests overweight and diabetic people on GLP-1s have a biological age two to three years younger than those on a placebo.</li><br><li><strong>Side effects range from mundane to alarming:</strong> Beyond common gastrointestinal issues, the drugs have been linked to pancreatitis, gallstones, and dozens of lawsuits alleging sudden vision loss—though both companies dispute the claims.</li><br><li><strong>Hair and nails may also be affected:</strong> A large study found increased hair loss among GLP-1 users, and a smaller study found 66% reported nail disorders—though researchers stop short of saying the drugs are to blame.</li><br><li><strong>Children are a growing concern:</strong> GLP-1 prescriptions for kids aged eight to eleven rose 310-fold between 2019 and 2026, yet the World Health Organization explicitly advises against drug treatment for children under 10, citing a lack of safety evidence.</li><br></ul>" data-chronoton-post-id="1146094" data-chronoton-expand-collapse="1" data-chronoton-analytics-enabled="1"></div>


<p>This week my colleague Antonio Regalado had an interesting update on GLP-1 weight-loss drugs. According to research presented at an aging meeting in Boston, these drugs seem to affect at least some measures of <a href="https://www.technologyreview.com/2026/10/02/1145610/younger-contest-race-to-biological-youth/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=*%7Cdate:m-d-y%7C*">biological age</a>.</p>



<p>Overweight and diabetic people who take GLP-1s <a href="https://www.technologyreview.com/2026/10/06/1145836/weight-loss-drugs-glp1-lilly-novo-aging-clocks/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=*%7Cdate:m-d-y%7C*">have a biological age around two to three years younger</a> than similar individuals who take a placebo, according to findings from Eli Lilly and Novo Nordisk, two pharmaceutical companies that make the drugs.</p>



<p>I’ve heard people in the aging field describe GLP-1s as longevity drugs for a while now (even if they only benefit people who are overweight or diabetic in the first place). This latest announcement comes after we’ve seen a raft of other benefits associated with taking these drugs. But there are also some weird side effects.</p>



<p>So far, GLP-1 agonist drugs—which repress hunger—have been approved for treating diabetes, chronic kidney disease, and obesity, and they can also be prescribed for some people who are overweight or at risk of certain cardiovascular diseases. But there is research to suggest they might also help people with substance-use disorders, and they’ve been investigated for potential benefits <a href="https://www.technologyreview.com/2025/11/28/1128511/what-we-still-dont-know-about-weight-loss-drugs/">in neurodegenerative disease and cancer</a>.</p>



<p>And a <em>lot</em> of people are taking them. According to <a href="https://news.gallup.com/poll/712157/glp-usage-reaches-new-high.aspx">a recent Gallup poll</a>, 11% of Americans are taking a GLP-1 drug for weight loss, up from 3% in 2024. And 15% of Americans say they’ve used one for weight loss at some point.</p>



<p>They can be incredibly effective. But, like any drug, they can come with side effects. And we’re still figuring out exactly what those might be, and how widespread they are.</p>



<p>The most common side effects are gastrointestinal—nausea, vomiting, diarrhea, and constipation. The drugs have also been linked to <a href="https://www.gov.uk/drug-safety-update/glp-1-receptor-agonists-reminder-of-the-potential-side-effects-and-to-be-aware-of-the-potential-for-misuse">pancreatitis and gallstone disease</a>. </p>



<p>Some claim that, in rare cases, the drugs might cause damage to nerves behind the eye. Dozens of people are <a href="https://www.wsj.com/health/pharma/patients-sue-glp-1-drugmakers-over-risk-of-sudden-vision-loss-f60d7acb">suing Novo and Eli Lilly after developing a condition that can lead to sudden vision loss</a>. They’re claiming that their symptoms were brought on by the GLP-1 drugs that these companies manufacture. Both companies dispute the claims. Research into the link is mixed.</p>



<p>We’re still getting to grips with the effects of weight-loss drugs on hair and nails, too. When Savanna Vidal at the George Washington University School of Medicine and Health Sciences in Washington, DC, and colleagues assessed electronic health data from 67 US health-care organizations, they found that <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12997224/">GLP-1 use was associated with an increased risk of hair loss</a>. It’s still not thought to be common, however.</p>



<p>And at a conference in Austria last week, another group presented <a href="https://eadv.org/wp-content/uploads/2026/09/EADV_2026_Bruno_GLP1_Press_Release_01_10.pdf">the results of a smaller study</a> suggesting that 66% of GLP-1 users reported at least one nail disorder—in some cases involving nail detachment. Nail conditions were also fairly common among people who didn’t take the drugs, though. The authors don’t claim that the drugs are causing nails to fall out (as I’m sure 11% of the American population will be relieved to hear).</p>



<p>The side effects might look different in children, but there’s not much data on those at the moment. Still, pediatric side effects will be something to watch given that, between 2019 and 2026, there was <a href="https://nyulangone.org/news/glp-1-use-among-young-children-obesity-us-remains-rare-rising-rapidly">a 310-fold increase in GLP-1 prescriptions for eight- to 11-year-old children</a> with obesity in the US. Child prescriptions are still rare, but they’ve been rising.</p>



<p>On Wednesday, the World Health Organization released <a href="https://www.who.int/news/item/07-10-2026-who-issues-first-global-guidelines-on-child-and-adolescent-obesity">its first guidelines on managing obesity in children and adolescents</a>. Despite the scale of the issue—the WHO estimates that 70 million children aged five to nine were living with obesity in 2024—the organization explicitly says it does <em>not</em> recommend pharmacological treatment for kids under 10.</p>



<p>“This recommendation accounts for the lack of evidence on both benefits and the potential adverse events and consequences of the different medications and/or their active ingredients on normal growth, development, physiological parameters, and mental health,” the <a href="https://iris.who.int/server/api/core/bitstreams/be4ad6b0-4a33-488c-a062-b9a57d068c2d/content">guidelines</a> state.</p>



<p>I get press releases about GLP-1s on an almost daily basis. There’s been a ton of research into these drugs, and there are probably hundreds of other studies underway. There will likely be plenty more on this from The Checkup as the evidence evolves.</p>



<p><em>This article first appeared in The Checkup, </em>MIT Technology Review’s<em> weekly biotech newsletter. To receive it in your inbox every Thursday, and read articles like this first, </em><a href="https://forms.technologyreview.com/newsletters/biotech-the-checkup/?_ga=2.241810882.15113993.1664981064-43237434.1647441349"><em>sign up here</em></a>.</p>]]> </content:encoded>
</item>

<item>
<title>How Preclinical Manufacturing Can De&#45;Risk the Path to GMP&#45;Ready Viral Vector Programs</title>
<link>https://edusehat.com/en/how-preclinical-manufacturing-can-de-risk-the-path-to-gmp-ready-viral-vector-programs</link>
<guid>https://edusehat.com/en/how-preclinical-manufacturing-can-de-risk-the-path-to-gmp-ready-viral-vector-programs</guid>
<description><![CDATA[ In this GEN webinar, Chris Nieder, an expert in viral vector programs, will examine how strategically designed preclinical manufacturing campaigns provide a practical foundation for GMP production. 
The post How Preclinical Manufacturing Can De-Risk the Path to GMP-Ready Viral Vector Programs appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Getty_2282040515_AAV-e1791478774265.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 09 Oct 2026 10:05:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>How, Preclinical, Manufacturing, Can, De-Risk, the, Path, GMP-Ready, Viral, Vector, Programs</media:keywords>
<content:encoded><![CDATA[<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"></div>
</div>


<p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Register Now</button></p>

<h3 class="w-full text-left">
    <strong>
        Panelists:
    </strong>
</h3>
<div class="flex flex-row m-0-auto items-stretch justify-center flex-wrap mb-4">
    
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/10/7_27_21_DL-13_ChrisNieder-scaled-e1791478062758.jpg" class="h-full w-full object-cover" alt="Image of Chris Nieder">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Chris Nieder</h2>
                <h5 class="mt-0 !text-[15px] !leading-[21px]">Senior Director and Head of Technical Development<br>SK pharmteco</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/10/7_27_21_DL-13_ChrisNieder-scaled-e1791478062758.jpg" alt="Image of Chris Nieder">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Chris Nieder</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Christopher Nieder is senior director and head of technical development at SK pharmteco, where he has spent more than five years supporting the development and scale-up of advanced therapies. He leads Technical Development across upstream, downstream, drug product, and analytical development and has supported a broad range of AAV, LVV, adenovirus, and HSV vector programs. Chris brings almost 20 years of industry experience spanning process development, scale-up, tech transfer, and GMP manufacturing.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog></div>



<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-malblocks-webinars-info"></p><div><strong>Broadcast Date:</strong> <time>Tuesday, November 17, 2026</time><br><ul><li><strong>Time:</strong> <time datetime="2026-11-17T16:00:00.000Z">08:00 PST, 11:00 EST, 16:00 GMT</time></li></ul></div>


<div aria-hidden="true" class="wp-block-spacer"></div>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow">
<p class="wp-block-paragraph">To move viral vector programs from early research toward the clinic, sponsors have to generate the right material and data during development. Non-GMP production of adeno-associated virus (AAV), lentiviral, and adenoviral vectors can support applications ranging from R&D and animal studies to assay development, toxicology planning, and early manufacturability assessments. But to be successful, sponsors have to align production scale, analytical testing, documentation, and material use with the specific questions their studies aim to answer.</p>


<p class="wp-block-paragraph">In this <em>GEN</em> webinar, Chris Nieder, an expert in viral vector programs, will examine how strategically designed preclinical manufacturing campaigns provide a practical foundation for GMP production. He will discuss topics such as how to select from among shake flasks, development-scale bioreactors, and pilot-scale approaches; and how to use early process and analytical data to identify yield and scalability challenges. Attendees will also learn how early CDMO engagement can clarify manufacturing scope, timelines, costs, and GMP-readiness without compromising expectations for non-GMP material. Key takeaways from the webinar include:</p>


<ul class="wp-block-list">
<li>How early-stage sponsors can use non-GMP AAV, lentiviral, and adenoviral production to support R&D, animal studies, toxicology planning, assay development, and manufacturability assessment</li>


<li>How process and analytical data generated before GMP can reduce duplicated prep work, lower technical risk, and streamline later scope definition</li>


<li>When shake flasks, development-scale bioreactors, or pilot-scale production can provide the most useful insight for the next development step</li>


<li>How to align material use, analytical testing, documentation, and expectations without over-positioning preclinical material as clinical-grade supply</li>
</ul>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><em>A live Q&A session will follow the presentation offering you a chance to pose questions to our expert panelist.</em></p>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><strong>Produced with support from:</strong></p>


<figure class="wp-block-image alignleft size-medium"><a href="https://www.skpharmteco.com/" target="_blank" rel=" noopener"><img decoding="async" width="300" height="106" src="https://www.genengnews.com/wp-content/uploads/2026/04/skpharmteco_logo-300x106.jpg" alt="skpharmteco logo" class="wp-image-331275" srcset="https://www.genengnews.com/wp-content/uploads/2026/04/skpharmteco_logo-300x106.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/04/skpharmteco_logo-1024x361.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/04/skpharmteco_logo-768x270.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/04/skpharmteco_logo-1193x420.jpg 1193w, https://www.genengnews.com/wp-content/uploads/2026/04/skpharmteco_logo-696x245.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/04/skpharmteco_logo-1392x493.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2026/04/skpharmteco_logo-1068x376.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/04/skpharmteco_logo.jpg 1400w" sizes="(max-width: 300px) 100vw, 300px"></a></figure>
</div>
</div>

<p>The post <a href="https://www.genengnews.com/multimedia/webinars/how-preclinical-manufacturing-can-de-risk-the-path-to-gmp-ready-viral-vector-programs/">How Preclinical Manufacturing Can De-Risk the Path to GMP-Ready Viral Vector Programs</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>From Discovery to Development</title>
<link>https://edusehat.com/en/from-discovery-to-development</link>
<guid>https://edusehat.com/en/from-discovery-to-development</guid>
<description><![CDATA[ The articles in this eBook examine key trends driving this transformation, from AI-enabled discovery and experimental validation to advanced cell, gene, and biologic platforms, and explore how the next generation of therapies will move from concept to clinic.
The post From Discovery to Development appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/iStock_2282725115_AntibodiesAndVirus.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 09 Oct 2026 10:05:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>From, Discovery, Development</media:keywords>
<content:encoded><![CDATA[<p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Read Now</button></p>


<h4 class="wp-block-heading"><strong>The Era of Modality Convergence: Why Drug Development Is Being Rewritten</strong></h4>


<figure class="wp-block-image alignright is-resized"><img decoding="async" width="232" height="300" src="https://www.genengnews.com/wp-content/uploads/2026/10/GEN_ProBio_cover-232x300.jpg" alt="From Discovery to Development: Navigating the New Era of Therapeutic Innovation eBook cover" class="wp-image-339116" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/GEN_ProBio_cover-232x300.jpg 232w, https://www.genengnews.com/wp-content/uploads/2026/10/GEN_ProBio_cover-791x1024.jpg 791w, https://www.genengnews.com/wp-content/uploads/2026/10/GEN_ProBio_cover-768x994.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/GEN_ProBio_cover-1187x1536.jpg 1187w, https://www.genengnews.com/wp-content/uploads/2026/10/GEN_ProBio_cover.jpg 1200w" sizes="(max-width: 232px) 100vw, 232px"></figure>


<p class="wp-block-paragraph">The life sciences industry is entering a new era, defined not by a single breakthrough technology but by the convergence of many. Artificial intelligence is accelerating drug discovery, cell and gene therapies are expanding treatment possibilities, and antibody engineering continues to evolve beyond traditional monoclonal antibodies. Meanwhile, mRNA platforms, viral vectors, antibody-drug conjugates (ADCs), multispecific antibodies, and other advanced therapeutic modalities are transforming how developers approach previously intractable diseases. Taken individually, each of these innovations represents a significant advancement. Together, they are reshaping the drug development landscape.</p>


<p class="wp-block-paragraph">For decades, therapeutic development followed a familiar path: identify a target, optimize a lead candidate, advance through preclinical studies, and move into clinical evaluation. While the science was challenging, the overall framework remained relatively consistent. Today, that framework is evolving rapidly. Developers are no longer limited to choosing between small molecules and conventional biologics. Instead, they have access to a growing toolkit of therapeutic technologies, each with unique advantages, manufacturing requirements, analytical challenges, and regulatory considerations. At the same time, advances in computational biology and AI-driven discovery are generating more candidates than ever before.</p>


<p class="wp-block-paragraph">As a result, the challenge is no longer simply finding promising molecules. Increasingly, success depends on identifying candidates that can be manufactured, scaled, and translated into viable therapies. Decisions once reserved for later stages, including developability, manufacturability, analytical characterization, and clinical strategy, must now be addressed much earlier in the process. Drug development is becoming a continuous, interconnected journey rather than a series of separate steps.</p>


<p class="wp-block-paragraph">The boundaries between traditional disciplines are also beginning to blur. Cell therapies may incorporate viral vectors. Gene therapies may leverage lipid nanoparticles. Antibody programs may evolve into multispecific or conjugated formats. The future of drug development is not defined by any single modality, but by the ability to integrate technologies effectively.</p>


<p class="wp-block-paragraph">Organizations that combine discovery expertise, modality-specific knowledge, CMC capabilities, and manufacturing execution will be best positioned to navigate this increasingly complex environment. The articles that follow examine key trends driving this transformation, from AI-enabled discovery and experimental validation to advanced cell, gene, and biologic platforms, and explore how the next generation of therapies will move from concept to clinic.</p>

<p>The post <a href="https://www.genengnews.com/resources/ebooks/from-discovery-to-development/">From Discovery to Development</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>DNA Typewriter, PEtracer Map Mouse Development Through Organogenesis</title>
<link>https://edusehat.com/en/dna-typewriter-petracer-map-mouse-development-through-organogenesis</link>
<guid>https://edusehat.com/en/dna-typewriter-petracer-map-mouse-development-through-organogenesis</guid>
<description><![CDATA[ Two DNA-recording systems traced cellular family trees across mouse embryogenesis, offering new insight into how organs form and when developing cells commit to specific fates.
The post DNA Typewriter, PEtracer Map Mouse Development Through Organogenesis appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GettyImages-523740840.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 09 Oct 2026 10:05:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>DNA, Typewriter, PEtracer, Map, Mouse, Development, Through, Organogenesis</media:keywords>
<content:encoded><![CDATA[<p>Researchers have used two DNA-recording systems to reconstruct cellular family trees across mouse embryonic development. The companion studies—“<a href="https://www.science.org/doi/10.1126/science.ael0508" target="_blank" rel="noopener">A DNA typewriter records the cell lineage history of a mouse, from zygote to late organogenesis</a>,” published in <em>Science</em>, and “<a href="https://www.cell.com/cell/fulltext/S0092-8674(26)01196-7?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867426011967%3Fshowall%3Dtrue" target="_blank" rel="noopener">Comprehensive lineage tracing maps the landscape of cell fate decisions in mouse embryogenesis</a>,” published in <em>Cell</em>—offer high-resolution views of mammalian development, which has been difficult to track because embryos develop inside the uterus and cannot be continuously observed.</p>
<p>The team from the <em>Science </em>study was led by co-senior authors Jay Shendure, PhD, professor of genome sciences at the University of Washington School of Medicine and a Howard Hughes Medical Institute investigator, and Chengxiang Qiu, PhD, a molecular and systems biologist at Dartmouth College. Their approach centered on DNA Typewriter, a lineage-tracing technology developed by Shendure and Junhong Choi, PhD, that uses a cell’s DNA as a recording medium.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>The researchers redesigned the system’s recording “tape” to make its history easier to recover from individual cells, then inserted it into the genome of a fertilized mouse egg. As cells divided, “a burst of editing unequivocally marks the daughters of the first cleavage, which serve as inline replicates,” the authors wrote in the <em>Science </em>paper. Because daughter cells inherited the marks already written before acquiring new ones, shared patterns revealed common ancestry and the order of developmental branching.</p>
<figure aria-describedby="caption-attachment-339110" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="size-medium wp-image-339110" src="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_DNA-Typewriter-Genome-Sciences-FigS1_injection-3-300x199.jpg" alt="DNA Typewriter is injected into the genetic material of a fertilized mouse egg. This technology taps into the genetic material in the fertilized egg and resulting embryonic cells as a recording device of the cells' histories. It tracks their relationships as the embryo develops." width="300" height="199" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_DNA-Typewriter-Genome-Sciences-FigS1_injection-3-300x199.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_DNA-Typewriter-Genome-Sciences-FigS1_injection-3.jpg 700w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">DNA Typewriter is injected into the genetic material of a fertilized mouse egg. This technology taps into the genetic material in the fertilized egg and resulting embryonic cells as a recording device of the cells’ histories. It tracks their relationships as the embryo develops. [Kyle O’Conner/Seattle Hub for Synthetic Biology]</figcaption></figure>
<p>“Most biological measurements are based on either live imaging, which is limited by the fact that most animal tissues are not transparent, or genomics, which are destructive and only measure a single timepoint,” Shendure said. “Recording techniques like the ones in these studies enable measurements over time including in settings that we can’t directly visualize.”</p>
<p>The experiment was attempted in 100 fertilized eggs and yielded 10 embryos for examination. One embryo carried the most informative record, allowing the team to trace nearly every profiled cell back to one of the first two cells formed after the fertilized egg divided. Although one founding cell produced more descendants, the two branches generated diverse cell types in nearly equal proportions.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>The ordered recording also allowed the researchers to estimate when cell types diverged from shared developmental paths. Blood and retinal cells committed relatively early, whereas cells forming the skin’s outer layer committed later. The results indicate that cell identity is not fixed in a single coordinated step; instead, different lineages become restricted on distinct schedules.</p>
<p>Earlier lineage-tracing approaches often relied on DNA-cutting enzymes that could damage cells, erase previous records, exhaust recording capacity, or leave unordered marks whose chronology had to be inferred. “DNA Typewriter avoids all of this,” said co-first author Haedong Kim, PhD, a postdoctoral scientist in genome sciences at UW Medicine. “It writes without fully severing the DNA, keeps recording relatively steadily, and writes everything in strict order, so we can record cell lineages at much higher resolution for a longer time.”</p>
<p>In the <em>Cell</em> paper, Jonathan Weissman, PhD, and colleagues used a prime-editing system called PEtracer to map lineage dynamics across more than 1.4 million cells from 16 mouse embryos. Together with the DNA Typewriter study in <em>Science</em>, the work demonstrates that mammalian cellular family trees can be reconstructed at unprecedented scale. “It’s really proof of principle that we can do what was done with the roundworm in 1983, but for mammals like you and me,” Weissman said.</p>
<p>The work provides a framework for investigating how normal organs form and where development can go awry. More complete lineage records could help researchers study congenital malformations, neurodevelopmental and genetic disorders, and cancer, as well as guide stem cell engineering. As Shendure explained, “Recording techniques like the ones in these studies enable measurements over time including in settings that we can’t directly visualize.” Scaling the methods across additional embryos and experimental conditions could support more quantitative—and eventually predictive—models of mammalian development.</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/dna-typewriter-petracer-map-mouse-development-through-organogenesis/">DNA Typewriter, PEtracer Map Mouse Development Through Organogenesis</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The State of AI in Drug Discovery</title>
<link>https://edusehat.com/en/the-state-of-ai-in-drug-discovery</link>
<guid>https://edusehat.com/en/the-state-of-ai-in-drug-discovery</guid>
<description><![CDATA[ GEN’s virtual summit returns on November 4 to examine how AI is reshaping R&amp;D timelines and real-world patient translation. From big pharma to AI-natives, this year’s program features the leaders of many of today’s outstanding companies and organizations powering the AI revolution!
The post The State of AI in Drug Discovery appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Getty_2242544252_DigitalDNAPill.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 09 Oct 2026 02:50:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, State, Drug, Discovery</media:keywords>
<content:encoded><![CDATA[<h3 class="w-full text-left">
    <strong>
        Panelists:
    </strong>
</h3>
<div class="flex flex-row m-0-auto items-stretch justify-center flex-wrap mb-4">
    
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/10/AlizaApple_headshot.jpg" class="h-full w-full object-cover" alt="Image of Aliza Apple, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Aliza Apple, PhD</h2>
                <h5 class="mt-0 !text-[15px] !leading-[21px]">Vice President<br>Catalyze360 AI/ML, Eli Lilly</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/10/AlizaApple_headshot.jpg" alt="Image of Aliza Apple, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Aliza Apple, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Aliza Apple, PhD, is a vice president of Catalyze360 AI/ML at Eli Lilly, where she leads the strategy, build and launch of Lilly’s external-facing AI/ML efforts for drug discovery. She previously served as the COO and head of Lilly Gateway Labs West Coast, where she supported the local biotech ecosystem through early engagement and providing tailored offerings to meet their needs. Prior to Lilly, Aliza served as a co-founder at Santa Ana Bio, a venture-backed precision biologics company focused on autoimmune disease, and as an advisor to the founders of Firefly Biologics. Prior to biotech, Aliza was a partner in McKinsey’s life sciences practice. During her nine years at McKinsey in New York and San Francisco, she collaborated with leaders from more than 20 biopharma companies to develop their corporate and portfolio strategies, evaluate business development opportunities, and improve their organizational effectiveness.</p>
<p>Aliza completed her PhD in bioengineering at UC Berkeley and UCSF and holds a BS in physics from Georgetown University. She completed a postdoctoral fellowship at Cornell Medical College, supported by the NIH Kirschstein National Research Service Award.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog>
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/10/Sam-Rodriques.jpeg" class="h-full w-full object-cover" alt="Image of Sam Rodriques, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Sam Rodriques, PhD</h2>
                <h5 class="mt-0 !text-[15px] !leading-[21px]">Co-Founder, Director, and CEO<br>Edison Scientific and FutureHouse</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/10/Sam-Rodriques.jpeg" alt="Image of Sam Rodriques, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Sam Rodriques, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Physicist and bioengineer Sam Rodriques, PhD, is the co-founder, director, and CEO of Edison Scientific and FutureHouse. Sam has invented technologies for spatial and temporal transcriptomics, brain mapping, gene therapy, and nanofabrication, and briefly ran an academic lab at the Francis Crick Institute in London prior to launching FutureHouse in San Francisco in 2023. FutureHouse is a new research lab focused on building an AI Scientist to accelerate research in biology and other complex sciences. In 2025, Sam launched Edison Scientific to commercialize the agents being built at FutureHouse, with the goal of wanting “science to move faster.”</p>
<p>Sam graduated summa cum laude with highest honors in physics from Haverford College, where he worked on new methods for calculating quantum entanglement in multipartite quantum systems. He holds a PhD in physics from MIT, having worked between the MIT Media Lab, the MIT Department of Brain and Cognitive Sciences, and the Broad Institute. Among his awards and fellowships are the Hertz Foundation Graduate Fellowship, an NSF Graduate Research Fellowship, and a Churchill Scholarship.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog>
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/10/Peyton-Greenside-Headshot-2026-e1791476441492.jpg" class="h-full w-full object-cover" alt="Image of Peyton Greenside, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Peyton Greenside, PhD</h2>
                <h5 class="mt-0 !text-[15px] !leading-[21px]">Co-Founder and CEO<br>BigHat Biosciences</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/10/Peyton-Greenside-Headshot-2026-e1791476441492.jpg" alt="Image of Peyton Greenside, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Peyton Greenside, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Peyton Greenside, PhD, is the co-founder and CEO of BigHat Biosciences, a Bay Area biotechnology company pioneering an ML-driven platform to accelerate the design of next-generation antibodies and other therapeutic proteins.</p>
<p>Peyton holds a BA in applied mathematics from Harvard University, a PhD from Stanford University, and an MPhil in computational biology from the University of Cambridge, U.K.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog>
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/10/Tessier-Lavigne-Xaira.jpg" class="h-full w-full object-cover" alt="Image of Marc Tessier-Lavigne, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Marc Tessier-Lavigne, PhD</h2>
                <h5 class="mt-0 !text-[15px] !leading-[21px]">Co-Founder, Chairman, and CEO<br>Xaira Therapeutics</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/10/Tessier-Lavigne-Xaira.jpg" alt="Image of Marc Tessier-Lavigne, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Marc Tessier-Lavigne, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Marc Tessier-Lavigne, PhD, is the co-founder, chairman, and CEO of Xaira Therapeutics. Previously, he held executive positions in the private sector at Genentech, where he was executive vice president for research and chief scientific officer, and in the academic sector, where he served as president of The Rockefeller University and then for seven years at Stanford University, where he remains a professor of biology (on leave). He also served previously on the faculty of the University of California, San Francisco, and was an investigator with the Howard Hughes Medical Institute. A Rhodes Scholar, Marc has been a leader in understanding mechanisms that direct the wiring of the brain and has helped elucidate mechanisms of neurodegeneration. He is the recipient of numerous scientific awards, including the 2020 Gruber Neuroscience Prize, and has been elected to multiple scientific societies, including the U.S. National Academy of Sciences and U.S. National Academy of Medicine; he is also an officer of the Order of Canada, one of that country’s highest honors. Marc is the co-founder of two neuroscience biotech companies, Renovis and Denali, and has served on the boards of Agios, Regeneron, Pfizer, Juno, and Denali.</p>
<p>Marc holds a BS degree in physics from McGill University in his native Canada. He earned a BA in philosophy and physiology from the University of Oxford as a Rhodes Scholar, and a PhD in physiology from the University of London.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog></div>



<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"></div>
</div>


<div class="wp-block-buttons is-content-justification-center is-layout-flex wp-container-core-buttons-is-layout-3e41869c wp-block-buttons-is-layout-flex">
<div class="wp-block-button"><a class="wp-block-button__link wp-element-button" href="https://events.zoom.us/ev/AhU-gkQDgAxdLnotC4XH9bsSU27D7B6VJ9r7cboVW7D-XBlhuQdY~ApctLSdDOQGhoFB6oDQ77y_R7tlH2uiWKtuSw3NzxTFvnxPWyLBVS6lxOudLAszRSm_7K8poqEpmZQQtSUa7tIp3_w" target="_blank" rel="noreferrer noopener">REGISTER NOW</a></div>
</div>


<div aria-hidden="true" class="wp-block-spacer"></div>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow">
<p class="wp-block-malblocks-webinars-info"></p><div><strong>Broadcast Date:</strong> <time>Tuesday, November 4, 2025</time><br><ul><li><strong>Time:</strong> <time datetime="2025-11-04T16:00:00.000Z">08:00 PST, 11:00 EST, 16:00 GMT</time></li></ul></div>


<p class="wp-block-paragraph">From billion-dollar funding rounds and waves of IPOs to the first AI-guided molecules entering the clinic, the industry is signaling a clear inflection point: AI is set to fundamentally reshape drug discovery. At the center of this shift are maturing foundation models for molecules and cellular systems that unveil insights into complex biology.</p>


<p class="wp-block-paragraph">Yet the challenge is no longer prediction alone. Building the infrastructure that connects accelerated computing, generative design, and experimental feedback will be critical for transforming AI into a fully integrated engine for therapeutic innovation.</p>


<p class="wp-block-paragraph"><em>GEN</em>’s virtual summit, <strong><em>The State of AI in Drug Discovery</em>,</strong> returns on <strong>November 4</strong> to examine how AI is reshaping R&D timelines and real-world patient translation. From big pharma to AI-natives, this year’s program features the leaders of many of today’s outstanding companies and organizations powering the AI revolution, including Xaira Therapeutics, Edison Scientific, Eli Lilly, Chai Discovery, Lila Sciences, BigHat Biosciences, and more!</p>


<p class="wp-block-paragraph">Among the program highlights during this 4-hour event are:</p>


<ul class="wp-block-list">
<li>Building the AI scientist with <strong>Sam Rodriques, PhD</strong> (Edison Scientific)  </li>


<li>A fireside chat with Xaira Therapeutics CEO <strong>Marc Tessier-Lavigne, PhD</strong> </li>


<li>Powering AI adoption through strategic enterprise partnerships with <strong>Aliza Apple, PhD</strong> (Lilly TuneLab), <strong>Simon Barnett</strong> (Dimension), and <strong>Elliot Hershberg, PhD</strong> (Amplify Ventures)  </li>


<li>The role of agentic workflows in accelerating drug discovery with <strong>Le Cong, PhD</strong> (Stanford and Phylo) and <strong>Andrew Beam, PhD</strong> (Lila Sciences) </li>


<li>The new era of programmable therapeutics with <strong>Josh Meier</strong> (Chai Discovery) and <strong>Peyton Greenside, PhD</strong> (BigHat Biosciences) </li>


<li>And breakout sessions from our four event sponsors: <strong>A-AlphaBio, Benchling,</strong> <strong>LabVantage,</strong> and <strong>Revvity Signals</strong>.</li>
</ul>




<p class="wp-block-paragraph">Don’t miss this exceptional virtual summit, featuring many of the visionaries shaping the future of AI in drug discovery and biotech. Registration, as always, is free.</p>




<p class="has-text-align-center wp-block-paragraph"><u><strong>Guest Speakers Include</strong></u></p>


<figure class="wp-block-image size-full"><img decoding="async" width="2224" height="1072" src="https://www.genengnews.com/wp-content/uploads/2026/10/AIDD-Speaker-Group-Image.jpg" alt="The State of AI in Drug Discovery speakers" class="wp-image-339067" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/AIDD-Speaker-Group-Image.jpg 2224w, https://www.genengnews.com/wp-content/uploads/2026/10/AIDD-Speaker-Group-Image-300x145.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/AIDD-Speaker-Group-Image-1024x494.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/AIDD-Speaker-Group-Image-768x370.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/AIDD-Speaker-Group-Image-1536x740.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2026/10/AIDD-Speaker-Group-Image-2048x987.jpg 2048w" sizes="(max-width: 2224px) 100vw, 2224px"></figure>
</div>


<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow">






<p class="has-text-align-center wp-block-paragraph"><strong>Produced with support from:</strong></p>


<figure class="wp-block-image aligncenter size-medium is-resized"><a href="https://www.benchling.com/" target="_blank" rel=" noreferrer noopener"><img loading="lazy" decoding="async" width="300" height="83" src="https://www.genengnews.com/wp-content/uploads/2022/07/Benchling_logo-300x83.jpg" alt="Benchling logo" class="wp-image-203139" srcset="https://www.genengnews.com/wp-content/uploads/2022/07/Benchling_logo-300x83.jpg 300w, https://www.genengnews.com/wp-content/uploads/2022/07/Benchling_logo.jpg 600w" sizes="auto, (max-width: 300px) 100vw, 300px"></a></figure>


<figure class="wp-block-image aligncenter size-full is-resized"><a href="https://www.revvity.com/" target="_blank" rel=" noopener"><img loading="lazy" decoding="async" width="300" height="163" src="https://www.genengnews.com/wp-content/uploads/2025/09/revvitysignals_logo-e1758737697993.jpg" alt="Revvity Signals logo" class="wp-image-321277"></a></figure>


<figure class="wp-block-image aligncenter size-medium is-resized is-style-default"><a href="https://www.labvantage.com/" target="_blank" rel=" noreferrer noopener"><img loading="lazy" decoding="async" width="300" height="57" src="https://www.genengnews.com/wp-content/uploads/2019/12/LV_logo-300x57.jpg" alt="LabVantage logo" class="wp-image-131319" srcset="https://www.genengnews.com/wp-content/uploads/2019/12/LV_logo-300x57.jpg 300w, https://www.genengnews.com/wp-content/uploads/2019/12/LV_logo-696x132.jpg 696w, https://www.genengnews.com/wp-content/uploads/2019/12/LV_logo-741x142.jpg 741w, https://www.genengnews.com/wp-content/uploads/2019/12/LV_logo.jpg 750w" sizes="auto, (max-width: 300px) 100vw, 300px"></a></figure>


<figure class="wp-block-image aligncenter size-full is-resized"><a href="https://www.aalphabio.com/" target="_blank" rel=" noreferrer noopener"><img loading="lazy" decoding="async" width="300" height="169" src="https://www.genengnews.com/wp-content/uploads/2026/10/aalphaBio_logo-1.jpg" alt="A-Alpha Bio logo" class="wp-image-339064"></a></figure>
</div>


<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"></div>


<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"></div>
</div>



<p>The post <a href="https://www.genengnews.com/multimedia/summits/the-state-of-ai-in-drug-discovery/">The State of AI in Drug Discovery</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Epigenetics Underlies Comparatively Accelerated Molecular Aging in Larger and Male Dogs</title>
<link>https://edusehat.com/en/epigenetics-underlies-comparatively-accelerated-molecular-aging-in-larger-and-male-dogs</link>
<guid>https://edusehat.com/en/epigenetics-underlies-comparatively-accelerated-molecular-aging-in-larger-and-male-dogs</guid>
<description><![CDATA[ Large dogs tend to be shorter lived than their smaller counterparts, and a new study found that male and larger dogs undergo accelerated molecular aging, with pronounced DNA methylation changes on the X chromosome and at transposable elements. 
The post Epigenetics Underlies Comparatively Accelerated Molecular Aging in Larger and Male Dogs appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/low-res-sophiedog.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 09 Oct 2026 02:50:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Epigenetics, Underlies, Comparatively, Accelerated, Molecular, Aging, Larger, and, Male, Dogs</media:keywords>
<content:encoded><![CDATA[<p>Domestic dogs offer a useful model for understanding the biology of aging because their lifespans vary dramatically with body size. Large dogs tend to be shorter lived than their smaller counterparts, but why? Headed by a team at Arizona State University, a study of nearly 900 dogs now suggests that the answer may be written into the animals’ epigenomes.</p>
<p>Research professor Noah Snyder-Mackler, PhD, at Arizona State University School of Life Sciences, and colleagues developed an epigenetic clock that predicted mortality in dogs and showed that epigenetic aging is fastest early in life. The study results indicated that male dogs and larger dogs undergo accelerated molecular aging, with male dogs exhibiting pronounced DNA methylation (DNAm) changes on the X chromosome, and larger animals exhibiting methylation changes at transposable elements (TEs), stretches of DNA that can influence genome stability and gene regulation.</p>
<p>Snyder-Mackler is senior and corresponding author of the researchers’ published paper in <em>Science</em> (“<a href="http://dx.doi.org/10.1126/science.aeb2986" target="_blank" rel="noopener">Epigenetic aging and transposon dysregulation reflect size-related lifespan compression in dogs</a>,”) in which they concluded, “Our findings broadly establish companion dogs as a translational model for uncovering molecular mechanisms of lifespan variation, epigenomic instability, and age-related disease.”</p>
<figure aria-describedby="caption-attachment-339073" class="wp-caption alignleft"><img fetchpriority="high" decoding="async" class="size-medium wp-image-339073" src="https://www.genengnews.com/wp-content/uploads/2026/10/low-res-3-300x169.jpeg" alt="Genome-wide DNA methylation in 894 dogs from the Dog Aging Project reveals accelerated aging in larger dogs and faster loss of repression of transposable elements. [Blaise Mariner & Brianah McCoy] " width="300" height="169" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/low-res-3-300x169.jpeg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/low-res-3.jpeg 700w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Genome-wide DNA methylation in 894 dogs from the Dog Aging Project reveals accelerated aging in larger dogs and faster loss of repression of transposable elements. [Blaise Mariner & Brianah McCoy]</figcaption></figure>
<p>Aging is a universal process, but its pace and biological mechanisms substantially differ between individuals within even the same species, the authors wrote. “Whether shorter-lived individuals simply die earlier or instead experience accelerated biological aging throughout life remains unclear,” they noted. And while comparative studies across species have identified mechanisms associated with exceptional longevity, they may not be as well suited to identifying the molecular drivers of aging variation. “Domestic dogs provide a model for addressing this challenge because body size strongly predicts lifespan, with larger breeds living substantially shorter lives than smaller breeds despite sharing many physiological and environmental conditions,” the team continued.</p>
<p>In fact, smaller breeds can live nearly twice as long as larger breeds. And companion dogs live in human environments, consume commercial diets, and receive routine medical care, making them a relevant translational model for studying how genetic background and environmental exposures shape aging, the investigators pointed out.</p>
<figure aria-describedby="caption-attachment-339072" class="wp-caption alignright"><img decoding="async" class="size-medium wp-image-339072" src="https://www.genengnews.com/wp-content/uploads/2026/10/low-res-4-300x200.jpeg" alt="Study author with dogs" width="300" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/low-res-4-300x200.jpeg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/low-res-4.jpeg 700w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Professor and School of Life Sciences Associate Director Noah Snyder-Mackler poses for portraits with his two dogs, 7-year-old Homer, bottom, and 4-year-old Juno, top, on the steps of Old Main on the ASU Tempe campus on Monday morning, September 28, 2026. Snyder-Mackler’s recent research focuses on dog epigenetics. [Deanna Dent/Arizona State University]</figcaption></figure>
<p>But how intrinsic factors such as size and biological sex influence variation in dog aging and lifespan remains unclear. “It is well established that size and sex influence lifespan in dogs, but it remains unclear whether shorter-lived dogs experience accelerated epigenetic aging,” they stated. Previous research has demonstrated that DNAm is a useful indicator of biological aging, with “epigenetic clocks” offering a way to understand the factors that accelerate or decelerate biological aging. “DNA methylation (DNAm) has emerged as a robust molecular biomarker of age, with ‘epigenetic clocks’ offering a quantitative framework for identifying factors that accelerate or decelerate biological age.”</p>
<p>For their newly reported study Snyder-Mackler, together with first author Blaise Mariner, PhD, and colleagues generated 1,640 methylomes from a cohort of 894 dogs in the Dog Aging Project. They combined the molecular data with detailed genetic and demographic data. The results indicated that molecular aging occurs most rapidly early in a dog’s life. The study also found that larger and male dogs—both of which have shorter lifespans than their respective counterparts—age more quickly at the molecular level.</p>
<p>The authors identified different epigenetic patterns underlying these effects. According to the findings, sex-related changes were concentrated on the X chromosome, while body-size-related changes were especially prominent in TEs. “Thus, size and sex, two axes associated with shorter expected lifespan in dogs, appear to shape aging through partially distinct epigenetic architectures,” they stated. “Larger dogs show greater methylation loss at TEs with age, consistent with increased immune remodeling and genomic instability … These data address a major gap in comparative epigenomics by providing evidence that, within a species, demographic groups with shorter expected lifespans show faster epigenetic aging.”</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/epigenetics-underlies-comparatively-accelerated-molecular-aging-in-larger-and-male-dogs/">Epigenetics Underlies Comparatively Accelerated Molecular Aging in Larger and Male Dogs</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>ARPA&#45;H’s BoSS Program Funds Three Teams Tackling Cold Chain Challenges for Cell Therapies</title>
<link>https://edusehat.com/en/arpa-hs-boss-program-funds-three-teams-tackling-cold-chain-challenges-for-cell-therapies</link>
<guid>https://edusehat.com/en/arpa-hs-boss-program-funds-three-teams-tackling-cold-chain-challenges-for-cell-therapies</guid>
<description><![CDATA[ Cell therapies and other biologics depend on ultracold storage and tightly controlled shipping. ARPA-H has funded teams of companies, research agencies, and universities developing alternatives, aiming to widen patient access to these therapies.
The post ARPA-H’s BoSS Program Funds Three Teams Tackling Cold Chain Challenges for Cell Therapies appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/06/Getty_2024513047_PharmaceuticalFactory.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 09 Oct 2026 02:50:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>ARPA-H’s, BoSS, Program, Funds, Three, Teams, Tackling, Cold, Chain, Challenges, for, Cell, Therapies</media:keywords>
<content:encoded><![CDATA[<p><span>The Advanced Research Projects Agency for Health, (ARPA-H), an agency within the United States’ Department of Health and Human Services (HHS), recently announced awards and teams involved in its BioStabilization Systems (BoSS) program, an initiative that aims to develop new methods for producing, storing, and transporting cell-based biologic medicines at room temperature. ARPA-H has committed to provide up to $87 million across the four-year program. This round of funding will support Phase I of the program.</span></p>
<p><span>The teams have been tasked with pursuing new technologies that confer long-term, shelf-life stability to cell-based therapies and biologics making it possible to store and ship them without refrigeration. To accomplish this goal, BoSS teams will work across two technical areas. They will work on interventions to stabilize cells for storage and then reactivate them on demand as well as on creating novel processing systems that ensure these interventions are efficient and scalable for manufacturing. </span></p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p><span>This week, members of the Reversible Ambient Temperature (RAB) team said that they have been awarded up to $7.3 million initially from ARPA-H. The RAB team includes representatives from Draper, a non-profit research, development, and manufacturing company, which serves as the administrative lead,and Likarda, a biotechnology company that develops hydrogel technologies for delivering and preserving cell therapies and biologics, which serves as the technical lead for the team. Other members of the team include scientists from CaseBioscience, CPSI Biotech, Fresenius Kabi, MiNK Therapeutics, and University of Colorado. </span></p>
<p><span>For their part, this team will use AI-assisted design of experiments to optimize formulation, quiescence induction parameters, hydrogel composition, and recovery media as well as freeze-assisted droplet drying to achieve a stable product. Specifically, the RAB team’s biostabilization strategy, led by Likarda, will focus on simultaneous control of cell state, physical environment, and the cellular stress responses activated during freezing, dehydration, storage, and recovery. Meanwhile, the bioprocessing engineering team, led by Draper, will convert the manual steps of biostabilization into an automated, commercially viable workflow and will develop custom instruments to scale up the processes.</span></p>
<p><span>Likarda will contribute its proprietary Core-Shell Spherification hydrogel technology, which is designed to encapsulate and protect living cells while maintaining viability and function. CaseBioscience will provide expertise in clinical media formulation, biopreservation, and cellular metabolism to the development and evaluation of novel approaches for long-term ambient stabilization of therapeutic cells.</span></p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p><span>“The RAB team brings together deep expertise in cryoprotection, encapsulation, and cell state, with a focus on protecting cell viability throughout the stabilization and reanimation process, and the team has direct experience bringing products to market,” said Jason Fiering, distinguished technical staff at Draper. “Working in parallel, our interdisciplinary engineering team will develop the customized instruments needed to transfer these processes to clinical manufacturing environments.” </span></p>
<p><span>In his comments, John Baust, PhD, an expert in biopreservation and collaborator on the project with CPSI Biotech noted that “the concept of preserving living cells in a dry state has been pursued for more than two decades, but significant scientific and engineering barriers have yielded limited success.” The BoSS program is an opportunity “to tackle this from multiple scientific and engineering directions simultaneously” that if successful “could represent a paradigm shift in how biologics are preserved, stored, and distributed.”</span></p>
<p><span>Other teams announced by ARPA-H include one led by DesiCorp. This team includes members from the University of Louisville, University of Texas at Austin, Via Therapeutics, VeriSIM Life, and Ossium Health. They will leverage high-throughput screening to identify biocompatible formulations that slow cellular metabolism and AI-assisted process optimization to develop a thin-film freeze-drying (TFFD) system that stabilizes cells at room temperature. </span></p>
<p><span>DesiCorp will lead integration of the overall workflow by using a high-throughput screening platform to rapidly identify biocompatible formulations that enable cells to survive TFFD and resume function after rehydration. Meanwhile, UT Austin researchers will help optimize the TFFD critical process parameters and composition/material attributes, while also contributing expertise in aseptic processing and scaling up the technology. </span></p>
<p><span>A third team is led by the University of California, Davis and includes scientists from Mayo Clinic, Case Western Reserve University, University of Georgia, and Sersense. The team will induce a low metabolic state in cells using light-responsive gels and microfluidic processing techniques to produce cells that are stable at room temperature. </span></p>
<p><span>Recently, that team announced that it had been awarded up to $6 million, initially,  from ARPA-H to fund its project dubbed CYBORGEL. Their efforts will leverage research done in the laboratory of Cheemeng Tan, PhD, a professor of biomedical engineering at UC Davis. Previously, he and his collaborators formed water-rich polymer networks inside living cells to create cell-material hybrids. This process, called intracellular gelation, forms a gel inside the cell and is capable of halting cell division while preserving cellular function. Tan and his team dubbed this cellular product a “cyborg” since the gelation process combines living cells with synthetic materials. </span></p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p><span>Through CYBORGEL, the collaborators will investigate whether this intracellular gelation process can be extended to reduce the cost and simplify the storage, transportation and delivery of cellular therapies. The researchers will also test whether CYBORGEL cells remain therapeutically useful after being returned to their original state. For instance, one study will test the effectiveness of reanimated CAR T cells for existing clinical trials on cancer immunotherapies. Another will test it on placental mesenchymal stem cells used to treat spina bifida, a medical intervention being developed by UC Davis researchers. </span></p>
<p><span>As part of the initiative, the American Type Culture Collection (ATCC) has been tapped to serve as the IV&V partner. ATCC will provide working cell banks of government-selected cell types that will be used for demonstrations. They will also provide unbiased assessments of both the viability and function of the preserved products and the design features of the preservation systems.  </span></p>
<p><span>The first phase of the BoSS program kicked off in September and is expected to run for 15 months. Over the four-year multi-phase program, the teams’ approaches will be evaluated against increasingly stringent benchmarks for cell viability, production speed, and shelf-life stability. If successful, work under the BoSS program could enable lower costs for cell-based drugs, reduce the risk of therapeutic and pharmaceutical product losses, and enable domestic reserves for public health preparedness. </span></p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/arpa-hs-boss-program-funds-three-teams-tackling-cold-chain-challenges-for-cell-therapies/">ARPA-H’s BoSS Program Funds Three Teams Tackling Cold Chain Challenges for Cell Therapies</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Gut Microbes Trigger Calprotectin to Protect Newborns from Infection</title>
<link>https://edusehat.com/en/gut-microbes-trigger-calprotectin-to-protect-newborns-from-infection</link>
<guid>https://edusehat.com/en/gut-microbes-trigger-calprotectin-to-protect-newborns-from-infection</guid>
<description><![CDATA[ Newborn gut microbes activate epithelial calprotectin production, strengthening early-life immunity and protecting against dangerous infections, potentially offering new strategies to prevent neonatal sepsis.
The post Gut Microbes Trigger Calprotectin to Protect Newborns from Infection appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2023/06/Microbiome-20-GettyImages-1402265767.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 08 Oct 2026 05:20:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Gut, Microbes, Trigger, Calprotectin, Protect, Newborns, from, Infection</media:keywords>
<content:encoded><![CDATA[<p>The immune systems of newborns are incredibly different from adults, however, the mechanisms that enable early-life immunity remain poorly understood. Because infection is a leading cause of neonatal morbidity and mortality, and infants are particularly vulnerable, understanding the immune mechanisms in early life is of the utmost importance. In addition, despite recognition that acquisition of the microbiota alters early host defense, there is limited understanding of the commensal-induced mechanisms that play a role in the neonate.</p>
<p>Now, a new study shows that the antimicrobial protein calprotectin, found in high concentrations in the guts of newborn mice, is expressed by intestinal epithelial cells in response to commensal bacteria colonizing the gut. More specifically, the healthy newborn mice “express high concentrations of the S100 calcium-binding protein A8/A9 antimicrobial heterodimer calprotectin” and that this early up-regulation in the intestine is driven by initial exposure to commensal bacteria.</p>
<p>They also found that newborn mice with impaired calprotectin expression or poor microbiota colonization were more susceptible to sepsis and death post-infection. However, when the mice were given calprotectin, it rescued the microbiota-depleted pups from infection.</p>
<p>This work is published in <em>Science Translational Medicine</em> in the paper, “<a href="https://www.science.org/doi/10.1126/scitranslmed.adx6147" target="_blank" rel="noopener">Early-life microbiota direct an epithelial S100 program required for neonatal immunity.</a>”</p>
<p>The main source of calprotectin in the neonatal intestine was found to be microbiota colonization induced S100A9 expression by intestinal epithelial cells (IECs) and epithelial cells. And neonatal IEC-specific S100A9 knockout pups were highly susceptible to infection.</p>
<p>The study also sheds light on the specific mechanisms that provide early-life immunity against potentially deadly pathogens such as <em>Staphylococcus aureus</em>, <em>Listeria monocytogenes, </em>and <em>Streptococcus pneumoniae</em>, at a crucial time when newborns lack other immune defenses.</p>
<p>In mice and in human intestinal organoids, the researchers demonstrated that commensal microbes such as <em>Lactobacillus </em>produce the metabolite indole-3-lactic acid (ILA), which activates signaling in neonatal epithelial cells to increase the production of intestinal calprotectin.</p>
<p>Together, these findings suggest that microbiota-epithelial dynamics at birth can help program early-life immunity, the researchers write, with potential implications for probiotic approaches that target epithelial cells to prevent neonatal sepsis. This result, plus the authors’ finding that calprotectin is present in the guts of human newborns less than two days old (but not in seven-year-old infants), suggests a similar early-life immune mechanism may be at play in humans.</p>
<p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/gut-microbes-trigger-calprotectin-to-protect-newborns-from-infection/">Gut Microbes Trigger Calprotectin to Protect Newborns from Infection</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Secrets of Oldest Land Animal’s 194&#45;Year Lifespan Revealed with Epigenetics</title>
<link>https://edusehat.com/en/secrets-of-oldest-land-animals-194-year-lifespan-revealed-with-epigenetics</link>
<guid>https://edusehat.com/en/secrets-of-oldest-land-animals-194-year-lifespan-revealed-with-epigenetics</guid>
<description><![CDATA[ Researchers studying a giant tortoise named Jonathan—who is the oldest known living land animal in the world today—say it’s not just good genes, but a lack of genetic wear and tear that may have kept him going for an estimated 194 years.
The post Secrets of Oldest Land Animal’s 194-Year Lifespan Revealed with Epigenetics appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/low-res.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 08 Oct 2026 05:20:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Secrets, Oldest, Land, Animal’s, 194-Year, Lifespan, Revealed, with, Epigenetics</media:keywords>
<content:encoded><![CDATA[<p>Researchers studying a giant tortoise named Jonathan—who at an estimated 194 years of age is the oldest known living land animal in the world today—say it’s not just good genes, but lack of genetic wear and tear that have kept him going for nearly two centuries.</p>
<p>Headed by Stephen Clark MD, PhD, founder of the Kallel Foundation, the team sequenced Jonathan’s genome and identified 287 unique gene variants in this remarkably old Aldabra giant tortoise (<em>Aldabrachelys gigantea</em>) that may reduce the usual effects of aging.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>When comparing Jonathan’s epigenome—the “on/off” switches on his genes—with that of younger giant tortoises of the same species, the team found that switches controlling Jonathan’s DNA repair and metabolism genes were very similar to those in his younger relatives. Usually, the epigenome changes over time, contributing to the aging process. This is a key reason why things start to go wrong in older bodies.</p>
<p>“We found that the gene regulators involved in energy production and DNA repair have remained incredibly stable in Jonathan over almost two centuries,” said Justin Gerlach, PhD, at Peterhouse at the University of Cambridge, who was involved in the study.</p>
<p>The study marks the first time the epigenome of a giant tortoise has been investigated. It was led by researchers at the longevity research non-profit Kallel in the U.S., who say that cracking the genetic code of a multi-century life offers unprecedented insights into extreme lifespan.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>Clark is senior and corresponding author of the researchers’ published paper in <em>Science Advances</em>, titled “<a href="http://dx.doi.org/10.1126/sciadv.adw8887" target="_blank" rel="noopener">Epigenetic insights into extreme longevity in the world’s oldest terrestrial animal, Jonathan</a>,” in which they concluded “Our findings support a model for aging wherein the maintenance of low methylation entropy in gene promoters is coupled to efficient mitochondrial energy production, efficient RNA processing, and efficient genomic repair.”</p>
<p>The giant tortoises of the Galapagos and Seychelles islands are the extraordinary last survivors of animals that used to dominate the ecology of many of the world’s islands. Aldabra giant tortoises are exceptionally long-lived, but Jonathan is about 100 years older than most of his species. He’s thought to have hatched in 1832—making him a contemporary of Charles Darwin and Queen Victoria.</p>
<figure aria-describedby="caption-attachment-339001" class="wp-caption alignleft"><img fetchpriority="high" decoding="async" class="size-medium wp-image-339001" src="https://www.genengnews.com/wp-content/uploads/2026/10/low-res-2-300x230.jpeg" alt="Jonathan arrived in St. Helena as a gift to Sir William Grey-Wilson in 1882, who later became governor of the island. This image was taken around that time - Jonathan is on the left. [A.L. Innes]" width="300" height="230" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/low-res-2-300x230.jpeg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/low-res-2.jpeg 700w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Jonathan arrived in St. Helena as a gift to Sir William Grey-Wilson in 1882, who later became governor of the island. This image was taken around that time—Jonathan is on the left. [A.L. Innes]</figcaption></figure>
<p>Jonathan has lived most of his life on the island of St. Helena—a British Overseas Territory in the South Atlantic Ocean—in the grounds of the residence of the governor of St. Helena. Jonathan arrived from the Seychelles 144 years ago, already fully grown, as a gift to the governor.</p>
<p>Gerlach has studied the ecology and conservation of giant tortoises for several decades, but this is the first time he has studied their exceptionally long lives. Gerlach said, “There are few creatures that could tell us more about aging than the giant tortoises of the Galapagos and Seychelles islands. Working with a really old giant tortoise is such a privilege: you get a sense of the tortoise being your collaborator, not your study subject.”</p>
<p>For their study the team extracted Jonathan’s genetic material from cheek scrapings rather than a blood draw (they teased the tortoise with a promise of food until he opened his jaws wide), so that they could compare his genome and methylome with those of four other Aldabras, ranging in age from juveniles to older adults. “Because of concerns for Jonathan’s health and his iconic status on St. Helena, a blood draw for DNA sequencing was not permitted,” the authors explained. “Instead, we collected buccal scrapes and saliva samples for genomic DNA (gDNA) isolation.”</p>
<p>The team’s analyses identified genetic variants associated with several known aging pathways, including DNA repair, telomere maintenance, insulin regulation, mitochondrial function, and cancer. The investigators also analyzed Jonathan’s genome’s methylome—or the total picture of his genome’s methylation, which refers to the addition to DNA of tiny methyl chemical tags that impact gene expression. Methylation entropy, a sign of aging, occurs as random changes in methylation patterns accumulate over time. This analysis showed low entropy within specific gene promoters for mitochondrial function, RNA processing, and genome repair. The regions of low methylation entropy observed in Jonathan “suggest that high-fidelity transcription of genes in these pathways may be crucial for long-lived species,” the researchers noted.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>“Nature has already solved the puzzle of aging in remarkable ways, and Jonathan’s genome provides a blueprint for cellular resilience,” said Clark. “Our goal is to take these evolutionary insights and immediately translate them into practical, affordable treatments for everyday people. Aging is the greatest risk factor for nearly every chronic disease we face, and through the generosity of philanthropic partners, we can democratize access to longevity medicine.”</p>
<p>In their paper the authors wrote in summary, “… while we identified many genetic variants in Jonathan associated with known aging pathways, our most notable finding is the low entropy maintained within specific gene promoters. This stability is exceptionally pronounced in promoters of genes involved in mitochondrial function and RNA processing. We hypothesize that maintaining this low-entropy state ensures high-fidelity expression in these critical pathways, partially protecting him from age-related decline.”</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/secrets-of-oldest-land-animals-194-year-lifespan-revealed-with-epigenetics/">Secrets of Oldest Land Animal’s 194-Year Lifespan Revealed with Epigenetics</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Adding Low&#45;Fidelity Data to ML Training Sets Could Yield Better Process Models</title>
<link>https://edusehat.com/en/adding-low-fidelity-data-to-ml-training-sets-could-yield-better-process-models</link>
<guid>https://edusehat.com/en/adding-low-fidelity-data-to-ml-training-sets-could-yield-better-process-models</guid>
<description><![CDATA[ Low-fidelity trend information should be incorporated into the data sets used to train machine learning-based biopharmaceutical process models, according to new analysis, which suggests the approach could also help identify the most manufacturable drug candidates.
The post Adding Low-Fidelity Data to ML Training Sets Could Yield Better Process Models appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GettyImages-2248132110-small.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 08 Oct 2026 01:40:12 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Adding, Low-Fidelity, Data, Training, Sets, Could, Yield, Better, Process, Models</media:keywords>
<content:encoded><![CDATA[<p>Combining trend information with high-fidelity experimentally-derived data could improve the accuracy of machine learning-based process models, according to researchers.</p>
<p>Machine learning models have the potential to make biopharmaceutical process development faster and more efficient by, in theory, allowing scientists to predict the impact of changes to parameters ahead of time.</p>
<p>The problem, according to <a href="https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/full/10.1002/bit.70213" target="_blank" rel="noopener">recent research</a>, is that the high-fidelity process information required to train machine learning models is expensive to generate and, as a result, in short supply.</p>
<p>One potential solution would be to include low-fidelity data, which indicate general process trends, in training sets, says lead author Mohammad Golzarijalal, PhD, a research fellow at the University of Melbourne’s digital bioprocess hub.</p>
<p>“The basic idea is that abundant low-fidelity data teach the model the broad global trend of the process, while a smaller amount of high-fidelity data corrects and refines these trends, aligning surrogate model predictions more closely with the available ground truth.</p>
<p>“A model trained only on limited high-fidelity data can overfit and perform poorly outside the conditions it has already observed. By learning useful trends from lower-cost data, a multi-fidelity model can improve predictive accuracy and explore a wider process space without requiring the same number of expensive experiments,” he says.</p>
<p>More accurate models could improve predictions about cell growth, viability, metabolite concentrations, and product titer. They could also guide media optimization, feeding schedules, seeding density, and operating conditions.</p>
<p>“One example discussed in our review is a recent study, which was performed in our own group, that combined 20,000 simulated CHO fed-batch data points with experimental data from 65 bioreactor runs.</p>
<p>“The multi-fidelity Gaussian-process models predicted final monoclonal-antibody titer more accurately than a model trained only on the experimental data,” Golzarijalal says.</p>
<h4><strong>Low-fidelity data </strong></h4>
<p>Low-fidelity process data can be from previous production runs or from cultures grown in bioreactor configurations that differ from those in the process under development. Such data can also be generated using low-cost mechanistic or empirical models.</p>
<p>Drug firms already use low-fidelity data to an extent, although, as Golzarijalal points out, use is usually limited. For example, scientists routinely draw on previous experiments to define parameter ranges, develop design-of-experiments studies, and guide process optimization.</p>
<p>“There is an opportunity to use these data more systematically,” he says, adding, “Multi-fidelity algorithms provide a structured way to determine how much information should be transferred from historical or simulated data to a current problem.</p>
<p>“This can make past experience more useful for prediction and decision-making, rather than treating each new program largely in isolation,” Golzarijalal adds.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/adding-low-fidelity-data-to-ml-training-sets-could-yield-better-process-models/">Adding Low-Fidelity Data to ML Training Sets Could Yield Better Process Models</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Big Data Opportunities in Biomanufacturing</title>
<link>https://edusehat.com/en/big-data-opportunities-in-biomanufacturing</link>
<guid>https://edusehat.com/en/big-data-opportunities-in-biomanufacturing</guid>
<description><![CDATA[ Industry-wide standardization and collaboration leverage big data in ways that help companies unleash optimizations enterprise-wide while simultaneously advancing industry knowledge, but succeeding also takes a lot of data prep and security.
The post Big Data Opportunities in Biomanufacturing appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2022/11/GettyImages-122204403-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 08 Oct 2026 01:40:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Big, Data, Opportunities, Biomanufacturing</media:keywords>
<content:encoded><![CDATA[<p>Is your data a predictive asset or something that merely takes up storage space? Odds are good the answer is the latter. Yet, data sets from R&D, tech transfer, facilities operations, supply chain operations, and quality optimization hold details that could be predictive assets for current and future biomanufacturing, product development, and supply chain operations.</p>
<p>Researchers led by Roger Hart, PhD, senior fellow, Big Data Project lead, National Institute for Innovation in Manufacturing Biopharmaceuticals, and senior researcher Kelvin Lee, PhD, professor, University of Delaware, make the case not only for leveraging big data in your own company, but standardizing and sharing key insights industry-wide…without compromising proprietary information.</p>
<p>That opinion is based on results from a big data model developed through the MELLODDY Consortium (Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, GSK, Janssen, Merck KGaA, Novartis, and Servier).</p>
<p>As Hart, Lee, and colleagues report in a <a href="https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2026.1886721/full" target="_blank" rel="noopener">recent paper</a>, the consortium pooled decades of proprietary data—some 2.6 billion data points spanning more than 21 million molecules and more than 40 thousand assays in on-target and secondary pharmacodynamics and pharmacokinetics—using a secure computing platform to jointly train a predictive drug-activity model. That shared quantitative structure-activity relationship model used “the chemical structure of potential drug compounds to predict how they will function,” they note.</p>
<p>Results, they say, significantly outperformed those of any of the individual members. Detailing those results in a separate <a href="https://pubs.acs.org/jcisd8/article-pdf/64/7/2331/10574102/ci3c00799.pdf" target="_blank" rel="noopener">article</a>, Wouter Heyndrickx, PhD, machine learning scientist from consortium lead Janssen Pharmaceuticals, reports benefits in “most of the classification or regression tasks,” writing that the model generally enhanced predictivity, sometimes substantially. Notably, the median Relative Improvement of Proximity to Perfection for conformal efficiency exceeded 12%, with one exceeding 20%.</p>
<h4><strong>Prepping to share</strong></h4>
<p>“Many organizations are already pursuing in-house solutions,” Lee tells <em>GEN</em>. “The benefits are the ability to tailor the solution to one’s specific situation. But by participating in larger-scale efforts, one can benefit from shared learnings and efforts to accelerate the digital transformation. Ecosystem-wide efforts can enable the entire industry to advance digital tools and benefits in ways that might not be apparent to individual organizations.”</p>
<p>Achieving such results takes a lot of data management preparation, the researchers admit. They must:</p>
<ul>
<li>Standardize ontologies, schemas, and holistic data integration and break down data silo enterprise-wide</li>
<li>Enable predictive strategies to optimize processes, such as those supported by digital twins, <em>in silico</em> process design, and hybrid mechanistic/ AI models</li>
<div class="my-8"><span data-render-ad="5"></span></div>
<li>Develop secure, shared datasets that enable data to be pooled while protecting sensitive and proprietary data</li>
<li>Ensure interoperability and real-time data connectivity among sensors from multiple vendors so they can communicate accurately and in real- or near-real time</li>
<li>Industry guidance and buy-in, including regulatory clarity, workforce development, and shared business cases that lower adoption barriers</li>
</ul>
<p>It is, in a word, challenging.</p>
<p>Redesigning legacy data infrastructure is expensive and time-consuming, and multivendor operability is a low priority for equipment developers, Hart says. There are additional barriers, too. Regulators have not yet determined how such models will be evaluated in data submissions. And, finally, workers with combined expertise in biomanufacturing and data science are scarce.</p>
<p>Yet, there are clear advantages to standardizing big data and using it to populate shared models.</p>
<p>“Many organizations face similar challenges and opportunities related to development and manufacturing,” Lee says. “Supporting an industry-wide set of solutions can accelerate the learnings of individual organizations, facilitate tech transfers…foster greater flexibility and interoperability, and support federated learning.”</p>
<p>As the team emphasizes, “Companies that do not adopt these capabilities are competitively disadvantaged from realizing the full benefits of their big data in the biopharmaceutical manufacturing marketplace.”</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/big-data-opportunities-in-biomanufacturing/">Big Data Opportunities in Biomanufacturing</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Hybrid Digital Twins Developed for Future Autonomous Labs</title>
<link>https://edusehat.com/en/hybrid-digital-twins-developed-for-future-autonomous-labs</link>
<guid>https://edusehat.com/en/hybrid-digital-twins-developed-for-future-autonomous-labs</guid>
<description><![CDATA[ An academic laboratory is developing a hybrid digital twin that integrates a mechanistic model with artificial intelligence, with the long-term goal of driving the future of next-generation autonomous robotic laboratories.
The post Hybrid Digital Twins Developed for Future Autonomous Labs appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/06/Getty_2147673480_ScientistsInLabDNAOnScreen.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 08 Oct 2026 01:40:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Hybrid, Digital, Twins, Developed, for, Future, Autonomous, Labs</media:keywords>
<content:encoded><![CDATA[<p>Researchers from South Korea are developing a digital twin that combines mechanistic modeling with artificial intelligence. They hope the model will eventually allow them to create a fully autonomous lab, capable of operating with minimal human intervention at academic and on larger scales.</p>
<p>“We’ve been focused on combining this mechanistic model with the data-driven AI model to create a hybridized model,” explains Dong-Yup Lee, PhD, professor and head of the Bioprocess Digital Twin Lab at Sungkyunkwan University.</p>
<p>According to Lee, their digital twin differs from a conventional simulator or standalone model because it’s continuously connected to a multi-sensory modeling system, which collects relevant data from the bioreactor in their lab. The team, he says, has developed mathematical models of mammalian Chinese Hamster Ovary (CHO) cells and uses them to make predictions about how the cells will behave under different bioreactor conditions.</p>
<p>However, he says, predictions from the mechanistic model alone do not always achieve the accuracy or adaptability required for real-time operation. As such, the team has incorporated data-driven AI as a complement to provide more adaptive control of the bioreactor.</p>
<p>“One of the limitations of AI is, if you have lots of data, it’s good for prediction, but it can’t explain why,” he says. “So, we use what is called explainable (XAI).”</p>
<p>XAI can provide information about what input conditions are most strongly affecting process outputs, he says, rather than just providing a prediction. This added interpretability can provide multiple options for improving and controlling bioprocess performance.</p>
<p>According to Lee, the biggest challenge for the team so far has been integrating the mechanistic model with XAI in a way that connects data collection, prediction, and forecasting directly with process control.</p>
<figure aria-describedby="caption-attachment-338956" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="size-medium wp-image-338956" src="https://www.genengnews.com/wp-content/uploads/2026/10/Bioreactor-setup-image-2-small-300x225.jpg" alt="" width="300" height="225" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Bioreactor-setup-image-2-small-300x225.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Bioreactor-setup-image-2-small-768x576.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/Bioreactor-setup-image-2-small.jpg 900w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Bioprocess Digital Twin Lab’s setup at Sungkyunkwan University. [Sungkyunkwan University]</figcaption></figure>
<p>“We’re probably at 80% on [developing] the hybridized model,” he says. “The remaining 20% is working out how these models can be linked to and interact with the control system and our future robotics.”</p>
<p>Bringing these aspects together, he says, will be a key focus of the team’s future research, with the ultimate aim of moving beyond predictive digital twins toward increasingly autonomous process operation.</p>
<p>Lee is open to industry collaborations, particularly around digital twins, advanced bioprocess monitoring, and autonomous biomanufacturing.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/hybrid-digital-twins-developed-for-future-autonomous-labs/">Hybrid Digital Twins Developed for Future Autonomous Labs</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Electrical Signals Sharpen Bioprocess Control</title>
<link>https://edusehat.com/en/electrical-signals-sharpen-bioprocess-control</link>
<guid>https://edusehat.com/en/electrical-signals-sharpen-bioprocess-control</guid>
<description><![CDATA[ Electrical signatures could give bioprocess engineers an earlier view of cell health, detecting apoptosis, refining harvest timing, and moving monitoring from destructive offline assays toward rapid, label-free, potentially automated control of biologics manufacturing operations.
The post Electrical Signals Sharpen Bioprocess Control appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Lapizco-Encinas_GBPN_IMAGE_01OCT26.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 08 Oct 2026 01:40:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Electrical, Signals, Sharpen, Bioprocess, Control</media:keywords>
<content:encoded><![CDATA[<p>For bioprocess engineers, knowing when a cell culture is beginning to fail can make the difference between an optimal harvest and a compromised batch. Yet many standard approaches provide only a delayed snapshot of cellular health. A <a href="https://doi.org/10.1002/elps.70146" target="_blank" rel="noopener">review</a> by Alaleh Vaghef-Koodehi, PhD, a postdoctoral researcher at the University of Massachusetts Amherst, and Blanca Lapizco-Encinas, PhD, professor of biomedical engineering at the Rochester Institute of Technology, suggests that cells’ electrical properties could provide a faster window into what is happening inside a bioprocess. Their review traces advances from 2015 through 2026 in using membrane capacitance, cytoplasmic conductivity, polarizability, and surface charge to assess cellular state without labels.</p>
<p>The opportunity is particularly compelling in biologics manufacturing, where the authors call real-time monitoring of cell health a “critical bottleneck.” Conventional apoptosis measurements, including offline fluorescent staining and lactate dehydrogenase release assays, can be destructive and provide limited temporal resolution. Dielectrophoresis (DEP), which exploits how polarizable cells respond to nonuniform electric fields, offers another approach: tracking the changing electrical signature of cells without labeling or destroying them.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>Chinese hamster ovary (CHO) cells, which the review calls the “industry workhorse,” provide a striking example. Studies using dual-frequency DEP cytometry followed CHO cells during nutrient-starvation-induced apoptosis and found two distinguishable electrical phases. First came membrane remodeling and a reduction in membrane capacitance. Then cytoplasmic conductivity dropped sharply as ionic homeostasis broke down. In one study, apoptotic populations began appearing between 24 and 36 hours, and cytoplasmic conductivity fell to approximately 0.05 siemens per meter (S/m) compared with about 0.45 S/m in viable cells. A follow-up similarly found membrane capacitance declining gradually before cytoplasmic conductivity plunged to 0.07 S/m in apoptotic cells by 52 hours. Together, the changes provide an electrical timeline of cell death rather than merely an endpoint measurement.</p>
<p>Speed could make those signatures especially valuable on the manufacturing floor. The commercially available 3DEP platform has been used to capture electrical signatures from populations of roughly 20,000 cells within seconds. According to the review, such measurements can reveal emerging apoptotic subpopulations “hours before traditional biochemical markers become detectable.” Earlier warning could allow operators to adjust a process or select a more favorable harvest time before culture performance deteriorates.</p>
<p>The next step might be turning those measurements into automated decisions. The review highlights a 2026 analysis integrating electrical impedance data with supervised machine learning; a tuned random-forest model achieved 90% predictive accuracy and was proposed as a label-free “traffic-light” system for batch monitoring. Combining rapid electrical measurements with computational analysis could ultimately support autonomous intervention and optimized harvesting.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>That vision is not yet routine bioprocess control, but the technology is moving beyond specialized laboratory experiments. Commercial DEP platforms are already increasing accessibility, and the authors see continued integration with computational modeling and machine learning as a route toward real-time automated systems. For biomanufacturing, the electrical life of a cell may become another process signal—one capable of warning that a culture is changing before conventional assays catch up.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/electrical-signals-sharpen-bioprocess-control/">Electrical Signals Sharpen Bioprocess Control</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Kagan, Soai Win 2026 Nobel Prize in Chemistry for Discoveries Related to Asymmetric Organic Synthesis</title>
<link>https://edusehat.com/en/kagan-soai-win-2026-nobel-prize-in-chemistry-for-discoveries-related-to-asymmetric-organic-synthesis</link>
<guid>https://edusehat.com/en/kagan-soai-win-2026-nobel-prize-in-chemistry-for-discoveries-related-to-asymmetric-organic-synthesis</guid>
<description><![CDATA[ Henri Kagan, PhD, and Kenso Soai, PhD, shared this year&#039;s award for the discovery of non-linear effects and autocatalysis in asymmetric organic synthesis respectively.
The post Kagan, Soai Win 2026 Nobel Prize in Chemistry for Discoveries Related to Asymmetric Organic Synthesis appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Nobel-prize-in-chemistry-2026.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 07 Oct 2026 22:05:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Kagan, Soai, Win, 2026, Nobel, Prize, Chemistry, for, Discoveries, Related, Asymmetric, Organic, Synthesis</media:keywords>
<content:encoded><![CDATA[<p><span>The 2026 Nobel Prize in Chemistry “is about making chemistry choose a mirror image.” With those words, members of the Nobel committee announced that they had awarded the 2026 prize to Henri B. Kagan, PhD, professor emeritus at Université Paris-Sud, and Kenso Soai, PhD, professor emeritus at Tokyo University of Science, for complementary breakthroughs related to the emergence of homochirality. Kagan received the award for his discovery of nonlinear effects in asymmetric organic synthesis, and Soai for the development of autocatalysis in asymmetric organic synthesis.</span></p>
<p><span>The year’s prize recognized foundational discoveries that helped explain a chemical asymmetry observed in living organisms.  Small molecules like amino acids exist as two variants that are mirror images, yet living organisms contain only one of these images while the other is rarely found in nature. Kagan and Soai’s work provided the answer to the question of how homochirality can emerge. Their discoveries have enabled chemists to drive chemical reactions that lead to homochirality, and have been beneficial to scientists that design reactions used in manufacturing to develop new drugs, flavors, scents, and other materials. </span></p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p><span>Their combined efforts “have provided a solution to a chemical mystery that is over a century old,” said Heiner Linke, PhD, chair of the Nobel Committee for Chemistry. “The chemical reactions they have developed are spectacular.”</span></p>
<p><span>How homochirality emerges is “probably the most fundamental question in life,” explained Peter Somfai, PhD, a professor of organic chemistry at Lund University and a member of the Nobel committee for Chemistry, in an interview. Scientists have long wondered how it happened billions of years ago. “Now we mimicked it in a lab today, not the way it happened four billion years ago, it’s important to stress, but we have for the first time mimicked it.”</span></p>
<h4><b>The core scientific question</b></h4>
<div class="my-8"><span data-render-ad="4"></span></div>
<p><span>Though chiral molecules exist as non-identical mirror images with potential biological effects, life is homochiral and built exclusively from left-handed amino acids and right-handed sugars. And different enantiomers can have dramatically different properties. “Many molecules occur in two different versions, like my hands. They are one another’s mirror image. They look alike, but they’re not identical,” Linke said. </span></p>
<p><span>When scientists began experimenting with chemical reactions that can form two mirrored molecules, they typically obtained equal proportions of both. But attempts to produce only one of the mirror images, in the context of pharmaceutical development, for example, proved challenging. Some of the earliest discoveries about chirality can be traced back to the mid-19<sup>th</sup> century to Louis Pasteur and his efforts to investigate the behavior of tartaric acid. The field also owes some insights to the work of the chemist Willy Marckwald, who carried out the first successful asymmetric reaction in the early 1900s. He succeeded by using a chiral catalyst which boosted the formation of one mirror image over the other. </span></p>
<p><span>In their respective laboratories, Kagan and Soai made their contributions to the question of how homochirality emerges spontaneously. In 1986, Kagan discovered a new way of manipulating chemical reactions that made it possible to create a larger quantity of one of the images than had previously been thought possible. </span></p>
<p><span>At the time, he and other chemists were working to refine asymmetric reactions with an eye towards producing pure enantiomers. Building on the work done by Marckwald and others, as well as mathematical contributions from Charles Frank, PhD, a theoretical physicist at the University of Bristol, scientists typically used catalysts comprising a metal atom and a chiral substance. They typically used an enantiomer that was as pure as possible the catalyst assuming that combining two mirrored enantiomers would result in a product with equivalent proportions of mirror images. </span></p>
<p><span>Kagan questioned this belief that mixing left- and right-handed catalysts would produce a linear relationship in product chirality, explained Somfai in his remarks during the announcement. “For a long time, it was believed that if we mix a left and right-handed catalyst, the proportion of an ancillary in the product would correlate linearly to that in the catalyst.”</span></p>
<p><span>Kagan’s question led him to test driving a reaction with different combinations of enantiomers in the catalyst. Ultimately, he realized that the relationship to the proportions of enantiomers in the product was not linear as previously thought. One form of the catalyst, the left-right catalyst, drove the chemical reaction in a different way than the two other forms of the catalyst — the right-right or left-left forms. This meant that he had found a way to enhance the formation of one enantiomer over the other. In 1986, he described at least three different asymmetric reactions that displayed what chemists call non-linear effects. </span></p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p><span>Other scientists were keen to build on Kagan’s discovery, including Soai. While studying an asymmetrical chemical reaction with a non-linear effect, he discovered similarities between the structure of the reaction’s catalyst and the products. That discovery suggested that it may be possible to design a reaction in which the catalyst formed itself in an autocatalytic process. After experimenting with different molecules, Soai published a paper in 1995, where he described finding a chiral substance that could create itself although it did not achieve 100 percent enantiomeric purity. </span></p>
<p><span>Eight years later, in 2003, he was finally able to present a chemical reaction, dubbed the </span><i><span>Soai reaction</span></i><span>,  in which only one of the two possible mirror images was formed. Specifically, the chemical reaction results in an excess of an enantiomer which then forms copies of itself, marking the first time a scientist successfully generated chirality from achiral or racemic conditions outside of nature.  As Somfai put it in his remarks “this is probably the coolest experiment in organic chemistry.”</span></p>
<p><span>Following the award announcement, Soai took questions from the press during which stated that he was out shopping near his home in Hiroshima, Japan when he got the call from the committee letting him know he and Kagan would share this year’s prize. “There are many excellent researchers in this field, so I’m very especially glad to receive this prize” and “to share the prize with Professor Henri Kagan, such a famous organic chemist,” he said. </span></p>
<h4><b>Basic research with a broad impact</b></h4>
<p><span>Though this award recognizes basic organic chemistry research, Kagan and Soai’s work has been hugely impactful in both industrial and pharmaceutical manufacturing. Many active drug molecules are also chiral with only one compound having a desired therapeutic effect. The other might have no therapeutic effect or even be harmful. Given these risks, “we need methods to selectively prepare them, and in developing such methods, the findings of this year’s Nobel laureates are important. They provided powerful tools for this,” Somfai said.</span></p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/kagan-soai-win-2026-nobel-prize-in-chemistry-for-discoveries-related-to-asymmetric-organic-synthesis/">Kagan, Soai Win 2026 Nobel Prize in Chemistry for Discoveries Related to Asymmetric Organic Synthesis</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>$2&#45;million investment accelerates psychedelic medicine research at St. Joseph’s Healthcare Hamilton</title>
<link>https://edusehat.com/en/2-million-investment-accelerates-psychedelic-medicine-research-at-st-josephs-healthcare-hamilton</link>
<guid>https://edusehat.com/en/2-million-investment-accelerates-psychedelic-medicine-research-at-st-josephs-healthcare-hamilton</guid>
<description><![CDATA[ St. Joseph’s Healthcare Hamilton is expanding research into the potential medical use of psychedelics following two $1-million philanthropic investments in its new Centre for Health Innovation and Research in Psychedelics (CHIRP). The $2 million in combined funding comes from Hamilton philanthropist Teresa Cascioli and The Juravinski Foundation and represents the first major philanthropic investments in […]
The post $2-million investment accelerates psychedelic medicine research at St. Joseph’s Healthcare Hamilton appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/ChatGPT-Image-Oct-7-2026-08_29_20-AM.png" length="49398" type="image/jpeg"/>
<pubDate>Wed, 07 Oct 2026 22:00:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>2-million, investment, accelerates, psychedelic, medicine, research, St., Joseph’s, Healthcare, Hamilton</media:keywords>
<content:encoded><![CDATA[<p>St. Joseph’s Healthcare Hamilton is expanding research into the potential medical use of psychedelics following two $1-million philanthropic investments in its new Centre for Health Innovation and Research in Psychedelics (CHIRP).</p>
<p>The $2 million in combined funding comes from Hamilton philanthropist Teresa Cascioli and The Juravinski Foundation and represents the first major philanthropic investments in the centre, which was launched last fall.</p>
<p>CHIRP is examining whether carefully controlled, medical-grade psychedelic compounds could eventually provide new treatment options for patients living with conditions that can be difficult to treat using existing therapies.</p>
<p>Research areas include chronic pain, addiction, treatment-resistant depression, post-traumatic stress disorder and neurodegenerative disease. Researchers are also investigating potential applications in women’s mental health and supportive care for people facing serious or terminal illnesses.</p>
<p>The centre is led by Dr. Anthony Adili, St. Joseph’s chief innovation officer and CHIRP’s founding director.</p>
<p>Importantly, the work is taking place in a clinical research environment rather than promoting recreational psychedelic use. Psychedelic compounds remain tightly regulated in Canada, and experimental treatments are being investigated through controlled research and regulatory pathways.</p>
<p>One of CHIRP’s research programs is examining psilocybin — the psychoactive compound found in some mushrooms — as a potential treatment for chronic pain.</p>
<p>The centre is also collaborating with the Michael G. DeGroote Centre for Medicinal Cannabis Research at McMaster University on research examining psilocybin-assisted therapy for cannabis use disorder.</p>
<p>St. Joseph’s is additionally participating in a national research initiative examining psychedelic-assisted therapies. According to the hospital, the centre’s work includes clinical trials authorized through appropriate Health Canada pathways.</p>
<p>The new funding will help CHIRP build research infrastructure, recruit specialized personnel and support clinical trials.</p>
<p>Interest in psychedelic medicine has increased considerably in recent years as researchers revisit substances that were largely excluded from mainstream medical research for decades.</p>
<p>Early studies have suggested potential therapeutic applications for certain psychedelic compounds, particularly for some mental health conditions, but significant questions remain about effectiveness, patient selection, dosing, safety and how treatments should be delivered.</p>
<p>That makes hospital-based research particularly important. Clinical trials can evaluate potential benefits while monitoring adverse effects and determining whether promising results can be reproduced in larger and more diverse patient populations.</p>
<p>For Canadian hospitals, the research also raises broader questions about how psychedelic-assisted treatments might eventually fit into existing mental health, pain, addiction and palliative-care programs if future clinical evidence supports their use.</p>
<p>CHIRP is part of the Research Institute of St. Joseph’s Health System. St. Joseph’s Healthcare Hamilton has longstanding clinical and research programs in mental health and addictions, making the hospital a significant Canadian centre for investigating emerging approaches to treatment.</p>
<p>The $2-million investment will allow researchers to move several areas of psychedelic research forward while building the clinical evidence needed to determine where — and whether — these therapies ultimately have a role in routine patient care.</p>
<p>The post <a href="https://www.hospitalnews.com/2-million-investment-accelerates-psychedelic-medicine-research-at-st-josephs-healthcare-hamilton/">$2-million investment accelerates psychedelic medicine research at St. Joseph’s Healthcare Hamilton</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Wearable ‘Skincubator’ could transform skin&#45;to&#45;skin care for premature babies</title>
<link>https://edusehat.com/en/wearable-skincubator-could-transform-skin-to-skin-care-for-premature-babies</link>
<guid>https://edusehat.com/en/wearable-skincubator-could-transform-skin-to-skin-care-for-premature-babies</guid>
<description><![CDATA[ A new wearable device being studied in neonatal intensive care units could make it possible for some of the smallest and most medically fragile premature babies to spend significantly more time in skin-to-skin contact with their parents. Called the Skincubator, the device is designed to bring some of the protective conditions of a neonatal incubator […]
The post Wearable ‘Skincubator’ could transform skin-to-skin care for premature babies appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/programme-01-umbilical-e1791379139809.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 07 Oct 2026 22:00:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Wearable, ‘Skincubator’, could, transform, skin-to-skin, care, for, premature, babies</media:keywords>
<content:encoded><![CDATA[<p data-pm-slice="1 1 []">A new wearable device being studied in neonatal intensive care units could make it possible for some of the smallest and most medically fragile premature babies to spend significantly more time in skin-to-skin contact with their parents.</p>
<p>Called the <strong>Skincubator</strong>, the device is designed to bring some of the protective conditions of a neonatal incubator directly onto a parent’s chest, allowing premature infants to receive prolonged skin-to-skin care while remaining warm, humidified and supported.</p>
<p>Children’s Memorial Hermann Hospital in Houston recently became the first hospital in the United States to introduce the technology as part of a clinical trial.</p>
<p>For extremely premature infants, skin-to-skin contact — often called kangaroo care — can be difficult to provide for extended periods. Babies may require respiratory support, intravenous lines, monitoring equipment and carefully controlled temperature and humidity.</p>
<p>Moving a medically fragile infant from an incubator to a parent can therefore require significant assistance from the neonatal care team and carries concerns about temperature loss and displacement of tubes and lines.</p>
<p>The Skincubator was developed to address those barriers.</p>
<p>The wearable, non-electrical system secures the infant to the caregiver’s chest while helping maintain warmth and humidity. It also provides a system for organizing and securing respiratory tubing, catheters, probes and other medical lines during transfer and while the baby is being held.</p>
<p>The technology is designed to allow infants receiving respiratory support to remain on a parent’s chest for hours rather than shorter periods of conventional skin-to-skin care.</p>
<p><span class="GIj5s3QLOAfwvnUTtguNxd7PhX1kaY8CM"></span></p>
<p><strong>Early research is encouraging.</strong></p>
<p>A 2026 study published in the <em>American Journal of Perinatology</em> evaluated the Skincubator 2.0 and found that it allowed infants to be transferred to and from skin-to-skin care within a warm and humidified environment. Parents participating in the study reported greater satisfaction with the device’s safety and convenience compared with traditional skin-to-skin care.</p>
<p>Researchers said the technology could help parents provide longer periods of skin-to-skin care for premature infants.</p>
<p>The potential benefits are significant. Skin-to-skin care has been associated with improved temperature regulation, more stable heart and breathing patterns, better sleep and growth, pain reduction and stronger parent-infant bonding.</p>
<p>For parents, the technology could also change the experience of having a child in intensive care.</p>
<p>Instead of watching their newborn primarily through the walls of an incubator, parents may be able to participate more directly in their baby’s care during the earliest and most vulnerable days of life.</p>
<p>The Skincubator has received <strong>Breakthrough Device Designation from the U.S. Food and Drug Administration</strong>, a designation intended to accelerate the development and regulatory review of certain technologies addressing serious or life-threatening conditions.</p>
<p>Importantly, Breakthrough Device Designation does <strong>not</strong> mean the device has received FDA marketing authorization. The technology remains under clinical investigation as researchers continue to evaluate its safety, performance and potential benefits.</p>
<p>The Skincubator has now been used with dozens of premature infants at clinical sites on several continents, according to its developer.</p>
<p>If larger clinical studies confirm its early results, the technology could represent an important shift in neonatal intensive care — allowing advanced medical support and prolonged parent-infant contact to occur at the same time rather than requiring clinicians and families to choose between them.</p>
<p>The post <a href="https://www.hospitalnews.com/wearable-skincubator-could-transform-skin-to-skin-care-for-premature-babies/">Wearable ‘Skincubator’ could transform skin-to-skin care for premature babies</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Screening physicians for cognitive impairment remains rare in U.S.</title>
<link>https://edusehat.com/en/screening-physicians-for-cognitive-impairment-remains-rare-in-us</link>
<guid>https://edusehat.com/en/screening-physicians-for-cognitive-impairment-remains-rare-in-us</guid>
<description><![CDATA[ While nearly one-quarter of U.S. physicians are 65 or older, a new study found that policies to root out cognitive decline among those doctors remain rare in American medicine. Research in JAMA Network noted that while many countries have mandatory retirement policies for judges, commercial pilots and air traffic controllers, no developed country has similar […]
The post Screening physicians for cognitive impairment remains rare in U.S. appeared first on Today&#039;s Hospitalist. ]]></description>
<enclosure url="https://todayshospitalist.com/wp-content/uploads/2026/10/cognitive-decline-in-docs-shutterstock_2514030851-10-7-26.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 07 Oct 2026 21:55:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Screening, physicians, for, cognitive, impairment, remains, rare, U.S.</media:keywords>
<content:encoded><![CDATA[<p>While nearly one-quarter of U.S. physicians are 65 or older, a new study found that policies to root out cognitive decline among those doctors remain rare in American medicine.</p>
<p><a href="https://jamanetwork.com/journals/jama-health-forum/fullarticle/2853528">Research in JAMA Network</a>  noted that while many countries have mandatory retirement policies for judges, commercial pilots and air traffic controllers, no developed country has similar policies policing physicians. “Most jurisdictions rely on self-regulation, collegial oversight and broad professional requirements for maintenance of competency rather than proactive cognitive screening,” researchers found.</p>
<p>Thee study pointed to possible signs of change as the physician workforce ages. The authors noted, for example, that in the U.S., 25 health systems had publicly available cognitive-screening policies for physicians between 70 and 75. Only three of those systems, however, said they used a validated screening instrument like the Montreal Cognitive Assessment, more commonly known as the MicroCog.</p>
<p>While researchers said that cognitive screening for physicians should be viewed as a patient-safety tool, not a punishment, attempts to implement age-based policies are often attacked as discriminatory. <a href="https://www.medpagetoday.com/publichealthpolicy/generalprofessionalissues/123025">A MedPage Today analysis of the study</a>, for example, looked at a cognitive screening program for physicians at Yale New Haven Hospital. That program was rolled out between 2016 and 2019.</p>
<p><a href="https://jamanetwork.com/journals/jama/article-abstract/2758602">A JAMA study of that policy</a> found that of 141 physicians screened for cognitive impairment, 13% had cognitive issues that were “likely” to impair their ability to practice medicine. Despite those findings, Yale New Haven was sued by the Employment Opportunity Commission for age and disability discrimination.</p>
<p>The lawsuit reached the courts in August of 2026, but no decision has been reached. Legal analysts said that any decision reached in the case will likely head to the Supreme Court.</p>
<p>The recent study in JAMA Network cited data that found increased 30-day mortality among patients cared for by physicians aged 60 years or older with low to medium caseloads. That study, however, found no differences among high-volume physicians.</p>
<p>Researchers in the JAMA Network study pointed out that other data have found that the trajectory of cognitive decline is “highly variable,” with many physicians remaining “cognitively intact” well into older age. Researchers said that makes evaluating cognitive impairment in older physicians “complex,” and that there are “substantial limitations to using age alone as a proxy for clinical ability.”</p>
<p>The MedPage Today article noted that when health care organizations launch programs to screen late-career physicians, there’s often a wave of retirements. One researcher interviewed by MedPage Today said that in those situations, physician retirements are often viewed a good thing for patient safety.</p>
<p>But there’s also a possibility that some physicians are retiring simply to avoid testing that they may think is unfair. And in a health care system with a chronic shortage of physicians, that outcome is likely hurting, not helping, patient safety.</p>
<p>The post <a href="https://todayshospitalist.com/screening-physicians-for-cognitive-impairment-remains-rare-in-u-s/">Screening physicians for cognitive impairment remains rare in U.S.</a> appeared first on <a href="https://todayshospitalist.com/">Today's Hospitalist</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Expanding the Possibilities of Next&#45;Generation Sequencing</title>
<link>https://edusehat.com/en/expanding-the-possibilities-of-next-generation-sequencing</link>
<guid>https://edusehat.com/en/expanding-the-possibilities-of-next-generation-sequencing</guid>
<description><![CDATA[ Sequencing by expansion (SBX) and Roche’s AXELIOS 1 platform introduce a new approach to single-molecule sequencing, designed to give researchers flexibility across sequencing workflows.
The post Expanding the Possibilities of Next-Generation Sequencing appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Roche_AXELIOS_10_Team_0400_RGB-1-Copy-e1791316584357.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 07 Oct 2026 07:45:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Expanding, the, Possibilities, Next-Generation, Sequencing</media:keywords>
<content:encoded><![CDATA[<p>Sponsored content brought to you by</p>
<p><a href="https://diagnostics.roche.com/" target="_blank" rel="noopener"><img loading="lazy" decoding="async" class="alignnone wp-image-57334 " src="https://www.genengnews.com/wp-content/uploads/2018/10/38_roche-logo-300x156.jpg" alt="Roche logo" width="227" height="118" srcset="https://www.genengnews.com/wp-content/uploads/2018/10/38_roche-logo-300x156.jpg 300w, https://www.genengnews.com/wp-content/uploads/2018/10/38_roche-logo.jpg 500w" sizes="auto, (max-width: 227px) 100vw, 227px"></a></p>
<p>As genomic research tackles increasingly complex biological questions, researchers need tools capable of looking beyond the most readily resolved regions of the genome. Repetitive sequences, structural variation, and other complex genomic features can be challenging to resolve with many conventional sequencing workflows. At the same time, laboratories must balance accuracy and speed with practical considerations, including read length, throughput, batch size, and access to data.</p>
<p>Sequencing by expansion (SBX), the technology underlying Roche’s AXELIOS 1 platform, takes a different approach to these challenges by physically expanding the space between encoded bases before detection.</p>
<h4><strong>Creating space for a clearer signal</strong></h4>
<p><figure aria-describedby="caption-attachment-338932" class="wp-caption alignright"><img loading="lazy" decoding="async" class="size-medium wp-image-338932" src="https://www.genengnews.com/wp-content/uploads/2026/10/Roche_AXELIOS_10_Team_0400_RGB-1-Copy-e1791316584357-300x197.jpg" alt="AXELIOS" width="300" height="197" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Roche_AXELIOS_10_Team_0400_RGB-1-Copy-e1791316584357-300x197.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Roche_AXELIOS_10_Team_0400_RGB-1-Copy-e1791316584357-1024x673.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/Roche_AXELIOS_10_Team_0400_RGB-1-Copy-e1791316584357-768x505.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/Roche_AXELIOS_10_Team_0400_RGB-1-Copy-e1791316584357.jpg 1083w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Credit: Roche</figcaption></figure></p>
<p>SBX leverages a specialized polymerase that converts the sequence of a target DNA or RNA molecule into a measurable surrogate polymer called an Xpandomer, using nucleotide analogs. The resulting Xpandomer is approximately 50 times longer than the original molecule, creating greater physical separation between encoded bases.</p>
<p>The Xpandomer is then measured as it passes through a reusable complementary metal-oxide semiconductor (CMOS) sensor containing millions of nanopores. Its high signal-to-noise reporters are designed to support accurate, ultra-rapid single-molecule sequencing with near real-time base calling and analysis. This architecture may help researchers investigate a range of genomic features, including single nucleotide variants, insertions and deletions, copy-number alterations, repetitive sequences and other complex structures.</p>
<h4><strong>Flexibility beyond chemistry</strong></h4>
<p>The utility of a sequencing technology depends on more than chemistry alone. Research needs can vary substantially from one project to another and even within the same laboratory. AXELIOS 1 pairs SBX chemistry with a sequencing architecture designed to accommodate that variability. The system offers configurable batch sizes, allowing researchers to run smaller batches without waiting to accumulate enough samples for a larger run.</p>
<p>Researchers can also adjust read length according to experimental needs, with reads up to approximately 1,500 base pairs (with a distribution from ~200bp to ~1500 bp) under appropriate sample and library preparation conditions. The platform is capable of end-to-end, same-day whole genome sequencing (WGS) in research workflows, while near real-time base calling and analysis enable access to data as a run progresses.</p>
<p>This flexibility extends across multiple research applications. SBX has been tested in proof-of-principle studies for WGS, RNA sequencing (RNA-seq), single-cell RNA sequencing (scRNA-seq), spatial analysis, and methylation studies. For each application, the AXELIOS 1 Platform sequences Xpandomer molecules that were created from libraries made with the AXELIOS 1 DNA Library Prep Kit. The data is then analyzed using the no-cost, open-source XOOS bioinformatics analysis suite tailored for SBX. Collaborations also support applications and tools across the sequencing ecosystem, including support for SBX through Google DeepVariant.</p>
<h4><strong>Broadening the genomic picture </strong></h4>
<p><figure aria-describedby="caption-attachment-338931" class="wp-caption alignright"><img loading="lazy" decoding="async" class="size-medium wp-image-338931" src="https://www.genengnews.com/wp-content/uploads/2026/10/Roche_AXELIOS_4x3-Copy-300x224.jpg" alt="AXELIOS" width="300" height="224" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Roche_AXELIOS_4x3-Copy-300x224.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Roche_AXELIOS_4x3-Copy.jpg 368w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Credit: Roche</figcaption></figure></p>
<p>Modern genomics rarely relies on a single experimental approach. Researchers may need to examine genomic variation, gene expression, cellular heterogeneity, or epigenetic changes to build a more complete biological picture. Sequencing platforms that accommodate different applications and project sizes can allow laboratories to design workflows around the scientific question rather than instrument constraints.</p>
<p>By combining a new approach to sequencing chemistry with flexible read lengths, batch sizes, and research applications, AXELIOS 1 is designed to expand the range of genomic questions researchers can pursue. As sequencing continues to evolve, these capabilities could help scientists interrogate previously challenging regions of the genome and build a more complete foundation for biological discovery.</p>
<p><em>For Research Use Only. Not for use in diagnostic procedures. AXELIOS is a trademark of Roche.</em></p>
<p><img loading="lazy" decoding="async" class="alignleft  wp-image-338930" src="https://www.genengnews.com/wp-content/uploads/2026/10/Roche_QR_AXELIOS1article-Copy.jpg" alt="Roche October 2026 sponsored content QR code" width="106" height="106" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Roche_QR_AXELIOS1article-Copy.jpg 210w, https://www.genengnews.com/wp-content/uploads/2026/10/Roche_QR_AXELIOS1article-Copy-150x150.jpg 150w" sizes="auto, (max-width: 106px) 100vw, 106px"></p>
<p>To learn more, visit <a href="https://go.roche.com/AXELIOS1article" target="_blank" rel="noopener">go.roche.com/AXELIOS1article</a></p>
<p>The post <a href="https://www.genengnews.com/sponsored/expanding-the-possibilities-of-next-generation-sequencing/">Expanding the Possibilities of Next-Generation Sequencing</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Biologics Standards for Innovation, Quality and Access</title>
<link>https://edusehat.com/en/biologics-standards-for-innovation-quality-and-access</link>
<guid>https://edusehat.com/en/biologics-standards-for-innovation-quality-and-access</guid>
<description><![CDATA[ This GEN Spotlight on Biologics Standards for Innovation, Quality and Access brings together experts from across biopharma, standards development, and analytical science to examine the challenges of testing increasingly complex modalities, including monoclonal antibodies, cell and gene therapies, and RNA therapeutics. 
The post Biologics Standards for Innovation, Quality and Access appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Getty_2266921838_Anitbody.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 07 Oct 2026 07:45:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Biologics, Standards, for, Innovation, Quality, and, Access</media:keywords>
<content:encoded><![CDATA[<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"></div>
</div>


<div class="wp-block-buttons is-content-justification-center is-layout-flex wp-container-core-buttons-is-layout-3e41869c wp-block-buttons-is-layout-flex">
<div class="wp-block-button"><a class="wp-block-button__link wp-element-button" href="https://events.zoom.us/ev/Ai3vvPMJHQoIUrI-pbyGLgZdQhqInEQhYV0XiOKR8M9jabGObaDx~As0uPqNwKJ7MXzWHm-GuyVwmMXwt3jYXihhnkUz8wb4ogwpTrqjzZYt-9Q" target="_blank" rel="noopener">Register Now</a></div>
</div>

<h3 class="w-full text-left">
    <strong>
        Panelists:
    </strong>
</h3>
<div class="flex flex-row m-0-auto items-stretch justify-center flex-wrap mb-4">
    
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/10/ErinDieveney_headshot.jpg" class="h-full w-full object-cover" alt="Image of Erin Dieveney">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Erin Dieveney</h2>
                <h5 class="mt-0 !text-[15px] !leading-[21px]">Vice President, Quality Assurance<br>Aldevron</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/10/ErinDieveney_headshot.jpg" alt="Image of Erin Dieveney">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Erin Dieveney</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Erin Dieveney leads quality assurance at Aldevron where she helps ensure the quality, compliance, and reliability of products that enable next-generation genomic medicines. Throughout her career, Erin has assumed increasing leadership responsibilities across quality, regulatory affairs, product development, and customer support, developing deep expertise in bringing innovative life sciences technologies to market.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog>
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/10/Khaled-Yamout-edit-1.jpg" class="h-full w-full object-cover" alt="Image of Khaled Yamout">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Khaled Yamout</h2>
                <h5 class="mt-0 !text-[15px] !leading-[21px]">Founder & CEO<br>Y-Chem Consulting</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/10/Khaled-Yamout-edit-1.jpg" alt="Image of Khaled Yamout">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Khaled Yamout</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Khaled Yamout is a thought leader in analytical sciences, quality and manufacturing. He was previously senior director of analytical services and quality control at TriLink Biotechnologies, where he oversaw the Analytical Sciences Center of Excellence and all analytical aspects of method development and validation to product release and stability, in support of regulatory filings for both small and large molecules. Prior to TriLink, Khaled held various positions in quality control, R&D, and manufacturing where he supported several drug products (small molecules and biologics) from clinical phase to commercial. His experience spans Fortune 500 firms as well as small entrepreneurial businesses in the areas of synthetic, analytical, colloidal, surface modification, protein, and antibody modification and purification.</p>
<p>Khaled holds a BS degree in chemistry from the University of Texas at Arlington.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog>
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/10/Kok-Seong-Lim-HQ-1.jpg" class="h-full w-full object-cover" alt="Image of Kok-Seong Lim, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Kok-Seong Lim, PhD</h2>
                <h5 class="mt-0 !text-[15px] !leading-[21px]">Founder and Principal<br>Eight Crest Strategies</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/10/Kok-Seong-Lim-HQ-1.jpg" alt="Image of Kok-Seong Lim, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Kok-Seong Lim, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Kok-Seong Lim, PhD, is a pharmaceutical leader with more than 20 years of experience in biological research and development, specializing in analytical sciences, quality control, and CMC strategy for advanced therapy platforms. He has held multiple management roles at Metagenomi, Aura Biosciences, Editas Medicine, and Thermo Fisher Scientific (formerly Brammer Bio), where he contributed to the advancement of more than ten gene therapies and CRISPR-based medicines for rare diseases and oncology indications.</p>
<p>Throughout his career, Kok-Seong has led the buildout of GMP-compliant facilities and analytical infrastructures to support early- and late-stage development. He has managed complex, multimillion-dollar budgets and contributed to regulatory submissions in both the U.S. and EU. Kok-Seong has served on committees such as the USP Biologics Expert Committee for Cell and Gene Therapy and the Standards Coordinating Body, helping to shape best practices and standards for the cell and gene therapy community.</p>
<p>Kok-Seong earned his PhD in biochemistry from the National University of Singapore and holds a BSc in pharmacy from the University of Strathclyde, Scotland.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog>
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/10/Michael_Lehmicke.jpg" class="h-full w-full object-cover" alt="Image of Michael Lehmicke">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Michael Lehmicke</h2>
                <h5 class="mt-0 !text-[15px] !leading-[21px]"> Senior Vice President, Scientific Affairs<br>Alliance for Regenerative Medicine</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/10/Michael_Lehmicke.jpg" alt="Image of Michael Lehmicke">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Michael Lehmicke</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Michael Lehmicke joined the Alliance for Regenerative Medicine in 2019 as its first director of science and industry affairs. Michael has over 20 years of R&D experience in biomaterials, medical devices, and regenerative medicine. He has led product development teams for class II devices, human cell and tissue-based products, and drug/device combination products. He is a creator and an inventor with multiple U.S. patents to his name.</p>
<p>Michael has an MSc in biomedical engineering, with a focus on tissue engineering, from Drexel University. Michael’s areas of expertise include cell-based tissue engineering, bioceramics, biodegradable polymers, project management, strategic pipeline development, and business development.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog></div>



<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-malblocks-webinars-info"></p><div><strong>Broadcast Date:</strong> <time>Wednesday, October 14, 2026</time><br><ul><li><strong>Time:</strong> <time datetime="2026-10-14T16:30:00.000Z">09:30 PDT, 12:30 EDT, 16:30 GMT</time></li></ul></div>


<div aria-hidden="true" class="wp-block-spacer"></div>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow">
<p class="wp-block-paragraph"><br>As biologics become more diverse, complex, and faster-moving, how can the biotech and biopharma industry ensure that quality standards keep pace with innovation? We will address this fundamental question in the latest <em>GEN</em> Spotlight <strong></strong>on <strong>Biologics</strong> <strong>Standards for Innovation, Quality and Access</strong>, presented in partnership with USP. This virtual event will explore how evolving standards can provide a stronger foundation for developing and manufacturing next-generation therapeutics.</p>


<p class="wp-block-paragraph">This Spotlight on <strong>Biologics</strong> <strong>Standards for Innovation, Quality and Access</strong> brings together experts from across biopharma, standards development, and analytical science to examine the challenges of testing increasingly complex modalities, including monoclonal antibodies, cell and gene therapies, and RNA therapeutics. Sessions will explore when and how to standardize emerging therapies, a practical layered framework for quality—from raw materials and analytical methods to identity, purity, and potency—and the growing importance of community input in developing standards for new modalities.</p>


<p class="wp-block-paragraph">Session highlights include:</p>


<ul class="wp-block-list">
<li>A roundtable explores layered frameworks to ensure quality in multi-modal therapeutic development featuring Erin Dieveney (Aldevron) and Kok-Seong Lim, PhD (Eight Crest Strategies).</li>


<li>A panel discussion on building standards for a multi-therapeutic modality future, featuring Khaled Yamout (Y-Chem Consulting) and Michael Lehmicke(Alliance for Regenerative Medicine)</li>


<li>And a discussion featuring senior executives from USP on the importance of community input in developing standards for new modalities.</li>
</ul>


<p class="wp-block-paragraph">Join us on <strong>Wednesday, October 14</strong>, to discover how standardization can reduce development risk, support innovation, and help establish a shared foundation for the future of biologics.</p>


<p class="wp-block-paragraph">Registration for this 2.5-hour event is free.</p>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><strong>Produced with support from:</strong></p>


<figure class="wp-block-image alignleft size-medium"><a href="https://www.usp.org/" target="_blank" rel=" noopener"><img decoding="async" width="300" height="165" src="https://www.genengnews.com/wp-content/uploads/2026/03/USP_Logo-300x165.jpg" alt="US Pharmacopeia logo" class="wp-image-329674" srcset="https://www.genengnews.com/wp-content/uploads/2026/03/USP_Logo-300x165.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/03/USP_Logo-768x421.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/03/USP_Logo-765x420.jpg 765w, https://www.genengnews.com/wp-content/uploads/2026/03/USP_Logo-696x385.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/03/USP_Logo.jpg 800w" sizes="(max-width: 300px) 100vw, 300px"></a></figure>
</div>
</div>



<p>The post <a href="https://www.genengnews.com/multimedia/biologics-standards-for-innovation-quality-and-access/">Biologics Standards for Innovation, Quality and Access</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Shionogi Grows Rare Disease Portfolio with $2B IntraBio Acquisition</title>
<link>https://edusehat.com/en/shionogi-grows-rare-disease-portfolio-with-2b-intrabio-acquisition</link>
<guid>https://edusehat.com/en/shionogi-grows-rare-disease-portfolio-with-2b-intrabio-acquisition</guid>
<description><![CDATA[ Shionogi signaled its intent to focus on rare disease drugs in April when it acquired Radicava (edaravone), an amyotrophic lateral sclerosis (ALS) treatment, from Tanabe Pharma for $2.5 billion and potential royalties.
The post Shionogi Grows Rare Disease Portfolio with $2B IntraBio Acquisition appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/facilities-collaborations-and-ip-strategy-img-01.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 07 Oct 2026 07:45:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Shionogi, Grows, Rare, Disease, Portfolio, with, 2B, IntraBio, Acquisition</media:keywords>
<content:encoded><![CDATA[<p>Shionogi has agreed to acquire IntraBio for $2 billion, in a deal intended to expand the Japanese pharma’s rare disease portfolio with a drug marketed in the U.S. and European Union for neurological manifestations of Niemann-Pick disease type C (NPC).</p>
<p>The drug, Aqneursa<sup>®</sup> (levacetylleucine), was approved by the FDA in September 2024 for neurological manifestations of Niemann-Pick disease Type C (NPC) in adults and children weighing 15 kg (33 pounds) or more,  and by the European Medicines Agency (EMA) in January.</p>
<p>On September 18, the FDA approved a supplemental New Drug Application expanding the label of Aqneursa to become the first and to date only drug approved for the treatment of ataxia in ataxia-telangiectasia (A-T) patients weighing 15 kg (33 pounds) or more. Aqneursa is now under review by the EMA for adults and children diagnosed with A-T.</p>
<p>“The planned acquisition of IntraBio actively demonstrates Shionogi’s solid commitment to building a leading global rare disease business,” Isao Teshirogi, PhD, Shionogi’s president, CEO, and representative director said Monday in a statement. “Bringing Aqneursa to Shionogi after our acquisition of Radicava<sup>®</sup> will deepen our commitment to rare disease communities, expand our capabilities and strengthen our portfolio as we advance future innovation for patients with significant unmet needs.”</p>
<p>Investors initially appeared less enthusiastic about the IntraBio acquisition, as Shionogi’s shares traded on the Tokyo Stock Exchange fell about 4.5% Monday, from ¥2,786 ($17.61) to ¥2,661 ($16.82)—but the stock bounced back Tuesday, all but recovering with a 3.8% gain that sent shares up to Y2,763 ($17.47).</p>
<p>However, Sumant Kulkarni, a senior analyst covering biotechnology with Canaccord Genuity, viewed the deal more positively.</p>
<p>“In summary, this transaction underscores our view that companies with approved products for rare indications, neuro or otherwise, present significant scarcity value for strategics and investors alike,” Kulkarni wrote Monday in a research note. “We are not entirely surprised by this development, but are encouraged by the upfront consideration.”</p>
<p>Kulkarni added: “In fact, we were surprised that IntraBio had remained independent for the time it did, but the timing makes sense given the recent approval for A-T, which adds another leg to its story.”</p>
<h4><strong>‘Plenty of financial firepower’</strong></h4>
<p>The acquisition of IntraBio comes two months after Teshirogi told <em>Bloomberg News</em> in an interview that Shionogi was “actively pursuing” at least three acquisition opportunities: “From a cash flow perspective, we’ve become a company with plenty of financial firepower. If a good opportunity comes along, there’s absolutely no reason for us to hesitate over any M&A.”</p>
<p>Teshirogi also said Shionogi was looking to expand its U.S. and European manufacturing capacity in order to diversify its production base beyond Japan and thus reduce geopolitical risk over the next decade.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>To that end, Shionogi pursued and won a U.S. government contract in April to establish a Stateside drug product manufacturing site for its Fetroja<sup>®</sup> cefiderocol), a cephalosporin antibacterial indicated to treat adults with complicated urinary tract infections (cUTI) including pyelonephritis; as well as hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP).</p>
<p>The contract—awarded through the Biomedical Advanced Research and Development Authority’s (BARDA) Project BioShield—was initially funded at $119 million with multiyear options for a total of up to $482 million.</p>
<p>Shionogi signaled its intent to focus on rare disease drugs in April when it agreed to acquire Radicava (edaravone), a small molecule treatment for amyotrophic lateral sclerosis (ALS), from Tanabe Pharma for $2.5 billion and a potential royalty on future sales. At the time, Shionogi said the deal would benefit it by adding approximately $700 million in annual global sales during the company’s current 2026 fiscal year, which began on April 1.</p>
<h4><strong>59% leap</strong></h4>
<p>That would represent a 59% leap from Shionogi’s entire FY 2025 earnings before interest taxes, depreciation, and amortization (EBITDA) of ¥187.72 billion ($1.187 billion), up 4.7% from ¥179.296 billion ($1.134 billion) in FY 2024.</p>
<p>Radicava generated ¥94.491 billion ($597.582 million) in the 2025 fiscal year that ended on March 31 of this year.</p>
<p>“Through this acquisition, the Company aims to strengthen its business foundation and enhance its corporate value over the medium to long term by maximizing the value of edaravone and expanding its provision of solutions in the rare disease area,” Shionogi explained in reporting fiscal Q1 (April-June) 2026 results in August.</p>
<p>Radicava is marketed under that name as an intravenous (IV) infusion, and as an oral suspension called Radicava ORS. The IV version was approved by the FDA in 2022 and the oral suspension version, two years later.</p>
<p>Based in Austin, TX, IntraBio was established in 2015 to discover, develop, and commercialize therapies for neurodegenerative diseases with high unmet medical need, by commercializing research generated by its scientific co-founders—Professors Grant Churchill, PhD, Antony Gallone, PhD, and Frances Platt, PhD, all of the University of Oxford; and Michael Strupp, MD, of the University of Munich.</p>
<div class="my-8"><span data-render-ad="6"></span></div>
<p>Privately held IntraBio finished last year with a $35.8 million net loss on net sales of $67.867 million—all of it generated from sales of Aqneursa—according to data disclosed by Shionogi in its announcement of the acquisition.</p>
<p>Shionogi is expected to close on its acquisition of IntraBio during this quarter, subject to customary closing conditions.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/shionogi-grows-rare-disease-portfolio-with-2b-intrabio-acquisition/">Shionogi Grows Rare Disease Portfolio with $2B IntraBio Acquisition</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Lock Down the Critical Factors in Oligo and Oligo&#45;Conjugate Characterization with Stunner and Honeybun</title>
<link>https://edusehat.com/en/lock-down-the-critical-factors-in-oligo-and-oligo-conjugate-characterization-with-stunner-and-honeybun</link>
<guid>https://edusehat.com/en/lock-down-the-critical-factors-in-oligo-and-oligo-conjugate-characterization-with-stunner-and-honeybun</guid>
<description><![CDATA[ This GEN webinar follows oligo quantification from method development through conjugate characterization.
The post Lock Down the Critical Factors in Oligo and Oligo-Conjugate Characterization with Stunner and Honeybun appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GettyImages-1826415379-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 07 Oct 2026 07:45:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Lock, Down, the, Critical, Factors, Oligo, and, Oligo-Conjugate, Characterization, with, Stunner, and, Honeybun</media:keywords>
<content:encoded><![CDATA[<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"></div>
</div>


<p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Register Now</button></p>

<h3 class="w-full text-left">
    <strong>
        Panelists:
    </strong>
</h3>
<div class="flex flex-row m-0-auto items-stretch justify-center flex-wrap mb-4">
    
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/10/Kevin_Unchained-Labs_Headshot-scaled.jpg" class="h-full w-full object-cover" alt="Image of Kevin Lance, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Kevin Lance, PhD</h2>
                <h5 class="mt-0 !text-[15px] !leading-[21px]">Director, Product Management<br>Unchained Labs</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/10/Kevin_Unchained-Labs_Headshot-scaled.jpg" alt="Image of Kevin Lance, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Kevin Lance, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Kevin Lance covers the Stunner portfolio globally at Unchained Labs. His expertise includes biophysical characterization of proteins, ADCs, nucleic acids, viral vectors, and LNPs. Prior to Unchained Labs, his research experience covered the fields of sustained antibody delivery and nanotechnology. He earned his Ph.D. in Bioengineering from the joint UC Berkeley – UCSF Bioengineering Graduate Program.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog></div>



<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-malblocks-webinars-info"></p><div><strong>Broadcast Date:</strong> <time>Thursday, November 12, 2026</time><br><ul><li><strong>Time:</strong> <time datetime="2026-11-12T16:00:00.000Z">08:00 PST, 11:00 EST, 16:00 GMT</time></li></ul></div>


<div aria-hidden="true" class="wp-block-spacer"></div>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow">
<p class="wp-block-paragraph">Oligonucleotide therapeutics, including ASOs, siRNAs, aptamers, and now antibody- and peptide-oligonucleotide conjugates (AOCs and POCs) are gaining momentum fast. But the chemical modifications and conjugations that make them work also make them harder to characterize than classic nucleic acids. Accurate quantification is the foundation of almost every assay and understanding how to arrive at the right concentration factor is the critical first step that echoes through every downstream decision.</p>


<p class="wp-block-paragraph">This webinar follows oligo quantification from method development through conjugate characterization. We’ll cover what to consider when setting concentration factors and how UV-Vis extends to measuring conjugation ratio in AOCs and POCs.</p>


<p class="wp-block-paragraph">We’ll also explore the boundaries of dynamic light scattering in oligo and nucleic acid formulation development. Oligos are flexible and sticky, which makes them hard to characterize by DLS. We’ll show what DLS can and can’t tell you across different lengths of nucleic acid constructs, up through mRNA.</p>


<p class="wp-block-paragraph">Finally, we’ll look at viscosity data for oligonucleotides and nucleic acids to answer in-demand questions on high-concentration formulation and subcutaneous delivery.</p>


<p class="wp-block-paragraph"><strong>Key learning objectives</strong></p>


<ul class="wp-block-list">
<li>Understand the pieces that influence concentration factors for oligonucleotide quantification</li>


<li>Extend UV-Vis quantification to AOC and POC characterization, including conjugation ratio</li>


<li>Set realistic expectations for DLS in nucleotide and nucleic acid characterization</li>


<li>Understand the relationships between viscosity, formulations, and nucleic acids</li>
</ul>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><em>A live Q&A session will follow the presentation offering you a chance to pose questions to our expert panelist.</em></p>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><strong>Produced with support from:</strong></p>


<figure class="wp-block-image alignleft size-medium"><a href="https://www.unchainedlabs.com/" target="_blank" rel=" noopener"><img decoding="async" width="300" height="67" src="https://www.genengnews.com/wp-content/uploads/2021/03/UNCHAINED-LABS-Logo_large-300x67.jpg" alt="UNCHAINED LABS Logo" class="wp-image-162665" srcset="https://www.genengnews.com/wp-content/uploads/2021/03/UNCHAINED-LABS-Logo_large-300x67.jpg 300w, https://www.genengnews.com/wp-content/uploads/2021/03/UNCHAINED-LABS-Logo_large.jpg 500w" sizes="(max-width: 300px) 100vw, 300px"></a></figure>
</div>
</div>

<p>The post <a href="https://www.genengnews.com/multimedia/webinars/lock-down-the-critical-factors-in-oligo-and-oligo-conjugate-characterization-with-stunner-and-honeybun/">Lock Down the Critical Factors in Oligo and Oligo-Conjugate Characterization with Stunner and Honeybun</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>New Calibration Framework Improves Confidence in AI Virtual Cell Models</title>
<link>https://edusehat.com/en/new-calibration-framework-improves-confidence-in-ai-virtual-cell-models</link>
<guid>https://edusehat.com/en/new-calibration-framework-improves-confidence-in-ai-virtual-cell-models</guid>
<description><![CDATA[ Across 14 genetic perturbation datasets and 18 evaluation metrics, commonly used measures such as mean squared error and control-referenced Pearson correlation were often poorly calibrated, particularly in datasets with weaker perturbations. 
The post New Calibration Framework Improves Confidence in AI Virtual Cell Models appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/Getty_2257382308_CellInterior-e1791306952785.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 07 Oct 2026 07:45:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>New, Calibration, Framework, Improves, Confidence, Virtual, Cell, Models</media:keywords>
<content:encoded><![CDATA[<p>AI virtual cell models may be more capable of predicting cellular responses to genetic perturbations than earlier benchmarks suggested—but only when researchers use evaluation metrics sensitive enough to detect biologically meaningful signals, according to a new study from Shift Bioscience and collaborators.</p>
<p>Published in <em>Nature Biotechnology</em>, the paper, “<a href="https://www.nature.com/articles/s41587-026-03307-w" target="_blank" rel="noopener">Deep Learning Perturbation Models Can Outperform Baselines on Calibrated Metrics</a>,” introduces a positive-control baseline and a framework for testing whether commonly used metrics can distinguish meaningful model predictions from less informative ones.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>Genetic perturbation models, a subset of AI virtual cells, predict how activating or inhibiting genes will alter a cell’s transcriptome. If reliable, these models could support scalable <em>in silico</em> screens for therapeutic targets. However, recent studies found that sophisticated deep learning systems often failed to outperform simple baselines, raising doubts about whether the models captured perturbation-specific biology.</p>
<p>The researchers argued that part of the problem lies in the benchmarks themselves. “The promise of <em>in silico</em> perturbation models, or ‘virtual cells,’ is that the same scaling laws will apply, and that providing them with ever-increasing quantities of biological data and compute will improve their prediction of real-world experimental results,” Brendan Swain, PhD, CSO and founder of Shift Bioscience, told <em>GEN</em>. “However, early benchmarks of virtual cell models revealed apparently poor performance, casting doubt on their potential.”</p>
<p>To assess this issue, the team developed an “interpolated duplicate” positive control that combines the average perturbation profile with an independent technical duplicate, weighting each gene by the strength of evidence that it was affected. They then introduced the dynamic range fraction, or DRF, which measures how effectively a metric separates this positive control from a negative control.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>Across 14 genetic perturbation datasets and 18 evaluation metrics, commonly used measures such as mean squared error and control-referenced Pearson correlation were often poorly calibrated, particularly in datasets with weaker perturbations. The authors also added that, “In contrast, weighted and rank-based metrics—including WMSE, weighted R<sub>Δ</sub><sup>2</sup>​, and normalized inverse rank (NIR)—consistently exhibited higher calibration across datasets, reflecting their shared design principle of emphasizing perturbation-specific signal.”</p>
<p>Using the better-calibrated measures, the researchers benchmarked nine deep learning models on tasks involving unseen single-gene perturbations and unseen gene combinations. Earlier models, including scGPT and GEARS, often surpassed uninformative baselines once their predictions were evaluated with calibrated metrics. More recent systems, including PRESAGE and scLambda, showed stronger performance, although results varied by dataset and metric.</p>
<p>The analysis also highlighted the importance of dataset design. In Norman19, where the training data covered only 0.63% of possible gene combinations, a simple additive baseline remained difficult to beat. In Wessels23, which covered 10.3% of possible combinations, multiple models surpassed the additive baseline, indicating that deep learning models can outperform additivity when trained on broader portions of the combinatorial landscape.</p>
<p>“Our findings show that by using well-calibrated metrics and the right dataset, virtual cell models can generate biologically meaningful insights,” said Swain. “As a result, we can use them with greater confidence to identify promising new targets that are relevant to aging and disease. We are applying this framework directly in our target identification program, focusing on targets whose inhibition can support both rejuvenation and treatment of age-related disease, giving us a clearly defined route towards clinical development.”</p>
<p>Shift Bioscience, a Cambridge, U.K.–based biotechnology company, plans to apply the framework in large-scale <em>in vitro</em> and <em>in silico</em> screens for inhibition targets relevant to cellular rejuvenation and age-related disease, initially focusing on fibrosis. “Ultimately, we hope these tools will guide researchers as they develop better and better virtual cell models,” Swain told <em>GEN</em>.</p>
<p>The post <a href="https://www.genengnews.com/topics/artificial-intelligence/new-calibration-framework-improves-confidence-in-ai-virtual-cell-models/">New Calibration Framework Improves Confidence in AI Virtual Cell Models</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Weight&#45;loss drugs show signs of slowing biological aging, say drugmakers</title>
<link>https://edusehat.com/en/weight-loss-drugs-show-signs-of-slowing-biological-aging-say-drugmakers</link>
<guid>https://edusehat.com/en/weight-loss-drugs-show-signs-of-slowing-biological-aging-say-drugmakers</guid>
<description><![CDATA[ Popular weight-loss drugs may do more than help people shed pounds. They might also melt away the years. Drug giants Eli Lilly and Novo Nordisk say patients taking their drugs age less quickly, according to readouts from molecular “aging clocks.” Such clocks assess a person’s biological age by looking at changes to DNA that accumulate… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/10/silo-clock2.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 07 Oct 2026 04:10:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Weight-loss, drugs, show, signs, slowing, biological, aging, say, drugmakers</media:keywords>
<content:encoded><![CDATA[<p>Popular weight-loss drugs may do more than help people shed pounds. They might also melt away the years.</p>



<p>Drug giants Eli Lilly and Novo Nordisk say patients taking their drugs age less quickly, according to readouts from molecular “aging clocks.”</p>



<p>Such clocks assess a person’s biological age by looking at changes to DNA that accumulate with time, or, in newer versions, by tracking levels of key proteins.</p>



<p>Both companies found that overweight or diabetic patients taking the drugs, called GLP-1s, had reduced biological age compared to those taking a placebo, although the difference varied widely, depending on which type of clock was used, and what organ was tested. </p>



<p>Overall, the difference was around “two to three years,” according to Nikolaj Roed, a global project leader at Novo, who says the company has been seeing “improved biological age in our patients across trials and across different tissues.” </p>



<p>The findings add to wide speculation among scientists that GLP-1 drugs, as they are known, are acting on basic causes of aging and might be a true longevity treatment.</p>





<p>“Two years is a pretty strong effect, in my book,” says Steve Horvath, a professor at the University of California, Los Angeles, who’s credited with<a href="https://www.technologyreview.com/2018/10/19/139463/want-to-know-when-youre-going-to-die/"> inventing aging clocks</a><em>. </em>Horvath says the emerging data could provide “evidence that these GLP-1 drugs are actually what is known as geroprotectors, medications that slow or possibly even reverse biologic aging.”</p>



<p>The companies shared their findings over the weekend during Aging Research & Drug Discovery, a conference devoted to seeking scientific remedies for old age. While that quest has not yet produced any clear-cut success, some scientists now think Novo’s drug semaglutide (sold under the names Ozempic and Wegovy) is coming close.</p>



<p>“In an unhealthy population, I do think it’s an anti-aging drug,” says Vadim Gladyshev, a Harvard biologist who assisted Novo with its molecular measurements. “But in a healthy population, no one knows.”</p>



<p>The drugs cause weight loss by stimulating a receptor, GLP-1, that tells your brain you’re not hungry. Yet real-world studies have shown much wider benefit. The drugs improve kidney function, reduce blood pressure, and even sharply cut the overall chance of death.</p>



<p>“If the question is,‘Can semaglutide reach several diseases relevant to health span and aging?’ we know we can say the answer is yes,” said Alejandro Aguayo-Orozco, a senior scientific director at Novo, the Danish drug giant, during the meeting.</p>



<p>The next question to answer, he said, is whether such effects are accompanied by changes to molecular measures of biological aging: “When you intervene with semaglutide, does it actually move the clocks in any direction? And the answer is yes.” </p>





<p>The company found that, over time, the drugs cause a wide slowdown in aging clocks—as much as 4 years in the case of a clock that looks at heart proteins. “I think it’s pretty clear that the organ age is shifting,” said Aguayo-Orozco.</p>



<p>The studies are also a huge boost for the science of aging clocks. Although these measures reflect a person’s age, it’s been uncertain if they are useful as true biomarkers. Now clock makers have evidence  that their readouts show a drop in age when people take drugs with broad, well-demonstrated benefits.  </p>



<p>“The clock people have been pushing for a decade to get this kind of study done,” says Yuge Ji, a biologist who previously worked in the field and now runs a startup, Reflector Bio. “It’s huge for them.”</p>



<p>As part of its study, Novo took blood draws from 10,052 people, half on the drug and half on a placebo. Their blood, collected at the start of the study as well as months later, was then measured with “proteomic clocks,” which use levels of key proteins to predict a person’s <a href="https://www.nature.com/articles/s41591-024-03164-7">age and risk of dying</a>. </p>



<p>Scientists at Eli Lilly performed similar research on their GLP-1 drug, tirzepatide, using so-called “epigenetic” clocks that assess age by counting accumulated changes to DNA. Lilly’s study was smaller, but also found that for the most part, molecular time moved more slowly for people on the drug.  </p>



<p>“All the clocks are telling a consistent story that we’re seeing a reduction in age,” Kevin Duffin, vice president for aging research at Lilly, said during the conference. “It’s not like we’re going to reverse age by 30 years or something, but it’s a significant reduction.”</p>



<p>The molecules have become the best selling drugs in the world,, with Lilly’s tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity, topping the list<a href="https://www.drugdiscoverytrends.com/pharma-50-keytruda-holds-the-top-brand-slot-but-tirzepatide-and-semaglutide-have-already-passed-it-at-the-molecule-level-in-fy2025"> with more than $36 billion in revenue to the company last year</a>. Novo’s semaglutide, also sold under more than one name, was a close second.</p>



<p>Alex Zhavoronkov, the founder of Insilico Medicine, and the organizer of the Boston meeting, says that extending lives by even one year across the world’s population would be equal to tens of millions of lifetimes.  </p>



<p>Last month Zhavoronkov showed that one of his company’s drugs, for a lung disease, also<a href="https://www.wsj.com/tech/biotech/insilicos-co-ceo-has-big-hopes-that-fibrosis-drug-can-reverse-aging-too-1c5bf5a6"> reversed the signals from aging clocks</a>. That drug is experimental, but Zhavoronkov has sought to promote the idea that humanity is entering a new era of longevity medicines. He also disclosed during the event that he has been “microdosing” the available weight-loss drugs, even though he is not overweight.</p>





<p>“I am on tirzepatide and I am an equal-opportunity injector of semaglutide as well,” Zhavoronkov said.</p>



<p>It was part of an effort to directly raise the question of whether the first mass-market anti-aging remedy is already here.</p>



<p>“Do you think a reasonable person should start taking semaglutide?” he asked Aguayo-Orozco, the Novo scientist, in front of a crowded audience.</p>



<p>“I am not a physician. I cannot answer that question,” Aguayo-Orozco replied.</p>



<p>Several people cautioned that GLP-1 drugs do have side effects, including muscle loss. That is one reason they might not help most people, says Horvath, who says he isn’t ready to take the drugs himself, although he’s thought about it.</p>



<p>“Clearly, the drugs have many benefits in obese people, but I did not yet see sufficient evidence that they will benefit skinny people,” he said. “I guess we will have to wait.”</p>



<p>Answers could start to emerge in a year or two. This past January, a US agency, ARPA-H, put $38 million toward a study in Texas that will attempt to determine whether semaglutide has anti-aging effects in healthy people over 60. That research will look at changes in cognition, mobility, and acuity of the senses.</p>



<p>That project also seeks to help define a regulatory pathway for anti-aging drugs and to “build a new therapeutic industry” around longevity.</p>]]> </content:encoded>
</item>

<item>
<title>Inside All&#45;ScaleFlow: Continuous End&#45;to&#45;End RNA&#45;LNP Manufacturing</title>
<link>https://edusehat.com/en/inside-all-scaleflow-continuous-end-to-end-rna-lnp-manufacturing</link>
<guid>https://edusehat.com/en/inside-all-scaleflow-continuous-end-to-end-rna-lnp-manufacturing</guid>
<description><![CDATA[ Dillico’s GMP-ready Continuous Manufacturing by Engineering, Not Hype
The post Inside All-ScaleFlow: Continuous End-to-End RNA-LNP Manufacturing appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Dillico-Copy.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 07 Oct 2026 04:10:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Inside, All-ScaleFlow:, Continuous, End-to-End, RNA-LNP, Manufacturing</media:keywords>
<content:encoded><![CDATA[<p>Sponsored content brought to you by</p>
<p><a href="https://dillico.com/" target="_blank" rel="noopener"><img loading="lazy" decoding="async" class="alignnone wp-image-338883 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/10/Dillico_logo-300x112.jpg" alt="Dillico logo" width="300" height="112" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Dillico_logo-300x112.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Dillico_logo-1024x383.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/Dillico_logo-768x287.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/Dillico_logo.jpg 1468w" sizes="auto, (max-width: 300px) 100vw, 300px"></a></p>
<p>Messenger RNA (mRNA) is expanding from pandemic-scale vaccines toward a wider therapeutic portfolio. Recent Phase 3 success for an individualized neoantigen therapy from Moderna reinforces the clinical relevance of the lower-volume end of that spectrum, while COVID-19 established the opposite extreme. Clinical success is encouraging emerging and established developers to advance RNA medicines either through CDMOs or by building internal capacities. For increased development and production efficiency, CDMOs and drug developers need fast changeovers and flexibility across sequences and scales. All-ScaleFlow<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> integrates RNA synthesis, purification, buffer exchange, and LNP formation to help democratize development.</p>
<h4><strong>A patented semi-continuous IVT core</strong></h4>
<p><figure aria-describedby="caption-attachment-338880" class="wp-caption alignright"><img loading="lazy" decoding="async" class="size-medium wp-image-338880" src="https://www.genengnews.com/wp-content/uploads/2026/10/Dillico_Figure1-Copy-Copy-300x226.jpg" alt="spiral-shaped semi-continuous reacto" width="300" height="226" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Dillico_Figure1-Copy-Copy-300x226.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Dillico_Figure1-Copy-Copy-768x579.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/Dillico_Figure1-Copy-Copy.jpg 900w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Figure 1. Dillico’s spiral-shaped semi-continuous reactor seamlessly handles batch reaction conditions without requiring larger batch vessels. [Dillico]</figcaption></figure></p>
<p>RNA synthesis begins with fixed IVT unit volumes injected into Dillico’s patented, spiral-shaped semi-continuous reactor (<em>Fig 1</em>). The reactor is held in a temperature-controlled environment. Each unitary volume (UnV) advances by one loop periodically and the mature IVT crude UnV exits for optional enzymatic treatment and quenching. This design preserves defined batch reaction conditions without relying on progressively larger batch vessels.</p>
<h4 class="no-clear"><strong>Continuous purification and RNA-LNP formulation</strong></h4>
<p>As illustrated in the process flow diagram (<em>Fig 2</em>), All-ScaleFlow integrates alternating multi-column chromatography (dT Oligo resin or monolith) and multi-stage SPTFF for RNA purification, concentration, and buffer exchange. Surge tanks buffer cyclic chromatography eluate and maintain controlled flow into continuous purification SPTFF and LNP mixing. After encapsulation, a second multi-stage SPTFF step removes ethanol and performs final buffer exchange before in-line dilution or excipient addition and sterile filtration. By coordinating flow rates and interfaces, the platform maintains continuous production from IVT crude to formulated mRNA-LNP while minimizing intermediate holds.</p>
<p><figure aria-describedby="caption-attachment-338881" class="wp-caption aligncenter"><img loading="lazy" decoding="async" class="wp-image-338881" src="https://www.genengnews.com/wp-content/uploads/2026/10/Dillico-Process-Diagram-Copy-1024x359.jpg" alt="ScaleFlowTM" width="796" height="279" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Dillico-Process-Diagram-Copy-1024x359.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/Dillico-Process-Diagram-Copy-300x105.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Dillico-Process-Diagram-Copy-768x269.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/Dillico-Process-Diagram-Copy.jpg 1400w" sizes="auto, (max-width: 796px) 100vw, 796px"><figcaption class="wp-caption-text">Figure 2. Simplified Process Flow Diagram of the All-ScaleFlowTM.</figcaption></figure></p>
<h4><strong>Automated cleaning and sterilization onboard</strong></h4>
<p>To reduce supply chain risks and achieve long-term sustainability, an automated clean-in-place and sterilization-in-place (CIP/SIP) station is integrated on the system. It uses common cleanroom utilities to clean and sanitize the stainless-steel process path. This could save up to 450 kg of single-use plastic (~200 k$) for a large-scale batch IVT production.</p>
<h4><strong>Demonstrated across RNA sequence types</strong></h4>
<p>The synthesis approach has been successfully demonstrated with multiple mRNA and self-amplifying RNA (saRNA) sequences with length ranging from 400 bp to 12,000 bp. Working across different sequences is important for a platform intended to serve diverse vaccines and therapeutics.</p>
<h4><strong>The Process Simulator turns a sequence into a master recipe</strong></h4>
<p><figure aria-describedby="caption-attachment-338877" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-338877 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/10/Dillico-Equipment-Copy-300x125.jpg" alt="Dillico Equipment" width="300" height="125" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Dillico-Equipment-Copy-300x125.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Dillico-Equipment-Copy.jpg 525w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Credit: Dillico</figcaption></figure></p>
<p>Dillico’s Process Simulator embeds mechanistic process models built from an empirical knowledge base generated through experiments with mainstream, off-the-shelf process components. From product and process requirements, it calculates the global constraints needed to operate the continuous process as a coordinated system and identifies robust conditions that meet quality attributes and throughput targets. This reduces the physical experiments required during process development and supports right-first-time execution, avoiding costly trial-and-error with production materials and analytical testing. Thanks to the Process Simulator, users will be guided through a structured, step-by-step workflow that facilitates technology transfer and lowers the entry barrier for teams new to continuous processing. As part of the digital infrastructure, real process data are contextualized, making them data-lake-ready.</p>
<p><img loading="lazy" decoding="async" class="alignleft wp-image-338878" src="https://www.genengnews.com/wp-content/uploads/2026/10/Dillico_QRCode-293x300.jpg" alt="Dillico October 2026 QR Code" width="112" height="115" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Dillico_QRCode-293x300.jpg 293w, https://www.genengnews.com/wp-content/uploads/2026/10/Dillico_QRCode.jpg 396w" sizes="auto, (max-width: 112px) 100vw, 112px"></p>
<p>Explore All-ScaleFlowTM and request the Evidence Package</p>
<p>The post <a href="https://www.genengnews.com/sponsored/inside-all-scaleflow-continuous-end-to-end-rna-lnp-manufacturing/">Inside All-ScaleFlow: Continuous End-to-End RNA-LNP Manufacturing</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Investigating Prions and Protein Aggregation at High Sensitivity and Throughput</title>
<link>https://edusehat.com/en/investigating-prions-and-protein-aggregation-at-high-sensitivity-and-throughput</link>
<guid>https://edusehat.com/en/investigating-prions-and-protein-aggregation-at-high-sensitivity-and-throughput</guid>
<description><![CDATA[ With no cure available for prion diseases, researchers are striving to improve assay sensitivity and exploit the benefits of real-time monitoring to support the development of better diagnostic and treatment approaches.
The post Investigating Prions and Protein Aggregation at High Sensitivity and Throughput appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/BMG_Labtech_AdobeStock_614101305-Copy.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 07 Oct 2026 04:10:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Investigating, Prions, and, Protein, Aggregation, High, Sensitivity, and, Throughput</media:keywords>
<content:encoded><![CDATA[<p>Sponsored content brought to you by</p>
<p><a href="https://www.bmglabtech.com/" target="_blank" rel="noopener"><img decoding="async" class="alignnone wp-image-76800 size-medium" src="https://www.genengnews.com/wp-content/uploads/2018/10/BMG_Logo1371381992-300x128.jpg" alt="BMG Labtech logo" width="300" height="128" srcset="https://www.genengnews.com/wp-content/uploads/2018/10/BMG_Logo1371381992-300x128.jpg 300w, https://www.genengnews.com/wp-content/uploads/2018/10/BMG_Logo1371381992-768x327.jpg 768w, https://www.genengnews.com/wp-content/uploads/2018/10/BMG_Logo1371381992-1024x436.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2018/10/BMG_Logo1371381992-696x296.jpg 696w, https://www.genengnews.com/wp-content/uploads/2018/10/BMG_Logo1371381992-1068x455.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2018/10/BMG_Logo1371381992-986x420.jpg 986w, https://www.genengnews.com/wp-content/uploads/2018/10/BMG_Logo1371381992.jpg 1249w" sizes="(max-width: 300px) 100vw, 300px"></a></p>
<h4><strong>Introduction</strong></h4>
<p>Prions are infectious proteins that cause neurodegenerative diseases in animals including bovine spongiform encephalopathy (cattle), Creutzfeldt-Jakob disease (humans), and chronic wasting disease (deer, elk and other cervids).<sup>1</sup> Prion diseases, also known as transmissible spongiform encephalopathies, result from misfolded proteins that accumulate primarily in the cells of the nervous system including the brains of infected animals. More widely, protein misfolding is linked to diverse neurological and non-neurological diseases and further research is needed in many areas due to the central importance of protein folding and aggregation in biology.</p>
<p>Prions propagate after regularly folded prion proteins (PrP<sup>C</sup>) are converted into misfolded, aggregation-prone PrP<sup>Sc</sup> proteins that build up and yield amyloids. These misfolded proteins and their aggregates damage nerve and other cells and, over time, lead to a decline in brain function and ultimately death.  With no cure available for prion diseases, researchers are striving to improve assay sensitivity and exploit the benefits of real-time monitoring to support the development of better diagnostic and treatment approaches.</p>
<h4><strong>RT-QuIC assays and microplate readers for prion analysis</strong></h4>
<p>Prions typically replicate by a series of sequential, amplifying events. Misfolded PrP<sup>Sc</sup> acts as a point of recruitment of normal PrP<sup>C</sup> cellular prion proteins. This interaction converts the recruited normal protein into the abnormal conformation setting in place a chain reaction where the protein-protein aggregates grow to produce a larger seed of misfolded proteins. As the aggregates grow, they can fragment to produce new nucleation sites. The seeds are eventually transformed into fibers of amyloid-rich assemblies that comprise significant amounts of beta-sheet conformations of the misfolded proteins.</p>
<p><figure aria-describedby="caption-attachment-338896" class="wp-caption alignleft"><img decoding="async" class="size-medium wp-image-338896" src="https://www.genengnews.com/wp-content/uploads/2026/10/BMG_Labtech_AN232-Fig1-Copy-300x182.jpg" alt="Kinetic RT-QuIC analysis" width="300" height="182" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/BMG_Labtech_AN232-Fig1-Copy-300x182.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/BMG_Labtech_AN232-Fig1-Copy-1024x621.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/BMG_Labtech_AN232-Fig1-Copy-768x465.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/BMG_Labtech_AN232-Fig1-Copy-1536x931.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2026/10/BMG_Labtech_AN232-Fig1-Copy-2048x1241.jpg 2048w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Figure 1. Kinetic RT-QuIC analysis of hamster tissue homogenate dilutions using thioflavin T (ThT) assays on a microplate reader.<br>[BMG LABTECH]</figcaption></figure></p>
<p>The most widely used assay for detecting misfolded prions in biological samples is the RT-QuIC (Real-time quaking-induced conversion) assay. RT-QuIC assays are highly sensitive, seeding amplification assays that detect disease-associated prion activity. Formation of amyloid proteins is measured in real time using the fluorescent dye thioflavin T (ThT) whose emission increases significantly upon binding to beta-sheet-rich amyloid structures. Other dyes such as Congo Red are available that bind to amyloid but show reduced specificity for fibril proteins. Cyclic shaking accelerates fragmentation of the growing fibrils and produces a rapid amplification of the original prion seed. In practice, RT-QuIC assays generate characteristic amplification curves (<em>figure 1</em>) that comprise a baseline phase, an exponential increase in fluorescence, and a plateau phase. The lag time, maximum fluorescence, and reaction kinetics can provide quantitative or semi-quantitative measurements of prion seeding activity.</p>
<p>In the experiments shown in figure 1, scrapie brain homogenates were harvested 10 days after inoculation, incubated over time with shaking for the specified serial dilutions of Syrian hamster 263K cells, and ThT fluorescence was measured. The assays were quantified by measuring the loss of seeding activity at the end-point dilution.</p>
<h4><strong>Microplate readers and detection technologies for the investigation of amyloid</strong></h4>
<p>Microplate readers offer a robust platform for performing prion assays and measuring protein misfolding and aggregation. The ability to combine sensitive, high-performance kinetic fluorescence measurements with periodic cycles of rigorous shaking and consistent temperature control makes them the most widely adopted and practicable system for effective RT-QuIC assays.</p>
<p>Originally, the RT-QuIC assay was developed on the FLUOstar<sup>®</sup> Omega microplate reader from BMG LABTECH which quickly became an international standard for prion analysis. BMG LABTECH readers, which continue to lead the way for prion detection and activity measurements, offer a robust platform for shaking for extended periods of time (over multiple days), while periodically reading the fluorescent signal as ThT is incorporated into amyloid aggregates.</p>
<h4><strong>Applications for protein misfolding</strong></h4>
<p>As mentioned earlier, protein misfolding has impact beyond prion disease and is a hallmark of impaired function in a wide range of conditions including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis. The way certain proteins misfold and aggregate is closely tied to how proteins become toxic and cause neurodegenerative diseases.</p>
<p>BMG LABTECH´s application note “Monitoring amyloid-beta aggregation in real-time using a FLUOstar Omega microplate reader<sup>2</sup>” provides one example where the accumulation of misfolded amyloid protein aggregates linked to Alzheimer’s disease is measured using ThT. <em>Figure 2</em> shows some signal curves for samples and controls where ThT incorporation into newly formed amyloid-beta fibrils is measured.</p>
<p><figure aria-describedby="caption-attachment-338895" class="wp-caption alignleft"><img loading="lazy" decoding="async" class="size-medium wp-image-338895" src="https://www.genengnews.com/wp-content/uploads/2026/10/BMG_Labtech_AN250-Fig2-Copy-Copy-300x176.jpg" alt="samples containing either fixed or freshly frozen wild type or APP23 brain homogenates" width="300" height="176" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/BMG_Labtech_AN250-Fig2-Copy-Copy-300x176.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/BMG_Labtech_AN250-Fig2-Copy-Copy-768x450.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/BMG_Labtech_AN250-Fig2-Copy-Copy.jpg 875w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Figure 2. Signal curves for samples containing either fixed or freshly frozen wild type or APP23 brain homogenates. [BMG LABTECH]</figcaption></figure></p>
<p>In figure 2, error bars represent the deviation of replicate wells within one plate from the mean. All signal curves show a clear increase in fluorescence with time. This increase illustrates the incorporation of ThT into the newly formed amyloid-beta fibrils. After some time, a plateau is reached that is considered as the endpoint of amyloid formation and ThT incorporation process.</p>
<p>Protein misfolding and aggregation are likely to play a critical role in many processes related to aging. Misfolded proteins are also thought to influence different aspects of metabolic dysfunction and amyloid accumulation although the mechanism for most of these effects remains poorly understood. ThT assays thus offer applications across multiple disease areas and research domains.</p>
<h4><strong>Future developments</strong></h4>
<p>RT-QuIC assays have significantly accelerated research and analysis into prions compared with earlier more costly and lengthy bioassays where infected animals were studied over months. RT-QuIC assays also offer potential for disease surveillance in populations of prion-infected animals in the wild that could impact public health. Researchers are also looking at ways to use RT-QuIC-based screening assays to ensure the safety of human food chains. In this context, microplate readers and RT-QuIC assays have been used in experimental settings to characterize prion-seeding activity in samples of tissue from wild and farmed deer that may have been exposed to chronic wasting disease.<sup>3</sup></p>
<p>Beyond surveillance, new drugs are actively being sought for different targets related to protein folding and amyloid accumulation. In clinical trials, translatable biomarkers are needed that track the progression and severity of the neurodegenerative diseases impacted by protein misfolding and aggregation. Progress in artificial intelligence and modeling techniques will enhance studies of protein folding and misfolding which should bring further advances to the drug discovery space.</p>
<p>Demand for ThT assays is poised to increase due to the lack of interventions for neurological and non-neurological diseases caused by protein misfolding and aggregation events and the potential for other high-impact applications.</p>
<p>ThT-related assays are therefore moving away from being a means for a rapid diagnosis towards offering a quantitative tool for disease surveillance, pathogenesis, and therapeutic development across a wide range of disease and fundamental research areas in the life sciences.</p>
<p>BMG LABTECH offers a portfolio of single- to multimode microplate readers ideally suited for studying protein misfolding and aggregation. While the FLUOstar Omega remains the gold standard for RT-QuIC and seeding assays, the PHERAstar<sup>®</sup> FSX was specifically conceived for screening campaigns and is the go-to reader for high-performance high-throughput screening. Both the VANTAstar<sup>®</sup> and CLARIOstar<sup>®</sup> Plus allow for wavelength flexibility and include Enhanced Dynamic Range technology for superior performance and ease of use. Collectively, these multimode readers combine high performance with miniaturized assays and short measurement times, delivering considerable savings on materials and other resources.</p>
<p><em>References</em></p>
<ol>
<li>Dong TT, Satoh K. The Latest Research on RT-QuIC Assays-A Literature Review. <em>Pathogens</em>. 2021 Mar 5;10(3):305. doi: 10.3390/pathogens10030305.</li>
<li>Baumann F. Following Abeta Fibrillization/Aggregation in Real-Time | BMG Labtech. n.d. [Last accessed: 9/14/2026].</li>
<li>Li M et al. RT-QuIC detection of CWD prion seeding activity in white-tailed deer muscle tissues. <em>Sci. Rep</em>. 2021 Aug 18;11(1):16759. doi: 10.1038/s41598-021-96127-8. PMID: 34408204; PMCID: PMC8373970.l</li>
</ol>
<p><img loading="lazy" decoding="async" class="alignleft wp-image-338898" src="https://www.genengnews.com/wp-content/uploads/2026/10/BMG_Labtech_QRCode-295x300.jpg" alt="BMG Labtech QR Code" width="162" height="165" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/BMG_Labtech_QRCode-295x300.jpg 295w, https://www.genengnews.com/wp-content/uploads/2026/10/BMG_Labtech_QRCode.jpg 307w" sizes="auto, (max-width: 162px) 100vw, 162px"></p>
<p>If you are interested in further details about microplate-based evaluation of prions and protein misfolding, please contact us at <a href="mailto:applications@bmglabtech.com">applications@bmglabtech.com</a> or scan the QR code on the right-hand side</p>
<p>The post <a href="https://www.genengnews.com/sponsored/investigating-prions-and-protein-aggregation-at-high-sensitivity-and-throughput/">Investigating Prions and Protein Aggregation at High Sensitivity and Throughput</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The Epitranscriptome Heads Toward Clinical Necessity</title>
<link>https://edusehat.com/en/the-epitranscriptome-heads-toward-clinical-necessity</link>
<guid>https://edusehat.com/en/the-epitranscriptome-heads-toward-clinical-necessity</guid>
<description><![CDATA[ Short-read RNA sequencing reporting the modifications that alter protein output is starting to make epitranscriptomics indispensable for patient selection in precision medicines.
The post The Epitranscriptome Heads Toward Clinical Necessity appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GEN_OCT_2026_GettyImages-1541079143-Copy-e1791300669134.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 07 Oct 2026 04:10:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, Epitranscriptome, Heads, Toward, Clinical, Necessity</media:keywords>
<content:encoded><![CDATA[<p class="wp-block-paragraph">A deep understanding of epitranscriptomics—RNA modifications—is the missing layer in the quest for more broadly effective precision medicines. That’s the view of Gudrun Stengel, PhD, CEO of Alida Biosciences, and the foundational belief that drives her company to build sequencing tools and scientifically relevant models linking RNA modifications to phenotype.</p>


<p class="wp-block-paragraph">Today, despite the astounding breakthroughs of the past quarter-century, positive responses to advanced therapies such as checkpoint inhibitors and cell and gene therapies are still limited to a relatively small subset of patients. To improve efficacy and understand patient response, Stengel says, “We need to consider all layers of epigenetic regulation to better understand gene regulation and build better models of biology, especially right now, with AI enabling the integration of huge amounts of data.”</p>
<div class="my-8"><span data-render-ad="3"></span></div>


<figure class="wp-block-image alignright size-medium is-resized"><img fetchpriority="high" decoding="async" width="300" height="300" src="https://www.genengnews.com/wp-content/uploads/2026/10/OYR_Stengel-G-Copy-300x300.jpg" alt="Gudrun Stengel" class="wp-image-338870" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/OYR_Stengel-G-Copy-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/OYR_Stengel-G-Copy-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/10/OYR_Stengel-G-Copy-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/OYR_Stengel-G-Copy.jpg 1000w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-element-caption">Gudrun Stengel, PhD<br>CEO of Alida Biosciences</figcaption></figure>


<p class="wp-block-paragraph">Despite the increasing influx of information, “We still have gaps in our understanding of how information flows from DNA to proteins and ultimately phenotype,” Stengel says. In a multiomics environment, RNA modifications—which she calls “an essential layer of that multiomic stack”—have received relatively little attention because they are considered particularly hard to measure accurately.</p>


<p class="wp-block-paragraph">To help resolve that issue, AlidaBio is focusing on three of the most important RNA modifications as a way to create better and more useful epitranscriptomics models to improve scientists’ understanding of the many layers of epigenetic regulation.</p>
<div class="my-8"><span data-render-ad="4"></span></div>


<h4 class="wp-block-heading"><strong>Why epitranscriptomics</strong></h4>


<p class="wp-block-paragraph">“Epitranscriptomics are a readout of the cell state,” Stengel says. “Single-cell transcriptomics and spatial transcriptomics have shown a huge amount of heterogeneity—similar cell types are characterized by different RNA expression patterns that define what a cell is doing at a given time.” As an example of the timescales of response, she says, “To reset DNA methylation can take up to two weeks. To reset an RNA expression pattern can take a day, and RNA modifications can change RNA expression within a few hours.” Understanding those patterns and their time to action can significantly affect a cell’s response to therapeutics.</p>


<p class="wp-block-paragraph">“RNA modifications don’t change the genetic code, but they change what RNA does,” Stengel emphasizes. “N6-methyladenosine (m6A), the most important mRNA modification, can quickly mark RNA transcripts associated with a previous cell state for degradation and, at the same time, promote the translation of genes that are associated with the future cell state. It is also involved in alternative splicing regulation, which creates more protein diversity.”</p>


<p class="wp-block-paragraph">Epitranscriptomics method development has gained significant momentum in recent years. Current nanopore-based direct RNA sequencing can detect a subset of modifications in native, long RNA molecules. However, the approach currently requires relatively large quantities of high-quality full-length RNA.</p>


<h4 class="wp-block-heading"><strong>Short-read, one-pot detection</strong></h4>


<p class="wp-block-paragraph">Alida Biosciences expanded the industry’s capabilities in 2025 by launching its EpiPlex<sup><img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"></sup> platform. It was the first commercial solution to analyze sparse and highly-degraded RNA often found in clinical samples and provide simultaneous, one-pot detection, localization, and quantification of three of the best-studied and most frequently occurring mRNA modifications: N6-methyladenosine (m6A), inosine, and pseudouridine, along with gene expression. The company offers kits, analysis software, and services.</p>
<div class="my-8"><span data-render-ad="5"></span></div>


<p class="wp-block-paragraph">“To develop clinical and translational applications, you need to look at clinical samples (fresh-frozen or formalin-fixed paraffin-embedded tissues, and liquid biopsies, for example) that are present at low quantities or that may be highly degraded,” she explains.</p>


<p class="wp-block-paragraph">The long list of potential applications includes patient stratification for specific therapies and response monitoring, as well as therapeutic development of cancer drugs and measuring immune cell fitness. “m6A, the most common modification, plays a huge role in cell differentiation and cell fate,” Stengel says.</p>


<h4 class="wp-block-heading"><strong>Entrepreneurial leanings</strong></h4>


<p class="wp-block-paragraph">Stengel formed the company five years ago, leaving a safe corporate position on the belief that she could create a company that would fill a key knowledge gap.</p>


<p class="wp-block-paragraph">“I had spent a significant number of years in large companies—including Illumina—developing genomics technologies,” she says. Researchers at such companies, however, tend to be involved in either the inception or the development of a product. “I wanted to see things through from the beginning to the end. I thought a smaller company would be the ideal environment to do exactly that. I resigned my job and started putting the pieces together.</p>


<p class="wp-block-paragraph">“When I started the company, many [in the industry] had never heard of epitranscriptomics,” she says. Nonetheless, she secured venture capital funding within six months and built a small, core team.</p>


<p class="wp-block-paragraph">Those early days found her in the lab, working with just a few scientists. “Getting the first, preliminary data was so exhilarating!” she recalls. “It’s a good day when everything works in the lab.”</p>


<p class="wp-block-paragraph">Epitranscriptomics is emerging from a niche discipline, so now most conference attendees, “regardless of the conference,” Stengel adds, are aware of the field. Although, she admits, “not everybody knows why they are important. Yet, that’s a huge step forward.”</p>


<h4 class="wp-block-heading"><strong>Commercial vision</strong></h4>
<div class="my-8"><span data-render-ad="6"></span></div>


<p class="wp-block-paragraph">As scientists increasingly recognize the role RNA modifications play in therapeutic development and outcomes, she can focus on scaling the company and its commercial capabilities. “We started out very R&D heavy,” and now are beginning to earn revenue to fund further innovations. Potential clients include multiomics companies, research hospitals, and “to some extent, diagnostics,” she says.</p>


<p class="wp-block-paragraph">Currently, AlidaBio is working with the oncology company STORM Therapeutics to understand the mechanism of action and to stratify patients for a Phase II drug that acts on methyltransferase-like 3 (Mettl3), the m6A writer enzyme. This is one of a few areas in which RNA modification can make breakthroughs in patient treatment and stratification, she says. “We’re also very interested in predicting response to PD-L1 inhibitors.”</p>


<p class="wp-block-paragraph">For AlidaBio, bioinformatics is an area of continual focus, along with making analysis output more interactive. “We also are applying machine learning models to integrate the amount of information between RNA modifications and gene expression, so there will be significant updates to the EpiScout<sup>®</sup> analysis software,” Stengel says. Other plans remain confidential.</p>


<p class="wp-block-paragraph">For both the company and the industry, “I think the next inflection point is when epitranscriptomics becomes part of mainstream multiomics,” Stengel says. When that happens, researchers will consider RNA expression data incomplete without information about RNA modification.</p>


<p class="wp-block-paragraph">Therefore, eventually, “RNA modifications will become another standard layer that’s integrated into AI models of biology,” she continues. “The real test will be demonstrating that this layer improves patient stratification, predicts treatment response, or identifies new therapeutic opportunities. Once that happens, I think the field will move from being scientifically interesting to clinically indispensable.”</p>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column sidebar is-layout-flow wp-block-column-is-layout-flow">
<h3 class="wp-block-heading"><strong><strong>Alida Biosciences (AlidaBio)</strong></strong></h3>


<p class="wp-block-paragraph"><strong>Location:</strong> 11535 Sorrento Valley Rd, Suite 407, San Diego, CA 92121</p>


<p class="wp-block-paragraph"><strong>Phone:</strong> (858) 922-3299</p>


<p class="wp-block-paragraph"><strong>Website:</strong> <a href="https://www.alidabio.com/">alidabio.com</a></p>


<p class="wp-block-paragraph"><strong>Principal:</strong> Gudrun Stengel, PhD, founder and CEO</p>


<p class="wp-block-paragraph"><strong>Number of Employees:</strong> 20</p>


<p class="wp-block-paragraph"><strong>Focus:</strong> Alida Biosciences developed a technology platform, kits, and services to read and analyze RNA and its modifications by short-read sequencing. The platform provides simultaneous, one-pot detection, localization, quantification, and gene expression information for several of the best-studied and most frequently occurring RNA modifications.</p>
</div>
</div>



<p>The post <a href="https://www.genengnews.com/topics/omics/the-epitranscriptome-heads-toward-clinical-necessity/">The Epitranscriptome Heads Toward Clinical Necessity</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Claire AI® Feature Spotlight: Summarize Key Concepts </title>
<link>https://edusehat.com/en/claire-aifeature-spotlight-summarize-key-concepts</link>
<guid>https://edusehat.com/en/claire-aifeature-spotlight-summarize-key-concepts</guid>
<description><![CDATA[ The post Claire AI® Feature Spotlight: Summarize Key Concepts  appeared first on BoardVitals Blog. ]]></description>
<enclosure url="https://blog.boardvitals.com/wp-content/uploads/2026/10/346-BLOG-Summarize-1200x900-1-1024x768.png" length="49398" type="image/jpeg"/>
<pubDate>Wed, 07 Oct 2026 03:40:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Claire, AI® Feature, Spotlight:, Summarize, Key, Concepts </media:keywords>
<content:encoded><![CDATA[<p class="wp-block-paragraph">Preparing for your boards means working through a lot of information in a limited amount of time. Answering practice questions is important, but so is understanding the concepts behind each answer, connecting related ideas, and knowing what deserves another look. When explanations cover several details at once, finding the main takeaway can slow down your review.  </p>



<p class="wp-block-paragraph">That’s where the new Claire AI summarize feature in BoardVitals can help. It turns the material behind each question into a concise, focused overview, making it easier to understand key concepts, revisit challenging topics, and keep your study sessions moving. </p>



<h3 class="wp-block-heading"><strong>Make Every Study Minute Count</strong> </h3>



<p class="wp-block-paragraph">Medical students and residents have a lot to learn and limited time to learn it. You need to understand the reasoning behind each question while reinforcing the high-yield takeaways most likely to matter on exam day. Claire AI helps bridge that gap by condensing complex topics into focused reviews. </p>



<p class="wp-block-paragraph">When you answer a BoardVitals question, Claire AI uses the question’s context to create an easy-to-digest overview of the related content and key concepts. Instead of sorting through every detail again, you can quickly focus on what matters most and get back to studying.  </p>



<p class="wp-block-paragraph">Use a summary when an explanation brings together several ideas, when a topic feels unfamiliar, or when you want to lock in the main point before moving on. With the key details easier to spot, you can spend less time sorting through information and more time practicing where it counts. </p>



<h3 class="wp-block-heading"><strong>Build Claire AI into Your Study Routine</strong> </h3>



<p class="wp-block-paragraph">During a focused review session, use Claire AI to quickly revisit a weak area without rereading every detail. As exam day approaches, turn to these overviews for a quick way to refresh. </p>



<p class="wp-block-paragraph">Claire AI works best alongside your own clinical reasoning. Use each summary to reinforce learning and guide your next step, and refer to the complete question explanation whenever you need more context or detail. </p>



<p class="wp-block-paragraph">As you work through your question bank, Claire AI summaries make it easier to return to missed or challenging material. They do not replace BoardVitals’ complete explanations; they give you another quick way to reinforce the central lesson and keep building momentum.  </p>



<h3 class="wp-block-heading"><strong>Meet Claire AI for BoardVitals</strong> </h3>



<p class="wp-block-paragraph">Meet Claire AI, now available with most BoardVitals question banks. From explaining challenging topics and summarizing key points to <a href="https://www.boardvitals.com/blog/claire-ai-feature-flashcards/" data-type="post" data-id="15822">creating flashcards</a> and <a href="https://www.boardvitals.com/blog/claire-ai-feature-more-questions/" data-type="post" data-id="15818">generating additional practice questions</a>, Claire AI gives you more ways to engage with the material you are already reviewing. And because Claire AI pulls only from BoardVitals’ up-to-date question bank content, you can trust that the study support stays grounded in the same reliable material you already use to prepare. </p>



<p class="wp-block-paragraph">With AI-powered support built directly into the BoardVitals experience, Claire AI makes each study session more focused and responsive. You’ll get the help you need to study effectively when you need it most. However you choose to use it, Claire AI can help you understand, review, and practice material with greater confidence throughout your board prep. </p>
<p>The post <a href="https://www.boardvitals.com/blog/claire-ai-feature-summarize/">Claire AI® Feature Spotlight: Summarize Key Concepts </a> appeared first on <a href="https://www.boardvitals.com/blog">BoardVitals Blog</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Claire AI® Feature Spotlight: Generate More Practice Questions</title>
<link>https://edusehat.com/en/claire-ai-feature-spotlight-generate-more-practice-questions</link>
<guid>https://edusehat.com/en/claire-ai-feature-spotlight-generate-more-practice-questions</guid>
<description><![CDATA[ The post Claire AI® Feature Spotlight: Generate More Practice Questions appeared first on BoardVitals Blog. ]]></description>
<enclosure url="https://blog.boardvitals.com/wp-content/uploads/2026/10/346-BLOG-Gen-Questions-1200x900-1-1024x768.png" length="49398" type="image/jpeg"/>
<pubDate>Wed, 07 Oct 2026 03:40:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Claire, AI®, Feature, Spotlight:, Generate, More, Practice, Questions</media:keywords>
<content:encoded><![CDATA[<p class="wp-block-paragraph">More questions means more ways to prepare for the boards. Practicing the same concept through different wording, details, and clinical presentations can help you move beyond memorization and learn how to apply what you know. </p>



<p class="wp-block-paragraph">Whether you are preparing for a <a href="https://boardvitals.com/medical-students">USMLE® exam</a>, a <a href="https://boardvitals.com/medical-students">shelf exam</a>, or <a href="https://boardvitals.com/medical-board-reviews">specialty boards</a>, Claire AI makes it easy to turn one review question into a focused learning session, allowing you to stay with a challenging concept and practice it from multiple angles before moving on. </p>



<p class="wp-block-paragraph">This kind of targeted practice is especially useful when you miss a question, hesitate between two answer choices, or reach the correct answer for the wrong reason. Instead of saving the topic to revisit later, you can reinforce it right away while the concept – and your reasoning – are still fresh.  </p>



<h3 class="wp-block-heading"><strong>More Questions, More Prep</strong> </h3>



<p class="wp-block-paragraph">Looking for additional ways to study a concept? Ask Claire AI to generate more questions related to the topic you are reviewing. The questions appear directly in your conversation, so you can keep practicing without stopping to create a separate quiz. </p>



<p class="wp-block-paragraph">For example, if a cardiology question reveals uncertainty about murmurs, ask Claire AI for additional questions about murmurs to keep reviewing. Confused two pharmacology mechanisms of action? Practice the concept again in a new context before moving on. </p>



<p class="wp-block-paragraph">These questions are designed for quick, in-the-moment reinforcement and are not saved as a quiz in your BoardVitals account. Use them as a flexible supplement to your broader study plan. Your question bank, performance insights, detailed explanations, and exam-style practice remain essential for tracking progress and preparing across the full exam blueprint. </p>



<h3 class="wp-block-heading"><strong>How More Questions Can Strengthen Your Board Prep</strong> </h3>



<h4 class="wp-block-heading"><strong>Practice Active Recall</strong> </h4>



<p class="wp-block-paragraph">Answering a question asks you to retrieve and use information, not simply recognize it on a page. More questions extend that practice and help you confirm what you know before returning to passive review. </p>



<h4 class="wp-block-heading"><strong>Apply Concepts in New Contexts</strong> </h4>



<p class="wp-block-paragraph">Board-style questions often test familiar material through unfamiliar clinical details. Related questions help you separate the core concept from one specific vignette and build the flexibility to apply your knowledge when the presentation changes. </p>



<h4 class="wp-block-heading"><strong>Find Gaps Before Test Day</strong> </h4>



<p class="wp-block-paragraph">One correct answer does not mean you have mastered a topic, and one missed question does not always mean the entire topic is weak. More practice gives you a clearer picture. If your reasoning holds across several questions, you can move forward with greater confidence. If it doesn’t, you have found a specific area to revisit before exam day. </p>



<h3 class="wp-block-heading">Meet Claire AI for BoardVitals </h3>



<p class="wp-block-paragraph">Meet Claire AI, now available with most BoardVitals question banks. From explaining challenging topics and <a href="https://www.boardvitals.com/blog/claire-ai-feature-summarize/" data-type="post" data-id="15824">summarizing key points</a> to <a href="https://www.boardvitals.com/blog/claire-ai-feature-flashcards/" data-type="post" data-id="15822">creating flashcards</a> and generating additional practice questions, Claire AI gives you more ways to engage with the material you are already reviewing. And because Claire AI pulls only from BoardVitals’ up-to-date question bank content, you can trust that the study support stays grounded in the same reliable material you already use to prepare. </p>



<p class="wp-block-paragraph">With AI-powered support built directly into the BoardVitals experience, Claire AI makes each study session more focused and responsive. You’ll get the help you need to study effectively when you need it most. However you choose to use it, Claire AI can help you understand, review, and practice material with greater confidence throughout your board prep. </p>



<p class="wp-block-paragraph"></p>
<p>The post <a href="https://www.boardvitals.com/blog/claire-ai-feature-more-questions/">Claire AI® Feature Spotlight: Generate More Practice Questions</a> appeared first on <a href="https://www.boardvitals.com/blog">BoardVitals Blog</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Claire AI® Feature Spotlight: Flashcards </title>
<link>https://edusehat.com/en/claire-aifeature-spotlight-flashcards</link>
<guid>https://edusehat.com/en/claire-aifeature-spotlight-flashcards</guid>
<description><![CDATA[ The post Claire AI® Feature Spotlight: Flashcards  appeared first on BoardVitals Blog. ]]></description>
<enclosure url="https://blog.boardvitals.com/wp-content/uploads/2026/10/346-BLOG-Flashcards-1200x900-1-1024x768.png" length="49398" type="image/jpeg"/>
<pubDate>Wed, 07 Oct 2026 03:40:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Claire, AI® Feature, Spotlight:, Flashcards </media:keywords>
<content:encoded><![CDATA[<p class="wp-block-paragraph">Getting the most out of your board prep means more than reviewing information once. Repetition is an effective way to reinforce key concepts, identify areas that need more attention, and make each study session more productive. We’re making it easier to add that practice to your routine with Claire AI flashcards.  </p>



<p class="wp-block-paragraph">Created from BoardVitals library of up-to-date content, these front-and-back cards give you a quick, focused way to review important information and strengthen your recall as you prepare for exam day. </p>



<h3 class="wp-block-heading"><strong>Why Add Flashcards to Your Study Routine?</strong> </h3>



<p class="wp-block-paragraph">It is easy to recognize a familiar fact on the page and assume you know it. Recalling that same fact without a prompt is harder. Flashcards put your memory to work by asking you to retrieve an answer, check your response, and return to important concepts over time. </p>



<p class="wp-block-paragraph">That repeated retrieval can support long-term retention and help you quickly spot the topics that need more attention. Whether you are a medical student balancing coursework and clinical rotations or a resident fitting study time into a demanding schedule, flashcards can help you make the most of shorter study sessions. </p>



<h3 class="wp-block-heading"><strong>Build Stronger Recall for Board Exam Day</strong> </h3>



<p class="wp-block-paragraph">Board exams require you to remember a wide range of information, retrieve it quickly, and apply it to specific situations. With Claire AI flashcards from BoardVitals, you’ll review these key terms and concepts with just a few clicks.  </p>



<p class="wp-block-paragraph">Claire AI flashcards reinforce the essential details and relationships found in your question content, helping you build a stronger foundation for answering board-style questions. Use them alongside your review questions to revisit what you have learned and keep important concepts fresh. </p>



<p class="wp-block-paragraph">After completing questions, review flashcards to strengthen your knowledge of terminology, mechanisms, diagnostic clues, and other high-yield connections. Over time, combining practice questions with active recall can help you move beyond recognizing the right answer to retrieving and applying what you know. </p>



<h3 class="wp-block-heading"><strong>Make Every Study Session Count</strong> </h3>



<p class="wp-block-paragraph">Add flashcards to the BoardVitals routine that already works for you. Review them after a quiz, return to them during a quick study break, and spend extra time on the concepts that are still difficult to recall. Flashcards should not be used as a replacement for practice questions, but as another way to reinforce the knowledge you need to pass your board exam.   </p>



<h3 class="wp-block-heading"><strong>Meet Claire AI for BoardVitals</strong> </h3>



<p class="wp-block-paragraph">Meet Claire AI, now available with most BoardVitals question banks. From explaining challenging topics and <a href="https://www.boardvitals.com/blog/claire-ai-feature-summarize/" data-type="post" data-id="15824">summarizing key points</a> to creating flashcards and <a href="https://www.boardvitals.com/blog/claire-ai-feature-more-questions/" data-type="post" data-id="15818">generating additional practice questions</a>, Claire AI gives you more ways to engage with the material you are already reviewing. And because Claire AI pulls only from BoardVitals’ up-to-date question bank content, you can trust that the study support stays grounded in the same reliable material you already use to prepare. </p>



<p class="wp-block-paragraph">With AI-powered support built directly into the BoardVitals experience, Claire AI makes each study session more focused and responsive. You’ll get the help you need to study effectively when you need it most. However you choose to use it, Claire AI can help you understand, review, and practice material with greater confidence throughout your board prep. </p>
<p>The post <a href="https://www.boardvitals.com/blog/claire-ai-feature-flashcards/">Claire AI® Feature Spotlight: Flashcards </a> appeared first on <a href="https://www.boardvitals.com/blog">BoardVitals Blog</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Sensible Biotechnologies Raises $47M to Expand Next&#45;Generation Platform for mRNA Medicines</title>
<link>https://edusehat.com/en/sensible-biotechnologies-raises-47m-to-expand-next-generation-platform-for-mrna-medicines</link>
<guid>https://edusehat.com/en/sensible-biotechnologies-raises-47m-to-expand-next-generation-platform-for-mrna-medicines</guid>
<description><![CDATA[ Sensible Biotechnologies raised $47 million to scale VECTOR, its integrated platform pairing AI-enabled mRNA design with manufacturing of naturally modified mRNA in living cells, aiming to develop novel therapeutics beyond vaccines. 
The post Sensible Biotechnologies Raises $47M to Expand Next-Generation Platform for mRNA Medicines appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/03/AList_GettyImages_1094685558_3DRNAChain-1392x770-1-1519x840-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 06 Oct 2026 20:55:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Sensible, Biotechnologies, Raises, 47M, Expand, Next-Generation, Platform, for, mRNA, Medicines</media:keywords>
<content:encoded><![CDATA[<p><span>Sensible Biotechnologies said that it has raised $47 million in financing that it will use to advance and scale its integrated mRNA technology. The financing includes a Series A and up to $20 million in non-dilutive funding from the Government of Slovakia and the European Union. </span></p>
<p><span>According to the company, the funds will support the development of what it claims is a first-of-its-kind platform for naturally modified mRNA medicines. The so-called Versatile Engine for Cell-based Therapeutic Optimization of RNA (VECTOR) platform integrates computational and artificial intelligence-enabled sequence optimization, high-throughput screening, and proprietary engineered eukaryotic cells to design and manufacture mRNA. Meanwhile, the company’s PromPT technology is designed to capture and protect mRNA inside cells before it is purified for therapeutic use. </span></p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p><span>Specifically, Sensible will use the funds to expand VECTOR’s AI-enabled mRNA design and automated high-throughput screening capabilities as well as support the development of clinical-grade manufacturing capabilities. Sensible’s platform harnesses the natural machinery of living cells to produce naturally modified mRNA with reduced immunogenicity and high protein expression while avoiding double-stranded RNA contamination. Furthermore, by using engineered living cells, Sensible reduces reliance on specialized raw materials and manufacturing inputs, enabling more scalable production and expanding mRNA into therapeutic applications that require higher or repeated dosing.</span></p>
<p><span>Rather than relying on synthetic manufacturing technology developed more than 40 years ago, “we are taking a fundamentally different approach, using living cells to produce naturally modified mRNA while reducing the cost and supply-chain constraints of conventional production,” said Miroslav Gasparek, Sensible’s co-founder and CEO. “With this financing, we can scale our platform and expand mRNA into therapeutic applications requiring high or repeated dosing that have historically been limited by cost.”</span></p>
<p><span>The Series A includes participation from new investors OTB Ventures and In-Q-Tel, alongside existing investors Recode Ventures, Isomer Capital, Y Combinator, Backed VC, Kaya VC, Civilization Ventures, and BlueYard Capital, as well as the family office of Christoph Huber, co-founder of BioNTech, and Tim Garnett, former chief medical officer of Eli Lilly, and other individual investors.</span></p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p><span>In connection with the financing, Vishal Gulati, MD, FMedSci, managing partner at Recode Ventures, and Joel Schoppig, partner at Oxford Science Enterprises, will join Sensible’s board of directors alongside Miroslav Gasparek and Marian Kupculak, PhD, CSO and co-founder.</span></p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/sensible-biotechnologies-raises-47m-to-expand-next-generation-platform-for-mrna-medicines/">Sensible Biotechnologies Raises $47M to Expand Next-Generation Platform for mRNA Medicines</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Canadian ‘virtual sitter’ technology expands as hospitals look to improve patient safety and ease staffing pressures</title>
<link>https://edusehat.com/en/canadian-virtual-sitter-technology-expands-as-hospitals-look-to-improve-patient-safety-and-ease-staffing-pressures</link>
<guid>https://edusehat.com/en/canadian-virtual-sitter-technology-expands-as-hospitals-look-to-improve-patient-safety-and-ease-staffing-pressures</guid>
<description><![CDATA[ Canadian hospitals are increasingly turning to remote patient observation technology as they look for new ways to protect patients at risk of falls and other adverse events while making better use of limited frontline staff. A Canadian-developed system known as HALO – Human Attended Live Observation – combines bedside audiovisual technology with trained remote safety […]
The post Canadian ‘virtual sitter’ technology expands as hospitals look to improve patient safety and ease staffing pressures appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/ChatGPT-Image-Oct-6-2026-08_35_00-AM.png" length="49398" type="image/jpeg"/>
<pubDate>Tue, 06 Oct 2026 20:50:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Canadian, ‘virtual, sitter’, technology, expands, hospitals, look, improve, patient, safety, and, ease, staffing, pressures</media:keywords>
<content:encoded><![CDATA[<p>Canadian hospitals are increasingly turning to remote patient observation technology as they look for new ways to protect patients at risk of falls and other adverse events while making better use of limited frontline staff.</p>
<p>A Canadian-developed system known as HALO – Human Attended Live Observation – combines bedside audiovisual technology with trained remote safety observers who continuously monitor patients considered at elevated risk.</p>
<p>The technology originated at University Health Network (UHN) in Toronto, where it was developed by clinicians to address the challenge of providing continuous observation for patients who might fall, wander, remove oxygen or other medical equipment, or otherwise require close supervision.</p>
<p>Traditionally, hospitals may assign a staff member to remain at the bedside of one patient requiring constant observation. The approach can provide important protection, but it also ties up healthcare workers who could otherwise be providing direct patient care.</p>
<p>HALO takes a different approach. A portable device equipped with cameras and two-way communication is placed near the patient’s bedside. Trained virtual safety observers monitor patients from a centralized command centre and can communicate directly with a patient if they identify potentially unsafe behaviour.</p>
<p>If further intervention is required, the observer alerts the patient’s care team.</p>
<p>According to HALO, one observer can monitor as many as 12 patients simultaneously. The company says the technology is now deployed at approximately 30 healthcare sites across Canada; more recent industry reporting places its footprint at 34 sites.</p>
<p>The system has grown considerably from its beginnings within UHN.</p>
<p>At UHN, virtual observation has become part of routine patient care across inpatient services. UHN describes the technology as a health human resources tool that can help allocate nursing and other healthcare staff where they are most needed while maintaining continuous observation of eligible patients.</p>
<p>Expansion has also moved well beyond Toronto.</p>
<p>Recent deployments or agreements have included Unity Health Toronto, Waterloo Regional Health Network, Niagara Health, Oak Valley Health, St. Joseph’s Healthcare Hamilton and Georgian Bay General Hospital. Deployments at Sunnybrook Health Sciences Centre and Montreal’s Jewish General Hospital are also planned for late 2026, according to recent reporting.</p>
<p>Newfoundland and Labrador represents one of the technology’s most significant expansions.</p>
<p>NL Health Services first introduced the system in four acute-care hospitals and healthcare centres in 2024. At the time, the health authority said the technology could help care teams identify changes in patients’ conditions and intervene when necessary while making more efficient use of healthcare personnel.</p>
<p>That deployment has since expanded substantially. Recent reporting says HALO now supports <strong>11 hospitals and six long-term-care homes in Newfoundland and Labrador</strong>, including rural and remote communities where maintaining one-to-one patient observation can be particularly challenging.</p>
<p>The technology may also offer measurable patient-safety benefits.</p>
<p>Recent Canadian Healthcare Technology reporting says one Western Canadian hospital experienced a <strong>75 per cent reduction in high-risk patient falls during its first year using the system</strong>. At UHN, HALO is reported to have reduced the need for one-to-one constant observation by an average of approximately 40 per cent.</p>
<p>Privacy and consent remain important considerations whenever cameras are introduced into patient-care environments.</p>
<p>UHN says the HALO system provides a secure livestream of images and sound rather than recording patients. Patients are informed about the monitoring and can decline the service.</p>
<p>The technology does not eliminate the role of nurses or other frontline caregivers. Instead, remote observers provide another layer of continuous surveillance and alert the clinical team when bedside intervention is required.</p>
<p>For Canadian hospitals facing simultaneous pressures around patient safety, workforce shortages and rising costs, virtual observation represents one example of how technology developed inside the healthcare system is moving from a local innovation to a broader model of care.</p>
<p>The post <a href="https://www.hospitalnews.com/canadian-virtual-sitter-technology-expands-as-hospitals-look-to-improve-patient-safety-and-ease-staffing-pressures/">Canadian ‘virtual sitter’ technology expands as hospitals look to improve patient safety and ease staffing pressures</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>In Rare Trials Summit keynote, BIO expert highlights lives touched by PPRV</title>
<link>https://edusehat.com/en/in-rare-trials-summit-keynote-bio-expert-highlights-lives-touched-by-pprv</link>
<guid>https://edusehat.com/en/in-rare-trials-summit-keynote-bio-expert-highlights-lives-touched-by-pprv</guid>
<description><![CDATA[ One afternoon in 2024, the BIO Federal Government Affairs team received a call from Hill staff who said, “We just met the most amazing […]
The post In Rare Trials Summit keynote, BIO expert highlights lives touched by PPRV appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/10/Michele-Oshman-and-Dions-keynote-rare-trials-summit.png" length="49398" type="image/jpeg"/>
<pubDate>Tue, 06 Oct 2026 13:50:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Rare, Trials, Summit, keynote, BIO, expert, highlights, lives, touched, PPRV</media:keywords>
<content:encoded><![CDATA[<p><span>One afternoon in 2024, the BIO Federal Government Affairs team received a call from Hill staff who said, “We just met the </span><a href="https://www.thedionfund.org/thedions"><span>most amazing family</span></a><span>. They came down from Boston. They have a story to share, and we think you guys need to know them.”</span></p>
<p><span>Joe and Courtney Dion came to Washington to share their story: Peter, age 10, and Maggie, age 6, were born with limb-girdle muscular dystrophy (LGMD-R5, formerly known as LGMD-2C), a rare disease that would eventually rob the children of their ability to walk, move independently, and breathe on their own. </span></p>
<p><span>At the time, there was little hope on the horizon.</span></p>
<p><span>“Our first conversation with the Dions was incredibly powerful—it became clear that they had done their homework. They identified a company with a promising gene therapy, but which could not progress to the clinic without significant investment,” explains Michele Oshman, BIO’s Chief Patient Advocate. “They also understood that investment could very well depend on the reauthorization of a little-known, but incredibly powerful federal program called the pediatric priority review voucher (PPRV). … For the cynics out there who think that maybe patient advocacy is not truly organic, they are wrong. It really is.”</span></p>
<p><span>From that day, the Dions made it their mission to get the PPRV reauthorized in time for Peter and Maggie to benefit from gene therapy. </span></p>
<p><span>Oshman, along with Maggie, mom Courtney, and dad Joe Dion, was a keynote speaker at the </span><a href="https://raretrialssummit.com/"><span>Rare Trials Summit</span></a><span>, held in Boston in September. The summit’s aim is to act as a working meeting for those responsible for advancing rare disease clinical programs. </span></p>
<p><span>Oshman and the Dion’s conversation was a perfect example of just how effective patient advocacy can be when patients, innovators, and Congress work together toward solutions.  </span></p>
<h3>What is the PPRV and how does it help patients?</h3>
<p><span>Developing medicines for rare childhood illnesses is very expensive and risky because the market favors medicines that will be used in larger populations. </span></p>
<p><span>Enter the Rare Pediatric Priority Review Voucher program. If a company develops and achieves FDA approval for a rare pediatric disease medicine, the FDA gives them a “voucher”. This voucher acts like a fast-pass ticket. The company can use it to buy time in the form of a 6-month FDA review instead of the standard 10-month review for their next innovation. The voucher is also an extremely high value asset that can be sold to another pharmaceutical company, thus enabling the rare disease innovator to invest tens of millions of dollars back into their R&D efforts.</span></p>
<p><span>The program is something many small, rare-disease-focused companies use to fund their current and future work, and has been a game changer for rare disease patients.</span></p>
<p><span>“Our children Maggie and Peter were diagnosed with limb-girdle muscular dystrophy in 2022,” explained Joe Dion. “At first, we didn’t know what to do. There was no cure. There were no trials. But there was one company that was potentially going to start a trial; it was a waiting game.”</span></p>
<p><span>But not content to just sit and wait, the Dion family got to work. </span></p>
<p><span>“We started advocating and, fast forward to 2025, we got the first ever trial started,” he continued. “At the time, the PPRV program was something that made sense because this is an ultra rare disease. There weren’t enough patients to make it lucrative for investors to come in and invest in the typical pathway to get a drug developed. So the PPRV program was a big, big part of what helped us move things forward.”</span></p>
<p><span>In addition to advocacy, the Dions also hit the fundraising trail to supplement the research and development of treatment—including Joe being on Harpoon Hunters, a Discovery Channel reality TV show, to raise awareness. But an interesting thing to note about the Dion’s story is that their advocacy played a major role in bringing research </span><i><span>into</span></i><span> the United States.</span></p>
<p><span>The company that the Dions were working with was originally based in France and had already compiled pre-clinical data as a foundation for their work. It was the PPRV program that incentivized them to bring their business stateside and break the technology in the American market first. </span></p>
<p><span>“The PPRV program was clutch in getting it to move forward,” said Joe.</span></p>
<p><span>Today, the company is still working to get their treatment to market and the Dions are continuing to ring the bell every step of the way. </span></p>
<h3>Navigating treatment—and recovery</h3>
<p><span>“When we had the chance to be able to get our children treated with gene therapy, we put everything else on hold,” explained Courtney Dion. “We would have moved mountains. We would have gone to France. We would have gone to a third-world country if we had to. We would have sold our house. We would have done anything that we could have to have this opportunity.”</span></p>
<p><span>Luckily, the Dions only had to move to Florida for a short time.</span></p>
<p><span>And so the family moved and worked directly with the team down in Florida to navigate the clinical trial process, as well as see how it affected Maggie and Peter differently. For example, Maggie, who was able to get the treatment at a younger age, had a 92% expression in her recovery—an unprecedentedly successful amount—indicating the importance of getting these treatments out into the world faster and to patients earlier.</span></p>
<p><span>As Oshman pointed out, however, the Dions are in the game for the long run because there are more trials that need to be done, and more children that need to be helped. “These trials aren’t getting stalled because the medicine’s not working,” she reminded. “But because of the financing.” As such, the Dions have prioritized their fundraising efforts so that more children just like theirs can get access to these trials. </span></p>
<p><span>Additionally, because of the work the Dions and advocates like them are doing, the PPRV program was reauthorized in February of 2026—ensuring that doors were opening for rare disease clinical research and development, not closing.</span></p>
<h3>The power of the patient voice</h3>
<p><span>The Dion’s experience is reflective of the power of patient advocacy: patient voices change the world, and their stories can put a human face on complex policy issues.</span></p>
<p><span>Another patient advocate at the event, Effie Parks, host of the</span><a href="https://effieparks.com/about-1"><span> Once Upon a Gene Podcast</span></a><span> and mother to her son Ford, who was diagnosed with CTNNB1 syndrome, opened the event by saying, “When a trial becomes a possibility, we bring our children, our hope, our questions, and our trust. We can want progress with everything we have and still be frightened by what comes next.”</span></p>
<p><span>As Maggie Dion explained, “I love fighting for kids who don’t get a chance to go up and talk.” Not every child has the opportunity to speak as she does, she said; it is not a responsibility she takes lightly. </span></p>
<p>The post <a href="https://bio.news/federal-policy/in-rare-trials-summit-keynote-bio-expert-highlights-lives-touched-by-pprv/">In Rare Trials Summit keynote, BIO expert highlights lives touched by PPRV</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>2026 Nobel Prize for Physiology or Medicine Goes to Optogenetics, Light&#45;Gated Ion Channels</title>
<link>https://edusehat.com/en/2026-nobel-prize-for-physiology-or-medicine-goes-to-optogenetics-light-gated-ion-channels</link>
<guid>https://edusehat.com/en/2026-nobel-prize-for-physiology-or-medicine-goes-to-optogenetics-light-gated-ion-channels</guid>
<description><![CDATA[ Today, the 2026 Nobel Prize for Physiology and Medicine has been awarded to Karl Deisseroth, MD, PhD, Peter Hegemann, PhD, and Georg Nagel, PhD, for their discoveries of light-gated ion channels and optogenetics.
The post 2026 Nobel Prize for Physiology or Medicine Goes to Optogenetics, Light-Gated Ion Channels appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GettyImages-2266497868.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 06 Oct 2026 13:45:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>2026, Nobel, Prize, for, Physiology, Medicine, Goes, Optogenetics, Light-Gated, Ion, Channels</media:keywords>
<content:encoded><![CDATA[<p>The Nobel Prize in Physiology or Medicine 2026 has been awarded to Karl Deisseroth, MD, PhD, Peter Hegemann, PhD, and Georg Nagel, PhD, for their discoveries of light-gated ion channels and optogenetics.</p>
<figure aria-describedby="caption-attachment-338818" class="wp-caption alignleft"><img loading="lazy" decoding="async" class="wp-image-338818 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/10/2026NobelPrizePhysiologyMedicine-300x132.jpg" alt="Karl Deisseroth, MD, PhD, Peter Hegemann, PhD, and Georg Nagel, PhD" width="300" height="132" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/2026NobelPrizePhysiologyMedicine-300x132.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/2026NobelPrizePhysiologyMedicine-768x338.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/2026NobelPrizePhysiologyMedicine.jpg 855w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text"><em>The 2026 Nobel Prize in Physiology or Medicine winners Karl Deisseroth, MD, PhD, Peter Hegemann, PhD, and Georg Nagel, PhD.</em></figcaption></figure>
<p>Deisseroth is a Professor of Bioengineering and of Psychiatry and Behavioral Sciences at Stanford University and an HHMI Investigator; Hegemann is the Hertie Senior Research Chair for Neurosciences and a professor of Experimental Biophysics at Humboldt University and Nagel is a professor at the Department for Neurophysiology at the University of Würzburg, in Germany.</p>
<p>“Optogenetics provides opportunities for mapping the brain in a way that we could once only dream of,” says Per Svenningsson, MD, PhD, Chair of the Nobel Committee for Physiology or Medicine.</p>
<p>Although optogenetics is a relatively new technology, the seminal paper from the Deisseroth lab was published in 2005. However, the concept of manipulating specific neuronal cell types within intact circuits on a millisecond timescale was considered long before. Indeed, Francis Crick, PhD, once proposed a method where “all neurons of just one type could be activated or inactivated, leaving the others more or less unaltered.” He speculated that to “turn the firing of one or more types of neurons on and off in the alert animal in a rapid manner … the ideal signal would be light,” acknowledging at the time that his idea was “rather far-fetched.” In addition, scientists have been working on laying the foundation for this technology since the 1970s. For example, when Richard Fork, PhD, at Bell Laboratories in New Jersey at the time, published the stimulation of neurons in<em> Aplysia</em> with laser light in <em>Science</em>.</p>
<p>It was the discovery of the algal protein channelrhodopsin that led the way in making the vision into a reality. Microbial rhodopsins—found across archaea, eubacteria, and eukaryotic microalgae—harness light for cellular bioenergetics. Channelrhodopsin is found on the surface of C<em>hlamydomonas</em>, a single-celled alga with the ability to swim towards a light source. Researchers discovered that the protein can directly convert photon energy into transmembrane ion flux.</p>
<p>The first direct evidence of a light-gated ion channel was named channelrhodopsin-1 (ChR1), discovered and coined by the Hegemann lab. The arguably more consequential breakthrough came just a year later: a collaborative team led by Georg Nagel, demonstrated that a second protein, named channelrhodopsin-2 (ChR2), functioned distinctly from ChR1, and exhibited a blue-shifted activation spectrum and operated as a broad, non-selective cation channel.</p>
<p>Finding a microbial protein that could act as a single unit, simultaneously as a photoreceptor and an ion channel, and the discovery that ChR1 and ChR2 were single-component, light-gated ion channels, provided the precise tools that neuroscientists had been looking for—for fast, genetically targetable optical activation of neurons.</p>
<p>The team in the Deisseroth lab took the baton and performed the first successful demonstration that ChR2 could be expressed in neurons, using a construct provided by Nagel. They introduced the gene for channel-rhodopsin into nerve cells from rats and was able to trigger a nerve signal by illuminating the cells with blue light.</p>
<p>Deisseroth’s lab published this breakthrough in 2005 in the <em>Nature Neuroscience</em> paper, “<a href="https://www.nature.com/articles/nn1525" target="_blank" rel="noopener">Millisecond-timescale, genetically targeted optical control of neural activity</a>.” The study demonstrated that expressing the microbial protein channelrhodopsin-2 (ChR2) from green algae in cultured mammalian neurons allowed precise, millisecond-timescale control of action potentials using flashes of blue light.</p>
<p>The paper’s first author was Ed Boyden, PhD, professor in Neurotechnology at MIT who has been developing the field of optogenetics for the past two decades. Interestingly, CRISPR pioneer Feng Zhang, PhD, is the second author on the 2005 paper. Two years later, Deisseroth’s lab made this light-controlled switch for nerve cells work in the brains of living mice.</p>
<p>Over the past two decades, optogenetics has been used to unpack many biological questions, primarily (but not exclusively) in the field of neuroscience. One early <em>in vivo</em> application of optogenetics probed the causal relationship between the activation of orexin/hypocretin neurons in the lateral hypothalamus and the transitions from sleep to wakefulness. Other notable applications were the search for the memory engram—the physical cellular substrate encoding a specific memory—and unpacking the complexity of dopaminergic neurons in the retina, showing that functionally distinct dopaminergic populations are anatomically intermingled yet strictly segregated by their circuit connectivity.</p>
<p>Optogenetics has also moved into clinical applications, such as the expression of ChR2 in retinal circuitry. In one experiment, intraocular injection of an adeno-associated viral (AAV) vector encoding ChR2 led to expression in retinal ganglion cells in rodents. More specifically, light depolarized the ChR2 expressing retinal ganglion cells, restoring retinal photosensitivity and allowing light signals to reach the visual cortex in a mouse model of retinitis pigmentosa. Expression of ChR2 in surviving retinal neurons could therefore serve as a potential strategy for restoring vision after rod and cone degeneration.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/2026-nobel-prize-for-physiology-and-medicine-goes-to-optogenetics-light-gated-ion-channels/">2026 Nobel Prize for Physiology or Medicine Goes to Optogenetics, Light-Gated Ion Channels</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>A Method for Assessing Lab&#45;Grown Stem Cell&#45;Derived Embryo Models</title>
<link>https://edusehat.com/en/a-method-for-assessing-lab-grown-stem-cell-derived-embryo-models</link>
<guid>https://edusehat.com/en/a-method-for-assessing-lab-grown-stem-cell-derived-embryo-models</guid>
<description><![CDATA[ Researchers developed a method for testing how closely lab-grown blastoid models resemble real human embryos, finding that while some models perform well, none fully captures the complexity of early human development. 
The post A Method for Assessing Lab-Grown Stem Cell-Derived Embryo Models appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/07/GettyImages-2174865889.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 06 Oct 2026 10:10:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Method, for, Assessing, Lab-Grown, Stem, Cell-Derived, Embryo, Models</media:keywords>
<content:encoded><![CDATA[<p>University of Sydney researchers have developed a powerful way to test how closely lab-grown biological models resemble real human embryos, finding that while some models perform well, none yet fully capture the complexity of early human development.</p>
<p>The scientists say the research creates one of the most comprehensive reference maps of early human embryo development, which they used to benchmark the biological accuracy of stem-cell-derived embryo models. They systematically evaluated four leading human blastoid-generation methods and found substantial differences in how faithfully they reproduce the cell types and developmental processes seen in natural human embryos.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>Pengyi Yang, PhD, associate professor at the University of Sydney and an ARC Future Fellow in the School of Mathematics and Statistics and Unit Head of Computational Systems Biology at the Children’s Medical Research Institute, said the work gives scientists a more objective way to understand the strengths and limitations of embryo models. “Human embryo models have enormous potential for studying the earliest days of an embryo’s development, but there has been no consistent way to assess how accurately these reflect real human development. Our framework allows researchers to compare these models against a detailed biological reference and determine which cell types and developmental processes are faithfully reproduced, and which are not.”</p>
<p>Yang, who also leads the Trans-Regulatory Biology group at the Charles Perkins Centre, is senior and corresponding author of the team’s published paper in <em>Cell Systems</em>, titled “<a href="https://doi.org/10.1016/j.cels.2026.101738" target="_blank" rel="noopener">Systematic transcriptomic evaluation of blastoid models of early human development</a>.” In their paper the team stated, “The reference map generated from this study enables the benchmarking of blastoids that may guide the optimization of the protocol for the generation of high-fidelity blastoid models that faithfully recapitulate the natural human blastocyst.”</p>
<p>The study of early human embryogenesis from blastocyst formation to gastrulation has been constrained by what the authors describe as “… technical challenges and ethical concerns associated with human embryo research.” But research on blastoid embryo models, which are derived from stem cells, offers scientists a way to study the biological events that underpin fertility, pregnancy success, and early human development without relying on donated human embryos.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<figure aria-describedby="caption-attachment-338825" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="size-medium wp-image-338825" src="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_Associate-Professor-Pengyi-Yang-at-desk.-University-of-Sydney-300x200.jpg" alt="Associate Professor Pengyi Yang at his desk. [University of Sydney] " width="300" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_Associate-Professor-Pengyi-Yang-at-desk.-University-of-Sydney-300x200.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_Associate-Professor-Pengyi-Yang-at-desk.-University-of-Sydney.jpg 700w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Associate professor Pengyi Yang, PhD, at his desk. [University of Sydney]</figcaption></figure>
<p>While these research models are not actual human embryos—current models cannot develop into a human embryo—they could help answer questions that have long been difficult to investigate because of technical and ethical constraints. “Recent achievements in generating blastocyst-like structures from stem cells, the blastoids, that are reminiscent of human blastocysts in morphology and cellular composition have opened an avenue to glean knowledge of the biology of early human embryogenesis,” the team continued.</p>
<p>However, just because something looks like an embryo, does that mean it is behaving like one biologically? The University of Sydney team developed a computational framework that helps answer that question. “Establishing a systematic evaluation framework for assessing the fidelity of blastoids in modeling the human blastocyst is critical for enhancing the quality of these stem cell-based embryo models (SCBEMs),” they noted. “… we set out to develop a computational workflow for systematically assessing how closely blastoids generated by current state-of-the-art protocols recapitulate human blastocyst cell states and develop mental features.”</p>
<p>To do this the team combined and harmonized more than 14,000 single-cell transcriptomes—the set of RNA molecules in a cell—from human embryos spanning key stages of their development. This allowed them to create a reference map of how cells normally differentiate and organize themselves during the days immediately before and after implantation.</p>
<p>The investigators then compared that reference against four widely used blastoid-generation protocols developed by international research groups. Rather than assessing whether the models simply resembled embryos under a microscope, the researchers examined their molecular identities, developmental timing, lineage structure, and other biological characteristics.</p>
<p>The results showed that some blastoid models reproduced all three major cell lineages of a natural human blastocyst, or the early embryo, relatively well, while others failed to accurately represent certain cell types or contained large numbers of cells that could not be confidently matched to any known embryonic state. No single model perfectly replicated a natural human blastocyst. “Results of the benchmarking revealed substantial differences between protocols in recapitulating the composition, developmental timing, and coordinated lineage specification of the human blastocyst, highlighting that high-fidelity SCBEMs should reproducibly generate appropriately staged and developmentally coordinated blastocyst cell states,” the authors reported.</p>
<p>Yang said the findings highlight both the promise and current limitations of embryo models. “The encouraging finding is that some models capture important aspects of early embryonic development relatively well, although each model has limitations,” he said. “But our study also shows that current models are not biologically equivalent to real human embryos, and researchers need to be careful about the conclusions they draw from them.”</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>By providing a standardized benchmark, the researchers hope future models can be improved more rapidly and evaluated more rigorously. “Collectively, our work provides a comprehensive and systematic evaluation of the developmental authenticity of <em>in vitro</em> cultured SCBEMs generated by the state-of-the-art protocols,” they concluded. “Yang added, “If we’re going to use these systems to answer important biological questions, we first need to know what they can reliably tell us. Our work provides a roadmap for improving embryo models and ensuring scientific claims remain grounded in what the models can actually support.”</p>
<p>The researchers have made their reference datasets and benchmarking tools publicly available, enabling scientists worldwide to test new embryo models against the same standards.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/a-method-for-assessing-lab-grown-stem-cell-derived-embryo-models/">A Method for Assessing Lab-Grown Stem Cell-Derived Embryo Models</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Flicking the Switch: Five Scientists Honored at 2026 Warren Alpert Foundation Symposium for Hemoglobinopathy Research</title>
<link>https://edusehat.com/en/flicking-the-switch-five-scientists-honored-at-2026-warren-alpert-foundation-symposium-for-hemoglobinopathy-research</link>
<guid>https://edusehat.com/en/flicking-the-switch-five-scientists-honored-at-2026-warren-alpert-foundation-symposium-for-hemoglobinopathy-research</guid>
<description><![CDATA[ Stuart Orkin, MD, and his former trainees Vijay Sankaran, MD, PhD, and Daniel Bauer, PhD, were joined by Swee-Lay Thein, MD, PhD, and John Tisdale, MD, both at the NIH. Their contributions helped to identify BCL11A as a major regulator of the fetal-to-adult hemoglobin switch.
The post Flicking the Switch: Five Scientists Honored at 2026 Warren Alpert Foundation Symposium for Hemoglobinopathy Research appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/IMG_0138.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 06 Oct 2026 06:35:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Flicking, the, Switch:, Five, Scientists, Honored, 2026, Warren, Alpert, Foundation, Symposium, for, Hemoglobinopathy, Research</media:keywords>
<content:encoded><![CDATA[<p><span data-contrast="auto"><strong>BOSTON</strong>—Four physician scientists and a molecular geneticist from Harvard Medical School (HMS) and the National Institutes of Health (NIH) were honored last week with the 2026 Warren Alpert Foundation prize. </span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Stuart Orkin, MD, and his former trainees Vijay Sankaran, MD, PhD, and Daniel Bauer, PhD, were joined by Swee-Lay Thein, MD, PhD, and John Tisdale, MD, both at the NIH. Their contributions helped to identify BCL11A as a major regulator of the fetal-to-adult hemoglobin switch, paving the way for the development of the first CRISPR medicine, Casgevy, for sickle cell disease (SCD) and thalassemia.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Opening the symposium, HMS Dean George Daley, MD, paid tribute to Janet Watson, MD, the Brooklyn pediatrician who concluded in 1948 that fetal hemoglobin (HbF) was somehow protective against SCD. “The mechanism behind the switch would remain an enigma for decades,” Daley said. </span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Each of the five honorees had “distinct and complementary roles” in the effort, Daley said, which culminated in the approval in December 2023 of Casgevy as well as Lyfgenia, a beta-globin gene therapy. Thein and Sankaran identified and characterized BCL11A as a critical regulator of HbF expression. Orkin and Bauer identified the enhancer sequence within </span><i><span data-contrast="auto">BCL11A</span></i><span data-contrast="auto"> that controls erythroid gene expression and would become the specific target for Casgevy to restart HbF production.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">“We should hustle to make therapies that are simpler, safer and scalable,” Daley said. Bolstering newborn screening for SCD and expanding global distribution would be major steps to producing a bigger impact, such that “fewer people will have their lives upended by these devastating hemoglobinopathies.”</span><span data-ccp-props="{}"> </span></p>
<h4><b><span data-contrast="auto">Editing out disease</span></b><span data-ccp-props="{}"> </span></h4>
<p><span data-contrast="auto">The symposium’s keynote speaker—2020 Nobel laureate Jennifer Doudna, PhD—said, “Drug success requires a deep understanding of </span><i><span data-contrast="auto">biology</span></i><span data-contrast="auto">.” Having a functional cure for SCD less than 15 years after her team’s initial development of CRISPR-Cas9 gene editing was “just incredible,” she said.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Doudna paid particular credit to patient volunteers such as Victoria Gray and Jimi Olaghere. “You can’t have success if you don’t have people willing to try it,” she said. According to Doudna, Casgevy is now approved in 39 countries across North America, Europe, and the Middle East. More than 90 percent of SCD patients in the U.S. qualify for reimbursement coverage for Casgevy. And more than 500 patients globally have begun Casgevy treatment. </span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Naturally, challenges remain. Doudna focused on four: 1) Conditioning toxicity, 2) cost, 3) infrastructure, and 4) expanding global access. “How do we get from one CRISPR therapeutic to CRISPR-for-many? I think it’s achievable,” she said, citing the 2025 Baby KJ story as an example. </span><i><span data-contrast="auto">In vivo</span></i><span data-contrast="auto"> gene editing will be critical in the future, Doudna said, but the toolbox for delivery is growing fast. She noted two recent preprints from her lab advancing novel strategies—</span><a href="https://www.biorxiv.org/content/10.64898/2026.01.13.699115v1" target="_blank" rel="noopener"><span data-contrast="none">NANITE</span></a><span data-contrast="auto"> and </span><a href="https://www.biorxiv.org/content/10.64898/2026.04.26.720920v2" target="_blank" rel="noopener"><span data-contrast="none">JET</span></a><span data-contrast="auto">—as examples of works in progress.</span><span data-ccp-props="{}"> </span></p>
<h4><b><span data-contrast="auto">Beginning with BCL11A</span></b><span data-ccp-props="{}"> </span></h4>
<p><span data-contrast="auto">The symposium was organized by Ed Benz, MD, a renowned hematologist and President and CEO emeritus of the Dana Farber Cancer Institute. In SCD, the red blood cells (RBCs) become rigid and adhere to blood vessel walls. Tissues become ischemic resulting in pain crises and start to deteriorate. Many patients lose the function of key organs, especially the kidney, heart, and lungs. Life for people with SCD is “constantly dealing with pain, anemia, brain fog, etc. They rarely live a normal lifespan.”</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Orkin noted that this was not his first time winning the Alpert prize. He previously won in 1993 for his research providing a complete molecular genetic description of thalassemia. “A lot has happened in 33 years,” Orkin joked, noting profound changes in presidents, AI, and scientific landmarks. </span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Orkin’s team has spent years defining the mechanism of BCL11A regulation of globin gene transcription, a process he likened to “going to the thermostat.” He highlighted a key paper along the way led by his former trainee Jian Xu, PhD, now at St. Jude Children’s Research Hospital. In 2011, Xu took an SCD mouse model, knocked out the </span><i><span data-contrast="auto">Bcl11a</span></i><span data-contrast="auto"> gene in the erythroid lineage, and rescued the phenotype of RBCs. This prevented SCD symptoms and validated BCL11A as a therapeutic target in humans. </span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">The Casgevy results, Orkin said, were “spectacular… remarkable, transformative.” Orkin listed several advantages of the HbF reactivation pathway (as opposed to correctional gene therapy), including the validation provided by Casgevy; the balance of globin gene expression, and the fact it offered “one-stop shopping” for all hemoglobinopathies. But this </span><i><span data-contrast="auto">ex vivo</span></i><span data-contrast="auto"> approach cannot reduce the global burden of SCD and thalassemia, Orkin said. Reasons include high cost, the complex nature of the process, and a lack of infrastructure.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Still,</span> <span data-contrast="auto">the clinical success of Casgevy points to a clear target for small molecule drug discovery programs. </span><b><span data-contrast="auto">“</span></b><span data-contrast="auto">I argue that BCL11A is the preferred target,” Orkin continued. The protein acts directly on the gamma-globin promoter and has a steeper dose-response than other regulators, such as LRF. The protein “looks like spaghetti,” based on AlphaFold, Orkin said. It is an obligate multimer, which is critical for gene repression activity. </span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Although highly stable, BCL11A is degraded in proteasomes as a monomer, raising the possibility that this pathway provides targeting opportunities for small molecules. “The goal should be development of therapies that can be delivered to the majority, if not all, patients with SCD and thalassemia,” Orkin closed.</span><span data-ccp-props="{}"> </span></p>
<h4><b><span data-contrast="auto">Oxford calling</span></b><span data-ccp-props="{}"> </span></h4>
<p><span data-contrast="auto">The focus of Thein’s research, beginning in Oxford when she joined Sir David Weatherall’s group in 1982, was a tantalizing question: Why are some patients with beta-thalassemia relatively mild and transfusion-independent?</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Thein focused on two large hemoglobinopathy families, finding high levels of HbF reduced the need for blood transfusions. She also found that HbF levels were independent of inherited mutations in the beta-globin gene. </span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">In 2007, Thein and colleagues performed a groundbreaking genome-wide association study (GWAS), looking at more than 5,000 participants of Northern European descent. Those with extreme phenotypes were genotyped using a panel of 300,000 single nucleotide polymorphisms. One of the three major signals was an unexpected signal that mapped to chromosome 2, which Thein further refined to the second intron of </span><i><span data-contrast="auto">BCL11A</span></i><span data-contrast="auto">. That unexpected signal eventually became a therapeutic target. </span><span data-ccp-props="{}"> </span></p>
<div class="my-8"><span data-render-ad="6"></span></div>
<p><span data-contrast="auto">Sankaran and Orkin independently confirmed Thein’s findings. That study was published in 2008 in </span><i><span data-contrast="auto">Science. </span></i><span data-contrast="auto">But how to go after </span><i><span data-contrast="auto">BCL11A</span></i><span data-contrast="auto">? Ironically, Sankaran observed, the answer was on the next page of the journal: a landmark paper in the early stages of CRISPR research published by Luciano Marraffini, PhD, and Eric Sontheimer, PhD. “I wish I’d paid more attention!” Sankaran quipped.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Sankaran asked: How can we improve available hemoglobinopathy therapies globally? “We need to invest in all of these pathways—</span><i><span data-contrast="auto">ex vivo</span></i><span data-contrast="auto">, </span><i><span data-contrast="auto">in vivo</span></i><span data-contrast="auto">, and small molecules,” he said. With perfect timing, Sankaran’s team had just published an interesting new candidate for an HbF regulator—BACH2, which inhibits binding of NRF2. Although very early days, inhibiting BACH2 offers another intriguing drug target. “Much more biology remains to be understood,” he said.</span><span data-ccp-props="{}"> </span></p>
<h4><b><span data-contrast="auto">Gene replacement</span></b><span data-ccp-props="{}"> </span></h4>
<p><span data-contrast="auto">While the other four awardees played a role in characterizing the Casgevy pathway, Tisdale was recognized for his work as the lead clinical site for the Lyfgenia trial, sponsored by Bluebird. </span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">“When I hit the scene in the ‘90s, we had zero drugs to treat [SCD],” he said. The disease produces complications “literally from head to toe,” including strokes in children. The pain is so crippling that patients “can’t plan and can’t hold a job.” Building on the first allogeneic bone marrow transplant in 1996, by Mark Walters, MD, Tisdale’s group looked for less toxic chemotherapy options and established a non-myeloablative approach.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">“Luigi Naldini threw us a lifeline,” Tisdale said,</span> <span data-contrast="auto">with</span> <span data-contrast="auto">a report in </span><i><span data-contrast="auto">Science</span></i><span data-contrast="auto"> in 1996 that lentiviruses could transduce non-dividing cells (like HSCs). Deleting the 3’ LTR reduced the risk of integration turning on adjacent genes. Tisdale’s group partnered with Bluebird for the HBG-206 clinical trial. While initial results were modest, in the Group C cohort, successfully treated patients behaved as if their disease had resolved to sickle cell trait. Lyfgenia was also approved by the FDA in December 2023 and is currently sponsored by Genetix Pharmaceuticals.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Tisdale was asked how he counsels patients interested in signing up for gene therapy. “Most patients don’t understand the options,” he said. The discussion starts with a bone marrow transplant, but many insist they want gene therapy. “The first thing is to optimize hydroxyurea,” which is an inclusion criterion. “Most [patients have failed to try; many can improve that way, especially children.” </span><span data-ccp-props="{}"> </span></p>
<h4><b><span data-contrast="auto">Cognitive dissonance</span></b><span data-ccp-props="{}"> </span></h4>
<p><span data-contrast="auto">“Our field is facing a moment of cognitive dissonance,” said Bauer, in the fifth and final talk from the 2026 laureates. The excitement over gene therapies is balanced, he said, by</span> <span data-contrast="auto">“the frustration that current therapies are too complex to even dent the global burden of disease.”</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Bauer briefly described </span><a href="https://www.genengnews.com/topics/genome-editing/prime-assembly-expands-genome-editing-with-precise-large-scale-dna-integration/" target="_blank" rel="noopener"><span data-contrast="none">prime assembly</span></a><span data-contrast="auto">, a new technology from his lab led by grad student Sebastian Levesque, which was published in </span><i><span data-contrast="auto">Nature </span></i><span data-contrast="auto">last month. The technology shows similar activity in dividing and non-dividing cells and “raises the prospect of mutation-agnostic gene correction for many diseases.”</span><span data-ccp-props="{}"> </span></p>
<div class="my-8"><span data-render-ad="7"></span></div>
<p><span data-contrast="auto">At the American Society for Hematology conference in 2016, Bauer recalled showing a slide of a mountain with several paths drawn to the top representing different potential approaches for treating SCD. He juxtaposed that slide with a photo of Casgevy trial volunteer Jimi Olaghere proudly standing at the summit of Mt. Kilimanjaro in 2024. </span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">The field has come a very long way, but still has further to travel.</span><span data-ccp-props="{}"> </span></p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/flicking-the-switch-five-scientists-honored-at-2026-warren-alpert-foundation-symposium-for-hemoglobinopathy-research/">Flicking the Switch: Five Scientists Honored at 2026 Warren Alpert Foundation Symposium for Hemoglobinopathy Research</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Anti&#45;Inflammatory Drug Target for Alzheimer’s, TBI, and Neurodegenerative Disease Identified</title>
<link>https://edusehat.com/en/anti-inflammatory-drug-target-for-alzheimers-tbi-and-neurodegenerative-disease-identified</link>
<guid>https://edusehat.com/en/anti-inflammatory-drug-target-for-alzheimers-tbi-and-neurodegenerative-disease-identified</guid>
<description><![CDATA[ A study in human monocyte-derived microglia and human brain tissue slices suggests that inflammatory brain conditions, including traumatic brain injury and neurodegenerative diseases such as Alzheimer&#039;s disease, could be treated using an existing drug candidate targeting P2X7R. 
The post Anti-Inflammatory Drug Target for Alzheimer’s, TBI, and Neurodegenerative Disease Identified appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-1869420709.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 06 Oct 2026 06:35:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Anti-Inflammatory, Drug, Target, for, Alzheimer’s, TBI, and, Neurodegenerative, Disease, Identified</media:keywords>
<content:encoded><![CDATA[<p>The results of research headed by a team at the University of Birmingham suggest that inflammatory conditions in the brain, including traumatic brain injury (TBI) and degenerative diseases such as Alzheimer’s disease and Parkinson’s disease, could be targeted with an existing developmental drug.</p>
<p>Using live cultures of human brain cells and slices of brain tissue obtained during neurosurgery, the researchers, headed by Nicholas Barnes, PhD, professor at the University of Birmingham College of Medicine and Health, investigated the role of the P2X7 receptor, which is responsible for triggering inflammatory signaling. Their findings revealed that these P2X7 receptors drive the release of cytokines involved in controlling inflammation. By blocking this receptor with a specific antagonist, the team was able to significantly reduce the inflammatory response in human brain tissue.</p>
<p>The team suggests that their results could open the door to treating a wide spectrum of chronic neurological conditions, including TBI, neurodegenerative diseases, and even psychiatric disorders such as depression and psychosis, which are increasingly understood to have a neuroinflammatory component.</p>
<p>Barnes said, “This exciting discovery marks a major step toward repurposing existing therapeutics to combat neuroinflammation at its source. The identification of this receptor could have far-reaching implications for some of the most debilitating and widespread brain disorders such as Alzheimer’s disease, Parkinson’s, and multiple sclerosis, or inflammation-linked psychiatric conditions like schizophrenia and depression.”</p>
<p>Barnes is senior and corresponding author of the team’s published paper in <em>Brain</em>, titled “<a href="https://doi.org/10.1093/brain/awag068" target="_blank" rel="noopener">P2X7 receptor-mediated IL-1β release by human brain tissue: the impact of CNS-penetrant potential therapeutics</a>,” in which they concluded “Our findings provide direct relevant evidence for the use of P2X7R antagonism to inhibit human microglia-mediated inflammation, with arising potential benefits for patients with TBI and other neuroinflammatory diseases.”</p>
<p>TBI is a major cause of death globally, and there are currently there are no approved therapeutic drugs to improve clinical outcomes, “… emphasizing the clear unmet substantial clinical need,” the authors wrote.</p>
<p>The mechanical damage associated with TBI drives a neuroinflammatory response. “The purinergic P2X7 receptor (P2X7R) is a key driver of neuroinflammation in a range of animal models of traumatic brain injury,” the team continued. P2X7R is expressed by microglia, the resident immune cells in the CNS that are involved in many developmental, homeostatic and pathological roles. “It is well recognized that microglial activation and the hostile neuroinflammatory response arising after the initial insult provide a therapeutic window for pharmacological intervention,” the investigators further stated.</p>
<p>For their reported study investigating how brain cells respond to and manage inflammation, the team developed a way of turning a type of white blood cell into microglia, replicating a normal cellular transformation that has recently been identified to occur in the brain as a natural part of human aging. These microglia are the central coordinators of the immune system in the brain.</p>
<p>Using readily accessible human peripheral monocytes taken from blood samples, the researchers converted them into microglia-like cells—human monocyte-derived microglia (hMDM)—that were used to see how microglia are likely to respond to the inflammation signals. “This enabled us to demonstrate the ability of clinically relevant P2X7R antagonists, including brain-penetrant molecules, to curtail pro-inflammatory cytokine release,” they wrote.</p>
<p>The team showed that administering a P2X7 receptor antagonist interrupted the triggers that these microglia give off as they are damaged and die. Barnes said, “Studying human microglia has long been a major challenge: once removed from their native brain environment, they rapidly lose their defining characteristics, likely due to the absence of critical regulatory signals. Our approach involved the use of monocyte-derived microglia which provide a powerful, scalable, and virtually unlimited platform for studying human microglial biology with unprecedented precision.”</p>
<p>The team confirmed their results using adult human precision-cut brain slices that had been generated subsequent to neurosurgical resections. “Having identified the response in the human monocyte-derived microglia, this provided the impetus to translate these findings with human brain obtained following neurosurgical procedures, Barnes continued. “This successful translation means the next stage for this research is the development of clinical trials in patients with neurodegenerative conditions and patients with TBI where there are no effective pharmacological treatments to reduce the neuroinflammation and arising damage.”</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>In their paper the authors concluded, “The present study provides direct translational evidence from human cellular and brain tissue models to support the clinical use of P2X7R antagonists to limit secondary ATP-driven neuroinflammatory events, such as those that occur in TBI, and thus might improve the clinical outcomes for patients.”</p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/anti-inflammatory-drug-target-for-alzheimers-tbi-and-neurodegenerative-disease-identified/">Anti-Inflammatory Drug Target for Alzheimer’s, TBI, and Neurodegenerative Disease Identified</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Phage Proteases Trigger a Conserved Bacterial Antiviral Defense Pathway</title>
<link>https://edusehat.com/en/phage-proteases-trigger-a-conserved-bacterial-antiviral-defense-pathway</link>
<guid>https://edusehat.com/en/phage-proteases-trigger-a-conserved-bacterial-antiviral-defense-pathway</guid>
<description><![CDATA[ Researchers have uncovered how phage proteases activate CBASS antiphage immunity, revealing a novel bacterial virus-sensing mechanism that could inform development of more effective phage therapies.
The post Phage Proteases Trigger a Conserved Bacterial Antiviral Defense Pathway appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_Bacteriophage_T4_Infection-e1791216945478.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 06 Oct 2026 06:35:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Phage, Proteases, Trigger, Conserved, Bacterial, Antiviral, Defense, Pathway</media:keywords>
<content:encoded><![CDATA[<p>Phages continue to garner excitement as potential treatments for bacterial infections, with a particular interest in targeting infections that are growing increasingly more difficult to treat with antibiotics. There are several challenges in that area of development, including that bacteria have their own defense systems against viruses.</p>
<p>Now, new research has revealed that bacteria detect viruses when a viral enzyme cuts an important sensor molecule in the bacterium, kicking off the immune response. Discoveries of bacterial defenses can pave the way for the development of better phage therapies that can evade the bacterial immune system.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>The results are published in <em>Science </em>in the paper, “<a href="https://www.science.org/doi/10.1126/science.aeg3949" target="_blank" rel="noopener">Phage proteases activate CBASS antiphage immunity</a>.”</p>
<p> “This is one of the most common forms of bacterial immunity, so when we finally figured it out, it was a total eureka moment,” said Sam Hobbs, PhD, assistant professor of biochemistry at University of Utah Health.</p>
<p>One component of the bacterial immune system is the cyclic oligonucleotide–based antiphage signaling systems (CBASS) which lead to a “last resort” immune response that kills the bacterium before viruses can spread to neighbors.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>Precise sensing of the viral trigger is a necessity. In CBASS, cGAS/DncV-like nucleotidyltransferase (CD-NTase) enzymes sense phage infection and synthesize nucleotide signals to initiate antiviral defense. This new work found that the sensing mechanism detects a molecule that the virus needs to survive. More specifically, that phage prohead protease activity is a widespread mechanism of CD-NTase activation.</p>
<p>“We found that the protease from the phage actually acts directly on the host protein, and that is the signal that turns on the whole signaling pathway,” explained Hobbs.</p>
<p>This trigger mechanism is distinct when compared to related antiviral immune pathways, which are activated by the presence of viral genetic material. “This is a totally new mechanism for how these host proteins are activated,” Hobbs said.</p>
<p>Hobbs added that understanding CBASS may advance our knowledge of the human immune system. CBASS is related to a similar immune pathway in humans, indicating that this pathway has persisted at least since bacteria and humans had a common ancestor. And because bacteria have such a rapid life cycle, scientists can use them to very quickly answer questions about how the immune system works, which they can then test in models closer to people.</p>
<p>“The fact that these systems are conserved between bacteria and humans suggests that they’ve been maintained in these different organisms for that entire evolutionary trajectory,” Hobbs said. “The cells are telling us that this is a really important pathway because they’ve maintained it for billions of years. It’s incredibly fascinating, and it’s a cool window into what’s important in maintaining the ability to fight viruses.”</p>
<p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/phage-proteases-trigger-a-conserved-bacterial-antiviral-defense-pathway/">Phage Proteases Trigger a Conserved Bacterial Antiviral Defense Pathway</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>HORIBA Expands Customer&#45;Focused Solutions with New East Coast Analytical Solution Plaza</title>
<link>https://edusehat.com/en/horiba-expands-customer-focused-solutions-with-new-east-coast-analytical-solution-plaza</link>
<guid>https://edusehat.com/en/horiba-expands-customer-focused-solutions-with-new-east-coast-analytical-solution-plaza</guid>
<description><![CDATA[ HORIBA recently unveiled an Applications Solutions Plaza (ASP) at its Piscataway, New Jersey facility. The ASP allows customers to bring samples for testing or receive on-site demonstrations using modular, laboratory setups configured around specific pain points.
The post HORIBA Expands Customer-Focused Solutions with New East Coast Analytical Solution Plaza appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2023/08/GettyImages-1432981265_2000px.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 06 Oct 2026 03:00:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>HORIBA, Expands, Customer-Focused, Solutions, with, New, East, Coast, Analytical, Solution, Plaza</media:keywords>
<content:encoded><![CDATA[<p><span>Last week, I drove to HORIBA’s facility in Piscataway, New Jersey to witness the ceremonial grand opening of its Analytical Solution Plaza (ASP), about 15,000 square feet of space within the larger facility that has been transformed into a lab environment focused squarely on working on applications and methods development with customers across multiple industries including materials, semiconductors, energy, life science, and biopharma. Over several hours, company representatives shared details of the company’s history, its current business, and specific plans for the new ASP and how it fits into HORIBA’s broader corporate strategy.</span></p>
<p><span>The New Jersey ASP is the 19<sup>th</sup> to open globally, with the first launching in Japan and then expanding globally to facilities in places like China, the United Kingdom, and now the United States. </span></p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p><span>During his opening remarks, Koutara Kato, executive vice president and assistant general manager, commercial operations, at HORIBA Instruments Incorporated, highlighted some of the industries that HORIBA is involved in, such as the semiconductor market, as well as where it plans to concentrate additional resources in future. That list includes energy and environment as well as biopharma and healthcare. Each area the company focuses on “gives us a lot of opportunities and challenges,” he said.</span></p>
<figure aria-describedby="caption-attachment-338814" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="size-medium wp-image-338814" src="https://www.genengnews.com/wp-content/uploads/2026/10/HORIBA-US-leadership-300x242.jpg" alt="Some members of the HORIBA team at the event. From L to R: Koutara Kato, executive vice president and assistant general manager, commercial operations; Jeff Julien, PhD, life science applications manager; and Jon Goldey, Manager, Administrative Operations." width="300" height="242" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/HORIBA-US-leadership-300x242.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/HORIBA-US-leadership.jpg 400w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Some members of the HORIBA leadership team at the event. From L to R: Koutara Kato, executive vice president and assistant general manager, commercial operations; Jeff Julien, PhD, life science applications manager; and Jon Goldey, administrative operations manager. [GEN]</figcaption></figure>
<p><span>ASPs provide a space for HORIBA to apply its technology and scientific expertise to customers’ challenges and try to find possible solutions. It could especially benefit customers working with tight budgets amidst rising costs for lab equipment, space, and other factors, noted Michael Oweimrin, national sales manager at HORIBA, in his remarks. “We have a plethora of capabilities to address many different markets.” </span></p>
<p><span>Over 280 heads at HORIBA report to the New Jersey facility which is about 130,000 square feet. And roughly 200 people work at the site. Among other features, the ASP features multiple labs, where HORIBA scientists work on customer projects as well as technical rooms for training application scientists. A key part of the ASP is its modularity. Instruments are placed or bolted to tables with wheels making it possible to move them seamlessly between labs as needed. </span></p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p><span>A tour of a section of HORIBA’s facility, following the opening remarks and a traditional sake barrel opening ceremony, revealed space for stockrooms, manufacturing, and rooms testing and quality control as well as for training field service engineers. The tour included a look at the ASP labs where scientists leverage HORIBA’s expertise in instruments for modular spectroscopy, particle characterization, and Raman microscopy. Scientists in the ASP labs utilize these technologies to address applications in energy and environment, healthcare, and materials and semiconductors. They utilize HORIBA instruments including LabRAM Odyssey and LabRAM Soleil Raman microscopes as well as the Veloci Biopharma Analyzer, which is designed specifically for biopharma and pharma applications. </span></p>
<p><span>Crucially, the ASP is HORIBA’s answer to an important question, Jeff Julien, PhD, life science applications manager at HORIBA, said in his opening comments. Specifically, “how to leverage what HORIBA does well” to shift the conversation from “what instrument is needed” to “what problem to solve.” Using biopharma as an example, he noted that companies developing therapeutic proteins often rely on input from multiple instruments and techniques during development. These are capabilities that the ASP scientists can provide, he said. </span></p>
<figure aria-describedby="caption-attachment-338816" class="wp-caption alignleft"><img decoding="async" class="size-medium wp-image-338816" src="https://www.genengnews.com/wp-content/uploads/2026/10/Sake_barrel_HORIBA-300x193.jpg" alt="Members of the HORIBA team at the event participate in a traditional sake barrel opening ceremony as part of the launch [Credit: HORIBA]." width="300" height="193" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Sake_barrel_HORIBA-300x193.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Sake_barrel_HORIBA.jpg 400w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Members of the HORIBA leadership team at the event participate in a traditional sake barrel opening ceremony as part of the launch. [HORIBA]</figcaption></figure>
<p><span>As noted earlier, in each ASP lab, instruments sit on modular wheel-based carts and lab benches. This makes it possible to reconfigure the lab space for different customers’ pain points as well as to bring in technologies that  “we think could be applicable to those use cases,” Julien said. “It’s really an exciting time to be a part of HORIBA and doing this ASP development” particularly “as the markets change in terms of requirements and what customers are after,” he added. “It changes the way we think [and] the way we approach all of these problems.”</span></p>
<h4><b>Shifting from sales to solutions</b></h4>
<p><span>HORIBA’s ASPs  reflect a broader corporate strategy to move beyond purely transactional sales towards problem-solving partnerships. In the NJ facility, the focus is specifically in the life science and biopharma sectors. Here, HORIBA is positioning its core technologies as an underutilized set of orthogonal tools for various applications including biotherapeutic characterization.</span></p>
<p><span>To be clear, HORIBA’s primary business is still selling instrumentation, but moving forward, the company wants to do more to help customers utilize its instruments to solve problems, Kato said during a conversation with the press where he discussed some of the thinking behind setting up the ASP. “If a customer [is] facing some issues and difficulties, prior to having those instrumentation, we can address this” through the ASP, he said, by showing them how they can use HORIBA’s instruments and what kinds of outcomes they can expect. In most cases, to use the ASP’s capabilities, customers bring samples in and work with HORIBA scientists and tools. There are some cases where HORIBA can deliver needed instruments to customers’ labs to run their analysis on site.  </span></p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p><span>The company has no current plans to increase its headcount, rather it is leveraging expertise it already has in house to support customers looking to utilize the ASP’s capabilities. There are a few types of customer profiles that ASP scientists are working with and these typically are people working in research and development with specific pain points that they hope HORIBA’s fluorescence or Raman spectroscopy or its particle characterization capabilities could solve, Julien explained. </span></p>
<p><span>Feasibility testing is a key step, often starting with simplified samples before graduating to real process samples. HORIBA emphasizes rapid pivoting between fluorescence, Raman, and particle characterization depending on what customer samples reveal. </span></p>
<p><span>For example, “perhaps we’re anticipating [doing] a demo with fluorescence and we very quickly learn more about the customer samples or their process and then say … we need to pivot to Raman because that’s actually going to be a better fit for your use case,” he explained. Furthermore, “if we’ve exhausted our options in terms of what we think we can provide as a solution and it’s not meeting customer needs, we then can engage in conversation and … perhaps work together and develop a custom solution or a fit for purpose solution that’s going to meet those particular needs.”</span></p>
<p><span>HORIBA plans to launch additional ASPs in other locations—setups differ across the company’s offices. The strategy is one ASP per country in strategic locations rather than multiple per country, Kato said. This way, rather than having U.S. customers send samples all the way to an ASP in Japan, for example,, they can access a facility closer to them. ASPs are also customized to local industry needs, for example the ASP in Taiwan is semiconductor focused. The U.S. ASP leverages HORIBA’s location in the tri-state biopharma corridor. Conversations with company representatives highlighted HORIBA’s intent to make deeper inroads into the biopharma and life sciences market in particular.  </span></p>
<p><span>One area that the company is interested in broadening its footprint is in the biotherapeutics market. A key solution for the market is the Veloci Biopharma Analyzer which is designed for tasks such as analyzing antibody-drug conjugates, differentiating AAV subtypes, and for analyzing protein stability, among others. “We [are] now in an age where for a lot of therapeutics … [with] some of these stable technologies like near-IR that have been used historically … you’re infringing on the limits of detection for that technology” leading customers to seek out novel orthogonal measurement methods, Julien said. “That’s ultimately where we feel like we can add value.”</span></p>
<p><span>The company is working on some new products but HORIBA representatives declined to provide specific details about what they are. </span></p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/horiba-expands-customer-focused-solutions-with-new-east-coast-analytical-solution-plaza/">HORIBA Expands Customer-Focused Solutions with New East Coast Analytical Solution Plaza</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>2026 Nobel Prize for Physiology and Medicine Goes to Optogenetics, Light&#45;Gated Ion Channels</title>
<link>https://edusehat.com/en/2026-nobel-prize-for-physiology-and-medicine-goes-to-optogenetics-light-gated-ion-channels</link>
<guid>https://edusehat.com/en/2026-nobel-prize-for-physiology-and-medicine-goes-to-optogenetics-light-gated-ion-channels</guid>
<description><![CDATA[ Today, the 2026 Nobel Prize for Physiology and Medicine has been awarded to Karl Deisseroth, MD, PhD, Peter Hegemann, PhD, and Georg Nagel, PhD, for their discoveries of light-gated ion channels and optogenetics.
The post 2026 Nobel Prize for Physiology and Medicine Goes to Optogenetics, Light-Gated Ion Channels appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GettyImages-2266497868.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 05 Oct 2026 23:25:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>2026, Nobel, Prize, for, Physiology, and, Medicine, Goes, Optogenetics, Light-Gated, Ion, Channels</media:keywords>
<content:encoded><![CDATA[<p>The Nobel Prize in Physiology or Medicine 2026 has been awarded to Karl Deisseroth, MD, PhD, Peter Hegemann, PhD, and Georg Nagel, PhD, for their discoveries of light-gated ion channels and optogenetics.</p>
<figure aria-describedby="caption-attachment-338818" class="wp-caption alignleft"><img decoding="async" class="wp-image-338818 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/10/2026NobelPrizePhysiologyMedicine-300x132.jpg" alt="Karl Deisseroth, MD, PhD, Peter Hegemann, PhD, and Georg Nagel, PhD" width="300" height="132" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/2026NobelPrizePhysiologyMedicine-300x132.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/2026NobelPrizePhysiologyMedicine-768x338.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/2026NobelPrizePhysiologyMedicine.jpg 855w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text"><em>The 2026 Nobel Prize in Physiology or Medicine winners Karl Deisseroth, MD, PhD, Peter Hegemann, PhD, and Georg Nagel, PhD.</em></figcaption></figure>
<p>Deisseroth is a Professor of Bioengineering and of Psychiatry and Behavioral Sciences at Stanford University and an HHMI Investigator; Hegemann is the Hertie Senior Research Chair for Neurosciences and a professor of Experimental Biophysics at Humboldt University and Nagel is a professor at the Department for Neurophysiology at the University of Würzburg, in Germany.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>“Optogenetics provides opportunities for mapping the brain in a way that we could once only dream of,” says Per Svenningsson, MD, PhD, Chair of the Nobel Committee for Physiology or Medicine.</p>
<p>Although optogenetics is a relatively new technology, the seminal paper from the Deisseroth lab was published in 2005. However, the concept of manipulating specific neuronal cell types within intact circuits on a millisecond timescale was considered long before. Indeed, Francis Crick, PhD, once proposed a method where “all neurons of just one type could be activated or inactivated, leaving the others more or less unaltered.” He speculated that to “turn the firing of one or more types of neurons on and off in the alert animal in a rapid manner … the ideal signal would be light,” acknowledging at the time that his idea was “rather far-fetched.” In addition, scientists have been working on laying the foundation for this technology since the 1970s. For example, when Richard Fork, PhD, at Bell Laboratories in New Jersey at the time, published the stimulation of neurons in<em> Aplysia</em> with laser light in <em>Science</em>.</p>
<p>It was the discovery of the algal protein channelrhodopsin that led the way in making the vision into a reality. Microbial rhodopsins—found across archaea, eubacteria, and eukaryotic microalgae—harness light for cellular bioenergetics. Channelrhodopsin is found on the surface of C<em>hlamydomonas</em>, a single-celled alga with the ability to swim towards a light source. Researchers discovered that the protein can directly convert photon energy into transmembrane ion flux.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>The first direct evidence of a light-gated ion channel was named channelrhodopsin-1 (ChR1), discovered and coined by the Hegemann lab. The arguably more consequential breakthrough came just a year later: a collaborative team led by Georg Nagel, demonstrated that a second protein, named channelrhodopsin-2 (ChR2), functioned distinctly from ChR1, and exhibited a blue-shifted activation spectrum and operated as a broad, non-selective cation channel.</p>
<p>Finding a microbial protein that could act as a single unit, simultaneously as a photoreceptor and an ion channel, and the discovery that ChR1 and ChR2 were single-component, light-gated ion channels, provided the precise tools that neuroscientists had been looking for—for fast, genetically targetable optical activation of neurons.</p>
<p>The team in the Deisseroth lab took the baton and performed the first successful demonstration that ChR2 could be expressed in neurons, using a construct provided by Nagel. They introduced the gene for channel-rhodopsin into nerve cells from rats and was able to trigger a nerve signal by illuminating the cells with blue light.</p>
<p>Deisseroth’s lab published this breakthrough in 2005 in the <em>Nature Neuroscience</em> paper, “<a href="https://www.nature.com/articles/nn1525" target="_blank" rel="noopener">Millisecond-timescale, genetically targeted optical control of neural activity</a>.” The study demonstrated that expressing the microbial protein channelrhodopsin-2 (ChR2) from green algae in cultured mammalian neurons allowed precise, millisecond-timescale control of action potentials using flashes of blue light.</p>
<p>The paper’s first author was Ed Boyden, PhD, professor in Neurotechnology at MIT who has been developing the field of optogenetics for the past two decades. Interestingly, CRISPR pioneer Feng Zhang, PhD, is the second author on the 2005 paper. Two years later, Deisseroth’s lab made this light-controlled switch for nerve cells work in the brains of living mice.</p>
<p>Over the past two decades, optogenetics has been used to unpack many biological questions, primarily (but not exclusively) in the field of neuroscience. One early <em>in vivo</em> application of optogenetics probed the causal relationship between the activation of orexin/hypocretin neurons in the lateral hypothalamus and the transitions from sleep to wakefulness. Other notable applications were the search for the memory engram—the physical cellular substrate encoding a specific memory—and unpacking the complexity of dopaminergic neurons in the retina, showing that functionally distinct dopaminergic populations are anatomically intermingled yet strictly segregated by their circuit connectivity.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>Optogenetics has also moved into clinical applications, such as the expression of ChR2 in retinal circuitry. In one experiment, intraocular injection of an adeno-associated viral (AAV) vector encoding ChR2 led to expression in retinal ganglion cells in rodents. More specifically, light depolarized the ChR2 expressing retinal ganglion cells, restoring retinal photosensitivity and allowing light signals to reach the visual cortex in a mouse model of retinitis pigmentosa. Expression of ChR2 in surviving retinal neurons could therefore serve as a potential strategy for restoring vision after rod and cone degeneration.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/2026-nobel-prize-for-physiology-and-medicine-goes-to-optogenetics-light-gated-ion-channels/">2026 Nobel Prize for Physiology and Medicine Goes to Optogenetics, Light-Gated Ion Channels</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>New approaches aim to reduce delays in diagnosing heart attacks in women</title>
<link>https://edusehat.com/en/new-approaches-aim-to-reduce-delays-in-diagnosing-heart-attacks-in-women</link>
<guid>https://edusehat.com/en/new-approaches-aim-to-reduce-delays-in-diagnosing-heart-attacks-in-women</guid>
<description><![CDATA[ Women experiencing heart attacks can face potentially dangerous delays in diagnosis and treatment, prompting growing calls for healthcare systems to adopt diagnostic approaches that better account for differences between women and men. For decades, much of cardiovascular research and many diagnostic standards were developed using evidence drawn predominantly from male patients. Researchers and clinicians are […]
The post New approaches aim to reduce delays in diagnosing heart attacks in women appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/ChatGPT-Image-Oct-5-2026-11_37_40-AM.png" length="49398" type="image/jpeg"/>
<pubDate>Mon, 05 Oct 2026 23:20:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>New, approaches, aim, reduce, delays, diagnosing, heart, attacks, women</media:keywords>
<content:encoded><![CDATA[<p>Women experiencing heart attacks can face potentially dangerous delays in diagnosis and treatment, prompting growing calls for healthcare systems to adopt diagnostic approaches that better account for differences between women and men.</p>
<p>For decades, much of cardiovascular research and many diagnostic standards were developed using evidence drawn predominantly from male patients. Researchers and clinicians are increasingly recognizing that this can affect how quickly cardiovascular disease is identified in women.</p>
<p>Heart & Stroke reports that approximately two-thirds of heart disease and stroke clinical research has focused on men, while half of women who experience a heart attack have their symptoms go unrecognized.</p>
<h3>One important issue involves how women experience and describe symptoms.</h3>
<p>Although chest pain or discomfort remains an important warning sign, women may also experience shortness of breath, unusual fatigue, nausea or indigestion, and pain in the back or neck. Women are also more likely to experience disease involving the heart’s smaller blood vessels, which can make some traditional diagnostic approaches less effective.</p>
<p>Canadian cardiovascular experts have identified disparities within emergency departments as a particular concern.</p>
<p>The Canadian Women’s Heart Health Alliance has reported that women experiencing ST-elevation myocardial infarction can encounter longer delays from arrival at hospital to receiving an electrocardiogram and subsequent treatment.</p>
<p>The Alliance recommends greater use of sex-specific diagnostic protocols, including sex-specific thresholds for high-sensitivity troponin testing in patients presenting with acute chest-pain symptoms. It also recommends incorporating differences in symptoms and female-specific cardiovascular risk factors into clinical assessment.</p>
<p>Troponin is released into the bloodstream when heart muscle is damaged and is commonly measured when clinicians suspect a heart attack. Using diagnostic thresholds that better account for biological differences between women and men may help identify cases that could otherwise be missed or recognized later.</p>
<h3>The issue extends beyond laboratory testing.</h3>
<p>Experts have called for greater education of healthcare professionals about cardiovascular disease in women, more representation of women in clinical trials and increased incorporation of sex and gender into cardiovascular guidelines and medical education.</p>
<p>Awareness among patients is also important. Symptoms such as fatigue, nausea, dizziness, sweating and shortness of breath can sometimes be attributed to other causes, potentially delaying emergency care.</p>
<p>Heart disease remains a major health burden in Canada. Statistics Canada reports that heart disease was the country’s second-leading cause of death in 2023, accounting for 57,890 deaths.</p>
<p>Efforts to close the cardiovascular gender gap increasingly focus on a combination of better research, clinician education, diagnostic protocols and greater public awareness.</p>
<p>For hospitals and emergency departments, the objective is straightforward: recognize cardiovascular disease in women sooner so appropriate treatment can begin sooner.</p>
<p>The post <a href="https://www.hospitalnews.com/new-approaches-aim-to-reduce-delays-in-diagnosing-heart-attacks-in-women/">New approaches aim to reduce delays in diagnosing heart attacks in women</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>New Brunswick expands free RSV immunization to all newborns</title>
<link>https://edusehat.com/en/new-brunswick-expands-free-rsv-immunization-to-all-newborns</link>
<guid>https://edusehat.com/en/new-brunswick-expands-free-rsv-immunization-to-all-newborns</guid>
<description><![CDATA[ New Brunswick has expanded its publicly funded respiratory syncytial virus (RSV) immunization program, making protection available free of charge to all newborns during their first RSV season. The province says the move is intended to protect infants from severe respiratory illness while reducing RSV-related emergency department visits and hospital admissions during the fall and winter […]
The post New Brunswick expands free RSV immunization to all newborns appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/ChatGPT-Image-Oct-5-2026-09_07_38-AM.png" length="49398" type="image/jpeg"/>
<pubDate>Mon, 05 Oct 2026 23:20:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>New, Brunswick, expands, free, RSV, immunization, all, newborns</media:keywords>
<content:encoded><![CDATA[<p>New Brunswick has expanded its publicly funded respiratory syncytial virus (RSV) immunization program, making protection available free of charge to all newborns during their first RSV season.</p>
<p>The province says the move is intended to protect infants from severe respiratory illness while reducing RSV-related emergency department visits and hospital admissions during the fall and winter respiratory season.</p>
<p>RSV affects the lungs and can cause illnesses including bronchiolitis and pneumonia. Although many infections are mild, the virus can cause serious disease in infants. According to the New Brunswick government, RSV is the leading cause of hospitalization among babies during their first year of life.</p>
<p>Under the expanded program, babies born between April 1 and October 12, 2026 can receive RSV immunization through regional public health clinics or their primary care provider.</p>
<p>Babies born between October 13, 2026 and March 31, 2027 will be able to receive the immunization following birth and before leaving hospital. Families can also access it later through regional public health offices or primary care providers. The timing is intended to provide protection as RSV circulation increases during the colder months.</p>
<p>“Immunizing in October, just before RSV season begins, will help ensure babies have the strongest protection against RSV during the time of year when it is most common,” New Brunswick Chief Medical Officer of Health Dr. Yves Léger said in announcing the program.</p>
<p>New Brunswick previously provided RSV monoclonal antibodies to infants considered at high risk during the 2025–26 respiratory season. The new approach extends publicly funded protection to all infants for the upcoming season.</p>
<p>The province has also progressively expanded RSV prevention among older adults. Publicly funded vaccination is available to several higher-risk groups, including adults 75 and older, Indigenous adults 60 and older, and certain older adults receiving long-term, rehabilitation or hospital care.</p>
<p>The broader infant program could also have implications for hospital capacity. Respiratory illnesses can contribute to significant seasonal pressure on pediatric services, emergency departments and inpatient units.</p>
<p>Dr. Ariadna Grigoriu, medical director of the New Brunswick Perinatal Health Program, described universal infant RSV protection as an important step toward reducing both severe illness and hospitalization.</p>
<p>The program comes as health systems across Canada prepare for the 2026–27 respiratory illness season.</p>
<p><em><strong>Source:</strong> Government of New Brunswick — Free RSV immunization for all New Brunswick newborns</em></p>
<p>The post <a href="https://www.hospitalnews.com/new-brunswick-expands-free-rsv-immunization-to-all-newborns/">New Brunswick expands free RSV immunization to all newborns</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>BIO on the American Road visits pioneering NC biotech hub</title>
<link>https://edusehat.com/en/bio-on-the-american-road-visits-pioneering-nc-biotech-hub</link>
<guid>https://edusehat.com/en/bio-on-the-american-road-visits-pioneering-nc-biotech-hub</guid>
<description><![CDATA[ Research Triangle Park resurgent with billions in investment in biotechnology manufacturing. With a famous biotech cluster in Research Triangle Park (RTP) established almost 70 […]
The post BIO on the American Road visits pioneering NC biotech hub appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/10/JFC-and-Deborah-Ross.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 05 Oct 2026 16:05:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>BIO, the, American, Road, visits, pioneering, biotech, hub</media:keywords>
<content:encoded><![CDATA[<h4>Research Triangle Park resurgent with billions in investment in biotechnology manufacturing.</h4>
<p><span>With a famous biotech cluster in Research Triangle Park (RTP) established almost 70 years ago, North Carolina is already a powerhouse of pharmaceutical R&D and manufacturing, and recent expansion plans worth billions of dollars will continue growth into the future.</span></p>
<p><span>A delegation from the Biotechnology Innovation Organization (BIO), led by BIO President & CEO John F. Crowley, learned about North Carolina’s biotech industry on an Oct. 2 visit to RTP, a 7,000-acre complex spread across the three cities of Raleigh, Durham, and Chapel Hill, N.C. It was the latest stop of the BIO on the American Road learning and networking tour of America’s biotech ecosystems.</span></p>
<p><span>BIO’s delegation met local members of industry, patient advocates, and Rep. Deborah Ross (D-NC), a champion of IP rights and biotech (<em>pictured at top, with Crowley</em>). The BIO delegation also toured the RTP facilities of Biogen, which are currently undergoing a $2 billion expansion.</span></p>
<p><span>“Companies come to North Carolina and RTP because of the investments, talent, partnerships and strong support from elected leaders, like Rep. Ross, that make innovation possible,” said Crowley. “RTP has built an ecosystem where biotechnology companies can develop medical breakthroughs and manufacture them right here in America. </span><span>The U.S. must continue to lead in biotechnology, and that requires building a stronger American biotech industry. North Carolina and RTP are demonstrating the power of bringing innovation, investment and manufacturing together.”</span></p>
<p><span>Biotech R&D, manufacturing, and distribution are all well represented in North Carolina, where the life sciences employed 103,107 as of 2024, according to a</span><a href="https://www.ncbiotech.org/sites/default/files/2025-01/NCBiotech%202024-TEConomy.pdf"> <span>TEConomy NCBiotech report</span></a><span>. These workers belonged to nearly 6,700 state businesses working in biotech, the report said.</span></p>
<p><span>BIO’s delegation met with several innovation leaders at an industry roundtable hosted at the offices of the North Carolina Biotech Center (NCBiotech). Founded in 1984, NCBiotech was the first state-sponsored initiative of its kind to support the biotech industry. They seek to “create North Carolina’s competitive advantage in the life sciences by engaging partners, maximizing opportunities, and delivering solutions to accelerate innovation, investment, and job creation.”</span></p>
<p><span>BIO also hosted a luncheon with patient advocates from across the state and met with  Rep. Ross, who represents the RTP area, at Biogen’s impressive manufacturing campus, which has roots dating back 30 years in the area.</span></p>
<p><span>Rep. Ross sits on the  House Judiciary Committee and has authored and supported several bills promoting IP and biotech.</span></p>
<p><span>Ross recently cosponsored</span><a href="https://www.biotech.senate.gov/press-releases/bipartisan-senate-and-house-members-introduce-legislation-to-boost-american-biotech-manufacturing-infrastructure-and-innovation/"> <span>H.R. 6089, the Biomanufacturing Excellence Act of 2025</span></a><span> which would establish a public-private partnership to allow innovators to scale their products in the U.S. with smarter, faster, more efficient manufacturing practices. The bill was inspired by recommendations from the National Security Commission on Emerging Biotechnology’s April 2025 Action Plan for Congress.</span></p>
<p><span>“I’m proud to represent North Carolina’s Research Triangle, where universities, startups, and major institutions are constantly pushing the boundaries of what’s possible,” Rep. Ross said. “That’s why I was grateful to visit Biogen’s RTP campus in Morrisville for an important discussion about the future of biomanufacturing in North Carolina. Biomanufacturing is a pillar of our economy and workforce, creating good-paying jobs and attracting some of the brightest minds to our community. It’s more important than ever that we develop new medications here at home that are accessible and affordable.”</span></p>
<h2>‘Bipartisan support for biotech’</h2>
<div class="gs">
<div class=" ">
<div class="ii gt adO">
<div class="a3s aiL ">
<div dir="ltr">
<div>
<p dir="ltr">In her work on IP, Rep. Ross has collaborated with another North Carolina legislator, Sen. Thom Tillis (R-NC), according to Laura Gunter, President of NCLifeSci, BIO’s affiliate in the state.</p>
<p dir="ltr">Gunter praised the pro-biotech work of North Carolina’s federal delegation in general. Reps. Gregory Murphy, M.D. (R-NC), Don Davis (D-NC), and Richard Hudson (R-NC)<a href="https://bio.news/health/epic-act-introduced-to-correct-iras-pill-penalty/" target="_blank" rel="noopener" data-saferedirecturl="https://www.google.com/url?q=https://bio.news/health/epic-act-introduced-to-correct-iras-pill-penalty/&source=gmail&ust=1791210808119000&usg=AOvVaw3B_EJDjUGN6YO4WWqH8u36"> introduced the EPIC Act</a>, designed to give small molecules the same protection from drug price negotiations as biologics. Tillis and Sen. Ted Budd (R-NC) co-sponsored EPIC in the Senate.</p>
</div>
</div>
</div>
</div>
</div>
</div>
<p><span>“Given the high level of biotech employment, the importance of the industry’s supply chain and research activities around the state, we see a lot of good bipartisan support for biotech from our federal delegation,” said Gunter.</span></p>
<p><span>She said NCLifeSci receives assistance and guidance from BIO when addressing federal issues that matter for North Carolina. These include: federal funding for the state’s top-tier research (R1) universities; SBIR federal seed funding for early-stage research; and national security priorities outlined by the NSCEB, Gunter said.</span></p>
<p><span>Founded in the early 1990s, NCLifeSci has focused on state policy affecting biotech.</span></p>
<p><span>“We’ve been able to have a real impact on the industry overall on the state level,” said Gunter. This has included “being one of the first states to really incorporate a matching fund for federal SBIR dollars,” getting state support for workforce development training programs, and tax incentives.</span></p>
<p><span>NCLifeSci was instrumental in establishing the NC Life Sciences Caucus, made up of lawmakers from both parties in both the state House and state Senate. Among its pro-biotech efforts, the Life Sciences Caucus supported the introduction of the first omnibus life sciences appropriation bill for inclusion in the state budget, NCLifeSci helped write the bill.</span></p>
<p><span>“Measures that matter to the industry were grouped in an omnibus package with the goal of saying, here’s a number of areas where the state can contribute to North Carolina’s life sciences,” Gunter said.</span></p>
<p><span>The pro-biotech policy environment and the existence of institutions like NCBiotech help North Carolina build one of the country’s leading biotech ecosystems, according to Gunter. Other attributes of that ecosystem include five R1 research universities, a broad range of small biotechs, a large concentration of clinical research organizations, and manufacturers—from major pharma firms to contract development manufacturing organizations.</span></p>
<p><span>“So we have the full soup-to-nuts of the biotech ecosystem, and it really works well together,” Gunter said.</span></p>
<h2>Biogen’s growth</h2>
<p><span>BIO’s team joined Rep. Ross for a tour of the RTP facilities of BIO member Biogen, a leading biotech company developing innovative treatments in neurology, immunology, and rare diseases. With more than 1,500 manufacturing and technical employees and more than 400 skilled contractors, Biogen is the largest biotech employer in North Carolina, and they’re still growing.</span></p>
<figure aria-describedby="caption-attachment-6498" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="wp-image-6498 size-medium" src="https://bio.news/wp-content/uploads/2026/10/visit-to-biogen-350x165.jpg" alt="BIO North Carolina" width="350" height="165" srcset="https://bio.news/wp-content/uploads/2026/10/visit-to-biogen-350x165.jpg 350w, https://bio.news/wp-content/uploads/2026/10/visit-to-biogen.jpg 600w" sizes="(max-width: 350px) 100vw, 350px"><figcaption class="wp-caption-text">Visiting Biogen’s facilities.</figcaption></figure>
<p><span>“Biogen announced a $2 billion investment in our existing Research Triangle Park (RTP), North Carolina manufacturing footprint in July 2025, and we’ve continued to progress this multi-project strategic investment plan since our announcement,” said Nicole Murphy, Biogen Executive Vice President and Head of Pharmaceutical Operations and Technology. “This year, Biogen’s facility in RTP has executed approximately $200 million year-to-date, supporting progress across multiple modality expansions, including a new ASO (antisense oligonucleotide) purification factory and additional synthesis capabilities.”</span></p>
<p><span>The expansion will also add new clinical product assembly and packaging capabilities, utility, environmental, and infrastructure improvements, continued digitalization and AI-enabled roadmap deployment, and initial engineering work for future biologics, fill-finish, lyophilization, and oral solid dose capabilities.</span></p>
<p><span>“The work happening here is helping Biogen reliably produce medicines for patients today while also building the capabilities we will need for the future,” Murphy said. “Given recent acquisitions, we are also evaluating additional potential investment opportunities based on our late-stage portfolio.”</span></p>
<p><span>While Biogen is headquartered in Kendall Square in Cambridge, MA, and has a new facility in San Francisco, it mainly conducts its U.S. manufacturing in North Carolina.</span></p>
<p><span>“RTP has become our largest manufacturing footprint because it offers the right environment for advanced biomanufacturing,” Murphy said. “You have leading universities, research institutions, life sciences companies and a deep technical workforce all in one region.”</span></p>
<p><span>Biogen is not just a beneficiary of the biotech expertise in RTP, it is also a major contributor to the ecosystem, Murphy noted.</span></p>
<p><span>“Biogen brings a large, established, and advanced manufacturing presence to RTP, along with continued investment in high-quality jobs, technical capabilities, and infrastructure. Our presence helps strengthen the broader life sciences ecosystem by creating opportunities for collaboration, training, and workforce development,” Murphy said. “We also work with local institutions and programs to help build pathways into biotech manufacturing careers, which is important both for Biogen and for the region’s long-term growth.”</span></p>
<p><span>Biogen’s North Carolina expansion is just one of several announced recently. Others include:</span></p>
<ul>
<li aria-level="1"><span> </span><span>BIO member</span><a href="https://www.gene.com/media/press-releases/15122/2026-08-18/genentech-marks-topping-out-milestone-fo"> <span>Genentech said it is planning to invest $2 billion</span></a><span> in its first East Coast manufacturing facility in Holly Springs, NC.</span></li>
<li aria-level="1"><span>BIO member</span><a href="https://www.novartis.com/news/media-releases/novartis-announces-plans-build-flagship-manufacturing-hub-north-carolina"> <span>Novartis said in November it will build</span></a><span> a flagship manufacturing hub in North Carolina, which will create an additional 700 jobs.</span></li>
<li aria-level="1"><a href="https://news.abbvie.com/2026-04-22-AbbVie-Selects-North-Carolina-for-New-1-4-Billion-Manufacturing-Campus"><span>AbbVie announced plans</span></a><span> for a $1.4 billion manufacturing facility in North Carolina in April.</span></li>
</ul>
<p><span>“North Carolina’s biotech sector is rooted in a long tradition of innovation, and its momentum continues to grow,” Crowley observed.</span></p>
<figure aria-describedby="caption-attachment-6501" class="wp-caption alignnone"><img decoding="async" class="wp-image-6501 size-full" src="https://bio.news/wp-content/uploads/2026/10/patient-luncheon.jpg" alt="NC BIO on the American Road" width="800" height="562" srcset="https://bio.news/wp-content/uploads/2026/10/patient-luncheon.jpg 800w, https://bio.news/wp-content/uploads/2026/10/patient-luncheon-350x246.jpg 350w, https://bio.news/wp-content/uploads/2026/10/patient-luncheon-768x540.jpg 768w" sizes="(max-width: 800px) 100vw, 800px"><figcaption class="wp-caption-text">The luncheon with patient advocates.</figcaption></figure>
<p>The post <a href="https://bio.news/state-policy/bio-on-the-american-road-visits-pioneering-nc-biotech-hub/">BIO on the American Road visits pioneering NC biotech hub</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Tariffs’ drag on innovation compounded by lack of guidance, experts say</title>
<link>https://edusehat.com/en/tariffs-drag-on-innovation-compounded-by-lack-of-guidance-experts-say</link>
<guid>https://edusehat.com/en/tariffs-drag-on-innovation-compounded-by-lack-of-guidance-experts-say</guid>
<description><![CDATA[ Continuing confusion about compliance is exacerbating the harms that new pharmaceutical tariffs cause the biotech industry, especially small innovative firms, experts say. Tariffs of […]
The post Tariffs’ drag on innovation compounded by lack of guidance, experts say appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/10/elevate-dI-aXC7DWpQ-unsplash.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 05 Oct 2026 16:05:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Tariffs’, drag, innovation, compounded, lack, guidance, experts, say</media:keywords>
<content:encoded><![CDATA[<p><span>Continuing confusion about compliance is exacerbating the harms that new pharmaceutical tariffs cause the biotech industry, especially small innovative firms, experts say.</span></p>
<p><span>Tariffs of up to 100% on patented pharmaceuticals and their ingredients that went into effect Sept. 29 are expected to increase costs for innovators, discourage drug development and investment, and potentially reduce patient access to drugs they need. They also weaken U.S. competitiveness at a time when China is seeking to replace America as the world leader in biotech, experts say.</span></p>
<p><span>Meanwhile, the lack of information on how to comply with the Administration’s guidance on tariff implementation is creating chaos that complicates day-to-day operations of drug makers, according to the biotech industry. Innovators of all sizes have questions, ranging from types of patents that will be considered to the process and criteria for seeking an exemption to the tariffs.</span></p>
<p><span>“With these tariffs, the United States has reversed decades of sound trade policy, creating new uncertainty for biotech innovators, and increasing the burden on the small- and mid-sized companies responsible for many of tomorrow’s breakthrough medicines,” according to a statement from the Biotechnology Innovation Organization (BIO).</span></p>
<p><span>As</span><a href="https://www.bio.org/toolkit/human-health/americas-innovation-engine-power-small-and-mid-sized-biotechs"> <span>BIO research shows</span></a><span>, small- to medium-sized biotechs are responsible for 71% of the industry’s output and 54% of the new drug applications. The smaller innovative companies generally have less available capital to adjust to shocks like tariffs or to take moves that could reduce the tariff burden, experts noted.</span></p>
<p><span>The tariffs are being implemented after a Department of Commerce Section 232 investigation determined that global supply chains are risky, and concluded that onshoring drug production bolsters national security. Yet, experts argue that the additional obstacles to global networks posed by the tariffs will weaken the supply chain and reduce our access to medicines we need.</span></p>
<p><span>Companies that agree to move their production to the U.S. can apply for reductions in tariffs, but this relief is out of reach for most small biotechs, which must outsource all of their production. Suddenly shifting their complex manufacturing processes from overseas contractors may be impossible, says Marta Wosińska, a senior fellow at the Brookings Institution, according to Axios.</span></p>
<p><span>These smaller firms also generally lack in-house capacity to adjust to new tariff reporting burdens for compliance, experts say.</span></p>
<h2><b>Insufficient guidance</b></h2>
<p><span>But even those firms seeking to comply do not have adequate guidance to do so, experts say.</span></p>
<p><span>As</span><a href="https://bio.news/federal-policy/with-pharmaceutical-tariffs-looming-guidance-on-compliance-is-still-lacking/"> <span>Bio.News reported on Sept. 14</span></a><span>, with two weeks until implementation, much of the necessary federal guidance was still missing, including information on how to qualify for exemptions based on the type of drug being imported, the country of origin, and engagement in Most Favored Nation (MFN) pricing agreements or onshoring commitments.</span></p>
<p><span>On Sept. 23, days before the tariff went into effect, the Department of Commerce did issue </span><a href="https://www.federalregister.gov/documents/2026/09/23/2026-19498/guidance-and-procedures-for-implementing-tariff-adjustments-for-specialty-pharmaceuticals-and"><span>new guidance</span></a><span>, but “its guidance has created more confusion,” according to a Sept. 27</span><a href="https://www.wsj.com/opinion/the-u-s-tariff-attack-on-u-s-biotech-c3406b92"> <span>Wall Street Journal editorial</span></a><span>.</span></p>
<p><span>“Biotech companies will have to apply for exemptions for each individual product, regardless of whether it meets one of the specified categories, and explain ‘why the import meets an urgent U.S. health need.’ Urgent will be in the eyes of the bureaucrats who rarely act with urgency,” says the editorial.</span></p>
<p><span>Indeed, the Commerce Department’s guidance does not seem to offer hard, fast rules on the definition of “urgent U.S. health need”, nor provide clarity on the criteria that Commerce will use to make case-by-case determinations.</span></p>
<p><span>“The rationale can include information such as the type of disease the product treats and an assessment of alternative therapies or lack of alternative therapies for the type of disease the product treats, the number of U.S. patients that use the product, and whether or not the product is available in other jurisdictions,”</span><a href="https://www.federalregister.gov/d/2026-19498/p-32"> <span>the Commerce department’s guidance says</span></a><span>. While the guidance notes. “Commerce will make an individual, fact-specific, company-specific decision for each request.”</span></p>
<p><span>There is no set time frame for these decisions, and companies still don’t know if those that are ultimately granted exemptions will have to pay full tariffs first and ask for refunds later.</span></p>
<h2><b>The challenge to competition</b></h2>
<p><span>Experts expressed concerns that both tariffs and the cost of compliance will eat away at funding that could be used for research, harming America’s competitiveness and the future of innovative therapies for the American people.</span></p>
<p><span>“One small company says tariff compliance could consume 2% to 4% of its working capital before it commercializes its first medicine,” says The Wall Street Journal’s editorial. “That means less money for research. It’s hard enough developing a new drug. Tariffs add more uncertainty that will discourage investment in U.S. biotech.”</span></p>
<p><span>While the justification given for the tariffs is strengthening national security, experts worry that by harming America’s ability to invest in biotech research, it will have the opposite effect.</span></p>
<p><span>“At a time when the United States should strengthen its biotechnology leadership to compete aggressively with China, these tariffs move us in the wrong direction,” says BIO’s statement.</span></p>
<p>The post <a href="https://bio.news/federal-policy/tariffs-drag-on-innovation-compounded-by-lack-of-guidance-experts-say/">Tariffs’ drag on innovation compounded by lack of guidance, experts say</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>FDA to Highlight Aging, Longevity Medicine in Planned FARS Updates</title>
<link>https://edusehat.com/en/fda-to-highlight-aging-longevity-medicine-in-planned-fars-updates</link>
<guid>https://edusehat.com/en/fda-to-highlight-aging-longevity-medicine-in-planned-fars-updates</guid>
<description><![CDATA[ FDA Chief Scientist Steven Kozlowski, MD, said the updated FARS would come out early in FY 2027 but offered no further specifics on timing.
The post FDA to Highlight Aging, Longevity Medicine in Planned FARS Updates appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/ARDD2026-Zeta-Kozlowski-FDA-Panel-100126-3732-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 03 Oct 2026 05:45:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>FDA, Highlight, Aging, Longevity, Medicine, Planned, FARS, Updates</media:keywords>
<content:encoded><![CDATA[<p><strong>BOSTON</strong>—The FDA’s top scientific official drew a round of applause by telling a longevity medicine conference here that the agency plans to include aging and longevity among topics it will highlight in the updated Focus Areas of Regulatory Science (FARS) report it plans to issue in the federal fiscal year that began Thursday.</p>
<p>“We all believe that there is a shared risk factor of aging for many, many chronic diseases. But to me, it’s interesting: Is there a way of beginning to start quantifying that, really working a lot on the biological side but also on the clinical side, what that looks like?” FDA Chief Scientist Steven Kozlowski, MD, told attendees at the 13<sup>th</sup> Aging Research & Drug Discovery Meeting (ARDD 2026), held at the David Rubinstein Treehouse at Harvard University.</p>
<p>Kozlowski said the updated FARS would come out early in FY 2027 but offered no further specifics on timing.</p>
<p>“It would be really good to have a shared endpoint [that was] pre-competitive, qualified, and shared broadly so that everybody can use that can serve as a bridge,” Kozlowski elaborated. “Attributes of that endpoint would be regulatory acceptance, right? You buy into that endpoint and it’s really useful, that it allows feasible clinical trial designs that it’s worth doing, that it serves as a standard for all the other novel things that come after it, and that to some extent helps with accessibility [to other researchers].”</p>
<p>Kozlowski spoke during “Matching Clinical Trials of Therapeutics & Regulatory Mandates,” a panel of four current FDA officials.</p>
<p>“Steve and his team have been working really hard to develop these key areas where I’ve been speaking to all of our stakeholders where there is a need for more regulatory science,” said Lowell M. Zeta, JD, Acting Chief of Staff in the FDA’s Office of the Commissioner. “To the extent that we can be and should be evolving our programs to help you all solve the challenges, that’s what we want to hear.”</p>
<p>Zeta called longevity and healthspan—the number of years a person lives free from long-term disease or disability—“an important topic for the agency and HHS [U.S. Department of Health and Human Services].</p>
<h4><strong>‘A defining moment’</strong></h4>
<p>“It’s really a defining moment, an inflection point for the future,” Zeta added. “It’s a test for the future of FDA and how to adapt to the rapidly evolving science in this space.”</p>
<p>Zeta was the highest ranking FDA official on the panel, which included Justin Penzenstadler, PharmD, acting associate director of the FDA’s Office of Cardiology, Hematology, Endocrinology, and Nephrology; and Jeffrey Siegel, MD, director of the FDA’s Office of Drug Evaluation Sciences.</p>
<p>Panel moderator was Andrew Brack, PhD, program manager, proactive health with ARPA-H. Brack oversees <a href="https://arpa-h.gov/explore-funding/programs/prospr" target="_blank" rel="noopener">PROSPR (PROactive Solutions for Prolonging Resilience)</a>, a $144 million research initiative designed to extend American healthspan by redefining how aging and functional decline are measured and treated.</p>
<p>Brack began the panel session by asking a question to the four FDA officials: What do you see as the most realistic regulatory path to date response of trying to develop a therapy that targets aging biology rather than a single disease?</p>
<p>Siegel replied that aging could be considered for approval of new therapies in two ways. One is taking into account that aging increases the prevalence of numerous chronic diseases, including types of cancer, Parkinson’s disease, Alzheimer’s disease, and cardiovascular disease.</p>
<p>“Once you get to two or three that the same mechanism impacts, you begin to think that maybe this general mechanism is having an effect overall on aging-related disorders. And maybe you would be able to generalize from that,” Siegel said</p>
<h4><strong>Impact on people</strong></h4>
<p>But there is another approach, Siegel continued, which entails looking at the ways that aging impacts people, such as increasing the risks of cognitive decline and frailty, and causes loss of senses such as hearing and vision.</p>
<p>“If you have a way to evaluate those general aspects of aging, and you can define a patient population who’s subject to that aging-related deterioration, then you have to make use of a clinical trial that could demonstrate an effect on aging more broadly,” he explained.</p>
<p>The trial would need to measure aging-related domains, showing that the progression of these domains is less in treated patients than in an untreated control group, Siegel said: “That would be an indication that this is impacting the way that patients function and feel and survive, and potentially could be a way towards demonstrating efficacy for a drug impacting aging.”</p>
<p>Basic science research in recent decades has identified general mechanisms that underlie the aging process. Experimental models blocking some of these mechanisms has been demonstrated to increase lifespan, sometimes by as much as 30%, Siegel explained.</p>
<h4><strong>‘Amazing implications’</strong></h4>
<p>Some newer studies, he added, have suggested that treatments that block these aging processes could potentially reverse aging.</p>
<p>“If this can be applied in therapeutics for people, this has amazing implications, potentially increasing lifespan, but also decreasing the adverse effects that aging has on people, including aging-related diseases.”</p>
<p>Officials and researchers have long ascribed economic as well as health benefits to lengthening healthspans: An <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10154220/" target="_blank" rel="noopener">economic analysis published in 2021</a> concluded that a slowdown in aging that increased life expectancy by one year would generate $38 trillion in economic gains—a figure that ballooned to $367 trillion for 10 years of increased life expectancy.</p>
<p>Siegel said earlier trials will look at prevention of age-related comorbidities or mortality as an endpoint, but will also collect measures of clinical outcome assessments. He cited drug development history: The first trial of insulin evaluated a single patient—<a href="https://www.genengnews.com/insights/the-right-protein-to-establish-recombinant-therapeutics/" target="_blank" rel="noopener">a 14-year-old boy with type 1 diabetes</a>—using a single endpoint, mortality.</p>
<p>“I see geroscience following a similar arc, where you start with enriched patients, you’re looking at the hard endpoints, right? And then as the field, the body of evidence builds, you’ll be able to say, hey, here’s some measures that track with mortality. And maybe we ought not run trials as long,” Penzenstadler said. “You might be able to start validating some other endpoints or biomarkers that predict mortality, and that could shorten your trials.”</p>
<p>The FARS focus on aging and longevity sparked a question from a panelist in the panel that followed.</p>
<p>“Let’s say aging will be designated as a disease, how do we define it? And suddenly we come to a decade-long question, what is aging?” asked Steve Horvath, PhD, professor, human genetics and biostatistics at University of California, Los Angeles (UCLA).</p>
<h4><strong>Huge progress</strong></h4>
<p>“I would say we’ve made huge progress in defining that. And in short, it’s complicated, but you will not—in my opinion, you will not be able to get there unless you also have molecular biomarkers of aging,” Horvath asserted. “Assessing function in 10 different ways and disease indication, that’s really easy and very well defined. But what can we, the scientists in the field, contribute to physiologic markers, molecular markers of aging, so that they can be folded into future clinical trials that target aging per se?”</p>
<p>The 2022 FARS report—completed within the tenure of then-FDA commissioner Robert M. Califf, MD, who served under Democratic presidents Joe Biden and Barack Obama—was written with the COVID-19 pandemic still fresh in recent memory. That explains why the first priority highlighted by that report was “Public Health Preparedness and Response.” Also identified were:</p>
<ul>
<li>Increasing Choice and Competition through Innovation.</li>
<li>Understanding the Power of Data.</li>
<li>Empowering Patients and Consumers.</li>
</ul>
<p>The terms “aging research” and “longevity medicine” do not appear in the 2022 FARS.</p>
<p>According to the FDA, a key purpose of FARS reports is to communicate the importance and impact of its ongoing regulatory science research activities that cut across its numerous centers, offices, and laboratories. The FDA defines regulatory science as the science of developing tools, standards and approaches to assess the safety, efficacy, quality, and performance of FDA-regulated products.</p>
<p>The FDA is now helmed by Acting Commissioner Kyle Diamantas, JD, who previously served as the agency’s deputy commissioner for food. President Donald Trump has nominated Heidi N. Overton, MD, PhD, as permanent commissioner. Overton’s nomination has yet to be voted by the U.S. Senate, whose Committee on Health, Education, Labor, and Pensions <a href="https://www.help.senate.gov/hearings/nomination-of-heidi-overton-to-be-commissioner-of-food-and-drugs" target="_blank" rel="noopener">heard testimony from her</a> on September 24.</p>
<h4><strong>Urging disease prevention</strong></h4>
<p>Before the FDA panel Admiral Brian Christine, MD, HHS assistant secretary for health, urged longevity drug developers and researchers to focus on modifying biological processes associated with aging over time and intervening to prevent disease before it occurs, rather than managing illness once someone gets sick.</p>
<p>Christine—who was appointed by President Donald Trump, confirmed by the U.S. Senate, and serves under HHS Secretary Robert F. Kennedy Jr.—aligned the push toward longevity medicine articulated by panelists at ARDD 2026 with Kennedy’s “Make America Healthy Again” (MAHA) policy framework. Kennedy has led an overhaul of federal policy on nutrition and disease prevention including vaccination schedules, prompting backlash from medical groups and researchers. David Robert Grimes, PhD, a professor of biostatistics at Trinity College Dublin and advocate, last year characterized MAHA as a movement that “<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12678486/" target="_blank" rel="noopener">thrives on science denialism</a>.”</p>
<p>Not so, according to Christine.</p>
<p>“At its core, our MAHA movement is about confronting chronic disease,” Christine contended. “It begins with a very simple question, deceptively simple: Why are so many Americans sick, and what are we willing to do differently about it?”</p>
<p>“For decades, we have too often responded to chronic disease one condition at a time, and frequently, unfortunately, measure the rate and course of the disease,” said Christine, who also leads the U.S. Public Health Service Commissioned Corps, which consists of about 5,300 public health professionals. “Good science must be willing to ask questions even when the answers challenge longstanding assumptions. That matters enormously in healthy aging because patients are already moving faster than many traditional institutions.”</p>
<p>He cited as examples growing interest by women in menopausal hormone replacement therapy, by men in testosterone replacement therapy, and by both in improving their health through peptides, dietary supplements, continuous glucose monitors, wearables, biological AIDS tests, and emerging diagnostic technologies.</p>
<p>“Increasingly, people are learning about these interventions from podcasts, from social media, from wellness clinics, and direct to consumer companies before they ever walk into a physician’s or a nurse’s office,” Christine said.</p>
<p>Christine and the FDA officials spoke during ARDD 2026’s initial series of sessions. Before they spoke, George Q. Daley, MD, PhD, dean of Harvard Medical School, opened the conference with a plea for caution when it comes to promoting the benefits of drugs designed to fight the effects of aging.</p>
<p>“I’m concerned that the optimistic claims being made by some in the aging community far exceed what one can responsibly conclude from our current understanding of the biology,” Daley told ARDD 2026 attendees. “I implore you all to listen attentively to the many compelling presentations scheduled over the next few days, but also skeptically and critically, so that we will emerge with a greater respect for the science, but proper restraint in forward-looking claims of life extension.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/fda-to-highlight-aging-longevity-medicine-in-planned-fars-update/">FDA to Highlight Aging, Longevity Medicine in Planned FARS Updates</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Neurons Involved in Generating Anxiety After Cannabinoid Drug Exposure Identified in Mice</title>
<link>https://edusehat.com/en/neurons-involved-in-generating-anxiety-after-cannabinoid-drug-exposure-identified-in-mice</link>
<guid>https://edusehat.com/en/neurons-involved-in-generating-anxiety-after-cannabinoid-drug-exposure-identified-in-mice</guid>
<description><![CDATA[ Working with mice, scientists have for the first time identified a set of neurons in the brain that play a role in generating anxiety after exposure to cannabinoid drugs, especially under stressful conditions.
The post Neurons Involved in Generating Anxiety After Cannabinoid Drug Exposure Identified in Mice appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/08/GettyImages-170614889.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 03 Oct 2026 05:45:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Neurons, Involved, Generating, Anxiety, After, Cannabinoid, Drug, Exposure, Identified, Mice</media:keywords>
<content:encoded><![CDATA[<p>Working with mice, Northwestern scientists have for the first time identified a set of neurons in the brain that play a role in generating anxiety after exposure to cannabinoid drugs, especially under stressful conditions. Cannabinoids are a class of substances that includes tetrahydrocannabinol (THC), the main psychoactive ingredient in cannabis and synthetic analogs.</p>
<p>Scientists exposed mice to a predator odor after giving them a placebo or a cannabinoid drug. Animals given the cannabinoid froze more and spent less time investigating the odor. Using small microscopes, scientists identified neurons activated by the drug that helped drive anxious behaviors. When those neurons were silenced the cannabinoid no longer triggered the same level of anxious behaviors.</p>
<p>The findings could help scientists better understand how cannabis exerts its psychoactive effects, and potentially point to strategies for holding back anxiety in affected individuals. The results could provide insights into strategies for reducing anxiety symptoms in other contexts, outside of cannabis use.</p>
<p>“The results of this study could explain why a good trip can turn bad pretty quickly if people consume too much cannabis or the situation they are in turns stressful or scary,” said Sachin Patel, MD, PhD, chair of psychiatry and behavioral sciences at Northwestern University Feinberg School of Medicine.</p>
<p>Patel is senior and corresponding author of the team’s published paper in <em>Nature Communications</em>, titled “<a href="https://doi.org/10.1038/s41467-026-77957-4" target="_blank" rel="noopener">Cannabinoid modulation of central amygdala population dynamics during threat investigation</a>.” In their paper the team concluded that their results “… could ultimately provide important insights into how cannabinoids augment threat reactivity and the interactions between cannabis use and anxiety disorders.”</p>
<p>Plant-derived cannabinoids are widely used for medicinal and recreational purposes, and exert broad-ranging behavioral and physiological effects on mood, anxiety, memory, appetite, and sleep, the authors noted. But they can also precipitate anxiety and panic reactions in people, and increase threat-related defensive responses in rodents. “Specifically, while tension and anxiety relief represent major reasons for cannabis use, paradoxical dose- and context-dependent increases in anxiety and panic are also well-documented, and some studies have suggested associations between cannabis use and the development and worsening of anxiety disorders, especially in heavy cannabis users.” However, they continued, Despite well-established research findings, “… how cannabinoids affect<em> in vivo</em> neural dynamics associated with threat-related behavior has not been examined.”</p>
<p>For their newly reported study the scientists exposed mice to a threatening odor. Before being exposed to the scent, derived from fox urine, the mice either received a placebo or a synthetic cannabinoid drug. Patel and colleagues tested several doses of the synthetic cannabinoid on mice and tracked how much time they spent near the predator odor, and whether they froze or fled from the scent.</p>
<p>To simultaneously record brain activity, the team implanted a small microscope into the mice’s brain. The results showed that mice receiving the cannabinoid drug froze more often and spent less time investigating the predator odor. These anxious behaviors were linked to the drug’s activation of a small group of somatostatin neurons (SOM) in the brain’s central amygdala (CeA), a region that processes fear and stress.</p>
<p>Importantly, when the scientists genetically silenced the somatostatin neurons, mice given the cannabinoid drug did not avoid the predator scent as much. The researchers also conducted brain tissue experiments to analyze how the cannabinoids affected interactions between neurons. They found that the drug weakened the brain’s natural “brake” on the somatostatin neurons, allowing them to become more active. “Our data suggest suppression of GABA release from local afferents onto CeA SOM neurons underlies cannabinoid effects on CeA SOM neurons,” they wrote.</p>
<figure aria-describedby="caption-attachment-338768" class="wp-caption alignright"><img decoding="async" class="size-medium wp-image-338768" src="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_Dr.Patel_50-300x200.jpg" alt="Study authors Drs. Sachin Patel (left) and Farhana Yasmin looking at brain recordings from central amygdala neurons [Gr8y Productions]" width="300" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_Dr.Patel_50-300x200.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_Dr.Patel_50.jpg 700w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Study authors Sachin Patel (left) and Farhana Yasmin looking at brain recordings from central amygdala neurons. [Gr8y Productions]</figcaption></figure>
<p>“Higher doses of cannabinoids and environmental stress worked together to synergistically release the ‘brake’ on the central amygdala, which in turn drove excessive anxiety,” Patel noted. “Understanding how cannabis affects brain function to generate its psychoactive effects could ultimately reveal new ways to counteract negative consequences should they arise in some people,” Patel said, also noting that the findings could have implications beyond cannabis. “Suppressing the activity of somatostatin neurons in the central amygdala could represent a final pathway for reducing anxiety symptoms, not just in the context of cannabis side effects,” he explained.</p>
<p>Cannabis use in the U.S. has steadily increased in recent years and so have emergency department visits related to adverse effects from the drug. <a href="https://pubmed.ncbi.nlm.nih.gov/32909828/" target="_blank" rel="noopener">Previous studies</a> have also found an association between cannabis use and increased risk of anxiety in the long term. What’s more, anxiety and mood disorders are also on the rise globally.</p>
<p>Commenting that their newly reported data begin to shed light on neural mechanisms subserving the “dark-side” adverse effects of cannabinoids, the authors concluded, “… we suggest cannabinoids could trigger context-dependent adverse anxiety and panic reactions, in part, via activation of CeA-related circuits and that cannabis-induced long-term adaptations in these circuits could contribute to observed associations between cannabis use and anxiety disorders.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/neurons-involved-in-generating-anxiety-after-cannabinoid-drug-exposure-identified-in-mice/">Neurons Involved in Generating Anxiety After Cannabinoid Drug Exposure Identified in Mice</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Watching Cancer Proteins in Real Time, with Help from Rare Earth Elements</title>
<link>https://edusehat.com/en/watching-cancer-proteins-in-real-time-with-help-from-rare-earth-elements</link>
<guid>https://edusehat.com/en/watching-cancer-proteins-in-real-time-with-help-from-rare-earth-elements</guid>
<description><![CDATA[ A long-duration single-molecule imaging platform from the Broad Institute and MIT has revealed unexpected stability in homodimers of HER3, one of the most enigmatic members of the ErbB receptor family. 
The post Watching Cancer Proteins in Real Time, with Help from Rare Earth Elements appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/PengLab_04-small.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 03 Oct 2026 05:45:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Watching, Cancer, Proteins, Real, Time, with, Help, from, Rare, Earth, Elements</media:keywords>
<content:encoded><![CDATA[<p>A long-duration single-molecule imaging platform from the Broad Institute and MIT has revealed unexpected stability in homodimers of HER3, one of the most enigmatic members of the ErbB receptor family. The research, published in <em>Cell</em>, shows wild-type HER3 forms unexpectedly stable homodimers, and that cancer mutations destabilize these homodimers. The findings could hopefully help shape new cancer therapies. Their paper is entitled, “<a href="https://www.cell.com/cell/fulltext/S0092-8674%2826%2900399-5" target="_blank" rel="noopener">ErbB family receptor dimerization dynamics and dysregulation via long-term single-molecule imaging</a>.”</p>
<p>But the tool that delivered it matters just as much: an upconverting nanoparticle (UCNP) probe, doped with heavy rare earth elements, that simply doesn’t photobleach.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>In one corner of Sam Peng’s lab, the imaging rig looks almost improvised. Cameras, lenses, and lasers are bolted directly onto a metal breadboard, like an enormous sheet of Legos built by hand rather than bought off a shelf.</p>
<p>Peng’s team engineered UCNPs doped with ytterbium, erbium, and thulium to track EGFR, HER2, and HER3 at the single-molecule level on live cells simultaneously, in three colors. The new imaging platform holds 100-millisecond resolution and runs for over 16 minutes straight. Conventional dyes lose signal within seconds. These UCNP probes do not photobleach.</p>
<figure aria-describedby="caption-attachment-338779" class="wp-caption alignleft"><img fetchpriority="high" decoding="async" class=" wp-image-338779" src="https://www.genengnews.com/wp-content/uploads/2026/10/PengLab_01-small-300x169.jpg" alt="" width="382" height="215" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/PengLab_01-small-300x169.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/PengLab_01-small-1024x576.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/PengLab_01-small-768x432.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/PengLab_01-small.jpg 1400w" sizes="(max-width: 382px) 100vw, 382px"><figcaption class="wp-caption-text">Researchers in Sam Peng’s lab at the Broad Institute work on the lab’s custom-built imaging rig, where cameras, lenses, and lasers are mounted directly on a metal breadboard. [Broad Institute]</figcaption></figure>
<p>Peng compares short-duration imaging to eavesdropping on a conversation that gets cut short: “If you’re trying to understand a conversation between two people… if all of a sudden I just cut off this conversation, then you have to guess my answer based on our previous two-minute interaction, which is often impossible to do.”</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>The real advantage isn’t a fixed window. Peng said the probe can run for hours. His team stopped at 16 minutes because they’d already captured the long EGFR homodimers they were after.</p>
<h4><strong>HER3’s stable pairing</strong></h4>
<p>The surprising finding was the unexpected stability of HER3 homodimers and the effects of cancer-associated mutations on these pairings.</p>
<p>“The first time we saw HER3 homodimers, we were really puzzled,” Peng told <em>GEN</em>. “We thought that maybe this was some experimental artifact.”</p>
<p>HER3’s kinase domain is too weak to signal on its own, so the prevailing model treated it as a heterodimer partner—something that pairs with other receptors. This does not rule out its forming homodimers. Peng’s team expected HER3 to serve as a negative control for dimer detection. It should have come back empty.</p>
<p>The team reran the experiment with different labels and probes. The result held every time: wild-type HER3 homodimers proved remarkably stable, far outlasting unstimulated EGFR homodimers.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>The group’s working model is that these homodimers form a signaling-inactive pool. In this model, they sequester HER3, limiting its availability to pair with other receptors and trigger cancer signaling.</p>
<figure aria-describedby="caption-attachment-338780" class="wp-caption alignright"><img decoding="async" class=" wp-image-338780" src="https://www.genengnews.com/wp-content/uploads/2026/10/PengLab_05-small-300x169.jpg" alt="" width="350" height="197" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/PengLab_05-small-300x169.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/PengLab_05-small-1024x576.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/PengLab_05-small-768x432.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/PengLab_05-small.jpg 1400w" sizes="(max-width: 350px) 100vw, 350px"><figcaption class="wp-caption-text">A researcher points to bright spots on the imaging display. Each spot can mark a single probe, allowing individual receptors to be followed over time. [Broad Institute]</figcaption></figure>
<p>Cancer mutations support the model, but EGFR and HER3 moved in opposite directions. Mutations like the exon-19 deletion make EGFR homodimers more stable, driving signaling that tracks with clinical aggressiveness. The more stable the dimer, Peng said, the more signaling it triggers. The HER3 mutations studied do the opposite, destabilizing the homodimer, potentially freeing HER3 to form signaling-active heterodimers.</p>
<p>HER2 rounds out a third pattern. The HER2 mutations studied only modestly enhance the stability of its homodimers. That tracks with the clinic: HER2 cancers are typically driven by gene amplification.</p>
<h4><strong>Sourcing the materials </strong></h4>
<p>Ytterbium and erbium are heavy rare earth elements. Unlike light rare earth elements such as neodymium, mined at industrial scale for electric vehicle (EV) motors and consumer electronics, heavy rare earth elements are produced in far smaller volumes, for a narrow set of high-performance uses where few substitutes exist. Peng’s imaging platform is one of them.</p>
<p>The supply chain for these materials is highly concentrated. China dominates global rare-earth separation and refining, and its share of the heavy subset is larger still. According to Benchmark Mineral Intelligence, China controlled 85% of total rare earth oxide production in 2025, including an estimated 99% of dysprosium oxide and terbium oxide. That concentration has shown up in prices for those magnet metals: in 2025, dysprosium oxide in North America on average cost 4.4 times the Chinese price.</p>
<p>China introduced export controls on seven rare earth elements in April 2025: samarium, gadolinium, terbium, dysprosium, lutetium, scandium, and yttrium. An October 2025 expansion added ytterbium, erbium, holmium, thulium, and europium, including the elements used in Peng’s probes. That expansion is currently suspended under a U.S.–China trade truce.</p>
<p>At bench scale, Peng’s lab works in milligrams to grams, small enough that global supply pressure doesn’t immediately register. His lab buys rare earth salts in vials from a U.S. distributor. “They come in as a form of powder, like salt, just like your kitchen salt,” he said. Erbium salts arrive in pink. “Pretty beautiful,” he noted.</p>
<h4><strong>An expertise gap, not a supply gap</strong></h4>
<div class="my-8"><span data-render-ad="6"></span></div>
<p>Heavy rare earth elements aren’t especially scarce in the earth’s crust. They’re just rarely found in concentrations worth mining—and separating them is difficult. While Peng’s lab doesn’t track where the material was mined, it likely comes from China.</p>
<p>Peng’s lab buys these salts the way other labs buy antibodies. Rare earth elements are used in TR-FRET, some forms of NIR-II imaging, mass cytometry, and UCNP tracking, although these methods use different elements and probe chemistries.</p>
<p>As Xi Jinping was recently in Washington for his first state visit in more than a decade, U.S. officials said the two sides had agreed to extend their trade truce, and with it the pause on China’s expanded rare earth controls, from November to January.</p>
<p>Currently, the bottleneck is expertise, not supply. Peng estimates roughly a dozen groups worldwide work at this intersection of UCNP imaging and single-molecule biology. It’s a small overlap, since the work demands nanomaterial chemistry, molecular labeling, advanced optics, and computation, all in one lab. “It’s the integration of this entire pipeline that makes it challenging,” Peng said.</p>
<p>The research of nanoparticle optics has lasted for years. For now, the rare earth salts are the easy part. The optics, and the people who can build them, are what’s scarce.</p>
<p><strong>References</strong></p>
<p>1. Broad Institute. Single-molecule tracker illuminates workings of cancer-related proteins. Broad Institute of MIT and Harvard. Published May 1, 2026. Accessed September 24, 2026. <a href="https://www.broadinstitute.org/news/single-molecule-tracker-illuminates-workings-cancer-related-proteins" target="_blank" rel="noopener">https://www.broadinstitute.org/news/single-molecule-tracker-illuminates-workings-cancer-related-proteins</a></p>
<p>2. Shida JF, Ma K, Toll HW, et al. Multicolor long-term single-particle tracking using 10 nm upconverting nanoparticles. <em>Nano Lett</em>. 2024;24(14):4194-4201. doi:10.1021/acs.nanolett.4c00207</p>
<p>3. Peng Lab, Broad Institute of MIT and Harvard. Accessed September 24, 2026. <a href="https://www.sampenglab.org/publications" target="_blank" rel="noopener">https://www.sampenglab.org/publications</a></p>
<p>4. Ingall G, Mukherjee N. Ex-China rare earths premium to grow, especially for heavies. Benchmark Mineral Intelligence. Published March 24, 2026. Accessed September 24, 2026. <a href="https://source.benchmarkminerals.com/article/ex-china-rare-earths-premium-to-grow-especially-for-heavies" target="_blank" rel="noopener">https://source.benchmarkminerals.com/article/ex-china-rare-earths-premium-to-grow-especially-for-heavies</a></p>
<div class="my-8"><span data-render-ad="7"></span></div>
<p>5. Shalal A. US, China agree to extend trade truce by two months, work on bigger deal, Bessent says. <em>Reuters</em>. Published September 23, 2026. Accessed September 24, 2026. <a href="https://www.reuters.com/world/asia-pacific/us-treasurys-bessent-chinas-he-meet-unfinished-business-before-trump-xi-summit-2026-09-23/" target="_blank" rel="noopener">https://www.reuters.com/world/asia-pacific/us-treasurys-bessent-chinas-he-meet-unfinished-business-before-trump-xi-summit-2026-09-23/</a></p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/watching-cancer-proteins-in-real-time-with-help-from-rare-earth-elements/">Watching Cancer Proteins in Real Time, with Help from Rare Earth Elements</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Newfoundland and Labrador expands addiction treatment and detox capacity in Corner Brook</title>
<link>https://edusehat.com/en/newfoundland-and-labrador-expands-addiction-treatment-and-detox-capacity-in-corner-brook</link>
<guid>https://edusehat.com/en/newfoundland-and-labrador-expands-addiction-treatment-and-detox-capacity-in-corner-brook</guid>
<description><![CDATA[ An $8.25-million expansion of the Humberwood Treatment Centre will add short-stay detox services and increase inpatient addiction-treatment capacity in western Newfoundland. Newfoundland and Labrador is expanding addiction treatment and recovery services in Corner Brook, with plans to introduce community-based detox beds and increase inpatient capacity at the Humberwood Treatment Centre. The multi-year project represents an […]
The post Newfoundland and Labrador expands addiction treatment and detox capacity in Corner Brook appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/ChatGPT-Image-Oct-2-2026-10_08_42-AM.png" length="49398" type="image/jpeg"/>
<pubDate>Fri, 02 Oct 2026 22:30:12 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Newfoundland, and, Labrador, expands, addiction, treatment, and, detox, capacity, Corner, Brook</media:keywords>
<content:encoded><![CDATA[<p>An $8.25-million expansion of the Humberwood Treatment Centre will add short-stay detox services and increase inpatient addiction-treatment capacity in western Newfoundland.</p>
<p>Newfoundland and Labrador is expanding addiction treatment and recovery services in Corner Brook, with plans to introduce community-based detox beds and increase inpatient capacity at the Humberwood Treatment Centre.</p>
<p>The multi-year project represents an investment of $8.25 million, including $3.75 million allocated through Budget 2026. The expansion will be completed in two phases and is intended to provide faster access to withdrawal management and residential addiction treatment in western Newfoundland.</p>
<h3>New short-stay detox beds</h3>
<p>During the first phase, four dedicated short-stay beds will be established for people requiring community-based detox services.</p>
<p>The beds are intended to accommodate individuals requiring same-day or next-day admission, providing more timely access to withdrawal management and helping patients transition to inpatient treatment when clinically appropriate.</p>
<p>NL Health Services has engaged CORE Engineering to complete detailed design work for the first phase, which is expected to begin this fall. The company is also developing a preliminary scope of work for the second phase.</p>
<p>The addition of community-based detox services on Newfoundland’s west coast is part of the province’s effort to make addiction recovery services available closer to where patients live.</p>
<h3>Inpatient capacity to increase</h3>
<p>The second phase will add six inpatient beds to Humberwood.</p>
<p>The centre currently operates 12 inpatient beds and provides a 28-day treatment program for adults living with substance use disorders and addictions. Once the expansion is complete, Humberwood will have <strong>18 inpatient treatment beds in addition to the four community-based detox beds</strong>.</p>
<p>The expansion is also intended to improve continuity between different levels of addiction care. Patients who begin with withdrawal management could transition more smoothly to inpatient treatment and ultimately to community-based recovery supports.</p>
<p>According to NL Health Services’ most recent annual reporting, the province had already increased Humberwood’s capacity from 11 to 12 beds and introduced measures aimed at reducing treatment wait times. NL Health Services reported a 34 per cent reduction in provincial wait times for adult inpatient addiction treatment during 2024-25.</p>
<p>The new expansion aligns with recommendations from Newfoundland and Labrador’s All-Party Committee on Mental Health, Substance Use and Addictions to improve access to detoxification and inpatient treatment services. It is also identified as a priority under the province’s Alcohol Action Plan.</p>
<p><strong>Source: Government of Newfoundland and Labrador / Newfoundland and Labrador Health Services</strong></p>
<p><em>Original Government of Newfoundland and Labrador announcement</em></p>
<p>The post <a href="https://www.hospitalnews.com/newfoundland-and-labrador-expands-addiction-treatment-and-detox-capacity-in-corner-brook/">Newfoundland and Labrador expands addiction treatment and detox capacity in Corner Brook</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Calgary’s first cyclotron to expand access to advanced diagnostic imaging and cancer care</title>
<link>https://edusehat.com/en/calgarys-first-cyclotron-to-expand-access-to-advanced-diagnostic-imaging-and-cancer-care</link>
<guid>https://edusehat.com/en/calgarys-first-cyclotron-to-expand-access-to-advanced-diagnostic-imaging-and-cancer-care</guid>
<description><![CDATA[ A $71-million investment in Calgary’s new Radiopharmaceutical Centre will bring southern Alberta its first cyclotron, expanding access to specialized diagnostic imaging and supporting new cancer treatments. Southern Albertans are set to gain greater access to advanced diagnostic imaging and specialized treatments with the development of Calgary’s first cyclotron facility. The Calgary Radiopharmaceutical Centre is being […]
The post Calgary’s first cyclotron to expand access to advanced diagnostic imaging and cancer care appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/ChatGPT-Image-Oct-2-2026-09_36_33-AM.png" length="49398" type="image/jpeg"/>
<pubDate>Fri, 02 Oct 2026 22:30:12 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Calgary’s, first, cyclotron, expand, access, advanced, diagnostic, imaging, and, cancer, care</media:keywords>
<content:encoded><![CDATA[<p>A $71-million investment in Calgary’s new Radiopharmaceutical Centre will bring southern Alberta its first cyclotron, expanding access to specialized diagnostic imaging and supporting new cancer treatments.</p>
<p>Southern Albertans are set to gain greater access to advanced diagnostic imaging and specialized treatments with the development of Calgary’s first cyclotron facility.</p>
<p>The Calgary Radiopharmaceutical Centre is being built at the Foothills Medical Centre and will house Calgary’s first cyclotron and Alberta’s third. The facility is intended to strengthen the supply of radiopharmaceuticals used in diagnostic imaging and treatments for cancer, cardiac and neurological conditions.</p>
<p>The project is supported by a combined $71-million investment from the Alberta government and donors. The province is providing $64 million over three years toward completion of the centre, while the Alberta Cancer Foundation is contributing an additional $7 million for specialized equipment and research laboratories, with support from donors.</p>
<h3>Bringing production closer to patients</h3>
<p>Cyclotrons produce radioactive isotopes that can be incorporated into radiopharmaceuticals used for medical imaging and treatment.</p>
<p>At present, Alberta’s two existing cyclotrons are located in Edmonton – one at the University of Alberta’s South Campus and another at the Cross Cancer Institute. The new Calgary facility will add capacity and provide a more local source of radiopharmaceuticals for patients in southern Alberta.</p>
<p>Location is particularly important because some radioisotopes decay quickly after they are produced. Producing them in Calgary rather than transporting all supplies from Edmonton is expected to reduce transportation time and strengthen the reliability of supply for southern Alberta.</p>
<p>The Calgary cyclotron is expected to produce isotopes including fluorine-18, carbon-11 and gallium-68. These can be used in diagnostic imaging, including PET and SPECT scans, to support the diagnosis and treatment of cancer as well as cardiac and neurological conditions.</p>
<h3>Preparing for growing imaging demand</h3>
<p>The investment comes as Alberta anticipates significant growth in demand for advanced diagnostic imaging. Demand for PET scans is expected to more than triple by 2040, according to information released about the project. The new centre is expected to more than triple Alberta’s capacity to produce medicines for PET scans and almost double production capacity supporting SPECT imaging. <a href="https://medicinehatnews.com/news/local-news/2026/10/01/province-puts-71-million-toward-new-radiopharmaceutical-centre-in-calgary/?utm_source=chatgpt.com">Medicine Hat News</a></p>
<p>Beyond clinical care, the centre is also expected to support research and clinical trials and the development of new radiopharmaceuticals, potentially giving patients access to emerging diagnostic and treatment options.</p>
<p>Construction of the Calgary Radiopharmaceutical Centre is underway at the Foothills Medical Centre campus, near the Arthur J.E. Child Comprehensive Cancer Centre and University of Calgary Foothills Campus. <a href="https://www.alberta.ca/index.php/calgary-radiopharmaceutical-centre?utm_source=chatgpt.com">Alberta.ca</a></p>
<p>Once operational, the centre will provide another link in Alberta’s radiopharmaceutical supply network while expanding specialized imaging capacity for patients across southern Alberta.</p>
<p><em>Source: Government of Alberta / Alberta Health Services</em></p>
<p>The post <a href="https://www.hospitalnews.com/calgarys-first-cyclotron-to-expand-access-to-advanced-diagnostic-imaging-and-cancer-care/">Calgary’s first cyclotron to expand access to advanced diagnostic imaging and cancer care</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>When Do You Take USMLE Step 1? 2026 Exam Dates &amp;amp; Costs</title>
<link>https://edusehat.com/en/when-do-you-take-usmle-step-1-2026-exam-dates-costs</link>
<guid>https://edusehat.com/en/when-do-you-take-usmle-step-1-2026-exam-dates-costs</guid>
<description><![CDATA[ This blog was updated in October 2026 by Rebecca Lapides.   The USMLE Step 1 exam is an important early step in the career of any aspiring US-licensed doctor. In this blog post we will review some frequently asked questions about the exam. This includes USMLE Step 1 2026 exam dates and costs, the scope […]
The post When Do You Take USMLE Step 1? 2026 Exam Dates &amp; Costs appeared first on Elite Medical Prep. ]]></description>
<enclosure url="https://elitemedicalprep.com/wp-content/uploads/2023/04/USMLE-Step-1-2023-Exam-Dates-and-Costs.png" length="49398" type="image/jpeg"/>
<pubDate>Fri, 02 Oct 2026 19:15:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>When, You, Take, USMLE, Step, 2026, Exam, Dates, Costs</media:keywords>
<content:encoded><![CDATA[<p><em>This blog was updated in October 2026 by <a href="https://elitemedicalprep.com/tutors/rebecca-lapides/">Rebecca Lapides</a>.</em></p>
<p> </p>
<p><span>The USMLE Step 1 exam is an important early step in the career of any aspiring US-licensed doctor. In this blog post we will review some frequently asked questions about the exam. This includes USMLE Step 1 2026 exam dates and costs, the scope and length of the exam and more!</span></p>
<p></p>
    
    <div class="table-section">
      <div class="table-wrapper blurred">
        
<table>
<tbody>
<tr>
<th>Question</th>
<th>Answer</th>
</tr>
<tr>
<td>When should I take Step 1?</td>
<td>Most students take Step 1 after completing their pre-clinical years, typically at the end of the second year of medical school.</td>
</tr>
<tr>
<td>How much does the Step 1 exam cost?</td>
<td><span>The exam fee is around </span><b>$695</b><span> for U.S. students, with an additional </span><b>international surcharge (~$210)</b><span> for those testing outside the U.S.</span></td>
</tr>
<tr>
<td>Can I take Step 1 in January?</td>
<td><span>Yes, except during the first 2 weeks of January when the system undergoes annual maintenance. </span></td>
</tr>
<tr>
<td>How long is the Step 1 exam?</td>
<td><span>One day, 14 blocks of 30 minutes (20 questions each), total 280 items, with 55 minutes of break time</span></td>
</tr>
</tbody>
</table>
<p>      </p></div>

      <!-- CTA Box -->
      <div class="cta-box-overlay">
        <div class="ctm-inner-wrap-tbl">
        <h4>Want to see the full table?</h4>
        <p>Unlock the full information – enter your email below.</p>
        <div></div>
        
      </div>
  </div>
    </div>

    
    
    
<p> </p>
<h2><strong>What is the USMLE Step 1 Exam?</strong></h2>
<p><span>The </span><a href="https://elitemedicalprep.com/category/usmle-step-1/"><span>USMLE Step 1</span></a><span> exam is a standardized examination administered by the National Board of Medical Examiners (NBME). It assesses the medical knowledge, concepts, and principles of students who are in the process of completing their medical education and preparing to enter clinical practice.</span></p>
<p><span> </span></p>
<p><span>The USMLE Step 1 is the first in a series of three exams that are required for medical licensure in the United States. It covers a broad range of topics, including anatomy, physiology, </span><a href="https://elitemedicalprep.com/anki-biochem-deck-download/"><span>biochemistry</span></a><span> , pharmacology, microbiology, pathology, and behavioral sciences.</span></p>
<p><span> </span></p>
<p><span>The </span><a href="https://www.usmle.org/prepare-your-exam/step-1-materials/step-1-content-outline-and-specifications"><span>NBME website</span></a><span> provides comprehensive content outlines for the exam. This provides more information on what could be on the test. There you can see the proportional representation of topics on the exam by systems, disciplines, and testable physician competencies. The USMLE Step 1 exam is designed to evaluate the student’s ability to apply scientific principles to the practice of medicine. It also tests their knowledge of the diagnosis and management of common medical conditions.</span></p>
<p><span> </span></p>
<p><span>Medical students typically take the Step 1 exam at the end of their second year of medical school. Passing the exam is an important factor in successfully progressing through medical school and the </span><a href="https://elitemedicalprep.com/residency-advising/"><span>residency matching</span></a><span> process. </span></p>
<p><span> </span></p>
<p><span>For more information on the effects that the pass/fail system is having on medical students, </span><a href="https://elitemedicalprep.com/observations-and-trends-after-the-switch-to-usmle-step-1-pass-fail-what-learning-specialists-are-saying/"><span>see what the experts are saying</span></a><span>.</span></p>
<p><span> </span></p>
<h2><strong>When Do Students Take Step 1?</strong></h2>
<p><span>Usually, students take Step 1 in between their second and third years of medical school because there is often built-in study time, known as the dedicated study period, that schools allow for prior to the start of clerkship rotations. However, unless schools have their own rules/expectations for when students have Step 1 done, there is no requirement to take Step 1 at this time and there is even no requirement to take the USMLE Step 1 before Step 2. However, for students still in medical school, we recommend taking the USMLE Step 1 first. </span></p>
<p><span> </span></p>
<p><span>Step 1 does not have fixed test dates. You register for the exam through the NBME website, procure a registration permit to select a 3-month eligibility window, and then book your exam appointment at a Prometric test center. You may schedule your Step 1 exam anytime within your assigned eligibility window. Available exam dates for USMLE Step 1 depend on each testing center’s availability. </span></p>
<p> </p>
<h2><strong>When Should You Schedule Your Step 1 Eligibility Window?</strong></h2>
<p><span>The USMLE Step 1 eligibility window is one of the first logistical steps medical students encounter in the Step 1 preparation process. This three-month block determines when you are permitted to sit for the exam at a Prometric location. Once you complete registration and receive your scheduling permit, you gain access to Prometric’s system, where you can select a specific date and time that works within your chosen eligibility period. Understanding how this window works – and planning around it – is critical for a successful experience.</span></p>
<p><span> </span></p>
<p><span>For many students, the question of when to take Step 1 is not just about the logistics of scheduling but also about the logic of predicting your readiness.  The answer depends heavily on your academic progress and personal readiness. Most students target the end of the second year of medical school, once their core pre-clinical curriculum is complete. At this point, the foundational sciences are still fresh, and students often have a built-in study block to prepare exclusively for the exam. My recommendation is that you think about these factors, select an exam date and secure it, and then focus on creating a </span><a href="https://elitemedicalprep.com/free-6-week-usmle-step-1-study-schedule/"><span>study schedule</span></a><span> around this date to have you prepared in time. </span></p>
<p><span> </span></p>
<p><span>Strategically choosing your window requires looking beyond academics alone. School calendars, family obligations, and even health should factor into your decision. It’s wise to allow room for unexpected challenges such as illness, burnout, or administrative delays in receiving your permit. Building flexibility into your plan makes a difference, particularly since some Prometric sites fill up fast. Limited availability at certain locations means last-minute scheduling can leave you stuck with inconvenient dates or long travel requirements. Plan ahead and consider that those hoping to test early may face higher competition for spring and summer dates, while later testers must balance preparation with the transition into clinical rotations. Adjusting your approach to match your academic goals is key.</span></p>
<p> </p>
<h3><strong>Step 1 Rescheduling & Cancellation Fees Explained</strong></h3>
<p><span>Once you’ve secured a date, life events may still require changes. Prometric applies a tiered structure for rescheduling and cancellations:</span></p>
<ul>
<li aria-level="1"><span>No fee if changed more than 30+ days before your appointment.</span></li>
<li aria-level="1"><span>A moderate fee if changed 5–29 days in advance.</span></li>
<li aria-level="1"><span>The highest fee if changed 4 days or fewer before your exam.</span></li>
</ul>
<p><span> </span></p>
<p><span>Students may reschedule within the same eligibility period but cannot move an appointment outside of that block unless they request an extension through NBME. Extensions usually involve additional charges and paperwork.</span></p>
<p><span> </span></p>
<p><span>In emergency situations – such as sudden illness or a family issue – students can submit documentation for review. Missing your exam entirely risks being marked as a “no-show,” which could forfeit fees under the test cancellation policy.</span></p>
<p><span> </span></p>
<h2><strong>What to wear for the USMLE?</strong></h2>
<p><span>We recommend you dress comfortably. You should wear comfortable clothes that are appropriate for a prolonged period of testing. Note that each testing center may have specific recommendations on attire. Call the testing center in advance and request answers to your questions around clothing. Note that wearing some clothing like hoodies might increase the time needed to enter and exit the testing room so plan accordingly.</span></p>
<p><span> </span></p>
<p><span>It is important to avoid wearing anything that may cause discomfort or distraction during the exam. You should also consider the weather and dress accordingly. For example, you may want to dress in layers in case the temperature of the exam room fluctuates. </span></p>
<p><span> </span></p>
<h3><strong>What to Bring (and Not Bring) to Your Step 1 Exam</strong></h3>
<p><span>Preparing for Step 1 doesn’t end with studying – it also involves knowing what you can and cannot bring to the exam. The rules are strict, and failing to follow them could jeopardize your ability to sit for the test.</span></p>
<p><span> </span></p>
<p><span>On test day, two items are absolutely mandatory: a valid government-issued photo ID that exactly matches the name on your registration, and your scheduling permit. These documents are checked carefully at the Prometric check-in desk. If the name on your ID doesn’t match the one used during USMLE Step 1 registration, you may be denied entry and forced to reschedule.</span></p>
<p><span> </span></p>
<p><span>Once checked in, all personal belongings must be stored in lockers provided at the test center. This includes phones, wallets, outerwear, snacks, and water bottles. During scheduled breaks, you may return to your locker to eat, drink, or take medications.</span></p>
<p><span> </span></p>
<p><span>Strict bans apply to prohibited items. Notes, books, calculators, electronic devices, and even accessories like smartwatches are not allowed inside the testing room. These restrictions exist to maintain the integrity of the exam and prevent distractions for both you and other students.</span></p>
<p><span> </span></p>
<p><span>To feel confident, review Prometric’s online tutorial and rules in advance so you know exactly what to bring to Prometric center locations.</span></p>
<p><span> </span></p>
<h2><strong>More USMLE Step 1 Help</strong></h2>
<p><span>If you’re navigating the challenges of the USMLE Step 1 exam, you’re not alone. Our subreddit, <a href="https://www.reddit.com/r/ask_a_USMLE_tutor/">r/ask_a_usmle_tutor</a>, is a community of experienced MD tutors and aspiring doctors discussing everything related to the USMLE. Whether you have questions about USMLE exam dates, study tips, a USMLE Step 1 cost breakdown to budget effectively, or need personalized advice, this is the place to be.</span></p>
<p><span> </span></p>
<p><a href="https://www.reddit.com/r/ask_a_usmle_tutor"><span>Join us now at r/ask_a_usmle_tutor</span></a><span> and connect with peers and experts who can help you on your journey towards USMLE success.</span></p>
<p><span> </span></p>
<p><span>For more resources, check out our </span><a href="https://elitemedicalprep.com/the-ultimate-10-week-step-1-study-schedule/"><span>10-week</span></a><span> or </span><a href="https://elitemedicalprep.com/free-6-week-usmle-step-1-study-schedule/"><span>6-week Step 1 study schedule</span></a><span> , our blog post on the </span><a href="https://elitemedicalprep.com/nbme-25-nbme-30-best-predictor-for-passing-step-1/"><span>best predictor for passing Step 1</span></a><span> , and more </span><a href="https://elitemedicalprep.com/category/usmle-step-1/"><span>Step 1 content</span></a><span>.</span></p>
<p><span> </span></p>
<p><span>If you are looking for more customized </span><a href="https://elitemedicalprep.com/category/usmle-step-1/"><span>USMLE Step 1</span></a><span> help, consider enlisting the help of a 1-on-1 Step 1 tutor. </span><a href="https://elitemedicalprep.com/contact/"><span>Schedule a complimentary consultation today</span></a><span> to hear more about what we can do to help you succeed!</span></p>
<p>The post <a href="https://elitemedicalprep.com/usmle-step-1-exam-dates-and-costs/">When Do You Take USMLE Step 1? 2026 Exam Dates & Costs</a> appeared first on <a href="https://elitemedicalprep.com/">Elite Medical Prep</a>.</p>]]> </content:encoded>
</item>

<item>
<title>A new contest pits competitors against each other in a race to biological youth</title>
<link>https://edusehat.com/en/a-new-contest-pits-competitors-against-each-other-in-a-race-to-biological-youth</link>
<guid>https://edusehat.com/en/a-new-contest-pits-competitors-against-each-other-in-a-race-to-biological-youth</guid>
<description><![CDATA[ This week, I officially signed up for an unusual competition. One that rewards competitors for getting younger. I recently turned 40, and I don’t need reminding that both time and my chronological age only tick forward. But this game is focused on competitors’ biological ages—figures that are meant to provide a better way to measure… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/09/healthy-habits.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 02 Oct 2026 19:00:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>new, contest, pits, competitors, against, each, other, race, biological, youth</media:keywords>
<content:encoded><![CDATA[<div data-chronoton-summary="<ul><br><li><strong>Biological age as a competition:</strong> A new six-month contest called pits around 500 participants against each other to reverse their biological age, using tools like epigenetic blood tests, brain scans, face-aging apps, and grip strength measurements.</li><br><li><strong>The science is promising but imperfect:</strong> Over 100 biological "aging clocks" exist, but experts caution they aren't yet reliable enough for individual use—nobody fully understands what each one actually measures.</li><br><li><strong>Data collection is a goal:</strong> Founder Christin Glorioso hopes the contest generates the world's most comprehensive aging-clock dataset, while also giving longevity companies a cheaper alternative to running formal clinical trials.</li><br><li><strong>The leaderboard is shaping up:</strong> One competitor's biological age clocks in nearly 29 years below their chronological age—while another 47-year-old received a biological age of 100 based on how slowly she rises from a chair</li></ul>" data-chronoton-post-id="1145610" data-chronoton-expand-collapse="1" data-chronoton-analytics-enabled="1"></div>


<p>This week, I officially signed up for an unusual competition. One that rewards competitors for getting <em>younger</em>.</p>



<p>I recently turned 40, and I don’t need reminding that both time and my chronological age only tick forward. But this game is focused on competitors’ <em>biological</em> ages—figures that are meant to provide a better way to measure the age-related health of our organs and bodies.</p>



<p>Over a six-month period, around 500 of us will try to reverse our biological age as measured in a bunch of different ways. There’s even a leaderboard! The winners will include the person who shows the greatest difference between their chronological and biological age, as well as the person who manages to reverse their biological age the most.</p>





<p><strong>The competition is the brainchild of the neuroscientist and physician Christin Glorioso,</strong> who is also founder and CEO of NeuroAge Therapeutics. The company offers tools to track brain health and aging and is <a href="https://www.neuroagetx.com/our-science">running a trial</a> to find out if biological brain age can predict the onset of Alzheimer’s disease.</p>



<p>Glorioso says she has several goals for <a href="https://www.neuroagetx.com/events/younger">the Younger contest</a>. The first, she tells me, is to “explain to the world what <a href="https://www.technologyreview.com/2022/04/15/1050019/aging-clocks/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=10-01-26">aging clocks</a> are.” Regular Checkup readers will be familiar with these tools, but for the uninitiated, they are basically designed to measure biological age.</p>



<p>Many measure chemical signatures that form a layer on top of our DNA and seem to change with age. But others might involve looking at proteins or lipids in blood. Some are designed to measure functional health, while others predict when a person will die. There are more than a hundred clocks out there, and they probably each capture a specific aspect of the biological process of aging.</p>



<p>These clocks are proving <a href="https://www.technologyreview.com/2025/10/14/1124977/aging-clocks-biology-mortality-longevity/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=10-01-26">very useful for scientists</a>, who use them to study aging and development in humans and many other species. But using them to estimate the biological age of an individual person is more controversial. They’re just not good enough for that yet.</p>



<p><strong>Part of the problem is that we don’t really understand what each clock is capturing. </strong>Glorioso hopes that data collected through the Younger contest might help answer that question. She’s hoping to generate “the world’s most comprehensive clock dataset.”</p>



<p>Some <a href="https://www.technologyreview.com/2024/03/18/1089888/the-quest-to-legitimize-longevity-medicine/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=10-01-26">longevity clinics</a> try to get around the limits of biological age testing by using multiple clocks. That’s this competition’s approach too. As a standard competitor, I’ll be sending a blood spot sample to TruDiagnostic, a company that measures epigenetic chemical groups on DNA and offers to reveal an overall biological age as well as a person’s pace of aging and the biological ages of each of 11 organ systems, including the heart and brain.</p>





<p>I’ll get a brain age score from NeuroAge once I complete the cognitive tasks on offer. I’ll also submit some physical measures like grip strength. And I’ll upload a series of selfies to an app developed by a team at Harvard that promises to tell me my face age. That’s exactly what it sounds like—an estimate of how old my face looks.</p>



<p>I’m intrigued to see my scores, even though I know I shouldn’t put too much stock in them. The first time I took a test, four years ago, the company I used <a href="https://www.technologyreview.com/2022/11/18/1063466/i-found-out-biological-age/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=10-01-26">gave me a biological age</a> that matched my chronological age, which was a little disappointing and, if I’m honest, a bit underwhelming. A year later, the same company <a href="https://www.technologyreview.com/2022/11/18/1063466/i-found-out-biological-age/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=10-01-26">told me I had a young heart</a> but a relatively old brain, liver, and hormonal system. My lifestyle hasn’t changed much since then. Will the years have made much difference?</p>



<p>(Ultra competitors—who pay $4,499 rather than the $999 cost of regular entry—are also offered a range of other blood tests and clocks, as well as MRI and DEXA scans. I’ve got complimentary press access to the standard package.)</p>



<p><strong>Glorioso is also hoping to gather information about the effects of some purported longevity approaches. </strong>During the competition, some participants will be offered red-light masks, access to a sauna, or other low-risk offerings that partner companies who are sponsoring the event to varying degrees might want to collect data on. “A lot of these companies just can’t afford to run [clinical] trials,” says Glorioso.</p>



<p>She also sees the event as a public health initiative. A couple of years ago, David Sinclair, who studies aging at Harvard Medical School, and his colleagues estimated that if we could slow down aging in the general population and increase life expectancy by one year, it <a href="https://www.nature.com/articles/s43587-021-00080-0">would save the US economy $38 trillion</a>.</p>



<p>The event officially kicks off in January, but around 120 people have already signed up, says Glorioso. Ultimately, she expects 500 participants. Each person’s six-month run starts as soon as they take their baseline measurements, whenever that may be. A handful of people have already started. “I think the majority of people are going to want to sign up after the holidays,” says Glorioso. “They’re not going to want to be trying to win an aging contest over Christmas and Hanukkah.”</p>





<p>Glorioso took her own baseline measurements back in August. Those initial tests suggested that her biological age was around 10 years below her chronological age. That sounded pretty impressive to me until I looked at the leaderboard and saw that competitor @Fred had a biological age 28.8 years below his chronological age.</p>



<p><strong>The leaderboard is pretty sparse at the moment,</strong> as only seven people have logged their baseline measurements so far. Six of them have biological ages tracking low, but one 47-year-old has been given a biological age of 68.1. She’s competing publicly, so I can see the breakdown of her scores. The worst is for the speed at which she can stand from sitting in a chair—by that measure, she’s been given a biological age of 100.</p>



<p>Hillary Lin, a longevity-focused physician in New York, has just started logging her baseline measurements for the competition. She tells me she’s taken biological age tests in the past and that they’ve tended to give scores below her chronological age, which is currently 37. Last year, the TruDiagnostic test put her pace of aging at 0.75—suggesting she’s only doing nine months’ worth of aging in a typical year. “That’s supposed to be quite good,” she says.</p>



<p>If it had been up to her, Lin says, she would have incorporated more blood tests into the competition, to build a fuller picture of a person’s health. And she’s worried that a six-month period might not be long enough to see changes in biological measures of aging. Still, she’s excited, and is already making plans to improve her sleep, diet, and exercise.</p>



<p>But she already follows a high-protein, low-carb diet and works out at the gym every day. She also visits a sauna every few days (sauna use <a href="https://lifestylemedicine.stanford.edu/sauna-use-as-a-lifestyle-practice/">has been linked to improved heart health</a>). Glorioso’s efforts are impressive too. She tells me she’s started drinking a smoothie made from <a href="https://www.neuroagetx.com/blog/the-duckweed-smoothie-behind-the">a pond plant that has been linked to health improvements</a>, and that she’s cut added sugar and deep-fried foods from her diet. She’s also bought “a bunch of fancy Korean sunscreens” in an attempt to lower her face age.</p>



<p>I haven’t received my kit or logged my baseline measurements yet, and I’ll wait until then to start setting health goals. I don’t fancy my chances against these two competitors. But at the very least, I hope I can stand up faster than a 100-year-old.</p>



<p><em>This article first appeared in The Checkup, </em>MIT Technology Review’s<em> weekly biotech newsletter. To receive it in your inbox every Thursday, and read articles like this first, </em><a href="https://forms.technologyreview.com/newsletters/biotech-the-checkup/?_ga=2.241810882.15113993.1664981064-43237434.1647441349"><em>sign up here</em></a>.</p>]]> </content:encoded>
</item>

<item>
<title>Proteomics Maps Eye&#45;Infecting Acanthamoeba Mitochondria Across Oxygen Levels</title>
<link>https://edusehat.com/en/proteomics-maps-eye-infecting-acanthamoeba-mitochondria-across-oxygen-levels</link>
<guid>https://edusehat.com/en/proteomics-maps-eye-infecting-acanthamoeba-mitochondria-across-oxygen-levels</guid>
<description><![CDATA[ A new catalog of 1,122 mitochondrial proteins reveals how Acanthamoeba adapts to oxygen loss—and may highlight possible targets for treating sight-threatening infections.
The post Proteomics Maps Eye-Infecting Acanthamoeba Mitochondria Across Oxygen Levels appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GettyImages-932734998.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 02 Oct 2026 11:45:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Proteomics, Maps, Eye-Infecting, Acanthamoeba, Mitochondria, Across, Oxygen, Levels</media:keywords>
<content:encoded><![CDATA[<p>Starve <em>Acanthamoeba</em> of oxygen, and its mitochondria do not simply shut down. Instead, the organelles retool their energy-producing machinery, enabling the amoeba to generate hydrogen gas. <em>Acanthamoeba</em> is a free-living, single-celled organism found in water, soil, and air. Although it rarely causes disease, it can infect the cornea and cause sight-threatening keratitis—and its metabolic flexibility may help it persist there.</p>
<p>That adaptability is one of several defenses that make <em>Acanthamoeba</em> infections difficult to eliminate. The pathogen can also retreat into a drug-resistant cyst, and the treatments available once an infection is diagnosed are limited and may damage human cells. By mapping the organism’s mitochondrial proteins, researchers now have a new way to probe the machinery behind its survival and search for more selective therapeutic targets.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>“It’s a big challenge. The lack of readily available diagnostics is a problem, and then even after you finally get to the diagnosis, we don’t have good drugs,” said Jon Stefely, PhD, a metabolism investigator at the Morgridge Institute for Research and assistant professor of biomolecular chemistry at the University of Wisconsin School of Medicine and Public Health. “Our current drugs are untargeted and toxic, and we just need more options for treating these infections.”</p>
<p>To begin expanding those options, Stefely and his colleagues created a high-confidence inventory of the proteins operating inside <em>Acanthamoeba castellanii</em> mitochondria. The experimentally defined mitoproteome reveals the pathogen’s metabolic flexibility while highlighting potential therapeutic vulnerabilities. Their paper, “<a href="https://www.cell.com/cell/fulltext/S0092-8674(26)01067-6?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867426010676%3Fshowall%3Dtrue" target="_blank" rel="noopener">Mitochondrial proteome of <em>Acanthamoeba</em> delineates aerobic and anaerobic pathways dynamically regulated by oxygen</a>,” was published in <em>Cell</em> as part of the <a href="https://sites.broadinstitute.org/mitocarta" target="_blank" rel="noopener">MitoCarta Tree of Life Consortium</a>, along with their other paper published in <em>Cell Press Blue, “<a href="https://www.genengnews.com/topics/omics/proteomics-maps-eye-infecting-acanthamoeba-mitochondria-across-oxygen-levels/Acanthamoeba%20castellanii%20genome%20reannotation%20and%20multi-omic%20encystation%20profiling%20reveals%20cyst%20wall%20proteins%20and%20carbohydrate-active%20enzymes" target="_blank" rel="noopener">Acanthamoeba castellanii </a></em><a href="https://www.genengnews.com/topics/omics/proteomics-maps-eye-infecting-acanthamoeba-mitochondria-across-oxygen-levels/Acanthamoeba%20castellanii%20genome%20reannotation%20and%20multi-omic%20encystation%20profiling%20reveals%20cyst%20wall%20proteins%20and%20carbohydrate-active%20enzymes" target="_blank" rel="noopener">genome reannotation and multiomic encystation profiling reveals cyst wall proteins and carbohydrate-active enzymes</a>.” The consortium was conceived by Vamsi Mootha, MD, of the Broad Institute, Massachusetts General Hospital, Harvard Medical School, and Howard Hughes Medical Institute; Stefely completed the work as a postdoctoral researcher in Mootha’s laboratory.</p>
<p>In their <em>Cell </em>paper, the researchers first improved the organism’s nuclear genome annotation—important because most mitochondrial proteins are encoded in the nucleus—from about 52% accuracy to 98% using long-read RNA sequencing and other empirical methods. “If you imagine a page of words in a book, it would be like all the words were squished together and in a language that you don’t know,” said Stefely. “You would have to ask, ‘Where are the words? How do I separate one word from the next?’ It’s hard to tease apart.”</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>They then combined mitochondrial immunoprecipitation, density-gradient purification, microscopy, mass spectrometry, and protein-correlation profiling. Proteins that became enriched as mitochondrial samples grew purer were assigned to the organelle. Blue native PAGE–mass spectrometry for complexome profiling further resolved 20 macromolecular assemblies.</p>
<p>The resulting AcMitoCarta catalog contains 1,122 proteins, including 381 without readily identifiable counterparts in human or yeast mitochondria. Just over 300 were described as unique when compared with those organisms. Such divergence could matter for drug discovery: a compound directed at a microbe-specific protein or pathway may be less likely to damage human cells. “What’s been proven historically,” Stefely said, “is that if you have a target protein in a biochemical pathway that’s completely unique to the microbe, it’s a better target than something that has a homolog in humans.”</p>
<p>Proteomic and transcriptomic profiling also showed that oxygen extensively rewires the amoeba’s bioenergetic machinery. Under oxygen-rich conditions, its mitochondria use aerobic pathways; under anoxia, they induce a pyruvate:ferredoxin oxidoreductase-to-hydrogenase pathway. The researchers demonstrated that eye-infection-derived <em>Acanthamoeba</em> cells can produce hydrogen gas without oxygen through a mitochondria-localized, oxygen-sensitive hydrogenase. That metabolic switch may help the organism persist in changing niches, including the cornea.</p>
<p>AcMitoCarta now provides a framework for testing which of these unusual proteins are essential to amoebal survival, cyst formation, or oxygen adaptation. Stefely plans to investigate the candidates and pathways in focused groups, with collaborators contributing expertise in mass spectrometry, RNA sequencing, metabolism, structural biology, and imaging. “A long-term goal is to annotate functions for all of those targets,” he said, “but we’ll take them one small set at a time and there is a lot of potential for new discoveries.”</p>
<p>The catalog does not yet identify a ready-to-use drug, but it narrows the search to experimentally supported mitochondrial components and pathways that differ from those in people. By moving from an incomplete genome annotation to a functional map of oxygen-responsive mitochondrial biology, the work lays a foundation for more selective treatments against an infection whose toughest form can withstand today’s therapies.</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/proteomics-maps-eye-infecting-acanthamoeba-mitochondria-across-oxygen-levels/">Proteomics Maps Eye-Infecting <i>Acanthamoeba</i> Mitochondria Across Oxygen Levels</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>MD vs. DO Programs: Which Path to Medicine is Right for You?</title>
<link>https://edusehat.com/en/md-vs-do-programs-which-path-to-medicine-is-right-for-you</link>
<guid>https://edusehat.com/en/md-vs-do-programs-which-path-to-medicine-is-right-for-you</guid>
<description><![CDATA[ When starting your medical school application, you will find that there are multiple paths you can choose, namely, MD vs DO. Should you apply to an Allopathic or an Osteopathic medical school? What&#039;s the difference between them, and which path is right for you?
The post MD vs. DO Programs: Which Path to Medicine is Right for You? appeared first on Elite Medical Prep. ]]></description>
<enclosure url="https://elitemedicalprep.com/wp-content/uploads/2021/11/MD-vs.-DO-Programs-Which-Path-to-Medicine-is-Right-for-You-1-1024x576.png" length="49398" type="image/jpeg"/>
<pubDate>Fri, 02 Oct 2026 04:55:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>vs., Programs:, Which, Path, Medicine, Right, for, You</media:keywords>
<content:encoded><![CDATA[<h3>This blog was originally published in November 2021, and updated on March 7th, 2025 by <a href="https://elitemedicalprep.com/tutors/rebecca-lapides/">Rebecca Lapides, MD Candidate</a>.</h3>
<p> </p>
<p>When deciding to pursue a career in medicine, you’ll find that there are two main paths you can choose from: MD (allopathic) vs DO (osteopathic). Should you apply to an allopathic or an osteopathic medical school? What’s the difference between them, and which path is right for you?</p>
<p> </p>
<p>With each year, the medical school application process becomes more and more competitive. While one might think that this competition is driven by an increased applicant pool and a limited number of program spots, this is actually not the case. Surprisingly, the choices of medical schools and thereby <a href="https://www.aamc.org/news/medical-school-enrollment-reaches-new-high">the number of program spots has been increasing</a> right along with the competition. So how can this be?</p>
<p><span> </span></p>
<p>The competition largely has to do with medical schools wanting to accept the most promising candidates that will drive high test scores and residency acceptance rates – an effective way to build the prestige of the school. The increase in institutions, however, has to do primarily with the rise of osteopathic (DO) medical schools. What exactly is a DO medical school? We’re glad you asked.</p>
<p> </p>
<h2>The Practical Difference Between MD vs DO</h2>
<p>MD and DO degrees both lead to careers as licensed physicians in the U.S., and graduates of either path can diagnose and treat patients, prescribe medication, perform procedures, and pursue any medical specialty. The biggest differences show up earlier, during medical school. DO students receive additional training in osteopathic principles and osteopathic manipulative treatment (OMT), reflecting the profession’s traditional emphasis on the relationship between structure and function. Admissions profiles and application systems can also differ between MD and DO programs. Since 2020, however, graduates from both paths have entered the same ACGME-accredited residency system. Neither degree is inherently higher than the other, but differences in training, admissions, and residency competitiveness can influence which route makes more sense for an individual applicant.</p>
<p> </p>
<h2><strong>MD vs. DO: The Basics</strong></h2>
<p><span> </span></p>
<p>The history of how traditional allopathic (MD) medical schools and osteopathic (DO) medical schools developed is long and complex. However, suffice it to say that allopathic programs, which bestow an MD degree upon completion, deliver the traditional Western style of evidence-based medicine developed in Europe during the period of the scientific revolution. The name “allopathic medicine” was actually coined as a derogatory term by the practitioners of homeopathic medicine, which today is widely considered a pseudoscience. Allopathic medicine follows from the historical transition from the work of Galen and Vesalius to Osler and Halsted and into the modern-day.</p>
<p> </p>
<p>On the other hand, osteopathic medicine, which grants successful students the DO degree, derives from a tradition of muscle, bone (‘osteon’), and joint manipulation developed in the late 1800s by Dr. Andrew Still. The modern osteopathic school curriculum is nearly identical in content coverage to the modern allopathic school curriculum with the addition of the osteopathic manipulation curriculum that these programs teach.</p>
<p> </p>
<p>Although the above summary can be helpful in understanding where these two strains of medical education come from, there are many questions that medical applicants ask us when trying to choose between DO medical school and MD medical school. Below we answer some of these questions.</p>
<p><span> </span></p>
<h2>Are there curriculum differences between Osteopathic medical schools and Allopathic medical schools?</h2>
<p><span> </span></p>
<p>As mentioned above, the two forms of medicine originally came from different historical lines of thought about disease and medical treatment. Over time, the curricula have become increasingly similar to the degree that they are almost indistinguishable from each other, except for one area.</p>
<p> </p>
<p>In osteopathic medical schools, students spend 300-500 hours learning the theory and technique of osteopathic manipulation throughout their four-year degree. For many DO students, this manifests as an increased emphasis on anatomy, especially during the preclinical years. <a href="https://pubmed.ncbi.nlm.nih.gov/25175885/">Studies of osteopathic manipulation suggest an indeterminate clinical benefit in the treatment of issues such as back pain</a>. As such, there tends to be a reputation among DO schools that they emphasize a holistic, patient-centered approach to care, though many MD schools teach this approach as well.</p>
<p> </p>
<p>Now is maybe a good time to mention that osteopathic manipulation is not to be confused with the field of chiropractic manipulation. The two fields differ in training, scope, and licensure rather than technique alone. DOs are trained in a broad range of manipulative approaches — including high-velocity, low-amplitude thrust techniques that can produce an audible release — and are also trained in the contraindications and screening required before cervical manipulation, given documented risks such as vertebral artery dissection.</p>
<p><span> </span></p>
<p><span>The similarity of curricula between MD and DO medical schools is best reflected in the licensing exams that students take in order to obtain their medical license to practice and compete for residency positions. During medical school, MD students take the </span><a href="https://elitemedicalprep.com/usmle-step-1-tutoring/"><span>USMLE Step 1</span></a><span> and </span><a href="https://elitemedicalprep.com/usmle-step-2ck-tutoring/"><span>Step 2</span></a><span> exams, and the </span><a href="https://elitemedicalprep.com/usmle-step-3-tutoring/"><span>Step 3</span></a><span> exam during residency (usually at some point during their intern year). Likewise, DO students take the </span><a href="https://elitemedicalprep.com/comlex-level-1-tutoring/"><span>COMLEX Level 1</span></a><span> and </span><a href="https://elitemedicalprep.com/comlex-level-2ce-tutoring/"><span>Level 2</span></a><span> exams during medical school and </span><a href="https://elitemedicalprep.com/comlex-level-3-tutoring/"><span>Level 3</span></a><span> during residency. Many DO students also take one or more of the </span><a href="https://elitemedicalprep.com/truelearn-review-comlex-2-2/"><span>USMLE exams in addition to the COMLEX exams</span></a><span> because it can help with improving one’s competitiveness in </span><a href="https://elitemedicalprep.com/residency-advising/"><span>residency applications.</span></a><span> </span></p>
<p><span> </span></p>
<h2>Do DO medical schools have the same admission requirements as MD schools?</h2>
<p><span> </span></p>
<p>Yes. Essentially there are no differences in the process of applying to an osteopathic (DO) medical school versus an allopathic (MD) medical school. Largely, yes. The application process is structurally similar, though the systems differ and matriculant profiles are not identical. The <a href="https://elitemedicalprep.com/mcat-tutoring/">MCAT</a> is generally a major factor in admissions decisions and <a href="https://gradschool.uworld.com/mcat/">the higher your score</a>, the better your chances are of being accepted. Your undergraduate GPA, namely your science GPA, is also quite important.</p>
<p> </p>
<p>Most differences in admissions requirements are particular to the medical school, for example, supplementary applications essays that focus on geographic or career interest (e.g., primary care or rural medicine-oriented) factors. The principal difference between the applications is that MD medical school applicants must use the AMCAS application system (created by the AAMC) and DO medical school applicants must use the AACOMAS application system (created by the AACOM). Both applications evaluate an applicant’s undergraduate grades and coursework and both rely on the MCAT as a major factor in evaluating whom to invite for interviews and whom to offer admission. The only exception is that for students applying to an allopathic or osteopathic medical school in Texas, there is a separate application portal called the TMDSAS.</p>
<p> </p>
<p>Note: If you are starting to notice that there seems to be a parallel set of organizations for MD and DO medical schools, you are correct!</p>
<p><span> </span></p>
<h2><strong>Why are there so many new Osteopathic medical schools?</strong></h2>
<p><span> </span></p>
<p>The reason that more new DO schools are being established than new MD schools is that the requirements for starting a new medical school in the US are less stringent for DO programs. To open and run an MD medical school in the US, the administration must receive recognition and accreditation from the AAMC’s Liaison Committee on Medical Education (LCME). To open and run an MD medical school in the US, the administration must receive recognition and accreditation from the Liaison Committee on Medical Education (LCME), which is jointly sponsored by the AAMC and the American Medical Association. Similarly, a DO medical school must receive accreditation from the American Osteopathic Association Commission on Osteopathic College Accreditation (COCA). The details of this accreditation process are complex and opaque.</p>
<p> </p>
<p>One major difference between these two accreditation processes is that the LCME traditionally required (and still prefers) that an MD medical school be a non-profit institution, whereas the COCA does not impose this requirement. Therefore, <a href="https://tcf.org/content/commentary/for-profit-medical-schools-once-banished-are-sneaking-back-onto-public-university-campuses/?agreed=1">many osteopathic medical schools are for-profit</a> and may be owned by individual investors or be a part of a larger corporate education system or media companies. However, this is not to say that all MD schools are non-profit. In particular, the numerous medical schools in the various Caribbean island countries are almost all for-profit, though they are allopathic medical schools.</p>
<p> </p>
<p>Personal communication with several medical school founding deans also noted that MD schools are required to have a much higher level of institutional research funding, many times far greater than that required at a DO school. Thus, most of the MD schools in the US are affiliated with large state or private universities with heavy funding.</p>
<p><span> </span></p>
<h2><strong>DO vs. MD: Why would someone choose DO over MD or MD over DO? </strong></h2>
<p><span> </span></p>
<p>When choosing between pursuing an MD degree or a DO degree, applicants must consider several different factors. Below are some common considerations.</p>
<p> </p>
<p><strong>MCAT Scores and Undergraduate GPA –</strong> The first factor often considered when choosing between applying to MD or DO medical schools is GPA and MCAT scores. According to data from the <a href="https://www.aamc.org/media/6056/download">AAMC</a> and AACOM, osteopathic medical schools tend to accept applicants with lower GPAs and MCAT scores compared to their allopathic medical school counterparts. On average, those matriculating into a DO program in 2023 had a mean GPA and MCAT score of 3.53 and 503.6 respectively while those matriculating into an MD program had a mean GPA and MCAT score of 3.71 and 511.7. It is important to evaluate your own scores and academic performance to consider which type of program you may be the most competitive for.</p>
<p> </p>
<p><strong>Cost of Medical School Attendance –</strong> Perhaps surprisingly, the average cost to attend an allopathic medical school or an osteopathic medical school is very similar. According to the 2024-2025 AAMC <a href="https://www.aamc.org/data-reports/reporting-tools/report/tuition-and-student-fees-reports">Tuition and Fees Report</a>, it costs an average of $54,323/year to go to an MD school while according to the 2023-2024 AACOM <a href="https://www.aacom.org/docs/default-source/research-reports/2023-24-coa_pdf.pdf?sfvrsn=a6e7e781_7">Report on Tuition, Fees, and Financial Aid</a>, it costs an average of $55,130/year to go to a DO school. It is very important to note, however, that these averages include both in-state and out-of-state tuition as well as both private and public institutions. This means the averages can easily be +/- $10,000 (or much more!) for a given student at a given medical school. We highly suggest looking at both of the tuition summaries linked above to find more information about the cost of attending both MD and DO medical schools.</p>
<p> </p>
<p><strong>Average Salary –</strong> While DO vs. MD status does not directly impact earning potential in the way an MS vs. MBA degree could for a business person, MDs on average earn slightly more than DOs because of their increased tendency to pursue and be matched into highly competitive (and highly paid) medical specialties. According to <a href="https://www.indeed.com/career-advice/pay-salary/do-vs-md-wages">Indeed Jobs</a>, DOs in the United States earn an average of $163,908 per year while MDs earn an average of $201,918. Salary isn’t typically the deciding factor for choosing MD or DO, but for many students, it is worth noting.</p>
<p> </p>
<p><strong>Residency Program Acceptance Rates –</strong> While this may seem like a faraway consideration when only just applying to medical school, according to the 2020 NRMP <a href="https://public.tableau.com/app/profile/national.resident.matching.program/viz/PDSurvey2020-Final/Desktoptablet">Program Director Survey</a>, DO residency applicants are at an overall disadvantage for program matching. While certain specialties are more friendly to DO applicants, only 64% of all surveyed program directors reported that they often interview senior DO applicants, compared with 94% for MD seniors.</p>
<p><span> </span></p>
<p><img fetchpriority="high" decoding="async" class="wp-image-16565 aligncenter" src="https://elitemedicalprep.com/wp-content/uploads/2021/11/MD-vs-DO-Applicant-types-interviewed-and-ranked-300x124.png" alt="" width="898" height="371" srcset="https://elitemedicalprep.com/wp-content/uploads/2021/11/MD-vs-DO-Applicant-types-interviewed-and-ranked-300x124.png 300w, https://elitemedicalprep.com/wp-content/uploads/2021/11/MD-vs-DO-Applicant-types-interviewed-and-ranked-1024x422.png 1024w, https://elitemedicalprep.com/wp-content/uploads/2021/11/MD-vs-DO-Applicant-types-interviewed-and-ranked-768x316.png 768w, https://elitemedicalprep.com/wp-content/uploads/2021/11/MD-vs-DO-Applicant-types-interviewed-and-ranked-272x112.png 272w, https://elitemedicalprep.com/wp-content/uploads/2021/11/MD-vs-DO-Applicant-types-interviewed-and-ranked.png 1376w" sizes="(max-width: 898px) 100vw, 898px"></p>
<p> </p>
<p> </p>
<h2><strong>DO vs. MD: So, which degree is better? </strong></h2>
<p><span> </span></p>
<p><span>All in all, which type of medical school is better for you to attend ultimately depends on YOU! In our experience, the deciding factor when considering DO vs. MD, and where to apply tends to be GPA and MCAT scores, while the deciding factor on where to actually attend tends to be cost, program offerings, and/or school prestige. </span></p>
<p><span> </span></p>
<p><span>For most students, we recommend starting with the </span><a href="https://elitemedicalprep.com/is-an-msar-subscription-worth-it/"><span>MSAR tool</span></a><span> to make a big list of medical schools where your GPA and MCAT score are on par with those of students who have been recently accepted. From there, cost-conscious students should look at the AAMC and/or AACOM tuition report spreadsheets to narrow down which schools are within their budget or offer in-state tuition and financial aid support. Finally, do your research about each school left on your list and see if you can talk to a current student about their experience there. In the end, it’s all about finding your dream program that you get really excited about no matter whether it’s a DO or MD school! </span></p>
<p><span> </span></p>
<p><span>We hope this post was helpful and wish everyone the best in their medical school applications!</span></p>
<p>The post <a href="https://elitemedicalprep.com/md-vs-do-programs-which-path-to-medicine-is-right-for-you/">MD vs. DO Programs: Which Path to Medicine is Right for You?</a> appeared first on <a href="https://elitemedicalprep.com/">Elite Medical Prep</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Talus Bio’s Structure&#45;Free AI Model Targets Unstructured Proteins in Their Native Cellular Context</title>
<link>https://edusehat.com/en/talus-bios-structure-free-ai-model-targets-unstructured-proteins-in-their-native-cellular-context</link>
<guid>https://edusehat.com/en/talus-bios-structure-free-ai-model-targets-unstructured-proteins-in-their-native-cellular-context</guid>
<description><![CDATA[ Intrinsically disordered proteins have resisted structure-based drug discovery because they lack a stable fold to model. Talus Bio&#039;s structure-free AI model sidesteps that limitation, targeting these proteins in their native environment instead of in isolation or from a predicted structure.
The post Talus Bio’s Structure-Free AI Model Targets Unstructured Proteins in Their Native Cellular Context appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GettyImages-1464739073-e1790880191557.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 02 Oct 2026 04:35:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Talus, Bio’s, Structure-Free, Model, Targets, Unstructured, Proteins, Their, Native, Cellular, Context</media:keywords>
<content:encoded><![CDATA[<p><span>Alex Federation, PhD, has been interested in undruggable targets since his days as a trainee in the laboratory of Jay Bradner, MD, then at Dana-Farber Cancer Institute now at Amgen. At the time, the lab was working on finding molecules that could bind to genomic targets, several of which made it into clinical use. This was also around the time that genome sequencing technologies were becoming more affordable and accessible to scientists. </span></p>
<p><span>“My big excitement when I was starting my independent career was trying to ask the question, ‘could these new technologies actually help us unlock these undruggable targets?’” he told </span><i><span>GEN</span></i><span> in an interview. “There is a lot of interest in this problem” of cracking challenging targets as well as in turning the findings into “something that has an impact in the real world and patients.”</span></p>
<p><span>Those early roots put him on the path that led to co-founding Talus Bioscience, a company that uses artificial intelligence (AI) to enable drug discovery for the disordered proteome, alongside Lindsay Pino, PhD, who also serves as the company’s chief technology officer and leads the development of the company’s screening platform.  In addition to being a co-founder, Federation is also the company’s CEO. He credits Pino with introducing him to proteomics as an effective approach for taking on the undruggable target problem.</span></p>
<p><figure aria-describedby="caption-attachment-338715" class="wp-caption alignleft"><img fetchpriority="high" decoding="async" class="size-medium wp-image-338715" src="https://www.genengnews.com/wp-content/uploads/2026/10/Talus-Founders-Standing-300x218.jpg" alt="An image showing Talus' co-founders, Lindsay Pino, PhD, and Alex Federation, PhD." width="300" height="218" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Talus-Founders-Standing-300x218.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Talus-Founders-Standing-768x559.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/Talus-Founders-Standing.jpg 900w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Talus Bio’s two co-founders, Lindsay Pino, PhD, and Alex Federation, PhD [Talus Bio]</figcaption></figure><span>The two founders met in Seattle about 10 years ago and have collaborated on multiple projects in the intervening decade including the technology that now underpins Talus’ platform. The technology measures proteins in their native environment inside cells. To date, the company has generated at least five years of proprietary data that serves as the foundation of the AI models that the company has developed and uses to make predictions. </span></p>
<p><span>This week, Talus released Ptarmigan-1, a solution powered by the company’s MARMOT platform, which it describes as a first-of-its-kind structure-free AI model that accurately predicts small molecule binding sites across the entire human proteome, including proteins that are too unstructured for traditional 3D modeling tools to resolve. MARMOT stands for Measuring Modulation of Transcription and is the underlying experimental assay that captures snapshots of proteins in their cellular environment without removing or tagging them.</span></p>
<p><span>On a separate note, the company’s name and the names of its products are somewhat whimsical as they are drawn from Seattle’s mountains and wildlife. But there is a link to the core challenge that company is taking on. Talus refers to a precarious boulder field requiring careful navigation which is a metaphor for navigating disordered proteins. Marmots and ptarmigans are wildlife that are native to the mountains—a possible reference to Talus’ way of measuring proteins in their native state. </span></p>
<p><span>Talus’ approach focuses on the approximately 40 percent of human proteins in cells that lack stable, defined 3D structures and cannot be studied or targeted using conventional structural biology methods. Outside cells, they fall apart, making them difficult to purify or analyze using standard experimental workflows, Federation noted. Even advanced AI tools like AlphaFold render these proteins as uninterpretable structures. </span></p>
<p><span>“Our platform is essentially a unique way to actually watch what these proteins are doing in the cell in their native state without having to take them out of the cell and letting them fold and function within that native environment where all their partners are,” he explained. “That gives us really for the first time the ability to see them in their native state and find molecules that can interact with these proteins in their native state.” </span></p>
<p><span>Importantly, the company’s technology is label free since adding tags to these proteins changes their dynamics. In a sense, it’s “like we’re taking a cell and taking snapshots of where the proteins are at any given time and what molecules are sticking to those proteins at any given time,” he said. “And we use these new label-free proteomics methods as our camera to take those snapshots. That’s the fundamental measurement that we’re taking.”</span></p>
<p><span>The company has adopted a two-pronged business model. First, they have identified a small number of targets that they are developing molecules for internally. The most advanced molecule in their pipeline targets a rare bone cancer called chordoma. Specifically, they are targeting the brachyury protein, which is encoded by the <em>TBXT</em> gene. This particular protein is typically only expressed in embryonic stem cells; the cancer reactivates it. Simultaneously, the company is open to partnering with other companies to work on targets in a range of disease areas.</span></p>
<p></p><h4><b>Finding molecules for invisible protein pockets</b></h4>

<div class="my-8"><span data-render-ad="5"></span></div>
<p><span>Ptarmigan-1 is the first version of Talus’ flagship structure-free model, and also a first of its kind AI model, according to its developers. There have been some approaches that have tried to accomplish similar goals, “but this is the first one that will actually tell you if a compound binds and where on the protein it binds,” Federation said.  </span></p>
<p><span>For targeting transcription factors, which Talus is interested in, this is an important capability. Despite clear biological validation of the disease relevance of transcription factors in disease, going after them as potential drug targets has proven to be an intractable challenge. It is “the type of target where the biology is so clear,” he said. “[W]e need molecules that can control these, and this is really the first step to make that possible.”</span></p>
<p><span>Ptarmigan-1 differs from other AI drug discovery tools, which rely on fitting a molecule onto a defined protein pocket. By eliminating the structure requirement entirely, Ptarmigan is designed to target the approximately 40% of the proteome, including many disease-relevant transcription factors and regulatory proteins that are flexible and lack a 3D structure that could be targeted by therapeutics developers. With this release, “we want to get a first tool out there that can really broaden the landscape … beyond just those structure targets,” Federation said. “We are excited for people to be able to take that and apply it broadly to the proteins that they care about.”</span></p>
<p><span>Talus has shared some results from a proof-of-concept study where they used Ptarmigan-1 to evaluate a STAT6 inhibitor series, a validated target for inflammatory disease with a hard-to-model binding site. The results showed that the model outperformed structure-based methods in selecting successful drug candidates even though it had not seen the target or molecules during training. The model also identified small molecules that bound to the flexible pocket on STAT6. These candidates were validated in a third-party lab. </span></p>
<p><span>“The data we’re building at Talus is structure-agnostic, meaning we can measure proteins whether or not they hold a fixed shape,” Pino said. “That means the model can learn just as well from flexible or intrinsically disordered proteins as it does from structured ones, which is what lets it generalize to targets nobody’s had a way to study before.”</span></p>
<p><span>Details of the AI model are provided in </span><a href="https://www.biorxiv.org/content/10.64898/2026.07.28.741295v1" target="_blank" rel="noopener"><span>a preprint </span></a><span>that describes its architecture and the data that went into training it. Rather than forcing proteins into a 3D structural space, Ptarmigan embeds proteins and compounds in a shared high-dimensional mathematical space and then identifies candidate compounds by proximity in that multidimensional space. The model also has a speed advantage over other methods based on internal benchmarks from the company. They claim that since it skips the protein folding process, it runs 5,000 times faster than structure-based methods, and is capable of screening over three billion compounds against the human proteome in a day. </span></p>
<p><span>Ptarmigan-1 is currently free to scientists through a public portal. Users will be able to run a limited number of experiments for free using the platform. But for expanded usage or larger target-specific campaigns that are a heavier lift computationally, Talus is open to direct collaboration for example, partnering with a company that has validated targets and an existing assay but lacks viable molecules. </span></p>
<p><span>Collaborations will make it possible to do “some of these really massive searches that allow us to break into that really novel chemical space” and “search screens on the order of billions of compounds.” Also, “we hope someday when we have the next iterations of these [AI models] to be able to partner on those as well,” Federation said. Oncology is one the company’s primary interests, but the Talus team is also interested in targets in immunology, neurology, and cardiometabolic disease. </span></p>
<p><span>The company is committed to ensure scientists have continued access to the model by maintaining a free-access tier for our Ptarmigan models over the long term.</span> <span>As of today, Talus Bio has announced $28M in venture and non-dilutive funding. </span></p>
<p>The post <a href="https://www.genengnews.com/topics/artificial-intelligence/talus-bios-structure-free-ai-model-targets-unstructured-proteins-in-their-native-cellular-context/">Talus Bio’s Structure-Free AI Model Targets Unstructured Proteins in Their Native Cellular Context</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Mitochondrial Transporter Connects Body Clock and Diet to Fat Burning</title>
<link>https://edusehat.com/en/mitochondrial-transporter-connects-body-clock-and-diet-to-fat-burning</link>
<guid>https://edusehat.com/en/mitochondrial-transporter-connects-body-clock-and-diet-to-fat-burning</guid>
<description><![CDATA[ Researchers found that SLC25A34, a little-studied protein in the mitochondria of fat cells, acts as a switch that connects the body clock, temperature, and diet to how fat cells store and spend energy. 
The post Mitochondrial Transporter Connects Body Clock and Diet to Fat Burning appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/04/GettyImages-1407267429.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 02 Oct 2026 04:35:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Mitochondrial, Transporter, Connects, Body, Clock, and, Diet, Fat, Burning</media:keywords>
<content:encoded><![CDATA[<p>Researchers at the University of Copenhagen’s NNF Center for Basic Metabolic Research (CBMR) have found that SLC25A34, a little-studied protein in the mitochondria of fat cells, acts as a switch that connects the body clock, temperature, and diet to how fat cells store and spend energy. Headed by associate professor Zach Gerhart-Hines, PhD, the findings could point to new approaches to therapeutically boost energy expenditure in metabolic disease.</p>
<p>“We usually think of the body clock, the response to temperature, and the response to food as separate systems,” said Gerhart-Hines. “A mitochondrial transporter that is tuned by the time of day, the temperature, and what we eat raises the possibility of therapies that shift when and how the body burns fuel. That would be a different kind of lever from today’s obesity and diabetes treatments.” Gerhart-Hines is co-corresponding author of the researchers’ published paper in <em>Science</em>, titled “<a href="https://doi.org/10.1126/science.adz4797" target="_blank" rel="noopener">Mitochondrial carrier SLC25A34 links clock, diet, and temperature control of adipocyte lipid cycling</a>.”</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>“The circadian clock synchronizes physiological processes with environmental cues, integrating signals from sunlight, diet, physical activity, and temperature to optimize metabolic function across tissues,” the authors wrote. Brown adipose tissue (BAT) burns fuel to make heat, and this activity is controlled by the body clock, dropping during sleep and rising before waking. “In mice and humans, BAT metabolic activity begins to increase just before waking, peaks late in the waking period, and then declines to its lowest point during sleep,” the team noted.</p>
<p>However, a cold morning or a skipped meal makes demands the clock never planned for. How the body keeps to a fixed energetic timetable while still improvising has long been a puzzle. “How thermogenic fat can seamlessly achieve both rhythmic continuity and acute responsiveness is a fundamental question of energy homeostasis that has remained unknown,” they continued.</p>
<p>For their reported study to investigate this, the researchers started by searching large datasets for proteins in mouse brown fat that respond to both the clock and the cold. They identified UCP1, the best-known heat-producing protein, and SLC25A34, a related transporter with an as yet unknown job. In mice kept comfortably warm, brown fat contains less SLC25A34 than almost any other organ. But after 24 hours in the cold its levels rose 90-fold, making brown fat the tissue with the most SLC25A34 in the body.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>To work out how the <em>Slc25a34</em> gene is controlled, the team studied mice engineered to lack specific regulatory proteins. They found three separate controls, each answering to a different signal. A clock protein, REV-ERBα, keeps it switched off during sleep and releases it before waking. “During the sleep phase, the adipocyte clock suppresses Slc25a34 expression through the REV-transcriptional repressors,” the authors explained further. “When animals wake and REV-ERB circadian repression is lifted, the peroxisome proliferator–activated receptors α and γ (PPARα and PPARγ) αre able to bind the <em>Slc25a34</em> promoter and restore expression.” Cold also lifts the brake at any hour, overriding the schedule when extra heat is needed. And fat, from the tissue’s own stores or the diet, switches the <em>Slc25a34</em> gene on through another protein, PPARα. “… at any time, when animals are suddenly confronted with an unanticipated need for adipocyte energy expenditure such as exposure to cold temperatures or eating a lipid-rich meal, REV-ERB repression is rapidly overridden and PPARs are activated by lipolytic signals to boost SLC25A34 levels. When the energy demand is met, the REV-ERB–mediated rhythmicity of <em>Slc25a34</em> is reestablished.”</p>
<p>Seemingly paradoxically, both fasting, which promotes using fat, and insulin, the hormone that promotes building fat, increase SLC25A34 levels. This means that signals for burning and storing fat run through the same transporter. However, this is explained by the fact that active brown fat actually builds new fat molecules to then burn, a cycle that generates heat and clears fat and sugar from the blood. SLC25A34 appears to keep the cycle turning by carrying a molecule called oxaloacetate back into the mitochondria. “Our biochemical and metabolic data support a functional model in which SLC25A34 transports oxaloacetate into mitochondria,” the authors noted. Without the transporter, brown fat cells burned less fuel, and in mice the tissue’s fat-burning response was significantly weaker. The team has yet to show directly that the transporter carries oxaloacetate, or what losing it means for long-term health.</p>
<p>The researchers also found that silencing the transporter in brown fat cells from three of four human donors also reduced their fuel burning. Across 24 clinical studies, people with more SLC25A34 in the white fat beneath their skin tended to be leaner and metabolically healthier. This result is an association and does not prove cause, the team points out.</p>
<p>“Many of these mitochondrial transporters still have no known function,” said first author Iuliia Karavaeva, PhD. “This one turned out to be needed both for building fat and for burning it. And we are only scratching the surface: SLC25A34 is also highly expressed in the heart and is implicated in brain and liver metabolism, but what it does in those organs remains a mystery.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/mitochondrial-transporter-connects-body-clock-and-diet-to-fat-burning/">Mitochondrial Transporter Connects Body Clock and Diet to Fat Burning</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The Hardest Residency Specialties and What to Expect</title>
<link>https://edusehat.com/en/the-hardest-residency-specialties-and-what-to-expect</link>
<guid>https://edusehat.com/en/the-hardest-residency-specialties-and-what-to-expect</guid>
<description><![CDATA[ This blog was originally published in 2023 by Dr. Alina Khil and updated for accuracy in February 2025 by Dr. Coco Stewart.   The Hardest Medical Specialties to Match Into Choosing a medical specialty is a challenging task, especially when it comes to many of the more competitive specialties. Is it worth it? Am I […]
The post The Hardest Residency Specialties and What to Expect appeared first on Elite Medical Prep. ]]></description>
<enclosure url="https://elitemedicalprep.com/wp-content/uploads/2023/07/The-Most-Difficult-Residency-Specialties-to-Match-Into-Why-Theyre-so-Competitive.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 02 Oct 2026 01:20:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, Hardest, Residency, Specialties, and, What, Expect</media:keywords>
<content:encoded><![CDATA[<h3>This blog was originally published in 2023 by <a href="https://elitemedicalprep.com/tutors/alina-khil/">Dr. Alina Khil</a> and updated for accuracy in February 2025 by <a href="https://elitemedicalprep.com/tutors/coco-stewart/">Dr. Coco Stewart</a>.</h3>
<p> </p>
<h2>The Hardest Medical Specialties to Match Into</h2>
<p>Choosing a medical specialty is a challenging task, especially when it comes to many of the more competitive specialties. Is it worth it? Am I competitive enough? Would I even like the specialty? More competitive specialties stand out not only for their intense competition, but also for the rigorous demands the residency often places on aspiring doctors. With a limited number of residency positions available, some specialties have garnered a reputation for being highly competitive.</p>
<p>In this blog post, we will delve into the factors that make these specialties the most difficult to pursue, including the lifestyle sacrifices, the high level of compensation, and the unwavering passion required to succeed. Whether you’re contemplating your career path or simply curious about these challenging specialties, join us as we explore what makes them some of the most difficult residency specialties.</p>
<p>Don’t forget to check out some of our other <a href="https://elitemedicalprep.com/category/residency-matching/" target="_blank" rel="noopener">residency resources</a>, such as our <a href="https://elitemedicalprep.com/match-cycle-residency-application-timeline/" target="_blank" rel="noopener">residency application timeline</a>.</p>
<p> </p>
<p> </p>
<h2>What are some of the Hardest Residency Specialties to Match?</h2>
<p>First, a disclaimer: all medical fields are demanding, respected, and vital to patient care. Every residency is challenging in its own way, and <a href="https://elitemedicalprep.com/types-of-medical-specialties/">specialties not on this list</a> are no less valuable or rigorous.</p>
<p> </p>
<p>That said, some residencies consistently rank among the hardest to match because applicant demand far exceeds available positions. These include:</p>
<p> </p>
<ul>
<li>Cardiothoracic surgery</li>
<li>Vascular surgery</li>
<li>Dermatology</li>
<li>General surgery</li>
<li>Neurosurgery</li>
<li>Orthopedic surgery</li>
<li>Ophthalmology</li>
<li>Otolaryngology (ENT)</li>
<li>Plastic surgery</li>
<li>Urology</li>
<li>Radiation oncology</li>
<li>Interventional radiology</li>
</ul>
<p> </p>
<p>Each year, these specialties attract far more applicants than spots, making them among the most competitive choices in the match. The question is: what factors drive this intense interest and sustain their reputation for competitiveness?</p>
<h2>What “Hardest to Get Into” Really Means</h2>
<p>When people talk about the hardest medical specialties to get into, they usually mean the fields with the toughest residency matches. That is different from asking which careers are the most challenging during residency or in practice. Some areas of medicine draw intense interest because of their compensation, lifestyle, prestige, or the type of work they involve, which can make competition especially strong. Applicant demand and the number of available residency positions can also shift over time, changing how difficult a field is to enter from one Match cycle to the next. Understanding that distinction can help you evaluate competitive fields without assuming that the hardest ones to match into are also the most demanding careers.</p>
<h3>Why Do Match Rates Vary?</h3>
<p>The match rates for a variety of specialties seem to vary from year to year. For example, emergency medicine was previously a much more competitive specialty, but the number of applicants has declined over the years. In 2023, the emergency medicine fill rate fell by <a href="https://www.nrmp.org/wp-content/uploads/2023/05/2023-Main-Match-Results-and-Data-Book-FINAL.pdf" target="_blank" rel="noopener">10.9 percentage points</a>. Among Urology applicants in <a href="https://www.auanet.org/documents/education/specialty-match/2022-Urology-Residency-Match-Statistics.pdf" target="_blank" rel="noopener">2022</a>, 556 applicants applied to 365 spots in Urology, but in <a href="https://www.auanet.org/documents/education/specialty-match/2024/2024%20Urology%20Residency%20Match%20Statistics%20-%20Final.pdf" target="_blank" rel="noopener">2024</a>, only 500 applicants applied to 394 positions.</p>
<p> </p>
<p>This ebb and flow of applications is often unexpected, but at times a decrease in the competitiveness of a field will drive more applicants to that field. Below you will find a table that reflects the changes of applicants to some of the most competitive specialties over the past 5 years.</p>
<p> </p>
<p>Match Rate for U.S. MD Seniors Who Matched Their Preferred Specialty Over the Past Five years</p>
<p> </p>
<table>
<tbody>
<tr>
<td></td>
<td><a href="https://www.nrmp.org/wp-content/uploads/2021/08/Charting-Outcomes-in-the-Match-2020_MD-Senior_final.pdf"><span>2020</span></a></td>
<td><a href="https://www.nrmp.org/match-data/2022/07/charting-outcomes-in-the-match-senior-students-of-u-s-md-medical-schools/"><span>2022</span></a></td>
<td><a href="https://www.nrmp.org/match-data/2024/08/charting-outcomes-characteristics-of-u-s-md-seniors-who-matched-to-their-preferred-specialty-2024-main-residency-match/"><span>2024</span></a></td>
</tr>
<tr>
<td><span>Anesthesia</span></td>
<td><span>89.6%</span></td>
<td><span>89.5%</span></td>
<td><span>85.2%</span></td>
</tr>
<tr>
<td><span>Vascular Surgery</span></td>
<td><span>78.2%</span></td>
<td><span>75.8%</span></td>
<td><span>88.5%</span></td>
</tr>
<tr>
<td><span>Dermatology</span></td>
<td><span>84.7%</span></td>
<td><span>71.6%</span></td>
<td><span>70.5%</span></td>
</tr>
<tr>
<td><span>General Surgery</span></td>
<td><span>83.2%</span></td>
<td><span>81.6%</span></td>
<td><span>81.8%</span></td>
</tr>
<tr>
<td><span>Neurosurgery</span></td>
<td><span>75.2%</span></td>
<td><span>74.3%</span></td>
<td><span>68.7%</span></td>
</tr>
<tr>
<td><span>Orthopedic Surgery</span></td>
<td><span>79.7%</span></td>
<td><span>65.8%</span></td>
<td><span>73.1%</span></td>
</tr>
<tr>
<td><span>Otolaryngology</span></td>
<td><span>74.9%</span></td>
<td><span>69.2%</span></td>
<td><span>81.9%</span></td>
</tr>
<tr>
<td><span>Plastic Surgery</span></td>
<td><span>72.1%</span></td>
<td><span>62.7%</span></td>
<td><span>74.3%</span></td>
</tr>
<tr>
<td><span>IR</span></td>
<td><span>81.3%</span></td>
<td><span>81.4%</span></td>
<td><span>82.8%</span></td>
</tr>
</tbody>
</table>
<p> </p>
<p>Of note, we did not list match rates for US MD seniors who matched their preferred specialty for cardiac and thoracic surgery, ophthalmology, and urology, because the NRMP does not publish data for these specialties.</p>
<p> </p>
<h2>How Competitiveness Varies by Applicant Background</h2>
<p>Each spring, the National Resident Matching Program runs the main residency match, and competitiveness varies widely by specialty and applicant type.</p>
<p> </p>
<p>Headline match rates don’t tell the full story. MD seniors generally match at higher rates, while DO and IMG candidates often face more variability in interviews and offers. These trends align with what programs report in the annual program director survey about screening priorities and selection signals.</p>
<p> </p>
<p>To assess your chances, start with data. Compare your Step 2 CK score with historic specialty cutoffs, and review which fields are labeled most competitive or show the lowest match rates. Watch for overapplied residencies, where applicant volume exceeds positions and interview spots are scarce.</p>
<p> </p>
<p>These numbers don’t decide outcomes but guide your strategy: how carefully to build your list, when to request letters, and how sharply to frame your message to target programs.</p>
<p> </p>
<p>Scores open doors, but performance and professionalism keep them open. Programs value consistent service, strong ward performance, and trusted recommendations. The more your application signals “ready to contribute on day one,” the stronger you’ll stand in competitive cycles.</p>
<p> </p>
<h3>What Factors Contribute to the Competitiveness of the Most Difficult Residency Specialties?</h3>
<p>When medical students choose their specialties, they carefully consider various aspects that define their career path. Among these, lifestyle, compensation, and procedural work emerge as important considerations for aspiring residents.</p>
<p> </p>
<h3>Active Lifestyles and Work-Life Balance</h3>
<p>Some competitive specialties are attractive because they’re seen as offering a healthier work-life balance, often with fewer hours and more personal time. For applicants who value flexibility and outside interests, this combination of lifestyle and compensation can be a strong draw.</p>
<p> </p>
<p>Still, lifestyle in medicine is shaped less by specialty alone and more by individual choices. A physician once reminded me: regardless of field, our careers are defined by what we choose to do—or not do. For instance, while surgical training often demands 80-hour weeks and dermatology closer to 40–50, attendings ultimately decide how much they work. A radiologist could take on 80–90 hours, while a surgeon might set boundaries at 40–50 with more vacation time.</p>
<p> </p>
<p>Specialty influences workload, but long-term lifestyle depends on the career path you create.</p>
<p> </p>
<h3>Lucrative Financial Compensation</h3>
<p>Competitive specialties are also known for their high compensation rates. After investing significant time and financial resources into their medical education, students may seek specialties that provide appropriate financial rewards. Many aspiring doctors carry substantial loans, and a higher income from their chosen specialty eases the burden of repayment. Considering the sacrifices made to become a physician, it’s only natural to seek appropriate financial compensation.</p>
<p> </p>
<p>While many of these residency specialties share desirable factors, each field possesses distinctive characteristics that attract a high number of applicants. By understanding the driving forces behind the competitiveness of these specialties, we gain valuable insights into the choices made by aspiring medical professionals. Let’s explore these specialties one by one.</p>
<p> </p>
<h3>Procedural-Based Specialties</h3>
<p>Many of the specialties discussed are procedural based. Whether it is surgery, a surgical subspecialty, or simply a specialty that performs a lot of in-office procedures, many medical students are attracted to the more active procedural-based specialties.</p>
<p> </p>
<p>I know that my own interest in urology certainly enjoyed (and continues to enjoy) the variety of procedures we can offer our patients. I enjoy working with my hands, and I find it fulfilling to solve a problem using my brain and my body.</p>
<p> </p>
<h2>What Makes a Strong Applicant for Competitive Specialties</h2>
<p>Success in competitive specialties requires more than high scores; it’s about achievement paired with a clear, human story of why you belong.</p>
<p> </p>
<p>Start with the work itself: what patients you want to treat and problems you want to solve. That clarity shapes mentor choices, projects, and rotations where faculty can see you in action.</p>
<p> </p>
<p>Programs look for three things: reliability on the wards, strong specialty-specific letters, and a record of effort that fits their culture. Research expectations differ: dermatology often values publications, orthopedics rewards sustained lab collaboration, and ENT favors long-term involvement. Choose projects you can complete and defend.</p>
<p> </p>
<p>Your narrative should connect the dots: why this path, at this time, with this team. Essays and interviews should highlight judgment, teachability, and kindness under pressure, which are traits that signal maturity and readiness in any competitive residency.</p>
<p> </p>
<h2>Exploring the Most Difficult Residency Specialties to Match Into</h2>
<p> </p>
<h3><a href="https://elitemedicalprep.com/applying-into-anesthesia-acceptance-factors/" target="_blank" rel="noopener">Anesthesia</a></h3>
<p>In 2024, there were 1,695 positions offered with a total of 3,034 applicants.</p>
<p>Anesthesia as a specialty has become more and more popular over the past several years. For many, anesthesia is a fascinating field with an opportunity to deeply expand one’s understanding of physiology. Although many in anesthesia spend much of their time in the OR, others also work in the critical care unit or in pain management. Anesthesia offers significant financial compensation, but also offers the opportunity for shift work. The lifestyle in combination with the financial compensation has drawn many to the field of anesthesia over the past few years. (And many anesthesiologists are proud to have plenty of Sudoku time during the surgeries!)</p>
<p> </p>
<h3>Cardiac and <a href="https://elitemedicalprep.com/matching-into-thoracic-surgery-for-residency/" target="_blank" rel="noopener">Thoracic Surgery</a></h3>
<p>In the 2024 Match, integrated (I-6) thoracic surgery offered 48 positions to 114 applicants who ranked it first. Most cardiothoracic surgeons instead train through general surgery followed by a CT fellowship, which these figures do not capture.</p>
<p>Cardiac and thoracic surgery involves long and complicated cases, and many are rightfully impressed by holding a beating heart in your hand. By treating some of the sickest patients, this specialty allows a surgeon to save lives, often in a high-paced and intense environment. Though this is a demanding specialty in terms of work hours, it is one of the few specialties that offer such an adrenaline rush. Considering that a lot of medical students were driven to become doctors based on the desire to save lives, it is not surprising that this desire influences their choice of specialty. With more than twice as many applicants as positions, competition for these spots is steep.</p>
<p> </p>
<h3><a href="https://elitemedicalprep.com/matching-into-vascular-surgery-for-residency/" target="_blank" rel="noopener">Vascular Surgery</a></h3>
<p>In the 2024 Match, integrated vascular surgery offered 100 positions to 163 applicants who ranked it first — 1.6 per position.</p>
<p>For those medical students looking for diversity in their daily surgical work life, vascular surgery is an excellent choice. Vascular surgeons operate on every blood vessel in the body besides the heart and brain. So, as you can imagine, each day varies drastically. Procedures range from elective vein treatments to emergency aortic aneurysm rupture repairs. This specialty also provides the desired patient continuity, unlike most other surgical specialties. Often, vascular patients have many diseased blood vessels and require close follow-ups with their surgeon for many years. This allows a strong patient-physician relationship to form over many years.</p>
<p> </p>
<h3><a href="https://elitemedicalprep.com/what-you-need-to-match-into-dermatology-for-residency/" target="_blank" rel="noopener">Dermatology</a></h3>
<p>In the 2024 Match, dermatology offered 547 positions — 30 at PGY-1 and 517 at PGY-2.</p>
<p>Besides an excellent lifestyle and work-life balance, and high financial compensation, dermatology allows for both medical and procedural aspects. This is appealing for medical students who desire a mostly clinic-based practice while also being able to perform short, detail-oriented procedures. Most dermatologic conditions carry low morbidity and mortality, which contributes to a lower-stress clinical environment — though subspecialties like cutaneous oncology manage serious disease, including melanoma.</p>
<p> </p>
<h3>General Surgery</h3>
<p>In the 2024 Match, categorical general surgery offered 1,717 positions to 3,164 applicants who ranked it first — 1.8 per position.</p>
<p>General surgery has grown steadily more competitive, drawing 3,164 applicants for 1,717 categorical positions in 2024. Its appeal lies in the wide range of diseases and organs treated. A general surgery residency includes training in abdominal, hepatobiliary, breast, endocrine, colorectal, and minimally invasive surgery, with rotations that provide exposure to thoracic, vascular, cardiac, and transplant surgery. From complex exploratory procedures to quick laparoscopic cholecystectomies, cases vary greatly.</p>
<p>As a general surgeon, you receive training not only in surgery but also in medicine. Surgical services manage their patients comprehensively, including conditions like diabetes and hypertension during hospitalization. General surgery residents also gain experience in caring for critically ill patients. Although surgical residency is challenging, sub-specializations such as breast, endocrine, hepatobiliary, colorectal, and minimally invasive surgery offer a more balanced lifestyle. By specializing further, surgeons can pursue their passion without sacrificing all their time. Moreover, general surgery serves as a gateway to other specialties, such as plastic, vascular, and CT surgery. Integrated programs in these specialties are often more competitive to match into than general surgery, providing applicants with another route to their preferred specialty.</p>
<p> </p>
<h3>Neurosurgery</h3>
<p>In the 2024 Match, neurosurgery offered 241 positions to 423 applicants who ranked it first — 1.8 per position.</p>
<p>Neurosurgery is appealing to applicants who are fascinated with the human brain and nervous system and enjoy surgery. With 423 applicants for 241 positions in 2024, it remains one of the most difficult specialties to match into. Neurosurgeons tackle diverse cases, each presenting unique challenges. This demands strong problem-solving and critical thinking skills under pressure. Aspiring neurosurgeons care for critically ill patients in fast-paced, high-pressure settings. Despite the lengthy seven-year residency, neurosurgery offers some of the highest financial compensation among physician careers.</p>
<p> </p>
<h3><a href="https://elitemedicalprep.com/matching-into-orthopaedic-surgery-for-residency/" target="_blank" rel="noopener">Orthopedic Surgery</a></h3>
<p>In the 2024 Match, orthopedic surgery offered 916 positions to 1,492 applicants who ranked it first — 1.6 per position.</p>
<p>Orthopedic surgery requires a deep knowledge and appreciation of the musculoskeletal system. One of the best parts of this field is helping patients recover and getting to see them return to their active lifestyle. This is appealing to many applicants who live an active lifestyle themselves and those who love surgery and want to see their patients from the start to the finish line. This specialty also allows for working with a variety of patients of all ages and performing a variety of surgeries, ranging from the repair of traumatic fractures to elective knee replacements. There is also a lot of ongoing innovation in this field, allowing room for research and creativity.</p>
<p> </p>
<h3>Ophthalmology</h3>
<p>In 2024, 779 students applied to 520 positions. This data is not reported by NRMP, but rather is reported by AUPO as ophthalmology is considered “outside of the match.”</p>
<p>Ophthalmology, one of the most difficult residency specialties to match into, offers a remarkable work-life balance. It minimizes call duties, and weekends are usually free, even during residency. What sets ophthalmology apart is the instant gratification it provides. Patients experience immediate relief and swift recovery after surgeries. With shorter procedure durations, ophthalmologists can care for a large number of patients. Attention to detail is crucial in this specialty, given the delicate nature of the operative field. Medical students who choose ophthalmology enjoy this meticulous work.</p>
<p> </p>
<h3>Otolaryngology</h3>
<p>In the 2024 Match, otolaryngology offered 382 positions to 513 applicants who ranked it first — 1.3 per position.</p>
<p>Besides being another surgical specialty that offers a great lifestyle, otolaryngology is a great field for those who love head and neck anatomy. This specialty also allows for the use of a wide variety of operative techniques, including large open operations, endoscopic procedures, and surgeries using microscopes. Along with a wide variety of operative techniques comes a broad range of conditions that are treated by otolaryngologists. These include cancers of the head and neck, hearing loss, and diseases of the vocal cords. Often, otolaryngologists have the opportunity to develop long-term relationships with their patients.</p>
<p> </p>
<h3><a href="https://elitemedicalprep.com/acceptance-factors-for-matching-into-plastic-surgery-for-residency/" target="_blank" rel="noopener">Plastic Surgery</a></h3>
<p>In the 2024 Match, integrated plastic surgery offered 213 positions to 362 applicants who ranked it first — 1.7 per position.</p>
<p>For those who enjoy the technically demanding aspect of surgery but also want to employ their creativity at work, plastic surgery is the perfect field. Very few specialties in medicine and surgery offer the chance to be creative. Plastic surgeons operate on nearly every part of the body. A large field of plastic surgery is reconstructive surgery, which is very appealing to many students. There is a particular accomplishment that is derived from reconstructive surgery that is unlike that of regular procedures. Plastic surgery has the power to make a substantial impact on patients’ quality of life. Though it is possible to have a great lifestyle with plastic surgery, especially if doing private practice, this specialty can require long hours and calls.</p>
<p> </p>
<h3>Urology</h3>
<p>Urology, like ophthalmology, is considered “outside the match.” The AUA reports urology statistics. In 2024, 500 students applied to the 394 urology positions offered.</p>
<p>To be fair, as a urology resident myself, I might be a bit biased when it comes to urology. But urology is a delightful field with a unique balance of clinic, clinic-based procedures, endoscopic procedures, and major surgeries. They take care of any conditions that impact the urinary tract in both females and males. A lot of the conditions that urologists treat impact patients’ lives significantly and results can be obtained rapidly. Urology is among the top innovative fields, using lasers and robots in practice. Because urologists take care of patients’ most intimate problems, they often develop genuine patient-physician relationships and have the opportunity to offer a dramatic improvement in a patient’s quality of life.</p>
<p> </p>
<h3><a href="https://elitemedicalprep.com/acceptance-factors-for-matching-into-radiology-for-residency/" target="_blank" rel="noopener">Interventional Radiology</a></h3>
<p>In interventional radiology, applicants must match both a prelim spot and a PGY2 spot for IR. In 2024, <a href="https://www.nrmp.org/wp-content/uploads/2024/03/Advance-Data-Tables-2024.pdf">349 applicants</a> applied to 137 PGY2 integrated positions.</p>
<p>The unique aspect of interventional radiology is being able to perform valuable and sometimes life-saving procedures in the most minimally invasive way possible, usually through a tiny incision. IR integrates imaging and procedures and is perfect for those who love both. This specialty includes a broad spectrum of practice, ranging from biopsies to peripheral arterial disease intervention. Interventional radiologists could tailor their practice and specialize further, or practice a wide range of procedures.</p>
<p> </p>
<h4>When to Start Preparing for a Competitive Specialty</h4>
<p>For MD students, the right time to prepare is earlier than you think. The goal isn’t rushing a decision, but giving yourself space to explore and then commit with confidence.</p>
<ul>
<li><strong>M1–early M2:</strong> Shadow broadly, meet mentors, join one project you can finish, and keep a short log of meaningful cases. These later fuel essays and interviews.</li>
<li><strong>Late M2–early M3:</strong> If leaning toward a highly competitive field, ask mentors what “commitment” means in that specialty. Identify key rotations and sub-internships, and time letter requests so writers can cite recent examples.</li>
<li><strong>Core clerkships:</strong> Treat every service like an audition. Be reliable, prepared, and proactive. After each block, note a story that shows judgment or communication under pressure, as this is ideal interview material.</li>
<li><strong>Late M3–early M4:</strong> Build a tiered program list, check early-application deadlines, and draft ERAS entries early. Confirm transcripts, test reporting, and practice interviews for clarity and brevity.</li>
<li><strong>Application season:</strong> Keep outreach professional. After each interview, note what you contributed and learned. This makes rank decisions easier.</li>
</ul>
<p>Residency is demanding but temporary: the step toward a career you’ll love. Careful planning and clear messaging improve your odds; outside advising can help convert effort into interviews without extra stress.</p>
<p> </p>
<h2>Embrace the Challenge and Good Luck!</h2>
<p>Residency is tough! Make sure that you pursue a specialty that you are genuinely interested in and excited to learn about for 3, 5, or even 7 years. And certainly, don’t be discouraged from applying to competitive specialties if you’re interested in them. Seek mentors in your desired specialty during medical school to gain insights and strengthen your application. Look for research in these specialties, and be sure to shadow as much as possible. Shadowing can be a great way to get to know if a specialty is the right fit for you!</p>
<p>For additional assistance with your residency application, consider consulting an <a href="https://elitemedicalprep.com/residency-advising/">Elite Medical Prep residency advisor</a>. <a href="https://elitemedicalprep.com/get-started/">Schedule a complimentary consultation</a> to discover how we can support your success. Best of luck!</p>
<p> </p>
<p>The post <a href="https://elitemedicalprep.com/the-most-difficult-residency-specialties-to-match-into-why-theyre-so-competitive/">The Hardest Residency Specialties and What to Expect</a> appeared first on <a href="https://elitemedicalprep.com/">Elite Medical Prep</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Could an AI ‘digital twin’ help doctors choose the best treatment for ICU patients?</title>
<link>https://edusehat.com/en/could-an-ai-digital-twin-help-doctors-choose-the-best-treatment-for-icu-patients</link>
<guid>https://edusehat.com/en/could-an-ai-digital-twin-help-doctors-choose-the-best-treatment-for-icu-patients</guid>
<description><![CDATA[ Researchers in the United States are developing artificial intelligence-powered “digital twins” of critically ill patients that could eventually allow doctors to test potential treatments virtually before administering them to the patient. The University of Vermont is leading the ambitious project after receiving a research and development award worth up to US$38 million from the Advanced […]
The post Could an AI ‘digital twin’ help doctors choose the best treatment for ICU patients? appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/10/ChatGPT-Image-Oct-1-2026-12_35_38-PM.png" length="49398" type="image/jpeg"/>
<pubDate>Fri, 02 Oct 2026 00:55:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Could, ‘digital, twin’, help, doctors, choose, the, best, treatment, for, ICU, patients</media:keywords>
<content:encoded><![CDATA[<p>Researchers in the United States are developing artificial intelligence-powered “digital twins” of critically ill patients that could eventually allow doctors to test potential treatments virtually before administering them to the patient.</p>
<p>The University of Vermont is leading the ambitious project after receiving a research and development award worth up to US$38 million from the Advanced Research Projects Agency for Health (ARPA-H).</p>
<p>Known as ReSCUED — Reprogramming Severe Critical Illness Using Extensible Digital Twins — the project will focus on some of the most challenging patients treated in intensive care units, including people experiencing sepsis, severe trauma and burns.</p>
<p>The concept involves creating a continuously updated computational model — or digital twin — representing an individual patient’s immune and inflammatory response.</p>
<p>Researchers plan to collect blood samples from critically ill patients every six hours while also gathering physiological and clinical information. Those data will be fed into mathematical models designed to track how the patient’s condition is changing.</p>
<p>Artificial intelligence would then be used to analyze the enormous number of biological interactions occurring within the patient and explore how different treatment strategies could affect the course of the illness.</p>
<p>In effect, researchers hope clinicians will eventually be able to test potential interventions on the digital patient before deciding which approach may be most appropriate for the real patient.</p>
<h3>The initial focus is on immune dysfunction.</h3>
<p>In conditions such as sepsis, the body’s response to infection can become dangerously dysregulated, triggering widespread inflammation, tissue damage and organ failure. Modern intensive care can support failing organs with technologies such as ventilators and dialysis, but determining how to correct the underlying immune response remains extremely difficult.</p>
<p>The ReSCUED project aims to give clinicians a more detailed, individualized picture of that response.</p>
<h3>The technology is not yet ready for routine clinical use.</h3>
<p>During the first three years of the project, researchers plan to develop and validate the digital-twin technology and determine whether it can accurately predict patient outcomes. If those milestones are achieved, later phases would test the system further before progressing toward clinical trials involving critically ill patients.</p>
<p>Patient information for the project will be collected at three U.S. clinical sites, including Wake Forest University School of Medicine, the University of Alabama at Birmingham and Washington University School of Medicine.</p>
<p>The University of Vermont team will lead development of the computational models and digital-twin platform.</p>
<p>The project is part of ARPA-H’s broader Critical Illness Immunological Reprogramming and Control Point Learning Engine, or CIRCLE, program. The agency’s goal is to develop technologies capable of better measuring, modelling and ultimately controlling dangerous immune responses in critically ill patients.</p>
<p>One of the program’s ambitious targets is to reduce the length of ICU stays for critically ill patients by at least 25 per cent.</p>
<p>Whether digital twins can achieve that goal remains to be demonstrated. But if the technology proves successful, it could represent a significant shift toward highly personalized critical care — where treatment decisions are informed not only by a patient’s diagnosis, but by a continuously evolving computer model of that individual patient’s biology.</p>
<p><em>Source: University of Vermont; Advanced Research Projects Agency for Health (ARPA-H)</em></p>
<p>The post <a href="https://www.hospitalnews.com/could-an-ai-digital-twin-help-doctors-choose-the-best-treatment-for-icu-patients/">Could an AI ‘digital twin’ help doctors choose the best treatment for ICU patients?</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Member Spotlight: YIELD Hub</title>
<link>https://edusehat.com/en/member-spotlight-yield-hub</link>
<guid>https://edusehat.com/en/member-spotlight-yield-hub</guid>
<description><![CDATA[ What if the way we solve complex global health challenges is by learning together?  Today’s global health challenges are increasingly complex and intersectional, and they rarely have straightforward solutions. They […] ]]></description>
<enclosure url="https://globalhealth.org/wp-content/uploads/2026/09/IMG-20260908-WA0006-768x576.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 01 Oct 2026 22:15:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Member, Spotlight:, YIELD, Hub</media:keywords>
<content:encoded><![CDATA[<div aria-hidden="true" class="wp-block-spacer"></div>



<h2 class="wp-block-heading"><strong>What if the way we solve complex global health challenges is by learning together?</strong> </h2>



<p class="wp-block-paragraph">Today’s global health challenges are increasingly complex and intersectional, and they rarely have straightforward solutions. They involve multiple actors, shifting contexts, competing priorities, and systems that are constantly evolving. Yet, organizations are often expected to act quickly and with precise certainty: developing the right strategy, delivering the intervention, demonstrating impact, and moving on. At YIELD Hub, we have been putting a different approach into practice: Action Learning.  </p>



<p class="wp-block-paragraph">Action Learning is a structured peer-learning and capacity-strengthening approach that brings diverse organizations together to learn from one another, work through real challenges, and turn those insights into action. </p>



<p class="wp-block-paragraph">In the words of our Co-Director, Richard Dzikunu: </p>



<p class="has-blue-color has-text-color has-link-color wp-elements-2 wp-block-paragraph"><em>“Organizations that would ordinarily be deemed quite different from each other seem to be aligned in what they hope to achieve through the action learning process.”</em></p>



<p class="wp-block-paragraph">Rather than beginning with a predetermined solution, Action Learning starts with a real challenge participants are already facing and creates the space, builds the relationships, and provides the process to work through them collectively. </p>



<p class="wp-block-paragraph">Our Action Learning Cycles (ALCs) bring together diverse stakeholders, including youth-led organizations, INGOs, researchers and funders, to collectively explore and respond to shared challenges in adolescent and youth sexual and reproductive health and rights (AYSRHR). To date, we have facilitated 14 Action Learning Cycles, engaging more than 200 organizations across 40+ countries and 10 themes. These themes provide a space for members to validate key issues and messages at the intersection of AYSRHR and other issues, such as gender, climate change and sustainable financing.   </p>



<p class="wp-block-paragraph">The process is intentionally iterative. Participants share experiences, successes, and challenges across different organizational and geographical contexts. Through facilitated reflection, they question assumptions, identify what is—and is not—working to develop a clear problem statement and action plan. They then test and adapt these processes in practice, while insights are captured and shared as practical resources for the wider sector. </p>



<p class="wp-block-paragraph">After four years of applying Action Learning, one lesson stands out: systems change rarely begins with ready-made solutions. More often, it starts with creating conditions for people to ask better questions. </p>



<p class="wp-block-paragraph">We have learned that there is no single blueprint for navigating complex challenges. Organizations need space to experiment, reflect, and adapt as realities change. In this sense, learning is not something that happens after implementation; it is part of the action itself. This is particularly relevant in global health, where responding to climate change, reducing health inequities, advancing meaningful youth partnership, and securing sustainable financing are beyond the reach of any single organization or intervention. Action Learning creates a space where different perspectives come together, turn experience into collective knowledge, and translate that knowledge into practical change. </p>



<p class="wp-block-paragraph">Interested in exploring how Action Learning could support your organization, partnership or response to a global health challenge? Get in touch with YIELD Hub to learn more about our approach and explore opportunities to work and learn together. </p>]]> </content:encoded>
</item>

<item>
<title>An AI “mind&#45;reading” tool can reconstruct what you’re looking at from a brain scan</title>
<link>https://edusehat.com/en/an-ai-mind-reading-tool-can-reconstruct-what-youre-looking-at-from-a-brain-scan</link>
<guid>https://edusehat.com/en/an-ai-mind-reading-tool-can-reconstruct-what-youre-looking-at-from-a-brain-scan</guid>
<description><![CDATA[ A new AI tool can guess what you’re looking at just by analyzing your brain scans—and re-create that image with remarkable precision. It can go the other way, too, and predict a person’s brain activity based on what they’re looking at.  In the image above, for example, the left-hand image of each pair is what… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/09/brain-image-output.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 01 Oct 2026 21:30:02 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>“mind-reading”, tool, can, reconstruct, what, you’re, looking, from, brain, scan</media:keywords>
<content:encoded><![CDATA[<div data-chronoton-summary="<ul><br><li><strong>Mind-reading, but make it science:</strong> Researchers at the Weizmann Institute have built an AI tool that reconstructs images people are looking at—just from their brain scans—with striking accuracy.</li><br><li><strong>A smarter decoder:</strong> The tool uses two AI branches—one tracking image structure, one tracking content—and cleverly trains itself on images never shown to real people, meaning it needs just one hour of brain scan data per person instead of the usual 40.</li><br><li><strong>Big promise, bigger questions:</strong> Scientists are excited about potential uses—helping paralyzed people communicate, decoding dreams, studying PTSD—but warn that as the technology moves toward consumer EEG devices, the risk of extracting someone's thoughts without consent becomes uncomfortably real.</li><br></ul>" data-chronoton-post-id="1145588" data-chronoton-expand-collapse="1" data-chronoton-analytics-enabled="1"></div>


<p>A new AI tool can guess what you’re looking at just by analyzing your brain scans—and re-create that image with remarkable precision. It can go the other way, too, and predict a person’s brain activity based on what they’re looking at. </p>



<p>In the image above, for example, the left-hand image of each pair is what the user actually saw—and its right-hand counterpart is what the model reconstructed from the brain scan.  </p>



<p>Michal Irani, who developed the tool with her colleagues at the Weizmann Institute of Science in Rehovot, Israel, hopes her “mind-reading” tool will ultimately reveal more about how the brain works, and could perhaps be used to help locked-in people communicate, or allow scientists to re-create the content of dreams. </p>



<p>Judy Illes, a neuroethicist and professor of neurology at the University of British Columbia in Canada, who was not involved in the research, describes the work as “magnificent.” “The idea [of using this approach] to help people with neurologic conditions … therapeutically is tremendously exciting,” she says.</p>



<p>But other scientists warn that a similar approach could be used to reveal people’s inner thoughts and mental imagery, potentially without their consent. “The results seem very impressive,” says Tommy Sprague, a neuroscientist at the University of California, Santa Barbara. “But if there’s a way to surreptitiously extract information about what you’re thinking about, then …1 50 years of sci-fi can come true anytime, and that’s worrisome in a lot of ways.”</p>



<h2 class="wp-block-heading"><strong>Peeking into the brain</strong></h2>



<p>Neuroscientists have been working for years on ways to use functional magnetic resonance imaging (fMRI) to reconstruct what people see and what’s going on in their minds. The first attempts produced images that were blurry and hard to make sense of. Advances in technology—both in the fMRI scans themselves and in the tools used to make sense of the results—have led to improvements over the years.</p>



<p>Irani and her colleagues started by analyzing publicly available brain-scan data. Other researchers had already collected scans from volunteers who were shown hundreds of images while they lay in fMRI scanners.</p>





<p>fMRI uses a giant magnet to track the flow of oxygenated blood through the brain. Brain areas that “light up” on the scans are thought to be those that are particularly active at any given moment. The results are not especially specific—in typical fMRI scanners, each highlighted “voxel” of activity covers around three cubic millimeters,<a href="https://www.nature.com/articles/s41593-024-01688-2"> containing around 16,000 neurons</a>.</p>



<p>But Irani and her colleagues used newer datasets collected using scanners with a higher resolution—each voxel covered around one cubic millimeter of neurons, she says. Those datasets showed what the brain activity of volunteers looked like when they viewed various images.</p>



<p>Other teams have done this too, and<a href="https://arxiv.org/abs/2305.18274"> several</a><a href="https://arxiv.org/abs/2404.07850"> other</a><a href="https://arxiv.org/abs/2403.18211"> tools</a> have been used to re-create images from brain-scan data. But they’re not good enough, says Irani. Say a person saw a banana. These models can generate an image of a banana, but it would look different, she says. “It wouldn’t have the same structure, the same position.”</p>



<h3 class="wp-block-heading"><strong>A better decoder</strong></h3>



<p>The researchers  wanted to more closely re-create the images that had been seen. The first step was to train an AI model on<a href="https://www.nature.com/articles/s41593-021-00962-x"> already available data</a> from eight people who each had been shown around 9,000 images while in a high-resolution fMRI scanner.</p>



<p>Crucially, their “brain decoder” has two branches—one to predict the structure of an image (where the colors are, for instance) and a second to predict its content (for example, a bunch of bananas on a plate). The predictions allow a <a href="https://www.technologyreview.com/2025/09/12/1123562/how-do-ai-models-generate-videos/">diffusion model</a>, a type of AI best known for creating video and images by gradually cleaning up a noisy mess of pixels, to produce a much more accurate representation of what the person saw.</p>



<p>But to improve the models they needed more data—far more than was actually available.  </p>



<p>To get around this problem, Irani and her colleagues trained another model—an <em>encoder</em> that can predict brain activity from an image. The team then used the encoder and decoder together to improve both tools.</p>



<p>It works like this: Start with a new image of, say, a leopard. Then use the encoder to predict what someone’s fMRI brain scan would look like when the person saw that picture. The decoder is then used to reconstruct the image. At first, the reconstruction probably won’t look much like a leopard, says Irani. But repeatedly training the models this way eventually leads to dramatic improvements.</p>



<p>This approach also allows the team to train their models on as many images as they want, even images that have never been shown to a person in an fMRI scanner. Irani says that around 70% of the training data is from images that were not originally paired with fMRI scans.</p>



<p>By combining data from multiple studies, they were also able to identify brain regions that seem to share functions across all individuals. One region seemed to respond to images of food, for example, while another responded to images of sports. Irani, a computer scientist, says she is now working with neuroscientists “to see if we can actually use these tools that we’ve developed to really find out new things about the brain.”</p>



<p>The resulting “universal brain encoder” can work on a scan from a new person with minimal calibration. In other attempts, a tool has typically required about 40 hours of fMRI data on anyone new before it can be used to predict what that person is seeing. Irani’s decoder only needs one hour of data, she says. The finding was presented at <a href="https://2026.ccneuro.org/">the Cognitive Computational Neuroscience conference</a> in New York last month.</p>



<p>That could make it valuable for neuroscientists studying the brain, says Sprague. “None of us can afford 40 hours of imaging for a new subject,” he says. “It’s something like $600 to $1,000 an hour.” Tools like this one could speed up research, he says.</p>



<h3 class="wp-block-heading"><strong>State of the art</strong></h3>



<p>The encoder and decoder aren’t perfect. “Of course we have failures,” says Irani. Over a Zoom call, she pointed out an image of a cake that her tool reconstructed as a pile of three sandwiches, and another of a dog in a bathtub that was reconstructed as a similarly colored goat in a bathtub.</p>



<p>But they represent the state of the art. In a comparison test, the tool was found to be much better than previously described ones. “All in all, really we outperformed the others by a significant margin,” Irani says. “Mind reading” is a “cute, jazzy name” for what they’re doing, she adds.</p>



<p>Irani is now planning to move beyond images to video and audio. She wants to be able to reconstruct what people are thinking about or imagining, and the contents of their dreams. “That’s something we don’t have yet,” she says. “But we’re striving to achieve it.”</p>



<p>Such a tool might enable <a href="https://www.technologyreview.com/2022/03/22/1047664/locked-in-patient-bci-communicate-in-sentences/">people who are “locked in”</a> and completely paralyzed to communicate using their brain activity alone, she says. It could also help scientists unpick some enduring mysteries surrounding the inner workings of our minds, such as what PTSD flashbacks look like.</p>



<p>Advances like this inevitably raise questions about mental privacy. What if some bad actor could reconstruct someone’s thoughts or memories?</p>



<p>“If you’d asked me that 10 years ago, I’d have laughed a lot,” says Sprague. Getting a willing person to lie still in a scanner and actively engage with a research question is hard enough; imagine making someone do it involuntarily. But Irani and other scientists are working on similar approaches to decode brain activity from EEG—electrical brain activity measures collected via a cap of electrodes or <a href="https://www.wired.com/story/this-brain-tracking-device-wants-to-help-you-work-smarter/">even through headphones</a>. </p>



<p>And as models improve, it will become even easier to analyze the brain activity collected this way. “We have to be a little more serious about the ethical considerations,” says Sprague. He thinks Irani’s approach would probably “work quite well” in predicting images that a person is thinking about but not looking at.</p>



<p>The move to EEG would be a “game changer,” says Marcello Ienca, a neuroscientist and philosopher at the Technical University of Munich, Germany. Once an EEG device has been calibrated to a user’s own brain, it could be relatively easy for companies to extract additional information from that person’s brain—potentially without consent. Ienca can also imagine some courts allowing mental image reconstructions as legal evidence.</p>



<p>“I have no doubt that this is, you know, well-intentioned research, but I think it’s also pretty obvious that it could be co-opted for … ethically and societally problematic commercial uses,” he says.</p>



<p>Irani acknowledges the potential for misuse with the use of EEG. But she’s not concerned for now. “I’m trying to think only of good things,” she says.</p>]]> </content:encoded>
</item>

<item>
<title>Designing Peptide Screens to Generate Knowledge, Not Just Hits</title>
<link>https://edusehat.com/en/designing-peptide-screens-to-generate-knowledge-not-just-hits</link>
<guid>https://edusehat.com/en/designing-peptide-screens-to-generate-knowledge-not-just-hits</guid>
<description><![CDATA[ The strongest binder from a primary screen is not necessarily the best drug starting point. Peptide discovery campaigns should capture molecular architecture, biological context, time, and developability from the outset.
The post Designing Peptide Screens to Generate Knowledge, Not Just Hits appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2274968200.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 01 Oct 2026 07:05:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Designing, Peptide, Screens, Generate, Knowledge, Not, Just, Hits</media:keywords>
<content:encoded><![CDATA[<p>Peptide discovery is entering an era of abundance. Researchers can build larger libraries, incorporate noncanonical residues, constrain backbones in multiple ways, and use increasingly capable computational tools to propose or rank candidates. Yet many programs still organize discovery around a narrow objective: identify the strongest binder.</p>
<p>Affinity is important, but it is not a drug profile. A peptide must also be selective, soluble, synthetically tractable, sufficiently stable, and able to reach the relevant biological compartment. Depending on the program, it may need to cross a membrane, remain extracellular, internalize into a specific cell type, or sustain activity after transient exposure. A screen that reports only binding leaves these questions for later, when changing molecular direction is more expensive.</p>
<p>The next advance will not come from choosing experimental screening over computation, or computation over screening. It will come from designing experiments so that each round produces a more informative map of the chemical and biological landscape.</p>
<p></p><h4><strong>Library is already part of the hypothesis</strong></h4>

<p>A peptide library is never truly unbiased. Its length distribution, residue alphabet, cyclization chemistry, topology, display format, and synthesis method determine which molecules can be produced and which conformations can be explored. These choices also influence stability, solubility, permeability, and presentation of binding groups.</p>
<p>Peptide function is not encoded by sequence alone. Two molecules with similar residue composition can behave differently when one is linear and the other is cyclic, when stereochemistry changes, or when a backbone amide is modified. For constrained peptides, linkage position and ring topology can reorganize the conformational ensemble. A sequence-only analysis may therefore group together molecules that are chemically and pharmacologically distinct.</p>
<p>Recent work illustrates the opportunity. A 2026 <a href="https://www.nature.com/articles/s41589-026-02237-7" target="_blank" rel="noopener">study</a> screened 15,360 fully random, sub-kilodalton cyclic peptides and identified a starting point against the intracellular Keap1–Nrf2 protein–protein interaction. Iterative design, synthesis, and testing produced a membrane-permeable inhibitor active in living cells. The broader lesson is that binding and permeability can be treated as connected design problems rather than sequential hurdles.</p>
<figure aria-describedby="caption-attachment-338658" class="wp-caption aligncenter"><img fetchpriority="high" decoding="async" class="wp-image-338658 size-large" src="https://www.genengnews.com/wp-content/uploads/2026/09/GEN_Sethera_Fig1_White-1-1024x474.jpg" alt="Figure 1. Conventional funnel versus information-rich workflow. The revised workflow introduces architecture diversity, counterscreens, functional assays, and property measurements before lead selection. [Sethera Therapeutics]" width="1024" height="474" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/GEN_Sethera_Fig1_White-1-1024x474.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/09/GEN_Sethera_Fig1_White-1-300x139.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/GEN_Sethera_Fig1_White-1-768x355.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/09/GEN_Sethera_Fig1_White-1-1536x710.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2026/09/GEN_Sethera_Fig1_White-1-2048x947.jpg 2048w" sizes="(max-width: 1024px) 100vw, 1024px"><figcaption class="wp-caption-text"><em>Figure 1. Conventional funnel versus information-rich workflow. The revised workflow introduces architecture diversity, counterscreens, functional assays, and property measurements before lead selection. [Sethera Therapeutics]</em></figcaption></figure>
<p></p><h4><strong>Screen in biological space, not only against a target</strong></h4>

<p>Purified-protein screens remain useful, particularly when material is limited or throughput is essential. But the assay format can become an unintended selection pressure. Peptides may recognize a purification tag, a surface, an exposed hydrophobic patch, or a conformation poorly represented in the native setting. High apparent affinity can also reflect nonspecific interactions that disappear in another assay.</p>
<p>The solution is not to force every primary screen into a complex cellular system. It is to design a staged assay hierarchy before screening begins. Early counterselections can remove binders to tags, matrices, related proteins, or abundant off-targets. Competition experiments can test dependence on the intended epitope. Homolog counterscreens can reveal selectivity within a target family.</p>
<p>Orthogonal confirmation through kinetic binding, solution-phase competition, biochemical function, or cell-based activity can distinguish reproducible target engagement from assay-specific behavior.</p>
<p>For intracellular programs, permeability and functional activity should enter the workflow as soon as candidate numbers permit. For extracellular targets, serum stability, target turnover, tissue context, and the consequences of sustained versus transient engagement may matter more. The objective is not to measure every property immediately, but to ensure that the screening cascade reflects where the molecule must ultimately work.</p>
<p>Most screening readouts are snapshots. Biology is not. An endpoint measurement can obscure differences in association rate, dissociation rate, target rebinding, internalization, degradation, or intracellular retention. A peptide with modest equilibrium affinity but a slow off-rate may produce stronger functional activity than a tighter binder that dissociates rapidly. Conversely, prolonged engagement may be undesirable when an off-target interaction creates risk.</p>
<p>Time can be incorporated in practical ways. Selection pressure can be increased by extending wash periods or adding soluble competitor. Candidates can be tested after defined exposure to serum, proteases, reducing conditions, or relevant tissue fluids. Cellular assays can separate immediate pathway modulation from activity that persists after washout. Internalization and cytosolic access can be measured at multiple time points rather than inferred from one image.</p>
<p>Round-by-round enrichment also contains temporal information. A sequence that rises steadily may be more credible than one that appears abruptly after a bottleneck. Intermediate sequencing data can reveal early enrichment, late artifacts, and architecture families that respond differently as selection pressure changes.</p>
<p></p><h4><strong>Preserve the reasons molecules fail</strong></h4>

<p>The final hit list is often the least informative version of a screening dataset. It contains the winners but discards much of the evidence needed to understand why they won.</p>
<p>For peptide programs, “inactive” is not a single label. A candidate may fail because it was not produced efficiently, did not display correctly, was not cyclized or otherwise modified, aggregated, degraded, bound nonspecifically, failed to enter cells, or reached the target without changing function. These outcomes should not be collapsed into one negative class. A model trained on them would be asked to learn biology from a mixture of technical and pharmacological failures.</p>
<p>Useful datasets require provenance. Starting-library abundance, enrichment by round, control behavior, counterscreen results, synthesis yield, purity, modification efficiency, assay conditions, batch identity, and detection limits should travel with each sequence. Missing values also need interpretation. “Not detected” can mean below an assay threshold, absent from the starting population, lost during processing, or simply not tested.</p>
<div class="my-8"><span data-render-ad="6"></span></div>
<p><figure aria-describedby="caption-attachment-338660" class="wp-caption aligncenter"><img decoding="async" class="wp-image-338660 size-full" src="https://www.genengnews.com/wp-content/uploads/2026/09/GEN_Sethera_Fig2-.jpg" alt="Figure 2. Four dimensions of a peptide dataset: sequence and architecture, biological context, time-dependent behavior, and developability. Technical failures remain distinct from biological negatives. [Sethera Therapeutics]" width="1000" height="750" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/GEN_Sethera_Fig2-.jpg 1000w, https://www.genengnews.com/wp-content/uploads/2026/09/GEN_Sethera_Fig2--300x225.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/GEN_Sethera_Fig2--768x576.jpg 768w" sizes="(max-width: 1000px) 100vw, 1000px"><figcaption class="wp-caption-text"><em>Figure 2. Four dimensions of a peptide dataset: sequence and architecture, biological context, time-dependent behavior, and developability. Technical failures remain distinct from biological negatives. [Sethera Therapeutics]</em></figcaption></figure>This discipline changes what computation can do. Instead of predicting one binding score, models can identify relationships among architecture, affinity, selectivity, stability, permeability, solubility, and synthetic performance. They can also expose uncertainty, which is often more useful for choosing the next experiment than a confident-looking rank order.</p>
<p>Physics-based modeling and machine learning are often presented as competing approaches. In peptide discovery, they are more useful when assigned complementary roles.</p>
<p>Physics-based calculations can examine conformational ensembles, intramolecular hydrogen bonding, solvent exposure, target contacts, and the consequences of a specific substitution. They are especially valuable when experimental data are sparse or a mechanistic explanation is needed. Their limitations include computational cost, sampling challenges, and sensitivity to the underlying model.</p>
<p>Machine learning can recognize relationships across larger datasets, rank candidates, propose combinations a human team might not prioritize, and support multi-parameter optimization. Recent <a href="https://www.nature.com/articles/s42256-026-01237-5" target="_blank" rel="noopener">work</a> has coupled generative models with Bayesian optimization and prospective synthesis and testing to improve peptide scaffolds under experimentally defined constraints. Deep-learning methods are also becoming more capable of cyclic-peptide structure prediction and redesign, although limited training data remain a central challenge.</p>
<p>The most productive workflow uses physical insight to define plausible chemical space, experimental data to anchor predictions, and machine learning to identify the next informative measurements. Optimization should not collapse every objective into one opaque score. Teams should examine trade-offs directly: a modest loss in affinity may be acceptable if it produces a major gain in selectivity, stability, permeability, or manufacturability.</p>
<p></p><h4><strong>Build the learning strategy before the first hit</strong></h4>

<p>An integrated peptide campaign can be organized around five decisions. First, define the intended product profile early. Target compartment, route of administration, dosing expectations, selectivity requirements, and minimum functional effect should shape the screen.</p>
<p>Second, make molecular architecture an explicit variable. Sequence diversity matters, but diversity of constraint, stereochemistry, backbone composition, and topology may reveal different solutions to the same target.</p>
<p>Third, establish the assay hierarchy and controls in advance. Primary enrichment, counterscreens, orthogonal binding, functional activity, and developability measurements should answer distinct questions rather than repeatedly measure the same one.</p>
<p>Fourth, retain complete and interpretable data, including technical failures and uncertain outcomes. Computational methods cannot repair labels that confound failed production with failed biology.</p>
<div class="my-8"><span data-render-ad="7"></span></div>
<p>Finally, test models prospectively. A model that explains an existing dataset may still fail on new architecture classes or assay conditions. The meaningful test is whether it selects the next peptides better than established heuristics—and whether those results improve the following round.</p>
<p>The output of a peptide screen should not be viewed only as a ranked list. It should be a calibrated map showing which sequences and architectures succeed under which conditions—and where uncertainty remains.</p>
<p>That map can reveal whether a target favors a particular topology, whether a stability gain repeatedly costs function, whether a permeability strategy generalizes, and which measurements best predict cellular activity. It can also prevent teams from optimizing an impressive binder that was never compatible with the intended medicine.</p>
<p>Peptide discovery will continue to benefit from larger libraries and more capable algorithms. But scale alone does not guarantee learning. The programs that move most efficiently will treat library design, screening, functional biology, physics, and machine learning as parts of one experimental system—built not merely to find a winner, but to understand how to make the next molecule better.</p>
<p class="trimmed"> </p>
<p><em>Karsten Eastman, PhD, is the CEO and co-founder of Sethera Therapeutics.</em></p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/designing-peptide-screens-to-generate-knowledge-not-just-hits/">Designing Peptide Screens to Generate Knowledge, Not Just Hits</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Autism Target Discovered in Endothelial Cells in Genetic Deletion Mouse Model</title>
<link>https://edusehat.com/en/autism-target-discovered-in-endothelial-cells-in-genetic-deletion-mouse-model</link>
<guid>https://edusehat.com/en/autism-target-discovered-in-endothelial-cells-in-genetic-deletion-mouse-model</guid>
<description><![CDATA[ Researchers reversed certain behavioral symptoms in a 16p11.2 deletion mouse model of autism spectrum disorder by activating the P2Y2 receptor in endothelial cells of brain blood vessels, which increased blood flow in the brain. 
The post Autism Target Discovered in Endothelial Cells in Genetic Deletion Mouse Model appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2022/05/Getty_1015900158_AutismBrain-1024x683.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 01 Oct 2026 07:05:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Autism, Target, Discovered, Endothelial, Cells, Genetic, Deletion, Mouse, Model</media:keywords>
<content:encoded><![CDATA[<p>Researchers at The Ottawa Hospital and at the University of Ottawa have been able to reverse certain behavioral symptoms in a mouse model of autism by fixing a problem in the endothelial cells (ECs) of brain blood vessels. Building on studies in a 16p11.2 deletion mouse model of ASD that identified brain endothelial cell abnormalities, the team linked 16p11.2 deletion with reduced levels of ATP in endothelial cells. They found that activating P2Y2 receptors rescued the 16p11.2-deletion-associated mouse behaviors.</p>
<p>The results present a promising new treatment target for autism spectrum disorder (ASD) symptoms. “The road from discovery to clinical trials is long, but we’re excited by the possibility that our findings might one day improve the daily lives of people with autism,” said Baptiste Lacoste, PhD, senior scientist at The Ottawa Hospital and professor at the University of Ottawa.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>Baptiste is senior author of the team’s published paper in <em>Neuron </em><em>(“</em><a href="https://doi.org/10.1016/j.neuron.2026.09.009" target="_blank" rel="noopener">Purinergic receptor activation rectifies autism-associated endothelial dysfunction</a>”), in which they concluded “These findings suggest that P2Y2 receptor activation represents a promising strategy to rescue brain EC dysfunction and, in turn, improve autism-related behaviors in the 16p11.2 deletion ASD syndrome.”</p>
<p>Autism is a neurodevelopmental condition with widely varying characteristics. Some of the behavioral symptoms can make life more challenging. While many people with autism have found ways to manage these symptoms, no drug treatment exists.</p>
<p>Lacoste’s team <a href="https://doi.org/10.1038/s41593-020-0663-1" target="_blank" rel="noopener">previously discovered</a> that blood vessels in the brain don’t work properly in mouse models with a 16p11.2 deletion, one of the most common genetic mutations seen in autism. They were the first to look at what was happening in the blood vessels of the brain. “Recent evidence in a 16p11.2 deletion mouse model of autism spectrum disorder (ASD) revealed brain endothelial abnormalities postnatally, but the endothelial alterations eliciting these changes remain unknown,” they wrote.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>Through their newly reported work the researchers have now found that the problem began in the endothelial cells lining the blood vessels. These cells make sure blood quickly gets to the parts of the brain that are active. This responsive blood supply is needed for proper brain function.</p>
<p>However, the endothelial cells in the 16p11.2 deletion mice don’t respond quickly enough. This happens early in brain development and causes behavioral symptoms later in life, including hyperactivity, repetitive movements, and motor learning impairment.</p>
<p>Headed by former PhD student, Julie Ouellette, PhD, the research team looked at what was wrong with these endothelial cells and whether it could be fixed. They discovered that the cells had half the normal level of ATP. “We demonstrate that 16p11.2 deletion induced EC dysfunction is caused by a bioenergetic failure with reduced intracellular ATP,” they explained. While ATP is usually considered an energy molecule, in this case the cell was missing its target, called a P2Y2 receptor, on its surface. “The identified energetic failure was restricted to ECs, emphasizing these cells as key contributors to ASD pathophysiology,” the investigators added.</p>
<p>By activating this P2Y2 receptor, the researchers were able to restore the cell’s function, increase blood flow in the brain, and reverse the behavioral symptoms in adult mice. This was achieved using a drug known to activate P2Y2 and which is currently approved for humans in Japan and South Korea to treat dry eye syndrome.</p>
<p>“Activation of ATP signaling via endothelial P2-class purinergic receptors, specifically P2Y2, rescued EC dysfunction, restoring angiogenic capacity <em>in vitro</em>, endothelium-dependent cerebrovascular reactivity <em>ex vivo</em>, and activity-dependent cerebral blood flow (CBF) <em>in vivo</em>,” the team stated. “A selective pharmacological P2Y2 agonist also rescued adult 16p11.2-deficient behavioral phenotypes.”</p>
<p>Lacoste said, “It’s as if these cells are asleep, and now we can wake them up. And we may only need to treat them once to wake them up permanently. We will test that further, but it’s an encouraging feature for a future treatment.”</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>In their paper the authors concluded, “Taken together, this study demonstrates that metabolic reprogramming of brain ECs via purinergic receptor engagement represents a promising therapeutic avenue for ASD.” They also point out that the study only looked at adult mice. This means targeting P2Y2 could reverse behavioral symptoms that were already well established.</p>
<p>Next, the team plans to treat mice earlier in life to see if early treatment has additional benefits. The team has also filed a patent application for using P2Y2 activation in the blood vessels to treat autism symptoms. They are interested in exploring drug development with the aim of eventual clinical trials.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/autism-target-discovered-in-endothelial-cells-in-genetic-deletion-mouse-model/">Autism Target Discovered in Endothelial Cells in Genetic Deletion Mouse Model</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Microbiome Patterns Vary Among Individuals with Different Cancer Types and Onset Age</title>
<link>https://edusehat.com/en/microbiome-patterns-vary-among-individuals-with-different-cancer-types-and-onset-age</link>
<guid>https://edusehat.com/en/microbiome-patterns-vary-among-individuals-with-different-cancer-types-and-onset-age</guid>
<description><![CDATA[ Researchers analyzing pre-treatment stool samples from 1,364 cancer patients across cancer types, stages, and treatments discovered that adults aged 50 years or younger with colorectal and breast cancers have distinct gut microbiome patterns compared with individuals diagnosed later in life. 
The post Microbiome Patterns Vary Among Individuals with Different Cancer Types and Onset Age appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/03/GettyImages-2151078512.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 01 Oct 2026 03:30:12 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Microbiome, Patterns, Vary, Among, Individuals, with, Different, Cancer, Types, and, Onset, Age</media:keywords>
<content:encoded><![CDATA[<p>Mayo Clinic researchers have discovered that adults aged 50 years or younger with colorectal and breast cancers have distinct gut microbiome patterns compared with individuals diagnosed later in life. The new finding results from the team’s analysis of stool samples from 1,364 cancer patients across cancer types, stages and treatments, enrolled into the Mayo Clinic Cancer Microbiome (MCCM) cohort, a real-world study that recruited cancer patients at Mayo Clinic in Arizona, Florida and Minnesota, representing 40 states. Stool samples were collected before treatment began and linked to detailed clinical data on side effects and outcomes.</p>
<p>Purna Kashyap, MBBS, director of the Mayo Clinic Microbiome Program and Bernard and Edith Waterman Director, Microbiomics Program, Mayo Clinic Center for Individualized Medicine, and Ruben Mars, PhD, a microbiome researcher at Mayo Clinic in Minnesota, are co-corresponding authors of the researchers’ published paper in <em>Cell</em>, titled “<a href="https://doi.org/10.1016/j.cell.2026.09.009" target="_blank" rel="noopener">Microbiome signatures linked to cancer and treatment adverse events in a real-world cohort</a>.”</p>
<p>“The gut microbiome reflects an individual’s environment, lifestyle, diet, and physiological state, making it a sensitive barometer of overall health,” the authors wrote. Increasing evidence is implicating the gut microbiome in cancer biology, pointing to links between composition and function to disease development and treatment outcomes. “As the field shifts from association to causality, a key challenge is prioritizing microbes and pathways most likely to drive specific cancers.”</p>
<p>For their reported study the investigators conducted a real-world study of 1,364 Mayo Clinic Cancer Microbiome cohort patients with different cancer types, before starting a new treatment. “This cohort captures the diversity of cancers and treatments encountered in clinical practice, providing a robust foundation for uncovering microbiome signatures specific to individual cancers,” they wrote.</p>
<p>The investigators compared the cancer patients with 287 people without cancer to identify broad microbiome differences. Comparisons across cancers then revealed more specific signals. After accounting for other health conditions, researchers pinpointed 341 bacterial species associated with five cancer groups.</p>
<p>Among those, neuroendocrine tumors showed a broad loss of common health-associated gut bacteria. Liver and intrahepatic bile duct cancers had higher levels of several bacteria, including <em>Enterococcus faecalis</em>. Esophageal cancer had higher levels of six species, including <em>Streptococcus</em> bacteria. Distinct links were also found in lymphoid leukemia and multiple myeloma and related plasma cell cancers.</p>
<p>“We can now narrow the search to those microbial changes that are most specific to individual cancers,” said Mars. “Those are the signals we need to understand first if we want to determine whether the microbiome plays a causal role in cancer and ultimately develop targeted interventions.”</p>
<p>The study findings indicated that among younger patients, those with colorectal cancer had higher lactate levels and more <em>Veillonella parvula</em>, a gut bacterium that feeds on lactate. Tumors can produce high levels of lactate, which <em>V. parvula</em> uses to grow. Whether that relationship plays a role in early-onset disease is not yet known.</p>
<p>Early-onset (EO) breast cancer showed changes across 64 bacterial species and lower levels of primary bile acids. In breast cancer, one of the 64 species that differed in younger patients was <em>Clostridium scindens</em>, a bacterium involved in bile acid and steroid metabolism.</p>
<p>Colorectal and breast cancer rates are rising among younger adults, the authors stated. Colorectal cancer incidence is increasing about three percent a year among adults ages 20 years to 49 years, while breast cancer incidence is rising 1.4% a year among women younger than 50 years, according to the American Cancer Society. And while the colorectal and breast cancer findings do not establish that these microbial or metabolic differences cause early-onset disease, but they identify links that warrant further study. No comparable age-related microbiome differences were found in brain cancer, the third cancer examined in the early-onset analysis.</p>
<p>Researchers identified gut bacteria associated with survival in colorectal, liver and intrahepatic bile duct, ovarian and prostate cancers, and melanoma. In liver and intrahepatic bile duct cancer, <em>Bifidobacterium longum</em> was associated with longer survival and <em>Blautia A massiliensis</em> with shorter survival.</p>
<p>Researchers also studied whether the gut microbiome before treatment was associated with diarrhea during chemotherapy, a side effect that can make treatment harder to tolerate. Among patients receiving 5-fluorouracil, or 5-FU, a chemotherapy used to treat many types of cancer, those who later developed diarrhea had lower levels of bacterial genes capable of breaking down the drug. Much of that function came from <em>Anaerostipes hadrus</em>, a common gut bacterium. “This example underscores the potential of leveraging our real-world mixed-cancer, mixed-treatment cohort to identify microbiome-driven mechanisms underlying cancer treatment-related adverse effects,” they wrote. The same signal was not linked to diarrhea in patients receiving carboplatin, another chemotherapy drug, suggesting the finding was specific to 5-FU.</p>
<p>“The microbiome is not the sole driver of cancer or treatment outcomes, but it is an underappreciated component that has not traditionally been considered in therapeutic approaches,” said Kashyap. “This gives us a proof of concept that we can begin to understand why some patients experience a particular side effect and identify a target that could potentially be acted upon.”</p>
<p>The researchers next aim to investigate whether cancer-specific microbial signals play a causal role in disease and validate the microbiome’s potential to predict treatment side effects in larger patient groups. In their paper the team concluded, “Our findings illustrate how MCCM, a large, real-world mixed-cancer, mixed-treatment cohort, complements traditional case-control designs by more precisely identifying microbial contributions to cancer pathogenesis, EO cancer, and treatment-related adverse events … These findings demonstrate the strength of our cohort and provide a foundational resource for the discovery of cancer-specific microbiome signatures and predictive biomarkers.”</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/microbiome-patterns-vary-among-individuals-with-different-cancer-types-and-onset-age/">Microbiome Patterns Vary Among Individuals with Different Cancer Types and Onset Age</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Advancing Brain Organoids from Research Models to Scalable Platforms</title>
<link>https://edusehat.com/en/advancing-brain-organoids-from-research-models-to-scalable-platforms</link>
<guid>https://edusehat.com/en/advancing-brain-organoids-from-research-models-to-scalable-platforms</guid>
<description><![CDATA[ In this GEN webinar, Joseph Shultz (VP of technical development and manufacturing, Ottimo Pharma) and Imroz Ghangas (VP of commercial sales, Asimov) discuss strategies for achieving high-performing clonal titers and advancing a dual-paratopic cancer immunotherapy from sequence to dosed patient in under a year. 
The post Advancing Brain Organoids from Research Models to Scalable Platforms appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2228457143.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 01 Oct 2026 03:30:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Advancing, Brain, Organoids, from, Research, Models, Scalable, Platforms</media:keywords>
<content:encoded><![CDATA[<p></p><p></p><div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex"><p class="is-layout-flow wp-block-column-is-layout-flow"></p><div class="wp-block-column"></div><p></p></div><p></p><p></p><p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Register Now</button></p><p></p><p></p><h3 class="w-full text-left">
    <strong>
        Panelists:
    </strong>
</h3>
<div class="flex flex-row m-0-auto items-stretch justify-center flex-wrap mb-4">
    
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/09/AliStrtak_Headshot.jpg" class="h-full w-full object-cover" alt="Image of Ali Strtak, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Ali Strtak, PhD</h2>
                <h5 class="mt-0 !text-[15px] !leading-[21px]">Product Manager, Organoids<br>Bio-Techne</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/09/AliStrtak_Headshot.jpg" alt="Image of Ali Strtak, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Ali Strtak, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Ali Strtak, PhD<strong>, </strong>is product manager for organoids at Bio-Techne. Ali earned her PhD studying the mechanisms of enteric viral infections, using intestinal organoid models to understand how nonstructural viral proteins co-opt host pathways and boost replication, and how that, in turn, translates to the physical manifestations of disease. She published the first functional characterization of a virally encoded calcium ion channel in the <em>Caliciviridae</em> family. Optimizing culture conditions as well as calcium imaging protocols for that work gave her firsthand experience with how culture variability and reagent selection underpin and undermine reproducibility in organoid models. In her current role, she focuses on standardizing organoid culture to make the model more consistent experiment over experiment and more accessible to all researchers interested in getting into organoids, regardless of prior 3D culture expertise.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog>
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/09/Fikri-Birey-headshot-e1790783645613.jpg" class="h-full w-full object-cover" alt="Image of Fikri Birey, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Fikri Birey, PhD</h2>
                <h5 class="mt-0 !text-[15px] !leading-[21px]">Assistant Professor, Department of Human Genetics<br>Emory University School of Medicine</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/09/Fikri-Birey-headshot-e1790783645613.jpg" alt="Image of Fikri Birey, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Fikri Birey, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Fikri Birey, PhD<strong>,</strong> is an assistant professor in the Department of Human Genetics at Emory University School of Medicine, where he leads a research program focused on uncovering the molecular and cellular mechanisms of human brain development and neurodevelopmental disorders. His lab employs stem cell-derived brain organoids and assembloids to model disease-relevant processes, with particular emphasis on disorders such as autism, epilepsy, and schizophrenia. Birey completed his PhD in genetics at Stony Brook University and postdoctoral research at Stanford University in the laboratory of Sergiu Pasca, MD, where he built the first assembloid platform and applied it to uncover previously inaccessible disease phenotypes and nominate novel therapeutics in Timothy syndrome. He also co-founded the Brain Organoid Hub at Emory, which serves as a central resource for scalable and standardized human brain organoid research. Through this work, Birey aims to bridge basic neurobiology with therapeutic discovery, advancing precision medicine for complex brain disorders.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog></div>

<p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-malblocks-webinars-info"></p><div><strong>Broadcast Date:</strong> <time>Thursday, October 22, 2026</time><br><ul><li><strong>Time:</strong> <time datetime="2026-10-22T15:00:00.000Z">08:00 PDT, 11:00 EDT, 15:00 GMT</time></li></ul></div><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p></p><div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex"><p></p><div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"><p class="wp-block-paragraph">Complex biologics such as bifunctional antibodies are opening new therapeutic possibilities in oncology, but these molecules present significant challenges for manufacturing teams. Non-standard architectures can often translate to low expression and difficult developability, making cell line development a critical bottleneck between a promising sequence and a viable clinical candidate.</p><p></p><p></p><p class="wp-block-paragraph"><br>In this <em>GEN </em>webinar, Joseph Shultz (vice president of technical development and manufacturing, Ottimo Pharma) and Imroz Ghangas (vice president of commercial sales, Asimov) discuss strategies for achieving high-performing clonal titers and advancing a dual-paratopic cancer immunotherapy from sequence to dosed patient in under a year. Attendees will learn about the unique attributes of Ottimo’s molecule and how a specialist partnership with Asimov accelerated the program. The presenters will also introduce the CHO Edge System, which combines Asimov’s proprietary GS knock-out CHO host, hyperactive transposase, library of characterized genetic elements, and AI-driven genetic design tools to routinely deliver clonal titers of 8-12 g/L.</p><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-paragraph"><em>A live Q&A session will follow the presentation offering you a chance to pose questions to our expert panelists.</em></p><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-paragraph"><strong>Produced with support from:</strong></p><p></p><p></p><p><figure class="wp-block-image alignleft size-medium"><a href="https://www.bio-techne.com/" target="_blank" rel=" noopener"><img decoding="async" width="300" height="56" src="https://www.genengnews.com/wp-content/uploads/2018/10/biotechne_CMYK_logo9124350201-300x56.jpg" alt="biotechne logo" class="wp-image-76009" srcset="https://www.genengnews.com/wp-content/uploads/2018/10/biotechne_CMYK_logo9124350201-300x56.jpg 300w, https://www.genengnews.com/wp-content/uploads/2018/10/biotechne_CMYK_logo9124350201.jpg 500w" sizes="(max-width: 300px) 100vw, 300px"></a></figure></p><p></p></div><p></p></div><p></p><p>The post <a href="https://www.genengnews.com/multimedia/webinars/advancing-brain-organoids-from-research-models-to-scalable-platforms/">Advancing Brain Organoids from Research Models to Scalable Platforms</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Genome&#45;Wide Analysis Identifies BACH2 as Potential Fetal Hemoglobin Activation Target</title>
<link>https://edusehat.com/en/genome-wide-analysis-identifies-bach2-as-potential-fetal-hemoglobin-activation-target</link>
<guid>https://edusehat.com/en/genome-wide-analysis-identifies-bach2-as-potential-fetal-hemoglobin-activation-target</guid>
<description><![CDATA[ This pathway, which the authors dub the “BACH2-NRF2 axis,” is independent of the well-known BCL11A transcription regulator, the target of the approved cell therapy Casgevy for sickle cell disease (SCD).
The post Genome-Wide Analysis Identifies BACH2 as Potential Fetal Hemoglobin Activation Target appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/Getty_532104607_BloodCells-e1790792336784.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 01 Oct 2026 03:30:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Genome-Wide, Analysis, Identifies, BACH2, Potential, Fetal, Hemoglobin, Activation, Target</media:keywords>
<content:encoded><![CDATA[<p>In a major new genome-wide meta-analysis, researchers at Boston Children’s Hospital and the Broad Institute led by Vijay G. Sankaran, MD, PhD, have identified a novel regulatory pathway that activates the expression of fetal hemoglobin (HbF). This pathway, which the authors dub the “BACH2-NRF2 axis,” is independent of the well-known BCL11A transcription regulator, the target of the approved cell therapy Casgevy for sickle cell disease (SCD).</p>
<p>The Boston study raises the interesting prospect of an accessible new target for therapeutic development. The paper, published today in <em>Nature</em>, is entitled: “<a href="https://www.nature.com/articles/s41586-026-11113-2" target="_blank" rel="noopener">Human genetics implicates a BACH2-NRF2 axis in fetal hemoglobin activation</a>.”</p>
<p>These new findings “establish the BACH2–NRF2 axis as a tractable and potentially therapeutically targetable regulatory node involved in HbF activation,” the authors write.</p>
<figure aria-describedby="caption-attachment-338680" class="wp-caption alignleft"><img decoding="async" class="wp-image-338680" src="https://www.genengnews.com/wp-content/uploads/2026/09/VijaySankaran_headshot-300x300.jpg" alt="Vijay Sankaran" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/VijaySankaran_headshot-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/VijaySankaran_headshot-1024x1024.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/09/VijaySankaran_headshot-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/09/VijaySankaran_headshot-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/09/VijaySankaran_headshot.jpg 1400w" sizes="(max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Vijay Sankaran, MD, PhD<br>[Boston Children’s Hospital]</figcaption></figure>
<p>For the past few decades, researchers have focused on the fetal-to-adult hemoglobin switch as a potential therapeutic avenue for SCD and thalassemia. Fetal hemoglobin expression declines naturally in the first 6-12 months after birth, replaced by adult hemoglobin. Almost 20 years ago, teams led by Swee-Lay Thein, MD, and, separately, Sankaran and Stuart Orkin, MD, identified BCL11A as a key regulator of that switch. The approval in December 2023 of Casgevy, the gene editing therapy sponsored by Vertex and CRISPR Therapeutics, provided clinical validation of that strategy and has transformed the lives of scores of SCD and thalassemia patients.</p>
<p>In the <em>Nature </em>report, Sankaran’s team analyzed a trove of genome-wide association study (GWAS) data from more than 28,000 individuals spread across European, African, and Asian populations. The study identified 91 discrete genetic associations across 12 genomic regions. One of the strongest signals, albeit weaker than the original GWAS findings two decades ago, highlighted a novel regulatory circuit—the BACH2–NRF2 axis—that directly governs γ-globin gene expression.</p>
<p></p><h4><strong>BACH2 variations </strong></h4>

<p>BACH2 is a known transcription regulator, Sankaran told <em>GEN</em>, but it was not previously suspected as having a role in HbF regulation. Sankaran’s team performed studies to pinpoint the precise genetic variant that contributed to the GWAS signal. The causal variant—rs1010474-C—reduces expression of BACH2 in erythroid progenitor cells. Genetic and biochemical experiments to block BACH2, either using short hairpin RNA knockdown, base editing, or pharmacological inhibition using a small-molecule inhibitor, led to marked elevation of γ-globin transcription (one of the two globin chains that make up HbF) and increased the proportion of HbF-containing red blood cells without disrupting normal erythropoiesis.</p>
<p>Sankaran’s team went on to demonstrate that BACH2 functions as a direct repressor at the γ-globin promoter and locus control region LCR. Under baseline conditions, BACH2 restricts chromatin occupancy of the transcriptional activator, NRF2. But if BACH2 is lost or inhibited, NRF2 binding is able to expand across γ-globin regulatory elements. Loss of BACH2 triggers the formation of discrete nuclear NRF2 foci that specifically colocalize with active sites of γ-globin transcription.</p>
<p>By mapping the transcription factor binding sites, the team identified overlapping consensus motifs for BACH2 (−94 to −106) and NRF2 (−96 to −105) within the upstream γ-globin promoter. Using base editors, the team engineered single-nucleotide substitutions to study the impact of targeted point mutations on gene expression. Promoter variants including −98G>A, −99G>A, and −104G>A—similar to those that might be contemplated in a therapeutic setting—reduced BACH2 binding affinity while enhancing NRF2 binding, resulting in robust HbF expression. Biochemical analysis further confirmed a direct protein interaction between domains of BACH2 and NRF2, indicating that BACH2 physically interacts with NRF2 to mute its transcriptional activity.</p>
<p></p><h4><strong>Parallel pathways </strong></h4>

<div class="my-8"><span data-render-ad="5"></span></div>
<p>The <em>Nature </em>study from Sankaran’s team also shows that the BACH2–NRF2 axis operates independently of BCL11A. The BACH2–NRF2 promoter motif is sandwiched between two BCL11A binding sites. The researchers found no evidence of direct physical contact between BCL11A and BACH2 or NRF2. Furthermore, simultaneous depletion of both BACH2 and BCL11A yielded additive increases in γ-globin expression, suggesting the potential for multi-target genetic or pharmacological therapies.</p>
<p>Sankaran tells <em>GEN </em>he is excited by the finding that the BACH2 pathway is “completely independent of the BCL11A repressive pathway and is primarily involved in activation of HbF. So, combined editing at the [gamma-globin] promoters,” in addition to what companies like Shanghai-based CorrectSequence Therapeutics is doing at the BCL11A binding site, “could also be beneficial.”</p>
<p>Addressing the translational potential of their work, Sankaran and colleagues emphasize that “the presence of high-confidence human genetic evidence is a more critical predictor of clinical success than the absolute magnitude of the variant effect size.”</p>
<p>Naturally, this report raises the intriguing prospect of new avenues for combining BCL11A-targeted strategies with BACH2/NRF2 modulation for treating SCD and β-thalassemia. “There are already small molecules in development for SCD that we suspect might target BACH2,” Sankaran said. “I think our findings add clarity on the mechanism by which this pathway might modulate HbF.”</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/genome-wide-analysis-identifies-bach2-as-potential-fetal-hemoglobin-activation-target/">Genome-Wide Analysis Identifies BACH2 as Potential Fetal Hemoglobin Activation Target</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>MRSA Exploits Kidney’s Inner Environment to Persist and Spread</title>
<link>https://edusehat.com/en/mrsa-exploits-kidneys-inner-environment-to-persist-and-spread</link>
<guid>https://edusehat.com/en/mrsa-exploits-kidneys-inner-environment-to-persist-and-spread</guid>
<description><![CDATA[ New research reveals how MRSA exploits the kidney’s hyperosmotic inner medulla to evade immune defenses, establish a persistent reservoir, and spread, while suggesting potential therapeutic strategies to limit infection.
The post MRSA Exploits Kidney’s Inner Environment to Persist and Spread appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/08/GettyImages-523568832.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 01 Oct 2026 03:30:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>MRSA, Exploits, Kidney’s, Inner, Environment, Persist, and, Spread</media:keywords>
<content:encoded><![CDATA[<p><span>Methicillin-­resistant <em>Staphylococcus aureus</em> (MRSA) has rapidly risen to become one of the gravest threats to global health, with deaths from <em>Staphylococcus aureus (</em><em>S. aureus)</em><em> </em>having doubled worldwide since 1990. In severe cases, the bacteria invade the bloodstream in life-threatening systemic infections, which have a high risk of kidney injury and failure.</span></p>
<p><span><em>S. aureus </em>is one of the most concerning bacterial pathogens, given that MRSA accounts for the largest increase in the global antimicrobial resistance burden. In addition, deaths attributable to <em>S. aureus</em> infections have doubled since 1990, making it a leading cause of bacterial mortality worldwide. Despite the continued focus on research, tissue reservoirs that permit bacterial persistence remain poorly defined.</span></p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p><span>Now, a new study reveals how MRSA exploits the osmotic environment of the inner kidneys to establish a bacterial reservoir and hide from the immune system. This work suggests that MRSA can establish niches in the kidneys and the findings provide a mechanistic explanation for a longstanding question in the field of MRSA biology, and could inform future strategies aimed at limiting kidney damage from infections.</span></p>
<p><span>This work is published in <em>Science Translational Medicine</em> in the paper, “<a href="https://www.science.org/doi/10.1126/scitranslmed.aed4200" target="_blank" rel="noopener">Hyperosmotic niche adaptation and tissue polyamines underlie MRSA persistence in the kidney</a>.”</span></p>
<p><span>Nobuhiro Kanazawa, PhD, and colleagues used intravenous MRSA infection in mice and combined with multi-plexed imaging, dual-species transcriptomics, host and bacterial genetics, and cell-­based assays, to understand the mechanisms of MRSA persistence in the kidney in a mouse model of systemic infection. The findings reveal the renal inner medulla, the site of urine concentration, as an MRSA reservoir. Here, in this hyperosmotic niche, MRSA evaded immune detection and co-opted tissue polyamines to grow and spread toward the renal cortex.</span></p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p><span>MRSA spread to other kidney tissues and grew by co-opting polyamines, which buttressed the bacterial membrane against osmotic stress and boosted the translation of a growth-fueling bacterial enzyme.</span></p>
<p><span>The extreme osmotic environment also shielded MRSA from immune detection and slowed the migration of neutrophils toward the infection site. More specifically, neutrophil recruitment to the inner medulla was delayed.</span></p>
<p><span>The team went on to find that the approved drug furosemide restored neutrophil infiltration and contained MRSA’s spread in the kidneys of mice, hinting that similar “washout” therapies might prove useful. The authors write, “disruption of medullary osmolality with the loop diuretic furosemide accelerated neutrophil infiltration, limited bacterial spread, and improved renal outcomes.”</span></p>
<p><span>The findings, the authors note, revealed the inner medulla as a physiologically immune-­restricted MRSA reservoir and supported “modulation of medullary osmolality and bacterial polyamine metabolism as candidate adjunctive strategies for limiting renal persistence and dissemination during MRSA bacteremia.”</span></p>
<p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/mrsa-exploits-kidneys-inner-environment-to-persist-and-spread/">MRSA Exploits Kidney’s Inner Environment to Persist and Spread</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>When care comes home: Rethinking what pediatric care can look like</title>
<link>https://edusehat.com/en/when-care-comes-home-rethinking-what-pediatric-care-can-look-like</link>
<guid>https://edusehat.com/en/when-care-comes-home-rethinking-what-pediatric-care-can-look-like</guid>
<description><![CDATA[ HN Summary • Care where children need it: Bayshore’s pediatric program provides specialized nursing and support for medically complex and fragile children in their homes, schools and communities. •Supporting the whole family: Community-based care helps children attend school, participate with peers and maintain everyday routines while giving parents essential respite and support.  • Recognized for […]
The post When care comes home: Rethinking what pediatric care can look like appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/09/Bayshore-e1790787275605.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 01 Oct 2026 03:25:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>When, care, comes, home:, Rethinking, what, pediatric, care, can, look, like</media:keywords>
<content:encoded><![CDATA[<p><strong>HN Summary</strong></p>
<p>• Care where children need it: Bayshore’s pediatric program provides specialized nursing and support for medically complex and fragile children in their homes, schools and communities.</p>
<p>•Supporting the whole family: Community-based care helps children attend school, participate with peers and maintain everyday routines while giving parents essential respite and support.<span class="Apple-converted-space"> </span></p>
<p>• Recognized for quality: Bayshore’s B.C. Pediatric and Specialty Nursing program achieved Accreditation with Exemplary Standing in 2026, recognizing its commitment to safety, quality and family-centred care.</p>
<hr>
<p>For families caring for a medically complex or fragile child, health care happens at the kitchen table, on the school bus and in the classroom. It can mean managing medications, monitoring a child’s condition, supporting mobility or providing specialized nursing care — while also trying to make space for homework, siblings, birthdays and simply being a family.</p>
<p>That is where community-based pediatric care can make a profound difference.</p>
<p>The Bayshore HealthCare Paediatric Program provides specialized nursing and support services for medically complex, fragile, and chronically ill children in their homes, schools, and communities. Care is delivered by registered nurses, licensed practical nurses, Allied Health Professionals and personal support workers through government-funded and private-pay programs.</p>
<p>In British Columbia, that work has been taking place for more than two decades through Bayshore’s Pediatric and Specialty Nursing (BPSN) program. Established in 2003, the program provides in-home and in-school respite nursing care across Vancouver Coastal Health, Fraser Health, and Island Health.</p>
<p>At its heart, the program is about more than delivering clinical care outside a hospital. It is about helping children remain connected to the places, people and routines that matter to them.<span class="Apple-converted-space"> </span></p>
<p>That approach was reinforced in January 2026, when the BPSN program in Burnaby achieved<span class="Apple-converted-space">  </span>Accreditation with Exemplary Standing, the highest possible recognition from Accreditation Canada.</p>
<p>“This recognition underscores the hard work and passion of Bayshore employees, whose expertise and compassion drive our efforts every day,” says Lisa Ternoway, Area Director<span class="Apple-converted-space">  </span>BPSN program, B.C.</p>
<p>Accreditation Canada assesses organizations against rigorous standards covering leadership, medication management, infection prevention and control, staffing, home care services, and service excellence. The process also includes interviews with staff, clients, families, and community partners, as well as direct observation of care.</p>
<p>For a pediatric program operating across homes, schools, and communities, that clinical practice and care consistency matters.</p>
<p>So does listening.</p>
<p>Bayshore’s Family Advisory Network in British Columbia was established to ensure that the experiences of children and families help shape how care is delivered. That is an important distinction. Family-centred care means providing care to a family as well as creating opportunities to understand what matters to the family.</p>
<p>For families of children with complex medical needs, the impact of that support<span class="Apple-converted-space">  </span>extends well beyond clinical care.</p>
<p>On B.C.’s Sunshine Coast, consistent nursing support and care has helped one child who is medically complex, shift from attending school only a few days a week to attending five days a week for the school year. At home, overnight respite has allowed both parents to work and sleep while caring for their son and his sibling.</p>
<p>Chloe Mustard, manager of clinical practice for Bayshore’s pediatric and specialty nursing programs, says the objective is to create as much normalcy as possible.</p>
<p>“The whole goal is to lessen the burden from parents,” Mustard says.</p>
<p>For the child, the support has meant more than regular school attendance. He has participated in classroom activities, delivered his first oral presentation, and developed relationships with classmates. This fall, he is entering high school.</p>
<p>These are milestones but for a child whose medical needs once made regular attendance difficult, they represent something much bigger: the opportunity to learn, grow and experience childhood alongside his peers.</p>
<p>Bayshore HealthCare’s Chief Nursing and Clinical Officer, Maureen Charlebois, says the accreditation reflects that broader commitment.</p>
<p>“We are proud to have met and surpassed national standards set by Accreditation Canada, which places the highest value on the safety, well-being, and dignity of patients, their families, and the communities we serve,” she says.</p>
<p>The journey to Exemplary Standing builds on a long-standing commitment to that philosophy. In 2017, Bayshore’s Paediatric Specialty Care Program in B.C. received an Exemplary Award from Accreditation Canada, recognizing its focus on quality, risk management in community settings, family-centred care, and client outcomes.</p>
<p>The latest Exemplary Award received this year suggests that the work has not stood still.</p>
<p>For the Burnaby Pediatric Respite Program, quality is lived out in the details: a nurse arriving at a family’s home, a child receiving support at school, a parent gaining some much-needed respite, or a medically fragile young person being able to participate more fully in everyday life. For many families, this is essential health care.</p>
<p>As health systems across Canada look for ways to provide care closer to home, programs such as Bayshore’s Paediatric Specialty Care Program offer an important lesson. The future of care is not necessarily about bringing every patient into a health-care setting. Sometimes, it is about bringing the right care into the patient’s world.</p>
<p><i>If you would like to learn more about our Pediatric Home & School Support Services, please contact<span class="Apple-converted-space">  </span>CQresponseteam@bayshore.ca</i></p>
<p><i>Simon Campbell, Communications Specialist PAC.</i></p>
<p>The post <a href="https://www.hospitalnews.com/when-care-comes-home-rethinking-what-pediatric-care-can-look-like/">When care comes home: Rethinking what pediatric care can look like</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>‘Hangry’ no more:  Overnight fasting no longer required for two common HHS cardiac procedures</title>
<link>https://edusehat.com/en/hangry-no-more-overnight-fasting-no-longer-required-for-two-common-hhs-cardiac-procedures</link>
<guid>https://edusehat.com/en/hangry-no-more-overnight-fasting-no-longer-required-for-two-common-hhs-cardiac-procedures</guid>
<description><![CDATA[ HN Summary • No more routine overnight fasting: Hamilton Health Sciences found that most patients undergoing coronary angiograms or PCIs can safely eat a light meal up to two hours beforehand and drink clear liquids until their procedure.  • Better patient experience without added safety concerns: Patients following the shorter fasting protocol reported less hunger, […]
The post ‘Hangry’ no more:  Overnight fasting no longer required for two common HHS cardiac procedures appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/09/Hangry.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 01 Oct 2026 03:25:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>‘Hangry’, more:, Overnight, fasting, longer, required, for, two, common, HHS, cardiac, procedures</media:keywords>
<content:encoded><![CDATA[<p><strong>HN Summary</strong></p>
<p>• No more routine overnight fasting: Hamilton Health Sciences found that most patients undergoing coronary angiograms or PCIs can safely eat a light meal up to two hours beforehand and drink clear liquids until their procedure.<span class="Apple-converted-space"> </span></p>
<p>• Better patient experience without added safety concerns: Patients following the shorter fasting protocol reported less hunger, greater comfort and less nausea, with no serious complications such as aspiration reported in either study group.<span class="Apple-converted-space"> </span></p>
<p>• Quality improvement driving broader change: The five-month HHS project contributed evidence supporting shorter fasting protocols, has been published in the Journal of Patient Safety, and has already helped prompt another Ontario hospital to change its fasting practices.</p>
<hr>
<p>Anyone who has fasted overnight before a medical procedure knows how uncomfortable it is to grow increasingly hungry and thirsty as they wait. And if their procedure is delayed, that discomfort can turn into feeling “hangry”—the familiar mix of hunger and anger, or irritability.</p>
<p>Close to 6,000 patients undergo coronary angiograms and percutaneous coronary interventions (PCIs) each year at Hamilton Health Sciences’ (HHS) Heart Investigation Unit, located at Hamilton General Hospital (HGH). A coronary angiogram checks for narrowing or blockages in the heart’s arteries, while a PCI is used to open them. Both procedures are performed using sedation, where patients are awake, relaxed and breathing on their own, and typically take less than an hour. Many patients visit the hospital for these procedures and return home afterwards.</p>
<p>It has long been standard practice for patients having a coronary angiogram or PCI to follow the same rigorous fasting rules as patients undergoing major surgeries with general anesthesia, where they’re unconscious and require breathing support. The `no food or drinks after midnight’ rule is an important safety precaution for preventing aspiration — a dangerous complication where stomach contents are inhaled into the lungs.</p>
<h2>Driving change through<span class="Apple-converted-space"> </span>Quality Improvement projects</h2>
<p>But several studies, and an HHS quality improvement (QI) patient safety project at the Heart Investigation Unit, all found that hours-long fasting is excessive and unnecessary for most coronary angiograms and PCIs. Instead, patients can safely eat a light meal up to two hours before their procedure. And they can drink clear liquids until the time of their procedure.</p>
<p>The project’s goal was to improve patients’ experience by demonstrating that the fasting window for coronary angiograms and PCIs could be safely shortened to two hours.</p>
<p>“Our sole motivation for this project was to improve the patient experience,” says Laura Sheehan, manager of the Heart Investigation Unit during the project. She has since changed to a different role at HHS.</p>
<p>Dr. Madhu Natarajan, an HHS interventional cardiologist at the Heart Investigation Unit, led the project. He was inspired after taking a QI patient safety course led by his HHS colleague, anesthesiologist Dr. Ekta Khemani.</p>
<p>Khemani is a co-director for the HHS Knowledge Centre and a QI expert. She develops and runs QI patient safety courses especially for physicians and other health-care providers who work directly with patients. Courses are offered through the Knowledge Centre’s Quality Improvement and Education Program.</p>
<p>“QI projects are a way for physicians to gather and use evidence in decision making around best practices and patient care,” says Khemani, adding that the Knowledge Centre recently started offering a very affordable two-day introductory course in QI and patient safety and will also offer a 12-week certification course.</p>
<h2>Studying HHS heart patients</h2>
<p>Natarajan drew on previously published meta analyses that combined results from several smaller trials at other hospitals examining shortened fasting windows. A meta analysis pulls together data from earlier studies to identify broader patterns and outcomes.</p>
<p>His five-month QI project, launched in April 2024 at the Heart Investigation Unit, included outpatients and inpatients having coronary angiograms and PCIs. Outpatients visit the hospital for tests and return home afterwards, while inpatients stay overnight in hospital.</p>
<p>The project, managed by Knowledge Centre research coordinator Marija Corovic, compared outcomes before and after the new two-hour fasting window.</p>
<p>The “before” patients had followed the longstanding practice of nothing to eat or drink after midnight, while the “after” patients could have a light meal, such as toast or cereal, up to two hours before their procedure, and drink clear liquids like water, black tea or coffee, right up until their procedure.</p>
<p>The project team partnered with the hospital’s Patient and Family Advisory Council to develop clear, easy-to-follow instructions for patients around eating and drinking. This council is made up of HHS patients and family members who share their hospital experiences and give feedback to help make care better. They play an important role in improving how HHS delivers health care across the region.</p>
<p>Study participants filled out a survey afterwards about their experience. While both groups gave high marks for their care, people with the two-hour fasting window reported feeling more comfortable and less hungry. They also experienced less nausea. No one from either group had serious complications, like aspiration.</p>
<h2>Sharing knowledge</h2>
<p>While some other hospitals, provincially and nationally, have moved to shorter fasting windows for coronary angiograms and PCIs, many still require overnight fasting. Natarajan stresses that patients should still follow exact instructions provided by their hospital for their particular procedure.</p>
<p>But QI projects like the one led by Natarajan could help move the needle. For example, a Toronto hospital changed to a two-hour window after hearing the results of Natarajan and team’s project.</p>
<p>A paper on the HHS project’s findings has been recently published by the Journal of Patient Safety.<span class="Apple-converted-space"> </span></p>
<p>The post <a href="https://www.hospitalnews.com/hangry-no-more-overnight-fasting-no-longer-required-for-two-common-hhs-cardiac-procedures/">‘Hangry’ no more:  Overnight fasting no longer required for two common HHS cardiac procedures</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>ICU nurses create toolkit to improve end&#45;of&#45;life care</title>
<link>https://edusehat.com/en/icu-nurses-create-toolkit-to-improve-end-of-life-care</link>
<guid>https://edusehat.com/en/icu-nurses-create-toolkit-to-improve-end-of-life-care</guid>
<description><![CDATA[ After nearly 11 years in nursing, Kelsey Stewart still remembers the passing of one of her first patients. “She was in her 40’s and gasping for breath, but much more alert than I expected someone to be at the end of life. I wasn’t mentally prepared for what was happening, and I think her family […]
The post ICU nurses create toolkit to improve end-of-life care appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/09/ChatGPT-Image-Sep-30-2026-03_51_39-PM.png" length="49398" type="image/jpeg"/>
<pubDate>Thu, 01 Oct 2026 03:25:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>ICU, nurses, create, toolkit, improve, end-of-life, care</media:keywords>
<content:encoded><![CDATA[<p>After nearly 11 years in nursing, Kelsey Stewart still remembers the passing of one of her first patients. “She was in her 40’s and gasping for breath, but much more alert than I expected someone to be at the end of life. I wasn’t mentally prepared for what was happening, and I think her family could see that in me,” says the critical care nurse from Abbotsford Regional Hospital and Cancer Centre. “It was a tough experience that stayed with me throughout my nursing career.”<span class="Apple-converted-space"> </span></p>
<p>To help ensure nurses have the confidence and resources to deal with difficult conversations and provide comfort during a patient’s final stages of life, Kelsey and critical care registered nurses Aisha Woodbury and Bronwyn Caldwell—also from Abbotsford Regional Hospital—are developing a practical bedside resource and digital toolkit.<span class="Apple-converted-space"> </span></p>
<p>Thanks to funding from the BC Nurses’ Union through the 2026 Knowledge Translation Challenge, the team will work with physicians, nurse practitioners, social workers, care aides, Indigenous health liaisons, spiritual health practitioners, patient partners and families to create culturally sensitive materials that fit the needs of patients and staff.</p>
<p>“I want nurses to have the right resources at their fingertips. When you’re caring for someone at the end of life and supporting their family at the same time, you shouldn’t have to search in multiple places for the information and resources you need” says Kelsey.</p>
<p>Once complete, the toolkit will be available in the ICU at Abbotsford Regional Hospital, with a plan to expand to other ICUs and B.C. health authorities in the future.<span class="Apple-converted-space"> </span></p>
<p>“Nurses from other health authorities have reached out, asking if they can access the toolkit as well,” says Kelsey.<span class="Apple-converted-space"> </span></p>
<p>That interest, she adds, reflects a shared commitment among nurses to strengthening compassionate, dignified and culturally safe end-of-life care for critically ill patients and their families.</p>
<p>“It’s a privilege to be at someone’s bedside when they pass,” says Kelsey. “For nurses, it may be one moment within a busy shift, but for that family, it’s a moment they will remember for the rest of their lives.”</p>
<p>The post <a href="https://www.hospitalnews.com/icu-nurses-create-toolkit-to-improve-end-of-life-care/">ICU nurses create toolkit to improve end-of-life care</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>A publicly funded diabetes prevention program could benefit Canada</title>
<link>https://edusehat.com/en/a-publicly-funded-diabetes-prevention-program-could-benefit-canada</link>
<guid>https://edusehat.com/en/a-publicly-funded-diabetes-prevention-program-could-benefit-canada</guid>
<description><![CDATA[ Adopting a diabetes prevention program (DPP) in Canada like the National Health System (NHS) England program could help prevent type 2 diabetes in people with prediabetes and save costs, according to a new study published in CMAJ (Canadian Medical Association Journal). “Our analyses indicate that implementing an NHS England–style DPP in Ontario and Quebec would […]
The post A publicly funded diabetes prevention program could benefit Canada appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/09/ChatGPT-Image-Sep-30-2026-03_48_14-PM.png" length="49398" type="image/jpeg"/>
<pubDate>Thu, 01 Oct 2026 03:25:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>publicly, funded, diabetes, prevention, program, could, benefit, Canada</media:keywords>
<content:encoded><![CDATA[<p>Adopting a diabetes prevention program (DPP) in Canada like the National Health System (NHS) England program could help prevent type 2 diabetes in people with prediabetes and save costs, according to a new study published in CMAJ (Canadian Medical Association Journal).</p>
<p>“Our analyses indicate that implementing an NHS England–style DPP in Ontario and Quebec would be cost-effective — and likely cost saving — over a 35-year horizon for adults with prediabetes,” write postdoctoral student Dr. Nisha Gupta, senior author Dr. Kaberi Dasgupta, and others from the Research Institute of the McGill University Health Centre and McGill University, Montréal, Quebec, with NHS DPP founder Dr. Jonathan Valabhji.</p>
<p>Based on evidence from clinical trials in several countries that showed structured programs combining dietary and physical activity can prevent diabetes in people with prediabetes, the NHS England adopted the world’s first national, publicly funded DPP. No publicly funded DPPs exist in Canada, despite estimates that as many as 1 in 4 adults in the country have prediabetes. In 2022, Canada released a diabetes framework that calls on provincial and Indigenous governing bodies to build community-based programs to help address increases in new cases of diabetes.<span class="Apple-converted-space"> </span></p>
<p>The authors modelled a DPP program and compared it to usual care in Quebec and Ontario, Canada’s most populous provinces. They found the program improved quality-adjusted life years and reduced costs compared to usual care. The costs of prevention appeared to be less than the cost of treating diabetes after it develops.</p>
<p>“The NHS England DPP represents a compelling model for Canada, given its demonstrated cost-effectiveness and the structural similarities between English and Canadian health systems. In both Canada and England, most of the population is White, but both countries have large proportions of people from other racial or ethnic backgrounds,” write the authors.</p>
<p>However, they note that Canada would need an Indigenous-led DPP to meet the specific needs of Indigenous Peoples to align with the Truth and Reconciliation Commission’s Calls to Action to address colonial injustices.<span class="Apple-converted-space"> </span></p>
<p>“Our findings support the potential value of investing in DPPs in Canadian provinces and highlight an opportunity to reduce the burden of type 2 diabetes. Successful implementation in a single province could facilitate broader adoption, reduce the number of people developing type 2 diabetes and downstream health care costs, and inform future federal coordination and funding efforts,” the authors conclude.</p>
<p>“Cost-effectiveness of implementing the National Health Service England Diabetes Prevention Programme in Canada: a modelling study” was published September 28, 2026.</p>
<p>The post <a href="https://www.hospitalnews.com/a-publicly-funded-diabetes-prevention-program-could-benefit-canada/">A publicly funded diabetes prevention program could benefit Canada</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Guideline to reduce vaccination distress offers menu of options</title>
<link>https://edusehat.com/en/guideline-to-reduce-vaccination-distress-offers-menu-of-options</link>
<guid>https://edusehat.com/en/guideline-to-reduce-vaccination-distress-offers-menu-of-options</guid>
<description><![CDATA[ A comprehensive guideline update with 16 recommendations to reduce vaccination distress, with suggestions ranging from applying topical pain relief to distractions, is published in CMAJ (Canadian Medical Association Journal). “Fear and pain — together referred to as distress — are among the most common negative effects of vaccine injections,” says Dr. Anna Taddio, Leslie Dan […]
The post Guideline to reduce vaccination distress offers menu of options appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/09/ChatGPT-Image-Sep-30-2026-03_44_20-PM.png" length="49398" type="image/jpeg"/>
<pubDate>Thu, 01 Oct 2026 03:25:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Guideline, reduce, vaccination, distress, offers, menu, options</media:keywords>
<content:encoded><![CDATA[<p>A comprehensive guideline update with 16 recommendations to reduce vaccination distress, with suggestions ranging from applying topical pain relief to distractions, is published in CMAJ (Canadian Medical Association Journal).</p>
<p>“Fear and pain — together referred to as distress — are among the most common negative effects of vaccine injections,” says Dr. Anna Taddio, Leslie Dan Faculty of Pharmacy, University of Toronto and The Hospital for Sick Children (SickKids), Toronto, Ontario, with coauthors. “Research shows there are effective ways to reduce distress, but these strategies are still not routinely built into vaccination programs or practices, even though clinical guidelines recommend them.”</p>
<p>This guideline is an update to the 2015 Help Eliminate Pain in Kids & Adults (HELPinKids&Adults) Collaborative recommendations. The authors hope this guideline, aimed at clinicians who administer vaccines, organizations that offer vaccination services, as well as people who receive vaccines and their support persons, will provide updated evidence-based guidance to help ease distress that may come with vaccination.<span class="Apple-converted-space"> </span></p>
<p>The authors suggest evidence-based interventions across the 5P framework: process, procedural, physical, pharmacologic, and psychological, emphasizing that people who are being vaccinated and their caregivers should choose the option that works best for them.<span class="Apple-converted-space"> </span></p>
<p><strong>Key recommendations:<span class="Apple-converted-space"> </span></strong></p>
<p>• Process: Education of all groups from administrators to vaccine recipients about distress-reducing interventions, and use of these</p>
<p>• Procedural: Adoption of methods, such as rapid injections, that minimize distress and promote more positive vaccination experiences<span class="Apple-converted-space"> </span></p>
<p>• Physical: For infants 12 months and younger, oral solutions such as breastfeeding, bottle-feeding, sweet-tasting liquids, or pacifiers</p>
<p>• Pharmacological: Topical anesthetics at injection sites for all ages</p>
<p>• Psychological: Distraction techniques, such as toys and singing for infants, and music and digital distractions or toys and games for older children and adults<span class="Apple-converted-space"> </span></p>
<p>“Building on earlier work, the guideline provides new research-based tools and practical strategies to help health system leaders, health care providers, people receiving vaccines, and those supporting them improve the vaccination experience. The goal is to make vaccination a more positive experience, reduce fear, and help people feel more comfortable getting vaccines in the future,” says Dr. Taddio.<span class="Apple-converted-space"> </span></p>
<p>To help reduce vaccination distress, the guideline recommends choosing coping strategies before and/or during vaccination, framed around the CARD system (Comfort–Ask–Relax–Distract), an evidence-based tool developed by several of the authors.<span class="Apple-converted-space"> </span></p>
<p>With this updated guidance, the authors hope to lessen the stigma around needles and encourage vaccination.</p>
<p>“Since the COVID-19 pandemic, confidence in vaccines has declined, and vaccination rates have been low among both adults and children,” Dr. Taddio says. “This makes the updated guidance especially timely for vaccine providers and organizations looking to follow best practices to make vaccination a more positive experience for everyone.”</p>
<p>“Reducing distress during vaccine injections: 2026 clinical practice guideline update” was published September 21, 2026.</p>
<p>The post <a href="https://www.hospitalnews.com/guideline-to-reduce-vaccination-distress-offers-menu-of-options/">Guideline to reduce vaccination distress offers menu of options</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Arthritis carries a $142&#45;billion annual price tag in Canada</title>
<link>https://edusehat.com/en/arthritis-carries-a-142-billion-annual-price-tag-in-canada</link>
<guid>https://edusehat.com/en/arthritis-carries-a-142-billion-annual-price-tag-in-canada</guid>
<description><![CDATA[ Arthritis costs Canada an estimated $142.4 billion annually, according to a new report from Arthritis Society Canada that measures both the economic and human impact of the country’s most common chronic disease. The Economic and Social Burden of Arthritis in Canada Report, commissioned from the Canadian Centre for Economic Analysis (CANCEA), examines the current and […]
The post Arthritis carries a $142-billion annual price tag in Canada appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/09/ChatGPT-Image-Sep-30-2026-03_40_38-PM.png" length="49398" type="image/jpeg"/>
<pubDate>Thu, 01 Oct 2026 03:25:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Arthritis, carries, 142-billion, annual, price, tag, Canada</media:keywords>
<content:encoded><![CDATA[<p>Arthritis costs Canada an estimated $142.4 billion annually, according to a new report from Arthritis Society Canada that measures both the economic and human impact of the country’s most common chronic disease.</p>
<p>The Economic and Social Burden of Arthritis in Canada Report, commissioned from the Canadian Centre for Economic Analysis (CANCEA), examines the current and projected burden of arthritis from 2025 to 2055.</p>
<p>More than six million Canadians currently live with arthritis, a number projected to reach at least 10 million by 2055. Over the same period, the report estimates the total annual economic and social burden will climb to $222.3 billion.</p>
<p>The economic burden alone was estimated at $45.9 billion in 2025. Productivity losses accounted for $25.2 billion, including absenteeism, reduced effectiveness at work and early withdrawal from the workforce. Direct health-care costs contributed approximately $14.8 billion, while private disability costs added $5.9 billion.</p>
<p>The analysis also attempts to quantify the less visible effects of arthritis through what it calls “social value loss” – the dollar-equivalent loss of wellbeing associated with chronic pain, disability, reduced independence and participation, and lower life satisfaction.</p>
<p>That burden was estimated at $96.5 billion in 2025, more than twice the measured economic cost, and is projected to reach $151.1 billion annually by 2055. The report also found women experience twice the social burden associated with arthritis compared with men.</p>
<p>“Arthritis is an economic and social crisis, placing an enormous burden on our society,” said Trish Barbato, President and CEO of Arthritis Society Canada.</p>
<p>The organization is calling for greater investment in arthritis research, prevention and treatment, along with policies aimed at helping Canadians maintain independence, participate in the workforce and live with less pain as the prevalence of arthritis continues to grow.</p>
<p>The post <a href="https://www.hospitalnews.com/arthritis-carries-a-142-billion-annual-price-tag-in-canada/">Arthritis carries a $142-billion annual price tag in Canada</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Empowering harm&#45;reduction behaviour with drug checking</title>
<link>https://edusehat.com/en/empowering-harm-reduction-behaviour-with-drug-checking</link>
<guid>https://edusehat.com/en/empowering-harm-reduction-behaviour-with-drug-checking</guid>
<description><![CDATA[ HN Summary • Drug checking can change behaviour: A B.C. study found people who learned their drugs contained unexpected active substances were more likely to take harm-reduction steps, including disposing of the drugs, taking a smaller dose or avoiding using alone.  • Unexpected substances were common: Among 447 people surveyed, 39 per cent reported an […]
The post Empowering harm-reduction behaviour with drug checking appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/09/shutterstock_2247186669.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 01 Oct 2026 03:25:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Empowering, harm-reduction, behaviour, with, drug, checking</media:keywords>
<content:encoded><![CDATA[<p><strong>HN Summary</strong></p>
<p>• Drug checking can change behaviour: A B.C. study found people who learned their drugs contained unexpected active substances were more likely to take harm-reduction steps, including disposing of the drugs, taking a smaller dose or avoiding using alone.<span class="Apple-converted-space"> </span></p>
<p>• Unexpected substances were common: Among 447 people surveyed, 39 per cent reported an unexpected active substance in a tested sample, with opioids containing unexpected benzodiazepines identified as a key concern.<span class="Apple-converted-space"> </span></p>
<p>• A tool for individuals and health systems: Researchers say drug-checking services can help people make informed decisions while also generating valuable data that health authorities could use to monitor changes in the potency, composition and complexity of the unregulated drug supply.</p>
<hr>
<p>Seeing a list of the unexpected active substances in their drugs empowered individuals to take harm-reduction steps, according to a new study led by Vancouver Coastal Health Research Institute researcher Dr. Mint (Lianping) Ti. Of the hundreds of individuals surveyed who used a drug-checking service, many reported engaging in risk-reduction practices following receipt of their results, including disposing of unregulated drugs containing one or more substances they did not want to consume.<span class="Apple-converted-space"> </span></p>
<p>“This study has shown that drug-checking services can be an invaluable source of information for individuals using these services and potentially for health authorities overseeing care provision for populations affected by the toxic drug supply,” shares Ti.<span class="Apple-converted-space"> </span></p>
<p>Drug-checking services are places where individuals can have unregulated drugs — acquired outside of the health care system, research or pharmacies — tested before consumption. Some examples of unregulated drugs are opioids like heroin and stimulants like methamphetamines or cocaine.</p>
<p>Often co-located with harm-reduction centres, such as supervised consumption and overdose prevention sites, drug-checking services help individuals make informed decisions, including disposing of a drug.</p>
<p>“People who use drug-checking services are concerned about what else might be in their drugs and to what extent,” says Ti.<span class="Apple-converted-space"> </span></p>
<p>For example, unregulated opioids can contain the unregulated drug fentanyl, which can become toxic even at very low concentrations. Opioids containing benzodiazepines can also become dangerous, increasing the risk of overdose and preventable death.</p>
<p>The toxicity and unpredictability of the drug supply are some of the main factors contributing to high rates of opioid-related overdoses. In B.C., the unparalleled drug crisis is now a leading cause of death among adults aged 19 to 59.</p>
<h2>A harm-reduction tool<span class="Apple-converted-space"> </span>to address the toxic drug emergency</h2>
<p>Ti’s study was designed and implemented in collaboration with people with lived/living experience consuming unregulated drugs and using drug-checking services.<span class="Apple-converted-space"> </span></p>
<p>For their study, researchers reviewed surveys previously administered over the phone or in-person on the drug-checking service use of 447 individuals ages 14 or older. All individuals included in the study reported consuming unregulated drugs and making use of at least one of the drug-checking services in B.C. sometime within the six months prior to completing the survey. Of these, 174 individuals — around 39 per cent of respondents — reported having unexpected active drugs detected in their checked sample.<span class="Apple-converted-space"> </span></p>
<p>The top concerning unregulated drug combination was an opioid sample containing unexpected benzodiazepines. “There is a well-established risk of toxicity associated with combining opioids and benzodiazepines,” says Ti.<span class="Apple-converted-space"> </span></p>
<p>Among survey respondents with an unexpected active substance in their drugs, the most common risk-reduction practice taken was to dispose of the drug, followed by taking a smaller dose of the drug, giving it away, changing the method of use or not using it alone. In addition, around 24 per cent “reported engaging in a risk-reduction practice after their drug check, compared to 13.5 per cent of those whose test result showed no presence of unexpected active substances,” says Ti.<span class="Apple-converted-space"> </span></p>
<p>“It goes to show that people who receive information that their drugs are adulterated with something they do not expect are more likely to change how they consume it to potentially avoid related harms,” Ti states.<span class="Apple-converted-space"> </span></p>
<p>Ti adds tht their research findings support the continuation of funding and infrastructure for drug-checking services within a suite of other harm-reduction tools. These services are particularly important in rural and remote settings, where harm-reduction services are fewer and less accessible.</p>
<p>Data collected from drug-checking services may also be assets for health authorities, health administrators and decision-makers to address the presence of toxic drugs circulating in the unregulated drug supply.<span class="Apple-converted-space"> </span></p>
<p>“One of our future research directions is to link drug-checking data with health administrative data for monitoring changes in the drug supply with respect to things like drug potency, complexity and composition,” states Ti. “We hope that this data could provide timely insights on how the emergence of adulterants like benzodiazepines or medetomidine in the unregulated drug supply are impacting health outcomes and health services.”</p>
<p>The post <a href="https://www.hospitalnews.com/empowering-harm-reduction-behaviour-with-drug-checking/">Empowering harm-reduction behaviour with drug checking</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Opioid use disorder among Ontario seniors more than doubles in eight years</title>
<link>https://edusehat.com/en/opioid-use-disorder-among-ontario-seniors-more-than-doubles-in-eight-years</link>
<guid>https://edusehat.com/en/opioid-use-disorder-among-ontario-seniors-more-than-doubles-in-eight-years</guid>
<description><![CDATA[ HN Summary • Opioid use disorder is rising among older Ontarians: The number of adults aged 55 and older interacting with the health-care system for OUD more than doubled, from 7,116 in 2017 to 15,231 in 2025.  • Opioid toxicity deaths are a growing concern: More than 1,000 older adults died from opioid toxicity in […]
The post Opioid use disorder among Ontario seniors more than doubles in eight years appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/09/opioid.png" length="49398" type="image/jpeg"/>
<pubDate>Wed, 30 Sep 2026 23:50:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Opioid, use, disorder, among, Ontario, seniors, more, than, doubles, eight, years</media:keywords>
<content:encoded><![CDATA[<p><strong>HN Summary</strong></p>
<p>• Opioid use disorder is rising among older Ontarians: The number of adults aged 55 and older interacting with the health-care system for OUD more than doubled, from 7,116 in 2017 to 15,231 in 2025.<span class="Apple-converted-space"> </span></p>
<p>• Opioid toxicity deaths are a growing concern: More than 1,000 older adults died from opioid toxicity in 2023 and 2024, with fentanyl involved in 62 per cent of deaths in 2024. Most deaths occurred in private residences.<span class="Apple-converted-space"> </span></p>
<p>• Health services need to adapt: Many older adults who died had recent contact with health or home-care services but had not received OUD-related care, highlighting opportunities for earlier intervention and more age-sensitive harm reduction, treatment and social supports.</p>
<hr>
<p>The number of Ontarians aged 55 and older with healthcare interactions related to opioid use disorder (OUD) has more than doubled in Ontario between 2017 and 2025, according to a new report published by the Ontario Drug Policy Research Network (ODPRN), based at St. Michael’s Hospital. <span class="Apple-converted-space"> </span></p>
<p><strong>Key findings:<span class="Apple-converted-space"> </span></strong></p>
<p>• The number of older adults engaging with the healthcare system about OUD grew from 7,116 people in 2017 to 15,231 people in 2025. In contrast, the number of older adults with OUD living in Long-Term Care (LTC) remained low (<130) and stable over the same period.<span class="Apple-converted-space"> </span></p>
<p>• Use of opioid agonist treatment (OAT) more than tripled between 2013 and 2025, rising from 2,661 to 13,370 recipients.<span class="Apple-converted-space"> </span></p>
<p>• Opioid toxicity death rates increased substantially between 2013 and 2024, peaking during the COVID-19 pandemic — with over 1,000 older adults dying of an opioid toxicity between 2023-24 alone.<span class="Apple-converted-space"> </span></p>
<p>• The unregulated drug supply played a growing role in deaths, with fentanyl’s involvement in opioid toxicity deaths doubling from 31 per cent of deaths in 2017 to 62 per cent 2024.<span class="Apple-converted-space"> </span></p>
<p>• There were 1,087 opioid toxicity deaths among older adults in 2023 and 2024, the equivalent of at least one death every day. Of these, 985 deaths could be linked to other healthcare records.<span class="Apple-converted-space"> </span></p>
<p><strong>Among these deaths:<span class="Apple-converted-space"> </span></strong></p>
<p>• Nearly 75 per cent occurred among people aged 55 to 64.<span class="Apple-converted-space"> </span></p>
<p>• About 80 per cent occurred in a private residence, and only one in five occurred with someone present who could intervene.<span class="Apple-converted-space"> </span></p>
<p>• More than half lived with a pain condition in the years before they died.<span class="Apple-converted-space"> </span></p>
<p>• Only one-third involved prescribed opioids only, although this increased with age.<span class="Apple-converted-space"> </span></p>
<p>• A quarter had a healthcare visit in the week before death, and 1 in 4 had received home care in the year before death<span class="Apple-converted-space"> </span></p>
<h2>How they did it<span class="Apple-converted-space"> </span></h2>
<p>Tara Gomes, PhD and Bisola Hamzat, MSc authored the report in collaboration with community partners and people with lived experience, drawing on population-based health-care data from ICES. <span class="Apple-converted-space"> </span></p>
<p>They used several datasets from ICES to identify older adults with OUD and opioid related deaths, including hospital and home care databases, coroners’ death investigations, and pharmacy dispensing data. <span class="Apple-converted-space"> </span></p>
<h2>Why it matters <span class="Apple-converted-space"> </span></h2>
<p>As the population living with OUD ages, healthcare and social services need to be prepared to provide care that addresses the complex care needs of this population, expertise that the system may currently lack.<span class="Apple-converted-space"> </span></p>
<p>Only 38 per cent of older adults who died of an opioid toxicity had engaged with the healthcare system around OUD in the past five years, below the more than 50 per cent seen in the general provincial population. Despite this, 1 in 4 had some contact with the healthcare system in the week before death.<span class="Apple-converted-space"> </span></p>
<p>Hamzat says, “What stands out is how many of older adults weren’t in contact with the health system for opioid use disorder before they died. With many older adults disengaged from medical care for substance use, responses that integrate both harm reduction, treatment services, and social supports that are accessible for a population with age-related needs remain imperative”.<span class="Apple-converted-space"> </span></p>
<p>Despite rapidly growing OUD among older adults, very few people were in LTC, and this didn’t change over time. In contrast, home care services in the year before an opioid toxicity death were higher, suggesting more community-based support in this population. <span class="Apple-converted-space"> </span></p>
<p>“Older adults with opioid use disorder aren’t in long-term care, they’re at home, often relying on home care services right up until a fatal overdose.” Says Gomes. “However, these sectors are often under-equipped to provide the best possible care to this population. Both the long-term care and home care sectors need to build the staff expertise and flexible, accessible supports that consider mobility issues, transportation barriers, disability, and pain management needs to actually reach and adequately support this growing and often invisible population” <span class="Apple-converted-space"> </span></p>
<p>The report recommends stronger education and awareness for older adults, their doctors, caregivers and families on recognizing and discussing substance use and knowing how to respond to an opioid toxicity. <span class="Apple-converted-space"> </span></p>
<p>Gomes adds, “I hope this report helps start a broader discussion about how our healthcare system can better identify and support older adults at risk of drug-related harms at critical points in their care, through enhanced screening and stronger expertise in substance use care”<span class="Apple-converted-space"> </span></p>
<h2>What’s next<span class="Apple-converted-space"> </span></h2>
<p>The findings highlight the urgency for health and social service systems to prepare now for an older population with OUD that will keep growing. That means building tailored, age-sensitive programs and supports, using existing points of contact to identify risk earlier, and designing supports that are accessible to older adults.<span class="Apple-converted-space"> </span></p>
<p><a href="https://odprn.ca/research/publications/2026-09-substance-use-harms-among-older-adults"><b>Read the full report here.</b></a><b></b></p>
<h3>About the authors<b><span class="Apple-converted-space"> </span></b><b></b></h3>
<p>Tara Gomes, PhD, is a Canada Research Chair in Drug Policy Research and Evaluation and principal investigator of the ODPRN. She is an epidemiologist, a scientist at St. Michael’s Hospital and ICES, and a professor at the University of Toronto’s Leslie Dan Faculty of Pharmacy.<span class="Apple-converted-space"> </span></p>
<p>Bisola is a Senior Epidemiologist with the ODPRN based at St. Michael’s Hospital. She received a Master of Science in Epidemiology and Biostatistics from Western University and has completed a Bachelor of Medical Sciences with an Honours Specialization in Epidemiology and Biostatistics<span class="Apple-converted-space"> </span></p>
<p><strong><i>Story by Zehra Goawala</i></strong></p>
<p>The post <a href="https://www.hospitalnews.com/opioid-use-disorder-among-ontario-seniors-more-than-doubles-in-eight-years/">Opioid use disorder among Ontario seniors more than doubles in eight years</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Mind the gap: Ontario hospitals face antimicrobial stewardship resource challenges</title>
<link>https://edusehat.com/en/mind-the-gap-ontario-hospitals-face-antimicrobial-stewardship-resource-challenges</link>
<guid>https://edusehat.com/en/mind-the-gap-ontario-hospitals-face-antimicrobial-stewardship-resource-challenges</guid>
<description><![CDATA[ HN Summary • Stewardship programs are widespread: 96 per cent of responding Ontario hospitals reported having an antimicrobial stewardship program or plans to implement one, but resources vary considerably across the province.  • Staffing and funding remain major gaps: Only 63 per cent of programs had designated funding or resources, with smaller hospitals particularly affected. […]
The post Mind the gap: Ontario hospitals face antimicrobial stewardship resource challenges appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/09/ChatGPT-Image-Sep-29-2026-12_02_37-PM.png" length="49398" type="image/jpeg"/>
<pubDate>Wed, 30 Sep 2026 23:50:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Mind, the, gap:, Ontario, hospitals, face, antimicrobial, stewardship, resource, challenges</media:keywords>
<content:encoded><![CDATA[<p><strong>HN Summary</strong></p>
<p>• Stewardship programs are widespread: 96 per cent of responding Ontario hospitals reported having an antimicrobial stewardship program or plans to implement one, but resources vary considerably across the province.<span class="Apple-converted-space"> </span></p>
<p>• Staffing and funding remain major gaps: Only 63 per cent of programs had designated funding or resources, with smaller hospitals particularly affected. Staffing levels also fell below national recommendations.</p>
<p>• Data needs to drive action: While 75 per cent of hospitals tracked antimicrobial use, only 44 per cent routinely shared reports with prescribers, highlighting opportunities to strengthen stewardship and the fight against antimicrobial resistance.</p>
<hr>
<p>Antimicrobial resistance is one of the most persistent threats facing modern health care. As bacteria and other microorganisms become resistant to the drugs designed to treat them, infections become more difficult to manage and the effectiveness of some of medicine’s most important treatments is put at risk.</p>
<p>Inside hospitals, antimicrobial stewardship programs are one of the key lines of defence.</p>
<p>These programs work to ensure antibiotics and other antimicrobial medications are used appropriately — selecting the right treatment, dose and duration while reducing unnecessary use that can contribute to resistance.</p>
<p>Canadian hospitals have been required to have antimicrobial stewardship programs since 2013. But a new Ontario study suggests that simply having a program in place doesn’t necessarily mean hospitals have the resources required to maximize its impact.</p>
<p>Researchers from Public Health Ontario and several Ontario academic and health-care institutions examined antimicrobial stewardship program resources and practices across the province, revealing significant differences in funding, staffing and implementation — particularly between larger and smaller hospitals.</p>
<p>The study, Mind the gap: a cross-sectional study of antimicrobial stewardship program resources and practice in Ontario hospitals, was published in September in the journal Antimicrobial Stewardship & Healthcare Epidemiology.</p>
<p>Researchers surveyed Ontario inpatient hospitals between January and March 2026. Of 128 eligible hospitals, 93 responded, representing a 73 per cent response rate.</p>
<p>The good news is that antimicrobial stewardship is now firmly established in most Ontario hospitals.</p>
<p>Ninety-six per cent of responding hospitals reported having a formal antimicrobial stewardship program or being in the process of implementing one within the next 12 months.</p>
<p>But beneath that high adoption rate, researchers found substantial differences in the resources available to support the work.</p>
<h2>A funding divide</h2>
<p>Overall, just 63 per cent of antimicrobial stewardship programs reported having designated funding or resources.</p>
<p>The divide was particularly noticeable when researchers looked at hospital size.</p>
<p>Among teaching hospitals, 89 per cent reported designated funding, as did 95 per cent of large hospitals. That fell to 63 per cent among medium-sized hospitals and just 21 per cent among small hospitals.</p>
<p>Staffing levels also fell below national recommendations.</p>
<p>For teaching, large and medium hospitals, researchers found an average of 0.19 pharmacist full-time equivalents and 0.04 physician full-time equivalents dedicated to antimicrobial stewardship for every 100 beds.</p>
<p>National recommendations call for at least 0.3 pharmacist and 0.1 physician full-time equivalents per 100 beds.</p>
<p>Smaller hospitals and complex continuing care and rehabilitation facilities were also below recommended minimum staffing levels.</p>
<p>Lack of resources — particularly funding and staffing — was identified as a challenge by 72 per cent of responding organizations.</p>
<p>The findings point to an important issue for hospitals: antimicrobial stewardship increasingly involves much more than establishing policies around antibiotic prescribing. Effective programs require clinical expertise, monitoring, data analysis, feedback and ongoing quality improvement.</p>
<h2>Collecting data is only part of the equation</h2>
<p>The study also uncovered a gap between hospitals collecting information about antimicrobial use and getting that information into the hands of prescribers.</p>
<p>Three-quarters of responding hospitals tracked hospital-wide antimicrobial use.</p>
<p>However, only 44 per cent routinely distributed antimicrobial-use reports to prescribers.</p>
<p>That distinction matters because tracking antibiotic use is most valuable when the information can help clinicians identify prescribing patterns, compare performance and determine where practice could be improved.</p>
<p>Only 36 per cent of antimicrobial stewardship programs reported that goals related to improving antimicrobial stewardship practices or antimicrobial use were formally included in their organization’s strategic or quality improvement plan.</p>
<p>Researchers identified metrics and benchmarking as an area where some organizations hope to improve.</p>
<h2>Stewardship is evolving</h2>
<p>Despite the resource challenges, the study also found evidence that antimicrobial stewardship practices are evolving.</p>
<p>Among the most commonly reported strategies were the use of antibiograms, which help clinicians understand local patterns of antimicrobial susceptibility; programs that support switching appropriate patients from intravenous to oral antibiotics; prospective audit and feedback; and hospital-specific prescribing guidelines.</p>
<p>Eighty-four per cent of respondents reported using antibiograms, while 67 per cent had IV-to-oral conversion initiatives. Sixty-five per cent reported prospective audit and feedback programs and 62 per cent used facility-specific guidelines.</p>
<h2>Newer approaches are also gaining ground</h2>
<p>Nearly half of hospitals reported antimicrobial stewardship involvement in allergy assessment, while half were using clinical decision-support tools.</p>
<p>These initiatives can help clinicians make more informed prescribing decisions and address issues that can lead to unnecessary use of broad-spectrum antibiotics.</p>
<p>However, researchers found considerable variation in how some strategies were delivered. Prospective audit and feedback — in which antimicrobial use is reviewed and recommendations are provided to prescribers — differed in its scope, frequency and target patient populations. Uptake was generally lower and implementation more variable among smaller hospitals.</p>
<h2>Moving beyond<span class="Apple-converted-space"> </span>compliance</h2>
<p>The findings suggest Ontario has made significant progress in establishing antimicrobial stewardship across its hospitals. The next challenge may be ensuring those programs have the resources and organizational support required to move beyond meeting basic requirements.</p>
<p>The researchers concluded that Ontario hospital programs are advancing in areas including allergy assessment and clinical decision support, but persistent under-resourcing continues to limit their scope and potential impact, particularly in smaller organizations.</p>
<p>They suggest that stronger provincial data infrastructure and scaled or regional approaches to stewardship could help hospitals participate more effectively in the broader fight against antimicrobial resistance.</p>
<p>Additional investment will also be important if programs are expected to incorporate benchmarking, expand quality-improvement initiatives and keep pace with evolving stewardship standards.</p>
<p>The study has limitations. Participation was voluntary and the information was self-reported at the organizational level. The authors note that hospitals with more established and better-resourced programs may have been more likely to participate.</p>
<p>Still, with responses from nearly three-quarters of eligible hospitals, the findings provide a broad snapshot of antimicrobial stewardship in Ontario in 2026.</p>
<p>The picture that emerges is one of progress — but also unfinished work.</p>
<p>Most hospitals now have antimicrobial stewardship programs. Many are introducing increasingly sophisticated tools and strategies to improve prescribing. But the study suggests that the ability to put those strategies into practice remains heavily influenced by something much more fundamental: having enough people, funding and organizational support to do the work.</p>
<p>As antimicrobial resistance continues to challenge health systems, closing those gaps could determine how effectively hospital stewardship programs can help preserve the medications clinicians rely on to treat infection.</p>
<p>Source: This article is based on Mind the gap: a cross-sectional study of antimicrobial stewardship program resources and practice in Ontario hospitals by Valerie Leung, Sera Thomas, Kevin A. Brown, Nick Daneman, Kevin L. Schwartz and Bradley J. Langford, published online September 14, 2026 in Antimicrobial Stewardship & Healthcare Epidemiology, Volume 6, Issue 1, by Cambridge University Press on behalf of the Society for Healthcare Epidemiology of America.</p>
<p><a href="https://www.cambridge.org/core/journals/antimicrobial-stewardship-and-healthcare-epidemiology/article/mind-the-gap-a-crosssectional-study-of-antimicrobial-stewardship-program-resources-and-practice-in-ontario-hospitals/A9757C10F8BE41F429859A76A190C3AF"><b>Read the original study in Antimicrobial Stewardship & Healthcare Epidemiology</b></a></p>
<p>The post <a href="https://www.hospitalnews.com/mind-the-gap-ontario-hospitals-face-antimicrobial-stewardship-resource-challenges/">Mind the gap: Ontario hospitals face antimicrobial stewardship resource challenges</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Could bacteriophages be a new weapon against antibiotic resistance?</title>
<link>https://edusehat.com/en/could-bacteriophages-be-a-new-weapon-against-antibiotic-resistance</link>
<guid>https://edusehat.com/en/could-bacteriophages-be-a-new-weapon-against-antibiotic-resistance</guid>
<description><![CDATA[ HN Summary • A potential weapon against superbugs: Bacteriophages are viruses that precisely target and destroy specific bacteria, offering a potential treatment option as antimicrobial resistance makes some infections increasingly difficult to treat.  • From last resort to clinical treatment: Unity Health Toronto researchers Dr. Gregory German and Dr. Steffanie Strathdee are helping advance phage […]
The post Could bacteriophages be a new weapon against antibiotic resistance? appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/09/shutterstock_2548677571.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 30 Sep 2026 23:50:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Could, bacteriophages, new, weapon, against, antibiotic, resistance</media:keywords>
<content:encoded><![CDATA[<p><strong>HN Summary</strong></p>
<p>• A potential weapon against superbugs: Bacteriophages are viruses that precisely target and destroy specific bacteria, offering a potential treatment option as antimicrobial resistance makes some infections increasingly difficult to treat.<span class="Apple-converted-space"> </span></p>
<p>• From last resort to clinical treatment: Unity Health Toronto researchers Dr. Gregory German and Dr. Steffanie Strathdee are helping advance phage therapy, which currently requires matching individual bacterial infections with suitable phages and remains difficult to access in Canada.</p>
<p>• Working alongside antibiotics: Researchers don’t expect phages to replace antibiotics. Instead, phage therapy could help treat resistant infections, reduce unnecessary antibiotic use and potentially make some bacteria susceptible to antibiotics again.</p>
<hr>
<p>Bacteriophages (phages) are all around us. They live in the soil, the oceans, even our gut. Roughly translating from Greek to mean “bacteria eater,” these tiny viruses have been used throughout history to combat bacterial infections, and are now being looked to as a secret weapon against antimicrobial resistance, which kills an estimated 1.27 million people a year.<span class="Apple-converted-space"> </span></p>
<p>Two of the leading minds in this race to harness the power of bacteriophages are at Unity Health Toronto: Dr. Gregory German, a Medical Microbiologist at St. Joseph’s Health Centre and Dr. Steffanie Strathdee, current Arthur Slutsky Scholar-in-Residence at Unity Health Toronto and Harold Simon Distinguished Professor in the University of California San Diego (UCSD) Department of Medicine.</p>
<p>They, like other researchers in this growing field, know that phage therapy could have a revolutionary impact not just on human health, but many other fields including veterinary medicine, agriculture, aquaculture, mining, and even prophylactic applications to prevent<span class="Apple-converted-space">  </span>outbreaks of bacterial infections in settings where there is armed conflict or environmental disasters. There is even scientific literature on the promise of phage therapy in war zones, where they could be used as a counter-measure or prophylactic agent to biological terrorism.<span class="Apple-converted-space"> </span></p>
<p>“People underappreciate how fundamental phages are to our world,” says German. “They are like nanobot police officers, going to the site of infection, setting up shop, and doing the work.”</p>
<p>An epidemiologist trained at U of T, Strathdee spent her career studying infectious diseases, particularly HIV, and crossing paths with patients and advocates whose activism reshaped access to life-saving treatments.</p>
<p>When Strathdee’s husband became critically ill with a drug-resistant bacterial infection, she found herself on the other end of the work she’d dedicated her career to.</p>
<p>“All of a sudden, I wasn’t the researcher anymore,” she says. “I was the caregiver. And I had to become the advocate.”</p>
<p>As the antibiotics being used to treat her husband failed, Strathdee remembered something she’d learned as an undergraduate student at the University of Toronto: bacteriophage.</p>
<p>While phage therapy has maintained its prominence in Eastern Europe, it largely fell out of use in Western medicine with the advent of antibiotics in the early 20th century, meaning it is not readily accessible in North America.<span class="Apple-converted-space"> </span></p>
<p>Strathdee reached out to researchers she had never met before, and managed to build a team willing to work together across borders, institutions and regulatory systems to help her husband. The phage treatment, which ultimately saved his life, was administered through a compassionate-use pathway in the U.S., which allows patients who have exhausted all other options to access experimental or last-resort treatments.</p>
<p>Recognizing the importance of sharing her learnings and experience, Strathdee authored a book called The Perfect Predator that recounts not only her family’s story, but also the history of phage therapy.</p>
<p>Strathdee, who Co-Directors UCSD’s Center for Innovative Phage Applications and Therapeutics (IPATH), now regularly hears from patients and family members around the world who are running out of standard treatment options and need help being connected to providers of phage therapy.<span class="Apple-converted-space"> </span></p>
<p>“I got to save my husband’s life,” she reflects. “But now I’m part of a movement.”</p>
<h2>A nightmare on top of a nightmare</h2>
<p>Antimicrobial resistance (AMR) is what Dr. Gregory German describes as a “nightmare on top of a nightmare.”</p>
<p>Projections by the Council of Canadian Academies show that if resistance to first-line antibiotics rises from 25 per cent in 2018 to 40 per cent in 2050, 13,700 people could die annually in Canada. Estimates from the Public Health Agency of Canada show that 1 resistant bacterial infection is detected for every 220 patients admitted to acute-care hospitals.</p>
<p>Despite these troubling trends, public awareness of the issue remains quite low.</p>
<p>“You don’t really notice it unless it affects your own life,” Strathdee says. “If I was blindsided as an epidemiologist, then the average person doesn’t stand a chance.”</p>
<p>Widespread antibiotic use, military conflict, international travel, and increasingly complex medical care like cancer therapies, transplants and joint replacements, have fueled AMR.</p>
<p>Phages are precise in their work. Each one targets specific bacteria and attaches to the bacterial cell before injecting it with genetic material to destroy it from within.</p>
<p>But phage therapy isn’t as simple as hooking a patient up to an IV and administering a medication.</p>
<p>Before a patient can receive phage therapy, their team has to isolate the bacteria causing their infection, and then a lab has to identify the right kind of phage for treatment. This isn’t a straightforward process. Some phages are less aggressive than others, and what researchers and clinicians are looking for is a phage that is ready for a fight – fondly referred to as a “rage phage” – but also safe enough and well-matched to the specific infection.</p>
<p>In the case of Strathdee’s husband, the perfect phage was sourced from human waste. This practice, of hunting for phages in sewage systems, is common for researchers, but it means that the process of cleaning, purifying and amplifying the phages adds hours and days to the patient’s treatment timeline and requires the work of specialized labs.</p>
<p>In Canada, most university and hospital labs aren’t designed for phage manufacturing, and regulatory approval for emergency use is extremely rigorous.</p>
<p>German has successfully treated patients with phage therapy, including one patient whose chronic urinary tract infection (UTI) had evaded antibiotics for years. He led a Canadian-first trial to study the use of phage therapy on these kinds of chronic infections.</p>
<p>Between 1995 and 2023, phages were administered in roughly 1,400 documented cases worldwide, with success rates around 80 per cent. But in Canada, only a handful of cases have been treated, prompting some patients to travel to other countries for treatment.</p>
<h2>Building a pathway forward</h2>
<p>In 2023, German co-founded Phage Canada, a non-profit organization to support and advance phage research and phage therapy across medical, environmental, and agricultural sectors. His hope is that in the next five to ten years there will be increased funding for phage research to support more clinical trials, national registries and networks to turn what is currently a last-resort, experimental option into a regulated, accessible treatment.</p>
<p>“If we can treat something like recurrent UTIs without using harsh antibiotics,” he says, “we preserve those antibiotics for when we really need them. That diffuses the pressure driving resistance.”</p>
<p>Neither German nor Strathdee envision a world where phages completely replace antibiotics, and one of the aspects they are most excited about is the fact that phages might actually be a tool for pulling antibiotics back from the brink of obsolescence.</p>
<p>When Strathdee’s husband was treated with phages and antibiotics simultaneously, the bacteria that had been wreaking havoc on his body were forced to make a genetic decision to try to evade their attackers. She describes it as the bacteria “taking off their outer layer like a coat” to escape the phages that were trying to attach and enter a receptor on its surface. This left the bacteria vulnerable to antibiotics which would otherwise not have worked.</p>
<p>But for now, the focus is on medicine and on patients who need urgent help.</p>
<p>“In ten years,” Strathdee says, “I see phage therapy used alongside antibiotics as standard of care.”</p>
<p><i>By Olivia Lavery</i></p>
<p>The post <a href="https://www.hospitalnews.com/could-bacteriophages-be-a-new-weapon-against-antibiotic-resistance/">Could bacteriophages be a new weapon against antibiotic resistance?</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Caring should never come with a threat</title>
<link>https://edusehat.com/en/caring-should-never-come-with-a-threat</link>
<guid>https://edusehat.com/en/caring-should-never-come-with-a-threat</guid>
<description><![CDATA[ Bill S-233 would send an overdue message to Canada’s healthcare workers: violence is not part of the job. A healthcare worker’s shift should end when they leave the hospital. For some, the fear does not. As one HealthCareCAN member told us, healthcare workers live alongside the patients and families they serve, without the anonymity available […]
The post Caring should never come with a threat appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/09/CEO.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 30 Sep 2026 23:50:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Caring, should, never, come, with, threat</media:keywords>
<content:encoded><![CDATA[<p>Bill S-233 would send an overdue message to Canada’s healthcare workers: violence is not part of the job.</p>
<p>A healthcare worker’s shift should end when they leave the hospital. For some, the fear does not.</p>
<p>As one HealthCareCAN member told us, healthcare workers live alongside the patients and families they serve, without the anonymity available in a large urban centre. When a worker is personally threatened, that threat can follow them beyond the hospital doors and into their homes, families and daily lives.</p>
<p>This is the reality behind the rise in workplace violence across Canada’s healthcare system.</p>
<p>Healthcare workers are estimated to experience workplace violence at four times the rate of any other profession. They are being threatened, harassed and assaulted while providing essential and lifesaving care. Yet a rooted culture continues to tell them that violence is simply “part of the job”.<span class="Apple-converted-space"> </span></p>
<h3>It is not. And accepting it comes at an enormous cost.<span class="Apple-converted-space"> </span></h3>
<p>Violence can cause physical injury, but its effects often last longer. Healthcare workers who experience violence report anxiety, depression, disrupted sleep, symptoms of post-traumatic stress, burnout and moral distress. It can erode their confidence, engagement and sense of safety at work.</p>
<p>For a health system already struggling to recruit and retain enough people, the consequences are serious. Violence contributes to absenteeism, disability claims and workforce departures. It also compromises patient safety. Workers cannot provide the safest, highest-quality care when they are exhausted, traumatized or afraid.</p>
<p>One HealthCareCAN member recorded 837 workplace-violence incidents in 2025–26. Incidents were most prevalent in emergency departments, mental health and addictions services, medicine, care of older adults and long-term care.</p>
<p>Behind every one of those incidents is a person who came to work to care for someone and faced harm instead.</p>
<p>HealthCareCAN, the national voice of hospitals, health authorities, health research institutes and healthcare organizations, recently surveyed members of its Health Human Resources Advisory Committee to better understand the violence occurring in healthcare workplaces and what organizations are doing in response.</p>
<p>More than 90 per cent of respondents have introduced de-escalation training and education and Code White procedures. Several have security guards stationed in emergency departments, while others have implemented panic alarms with geolocation, patient-flagging processes, centralized incident-reporting systems and behavioural emergency response teams.</p>
<h3>These efforts matter. But our members are clear: they are not enough.</h3>
<p>“Despite significant organizational investment in violence-prevention and response training, alerts and technology, many healthcare workers continue to work in fear for their safety,” one member told us. “This has a serious impact on staff engagement, retention and attendance and ultimately, on the care that patients and communities receive.”</p>
<p>St. Joseph’s Healthcare Hamilton has brought important public attention to this reality through a campaign featuring its own staff and their experiences of workplace violence. A photo exhibit displayed across its hospital campuses makes the human consequences impossible to dismiss. The hospital reported a 30 percent increase in violence in the last year.<span class="Apple-converted-space"> </span></p>
<p>Healthcare organizations must continue strengthening prevention, training, reporting and support. We must also recognize the complex health and social conditions that can contribute to violent situations and ensure patients experiencing illness or crisis continue to receive compassionate care.</p>
<h3>Compassion, however, cannot mean accepting violence.</h3>
<p>That is why HealthCareCAN supports Bill S-233. The legislation would amend the Criminal Code to require courts to consider an assault against someone providing health or personal care services as an aggravating factor at sentencing.</p>
<p>Its predecessor, Bill C-321, received unanimous support in the House of Commons before dying when Parliament was prorogued. Bill S-233 now gives parliamentarians another opportunity to finish the work.</p>
<p>Passing it will not prevent every incident, nor will legislation replace the responsibility of healthcare organizations to provide safe workplaces. It will, however, provide explicit recognition that violence against people delivering care is a serious offence with consequences.</p>
<p>Workers must also feel safe reporting every incident. What remains unreported remains too easily unseen and what remains unseen is too easily normalized.</p>
<p>There is no healthcare system without the people who care for Canadians. Parliament should pass Bill S-233 and affirm that caring for others should never require sacrificing one’s own safety.<span class="Apple-converted-space"> </span></p>
<p>The post <a href="https://www.hospitalnews.com/caring-should-never-come-with-a-threat/">Caring should never come with a threat</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>A new avenue for bipolar depression</title>
<link>https://edusehat.com/en/a-new-avenue-for-bipolar-depression</link>
<guid>https://edusehat.com/en/a-new-avenue-for-bipolar-depression</guid>
<description><![CDATA[ HN Summary • Promising new treatment: A UHN-led randomized clinical trial found that repeated ketamine infusions significantly reduced symptoms in adults with treatment-resistant bipolar depression. • Meaningful response: More than one-third of participants receiving ketamine experienced a clinical response, compared with about 12 per cent in the comparison group, with benefits lasting approximately one week […]
The post A new avenue for bipolar depression appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/09/Bipolar.png" length="49398" type="image/jpeg"/>
<pubDate>Wed, 30 Sep 2026 23:50:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>new, avenue, for, bipolar, depression</media:keywords>
<content:encoded><![CDATA[<p><strong>HN Summary</strong></p>
<p>• Promising new treatment: A UHN-led randomized clinical trial found that repeated ketamine infusions significantly reduced symptoms in adults with treatment-resistant bipolar depression.</p>
<p>• Meaningful response: More than one-third of participants receiving ketamine experienced a clinical response, compared with about 12 per cent in the comparison group, with benefits lasting approximately one week after treatment.<span class="Apple-converted-space"> </span></p>
<p>• Encouraging safety findings: Researchers observed no cases of mania, hypomania or psychosis. Larger and longer studies are still needed, but the findings support ketamine as a potential additional treatment option for difficult-to-treat bipolar depression.</p>
<hr>
<p>For many people living with bipolar depression, standard treatments do not provide enough relief. Even after trying multiple medications, symptoms can persist, disrupting work, relationships, and daily life. New treatment options are urgently needed.<span class="Apple-converted-space"> </span></p>
<p>Researchers led by Dr. Joshua Rosenblat at UHN’s Krembil Brain Institute, Ontario Shores Centre for Mental Health Sciences, and the University of Toronto have found that ketamine may help fill that gap. In a randomized clinical trial published in JAMA Psychiatry, the team found that repeated ketamine infusions significantly reduced symptoms in adults with treatment-resistant bipolar depression.<span class="Apple-converted-space"> </span></p>
<p>While ketamine has been studied extensively in major depressive disorders, evidence in bipolar depression has remained limited. Previous randomized trials in bipolar disorder examined only a single infusion. This study is the first randomized controlled trial to evaluate a short course of repeated ketamine infusions for treatment-resistant bipolar depression. <span class="Apple-converted-space"> </span></p>
<p>The trial enrolled 68 adults with bipolar I or II disorder who were experiencing a moderate to severe depressive episode despite at least two previous treatment attempts. Participants received four intravenous infusions over two weeks, either ketamine or midazolam, a sedative used as an active comparison treatment. They continued taking their prescribed mood stabilizers or antipsychotic medications throughout the study. <span class="Apple-converted-space"> </span></p>
<p>By the end of treatment, participants who received ketamine had significantly lower depression scores than those who received midazolam. More than one-third of participants in the ketamine group met the study’s definition of a clinical response, compared with about 12 per cent of those in the comparison group. The benefits continued for approximately one week after the final infusion. <span class="Apple-converted-space"> </span></p>
<p>The study also addressed a challenge that has complicated earlier ketamine research. Because ketamine can produce noticeable short-term effects, participants may be able to guess which treatment they received. To help maintain blinding, the researchers used midazolam as an active placebo. Participants identified their treatment assignment only about half the time after the first infusion, suggesting treatment expectations were unlikely to explain the findings. <span class="Apple-converted-space"> </span></p>
<p>Equally important were the safety results. Researchers observed no cases of mania, hypomania, or psychosis in either treatment group; concerns that have often limited the use and study of ketamine in people with bipolar disorder. <span class="Apple-converted-space"> </span></p>
<p>“Currently available treatments are often ineffective for treatment-resistant bipolar depression, with new treatments urgently needed,” says Dr. Rosenblat. “The present trial supports the antidepressant efficacy, safety, and tolerability of serial ketamine infusions for treatment-resistant bipolar depression.” <span class="Apple-converted-space"> </span></p>
<p>The researchers note that larger studies with longer follow-ups are still needed. However, the findings provide important evidence that ketamine could become an additional treatment option for people living with one of the most difficult-to-treat forms of depression. <span class="Apple-converted-space"> </span></p>
<p>Dr. Joshua Rosenblat is a Clinician Investigator in the Poul Hansen Family Centre for Depression, UHN’s Krembil Brain Institute and Centre for Mental Health, and an Associate Professor in the Department of Psychiatry and the Department of Pharmacology and Toxicology at the University of Toronto. <span class="Apple-converted-space"> </span></p>
<p>Co-first authors of the study are Diana K. Orsini and Sara Di Luch. The study was conducted by researchers at UHN and Ontario Shores Centre for Mental Health Sciences. <span class="Apple-converted-space"> </span></p>
<p>This research was supported by the Canadian Institutes of Health Research and UHN Foundation.<span class="Apple-converted-space"> </span></p>
<p>The post <a href="https://www.hospitalnews.com/a-new-avenue-for-bipolar-depression/">A new avenue for bipolar depression</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>AI models forecast operating room demand for unpredictable trauma cases</title>
<link>https://edusehat.com/en/ai-models-forecast-operating-room-demand-for-unpredictable-trauma-cases</link>
<guid>https://edusehat.com/en/ai-models-forecast-operating-room-demand-for-unpredictable-trauma-cases</guid>
<description><![CDATA[ Researchers at Sunnybrook Health Sciences Centre have developed an artificial intelligence (AI) framework capable of accurately predicting daily emergency surgical workloads, offering hospital administrators a data-driven tool to optimize operating room (OR) scheduling and reduce patient wait times. “Trauma centres regularly struggle with unpredictable surgical volumes driven by shifts in weather, day of the week, […]
The post AI models forecast operating room demand for unpredictable trauma cases appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/09/Sunnybrook-e1790783749420.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 30 Sep 2026 23:50:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>models, forecast, operating, room, demand, for, unpredictable, trauma, cases</media:keywords>
<content:encoded><![CDATA[<p>Researchers at Sunnybrook Health Sciences Centre have developed an artificial intelligence (AI) framework capable of accurately predicting daily emergency surgical workloads, offering hospital administrators a data-driven tool to optimize operating room (OR) scheduling and reduce patient wait times.</p>
<p>“Trauma centres regularly struggle with unpredictable surgical volumes driven by shifts in weather, day of the week, and regional activity, but the findings of our study show our AI model substantially outperformed current scheduling tools by predicting total daily surgical hours within a margin of error under two hours,” says Dr. Aazad Abbas, lead author of the study and an orthopaedic surgery resident with Sunnybrook’s Holland Bone & Joint Program and with the Department of Surgery and Institute of Biomedical Engineering at University of Toronto’s Temerty Faculty of Medicine.</p>
<p>Traditionally, hospitals rely on simple historical averages or rough estimates based on daily patient admissions to plan OR availability, but these conventional approaches only correctly predict whether daily demand will exceed a day’s surgical block only about half the time; “a rate no better than flipping a coin,” say the study authors.</p>
<p>Published in The Journal of Bone & Joint Surgery, the study analyzed 9,637 orthopaedic trauma procedures performed between 2012 and 2023.<span class="Apple-converted-space"> </span></p>
<h3>Researchers combined historical surgical records with real-world variables, including:</h3>
<p>• Environmental data: local weather, daily temperature shifts, and icy conditions;</p>
<p>• Temporal patterns: day of the week, seasonality, and proximity to holidays, and</p>
<p>• System operations: regional population statistics, air ambulance arrivals, and daily patient admission counts.</p>
<p>By processing these inputs through advanced machine learning and time-series models, the study’s AI model predicted total daily surgical hours within the margin of error under two hours.</p>
<p>The top-performing machine learning models correctly predicted whether daily surgical demand would exceed standard seven or eight-hour OR block thresholds more than 85 per cent of the time, significantly beating seven-day, 14-day and 30-day rolling averages, which failed to account for sudden spikes or seasonal shifts. Thursdays were found to be the busiest days for orthopaedic trauma surgeries, while summer recorded the highest seasonal workload, averaging over nine hours of daily operative time.</p>
<p>“By forecasting surgical volume hours or months in advance, hospital leaders can transition from fixed scheduling to dynamic resource allocation,” says Dr. Cari Whyne, senior author of the study and Program Director of the Holland Bone & Joint Research Program at Sunnybrook Research Institute. “On anticipated high-volume days, administrators can pre-emptively open overflow trauma rooms or convert elective surgical spaces. Conversely, during low-demand periods, staffing levels can be adjusted without risking surgical delays.”</p>
<p>While the study was conducted at a single Level-I trauma centre, the authors emphasize that the framework can be calibrated using local weather, population, and referral data at hospitals worldwide.</p>
<p>The post <a href="https://www.hospitalnews.com/ai-models-forecast-operating-room-demand-for-unpredictable-trauma-cases/">AI models forecast operating room demand for unpredictable trauma cases</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>A better way to  heal diabetic foot ulcers</title>
<link>https://edusehat.com/en/a-better-way-to-heal-diabetic-foot-ulcers</link>
<guid>https://edusehat.com/en/a-better-way-to-heal-diabetic-foot-ulcers</guid>
<description><![CDATA[ Community wound clinics are seeing faster healing, fewer visits and the potential to prevent amputations through total contact casting. For people living with diabetic foot ulcers, a wound that refuses to heal can have life-changing consequences. Treatment can stretch over months, limiting mobility and independence while increasing the risk of infection and, in serious cases, lower-limb […]
The post A better way to  heal diabetic foot ulcers appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/09/shutterstock_1462508231.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 30 Sep 2026 23:50:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>better, way, heal, diabetic, foot, ulcers</media:keywords>
<content:encoded><![CDATA[<p>Community wound clinics are seeing faster healing, fewer visits and<span class="Apple-converted-space"> </span>the potential to prevent amputations through total contact casting.</p>
<p>For people living with diabetic foot ulcers, a wound that refuses to heal can have life-changing consequences. Treatment can stretch over months, limiting mobility and independence while increasing the risk of infection and, in serious cases, lower-limb amputation.</p>
<p>A wound-care initiative in Western Canada is demonstrating how an evidence-based treatment known as total contact casting (TCC) can dramatically change that trajectory.</p>
<p>Total contact casting is considered the gold standard for offloading neuropathic plantar diabetic foot ulcers. By distributing pressure away from the wound and limiting repetitive trauma during walking, the cast gives the ulcer an opportunity to heal.</p>
<p>Despite strong clinical guidelines supporting TCC, its use remains inconsistent. Lack of training, concerns about patient safety and clinic workflow, resource limitations and uncertainty about how to introduce casting into existing wound-care programs can all stand in the way.</p>
<p>A Health Authority’s Wound Care Strategy Team set out to change that by developing a practical model for bringing TCC into community clinics.</p>
<p>The need was significant. Approximately 12,000 clients receive community wound care within the Health Authority each year, with diabetic foot ulcers accounting for roughly one-third of complex chronic wounds. These ulcers contribute to more than 100 amputations annually.</p>
<p>Before the initiative, average healing time for diabetic foot ulcers was 162 days and the healing rate was 46 per cent. The organization had also experienced a 16 per cent increase in diabetic foot ulcers alongside declining healing rates.</p>
<h2>From evidence to everyday practice</h2>
<p>The initiative began at three community ambulatory clinics representing different settings and levels of experience with diabetic foot offloading.</p>
<p>Rather than simply introducing a new clinical technique, the team focused on building the infrastructure needed to make TCC sustainable.</p>
<p>Clinical champions were identified, leadership support and funding were secured, standardized protocols and patient-selection criteria were established, and nurses received both theoretical and hands-on training.</p>
<p>Clinics were provided with approximately $10,000 in start-up funding for equipment and initial supplies. Nurses specializing in wound, ostomy and continence care received education in offloading, diabetic foot ulcer management and TCC application and removal, followed by supervised hands-on practice.</p>
<p>Most required about two weeks of practice – approximately eight cast changes – before feeling confident performing the procedure independently.</p>
<p>Clinics also adapted their schedules to accommodate casting. Initial casts were generally applied early in the week, followed by reassessment within 48 to 72 hours. Subsequent casts were typically changed every five to seven days.</p>
<p>The average course of TCC therapy lasted just 36 days.</p>
<h2>Healing faster</h2>
<p>The results were striking.</p>
<p>Across the three demonstration sites, 71 per cent of wounds treated with TCC healed, compared with 38 per cent of wounds receiving standard care – an absolute difference of 33 percentage points.</p>
<p>The improvement wasn’t limited to healing rates.</p>
<p>Among wounds that ultimately healed, clients had received an average of 188 days of treatment before TCC was initiated. Once casting began, average healing time was 36 days.</p>
<p>The faster healing also translated into fewer health-care encounters. Clients receiving standard care at the demonstration sites required an average of 20 nursing assessments, compared with 11 for clients treated with TCC.</p>
<p>For a health system facing workforce pressures and increasing demand for community care, reducing the number of visits required to heal a chronic wound can free nursing capacity for other patients.</p>
<p>There are potential benefits beyond the clinic as well. Cost modelling suggested faster healing reduced cumulative treatment costs, while fewer clinic visits were projected to reduce travel-related carbon emissions.</p>
<p>Most importantly, better wound healing could help prevent some of the most devastating consequences of diabetic foot disease.</p>
<p>Modelling based on the program’s findings suggests that broader implementation of TCC among appropriate patients could reduce amputations and associated mortality.</p>
<h2>More than healing a wound</h2>
<p>Clinicians also saw changes that weren’t captured in the formal study outcomes.</p>
<p>One client had been attending a wound clinic twice weekly for approximately 15 months, accumulating more than 240 visits with little improvement. After starting total contact casting, the client’s foot pain resolved within two days and the wound subsequently healed.</p>
<p>Another client who had relied on a walker because of the severity of an ulcer regained the ability to walk independently following successful wound closure.</p>
<p>Staff reported benefits too. Nurses described the satisfaction of seeing chronic wounds finally heal after months of ongoing treatment – an important consideration at a time when health-care organizations continue to grapple with workforce burnout.</p>
<p>The experience also reinforced that healing the ulcer is not the end of treatment. Some patients experienced recurrence after leaving the cast, prompting the team to strengthen the transition to removable offloading boots, customized insoles and appropriate footwear.</p>
<p>The initiative demonstrates that closing the gap between clinical evidence and everyday practice requires more than simply recommending a treatment. It requires leadership, training, standardized protocols, appropriate patient selection and ongoing measurement.</p>
<p>For community wound-care programs considering total contact casting, the experience provides a practical roadmap – and evidence that relatively modest investments in training and infrastructure can translate into meaningful improvements for patients.</p>
<p>For people living with diabetic foot ulcers, those improvements can mean far more than a healed wound. They can mean fewer months in treatment, greater mobility and independence, and potentially avoiding the loss of a limb.</p>
<p><i>By Christina E. Hagne, MN RN NSWOC WOCC(C), Jeff Wang, RN NSWOC, and Nicholas Salterio, M.Sc.</i></p>
<p>The post <a href="https://www.hospitalnews.com/a-better-way-to-heal-diabetic-foot-ulcers/">A better way to  heal diabetic foot ulcers</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>B.C. can’t recruit its way out of a health care staffing shortage</title>
<link>https://edusehat.com/en/bc-cant-recruit-its-way-out-of-a-health-care-staffing-shortage</link>
<guid>https://edusehat.com/en/bc-cant-recruit-its-way-out-of-a-health-care-staffing-shortage</guid>
<description><![CDATA[ B.C. is investing billions of dollars to increase health care capacity and recruit more health-care workers. But we cannot recruit our way out of a staffing shortage if experienced workers continue to be sidelined by workplace injuries. In 2025, workers in long-term care and home and community health lost more than 106,000 workdays to injury. […]
The post B.C. can’t recruit its way out of a health care staffing shortage appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/09/ChatGPT-Image-Sep-30-2026-11_34_03-AM.png" length="49398" type="image/jpeg"/>
<pubDate>Wed, 30 Sep 2026 23:50:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>B.C., can’t, recruit, its, way, out, health, care, staffing, shortage</media:keywords>
<content:encoded><![CDATA[<p>B.C. is investing billions of dollars to increase health care capacity and recruit more health-care workers. But we cannot recruit our way out of a staffing shortage if experienced workers continue to be sidelined by workplace injuries.</p>
<p>In 2025, workers in long-term care and home and community health lost more than 106,000 workdays to injury. In a system already being asked to care for a growing and aging population, those lost days represent capacity B.C. cannot afford to lose.<span class="Apple-converted-space"> </span></p>
<p>Care is built on familiarity. Its foundation relies on a worker knowing how to approach someone who’s anxious, when to slow down, when a small change in behaviour means something is wrong, or how to support someone safely through a difficult moment. That knowledge is developed through time, trust and experience.<span class="Apple-converted-space"> </span></p>
<p>When a caregiver is injured and away from work, that experience is suddenly missing from the team. For the worker, the impact is personal. For the people they care for, it can mean a disruption in routine, familiarity and trust. For coworkers, that translates to another shift to cover, a heavier workload or less time to recover before coming back the next day.<span class="Apple-converted-space"> </span></p>
<p>There is encouraging news in the 2025 data. Injury rates fell 15 per cent in long-term care and 19 per cent in home and community health. These improvements demonstrate that progress is possible when employers, workers and prevention partners make safety a shared priority. Look a little closer, though, and the picture becomes more complicated.<span class="Apple-converted-space"> </span></p>
<p>Long-term care workers lost more than 94,000 workdays to injury, slightly more than the year before. In home and community health, serious injuries made up a greater share of injuries than they did in 2024. The numbers can improve, and serious injuries can still leave a lasting mark on workers, teams and the care around them. The numbers also point us toward some of the pressures that have yet to ease.<span class="Apple-converted-space"> </span></p>
<p>Overexertion remained the leading cause of claims in both sectors, while violence continued to account for a significant share of injuries. These are not abstract risks. They affect whether workers can remain in the jobs for which they have developed valuable skills, knowledge and relationships.<span class="Apple-converted-space"> </span></p>
<p>For employers, that’s where the conversation needs to go next. Beyond whether the rate rose or fell, and into where people are still being hurt. The provincial picture will not be reflected equally in every workplace. An employer may see an improving overall rate while serious injuries remain concentrated in a particular task, location or team.<span class="Apple-converted-space"> </span></p>
<p>Looking at injury type, severity, time away from work and recurring patterns can show where progress is taking hold and where attention is still needed. Workers are essential to the analysis. They see where a task has become safer, where a workaround has quietly become routine, where staffing pressures are creating strain and where a change in equipment, training or process has genuinely helped. Employers have the most immediate responsibility to act on the risks within their workplaces, but this is not solely an employer issue.<span class="Apple-converted-space"> </span></p>
<p>Government, funders and healthsystem planners should recognize injury prevention as part of B.C.’s workforce strategy. Decisions about recruitment, service expansion, new models of care and new facilities must consider how workers will be kept safe once they are on the job.</p>
<p>B.C. will need more care in the years ahead, not less. Recruiting more workers will be essential, but recruitment alone will not create a sustainable workforce. We must also reduce the injuries that remove experienced people from the workplace and make it harder for their colleagues to continue. Employers can begin by listening to workers, investigating incidents and near misses, and using available prevention resources to address recurring risks.<span class="Apple-converted-space"> </span></p>
<p>At a system level, injury prevention must be treated as an investment in retention, capacity and quality of care. We cannot build health-care capacity while treating the loss of experienced workers to injury as a separate issue. Every worker B.C. can keep healthy, safe and providing care is capacity we do not have to rebuild.</p>
<p><strong><em>By Saleema Dhalla</em></strong></p>
<p><i>Saleema Dhalla is the CEO of SafeCare BC, the health and safety association for 1,000+ long-term care and home and community care organizations across BC.</i></p>
<p>The post <a href="https://www.hospitalnews.com/b-c-cant-recruit-its-way-out-of-a-health-care-staffing-shortage/">B.C. can’t recruit its way out of a health care staffing shortage</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Michael Garron Hospital fills gap in mental health support for pregnant women in East Toronto</title>
<link>https://edusehat.com/en/michael-garron-hospital-fills-gap-in-mental-health-support-for-pregnant-women-in-east-toronto</link>
<guid>https://edusehat.com/en/michael-garron-hospital-fills-gap-in-mental-health-support-for-pregnant-women-in-east-toronto</guid>
<description><![CDATA[ HN Summary • Closing a gap in perinatal mental health care: Michael Garron Hospital’s Women’s Reproductive Mental Health Program provides specialized support for pregnant and postpartum patients experiencing mood and anxiety disorders.  • Faster, community-based access: Average referral-to-appointment wait times have dropped from as long as six to nine months to 27 days in 2026, […]
The post Michael Garron Hospital fills gap in mental health support for pregnant women in East Toronto appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/09/Garron-2-e1790781253697.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 30 Sep 2026 23:50:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Michael, Garron, Hospital, fills, gap, mental, health, support, for, pregnant, women, East, Toronto</media:keywords>
<content:encoded><![CDATA[<p><strong>HN Summary</strong></p>
<p>• Closing a gap in perinatal mental health care: Michael Garron Hospital’s Women’s Reproductive Mental Health Program provides specialized support for pregnant and postpartum patients experiencing mood and anxiety disorders.<span class="Apple-converted-space"> </span></p>
<p>• Faster, community-based access: Average referral-to-appointment wait times have dropped from as long as six to nine months to 27 days in 2026, with psychiatric care also available at The Midwives’ Clinic of East York-Don Mills.<span class="Apple-converted-space"> </span></p>
<p>• Support continues after birth: The program connects patients with ongoing postpartum resources, including cognitive behavioural therapy groups, creating a more seamless continuum of mental health care from pregnancy through postpartum.</p>
<hr>
<p>Perinatal Mood and Anxiety Disorders (PMADs) affect up to 20% of pregnant individuals – yet most cases remain untreated.</p>
<p>Michael Garron Hospital’s (MGH) Women’s Reproductive Mental Health Program is changing this by dramatically lowering wait times for support and destigmatizing getting help for mental health.<span class="Apple-converted-space"> </span></p>
<p>This program connects pregnant patients with MGH psychiatrist, Dr. Neda Askari, who sees each person on a one-on-one basis.</p>
<p>“Women are more prone to psychiatric illness during periods of large hormonal changes, like during pregnancy. This period is one of the most vulnerable times for psychiatric illness and can negatively affect maternal health, obstetric outcomes, infant development and family well-being,” says Dr. Askari.</p>
<h2>Support available right in the community</h2>
<p>To make support as accessible as possible, pregnant people can access the program at MGH or directly in the community at The Midwives’ Clinic of East York-Don Mills (TMC).</p>
<p>Dr. Askari travels to TMC once a week, making TMC the first midwifery clinic in the province to offer access to an on-site psychiatrist.<span class="Apple-converted-space"> </span></p>
<p>“Having perinatal psychiatry within a midwife clinic normalizes receiving mental healthcare as part of the spectrum of care available in the community,” says Christie Lockhart, Chief of Midwifery at MGH. “The clinic is already a place where people come for their primary care during pregnancy and this ensures they are getting holistic person-centred care that meets both their physical and mental health needs.”</p>
<h2>Faster access to care<span class="Apple-converted-space"> </span></h2>
<p>Prior to the launch of this program, pregnant patients at MGH who needed mental health support could face long wait times of six to nine months – meaning they could give birth before their first appointment.</p>
<p>“In 2026, the program’s average wait time from referral to an appointment is only 27 days,” Dr. Askari explains. “We also ensure appointments are reserved each week for those who need care more urgently.”</p>
<p>Sharika, a client of TMC, was pregnant with her second baby when she was referred to MGH’s Women’s Reproductive Mental Health Program.</p>
<p>“I gave birth to my first child in 2020 at the beginning of the COVID-19 pandemic. I developed severe postpartum depression, anxiety and rage,” Sharika shares. “When I became pregnant last year, I knew I didn’t want to go through that again. I told my midwives about my history and they immediately referred me to this program.”</p>
<p>“My experience has been very positive – I had an appointment within a week of the referral. Everyone I met made me feel so safe, informed and welcome. This program helped me feel in control of this pregnancy and prepared me for what would happen after I gave birth the second time – and what I should do if I start experiencing symptoms of postpartum depression again.”</p>
<h2>Seamless support into postpartum</h2>
<p>This program supports women throughout their reproductive years, from pregnancy to post-partum and beyond.</p>
<p>For Sharika, the transition to postpartum resources was seamless. After having Baby Z, she was connected to a postpartum cognitive behavioural therapy (CBT) group at MGH.</p>
<p>“The group is made up of moms who meet weekly,” says Sharika. “I really enjoy going – it has made me realize we are all going through the same experiences. It makes me feel a lot less lonely, which is really important.”</p>
<h2>How to access the program</h2>
<p>MGH’s Women’s Reproductive Mental Health Program is available to pregnant individuals planning to give birth at MGH under prenatal care of a midwife, OB/GYN or Family Practice Obstetrician.</p>
<p>During pregnancy, speak to your prenatal care provider for a direct referral.</p>
<p>Referrals in postpartum are available by the same care providers or via MGH clinics such as the Family and Newborn Clinic or Breastfeeding Clinic.</p>
<p><i>Amy Tran Cassell, Senior Communications Specialist, Digital Media, Michael Garron Hospital.<span class="Apple-converted-space"> </span></i></p>
<p>The post <a href="https://www.hospitalnews.com/michael-garron-hospital-fills-gap-in-mental-health-support-for-pregnant-women-in-east-toronto/">Michael Garron Hospital fills gap in mental health support for pregnant women in East Toronto</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>A new possible treatment for severe bipolar depression</title>
<link>https://edusehat.com/en/a-new-possible-treatment-for-severe-bipolar-depression</link>
<guid>https://edusehat.com/en/a-new-possible-treatment-for-severe-bipolar-depression</guid>
<description><![CDATA[ HN Summary • Promising alternative for severe bipolar depression: A first-of-its-kind study found magnetic seizure therapy (MST) reduced depressive symptoms in 48 per cent of participants, compared with 50 per cent receiving right unilateral ultrabrief-pulse electroconvulsive therapy (RUL-UB ECT). • Fewer cognitive effects and faster recovery: About seven per cent of MST patients experienced clinically […]
The post A new possible treatment for severe bipolar depression appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/09/Vancouver.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 30 Sep 2026 23:50:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>new, possible, treatment, for, severe, bipolar, depression</media:keywords>
<content:encoded><![CDATA[<p><strong>HN Summary</strong></p>
<p>• Promising alternative for severe bipolar depression: A first-of-its-kind study found magnetic seizure therapy (MST) reduced depressive symptoms in 48 per cent of participants, compared with 50 per cent receiving right unilateral ultrabrief-pulse electroconvulsive therapy (RUL-UB ECT).</p>
<p>• Fewer cognitive effects and faster recovery: About seven per cent of MST patients experienced clinically important worsening of autobiographical memory compared with 22 per cent receiving RUL-UB ECT. MST patients also recovered orientation in about 10 minutes versus 20 minutes with ECT.</p>
<p>• More research is needed: The study involved 55 adults with treatment-resistant bipolar depression. Vancouver Coastal Health researchers are now looking to expand MST research to larger and potentially multi-site studies to determine its role as an alternative treatment.</p>
<hr>
<p>A first-of-its-kind study for bipolar depression is an encouraging first step toward the discovery of an effective therapy for patients with the condition.</p>
<p>Vancouver Coastal Health Research Institute researcher Dr. Fidel Vila-Rodriguez compared the off-label use of magnetic seizure therapy (MST) and a Health Canada-approved type of electroconvulsive therapy (ECT) for bipolar depression. Researchers found that MST was virtually as effective at lowering depressive symptoms as right unilateral ultrabrief-pulse (RUL-UB) ECT — an approved treatment — but with fewer side effects and minimal post-treatment recovery time.<span class="Apple-converted-space"> </span></p>
<p>“MST significantly decreased symptoms of bipolar depression in 48 per cent compared to 50 per cent of individuals who received RUL-UB ECT,” says Vila-Rodriguez. “Given the severity of bipolar depression and its links to suicidality, this degree of reduction in depressive symptoms could be potentially life-saving for some patients.”</p>
<p>Bipolar disorder is characterized by intense highs and lows, with some patients experiencing manic episodes ranging from an extremely elevated mood to hallucinations and/or delusions. Other patients may experience a more subdued form of elevated mood called hypomania, which can lead to racing thoughts, restlessness, euphoria and irritability.<span class="Apple-converted-space"> </span></p>
<p>Depression accounts for around 75 per cent of the disorder’s concerning symptoms. Similar to major depressive disorder, bipolar depression can lower motivation and lead to persistent sadness, fatigue, lethargy and suicidality.<span class="Apple-converted-space"> </span></p>
<h2>Maintaining treatment<span class="Apple-converted-space"> </span>efficacy with reduced<span class="Apple-converted-space"> </span>side effects<span class="Apple-converted-space"> </span></h2>
<p>ECT is an established secondary option for treatment-resistant bipolar depression, following medication and other therapeutic interventions. However, the treatment, which uses electrical current to stimulate areas of the brain, might be associated with transient short-term memory and autobiographical memory loss — the loss of memories of specific personal events, such as what happened at a recent dinner with friends.<span class="Apple-converted-space"> </span></p>
<p>The RUL-UB ECT tested in Vila-Rodriguez’s study has a reduced risk of autobiographical memory loss, possibly because the electrical current used in the treatment targets a narrower region of the brain.</p>
<p>“We wanted to compare MST to the form of ECT associated with the least risk of cognitive side effects to provide a fair comparison between the two modalities,” Vila-Rodriguez explains.<span class="Apple-converted-space"> </span></p>
<p>Because MST directs electromagnetic induction energy — similar to that used to wirelessly charge a smartphone — to an even more focused region of the brain than RUL-UB ECT, researchers hoped it would provide significant therapeutic outcomes with fewer concerning side effects like autobiographical memory loss. This, they believed, could ultimately help lower barriers to treatment for some patients concerned about the cognitive risks of ECT. 2</p>
<p>The 55 adults with treatment-resistant bipolar depression who participated in the study were randomly assigned to either receive MST or RUL-UB ECT, with researchers and participants blinded to the selected treatment modality. Of these, 45 research participants completed at least eight MST or RUL-UB ECT sessions, up to 21, with a maximum of one treatment per day.<span class="Apple-converted-space"> </span></p>
<p>Results showed that remission of depressive symptoms was achieved among 20 per cent of participants in the MST group and 30 per cent in the RUL-UB ECT group. Most research participants did not experience clinically important worsening in autobiographical memory, specifically around 22 per cent of participants in the RUL-UB ECT group and approximately seven per cent in the MST group experienced this side effect.<span class="Apple-converted-space"> </span></p>
<p>Participants who received MST experienced a faster reorientation time, recovering from the treatment within 10 minutes compared with 20 minutes among patients who received RUL-UB ECT.<span class="Apple-converted-space"> </span></p>
<p>“Faster recovery time is also associated with less time in the recovery room and earlier discharge,” explains Vila-Rodriguez. “This means that patients can get back to work or their daily activities sooner, making the overall treatment experience more palatable.”<span class="Apple-converted-space"> </span></p>
<p>With around half of MST and RUL-UB ECT patients showing at least a 50 per cent decrease in symptoms of depression, researchers believe that MST holds promise as an alternative therapy for treatment-resistant bipolar depression.</p>
<p>The research team is seeking opportunities to expand their research into MST for bipolar depression to more patients and, possibly, multiple sites. Additionally, Vila-Rodriguez and his team are in the midst of recruiting patients for another study testing the efficacy of MST to treat schizophrenia.</p>
<p><i>To inquire about participating in the ongoing “Magnetic Seizure Therapy for Schizophrenia (MAST) Trial,” contact 604-827-1361 or ninet.lab@ubc.ca.<span class="Apple-converted-space"> </span></i><i></i></p>
<p>The post <a href="https://www.hospitalnews.com/a-new-possible-treatment-for-severe-bipolar-depression/">A new possible treatment for severe bipolar depression</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Your Blood Is Precious: How Bloodless Techniques Preserve What Your Body Already Has</title>
<link>https://edusehat.com/en/your-blood-is-precious-how-bloodless-techniques-preserve-what-your-body-already-has</link>
<guid>https://edusehat.com/en/your-blood-is-precious-how-bloodless-techniques-preserve-what-your-body-already-has</guid>
<description><![CDATA[ The Case for Conserving What You Have Blood is one of the most remarkable resources your body produces. It carries oxygen to every cell, delivers nutrients, fights infection, and helps your body heal. It is, quite literally, life-sustaining. So it makes sense that preserving your own blood, rather than relying on donor transfusions, has become […] ]]></description>
<enclosure url="" length="49398" type="image/jpeg"/>
<pubDate>Wed, 30 Sep 2026 20:15:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Your, Blood, Precious:, How, Bloodless, Techniques, Preserve, What, Your, Body, Already, Has</media:keywords>
<content:encoded><![CDATA[<h2><b>The Case for Conserving What You Have</b></h2>
<p><span>Blood is one of the most remarkable resources your body produces. It carries oxygen to every cell, delivers nutrients, fights infection, and helps your body heal. It is, quite literally, life-sustaining. So it makes sense that preserving your own blood, rather than relying on donor transfusions, has become a growing priority in modern surgical care.</span></p>
<p><a href="https://heartsurgeryinfo.com/bloodless-heart-surgery/"><span>Bloodless heart surgery</span></a><span> is built around this idea. Rather than treating blood transfusion as a routine part of the operation, bloodless techniques focus on minimizing blood loss and preserving the blood your body already has. For many patients, this approach offers meaningful benefits and reflects a thoughtful respect for the body’s own resources.</span></p>
<h2><b>What Bloodless Heart Surgery Actually Means</b></h2>
<p><span>The term bloodless surgery can be a little misleading at first. It does not mean surgery without any blood, which would be impossible. Instead, it refers to surgery performed without donor blood transfusions. The goal is to complete the procedure while conserving the patient’s own blood as much as possible.</span></p>
<p><span>This is achieved through a combination of careful surgical technique, specialized tools, and thoughtful planning before, during, and after the operation. It represents a shift in mindset, from viewing transfusion as the default solution for blood loss to actively preserving and protecting the patient’s own blood supply from the start.</span></p>
<p><span>Bloodless techniques can be used across a range of cardiac procedures, and they pair especially well with minimally invasive approaches, which already reduce blood loss through smaller incisions and less tissue disruption.</span></p>
<h2><b>How Surgeons Preserve Your Blood</b></h2>
<p><span>Preserving a patient’s own blood involves a coordinated set of strategies that begin well before surgery and continue through recovery. Here is how it works.</span></p>
<h3><b>Optimizing Before Surgery</b></h3>
<p><span>Preparation begins before the patient ever reaches the operating room. In the weeks leading up to surgery, doctors may work to increase a patient’s blood count, address any anemia, and support the body’s ability to produce healthy blood cells. A patient who enters surgery with a strong blood supply has more reserve to draw on.</span></p>
<h3><b>Minimizing Blood Loss During Surgery</b></h3>
<p><span>During the procedure itself, surgeons use meticulous techniques and specialized tools to limit bleeding. Minimally invasive approaches, with their smaller incisions, naturally reduce blood loss compared to traditional open surgery. Careful control of bleeding at every step helps preserve the patient’s blood throughout the operation.</span></p>
<h3><b>Recycling the Body’s Own Blood</b></h3>
<p><span>One of the key tools in bloodless surgery is the ability to collect, clean, and return blood lost during the procedure to the patient. Rather than being discarded, the patient’s own blood can be recovered and put back to use, further reducing the need for donor blood.</span></p>
<h3><b>Supporting Recovery Afterward</b></h3>
<p><span>After surgery, care continues to focus on preserving and rebuilding the patient’s blood supply. This includes minimizing unnecessary blood draws, supporting healthy blood production, and monitoring recovery closely to keep the patient on track.</span></p>
<h2><b>Why Preserving Your Own Blood Matters</b></h2>
<p><span>There are compelling reasons to prioritize conserving your own blood. These benefits explain why bloodless techniques have gained such traction in cardiac care.</span></p>
<h3><b>Avoiding Transfusion Risks</b></h3>
<p><span>While donor blood transfusions are generally safe, they are not entirely without risk. Transfusion reactions, though uncommon, can occur, and there are small risks associated with receiving blood from another person. Preserving your own blood sidesteps these concerns entirely.</span></p>
<h3><b>Lower Infection Risk</b></h3>
<p><span>Research has associated blood transfusions with a somewhat higher risk of infection and certain complications. By minimizing or avoiding transfusion, bloodless techniques may help reduce these risks, which is especially valuable when your body is already working hard to heal.</span></p>
<h3><b>Your Blood Is a Perfect Match</b></h3>
<p><span>No donor blood, however carefully screened and matched, is a perfect match for your body the way your own blood is. Your blood is uniquely yours, tailored precisely to your body’s needs. Preserving it means your body works with exactly what it was designed to use.</span></p>
<h3><b>Faster, Smoother Recovery</b></h3>
<p><span>Patients who avoid transfusion often experience smoother recoveries. Combined with the reduced trauma of minimally invasive techniques, blood conservation can contribute to shorter hospital stays and a quicker return to normal life.</span></p>
<h2><b>Who Can Benefit From Bloodless Techniques</b></h2>
<p><span>There is a common misconception that bloodless surgery is only for a narrow group of patients. In reality, the benefits of preserving your own blood extend to almost anyone facing heart surgery.</span></p>
<p><span>Some patients seek out bloodless techniques for personal or medical reasons. Others simply prefer to avoid the risks, however small, associated with donor blood. And many are drawn to the broader benefits that blood conservation can offer, such as lower infection risk and smoother </span><a href="https://heartsurgeryinfo.com/psychological-aspects-of-recovery/"><span>recovery</span></a><span>.</span></p>
<p><span>The point is that you do not need a special circumstance to benefit from these techniques. Preserving your own blood is a sensible goal for most surgical patients, and the strategies that make it possible reflect good surgical care overall.</span></p>
<h2><b>The Connection to Minimally Invasive Surgery</b></h2>
<p><span>Bloodless techniques and </span><a href="https://heartsurgeryinfo.com/minimally-invasive-heart-surgery/"><span>minimally invasive surgery</span></a><span> work hand in hand. Minimally invasive approaches, by their very nature, involve smaller incisions, less tissue disruption, and reduced blood loss compared to traditional open surgery. This makes them a natural fit for a blood-conservation philosophy.</span></p>
<p><span>When a surgeon combines minimally invasive techniques with a thoughtful, comprehensive approach to preserving blood, the result is often a smoother experience for the patient: less trauma, less blood loss, fewer complications, and a faster recovery. It is a powerful combination that reflects the best of what modern cardiac surgery has to offer.</span></p>
<h2><b>The Importance of Experience</b></h2>
<p><span>Bloodless heart surgery requires more than just good intentions. It demands genuine expertise, careful planning, and a surgical team experienced in the full range of blood conservation strategies. From optimizing a patient before surgery to using specialized tools during the procedure to supporting recovery afterward, every step benefits from experience and skill.</span></p>
<p><span>Surgeons who have dedicated their careers to advancing and perfecting these techniques bring a depth of knowledge that makes a real difference in outcomes. Choosing a surgical team with this kind of expertise means you can trust that your blood and your health are being preserved with the greatest possible care.</span></p>
<h2><b>A Thoughtful Approach to Your Care</b></h2>
<p><span>At its heart, the philosophy behind bloodless surgery is one of respect: respect for your body, for its remarkable resources, and for the value of preserving what you already have. Rather than treating transfusion as an automatic solution, bloodless techniques ask a better question. How can we protect and conserve the patient’s own blood while achieving an excellent surgical result?</span></p>
<p><span>For many patients, this thoughtful approach offers real peace of mind. Knowing that your surgical team is committed to preserving your blood, minimizing your risks, and supporting your recovery reflects a standard of care that treats you as a whole person, not just a procedure.</span></p>
<h2><b>Schedule Your Consultation Today</b></h2>
<p><span>If you are facing heart surgery and want to understand how bloodless techniques could benefit you, we are here to help. Preserving your own blood is one of the many ways modern cardiac care can make your surgical experience safer, smoother, and more respectful of your body’s own resources.</span></p>
<p><span>Contact our office today to </span><a href="https://heartsurgeryinfo.com/contact-us/"><span>schedule a consultation</span></a><span> and learn more about bloodless heart surgery. We will evaluate your specific situation, explain how these techniques apply to your care, and help you understand all of your options. Your blood is precious, and so is your health. Let us help you protect both with the thoughtful, expert care you deserve.</span></p>
<p><span>Want to go deeper into heart health and recovery? Understanding how your body works, how it heals, and how it uses its own remarkable resources helps you make informed decisions about your care. </span><a href="https://heartsurgeryinfo.com/about-dr-ciuffo/"><span>Dr. Ciuffo’s</span></a><span> expertise in Minimally Invasive Heart Surgery and Bloodless Heart Surgery is the result of a career dedicated to advancing and perfecting these life-saving techniques.</span></p>]]> </content:encoded>
</item>

<item>
<title>Recruiting physicians: Which specialties are the most challenging?</title>
<link>https://edusehat.com/en/recruiting-physicians-which-specialties-are-the-most-challenging</link>
<guid>https://edusehat.com/en/recruiting-physicians-which-specialties-are-the-most-challenging</guid>
<description><![CDATA[ Recruiters are still struggling to find physicians, with average searches taking more than 100 days—longer for specialties like endocrinology—and about half of all searches going unfilled. According to a survey by the Association for Advancing Physician and Provider Recruitment, the volume of searches for physicians and advanced practice providers held steady in 2025. But physician […]
The post Recruiting physicians: Which specialties are the most challenging? appeared first on Today&#039;s Hospitalist. ]]></description>
<enclosure url="https://todayshospitalist.com/wp-content/uploads/2026/09/help-wanted-shutterstock_144091297-9-30-26.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 30 Sep 2026 20:05:14 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Recruiting, physicians:, Which, specialties, are, the, most, challenging</media:keywords>
<content:encoded><![CDATA[<p>Recruiters are still struggling to find physicians, with average searches taking more than 100 days—longer for specialties like endocrinology—and about half of all searches going unfilled.</p>
<p>According to a survey by the Association for Advancing Physician and Provider Recruitment, the volume of searches for physicians and advanced practice providers held steady in 2025. But physician recruiters reported that they continue to face significant workloads, lengthy hiring timelines and persistent physician vacancies.</p>
<p>The association’s survey collected information on more than 10,000 physician and provider searches in 2025 from recruiters representing 21,000 hospitals, clinics and practices. Here are highlights of that survey.</p>
<h4><strong>Recruitment challenges by physician specialty</strong></h4>
<p>The report said that as of the end of 2025, 50% of physician job searches remained open. That was up from 49% in 2024 and 47% in 2023.</p>
<p>The most challenging specialty for physician recruiters in 2025 was urology. The survey found that only 28.3% of urology searches were filled by the end of 2025, compared to one-third of searches in neurology and cardiology, 40% of anesthesia searches and 40.5% of GI searches.</p>
<h4><strong>Which specialties were most recruited?</strong></h4>
<p>The report found that family medicine accounted for 11.6% of physician searches in 2025, followed by hospital medicine (10.9%) and general ob/gyn (6.6%).</p>
<h4><strong>How long does it take to fill physician jobs?</strong></h4>
<p>The survey found that physician recruiters spent an average of 119 days to fill jobs. The toughest specialties to fill were endocrinology and metabolism (an average of 321 days) and oncology (244 days).</p>
<p>On average, physicians began working in new jobs 229 days after the position was posted, the report noted. Even after contracts were signed by physicians, more time was needed for credentialing, licensing, privileging and onboarding.</p>
<h4><strong>Volume of physician recruitment</strong></h4>
<p>The survey found that in 2025, recruiters said their organizations managed 100 searches for physicians and advanced practice providers. In 2023, by comparison, that number was 115.</p>
<p>Individual recruiters reported that they personally managed an average of 36.5 searches. That number was essentially unchanged from 2024, when it was 35.6.</p>
<p>Finally, the median annual budget for internal physician recruitment dropped 7.4% from $553,376 in 2024 to $512,500 in 2025.</p>
<p><a href="https://aappr.org/2026/09/16/physician-hiring-challenges-persist-as-recruitment-budgets-decline-aappr-report-finds/">A press release has more details from the report. </a></p>
<p>The post <a href="https://todayshospitalist.com/recruiting-physicians-which-specialties-are-the-toughest/">Recruiting physicians: Which specialties are the most challenging?</a> appeared first on <a href="https://todayshospitalist.com/">Today's Hospitalist</a>.</p>]]> </content:encoded>
</item>

<item>
<title>AI and Proteomics Accelerate VAV1 Molecular Glue Discovery</title>
<link>https://edusehat.com/en/ai-and-proteomics-accelerate-vav1-molecular-glue-discovery</link>
<guid>https://edusehat.com/en/ai-and-proteomics-accelerate-vav1-molecular-glue-discovery</guid>
<description><![CDATA[ High-throughput proteomics combined with AI-based structural modeling helped researchers discover molecular glues that degrade VAV1. The approach could support new therapies for blood cancers and autoimmune diseases.
The post AI and Proteomics Accelerate VAV1 Molecular Glue Discovery appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2023/02/GettyImages-1463834926-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 30 Sep 2026 13:05:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>and, Proteomics, Accelerate, VAV1, Molecular, Glue, Discovery</media:keywords>
<content:encoded><![CDATA[<p>Molecular glues act as matchmakers with a destructive streak: They bring disease-linked proteins into contact with the cell’s disposal machinery, marking them for elimination. Now, researchers have combined high-throughput proteomics with artificial intelligence (AI) to discover and optimize molecular glues that degrade VAV1, an immune-cell signaling protein implicated in blood cancers and autoimmune diseases.</p>
<p>The Baylor College of Medicine-led study, “<a href="https://www.nature.com/articles/s41467-026-77657-z" target="_blank" rel="noopener">Leveraging high-throughput proteomics and AI-based protein folding to accelerate VAV1 molecular glue discovery</a>,” was published in <em>Nature Communications</em>. The team was led by senior and co-corresponding author Jin Wang, PhD, director of Baylor’s Center for NextGen Therapeutics, and first and co-corresponding author Hanfeng Lin, PhD, a postdoctoral researcher in Wang’s laboratory.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>“Many scientists are increasingly exploring a new way to treat disease: instead of blocking harmful proteins, they aim at eliminating them entirely,” Wang said. Because degradation via molecular glue removes the whole protein rather than inhibiting one of its functions, the strategy could produce a more complete therapeutic effect.</p>
<p>“To find compounds capable of degrading VAV1, we screened a library of molecules using high-throughput proteomics, a technology that can assess thousands of proteins simultaneously. This unbiased analysis revealed a series of compounds, including NGT-201-12, that caused VAV1 levels to drop while affecting relatively few other proteins,” added Lin. Follow-up studies showed that degradation depended on the proteasome and cereblon (CRBN), a component of the cell’s protein-degradation pathway.</p>
<p>The team then developed GluePlex, a computational workflow that integrates AI-based protein-structure prediction with physics-based modeling. Without relying on an experimental structure of the ternary complex, GluePlex modeled how VAV1, CRBN, and the molecular glue assemble. “The model identified a specific region of VAV1, known as the SH3-2 domain, as being essential for degradation. Experimental tests confirmed the prediction and pinpointed the exact spot the glue uses: a small surface loop on VAV1 that acts as a degradation signal, or ‘degron.’ This loop is different from degradation signals commonly associated with cereblon-targeting molecular glues,” Lin said.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>“Applying Free Energy Perturbation (FEP) to predicted ternary structures yields cooperativity metrics that correlate with degradation potency, overcoming limitations of standard docking and enabling prospective ranking of analogs—even from weak initial binders,” the authors wrote. Adding halogen substitutions restricted molecular flexibility and improved degradation efficiency, producing NGT-201-18, a more potent degrader that formed a stronger degradation complex. In primary human T cells, NGT-201-18 reduced VAV1 levels and suppressed T-cell activation. Dose-response proteomics identified VAV1 as the principal target but also revealed degradation of LIMD1, an off-target carrying a canonical G-loop degron. The finding shows that one molecular glue can engage structurally distinct degrons and underscores the importance of proteome-wide profiling.</p>
<p>The compounds remain preclinical, and additional studies will be needed to assess their pharmacology, safety, selectivity, and activity in disease models. Still, the work offers both a starting point for therapies aimed at VAV1-driven autoimmune disorders and hematologic malignancies and a broader discovery strategy. “This work introduces a series of VAV1-targeting molecular glues and, just as importantly, shows how artificial intelligence, structural modeling and proteomics can work together at the earliest stage of a project,” Wang said.</p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/ai-and-proteomics-accelerate-vav1-molecular-glue-discovery/">AI and Proteomics Accelerate VAV1 Molecular Glue Discovery</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>RVH becomes the first hospital in Canada to introduce AngelEye technology in its NICU</title>
<link>https://edusehat.com/en/rvh-becomes-the-first-hospital-in-canada-to-introduce-angeleye-technology-in-its-nicu</link>
<guid>https://edusehat.com/en/rvh-becomes-the-first-hospital-in-canada-to-introduce-angeleye-technology-in-its-nicu</guid>
<description><![CDATA[ Royal Victoria Regional Health Centre (RVH) is the first hospital in Canada to introduce the AngelEye CameraSystem, an innovative technology that allows parents and loved ones to securely view their newborn in the Neonatal Intensive Care Unit (NICU) from anywhere, at any time, using a phone, tablet or computer. The new system provides families with […]
The post RVH becomes the first hospital in Canada to introduce AngelEye technology in its NICU appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/09/Croft-Family-in-NICU.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 30 Sep 2026 09:25:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>RVH, becomes, the, first, hospital, Canada, introduce, AngelEye, technology, its, NICU</media:keywords>
<content:encoded><![CDATA[<p>Royal Victoria Regional Health Centre (RVH) is the first hospital in Canada to introduce the AngelEye CameraSystem, an innovative technology that allows parents and loved ones to securely view their newborn in the Neonatal Intensive Care Unit (NICU) from anywhere, at any time, using a phone, tablet or computer.</p>
<p>The new system provides families with a secure livestream of their baby and enables care teams to share updates, helping parents stay connected during one of the most challenging times in their lives.</p>
<p>For families and caregivers with a baby in the NICU, separation can be unavoidable. Whether recovering from childbirth, caring for other children, balancing work responsibilities, or navigating transportation, financial or other challenges, being away from your newborn can be incredibly difficult.</p>
<p>AngelEye helps bridge that gap by providing secure access to a baby’s bedside, supporting parent-infant bonding, reducing stress and anxiety, and strengthening family connections. It also helps mothers feel connected during feeding and pumping routines, supporting breastfeeding and maternal well-being during a critical time for both parent and baby.</p>
<p>The inspiration for bringing AngelEye to RVH began during the COVID-19 pandemic, when visiting restrictions prompted NICU staff to find new ways to keep families connected to their babies through video technology.</p>
<p>“What started as a way to support new parents and caregivers during a difficult period made us realize just how valuable that connection is, regardless of visitor restrictions,” said Natalie Sherrit, Manager, NICU and Paediatrics at RVH. “They told us how meaningful it was to see their baby when they couldn’t be there. Now, bringing AngelEye to RVH builds on that experience by giving families and their support systems secure, reliable access to their newborn around the clock and helping them feel more involved and engaged in their baby’s care journey. It also helps mothers in their post-natal recovery and supports breastfeeding and milk production while their baby is receiving specialized care.”</p>
<p>RVH’s NICU cares for some of the region’s smallest and most vulnerable patients, admitting nearly 400 newborns each year. While the unit’s physical space is constrained and in need of future expansion, the team continually seeks innovative ways to enhance the experience of patients and families.</p>
<p>“Our team is incredibly committed to making every family’s experience as positive and supportive as possible,” said Sherrit. “While we’re mindful of the great need for expansion in our small and aging space, that has never stopped our staff from finding new ways to innovate, improve care and create exceptional experiences for families when they need us most.”</p>
<p>When their daughter Soleil arrived unexpectedly at 33 weeks and one day, first-time parents Brieanna and Rainier Croft found themselves navigating the uncertainty of a NICU stay. As the first family at RVH to use the AngelEye system, they experienced firsthand how the technology can provide comfort, reassurance, and connection during a difficult time.</p>
<p>“It’s so hard being separated from your baby,” said Brieanna. “Being able to see Soleil and know she was okay and receiving the best care possible was truly amazing. As first-time parents, it helped lessen so much of the anxiety that comes with having your baby in the NICU.”</p>
<p>For dad, Rainier, the technology helped the entire family feel connected.<br>
“There’s a sense of closeness that comes from being able to pull up your phone and see your baby whenever you need to,” he said. “It’s incredible for parents, but also for grandparents and family members who may not be able to make the trip to the hospital. It helps everyone feel connected and involved during a very important time.”</p>
<p>The introduction of AngelEye is another example of RVH’s commitment to delivering an exceptional patient, family and caregiver experience while embracing innovative solutions that improve care and strengthen connections.</p>
<p>“We know that family presence is an important part of a baby’s development, building those early bonds and supporting the well-being of everyone involved in their care,” said Sherrit. “While technology can never replace being at the bedside, AngelEye helps families, caregivers and loved ones remain connected when circumstances don’t allow it.”</p>
<p>By reducing barriers to participation and supporting bonding, breastfeeding and family engagement in neonatal care, RVH is helping create a more compassionate and equitable experience for when families need it most.</p>
<p>The post <a href="https://www.hospitalnews.com/rvh-becomes-the-first-hospital-in-canada-to-introduce-angeleye-technology-in-its-nicu/">RVH becomes the first hospital in Canada to introduce AngelEye technology in its NICU</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Merck, SciBrunch Launch Up&#45;to&#45;$2.13B Collaboration to Develop Preclinical KRAS&#45;Inhibiting Molecular Glue</title>
<link>https://edusehat.com/en/merck-scibrunch-launch-up-to-213b-collaboration-to-develop-preclinical-kras-inhibiting-molecular-glue</link>
<guid>https://edusehat.com/en/merck-scibrunch-launch-up-to-213b-collaboration-to-develop-preclinical-kras-inhibiting-molecular-glue</guid>
<description><![CDATA[ Merck agreed to pay SciBrunch up to $2.13 billion consisting of $400 million upfront and the remainder in payments tied to achieving milestones across multiple indications.
The post Merck, SciBrunch Launch Up-to-$2.13B Collaboration to Develop Preclinical KRAS-Inhibiting Molecular Glue appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/SciBrunch-shot-1520.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 30 Sep 2026 05:55:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Merck, SciBrunch, Launch, Up-to-2.13B, Collaboration, Develop, Preclinical, KRAS-Inhibiting, Molecular, Glue</media:keywords>
<content:encoded><![CDATA[<p>Merck & Co. has acquired exclusive global rights to develop, manufacture, and commercialize SciBrunch Therapeutics’ preclinical oral precision cancer candidate SPR2015, through a licensing and collaboration deal that could generate up to $2.13 billion for the Chinese small molecule oncology drug developer.</p>
<p>SPR2015 is a preclinical molecular glue, more specifically an oral KRAS G12D (ON) inhibitor that SciBrunch is developing for forms of cancer that include colorectal cancer (CRC), non-small cell lung cancer (NSCLC), and pancreatic ductal adenocarcinoma (PDAC)—the most common and aggressive type of pancreatic cancer.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>KRAS G12D is the most common oncogenic RAS mutation in human tumors—with a 38% prevalence in pancreatic cancer, CRC, and NSCLC, according to a <a href="https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.e15151">2023 study</a>. The mutation results from a substitution of glycine with aspartate at position 12, a change that leaves KRAS active and continuously signaling for cell proliferation and survival, SciBrunch said.</p>
<p>According to SciBrunch, SPR2015 has shown nanomolar antiproliferative activities in various KRAS G12D-mutant cell lines while maintaining good selectivity over KRAS wildtype cells.</p>
<p>At the 2026 American Association for Cancer Research (AACR) Annual Meeting, a team of SciBrunch researchers that included founder, chairman, and CEO Tao Hu, PhD, presented preclinical data showing SPR2015 to have demonstrated what it termed compelling antitumor efficacy as a monotherapy across multiple <em>in vivo</em> cell-derived and patient-derived xenograft (CDX and PDX) models.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>“SPR2015 is a highly potent and selective KRAS G12D (on) inhibitor with nanomolar proliferation inhibitory activities in various KRAS G12D cell lines while with good selectivity over KRAS wild type,” Hu and SciBrunch researcher colleagues reported in a <a href="https://aacrjournals.org/cancerres/article/86/7_Supplement/5978/778768/Abstract-5978-SPR2015-a-highly-potent-and">poster presentation</a> during AACR 2026. They added that PR2015 was expected at the time to human Phase I studies by the end of this year.</p>
<p>In a head-to-head mouse study comparing a single oral once-daily dose at 100 mg/kg of SPR2015 to another unspecified G12D (ON) inhibitor in over 15 CRC CDX or PDX models, SPR2015 showed significantly superior efficacy in the <em>in vivo</em> CRC xenograft models, achieving a 64.7% objective response rate (ORR) and 94.1% disease control rate (DCR) as monotherapy.</p>
<p>“The diligence question is whether those properties survive translation into humans strongly enough to compensate for SPR2015’s later start,” Sreyashi Paul, PhD, business analyst with Lucidquest Ventures, <a href="https://www.lqventures.com/merck-scibrunch-spr2015-deal-diligence-brief/amp/">commented</a> on the firm’s website.</p>
<p>Paul cited the 52% confirmed ORR and 93% disease control rate of Revolution Medicines’ zoldonrasib (RMC-9805) in 27 efficacy-evaluable previously treated KRAS G12D NSCLC patients, <a href="https://aacrjournals.org/cancerres/article/86/8_Supplement/CT021/785173/Abstract-CT021-Preliminary-safety-and-clinical">reported in May</a>, as well as the early human clinical data produced by Verastem’s VS-7375 in the Phase I/II<strong> </strong>TARGET-D 101 dose escalation and dose expansion trial (<a href="https://clinicaltrials.gov/study/NCT07020221">NCT07020221</a>). In June, Verastem reported Phase I/II trial (<a href="https://clinicaltrials.gov/study/NCT06162221">NCT06162221</a>) data showing 93% (13/14) of heavily pretreated (second- to fourth-line) patients with metastatic PDAC who received 900 mg once-daily monotherapy achieved greater than 50% reduction in the tumor marker CA19-9.</p>
<p>In their announcement, Merck and SciBrunch did not disclose a current timeframe for taking SPR2015 into Phase I.</p>
<p></p><h4><strong>“Validates R&D strength”</strong></h4>

<div class="my-8"><span data-render-ad="5"></span></div>
<p>“This agreement with Merck not only validates the R&D strength of our platform but also underscores the potential of SPR2015 in addressing longstanding unmet medical needs in oncology,” Hu said in the companies’ statement. “We are excited that Merck, a global leader in oncology, will take SPR2015 forward.”</p>
<p>Merck agreed to pay SciBrunch up to $2.13 billion consisting of $400 million upfront and the remainder in payments tied to achieving development, commercialization, and other milestones across multiple indications.</p>
<p>Merck will record a pre-tax charge of $400 million related to the SciBrunch agreement, or approximately $0.13 per share, to be included in its GAAP and non-GAAP results for the third quarter. The transaction has closed.</p>
<p>“Evidence continues to accumulate for the therapeutic potential of targeting the KRAS pathway, a well-characterized factor in tumor cell growth,” stated George Addona, senior vice president, discovery, preclinical development and translational medicine, Merck Research Laboratories. “This agreement complements and diversifies our expanding pipeline of precision targeted candidates with SPR2015, a potent engineered inhibitor for one of the most prevalent mutant forms of KRAS found in human cancers.”</p>
<p>The deal continues the trend of U.S. and other Western pharmas partnering with Chinese biotechs on drug development—and in Merck’s case, a trend of striving to rebuild its cancer pipeline in hopes of recouping sales that it stands to lose when its anchor drug, the multi-indication cancer immunotherapy Keytruda® (pembrolizumab), loses exclusivity for key U.S. patents in 2028.</p>
<p>Keytruda generated $15.81 billion in Q1–Q2 2026 sales in addition to the $31.641 billion it generated last year. Those figures do not include the $590 million racked up by Keytruda Qlex, a subcutaneous injection form of Keytruda that won FDA approval in September 2025. A consensus of Wall Street analysts has forecast peak annual revenue for Keytruda of approximately $33 billion by 2028.</p>
<p></p><h4><strong>$70B potential opportunity</strong></h4>

<p>However, Merck envisions more than making up for the loss of Keytruda, having foreseen more than $70 ​billion of potential ⁠commercial opportunity by the mid-2030s, Louise Chen, a managing director with Scotiabank, told Reuters.</p>
<p>Founded in 2014, Shanghai-based SciBrunch focuses on small molecule oncology therapeutics based on clinically validated targets and differentiated product design strategies. Hu, a serial entrepreneur, founded SciBrunch with medicinal chemist Yang Zhang, PhD, who is the company’s CSO.</p>
<div class="my-8"><span data-render-ad="6"></span></div>
<p>In January, SciBrunch completed an oversubscribed Pre-A round financing of over $35 million, bringing its total capital raised to $65 million over two rounds. Among intended uses for the proceeds, the company announced at the time, was “advancing IND-enabling studies for a new generation of innovative molecular glue RAS inhibitors, exploring their clinical potential in RAS-mutated refractory tumors including colorectal cancer, pancreatic cancer, and non-small cell lung cancer, with the goal of developing preferred therapies for RAS-driven cancers.”</p>
<p>HighLight Capital led the $35 million Pre-A round, with participation from new investor InnoPinnacle Fund and existing shareholders that increased their investments in SciBrunch, including Hankang Capital, BioTrack Capital, LongRiver Investments, and Elikon Venture.</p>
<p>“Since our founding, SciBrunch has remained focused on advancing innovative therapies targeting the RAS pathway and is committed to delivering transformative treatment options for patients with pancreatic, colorectal, lung, and other major malignant tumors,” Hu added.</p>
<p>SPR2015 is not SciBrunch’s lead candidate. That distinction belongs to SPR1020, a brain-penetrant PARP1 selective inhibitor being developed to fight metastatic brain cancer (mBC, with or without brain metastases), ovarian cancer, PDAC, prostate cancer, and glioblastoma. SPR1020 is under study in patients with advanced solid tumors in a Phase I/II open-label, first-in-human trial (<a href="https://clinicaltrials.gov/study/NCT07359066">NCT07359066</a>)  which dosed its first patient on January 8.</p>
<p>“SPR1020 is expected to demonstrate significant efficacy against tumors harboring BRCA mutations or homologous recombination repair (HRR) pathway gene alterations (e.g., breast cancer, prostate cancer),” SciBrunch predicted in the trial’s page on ClinicalTrials,gov.</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/merck-scibrunch-launch-up-to-2-13b-collaboration-to-develop-preclinical-kras-inhibiting-molecular-glue/">Merck, SciBrunch Launch Up-to-$2.13B Collaboration to Develop Preclinical KRAS-Inhibiting Molecular Glue</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Current Challenges in CAR T Manufacturing</title>
<link>https://edusehat.com/en/current-challenges-in-car-t-manufacturing</link>
<guid>https://edusehat.com/en/current-challenges-in-car-t-manufacturing</guid>
<description><![CDATA[ Predictive cell intelligence can be used to reveal cellular states and emerging cellular trajectories earlier in the manufacturing process and to support more informed bioprocessing decisions.
The post Current Challenges in CAR T Manufacturing appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2287901746.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 30 Sep 2026 02:20:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Current, Challenges, CAR, Manufacturing</media:keywords>
<content:encoded><![CDATA[<p>CAR T therapy has undergone a remarkable transformation over the past decade, evolving from an experimental treatment into a clinically validated therapeutic platform with seven FDA-approved therapies and a rapidly expanding global market estimated at $6 billion.<sup>1,2</sup></p>
<p>Yet despite its clinical success, manufacturing remains a fundamental bottleneck to broader patient access.</p>
<p>The challenge facing CAR T is no longer clinical validation; it is scalable delivery. Manufacturing remains constrained by donor-to-donor variability, patient-specific production, and complex multi-step workflows operating within tightly controlled GMP environments.<sup>3,4</sup> These factors drive up cost, increase process variability, and limit manufacturing throughput, ultimately restricting patient access to potentially life-saving therapies.</p>
<p>In addition, existing analytical approaches were either never designed to work in real time or have limited capacity to predict manufacturing outcomes. Most inline sensors or probes rely on downstream or metabolite-based measurements that describe what a cell has done, rather than what a cell can become. This limits process visibility and reduces opportunities for informed intervention before failure occurs.<sup>5</sup></p>
<p>As the field moves toward larger patient populations and commercial-scale manufacturing, the industry faces a critical challenge: how do we move from reactive manufacturing to predictive control? Solving this challenge is essential to improve manufacturing robustness, reduce the cost of goods, increase manufacturing capacity, and expand patient access to advanced cell therapies.</p>
<p>Achieving these goals will require more than automation alone. It will need technologies capable of revealing cellular states earlier in the manufacturing process, enabling informed intervention, and a transition from retrospective testing to proactive process control.<sup>5</sup></p>
<p>To address this challenge, Cytomos has developed AuraCyt<sup>®</sup>, a predictive cell intelligence platform designed to reveal cellular states earlier in the manufacturing process and support more informed manufacturing decisions.</p>
<p></p><h4><strong>From dielectric signatures to predictive cell intelligence</strong></h4>

<p>Cells carry rich biophysical information that is not always visible through conventional biological markers. Dielectric spectroscopy accesses this information by measuring the frequency-dependent electrical behavior that arises from a cell’s intrinsic structure.<sup>6-9</sup></p>
<p>Specifically, the cell membrane separates the conductive interior of the cell from its surrounding environment, shaping how the cell responds to an applied electric field. As the frequency increases, the influence of the cell membrane decreases, allowing the electrical response to become progressively more sensitive to intracellular structure and composition as well as membrane properties.<sup>6,8,9</sup> The resulting electrical response reflects the intrinsic physical state of the cell.</p>
<p>AuraCyt captures this response at the single-cell level using ultra-wideband dielectric spectroscopy. By measuring each cell across more than 200 frequencies, the platform generates a high-dimensional digital fingerprint of every cell that reflects the cellular state and captures subtle changes associated with emerging behavior. In the current configuration, this produces 507 parameters per cell, generating biologically grounded, AI-ready digital datasets for cell characterization and predictive analysis.<sup>10</sup></p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>This approach represents a paradigm shift in cell analytics: using physics to predict biology. As changes in cellular state often precede measurable biological outcomes, AuraCyt signatures can reveal early signals and emerging cellular trajectories before they are detected by conventional assays. This provides a biophysics-first route to predictive cell intelligence.<sup>5,10</sup></p>
<p></p><h4><strong>Applying predictive cell intelligence to CAR T manufacturing</strong></h4>

<p>To demonstrate how predictive cell intelligence can be applied in a real manufacturing workflow, AuraCyt was evaluated in a CAR T manufacturing case study focused on transduction efficiency and process risk.</p>
<p>Transduction efficiency is a critical determinant of the CAR T manufacturing success, yet current analytical methods typically confirm transduction only after key manufacturing decisions have been made. Cytomos decided to investigate whether predictive cell intelligence could provide earlier insights into manufacturing outcomes.</p>
<p>AuraCyt was evaluated as a rapid, label-free platform for monitoring transduction efficiency and characterizing transduced and non-transduced T-cell populations over an eight-day manufacturing workflow.</p>
<p>Donor-derived T cells were activated with IL-2 and expanded using a standard CAR T manufacturing process. Following activation, the cell population was divided into two arms: one transduced with a CD34-CAR construct and a matched non-transduced control.</p>
<p>AuraCyt analysis was performed on Days 0, 4, 6, and 8. Flow cytometry was performed on Day 6 to confirm CAR-CD34 expression, providing a conventional benchmark for transduction assessment against which earlier AuraCyt measurements could be compared. Cell viability and concentration were monitored throughout the process (<em>Figure 1</em>).</p>
<p><figure aria-describedby="caption-attachment-338539" class="wp-caption aligncenter"><img fetchpriority="high" decoding="async" class="wp-image-338539 size-large" src="https://www.genengnews.com/wp-content/uploads/2026/09/Slide1-scaled-e1790612466922-1024x204.jpeg" alt="Figure 1. Eight-day CAR-T manufacturing workflow showing activation, transduction, expansion, and analytical assessment timepoints. AuraCyt analysis was performed on Days 0, 4, 6 and 8, while CAR-CD34 expression was confirmed by flow cytometry on Day 6. Non-transduced control cells followed the same process without transduction. [Cytomos]" width="1024" height="204" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/Slide1-scaled-e1790612466922-1024x204.jpeg 1024w, https://www.genengnews.com/wp-content/uploads/2026/09/Slide1-scaled-e1790612466922-300x60.jpeg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/Slide1-scaled-e1790612466922-768x153.jpeg 768w, https://www.genengnews.com/wp-content/uploads/2026/09/Slide1-scaled-e1790612466922-1536x305.jpeg 1536w, https://www.genengnews.com/wp-content/uploads/2026/09/Slide1-scaled-e1790612466922-2048x407.jpeg 2048w" sizes="(max-width: 1024px) 100vw, 1024px"><figcaption class="wp-caption-text">Figure 1. Eight-day CAR T manufacturing workflow showing activation, transduction, expansion, and analytical assessment timepoints. AuraCyt analysis was performed on Days 0, 4, 6 and 8, while CAR-CD34 expression was confirmed by flow cytometry on Day 6. Non-transduced control cells followed the same process without transduction. [Cytomos]</figcaption></figure>AuraCyt identified distinct dielectric signatures associated with donor T cells (Day 0), T-cell activation, and CAR-CD34 transduction. Flow cytometry confirmed CAR-CD34 expression on Day 6, providing a conventional benchmark for transduction and CAR expression. This aligned with AuraCyt analysis, which showed clear separation between non-transduced, activated, and CAR-CD34⁺ T cell populations using label-free single-cell measurements (<em>Figure 2</em>).</p>
<p><figure aria-describedby="caption-attachment-338540" class="wp-caption aligncenter"><img decoding="async" class="wp-image-338540 size-large" src="https://www.genengnews.com/wp-content/uploads/2026/09/Slide2-scaled-e1790612521984-1024x358.jpeg" alt="Figure 2. (A) Flow cytometry showing CAR-CD34 expression on Day 6 in transduced T cells and (B) flow cytometry of non-transduced control cells; (C) Predictive cell analytics showing clear separation of non-transduced control cells, activated T cells, and CAR-CD34+ T cells at Day 8. [Cytomos]" width="1024" height="358" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/Slide2-scaled-e1790612521984-1024x358.jpeg 1024w, https://www.genengnews.com/wp-content/uploads/2026/09/Slide2-scaled-e1790612521984-300x105.jpeg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/Slide2-scaled-e1790612521984-768x268.jpeg 768w, https://www.genengnews.com/wp-content/uploads/2026/09/Slide2-scaled-e1790612521984-1536x536.jpeg 1536w, https://www.genengnews.com/wp-content/uploads/2026/09/Slide2-scaled-e1790612521984-2048x715.jpeg 2048w" sizes="(max-width: 1024px) 100vw, 1024px"><figcaption class="wp-caption-text">Figure 2. (A) Flow cytometry showing CAR-CD34 expression on Day 6 in transduced T cells and (B) flow cytometry of non-transduced control cells; (C) Predictive cell analytics showing clear separation of non-transduced control cells, activated T cells, and CAR-CD34+ T cells at Day 8. [Cytomos]</figcaption></figure>Across the eight-day workflow, the AuraCyt Signatures of CAR T cells and non-transduced controls followed distinct trajectories (<em>Figure 3</em>).</p>
<div class="my-8"><span data-render-ad="6"></span></div>
<p>Using Day 0 donor T cells as a reference population, AuraCyt tracked the evolution of both transduced and non-transduced cells over time. Comparison of the resulting dielectric signatures using effect size analysis demonstrated divergence between the two populations by Day 4, prior to conventional confirmation of CAR expression by flow cytometry on Day 6 (<em>Figure 3</em>).</p>
<p><figure aria-describedby="caption-attachment-338542" class="wp-caption aligncenter"><img decoding="async" class="wp-image-338542 size-large" src="https://www.genengnews.com/wp-content/uploads/2026/09/Slide3-1-scaled-e1790612568545-1024x430.jpeg" alt="Figure 3. AuraCyt reveals progressive divergence between transduced CAR-T cells and non-transduced controls during manufacturing. The effect-size plot quantifies the increasing separation from the baseline donor T-cell state, while the accompanying trajectory plots visualise the emergence of distinct cellular phenotypes over time. Minimal separation is observed at Day 0, with divergence evident by Day 4 and becoming increasingly pronounced through Days 6 and 8. The appearance of distinct cellular trajectories before conventional confirmation of CAR expression suggests that transduction-associated cellular changes are detectable at an earlier stage of the manufacturing process. [Cytomos]" width="1024" height="430" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/Slide3-1-scaled-e1790612568545-1024x430.jpeg 1024w, https://www.genengnews.com/wp-content/uploads/2026/09/Slide3-1-scaled-e1790612568545-300x126.jpeg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/Slide3-1-scaled-e1790612568545-768x322.jpeg 768w, https://www.genengnews.com/wp-content/uploads/2026/09/Slide3-1-scaled-e1790612568545-1536x644.jpeg 1536w, https://www.genengnews.com/wp-content/uploads/2026/09/Slide3-1-scaled-e1790612568545-2048x859.jpeg 2048w" sizes="(max-width: 1024px) 100vw, 1024px"><figcaption class="wp-caption-text">Figure 3. AuraCyt reveals progressive divergence between transduced CAR T cells and non-transduced controls during manufacturing. The effect-size plot quantifies the increasing separation from the baseline donor T-cell state, while the accompanying trajectory plots visualize the emergence of distinct cellular phenotypes over time. Minimal separation is observed at Day 0, with divergence evident by Day 4 and becoming increasingly pronounced through Days 6 and 8. The appearance of distinct cellular trajectories before conventional confirmation of CAR expression suggests that transduction-associated cellular changes are detectable at an earlier stage of the manufacturing process. [Cytomos]</figcaption></figure>These findings suggest that AuraCyt can detect transduction-associated changes in cellular states and identify emerging CAR T manufacturing trajectories before conventional transduction assessment. This supports its potential as a rapid, label-free analytical approach for improving process visibility and enabling earlier manufacturing insight.<sup>10</sup></p>
<p></p><h4><strong>Implications for CAR T manufacturing and beyond</strong></h4>

<p>These findings demonstrate how early AuraCyt signatures can reveal CAR T manufacturing trajectories before conventional assessment. By providing earlier insight into cellular states, AuraCyt has the potential to move manufacturing from retrospective quality control towards predictive process control.</p>
<p>Earlier visibility of process trajectory could improve manufacturing consistency, reduce variability, and support more informed decision-making during critical manufacturing windows. In turn, this may help lower the cost and complexity of delivering advanced cell therapies at scale.</p>
<p>Beyond CAR T, the same biophysics-first approach could be applied across cell therapy, biologics, and other advanced manufacturing workflows, providing a foundation for predictive biomanufacturing and AI-enabled process optimization.</p>
<p class="trimmed"> </p>
<p><em>Lindsay Fraser, PhD, is CSO at Cytomos.</em></p>
<p class="trimmed"> </p>
<p><em><strong>References</strong></em></p>
<div class="my-8"><span data-render-ad="7"></span></div>
<p>1. U.S. Food and Drug Administration (FDA). <em>Approved Cellular and Gene Therapy Products.</em> Center for Biologics Evaluation and Research, FDA.</p>
<p>2. MarketsandMarkets. <em>CAR T-Cell Therapy Market Report 2026–2031.</em></p>
<p>3. Ayala Ceja M, Khericha M, Harris CM, Puig-Saus C, Chen YY. <em>CAR T Cell Manufacturing: Major Process Parameters and Next-Generation Strategies.</em> Journal of Experimental Medicine. 2024.</p>
<p>4. Baguet C, Larghero J, Mebarki M. <em>Early Predictive Factors of Failure in Autologous CAR T-Cell Manufacturing and/or Efficacy in Hematologic Malignancies.</em> Blood Advances. 2024.</p>
<p>5. Mendoza R, Carter K, Peterson S. <em>Early-stage Analytical Development Strategies for Cell Therapy.</em> Cell & Gene Therapy Insights. 2024;10(11):1493–1503.</p>
<p>6. Gawad S, Schild L, Renaud P. <em>Micromachined Impedance Spectroscopy Flow Cytometer for Cell Analysis and Particle Sizing.</em> Lab on a Chip. 2001.</p>
<p>7. Cheung K, Gawad S, Renaud P. <em>Impedance Spectroscopy Flow Cytometry: On-Chip Label-Free Cell Differentiation.</em> Cytometry Part A. 2005.</p>
<p>8. Liang W, Zhao Y, Liu L, et al. <em>Determination of Cell Membrane Capacitance and Conductance via Optically Induced Electrokinetics.</em> Biophysical Journal. 2017.</p>
<p>9. Tehrani FD, O’Toole MD, Collins DJ. <em>Tutorial on Impedance and Dielectric Spectroscopy for Single-Cell Characterisation on Microfluidic Platforms: Theory, Practice, and Recent Advances.</em> Lab on a Chip. 2025.</p>
<p>10. Fraser L, Wright D, Hunter B, Giakoumelou S, Bellot F, et al. <em>Biology Empowering AI: Rethinking Prediction in Biomanufacturing.</em> Poster presented at the International Society of Cell & Gene Therapy (ISCT) Annual Meeting, Dublin, Ireland; 6–9 May 2026. Supported by the attached ISCT poster.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/current-challenges-in-car-t-manufacturing/">Current Challenges in CAR T Manufacturing</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>How Cells Respond Differently to a Cancer&#45;Causing Gene</title>
<link>https://edusehat.com/en/how-cells-respond-differently-to-a-cancer-causing-gene</link>
<guid>https://edusehat.com/en/how-cells-respond-differently-to-a-cancer-causing-gene</guid>
<description><![CDATA[ Chemotherapies frequently cause cancer cells to enter senescence, but do not fully eliminate these cells. Therefore, it is useful to target these therapy-induced senescent cells with senolytics that eliminate them.
The post How Cells Respond Differently to a Cancer-Causing Gene appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-183281076.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 30 Sep 2026 02:20:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>How, Cells, Respond, Differently, Cancer-Causing, Gene</media:keywords>
<content:encoded><![CDATA[<p><span>Scientists at NYU Abu Dhabi say they have discovered that a single cancer-causing gene can trigger different responses in cells, with some helping to prevent tumors while others may contribute to their development.</span></p>
<p><span>The study “<a href="https://link.springer.com/article/10.1038/s44319-026-00941-y" target="_blank" rel="noopener">UHRF1 overexpression generates senescent states with different T53 dependencies</a>,” published in <em>EMBO Reports</em>, found that the gene can trigger several forms of cellular senescence, a natural defense in which damaged cells stop dividing to help prevent cancer, a tumor-suppressive function inherent to all cells.</span></p>
<p><span>Using a zebrafish model of liver cancer, the researchers investigated the initial response to a cancer-causing gene and found that some of these precancerous cells are terminally senescent, meaning they cannot generate tumors, while others can regain the ability to divide and potentially contribute to cancer.</span></p>
<p><span>Commonly used chemotherapies frequently cause cancer cells to enter senescence, but do not fully eliminate these cells. Therefore, it is useful to target these therapy-induced senescent cells with senolytics that eliminate them, say the researchers.</span></p>
<p><span>In this study, the team tested a common senolytic to investigate its ability to target senescent cells and found that it was effective against only some of the precancerous cells but not others. The findings suggest that treatments targeting senescent cells may need to account for the different ways these cells behave.</span></p>
<p><span>“Cancer is not simply a matter of whether a cell stops dividing or continues to grow. Our study shows that there are different types of cellular senescence, and depending on the type acquired by a pre-cancerous cell, the outcome can make the difference between turning into a cancer cell or not,” explained Professor of Biology at NYU Abu Dhabi and senior author Kirsten Sadler Edepli, PhD.</span></p>
<p><span>“We also show that these different forms of senescent cells have hugely different responses to treatments, which is important when developing and applying cancer therapies. It is particularly exciting that our undergraduate capstone researchers contributed to this discovery. Their work demonstrates the valuable role students can play in high-impact research when they are given the opportunity to engage directly with important scientific questions and are given dedicated mentors to guide their efforts.”</span></p>
<p><span>The research was conducted by NYU Abu Dhabi researchers in collaboration with the University’s Center for Genomics and Systems Biology. The findings provide new insight into how cells respond when cancer-causing genes are activated and could help researchers better understand how different types of senescent cells should be targeted in cancer treatment, according to the investigators.</span></p>
<p class="trimmed"> </p>
<p class="trimmed"> </p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/how-cells-respond-differently-to-a-cancer-causing-gene/">How Cells Respond Differently to a Cancer-Causing Gene</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Ginkgo Datapoints, Apheris Announce Founding Members of Antibody Developability Consortium</title>
<link>https://edusehat.com/en/ginkgo-datapoints-apheris-announce-founding-members-of-antibody-developability-consortium</link>
<guid>https://edusehat.com/en/ginkgo-datapoints-apheris-announce-founding-members-of-antibody-developability-consortium</guid>
<description><![CDATA[ The consortium aims to address antibody development bottlenecks by creating standardized datasets and AI models that support earlier risk detection and more informed candidate selection.
The post Ginkgo Datapoints, Apheris Announce Founding Members of Antibody Developability Consortium appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/03/Getty_1914734029_Antibody.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 30 Sep 2026 02:20:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Ginkgo, Datapoints, Apheris, Announce, Founding, Members, Antibody, Developability, Consortium</media:keywords>
<content:encoded><![CDATA[<p><span>Ginkgo Datapoints and Apheris have announced the founding members of the Antibody Developability Consortium, a new industry collaboration designed to help pharmaceutical and biotech companies predict antibody manufacturability and developability risks earlier. The consortium aims to do so by building what they claim will be the field’s largest standardized antibody developability dataset. </span></p>
<p><span>The founding members listed in today’s announcement include AbbVie, argenx, Lundbeck, and Takeda, and the consortium remains open to additional pharma and biotech companies interested in joining. Under the terms of the consortium, each founding member will contribute proprietary antibody sequencing with Gingko Datapoints, an offering of Gingko Bioworks, filling any remaining capacity from publicly available sources. The goal is to reach 10,000 antibodies in total.</span></p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p><span>“This consortium represents an important step forward in building predictive models for antibody developability by creating datasets that are designed for machine learning, addressing limitations associated with convenience datasets,” said Athena Hadjixenofontos, PhD, director of data science, head of AI in biotherapeutics and genetic medicine at AbbVie. “Federated infrastructure enables participants to contribute data while keeping proprietary sequences private. These capabilities could meaningfully accelerate antibody discovery and help advance new medicines for patients.” </span></p>
<p><span>Antibody developability encompasses the biophysical properties that influence whether a candidate antibody can be manufactured, formulated, and successfully advanced into a clinical product. Predicting barriers that could prevent promising antibody candidates from progressing early could support more informed candidate selection and reduce development time and investment.</span></p>
<p><span>This is important, for example, “in complex therapeutic areas such as CNS” where “the ability to select well behaved candidates with superior developability properties is essential,” said Allan Jensen, PhD, vice president, biotherapeutic discovery at Lundbeck. “By bringing together diverse antibody dataset[s], this collaboration has the potential to strengthen predictive approaches.”</span></p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p><span>According to the partners, Gingko Datapoints is leading the scientific design and execution of the consortium. This includes designing the sequence selection approach, overseeing antibody production, and conducting high-throughput wet-lab characterization across core developability endpoints. Gingko is also training a foundation antibody developability model on the dataset in Apheris’ secure environment. </span></p>
<p><span>For its part, Apheris’ federated infrastructure is being used to deliver the foundation model into each participating member’s environment where they can fine-tune it on their proprietary data. Furthermore, members will be able to train, benchmark, and refine their own internal models in Apheris’ environment using the full consortium dataset as well as their own sequence data, without exposing their proprietary information to other members. The consortium has also tapped Charlotte Deane, PhD, professor of structural bioinformatics at the University of Oxford and Peter Tessier, PhD, professor of pharmaceutical sciences and chemical engineering at the University of Michigan, to provide independent scientific oversight.</span></p>
<p><span>Members are expected to have access to the initial dataset by early 2027. There are also plans to explore the addition of more complex antibody formats over time to enable new drug classes and other key properties that help the members predict which drugs will succeed or fail. </span></p>
<p><span>“Pooling standardized developability data across the industry can create stronger predictive models than any one company could build alone,” said Yves Fomekong Nanfack, PhD, head of AI/ML research at Takeda. “As we advance Takeda Research’s ambition to become an AI-native discovery organization, this capability can help identify promising antibody candidates earlier, inform better development decisions, and bring new therapies to patients faster.”</span></p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/ginkgo-datapoints-apheris-announce-founding-members-of-antibody-developability-consortium/">Ginkgo Datapoints, Apheris Announce Founding Members of Antibody Developability Consortium</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Health PEI reports cybersecurity incident involving personal health information</title>
<link>https://edusehat.com/en/health-pei-reports-cybersecurity-incident-involving-personal-health-information</link>
<guid>https://edusehat.com/en/health-pei-reports-cybersecurity-incident-involving-personal-health-information</guid>
<description><![CDATA[ A cybersecurity incident involving a third-party service provider resulted in unauthorized access to a Health PEI file containing personal health information. Health PEI is notifying the public following a cybersecurity incident in which an unauthorized person obtained a copy of a file containing personal health information. The incident occurred within the systems of a company […]
The post Health PEI reports cybersecurity incident involving personal health information appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/09/ChatGPT-Image-Sep-29-2026-09_05_27-AM.png" length="49398" type="image/jpeg"/>
<pubDate>Tue, 29 Sep 2026 22:40:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Health, PEI, reports, cybersecurity, incident, involving, personal, health, information</media:keywords>
<content:encoded><![CDATA[<p>A cybersecurity incident involving a third-party service provider resulted in unauthorized access to a Health PEI file containing personal health information.</p>
<p>Health PEI is notifying the public following a cybersecurity incident in which an unauthorized person obtained a copy of a file containing personal health information.</p>
<p>The incident occurred within the systems of a company providing services to Health PEI. Health PEI says its own systems and those of the Government of Prince Edward Island were not compromised, and records stored within government systems were not improperly accessed.</p>
<p>The affected file was created in 2011 and relates to people who were eligible for health-care services in Prince Edward Island during or before that year, as well as some non-residents who received health services in the province between 2008 and 2011.</p>
<p>According to Health PEI, information contained in the file could include names, dates of birth, gender, personal health numbers, health-card issue and expiry dates, and Medicare eligibility information.</p>
<p>Based on information currently available, Health PEI says it considers the risk of the information being misused to be low. However, potentially affected individuals are being advised to remain alert for suspicious emails, text messages and telephone calls requesting personal information or claiming to involve health coverage, government programs or identity verification.</p>
<p>The incident has been reported to the Office of the Information and Privacy Commissioner of Prince Edward Island, which has opened a file. Health PEI says the third-party company is also reviewing its processes and implementing measures intended to reduce the likelihood of a similar incident.</p>
<p>The incident underscores the cybersecurity and privacy challenges facing health-care organizations as patient information increasingly moves through interconnected systems and external service providers.</p>
<p>Health PEI has established a dedicated contact point for people with questions or those wishing to report suspicious activity potentially related to the incident.</p>
<p><em>Source: Health PEI, Government of Prince Edward Island</em></p>
<p>The post <a href="https://www.hospitalnews.com/health-pei-reports-cybersecurity-incident-involving-personal-health-information/">Health PEI reports cybersecurity incident involving personal health information</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>AI&#45;powered imaging advances stroke care at Lakeridge Health</title>
<link>https://edusehat.com/en/ai-powered-imaging-advances-stroke-care-at-lakeridge-health</link>
<guid>https://edusehat.com/en/ai-powered-imaging-advances-stroke-care-at-lakeridge-health</guid>
<description><![CDATA[ New CT perfusion technology is helping physicians assess brain blood flow and make faster, more informed treatment decisions for stroke patients. Lakeridge Health has introduced new advanced brain-imaging technology designed to help physicians quickly determine the most appropriate treatment for patients experiencing a stroke. CT Perfusion with RapidAI is now available at Ajax Pickering Hospital […]
The post AI-powered imaging advances stroke care at Lakeridge Health appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/09/ChatGPT-Image-Sep-29-2026-08_58_14-AM.png" length="49398" type="image/jpeg"/>
<pubDate>Tue, 29 Sep 2026 22:40:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>AI-powered, imaging, advances, stroke, care, Lakeridge, Health</media:keywords>
<content:encoded><![CDATA[<p>New CT perfusion technology is helping physicians assess brain blood flow and make faster, more informed treatment decisions for stroke patients.</p>
<p>Lakeridge Health has introduced new advanced brain-imaging technology designed to help physicians quickly determine the most appropriate treatment for patients experiencing a stroke.</p>
<p>CT Perfusion with RapidAI is now available at Ajax Pickering Hospital and Oshawa Hospital, marking the first use of the technology in Durham Region. <a href="https://www.lh.ca/news-and-stories/posts/first-in-durham-region-new-technology-advances-life-saving-stroke-care/?utm_source=chatgpt.com">Lakeridge Health</a></p>
<p>During an ischemic stroke, a blood clot can prevent blood and oxygen from reaching part of the brain. Rapid assessment is critical because brain tissue can become damaged as the interruption continues.</p>
<p>CT perfusion provides physicians with detailed information about how blood is moving through a patient’s brain. RapidAI then uses artificial intelligence to analyze the imaging, helping clinical teams identify areas that may already have been damaged as well as brain tissue that could potentially be saved through treatment.</p>
<p>The additional information can help physicians make timely decisions about the treatment most appropriate for an individual patient.</p>
<p>The technology is intended to support—not replace—the expertise of physicians and clinical teams. Lakeridge Health says the imaging provides clinicians with more detailed information to help them understand individual patient needs and make informed treatment decisions.</p>
<p>The introduction is also part of a broader investment in technology across the health system.</p>
<p>Earlier this year, Lakeridge Health introduced the Stryker 4.0 Orthopedic Robotics Platform at Ajax Pickering Hospital. The robotic system assists surgical teams in planning and performing joint replacement procedures with greater precision.</p>
<p>Both initiatives support Lakeridge Health’s 2026–2031 strategic plan, which identifies innovation and technology as a priority for improving patient care.</p>
<p>Lakeridge Health is one of Ontario’s largest community health systems, operating five hospitals along with a same-day surgical centre, long-term care home and more than 30 community locations across Durham Region and surrounding communities.</p>
<p>The post <a href="https://www.hospitalnews.com/ai-powered-imaging-advances-stroke-care-at-lakeridge-health/">AI-powered imaging advances stroke care at Lakeridge Health</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>AI Tool Helps Link BRSK1 Variants to Neurodevelopmental Disorder</title>
<link>https://edusehat.com/en/ai-tool-helps-link-brsk1-variants-to-neurodevelopmental-disorder</link>
<guid>https://edusehat.com/en/ai-tool-helps-link-brsk1-variants-to-neurodevelopmental-disorder</guid>
<description><![CDATA[ AI-assisted genomic analysis was combined with human genetics and fruit fly experiments to link reduced BRSK1 function to a variable neurodevelopmental disorder. 
The post AI Tool Helps Link BRSK1 Variants to Neurodevelopmental Disorder appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/07/GettyImages-1702217813.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 29 Sep 2026 07:50:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Tool, Helps, Link, BRSK1, Variants, Neurodevelopmental, Disorder</media:keywords>
<content:encoded><![CDATA[<p>For many families affected by rare genetic conditions, genomic testing does not immediately deliver an answer. Now, researchers have combined artificial intelligence, human genetics, and fruit fly experiments to connect variants in <em>BRSK1</em> with a complex neurodevelopmental disorder. The findings provide a potential diagnosis for several previously unexplained cases while offering clues about how reduced activity of the gene may disrupt nervous system development.</p>
<p>The study, “<a href="https://www.cell.com/ajhg/abstract/S0002-9297(26)00346-0?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0002929726003460%3Fshowall%3Dtrue" target="_blank" rel="noopener">Monoallelic variants in <em>BRSK1</em> are associated with a neurodevelopmental disorder with or without epilepsy</a>,” was led by researchers at Baylor College of Medicine, the Duncan Neurological Research Institute at Texas Children’s Hospital, and the Texome Project, together with collaborating institutions. It was published in the <em>American Journal of Human Genetics</em>.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>According to Hugo Bellen, PhD, who is co-lead author of the study, the work began with a child enrolled in the Texome Project, which provides genetic testing to medically underserved people with rare, undiagnosed conditions in Texas. Standard analysis of the child’s and parent’s genomes had not identified a cause. <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11221788/" target="_blank" rel="noopener">AI-MARRVEL</a>, an artificial intelligence–based tool that analyzes genomic and clinical information to prioritize candidate disease variants, highlighted a rare change in <em>BRSK1</em>. Through GeneMatcher, the researchers identified nine additional affected individuals with rare heterozygous variants in the gene, bringing the group to 10 people from seven unrelated families. The team then modeled three patient-derived variants in <em>Drosophila melanogaster</em> to test their effects in a living organism.</p>
<p>The “affected individuals present with developmental delay and variable phenotypes including anxiety, attention-deficit hyperactivity disorder (ADHD), autism, and seizures,” the authors wrote, adding that the severity and symptoms varied. Symptoms differed even among relatives carrying the same variant, suggesting variable expressivity.</p>
<p>“We studied the fly equivalent of <em>BRSK1</em>, called <em>sff</em> (sugar-free frosting), and found that this gene is active primarily in neurons, mirroring the expression pattern seen in humans,” added Mingxi Deng, PhD, who is first author and a postdoctoral fellow in the Bellen lab. “When the fly gene was disabled, the flies developed difficulties moving, showed increased sensitivity to stressors that can trigger seizure-like behavior, became more vulnerable to heat-induced paralysis and lived shorter lives. These findings indicated that the gene is essential for normal nervous system function.”</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>Introducing normal human <em>BRSK1</em> largely corrected the behavioral and neurological defects, whereas three variants (<em>BRSK1<sup>p.Ile202Val</sup></em>, <em>BRSK1<sup>p.Arg237Cys</sup></em>, and <em>BRSK1<sup>p.Thr406Ile</sup></em>) found in affected individuals produced only a partial rescue. The patient variants also failed to normalize neuromuscular junction structure or levels of Futsch, a protein involved in organizing neuronal microtubules. Together, the experiments suggest that the variants partially reduce <em>BRSK1</em> activity rather than eliminating it.</p>
<p>“Microtubule disruption has been linked to several neurodevelopmental and neurological disorders,” Deng said. “Our findings suggest that reduced <em>BRSK1</em> function interferes with the cellular machinery needed for healthy brain development and communication between neurons.”</p>
<p><em>BRSK1</em> encodes a kinase involved in neuronal polarization, synaptic function, and the internal organization of nerve cells. Reduced activity may therefore interfere with the cellular machinery neurons need to develop and communicate. “This work improves our understanding of the genetic causes of neurodevelopmental disorders and highlights the power of combining AI-driven gene discovery with experimental studies in model organisms to uncover new rare diseases and their underlying biology,” Bellen said.</p>
<p>The diagnosis may help participating families understand the source of their condition and could guide recognition of additional cases. Future studies will be needed to determine why the same variant can produce markedly different symptoms and to define more precisely how altered <em>BRSK1</em> activity affects the developing brain.</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/ai-tool-helps-link-brsk1-variants-to-neurodevelopmental-disorder/">AI Tool Helps Link <i>BRSK1</i> Variants to Neurodevelopmental Disorder</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Antibody Blocks T Cell Infiltration and Limits Neurodegeneration in Alzheimer’s Mice</title>
<link>https://edusehat.com/en/antibody-blocks-t-cell-infiltration-and-limits-neurodegeneration-in-alzheimers-mice</link>
<guid>https://edusehat.com/en/antibody-blocks-t-cell-infiltration-and-limits-neurodegeneration-in-alzheimers-mice</guid>
<description><![CDATA[ Researchers developed a potential antibody-based approach to reducing neurodegeneration in tauopathies, with studies showing that in a mouse Alzheimer’s model anti-CXCR3-treated animals retained more brain tissue and had better memory, even though tau levels stayed the same.
The post Antibody Blocks T Cell Infiltration and Limits Neurodegeneration in Alzheimer’s Mice appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2018/11/9067712022200.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 29 Sep 2026 04:15:14 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Antibody, Blocks, Cell, Infiltration, and, Limits, Neurodegeneration, Alzheimer’s, Mice</media:keywords>
<content:encoded><![CDATA[<p>Researchers at Washington University School of Medicine in St. Louis have developed a potential antibody-based approach to reducing neurodegeneration in diseases known as tauopathies, including Alzheimer’s disease. Studying mice with Alzheimer’s-like tau protein accumulation in their brains, the team showed that injecting the animals with an antibody to a protein called CXCR3 over several months blocked the route used by T cells to get into the brain, reducing the number of those cells in the brain by about half.</p>
<p>The treated mice kept roughly 40% more tissue in memory centers of the brain and did better on a memory test compared with untreated mice—even though the levels of tau in their brains didn’t change. “In tauopathies, including Alzheimer’s disease, there’s no treatment right now that actually decreases neurodegeneration,” said David M. Holtzman, MD, the Barbara Burton and Reuben M. Morriss III Distinguished Professor in WashU Medicine’s Department of Neurology. “If we can show that we’re really decreasing brain cell death, it’s certainly worth trying to pursue that pathway to prevent the most devastating consequences of these diseases.”</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>Holtzman is senior author of the team’s published paper in <em>Neuron</em>, titled “<a href="https://doi.org/10.1016/j.neuron.2026.08.030" target="_blank" rel="noopener">Peripheral CXCR3 blockade mitigates T cell infiltration and neurodegeneration in a mouse model of tauopathy</a>,” in which they concluded “Our study defines the CXCR3 axis as a critical target that, when blocked, mitigates CD4+ and CD8+ T cell infiltration and confers neuroprotection in a model of tau-mediated neurodegeneration <em>in vivo</em> without influencing levels of soluble or insoluble tau.”</p>
<p>There is no treatment available today to stop the death of brain cells in tauopathies—including Alzheimer’s disease—in which twisted clumps of a protein called tau accumulate in the brain. Cells near those clumps begin to die after tau accumulates, but growing evidence suggests that much of the damage doesn’t come from the protein directly. Instead, it’s the immune system’s response to tau that’s to blame for the damage that eventually robs people of their memory and independence.</p>
<p>The two existing Alzheimer’s drugs on the market—lecanemab and donanemab—target amyloid protein, which forms plaques between brain cells in the early stages of the disease, disrupts cell communication, triggers tau tangles to form inside neurons and eventually leads to cell death. These anti-amyloid medications can slow a person’s decline, but they haven’t been shown to keep brain cells from dying, and they don’t work against primary tauopathies—diseases marked by tau buildup in which amyloid never appears. Alzheimer’s is a secondary tauopathy in which both amyloid and tau proteins accumulate.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>Earlier research led by the Holtzman lab raised the possibility that targeting T cells could be an alternative route to treating tauopathies, including Alzheimer’s. In a paper published in 2023 in <a href="https://www.nature.com/articles/s41586-023-05788-0" target="_blank" rel="noopener"><em>Nature</em></a>, Holtzman’s lab showed that in mice with tau buildup, T cells flood into the brain, especially in areas where tau is most abundant, and cause neurodegeneration. In a <a href="https://www.genengnews.com/topics/translational-medicine/immune-cells-driving-alzheimers-like-neurodegeneration-traced-to-lymph-nodes/" target="_blank" rel="noopener">related paper published earlier this month</a> in <em><a href="https://www.nature.com/articles/s41593-026-02427-5" target="_blank" rel="noopener">Nature Neuroscience</a></em>, the team showed that those T cells get their instructions from lymph nodes outside the brain.</p>
<p>In their newly published paper the team noted, “Beyond the roles of reactive microglia and astrocytes, recent work has demonstrated an important role of T cells and adaptive immunity in tau-mediated neurodegeneration, as suggested in human brains with advanced tauopathy and demonstrated in transgenic models.”</p>
<p>How T cells got into the brain once activated remained unknown, however. “The signaling pathways driving brain T cell homing and infiltration in tauopathies remain unknown, and identifying and targeting mechanisms for the prevention of such entry may offer therapeutic potential,” the investigators added.</p>
<p>The cells are known to navigate by following chemical trails called chemokines, and Holtzman’s team had previously found that one chemokine—called CXCL10—was elevated in the tau-mouse model they were utilizing. Other groups had shown that CXCL10 was elevated in Alzheimer’s. Activated T cells carry a protein on their surface, CXCR3, that follows this particular trail. “We hypothesized that the CXCR3 axis is an important chemotactic gradient for brain-infiltrating T cells in tauopathy, thereby linking peripheral immune activation to tau-driven brain injury,” they stated.</p>
<p>For their latest reported study the researchers, including co-senior author Jason Ulrich, PhD, a professor of neurology at WashU Medicine, and first author Joshua T. Emmerson, PhD, a postdoctoral researcher in Holtzman’s lab, examined the brains of mice with tau accumulation, as happens in Alzheimer’s disease. They found that in mice that lacked the CXCL10 chemokine, or the receptor protein CXCR3 on T cells that binds to CXCL10, T cells did not infiltrate the brain, even when researchers deliberately provoked inflammation to elicit an immune response.</p>
<p>The team then injected an antibody that blocked CXCR3 into young mice that had tau buildup in their brains but hadn’t yet had major brain cell loss. Treatment was administered every five days for three and a half months. The results showed that compared with the untreated mice, treated animals had about half as many T cells in their brains at the end of treatment. The treated animals also preserved more brain tissue and exhibited less evidence of nerve cell damage. “In a mouse model of tauopathy and neurodegeneration, chronic systemic anti-CXCR3 treatment markedly reduced parenchymal CD4+ and CD8+ T cell accumulation, attenuated neurodegeneration, and improved aspects of cognition,” they noted.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>Yet tau tangles appeared the same in treated and untreated animals. “A key point of interest was the rescue from neurodegeneration but no overt changes to tau pathology,” the researchers added.</p>
<p>Tests by Holtzman’s team also revealed that the antibody traveled to the border of each animal’s brain but not into the brain tissue—an important finding indicating that neurodegeneration can be treated without having to get a therapy into the brain itself.</p>
<p>“Our findings implicate a critical role of CD4+ T cells in accelerating tau-mediated neurodegeneration and suggest that peripheral CXCR3 inhibition could be a therapeutic approach in tauopathies,” the investigators said.</p>
<p>While more research is needed before the approach could be tested in people, Holtzman noted that existing drugs that target T cells—such as some therapies used for multiple sclerosis and other autoimmune disorders that occur when the body’s immune system attacks its own healthy cells—could be evaluated as Alzheimer’s therapies, opening a new therapeutic avenue for the disease.</p>
<p>“Tauopathies aren’t thought of as autoimmune disorders, so they haven’t been treated the same way, but this study shows for the first time in an animal model that these diseases respond to a specific T-cell therapy,” said Holtzman, who also directs WashU’s Hope Center for Neurological Disorders and the Knight Alzheimer Disease Research Center at WashU Medicine. “For this therapeutic approach, if it is safe, you wouldn’t have to design the drug to get into the brain—which is a big deal since most molecules don’t cross the blood-brain barrier well—and you don’t have to get rid of the tau to get this therapeutic effect.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/antibody-blocks-t-cell-infiltration-and-limits-neurodegeneration-in-alzheimers-mice/">Antibody Blocks T Cell Infiltration and Limits Neurodegeneration in Alzheimer’s Mice</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Derm Deep Dive: Rosacea Symptoms &amp;amp; Treatments</title>
<link>https://edusehat.com/en/derm-deep-dive-rosacea-symptoms-treatments</link>
<guid>https://edusehat.com/en/derm-deep-dive-rosacea-symptoms-treatments</guid>
<description><![CDATA[ What You Should Know About Rosacea and How to Best Treat It We’re back with another Derm Deep Dive, a…
The post Derm Deep Dive: Rosacea Symptoms &amp; Treatments appeared first on Optima Dermatology. ]]></description>
<enclosure url="https://optimadermatology.com/wp-content/uploads/2023/12/BlogWebsiteHeader_Dec-02-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 29 Sep 2026 04:15:13 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Derm, Deep, Dive:, Rosacea, Symptoms, Treatments</media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="2560" height="854" src="https://optimadermatology.com/wp-content/uploads/2023/12/BlogWebsiteHeader_Dec-01-scaled.jpg" alt="" class="wp-image-85008" srcset="https://optimadermatology.com/wp-content/uploads/2023/12/BlogWebsiteHeader_Dec-01-scaled.jpg 2560w, https://optimadermatology.com/wp-content/uploads/2023/12/BlogWebsiteHeader_Dec-01-300x100.jpg 300w, https://optimadermatology.com/wp-content/uploads/2023/12/BlogWebsiteHeader_Dec-01-1024x342.jpg 1024w, https://optimadermatology.com/wp-content/uploads/2023/12/BlogWebsiteHeader_Dec-01-768x256.jpg 768w, https://optimadermatology.com/wp-content/uploads/2023/12/BlogWebsiteHeader_Dec-01-1536x512.jpg 1536w, https://optimadermatology.com/wp-content/uploads/2023/12/BlogWebsiteHeader_Dec-01-2048x683.jpg 2048w" sizes="(max-width: 2560px) 100vw, 2560px"></figure>



<h2 class="wp-block-heading"><strong>What You Should Know About Rosacea and How to Best Treat It</strong></h2>



<p class="wp-block-paragraph">We’re back with another Derm Deep Dive, a series where we provide expert advice from one of our board-certified dermatologists about common skin conditions or treatments. For this edition, we’re discussing <a href="https://optimadermatology.com/2022/04/01/derm-deep-dive-rosacea-treatment">rosacea treatment</a> with <a href="https://optimadermatology.com/provider/lori-schaen-md" target="_blank" rel="noreferrer noopener">Dr. Lori Schaen, MD</a>, of our <a href="https://optimadermatology.com/locations/oh/milford-oh" target="_blank" rel="noreferrer noopener">Milford, OH location,</a> servicing the Cincinnati area. </p>



<h2 class="wp-block-heading"><strong>What is Rosacea and How Do You Know if You Have It?</strong></h2>



<p class="wp-block-paragraph">I see a lot of patients who are experiencing symptoms of Rosacea but are unsure what it is or how to treat it. First and foremost, if you have any skin issue and you aren’t sure what it is, the best thing to do before any at-home treatment is to visit your dermatologist and get an official diagnosis. </p>



<p class="wp-block-paragraph">Rosacea in particular is a skin condition that requires a more specific treatment plan, so understanding what it is and how it manifests for you is most important for proper treatment. </p>



<p class="wp-block-paragraph">While some people think of Rosacea as facial redness, it is a bit more complicated than that. Rosacea is a chronic condition that can cause inflammation on the cheeks, nose, chin, forehead, or eyelids. This inflammation can also lead to redness, broken blood vessels, swelling, pimples, pustules, and sometimes ocular/ eye symptoms.</p>



<p class="wp-block-paragraph">Rosacea is a fairly common condition, affecting about 16 million Americans. There is no known cause for Rosacea, and because it is a chronic condition, it can only be managed and controlled but not completely cured.  </p>



<h2 class="wp-block-heading"><strong>How Can You Manage Your Rosacea?</strong></h2>



<p class="wp-block-paragraph">Because there is no known cause – and no definitive cure – I work with patients to identify two important aspects of their Rosacea:</p>



<ol start="1" class="wp-block-list">
<li>What triggers seem to cause Rosacea flare-ups</li>



<li>How those triggers can be managed or mitigated to reduce Rosacea flare-ups</li>
</ol>



<h2 class="wp-block-heading"><strong>Identifying Potential Triggers</strong></h2>



<p class="wp-block-paragraph">Many individuals who have Rosacea are able to identify triggers that seem to bring on flare-ups. While these triggers vary naturally from person to person, there are some that are more common:</p>



<ul class="wp-block-list">
<li>Sun exposure </li>



<li>Hot or cold weather conditions, including humidity or indoor heat</li>



<li>Hot baths, showers, hot tubs, or saunas</li>



<li>Heavy exercise</li>



<li>Alcohol consumption, especially red wine</li>



<li>Harsh winds</li>



<li>Emotional stressors, such as anger, anxiety, embarrassment, or general stress</li>



<li>Certain foods, including spicy foods, aged cheeses, dairy products, and some chocolates</li>



<li>Hot drinks, including coffee and tea</li>
</ul>



<p class="wp-block-paragraph">I understand this list can seem pretty daunting and limiting – or simply hard to avoid, such as hot or cold weather conditions. However, the good news is that Rosacea can typically be brought under control, even if you can’t avoid your trigger or triggers 100 percent of the time. Here are some basic tips:</p>



<ul class="wp-block-list">
<li>On hot, sunny days, seek out shade, wear protective clothing, and use sunscreen with an SPF of 30 or higher</li>



<li>Protect your face and neck from cold weather, especially harsh winds</li>



<li>Try to manage emotional stress through deep breathing exercises, meditation, or calming, relaxing activities like yoga or simply reading a book. </li>



<li>Keep showers short to avoid overheating. If exercising, recognize when it’s time to take a break and drink water, and keep cold water on hand. </li>



<li>Choose white wine instead of red if alcohol is a trigger, or try to avoid alcohol and opt for a mocktail or water. </li>
</ul>



<h2 class="wp-block-heading"><strong>Products to Avoid that Can Aggravate Your Rosacea</strong></h2>



<p class="wp-block-paragraph">Every individual’s skin is different, and not all skin care products work for everyone. If you have Rosacea, there are a handful of products that are best to avoid as they’ve been known to make symptoms worse or bring about flare-ups. </p>



<ul class="wp-block-list">
<li>Topical steroids on the face, especially if used for more than a few days. </li>



<li>Cosmetics and hair sprays that contain alcohol, witch hazel, menthol, camphor, eucalyptus oil, propylene glycol, or fragrances. Instead of these products, I recommend L’Oreal alcohol-free hairspray.</li>



<li>Soaps, astringents, and alcohol-based toners. </li>



<li>Chemical peels or acids, including glycolic acid and hydroxy acids, exfoliants, and dermabrasion. </li>



<li>Sodium lauryl sulfate, which is a common skin irritant present in many shampoos, and chemical sunscreens.  </li>
</ul>



<p class="wp-block-paragraph">When it comes to sunscreens, mineral blockers zinc and titanium are often best tolerated by individuals with rosacea.</p>



<h2 class="wp-block-heading"><strong>Treatment Options for Rosacea</strong></h2>



<p class="wp-block-paragraph">Avoiding triggers is a critical way to manage your Rosacea, but I also work with patients to identify treatment options that can help manage or mitigate flare-ups altogether. It’s important to note that there are different types of Rosacea, and treatment options differ depending on the type and severity of your Rosacea. </p>



<p class="wp-block-paragraph">Some treatment options can include:</p>



<ul class="wp-block-list">
<li><strong>Antibiotics</strong> (typically Doxycycline): If Doxycycline is prescribed, be aware of common side effects and closely follow the recommendations for taking this medication.</li>



<li><strong>Oracea</strong>: Oracea is a lower dose of Doxycycline that acts as an anti-inflammatory rather than an antibiotic. This helps minimize the risks associated with the antibiotic dosing of doxycyline and is a safer long-term choice for rosacea. </li>



<li><strong>Topical medications</strong>: I help my patients understand which topical treatment is best for their Rosacea. </li>



<li><strong>Laser treatment</strong>: Typically, laser treatments are used in conjunction with one of the above treatment regimens and depends entirely on your specific type and severity of Rosacea.  Laser treatment for rosacea are not covered by insurance.</li>
</ul>



<h3 class="wp-block-heading"><strong>What Can You Do to Manage Your Rosacea at Home?</strong></h3>



<p class="wp-block-paragraph">After you have seen your dermatologist and identified the best treatment plan for your Rosacea, there are other steps you can take at home to adjust your skin care routine for better Rosacea management. </p>



<p class="wp-block-paragraph"><strong>Simplify, simplify, simplify</strong>. Keep your skin care routine simple. The more products you’re using on your face, the more irritated your skin can become, which can trigger Rosacea symptoms. </p>



<p class="wp-block-paragraph"><strong>Wash your face.</strong> A gentle wash with lukewarm water and a soap-free unscented cleanser is perfect for your face. Don’t scrub or rub your skin. My favorite products include:</p>



<ul class="wp-block-list">
<li>CeraVe Hydrating Cleanser</li>



<li>Cetaphil Gentle Cleanser</li>



<li>Neutrogena Ultra Gentle Hydrating Cleanser</li>



<li>Vanicream Gentle Facial Cleanser</li>



<li>Avene Antirougeurs Clean </li>
</ul>



<p class="wp-block-paragraph"><strong>Establish a regimen. </strong>Any prescription medications should be applied prior to any other products. </p>



<p class="wp-block-paragraph"><strong>Tackle dry skin right away. </strong>Apply thicker moisturizers to dry skin, such as CeraVe, Cetaphil, or Vanicream Moisturizing Skin Cream to mitigate dry skin before it becomes worse. </p>



<p class="wp-block-paragraph"><strong>Protect your skin! </strong>Apply a sunblock every morning with an SPF of at least 30. As I mentioned, physical sunblocks containing Zinc Oxide and/or Titanium Dioxide over chemical sunscreens are recommended for sensitive skin and are typically better tolerated by individuals with Rosacea. My favorite sunscreens include:</p>



<ul class="wp-block-list">
<li>La Roche-Posay Anthelios Mineral Tinted or Un-tinted SPF 50</li>



<li>Cetaphil or CeraVe Mineral SPF</li>



<li>Elta MD UV Elements 44 (Tinted in moisturizing base with antioxidants)</li>
</ul>



<p class="wp-block-paragraph">Switch up your makeup. Tinted SPF or mineral-based makeup is recommended for individuals with Rosacea as the minerals sit on the surface of the skin rather than being absorbed. You should avoid:</p>



<ul class="wp-block-list">
<li>Liquid makeups, which contain emulsifiers which can irritate the skin</li>



<li>Mineral makeup that contains bismuth oxychloride, a common skin irritant that can cause facial redness and rash</li>



<li>Oil-based and/or waterproof makeup</li>
</ul>



<p class="wp-block-paragraph">I recommend using makeup made by Neutrogena Mineral, Clinique Mineral, and Jane Iredale. </p>



<h2 class="wp-block-heading"><strong>When Should You Schedule a Visit With Your Dermatologist?</strong></h2>



<p class="wp-block-paragraph">I recommend that you schedule a visit with your dermatologist as soon as you begin experiencing Rosacea symptoms. Because it is a chronic condition with no known cause or cure, it’s best to speak with a professional rather than try and treat it at home.</p>



<p class="wp-block-paragraph">When you schedule an appointment with me, I first listen to your symptoms and concerns, perform an examination of the affected skin, and work with you to establish a treatment plan. You can expect to see improvements within the first few weeks of treatment, with ideal and more noticeable improvement occurring between eight and 12 weeks. </p>



<p class="wp-block-paragraph">I know Rosacea, like any skin condition, can be difficult to manage and frustrating to live with. However, the best way to manage it and get back to your life is to work with a dermatologist to establish the best treatment plan for your specific situation. </p>



<p class="wp-block-paragraph">I’d love to meet with you to start a conversation about treating your Rosacea. <a href="https://optimadermatology.com/provider/lori-schaen-md">Schedule an appointment with me</a> at Optima Dermatology’s <a href="https://optimadermatology.com/locations/oh/milford-oh" target="_blank" rel="noreferrer noopener">Milford, OH </a> practice for an initial consultation and to get started on a path to healthier, happier skin. </p>
<p>The post <a href="https://optimadermatology.com/2023/12/01/derm-deep-dive-rosacea-treatment-2">Derm Deep Dive: Rosacea Symptoms & Treatments</a> appeared first on <a href="https://optimadermatology.com/">Optima Dermatology</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Step 3 Percentiles and Placing in the Top</title>
<link>https://edusehat.com/en/step-3-percentiles-and-placing-in-the-top</link>
<guid>https://edusehat.com/en/step-3-percentiles-and-placing-in-the-top</guid>
<description><![CDATA[ This article was updated by Rebecca Lapides in September 2026.   Grant yourself a moment to take a nice deep congratulatory breath! You’ve survived undergrad, the MCAT, medical school, Step 1 and 2, and the match. That’s something to be incredibly proud of! What better way to celebrate than another 2-day, ~16-hour exam? In this […]
The post Step 3 Percentiles and Placing in the Top appeared first on Elite Medical Prep. ]]></description>
<enclosure url="https://elitemedicalprep.com/wp-content/uploads/2023/04/Step-3-Percentiles-and-Placing-in-the-Top.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 29 Sep 2026 01:00:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Step, Percentiles, and, Placing, the, Top</media:keywords>
<content:encoded><![CDATA[<p><em>This article was updated by <a href="https://elitemedicalprep.com/tutors/rebecca-lapides/">Rebecca Lapides</a> in September 2026.</em></p>
<p> </p>
<p><span>Grant yourself a moment to take a nice deep congratulatory breath! You’ve survived undergrad, the MCAT, medical school, Step 1 and 2, and the match. That’s something to be incredibly proud of! What better way to celebrate than another 2-day, ~16-hour exam? In this blog post, we will discuss the last step in becoming an MD, the </span><a href="https://elitemedicalprep.com/usmle-step-3-tutoring/"><span>USMLE Step 3</span></a><span> exam, its percentiles, and how to score on top!</span></p>
<p><span> </span></p>
<h2><strong>USMLE Step 3: How Important is Achieving a Score in the Top Percentiles?</strong></h2>
<p><span>The importance of a top percentile score depends on your goals and current position in residency. Most students are fully matched to a residency program when they take Step 3, so there is less pressure to get a high score. Other students may be unmatched and planning to re-apply in the following match cycle, making Step 3 a bit more of a consideration. Whatever goal score you have, you should always keep the following in mind:</span></p>
<p><span> </span></p>
<ol>
<li aria-level="1"><span>You are not ready to sit for this exam until you are confident that you are going to pass. Although scoring high may not have an impact on your future, failing this exam might. The test is also way too expensive to pay for twice with our residency salary!</span></li>
<li aria-level="1"><span>You have a lot on your plate and you need to preserve your mental wellness.</span></li>
<li aria-level="1"><span>You should do as well as you can while also remembering #2.</span></li>
</ol>
<p><span> </span></p>
<h2><strong>What is Needed to Pass the USMLE Step 3?</strong></h2>
<p><span>Alright, let’s get down to business. A few numbers you should know are 200, 227, and 15, which are the passing score, the mean score, and the standard deviation respectively. A failing score on Step 3 falls somewhere between the 2nd and 3rd percentiles. Although the USMLE is not entirely transparent with its scoring algorithm, a passing score correlates with about 60% correct. The mean score, 227, is much lower than the mean score for step 2 (250), which speaks to the fact that these tests are approached very differently. In general, you should aim to score somewhere within 1 SD of the mean (215-242).</span></p>
<p><span> </span></p>
<h2><strong>Staying on Track to Pass</strong></h2>
<p><span>Now that we’ve established a target score, what are some things you can do to accomplish that goal? Here are 5 tips to get you started on the right track to passing your USMLE Step 3.</span></p>
<p><span> </span></p>
<h3><strong>1. Don’t Test Until You Are Ready</strong></h3>
<p><span>It’s really important to set realistic study goals bearing in mind the rigor of your residency program and schedule practice exams for weeks that have a bit of a lighter schedule. Make sure you still keep up with practice questions and practice exams for an accurate prediction of how you’ll do on test day. Even if fatigue after a call shift, a distracting pet, or an interruption during a practice block affects your score, don’t expect a significant jump on test day. As much as there are distractions and complicating factors at home, there are also unique factors that will come up on test day, such as anxiety, </span><a href="https://elitemedicalprep.com/usmle-step-3-day-1-anxiety/"><span>especially if day 1 didn’t go as planned</span></a><span>. Make this a one-and-done ordeal so schedule the exam strategically so you have enough time to prepare in a targeted fashion. </span></p>
<p><span> </span></p>
<h3><strong>2. Apply Knowledge From Patient Care</strong></h3>
<p><span>This test is designed to make sure you are safe to provide patient care so it really should be a test of what you do every day at work. Of course, this may vary based on your specialty, but much of this exam does rely on knowledge that a resident would regularly use (including the interpretation of medical literature). Make sure you focus on understanding why you do things in the hospital, the timing and urgency of labs/procedures, and paying attention to management from consulting teams.</span></p>
<p><span> </span></p>
<h3><strong>3. Focus on Your Weaknesses</strong></h3>
<p><span>We’ve all got ’em! Depending on your residency specialty, some test takers may have larger gaps than others. In general, residents in internal medicine, family medicine, emergency medicine, and general surgery encounter a broader range of topics covered on this exam. These test takers should focus on the topics they encounter least often in their work. Test takers in the more niche specialties may need to dedicate more time to covering the broad sweeping, general concepts. As good as it may feel to do questions in your comfort zone, this isn’t going to give you as much of a benefit in preparing for test day.</span></p>
<p><span> </span></p>
<h3><strong>4. Don’t Forget About Biostatistics for USMLE Step 3</strong></h3>
<p><span>Eye roll. I know. But this test is </span><i><span>extremely</span></i><span> heavy on biostatistics because the test writers want to know that you are able to critically engage with medical literature. After all, they have a good point! The good news is that it is relatively easy to do a quick, deep dive into the world of USMLE biostatistics. You should watch a few videos, </span><b>memorize and understand your equations</b><span>, and zip through the practice questions in UWorld. Remember to also focus on how to interpret test results because many biostatistics questions on USMLE are not just plug-and-chug with equations, but actually ask you to interpret study findings. </span></p>
<p><span> </span></p>
<h3><strong>5. Work Around Your Residency Schedule</strong><span> </span></h3>
<p><span>If you are shooting for the mean and you are in a broad residency field, you really should be able to fit in enough studying without using up a vacation or elective block. However, if you are struggling to pass or if you are looking to score in the highest percentile, you may want to consider lining up your test with the lightest workload in your schedule. For example, an outpatient/elective block going into vacation block would be a great set-up for someone who is really looking to put in more time.</span></p>
<p><span> </span></p>
<p><span><strong>#1-3 are non-negotiable.</strong>  These are an absolute must if you are going to be successful on the test. #4-5 become more important based on how high you aim to score on this exam. Now go out there and show them what you’re made of! If you are looking for some extra assistance, consider enlisting the help of a USMLE Step 3 tutor. </span><a href="https://elitemedicalprep.com/contact/"><span>Schedule a consultation</span></a><span> today to hear more about how Elite Medical Prep can help you succeed!</span></p>
<p>The post <a href="https://elitemedicalprep.com/step-3-percentiles-and-placing-in-the-top/">Step 3 Percentiles and Placing in the Top</a> appeared first on <a href="https://elitemedicalprep.com/">Elite Medical Prep</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Scientists Observe Enzymes Breaking Down DNA in Real Time</title>
<link>https://edusehat.com/en/scientists-observe-enzymes-breaking-down-dna-in-real-time</link>
<guid>https://edusehat.com/en/scientists-observe-enzymes-breaking-down-dna-in-real-time</guid>
<description><![CDATA[ The research may be useful for the development of DNA-based therapeutics and gene-delivery systems. Packaging genetic material into structures that restrict nuclease access could potentially increase its resistance to degradation.
The post Scientists Observe Enzymes Breaking Down DNA in Real Time appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2240900378.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 29 Sep 2026 00:40:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Scientists, Observe, Enzymes, Breaking, Down, DNA, Real, Time</media:keywords>
<content:encoded><![CDATA[<p>Researchers at the Nano Life Science Institute at Kanazawa University in Japan say they have directly visualized how enzymes find and break DNA molecules in real time. Using high-speed atomic force microscopy, the team followed individual enzymes as they moved along DNA and found that they repeatedly returned to vulnerable regions before breaking them apart.</p>
<p>The findings “<a href="https://www.nature.com/articles/s41467-026-77354-x">Shield strike shatter in DNA topology and nuclease interactions</a>,” which were published in <em>Nature Communications</em>, reveal how the structure of DNA influences its vulnerability to enzymatic breakdown.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>According to the scientists, the study provides a dynamic view of a fundamental biological problem: why some DNA is accessible to enzymes while other DNA remains protected.</p>
<p>“Our high-speed AFM imaging allows us to follow the interaction between individual nuclease enzymes and DNA as it happens,” says student Jingge Yang. “We can see that DNA is not simply a passive target. Its local shape and higher-order organization strongly influence where enzymes interact and whether degradation can proceed,” adds Richard Wong, PhD, professor and team leader.</p>
<p></p><h4><strong>Watching DNA degradation molecule by molecule</strong></h4>

<div class="my-8"><span data-render-ad="4"></span></div>
<p>DNA is constantly exposed to processes that can damage or break it. Some enzymes, nucleases, can deliberately break down DNA. They  play important roles in maintaining cells and clearing unwanted DNA.</p>
<p>One of the best-known of these enzymes is DNase I, which helps remove DNA released from damaged or dying cells. Problems with this clearance process have been associated with inflammatory and autoimmune diseases.</p>
<p>Although scientists know a great deal about the chemistry of DNase I, it has been difficult to see exactly how individual enzyme molecules approach DNA, where they remain and what happens immediately before and after the DNA is cut.</p>
<p><figure aria-describedby="caption-attachment-338535" class="wp-caption alignleft"><img fetchpriority="high" decoding="async" class="size-medium wp-image-338535" src="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-1016112584-300x200.jpg" alt="Placing samples into an atomic force microscope, a high-resolution type of scanning probe microscopy with demonstrated resolution on the order of fractions of a nanometer. " width="300" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-1016112584-300x200.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-1016112584.jpg 724w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text"><em>Placing samples into an atomic force microscope, a high-resolution type of scanning probe microscopy with demonstrated resolution on the order of fractions of a nanometer. [Casarsa Guru/Getty Images]</em></figcaption></figure>The Kanazawa scientists researchers addressed this problem using high-speed atomic force microscopy (HS-AFM), a technique that can record nanoscale changes in biological molecules in liquid without requiring them to be fixed, stained, or crystallized. This allowed the researchers to observe in real time how individual nuclease enzymes interacted with and gradually broke apart DNA.</p>
<p>The HS-AFM movies revealed that DNase I did not interact with every part of a DNA molecule in the same way. The enzyme was frequently found near exposed DNA ends and regions where the DNA was curved or locally bent. Individual DNase I molecules could repeatedly return to restricted regions before visible fragmentation occurred.</p>
<p>Longer-lasting interactions were also more common around curved regions where DNA was more likely to be cut. Together, these observations showed that the shape of DNA influenced where the enzymes interacted with it.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>Importantly, the HS-AFM cannot directly show the chemical reaction occurring at the enzyme’s active site. The researchers therefore describe the relationship between DNA shape, repeated enzyme engagement, and subsequent cleavage as a spatial and temporal correlation rather than direct observation of the catalytic reaction.</p>
<p></p><h4><strong>Five stages of DNA degradation</strong></h4>

<p><figure aria-describedby="caption-attachment-338533" class="wp-caption alignright"><img decoding="async" class="size-medium wp-image-338533" src="https://www.genengnews.com/wp-content/uploads/2026/09/884d8ff8057f0bc570d39ea7e6a6fba1-241x300.jpg" alt="Visualizing DNA protection and degradation by high-speed AFM. Higher-order DNA structures protect DNA from nuclease degradation, whereas exposed DNA is bound, cleaved, and progressively fragmented by nucleases. High-speed atomic force microscopy (HS-AFM) enables these dynamic processes of DNA "protection, attack, and destruction" to be visualized at the nanoscale. The AFM tip is illustrated at the upper right. [Richard W. Wong, PhD, Kanazawa University and image created in part using OpenAI's ChatGPT]" width="241" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/884d8ff8057f0bc570d39ea7e6a6fba1-241x300.jpg 241w, https://www.genengnews.com/wp-content/uploads/2026/09/884d8ff8057f0bc570d39ea7e6a6fba1.jpg 500w" sizes="(max-width: 241px) 100vw, 241px"><figcaption class="wp-caption-text">Visualizing DNA protection and degradation by high-speed AFM. Higher-order DNA structures protect DNA from nuclease degradation, whereas exposed DNA is bound, cleaved, and progressively fragmented by nucleases. High-speed atomic force microscopy (HS-AFM) enables these dynamic processes of DNA “protection, attack, and destruction” to be visualized at the nanoscale. The AFM tip is illustrated at the upper right. [Richard W. Wong, PhD / Kanazawa University / Image created in part using OpenAI’s ChatGPT]</figcaption></figure>Based on these recurring patterns of interaction, the researchers developed a conceptual framework that they call STORM: Scan–Target–Occupy–Rupture–Mobilize. In this framework, an enzyme samples the DNA, becomes localized at a particular region, remains associated with it, fragmentation occurs and the resulting pieces are redistributed.</p>
<p>The researchers emphasize that STORM is a framework for describing the interaction patterns revealed by the experiments rather than a fixed sequence through which every enzyme molecule must pass.</p>
<p class="trimmed"> </p>
<p>The team also examined another DNA-cutting enzyme, micrococcal nuclease (MNase). Despite differences between DNase I and MNase, the team observed similar patterns of DNA sampling, localized interaction, repeated association, disruption and fragment redistribution. This suggests that STORM-like behavior may reflect broader physical principles governing how different nucleases interact with DNA.</p>
<p>The experiments also revealed how the physical organization of DNA can protect it from degradation. The researchers examined DNA condensed by protamine, a small protein that binds strongly to DNA. Protamines are particularly important in sperm cells, where they help package the paternal genome into an extremely compact form.</p>
<p>Under the experimental conditions, protamine caused DNA to form mainly two compact structures: elongated rod-like structures and ring-shaped structures called toroids. High-speed microscopy showed that DNase I molecules could gather around these condensed structures without destroying them. The toroidal structures were particularly compact. DNase I rarely penetrated their central regions, and the structures remained intact during continuous observation for more than six minutes despite the presence of the enzyme.</p>
<p>When the condensed structures were partially loosened, however, exposed regions again became susceptible to degradation. The results suggest that protection does not arise simply from the electrical interaction between protamine and DNA. Instead, tightly packing DNA into particular three-dimensional structures creates a physical barrier that limits the enzyme’s access.</p>
<div class="my-8"><span data-render-ad="6"></span></div>
<h4><strong>Possible framework for understanding DNA protection and clearance</strong></h4>
<p>The findings could contribute to understanding how compact structures help preserve genetic information, including the exceptionally dense packaging found in sperm cells. They could also be relevant to extracellular DNA released from damaged or dying cells, which can stimulate immune responses if it is not efficiently removed.</p>
<p>The results may additionally be useful for the development of DNA-based therapeutics and gene-delivery systems. Packaging genetic material into structures that restrict nuclease access could potentially increase its resistance to degradation.</p>
<p class="trimmed"> </p>
<p>The post <a href="https://www.genengnews.com/topics/omics/scientists-observe-enzymes-breaking-down-dna-in-real-time/">Scientists Observe Enzymes Breaking Down DNA in Real Time</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>UHN launches new robotic cardiac surgery program</title>
<link>https://edusehat.com/en/uhn-launches-new-robotic-cardiac-surgery-program</link>
<guid>https://edusehat.com/en/uhn-launches-new-robotic-cardiac-surgery-program</guid>
<description><![CDATA[ University Health Network (UHN) has launched a new robotic cardiac surgery program at Toronto’s Peter Munk Cardiac Centre, expanding access to minimally invasive approaches for patients undergoing complex heart procedures. The program is being led by Dr. Ali Hage, UHN’s Director of Robotic Cardiac Surgery, who recently joined the organization from NYU Langone Health, where […]
The post UHN launches new robotic cardiac surgery program appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/09/ChatGPT-Image-Sep-28-2026-09_22_12-AM.png" length="49398" type="image/jpeg"/>
<pubDate>Mon, 28 Sep 2026 21:00:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>UHN, launches, new, robotic, cardiac, surgery, program</media:keywords>
<content:encoded><![CDATA[<p>University Health Network (UHN) has launched a new robotic cardiac surgery program at Toronto’s Peter Munk Cardiac Centre, expanding access to minimally invasive approaches for patients undergoing complex heart procedures.</p>
<p>The program is being led by <strong>Dr. Ali Hage, UHN’s Director of Robotic Cardiac Surgery</strong>, who recently joined the organization from NYU Langone Health, where he worked as an attending cardiac surgeon in a major robotic mitral valve program.</p>
<p>Hage brings specialized experience in robotic cardiac surgery, complex mitral and tricuspid valve repair, cardiac arrhythmia surgery and structural heart disease. His training includes a fellowship in robotic cardiac surgery and complex mitral valve reconstruction at Cleveland Clinic.</p>
<p>Robotic cardiac surgery allows surgeons to perform certain procedures through smaller incisions rather than the traditional approach of opening the breastbone. For appropriate patients, minimally invasive approaches can offer benefits including less pain, smaller incisions, shorter hospital stays and a faster return to daily activities.</p>
<p>The new robotic program builds on UHN’s existing expertise in minimally invasive cardiac surgery. The Peter Munk Cardiac Centre already performs minimally invasive procedures involving coronary bypass surgery, aortic surgery and mitral and tricuspid valve repair and replacement.</p>
<h2>An important part of the initiative will also be education and training.</h2>
<p>The program is expected to help develop robotic cardiac surgery expertise among Canadian physicians. UHN already supports robotic-assisted surgical training through the Michener Institute of Education and its advanced surgical education and simulation facilities, where surgical teams can practise robotic techniques in simulated operating-room environments.</p>
<p>Hage’s work at UHN is also expected to combine surgery with research and technological innovation. His research interests include integrating artificial intelligence, computer vision and advanced imaging into cardiac surgery, particularly robotic mitral valve procedures.</p>
<p>The launch adds robotic cardiac surgery to UHN’s growing portfolio of advanced surgical technologies and could help expand both patient access and Canadian expertise in minimally invasive heart surgery.</p>
<p>The post <a href="https://www.hospitalnews.com/uhn-launches-new-robotic-cardiac-surgery-program/">UHN launches new robotic cardiac surgery program</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Bayh&#45;Dole Act’s benefits include $3 trillion in U.S. output, report finds</title>
<link>https://edusehat.com/en/bayh-dole-acts-benefits-include-3-trillion-in-us-output-report-finds</link>
<guid>https://edusehat.com/en/bayh-dole-acts-benefits-include-3-trillion-in-us-output-report-finds</guid>
<description><![CDATA[ It’s been a long day at the university lab, but the researchers, who have been working on a niche bit of molecular biology research, […]
The post Bayh-Dole Act’s benefits include $3 trillion in U.S. output, report finds appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/09/bayh-dole-report-cover.png" length="49398" type="image/jpeg"/>
<pubDate>Mon, 28 Sep 2026 17:30:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Bayh-Dole, Act’s, benefits, include, trillion, U.S., output, report, finds</media:keywords>
<content:encoded><![CDATA[<p>It’s been a long day at the university lab, but the researchers, who have been working on a niche bit of molecular biology research, are happy. They have just made a profound discovery that could change the way some cancers are treated, and investors are already lined up to support the work.</p>
<p>Before we know it, they think to themselves, lives will be saved.</p>
<p>In the United States, such technology transfer is often taken for granted—but it hasn’t always been this way. As recently as 45 years ago, if the university researcher had gotten a grant from the federal government, then the federal government took ownership over what was invented.</p>
<p>This system stymied innovation. At the time, the federal government held the patents on roughly 28,000 discoveries, yet licensed fewer than 5% for commercialization. Something had to change.</p>
<p>And so, in 1980 Senator Birch Bayh (D-IN) and Senator Bob Dole (R-KS) drafted the Bayh-Dole Act of 1980 (Patent and Trademark Law Amendments Act, P.L. 96-517) to allow universities, small businesses, and non-profits to retain ownership and patent rights of inventions developed through research supported by federally funding—incentivizing the public-private collaborations required to transform scientific discoveries into new technologies, industries, products and companies.</p>
<p>The results have been a renaissance of innovation and licensing. The legislation’s ongoing success is highlighted in a new report by the Bayh-Dole Coalition, which includes the Biotechnology Innovation Organization (BIO) as a member. The 2026 report, “<a href="https://bayhdolecoalition.org/new-report-shows-3-3-trillion-in-u-s-economic-output-from-bayh-dole-innovation/" target="_blank" rel="noopener">The Economic Impact of the Bayh-Dole Act</a>,” provides impressive statistics.</p>
<h3>Overall economic impact is enormous</h3>
<p>In the last 30 years alone, technology transfer facilitated by the Bayh-Dole Act between federal supported universities and non-profits and the private sector contributed as much as:</p>
<ul>
<li>$3.3 trillion to U.S. gross economic output,</li>
<li>$1.7 trillion to the U.S. GDP, and</li>
<li>6 million job-years of U.S. employment.</li>
</ul>
<p>Since 1980, the annual number of patents on inventions benefiting from government funding has increased more than 70-fold.</p>
<p>And in more recent years, from 2001-2025, technology transfer at academic institutions led to the launch of more than 19,000 startups and the introduction of more than 17,000 new products. It has also seen:</p>
<ul>
<li>$288 billion in GDP,</li>
<li>$577 billion in gross economic output, and</li>
<li>08 million job-years of U.S. employment.</li>
</ul>
<p>In fact, universities and nonprofit research institutions averaged about 19,387 income-generating licenses annually from 2021–2025, that is roughly twice the annual average in 2001–2005.</p>
<p>And furthermore, the report found that there have been:</p>
<ul>
<li>5,972 running-royalty licenses annually from 2021–2025,</li>
<li>$3.2 billion in average annual gross licensing income, and</li>
<li>$1.9 billion in average annual running royalty income.</li>
</ul>
<p>And while that doesn’t necessarily translate one-to-one to on-the-market products, it does reflect the pace at which private-public partnerships are moving and continuing to grow.</p>
<p>Put simply, the legislation did not just spur economic development in the short term, but has continued to generate significant innovation, progress, and economic activity year after year—continuing today.</p>
<p>And the benefits are both micro and macro to economic development.</p>
<h3>A closer look—the regional benefits of Bayh Dole</h3>
<p>This economic impact Bayh-Dole has positively affected every corner of the United States, generating economic activity in every state in the union. The economic development from 2021–2025 alone is notable.</p>
<p>For example, in the South (AL, AR, DE, DC, FL, GA, KY, LA, MD, MS, NC, OK, PR, SC, TN, TX, VA, WV) Bayh-Dole helped facilitate 5,482 startups, and the development of 4,772 products.</p>
<p>Comparatively, in the West (AK, AZ, CA, CO, HI, ID, MT, NV, NM, OR, UT, WA, WY) Bayh-Dole helped facilitate 4,931 startups, and the development of 3,667 products.</p>
<p>And in the Northeast (CT, ME, MA, NH, NJ, NY, PA, RI, VT) Bayh-Dole helped facilitate 4,823 startups, and the development of 2,331 products.</p>
<p>And finally, in the Midwest (IL, IN, IA, KS, MI, MN, MO, NE, ND, OH, SD, WI) Bayh-Dole helped facilitate 3,791 startups, and the development of 6,482 products.</p>
<p>States like Pennsylvania, Massachusetts, California, and Texas benefited particularly with Pennsylvania seeing $4.49B in gross licensing income and $2.30B in running royalties; Massachusetts seeing $1.98B and $924M; California seeing $1.48B and $578M; and Texas seeing $905M; $876M.</p>
<p>Following up the lead, New York saw $911M in gross licensing income and $517M in running royalties; Georgia saw $655M and $598M; Minnesota saw $733M and $389M; and North Carolina saw $641M and $418M.</p>
<p>And finally, from 2001–2025, Pennsylvania reported the facilitated creation of 1,100 startups, Massachusetts 1,762, California 2,488, and Texas 1,101.</p>
<p>The impact on the growth of the biotechnology industry was especially seen in the Northeast and West regions.</p>
<p>As the report notes, in the Northeast: “Notable innovations benefiting from federal funding emerging from the region’s research institutions include the HIV/AIDS therapy Zerit from Yale University, high-definition video and audio technologies from Columbia University, and mRNA and CAR T-cell technologies from the University of Pennsylvania.”</p>
<p>While in the West: “The University of Arizona has used federal funding to develop…. innovations benefiting from federal funding for the early detection and prevention of osteoporosis began in University of Washington labs.”</p>
<h3>The 2026 Bayh-Dole Report supports BIO’s own research</h3>
<p>The numbers uncovered in the 2026 Bayh-Dole report are supported by BIO’s own commissioned report from AUTM.</p>
<p>When it comes to biotech and life sciences, this report found that biotech and life sciences licensing is especially impactful within the Bayh-Dole landscape. Historically, about 80% of university licensing income and 90% or more of hospital/research-institute licensing income has historically come from life sciences, while 60%–70% of licenses were to small companies or startups.</p>
<p>Ultimately, the picture is clear. The public-private collaboration built by the Bayh-Dole Act has changed the fact of biotech and life sciences innovation and development across the U.S.—and the world. And the lives saved, and improved, are likely incalculable.</p>
<p><a href="https://bayhdolecoalition.org/new-report-shows-3-3-trillion-in-u-s-economic-output-from-bayh-dole-innovation/" target="_blank" rel="noopener"><strong>Read “The Economic Impact of the Bayh-Dole Act.”</strong></a></p>
<p>The post <a href="https://bio.news/federal-policy/bayh-dole-acts-benefits-include-3-trillion-in-u-s-output-report-finds/">Bayh-Dole Act’s benefits include $3 trillion in U.S. output, report finds</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Viral Protein Helps Self&#45;Amplifying RNA Overcome Cellular Defenses</title>
<link>https://edusehat.com/en/viral-protein-helps-self-amplifying-rna-overcome-cellular-defenses</link>
<guid>https://edusehat.com/en/viral-protein-helps-self-amplifying-rna-overcome-cellular-defenses</guid>
<description><![CDATA[ Adding a viral protein, NoV B2, helped self-amplifying RNA overcome cellular defenses and produce more target protein without diminishing immune stimulation, potentially enabling future vaccines to use lower doses.
The post Viral Protein Helps Self-Amplifying RNA Overcome Cellular Defenses appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/04/GettyImages-1450368712.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 28 Sep 2026 17:25:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Viral, Protein, Helps, Self-Amplifying, RNA, Overcome, Cellular, Defenses</media:keywords>
<content:encoded><![CDATA[<p><span>A new study led by scientists at Queen Mary University of London describes a way to overcome a cell’s natural defenses against self-amplifying RNA vaccines. According to details provided in a new </span><i><span>Nature Communications </span></i><span>paper, adding a viral protein dubbed NoV B2 helps overcome this issue, while preserving saRNA’s ability to stimulate the immune system. </span></p>
<p><span>According to details provided in the paper, which is titled “</span><a href="https://www.nature.com/articles/s41467-026-77816-2" target="_blank" rel="noopener"><span>Tuning intracellular immunity by Nodamura virus B2 protein enhances self-1 amplifying RNA activity</span></a><span>,” found that adding this protein, which is known to suppress RNA interference, reduced the extent to which the cells restrict saRNA, allowing it to provide far more of the intended protein in both stem cells and regular cells. It addresses a major challenge with saRNA vaccines that hampered their application in gene therapies, cancer immunotherapies, and protein replacement therapies. </span></p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p><span>Most people are familiar with mRNA-based vaccines because of the Covid-19 pandemic. Since then scientists have worked on developing saRNA which replicates within host cells. The goal is to use the technology to develop vaccines and therapies that provide longer-lasting protection at lower doses that are safe and affordable.</span></p>
<p><span>Specifically, during the self-replicating process, saRNA generates double-stranded RNA which triggers cells’ anti-virus defenses. This makes the saRNA less stable, less able to replicate, and less able to instruct cells to produce the protein that trains the immune system. To date, this has limited the effectiveness of saRNA vaccines. But this development could help scientists develop effective saRNA vaccines that work at lower doses and could be rolled out further and faster than has been possible. </span></p>
<p><span>According to Pierre Maillard, PhD, senior lecturer in antiviral immunity at Queen Mary University of London, and one of the authors on the study, “our findings identify a strategy to overcome a fundamental barrier limiting self-amplifying vaccines” and “if this translates successfully <em>in vivo</em>, it could open new possibilities for vaccine design as well for gene therapies and cancer treatment.”</span></p>
<p>The post <a href="https://www.genengnews.com/topics/omics/viral-protein-helps-self-amplifying-rna-overcome-cellular-defenses/">Viral Protein Helps Self-Amplifying RNA Overcome Cellular Defenses</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>StockWatch: Nektar Shares Flat as $90M Jury Verdict Less than Sought in Lilly Suit</title>
<link>https://edusehat.com/en/stockwatch-nektar-shares-flat-as-90m-jury-verdict-less-than-sought-in-lilly-suit</link>
<guid>https://edusehat.com/en/stockwatch-nektar-shares-flat-as-90m-jury-verdict-less-than-sought-in-lilly-suit</guid>
<description><![CDATA[ This past week, Nektar Therapeutics (Nasdaq: NKTR) offered an uncommon example of victory in court translating into defeat on Wall Street. Nektar’s shares finished Friday flat, dipping 4% from $59.38 to $57.06 despite a jury siding with the San Francisco biotech over Eli Lilly (NYSE: LLY) in a three-year-old legal dispute over the pharma giant’s terminating a collaboration agreement to co-develop Nektar’s lead pipeline candidate rezpegaldesleukin (rezpeg).
The post StockWatch: Nektar Shares Flat as $90M Jury Verdict Less than Sought in Lilly Suit appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/Nektar-Therapeutics-CROPPED11111-JPEG-1024x586-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 28 Sep 2026 06:40:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>StockWatch:, Nektar, Shares, Flat, 90M, Jury, Verdict, Less, than, Sought, Lilly, Suit</media:keywords>
<content:encoded><![CDATA[<p>This past week, <strong>Nektar Therapeutics (Nasdaq: NKTR)</strong> offered an uncommon example of victory in court translating into defeat on Wall Street.</p>
<p>Nektar’s shares finished Friday flat, <strong>dipping 4%</strong> from $59.38 to $57.06 despite a jury siding with the San Francisco biotech over <strong>Eli Lilly (NYSE: LLY)</strong> in a three-year-old legal dispute over the pharma giant’s terminating a collaboration agreement to co-develop Nektar’s lead pipeline candidate rezpegaldesleukin (rezpeg).</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>A jury in the Northern District of California awarded Nektar $90 million, plus additional interest to be determined by the court, after agreeing with Nektar that Lilly breached a covenant of good faith and fair dealing implied through the companies’ up-to-$400 million agreement to co-develop rezpeg, initially for autoimmune and other chronic inflammatory conditions.</p>
<p>“We are pleased with the jury’s verdict in Nektar’s favor finding that Lilly breached the implied covenant of good faith and fair dealing in the license agreement,” Nektar said in a statement to <em>GEN</em> and other news outlets.</p>
<p>At deadline, a Lilly spokesperson had not responded to a <em>GEN</em> query seeking comment on the Nektar jury verdict.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>The legal victory was ultimately viewed as anything but by investors, since Nektar had sought a verdict of $1 billion against Lilly. True, pre-market investors sparked a mini-buying surge that was enough to send Nektar shares <span><strong>rising ~4.92%</strong></span> early on Friday, Edward Nash, a managing director and senior biotechnology analyst with Canaccord Genuity, reported in a research note.</p>
<p>But when the opening bell sounded, Nektar shares swung back down, <span><strong>slipping 4.6%</strong></span> from an opening price of an even $60 a share the first minute of trading down to $57.22 at 9:48 a.m. That is below expectation based on the 34.14 million outstanding Nektar shares as of Friday morning.</p>
<p>“A judgment of $90M represents $2.64 in cash per share and would imply a 4.4% move upward in the stock compared to [Thursday]’s closing price of $59.38,” Nash explained.</p>
<p></p><h4><strong>Silver lining</strong></h4>

<p>Nash did see a silver lining behind the proverbial cloud of Nektar’s failure to surge on the good legal news.</p>
<p>“While the company was seeking $1B in damages and the $90M falls short of this number, our model does not include any windfall from the case. Importantly, the company also did not require any monies from the case in order to continue developing their pipeline assets,” Nash commented. “Therefore, any sum awarded in the case represents a non-dilutive capital addition to the balance sheet which we have not been factoring into our valuation.”</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>Because the jury’s verdict is still subject to post-trial proceedings and an all-but-expected appeals process, Canaccord Genuity has left out a jury verdict payout from its model for Nektar: “If Lilly appeals the verdict, it could be months or years before Nektar would receive any payment. We will move to include the sum in our model when and if it is paid.”</p>
<p>Nektar said rezpeg is a first-in-class therapeutic designed to target the CD25 sub-receptor in the interleukin-2 (IL-2) receptor complex to stimulate proliferation and growth of regulatory T cells (Tregs). By activating these cells, Nektar reasons, rezpeg could restore balance between Tregs and effector T cells (Teffs) and thus address the underlying immune system imbalance seen in many autoimmune and inflammatory conditions.</p>
<p></p><h4><strong>Dose-dependent AD improvement</strong></h4>

<p>In August, Nektar researchers <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01143-8/abstract">published data in <em>The Lancet</em></a> from the 16-week induction period of the 52-week REZOLVE-AD trial (<a href="https://url.us.m.mimecastprotect.com/s/sYEWCpYWpMszG1RMtPfkIG_9Mw?domain=clinicaltrials.gov">NCT06136741</a>) assessing rezpeg in patients with moderate-to-severe atopic dermatitis (AD). Patients treated with rezpeg showed statistically significant, dose-dependent improvement in mean percent reduction in Eczema Area and Severity Index (EASI) from baseline at Week 16: 61% of patients dosed at the 24 μg/kg once every 2 weeks (q2w) arm; 58% of patients at the 18 μg/kg q2w arm, and 53% of patients dosed at 24 μg/kg once every 4 weeks (p<0.0001, p<0.0001, and p=0.0002, respectively), vs. 31% for placebo.</p>
<p>Nektar shares nearly doubled in February after it announced positive data from the 36-week blinded maintenance period of REZOLVE-AD. Among 55 patients dosed at 24 µg/kg every month, 71% (36) achieved EASI score reductions of at least 75% (EASI-75). Half those patients (18, or 80%) achieved EASI-90. The percentage climbed to 83% among the 56 patients receiving the same dosage of rezpeg every three months. Of those, 63% (21) maintained validated Investigator Global Assessment of Atopic Dermatitis (vIGA-AD) 0/1 response after quarterly dosing, as did 85% (14) of patients dosed monthly.</p>
<p>Perhaps most encouraging to patients, 75% (25) of patients dosed monthly stopped itching—a percentage that rose to 77% (17) among those who were dosed every quarter.</p>
<p></p><h4><strong>AA durability data</strong></h4>

<p>In its Friday statement, Nektar said it recently advanced rezpeg into pivotal studies in AD and is initiating a pivotal study in alopecia areata (AA), where the company reported positive data in April from a blinded 16-week treatment extension period in its Phase IIb REZOLVE-AA trial (<a href="https://clinicaltrials.gov/study/NCT06340360">NCT06340360</a>).</p>
<p>From week 36 to week 52, 29% of 14 patients at low dose of 18 µg/kg and 31% of 13 patients at high dose of 24 µg/kg achieved new SALT Score ≤20 responses as compared to none in the placebo arm. A SALT Score ≤20 is achieved when a patient has 80% or more of their scalp covered by hair.</p>
<div class="my-8"><span data-render-ad="6"></span></div>
<p>“For me, as a scientist, this is really exciting, because most drugs are inhibitors,” Jonathan Zalevsky, PhD, Nektar’s chief research and development officer, told <em>GEN</em> in June in an interview during the 2026 Biotechnology Innovation Organization (BIO) International Convention, held in San Diego. “Inhibitors work at the beginning, and then they get worse, because it’s just how biology works. We always have escape pathways to any single inhibition. Repression requires workaround; that’s just basic biology. But rezpeg doesn’t work that way. It’s not an inhibitor. It’s healing your immune system, and it’s allowing you to resolve inflammation naturally, the way you’re normally meant to.”</p>
<p>“We think that might be one of the things we’re seeing reflected in the durability of rezpeg. It really seems much more durable than other mechanisms, and it has an activity that really preserves itself, and it long outlasts its own pharmacokinetics. That’s something we’re very excited about,” Zalevsky added.</p>
<p>The company has said it aims to submit a Biologics License Application (BLA) for rezpeg in AD in 2029.</p>
<p>“We remain focused on delivering this important potential new treatment as quickly as possible to patients battling chronic auto-immune conditions,” Nektar stated.</p>
<p></p><h4><strong>Relationship sours</strong></h4>

<p>Nektar’s relationship with Lilly soured in February 2023, soon after rezpeg failed the Phase II ISLAND trial (<a href="https://clinicaltrials.gov/study/NCT04433585">NCT04433585</a>) in its initial development indication of moderately-to-severely active systemic lupus erythematosus (SLE). Lilly halted its collaboration immediately in that indication, followed by the companies determining whether to move forward in AD.</p>
<p>Two months later, Lilly handed back to Nektar all rights to rezpeg (which Lilly labeled LY3471851) in all indications, including AD and psoriasis. That ended a <a href="https://www.genengnews.com/news/lilly-to-co-develop-nektar-autoimmune-candidate-nktr-358/">collaboration launched in 2017</a>, when Lilly agreed to pay Nektar $150 million upfront and up to $250 million tied to achieving development and regulatory milestones toward rezpeg, then called NKTR-358.</p>
<p>Nektar responded to the termination in August 2023 by suing Lilly in U.S. District Court for the Northern District of California in San Francisco, alleging breach of contract and breach of implied covenant of good faith and fair dealing: “This case involves the all-too-familiar story of a large pharmaceutical company elevating profits over all else,” Nektar stated in its initial complaint.</p>
<p>In that complaint, Nektar asserted that Lilly failed to recruit enough patients for the ISLAND trial in lupus, leading to its failure. Nektar also alleged that Lilly incorrectly calculated data from the companies’ AD and psoriasis trials of rezpeg that was presented at the 2022 European Academy of Dermatology and Venereology (EADV) Congress; Lilly has denied the allegations on recruitment failures yet confirmed that the data were incorrectly calculated for both AD and psoriasis trials.</p>
<p></p><h4><strong>Clash over Dermira acquisition</strong></h4>

<div class="my-8"><span data-render-ad="7"></span></div>
<p>Nektar also alleged—and Lilly has strongly denied—that the pharma giant soured, then sought to undermine, their collaboration after Lilly agreed to acquire Dermira for approximately $1.1 billion in 2020. Dermira focused on developing a pipeline of dermatological drugs led by lebrikizumab, a monoclonal antibody designed to bind IL-13 with high affinity. Today Lilly markets that drug under the name Ebglyss® (lebrikizumab-lbkz), following FDA approval in 2024 in moderate-to-severe AD.</p>
<p>Lilly then tried to get Nektar’s lawsuit dismissed—but when it couldn’t do so, it counter-sued, alleging breach of specified confidentiality provisions and defamation–a countersuit the pharma giant was allowed to voluntarily dismiss in October 2025.</p>
<p>A jury trial was initially scheduled to begin on October 27, 2025, was postponed due to the federal government shutdown, and instead began September 8, 2026. The case, Nektar Therapeutics v. Eli Lilly & Co (3:23-cv-03943), was assigned to Judge James Donato, who was appointed by President Barack Obama and confirmed by the U.S. Senate in 2014.</p>
<p>“In May 2023, after rezpeg failed to meet its primary endpoints in two separate Phase II trials, Lilly terminated its collaboration with Nektar and returned the rights to rezpeg at Nektar’s request,” Lilly told <em>GEN</em> in February 2026 through a spokesperson. “Our decision was consistent with Lilly’s normal practices and was made following a review of the compound’s competitive profile, including a high incidence of injection site reactions, which were also reflected in Nektar’s REZOLVE-AD trial.”</p>
<p>“The litigation between Lilly and Nektar remains ongoing, and we stand behind our decision to terminate the collaboration,” Lilly added at the time.</p>
<p></p><h4><strong>Anthropic’s “reminiscent of CRISPR” discovery d</strong><strong>ents gene editing stocks</strong></h4>

<p><strong>Anthropic, </strong>the artificial intelligence (AI) giant that has filed for an initial public offering (IPO) that would value the company at an eye-popping $2 trillion, wreaked some havoc on gene editing stocks this past week after making global headlines with its announcement that its Claude large-language model “discovered a novel enzyme system with properties reminiscent of CRISPR, with only high-level direction from our scientists.”</p>
<p>The discovery emerged from a research group formed earlier this year “to see whether general AI models can systematize and accelerate discoveries capable of revolutionizing biology and medicine,” as Anthropic explained in its <a href="https://www.anthropic.com/news/claude-discovers-novel-enzyme-system">announcement</a>. “Our focus is on fundamental biology research using Claude: exploring datasets of DNA to identify uncharacterized protein families, generating hypotheses at scale, and testing them through experiments in the lab.”</p>
<p>In one of the group’s first research programs, Claude autonomously discovered a novel enzyme system that is associated with an array of DNA repeats—what the company called “a pattern reminiscent of CRISPR.”</p>
<p>“Although we don’t yet know its function, the system that Claude discovered has a set of characteristics that have only ever been found together in a handful of other systems, all of which are programmable and perform operations like cutting, copying, and pasting DNA,” Anthropic explained.</p>
<p>Anthropic CEO Dario Amodei elaborated further <a href="https://x.com/DarioAmodei/status/2102831170299834652?s=43">in a post on X</a>, describing the novel enzyme system as “a molecular machine that we suspect could represent a new gene editing mechanism. Its precise function, biotechnological utility (if any), or level of significance is not yet clear, but at minimum it is work I would have been proud to do as a PhD student.”</p>
<p></p><h4><strong>“Mostly” by Claude</strong></h4>

<p>“The work was done mostly, though not entirely, by Claude: our life sciences team suggested a broad area of research, Claude read through the literature and a bunch of genome data and discovered something interesting, then Claude proposed experiments to verify the discovery and our team carried them out,” Amodei added.</p>
<p>Anthropic’s statement and Amodei’s elaboration led investors to briefly sell off shares of gene editing company stocks on Wednesday, resulting in declines in high single digit percentages that day. The declines slowed down or turned into single digit gains Thursday, but the stocks all slid again Friday, albeit by low single digits.</p>
<p>Here’s how seven gene editing stocks performed between Tuesday and Friday:</p>
<ul>
<li><strong>Beam Therapeutics (Nasdaq: BEAM)</strong>—<span><strong>Slipping 6%</strong></span> from $25.93 Tuesday to $24.37, finishing the week at $24.27.</li>
<li><strong>CRISPR Therapeutics (Nasdaq: CRSP)—<span>Sliding 8%</span></strong> from $59.03 to $55.76, finishing at $54.23.</li>
<li><strong>Editas Medicine (Nasdaq: EDIT)—<span>Shrinking 12%</span></strong> from $2.92 to $2.69, finishing at $2.58.</li>
<li><strong>Intellia Therapeutics (Nasdaq: NTLA)—<span>Dropping 7%</span></strong> from $12.69 to $12.33, finishing at $11.75.</li>
<li><strong>Lenz Therapeutics (Nasdaq: LENZ)—<span>Dipping 5%</span></strong> from $4.13 to $3.76, finishing at $3.92.</li>
<li><strong>Prime Medicine (Nasdaq: PRME)—<span>Tumbling 18%</span></strong> from $3.54 to $3.13, finishing at $2.90.</li>
<li><strong>Q32 Bio (Nasdaq: QTTB)—<span>Falling 17%</span></strong> from $10.57 to $9.56, finishing at $8.77.</li>
</ul>
<p>Puneet Souda, senior managing director, life science tools and diagnostics and a senior research analyst with Leerink Partners, wrote in a research note that Anthropic’s discoveries along with other biotech-focused AI research would prove beneficial to life sciences tools companies—especially <strong>Twist Biosciences (Nasdaq: TWST)</strong>, citing an earlier July 16 research note reporting that Twist has said its growth ramp of orders for its tools has grown by triple digits.</p>
<p>“We see TWST as the single most important beneficiary today from growing Bio AI efforts but expect all LST [life sciences tools] names to benefit in the long run as the need for automation and large-scale data grows (driven largely by industry funding vs academic),” Souda observed.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/stockwatch-nektar-shares-flat-as-90m-jury-verdict-less-than-sought-in-lilly-suit/">StockWatch: Nektar Shares Flat as $90M Jury Verdict Less than Sought in Lilly Suit</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Answering “Tell Me About Yourself” in Residency Interviews</title>
<link>https://edusehat.com/en/answering-tell-me-about-yourself-in-residency-interviews</link>
<guid>https://edusehat.com/en/answering-tell-me-about-yourself-in-residency-interviews</guid>
<description><![CDATA[ This article was updated by Rebecca Lapides in September 2026.   “Tell me about yourself.” This is probably the first question you’ll be asked in any residency interview. Certainly makes you wonder why you spent countless hours writing and rewriting that blasted personal statement.   The truth is that the “Tell me about yourself” question […]
The post Answering “Tell Me About Yourself” in Residency Interviews appeared first on Elite Medical Prep. ]]></description>
<enclosure url="https://elitemedicalprep.com/wp-content/uploads/2023/01/Shutterstock_2253792707-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sun, 27 Sep 2026 05:55:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Answering, “Tell, About, Yourself”, Residency, Interviews</media:keywords>
<content:encoded><![CDATA[<p><em>This article was updated by <a href="https://elitemedicalprep.com/tutors/rebecca-lapides/">Rebecca Lapides</a> in September 2026.</em></p>
<p> </p>
<p><span><strong>“Tell me about yourself.”</strong> </span><span>This is probably the first question you’ll be asked in any residency interview. Certainly makes you wonder why you spent countless hours writing and rewriting that blasted personal statement.</span></p>
<p> </p>
<p><span>The truth is that the “Tell me about yourself” question in residency interviews is meant to be more of a polished ice-breaker and not a deep dive into your life. This is an important realization. </span></p>
<p> </p>
<h2><strong>High Yield Preparation</strong></h2>
<p><span>During your residency interviews, you will be asked to “tell me about yourself” dozens of times. Perhaps even multiple times on a single </span><a href="https://elitemedicalprep.com/the-medical-school-interview-what-to-expect/"><span>interview day</span></a><span>.  So it really pays dividends to have an organized response you can share. It’s going to sound so polished and natural. I can see it already. They’ll want to rank you just because of how well-spoken you are.</span></p>
<p> </p>
<p><span>Now, feeling unsure about where to start? Download our Residency Interview Toolkit for a detailed preparation guide, checklist, sample questions to ask programs, a practice interview script, and thank-you email templates—all designed to help you nail your interviews. Enter your email and expected graduation year below to get this free resource sent straight to your inbox! </span></p>
<p> </p>
<h2><strong>How Should I Answer the Question “Tell Me About Yourself” in a Residency Interview?</strong></h2>
<p><span>It’s helpful to think of your life story in chunks.  Brainstorm each chunk separately.  Step back, zoom out, and identify the storyline that flows naturally. They don’t need to hear about every single detail. They want to hear an overview about what experiences make you who you are and inform your life goals. </span></p>
<p> </p>
<p><span>Telling a chronological story makes the most sense to me.</span></p>
<p> </p>
<h3><b>Background/Upbringing:</b></h3>
<p><span>This is your origin story. More like your origin sentence. Some people will have formative experiences that make the cut, for most of us, this is a brief statement that provides the context for how you got to where you are right now. Your name, where you’re from, and a little bit about your educational background might be all you share here. And that’s fine! Remember, prioritize brevity!</span></p>
<h3><strong>Educational/Work Background: </strong></h3>
<p><span>Touch on any relevant work experience, unique adult life experience, or educational feats you are proud of. Bonus points if it’s something not in your personal statement already or something you briefly touched on in your personal statement that you can expand upon using this opportunity.</span></p>
<h3><b>Medical School Experience:</b></h3>
<p><span>Treat medical school as a separate category. This is likely the most up-to-date information and closes the gap between your origin story and why you’re in the interview today.  Here you might include a (brief) summary of important leadership activities, professional interests, and experiences that guided you toward your </span><a href="https://elitemedicalprep.com/how-does-residency-matching-work-get-your-dream-residency/"><span>specialty of choice</span></a><span>.</span></p>
<p> </p>
<p><span>Remember how I said this isn’t a deep dive into your life? Well, remember this while you’re trying to draft your answer. This should be casual information you want your interviewer to know about you.  It helps them understand what is important to you. It also allows you to steer the conversation, so mention things you’d like to talk more about. </span></p>
<p> </p>
<h2><strong>How Long Should it Take?</strong></h2>
<p><span>Keep your answer to less than 2 minutes. Ideally, about 90 seconds.</span></p>
<p> </p>
<p><span>Remember, you probably only get 8-12 minutes per interview. Interviewers are often tasked with asking some </span><a href="https://elitemedicalprep.com/what-questions-do-they-ask-in-a-residency-interview/"><span>canned “behavioral” questions</span></a><span> they are supposed to ask everyone, so you want to leave them time to get through those. Most importantly, you want to have enough time to make a connection and</span><a href="https://thevitalcurriculum.com/posts/ask-intelligent-questions-residency-interviews"><span> demonstrate genuine interest</span></a><span> in the program.</span></p>
<p> </p>
<p><span>The last thing you want to do is accidentally ramble for 7 minutes straight.</span></p>
<p> </p>
<p><span>Let’s budget time for each of the things we’ve discussed so far:</span></p>
<ul>
<li aria-level="1"><span>First 15 seconds: who you are, where you’re from, your educational background.</span></li>
<li aria-level="1"><span>Next 30 seconds: your medical school, relevant work experience, and unique life experience.</span></li>
<li aria-level="1"><span>Next 30 seconds: experiences specifically from med school (leadership, impactful things that pushed you towards your specialty, professional interests)</span></li>
<li aria-level="1"><span>Final 15 seconds: BRIEFLY transition to how you became interested in the specialty and maybe why you’re so stoked to interview with this particular program.</span></li>
</ul>
<p> </p>
<p><span>You will probably have far more than 10 minutes of material you could draw from to answer this question. This can be helpful because you may get variations of this question and you can adjust your response according to the situation.</span></p>
<p> </p>
<p><span>I suggest that you practice your response extensively before your first interview day. However, remember that you want your answer to sound polished but not too rehearsed. I would recommend against writing out a specific script to memorize, rather, glance at some bullet points and let the response come out naturally. Practice this natural delivery instead of a memorized script. </span></p>
<p> </p>
<p><span>I remember sitting at my desk with my stopwatch app on my phone. Having delivered my “tell me about yourself” answer 42 times in one 60-minute lunch break, I practiced it at least another 30 times in front of a mirror. Each time came out a bit differently but got the same information across. The more I practiced, the better I became at incorporating natural variation into my answer. </span>During my interviews, interviewers asked me this question more often than any other. I entered every interview with rock-solid confidence that I had the first question pegged. And when the interview starts off on the right note it sets the tone for the rest of the day.</p>
<p> </p>
<h2><strong>Example Residency Interview Responses to “Tell Me About Yourself”</strong></h2>
<p><i><span>I’m a 4th year at UWSOM.  I grew up in South Eastern Washington in a small town on the Snake River. I earned my AA degree during my junior and senior year of high school, and then took a break from school to serve a 2-year mission through my church to Curitiba, Brazil.  When I returned, I studied Chemistry and Exercise Physiology at BYU-Idaho where I met my wife.  I took another short break to work while my wife earned her degree in Dental Hygiene.  I’ve worked as a diesel mechanic’s apprentice, worked several construction jobs, and spent a year working in physical therapy before starting medical school at UW.</span></i></p>
<p> </p>
<p><i><span>During medical school I have been able to lead interest groups, serve as a wellness representative, contribute to curriculum committees and career advisory boards. I’ve also worked closely with fellow students as a peer-tutor, which I have enjoyed immensely.  My interest in radiology was initially piqued after seeing how much we relied on radiologists during research projects and in my clinical rotations.  The more I learned about it the more my interest grew.  I’m super excited to be interviewing with _______ because I am really impressed with ________.</span></i></p>
<p> </p>
<p><span>This lands right at 1 minute. What you actually say during my interviews may have varied a bit from this original script, so you can filter as necessary based on the situation. Sometimes I added other tidbits as well. Doesn’t have to be </span><i><span>rigid</span></i><span> but it should be </span><i><span>polished</span></i><span>.</span></p>
<p> </p>
<p><span>Another suggestion I have is to briefly pause naturally like you’ve having a regular conversation. This gives the interviewer a chance to chime in and react to something you shared. This will create the opportunity for conversation rather than a stiff question and answer dynamic, which helps everyone to relax and makes the interviewer feel like part of your story. They will remember this!</span></p>
<p> </p>
<p><span>Do your own brainstorming and figure out what you want your interviewer to know about you. </span><span>And don’t forget to practice, practice, practice!</span></p>
<p> </p>
<p><span>For residency advising, mock interviews, help with your rank list and more, consider enlisting the help of a </span><a href="https://elitemedicalprep.com/residency-advising/"><span>residency advisor</span></a><span>! <a href="https://elitemedicalprep.com/contact/">Schedule a complimentary consultation</a> to learn how a residency advisor can help you prepare for interviews, build your rank list, and pursue a residency match.</span></p>
<p>The post <a href="https://elitemedicalprep.com/answering-tell-me-about-yourself-in-residency-interviews/">Answering “Tell Me About Yourself” in Residency Interviews</a> appeared first on <a href="https://elitemedicalprep.com/">Elite Medical Prep</a>.</p>]]> </content:encoded>
</item>

<item>
<title>New CRISPR&#45;Based Tool Enables Genome&#45;Wide Mutagenesis of Bacteriophages</title>
<link>https://edusehat.com/en/new-crispr-based-tool-enables-genome-wide-mutagenesis-of-bacteriophages</link>
<guid>https://edusehat.com/en/new-crispr-based-tool-enables-genome-wide-mutagenesis-of-bacteriophages</guid>
<description><![CDATA[ A CRISPR-based method for disrupting genes across bacteriophage genomes has been developed, creating a faster route to uncover gene functions and engineer phages for potential therapeutic and biotechnology applications.
The post New CRISPR-Based Tool Enables Genome-Wide Mutagenesis of Bacteriophages appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/07/GettyImages-1830659494.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 26 Sep 2026 04:15:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>New, CRISPR-Based, Tool, Enables, Genome-Wide, Mutagenesis, Bacteriophages</media:keywords>
<content:encoded><![CDATA[<p>Researchers at the University of Otago – Ōtākou Whakaihu Waka in New Zealand have developed a CRISPR-based method for systematically disrupting genes across bacteriophage genomes, creating a faster route to uncover gene functions and engineer phages for potential therapeutic and biotechnology applications. The study, titled “<a href="https://dx.doi.org/10.1038/s41564-026-02486-1" target="_blank" rel="noopener">Defining the essential genome of diverse phages with phage Tn-seq</a>,” was published in <em>Nature Microbiology.</em></p>
<p>Bacteriophages, or phages, are viruses that infect bacteria. Their ability to destroy bacterial cells has made them promising candidates for addressing antimicrobial resistance and reducing reliance on agrochemicals. However, many phage genes encode unknown functions, making it difficult to predict how the viruses behave or to modify them reliably.</p>
<p>“Our knowledge of phages is probably like the understanding of antibiotics back in the 1950s,” senior author Peter Fineran, PhD, said. “Many phage genes are currently in the area of microbial dark matter—encoding functions we just don’t understand—which is limiting our ability to use phages in healthcare and biotechnology.”</p>
<p>To address that gap, the team combined transposon insertion sequencing with CRISPR–anti-CRISPR selection. A transposon jumps into a phage genome and disrupts a gene. The selection system then recovers phages carrying those mutations, allowing researchers to determine which genes can be disrupted without preventing the virus from surviving and which are essential for phage function.</p>
<p>After establishing the mutagenesis workflow, the researchers extended it to introduce new genetic cargo. Rather than using the transposon only to disrupt genes, they loaded it with an additional sequence and inserted a fluorescent marker into phage genomes. The approach could also be used to add genes that help phages overcome bacterial defense systems, potentially improving their effectiveness against target pathogens.</p>
<p>“Once we had that established, we thought we could expand the technique and also use it to add genes directly into the phage genomes,” co-lead author Manuela Fuchs, PhD, said.</p>
<p>“This is a systematic, broadly applicable, and cost-effective way to not only investigate gene function, but also rapidly engineer phage genomes,” senior author Leah Smith, PhD, said, in a statement.</p>
<p>The platform could therefore serve two related goals: mapping the largely uncharacterized genetic landscape of phages and building variants with new capabilities. The researchers said the work opens opportunities for fundamental studies as well as future therapeutic development, although engineered phages would still require further testing to establish their safety and effectiveness in specific applications.</p>
<p>The post <a href="https://www.genengnews.com/topics/genome-editing/new-crispr-based-tool-enables-genome-wide-mutagenesis-of-bacteriophages/">New CRISPR-Based Tool Enables Genome-Wide Mutagenesis of Bacteriophages</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>How Bladder Cells Fight Hidden E. coli: New Insights Into Recurrent UTIs</title>
<link>https://edusehat.com/en/how-bladder-cells-fight-hidden-e-coli-new-insights-into-recurrent-utis</link>
<guid>https://edusehat.com/en/how-bladder-cells-fight-hidden-e-coli-new-insights-into-recurrent-utis</guid>
<description><![CDATA[ A new study finds the drug OM-89 may help bladder cells eliminate hidden E. coli by activating lysosomal pathways and increasing antibiotic uptake, potentially reducing bacterial regrowth in recurrent UTIs.
The post How Bladder Cells Fight Hidden E. coli: New Insights Into Recurrent UTIs appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-956351578.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 26 Sep 2026 04:15:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>How, Bladder, Cells, Fight, Hidden, coli:, New, Insights, Into, Recurrent, UTIs</media:keywords>
<content:encoded><![CDATA[<p>Urinary tract infections (UTIs) are among the most common bacterial infections, frequently caused by <em>Escherichia coli. </em>But UTIs are known to be recurrent, even after antibiotic treatment. One reason is that the bacterium can enter the cells of the bladder epithelium to evade both antibiotics and the patient’s immune system, and re-emerge. Researchers have now identified a way to strengthen the bladder cells’ own ability to eliminate these hidden bacteria.</p>
<p>The study, published in<em> PLOS Pathogens</em>, is entitled, “<a href="https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1014448" target="_blank" rel="noopener">Targeted lysosomal activation in bladder epithelium enhances clearance of intracellular uropathogenic <em>Escherichia coli</em></a>.”</p>
<p>The findings suggest that the drug OM-89 (marketed as Uro-Vaxom<sup>®</sup>) activates cellular degradation pathways in bladder epithelial cells while also increasing antibiotic uptake. OM-89 has been used for decades to help prevent recurrent UTIs. It is mainly known for stimulating the immune system, but the new study reveals a second mechanism of action: a direct effect on the cells lining the bladder.</p>
<p>The researchers studied mouse and human bladder epithelial cells using organoid models and differentiated cell cultures. They exposed the cells to OM-89, infected them with different strains of <em>E. coli, </em>and treated them with antibiotics. They then tracked bacterial survival, antibiotic uptake, and changes in cellular pathways involved in destroying intracellular material.</p>
<p>The findings show that OM-89 increased lysosomal acidification as well as the activity of lysosomal enzymes. When the researchers blocked lysosomal acidification, OM-89’s protective effect was lost, suggesting that lysosomal activity is directly involved in reducing bacterial regrowth in recurrent UTIs. In addition, OM-89 increased the accumulation of antibiotics inside bladder epithelial cells—an effect that extended across different antibiotic classes and several bacterial strains, including clinical samples from patients.</p>
<p>“We found that OM-89 doesn’t just stimulate the innate immune system as previously assumed,” says Kathrin Tomasek, PhD, project leader at the Laboratory of Microbiology and Microtechnology at EPFL. “It acts directly on bladder cells, strengthening their degradation pathways so they can destroy hidden bacteria more effectively while also helping antibiotics reach those bacteria—together reducing regrowth of the bacteria after treatment ends.”</p>
<p>The findings point toward a host-directed approach to recurrent infection: rather than targeting bacteria alone, treatment could also reinforce the antimicrobial machinery of the infected tissue itself.</p>
<p>More broadly, the study identifies lysosomal pathways in the bladder epithelium as a potential target for future treatment combinations designed to improve antibiotic outcomes.</p>
<p>“While the results come from preclinical models and do not change the approved indication or use of Uro-Vaxom<sup>®</sup>, they deepen our understanding of how OM-89 may help strengthen the bladder’s natural defenses against recurrent infection and reinforce the scientific foundation supporting its use,” adds Christian Pasquali, senior scientific liaison director at OM Pharma and former head of preclinical research.</p>
<p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/how-bladder-cells-fight-hidden-e-coli-new-insights-into-recurrent-utis/">How Bladder Cells Fight Hidden <i>E. coli</i>: New Insights Into Recurrent UTIs</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Stroke Remodels Tumor Microenvironment to Promote Glioma Growth</title>
<link>https://edusehat.com/en/stroke-remodels-tumor-microenvironment-to-promote-glioma-growth</link>
<guid>https://edusehat.com/en/stroke-remodels-tumor-microenvironment-to-promote-glioma-growth</guid>
<description><![CDATA[ A study in mouse and human models showed how stroke promotes glioma growth by remodeling the tumor microenvironment, with the emergence of a distinct population of tumor-associated astrocytes with reduced Ca2+ activity, and enrichment of tumor-associated microglia and macrophages (TAMs).
The post Stroke Remodels Tumor Microenvironment to Promote Glioma Growth appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2023/11/GettyImages-1172511190-e1701113426323.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 26 Sep 2026 04:15:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Stroke, Remodels, Tumor, Microenvironment, Promote, Glioma, Growth</media:keywords>
<content:encoded><![CDATA[<p>The results of a study by researchers at Texas Children’s Duncan Neurological Research Institute (Duncan NRI), at Baylor College of Medicine and collaborating institutions have shown that stroke promotes glioma growth, and point to cellular and molecular mediators involved in the process, linking brain injury to malignant brain tumors.</p>
<p>Working with mouse and human models, the team discovered that stroke induces tumor microenvironment (TME) remodeling, alongside the emergence of a distinct population of tumor-associated astrocytes (TAAs) exhibiting reduced Ca<sup>2+</sup> activity, and enrichment of tumor-associated microglia and macrophages (TAMs). Restoring TAA Ca<sup>2+</sup>  signaling or depleting TAMs, suppressed stroke-induced glioma progression, pointing to the importance of both cell type types in injury response.</p>
<p>Research lead Hyun Kyoung Lee, PhD, principal investigator at the Duncan NRI, and an associate professor of pediatrics – neurology and member of the Dan L Duncan Comprehensive Cancer Center at Baylor, and colleagues reported on their findings in <em>Nature Cancer</em>, in a paper titled “<a href="https://doi.org/10.1038/s43018-026-01238-8" target="_blank" rel="noopener">Stroke drives glioma progression through the emergence of tumor-associated astrocytes with reduced Ca<sup>2+</sup> activity</a>.” In their paper the investigators concluded, “Collectively, our findings establish stroke-induced remodeling of astrocytic Ca<sup>2+</sup> signaling and TAMs as drivers of glioma progression and link brain injury to malignant disease.”</p>
<p>Glioblastoma (GBM) is the most prevalent and aggressive malignant brain tumor in adults,  and has what the researchers describe as “… a notably dismal 5-year survival rate.”  Research has catalogued a number of genetic mutations associated with GBM, the team pointed out, but the risk factors predisposing individuals to glioma are not well understood. “Recent clinical cohort studies and case reports have identified a correlation between glioma and brain injuries, where ischemic stroke shows significant co-occurrence with brain tumors, including glioma,” they further noted.</p>
<p>Lee added, “Epidemiological and clinical studies suggest that patients with a history of stroke or traumatic brain injury are at increased risk of developing brain tumors.  The risk can be about three-fold to seven-fold, depending on the age and sex of the patient.” However, Lee continued, “Despite these clinical observations, the mechanism that connects brain injury and cancer remains unclear.”</p>
<p>For their newly reported study the researchers, including Qi Ye, PhD, and graduate student Christine Madamba, at the Lee lab, worked with human and mouse models to investigate whether stroke promotes glioma growth and the factors mediating the connection. The team discovered the emergence of a distinct population of brain cells—tumor-associated astrocytes—with distinct physiological and molecular characteristics, including diminished calcium activity. TAAs were accompanied by the accumulation of two other cell types, remodeled tumor-associated microglia and immune cells called macrophages (TAMs). “Mechanistically, we identified SLC4A4 as a key regulator of Ca<sup>2+</sup>  activity in TAAs and CCL2-mediated TAM recruitment,” they reported in their study.</p>
<p>The researchers also showed that restoring TAA calcium signaling or removing TAMs suppressed stroke-induced glioma progression, “… identifying both populations as critical mediators of the stroke response.” The findings suggest that these injury-induced, tumor-promoting pathways are potential therapeutic targets and support continuing research into strategies that could reduce the risk of glioma growth in patients with a history of brain injury.</p>
<p>“We show that stroke promoted tumor infiltration into injured brain regions in human and mouse glioma models, and reduced overall survival,” Lee said. “Looking closer into the cellular and molecular makeup of the tumors, we found that stroke triggers remodeling of the tumor microenvironment.”</p>
<p>The authors stated “In summary, our study reveals that ischemic stroke remodels the TME to promote glioma progression, highlighting injury-induced tumor-promoting pathways as potential therapeutic targets for persons with a history of brain injury … More broadly, our work establishes a framework for investigating TAA-mediated immune regulation, TME remodeling, and the mechanisms linking brain injury to glioma progression and tumorigenesis.”</p>
<p>Lee added, “Our study supports that brain injury can be a risk factor for brain cancer. In addition, our findings contribute to growing evidence pointing at a role of astrocytes in brain tumor growth. Neuron-tumor interactions have been shown to contribute to cancer growth. We show that other brain cells, astrocytes, also seem to communicate with brain cancer cells and influence their behavior. They should be considered when studying cancer mechanisms and therapies.”</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/stroke-remodels-tumor-microenvironment-to-promote-glioma-growth/">Stroke Remodels Tumor Microenvironment to Promote Glioma Growth</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Thar Process Partners with ExtrateX to Bring Prep to Process&#45;Scale SFC to Europe</title>
<link>https://edusehat.com/en/thar-process-partners-with-extratex-to-bring-prep-to-process-scale-sfc-to-europe</link>
<guid>https://edusehat.com/en/thar-process-partners-with-extratex-to-bring-prep-to-process-scale-sfc-to-europe</guid>
<description><![CDATA[ SFC is a platform technology that utilizes upcycled CO2 for the purification of natural and synthetic molecules that is both highly efficient and sustainable at the same time.
The post Thar Process Partners with ExtrateX to Bring Prep to Process-Scale SFC to Europe appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2262544009-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 26 Sep 2026 04:15:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Thar, Process, Partners, with, ExtrateX, Bring, Prep, Process-Scale, SFC, Europe</media:keywords>
<content:encoded><![CDATA[<p>Thar Process, based in Pittsburgh, PA, a specialist in supercritical CO<sub>2</sub> extraction and purification technology (SFE and SFC), partnered with  ExtrateX, a French expert firm in supercritical fluid systems, to represent and distribute its advanced SFC systems throughout Europe. The deal provides clients with sales and technical support in pharmaceutical, biotech, and specialty chemical labs across the region, according to Todd Palcic, CEO of Thar Process.</p>
<p>“SFC is a platform technology that utilizes upcycled CO<sub>2 </sub>for purification of natural  and synthetic molecules that is both highly efficient and sustainable at the same time,” said Palcic. “ExtrateX’s deep expertise in supercritical CO<sub>2</sub> systems and strong presence across Europe make them the ideal partner.”</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p><figure aria-describedby="caption-attachment-338472" class="wp-caption alignleft"><img fetchpriority="high" decoding="async" class="wp-image-338472 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/09/13172578-isolator-sfc-10-1-300x225.jpg" alt="Thar Process's Isolator™ SFC systems are designed for high-resolution separation and purification bioprocessing applications, including  pharmaceutical APIs and excipients, fermented products, peptides (GLP-1s, etc.) and natural products like omega-3s and cannabinoids." width="300" height="225" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/13172578-isolator-sfc-10-1-300x225.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/13172578-isolator-sfc-10-1-768x576.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/09/13172578-isolator-sfc-10-1.jpg 1024w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Thar Process’s Isolator<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> SFC systems are designed for high-resolution separation and purification bioprocessing, including pharmaceutical APIs and excipients, fermented products, peptides (GLP-1s, etc.) and natural products like omega-3s and cannabinoids. [Thar Process]</figcaption></figure>The technology offers advantages in speed, efficiency, and environmental sustainability compared to conventional separation methods, continued Palcic.</p>
<p>According to Gonzague Choppe, CEO of ExtrateX, “This strategic collaboration brings together the complementary strengths of two companies with extensive expertise in supercritical fluid technologies. Thar Process brings some of the most advanced SFC solutions and deep chromatography expertise, while ExtrateX contributes its extensive experience in supercritical fluid technologies, process expertise, scale-up capabilities and strong European presence.”</p>
<p>The partnership becomes effective on the first day of 2027, with ExtrateX establishing sales and support operations to serve European customers. The company will handle equipment sales, technical installation, maintenance, and customer training.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p> </p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/thar-process-partners-with-extratex-to-bring-prep-to-process-scale-sfc-to-europe/">Thar Process Partners with ExtrateX to Bring Prep to Process-Scale SFC to Europe</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Studying for the Shelf Exam During Your OB/GYN Rotations</title>
<link>https://edusehat.com/en/studying-for-the-shelf-exam-during-your-obgyn-rotations</link>
<guid>https://edusehat.com/en/studying-for-the-shelf-exam-during-your-obgyn-rotations</guid>
<description><![CDATA[ Studying for the OB/GYN Shelf So, you’ve made it to your Obstetrics and Gynecology clerkship. OB/GYN is a fun and exciting field. However, between delivering babies, scrubbing into surgeries, and working in the outpatient clinic, you somehow must find time to study for a shelf as well? On top of that, you have to master […]
The post Studying for the Shelf Exam During Your OB/GYN Rotations appeared first on Elite Medical Prep. ]]></description>
<enclosure url="https://elitemedicalprep.com/wp-content/uploads/2023/12/Studying-for-the-Shelf-Exam-During-Your-OBGYN-Rotations.png" length="49398" type="image/jpeg"/>
<pubDate>Sat, 26 Sep 2026 01:00:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Studying, for, the, Shelf, Exam, During, Your, OBGYN, Rotations</media:keywords>
<content:encoded><![CDATA[<h2>Studying for the OB/GYN Shelf</h2>
<p>So, you’ve made it to your Obstetrics and Gynecology clerkship. OB/GYN is a fun and exciting field. However, between delivering babies, scrubbing into surgeries, and working in the outpatient clinic, you somehow must find time to study for a shelf as well? On top of that, you have to master both Obstetrics <em>and</em> Gynecology for your shelf!</p>
<p>Here we will cover some tips and tricks for how to study for your <a href="https://elitemedicalprep.com/obgyn-shelf-exam-tutor/">OB/GYN shelf</a>!</p>
<p> </p>
<h3>What Exactly Is the NBME OB/GYN Shelf Exam?</h3>
<p>The National Board of Medical Examiners (NBME) OB/GYN shelf exam is a standardized exam taken at the end of most Obstetrics and Gynecology clerkships in medical school. The exam contains <strong>110 multiple-choice questions</strong> completed in <strong>165 minutes</strong> and is designed to assess your ability to apply clinical knowledge rather than simply recall isolated facts. While the exam is roughly divided between obstetrics and gynecology, questions often require you to integrate concepts from both disciplines when making patient care decisions.</p>
<p>Unlike many exams you may have taken in medical school, the <strong>OB/GYN shelf exam</strong> is scored against national performance, with your results converted to a scaled score and percentile ranking. Understanding the exam format before you begin studying can help you build a realistic study plan, pace yourself during practice exams, and focus on developing the clinical reasoning skills that are essential for success.</p>
<p> </p>
<h2>Find Time to Study Every Day in Small Chunks</h2>
<p>One of the #1 issues students run into is finding the time to study. On a difficult rotation where there are early morning wake-ups, long calls, and maybe even overnight shifts, this can be a real challenge. You might find yourself running to the OR or between deliveries with little downtime or dedicated study time.</p>
<p>Studying while on a clerkship is very different from the studying you may have done during your pre-clinical years or for <a href="https://elitemedicalprep.com/usmle-step-1-tutoring/">USMLE Step 1</a>. It requires a shift in your mindset from having long periods of dedicated time in a day to study to now having to study in small blocks of time. The key to doing well and not falling behind is to study every day in short but frequent sessions.</p>
<p>Maximize any downtime you have during your workday – from your morning commute to waiting in line for lunch at the hospital cafeteria. Download Question Banks, the UpToDate app, and – if you’re a flashcard person – the Anki app to your smartphone and pack a quick study reference in your work bag. While it may not feel very productive, even doing 5 questions or 20 flashcards during downtime is helpful to chip away at your studying.</p>
<p>When you get home from the hospital, it may feel very difficult to study for a long time. Allow yourself some time to decompress and then set aside at least an hour each night to dedicate to studying. This will help you both shine on your clerkship and keep you on track toward shelf success!</p>
<p> </p>
<h2>Questions Are Key</h2>
<p>Questions, questions, and more questions. I cannot emphasize this study strategy enough! Questions are a great form of active learning and a good question bank also serves as a text and resource to learn from. Choose one question bank as your primary resource and aim to get through all the questions before your shelf. As you review each question block, spend just as much time understanding why you missed a question as you did answering it. Reviewing incorrect answers helps identify knowledge gaps, reinforces clinical reasoning, and reduces the likelihood of making the same mistake again. If you use Anki or another spaced repetition tool, consider creating flashcards for concepts you consistently miss. Combining active recall with spaced repetition helps strengthen long-term retention and makes high-yield information easier to recall on exam day.</p>
<p>The gold standard QBank to use to prepare for your shelf exam is UWorld for Step 2 CK. <a href="https://medical.uworld.com/blog/usmle/upgrading-your-step-2-ck-qbank-hello-shelf-review/">You can toggle between “Step 2 Review” and “Shelf Review” modes</a>. The questions under “OBGYN” cover the information that will be tested on your shelf.</p>
<p><a href="https://www.amboss.com/us/shelf/study-for-ob-gyn">AMBOSS</a> is another excellent QBank to prepare for the shelf. It has over 400+ NBME-style questions. Another benefit of AMBOSS is its knowledge library, which is an extremely handy reference tool for clerkship-level learning. Even if you do not complete the <a href="https://elitemedicalprep.com/amboss-usmle-prep-platform-reviews/">AMBOSS QBank</a>, the library alone is an incredible resource to have as a learning tool and reference to look up information quickly while studying or seeing patients at the hospital.</p>
<p>Another resource some students have access to is <a href="https://apgo.org/page/uwisev3-2">uWISE through APGO</a>, The Association of Professors of Gynecology and Obstetrics. This is often provided through your OB/GYN clerkship’s subscription. There are approximately 600 questions in this QBank. Many students find them helpful, and overall, they are shorter and quicker to get through than UWorld or AMBOSS. If your school can provide this, it is a good supplemental resource but still aim to complete either <a href="https://elitemedicalprep.com/amboss-vs-uworld-which-is-a-better-usmle-resource/">AMBOSS or UWorld</a> as your primary QBank.</p>
<p> </p>
<h2>Learn From Your OB/GYN Patients for Shelfs</h2>
<p>One of the other key differences between studying before clerkships and after is now you have patients to learn from. It is a privilege to be able to take care of patients and to be able to learn from them. Seeing what you’ve been studying in real life and knowing a patient’s story often make the information more memorable and will help you consolidate what you’ve been reading about.</p>
<p>At the end of each day, try to read up on one chief complaint you saw, whether it was fibroids, endometrial cancer, or preterm labor. Easy ways to do this include the following:</p>
<ul>
<li>Look up the UpToDate article. UpToDate subscriptions can often be accessed through your medical school and will have a very detailed overview of the subject with links to articles that they have cited.</li>
<li>Search for the topic in the AMBOSS library. AMBOSS library is another highly educational resource to draw on with excellent summaries and graphics.</li>
<li>Find the ACOG practice bulletin on the topic. ACOG practice bulletins are written and reviewed by the American Congress of Obstetricians and Gynecologists. For a full list of ACOG practice bulletins, see <a href="https://www.acog.org/clinical/search?t=#f:@selectedcontenttype=%5BPractice%20Bulletin%5D">here</a>.</li>
<li>Finally, for those who are looking for a book read the corresponding chapter in Case Files. Case Files for Obstetrics and Gynecology has 60 cases dedicated to the most important clinical concepts to master for your shelf.</li>
</ul>
<p>Remember, you don’t have to do them all. Find the resource that works best for you! Focus on clinical presentation, diagnosis, treatment, and management as these are the most commonly tested items about a clinical condition.</p>
<p> </p>
<h3>High-Yield Topics to Prioritize</h3>
<p>Not every topic on the <strong>OB/GYN shelf exam</strong> is tested equally, so it’s important to spend your study time wisely. Obstetrics questions frequently focus on prenatal care, normal physiologic changes during pregnancy, labor and delivery management, pregnancy complications, postpartum hemorrhage, and preeclampsia. You’ll also want to become comfortable interpreting fetal heart rate tracings, as they are a frequent feature of the exam.</p>
<p>On the gynecology side, expect to review contraception, abnormal uterine bleeding, cervical cancer screening recommendations, sexually transmitted infections, vaginitis, and common gynecologic conditions. Rather than memorizing isolated facts, focus on understanding diagnostic and treatment algorithms and identifying the next-best step in patient management. Clinical reasoning is a major emphasis of the OB/GYN <strong>shelf exam and</strong> practicing how to apply your knowledge to patient scenarios will better prepare you for test day than memorization alone.</p>
<p> </p>
<h2>Make an OB/GYN Shelf Study Schedule and Stick to It</h2>
<p>While your clerkship is likely several weeks long, it is important to stay on top of your studying as time can fly by. Calculate how many questions per week you need to do to complete your QBank. For a clerkship that is about 6 weeks long, you likely need to do on average <20 questions/day to complete the OB/GYN section (always check at the beginning of your rotation because QBanks are constantly being updated and the number is always changing).</p>
<p>Once you’ve calculated the number you’ll need to get through per week, start crafting your study schedule. You will inherently have some lighter days and some busier days on this rotation so giving yourself weekly goals gives you the flexibility to do more questions one day and keep on top of your schedule. As you complete practice questions and NBME self-assessments, keep track of the topics that consistently give you trouble. Revisit those weaker areas each week and adjust your study plan as your performance improves. Focusing additional time on your weakest subjects can help you make steady progress throughout the rotation while ensuring you continue strengthening your overall knowledge base.</p>
<p>OnlineMedEd has wonderful overviews of key clinical topics broken down into both Obstetrics and Gynecology. Mapping these onto your study schedule and getting them done within the first 2 weeks of your rotation is key to setting yourself up for success and building your fund of knowledge.</p>
<p>Schedule days to set aside for practice exams in the second half of your clerkship. Try to choose days when you aren’t scheduled to be on call so you can devote your full mental energy and treat this like a true practice exam. The NBME OB/GYN self-assessments are the best practice tests available, and there are currently more than 4 forms available. Each is only 50 questions, so try to complete all if possible.</p>
<p> </p>
<h3>Final Week and Exam Day Tips</h3>
<p>As your <strong>OB/GYN shelf exam</strong> approaches, shift your focus from learning brand-new material to reinforcing what you already know. If possible, complete one final NBME self-assessment early in the week so you have time to review missed questions and strengthen any remaining weak areas. During your final review sessions, concentrate on high-yield concepts, management algorithms, and clinical reasoning rather than trying to memorize every detail.</p>
<p>On exam day, pace yourself carefully and don’t spend too much time on any single question. If you’re unsure of an answer, make your best choice, flag the question if needed, and move on so you have time to return later. Finally, don’t underestimate the importance of a good night’s sleep, proper nutrition, and arriving at the testing center with plenty of time to spare. Feeling rested and prepared can help you stay focused and perform your best throughout the <strong>shelf exam</strong>.</p>
<p> </p>
<h2>Don’t Be Afraid to Ask for Help</h2>
<p>This clerkship can be demanding. Don’t forget that there are many people you can turn to for help if needed! Be proactive about asking for help early. Your clerkship director and your attendings are wonderful resources who are dedicated to teaching students. Forming study groups with peers who are also learning can be a helpful way to keep yourself accountable and talk through difficult concepts.</p>
<p>Finally, if you find yourself struggling, you may benefit from the help of a tutor. If you would like to learn how the tutors at Elite Medical Prep can help you with your OB/GYN shelf exam, do not hesitate to <a href="https://elitemedicalprep.com/get-started/">contact us to schedule a consultation</a>.</p>
<p>Good luck, and happy studying!</p>
<p>The post <a href="https://elitemedicalprep.com/studying-for-the-shelf-exam-during-your-ob-gyn-rotations/">Studying for the Shelf Exam During Your OB/GYN Rotations</a> appeared first on <a href="https://elitemedicalprep.com/">Elite Medical Prep</a>.</p>]]> </content:encoded>
</item>

<item>
<title>What You Need to Match into Psychiatry for Residency</title>
<link>https://edusehat.com/en/what-you-need-to-match-intopsychiatry-for-residency</link>
<guid>https://edusehat.com/en/what-you-need-to-match-intopsychiatry-for-residency</guid>
<description><![CDATA[ The NRMP Program directors survey “at a glance” tool is extremely helpful in gauging where your application packet stands compared to the applicant pool. Here are the major components to consider when applying into Psychiatry.
The post What You Need to Match into Psychiatry for Residency appeared first on Elite Medical Prep. ]]></description>
<enclosure url="https://elitemedicalprep.com/wp-content/uploads/2019/09/What-You-Need-to-Match-into-Psychiatry-for-Residency-1024x576.png" length="49398" type="image/jpeg"/>
<pubDate>Sat, 26 Sep 2026 01:00:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>What, You, Need, Match, into Psychiatry, for, Residency</media:keywords>
<content:encoded><![CDATA[<h2><b>How to Match into a </b><b>Psychiatry Residency Program</b></h2>
<p> </p>
<p><span><a href="https://elitemedicalprep.com/match-cycle-residency-application-timeline/">Residency application season</a> is upon us and today we’re looking at what makes a strong psychiatry residency application! The NRMP conducted a survey to determine what factors Program Directors consider when deciding which candidates to interview and rank for their residency program. The results were compiled into a “at a glance” tool, which is extremely helpful in gauging where your application packet stands compared to the applicant pool, and whether adding additional components, like a <strong><a href="https://elitemedicalprep.com/residency-letters-of-recommendation-everything-you-need-to-know/">letter of recommendation (LOR)</a></strong> in the specialty, could give you a leg up as programs review your application.</span></p>
<p> </p>
<h2>Is It Hard to Get a Psychiatry Residency</h2>
<p>Psychiatry has become increasingly competitive in recent years, but it remains an <a href="https://elitemedicalprep.com/match-into-psychiatry-for-residency/">attainable specialty</a> for applicants who prepare early and build a strong, well-rounded application. As more medical students pursue careers in mental health, psychiatry residency programs often receive more applications than available positions. Increased awareness of mental health, expanding career opportunities, and better work-life balance have helped make psychiatry more popular with medical students. Many psychiatry residency programs use a holistic review process instead of relying solely on test scores. They also consider clinical performance, leadership, volunteer experiences, professionalism, communication skills, resilience, and dedication to psychiatry. Residency program directors also look for applicants who demonstrate a sincere interest in psychiatry. Strong interpersonal skills help future residents build trust, communicate effectively with patients and families, and collaborate with colleagues. Understanding what programs value before you apply can help you build a well-rounded application and improve your chances of matching into psychiatry.</p>
<p> </p>
<h2><b>For psychiatry residency, major components of the survey you should pay attention to include: (from top to bottom of the page):</b></h2>
<p> </p>
<ul>
<li><b>Selection Criteria for an Interview </b><b>–</b><span> LOR in the specialty is a MAJOR factor. It is worth noting that while Step 1/COMLEX scores are listed number 1 according to NRMP, </span><b>you do not have to have an ultra-competitive score</b><span>; as long as your score is within the normal range for psych (see below) you should be fine. Unsurprisingly for a field based so strongly around interpersonal interactions, your letters of rec and dean’s letter will also factor heavily into your applications.</span></li>
</ul>
<p><img decoding="async" class="aligncenter size-full wp-image-9687" src="https://elitemedicalprep.com/wp-content/uploads/2019/09/PS1.png" alt=""></p>
<ul>
<li>
<h3><b>Step 1 and Step 2 Scores:</b></h3>
</li>
</ul>
<p><img decoding="async" class="aligncenter size-full wp-image-9690" src="https://elitemedicalprep.com/wp-content/uploads/2019/09/PS2.png" alt=""></p>
<ul>
<li><strong>Step 1 – Score</strong></li>
</ul>
<p> </p>
<ul>
<li>
<ul>
<li>
<ul>
<li><b>240+</b><span> is a </span><i><span>very</span></i><span> solid score in </span><b>psychiatry,</b><span> with the median being </span><b>220.</b></li>
<li><span>Range programs do NOT typically offer interviews: </span><b>200-220</b><span> seems to be the </span><i><span>minimum</span></i><span> threshold we would recommend for having a good chance at enough interviews. If you’re below 200-220 range, we suggest having a back-up specialty you could consider.</span></li>
<li><span>Range programs DO typically offer interviews: </span><b>230+ </b><span>seems to be the range at which you can feel comfortable in being offered interviews by a decent number of programs. If you’re in the </span><b>240+</b><span> range, you can likely be selective about where you apply.</span></li>
</ul>
</li>
</ul>
</li>
</ul>
<p> </p>
<ul>
<li><b>Step 2CK – Score</b></li>
</ul>
<p> </p>
<ul>
<li>
<ul>
<li>
<ul>
<li><b>200-220</b><span> seems to be the minimum threshold at which programs will grant interviews</span></li>
<li><span>Scores </span><b>below 200</b><span> generally will place you in a unfavorable position to receive an interview </span></li>
</ul>
</li>
</ul>
</li>
</ul>
<p> </p>
<ul>
<li><b>Step 2CK – Timing of Taking the Exam</b></li>
</ul>
<ul>
<li>Only 26% of programs required at least passing CK, while 53% did not require the test at all. For now we recommend timing your CK on a case-by-case basis; in many cases we would recommend taking it before you’ve submitted ERAS, but depending on where you’re applying (especially if you’re looking at the 53% of programs that don’t require a passing score!) you could be perfectly fine waiting until later.</li>
</ul>
<p> </p>
<ul>
<li><b>Failing Step 1 is not likely to be a show stopper</b><span>:</span><span> </span>
<ul>
<li><span>Failing Step 1 is a big deal in ANY specialty, but psychiatry is more forgiving of this than most. Only a slim 3% of programs report never interviewing candidates who have failed Step 1. It is important to note, however, that 62% of programs report “seldom” interviewing candidates who have failed the Step. If you’ve failed this exam you should consider applying more broadly than you would otherwise, and make sure the other aspects of your application are as strong as possible (remember that strong LORs count for a lot in this specialty!), but you should not have a problem matching solely because of this. </span></li>
</ul>
</li>
</ul>
<p><img decoding="async" class="aligncenter size-full wp-image-9690" src="https://elitemedicalprep.com/wp-content/uploads/2019/09/PS3.png" alt=""></p>
<ul>
<li>
<h2><b>Types of Applicants Considered:</b></h2>
<ul>
<li><b>International Grads </b><b><i>(U.S. and non-U.S.)</i></b><b> should not have significant trouble matching into psychiatry, but can face barriers</b><span>:</span><span> 51% of US programs often interview US IMGs, while 32% often interview non-US IMGs. Only a scant 4% of programs report never interviewing US IMGs, although 26% report never interviewing non-US IMGs. If you are a US international grad this element should not present a significant barrier to you; while you can anticipate it being a challenge for some programs, don’t let it hold you back. If you are a non-US international grad you should look a little more carefully at the programs you’re considering; be sure to look for programs that have one or more active IMGs who you could talk to about their application experience.</span></li>
<li><b>Osteopathic graduates should have no problem matching into psychiatry:</b><span> Only 7% of programs will never interview DO applicants, and the same percentage never rank them. A tremendous 77% of US psychiatry programs report both interviewing and ranking DO applicants often. While 16% of programs report “seldom” interviewing and ranking DO applicants, this degree should overall present no significant barrier towards matching in psychiatry.</span></li>
</ul>
</li>
</ul>
<p><img decoding="async" class="aligncenter size-full wp-image-9690" src="https://elitemedicalprep.com/wp-content/uploads/2019/09/PS4.png" alt=""></p>
<ul>
<li><b>Interviewees Get Ranked!</b><b>:</b><span> If you get an <a href="https://elitemedicalprep.com/scheduling-residency-interviews/">interview invitation</a>, you are very likely to end up on the rank list if you interview. We recommend ranking at least 8-10 programs, so once you receive 10 interview invitations, you can feel okay with starting to prioritize and cancel as more come in given you are likely to get ranked.</span></li>
<li><b>Expect to receive interview invitations in October:</b><span> 54% of the interview invitations will be sent out during October, with close to 20% in both September and November.</span></li>
<li><b>Expect to interview in November/December:</b><span> The majority of psychiatry interviews happen in November and December, with around 30% of interviews in each of these months, but this specialty provides one of the more evenly spread-out seasons. About 20% of interviews occur in October and January, so you should have a wide window for when these can occur. For further discussion on how to prep for your interview, see our blog post on <strong><a href="https://elitemedicalprep.com/preparing-for-your-residency-interview/">How to Crush your Residency Interview. </a></strong></span></li>
</ul>
<p> </p>
<h2><b>After you’ve browsed your specialty, take a look at a few other specialties and note what’s NOT important for psychiatry residency:</b></h2>
<ul>
<li>Getting a phenomenal Step 1 score isn’t particularly important in psychiatry, although passing the exam is very helpful.</li>
<li>Strong letters of recommendation and the MSPE/Dean’s letter are both very important for psychiatry.</li>
<li>A background solely dedicated to the specialty is not as important! Psychiatry loves to take all comers, even if they’ve explored many other specialties or walks of life before.</li>
</ul>
<p> </p>
<p> </p>
<h2><b>Summary for Psychiatry Residency Applications:</b></h2>
<p> </p>
<ul>
<li><strong>A solid psychiatry application would include a 220+ on Step 1, 220+ on Step 2, a LOR from 1-3 psychiatrists, and a good MSPE.</strong></li>
</ul>
<ul>
<li>Psychiatry is relatively IMG friendly, although if you’re a non-US IMG this may be a moderate barrier. It certainly is possible to match as a non-US IMG if you do your research to identify programs with active IMG residents and establish proper connections.</li>
</ul>
<ul>
<li>Psychiatry is extremely friendly to DO applicants.</li>
</ul>
<ul>
<li>If you’ve failed an exam, you can still apply in psychiatry, but you should apply more broadly than you would otherwise.</li>
<li>Expect Interviews in November-December. Reach out to programs you have high interest in if you haven’t heard from them by mid-November. Once you have about 10 interview invitations, you can consider being a bit more selective about which ones you actually take (but not before).</li>
</ul>
<p> </p>
<p><span>Good Luck! ☺ </span></p>
<p><span>Wondering about your chances of matching into other specialties for residency? Check out our analysis of the NRMP directors survey “at a glance” tool for areas including</span><a href="https://elitemedicalprep.com/applying-into-anesthesia-acceptance-factors/"> <span>anesthesia</span></a><span>,</span><a href="https://elitemedicalprep.com/what-you-need-to-match-into-dermatology-for-residency/"> <span>dermatology</span></a><span>,</span><a href="https://elitemedicalprep.com/match-into-family-medicine-residency/"> <span>family medicine</span></a><span>,</span><a href="https://elitemedicalprep.com/criteria-for-matching-into-a-ty-residency/"> <span>transitional year</span></a><span>,</span> <a href="https://elitemedicalprep.com/matching-into-neurology-residency/">neurology</a><span>,</span><a href="https://elitemedicalprep.com/matching-into-emergency-medicine-for-residency/"> <span>emergency medicine</span></a><span>, and more under the</span><strong><a href="https://elitemedicalprep.com/category/medical-residency-application-advise-elite-medical-prep/"> Residency Applications</a></strong><span> category of our blog! If you need further or specialized assistance understanding which residency specialties you are best suited to apply to, you can</span><strong><a href="https://elitemedicalprep.com/contact/"> contact us</a></strong><span> or visit our</span><strong><a href="https://elitemedicalprep.com/residency-advising/"> residency advising</a></strong><span> page to learn more about how Elite Medical Prep’s residency advising services can help you.</span></p>
<p>The post <a href="https://elitemedicalprep.com/match-into-psychiatry-for-residency/">What You Need to Match into Psychiatry for Residency</a> appeared first on <a href="https://elitemedicalprep.com/">Elite Medical Prep</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Young organs may not be a fountain of youth for recipients</title>
<link>https://edusehat.com/en/young-organs-may-not-be-a-fountain-of-youth-for-recipients</link>
<guid>https://edusehat.com/en/young-organs-may-not-be-a-fountain-of-youth-for-recipients</guid>
<description><![CDATA[ Around this time last year I was attending an aging conference in Manchester, listening to a talk about fly aging, when my phone started pinging. News outlets were reporting that a hot mic had caught Russia’s and China’s leaders discussing the possibility of living forever. “With the developments of biotechnology, human organs can be continuously… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/09/young-old-heart.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 25 Sep 2026 21:05:02 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Young, organs, may, not, fountain, youth, for, recipients</media:keywords>
<content:encoded><![CDATA[<div data-chronoton-summary="<ul>
<li><strong>Young hearts don't stay young for long:</strong> New research shows that transplanted hearts quickly take on the biological age of whoever receives them — meaning a 30-year-old heart given to a 70-year-old recipient will soon "act" 70.</li>
<li><strong>The body's environment calls the shots:</strong> Researchers found that neither the recipient's blood nor other organs were meaningfully affected by the donor heart's age, suggesting the body's broader environment overpowers any rejuvenating potential a young organ might carry.</li>
<li><strong>A silver lining for transplant medicine:</strong> The findings could push surgeons to stop discarding older donor hearts, since biological age appears to reset after transplant anyway — potentially expanding a critically short supply of viable organs.</li>
<li><strong>Immortality remains out of reach:</strong> The study underscores just how stubbornly complex aging is — reversing it entirely would require unwinding DNA damage, structural decay, and cellular wear across every tissue simultaneously, which scientists say is an enormous, likely impossible, challenge.</li>
</ul>" data-chronoton-post-id="1145083" data-chronoton-expand-collapse="1" data-chronoton-analytics-enabled="1"></div>


<p>Around this time last year I was attending an aging conference in Manchester, listening to a talk about fly aging, when my phone started pinging. News outlets were reporting that a hot mic had caught Russia’s and China’s leaders <a href="https://www.technologyreview.com/2025/09/05/1123113/putin-organ-transplants-immortality-longevity-replacement/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=09-24-26">discussing the possibility of living forever</a>.</p>



<p>“With the developments of biotechnology, human organs can be continuously transplanted, and people can live younger and younger, and even achieve immortality,” Russia’s Vladimir Putin reportedly told China’s Xi Jinping.</p>



<p>He seems to have been referring to the “replacement” theory of longevity, which has been supported by multiple <strong><a href="https://www.technologyreview.com/2016/11/22/155895/blood-from-old-mice-makes-young-mice-decrepit/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=09-24-26" target="_blank" rel="noreferrer noopener">experiments</a></strong> that involved physically stitching young mice to old ones. Something about the young blood rejuvenated the old mice. Perhaps young organs could rejuvenate world leaders in their 70s, too.</p>





<p>Unfortunately for Putin, new research pours a little cold water on this idea. Studies on transplanted hearts in both mice and humans suggest that new hearts soon adopt the biological age of the recipient, no matter how young they were to begin with. The finding could be important for transplantation, but it also highlights just how complex aging—and rejuvenation—are.</p>



<p>Jesse Poganik at Brigham and Women’s Hospital in Boston is one of the many scientists trying to understand exactly what it is about the bodies of young mice that rejuvenates old ones. Plenty of research has focused on seeking the secrets of youth in <a href="https://www.technologyreview.com/2026/08/27/1143037/startup-claims-its-found-a-drug-to-make-your-blood-young/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=09-24-26">young blood</a>. But what if it’s something about young organs instead?</p>



<p>To find out, he and his colleagues performed a set of heart transplants in mice. In humans, heart transplants typically involve removing a damaged or injured heart and replacing it with another from a donor who is usually much younger than the recipient. (When Poganik assessed hospital records, he found that most recipients were about 20 years older than their donors.)</p>



<p><strong>The mouse transplants were different:</strong> Mice received a <em>second</em> heart, implanted in the neck—a procedure that’s slightly simpler and allows scientists to compare the new hearts with the existing ones. In some cases, young adult mice were given a heart from a middle-aged donor. In others, middle-aged mice got young hearts.</p>



<p>The team used a trio of <a href="https://www.technologyreview.com/2025/10/14/1124977/aging-clocks-biology-mortality-longevity/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=09-24-26">“aging clocks”</a>—molecular tools used to estimate the biological ages of tissues and whole organisms—to assess whether the additional hearts affected the mice in any way. These clocks were good at predicting the chronological age of mice that didn’t get new hearts.</p>





<p>Poganik says he was expecting to see a reciprocal effect, and that young hearts might benefit older animals, for example. In previous work by other members of his team, young mice that got old hearts experienced a buildup of senescent cells in their other organs. These cells are thought to contribute to the aging process, suggesting that receiving an old organ might prematurely age an animal.</p>



<p><strong>But that’s not what he found.</strong> When he and his colleagues analyzed the transplanted hearts between four and six months after surgery, they found that the hearts seemed to have adopted the biological age of the recipients. Young hearts got older, and old hearts got younger. “The environment of the transplanted organ really dictates how it seems to behave biologically,” he says. The findings were published online at <a href="https://www.biorxiv.org/content/10.64898/2026.09.15.751836v1">bioRxiv</a> last week.</p>



<p>The team also looked at each mouse’s blood and other organs—including its original heart—and were surprised to find that they seemed to be unaffected by the presence of the new heart, despite the age of its donor.</p>



<p><strong>The finding was backed up by data from human heart transplants.</strong> People who receive a donor heart must typically undergo a series of heart biopsies after surgery. The tiny pieces of heart tissue collected from people who had heart transplants at Brigham and Women’s have been stored for decades. And when Poganik and his colleagues tested their biological ages with the aging clocks, they found a similar pattern: No matter the age of the donor, a new heart quickly adopts the biological age of the person who received it.</p>





<p>It’s not clear why this is, but João Pedro de Magalhães, who studies aging at the University of Birmingham in the UK and was not involved in the study, thinks it might have something to do with the recipient’s immune system. Perhaps immune cells circulating in the blood might affect markers of aging in the new organ, he says.</p>



<p>Perhaps the potential rejuvenating effects of a young heart end up being diluted by all the other aged components of an older body, Poganik suggests. Or maybe a single organ just isn’t enough to see an effect.</p>



<p>Poganik hopes his finding will encourage surgeons to consider using hearts from older donors, many of which are discarded on the assumption they won’t function as well. (Machines used to preserve organs before transplantation are changing that already—and Poganik has worked on another study showing that these devices <a href="https://www.technologyreview.com/2026/09/14/1144010/donated-livers-can-be-made-biologically-younger/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=09-24-26">seem to rejuvenate donor livers</a> to some extent.)</p>



<p><strong>But the study also highlights just how complicated aging is.</strong> If organs seem to be getting older by one measure but not by another, how can we get a full picture of the biological age of an organ, or a person?</p>



<p>This complexity means that scientists are not likely to discover a true way to completely reverse aging, says Poganik. “That would mean that every aspect of aging has to go back in time,” he says. Reversing DNA damage, structural damage, and all the other degradations that are part of the aging package, across all our various cells and tissues, presents an <em>enormous</em> challenge.</p>



<p>“There are aspects of biological age that are probably reversible, and there are aspects that are probably not,” he says. Sorry, Putin.</p>



<p><em>This article first appeared in The Checkup, </em>MIT Technology Review’s<em> weekly biotech newsletter. To receive it in your inbox every Thursday, and read articles like this first, </em><a href="https://forms.technologyreview.com/newsletters/biotech-the-checkup/?_ga=2.241810882.15113993.1664981064-43237434.1647441349"><em>sign up here</em></a>.<br></p>]]> </content:encoded>
</item>

<item>
<title>Hamilton Health Sciences plans to eliminate more than 400 positions amid budget pressures</title>
<link>https://edusehat.com/en/hamilton-health-sciences-plans-to-eliminate-more-than-400-positions-amid-budget-pressures</link>
<guid>https://edusehat.com/en/hamilton-health-sciences-plans-to-eliminate-more-than-400-positions-amid-budget-pressures</guid>
<description><![CDATA[ Hamilton Health Sciences (HHS) is planning to eliminate more than 400 positions as the hospital network works to address a projected $150-million deficit for the 2026–27 fiscal year. The planned reduction involves approximately 413 union and non-union positions across the organization. About one-third of the affected positions are currently vacant, which is expected to reduce […]
The post Hamilton Health Sciences plans to eliminate more than 400 positions amid budget pressures appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/09/shutterstock_2708211297.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 25 Sep 2026 20:55:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Hamilton, Health, Sciences, plans, eliminate, more, than, 400, positions, amid, budget, pressures</media:keywords>
<content:encoded><![CDATA[<p data-pm-slice="1 1 []">Hamilton Health Sciences (HHS) is planning to eliminate more than 400 positions as the hospital network works to address a projected $150-million deficit for the 2026–27 fiscal year.</p>
<p>The planned reduction involves approximately 413 union and non-union positions across the organization. About one-third of the affected positions are currently vacant, which is expected to reduce the number of employees who ultimately lose their jobs.</p>
<p>The reductions are expected to include approximately 143 nursing positions and 84 health-care aide positions. Because a significant number of positions in those areas are currently vacant, HHS has indicated that few, if any, employees in those categories are expected to lose their jobs.</p>
<p>The measures come as Ontario hospitals facing deficits have been directed by the province to develop multi-year plans to return to balanced budgets.</p>
<p>HHS achieved approximately $40 million in cost reductions last year but says additional measures are necessary as operating expenses continue to rise and demand for hospital care remains high.</p>
<p>For the current fiscal year, the organization has established savings targets of two per cent for clinical budgets and five per cent for administrative budgets.</p>
<p>HHS president and CEO Tracey MacArthur has said some staffing capacity added during and following the COVID-19 pandemic was created to address exceptional circumstances and is not supported by continuing funding. The organization now needs to adjust that capacity to a level it says can be sustained with available funding.</p>
<p>The Ontario government increased hospital funding by four per cent this year, representing approximately $1.1 billion in additional funding. However, the Ontario Hospital Association has previously indicated that hospitals require substantially more funding to address their financial pressures.</p>
<p>The province maintains that the changes at HHS will not affect patient services or access to care.</p>
<h2>Hospital unions have expressed a different view.</h2>
<p>CUPE Local 7800, which represents thousands of workers at HHS, has warned that reducing staffing will put additional pressure on employees and could affect patient care. The union has announced a campaign opposing the cuts.</p>
<p>The Ontario Nurses’ Association has also raised concerns about reductions to nursing positions and their potential effect on patient care.</p>
<p>Hamilton Health Sciences is not alone in facing difficult financial decisions. Other Ontario hospital organizations have announced workforce reductions or vacancy-management measures as they attempt to balance their budgets.</p>
<p>The Ottawa Hospital previously announced plans to reduce its workforce by approximately three per cent, while London Health Sciences Centre has pursued nursing reductions through attrition. Chatham-Kent Health Alliance has also announced plans to eliminate positions largely by leaving vacancies unfilled.</p>
<p>The developments highlight the growing financial challenge facing Ontario hospitals as health-care organizations attempt to reconcile rising operating costs and increasing demand for services with available provincial funding.</p>
<p>The post <a href="https://www.hospitalnews.com/hamilton-health-sciences-plans-to-eliminate-more-than-400-positions-amid-budget-pressures/">Hamilton Health Sciences plans to eliminate more than 400 positions amid budget pressures</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Intense Media Pressure an Emerging Challenge in CHO Business</title>
<link>https://edusehat.com/en/intense-media-pressure-an-emerging-challenge-in-cho-business</link>
<guid>https://edusehat.com/en/intense-media-pressure-an-emerging-challenge-in-cho-business</guid>
<description><![CDATA[ Process intensification and the adoption of continuous-mode manufacturing has increased the consumption of culture media. Managing these ever-growing culture volumes in a cost and space efficient manner has become a major challenge for drug manufacturers, says Just – Evotec Biologics.
The post Intense Media Pressure an Emerging Challenge in CHO Business appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-115860608-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 25 Sep 2026 06:40:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Intense, Media, Pressure, Emerging, Challenge, CHO, Business</media:keywords>
<content:encoded><![CDATA[<p>Storing and preparing the culture media required to make protein therapeutics is a major challenge for biopharma, particularly given the growing interest in boosting output through intensification and continuous processing.</p>
<p>So says Guy Rachmuth, from Seattle services firm Just – Evotec Biologics, who told <em>GEN</em>, “Cell culture media requires significant footprint for both batching and storing media, including cold temperature storage for many final liquid media formulations.</p>
<p>“Manufacturers often need tens to hundreds of thousands of liters of media, making storage efficiency an increasingly important consideration. In addition, mixing equipment limitations can necessitate compounding multiple media batches per run and increase operational complexity in manufacturing.”</p>
<p>Rachmuth added, “These challenges become even more pronounced in intensified production processes, where continuous perfusion of bioreactors significantly increases cell culture medium volume requirements.”</p>
<p>With this in mind, Just – Evotec developed J.Media, a concentrated, room-temperature stable powder format that, the firm claims, reduces storage footprint, simplifies logistics and supports more flexible and efficient manufacturing operations.</p>
<p>The product was developed to meet the demands of Just – Evotec’s own manufacturing programs and has since become a core platform technology across the organization supporting nearly 70 projects.</p>
<p>Rachmuth told us, “Given the success we’ve seen internally, we recognized an opportunity to make J.Media available more broadly to the industry. By offering it as a standalone product, we aim to help other organizations benefit from the same combination of productivity, scalability, and cost efficiency.”</p>
<p>In tests, details of which were presented at the <a href="https://www.evotec.com/events/bioprocess-international-us-east-2026" target="_blank" rel="noopener">BPI conference and exhibition in Boston</a>, the media outperformed several commercially available products, exhibiting higher volumetric productivity and cumulative titer.</p>
<p>According to Rachmuth, “The media routinely runs at 80-100 10E6 cells/mL maintaining high viability over a period of 15-25 days, or longer. Our productivity is higher than competitor media.</p>
<p>“In perfusion operations, volumetric productivities of up to 4-5 g/L/day have been achieved, highlighting the platform’s ability to support highly efficient manufacturing processes,” he said.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/intense-media-pressure-an-emerging-challenge-in-cho-business/">Intense Media Pressure an Emerging Challenge in CHO Business</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>JNC Targets Bigger Molecules with Cellufine</title>
<link>https://edusehat.com/en/jnc-targets-bigger-molecules-with-cellufine</link>
<guid>https://edusehat.com/en/jnc-targets-bigger-molecules-with-cellufine</guid>
<description><![CDATA[ JNC is using BioProcess International 2026 to spotlight Cellufine and its emerging MLP chromatography media, developed to address purification challenges posed by viral vectors, vaccines, and other increasingly large and complex biological products.
The post JNC Targets Bigger Molecules with Cellufine appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/JNC-BPI_GBPN_IMAGE-1.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 25 Sep 2026 06:40:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>JNC, Targets, Bigger, Molecules, with, Cellufine</media:keywords>
<content:encoded><![CDATA[<p>The rapid expansion of viral vectors, vaccines, and other complex biologics is creating a familiar downstream-processing problem in a new form: the molecules and particles that manufacturers need to purify are getting bigger. JNC is addressing that challenge at BioProcess International 2026, where the company is showcasing its Cellufine chromatography portfolio alongside monolith-like particle (MLP) products currently under development.</p>
<p>Cellufine is JNC’s family of cellulose-based chromatography media for biopharmaceutical purification. The company’s newer MLP platform takes that foundation in a different direction by using a large-pore bead architecture intended to improve access for bulky biological targets that can be difficult to accommodate with conventional porous media.</p>
<p>That design was the focus of a presentation by Chigusa Mori, R&D scientist at JNC, titled “Cellufine MLP: Wide Pore Cellulose Base Bead 3D Architecture for Large Biomolecule Chromatography Applications.”</p>
<p>JNC is also highlighting two development-stage MLP products through poster presentations. One examines Cellufine MLP DexQ for separating empty and full adeno-associated virus (AAV) particles, which is a persistent purification challenge in AAV manufacturing. Another explores Cellufine MLP DexS for viral-vector purification.</p>
<p>MLP DexS uses dextran sulfate as a ligand and is being investigated for large-particle applications, including vaccines. Data reported by JNC show that the resin concentrated inactivated influenza virus 13-fold while cutting protein impurities by 90.3%. In testing with human coronavirus OC43, JNC reported a 97.3% reduction in protein impurities together with 91% virus recovery. Those results point to the broader bioprocessing question behind JNC’s showcase: how chromatography can evolve as therapeutic modalities move beyond traditional proteins toward particles and assemblies with very different physical properties.</p>
<p>For downstream developers, pore architecture is becoming more than a resin-design detail. It can determine how effectively large targets enter the bead, interact with ligands, and ultimately separate from process-related impurities.</p>
<p>By bringing its MLP technology to BPI26, JNC is positioning large-pore cellulose chromatography as one approach to extending conventional column purification into areas where the size of the product itself increasingly shapes process performance.</p>
<p class="trimmed"> </p>
<p class="trimmed"> </p>
<p class="trimmed"> </p>
<p class="trimmed"> </p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/jnc-targets-bigger-molecules-with-cellufine/">JNC Targets Bigger Molecules with Cellufine</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Muscle Cell Calcium Channel Structure, Synchronicity Could Advance Muscle Disease Therapeutics</title>
<link>https://edusehat.com/en/muscle-cell-calcium-channel-structure-synchronicity-could-advance-muscle-disease-therapeutics</link>
<guid>https://edusehat.com/en/muscle-cell-calcium-channel-structure-synchronicity-could-advance-muscle-disease-therapeutics</guid>
<description><![CDATA[ Researchers captured the first high-resolution 3D images of the muscle cell calcium channel RyR1 at six stages of opening inside the intact sarcoplasmic reticulum membrane, potentially helping to explain mechanisms behind certain muscle diseases. 
The post Muscle Cell Calcium Channel Structure, Synchronicity Could Advance Muscle Disease Therapeutics appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/01/Trends-Biotech-GettyImages-1441662854.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 25 Sep 2026 06:40:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Muscle, Cell, Calcium, Channel, Structure, Synchronicity, Could, Advance, Muscle, Disease, Therapeutics</media:keywords>
<content:encoded><![CDATA[<p>Every step we take begins with a burst of calcium inside our muscle cells, causing them to contract. Using cryo-electron microscopy (cryo-EM), researchers at the Max Delbrück Center have revealed how muscle cell calcium channels, known as type-1 ryanodine receptors (RyR1), open synchronously. The team, led by Vasilii Mikirtumov, PhD, a former doctoral student in the <em>in situ</em> structural biology lab of Misha Kudryashev, PhD, suggests that their findings may explain a mechanism behind serious muscle diseases and potentially point to therapeutic targets.</p>
<p>Kudryashev is senior and corresponding author of the scientists’ published paper in <em>Nature Communications</em>, titled “<a href="https://doi.org/10.1038/s41467-026-75504-9" target="_blank" rel="noopener">Ligand-induced activation of RyR1 in native membranes</a>,” in which they conclude that their findings “… explain the mechanism of ligand-gated activation of RyR1 in native membranes and provide structural insights critical for understanding RyR1-associated skeletal muscle diseases and developing targeted therapeutic strategies.”</p>
<p>Skeletal muscle contraction relies on “… a precise interplay between electrical signals and Ca2+ release from internal stores,” the authors explained. Maintaining readiness for contraction, the cells keep calcium locked in this internal compartment, the sarcoplasmic reticulum (SR). Studding its membrane are thousands of RyR1 channels—the largest known ion channels—containing pores that release calcium.</p>
<p>For a muscle to contract properly, RyR1 channels must open synchronously via a mechanism known as “coupled gating.” How they accomplish this has been unclear since it was described almost 30 years ago. “…  the physical mechanism orchestrating this cooperativity has remained unknown,” the authors noted in their paper.</p>
<p>Through their reported studies Mikirtumov, Kudryashev, and colleagues have captured the first high-resolution 3D images of RyR1 at six stages of opening inside the intact sarcoplasmic reticulum membrane. The structure of RyR1 has been described before, but previous studies used channels that had been removed from the membrane. Instead, the Kudryashev lab studied the structure of RyR1 in its natural environment using the advanced imaging techniques of cryo-EM and tomography. “Because RyR1 is a membrane protein, you have to pull it out with detergents to purify it. But that environment can be disruptive to such a sensitive protein,” explained Mikirtumov, who is now a postdoctoral researcher in the lab of Christian Spahn at Charité – Universitätsmedizin Berlin. “We wanted to capture the structure of the channel in its native membrane and find out whether its opening mechanism looks different there.”</p>
<p>The team isolated the SR from rabbit muscle and imaged it at the Core Facility for Cryo-Electron Microscopy, which is run jointly by Charité – Universitätsmedizin Berlin, the Max Delbrück Center, and the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP). The Kudryashev lab has specialized expertise in cryo-EM and tomography and the computational tools necessary to analyze the resulting data.</p>
<p>“We shoot electrons through the sample and take thousands of pictures, each with many copies of the same protein,” explained Mikirtumov. “Then we average them all together, and that gives us a high-resolution 3D reconstruction.”</p>
<p>By adding small molecules to initiate channel opening, the researchers caught RyR1 at six stages between fully closed and fully open. “Comparing the structures revealed the full opening motion: The bulky outer part rotates within the plane of the membrane, like turning the ring of a camera lens, while the pore in the channel widens to roughly twice its original width.</p>
<p>The resulting images showed that neighboring channels remain in contact with each other when transitioning from the closed to open states. This contact, or interface, mediates coupled gating: as one channel rotates open, it strains the interface with its neighbor, making it easier for that channel to rotate and open too. “It’s like the cogs in a clock,” said Kudryashev. “Once one cog turns, it primes its neighbors to turn, too.”</p>
<p>In their paper the team wrote in summary, “The RyR1 structures in four distinct as well as two intermediate functional states induced by activating ligands showed that the activation of RyR1 includes a large rotation component in the membrane plane. The structures reveal direct, corner-to-corner physical contacts between receptors, providing a high-resolution view of the interface that mediates coupled gating.”</p>
<p>Using cryo-electron tomography, the team also imaged pairs of neighboring channels at five stages of opening. They found neighboring channels were more likely to be synchronized, and that two interacting closed channels were more stable than two closed channels in isolation. These findings support coupled gating and suggest that channels hold each other shut.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>Mutations in the RYR1 gene cause malignant hyperthermia, a life-threatening reaction to some anesthetics, and congenital myopathies that weaken muscles. Many of these mutations alter the channel exactly where it touches its neighbor.</p>
<p>Mikirtumov added, “A lot of these mutations don’t seem to affect how a single channel opens, but rather how channels cooperate with their neighbors. We mapped several of them onto the interface, and we think that in these cases, it’s the cooperation between channels that breaks down.”</p>
<p>The researchers propose that disruption at the interface between channels makes them leaky, releasing calcium when they should retain it. This makes the interface itself a target for therapies. “We propose a mechanism for RyR1 activation, shifting the focus from an individual channel event to a cooperative process orchestrated by a mechanically coupled receptor lattice,” they stated.</p>
<p>The team is already testing the idea. “We need to prevent the channels from opening spontaneously,” said Kudryashev. “Now that we know how the inactive state is organized, we can design biologics or small molecules to stabilize this closed state.” The authors concluded, “These results emphasize the physiological importance of RyR1 arrays as integrated functional units and provide new perspectives on EC-coupling and the development of targeted therapeutics for RyR1-linked channelopathies.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/muscle-cell-calcium-channel-structure-synchronicity-could-advance-muscle-disease-therapeutics/">Muscle Cell Calcium Channel Structure, Synchronicity Could Advance Muscle Disease Therapeutics</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>APOE4 Linked to Potentially Reversible Mechanisms of Brain Blood Vessel Damage in Alzheimer’s</title>
<link>https://edusehat.com/en/apoe4-linked-to-potentially-reversible-mechanisms-of-brain-blood-vessel-damage-in-alzheimers</link>
<guid>https://edusehat.com/en/apoe4-linked-to-potentially-reversible-mechanisms-of-brain-blood-vessel-damage-in-alzheimers</guid>
<description><![CDATA[ Two studies reveal how APOE4, a major genetic risk factor for Alzheimer’s, disrupts brain blood vessels and promotes abnormal protein accumulation, pointing to potentially reversible disease mechanisms.
The post APOE4 Linked to Potentially Reversible Mechanisms of Brain Blood Vessel Damage in Alzheimer’s appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2023/12/GettyImages-1410984882.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 25 Sep 2026 06:40:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>APOE4, Linked, Potentially, Reversible, Mechanisms, Brain, Blood, Vessel, Damage, Alzheimer’s</media:keywords>
<content:encoded><![CDATA[<p><span>Data from two studies using models of brain tissue and aged mice help explain how APOE4, a genetic risk factor for Alzheimer’s disease, damages the brain’s blood vessels and promotes the buildup of abnormal protein. The findings are published in two papers in the journals </span><i><span>Cell </span></i><span>and </span><i><span>Cell Stem Cell</span></i><span>. The </span><i><span>Cell</span></i><span> paper is titled “</span><a href="https://www.cell.com/cell/abstract/S0092-8674(26)01069-X" target="_blank" rel="noopener"><span>A pericyte-to-myofibroblast transition links APOE4 to cerebrovascular degeneration</span></a><span>.” The </span><i><span>Cell Stem Cell</span></i><span> paper is titled “</span><a href="https://www.cell.com/cell-stem-cell/fulltext/S1934-5909(26)00302-4" target="_blank" rel="noopener"><span>Cholesterol dysregulation in APOE4 astrocytes promotes α-synuclein pathology in miBrains</span></a><span>.”</span></p>
<p><span>Both studies are led by scientists at the Icahn School of Medicine at Mount Sinai. They help answer questions about the exact mechanism by which blood vessels deteriorate as Alzheimer’s progresses, particularly in people with APOE4. The </span><i><span>Cell</span></i><span> study details how the Mount Sinai researchers combined existing datasets to create a single-cell transcriptomic atlas of the human brain’s vasculature, resulting in a detailed map of gene activity across cells that form and support blood vessels. </span></p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p><span>By analyzing the map, they found that APOE4 caused pericytes, which are cells that stabilize small blood vessels and help maintain the blood-brain barrier, to transform into scar-forming myofibroblast-like cells. This change promoted vascular fibrosis and increased amyloid accumulation around the vessels. This created conditions that may compromise blood flow and promote neurodegeneration. Using aged APOE4 mice, the scientists observed the effects of blocking TGF-β signaling, a pathway involved in cellular communication and tissue remodeling. They found that it restored pericyte coverage and reduced both fibrosis and vascular amyloid, effectively demonstrating that it may be possible to reverse APOE4-associated cerebrovascular degeneration therapeutically.</span></p>
<p><span>These results show that “damage to the brain’s blood vessels is not simply a late consequence of Alzheimer’s disease; it is a biologically active process caused by APOE4 that may be reversible,” said Joel Blanchard, PhD, associate professor of neuroscience, and stem cell biology and regenerative medicine at Mount Sinai and a corresponding author on the study. Furthermore, “ through our experiments, we were able to block this protein buildup process, revealing possible new therapeutic treatment options and strategies for protecting the brain’s circulation in people at high genetic risk for Alzheimer’s disease,” said Braxton Schuldt, MD/PhD candidate in neuroscience and researcher in the Blanchard Laboratory at Mount Sinai. He is also the first author on the paper. </span></p>
<p><span>For the </span><i><span>Cell Stem Cell </span></i><span>study, the Mount Sinai scientists and their collaborators elsewhere used miBrains to investigate how APOE4 promotes abnormal protein build up in diseases like Alzheimer’s and Parkinson’s. Derived from induced pluripotent stem cells, miBrains are three-dimensional human brain tissues developed by the Mount Sinai team to model key features of the human brain and its vascular network. These 3D tissues contain all the major cell types, including neurons, supporting glial cells, myelin-producing cells, and cells that form blood vessels. </span></p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p><span>They also mimic the behavior of human brains carrying APOE4. Specifically, miBrains carrying APOE4 accumulate higher levels of abnormal alpha-synuclein, the protein commonly associated with Lewy body dementia and Parkinson’s disease. Experiments reported in the paper showed that APOE4 causes cholesterol to accumulate in astrocytes, and that this excess cholesterol impairs the astrocytes’ lysosomal waste-disposal system, reducing their ability to break down alpha-synuclein. The protein instead aggregates and spreads to neurons, leading to harmful protein deposits. The findings identify cholesterol metabolism in astrocytes and lysosomal function as promising therapeutic targets for Alzheimer’s and Parkinson’s disease.</span></p>
<p><span>“A key advance of our technology is that miBrains with predefined cellular compositions and disease-related factors can be cryopreserved,” said Louise Mesentier-Louro, PhD, assistant professor of neuroscience, and stem cell biology and regenerative medicine at Mount Sinai and first author of the study. “This capability improves reproducibility and scalability of complex disease modeling and supports more efficient drug development and validation.”</span></p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/apoe4-linked-to-potentially-reversible-mechanisms-of-brain-blood-vessel-damage-in-alzheimers/">APOE4 Linked to Potentially Reversible Mechanisms of Brain Blood Vessel Damage in Alzheimer’s</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>National Cancer Institute explainer for CSBA: Why and how to apply for SBIR</title>
<link>https://edusehat.com/en/national-cancer-institute-explainer-for-csba-why-and-how-to-apply-for-sbir</link>
<guid>https://edusehat.com/en/national-cancer-institute-explainer-for-csba-why-and-how-to-apply-for-sbir</guid>
<description><![CDATA[ The SBIR and STTR federal seed funding programs—essential to many biotech start-ups—have been updated with important changes that provide new opportunities to applicants. These […]
The post National Cancer Institute explainer for CSBA: Why and how to apply for SBIR appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2023/09/towfiqu-barbhuiya-joqWSI9u_XM-unsplash.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 25 Sep 2026 03:10:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>National, Cancer, Institute, explainer, for, CSBA:, Why, and, how, apply, for, SBIR</media:keywords>
<content:encoded><![CDATA[<p><span>The SBIR and STTR federal seed funding programs—essential to many biotech start-ups—have been updated with important changes that provide new opportunities to applicants.</span></p>
<p><span>These changes include a new Strategic Breakthrough Program, which can bring up to $30 million to impactful innovations addressing pediatric and rare cancers, experts from the National Cancer Institute (NCI) told a Sept. 17 webinar for the</span><a href="https://www.bio.org/csba"> <span>Council of State Bioscience Associations (CSBA)</span></a><span>.</span></p>
<p><span>Their presentations offer useful information for oncology biotechs, and any biotech needing seed funding to start their work.</span></p>
<p><span>“We tend to be the first source of funds that a company will look for after they’ve raised funds from friends and family,” said Michael Weingarten, Director of NCI’s SBIR Program.</span></p>
<p><span>Organized by the Biotechnology Innovation Organization (BIO) as a service for its state affiliates in the CSBA, the webinar covered National Institutes of Health (NIH) Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grants—particularly NCI cancer research grants.</span></p>
<h2>About SBIR/STTR</h2>
<p><span>The most recent changes to SBIR and STTR were added in March, when</span><a href="https://bio.news/latest-news/sbir-reauthorization-a-top-bio-priority-is-passed-by-congress/"> <span>the programs were reauthorized by Congress</span></a><span> until September 2031. The next application deadline is Jan. 5, which is why this information matters now, the experts told the webinar.</span></p>
<p><span>Much of the conversation focused on SBIR grants, which individual start-ups can seek by themselves. STTR grants tend to be larger and support technology transfer. Along with a start-up, STTR grants must include an institutional partner, such as a university, that is transferring the technology.</span></p>
<p><span>The impact for start-ups, and American innovation, can be huge. Weingarten cited a 2018 study of Phase II SBIR/STTR grants given out by the NCI for cancer work between 1998-2010. Of those 690 projects, 247 went commercial, achieving over $26 billion in total economic output nationwide and creating over 108,000 jobs with an average salary of $75,000.</span></p>
<p><span>“We invested a total of $787 million in those companies to produce that $26 billion return. So overall return on investment for NCI’s money was about 33-to-1,” he said.</span></p>
<h2>The new Breakthrough Program</h2>
<p><span>One of the changes in the SBIR program that received special focus during the webinar was the new Strategic Breakthrough Award. The program can bring a start-up developing an important innovation for an unmet need as much as $30 million in capital at a critical phase of development, explained Billy Baza, Program Director within the NCI SBI Development Center.</span></p>
<p><span>“It really has to be a significant improvement to existing standard of care,” said Baza, describing the type of innovation targeted by the Breakthrough Award. “It really has to have an impact on the patients.”</span></p>
<p><span>The Strategic Breakthrough Awards differ among the various institutes of the NIH. At the NCI, “our goal is to really fund pivotal clinical studies for pediatric and rare cancers,” Weingarten said.</span></p>
<p><span>Investigation showed that the largest amount of private venture capital for oncology development goes to the most common types of cancer. NCI is hoping this program will encourage private investment in the rarer cancers, Baza said.</span></p>
<p><span>One way the program attracts private capital is through its 1-to-1 matching provision: applicants must use the grant to attract an equal amount of external funding, whether from a private investor, a partner company or another government program.</span></p>
<p><span>“Matching funds need to be secured after the application is submitted, but before the award is made,” Baza said. “That means you’re going to have explain your matching capital fundraising strategy within the commercialization plan.”</span></p>
<p><span>Other requirements, according to Baza:</span></p>
<ul>
<li aria-level="1"><span>“The technology has to be at a clinical stage, with some promising early human clinical data as well.”</span></li>
<li aria-level="1"><span>Patient unmet need has to be clearly demonstrated. “We’re not looking for incremental improvements,” Baza said. “We want innovations that can really impact high-need patient populations.”</span></li>
<li aria-level="1"><span>There must be a credible study plan addressing clinical trial operation and enrollment, and strong interactions with the Food and Drug Administration (FDA).</span></li>
</ul>
<p><span>It can also help to show applicants are receiving FDA support, including Fast Track and orphan designation, or accelerated approval allowing use of surrogate endpoints.</span></p>
<h2>Other procedural and funding changes</h2>
<p><span>Weingarten outlined several changes under the newly reauthorized programs, including a limit of nine applications a year to Health and Human Services SBIR programs. One helpful change allows applicants seeking their first STTR grants to apply for “Direct to Phase II Award,” receiving higher Phase II funding right away without going through Phase I.</span></p>
<p><span>Weingarten also discussed the amounts of the awards available from NCI, including changes in those awards:</span></p>
<ul>
<li aria-level="1"><span>The relatively new Concept Award provides very early-stage SBIR funding for a technology that is still just a concept, without supporting data. “We are looking for out-of-the-box ideas and disruptive technologies in the areas of pediatric or rare cancers,” Weingarten said. Applicants can receive up to $300,000.</span></li>
<li aria-level="1"><span>NCI increased Phase I awards from a maximum of $400,000 to $700,000. “Typically, those are for proof-of-concept studies,” Weingarten said.</span></li>
<li aria-level="1"><span>NCI Phase II awards go up to $2.5 million, usually for 2-3 years. “We tend to think of Phase II as funding IND enabling work,” he said.</span></li>
<li aria-level="1"><span>The Commercialization Readiness Program (CRP), for post Phase II, funds early clinical studies and provides up to $4.2 million.</span></li>
<li aria-level="1"><span>The above-mentioned Strategic Breakthrough Program is capped at $15 million from SBIR, before private matching funds are added.</span></li>
</ul>
<p><span>“If you look across all these different funding streams, companies can access up to $22 million in funding from our program, which is larger than award sizes from any of the other institutes at the NIH,” Weingarten said.</span></p>
<p><b>To learn more:</b></p>
<ul>
<li aria-level="1"><a href="https://sbir.cancer.gov/small-business-funding/application-process/step"><b>Join NCI’s training on how to apply for SBIR/STTR grants.</b></a></li>
<li aria-level="1"><a href="https://sbir.cancer.gov/"><b>NCI SBIR web site.</b></a></li>
</ul>
<p>The post <a href="https://bio.news/federal-policy/national-cancer-institute-explainer-for-csba-why-and-how-to-apply-for-sbir/">National Cancer Institute explainer for CSBA: Why and how to apply for SBIR</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Altruist Biologics’ Suzhou Site Receives EMA GMP Certification</title>
<link>https://edusehat.com/en/altruist-biologics-suzhou-site-receives-ema-gmp-certification</link>
<guid>https://edusehat.com/en/altruist-biologics-suzhou-site-receives-ema-gmp-certification</guid>
<description><![CDATA[ The company’s Quality Risk Management framework enabled proactive identification of compliance risks, reduced uncertainties associated with cross-regional technology transfer, and provided greater predictability as therapies advance toward regulatory submission and commercialization.
The post Altruist Biologics’ Suzhou Site Receives EMA GMP Certification appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/06/Getty_2024513047_PharmaceuticalFactory.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 25 Sep 2026 03:05:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Altruist, Biologics’, Suzhou, Site, Receives, EMA, GMP, Certification</media:keywords>
<content:encoded><![CDATA[<p>Altruist Biologics, a CDMO based in China, reports that its Suzhou commercial manufacturing facility has successfully passed a GMP inspection by the European Medicines Agency (EMA) with zero critical findings. This marks the first time the facility has successfully received EMA GMP certification.</p>
<p>The inspection supported the European Union marketing authorization application for a biologics product from a biopharmaceutical client. The EMA inspection involved an assessment covering the full biologics manufacturing lifecycle and a review of the facility’s quality systems and operational performance.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>The Suzhou facility’s quality management system, infrastructure, technical capabilities, data integrity controls and organizational management were recognized by the EMA, according to the company. The company’s Quality Risk Management (QRM) framework has enabled proactive identification of compliance risks, reduced uncertainties associated with cross-regional technology transfer, and provided greater predictability as innovative therapies advance toward global regulatory submission and commercialization, stated Kaisong Zhou, PhD, chairman and CEO of Altruist Biologics.</p>
<p>“Quality spans the entire biologics lifecycle, ensuring compliance with rigorous regulatory requirements from development through commercialization,” he said. “The recent EMA GMP certification exemplifies that our robust manufacturing processes, quality systems, talent and world-class facility meet regulatory requirements, and we have the agency’s trust to manufacture and deliver products on behalf of our global partners and the patients they serve.”</p>
<p>Altruist’s Suzhou and Hangzhou sites are designed and operated to meet GMP requirements across multiple regulatory authorities, including the EMA, FDA, the Pharmaceutical and Medical Devices Agency (PMDA) of Japan, and the National Medical Products Administration (NMPA) of China, pointed out Zhou.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>Equipped with 60,000 liters of antibody manufacturing capacity and an ADC clinical manufacturing line, the Suzhou facility provides end-to-end services for antibodies, fusion proteins and antibody-drug conjugates, he continued. The Hangzhou site is designed with a total antibody manufacturing capacity of 172,000 liters, with 80,000 liters currently operational across four 20,000-liter stainless steel bioreactors. A 2,000-liter antibody production line is currently under construction and is expected to be operational by mid-2027.</p>
<p>Altruist collectively has 140,000 liters of operational CDMO manufacturing capacity, representing approximately 20% of China’s total capacity, explained Zhou. As additional planned capacity comes online, Altruist’s total manufacturing capacity is expected to reach 232,000 liters.</p>
<p>In addition to the EMA, the Suzhou site has received multiple recognitions from other global regulatory authorities, said Zhou. It has successfully completed remote interactive evaluation by the FDA, and has passed inspections by the NMPA and the Federal Committee for Protection from Sanitary Risks (COFEPRIS) of Mexico, as well as more than 40 quality audits conducted by global clients.</p>
<p>Altruist Biologics, which will be exhibiting at booth 1027 at BPI, is a wholly-owned subsidiary of Innovent Biologics.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/altruist-biologics-suzhou-site-receives-ema-gmp-certification/">Altruist Biologics’ Suzhou Site Receives EMA GMP Certification</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Basecamp Research Raise $140M Series C Financing Toward Advancing AI&#45;Designed Drugs</title>
<link>https://edusehat.com/en/basecamp-research-raise-140m-series-c-financing-toward-advancing-ai-designed-drugs</link>
<guid>https://edusehat.com/en/basecamp-research-raise-140m-series-c-financing-toward-advancing-ai-designed-drugs</guid>
<description><![CDATA[ According to Basecamp, EDEN offers the ability to design long and complex DNA sequences with large serine recombinases capable of delivering those sequences precisely. 
The post Basecamp Research Raise $140M Series C Financing Toward Advancing AI-Designed Drugs appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/BASECAMP-RESEARCH-GLENOLLIEBASE-1-696x464-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 24 Sep 2026 09:05:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Basecamp, Research, Raise, 140M, Series, Financing, Toward, Advancing, AI-Designed, Drugs</media:keywords>
<content:encoded><![CDATA[<p>Basecamp Research said today it has completed an oversubscribed $140 million Series C financing whose proceeds are intended to fund the training of next generation EDEN models and apply them toward developing improved <em>in vivo</em> cell therapies for a variety of diseases.</p>
<p>Basecamp, a frontier AI company focused on therapeutic design, focuses on leveraging EDEN (short for “environmentally-derived evolutionary network), its biological foundation model, to develop<em> in vivo</em> cell therapies designed to reprogram a patient’s cells inside the body.</p>
<p>EDEN is Basecamp’s new class of foundation models trained on what the company says is the world’s largest and most diverse evolutionary dataset. According to Basecamp, EDEN offers the ability to design long and complex DNA sequences with large serine recombinases capable of delivering those sequences precisely.</p>
<p>EDEN-designed cell therapies are also designed to overcome the high manufacturing cost and limited complexity of present-day cell therapies. As a result, Basecamp said in its announcement, its EDEN-designed therapeutics offer the potential to treat complex diseases that include cancer and autoimmune disease, aiming “to underpin the future of cell therapies, making them more sophisticated, more customizable and simpler to administer” than current cell therapies.</p>
<p>“We believe the future of medicine lies in reprogramming the body to repair itself. We design the models and the medicines to teach it how,” Glen Gowers, PhD, Basecamp’s co-founder and CEO, said in the statement. Gowers co-founded Basecamp with Oliver Vince, PhD.</p>
<p>Basecamp says it has shown strong preclinical results across multiple modalities and disease areas. Aiming to expand its partnerships with biopharmas, Basecamp in April appointed Richard Pearce as chief business officer. Pearce previously served as Biogen’s head of business development, strategy, and portfolio management.</p>
<p>“AI-based approaches promise to change what’s possible for patients who currently have few alternatives. This funding brings this technology closer to those who need it most,” Gowers added.</p>
<p></p><h4><strong>Prominent investors</strong></h4>

<p>One prominent investor participating in the financing is Silicon Valley-based VC firm Menlo Ventures, which invested in Basecamp through the Menlo Anthology Fund, a $100 million fund financed by Menlo Ventures and launched in 2024 in partnership with Anthropic, the AI model builder behind the Claude family of large language models. Startups financed by the Menlo Anthology Fund receive access to Anthropic products and research, $25,000 in free credits towards Anthropic’s most advanced models, and what the company calls “best-in-class” venture support from Menlo.</p>
<p>“We’re particularly interested in ventures that leverage AI to enhance human capabilities and productivity in fields such as healthcare, legal services, education, energy, infrastructure, and scientific research,” Daniela Amodei, Anthropic’s co-founder and president, stated in announcing the launch of the Menlo Anthology Fund.</p>
<p>Anthropic’s offerings include Claude Science, the AI research workbench <a href="https://www.genengnews.com/topics/artificial-intelligence/claude-science-is-here-antibiotics-designed-by-text-prompt-among-applications/" target="_blank" rel="noopener">launched in June</a> and featuring Basecamp’s antibiotic design and vaccine prediction AI models.</p>
<p>Another prominent investor is NVentures, the venture capital arm of Nvidia—the Silicon Valley microprocessing giant<strong> </strong>with which Basecamp has <a href="https://www.genengnews.com/topics/artificial-intelligence/basecamp-research-achieves-programmable-gene-insertion-with-eden-ai-models/" target="_blank" rel="noopener">leveraged AI to unlock programmable gene insertion</a>, which places large therapeutic DNA sequences at precise locations in the human genome.</p>
<p>Researchers from Nvidia joined partners from Basecamp, Microsoft, and two research institutions in detailing EDEN in a <a href="https://www.biorxiv.org/content/10.64898/2026.01.12.699009v1" target="_blank" rel="noopener">preprint posted January 12 on bioRxiv</a>.</p>
<p></p><h4><strong>63% hit rate</strong></h4>

<p>The investigators showed EDEN to achieve an overall functional hit rate of 63.2% across diverse DNA prompts when prompted on only 30bp of DNA from outside the training data. Half (50%) of EDEN-generated LSRs were active in human cells, achieving therapeutically relevant levels of chimeric antigen receptor (CAR) insertion in primary human T cells. Also, an EDEN-generated synthetic microbiome was shown in the preprint to cover 9,067 species with a biome-specific taxonomic accuracy of 99%.</p>
<p>Nvidia and Anthropic were among partners of Basecamp that built its Trillion Gene Atlas, which draws on biological data collected through access and benefit-sharing partnerships in more than 30 countries across all seven continents. The Atlas is at the center of Basecamp’s AI platform, and according to the company is the world’s largest proprietary biological AI training dataset. Pacific Biosciences of California (PacBio) and Ultima Genomics also partnered in building the Atlas.</p>
<p>Trained on data from the Atlas, Basecamp’s EDEN models deliver a universal understanding of how DNA works across all of life. Its capabilities include designing cell and gene therapies, enzymes and peptides.</p>
<p>Unlike AI systems developed for a single scientific task, EDEN models are trained to recognize patterns across biology. As a result, it can generate potential therapeutic candidates directly from information about a disease, an approach already demonstrated through Basecamp’s collaboration with Anthropic on Claude Science.</p>
<p>Anthropic and NVentures are among participants in the financing, along with Catalio, European Tech Collective, Firebrand River Capital, King Philanthropies, NATO Innovation Fund, Redalpine, The Rockefeller Foundation, Singular, Sovereign AI, and True Ventures.</p>
<p></p><h4><strong>‘Next transformation’</strong></h4>

<div class="my-8"><span data-render-ad="6"></span></div>
<p>Basecamp has garnered additional investment from senior leaders across biopharma and global industry, including André Hoffmann, vice chairman of Roche, a board member of Roche subsidiary Genentech, and co-chair of the World Economic Forum.</p>
<p>“The biotechnology revolution that began fifty years ago transformed how we make medicines. Personalized, AI-designed therapeutics represent the next transformation of that journey,” Hoffmann stated. “Basecamp Research has built the full platform to deliver it, from biological data to trained models to designed therapies. This will be key in helping the industry to continue to innovate.”</p>
<p>Basecamp raised $60 million in Series B financing in 2024, and a $20 million Series A round two years earlier.</p>
<p>The Series C financing was led by S32, a Palo Alto, CA-based venture firm. S32 has about $3.5 billion in assets under management after closing earlier this year on a $517 million sixth flagship fund, according to PitchBook.</p>
<p>As a result of the latest financing, Andy Conrad, General Partner at S32 and former CEO of Google’s Verily, will join Basecamp’s board.</p>
<p>“AI is opening up new possibilities across every part of society, but perhaps nowhere is the potential more meaningful than in human health. The ability to combine AI, biological data and scientific insight could transform how we understand disease, discover medicines and ultimately improve and extend people’s lives,” Conrad stated. “Basecamp Research is building an important technology platform at the center of that opportunity.”</p>
<p>The post <a href="https://www.genengnews.com/topics/artificial-intelligence/anthropic-nvidia-backed-basecamp-research-raise-140m-series-c-financing-toward-advancing-ai-designed-drugs/">Basecamp Research Raise $140M Series C Financing Toward Advancing AI-Designed Drugs</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Genialis and Inventia Life Science Collaborate to Link Patient Biology with 3D Pancreatic Cancer Models</title>
<link>https://edusehat.com/en/genialis-and-inventia-life-science-collaborate-to-link-patient-biology-with-3d-pancreatic-cancer-models</link>
<guid>https://edusehat.com/en/genialis-and-inventia-life-science-collaborate-to-link-patient-biology-with-3d-pancreatic-cancer-models</guid>
<description><![CDATA[ The collaboration pairs the Genialis Supermodel with Inventia Life Science’s RASTRUM 3D cell model platform to test therapeutic hypotheses in models that mirror the tumor biology of specific patient groups.
The post Genialis and Inventia Life Science Collaborate to Link Patient Biology with 3D Pancreatic Cancer Models appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-1467893187.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 24 Sep 2026 09:05:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Genialis, and, Inventia, Life, Science, Collaborate, Link, Patient, Biology, with, Pancreatic, Cancer, Models</media:keywords>
<content:encoded><![CDATA[<p>Genialis and Inventia Life Sciences agreed to work together to improve how new treatments for pancreatic cancer are tested and matched to the patients most likely to benefit. The companies will combine Genialis’ AI-powered patient insights with Inventia’s RASTRUM 3D cell model platform to build human-relevant models of pancreatic ductal adenocarcinoma (PDAC) that correspond to the tumor biology of identifiable patient populations.</p>
<p>Initial results from this collaboration will be presented this week at the <a href="https://pancan.org/research/community-for-progress/pancan-scientific-summit-2026/" target="_blank" rel="noopener">Pancreatic Cancer Action Network (PanCAN)’s 2026 Scientific Summit</a> in San Diego.</p>
<p>Recent advances in targeted therapies for pancreatic cancer have brought renewed attention to PDAC and underscored the need for better strategies to identify which patients are most likely to benefit from new treatments. <a href="https://inventialifescience.com/platform/rastrum" target="_blank" rel="noopener">Inventia’s RASTRUM</a> platform prints reproducible 3D pancreatic cancer models in which tumor and stromal components can be controlled and perturbed independently.</p>
<p>Genialis characterizes those models with the <a href="https://www.genialis.com/supermodel/">Genialis<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> Supermodel</a>—a large molecular model trained on a proprietary harmonized and curated transcriptomics dataset— and connects them to molecular states observed in the clinic. The collaboration also draws on data generated through Genialis’ long standing collaboration with PanCAN.</p>
<p>In the study being presented on Friday, September 25, Genialis identified PDAC patients with poor prognosis based on the composition and activity of the tumor microenvironment across 644 pancreatic cancer patient tumors taken from the <a href="https://pubmed.ncbi.nlm.nih.gov/38166233/">PanCAN SPARK</a> “<a href="https://pancan.org/facing-pancreatic-cancer/patient-services/know-your-tumor/">Know Your Tumor</a>” cohort.</p>
<p><figure aria-describedby="caption-attachment-338142" class="wp-caption aligncenter"><img fetchpriority="high" decoding="async" class=" td-center wp-image-338142 " src="https://www.genengnews.com/wp-content/uploads/2026/09/2026-Genialis-software-schematic-1024x418.jpg" alt="Genialis Supermodel Workflow [Genialis]" width="799" height="326" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/2026-Genialis-software-schematic-1024x418.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/09/2026-Genialis-software-schematic-300x122.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/2026-Genialis-software-schematic-768x313.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/09/2026-Genialis-software-schematic-1536x627.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2026/09/2026-Genialis-software-schematic-2048x836.jpg 2048w, https://www.genengnews.com/wp-content/uploads/2026/09/2026-Genialis-software-schematic-1029x420.jpg 1029w, https://www.genengnews.com/wp-content/uploads/2026/09/2026-Genialis-software-schematic-696x284.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/09/2026-Genialis-software-schematic-1392x568.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2026/09/2026-Genialis-software-schematic-1068x436.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/09/2026-Genialis-software-schematic-1920x783.jpg 1920w" sizes="(max-width: 799px) 100vw, 799px"><figcaption class="wp-caption-text">Genialis Supermodel Workflow [Genialis]</figcaption></figure>Genialis then mapped those patient profiles to tumor-fibroblast co-culture models generated on RASTRUM, allowing researchers to investigate the biology associated with poor outcomes and identify potential therapeutic strategies. This gives drug developers a way to test new approaches in models that reflect the biology of the patients they are intended to treat.</p>
<p>“This collaboration closes an important gap in drug discovery by connecting what we learn from patients with what we can test in the lab,” said Cameron Ferris, PhD, CEO and co-founder of Inventia Life Science. “Genialis can identify clinically meaningful biological states in real tumors, while RASTRUM allows us to model and perturb those states at scale. Together, that creates a powerful way to generate and test therapeutic hypotheses that are grounded in the biology of the patients we ultimately want to treat.”</p>
<p>The design closes a loop that translational programs usually leave open: hypotheses are derived from patient data, tested experimentally in human-relevant systems, and returned to the clinical population to determine where they are most likely to apply, noted Ferris.</p>
<p>“Our pharma partners need to make critical decisions about which patients to enroll and which combinations to pursue, yet historically, whether a preclinical result would translate to patients often wasn’t clear until Phase II,” said Rafael Rosenbarten PhD, CEO and co-founder of Genialis. “Inventia gives us a model where we can test those hypotheses experimentally, while the Supermodel helps identify the patients most likely to benefit.”</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/genialis-and-inventia-life-science-collaborate-to-link-patient-biology-with-3d-pancreatic-cancer-models/">Genialis and Inventia Life Science Collaborate to Link Patient Biology with 3D Pancreatic Cancer Models</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Tautomer&#45;Predictor AI Tool Identifies Stable Molecules for Drug Discovery</title>
<link>https://edusehat.com/en/tautomer-predictor-ai-tool-identifies-stable-molecules-for-drug-discovery</link>
<guid>https://edusehat.com/en/tautomer-predictor-ai-tool-identifies-stable-molecules-for-drug-discovery</guid>
<description><![CDATA[ Researchers trained an AI model to learn chemical patterns associated with stability in drug-like molecules and accurately predict where their hydrogen atoms should be positioned.
The post Tautomer-Predictor AI Tool Identifies Stable Molecules for Drug Discovery appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/04/GettyImages-1464561575.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 24 Sep 2026 09:05:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Tautomer-Predictor, Tool, Identifies, Stable, Molecules, for, Drug, Discovery</media:keywords>
<content:encoded><![CDATA[<p>New York University (NYU) researchers have trained an AI model to learn chemical patterns associated with stability in drug-like molecules and accurately predict where their hydrogen atoms should be positioned.</p>
<p>The team’s research, headed by Yingkai Zhang, PhD, professor of chemistry at NYU, addresses a longstanding challenge in molecular design and drug discovery, which is how to rapidly and reliably determine the stable form of molecules that share a molecular formula but readily convert into different forms. The researchers have released their method as an open-source tool, <a href="https://github.com/xiaolinpan/Tautomer-Predictor" target="_blank" rel="noopener">Tautomer-Predictor</a>, which can rapidly analyze very large molecular libraries.  Zhang is senior author of the scientists’ published paper in <em>Chemical Science</em> (“<a href="http://dx.doi.org/10.1039/d6sc03714c" target="_blank" rel="noopener">Deep learning of tautomer stability from crystallographic proton positions</a>.”)</p>
<p>Many drug-like molecules can exist in two or more closely related forms called tautomers. A hydrogen atom moves from one site to another, accompanied by a change in the bonding pattern. “Although this may seem like a small change, different tautomers of the same molecule can alter how a molecule interacts with a protein target,” explained Zhang. “Correct tautomer assignment is consequently important for molecular modeling and structure-based drug discovery.”</p>
<p>And as the team noted in their paper, “… incorrect tautomer assignment can compromise molecular docking, free-energy calculations, virtual screening, and other tasks in structure-based drug design.”</p>
<p>However, determining the correct tautomer remains a challenge—akin to finding a needle in a moving haystack. The scientists further commented, “Tautomerism plays a central role in molecular recognition, physicochemical properties, and chemical reactivity, yet rapid identification of stable tautomeric states remains a persistent challenge in molecular design and structure-based drug discovery.”</p>
<p>This challenge exists, in part, because of a scarcity of experimental data that characterizes tautomer structures. For instance, in the Protein Data Bank, a worldwide repository of the 3D structures of large biological molecules that is widely used in biological research, the location of hydrogen atoms that distinguish one tautomer from another are typically not available. The Protein Data Bank contains molecular structures that are largely determined using experimental methods such as X-ray crystallography, but the resolution of macromolecular X-ray structures is generally insufficient to locate the position of hydrogen atoms reliably. As a result, hydrogen positions—and therefore the tautomeric state of a molecule—often have to be inferred by scientists.</p>
<p>Other methods also fall short. Using quantum mechanics to assess tautomers is often too computationally demanding and expensive for screening full libraries, while machine learning is limited by the relatively small datasets of experimentally characterized tautomers in solution, which tend to contain only a few hundred molecules. “A variety of computational methods have been developed to address tautomer prediction, but each faces important trade-offs between accuracy, throughput, and generalizability,” Zhang <em>et al.</em> stated.</p>
<p>In contrast, many high-resolution small-molecule X-ray crystal structures in the Cambridge Structural Database (CSD)—the largest repository of experimental crystal structures in the world—show the position of hydrogen atoms. “Because many CSD structures contain explicitly assigned hydrogen atoms, they offer direct experimental information about tautomeric states in the crystalline environment,” the authors pointed out. “We realized that experimentally resolved hydrogen positions in high-resolution small-molecule crystal structures provide a largely untapped source of experimental information about tautomer stability,” added Zhang, who is also part of the NYU Simons Center for Computational Physical Chemistry.</p>
<p><figure aria-describedby="caption-attachment-338368" class="wp-caption alignright"><img decoding="async" class="size-medium wp-image-338368" src="https://www.genengnews.com/wp-content/uploads/2026/09/Low-Res_2bpm_tautomer-1-300x135.jpg" alt="Two panels depict the same molecule, with the original tautomer on the right and the tautomer predicted by the model on the left. The green region shows where the hydrogen position and bonding pattern change, while the dashed lines show hydrogen-bonding interactions with nearby protein residues. [Image courtesy of study author Xiaolin Pan]" width="300" height="135" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/Low-Res_2bpm_tautomer-1-300x135.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/Low-Res_2bpm_tautomer-1-696x314.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/09/Low-Res_2bpm_tautomer-1.jpg 700w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Two panels depict the same molecule, with the original tautomer on the right and the tautomer predicted by the model on the left. The green region shows where the hydrogen position and bonding pattern change, while the dashed lines show hydrogen-bonding interactions with nearby protein residues. [Xiaolin Pan, PhD]</figcaption></figure>Study first author Xiaolin Pan, PhD, a postdoc in Zhang’s lab, systematically mined the Cambridge Structural Database to construct a dataset containing more than 1.1 million tautomeric states, which is orders of magnitude larger than existing experimental datasets. Pan then trained a graph neural network—a type of artificial intelligence that uses deep learning to find patterns between connected data points—to predict stable tautomers directly from 2D molecular forms, without requiring 3D structures or quantum-mechanical calculations. “The model showed strong performance across crystal-structure, aqueous-solution, and drug-like benchmarks, indicating that transferable and chemically meaningful rules of tautomer stability can be learned from crystallographic proton placements,” the team commented.</p>
<p>When the researchers applied their model to 5,075 PDBbind ligands—biomolecular complexes found in the Protein Data Bank—with multiple possible tautomeric states, they identified 126 cases—approximately 2.5%—in which the assigned ligand tautomer was likely incorrect. In each of these cases, the model reassigned an alternative stable tautomer, which showed improved hydrogen bonding patterns.</p>
<p>“Reassigning these tautomers generally produced more chemically reasonable interactions,” noted Zhang. “This does not mean that the experimentally determined protein structures themselves are incorrect; rather, our results suggest that the previously assigned chemical representation may warrant revision.”</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>For instance, in one of the molecules in the Protein Data Bank, the AI model predicted a tautomer with a differently positioned hydrogen atom than in the original assignment. As a result of this change, the ligand forms additional hydrogen bonding with nearby protein residues—illustrating how a seemingly small change can alter the molecule’s interactions with its protein environment.</p>
<p>Using this model to more accurately identify a tautomer for drug discovery could not only help determine how it fits into a protein binding site but could also improve subsequent computer simulations. When assessing drug candidates, molecular dynamics simulations follow a molecule and its protein target to see how they interact and move over time.</p>
<p>“These calculations require the molecule’s hydrogen positions and chemical bonding to be correctly assigned, and using the wrong tautomer could alter the predicted interactions and dynamics,” said Zhang.</p>
<p>The team also showed that in one test, their open-source tool <a href="https://github.com/xiaolinpan/Tautomer-Predictor" target="_blank" rel="noopener">Tautomer-Predictor</a>, processed the 4.6 million compound Enamine collection in 3.2 hours on a single GPU-enabled node. “Together, these results establish crystallographic proton placement as a rich and underexploited source of chemical knowledge for learning tautomer stability, and provide a practical route to large-scale tautomer assignment for molecular discovery,” the authors concluded.</p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/tautomer-predictor-ai-tool-identifies-stable-molecules-for-drug-discovery/">Tautomer-Predictor AI Tool Identifies Stable Molecules for Drug Discovery</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>New Liposome Design Could Provide Effective Slow&#45;Release Drug Delivery System</title>
<link>https://edusehat.com/en/new-liposome-design-could-provide-effective-slow-release-drug-delivery-system</link>
<guid>https://edusehat.com/en/new-liposome-design-could-provide-effective-slow-release-drug-delivery-system</guid>
<description><![CDATA[ A slow-release liposome system delivered local anesthesia for weeks in rats, potentially enabling longer-lasting nerve blocks and new approaches to pain management.
The post New Liposome Design Could Provide Effective Slow-Release Drug Delivery System appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2293154130.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 24 Sep 2026 09:05:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>New, Liposome, Design, Could, Provide, Effective, Slow-Release, Drug, Delivery, System</media:keywords>
<content:encoded><![CDATA[<p>Drug delivery systems that can carry a large amount of a drug and release it slowly over time are useful for keeping drug levels effective either at a specific site or throughout the body. Extending how long a drug works can reduce how often it needs to be administered, which is especially helpful for injectable treatments that need to be given repeatedly. However, maintaining drug release over very long periods of time is difficult. Indeed, most local anesthetics used in medicine only last eight to 12 hours or a day, at the most.</p>
<p>Now, researchers have formulated a more effective slow-release injectable drug delivery system that achieved pain-numbing anesthetic effects lasting two to three weeks in rats compared to a commercial formulation lasting about four to eight hours. Because nerve blocks in humans tend to work longer than in rats, this advancement could blow the effective time of currently used anesthetics out of the water and have implications for other types of pain.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>This work is published in <em>Nature Biomedical Engineering </em>in the paper, “<a href="https://www.nature.com/articles/s41551-026-01793-6" target="_blank" rel="noopener">Ultra-slow release of hydrophilic drugs via multilamellar–multivesicular liposomes formed by unsaturated phospholipids.</a>“</p>
<p>Liposome composition determines how fast drugs leak out, with faster leaking leading to a more potent drug effect over a shorter time period with potentially more toxicity. Up until now, researchers believed that molecules leaked fastest from liposomes made of more “fluid” lipids. However, Yuan Wang, PhD, a research engineer in the laboratory of Daniel Kohane, MD, PhD, challenged this theory by showing that liposomes made of more fluid lipids release drugs that mix well with or dissolve in water, known as “hydrophilic” drugs, extremely slowly. One way to make lipids more fluid is by adding many double chemical bonds to their tails so that the lipids can’t pack together as tightly.</p>
<p>The team demonstrated that the liposomes with many double bonds had a structure with multiple compartments, while those without had a simple spherical structure. As a result, in liposomes with many double bonds, hydrophilic drugs had more lipid barriers to cross leading to slower drug release.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>“The more fluid membranes in liposomes with many double bonds may be easier to cross, but the greater number of barriers slow down the drug’s release,” says Wang. “The more fluid liposomes with more double bonds may form concentric spheres that are like onions with many layers or could even potentially be even spheres within spheres.”</p>
<p>Knowing a hydrophilic drug will leak slower from a more fluid liposome, the researchers tested out a proof-of-principle experiment. The team filled their more fluid liposomes with potent tetrodotoxin—a powerful neurotoxin found in pufferfish and blue-ringed octopuses that serves as a powerful numbing agent. When injected near a nerve in the leg of rats, they showed very prolonged local anesthesia, but no toxicity at the injection site or throughout the body. This means the drug released slowly enough to be cleared by the body, but still at high enough levels to be an effective anesthetic. Tetrodotoxin isn’t commercially used in patients yet but could one day be developed as a therapeutic.</p>
<p>“This extended-release combination could be used for longer term perioperative pain instead of opioids, and we are starting to consider using these potentially for chronic pain, as well,” says Kohane, senior associate in pediatric critical care at Boston Children’s and director of Laboratory for Biomaterials and Drug Delivery. “These liposomes can also provide slow release of a wide range of hydrophilic molecules.”</p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/new-liposome-design-could-provide-effective-slow-release-drug-delivery-system/">New Liposome Design Could Provide Effective Slow-Release Drug Delivery System</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Multi&#45;Controller System: Major Boost to Continuous CHO Perfusion</title>
<link>https://edusehat.com/en/multi-controller-system-major-boost-to-continuous-cho-perfusion</link>
<guid>https://edusehat.com/en/multi-controller-system-major-boost-to-continuous-cho-perfusion</guid>
<description><![CDATA[ A novel multi-strategy nonlinear predictive control system maximizes CHO cell perfusion productivity in a continuous bioprocessing environment by optimizing feed, bleed, and harvest flows, and letting biomanufacturers switch seamlessly among controller priorities.
The post Multi-Controller System: Major Boost to Continuous CHO Perfusion appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/07/GettyImages-1092323774.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 24 Sep 2026 01:50:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Multi-Controller, System:, Major, Boost, Continuous, CHO, Perfusion</media:keywords>
<content:encoded><![CDATA[<p>A nonlinear model predictive control system developed by researchers at Sartorius is making fully-continuous biomanufacturing for Chinese hamster ovary (CHO) cells more productive. By simultaneously controlling feed, bleed, and harvest flows, they increased production by 68% and maintained viable cell density at or above 95%.</p>
<p>This multi-strategy nonlinear model predictive control (NMPC) system allows biomanufacturers to switch seamlessly between such objectives as stable operation and economic optimization, according to Mahshad Valipour, PhD, senior research scientist, and Christopher McCready, head of product innovation, both of Sartorius, writing in a recent <a href="https://link.springer.com/article/10.1007/s12257-026-00318-x" target="_blank" rel="noopener">paper</a>. The control system also accounts for unknown states—many of which are rarely, if ever, measured—through a moving horizontal estimate that considers the process and its constraints.</p>
<p>After the process is stabilized, an economic NMPC (ENMPC) mode further maximizes performance objectives. It does this, Valipour and McCready explain, “by determining optimal operating conditions in real-time… while explicitly enforcing dynamic process feasibility and biological constraints throughout the perfusion run. [It] improves numerical conditioning and avoids instability issues [commonly encountered in standard ENMPC formulations,] eliminating the need for <em>ad hoc</em> damping/terminal functions or frequent weight retuning.”</p>
<p>Combining a multifunction NMPC and an economic mode within one framework enables “seamless transition between operating modes without controller switching or reformulation,” they add. The primary benefit of this approach may be that biomanufacturers can determine maximum feasible operating conditions safely in real time, while accounting for the accumulation of biomaterials that inhibit cell productivity.</p>
<p>The most important step in making this approach work, they indicate, is “capturing the impact of accumulated inhibitory biomaterials on growth and death dynamics.” Conventional models, they point out, do not account for trade-offs among perfusion rate, inhibitor removal, and cell growth. Therefore, conventional models cannot be used to maximize viable cell density.</p>
<p>Experiments using digital twins showed the NMPC transitioned smoothly among process controller strategies while maintaining a healthy cell culture and increasing upstream productivity. Evaluations under realistic real-world conditions showed online and inline measurements of viable cell density and viability matched predictions, as did dead cell density.</p>
<p>Notably, rather than merely maintaining a stable cell culture and viability rate for a prolonged period, this multi-strategy lets biomanufacturers change objectives as the process is running. Even when tested against what they call “a significant plant-model mismatch,” operations, they said, remained stable.</p>
<p>For bioprocessors, this study suggests that advanced automation strategies can resolve the hurdles associated with continuous CHO perfusion, making it more predictable and more efficient.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/multi-controller-system-major-boost-to-continuous-cho-perfusion/">Multi-Controller System: Major Boost to Continuous CHO Perfusion</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Media Cleaning Could Help Biopharma Cut Costs and Fully Embrace Perfusion</title>
<link>https://edusehat.com/en/media-cleaning-could-help-biopharma-cut-costs-and-fully-embrace-perfusion</link>
<guid>https://edusehat.com/en/media-cleaning-could-help-biopharma-cut-costs-and-fully-embrace-perfusion</guid>
<description><![CDATA[ A novel media cleaning process could help drug companies significantly reduce production costs, according to MIT researchers, who say the approach could improve the economic case for perfusion bioreactors and continuous manufacturing processes.
The post Media Cleaning Could Help Biopharma Cut Costs and Fully Embrace Perfusion appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2023/08/GettyImages-542712324.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 24 Sep 2026 01:50:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Media, Cleaning, Could, Help, Biopharma, Cut, Costs, and, Fully, Embrace, Perfusion</media:keywords>
<content:encoded><![CDATA[<p>A novel “electrokinetic cleaning” process could let drug manufacturers recycle a greater proportion of culture media, according to researchers, who predict the approach could make perfusion-based processes more economically viable.</p>
<p>Perfusion bioreactors have been a mainstay of the development lab for decades. However, few firms have embraced them at commercial scale, in part, due to concerns about media costs, says Eric Wynne, PhD, a postdoctoral associate at MIT’s electronics research lab.</p>
<p>“While many factors have constrained adoption of perfusion bioreactors, media cost has often been cited as the main issue,” Wynne tells <em>GEN</em>, adding, “We believe recycling has the potential to lower costs as well as the overall volume of media involved in the manufacturing process.”</p>
<p>The idea, detailed in a new study, is to use a process called electrokinetic waste separation to remove cellular debris, reagents, and other potential contaminants from culture media after cultivation.</p>
<p>The approach uses an electric field to split media into a harvest stream that contains uncharged molecules—primarily the nutrients cells need to grow—and a waste stream in which there is a higher concentration of charged molecules, like ammonia and lactate.</p>
<p>“Electrokinetic waste separation provides a way of cleaning media thoroughly before recycling it. This process is what differentiates our work from previous groups that recycled media directly.</p>
<p>“In this work we improve the yield of this process by taking the ‘waste’ stream and processing it again to harvest additional media,” Wynne says.</p>
<p>The aim is to allow manufacturers to reuse a greater proportion of media—in studies, Wynne and colleagues have recovered 87.5% of spent volume—in subsequent culturing processes.</p>
<p>“The advantage is that, by separating waste, you can replace greater quantities of fresh media with recycled media without significantly impacting cell growth or productivity.</p>
<p>“Companies that use perfusion technologies already recycle media. However, typically the volume of reused media is less than 50%. Also, without a cleaning step, the reused media can negatively impact cellular growth and productivity.</p>
<p>“Electrokinetic waste separation has the potential to both increase the amount recycled and reduce any negative impact on productivity,” he adds.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>The approach is still at a pilot stage, but the cost-saving potential is significant, particularly in combination with hybrid and fully continuous-mode manufacturing processes, Wynne says.</p>
<p>“More development is necessary before the technology is ready for adoption, particularly in the area of characterizing how media recycling does or does not affect product quality attributes.</p>
<p>“Adoption would likely require more testing at small scale and pilot scale perfusion bioreactors. Additionally, recycling and waste separation would likely be best suited for a fully continuous mAb production process with continuous chromatography downstream,” he says.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/media-cleaning-could-help-biopharma-cut-costs-and-fully-embrace-perfusion/">Media Cleaning Could Help Biopharma Cut Costs and Fully Embrace Perfusion</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>CGT Collaboration Moves from Aspirations to Infrastructure</title>
<link>https://edusehat.com/en/cgt-collaboration-moves-from-aspirations-to-infrastructure</link>
<guid>https://edusehat.com/en/cgt-collaboration-moves-from-aspirations-to-infrastructure</guid>
<description><![CDATA[ Act for Hope founder Alexander Seyf says cell and gene therapy’s next challenge is not proving the science, but building a connected ecosystem that can turn breakthrough treatments into reliable, scalable, and equitable patient access.
The post CGT Collaboration Moves from Aspirations to Infrastructure appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/Mike-Act-for-Hope_GBPN_IMAGE_24SEPT26.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 24 Sep 2026 01:50:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>CGT, Collaboration, Moves, from, Aspirations, Infrastructure</media:keywords>
<content:encoded><![CDATA[<p>Cell and gene therapy (CGT) has spent much of its young history proving what was once considered improbable: that advanced therapies can tackle diseases previously viewed as untreatable and, in some cases, offer the prospect of a cure. Now, according to Alexander Seyf, CEO and founder of Act for Hope, the sector faces another test—whether the ecosystem surrounding those therapies can work together well enough to deliver them at scale.</p>
<p>“Scientific possibility alone does not create patient access,” Seyf says.</p>
<p>That distinction sits at the heart of Act for Hope, a not-for-profit, member-led initiative created to accelerate growth across the CGT industry through collaboration. Seyf argues that advanced therapies demand a fundamentally different model from conventional pharmaceuticals because their delivery depends on a tightly connected chain of stakeholders.</p>
<p>From patient identification and starting-material collection through manufacturing, testing, release, logistics, treatment, and long-term follow-up, CGT can involve hospitals, manufacturers, contract development and manufacturing organizations, technology suppliers, regulators, payers, academics, and patients.</p>
<p>“No single organization controls that entire journey,” Seyf says. “That makes collaboration not simply desirable, but foundational.”</p>
<p>While the industry frequently discusses expanding manufacturing capacity, Seyf believes another capability must scale alongside it: collaboration. Shared standards, interoperable digital systems, responsible data exchange, and greater alignment between organizations could become increasingly important as more therapies progress toward commercialization and wider patient populations.</p>
<p>“A therapy may be developed by one organization, but access can only be delivered by an ecosystem,” he adds. “Collaboration has to become infrastructure rather than aspiration.”</p>
<p></p><h4><strong>Fragmentation carries a hidden cost</strong></h4>

<p>One obstacle is that CGT’s rapid development has also produced a highly fragmented operating environment. Companies and institutions have built their own processes, terminology, data structures, and technology platforms—often for sound individual reasons. Collectively, however, those differences can create duplicated work, manual handoffs, disconnected systems, and repeated attempts to solve similar problems.</p>
<p>At relatively low treatment volumes, those inefficiencies might be manageable. At global scale, Seyf says, they risk becoming barriers to patient access by increasing cost, complexity, and time.</p>
<p>The challenge is not to standardize the underlying science, he stresses. Rather, the opportunity lies in harmonizing interfaces and processes where differentiation provides little competitive value.</p>
<p>“The industry has historically been exceptionally good at protecting intellectual property and competing on innovation,” Seyf says. “The next phase requires us to become equally good at identifying the areas where we should not compete.”</p>
<p>Act for Hope aims to provide a neutral setting for that work. Its focus includes standardization, digitization, implementation tools, and responsible, permissioned benchmarking, bringing organizations together to address common bottlenecks without compromising proprietary technologies or intellectual property.</p>
<p>“Collaboration should not mean giving away competitive advantage,” Seyf adds. “It should mean collectively removing the inefficiencies that provide no competitive advantage to anyone.”</p>
<p></p><h4><strong>Connecting innovation with patients</strong></h4>

<p>Two planned projects illustrate that approach. Act for Hope is developing a clinical-trial portal intended to make advanced therapy trials easier to discover and navigate. Despite rapid global innovation, Seyf says, connecting potentially eligible patients with trials remains unnecessarily complicated. A second project, the initiatives hub, is a patient-access portal intended to improve connections among stakeholders involved in moving therapies from scientific development to treatment. Both projects reflect a broader premise: increasing manufacturing output alone will not solve CGT’s access challenge.</p>
<p>“The first chapter of CGT was about proving that the science could work,” Seyf says. “The next chapter must be about proving that the ecosystem can work at scale.”</p>
<p>Technology, automation, and artificial intelligence are likely to play major roles in that transition, but Seyf cautions that technology cannot resolve organizational fragmentation by itself.</p>
<p>“Technology can connect systems. Collaboration connects people, organizations, and purpose,” he adds. “We need both.”</p>
<p>For Seyf, the ultimate benchmark is therefore not the number of therapies approved, facilities constructed, or technologies deployed. It is whether the expanding CGT ecosystem can translate those advances into treatment for the patients who need them. That, he argues, will make collaboration not a supporting feature of CGT’s next era, but one of its defining pieces of infrastructure.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/cgt-collaboration-moves-from-aspirations-to-infrastructure/">CGT Collaboration Moves from Aspirations to Infrastructure</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Digital Shadows to Aid Complexity in Handling Process Intensification</title>
<link>https://edusehat.com/en/digital-shadows-to-aid-complexity-in-handling-process-intensification</link>
<guid>https://edusehat.com/en/digital-shadows-to-aid-complexity-in-handling-process-intensification</guid>
<description><![CDATA[ AI-augmented digital twins that merely report, rather than control processes, could help biotechnology companies untangle the complexities of analyzing big multidimensional nonlinear datasets to help simplify and improve process intensification.
The post Digital Shadows to Aid Complexity in Handling Process Intensification appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2227991145-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 24 Sep 2026 01:50:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Digital, Shadows, Aid, Complexity, Handling, Process, Intensification</media:keywords>
<content:encoded><![CDATA[<p><em>In silico</em> AI-augmented models that report on manufacturing processes rather than controlling them offer a convenient way to help companies engage in process intensification without causing regulatory issues. That’s the view of biotechnology expert William Whitford, PhD.</p>
<p>According to Whitford, who is the founder of Oamaru BioSystems, digital shadows are like digital twins in being real-time digital copies of a process or piece of equipment. Unlike them, however, they aren’t designed to actively control a process. Instead, they simply report back on what’s going on.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>This makes them easier to set up than digital twins, he says. “They’re not as comprehensive [as a digital twin], but that might be all you need if you don’t want active control for regulatory reasons.”</p>
<p>Nonetheless, he believes digital shadows are valuable for managing the large, complex datasets being generated by today’s bioprocess analytics. “Machine learning can handle the complexity, the amount, the nonlinearity and high dimensionality of the data we’re getting,” he says.</p>
<p>Such data can include time series, imaging and analytical data, as well as historical data collected during process development.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>“For example, you might take the outgassing of a [bio]reactor, look at carbon dioxide and oxygen levels and, from there, infer the metabolic activity,” he says. “And [if you add the historical data] you can infer the number of viable cells.”</p>
<p>By contrast, he says, more simple analytics, such as an equation or simple algorithm, can’t digest the variety of data coming in.</p>
<p>The digital shadow, he says, can make inferences or future predictions by simultaneously integrating process measurements, analytical results, biological observations, historical manufacturing data, and contextual production information. This, in turn, can help manufacturers get more product per square foot of plant, per unit of bioreactor volume or time, he says, and thus aid process intensification.</p>
<p>“Once you’ve defined that goal for your process intensification, you want to know what tools are out there and I want people to know about the tools we have,” he says.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/digital-shadows-to-aid-complexity-in-handling-process-intensification/">Digital Shadows to Aid Complexity in Handling Process Intensification</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Important Considerations to Help You Pass the NCLEX&#45;RN®</title>
<link>https://edusehat.com/en/important-considerations-to-help-you-pass-the-nclex-rn</link>
<guid>https://edusehat.com/en/important-considerations-to-help-you-pass-the-nclex-rn</guid>
<description><![CDATA[ The post Important Considerations to Help You Pass the NCLEX-RN® appeared first on BoardVitals Blog. ]]></description>
<enclosure url="https://blog.boardvitals.com/wp-content/uploads/2018/06/NCLEXRN_85221892-1024x683.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 24 Sep 2026 01:20:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Important, Considerations, Help, You, Pass, the, NCLEX-RN®</media:keywords>
<content:encoded><![CDATA[<p class="wp-block-paragraph"><span>If you’re wrapping up nursing school and facing the NCLEX-RN</span>®<span>, you might be intimidated by the career-making (or breaking) exam. The NCLEX-RN® exam tests more than your knowledge of content – it tests your ability to use that knowledge, and apply critical thinking skills when presented with a clinical scenario. This means your questions will require more than regurgitating a memorized list of facts, which is what you’ve seen and been tested on throughout nursing school. </span></p>



<h1 class="wp-block-heading">Breaking Down the Exam</h1>



<p class="wp-block-paragraph"><span>The</span> <span>NCLEX-RN® ranges from 85-150 questions depending on how consistently you are able to demonstrate knowledge of content and, more importantly, your ability to integrate your knowledge of content with hypothetical “real-life” situations. The <a href="https://www.boardvitals.com/blog/boardvitals-nclex-cat-score/">CAT (Computer Adaptive Testing) Technology</a> serves questions of varying difficulty, but this may not mean what you think. “High level of difficulty” does not refer to questions with more obscure content, but to the extent to which critical thinking and analysis are required.</span></p>



<h2 class="wp-block-heading">Limited – but Enough – Information</h2>



<p class="wp-block-paragraph"><span>Nurses understand that decisions in healthcare must be made in a timely manner, based on the best information available. Similarly, questions on the NCLEX-RN® exam have a finite amount of information – but the critical information needed to make a decision is always provided. When answering questions on the NCLEX-RN® exam, you may sometimes wish for “more information.” Don’t waste valuable time – everything you need to provide an answer is in the stem and your task is to distill that information, recognize themes and priorities, and avoid pitfalls that could cause harm to the hypothetical client. </span></p>



<h1 class="wp-block-heading">Online Practice Questions</h1>



<p class="wp-block-paragraph"><span>The <a href="https://www.boardvitals.com/nclex-rn-review-questions" rel="noopener">BoardVitals NCLEX-RN® Practice Question Bank</a> offers more than 3,700 practice questions with the same CAT platform found on the exam. These questions are divided into categories so you can assess your strength and weaknesses based on topics. The exam is broken down, as follows, according to the 2026 <a href="https://www.nclex.com/files/2026_RN_Test%20Plan_English-F.pdf">NCLEX-RN® Test Plan:</a></span></p>



<ul class="wp-block-list">
<li><strong>Safe and Effective Care Environment</strong>
<ul class="wp-block-list">
<li>Management of Care 15-21%</li>



<li>Safety and Infection Control 10-16%</li>
</ul>
</li>



<li><strong>Health Promotion and Maintenance</strong> 6-12%</li>



<li><strong>Psychosocial Integrity</strong> 6-12%</li>



<li><strong>Physiological Integrity</strong>
<ul class="wp-block-list">
<li>Basic Care and Comfort 6-12%</li>



<li>Pharmacological and Parenteral Therapies 13-19%</li>



<li>Reduction of Risk Potential 9-15%</li>



<li>Physiological Adaptation 11-17%</li>
</ul>
</li>
</ul>



<p class="wp-block-paragraph"><span>We recommend beginning your NCLEX-RN® prep 3-6 months before the test. Many people find it helpful to begin earlier, by using the question bank to supplement your studies and to help you focus on key points. Practicing test questions will prompt you to integrate the nursing process and critical thinking skills with the content you are mastering.  </span></p>



<h2 class="wp-block-heading">Quizzing Yourself</h2>



<p class="wp-block-paragraph"><span>To become accustomed to the test, we recommend practicing 85 questions each day you can, keeping your time to a reasonable 1-2 minutes. Begin your review of your test by determining your areas of weakness. Study those explanations carefully and refer to other sources if necessary – the referenced books are standard nursing texts, in most cases – but there is a wealth of information online in a variety of formats – video explainers, outlines, concise nursing journal articles, and power point presentations. </span></p>



<h2 class="wp-block-heading">Other Resources</h2>



<p class="wp-block-paragraph"><span>When choosing an extra reference for study, be sure it is reputable, preferably reviewed by nurses and academics. There is a lot of incorrect or sloppy information on the internet and it’s worse than a waste of your time. If you decide to use a review book, be sure it is highly rated by your professors or licensed RNs who have recently taken the NCLEX-RN®. If something you read seems unclear or wrong, check the reference provided and compare the information to your nursing texts. There are some topics that are debated, but they most likely won’t be on your test.</span></p>



<p class="wp-block-paragraph"><span>Here’s a list of (free) reference sources – for the NCLEX®. Use them as needed to find a quick and reliable explanation, diagram, or flow-chart. As you continue in your career, you will find them helpful to add to your knowledge and to quickly find answers to questions that arise in the course of your work. Since you probably already have your favorite nursing sources, these are limited to non-nursing resources for learning and reference:</span></p>



<ul class="wp-block-list">
<li><span><a href="https://emedicine.medscape.com/" target="_blank" rel="noopener noreferrer"><strong>eMedicine</strong></a> – In addition to detailed and clearly written articles about every possible medical condition or procedure, eMedicine has a number of articles on nursing practice. They also have a free drug reference with a lot of good, clearly presented information.</span></li>



<li><strong><a href="https://www.samhsa.gov/" target="_blank" rel="noopener noreferrer">SAMHSA</a></strong><span> – Substance Abuse and Mental Health Services Administration</span></li>



<li><span><a href="https://lifeinthefastlane.com/" target="_blank" rel="noopener noreferrer"><strong>Life in the Fast Lane</strong></a> – This is a great site for learning ECGs, but also for critical care and emergency practice. It’s maintained by an ER doctor in England and he, with his contributors, provide back to basic explanations for many things you may wonder about.</span></li>



<li><span><strong><a href="http://slideshare.com/" target="_blank" rel="noopener noreferrer">Slideshare</a></strong> – Slide presentations by healthcare professionals (among others), including physicians, nurses, respiratory therapists, etc. Just do a search for your topic. Slide presentations are usually concise and also provide visual cues for learning.</span></li>



<li><span><a href="https://www.aad.org/" target="_blank" rel="noopener noreferrer"><strong>American Academy of Dermatology</strong></a> (AAD) – The AAD has an atlas for skin lesions you may wonder about.</span></li>



<li><span><a href="https://www.cdc.gov/infectioncontrol/guidelines/isolation/index.html" target="_blank" rel="noopener noreferrer"><strong>Centers for Disease Control</strong></a> – The CDC has all the information you need about Standard and Isolation Precautions; important infectious disease; the site has the <a href="https://www.cdc.gov/vaccines/pubs/pinkbook/index.html" target="_blank" rel="noopener noreferrer">Pink Book</a>, which contains all the information you will ever need about vaccines, including administration, storage, contraindications, etc.; and the <a href="https://www.cdc.gov/features/yellowbook/index.html" target="_blank" rel="noopener noreferrer">Yellow Book</a>, which tells you all you need to know about travel medicine, including rare but serious diseases like Ebola.</span></li>



<li><span><strong><a href="https://www.uspreventiveservicestaskforce.org/" target="_blank" rel="noopener noreferrer">US Preventive Services Task Force</a></strong> site has detailed recommendations for preventive medicine, including current screening recommendations and the research that supports those recommendations.</span></li>



<li><span><strong><a href="http://www.who.int/" target="_blank" rel="noopener noreferrer">World Health Organization</a></strong> posts numerous health articles that range from Avian Flu to Zika virus, with Palliative Care, Burns, Epidemiology, Statistical Methods and many other topics in between. They also have a number of charts and diagrams.</span></li>



<li><span><a href="http://www.osha.gov/"><strong>OSHA</strong></a> – Of course, there is a wealth of information you may need at OSHA, Department of HHS (CMS, HIPAA, etc.)</span></li>



<li><span><strong><a href="http://radiopedia.com/" target="_blank" rel="noopener noreferrer">Radiopedia</a></strong> – if you want to learn what community-acquired pneumonia looks like on X-ray compared to pulmonary tuberculosis – a picture is worth 1,000 words, but they also explain the films.</span></li>



<li><span><strong><a href="https://www.aafp.org/home.html" target="_blank" rel="noopener noreferrer">American Academy of Family Physicians</a></strong> has a great section of educational articles and guidelines available free to non-members. A good place to find out more about a wide variety of conditions.</span></li>
</ul>



<p class="wp-block-paragraph"><span>Don’t get stuck on a particular question. Remember, the NCLEX-RN® exam doesn’t require a perfect score, but you do have to answer enough questions correctly to demonstrate your ability to think like a nurse. Sometimes it’s easier to put the troublesome question aside for a couple of days and revisit after the frustration level has diminished</span>.</p>
<p>The post <a href="https://www.boardvitals.com/blog/important-considerations-pass-nclex-rn/">Important Considerations to Help You Pass the NCLEX-RN®</a> appeared first on <a href="https://www.boardvitals.com/blog">BoardVitals Blog</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Free NCLEX&#45;RN Practice Questions</title>
<link>https://edusehat.com/en/free-nclex-rn-practice-questions</link>
<guid>https://edusehat.com/en/free-nclex-rn-practice-questions</guid>
<description><![CDATA[ The post Free NCLEX-RN Practice Questions appeared first on BoardVitals Blog. ]]></description>
<enclosure url="https://blog.boardvitals.com/wp-content/uploads/2015/02/dreamstime_l_38209216-e1490734618570.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 24 Sep 2026 01:20:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Free, NCLEX-RN, Practice, Questions</media:keywords>
<content:encoded><![CDATA[<p class="wp-block-paragraph">Are you getting ready for your NCLEX-RN exam? We know it can be daunting. It’s been shown that the best results come from those who take many practice questions and tests. With the <a href="https://www.boardvitals.com/nclex-rn-review-questions?q=NCLEX-RN">BoardVitals NCLEX-RN Question Bank</a>, you’ll be sure to get the practice you need to be prepared. Our bank is filled with notoriously difficult questions to make sure you’re in shape for your exam.</p>



<p class="wp-block-paragraph">Try out a few for yourself. Can you answer these 4 Free Practice NCLEX-RN Questions?</p>



<div class="riddle_target" data-rid-id="421913" data-fg="#1486cd" data-bg="#54d3d1" data-auto-scroll="true" data-auto-scroll-offset="5">

<link href="https://www.riddle.com/embed/files/css/embed.css" rel="stylesheet">
<section><h2>NCLEX RN Practice Questions</h2><p></p></section><section><h2>What would be the most appropriate response by the nurse?</h2><p></p><p>The nurse is providing care for a client on a medical-surgical unit. The nurse notes the client is very weak when walking, struggles to complete their activities of daily living and appears to have a limited range of motion in their extremities. What would be the most appropriate response by the nurse?</p></section><section><h3>Which statement by the client indicates teaching has been effective?</h3><p></p><p>The nurse is providing client teaching for a client newly diagnosed with diabetes. Which statement by the client indicates teaching has been effective?<br></p></section><section><h3>Which of the following is one of the five “Rights of Delegation”?</h3></section><section><h3>What should you offer this client to eat as his first meal after discontinuation of NPO status?</h3><p></p><p>You are caring for a client who had surgery 24 hours ago. The doctor has ordered the discontinuation of NPO status and the advancement of the client’s diet “as tolerated.” What should you offer this client to eat as his first meal after discontinuation of NPO status?</p></section><section><h2>You’re Almost Ready</h2><p></p><p>But there’s always room for improvement. Study anywhere, any time with BoardVitals. 100% pass guarantee. Share your result with friends and go to www.boardvitals.com today!</p></section><section><h3>You’re Ready</h3><p>But there’s always room for improvement. Study anywhere, any time with BoardVitals. 100% pass guarantee. Share your result with friends and go to <a class="accent-link" href="http://www.boardvitals.com/" target="_blank" rel="noopener">www.boardvitals.com</a> today!</p></section><section><h3></h3></section>
</div>



<p class="wp-block-paragraph">These questions come from the NCLEX-RN question bank which features Computer Adaptive Testing to simulate the same experience you’ll see on test day. This means that for each question you get right, you’ll be served a more challenging question, and if you answer a question wrong, the following question will be easier. You pass this exam by answering the more difficult questions consistently, not by a set number that you’ve answered correctly.</p>



<p class="wp-block-paragraph">The NCLEX-RN exam consists of 75 to 265 questions; depending on how many difficult questions you answer correctly, your exam might be shorter than your peers. These questions might be multiple response, fill-in-the-blank, or hot spot multiple choice questions.</p>



<p class="wp-block-paragraph">According to the <a href="https://www.nclex.com/files/2026_RN_Test%20Plan_English-F.pdf" target="_blank" rel="noreferrer noopener">NCSBN NCLEX-RN Test Plan</a>, the following 4 categories are found on the exam:</p>



<ul class="wp-block-list">
<li><strong>Safe and Effective Care Environment</strong>
<ul class="wp-block-list">
<li>Management of Care 15-21%</li>



<li>Safety and Infection Control 10-16%</li>
</ul>
</li>



<li><strong>Health Promotion and Maintenance</strong> 6-12%</li>



<li><strong>Psychosocial Integrity</strong> 6-12%</li>



<li><strong>Physiological Integrity</strong>
<ul class="wp-block-list">
<li>Basic Care and Comfort 6-12%</li>



<li>Pharmacological and Parenteral Therapies 13-19%</li>



<li>Reduction of Risk Potential 9-15%</li>



<li>Physiological Adaptation 11-17%</li>
</ul>
</li>
</ul>



<p class="wp-block-paragraph">Want more questions? The BoardVitals <a href="https://www.boardvitals.com/nclex-rn-review-questions">NCLEX-RN Question Bank</a> has over 3,500 NCLEX-RN questions targeted to the NCLEX-RN Exam. Not ready to commit? Start with a <a href="https://www.boardvitals.com/#/exams/trial?question_bank_id=28">Free Trial.</a></p>
<p>The post <a href="https://www.boardvitals.com/blog/nclex-rn-free-sample-questions/">Free NCLEX-RN Practice Questions</a> appeared first on <a href="https://www.boardvitals.com/blog">BoardVitals Blog</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Anthropic&#45;, Nvidia&#45;Backed Basecamp Research Raise $140M Series C Financing Toward Advancing AI&#45;Designed Drugs</title>
<link>https://edusehat.com/en/anthropic-nvidia-backed-basecamp-research-raise-140m-series-c-financing-toward-advancing-ai-designed-drugs</link>
<guid>https://edusehat.com/en/anthropic-nvidia-backed-basecamp-research-raise-140m-series-c-financing-toward-advancing-ai-designed-drugs</guid>
<description><![CDATA[ According to Basecamp, EDEN offers the ability to design long and complex DNA sequences with large serine recombinases capable of delivering those sequences precisely. 
The post Anthropic-, Nvidia-Backed Basecamp Research Raise $140M Series C Financing Toward Advancing AI-Designed Drugs appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/BASECAMP-RESEARCH-GLENOLLIEBASE-1-696x464-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 23 Sep 2026 22:15:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Anthropic-, Nvidia-Backed, Basecamp, Research, Raise, 140M, Series, Financing, Toward, Advancing, AI-Designed, Drugs</media:keywords>
<content:encoded><![CDATA[<p>Basecamp Research said today it has completed an oversubscribed $140 million Series C financing whose proceeds are intended to fund the training of next generation EDEN models and apply them toward developing improved <em>in vivo</em> cell therapies for a variety of diseases.</p>
<p>Basecamp, a frontier AI company focused on therapeutic design, focuses on leveraging EDEN (short for “environmentally-derived evolutionary network), its biological foundation model, to develop<em> in vivo</em> cell therapies designed to reprogram a patient’s cells inside the body.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>EDEN is Basecamp’s new class of foundation models trained on what the company says is the world’s largest and most diverse evolutionary dataset. According to Basecamp, EDEN offers the ability to design long and complex DNA sequences with large serine recombinases capable of delivering those sequences precisely.</p>
<p>EDEN-designed cell therapies are also designed to overcome the high manufacturing cost and limited complexity of present-day cell therapies. As a result, Basecamp said in its announcement, its EDEN-designed therapeutics offer the potential to treat complex diseases that include cancer and autoimmune disease, aiming “to underpin the future of cell therapies, making them more sophisticated, more customizable and simpler to administer” than current cell therapies.</p>
<p>“We believe the future of medicine lies in reprogramming the body to repair itself. We design the models and the medicines to teach it how,” Glen Gowers, PhD, Basecamp’s co-founder and CEO, said in the statement. Gowers co-founded Basecamp with Oliver Vince, PhD.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>Basecamp says it has shown strong preclinical results across multiple modalities and disease areas. Aiming to expand its partnerships with biopharmas, Basecamp in April appointed Richard Pearce as chief business officer. Pearce previously served as Biogen’s head of business development, strategy, and portfolio management.</p>
<p>“AI-based approaches promise to change what’s possible for patients who currently have few alternatives. This funding brings this technology closer to those who need it most,” Gowers added.</p>
<p></p><h4><strong>Big-name investors</strong></h4>

<p>One big-name investor participating in the financing is Anthropic—the AI model builder behind the Claude family of large language models. Anthropic invested in Basecamp through its Anthology Fund, a $100 million fund launched in 2024 and financed by Silicon Valley-based VC firm Menlo Ventures. Startups financed by the Anthology Fund receive access to Anthropic products and research, $25,000 in free credits towards Anthropic’s most advanced models, and what the company calls “best-in-class” venture support from Menlo.</p>
<p>“We’re particularly interested in ventures that leverage AI to enhance human capabilities and productivity in fields such as healthcare, legal services, education, energy, infrastructure, and scientific research,” Daniela Amodei, Anthropic’s co-founder and president, stated in announcing the launch of the Anthology Fund.</p>
<p>Anthropic’s offerings include Claude Science, the AI research workbench <a href="https://www.genengnews.com/topics/artificial-intelligence/claude-science-is-here-antibiotics-designed-by-text-prompt-among-applications/" target="_blank" rel="noopener">launched in June</a> and featuring Basecamp’s antibiotic design and vaccine prediction AI models.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>Another name investor is NVentures, the venture capital arm of Nvidia—the Silicon Valley microprocessing giant<strong> </strong>with which Basecamp has <a href="https://www.genengnews.com/topics/artificial-intelligence/basecamp-research-achieves-programmable-gene-insertion-with-eden-ai-models/" target="_blank" rel="noopener">leveraged AI to unlock programmable gene insertion</a>, which places large therapeutic DNA sequences at precise locations in the human genome.</p>
<p>Researchers from Nvidia joined partners from Basecamp, Microsoft, and two research institutions in detailing EDEN in a <a href="https://www.biorxiv.org/content/10.64898/2026.01.12.699009v1" target="_blank" rel="noopener">preprint posted January 12 on bioRxiv</a>.</p>
<p></p><h4><strong>63% hit rate</strong></h4>

<p>The investigators showed EDEN to achieve an overall functional hit rate of 63.2% across diverse DNA prompts when prompted on only 30bp of DNA from outside the training data. Half (50%) of EDEN-generated LSRs were active in human cells, achieving therapeutically relevant levels of chimeric antigen receptor (CAR) insertion in primary human T cells. Also, an EDEN-generated synthetic microbiome was shown in the preprint to cover 9,067 species with a biome-specific taxonomic accuracy of 99%.</p>
<p>Nvidia and Anthropic were among partners of Basecamp that built its Trillion Gene Atlas, which draws on biological data collected through access and benefit-sharing partnerships in more than 30 countries across all seven continents. The Atlas is at the center of Basecamp’s AI platform, and according to the company is the world’s largest proprietary biological AI training dataset. Pacific Biosciences of California (PacBio) and Ultima Genomics also partnered in building the Atlas.</p>
<p>Trained on data from the Atlas, Basecamp’s EDEN models deliver a universal understanding of how DNA works across all of life. Its capabilities include designing cell and gene therapies, enzymes and peptides.</p>
<p>Unlike AI systems developed for a single scientific task, EDEN models are trained to recognize patterns across biology. As a result, it can generate potential therapeutic candidates directly from information about a disease, an approach already demonstrated through Basecamp’s collaboration with Anthropic on Claude Science.</p>
<p>Anthropic and NVentures are among participants in the financing, along with Catalio, European Tech Collective, Firebrand River Capital, King Philanthropies, NATO Innovation Fund, Redalpine, The Rockefeller Foundation, Singular, Sovereign AI, and True Ventures.</p>
<p></p><h4><strong>‘Next transformation’</strong></h4>

<div class="my-8"><span data-render-ad="6"></span></div>
<p>Basecamp has garnered additional investment from senior leaders across biopharma and global industry, including André Hoffmann, vice chairman of Roche, a board member of Roche subsidiary Genentech, and co-chair of the World Economic Forum.</p>
<p>“The biotechnology revolution that began fifty years ago transformed how we make medicines. Personalized, AI-designed therapeutics represent the next transformation of that journey,” Hoffmann stated. “Basecamp Research has built the full platform to deliver it, from biological data to trained models to designed therapies. This will be key in helping the industry to continue to innovate.”</p>
<p>Basecamp raised $60 million in Series B financing in 2024, and a $20 million Series A round two years earlier.</p>
<p>The Series C financing was led by S32, a Palo Alto, CA-based venture firm. S32 has about $3.5 billion in assets under management after closing earlier this year on a $517 million sixth flagship fund, according to PitchBook.</p>
<p>As a result of the latest financing, Andy Conrad, General Partner at S32 and former CEO of Google’s Verily, will join Basecamp’s board.</p>
<p>“AI is opening up new possibilities across every part of society, but perhaps nowhere is the potential more meaningful than in human health. The ability to combine AI, biological data and scientific insight could transform how we understand disease, discover medicines and ultimately improve and extend people’s lives,” Conrad stated. “Basecamp Research is building an important technology platform at the center of that opportunity.”</p>
<p>The post <a href="https://www.genengnews.com/topics/artificial-intelligence/anthropic-nvidia-backed-basecamp-research-raise-140m-series-c-financing-toward-advancing-ai-designed-drugs/">Anthropic-, Nvidia-Backed Basecamp Research Raise $140M Series C Financing Toward Advancing AI-Designed Drugs</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Canadian Hospitals Rank Among World’s Best for Specialized Care</title>
<link>https://edusehat.com/en/canadian-hospitals-rank-among-worlds-best-for-specialized-care</link>
<guid>https://edusehat.com/en/canadian-hospitals-rank-among-worlds-best-for-specialized-care</guid>
<description><![CDATA[ Hospitals across five provinces have earned international recognition, highlighting Canadian expertise in pediatrics, cancer care, cardiology and other specialties. Canadian hospitals have earned prominent positions in the newly released World’s Best Specialized Hospitals 2027 rankings, with healthcare institutions in Ontario, Quebec, British Columbia, Alberta and Nova Scotia recognized internationally. The rankings, produced by Newsweek in […]
The post Canadian Hospitals Rank Among World’s Best for Specialized Care appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/09/shutterstock_2666855883.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 23 Sep 2026 22:10:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Canadian, Hospitals, Rank, Among, World’s, Best, for, Specialized, Care</media:keywords>
<content:encoded><![CDATA[<p>Hospitals across five provinces have earned international recognition, highlighting Canadian expertise in pediatrics, cancer care, cardiology and other specialties.</p>
<p>Canadian hospitals have earned prominent positions in the newly released <strong>World’s Best Specialized Hospitals 2027 </strong>rankings, with healthcare institutions in Ontario, Quebec, British Columbia, Alberta and Nova Scotia recognized internationally.</p>
<p>The rankings, produced by Newsweek in partnership with global data intelligence firm Statista, evaluate hospitals across 13 medical specialties.</p>
<h2><strong>Canada’s strongest showing came in pediatric care.</strong></h2>
<p>Toronto’s <strong>Hospital for Sick Children (SickKids)</strong> was ranked the <strong>No. 1 pediatric hospital in the world</strong> for the second consecutive year. SickKids has now ranked among the world’s top two pediatric hospitals for six consecutive years and has earned the No. 1 position three times.</p>
<p>Other Canadian children’s hospitals also performed strongly. <strong>BC Children’s Hospital</strong> in Vancouver ranked ninth globally, followed by <strong>Alberta Children’s Hospital</strong> in Calgary at No. 15, <strong>Stollery Children’s Hospital</strong> in Edmonton at No. 45 and <strong>IWK Health Centre</strong> in Halifax at No. 68. CHEO in Ottawa, CHU Sainte-Justine in Montreal and McMaster Children’s Hospital in Hamilton also appeared in the international pediatric rankings.</p>
<h2><strong>Canadian hospitals also achieved impressive results in adult specialized care.</strong></h2>
<p>Toronto’s <strong>University Health Network, Toronto General Hospital/Peter Munk Cardiac Centre</strong> ranked 10th globally for cardiac surgery and 16th for cardiology. Toronto General also placed among the world’s leading hospitals in nephrology, gastroenterology, pulmonology and endocrinology.</p>
<p>The <strong>Princess Margaret Cancer Centre</strong> ranked 12th worldwide in oncology, while Vancouver General Hospital placed 35th in orthopedics and appeared in several other specialties. Montreal hospitals were represented across cardiology, oncology, neurology, neurosurgery and other fields.</p>
<p>The rankings rely heavily on recommendations from medical professionals, while also considering hospital accreditation and certification and the implementation of patient-reported outcome measures.</p>
<p>International rankings are not a complete measure of hospital quality and should not be interpreted as determining the best hospital for an individual patient. Still, Canada’s strong showing provides international recognition for the healthcare professionals, researchers and specialized programs working within hospitals across the country.</p>
<p>For a healthcare system often discussed in terms of its challenges, <strong>the results also highlight an important strength: Canadian hospitals continue to deliver specialized care that is recognized among the best in the world.</strong></p>
<p>The post <a href="https://www.hospitalnews.com/canadian-hospitals-rank-among-worlds-best-for-specialized-care/">Canadian Hospitals Rank Among World’s Best for Specialized Care</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>AI scribes in the hospital: What works for physicians</title>
<link>https://edusehat.com/en/ai-scribes-in-the-hospital-what-works-for-physicians</link>
<guid>https://edusehat.com/en/ai-scribes-in-the-hospital-what-works-for-physicians</guid>
<description><![CDATA[ An early adopter of AI scribes in the hospital found relatively few physicians were willing to use the tech, in part because of the tech’s shortcomings in the inpatient setting. A study published in the Sept. 14, 2026, Journal of Hospital Medicine looked at a rollout of ambient AI in 20 hospitals in March 2025 at […]
The post AI scribes in the hospital: What works for physicians appeared first on Today&#039;s Hospitalist. ]]></description>
<enclosure url="https://todayshospitalist.com/wp-content/uploads/2026/09/AI-scribes-in-the-hospital-shutterstock_2736159947-9-23-26.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 23 Sep 2026 18:05:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>scribes, the, hospital:, What, works, for, physicians</media:keywords>
<content:encoded><![CDATA[<p>An early adopter of AI scribes in the hospital found relatively few physicians were willing to use the tech, in part because of the tech’s shortcomings in the inpatient setting.</p>
<p><a href="https://shmpublications.onlinelibrary.wiley.com/doi/full/10.1002/jhm.70451?campaign=wolearlyview">A study published in the Sept. 14, 2026, Journal of Hospital Medicine</a> looked at a rollout of ambient AI in 20 hospitals in March 2025 at Sutter Health, a large health system in northern and central California.</p>
<p>Just 59 physicians participated in the study, half of them hospitalists. Among those who did participate, hospital physicians used AI scribes for less than half of their patient notes. Just over half (53%) said they had a “high degree of success” with AI documentation.</p>
<p>Researchers concluded that while AI scribes hold promise in the inpatient setting, the technology has “significant room for improvement” for physicians in the hospital. Here’s a look at what worked—and what didn’t work—for hospitalists and other inpatient physicians using ambient AI in the study.</p>
<h4><strong>What’s wrong with AI scribes in the hospital?</strong></h4>
<p>Researchers looked at a rollout of Abridge, an AI scribe that makes an audio recording of clinician-patient encounters and generates a transcript and draft progress note components that clinicians can edit, review and insert into the EHR. Sutter Health was the first health system in the United States to fully integrate Abridge within Epic.</p>
<p>From the start, physicians’ embrace of ambient AI was underwhelming. “We had a large number of inpatient physicians who did not use ambient AI to create even a single note,” the researchers said.</p>
<p>There were some reasons behind that reluctance. When ambient AI was first launched at Sutter, for example, the tech was unable to be used by inpatient providers for patient consultations in the emergency department.</p>
<p>An even bigger problem quickly surfaced: The AI scribe didn’t offer a copy-forward function for progress notes, which is a staple of inpatient documentation. Researchers said that forced physicians to essentially create a new progress note every time they saw a patient, which likely drove down use of the technology.</p>
<h4><strong>Physician reviews of ambient AI in the hospital</strong></h4>
<p>Ambient AI was more helpful for other uses. After the rollout of AI scribes, the number of physicians who said they felt like they could give patients their undivided attention jumped slightly (from 14 to 16 respondents). The same was true with the number of physicians who said their patients could more easily understand their notes, going from 13 to 15 physicians.</p>
<p>Some physicians said that ambient AI allowed them to give patients their “undivided attention,” “make eye contact,” and even have “a few extra seconds to be human with the patient.” They said the tech also gave them more time to identify questions that could help form a diagnosis.</p>
<p>Most physicians in the study said ambient AI improved efficiency by “saving time” and allowing them to complete other tasks. Researchers, however, noted that those comments were offset by complaints that in some cases, time savings produced by AI were offset by needing to edit and remove “extra information.”</p>
<p>Some respondents said the history of present illness (HPI) section made patient histories more comprehensive and easier to complete because physicians didn’t need to “memorize the HPI.” Other physicians added that AI helped with admission/triage notes, especially during “back-to-back admissions” for inpatient care.</p>
<p>And while some hospital physicians said AI scribes made their notes more “comprehensive,” others felt the notes were “too generic.” Some found inaccurate information in notes generated by ambient AI, such new problems that were not discussed during patient encounters.</p>
<p>Some respondents suggested that AI offer “custom smart lists.” Others asked for the ability to incorporate structured data from the EHR to create A&P sections and to have the ability to “pull forward” or add onto previously generated notes.</p>
<h4><strong>How AI helped physician time/productivity</strong></h4>
<p>Researchers found that AI scribes helped hospital physicians reduce time spent on patient notes, but the differences they found in in pre- and post -surveys were not significant. The study noted that doctors who used ambient AI for more than 10% of their notes reported a slightly larger decrease in time spent on notes than physicians who used the technology for less than 10% of their notes. Researchers pointed out that previous studies have similarly shown that the more time physicians spend using AI, the more benefits they see in terms of time spent on notes.</p>
<p>Finally, the study noted that even physicians who went into the trial of AI scribes in the hospital optimistic that the tech could boost their productivity changed their minds. Comparing pre- and post-study surveys, researchers found that the number of physicians who thought ambient AI could help them see one additional patient per shift dropped from 55% to 45% of doctors in the study.</p>
<p>The post <a href="https://todayshospitalist.com/ai-scribes-in-the-hospital-what-works-for-physicians/">AI scribes in the hospital: What works for physicians</a> appeared first on <a href="https://todayshospitalist.com/">Today's Hospitalist</a>.</p>]]> </content:encoded>
</item>

<item>
<title>BrainStorm Therapeutics combines brain organoids and AI for CNS drug discovery</title>
<link>https://edusehat.com/en/brainstorm-therapeutics-combines-brain-organoids-and-ai-for-cns-drug-discovery</link>
<guid>https://edusehat.com/en/brainstorm-therapeutics-combines-brain-organoids-and-ai-for-cns-drug-discovery</guid>
<description><![CDATA[ BIO 2026 Start-Up Stadium winner generates human data to improve clinical translation. Artificial intelligence is opening new possibilities for drug discovery. But in neuroscience, […]
The post BrainStorm Therapeutics combines brain organoids and AI for CNS drug discovery appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/09/Maya-from-Brainstorm.JPG.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 23 Sep 2026 14:40:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>BrainStorm, Therapeutics, combines, brain, organoids, and, for, CNS, drug, discovery</media:keywords>
<content:encoded><![CDATA[<h4>BIO 2026 Start-Up Stadium winner generates human data to improve clinical translation.</h4>
<p>Artificial intelligence is opening new possibilities for drug discovery. But in neuroscience, AI is only as powerful as the biological data behind it, and BrainStorm Therapeutics believes AI combined with human brain biology can be better.</p>
<p>BrainStorm is generating that biology in the laboratory using patient-derived human brain organoids. These living, three-dimensional models reproduce features of the human brain, generating rich datasets that BrainStorm uses for phenotypic drug discovery and to train AI models.</p>
<p>By combining patient-derived brain organoids with AI, the company aims to uncover disease mechanisms, identify therapeutic targets, screen drug candidates, and determine whether potential treatments can reverse disease-associated dysfunction before they enter clinical trials.</p>
<p>BrainStorm is applying the platform across neurological diseases, with a lead therapeutic program in CDKL5 deficiency disorder, or CDD, and discovery programs in Parkinson’s and Alzheimer’s diseases. The approach also builds on earlier work in Rett syndrome, advancing a repurposed therapeutic candidate from organoid screening to an FDA-cleared Investigational New Drug application for a Phase 2 clinical trial.</p>
<p>The company has attracted attention from the scientific and investment communities, most recently earning the Seed-Stage Start-Up Stadium Award at the 2026 BIO International Convention.</p>
<p>The competition recognizes two companies selected by investor judges from approximately 50 presenting start-ups. BrainStorm received the Seed-Stage Award for companies that had raised less than $1 million, while NF1-focused iNFixion Bioscience received the Emerging Company Award for companies that had raised between $1 million and $10 million.</p>
<h2>The brain power behind the platform</h2>
<p>BrainStorm generates three-dimensional brain organoids from induced pluripotent stem cells derived from patients carrying disease-causing mutations. The cells are differentiated into regionally defined brain organoids containing multiple interacting neural cell types and functional synaptic networks.</p>
<p>Although organoids do not reproduce an entire human brain, they can model selected cellular, molecular, and functional features of specific human brain regions that are difficult to capture in conventional cell cultures or animal models.</p>
<p>“When we measure calcium signaling and electrophysiological activity in these brain organoids, we can detect patterns of neuronal and network dysfunction associated with specific neurological disorders,” said Maya Gosztyla, Ph.D., BrainStorm’s co-founder and chief scientific officer. “These models bring us closer to studying human disease biology in the laboratory and give us a powerful system for evaluating whether a potential therapy can correct that disease biology.”</p>
<p>BrainStorm uses organoid data to investigate disease mechanisms, identify therapeutic targets, screen drug candidates, and determine whether treatments reverse disease-associated phenotypes. Those experiments also generate proprietary, human-relevant datasets to train and refine the company’s AI models.</p>
<p>“This allows us to do two things at once,” Gosztyla said. “We can directly test whether a potential therapy rescues a disease phenotype while generating rich, high-quality human datasets that improve our AI models.”</p>
<p>BrainStorm uses those data to identify disease-associated gene networks and potential therapeutic targets, then brings AI-generated hypotheses back into its organoid platform for experimental testing.</p>
<p>“That creates a closed loop between computation and experiment,” Gosztyla said. “By grounding our AI models in patient-derived human biology and then experimentally testing their predictions, we believe we can improve the likelihood that discoveries made in the laboratory will translate into meaningful benefits for patients.”</p>
<h2>Platform validation in Rett syndrome</h2>
<p>BrainStorm’s strategy builds on work led by founder and CEO Robert T. Fremeau, Jr., Ph.D., while he was chief scientific officer of Vyant Bio. Using patient-derived brain organoids, the Vyant team identified repurposed drug candidates for Rett syndrome and a novel therapeutic target and small-molecule hit scaffold for CDD. Rett syndrome is a rare genetic neurological disorder that primarily affects girls and can cause developmental regression, impaired communication and movement, seizures, and other serious symptoms.</p>
<p>“Our most clinically advanced proof point originated from work I led as chief scientific officer of Vyant Bio,” Fremeau said. “Working with the International Rett Syndrome Foundation, we used patient-derived brain organoids to conduct phenotypic screening and identified donepezil as a potential repurposed therapy for Rett syndrome.”</p>
<p>Donepezil is FDA-approved for Alzheimer’s disease but not for Rett syndrome. The program progressed from organoid screening to submission of a Phase 2 clinical trial application in approximately nine months. The FDA subsequently cleared the Investigational New Drug application, allowing the Phase 2 program to proceed. The translational package included efficacy evidence generated in patient-derived human brain organoids, without requiring new animal efficacy studies for the repurposed drug.</p>
<p>“To our knowledge, donepezil represents the first therapeutic candidate identified through phenotypic screening in a patient-derived brain organoid to progress to an FDA-cleared IND,” Fremeau said. “For us, that provided important translational and regulatory validation of the organoid-based approach demonstrating that human brain organoids can move beyond disease modeling to become a practical drug-discovery platform capable of generating therapeutic hypotheses that advance toward the clinic.”</p>
<h2>The lead program: CDKL5 deficiency disorder</h2>
<p>While the Rett program provided an important example of clinical translation, CDD is now the focus of BrainStorm’s therapeutic development efforts.</p>
<p>CDD is a rare developmental and epileptic encephalopathy caused by pathogenic variants in the CDKL5 gene. It typically presents in early infancy with severe, treatment-resistant seizures and profound developmental, motor, communication, and visual impairments. Existing treatments can reduce seizures in some patients, but no approved therapy addresses the underlying disease biology and neurodevelopmental impairments.</p>
<p>One challenge in developing therapies for CDD is the disorder’s genetic diversity. Different patients carry different pathogenic variants in CDKL5, raising an important question for drug discovery: Can a treatment correct disease biology across multiple genetic backgrounds?</p>
<p>To address that question, BrainStorm is working with the CURE5 Foundation, a patient-led CDD organization, to develop patient-derived brain organoid models representing multiple pathogenic CDKL5 variants.</p>
<p>“We’re growing several new stem-cell-derived brain organoid models from patients with different types of CDKL5 mutations,” Gosztyla said. “These models allow us to ask whether a therapy can work across the genetic diversity of CDD.”</p>
<p>The models provide BrainStorm with a genetically diverse human platform for studying CDD biology and evaluating therapeutic response. They can also support systematic screening of approved drugs to identify potential repurposing opportunities for patients.</p>
<p>At the same time, BrainStorm is advancing its own proprietary therapeutic program for CDD. The program builds on a novel therapeutic target and small-molecule hit scaffold originally identified through phenotypic screening in patient-derived CDD brain organoids.</p>
<p>“Our goal is to develop a first-in-class, disease-modifying therapy that addresses the underlying neuronal dysfunction rather than only treating the symptoms,” Gosztyla said.</p>
<p>CDD organoids exhibit reproducible hyperexcitability that can be measured using high-throughput calcium imaging and electrophysiology. BrainStorm’s hit compound reverses aspects of this disease-associated neuronal dysfunction in CDD organoids while showing little or no effect in healthy controls, suggesting disease-state-selective activity.</p>
<p>The company is now validating the therapeutic response across multiple patient genotypes while advancing the chemistry through hit-to-lead optimization toward selection of a development candidate.</p>
<p>Together, the CURE5 collaboration and BrainStorm’s proprietary program are designed to answer complementary questions: whether existing medicines can be repurposed for genetically diverse CDD patients, and whether a new disease-modifying therapy can be developed specifically to correct the disorder’s underlying neuronal dysfunction.</p>
<h2>Advancing toward a development candidate</h2>
<p>BrainStorm is now raising a seed financing round to advance its CDD program through hit-to-lead optimization toward a development candidate and expand its therapeutic pipeline.</p>
<p>“The main focus of our current fundraising is to bring the CDD program forward toward a development candidate,” Gosztyla said.</p>
<p>The company has attracted more than $1 million in non-dilutive support. A Phase I Small Business Innovation Research award from the National Science Foundation supported development of BrainStorm’s AI foundation-model capabilities and Parkinson’s disease research, including identifying potential disease-modifying targets.</p>
<p>BrainStorm is also collaborating with Novoron Bioscience and Defined Bioscience on a National Institute on Aging Direct-to-Phase II SBIR award. The project uses three-dimensional cortical organoids to model pathological prion-like tau propagation and identify potential treatments for Alzheimer’s disease.</p>
<p>The company has received recognition from organizations including California Life Sciences, NVIDIA, BioMarin, and Servier. BrainStorm has also entered a master collaboration agreement with BioSymetrics, part of Lunai Bioworks (NASDAQ LNAI), to support translational validation.</p>
<p>Its latest recognition, the BIO Start-Up Stadium Award, came after BrainStorm presented at the 2026 BIO International Convention.</p>
<p>Along with exposure to biotechnology investors, the award includes participation in the Science Inc. Accelerator operated by The Innovation Space.</p>
<p>“The accelerator has been extremely valuable in helping us address the practical steps required to move from early therapeutic discovery through development, regulatory strategy, and financing,” Gosztyla said.</p>
<p>The Start-Up Stadium competition also provided BrainStorm with exposure to investors, including members of the judging panel.</p>
<p>“Winning the Seed-Stage Start-Up Stadium Award provides important external validation of our science, our team, and our opportunity to build a differentiated CNS therapeutics company,” Fremeau said. “We are currently raising our seed round to advance our lead CDD program toward a development candidate and demonstrate that patient-derived human brain models can help identify therapies with a greater likelihood of translating into meaningful benefit for patients with devastating neurological diseases.”</p>
<p>After all, developing new neurotherapeutics requires money—and brains.</p>
<p>The post <a href="https://bio.news/bio-convention/brainstorm-therapeutics-combines-brain-organoids-and-ai-for-cns-drug-discovery/">BrainStorm Therapeutics combines brain organoids and AI for CNS drug discovery</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Biomimetic Nanoparticles Trigger Light Responses in Blind Mouse Retinas</title>
<link>https://edusehat.com/en/biomimetic-nanoparticles-trigger-light-responses-in-blind-mouse-retinas</link>
<guid>https://edusehat.com/en/biomimetic-nanoparticles-trigger-light-responses-in-blind-mouse-retinas</guid>
<description><![CDATA[ A biomimetic nanoparticle platform inspired by photosynthesis helped activate surviving retinal nerve cells in mice with advanced retinal degeneration.
The post Biomimetic Nanoparticles Trigger Light Responses in Blind Mouse Retinas appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/03/POV-GettyImages-1227553397.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 23 Sep 2026 11:05:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Biomimetic, Nanoparticles, Trigger, Light, Responses, Blind, Mouse, Retinas</media:keywords>
<content:encoded><![CDATA[<p>Even after a retina loses its natural light-sensing cells, some of its nerve circuitry can remain intact. In a new preclinical study, researchers showed that injectable, light-sensitive nanoparticles can lodge near surviving retinal nerve cells and help degenerated mouse retinas respond to illumination.</p>
<p>The work, described in the paper titled “<a href="https://www.nature.com/articles/s41551-026-01773-w" target="_blank" rel="noopener">Biomimetic graphitic carbon nitride nanoparticles for multiscale photomodulation and therapeutic intervention</a>,” was published in <em>Nature Biomedical Engineering</em>. The international team was led by Menglin Chen, PhD, at Aarhus University, with collaborators from the University of Chicago, the University of Eastern Finland, Aarhus University Hospital, and the University of Copenhagen.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>The study addresses a central challenge in retinal degeneration: even after light-sensitive photoreceptors are lost, other retinal neurons can persist. The researchers aimed to create a wireless interface between light and those remaining cells without relying on mutation-specific gene therapy, optogenetic modification, or surgically implanted electronics.</p>
<p>“When we started, our fundamental question was whether we could create a material that could act as a wireless interface between light and living cells,” said Chen, who is an associate professor at the Department of Biological and Chemical Engineering. “We can now see that the particles are able to activate nerve cells in blind retinas. That brings us closer to our long-term goal of developing a new type of retinal prosthesis.”</p>
<p><figure aria-describedby="caption-attachment-338351" class="wp-caption alignleft"><img fetchpriority="high" decoding="async" class="size-medium wp-image-338351" src="https://www.genengnews.com/wp-content/uploads/2026/09/Low-Res_Menglin-08-300x200.jpg" alt="" width="300" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/Low-Res_Menglin-08-300x200.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/Low-Res_Menglin-08-630x420.jpg 630w, https://www.genengnews.com/wp-content/uploads/2026/09/Low-Res_Menglin-08-696x464.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/09/Low-Res_Menglin-08.jpg 700w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Associate professor Menglin Chen, PhD, studies how the light-sensitive nanoparticles affect living cells. The screen shows calcium being released inside a cell after nanoparticles taken up by the cell are exposed to blue light. Calcium plays an important role in cellular signaling, and the experiment helped the researchers understand how the nanoparticles can translate light into biological activity. [Aarhus University/Johanne Holm Jensen]</figcaption></figure>The nanoparticles are hollow spheres made from graphitic carbon nitride, a light-responsive semiconductor. Inspired in part by chloroplasts, the plant structures that capture sunlight during photosynthesis, the particles convert light into local photoelectrochemical and photothermal effects that can influence cell signaling. In cell experiments, focused laser stimulation induced “inducing calcium-transient release in multiple cells and propagation in primary cardiomyocytes and cardiac fibroblasts,” the authors wrote. At a multicellular scale, light-emitting diode (LED) light helped pace and synchronize beating in cardiomyocytes.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>The retinal experiments moved the platform toward a more specific therapeutic application. After the nanoparticles were injected into mouse eyes with advanced retinitis pigmentosa, they accumulated near retinal ganglion cells, which help relay visual information from the eye to the brain. When the eyes were illuminated, the team detected light-induced activity in the visual cortex and observed behavioral responses to light. The researchers also showed that the nanoparticles could activate retinal ganglion cells in isolated porcine retinal tissue under LED photostimulation.</p>
<p>The findings do not show restored normal vision, but they suggest a possible route for restoring light sensitivity in retinas where photoreceptors have degenerated. “Instead of genetically modifying these cells, we use the nanoparticles to create a new connection between light and the nerve cells,” Chen said. “In this way, we are trying to make a blind retina respond to light again.”</p>
<p>The next steps are substantial. The team will need to refine delivery, assess how long the nanoparticles remain functional in the eye, study their long-term safety, and determine whether the light-evoked responses can be strengthened and controlled in ways that are useful for vision restoration.</p>
<p>For now, the work marks an early but notable step: a biomimetic material that can translate light into biological signals across scales, from individual cells to degenerated retinal tissue. Whether that microscopic “solar cell” concept can ultimately help people with vision loss will depend on the next phase of preclinical development.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/biomimetic-nanoparticles-trigger-light-responses-in-blind-mouse-retinas/">Biomimetic Nanoparticles Trigger Light Responses in Blind Mouse Retinas</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Cell Senescence ‘Barcodes’ Identified with Raman Microscopy and Gene Expression Data</title>
<link>https://edusehat.com/en/cell-senescence-barcodes-identified-with-raman-microscopy-and-gene-expression-data</link>
<guid>https://edusehat.com/en/cell-senescence-barcodes-identified-with-raman-microscopy-and-gene-expression-data</guid>
<description><![CDATA[ Researchers combined Raman microscopy with gene expression data at single-cell resolution from the same cells, and AI, to develop RamanOmics, a noninvasive way to detect biomarkers of cellular senescence as “barcodes.&quot;
The post Cell Senescence ‘Barcodes’ Identified with Raman Microscopy and Gene Expression Data appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2261205514.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 23 Sep 2026 07:25:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Cell, Senescence, ‘Barcodes’, Identified, with, Raman, Microscopy, and, Gene, Expression, Data</media:keywords>
<content:encoded><![CDATA[<p>As we age, some of the cells in our body enter a state of senescence, in which they stop dividing but do not die. Those senescent cells can contribute to age-related disorders such as cancer, tissue degeneration, and inflammatory diseases.</p>
<p>In an advance that could lead to better ways to diagnose and treat those diseases, MIT researchers have developed a noninvasive way to detect biomarkers of senescence. Their method is based on Raman microscopy, which can reveal the biochemical composition of cells without harming them.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>Using the new technique, “RamanOmics”, which combines Raman microscopy with gene expression data at single-cell resolution from the same cells, the researchers were able to identify unique “barcodes” that can be used to quickly identify senescent cells. And while their reported study was carried out in mouse cells, the scientists are now working on adapting it for use with human tissue.</p>
<p>“You can imagine that one day we may develop an endoscope that can look inside your body and identify cellular senescence,” says Jeon Woong Kang, PhD, an MIT research scientist and co-senior author of the team’s published study in <em>Nature Aging</em>, titled “<a href="https://doi.org/10.1038/s43587-026-01219-7" target="_blank" rel="noopener">RamanOmics decodes the spatial vibrational–molecular architecture of senescence in aging and repair</a>,” in which they concluded, “Together, RamanOmics provides a tissue-agnostic framework for scalable, multimodal profiling of cellular states.”</p>
<p>The paper’s co-senior authors are Peter So, PhD, director of the MIT Laser Biomedical Research Center (LBCR) and an MIT professor of biological engineering and mechanical engineering, and Jian Shu, PhD, an assistant professor at Massachusetts General Hospital (MGH) and Harvard Medical School, and an associate member of the Broad Institute and Ragon Institute. The research is part of a National Institutes of Health initiative called the Cellular Senescence Network, which is pursuing a deeper understanding of senescence in hopes of developing therapies that could combat some of the tissue-damaging effects of senescent cells.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>Cell senescence is often triggered by DNA damage, which leads to an irreversible arrest of the cell cycle. These cells don’t die, but they undergo significant changes to their shape, metabolic processes, and gene expression profiles.</p>
<p>The immune system is responsible for clearing out these “zombie cells,” but as people age, this clearing process becomes less efficient. When senescent cells accumulate, they may contribute to sagging skin, muscle weakness, and chronic conditions such as osteoarthritis and type 2 diabetes (T2D).</p>
<p>Cellular senescence also has beneficial effects, playing critical roles in embryonic development and tissue regeneration. “Senescence is not just a pathological condition,” So said. “The idea behind the NIH Cellular Senescence Network is to take a very comprehensive approach to understand senescence and identify senescent cells, because it plays a role in so many normal physiological conditions and many pathological conditions.”</p>
<p>Scientists have already identified a few biomarkers for senescence, including two proteins, p16 and p21, which are involved in halting the cell cycle. However, those proteins can only be identified using a process that ends up destroying the cells. “Aging reshapes tissues through the accumulation of senescent cells, yet current definitions of senescence still depend largely on transcriptomic or histological markers that fail to capture its underlying biochemical remodeling,” the team further pointed out.</p>
<p>The MIT team wanted to find a way to noninvasively identify senescent cells using Raman microscopy. Unlike RNA-sequencing, which consumes the cells as it analyzes them, Raman microscopy is a nondestructive technique that reveals the chemical composition of tissues or cells by shining near-infrared or visible light on them.</p>
<p>For their newly reported study the researchers used Raman microscopy in conjunction with spatial RNA sequencing—a technique that reveals where genes are active within a tissue—to identify new markers of senescence. By combining these two techniques the team was able to generate a much broader picture of the distinctive features of senescent cells, including gene expression levels, spatial location, and other biochemical information.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>“Our idea was to look at many different features to characterize senescence,” Shu noted. “That’s why we wanted to combine both single-cell gene expression and Raman microscopy, so that we can characterize the senescence from two complementary views.”</p>
<p>Using both methods of analysis, the researchers examined skin and lung tissue from 2-month-old mice and from 26-month-old mice. One of the most dramatic changes seen in both lung and skin cells was an increase in lipid synthesis in older cells, along with accumulation of lipids. How this affects the physiology of the cells is not yet known, the researchers say.</p>
<p>They also found some effects that were specific to each tissue. In senescent skin cells it was discovered that cellular pathways associated with muscle contraction and with remodeling of collagen and the extracellular matrix (ECM) were significantly affected. And in aged lung tissue, there was increased activity of genes involved in immune activation and inflammation. “Together, these results reveal tissue-specific aging patterns: immune activation and vascular remodeling with diminished epithelial renewal in lung, versus metabolic decline and impaired ion homeostasis with partial preservation of epithelial programs in skin,” they stated. In future work, the researchers hope to study further what role these changes play in senescent cells.</p>
<p>Using these data, the researchers were able to identify combinations of Raman peaks that correlate with senescence. These peaks, which represent specific chemical bonds, are linked to the presence of certain lipids, proteins, or other molecules.</p>
<p>“Combining the most important Raman features with the most important gene signatures, we were able to create a barcode that can help us to identify senescent cells in a more unbiased way,” commented Salvatore Sorrentino, PhD, a postdoc at MIT and study co-first author. “Using this barcode, we can focus on a few Raman bands that emerged as the most informative in this work.” Using these bands, it could be possible to identify senescent cells by looking for just those bands of the Raman spectrum. This could help to enable diagnostics that would detect cells that have become senescent.</p>
<p>“Nondestructive Raman features alone could serve as biomarkers of senescence, enabling <em>in vivo</em> monitoring of tissue aging or evaluation of senolytic therapies in humans,” the authors stated. “Coupling biochemical readouts with transcriptomic programs also opens opportunities for high-throughput screening of lipid-pathway modulators and longitudinal tracking of senescence in translational contexts such as skin aging, fibrosis or wound repair.”</p>
<p>To help make that possible, the researchers are now working on a higher-speed version of their Raman imaging system. Currently, it takes about 30 hours to analyze a tissue sample about one square millimeter in size, but they hope to develop a system that can quickly pick out the Raman barcodes they identified from larger samples.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/cell-senescence-barcodes-identified-with-raman-microscopy-and-gene-expression-data/">Cell Senescence ‘Barcodes’ Identified with Raman Microscopy and Gene Expression Data</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Syngene Expands Integrated Drug Development and Manufacturing Services with BMS</title>
<link>https://edusehat.com/en/syngene-expands-integrated-drug-development-and-manufacturing-services-with-bms</link>
<guid>https://edusehat.com/en/syngene-expands-integrated-drug-development-and-manufacturing-services-with-bms</guid>
<description><![CDATA[ The collaboration between Syngene and Bristol Myers Squibb began in 1998, culminating in the establishment of the Biocon Bristol Myers Squibb Research and Development Center, Syngene&#039;s first dedicated R&amp;D Center.
The post Syngene Expands Integrated Drug Development and Manufacturing Services with BMS appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-1368058797.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 23 Sep 2026 03:50:39 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Syngene, Expands, Integrated, Drug, Development, and, Manufacturing, Services, with, BMS</media:keywords>
<content:encoded><![CDATA[<p>CRDMO Syngene International extended its long-standing strategic collaboration with Bristol Myers Squibb (BMS) through 2035. The expanded agreement broadens the scope of integrated services across the drug development lifecycle spanning discovery, translational sciences, pharmaceutical development and manufacturing, clinical trials, data and information technology services to enable seamless progression from research to commercialization, according to Syngene officials.</p>
<p>“Our collaboration with Bristol Myers Squibb, which now spans more than 25 years, is anchored in scientific excellence, operational reliability, and a shared commitment to advancing innovative therapies,” said Peter Bains, managing director and CEO of Syngene.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>“The agreement to extend this partnership through 2035 enables us to plan together for the future in terms of building new capabilities and infrastructure with a decade long horizon. Taking a long-term perspective is a key feature of our partnership which adds strategic value to both companies.”</p>
<p>“At Bristol Myers Squibb, everything we do begins with patients. We greatly value our long-standing partnership with Syngene, which has been instrumental in advancing our scientific ambitions,” added Payal Sheth, senior vice president, therapeutic discovery sciences, Bristol Myers Squibb.</p>
<p>“This expanded collaboration reflects our commitment to advancing innovative science by effective integration of our research, development, and manufacturing capabilities to accelerate the delivery of transformative medicines and bring hope to patients around the world who are waiting for new treatment options.”</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>The collaboration between Syngene and Bristol Myers Squibb began in 1998, culminating in the establishment of the Biocon Bristol Myers Squibb Research and Development Center (BBRC), Syngene’s first dedicated R&D Center, which was fully commissioned in 2009. Bains noted that the BBRC has evolved into a major strategic R&D site for Bristol Myers Squibb.</p>
<p class="trimmed"> </p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/syngene-expands-integrated-drug-development-and-manufacturing-services-with-bms/">Syngene Expands Integrated Drug Development and Manufacturing Services with BMS</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Stress Awareness Month: Why Smaller Incisions Mean Peace of Mind for Heart Patients</title>
<link>https://edusehat.com/en/stress-awareness-month-why-smaller-incisions-mean-peace-of-mind-for-heart-patients</link>
<guid>https://edusehat.com/en/stress-awareness-month-why-smaller-incisions-mean-peace-of-mind-for-heart-patients</guid>
<description><![CDATA[ The Hidden Burden of Heart Surgery Stress April marks Stress Awareness Month, a time to recognize how stress affects our health and wellbeing. For heart patients facing surgery, stress isn’t just an emotional concern but a medical one. The anxiety surrounding cardiac procedures can elevate blood pressure, interfere with sleep, delay healing, and even impact […] ]]></description>
<enclosure url="https://heartsurgeryinfo.com/wp-content/uploads/2026/03/image1-e1774886038315.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 23 Sep 2026 03:50:35 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Stress, Awareness, Month:, Why, Smaller, Incisions, Mean, Peace, Mind, for, Heart, Patients</media:keywords>
<content:encoded><![CDATA[<h2><b>The Hidden Burden of Heart Surgery Stress</b></h2>
<p><span>April marks Stress Awareness Month, a time to recognize how stress affects our health and wellbeing. For heart patients facing surgery, stress isn’t just an emotional concern but a medical one. The anxiety surrounding cardiac procedures can elevate blood pressure, interfere with sleep, delay healing, and even impact surgical outcomes.</span></p>
<p><span>What many patients don’t realize is that the type of surgery they choose can significantly influence their stress levels, not just during the procedure but throughout the entire recovery journey and beyond.</span></p>
<h2><b>The Psychology of the Incision</b></h2>
<p><span>The human mind is remarkably visual. When we think about heart surgery, many of us immediately picture a long vertical scar down the chest, a physical reminder of major trauma to the body. This mental image carries weight, literally and figuratively, influencing how we perceive the surgery before it happens and how we experience recovery afterward.</span></p>
<p><span>Minimally invasive heart surgery fundamentally changes this equation. With incisions typically measuring just a few inches and often hidden under the breast or between ribs, the psychological impact shifts dramatically. The surgery becomes less of a life-defining event and more of a medical correction, allowing patients to move forward without the constant visual reminder of major intervention.</span></p>
<h2><b>Stress Before Surgery: The Anticipation Factor</b></h2>
<p><span>The weeks leading up to heart surgery are often described by patients as the most stressful period of their lives. This pre-surgical anxiety isn’t trivial. Research shows that high stress levels before surgery can:</span></p>
<p><span>Increase the risk of complications, slow wound healing, elevate pain perception, interfere with sleep quality, weaken immune function, and raise blood pressure.</span></p>
<p><span>Patients scheduled for minimally invasive procedures consistently report lower anxiety levels than those facing traditional open-heart surgery. Why? The perceived severity of the procedure feels different. While all heart surgery is serious, knowing you won’t have your chest opened provides genuine psychological relief.</span></p>
<p><span>This reduced anticipatory stress has physiological benefits. Patients enter surgery in a calmer state, with lower cortisol levels and better-regulated cardiovascular function. They’ve spent less time catastrophizing about recovery and more time planning their return to normal life.</span></p>
<h2><b>The Hospital Stay: Where Less Trauma Means Less Stress</b></h2>
<p><span>The immediate post-operative period can be disorienting and anxiety-provoking. Pain, limited mobility, unfamiliar surroundings, and dependence on others create a perfect storm for stress. Minimally invasive approaches address many of these stressors directly.</span></p>
<h3><b>Pain and Comfort</b></h3>
<p><span>Pain is one of the most significant sources of stress after heart surgery. Traditional open-heart surgery requires cutting through the sternum, a procedure that results in substantial pain that can last for months. Every breath, movement, and cough reminds patients of their surgery.</span></p>
<p><span>Minimally invasive techniques spare the breastbone entirely. While discomfort remains, it’s dramatically reduced. Patients typically require less pain medication, experience better sleep, and can move more freely within days rather than weeks. This physical comfort translates directly to emotional well-being.</span></p>
<h3><b>Mobility and Independence</b></h3>
<p><span>Being unable to perform basic self-care tasks is deeply stressful for most people. Traditional heart surgery comes with extensive restrictions: no lifting, limited arm movement, difficulty getting in and out of bed, and complete dependence on others for basic needs.</span></p>
<p><span>With smaller incisions and no sternal precautions, minimally invasive patients regain independence much faster. They can typically perform basic self-care within days, reducing the psychological burden of helplessness. This faster return to autonomy is consistently cited by patients as one of the most stress-relieving aspects of their recovery.</span></p>
<h3><b>The Hospital Environment</b></h3>
<p><span>Hospital stays are inherently stressful. The desire to return home, to familiar surroundings and loved ones, is universal. Minimally invasive heart surgery typically reduces hospital stays from a week or more to just a few days. This shortened exposure to the hospital environment means less disruption to sleep patterns, reduced risk of hospital-acquired infections, and faster return to normal routines.</span></p>
<h2><b>Recovery at Home: The Long Game of Stress Reduction</b></h2>
<p><span>The real stress of heart surgery often emerges during home recovery. This is when the full impact of the procedure becomes clear, when patients confront the reality of healing and the slow return to normal life.</span></p>
<h3><b>Physical Limitations and Daily Life</b></h3>
<p><span>Traditional heart surgery imposes months of significant restrictions. No driving for weeks, no lifting anything over a few pounds, no reaching overhead, careful attention to how you get out of bed or up from a chair. Every movement requires thought and caution.</span></p>
<p><span>These limitations affect every aspect of life. Parents can’t lift their children. Professionals struggle to return to work. Hobbies and exercise routines disappear. The cumulative stress of these restrictions weighs heavily on mental health.</span></p>
<p><span>Minimally invasive patients face far fewer limitations. Many can drive within two weeks, return to light activities quickly, and resume normal routines within a month. This faster return to normalcy prevents the depression and anxiety that often accompany prolonged disability.</span></p>
<h3><b>The Mirror Effect</b></h3>
<p><span>Looking at your incision site matters more than many people realize. A large chest scar is an unavoidable daily reminder of major surgery, vulnerability, and changed health status. For some patients, this becomes a source of ongoing stress, affecting body image, intimacy, and self-perception.</span></p>
<p><span>Smaller incisions, especially those hidden under clothing or in the natural folds of skin, minimize this visual reminder. Patients report feeling more “like themselves” sooner, with less self-consciousness about their appearance. This might seem superficial, but psychological research confirms that body image directly impacts mental health and recovery outcomes.</span></p>
<h2><b>The Caregiver Stress Factor</b></h2>
<p><span>Heart surgery doesn’t just stress patients; it profoundly impacts families. Caregivers face their own anxiety about their loved one’s surgery and recovery. The demands of post-surgical care, assistance with basic needs, medication management, and emotional support can overwhelm family members.</span></p>
<p><span>Minimally invasive surgery reduces caregiver burden significantly. With shorter hospital stays, less pain, faster mobility, and fewer complications, caregivers face less intensive and shorter duration care responsibilities. This benefits the entire family system, reducing household stress and allowing everyone to return to normal life sooner.</span></p>
<p><span>Spouses report sleeping better when their partner has less pain and can move independently. Children feel less frightened when recovery is faster and parents are less visibly impaired. The ripple effects of reduced surgical trauma extend throughout the family.</span></p>
<h2><b>The Return to Work and Life</b></h2>
<p><span>Financial stress is a significant but often unspoken aspect of heart surgery recovery. Extended time away from work, disability concerns, and uncertainty about returning to full function create genuine anxiety.</span></p>
<p><span>Patients who undergo minimally invasive procedures typically return to work weeks or even months earlier than those who have traditional surgery. For many, this reduces financial pressure and the stress of lost productivity. It also provides psychological benefits: work gives structure to days, social connection, and a sense of normalcy and purpose.</span></p>
<p><span>The ability to resume exercise, hobbies, travel, and other valued activities also happens much faster. These activities aren’t luxuries; they’re essential for mental health. When recovery is shorter, the disruption to meaningful life activities is minimized.</span></p>
<h2><b>The Long-Term Psychological Outcome</b></h2>
<p><span>Years after surgery, the psychological differences between traditional and minimally invasive approaches remain evident. Patients with smaller incisions report:</span></p>
<p><span>Less trauma-related anxiety about their cardiac history, greater willingness to address future health concerns, better overall quality of life scores, reduced health-related anxiety, and more positive memories of their surgical experience.</span></p>
<p><span>This isn’t about denying the seriousness of heart disease. Rather, it’s about minimizing the additional psychological burden that surgery itself imposes. When the intervention is less traumatic, patients can focus on managing their cardiac health rather than recovering from the cure.</span></p>
<h2><b>Stress and Heart Health: The Bidirectional Relationship</b></h2>
<p><span>There’s deep irony in the fact that stress itself is bad for heart health. Chronic stress contributes to hypertension, inflammation, and cardiovascular disease. Yet traditional heart surgery, while addressing structural heart problems, imposes its own significant stress on patients.</span></p>
<p><span>Minimally invasive approaches break this cycle. By reducing surgical stress, these techniques may actually improve long-term cardiovascular outcomes beyond the direct surgical repair. Lower stress means better blood pressure control, less inflammation, better medication adherence, and more engagement with cardiac rehabilitation.</span></p>
<p><span>Understanding this relationship between stress and heart health is crucial for long-term wellness. Your heart rate, blood pressure response to stress, and overall cardiovascular resilience are all interconnected. When surgical trauma is minimized, your body can focus its healing energy where it matters most.</span></p>
<h2><b>Making the Choice That’s Right for Your Peace of Mind</b></h2>
<p><span>Not every patient is a candidate for minimally invasive heart surgery, but many more are eligible than realize it. If you’re facing a cardiac procedure, understanding your options isn’t just about physical outcomes but about your emotional and psychological wellbeing through the entire journey.</span></p>
<p><span>Ask your surgical team about minimally invasive possibilities. Understand how different approaches might affect your recovery experience, your stress levels, and your return to the life you value. The right choice considers not just surgical success rates but your whole-person wellbeing.</span></p>
<h2><b>Take Control of Your Surgical Journey</b></h2>
<p><span>This Stress Awareness Month, recognize that you have more control over your surgical experience than you might think. Choosing a less invasive approach, when possible, isn’t about taking the easy way out; it’s about being smart about minimizing unnecessary stress on your body and mind.</span></p>
<p><span>Your heart health matters, but so does your peace of mind. A successful surgery is one that not only fixes the problem but also allows you to move forward with confidence, minimal disruption, and the ability to focus on living rather than recovering.</span></p>
<h2><b>Begin Your Journey to Less Stressful Heart Surgery</b></h2>
<p><span>Ready to explore whether minimally invasive heart surgery could reduce your surgical stress? When you choose to work with specialists who have dedicated their careers to perfecting these advanced techniques, you’re choosing expertise that comes from years of focused practice. This level of commitment to bloodless and minimally invasive approaches means you benefit from refined skills, innovative solutions, and a deep understanding of how to achieve the best outcomes with the least trauma to your body.</span></p>
<p><span>Schedule a consultation to discuss your options, assess your candidacy, and make an informed decision about the approach that’s right for your body, mind, and life. Learn more about how your heart responds to stress and what that means for your overall cardiovascular health.</span></p>
<p><span>Your path to better heart health doesn’t have to be as stressful as you might fear. Discover how the right surgical approach can make all the difference. </span><a href="https://heartsurgeryinfo.com/contact-us/"><span>Contact our office</span></a><span> today to begin your journey toward peace of mind and a healthier heart.</span></p>]]> </content:encoded>
</item>

<item>
<title>The Heart Tumor No One Talks About: Atrial Myxoma Symptoms You Might Miss</title>
<link>https://edusehat.com/en/the-heart-tumor-no-one-talks-about-atrial-myxoma-symptoms-you-might-miss</link>
<guid>https://edusehat.com/en/the-heart-tumor-no-one-talks-about-atrial-myxoma-symptoms-you-might-miss</guid>
<description><![CDATA[ When most people think about heart problems, they picture blocked arteries or irregular rhythms. But there’s a lesser-known cardiac condition that can cause serious complications yet often goes undiagnosed for months or even years: atrial myxoma. This rare heart tumor accounts for approximately 50% of all primary cardiac tumors, yet many people have never heard […] ]]></description>
<enclosure url="https://heartsurgeryinfo.com/wp-content/uploads/2026/04/image1-e1777399720962.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 23 Sep 2026 03:50:32 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, Heart, Tumor, One, Talks, About:, Atrial, Myxoma, Symptoms, You, Might, Miss</media:keywords>
<content:encoded><![CDATA[<p><span>When most people think about heart problems, they picture blocked arteries or irregular rhythms. But there’s a lesser-known cardiac condition that can cause serious complications yet often goes undiagnosed for months or even years: atrial myxoma.</span></p>
<p><span>This rare heart tumor accounts for approximately 50% of all primary cardiac tumors, yet many people have never heard of it. Even more concerning, its symptoms can easily be mistaken for other common conditions, leading to delayed diagnosis and treatment. Understanding what atrial myxoma is and recognizing its subtle warning signs could be lifesaving.</span></p>
<h2><b>What Is Atrial Myxoma?</b></h2>
<p><span>Atrial myxoma is a benign (non-cancerous) tumor that develops inside the heart, most commonly in the left atrium. While the word “tumor” can be frightening, it’s important to understand that these growths are typically not malignant. However, “benign” doesn’t mean harmless.</span></p>
<p><span>These gelatinous masses attach to the heart’s inner wall, usually near the septum (the wall dividing the heart’s chambers). They can grow quite large, sometimes reaching the size of a golf ball or even larger. As they grow, they can interfere with blood flow through the heart and may break apart, sending fragments into the bloodstream.</span></p>
<p><a href="https://heartsurgeryinfo.com/atrial-myxoma-surgery/"><span>Atrial myxomas</span></a><span> can occur at any age but are most commonly diagnosed in adults between 30 and 60 years old. Women are slightly more likely to develop them than men. While most cases occur sporadically, about 10% are familial, meaning they run in families as part of a genetic syndrome.</span></p>
<h2><b>The Mimicry Problem: Why Atrial Myxoma Is So Easily Missed</b></h2>
<p><span>The biggest challenge with atrial myxoma is that its symptoms mimic many other, more common conditions. Patients and even physicians might initially attribute these signs to other health issues, delaying the correct diagnosis.</span></p>
<h3><b>Symptoms That Look Like Other Conditions</b></h3>
<p><b>Fatigue and Weakness</b></p>
<p><span>One of the most common symptoms of atrial myxoma is persistent fatigue that doesn’t improve with rest. Many patients dismiss this as stress, aging, or simply being out of shape. When you have a tumor obstructing blood flow through your heart, your body isn’t getting the oxygen-rich blood it needs, leading to that constant tired feeling.</span></p>
<p><b>Shortness of Breath</b></p>
<p><span>Difficulty breathing, especially during physical activity or when lying flat, is another hallmark symptom. This often gets mistaken for asthma, anxiety, or simply being out of condition. But when a myxoma blocks the mitral valve (the valve between the left atrium and left ventricle), it prevents blood from flowing efficiently through the heart, causing fluid to back up into the lungs.</span></p>
<p><b>Dizziness and Fainting</b></p>
<p><span>Sudden episodes of lightheadedness or fainting, particularly when changing positions, can occur when the tumor shifts and temporarily blocks blood flow. These symptoms are often attributed to low blood pressure, dehydration, or inner ear problems, when in reality, they could indicate a tumor moving within the heart.</span></p>
<p><b>Fever and Weight Loss</b></p>
<p><span>Some patients with atrial myxoma experience unexplained fever and weight loss, symptoms that might prompt an investigation for infection or cancer elsewhere in the body. The tumor can trigger an immune response, causing these constitutional symptoms that lead doctors down the wrong diagnostic path.</span></p>
<p><b>Heart Palpitations</b></p>
<p><span>An irregular or racing heartbeat is common with atrial myxoma, as the tumor can irritate the heart muscle and disrupt its normal electrical signals. This symptom alone might lead to a diagnosis of atrial fibrillation or another arrhythmia, without investigating the underlying cause.</span></p>
<h2><b>The Dangerous Complications You Need to Know About</b></h2>
<p><span>Beyond the symptoms themselves, atrial myxoma poses several serious risks:</span></p>
<p><b>Stroke Risk</b></p>
<p><span>Pieces of the tumor can break off and travel through the bloodstream to the brain, causing a stroke. In fact, stroke is sometimes the first sign that prompts doctors to discover an atrial myxoma. Young patients who experience a stroke without typical risk factors should always be evaluated for cardiac sources, including tumors.</span></p>
<p><b>Heart Valve Damage</b></p>
<p><span>As the tumor moves with each heartbeat, it can damage the heart valves, particularly the mitral valve. Over time, this can lead to valve dysfunction that requires additional surgical intervention beyond just removing the tumor.</span></p>
<p><b>Heart Failure</b></p>
<p><span>When the tumor grows large enough or is positioned in a way that significantly obstructs blood flow, it can lead to heart failure. The heart has to work much harder to pump blood around the obstruction, which can weaken the muscle over time.</span></p>
<p><b>Sudden Cardiac Death</b></p>
<p><span>In rare cases, the tumor can completely block blood flow through the heart, causing sudden death. This is why prompt diagnosis and treatment are so critical.</span></p>
<h2><b>How Is Atrial Myxoma Diagnosed?</b></h2>
<p><span>If your doctor suspects an atrial myxoma based on your symptoms and physical examination (they might hear an unusual heart sound called a “tumor plop”), several diagnostic tests can confirm it:</span></p>
<p><b>Echocardiography</b><span> is usually the first test ordered. This ultrasound of the heart can clearly show the tumor, its location, size, and how it’s affecting blood flow. A transesophageal echocardiogram (TEE), where the ultrasound probe is passed down the esophagus for a closer view, provides even more detailed images.</span></p>
<p><b>Cardiac MRI or CT scan</b><span> may be used to get additional information about the tumor’s characteristics and to help plan surgical removal.</span></p>
<p><b>Blood tests</b><span> might show elevated inflammatory markers or anemia, which can support the diagnosis alongside imaging findings.</span></p>
<h2><b>Treatment: Why Surgery Is the Only Option</b></h2>
<p><span>Unlike many heart conditions that can be managed with medications, atrial myxoma requires surgical removal. The good news is that surgery is usually curative, with excellent long-term outcomes when performed before complications occur.</span></p>
<p><span>The surgery is performed using minimally invasive or bloodless techniques, where possible, depending on the tumor’s size and location. The surgeon removes the entire tumor along with a portion of the heart wall where it was attached to prevent recurrence. Most patients recover well and can return to normal activities within weeks to months.</span></p>
<p><span>The recurrence rate after complete surgical removal is low, typically less than 5% for sporadic cases. However, patients with familial myxoma syndromes may be at higher risk for recurrence and often need ongoing cardiac surveillance.</span></p>
<h2><b>When Should You Be Concerned?</b></h2>
<p><span>You should talk to your doctor if you experience:</span></p>
<ul>
<li aria-level="1"><span>Unexplained shortness of breath that’s getting worse</span></li>
<li aria-level="1"><span>Persistent fatigue that doesn’t improve with rest</span></li>
<li aria-level="1"><span>Fainting episodes, especially when changing positions</span></li>
<li aria-level="1"><span>New or unusual heart palpitations</span></li>
<li aria-level="1"><span>Unexplained fever with joint pain or rash</span></li>
<li aria-level="1"><span>Any combination of these symptoms</span></li>
</ul>
<p><span>While atrial myxoma is rare, early detection makes all the difference. If you have a family history of cardiac tumors or have been experiencing puzzling symptoms that haven’t been adequately explained, advocating for comprehensive cardiac imaging could be crucial.</span></p>
<h2><b>Don’t Ignore What Your Body Is Telling You</b></h2>
<p><span>Atrial myxoma remains under-recognized despite being the most common primary heart tumor. Its chameleon-like symptoms make it easy to overlook, but the consequences of delayed diagnosis can be severe. If you’re experiencing unexplained cardiac symptoms, particularly a combination of fatigue, breathing difficulties, and dizziness, don’t accept vague explanations. Push for a thorough evaluation.</span></p>
<p><span>Your heart deserves expert attention. Our team of cardiovascular specialists has extensive experience in diagnosing and treating even the most complex cardiac conditions, including rare tumors like atrial myxoma. We utilize the latest diagnostic technology and surgical techniques to provide the highest level of care.</span></p>
<p><span>Ready to get answers about your cardiac symptoms? </span><a href="https://heartsurgeryinfo.com/contact-us/"><span>Schedule your appointment today</span></a><span> and take the first step toward peace of mind and better heart health.</span></p>
<p><span>Our dedicated team combines decades of experience with a commitment to personalized, compassionate care. We believe in taking the time to listen to your concerns, thoroughly investigating your symptoms, and developing a treatment plan tailored specifically to your needs. Your heart health is too important to leave to chance.</span></p>]]> </content:encoded>
</item>

<item>
<title>Simple Kidney Cyst vs. Complex Cyst: Why the Radiologist’s Word Choice Matters</title>
<link>https://edusehat.com/en/simple-kidney-cyst-vs-complex-cyst-why-the-radiologists-word-choice-matters</link>
<guid>https://edusehat.com/en/simple-kidney-cyst-vs-complex-cyst-why-the-radiologists-word-choice-matters</guid>
<description><![CDATA[ You’ve just had an imaging study for an unrelated issue, and buried in the report is a sentence about a “cyst” on your kidney. Your doctor says not to worry, but you’re left wondering: what exactly did they find, and should you be concerned? The truth is, not all kidney cysts are created equal. The […] ]]></description>
<enclosure url="https://heartsurgeryinfo.com/wp-content/uploads/2026/04/image2-e1777400270772.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 23 Sep 2026 03:50:29 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Simple, Kidney, Cyst, vs., Complex, Cyst:, Why, the, Radiologist’s, Word, Choice, Matters</media:keywords>
<content:encoded><![CDATA[<p><span>You’ve just had an imaging study for an unrelated issue, and buried in the report is a sentence about a “cyst” on your kidney. Your doctor says not to worry, but you’re left wondering: what exactly did they find, and should you be concerned?</span></p>
<p><span>The truth is, not all kidney cysts are created equal. The distinction between a “simple” and “complex” cyst isn’t just medical jargon. It’s a critical difference that determines whether you need routine monitoring, further investigation, or immediate intervention. Understanding what these terms mean can help you ask the right questions and ensure you’re getting appropriate follow-up care.</span></p>
<h2><b>Kidney Cysts Are More Common Than You Think</b></h2>
<p><span>First, let’s put your mind at ease: kidney cysts are incredibly common, especially as we age. Studies show that more than 25% of people over age 50 have at least one kidney cyst, and that number increases with each passing decade. Many people live their entire lives without knowing they have them because most cysts cause no symptoms and are discovered incidentally during imaging for other reasons.</span></p>
<p><span>A kidney cyst is a round or oval fluid-filled sac that develops within the kidney tissue. Think of it like a small water balloon nestled in your kidney. Most are benign and require no treatment, but the radiologist’s description of your cyst tells your doctor everything they need to know about the next steps.</span></p>
<h2><b>Simple Kidney Cysts: The “Don’t Worry” Category</b></h2>
<p><span>When a radiologist describes a cyst as “simple,” this is actually excellent news. Simple kidney cysts are the most common type and are almost always benign (non-cancerous). They have very specific characteristics that radiologists look for on imaging studies.</span></p>
<h3><b>What Makes a Cyst “Simple”?</b></h3>
<p><span>To qualify as a simple cyst, it must meet strict criteria:</span></p>
<p><b>Thin, Smooth Walls</b></p>
<p><span>The cyst has a very thin wall (often barely visible on imaging) that is perfectly smooth with no irregularities, bumps, or thickening. This uniformity is reassuring because cancerous growths typically have irregular, thickened walls.</span></p>
<p><b>Homogeneous Fluid Content</b></p>
<p><span>The entire cyst is filled with clear fluid that looks the same throughout, like water. There are no solid components, debris, blood products, or separations (called septations) inside.</span></p>
<p><b>Round or Oval Shape</b></p>
<p><span>Simple cysts are well-defined and perfectly round or oval, like a bubble. They have sharp, distinct borders that are easy to identify.</span></p>
<p><b>No Enhancement with Contrast</b></p>
<p><span>When contrast dye is given during a CT or MRI scan, simple cysts don’t “light up” or enhance. This is crucial because tissues that have blood supply (like tumors) will enhance with contrast, while fluid-filled cysts will not.</span></p>
<p><b>No Calcium Deposits</b></p>
<p><span>There are no calcifications (calcium deposits) in the wall or within the cyst itself.</span></p>
<p><span>If your cyst meets all these criteria, it’s classified as a Bosniak Category I cyst, the lowest risk category. These cysts have essentially zero risk of being cancerous and typically require no follow-up imaging. Your doctor will likely tell you to forget about it.</span></p>
<h3><b>Do Simple Cysts Cause Symptoms?</b></h3>
<p><span>Most simple cysts cause no symptoms at all. However, if a simple cyst grows very large (more than 4-5 centimeters), it can occasionally cause:</span></p>
<ul>
<li aria-level="1"><span>Dull ache or pain in your side or back</span></li>
<li aria-level="1"><span>Feeling of fullness in your abdomen</span></li>
<li aria-level="1"><span>High blood pressure (in rare cases)</span></li>
<li aria-level="1"><span>Blood in your urine (if the cyst ruptures or bleeds, though this is uncommon)</span></li>
</ul>
<p><span>Even when simple cysts do cause symptoms, treatment is usually conservative. Most doctors will only recommend intervention if symptoms are significantly affecting your quality of life.</span></p>
<h2><b>Complex Kidney Cysts: Why Your Doctor Pays Attention</b></h2>
<p><span>This is where the radiologist’s word choice becomes critical. When a cyst is described as “complex,” it means it has features that deviate from the simple cyst criteria. Complex cysts exist on a spectrum from “slightly more complicated than simple but still benign” to “suspicious for cancer and requiring surgery.”</span></p>
<h3><b>The Bosniak Classification System</b></h3>
<p><span>Radiologists use the Bosniak classification system to categorize complex cysts based on their appearance and risk of malignancy. Understanding this system helps you grasp why your doctor may recommend different approaches:</span></p>
<p><b>Bosniak Category II: Minimally Complex</b></p>
<p><span>These cysts have minor deviations from simple cysts but are still very likely benign (less than 5% risk of cancer). They might have a few thin septations (internal walls), minimal calcification, or be slightly larger than typical simple cysts. These usually don’t require treatment but may warrant a single follow-up imaging study to ensure stability.</span></p>
<p><b>Bosniak Category IIF: Follow Closely</b></p>
<p><span>The “F” stands for “follow.” These cysts have more complex features like multiple thin septations, minimal wall thickening, or small calcifications. While still probably benign, they carry a 5-10% risk of malignancy. Your doctor will typically recommend imaging surveillance every 6-12 months initially, then annually if the cyst remains stable.</span></p>
<p><b>Bosniak Category III: Indeterminate</b></p>
<p><span>Now we’re in the gray zone. These cysts have thickened or irregular walls, larger areas of calcification, or enhancement with contrast dye. The risk of malignancy jumps to 40-60%. Because of this significant cancer risk, most urologists recommend surgical removal rather than continued observation.</span></p>
<p><b>Bosniak Category IV: Highly Suspicious</b></p>
<p><span>These cysts have clearly abnormal features such as solid components, extensive irregular enhancement, or obvious soft tissue involvement. The cancer risk exceeds 85-100%. Surgical removal is almost always recommended.</span></p>
<h2><b>Why These Distinctions Matter for Your Health</b></h2>
<p><span>The difference between simple and complex isn’t academic. It directly impacts your care plan:</span></p>
<p><b>Surveillance vs. Intervention</b></p>
<p><span>A simple cyst means you can move on with your life. A Bosniak IIF cyst means you’ll need regular imaging studies for several years. A Bosniak III or IV cyst likely means surgery is in your future. Getting the classification right ensures you’re neither over-treated (unnecessary surgery for a benign cyst) nor under-treated (missing a cancer that should be removed).</span></p>
<p><b>Peace of Mind</b></p>
<p><span>Understanding your specific type of cyst helps reduce anxiety. If you have a simple cyst or Bosniak II, you can genuinely stop worrying. If you have a higher category, understanding the risk helps you make informed decisions about your care.</span></p>
<p><b>Timing of Treatment</b></p>
<p><span>With complex cysts, timing matters. Bosniak III and IV cysts should be evaluated by a urologist relatively quickly. Delaying evaluation could mean missing a window for easier surgical intervention if the cyst is cancerous.</span></p>
<h2><b>What Happens During Surveillance?</b></h2>
<p><span>If you have a complex cyst that requires monitoring, here’s what to expect:</span></p>
<p><b>Initial Imaging</b></p>
<p><span>Your doctor will likely order a CT scan or MRI with contrast to better characterize the cyst. These provide more detail than an ultrasound or basic CT scan.</span></p>
<p><b>Follow-Up Schedule</b></p>
<p><span>The timing depends on your cyst category. Bosniak IIF cysts typically get reimaged at 6 months, then annually for 5 years if stable. Higher risk cysts may need more frequent monitoring.</span></p>
<p><b>What We’re Looking For</b></p>
<p><span>During surveillance, radiologists compare each new scan to previous ones, looking for any changes in size, internal characteristics, or enhancement pattern. Stability over time is reassuring; any growth or changing features prompts reassessment.</span></p>
<h2><b>When Surgery Becomes Necessary</b></h2>
<p><span>For Bosniak III and IV cysts, surgical removal is usually recommended. The good news is that many of these procedures can now be performed using minimally invasive techniques.</span></p>
<p><b>Partial Nephrectomy</b></p>
<p><span>This surgery removes the cyst and a small margin of surrounding kidney tissue while preserving the rest of the kidney. It’s the preferred approach when feasible, especially for smaller cysts in accessible locations.</span></p>
<p><b>Radical Nephrectomy</b></p>
<p><span>In cases where the cyst is very large, centrally located, or if there are multiple concerning cysts, removing the entire kidney may be necessary. Fortunately, most people function perfectly well with one healthy kidney.</span></p>
<p><span>Many of these surgeries can be performed using robotic or laparoscopic techniques, which means smaller incisions, less pain, shorter hospital stays, and faster recovery compared to traditional open surgery.</span></p>
<h2><b>Questions to Ask Your Doctor</b></h2>
<p><span>When you receive a report mentioning a kidney cyst, here are essential questions to ask:</span></p>
<ul>
<li aria-level="1"><span>What is the Bosniak classification of my cyst?</span></li>
<li aria-level="1"><span>Do I need any follow-up imaging, and if so, when?</span></li>
<li aria-level="1"><span>Are there any symptoms I should watch for?</span></li>
<li aria-level="1"><span>At what point would we consider treatment?</span></li>
<li aria-level="1"><span>Should I see a urologist or kidney specialist?</span></li>
</ul>
<p><span>Don’t hesitate to request a copy of your imaging report. The radiologist’s detailed description contains valuable information about your specific situation.</span></p>
<h2><b>The Bottom Line</b></h2>
<p><span>The difference between simple and complex kidney cysts isn’t just semantics. It’s the difference between “forget about it” and “let’s keep a close eye on this,” or even “we need to take action.” Simple cysts are incredibly common, harmless, and require no treatment. Complex cysts require individualized assessment based on their specific features and risk category.</span></p>
<p><span>If you’ve been told you have a kidney cyst, make sure you understand which type you have and what follow-up, if any, is recommended. The right diagnosis leads to the right care plan, giving you either the peace of mind to move forward or the timely intervention you need.</span></p>
<p><span>Concerned about a kidney cyst finding? Our experienced team specializes in the evaluation and treatment of kidney conditions, using the most advanced imaging and minimally invasive surgical techniques available. </span><a href="https://heartsurgeryinfo.com/contact-us/"><span>Schedule your consultation</span></a><span> today to get expert guidance tailored to your specific situation.</span></p>
<p><span>Our specialists take the time to thoroughly review your imaging, explain your diagnosis in terms you can understand, and work with you to develop a personalized care plan. Whether you need reassurance, surveillance, or treatment, we’re here to provide the expert care you deserve.</span></p>]]> </content:encoded>
</item>

<item>
<title>Wedding Season and Heart Surgery: Why the Timing Doesn’t Have to Be Either/Or</title>
<link>https://edusehat.com/en/wedding-season-and-heart-surgery-why-the-timing-doesnt-have-to-be-eitheror</link>
<guid>https://edusehat.com/en/wedding-season-and-heart-surgery-why-the-timing-doesnt-have-to-be-eitheror</guid>
<description><![CDATA[ When your cardiologist recommends heart surgery, it often feels like life comes to a screeching halt. For many patients, especially those planning major life events like weddings, the diagnosis can feel like a cruel choice: your health or your celebration. But what if you didn’t have to choose? Thanks to advances in minimally invasive and […] ]]></description>
<enclosure url="https://heartsurgeryinfo.com/wp-content/uploads/2026/05/image1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 23 Sep 2026 03:50:26 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Wedding, Season, and, Heart, Surgery:, Why, the, Timing, Doesn’t, Have, EitherOr</media:keywords>
<content:encoded><![CDATA[<p><span>When your cardiologist recommends </span><a href="https://heartsurgeryinfo.com/mental-preparation-for-heart-surgery-reducing-anxiety-and-stress/"><span>heart surgery</span></a><span>, it often feels like life comes to a screeching halt. For many patients, especially those planning major life events like weddings, the diagnosis can feel like a cruel choice: your health or your celebration. But what if you didn’t have to choose?</span></p>
<p><span>Thanks to advances in minimally invasive and bloodless heart surgery techniques, the recovery timeline that once meant months of cancelled plans and missed milestones has been dramatically shortened. For those facing heart surgery during engagement season, wedding planning, or even just weeks before walking down the aisle, understanding these modern approaches can mean the difference between postponing joy and celebrating on schedule.</span></p>
<h2><b>The Traditional Heart Surgery Timeline: Why It Conflicted with Life</b></h2>
<p><span>Traditional open-heart surgery, while life-saving, has always demanded significant sacrifice. The standard approach involves sawing through the breastbone (sternotomy), spreading the ribs, and requiring eight to twelve weeks of recovery before patients can return to normal activities.</span></p>
<p><span>For someone planning a wedding, this timeline creates impossible choices. The traditional restrictions include no lifting anything heavier than five to ten pounds for at least six weeks, no driving for four to six weeks, limited </span><a href="https://heartsurgeryinfo.com/?s=physical+activity"><span>physical activity</span></a><span> and exercise, restrictions on travel, and significant fatigue that can last for months.</span></p>
<p><span>Imagine being told you need heart surgery three months before your wedding day. With traditional surgery, you would barely be cleared for light activity by the time you’re supposed to be handling the physical and emotional demands of your big day. Many patients in this situation face two equally heartbreaking options: postpone the wedding indefinitely or delay necessary medical treatment and risk their health deteriorating further.</span></p>
<h2><b>How Minimally Invasive Heart Surgery Changes the Timeline</b></h2>
<p><span>Minimally invasive heart surgery represents a fundamental shift in how cardiac procedures are performed. Instead of the large incision and bone-cutting required in traditional approaches, surgeons make small incisions between the ribs, typically just two to four inches long.</span></p>
<p><span>The benefits of this approach extend far beyond aesthetics. Because the breastbone remains intact, patients experience significantly less trauma, reduced pain, and faster healing. The recovery timeline shrinks from months to weeks, and in many cases, patients report feeling like themselves again in just a fraction of the time required by traditional surgery.</span></p>
<p><span>For heart valve repairs and replacements, coronary artery bypass surgery, atrial septal defect repairs, and certain types of tumor removal, minimally invasive techniques can deliver the same life-saving results with dramatically less disruption to your life and plans.</span></p>
<h2><b>Bloodless Heart Surgery: An Additional Advantage for Faster Recovery</b></h2>
<p><span>Bloodless heart surgery takes the benefits of minimally invasive techniques even further. This approach eliminates or drastically reduces the need for blood transfusions during surgery, which can significantly impact recovery speed and quality.</span></p>
<p><span>Blood transfusions, while sometimes necessary, can introduce complications. They may suppress the immune system temporarily, increase the risk of infection, and prolong hospital stays. For patients who refuse transfusions for religious reasons, have rare blood types, or simply want to avoid potential transfusion-related complications, bloodless techniques offer a powerful alternative.</span></p>
<p><span>The combination of minimally invasive and bloodless approaches creates an ideal scenario for patients who need surgery but cannot afford months of recovery time. These techniques work together to minimize trauma, reduce complications, optimize healing, and accelerate the return to normal activities.</span></p>
<h2><b>Real Recovery Timelines for Wedding-Season Surgery</b></h2>
<p><span>Let’s get specific about what recovery actually looks like with modern minimally invasive and bloodless heart surgery techniques, because the numbers might surprise you.</span></p>
<p><span>Most patients undergoing minimally invasive heart surgery spend just two to four days in the hospital, compared to five to seven days for traditional surgery. Many patients report feeling well enough to handle light activities within one to two weeks. By three to four weeks post-surgery, most patients have returned to the majority of their daily routines.</span></p>
<p><span>The six-week mark, which represents barely-cleared-for-basics with traditional surgery, often represents full or near-full recovery with minimally invasive approaches. Patients at this point are typically cleared for exercise, travel, and physically demanding activities.</span></p>
<p><span>This accelerated timeline means that heart surgery scheduled three months before a wedding no longer guarantees missing the big day. In many cases, patients are not only present but feeling genuinely well enough to enjoy the celebration.</span></p>
<h2><b>Strategic Timing: When to Schedule Surgery Around Your Wedding</b></h2>
<p><span>If you’re facing heart surgery and have a wedding on the calendar, whether you’re the couple or a guest with an important role, strategic timing matters enormously.</span></p>
<p><span>The ideal scenario involves scheduling surgery as early as possible. If you can plan surgery three to four months before the wedding, you will have ample recovery time even with conservative estimates. You can participate fully in planning and preparation, and you’ll likely feel completely back to normal by the celebration.</span></p>
<p><span>If time is tighter, a two to three month window before the wedding still works well for many patients with minimally invasive procedures. You should be well-recovered for the event itself, though you might need to delegate some physical setup tasks in the final weeks before the wedding.</span></p>
<p><span>Even with just four to eight weeks before the wedding, many patients successfully undergo minimally invasive surgery and attend their celebrations. However, this timeline requires realistic expectations about energy levels and the need for help with wedding tasks.</span></p>
<p><span>What about surgery after the wedding? While postponing necessary cardiac care is never ideal, if your surgery can safely wait and you’re just a few weeks out from your celebration, completing the event first and scheduling surgery immediately afterward might be the pragmatic choice. Always consult your cardiologist about whether delay poses significant risks.</span></p>
<h2><b>What You Can Realistically Do at Different Recovery Milestones</b></h2>
<p><span>Understanding what you’ll actually be capable of at various points in recovery helps set realistic expectations and make informed decisions about timing.</span></p>
<p><span>At two weeks post-surgery with minimally invasive techniques, most patients can attend events as a guest with minimal physical demands. They can handle light walking and standing, participate in conversations and socializing, and pose for photos, though they will likely need frequent rest breaks and should avoid lifting or strenuous activity.</span></p>
<p><span>By four weeks post-surgery, capabilities expand significantly. Patients can typically attend rehearsal dinners and ceremonies, participate in wedding party activities with modifications, handle light dancing and celebration, travel short to moderate distances, and manage most wedding-day logistics, though they should still avoid heavy lifting and extremely long days without rest.</span></p>
<p><span>At six to eight weeks post-surgery, most minimally invasive patients report near-complete recovery. They can fully participate in all wedding activities, dance and celebrate without significant restrictions, travel for destination weddings, lift moderate weights, and feel confident in their stamina throughout a full day of events.</span></p>
<p><span>These timelines assume uncomplicated recovery and vary by individual health factors, but they represent realistic expectations for minimally invasive and bloodless approaches.</span></p>
<h2><b>Making the Decision: Health Cannot Wait, But Life Doesn’t Have to Stop</b></h2>
<p><span>The most important message for anyone facing this decision is this: your heart surgery should not be postponed if your cardiologist recommends prompt treatment. Delaying necessary cardiac care can lead to worsening symptoms, increased surgical risk, emergency situations that eliminate choice in timing and approach, and potentially permanent heart damage.</span></p>
<p><span>However, understanding that modern surgical techniques can dramatically shorten recovery time means you may not have to choose between your health and your celebration.</span></p>
<p><span>The conversation with your cardiac surgeon should include specific questions. Ask about your candidacy for minimally invasive approaches, realistic recovery timelines for your specific procedure and health status, strategies to optimize healing speed, and restrictions or limitations during your recovery period.</span></p>
<p><span>Be honest about your upcoming wedding and why the timing matters to you. Experienced surgeons who perform minimally invasive and bloodless procedures understand that life doesn’t stop for medical treatment, and they can help you develop a realistic plan that prioritizes your health while respecting your life goals.</span></p>
<h2><b>Beyond Weddings: Other Life Events That Benefit from Faster Recovery</b></h2>
<p><span>While weddings represent one major life event that patients worry about missing, the advantages of minimally invasive and bloodless heart surgery extend to countless other situations. Graduations, family reunions, milestone birthdays, planned vacations and travel, returning to work and career obligations, and caring for young children or elderly parents all benefit from </span><a href="https://heartsurgeryinfo.com/shorter-recovery-times-with-minimally-invasive-heart-surgery-techniques/"><span>shortened recovery times</span></a><span>.</span></p>
<p><span>The broader point is this: modern heart surgery techniques recognize that patients are whole people with lives, responsibilities, and dreams that extend far beyond the operating room. The goal is not just to repair your heart but to return you to your life as quickly and completely as possible.</span></p>
<h2><b>The Bottom Line</b></h2>
<p><span>Wedding season and heart surgery do not have to be mutually exclusive. Thanks to minimally invasive and bloodless heart surgery techniques, the recovery timeline that once meant missing months of your life has been compressed to weeks for many patients.</span></p>
<p><span>If you are facing heart surgery and have a wedding or other major life event on your calendar, do not assume you must choose between your health and your celebration. Instead, seek out surgeons who specialize in minimally invasive and bloodless approaches, ask specific questions about recovery timelines for your situation, and work with your surgical team to develop a plan that prioritizes your cardiac health while respecting the life events that matter to you.</span></p>
<p><span>Your heart surgery is not the end of your plans. With the right surgical approach and realistic expectations, it can simply be a brief pause before you return to celebrating all of life’s most important moments.</span></p>
<p><span>Ready to explore your options?</span><a href="https://heartsurgeryinfo.com/contact-us/"> <span>Schedule your consultation</span></a><span> to learn how minimally invasive and bloodless heart surgery techniques could fit into your life timeline.</span></p>
<h2><b>Want to Go Deeper Into Heart Health and Recovery?</b></h2>
<p><span>Learn more about</span><a href="https://heartsurgeryinfo.com/"> <span>heart surgery recovery</span></a><span> from Dr. Ciuffo.</span></p>
<p><span>Dr. Ciuffo’s expertise in Minimally Invasive Heart Surgery and Bloodless Heart Surgery is the result of a career dedicated to advancing and perfecting these life-saving techniques.</span></p>]]> </content:encoded>
</item>

<item>
<title>Summer Travel After Heart Surgery: Why Minimally Invasive Techniques Get You Back to Your Bucket List Faster</title>
<link>https://edusehat.com/en/summer-travel-after-heart-surgery-why-minimally-invasive-techniques-get-you-back-to-your-bucket-list-faster</link>
<guid>https://edusehat.com/en/summer-travel-after-heart-surgery-why-minimally-invasive-techniques-get-you-back-to-your-bucket-list-faster</guid>
<description><![CDATA[ You have been dreaming about this trip for years. Maybe it is that European river cruise, the national parks road trip, or finally visiting family across the country. Then your cardiologist delivers unexpected news: you need heart surgery. For many patients, the immediate assumption is that travel plans, especially ambitious summer adventures, must be cancelled […] ]]></description>
<enclosure url="https://heartsurgeryinfo.com/wp-content/uploads/2026/05/image2.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 23 Sep 2026 03:50:23 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Summer, Travel, After, Heart, Surgery:, Why, Minimally, Invasive, Techniques, Get, You, Back, Your, Bucket, List, Faster</media:keywords>
<content:encoded><![CDATA[<p><span>You have been dreaming about this trip for years. Maybe it is that European river cruise, the national parks road trip, or finally visiting family across the country. Then your cardiologist delivers unexpected news: you need heart surgery. For many patients, the immediate assumption is that </span><a href="https://heartsurgeryinfo.com/traveling-with-heart-conditions-what-you-should-know-before-your-summer-vacation/"><span>travel plans</span></a><span>, especially ambitious summer adventures, must be cancelled indefinitely.</span></p>
<p><span>But here is what most people do not realize. The heart surgery recovery timeline has fundamentally changed. Modern minimally invasive and bloodless heart surgery techniques have transformed what was once a six to twelve month journey back to normal life into a matter of weeks for many patients. That summer bucket list trip might not need to be cancelled at all, just strategically timed.</span></p>
<h2><b>The Old Paradigm: Heart Surgery Meant Grounded for Months</b></h2>
<p><span>Traditional open-heart surgery has long been synonymous with extended, restrictive recovery periods. The sternotomy approach, which involves sawing through the breastbone and spreading the ribs to access the heart, creates significant trauma that takes months to heal.</span></p>
<p><span>Patients who underwent traditional heart surgery faced a daunting list of travel restrictions. No flying for at least four to six weeks post-surgery due to concerns about cabin pressure, blood clots, and limited access to emergency care. No long car trips due to the inability to sit comfortably for extended periods and the risk of deep vein thrombosis. Extreme caution about destinations without easy access to advanced medical facilities. Limitations on physical activities like hiking, swimming, or even extended walking.</span></p>
<p><span>The timeline was painfully clear. Expect to stay close to home and close to your surgical team for at least two to three months. Plan on limited physical activity and stamina for even longer. Accept that the first summer post-surgery would be spent recovering, not adventuring.</span></p>
<p><span>For patients whose surgery happened in spring or early summer, this meant writing off the entire travel season. The psychological toll of cancelled trips compounded the physical challenge of recovery, leaving many patients feeling like their lives had been put on hold indefinitely.</span></p>
<h2><b>How Minimally Invasive Heart Surgery Rewrites the Travel Timeline</b></h2>
<p><span>Minimally invasive heart surgery changes everything about the recovery experience and, by extension, the timeline for returning to travel.</span></p>
<p><span>Instead of a large incision through the breastbone, surgeons access the heart through small incisions between the ribs, typically just two to four inches long. The breastbone remains intact, which eliminates the months-long bone healing process that creates so many restrictions in traditional surgery.</span></p>
<p><span>The difference in recovery timeline is dramatic. Hospital stays shrink from a week or more to just two to four days for most procedures. Pain levels are significantly lower, reducing dependence on strong medications that can limit travel safety. Patients regain mobility and stamina much faster, with many feeling nearly normal within three to four weeks. Physical restrictions ease quickly, allowing earlier return to activities like walking, light exercise, and eventually more adventurous pursuits.</span></p>
<p><span>For procedures like mitral valve repair, aortic valve replacement, atrial septal defect closure, and some types of coronary artery bypass surgery, minimally invasive techniques offer the same excellent outcomes as traditional surgery but with a fraction of the recovery time.</span></p>
<p><span>This compressed timeline means that heart surgery scheduled in early spring does not automatically eliminate your summer travel plans. In many cases, patients are cleared for travel within six to eight weeks, and some even sooner depending on the specific procedure and individual recovery progress.</span></p>
<h2><b>Adding Bloodless Techniques: Another Layer of Recovery Advantage</b></h2>
<p><span>Bloodless heart surgery techniques, which minimize or eliminate the need for blood transfusions during and after surgery, add another significant advantage for patients eager to return to travel.</span></p>
<p><span>Blood transfusions, while sometimes life-saving, can complicate recovery in ways that impact travel readiness. Transfusions may temporarily suppress immune function, increasing vulnerability to infections during travel. They can cause inflammatory responses that slow overall healing. They may increase the risk of blood clots, a particular concern during long flights or car trips. Recovery timelines can extend as the body processes and adapts to transfused blood.</span></p>
<p><span>Bloodless techniques avoid these complications, potentially accelerating the timeline to travel-ready status. Patients often experience faster healing, fewer post-operative complications, stronger immune function sooner after surgery, and reduced risk of blood clot formation.</span></p>
<p><span>When minimally invasive and bloodless approaches are combined, the result is optimal conditions for rapid, uncomplicated recovery and earlier clearance for travel.</span></p>
<h2><b>Realistic Travel Timelines After Minimally Invasive Heart Surgery</b></h2>
<p><span>Let’s break down what travel actually looks like at different recovery milestones following minimally invasive heart surgery.</span></p>
<p><span>At two to three weeks post-surgery, some types of travel become feasible for patients with uncomplicated recoveries. Short car trips, generally under two hours with rest stops, work well for many patients. Local or regional travel staying close to medical facilities is reasonable. Low-key visiting with family or friends in familiar settings is manageable. However, air travel is typically not yet recommended, and patients should stick close to their surgical team’s geographic area.</span></p>
<p><span>By four to six weeks post-surgery, travel options expand significantly. Short flights, typically under three hours, are often approved by surgeons. Longer car trips with frequent breaks become comfortable for most patients. Domestic travel to destinations with good medical infrastructure is reasonable. Light touring, museum visits, and gentle sightseeing are usually manageable. Physical activities like short hikes on flat terrain may be cleared.</span></p>
<p><span>At eight to twelve weeks post-surgery, most patients with minimally invasive procedures are cleared for essentially normal travel. International flights are typically approved. Adventure travel with moderate physical demands becomes possible. Destinations without immediate access to major medical centers are reasonable options. Activities like snorkeling, cycling, and moderate hiking are usually cleared. Multi-week trips are feasible without concerns about follow-up appointments.</span></p>
<p><span>These timelines assume smooth, uncomplicated recovery and always require clearance from your cardiac surgeon before booking travel. Individual factors like age, overall health, specific procedure performed, and presence of other medical conditions all influence personal timelines.</span></p>
<h2><b>Smart Travel Planning: Optimizing Your Post-Surgery Adventures</b></h2>
<p><span>If you are determined to salvage summer travel plans after heart surgery, strategic planning makes all the difference.</span></p>
<p><span>First, communicate openly with your surgeon about your travel goals. Be specific about your planned destinations, activities, and travel dates. Ask explicitly whether your procedure and </span><a href="https://heartsurgeryinfo.com/shorter-recovery-times-with-minimally-invasive-heart-surgery-techniques/"><span>recovery trajectory</span></a><span> will allow for your planned trip. Discuss any special precautions or preparations needed for travel at your recovery stage. Get written clearance before booking non-refundable travel.</span></p>
<p><span>Choose your first post-surgery destination wisely. Prioritize locations with excellent medical infrastructure and easy access to cardiac care. Consider destinations where you have local contacts who could help in an emergency. Start with domestic travel or close international destinations before planning more remote adventures. Select accommodations near medical facilities for peace of mind.</span></p>
<p><span>Build flexibility and rest into your itinerary. Plan shorter travel days with more rest breaks than you would normally need. Build in rest days between more active excursion days. Choose accommodations that allow for relaxation and recovery time. Avoid jam-packed itineraries that would exhaust even a fully healthy traveler.</span></p>
<p><span>Prepare comprehensively for medical needs while traveling. Bring more than enough of all prescribed medications. Carry a letter from your surgeon describing your surgery and current status. Have your surgeon’s contact information and your medical records accessible digitally. Research cardiac care facilities at your destination in advance. Consider travel insurance that covers pre-existing conditions and medical evacuation.</span></p>
<h2><b>Activities to Embrace and Avoid at Different Recovery Stages</b></h2>
<p><span>Understanding which travel activities are appropriate at different points in recovery helps you plan realistic and enjoyable trips.</span></p>
<p><span>In weeks four to six post-surgery, appropriate activities include gentle walking tours of cities or nature areas, museum visits and cultural sightseeing that involve mostly indoor, controlled environments, boat tours or cruises with minimal physical demands, scenic drives where you are a passenger, and light shopping or dining experiences.</span></p>
<p><span>Activities to avoid at this stage include strenuous hiking, especially at altitude, water sports or swimming unless specifically cleared, activities with fall risk like skiing or cycling, heavy lifting including managing your own heavy luggage, and extremely long days without adequate rest periods.</span></p>
<p><span>By weeks eight to twelve, you can typically add moderate hiking on well-maintained trails, swimming and snorkeling in calm conditions, cycling on flat or gently rolling terrain, light kayaking or paddleboarding, and golf or other low-impact sports.</span></p>
<p><span>You should still be cautious about highly strenuous mountain climbing or trekking, scuba diving unless cleared by both your surgeon and a dive medicine specialist, contact sports or activities with significant injury risk, and extreme environmental conditions like high altitude or extreme heat.</span></p>
<p><span>Beyond three months with good recovery, most patients are cleared for essentially normal activities, though you should always discuss specific adventure activities with your surgical team.</span></p>
<h2><b>Types of Trips That Work Best at Different Recovery Points</b></h2>
<p><span>Certain travel styles align better with different recovery stages, helping you maximize enjoyment while respecting your healing timeline.</span></p>
<p><span>Early recovery travel at four to six weeks works best for city breaks in walkable cities with good public transportation, visiting family or friends where you can control your activity level and have support available, cruise vacations which offer built-in medical facilities and require minimal physical exertion to enjoy, and gentle cultural tours that focus on history, art, and food rather than physical challenges.</span></p>
<p><span>Mid-recovery travel at eight to ten weeks opens up national parks with accessible viewpoints and easy trails, beach vacations with opportunities for both rest and moderate activity, European river cruises combining culture with manageable physical demands, wine country tours that involve light walking and plenty of dining, and wellness retreats focused on gentle healing practices.</span></p>
<p><span>Later recovery travel at twelve weeks and beyond typically allows for most bucket list adventures including more challenging hiking destinations, international adventure travel, multi-country backpacking trips, safari adventures, and active outdoor pursuits.</span></p>
<h2><b>Real Patient Perspectives: Summer Travel After Minimally Invasive Surgery</b></h2>
<p><span>While every patient’s experience is unique, many who have undergone minimally invasive heart surgery report surprisingly quick returns to travel.</span></p>
<p><span>Patients commonly describe feeling well enough for short local trips within three to four weeks, though they emphasize the importance of listening to their bodies and not pushing too hard. Many report successfully taking domestic flights and enjoying week-long vacations at the six to eight week mark. By three months post-surgery, numerous patients report feeling completely back to their normal travel selves, tackling international trips and physically demanding adventures with confidence.</span></p>
<p><span>The consistent theme across patient experiences is surprise at how much faster recovery progressed compared to their expectations based on traditional surgery timelines. Many express gratitude that minimally invasive techniques allowed them to maintain quality of life and not miss out on planned experiences with family and friends.</span></p>
<h2><b>When to Postpone Travel: Listening to Your Body and Your Surgeon</b></h2>
<p><span>While modern surgical techniques enable much faster return to travel, there are absolutely situations where postponing a trip is the right decision.</span></p>
<p><span>You should seriously consider postponing or cancelling travel if you experience concerning symptoms like new or worsening chest pain or pressure, significant shortness of breath with minimal activity, excessive fatigue that is not improving as expected, fever or signs of infection, irregular heartbeat or palpitations, or significant wound healing issues.</span></p>
<p><span>Additionally, if your surgeon advises against travel based on your specific recovery progress, you should always follow that guidance. If you feel uncertain or anxious about traveling, trust your instincts. And if your destination would make you feel unsafe or unable to access help if needed, choose a different location or timing.</span></p>
<p><span>The goal is to return to full, joyful living, not to rush back to activity before your body is ready. A delayed trip enjoyed in good health beats a miserable experience pushing through recovery.</span></p>
<h2><b>The Psychological Benefits of Near-Term Travel Goals</b></h2>
<p><span>Beyond the practical aspects, having realistic travel goals after heart surgery provides significant psychological benefits that actually support better recovery.</span></p>
<p><span>Looking forward to a trip gives patients something positive to focus on during recovery rather than fixating on limitations or discomfort. It provides motivation to adhere to rehabilitation programs, medication regimens, and lifestyle changes. It reinforces the reality that life continues after heart surgery and that this is a temporary setback, not a permanent limitation. It offers tangible proof that recovery is progressing when you reach milestones that allow for each new phase of travel.</span></p>
<p><span>For many patients, that first successful post-surgery trip becomes a powerful emotional milestone, a moment of reclaiming normalcy and independence after a frightening health crisis.</span></p>
<h2><b>The Bottom Line</b></h2>
<p><span>Summer travel after heart surgery is not the impossibility it once was. Thanks to minimally invasive and bloodless heart surgery techniques, the recovery timeline that used to cancel entire seasons of life has compressed dramatically.</span></p>
<p><span>If you are facing heart surgery and worried about upcoming travel plans, do not assume you must cancel everything. Instead, have an honest conversation with your surgical team about your goals. Seek out surgeons who specialize in minimally invasive approaches. Ask specific questions about realistic timelines for your situation. Then plan strategically, building appropriate rest and flexibility into your post-surgery adventures.</span></p>
<p><span>Your bucket list does not have to wait. With modern surgical techniques and smart planning, that dream trip might be just weeks away rather than months or years. Your heart surgery is not the end of your adventures. It is simply a brief pause before you return to exploring the world with renewed health and energy.</span></p>
<p><span>Ready to discuss your travel timeline?</span><a href="https://heartsurgeryinfo.com/contact-us/"> <span>Schedule your consultation</span></a><span> to learn how minimally invasive and bloodless heart surgery can help you get back to your bucket list faster.</span></p>
<h2><b>Want to Go Deeper Into Heart Health and Recovery?</b></h2>
<p><span>Learn more about</span><a href="https://heartsurgeryinfo.com/"> <span>heart rate and recovery</span></a><span> from Dr. Ciuffo.</span></p>
<p><span>Dr. Ciuffo’s expertise in Minimally Invasive Heart Surgery and Bloodless Heart Surgery is the result of a career dedicated to advancing and perfecting these life-saving techniques.</span></p>]]> </content:encoded>
</item>

<item>
<title>Protecting Your Healing Incision This Summer: Sun Safety After Heart Surgery</title>
<link>https://edusehat.com/en/protecting-your-healing-incision-this-summer-sun-safety-after-heart-surgery</link>
<guid>https://edusehat.com/en/protecting-your-healing-incision-this-summer-sun-safety-after-heart-surgery</guid>
<description><![CDATA[ Summer is finally here, and with it comes travel plans, beach days, family vacations, and long-awaited time outdoors. But if you have recently undergone heart surgery, whether through a minimally invasive or traditional approach, the season comes with one important consideration that often gets overlooked in recovery conversations: protecting your healing incision from the sun. […] ]]></description>
<enclosure url="https://heartsurgeryinfo.com/wp-content/uploads/2026/06/image1-1-e1782486877996.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 23 Sep 2026 03:50:20 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Protecting, Your, Healing, Incision, This, Summer:, Sun, Safety, After, Heart, Surgery</media:keywords>
<content:encoded><![CDATA[<p><span>Summer is finally here, and with it comes </span><a href="https://heartsurgeryinfo.com/traveling-with-heart-conditions-what-you-should-know-before-your-summer-vacation/"><span>travel plans,</span></a><span> beach days, family vacations, and long-awaited time outdoors. But if you have recently undergone heart surgery, whether through a minimally invasive or traditional approach, the season comes with one important consideration that often gets overlooked in recovery conversations: protecting your healing incision from the sun.</span></p>
<p><span>Most patients leave the hospital with detailed instructions about medications, activity restrictions, and follow-up appointments. Sun protection for surgical incisions, however, does not always receive the same level of attention. The truth is that UV exposure during the healing process can cause lasting cosmetic damage, slow the healing timeline, and create complications that are entirely preventable with the right precautions.</span></p>
<p><span>Here is what you need to know to enjoy a safe, sun-smart summer while your incision heals.</span></p>
<h2><b>Why Sun Exposure Is Different After Surgery</b></h2>
<p><span>Your skin goes through a remarkable process after any surgical incision. In the weeks and months following surgery, the tissue along your incision line is actively regenerating. New skin cells are forming, collagen is being produced, and the complex process of scar formation is underway.</span></p>
<p><span>During this regenerative phase, the skin along your incision is uniquely vulnerable to UV radiation. Normal, healthy skin contains melanin, the pigment that provides some natural protection against sun damage. But healing scar tissue does not produce melanin the same way intact skin does. This means your incision site has far less natural defense against UV rays than the surrounding skin.</span></p>
<p><span>When UV light hits healing scar tissue, it can trigger hyperpigmentation, causing the scar to darken permanently and become significantly more visible. It can also damage the delicate new collagen fibers forming in the wound, potentially weakening the scar and slowing the maturation process. In some cases, UV exposure during healing leads to thickened, raised, or discolored scars that become a long-term cosmetic concern.</span></p>
<p><span>The good news is that this is almost entirely preventable. A consistent approach to sun protection during the healing period, typically one to two years following surgery, dramatically reduces the risk of these outcomes.</span></p>
<h2><b>The Minimally Invasive Advantage: Smaller Incisions, Easier to Protect</b></h2>
<p><span>One significant benefit of minimally invasive heart surgery when it comes to sun protection is the size and location of the incisions involved. Traditional open-heart surgery requires a large sternal incision running down the center of the chest, often eight to ten inches long. Protecting an incision of that size from sun exposure requires significant coverage and planning.</span></p>
<p><span>Minimally invasive heart surgery, by contrast, involves small incisions typically between two and four inches in length, made between the ribs on the side of the chest. These smaller incisions are not only easier to heal from but also easier to protect. They can often be covered by normal swimwear, athletic wear, or lightweight clothing without the need for full sun avoidance.</span></p>
<p><span>This practical difference matters enormously during the summer months. Patients recovering from minimally invasive procedures can participate more comfortably in outdoor activities while keeping their incision protected, since the smaller site requires less coverage and is less affected by movement, heat, and perspiration than a long sternal scar.</span></p>
<h2><b>When Can You Expose Your Incision to the Sun?</b></h2>
<p><span>The general guidance from most cardiac surgeons and dermatologists is to keep your incision completely protected from direct sun exposure for at least twelve months after surgery. Some providers extend this recommendation to two years for optimal scar outcomes.</span></p>
<p><span>This does not mean you must stay indoors or avoid the sun entirely. It means that during this healing window, your incision site specifically needs to be shielded from direct UV exposure through clothing, bandaging, or sunscreen.</span></p>
<p><span>In the first four to six weeks after surgery, your incision is at its most vulnerable. The wound is actively closing, infection risk is still present, and the skin is far from ready for any kind of sun exposure. During this phase, the incision should be covered with clothing or bandaging whenever you are outdoors, even on overcast days, since UV rays penetrate cloud cover.</span></p>
<p><span>From six weeks to six months, your incision will likely be fully closed and begin the process of scar maturation. During this period, sunscreen specifically formulated for sensitive or healing skin should be applied to the site anytime it might be exposed, and physical coverage remains the most reliable protection.</span></p>
<p><span>From six months to twelve months and beyond, the scar continues to mature and fade. Consistent sunscreen application remains important, and avoiding prolonged direct sun exposure to the site is still recommended even as other restrictions ease.</span></p>
<h2><b>Choosing the Right Sunscreen for a Healing Incision</b></h2>
<p><span>Not all sunscreens are created equal, and for a healing surgical incision, the formulation matters.</span></p>
<p><span>Look for sunscreens with an SPF of 30 or higher, with broad-spectrum protection covering both UVA and UVB rays. Physical or mineral sunscreens containing zinc oxide or titanium dioxide are generally better tolerated on sensitive healing tissue than chemical sunscreens, which rely on UV-absorbing compounds that can sometimes irritate healing skin.</span></p>
<p><span>Fragrance-free formulations are important, since fragrances can cause contact dermatitis and skin reactions that are particularly problematic on healing tissue. Hypoallergenic products designed for sensitive skin are a good starting point.</span></p>
<p><span>Before applying any sunscreen to your incision site, confirm with your surgeon that your wound is fully closed and healed enough for topical product application. In the earliest phase of healing, products should not be applied to incisions that are still actively healing or not fully closed.</span></p>
<p><span>Apply sunscreen generously to the incision site and the surrounding skin at least fifteen to thirty minutes before outdoor exposure, and reapply every two hours or immediately after swimming or sweating.</span></p>
<h2><b>Practical Strategies for Sun Protection This Summer</b></h2>
<p><span>Protecting your incision this summer does not have to mean missing out on outdoor activities. With the right strategies, you can enjoy the season safely.</span></p>
<p><span>Clothing is your most reliable protection. Lightweight, long-sleeved UV-protective shirts, known as UPF clothing, provide consistent coverage without requiring you to remember reapplication. For a side incision from minimally invasive surgery, a simple lightweight shirt or rash guard covers the area entirely during beach trips, pool days, or outdoor events.</span></p>
<p><span>Timing your outdoor activities reduces UV exposure overall. The sun’s UV rays are most intense between ten in the morning and four in the afternoon. Planning outdoor activities for the early morning or evening hours reduces the intensity of sun exposure to all skin, including your healing incision.</span></p>
<p><span>Shade is your friend. Umbrellas, canopies, and shaded seating allow you to enjoy outdoor environments without continuous direct sun exposure. At beach outings or backyard gatherings, positioning yourself in shade while others are in direct sun reduces your overall UV load.</span></p>
<p><span>Water activities require extra caution. If your surgeon has cleared you for swimming, remember that water reflects UV radiation and can actually intensify sun exposure. Apply water-resistant sunscreen to your incision area before getting in the water, and cover up immediately after exiting.</span></p>
<h2><b>Scar Care Beyond Sun Protection</b></h2>
<p><span>While sun protection is one of the most important aspects of incision care during summer, it works best as part of a comprehensive approach to scar care.</span></p>
<p><span>Keep your incision moisturized. Dry, tight scar tissue is more prone to itching, discomfort, and poor cosmetic outcomes. Fragrance-free moisturizers or products specifically designed for scar care help keep healing tissue supple and comfortable.</span></p>
<p><span>Silicone-based scar products, including silicone sheets and silicone gels, have strong evidence supporting their use in scar management. Many surgeons recommend these products once the incision is fully closed, as they help flatten and fade scars while providing some degree of UV protection.</span></p>
<p><span>Stay hydrated. Adequate hydration supports skin health and healing throughout the body, including at your incision site.</span></p>
<p><span>Avoid picking, scratching, or irritating the incision site, even when summer heat causes perspiration and discomfort around the healing tissue.</span></p>
<h2><b>Signs That Your Incision Needs Medical Attention</b></h2>
<p><span>While sun protection and scar care are important, knowing when to contact your surgical team is equally critical. During the summer months, heat and activity can sometimes exacerbate or obscure warning signs.</span></p>
<p><span>Contact your surgeon if you notice increased redness, warmth, or swelling around the incision that is spreading rather than improving. Discharge, especially if it is thick, discolored, or has an odor, warrants prompt attention. Reopening of any portion of the incision requires immediate medical evaluation. Significant itching or burning that is worsening rather than improving should also be discussed with your surgical team.</span></p>
<p><span>A small amount of itching is normal as nerves regenerate during healing, but persistent or intense itching can sometimes indicate infection or an allergic reaction to wound care products.</span></p>
<h2><b>Enjoying Summer While Protecting Your Recovery</b></h2>
<p><a href="https://heartsurgeryinfo.com/surgery-recovery/"><span>Heart surgery recovery</span></a><span> during the summer months is entirely manageable with the right approach. The season does not have to be spent indoors or in avoidance of all outdoor activity. It simply requires a thoughtful, consistent approach to protecting your healing incision from UV exposure while enjoying the activities that matter to you.</span></p>
<p><span>Patients who undergo </span><a href="https://heartsurgeryinfo.com/heart-surgery/"><span>minimally invasive heart surgery</span></a><span> particularly benefit from how the smaller, side-positioned incisions are easier to cover and protect during outdoor summer activities. The combination of shorter recovery timelines and more manageable incision care makes minimally invasive techniques an advantage far beyond the operating room.</span></p>
<p><span>With consistent sun protection, appropriate scar care, and open communication with your surgical team, you can have a summer that honors both your healing body and your desire to enjoy the season.</span></p>
<p><span>Your recovery is important, and so is your quality of life this summer.</span><a href="https://heartsurgeryinfo.com/contact-us/"> <span>Schedule your consultation</span></a><span> to talk through your recovery timeline, incision care, and what to expect in the months ahead.</span></p>
<h2><b>Want to Go Deeper Into Heart Health and Recovery?</b></h2>
<p><span>Learn more about</span><a href="https://heartsurgeryinfo.com/"> <span>heart surgery recovery</span></a><span> from Dr. Ciuffo.</span></p>
<p><span>Dr. Ciuffo’s expertise in Minimally Invasive Heart Surgery and Bloodless Heart Surgery is the result of a career dedicated to advancing and perfecting these life-saving techniques.</span></p>]]> </content:encoded>
</item>

<item>
<title>Mid&#45;Year Heart Check&#45;In: Is It Time to Consider Minimally Invasive Options?</title>
<link>https://edusehat.com/en/mid-year-heart-check-in-is-it-time-to-consider-minimally-invasive-options</link>
<guid>https://edusehat.com/en/mid-year-heart-check-in-is-it-time-to-consider-minimally-invasive-options</guid>
<description><![CDATA[ We are halfway through the year. For many people, that milestone prompts a look back at New Year’s resolutions, a review of financial goals, and a reassessment of priorities. But for those living with known heart conditions, a mid-year check-in carries a different and more urgent weight. If you have been managing a heart condition […] ]]></description>
<enclosure url="https://heartsurgeryinfo.com/wp-content/uploads/2026/06/image2-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 23 Sep 2026 03:50:18 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Mid-Year, Heart, Check-In:, Time, Consider, Minimally, Invasive, Options</media:keywords>
<content:encoded><![CDATA[<p><span>We are halfway through the year. For many people, that milestone prompts a look back at New Year’s resolutions, a review of financial goals, and a reassessment of priorities. But for those living with known heart conditions, a mid-year check-in carries a different and more urgent weight.</span></p>
<p><span>If you have been managing a heart condition conservatively, watching symptoms, and delaying surgical conversations, the midpoint of the year is an ideal moment to ask an honest question: is it time to consider a more definitive treatment? And if surgery is part of that conversation, do you know what options are available to you beyond the traditional open-heart approach?</span></p>
<p><a href="https://heartsurgeryinfo.com/heart-surgery/"><span>Minimally invasive heart surgery</span></a><span> has transformed what cardiac care looks like for many patients. Understanding what these techniques offer, who qualifies, and what the signs are that your condition may be progressing can empower you to have a more productive and proactive conversation with your cardiac care team.</span></p>
<h2><b>Why the Mid-Year Moment Matters</b></h2>
<p><span>There is something psychologically significant about the middle of a year. It creates natural distance from the anxiety of a recent diagnosis and a natural pause before the busy holiday season ahead. It is a moment when patients often have clearer heads and more bandwidth for serious medical conversations than they did in the immediate aftermath of receiving difficult news.</span></p>
<p><span>For patients managing conditions like valvular heart disease, coronary artery disease, atrial fibrillation, or congenital heart defects, the mid-year period is also practically significant. Scheduling elective cardiac surgery in summer or early fall often means completing </span><a href="https://heartsurgeryinfo.com/surgery-recovery/"><span>recovery </span></a><span>before the winter holiday season, allowing patients to be fully present and physically able to enjoy the latter part of the year with family.</span></p>
<p><span>Understanding where you are in your cardiac care journey right now, and whether your current approach is still the right one, is a valuable exercise at any point. But the middle of the year, with its combination of reflective distance and practical planning advantages, makes it a particularly good time to take stock.</span></p>
<h2><b>Common Conditions That May Warrant a Surgical Conversation</b></h2>
<p><span>If you have been diagnosed with any of the following conditions and manage them conservatively, the mid-year period is a good time to revisit whether that approach remains appropriate.</span></p>
<p><a href="https://heartsurgeryinfo.com/?s=Aortic+stenosis"><span>Aortic stenosis</span></a><span> involves the narrowing of the aortic valve, which restricts blood flow from the heart to the rest of the body. Many patients are diagnosed and monitored for years before symptoms become significant. But once symptoms like chest pain, shortness of breath, or dizziness develop, research consistently shows that outcomes are significantly better with intervention than with continued watchful waiting. If your symptoms have changed or your most recent echocardiogram showed progression, the conversation about surgical options is timely.</span></p>
<p><span>Mitral valve regurgitation occurs when the mitral valve does not close properly, allowing blood to flow backward in the heart. This is actually one of the conditions best suited for minimally invasive repair, and many cardiac surgeons recommend intervention before the heart begins to compensate in ways that can cause long-term damage. If you have been monitoring mitral valve regurgitation, ask specifically about minimally invasive repair options at your next appointment.</span></p>
<p><span>Coronary artery disease ranges from mild to severe, and the decision about when to move from medical management to intervention involves a complex weighing of risk factors, symptom burden, and disease progression. If your current medications are not adequately controlling your symptoms, or if your most recent stress test or imaging showed progression, it may be time to discuss whether a more definitive approach is warranted.</span></p>
<p><span>Atrial septal defects and other structural heart conditions are often managed conservatively for years, especially when diagnosed in adulthood. But if your condition has been progressing or causing symptoms like exercise intolerance, shortness of breath, or irregular heart rhythms, minimally invasive closure techniques may offer a highly effective solution with minimal recovery time.</span></p>
<h2><b>Signs That Your Condition May Be Progressing</b></h2>
<p><span>Patients who have been managing heart conditions for months or years often become accustomed to a certain baseline of symptoms. This gradual adaptation can sometimes mask the slow progression of a condition, making it easy to attribute new or worsening symptoms to aging, stress, or other factors rather than recognizing them as signs of cardiac progression.</span></p>
<p><span>A mid-year check-in is a good time to honestly assess whether your symptom picture has changed. Ask yourself whether you are getting winded doing things that did not bother you six months ago, whether your exercise tolerance has declined, whether you are experiencing more frequent episodes of chest discomfort, palpitations, or lightheadedness, whether you have adjusted your daily activities to avoid triggering symptoms, and whether you are sleeping differently or waking with breathlessness or discomfort.</span></p>
<p><span>These kinds of gradual changes are easy to normalize over time. Bringing them to your cardiologist’s attention, especially alongside updated imaging or testing, can reveal whether your condition has progressed to a point where intervention offers better long-term outcomes than continued conservative management.</span></p>
<h2><b>What Minimally Invasive Heart Surgery Actually Involves</b></h2>
<p><span>Despite the growing prevalence of minimally invasive techniques in cardiac surgery, many patients still have an outdated mental picture of what heart surgery looks like. Understanding what modern minimally invasive surgery actually involves can significantly reduce the anxiety that keeps some patients from pursuing timely intervention.</span></p>
<p><span>Minimally invasive heart surgery uses small incisions, typically two to four inches, made between the ribs rather than through the breastbone. Surgeons use specialized instruments and, in some cases, robotic assistance to access and repair the heart through these small openings. The heart’s structures are repaired with the same precision and durability as traditional open-heart surgery, but without the significant trauma associated with splitting the breastbone.</span></p>
<p><span>The practical differences for patients are significant. Hospital stays are shorter, typically two to four days compared to a week or more for traditional surgery. Pain is less severe, and dependence on strong pain medications is reduced. The breastbone remains intact, which eliminates the months-long bone healing process that creates so many of the restrictions associated with traditional cardiac surgery recovery. Most patients return to normal activities within three to six weeks rather than the two to three months typical of open-heart recovery.</span></p>
<p><span>Importantly, the outcomes for appropriately selected patients are comparable to those of traditional surgery. Minimally invasive techniques are not a compromise or a shortcut. For the right candidates, they represent the optimal approach, offering equivalent or superior results with significantly less patient burden.</span></p>
<h2><b>Who Qualifies for Minimally Invasive Heart Surgery?</b></h2>
<p><span>Candidacy for minimally invasive heart surgery depends on several factors, including the specific condition being treated, the patient’s overall health and anatomy, and the expertise of the surgical team.</span></p>
<p><span>Many patients assume they are not candidates without ever having the conversation with a surgeon who specializes in these techniques. The reality is that the range of conditions treatable through minimally invasive approaches has expanded significantly over the past decade. Valve repair and replacement, coronary artery bypass in some cases, correction of structural defects, and removal of certain cardiac tumors can all be performed using minimally invasive techniques in appropriately selected patients.</span></p>
<p><span>Factors that may affect candidacy include prior chest surgeries, which can create scar tissue that complicates access, severe obesity, certain anatomical variations, and the presence of other conditions that affect surgical risk. But these are conversations to have with a specialist, not assumptions to make on your own.</span></p>
<p><span>If you have never specifically asked your cardiac care team whether you are a candidate for minimally invasive surgery, the mid-year check-in is the time to raise that question directly.</span></p>
<h2><b>The Role of Bloodless Techniques in Your Surgical Conversation</b></h2>
<p><span>For patients exploring minimally invasive surgery, bloodless techniques represent another layer of the conversation worth having. Bloodless heart surgery minimizes or eliminates the need for blood transfusions during the procedure, which can affect recovery in meaningful ways.</span></p>
<p><span>Transfusion-related complications, while relatively uncommon, include immune suppression, inflammatory responses, and increased infection risk. For patients who prefer to avoid transfusions for personal or religious reasons, bloodless techniques make surgery possible without compromising care. For patients who simply want the fastest and cleanest recovery possible, bloodless approaches reduce the variables that can complicate post-operative healing.</span></p>
<p><span>When combined with minimally invasive techniques, bloodless approaches create an optimal surgical environment for rapid recovery and return to normal life. Ask your surgeon specifically about bloodless options and whether they are part of their practice.</span></p>
<h2><b>Preparing for a More Productive Surgical Consultation</b></h2>
<p><span>If your mid-year assessment suggests it is time to have a more serious surgical conversation, preparing for that consultation makes a significant difference in the quality of information you receive.</span></p>
<p><span>Come with a written summary of any symptom changes you have noticed since your last appointment. Bring a list of all current medications and supplements. Request that your most recent imaging and testing results be available for review during the appointment. Write down your specific questions in advance, including whether minimally invasive and bloodless techniques are options for your condition, what the surgeon’s experience and volume is with these specific approaches, what realistic recovery timelines look like, and how outcomes with minimally invasive techniques compared to traditional surgery for your specific diagnosis.</span></p>
<p><span>Do not hesitate to seek a second opinion if you want to ensure you are getting the full picture of what is available to you. Surgeons who specialize in minimally invasive techniques may offer options that generalist cardiac surgeons do not routinely perform, and understanding the full range of possibilities empowers you to make the best decision for your health and your life.</span></p>
<h2><b>The Right Time Is Rarely Later</b></h2>
<p><span>One of the most consistent findings in cardiac surgery research is that outcomes are generally better when intervention happens before a condition causes significant secondary damage to the heart muscle, before emergency situations arise, and before patients have spent years compensating for their symptoms in ways that affect overall health.</span></p>
<p><span>Proactive, informed decision-making about cardiac care is one of the most powerful things you can do for your long-term health. The mid-year moment is an invitation to take that step.</span></p>
<p><span>Your heart has been working for you every minute of this year. This is a good time to ask whether you are doing everything you can for it in return.</span></p>
<p><span>Not sure if it is time to consider surgical options?</span><a href="https://heartsurgeryinfo.com/contact-us/"> <span>Schedule a consultation</span></a><span> to review your current condition, explore minimally invasive options, and get the information you need to make a confident decision about your heart health.</span></p>
<h2><b>Want to Go Deeper Into Heart Health and Recovery?</b></h2>
<p><span>Learn more about</span><a href="https://heartsurgeryinfo.com/"> <span>your heart health</span></a><span> from Dr. Ciuffo.</span></p>
<p><span>Dr. Ciuffo’s expertise in Minimally Invasive Heart Surgery and Bloodless Heart Surgery is the result of a career dedicated to advancing and perfecting these life-saving techniques.</span></p>]]> </content:encoded>
</item>

<item>
<title>Back to School, Back to Life: How Minimally Invasive Heart Surgery Gets Parents Home Faster</title>
<link>https://edusehat.com/en/back-to-school-back-to-life-how-minimally-invasive-heart-surgery-gets-parents-home-faster</link>
<guid>https://edusehat.com/en/back-to-school-back-to-life-how-minimally-invasive-heart-surgery-gets-parents-home-faster</guid>
<description><![CDATA[ The Timing Dilemma Every Parent Understands The start of the school year is one of the busiest, most demanding times for any parent. There are supplies to buy, schedules to coordinate, carpools to arrange, and a hundred small tasks that pile up before the first bell rings. Now imagine facing all of that while also […] ]]></description>
<enclosure url="https://heartsurgeryinfo.com/wp-content/uploads/2026/07/image1-e1785338700710.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 23 Sep 2026 03:50:16 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Back, School, Back, Life:, How, Minimally, Invasive, Heart, Surgery, Gets, Parents, Home, Faster</media:keywords>
<content:encoded><![CDATA[<h2><span>The Timing Dilemma Every Parent Understands</span></h2>
<p><span>The start of the school year is one of the busiest, most demanding times for any parent. There are supplies to buy, schedules to coordinate, carpools to arrange, and a hundred small tasks that pile up before the first bell rings. Now imagine facing all of that while also needing heart surgery.</span></p>
<p><span>For parents diagnosed with a cardiac condition, the timing can feel impossible. How do you take weeks or months to recover when your kids need you to pack lunches, help with homework, and get them to soccer practice on time? For many, the fear of being sidelined during such a critical period leads to a dangerous decision: postponing necessary surgery.</span></p>
<p><span>The good news is that modern cardiac care has changed what recovery looks like. Minimally invasive heart surgery is helping parents get home faster, back on their feet sooner, and returning to the daily rhythms their families depend on without the long absence traditional surgery once required.</span></p>
<h2><span>Why Traditional Recovery Feels Impossible for Parents</span></h2>
<p><span>To understand why minimally invasive approaches matter so much for busy families, it helps to understand what conventional heart surgery demands.</span></p>
<p><span>Traditional open-heart surgery requires splitting the sternum, or breastbone, to access the heart. This is a significant trauma to the body, and it comes with a lengthy recovery. Patients typically spend a week or more in the hospital, followed by six to eight weeks before they can drive and three to six months before returning to full activity.</span></p>
<p><span>During this time, there are strict restrictions. No lifting more than a few pounds, which rules out carrying a toddler or a heavy backpack. No reaching overhead, which complicates everything from grabbing dishes to helping a child into a car seat. Fatigue is profound, and even simple parenting tasks can feel overwhelming.</span></p>
<p><span>For a parent, this timeline isn’t just inconvenient. It can mean missing the first day of school, being unable to attend back-to-school events, and relying heavily on others for months during one of the year’s most demanding stretches.</span></p>
<h2><span>The Minimally Invasive Alternative</span></h2>
<p><a href="https://heartsurgeryinfo.com/minimally-invasive-heart-surgery/"><span>Minimally invasive heart surgery</span></a><span> offers a fundamentally different experience. Rather than splitting the breastbone, surgeons work through small incisions between the ribs, often just a few inches long. This preserves the structural integrity of the chest and dramatically reduces the trauma to the body.</span></p>
<p><span>The results are meaningful for parents. Most minimally invasive patients spend only three to five days in the hospital. Many can drive again within about 2 weeks, and a good number return to most normal activities within 4 to 6 weeks. Because there is no healing breastbone to protect, the restrictions on lifting and reaching are far less severe.</span></p>
<p><span>For a parent, this can mean the difference between missing an entire season of school activities and being back in the swing of things within a matter of weeks. It transforms heart surgery from a family-disrupting event into a manageable interruption.</span></p>
<h2><span>What Faster Recovery Actually Means at Home</span></h2>
<p><span>Recovery statistics are helpful, but what parents really want to know is what daily life looks like. Here is how faster recovery translates into real family moments.</span></p>
<h3><span>Getting Back to the School Run</span></h3>
<p><span>The ability to drive is one of the biggest markers of independence for a parent. Being unable to drive for 6 to 8 weeks after traditional surgery means relying on others for every school pickup, doctor’s appointment, and grocery run. With minimally invasive surgery, many patients return to driving in about two weeks, restoring a crucial piece of family routine much sooner.</span></p>
<h3><span>Physical Interaction With Your Kids</span></h3>
<p><span>Traditional surgery restrictions make picking up young children off-limits for weeks. For parents of little ones, this can be emotionally painful. Minimally invasive approaches, with their reduced lifting restrictions, allow parents to return to gentle physical interaction with their children sooner, though always within the guidelines their surgeon provides.</span></p>
<h3><span>Being Present for the Moments That Matter</span></h3>
<p><span>The back-to-school season is full of milestones: first days, open houses, meet-the-teacher nights, and the start of sports and activities. A faster recovery means parents are far more likely to be present and engaged for these moments rather than watching from the sidelines or missing them entirely.</span></p>
<h2><span>The Emotional Weight Parents Carry</span></h2>
<p><span>There is an emotional dimension to heart surgery that deserves attention, especially for parents. Many mothers and fathers feel guilty about needing time to recover. They worry about being a burden, about their kids being scared, and about disrupting the family’s carefully balanced schedule.</span></p>
<p><span>This guilt can lead to poor decisions, like delaying surgery until “a better time” that never actually comes. The reality is that a cardiac condition rarely waits for convenience, and postponing necessary treatment can allow the underlying problem to worsen.</span></p>
<p><span>Minimally invasive surgery helps ease this emotional burden. Knowing that recovery will be measured in weeks rather than months makes the decision to move forward far less daunting. Parents can address their health without feeling they are abandoning their families for an extended period. That peace of mind is valuable, both for the parent and for the children who worry about them.</span></p>
<h2><span>Talking to Your Kids About Heart Surgery</span></h2>
<p><span>If you are a parent facing heart surgery, involving your children in age-appropriate conversations can help ease everyone’s anxiety. Here are some approaches that families find helpful.</span></p>
<p><span>Be honest but reassuring. Explain that you have a heart problem that doctors can fix, and that you will need some time to rest afterward. Children often imagine worst-case scenarios, so clear and calm information helps.</span></p>
<p><span>Emphasize the recovery timeline. Letting kids know that you will be home soon and getting stronger every day gives them something concrete to hold onto. With minimally invasive surgery, that timeline is genuinely encouraging.</span></p>
<p><span>Give them a role. Children often feel better when they can help. Assigning small, safe tasks makes them feel involved and less helpless during your recovery.</span></p>
<p><span>Keep routines steady. Maintaining as much normalcy as possible in daily schedules provides children with a sense of security during an uncertain time.</span></p>
<h2><span>Planning Your Surgery Around the School Calendar</span></h2>
<p><span>One advantage of minimally invasive surgery is that its predictable, shorter recovery makes it easier to plan around your family’s calendar.</span></p>
<p><span>Some parents choose to schedule surgery during summer break, allowing recovery to happen before the school year begins. Others opt for the period right after school starts, once children are settled into routines and the day has more structure. Still others plan around long breaks when extra help from family may be available.</span></p>
<p><span>The key is that with recovery measured in weeks, you have far more flexibility. A procedure scheduled in early summer can have you fully recovered well before the first day of school. A late-summer surgery might still allow you to be driving and largely back to normal within the first few weeks of the school year.</span></p>
<h2><span>Building Your Support System</span></h2>
<p><span>Even with a faster recovery, having support in place makes the transition smoother. Consider the following as you prepare.</span></p>
<p><span>Arrange help for the first week or two at home, when you will most need assistance with meals, driving, and household tasks. Line up backup for school transportation in case you need a bit more time before returning to driving. Prepare meals in advance or set up a meal train with friends and family. Stock up on school supplies and handle as much back-to-school preparation as possible before your surgery date.</span></p>
<p><span>A little planning up front means less stress during recovery and a smoother return to your family’s routine.</span></p>
<h2><span>Is Minimally Invasive Surgery Right for You?</span></h2>
<p><span>Not every patient is a candidate for minimally invasive techniques, but many more qualify than they realize. Eligibility depends on the specific cardiac condition, your overall health, and your individual anatomy. Conditions commonly treated with minimally invasive approaches include valve repair and replacement, certain bypass procedures, and various structural heart issues.</span></p>
<p><span>The best way to know whether you are a candidate is a thorough evaluation with a surgeon experienced in these techniques. The expertise that comes from years of dedicated practice makes a real difference, both in determining candidacy and in achieving the smooth, faster recoveries that matter to busy parents.</span></p>
<h2><span>Your Family Needs You Healthy</span></h2>
<p><span>Perhaps the most important message for any parent is this: taking care of your heart is taking care of your family. Delaying necessary surgery to avoid disrupting the school year is understandable, but it can put your long-term health and your ability to be there for your children at risk.</span></p>
<p><span>Minimally invasive heart surgery makes it possible to address your cardiac health while minimizing the disruption to your family’s life. You can get the care you need and get back to the school runs, homework help, and bedtime stories that your children depend on, all without the extended absence that traditional surgery once required.</span></p>
<p><span>Your kids need you to be present, healthy, and around for years to come. Choosing to address a heart condition sooner rather than later, with the least disruptive approach available, is one of the best things you can do for them.</span></p>
<h2><span>Schedule Your Consultation Today</span></h2>
<p><span>If you are a parent facing a heart condition, do not let the demands of the school year keep you from getting the care you need. Minimally invasive heart surgery may allow you to address your health and get back home to your family faster than you ever thought possible.</span></p>
<p><span>Contact our office today to </span><a href="https://heartsurgeryinfo.com/contact-us/"><span>schedule a consultation</span></a><span> and find out whether you are a candidate for minimally invasive heart surgery. We will evaluate your specific situation, walk you through realistic recovery timelines, and help you create a plan that fits your family’s life. Your health and your family are worth it, and the sooner you take that first step, the sooner you can get back to the life you love.</span></p>
<p><span>Want to go deeper into heart health and recovery? Understanding how your heart works, how it responds to stress and daily demands, and what recovery truly involves helps you make informed decisions for yourself and your family. </span><a href="https://heartsurgeryinfo.com/about-dr-ciuffo/"><span>Dr. Ciuffo’s</span></a><span> expertise in Minimally Invasive Heart Surgery and Bloodless Heart Surgery is the result of a career dedicated to advancing and perfecting these life-saving techniques.</span></p>]]> </content:encoded>
</item>

<item>
<title>Flu Season Prep: Why Recent Heart Surgery Patients Need Extra Protection</title>
<link>https://edusehat.com/en/flu-season-prep-why-recent-heart-surgery-patients-need-extra-protection</link>
<guid>https://edusehat.com/en/flu-season-prep-why-recent-heart-surgery-patients-need-extra-protection</guid>
<description><![CDATA[ When Recovery Meets Flu Season Every fall, as temperatures drop and children head back into crowded classrooms, flu season arrives. For most people, it means an annual reminder to get a flu shot and wash their hands more often. But for someone recovering from recent heart surgery, flu season carries higher stakes and demands extra […] ]]></description>
<enclosure url="https://heartsurgeryinfo.com/wp-content/uploads/2026/07/image2-e1785340083151.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 23 Sep 2026 03:50:13 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Flu, Season, Prep:, Why, Recent, Heart, Surgery, Patients, Need, Extra, Protection</media:keywords>
<content:encoded><![CDATA[<h2><span>When Recovery Meets Flu Season</span></h2>
<p><span>Every fall, as temperatures drop and children head back into crowded classrooms, flu season arrives. For most people, it means an annual reminder to get a flu shot and wash their hands more often. But for someone recovering from recent heart surgery, flu season carries higher stakes and demands extra attention.</span></p>
<p><span>If you have had heart surgery in the past several months, your body is still healing, your immune system may be working harder than usual, and your cardiovascular system is in a more vulnerable state. Understanding why this matters and what steps you can take to protect yourself can make a meaningful difference in your recovery and long-term health.</span></p>
<h2><span>Why Heart Surgery Patients Are More Vulnerable</span></h2>
<p><span>Recovering from heart surgery places significant demands on the body. Even with </span><a href="https://heartsurgeryinfo.com/minimally-invasive-heart-surgery/"><span>minimally invasive techniques</span></a><span> that reduce trauma and speed healing, your system is still directing energy toward recovery. Several factors make recent surgical patients more susceptible to flu-related complications.</span></p>
<p><span>Your immune system is focused on healing. After surgery, the body dedicates resources to repairing tissue and regaining strength, leaving fewer reserves to fight off a viral infection.</span></p>
<p><span>Your heart is still recovering. The flu places extra strain on the cardiovascular system. Fever, dehydration, and the body’s inflammatory response to infection all force the heart to work harder, which is far from ideal when it is still healing.</span></p>
<p><span>Respiratory complications are a concern. The flu can lead to pneumonia and other respiratory issues. For someone recovering from cardiac surgery, breathing complications are particularly risky and can slow the healing process.</span></p>
<p><span>Inflammation is a factor. Influenza triggers an inflammatory response throughout the body. Research has linked flu infection to an increased risk of cardiac events, making prevention especially important for heart patients.</span></p>
<h2><span>The Connection Between Flu and Heart Health</span></h2>
<p><span>Many people do not realize how closely respiratory infections and heart health are connected. Studies have shown that the risk of a heart attack rises significantly in the days and weeks following a flu infection. The reasons include the added strain that fever and rapid heart rate place on the cardiovascular system, the inflammation that infection triggers, and the way illness can destabilize existing cardiac conditions.</span></p>
<p><span>For a recent surgery patient, these risks are amplified. Your heart has just undergone a significant procedure and is in a delicate stage of recovery. Adding the stress of a serious viral infection can complicate healing and, in some cases, lead to setbacks. This is why flu prevention is not just general good advice for heart patients. It is an important part of protecting the results of your surgery.</span></p>
<h2><span>The Flu Vaccine and Heart Patients</span></h2>
<p><span>For most heart surgery patients, the flu vaccine is not only safe but strongly recommended. In fact, major cardiology organizations consider annual flu vaccination an important part of cardiovascular care.</span></p>
<p><span>The flu shot helps your body build defenses against the most common circulating strains, reducing both the likelihood of infection and the severity of illness if you do get sick. For heart patients, this protection is especially valuable given the flu’s elevated risk.</span></p>
<p><span>Timing matters. It generally takes about two weeks after vaccination for your body to build full protection, so getting vaccinated early in the season, ideally before flu begins circulating widely, is ideal. If you have had recent surgery, talk with your care team about the best timing for your vaccination based on your individual recovery.</span></p>
<p><span>Always consult your surgeon or cardiologist before getting vaccinated after surgery. In most cases, they will encourage it, but they can advise on the ideal timing relative to your procedure and recovery.</span></p>
<h2><span>Practical Steps to Protect Yourself This Flu Season</span></h2>
<p><span>Beyond vaccination, there are many practical measures recent heart surgery patients can take to reduce their risk during flu season.</span></p>
<h3><span>Practice Diligent Hand Hygiene</span></h3>
<p><span>Frequent handwashing with soap and water for at least twenty seconds is one of the most effective ways to prevent infection. When soap and water are not available, an alcohol-based hand sanitizer is a good alternative. Be especially mindful after being in public spaces or touching shared surfaces.</span></p>
<h3><span>Avoid Crowds When Possible</span></h3>
<p><span>During peak flu season, consider limiting time in crowded indoor spaces where viruses spread easily. If you must be in crowded settings, wearing a mask can add a layer of protection during your vulnerable recovery period.</span></p>
<h3><span>Keep Your Distance From Sick Individuals</span></h3>
<p><span>If family members or friends are ill, maintain distance until they have recovered. It is perfectly reasonable to ask visitors to postpone their visit if they are feeling unwell, especially while you are healing.</span></p>
<h3><span>Support Your Immune System</span></h3>
<p><span>Getting adequate rest, staying hydrated, eating nutritious foods, and following your recovery plan all help support your immune system. A well-nourished, well-rested body is better equipped to fight off infection.</span></p>
<h3><span>Keep Surfaces Clean</span></h3>
<p><span>Regularly disinfect frequently touched surfaces in your home, such as doorknobs, light switches, remote controls, and phones, particularly if someone in your household is sick.</span></p>
<h2><span>Recognizing Warning Signs</span></h2>
<p><span>Even with the best precautions, it is important to know the warning signs of flu and when to seek medical care. For heart surgery patients, prompt attention to symptoms is especially important.</span></p>
<p><span>Watch for fever, body aches, fatigue, cough, sore throat, and congestion, which are common flu symptoms. If you develop these, contact your doctor promptly, as early treatment with antiviral medication can reduce severity.</span></p>
<p><span>Seek immediate medical attention if you experience difficulty breathing or shortness of breath, chest pain or pressure, a rapid or irregular heartbeat, confusion, or a high fever that will not come down. For a recovering heart patient, these symptoms warrant urgent evaluation.</span></p>
<p><span>Do not wait to see if symptoms improve on their own. Your recovery is too important, and early intervention can prevent a manageable illness from becoming a serious complication.</span></p>
<h2><span>Protecting Those Around You</span></h2>
<p><span>One of the best ways to protect yourself during recovery is to encourage the people around you to take precautions too. When family members, caregivers, and close contacts are vaccinated and practicing good hygiene, they are less likely to bring illness into your home.</span></p>
<p><span>Encourage everyone in your household to get their flu shot. Ask visitors to stay home if they are feeling unwell. Create a household culture of handwashing and cleanliness during flu season. These collective efforts create a protective buffer around you while your body heals.</span></p>
<h2><span>The Bigger Picture of Recovery</span></h2>
<p><span>Protecting yourself during flu season is one piece of a larger commitment to your recovery. The care you put into your surgery does not end when you leave the operating room. It continues through the weeks and months of healing, and protecting yourself from preventable illness is an important part of that process.</span></p>
<p><span>The good news is that with minimally invasive surgical techniques, recovery is often faster and less taxing on the body, helping you regain your strength and resilience more quickly. Combined with sensible flu season precautions, this puts you in the strongest possible position to heal well and get back to the life you love.</span></p>
<p><span>Your surgical team’s expertise, built over years of dedicated practice, gives you the best foundation for recovery. Your job is to support that foundation with smart choices, including protecting yourself during flu season.</span></p>
<h2><span>Take Charge of Your Recovery</span></h2>
<p><span>Flu season does not have to be a source of anxiety for recent heart surgery patients. With the right precautions, including vaccination, good hygiene, and awareness of warning signs, you can significantly reduce your risk and protect the results of your surgery.</span></p>
<p><span>If you have questions about protecting your heart health during flu season, or if you are considering heart surgery and want to understand what recovery entails, we are here to help. Contact our office today to </span><a href="https://heartsurgeryinfo.com/contact-us/"><span>schedule a consultation</span></a><span>. Whether you are recovering from a recent procedure or exploring your options, we will provide the guidance and personalized care you need to protect your heart and your health.</span></p>
<p><span>Do not leave your recovery to chance. Take the steps now to stay healthy this flu season, and reach out to us with any concerns about your cardiac care. Your heart health is worth protecting, this season and every season.</span></p>
<p><span>Want to go deeper into heart health and recovery? Understanding how your heart responds to illness, stress, and the demands of everyday life helps you make informed choices that protect your long-term health. </span><a href="https://heartsurgeryinfo.com/about-dr-ciuffo/"><span>Dr. Ciuffo’s</span></a><span> expertise in Minimally Invasive Heart Surgery and Bloodless Heart Surgery is the result of a career dedicated to advancing and perfecting these life-saving techniques.</span></p>]]> </content:encoded>
</item>

<item>
<title>Retirement on the Horizon: Why Minimally Invasive Heart Surgery Protects the Active Years You Worked For</title>
<link>https://edusehat.com/en/retirement-on-the-horizon-why-minimally-invasive-heart-surgery-protects-the-active-years-you-worked-for</link>
<guid>https://edusehat.com/en/retirement-on-the-horizon-why-minimally-invasive-heart-surgery-protects-the-active-years-you-worked-for</guid>
<description><![CDATA[ The Years You Planned For Deserve Protection You spent decades working, saving, and looking forward to the day you could finally slow down and enjoy life on your own terms. Retirement is meant to be the reward: time for travel, hobbies, grandchildren, and the pursuits you never had enough hours for. So when a heart […] ]]></description>
<enclosure url="" length="49398" type="image/jpeg"/>
<pubDate>Wed, 23 Sep 2026 03:50:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Retirement, the, Horizon:, Why, Minimally, Invasive, Heart, Surgery, Protects, the, Active, Years, You, Worked, For</media:keywords>
<content:encoded><![CDATA[<h2><b>The Years You Planned For Deserve Protection</b></h2>
<p><span>You spent decades working, saving, and looking forward to the day you could finally slow down and enjoy life on your own terms. Retirement is meant to be the reward: time for travel, hobbies, grandchildren, and the pursuits you never had enough hours for. So when a heart condition enters the picture just as you approach or settle into these years, it can feel like a cruel twist of timing.</span></p>
<p><span>For many patients nearing retirement, the fear is not just about the surgery itself. It is about what recovery will cost them. Will months of healing eat into the active years they worked so hard to earn? Will they finally have the freedom to travel, only to spend it recovering at home?</span></p>
<p><span>The reassuring truth is that modern cardiac care has changed the equation. Minimally invasive heart surgery offers faster recovery and less disruption, helping to protect the very years you have been counting on rather than stealing them away.</span></p>
<h2><b>Why Recovery Time Matters More in Retirement</b></h2>
<p><span>When you are younger and working, time away for surgery feels like a temporary pause. But in retirement, active years carry a different weight. The window for doing the things you dreamed about, the international trips, the physically demanding hobbies, the energetic play with grandchildren, is precious and finite.</span></p>
<p><span>Traditional open-heart surgery, which requires splitting the breastbone, comes with a lengthy recovery. Patients often spend a week or more in the hospital, followed by six to eight weeks before they can drive and three to six months before returning to full activity. During this time, lifting, reaching, and physical exertion are all restricted.</span></p>
<p><span>For a retiree, three to six months of limited activity is not a small thing. It could mean missing an entire travel season, skipping a grandchild’s milestone, or losing a summer of gardening and outdoor time. When your active years are the whole point, protecting them becomes a priority.</span></p>
<h2><b>The Minimally Invasive Difference</b></h2>
<p><span>Minimally invasive heart surgery takes a fundamentally different approach. Instead of splitting the breastbone, surgeons work through small incisions between the ribs, often just a few inches long. This preserves the chest’s structural integrity and greatly reduces trauma to the body.</span></p>
<p><span>The recovery advantages are significant, especially for those focused on getting back to an active retirement. Most minimally invasive patients spend only three to five days in the hospital. Many can drive within about two weeks and return to most normal activities within four to six weeks. Because there is no healing breastbone to protect, restrictions on lifting and movement are far less severe.</span></p>
<p><span>For a retiree, this can transform heart surgery from a season-stealing ordeal into a manageable interruption. Rather than losing months of active living, you may be back to your routines and your plans within a matter of weeks.</span></p>
<h2><b>Getting Back to the Retirement You Envisioned</b></h2>
<p><a href="https://heartsurgeryinfo.com/psychological-aspects-of-recovery/"><span>Recovery</span></a><span> statistics are helpful, but what retirees really want to know is how quickly they can return to the activities that make retirement meaningful. Here is what a faster recovery can mean.</span></p>
<h3><b>Travel and Adventure</b></h3>
<p><span>For many, retirement is synonymous with travel. Whether it is a long-awaited cruise, a national parks road trip, or visits to family across the country, travel is often at the top of the list. Minimally invasive surgery, with its faster recovery, means you may be cleared to travel again in weeks rather than being grounded for the better part of a year.</span></p>
<h3><b>Physical Hobbies and Recreation</b></h3>
<p><span>Golf, tennis, cycling, hiking, gardening, and countless other pursuits require a level of physical function that traditional surgery restricts for months. The reduced lifting and movement restrictions of minimally invasive approaches allow a quicker return to the activities that keep you engaged and fulfilled, always within your surgeon’s guidelines.</span></p>
<h3><b>Time With Grandchildren</b></h3>
<p><span>Being an active grandparent means getting down on the floor to play, lifting little ones, and keeping up with their boundless energy. Traditional surgery restrictions make these interactions off-limits for weeks. A faster recovery means less time on the sidelines and more time doing what matters most.</span></p>
<h3><b>Staying Socially Connected</b></h3>
<p><span>Retirement is also about community: clubs, volunteer work, social gatherings, and staying active in the lives of friends and family. Getting back on your feet sooner means less isolation during recovery and a quicker return to the social connections that keep retirement rich and rewarding.</span></p>
<h2><b>The Mindset Shift: Surgery as Protection, Not Loss</b></h2>
<p><span>One of the most important reframes for patients approaching retirement is to see heart surgery not as something that takes away from their active years but as something that protects them.</span></p>
<p><span>A heart condition left untreated does not stay still. Symptoms often worsen over time, and the underlying problem can progress, eventually limiting your activity far more than a well-timed surgery ever would. Fatigue, shortness of breath, and reduced stamina can quietly erode your ability to do the things you love long before you realize what is happening.</span></p>
<p><span>Addressing a cardiac condition, especially with a less disruptive minimally invasive approach, is an investment in your future activity. It is choosing a few weeks of recovery now to protect years of vitality ahead. When you look at it that way, the decision to move forward becomes far less daunting.</span></p>
<h2><b>Timing Your Surgery Around Your Retirement Plans</b></h2>
<p><span>One advantage of minimally invasive surgery is that its predictable, shorter recovery makes it easier to plan around your life. Retirees often have more flexibility in scheduling than working patients, which can be a real advantage.</span></p>
<p><span>Some patients choose to have surgery during a quieter season, allowing recovery to happen before a big trip or an active summer. Others plan around family visits so that support is readily available during the initial recovery period. Because recovery is measured in weeks, you have far more room to fit surgery into your life without sacrificing the experiences that matter to you.</span></p>
<p><span>The key is having an honest conversation with your surgical team about your plans and priorities. A good surgeon will help you find a timing that addresses your health promptly while respecting the life you want to keep living.</span></p>
<h2><b>Are You a Candidate?</b></h2>
<p><span>Not every patient is a candidate for </span><a href="https://heartsurgeryinfo.com/minimally-invasive-heart-surgery/"><span>minimally invasive techniques</span></a><span>, but many more qualify than they realize. Eligibility depends on your specific cardiac condition, overall health, and anatomy. Conditions commonly treated with minimally invasive approaches include valve repair and replacement, certain bypass procedures, and a range of structural heart issues.</span></p>
<p><span>Age alone is rarely a barrier. In fact, older patients often benefit especially from the reduced trauma of minimally invasive surgery, as their bodies may tolerate a less invasive approach better than a full sternotomy. The best way to know whether you are a candidate is a thorough evaluation with a surgeon experienced in these techniques.</span></p>
<p><span>The expertise that comes from years of dedicated practice makes a real difference here, both in determining who qualifies and in achieving the smooth, faster recoveries that let patients get back to the active retirement they envisioned.</span></p>
<h2><b>Prioritizing Your Health Without Sacrificing Your Dreams</b></h2>
<p><span>There is a common temptation among those approaching retirement to put off addressing a heart condition, to wait until after the next trip, the next family gathering, the next season. But delaying necessary care carries real risks, and a cardiac condition rarely waits for a convenient time.</span></p>
<p><span>The beauty of minimally invasive surgery is that it removes much of the reason for delay. When recovery is measured in weeks rather than months, there is far less to fear and far less to lose. You can address your health promptly and still get back to your plans, your travels, and your active life sooner than you might have thought possible.</span></p>
<p><span>Your retirement years are meant to be lived fully. Protecting your heart is one of the most important things you can do to make sure you have the health and vitality to enjoy every one of them.</span></p>
<h2><b>Schedule Your Consultation Today</b></h2>
<p><span>If a heart condition is standing between you and the active retirement you worked so hard to earn, do not let fear of a long recovery hold you back. Minimally invasive heart surgery may allow you to address your health and get back to your life faster than you ever imagined.</span></p>
<p><a href="https://heartsurgeryinfo.com/contact-us/"><span>Contact our office today to schedule a consultation</span></a><span> and find out whether you are a candidate for minimally invasive heart surgery. We will evaluate your specific situation, walk you through realistic recovery timelines, and help you create a plan that protects both your heart and the retirement you have been dreaming about. The active years ahead are worth it, and the sooner you take that first step, the sooner you can get back to living them to the fullest.</span></p>
<p><span>Want to go deeper into heart health and recovery? Understanding how your heart works, how it responds to activity and stress, and what recovery truly involves helps you make informed decisions about your future. </span><a href="https://heartsurgeryinfo.com/about-dr-ciuffo/"><span>Dr. Ciuffo’s</span></a><span> expertise in Minimally Invasive Heart Surgery and </span><a href="https://heartsurgeryinfo.com/bloodless-heart-surgery/"><span>Bloodless Heart Surgery</span></a><span> is the result of a career dedicated to advancing and perfecting these life-saving techniques.</span></p>]]> </content:encoded>
</item>

<item>
<title>Best Practices for Establishing Data Integrity in Western Blotting</title>
<link>https://edusehat.com/en/best-practices-for-establishing-data-integrity-in-western-blotting</link>
<guid>https://edusehat.com/en/best-practices-for-establishing-data-integrity-in-western-blotting</guid>
<description><![CDATA[ Despite advances in other proteomic methods, including mass spectrometry, western blotting remains one of the most widely-used techniques across life sciences research due to its affordability, specificity, and widespread accessibility.
The post Best Practices for Establishing Data Integrity in Western Blotting appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-1433163698.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 23 Sep 2026 00:15:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Best, Practices, for, Establishing, Data, Integrity, Western, Blotting</media:keywords>
<content:encoded><![CDATA[<p>Western blotting is a fundamental technique, supporting protein detection, identification, quantitation, and providing insight into post-translational modifications. Despite advances in other proteomic methods, including mass spectrometry, western blotting remains one of the most widely used techniques across life sciences research due to its affordability, specificity, and widespread accessibility.</p>
<p>However, the integrity of western blot data has come under scrutiny in recent years following the <a href="https://www.the-scientist.com/data-integrity-in-scientific-research-insights-from-elisabeth-bik-73119" target="_blank" rel="noopener">retraction of a number of papers due to image irregularities</a>. To that end, many major journals, including the <a href="https://www.jbc.org/article/S0021-9258(20)39480-1/fulltext" target="_blank" rel="noopener"><em>Journal of Biological Chemistry</em></a>, <a href="https://www.cell.com/cell/information-for-authors/journal-policies" target="_blank" rel="noopener"><em>Cell</em></a>, and <a href="https://www.nature.com/nature-portfolio/editorial-policies/image-integrity" target="_blank" rel="noopener"><em>Nature</em></a> have specific submission guidelines, with data quality and transparency being top priorities. With this in mind, it is crucial for researchers to understand where to draw the line between improving image presentation and data manipulation when it comes to western blotting.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<h4><strong>Understanding data misrepresentation through image manipulation</strong></h4>
<p>Western blot image integrity can be compromised through undisclosed, seemingly minor adjustments to the contrast, brightness, and exposure through to more deliberate edits, such as cropping out or duplicating bands or lanes, combining lanes from different gels, or rotating bands. While many of these practices can be performed inadvertently, they can mislead data interpretation.</p>
<p>For presentation purposes, non-destructive adjustments, such as image transformation and background subtraction are reasonable and often scientifically necessary depending on sample complexity and signal specificity. However, these adjustments must be made consistently across all lanes being analyzed and must be fully disclosed in figure legends or methods.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p><figure aria-describedby="caption-attachment-338264" class="wp-caption alignleft"><img fetchpriority="high" decoding="async" class="size-medium wp-image-338264" src="https://www.genengnews.com/wp-content/uploads/2026/09/Nik_Formal_Headshot10MB-300x242.jpg" alt="Nikolas Chmiel, PhD [Bio-Rad Labs]" width="300" height="242" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/Nik_Formal_Headshot10MB-300x242.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/Nik_Formal_Headshot10MB-1024x825.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/09/Nik_Formal_Headshot10MB-768x618.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/09/Nik_Formal_Headshot10MB-1536x1237.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2026/09/Nik_Formal_Headshot10MB-2048x1649.jpg 2048w, https://www.genengnews.com/wp-content/uploads/2026/09/Nik_Formal_Headshot10MB-522x420.jpg 522w, https://www.genengnews.com/wp-content/uploads/2026/09/Nik_Formal_Headshot10MB-1043x840.jpg 1043w, https://www.genengnews.com/wp-content/uploads/2026/09/Nik_Formal_Headshot10MB-696x561.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/09/Nik_Formal_Headshot10MB-1392x1121.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2026/09/Nik_Formal_Headshot10MB-1068x860.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/09/Nik_Formal_Headshot10MB-1920x1546.jpg 1920w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Nikolas Chmiel, PhD [Bio-Rad Labs]</figcaption></figure>Thorough documentation of unprocessed image files is the most practical approach to demonstrating image integrity and strengthening the credibility of the research, while expediting the review process, as access to raw images is increasingly demanded during journal submissions. These documents include the original, unprocessed gel image; the processed image submitted for publication, with clear disclosure of adjustments; details of the image detection and processing software, and parameters used; and evidence that identical adjustments were applied to all samples being comparatively analyzed.</p>
<p>There are several image analysis software packages available to researchers to aid gel image analysis and quantitation. These include <a href="https://imagej.net/" target="_blank" rel="noopener">ImageJ</a>, developed by the National Institutes of Health, which is widely accepted by many journals. The software preserves image data and allows creation of macros, enabling identical processing to be applied across multiple images. ImageJ quantifies signal intensity directly, so it’s suitable for a range of workflows including total protein normalization from stain-free approaches or stained images.</p>
<p>As with any densitometry tool, quantitation should be performed on raw images within the linear range of detection, and macros should be validated against a known standard to confirm they produce accurate, reproducible results across all images in a set. <a href="https://fiji.sc/" target="_blank" rel="noopener">Fiji</a> is an image processing package that facilitates analysis in ImageJ, offering integration and comprehensive documentation, and is recommended for first-time users.</p>
<p>Beyond this widely used option, a number of other tools serve more specific purposes, from general image editing to acquisition-integrated workflows. GNU Image Manipulation Program (<a href="https://www.gimp.org/" target="_blank" rel="noopener">GIMP</a>), <a href="https://scikit-image.org/" target="_blank" rel="noopener">Python with scikit-image</a>, <a href="https://bioconductor.org/packages/release/bioc/html/EBImage.html" target="_blank" rel="noopener">EBImage</a>, and <a href="https://www.bio-rad.com/en-uk/product/image-lab-software?ID=KRE6P5E8Z" target="_blank" rel="noopener">Image Lab</a> are also available to researchers and offer various capabilities:</p>
<ul>
<li><strong>GIMP:</strong> GIMP is not designed for scientific quantitation but offers general-purpose image editing for cropping, documentation and annotation.</li>
<div class="my-8"><span data-render-ad="5"></span></div>
<li><strong>Python with scikit-image:</strong> For researchers with programming expertise, Python with scikit-image provides full control over imaging processing pipelines.</li>
<li><strong>EBImage:</strong> Hosted within the Bioconductor Project, EBImage allows seamless integration with downstream statistical analysis using R programming.</li>
<li><strong>Image Lab:</strong> The software preserves the full context of data from acquisition through analysis within a secure traceable environment, enabling documentation and transparency of image generation and processing.</li>
</ul>
<p></p><h4><strong>Choosing the most reliable normalization method</strong></h4>

<p>Alongside the choice of analysis software, reliable protein quantitation also depends on the normalization strategy used to correct for any non-biological differences between test samples prior to comparison, and the choice of method has direct implications for data integrity.</p>
<p><em>Single “Housekeeping” Protein Normalization. </em>Traditionally, western blots have been quantified via normalization against a single loading control, typically housekeeping proteins (HKPs) such as GAPDH, β-actin or β-tubulin, which are ubiquitous, abundant and assumed to be consistently expressed. This approach is widely used, however, HKPs must be validated against positive and negative controls within the researcher’s specific experimental context to <a href="https://www.science.org/doi/10.1126/scisignal.2005966" target="_blank" rel="noopener">confirm consistent expression levels across samples</a>.</p>
<p>As HKP expression is often considerably higher than that of target proteins, rigorous linear range determination must be established to <a href="https://onlinelibrary.wiley.com/doi/10.1155/2014/361590" target="_blank" rel="noopener">avoid oversaturation and loss of quantitative accuracy</a>. This process often requires several rounds of optimization of primary and secondary antibody dilution ratios, which can add significant time and complexity to the experiment.</p>
<p>Despite HKPs’ ubiquitous expression, their expression levels have been shown to fluctuate across different cell types, cell states, and disease states, including in <a href="https://www.oncotarget.com/article/11439/text/" target="_blank" rel="noopener">cancer</a>. Therefore, it is critical for researchers to validate their HKPs for consistent expression across different sample types and experimental conditions.</p>
<div class="my-8"><span data-render-ad="6"></span></div>
<p>Normalizing western blots using a single loading control may require stripping and reprobing of the membrane to detect both target and control signals if the proteins run at similar molecular weights. This process can introduce variability and the potential for incomplete stripping or uneven reprobing, increasing the risk of signal variation and reducing result reliability.</p>
<p><em>Total Protein Normalization. </em><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10214384/" target="_blank" rel="noopener">Total protein normalization (TPN)</a> overcomes both the linearity challenges of immunodetection and the reliance on a single control protein to represent the entire protein population (<em>Table 1</em>). Instead, TPN quantifies the total protein loaded in each lane, measured by collecting the signal on the membrane, to produce a normalization factor that is comprehensive and inherently stable. This can be achieved using Stain-Free technology or reversible staining methods such as Ponceau S.</p>
<p>One <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10214384/" target="_blank" rel="noopener">study</a> compared the accuracy and precision of normalization of three HKPs (β-tubulin, actin and GAPDH) against Stain-Free TPN. Although β-tubulin and actin showed accuracy comparable to that of Stain-Free TPN, they exhibited lower precision, potentially reducing the reliability of the measurements. At the same time, GAPDH plateaued rapidly due to oversaturation, resulting in poor accuracy.</p>
<p><a href="https://www.bio-rad.com/webroot/web/pdf/lsr/literature/Bulletin_6360.pdf" target="_blank" rel="noopener">Another study</a> reported similar findings by comparing the linearity of a series of dilutions obtained by Stain-Free TPN measurement as well as HKPs immunodetection, further demonstrating that Stain-Free TPN can serve as a more reliable and accurate loading control than HKPs (<em>Figure 1</em>).</p>
<p><figure aria-describedby="caption-attachment-338261" class="wp-caption alignnone"><img decoding="async" class="wp-image-338261 size-large" src="https://www.genengnews.com/wp-content/uploads/2026/09/Table-1-1024x641.jpg" alt="Table 1. Comparison between HKP normalization and TPN" width="696" height="436" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/Table-1-1024x641.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/09/Table-1-300x188.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/Table-1-768x481.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/09/Table-1-1536x962.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2026/09/Table-1-2048x1283.jpg 2048w, https://www.genengnews.com/wp-content/uploads/2026/09/Table-1-671x420.jpg 671w, https://www.genengnews.com/wp-content/uploads/2026/09/Table-1-1341x840.jpg 1341w, https://www.genengnews.com/wp-content/uploads/2026/09/Table-1-696x436.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/09/Table-1-1392x872.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2026/09/Table-1-1068x669.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/09/Table-1-1920x1203.jpg 1920w" sizes="(max-width: 696px) 100vw, 696px"><figcaption class="wp-caption-text">Table 1. Comparison between HKP normalization and TPN</figcaption></figure></p>
<p class="trimmed"> </p>
<p><figure aria-describedby="caption-attachment-338226" class="wp-caption alignnone"><img loading="lazy" decoding="async" class=" td-center wp-image-338226 size-large" src="https://www.genengnews.com/wp-content/uploads/2026/09/Figure-1_Hammond-et-al_-1024x576.png" alt="Figure 1. Comparison of Stain-Free total protein measurement and immunodetection of housekeeping proteins in cell lysate. (A) Representative western blot images. (B) Relative intensity of protein bands compared to a predicted quantitative response. Adapted from Hammond et al. 2020." width="696" height="392" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/Figure-1_Hammond-et-al_-1024x576.png 1024w, https://www.genengnews.com/wp-content/uploads/2026/09/Figure-1_Hammond-et-al_-300x169.png 300w, https://www.genengnews.com/wp-content/uploads/2026/09/Figure-1_Hammond-et-al_-768x432.png 768w, https://www.genengnews.com/wp-content/uploads/2026/09/Figure-1_Hammond-et-al_-1536x864.png 1536w, https://www.genengnews.com/wp-content/uploads/2026/09/Figure-1_Hammond-et-al_-2048x1152.png 2048w, https://www.genengnews.com/wp-content/uploads/2026/09/Figure-1_Hammond-et-al_-747x420.png 747w, https://www.genengnews.com/wp-content/uploads/2026/09/Figure-1_Hammond-et-al_-1493x840.png 1493w, https://www.genengnews.com/wp-content/uploads/2026/09/Figure-1_Hammond-et-al_-696x392.png 696w, https://www.genengnews.com/wp-content/uploads/2026/09/Figure-1_Hammond-et-al_-1392x783.png 1392w, https://www.genengnews.com/wp-content/uploads/2026/09/Figure-1_Hammond-et-al_-1068x601.png 1068w, https://www.genengnews.com/wp-content/uploads/2026/09/Figure-1_Hammond-et-al_-1920x1080.png 1920w" sizes="auto, (max-width: 696px) 100vw, 696px"><figcaption class="wp-caption-text">Figure 1. Comparison of Stain-Free total protein measurement and immunodetection of housekeeping proteins in cell lysate. (A) Representative western blot images. (B) Relative intensity of protein bands compared to a predicted quantitative response. Adapted from Hammond et al. 2020.</figcaption></figure></p>
<p>Stain-Free TPN methods were introduced to address variation in membrane sensitivity, allowing the gel and blot to be visualized through an imaging step that does not interfere with downstream immunodetection. This is particularly useful for enhancing data integrity as Stain-Free approaches provide a true scalar relationship between loading amount and signal intensity, so both target and loading signals can be quantified accurately <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3809032/" target="_blank" rel="noopener">within a linear dynamic range</a> by normalizing each band to the total protein in each lane. This approach improves the reproducibility of TPN, and was recently shown to <a href="https://www.sciencedirect.com/science/article/abs/pii/S0003269722003001" target="_blank" rel="noopener">reduce variability compared to actin or β-tubulin normalization while also reducing the sample size needed for statistical significance by >50%</a>.</p>
<p>However, researchers should be aware that since TPN reflects the whole protein population, it can obscure treatment-induced global shifts in protein expression, so the normalization approach chosen should be matched to the biological context of the experiment.</p>
<p><em>Upholding data integrity. </em>A western blot’s quantitative reliability is dependent on the decisions made at every stage, from image acquisition and processing through to the normalization strategy applied. Rigorous documentation is essential for the transparency and integrity of published data but does not negate the other steps needed to ensure biological validity and quantitative accuracy. Central to this is the normalization method chosen to account for non-biological differences between samples.</p>
<div class="my-8"><span data-render-ad="7"></span></div>
<p>Whichever approach is used, it must be reported and accompanied by an explanation of why it was the most suitable choice for the experiment and its biological context. While there are no fixed requirements on which normalization method researchers should follow, many journals now strongly recommend the use of TPN and stress that HKPs should only be used where there is strong evidence that their expression is unaffected by the experimental conditions.</p>
<p>Together, transparent audit-ready documentation, careful tool selection and a well-justified normalization strategy form the foundation of credible, reproducible western blot data, and meet the growing expectations of journals and the wider research community.</p>
<p class="trimmed"> </p>
<p><em>Nikolas Chmiel, PhD, is associate director R&D, life science group, Bio-Rad Laboratories.</em></p>
<p><em> </em></p>
<p class="trimmed"> </p>
<p class="trimmed"> </p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/best-practices-for-establishing-data-integrity-in-western-blotting/">Best Practices for Establishing Data Integrity in Western Blotting</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Advancing AAV Development: From Production to Performance</title>
<link>https://edusehat.com/en/advancing-aav-development-from-production-to-performance</link>
<guid>https://edusehat.com/en/advancing-aav-development-from-production-to-performance</guid>
<description><![CDATA[ In this GEN Learning Lab, our expert panelists Guangping Gao, PhD, and Thomas Quinn will explore critical steps in the AAV workflow that influence vector quality and downstream experimental success.
The post Advancing AAV Development: From Production to Performance appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/Getty_2282040570_AdenoAssociatedVirusVirions-e1790089840193.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 23 Sep 2026 00:15:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Advancing, AAV, Development:, From, Production, Performance</media:keywords>
<content:encoded><![CDATA[<p></p><p></p><div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex"><p class="is-layout-flow wp-block-column-is-layout-flow"></p><div class="wp-block-column"></div><p></p></div><p></p><p></p><p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Register Now</button></p><p></p><p></p><h3 class="w-full text-left">
    <strong>
            </strong>
</h3>
<div class="flex flex-row m-0-auto items-stretch justify-center flex-wrap mb-4">
    
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3 presenter-card">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/09/headshot.jpg" class="h-full w-full object-cover" alt="Image of Thomas Quinn">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Thomas Quinn</h2>
                <h5 class="mt-0 !text-[15px]">R&D Group Leader<br>Takara Bio USA</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/09/headshot.jpg" alt="Image of Thomas Quinn">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Thomas Quinn</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Thomas Quinn earned a BS in zoology (genetics) from Michigan State University and an MS in molecular medicine and genetics from Wayne State University, where his thesis involved viral vector development for CAR T therapies targeting melanoma and lung cancers. Since 1998, he has led the viral delivery R&D group at Takara Bio USA, focusing on high-efficiency viral delivery systems (adenoviral, retroviral, lentiviral, and AAV) and CRISPR/Cas9 genome editing products.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog>
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3 presenter-card">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/09/GuangpingGao_Headshot.jpg" class="h-full w-full object-cover" alt="Image of Guangping Gao, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Guangping Gao, PhD</h2>
                <h5 class="mt-0 !text-[15px]">Professor and Chair<br>Dept. of Genetic and Cellular Medicine<br>UMass Chan Medical School</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/09/GuangpingGao_Headshot.jpg" alt="Image of Guangping Gao, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Guangping Gao, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Guangping Gao, PhD, is an internationally recognized gene therapy researcher who played a key role in the discovery and characterization of a new family of adeno-associated virus (AAV) serotypes, which was instrumental in reviving the gene therapy field. His scientific research career has primarily focused on molecular genetics and viral vector gene therapy of rare genetic diseases, encompassing disease gene cloning, causative mutation identification, pathomechanism investigation, animal modeling, novel viral vector discovery, and engineering for <em>in vivo</em> gene delivery, vector biology, preclinical and clinical gene therapy product development, viral vector manufacturing for preclinical and clinical gene therapy applications as well as technology platforms development as novel approaches for human gene therapy. He has also co-founded several gene therapy companies.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog></div>

<p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-malblocks-webinars-info"></p><div><strong>Broadcast Date:</strong> <time>Wednesday, October 21, 2026</time><br><ul><li><strong>Time:</strong> <time datetime="2026-10-21T15:00:00.000Z">08:00 PDT, 11:00 EDT, 15:00 GMT</time></li></ul></div><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p></p><div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex"><p></p><div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"><p class="wp-block-paragraph">Technologies for adeno-associated virus (AAV) development are advancing rapidly, driven by innovations in vector engineering and production. New insights into vector quality and performance are supporting the development of new strategies and tools for AAV workflows. These include advances in capsid engineering and workflow standardization—which are accelerating the development of more effective gene therapies.</p><p></p><p></p><p class="wp-block-paragraph">In this <em>GEN Learning Lab</em>, our expert panelists Guangping Gao, PhD, and Thomas Quinn will explore critical steps in the AAV workflow that influence vector quality and downstream experimental success. The discussion will highlight advances in purification and recovery strategies, followed by approaches for accurate AAV titration and vector characterization to support reproducible research and scalable AAV production. The panelists will also discuss innovations in next-generation AAV designs that are empowering researchers to improve gene delivery performance and expand the potential of gene therapies.</p><p></p><p></p><p class="wp-block-paragraph">Key takeaways include:</p><p></p><p></p><p></p><ul class="wp-block-list"><p></p><li>Practical approaches to overcoming challenges in AAV purification, titration, and downstream analysis</li><p></p><p></p><p></p><li>Best practices for AAV production and workflow standardization</li><p></p><p></p><p></p><li>Emerging technologies that support reproducible and scalable AAV production workflows</li><p></p></ul><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-paragraph"><strong>Produced with support from:</strong></p><p></p><p></p><div class="wp-block-image"><p><figure class="alignleft size-medium"><a href="https://www.takarabio.com/" target="_blank" rel=" noreferrer noopener"><img decoding="async" width="300" height="104" src="https://www.genengnews.com/wp-content/uploads/2024/10/Takara_logo-300x104.jpg" alt="Takara logo" class="wp-image-303591" srcset="https://www.genengnews.com/wp-content/uploads/2024/10/Takara_logo-300x104.jpg 300w, https://www.genengnews.com/wp-content/uploads/2024/10/Takara_logo-1024x354.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2024/10/Takara_logo-768x266.jpg 768w, https://www.genengnews.com/wp-content/uploads/2024/10/Takara_logo-1215x420.jpg 1215w, https://www.genengnews.com/wp-content/uploads/2024/10/Takara_logo-696x241.jpg 696w, https://www.genengnews.com/wp-content/uploads/2024/10/Takara_logo-1392x484.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2024/10/Takara_logo-1068x369.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2024/10/Takara_logo.jpg 1400w" sizes="(max-width: 300px) 100vw, 300px"></a></figure></p><p></p></div></div><p></p></div><p></p><p>The post <a href="https://www.genengnews.com/multimedia/advancing-aav-development-from-production-to-performance/">Advancing AAV Development: From Production to Performance</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Point&#45;of&#45;Care Testing Helps Keep Rural Emergency Departments Open in Saskatchewan</title>
<link>https://edusehat.com/en/point-of-care-testing-helps-keep-rural-emergency-departments-open-in-saskatchewan</link>
<guid>https://edusehat.com/en/point-of-care-testing-helps-keep-rural-emergency-departments-open-in-saskatchewan</guid>
<description><![CDATA[ A Saskatchewan initiative that allows trained healthcare workers to perform essential diagnostic tests when laboratory professionals are temporarily unavailable is helping rural emergency departments remain open. The Saskatchewan Health Authority (SHA) has introduced point-of-care testing at Canora Hospital’s emergency department, expanding a program now operating in rural communities across the province. The technology allows trained […]
The post Point-of-Care Testing Helps Keep Rural Emergency Departments Open in Saskatchewan appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/09/ChatGPT-Image-Sep-22-2026-11_35_26-AM.png" length="49398" type="image/jpeg"/>
<pubDate>Wed, 23 Sep 2026 00:10:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Point-of-Care, Testing, Helps, Keep, Rural, Emergency, Departments, Open, Saskatchewan</media:keywords>
<content:encoded><![CDATA[<p data-pm-slice="1 1 []">A Saskatchewan initiative that allows trained healthcare workers to perform essential diagnostic tests when laboratory professionals are temporarily unavailable is helping rural emergency departments remain open.</p>
<p>The Saskatchewan Health Authority (SHA) has introduced point-of-care testing at Canora Hospital’s emergency department, expanding a program now operating in rural communities across the province.</p>
<p>The technology allows trained members of the local healthcare team to conduct several important diagnostic tests directly at the facility. These include hemoglobin testing to assess anemia and blood loss, white blood cell counts that can help identify infection, urinalysis to assess kidney function and detect urinary tract infections, and cardiac marker testing to evaluate heart health.</p>
<p>The goal is to provide clinicians with diagnostic information when regular laboratory professionals are temporarily unavailable, helping physicians and other healthcare providers make timely decisions about patient care.</p>
<p>The approach is particularly significant for rural hospitals, where the temporary loss of one component of the healthcare team can affect the ability of an emergency department to remain operational.</p>
<p>According to the SHA, point-of-care testing is now supporting emergency department services in 13 other rural Saskatchewan communities in addition to Canora.</p>
<p>The health authority reports that, as of September 15, <strong>the program has prevented 860 potential emergency department service disruptions since its introduction in 2023.</strong></p>
<p>Point-of-care testing does not replace regular laboratory services. Rather, it provides an additional option that can help maintain emergency services when laboratory professionals are temporarily unavailable.</p>
<p>The initiative is part of Saskatchewan’s broader strategy to improve access to emergency care in rural and remote communities. Recruitment of laboratory professionals for rural areas is continuing alongside the expansion of point-of-care testing.</p>
<p>Keeping rural emergency departments operating has become an important healthcare challenge across Canada, where smaller communities can be particularly vulnerable to temporary service interruptions caused by staffing shortages.</p>
<p>Saskatchewan’s experience demonstrates how point-of-care diagnostics can provide another tool for rural healthcare teams working to maintain access to emergency services close to home.</p>
<p data-pm-slice="1 1 []"><em>Source: Saskatchewan Health Authority</em></p>
<p>The post <a href="https://www.hospitalnews.com/point-of-care-testing-helps-keep-rural-emergency-departments-open-in-saskatchewan/">Point-of-Care Testing Helps Keep Rural Emergency Departments Open in Saskatchewan</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>$210M Burnaby Hospital Expansion to Add Emergency and Surgical Capacity</title>
<link>https://edusehat.com/en/210m-burnaby-hospital-expansion-to-add-emergency-and-surgical-capacity</link>
<guid>https://edusehat.com/en/210m-burnaby-hospital-expansion-to-add-emergency-and-surgical-capacity</guid>
<description><![CDATA[ Burnaby Hospital is moving ahead with a $210-million expansion and upgrade of its emergency and surgical departments as British Columbia renews plans for the hospital’s redevelopment. The provincial investment will support immediate improvements to emergency and surgical services, while planning continues for expanded cancer care and additional acute-care capacity. The project builds on the first […]
The post $210M Burnaby Hospital Expansion to Add Emergency and Surgical Capacity appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/09/BH_Health-Care-Pavilion_Header.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 23 Sep 2026 00:10:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>210M, Burnaby, Hospital, Expansion, Add, Emergency, and, Surgical, Capacity</media:keywords>
<content:encoded><![CDATA[<p>Burnaby Hospital is moving ahead with a $210-million expansion and upgrade of its emergency and surgical departments as British Columbia renews plans for the hospital’s redevelopment.</p>
<p>The provincial investment will support immediate improvements to emergency and surgical services, while planning continues for expanded cancer care and additional acute-care capacity.</p>
<p>The project builds on the first phase of the Burnaby Hospital redevelopment, which opened earlier this year. That phase included a new six-storey health-care pavilion with 83 beds, new maternity and neonatal intensive care services, mental-health and medical units, six operating rooms and expanded emergency department space. <a href="https://www.fraserhealth.ca/news/2026/Sep/Moving-forward-on-renewed-plan-to-redevelop-Burnaby-Hospital?utm_source=chatgpt.com">Fraser Health</a></p>
<h3>Expanded emergency department</h3>
<p>The next stage will add <strong>16 emergency department treatment spaces</strong>, along with a combined waiting and patient check-in area, a new decontamination zone and ambulance entrance.</p>
<p>The expansion will also include upgraded mechanical, electrical and information technology systems and separate pathways for patients and staff.</p>
<h3>Major surgical expansion</h3>
<p>Burnaby Hospital’s surgical department will also undergo significant expansion and modernization.</p>
<p>Four operating rooms will be upgraded and combined with the six operating rooms that opened earlier this year, providing the hospital with <strong>10 standardized operating rooms</strong>.</p>
<p>Plans also include an integrated sterile core serving the operating rooms, <strong>four minor procedure rooms and 42 renovated perioperative preparation and recovery bays — 17 more than currently available</strong>.</p>
<p>The redesigned surgical areas will also provide separate pathways for patients and staff. <a href="https://www.fraserhealth.ca/news/2026/Sep/Moving-forward-on-renewed-plan-to-redevelop-Burnaby-Hospital?utm_source=chatgpt.com">Fraser Health</a></p>
<h3>More hospital capacity planned</h3>
<p>The province says the $210-million investment is part of a renewed approach to the larger Burnaby Hospital redevelopment.</p>
<p>The project’s timeline was adjusted in the 2026 provincial budget after updated estimates showed the redevelopment was significantly over budget. An independent review subsequently produced 25 recommendations aimed at controlling costs and determining how the project could proceed.</p>
<p>Further phases are expected to include expanded cancer services and increased patient-care capacity through a new acute-care tower.</p>
<p>Work on the emergency and surgical improvements is beginning immediately, with initial procurement expected to be completed in early 2027, followed by detailed design and construction. <a href="https://www.fraserhealth.ca/news/2026/Sep/Moving-forward-on-renewed-plan-to-redevelop-Burnaby-Hospital?utm_source=chatgpt.com">Fraser Health</a></p>
<p><em>Hospital News reporting based on information released by Fraser Health and the Government of British Columbia.</em></p>
<p>The post <a href="https://www.hospitalnews.com/210m-burnaby-hospital-expansion-to-add-emergency-and-surgical-capacity/">$210M Burnaby Hospital Expansion to Add Emergency and Surgical Capacity</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>iNFixion seeks NF1 treatment by enhancing what the body is doing right</title>
<link>https://edusehat.com/en/infixion-seeks-nf1-treatment-by-enhancing-what-the-body-is-doing-right</link>
<guid>https://edusehat.com/en/infixion-seeks-nf1-treatment-by-enhancing-what-the-body-is-doing-right</guid>
<description><![CDATA[ The BIO 2026 Start-up Stadium winner targets a rare disease. As Herb Sarnoff sits in the hospital, waiting for a pain specialist to see […]
The post iNFixion seeks NF1 treatment by enhancing what the body is doing right appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/09/herb-sarnoff-4.png" length="49398" type="image/jpeg"/>
<pubDate>Tue, 22 Sep 2026 16:45:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>iNFixion, seeks, NF1, treatment, enhancing, what, the, body, doing, right</media:keywords>
<content:encoded><![CDATA[<h4>The BIO 2026 Start-up Stadium winner targets a rare disease.</h4>
<p>As Herb Sarnoff sits in the hospital, waiting for a pain specialist to see his daughter, he describes how a mutation on just one side of the NF1 gene causes neurofibromatosis type 1 (NF1).</p>
<p>“You have one good NF1 gene producing the neurofibromin protein your body needs, and one missing or mutant allele that isn’t, so every cell is not getting enough normal NF1 protein,” he explains. The result is a wide range of difficult symptoms, including painful tumors, bone conditions like scoliosis and osteoporosis, high rates of cancer, and neurocognitive manifestations such as learning disabilities, autism and sleep dysregulation.</p>
<p>Since discovering his daughter’sNF1, a rare disease impacting 1 in 3000 people, nearly 25 years ago, Sarnoff has slowly transformed himself from a tech entrepreneur with limited knowledge of biology to leading iNFixion Bioscience, a biotech developing treatments for NF1. Infixion’s novel NF1 approach aims to supercharge the function of the one good allele rather than trying to fix the mutant one. And the judges were impressed enough to award Infixion a Start-Up Stadium top prize at the 2026 BIO International Convention.</p>
<p>The award recognizes just two start-ups—from among 50 presenting—that investor judges deem to be most promising. iNFixion Bioscience won the Emerging Company Category (between $1 million-$10 million raised). The Seed-Stage winner, with less than $1 million raised, is BrainStorm Therapeutics.</p>
<h2>iNFixion’s innovation</h2>
<p>Gene therapies often seek to correct mutations, but as Sarnoff explains, “fixing” mutant NF1 genes is difficult. “The gene itself is extremely large: 320,000 base pairs of DNA,” he says, adding that sequencing has identified over 5,000 unique NF1 gene mutations, with no hotspots. “So gene therapy for NF1 is really, really challenging.”</p>
<p>Instead, iNFixion is targeting the healthy allele, increasing the amount of NF1 protein it can produce by blocking microRNAs that modulate protein expression.</p>
<p>“MicroRNAs are basically a feedback loop regulating protein in the body by putting a brake on protein production when necessary,” Sarnoff explains. “If you can block the right microRNAs, you’re essentially taking the brake off. But microRNAs are not specific to one gene. So if you take out a microRNA, you’ll likely have off-target effects.”</p>
<p>Instead of completely blocking the targeted microRNA, iNFixion seeks to block its function exclusively in the NF1 gene.</p>
<p>“The approach being pursued utilizes antisense oligonucleotides (ASOs) that block microRNA binding only on NF1 mRNA. This prevents that microRNA from putting a brake on NF1 protein production,” Sarnoff explains. “But that microRNA is still free to work on other genes, thus limiting potential off-target effects.”</p>
<p>iNFixion has shown in early cellular <em>in vitro</em> experiments that its ASO can boost NF1 protein expression by up to 70-80%. They have also adapted their ASO from the human version to a mouse version and shown they can boost NF1 protein expression in the brains of mice. The next step is to optimize for safety and efficacy in both human NF1 organoids and NF1 animal models.</p>
<h2>The drive for funding</h2>
<p>As with all start-ups, iNFixion is constantly seeking funding to continue its work. Thus far, most of the work has been funded by the National Institutes of Health (NIH), Department of Defense (DoD), and foundation grants, Sarnoff says.</p>
<p>“We’ve also been fortunate to get lab space at J&J’s San Diego incubator called JLABS,” he says. “It’s a prestigious and collaborative environment for drug discovery start-ups.”</p>
<p>As he seeks future funding, Sarnoff is hopeful of attracting investor interest. One advantage: Even though NF1 is a rare disease it is not that rare, affecting 125,000 Americans and 2.5 million worldwide.</p>
<p>“So it’s a bit of a sweet spot,” he explains. “We get all the benefits of orphan disease, including special treatment at the FDA, access to priority review vouchers and R&D tax incentives, but it’s a big enough market that there’s definitely interest from pharma.”</p>
<p>Sarnoff says iNFixion is in discussions with pharmaceutical companies interested in iNFixion. As for venture capital, Sarnoff notes that few VC’s provide early-stage funding for orphan disease, although a handful of professional investors are showing interest.</p>
<h2>Personal motivation</h2>
<p>Having explained the disease and Infixion’s approach, Sarnoff begins to grow impatient waiting for his daughter’s pain specialist. Managing pain is a big part of NF1, according to Sarnoff, who says his daughter has had chronic pain for over 10 years related to tumors and bone issues.</p>
<p>His daughter has had 10 major surgeries for scoliosis and tumor removal, and lives with neurocognitive “executive functioning issues,” Sarnoff says. “She’s certainly had her challenges along the way.”</p>
<p>Sarnoff isn’t the only one in his company with personal motivation. Of the seven members in iNFixion’s core team, Sarnoff and three others are NF1 parents, including a pathologist and PhD scientist.</p>
<p>“I made a commitment back in 2017. I said, ‘I’m going to do this.’, and I’ve been working full time on it since,” he says.</p>
<p>An inventor with several patents and previous CEO experience launching a (retail/tech) start-up, Sarnoff is comfortable in the start-up world, but biotech was new.</p>
<p>“I’ve had to start a new career, learning biology and drug discovery, which were completely foreign,” he explains. “I just started gathering resources like any start-up. You begin with an idea and limited resources, and you start building pieces.”</p>
<p>iNFixion is now winning prizes and impressing investors, and Sarnoff clearly seems dedicated to building the other pieces needed for Infixion’s success—and his daughter’s health.</p>
<p>The post <a href="https://bio.news/bio-convention/infixion-seeks-nf1-treatment-by-enhancing-what-the-body-is-doing-right/">iNFixion seeks NF1 treatment by enhancing what the body is doing right</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>SARS&#45;CoV&#45;2 Protein Fuels Lung Inflammation by Hijacking Macrophages</title>
<link>https://edusehat.com/en/sars-cov-2-protein-fuels-lung-inflammation-by-hijacking-macrophages</link>
<guid>https://edusehat.com/en/sars-cov-2-protein-fuels-lung-inflammation-by-hijacking-macrophages</guid>
<description><![CDATA[ The SARS-CoV-2 protein ORF8 reprograms macrophages to promote viral replication and lung inflammation. Blocking the ORF8-linked receptor IL-17RA reduced inflammation and fibrosis in mice, pointing to a potential therapeutic target.
The post SARS-CoV-2 Protein Fuels Lung Inflammation by Hijacking Macrophages appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2022/12/GettyImages-1354651238-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 22 Sep 2026 13:05:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>SARS-CoV-2, Protein, Fuels, Lung, Inflammation, Hijacking, Macrophages</media:keywords>
<content:encoded><![CDATA[<p>Even now, scientists are still untangling how the SARS-CoV-2 virus can leave such lasting damage in the lungs. Severe COVID-19 is not simply a matter of infected airway cells. In the sickest patients, the virus can help set off a destructive inflammatory loop, in which immune cells that should be fighting infection instead become part of the problem.</p>
<p>A new study from researchers at Gladstone Institutes and the University of California, San Francisco (UCSF), identifies one viral protein, ORF8, as a key driver of that process. The paper, “<a href="https://www.science.org/doi/10.1126/sciadv.aee5421" target="_blank" rel="noopener">Secreted ORF8 reprograms macrophages to enhance SARS-CoV-2 infection of lung epithelial cells</a>,” was published in <em>Science Advances</em>.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>The work builds on earlier efforts by Gladstone and UCSF scientists to map interactions between SARS-CoV-2 proteins and human proteins in search of viral vulnerabilities that could be targeted with drugs. ORF8 had emerged as an intriguing but puzzling candidate. In isolated lung cells, ORF8 appeared to limit viral replication, yet SARS-CoV-2 variants lacking ORF8 have tended to cause milder disease.</p>
<p>To resolve that contradiction, Melanie Ott, MD, PhD, director of the Gladstone Infectious Disease Institute, and colleagues focused on macrophages, immune cells that help shape the body’s response to infection and inflammation. The team exposed macrophages to ORF8, studied how the cells responded to SARS-CoV-2 infection, and then tested how those immune-cell changes affected nearby alveolar type II lung epithelial cells. They also evaluated ORF8’s effects in mice infected with SARS-CoV-2.</p>
<p>The researchers found that ORF8 increased macrophage expression of angiotensin converting enzyme 2, or ACE2, the receptor SARS-CoV-2 uses to enter cells, making the immune cells more permissive to infection. Once infected, ORF8-exposed macrophages were more likely to lose antiviral function, undergo inflammatory cell death, and release signals that promoted lung inflammation and made surrounding lung epithelial cells more vulnerable to viral replication.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>“We were surprised to see how effectively ORF8 turns our own immune defenses against us,” said first author Yusuke Matsui, MD, PhD, a staff research scientist in Ott’s lab. “ORF8 is hijacking macrophages to enhance infection of the surrounding tissue.”</p>
<p>In co-culture experiments, the presence of macrophages changed ORF8’s effect on infection. As the authors wrote in the paper, macrophage co-culture “overrides ORF8’s previously reported inhibition of AT2 [human alveolar type II] infection, restoring infectious viral production.” In mice, SARS-CoV-2 carrying ORF8 caused greater lung inflammation, viral burden, and scarring than virus lacking the protein, supporting the idea that ORF8 helps create a feedforward circuit linking immune-cell infection to lung pathology.</p>
<p>The work also highlights a potential therapeutic target. Researchers tested brodalumab, an antibody already FDA-approved for psoriasis that blocks IL-17RA, the receptor previously linked to ORF8. In mice, IL-17RA blockade countered “ORF8 activity, lowering viral burden and attenuating pulmonary inflammation and fibrosis,” the authors wrote. Ott said the findings could support more targeted treatments for severe COVID-19. “By showing that this single viral protein is the main bridge between viral growth and tissue damage, we’ve found a clear target for new treatments,” she added.</p>
<p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/sars-cov-2-protein-fuels-lung-inflammation-by-hijacking-macrophages/">SARS-CoV-2 Protein Fuels Lung Inflammation by Hijacking Macrophages</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Genes Involved in Flatworm Brain Regeneration Identified</title>
<link>https://edusehat.com/en/genes-involved-in-flatworm-brain-regeneration-identified</link>
<guid>https://edusehat.com/en/genes-involved-in-flatworm-brain-regeneration-identified</guid>
<description><![CDATA[ Researchers identified genes that enable the regeneration of dopamine-producing neurons in planarians. This provides a roadmap for investigating whether similar pathways can be activated in humans and potentially leveraged to treat traumatic brain injuries and neurodegenerative diseases.
The post Genes Involved in Flatworm Brain Regeneration Identified appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2021/09/Getty_170025445_NNehring_Flatworm_grey.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 22 Sep 2026 05:45:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Genes, Involved, Flatworm, Brain, Regeneration, Identified</media:keywords>
<content:encoded><![CDATA[<p>The human brain is terrible at healing itself from injury or disease. But some animals can harness their own cellular abilities to not only repair injuries but also to regrow their brains entirely. Researchers from the University of Georgia have now pinpointed several of the genes that make brain regeneration possible in planarians, a type of flatworm that exhibits what the team describes in their newly published report in <em>Nature Communications</em>, as “extraordinary capacity for brain regeneration.”</p>
<p>Both flatworm and human brains are made up of networks of neurons that communicate with each other by sending electrical or chemical signals. Some neurons react to stimuli, such as light or touch, while others control movement. Flatworms can use stem cells to replace neurons after injury. But while humans also have stem cells, they are unable to transform into new neurons effectively enough to heal injury.</p>
<p>The new study sheds light on how shared genes work in flatworms and lays the groundwork for researchers to investigate similar pathways that might be activated in humans to design better therapies for traumatic brain injuries or diseases.</p>
<p>Rachel Roberts-Galbraith, PhD, associate professor in UGA’s Franklin College of Arts and Sciences, said, “Big picture: We would like to come up with ideas for how to better empower the human brain to regenerate itself. The understanding of brain regeneration that we can develop using simple animals gives us a reason to be optimistic. It’s not an inherent property of brains that makes them bad at regeneration. It’s something specific to humans.”</p>
<p>Roberts-Galbraith is senior and corresponding author, and Kendall Clay, PhD, and Taylor Medlock-Lanier, PhD, are co-first authors of the team’s study, titled “<a href="http://dx.doi.org/10.1038/s41467-026-76397-4" target="_blank" rel="noopener">Combinatorial mechanisms specify cellular location and neurotransmitter identity during planarian neurogenesis</a>.” In their paper the team concluded “Our work suggests that combinatorial instruction of cell type and spatial identity could improve exogenous stem cell therapies aimed at precisely replacing neurons after localized injuries.”</p>
<p>Planarians can be found in freshwater, salt water, and even on land. They don’t have circulatory or respiratory systems. But they do have stem cells that can differentiate into whatever their body needs at a given time. Using stem cells, planarians can regrow their entire body from just a sliver of a body fragment. They can rebuild tissues, muscles, and even their brain. Planarian flatworms are known for their regenerative abilities, including<em> de novo</em> brain regrowth after nearly any injury,” the authors wrote. “Critically, neurons are produced in the correct numbers, diversity, pattern, and connectivity to restore function … In addition to regenerative capacity, the planarian nervous system has spatial and cell type complexity, making it suitable for study.”</p>
<p>But how do these tiny creatures know what type of cell to make and where to send it? “… the full pathway from pluripotent stem cell to mature neuron has not been determined for any cell type in the planarian nervous system,” the authors stated. “To better understand how regenerative neurogenesis proceeds in planarians, we focused on a single, conserved cell type: dopaminergic neurons.”</p>
<p>Known as the “feel good” chemical, dopamine is more than just the brain’s reward and pleasure chemical. It also acts as a signal to help neurons communicate with one another and plays a key role in controlling movement. People with Parkinson’s disease, for example, experience tremors and stiffness due to low levels of dopamine.</p>
<p>Through their study the researchers identified almost a dozen genes responsible for instructing stem cells to turn into dopamine-producing neurons and directing those new neurons to the right locations in the worm’s body. “Altogether, we identified ten genes and characterized six genes critical for specifying mature dopaminergic neurons throughout the planarian nervous system, identifying factors that regulate both neurotransmitter identity and cellular location,” they wrote. “Our results demonstrate that planarian neurogenesis requires coordination of factors that initiate neurotransmitter choice and regional location.”</p>
<p>When the researchers knocked out some of the genes discovered in this study, they found the planarians struggled to make new dopamine-producing neurons and also experienced slow movement, similar to the effects of low dopamine in people and other mammals.</p>
<p>Currently, healthcare providers don’t have many options to treat conditions like Parkinson’s, Alzheimer’s or traumatic brain injuries. Harnessing the body’s own cells in the same way planarians do to heal wounds would be a game changer. “The ability to create new neurons in predictable types, numbers, and locations for a given injury or disease would revolutionize treatments of neurodegenerative diseases and other brain injuries,” the researchers noted in their paper. “Our work aims to leverage highly regenerative animals to understand principles of successful neuron replacement.”</p>
<p>Roberts-Galbraith  added, “We figured out the genetic recipe for making these cell types in planarians. We’re hoping this work helps others figure out how to create dopamine-producing neurons from stem cells that can be more effectively transplanted into patients.”</p>
<p>The Roberts-Galbraith lab in the department of cellular biology is part of UGA’s Regenerative Bioscience Center, an interdisciplinary research hub focused on the potential of regenerative medicine.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/genes-involved-in-flatworm-brain-regeneration-identified/">Genes Involved in Flatworm Brain Regeneration Identified</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>StockWatch: Novo’s 2030 Strategy Underwhelms Investors at Capital Markets Day</title>
<link>https://edusehat.com/en/stockwatch-novos-2030-strategy-underwhelms-investors-at-capital-markets-day</link>
<guid>https://edusehat.com/en/stockwatch-novos-2030-strategy-underwhelms-investors-at-capital-markets-day</guid>
<description><![CDATA[ Novo said it planned to launch “more than five multi-blockbusters” or drugs with multiple billions of dollars in sales every year through 2030, and generate more than DKK 150 billion (just over $23 billion) in risk-adjusted pipeline sales by 2035.
The post StockWatch: Novo’s 2030 Strategy Underwhelms Investors at Capital Markets Day appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/NovoNordisk-Bagsvaerd-HQ-JPEG-drone-1280px-contact-us.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 22 Sep 2026 05:45:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>StockWatch:, Novo’s, 2030, Strategy, Underwhelms, Investors, Capital, Markets, Day</media:keywords>
<content:encoded><![CDATA[<p>A week after loosening up its branding to “Novo,” <strong>Novo Nordisk (Nasdaq Copenhagen: NOVO-B; NYSE: NVO)</strong> laid out a strategy for 2030 that underwhelmed investors of the Danish metabolic biotech giant.</p>
<p>Addressing investors at its 2026 Capital Markets Day, Novo CEO Maziar (Mike) Doustdar and other company executives laid out a series of initiatives aimed at restoring its edge in metabolic and other drugs by growing and diversifying its pipeline, as well as driving sustainable growth, and delivering attractive returns.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>To that end, Doustdar and colleagues said Novo planned to launch “more than five multi-blockbusters” or drugs with multiple billions of dollars in sales every year through 2030. Those five are expected to emerge from more than five Phase III programs in obesity and diabetes, and another 5+ Phase III programs in other therapeutic areas.</p>
<p>Doustdar also committed Novo to generating more than DKK 150 billion (just over $23 billion) in risk-adjusted pipeline sales by 2035, a figure that includes current pipeline assets. Novo plans to combine internal pipeline growth with external growth through merger-and-acquisition (M&A) activity.</p>
<p>“Novo is targeting 2026-2030 revenue growth in line with industry peers, likely underwhelming for investors,” cautioned Evan David Seigerman, a managing director and head of healthcare research at BMO Capital Markets, in a research note.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>Seigerman cited a consensus of analysts that estimates a 3.53% compound annual growth rate (CAGR) for Novo, vs. ~3.65% CAGR for its pharma peers. However, he added, “Novo’s outlined growth expectation appears already priced in to [Wall] Street estimates, reading negatively to shares.”</p>
<p>Key to Novo’s new strategy, Doustdar said, was planning for the eventual loss of U.S. patent exclusivity in 2032 for its best-selling drug semaglutide, the glucagon-like peptide-1 (GLP-1) drug marketed as Ozempic<sup class="wp-sup-text">®</sup> for type 2 diabetes in adults and as Wegovy<sup class="wp-sup-text">®</sup> for obesity/weight control—what the CEO called “the elephant in the room.”</p>
<p>“We plan to come on the other side of the LOE [loss of exclusivity] as a bigger company than we are today and a much more diversified version of it,” Doustdar said. “We created an incredibly attractive market, and now almost every other single pharma company, big or small, is trying to come and compete with us. We need to be ready for that.”</p>
<p></p><h4><strong>‘Not seeing concrete news’</strong></h4>

<p>Those and other priorities laid out at the annual capital markets event failed to reassure Novo investors. The company’s primary shares on Nasdaq Copenhagen <span><strong>slumped nearly 8%</strong></span> this morning from DKK 281.55 ($43.19) to an even DKK 260.00 ($39.89). On the New York Stock Exchange, Novo’s American depositary receipts (ADRs) also <span><strong>tumbled</strong> <strong>8%</strong></span> from $43.24 to $39.81.</p>
<p>“Investors are selling the shares because they are not seeing concrete news that could drive the stock higher,” Per Hansen, investment economist at Nordnet, wrote in a research note, as reported by Bloomberg News.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>Speaking on CNBC, Hansen elaborated: “Investors hoped for a project ‘miracle’ that could turn the momentum around short term. For obvious reasons that miracle does not exist.”</p>
<p>Markus Manns, a portfolio manager ​at Union Investment, told Reuters he was less than impressed by Novo’s projections of 2030 sales and a “broadly stable” operating margin.</p>
<p>“They (also) did not say much in terms of ‌how to ⁠tackle the semaglutide patent expiration in 2032,” said Manns, who added that he thought Novo made a credible case for pursuing next-generation obesity drugs and a broader early-stage pipeline.</p>
<p>In its presentation, Novo detailed the drugs it expects to launch each year through 2030—starting with next year, when the company plans to launch once-weekly CagriSema (cagrilintide and semaglutide), a diabetes and obesity drug which combines the long-acting amylin receptor agonist with the GLP-1 receptor agonist. Cagrilintide and a high-dose version of CagriSema are scheduled for a 2028 launch, while 2029 is expected to deliver launches of high-dose cagrilintide; zenagamtide, a multi-receptor peptide agonist targeting GLP-1, amylin, and calcitonin receptors; an oral form of zenagamtide; and a next-generation GLP-1.</p>
<p>In 2030, Novo’s launch calendar includes a monthly-dose or “QM” GLP-1; a thermostable GLP-1; an oral high-yield GLP-1; Amylin 355 and an oral version, both long-acting amylin analogues; an oral ACSL5 inhibitor LX9851, co-developed with Lexicon Pharmaceuticals; and UBT251, a long-acting synthetic peptide triple agonist that targets GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors and is being co-developed by Novo with Chinese-owned United Biotechnology.</p>
<p>Monday’s selloff of Novo shares and ADRs lowered the company’s one-year stock performance to a <span><strong>33% decline</strong> </span>year over year on Nasdaq Copenhagen and a <span><strong>35% drop</strong></span> on the NYSE.</p>
<p>By contrast, shares of Novo’s archrival in obesity and diabetes drug development, <strong>Eli Lilly (NYSE: LLY), </strong>have <span><strong>soared 55% </strong></span>year over year, from $754.95 on September 22, 2025 (September 21 was a Sunday) to $1,164.66, <span><strong>up 1%</strong></span> from Friday’s close of $1,152.93.</p>
<p>While Bagsvaerd, Denmark-based Novo Nordisk was first to market with a GLP-1 drug when Ozempic became commercially available in February 2018, Indianapolis-based Lilly has grown to a majority share of GLP-1 drug sales—though Lilly’s blockbuster tirzepatide, marketed for diabetes as Mounjaro<sup class="wp-sup-text">®</sup> and for obesity as Zepbound<sup class="wp-sup-text">®</sup>, are dual-agonists of GLP-1 and GIP receptors.</p>
<p></p><h4><strong>2-to-1 sales edge</strong></h4>

<div class="my-8"><span data-render-ad="6"></span></div>
<p>Lilly has grown its GLP-1-based drug sales so far this year to a nearly 2-to-1 edge over Novo. The two Lilly drugs have racked up a combined $27.6 billion-plus in revenue—$18.605 billion for Mounjaro, $9.088 billion for Zepbound—accounting for about 65% of Lilly’s total $42.773 billion in revenue between January and June 2026.</p>
<p>By contrast, Novo’s GLP-1 blockbusters have racked up a combined DKK 102.393 billion ($15.715 billion) in sales in the first half of 2026, accounting for about 69% of the company’s total DKK 148.551 billion ($22.798 billion) in adjusted sales.</p>
<p>Ozempic garnered DKK 59.2 billion ($9.085 billion), down 8% from DKK 64.52 billion ($9.902 billion) year over year, while its injectable Wegovy generated sales of DKK 37.719 billion ($5.789 billion), up 2% from DKK 36.888 billion ($5.661 billion) in Q1-Q2 2025. The company also made DKK 5.474 billion ($840 million) in sales from oral Wegovy, which reached the U.S. market on January 5.</p>
<p>Lilly’s competing oral obesity drug Foundayo<sup>®</sup> (orforglipron), a small molecule GLP-1 receptor agonist, generated $98 million in its first quarter on the market, having won FDA approval on April 1.</p>
<p>Doustdar took Novo’s helm in August 2025, intent on regaining the company’s competitive edge in GLP-1 based obesity and diabetes drugs after Lilly’s sales successes with Mounjaro and Zepbound. A year ago this month, Doustdar led the company’s deepest personnel reduction, which <a href="https://www.genengnews.com/topics/translational-medicine/stockwatch-analysts-see-pain-and-necessity-in-novo-nordisks-9000-layoffs/" target="_blank" rel="noopener">eliminated about 9,000 jobs</a>.</p>
<p>In addition to those initial layoffs, Novo said Monday that 4,000 additional staffers exited the company, resulting in 13,000 fewer employees than a year ago, bringing the company’s workforce down to approximately 66,000 employees.</p>
<p>Novo said its restructuring generated more than DKK 10 billion ($1.534 billion) in savings that is being allocated to its R&D operations, commercial growth brands, and manufacturing right-sizing efforts. The company also said it reduced its spending on external services by ~30% year-to-date and has renegotiated agreements with suppliers to squeeze out further savings.</p>
<p></p><h4><strong>Flurry of announcements</strong></h4>

<p>In the week leading to and including Monday’s Capital Markets Day, Novo issued a flurry of announcements—including a poke at Lilly by highlighting during the event positive topline results from the Phase III REIMAGINE 5 trial (<a href="https://clinicaltrials.gov/study/NCT06534411" target="_blank" rel="noopener">NCT06534411</a>) and REDEFINE 9 trial (<a href="https://clinicaltrials.gov/study/NCT06388187" target="_blank" rel="noopener">NCT06388187</a>) assessing CagriSema, which the company trumpeted as “Novo’s next innovation in weight management and type 2 diabetes.”</p>
<p>In REIMAGINE 5, CagriSema 1.0 mg/1.0 mg showed superiority to tirzepatide 5 mg for weight loss, achieving an estimated average weight loss of 12.4%, compared with 9.1% for the Lilly drug. CagriSema also confirmed a non-inferior reduction in HbA<sub>1c</sub> of 1.71% vs. 1.67% for tirzepatide.</p>
<div class="my-8"><span data-render-ad="7"></span></div>
<p>In REDEFINE 9, CagriSema 1.0 mg/1.0 mg showed a dramatic weight reduction of 21.0% vs. 2.0% for placebo, meeting that study’s primary superiority endpoint. CagriSema also showed greater improvements than placebo across prespecified endpoints that included systolic blood pressure, waist-to-height ratio, and fasting lipid profile.</p>
<p>The rush of announcements started September 14 with a rebrand that shortened the company’s name in marketing materials to “Novo,” accompanies by an updated Apis bull logo, while keeping “Novo Nordisk” as its legal name.  The company also unveiled a new slogan, “Lasting Health Starts Now.”</p>
<p>“The rebrand is designed to be more memorable and relevant to the way people engage with their health today,” Novo stated in a press release announcing the rebrand. “It also reflects the company’s ambition to bring breakthrough science closer to people’s daily lives and to strengthen recognition and trust as Novo reaches more people in more ways.”</p>
<p></p><h4><strong>Anthropic, Orbis partnerships</strong></h4>

<p>Novo also announced a collaboration of undisclosed value with <strong>Anthropic</strong> (draft Form S-1 Registration Statement filed June 1) to bolster artificial intelligence (AI)-based drug development. Novo agreed to use Anthropic models and Claude Science to advance scientific reasoning for R&D and agentic software engineering, with the aim of helping Novo discover and develop new treatments faster.</p>
<p><a href="https://www.genengnews.com/topics/artificial-intelligence/claude-science-is-here-antibiotics-designed-by-text-prompt-among-applications/" target="_blank" rel="noopener">Launched in June</a>, Claude Science is an AI workbench for scientists that consolidates fragmented research tools, including more than 60 scientific databases and connectors pre-configured for genomics, proteomics, structural biology, and more, into a single reasoning layer.</p>
<p>On Thursday, privately held <strong>Orbis Medicines</strong> announced an up-to-$1.4 billion strategic collaboration and license agreement with Novo, bringing together the two Danish-based drug developers to discover and develop an undisclosed number of next-generation oral macrocycle therapeutics for unspecified cardiometabolic diseases.</p>
<p>The potential $1.4 billion reflects an upfront payment and payments tied to achieving development and commercial milestone payments. Copenhagen-based Orbis will also gain a strategic investment of undisclosed amount from Novo, and potentially gain tiered royalties on future product sales.</p>
<p>Novo plans to apply Orbis’ lab-in-the-loop <sup>n</sup>Gen platform which integrates generative AI and high-throughput synthesis, using a multi-parameter optimization (MPO) engine to design <sup>n</sup>Cycles with desirable properties—detailed in a <a href="https://www.nature.com/articles/s41589-023-01496-y" target="_blank" rel="noopener">2023 <em>Nature Chemical Biology</em> paper</a> as including target biding and other key properties for oral availability, such as proteolytic stability, membrane permeability and metabolic stability. Orbis says it continuously improves its <sup>n</sup>Cycles through one of the industry’s largest experimental macrocycle datasets, which the company generates in real time via its platform.</p>
<p>Novo’s interest in macrocycles appears to reflect a desire to overcome limitations associated with traditional oral peptide treatments, such as low digestive absorption. The 2023 paper showed Orbis’ macrocycles to have an oral bioavailability of up to 18% in rats: “This method for generating orally available peptides is general and provides a promising push toward unlocking the full potential of peptides as therapeutics.”</p>
<p>Other announcements:</p>
<ul>
<li><strong>Frehemgo<sup class="wp-sup-text">®</sup> (denecmig)</strong> won a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use recommending approval for the next-generation factor VIIIa mimetic bispecific antibody to treat hemophilia A, with or without inhibitors, in adults and children.</li>
<li><strong>Denecimig</strong> generated positive results in the Phase III FRONTIER5 trial (<a href="https://clinicaltrials.gov/study/NCT05878938" target="_blank" rel="noopener">NCT05878938</a>), showing that a direct switch to a subcutaneous denecimig pen injector from a vial and syringe injection system for a current Hemophilia A treatment emicizumab, marketed by Genentech as Hemlibra<sup class="wp-sup-text">®</sup>, was well tolerated with no unforeseen safety concerns in adolescents and adults with hemophilia A.</li>
<li><strong>Sogroya<sup class="wp-sup-text">®</sup> (somapacitan) </strong>also won a positive CHMP opinion for the human growth hormone analogue as a once-weekly treatment for children with idiopathic short stature (ISS) with persistent growth disturbance. The drug won FDA approval in 2020.</li>
</ul>
<p class="trimmed"> </p>
<p></p><h2><strong>Leaders & Laggards</strong></h2>

<ul>
<li><strong>BlossomHill Therapeutics (Nasdaq: BLSM)</strong> shares <span><strong>jumped 21%</strong></span> over two days, from $22.17 Tuesday to $26.82 Thursday, after the small molecule cancer drug developer announced positive updated data from the ongoing Phase I/II SOLARA trial (<a href="https://na01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06706076&data=05%7C02%7C%7C910e8a28d5b44d79e93508df16b4a643%7C84df9e7fe9f640afb435aaaaaaaaaaaa%7C1%7C0%7C639254640331799833%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=66HNYXwsL%2FkUCzbwX5byzEvK10dAyp4Qb73DsSj1lSQ%3D&reserved=0" target="_blank" rel="noopener">NCT06706076</a>) assessing BH-30643 in non-small cell lung cancer (NSCLC) patients with secondary epidermal growth factor receptor (EGFR) resistance mutations such as EGFR C797S. In patients with EGFR C797S-positive resistance to prior EGFR inhibitor treatment, with or without concurrent T790M, BH-30643 showed a 45% objective response rate (18 of 40 patients) and an 88% disease control rate (35 of 40 patients). At the time of efficacy follow-up, 25 of 40 patients (63%) remained on treatment with a median follow-up of 6.9 months. BlossomHill presented the data at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer in Seoul.</li>
<li><strong>Xenon Pharmaceuticals (Nasdaq: XENE)</strong> shares <span><strong>tumbled 31%</strong></span> from $57.35 to $39.75 Friday, after the neuroscience-focused drug developer acknowledged that it voluntarily paused enrollment of new patients in two Phase III programs encompassing five trials assessing its potent KV7 potassium channel opener azetukalner—the three-program X-NOVA program in major depressive disorder (MDD), and the two-trial X-CEED program in bipolar depression—following an analysis of neuropsychiatric adverse events. “In a very small number of patients, we have seen an adverse event captured under the broad preferred term of psychosis,” Xenon chief medical officer Christopher Kenney, MD, told analysts on a conference call. Those events had not previously been seen in the Phase II X‑NOVA trial in MDD (<a href="https://na01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT05376150&data=05%7C02%7C%7C910e8a28d5b44d79e93508df16b4a643%7C84df9e7fe9f640afb435aaaaaaaaaaaa%7C1%7C0%7C639254640331924574%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=U1cOhoMva78qYqG5FM%2F4Wz9R%2BKtAqeW0qY9GE4ZsvQ8%3D&reserved=0" target="_blank" rel="noopener">NCT05376150</a>), Xenon said, adding that the observed events, their rate of occurrence, and their severity, were consistent with the known safety and tolerability profile of azetukalner and its mechanism.</li>
</ul>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/stockwatch-novos-2030-strategy-underwhelms-investors-at-capital-markets-day/">StockWatch: Novo’s 2030 Strategy Underwhelms Investors at Capital Markets Day</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Emerging Trends in Fluid Transfers and Freeze&#45;Thaw Workflows</title>
<link>https://edusehat.com/en/emerging-trends-in-fluid-transfers-and-freeze-thaw-workflows</link>
<guid>https://edusehat.com/en/emerging-trends-in-fluid-transfers-and-freeze-thaw-workflows</guid>
<description><![CDATA[ In this GEN webinar, our expert speakers will discuss the latest trends, challenges, and innovations shaping fluid transfer and freeze-thaw workflows. 
The post Emerging Trends in Fluid Transfers and Freeze-Thaw Workflows appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/Getty_98412794_LiquidNitrogenContainer.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 22 Sep 2026 05:45:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Emerging, Trends, Fluid, Transfers, and, Freeze-Thaw, Workflows</media:keywords>
<content:encoded><![CDATA[<p></p><p></p><div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex"><p class="is-layout-flow wp-block-column-is-layout-flow"></p><div class="wp-block-column"></div><p></p></div><p></p><p></p><p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Register Now</button></p><p></p><p></p><h3 class="w-full text-left">
    <strong>
            </strong>
</h3>
<div class="flex flex-row m-0-auto items-stretch justify-center flex-wrap mb-4">
    
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3 presenter-card">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/09/AlexanderFuchs_headshot.jpg" class="h-full w-full object-cover" alt="Image of Alex Fuchs">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Alex Fuchs</h2>
                <h5 class="mt-0 !text-[15px]">Director of Product Innovation<br>Single Use Support <br>Colder Products Company</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/09/AlexanderFuchs_headshot.jpg" alt="Image of Alex Fuchs">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Alex Fuchs</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Alexander Fuchs is the director of product innovation at Single Use Support. Due to his highly technical education and intensive insights, he has a wide range of experience and knowledge in various industries, such as jewelry, manufacturing, and biopharma, as well as multiple areas of activity. Passionate about automation, engineering, and process management, Alexander contributes to the innovative focus of advancing fluid and cold chain management within the biopharmaceutical industry.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog>
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3 presenter-card">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/09/Jascha-Rosenbaum-CPC-Biotech-scaled-e1789775733875.jpg" class="h-full w-full object-cover" alt="Image of Jascha Rosenbaum">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Jascha Rosenbaum</h2>
                <h5 class="mt-0 !text-[15px]">Regional Director for Applications & Business Development<br>Colder Products Company</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/09/Jascha-Rosenbaum-CPC-Biotech-scaled-e1789775733875.jpg" alt="Image of Jascha Rosenbaum">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Jascha Rosenbaum</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Jascha Rosenbaum is the regional director for applications and business development in Europe. Jascha holds a master’s degree in chemical engineering, and he has worked in the single-use industry for the last 10 years in both the U.S. and Europe. He has supported some of the largest biopharmaceutical manufacturers across Europe, where he has experience at every stage of single-use solutions.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog></div>

<p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-malblocks-webinars-info"></p><div><strong>Broadcast Date:</strong> <time>Tuesday, October 20, 2026</time><br><ul><li><strong>Time:</strong> <time datetime="2026-10-20T15:00:00.000Z">08:00 PDT, 11:00 EDT, 15:00 GMT</time></li></ul></div><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p></p><div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex"><p></p><div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"><p class="wp-block-paragraph">In cell and gene therapy manufacturing, fluid transfer and freeze-thaw workflows are paramount to process efficiency, product quality, and operational flexibility. From scaling and closed-system processing to automation and the growing use of cryopreservation, manufacturers are rethinking how materials move through the process—both during manufacturing and between unit operations.<br><br>In this <em>GEN</em> webinar, our expert speakers will discuss the latest trends, challenges, and innovations shaping fluid transfer and freeze-thaw workflows. The panel will explore how cell and gene therapy manufacturers are addressing complex process requirements while reducing manual interventions, minimizing contamination risk, improving workflow efficiency, and preparing processes for scale. Key takeaways from the webinar include:</p><p></p><p></p><p></p><ul class="wp-block-list"><p></p><li>Emerging approaches to fluid transfers,</li><p></p><p></p><p></p><li>Single-use technologies and sterile connections,</li><p></p><p></p><p></p><li>Freeze-thaw considerations,</li><p></p><p></p><p></p><li>Automation and closed processing,</li><p></p><p></p><p></p><li>Strategies for building more flexible and robust workflows for cell and gene therapy manufacturing</li><p></p></ul><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-paragraph"><em>A live Q&A session will follow the conversation offering you a chance to pose questions to our expert panelists.</em></p><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-paragraph"><strong>Produced with support from:</strong></p><p></p><p></p><div class="wp-block-image"><p><figure class="alignleft size-medium"><a href="https://www.cpcworldwide.com/" target="_blank" rel=" noreferrer noopener"><img decoding="async" width="300" height="121" src="https://www.genengnews.com/wp-content/uploads/2024/07/CPC_Logo-300x121.jpg" alt="CPC logo" class="wp-image-298424" srcset="https://www.genengnews.com/wp-content/uploads/2024/07/CPC_Logo-300x121.jpg 300w, https://www.genengnews.com/wp-content/uploads/2024/07/CPC_Logo-1024x413.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2024/07/CPC_Logo-768x310.jpg 768w, https://www.genengnews.com/wp-content/uploads/2024/07/CPC_Logo-1536x620.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2024/07/CPC_Logo-1041x420.jpg 1041w, https://www.genengnews.com/wp-content/uploads/2024/07/CPC_Logo-696x281.jpg 696w, https://www.genengnews.com/wp-content/uploads/2024/07/CPC_Logo-1392x562.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2024/07/CPC_Logo-1068x431.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2024/07/CPC_Logo.jpg 1695w" sizes="(max-width: 300px) 100vw, 300px"></a></figure></p><p></p></div></div><p></p></div><p></p><p>The post <a href="https://www.genengnews.com/multimedia/webinars/emerging-trends-in-fluid-transfers-and-freeze-thaw-workflows/">Emerging Trends in Fluid Transfers and Freeze-Thaw Workflows</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Advancing Cell Therapy for Cardiovascular Disease</title>
<link>https://edusehat.com/en/advancing-cell-therapy-for-cardiovascular-disease</link>
<guid>https://edusehat.com/en/advancing-cell-therapy-for-cardiovascular-disease</guid>
<description><![CDATA[ In this GEN webinar, our expert speaker Joshua Michael Hare, MD, will examine how therapeutically relevant research is helping shape the development of cell therapies for cardiovascular disease. 
The post Advancing Cell Therapy for Cardiovascular Disease appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/Getty_2224747882_cardiology.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 22 Sep 2026 05:45:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Advancing, Cell, Therapy, for, Cardiovascular, Disease</media:keywords>
<content:encoded><![CDATA[<p></p><p></p><div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex"><p class="is-layout-flow wp-block-column-is-layout-flow"></p><div class="wp-block-column"></div><p></p></div><p></p><p></p><p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Register Now</button></p><p></p><p></p><h3 class="w-full text-left">
    <strong>
            </strong>
</h3>
<div class="flex flex-row m-0-auto items-stretch justify-center flex-wrap mb-4">
    
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3 presenter-card">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/09/Hare-headshot-e1789774840810.jpg" class="h-full w-full object-cover" alt="Image of Joshua Michael Hare, MD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Joshua Michael Hare, MD</h2>
                <h5 class="mt-0 !text-[15px]">Founding Director,<br>Interdisciplinary Stem Cell Institute<br>University of Miami<br>Miller School of Medicine</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/09/Hare-headshot-e1789774840810.jpg" alt="Image of Joshua Michael Hare, MD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Joshua Michael Hare, MD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Joshua Hare, MD, is a board-certified practicing cardiologist and holds the Louis Lemberg Professorship of Medicine at the University of Miami Miller School of Medicine. Hare currently serves as the founding director of the Interdisciplinary Stem Cell Institute at the University of Miami. He is widely published and has authored or co-authored over 450 articles. Hare has pioneered the use of cells as medicines for human heart disease, Alzheimer’s disease, stroke, and diseases of aging. His research has been funded by the National Institutes of Health and the Department of Defense, and he currently oversees multiple clinical trials using cell and gene therapy to treat human ischemic and non-ischemic cardiomyopathy.  Hare is an inducted member of the American Association of Physicians and the National Academy of Inventors.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog></div>

<p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-malblocks-webinars-info"></p><div><strong>Broadcast Date:</strong> <time>Thursday, October 15, 2026</time><br><ul><li><strong>Time:</strong> <time datetime="2026-10-15T15:00:00.000Z">08:00 PDT, 11:00 EDT, 15:00 GMT</time></li></ul></div><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p></p><div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex"><p></p><div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"><p class="wp-block-paragraph">Cardiovascular diseases offer a compelling opportunity for regenerative and cellular therapies that can repair damaged tissue, promote vascularization, modulate inflammation, or restore cardiac function. However, translating research advances into meaningful therapeutics requires connecting a strong biological rationale with appropriate cell types, indications and therapeutic strategies, and patients who are most likely to benefit.</p><p></p><p></p><p class="wp-block-paragraph">In this <em>GEN</em> webinar, our expert speaker will examine how therapeutically relevant research is helping shape the development of cell therapies for cardiovascular disease. His presentation will cover strategies for selecting indications, biological targets, and cell types based on disease pathophysiology and unmet clinical need. Attendees will also learn about the path from laboratory research to clinical investigation, including considerations around cell delivery and patient selection, and the clinical endpoints needed to evaluate safety and therapeutic benefit.</p><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-paragraph"><em>A live Q&A session will follow the presentation offering you a chance to pose questions to our expert panelist.</em></p><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-paragraph"><strong>Produced with support from:</strong></p><p></p><p></p><div class="wp-block-image"><p><figure class="alignleft size-medium"><a href="https://www.lonza.com/" target="_blank" rel=" noreferrer noopener"><img decoding="async" width="300" height="55" src="https://www.genengnews.com/wp-content/uploads/2021/03/LONZA_Logo-300x55.jpg" alt="LONZA Logo" class="wp-image-162617" srcset="https://www.genengnews.com/wp-content/uploads/2021/03/LONZA_Logo-300x55.jpg 300w, https://www.genengnews.com/wp-content/uploads/2021/03/LONZA_Logo-485x91.jpg 485w, https://www.genengnews.com/wp-content/uploads/2021/03/LONZA_Logo.jpg 500w" sizes="(max-width: 300px) 100vw, 300px"></a></figure></p><p></p></div></div><p></p></div><p></p><p>The post <a href="https://www.genengnews.com/multimedia/webinars/advancing-cell-therapy-for-cardiovascular-disease/">Advancing Cell Therapy for Cardiovascular Disease</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>8 Things to Know Before Taking the Next Gen NCLEX®</title>
<link>https://edusehat.com/en/8-things-to-know-before-taking-the-next-gen-nclex</link>
<guid>https://edusehat.com/en/8-things-to-know-before-taking-the-next-gen-nclex</guid>
<description><![CDATA[ The post 8 Things to Know Before Taking the Next Gen NCLEX® appeared first on BoardVitals Blog. ]]></description>
<enclosure url="https://blog.boardvitals.com/wp-content/uploads/2020/07/what-to-know-nclex-1024x768.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 22 Sep 2026 05:15:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Things, Know, Before, Taking, the, Next, Gen, NCLEX®</media:keywords>
<content:encoded><![CDATA[<p class="wp-block-paragraph"><span>The National Council Licensure Examination (</span><a href="https://www.ncsbn.org/nclex.htm"><span>NCLEX®</span></a><span>), is used by all state nursing boards to determine whether or not a nurse is ready to practice at an entry-level. There are two Next Gen NCLEX examinations, the <a href="https://www.boardvitals.com/nclex-pn-review-questions" target="_blank" rel="noreferrer noopener">NCLEX-PN®</a>, for practical and vocational nurses, and the <a href="https://www.boardvitals.com/nclex-rn-review-questions" target="_blank" rel="noreferrer noopener">NCLEX-RN®</a>, for registered nurses. Although many concepts are overlapping, this post will solely discuss the NCLEX-RN® for the sake of simplicity. The following are eight things you should know prior to taking the NCLEX®. </span></p>



<h2 class="wp-block-heading"><b>What does NCLEX® stand for?</b></h2>



<p class="wp-block-paragraph"><span>“NCLEX” is an acronym for The National Council Licensure Examination (</span><a href="https://www.ncsbn.org/nclex.htm"><span>NCLEX®</span></a><span>). The NCLEX® determines whether a nurse can obtain licensure to practice. </span></p>



<h2 class="wp-block-heading">What is the Next Gen NCLEX<b>®</b> (NGN)?</h2>



<p class="wp-block-paragraph">The <a href="https://www.boardvitals.com/blog/what-is-nclex-next-gen/">Next Generation NCLEX® (NGN)</a> launched in 2023 and is the latest iteration of the NCLEX<span>®</span> exam for aspiring registered nurses and licensed practical nurses. While its scoring system bears resemblance to its predecessor, the NGN introduces the possibility of earning partial credit through a polytomous scoring approach, rewarding test-takers for a partial grasp of the material. Combining traditional NCLEX<span>®</span> question formats with new items, the exam is crafted to assess foundational nursing competencies, clinical judgment, and comprehensive knowledge required for entry-level practice.</p>



<h2 class="wp-block-heading"><b>Who writes the NCLEX®?</b></h2>



<p class="wp-block-paragraph"><span>The NCLEX® is developed and owned by the The National Council of State Boards of Nursing (</span><a href="https://www.ncsbn.org/index.htm"><span>NCSBN)</span></a><span>. The NCSBN is a not-for-profit organization whose members include the nursing regulatory bodies (NRB) for all 50 states, the District of Columbia, </span><span>American Samoa, Guam, Northern Mariana Islands, and the U.S. Virgin Islands.</span><span> </span></p>



<h2 class="wp-block-heading"><b>Can you take the NCLEX® without a degree? </b></h2>



<p class="wp-block-paragraph"><span>No. You must have a degree in nursing to sit for the <a href="https://www.boardvitals.com/understanding-the-nclex">NCLEX® examination</a>. Each state Nursing Regulatory Body (</span><a href="https://www.ncsbn.org/membership.htm"><span>NRB</span></a><span>) is allowed to have different requirements, but all require a nursing degree to take the NCLEX®. </span></p>



<h2 class="wp-block-heading"><b>How is the NCLEX® scored?</b></h2>



<p class="wp-block-paragraph"><span>The NCLEX® is a computerized, multiple choice exam. It includes alternate item format questions such as select-all-that-apply, fill-in-the-blank, and drag-and-drop ordering questions. The NCLEX® uses <a href="https://www.boardvitals.com/blog/boardvitals-nclex-cat-score/">computerized adaptive testing</a> (</span><a href="https://www.ncsbn.org/1216.htm"><span>CAT</span></a><span>) to administer and score the exam. CAT merges computer technology with modern measurement theory to create an algorithm to individualize and increase the efficiency of the exam. </span></p>



<p class="wp-block-paragraph"><span>Scoring with CAT technology reduces item exposure and security risks. Next, it calculates the test taker’s ability based on the answer chosen for every question in an effort to provide a following question that matches the test taker’s ability. Therefore, each test taker should receive questions that she or he has a 50% chance of answering correctly. In other words, each question should not be too hard or too easy, individualizing the exam to each person’s ability. The computer will stop giving questions when it is 95% certain (</span><a href="https://www.ncsbn.org/5908.htm"><span>95% Confidence Interval</span></a><span>) the test taker is above or below that standard of passing. </span></p>



<h2 class="wp-block-heading"><b>How many questions are on the NCLEX®?</b></h2>



<p class="wp-block-paragraph"><span>The NCLEX® has 85 to 150 questions including 15 pretest items that are not scored. It has a time limit of 6 hours.</span></p>



<p class="wp-block-paragraph"><span>As mentioned above, the NCLEX® uses CAT technology to determine the number of questions. The test ending is dependent on how fast the test taker reaches the required zone of competency established by the National Council of State Boards of Nursing (NCSBN). The test ends when the test taker has answered enough questions to stay above the passing line with a 95% confidence interval, or alternatively when the test taker has failed enough questions to fall below the 95% confidence interval. Therefore, someone can pass or fail the test with anywhere between 85 and 150 questions. </span></p>



<h2 class="wp-block-heading"><b>How hard is the NCLEX®?</b><span> </span></h2>



<p class="wp-block-paragraph"><span>In 2025, 328,430 total people took the NCLEX® with an <a href="https://www.ncsbn.org/exams/exam-statistics-and-publications/nclex-pass-rates.page">overall pass rate of 69.1%</a>. Of the total test takers, 192,916 were first-time, U.S. educated test takers, and 86.7% passed. In other words, if the student has a U.S. education, is taking the exam for the first time, and has received a bachelor’s degree, her or his chances of passing are higher. The NCSBN publishes the pass rates and statistics of the NCLEX® annually which can be viewed </span><a href="https://www.ncsbn.org/1237.htm"><span>here</span></a><span>. </span></p>



<p class="wp-block-paragraph"><span>With all licensure and certification exams, preparation is key. BoardVitals offers comprehensive online </span><a href="https://www.boardvitals.com/nclex-rn-review-questions"><span>NCLEX-RN® question banks</span></a><span> and </span><a href="https://www.boardvitals.com/nclex-pn-review-questions"><span>NCLEX-PN® question banks</span></a><span> that mirror the CAT technology used for the NCLEX® to help users combat test anxiety. With BoardVitals NGN NCLEX® question banks, study with unlimited customizable practice exams, 3,500+ NCLEX-RN® practice questions which follows the exam content outline recommended by the NCSBN, plus a </span><a href="https://www.boardvitals.com/blog/boardvitals-mobile-app-launch/"><span>convenient mobile app</span></a><span>.</span></p>



<h2 class="wp-block-heading"><b>What should I do if I can’t pass the NCLEX®? </b></h2>



<p class="wp-block-paragraph"><span>Detailed information regarding what to do if you did not pass the NCLEX® can be found </span><a href="https://www.boardvitals.com/blog/fail-nclex/"><span>here</span></a><span>. However, the short answer is not to lose hope. Most state Boards of Nursing allow students to retest multiple times. Often, the student does not pass solely because she or he did not understand the format of the exam. A quick change in your study strategy can help you pass the next time around. So, most importantly, do not give up! </span><a href="https://blog.boardvitals.com/wp-content/uploads/2019/11/Danille-LeVecK-headshot.jpg"></a></p>
<p>The post <a href="https://www.boardvitals.com/blog/nclex-what-to-know-before-taking-the-exam/">8 Things to Know Before Taking the Next Gen NCLEX®</a> appeared first on <a href="https://www.boardvitals.com/blog">BoardVitals Blog</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Andelyn Curator Biomanufacturing Platform Supports Fayuvi Gene Therapy Approval</title>
<link>https://edusehat.com/en/andelyn-curator-biomanufacturing-platform-supports-fayuvi-gene-therapy-approval</link>
<guid>https://edusehat.com/en/andelyn-curator-biomanufacturing-platform-supports-fayuvi-gene-therapy-approval</guid>
<description><![CDATA[ Sanfilippo syndrome type A (MPS IIIA) is a rare, fatal lysosomal storage disease that primarily affects the central nervous system and is marked by rapid neurodegeneration beginning in early childhood. 
The post Andelyn Curator Biomanufacturing Platform Supports Fayuvi Gene Therapy Approval appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2177211585.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 22 Sep 2026 02:10:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Andelyn, Curator, Biomanufacturing, Platform, Supports, Fayuvi, Gene, Therapy, Approval</media:keywords>
<content:encoded><![CDATA[<p>CDMO Andelyn Biosciences is now manufacturing Fayuvi<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> (rebisufligene etisparvovec-hopf), an FDA-approved gene therapy for commercial supply at its Columbus, OH facility. The FDA last week approved the product developed by Ultragenyx Pharmaceutical for the treatment of Sanfilippo syndrome type A, also known as mucopolysaccharidosis type IIIA (MPS IIIA). Fayuvi is also being manufactured ay Ultragenyx’s gene therapy manufacturing facility in Bedford, MA.</p>
<p>Sanfilippo syndrome type A (MPS IIIA) is a rare, fatal lysosomal storage disease that primarily affects the central nervous system (CNS) and is marked by rapid neurodegeneration beginning in early childhood. MPS IIIA is estimated to affect 3,000 to 5,000 patients worldwide, with a median life expectancy of 15 years.</p>
<p>‍Fayuvi is the first FDA-approved gene therapy manufactured using the <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.andelynbio.com%2Fplatforms%2Faav-curator-platform&data=05%7C02%7CJohn.Sterling%40sagepub.com%7Ce9ba7ce1b68b4a30d66c08df15b65744%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639253545024182941%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=FRlIAUjP3H7sTKJUE6mNV1zXPc6IZj4AiS2MHnRyWxU%3D&reserved=0" target="_blank" rel="noopener">Andelyn AAV Curator<sup class="wp-sup-text">®</sup> Platform</a> process. ‍</p>
<p>“We congratulate Ultragenyx on this significant achievement and recognize the MPS IIIA community, investigators, and everyone who contributed to advancing this program,” said Wade Macedone, CEO of Andelyn Biosciences. “We are proud to manufacture an FDA-approved gene therapy for commercial use using an AAV Curator Platform process.”</p>
<p>Andelyn’s AAV Curator Platform uses a configurable, data-informed approach to AAV process development and manufacturing, according to Macedone, who added that it integrates process knowledge, modular manufacturing strategies, and fit-for-purpose analytics to support gene therapy programs from development through commercial launch.</p>
<p class="trimmed"> </p>
<p class="trimmed"> </p>
<p class="trimmed"> </p>
<p>The post <a href="https://www.genengnews.com/topics/omics/andelyn-curator-biomanufacturing-platform-supports-fayuvi-gene-therapy-approval/">Andelyn Curator Biomanufacturing Platform Supports Fayuvi Gene Therapy Approval</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Precure Selects Helix as Multiomics Lab and AI Tools Provider</title>
<link>https://edusehat.com/en/precure-selects-helix-as-multiomics-lab-and-ai-tools-provider</link>
<guid>https://edusehat.com/en/precure-selects-helix-as-multiomics-lab-and-ai-tools-provider</guid>
<description><![CDATA[ Mayo Clinic recently launched Precure with founding partner Thermo Fisher Scientific to help transform how the life sciences community understands the biological changes that occur as disease develops before symptoms occur.
The post Precure Selects Helix as Multiomics Lab and AI Tools Provider appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-1874099648.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 22 Sep 2026 02:10:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Precure, Selects, Helix, Multiomics, Lab, and, Tools, Provider</media:keywords>
<content:encoded><![CDATA[<p>Precure officials say they have selected Helix as its multiomic laboratory and AI tools provider supporting plans to generate molecular data from approximately one million biospecimens. The goal is to accelerate the integration of molecular insights into routine clinical care at the Mayo Clinic and across health systems more broadly.</p>
<p>The Mayo Clinic last week launched Precure with founding partner Thermo Fisher Scientific to help transform how the life sciences community understands the biological changes that occur as disease develops before symptoms occur. Precure brings together clinical expertise, de-identified longitudinal health information, and population-scale molecular data to accelerate the development of new approaches with healthcare applications.</p>
<p>Helix will provide both advanced AI tools for delivery of genomics into the clinic and biomarker driven research, and population scale multiomic capability that encompasses clinical whole genome sequencing (WGS) and research grade proteome sequencing. Linked with longitudinal clinical information and high performance compute infrastructure, the objective is to create new opportunities for prevention, diagnosis, and treatment, according to Aaron Mangold, MD, chief medical officer, Precure.</p>
<p>“Our goal is to generate genomic information that can help inform patient care while creating a powerful resource for discovery,” said Mangold. “We are working to make clinical whole genome sequencing and multiomics a foundation of care, helping us detect disease sooner and act earlier.”</p>
<p>Building on Mayo Clinic’s <a href="https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-to-sequence-100k-participants-to-build-genomic-database-for-improved-care-and-research-in-collaboration-with-helix/" target="_blank" rel="noopener">Tapestry study</a>, which utilized Helix’s Exome+ sequencing technology and reached 100,000 participants, Precure is extending that collaboration by leveraging Helix’s experience providing workflow orchestration, (CLIA/CAP) genomic sequencing, data infrastructure, and AI tools to its health system partners.</p>
<p>Precure and Helix have selected Ultima Genomics’ UG200<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> Ultra Sequencing Platform as part of the program’s large-scale multiomics initiative. Helix will use a fleet of Ultima’s next-generation platforms to generate genomic data for WGS and read-out for proteomics at scale.</p>
<p>“The genome is becoming an enduring patient resource, providing a precision baseline for a lifetime of care,” noted James Lu, MD, PhD, CEO of Helix. “Helix brings together the laboratory and data capabilities to make this possible at scale.”</p>
<p>Helix joins Precure as a collaborator and minority owner. Mayo Clinic’s involvement in Precure is intended to advance its nonprofit mission. Any financial returns to Mayo Clinic would be reinvested in its mission of patient care, research and education. Visit <a href="https://www.mayo.edu/research/precure" target="_blank" rel="noopener">mayo.edu/research/precure</a> for more information.</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/precure-selects-helix-as-multiomics-lab-and-ai-tools-provider/">Precure Selects Helix as Multiomics Lab and AI Tools Provider</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>H5N1 Spreads Among Australian Wildlife as Flu Season Ramps Up</title>
<link>https://edusehat.com/en/h5n1-spreads-among-australian-wildlife-as-flu-season-ramps-up</link>
<guid>https://edusehat.com/en/h5n1-spreads-among-australian-wildlife-as-flu-season-ramps-up</guid>
<description><![CDATA[ Australia is closely monitoring the H5N1 influenza strain after detections in sea lions, seals, dolphins, and foxes, prompting surveillance for mammal adaptation while authorities report low human health risk.
The post H5N1 Spreads Among Australian Wildlife as Flu Season Ramps Up appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/04/GettyImages-1386012927.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 22 Sep 2026 02:10:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>H5N1, Spreads, Among, Australian, Wildlife, Flu, Season, Ramps</media:keywords>
<content:encoded><![CDATA[<p>With flu season ramping up in certain areas of the world (it’s time to get that flu shot!) everyone is watching what strains are circulating—and how well they may match the current vaccine formulations.</p>
<p>Some strains are watched more closely than others, and the highly pathogenic avian H5N1, a subtype of the influenza A virus that causes avian influenza (“bird flu”), may garner the most attention as it is regarded as one of the largest pandemic threats.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>Although H5N1 primarily infects birds, it can also infect mammals. Human infections are uncommon and have generally occurred after close contact with infected animals or contaminated environments. The World Health Organization reports no sustained person-to-person transmission.</p>
<p>The Global Virus Network (GVN) is closely monitoring detections of H5N1 in several mammal species in Australia as the virus continues to spread. Last week, Australian authorities confirmed the first detection in an Australian sea lion, an endangered species, at Seal Bay on Kangaroo Island.</p>
<p>Australia reported its first confirmed detection in a mammal on August 23, when a long-nosed fur seal found at Beachport in South Australia tested positive. A second long-nosed fur seal near Kangaroo Island was confirmed two days later and subsequent detections included red foxes and a common dolphin. Australian authorities report no evidence of mammal-to-mammal transmission of the virus in Australia.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>The detections show the virus infecting several mammal species in Australia within weeks of its first reported appearance in the country’s wildlife. Globally, H5N1 has infected a growing range of mammals, including seals and other marine mammals, dairy cattle, cats and wild carnivores. Scientists are monitoring these infections for changes in the virus and evidence of transmission between mammals.</p>
<p>“Given what we have seen with this H5N1 genotype in seal and sea lion populations overseas, a spillover into Australian marine mammals was a possibility we had been concerned about and actively monitoring for,” said Michelle Wille, PhD, an avian influenza researcher affiliated with the University of Melbourne and the WHO Collaborating Centre for Reference and Research on Influenza and the Peter Doherty Institute for Infection and Immunity, a GVN Center of Excellence in Australia. “While it is sobering to see that possibility become a reality, the priority now is detailed genomic analysis of this and any future detections. We need to closely monitor for mutations associated with better adaptation to mammals and determine whether infections represent separate spillover events from birds or evidence of transmission between seals. That distinction will be critical to understanding the risk posed by the virus as it continues to circulate in wildlife.”</p>
<p>Australia first detected H5N1 clade 2.3.4.4b in wild seabirds in June. The virus has since been found in wild birds across several parts of the country. As of September 17, Australia had reported 576 confirmed events in wildlife, including mass mortality events in greater crested terns. An event may involve one or more animals.</p>
<p>In April 2025, GVN published an analysis in <em>The Lancet Regional Health—Americas</em> calling for stronger surveillance, biosecurity, genomic monitoring and preparedness as H5N1 spread. In April 2026, GVN issued a statement on H5N1 vaccine developments, emphasizing the need for continued vaccine development and broader pandemic preparedness.</p>
<p>“Australia is another reminder that H5N1 is a global animal health issue with implications for human health that we need to continue watching closely,” said Sten H. Vermund, MD, PhD, GVN’s chief medical officer and dean of the University of South Florida College of Public Health. “There is no reason for alarm, but there is every reason to remain vigilant. Surveillance across species, rapid genomic analysis and open sharing of what we learn give us the best chance to recognize an important change in the virus early.”</p>
<p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/h5n1-spreads-among-australian-wildlife-as-flu-season-ramps-up/">H5N1 Spreads Among Australian Wildlife as Flu Season Ramps Up</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Ontario hospitals cut more than 215 RN positions</title>
<link>https://edusehat.com/en/ontario-hospitals-cut-more-than-215-rn-positions</link>
<guid>https://edusehat.com/en/ontario-hospitals-cut-more-than-215-rn-positions</guid>
<description><![CDATA[ More than 215 registered nurse positions have been cut at Ontario hospitals over a two-month period, according to the Ontario Nurses’ Association (ONA), which is warning that the reductions could affect patient care and safety. ONA says RN positions have been eliminated or replaced at hospitals across the province, including in clinical areas where patients […]
The post Ontario hospitals cut more than 215 RN positions appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/09/Codex-Image-Sep-21-2026-09_18_27-AM.png" length="49398" type="image/jpeg"/>
<pubDate>Mon, 21 Sep 2026 20:45:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Ontario, hospitals, cut, more, than, 215, positions</media:keywords>
<content:encoded><![CDATA[<p>More than 215 registered nurse positions have been cut at Ontario hospitals over a two-month period, according to the Ontario Nurses’ Association (ONA), which is warning that the reductions could affect patient care and safety.</p>
<p>ONA says RN positions have been eliminated or replaced at hospitals across the province, including in clinical areas where patients can deteriorate quickly and require advanced assessment and intervention.</p>
<p>The association identified numerous organizations where reductions have been announced, including North York General Hospital, Halton Healthcare, London Health Sciences Centre, Sunnybrook Health Sciences Centre, Lakeridge Health, Niagara Health and several others.</p>
<p>ONA argues that registered nurses bring specific education and clinical expertise that is particularly important when a patient’s condition changes unexpectedly.</p>
<p>The union says some of the changes involve RN positions in areas such as operating rooms, dialysis and postpartum care being replaced by other health professionals.</p>
<p>ONA Provincial President Erin Ariss said the reductions should not be viewed simply as changes in staffing mix, arguing that RNs play an important role in identifying warning signs and responding when patients become unstable.</p>
<p>The union is calling for a moratorium on further RN position cuts.</p>
<p>The issue comes as hospitals across Ontario continue to balance staffing pressures, increasing demand for services and financial constraints.</p>
<p>ONA represents approximately 68,000 nurses and health-care professionals as well as 18,000 nursing student affiliates.</p>
<p>The post <a href="https://www.hospitalnews.com/ontario-hospitals-cut-more-than-215-rn-positions/">Ontario hospitals cut more than 215 RN positions</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Lilly’s GIP/GLP&#45;1 Candidate Brenipatide Shows Early Clinical Promise in Substance, Psych Disorders</title>
<link>https://edusehat.com/en/lillys-gipglp-1-candidate-brenipatide-shows-early-clinical-promise-in-substance-psych-disorders</link>
<guid>https://edusehat.com/en/lillys-gipglp-1-candidate-brenipatide-shows-early-clinical-promise-in-substance-psych-disorders</guid>
<description><![CDATA[ Brenipatide showed a mean half-life ranging between 9.08 days and 12.5 days, with the longer half-life seen in participants given the highest dose of the drug at 4.5 mg. 
The post Lilly’s GIP/GLP-1 Candidate Brenipatide Shows Early Clinical Promise in Substance, Psych Disorders appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/Lilly-research-33333.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sun, 20 Sep 2026 03:45:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Lilly’s, GIPGLP-1, Candidate, Brenipatide, Shows, Early, Clinical, Promise, Substance, Psych, Disorders</media:keywords>
<content:encoded><![CDATA[<p>Eli Lilly presented early positive clinical data supporting once-weekly dosing for its GIP/GLP-1 receptor agonist candidate brenipatide in substance use, psychiatric, and immunologic disorders—and detailed the design of Phase III trials that will assess the drug in major depressive disorder (MDD) and alcohol use disorder (AUD).</p>
<p>Brenipatide is a dual-agonist of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors—the same modality as its blockbuster tirzepatide, marketed for type 2 diabetes in adults as Mounjaro® and for obesity as Zepbound®. The two drugs have racked up a combined $27.6 billion-plus in revenue for Lilly so far this year—$18.605 billion for Mounjaro, $9.088 billion for Zepbound—accounting for about 65% of Lilly’s total $42.773 billion in revenue between January and June 2026.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>Unlike tirzepatide, brenipatide is designed to target GIP and GLP-1 receptors in central nervous system and inflammatory pathways that include receptors linked to reward and addiction in the brain.</p>
<p>At the Psych Congress 2026, held in New Orleans, Lilly presented “Brenipatide, a GIP/GLP-1 Receptor Agonist: Clinical Data Supporting Dose Selection for Substance Use, Psychiatric and Immunologic Disorders,” a poster detailing results from its Phase I J2S-MC-GZMD trial (<a href="https://clinicaltrials.gov/study/NCT06606106">NCT06606106</a>).</p>
<p>The Lilly-sponsored study was designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of brenipatide in healthy, overweight, and obese participants as measured by body mass index (BMI), with the goal of determining a brenipatide dosing regimen suitable for substance use, psychiatric, and immunologic disorders.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>Brenipatide showed a mean half-life ranging between 9.08 days and 12.5 days, with the longer half-life seen in participants given the highest dose of the drug at 4.5 mg. Participants treated with brenipatide received doses of 4.5 mg or lower (0.3 mg, 0.75 mg, 1.5 mg, or 3 mg).</p>
<p>“That allows us to have a durability of exposure that can go beyond the weekly dosing interval, which is what we’re testing benepatide in within the neuroscience space,” Robert Nicholson, PhD, associate vice president, U.S. & global neuroscience medical affairs, psychiatry & substance use disorders with Eli Lilly, told <em>GEN</em>.</p>
<p>The data, Lilly researchers concluded in the poster, “support the selection of weekly maintenance doses across a broad range of BMIs, including normal body weight, that optimize safety, tolerability, and incretin pharmacology” in substance use, psychiatric, and immunological disorders.</p>
<p></p><h4><strong>“Potentially a really good option”</strong></h4>

<p>“As we think through those living with substance use disorders, psychiatric disorders, and certainly in our Phase III trials right now within alcohol use disorder and those with recurrent major depressive disorder, that weekly dosing could be potentially a really good option for those people,” Nicholson added. “Having that longer half-life is some of the reason why we think there’s a distinct profile for brenipatide relative to currently available incretin therapies.”</p>
<p>The Phase I trial was an investigator- and participant-blind, multiple ascending dose study of brenipatide with an eight-week follow-up period. More than 200 people participated in the trial, a population split into three parts:</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<ul>
<li>Part A: BMIs of 27.0–45.0 kg/m2, randomized 16:2 (96 to brenipatide, 12 to placebo).</li>
<li>Part B: BMIs of 22.0–26.9 kg/m2: randomized 16:2 (64 to brenipatide, 8 to placebo).</li>
<li>Part C: BMIs of 22.0–26.9 kg/m2 in Japanese and Chinese participants, randomized 6:2 (24 to brenipatide, 8 to placebo).</li>
</ul>
<p>Part A participants at the highest 4.5 mg dose showed a mean plasma concentration of the drug of just over 1,000 ng/mL on Day 78, with plasma concentration being dose-dependent—a correlation that was also seen with participants in parts B and C, Lilly said.</p>
<p>The Phase I trial also showed brenipatide to have met the study’s primary outcome measure of positive safety data measured by one or more adverse events, including severe and treatment-emergent, that investigators considered related to the study drug. Researchers reported no deaths or serious adverse events (SAEs), with only four participants (2.2%) discontinuing the study due to a treatment-emergent adverse event (TEAE). Brenipatide was generally well-tolerated across all doses studied in participants with a wide range of BMI and different ethnicities, Lilly said.</p>
<p>The most frequently reported TEAEs were gastrointestinal (GI)-related, with an overall GI TEAE frequency of 25% in both brenipatide- and placebo-treated participants. Dysesthesia-related TEAEs were reported in 15.2% of brenipatide-treated participants, but none on placebo.</p>
<p>The GI tolerability could be related to brenipatide’s low peak-to-trough ratio, which Nicholson said is more narrow than for the other incretin therapies that are currently available.</p>
<div class="my-8"><span data-render-ad="6"></span></div>
<h4><strong>MDD, AUD trial designs</strong></h4>
<p>Lilly is building on that early success in part by carrying out a pair of Phase III trials for brenipatide in two indications with large patient populations. During Psych Congress 2026, Lilly presented posters detailing the designs of those two trials—one assessing brenipatide in MDD, the other in alcohol use disorder AUD.</p>
<p>In MDD, Lilly has launched the Phase III RENEW-MDD-1 trial (<a href="https://clinicaltrials.gov/study/NCT07412756">NCT07412756</a>), a multicenter, double-blind, placebo-controlled study evaluating brenipatide plus standard of care (SoC) compared to placebo plus SoC in delaying the return of major depressive symptoms.</p>
<p>The trial is designed to enroll approximately 1,000 participants across 14 countries. The primary endpoint is time to relapse, measured in days from randomization, while the study has numerous secondary endpoints that include MADRS Total Score, PGI-S, GAD-7 Total Score, ReQoL-20 Total Score, patient-rated symptom and disease severity, PROMIS Short Form, SDS global functional impairment score, and body weight (on and not on an atypical antipsychotic).</p>
<p>In AUD, Lilly has launched a pair of 56-week Phase III trials: RENEW-ALC-1, designed to assess brenipatide in participants with moderate-to-severe AUD (<a href="https://clinicaltrials.gov/study/NCT07219966">NCT07219966</a>); and RENEW-ALC-2 (<a href="https://clinicaltrials.gov/study/NCT07219953">NCT07219953</a>), intended to evaluate the safety and effectiveness of brenipatide compared to placebo in people with AUD and hazardous alcohol use. The two trials are designed to enroll 2,200 participants—1,100 each—in eight countries.</p>
<p>Primary outcome for both studies is change in drinking patterns using the Timeline Followback Method (TFBM).</p>
<p></p><h4><strong>Straight to Phase III</strong></h4>

<p>For both MDD and AUD, Lilly advanced brenipatide straight to Phase III, launching the late-stage trials directly following positive Phase I studies, rather than pursuing Phase II studies first, because of the patient populations for both conditions.</p>
<p>In MDD, an estimated <a href="https://www.nimh.nih.gov/health/statistics/major-depression">21 million American adults</a> (about 8.3% of the adult population) had experienced a major depressive episode each year as of 2021, according to data last updated in 2023 by the NIH’s National Institute of Mental Health. Globally, <a href="https://www.who.int/news-room/fact-sheets/detail/depression">approximately 322 million people</a> have MDD, according to a 2023 study cited by the World Health Organization.</p>
<p>As for AUD, <a href="https://www.niaaa.nih.gov/alcohols-effects-health/alcohol-topics/alcohol-facts-and-statistics/alcohol-use-disorder-aud-united-states-age-groups-and-demographic-characteristics">27.9 million Americans ages 12 and older</a> had an alcohol use disorder in the past year, according to data from the National Survey on Drug Use and Health published in 2025 by the NIH’s National Institute on Alcohol Abuse and Alcoholism (NIAAA). An estimated <a href="https://www.who.int/news-room/fact-sheets/detail/alcohol">400 million people</a>, or 7% of the world’s population aged 15 years and older, lived with alcohol use disorders, according to WHO data last updated in 2024.</p>
<div class="my-8"><span data-render-ad="7"></span></div>
<p>“When we look at AUD and MDD, both of those have existing needs that when people think about either having different or better therapies, as well as different types of outcomes, those are the needs where we think about the opportunity and why we thought it was worth going straight to Phase III in those conditions,” Nicholson explained.</p>
<p></p><h4><strong>FDA-approved AUD drugs</strong></h4>

<p>According to NIAAA, three drugs are FDA-approved for AUD: Naltrexone, designed to help reduce the urge to drink, available in several branded or generic versions; acamprosate, a pill sold in several generic versions that is designed to decrease the negative symptoms that are sometimes felt during abstinence from alcohol, making abstinence easier to maintain; and disulfiram<strong>, </strong>a pill that discourages drinking by causing unpleasant symptoms when alcohol is consumed, and is also sold in generic versions.</p>
<p>“The current medications themselves that are approved for alcohol use disorder assume abstinence is what you’re either supporting further or driving towards. But for some individuals, that may not be the outcome that they’re thinking about. So from an AUD perspective, having a different or potentially better treatment or treatment or an outcome that we’re aiming for could be important,” Nicholson said.</p>
<p>That explains, he said, why Lilly’s focus in the AUD trials is an overall change in drinking patterns: “It’s something that is a little different from thinking about abstinence being what we’re aiming for, specifically.”</p>
<p>The Phase III trials in AUD and MDD are among 13 Phase II and III studies in progress for brenipatide, Nicholson said. Other potential indications for the drug that are under study include Phase II studies currently going on for two substance abuse indications, tobacco use disorder and opioid use disorder; and two psychiatric indications, bipolar disorder and schizophrenia.</p>
<p>In the immunology space, brenipatide is being evaluated in forms of asthma, irritable bowel syndrome, and chronic obstructive pulmonary disease (COPD).</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/lillys-gip-glp-1-candidate-brenipatide-shows-early-clinical-promise-in-substance-psych-disorders/">Lilly’s GIP/GLP-1 Candidate Brenipatide Shows Early Clinical Promise in Substance, Psych Disorders</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Palomar Labs Spins Out Ariadne Bio to Advance Non&#45;Hallucinogenic Therapy for Parkinson’s Apathy</title>
<link>https://edusehat.com/en/palomar-labs-spins-out-ariadne-bio-to-advance-non-hallucinogenic-therapy-for-parkinsons-apathy</link>
<guid>https://edusehat.com/en/palomar-labs-spins-out-ariadne-bio-to-advance-non-hallucinogenic-therapy-for-parkinsons-apathy</guid>
<description><![CDATA[ Backed by preclinical data and funding from The Michael J. Fox Foundation, Ariadne Bio is advancing AB-300, a serotonin 2A receptor agonist, as a potential treatment for Parkinson’s-related apathy.
The post Palomar Labs Spins Out Ariadne Bio to Advance Non-Hallucinogenic Therapy for Parkinson’s Apathy appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/08/GettyImages-2162090799.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 19 Sep 2026 06:15:15 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Palomar, Labs, Spins, Out, Ariadne, Bio, Advance, Non-Hallucinogenic, Therapy, for, Parkinson’s, Apathy</media:keywords>
<content:encoded><![CDATA[<p><span>There is considerable room for innovation in neuropsychiatric drug development and Palomar Labs, a venture studio, is hoping to capitalize on that by building companies around drug candidates with prior human validation. As Shlomi Raz, a managing partner at Palomar Labs, explained it, the company’s “mission is to find promising drug candidates with some history of human use” that specifically target “conditions associated with late life.” The goal is to take candidates, which already have some documented evidence of safety and efficacy, through the clinic and through to proof-of-concept.</span></p>
<p><span>And now the venture studio, which was formerly called Negev Labs, has made its first move towards those goals by spinning out its first portfolio company, Ariadne Bio, with a lead program already in hand. Raz steps into the role of CEO for the company and Daniel Jeffries, PhD, a partner at Palomar Labs, will take on the role of chief development officer for the company. Ariadne Bio will focus on developing AB-300, a clinical-stage molecule that functions as a non-hallucinogenic serotonin 2A receptor agonist. The company is developing the molecule to treat apathy in people with Parkinson’s disease.</span></p>
<figure aria-describedby="caption-attachment-338095" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-338095 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/09/ShlomiRaz_AriadneBio_Portrait_White-248x300.jpg" alt="Shlomi Raz, Founder & Chief Executive Officer, Ariadne Bio " width="248" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/ShlomiRaz_AriadneBio_Portrait_White-248x300.jpg 248w, https://www.genengnews.com/wp-content/uploads/2026/09/ShlomiRaz_AriadneBio_Portrait_White.jpg 331w" sizes="auto, (max-width: 248px) 100vw, 248px"><figcaption class="wp-caption-text">Shlomi Raz, Founder & CEO, Ariadne Bio</figcaption></figure>
<p><span>“A significant portion of people with Parkinson’s will lose the drive to do the things that make life worth living, and not a single approved medicine is designed to bring it back,” Raz said. “We built Ariadne Bio around a single question: whether motivation can be restored pharmacologically. AB-300 is how we intend to answer it.” </span></p>
<p><span>Ariadne Bio makes a compelling case for targeting apathy. As Jeffries notes, “apathy is among the most disabling non-motor features of Parkinson’s disease.” The condition is defined clinically as a persistent reduction in goal-directed behavior. It is estimated to affect approximately 40% of people with Parkinson’s disease over the course of the illness. </span></p>
<p><span>Higher rates of the condition are reported in people in the mid to late stages of the disease. In fact, studies of caregiver burden in Parkinson’s rank neuropsychiatric symptoms like apathy ahead of motor symptoms as drivers of distress. It is important to note here that while apathy and depression have some overlapping features, they are distinct conditions. Selective serotonin reuptake inhibitors (SSRIs) remain the appropriate treatment for Parkinson’s associated depression, but some evidence links their use to emotional blunting and worsening apathy. </span></p>
<p><span>In contrast, there are currently no approved therapies for apathy in any indication. If AB-300 successfully makes its way through clinical trials and clears regulatory approval, it could be one of the first. And Raz and his team are driven to accomplish that goal. In fact, this is the second neuropsychiatry-focused company that Raz is launching. Previously, he founded Eleusis, which claims to be the first company that was dedicated to developing medicines derived from psychedelic compounds. Eleusis was acquired by Beckley Psytech in 2022. That company combined Atai Life Sciences to form AtaiBeckley in 2025. As of July, 2026, Eli Lilly entered into a definitive agreement to acquire AtaiBeckley. </span></p>
<p></p><h4><b>A non-hallucinogenic history</b></h4>

<p><span>Raz moved to Palomar Labs after a stint at Beckley Psytech because of what he saw as a “significant opportunity” with similar themes to psychedelics—drugs with demonstrated therapeutic potential that never translated into U.S. Food and Drug Administration-approved therapies. There are several drugs that could fall into this category but Raz admits he is a bit biased towards serotonin therapies because of his background in psychedelics. “Coming out of the psychedelic space, the way I view it is that the first generation of that drug class were these very potent classical psychedelics like psilocybin and LSD,” he said during the conversation. The second generation featured drugs with formulation changes that altered their pharmacodynamics in different ways. </span></p>
<p><span>Raz and his team are most interested in what he categorized as the third-generation. These are potential therapies that activate the same receptors as psychedelic drugs without the corresponding hallucinogenic effects, making them ideal for use in older adults. AB-300 is one such compound. For some of its back story, the compound is based on one that was previously tested in the 1970s and documented to lack hallucinogenic effects, Jefferies told <em>GEN</em>. Since then, several groups have dug into why this particular molecule does not cause hallucinations like other serotonin agonists. </span></p>
<p><span>Earlier this year, scientists published a paper in January in </span><a href="https://www.nature.com/articles/s41586-025-10061-7" target="_blank" rel="noopener"><i><span>Nature</span></i></a><span> that pointed to signaling bias as the likely reason. “When you activate serotonin 2A, there’s multiple intracellular pathways that can be engaged,” Jeffries said. According to the paper’s findings in a preclinical model, the parent compound that AB-300 is based on “preferentially activated the non-hallucinogenic pathway” without removing any therapeutic benefit.</span></p>
<figure aria-describedby="caption-attachment-338098" class="wp-caption alignleft"><img loading="lazy" decoding="async" class="wp-image-338098 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/09/DanielJeffries_AriadneBio_Portrait_White-300x293.jpg" alt="Daniel Jeffries, PhD, Chief Development Officer, Ariadne Bio" width="300" height="293" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/DanielJeffries_AriadneBio_Portrait_White-300x293.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/DanielJeffries_AriadneBio_Portrait_White.jpg 400w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Daniel Jeffries, PhD, Chief Development Officer, Ariadne Bio</figcaption></figure>
<p><span>The fact that this compound does not act on dopamine receptors is crucial. “Classically, mental stimulation comes through a variety of drugs that either block the re-uptake of dopamine or activate dopamine receptors directly,” Raz notes. “The problem of course is that they aren’t necessarily well tolerated by older adults. And so we saw the promise of developing a therapy that indirectly modulates motivation through serotonin receptor activation” without the hallucinogenic effects. Apathy in Parkinson’s disease cases is the immediate target but Raz acknowledged that there are other diseases of aging that involve unaddressed apathy. And Ariadne Bio is actively exploring ways to address those conditions in future. “The more research we did, the more we realized how profound the unmet need there was.”</span></p>
<p></p><h4><b>Building up to Phase Ib</b></h4>

<p><span>In May 2026, at the American Society of Clinical Psychopharmacology, (ASCP) Ariadne Bio presented results from tests of its lead candidate in a preclinical model of tetrabenazine (TBZ)-induced motivational deficit, assessed by progressive-ratio lever pressing. In this model of effort-based motivated behavior, AB-300 plus TBZ increased motivational behavior by 89% relative to the TBZ only group, which is a statistically significant improvement.  </span></p>
<p><span>The company claims that AB-300 is the first serotonin 2A receptor agonist drug candidate shown to restore motivated behavior in a dopamine-depleted model. They also claim that in off-target screening, AB-300 shows no measurable activity at dopamine receptors or the dopamine transporter, which indicates that it engages motivational circuitry through a mechanism independent of dopaminergic signaling. </span></p>
<p><span>Raz and Jeffries dug into the details of the study using the tetrabenazine-induced model in more detail during their conversation with </span><i><span>GEN</span></i><span>. “One of the interesting things about developing apathy, is that this indication has an<em> in vivo</em> model that’s arguably more translatable than some of the other more mainstream neuropsychiatric indications,” Jeffries explained. Tetrabenazine is an FDA-approved drug used in Huntington’s disease with detailed data on its ability to induce a low motivational apathetic phenotype in clinical and preclinical models. Part of what makes the drug so interesting is that it depletes the levels of circulating dopamine in the brain, similar to what is seen in Parkinson’s cases. </span></p>
<p><span>That is an important point, Jefferies emphasized. Because “essentially what that allows developers to do is to test their investigative agent in a motivational model with the background of dopamine depletion,” he said. In terms of the results, the team saw positive effects at doses that are predicted to be within a therapeutic range in the clinic. Furthermore,  the team also observed some of the negative effects of using SSRIs to treat apathy in their model. These results mirrored clinical observations of patients, whose apathy was treated with SSRIs and saw their symptoms worsen. These results show the efficacy of AB-300 and “it’s giving us a lot of motivation … to move forward,” he added. </span></p>
<p><span>That next step is a Phase Ib clinical trial that will test AB-300 in healthy volunteers and Parkinson’s patients, most of whom will be receiving the current standard of care treatments and potentially on antidepressants for their apathy. In addition to assessing safety and efficacy of the treatment, Ariadne’s team and their partners will also assess potential interactions between their compound and those other drugs. </span></p>
<p><span>The trial will begin likely at the end of Q3 or the beginning of Q4 at centers in Austria and Israel. Ariadne Bio has already had a Type B pre-IND meeting with the FDA regarding the development of AB-300 for Parkinson’s disease-associated apathy. </span></p>
<p><span>The planned trial will be a three-part study, Jeffries told<em> GEN.</em> The first part will be a single ascending dose in healthy patients followed by a single ascending dose in Parkinson’s disease patients. In both parts, the scientist will explore “a variety of biomarkers [and a] range of doses” to identify the maximally efficacious dose. “We have the preclinical data [that] tells us generally where we should be looking, but we need to really see that in patients who are on Parkinson’s disease medications to confirm that in fact that is the right range for what we anticipate to be a clinically effective dose or at least to evaluate that potential,” Raz added. The third part of the trial will be a 28-day placebo-controlled double-blind of AB-300 against placebo in patients with clinically relevant apathy. </span></p>
<p><span>Ariadne Bio’s launch is backed by funding from Palomar Labs as well as from The Michael J. Fox Foundation through its Parkinson’s disease therapeutics pipeline program. That program supports preclinical and translation research aimed at evaluating promising therapeutic approaches and helping to support their clinical development. While Ariadne officials declined to disclose exactly how much it has received in funding, Raz told </span><i><span>GEN</span></i><span> that the company has enough in house to complete the proposed clinical trial at this time.</span></p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/palomar-labs-spins-out-ariadne-bio-to-advance-non-hallucinogenic-therapy-for-parkinsons-apathy/">Palomar Labs Spins Out Ariadne Bio to Advance Non-Hallucinogenic Therapy for Parkinson’s Apathy</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Two&#45;Organ View of the Human Brain Emerges</title>
<link>https://edusehat.com/en/two-organ-view-of-the-human-brain-emerges</link>
<guid>https://edusehat.com/en/two-organ-view-of-the-human-brain-emerges</guid>
<description><![CDATA[ Research suggests that the brain is two distinct organs that evolved independently and comprise two ancient nervous systems packaged together; a hindbrain that regulates essential functions, and a forebrain that handles higher level thinking.
The post Two-Organ View of the Human Brain Emerges appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/06/robina-weermeijer-3KGF9R_0oHs-unsplash.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 19 Sep 2026 06:15:14 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Two-Organ, View, the, Human, Brain, Emerges</media:keywords>
<content:encoded><![CDATA[<p>Scientists have traditionally thought of the brain as a single, unified organ. But new research by Stanford Medicine scientists, working with collaborators California Institute of Technology and the University of California, San Francisco, indicates that what we call the brain is two distinct organs that evolved independently over hundreds of millions of years.</p>
<p>The discovery overturns a prevailing model of brain development, based on the theory that there is a single progenitor cell early in development that gives rise to the entire brain. This model suggested that all parts of the brain shared a common developmental origin. The newly reported findings show that the human brain consists of two ancient nervous systems cleverly packaged together—a more primitive part that regulates the heart beating, our breathing and other functions, and another part that makes us distinctly human, capable of poetry, mathematics and wondering about our own origins.</p>
<p>The results could help explain why scientists have struggled for decades to grow certain types of brain cells in the laboratory—and it opens new avenues for studying devastating diseases that affect the brain stem, such as spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS).</p>
<p>“We’ve shown for the first time that the front of the brain arises from a totally different progenitor cell than the back of the brain,” said Kyle Loh, PhD, associate professor of developmental biology. “Our discovery means that we can now grow neurons from the back of the brain, the hindbrain, in a petri dish and study their functions.” Loh is senior author, and Carolyn Dundes, PhD, and Rayyan Jokhai are co-first authors of the scientists’ published paper in <em>Nature Neuroscience</em>, titled “<a href="https://doi.org/10.1038/s41593-026-02433-7" target="_blank" rel="noopener">Two parallel neural ectoderm progenitors contribute to the developing brain</a>,” in which they concluded that “… the emerging notion of two parallel brain progenitors has a number of ramifications for development, differentiation and evolution.”</p>
<p>The adult brain has three main regions: the forebrain, midbrain and hindbrain. The forebrain handles higher-level thinking—language, consciousness and abstract reasoning. In contrast, the hindbrain, located at the back of the skull and often called the brain stem, controls essential, automatic functions that keep us alive: breathing, sleeping, and regulating our heartbeat and hunger urges. “Consequently, hindbrain injury and diffuse intrinsic pontine glioma (a childhood hindbrain cancer) are both deadly, as they impair consciousness, sensation, reflexes and breathing,” the authors wrote. The hindbrain neurons also control the muscles of the face, tongue and throat, which affect speech and swallowing.</p>
<p>Despite the critical importance of the hindbrain, scientists have struggled for decades to generate human hindbrain neurons in the laboratory. This gap has hampered research into devastating diseases affecting the brain stem, including spinal muscular atrophy and amyotrophic lateral sclerosis.</p>
<p>SMA is a leading genetic cause of death in children under one year of age. ALS, which is often diagnosed between the ages of 40 years and 70 years of age, affects both the forebrain and the hindbrain. In both disorders, certain hindbrain neurons gradually cease to function, and the patient loses the ability to swallow, which can cause pneumonia when food or liquid is inhaled into the lungs; eventually, patients lose the ability to breathe. “… degeneration of hindbrain motor neurons probably compromises eating and swallowing in diseases such as spinal muscular atrophy and amyotrophic lateral sclerosis, leading to choking, aspiration, pneumonia and, in some cases, death,” the team continued.</p>
<p>The researchers’ newly reported discoveries emerged from studying the earliest moments of embryonic development, during a stage called gastrulation when the body first takes shape. Jokhai and Dundes discovered that the hindbrain follows a separate developmental path, running in parallel to, rather than branching off from, the pathway that creates the forebrain and midbrain.</p>
<p>The researchers learned this from examining developing mouse embryos. They identified two different brain progenitor cells. “Two parallel brain progenitors emerge simultaneously during gastrulation: anterior neural ectoderm (forebrain/midbrain progenitor) and posterior neural ectoderm (hindbrain progenitor),” they stated. One, which expresses a gene called <em>Otx2</em>, is destined to become the forebrain and midbrain. The other, which expresses a gene called <em>Gbx2</em>, is committed to forming the hindbrain. They showed that these two cell populations never overlap; they are mutually exclusive from the earliest stages of development. “Differentiation of human pluripotent stem cells into anterior or posterior neural ectoderm-like cells revealed these were lineage committed to forebrain/midbrain versus hindbrain fates, respectively.”</p>
<p>The team then examined the DNA packaging, or chromatin, in these cells. Chromatin is a way cells determine which genes can be easily accessed and which are bundled away out of reach. What they found was striking: The anterior neural ectoderm (aNE; future forebrain and midbrain) and posterior neural ectoderm (pNE; future hindbrain) have fundamentally different chromatin configurations. “They harbored diverging chromatin landscapes foreshadowing future forebrain/midbrain versus hindbrain identities,” the team noted. These differences essentially locked each progenitor cell into its respective fate, like travelers on parallel tracks that never cross.</p>
<p>This revelation explained decades of frustration in the field—scientists had been trying to turn one type of progenitor cell into another that it is fundamentally incapable of becoming. “Previous attempts to make hindbrain neurons likely tried to coax forebrain and midbrain progenitors into hindbrain cells, which our study shows is not possible,” Jokhai said. “In stem cell biology, people are always fixated with creating the end cell type, like the neuron. But it’s important to begin at the earliest stages of embryonic development. Our careful attention to that early time point allowed us to find this fundamental split in brain development.”</p>
<p>Armed with this knowledge, the researchers for the first time successfully coaxed human pluripotent stem cells (a kind of cell that can create any cell in the human body) to become functional hindbrain motor neurons in the laboratory.</p>
<p>These lab-grown neurons displayed all the hallmarks of authentic hindbrain cells: They exhibited waves of electrical activity called action potentials and made proteins that identify the segments of the hindbrain that control facial and swallowing muscles. “Discovering this lineage bifurcation provided a roadmap to differentiate hPS cells into pNE and subsequently specific types of hindbrain neuron <em>in vitro</em>, thus enabling future explorations of human hindbrain biology and disease,” the scientists noted.</p>
<p>Finally, the researchers looked back over 550 million years of evolutionary time. They found the same two-origin brain pattern in chickens, zebrafish and, remarkably, in acorn worms, tiny creatures living on the ocean floor that share a distant common ancestor with humans. “Separate anterior and posterior ectoderm populations arise during gastrulation across deuterostome species as diverse as acorn worm, zebrafish, chicken, mouse and primate, implying that this distinction between two different types of ectoderm predates the origins of chordates and arose ~550–600 million years ago,” the team further stated. Jellyfish, which diverged from humans about 600 to 700 million years ago, have two nervous systems at different ends of their body.</p>
<p>“Our research suggests that evolution took two existing neural systems and pushed them together spatially,” Loh said. “Having the brain as one organ would probably be more efficient, but we rely on this primordial way to make the brain as two separate pieces.”</p>
<p>“I was surprised at our findings because the word ‘brain’ implies a contiguous organ that likely has a singular origin,” Jokhai added. “But even 500 million years ago, there were these separate neural systems, which now almost operate as one, which is very cool.”</p>
<p>The research also has implications for investigating treatments for SMA, ALS and other conditions affecting the brain stem. Until now, studying these diseases has been nearly impossible because scientists cannot obtain brain stem tissue from living patients. The ability to grow these neurons in a dish opens new possibilities for understanding what goes wrong. There’s even an unexpected connection to obesity treatment: The hindbrain contains circuits that regulate hunger—which is precisely how weight-loss drugs like semaglutide work.</p>
<p>The researchers would like to extend their studies to determine the developmental origins of the spinal cord and to learn exactly how SMA and ALS compromise the function of hindbrain neurons. “Now we have a model to better understand these devastating diseases, and work toward regenerative therapies for them,” Jokhai said. “This is a very exciting new frontier in brain research.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/two-organ-view-of-the-human-brain-emerges/">Two-Organ View of the Human Brain Emerges</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The Saga of Sickle Cell Disease</title>
<link>https://edusehat.com/en/the-saga-of-sickle-cell-disease</link>
<guid>https://edusehat.com/en/the-saga-of-sickle-cell-disease</guid>
<description><![CDATA[ In his new book Curved Air, Kevin Davies, PhD, portrays the fascinating story of sickle cell disease, from its origins in sub-Saharan Africa to advances in gene therapy, along with powerful personal insights from patients, including some who are finally living pain-free.
The post The Saga of Sickle Cell Disease appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/Victoria-Gray-church.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 19 Sep 2026 06:15:13 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, Saga, Sickle, Cell, Disease</media:keywords>
<content:encoded><![CDATA[<p>The approval in December 2023 of Casgevy and Lyfgenia marked a major milestone in the treatment of sickle cell disease (SCD). This genetic disease, caused by a recessive point mutation in the gene for beta-globin, was first described in the medical literature in 1910.</p>
<p>This month—appropriately Sickle Cell Awareness month—sees the publication of a new popular science book on SCD, <em>Curved Air</em>, written by Kevin Davies, PhD, and published by Harvard University Press. I sat down with Kevin to ask him about the genesis of the book and the extraordinary story of SCD.</p>
<p>(<em>This interview has been lightly edited for length and clarity</em>.)</p>
<p class="trimmed"> </p>
<p><span><strong><em>GEN</em></strong></span><strong><span>:</span> Kevin, how did the idea for <em>Curved Air</em> come about? </strong></p>
<p><strong>Kevin Davies:</strong> My last book, <em>Editing Humanity</em>, which was about the CRISPR revolution, came out six years ago. Whenever I was asked about the most exciting application of gene editing, I would invariably answer: ‘sickle cell.’ That’s because, like many people, I’d been moved to learn about the journey of Victoria Gray, the first SCD patient to undergo CRISPR cell therapy, back in July 2019. She talked openly about her therapy and recovery in a series of interviews on National Public Radio.</p>
<p>I found it ironic that CRISPR—this incredible 21<sup>st</sup> century, Nobel Prize-winning technology for performing DNA surgery—should find its first clinical success treating patients with a disease that, many would argue, has been underfunded and forgotten by large sections of the medical and pharma communities.</p>
<p>I also have to give a shout-out to John Evans, the CEO of Beam Therapeutics. During an interview he gave to <em>GEN</em> about five years ago, John described SCD as ‘the most famous genetic mutation in the world.’ That quote really hit home and gave me added impetus to write the book proposal that became <em>Curved Air</em>.</p>
<p class="trimmed"> </p>
<figure aria-describedby="caption-attachment-338116" class="wp-caption alignright"><img decoding="async" class="size-medium wp-image-338116" src="https://www.genengnews.com/wp-content/uploads/2026/09/Curved-Air-cover-201x300.jpg" alt="Curved Air book cover" width="201" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/Curved-Air-cover-201x300.jpg 201w, https://www.genengnews.com/wp-content/uploads/2026/09/Curved-Air-cover-685x1024.jpg 685w, https://www.genengnews.com/wp-content/uploads/2026/09/Curved-Air-cover-768x1148.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/09/Curved-Air-cover-281x420.jpg 281w, https://www.genengnews.com/wp-content/uploads/2026/09/Curved-Air-cover-562x840.jpg 562w, https://www.genengnews.com/wp-content/uploads/2026/09/Curved-Air-cover-696x1041.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/09/Curved-Air-cover.jpg 909w" sizes="(max-width: 201px) 100vw, 201px"><figcaption class="wp-caption-text"><i>Curved Air</i>, the latest book from Kevin Davies, PhD. [Harvard University Press]</figcaption></figure>
<p><span><strong><em>GEN</em></strong></span><strong><span>:</span> I do like the title of the book. Where did it come from?</strong></p>
<p><strong>Davies:</strong> As you probably know John, ‘Curved Air’ was a British progressive rock band in the 1970s. I’m a huge fan of the genre, although not that band specifically. But the phrase seemed to fit perfectly. ‘Curved’ reflects the trademark crescent- or sickle-shaped red blood cells (RBCs) in SCD. And ‘Air’ corresponds to the compromised ability of those sickled RBCs to transport oxygen around the body, hence the anemia. I kept waiting for my editor at Harvard University Press, Rachel Field, to say something, but she was happy to keep the working title.</p>
<p class="trimmed"> </p>
<p><span><strong><em>GEN</em></strong></span><strong><span>:</span> When did you first encounter or remember learning about SCD?</strong></p>
<p><strong>Davies:</strong> That’s the thing. It was the first genetic disease I learned about in school in the U.K. some half a century ago! I remember sketching the healthy and diseased RBCs and learning about the sort of superpower that carriers of the sickle cell gene have against malaria. So many milestones in molecular biology revolve around the study of hemoglobin and SCD. Linus Pauling, PhD, dubbed sickle cell ‘the first molecular disease’ back in 1949. And yet, prior to the advent of CRISPR, the only effective therapy had been hydroxyurea, a generic chemotherapy drug. This community—an estimated 100,000 patients in the United States—has been waiting an eternity for something to get excited about.</p>
<p class="trimmed"> </p>
<p><span><strong><em>GEN</em></strong></span><strong><span>:</span> You mentioned Victoria Gray. Is she a big part of the book? What makes her story so compelling?</strong></p>
<p><strong>Davies:</strong> Oh yes, absolutely! She was a guest on one of <a href="https://www.genengnews.com/multimedia/summits/the-state-of-cell-and-gene-therapy-2024/"><em>GEN</em>’s virtual summits a few years ago</a>. I met her in person a few months later and she invited me down to her home in Mississippi for an in-depth interview. We did that in her local church, which was special because I know how important her faith is. She opened up about the many episodes of discrimination that she experienced, something that is all too prevalent in the way people with SCD—almost exclusively persons of color—are treated in the medical system on both sides of the Atlantic.</p>
<figure aria-describedby="caption-attachment-338118" class="wp-caption alignright"><img decoding="async" class="size-medium wp-image-338118" src="https://www.genengnews.com/wp-content/uploads/2026/09/Victoria-Gray-church-300x225.jpeg" alt="Victoria Gray" width="300" height="225" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/Victoria-Gray-church-300x225.jpeg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/Victoria-Gray-church-1024x768.jpeg 1024w, https://www.genengnews.com/wp-content/uploads/2026/09/Victoria-Gray-church-768x576.jpeg 768w, https://www.genengnews.com/wp-content/uploads/2026/09/Victoria-Gray-church-1536x1152.jpeg 1536w, https://www.genengnews.com/wp-content/uploads/2026/09/Victoria-Gray-church-560x420.jpeg 560w, https://www.genengnews.com/wp-content/uploads/2026/09/Victoria-Gray-church-1120x840.jpeg 1120w, https://www.genengnews.com/wp-content/uploads/2026/09/Victoria-Gray-church-80x60.jpeg 80w, https://www.genengnews.com/wp-content/uploads/2026/09/Victoria-Gray-church-160x120.jpeg 160w, https://www.genengnews.com/wp-content/uploads/2026/09/Victoria-Gray-church-696x522.jpeg 696w, https://www.genengnews.com/wp-content/uploads/2026/09/Victoria-Gray-church-1392x1044.jpeg 1392w, https://www.genengnews.com/wp-content/uploads/2026/09/Victoria-Gray-church-1068x801.jpeg 1068w, https://www.genengnews.com/wp-content/uploads/2026/09/Victoria-Gray-church-1920x1440.jpeg 1920w, https://www.genengnews.com/wp-content/uploads/2026/09/Victoria-Gray-church-265x198.jpeg 265w, https://www.genengnews.com/wp-content/uploads/2026/09/Victoria-Gray-church-530x396.jpeg 530w, https://www.genengnews.com/wp-content/uploads/2026/09/Victoria-Gray-church.jpeg 2048w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Victoria Gray, photographed in her local church in Forest, MS. [Kevin Davies]</figcaption></figure>
<p>Victoria deserves all her flowers. By going public with her story, she literally inspired other warriors to enroll in the CRISPR trial (sponsored by Vertex). I’m thrilled that she’s healthy and serving now as a patient advocate to raise awareness and help educate others with the disease. I also interviewed many other warriors in the book. I really hope readers will enjoy meeting LaRae, Danielle, Kwanzaa, Ray’Neshia, Jimi, and others. Every person’s story is unique and special in its own right.</p>
<div class="my-8"><span data-render-ad="6"></span></div>
<p> </p>
<p><span><strong><em>GEN</em></strong></span><strong><span>:</span> Much of your book is spent detailing the story behind Casgevy. What was notable about that work?</strong></p>
<p><strong>Davies:</strong> Casgevy works not by fixing the SCD mutation directly but via a clever workaround: boosting the levels of fetal hemoglobin (HbF) to compensate for the inherited mutation in adult hemoglobin. The first inkling of that strategy dates back to 1948 and the clinical observations of a New York pediatrician named Janet Watson. Two decades ago, researchers made the key discovery that variants in a transcription factor called <em>BCL11A</em> influence HbF levels. It is great to see the scientists behind that fundamental discovery—Swee-Lay Thein, MD (NIH) and Stuart Orkin, MD (Harvard Medical School)—belatedly receive recognition in the form of the 2026 Breakthrough Prize.</p>
<p>I talk about the work at CRISPR Therapeutics and Vertex that led to the commercial approval of Casgevy. It’s impressive that Vertex has also driven the discovery of life-changing small-molecule drugs for cystic fibrosis, another classic genetic disease that also rose in frequency because carriers had a selective advantage, most likely against an infectious disease.</p>
<p class="trimmed"> </p>
<p><span><strong><em>GEN</em></strong></span><strong><span>:</span> Many GEN readers will be broadly familiar with the story of SCD. Did you discover anything new or surprising in your research?</strong></p>
<figure aria-describedby="caption-attachment-338121" class="wp-caption alignright"><img loading="lazy" decoding="async" class="size-medium wp-image-338121" src="https://www.genengnews.com/wp-content/uploads/2026/09/KevinDavies_Catoctin-300x225.jpg" alt="Catoctin Furnace" width="300" height="225" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/KevinDavies_Catoctin-300x225.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/KevinDavies_Catoctin-1024x768.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/09/KevinDavies_Catoctin-768x576.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/09/KevinDavies_Catoctin-560x420.jpg 560w, https://www.genengnews.com/wp-content/uploads/2026/09/KevinDavies_Catoctin-1120x840.jpg 1120w, https://www.genengnews.com/wp-content/uploads/2026/09/KevinDavies_Catoctin-80x60.jpg 80w, https://www.genengnews.com/wp-content/uploads/2026/09/KevinDavies_Catoctin-160x120.jpg 160w, https://www.genengnews.com/wp-content/uploads/2026/09/KevinDavies_Catoctin-696x522.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/09/KevinDavies_Catoctin-1392x1044.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2026/09/KevinDavies_Catoctin-1068x801.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/09/KevinDavies_Catoctin-265x198.jpg 265w, https://www.genengnews.com/wp-content/uploads/2026/09/KevinDavies_Catoctin-530x396.jpg 530w, https://www.genengnews.com/wp-content/uploads/2026/09/KevinDavies_Catoctin.jpg 1400w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Catoctin Furnace (Catoctin, MD), where DNA evidence points to the presence of sickle cell amongst enslaved people in the early 1800s. [Kevin Davies]</figcaption></figure>
<p><strong>Davies:</strong> Hopefully a few surprises, yes! One is in regard to the first documented case in the United States—Walter Clement Noel, a dental student from Grenada, who was treated in Chicago in 1904. It was his case that was first documented in a medical journal in 1910. But obviously there were thousands of patients with SCD who reached the Americas during the Middle Passage. I spoke to a researcher at 23andMe who was an author on a major paper in <em>Science</em> two years ago analyzing the remains of some 30 enslaved African Americans at the Catoctin Furnace, an iron foundry in northern Maryland. She told me that forensic DNA sequencing revealed that three children buried there, dating back to the early 1800s, carried the SCD mutation.</p>
<p>I also interviewed the first patient to be cured of SCD via gene therapy more than a decade ago, a young Frenchman named Leeroy Tegar. Initially, his physician, Marina Cavazzana, MD, in Paris, didn’t think he’d want to talk to a journalist. But he did, with a big assist from Google Translate and Rodolphe Barrangou, PhD, the editor of <em>The CRISPR Journal</em>, who is French.</p>
<p class="trimmed"> </p>
<div class="my-8"><span data-render-ad="7"></span></div>
<p><span><strong><em>GEN</em></strong></span><strong><span>:</span> You also visited the site of Walter Noel’s grave in Grenada?</strong></p>
<p><strong>Davies:</strong> After dental school, Walter returned to his home on the Caribbean island of Grenada in 1907 and set up his own practice, only to die in 1916. His identity was uncovered decades after the famous 1910 medical journal paper by Todd Savitt, PhD, a retired history professor. A few years ago, I felt compelled to follow in Savitt’s footsteps, hiring a driver to take me from the capital of Grenada to Sauteurs, a town on the north coast of the island, where Noel is buried in a Catholic cemetery.</p>
<p class="trimmed"> </p>
<p><span><strong><em>GEN</em></strong></span><strong><span>:</span> Despite the excitement over CRISPR and gene therapy, you depict a much darker side of sickle cell care. Tell me about Brittany Hightower.</strong></p>
<p><strong>Davies:</strong> Early on in my reporting, I watched some videos that had been live-streamed by Brittany Hightower, a 30-something sickle cell warrior in Texas. Brittany documented some distressing scenes at a major Dallas hospital, staff not wanting to care for her. In one viral video, two security guards informed her that she was being kicked out of the hospital—in the middle of a pain crisis. She died of pneumonia a couple of years ago.</p>
<p>I tracked down Brittany’s best friend and fellow sickle cell warrior, Kwanzaa, who ironically had taken part in the Lyfgenia gene therapy trial at NIH. Kwanzaa graciously shared Brittany’s final texts to her, sent just days before she died. I included them in the book as a poignant reminder that medical progress is one thing, but we can do so much better in educating medical professionals about this disease.</p>
<p class="trimmed"> </p>
<p><span><strong><em>GEN</em></strong></span><strong><span>:</span> What impact will Casgevy and Lyfgenia have on sickle cell treatments in the long run?</strong></p>
<p><strong>Davies:</strong> We have to keep these launches in perspective. The experiences of the first cohort of patients taking these therapies have been amazing—almost all report no pain crises or hospitalizations or even the need for blood transfusions. Those that do typically had too much vascular damage before they received therapy. As Haydar Frangoul, MD, the physician who treated Victoria, says: ‘I can take the hammer away, but I can’t fix the wall.’</p>
<p>Remember this is <em>ex vivo </em>therapy, requiring months in hospital and a brutal chemotherapy regimen prior to therapy. The dream is to develop a much less complex <em>in vivo </em>gene therapy. Of course, even that will be of limited benefit to the millions of SCD patients across Africa, India and other parts of the world. I am optimistic that eventually scientists will develop a small molecule drug that can mimic the effects of Casgevy. Wouldn’t that be something?</p>
<p class="trimmed"> </p>
<figure aria-describedby="caption-attachment-338119" class="wp-caption alignright"><img loading="lazy" decoding="async" class="size-medium wp-image-338119" src="https://www.genengnews.com/wp-content/uploads/2026/09/Casgevy-Vertex-241x300.jpeg" alt="Casgevy display" width="241" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/Casgevy-Vertex-241x300.jpeg 241w, https://www.genengnews.com/wp-content/uploads/2026/09/Casgevy-Vertex-822x1024.jpeg 822w, https://www.genengnews.com/wp-content/uploads/2026/09/Casgevy-Vertex-768x956.jpeg 768w, https://www.genengnews.com/wp-content/uploads/2026/09/Casgevy-Vertex-1234x1536.jpeg 1234w, https://www.genengnews.com/wp-content/uploads/2026/09/Casgevy-Vertex-337x420.jpeg 337w, https://www.genengnews.com/wp-content/uploads/2026/09/Casgevy-Vertex-675x840.jpeg 675w, https://www.genengnews.com/wp-content/uploads/2026/09/Casgevy-Vertex-696x867.jpeg 696w, https://www.genengnews.com/wp-content/uploads/2026/09/Casgevy-Vertex-1392x1733.jpeg 1392w, https://www.genengnews.com/wp-content/uploads/2026/09/Casgevy-Vertex-1068x1330.jpeg 1068w, https://www.genengnews.com/wp-content/uploads/2026/09/Casgevy-Vertex.jpeg 1501w" sizes="auto, (max-width: 241px) 100vw, 241px"><figcaption class="wp-caption-text">Display at Vertex facility in Boston marking FDA approval of Casgevy in 2023. [Kevin Davies]</figcaption></figure>
<p><span><strong><em>GEN</em></strong></span><strong><span>:</span> The elephant in the room of course is that Casgevy costs $2.2 million, and Lyfgenia more than $3 million. What happens to patients who really need it but cannot afford the therapy? </strong></p>
<p><strong>Davies:</strong> True, the costs are very high, but that doesn’t appear to be the big stumbling block. Most private insurance companies and a majority of states in the U.S. are covering these therapies. $2–3 million in a one-time therapy is still good value compared to the costs of treating patients for recurring pain crises and organ failure over decades. The manufacturing process is also improving, which is helping to shorten the treatment timeline.</p>
<p class="trimmed"> </p>
<p><strong><span><em>GEN</em>:</span> Thanks for speaking with me and congratulations, Kevin. Best of luck with the book!</strong></p>
<p>The post <a href="https://www.genengnews.com/topics/genome-editing/the-saga-of-sickle-cell-disease/">The Saga of Sickle Cell Disease</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Model&#45;Free, Pure Component Analysis Could Help Biopharma Cut Costs</title>
<link>https://edusehat.com/en/model-free-pure-component-analysis-could-help-biopharma-cut-costs</link>
<guid>https://edusehat.com/en/model-free-pure-component-analysis-could-help-biopharma-cut-costs</guid>
<description><![CDATA[ Spectroscopic analysis techniques rely on empirical models that are time consuming and expensive to make. Biopharma companies could speed development and reduce costs using a model-free measuring approach called pure-component analysis, says Nirrin Technologies.
The post Model-Free, Pure Component Analysis Could Help Biopharma Cut Costs appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-1356760192.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 19 Sep 2026 06:15:12 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Model-Free, Pure, Component, Analysis, Could, Help, Biopharma, Cut, Costs</media:keywords>
<content:encoded><![CDATA[<p>Spectroscopy can be used to analyze process streams for proteins and analytes of interest in real-time. The problem is that many spectroscopic techniques, including NIR and Raman, rely on models to separate signals from background noise.</p>
<p>Developing these models takes time and money, according to Nirrin Technologies CEO, Bryan Hassell, who told <em>GEN</em>, “They are built empirically, from large, designed experiments that span every condition the method will ever encounter. They are expensive to build, tied to the process and instrument they were built on, and to be rebuilt when the process, scale, or instrument changes.”</p>
<p></p><h4><strong>Pure component analysis</strong></h4>

<p>An alternative is the model-free approach “pure-component analysis,” continued Hassell. “In PCA each component has a known spectrum, and the measured spectrum is resolved into the concentrations of those components directly. There is no empirical model to develop and no DOE campaign behind it. A method built in development runs the same way in manufacturing, and on a different system at a different site.”</p>
<p>Hassell pointed to Nirrin’s new tunable laser near-infrared (TL-NIR) platform, which will be showcased at the Bioprocess International (BPI) East conference in Boston. to illustrate the potential benefits of pure-component analysis.</p>
<p>“It is a near-infrared measurement platform built around a tunable laser instead of a broadband lamp. The laser puts far more optical power into each individual wavelength, which gives a much higher signal-to-noise ratio than conventional NIR,” he explained. “Spectroscopic methods return spectra that must be interpreted through a model before anyone can act on them. TL-NIR returns concentrations. That is the number an engineer already makes decisions on, available in seconds or continuously, rather than a signal that needs deciphering first.”</p>
<p>But eliminating models is just one of the potential benefits, according to Hassell, who said “For protein analysis, a TL-NIR measurement is five times faster than variable-pathlength UV, and requires no dilution, no sample prep and no pathlength adjustment. The larger savings are upstream of that. Companies avoid the model-building campaigns that Raman and broadband NIR methods require, and they can bring in-house measurements that are currently sent out to HPLC, which removes both the cost per sample and the days of waiting for results.”</p>
<p>At present, five to 10 “top biopharmaceutical companies” use TL-NIR systems in process development, pointed out Hassell, and said the plan now is to raise awareness about the potential benefits of using the technology in commercial production.</p>
<p>“We are at the beginning of bringing this into manufacturing environments. These processes have been in place for a long time, and the industry will not convert to data-driven manufacturing overnight. We start in process development, where the technology is proven and validated and where transferability is demonstrated, and we are now working with key customers on manufacturing deployment from there.”</p>
<p class="trimmed"> </p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/model-free-pure-component-analysis-could-help-biopharma-cut-costs/">Model-Free, Pure Component Analysis Could Help Biopharma Cut Costs</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Nu&#45;Tek Brings Topic of Raw&#45;Material Risk to BPI</title>
<link>https://edusehat.com/en/nu-tek-brings-topic-of-raw-material-risk-to-bpi</link>
<guid>https://edusehat.com/en/nu-tek-brings-topic-of-raw-material-risk-to-bpi</guid>
<description><![CDATA[ Nu-Tek BioSciences will use BPI East to highlight animal-origin-free peptones and hydrolysates designed to strengthen media consistency, reduce raw-material risk, and support more reliable cell culture and fermentation processes for biologics manufacturers.
The post Nu-Tek Brings Topic of Raw-Material Risk to BPI appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/Nu-Tek-BPI_GBPN_IMAGE.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 19 Sep 2026 06:15:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Nu-Tek, Brings, Topic, Raw-Material, Risk, BPI</media:keywords>
<content:encoded><![CDATA[<p>As biopharmaceutical manufacturers push for tighter process control and more resilient supply chains, raw materials used in cell-culture media are receiving closer scrutiny. Nu-Tek BioSciences is bringing that conversation to BioProcess International East (BPI East) in Boston, where the company will highlight its portfolio of 100% animal-origin-free peptones and protein hydrolysates.</p>
<p>The Minnetonka, MN-based supplier says its plant- and yeast-derived nutrients are intended for cell culture and microbial fermentation applications supporting vaccines, therapeutics, and other biologics. At BPI East, Nu-Tek will focus discussions with pharmaceutical leaders on product performance, media consistency, supply continuity, and the qualification of critical raw materials.</p>
<p>That emphasis reflects a broader challenge in bioprocessing: seemingly upstream choices in media composition can influence process robustness much later in manufacturing. Variability in complex raw materials can complicate process development and scale-up, while supply disruptions can force manufacturers to evaluate alternative sources or requalify components.</p>
<p>According to Joy Aho, PhD, Nu-Tek’s director of technical program management, “Bioprocessing relies on the control of critical raw materials from start to finish.” She added that the company’s products are designed to provide “quality, control, and customization options” for customers seeking to improve production performance while reducing risk.</p>
<p>Animal-origin-free materials can also help manufacturers simplify sourcing strategies where animal-derived components might create additional regulatory, traceability, or contamination concerns. Nu-Tek positions its peptones and hydrolysates as tools for reducing those risks without giving up the nutrient complexity often needed in demanding culture and fermentation systems.</p>
<p>During the meeting, Nu-Tek also plans to discuss its variability reduction program with teams looking to improve media consistency. The company also operates a purpose-built manufacturing facility dedicated to animal-origin-free peptones and protein hydrolysates.</p>
<p>For Nu-Tek, BPI East is less about introducing a single new product than about making the case that raw-material strategy has become a competitive part of bioprocess design. As biologics manufacturing grows more complex, suppliers are increasingly being asked to deliver not only performance, but also consistency, traceability, and dependable access.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/nu-tek-brings-topic-of-raw-material-risk-to-bpi/">Nu-Tek Brings Topic of Raw-Material Risk to BPI</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>GBI Biomanufacturing Set to Launch SmartScale GMP Solutions</title>
<link>https://edusehat.com/en/gbi-biomanufacturing-set-to-launch-smartscale-gmp-solutions</link>
<guid>https://edusehat.com/en/gbi-biomanufacturing-set-to-launch-smartscale-gmp-solutions</guid>
<description><![CDATA[ Many early-stage drug developers need a more efficient path to obtaining the GMP material required to reach the clinic. SmartScale was designed to help close that gap.
The post GBI Biomanufacturing Set to Launch SmartScale GMP Solutions appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-936335404.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 19 Sep 2026 06:15:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>GBI, Biomanufacturing, Set, Launch, SmartScale, GMP, Solutions</media:keywords>
<content:encoded><![CDATA[<p>CDMO GBI Biomanufacturing will announce the launch of its new SmartScale<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> GMP Solutions platform at BioProcess International (BPI) East 2026. SmartScale is an accelerated, small-scale cGMP manufacturing platform designed to help early-stage biologics developers generate GMP material for first-in-human studies faster and more efficiently, according to Jesse McCool, PhD, CEO.</p>
<p>The platform combines technologies from industry partners ATUM and Thomson Instrument to streamline cell line development, process scaleup, and manufacturing, he added.</p>
<p>“When developing life-saving therapies, speed and simplicity can make a significant difference,” continued McCool. “Many early-stage drug developers need a more efficient path to obtaining the GMP material required to reach the clinic. SmartScale was designed to help close that gap by providing a right-sized manufacturing approach that accelerates the journey to first-in-human studies.”</p>
<p>Developers increasingly seek approaches that enable earlier clinical evaluation of promising candidates while reducing development risk, timelines, and capital requirements.</p>
<p>“SmartScale is a stable pool-based manufacturing platform that can deliver GMP material for first-in-human studies in as little as eight months,” McCool said. “Our goal is to help customers reach the critical milestone of generating human clinical data that supports future regulatory and commercial decisions.”</p>
<p>GBI noted that the platform aligns with the FDA’s Operation TrialBlazer initiative, which seeks to accelerate the development of innovative therapies and modernize drug development pathways.</p>
<p>GBI partnered with ATUM to integrate ATUM’s Leap-In Transposase<sup class="wp-sup-text">®</sup> cell lines into its SmartScale platform, aimed at maximizing drug substance yield at smaller scales. ATUM brings cell line expertise, having enabled over 60 INDs across multiple therapeutic areas.</p>
<p>“The Optimum Growth<sup>®</sup> Flask was designed to simplify scaleup while maintaining high-performance cell culture conditions,” said Sam Ellis, CEO of Thomson Instrument, about his company’s other contribution to the collaboration. “As part of the SmartScale platform, our technology helps streamline the transition from research and development into GMP manufacturing.”</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/gbi-biomanufacturing-set-to-launch-smartscale-gmp-solutions/">GBI Biomanufacturing Set to Launch SmartScale GMP Solutions</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Asahi Kasei Introduces VANTIJ® SU&#45;VFC Benchtop Virus&#45;Filtration System</title>
<link>https://edusehat.com/en/asahi-kasei-introduces-vantij-su-vfc-benchtop-virus-filtration-system</link>
<guid>https://edusehat.com/en/asahi-kasei-introduces-vantij-su-vfc-benchtop-virus-filtration-system</guid>
<description><![CDATA[ The instrument, the first benchtop-scale platform in Asahi Kasei Bioprocess’s VANTIJ family, extends the automation and operator-focused design principles of the existing portfolio while simplifying virus filtration processes.
The post Asahi Kasei Introduces VANTIJ® SU-VFC Benchtop Virus-Filtration System appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2196602690.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 19 Sep 2026 06:15:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Asahi, Kasei, Introduces, VANTIJ®, SU-VFC, Benchtop, Virus-Filtration, System</media:keywords>
<content:encoded><![CDATA[<p>Asahi Kasei Bioprocess will unveil its VANTIJ<sup class="wp-sup-text">®</sup> SU-VFC benchtop at Bioprocess International (BPI) East in Boston this week. This new small-format system is designed to deliver automated, single-use virus filtration for laboratory-scale and process development applications. The system will be available on site at Booth 606.</p>
<p>The instrument is the first benchtop-scale platform in Asahi Kasei Bioprocess’s <a href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ffluidmgmt.ak-bio.com%2Fproducts%2Fbioprocess-filtration%2Fvirus-filtration-system%2F&esheet=54603648&newsitemid=20260915583092&lan=en-US&anchor=VANTIJ%26%23174%3B+family&index=1&md5=10f9fd865371147b2b354446b44fea72" target="_blank" rel="noopener">VANTIJ family</a>. The system extends the automation and operator-focused design principles of the existing portfolio while simplifying virus filtration processes, according to the company.</p>
<p>Its design accommodates workflows using 0.12 m² or 0.3 m² <a href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fplanova.ak-bio.com%2Fproducts%2Fplanova-n%2F&esheet=54603648&newsitemid=20260915583092&lan=en-US&anchor=Planova%26%238482%3B+35N+virus-removal+filters&index=2&md5=47eadeec440d90c659459ff059536855" target="_blank" rel="noopener">Planova<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> 35N virus-removal filters</a>. The VANTIJ simplifies small-scale Planova virus filtration while maintaining the process control and data-focused capabilities expected in biopharmaceutical development, explains an Asahi spokesperson.</p>
<p>Initially designed for gene therapy manufacturing, the new benchtop helps address the operational complexities associated with long production timelines, regulatory requirements, operator training, and therapy-specific needs, continues the company official, who adds that the system offers clear setup through a guided shadow-board layout, tool-free tube set installation and replacement, intuitive connection points, and recipe-driven software. It also enables batch reporting and supports the execution of key filtration processes.</p>
<p>“The biopharmaceutical industry continues to pursue more efficient pathways for bringing innovative therapies to patients,” said Chris Rombach, president of Asahi Kasei Bioprocess America. “The VANTIJ SU-VFC Benchtop reflects Asahi Kasei Bioprocess’s commitment to supporting manufacturers with solutions that simplify critical process steps.”</p>
<p><figure aria-describedby="caption-attachment-338074" class="wp-caption alignleft"><img fetchpriority="high" decoding="async" class="size-medium wp-image-338074" src="https://www.genengnews.com/wp-content/uploads/2026/09/The_VANTIJ%C2%AE_SU-VFC_Benchtop_by_Asahi_Kasei_Bioprocess-300x169.jpg" alt="VANTIJ® SU-VFC benchtop" width="300" height="169" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/The_VANTIJ®_SU-VFC_Benchtop_by_Asahi_Kasei_Bioprocess-300x169.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/The_VANTIJ®_SU-VFC_Benchtop_by_Asahi_Kasei_Bioprocess-696x392.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/09/The_VANTIJ®_SU-VFC_Benchtop_by_Asahi_Kasei_Bioprocess.jpg 711w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">VANTIJ<sup class="wp-sup-text">®</sup> SU-VFC benchtop [Asahi Kasei]</figcaption></figure>Rombach explains that the fluid management business unit of Asahi Kasei Bioprocess focuses on solving therapeutic product safety, efficiency, and purity challenges within the pharmaceutical and bioprocessing industries. With technology platforms for virus filtration, chromatography, inline buffer formulation and oligonucleotide synthesis, the company’s  bioprocessing systems, columns, and automation solutions advance GMP manufacturing of critical drug substances around the world, he continued.</p>
<p>BPI East attendees can visit Booth 606 in Boston from September 22<sup class="wp-sup-text">nd</sup> to 25<sup class="wp-sup-text">th</sup>.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/asahi-kasei-introduces-vantij-su-vfc-benchtop-virus-filtration-system/">Asahi Kasei Introduces VANTIJ<sup>®</sup> SU-VFC Benchtop Virus-Filtration System</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Time&#45;Restricted Eating Linked to Improved Huntington’s Disease Markers</title>
<link>https://edusehat.com/en/time-restricted-eating-linked-to-improved-huntingtons-disease-markers</link>
<guid>https://edusehat.com/en/time-restricted-eating-linked-to-improved-huntingtons-disease-markers</guid>
<description><![CDATA[ A 12-week pilot study found time-restricted eating was safe and feasible for people with early Huntington’s disease, with improvements in disease severity, neurofilament light, and mitochondrial function.
The post Time-Restricted Eating Linked to Improved Huntington’s Disease Markers appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2266283707.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 19 Sep 2026 06:15:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Time-Restricted, Eating, Linked, Improved, Huntington’s, Disease, Markers</media:keywords>
<content:encoded><![CDATA[<div>
<p>The first clinical study to understand the potential effects of time-restricted eating in people with Huntington’s disease finds that time-restricted eating is feasible, safe, and linked to improvements in disease markers.</p>
</div>
<div>
<p>In a 12-week pilot study, researchers found that people with early-stage Huntington’s Disease were able to safely follow a form of intermittent fasting known as time-restricted eating—limiting food consumption to a six-to-eight-hour window each day. Participants avoided unintended weight loss and showed improvements in measures of disease severity; in a blood biomarker linked to nerve cell damage; and in cellular energy production.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
</div>
<div>
<p>The findings are published today in<span class="apple-converted-space"> </span><em>Nature Metabolism</em>, in the paper “<a href="https://www.nature.com/articles/s42255-026-01612-x" target="_blank" rel="noopener">Effects of time-restricted eating in early-stage Huntington’s disease: a pilot study.</a>”</p>
</div>
<div>
<p>“This is the first time this approach has been formally studied in people with Huntington’s disease,” said<span class="apple-converted-space"> </span>Russell Wells, a medical student at Oregon Health & Science University. “We found that participants were able to follow the eating schedule, maintain their weight and show encouraging improvements in clinical and biological measures that are important in Huntington’s disease. These results suggest time-restricted eating deserves further study in a larger clinical trial.”</p>
</div>
<div>
<p>Huntington’s disease is a rare, inherited neurological disease that gradually damages nerve cells responsible for movement, cognitive and emotional regulation. Although researchers have known the genetic cause of the disease for decades, no treatments have been approved that slow or stop its progression.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
</div>
<div>
<p>Prior research in animal models suggests that intermittent fasting can activate cellular pathways that help protect brain cells. Yet researchers were unsure whether the approach would be safe for people with Huntington’s disease because unintended weight loss is already a concern.</p>
</div>
<div>
<p>“When Russell first brought me the idea, I was skeptical,” notes Amie Hiller, MD, professor of neurology in the OHSU School of Medicine and director of the Portland Veteran’s Administration Northwest Parkinson’s Disease Research, Education and Clinical Center. “Weight loss is a major challenge for many people with Huntington’s disease, so asking them to eat within a limited time window seemed counterintuitive.</p>
</div>
<div>
<p>“What was exciting about this study is that participants were able to maintain their weight while showing signs that the intervention may be positively affecting the disease itself,” Hiller notes.</p>
</div>
<div>
<p>The 20 participants selected an eating window that fit their daily routine, typically between late morning and early evening, and followed it for 12 weeks. Researchers encouraged participants to maintain their normal calorie intake and monitored weight and safety throughout the study.</p>
</div>
<div>
<p>The approach appeared well-tolerated. Participants followed the eating schedule on average more than five days per week; reported few side effects; and maintained both body weight and lean muscle mass. Most adapted to the schedule within the first one to two weeks. Participants used a smartphone app to document their first meal of the day with a photo and timestamp.</p>
</div>
<div>
<p>Participants experienced an average improvement of 0.5 points on a widely used Huntington’s disease severity scale known as the composite Unified Huntington’s Disease Rating Scale (cUHDRS). The score typically declines by about one point annually in people with early-stage disease.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
</div>
<div>
<p>In addition, blood levels of neurofilament light, a biomarker released when nerve cells are damaged, fell by an average of 13%. In Huntington’s disease, those levels usually increase over time as the disease progresses.</p>
</div>
<div>
<p>“We saw a reversal of the trend we would normally expect,” Wells said. “Neurofilament light typically rises as neurodegeneration continues, but after three months we observed a significant decrease. For a pilot study, that was a remarkable finding.”</p>
</div>
<div>
<p>The research team also examined mitochondrial function in participants’ blood cells and found improvements in several measures of mitochondrial activity after the intervention.</p>
</div>
<div>
<p>“One theory is that fasting acts as a mild stressor that prompts cells to become more efficient,” Wells said. “If cells, including brain cells, become better at producing energy and handling stress, they may be more resilient to the disease process.”</p>
</div>
<div>
<p>Because the study was small and did not include a comparison group, researchers caution that the findings should not be considered proof that time-restricted eating slows Huntington’s disease. Larger, randomized controlled trials will be needed to determine whether the benefits are real and sustained over time.</p>
</div>
<div>
<p>Still, researchers say the results are especially promising because the intervention is relatively simple and could be accessible to many people as there are no disease-modifying treatments for Huntington’s disease currently available. The team is currently pursuing funding for a larger, randomized clinical trial that would compare time-restricted eating with standard dietary habits.</p>
</div>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/time-restricted-eating-linked-to-improved-huntingtons-disease-markers/">Time-Restricted Eating Linked to Improved Huntington’s Disease Markers</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>New Survey of America’s Physicians Finds Practice Conditions Are Driving Physician Distress</title>
<link>https://edusehat.com/en/new-survey-of-americas-physicians-finds-practice-conditions-are-driving-physician-distress</link>
<guid>https://edusehat.com/en/new-survey-of-americas-physicians-finds-practice-conditions-are-driving-physician-distress</guid>
<description><![CDATA[ On National Physician Suicide Awareness Day, The Physicians Foundation releases new findings on how practice conditions shape physician wellbeing and brings the healthcare community together to advance systemic solutions. BOSTON, September 17, 2026 — In recognition of National Physician Suicide Awareness Day, The Physicians Foundation today released findings from its 2026 Survey of America’s Physicians, […]
The post New Survey of America’s Physicians Finds Practice Conditions Are Driving Physician Distress appeared first on The Physicians Foundation. ]]></description>
<enclosure url="https://physiciansfoundation.org/wp-content/themes/physicians-foundation/assets/build/images/admin/defaults/default-image.webp" length="49398" type="image/jpeg"/>
<pubDate>Sat, 19 Sep 2026 02:15:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>New, Survey, America’s, Physicians, Finds, Practice, Conditions, Are, Driving, Physician, Distress</media:keywords>
<content:encoded><![CDATA[<p class="wp-block-paragraph"><em><em><em>On National Physician Suicide Awareness Day, The Physicians Foundation releases new findings on how practice conditions shape physician wellbeing and brings the healthcare community together to advance systemic solutions.</em></em></em></p>



<p class="wp-block-paragraph"><strong><strong>BOSTON, September 17, 2026</strong> </strong>— In recognition of <a href="https://npsaday.org/">National Physician Suicide Awareness Day</a>, The Physicians Foundation today released findings from its 2026 Survey of America’s Physicians, <a href="http://www.physiciansfoundation.org/research/how-practice-conditions-shape-physician-wellbeing"><em>How Practice Conditions Shape Physician Wellbeing</em></a>, examining differences in wellbeing by employment setting, gender, age, and geography.</p>



<p class="wp-block-paragraph">Conducted with <em>Medscape</em> in August 2026 among 1,000 physicians, the survey found that nearly six in 10 physicians (58%) experienced debilitating stress in the past year, with notable differences across physician populations—underscoring that distress is shaped not only by individual experience but also by the conditions in which physicians practice.</p>



<p class="wp-block-paragraph"><strong>Among the findings:</strong></p>



<ul class="wp-block-list">
<li>67% of employed physicians experienced inappropriate feelings of anger, tearfulness, or anxiety in the past year, compared with 54% of independent physicians.</li>



<li>34% of employed physicians cite organizational policies, productivity expectations, or internal pressures that limit clinical autonomy as a contributor to distress—more than twice the share of independent physicians (13%).</li>



<li>Only 23% of female physicians report either a great deal of or complete control over expected patient volume, compared with 36% of male physicians.</li>
</ul>



<p class="wp-block-paragraph">“Physician wellbeing is a reflection of the conditions in which physicians are asked to practice medicine,” said Gary Price, MD, president of The Physicians Foundation. “We have made important progress in reducing barriers to mental health care, but these findings show that we must also address the workplace conditions that contribute to distress in the first place. That means creating practice environments that support physicians’ wellbeing, preserve meaningful autonomy, and ensure they feel valued throughout their careers.”</p>



<p class="wp-block-paragraph">The path forward requires proactive, system-level action to protect physician wellbeing, reduce the risk of tragic outcomes, and sustain a healthy, effective healthcare workforce. Together, The Physicians Foundation and the Dr. Lorna Breen Foundation are calling on healthcare leaders and stakeholders to advance systemic solutions that reduce administrative burden, ensure physicians can access mental health care without fear of professional repercussions, and foster workplace cultures where seeking help is supported rather than stigmatized.</p>



<p class="wp-block-paragraph"><strong>Explore the full survey findings</strong> <a href="http://www.physiciansfoundation.org/research/how-practice-conditions-shape-physician-wellbeing"><strong><em>here</em></strong></a><strong><em>.</em></strong><strong></strong></p>



<h3 class="wp-block-heading"><strong>Creating a Culture of Wellbeing</strong></h3>



<p class="wp-block-paragraph">Throughout September, NPSA Day Supporting Organizations are <a href="https://npsaday.org/2026-physician-wellbeing-activities/">hosting wellbeing events</a> for physicians, healthcare organizations, and others to take action through educational programs, peer support, CME opportunities, and other physician wellbeing activities.</p>



<p class="wp-block-paragraph">Despite progress in reducing barriers to mental health care, significant challenges remain. More than one-third of physicians say their workplace culture does not prioritize physician wellbeing, while 71% say stigma surrounding mental health and seeking mental health care persists within the profession.</p>



<p class="wp-block-paragraph">“The steady decline in mental health care stigma over the past four years demonstrates that systemic changes, like eliminating intrusive mental health questions on licensure and credentialing applications, are making a meaningful difference,” said Corey Feist, CEO and Co-Founder of the <a href="https://drlornabreen.org/">Dr. Lorna Breen Foundation</a>. “At the same time, policy reform is just the first step. True cultural and systemic transformation takes time and continuous commitment. We must keep building on this momentum to ensure this progress translates into supportive workplace environments where every health worker feels valued and supported.”</p>



<p class="wp-block-paragraph">National Physician Suicide Awareness Day is a call to build on that progress by addressing the conditions that contribute to physician distress, removing remaining barriers to mental health care, and creating practice environments where physicians can thrive.</p>



<p class="wp-block-paragraph"><strong>Explore upcoming wellbeing events</strong> <a href="https://npsaday.org/2026-physician-wellbeing-activities/"><strong><em>here</em></strong></a><strong><em>.</em></strong><strong></strong></p>



<p class="wp-block-paragraph">Learn more about National Physician Suicide Awareness Day at <a href="https://npsaday.org/"><em>NPSADay.org</em></a>.</p>



<p class="wp-block-paragraph"><em>If you or someone you know is struggling or in crisis, call or text 988 or visit</em> <a href="https://988lifeline.org/"><em>988lifeline.org</em></a><em>.</em></p>



<h3 class="wp-block-heading"><strong>About The Survey of America’s Physicians</strong></h3>



<p class="wp-block-paragraph">The Survey of America’s Physicians, conducted annually by The Physicians Foundation in collaboration with <em>Medscape</em>, captures the perspectives of more than 1,000 practicing physicians nationwide on the issues shaping the practice of medicine and patient care. By tracking physician experiences and sentiment over time, the survey provides insight into the evolving health care landscape and identifies opportunities to strengthen physician practice and improve patient health outcomes.</p>



<h3 class="wp-block-heading"><strong>About The Physicians Foundation </strong></h3>



<p class="wp-block-paragraph">The Physicians Foundation is a public charity seeking to advance the work of practicing physicians and help them facilitate the delivery of high-quality health care to patients. As the U.S. health care system continues to evolve, The Physicians Foundation is steadfast in strengthening the physician-patient relationship, supporting medical practices’ sustainability and helping physicians navigate the changing health care system. The Physicians Foundation pursues its mission through research, education and innovative grant making that improves physician wellbeing, strengthens physician leadership, addresses drivers of health and lifts physician perspectives. For more information, visit <a href="https://www.physiciansfoundation.org/">www.physiciansfoundation.org</a>.</p>
<p>The post <a href="https://physiciansfoundation.org/new-survey-of-americas-physicians-finds-practice-conditions-are-driving-physician-distress/">New Survey of America’s Physicians Finds Practice Conditions Are Driving Physician Distress</a> appeared first on <a href="https://physiciansfoundation.org/">The Physicians Foundation</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The specter of AI&#45;enabled bioweapons is a wake&#45;up call for biotech</title>
<link>https://edusehat.com/en/the-specter-of-ai-enabled-bioweapons-is-a-wake-up-call-for-biotech</link>
<guid>https://edusehat.com/en/the-specter-of-ai-enabled-bioweapons-is-a-wake-up-call-for-biotech</guid>
<description><![CDATA[ In recent weeks, leaders of some of the biggest AI companies have warned that the very tech they are developing is dangerous. Last weekend, Anthropic CEO Dario Amodei argued that AI carries serious risk and that progress should be slowed. OpenAI CEO Sam Altman responded on X: “I agree with Dario that we need to pace the… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/09/260915_TheCheckup.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 18 Sep 2026 23:05:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, specter, AI-enabled, bioweapons, wake-up, call, for, biotech</media:keywords>
<content:encoded><![CDATA[<div data-chronoton-summary="<ul>
<li><strong>AI could make bioweapons disturbingly easy to build:</strong> In 2022, researchers accidentally generated 40,000 potential chemical warfare agents in under six hours using a drug-discovery AI — some more toxic than known nerve agents.</li>
<li><strong>Existing safeguards have real limits:</strong> Anthropic recently confirmed users had tried exploiting its models to make viruses more transmissible and dangerous, highlighting an ongoing cat-and-mouse game between protections and workarounds.</li>
<li><strong>Scientists disagree on how worried to be:</strong> Some biologists argue AI tools aren't yet capable enough to fully develop bioweapons, while others warn that a determined actor would "eventually succeed" — and urge preparing now.</li>
</ul>" data-chronoton-post-id="1144329" data-chronoton-expand-collapse="1" data-chronoton-analytics-enabled="1"></div>


<p>In recent weeks, leaders of some of the biggest AI companies have warned that the very tech they are developing is dangerous. Last weekend, Anthropic CEO Dario Amodei argued that AI <a href="https://darioamodei.com/post/we-must-pace-the-frontier">carries serious risk</a> and that progress should be slowed. OpenAI CEO Sam Altman <a href="https://x.com/sama/status/2098811563415150910">responded on X</a>: “I agree with Dario that we need to pace the frontier.”</p>



<p>Those posts came a few days after the AI researcher Jacob Coxon announced that he was leaving a role at Anthropic, charging that neither it nor OpenAI (where he had also worked) was acting responsibly. “The people building AI earnestly believe that it could kill us all by the end of the decade,” <a href="https://x.com/hilbertspaess/status/2097476203863224394">he posted on X</a>. Another Anthropic employee, Evan Hubinger, publicly agreed with him. “We really do earnestly believe AI could kill all humans!” <a href="https://x.com/EvanHub/status/2097497037956891126?s=20">he responded on X</a>. “I personally think it is >10% within the next decade.”</p>





<p>One of the ways they fear AI might end us all is by somehow aiding the design, creation, and release of some kind of bioweapon. Let’s take a closer look at why.</p>



<p>A bioweapon might be a highly lethal virus that targets people according to their genes. It could be a fungus that wipes out a crop and causes food insecurity. Perhaps it would be a tasteless, odorless toxin that could be slipped into a region’s water supply, undetected.</p>



<p>The concern is that AI tools can be used to help generate agents like these. In 2022, researchers at Collaborations Pharmaceuticals found that it was remarkably easy to do so using an AI “molecule generator” they’d developed to find potential drugs for human disease. In less than six hours, the model generated <em>40,000 molecules</em> with the potential to serve as chemical warfare agents. Some of them were designed to be even more toxic than known nerve agents. “Without being overly alarmist, this should serve as a wake-up call for our colleagues in the ‘AI in drug discovery’ community,” the authors <a href="https://www.nature.com/articles/s42256-022-00465-9">wrote at the time</a>.</p>



<p>It <em>was</em> a wake-up call for David Magnus, a professor of medicine and biomedical ethics at Stanford University, even though he had been assessing the risks associated with the misuse of medical science and biotechnology since the late 1990s. “That was very scary to me,” he says. “Of course, everything since then has just sort of blown up.”</p>



<p>Today, AI bots can answer questions on topics spanning all realms of science. Anyone can use large language models trained on the knowledge and experience of “almost every scientist who ever lived on this planet,” says Dunja Sabra, a biosecurity researcher at the University of Hamburg in Germany. Those models can provide instructions and video training on how to conduct experiments.</p>



<p>Combine that with advances in biotech that have made gene editing and synthetic biology tools much more accessible (the <a href="https://www.technologyreview.com/2012/02/14/187917/doing-biotech-in-my-bedroom/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=09-17-26">“DIY biology” movement</a> has already enabled many people to set up labs at home), and you’ve got a potentially very dangerous situation. “The chances are that someone determined would succeed eventually,” Sabra says.</p>



<p>There are safeguards in place. People who want to build new genomes <a href="https://www.technologyreview.com/2025/10/02/1124767/microsoft-says-ai-can-create-zero-day-threats-in-biology/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=09-17-26">must typically order the pieces of DNA from companies that screen for suspicious requests</a>. Responsible researchers put potentially risky research through rounds of analysis called “red-teaming,” in which independent scientists look for ways the work might be misused, and “blue-teaming,” where others come up with potential mitigations. And AI companies have tweaked their tools in attempts to prevent them from offering up scientific information that could be misused. But none of these protections are ironclad.</p>





<p>In <a href="https://www-cdn.anthropic.com/e50be2e51e7695dc4b1366a37a245a597377d3b5/Anthropic-Detecting-and-countering-091026.pdf">a report</a> published last week, Anthropic acknowledged that people had attempted to use its models to explore ways to make the chikungunya virus more transmissible, create a form of bird flu that is more dangerous to humans, and build an “atlas of venom toxin peptides,” among other things.</p>



<p>“We’ve got a constant back and forth,” says Magnus. “We have to build better surveillance and screening tools, [but] AI is really good at figuring out ways around them.” We’ll probably need to use AI to find ways to restrict the use of AI, he says.</p>



<p>I should add here that not all scientists agree on the level of risk. At a recent media briefing, some biologists at Imperial College London argued that AI tools just aren’t good enough to fully develop bioweapons, and that testing new pathogens requires difficult, time-consuming, human work. Some think the guardrails we have in place are sufficient.</p>



<p>And Wendy Barclay, a professor of infectious disease at Imperial, pointed out that, as things stand, the greatest risk of a pandemic isn’t from a bioweapon, but from pathogens that are already circulating. Take H5N1, <a href="https://www.technologyreview.com/2024/11/29/1107552/risk-of-bird-flu-pandemic-rising/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=09-17-26">the bird flu virus</a> that has already killed millions of birds and spread widely through US dairy cattle; last month it was also <a href="https://www.aphis.usda.gov/livestock-poultry-disease/avian/avian-influenza/hpai-detections/mammals?page=1">detected in captive mink</a> at a farm in Utah.</p>



<p>Sabra, on the other hand, likes to think five to 10 years ahead. Countries should be strengthening their health-care systems, preparing antidotes to known toxins, and stockpiling medicines, she says: “We need to be prepared.”</p>



<p>Kevin Esvelt, an MIT biologist who invented both technology to fast-track the propagation of a genetic feature through an entire population <em>and </em>ways to limit that technology, echoed these concerns in an <a href="https://x.com/kesvelt/status/2100238200207716488">X post</a> on Wednesday, stating that a large language model had “disclosed a novel form of bioweapon that I hadn’t realized was possible.”</p>



<p>He added, “Please, for the love of God, children, the future of humanity, or whatever you consider holy, let’s err on the side of caution here.”</p>



<p><em>This article first appeared in The Checkup, </em>MIT Technology Review’s<em> weekly biotech newsletter. To receive it in your inbox every Thursday, and read articles like this first, </em><a href="https://forms.technologyreview.com/newsletters/biotech-the-checkup/?_ga=2.241810882.15113993.1664981064-43237434.1647441349"><em>sign up here</em></a>.</p>]]> </content:encoded>
</item>

<item>
<title>SickKids named world’s best children’s hospital for second consecutive year</title>
<link>https://edusehat.com/en/sickkids-named-worlds-best-childrens-hospital-for-second-consecutive-year</link>
<guid>https://edusehat.com/en/sickkids-named-worlds-best-childrens-hospital-for-second-consecutive-year</guid>
<description><![CDATA[ Toronto’s Hospital for Sick Children (SickKids) has been named the world’s best children’s hospital for the second year in a row, placing first among more than 250 paediatric hospitals worldwide in the latest global ranking by Newsweek and Statista. The back-to-back No. 1 ranking is a first for SickKids and marks the sixth consecutive year […]
The post SickKids named world’s best children’s hospital for second consecutive year appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/09/newsweek-teaser-1200x800-1.webp" length="49398" type="image/jpeg"/>
<pubDate>Fri, 18 Sep 2026 23:00:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>SickKids, named, world’s, best, children’s, hospital, for, second, consecutive, year</media:keywords>
<content:encoded><![CDATA[<p>Toronto’s Hospital for Sick Children (SickKids) has been named the <strong>world’s best children’s hospital for the second year in a row</strong>, placing first among more than 250 paediatric hospitals worldwide in the latest global ranking by Newsweek and Statista.</p>
<p>The back-to-back No. 1 ranking is a first for SickKids and marks the <strong>sixth consecutive year</strong> the Toronto hospital has ranked among the world’s top two paediatric hospitals. It is also the third time SickKids has earned the No. 1 position. <strong><a href="https://www.sickkids.ca/en/news/archive/2026/sickkids-named-worlds-best-childrens-hospital-for-second-year-in-a-row/?utm_source=chatgpt.com">SickKids</a></strong></p>
<p>The recognition highlights SickKids’ international reputation for highly specialized paediatric care, research and education. Founded in 1875 as Canada’s first children’s hospital, SickKids is affiliated with the University of Toronto and has become one of Canada’s most research-intensive hospitals, with discoveries and clinical advances that have influenced the treatment of children around the world.</p>
<p>The global hospital rankings are developed by Newsweek in partnership with research and data firm Statista. The methodology relies heavily on recommendations from thousands of medical professionals internationally and also considers hospital accreditations, certifications and the implementation of patient-reported outcome measures. The broader specialized-hospital assessment evaluates thousands of hospitals worldwide across major areas of medicine. <strong><a href="https://rankings.statista.com/en/healthcare/rankings/best-specialized-hospitals-world-2026/?utm_source=chatgpt.com">Statista Rankings</a></strong></p>
<p>SickKids says the recognition reflects the combined contributions of its physicians, nurses, researchers, trainees, volunteers, donors and wider community.</p>
<p>The hospital is also continuing to advance its <strong>Precision Child Health</strong> strategy, which aims to move beyond a one-size-fits-all model of care. The approach considers the individual characteristics and circumstances of each child — ranging from genetics to environmental and social factors — to improve diagnosis, treatment and prediction of health outcomes. Data, technology and the responsible use of artificial intelligence are increasingly part of that work. <a href="https://www.sickkids.ca/en/news/archive/2026/sickkids-named-worlds-best-childrens-hospital-for-second-year-in-a-row/?utm_source=chatgpt.com">SickKids</a></p>
<p>The latest recognition is particularly significant for Canadian health care. A Canadian institution occupying the top position in a global field of leading paediatric hospitals demonstrates the expertise and innovation taking place within the country’s child-health system.</p>
<p>For SickKids, the achievement builds on more than 150 years of paediatric care while reinforcing its stated vision: <strong>Healthier Children. A Better World.</strong></p>
<p><strong><a href="https://www.sickkids.ca/en/news/archive/2026/sickkids-named-worlds-best-childrens-hospital-for-second-year-in-a-row/?utm_source=chatgpt.com">Read the SickKids announcement</a></strong></p>
<p>The post <a href="https://www.hospitalnews.com/sickkids-named-worlds-best-childrens-hospital-for-second-consecutive-year/">SickKids named world’s best children’s hospital for second consecutive year</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Best USMLE Preparation Resources: A Step&#45;by&#45;Step Guide</title>
<link>https://edusehat.com/en/best-usmle-preparation-resources-a-step-by-step-guide</link>
<guid>https://edusehat.com/en/best-usmle-preparation-resources-a-step-by-step-guide</guid>
<description><![CDATA[ Preparing for the United States Medical Licensing Examination (USMLE) can feel overwhelming, not because there is a shortage of study materials, but because there are so many options. Question banks, review books, videos, flashcards, practice exams, and study schedules all compete for your attention.   The challenge is deciding which USMLE preparation resources match your […]
The post Best USMLE Preparation Resources: A Step-by-Step Guide appeared first on Elite Medical Prep. ]]></description>
<enclosure url="https://elitemedicalprep.com/wp-content/uploads/2026/09/pexels-katerina-holmes-5905878-1536x1024-1.webp" length="49398" type="image/jpeg"/>
<pubDate>Fri, 18 Sep 2026 19:45:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Best, USMLE, Preparation, Resources:, Step-by-Step, Guide</media:keywords>
<content:encoded><![CDATA[<p><span>Preparing for the United States Medical Licensing Examination (USMLE) can feel overwhelming, not because there is a shortage of study materials, but because there are so many options. Question banks, review books, videos, flashcards, practice exams, and study schedules all compete for your attention.</span></p>
<p> </p>
<p><span>The challenge is deciding which USMLE preparation resources match your exam, baseline performance, learning needs, and available study time.</span></p>
<p> </p>
<p><span>An effective USMLE study plan does not require every popular resource. Instead, it requires a focused system: understand what the exam tests, assess your starting point, learn through questions, review your weaknesses deliberately, and use realistic assessments to determine whether you are ready.</span></p>
<p> </p>
<p><span>The best USMLE preparation plan typically combines:njkuihbi</span></p>
<ul>
<li aria-level="1"><span>Official USMLE materials</span></li>
<li aria-level="1"><span>NBME self-assessments</span></li>
<li aria-level="1"><span>One primary question bank</span></li>
<li aria-level="1"><span>A concise content review resource</span></li>
<li aria-level="1"><span>A personalized study schedule</span></li>
<li aria-level="1"><span>Strategic use of flashcards and practice exams</span></li>
</ul>
<p> </p>
<p><span>The real value comes from using a small selection of resources consistently, not collecting every study tool available.</span></p>
<p> </p>
<p>The post <a href="https://elitemedicalprep.com/best-usmle-preparation-resources-a-step-by-step-guide/">Best USMLE Preparation Resources: A Step-by-Step Guide</a> appeared first on <a href="https://elitemedicalprep.com/">Elite Medical Prep</a>.</p>]]> </content:encoded>
</item>

<item>
<title>A national security priority: BIO pushes PAHPA reauthorization in 2026</title>
<link>https://edusehat.com/en/a-national-security-priority-bio-pushes-pahpa-reauthorization-in-2026</link>
<guid>https://edusehat.com/en/a-national-security-priority-bio-pushes-pahpa-reauthorization-in-2026</guid>
<description><![CDATA[ For decades, Congress has passed legislation to protect Americans from public health emergencies, ranging from national security threats to disease outbreaks and natural disasters, […]
The post A national security priority: BIO pushes PAHPA reauthorization in 2026 appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/09/navy-medicine-jhgw6bsaou8-unsplash-e1789724773236.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 18 Sep 2026 19:30:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>national, security, priority:, BIO, pushes, PAHPA, reauthorization, 2026</media:keywords>
<content:encoded><![CDATA[<p><span>For decades, Congress has passed legislation to protect Americans from public health emergencies, ranging from national security threats to </span><span>disease outbreaks </span><span>and </span><span>natural disasters</span><span>, but that protection has lapsed.</span></p>
<p><span>The Biotechnology Innovation Organization (BIO) is working to support Congress in ensuring our national health security by reauthorizing the Pandemic and All Hazards Preparedness Act (PAHPA) before year’s end. In a recent action, BIO joined over 80 other organizations and companies in signing</span><a href="https://centerforhealthsecurity.org/2026/biosecurity-partners-co-sign-letter-urging-congress-to-fully-reauthorize-pahpa" target="_blank" rel="noopener"> <span>a Sept. 14 letter</span></a><span> urging congressional leaders to pass a PAHPA bill.</span></p>
<p><span>“This is a national security priority, an important way to protect Americans,” explains Phyllis Arthur, BIO’s EVP and Chief of Global Health. “PAHPA funds so many things that are essential for our national readiness and resilience. We are at a time when Americans care a great deal about what’s happening in terms of our nation being ready for known and unknown threats.”</span></p>
<p><span>Historically reauthorized on a five-year basis since it was initiated in 2005, PAHPA has not been reauthorized after the previous funding period ended in September 2023. While most PAHPA programs continue with short-term, temporary extensions, five-year funding is essential to incentivize research </span><span>and </span><span>development in medical countermeasures (MCMs), which can often take more than a decade to develop.</span></p>
<p><span>As a national security measure protecting civilians and the military, PAHPA has bipartisan support in Congress, and there is reason for optimism about reauthorization before the end of the year, according to Praneel Jadav,</span> <span>Manager, Infectious Disease Policy at BIO. “We commend the bipartisan champions in the House and Senate who are working to reauthorize PAHPA and we are committed to supporting their efforts,” he says.</span></p>
<p><span>While Congress has not yet put forth a bill for PAHPA reauthorization, it is expected to be aligned with earlier legislative proposals that  BIO would support, according to Jadav. He says BIO’s priorities for any PAHPA legislation are:</span></p>
<ul>
<li aria-level="1"><span>Reauthorization of</span> several key <a href="https://www.aspr.gov/" target="_blank" rel="noopener"><span>Administration for Strategic Preparedness and Response (ASPR) programs, </span></a><span>including the Biomedical Advanced Research and Development Authority (BARDA), the Strategic National Stockpile (SNS), Project BioShield, and the Pandemic Influenza Program.</span></li>
<li aria-level="1"><span>Reauthorization of the</span><a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/material-threat-medical-countermeasure-priority-review-vouchers-draft-guidance-industry" target="_blank" rel="noopener"> <span>Medical Countermeasure Priority Review Voucher (MCM PRV)</span></a><span> program.</span></li>
<li aria-level="1"><span>Authorization of a Pathogen-Agnostic Viral Family program at BARDA.</span></li>
</ul>
<h2>Why ASPR matters</h2>
<p><span>ASPR oversees most public health preparedness efforts and programs, including BARDA. BARDA works with industry to support the late-stage development of MCMs against chemical, biological, radiological, and nuclear threats, and emerging infectious diseases, all of which pose a real and present danger, Arthur explains.</span></p>
<p><span>“We know for instance that a flu pandemic is a threat every single year,” she says. “BARDA has been seeking to support companies working on vaccines against the various flu pandemic strains that pop up all over the world.”</span></p>
<p><span>ASPR also oversees the Strategic National Stockpile (SNS), a ready supply of MCMs ranging from smallpox vaccines to treatments protecting members of the military against nerve agents. Other vital ASPR programs include Project BioShield, which provides money and market incentives for private development of life-saving products that lack a commercial market.</span></p>
<h2>Why the MCM PRV matters</h2>
<p><span>An important part of the work PAHPA supports is industry-government collaboration to ensure drug companies develop new MCMs against potential threats and produce these drugs for stockpiling in the SNS.</span></p>
<p><span>“You can’t be standing around waiting for drug development in an emergency,” Arthur says. But since the hope is that we never need to use MCMs, regular market considerations would not encourage their development.</span></p>
<p><span>“We must have MCMs ready, though they often cannot be supported commercially,” Arthur explains. “Their marketplace is primarily government, and the U.S. government is the main global purchaser.”</span></p>
<p><span>Government support for this type of drug development is vital because most early research and development of MCMs is handled by small and mid-sized biotechs, with moderate budgets, Jadav notes.</span></p>
<p><span>“Anything we can do to show there is government support really helps these companies make a case with investors to continue funding innovative medical countermeasures that protect both civilians and the warfighter,” he says.</span></p>
<p><span>One mechanism to reduce the financial risks of developing a new MCM is the MCMPRV, a voucher that grants developers of MCMs priority Food and Drug Administration (FDA) review of a future drug candidate.</span></p>
<p><span>The faster time to market is a financial boost to drug developers, and MCM developers seeking capital can also sell the vouchers to other companies. While vouchers offer real value for drug makers, they cost taxpayers nothing.</span></p>
<h2>Why viral families matter</h2>
<p><span>Another key PAHPA initiative BIO wants to see is authorization of a dedicated Pathogen-Agnostic Viral Family program at BARDA. Examples of viral families include mpox and smallpox, which are both treated with one vaccine. We can more quickly achieve a range of treatments by developing vaccines or antivirals for other viral families—like the family that includes Marburg and Ebola, or the COVID-SARS-MERS family.</span></p>
<p><span>“This is more of a progressive method to address threats in emerging infectious diseases,” says Jadav. “It focuses research on medical countermeasures that address a whole host of viruses instead of doing a one bug, one drug approach.”</span></p>
<p><span>While BARDA has initiatives to encourage MCMs for viral families, a dedicated program would improve efficiencies in this area.</span></p>
<p><span>With PAHPA’s power to promote these essential health defense measures, BIO and its co-signers on <a href="https://centerforhealthsecurity.org/2026/biosecurity-partners-co-sign-letter-urging-congress-to-fully-reauthorize-pahpa" target="_blank" rel="noopener">the Sept. 14 letter to Congress</a> see risks in delaying the legislation.</span></p>
<p><span>“Failing to reauthorize PAHPA now would have serious effects on our country’s economic wellbeing, national security, and health given the rapidly changing threat landscape,” the letter explains.</span></p>
<p>The post <a href="https://bio.news/national-security/a-national-security-priority-bio-pushes-pahpa-reauthorization-in-2026/">A national security priority: BIO pushes PAHPA reauthorization in 2026</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>High&#45;Grade Glioma Biology Varies by Age and Sex, Revealing Potential Treatment Targets</title>
<link>https://edusehat.com/en/high-grade-glioma-biology-varies-by-age-and-sex-revealing-potential-treatment-targets</link>
<guid>https://edusehat.com/en/high-grade-glioma-biology-varies-by-age-and-sex-revealing-potential-treatment-targets</guid>
<description><![CDATA[ Researchers carrying out multiomics analyses of tumors from high-grade glioma patients found distinct molecular profiles and survival outcomes in different age groups and according to sex, and identified candidate treatment targets and potential prognostic markers. 
The post High-Grade Glioma Biology Varies by Age and Sex, Revealing Potential Treatment Targets appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2023/04/GettyImages-1426197869.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 18 Sep 2026 12:15:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>High-Grade, Glioma, Biology, Varies, Age, and, Sex, Revealing, Potential, Treatment, Targets</media:keywords>
<content:encoded><![CDATA[<p>Researchers at the Icahn School of Medicine at Mount Sinai and collaborators have identified candidate treatment targets and potential prognostic markers for high-grade glioma (HGG), an aggressive brain cancer in children, adolescents, and young adults (AYA). The study found that high-grade glioma varies by developmental stage and sex, showing distinct tumor biology and outcomes across patient groups.</p>
<p>The team carried out proteogenomic analyses of tumors from more than 100 HGG patients aged 0–40 years. Their multiomics analysis identified two AYA age groups with distinct molecular profiles and survival outcomes.</p>
<p>The researchers suggest that using the study results to guide clinical trial design and develop new therapies could advance more precise treatment strategies.</p>
<p>“Our goal was to understand high-grade glioma from infancy through young adulthood and identify tumor-related changes tied to outcomes such as survival,” said Pei Wang, PhD, professor of genetics and genomic sciences at the Icahn School of Medicine at Mount Sinai. “Because age and sex shape normal brain development, we wanted to separate features of the cancer from those associated with a patient’s developmental stage.”</p>
<p>The study was conducted by the Clinical Proteomic Tumor Analysis Consortium (CPTAC) of the National Cancer Institute (NCI), the Children’s Brain Tumor Network, and the Philadelphia Coalition for a Cure.</p>
<p>Wang, and Avi Ma’ayan, PhD, Mount Sinai endowed professor in bioinformatics and director of the Mount Sinai Center for Bioinformatics, are principal investigators of the Proteogenomic Data Analysis Center at the Icahn School of Medicine, part of CPTAC.</p>
<p>Wang is co-senior and co-corresponding author of the researchers’ published paper in <em>Cell Reports Medicine</em>, titled “<a href="https://doi.org/10.1016/j.xcrm.2026.103024" target="_blank" rel="noopener">Proteogenomic analysis of pediatric and AYA high-grade glioma reveals age-dependent biology, female-male differences, and candidate kinase targets</a>.” In their paper the investigators concluded, “This study provides an integrated multiomics analysis of HGGs across development, establishing a framework in which age and developmental context shape tumor biology.”</p>
<p>High-grade glioma is among the most aggressive primary brain tumors, with a five-year survival rate below 10%. Tumors in children differ markedly from those in adults, while adolescents and young adults remain especially understudied because their tumors do not fit neatly into either pediatric or adult disease. “High-grade gliomas (HGGs) in children and adolescents and young adults (AYA) exhibit distinct biology across the neurodevelopmental spectrum,” the authors wrote. “Differences between male and female patients, which influence both brain development and cancer biology, represent another underexplored dimension.”</p>
<p>Because age and sex shape normal brain development, the researchers sought to distinguish tumor-related molecular features from those associated with developmental stages. Working with CPTAC, the team profiled tumors—samples were collected through the Children’s Brain Tumor Network—from 112 patients aged 83 days to 40 years, measuring DNA, RNA, proteins, and chemical changes made to proteins after they are produced, including phosphorylation and glycosylation.</p>
<p>Those measurements were combined with data from 99 adult glioblastoma tumors and clinical and genetic information from a reference group of more than 5,000 people with high-grade glioma, to trace how tumor biology changes across the lifespan.</p>
<p>Using computational analysis and laboratory validation the team identified as potential treatment targets several kinases—enzymes that help control cell signaling—including CDK8, ATM, ATR, and LCK.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>Studies showed that in tumor-derived cell lines, blocking these kinases through gene editing or drug treatment slowed growth when the corresponding kinase was most active. CDK8 emerged as a particularly notable candidate because it is less well characterized in high-grade glioma than established targets such as ATM and ATR. Analyses indicated that CDK8 suppresses oxidative phosphorylation (OXPHOS), a key energy-producing process that the study linked to more favorable survival. “Causal network analysis and cell line studies provide a rationale for personalized therapies targeting candidate kinases, such as CDK8,” the investigators noted.</p>
<p>By tracing molecular profiles continuously across age rather than sorting patients into established tumor subtypes the researchers identified a clear shift around age 26 years within an age range often grouped clinically as adolescents and young adults. The two study groups (adolescents aged 15 years to 26 years and young adults aged 26 years to 40 years) had distinct molecular profiles and survival outcomes and relied on different signaling programs.</p>
<p>Comparing tumors with normal brain tissue across the same age span sharpened the picture. Oxidative phosphorylation showed age- and sex-related changes in tumors that were not seen in normal brains, suggesting these differences arise from tumor processes rather than normal development.</p>
<p>About 27% of the proteins the team measured showed different age-related trajectories in male and female patients. A prognostic score established in earlier work was associated with outcomes in male patients but not in female patients. Glycosylation proved especially informative in male patients, with far more survival-associated features than in female patients. Protein-based grouping also revealed a previously unrecognized male subgroup with the poorest survival in the study, distinguished by immune signaling and features of the tissue surrounding the tumor.</p>
<p>“CPTAC allows us to examine the same genes across several layers of biology, from DNA and RNA to proteins and protein modifications,” said first author Nicole Tignor, PhD, assistant professor of genetics and genomic sciences at the Icahn School of Medicine “In this study, glycosylation captured aspects of tumor biology missed in other molecular data. It may be especially valuable for understanding differences between male and female patients in immune responses and, potentially, treatment response.”</p>
<p>Higher levels of infiltrating T cells were associated with better outcomes in female patients but not in male patients, while a pattern involving the immune checkpoint gene<em> PDCD1</em>, which codes the protein PD-1, was seen only in male pediatric and young adult patients. Because PD-1 inhibitors are already being studied in this population, the authors say the findings support further study of treatment strategies that account for these differences. “Our integrated analysis also revealed immune cell types associated with survival,” they noted. “T cell infiltration was linked with favorable outcomes in female PED/AYA HGG patients but not in male counterparts and correlated with PD-1 expression only in males, a pattern absent in adult tumors (>40 years),” the investigators stated.</p>
<p>They pointed out that that sex-related differences have emerged as an important determinant of immune response in glioblastoma, with evidence indicating that that male patients may exhibit greater sensitivity to the immune checkpoint blockade. “As PD-1 inhibition therapies are under active investigation in clinical trials involving PED/AYA HGG patients, our findings support the development of male and female-specific treatment strategies.”</p>
<p>The authors further noted that sample sizes are limited, which is a persistent challenge in rare pediatric cancers that is more pronounced when patient data are divided by age, sex, and tumor features. The team developed an analytic approach that uses molecular trajectories learned in one group to help interpret survival patterns in another. Even so, the team noted, some findings will need confirmation in larger studies, and targets such as CDK8 will require validation in animal models before clinical testing.</p>
<p>The mechanisms underlying the observed differences between male and female patients also remain to be defined. Nevertheless, the investigators concluded, despite limitations, “… our study advances understanding of the developmental patterns in male and female HGGs and identifies molecular and immunologic features with translational potential.”</p>
<div class="my-8"><span data-render-ad="6"></span></div>
<p>Wang added, “Patient data are becoming increasingly rich, but they also reflect cancers arising at different ages and in different biological settings. How we account for that variation affects which biological signals we can detect. Analyzing tumors in their developmental context can help us make better use of these data and identify patterns that might otherwise be missed.”</p>
<p>The Children’s Brain Tumor Network and CPTAC are continuing to collect samples and generate data across pediatric brain tumors and other childhood cancers. The team will use those larger datasets to determine which patterns hold across cancers, which are specific to high-grade glioma, and which are most promising for therapeutic development.</p>
<p>The study’s proteogenomic datasets are publicly available through the NCI Proteomic Data Commons and the Children’s Brain Tumor Network, and the analysis code has been released openly.</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/high-grade-glioma-biology-varies-by-age-and-sex-revealing-potential-treatment-targets/">High-Grade Glioma Biology Varies by Age and Sex, Revealing Potential Treatment Targets</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Molecular Devices and STEMCELL Technologies Team Up to Automate Organoid Research</title>
<link>https://edusehat.com/en/molecular-devices-and-stemcell-technologies-team-up-to-automate-organoid-research</link>
<guid>https://edusehat.com/en/molecular-devices-and-stemcell-technologies-team-up-to-automate-organoid-research</guid>
<description><![CDATA[ Validated on the CellXpress.ai automated cell culture system, the new workflow combines organoid biology expertise and laboratory automation to help researchers reduce variability, expand scale, and move discoveries toward impact with more confidence.
The post Molecular Devices and STEMCELL Technologies Team Up to Automate Organoid Research appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2254461524.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 18 Sep 2026 12:15:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Molecular, Devices, and, STEMCELL, Technologies, Team, Automate, Organoid, Research</media:keywords>
<content:encoded><![CDATA[<p>Molecular Devices and STEMCELL Technologies said they have a developed a validated automated workflow that can be used with STEMCELL’s IntestiCult<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> Plus organoid growth medium for human intestinal organoids culture on the Molecular Devices CellXpress.ai automated cell culture system.</p>
<p>Available as a downloadable protocol, the workflow provides researchers with a ready-to-implement approach to automating organoid culture, helping reduce hands-on time and experimental variability while enabling more consistent, scalable generation of human-relevant research models and accelerating discovery, according to an official at Molecular Devices.</p>
<p>The workflow marks the first milestone in a strategic collaboration to automate STEMCELL’s portfolio of organoid culture kits on the CellXpress.ai system. By combining STEMCELL’s expertise in organoid biology with Molecular Devices’ automation capabilities, the companies aim to help researchers more easily adopt and scale human-relevant models, reducing barriers to implementation and accelerating research workflows in laboratories worldwide, explained Mary Duseau, president of Molecular Devices.</p>
<p>Under the collaboration, Molecular Devices develops and validates automated workflows, while STEMCELL provides tissue-specific science for performance criteria and cell-based functional characterization to support protocol development and validation.</p>
<p>“Organoids have the potential to give researchers a more human-relevant view of disease and treatment response, but their broader use depends on making these models easier to implement at scale,” continued Duseau. “This collaboration is an important step toward giving more scientists practical access to advanced cellular models while freeing them to focus on the biological questions that can inform the development of better therapies.”</p>
<p>The workflow reportedly enables automated culture, monitoring, and analysis of human intestinal organoids within a standardized process on the CellXpress.ai system. Researchers can implement the validated protocol as provided or adapt it to meet specific experimental requirements, providing flexibility for a range of organoid research applications, noted Allen Eaves, PhD, president and CEO of STEMCELL Technologies.</p>
<p>“This collaboration helps make advanced organoid workflows more accessible to scientists working across drug discovery, disease research, and translational biology,” he said. “Together, we’re enabling researchers to combine well-established organoid culture systems with automation, supporting the adoption of new approach methodologies (NAMs) and making it easier to generate reproducible results and scale their work as research needs evolve.”</p>
<p>The companies plan to evaluate additional organoid models and workflows for automation on the CellXpress.ai system, creating a portfolio of validated applications for drug discovery, disease modeling, toxicology, and translational research.</p>
<p class="trimmed"> </p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/molecular-devices-and-stemcell-technologies-team-up-to-automate-organoid-research/">Molecular Devices and STEMCELL Technologies Team Up to Automate Organoid Research</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Kidney Organoids Reveal Inflammatory Drivers of Diabetic Kidney Disease</title>
<link>https://edusehat.com/en/kidney-organoids-reveal-inflammatory-drivers-of-diabetic-kidney-disease</link>
<guid>https://edusehat.com/en/kidney-organoids-reveal-inflammatory-drivers-of-diabetic-kidney-disease</guid>
<description><![CDATA[ In kidney organoids, elevated glucose triggered tissue-intrinsic inflammation and epithelial cell detachment without overt cytotoxicity. Inhibiting MIF, TNF-alpha, or MAPK-related signaling helped protect the organoids, suggesting inflammatory pathways may be targetable in diabetic kidney disease.
The post Kidney Organoids Reveal Inflammatory Drivers of Diabetic Kidney Disease appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/02/Getty_1360263908_kidney.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 18 Sep 2026 12:15:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Kidney, Organoids, Reveal, Inflammatory, Drivers, Diabetic, Kidney, Disease</media:keywords>
<content:encoded><![CDATA[<p>Diabetic kidney disease is one of the most common and serious complications of diabetes, yet the chain of events linking high blood sugar to kidney damage remains incompletely understood. Now, a stem cell-based model suggests that glucose itself may help trigger an inflammatory response inside kidney tissue—one that can damage key epithelial cells.</p>
<p>Researchers led by Benjamin S. Freedman, PhD, at the University of Washington and University of Miami, report that human kidney organoids exposed to elevated glucose developed tissue-intrinsic inflammation and epithelial cell detachment, including detachment of podocytes, specialized cells essential for the kidney’s filtration barrier. The study, “<a href="https://www.cell.com/stem-cell-reports/fulltext/S2213-6711(26)00292-4" target="_blank" rel="noopener">Elevated glucose in kidney organoids induces tissue-intrinsic inflammation driving epithelial detachment</a>,” was published recently in <em>Stem Cell Reports</em>.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>“High sugar causes inflammation in these organoids even though they lack an immune system,” Freedman said. “This was unexpected and gives us a new way to think about how diabetes can affect kidneys and other organs.”</p>
<p>Diabetic kidney disease affects about 40% of people with diabetes and can progress to kidney failure due to persistently high blood pressure. Although current therapies can help control blood sugar and blood pressure, few treatments directly address the cellular damage that occurs in the kidney. The researchers set out to model that damage using human kidney organoids, which are generated from pluripotent stem cells through a stepwise differentiation process that recapitulates aspects of kidney development.</p>
<p>To mimic diabetic conditions, the team cultured kidney organoids in media containing different glucose concentrations. Organoids maintained in lower glucose conditions remained largely intact, but those exposed to higher glucose levels showed progressive morphological deterioration. Importantly, live/dead and lactate dehydrogenase assays suggested the changes were not caused by overt cytotoxicity. Instead, the researchers observed detachment of podocytes and tubular epithelial cells from the main organoid body, a phenotype reminiscent of changes reported in kidney biopsies and urine samples from patients with diabetic kidney disease.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>Single-cell RNA sequencing pointed to activation of inflammatory pathways in the high-glucose organoids. MIF emerged as the top upregulated gene across the complete dataset, epithelial cluster, and podocyte subcluster, while TNF-alpha/NF-kB signaling was among the pathways enriched in epithelial and proximal tubule subclusters. Several pathway-level changes, including TNF-alpha/NF-kB signaling, also overlapped with transcriptomic data from human diabetic kidney disease biopsies. “Thus, our scRNA-seq analysis suggested that high glucose levels promote TNF-alpha and MIF expression, driving inflammation and podocyte injury,” the authors wrote.</p>
<p>The researchers then tested whether blocking these inflammatory pathways could blunt the injury phenotype. Inhibiting MIF with ISO-1 or TNF-alpha with etanercept protected organoids from podocyte injury under high-glucose conditions. MAPK pathway inhibitors also partially rescued podocyte morphology. These findings suggest that inflammation may be more than a secondary consequence of diabetic kidney damage.</p>
<p>The authors caution that further work is needed before these findings can be translated into patient therapies. The model required relatively high glucose levels to induce injury in the absence of TNF-alpha, and organoids lack a functional vasculature and immune system. Still, the study provides a controlled human platform for dissecting how hyperglycemia affects kidney cells and for evaluating potential anti-inflammatory strategies.</p>
<p>“While our findings suggest that inhibitors of MIF, TNF-alpha, or MEK can be used to intervene in this process, careful consideration and preclinical studies are needed to determine which of these treatment strategies is likely to be most effective,” the authors wrote.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/kidney-organoids-reveal-inflammatory-drivers-of-diabetic-kidney-disease/">Kidney Organoids Reveal Inflammatory Drivers of Diabetic Kidney Disease</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Residency Matching: How to Cancel an Interview the Right Way</title>
<link>https://edusehat.com/en/residency-matching-how-to-cancel-an-interview-the-right-way</link>
<guid>https://edusehat.com/en/residency-matching-how-to-cancel-an-interview-the-right-way</guid>
<description><![CDATA[ After four years of college, four years of medical school, countless research projects and long hours shadowing you finally got a residency interview and you want to cancel it?! Yes, it happens. And here&#039;s how to respectfully decline.
The post Residency Matching: How to Cancel an Interview the Right Way appeared first on Elite Medical Prep. ]]></description>
<enclosure url="https://elitemedicalprep.com/wp-content/uploads/2020/08/pexels-mikhail-nilov-8872741-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 18 Sep 2026 09:00:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Residency, Matching:, How, Cancel, Interview, the, Right, Way</media:keywords>
<content:encoded><![CDATA[<p><em>This article was updated in September 2026 by EMP tutor <a href="https://elitemedicalprep.com/tutors/rebecca-lapides/">Rebecca Lapides</a> to reflect current residency interview guidance and best practices.</em></p>
<p> </p>
<p><span>After four years of college, four years of medical school, countless research projects, long clinical hours, and multiple board exams you finally got a residency interview and you want to cancel it?!</span></p>
<p> </p>
<p><span>Kidding, this situation definitely comes up more often than you might think! But it’s </span><b>very</b><span> important to handle it in an appropriate way. </span></p>
<p> </p>
<h2><strong>Let’s first take a step back. </strong></h2>
<p><span>When applying to residency, it’s important to apply broadly and develop a thoughtful <a class="decorated-link" href="https://elitemedicalprep.com/6-tips-for-contacting-medical-residency-programs-for-an-interview/" target="_new" rel="noopener" data-start="267" data-end="396">residency application strategy</a>. With program signaling now implemented across many specialties, applicants may apply to fewer programs that appear to be a more targeted fit. However, if you’ve applied broadly enough, it’s possible that you will have interviews scheduled you decide to not to attend. This is a great situation to be in because it means you have a solid number of interviews at programs that you feel good about already. A perhaps more challenging situation is when, unfortunately, two interviews conflict with one another so you have to choose your preferred program to take the interview at. </span></p>
<p> </p>
<p><strong>These two scenarios are slightly different. Let’s start with scenario #1.</strong></p>
<p> </p>
<h3><strong>Scenario #1: You Scheduled the Interview but you have a Solid Number of Interviews and are Unlikely to Rank this Program Highly</strong></h3>
<p><span>This is a common scenario as the interview season goes on. Some applicants have heard rumors that program directors intentionally schedule interviews later in the season because they believe applicants who attend later dates may have a stronger interest in the program. If you determine that the program no longer aligns with your goals, politely decline the interview to save both yourself and the program time and effort.</span></p>
<p> </p>
<p><b>The key is to do your research and cancel the interview early</b><span>. Better yet, do not even schedule the interview and politely decline the invitation allowing the spot to remain open for a more interested applicant. You do not need to provide a lengthy explanation. Simply email the program coordinator or director, express your gratitude for the opportunity, and politely decline the invitation.</span></p>
<p> </p>
<h3><strong>Scenario #2: The Interview Conflicts with Another Interview</strong></h3>
<p><span>Residencies set their interview dates in advance and do not coordinate with other programs. While students vie for a date that fits best in their schedule, following a clear strategy for <a class="decorated-link" href="https://elitemedicalprep.com/scheduling-residency-interviews/" target="_new" rel="noopener" data-start="715" data-end="811">scheduling residency interviews </a>can make conflicts easier to avoid.</span><span> Therefore, if you have a conflicting interview or the interview is scheduled too close to your interview with another program, it is OK to request a date that is full. However, bear in mind that residencies do not often accommodate students with conflict as this shows you are less serious about their program. Also remember, </span><b>if you email a program asking to be accommodated for an interview, and the program accommodates you, you should not cancel</b><span>. </span></p>
<p> </p>
<p><i><span>Cancelling after a program already made an accommodation for you is considered highly disrespectful. </span></i><span>While it may not seem that this would have any bearing on your match, program directors </span><b>do</b><span> speak to each other and disrespect towards one program can make its way through the rumor mill to other programs. So, if you do ask a program for an accommodation to better fit your schedule, be 100% sure that you can attend the interview if the program agrees.</span></p>
<p> </p>
<p><span>However, if you receive an interview invitation that conflicts with another commitment, you may decide to decline it. </span><i><span>Simply email back the program coordinator/director, extend your gratitude, and politely decline citing a prior commitment or scheduling issues as the reason.</span></i><span> Once your interview schedule is finalized, review these <a class="decorated-link" href="https://elitemedicalprep.com/preparing-for-your-residency-interview/" target="_new" rel="noopener" data-start="947" data-end="1055">residency interview preparation tips</a> so you can approach each program with confidence.</span></p>
<p> </p>
<h3><strong>Be 100% Certain Prior to Cancelling an Interview</strong></h3>
<p><span>Be sure you </span><b>definitely</b><span> wouldn’t want to match at this program. You should ask yourself, “if I don’t match at all, will I regret declining this interview and not considering this program?” If so, re-consider your decision to cancel. You cannot cancel an interview and then ask for it again if you change your mind. </span></p>
<p> </p>
<h3><strong>How Early is Early Enough to Cancel?</strong></h3>
<p><span>A good rule of thumb would be at least </span><b>three weeks</b><span> in advance. Programs will have wait list spots for applicants, so you may as well give someone else the opportunity to interview.  </span></p>
<p> </p>
<p><b>It is not okay to cancel within one week of the interview.</b><span> I can not stress how important it is to respect the time of the program faculty and staff as well as other applicants. While it is true that programs technically </span><i><span>could</span></i><span> find another person to fill your empty interview spot if you were to cancel a couple days before your interview, you run the major risk of upsetting program directors who will have to scramble or causing them to leave an empty spot. Don’t be a problem for a program before you’ve even matched yet. </span></p>
<p> </p>
<h2><strong>The Bottom Line</strong></h2>
<p><span>As a final word, always, always, ALWAYS make sure to cancel interviews that you decide not to attend. It looks extremely unprofessional and rude if you simply don’t show up. Either cancel the interview well in advance or commit to showing up prepared and ready to <a class="decorated-link" href="https://elitemedicalprep.com/what-questions-do-they-ask-in-a-residency-interview/" target="_new" rel="noopener" data-start="1247" data-end="1375">answer common residency interview questions</a> thoughtfully. Especially since many interviews are online, triple check time zone conversions and make sure you do not accidentally sleep through or forget about your meeting time. If you’ll attend your interview online, review these <a class="decorated-link" href="https://elitemedicalprep.com/residency-virtual-interviews/" target="_new" rel="noopener" data-start="55" data-end="149">virtual residency interview tips</a> to prepare your technology, setting, and presentation beforehand. And, be 100% sure that you do not want to attend an interview before you cancel it with the program. </span></p>
<p> </p>
<h2><strong>Prepare for Your Residency Interviews with Our Comprehensive Toolkit</strong></h2>
<p><span>Take the stress out of residency interview season with our Residency Interview Prep Toolkit. This free resource gives you essential tools to approach residency interviews with confidence, including:</span></p>
<ul>
<li aria-level="1"><span>A detailed checklist to keep you organized.</span></li>
<li aria-level="1"><span>Ready-to-use thank-you email templates.</span></li>
<li aria-level="1"><span>A sample interview script with tips on answering commonly asked questions and sample responses.</span></li>
<li aria-level="1"><span>A curated list of thoughtful questions to ask programs during your interview.</span></li>
</ul>
<p> </p>
<p><span>After the interview, be sure to follow appropriate <a class="decorated-link" href="https://elitemedicalprep.com/a-quick-psa-on-post-residency-interview-communication/" target="_new" rel="noopener" data-start="943" data-end="1093">residency interview thank-you email and communication practices</a>. Set yourself up for success—download the toolkit now and ace your residency interviews!</span></p>
<h4><strong>Fill out the form below to receive your free Residency Interview Toolkit via email!</strong></h4>
<p></p>
<p><span> </span></p>
<p><span>If you need help preparing for your residency interviews, </span><a href="https://elitemedicalprep.com/contact/"><span>contact</span></a><span> Elite Medical Prep residency advising services to set up an online mock interview.</span></p>
<p>The post <a href="https://elitemedicalprep.com/how-to-cancel-a-residency-interview-the-right-way/">Residency Matching: How to Cancel an Interview the Right Way</a> appeared first on <a href="https://elitemedicalprep.com/">Elite Medical Prep</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Mithrl Raises $20M to Expand Deployment of Its Biomedical World Model Across Biopharma</title>
<link>https://edusehat.com/en/mithrl-raises-20m-to-expand-deployment-of-its-biomedical-world-model-across-biopharma</link>
<guid>https://edusehat.com/en/mithrl-raises-20m-to-expand-deployment-of-its-biomedical-world-model-across-biopharma</guid>
<description><![CDATA[ Mithrl’s platform embeds its biomedical world model and AI agents within biopharma companies’ own environments, providing the context and orchestration needed to apply frontier AI to proprietary data and pipelines.
The post Mithrl Raises $20M to Expand Deployment of Its Biomedical World Model Across Biopharma appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/01/GettyImages-2233977474.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 17 Sep 2026 21:55:14 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Mithrl, Raises, 20M, Expand, Deployment, Its, Biomedical, World, Model, Across, Biopharma</media:keywords>
<content:encoded><![CDATA[<p><span>Vivek Adarsh’s reasons for founding Mithrl are quite personal. About 15 years ago, his grandfather passed away from acute kidney disease. And while today there are approved treatments for the disease, 15 years ago there were no FDA-approved drugs specifically for the condition. Adarsh, a trained computer scientist, wanted to address this problem across multiple disease areas that still lack effective treatments today. Three years ago, he co-founded Mithrl, a company whose stated mission is to “help R&D teams go from idea to IND, 50% faster.” </span></p>
<p><span>As he explained in a conversation with </span><i><span>GEN</span></i><span> this week,  “the question for me has been, what can technology do to accelerate getting medicines to patients a lot faster?” He and the Mithrl team believe that their artificial intelligence platform may be one of the keys. This week, the company announced a $20 million Series A funding round led by Obvious Ventures, with participation from Headline, AGI House, and several pharma executives, that will support the development of the second generation of Mithrl’s platform. The platform, dubbed Mithrl-1, comprises the company’s proprietary biomedical world model and an agentic harness for model routing, token optimization, and content orchestration. Mithrl is launching an early access program for the second-generation of the platform that will launch on September 21.</span></p>
<p><span>Mithrl’s platform combines validated biology curated from decades of peer-reviewed research as well as public and partnered datasets with agentic AI. Biopharmaceutical teams that deploy the company’s solution can combine that data, AI agents, and their proprietary data in their own environments. The platform cross-references data across disciplines to surface non-obvious connections using only published and verified data. Because the AI agents only reason over validated biology, rather than searching their way to answer from a broader pool of information, they require much less compute power to complete their tasks, according to the company. </span></p>
<p><span>That assertion is supported by results from a recent benchmark analysis, shared by Mithrl, that showed that running its infrastructure used 45% fewer tokens than standard workflows running the same frontier base models without customization. Finally, when the system generates hypotheses, it includes details about the sources used as well as a confidence score that captures what the system read, how it got there, and how much to trust its output. </span></p>
<p><span>Mithrl-1 is deployed in each client’s environment and harmonizes across existing frontier models. Each client’s implementation is then extended using their own proprietary data and pipelines. From there, teams can build and manage their own bespoke biomedical agents in-house. As new studies come in, Mithrl updates its knowledgebase and those changes are pushed out to customers on a regular basis giving them access to studies that are relevant to their work, and that could influence how they approach research questions. </span></p>
<p><span>These kinds of capabilities are important as AI systems become more embedded in biotech and biopharma labs. “Every player in this category is racing to generate more raw hypotheses, faster. But the industry is cracking under the weight of hypotheses it can’t triage or validate,” said Adarsh, who also serves as the company’s CEO. Mithrl set out to answer a different question. “Which of these will actually hold up in downstream experiments, and ultimately in patients? The platform doesn’t guess. It reasons from trusted studies and each client’s in-house evidence the way a client’s best scientists do, and it shows its work every time.” </span></p>
<p><span>To date, Mithrl’s platform has been used by several top-10 pharmaceutical companies, clinical-stage biotech companies, and genomics platform partners, according to the company. That list includes Elephas Biosciences, a company that develops an<em> ex vivo</em> tumor profiling platform. In April this year, the companies announced a scientific collaboration aimed at combining functional tumor profiling with AI-driven analysis to discover novel immunotherapy responses signals. The company could announce additional customer deals in Q4 of this year.</span></p>
<p><span>Some companies are already “AI-ready” which makes implementing Mithrl’s infrastructure more straightforward but most need some support to efficiently implement the company’s infrastructure, Adarsh says. “We have forward deployed scientists that go in, work with them, [help] them understand what knowledgebase does, and how we can make everything standardized.” </span></p>
<p><span>As the AI market matures, it has also become easier to make the case for implementing AI and communicating their platform’s benefits. A year ago, “you kind of had to work a little bit to educate where the value is” but that has changed in recent months, Adarsh noted. “I think there is a systemic level of education that has gone on over the past 12 months, mostly led by Frontier Labs, which is good for us.” There are also management changes happening across the biopharma industry and those shifts seem to be driving interest in onboarding AI, Adarsh said. He told </span><i><span>GEN</span></i><span> that he has noticed an uptick in conversations with company executives who “have a notion of the value that they are looking for” and are interested in understanding how Mithrl’s platform can help them get there.</span></p>
<p><span>So far the company’s tools seem to be making their mark on the industry. According to Mithrl, discoveries powered by its platform have contributed to over half a dozen customer-owned patent filings. It also claims that its biomedical world model delivers 16x more primary evidence per answer than frontier models alone and scored 0.96 for scientific correctness in expert-rated biomedical benchmarks, compared to 0.6 without its platform. </span></p>
<p><span>These proof points are helpful in a crowded market of AI-focused companies targeting drug discovery. Adarsh acknowledged the hype while discussing what sets Mithrl apart from other companies in the space. “Our north star is to be able to give scientific value and uniqueness to our partners,” he said. “What truly draws the revenue, and the topline for pharmaceutical companies, is uniqueness” specifically “patents.” He pointed to the platform’s contributions to multiple patents noting that customers have highlighted the competitive edge it gives. Those outcomes are “what differentiates us.”</span></p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p><span>And those outcomes, at least in part, are driving growing interest in the company’s platform. Adarsh told </span><i><span>GEN</span></i><span> that the current fundraising round was motivated to an extent by greater customer demand as well as a need to expand its capabilities. To the end, the new funding will support further development of the underlying biomedical world model as well as allow Mithrl add to its headcount, which currently stands at about 30 people. “In the order of priority, we have more demand to do deployments of our platform within big organizations, which obviously requires headcount,” Adarsh said. “Second is expansion across therapeutic areas.” The primary focus for now will be on disease areas that its target customer base works on including, immune-related diseases, oncology, diabetes, metabolic disease, and cardiovascular disease. </span></p>
<p><span>If all goes well, developing new medicines “won’t take 15 years” but “five years,” Adarsh said. “That is the personal motivation that led us to create Mithrl and that’s the path we’re on.”</span></p>
<p>The post <a href="https://www.genengnews.com/topics/artificial-intelligence/mithrl-raises-20m-to-expand-deployment-of-its-biomedical-world-model-across-biopharma/">Mithrl Raises $20M to Expand Deployment of Its Biomedical World Model Across Biopharma</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Sartorius and NIBRT Partner on Intensified and Continuous Bioprocessing Training Center</title>
<link>https://edusehat.com/en/sartorius-and-nibrt-partner-on-intensified-and-continuous-bioprocessing-training-center</link>
<guid>https://edusehat.com/en/sartorius-and-nibrt-partner-on-intensified-and-continuous-bioprocessing-training-center</guid>
<description><![CDATA[ Officials at Sartorius and the NIBRT said their partnership will strengthen global workforce readiness and accelerate the industry transition toward more efficient and sustainable biopharmaceutical production.
The post Sartorius and NIBRT Partner on Intensified and Continuous Bioprocessing Training Center appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-171225477.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 17 Sep 2026 21:55:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Sartorius, and, NIBRT, Partner, Intensified, and, Continuous, Bioprocessing, Training, Center</media:keywords>
<content:encoded><![CDATA[<p>Sartorius and the Ireland-based National Institute for Bioprocessing Research and Training (NIBRT) are partnering to establish a training center for intensified and fully continuous bioprocessing in Dublin. Starting in the fourth quarter of 2026, the center will serve as a hub for practical training and knowledge sharing to help the biopharmaceutical industry adopt intensified, digitalized, and continuous manufacturing processes, according to Sartorius officials.</p>
<p>As part of the collaboration, Sartorius will equip NIBRT with its Pionic technology—an end-to-end modular cGMP platform for integrated continuous bioprocessing with advanced analytics and digital tools. Through the collaboration, the new facility is expected to provide more than 1,000 scientists, engineers, and students each year with hands-on experience in intensified upstream and downstream processes designed for efficiency, flexibility, and sustainability.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>René Fáber, head of the bioprocess solutions division and member of the executive board at Sartorius, pointed out that biopharmaceutical manufacturing is undergoing a major shift from batch processes toward more efficient, continuous processes.</p>
<p>“While technological innovation is the first step, training current and future engineers and operators is critical to making the change a reality,” he said. “Our partnership with NIBRT underscores Sartorius’ commitment to building global capabilities and accelerating the adoption of innovative and sustainable bioprocessing technologies.”</p>
<p>“This collaboration marks a significant step in advancing workforce training and supporting the transition toward intensified and connected manufacturing,” added Darrin Morrissey, CEO of NIBRT. “By integrating the Pionic platform into our training facility, we will give biopharma professionals the chance to gain first-hand experience with cutting-edge technologies that drive process efficiency and performance.”</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>The Process Intensification Training Center will become a key element of NIBRT’s global training and education network, serving industry professionals and academic partners in Ireland, Europe, and worldwide, noted a NIBRT spokesperson. Beyond training, the center will also enable collaborative research and pilot-scale demonstrations, strengthening the global biomanufacturing ecosystem, said the center official.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/sartorius-and-nibrt-partner-on-intensified-and-continuous-bioprocessing-training-center/">Sartorius and NIBRT Partner on Intensified and Continuous Bioprocessing Training Center</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Cellares and GenomeFrontier Therapeutics Partner to Advance Automated Manufacturing of GF&#45;CART01</title>
<link>https://edusehat.com/en/cellares-and-genomefrontier-therapeutics-partner-to-advance-automated-manufacturing-of-gf-cart01</link>
<guid>https://edusehat.com/en/cellares-and-genomefrontier-therapeutics-partner-to-advance-automated-manufacturing-of-gf-cart01</guid>
<description><![CDATA[ The partnership marks Cellares’ first collaboration with a cell therapy developer in Asia and will evaluate automated manufacturing of GenomeFrontier’s virus-free CAR T process for clinical manufacturing in the U.S.
The post Cellares and GenomeFrontier Therapeutics Partner to Advance Automated Manufacturing of GF-CART01 appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/Home-CS-Floor-scaled-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 17 Sep 2026 07:35:14 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Cellares, and, GenomeFrontier, Therapeutics, Partner, Advance, Automated, Manufacturing, GF-CART01</media:keywords>
<content:encoded><![CDATA[<p>Cellares, an integrated development and manufacturing organization (IDMO), and GenomeFrontier Therapeutics, a Taiwanese cell therapy company developing virus-free CAR T therapies, formed a partnership to evaluate automated manufacturing for GF-CART01, GenomeFrontier’s investigational CAR T-cell therapy, on Cellares’ Cell Shuttle platform.</p>
<p>The collaboration will focus on the translation of GenomeFrontier’s manufacturing process to the Cell Shuttle, with an emphasis on supporting transfection unit operation using Cellares’ integrated electroporator. The partnership marks Cellares’ first development collaboration in Asia and is intended to support GenomeFrontier’s U.S. clinical initiative as it advances GF-CART01.</p>
<p>GenomeFrontier is developing GF-CART01 for B-cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, primary mediastinal large B-cell lymphoma, and high-grade B-cell lymphoma. The company reports that it has demonstrated promising clinical data in Taiwan and is now recruiting for a Phase I clinical trial in the U.S.</p>
<p>“As we advance GF-CART01, it is important that our manufacturing strategy can support both clinical development and future scale,” said Sareina Wu, PhD, founder, CEO, and CSO of GenomeFrontier. “Our virus-free approach is central to the development of GF-CART01, and this collaboration with Cellares allows us to evaluate how that process can be translated to an automated manufacturing platform as we expand our clinical development in the U.S.”</p>
<p>“GenomeFrontier’s approach reflects the increasing complexity of next-generation cell therapy manufacturing,” added Fabian Gerlinghaus, co-founder and CEO of Cellares. “The Cell Shuttle is built to automate complex processes, including electroporation-based workflows, with the scalability and reliability needed as therapies advance through clinical development.”</p>
<p>Autologous CAR T manufacturing remains labor-intensive, variable and difficult to scale, creating challenges for clinical development, manufacturing reliability, cost, and ultimately patient access. The Cell Shuttle is an end-to-end automated cell therapy manufacturing platform designed to improve the scalability and reliability of autologous cell therapy manufacturing, according to Cellares.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/cellares-and-genomefrontier-therapeutics-partner-to-advance-automated-manufacturing-of-gf-cart01/">Cellares and GenomeFrontier Therapeutics Partner to Advance Automated Manufacturing of GF-CART01</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Prophylactic Phage Therapy Protects Mice Against Oral Salmonella Infection</title>
<link>https://edusehat.com/en/prophylactic-phage-therapy-protects-mice-against-oral-salmonella-infection</link>
<guid>https://edusehat.com/en/prophylactic-phage-therapy-protects-mice-against-oral-salmonella-infection</guid>
<description><![CDATA[ Researchers developed a prophylactic phage therapy targeting Salmonella enterica Typhimurium that in mouse models colonized the gut, and produced lytic phages that protected against future infection by the pathogen, improving survival.
The post Prophylactic Phage Therapy Protects Mice Against Oral Salmonella Infection appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2022/06/GettyImages-1264547051-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 17 Sep 2026 07:35:13 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Prophylactic, Phage, Therapy, Protects, Mice, Against, Oral, Salmonella, Infection</media:keywords>
<content:encoded><![CDATA[<p>Researchers at Virginia Tech have developed a prophylactic phage therapy approach to protecting against potential future infections by pathogenic gut bacteria. Bacteriophages, or phages, are viruses of bacteria and do not infect humans or animals. Headed by associate professor and Blackwood Junior Faculty Fellow Bryan Hsu, PhD, the team engineered a nonpathogenic <em>Escherichia coli</em> bacterium that produces a phage targeting the enteric pathogen <em>Salmonella enterica</em> Typhimurium (STm).</p>
<p>Tests in mouse models of STm-induced colitis showed that the prophage-encoding bacterium colonized the gut, produced high levels of lytic phage and protected mice from subsequent oral salmonella infection, improving survival. The team believes their results represent a step toward the development of new weapons against different diseases.</p>
<p>“Eventually, in the future, this could be used to treat other diseases,” said Rogerio A. Bataglioli, PhD, a postdoctoral fellow in the Department of Biological Sciences. “It’s not about replacing antibiotics but having one more option on the shelf to fight infections.”</p>
<p>Hsu is senior and co-corresponding author, and Bataglioli first and co-corresponding author of the researchers’ published paper in <em>Nature Microbiology</em>, titled “<a href="https://doi.org/10.1038/s41564-026-02484-3" target="_blank" rel="noopener">Prophage-encoding engineered bacteria enable prophylactic lytic phage therapy for enteric infection in mice</a>.” In their paper the authors wrote, “In this study, we show that a nonpathogenic <em>E. coli</em> gut  bacterium can be engineered to produce an obligately lytic antipathogen phage, and the application of this lyto-lysogen before oral STm infection can improve survival in mouse models and reduce intestinal colonization of the pathogen.”</p>
<p>The mammalian gut microbiome is teeming with a delicate balance of bacteria and the bacteriophage viruses that keep them in check phages. Each bacterial species usually has its own set of phage partners.</p>
<p>When bad bacteria enter the gut microbiome ecosystem there are typically no phages present, allowing the bacteria to cause mayhem. By the time the host is sick, it is too late for phages, and they’ll simply reach a balance with the bad bacteria. Hsu said phage therapy, the use of phages to treat bacterial infections, is particularly hard to make successful for treating intestinal pathogens. “Phage therapy is a promising antibacterial approach but it has limited efficacy against enteric bacterial infections, such as <em>Salmonella enterica Typhimurium</em> (STm),” the authors wrote in their paper.</p>
<p><figure aria-describedby="caption-attachment-338006" class="wp-caption alignright"><img decoding="async" class="size-medium wp-image-338006" src="https://www.genengnews.com/wp-content/uploads/2026/09/Low-Res_image-3-300x152.jpg" alt="(From left) Roger Bataglioli and Hiba Baaziz in the lab. [Photo by Felicia Spencer for Virginia Tech.]" width="300" height="152" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/Low-Res_image-3-300x152.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/Low-Res_image-3-696x354.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/09/Low-Res_image-3.jpg 700w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">(From left) Roger Bataglioli and Hiba Baaziz in the lab. [Felicia Spencer / Virginia Tech]</figcaption></figure>“It’s challenging, especially in the gut, because phages and bacteria tend to coexist for long periods of time,” said Hsu, an affiliate with Fralin Life Sciences Institute’s Center for Emerging, Zoonotic, Arthropod-borne Pathogens.</p>
<p>This coexistence makes establishing the high phage-to-bacteria ratio needed to treat intestinal infections hard to achieve. “That’s extremely challenging to achieve in your gut,” Hsu said. “And then once you have a bacterial infection in your gut, a lot of times it’s just not even accessible to phages. It’s already hidden away in the mucosa or cells of your body; it’s not just free flowing to where the phages would be able to access them.”</p>
<p>But what if the phages in the gut could prepare for the orally ingested pathogen and strike it down as it enters the gut, negating the need for a battle? “… We hypothesized that establishing high concentrations of a pathogen-targeting phage in the gut before infection would prophylactically protect against future infection,” the team further wrote.</p>
<p>For their study they engineered a nonpathogenic <em>E. coli</em> bacterium to encode a prophage that produces lytic phages that only infect the target STm bacterium. Usually, this type of <em>Salmonella</em> phage remains dormant in the <em>Salmonella</em> bacterial genome, but Hsu’s team made several genetic modifications so that the phage is carried by <em>E. coli</em>. Once released into the gut, the phage targets and kills the<em> Salmonella</em> by lysis. This process rapidly increases the number of phages to fight the bacteria. The researchers coined this new type of phage-bacterial combination a “lytic phage-producing lysogen,” or “lyto-lysogen.”</p>
<p><em>Salmonella</em> can typically detect phage DNA produced by non-<em>Salmonella</em> bacteria and prevent it from replicating. But in this case, the researchers were able to disguise the phage. “We were able to trick the <em>Salmonella</em> bacteria into thinking the phage from <em>E. coli </em>was ‘not foreign’ by adding a <em>Salmonella</em> gene into the <em>E. coli</em> genome,” Bataglioli said. “A phage that comes from our <em>E. coli</em> can infect <em>Salmonella</em>, can propagate easily in <em>Salmonella</em>, lyse it, and then all the phages that are produced from <em>Salmonella</em> can just keep replicating.”</p>
<p>This rapid reproduction eventually leads to the eradication of the infection from the gut. “What happens is that this good bacteria, the <em>E. coli</em>, produces all this antipathogen phage, and there is now a protective lining so that when <em>Salmonella</em> comes in, just after passing through the stomach and at its weakest point, it meets this high, killer density of phages,” Hsu said. In their paper the authors further noted, “Within the context of the mouse model of STm infection that we use here, we found that this prophylactic application of prophage therapy was superior to its therapeutic application post infection, and superior to the prophylactic or therapeutic application of free phage.”</p>
<p>The researchers say they targeted <em>Salmonella</em> because the pathogen has high global disease burden, and can be deadly in the elderly, children, and those with HIV. The bacterium also has a high prevalence of antibiotic resistance, and has been upgraded to a high-priority pathogen by the Centers for Disease Control and Prevention.</p>
<p>The researchers believe their work also has strong implications for other illnesses. “We’re starting off with <em>Salmonella</em>, but expanding, obviously, with the correct adaptations to target other diseases; other bacterial pathogens, would be an interesting route to explore,” Bataglioli said. The team further noted, “Collectively, our work shows that the lyto-lysogen strategy is a feasible prophylactic approach and represents an advancement in how phage therapy is conventionally conceived.” Hsu added, “We have a framework in place that shows that we could potentially put other phages in there and target other bacteria.”</p>
<p>Bataglioli plans to continue his bacteriophage research with the School of Chemical Engineering at the State University of Campinas in São Paulo, Brazil, in the fall.</p>
<p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/prophylactic-phage-therapy-protects-mice-against-oral-salmonella-infection/">Prophylactic Phage Therapy Protects Mice Against Oral <i>Salmonella</i> Infection</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Brain Protein in Mice Offers Insights Into Brain Development and ADHD</title>
<link>https://edusehat.com/en/brain-protein-in-mice-offers-insights-into-brain-development-and-adhd</link>
<guid>https://edusehat.com/en/brain-protein-in-mice-offers-insights-into-brain-development-and-adhd</guid>
<description><![CDATA[ Researchers identified a brain protein, NSF, that is important for maintaining dopamine-related cells and normal development, providing new insights into ADHD and potential therapeutic strategies.
The post Brain Protein in Mice Offers Insights Into Brain Development and ADHD appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/08/Getty_769722823_BrainNeuralNetwork_RESIZE11111.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 17 Sep 2026 07:35:12 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Brain, Protein, Mice, Offers, Insights, Into, Brain, Development, and, ADHD</media:keywords>
<content:encoded><![CDATA[<p>Attention-deficit/hyperactivity disorder (ADHD), marked by excessive activity and impulsivity, is linked to changes in the brain’s dopamine system, though the mechanisms remain unclear. Researchers at the University of Fukui have now found that in genetically modified, conditional knockout mice, loss of a protein called N-ethylmaleimide-sensitive factor (NSF)—which is linked to dopamine receptors—in D2 receptor-expressing cells led to lower dopamine levels and ADHD-like behaviors. Their results also pointed to a potential therapeutic strategy.</p>
<p>The team, headed by assistant professor Min-Jue Xie, PhD, at the Division of Development of Mental Functions, Research Centre for Child Mental Development, suggests that the results offer insight into how brain changes may contribute to ADHD and informing future treatments.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>“This is basic research and will not immediately lead to a new treatment,” Xie acknowledged. “However, it provides important clues for understanding how dopaminergic dysfunction may contribute to ADHD. In the future, these findings may help develop new therapeutic strategies targeting D2R function and striatal dopamine signaling, especially for treatment-resistant ADHD.”</p>
<p>Xie is first and corresponding author of the researchers’ published paper in <em>Neuropsychopharmacology</em>, titled “<a href="https://doi.org/10.1038/s41386-026-02526-8" target="_blank" rel="noopener">Deletion of N-ethylmaleimide-sensitive factor in dopamine D2 receptor-expressing cells impairs striatal development and dopaminergic function and induces ADHD-like behaviors in mice</a>.”</p>
<p>ADHD is a neurodevelopmental disorder that can affect attention, activity levels, and impulse control, with symptoms often beginning in childhood and sometimes continuing into adulthood. Although the exact causes of ADHD are not fully understood, changes in the brain’s dopamine system have long been linked to the condition. Dopamine is a chemical messenger that helps brain cells communicate and plays an important role in movement, motivation, and behavior.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>While dopamine-related changes have been associated with ADHD, it remains unclear how the brain cells that respond to dopamine are maintained and how their disruption may contribute to ADHD-related behaviors. This is particularly relevant to dopamine D2 receptor (D2R)-expressing cells, which are found in the striatum, a brain region involved in movement and behavioral control. Understanding what helps these cells develop and function normally could provide new insights into the biological processes involved in ADHD. “Although D2R has been extensively studied, the upstream mechanisms regulating its function and localization remain unclear,” the authors wrote.</p>
<p>Against this backdrop, a research team from Japan, led by Xie, set out to investigate the role of NSF in these dopamine-related brain cells. NSF regulates membrane fusion, helping brain cells release chemical messengers and move proteins within their membranes. “NSF dysfunction is implicated in neuropsychiatric disorders, with reduced expression in autism spectrum disorder (ASD) and schizophrenia and aggregates in Parkinson’s disease,” the investigators noted.</p>
<p>“The motivation for this study came from previous findings suggesting that NSF may be involved in neurodevelopmental and neuropsychiatric disorders,” Xie explained. “NSF was known to interact with D2R; however, the role of this interaction<em> in vivo</em> remained unclear. Because ADHD is thought to involve reduced striatal dopaminergic function and D2R dysfunction, we hypothesized that NSF may be important for maintaining D2R-expressing neurons and dopaminergic function. This led us to initiate the present study.”</p>
<p>For their study the team created knockout mice in which NSF was removed specifically from D2R-expressing neurons. “… we generated D2R-specific Nsf conditional knockout (<em>Nsf <sup>f/f</sup>;</em>D2R-Cre) mice to examine NSF function in D2R-expressing cells <em>in vivo</em>,” they explained. They then studied the animals’ brain development, dopamine levels, and behavior. The team also tested whether drugs that affect dopamine signaling could reduce the behavioral changes seen in the modified mice.</p>
<p>The loss of NSF affected the developing brain, resulting in fewer dopamine D2R-expressing cells, increased early developmental cell death, and a smaller striatum. The mice also had markedly lower dopamine levels in this brain region. Together, these findings suggest that NSF helps maintain dopamine-related cells and supports normal development and dopamine function.</p>
<p>The brain changes were accompanied by ADHD-like behaviors. “<em>Nsf <sup>f/f</sup>;</em>D2R-Cre mice exhibited attention-deficit/hyperactivity disorder (ADHD)-like behaviors, including hyperactivity and impulsivity,” the team reported. The knockout mice were more hyperactive than control mice and showed more impulsive-like behavior in a test that measured how quickly they jumped from an elevated platform. By the end of the seven-minute test, 86% of the experimental group mice had jumped, compared with 31% of the control group mice. “These findings indicate that a reduction in D2R-expressing cells coincides with ADHD-like behaviors, suggesting a link between D2R dysfunction and these abnormalities.”</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>The researchers then explored whether these behaviors could be reduced by changing dopamine signaling. Methylphenidate, a medicine commonly used to treat ADHD, did not significantly reduce hyperactivity when given alone to the modified mice. However, when it was given together with quinpirole, a drug that activates D2R, the mice became less hyperactive and showed less impulsive-like behavior. During the seven-minute test, the proportion of knockout mice that jumped fell from 78% without treatment to 11% after the two drugs were given together. “Combined administration of methylphenidate and a D2R agonist, quinpirole, alleviated both behaviors, suggesting a potential complementary approach for ADHD treatment,” the investigators wrote.</p>
<p>“This study supports the translational relevance of the<em> Nsf <sup>f/f</sup>;</em>D2R-Cre model for ADHD and indicates that targeting D2R dysfunction, particularly in treatment-resistant ADHD, may be a promising therapeutic strategy.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/brain-protein-in-mice-offers-insights-into-brain-development-and-adhd/">Brain Protein in Mice Offers Insights Into Brain Development and ADHD</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Meet a mouse whose brain cortex is made up of human cells</title>
<link>https://edusehat.com/en/meet-a-mouse-whose-brain-cortex-is-made-up-of-human-cells</link>
<guid>https://edusehat.com/en/meet-a-mouse-whose-brain-cortex-is-made-up-of-human-cells</guid>
<description><![CDATA[ Multiple cameras tracked a mouse as it wandered around a small arena. A computer charted its position and speed, leaving Pong-like traces on a monitor.  The reason to watch this rodent so carefully? Nearly half its brain volume had been replaced with human cells. The effort to mix the brain tissues of distant species is… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/09/260915_HumanBrainTissueMice.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 17 Sep 2026 04:00:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Meet, mouse, whose, brain, cortex, made, human, cells</media:keywords>
<content:encoded><![CDATA[<div data-chronoton-summary="<ul><br><li><strong>Human brain cells, mouse body:</strong> Scientists have grown human brain tissue inside mice, creating a hybrid creature whose cortex is largely made of human cells.</li><br><li><strong>Why it matters:</strong> The research could unlock new ways to study brain injuries.</li><br><li><strong>Ethical questions loom:</strong> Mixing human brain tissue with animals raises uncomfortable questions about what it means to be human.</li><br></ul>" data-chronoton-post-id="1144210" data-chronoton-expand-collapse="1" data-chronoton-analytics-enabled="1"></div>


<p>Multiple cameras tracked a mouse as it wandered around a small arena. A computer charted its position and speed, leaving Pong-like traces on a monitor. </p>



<p>The reason to watch this rodent so carefully? Nearly half its brain volume had been replaced with human cells.</p>



<p>The effort to mix the brain tissues of distant species is being reported today in the journal <em>Nature</em> by a team at Stanford University, led by neuroscientist Sergiu Pașca. </p>



<p>Pașca’s group previously showed that human brain “organoids”—small blobs of neural tissue—could survive, and even function, after being injected<a href="https://www.technologyreview.com/2022/10/12/1061204/human-brain-cells-transplanted-baby-rats-brains/"> into the heads of baby rodents</a>.</p>



<p>Now, Pașca has taken things a step further by genetically modifying mice so their brains don’t fully develop in the first place. These modified mice are missing most cells of both the cortex and the hippocampus, two key brain areas.</p>



<p>That creates much more room for the human cells to take hold, he says. “Human cells that are placed in these animals will divide, will grow, and within a few weeks to a few months they will take most of that space,” he says. Pașca says one surprising discovery is that the mice lacking brain tissue seemed fairly normal—they walked around and squeaked. But they did have memory problems. In a maze test, they couldn’t remember what parts they’d explored. </p>



<p>The mice with the added human cells, by contrast, performed better on the maze test. That means the human tissue is playing some role in the animals’ cognition.</p>



<p>Pașca believes what he is calling “xenocortical mice” could be useful in studying brain injuries. However, the report is also a dramatic demonstration of “the combined power of genetic engineering and stem-cell technology to reshape biology,” says Carsten Charlesworth, a scientist who works in a different Stanford lab and was not involved in the research.</p>



<p>Already, brain organoids are being tested in labs to see if they can be <a href="https://www.technologyreview.com/2023/12/11/1084926/human-brain-cells-chip-organoid-speech-recognition/">connected to computers</a> to play video games. Other scientists have proposed using them like replacement parts to treat stroke victims. </p>



<p>“What’s most remarkable to me is the extent to which human neural tissue introduced after birth grew and connected with the mouse nervous system across a species barrier,” says Charlesworth. “As these technologies advance, they’ll increasingly force us to challenge our traditional assumptions.”</p>



<p>Last year, Pașca <a href="https://neuroscience.stanford.edu/sites/default/files/2026-09/Exec%20Summary%20-%202025%20Asilomar%20Conference%20on%20Oversight%20of%20Neural%20Organoids_0.pdf">convened a group of ethics experts</a> to study the implications of neural organoid technology, including the odds that an animal could develop human consciousness and the risk that “organoid therapy clinics” might offer scam treatments to desperate patients.</p>



<p>For now, he says, he’s not concerned that the rodents have any type of human cognitive capacities. That is because their brains are relatively tiny and the evolutionary distance between man and mouse is so great. </p>



<p>But that’s also why Pașca says this type of experiment should not be carried out on higher species: They could end up with large volumes of functioning human brain tissue, potentially blurring the cognitive boundaries between people and animals. </p>



<p>Pașca specifically cautioned against adding human brain organoids to a monkey engineered to lack a cortex.</p>



<p>“One of the things that I see as a very clear red line is doing this experiment in a primate,” he says. “I don’t think that is justified at this point in any way.”</p>]]> </content:encoded>
</item>

<item>
<title>Lifecycle Approach Could Solve CGT Scale&#45;Up Challenges</title>
<link>https://edusehat.com/en/lifecycle-approach-could-solve-cgt-scale-up-challenges</link>
<guid>https://edusehat.com/en/lifecycle-approach-could-solve-cgt-scale-up-challenges</guid>
<description><![CDATA[ Cell and gene therapy developers often struggle to scale manufacturing, according to the authors of a new review, who suggest that part of the problem is the practice of developing unit operations in isolation. 
The post Lifecycle Approach Could Solve CGT Scale-Up Challenges appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2023/07/GettyImages-1460261281.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 17 Sep 2026 04:00:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Lifecycle, Approach, Could, Solve, CGT, Scale-Up, Challenges</media:keywords>
<content:encoded><![CDATA[<p>Scaleup will remain a challenge for the cell and gene therapy industry until developers adopt a more integrated approach that envisions manufacturing as a single process.</p>
<p>At least, that is according to researchers at the Manipal Academy of Higher Education in Karnataka, India, who argue in a <a href="https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/full/10.1002/bit.70361?campaign=wolearlyview" target="_blank" rel="noopener">new review</a> that developers struggle because they treat manufacturing, analytics, and regulatory compliance as separate issues.</p>
<p>“Historically, the field has tackled these problems separately: one group focused on CAR T manufacturing, another on viral vector production, and another on logistics or regulatory strategy, rather than treating the whole product lifecycle as a single connected system.</p>
<p>“Our review argues that scalability must be built in from the start, using lifecycle-oriented tools that allow manufacturers to embed flexibility into the process from early development through commercial-scale production, rather than trying to bolt scalability on afterward, once problems appear,” study co-author Sachin Dattram Pawar, PhD, tells <em>GEN</em>.</p>
<p>The key, Pawar and colleagues suggest, is to treat all parts of CGT production as a single, unified process designed with scalability in mind.</p>
<p>“The idea is to stop treating early development, scale-up, and commercial manufacturing as separate problems and instead manage manufacturing knowledge continuously across the product’s lifecycle,” he says.</p>
<p>The lifecycle approach is also in keeping with trends in bioprocessing technology development, Pawar says, pointing to decentralized systems like the CliniMACS Prodigy or Lonza Cocoon platforms as examples.</p>
<p>“The approach would involve closed and automated manufacturing systems, real-time process monitoring, advanced analytics, digital tools, scalable cell and vector platforms, and robust cryopreservation and cold-chain infrastructure.</p>
<p>He adds, “Emerging approaches, such as digital twins, AI, allogeneic and iPSC-derived platforms, and improved vector production technologies, could further enhance scalability and consistency.”</p>
<p>In addition, treating manufacturing as a single process would also be a better reflection of the complex interactions that take place between unit operations, Pawar says, citing cell culture systems as an example.</p>
<p>“Switching from one to another can simultaneously alter product yield, purity, and even cell behavior, which in turn has knock-on effects on analytics and regulatory submissions.”</p>
<p></p><h4><strong>Regulations</strong></h4>

<p>A lifecycle-based view of manufacturing also fits with evolving regulations, according to Pawar, who points to the development of “concrete regulatory mechanisms” as evidence of growing support for the approach.</p>
<p>“ICH Q12 provides tools such as established conditions (ECs) and post-approval change management protocols (PACMPs) to help manufacturers manage process changes based on risk and accumulated knowledge.</p>
<p>“Likewise, the FDA’s flexible CMC approach for CGTs also supports greater flexibility during development, while the agency’s RMAT designation and the EMA’s PRIME scheme encourage early regulatory engagement. Overall, regulators are moving toward a more risk-based, lifecycle-oriented approach that supports innovation while maintaining product quality and patient safety,” he concludes.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/a-lifecycle-approach-could-solve-cgt-scale-up-challenges/">Lifecycle Approach Could Solve CGT Scale-Up Challenges</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Choice of Excipients Dramatically Affects Antibody Solubility</title>
<link>https://edusehat.com/en/choice-of-excipients-dramatically-affects-antibody-solubility</link>
<guid>https://edusehat.com/en/choice-of-excipients-dramatically-affects-antibody-solubility</guid>
<description><![CDATA[ More predictive, rational therapeutic antibody formulation designs can be grounded in interactions between antibodies and common excipients that biomanufacturers often consider generic.
The post Choice of Excipients Dramatically Affects Antibody Solubility appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-1124671877-1small-short.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 17 Sep 2026 04:00:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Choice, Excipients, Dramatically, Affects, Antibody, Solubility</media:keywords>
<content:encoded><![CDATA[<p>The excipients added to therapeutic protein formulations are more specific than biomanufacturers typically realize. As it turns out, these inactive ingredients have markedly different effects on solubility, and those differences are based on certain specific physicochemical factors.</p>
<p>In a recent <a href="https://doi.org/10.1080/19420862.2026.2722444" target="_blank" rel="noopener">paper</a>, researchers from the University of Cambridge, Eindhoven University of Technology, and Merck identified solubility differences among commonly used antibodies that ranged from approximately 7-fold to 200-fold. The differences came down to molecular specificity and the complexity of the antibody-excipient interactions. By understanding these indicators and their effects, biomanufacturers can design mAb formulations using a more predictive, rational design approach.</p>
<p>A team of eight, including first author Zexiang Han, a PhD candidate in the Knowles lab; and senior authors Tuomas Knowles, PhD, professor; and Pietro Sormanni, PhD, all of the University of Cambridge, analyzed the effects of four common pharmaceutical excipients (histidine, sodium chloride, arginine, and sucrose) on the solubility of a panel of therapeutic immunoglobulin G (IgG) antibodies using a high-throughput droplet microfluidic platform. They determined that excipient-mediated solubility depends strongly upon the antibodies themselves, and that solubility “can be quantitatively linked to specific molecular features derived from sequence and structure.”</p>
<p>For example, when looking at the solubility of 1 mg mL<sup>−1</sup> cetuximab in the presence of each of the four excipients, they reported that as excipient concentration increased, greater percentages of polyethylene glycol (PEG) crowder were needed to cause mAb precipitation. That was true for each of the excipients.</p>
<p>The scatter plots in the paper showed the relative concentrations of each excipient needed to meaningfully shift the solubility boundary. The histidine plot, for example, stops at about 35 mM, while the plot for sucrose stops at about 500 mM. For cetuximab, a relatively low concentration of histidine shifted the boundary, while a significantly higher concentration of sucrose was needed to cause a similar shift. The contrast among the various excipients, given the same antibody and same concentrations of PEG, underscores that the shifts were caused through molecularly specific interactions between the antibody and the excipient rather than by PEG’s excluded volume effect (i.e., crowding).</p>
<p>More specifically, they noted:</p>
<ul>
<li>“Histidine stabilization is fundamentally polar, correlating with antibody dipole moments.</li>
<li>“Sodium chloride operates via nonspecific electrostatic screening to suppress self-association in low-pI variants [those in which the pI—the isoelectric point—is below that of the pH and have no charge].</li>
<li>“Arginine efficiency reflects a competitive tradeoff between electrostatic screening and chaotropic effect.”</li>
</ul>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>The takeaway, they reported, is that “formulation additives do not exert universal actions.” Instead, common excipients behave differently with different molecules. This work, therefore, provides “a mechanistic, physics-based framework that can support the rational design and optimization of antibody formulations,” the team pointed out.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/choice-of-excipients-dramatically-affects-antibody-solubility/">Choice of Excipients Dramatically Affects Antibody Solubility</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Red Light Supercharges Anti&#45;Obesity Drug Precursor</title>
<link>https://edusehat.com/en/red-light-supercharges-anti-obesity-drug-precursor</link>
<guid>https://edusehat.com/en/red-light-supercharges-anti-obesity-drug-precursor</guid>
<description><![CDATA[ Scientists in New Delhi found that red light dramatically boosted lipstatin production in Streptomyces, while reshaping its growth. The work points to illumination as a simple, non-invasive lever for improving yields in microbial biomanufacturing.
The post Red Light Supercharges Anti-Obesity Drug Precursor appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/Mike-Dubey_GBPN_IMAGE_17SEPT26.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 17 Sep 2026 04:00:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Red, Light, Supercharges, Anti-Obesity, Drug, Precursor</media:keywords>
<content:encoded><![CDATA[<p>Sometimes, getting microbes to make more of a valuable compound requires genetic engineering, new nutrients, or a painstakingly redesigned fermentation process. <a href="https://doi.org/10.1007/s00449-026-03411-w" target="_blank" rel="noopener">Researchers in New Delhi have now shown</a> that, for one medically important bacterium, part of the answer could be much simpler: change the color of the light.</p>
<p>Deepanshi Rajput, a doctoral student in biotechnology, and Kashyap Kumar Dubey, PhD, associate professor in the School of Biotechnology at Jawaharlal Nehru University in India, studied <em>Streptomyces toxytricini</em>, a filamentous soil bacterium that naturally produces lipstatin. Lipstatin is especially interesting because it is the natural precursor of orlistat, an anti-obesity drug that works by inhibiting enzymes involved in breaking down dietary fats.</p>
<p>The team grew the bacterium under a spectrum of lighting conditions, including red, green, indigo, blue, yellow, violet, orange, and white light, with darkness serving as a control. What happened under red illumination stood out.</p>
<p>Lipstatin production reached roughly 6 g/L under red light, compared with about 1.2 g/L under white light and just 0.02 g/L in darkness. That translates to roughly a five-fold improvement over white light and about a 300-fold jump over the dark control.</p>
<p>Light was not merely changing how much of the compound the bacteria produced. It was also changing how they physically grew. Microscopy revealed that the bacteria formed dramatically smaller, looser structures under red illumination. Pellets averaged about 81 µm across, compared with roughly 333 µm under white light and 785 µm in darkness.</p>
<p>That architectural shift could matter in industrial fermentation. Dense clumps of filamentous bacteria can hinder the movement of nutrients and oxygen through a culture. Smaller, more dispersed structures might improve mass transfer and create conditions that favor production of secondary metabolites, such as lipstatin.</p>
<p>As the authors reported, their results show that “light acts as an important environmental factor” influencing both the morphology and metabolism of <em>S. toxytricini</em>. A search of the bacterium’s proteins also uncovered two putative bacteriophytochromes—possible red-light-sensing proteins that could help explain how the organism detects illumination.</p>
<p>But the biological mechanism remains unresolved. The researchers stressed that “a direct causal link cannot be established” between the altered pellet structure and increased lipstatin production from the current experiments alone. Functional studies of the suspected photoreceptors, molecular profiling, and validation in larger bioreactors will be needed.</p>
<p>Still, the results suggest that fermentation facilities might eventually gain another surprisingly straightforward control dial. Rather than modifying the microbe itself, a manufacturer could potentially influence what it produces simply by illuminating the bacteria differently—a “useful, non-invasive parameter” that the researchers argued deserves further investigation.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/red-light-supercharges-anti-obesity-drug-precursor/">Red Light Supercharges Anti-Obesity Drug Precursor</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Prime Assembly Expands Genome Editing with Precise, Large&#45;Scale DNA Integration</title>
<link>https://edusehat.com/en/prime-assembly-expands-genome-editing-with-precise-large-scale-dna-integration</link>
<guid>https://edusehat.com/en/prime-assembly-expands-genome-editing-with-precise-large-scale-dna-integration</guid>
<description><![CDATA[ A new genome-editing method, prime assembly, precisely inserts long DNA sequences into targeted genomic locations, potentially enabling mutation-agnostic gene therapies for diverse genetic diseases with fewer individualized edits.
The post Prime Assembly Expands Genome Editing with Precise, Large-Scale DNA Integration appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/01/GettyImages-1189916170.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 17 Sep 2026 04:00:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Prime, Assembly, Expands, Genome, Editing, with, Precise, Large-Scale, DNA, Integration</media:keywords>
<content:encoded><![CDATA[<p>The genome editing toolbox provides unprecedented opportunities to engineer the human genome. However, genome editing for therapeutic benefit continues to have its limitations. Most current methods rely on untargeted gene delivery or short DNA edits that need to be individualized to each patient.</p>
<p>Now, a new paper describes a novel genome engineering method, prime assembly, that allows long DNA fragments to be integrated into precise and programmable target positions within living cells. This approach, which leverages CRISPR-targeted dual flap synthesis, may allow for the development of universal gene therapies.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>This work is published in <em>Nature</em> in the paper, “<a href="https://www.nature.com/articles/s41586-026-11024-2" target="_blank" rel="noopener">Targeted genomic integration and rearrangement using prime assembly</a>.”</p>
<p>Prime assembly builds upon the techniques of prime editing, a technology that allows for precise yet small insertions, deletions, and base swaps. The new method, the authors note, “enables RNA-programmable site-specific integration of single or double-stranded DNA fragments. Unlike homology-directed repair, prime assembly is similarly active in dividing and non-dividing cells.”</p>
<p>The team applied prime assembly to perform targeted exon recoding, transgene integration, and megabase-scale rearrangements, including at therapeutically relevant loci in primary human cells.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>Prime assembly’s single step process writes in new DNA flaps to specific locations in the genome. The flaps serve as tethers designed to grab onto DNA fragments with matching ends. The precisely assembled DNA inserts, which can be one or more gene-sized DNA pieces, become large permanent edits.</p>
<p>“By using prime editing to write in one flap per strand of the genome, the method controls exactly where the DNA replacement starts and ends,” explained Daniel Bauer, MD, PhD, director of the Gene Therapy Program at Boston Children’s Hospital. “Because the method is based on prime editing, it is much less likely to cause off-target effects compared to other gene editing methods.”</p>
<p>One such off-target effect is the potential for toxicity. Untargeted insertion methods can turn on the wrong genes in the wrong context, leading to potentially cancerous outcomes, whereas prime assembly’s targeted insertion approach circumvents the risk. Prime assembly also does not rely on DNA double strand breaks or DNA double strand donors, both of which can be toxic and cause unwanted cell stress. And while other gene editing methods are mostly limited to dividing cells which are rare in the body and more susceptible to unwanted DNA changes, prime assembly works in nondividing cells.</p>
<p>Building on this milestone, the team is looking to further investigate the molecular mechanisms which would allow them to engineer even more efficient and precise systems. As they fine tune their approach, they hope this technology will have downstream impact in the clinic. With the ability to correct multiple mutations at once, this technology could lead to generalizable solutions for treating genetic disorders.</p>
<p>“We’re working to improve the delivery of the prime assembly components to disease-relevant human cells <em>in vivo</em>, such as hematopoietic stem cells for blood disorder therapies,” said Bauer. “We’re also exploring a number of applications of prime assembly to deliver genetic payloads as mutation-agnostic therapies to restore gene control for devastating inherited human diseases with unmet clinical need.”</p>
<p>The post <a href="https://www.genengnews.com/topics/genome-editing/prime-assembly-expands-genome-editing-with-precise-large-scale-dna-integration/">Prime Assembly Expands Genome Editing with Precise, Large-Scale DNA Integration</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Optima Dermatology Welcomes Megan Metheny, NP&#45;C, to Our Stratham, NH Practice </title>
<link>https://edusehat.com/en/optima-dermatology-welcomes-megan-metheny-np-c-to-our-stratham-nh-practice</link>
<guid>https://edusehat.com/en/optima-dermatology-welcomes-megan-metheny-np-c-to-our-stratham-nh-practice</guid>
<description><![CDATA[ Megan Brings More Than a Decade of Experience to Patients in the Seacoast, NH Area  We’re excited to welcome Megan…
The post Optima Dermatology Welcomes Megan Metheny, NP-C, to Our Stratham, NH Practice  appeared first on Optima Dermatology. ]]></description>
<enclosure url="https://optimadermatology.com/wp-content/uploads/2026/09/Blog_Meet-Megan-Metheny_Square.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 17 Sep 2026 00:20:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Optima, Dermatology, Welcomes, Megan, Metheny, NP-C, Our, Stratham, Practice </media:keywords>
<content:encoded><![CDATA[<figure class="wp-block-image size-large"><img fetchpriority="high" decoding="async" width="1024" height="341" src="https://optimadermatology.com/wp-content/uploads/2026/09/Blog_Meet-Megan-Metheny_Banner-1024x341.jpg" alt="" class="wp-image-205152" srcset="https://optimadermatology.com/wp-content/uploads/2026/09/Blog_Meet-Megan-Metheny_Banner-1024x341.jpg 1024w, https://optimadermatology.com/wp-content/uploads/2026/09/Blog_Meet-Megan-Metheny_Banner-300x100.jpg 300w, https://optimadermatology.com/wp-content/uploads/2026/09/Blog_Meet-Megan-Metheny_Banner-768x256.jpg 768w, https://optimadermatology.com/wp-content/uploads/2026/09/Blog_Meet-Megan-Metheny_Banner.jpg 1200w" sizes="(max-width: 1024px) 100vw, 1024px"></figure>



<h2 class="wp-block-heading"><strong>Megan Brings More Than a Decade of Experience to Patients in the Seacoast, NH Area</strong> </h2>



<p class="wp-block-paragraph">We’re excited to welcome Megan Metheny, NP-C, to Optima Dermatology’s Stratham, NH practice as our newest board-certified nurse practitioner.  </p>



<p class="wp-block-paragraph">Megan has been serving patients since 2010 providing medical dermatology care for individuals 13 and older, including skin cancer screenings and treatment for skin cancer, acne, psoriasis, eczema, and more.  </p>



<p class="wp-block-paragraph">After developing clinical expertise as a registered nurse in multiple hospital settings, Megan earned her Master of Science in Nursing at Quinnipiac University, and her Bachelor of </p>



<p class="wp-block-paragraph">Science in Nursing from the University of Saint Joseph, graduating summa cum laude.  </p>



<p class="wp-block-paragraph">She currently maintains membership in the Dermatology Nurses Association, the American Association of Nurse Practitioners, and Sigma Theta Tau International Honor Society of Nursing. </p>



<p class="wp-block-paragraph">Megan is committed to delivering an unparalleled patient experience and looks forward to serving patients in Stratham and around the Seacoast with personalized, comprehensive care. </p>



<h2 class="wp-block-heading"><strong>Passionate Care Delivered by Passionate Experts</strong> </h2>



<p class="wp-block-paragraph">Megan’s approach to care mirrors Optima Dermatology’s mission of treating patients as we would our own family and friends, and she ensures every patient feels seen and cared for during their visit and in ongoing follow-up.  </p>



<p class="wp-block-paragraph">We recently had the opportunity to learn more about Megan, her approach, and the path that led her to become a nurse practitioner. </p>



<hr class="wp-block-separator has-alpha-channel-opacity">



<p class="wp-block-paragraph"><strong>What made you decide to pursue a career in dermatology? What did the path to getting there look like for you?</strong> </p>



<p class="wp-block-paragraph">My path to dermatology started during graduate school at Quinnipiac University when I was placed in a dermatology rotation. I was fortunate to work with an incredible mentor who was passionate about dermatology. She showed me how meaningful the specialty was, and she continues to be my mentor today. </p>



<p class="wp-block-paragraph">After graduation, I began my career as a nurse practitioner in vascular surgery in Connecticut, where my husband and I were living at the time. That experience gave me a strong clinical and procedural foundation early in my career. When we later moved to the Seacoast area in New Hampshire, the door to dermatology finally opened for me, and it felt like the perfect fit. I have been treating patients in the area for 4 years. </p>



<p class="wp-block-paragraph"><strong>What is your favorite aspect of being a board-certified nurse practitioner?</strong> </p>



<p class="wp-block-paragraph">I love the relationships I build with patients over time. In this career, I often have the opportunity to care for patients for many years, whether through managing chronic conditions, performing routine skin checks, or administering regular neurotoxin injections. </p>



<p class="wp-block-paragraph"><strong>What is your approach to treating your patients?</strong> </p>



<p class="wp-block-paragraph">My approach starts with listening. Everyone’s skin, lifestyle, and goals are different, so I like to understand what matters most to each patient before deciding on a treatment plan. </p>



<p class="wp-block-paragraph"><strong>What is your top tip for taking care of your skin?</strong> </p>



<p class="wp-block-paragraph">Wear sunscreen! It’s one of the most important things you can do for your skin every day. I’m a big fan of tinted sunscreen. It provides great sun protection, helps blur imperfections, and gives your skin a really nice, natural glow. </p>



<p class="wp-block-paragraph"><strong>What is one thing you want your patients to know about you?</strong> </p>



<p class="wp-block-paragraph">I value the relationships I build with my patients and want them to feel comfortable (and heard) during their visits. If you’ve researched your condition or have a treatment you’re curious about, I am all ears. Let’s talk about it and work together to find the best plan for your skin and your lifestyle. </p>



<p class="wp-block-paragraph"><strong>What do you like to do when you are not in the office treating patients?</strong> </p>



<p class="wp-block-paragraph">I live on the Seacoast with my husband and our two young kids. Life outside of work is usually busy and fun. We love being outdoors. We enjoy afternoon beach trips, grabbing a sandwich to eat by the water, and stopping for ice cream on the way home. When time allows, I also enjoy fitting in a yoga class. </p>



<hr class="wp-block-separator has-alpha-channel-opacity">



<h2 class="wp-block-heading"><strong>What to Expect From Dermatological Care Delivered by Megan and Her Team</strong> </h2>



<p class="wp-block-paragraph">Patients visiting with Megan and her team at Optima Dermatology will receive the highest quality care backed by decades of advanced training and experience. </p>



<p class="wp-block-paragraph">She is currently accepting new patients at our Stratham, NH location. <a href="https://s.odoro.com/optimaderm/" target="_blank" rel="noreferrer noopener">Request an appointment</a> online or call us at (603) 942-2171.</p>
<p>The post <a href="https://optimadermatology.com/2026/09/16/optima-dermatology-welcomes-megan-metheny-np-c-to-our-stratham-nh-practice">Optima Dermatology Welcomes Megan Metheny, NP-C, to Our Stratham, NH Practice </a> appeared first on <a href="https://optimadermatology.com/">Optima Dermatology</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Call pay for physicians: Who gets it and how much?</title>
<link>https://edusehat.com/en/call-pay-for-physicians-who-gets-it-and-how-much</link>
<guid>https://edusehat.com/en/call-pay-for-physicians-who-gets-it-and-how-much</guid>
<description><![CDATA[ A new report found that only one in five physicians are paid for call, and the amounts that they receive go from a high of more than $2,000 per shift to almost nothing. A Marit Health survey of more than 15,000 physicians in 34 specialties asked physicians whether and how much they’re paid for call. […]
The post Call pay for physicians: Who gets it and how much? appeared first on Today&#039;s Hospitalist. ]]></description>
<enclosure url="https://todayshospitalist.com/wp-content/uploads/2026/09/doc-call-shutterstock_2819406097-9-16-26.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 17 Sep 2026 00:10:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Call, pay, for, physicians:, Who, gets, and, how, much</media:keywords>
<content:encoded><![CDATA[<p>A new report found that only one in five physicians are paid for call, and the amounts that they receive go from a high of more than $2,000 per shift to almost nothing.</p>
<p><a href="https://www.marithealth.com/posts/call-pay-in-medicine-1-in-5-physicians-on-call-are-paid-for-it">A Marit Health survey of more than 15,000 physicians in 34 specialties</a> asked physicians whether and how much they’re paid for call. An analysis of the data from Marit looked at the factors behind hospitals’ decisions to pay for call and the fairness of pay for physicians who take call in the hospital.</p>
<h4><strong>Which specialties are paid to take call?</strong></h4>
<p>Orthopedic surgeons reported being paid for call more than any other specialty, with nearly half (48%) getting compensation. Other specialties that are most likely to be paid for call included neurosurgery (47%), anesthesiology (41%) and oral maxillofacial surgery (39%).</p>
<p>On Marit’s list of specialties that are paid for call, internal medicine was ranked No. 19. That means only 12.6% of internists reported they’re paid for call. (Hospitalists weren’t specified on the list.)</p>
<p>There were specialties that fared worse when it came to taking call. Not a single allergist/immunologist, for example, said they are paid to take call. Among radiation oncologists, 2% were paid for call. The numbers were similarly low for nephrology (4%) and family medicine (9%).</p>
<h4><strong>How much are docs paid per shift for call?</strong></h4>
<p>When it comes to how much physicians are paid for call, neurology topped the list with an average call reimbursement of $2,200. Anesthesiology and radiology tied for the No. 2 spot for call pay at $2,000.</p>
<p>While only about 13% of internists are paid for call, the amount they reported receiving was seventh on Marit’s list: $1,200.</p>
<p>Here’s a look at the highest- and lowest-paid specialties when it comes to call:</p>
<p><strong>Top specialties for call pay</strong></p>
<p>Neurosurgeons: $2,200.</p>
<p>Anesthesiology: $2,000.</p>
<p>Radiology: $2,000.</p>
<p>Oncology: $1,500.</p>
<p>Ob/gyn: $1,325.</p>
<p><strong>Worst specialties for call pay</strong></p>
<p>Pulmonology: $232.</p>
<p>Infectious diseases: $300.</p>
<p>Podiatry: $350.</p>
<p>Pathology: $429.</p>
<p>Family medicine: $480.</p>
<h4><strong>Factors in paying physicians for call</strong></h4>
<p>Analysis from Marit said the decision to pay physicians for call comes down to reimbursement and coverage.</p>
<p>“A hospital that holds a trauma designation needs orthopedics and neurosurgery available around the clock,” Marit said, “or it loses that status. An OR does not run without anesthesia.”</p>
<p>Marit’s analysis also said that cognitive specialties tend to suffer the most financially when it comes to taking call. “These physicians take overnight calls that require clinical judgment,” the analysis concluded, “and roughly six in seven are not paid for it.”</p>
<p>One exception, Marit found, was psychiatry. On the list of specialties paid for call, psychiatry ranked seventh, with 31% of its physicians reporting they’re paid for call. That put psychiatry ahead of general surgery, plastic surgery and gastroenterology.</p>
<p>While the report noted that “nobody bills a procedure for a psychiatric consult at 2 a.m.,” it added that hospitals need to be prepared to cover a psychiatric hold in the ED. As a result, they’re willing to pay psychiatrists for call coverage.</p>
<h4><strong>Where do physicians take call from?</strong></h4>
<p>Marit’s analysis discussed one other factor in physician call: where they’re located when taking call. Marit said the distinction is important because “a meaningful percentage of physicians across several specialties” take call from the hospital, not their homes.‍</p>
<p>Rob Anderson, MD, a founder of Marit and an anesthesiologist, argued “there should be no debate about whether those physicians should be paid.” When physicians give up their sleep and personal time to be in the hospital, he said, they should be paid.</p>
<p>“The fact that a significant portion of internal medicine, ob/gyn and anesthesiology physicians do exactly that without separate call compensation is one of the most striking findings in this data,” Anderson wrote.</p>
<p><a href="https://www.marithealth.com/posts/call-pay-in-medicine-1-in-5-physicians-on-call-are-paid-for-it">For more information, see Marit’s analysis of its survey data. </a></p>
<p>The post <a href="https://todayshospitalist.com/call-pay-for-physicians-who-gets-it-and-how-much/">Call pay for physicians: Who gets it and how much?</a> appeared first on <a href="https://todayshospitalist.com/">Today's Hospitalist</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Microprotein Atlas Links Brain Immune Cell Dysfunction to Alzheimer’s</title>
<link>https://edusehat.com/en/microprotein-atlas-links-brain-immune-cell-dysfunction-to-alzheimers</link>
<guid>https://edusehat.com/en/microprotein-atlas-links-brain-immune-cell-dysfunction-to-alzheimers</guid>
<description><![CDATA[ Built from transcriptomic and mass spectrometry data, the atlas uncovered more than 1,000 previously uncharacterized microproteins and pointed to a potential connection between one microprotein and microglial dysfunction in Alzheimer’s disease.
The post Microprotein Atlas Links Brain Immune Cell Dysfunction to Alzheimer’s appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-1869420709.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 16 Sep 2026 11:40:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Microprotein, Atlas, Links, Brain, Immune, Cell, Dysfunction, Alzheimer’s</media:keywords>
<content:encoded><![CDATA[<p>Scientists studying Alzheimer’s disease have long focused on genes, proteins, and cells, but one class of molecules has remained largely outside the playbook: microproteins. These small proteins, produced from small open reading frames (ORFs) and typically measuring 150 amino acids or fewer, have been difficult to detect and study. Yet growing evidence suggests they may have important roles in health and disease.</p>
<p>Now, researchers at the Salk Institute have created what they describe as the first microprotein atlas of the human frontal cortex with and without Alzheimer’s disease. The study, “<a href="https://www.nature.com/articles/s43587-026-01207-x" target="_blank" rel="noopener">A microprotein atlas of the human frontal cortex in Alzheimer’s disease</a>,” was published in <em>Nature Aging</em>. The resource integrates transcriptomics, mass spectrometry, and deep-learning-predicted spectra across postmortem brain samples to identify microproteins that have been overlooked in standard protein catalogs.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>“We still do not fully understand the molecular mechanisms of healthy aging, and that is especially true for microproteins, which have been inadvertently overlooked for decades,” said senior and co-corresponding author Alan Saghatelian, PhD, professor and the Dr. Frederik Paulsen Chair at Salk, in a press release. “Our atlas allows scientists to systemically investigate microproteins in aging and neurodegeneration, which should bring us closer to understanding and tackling diseases like Alzheimer’s or Parkinson’s.”</p>
<p>Saghatelian told <em>GEN </em>the work began with a basic limitation in how proteomes are annotated. “Every reference proteome is built on gene models that exclude smORFs by construction. So the first motivation was straightforward: build a search database that can actually see these sequences, and point it at the deepest human brain proteomics data that exists.”</p>
<p>The atlas was built using data from hundreds of postmortem human frontal cortex samples from individuals with and without Alzheimer’s disease, including samples made available through the Religious Orders Study/Memory and Aging Project cohort. The team analyzed existing native transcriptomic and mass spectrometry data with custom computational tools, including ShortStop, an AI-powered microprotein-finding tool developed in Saghatelian’s lab.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>“We were able to take all these technologies and tools and reapply them to existing data from nearly 500 brains to find new microproteins,” said first and co-corresponding author Brendan Miller, PhD, a postdoctoral researcher in Saghatelian’s lab. “We were able to create an entirely new database that researchers can download and use to better interpret functions of genes.”</p>
<p>In total, the researchers identified 1,067 previously uncharacterized microproteins absent from reviewed UniProtKB entries, supported by high-confidence spectral support, according to the paper. Some of these microproteins were expressed differently in Alzheimer’s disease samples compared with non-Alzheimer’s samples, and the paper reports that Alzheimer’s disease cells tended to show higher overall microprotein expression.</p>
<p>The investigators then focused on microglia, which are known to change with aging and neurodegeneration. Their analysis highlighted a small open reading frame at the MKKS locus encoding a 63-amino-acid microprotein that appeared to be the predominant translation product at that locus and is downregulated in Alzheimer’s disease. When the researchers knocked out the microprotein-making gene in microglia, mitochondrial respiration was impaired, suggesting a role for the microprotein in microglial bioenergetics.</p>
<p>The MKKS finding also underscored a broader issue with relying only on canonical protein annotations. “The general implication is uncomfortable: the most abundant and most tissue-relevant protein product at a locus can be the one that isn’t annotated,” added Saghatelian.</p>
<p>He also cautioned that not every microprotein identified in the atlas should be assumed to be functional. “There are two ways to read an expressed microprotein. It may be a marker—evidence that its gene’s transcription or splicing is disrupted—without the peptide itself doing anything. Or it may be a bioactive molecule with biology distinct from the canonical product at that locus.”</p>
<p>The findings point to a possible connection between microproteins and immune cell dysfunction in Alzheimer’s disease. “There is sometimes an assumption that we know everything about our genome, and we know all the genes our cells can make—that’s just not true,” Saghatelian said. “What we know is constantly expanding, and this atlas makes it that much easier to study microproteins in life science research.” Beyond Alzheimer’s disease, the publicly available atlas could serve as a framework for mapping microproteins in other brain regions, tissues, and disease contexts.</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/microprotein-atlas-links-brain-immune-cell-dysfunction-to-alzheimers/">Microprotein Atlas Links Brain Immune Cell Dysfunction to Alzheimer’s</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>How to Manage Stress During Medical School Without Sacrificing Your Performance</title>
<link>https://edusehat.com/en/how-to-manage-stress-during-medical-school-without-sacrificing-your-performance</link>
<guid>https://edusehat.com/en/how-to-manage-stress-during-medical-school-without-sacrificing-your-performance</guid>
<description><![CDATA[ Stress is part of medical school. Between lectures, clinical rotations, research, exams, residency extracurriculars, and somehow trying to make time for what you enjoy, it’s normal to feel overwhelmed at times.   The challenge isn’t eliminating stress completely, that simply isn’t realistic. Instead, the goal is learning how to manage stress in a way that […]
The post How to Manage Stress During Medical School Without Sacrificing Your Performance appeared first on Elite Medical Prep. ]]></description>
<enclosure url="https://elitemedicalprep.com/wp-content/uploads/2026/09/pexels-anthonyshkraba-production-8278873-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 16 Sep 2026 04:50:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>How, Manage, Stress, During, Medical, School, Without, Sacrificing, Your, Performance</media:keywords>
<content:encoded><![CDATA[<p><span>Stress is part of medical school. Between lectures, clinical rotations, research, exams, residency extracurriculars, and somehow trying to make time for what you enjoy, it’s normal to feel overwhelmed at times.</span></p>
<p> </p>
<p><span>The challenge isn’t eliminating stress completely, that simply isn’t realistic. Instead, the goal is learning how to manage stress in a way that allows you to continue performing well academically without feeling like you’re constantly running on empty.</span></p>
<p> </p>
<p><span>Many students assume they have to choose between taking care of themselves and succeeding in medical school. Fortunately, that isn’t true. Too much stress is unhealthy but using a typical amount of stress to your advantage may actually improve your productivity, learning, memory, and long-term academic performance.</span></p>
<p> </p>
<h2><strong>Stop Waiting for Life to “Calm Down”</strong></h2>
<p><span>One of the biggest mistakes students make is believing stress management can wait until after the next milestone.</span></p>
<ul>
<li><span>After this anatomy exam.</span></li>
<li>After <a href="https://elitemedicalprep.com/shelf-exams-vs-step-2-ck/">shelf exams</a>.</li>
<li>After <a href="https://elitemedicalprep.com/usmle-step-1-tutoring/">Step 1</a>.</li>
<li>After <a href="https://elitemedicalprep.com/usmle-step-2ck-tutoring/">Step 2</a>.</li>
<li>After <a href="https://elitemedicalprep.com/category/residency-matching/">residency applications</a>.</li>
</ul>
<p> </p>
<p><span>The problem is that medical training is built around continuous milestones. And these milestones don’t stop coming for </span><i><span>years</span></i><span>. If you postpone taking care of yourself until everything feels easier, you’ll find that an entire decade of your life is passing by! </span><span>Instead of searching for a completely <a href="https://elitemedicalprep.com/spotting-early-signs-of-burnout-in-medical-students/">stress-free season</a>, focus on building small habits that fit into your current schedule.</span></p>
<p> </p>
<h2><strong>Prioritize Consistency Over Marathon Study Sessions</strong></h2>
<p><span>Many students believe productivity means studying for as many hours as possible. </span><span>In reality, consistency usually produces much better results.</span></p>
<p> </p>
<p><span>Studying effectively for several focused hours each day often leads to stronger retention than repeated cycles of procrastination followed by exhausting all-night study sessions. In fact, taking mental health breaks can give your brain time to cool off and reset, making your studying more effective when you return. </span></p>
<p> </p>
<p><span>Building a routine also reduces decision fatigue. When your <a href="https://elitemedicalprep.com/the-ultimate-10-week-step-1-study-schedule/">study schedule</a> becomes predictable, you spend less mental energy deciding what to do and more energy actually learning.</span></p>
<p> </p>
<h2><strong>Schedule Breaks </strong></h2>
<p><span>One common misconception is that breaks should only happen after you’ve finished all your work. </span><span>Unfortunately, in medical school there is almost always more work waiting. </span><span>Instead of treating breaks as rewards, think of them as maintenance.</span></p>
<p> </p>
<p><span>Taking a short walk, eating lunch away from your computer, calling a friend, or spending thirty minutes doing something enjoyable can help reset your focus and improve the quality of your studying afterward. </span><span>Short breaks often increase productivity far more than trying to push through mental fatigue.</span></p>
<p> </p>
<h2><strong>Learn the Difference Between Busy and Productive</strong></h2>
<p><span>Medical students often confuse activity with progress. </span><span>Watching six hours of lectures without testing yourself may make you feel like you accomplished something, but <a href="https://elitemedicalprep.com/category/flashcards/">active recall</a> and practice questions usually produce much stronger learning. </span><span>The same principle applies to stress.</span></p>
<p> </p>
<p><span>Sometimes students feel overwhelmed because they are trying to do everything rather than focusing on the highest-yield tasks. </span><span>Before each study session, ask yourself: </span><i><span>What is the single most important thing I need to accomplish today? </span></i><span>That simple question can make large workloads feel much more manageable.</span></p>
<p> </p>
<h2><strong>Protect Your Sleep</strong></h2>
<p><span>When exams approach, sleep is often the first thing students sacrifice. </span><span>While staying up late may seem productive in the moment, chronic sleep deprivation affects concentration, memory formation, decision-making, and emotional regulation, all skills that medical students rely on every day.</span></p>
<p> </p>
<p><span>The irony is that studying an extra hour while exhausted is often less effective than sleeping and approaching the material with a rested brain. </span><span>Sleep isn’t time lost. It is part of learning. And it’s </span><i><span>essential</span></i><span> to maintaining your health and longevity. </span></p>
<p> </p>
<h2><strong>Build and Maintain Your Support System</strong></h2>
<p><span>Stress feels much heavier when you’re carrying it alone. </span><span>One of the healthiest things students can do is develop relationships with classmates, mentors, faculty members, friends, and family before difficult periods arise. </span><span>Sometimes managing stress simply means having someone who understands what you’re experiencing.</span></p>
<p> </p>
<p>Whether it’s discussing difficult rotations, reviewing challenging concepts together, or working with a <a class="decorated-link" href="https://elitemedicalprep.com/get-started/" target="_new" rel="noopener" data-start="2597" data-end="2650">medical school tutor</a>, supportive relationships can make medical school feel much less isolating.</p>
<p> </p>
<h2><strong>Accept That Perfection is Simply Impossible</strong></h2>
<p><span>Medicine offers endless opportunities to feel behind. </span><span>There is always another research project, another leadership position, another volunteer opportunity, another question bank, or another resource someone recommends. </span><span>Trying to maximize every area simultaneously is one of the fastest ways to increase stress.</span></p>
<p> </p>
<p><span>Successful students learn how to prioritize. They recognize that saying yes to every opportunity often means doing none of them particularly well. </span><span>Sometimes protecting your well-being means giving yourself permission to do “enough” instead of chasing perfection.</span></p>
<p> </p>
<h2><strong>Don’t Ignore Physical Health</strong></h2>
<p><span>Stress management isn’t only psychological. </span><span>Simple habits like regular exercise, staying hydrated, eating consistently, and getting outside can have surprisingly powerful effects on concentration and mood. </span><span>You don’t need a complicated wellness routine.</span></p>
<p> </p>
<p><span>Even twenty minutes of movement, a healthy meal, or a walk between study sessions can improve both mental clarity and emotional resilience. Throughout medical school I personally always fit in my nightly workouts and they always helped me stay healthy and productive.  </span><span>These habits may feel small, but their cumulative effect over months of training can be significant.</span></p>
<p> </p>
<h2><strong>Know When Stress Is Becoming Something More</strong></h2>
<p><span>Stress will wax and wane throughout medical school and in life in general and that’s normal. Feeling stressed before an exam is normal. </span><span>Feeling overwhelmed during a difficult rotation is normal. </span><span>However, if stress becomes persistent, begins affecting sleep, relationships, concentration, or your ability to function day to day, it’s important to seek support.</span></p>
<p> </p>
<p><span>Medical schools increasingly recognize the importance of student well-being and often provide confidential counseling, wellness resources, and academic support services. </span><span>Seeking help is not a sign that you’re falling behind. It is simply another way of taking care of yourself as you work toward becoming a physician. Get to know your school’s resources </span><i><span>before</span></i><span> you need to use them. </span></p>
<p> </p>
<h2><strong>The Bottom Line</strong></h2>
<p><span>Medical school will always involve some degree of stress, but stress does not have to control your experience or your performance.</span></p>
<p> </p>
<p><span>The students who thrive over the long term are usually not those who never feel overwhelmed. They are the ones who develop healthy routines, protect their sleep, study efficiently instead of endlessly, maintain supportive relationships, and understand that taking care of themselves actually helps them become better learners.</span></p>
<p> </p>
<p><span>You don’t have to choose between academic success and personal well-being. More often than not, they go hand in hand. By managing stress intentionally instead of reacting to it, you’ll not only perform better during medical school, you’ll also build habits that will serve you throughout residency and the rest of your medical career.</span></p>
<p> </p>
<p>If managing your workload or preparing for an upcoming exam still feels overwhelming, you don’t have to figure it out alone. An <a class="decorated-link" href="https://elitemedicalprep.com/get-started/" target="_new" rel="noopener" data-start="931" data-end="988">Elite Medical Prep tutor</a> can help you create a personalized, manageable study plan based on your schedule, learning needs, and academic goals.</p>
<p>The post <a href="https://elitemedicalprep.com/how-to-manage-stress-during-medical-school/">How to Manage Stress During Medical School Without Sacrificing Your Performance</a> appeared first on <a href="https://elitemedicalprep.com/">Elite Medical Prep</a>.</p>]]> </content:encoded>
</item>

<item>
<title>AI models need more data about biology, and OpenAI is paying to create it</title>
<link>https://edusehat.com/en/ai-models-need-more-data-about-biology-and-openai-is-paying-to-create-it</link>
<guid>https://edusehat.com/en/ai-models-need-more-data-about-biology-and-openai-is-paying-to-create-it</guid>
<description><![CDATA[ Last year Ruxandra Teslo, a policy analyst who focuses on clinical trials, posted an idea for supercharging medical AI systems: Use data from failed biotech companies. By bidding at their bankruptcy proceedings, she proposed, it might be possible to obtain detailed regulatory filings, manufacturing strategies, and safety data—types of information usually considered trade secrets. She… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/09/OpenAI-grants.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 16 Sep 2026 04:35:01 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>models, need, more, data, about, biology, and, OpenAI, paying, create</media:keywords>
<content:encoded><![CDATA[<p></p>





<p>Last year Ruxandra Teslo, a policy analyst who focuses on clinical trials, posted an idea for supercharging medical AI systems: Use data from failed biotech companies.</p>



<p>By bidding at their bankruptcy proceedings, she proposed, it might be possible to obtain detailed regulatory filings, manufacturing strategies, and safety data—types of information usually considered trade secrets. She called these documents “<a href="https://ifp.org/biotechs-lost-archive/">biotech’s lost archive</a>” and said they could be used to help train AIs that would act as powerful copilots in the often opaque drug approval process. </p>



<p>Today the OpenAI Foundation, the <a href="https://openai.com/our-structure/">nonprofit parent of OpenAI</a>, said it would fund her idea as part of a new effort it calls Public Data for Health, which aims to help artificial intelligence make big leaps in medicine by paying to create “high-quality scientific datasets.”</p>



<p>The basic idea is that AI isn’t going to be capable of making important breakthroughs in curing disease unless researchers can feed the models much more information than they have so far. </p>



<p>“Everyone is recognizing that data is the biggest bottleneck in successfully applying AI to biology,” says Morgan Levine, a former vice president for computation at Altos Labs, a longevity company.</p>





<p>In its initial round of data grants, the OpenAI Foundation also announced that it would give $40 million to a program to collect data about novel cancer vaccines at the University of North Carolina, Chapel Hill, and support <a href="https://openadmet.org/">OpenAdmet,</a> a group that runs competitions in which researchers try to predict drug effects. </p>



<p>Teslo’s idea for a biotech archive received $500,000 and will be pursued by 1Day Sooner, an advocacy group representing clinical trial volunteers, which she advises.</p>



<p>“We expect many remaining breakthroughs in preventing and curing disease to come from pairing the intelligence of new models with more observations of the world—in other words, more data,” the OpenAI Foundation said in a statement.</p>



<p>OpenAI started as a nonprofit, but leader Sam Altman restructured it to form a for-profit corporation that develops new models, launches products, and is now planning an initial public offering of stock that could value it<a href="https://www.reuters.com/business/openai-lays-groundwork-juggernaut-ipo-up-1-trillion-valuation-2025-10-29/"> at $1 trillion</a>.</p>



<p>Because the foundation holds a<a href="https://openai.com/our-structure"> 26% equity stake</a> in OpenAI, it is now be on track to become the richest charitable organization on the planet, potentially sitting on $250 billion in stock value. (By comparison, the Gates Foundation and a trust associated with it held about $180 billion at the end of 2025.)  </p>



<p>Making good use of that kind of money will not be easy. The foundation, based in San Francisco, is still hiring for<a href="https://openaifoundation.org/careers#open-roles"> many key roles</a> and started ramping up its grantmaking only this year. Its largest single gift so far, of $100 million, was awarded in August to the<a href="https://files.commonhealthcoalition.org/storage/v1/object/public/resource-files/B2FNews.pdf"> Common Health Coalition</a>, an organization that helps patients get access to drugs for hepatitis C.</p>



<p>OpenAI’s charitable efforts come even as apocalyptic fears have broken out about the possibility that runaway AI could<a href="https://www.nytimes.com/2026/09/10/science/ai-humanity-risk.html"> wipe out all human life</a>, possibly by launching a deadly bioweapon.</p>



<p>Those fears have been stoked by AI company insiders, some of whom say the chance of human extinction within the next decade is <a href="https://x.com/EvanHub/status/2097497037956891126">10% or more</a>. Last week, Altman and xAI founder Elon Musk both<a href="https://www.theguardian.com/technology/2026/sep/14/ai-ceo-safety-slowdown"> endorsed</a> a call by Anthropic CEO Dario Amodei to “slow the pace at which we improve the capabilities of AI models” so that risk prevention can catch up.</p>



<p>Jacob Trefethen, an executive at the foundation, says it essentially operates separately from OpenAI but shares an official mission of ensuring that artificial intelligence “benefits all of humanity.”</p>



<p>“We’re starting grantmaking when we think the best way to achieve that mission is to make grants to external nonprofits, research institutions, and other third parties,” Trefethen said in an interview. He says the foundation hopes to give away $1 billion by the end of the year. </p>



<p>The $500,000 grant to 1Day Sooner will help the group prove it can obtain the data troves of bankrupt companies, says the organization’s president and cofounder, Josh Morrison. He thinks nonexclusive copies of company datasets could be acquired for only “a few tens of thousands of dollars” each.</p>





<p>His organization is currently in possession of <a href="https://www.ctdcommons.org/">three datasets,</a> two of them donated by Lumen Bioscience, a biotech that previously used the Chapter 11 strategy to gain insights into another company’s drug development efforts. </p>



<p>Morrison says two other attempts to obtain drug company files this year proved unsuccessful, after 1Day Sooner’s bids were not accepted. </p>



<p>Bankruptcies could become what some are calling a <a href="https://arstechnica.com/tech-policy/2026/09/panic-builds-over-bankrupt-spirits-looming-data-sale-to-google/">“new land grab”</a> for AI training. Last month, Google won a bid to take over the corporate data of the failed carrier Spirit Airlines, <a href="https://time.com/article/2026/08/25/google-spirit-airlines-ai-data-RL/">including 100 million emails</a>. That led to objections from flight attendants and others who worried that private or proprietary data could be exposed. </p>



<p>The drug company files that 1Day Sooner is seeking are known as common technical documents. They typically contain the back-and-forth between companies and regulators, as well as detailed scientific and medical measurements, and essentially provide everything that is known about a drug.</p>



<p>According to Teslo, who is a writer for <a href="https://worksinprogress.co/our-authors/ruxandra-tesloianu/">Works In Progress</a> and a nonresident fellow at the Institute for Progress, a think tank in Washington, DC, a stockpile of such files could help turn an AI into a regulatory expert, which in her view could be one of the main ways AI helps speed cures to market.</p>



<p>“People say ‘We will invent AI, and AI will cure cancer,’ but that’s very removed from the messy reality and the regulatory process,” she says. “About 70% of the money and time in drug development is spent in clinical development—organizing the trials and testing the drug—but despite that, the process is basically a black box, especially for small biotech companies generating the innovations.” </p>]]> </content:encoded>
</item>

<item>
<title>Exosomes Linked to Nerve Irritation, Dysfunction, and Lingering Pain After Shingles</title>
<link>https://edusehat.com/en/exosomes-linked-to-nerve-irritation-dysfunction-and-lingering-pain-after-shingles</link>
<guid>https://edusehat.com/en/exosomes-linked-to-nerve-irritation-dysfunction-and-lingering-pain-after-shingles</guid>
<description><![CDATA[ The study suggests that exosomes in the blood may promote the continued nerve irritation and dysfunction that underly why some people with shingles experience lingering pain long after the varicella zoster virus has cleared the body. 
The post Exosomes Linked to Nerve Irritation, Dysfunction, and Lingering Pain After Shingles appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/07/GettyImages-1466684658.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 16 Sep 2026 04:30:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Exosomes, Linked, Nerve, Irritation, Dysfunction, and, Lingering, Pain, After, Shingles</media:keywords>
<content:encoded><![CDATA[<p>The results of a study by researchers at the University of Colorado Anschutz suggest that that extracellular vesicles known as exosomes in the blood are the likely culprit behind why some people with shingles experience lingering pain—post-herpetic neuralgia (PHN)—long after the causative varicella zoster virus (VZV) has cleared the body.</p>
<p>Exosomes are microscopic packages released by cells that carry proteins and other molecules throughout the body. The research team found that a shingles infection can cause nerve cells to release inflammatory signals and become highly active. When investigators exposed healthy nerve cells in the lab to exosomes collected from the blood of people with PHN, they found that the exosomes triggered in the nerve cells many of the same harmful changes seen during viral infection, even though no virus was present.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>The findings suggest that PHN may develop because the body fails to fully turn off the healing response after shingles. Even after the virus has been cleared, exosomes continue delivering damaging messages that prevent nerves from recovering normally.</p>
<p>The study results indicate that chronic shingles pain may not simply be the result of damage caused during the initial infection, the study authors noted. Instead, biological signals carried by exosomes may continue to keep nerve cells in an irritated, dysfunctional state and prevent them from healing. The researchers describe this as a “failure-to-resolve” model, where the nervous system becomes stuck in a cycle of inflammation and abnormal nerve remodeling. This opens the door to entirely new approaches for predicting, preventing, and treating post-herpetic neuralgia.</p>
<p>The researchers, headed by Andrew Bubak, PhD, associate professor of neurology at CU Anschutz who studies the role of exosomes in infectious disease, reported their findings in Annals of Neurology, in a paper titled, “<a href="https://doi.org/10.1002%2Fana.78352" target="_blank" rel="noopener">Circulating Exosomes Drive Persistent Neuronal Dysfunction in Post-Herpetic Neuralgia Patients</a>,” concluding, “These findings establish a failure-to-resolve model in which persistent exosome-mediated signaling sustains maladaptive neuronal remodeling after viral clearance, identifying circulating exosome cargo as previously unreported mechanistic contributors to PHN pathogenesis and potential therapeutic targets.”</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>Varicella zoster virus can establish lifelong latency in sensory ganglia subsequent to primary infection and reactivate to cause herpes zoster—HZ; shingles—the authors explained. “Whereas most individuals recover from HZ, a substantial subset develop post-herpetic neuralgia (PHN), commonly defined as pain persisting for more than three months after rash …”. However, the mechanisms driving the change from acute viral injury to chronic neuropathic pain aren’t well understood. Bubak said, “We can completely stop the infection, yet in some patients the pain does not go away.”</p>
<p>The team’s prior work had demonstrated that plasma-derived exosomes from individuals with acute zoster infection, while non-infectious, carry prothrombotic and immunoregulatory cargo, and can activate platelets and induce proinflammatory cytokine production in vascular cells, promoting an inflammatory state.</p>
<p>Through their newly reported study the scientists discovered that nerve cells infected with the shingles virus in the laboratory became inflamed and showed signs of stress and irritation. Exposure to PHN patient-derived exosomes triggered inflammation in nerve cells and reduced the ability of nerves to grow and repair themselves. Exosome exposure also caused structural changes that may make nerves function abnormally and led to increased production of molecules associated with chronic pain. The exosomes didn’t kill the nerve cells and rather appeared to keep them in an unhealthy, dysfunctional state.</p>
<p>The researchers expected to see increases in the usual pain-signaling channels found on nerve cells. Instead, they found those channels were actually reduced. At the same time, levels of substance P, a chemical messenger involved in pain transmission, increased. This suggests that chronic shingles pain may be driven less by traditional nerve firing and more by ongoing chemical signals that keep the pain system activated. “Collectively, our findings point toward a potential ‘failure-to- resolve’ model in which PHN arises not from a fundamentally distinct biological process, but from the persistence and amplification of an initially adaptive, exosome-driven neuronal response,” the authors noted. Bubak said the findings could lead to new therapies to target these exosomes and relieve the pain.</p>
<p>Typical antiviral therapies such as acyclovir and valacyclovir target the replicating virus but do not consistently prevent PHN, “… reinforcing the notion that mechanisms independent of ongoing viral replication sustain the pathological state,” the team continued. “This is consistent with our findings, which suggest that non-infectious circulating exosomes, once generated during acute infection, persist and drive neuronal dysfunction independently of ongoing viral replication.”</p>
<p>At the same time, Bubak said, if the exosomes maintain this irritable state within the cell, they could also carry therapeutic agents to the target that block specific proteins and help nerves recover and regrow normally after shingles. “If exosome cargo contributes to the maintenance of the irritable nociceptor state, then circulating exosomes may represent both a source of therapeutic targets and a minimally invasive biomarker platform,” the authors also noted. “Early exosome profiles during acute HZ could potentially identify individuals at risk of developing PHN, enabling stratification and targeted intervention prior to the establishment of chronic symptoms.”</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>Bubak added: “This is an important discovery, one that offers hope to those who continue to struggle with often intense pain following infection with shingles.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/exosomes-linked-to-nerve-irritation-dysfunction-and-lingering-pain-after-shingles/">Exosomes Linked to Nerve Irritation, Dysfunction, and Lingering Pain After Shingles</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Consolidating Antibody Discovery Data with an AI Platform</title>
<link>https://edusehat.com/en/consolidating-antibody-discovery-data-with-an-ai-platform</link>
<guid>https://edusehat.com/en/consolidating-antibody-discovery-data-with-an-ai-platform</guid>
<description><![CDATA[ The Sapio Scientific AI platform gives scientists a single, structured environment where experimental records connect directly to client deliverables and where time spent on data consolidation becomes time spent on science.
The post Consolidating Antibody Discovery Data with an AI Platform appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-1209662272.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 16 Sep 2026 00:20:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Consolidating, Antibody, Discovery, Data, with, Platform</media:keywords>
<content:encoded><![CDATA[<p>FairJourney Bio (FJBio) selected the Sapio Scientific AI platform, including Sapio’s LIMS, ELN, and AI co-scientist solutions to replace spreadsheet-based records and manual reporting processes across its international operations.</p>
<p>FJBio is a global antibody discovery and engineering partner. Founded in 2012, the company works on taking programs from target to preclinical candidate within a single integrated workflow, run by one team across three centers of excellence: Porto (Portugal), Cambridge (U.K.), and San Diego (U.S.). The antibody company completed more than 1,400 programs for over 250 industry partners across pharma, biotech, and academia, with 20 partner assets in clinical trials.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>The volume and complexity of experimental data generated across those programs made consistent, structured records a scientific and operational priority for FJBio, according to Sapio Sciences’ CCO Mike Hampton, who added that the company’s AI platform will serve as the informatics backbone across all of FJBio’s discovery and cell sciences operations.</p>
<p></p><h4><strong>Provides a single entity registry</strong></h4>

<p>Sapio’s ELN solution will record experimental data across phage display, screening, and cell sciences programs, replacing the need for scientists to capture data on paper templates before manually re-entering results into spreadsheets. As FJBio’s program portfolio has grown across three sites, the Sapio LIMS gives the company a single entity registry, from target registration through clone identification and screening results, searchable across programs, points out Hampton.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>The solution is also designed to ensure integration of lab instruments, connecting instrument output directly to Sapio’s experiment records and eliminating manual data transcription at the bench. Structured client data reports, that were assembled by hand from individual experiment records will now come straight out of the platform, expected to return up to 40% of scientific staff time back to discovery, says a Sapio spokesperson.</p>
<p>“FairJourney Bio runs discovery programs of genuine depth and complexity across multiple international sites,” comments the spokesperson. “The Sapio Scientific AI platform gives their scientists a single, structured environment where experimental records connect directly to client deliverables and where time spent on data consolidation becomes time spent on science.”</p>
<p><figure aria-describedby="caption-attachment-337942" class="wp-caption alignleft"><img decoding="async" class="size-medium wp-image-337942" src="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2244339001-300x150.jpg" alt="digital dna" width="300" height="150" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2244339001-300x150.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2244339001-768x384.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2244339001-696x348.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2244339001.jpg 836w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">FairJourney Bio selected the Sapio Scientific AI platform, including Sapio’s LIMS, ELN, and AI co-scientist solutions. [BlackJack3D/Getty Images]</figcaption></figure>Sapio’s Scientific AI Platform data model, and its ability to support full traceability from target registration through screening and hit identification, provided the technical foundation FJBio needed, states José Vidal, COO at FJBio. The inclusion of Elain, Sapio’s native AI co-scientist, rather than a bolt-on capability, was a further differentiator for FJBio as it looks to build long-term informatics capability alongside its expanding discovery operations.</p>
<p>“As our operations have grown across three international sites, we needed an informatics platform that could keep pace with that responsibility,” says Vidal. “The Sapio Platform gives our scientists a single connected environment for every experiment, every sample and every result, and it holds that data to the integrity and security standards our clients expect.”</p>
<p>Elain brings intelligence directly into FJBio’s scientific workflows, says Hampton. Working across the structured experimental data held within the Sapio Platform, Elain enables scientists to interact with their data using natural language, without leaving the environment where their experiments, samples and results are managed, he explains.</p>
<p class="trimmed"> </p>
<p>The post <a href="https://www.genengnews.com/topics/artificial-intelligence/consolidating-antibody-discovery-data-with-an-ai-platform/">Consolidating Antibody Discovery Data with an AI Platform</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Right Resin, Right Order: A Two&#45;Step Polishing Strategy for Bispecific Antibodies</title>
<link>https://edusehat.com/en/right-resin-right-order-a-two-step-polishing-strategy-for-bispecific-antibodies</link>
<guid>https://edusehat.com/en/right-resin-right-order-a-two-step-polishing-strategy-for-bispecific-antibodies</guid>
<description><![CDATA[ In this GEN webinar, our expert speaker, Emily Gaither, will present a systematic path from high-throughput resin screening to the selection and sequencing of two polishing steps, using emicizumab, an asymmetric IgG4 bsAb as a case study. 
The post Right Resin, Right Order: A Two-Step Polishing Strategy for Bispecific Antibodies appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/Getty_2238464565_HPLCAutosampler.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 16 Sep 2026 00:20:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Right, Resin, Right, Order:, Two-Step, Polishing, Strategy, for, Bispecific, Antibodies</media:keywords>
<content:encoded><![CDATA[<p></p><p></p><div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex"><p class="is-layout-flow wp-block-column-is-layout-flow"></p><div class="wp-block-column"></div><p></p></div><p></p><p></p><p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Register Now</button></p><p></p><p></p><h3 class="w-full text-left">
    <strong>
            </strong>
</h3>
<div class="flex flex-row m-0-auto items-stretch justify-center flex-wrap mb-4">
    
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3 presenter-card">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/09/EG-Headhsot.jpg" class="h-full w-full object-cover" alt="Image of Emily Gaither">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Emily Gaither</h2>
                <h5 class="mt-0 !text-[15px]">Engineer III, Downstream Purification<br>Thermo Fisher Scientific</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/09/EG-Headhsot.jpg" alt="Image of Emily Gaither">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Emily Gaither</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Emily Gaither is a bioprocessing engineer specializing in downstream purification at Thermo Fisher Scientific. She has over five years of experience in downstream process development, with expertise in downstream process development, characterization, scale up and manufacturing implementation. Prior to joining Thermo Fisher Scientific in 2021, Emily worked at the University of Illinois Urbana-Champaign, where she supported bioengineering research and laboratory automation. Emily holds a bachelor’s degree in biology from North Central College.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog></div>

<p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-malblocks-webinars-info"></p><div><strong>Broadcast Date:</strong> <time>Thursday, October 8, 2026</time><br><ul><li><strong>Time:</strong> <time datetime="2026-10-08T15:00:06.000Z">08:00 PDT, 11:00 EDT, 17:00 CET</time></li></ul></div><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p></p><div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex"><p></p><div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"><p class="wp-block-paragraph">Bispecific antibodies can create purification challenges that conventional monoclonal antibody platform polishing is not always equipped to solve, with product-related variants “misbehaving” and closely resembling the desired heterodimer. Effective and efficient process development depends not only on identifying the appropriate selectivity from a toolbox of chromatography resins, but also how efficiently complementary unit operations interconnect for manufacturing.</p><p></p><p></p><p class="wp-block-paragraph">In this <em>GEN</em> webinar, our expert speaker, Emily Gaither, will present a systematic path from high-throughput resin screening to the selection and sequencing of two polishing steps, using emicizumab, an asymmetric IgG4 bsAb as a case study. She will compare alternative process configurations and examine the purity, recovery, and process-performance tradeoffs used to identify a preferred downstream polishing train. Key takeaways from the webinar include:</p><p></p><p></p><p></p><ul class="wp-block-list"><p></p><li>A systematic approach to screening polishing resins for bsAbs</li><p></p><p></p><p></p><li>Strategies for matching resin selectivity to key impurities</li><p></p><p></p><p></p><li>Insights into how polishing resin selection affects process performance</li><p></p><p></p><p></p><li>Criteria for balancing purity, yield, loading, and robustness</li><p></p></ul><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-paragraph"><em>A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelist.</em></p><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-paragraph"><strong>Produced with support from:</strong></p><p></p><p></p><div class="wp-block-image"><p><figure class="alignleft size-medium"><a href="https://www.thermofisher.com/" target="_blank" rel=" noreferrer noopener"><img decoding="async" width="300" height="138" src="https://www.genengnews.com/wp-content/uploads/2023/03/ThermoFisher_logo-300x138.png" alt="Thermo Fisher logo" class="wp-image-221790" srcset="https://www.genengnews.com/wp-content/uploads/2023/03/ThermoFisher_logo-300x138.png 300w, https://www.genengnews.com/wp-content/uploads/2023/03/ThermoFisher_logo.png 558w" sizes="(max-width: 300px) 100vw, 300px"></a></figure></p><p></p></div></div><p></p></div><p></p><p>The post <a href="https://www.genengnews.com/multimedia/webinars/right-resin-right-order-a-two-step-polishing-strategy-for-bispecific-antibodies/">Right Resin, Right Order: A Two-Step Polishing Strategy for Bispecific Antibodies</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Closing immunization gaps could boost health and the economy</title>
<link>https://edusehat.com/en/closing-immunization-gaps-could-boost-health-and-the-economy</link>
<guid>https://edusehat.com/en/closing-immunization-gaps-could-boost-health-and-the-economy</guid>
<description><![CDATA[ HN Summary • Adult vaccination supports healthy aging, helping older Canadians remain healthy, independent and active in the workforce.  • Significant immunization gaps remain, with only 39% of Canadians over 50 vaccinated against shingles despite national recommendations. • Closing these gaps could deliver major economic benefits, reducing healthcare costs and improving productivity while preventing illness. […]
The post Closing immunization gaps could boost health and the economy appeared first on Hospital News. ]]></description>
<enclosure url="https://www.hospitalnews.com/wp-content/uploads/2026/08/shutterstock_2633403903.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 16 Sep 2026 00:15:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Closing, immunization, gaps, could, boost, health, and, the, economy</media:keywords>
<content:encoded><![CDATA[<p><span><strong>HN Summary</strong></span></p>
<p>• Adult vaccination supports healthy aging, helping older Canadians remain healthy, independent and active in the workforce.<span class="Apple-converted-space"> </span></p>
<p>• Significant immunization gaps remain, with only 39% of Canadians over 50 vaccinated against shingles despite national recommendations.</p>
<p>• Closing these gaps could deliver major economic benefits, reducing healthcare costs and improving productivity while preventing illness.</p>
<hr>
<p>Canada’s population is aging fast. While aging well is fundamental to individual well-being, with Canadians aged 55 and older accounting for about 20 per cent of the labour force and the average retirement age now 65.3, four years higher than it was just two decades ago, healthy aging has also become an important factor for the country’s economic prosperity. <span class="Apple-converted-space"> </span></p>
<p>Adults aged 50 and older make up almost 40 per cent of the population and as Canadians live and work longer, prevention becomes more important than ever. Vaccination remains one of our most effective tools to support healthy ageing.</p>
<p>When people are in good health, they are better able to remain independent, contribute in the workforce, and stay active in their communities. Yet gaps persist between National Advisory Committee on Immunization (NACI) recommendations and publicly funded vaccination coverage, creating unequal protection for older Canadians across the country. <span class="Apple-converted-space"> </span></p>
<p>Shingles provides a great example, affecting 1 in 3 Canadians in their lifetime. NACI recommends shingles vaccination for adults aged 50 and older. Despite this recommendation being in place for almost a decade, just 39 per cent of Canadians over 50 are vaccinated. Only 7 out of the 13 provinces and territories have a publicly funded shingles immunization program for older adults, and eligibility varies among those that do.<span class="Apple-converted-space"> </span></p>
<p>Shingles can be incredibly disruptive and even debilitating – with many experiencing intense burning pain, fatigue, and having to step away from work and daily life. A 2012 study by researchers out of Quebec found that people lose an average of 58 productive hours to absenteeism and presenteeism in the first six months of having shingles. To a greater extent, those who develop post-herpetic neuralgia – the most common complication, causing persistent and severe nerve pain – lose 159 hours.<span class="Apple-converted-space"> </span></p>
<p>A recent report from Signal49 Research highlighted that vaccinating 80 per cent of Canadians aged 50 and older against shingles would provide a return on investment of 1.69. This means that for every dollar spent on publicly funded shingles vaccination, there is a corresponding benefit of $1.69 through health and productivity benefits. This equates to $816 million in savings to the healthcare system through things like avoided visits to primary care providers and emergency departments; $1.5 billion in productivity gains by enabling continuous work, volunteerism, and caregiving; and $4.2 billion in health benefits from reduced illnesses and maintaining quality of life.<span class="Apple-converted-space"> </span></p>
<h3>A Prevention-Focused Future</h3>
<p>Despite clear benefits, adult immunization is often underutilized. Too often, public adult vaccination programs are underfunded and do not align with NACI recommendations—creating real health consequences, avoidable economic impacts, and critical equity barriers. When public funding falls short, out-of-pocket costs become a noted barrier to vaccination uptake, putting protection out of reach for many Canadians.</p>
<p>Vaccination is a strategic investment with benefits that go beyond healthcare savings, preventing illness and suffering and helping to strengthen workforce productivity and the economy. Health system leaders and health care professionals can help support healthy aging goals for Canadians by integrating vaccination into preventive care planning and proactively engaging patients in discussions about risk and immunization options for shingles and other vaccine-preventable diseases.</p>
<p><i>Maaike de Vries, Senior Research Associate, Health, Signal49 Research</i><span class="Apple-converted-space"> </span></p>
<p>The post <a href="https://www.hospitalnews.com/closing-immunization-gaps-could-boost-health-and-the-economy/">Closing immunization gaps could boost health and the economy</a> appeared first on <a href="https://www.hospitalnews.com/">Hospital News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Donated livers can be made biologically younger</title>
<link>https://edusehat.com/en/donated-livers-can-be-made-biologically-younger</link>
<guid>https://edusehat.com/en/donated-livers-can-be-made-biologically-younger</guid>
<description><![CDATA[ Once an organ is removed from a donor’s body, the clock starts ticking. Surgeons usually flush the organ with a preservative solution, bag it, and put it on ice—where it immediately starts to degrade. The team has a matter of hours to get it into a recipient’s body. There’s another option—one that has been growing… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/09/liver-perfusion.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 15 Sep 2026 03:30:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Donated, livers, can, made, biologically, younger</media:keywords>
<content:encoded><![CDATA[<div data-chronoton-summary="<ul>
<li><strong>Perfusion machines may be turning back the clock on donated organs.</strong> Scientists found that livers kept on nutrient-pumping perfusion machines were biologically younger—by around 30%—than cold-stored livers, even when the perfused organs came from older donors.</li>
<li><strong>Molecular changes hint at why perfusion works.</strong> Researchers spotted shifts in gene activity linked to inflammation, tissue structure, and cellular recycling—clues that could eventually lead to cheaper drug-based treatments that mimic perfusion's rejuvenating effects.</li>
<li><strong>The technology is already reshaping transplant surgery.</strong> Surgeons who once avoided livers from circulatory-death donors over 40 now routinely use organs from donors over 70. "Perfusion has completely changed the landscape of transplantation in the last three years," says transplant surgeon Heidi Yeh.</li>
</ul>" data-chronoton-post-id="1144010" data-chronoton-expand-collapse="1" data-chronoton-analytics-enabled="1"></div>


<p>Once an organ is removed from a donor’s body, the clock starts ticking. Surgeons usually flush the organ <a href="https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/university-of-wisconsin-solution">with a preservative solution</a>, bag it, and put it on ice—where it immediately starts to degrade. The team has a matter of hours to get it into a recipient’s body.</p>



<p>There’s another option—one that has been growing in popularity in recent years, especially for donated organs that aren’t in the healthiest state. Some hospitals opt to put them on machines that pump them with nutrients and remove waste products, usually for around six to 12 hours. It’s a bit like being back in a body.</p>





<p>This allows doctors to assess the organs, and some <a href="https://pubmed.ncbi.nlm.nih.gov/34985503/">recent studies</a> suggest that time spent on these perfusion machines helps them do better once they’re transplanted. Now, scientists have found that perfused organs seem to get <em>younger</em>, at least at a molecular level.</p>



<p>The research, shared with <em>MIT Technology Review</em>, provides molecular clues as to why organs from younger donors are known to have a higher success rate. It might also help explain why perfused organs are less likely to fail once they make it into a recipient. </p>



<p>The researchers behind the study hope to find new ways to test the health of donated organs and potentially develop additional tools to repair organs that might otherwise be discarded. “If [we] can improve the utilization of organs beyond what the current systems can do, then that’s a win in my book,” says Jesse Poganik, who studies aging at Brigham and Women’s Hospital in Boston and coauthored the study.</p>



<h3 class="wp-block-heading">Clocking organs</h3>



<p>Poganik—along with colleagues including Heidi Yeh and Alban Longchamp, transplant surgeons at Mass General Brigham—used<a href="https://www.technologyreview.com/2025/10/14/1124977/aging-clocks-biology-mortality-longevity/"> “aging clocks”</a> to assess donated livers. These are scientific tools designed to measure biological age—a result that is meant to convey more about the health status of an organ (or person) than chronological age.</p>



<p>In an initial experiment, the team used a clock to look at the patterns of chemical marks on DNA in 37 samples taken from 19 donated livers. Such epigenetic patterns are known to change as we age. But when the team compared samples from livers kept on ice and those that were perfused, the team found a “striking” pattern in the latter.</p>





<p>“Machine-perfused livers, in spite of being older or having other disadvantageous characteristics, had a biological age that was lower than [non-perfused] livers that were chronologically younger,” says Yeh, who led the work.</p>



<p>To investigate further, Yeh and her colleagues analyzed another 208 samples from 103 donated livers. This time, they used different aging clocks—ones that essentially measure how genes are working. They studied samples biopsied from the livers after they had been stored for up to around six hours either in cold storage or on machine perfusion.</p>



<p>In most cases, they also assessed a second sample taken around an hour after the livers had been transplanted into a recipient. Once the organ’s blood supply is reestablished in the body, “you have a few other things to do,” says Longchamp. “Then you just do a quick biopsy before you close.”</p>



<p>According to the clocks, which were developed to measure age and risk of death, the machine-perfused livers were biologically younger, the team found. “Pumping them at 34 degrees with oxygen and nutrients actually reversed the biological age,” says Longchamp. The results have been been shared with colleagues at an industry conference, he says. </p>



<p>“If you adjust out chronological age … to have a fair head-to-head comparison, the difference between the two is on the order of 30%,” says Poganik. “It’s logical to say that perfusion drives this effect.”</p>



<p>The biological ages of all the livers tended to increase as soon as they were put into a recipient’s body, probably as a result of stresses on the organs. But still, the effect endured—the perfused organs remained biologically younger. </p>



<p>Nathanael Raschzok, a transplant surgeon at Charité Universitätsmedizin Berlin in Germany who was not involved in the research, says the work is impressive. But it’s not yet clear what these changes might mean for the recipients of these organs, he says. The organs in the study were donated by people in their 30s, 40s, and 50s. Raschzok wants to know the effect of perfusion on the liver of an 80-year-old. “Every so often, we use organs from 70-, 80-, 85-year-old donors,” he says.</p>



<p>A better understanding of <em>why</em> the organs appear to be getting biologically younger might lead to therapies that achieve the same effect with a drug that could potentially be used to treat a donated organ for a fraction of the price, he adds. That’s important because perfusion is expensive—Raschzok says it costs around €10,000 in Germany (a quarter of the budget for a transplant), while the cost in the US comes to around $80,000 to $100,000 per organ, says Yeh.</p>



<h3 class="wp-block-heading">Molecular repair</h3>



<p>Yeh and her colleagues weren’t able to study most of the livers before perfusion. That’s because donated organs are generally not considered to be under the purview of the hospital until they’ve been placed on perfusion machines, she says. (Organ procurement procedures vary, but for the team as Mass General Brigham, donated organs are put on perfusion devices at the donor’s hospital. “There’s this sort of nebulous period where it’s not clear who the organ belongs to,” says Yeh.)</p>





<p>Still, by looking at the genes and molecular pathways that seem to be altered in perfused organs, she and her colleagues can garner some clues. At a molecular level, the team saw changes in cell pathways linked to inflammation and the structure of tissues, for example. They also saw more activity in a pathway that allows cells to remove and recycle damaged cell parts, says Yeh.</p>



<p>Poganik hopes to develop some kind of test that would determine which organs, on the basis of their biological age, are suitable for transplantation. He and his colleagues are also experimenting with potential drug treatments that might push the biological age of an organ even lower.</p>



<p>In the meantime, any liver that is not from a “perfect, young, brain-dead donor” could probably benefit from perfusion, says Yeh. The devices are already transforming transplant surgery. Just a few years ago, she says, she and her colleagues would avoid using livers from people who’d suffered a circulatory death (when the heart stops beating and there’s a damaging lack of blood flow to organs) and were over 40. Today, they use livers from such donors over the age of 70. “Perfusion has completely changed the landscape of transplantation in the last three years,” she says.</p>]]> </content:encoded>
</item>

<item>
<title>Why Does a Particular Genetic Variant Lead to Accelerated Huntington Disease Development?</title>
<link>https://edusehat.com/en/why-does-a-particular-genetic-variant-lead-to-accelerated-huntington-disease-development</link>
<guid>https://edusehat.com/en/why-does-a-particular-genetic-variant-lead-to-accelerated-huntington-disease-development</guid>
<description><![CDATA[ Study results suggest how a particular genetic variant can speed onset of Huntington disease motor symptoms by up to 12.5 years and accelerate clinical measures of disease progression, by driving runaway DNA changes inside the brain&#039;s most vulnerable neurons. 
The post Why Does a Particular Genetic Variant Lead to Accelerated Huntington Disease Development? appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/05/GettyImages-1495440392.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 15 Sep 2026 03:25:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Why, Does, Particular, Genetic, Variant, Lead, Accelerated, Huntington, Disease, Development</media:keywords>
<content:encoded><![CDATA[<p>Research headed by scientists at the University of British Columbia has revealed why some people with Huntington disease (HD) may develop an earlier onset, more aggressive form of the disease. The study shows how a particular genetic variant can speed onset of HD motor symptoms by up to 12.5 years and accelerate clinical measures of disease progression by driving runaway DNA changes inside the brain’s most vulnerable neurons.</p>
<p>“People with this genetic variant have dramatically hastened onset of disease, but we didn’t know why,” said Michael Hayden, MBChB, PhD, professor at the Centre for Molecular Medicine and Therapeutics at UBC. “This work answers that question and provides dramatic evidence that repeated expansion of the mutation is an important driver of Huntington disease and a potential treatment target.” Hayden is senior author of the researchers’ published paper in <em>Neuron</em>, titled “<a href="https://doi.org/10.1016/j.neuron.2026.08.010" target="_blank" rel="noopener">Loss of interruption in the <em>HTT</em> CAG repeat is associated with increased somatic expansion and loss of medium spiny neurons in HD</a>.”</p>
<p>Huntington disease is a rare, inherited neurological disorder that causes the progressive breakdown of nerve cells in the brain. The condition affects movement, thinking and emotional well-being, and there is currently no cure or treatment to slow progression.</p>
<p>One way to think about the process is like a typo in a document that keeps getting copied. With every copy, the mistake is replicated and interferes with the message. “HD is caused by 36 or more uninterrupted CAG repeats in exon 1 of the Huntingtin gene (<em>HTT</em>), and the number of inherited CAG repeats is the primary determinant of the age at which symptoms first emerge,” the authors explained.</p>
<p>In Huntington disease the mutation continues to repeat and expand within neurons over time. As those repeats become longer, they interfere with normal cell function and make brain cells increasingly vulnerable to damage and death. “Medium spiny neurons (MSNs) are gradually lost in HD and undergo selective somatic CAG expansion, but it is unclear how somatic expansion relates to MSN pathology,” they continued.</p>
<p>Hayden added, “When we looked at the neurons that are dying in Huntington disease, we saw much greater expansion of the genetic mutation. This continues to strengthen the argument that DNA expansion is an important cause of disease.”</p>
<p>A small proportion of people with HD have a particular genetic variant, and researchers have known for years that these individuals develop Huntington disease earlier in life. “CAG and CCG loss-of-interruption (CAG-CCG LOI) variant hastens the onset of HD motor symptoms by up to 12.5 years and accelerates clinical measures of disease progression when compared with patients with the canonical sequence,” the team noted.</p>
<p>But it wasn’t known why this seemingly small change in DNA had such a dramatic effect on disease onset and progression. People carrying the variant had dramatically larger expansions of the Huntington mutation inside their neurons, occurring about five times more frequently than in patients without the variant. They also had fewer surviving neurons and earlier loss of particularly vulnerable nerve cells.</p>
<p>For their reported study the researchers analyzed blood samples and post-mortem brain tissue. “Here, we apply complementary approaches to assess somatic <em>HTT</em> CAG expansion from peripheral blood, postmortem brain tissues, and isolated MSNs of HD patients with and without the CAG-CCG LOI modifier variant and quantify MSN loss in the CAG-CCG LOI donor caudate.” They found a clue that helps explain one of the mysteries of Huntington disease, which is why a mutation that is present in every cell of the body primarily damages the brain.</p>
<p>Although the mutation exists throughout the body, the researchers found that the expansion process appears to be highly concentrated in certain cells of the brain. Blood samples, by contrast, showed little evidence of the dramatic changes that take place within the brain’s neurons. “Our interrogations of somatic expansion in blood, brain, and striatal MSNs of donors with and without the CAG-CCG LOI show this modifier does not increase small expansions in blood or bulk brain tissues, yet profoundly increases the proportion of genomic large (111–150) and very large (>150) CAG expansions in affected striatal MSNs,” they wrote.</p>
<p>“The mutational expansion seems to be selective for the brain,” Hayden added. “That may help explain why Huntington disease, even though the mutation is in every cell, is fundamentally a brain disease.”</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>The findings suggest blood tests are not a reliable indicator of the disease unfolding inside the brain, which is an important consideration for future Huntington disease research and clinical trials. “Peripheral blood DNA does not capture increased somatic expansion in MSNs, suggesting that blood DNA is a poor biomarker for disease-relevant somatic expansion in HD-affected neurons,” they noted.</p>
<p>While other factors besides expansion likely contribute to neuron loss, the findings provide some of the strongest human evidence to date that expansion of the Huntington mutation is a key factor in disease progression. “It validates repeat expansion of the DNA as an important therapeutic target in Huntington disease,” Hayden said. “If we can suppress that expansion, it may be possible to delay progression or delay the onset of disease.” And as the authors further commented, “Our study further underscores the need for cell-type-specific studies across other repeat expansion disorders that preferentially affect specific neuron populations.”</p>
<p>Several experimental therapies in development aim to slow or prevent this mutation growth before the damage occurs. While more research is needed, this study’s findings show research is moving in the right direction for a disease which has been so difficult to treat.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/why-does-a-particular-genetic-variant-lead-to-accelerated-huntington-disease-development/">Why Does a Particular Genetic Variant Lead to Accelerated Huntington Disease Development?</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Pneumococcal Subtypes Influence the Impact of Air Pollution on Disease Risk</title>
<link>https://edusehat.com/en/pneumococcal-subtypes-influence-the-impact-of-air-pollution-on-disease-risk</link>
<guid>https://edusehat.com/en/pneumococcal-subtypes-influence-the-impact-of-air-pollution-on-disease-risk</guid>
<description><![CDATA[ Pneumococcal bacterial subtypes influence how air pollution affects invasive disease risk, with certain strains linked to greater or faster risks of pneumonia, sepsis, and meningitis.
The post Pneumococcal Subtypes Influence the Impact of Air Pollution on Disease Risk appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2203265939.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 15 Sep 2026 03:25:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Pneumococcal, Subtypes, Influence, the, Impact, Air, Pollution, Disease, Risk</media:keywords>
<content:encoded><![CDATA[<p><em>Streptococcus pneumoniae</em> is a member of the respiratory microbiome and can be found in almost 20 percent of adults globally. While many adults and children carry the bacteria without symptoms, the bacterium can lead to invasive pneumococcal disease (IPD) which includes bacterial sepsis, pneumonia, and meningitis.</p>
<p>There are currently over 100 different serotypes of <em>S. pneumoniae</em>. While it is known that different subtypes of <em>S. pneumoniae</em> can lead to varying infection rates in different populations, important gaps remain in our collective understanding of how things such as humidity, temperature, and air pollution impact the timing of disease, and how risks vary by individual age and bacterial subtype.</p>
<p>Now, researchers suggest that the subtype of <em>S. pneumoniae</em>, together with air pollution exposure, impacts the rate and timing of invasive disease—with some strains linked to immediate infection after air pollution exposure, and others taking several weeks. The findings also suggest that older adults and young children are more vulnerable during periods of high air pollution, and that improving air quality could lower disease risk. Understanding what type of bacterial strains are circulating, and how environmental factors shape infection rates, could inform future public health policies, protect those most at risk, and prepare hospitals for outbreaks.</p>
<p>The work is published in <em>Nature Microbiology</em> in the paper, “<a href="https://www.nature.com/articles/s41564-026-02458-5" target="_blank" rel="noopener">Pneumococcal population structure influences the effects of air pollution on invasive disease risk in South Africa</a>.”</p>
<p>“While we found that temperature and air pollution generally increase the risk of invasive pneumococcal diseases, such as bacterial meningitis, our research also suggests that it is the bacterial subtypes a person is carrying that modulate infection rates,” notes Sophie Belman, PhD, previously at the Wellcome Sanger Institute and Barcelona Supercomputing Center, and currently an assistant professor at Yale School of Public Health. “The strain of bacteria impacts the timing of disease and who might be more at risk depending on their respiratory microbiome, meaning that the risk is not the same in every situation or for every person. By extending our findings to other parts of the globe, we will better understand who has the highest health risk from environmental exposures, and what factors need to be addressed in different regions, such as improving air quality in cities.”</p>
<p>This new study examined roughly 59,000 cases of IPD across 19 years from South Africa’s national GERMS-SA surveillance program. In South Africa, between 40-60 per cent of children carry <em>S. pneumoniae</em>. The researchers found that different subtypes of <em>S. pneumoniae</em> responded differently to higher air pollution exposure, noting three subtypes (14, 19A, and 8) were linked to the greatest risk of IPD following exposure.</p>
<p>Additionally, they found that different subtypes were linked to differences in the timing of disease risk. While the highest risk of IPD peaked roughly two weeks after air pollution exposure, in areas where subtypes 4, 8, 23F, and 19F were common, there was an immediate increase in disease risk, occurring within the same week.</p>
<p>The team accounted for other factors including temperature, humidity, and population density to ensure that the effects were measured as accurately as possible. They also noted that high temperatures were associated with an immediate increase in disease risk, and cold temperatures led to a delayed rise in cases. The team suggests that cold weather slows bacterial transmission or that damage from seasonal viruses could make it easier for bacterial infections to follow.</p>
<p>The authors suggest that integrating environmental monitoring with genomic surveillance of <em>S. pneumoniae</em> could help predict infection spikes, inform vaccination strategies, and support healthcare providers prepare during periods of poor air quality. The study also provides further evidence that reducing air pollution may yield important benefits for infectious disease prevention, particularly in areas with high levels of exposure, such as cities.</p>
<p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/pneumococcal-subtypes-influence-the-impact-of-air-pollution-on-disease-risk/">Pneumococcal Subtypes Influence the Impact of Air Pollution on Disease Risk</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Evonik Expands in Slovakia</title>
<link>https://edusehat.com/en/evonik-expands-in-slovakia</link>
<guid>https://edusehat.com/en/evonik-expands-in-slovakia</guid>
<description><![CDATA[ Compared with the conventional synthesis of chemicals, fermentation-based processes can offer a more sustainable route to selected intermediates by reducing the need for organic solvents and minimizing process-related waste. 
The post Evonik Expands in Slovakia appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2216056406.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 15 Sep 2026 03:25:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Evonik, Expands, Slovakia</media:keywords>
<content:encoded><![CDATA[<p>Germany-based Evonik has broken ground on a new biotechnology expansion project at its Fermas site in Slovenská Ľupča, Slovakia. The company notes that this marks the next major milestone in the approximately EUR 80 million investment to expand Evonik’s biotechnology capabilities and strengthen its contract manufacturing services for the company’s drug substance business. The project is expected to be completed in early 2028.</p>
<p>The investment will add downstream fermentation technology to the site, increasing capacity for the development and manufacture of complex pharmaceutical intermediate. Creating approximately 50 new jobs, the expansion will further reinforce the Fermas site as one of Evonik’s key biotechnology hubs, said Lauren Kjeldsen, member of the management board and COO at custom solutions, Evonik.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>“Today is an important step in our strategy to expand our biotechnology platform and support our customers with innovative, scalable, and sustainable manufacturing solutions,” continued Kjeldsen. “Biotechnology demonstrates how economic growth and sustainability can go hand in hand.”</p>
<p>Compared with conventional chemical synthesis, fermentation-based processes can offer a more sustainable route to selected intermediates by reducing the need for organic solvents and minimizing process-related waste. The Fermas site already operates on 100 percent green electricity and uses renewable and certified raw materials in selected production processes.</p>
<p>“This investment demonstrates the company’s confidence in biotechnology and in Slovakia as a location where innovation turns into industrial scale products,” added Miroslav Havlik, general manager of Evonik Fermas.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>Evonik Fermas, which was founded in 1992, has evolved from amino acid production into a biotechnology manufacturing hub serving the pharmaceutical, personal care, nutrition, and specialty chemical industries. In recent years, the site has also become a major location for Evonik’s biotechnology activities, including the launch of an industrial-scale <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fcisionone-email.news.evonik.com%2Fc%2FeJw0kM2OpSAQhZ9Gd2UE_IGFi974Gp0Cira6URzAvq8_4WZmRfJxTr7U8RtpM2nZ0yZWbZRZ1Gz6YxOzXiahg5FIdkRH0ktrZRidt8LZqedtQdTjvOr2hZ9CULCjGYUR3TQW9vTDf-BEjpQLODM57ecQYH7N325ovI_bUetdOvXRyb2T-_3YyA4rp6sM9Jsu_hlcOju509XJ_STP2GKZSoFMkbBQ6eTuUr5Txkot-a6BfTj6Aq-U2xM4lwp8-afUzBihOIwEd07-cU0Hd8SrQkgZ8oHnlSLf7AuIRU96HY56xv6t_68F9tsbfP4DnfpQ8yjF1OftOx3XUCrlyNdXGwO_6H5su6UvNROdra7M6sgLA9pKCROtAawKCqTxiMt7Z9X_bvJvAAAA__9mhYo7&data=05%7C02%7Cjohn.sterling%40sagepub.com%7C1e24453562fe4ed2c0a208df126d07ed%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639249931683823809%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=NpOk5%2BSj%2FRKwptAHWz2EPag3KnP2l4HwXPls9UTHLMI%3D&reserved=0" target="_blank" rel="noopener">rhamnolipid biosurfactant production</a> facility.</p>
<p class="trimmed"> </p>
<p class="trimmed"> </p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/evonik-expands-in-slovakia/">Evonik Expands in Slovakia</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>With pharmaceutical tariffs looming, guidance on compliance is still lacking</title>
<link>https://edusehat.com/en/with-pharmaceutical-tariffs-looming-guidance-on-compliance-is-still-lacking</link>
<guid>https://edusehat.com/en/with-pharmaceutical-tariffs-looming-guidance-on-compliance-is-still-lacking</guid>
<description><![CDATA[ With tariffs on patented pharmaceuticals and input materials set to take effect for all companies on Sept. 29, the lack of clarity about rules […]
The post With pharmaceutical tariffs looming, guidance on compliance is still lacking appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/09/rinson-chory-2vPGGOU-wLA-unsplash.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 14 Sep 2026 20:20:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>With, pharmaceutical, tariffs, looming, guidance, compliance, still, lacking</media:keywords>
<content:encoded><![CDATA[<p><span>With tariffs on patented pharmaceuticals and input materials set to take effect for all companies on Sept. 29, the lack of clarity about rules and exemptions is complicating business decisions and creating uncertainty for investors.</span></p>
<p><span>What does seem certain is that pharmaceutical tariffs will reduce the funds biotechnology firms have to develop treatments, discourage investors, and threaten patients’ access to drugs. For these reasons, pharmaceuticals have traditionally been considered off-limits for tariffs.</span></p>
<p><span>“At a time when the U.S. is competing to maintain global leadership in biotechnology, policies that raise costs, discourage innovation, and weaken our competitive position ultimately make it harder to deliver for patients and strengthen the economy,” warns Kelly Seagraves, VP of National Security & International Affairs at the Biotechnology Innovation Organization (BIO). “We urge the Administration to consider alternative policies for bolstering U.S. manufacturing and resilient supply chains.”</span></p>
<p><span>For now, BIO continuously seeks guidance on tariff compliance and potential exemptions, to inform the industry.</span></p>
<p><span>On Sept. 14, with two weeks until implementation, BIO’s experts say much of the necessary federal guidance is still missing, and the lack of information adds further challenges to an already challenging situation.</span></p>
<h2>What is known</h2>
<p><span>Based on</span><a href="https://www.federalregister.gov/documents/2026/04/09/2026-06956/adjusting-imports-of-pharmaceuticals-and-pharmaceutical-ingredients-into-the-united-states"><span> a </span><span>Presidential Proclamation</span></a><span> signed April 2, 100% </span><i><span>ad valorem</span></i><span> tariffs on patented pharmaceutical products and associated input materials go fully into effect on Sept. 29.</span></p>
<p><span>There are several potential reductions or exemptions for specific companies, countries, and products:</span></p>
<ul>
<li aria-level="1"><span> </span><b>Countries </b><span>of origin matter:</span> <span>The tariff is reduced to 15% for non-exempt products from Japan, the EU, Korea, and Switzerland/Liechtenstein. Tariffs on U.K. imports are 0% following an August 4 Federal Register Notice from the Department of Commerce.</span></li>
<li aria-level="1"><b>Companies</b><span> can reduce tariffs to 20% or 0%, by negotiating an onshoring plan with the Department of Commerce or by negotiating both an onshoring plan and a Most Favored Nation (MFN) pricing agreement with the Department of Health and Human Services. These reductions are temporary, expiring April 2, 2030 and January 20, 2029, respectively.</span></li>
<li aria-level="1"><b>Products</b><span> that are exempt include generics and biosimilars until April 2, 2027, with a mandate to reconsider generic eligibility in 2027. The Proclamation also notes several classes of drugs that may be exempt, but only if they originate from a country with a trade and security framework agreement or they meet an urgent U.S. health need.</span></li>
</ul>
<h2>What is unknown</h2>
<p><span>The lack of specific guidance for the industry on what products will be exempted and how exemptions will be granted means both industry and the U.S. government will be under immense time pressure, making it highly unlikely the pharmaceutical tariff regime can be fully implemented on Sept. 29. Implementation will require further guidance, including:</span></p>
<ul>
<li aria-level="1"><b>Specifics on product exemptions:</b><span> Companies need to know whether their products qualify for Clause (3)(d)</span> <span>exemptions. These may include orphan drugs, nuclear medicines, plasma-derived therapies, fertility treatments, cell and gene therapies, antibody drug conjugates, and medical countermeasures for public health threats. However, there is uncertainty about the details of qualifying for these exemptions. Other questions concern importing branded, off-patent drugs, or the input materials to manufacture in the U.S. patented pre-commercial products that are not yet making money.</span></li>
<li aria-level="1"><b>Case-by-case product decisions for an “urgent U.S. health need”:</b><span> The Commerce Department has indicated decisions about exemptions for meeting an “urgent U.S. heath need” will be made on a case-by-case basis. Yet companies are still awaiting Commerce guidance on the process to request an exemption.</span></li>
<li aria-level="1"><b>Preparing the requested information </b><span>undoubtedly increases compliance and administration costs—a particular challenge for smaller and mid-size biotech companies with small teams and limited capital. Further, application and government review could be time-consuming, adding to uncertainty about when tariffs apply and how much they will be.</span></li>
<li aria-level="1"><b>Countries with trade and security framework agreements: </b><span>The second avenue for a Clause 3(d) exemption is that the product originates from a specific set of countries. The U.S. government has still not shared which countries these are.</span><b> </b></li>
<li aria-level="1"><b>MFNs and onshoring:</b><span> There are no clear parameters for MFN or onshoring deals, which are apparently handled case-by-case.</span></li>
</ul>
<p><span>This continued uncertainty raises questions about short-term implementation. In one scenario, all eligible pharmaceutical products would be charged tariffs based on country of origin, and companies granted exemptions might receive refunds later. Alternatively, the government could delay collection of tariffs on potentially exempt products but collect retroactively. A final option would be a Presidential decision to forego or delay implementation, giving both companies and the government sufficient time to determine eligibility for exemptions.</span></p>
<h2>Impacts on biopharma and patients</h2>
<p><span>Impacts are hard to predict with so many unknowns about the total amount of tariffs that will be collected and what companies and products will be charged, BIO experts say.</span></p>
<p><span>For many companies, an exemption could be the difference between 100% tariff rates and no tariffs. The resulting uncertainty around costs for the industry and individual companies is an impact itself. It frightens investors and complicates business planning, making companies hesitant to spend on R&D when their capital needs are uncertain.</span></p>
<p><span>The challenge is particularly acute for the small- to medium-sized companies that are responsible for 71% of the industry’s output and 54% of the new drug applications,</span><a href="https://www.bio.org/toolkit/human-health/americas-innovation-engine-power-small-and-mid-sized-biotechs"> <span>according to BIO</span></a><span>. The smaller innovative companies generally have less available capital to adjust to shocks like tariffs.</span></p>
<p><span>The anticipated impact on patients will be two-fold. First, out-of-pocket costs can be expected to rise when importing drugs is 100% more expensive. Second, there will be negative impacts on innovation as companies that lose income due to tariffs spend less on R&D. Access challenges may arise if some companies stop importing certain drugs into the U.S. altogether.</span></p>
<h2>What to do instead of tariffs</h2>
<p><span>The tariffs are being implemented after a Department of Commerce Section 232 investigation determined that global supply chains are risky, and that onshoring drug production bolsters national security. But BIO experts note that tariffs actually create new disturbances in the existing supply chain.</span></p>
<p><span>There are better ways to protect global supply and attract manufacturing back to the U.S., according to BIO. These include strategic incentives, such as tax credits for building domestic manufacturing, and investments in U.S. biotechnology and biomanufacturing workforce development.</span></p>
<p><span>Appropriately targeted, non-tariff measures could secure supply chains while freeing small- and medium-sized biotechs to invest more in innovation. The improved clarity and certainty would benefit biotechs, investors, and patients.</span></p>
<p>The post <a href="https://bio.news/federal-policy/with-pharmaceutical-tariffs-looming-guidance-on-compliance-is-still-lacking/">With pharmaceutical tariffs looming, guidance on compliance is still lacking</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>StockWatch: Novartis Loses More than Market Value After Phase III Failure</title>
<link>https://edusehat.com/en/stockwatch-novartis-loses-more-than-market-value-after-phase-iii-failure</link>
<guid>https://edusehat.com/en/stockwatch-novartis-loses-more-than-market-value-after-phase-iii-failure</guid>
<description><![CDATA[ Del-desiran was one of three clinical setbacks for Novartis within a week. On September 4, the company and partner Ionis Pharmaceuticals (Nasdaq: IONS) acknowledged that their co-developed pelacarsen failed the Phase III Lp(a)HORIZON trial (NCT04023552) by missing its primary endpoint of reducing the risk, compared with placebo, of cardiovascular events. Two days earlier, Novartis paused eight trials assessing its autoimmune and neurological disease candidate rapcabtagene autoleucel (rap-cel), after three patients treated with the personalized, CD19-directed chimeric antigen receptor T cell (CAR T) therapy died after experiencing immune effector cell-associated hemophagocytic syndrome.
The post StockWatch: Novartis Loses More than Market Value After Phase III Failure appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/reigniting-a-passion-for-1-science.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 14 Sep 2026 05:55:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>StockWatch:, Novartis, Loses, More, than, Market, Value, After, Phase, III, Failure</media:keywords>
<content:encoded><![CDATA[<p><strong>Novartis (SIX Swiss: NOVN and NYSE: NVS) </strong>lost more than just the roughly $30 billion in market capitalization (share price times the number of outstanding shares) that dried up this past week when the company said its neuromuscular candidate delpacibart etedesiran (del-desiran) failed a Phase III trial.</p>
<p>Arguably the most dramatic loss faced by Novartis is satisfaction with its direction by major investors—one of which, Artisan Partners, went public with criticism of the company’s board.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>M. David Samra, managing director at Artisan Partners and founding partner of International Value Group, called on the board—specifically, its chairman Giovanni Caforio—to strengthen its oversight of the company’s acquisitions.</p>
<p>“I think he needs to make changes at the board level. One of them should be on improving the team that’s doing ​these deals because clearly they have been uninspiring at best,” Samra told Reuters in an interview.</p>
<p>“The party is over,” Samra declared, complaining that the acquisition deals lowered the value of Novartis shares. “The acquisition track record is not very good.”</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<figure aria-describedby="caption-attachment-337820" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="size-medium wp-image-337820" src="https://www.genengnews.com/wp-content/uploads/2026/09/N-David-Samra-Artisan-Partners-CROP11111SQUARE-300x300.jpg" alt="" width="300" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/N-David-Samra-Artisan-Partners-CROP11111SQUARE-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/N-David-Samra-Artisan-Partners-CROP11111SQUARE-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/09/N-David-Samra-Artisan-Partners-CROP11111SQUARE-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/09/N-David-Samra-Artisan-Partners-CROP11111SQUARE-420x420.jpg 420w, https://www.genengnews.com/wp-content/uploads/2026/09/N-David-Samra-Artisan-Partners-CROP11111SQUARE-696x696.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/09/N-David-Samra-Artisan-Partners-CROP11111SQUARE.jpg 810w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">M. David Samra, managing director at Artisan Partners and founding partner of International Value Group</figcaption></figure>
<p>Among the acquisitions cited by Samra were Novartis’ <a href="https://www.genengnews.com/topics/translational-medicine/novartis-to-acquire-avidity-for-12b-bolstering-neuroscience-pipeline/">$12 billion buyout of Avidity Partners</a>, a deal completed in February with the aim of bolstering the buyer’s neuroscience pipeline with three late-stage programs—del-desiran and two other candidates in a new class of RNA therapeutics that Avidity and now Novartis call Antibody Oligonucleotide Conjugates (AOCs<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley">).</p>
<p>The companies have reasoned that the AOC approach can safely and effectively treat serious genetic neuromuscular disorders by delivering RNA to muscle tissue via TfR1 mAb, in order to enable modulation of the genetic mechanism of disease.</p>
<p>But that argument was undermined when Novartis acknowledged that del-desiran <a href="https://www.genengnews.com/topics/translational-medicine/novartis-shares-slide-after-neuromuscular-candidate-acquired-with-avidity-fails-phase-iii-trial/">failed the pivotal trial</a> (HARBOR, <a href="https://clinicaltrials.gov/study/NCT06411288">NCT06411288</a>) by missing the study’s primary endpoint of statistically significant improvement vs. placebo in video Hand Opening Time (vHOT) through week 54. vHOT is a frequently used measure of hand myotonia, according to a <a href="https://www.nmd-journal.com/article/S0960-8966(24)00692-8/fulltext">2024 study</a>, and involves clinical experts reviewing videos to measure the time from hand grip to opening.</p>
<p>Del-desiran is an AOC candidate designed to target the underlying cause of DM1. The therapy consists of a muscle-targeting monoclonal antibody that binds to the transferrin receptor 1 (TfR1) and is conjugated to a small interfering RNA (siRNA) designed to induce degradation of the disease-causing toxic myotonic dystrophy protein kinase (DMPK) mRNA.</p>
<p>Del-desiran has received the FDA’s Orphan Drug, Fast Track, and Breakthrough Therapy designations, as well as the European Medicines Agency’s Orphan Medicinal Product Designation.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<h4><strong>“Needs to be penalized”</strong></h4>
<p>“If you do a $12 billion deal and it goes to zero, the management needs to be penalized for that,” Samra said, though he acknowledged that the Avidity acquisition may yet yield successful candidates that can be developed into marketable drugs.</p>
<p>Samra also took issue with <a href="https://www.genengnews.com/topics/cancer/novartis-to-acquire-morphosys-for-2-9b-bolstering-oncology-pipeline/">Novartis’ acquisition of MorphoSys</a> for €2.7 billion ($3.1 billion), completed in May 2024. That deal was intended to bolster the buyer’s oncology pipeline with what seemed like a promising late-stage myelofibrosis candidate in pelabresib, as well as an early-stage candidate under study in patients with solid tumors or lymphomas.</p>
<p>Within months, Novartis delayed earlier plans to pursue mid-2024 approval filings for pelabresib and later said more time was needed to decide a regulatory path for the drug based on 48-week data from the Phase III MANIFEST-2 trial (<a href="https://clinicaltrials.gov/study/NCT04603495">NCT04603495</a>). However, the combination of pelabresib plus ruxolitinib met the study’s primary endpoint, a reduction of at least 35% in spleen volume from baseline (SVR35) at 24 weeks: 65.9% of pelabresib-ruxolitinib patients (N=214) vs. 35.2% of placebo-ruxolitinib patients (N=216)</p>
<p>Earlier this year, Novartis launched the Phase III MANIFEST-3 trial (<a href="https://clinicaltrials.gov/study/NCT07357727">NCT07357727</a>) assessing pelabresib in combination with ruxolitinib in patients with myelofibrosis. Novartis markets ruxolitinib outside the United States as Jakavi®, while Incyte markets the drug Stateside as Jakafi®. The trial’s estimated completion date is May 2028.</p>
<p>Del-desiran was one of three clinical setbacks for Novartis within a week. On September 4, the company and partner <strong>Ionis Pharmaceuticals (Nasdaq: IONS)</strong> acknowledged that their co-developed pelacarsen failed the Phase III Lp(a)HORIZON trial (<a href="https://clinicaltrials.gov/study/NCT04023552">NCT04023552</a>) by missing its primary endpoint of reducing the risk, compared with placebo, of cardiovascular events.</p>
<p>Two days earlier, Novartis paused eight trials assessing its autoimmune and neurological disease candidate rapcabtagene autoleucel (rap-cel), after three patients treated with the personalized, CD19-directed chimeric antigen receptor T cell (CAR T) therapy died after experiencing immune effector cell-associated hemophagocytic syndrome.</p>
<p></p><h4><strong>Not Blaming CEO</strong></h4>

<p>Samra stopped short of blaming Vas Narasimhan, who has been Novartis’ CEO since 2018, for the company’s clinical setbacks, saying the chief did a “very good job”—with Reuters suggesting by juxtaposition a possible explanation: The company’s shares have <span><strong>jumped 60%</strong></span> in value during his tenure at the helm.</p>
<div class="my-8"><span data-render-ad="6"></span></div>
<p>But Novartis’ primary shares in Switzerland have only <span><strong>risen 2%</strong></span> from CHF 108.50 ($132.88) so far this year and <span><strong>climbed 11%</strong></span> from CHF 101.78 ($124.65) year-over-year.</p>
<p>Worse, the announced failure of del-desiran on September 8 propelled Novartis shares to their worst one-day selloff since March 2020, early in the COVID-19 pandemic. Shares trading on the SIX Swiss Exchange <span><strong>skidded 11%</strong></span> from CHF 125.46 ($153.64) to CHF 111.80 ($136.91), while Novartis’ American depositary shares traded on the New York Stock Exchange <span><strong>slid 14%</strong></span> from $159.99 to $137.72.</p>
<p>Both shares all but plateaued for the rest of the week, failing to regain momentum. At the end of trading Friday, the SIX Swiss shares <span><strong>inched up 0.2%</strong></span> to CHF 112.04 ($137.21), while the NYSE shares <span><strong>dipped a further 0.4%</strong></span>, finishing the week at $137.16.</p>
<p>Artisan’s flagship fund, the Artisan International Value Fund, listed Novartis as fourth among its top 10 holdings, accounting for <a href="https://www.artisanpartners.com/content/dam/documents/fact-sheets/vr/2026/2q/ARTKX-APDKX-APHKX-Fact-Sheet-2Q26-vR.pdf">3.6% of its total portfolio as of June 30</a>, according to its most recent quarterly fact sheet. As of that date, Artisan reported $45.184 billion in assets, which would have made the value of Artisan’s stake in Novartis approximately $1.627 billion.</p>
<p>That stake likely increased later in the summer before the del-desiran news, since Artisan’s website lists the total value of the value fund at <a href="https://www.artisanpartners.com/individual-investors/investments/international-value-group/international-value-fund-aphkx.html">$46.001 billion as of August 31</a>.</p>
<p>In addition to del-desiran, Novartis acquired delpacibart zotadirsen (del-zota<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley">), an Exon 44-targeting AOC designed to treat Duchenne muscular dystrophy (DMD), and delpacibart braxlosiran (del-brax<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley">), an AOC intended to treat facioscapulohumeral muscular dystrophy (FSHD) by targeting DUX4.</p>
<p>Del-zota is under evaluation in the Phase II EXPLORE44OLE<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> (<a href="https://clinicaltrials.gov/study/NCT06244082">NCT06244082</a>) trial following completion in November 2024 of the Phase I/II EXPLORE44<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> (<a href="https://clinicaltrials.gov/study/NCT05670730">NCT05670730</a>) study. Del-brax is being assessed in the Phase III FORTITUDE-3<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> trial (<a href="https://clinicaltrials.gov/study/NCT07038200">NCT07038200</a>).</p>
<p>In June, Novartis trumpeted positive data from the FORTITUDE Phase I/II trial (<a href="https://clinicaltrials.gov/study/NCT05747924">NCT05747924</a>) of del-brax, saying the study’s biomarker cohort met its primary and key secondary endpoints, with reductions in KHDC1L (cDUX) and creatine kinase biomarker levels indicating both strong target engagement and reduction in muscle damage in patients with FSHD.</p>
<p></p><h4><strong>Investors weigh in</strong></h4>

<p></p><h4><span>Samra’s criticism of Novartis’ board was echoed by what Reuters said was some of seven other representatives of shareholders, five of whom were quoted by name in a follow-up article.</span></h4>

<div class="my-8"><span data-render-ad="7"></span></div>
<p>“It’s ​going to take a while for confidence to return,” said Gillian Hollenstein, lead manager at Point Capital Navigator Fund, which, as of September 10, listed Novartis as tenth of its top 10 holdings, accounting for 1.8% of its total portfolio. The fund reported CHF 124.38 million ($152.33 million) in total assets as of that date, making Point Capital’s stake total CHF 2,238,840 (more than $2.7 million).</p>
<p>“They ​would have been better off doing some more smaller acquisitions, bolt-on ones rather than trying to hit it out of the park,” Hollenstein added.</p>
<p>Avidity was the largest of 11 biopharma acquisitions Novartis has carried out since 2023. They all could total up to $32.9 billion if Novartis achieves the milestones called for in five of the deals.</p>
<p>“It’s a little bit premature to call for heads at this point,” said Daniel Bolanowski, portfolio manager at investor Arctic Asset Management, since Avidity-created del-zota and del-brax could ultimately succeed in the clinic and generate revenue. But Bolanowski added that the stock selloff suggested “a deeper trust issue” with the company’s business development approach, beyond the failure or reduced value of del-desiran.</p>
<p>Arctic Aurora, <a href="https://cdn.arctic.com/documents/AAM-Documents/Arctic-Funds-Plc-Annual-and-Interim-Report/C21397_C67157_20260630_FSIIFS.pdf">as of June 30,</a> had a Novartis investment it quantified as 2,660 shares valued at a total NOK 4,124,818 ($443,994.25), accounting for 1.23% of its portfolio.</p>
<p>Michael Hannig, a buy-side analyst covering global healthcare and portfolio manager of a DACH [Germany, Austria, and Switzerland] small- and mid-cap fund at DJE Kapital, suggested to Reuters that Novartis could regain investor confidence and replenish its pipeline following patent cliff exclusivity expirations by pursuing deals in the $5 billion to $10 billion range for late-stage assets or ​drugs nearing approval, subject to due diligence: “Larger transactions will likely be assessed carefully by ‌investors considering ⁠the mixed market reception to several prior deals.”</p>
<p>DJE Kapital has disclosed having <a href="https://www.dje.de/en/about-dje/">more than €18.9 billion</a> ($21.9 billion) in total assets under management across its funds as of  but does not disclose the portfolio details of its individual funds.</p>
<p>Executives at two other Novartis investors, Bellevue Asset Management and Union Investment, defended Novartis: Guy Bettschart-Ghassabi, healthcare analyst at Bellevue Asset Management, noted that the HARBOR study was designed by Avidity before its acquisition by Novartis, while Markus Manns, portfolio manager at Union Investment, said the failure of del-desiran and pelacarsen was unfortunate but within normal probabilities of drug development success.</p>
<p>“They have to work harder to fulfill their post-2030 goals,” Manns said, “but it’s in the same camp as most other pharma companies.”</p>
<p>Bellevue Asset Management finished last year with AUM of CHF 5.3 billion (nearly $6.5 billion) while Union Investment reported €534.6 billion (about $620.3 billion), according to public disclosures that also exclude portfolio details.</p>
<p></p><h4><strong>Good news for competitors </strong></h4>

<p>Myles R. Minter, PhD, a partner and biotechnology analyst with William Blair, wrote in a research note that Novartis’ clinical miss for del-desiran is a positive development for several potential competitors, which, like the Swiss pharma giant, are also developing drugs designed to treat DM1 by targeting DMPK. These include:</p>
<ul>
<li><strong>Dyne Therapeutics (Nasdaq: DYN)</strong>, which is developing zeleciment basivarsen (z-basivarsen or DYNE-101), an anti-TfR1 FAb-conjugated antisense oligonucleotide (ASO). Z-basivarsen is under study in the Phase III HARMONIA trial (<a href="https://clinicaltrials.gov/study/NCT07486934">NCT07486934</a>), after generating positive strength and cognition data in March from the Phase I/II ACHIEVE trial (<a href="https://clinicaltrials.gov/study/NCT05481879">NCT05481879</a>), set to read out new one-year data later this month. Topline data is expected from ACHIEVE’s registrational expansion cohort in the first quarter of 2027.</li>
<li><strong>Sarepta Therapeutics (Nasdaq: SRPT)</strong> and <strong>Arrowhead Pharmaceuticals (Nasdaq: ARWR)</strong>, which are co-developing SRP-1003 (formerly ARO-DM1), an RNA interference (RNAi) conjugate being assessed in a Phase I/IIa trial (<a href="https://clinicaltrials.gov/study/NCT06138743">NCT06138743</a>) that generated positive early clinical results and is set to read out multiple ascending dose data later in the second half. Sarepta is in-licensing SRP-1003 from Arrowhead under a collaboration announced in 2024 that generated for Arrowhead $825 million in upfront cash and equity and could generate an eye-popping $10 billion in milestone payments.</li>
<li><strong>PepGen (Nasdaq: PEPG)</strong>, which is developing PGN-EDODM1, which uses the company’s enhanced delivery oligonucleotide (EDO) technology to deliver a therapeutic oligonucleotide designed to restore the normal splicing function of MBNL1, a key RNA splicing protein. PGN-EDODM1 is under study in the Phase II FREEDOM2 trial, where PepGen has fully enrolled the 10 mg/kg MAD cohort, data from which are expected to be reported in November. In August, the trial’s independent data and safety monitoring board (DSMB) approved advancing to the highest dosage cohort of 12.5mg/kg.</li>
<li><strong>Vertex Pharmaceuticals (Nasdaq: VRTX)</strong> and <strong>Entrada Therapeutics (Nasdaq: TRDA)</strong>, which are co-developing VX-670, which is expected to read out data from the Phase I/II GALILEO trial (<a href="https://clinicaltrials.gov/study/NCT06185764">NCT06185764</a>) later in the second half of this year. VX-670 is a phosphorodiamidate morpholino oligonucleotide (PMO) connected to a cyclic peptide containing motif that Vertex in-licenses from Entrada under an up-to-$735 million collaboration announced in 2022.</li>
</ul>
<p>“Today’s miss from del-desiran leaves open space to fill within the DM1 patient class, and we view Vertex/Entrada’s VX-670 as compelling,” Minter wrote, based on its endosomal escape vehicle (EEV) platform: “We view Entrada’s muscle-targeted EEV as possessing an impressive safety profile to date, which we view as important for entrance into higher dosing regimes that may be required for sufficient muscle tissue penetration and vHOT improvements to translate into a registrational trial setting.”</p>
<p></p><h4><strong>Lower projected sales</strong></h4>

<p>Novartis’ disappointing outcome for del-desiran in the HARBOR trial compelled analysts to cut their sales forecasts for the candidate, which Narasimhan projected had “$5 billion-plus peak sales potential” in an interview with Bloomberg TV.</p>
<p>Stefan Schneider, PhD, senior equity analyst, pharma with Vontobel Asset Management, removed the firm’s previous peak annual sales projection of $3 billion for del-desiran from its valuation model and cut its Novartis price target from CHF 128 ($156.77) to CHF 125 ($153.09). Vontobel previously gave Novartis a 50% probability of success for del-desiran.</p>
<p>Michael Schmidt, PhD, a senior biotech analyst and senior managing director at Guggenheim, slashed the firm’s risk-adjusted 2033 sales forecast for del-desiran by 45% from $1.76 billion to $960 million, with a 60% probability of success. The firm previously identified del-desiran and pelecarsen as critical to Novartis’ success from 2030 onward, along with a third candidate that recently succeeded in the clinic—remibrutinib, which generated positive topline data in the Phase III REMODEL-1 (<a href="https://clinicaltrials.gov/study/NCT05147220">NCT05147220</a>) and REMODEL-2 (<a href="https://clinicaltrials.gov/study/NCT05156281">NCT05156281</a>) in relapsing multiple sclerosis, Novartis said.</p>
<p>Remibrutinib is now marketed by the company as Rhapsido® in chronic spontaneous urticaria (CSU) in adults who remain symptomatic despite H1 antihistamine treatment.</p>
<p>Novartis has maintained its guidance to investors, foreseeing net sales growth at a compound annual rate of 5% to 6% at constant currencies between 2025 and 2030.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/stockwatch-novartis-loses-more-than-market-value-after-phase-iii-failure/">StockWatch: Novartis Loses More than Market Value After Phase III Failure</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>How to Apply for USMLE Step 3 and What’s Required to Register?</title>
<link>https://edusehat.com/en/how-to-apply-for-usmle-step-3-and-whats-required-to-register</link>
<guid>https://edusehat.com/en/how-to-apply-for-usmle-step-3-and-whats-required-to-register</guid>
<description><![CDATA[ If you’re on the journey to becoming a licensed physician in the United States, USMLE Step 3 is the final hurdle in the United States Medical Licensing Examination (USMLE) series. Passing Step 3 is crucial for obtaining an independent medical license and is often required before completing residency. In this guide, we’ll break down when […]
The post How to Apply for USMLE Step 3 and What’s Required to Register? appeared first on Elite Medical Prep. ]]></description>
<enclosure url="https://elitemedicalprep.com/wp-content/uploads/2026/09/pexels-george-pak-7972381-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 14 Sep 2026 02:35:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>How, Apply, for, USMLE, Step, and, What’s, Required, Register</media:keywords>
<content:encoded><![CDATA[<p><span>If you’re on the journey to becoming a licensed physician in the United States, USMLE Step 3 is the final hurdle in the United States Medical Licensing Examination (USMLE) series. Passing Step 3 is crucial for obtaining an independent medical license and is often required before completing residency. In this guide, we’ll break down </span><b>when to take USMLE Step 3, how to apply, and key requirements</b><span> to help you plan this important milestone efficiently.</span></p>
<p> </p>
<h2><b>When Should I Take Step 3 Exam?</b></h2>
<p><span>The ideal timing for taking USMLE Step 3 depends on your career goals and residency demands. Many residents aim to take the exam </span><b>during the first year (PGY-1) or early second year (PGY-2) of residency</b><span> to check off this requirement early. Since there are many <a href="https://elitemedicalprep.com/step-2-prep-tips-resources-and-common-mistakes/">similarities between Step 3 and Step 2CK</a>, many residents want to get this test done quickly so they do not forget some of the critical information they learned in medical school about other specialities. However, many residents may also look to take this test near the end of their residency training as they are not in a rush to get it done and they want to focus on their clinical training. Here are some factors to consider:</span></p>
<ul>
<li aria-level="1"><b>If your residency requires Step 3 early</b><span> – Some residency programs mandate that you pass Step 3 to advance to PGY-2.</span></li>
<li aria-level="1"><b>If you want to apply for a fellowship</b><span> – Some competitive fellowships require a passing Step 3 score at the time of application. However, many do not, and many residents will actually take Step 3 </span><i><span>after</span></i><span> they are accepted to fellowship in case they score lower on the test and to avoid having a blemish on their application.</span></li>
<li aria-level="1"><b>If you need a visa sponsorship</b><span> – International Medical Graduates (IMGs) on H-1B visas must pass Step 3 before applying for sponsorship.</span></li>
<li aria-level="1"><b>If you want more study time</b><span> – Some residents prefer to delay Step 3 until PGY-2 or later, giving them more time to prepare and more time to gain clinical experience which can come in handy on the <a href="https://elitemedicalprep.com/how-to-study-for-ccs-on-step-3/">CCS portion of Step 3</a>.</span></li>
</ul>
<p> </p>
<h3><b>Do You Have to Take USMLE Step 3 Before Residency?</b></h3>
<p><span>No, </span><b>USMLE Step 3 is not required before starting residency</b><span>. However, some residency programs encourage or require residents to pass it early in training. IMGs who need an H-1B visa must pass Step 3 before starting residency, but most U.S. medical graduates take it during residency.</span></p>
<p> </p>
<h2><b>When Can You Take USMLE Step 3?</b></h2>
<p><span>You are eligible to take Step 3 once you:</span></p>
<ol>
<li aria-level="1"><b>Pass USMLE Step 1 and Step 2 CK</b><span> – Step 3 is only available to those who have successfully completed the first two exams.</span></li>
<li aria-level="1"><b>Earn your MD or DO degree</b><span> – You must have graduated from an accredited U.S. or Canadian medical school or an internationally recognized institution.</span></li>
<li aria-level="1"><b>Obtain ECFMG Certification (for IMGs)</b><span> – International graduates must be certified by the Educational Commission for Foreign Medical Graduates (ECFMG) before registering.</span></li>
</ol>
<p> </p>
<p><span>Many applicants take Step 3 </span><b>shortly after starting residency</b><span>, but you can take it </span><b>as soon as you have your MD/DO and pass Step 1 & 2 CK</b><span>.</span></p>
<p> </p>
<h2><b>What Is the 7-Year Rule for Step 3?</b></h2>
<p><span>The </span><b>7-year rule</b><span> means that you must complete all three USMLE Steps </span><b>within seven years</b><span> of passing your first exam (Step 1) in most states. If you exceed this timeframe, you may have to retake earlier steps. However, some </span><a href="https://www.fsmb.org/step-3/state-licensure/#:~:text=1%20year-,Time%20Limit%20for%20Completing%20Licensing%20Examination%20Sequence,additional%20attempts%20at%20Step%203."><span>states</span></a><span> offer exceptions, so be sure to check with your state medical board.</span></p>
<p> </p>
<h2><b>Step-by-Step Guide: How to Apply for USMLE Step 3</b></h2>
<h3><b>Step 1: Confirm Eligibility</b></h3>
<p><span>Before applying, ensure that you meet the following:</span></p>
<ul>
<li aria-level="1"><span>Passed Step 1 and Step 2 CK</span></li>
<li aria-level="1"><span>Graduated from an accredited medical school</span></li>
<li aria-level="1"><span>Obtained ECFMG certification (if applicable)</span></li>
</ul>
<p> </p>
<h3><b>Step 2: Register via FSMB</b></h3>
<p><span>Step 3 is administered by the </span><b>Federation of State Medical Boards (FSMB)</b><span>, not the NBME. To register:</span></p>
<ol>
<li aria-level="1"><b>Create an account</b><span> on</span><a href="https://www.fsmb.org/"> <span>FSMB’s website</span></a><span>.</span></li>
<li aria-level="1"><b>Complete the application</b><span> – This includes personal information, education history, and transcripts of prior USMLE exam details.</span></li>
<li aria-level="1"><b>Pay the exam fee</b><span> – The 2025 fee is </span><b>$935</b><span> (subject to change).</span></li>
<li aria-level="1"><b>Submit required documentation</b><span> – IMGs may need to provide additional credentials.</span></li>
</ol>
<p> </p>
<h3><b>Step 3: Receive Scheduling Permit</b></h3>
<p><span>After processing, FSMB will send your scheduling permit, which allows you to book your test dates. Processing may take </span><b>several weeks</b><span> (estimated by FSMB to be 2 weeks), so apply early!</span></p>
<p> </p>
<h3><b>Step 4: Schedule Your Exam Dates</b></h3>
<p><a href="https://elitemedicalprep.com/usmle-step-3-format-and-content/"><span>USMLE Step 3 is a </span><b>two-day</b></a><span> exam, and you must schedule both days within a 14-day window. You can book your exam through </span><b>Prometric</b><span>, a national testing center.</span></p>
<ul>
<li aria-level="1"><b>Day 1:</b><span> Foundations of Independent Practice (FIP) – 232 multiple-choice questions (MCQs) over 7 hours.</span></li>
<li aria-level="1"><b>Day 2:</b><span> Advanced Clinical Medicine (ACM) – 180 MCQs plus 13 Computer-Based Case Simulations over 9 hours.</span></li>
</ul>
<p> </p>
<h3><b>How to Schedule Step 3 USMLE?</b></h3>
<p><span>Once you receive your scheduling permit, visit</span><a href="https://www.prometric.com/exams/usmle"><span> Prometric’s website</span></a><span> to select available dates and locations. Spots fill quickly, so schedule early!</span></p>
<p> </p>
<h2><b>How to Fit Step 3 into Your Busy Residency Schedule</b></h2>
<p><span>Residency is demanding, so balancing Step 3 prep with clinical duties is crucial. Here are some tips:</span></p>
<p> </p>
<h3><b>Create a Study Plan</b></h3>
<p><a href="https://elitemedicalprep.com/how-much-time-should-you-spend-studying-for-step-3/"><span>Dedicate at least </span><b>4-6 weeks</b></a><span> of structured study time. Many residents choose to study during lighter rotations.</span></p>
<p><b>Use High-Yield Resources (must have)</b></p>
<ul>
<li aria-level="1"><b>UWorld or AMBOSS Step 3 QBank</b><span> – Best question banks for practice. Ideally, you would complete all questions before test day but we recognize that residents have many commitments and may not be able to get through them all.</span></li>
<li aria-level="1"><b>CCS Cases (Computer-Based Simulations)</b><span> – Essential for Day 2 prep. The CCS cases will be brand new to you! Understanding the format of the CCS cases and the user interface is critical to your success.</span></li>
</ul>
<p> </p>
<h3><b>Practice Time Management</b></h3>
<ul>
<li aria-level="1"><span>Allocate </span><b>1-2 hours/day</b><span> for studying – again, we recognize how busy your clinical schedule is!</span></li>
<li aria-level="1"><span>Use weekends for </span><b>longer study sessions</b><span>.</span></li>
<li aria-level="1"><b>Take a practice test</b><span> 2-3 weeks before the exam.</span></li>
</ul>
<p> </p>
<h3><b>Consider a Tutor for Targeted Prep</b></h3>
<p><span>If you’re short on time or need guidance, </span><b>a USMLE Step 3 tutor can help you focus on weak areas and boost your confidence.</b><span> A tutor can personalize your study plan and help with CCS case strategies.</span></p>
<p><b>Need help preparing?</b><span> Check out</span><a href="https://elitemedicalprep.com/usmle-step-3-tutoring/"> <span>Elite Medical Prep’s USMLE Step 3 Tutoring</span></a><span> for expert coaching!</span></p>
<p> </p>
<h2><b>Final Thoughts: Plan Ahead for Step 3 Success</b></h2>
<ul>
<li aria-level="1"><b>Apply early</b><span> – Registration can take weeks, so plan ahead.</span></li>
<li aria-level="1"><b>Schedule wisely</b><span> – Choose a test date that aligns with your clinical workload and career plans.</span></li>
<li aria-level="1"><b>Study efficiently</b><span> – Use high-yield resources and practice CCS cases.</span></li>
<li aria-level="1"><b>Consider tutoring</b><span> – A personalized study plan can maximize efficiency.</span></li>
</ul>
<p> </p>
<p><b>Still wondering, “When do you take USMLE Step 3?”</b><span> The best time is when you feel ready and have adequate study time. Whether you take it early (or even before for our IMGs) in residency or later, careful planning will help you pass on the first attempt!</span></p>
<p> </p>
<p><b>Need help prepping?</b><a href="https://elitemedicalprep.com/usmle-step-3-tutoring/"> <span>Sign up for USMLE Step 3 tutoring</span></a><span> today!</span></p>
<p>The post <a href="https://elitemedicalprep.com/how-to-apply-for-usmle-step-3-and-whats-required-to-register/">How to Apply for USMLE Step 3 and What’s Required to Register?</a> appeared first on <a href="https://elitemedicalprep.com/">Elite Medical Prep</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Bone Marrow&#45;on&#45;a&#45;Chip Model Offers New Window Into Immune Cell Development and Behavior</title>
<link>https://edusehat.com/en/bone-marrow-on-a-chip-model-offers-new-window-into-immune-cell-development-and-behavior</link>
<guid>https://edusehat.com/en/bone-marrow-on-a-chip-model-offers-new-window-into-immune-cell-development-and-behavior</guid>
<description><![CDATA[ By reproducing elements of human bone marrow on a chip, scientists have created a new tool that will help them gain new insights into how immune cells develop and function. 
The post Bone Marrow-on-a-Chip Model Offers New Window Into Immune Cell Development and Behavior appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2023/04/GettyImages-685024457-e1716932111660.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 12 Sep 2026 06:50:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Bone, Marrow-on-a-Chip, Model, Offers, New, Window, Into, Immune, Cell, Development, and, Behavior</media:keywords>
<content:encoded><![CDATA[<p><span>With support from the National Institutes of Health, a team of scientists have developed a laboratory model that reveals how antibody-producing plasma cells migrate, mature, and survive in human bone marrow. According to its developers, the platform combines a lymph node that mimics an organoid with a tissue chip that mimics bone marrow, and supports studies into the key stages of plasma cell development. Full details of the work are published in a new </span><i><span>Science Advances </span></i><span>study titled “</span><a href="https://www.science.org/doi/10.1126/sciadv.adz3976" target="_blank" rel="noopener"><span><em>Ex Vivo</em> Bone Marrow Subniches Influence the Fate of Human Antibody-Secreting Cells</span></a><span>.”</span></p>
<p><span>The work was done by scientists from Georgia Tech and Vanderbilt University. The human lymphoid organoid was developed by a team led by Ankur Singh, PhD, a professor of bioengineering and director of the Center for Immunoengineering at Georgia Tech. They developed it by isolating B cells from human tonsil tissue and blood sources and growing them in an environment similar to lymphoid tissue. They used inactivated influenza virus to overcome challenges associated with culturing B cells and getting to transform into antibody secreting plasma cells. </span></p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p><span>Meanwhile, scientists in the lab of Krishnendu Roy, PhD, dean of engineering and professor of biomedical engineering at Vanderbilt University, designed a microfluidics-based vascularized microenvironment for the bone marrow chip that mimics the conditions found in human bone marrow. Essentially, they tried to “mimic the structure, fundamental biological functions, and spatial microenvironments” of human bone marrow in order “to ask questions about human organ-like behavior in this more simplified model,” Roy explained. </span></p>
<p><span>As explained by the developers, the final model is assembled within a three-by-five stack of 96-well plastic plates, that are each less than half-an-inch thick. It features multiple channels that are coated with a gel-like material similar to bone marrow with nutrients and growth factors to support plasma cell function and maintenance.  Its layers correspond to an area at the outer edge of the bone marrow cavity, known as the endosteal subniche, where plasma cells are stored. The model also replicates an area deeper inside the center of the bone marrow, the perivascular subniche, which surrounds a network of blood vessels, where plasma cells proliferate and are activated.</span></p>
<p><span>“It is nearly impossible to achieve high imaging resolution of plasma cells in living human bone marrow,” Singh said. Though it is possible to “do some level of imaging in the bone marrow of a mouse” which is where some previous efforts have been focused. </span></p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p><span>Now with this new model, scientists will be able to run new types of experiments. “A fundamental question [that] our study addresses [is] why it is that when B cells are ready to make antibodies, they relocate from lymph nodes, the spleen, and other organs and enter and take up residence in bone marrow,” Singh said. “Another is a question of the role that the environment of bone marrow plays in orienting those cells and responses to reinfection.”</span></p>
<p><span>Furthermore, the model can be seeded with cells from unique patient populations to study things like the effects of aging on plasma cell function. It could also be used to study cells from people with autoimmune or allergic diseases to understand how autoimmunity or allergy-promoting plasma cells are produced and maintained. Other studies could focus on addressing questions such as why B cells show a stop-and-go pattern of movement and whether it is part of a migration pattern in the bone marrow. </span></p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/bone-marrow-on-a-chip-model-offers-new-window-into-immune-cell-development-and-behavior/">Bone Marrow-on-a-Chip Model Offers New Window Into Immune Cell Development and Behavior</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Transcenta Therapeutics and WuXi Biologics Team Up to Accelerate Commercialization of HiCB Technology</title>
<link>https://edusehat.com/en/transcenta-therapeutics-and-wuxi-biologics-team-up-to-accelerate-commercialization-of-hicb-technology</link>
<guid>https://edusehat.com/en/transcenta-therapeutics-and-wuxi-biologics-team-up-to-accelerate-commercialization-of-hicb-technology</guid>
<description><![CDATA[ Transcenta, headquartered in China and with a pipeline of over ten therapeutic antibody candidates, is a clinical-stage biopharmaceutical company with expertise in biologics discovery, translational research, clinical, and process development. 
The post Transcenta Therapeutics and WuXi Biologics Team Up to Accelerate Commercialization of HiCB Technology appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-115860765.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 12 Sep 2026 03:10:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Transcenta, Therapeutics, and, WuXi, Biologics, Team, Accelerate, Commercialization, HiCB, Technology</media:keywords>
<content:encoded><![CDATA[<p>Transcenta Therapeutics says it will grant WuXi Biologics and its affiliates a non-exclusive license to certain technologies relating to Transcenta’s intensified continuous bioprocessing (HiCB) platform and ExcelPro cell culture media.</p>
<p>Transcenta will receive an upfront payment of $1.5 million and will be eligible for milestone payments upon the achievement of specified conditions. Through this collaboration, WuXi Biologics will become Transcenta’s strategic partner for CMC development and supporting molecules across Transcenta’s development pipeline.</p>
<p>A Transcenta spokesperson explained that the HiCB platform integrates intensified continuous perfusion upstream processing with hybrid continuous downstream purification, enabling a step-change in productivity, achieving an increase in productivity compared with conventional fed-batch processes.</p>
<p>HiCB can significantly reduce cost of goods, lower capital investment, and enable agile production, claims the company official, while providing a solution for improving recovering yield and product quality for complex biologics.</p>
<p>Transcenta, headquartered in Suzhou, China, is a clinical-stage biopharmaceutical company with expertise in biologics discovery, translational research, clinical, and process development. The company develops a pipeline of over ten therapeutic antibody candidates spanning oncology, bone, and kidney disorders.</p>
<p class="trimmed"> </p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/transcenta-therapeutics-and-wuxi-biologics-team-up-to-accelerate-commercialization-of-hicb-technology/">Transcenta Therapeutics and WuXi Biologics Team Up to Accelerate Commercialization of HiCB Technology</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>CloudScope Enables Continuous Remote Monitoring of Brain Activity in Freely Moving Mice</title>
<link>https://edusehat.com/en/cloudscope-enables-continuous-remote-monitoring-of-brain-activity-in-freely-moving-mice</link>
<guid>https://edusehat.com/en/cloudscope-enables-continuous-remote-monitoring-of-brain-activity-in-freely-moving-mice</guid>
<description><![CDATA[ Johns Hopkins researchers developed CloudScope, a cloud-based microscope enabling continuous, remote brain imaging in freely moving mice, revealing disease progression, seizures, cellular changes and behavior over extended periods.
The post CloudScope Enables Continuous Remote Monitoring of Brain Activity in Freely Moving Mice appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/Low-Res_Pathak-big.png-e1789134393597.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 12 Sep 2026 03:10:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>CloudScope, Enables, Continuous, Remote, Monitoring, Brain, Activity, Freely, Moving, Mice</media:keywords>
<content:encoded><![CDATA[<p>In order to understand and characterize preclinical models of diseases of the central nervous system (CNS), it is critical to be able to conduct continuous neuroimaging of multiple physiological variables—neuronal activity, blood flow, blood volume, oxygenation, and cellular dynamics—within the CNS microenvironment. This continuous multimodality neuroimaging capability is known as neurosurveillance.</p>
<p>However, a long-standing challenge in neuroscience and neuropathology has been how to continuously observe biological processes that unfold over hours, days, and even weeks in the brain.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>Now, researchers at Johns Hopkins Medicine have demonstrated a new approach to brain imaging that enables continuous monitoring of brain activity and the physiologic changes associated with neurological disease progression for more than 24 hours in freely moving mouse models. The cloud-based miniaturized microscope, CloudScope, operates autonomously and allows scientists to access live imaging data remotely from anywhere in the world, creating new opportunities to study diseases as they develop over time.</p>
<p>The study demonstrates the ability to remotely capture and analyze changes in brain activity, blood flow, blood vessel remodeling, oxygenation and cellular behavior over extended periods, providing a more holistic picture of brain disease progression than conventional imaging approaches.</p>
<p>This work is published in <em>Nature Methods</em> in the paper, “<a href="https://www.nature.com/articles/s41592-026-03111-z" target="_blank" rel="noopener">A cloud-based miniscope for neurosurveillance of brain health and disease in freely behaving animals</a>.”</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>“We started with a fundamental question: If we wanted to image a seizure or brain tumor formation continuously in a preclinical or animal model over 24 hours or longer, how would we do that?” says Arvind Pathak, PhD, professor of radiology, oncology, and biomedical and electrical engineering at Johns Hopkins. “The consequence of us working through this question and its associated challenges is what resulted in this innovation.”</p>
<p>Using this approach, the team captured spontaneous seizures occurring several hours after a drug-induced seizure in mice, events that would have been missed using conventional short-term imaging methods. In separate studies of brain cancer, researchers were able to characterize the behavior of individual cancer cells and observe dynamic changes in the brain’s microenvironment as the disease progressed. These findings suggest that continuous monitoring may reveal critical biological events that occur outside the limited observation windows typically used in laboratory research.</p>
<p>“Most central nervous system diseases develop over hours, days or even weeks. Yet modern imaging tools are designed to continuously probe only a small fraction of this time window,” says Janaka Senarathna, PhD, assistant professor of radiology at Johns Hopkins. “We developed a device to break this time barrier.”</p>
<p>In addition to advancing neuroimaging research, the investigators have also demonstrated a promising application involving artificial intelligence. By combining the first-ever 24-hour brain imaging dataset with video recordings of the lab animals’ behavior, the team successfully trained an AI framework to predict whether an animal was minimally mobile, moderately active, or running based solely on neuronal activity measurements made with the device. The researchers believe this approach could help scientists better understand the neurological effects of conditions such as stroke or Parkinson’s disease and potentially reveal new insights into the relationship between brain activity and behavior. Additionally, researchers say the device enables time-shared imaging from anywhere in the world, and it creates a pathway to reduce animal use while enabling neuroscientific and neuropathological insights. Lastly, CloudScope’s architecture enables “time-shared” imaging, which potentially reduces animal use.</p>
<p>To explore the effect of disease on different brain regions, the team plans to continue expanding the platform’s capabilities, such as imaging larger regions of the animals’ brains and leveraging AI to accelerate brain imaging and cancer cell tracking.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/cloudscope-enables-continuous-remote-monitoring-of-brain-activity-in-freely-moving-mice/">CloudScope Enables Continuous Remote Monitoring of Brain Activity in Freely Moving Mice</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>How Long is COMLEX Level 1 &amp;amp; How Many Questions are On the Exam?</title>
<link>https://edusehat.com/en/how-long-is-comlex-level-1-how-many-questions-are-on-the-exam</link>
<guid>https://edusehat.com/en/how-long-is-comlex-level-1-how-many-questions-are-on-the-exam</guid>
<description><![CDATA[ The Comprehensive Osteopathic Medical Licensing Examination (COMLEX) Level 1 is a critical milestone for osteopathic medical students. It serves as one of the standardized examinations that students will need to overcome prior to clinical training and residency applications. This high-stakes exam assesses a student’s foundational medical knowledge and ability to apply osteopathic principles in patient […]
The post How Long is COMLEX Level 1 &amp; How Many Questions are On the Exam? appeared first on Elite Medical Prep. ]]></description>
<enclosure url="https://elitemedicalprep.com/wp-content/uploads/2026/09/pexels-george-pak-7972380-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 11 Sep 2026 23:55:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>How, Long, COMLEX, Level, How, Many, Questions, are, the, Exam</media:keywords>
<content:encoded><![CDATA[<p><span>The Comprehensive Osteopathic Medical Licensing Examination (COMLEX) Level 1 is a critical milestone for osteopathic medical students. It serves as one of the standardized examinations that students will need to overcome prior to clinical training and residency applications. This high-stakes exam assesses a student’s foundational medical knowledge and ability to apply osteopathic principles in patient care. </span></p>
<p> </p>
<p><span>One of the most frequently asked questions about COMLEX Level 1 is its duration and question format. In this comprehensive guide, we will break down the structure, timing, and number of questions on the exam to help students prepare effectively.</span></p>
<p> </p>
<h2><b>Background to COMLEX Level 1</b></h2>
<p><span>COMLEX is administered by the National Board of Osteopathic Medical Examiners (NBOME). It consists of multiple levels, with Level 1 being the first major step in the licensing process. Students who are new to the licensing process may also benefit from learning more about <a class="decorated-link" href="https://elitemedicalprep.com/what-are-the-comlex-exams/" target="_new" rel="noopener" data-start="558" data-end="642">what the COMLEX exams are </a>and how each level fits into osteopathic medical training. Per the NBOME, “</span><span>COMLEX-USA Level 1 integrates foundational biomedical sciences with other areas of osteopathic medical knowledge relevant to clinical problem-solving and the promotion of health maintenance”.</span></p>
<p> </p>
<p><a href="https://www.ama-assn.org/medical-students/usmle-step-1-2/comlex-level-1-s-move-pass-fail-what-it-means-do-students"><span>COMLEX Level 1 transitioned to a pass/fail scoring system in 2022</span></a><span>. This change was made to reduce stress on students and shift focus from numerical scores to overall competency. While this eliminates score-based competition, the rigorous nature of the exam remains unchanged.</span></p>
<p> </p>
<p><span>To find all of the most up to date information on the COMLEX, we recommend visiting the </span><a href="https://www.nbome.org/assessments/comlex-usa/"><span>NBOME website</span></a><span> on the COMLEX examinations.</span></p>
<p> </p>
<h2><b>How Long is the COMLEX Level 1 Exam?</b></h2>
<p><span>The total testing time for COMLEX Level 1 is approximately </span><b>8 hours</b><span>, divided into </span><b>two 4-hour sessions</b><span>, which are further subdivided with scheduled breaks in between. The exam is administered in a</span><b> single day</b><span> and follows a strict schedule:</span></p>
<p> </p>
<h3><b>Breakdown of Testing Time</b></h3>
<p><span>Students must complete each session within the allotted time, and any remaining time does not carry over to the next session. The two 10-minute breaks (between sections 2 and 3, and 6 and 7) and the 40-minute lunch break (between sections 4 and 5) provide an opportunity to rest and refresh, which is crucial for maintaining focus and stamina throughout the day.</span></p>
<p> </p>
<h2><b>How Many Questions are on COMLEX Level 1?</b></h2>
<p><span>The COMLEX Level 1 exam consists of </span><b>352 multiple-choice questions (MCQs)</b><span>, distributed evenly across </span><b>eight sections</b><span>, each containing </span><b>44 questions</b><span>. Each section is timed separately, requiring students to pace themselves effectively to answer all questions within the given time constraints.</span></p>
<p> </p>
<h3><b>Question Format</b></h3>
<p><span>The questions on COMLEX Level 1 are </span><b>single-best answer, multiple-choice</b><span> format and may include audio-visual elements. Each question presents a clinical vignette or scenario, followed by a question and possible answer choices. </span><span>Questions can be answered, reviewed, and changed one section at a time. The exam does not time individual sections. However, once you advance to a new section, you can no longer return to the previous one.</span></p>
<p> </p>
<p><span> The exam tests:</span></p>
<ul>
<li aria-level="1"><b>Basic biomedical sciences</b><span> (anatomy, physiology, biochemistry, pharmacology, microbiology, pathology, and genetics)</span></li>
<li aria-level="1"><b>Osteopathic principles and manipulative medicine (OMM)</b></li>
<li aria-level="1"><b>Clinical decision-making</b><span> and patient management</span></li>
</ul>
<p> </p>
<h3><b>Time Management per Question</b></h3>
<p><span>Since each section has </span><b>44 questions</b><span> to be completed in </span><b>1 hour</b><span>, students have approximately </span><b>1 minute and 22 seconds per question</b><span>. Efficient time management helps students answer every question within the allotted time.</span></p>
<p> </p>
<h2><b>What kind of questions can I expect to answer?</b></h2>
<p><span>The specific breakdown for each COMLEX exam can be found in the figure below and at the following </span><a href="https://www.nbome.org/assessments/comlex-usa/comlex-usa-blueprint/"><span>website</span></a><span>. Specifically, COMLEX has a </span><i><span>Blueprint</span></i><span> regarding the concepts that students are expected to master, and these concepts are broken down into two dimensions. Dimension 1 refers to competency domains while Dimension 2 refers to Clinical Presentations. Students should review the <a class="decorated-link" href="https://elitemedicalprep.com/comlex-blueprint-and-aoa-acgme-merger/" target="_new" rel="noopener" data-start="29" data-end="129">COMLEX Level 1 exam blueprint</a> to understand how it organizes and weights these topics.</span></p>
<p> </p>
<h2><b>What to Expect on Exam Day?</b></h2>
<p><span>Understanding the exam structure and timing is only part of the preparation process. </span><a href="https://www.nbome.org/assessments/comlex-usa/what-to-expect-on-exam-day/"><span>On the day of the exam,</span></a><span> students should arrive at the testing center early to allow enough time for check-in procedures, including identification verification, fingerprint scanning, and security screening.</span></p>
<p> </p>
<h3><b>Tips for Exam Day Success</b></h3>
<ul>
<li aria-level="1"><b>Arrive early:</b><span> Plan to arrive at least </span><b>30-60 minutes before</b><span> your scheduled exam time to complete check-in procedures. Often times the staff at the testing center will allow you to begin your exam early.</span></li>
<li aria-level="1"><b>Dress comfortably:</b><span> Testing centers have varying temperatures, so wear layers to stay comfortable that you can remove on breaks if it gets too hot.</span></li>
<li aria-level="1"><b>Bring necessary identification:</b><span> You must bring a government-issued photo ID.</span></li>
<li aria-level="1"><b>Use your breaks wisely:</b><span> Eat a light meal during lunch and stay hydrated to maintain energy levels (always bring more food than you think you will need)</span></li>
<li aria-level="1"><b>Stay calm and focused:</b><span> If you encounter a difficult question, make an educated guess and move forward to save time.</span></li>
</ul>
<p> </p>
<h2><b>How to Prepare for the Length and Question Volume?</b></h2>
<p><span>The sheer length and number of questions on COMLEX Level 1 can be daunting, but effective preparation strategies can help students build endurance and confidence.</span></p>
<h3><b>1. Take Full-Length Practice Exams</b></h3>
<p><span>Simulating the actual test by taking </span><b>full-length practice exams</b><span> under timed conditions is one of the best ways to prepare. This helps students develop stamina and improve time management. Along with taking full-length assessments, review the <a class="decorated-link" href="https://elitemedicalprep.com/best-comlex-level-1-study-resources/" target="_new" rel="noopener" data-start="391" data-end="495">best COMLEX Level 1 study resources</a> to determine which tools may be most helpful during each stage of your preparation.</span></p>
<h3><b>2. Follow a Study Schedule</b></h3>
<p><span>A structured study plan that includes reviewing high-yield topics, taking practice questions, and scheduling rest days can optimize learning and retention. Students who need help organizing their preparation can use EMP’s <a class="decorated-link" href="https://elitemedicalprep.com/emps-free-comlex-level-1-10-week-study-calendar/" target="_new" rel="noopener" data-start="386" data-end="509">free COMLEX Level 1 10-week study calendar</a> as a starting point.</span></p>
<h3><b>3. Use Question Banks</b></h3>
<p><span>Resources like UWorld, TrueLearn, and COMBANK offer question banks designed to mimic the COMLEX exam format. These are valuable tools for reinforcing concepts and improving test-taking strategies. Before selecting a question bank, read our detailed <a class="decorated-link" href="https://elitemedicalprep.com/truelearn-review-comlex/" target="_new" rel="noopener" data-start="853" data-end="949">TrueLearn review for COMLEX preparation</a> to understand its features, strengths, and limitations.</span></p>
<h3><b>4. Focus on OMM</b></h3>
<p><span>Osteopathic principles and manipulative medicine (OMM) are unique to the COMLEX exam. Many students find this section challenging because medical school courses often place less emphasis on OMM than on the basic biomedical sciences. Therefore, dedicating sufficient time to OMM review is crucial. If this is one of your weaker areas, learn <a class="decorated-link" href="https://elitemedicalprep.com/how-to-study-for-omm-osteopathic-manipulative-medicine-questions/" target="_new" rel="noopener" data-start="1371" data-end="1499">how to study for OMM questions</a> more effectively.</span></p>
<h3><b>5. Build Stamina with Timed Study Sessions</b></h3>
<p><span>Studying in timed blocks, similar to the exam’s structure, can help condition students for long periods of focused work.</span></p>
<h3><b>6. Ask for Help!</b></h3>
<p><span>Studying with friends and classmates is a great way to get support during these challenging times. Tutors are also available to help you craft an individualized study plan. Students who need more individualized support may benefit from working with a <a class="decorated-link" href="https://elitemedicalprep.com/comlex-level-1-tutoring/" target="_new" rel="noopener" data-start="1837" data-end="1914">COMLEX Level 1 tutor</a> to develop a personalized schedule, address knowledge gaps, and strengthen their test-taking strategy.</span></p>
<p> </p>
<h2><b>Conclusion</b></h2>
<p><span>COMLEX Level 1 is a demanding exam that requires both knowledge and endurance. Understanding its structure—</span><b>8 hours in total, divided into eight 1-hour testing sections, with 352 multiple-choice questions</b><span>—is essential for effective preparation. By practicing with timed exams, using question banks, and maintaining a structured study schedule, you can improve their performance and increase their confidence on exam day. Do not be afraid to ask for help – tutors can be a wonderful resource to improve your scores.</span></p>
<p> </p>
<p><span>With adequate preparation and the right mindset, you can successfully navigate COMLEX Level 1 and move forward in your medical careers with a strong foundation in osteopathic medicine.</span></p>
<p>The post <a href="https://elitemedicalprep.com/how-long-is-comlex-level-1-and-how-many-questions-are-on-the-exam/">How Long is COMLEX Level 1 & How Many Questions are On the Exam?</a> appeared first on <a href="https://elitemedicalprep.com/">Elite Medical Prep</a>.</p>]]> </content:encoded>
</item>

</channel>
</rss>